Anaphase Anaphase 1 0 0 0 0 0 0 0 8 0 NONE NONE NN NN IN B_TIMEXCCP
inactivation inactivation 0 0 0 0 0 0 0 0 12 0 NONE NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
spindle spindle 0 0 0 0 0 0 0 0 7 0 IN DT NN NNP NNP O
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 DT NN NNP NNP NNP B_TIMEXCCP
Palframan Palframan 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP NNP O
WJ, WJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Meehl Meehl 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
JB, JB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Jaspersen Jaspersen 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
SL, SL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Winey Winey 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Murray Murray 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
AW. AW. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Cellular Cellular 1 0 0 0 0 0 0 0 8 0 NNP CC NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 CC NNP NNP NNP NNP O
Biological Biological 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Laboratories, Laboratories, 1 0 0 0 1 0 0 0 13 0 NNP NNP NNP NNP NNP O
Harvard Harvard 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP CD O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP CD NNP O
16 16 0 0 0 0 0 0 1 1 2 0 NNP NNP CD NNP NNP O
Divinity Divinity 1 0 0 0 0 0 0 0 8 0 NNP CD NNP NNP NNP O
Avenue, Avenue, 1 0 0 0 1 0 0 0 7 0 CD NNP NNP NNP NNP O
Cambridge, Cambridge, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP CD O
MA MA 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
02138, 02138, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN NN O
spindle spindle 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN NNS O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NNP NN NN NNS VBP O
delays delays 0 0 0 0 0 0 0 0 6 0 NN NN NNS VBP NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NNS VBP NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NNS VBP NN NN IN O
progression progression 0 0 0 0 0 0 0 0 11 0 VBP NN NN IN NNS O
until until 0 0 0 0 0 0 0 0 5 0 NN NN IN NNS VBP O
microtubules microtubules 0 0 0 0 0 0 0 0 12 0 NN IN NNS VBP DT O
attach attach 0 0 0 0 0 0 0 0 6 0 IN NNS VBP DT NN O
each each 0 0 0 0 0 0 0 0 4 0 NNS VBP DT NN IN O
pair pair 0 0 0 0 0 0 0 0 4 0 VBP DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
sister sister 0 0 0 0 0 0 0 0 6 0 NN IN NN NNS TO O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 IN NN NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO VB NNS O
opposite opposite 0 0 0 0 0 0 0 0 8 0 NNS TO VB NNS IN O
poles poles 0 0 0 0 0 0 0 0 5 0 TO VB NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VB NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NNP O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NNP NNP B_TIMEXCCP
spindle. spindle. 0 0 0 0 0 0 0 0 8 0 DT JJ NNP NNP NN O
Following Following 1 0 0 0 0 0 0 0 9 0 JJ NNP NNP NN VBD O
sister sister 0 0 0 0 0 0 0 0 6 0 NNP NNP NN VBD JJ O
chromatid chromatid 0 0 0 0 0 0 0 0 9 0 NNP NN VBD JJ NN O
separation, separation, 0 0 0 0 1 0 0 0 11 0 NN VBD JJ NN DT O
however, however, 0 0 0 0 1 0 0 0 8 0 VBD JJ NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NN NNS O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NN DT NN NNS VBZ O
ignores ignores 0 0 0 0 0 0 0 0 7 0 DT NN NNS VBZ WP$ O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 NN NNS VBZ WP$ NNS O
whose whose 0 0 0 0 0 0 0 0 5 0 NNS VBZ WP$ NNS VBP O
kinetochores kinetochores 0 0 0 0 0 0 0 0 12 0 VBZ WP$ NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 WP$ NNS VBP VBN TO O
attached attached 0 0 0 0 0 0 0 0 8 0 NNS VBP VBN TO RB O
to to 0 0 0 0 0 0 0 0 2 0 VBP VBN TO RB CD O
only only 0 0 0 0 0 0 0 0 4 0 VBN TO RB CD NN O
one one 0 0 0 0 0 0 0 0 3 0 TO RB CD NN -NONE- O
spindle spindle 0 0 0 0 0 0 0 0 7 0 RB CD NN -NONE- DT O
pole, pole, 0 0 0 0 1 0 0 0 5 0 CD NN -NONE- DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN -NONE- DT NN WDT O
state state 0 0 0 0 0 0 0 0 5 0 -NONE- DT NN WDT VBZ O
that that 0 0 0 0 0 0 0 0 4 0 DT NN WDT VBZ DT O
activates activates 0 0 0 0 0 0 0 0 9 0 NN WDT VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 WDT VBZ DT NN RB O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 VBZ DT NN RB TO B_TIMEXCCP
prior prior 0 0 0 0 0 0 0 0 5 0 DT NN RB TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NN RB TO NNP NNP O
metaphase. metaphase. 0 0 0 0 0 0 0 0 10 0 RB TO NNP NNP NN B_TIMEXCCP
We We 1 0 0 0 0 0 0 0 2 0 TO NNP NNP NN -NONE- O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 NNP NNP NN -NONE- IN O
that, that, 0 0 0 0 1 0 0 0 5 0 NNP NN -NONE- IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN -NONE- IN NN NN O
budding budding 0 0 0 0 0 0 0 0 7 0 -NONE- IN NN NN JJ O
yeast, yeast, 0 0 0 0 1 0 0 0 6 0 IN NN NN JJ NN O
mutual mutual 0 0 0 0 0 0 0 0 6 0 NN NN JJ NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 NN JJ NN IN DT O
between between 0 0 0 0 0 0 0 0 7 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
anaphase-promoting anaphase-promoting 0 0 1 0 0 0 0 0 18 0 IN DT JJ NN NN B_TIMEXCCP
complex complex 0 0 0 0 0 0 0 0 7 0 DT JJ NN NN CC O
(APC) (APC) 0 1 0 0 0 0 0 0 5 0 JJ NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP DT O
Mps1, Mps1, 1 0 0 0 1 0 0 1 5 0 NN CC NNP DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 CC NNP DT JJ NN O
essential essential 0 0 0 0 0 0 0 0 9 0 NNP DT JJ NN IN O
component component 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNS O
checkpoint, checkpoint, 0 0 0 0 1 0 0 0 11 0 IN DT JJ NNS TO B_TIMEXCCP
leads leads 0 0 0 0 0 0 0 0 5 0 DT JJ NNS TO VBN O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO VBN NN O
sustained sustained 0 0 0 0 0 0 0 0 9 0 NNS TO VBN NN IN O
inactivation inactivation 0 0 0 0 0 0 0 0 12 0 TO VBN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
spindle spindle 0 0 0 0 0 0 0 0 7 0 IN DT NN NNP NNP O
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 DT NN NNP NNP NN B_TIMEXCCP
Mps1 Mps1 1 0 0 0 0 0 0 1 4 0 NN NNP NNP NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN NNS O
abundance abundance 0 0 0 0 0 0 0 0 9 0 NNP NN NN NNS IN O
decreases decreases 0 0 0 0 0 0 0 0 9 0 NN NN NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ CC O
anaphase, anaphase, 0 0 0 0 1 0 0 0 9 0 NNS IN JJ CC NNP B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC NNP VBZ O
Mps1 Mps1 1 0 0 0 0 0 0 1 4 0 JJ CC NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 CC NNP VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT NN IN O
target target 0 0 0 0 0 0 0 0 6 0 VBZ DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
APC. APC. 1 1 0 0 0 0 0 0 4 0 IN DT NNP NNP NN O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 DT NNP NNP NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP IN O
Mps1 Mps1 1 0 0 0 0 0 0 1 4 0 NN IN NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP CC O
anaphase, anaphase, 0 0 0 0 1 0 0 0 9 0 NNP IN NNP CC NN B_TIMEXCCP
or or 0 0 0 0 0 0 0 0 2 0 IN NNP CC NN IN O
repression repression 0 0 0 0 0 0 0 0 10 0 NNP CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP IN O
APC APC 1 1 0 0 0 0 0 0 3 0 IN DT NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 DT NNP IN NNP NNS O
anaphase, anaphase, 0 0 0 0 1 0 0 0 9 0 NNP IN NNP NNS DT B_TIMEXCCP
reactivates reactivates 0 0 0 0 0 0 0 0 11 0 IN NNP NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNS DT NN NNP O
spindle spindle 0 0 0 0 0 0 0 0 7 0 NNS DT NN NNP NNP O
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 DT NN NNP NNP NNP O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NNP NN O
APC-Mps1 APC-Mps1 1 0 1 0 0 0 0 1 8 0 NNP NNP NNP NN NN O
feedback feedback 0 0 0 0 0 0 0 0 8 0 NNP NNP NN NN VBZ O
circuit circuit 0 0 0 0 0 0 0 0 7 0 NNP NN NN VBZ NNS O
allows allows 0 0 0 0 0 0 0 0 6 0 NN NN VBZ NNS TO O
cells cells 0 0 0 0 0 0 0 0 5 0 NN VBZ NNS TO RB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ NNS TO RB VB O
irreversibly irreversibly 0 0 0 0 0 0 0 0 12 0 NNS TO RB VB DT O
inactivate inactivate 0 0 0 0 0 0 0 0 10 0 TO RB VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VB DT NN IN O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 VB DT NN IN NNP B_TIMEXCCP
during during 0 0 0 0 0 0 0 0 6 0 DT NN IN NNP NNP O
anaphase. anaphase. 0 0 0 0 0 0 0 0 9 0 NN IN NNP NNP IN B_TIMEXCCP
Comment Comment 1 0 0 0 0 0 0 0 7 0 IN NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP NNP O
biology. biology. 0 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP DT O
Extinguishing Extinguishing 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP DT NN NN NNP O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN NNP NNP O
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP CD O
[Science. [Science. 0 0 0 0 0 0 0 0 9 0 NN NNP NNP CD -NONE- O
2006] 2006] 0 0 0 0 0 0 0 1 5 0 NNP NNP CD -NONE- CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNP CD -NONE- CD JJ O
16825537 16825537 0 0 0 0 0 0 1 1 8 0 CD -NONE- CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 -NONE- CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
In In 1 0 0 0 0 0 0 0 2 0 NONE NONE IN NN IN O
pursuit pursuit 0 0 0 0 0 0 0 0 7 0 NONE IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP DT O
excellence: excellence: 0 0 0 0 0 0 0 0 11 0 NN IN NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NNP DT NN NNP O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NNP DT NN NNP NNP B_TIMEXCCP
journey. journey. 0 0 0 0 0 0 0 0 8 0 DT NN NNP NNP NNP O
Shabino Shabino 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Richardson Richardson 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
D. D. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Wisconsin Wisconsin 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Hospital Hospital 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Association, Association, 1 0 0 0 1 0 0 0 12 0 NNP NNP NNP NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP CD O
March March 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP CD DT O
2004, 2004, 0 0 0 0 1 0 0 1 5 0 NNP NNP CD DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP CD DT NNP NNP O
Wisconsin Wisconsin 1 0 0 0 0 0 0 0 9 0 CD DT NNP NNP NNP O
Hospital Hospital 1 0 0 0 0 0 0 0 8 0 DT NNP NNP NNP VBD O
Association Association 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP VBD NNS O
launched launched 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD NNS -NONE- O
CheckPoints CheckPoints 1 0 0 0 0 0 0 0 11 0 NNP VBD NNS -NONE- TO O
(www.wicheckpoint.org) (www.wicheckpoint.org) 0 0 0 0 0 0 0 0 22 0 VBD NNS -NONE- TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNS -NONE- TO VB NNS O
provide provide 0 0 0 0 0 0 0 0 7 0 -NONE- TO VB NNS IN O
consumers consumers 0 0 0 0 0 0 0 0 9 0 TO VB NNS IN NN O
with with 0 0 0 0 0 0 0 0 4 0 VB NNS IN NN IN O
information information 0 0 0 0 0 0 0 0 11 0 NNS IN NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN CC O
quality quality 0 0 0 0 0 0 0 0 7 0 IN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
safety safety 0 0 0 0 0 0 0 0 6 0 NN CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NN O
hospital hospital 0 0 0 0 0 0 0 0 8 0 NN IN NN NN CC O
care, care, 0 0 0 0 1 0 0 0 5 0 IN NN NN CC TO O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN CC TO VB NNS O
assist assist 0 0 0 0 0 0 0 0 6 0 CC TO VB NNS CC O
hospitals hospitals 0 0 0 0 0 0 0 0 9 0 TO VB NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 VB NNS CC NNS IN O
physicians physicians 0 0 0 0 0 0 0 0 10 0 NNS CC NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CC NNS IN NN NN O
quality quality 0 0 0 0 0 0 0 0 7 0 NNS IN NN NN NNP O
improvement improvement 0 0 0 0 0 0 0 0 11 0 IN NN NN NNP NNP O
activities. activities. 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP PRP$ O
Since Since 1 0 0 0 0 0 0 0 5 0 NN NNP NNP PRP$ NNP O
its its 0 0 0 0 0 0 0 0 3 0 NNP NNP PRP$ NNP DT O
inception, inception, 0 0 0 0 1 0 0 0 10 0 NNP PRP$ NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP$ NNP DT NN NN O
state state 0 0 0 0 0 0 0 0 5 0 NNP DT NN NN NN O
average average 0 0 0 0 0 0 0 0 7 0 DT NN NN NN IN O
achievement achievement 0 0 0 0 0 0 0 0 11 0 NN NN NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN DT NNP O
all all 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP VBZ O
CheckPoint CheckPoint 1 0 0 0 0 0 0 0 10 0 IN DT NNP VBZ VBZ B_TIMEXCCP
measures measures 0 0 0 0 0 0 0 0 8 0 DT NNP VBZ VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP VBZ VBZ VBN CC O
increased increased 0 0 0 0 0 0 0 0 9 0 VBZ VBZ VBN CC VBN O
or or 0 0 0 0 0 0 0 0 2 0 VBZ VBN CC VBN DT O
maintained maintained 0 0 0 0 0 0 0 0 10 0 VBN CC VBN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 CC VBN DT JJ JJ O
high high 0 0 0 0 0 0 0 0 4 0 VBN DT JJ JJ NN O
initial initial 0 0 0 0 0 0 0 0 7 0 DT JJ JJ NN IN O
rate, rate, 0 0 0 0 1 0 0 0 5 0 JJ JJ NN IN CD O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN CD IN O
99% 99% 0 0 0 0 0 0 0 1 3 0 NN IN CD IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN CD IN NNP NNS O
Wisconsin Wisconsin 1 0 0 0 0 0 0 0 9 0 CD IN NNP NNS RB O
hospitals hospitals 0 0 0 0 0 0 0 0 9 0 IN NNP NNS RB NNP O
voluntarily voluntarily 0 0 0 0 0 0 0 0 11 0 NNP NNS RB NNP NNP O
participating. participating. 0 0 0 0 0 0 0 0 14 0 NNS RB NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 RB NNP NNP JJ NN O
current current 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NN NN O
state state 0 0 0 0 0 0 0 0 5 0 NNP JJ NN NN VBZ O
average average 0 0 0 0 0 0 0 0 7 0 JJ NN NN VBZ JJR O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ JJR IN O
greater greater 0 0 0 0 0 0 0 0 7 0 NN VBZ JJR IN CD O
than than 0 0 0 0 0 0 0 0 4 0 VBZ JJR IN CD CC O
90% 90% 0 0 0 0 0 0 0 1 3 0 JJR IN CD CC CD O
or or 0 0 0 0 0 0 0 0 2 0 IN CD CC CD NNS O
90 90 0 0 0 0 0 0 1 1 2 0 CD CC CD NNS JJ O
points points 0 0 0 0 0 0 0 0 6 0 CC CD NNS JJ CD O
(scale (scale 0 0 0 0 0 0 0 0 6 0 CD NNS JJ CD NN O
0-100 0-100 0 0 1 0 0 0 0 1 5 0 NNS JJ CD NN IN O
points) points) 0 0 0 0 0 0 0 0 7 0 JJ CD NN IN CD O
on on 0 0 0 0 0 0 0 0 2 0 CD NN IN CD IN O
11 11 0 0 0 0 0 0 1 1 2 0 NN IN CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN CD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT JJ CD O
original original 0 0 0 0 0 0 0 0 8 0 IN DT JJ CD NNP O
19 19 0 0 0 0 0 0 1 1 2 0 DT JJ CD NNP NNP O
measures. measures. 0 0 0 0 0 0 0 0 9 0 JJ CD NNP NNP DT O
Over Over 1 0 0 0 0 0 0 0 4 0 CD NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ CD O
next next 0 0 0 0 0 0 0 0 4 0 NNP DT JJ CD NN O
2 2 0 0 0 0 0 0 1 1 1 0 DT JJ CD NN JJ O
years, years, 0 0 0 0 1 0 0 0 6 0 JJ CD NN JJ NNS O
additional additional 0 0 0 0 0 0 0 0 10 0 CD NN JJ NNS MD O
measures measures 0 0 0 0 0 0 0 0 8 0 NN JJ NNS MD VB O
will will 0 0 0 0 0 0 0 0 4 0 JJ NNS MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB VBN IN O
added added 0 0 0 0 0 0 0 0 5 0 MD VB VBN IN MD O
that that 0 0 0 0 0 0 0 0 4 0 VB VBN IN MD VB O
will will 0 0 0 0 0 0 0 0 4 0 VBN IN MD VB DT O
expand expand 0 0 0 0 0 0 0 0 6 0 IN MD VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NN IN O
scope scope 0 0 0 0 0 0 0 0 5 0 VB DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN JJ O
information information 0 0 0 0 0 0 0 0 11 0 NN IN NN JJ IN O
available available 0 0 0 0 0 0 0 0 9 0 IN NN JJ IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NN JJ IN NNP NNP O
CheckPoint. CheckPoint. 1 0 0 0 0 0 0 0 11 0 JJ IN NNP NNP CD B_TIMEXCCP
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 IN NNP NNP CD JJ O
17256706 17256706 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Histone Histone 1 0 0 0 0 0 0 0 7 0 NONE NONE NNP NN IN O
synthesis synthesis 0 0 0 0 0 0 0 0 9 0 NONE NNP NN IN NNS O
by by 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNS IN O
lymphocytes lymphocytes 0 0 0 0 0 0 0 0 11 0 NN IN NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN NNP CC O
G0 G0 1 1 0 0 0 0 0 1 2 0 NNS IN NNP CC NNP B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
G1. G1. 1 1 0 0 0 0 0 1 3 0 NNP CC NNP NNP NNP B_TIMEXCCP
Waithe Waithe 1 0 0 0 0 0 0 0 6 0 CC NNP NNP NNP NNP O
WI, WI, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Renaud Renaud 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Nadeau Nadeau 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Pallotta Pallotta 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
D. D. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
Peripheral Peripheral 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NN VBZ O
blood blood 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ VBP O
lymphocytes lymphocytes 0 0 0 0 0 0 0 0 11 0 NNP NN VBZ VBP DT O
are are 0 0 0 0 0 0 0 0 3 0 NN VBZ VBP DT RB O
a a 0 0 0 0 0 0 0 0 1 0 VBZ VBP DT RB VBG O
naturally naturally 0 0 0 0 0 0 0 0 9 0 VBP DT RB VBG NN O
occurring occurring 0 0 0 0 0 0 0 0 9 0 DT RB VBG NN IN O
population population 0 0 0 0 0 0 0 0 10 0 RB VBG NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBG NN IN NNP NNS O
G0 G0 1 1 0 0 0 0 0 1 2 0 NN IN NNP NNS WDT B_TIMEXCCP
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS WDT MD O
which which 0 0 0 0 0 0 0 0 5 0 NNP NNS WDT MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NNS WDT MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 WDT MD VB VBN IN O
activated activated 0 0 0 0 0 0 0 0 9 0 MD VB VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VB VBN IN NN TO O
vitro vitro 0 0 0 0 0 0 0 0 5 0 VBN IN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB CC O
grow grow 0 0 0 0 0 0 0 0 4 0 NN TO VB CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 TO VB CC NNP NNP O
divide. divide. 0 0 0 0 0 0 0 0 7 0 VB CC NNP NNP NN O
Upon Upon 1 0 0 0 0 0 0 0 4 0 CC NNP NNP NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NNP NN IN NN -NONE- O
phytohemagglutinin phytohemagglutinin 0 0 0 0 0 0 0 0 18 0 NN IN NN -NONE- PRP O
(PHA), (PHA), 0 1 0 0 1 0 0 0 6 0 IN NN -NONE- PRP VBP O
they they 0 0 0 0 0 0 0 0 4 enter NN -NONE- PRP VBP NNP O
enter enter 0 0 0 0 0 0 0 0 5 0 -NONE- PRP VBP NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 PRP VBP NNP NNP IN B_TIMEXCCP
and, and, 0 0 0 0 1 0 0 0 4 0 VBP NNP NNP IN DT O
after after 0 0 0 0 0 0 0 0 5 0 NNP NNP IN DT CD O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT CD NN O
24-h 24-h 0 0 1 0 0 0 0 1 4 0 IN DT CD NN NN O
lag, lag, 0 0 0 0 1 0 0 0 4 0 DT CD NN NN NNP O
begin begin 0 0 0 0 0 0 0 0 5 0 CD NN NN NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN NN NNP NN NNS O
replication replication 0 0 0 0 0 0 0 0 11 0 NN NNP NN NNS NNP O
(S (S 0 1 0 0 0 0 0 0 2 0 NNP NN NNS NNP NNP I_TIMEXCCP
phase). phase). 0 0 0 0 0 0 0 0 7 0 NN NNS NNP NNP NN O
Using Using 1 0 0 0 0 0 0 0 5 0 NNS NNP NNP NN VBG O
radioisotope radioisotope 0 0 0 0 0 0 0 0 12 0 NNP NNP NN VBG CC O
labeling labeling 0 0 0 0 0 0 0 0 8 0 NNP NN VBG CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN VBG CC NN NN O
gel gel 0 0 0 0 0 0 0 0 3 0 VBG CC NN NN IN O
electrophoresis electrophoresis 0 0 0 0 0 0 0 0 15 0 CC NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
acid-soluble acid-soluble 0 0 1 0 0 0 0 0 12 0 NN IN JJ NN NN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 IN JJ NN NN PRP O
proteins, proteins, 0 0 0 0 1 0 0 0 9 0 JJ NN NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NN NN PRP VBD NN O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NN PRP VBD NN NN O
histone histone 0 0 0 0 0 0 0 0 7 0 PRP VBD NN NN IN O
synthesis synthesis 0 0 0 0 0 0 0 0 9 0 VBD NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
G0, G0, 1 1 0 0 1 0 0 1 3 0 NN IN NNP NNP CC B_TIMEXCCP
G1, G1, 1 1 0 0 1 0 0 1 3 0 IN NNP NNP CC NNP B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase NNP CC NNP NN NNS B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 CC NNP NN NNS IN O
cultures cultures 0 0 0 0 0 0 0 0 8 0 NNP NN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ CC O
human human 0 0 0 0 0 0 0 0 5 0 NNS IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NNP O
pig pig 0 0 0 0 0 0 0 0 3 0 JJ CC JJ NNP NNP O
lymphocytes. lymphocytes. 0 0 0 0 0 0 0 0 12 0 CC JJ NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NNP CC O
G0 G0 1 1 0 0 0 0 0 1 2 0 NNP NNP NNP CC NNP B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 NNP CC NNP NNP WDT B_TIMEXCCP
cultures, cultures, 0 0 0 0 1 0 0 0 9 0 CC NNP NNP WDT VBP O
which which 0 0 0 0 0 0 0 0 5 0 NNP NNP WDT VBP JJR O
have have 0 0 0 0 0 0 0 0 4 0 NNP WDT VBP JJR IN O
less less 0 0 0 0 0 0 0 0 4 0 WDT VBP JJR IN CD O
than than 0 0 0 0 0 0 0 0 4 0 VBP JJR IN CD NNP O
0.1% 0.1% 0 0 0 0 0 0 0 1 4 0 JJR IN CD NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase IN CD NNP NN -NONE- O
phase phase 0 0 0 0 0 0 0 0 5 0 CD NNP NN -NONE- DT O
cells, cells, 0 0 0 0 1 0 0 0 6 0 NNP NN -NONE- DT CD O
all all 0 0 0 0 0 0 0 0 3 0 NN -NONE- DT CD NNS O
five five 0 0 0 0 0 0 0 0 4 0 -NONE- DT CD NNS VBP O
histones histones 0 0 0 0 0 0 0 0 8 0 DT CD NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 CD NNS VBP VBN CC O
synthesized synthesized 0 0 0 0 0 0 0 0 11 0 NNS VBP VBN CC VBP O
and and 0 0 0 0 0 0 0 0 3 0 VBP VBN CC VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 VBN CC VBP VBN IN O
incorporated incorporated 0 0 0 0 0 0 0 0 12 0 CC VBP VBN IN NN O
into into 0 0 0 0 0 0 0 0 4 0 VBP VBN IN NN IN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 VBN IN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NNP O
equimolar equimolar 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNP NNP O
amounts. amounts. 0 0 0 0 0 0 0 0 8 0 IN JJ NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NNP VBZ O
G0 G0 1 1 0 0 0 0 0 1 2 0 NNP NNP NNP VBZ NN B_TIMEXCCP
lymphocytes lymphocytes 0 0 0 0 0 0 0 0 11 0 NNP NNP VBZ NN NN O
histone histone 0 0 0 0 0 0 0 0 7 0 NNP VBZ NN NN NNS O
synthesis synthesis 0 0 0 0 0 0 0 0 9 0 VBZ NN NN NNS IN O
accounts accounts 0 0 0 0 0 0 0 0 8 0 NN NN NNS IN IN O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN IN JJS O
at at 0 0 0 0 0 0 0 0 2 0 NNS IN IN JJS CD O
least least 0 0 0 0 0 0 0 0 5 0 IN IN JJS CD IN O
6% 6% 0 0 0 0 0 0 0 1 2 0 IN JJS CD IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJS CD IN JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 CD IN JJ NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 IN JJ NN NN CC O
radioactivity, radioactivity, 0 0 0 0 1 0 0 0 14 0 JJ NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 CC DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN VBZ O
synthesis synthesis 0 0 0 0 0 0 0 0 9 0 NN IN NN VBZ IN O
is is 0 0 0 0 0 0 0 0 2 0 IN NN VBZ IN CD O
about about 0 0 0 0 0 0 0 0 5 0 NN VBZ IN CD IN O
2-3% 2-3% 0 0 1 0 0 0 0 1 4 0 VBZ IN CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN CD IN DT IN O
that that 0 0 0 0 0 0 0 0 4 0 CD IN DT IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN DT IN NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase DT IN NNP NN NNP B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN NNP NN NNP NNP O
lymphocytes. lymphocytes. 0 0 0 0 0 0 0 0 12 0 NNP NN NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NN TO O
contrast contrast 0 0 0 0 0 0 0 0 8 0 NNP NNP NN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO NN NN O
histone histone 0 0 0 0 0 0 0 0 7 0 NN TO NN NN IN O
synthesis synthesis 0 0 0 0 0 0 0 0 9 0 TO NN NN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase NN IN NNP NN -NONE- B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN NNP NN -NONE- NNP O
cultures, cultures, 0 0 0 0 1 0 0 0 9 0 NNP NN -NONE- NNP CC O
G0 G0 1 1 0 0 0 0 0 1 2 0 NN -NONE- NNP CC NNP B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NNP CC NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 0 NNP CC NNP NN NN B_TIMEXCCP
histone histone 0 0 0 0 0 0 0 0 7 0 CC NNP NN NN VBD O
synthesis synthesis 0 0 0 0 0 0 0 0 9 0 NNP NN NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD RB JJ O
completely completely 0 0 0 0 0 0 0 0 10 0 NN VBD RB JJ TO O
resistant resistant 0 0 0 0 0 0 0 0 9 0 VBD RB JJ TO NN O
to to 0 0 0 0 0 0 0 0 2 0 RB JJ TO NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 JJ TO NN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 TO NN IN NNP NNP O
hydroxyurea. hydroxyurea. 0 0 0 0 0 0 0 0 12 0 NN IN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 IN NNP NNP CD JJ O
6849885 6849885 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Reappraisal Reappraisal 1 0 0 0 0 0 0 0 11 0 NONE NONE NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NONE NNP IN JJ NN O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 arrest NNP IN JJ NN CC B_TIMEXCCP
arrest arrest 0 0 0 0 0 0 0 0 6 0 IN JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN IN O
synchronization synchronization 0 0 0 0 0 0 0 0 15 0 NN CC NN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NNP O
lovastatin. lovastatin. 0 0 0 0 0 0 0 0 11 0 NN IN NNP NNP NNP O
Cooper Cooper 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
S. S. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Microbiology Microbiology 1 0 0 0 0 0 0 0 12 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Immunology, Immunology, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Michigan Michigan 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
School, School, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Ann Ann 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Arbor, Arbor, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP CD O
MI MI 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
48109-0620, 48109-0620, 0 0 1 0 1 0 0 1 11 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
cooper@umich.edu cooper@umich.edu 0 0 0 0 0 0 0 0 16 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP NNP VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBN VBN IN O
proposed proposed 0 0 0 0 0 0 0 0 8 0 VBZ VBN VBN IN NN O
that that 0 0 0 0 0 0 0 0 4 0 VBN VBN IN NN NNS O
lovastatin lovastatin 0 0 0 0 0 0 0 0 10 arrests VBN IN NN NNS NNS O
arrests arrests 0 0 0 0 0 0 0 0 7 0 IN NN NNS NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NNS NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNS NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 IN DT NN IN DT B_TIMEXCCP
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
division division 0 0 0 0 0 0 0 0 8 0 IN DT NN NN CC O
cycle, cycle, 0 0 0 0 1 0 0 0 6 0 DT NN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NN CC IN NN IN O
release release 0 0 0 0 0 0 0 0 7 0 CC IN NN IN NN O
from from 0 0 0 0 0 0 0 0 4 0 IN NN IN NN NN O
lovastatin lovastatin 0 0 0 0 0 0 0 0 10 0 NN IN NN NN NNS O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 IN NN NN NNS DT O
produces produces 0 0 0 0 0 0 0 0 8 0 NN NN NNS DT VBN O
a a 0 0 0 0 0 0 0 0 1 0 NN NNS DT VBN NNP O
synchronized synchronized 0 0 0 0 0 0 0 0 12 0 NNS DT VBN NNP NNP O
culture. culture. 0 0 0 0 0 0 0 0 8 0 DT VBN NNP NNP JJ O
A A 1 1 0 0 0 0 0 0 1 0 VBN NNP NNP JJ NN O
new new 0 0 0 0 0 0 0 0 3 0 NNP NNP JJ NN IN O
method method 0 0 0 0 0 0 0 0 6 0 NNP JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN JJ O
methocel methocel 0 0 0 0 0 0 0 0 8 0 NN IN NN JJ VBZ O
time-lapse-videography time-lapse-videography 0 0 1 0 0 0 0 0 22 0 IN NN JJ VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NN JJ VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 JJ VBZ VBN VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 VBZ VBN VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO VB NN O
analyse analyse 0 0 0 0 0 0 0 0 7 0 VBN TO VB NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 TO VB NN NN NNS O
division division 0 0 0 0 0 0 0 0 8 0 VB NN NN NNS VBG O
patterns patterns 0 0 0 0 0 0 0 0 8 0 NN NN NNS VBG NN O
following following 0 0 0 0 0 0 0 0 9 0 NN NNS VBG NN NNP O
lovastatin lovastatin 0 0 0 0 0 0 0 0 10 0 NNS VBG NN NNP NNP O
treatment. treatment. 0 0 0 0 0 0 0 0 10 0 VBG NN NNP NNP IN O
Release Release 1 0 0 0 0 0 0 0 7 0 NN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNS O
L1210 L1210 1 1 0 0 0 0 0 1 5 0 NNP IN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS IN NN O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNS IN NN NN O
lovastatin lovastatin 0 0 0 0 0 0 0 0 10 0 NNS IN NN NN VBD O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 IN NN NN VBD TO O
failed failed 0 0 0 0 0 0 0 0 6 0 NN NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB VBN O
produce produce 0 0 0 0 0 0 0 0 7 0 VBD TO VB VBN NNP O
synchronized synchronized 0 0 0 0 0 0 0 0 12 0 TO VB VBN NNP NNP O
divisions. divisions. 0 0 0 0 0 0 0 0 10 0 VB VBN NNP NNP NN O
Moreover, Moreover, 1 0 0 0 1 0 0 0 9 0 VBN NNP NNP NN TO O
contrary contrary 0 0 0 0 0 0 0 0 8 0 NNP NNP NN TO JJR O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO JJR JJ O
earlier earlier 0 0 0 0 0 0 0 0 7 0 NN TO JJR JJ NN O
proposals, proposals, 0 0 0 0 1 0 0 0 10 0 TO JJR JJ NN VBD O
lovastatin lovastatin 0 0 0 0 0 0 0 0 10 0 JJR JJ NN VBD RB O
did did 0 0 0 0 0 0 0 0 3 0 JJ NN VBD RB VB O
not not 0 0 0 0 0 0 0 0 3 arrest NN VBD RB VB NNS O
arrest arrest 0 0 0 0 0 0 0 0 6 0 VBD RB VB NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 RB VB NNS IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VB NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ NN O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 IN DT JJ NN IN B_TIMEXCCP
amount amount 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
DNA. DNA. 1 1 0 0 0 0 0 0 4 0 NN IN NNP NNP IN O
Analysis Analysis 1 0 0 0 0 0 0 0 8 0 IN NNP NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ NNS O
previous previous 0 0 0 0 0 0 0 0 8 0 NNP IN JJ NNS IN O
reports reports 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP CC O
'synchronization' 'synchronization' 0 0 0 0 0 1 0 0 17 0 NNS IN NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC JJ NN O
growth-arrest growth-arrest 0 0 1 0 0 0 0 0 13 0 NNP CC JJ NN DT O
support support 0 0 0 0 0 0 0 0 7 0 CC JJ NN DT NNP O
these these 0 0 0 0 0 0 0 0 5 0 JJ NN DT NNP NNP O
findings. findings. 0 0 0 0 0 0 0 0 9 0 NN DT NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 DT NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
concluded concluded 0 0 0 0 0 0 0 0 9 0 NNP VBZ VBN IN NN O
that that 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN NN DT O
lovastatin lovastatin 0 0 0 0 0 0 0 0 10 0 VBN IN NN DT NNS O
neither neither 0 0 0 0 0 0 0 0 7 0 IN NN DT NNS -NONE- O
synchronizes synchronizes 0 0 0 0 0 0 0 0 12 0 NN DT NNS -NONE- CC O
cells, cells, 0 0 0 0 1 0 0 0 6 0 DT NNS -NONE- CC NNS O
nor nor 0 0 0 0 0 0 0 0 3 arrests NNS -NONE- CC NNS NNS O
arrests arrests 0 0 0 0 0 0 0 0 7 0 -NONE- CC NNS NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 CC NNS NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNS NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 IN DT NN IN DT B_TIMEXCCP
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
division division 0 0 0 0 0 0 0 0 8 0 IN DT NN NNP NNP O
cycle. cycle. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP CD O
Copyright Copyright 1 0 0 0 0 0 0 0 9 0 NN NNP NNP CD NNP O
2002 2002 0 0 0 0 0 0 1 1 4 0 NNP NNP CD NNP NNP O
Elsevier Elsevier 1 0 0 0 0 0 0 0 8 0 NNP CD NNP NNP NNP O
Science Science 1 0 0 0 0 0 0 0 7 0 CD NNP NNP NNP NNP O
Ltd. Ltd. 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNP NNP NNP CD JJ O
12175675 12175675 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
E2F4 E2F4 1 1 0 0 0 0 0 1 4 0 NONE NONE NNP NN IN O
function function 0 0 0 0 0 0 0 0 8 0 NONE NNP NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NN O
G2: G2: 1 1 0 0 0 0 0 1 3 0 NN IN NNP NN JJS B_TIMEXCCP
maintaining maintaining 0 0 0 0 0 0 0 0 11 0 IN NNP NN JJS TO O
G2-arrest G2-arrest 1 0 1 0 0 0 0 1 9 0 NNP NN JJS TO VB B_TIMEXCCP
to to 0 0 0 0 0 0 0 0 2 0 NN JJS TO VB JJ O
prevent prevent 0 0 0 0 0 0 0 0 7 0 JJS TO VB JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 TO VB JJ NN IN O
entry entry 0 0 0 0 0 0 0 0 5 0 VB JJ NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN JJ NNP O
damaged damaged 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNP NNP O
DNA. DNA. 1 1 0 0 0 0 0 0 4 0 IN JJ NNP NNP NNP O
Plesca Plesca 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Crosby Crosby 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
ME, ME, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Gupta Gupta 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Almasan Almasan 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
A. A. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Lerner Lerner 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Institute, Institute, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Cleveland, Cleveland, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP CD O
Ohio Ohio 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP CD NNP O
44195, 44195, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP VBZ O
Mammalian Mammalian 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP VBZ NN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ NN NN O
undergo undergo 0 0 0 0 0 0 0 0 7 0 NNP VBZ NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBZ NN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest NN NN NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN TO O
response response 0 0 0 0 0 0 0 0 8 0 NN IN NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN TO NNP NN IN O
damage damage 0 0 0 0 0 0 0 0 6 0 TO NNP NN IN NN O
through through 0 0 0 0 0 0 0 0 7 0 NNP NN IN NN NN O
multiple multiple 0 0 0 0 0 0 0 0 8 0 NN IN NN NN NNP O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 IN NN NN NNP CD B_TIMEXCCP
mechanisms. mechanisms. 0 0 0 0 0 0 0 0 11 0 NN NN NNP CD JJ O
One One 1 0 0 0 0 0 0 0 3 0 NN NNP CD JJ NN O
such such 0 0 0 0 0 0 0 0 4 0 NNP CD JJ NN NN O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 CD JJ NN NN VBZ O
pathway pathway 0 0 0 0 0 0 0 0 7 0 JJ NN NN VBZ JJ O
maintains maintains 0 0 0 0 0 0 0 0 9 0 NN NN VBZ JJ NN O
genomic genomic 0 0 0 0 0 0 0 0 7 0 NN VBZ JJ NN IN O
integrity integrity 0 0 0 0 0 0 0 0 9 0 VBZ JJ NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN JJ O
delaying delaying 0 0 0 0 0 0 0 0 8 0 NN IN NN JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 IN NN JJ NN IN B_TIMEXCCP
progression progression 0 0 0 0 0 0 0 0 11 0 NN JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN TO O
response response 0 0 0 0 0 0 0 0 8 0 NN IN NN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO JJ NNP O
genotoxic genotoxic 0 0 0 0 0 0 0 0 9 0 NN TO JJ NNP NNP O
stress. stress. 0 0 0 0 0 0 0 0 7 0 TO JJ NNP NNP IN O
Transition Transition 1 0 0 0 0 0 0 0 10 0 JJ NNP NNP IN DT O
though though 0 0 0 0 0 0 0 0 6 0 NNP NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP NN O
G2 G2 1 1 0 0 0 0 0 1 2 phase IN DT NNP NN CC B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN IN O
entry entry 0 0 0 0 0 0 0 0 5 0 NN CC NN IN NN O
into into 0 0 0 0 0 0 0 0 4 0 CC NN IN NN VBZ O
mitosis mitosis 0 0 0 0 0 0 0 0 7 0 NN IN NN VBZ VBN B_TIMEXCCP
is is 0 0 0 0 0 0 0 0 2 0 IN NN VBZ VBN TO O
considered considered 0 0 0 0 0 0 0 0 10 0 NN VBZ VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ VBN TO VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB VBN RB O
regulated regulated 0 0 0 0 0 0 0 0 9 0 TO VB VBN RB IN O
primarily primarily 0 0 0 0 0 0 0 0 9 0 VB VBN RB IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBN RB IN NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 RB IN NN NNP CC O
B1 B1 1 1 0 0 0 0 0 1 2 0 IN NN NNP CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC PRP$ VBN O
its its 0 0 0 0 0 0 0 0 3 0 NNP CC PRP$ VBN RB O
associated associated 0 0 0 0 0 0 0 0 10 0 CC PRP$ VBN RB JJ O
catalytically catalytically 0 0 0 0 0 0 0 0 13 0 PRP$ VBN RB JJ NN O
active active 0 0 0 0 0 0 0 0 6 0 VBN RB JJ NN NNP O
partner partner 0 0 0 0 0 0 0 0 7 0 RB JJ NN NNP NNP O
Cdk1. Cdk1. 1 0 0 0 0 0 0 1 5 0 JJ NN NNP NNP RB O
While While 1 0 0 0 0 0 0 0 5 0 NN NNP NNP RB JJ O
not not 0 0 0 0 0 0 0 0 3 0 NNP NNP RB JJ IN O
necessary necessary 0 0 0 0 0 0 0 0 9 0 NNP RB JJ IN PRP$ O
for for 0 0 0 0 0 0 0 0 3 0 RB JJ IN PRP$ JJ O
its its 0 0 0 0 0 0 0 0 3 0 JJ IN PRP$ JJ DT O
initiation, initiation, 0 0 0 0 1 0 0 0 11 0 IN PRP$ JJ DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 PRP$ JJ DT NNP CC O
p130 p130 0 0 0 0 0 0 0 1 4 0 JJ DT NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC JJ NN O
Rb-dependent Rb-dependent 1 0 1 0 0 0 0 0 12 0 NNP CC JJ NN NNS O
target target 0 0 0 0 0 0 0 0 6 0 CC JJ NN NNS VBP O
genes genes 0 0 0 0 0 0 0 0 5 0 JJ NN NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NN NNS VBP VBN IN O
emerged emerged 0 0 0 0 0 0 0 0 7 0 NNS VBP VBN IN VBG O
as as 0 0 0 0 0 0 0 0 2 0 VBP VBN IN VBG JJ O
being being 0 0 0 0 0 0 0 0 5 0 VBN IN VBG JJ IN O
important important 0 0 0 0 0 0 0 0 9 0 IN VBG JJ IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VBG JJ IN JJ NN O
stable stable 0 0 0 0 0 0 0 0 6 0 JJ IN JJ NN IN O
maintenance maintenance 0 0 0 0 0 0 0 0 11 0 IN JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NNP NNP O
G2 G2 1 1 0 0 0 0 0 1 2 0 IN DT NNP NNP NNP B_TIMEXCCP
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 DT NNP NNP NNP VBD O
It It 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD RB VBN O
recently recently 0 0 0 0 0 0 0 0 8 0 NNP VBD RB VBN IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 VBD RB VBN IN IN O
that that 0 0 0 0 0 0 0 0 4 0 RB VBN IN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBN IN IN NN IN O
interacting interacting 0 0 0 0 0 0 0 0 11 0 IN IN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN JJ NNP O
p130, p130, 0 0 0 0 1 0 0 1 5 0 NN IN JJ NNP VBZ O
E2F4 E2F4 1 1 0 0 0 0 0 1 4 0 IN JJ NNP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 JJ NNP VBZ JJ IN O
present present 0 0 0 0 0 0 0 0 7 0 NNP VBZ JJ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBZ JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN CC O
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 IN DT NN CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC VBZ DT O
plays plays 0 0 0 0 0 0 0 0 5 0 NN CC VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 CC VBZ DT JJ NN O
key key 0 0 0 0 0 0 0 0 3 0 VBZ DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
maintenance maintenance 0 0 0 0 0 0 0 0 11 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN NNP O
stable stable 0 0 0 0 0 0 0 0 6 0 IN DT NN NNP NNP O
G2 G2 1 1 0 0 0 0 0 1 2 0 DT NN NNP NNP NNP B_TIMEXCCP
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 NN NNP NNP NNP NNP O
Increased Increased 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNS O
E2F4 E2F4 1 1 0 0 0 0 0 1 4 0 NNP NNP NNP NNS CC O
levels levels 0 0 0 0 0 0 0 0 6 0 NNP NNP NNS CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNS CC PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NNS CC PRP$ NN TO O
translocation translocation 0 0 0 0 0 0 0 0 13 0 CC PRP$ NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 PRP$ NN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT NN VBG O
nucleus nucleus 0 0 0 0 0 0 0 0 7 0 TO DT NN VBG JJ O
following following 0 0 0 0 0 0 0 0 9 0 DT NN VBG JJ NN O
genotoxic genotoxic 0 0 0 0 0 0 0 0 9 0 NN VBG JJ NN NN O
stress stress 0 0 0 0 0 0 0 0 6 0 VBG JJ NN NN IN O
result result 0 0 0 0 0 0 0 0 6 0 JJ NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN IN O
downregulation downregulation 0 0 0 0 0 0 0 0 14 0 NN IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ JJ O
many many 0 0 0 0 0 0 0 0 4 0 NN IN JJ JJ NNS O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 IN JJ JJ NNS CC B_TIMEXCCP
genes genes 0 0 0 0 0 0 0 0 5 0 JJ JJ NNS CC IN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NNS CC IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 CC IN DT NN NN O
result result 0 0 0 0 0 0 0 0 6 0 IN DT NN NN DT O
promote promote 0 0 0 0 0 0 0 0 7 0 DT NN NN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN NN DT JJ NNP O
G0-like G0-like 1 0 1 0 0 0 0 1 7 0 NN DT JJ NNP NNP B_TIMEXCCP
state. state. 0 0 0 0 0 0 0 0 6 0 DT JJ NNP NNP IN O
Irradiation Irradiation 1 0 0 0 0 0 0 0 11 0 JJ NNP NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ NNS O
E2F4-depleted E2F4-depleted 1 0 1 0 0 0 0 1 13 0 NNP IN JJ NNS NNS O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS NNS TO O
leads leads 0 0 0 0 0 0 0 0 5 0 JJ NNS NNS TO VBN O
to to 0 0 0 0 0 0 0 0 2 0 NNS NNS TO VBN JJ O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 NNS TO VBN JJ NNP O
cellular cellular 0 0 0 0 0 0 0 0 8 0 TO VBN JJ NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 VBN JJ NNP NNP VBZ O
double-strand double-strand 0 0 1 0 0 0 0 0 13 0 JJ NNP NNP VBZ IN O
breaks breaks 0 0 0 0 0 0 0 0 6 0 NNP NNP VBZ IN MD O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBZ IN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 VBZ IN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 IN MD VB VBN IN O
measured measured 0 0 0 0 0 0 0 0 8 0 MD VB VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VB VBN IN NN NNP O
comet comet 0 0 0 0 0 0 0 0 5 0 VBN IN NN NNP NNP O
assays. assays. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NNP RB O
It It 1 0 0 0 0 0 0 0 2 0 NN NNP NNP RB VBZ O
also also 0 0 0 0 0 0 0 0 4 0 NNP NNP RB VBZ IN O
results results 0 0 0 0 0 0 0 0 7 0 NNP RB VBZ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 RB VBZ IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBZ IN NN NN WDT O
death death 0 0 0 0 0 0 0 0 5 0 IN NN NN WDT VBZ O
that that 0 0 0 0 0 0 0 0 4 0 NN NN WDT VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN WDT VBZ VBN IN O
characterized characterized 0 0 0 0 0 0 0 0 13 0 WDT VBZ VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN NN -NONE- O
caspase caspase 0 0 0 0 0 0 0 0 7 0 VBN IN NN -NONE- -NONE- O
activation, activation, 0 0 0 0 1 0 0 0 11 0 IN NN -NONE- -NONE- CC O
sub-G1 sub-G1 0 0 1 0 0 0 0 1 6 0 NN -NONE- -NONE- CC -NONE- B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- CC -NONE- NNP O
sub-G2 sub-G2 0 0 1 0 0 0 0 1 6 0 -NONE- CC -NONE- NNP NNP B_TIMEXCCP
DNA DNA 1 1 0 0 0 0 0 0 3 0 CC -NONE- NNP NNP CC O
content, content, 0 0 0 0 1 0 0 0 8 0 -NONE- NNP NNP CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC VBD JJ O
decreased decreased 0 0 0 0 0 0 0 0 9 0 NNP CC VBD JJ NN O
clonogenic clonogenic 0 0 0 0 0 0 0 0 10 0 CC VBD JJ NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 VBD JJ NN NNP NNP O
survival. survival. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NNP PRP O
Here Here 1 0 0 0 0 0 0 0 4 0 NN NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP DT O
review review 0 0 0 0 0 0 0 0 6 0 NNP PRP VBP DT JJ O
these these 0 0 0 0 0 0 0 0 5 0 PRP VBP DT JJ NNS O
recent recent 0 0 0 0 0 0 0 0 6 0 VBP DT JJ NNS CC O
findings findings 0 0 0 0 0 0 0 0 8 0 DT JJ NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC NNS DT O
discuss discuss 0 0 0 0 0 0 0 0 7 0 NNS CC NNS DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 CC NNS DT NNS IN O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 NNS DT NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NNP NN O
G2 G2 1 1 0 0 0 0 0 1 2 phase NNS IN NNP NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN NNP NN NN NN O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NNP NN NN NN CC B_TIMEXCCP
activation activation 0 0 0 0 0 0 0 0 10 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
maintenance maintenance 0 0 0 0 0 0 0 0 11 0 NN CC NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 CC NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
particular particular 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN IN O
focus focus 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
E2F4. E2F4. 1 1 0 0 0 0 0 1 5 0 NN IN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 IN NNP NNP CD JJ O
17507799 17507799 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NN O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NN NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
PMC2596058 PMC2596058 1 1 0 0 0 0 0 1 10 0 JJ NN NNP NONE NONE O
Interphase Interphase 1 0 0 0 0 0 0 0 10 0 NONE NONE NN NNS IN B_TIMEXCCP
cytogenetics cytogenetics 0 0 0 0 0 0 0 0 12 0 NONE NN NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN CC O
glioblastoma glioblastoma 0 0 0 0 0 0 0 0 12 0 NNS IN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NNP NNP O
gliosarcoma. gliosarcoma. 0 0 0 0 0 0 0 0 12 0 NN CC NNP NNP NNP O
Paulus Paulus 1 0 0 0 0 0 0 0 6 0 CC NNP NNP NNP NNP O
W, W, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Bayas Bayas 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ott Ott 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Roggendorf Roggendorf 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
W. W. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pathology, Pathology, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Würzburg, Würzburg, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Germany. Germany. 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Interphase Interphase 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP B_TIMEXCCP
cytogenetics, cytogenetics, 0 0 0 0 1 0 0 0 13 0 NNP NNP NNP NNP IN O
i.e., i.e., 0 0 0 0 1 0 0 0 5 0 NNP NNP NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN NN O
situ situ 0 0 0 0 0 0 0 0 4 0 NNP IN NN NN VBG O
hybridization hybridization 0 0 0 0 0 0 0 0 13 0 IN NN NN VBG NNS O
using using 0 0 0 0 0 0 0 0 5 0 NN NN VBG NNS TO O
probes probes 0 0 0 0 0 0 0 0 6 0 NN VBG NNS TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 VBG NNS TO JJ NN O
chromosome-specific chromosome-specific 0 0 1 0 0 0 0 0 19 0 NNS TO JJ NN NNS O
DNA, DNA, 1 1 0 0 1 0 0 0 4 0 TO JJ NN NNS JJ O
enables enables 0 0 0 0 0 0 0 0 7 0 JJ NN NNS JJ NN O
histological histological 0 0 0 0 0 0 0 0 12 0 NN NNS JJ NN IN O
identification identification 0 0 0 0 0 0 0 0 14 0 NNS JJ NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS VBG O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS VBG JJ O
bearing bearing 0 0 0 0 0 0 0 0 7 0 IN NNS VBG JJ NN O
numerical numerical 0 0 0 0 0 0 0 0 9 0 NNS VBG JJ NN NNS O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 VBG JJ NN NNS CC O
aberrations aberrations 0 0 0 0 0 0 0 0 11 0 JJ NN NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC JJ NN O
cytogenetic cytogenetic 0 0 0 0 0 0 0 0 11 0 NNS CC JJ NN IN O
analysis analysis 0 0 0 0 0 0 0 0 8 0 CC JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNP O
composite composite 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNP NNP O
tumors. tumors. 0 0 0 0 0 0 0 0 7 0 IN JJ NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP VBD RB O
studied studied 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD RB VBN O
routinely routinely 0 0 0 0 0 0 0 0 9 0 NNP VBD RB VBN NNS O
processed processed 0 0 0 0 0 0 0 0 9 0 VBD RB VBN NNS IN O
tissues tissues 0 0 0 0 0 0 0 0 7 0 RB VBN NNS IN CD O
from from 0 0 0 0 0 0 0 0 4 0 VBN NNS IN CD NNS O
seven seven 0 0 0 0 0 0 0 0 5 0 NNS IN CD NNS CC O
glioblastomas glioblastomas 0 0 0 0 0 0 0 0 13 0 IN CD NNS CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD NNS CC CD NNS O
three three 0 0 0 0 0 0 0 0 5 0 NNS CC CD NNS VBG O
gliosarcomas gliosarcomas 0 0 0 0 0 0 0 0 12 0 CC CD NNS VBG VBN O
using using 0 0 0 0 0 0 0 0 5 0 CD NNS VBG VBN NNS O
biotinylated biotinylated 0 0 0 0 0 0 0 0 12 0 NNS VBG VBN NNS TO O
probes probes 0 0 0 0 0 0 0 0 6 0 VBG VBN NNS TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 VBN NNS TO JJ JJ O
pericentromeric pericentromeric 0 0 0 0 0 0 0 0 15 0 NNS TO JJ JJ NNS O
alpha-satellite alpha-satellite 0 0 1 0 0 0 0 0 15 0 TO JJ JJ NNS IN O
sequences sequences 0 0 0 0 0 0 0 0 9 0 JJ JJ NNS IN NNS O
on on 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNS CD O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 NNS IN NNS CD CD O
10, 10, 0 0 0 0 1 0 0 1 3 0 IN NNS CD CD CC O
17 17 0 0 0 0 0 0 1 1 2 0 NNS CD CD CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 CD CD CC NNP NNP O
X. X. 1 1 0 0 0 0 0 0 2 0 CD CC NNP NNP NN O
By By 1 0 0 0 0 0 0 0 2 0 CC NNP NNP NN JJ O
applying applying 0 0 0 0 0 0 0 0 8 0 NNP NNP NN JJ NN O
various various 0 0 0 0 0 0 0 0 7 0 NNP NN JJ NN NN O
pretreatment pretreatment 0 0 0 0 0 0 0 0 12 0 NN JJ NN NN DT O
protocols, protocols, 0 0 0 0 1 0 0 0 10 0 JJ NN NN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN NN DT JJ NN O
evaluable evaluable 0 0 0 0 0 0 0 0 9 0 NN DT JJ NN IN O
compromise compromise 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN NN O
between between 0 0 0 0 0 0 0 0 7 0 JJ NN IN NN CC O
morphology morphology 0 0 0 0 0 0 0 0 10 0 NN IN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC JJ NN O
signal signal 0 0 0 0 0 0 0 0 6 0 NN CC JJ NN VBD O
intensity intensity 0 0 0 0 0 0 0 0 9 0 CC JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN IN O
obtained obtained 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN JJS O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJS NNP O
most most 0 0 0 0 0 0 0 0 4 0 VBN IN JJS NNP NNP O
cases. cases. 0 0 0 0 0 0 0 0 6 0 IN JJS NNP NNP TO O
Compared Compared 1 0 0 0 0 0 0 0 8 0 JJS NNP NNP TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNP NNP TO VB NNS O
vascular vascular 0 0 0 0 0 0 0 0 8 0 NNP TO VB NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 TO VB NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VB NNS IN JJ JJ O
normal normal 0 0 0 0 0 0 0 0 6 0 NNS IN JJ JJ NN O
chromosomal chromosomal 0 0 0 0 0 0 0 0 11 0 IN JJ JJ NN DT O
counts, counts, 0 0 0 0 1 0 0 0 7 0 JJ JJ NN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 JJ NN DT JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 NN DT JJ NN IN O
subpopulation subpopulation 0 0 0 0 0 0 0 0 13 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNS O
glioblastoma glioblastoma 0 0 0 0 0 0 0 0 12 0 NN IN NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NN NNS VBD NN O
showed showed 0 0 0 0 0 0 0 0 6 0 NN NNS VBD NN CD O
monosomy monosomy 0 0 0 0 0 0 0 0 8 0 NNS VBD NN CD JJ O
10 10 0 0 0 0 0 0 1 1 2 0 VBD NN CD JJ IN O
(four (four 0 0 0 0 0 0 0 0 5 0 NN CD JJ IN CD O
of of 0 0 0 0 0 0 0 0 2 0 CD JJ IN CD JJ O
five five 0 0 0 0 0 0 0 0 4 0 JJ IN CD JJ NN O
cases), cases), 0 0 0 0 1 0 0 0 7 0 IN CD JJ NN CD O
monosomy monosomy 0 0 0 0 0 0 0 0 8 0 CD JJ NN CD NN O
17 17 0 0 0 0 0 0 1 1 2 0 JJ NN CD NN IN O
(one (one 0 0 0 0 0 0 0 0 4 0 NN CD NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN CD NN O
seven seven 0 0 0 0 0 0 0 0 5 0 NN IN CD NN CC O
cases) cases) 0 0 0 0 0 0 0 0 6 0 IN CD NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 CD NN CC NN IN O
loss loss 0 0 0 0 0 0 0 0 4 0 NN CC NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN CD NNP O
one one 0 0 0 0 0 0 0 0 3 0 NN IN CD NNP NN O
X X 1 1 0 0 0 0 0 0 1 0 IN CD NNP NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 CD NNP NN NN IN O
(one (one 0 0 0 0 0 0 0 0 4 0 NNP NN NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN CD NNP O
seven seven 0 0 0 0 0 0 0 0 5 0 NN IN CD NNP NNP O
cases). cases). 0 0 0 0 0 0 0 0 7 0 IN CD NNP NNP NN O
All All 1 0 0 0 0 0 0 0 3 0 CD NNP NNP NN CD O
monosomy monosomy 0 0 0 0 0 0 0 0 8 0 NNP NNP NN CD NNS O
10 10 0 0 0 0 0 0 1 1 2 0 NNP NN CD NNS VBN O
cases cases 0 0 0 0 0 0 0 0 5 0 NN CD NNS VBN JJ O
comprised comprised 0 0 0 0 0 0 0 0 9 0 CD NNS VBN JJ NNS O
additional additional 0 0 0 0 0 0 0 0 10 0 NNS VBN JJ NNS WRB O
areas areas 0 0 0 0 0 0 0 0 5 0 VBN JJ NNS WRB CD O
where where 0 0 0 0 0 0 0 0 5 0 JJ NNS WRB CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 NNS WRB CD NNS IN O
copies copies 0 0 0 0 0 0 0 0 6 0 WRB CD NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN NN CD O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NNS IN NN CD VBD O
10 10 0 0 0 0 0 0 1 1 2 0 IN NN CD VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 NN CD VBD NNP NNP O
retained. retained. 0 0 0 0 0 0 0 0 9 0 CD VBD NNP NNP DT O
Among Among 1 0 0 0 0 0 0 0 5 0 VBD NNP NNP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNP DT O
gliosarcomas, gliosarcomas, 0 0 0 0 1 0 0 0 13 0 NNP DT NNP DT DT O
both both 0 0 0 0 0 0 0 0 4 0 DT NNP DT DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP DT DT NN CC O
glioma glioma 0 0 0 0 0 0 0 0 6 0 DT DT NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN NN O
sarcoma sarcoma 0 0 0 0 0 0 0 0 7 0 CC DT NN NN VBD O
portion portion 0 0 0 0 0 0 0 0 7 0 DT NN NN VBD NN O
showed showed 0 0 0 0 0 0 0 0 6 0 NN NN VBD NN CD O
monosomy monosomy 0 0 0 0 0 0 0 0 8 0 NN VBD NN CD IN O
10 10 0 0 0 0 0 0 1 1 2 0 VBD NN CD IN CD O
in in 0 0 0 0 0 0 0 0 2 0 NN CD IN CD NN O
one one 0 0 0 0 0 0 0 0 3 0 CD IN CD NN CC O
case case 0 0 0 0 0 0 0 0 4 0 IN CD NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 CD NN CC NN CD O
monosomy monosomy 0 0 0 0 0 0 0 0 8 0 NN CC NN CD IN O
17 17 0 0 0 0 0 0 1 1 2 0 CC NN CD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN CD IN DT NNP O
another another 0 0 0 0 0 0 0 0 7 0 CD IN DT NNP NNP O
case. case. 0 0 0 0 0 0 0 0 5 0 IN DT NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 DT NNP NNP NNP IN O
contrast, contrast, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ NN O
third third 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN IN O
case case 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
gliosarcoma, gliosarcoma, 0 0 0 0 1 0 0 0 12 0 NN IN NNP NN CD O
monosomy monosomy 0 0 0 0 0 0 0 0 8 0 IN NNP NN CD VBD O
10 10 0 0 0 0 0 0 1 1 2 0 NNP NN CD VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN CD VBD VBN RB O
found found 0 0 0 0 0 0 0 0 5 0 CD VBD VBN RB IN O
only only 0 0 0 0 0 0 0 0 4 0 VBD VBN RB IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBN RB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NN NN O
glioma glioma 0 0 0 0 0 0 0 0 6 0 IN DT NN NN NNS O
portion, portion, 0 0 0 0 1 0 0 0 8 0 DT NN NN NNS DT O
whereas whereas 0 0 0 0 0 0 0 0 7 0 NN NN NNS DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN NNS DT NN IN O
gain gain 0 0 0 0 0 0 0 0 4 0 NNS DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNP O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NN IN NN NNP VBD O
X X 1 1 0 0 0 0 0 0 1 0 IN NN NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NNP VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NNP O
sarcoma sarcoma 0 0 0 0 0 0 0 0 7 0 IN DT NN NNP NNP O
portion. portion. 0 0 0 0 0 0 0 0 8 0 DT NN NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBP -NONE- O
conclude conclude 0 0 0 0 0 0 0 0 8 0 NNP NNP VBP -NONE- -NONE- O
that: that: 0 0 0 0 0 0 0 0 5 0 NNP VBP -NONE- -NONE- JJ O
(1) (1) 0 0 0 0 0 0 0 1 3 0 VBP -NONE- -NONE- JJ NN O
numerical numerical 0 0 0 0 0 0 0 0 9 0 -NONE- -NONE- JJ NN NNS O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 -NONE- JJ NN NNS MD O
aberrations aberrations 0 0 0 0 0 0 0 0 11 0 JJ NN NNS MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN NNS MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB VBN IN O
detected detected 0 0 0 0 0 0 0 0 8 0 MD VB VBN IN RB O
in in 0 0 0 0 0 0 0 0 2 0 VB VBN IN RB VBN O
routinely routinely 0 0 0 0 0 0 0 0 9 0 VBN IN RB VBN NN O
processed processed 0 0 0 0 0 0 0 0 9 0 IN RB VBN NN NN O
brain brain 0 0 0 0 0 0 0 0 5 0 RB VBN NN NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 VBN NN NN NN NNS O
biopsy biopsy 0 0 0 0 0 0 0 0 6 0 NN NN NN NNS VBG O
specimens specimens 0 0 0 0 0 0 0 0 9 0 NN NN NNS VBG NN O
using using 0 0 0 0 0 0 0 0 5 0 NN NNS VBG NN -NONE- O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NNS VBG NN -NONE- VBG B_TIMEXCCP
cytogenetics, cytogenetics, 0 0 0 0 1 0 0 0 13 0 VBG NN -NONE- VBG JJ O
making making 0 0 0 0 0 0 0 0 6 0 NN -NONE- VBG JJ NNS O
retrospective retrospective 0 0 0 0 0 0 0 0 13 0 -NONE- VBG JJ NNS -NONE- O
studies studies 0 0 0 0 0 0 0 0 7 0 VBG JJ NNS -NONE- -NONE- O
feasible; feasible; 0 0 0 0 0 0 0 0 9 0 JJ NNS -NONE- -NONE- VBZ O
(2) (2) 0 0 0 0 0 0 0 1 3 0 NNS -NONE- -NONE- VBZ NN O
glioblastomas glioblastomas 0 0 0 0 0 0 0 0 13 0 -NONE- -NONE- VBZ NN JJ O
show show 0 0 0 0 0 0 0 0 4 0 -NONE- VBZ NN JJ JJ O
intratumoral intratumoral 0 0 0 0 0 0 0 0 12 0 VBZ NN JJ JJ NN O
cytogenetic cytogenetic 0 0 0 0 0 0 0 0 11 0 NN JJ JJ NN IN O
heterogeneity heterogeneity 0 0 0 0 0 0 0 0 13 0 JJ JJ NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN NN IN O
formation formation 0 0 0 0 0 0 0 0 9 0 NN IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NN O
monoclonal monoclonal 0 0 0 0 0 0 0 0 10 0 NN IN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN CC O
clusters; clusters; 0 0 0 0 0 0 0 0 9 0 JJ NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NN O
(3) (3) 0 0 0 0 0 0 0 1 3 0 NN CC NNP NN CC O
sarcoma sarcoma 0 0 0 0 0 0 0 0 7 0 CC NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN NNS O
glioma glioma 0 0 0 0 0 0 0 0 6 0 NN CC NN NNS IN O
elements elements 0 0 0 0 0 0 0 0 8 0 CC NN NNS IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNS MD O
gliosarcomas gliosarcomas 0 0 0 0 0 0 0 0 12 0 NNS IN NNS MD VB O
may may 0 0 0 0 0 0 0 0 3 0 IN NNS MD VB DT O
exhibit exhibit 0 0 0 0 0 0 0 0 7 0 NNS MD VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT JJ CC O
same same 0 0 0 0 0 0 0 0 4 0 VB DT JJ CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 DT JJ CC JJ JJ O
different different 0 0 0 0 0 0 0 0 9 0 JJ CC JJ JJ NN O
numerical numerical 0 0 0 0 0 0 0 0 9 0 CC JJ JJ NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 JJ JJ NN NN VBG O
aberrations, aberrations, 0 0 0 0 1 0 0 0 12 0 JJ NN NN VBG JJ O
suggesting suggesting 0 0 0 0 0 0 0 0 10 0 NN NN VBG JJ JJ O
various various 0 0 0 0 0 0 0 0 7 0 NN VBG JJ JJ NNS O
histogenetic histogenetic 0 0 0 0 0 0 0 0 12 0 VBG JJ JJ NNS IN O
pathways pathways 0 0 0 0 0 0 0 0 8 0 JJ JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NNP O
sarcoma-like sarcoma-like 0 0 1 0 0 0 0 0 12 0 IN DT JJ NNP NNP O
portion. portion. 0 0 0 0 0 0 0 0 8 0 DT JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
7847070 7847070 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Pulsatory Pulsatory 1 0 0 0 0 0 0 0 9 0 NONE NONE NNP NN IN O
motor motor 0 0 0 0 0 0 0 0 5 0 NONE NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NNP O
mitosis. mitosis. 0 0 0 0 0 0 0 0 8 0 NN IN NNP NNP NNP B_TIMEXCCP
McLardy McLardy 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
T. T. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP JJ NN O
basic basic 0 0 0 0 0 0 0 0 5 0 NNP NNP JJ NN NN O
building building 0 0 0 0 0 0 0 0 8 0 NNP JJ NN NN IN O
block block 0 0 0 0 0 0 0 0 5 0 JJ NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN VBZ O
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 IN NN NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ VBN TO O
postulated postulated 0 0 0 0 0 0 0 0 10 0 NN VBZ VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ VBN TO VB DT O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT NN VBG O
macromolecule macromolecule 0 0 0 0 0 0 0 0 13 0 VB DT NN VBG IN O
consisting consisting 0 0 0 0 0 0 0 0 10 0 DT NN VBG IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN VBG IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 VBG IN DT NN IN O
exon exon 0 0 0 0 0 0 0 0 4 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP VBD O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN IN NNP VBD RB O
linked linked 0 0 0 0 0 0 0 0 6 0 IN NNP VBD RB IN O
laterally laterally 0 0 0 0 0 0 0 0 9 0 NNP VBD RB IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBD RB IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 RB IN DT NN WP$ O
polypeptide polypeptide 0 0 0 0 0 0 0 0 11 0 IN DT NN WP$ JJ O
whose whose 0 0 0 0 0 0 0 0 5 0 DT NN WP$ JJ NNP O
DNA-distalmost DNA-distalmost 1 0 1 0 0 0 0 0 14 0 NN WP$ JJ NNP JJ O
NH2 NH2 1 1 0 0 0 0 0 1 3 0 WP$ JJ NNP JJ VBZ O
radical radical 0 0 0 0 0 0 0 0 7 0 JJ NNP JJ VBZ IN O
is is 0 0 0 0 0 0 0 0 2 0 NNP JJ VBZ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ VBZ IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 VBZ IN DT JJ NN O
electronic electronic 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN NN O
pulsatory pulsatory 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN WDT O
state state 0 0 0 0 0 0 0 0 5 0 JJ NN NN WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBZ DT O
constitutes constitutes 0 0 0 0 0 0 0 0 11 0 NN WDT VBZ DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 WDT VBZ DT NNP NNP O
centriole. centriole. 0 0 0 0 0 0 0 0 10 0 VBZ DT NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 DT NNP NNP NN NN O
pulsating pulsating 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NN NNS O
centriole centriole 0 0 0 0 0 0 0 0 9 0 NNP NN NN NNS VBG O
impresses impresses 0 0 0 0 0 0 0 0 9 0 NN NN NNS VBG NN O
oscillating oscillating 0 0 0 0 0 0 0 0 11 0 NN NNS VBG NN IN O
excitation excitation 0 0 0 0 0 0 0 0 10 0 NNS VBG NN IN DT O
along along 0 0 0 0 0 0 0 0 5 0 VBG NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN TO O
polypeptide polypeptide 0 0 0 0 0 0 0 0 11 0 IN DT NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 TO DT NNP NN DT O
rendering rendering 0 0 0 0 0 0 0 0 9 0 DT NNP NN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT NNP RB O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN DT NNP RB JJ O
partially partially 0 0 0 0 0 0 0 0 9 0 DT NNP RB JJ IN O
oxidative oxidative 0 0 0 0 0 0 0 0 9 0 NNP RB JJ IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 RB JJ IN NNS IN O
substances substances 0 0 0 0 0 0 0 0 10 0 JJ IN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NNP O
fluid fluid 0 0 0 0 0 0 0 0 5 0 IN DT NN NNP NNP O
environment. environment. 0 0 0 0 0 0 0 0 12 0 DT NN NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NN VBZ O
oxidation oxidation 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBZ DT O
activates activates 0 0 0 0 0 0 0 0 9 0 NNP NN VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT JJ NN O
second second 0 0 0 0 0 0 0 0 6 0 VBZ DT JJ NN IN O
type type 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN VBG NN O
oscillating oscillating 0 0 0 0 0 0 0 0 11 0 NN IN VBG NN NN O
excitation excitation 0 0 0 0 0 0 0 0 10 0 IN VBG NN NN IN O
distad distad 0 0 0 0 0 0 0 0 6 0 VBG NN NN IN DT O
along along 0 0 0 0 0 0 0 0 5 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBG O
polypeptide, polypeptide, 0 0 0 0 1 0 0 0 12 0 IN DT NN VBG DT O
keeping keeping 0 0 0 0 0 0 0 0 7 0 DT NN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT NN IN O
centriole centriole 0 0 0 0 0 0 0 0 9 0 VBG DT NN IN PRP$ O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NN IN PRP$ NN NNP O
pulsatory pulsatory 0 0 0 0 0 0 0 0 9 0 IN PRP$ NN NNP NNP O
state. state. 0 0 0 0 0 0 0 0 6 0 PRP$ NN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNP NN O
exon-polypeptide-centriole exon-polypeptide-centriole 0 0 1 0 0 0 0 0 26 0 NNP NNP NNP NN -NONE- O
macromolecule macromolecule 0 0 0 0 0 0 0 0 13 0 NNP NNP NN -NONE- IN O
is, is, 0 0 0 0 1 0 0 0 3 0 NNP NN -NONE- IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN -NONE- IN NNP IN O
brief, brief, 0 0 0 0 1 0 0 0 6 0 -NONE- IN NNP IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN JJ NN O
unique unique 0 0 0 0 0 0 0 0 6 0 NNP IN JJ NN NN O
inter-end-dependent inter-end-dependent 0 0 1 0 0 0 0 0 19 0 IN JJ NN NN JJ O
steadystate steadystate 0 0 0 0 0 0 0 0 11 0 JJ NN NN JJ NNP O
dynamic dynamic 0 0 0 0 0 0 0 0 7 0 NN NN JJ NNP NNP O
equilibrium. equilibrium. 0 0 0 0 0 0 0 0 12 0 NN JJ NNP NNP IN O
Replication Replication 1 0 0 0 0 0 0 0 11 0 JJ NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN CC O
exon exon 0 0 0 0 0 0 0 0 4 0 IN DT NN CC RB O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC RB DT O
then then 0 0 0 0 0 0 0 0 4 0 NN CC RB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC RB DT NN NNS O
polypeptide polypeptide 0 0 0 0 0 0 0 0 11 0 RB DT NN NNS IN O
occurs occurs 0 0 0 0 0 0 0 0 6 0 DT NN NNS IN NN O
through through 0 0 0 0 0 0 0 0 7 0 NN NNS IN NN -NONE- O
oscillatory oscillatory 0 0 0 0 0 0 0 0 11 0 NNS IN NN -NONE- -NONE- O
resonance-attraction, resonance-attraction, 0 0 1 0 1 0 0 0 21 0 IN NN -NONE- -NONE- IN O
seriatim, seriatim, 0 0 0 0 1 0 0 0 9 0 NN -NONE- -NONE- IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 -NONE- -NONE- IN JJ NNS O
identical identical 0 0 0 0 0 0 0 0 9 0 -NONE- IN JJ NNS IN O
sub-entities sub-entities 0 0 1 0 0 0 0 0 12 0 IN JJ NNS IN DT O
from from 0 0 0 0 0 0 0 0 4 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NNP O
fluid fluid 0 0 0 0 0 0 0 0 5 0 IN DT NN NNP NNP O
environment. environment. 0 0 0 0 0 0 0 0 12 0 DT NN NNP NNP NN O
Final Final 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NN IN O
duplication duplication 0 0 0 0 0 0 0 0 11 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNS O
centriole centriole 0 0 0 0 0 0 0 0 9 0 IN DT NN NNS IN O
occurs occurs 0 0 0 0 0 0 0 0 6 0 DT NN NNS IN NN O
through through 0 0 0 0 0 0 0 0 7 0 NN NNS IN NN NN O
pulsatory pulsatory 0 0 0 0 0 0 0 0 9 0 NNS IN NN NN VBG O
resonance-induction resonance-induction 0 0 1 0 0 0 0 0 19 0 IN NN NN VBG IN O
acting acting 0 0 0 0 0 0 0 0 6 0 NN NN VBG IN DT O
upon upon 0 0 0 0 0 0 0 0 4 0 NN VBG IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBG IN DT NN VBZ O
daughter daughter 0 0 0 0 0 0 0 0 8 0 IN DT NN VBZ JJ O
polypeptide's polypeptide's 0 0 0 0 0 1 0 0 13 0 DT NN VBZ JJ NNP O
terminal terminal 0 0 0 0 0 0 0 0 8 0 NN VBZ JJ NNP NNP O
NH2. NH2. 1 1 0 0 0 0 0 1 4 0 VBZ JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN NN O
resultant resultant 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NN NN O
daughter daughter 0 0 0 0 0 0 0 0 8 0 NNP NN NN NN NN O
centriole centriole 0 0 0 0 0 0 0 0 9 0 NN NN NN NN NN O
is, is, 0 0 0 0 1 0 0 0 3 0 NN NN NN NN IN O
however, however, 0 0 0 0 1 0 0 0 8 0 NN NN NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN CD NNS O
180 180 0 0 0 0 0 0 1 1 3 0 NN IN CD NNS JJ O
degrees degrees 0 0 0 0 0 0 0 0 7 0 IN CD NNS JJ NN O
opposite opposite 0 0 0 0 0 0 0 0 8 0 CD NNS JJ NN NNP O
pulsatory pulsatory 0 0 0 0 0 0 0 0 9 0 NNS JJ NN NNP NN O
phase. phase. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NN NNS O
Opposite-phase Opposite-phase 1 0 1 0 0 0 0 0 14 0 NN NNP NN NNS VBP O
pulsators pulsators 0 0 0 0 0 0 0 0 9 0 NNP NN NNS VBP JJ O
repel repel 0 0 0 0 0 0 0 0 5 0 NN NNS VBP JJ NN O
one-another; one-another; 0 0 1 0 0 0 0 0 12 0 NNS VBP JJ NN NNS O
like-phase like-phase 0 0 1 0 0 0 0 0 10 0 VBP JJ NN NNS VBP O
pulsators pulsators 0 0 0 0 0 0 0 0 9 0 JJ NN NNS VBP NNP O
attract attract 0 0 0 0 0 0 0 0 7 0 NN NNS VBP NNP NNP O
one-another. one-another. 0 0 1 0 0 0 0 0 12 0 NNS VBP NNP NNP VBD O
These These 1 0 0 0 0 0 0 0 5 0 VBP NNP NNP VBD NNP O
postulated postulated 0 0 0 0 0 0 0 0 10 0 NNP NNP VBD NNP CC O
pulsator, pulsator, 0 0 0 0 1 0 0 0 9 0 NNP VBD NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VBD NNP CC NNP NNS O
oscillator, oscillator, 0 0 0 0 1 0 0 0 11 0 NNP CC NNP NNS VBD O
principles principles 0 0 0 0 0 0 0 0 10 0 CC NNP NNS VBD NN O
afford afford 0 0 0 0 0 0 0 0 6 0 NNP NNS VBD NN IN O
explanation explanation 0 0 0 0 0 0 0 0 11 0 NNS VBD NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
main main 0 0 0 0 0 0 0 0 4 0 IN DT JJ NN IN O
phenomena phenomena 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
mitosis. mitosis. 0 0 0 0 0 0 0 0 8 0 NN IN NNP NNP NN B_TIMEXCCP 
Pathological Pathological 1 0 0 0 0 0 0 0 12 0 IN NNP NNP NN IN O
foreshortening foreshortening 0 0 0 0 0 0 0 0 14 0 NNP NNP NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NN O
polypeptide polypeptide 0 0 0 0 0 0 0 0 11 0 NN IN NN NN NNS O
replication replication 0 0 0 0 0 0 0 0 11 0 IN NN NN NNS NN O
offers offers 0 0 0 0 0 0 0 0 6 0 NN NN NNS NN IN O
explanation explanation 0 0 0 0 0 0 0 0 11 0 NN NNS NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNS NN IN JJ NNP O
malignant malignant 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNP NNP O
mitosis. mitosis. 0 0 0 0 0 0 0 0 8 0 IN JJ NNP NNP CD B_TIMEXCCP
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
7289897 7289897 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NN NN O
oocyte oocyte 0 0 0 0 0 0 0 0 6 0 NONE DT NN NN NNP O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 DT NN NN NNP NNP B_TIMEXCCP
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP NNP O
Colas Colas 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Guerrier Guerrier 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
P. P. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP IN NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP NNP O
Massachusetts Massachusetts 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
General General 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Hospital, Hospital, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP CD O
Boston Boston 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP CD NNP O
02114, 02114, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NN O
Usually, Usually, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NN NN O
oocyte oocyte 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NN NN O
meiosis meiosis 0 0 0 0 0 0 0 0 7 0 NNP NN NN NN VBZ B_TIMEXCCP
reinitiation reinitiation 0 0 0 0 0 0 0 0 12 0 NN NN NN VBZ IN O
appears appears 0 0 0 0 0 0 0 0 7 0 NN NN VBZ IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NN VBZ IN DT CD O
a a 0 0 0 0 0 0 0 0 1 0 VBZ IN DT CD NN O
two two 0 0 0 0 0 0 0 0 3 0 IN DT CD NN NN O
step step 0 0 0 0 0 0 0 0 4 0 DT CD NN NN IN O
process process 0 0 0 0 0 0 0 0 7 0 CD NN NN IN WDT O
during during 0 0 0 0 0 0 0 0 6 0 NN NN IN WDT NN O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT NN IN O
release release 0 0 0 0 0 0 0 0 7 0 IN WDT NN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 WDT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
prophase prophase 0 0 0 0 0 0 0 0 8 0 IN DT NN NN VBZ O
block block 0 0 0 0 0 0 0 0 5 0 DT NN NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ VBN IN O
followed followed 0 0 0 0 0 0 0 0 8 0 NN VBZ VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NN O
second second 0 0 0 0 0 0 0 0 6 arrest IN DT JJ NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN PRP O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 NN IN NN PRP CC B_TIMEXCCP
I I 1 1 0 0 0 0 0 0 1 0 IN NN PRP CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 NN PRP CC NNP NNP O
II. II. 1 1 0 0 0 0 0 0 3 0 PRP CC NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 CC NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
review, review, 0 0 0 0 1 0 0 0 7 0 NNP DT NN PRP MD O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP MD VB O
will will 0 0 0 0 0 0 0 0 4 0 NN PRP MD VB DT O
examine examine 0 0 0 0 0 0 0 0 7 0 PRP MD VB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NNS VBN O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 VB DT NNS VBN TO O
required required 0 0 0 0 0 0 0 0 8 0 DT NNS VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBN TO VB DT O
maintain maintain 0 0 0 0 0 0 0 0 8 0 VBN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN NN O
metaphase metaphase 0 0 0 0 0 0 0 0 9 arrest VB DT NN NN CC B_TIMEXCCP
arrest arrest 0 0 0 0 0 0 0 0 6 0 DT NN NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VB NNP O
stabilize stabilize 0 0 0 0 0 0 0 0 9 0 NN CC VB NNP NN O
MPF MPF 1 1 0 0 0 0 0 0 3 0 CC VB NNP NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 VB NNP NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NNP O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NNP NNP O
stage. stage. 0 0 0 0 0 0 0 0 6 0 IN DT NNP NNP PRP O
Then, Then, 1 0 0 0 1 0 0 0 5 0 DT NNP NNP PRP MD O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP MD VB O
will will 0 0 0 0 0 0 0 0 4 0 NNP PRP MD VB DT O
analyse analyse 0 0 0 0 0 0 0 0 7 0 PRP MD VB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NNS VBN O
processes processes 0 0 0 0 0 0 0 0 9 0 VB DT NNS VBN TO O
required required 0 0 0 0 0 0 0 0 8 0 DT NNS VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBN TO VB IN O
exit exit 0 0 0 0 0 0 0 0 4 0 VBN TO VB IN DT O
from from 0 0 0 0 0 0 0 0 4 0 TO VB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VB IN DT NN NNP O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 IN DT NN NNP NNP B_TIMEXCCP
block. block. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP MD O
These These 1 0 0 0 0 0 0 0 5 0 NN NNP NNP MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NNP NNP MD VB DT O
drive drive 0 0 0 0 0 0 0 0 5 0 NNP MD VB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NNS RB O
cells cells 0 0 0 0 0 0 0 0 5 0 VB DT NNS RB TO O
forward forward 0 0 0 0 0 0 0 0 7 0 DT NNS RB TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNS RB TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB TO DT NN NN O
metaphase-anaphase metaphase-anaphase 0 0 1 0 0 0 0 0 18 0 TO DT NN NN IN B_TIMEXCCP
transition, transition, 0 0 0 0 1 0 0 0 11 0 DT NN NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN IN O
result result 0 0 0 0 0 0 0 0 6 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
fertilization, fertilization, 0 0 0 0 1 0 0 0 14 0 NN IN NN NN CC O
activation activation 0 0 0 0 0 0 0 0 10 0 IN NN NN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 NN NN CC NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 NN CC NN NN NNP O
synthesis synthesis 0 0 0 0 0 0 0 0 9 0 CC NN NN NNP NNP O
inhibition. inhibition. 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP NN O
Instead, Instead, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP NN NN O
inhibiting inhibiting 0 0 0 0 0 0 0 0 10 0 NNP NNP NN NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 NNP NN NN NN NNS O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 NN NN NN NNS DT O
drives drives 0 0 0 0 0 0 0 0 6 0 NN NN NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NNS DT NN RB O
oocyte oocyte 0 0 0 0 0 0 0 0 6 0 NNS DT NN RB TO O
back back 0 0 0 0 0 0 0 0 4 0 DT NN RB TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NN RB TO NNP NNP O
interphase. interphase. 0 0 0 0 0 0 0 0 11 0 RB TO NNP NNP DT B_TIMEXCCP
All All 1 0 0 0 0 0 0 0 3 0 TO NNP NNP DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT NNS VBP O
treatments treatments 0 0 0 0 0 0 0 0 10 0 NNP DT NNS VBP IN O
result result 0 0 0 0 0 0 0 0 6 0 DT NNS VBP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBP IN NN IN O
derepression derepression 0 0 0 0 0 0 0 0 12 0 VBP IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNP NNP O
synthesis. synthesis. 0 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP CD B_TIMEXCCP
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNP NNP NNP CD JJ O
9552372 9552372 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Meiotic Meiotic 1 0 0 0 0 0 0 0 7 0 NONE NONE JJ NN NNS O
cohesin cohesin 0 0 0 0 0 0 0 0 7 0 NONE JJ NN NNS VBG O
promotes promotes 0 0 0 0 0 0 0 0 8 0 JJ NN NNS VBG IN O
pairing pairing 0 0 0 0 0 0 0 0 7 0 NN NNS VBG IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNS VBG IN JJ NNS O
nonhomologous nonhomologous 0 0 0 0 0 0 0 0 13 0 VBG IN JJ NNS IN O
centromeres centromeres 0 0 0 0 0 0 0 0 11 0 IN JJ NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ JJ O
early early 0 0 0 0 0 0 0 0 5 0 NNS IN JJ JJ NNP O
meiotic meiotic 0 0 0 0 0 0 0 0 7 0 IN JJ JJ NNP NNP O
prophase. prophase. 0 0 0 0 0 0 0 0 9 0 JJ JJ NNP NNP NNP B_TIMEXCCP
Bardhan Bardhan 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Chuong Chuong 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Dawson Dawson 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
DS. DS. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP CC O
Cycle Cycle 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP CC NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 CC NNP NNP NNP NNP O
Oklahoma Oklahoma 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Foundation, Foundation, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Oklahoma Oklahoma 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
City, City, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP CD O
OK OK 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
73104, 73104, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NN O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NN IN O
period period 0 0 0 0 0 0 0 0 6 0 NNP NNP NN IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN VBG IN O
pairing pairing 0 0 0 0 0 0 0 0 7 0 NN IN VBG IN JJ O
between between 0 0 0 0 0 0 0 0 7 0 IN VBG IN JJ NNS O
nonhomologous nonhomologous 0 0 0 0 0 0 0 0 13 0 VBG IN JJ NNS NNS O
centromeres centromeres 0 0 0 0 0 0 0 0 11 0 IN JJ NNS NNS RB O
occurs occurs 0 0 0 0 0 0 0 0 6 0 JJ NNS NNS RB IN O
early early 0 0 0 0 0 0 0 0 5 0 NNS NNS RB IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNS RB IN NN IN O
meiosis meiosis 0 0 0 0 0 0 0 0 7 0 RB IN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
diverse diverse 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN IN O
collection collection 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
organisms. organisms. 0 0 0 0 0 0 0 0 10 0 NN IN NNP NNP NNP O
This This 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNP O
early, early, 0 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP VBD O
homology-independent, homology-independent, 0 0 1 0 1 0 0 0 21 0 NNP NNP NNP VBD NNP O
centromere centromere 0 0 0 0 0 0 0 0 10 0 NNP NNP VBD NNP VBD O
pairing, pairing, 0 0 0 0 1 0 0 0 8 0 NNP VBD NNP VBD TO O
referred referred 0 0 0 0 0 0 0 0 8 0 VBD NNP VBD TO IN O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBD TO IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 VBD TO IN JJ NN O
centromere centromere 0 0 0 0 0 0 0 0 10 0 TO IN JJ NN IN O
coupling coupling 0 0 0 0 0 0 0 0 8 0 IN JJ NN IN VBG O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN VBG NN O
budding budding 0 0 0 0 0 0 0 0 7 0 NN IN VBG NN VBZ O
yeast, yeast, 0 0 0 0 1 0 0 0 6 0 IN VBG NN VBZ NN O
gives gives 0 0 0 0 0 0 0 0 5 0 VBG NN VBZ NN TO O
way way 0 0 0 0 0 0 0 0 3 0 NN VBZ NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBZ NN TO DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NN TO DT NN IN O
alignment alignment 0 0 0 0 0 0 0 0 9 0 TO DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
homologous homologous 0 0 0 0 0 0 0 0 10 0 NN IN JJ NNS IN O
centromeres centromeres 0 0 0 0 0 0 0 0 11 0 IN JJ NNS IN NNS O
as as 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNS VBP O
homologues homologues 0 0 0 0 0 0 0 0 10 0 NNS IN NNS VBP JJ O
synapse synapse 0 0 0 0 0 0 0 0 7 0 IN NNS VBP JJ IN O
later later 0 0 0 0 0 0 0 0 5 0 NNS VBP JJ IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBP JJ IN JJ NNP O
meiotic meiotic 0 0 0 0 0 0 0 0 7 0 JJ IN JJ NNP NNP O
prophase. prophase. 0 0 0 0 0 0 0 0 9 0 IN JJ NNP NNP NN B_TIMEXCCP
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
regulation regulation 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN VBG O
centromere centromere 0 0 0 0 0 0 0 0 10 0 NN IN NN VBG CC O
coupling coupling 0 0 0 0 0 0 0 0 8 0 IN NN VBG CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 NN VBG CC PRP$ JJ O
its its 0 0 0 0 0 0 0 0 3 0 VBG CC PRP$ JJ NN O
underlying underlying 0 0 0 0 0 0 0 0 10 0 CC PRP$ JJ NN VBP O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 PRP$ JJ NN VBP RB O
have have 0 0 0 0 0 0 0 0 4 0 JJ NN VBP RB VBN O
not not 0 0 0 0 0 0 0 0 3 0 NN VBP RB VBN NNP O
been been 0 0 0 0 0 0 0 0 4 0 VBP RB VBN NNP NNP O
elucidated. elucidated. 0 0 0 0 0 0 0 0 11 0 RB VBN NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 VBN NNP NNP NN NN O
budding budding 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN DT O
yeast, yeast, 0 0 0 0 1 0 0 0 6 0 NNP NN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NN NNP O
protein protein 0 0 0 0 0 0 0 0 7 0 NN DT NN NNP VBZ O
Zip1p Zip1p 1 0 0 0 0 0 0 1 5 0 DT NN NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN NNP VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT JJ NN O
major major 0 0 0 0 0 0 0 0 5 0 VBZ DT JJ NN IN O
component component 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
central central 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN IN O
element element 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
synaptonemal synaptonemal 0 0 0 0 0 0 0 0 12 0 IN DT JJ NN IN O
complex complex 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
pachytene pachytene 0 0 0 0 0 0 0 0 9 0 NN IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP CC O
meiosis, meiosis, 0 0 0 0 1 0 0 0 8 0 NN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP VBZ O
earlier, earlier, 0 0 0 0 1 0 0 0 8 0 NNP CC NNP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 CC NNP VBZ JJ IN O
essential essential 0 0 0 0 0 0 0 0 9 0 NNP VBZ JJ IN RB O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN RB NNP O
centromere centromere 0 0 0 0 0 0 0 0 10 0 JJ IN RB NNP NNP O
coupling. coupling. 0 0 0 0 0 0 0 0 9 0 IN RB NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 RB NNP NNP NNS VBD O
experiments experiments 0 0 0 0 0 0 0 0 11 0 NNP NNP NNS VBD RB O
reported reported 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD RB JJ O
here here 0 0 0 0 0 0 0 0 4 0 NNS VBD RB JJ IN O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 VBD RB JJ IN WRB O
that that 0 0 0 0 0 0 0 0 4 0 RB JJ IN WRB VBG O
centromere centromere 0 0 0 0 0 0 0 0 10 0 JJ IN WRB VBG VBZ O
coupling coupling 0 0 0 0 0 0 0 0 8 0 IN WRB VBG VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 WRB VBG VBZ RB JJ O
mechanistically mechanistically 0 0 0 0 0 0 0 0 15 0 VBG VBZ RB JJ IN O
distinct distinct 0 0 0 0 0 0 0 0 8 0 VBZ RB JJ IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 RB JJ IN JJ NN O
synaptonemal synaptonemal 0 0 0 0 0 0 0 0 12 0 JJ IN JJ NN NNP O
complex complex 0 0 0 0 0 0 0 0 7 0 IN JJ NN NNP NNP O
assembly. assembly. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NNP NNP O
Zip2p, Zip2p, 1 0 0 0 1 0 0 1 6 0 NN NNP NNP NNP CC O
Zip3p, Zip3p, 1 0 0 0 1 0 0 1 6 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP VBP O
Red1p Red1p 1 0 0 0 0 0 0 1 5 0 NNP CC NNP VBP DT O
are are 0 0 0 0 0 0 0 0 3 0 CC NNP VBP DT VBN O
all all 0 0 0 0 0 0 0 0 3 0 NNP VBP DT VBN IN O
required required 0 0 0 0 0 0 0 0 8 0 VBP DT VBN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 DT VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
assembly assembly 0 0 0 0 0 0 0 0 8 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
Zip1 Zip1 1 0 0 0 0 0 0 1 4 0 NN IN NNP IN DT O
into into 0 0 0 0 0 0 0 0 4 0 IN NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ NN O
synaptonemal synaptonemal 0 0 0 0 0 0 0 0 12 0 IN DT JJ NN CC O
complex complex 0 0 0 0 0 0 0 0 7 0 DT JJ NN CC VBP O
but but 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NN CC VBP JJ IN O
dispensable dispensable 0 0 0 0 0 0 0 0 11 0 CC VBP JJ IN RB O
for for 0 0 0 0 0 0 0 0 3 0 VBP JJ IN RB NNP O
centromere centromere 0 0 0 0 0 0 0 0 10 0 JJ IN RB NNP NNP O
coupling. coupling. 0 0 0 0 0 0 0 0 9 0 IN RB NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 RB NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NN O
meiotic meiotic 0 0 0 0 0 0 0 0 7 0 NNP DT JJ NN NNP O
cohesin cohesin 0 0 0 0 0 0 0 0 7 0 DT JJ NN NNP VBZ O
Rec8p Rec8p 1 0 0 0 0 0 0 1 5 0 JJ NN NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN NNP VBZ VBN IN O
required required 0 0 0 0 0 0 0 0 8 0 NNP VBZ VBN IN RB O
for for 0 0 0 0 0 0 0 0 3 0 VBZ VBN IN RB NNP O
centromere centromere 0 0 0 0 0 0 0 0 10 0 VBN IN RB NNP NNP O
coupling. coupling. 0 0 0 0 0 0 0 0 9 0 IN RB NNP NNP IN O
Loading Loading 1 0 0 0 0 0 0 0 7 0 RB NNP NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ NNS O
meiotic meiotic 0 0 0 0 0 0 0 0 7 0 NNP IN JJ NNS TO O
cohesins cohesins 0 0 0 0 0 0 0 0 8 0 IN JJ NNS TO NNS O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO NNS CC O
centromeres centromeres 0 0 0 0 0 0 0 0 11 0 NNS TO NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 TO NNS CC JJ NNS O
cohesin-associated cohesin-associated 0 0 1 0 0 0 0 0 18 0 NNS CC JJ NNS VBZ O
regions regions 0 0 0 0 0 0 0 0 7 0 CC JJ NNS VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 JJ NNS VBZ VBN IN O
required required 0 0 0 0 0 0 0 0 8 0 NNS VBZ VBN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBZ VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
association association 0 0 0 0 0 0 0 0 11 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
Zip1 Zip1 1 0 0 0 0 0 0 1 4 0 NN IN NNP IN DT O
with with 0 0 0 0 0 0 0 0 4 0 IN NNP IN DT JJ O
these these 0 0 0 0 0 0 0 0 5 0 NNP IN DT JJ CC O
sites, sites, 0 0 0 0 1 0 0 0 6 0 IN DT JJ CC DT O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ CC DT NN IN O
association association 0 0 0 0 0 0 0 0 11 0 CC DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
Zip1 Zip1 1 0 0 0 0 0 0 1 4 0 NN IN NNP IN DT O
with with 0 0 0 0 0 0 0 0 4 0 IN NNP IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNS RB O
centromeres centromeres 0 0 0 0 0 0 0 0 11 0 IN DT NNS RB VBZ O
then then 0 0 0 0 0 0 0 0 4 0 DT NNS RB VBZ NNP O
promotes promotes 0 0 0 0 0 0 0 0 8 0 NNS RB VBZ NNP NNP O
coupling. coupling. 0 0 0 0 0 0 0 0 9 0 RB VBZ NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 VBZ NNP NNP NNS VBP O
findings findings 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBP DT O
reveal reveal 0 0 0 0 0 0 0 0 6 0 NNP NNS VBP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNS VBP DT NN WDT O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 VBP DT NN WDT VBZ O
that that 0 0 0 0 0 0 0 0 4 0 DT NN WDT VBZ NNS O
promotes promotes 0 0 0 0 0 0 0 0 8 0 NN WDT VBZ NNS IN O
associations associations 0 0 0 0 0 0 0 0 12 0 WDT VBZ NNS IN NNS O
between between 0 0 0 0 0 0 0 0 7 0 VBZ NNS IN NNS IN O
centromeres centromeres 0 0 0 0 0 0 0 0 11 0 NNS IN NNS IN DT O
before before 0 0 0 0 0 0 0 0 6 0 IN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
assembly assembly 0 0 0 0 0 0 0 0 8 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
synaptonemal synaptonemal 0 0 0 0 0 0 0 0 12 0 IN DT JJ NN CC O
complex, complex, 0 0 0 0 1 0 0 0 8 0 DT JJ NN CC PRP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC PRP VBP O
they they 0 0 0 0 0 0 0 0 4 0 NN CC PRP VBP IN O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 CC PRP VBP IN NNS O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN NNS VBP O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 VBP IN NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 IN NNS VBP VBN IN O
preloaded preloaded 0 0 0 0 0 0 0 0 9 0 NNS VBP VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBP VBN IN NNP IN O
Zip1p Zip1p 1 0 0 0 0 0 0 1 5 0 VBN IN NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT NN WDT O
manner manner 0 0 0 0 0 0 0 0 6 0 IN DT NN WDT MD O
that that 0 0 0 0 0 0 0 0 4 0 DT NN WDT MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN WDT MD VB NNP O
promote promote 0 0 0 0 0 0 0 0 7 0 WDT MD VB NNP NNP O
synapsis. synapsis. 0 0 0 0 0 0 0 0 9 0 MD VB NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 VB NNP NNP CD JJ O
20375150 20375150 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NN O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NN NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
PMC2877639 PMC2877639 1 1 0 0 0 0 0 1 10 0 JJ NN NNP NONE NONE O
Identification Identification 1 0 0 0 0 0 0 0 14 0 NONE NONE NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NNP NN O
cDNA cDNA 0 0 0 0 0 0 0 0 4 0 IN DT NNP NN NN O
clone clone 0 0 0 0 0 0 0 0 5 0 DT NNP NN NN IN O
specific specific 0 0 0 0 0 0 0 0 8 0 NNP NN NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
taxol taxol 0 0 0 0 0 0 0 0 5 0 IN DT NN NN NN O
synthesis synthesis 0 0 0 0 0 0 0 0 9 phase DT NN NN NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 NN NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NN O
Taxus Taxus 1 0 0 0 0 0 0 0 5 0 NN IN NNP NN NNS O
chinensis chinensis 0 0 0 0 0 0 0 0 9 0 IN NNP NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NN NNS IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP JJ O
mRNA mRNA 0 0 0 0 0 0 0 0 4 0 NNS IN NNP JJ NNP O
differential differential 0 0 0 0 0 0 0 0 12 0 IN NNP JJ NNP NNP O
display. display. 0 0 0 0 0 0 0 0 8 0 NNP JJ NNP NNP NNP O
Hu Hu 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Fan Fan 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Mei Mei 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
X. X. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
College College 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Marine Marine 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNP O
Life Life 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Ocean Ocean 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
China, China, 1 0 0 0 1 0 0 0 6 0 NNP IN NNP NNP CD O
Qingdao Qingdao 1 0 0 0 0 0 0 0 7 0 IN NNP NNP CD NNP O
266003, 266003, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
huguobin@mail.ouc.edu.cn huguobin@mail.ouc.edu.cn 0 0 0 0 0 0 0 0 24 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NN TO O
order order 0 0 0 0 0 0 0 0 5 0 NNP NNP NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO VB NNS O
identify identify 0 0 0 0 0 0 0 0 8 0 NN TO VB NNS VBN O
genes genes 0 0 0 0 0 0 0 0 5 0 TO VB NNS VBN TO O
related related 0 0 0 0 0 0 0 0 7 0 VB NNS VBN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBN TO NNP NNP O
Taxol Taxol 1 0 0 0 0 0 0 0 5 0 VBN TO NNP NNP DT O
biosynthesis, biosynthesis, 0 0 0 0 1 0 0 0 13 0 TO NNP NNP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNP JJ O
mRNA mRNA 0 0 0 0 0 0 0 0 4 0 NNP DT NNP JJ NN O
differential differential 0 0 0 0 0 0 0 0 12 0 DT NNP JJ NN NN O
display display 0 0 0 0 0 0 0 0 7 0 NNP JJ NN NN VBD O
method method 0 0 0 0 0 0 0 0 6 0 JJ NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN TO O
employed employed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB NNP O
compare compare 0 0 0 0 0 0 0 0 7 0 VBN TO VB NNP NNS O
mRNA mRNA 0 0 0 0 0 0 0 0 4 0 TO VB NNP NNS IN O
populations populations 0 0 0 0 0 0 0 0 11 0 VB NNP NNS IN NN O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNS IN NN VBD O
suspension suspension 0 0 0 0 0 0 0 0 10 0 NNS IN NN VBD NNP O
cultured cultured 0 0 0 0 0 0 0 0 8 0 IN NN VBD NNP NN O
Taxus Taxus 1 0 0 0 0 0 0 0 5 0 NN VBD NNP NN NNS O
chinensis chinensis 0 0 0 0 0 0 0 0 9 0 VBD NNP NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NN NNS IN CC O
before before 0 0 0 0 0 0 0 0 6 0 NN NNS IN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NNS IN CC IN NN O
after after 0 0 0 0 0 0 0 0 5 0 IN CC IN NN TO O
beginning beginning 0 0 0 0 0 0 0 0 9 0 CC IN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB NNP O
produce produce 0 0 0 0 0 0 0 0 7 0 NN TO VB NNP NNP O
Taxol. Taxol. 1 0 0 0 0 0 0 0 6 0 TO VB NNP NNP DT O
From From 1 0 0 0 0 0 0 0 4 0 VB NNP NNP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT NN NN O
total total 0 0 0 0 0 0 0 0 5 0 NNP DT NN NN IN O
display display 0 0 0 0 0 0 0 0 7 0 DT NN NN IN RB O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN RB CD O
about about 0 0 0 0 0 0 0 0 5 0 NN IN RB CD NNP O
4000 4000 0 0 0 0 0 0 1 1 4 0 IN RB CD NNP NNP O
PCR PCR 1 1 0 0 0 0 0 0 3 0 RB CD NNP NNP CD O
products, products, 0 0 0 0 1 0 0 0 9 0 CD NNP NNP CD VBD O
104 104 0 0 0 0 0 0 1 1 3 0 NNP NNP CD VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP CD VBD VBN IN O
derived derived 0 0 0 0 0 0 0 0 7 0 CD VBD VBN IN NNS O
from from 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 VBN IN NNS IN DT O
during during 0 0 0 0 0 0 0 0 6 0 IN NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NN O
Taxol Taxol 1 0 0 0 0 0 0 0 5 0 IN DT NNP NN NN O
synthesis synthesis 0 0 0 0 0 0 0 0 9 phase DT NNP NN NN CC B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 NNP NN NN CC RB O
but but 0 0 0 0 0 0 0 0 3 0 NN NN CC RB DT O
not not 0 0 0 0 0 0 0 0 3 0 NN CC RB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CC RB DT JJ NN O
non-Taxol non-Taxol 0 0 1 0 0 0 0 0 9 0 RB DT JJ NN NNP O
synthesis synthesis 0 0 0 0 0 0 0 0 9 0 DT JJ NN NNP NNP O
phase. phase. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNS VBD O
products products 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD JJ CC O
cloned, cloned, 0 0 0 0 1 0 0 0 7 0 NNS VBD JJ CC CD O
and and 0 0 0 0 0 0 0 0 3 0 VBD JJ CC CD JJ O
one one 0 0 0 0 0 0 0 0 3 0 JJ CC CD JJ NNP O
such such 0 0 0 0 0 0 0 0 4 0 CC CD JJ NNP NNP O
cDNA cDNA 0 0 0 0 0 0 0 0 4 0 CD JJ NNP NNP VBD O
clone, clone, 0 0 0 0 1 0 0 0 6 0 JJ NNP NNP VBD NNP O
named named 0 0 0 0 0 0 0 0 5 0 NNP NNP VBD NNP VBD O
TS1, TS1, 1 1 0 0 1 0 0 1 4 0 NNP VBD NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 VBD NNP VBD VBN TO O
confirmed confirmed 0 0 0 0 0 0 0 0 9 0 NNP VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB RB O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB RB VBN O
specifically specifically 0 0 0 0 0 0 0 0 12 0 TO VB RB VBN IN O
expressed expressed 0 0 0 0 0 0 0 0 9 0 VB RB VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NN O
Taxol Taxol 1 0 0 0 0 0 0 0 5 0 IN DT NNP NN NN O
synthesis synthesis 0 0 0 0 0 0 0 0 9 phase DT NNP NN NN IN O
phase phase 0 0 0 0 0 0 0 0 5 0 NNP NN NN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
northern northern 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN NNP O
blot blot 0 0 0 0 0 0 0 0 4 0 IN JJ NN NNP NNP O
analysis. analysis. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
length length 0 0 0 0 0 0 0 0 6 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBG O
transcript transcript 0 0 0 0 0 0 0 0 10 0 IN DT NN VBG NNP O
corresponding corresponding 0 0 0 0 0 0 0 0 13 0 DT NN VBG NNP VBD O
TS1 TS1 1 1 0 0 0 0 0 1 3 0 NN VBG NNP VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 VBG NNP VBD RB CD O
approximately approximately 0 0 0 0 0 0 0 0 13 0 NNP VBD RB CD NNP O
2.1 2.1 0 0 0 0 0 0 0 1 3 0 VBD RB CD NNP NNP O
kb. kb. 0 0 0 0 0 0 0 0 3 0 RB CD NNP NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 CD NNP NNP NN CC O
sequencing sequencing 0 0 0 0 0 0 0 0 10 0 NNP NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN NN O
homology homology 0 0 0 0 0 0 0 0 8 0 NN CC NN NN VBD O
search search 0 0 0 0 0 0 0 0 6 0 CC NN NN VBD DT O
showed showed 0 0 0 0 0 0 0 0 6 0 NN NN VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBD DT NN IN O
sequence sequence 0 0 0 0 0 0 0 0 8 0 VBD DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP VBZ O
TS1 TS1 1 1 0 0 0 0 0 1 3 0 NN IN NNP VBZ DT O
contains contains 0 0 0 0 0 0 0 0 8 0 IN NNP VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT JJ JJ O
partial partial 0 0 0 0 0 0 0 0 7 0 VBZ DT JJ JJ NN O
open open 0 0 0 0 0 0 0 0 4 0 DT JJ JJ NN NN O
reading reading 0 0 0 0 0 0 0 0 7 0 JJ JJ NN NN CC O
frame frame 0 0 0 0 0 0 0 0 5 0 JJ NN NN CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBZ DT O
has has 0 0 0 0 0 0 0 0 3 0 NN CC VBZ DT NNS O
no no 0 0 0 0 0 0 0 0 2 0 CC VBZ DT NNS IN O
homologies homologies 0 0 0 0 0 0 0 0 10 0 VBZ DT NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 DT NNS IN JJ VBN O
other other 0 0 0 0 0 0 0 0 5 0 NNS IN JJ VBN NNP O
known known 0 0 0 0 0 0 0 0 5 0 IN JJ VBN NNP NNP O
genes. genes. 0 0 0 0 0 0 0 0 6 0 JJ VBN NNP NNP DT O
Hence, Hence, 1 0 0 0 1 0 0 0 6 0 VBN NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN VBD O
report report 0 0 0 0 0 0 0 0 6 0 NNP DT NN VBD DT O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 DT NN VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN VBD DT JJ IN O
potential potential 0 0 0 0 0 0 0 0 9 0 VBD DT JJ IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT JJ IN NNP JJ O
mRNA mRNA 0 0 0 0 0 0 0 0 4 0 JJ IN NNP JJ NN O
differential differential 0 0 0 0 0 0 0 0 12 0 IN NNP JJ NN IN O
display display 0 0 0 0 0 0 0 0 7 0 NNP JJ NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
isolation isolation 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS JJ O
genes genes 0 0 0 0 0 0 0 0 5 0 NN IN NNS JJ IN O
specific specific 0 0 0 0 0 0 0 0 8 0 IN NNS JJ IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NNS JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN IN O
period period 0 0 0 0 0 0 0 0 6 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
secondary secondary 0 0 0 0 0 0 0 0 9 0 NN IN JJ NN NN O
metabolite metabolite 0 0 0 0 0 0 0 0 10 0 IN JJ NN NN IN O
production production 0 0 0 0 0 0 0 0 10 0 JJ NN NN IN RB O
as as 0 0 0 0 0 0 0 0 2 0 NN NN IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NN IN RB IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NN IN O
feasibility feasibility 0 0 0 0 0 0 0 0 11 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
approach approach 0 0 0 0 0 0 0 0 8 0 IN DT NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
identification identification 0 0 0 0 0 0 0 0 14 0 IN DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS RB O
genes genes 0 0 0 0 0 0 0 0 5 0 NN IN NNS RB VBN O
potentially potentially 0 0 0 0 0 0 0 0 11 0 IN NNS RB VBN TO O
related related 0 0 0 0 0 0 0 0 7 0 NNS RB VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 RB VBN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN TO DT NN IN O
synthesis synthesis 0 0 0 0 0 0 0 0 9 0 TO DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
secondary secondary 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNS IN O
metabolites metabolites 0 0 0 0 0 0 0 0 11 0 IN JJ NNS IN JJR O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJR NNP O
higher higher 0 0 0 0 0 0 0 0 6 0 NNS IN JJR NNP NNP O
plants. plants. 0 0 0 0 0 0 0 0 7 0 IN JJR NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJR NNP NNP CD JJ O
15214490 15214490 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NN NN O
telophase telophase 0 0 0 0 0 0 0 0 9 0 NONE DT NN NN PRP$ B_TIMEXCCP
disc: disc: 0 0 0 0 0 0 0 0 5 0 DT NN NN PRP$ JJ O
its its 0 0 0 0 0 0 0 0 3 0 NN NN PRP$ JJ NN O
possible possible 0 0 0 0 0 0 0 0 8 0 NN PRP$ JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 PRP$ JJ NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 NN IN JJ NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN JJ NN NNP NNP O
cleavage. cleavage. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NNP NNP O
Margolis Margolis 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NNP NNP O
RL, RL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Andreassen Andreassen 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
PR. PR. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Institut Institut 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biologie Biologie 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Structurale, Structurale, 1 0 0 0 1 0 0 0 12 0 IN NNP NNP NNP NNP O
Grenoble, Grenoble, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
France. France. 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN VBZ O
molecular molecular 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBZ IN O
signals signals 0 0 0 0 0 0 0 0 7 0 NNP NN VBZ IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NN VBZ IN NN DT O
determine determine 0 0 0 0 0 0 0 0 9 0 VBZ IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN CC O
position position 0 0 0 0 0 0 0 0 8 0 NN DT NN CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC VBG IN O
timing timing 0 0 0 0 0 0 0 0 6 0 NN CC VBG IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC VBG IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBG IN DT NN IN O
furrow furrow 0 0 0 0 0 0 0 0 6 0 IN DT NN IN NNS O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN NNS IN O
forms forms 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 IN NNS IN JJ NN O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN VBP O
cytokinesis cytokinesis 0 0 0 0 0 0 0 0 11 0 JJ NN NN VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 NN NN VBP RB NNP O
presently presently 0 0 0 0 0 0 0 0 9 0 NN VBP RB NNP PRP O
unknown. unknown. 0 0 0 0 0 0 0 0 8 0 VBP RB NNP PRP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 RB NNP PRP VBZ -NONE- O
is is 0 0 0 0 0 0 0 0 2 0 NNP PRP VBZ -NONE- -NONE- O
apparent, apparent, 0 0 0 0 1 0 0 0 9 0 PRP VBZ -NONE- -NONE- DT O
however, however, 0 0 0 0 1 0 0 0 8 0 VBZ -NONE- -NONE- DT DT O
that that 0 0 0 0 0 0 0 0 4 0 -NONE- -NONE- DT DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 -NONE- DT DT NNS VBP O
signals signals 0 0 0 0 0 0 0 0 7 0 DT DT NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 DT NNS VBP VBN IN O
generated generated 0 0 0 0 0 0 0 0 9 0 NNS VBP VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBP VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN IN B_TIMEXCCP
spindle spindle 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN DT O
after after 0 0 0 0 0 0 0 0 5 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
onset onset 0 0 0 0 0 0 0 0 5 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
anaphase. anaphase. 0 0 0 0 0 0 0 0 9 0 NN IN NNP NNP PRP B_TIMEXCCP
Recently Recently 1 0 0 0 0 0 0 0 8 0 IN NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP PRP VBP VBN DT O
described described 0 0 0 0 0 0 0 0 9 0 PRP VBP VBN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBP VBN DT NN WDT O
structure structure 0 0 0 0 0 0 0 0 9 0 VBN DT NN WDT VBZ O
that that 0 0 0 0 0 0 0 0 4 0 DT NN WDT VBZ DT O
bisects bisects 0 0 0 0 0 0 0 0 7 0 NN WDT VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 WDT VBZ DT NN IN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBZ DT NN IN NN O
during during 0 0 0 0 0 0 0 0 6 0 DT NN IN NN IN O
telophase telophase 0 0 0 0 0 0 0 0 9 0 NN IN NN IN DT B_TIMEXCCP
at at 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
position position 0 0 0 0 0 0 0 0 8 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
cytokinetic cytokinetic 0 0 0 0 0 0 0 0 11 0 IN DT JJ NNP NNP O
furrow. furrow. 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NNP NNP O
This This 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NNP DT O
structure, structure, 0 0 0 0 1 0 0 0 10 0 NNP NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
telophase telophase 0 0 0 0 0 0 0 0 9 0 NNP DT NN NN VBZ B_TIMEXCCP
disc, disc, 0 0 0 0 1 0 0 0 5 0 DT NN NN VBZ TO O
appears appears 0 0 0 0 0 0 0 0 7 0 NN NN VBZ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBZ TO VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 VBZ TO VB VBN IN O
templated templated 0 0 0 0 0 0 0 0 9 0 TO VB VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VB VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN IN B_TIMEXCCP
spindle spindle 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 JJ NN IN JJ CC O
anaphase, anaphase, 0 0 0 0 1 0 0 0 9 0 NN IN JJ CC VBZ B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC VBZ DT O
precedes precedes 0 0 0 0 0 0 0 0 8 0 JJ CC VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC VBZ DT NN IN O
formation formation 0 0 0 0 0 0 0 0 9 0 VBZ DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
cytokinetic cytokinetic 0 0 0 0 0 0 0 0 11 0 IN DT JJ NNP NNP O
furrow. furrow. 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
relationship relationship 0 0 0 0 0 0 0 0 12 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
telophase telophase 0 0 0 0 0 0 0 0 9 0 IN DT NN NN TO B_TIMEXCCP
disc disc 0 0 0 0 0 0 0 0 4 0 DT NN NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT NN CC O
myosin myosin 0 0 0 0 0 0 0 0 6 0 TO DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN VBN O
actin actin 0 0 0 0 0 0 0 0 5 0 NN CC NN VBN VBG O
based based 0 0 0 0 0 0 0 0 5 0 CC NN VBN VBG NN O
furrowing furrowing 0 0 0 0 0 0 0 0 9 0 NN VBN VBG NN VBZ O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 VBN VBG NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 VBG NN VBZ VBN -NONE- O
discussed discussed 0 0 0 0 0 0 0 0 9 0 NN VBZ VBN -NONE- PRP O
here. here. 0 0 0 0 0 0 0 0 5 0 VBZ VBN -NONE- PRP VBP O
We We 1 0 0 0 0 0 0 0 2 0 VBN -NONE- PRP VBP IN O
propose propose 0 0 0 0 0 0 0 0 7 0 -NONE- PRP VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NN NN O
telophase telophase 0 0 0 0 0 0 0 0 9 0 IN DT NN NN MD B_TIMEXCCP
disc disc 0 0 0 0 0 0 0 0 4 0 DT NN NN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN NN MD VB DT O
determine determine 0 0 0 0 0 0 0 0 9 0 NN MD VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NN CC O
position position 0 0 0 0 0 0 0 0 8 0 VB DT NN CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC VBG IN O
timing timing 0 0 0 0 0 0 0 0 6 0 NN CC VBG IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC VBG IN NN IN O
cleavage cleavage 0 0 0 0 0 0 0 0 8 0 VBG IN NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 IN NN IN NN CC O
recruitment recruitment 0 0 0 0 0 0 0 0 11 0 NN IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN IN O
alignment alignment 0 0 0 0 0 0 0 0 9 0 NN CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NNP O
myosin. myosin. 0 0 0 0 0 0 0 0 7 0 NN IN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 IN NNP NNP CD JJ O
8489526 8489526 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Specificity Specificity 1 0 0 0 0 0 0 0 11 0 NONE NONE NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NONE NN CC NNP IN O
Regenerability Regenerability 1 0 0 0 0 0 0 0 14 0 NN CC NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NNP IN NNP NNP O
Short Short 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNPS O
Peptide Peptide 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNPS NNP O
Ligands Ligands 1 0 0 0 0 0 0 0 7 0 NNP NNP NNPS NNP IN O
Supported Supported 1 0 0 0 0 0 0 0 9 0 NNP NNPS NNP IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NNPS NNP IN NNP NNP O
Polymer Polymer 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP IN O
Layers Layers 1 0 0 0 0 0 0 0 6 0 IN NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNP O
Immunoglobulin Immunoglobulin 1 0 0 0 0 0 0 0 14 0 NNP IN NNP NNP NNP O
G G 1 1 0 0 0 0 0 0 1 0 IN NNP NNP NNP CC O
Binding Binding 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Detection. Detection. 1 0 0 0 0 0 0 0 10 0 NNP CC NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 CC NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Islam Islam 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Carbonell Carbonell 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
RG, RG, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Rojas Rojas 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
OJ. OJ. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Forest Forest 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNP O
Biomaterials, Biomaterials, 1 0 0 0 1 0 0 0 13 0 IN NNP NNP NNP NNP O
North North 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Carolina Carolina 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
State State 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP , O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP , NNP O
, , 0 0 0 0 1 0 0 0 1 0 NNP NNP , NNP NNP O
Raleigh, Raleigh, 1 0 0 0 1 0 0 0 8 0 NNP , NNP NNP NNP O
North North 1 0 0 0 0 0 0 0 5 0 , NNP NNP NNP CD O
Carolina Carolina 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP CD NNP O
27695, 27695, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
United United 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
States. States. 1 0 0 0 0 0 0 0 7 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NN DT O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 NNP NNP NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT NN NN O
specificity, specificity, 0 0 0 0 1 0 0 0 12 0 NN DT NN NN CC O
regenerability, regenerability, 0 0 0 0 1 0 0 0 15 0 DT NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
excellent excellent 0 0 0 0 0 0 0 0 9 0 NN CC NN NN NN O
storage storage 0 0 0 0 0 0 0 0 7 0 CC NN NN NN IN O
stability stability 0 0 0 0 0 0 0 0 9 0 NN NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ JJ O
short short 0 0 0 0 0 0 0 0 5 0 NN IN JJ JJ NNS O
peptide-based peptide-based 0 0 1 0 0 0 0 0 13 0 IN JJ JJ NNS IN O
systems systems 0 0 0 0 0 0 0 0 7 0 JJ JJ NNS IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN NN IN O
detection detection 0 0 0 0 0 0 0 0 9 0 NNS IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NNP O
immunoglobulin immunoglobulin 0 0 0 0 0 0 0 0 14 0 NN IN NN NNP NNP O
G G 1 1 0 0 0 0 0 0 1 0 IN NN NNP NNP NNP O
(IgG). (IgG). 0 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP JJ NN O
bioactive bioactive 0 0 0 0 0 0 0 0 9 0 NNP NNP JJ NN VBD O
component component 0 0 0 0 0 0 0 0 9 0 NNP JJ NN VBD IN O
consisted consisted 0 0 0 0 0 0 0 0 9 0 JJ NN VBD IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN VBD IN NNP NNP O
acetylated-HWRGWVA acetylated-HWRGWVA 0 0 1 0 0 0 0 0 18 0 VBD IN NNP NNP DT O
(Ac-HWRGWVA), (Ac-HWRGWVA), 0 0 1 0 1 0 0 0 13 0 IN NNP NNP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT NN IN O
peptide peptide 0 0 0 0 0 0 0 0 7 0 NNP DT NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 DT NN IN JJ NNP O
high high 0 0 0 0 0 0 0 0 4 0 NN IN JJ NNP NN O
IgG IgG 1 0 0 0 0 0 0 0 3 0 IN JJ NNP NN -NONE- O
binding binding 0 0 0 0 0 0 0 0 7 0 JJ NNP NN -NONE- WDT O
affinity, affinity, 0 0 0 0 1 0 0 0 9 0 NNP NN -NONE- WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 NN -NONE- WDT VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 -NONE- WDT VBD VBN IN O
immobilized immobilized 0 0 0 0 0 0 0 0 11 0 WDT VBD VBN IN NN O
onto onto 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NN NNS O
copolymer copolymer 0 0 0 0 0 0 0 0 9 0 VBN IN NN NNS IN O
matrixes matrixes 0 0 0 0 0 0 0 0 8 0 IN NN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NN O
poly(2-aminoethyl poly(2-aminoethyl 0 0 1 0 0 0 0 1 17 0 NNS IN JJ NN NN O
methacrylate methacrylate 0 0 0 0 0 0 0 0 12 0 IN JJ NN NN NN O
hydrochloride-co-2-hydroxyethyl hydrochloride-co-2-hydroxyethyl 0 0 1 0 0 0 0 1 31 0 JJ NN NN NN NNP O
methacrylate) methacrylate) 0 0 0 0 0 0 0 0 13 0 NN NN NN NNP NNP O
(poly(AMA-co-HEMA)). (poly(AMA-co-HEMA)). 0 0 1 0 0 0 0 0 20 0 NN NN NNP NNP NN O
Surface Surface 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NN NN O
plasmon plasmon 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN NN O
resonance resonance 0 0 0 0 0 0 0 0 9 0 NNP NN NN NN CC O
(SPR) (SPR) 0 1 0 0 0 0 0 0 5 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
quartz quartz 0 0 0 0 0 0 0 0 6 0 NN CC NN NN NN O
crystal crystal 0 0 0 0 0 0 0 0 7 0 CC NN NN NN NN O
microgravimetry microgravimetry 0 0 0 0 0 0 0 0 15 0 NN NN NN NN VBD O
(QCM) (QCM) 0 1 0 0 0 0 0 0 5 0 NN NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN IN O
utilized utilized 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN JJ JJ O
other other 0 0 0 0 0 0 0 0 5 0 VBN IN JJ JJ NNS O
complementary complementary 0 0 0 0 0 0 0 0 13 0 IN JJ JJ NNS TO O
techniques techniques 0 0 0 0 0 0 0 0 10 0 JJ JJ NNS TO RB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO RB VB O
systematically systematically 0 0 0 0 0 0 0 0 14 0 NNS TO RB VB JJ O
investigate investigate 0 0 0 0 0 0 0 0 11 0 TO RB VB JJ NN O
interfacial interfacial 0 0 0 0 0 0 0 0 11 0 RB VB JJ NN RB O
activities, activities, 0 0 0 0 1 0 0 0 11 0 VB JJ NN RB NNP O
mainly mainly 0 0 0 0 0 0 0 0 6 0 JJ NN RB NNP NN O
IgG IgG 1 0 0 0 0 0 0 0 3 0 NN RB NNP NN NN O
binding binding 0 0 0 0 0 0 0 0 7 0 RB NNP NN NN IN O
performance performance 0 0 0 0 0 0 0 0 11 0 NNP NN NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN IN O
function function 0 0 0 0 0 0 0 0 8 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
graft graft 0 0 0 0 0 0 0 0 5 0 IN DT NN NN CC O
density density 0 0 0 0 0 0 0 0 7 0 DT NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
degree degree 0 0 0 0 0 0 0 0 6 0 NN CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN IN O
polymerization polymerization 0 0 0 0 0 0 0 0 14 0 NN IN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
poly(AMA-co-HEMA) poly(AMA-co-HEMA) 0 0 1 0 0 0 0 0 17 0 IN DT JJ NN NNP O
support support 0 0 0 0 0 0 0 0 7 0 DT JJ NN NNP NNP O
layer. layer. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP IN O
Results Results 1 0 0 0 0 0 0 0 7 0 NN NNP NNP IN NN O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNP IN NN NN O
sodium sodium 0 0 0 0 0 0 0 0 6 0 NNP IN NN NN NN O
dodecyl dodecyl 0 0 0 0 0 0 0 0 7 0 IN NN NN NN NN O
sulfate sulfate 0 0 0 0 0 0 0 0 7 0 NN NN NN NN NN O
polyacrylamide polyacrylamide 0 0 0 0 0 0 0 0 14 0 NN NN NN NN NN O
gel gel 0 0 0 0 0 0 0 0 3 0 NN NN NN NN CC O
electrophoresis electrophoresis 0 0 0 0 0 0 0 0 15 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
fluorescence fluorescence 0 0 0 0 0 0 0 0 12 0 NN CC NN NN NN O
microscopy microscopy 0 0 0 0 0 0 0 0 10 0 CC NN NN NN WDT O
indicate indicate 0 0 0 0 0 0 0 0 8 0 NN NN NN WDT DT O
that that 0 0 0 0 0 0 0 0 4 0 NN NN WDT DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN WDT DT JJ NN O
bioactive bioactive 0 0 0 0 0 0 0 0 9 0 WDT DT JJ NN VBZ O
system system 0 0 0 0 0 0 0 0 6 0 DT JJ NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ RB JJ O
highly highly 0 0 0 0 0 0 0 0 6 0 NN VBZ RB JJ TO O
specific specific 0 0 0 0 0 0 0 0 8 0 VBZ RB JJ TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 RB JJ TO NNP CC O
IgG IgG 1 0 0 0 0 0 0 0 3 0 JJ TO NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 TO NNP CC JJ TO O
resistant resistant 0 0 0 0 0 0 0 0 9 0 NNP CC JJ TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 CC JJ TO JJ NNS O
nonspecific nonspecific 0 0 0 0 0 0 0 0 11 0 JJ TO JJ NNS WRB O
interactions interactions 0 0 0 0 0 0 0 0 12 0 TO JJ NNS WRB VBN O
when when 0 0 0 0 0 0 0 0 4 0 JJ NNS WRB VBN IN O
tested tested 0 0 0 0 0 0 0 0 6 0 NNS WRB VBN IN VBN O
in in 0 0 0 0 0 0 0 0 2 0 WRB VBN IN VBN NN O
mixed mixed 0 0 0 0 0 0 0 0 5 0 VBN IN VBN NN NNP O
protein protein 0 0 0 0 0 0 0 0 7 0 IN VBN NN NNP NONE O
solutions. solutions. 0 0 0 0 0 0 0 0 10 0 VBN NN NNP NONE NONE O
Movements Movements 1 0 0 0 0 0 0 0 9 0 NONE NONE NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NONE NNS CC JJ IN O
Habitat-Use Habitat-Use 1 0 1 0 0 0 0 0 11 0 NNS CC JJ IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC JJ IN NNP NNP O
Loggerhead Loggerhead 1 0 0 0 0 0 0 0 10 0 JJ IN NNP NNP NNP O
Sea Sea 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP IN O
Turtles Turtles 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP NNP O
Northern Northern 1 0 0 0 0 0 0 0 8 0 IN DT NNP NNP IN O
Gulf Gulf 1 0 0 0 0 0 0 0 4 0 DT NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP IN O
Mexico Mexico 1 0 0 0 0 0 0 0 6 0 NNP IN NNP IN DT O
during during 0 0 0 0 0 0 0 0 6 0 IN NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP NNP O
Reproductive Reproductive 1 0 0 0 0 0 0 0 12 0 IN DT NNP NNP NNP O
Period. Period. 1 0 0 0 0 0 0 0 7 0 DT NNP NNP NNP NNP O
Hart Hart 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
KM, KM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Lamont Lamont 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
MM, MM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Sartain Sartain 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
AR, AR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Fujisaki Fujisaki 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
I, I, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Stephens Stephens 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BS. BS. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Southeast Southeast 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Ecological Ecological 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Science Science 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Center, Center, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
U.S. U.S. 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Geological Geological 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Survey, Survey, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Davie, Davie, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
Florida, Florida, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNPS O
United United 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNPS IN O
States States 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
America. America. 1 0 0 0 0 0 0 0 8 0 NNPS IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNS O
Nesting Nesting 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNS CC O
strategies strategies 0 0 0 0 0 0 0 0 10 0 NNP NNP NNS CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNS CC VB IN O
use use 0 0 0 0 0 0 0 0 3 0 NNS CC VB IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC VB IN JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 VB IN JJ NN NNS O
in-water in-water 0 0 1 0 0 0 0 0 8 0 IN JJ NN NNS IN O
habitats habitats 0 0 0 0 0 0 0 0 8 0 JJ NN NNS IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN JJ NN O
far-ranging far-ranging 0 0 1 0 0 0 0 0 11 0 NNS IN JJ NN NNS O
marine marine 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNS MD O
turtles turtles 0 0 0 0 0 0 0 0 7 0 JJ NN NNS MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN NNS MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB VBN VBG O
determined determined 0 0 0 0 0 0 0 0 10 0 MD VB VBN VBG NN O
using using 0 0 0 0 0 0 0 0 5 0 VB VBN VBG NN NNP O
satellite satellite 0 0 0 0 0 0 0 0 9 0 VBN VBG NN NNP NNP O
telemetry. telemetry. 0 0 0 0 0 0 0 0 10 0 VBG NN NNP NNP IN O
Because Because 1 0 0 0 0 0 0 0 7 0 NN NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT NN IN O
lack lack 0 0 0 0 0 0 0 0 4 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
information information 0 0 0 0 0 0 0 0 11 0 NN IN NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ IN O
habitat-use habitat-use 0 0 1 0 0 0 0 0 11 0 NN IN JJ IN NN O
by by 0 0 0 0 0 0 0 0 2 0 IN JJ IN NN NNS O
marine marine 0 0 0 0 0 0 0 0 6 0 JJ IN NN NNS IN O
turtles turtles 0 0 0 0 0 0 0 0 7 0 IN NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NNP O
northern northern 0 0 0 0 0 0 0 0 8 0 IN DT JJ NNP IN O
Gulf Gulf 1 0 0 0 0 0 0 0 4 0 DT JJ NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNP IN NNP PRP O
Mexico, Mexico, 1 0 0 0 1 0 0 0 7 0 NNP IN NNP PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 IN NNP PRP VBD JJ O
used used 0 0 0 0 0 0 0 0 4 0 NNP PRP VBD JJ NNS O
satellite satellite 0 0 0 0 0 0 0 0 9 0 PRP VBD JJ NNS IN O
transmitters transmitters 0 0 0 0 0 0 0 0 12 0 VBD JJ NNS IN CD O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN CD IN O
2010 2010 0 0 0 0 0 0 1 1 4 0 NNS IN CD IN CD O
through through 0 0 0 0 0 0 0 0 7 0 IN CD IN CD TO O
2012 2012 0 0 0 0 0 0 1 1 4 0 CD IN CD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN CD TO VB NNS O
track track 0 0 0 0 0 0 0 0 5 0 CD TO VB NNS IN O
movements movements 0 0 0 0 0 0 0 0 9 0 TO VB NNS IN CD O
of of 0 0 0 0 0 0 0 0 2 0 VB NNS IN CD NN O
39 39 0 0 0 0 0 0 1 1 2 0 NNS IN CD NN NN O
adult adult 0 0 0 0 0 0 0 0 5 0 IN CD NN NN VBG O
female female 0 0 0 0 0 0 0 0 6 0 CD NN NN VBG NN O
breeding breeding 0 0 0 0 0 0 0 0 8 0 NN NN VBG NN NNS O
loggerhead loggerhead 0 0 0 0 0 0 0 0 10 0 NN VBG NN NNS -NONE- O
turtles turtles 0 0 0 0 0 0 0 0 7 0 VBG NN NNS -NONE- -NONE- O
(Caretta (Caretta 0 0 0 0 0 0 0 0 8 0 NN NNS -NONE- -NONE- VBD O
caretta) caretta) 0 0 0 0 0 0 0 0 8 0 NNS -NONE- -NONE- VBD IN O
tagged tagged 0 0 0 0 0 0 0 0 6 0 -NONE- -NONE- VBD IN NN O
on on 0 0 0 0 0 0 0 0 2 0 -NONE- VBD IN NN NNS O
nesting nesting 0 0 0 0 0 0 0 0 7 0 VBD IN NN NNS IN O
beaches beaches 0 0 0 0 0 0 0 0 7 0 IN NN NNS IN CD O
at at 0 0 0 0 0 0 0 0 2 0 NN NNS IN CD NNS O
three three 0 0 0 0 0 0 0 0 5 0 NNS IN CD NNS IN O
sites sites 0 0 0 0 0 0 0 0 5 0 IN CD NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CD NNS IN NNP CC O
Florida Florida 1 0 0 0 0 0 0 0 7 0 NNS IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Alabama. Alabama. 1 0 0 0 0 0 0 0 8 0 NNP CC NNP NNP DT O
During During 1 0 0 0 0 0 0 0 6 0 CC NNP NNP DT VBG O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT VBG NN O
nesting nesting 0 0 0 0 0 0 0 0 7 0 NNP DT VBG NN VBD O
season, season, 0 0 0 0 1 0 0 0 7 0 DT VBG NN VBD NNS O
recaptured recaptured 0 0 0 0 0 0 0 0 10 0 VBG NN VBD NNS VBN O
turtles turtles 0 0 0 0 0 0 0 0 7 0 NN VBD NNS VBN TO O
emerged emerged 0 0 0 0 0 0 0 0 7 0 VBD NNS VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBN TO VB CD O
nest nest 0 0 0 0 0 0 0 0 4 0 VBN TO VB CD TO O
1 1 0 0 0 0 0 0 1 1 1 0 TO VB CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 VB CD TO CD NN O
5 5 0 0 0 0 0 0 1 1 1 0 CD TO CD NN IN O
times, times, 0 0 0 0 1 0 0 0 6 0 TO CD NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 CD NN IN JJ NN O
mean mean 0 0 0 0 0 0 0 0 4 0 NN IN JJ NN IN O
distance distance 0 0 0 0 0 0 0 0 8 0 IN JJ NN IN NNS O
between between 0 0 0 0 0 0 0 0 7 0 JJ NN IN NNS IN O
emergences emergences 0 0 0 0 0 0 0 0 10 0 NN IN NNS IN CD O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN CD JJ O
27.5 27.5 0 0 0 0 0 0 0 1 4 0 NNS IN CD JJ NN O
km; km; 0 0 0 0 0 0 0 0 3 0 IN CD JJ NN JJ O
however, however, 0 0 0 0 1 0 0 0 8 0 CD JJ NN JJ NNS O
several several 0 0 0 0 0 0 0 0 7 0 JJ NN JJ NNS VBN O
turtles turtles 0 0 0 0 0 0 0 0 7 0 NN JJ NNS VBN IN O
nested nested 0 0 0 0 0 0 0 0 6 0 JJ NNS VBN IN NNS O
on on 0 0 0 0 0 0 0 0 2 0 NNS VBN IN NNS VBN O
beaches beaches 0 0 0 0 0 0 0 0 7 0 VBN IN NNS VBN IN O
separated separated 0 0 0 0 0 0 0 0 9 0 IN NNS VBN IN -NONE- O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBN IN -NONE- NN O
∼250 ∼250 0 0 0 0 0 0 0 1 4 0 VBN IN -NONE- NN IN O
km km 0 0 0 0 0 0 0 0 2 0 IN -NONE- NN IN DT O
within within 0 0 0 0 0 0 0 0 6 0 -NONE- NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NNP O
single single 0 0 0 0 0 0 0 0 6 0 IN DT JJ NNP NNP O
season. season. 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NNP NN O
Mean Mean 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NN NNS O
total total 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NNS VBD O
distances distances 0 0 0 0 0 0 0 0 9 0 NNP NN NNS VBD IN O
traveled traveled 0 0 0 0 0 0 0 0 8 0 NN NNS VBD IN JJ O
throughout throughout 0 0 0 0 0 0 0 0 10 0 NNS VBD IN JJ NNS O
inter-nesting inter-nesting 0 0 1 0 0 0 0 0 13 0 VBD IN JJ NNS IN O
periods periods 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN DT NNS O
all all 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNS VBD O
turtles turtles 0 0 0 0 0 0 0 0 7 0 IN DT NNS VBD CD O
was was 0 0 0 0 0 0 0 0 3 0 DT NNS VBD CD NNP O
1422.0±930.8 1422.0±930.8 0 0 0 0 0 0 0 1 12 0 NNS VBD CD NNP NNP O
km. km. 0 0 0 0 0 0 0 0 3 0 VBD CD NNP NNP NNP O
In-water In-water 1 0 1 0 0 0 0 0 8 0 CD NNP NNP NNP NNP O
inter-nesting inter-nesting 0 0 1 0 0 0 0 0 13 0 NNP NNP NNP NNP VBD O
sites, sites, 0 0 0 0 1 0 0 0 6 0 NNP NNP NNP VBD VBG O
delineated delineated 0 0 0 0 0 0 0 0 10 0 NNP NNP VBD VBG CD O
using using 0 0 0 0 0 0 0 0 5 0 NNP VBD VBG CD NN O
50% 50% 0 0 0 0 0 0 0 1 3 0 VBD VBG CD NN NN O
kernel kernel 0 0 0 0 0 0 0 0 6 0 VBG CD NN NN NN O
density density 0 0 0 0 0 0 0 0 7 0 CD NN NN NN NN O
estimation estimation 0 0 0 0 0 0 0 0 10 0 NN NN NN NN VBD O
(KDE), (KDE), 0 1 0 0 1 0 0 0 6 0 NN NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN DT O
located located 0 0 0 0 0 0 0 0 7 0 NN VBD VBN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBD VBN DT JJ NN O
mean mean 0 0 0 0 0 0 0 0 4 0 VBN DT JJ NN IN O
distance distance 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN CD NN O
33.0 33.0 0 0 0 0 0 0 0 1 4 0 NN IN CD NN IN O
km km 0 0 0 0 0 0 0 0 2 0 IN CD NN IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 CD NN IN NNP IN O
land, land, 0 0 0 0 1 0 0 0 5 0 NN IN NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NN IN O
water water 0 0 0 0 0 0 0 0 5 0 NNP IN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN JJ NN O
mean mean 0 0 0 0 0 0 0 0 4 0 NN IN JJ NN IN O
depth depth 0 0 0 0 0 0 0 0 5 0 IN JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
-31.6 -31.6 0 0 1 0 0 0 0 1 5 0 NN IN NNP NNP JJ O
m; m; 0 0 0 0 0 0 0 0 2 0 IN NNP NNP JJ JJ O
other other 0 0 0 0 0 0 0 0 5 0 NNP NNP JJ JJ JJ O
in-water in-water 0 0 1 0 0 0 0 0 8 0 NNP JJ JJ JJ NN O
inter-nesting inter-nesting 0 0 1 0 0 0 0 0 13 0 JJ JJ JJ NN VBD O
sites, sites, 0 0 0 0 1 0 0 0 6 0 JJ JJ NN VBD VBG O
delineated delineated 0 0 0 0 0 0 0 0 10 0 JJ NN VBD VBG JJ O
using using 0 0 0 0 0 0 0 0 5 0 NN VBD VBG JJ NN O
minimum minimum 0 0 0 0 0 0 0 0 7 0 VBD VBG JJ NN NN O
convex convex 0 0 0 0 0 0 0 0 6 0 VBG JJ NN NN NN O
polygon polygon 0 0 0 0 0 0 0 0 7 0 JJ NN NN NN NN O
(MCP) (MCP) 0 1 0 0 0 0 0 0 5 0 NN NN NN NN VBD O
approach, approach, 0 0 0 0 1 0 0 0 9 0 NN NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN DT O
located located 0 0 0 0 0 0 0 0 7 0 NN VBD VBN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBD VBN DT JJ CD O
mean mean 0 0 0 0 0 0 0 0 4 0 VBN DT JJ CD NN O
13.8 13.8 0 0 0 0 0 0 0 1 4 0 DT JJ CD NN IN O
km km 0 0 0 0 0 0 0 0 2 0 JJ CD NN IN NN O
from from 0 0 0 0 0 0 0 0 4 0 CD NN IN NN CC O
land land 0 0 0 0 0 0 0 0 4 0 NN IN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN CC IN NN IN O
water water 0 0 0 0 0 0 0 0 5 0 CC IN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
mean mean 0 0 0 0 0 0 0 0 4 0 IN DT JJ NN IN O
depth depth 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN -NONE- NNP O
-15.8 -15.8 0 0 1 0 0 0 0 1 5 0 NN IN -NONE- NNP NNP O
m. m. 0 0 0 0 0 0 0 0 2 0 IN -NONE- NNP NNP NN O
Mean Mean 1 0 0 0 0 0 0 0 4 0 -NONE- NNP NNP NN IN O
size size 0 0 0 0 0 0 0 0 4 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ JJ O
in-water in-water 0 0 1 0 0 0 0 0 8 0 NN IN JJ JJ NNS O
inter-nesting inter-nesting 0 0 1 0 0 0 0 0 13 0 IN JJ JJ NNS VBD O
habitats habitats 0 0 0 0 0 0 0 0 8 0 JJ JJ NNS VBD CD O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD CD -NONE- O
61.9 61.9 0 0 0 0 0 0 0 1 4 0 NNS VBD CD -NONE- JJ O
km(2) km(2) 0 0 0 0 0 0 0 1 5 0 VBD CD -NONE- JJ NN O
(50% (50% 0 0 0 0 0 0 0 1 4 0 CD -NONE- JJ NN NN O
KDEs, KDEs, 1 0 0 0 1 0 0 0 5 0 -NONE- JJ NN NN : O
n n 0 0 0 0 0 0 0 0 1 0 JJ NN NN : CD O
= = 0 0 0 0 0 0 0 0 1 0 NN NN : CD CC O
10) 10) 0 0 0 0 0 0 0 1 3 0 NN : CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 : CD CC CD NN O
741.4 741.4 0 0 0 0 0 0 0 1 5 0 CD CC CD NN -NONE- O
km(2) km(2) 0 0 0 0 0 0 0 1 5 0 CC CD NN -NONE- NN O
(MCPs, (MCPs, 0 0 0 0 1 0 0 0 6 0 CD NN -NONE- NN : O
n n 0 0 0 0 0 0 0 0 1 0 NN -NONE- NN : CD O
= = 0 0 0 0 0 0 0 0 1 0 -NONE- NN : CD DT O
30); 30); 0 0 0 0 0 0 0 1 4 0 NN : CD DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 : CD DT NNS VBD O
areas areas 0 0 0 0 0 0 0 0 5 0 CD DT NNS VBD RB O
overlapped overlapped 0 0 0 0 0 0 0 0 10 0 DT NNS VBD RB IN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNS VBD RB IN VBG O
with with 0 0 0 0 0 0 0 0 4 0 VBD RB IN VBG CC O
trawling trawling 0 0 0 0 0 0 0 0 8 0 RB IN VBG CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN VBG CC NN CC O
oil oil 0 0 0 0 0 0 0 0 3 0 VBG CC NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 CC NN CC NN NN O
gas gas 0 0 0 0 0 0 0 0 3 0 NN CC NN NN NNP O
extraction extraction 0 0 0 0 0 0 0 0 10 0 CC NN NN NNP NNP O
activities. activities. 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP VBZ O
Abundance Abundance 1 0 0 0 0 0 0 0 9 0 NN NNP NNP VBZ IN O
estimates estimates 0 0 0 0 0 0 0 0 9 0 NNP NNP VBZ IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NNP VBZ IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 VBZ IN DT NN NN O
nesting nesting 0 0 0 0 0 0 0 0 7 0 IN DT NN NN MD O
subpopulation subpopulation 0 0 0 0 0 0 0 0 13 0 DT NN NN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN NN MD VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB JJ IN O
inaccurate inaccurate 0 0 0 0 0 0 0 0 10 0 MD VB JJ IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VB JJ IN JJ IN O
light light 0 0 0 0 0 0 0 0 5 0 JJ IN JJ IN WRB O
of of 0 0 0 0 0 0 0 0 2 0 IN JJ IN WRB JJ O
how how 0 0 0 0 0 0 0 0 3 0 JJ IN WRB JJ NN O
much much 0 0 0 0 0 0 0 0 4 0 IN WRB JJ NN EX O
spread spread 0 0 0 0 0 0 0 0 6 0 WRB JJ NN EX VBZ O
there there 0 0 0 0 0 0 0 0 5 0 JJ NN EX VBZ IN O
is is 0 0 0 0 0 0 0 0 2 0 NN EX VBZ IN NNS O
between between 0 0 0 0 0 0 0 0 7 0 EX VBZ IN NNS IN O
nests nests 0 0 0 0 0 0 0 0 5 0 VBZ IN NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NNP O
same same 0 0 0 0 0 0 0 0 4 0 IN DT JJ NNP NNP O
individual. individual. 0 0 0 0 0 0 0 0 11 0 DT JJ NNP NNP PRP$ O
Further, Further, 1 0 0 0 1 0 0 0 8 0 JJ NNP NNP PRP$ NNS O
our our 0 0 0 0 0 0 0 0 3 0 NNP NNP PRP$ NNS RB O
results results 0 0 0 0 0 0 0 0 7 0 NNP PRP$ NNS RB VBP O
also also 0 0 0 0 0 0 0 0 4 0 PRP$ NNS RB VBP NNS O
have have 0 0 0 0 0 0 0 0 4 0 NNS RB VBP NNS IN O
consequences consequences 0 0 0 0 0 0 0 0 12 0 RB VBP NNS IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VBP NNS IN JJ NN O
critical critical 0 0 0 0 0 0 0 0 8 0 NNS IN JJ NN NNS O
habitat habitat 0 0 0 0 0 0 0 0 7 0 IN JJ NN NNS IN O
designations designations 0 0 0 0 0 0 0 0 12 0 JJ NN NNS IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN JJ NNP O
northern northern 0 0 0 0 0 0 0 0 8 0 NNS IN JJ NNP NNP O
Gulf Gulf 1 0 0 0 0 0 0 0 4 0 IN JJ NNP NNP IN O
loggerheads, loggerheads, 0 0 0 0 1 0 0 0 12 0 JJ NNP NNP IN NN O
as as 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN IN O
protection protection 0 0 0 0 0 0 0 0 10 0 NNP IN NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN CD VBG O
one one 0 0 0 0 0 0 0 0 3 0 NN IN CD VBG NN O
nesting nesting 0 0 0 0 0 0 0 0 7 0 IN CD VBG NN MD O
beach beach 0 0 0 0 0 0 0 0 5 0 CD VBG NN MD RB O
would would 0 0 0 0 0 0 0 0 5 0 VBG NN MD RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NN MD RB VB DT O
encompass encompass 0 0 0 0 0 0 0 0 9 0 MD RB VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 RB VB DT JJ NN O
entire entire 0 0 0 0 0 0 0 0 6 0 VB DT JJ NN VBN O
range range 0 0 0 0 0 0 0 0 5 0 DT JJ NN VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 JJ NN VBN IN NNS O
by by 0 0 0 0 0 0 0 0 2 0 NN VBN IN NNS IN O
turtles turtles 0 0 0 0 0 0 0 0 7 0 VBN IN NNS IN VBG O
during during 0 0 0 0 0 0 0 0 6 0 IN NNS IN VBG NNP O
breeding breeding 0 0 0 0 0 0 0 0 8 0 NNS IN VBG NNP NONE O
seasons. seasons. 0 0 0 0 0 0 0 0 8 0 IN VBG NNP NONE NONE O
Fangchinoline Fangchinoline 1 0 0 0 0 0 0 0 13 0 NONE NONE NNP NNS -NONE- O
induces induces 0 0 0 0 0 0 0 0 7 0 NONE NNP NNS -NONE- VBP O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 arrest NNP NNS -NONE- VBP IN B_TIMEXCCP
arrest arrest 0 0 0 0 0 0 0 0 6 0 NNS -NONE- VBP IN NN O
by by 0 0 0 0 0 0 0 0 2 0 -NONE- VBP IN NN DT O
modulating modulating 0 0 0 0 0 0 0 0 10 0 VBP IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP CC O
CDKN1A CDKN1A 1 1 0 0 0 0 0 1 6 0 NN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP IN O
CCND2 CCND2 1 1 0 0 0 0 0 1 5 0 NNP CC NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CC NNP IN NNP NN O
K562 K562 1 1 0 0 0 0 0 1 4 0 NNP IN NNP NN NN O
human human 0 0 0 0 0 0 0 0 5 0 IN NNP NN NN JJ O
chronic chronic 0 0 0 0 0 0 0 0 7 0 NNP NN NN JJ NN O
myelogenous myelogenous 0 0 0 0 0 0 0 0 11 0 NN NN JJ NN NNP O
leukemia leukemia 0 0 0 0 0 0 0 0 8 0 NN JJ NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Huang Huang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Leng Leng 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
G. G. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Shanghai Shanghai 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Key Key 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP IN O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Signaling Signaling 1 0 0 0 0 0 0 0 9 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Disease Disease 1 0 0 0 0 0 0 0 7 0 NNP CC NNP NNP NNP O
Research, Research, 1 0 0 0 1 0 0 0 9 0 CC NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Life Life 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP CC O
Science Science 1 0 0 0 0 0 0 0 7 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Technology, Technology, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP NNP O
Tongji Tongji 1 0 0 0 0 0 0 0 6 0 CC NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP CD O
Shanghai Shanghai 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP CD : O
200092; 200092; 0 0 0 0 0 0 0 1 7 0 NNP NNP CD : NNP O
; ; 0 0 0 0 0 0 0 0 1 0 NNP CD : NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 CD : NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 : NNP IN NNP NNP O
Biochemistry, Biochemistry, 1 0 0 0 1 0 0 0 13 0 NNP IN NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Jinggangshan Jinggangshan 1 0 0 0 0 0 0 0 12 0 IN NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP CD O
Jiangxi Jiangxi 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP CD NNP O
343009; 343009; 0 0 0 0 0 0 0 1 7 0 NNP NNP CD NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP CD NNP NNP VBD O
Chronic Chronic 1 0 0 0 0 0 0 0 7 0 CD NNP NNP VBD NN O
myeloid myeloid 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD NN -NONE- O
leukemia leukemia 0 0 0 0 0 0 0 0 8 0 NNP VBD NN -NONE- VBZ O
(CML) (CML) 0 1 0 0 0 0 0 0 5 0 VBD NN -NONE- VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN -NONE- VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- VBZ DT JJ NN O
hematopoietic hematopoietic 0 0 0 0 0 0 0 0 13 0 VBZ DT JJ NN NN O
stem stem 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN VBD O
disease disease 0 0 0 0 0 0 0 0 7 0 NN NN NN VBD IN O
caused caused 0 0 0 0 0 0 0 0 6 0 NN NN VBD IN DT O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN NN O
oncoprotein oncoprotein 0 0 0 0 0 0 0 0 11 0 IN DT NN NN WDT O
BCR-ABL, BCR-ABL, 1 1 1 0 1 0 0 0 8 0 DT NN NN WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBZ DT O
exhibits exhibits 0 0 0 0 0 0 0 0 8 0 NN WDT VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 WDT VBZ DT JJ NN O
constitutive constitutive 0 0 0 0 0 0 0 0 12 0 VBZ DT JJ NN NN O
tyrosine tyrosine 0 0 0 0 0 0 0 0 8 0 DT JJ NN NN NNP O
kinase kinase 0 0 0 0 0 0 0 0 6 0 JJ NN NN NNP NNP O
activity. activity. 0 0 0 0 0 0 0 0 9 0 NN NN NNP NNP NN O
Imatinib Imatinib 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NN -NONE- O
mesylate mesylate 0 0 0 0 0 0 0 0 8 0 NNP NNP NN -NONE- DT O
(IM), (IM), 0 1 0 0 1 0 0 0 5 0 NNP NN -NONE- DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NN -NONE- DT NN IN O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 -NONE- DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
tyrosine tyrosine 0 0 0 0 0 0 0 0 8 0 IN DT NN NN NN O
kinase kinase 0 0 0 0 0 0 0 0 6 0 DT NN NN NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NN NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ VBZ O
BCR-ABL, BCR-ABL, 1 1 1 0 1 0 0 0 8 0 NN IN JJ VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 IN JJ VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 JJ VBZ VBN VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 VBZ VBN VBN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VBN VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NN O
first-line first-line 0 0 1 0 0 0 0 0 10 0 IN DT JJ NN IN O
therapy therapy 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NNP NNP O
CML. CML. 1 1 0 0 0 0 0 0 4 0 NN IN NNP NNP NNP O
However, However, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP VBZ O
IM IM 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP VBZ JJR O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ JJR JJ O
less less 0 0 0 0 0 0 0 0 4 0 NNP VBZ JJR JJ IN O
effective effective 0 0 0 0 0 0 0 0 9 0 VBZ JJR JJ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJR JJ IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT VBN NN O
accelerated accelerated 0 0 0 0 0 0 0 0 11 phase IN DT VBN NN CC O
phase phase 0 0 0 0 0 0 0 0 5 0 DT VBN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBN NN CC JJ NNS O
blastic blastic 0 0 0 0 0 0 0 0 7 phases NN CC JJ NNS IN O
phases phases 0 0 0 0 0 0 0 0 6 0 CC JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP CC O
CML CML 1 1 0 0 0 0 0 0 3 0 NNS IN NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC JJ NNS O
certain certain 0 0 0 0 0 0 0 0 7 0 NNP CC JJ NNS VB O
patients patients 0 0 0 0 0 0 0 0 8 0 CC JJ NNS VB NNP O
develop develop 0 0 0 0 0 0 0 0 7 0 JJ NNS VB NNP NN O
IM IM 1 1 0 0 0 0 0 0 2 0 NNS VB NNP NN JJ O
resistance resistance 0 0 0 0 0 0 0 0 10 0 VB NNP NN JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 NNP NN JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN JJ TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ TO DT NN CC O
mutation mutation 0 0 0 0 0 0 0 0 8 0 TO DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
amplification amplification 0 0 0 0 0 0 0 0 13 0 NN CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
BCR-ABL BCR-ABL 1 1 1 0 0 0 0 0 7 0 IN DT JJ NNP NNP O
gene. gene. 0 0 0 0 0 0 0 0 5 0 DT JJ NNP NNP DT O
Fangchinoline, Fangchinoline, 1 0 0 0 1 0 0 0 14 0 JJ NNP NNP DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNP NNP DT JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 NNP DT JJ NN NN O
chemical chemical 0 0 0 0 0 0 0 0 8 0 DT JJ NN NN IN O
constituent constituent 0 0 0 0 0 0 0 0 11 0 JJ NN NN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNS O
dried dried 0 0 0 0 0 0 0 0 5 0 IN DT JJ NNS IN O
roots roots 0 0 0 0 0 0 0 0 5 0 DT JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NN O
Stephaniae Stephaniae 1 0 0 0 0 0 0 0 10 0 NNS IN NNP NN NNP O
tetrandrae tetrandrae 0 0 0 0 0 0 0 0 10 0 IN NNP NN NNP NNP O
S. S. 1 1 0 0 0 0 0 0 2 0 NNP NN NNP NNP VBZ O
Moore, Moore, 1 0 0 0 1 0 0 0 6 0 NN NNP NNP VBZ JJ O
exhibits exhibits 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 NNP VBZ JJ NN NN O
antitumor antitumor 0 0 0 0 0 0 0 0 9 0 VBZ JJ NN NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 JJ NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNS O
various various 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNS IN O
types types 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ VBG O
cancers, cancers, 0 0 0 0 1 0 0 0 8 0 NNS IN JJ VBG NN O
including including 0 0 0 0 0 0 0 0 9 0 IN JJ VBG NN NN O
breast, breast, 0 0 0 0 1 0 0 0 7 0 JJ VBG NN NN CC O
prostate prostate 0 0 0 0 0 0 0 0 8 0 VBG NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NNP O
hepatocellular hepatocellular 0 0 0 0 0 0 0 0 14 0 NN CC JJ NNP NNP O
carcinoma. carcinoma. 0 0 0 0 0 0 0 0 10 0 CC JJ NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 JJ NNP NNP DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNS CC O
effects effects 0 0 0 0 0 0 0 0 7 0 NNP DT NNS CC DT O
and and 0 0 0 0 0 0 0 0 3 0 DT NNS CC DT VBG O
the the 0 0 0 0 0 0 0 0 3 0 NNS CC DT VBG NNS O
underlying underlying 0 0 0 0 0 0 0 0 10 0 CC DT VBG NNS IN O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 DT VBG NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBG NNS IN NN IN O
fangchinoline fangchinoline 0 0 0 0 0 0 0 0 13 0 NNS IN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NN O
CML CML 1 1 0 0 0 0 0 0 3 0 NN IN NNP NN NNP O
remain remain 0 0 0 0 0 0 0 0 6 0 IN NNP NN NNP NNP O
unclear. unclear. 0 0 0 0 0 0 0 0 8 0 NNP NN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
present present 0 0 0 0 0 0 0 0 7 0 NNP DT NN NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 DT NN NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NN NN PRP VBD IN O
identified identified 0 0 0 0 0 0 0 0 10 0 NN PRP VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBD IN NN NNS O
fangchinoline fangchinoline 0 0 0 0 0 0 0 0 13 0 VBD IN NN NNS VBP O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 IN NN NNS VBP NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NNS VBP NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NNS VBP NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBP NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN CC O
dose- dose- 0 0 1 0 0 0 0 0 5 0 IN DT NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC JJ NN O
time-dependent time-dependent 0 0 1 0 0 0 0 0 14 0 NN CC JJ NN IN O
manner manner 0 0 0 0 0 0 0 0 6 0 CC JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNS O
K562 K562 1 1 0 0 0 0 0 1 4 0 NN IN NNP NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS VBD IN O
derived derived 0 0 0 0 0 0 0 0 7 0 NNP NNS VBD IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN NN O
blast blast 0 0 0 0 0 0 0 0 5 0 IN DT NN NN IN O
crisis crisis 0 0 0 0 0 0 0 0 6 0 DT NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
CML. CML. 1 1 0 0 0 0 0 0 4 0 NN IN NNP NNP NNS O
Additional Additional 1 0 0 0 0 0 0 0 10 0 IN NNP NNP NNS VBD O
experiments experiments 0 0 0 0 0 0 0 0 11 0 NNP NNP NNS VBD IN O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NN NNS O
fangchinoline fangchinoline 0 0 0 0 0 0 0 0 13 0 VBD IN NN NNS VBP O
induces induces 0 0 0 0 0 0 0 0 7 0 IN NN NNS VBP NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NNS VBP NN JJS O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest NNS VBP NN JJS IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 VBP NN JJS IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NN JJS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 JJS IN DT NNP NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase IN DT NNP NN CC B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NNP NN CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC VBZ DT O
has has 0 0 0 0 0 0 0 0 3 0 NN CC VBZ DT NN O
no no 0 0 0 0 0 0 0 0 2 0 CC VBZ DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 VBZ DT NN IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP WDT O
apoptosis, apoptosis, 0 0 0 0 1 0 0 0 10 0 NN IN NNP WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 IN NNP WDT VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP WDT VBZ VBN IN O
mediated mediated 0 0 0 0 0 0 0 0 8 0 WDT VBZ VBN IN DT O
through through 0 0 0 0 0 0 0 0 7 0 VBZ VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
upregulation upregulation 0 0 0 0 0 0 0 0 12 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
cyclin-dependent cyclin-dependent 0 0 1 0 0 0 0 0 16 0 NN IN JJ NN NN O
kinase kinase 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN CC O
(CDK)-N1A (CDK)-N1A 0 1 1 0 0 0 0 1 9 0 JJ NN NN CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC -NONE- NNP O
MCL-1 MCL-1 1 1 1 0 0 0 0 1 5 0 NN CC -NONE- NNP NNP O
mRNA mRNA 0 0 0 0 0 0 0 0 4 0 CC -NONE- NNP NNP IN O
levels, levels, 0 0 0 0 1 0 0 0 7 0 -NONE- NNP NNP IN RB O
as as 0 0 0 0 0 0 0 0 2 0 NNP NNP IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NNP IN RB IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NN IN O
downregulation downregulation 0 0 0 0 0 0 0 0 14 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP NNP O
D2 D2 1 1 0 0 0 0 0 1 2 0 IN NN NNP NNP NNP O
(CCND2) (CCND2) 0 1 0 0 0 0 0 1 7 0 NN NNP NNP NNP NNP O
mRNA mRNA 0 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
levels. levels. 0 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNS VBP O
findings findings 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBP DT O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNP NNS VBP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBP DT NN IN O
potential potential 0 0 0 0 0 0 0 0 9 0 VBP DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
fangchinoline fangchinoline 0 0 0 0 0 0 0 0 13 0 NN IN NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN NN IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT JJ NN O
effective effective 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN NN O
antitumor antitumor 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN IN O
agent agent 0 0 0 0 0 0 0 0 5 0 JJ NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
CML. CML. 1 1 0 0 0 0 0 0 4 0 NN IN NNP NNP NNP O
KEYWORDS: KEYWORDS: 1 1 0 0 0 0 0 0 9 0 IN NNP NNP NNP NNP O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NNP NNP NNP NNP JJ B_TIMEXCCP
arrest, arrest, 0 0 0 0 1 0 0 0 7 0 NNP NNP NNP JJ JJ O
chronic chronic 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ JJ NN O
myelogenous myelogenous 0 0 0 0 0 0 0 0 11 0 NNP JJ JJ NN NN O
leukemia, leukemia, 0 0 0 0 1 0 0 0 9 0 JJ JJ NN NN NN O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN NN O
D2, D2, 1 1 0 0 1 0 0 1 3 0 NN NN NN NN NN O
cyclin-dependent cyclin-dependent 0 0 1 0 0 0 0 0 16 0 NN NN NN NN NN O
kinase kinase 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NN O
N1A, N1A, 1 1 0 0 1 0 0 1 4 0 NN NN NN NN NONE O
fangchinoline fangchinoline 0 0 0 0 0 0 0 0 13 0 NN NN NN NONE NONE O
C-Phycocyanin C-Phycocyanin 1 0 1 0 0 0 0 0 13 0 NONE NONE JJ IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NONE JJ IN NNP NNS O
Oscillatoria Oscillatoria 1 0 0 0 0 0 0 0 12 0 JJ IN NNP NNS VBD O
tenuis tenuis 0 0 0 0 0 0 0 0 6 0 IN NNP NNS VBD DT O
exhibited exhibited 0 0 0 0 0 0 0 0 9 0 NNP NNS VBD DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NNS VBD DT NN CC O
antioxidant antioxidant 0 0 0 0 0 0 0 0 11 0 VBD DT NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN CC IN NN JJ O
vitro vitro 0 0 0 0 0 0 0 0 5 0 CC IN NN JJ NN O
antiproliferative antiproliferative 0 0 0 0 0 0 0 0 17 0 IN NN JJ NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NN JJ NN IN NN O
through through 0 0 0 0 0 0 0 0 7 0 JJ NN IN NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 NN IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN CC O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN IN NN CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC -NONE- NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NN CC -NONE- NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 CC -NONE- NN NN NNP O
cycle cycle 0 0 0 0 0 0 0 0 5 0 -NONE- NN NN NNP NNP O
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP NNP O
Thangam Thangam 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Suresh Suresh 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
V, V, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Asenath Asenath 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Princy Princy 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
W, W, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Rajkumar Rajkumar 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Senthilkumar Senthilkumar 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Gunasekaran Gunasekaran 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Rengasamy Rengasamy 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Anbazhagan Anbazhagan 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kaveri Kaveri 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kannan Kannan 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
S. S. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP CC O
Proteomics Proteomics 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP CC NNP O
& & 0 0 0 0 0 0 0 0 1 0 NNP NNP CC NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP CC NNP NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 CC NNP NNP NNP NNP O
Physiology Physiology 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Lab, Lab, 1 0 0 0 1 0 0 0 4 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Zoology, Zoology, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP NNP O
Bharathiar Bharathiar 1 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Coimbatore, Coimbatore, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
TN, TN, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
India. India. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
thangam1985@yahoo.co.in thangam1985@yahoo.co.in 0 0 0 0 0 0 0 1 23 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN TO O
undertaken undertaken 0 0 0 0 0 0 0 0 10 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB DT O
develop develop 0 0 0 0 0 0 0 0 7 0 VBN TO VB DT NN O
an an 0 0 0 0 0 0 0 0 2 0 TO VB DT NN NN O
efficient efficient 0 0 0 0 0 0 0 0 9 0 VB DT NN NN NN O
single single 0 0 0 0 0 0 0 0 6 0 DT NN NN NN NN O
step step 0 0 0 0 0 0 0 0 4 0 NN NN NN NN NN O
chromatographic chromatographic 0 0 0 0 0 0 0 0 15 0 NN NN NN NN IN O
method method 0 0 0 0 0 0 0 0 6 0 NN NN NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NN IN O
purification purification 0 0 0 0 0 0 0 0 12 0 NN IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NN O
C-phycocyanin C-phycocyanin 1 0 1 0 0 0 0 0 13 0 NN IN JJ NN IN O
(CPC) (CPC) 0 1 0 0 0 0 0 0 5 0 IN JJ NN IN NNS O
from from 0 0 0 0 0 0 0 0 4 0 JJ NN IN NNS IN O
species species 0 0 0 0 0 0 0 0 7 0 NN IN NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN NNP NNP O
Oscillatoria Oscillatoria 1 0 0 0 0 0 0 0 12 0 NNS IN NNP NNP NNP O
tenuis. tenuis. 0 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP IN O
Purification Purification 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP VBZ O
CPC CPC 1 1 0 0 0 0 0 0 3 0 NNP IN NNP VBZ DT O
involves involves 0 0 0 0 0 0 0 0 8 0 IN NNP VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT NN NN O
multistep multistep 0 0 0 0 0 0 0 0 9 0 VBZ DT NN NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 DT NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
crude crude 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN IN O
extract extract 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
precipitation precipitation 0 0 0 0 0 0 0 0 13 0 NN IN NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN NN -NONE- O
ammonium ammonium 0 0 0 0 0 0 0 0 8 0 NN IN NN -NONE- VBN O
sulphate, sulphate, 0 0 0 0 1 0 0 0 9 0 IN NN -NONE- VBN IN O
followed followed 0 0 0 0 0 0 0 0 8 0 NN -NONE- VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 -NONE- VBN IN NN NN O
gel gel 0 0 0 0 0 0 0 0 3 0 VBN IN NN NN NNP O
filtration filtration 0 0 0 0 0 0 0 0 10 0 IN NN NN NNP NNP O
chromatography. chromatography. 0 0 0 0 0 0 0 0 15 0 NN NN NNP NNP NNP O
Pure Pure 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NNP VBD O
CPC CPC 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD RB VBN O
finally finally 0 0 0 0 0 0 0 0 7 0 NNP VBD RB VBN IN O
obtained obtained 0 0 0 0 0 0 0 0 8 0 VBD RB VBN IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 RB VBN IN NNP NNS O
O. O. 1 1 0 0 0 0 0 0 2 0 VBN IN NNP NNS IN O
tenuis tenuis 0 0 0 0 0 0 0 0 6 0 IN NNP NNS IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNS IN NN NN O
purity purity 0 0 0 0 0 0 0 0 6 0 NNS IN NN NN NN O
ratio ratio 0 0 0 0 0 0 0 0 5 0 IN NN NN NN CD O
(A620/A280) (A620/A280) 0 1 0 1 0 0 0 1 11 0 NN NN NN CD NN O
4.88. 4.88. 0 0 0 0 0 0 0 1 5 0 NN NN CD NN IN O
SDS-PAGE SDS-PAGE 1 1 1 0 0 0 0 0 8 0 NN CD NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN NN NNP O
pure pure 0 0 0 0 0 0 0 0 4 0 NN IN NN NNP VBD O
CPC CPC 1 1 0 0 0 0 0 0 3 0 IN NN NNP VBD CD O
yielded yielded 0 0 0 0 0 0 0 0 7 0 NN NNP VBD CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 NNP VBD CD NNS VBG O
bands bands 0 0 0 0 0 0 0 0 5 0 VBD CD NNS VBG TO O
corresponding corresponding 0 0 0 0 0 0 0 0 13 0 CD NNS VBG TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBG TO VB CC O
α α 0 0 0 0 0 0 0 0 1 0 VBG TO VB CC . O
and and 0 0 0 0 0 0 0 0 3 0 TO VB CC . NN O
β β 0 0 0 0 0 0 0 0 1 0 VB CC . NN DT O
subunits; subunits; 0 0 0 0 0 0 0 0 9 0 CC . NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 . NN DT JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 NN DT JJ NN IN O
weight weight 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
α α 0 0 0 0 0 0 0 0 1 0 NN IN NNP NN VBZ O
subunit subunit 0 0 0 0 0 0 0 0 7 0 IN NNP NN VBZ CD O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ CD -NONE- O
17.0 17.0 0 0 0 0 0 0 0 1 4 0 NN VBZ CD -NONE- IN O
kDa, kDa, 0 0 0 0 1 0 0 0 4 0 VBZ CD -NONE- IN DT O
whereas whereas 0 0 0 0 0 0 0 0 7 0 CD -NONE- IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- IN DT JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN IN O
weight weight 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
β β 0 0 0 0 0 0 0 0 1 0 NN IN NNP NN VBZ O
subunit subunit 0 0 0 0 0 0 0 0 7 0 IN NNP NN VBZ CD O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ CD NNP O
19.5 19.5 0 0 0 0 0 0 0 1 4 0 NN VBZ CD NNP NNP O
kDa. kDa. 0 0 0 0 0 0 0 0 4 0 VBZ CD NNP NNP CC O
Fluorescence Fluorescence 1 0 0 0 0 0 0 0 12 0 CD NNP NNP CC VB O
and and 0 0 0 0 0 0 0 0 3 phase NNP NNP CC VB JJ O
phase phase 0 0 0 0 0 0 0 0 5 0 NNP CC VB JJ NN O
contrast contrast 0 0 0 0 0 0 0 0 8 0 CC VB JJ NN VBD O
microscopy microscopy 0 0 0 0 0 0 0 0 10 0 VB JJ NN VBD JJ O
revealed revealed 0 0 0 0 0 0 0 0 8 0 JJ NN VBD JJ JJ O
characteristic characteristic 0 0 0 0 0 0 0 0 14 0 NN VBD JJ JJ NNS O
apoptotic apoptotic 0 0 0 0 0 0 0 0 9 0 VBD JJ JJ NNS IN O
features features 0 0 0 0 0 0 0 0 8 0 JJ JJ NNS IN NN O
like like 0 0 0 0 0 0 0 0 4 0 JJ NNS IN NN -NONE- O
cell cell 0 0 0 0 0 0 0 0 4 0 NNS IN NN -NONE- NN O
shrinkage, shrinkage, 0 0 0 0 1 0 0 0 10 0 IN NN -NONE- NN -NONE- O
membrane membrane 0 0 0 0 0 0 0 0 8 0 NN -NONE- NN -NONE- JJ O
blebbing, blebbing, 0 0 0 0 1 0 0 0 9 0 -NONE- NN -NONE- JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 NN -NONE- JJ NN CC O
condensation condensation 0 0 0 0 0 0 0 0 12 0 -NONE- JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN CC NNP NNP NNP O
fragmentation. fragmentation. 0 0 0 0 0 0 0 0 14 0 CC NNP NNP NNP VBD O
CPC CPC 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP VBD JJ O
exhibited exhibited 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD JJ CC O
antioxidant antioxidant 0 0 0 0 0 0 0 0 11 0 NNP VBD JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBD JJ CC JJ NN O
antiproliferative antiproliferative 0 0 0 0 0 0 0 0 17 0 JJ CC JJ NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 CC JJ NN IN JJ O
against against 0 0 0 0 0 0 0 0 7 0 JJ NN IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN JJ O
through through 0 0 0 0 0 0 0 0 7 0 NN NNS IN JJ JJ O
apoptosis; apoptosis; 0 0 0 0 0 0 0 0 10 0 NNS IN JJ JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 IN JJ JJ NN NN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 JJ JJ NN NN VBD O
induction induction 0 0 0 0 0 0 0 0 9 0 JJ NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
accompanied accompanied 0 0 0 0 0 0 0 0 11 0 NN VBD VBN IN -NONE- O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN -NONE- NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase VBN IN -NONE- NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 arrest IN -NONE- NN NN CC O
arrest arrest 0 0 0 0 0 0 0 0 6 0 -NONE- NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN CC NNP NNP NNP O
fragmentation. fragmentation. 0 0 0 0 0 0 0 0 14 0 CC NNP NNP NNP VBZ O
CPC CPC 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT JJ NN O
natural natural 0 0 0 0 0 0 0 0 7 0 VBZ DT JJ NN IN O
pigment pigment 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN JJ IN O
potential potential 0 0 0 0 0 0 0 0 9 0 NN IN JJ IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN JJ IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 JJ IN DT NN NNP O
anticancer anticancer 0 0 0 0 0 0 0 0 10 0 IN DT NN NNP NNP O
agent. agent. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP NNP O
Copyright Copyright 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP CD O
© © 0 0 0 0 0 0 0 0 1 0 NNP NNP NNP CD NNP O
2013 2013 0 0 0 0 0 0 1 1 4 0 NNP NNP CD NNP NNP O
Elsevier Elsevier 1 0 0 0 0 0 0 0 8 0 NNP CD NNP NNP NNP O
Ltd. Ltd. 1 0 0 0 0 0 0 0 4 0 CD NNP NNP NNP NNS O
All All 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS NNP O
rights rights 0 0 0 0 0 0 0 0 6 0 NNP NNP NNS NNP NONE O
reserved. reserved. 0 0 0 0 0 0 0 0 9 0 NNP NNS NNP NONE NONE O
Suppression Suppression 1 0 0 0 0 0 0 0 11 0 NONE NONE NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NNP NNS O
STIM1 STIM1 1 1 0 0 0 0 0 1 5 0 NN IN NNP NNS JJ O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 IN NNP NNS JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NNP NNS JJ NN NN O
glioblastoma glioblastoma 0 0 0 0 0 0 0 0 12 0 NNS JJ NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NN NN NN CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNS -NONE- O
induces induces 0 0 0 0 0 0 0 0 7 0 NN CC NNS -NONE- VB O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase CC NNS -NONE- VB NNP B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 NNS -NONE- VB NNP NNP O
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 -NONE- VB NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 VB NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ma Ma 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
W, W, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yang Yang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wei Wei 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wei Wei 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Y. Y. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Neurosurgery, Neurosurgery, 1 0 0 0 1 0 0 0 13 0 NNP IN NNP NNP NNP O
Peking Peking 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
Union Union 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
College College 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Hospital, Hospital, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Peking Peking 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Union Union 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP CC O
College College 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NNP O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 NNP CC JJ NNP IN O
Academy Academy 1 0 0 0 0 0 0 0 7 0 CC JJ NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNP IN NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
No.1 No.1 1 0 0 0 0 0 0 1 4 0 NNP NNP NNP NNP NNP O
Shuaifuyuan, Shuaifuyuan, 1 0 0 0 1 0 0 0 12 0 NNP NNP NNP NNP NNP O
Wangfujing, Wangfujing, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Dongcheng Dongcheng 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
District, District, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP CD O
Beijing Beijing 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP CD NNP O
100730, 100730, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP NNP O
PR PR 1 1 0 0 0 0 0 0 2 0 NNP CD NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP IN O
Depletion Depletion 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN NN O
calcium calcium 0 0 0 0 0 0 0 0 7 0 NNP IN NN NN IN O
(Ca2+) (Ca2+) 0 0 0 0 0 0 0 1 6 0 IN NN NN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
endoplasmic endoplasmic 0 0 0 0 0 0 0 0 11 0 IN DT JJ NN NN O
reticulum reticulum 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN VBZ O
(ER) (ER) 0 1 0 0 0 0 0 0 4 0 JJ NN NN VBZ DT O
activates activates 0 0 0 0 0 0 0 0 9 0 NN NN VBZ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT JJ JJ O
ubiquitous ubiquitous 0 0 0 0 0 0 0 0 10 0 VBZ DT JJ JJ NN O
store-operated store-operated 0 0 1 0 0 0 0 0 14 0 DT JJ JJ NN NN O
Ca2+ Ca2+ 1 0 0 0 0 0 0 1 4 0 JJ JJ NN NN NN O
entry entry 0 0 0 0 0 0 0 0 5 0 JJ NN NN NN NN O
(SOCE) (SOCE) 0 1 0 0 0 0 0 0 6 0 NN NN NN NN WDT O
pathway pathway 0 0 0 0 0 0 0 0 7 0 NN NN NN WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBZ JJ O
sustains sustains 0 0 0 0 0 0 0 0 8 0 NN WDT VBZ JJ NN O
long-term long-term 0 0 1 0 0 0 0 0 9 0 WDT VBZ JJ NN NNS O
Ca2+ Ca2+ 1 0 0 0 0 0 0 1 4 0 VBZ JJ NN NNS CC O
signals signals 0 0 0 0 0 0 0 0 7 0 JJ NN NNS CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNS CC VBZ JJ IN O
critical critical 0 0 0 0 0 0 0 0 8 0 CC VBZ JJ IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN JJ NNP O
cellular cellular 0 0 0 0 0 0 0 0 8 0 JJ IN JJ NNP NNP O
functions. functions. 0 0 0 0 0 0 0 0 10 0 IN JJ NNP NNP NN O
Stromal Stromal 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP NN NN O
interacting interacting 0 0 0 0 0 0 0 0 11 0 NNP NNP NN NN CD O
molecule molecule 0 0 0 0 0 0 0 0 8 0 NNP NN NN CD NN O
1 1 0 0 0 0 0 0 1 1 1 0 NN NN CD NN NNS O
(STIM1) (STIM1) 0 1 0 0 0 0 0 1 7 0 NN CD NN NNS DT O
serves serves 0 0 0 0 0 0 0 0 6 0 CD NN NNS DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN NNS DT JJ NN O
dual dual 0 0 0 0 0 0 0 0 4 0 NNS DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNP O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT NNP NNP O
ER ER 1 1 0 0 0 0 0 0 2 0 IN DT NNP NNP NN O
Ca2+ Ca2+ 1 0 0 0 0 0 0 1 4 0 DT NNP NNP NN CC O
sensor sensor 0 0 0 0 0 0 0 0 6 0 NNP NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN IN O
activator activator 0 0 0 0 0 0 0 0 9 0 NN CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NNP O
SOCE. SOCE. 1 1 0 0 0 0 0 0 5 0 NN IN NNP NNP NN O
Aberrant Aberrant 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP MD O
STIM1 STIM1 1 1 0 0 0 0 0 1 5 0 NN IN NNP MD VB O
could could 0 0 0 0 0 0 0 0 5 0 IN NNP MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NNP MD VB VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 MD VB VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VB VBN IN JJ JJ O
several several 0 0 0 0 0 0 0 0 7 0 VBN IN JJ JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 IN JJ JJ NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
role role 0 0 0 0 0 0 0 0 4 0 NNP DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
STIM1 STIM1 1 1 0 0 0 0 0 1 5 0 NN IN NNP IN VBG O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN VBG NN O
regulating regulating 0 0 0 0 0 0 0 0 10 0 NNP IN VBG NN IN O
tumorigenesis tumorigenesis 0 0 0 0 0 0 0 0 13 0 IN VBG NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBG NN IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN RB O
glioblastoma glioblastoma 0 0 0 0 0 0 0 0 12 0 IN JJ NN RB VBZ O
still still 0 0 0 0 0 0 0 0 5 0 JJ NN RB VBZ NNP O
remains remains 0 0 0 0 0 0 0 0 7 0 NN RB VBZ NNP NNP O
unclear. unclear. 0 0 0 0 0 0 0 0 8 0 RB VBZ NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 VBZ NNP NNP NNP IN O
Expression Expression 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NN O
STIM1 STIM1 1 1 0 0 0 0 0 1 5 0 NNP IN NNP NN IN O
protein protein 0 0 0 0 0 0 0 0 7 0 IN NNP NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN IN O
panel panel 0 0 0 0 0 0 0 0 5 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN NN NN NN O
glioblastoma glioblastoma 0 0 0 0 0 0 0 0 12 0 IN NN NN NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NNS -NONE- O
lines lines 0 0 0 0 0 0 0 0 5 0 NN NN NNS -NONE- NNP O
(U251, (U251, 0 1 0 0 1 0 0 1 6 0 NN NNS -NONE- NNP CC O
U87 U87 1 1 0 0 0 0 0 1 3 0 NNS -NONE- NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NNP CC NNP IN O
U373) U373) 1 1 0 0 0 0 0 1 5 0 NNP CC NNP IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 CC NNP IN JJ NN O
different different 0 0 0 0 0 0 0 0 9 0 NNP IN JJ NN NN O
transformation transformation 0 0 0 0 0 0 0 0 14 0 IN JJ NN NN VBD O
level level 0 0 0 0 0 0 0 0 5 0 JJ NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN IN O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NN O
Western Western 1 0 0 0 0 0 0 0 7 0 VBN IN NNP NN NNP O
blot blot 0 0 0 0 0 0 0 0 4 0 IN NNP NN NNP NNP O
method. method. 0 0 0 0 0 0 0 0 7 0 NNP NN NNP NNP NN O
STIM1 STIM1 1 1 0 0 0 0 0 1 5 0 NN NNP NNP NN IN O
loss loss 0 0 0 0 0 0 0 0 4 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN VBD O
function function 0 0 0 0 0 0 0 0 8 0 NN IN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 IN NN VBD VBN IN O
performed performed 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
U251 U251 1 1 0 0 0 0 0 1 4 0 VBN IN NNP NNP VBD O
cells, cells, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP VBD IN O
derived derived 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD IN NN O
from from 0 0 0 0 0 0 0 0 4 0 NNP VBD IN NN NNP O
grade grade 0 0 0 0 0 0 0 0 5 0 VBD IN NN NNP NNP O
IV IV 1 1 0 0 0 0 0 0 2 0 IN NN NNP NNP NN O
astrocytomas-glioblastoma astrocytomas-glioblastoma 0 0 1 0 0 0 0 0 25 0 NN NNP NNP NN IN O
multiforme multiforme 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NNP NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
lentvirus-mediated lentvirus-mediated 0 0 1 0 0 0 0 0 18 0 IN DT JJ NN NN O
short short 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN NNP O
harpin harpin 0 0 0 0 0 0 0 0 6 0 JJ NN NN NNP NNP O
RNA RNA 1 1 0 0 0 0 0 0 3 0 NN NN NNP NNP NNP O
(shRNA) (shRNA) 0 0 0 0 0 0 0 0 7 0 NN NNP NNP NNP NNP O
method. method. 0 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP JJ NNS O
biological biological 0 0 0 0 0 0 0 0 10 0 NNP NNP JJ NNS IN O
impacts impacts 0 0 0 0 0 0 0 0 7 0 NNP JJ NNS IN NN O
after after 0 0 0 0 0 0 0 0 5 0 JJ NNS IN NN IN O
knock knock 0 0 0 0 0 0 0 0 5 0 NNS IN NN IN IN O
down down 0 0 0 0 0 0 0 0 4 0 IN NN IN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN IN IN NNP IN O
STIM1 STIM1 1 1 0 0 0 0 0 1 5 0 IN IN NNP IN NN O
on on 0 0 0 0 0 0 0 0 2 0 IN NNP IN NN NNS O
glioblastoma glioblastoma 0 0 0 0 0 0 0 0 12 0 NNP IN NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NNS VBD VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN CC O
vitro vitro 0 0 0 0 0 0 0 0 5 0 VBN IN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN CC IN NNP NNP O
vivo. vivo. 0 0 0 0 0 0 0 0 5 0 CC IN NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 IN NNP NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBD IN O
discovered discovered 0 0 0 0 0 0 0 0 10 0 NNP NNP VBD IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBD IN NNP NN O
STIM1 STIM1 1 1 0 0 0 0 0 1 5 0 VBD IN NNP NN VBD O
protein protein 0 0 0 0 0 0 0 0 7 0 IN NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
expressed expressed 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
U251, U251, 1 1 0 0 1 0 0 1 5 0 VBN IN NNP NNP CC O
U87 U87 1 1 0 0 0 0 0 1 3 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
U373 U373 1 1 0 0 0 0 0 1 4 0 NNP CC NNP NNP CC O
cells, cells, 0 0 0 0 1 0 0 0 6 0 CC NNP NNP CC RB O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC RB JJR O
especially especially 0 0 0 0 0 0 0 0 10 0 NNP CC RB JJR IN O
higher higher 0 0 0 0 0 0 0 0 6 0 CC RB JJR IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 RB JJR IN NNP NNP O
U251 U251 1 1 0 0 0 0 0 1 4 0 JJR IN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NN O
RNA RNA 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NN RB O
interference interference 0 0 0 0 0 0 0 0 12 0 NNP NNP NN RB VBN O
efficiently efficiently 0 0 0 0 0 0 0 0 11 0 NNP NN RB VBN DT O
downregulated downregulated 0 0 0 0 0 0 0 0 13 0 NN RB VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBN DT NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 VBN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
STIM1 STIM1 1 1 0 0 0 0 0 1 5 0 NN IN NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NNS O
U251 U251 1 1 0 0 0 0 0 1 4 0 NNP IN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT NNP O
both both 0 0 0 0 0 0 0 0 4 0 NNS IN DT NNP CC O
mRNA mRNA 0 0 0 0 0 0 0 0 4 0 IN DT NNP CC VB O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC VB NNP O
protein protein 0 0 0 0 0 0 0 0 7 0 NNP CC VB NNP NNP O
levels. levels. 0 0 0 0 0 0 0 0 7 0 CC VB NNP NNP NN O
Specific Specific 1 0 0 0 0 0 0 0 8 0 VB NNP NNP NN IN O
downregulation downregulation 0 0 0 0 0 0 0 0 14 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP VBD O
STIM1 STIM1 1 1 0 0 0 0 0 1 5 0 NN IN NNP VBD NNP O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 IN NNP VBD NNP NN O
U251 U251 1 1 0 0 0 0 0 1 4 0 NNP VBD NNP NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBD NNP NN NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NNP NN NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
inducing inducing 0 0 0 0 0 0 0 0 8 0 NN IN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN NN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest NN NN NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN IN -NONE- O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN -NONE- NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase NN IN -NONE- NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN -NONE- NN IN NN O
through through 0 0 0 0 0 0 0 0 7 0 -NONE- NN IN NN IN O
regulation regulation 0 0 0 0 0 0 0 0 10 0 NN IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN JJ O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN JJ NN O
cycle-related cycle-related 0 0 1 0 0 0 0 0 13 0 IN NN JJ NN JJ O
genes, genes, 0 0 0 0 1 0 0 0 6 0 NN JJ NN JJ IN O
such such 0 0 0 0 0 0 0 0 4 0 JJ NN JJ IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 NN JJ IN JJ NN O
p21Waf1/Cip1, p21Waf1/Cip1, 0 0 0 1 1 0 0 1 13 0 JJ IN JJ NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNP CC O
D1 D1 1 1 0 0 0 0 0 1 2 0 JJ NN NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC JJ NN O
cyclin-dependent cyclin-dependent 0 0 1 0 0 0 0 0 16 0 NNP CC JJ NN CD O
kinase kinase 0 0 0 0 0 0 0 0 6 0 CC JJ NN CD NN O
4 4 0 0 0 0 0 0 1 1 1 0 JJ NN CD NN CC O
(CDK4), (CDK4), 0 1 0 0 1 0 0 1 7 0 NN CD NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 CD NN CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT JJ NN O
antiproliferative antiproliferative 0 0 0 0 0 0 0 0 17 0 CC DT JJ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
STIM1 STIM1 1 1 0 0 0 0 0 1 5 0 NN IN NNP NN VBD O
silencing silencing 0 0 0 0 0 0 0 0 9 0 IN NNP NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD RB VBN O
also also 0 0 0 0 0 0 0 0 4 0 NN VBD RB VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 VBD RB VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN NNP NN O
U251 U251 1 1 0 0 0 0 0 1 4 0 VBN IN NNP NN NN O
glioma glioma 0 0 0 0 0 0 0 0 6 0 IN NNP NN NN NN O
xenograft xenograft 0 0 0 0 0 0 0 0 9 0 NNP NN NN NN NNP O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NN NN NN NNP NNP O
model. model. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP NNP O
CONCLUSION: CONCLUSION: 1 1 0 0 0 0 0 0 11 0 NN NNP NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS NN O
findings findings 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS NN NNP O
confirm confirm 0 0 0 0 0 0 0 0 7 0 NNP NNS NN NNP IN O
STIM1 STIM1 1 1 0 0 0 0 0 1 5 0 NNS NN NNP IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NN NNP IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT JJ JJ O
rational rational 0 0 0 0 0 0 0 0 8 0 IN DT JJ JJ NN O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 DT JJ JJ NN IN O
target target 0 0 0 0 0 0 0 0 6 0 JJ JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN NN NN CC O
glioblastoma, glioblastoma, 0 0 0 0 1 0 0 0 13 0 IN NN NN CC RB O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC RB VBP O
also also 0 0 0 0 0 0 0 0 4 0 NN CC RB VBP IN O
indicate indicate 0 0 0 0 0 0 0 0 8 0 CC RB VBP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 RB VBP IN JJ NNP O
lentivirus-mediated lentivirus-mediated 0 0 1 0 0 0 0 0 19 0 VBP IN JJ NNP NN O
STIM1 STIM1 1 1 0 0 0 0 0 1 5 0 IN JJ NNP NN VBZ O
silencing silencing 0 0 0 0 0 0 0 0 9 0 JJ NNP NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT NN JJ O
promising promising 0 0 0 0 0 0 0 0 9 0 VBZ DT NN JJ NN O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 DT NN JJ NN IN O
strategy strategy 0 0 0 0 0 0 0 0 8 0 NN JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN NNP O
human human 0 0 0 0 0 0 0 0 5 0 NN IN NN NNP NONE O
glioblastoma. glioblastoma. 0 0 0 0 0 0 0 0 13 0 IN NN NNP NONE NONE O
Diazepam Diazepam 1 0 0 0 0 0 0 0 8 0 NONE NONE NNP VBZ NN O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 NONE NNP VBZ NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NNP VBZ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBZ NN IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NNS O
glioblastoma glioblastoma 0 0 0 0 0 0 0 0 12 0 IN JJ NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN VBG O
through through 0 0 0 0 0 0 0 0 7 0 NN NNS IN VBG DT O
triggering triggering 0 0 0 0 0 0 0 0 10 0 NNS IN VBG DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 IN VBG DT JJ NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 VBG DT JJ NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN NNP O
cycle cycle 0 0 0 0 0 0 0 0 5 0 JJ NN NN NNP NNP O
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ouyang Ouyang 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Cao Cao 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhu Zhu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
W, W, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhou Zhou 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhou Zhou 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yang Yang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Mao Mao 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lin Lin 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lin Lin 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hu Hu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yan Yan 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
G. G. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pharmacology, Pharmacology, 1 0 0 0 1 0 0 0 13 0 NNP IN NNP NNP NNP O
Zhongshan Zhongshan 1 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Sun Sun 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
Yat-sen Yat-sen 1 0 1 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Guangzhou, Guangzhou, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
PR PR 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
Glioblastoma Glioblastoma 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP DT O
(GBM), (GBM), 0 1 0 0 1 0 0 0 6 0 NNP NNP NNP DT RBS O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT RBS JJ O
most most 0 0 0 0 0 0 0 0 4 0 NNP DT RBS JJ JJ O
common common 0 0 0 0 0 0 0 0 6 0 DT RBS JJ JJ NN O
primary primary 0 0 0 0 0 0 0 0 7 0 RBS JJ JJ NN NN O
brain brain 0 0 0 0 0 0 0 0 5 0 JJ JJ NN NN VBZ O
tumor, tumor, 0 0 0 0 1 0 0 0 6 0 JJ NN NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ DT RBS O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT RBS JJ O
most most 0 0 0 0 0 0 0 0 4 0 VBZ DT RBS JJ NN O
aggressive aggressive 0 0 0 0 0 0 0 0 10 0 DT RBS JJ NN IN O
malignancy malignancy 0 0 0 0 0 0 0 0 10 0 RBS JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
humans. humans. 0 0 0 0 0 0 0 0 7 0 NN IN NNP NNP VBD O
Its Its 1 0 0 0 0 0 0 0 3 0 IN NNP NNP VBD NN O
rapid rapid 0 0 0 0 0 0 0 0 5 0 NNP NNP VBD NN VBZ O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NNP VBD NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 VBD NN VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT JJ NN O
major major 0 0 0 0 0 0 0 0 5 0 VBZ DT JJ NN TO O
obstacle obstacle 0 0 0 0 0 0 0 0 8 0 DT JJ NN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO JJ NNP O
successful successful 0 0 0 0 0 0 0 0 10 0 NN TO JJ NNP NNP O
treatment. treatment. 0 0 0 0 0 0 0 0 10 0 TO JJ NNP NNP IN O
Patients Patients 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNP IN NNP RB O
GBM GBM 1 1 0 0 0 0 0 0 3 0 NNP IN NNP RB VBP O
often often 0 0 0 0 0 0 0 0 5 0 IN NNP RB VBP IN O
suffer suffer 0 0 0 0 0 0 0 0 6 0 NNP RB VBP IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 RB VBP IN JJ NNS O
psychological psychological 0 0 0 0 0 0 0 0 13 0 VBP IN JJ NNS VBN O
disturbances disturbances 0 0 0 0 0 0 0 0 12 0 IN JJ NNS VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 JJ NNS VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBN IN JJ NNS O
poor poor 0 0 0 0 0 0 0 0 4 0 VBN IN JJ NNS CC O
prognosis prognosis 0 0 0 0 0 0 0 0 9 0 IN JJ NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC JJ NNP O
physical physical 0 0 0 0 0 0 0 0 8 0 NNS CC JJ NNP NNP O
discomfort. discomfort. 0 0 0 0 0 0 0 0 11 0 CC JJ NNP NNP VBZ O
Diazepam Diazepam 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP VBZ CD O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ CD IN O
one one 0 0 0 0 0 0 0 0 3 0 NNP VBZ CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBZ CD IN DT RBS O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT RBS RB O
most most 0 0 0 0 0 0 0 0 4 0 IN DT RBS RB JJ O
frequently frequently 0 0 0 0 0 0 0 0 10 0 DT RBS RB JJ NNS O
used used 0 0 0 0 0 0 0 0 4 0 RBS RB JJ NNS -NONE- O
benzodiazepines benzodiazepines 0 0 0 0 0 0 0 0 15 0 RB JJ NNS -NONE- IN O
(BZs) (BZs) 0 0 0 0 0 0 0 0 5 0 JJ NNS -NONE- IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNS -NONE- IN NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 -NONE- IN NN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 IN NN NNS IN PRP$ O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN PRP$ JJ O
its its 0 0 0 0 0 0 0 0 3 0 NNS IN PRP$ JJ JJ O
desirable desirable 0 0 0 0 0 0 0 0 9 0 IN PRP$ JJ JJ NNP O
psychotropic psychotropic 0 0 0 0 0 0 0 0 12 0 PRP$ JJ JJ NNP NNP O
effects. effects. 0 0 0 0 0 0 0 0 8 0 JJ JJ NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP JJ NNS O
central central 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 NNP JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP VBP O
BZs BZs 1 0 0 0 0 0 0 0 3 0 NNS IN NNP VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 IN NNP VBP VBN IN O
mediated mediated 0 0 0 0 0 0 0 0 8 0 NNP VBP VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBP VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
central central 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNP NNP O
BZ BZ 1 1 0 0 0 0 0 0 2 0 IN JJ NNP NNP NNP O
receptors. receptors. 0 0 0 0 0 0 0 0 10 0 JJ NNP NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NN VBZ O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ IN O
investigates investigates 0 0 0 0 0 0 0 0 12 0 NNP NN VBZ IN NN O
whether whether 0 0 0 0 0 0 0 0 7 0 NN VBZ IN NN VBZ O
diazepam diazepam 0 0 0 0 0 0 0 0 8 0 VBZ IN NN VBZ NN O
has has 0 0 0 0 0 0 0 0 3 0 IN NN VBZ NN NN O
inhibitory inhibitory 0 0 0 0 0 0 0 0 10 0 NN VBZ NN NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 VBZ NN NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NN NN IN NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NN IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NN O
GBM GBM 1 1 0 0 0 0 0 0 3 0 NN IN NNP NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN NNP NN NN NNP O
line line 0 0 0 0 0 0 0 0 4 0 NNP NN NN NNP CC O
T98G T98G 1 1 0 0 0 0 0 1 4 0 NN NN NNP CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNS PRP$ O
explores explores 0 0 0 0 0 0 0 0 8 0 NNP CC NNS PRP$ JJ O
its its 0 0 0 0 0 0 0 0 3 0 CC NNS PRP$ JJ NNP O
possible possible 0 0 0 0 0 0 0 0 8 0 NNS PRP$ JJ NNP NNP O
mechanism. mechanism. 0 0 0 0 0 0 0 0 10 0 PRP$ JJ NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 JJ NNP NNP NNP NN O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NN CC O
viability viability 0 0 0 0 0 0 0 0 9 0 NNP NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN VBD O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NN CC NN VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 CC NN VBD RB VBN O
respectively respectively 0 0 0 0 0 0 0 0 12 0 NN VBD RB VBN IN O
determined determined 0 0 0 0 0 0 0 0 10 0 VBD RB VBN IN CD O
by by 0 0 0 0 0 0 0 0 2 0 RB VBN IN CD NN O
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium 0 0 1 0 1 0 0 1 53 0 VBN IN CD NN -NONE- O
bromide bromide 0 0 0 0 0 0 0 0 7 0 IN CD NN -NONE- VBP O
(MTT) (MTT) 0 1 0 0 0 0 0 0 5 0 CD NN -NONE- VBP CC O
assay assay 0 0 0 0 0 0 0 0 5 0 NN -NONE- VBP CC CD O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- VBP CC CD NN O
5-bromo-2'-deoxyuridine 5-bromo-2'-deoxyuridine 0 0 1 0 0 1 0 1 23 0 VBP CC CD NN NN O
(BrdU) (BrdU) 0 0 0 0 0 0 0 0 6 0 CC CD NN NN NNP O
incorporation incorporation 0 0 0 0 0 0 0 0 13 0 CD NN NN NNP NNP O
assay. assay. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP NN O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NN VBD O
distribution distribution 0 0 0 0 0 0 0 0 12 0 NNP NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
examined examined 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN NNP O
flow flow 0 0 0 0 0 0 0 0 4 0 VBN IN NN NNP NNP O
cytometry. cytometry. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP NN O
Western Western 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NN IN O
blot blot 0 0 0 0 0 0 0 0 4 0 NNP NNP NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNP NN IN JJ NN O
specific specific 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN NNS O
protein protein 0 0 0 0 0 0 0 0 7 0 IN JJ NN NNS VBD O
antibodies antibodies 0 0 0 0 0 0 0 0 10 0 JJ NN NNS VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NNS VBD VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 NNS VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB JJ O
detect detect 0 0 0 0 0 0 0 0 6 0 VBN TO VB JJ NNS O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 TO VB JJ NNS VBN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 VB JJ NNS VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 JJ NNS VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBN IN NN NN NNP O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN NNP NNP O
regulation. regulation. 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 NN NNP NNP NNP RB O
Diazepam Diazepam 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP RB VBD O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNP NNP RB VBD DT O
decreased decreased 0 0 0 0 0 0 0 0 9 0 NNP RB VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBD DT NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VBD DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNS O
T98G T98G 1 1 0 0 0 0 0 1 4 0 NN IN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ CC O
dose-dependent dose-dependent 0 0 1 0 0 0 0 0 14 0 IN DT JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC JJ NNP O
time-dependent time-dependent 0 0 1 0 0 0 0 0 14 0 JJ CC JJ NNP NNP O
manner. manner. 0 0 0 0 0 0 0 0 7 0 CC JJ NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NN VBD O
effect effect 0 0 0 0 0 0 0 0 6 0 NNP NNP NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD RB VBN O
not not 0 0 0 0 0 0 0 0 3 0 NN VBD RB VBN IN O
reversed reversed 0 0 0 0 0 0 0 0 8 0 VBD RB VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 RB VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNP O
central central 0 0 0 0 0 0 0 0 7 0 IN DT JJ NNP NN O
BZ BZ 1 1 0 0 0 0 0 0 2 0 DT JJ NNP NN NN O
receptor receptor 0 0 0 0 0 0 0 0 8 0 JJ NNP NN NN NN O
antagonist antagonist 0 0 0 0 0 0 0 0 10 0 NNP NN NN NN CC O
flumazenil flumazenil 0 0 0 0 0 0 0 0 10 0 NN NN NN CC DT O
or or 0 0 0 0 0 0 0 0 2 0 NN NN CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT JJ NNP O
peripheral peripheral 0 0 0 0 0 0 0 0 10 0 CC DT JJ NNP NN O
BZ BZ 1 1 0 0 0 0 0 0 2 0 DT JJ NNP NN NN O
receptor receptor 0 0 0 0 0 0 0 0 8 0 JJ NNP NN NN NN O
antagonist antagonist 0 0 0 0 0 0 0 0 10 0 NNP NN NN NN VBG O
PK11195, PK11195, 1 1 0 0 1 0 0 1 8 0 NN NN NN VBG IN O
indicating indicating 0 0 0 0 0 0 0 0 10 0 NN NN VBG IN PRP O
that that 0 0 0 0 0 0 0 0 4 0 NN VBG IN PRP VBD O
it it 0 0 0 0 0 0 0 0 2 0 VBG IN PRP VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 IN PRP VBD RB VBN O
not not 0 0 0 0 0 0 0 0 3 0 PRP VBD RB VBN IN O
mediated mediated 0 0 0 0 0 0 0 0 8 0 VBD RB VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 RB VBN IN NNP NNP O
BZ BZ 1 1 0 0 0 0 0 0 2 0 VBN IN NNP NNP NNP O
receptors. receptors. 0 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP NN O
Flow Flow 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NN VBD O
cytometry cytometry 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBD IN O
indicated indicated 0 0 0 0 0 0 0 0 9 0 NNP NN VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN NN VBD O
diazepam diazepam 0 0 0 0 0 0 0 0 8 0 VBD IN NN VBD DT O
caused caused 0 0 0 0 0 0 0 0 6 0 IN NN VBD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN VBD DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBD DT NN NN IN O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 DT NN NN IN -NONE- O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN -NONE- JJ O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NN IN -NONE- JJ NN B_TIMEXCCP
phase, phase, 0 0 0 0 1 0 0 0 6 0 IN -NONE- JJ NN VBG O
thereby thereby 0 0 0 0 0 0 0 0 7 0 -NONE- JJ NN VBG TO O
contributing contributing 0 0 0 0 0 0 0 0 12 0 JJ NN VBG TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBG TO VB NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBG TO VB NN NNP O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 TO VB NN NNP NNP O
inhibition. inhibition. 0 0 0 0 0 0 0 0 11 0 VB NN NNP NNP PRP$ O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 NN NNP NNP PRP$ NNS O
our our 0 0 0 0 0 0 0 0 3 0 NNP NNP PRP$ NNS VBD O
findings findings 0 0 0 0 0 0 0 0 8 0 NNP PRP$ NNS VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 PRP$ NNS VBD IN VBN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN VBN NN O
lessened lessened 0 0 0 0 0 0 0 0 8 0 VBD IN VBN NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 IN VBN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNP VBD O
Rb Rb 1 0 0 0 0 0 0 0 2 0 NN IN NNP VBD IN O
accounted accounted 0 0 0 0 0 0 0 0 9 0 IN NNP VBD IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NNP VBD IN JJ -NONE- O
diazepam-induced diazepam-induced 0 0 1 0 0 0 0 0 16 0 VBD IN JJ -NONE- NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase IN JJ -NONE- NN NNP B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 JJ -NONE- NN NNP NNP O
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 -NONE- NN NNP NNP NNP O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 NN NNP NNP NNP VBZ O
Diazepam Diazepam 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP VBZ DT O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VBZ DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ NNP NNP O
GBM GBM 1 1 0 0 0 0 0 0 3 0 IN JJ NNP NNP VBZ O
T98G T98G 1 1 0 0 0 0 0 1 4 0 JJ NNP NNP VBZ IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN NN -NONE- O
inducing inducing 0 0 0 0 0 0 0 0 8 0 VBZ IN NN -NONE- NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase IN NN -NONE- NN NNP B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 NN -NONE- NN NNP NNP O
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 -NONE- NN NNP NNP VBZ O
Diazepam Diazepam 1 0 0 0 0 0 0 0 8 0 NN NNP NNP VBZ JJ O
has has 0 0 0 0 0 0 0 0 3 0 NNP NNP VBZ JJ TO O
potential potential 0 0 0 0 0 0 0 0 9 0 NNP VBZ JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO VB DT O
be be 0 0 0 0 0 0 0 0 2 0 JJ TO VB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT NN IN O
lead lead 0 0 0 0 0 0 0 0 4 0 VB DT NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN JJ NNS O
new new 0 0 0 0 0 0 0 0 3 0 NN IN JJ NNS IN O
drugs drugs 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NN O
GBM GBM 1 1 0 0 0 0 0 0 3 0 NNS IN NNP NN IN O
therapy therapy 0 0 0 0 0 0 0 0 7 0 IN NNP NN IN IN O
because because 0 0 0 0 0 0 0 0 7 0 NNP NN IN IN PRP$ O
of of 0 0 0 0 0 0 0 0 2 0 NN IN IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 IN IN PRP$ NN NNP O
antitumor antitumor 0 0 0 0 0 0 0 0 9 0 IN PRP$ NN NNP NONE O
activity. activity. 0 0 0 0 0 0 0 0 9 0 PRP$ NN NNP NONE NONE O
Effect Effect 1 0 0 0 0 0 0 0 6 0 NONE NONE NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NNP IN O
bFGF bFGF 0 0 0 0 0 0 0 0 4 0 NN IN NNP IN DT O
on on 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP NNP O
MCF-7 MCF-7 1 1 1 0 0 0 0 1 5 0 IN DT NNP NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 DT NNP NNP NNP IN O
Cycle Cycle 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNP IN JJ NNP O
CD44(+)/CD24(-): CD44(+)/CD24(-): 1 1 1 1 0 0 0 1 16 0 NNP IN JJ NNP DT O
Promoting Promoting 1 0 0 0 0 0 0 0 9 0 IN JJ NNP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 JJ NNP DT NNP NNP O
G0/G1→G2/S G0/G1→G2/S 1 1 0 1 0 0 0 1 10 0 NNP DT NNP NNP NNP to
Transition. Transition. 1 0 0 0 0 0 0 0 11 0 DT NNP NNP NNP NNP O
Yang Yang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
ZL, ZL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Cheng Cheng 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Han Han 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
ZD. ZD. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
First First 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Affilated Affilated 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP IN O
Hospital Hospital 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Binzhou Binzhou 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Binzhou, Binzhou, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
PURPOSE: PURPOSE: 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
Few Few 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP VBZ IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NNP VBZ IN NN NN O
stem stem 0 0 0 0 0 0 0 0 4 0 VBZ IN NN NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 IN NN NN NNS VBP O
characteristics characteristics 0 0 0 0 0 0 0 0 15 0 NN NN NNS VBP NNS O
possess possess 0 0 0 0 0 0 0 0 7 0 NN NNS VBP NNS IN O
capabilities capabilities 0 0 0 0 0 0 0 0 12 0 NNS VBP NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBP NNS IN JJ CC O
self-renewal self-renewal 0 0 1 0 0 0 0 0 12 0 NNS IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ WDT O
differentiation, differentiation, 0 0 0 0 1 0 0 0 16 0 JJ CC JJ WDT NNS O
which which 0 0 0 0 0 0 0 0 5 0 CC JJ WDT NNS TO O
leads leads 0 0 0 0 0 0 0 0 5 0 JJ WDT NNS TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 WDT NNS TO JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 NNS TO JJ NN CC O
tumorigenesis tumorigenesis 0 0 0 0 0 0 0 0 13 0 TO JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN TO O
resistance resistance 0 0 0 0 0 0 0 0 10 0 NN CC NN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 CC NN TO JJ JJ O
standard standard 0 0 0 0 0 0 0 0 8 0 NN TO JJ JJ NNP O
chemotherapeutic chemotherapeutic 0 0 0 0 0 0 0 0 16 0 TO JJ JJ NNP NNP O
agents. agents. 0 0 0 0 0 0 0 0 7 0 JJ JJ NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP NNS VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNS VBP RB JJ O
mostly mostly 0 0 0 0 0 0 0 0 6 0 NNS VBP RB JJ CC O
quiescent, quiescent, 0 0 0 0 1 0 0 0 10 0 VBP RB JJ CC JJS O
and and 0 0 0 0 0 0 0 0 3 arrest RB JJ CC JJS NNS O
arrest arrest 0 0 0 0 0 0 0 0 6 0 JJ CC JJS NNS IN O
occurs occurs 0 0 0 0 0 0 0 0 6 0 CC JJS NNS IN DT O
at at 0 0 0 0 0 0 0 0 2 0 JJS NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN NN mitotic
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase DT JJ NN NN IN mitotic
phase phase 0 0 0 0 0 0 0 0 5 0 JJ NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
mitosis. mitosis. 0 0 0 0 0 0 0 0 8 0 NN IN NNP NNP VBD B_TIMEXCCP 
We We 1 0 0 0 0 0 0 0 2 0 IN NNP NNP VBD DT O
explored explored 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 VBD DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NN O
basic basic 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NN NN O
fibroblast fibroblast 0 0 0 0 0 0 0 0 10 0 IN JJ NN NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN NN O
factor factor 0 0 0 0 0 0 0 0 6 0 NN NN NN NN IN O
(bFGF) (bFGF) 0 0 0 0 0 0 0 0 6 0 NN NN NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
MCF-7 MCF-7 1 1 1 0 0 0 0 1 5 0 IN DT NNP NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 DT NNP NN NN IN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NNP NN NN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN NNP NNP O
CD44(+)/CD24(-). CD44(+)/CD24(-). 1 1 1 1 0 0 0 1 16 0 NN IN NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 IN NNP NNP NNP VBZ O
Cancer-initiating Cancer-initiating 1 0 1 0 0 0 0 0 17 0 NNP NNP NNP VBZ VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBD VBN IN O
propagated propagated 0 0 0 0 0 0 0 0 10 0 VBZ VBD VBN IN NNP O
as as 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
mammospheres. mammospheres. 0 0 0 0 0 0 0 0 13 0 VBN IN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP NN O
CD44(+)/CD24(-) CD44(+)/CD24(-) 1 1 1 1 0 0 0 1 15 0 NNP NNP NNP NN VBD O
subpopulation subpopulation 0 0 0 0 0 0 0 0 13 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
sorted sorted 0 0 0 0 0 0 0 0 6 0 NN VBD VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NN VBG O
fluorescence fluorescence 0 0 0 0 0 0 0 0 12 0 IN DT NN VBG NN O
activating activating 0 0 0 0 0 0 0 0 10 0 DT NN VBG NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN VBG NN NN NN O
sorter-Vantage sorter-Vantage 0 0 1 0 0 0 0 0 14 0 VBG NN NN NN NNP O
flow flow 0 0 0 0 0 0 0 0 4 0 NN NN NN NNP DT O
cytometer. cytometer. 0 0 0 0 0 0 0 0 10 0 NN NN NNP DT NN O
A A 1 1 0 0 0 0 0 0 1 0 NN NNP DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP DT NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NN NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
performed performed 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN JJ NNP O
different different 0 0 0 0 0 0 0 0 9 0 VBN IN JJ NNP NNP O
bFGF bFGF 0 0 0 0 0 0 0 0 4 0 IN JJ NNP NNP NNP O
concentrations. concentrations. 0 0 0 0 0 0 0 0 15 0 JJ NNP NNP NNP NNPS O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNPS IN O
Differences Differences 1 0 0 0 0 0 0 0 11 0 NNP NNP NNPS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNPS IN DT NN NN O
CD44(+)/CD24(-) CD44(+)/CD24(-) 1 1 1 1 0 0 0 1 15 0 IN DT NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 DT NN NN NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NN NN NN IN JJ O
under under 0 0 0 0 0 0 0 0 5 0 NN NN IN JJ NNP O
different different 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNP NNS O
bFGF bFGF 0 0 0 0 0 0 0 0 4 0 IN JJ NNP NNS VBD O
concentrations concentrations 0 0 0 0 0 0 0 0 14 0 JJ NNP NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD VBN -NONE- O
observed observed 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN -NONE- WRB O
(p=0.001). (p=0.001). 0 0 0 0 0 0 0 1 10 0 VBD VBN -NONE- WRB DT O
When When 1 0 0 0 0 0 0 0 4 0 VBN -NONE- WRB DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- WRB DT NNP NN O
bFGF bFGF 0 0 0 0 0 0 0 0 4 0 WRB DT NNP NN VBD O
concentration concentration 0 0 0 0 0 0 0 0 13 0 DT NNP NN VBD JJ O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD JJ DT O
increased, increased, 0 0 0 0 1 0 0 0 10 0 NN VBD JJ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD JJ DT NN IN O
proportion proportion 0 0 0 0 0 0 0 0 10 0 JJ DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
CD44(+)/CD24(-) CD44(+)/CD24(-) 1 1 1 1 0 0 0 1 15 0 NN IN NNP IN -NONE- O
at at 0 0 0 0 0 0 0 0 2 0 IN NNP IN -NONE- VBN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NNP IN -NONE- VBN NNP B_TIMEXCCP
decreased decreased 0 0 0 0 0 0 0 0 9 0 IN -NONE- VBN NNP NNP O
(p=0.023). (p=0.023). 0 0 0 0 0 0 0 1 10 0 -NONE- VBN NNP NNP NNP O
CONCLUSION: CONCLUSION: 1 1 0 0 0 0 0 0 11 0 VBN NNP NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBP IN O
conclude conclude 0 0 0 0 0 0 0 0 8 0 NNP NNP VBP IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBP IN NNP MD O
bFGF bFGF 0 0 0 0 0 0 0 0 4 0 VBP IN NNP MD VB O
may may 0 0 0 0 0 0 0 0 3 0 IN NNP MD VB -NONE- O
sustain sustain 0 0 0 0 0 0 0 0 7 0 NNP MD VB -NONE- NN O
CD44(+)/CD24(-) CD44(+)/CD24(-) 1 1 1 1 0 0 0 1 15 0 MD VB -NONE- NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VB -NONE- NN NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 -NONE- NN NN CC MD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC MD VB O
could could 0 0 0 0 0 0 0 0 5 0 NN CC MD VB NN O
promote promote 0 0 0 0 0 0 0 0 7 0 CC MD VB NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 MD VB NN NN IN O
progression progression 0 0 0 0 0 0 0 0 11 0 VB NN NN IN DT O
through through 0 0 0 0 0 0 0 0 7 0 NN NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS VBP O
G0/G1→G2/S G0/G1→G2/S 1 1 0 1 0 0 0 1 10 phase IN DT NNS VBP NNP to
phase phase 0 0 0 0 0 0 0 0 5 0 DT NNS VBP NNP NNP O
transition. transition. 0 0 0 0 0 0 0 0 11 0 NNS VBP NNP NNP NNP O
KEYWORDS: KEYWORDS: 1 1 0 0 0 0 0 0 9 0 VBP NNP NNP NNP NNP O
Breast Breast 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
neoplasms, neoplasms, 0 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
cycle, cycle, 0 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NN O
Fibroblast Fibroblast 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NN -NONE- O
growth growth 0 0 0 0 0 0 0 0 6 0 NNP NNP NN -NONE- NNP O
factors, factors, 0 0 0 0 1 0 0 0 8 0 NNP NN -NONE- NNP NNS O
Stem Stem 1 0 0 0 0 0 0 0 4 0 NN -NONE- NNP NNS NONE O
cells cells 0 0 0 0 0 0 0 0 5 0 -NONE- NNP NNS NONE NONE O
Glibenclamide Glibenclamide 1 0 0 0 0 0 0 0 13 0 NONE NONE NNP VBZ NN O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 NONE NNP VBZ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP VBZ NN NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 VBZ NN NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NN -NONE- O
inducing inducing 0 0 0 0 0 0 0 0 8 0 NN IN NN -NONE- JJS O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 arrest IN NN -NONE- JJS IN B_TIMEXCCP
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN -NONE- JJS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- JJS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJS IN DT JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN NN O
breast breast 0 0 0 0 0 0 0 0 6 0 DT JJ NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN NNP O
line line 0 0 0 0 0 0 0 0 4 0 NN NN NN NNP NNP O
MDA-MB-231. MDA-MB-231. 1 1 1 0 0 0 0 1 11 0 NN NN NNP NNP NNP O
Núñez Núñez 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Medina Medina 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
V, V, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Cricco Cricco 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Croci Croci 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Cocca Cocca 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Rivera Rivera 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
E, E, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Bergoc Bergoc 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Martín Martín 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
G. G. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Radioisotopes Radioisotopes 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
Laboratory, Laboratory, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Pharmacy Pharmacy 1 0 0 0 0 0 0 0 8 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Biochemistry, Biochemistry, 1 0 0 0 1 0 0 0 13 0 NNP CC NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Buenos Buenos 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNP O
Aires, Aires, 1 0 0 0 1 0 0 0 6 0 IN NNP NNP NNP NNP O
Buenos Buenos 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Aires, Aires, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
Argentina. Argentina. 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
Glibenclamide Glibenclamide 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP VBZ O
(Gli) (Gli) 0 0 0 0 0 0 0 0 5 0 NNP NNP NNP VBZ TO O
binds binds 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBZ TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBZ TO DT NN NN O
sulphonylurea sulphonylurea 0 0 0 0 0 0 0 0 13 0 TO DT NN NN NN O
receptor receptor 0 0 0 0 0 0 0 0 8 0 DT NN NN NN WDT O
(SUR) (SUR) 0 1 0 0 0 0 0 0 5 0 NN NN NN WDT VBZ O
that that 0 0 0 0 0 0 0 0 4 0 NN NN WDT VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN WDT VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 WDT VBZ DT JJ NN O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 VBZ DT JJ NN IN O
subunit subunit 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
ATP-sensitive ATP-sensitive 1 0 1 0 0 0 0 0 13 0 NN IN JJ NN NNS O
potassium potassium 0 0 0 0 0 0 0 0 9 0 IN JJ NN NNS -NONE- O
channels channels 0 0 0 0 0 0 0 0 8 0 JJ NN NNS -NONE- NNP O
(KATP (KATP 0 1 0 0 0 0 0 0 5 0 NN NNS -NONE- NNP NNP O
channels). channels). 0 0 0 0 0 0 0 0 10 0 NNS -NONE- NNP NNP IN O
Binding Binding 1 0 0 0 0 0 0 0 7 0 -NONE- NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP TO O
Gli Gli 1 0 0 0 0 0 0 0 3 0 NNP IN NNP TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 IN NNP TO NNP NNS O
SUR SUR 1 1 0 0 0 0 0 0 3 0 NNP TO NNP NNS DT O
produces produces 0 0 0 0 0 0 0 0 8 0 TO NNP NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNS DT NN IN O
closure closure 0 0 0 0 0 0 0 0 7 0 NNS DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNS O
KATP KATP 1 1 0 0 0 0 0 0 4 0 NN IN NNP NNS CC O
channels channels 0 0 0 0 0 0 0 0 8 0 IN NNP NNS CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNS CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS CC DT NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 CC DT NN IN PRP$ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN PRP$ NNP O
their their 0 0 0 0 0 0 0 0 5 0 NN IN PRP$ NNP NNP O
activity. activity. 0 0 0 0 0 0 0 0 9 0 IN PRP$ NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 PRP$ NNP NNP NN VBZ O
drug drug 0 0 0 0 0 0 0 0 4 0 NNP NNP NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ RB VBN O
widely widely 0 0 0 0 0 0 0 0 6 0 NN VBZ RB VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 VBZ RB VBN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 RB VBN IN NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 VBN IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NNS O
type type 0 0 0 0 0 0 0 0 4 0 NN IN NN NNS CC O
2-diabetes 2-diabetes 0 0 1 0 0 0 0 1 10 0 IN NN NNS CC PRP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NNS CC PRP VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 CC PRP VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 PRP VBZ VBN VBN IN O
signaled signaled 0 0 0 0 0 0 0 0 8 0 VBZ VBN VBN IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 VBN VBN IN JJ IN O
antiproliferative antiproliferative 0 0 0 0 0 0 0 0 17 0 VBN IN JJ IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN JJ IN JJ NN O
several several 0 0 0 0 0 0 0 0 7 0 JJ IN JJ NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 IN JJ NN NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NNP NNP O
lines. lines. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP JJ O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP JJ NNS O
previous previous 0 0 0 0 0 0 0 0 8 0 NNP NNP JJ NNS PRP O
experiments experiments 0 0 0 0 0 0 0 0 11 0 NNP JJ NNS PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 JJ NNS PRP VBD DT O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 NNS PRP VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT JJ NN O
antitumoral antitumoral 0 0 0 0 0 0 0 0 11 0 VBD DT JJ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP IN O
Gli Gli 1 0 0 0 0 0 0 0 3 0 NN IN NNP IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN JJ NNS O
mammary mammary 0 0 0 0 0 0 0 0 7 0 NNP IN JJ NNS VBN O
tumors tumors 0 0 0 0 0 0 0 0 6 0 IN JJ NNS VBN IN O
induced induced 0 0 0 0 0 0 0 0 7 0 JJ NNS VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBN IN NNP NNP O
rats. rats. 0 0 0 0 0 0 0 0 5 0 VBN IN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NN IN O
aim aim 0 0 0 0 0 0 0 0 3 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
present present 0 0 0 0 0 0 0 0 7 0 IN DT NN NN VBD O
work work 0 0 0 0 0 0 0 0 4 0 DT NN NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB DT O
investigate investigate 0 0 0 0 0 0 0 0 11 0 VBD TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 VB DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
Gli Gli 1 0 0 0 0 0 0 0 3 0 NN IN NNP IN -NONE- O
on on 0 0 0 0 0 0 0 0 2 0 IN NNP IN -NONE- JJ O
MDA-MB-231 MDA-MB-231 1 1 1 0 0 0 0 1 10 0 NNP IN -NONE- JJ NN O
breast breast 0 0 0 0 0 0 0 0 6 0 IN -NONE- JJ NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 -NONE- JJ NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NN NN NN CC TO O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN CC TO VB DT O
examine examine 0 0 0 0 0 0 0 0 7 0 CC TO VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJ NNS O
possible possible 0 0 0 0 0 0 0 0 8 0 VB DT JJ NNS VBN O
pathways pathways 0 0 0 0 0 0 0 0 8 0 DT JJ NNS VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 JJ NNS VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBN IN DT NNP O
this this 0 0 0 0 0 0 0 0 4 0 VBN IN DT NNP NNP O
action. action. 0 0 0 0 0 0 0 0 7 0 IN DT NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 DT NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NN O
mRNA mRNA 0 0 0 0 0 0 0 0 4 0 NNP NNP NNP NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNS O
different different 0 0 0 0 0 0 0 0 9 0 IN DT JJ NNS WDT O
subunits subunits 0 0 0 0 0 0 0 0 8 0 DT JJ NNS WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 JJ NNS WDT NN DT O
compose compose 0 0 0 0 0 0 0 0 7 0 NNS WDT NN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 WDT NN DT NNP VBZ O
KATP KATP 1 1 0 0 0 0 0 0 4 0 NN DT NNP VBZ VBD O
channels channels 0 0 0 0 0 0 0 0 8 0 DT NNP VBZ VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP VBZ VBD VBN IN O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 VBZ VBD VBN IN -NONE- O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN -NONE- NNS O
MDA-MB-231 MDA-MB-231 1 1 1 0 0 0 0 1 10 0 VBN IN -NONE- NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN -NONE- NNS IN NN O
by by 0 0 0 0 0 0 0 0 2 0 -NONE- NNS IN NN NN O
reverse reverse 0 0 0 0 0 0 0 0 7 0 NNS IN NN NN NN O
transcriptase-polymerase transcriptase-polymerase 0 0 1 0 0 0 0 0 24 0 IN NN NN NN NNP O
chain chain 0 0 0 0 0 0 0 0 5 0 NN NN NN NNP NNP O
reaction. reaction. 0 0 0 0 0 0 0 0 9 0 NN NN NNP NNP VBD O
Results Results 1 0 0 0 0 0 0 0 7 0 NN NNP NNP VBD DT O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 VBD DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
mRNA mRNA 0 0 0 0 0 0 0 0 4 0 NN IN NNP IN DT O
for for 0 0 0 0 0 0 0 0 3 0 IN NNP IN DT JJ O
both both 0 0 0 0 0 0 0 0 4 0 NNP IN DT JJ NNS O
pore-forming pore-forming 0 0 1 0 0 0 0 0 12 0 IN DT JJ NNS -NONE- O
isoforms isoforms 0 0 0 0 0 0 0 0 8 0 DT JJ NNS -NONE- CC O
Kir6.1 Kir6.1 1 0 0 0 0 0 0 1 6 0 JJ NNS -NONE- CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC -NONE- CC O
Kir6.2 Kir6.2 1 0 0 0 0 0 0 1 6 0 -NONE- CC -NONE- CC IN O
and and 0 0 0 0 0 0 0 0 3 0 CC -NONE- CC IN DT O
for for 0 0 0 0 0 0 0 0 3 0 -NONE- CC IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CC IN DT JJ NN O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN NNP O
isoform isoform 0 0 0 0 0 0 0 0 7 0 DT JJ NN NNP IN O
SUR2B SUR2B 1 1 0 0 0 0 0 1 5 0 JJ NN NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNP IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP IN DT NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NNP NNP O
line. line. 0 0 0 0 0 0 0 0 5 0 DT NN NNP NNP VBD O
Gli Gli 1 0 0 0 0 0 0 0 3 0 NN NNP NNP VBD NN O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP VBD NN NN VBD O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VBD NN NN VBD IN O
assessed assessed 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN DT O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBD IN DT JJ NN O
clonogenic clonogenic 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN IN O
method method 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN NN O
dose dose 0 0 0 0 0 0 0 0 4 0 IN DT NN NN NN O
dependent dependent 0 0 0 0 0 0 0 0 9 0 DT NN NN NN IN O
manner, manner, 0 0 0 0 1 0 0 0 7 0 NN NN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT NN IN O
increment increment 0 0 0 0 0 0 0 0 9 0 IN DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBG O
population population 0 0 0 0 0 0 0 0 10 0 IN DT NN VBG NNP O
doubling doubling 0 0 0 0 0 0 0 0 8 0 DT NN VBG NNP NNP O
time. time. 0 0 0 0 0 0 0 0 5 0 NN VBG NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 VBG NNP NNP NNP NN O
KATP KATP 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP NN NN O
channel channel 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN NN O
opener opener 0 0 0 0 0 0 0 0 6 0 NNP NN NN NN VBD O
minoxidil minoxidil 0 0 0 0 0 0 0 0 9 0 NN NN NN VBD JJ O
increased increased 0 0 0 0 0 0 0 0 9 0 NN NN VBD JJ NN O
clonogenic clonogenic 0 0 0 0 0 0 0 0 10 0 NN VBD JJ NN NN O
proliferation, proliferation, 0 0 0 0 1 0 0 0 14 0 VBD JJ NN NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 JJ NN NN IN VBD O
that that 0 0 0 0 0 0 0 0 4 0 NN NN IN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN IN VBD VBN IN O
counteracted counteracted 0 0 0 0 0 0 0 0 12 0 IN VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
Gli. Gli. 1 0 0 0 0 0 0 0 4 0 VBN IN NNP NNP NN O
When When 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NNP NN NN NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NN NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
performed performed 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN -NONE- O
flow flow 0 0 0 0 0 0 0 0 4 0 VBN IN NN -NONE- NNP O
cytometry, cytometry, 0 0 0 0 1 0 0 0 10 0 IN NN -NONE- NNP VBD O
Gli Gli 1 0 0 0 0 0 0 0 3 0 NN -NONE- NNP VBD DT O
induced induced 0 0 0 0 0 0 0 0 7 0 -NONE- NNP VBD DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBD DT JJ JJ O
significant significant 0 0 0 0 0 0 0 0 11 0 VBD DT JJ JJ NN O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 arrest DT JJ JJ NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 JJ JJ NN IN -NONE- O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN -NONE- JJ O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NN IN -NONE- JJ NN B_TIMEXCCP
phase, phase, 0 0 0 0 1 0 0 0 6 0 IN -NONE- JJ NN IN O
together together 0 0 0 0 0 0 0 0 8 0 -NONE- JJ NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT NN IN O
up-regulation up-regulation 0 0 1 0 0 0 0 0 13 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNS O
p27 p27 0 0 0 0 0 0 0 1 3 0 NN IN NNP NNS CC O
levels levels 0 0 0 0 0 0 0 0 6 0 IN NNP NNS CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNS CC DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNS CC DT NN IN O
diminution diminution 0 0 0 0 0 0 0 0 10 0 CC DT NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP NNP O
E E 1 1 0 0 0 0 0 0 1 0 IN NN NNP NNP DT O
expression, expression, 0 0 0 0 1 0 0 0 11 0 NN NNP NNP DT VBD O
both both 0 0 0 0 0 0 0 0 4 0 NNP NNP DT VBD IN O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 NNP DT VBD IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 DT VBD IN NNP NNP O
immunoblot. immunoblot. 0 0 0 0 0 0 0 0 11 0 VBD IN NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP DT NN O
neither neither 0 0 0 0 0 0 0 0 7 0 NNP NNP DT NN VBD O
differentiation differentiation 0 0 0 0 0 0 0 0 15 0 NNP DT NN VBD IN O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 DT NN VBD IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN JJ JJ O
neutral neutral 0 0 0 0 0 0 0 0 7 0 VBD IN JJ JJ NN O
lipid lipid 0 0 0 0 0 0 0 0 5 0 IN JJ JJ NN CC O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 JJ JJ NN CC NN O
nor nor 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN VBD O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN CC NN VBD IN O
assessed assessed 0 0 0 0 0 0 0 0 8 0 CC NN VBD IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN JJ NNS O
different different 0 0 0 0 0 0 0 0 9 0 VBD IN JJ NNS VBD O
methodologies methodologies 0 0 0 0 0 0 0 0 13 0 IN JJ NNS VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD NNP NNP O
detected. detected. 0 0 0 0 0 0 0 0 9 0 NNS VBD NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 VBD NNP NNP NNP NN O
cytostatic, cytostatic, 0 0 0 0 1 0 0 0 11 0 NNP NNP NNP NN NN O
non non 0 0 0 0 0 0 0 0 3 0 NNP NNP NN NN NN O
toxic toxic 0 0 0 0 0 0 0 0 5 0 NNP NN NN NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 NN NN NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN VBD O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 IN NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
confirmed confirmed 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN IN O
removal removal 0 0 0 0 0 0 0 0 7 0 VBN IN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
drug.Combination drug.Combination 0 0 0 0 0 0 0 0 16 0 IN DT NN NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 DT NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP IN O
Gli Gli 1 0 0 0 0 0 0 0 3 0 NN IN NNP IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NNP IN JJ CC O
tamoxifen tamoxifen 0 0 0 0 0 0 0 0 9 0 NNP IN JJ CC NN O
or or 0 0 0 0 0 0 0 0 2 0 IN JJ CC NN VBD O
doxorubicin doxorubicin 0 0 0 0 0 0 0 0 11 0 JJ CC NN VBD DT O
showed showed 0 0 0 0 0 0 0 0 6 0 CC NN VBD DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NN VBD DT NN IN O
increment increment 0 0 0 0 0 0 0 0 9 0 VBD DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
antiproliferative antiproliferative 0 0 0 0 0 0 0 0 17 0 IN DT JJ NN RB O
effect effect 0 0 0 0 0 0 0 0 6 0 DT JJ NN RB IN O
only only 0 0 0 0 0 0 0 0 4 0 JJ NN RB IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NN RB IN NNP NNP O
doxorubicin. doxorubicin. 0 0 0 0 0 0 0 0 12 0 RB IN NNP NNP NNP O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 IN NNP NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS RB O
data data 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS RB VBN O
clearly clearly 0 0 0 0 0 0 0 0 7 0 NNP NNS RB VBN DT O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 NNS RB VBN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 RB VBN DT JJ NN O
cytostatic cytostatic 0 0 0 0 0 0 0 0 10 0 VBN DT JJ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP IN O
Gli Gli 1 0 0 0 0 0 0 0 3 0 NN IN NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NNS O
MDA-MB-231 MDA-MB-231 1 1 1 0 0 0 0 1 10 0 NNP IN NNP NNS WDT O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS WDT MD O
that that 0 0 0 0 0 0 0 0 4 0 NNP NNS WDT MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NNS WDT MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 WDT MD VB VBN IN O
mediated mediated 0 0 0 0 0 0 0 0 8 0 MD VB VBN IN NNP O
through through 0 0 0 0 0 0 0 0 7 0 VB VBN IN NNP NNP O
KATP KATP 1 1 0 0 0 0 0 0 4 0 VBN IN NNP NNP VBD O
channels, channels, 0 0 0 0 1 0 0 0 9 0 IN NNP NNP VBD TO O
associated associated 0 0 0 0 0 0 0 0 10 0 NNP NNP VBD TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBD TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD TO DT NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 TO DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
G1-S G1-S 1 1 1 0 0 0 0 1 4 phase IN DT JJ NN NNP B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT JJ NN NNP NNP O
progression. progression. 0 0 0 0 0 0 0 0 12 0 JJ NN NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NNP DT O
addition, addition, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNP NNP DT JJ NN O
interesting interesting 0 0 0 0 0 0 0 0 11 0 NNP DT JJ NN IN O
observation observation 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN DT O
about about 0 0 0 0 0 0 0 0 5 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
combination combination 0 0 0 0 0 0 0 0 11 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
Gli Gli 1 0 0 0 0 0 0 0 3 0 NN IN NNP IN NN O
with with 0 0 0 0 0 0 0 0 4 0 IN NNP IN NN NNS O
doxorubicin doxorubicin 0 0 0 0 0 0 0 0 11 0 NNP IN NN NNS TO O
leads leads 0 0 0 0 0 0 0 0 5 0 IN NN NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO VB NN O
future future 0 0 0 0 0 0 0 0 6 0 NNS TO VB NN IN O
research research 0 0 0 0 0 0 0 0 8 0 TO VB NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VB NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
potential potential 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN IN O
role role 0 0 0 0 0 0 0 0 4 0 JJ NN NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NNP IN O
Gli Gli 1 0 0 0 0 0 0 0 3 0 NN IN NNP IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNP IN DT JJ IN O
adjuvant adjuvant 0 0 0 0 0 0 0 0 8 0 IN DT JJ IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 DT JJ IN JJ NN O
breast breast 0 0 0 0 0 0 0 0 6 0 JJ IN JJ NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
treatment. treatment. 0 0 0 0 0 0 0 0 10 0 JJ NN NNP NONE NONE O
Mirk/Dyrk1B Mirk/Dyrk1B 1 0 0 1 0 0 0 1 11 0 NONE NONE NN NNS -NONE- O
mediates mediates 0 0 0 0 0 0 0 0 8 0 NONE NN NNS -NONE- TO O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NN NNS -NONE- TO NNP B_TIMEXCCP
to to 0 0 0 0 0 0 0 0 2 0 NNS -NONE- TO NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase -NONE- TO NNP NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 TO NNP NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP NN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NN NN NN NN CC O
progression progression 0 0 0 0 0 0 0 0 11 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN CC NN NN VBG O
survival survival 0 0 0 0 0 0 0 0 8 0 CC NN NN VBG NN O
involving involving 0 0 0 0 0 0 0 0 9 0 NN NN VBG NN VBG O
MAPK/ERK MAPK/ERK 1 1 0 1 0 0 0 0 8 0 NN VBG NN VBG IN O
signaling signaling 0 0 0 0 0 0 0 0 9 0 VBG NN VBG IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN VBG IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 VBG IN JJ NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP NNP O
Gao Gao 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhao Zhao 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lv Lv 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wei Wei 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tian Tian 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yang Yang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kong Kong 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Pang Pang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Liu Liu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Shi Shi 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
H. H. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Obstetrics Obstetrics 1 0 0 0 0 0 0 0 10 0 NNP IN NNP CC NNP O
& & 0 0 0 0 0 0 0 0 1 0 IN NNP CC NNP NNP O
Gynecology, Gynecology, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP NNP O
First First 1 0 0 0 0 0 0 0 5 0 CC NNP NNP NNP NNP O
Affiliated Affiliated 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP IN O
Hospital Hospital 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Dalian Dalian 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Zhongshan Zhongshan 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP CD O
Road Road 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP CD -NONE- O
222, 222, 0 0 0 0 1 0 0 1 4 0 NNP NNP CD -NONE- NNP O
Dalian, Dalian, 1 0 0 0 1 0 0 0 7 0 NNP CD -NONE- NNP CD O
Liaoning Liaoning 1 0 0 0 0 0 0 0 8 0 CD -NONE- NNP CD NNP O
116011, 116011, 0 0 0 0 1 0 0 1 7 0 -NONE- NNP CD NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
Jingchun_gao@yahoo.com. Jingchun_gao@yahoo.com. 1 0 0 0 0 0 0 0 23 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP VBZ O
Mirk/Dyrk1B Mirk/Dyrk1B 1 0 0 1 0 0 0 1 11 0 NNP NNP NNP VBZ TO O
contributes contributes 0 0 0 0 0 0 0 0 11 0 NNP NNP VBZ TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBZ TO NNP JJS O
G0 G0 1 1 0 0 0 0 0 1 2 arrest VBZ TO NNP JJS IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 TO NNP JJS IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNP JJS IN NN IN O
destabilization destabilization 0 0 0 0 0 0 0 0 15 0 JJS IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP CC O
D1 D1 1 1 0 0 0 0 0 1 2 0 IN NN NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NN IN O
stabilization stabilization 0 0 0 0 0 0 0 0 13 0 NNP CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP TO O
p27kip1 p27kip1 0 0 0 0 0 0 0 1 7 0 NN IN NNP TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NNP TO VB DT O
maintain maintain 0 0 0 0 0 0 0 0 8 0 NNP TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
viability viability 0 0 0 0 0 0 0 0 9 0 VB DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
quiescent quiescent 0 0 0 0 0 0 0 0 9 0 NN IN NN NN NN O
human human 0 0 0 0 0 0 0 0 5 0 IN NN NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN NN NN NN CC O
cells, cells, 0 0 0 0 1 0 0 0 6 0 NN NN NN CC PRP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC PRP MD O
it it 0 0 0 0 0 0 0 0 2 0 NN CC PRP MD VB O
could could 0 0 0 0 0 0 0 0 5 0 CC PRP MD VB RB O
be be 0 0 0 0 0 0 0 0 2 0 PRP MD VB RB VBN O
negatively negatively 0 0 0 0 0 0 0 0 10 0 MD VB RB VBN IN O
regulated regulated 0 0 0 0 0 0 0 0 9 0 VB RB VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 RB VBN IN JJ NN O
mitogenic-activated mitogenic-activated 0 0 1 0 0 0 0 0 19 0 VBN IN JJ NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 IN JJ NN NN JJ O
kinase kinase 0 0 0 0 0 0 0 0 6 0 JJ NN NN JJ JJ O
(MAPK)/extracellular (MAPK)/extracellular 0 0 0 1 0 0 0 0 20 0 NN NN JJ JJ NN O
signal-regulated signal-regulated 0 0 1 0 0 0 0 0 16 0 NN JJ JJ NN NN O
kinase kinase 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NN NNP O
(ERK) (ERK) 0 1 0 0 0 0 0 0 5 0 JJ NN NN NNP NNP O
signaling. signaling. 0 0 0 0 0 0 0 0 10 0 NN NN NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN TO O
performed performed 0 0 0 0 0 0 0 0 9 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB DT O
investigate investigate 0 0 0 0 0 0 0 0 11 0 VBN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 VB DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ IN O
Mirk/Dyrk1B Mirk/Dyrk1B 1 0 0 1 0 0 0 1 11 0 NN IN JJ IN NN O
on on 0 0 0 0 0 0 0 0 2 0 IN JJ IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ IN NN NN CC O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
survival survival 0 0 0 0 0 0 0 0 8 0 NN CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNS VBG O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS VBG JJ O
involving involving 0 0 0 0 0 0 0 0 9 0 NN NNS VBG JJ NNP O
MAPK/ERK MAPK/ERK 1 1 0 1 0 0 0 0 8 0 NNS VBG JJ NNP NNP O
signaling. signaling. 0 0 0 0 0 0 0 0 10 0 VBG JJ NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 JJ NNP NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS IN O
correlations correlations 0 0 0 0 0 0 0 0 12 0 NNP NNP NNS IN JJ O
between between 0 0 0 0 0 0 0 0 7 0 NNP NNS IN JJ NN O
Mirk/Dyrk1B Mirk/Dyrk1B 1 0 0 1 0 0 0 1 11 0 NNS IN JJ NN CC O
expression expression 0 0 0 0 0 0 0 0 10 0 IN JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NN O
active active 0 0 0 0 0 0 0 0 6 0 NN CC JJ NN VBD O
ERK1/2 ERK1/2 1 1 0 1 0 0 0 1 6 0 CC JJ NN VBD IN O
detected detected 0 0 0 0 0 0 0 0 8 0 JJ NN VBD IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN JJ NN O
western western 0 0 0 0 0 0 0 0 7 0 VBD IN JJ NN IN O
blot blot 0 0 0 0 0 0 0 0 4 0 IN JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
both both 0 0 0 0 0 0 0 0 4 0 NN IN DT JJ NN O
ovarian ovarian 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN CC O
cancer cancer 0 0 0 0 0 0 0 0 6 0 DT JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NN O
non-small non-small 0 0 1 0 0 0 0 0 9 0 NN CC JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 CC JJ NN NN NN O
lung lung 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NNS O
(NSCLC) (NSCLC) 0 1 0 0 0 0 0 0 7 0 NN NN NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
analyzed analyzed 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NNP O
simple simple 0 0 0 0 0 0 0 0 6 0 VBN IN JJ NNP NNP O
regression. regression. 0 0 0 0 0 0 0 0 11 0 IN JJ NNP NNP NN O
Mirk/Dyrk1B Mirk/Dyrk1B 1 0 0 1 0 0 0 1 11 0 JJ NNP NNP NN VBZ O
unique unique 0 0 0 0 0 0 0 0 6 0 NNP NNP NN VBZ IN O
phosphopeptides phosphopeptides 0 0 0 0 0 0 0 0 15 0 NNP NN VBZ IN NNS O
with with 0 0 0 0 0 0 0 0 4 0 NN VBZ IN NNS VBN O
sites sites 0 0 0 0 0 0 0 0 5 0 VBZ IN NNS VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 IN NNS VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBN IN JJ NN O
Mirk/Dyrk1B Mirk/Dyrk1B 1 0 0 1 0 0 0 1 11 0 VBN IN JJ NN VBD O
protein protein 0 0 0 0 0 0 0 0 7 0 IN JJ NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NN VBD VBN CC O
isolated isolated 0 0 0 0 0 0 0 0 8 0 NN VBD VBN CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 VBD VBN CC VBN IN O
quantitated quantitated 0 0 0 0 0 0 0 0 11 0 VBN CC VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 CC VBN IN NN NN O
liquid liquid 0 0 0 0 0 0 0 0 6 0 VBN IN NN NN VBN O
chromatography chromatography 0 0 0 0 0 0 0 0 14 0 IN NN NN VBN TO O
coupled coupled 0 0 0 0 0 0 0 0 7 0 NN NN VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBN TO VB JJ O
tandem tandem 0 0 0 0 0 0 0 0 6 0 VBN TO VB JJ NN O
mass/mass mass/mass 0 0 0 1 0 0 0 0 9 0 TO VB JJ NN NN O
spectrometry spectrometry 0 0 0 0 0 0 0 0 12 0 VB JJ NN NN NNS O
(LC-MS/MS) (LC-MS/MS) 0 1 1 1 0 0 0 0 10 0 JJ NN NN NNS NNP O
proteomics proteomics 0 0 0 0 0 0 0 0 10 0 NN NN NNS NNP NNP O
analysis. analysis. 0 0 0 0 0 0 0 0 9 0 NN NNS NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNS NNP NNP NN NN O
human human 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NNP NN NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
treated treated 0 0 0 0 0 0 0 0 7 0 NNS VBD VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN JJ VBG O
small small 0 0 0 0 0 0 0 0 5 0 VBN IN JJ VBG NNP O
interfering interfering 0 0 0 0 0 0 0 0 11 0 IN JJ VBG NNP NNP O
RNAs RNAs 1 0 0 0 0 0 0 0 4 0 JJ VBG NNP NNP NNP O
(siRNAs) (siRNAs) 0 0 0 0 0 0 0 0 8 0 VBG NNP NNP NNP NNP O
and/or and/or 0 0 0 1 0 0 0 0 6 0 NNP NNP NNP NNP DT O
U0126, U0126, 1 1 0 0 1 0 0 1 6 0 NNP NNP NNP DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NNP NNP DT NN IN O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 NNP DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
MEK MEK 1 1 0 0 0 0 0 0 3 0 NN IN NNP IN VBN O
for for 0 0 0 0 0 0 0 0 3 0 IN NNP IN VBN -NONE- O
indicated indicated 0 0 0 0 0 0 0 0 9 0 NNP IN VBN -NONE- VBN O
duration, duration, 0 0 0 0 1 0 0 0 9 0 IN VBN -NONE- VBN IN O
followed followed 0 0 0 0 0 0 0 0 8 0 VBN -NONE- VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 -NONE- VBN IN NN DT O
investigating investigating 0 0 0 0 0 0 0 0 13 0 VBN IN NN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NNS IN O
alterations alterations 0 0 0 0 0 0 0 0 11 0 NN DT NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN CC O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN CC NN IN RB O
as as 0 0 0 0 0 0 0 0 2 0 CC NN IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NN IN RB IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN JJ NNS O
related related 0 0 0 0 0 0 0 0 7 0 RB IN JJ NNS VBN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 IN JJ NNS VBN IN O
examined examined 0 0 0 0 0 0 0 0 8 0 JJ NNS VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBN IN NN NN O
flow flow 0 0 0 0 0 0 0 0 4 0 VBN IN NN NN CC O
cytometry cytometry 0 0 0 0 0 0 0 0 9 0 IN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
Western Western 1 0 0 0 0 0 0 0 7 0 NN CC NNP NNP NNP O
blot, blot, 0 0 0 0 1 0 0 0 5 0 CC NNP NNP NNP NNP O
respectively. respectively. 0 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
Our Our 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD DT O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 NNP NN VBD DT RB O
the the 0 0 0 0 0 0 0 0 3 0 NN VBD DT RB VBN O
widely widely 0 0 0 0 0 0 0 0 6 0 VBD DT RB VBN -NONE- O
expressed expressed 0 0 0 0 0 0 0 0 9 0 DT RB VBN -NONE- VBZ O
Mirk/Dyrk1B Mirk/Dyrk1B 1 0 0 1 0 0 0 1 11 0 RB VBN -NONE- VBZ IN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 VBN -NONE- VBZ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- VBZ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBZ IN DT JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 DT JJ NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD RB VBN O
positively positively 0 0 0 0 0 0 0 0 10 0 NNS VBD RB VBN IN O
correlated correlated 0 0 0 0 0 0 0 0 10 0 VBD RB VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 IN DT NNS IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN VBN NNP O
activated activated 0 0 0 0 0 0 0 0 9 0 NNS IN VBN NNP NNP O
ERK1/2. ERK1/2. 1 1 0 1 0 0 0 1 7 0 IN VBN NNP NNP NNP O
Moreover, Moreover, 1 0 0 0 1 0 0 0 9 0 VBN NNP NNP NNP NN O
Mirk/Dyrk1B Mirk/Dyrk1B 1 0 0 1 0 0 0 1 11 0 NNP NNP NNP NN NNS O
protein protein 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NNS NN O
expressions expressions 0 0 0 0 0 0 0 0 11 0 NNP NN NNS NN IN O
consistent consistent 0 0 0 0 0 0 0 0 10 0 NN NNS NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NNS NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBD O
tyrosine tyrosine 0 0 0 0 0 0 0 0 8 0 IN DT NN VBD NNS O
autophosphorylated autophosphorylated 0 0 0 0 0 0 0 0 18 0 DT NN VBD NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 NN VBD NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 DT JJ NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
increased increased 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP CC O
U0126 U0126 1 1 0 0 0 0 0 1 5 0 VBN IN NNP CC NN O
or or 0 0 0 0 0 0 0 0 2 0 IN NNP CC NN JJ O
growth growth 0 0 0 0 0 0 0 0 6 0 NNP CC NN JJ NNP O
factor-depleted factor-depleted 0 0 1 0 0 0 0 0 15 0 CC NN JJ NNP NNP O
culture. culture. 0 0 0 0 0 0 0 0 8 0 NN JJ NNP NNP NN O
Conversely, Conversely, 1 0 0 0 1 0 0 0 11 0 JJ NNP NNP NN IN O
knockdown knockdown 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ IN O
Mirk/Dyrk1B Mirk/Dyrk1B 1 0 0 1 0 0 0 1 11 0 NN IN JJ IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 IN JJ IN NNP VBD O
siRNA siRNA 0 0 0 0 0 0 0 0 5 0 JJ IN NNP VBD TO O
led led 0 0 0 0 0 0 0 0 3 0 IN NNP VBD TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBD TO JJ NN O
up-regulated up-regulated 0 0 1 0 0 0 0 0 12 0 VBD TO JJ NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 TO JJ NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN -NONE- NN O
c-Raf-MEK-ERK1/2 c-Raf-MEK-ERK1/2 0 0 1 1 0 0 0 1 16 0 NN IN -NONE- NN CC O
pathway pathway 0 0 0 0 0 0 0 0 7 0 IN -NONE- NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NN CC NN NNS O
subsequent subsequent 0 0 0 0 0 0 0 0 10 0 NN CC NN NNS IN O
changes changes 0 0 0 0 0 0 0 0 7 0 CC NN NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN NNS O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN NNS JJ O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NN NN NNS JJ NN O
(cyclin (cyclin 0 0 0 0 0 0 0 0 7 0 NN NNS JJ NN NN O
D1, D1, 1 1 0 0 1 0 0 1 3 0 NNS JJ NN NN VBD O
p27kip1), p27kip1), 0 0 0 0 1 0 0 1 9 0 JJ NN NN VBD IN O
accompanied accompanied 0 0 0 0 0 0 0 0 11 0 NN NN VBD IN VBN O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN VBN NN O
increased increased 0 0 0 0 0 0 0 0 9 0 VBD IN VBN NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 IN VBN NN NN CC O
rate rate 0 0 0 0 0 0 0 0 4 0 VBN NN NN CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN CC NNS IN -NONE- O
from from 0 0 0 0 0 0 0 0 4 0 CC NNS IN -NONE- IN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NNS IN -NONE- IN NNP B_TIMEXCCP
into into 0 0 0 0 0 0 0 0 4 0 IN -NONE- IN NNP IN O
S S 1 1 0 0 0 0 0 0 1 0 -NONE- IN NNP IN NN B_TIMEXCCP
of of 0 0 0 0 0 0 0 0 2 0 IN NNP IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP IN NN NN WDT O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN WDT MD O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT MD VB O
could could 0 0 0 0 0 0 0 0 5 0 NN WDT MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 WDT MD VB VBN IN O
blocked blocked 0 0 0 0 0 0 0 0 7 0 MD VB VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VB VBN IN NNP IN O
U0126 U0126 1 1 0 0 0 0 0 1 5 0 VBN IN NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT JJ NN O
dose-dependent dose-dependent 0 0 1 0 0 0 0 0 14 0 IN DT JJ NN VBG O
manner, manner, 0 0 0 0 1 0 0 0 7 0 DT JJ NN VBG NN O
indicating indicating 0 0 0 0 0 0 0 0 10 0 JJ NN VBG NN MD O
Mirk/Dyrk1B Mirk/Dyrk1B 1 0 0 1 0 0 0 1 11 0 NN VBG NN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 VBG NN MD VB JJ O
sequester sequester 0 0 0 0 0 0 0 0 9 0 NN MD VB JJ NN O
MAPK/ERK MAPK/ERK 1 1 0 1 0 0 0 0 8 0 MD VB JJ NN CC O
pathway, pathway, 0 0 0 0 1 0 0 0 8 0 VB JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NNP O
vice vice 0 0 0 0 0 0 0 0 4 0 NN CC NN NNP NNP O
versa. versa. 0 0 0 0 0 0 0 0 6 0 CC NN NNP NNP VBD O
Whereas, Whereas, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP VBD NNP O
combined combined 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD NNP NNP O
Mirk Mirk 1 0 0 0 0 0 0 0 4 0 NNP VBD NNP NNP CC O
siRNA siRNA 0 0 0 0 0 0 0 0 5 0 VBD NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP VBD O
U0126 U0126 1 1 0 0 0 0 0 1 5 0 NNP CC NNP VBD NN O
induced induced 0 0 0 0 0 0 0 0 7 0 CC NNP VBD NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP VBD NN NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 VBD NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 DT JJ NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP NNP O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 NN NNP NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNS RB O
data data 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS RB VBP O
together together 0 0 0 0 0 0 0 0 8 0 NNP NNS RB VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NNS RB VBP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 RB VBP IN JJ NNS O
Mirk/Dyrk1B Mirk/Dyrk1B 1 0 0 1 0 0 0 1 11 0 VBP IN JJ NNS VBP O
mediates mediates 0 0 0 0 0 0 0 0 8 0 IN JJ NNS VBP NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NNS VBP NN CC O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NNS VBP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VBP NN CC NN IN O
survival survival 0 0 0 0 0 0 0 0 8 0 NN CC NN IN VBG O
via via 0 0 0 0 0 0 0 0 3 0 CC NN IN VBG IN O
interacting interacting 0 0 0 0 0 0 0 0 11 0 NN IN VBG IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN VBG IN JJ NNS O
MAPK/ERK MAPK/ERK 1 1 0 1 0 0 0 0 8 0 VBG IN JJ NNS CC O
signals signals 0 0 0 0 0 0 0 0 7 0 IN JJ NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC JJ NN O
simultaneous simultaneous 0 0 0 0 0 0 0 0 12 0 NNS CC JJ NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 CC JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNS O
both both 0 0 0 0 0 0 0 0 4 0 NN IN DT NNS MD O
pathways pathways 0 0 0 0 0 0 0 0 8 0 IN DT NNS MD VB O
may may 0 0 0 0 0 0 0 0 3 0 DT NNS MD VB DT O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT NN JJ O
novel novel 0 0 0 0 0 0 0 0 5 0 VB DT NN JJ NN O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 DT NN JJ NN IN O
target target 0 0 0 0 0 0 0 0 6 0 NN JJ NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN JJ NNP O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ NNP NONE O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 IN JJ NNP NONE NONE O
A A 1 1 0 0 0 0 0 0 1 0 NONE NONE DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 NONE DT NN NN NN O
muscarinic muscarinic 0 0 0 0 0 0 0 0 10 0 DT NN NN NN NNP O
antagonist antagonist 0 0 0 0 0 0 0 0 10 0 NN NN NN NNP VBZ O
R2HBJJ R2HBJJ 1 1 0 0 0 0 0 1 6 0 NN NN NNP VBZ JJ O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 NN NNP VBZ JJ NN O
non-small non-small 0 0 1 0 0 0 0 0 9 0 NNP VBZ JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBZ JJ NN NN NN O
lung lung 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN CC O
growth growth 0 0 0 0 0 0 0 0 6 0 NN NN NN CC NNS O
and and 0 0 0 0 0 0 0 0 3 arrests NN NN CC NNS DT O
arrests arrests 0 0 0 0 0 0 0 0 7 0 NN CC NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC NNS DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNS DT NN NN IN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
G0/G1. G0/G1. 1 1 0 1 0 0 0 1 6 0 NN IN NNP NNP NNP B_TIMEXCCP
Hua Hua 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wei Wei 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Liu Liu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ma Ma 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
He He 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhuo Zhuo 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhao Zhao 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yan Yan 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhong Zhong 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zheng Zheng 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
J. J. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Beijing Beijing 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Pharmacology Pharmacology 1 0 0 0 0 0 0 0 12 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Toxicology, Toxicology, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP NNP O
Beijing, Beijing, 1 0 0 0 1 0 0 0 8 0 CC NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNS O
Lung Lung 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNS VBP O
cancers cancers 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP DT O
express express 0 0 0 0 0 0 0 0 7 0 NNP NNS VBP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBP DT JJ NN O
cholinergic cholinergic 0 0 0 0 0 0 0 0 11 0 VBP DT JJ NN NN O
autocrine autocrine 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN WDT O
loop, loop, 0 0 0 0 1 0 0 0 5 0 JJ NN NN WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBZ DT O
facilitates facilitates 0 0 0 0 0 0 0 0 11 0 NN WDT VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 WDT VBZ DT NN IN O
progression progression 0 0 0 0 0 0 0 0 11 0 VBZ DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS IN O
antagonists antagonists 0 0 0 0 0 0 0 0 11 0 NNP NNP NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NNP VBP O
mAChRs mAChRs 0 0 0 0 0 0 0 0 6 0 NNS IN NNP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 IN NNP VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNP VBP VBN VBN TO O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 VBP VBN VBN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO NN DT O
depress depress 0 0 0 0 0 0 0 0 7 0 VBN TO NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO NN DT NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 NN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
small small 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN NNS O
lung lung 0 0 0 0 0 0 0 0 4 0 JJ NN NN NNS NNP O
cancers cancers 0 0 0 0 0 0 0 0 7 0 NN NN NNS NNP NNP O
(SCLCs). (SCLCs). 0 0 0 0 0 0 0 0 8 0 NN NNS NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NNS NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
study study 0 0 0 0 0 0 0 0 5 0 NNP DT NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBD TO O
intended intended 0 0 0 0 0 0 0 0 8 0 NN PRP VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 PRP VBD TO VB DT O
investigate investigate 0 0 0 0 0 0 0 0 11 0 VBD TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 VB DT NN NN NN O
inhibitory inhibitory 0 0 0 0 0 0 0 0 10 0 DT NN NN NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 NN NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP DT O
R2HBJJ, R2HBJJ, 1 1 0 0 1 0 0 1 7 0 NN IN NNP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 IN NNP DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 NNP DT NN NN NN O
muscarinic muscarinic 0 0 0 0 0 0 0 0 10 0 DT NN NN NN IN O
antagonist, antagonist, 0 0 0 0 1 0 0 0 11 0 NN NN NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
non-small non-small 0 0 1 0 0 0 0 0 9 0 NN IN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN NN O
lung lung 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NNS O
(NSCLC) (NSCLC) 0 1 0 0 0 0 0 0 7 0 NN NN NN NNS CC O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS CC DT JJ NNP O
possible possible 0 0 0 0 0 0 0 0 8 0 CC DT JJ NNP NNP O
mechanisms. mechanisms. 0 0 0 0 0 0 0 0 11 0 DT JJ NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP JJ NN O
competitive competitive 0 0 0 0 0 0 0 0 11 0 NNP NNP JJ NN NN O
binding binding 0 0 0 0 0 0 0 0 7 0 NNP JJ NN NN VBD O
assay assay 0 0 0 0 0 0 0 0 5 0 JJ NN NN VBD IN O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN NNP VBD O
R2HBJJ R2HBJJ 1 1 0 0 0 0 0 1 6 0 VBD IN NNP VBD DT O
had had 0 0 0 0 0 0 0 0 3 0 IN NNP VBD DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBD DT JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 VBD DT JJ NN TO O
affinity affinity 0 0 0 0 0 0 0 0 8 0 DT JJ NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO NNP CC O
M3 M3 1 1 0 0 0 0 0 1 2 0 NN TO NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 TO NNP CC NNP NNP O
M1 M1 1 1 0 0 0 0 0 1 2 0 NNP CC NNP NNP NNP O
AChRs. AChRs. 1 0 0 0 0 0 0 0 6 0 CC NNP NNP NNP VBD O
R2HBJJ R2HBJJ 1 1 0 0 0 0 0 1 6 0 NNP NNP NNP VBD DT O
presented presented 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBD DT JJ NN O
strong strong 0 0 0 0 0 0 0 0 6 0 VBD DT JJ NN NN O
anticholinergic anticholinergic 0 0 0 0 0 0 0 0 15 0 DT JJ NN NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 JJ NN NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
carbachol-induced carbachol-induced 0 0 1 0 0 0 0 0 17 0 NN IN JJ NN IN O
contraction contraction 0 0 0 0 0 0 0 0 11 0 IN JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNP O
guinea-pig guinea-pig 0 0 1 0 0 0 0 0 10 0 NN IN JJ NNP NNP O
trachea. trachea. 0 0 0 0 0 0 0 0 8 0 IN JJ NNP NNP RB O
R2HBJJ R2HBJJ 1 1 0 0 0 0 0 1 6 0 JJ NNP NNP RB VBD O
markedly markedly 0 0 0 0 0 0 0 0 8 0 NNP NNP RB VBD DT O
suppressed suppressed 0 0 0 0 0 0 0 0 10 0 NNP RB VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBD DT NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 VBD DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
NSCLC NSCLC 1 1 0 0 0 0 0 0 5 0 NN IN NNP NNP JJ O
cells, cells, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP JJ IN O
such such 0 0 0 0 0 0 0 0 4 0 NNP NNP JJ IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 NNP JJ IN JJ NNP O
H1299, H1299, 1 1 0 0 1 0 0 1 6 0 JJ IN JJ NNP CC O
H460 H460 1 1 0 0 0 0 0 1 4 0 IN JJ NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNP CC NNP NNP O
H157. H157. 1 1 0 0 0 0 0 1 5 0 NNP CC NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 CC NNP NNP NNP NNP O
H1299 H1299 1 1 0 0 0 0 0 1 5 0 NNP NNP NNP NNP DT O
cells, cells, 0 0 0 0 1 0 0 0 6 0 NNP NNP NNP DT NNP O
both both 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NNP CC O
R2HBJJ R2HBJJ 1 1 0 0 0 0 0 1 6 0 NNP DT NNP CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC PRP$ VBG O
its its 0 0 0 0 0 0 0 0 3 0 NNP CC PRP$ VBG NN O
leading leading 0 0 0 0 0 0 0 0 7 0 CC PRP$ VBG NN NN O
compound compound 0 0 0 0 0 0 0 0 8 0 PRP$ VBG NN NN VBD O
R2-PHC R2-PHC 1 1 1 0 0 0 0 1 6 0 VBG NN NN VBD JJ O
displayed displayed 0 0 0 0 0 0 0 0 9 0 NN NN VBD JJ JJ O
significant significant 0 0 0 0 0 0 0 0 11 0 NN VBD JJ JJ NN O
anti-proliferative anti-proliferative 0 0 1 0 0 0 0 0 18 0 VBD JJ JJ NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 JJ JJ NN IN NNP O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
M3 M3 1 1 0 0 0 0 0 1 2 0 NN IN NNP NN NN O
receptor receptor 0 0 0 0 0 0 0 0 8 0 IN NNP NN NN NNP O
antagonist antagonist 0 0 0 0 0 0 0 0 10 0 NNP NN NN NNP NNP O
darifenacin. darifenacin. 0 0 0 0 0 0 0 0 12 0 NN NN NNP NNP NN O
Exogenous Exogenous 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NN IN O
replenish replenish 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP MD O
ACh ACh 1 0 0 0 0 0 0 0 3 0 NN IN NNP MD VB O
could could 0 0 0 0 0 0 0 0 5 0 IN NNP MD VB JJ O
attenuate attenuate 0 0 0 0 0 0 0 0 9 0 NNP MD VB JJ NN O
R2HBJJ-induced R2HBJJ-induced 1 0 1 0 0 0 0 1 14 0 MD VB JJ NN NNP O
growth growth 0 0 0 0 0 0 0 0 6 0 VB JJ NN NNP NNP O
inhibition. inhibition. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP NNP NNP O
Silencing Silencing 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP NN O
M3 M3 1 1 0 0 0 0 0 1 2 0 NNP NNP NNP NN CC O
receptor receptor 0 0 0 0 0 0 0 0 8 0 NNP NNP NN CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 NNP NN CC NNP IN O
ChAT ChAT 1 0 0 0 0 0 0 0 4 0 NN CC NNP IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 CC NNP IN NNP VBD O
specific-siRNAs specific-siRNAs 0 0 1 0 0 0 0 0 15 0 NNP IN NNP VBD IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 IN NNP VBD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP VBD IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBD IN DT NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 IN DT NN NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 DT NN NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN CD CC O
55.5% 55.5% 0 0 0 0 0 0 0 1 5 0 NN IN CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 IN CD CC CD IN O
37.9% 37.9% 0 0 0 0 0 0 0 1 5 0 CD CC CD IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 CC CD IN NNP NNS O
H1299 H1299 1 1 0 0 0 0 0 1 5 0 CD IN NNP NNS CD O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS CD NN O
96 96 0 0 0 0 0 0 1 1 2 0 NNP NNS CD NN NN O
h h 0 0 0 0 0 0 0 0 1 0 NNS CD NN NN NN O
post post 0 0 0 0 0 0 0 0 4 0 CD NN NN NN NNP O
transfection, transfection, 0 0 0 0 1 0 0 0 13 0 NN NN NN NNP NNP O
respectively. respectively. 0 0 0 0 0 0 0 0 13 0 NN NN NNP NNP NNS O
Further Further 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NNS VBD O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD IN O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 VBD IN NN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN NNP VBD O
R2HBJJ R2HBJJ 1 1 0 0 0 0 0 1 6 0 NN IN NNP VBD DT O
arrested arrested 0 0 0 0 0 0 0 0 8 0 IN NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBD DT NN NN IN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN IN -NONE- O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN -NONE- IN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NN IN -NONE- IN NN B_TIMEXCCP
by by 0 0 0 0 0 0 0 0 2 0 IN -NONE- IN NN IN O
down-regulation down-regulation 0 0 1 0 0 0 0 0 15 0 -NONE- IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP NNP O
D1-CDK4/6-Rb. D1-CDK4/6-Rb. 1 0 1 1 0 0 0 1 13 0 IN NN NNP NNP DT O
Therefore, Therefore, 1 0 0 0 1 0 0 0 10 0 NN NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NN O
current current 0 0 0 0 0 0 0 0 7 0 NNP DT JJ NN NNS O
study study 0 0 0 0 0 0 0 0 5 0 DT JJ NN NNS WDT O
reveals reveals 0 0 0 0 0 0 0 0 7 0 JJ NN NNS WDT NNP O
that that 0 0 0 0 0 0 0 0 4 0 NN NNS WDT NNP VBZ O
NSCLC NSCLC 1 1 0 0 0 0 0 0 5 0 NNS WDT NNP VBZ NN O
cells cells 0 0 0 0 0 0 0 0 5 0 WDT NNP VBZ NN DT O
express express 0 0 0 0 0 0 0 0 7 0 NNP VBZ NN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 VBZ NN DT NN CC O
autocrine autocrine 0 0 0 0 0 0 0 0 9 0 NN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN NN O
paracrine paracrine 0 0 0 0 0 0 0 0 9 0 NN CC NN NN NN O
cholinergic cholinergic 0 0 0 0 0 0 0 0 11 0 CC NN NN NN WDT O
system system 0 0 0 0 0 0 0 0 6 0 NN NN NN WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBZ DT O
stimulates stimulates 0 0 0 0 0 0 0 0 10 0 NN WDT VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 WDT VBZ DT NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 VBZ DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
NSCLC NSCLC 1 1 0 0 0 0 0 0 5 0 NN IN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP IN O
R2HBJJ, R2HBJJ, 1 1 0 0 1 0 0 1 7 0 NNP NNP NNP IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT NN NNP O
novel novel 0 0 0 0 0 0 0 0 5 0 IN DT NN NNP NNP O
mAChRs mAChRs 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP MD O
antagonist, antagonist, 0 0 0 0 1 0 0 0 11 0 NN NNP NNP MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NNP NNP MD VB DT O
block block 0 0 0 0 0 0 0 0 5 0 NNP MD VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT JJ NN O
local local 0 0 0 0 0 0 0 0 5 0 VB DT JJ NN NN O
cholinergic cholinergic 0 0 0 0 0 0 0 0 11 0 DT JJ NN NN IN O
loop loop 0 0 0 0 0 0 0 0 4 0 JJ NN NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NN RB O
antagonizing antagonizing 0 0 0 0 0 0 0 0 12 0 NN IN NN RB NNP O
predominantly predominantly 0 0 0 0 0 0 0 0 13 0 IN NN RB NNP NNS O
M3 M3 1 1 0 0 0 0 0 1 2 0 NN RB NNP NNS CC O
receptors receptors 0 0 0 0 0 0 0 0 9 0 RB NNP NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNS CC NN NNP O
inhibit inhibit 0 0 0 0 0 0 0 0 7 0 NNS CC NN NNP NN O
NSCLC NSCLC 1 1 0 0 0 0 0 0 5 0 CC NN NNP NN -NONE- O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NNP NN -NONE- WDT O
growth, growth, 0 0 0 0 1 0 0 0 7 0 NNP NN -NONE- WDT JJS O
which which 0 0 0 0 0 0 0 0 5 0 NN -NONE- WDT JJS IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 -NONE- WDT JJS IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 WDT JJS IN NNP NN O
M3 M3 1 1 0 0 0 0 0 1 2 0 JJS IN NNP NN NN O
receptor receptor 0 0 0 0 0 0 0 0 8 0 IN NNP NN NN MD O
antagonist antagonist 0 0 0 0 0 0 0 0 10 0 NNP NN NN MD VB O
might might 0 0 0 0 0 0 0 0 5 0 NN NN MD VB DT O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT JJ JJ O
potential potential 0 0 0 0 0 0 0 0 9 0 VB DT JJ JJ NNS O
chemotherapeutic chemotherapeutic 0 0 0 0 0 0 0 0 16 0 DT JJ JJ NNS IN O
regimen regimen 0 0 0 0 0 0 0 0 7 0 JJ JJ NNS IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN NNP NONE O
NSCLC. NSCLC. 1 1 0 0 0 0 0 0 6 0 NNS IN NNP NONE NONE O
Tetramethylpyrazine Tetramethylpyrazine 1 0 0 0 0 0 0 0 19 0 NONE NONE NNP NNS -NONE- O
induces induces 0 0 0 0 0 0 0 0 7 0 NONE NNP NNS -NONE- VBP O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NNP NNS -NONE- VBP NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 NNS -NONE- VBP NN JJS O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest -NONE- VBP NN JJS CC O
arrest arrest 0 0 0 0 0 0 0 0 6 0 VBP NN JJS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NN JJS CC NNS JJ O
stimulates stimulates 0 0 0 0 0 0 0 0 10 0 JJS CC NNS JJ CC O
mitochondrial-mediated mitochondrial-mediated 0 0 1 0 0 0 0 0 22 0 CC NNS JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNS JJ CC JJ NN O
caspase-dependent caspase-dependent 0 0 1 0 0 0 0 0 17 0 JJ CC JJ NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 CC JJ NN IN VBG O
through through 0 0 0 0 0 0 0 0 7 0 JJ NN IN VBG -NONE- O
modulating modulating 0 0 0 0 0 0 0 0 10 0 NN IN VBG -NONE- VBG O
ERK/p53 ERK/p53 1 0 0 1 0 0 0 1 7 0 IN VBG -NONE- VBG IN O
signaling signaling 0 0 0 0 0 0 0 0 9 0 VBG -NONE- VBG IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- VBG IN JJ NN O
hepatic hepatic 0 0 0 0 0 0 0 0 7 0 VBG IN JJ NN NNS O
stellate stellate 0 0 0 0 0 0 0 0 8 0 IN JJ NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP NNP O
vitro. vitro. 0 0 0 0 0 0 0 0 6 0 NNS IN NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kong Kong 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
DS, DS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
ZL, ZL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Lei Lei 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhu Zhu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
XJ, XJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
XP, XP, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lu Lu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zheng Zheng 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
SZ. SZ. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Clinical Clinical 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Pharmacy, Pharmacy, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP IN O
College College 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pharmacy, Pharmacy, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Nanjing Nanjing 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ NN O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 NNP IN JJ NN CD O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 IN JJ NN CD NNP O
282 282 0 0 0 0 0 0 1 1 3 0 JJ NN CD NNP NNP O
Hanzhong Hanzhong 1 0 0 0 0 0 0 0 8 0 NN CD NNP NNP NNP O
Road, Road, 1 0 0 0 1 0 0 0 5 0 CD NNP NNP NNP CD O
Nanjing Nanjing 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP CD -NONE- O
210029, 210029, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD -NONE- NNP O
Jiangsu, Jiangsu, 1 0 0 0 1 0 0 0 8 0 NNP CD -NONE- NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 CD -NONE- NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 -NONE- NNP NNP NNP IN O
Activation Activation 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ NN O
hepatic hepatic 0 0 0 0 0 0 0 0 7 0 NNP IN JJ NN NNS O
stellate stellate 0 0 0 0 0 0 0 0 8 0 IN JJ NN NNS -NONE- O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS -NONE- VBZ O
(HSCs) (HSCs) 0 0 0 0 0 0 0 0 6 0 NN NNS -NONE- VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNS -NONE- VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- VBZ DT JJ NN O
pivotal pivotal 0 0 0 0 0 0 0 0 7 0 VBZ DT JJ NN IN O
event event 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
pathogenesis pathogenesis 0 0 0 0 0 0 0 0 12 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNP O
liver liver 0 0 0 0 0 0 0 0 5 0 NN IN NN NNP NNP O
fibrosis. fibrosis. 0 0 0 0 0 0 0 0 9 0 IN NN NNP NNP NN O
Pharmacological Pharmacological 1 0 0 0 0 0 0 0 15 0 NN NNP NNP NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NN O
HSC HSC 1 1 0 0 0 0 0 0 3 0 NN IN NNP NN MD O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 IN NNP NN MD VB O
could could 0 0 0 0 0 0 0 0 5 0 NNP NN MD VB DT O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT NN NN O
promising promising 0 0 0 0 0 0 0 0 9 0 VB DT NN NN IN O
strategy strategy 0 0 0 0 0 0 0 0 8 0 DT NN NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NN NNP O
fibrosis fibrosis 0 0 0 0 0 0 0 0 8 0 NN IN NN NNP NNP O
regression. regression. 0 0 0 0 0 0 0 0 11 0 IN NN NNP NNP NN O
Natural Natural 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NN NN O
product product 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN NN O
tetramethylpyrazine tetramethylpyrazine 0 0 0 0 0 0 0 0 19 0 NNP NN NN NN VBZ O
(TMP) (TMP) 0 1 0 0 0 0 0 0 5 0 NN NN NN VBZ NN O
exhibits exhibits 0 0 0 0 0 0 0 0 8 0 NN NN VBZ NN JJ O
potent potent 0 0 0 0 0 0 0 0 6 0 NN VBZ NN JJ NNS O
antifibrotic antifibrotic 0 0 0 0 0 0 0 0 12 0 VBZ NN JJ NNS IN O
activities activities 0 0 0 0 0 0 0 0 10 0 NN JJ NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NNP O
vivo. vivo. 0 0 0 0 0 0 0 0 5 0 NNS IN NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NNS O
molecular molecular 0 0 0 0 0 0 0 0 9 0 NNP DT JJ NNS VBP O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 DT JJ NNS VBP TO O
remain remain 0 0 0 0 0 0 0 0 6 0 JJ NNS VBP TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBP TO VB NNP O
be be 0 0 0 0 0 0 0 0 2 0 VBP TO VB NNP NNP O
defined. defined. 0 0 0 0 0 0 0 0 8 0 TO VB NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 VB NNP NNP NN NN O
present present 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN VBN O
study study 0 0 0 0 0 0 0 0 5 0 NNP NN NN VBN IN O
aimed aimed 0 0 0 0 0 0 0 0 5 0 NN NN VBN IN NN O
at at 0 0 0 0 0 0 0 0 2 0 NN VBN IN NN DT O
investigating investigating 0 0 0 0 0 0 0 0 13 0 VBN IN NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT JJ CC O
anti-proliferative anti-proliferative 0 0 1 0 0 0 0 0 18 0 NN DT JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC JJ NNS O
pro-apoptotic pro-apoptotic 0 0 1 0 0 0 0 0 13 0 JJ CC JJ NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 CC JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP IN O
TMP TMP 1 1 0 0 0 0 0 0 3 0 NNS IN NNP IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP CC O
HSCs HSCs 1 0 0 0 0 0 0 0 4 0 NNP IN NNP CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC VBG DT O
elucidating elucidating 0 0 0 0 0 0 0 0 11 0 NNP CC VBG DT VBG O
the the 0 0 0 0 0 0 0 0 3 0 CC VBG DT VBG NNP O
underlying underlying 0 0 0 0 0 0 0 0 10 0 VBG DT VBG NNP NNP O
mechanisms. mechanisms. 0 0 0 0 0 0 0 0 11 0 DT VBG NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 VBG NNP NNP NNS VBD O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 NNP NNS VBD IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NNP VBD O
TMP TMP 1 1 0 0 0 0 0 0 3 0 VBD IN NNP VBD DT O
had had 0 0 0 0 0 0 0 0 3 0 IN NNP VBD DT NN O
no no 0 0 0 0 0 0 0 0 2 0 NNP VBD DT NN JJ O
apparent apparent 0 0 0 0 0 0 0 0 8 0 VBD DT NN JJ NNS O
cytotoxic cytotoxic 0 0 0 0 0 0 0 0 9 0 DT NN JJ NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 NN JJ NNS IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ CC O
hepatocytes, hepatocytes, 0 0 0 0 1 0 0 0 12 0 NNS IN JJ CC RB O
but but 0 0 0 0 0 0 0 0 3 0 IN JJ CC RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 JJ CC RB VBN NNP O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 CC RB VBN NNP NN O
HSC HSC 1 1 0 0 0 0 0 0 3 0 RB VBN NNP NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VBN NNP NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC VBD NN O
induced induced 0 0 0 0 0 0 0 0 7 0 NN CC VBD NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 CC VBD NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest VBD NN NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 IN DT NNP NNP NNP G0/G1
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 DT NNP NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNS VBD O
effects effects 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NNS VBD VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNP NN O
TMP TMP 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NN IN O
regulation regulation 0 0 0 0 0 0 0 0 10 0 IN NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NN O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN IN NN NN NN O
D1, D1, 1 1 0 0 1 0 0 1 3 0 IN NN NN NN NNP O
p21, p21, 0 0 0 0 1 0 0 1 4 0 NN NN NN NNP CC O
p27 p27 0 0 0 0 0 0 0 1 3 0 NN NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP NNP O
p53. p53. 0 0 0 0 0 0 0 1 4 0 NNP CC NNP NNP PRP O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 CC NNP NNP PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD IN O
found found 0 0 0 0 0 0 0 0 5 0 NNP PRP VBD IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBD IN NNP VBD O
TMP TMP 1 1 0 0 0 0 0 0 3 0 VBD IN NNP VBD JJ O
disrupted disrupted 0 0 0 0 0 0 0 0 9 0 IN NNP VBD JJ NNS O
mitochondrial mitochondrial 0 0 0 0 0 0 0 0 13 0 NNP VBD JJ NNS CC O
functions functions 0 0 0 0 0 0 0 0 9 0 VBD JJ NNS CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC VBD TO O
led led 0 0 0 0 0 0 0 0 3 0 NNS CC VBD TO NN O
to to 0 0 0 0 0 0 0 0 2 0 CC VBD TO NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 VBD TO NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 TO NN IN NN NNS O
caspase caspase 0 0 0 0 0 0 0 0 7 0 NN IN NN NNS IN O
cascades cascades 0 0 0 0 0 0 0 0 8 0 IN NN NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP NNP O
HSCs. HSCs. 1 0 0 0 0 0 0 0 5 0 NNS IN NNP NNP NNS O
Mechanistic Mechanistic 1 0 0 0 0 0 0 0 11 0 IN NNP NNP NNS VBD O
investigations investigations 0 0 0 0 0 0 0 0 14 0 NNP NNP NNS VBD IN O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NNP RB O
TMP TMP 1 1 0 0 0 0 0 0 3 0 VBD IN NNP RB VBD O
selectively selectively 0 0 0 0 0 0 0 0 11 0 IN NNP RB VBD DT O
blocked blocked 0 0 0 0 0 0 0 0 7 0 NNP RB VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 RB VBD DT JJ JJ O
extracellular extracellular 0 0 0 0 0 0 0 0 13 0 VBD DT JJ JJ NN O
signal-regulated signal-regulated 0 0 1 0 0 0 0 0 16 0 DT JJ JJ NN NN O
kinase kinase 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NN VBG O
(ERK) (ERK) 0 1 0 0 0 0 0 0 5 0 JJ NN NN VBG CC O
signaling signaling 0 0 0 0 0 0 0 0 9 0 NN NN VBG CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NN VBG CC VBD JJ O
activated activated 0 0 0 0 0 0 0 0 9 0 VBG CC VBD JJ WDT O
p53, p53, 0 0 0 0 1 0 0 1 4 0 CC VBD JJ WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 VBD JJ WDT VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ WDT VBD VBN IN O
required required 0 0 0 0 0 0 0 0 8 0 WDT VBD VBN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN NNP NN O
TMP TMP 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 IN NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ JJ O
caspase-dependent caspase-dependent 0 0 1 0 0 0 0 0 17 0 NN IN JJ JJ NN O
mitochondrial mitochondrial 0 0 0 0 0 0 0 0 13 0 IN JJ JJ NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 JJ JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
HSCs. HSCs. 1 0 0 0 0 0 0 0 5 0 NN IN NNP NNP NNS O
Autodock Autodock 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNS VBD O
simulations simulations 0 0 0 0 0 0 0 0 11 0 NNP NNP NNS VBD IN O
predicted predicted 0 0 0 0 0 0 0 0 9 0 NNP NNS VBD IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NNP MD O
TMP TMP 1 1 0 0 0 0 0 0 3 0 VBD IN NNP MD RB O
could could 0 0 0 0 0 0 0 0 5 0 IN NNP MD RB VB O
directly directly 0 0 0 0 0 0 0 0 8 0 NNP MD RB VB TO O
bind bind 0 0 0 0 0 0 0 0 4 0 MD RB VB TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 RB VB TO NNP IN O
ERK2 ERK2 1 1 0 0 0 0 0 1 4 0 VB TO NNP IN CD O
with with 0 0 0 0 0 0 0 0 4 0 TO NNP IN CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 NNP IN CD NNS NNS O
hydrogen hydrogen 0 0 0 0 0 0 0 0 8 0 IN CD NNS NNS CC O
bonds bonds 0 0 0 0 0 0 0 0 5 0 CD NNS NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNS NNS CC JJ NN O
low low 0 0 0 0 0 0 0 0 3 0 NNS CC JJ NN NN O
energy energy 0 0 0 0 0 0 0 0 6 0 CC JJ NN NN VBG O
score, score, 0 0 0 0 1 0 0 0 6 0 JJ NN NN VBG IN O
indicating indicating 0 0 0 0 0 0 0 0 10 0 NN NN VBG IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NN VBG IN NNP MD O
ERK2 ERK2 1 1 0 0 0 0 0 1 4 0 VBG IN NNP MD VB O
could could 0 0 0 0 0 0 0 0 5 0 IN NNP MD VB DT O
be be 0 0 0 0 0 0 0 0 2 0 NNP MD VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT JJ NN O
direct direct 0 0 0 0 0 0 0 0 6 0 VB DT JJ NN NN O
target target 0 0 0 0 0 0 0 0 6 0 DT JJ NN NN IN O
molecule molecule 0 0 0 0 0 0 0 0 8 0 JJ NN NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NNP IN O
TMP TMP 1 1 0 0 0 0 0 0 3 0 NN IN NNP IN NNP O
within within 0 0 0 0 0 0 0 0 6 0 IN NNP IN NNP NNP O
HSCs. HSCs. 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Moreover, Moreover, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP VBD O
TMP TMP 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP VBD NN O
altered altered 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP VBD NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN DT NN O
some some 0 0 0 0 0 0 0 0 4 0 NN IN DT NN NNS O
marker marker 0 0 0 0 0 0 0 0 6 0 IN DT NN NNS VBP O
proteins proteins 0 0 0 0 0 0 0 0 8 0 DT NN NNS VBP TO O
relevant relevant 0 0 0 0 0 0 0 0 8 0 NN NNS VBP TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBP TO NNP NNP O
HSC HSC 1 1 0 0 0 0 0 0 3 0 VBP TO NNP NNP NNP O
activation. activation. 0 0 0 0 0 0 0 0 11 0 TO NNP NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNS RB O
data data 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS RB VBN O
collectively collectively 0 0 0 0 0 0 0 0 12 0 NNP NNS RB VBN IN O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NNS RB VBN IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 RB VBN IN NNP NN O
TMP TMP 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NN IN O
modulation modulation 0 0 0 0 0 0 0 0 10 0 IN NNP NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN -NONE- VBG O
ERK/p53 ERK/p53 1 0 0 1 0 0 0 1 7 0 NN IN -NONE- VBG VBN O
signaling signaling 0 0 0 0 0 0 0 0 9 0 IN -NONE- VBG VBN TO O
led led 0 0 0 0 0 0 0 0 3 0 -NONE- VBG VBN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 VBG VBN TO JJ CC O
mitochondrial-mediated mitochondrial-mediated 0 0 1 0 0 0 0 0 22 0 VBN TO JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 TO JJ CC JJ NN O
caspase-dependent caspase-dependent 0 0 1 0 0 0 0 0 17 0 JJ CC JJ NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 CC JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP IN O
HSCs HSCs 1 0 0 0 0 0 0 0 4 0 NN IN NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NNP O
vitro. vitro. 0 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNS VBD O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD JJ O
provided provided 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD JJ NNS O
mechanistic mechanistic 0 0 0 0 0 0 0 0 11 0 NNS VBD JJ NNS IN O
insights insights 0 0 0 0 0 0 0 0 8 0 VBD JJ NNS IN DT O
into into 0 0 0 0 0 0 0 0 4 0 JJ NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NNS O
antifibrotic antifibrotic 0 0 0 0 0 0 0 0 12 0 IN DT JJ NNS IN O
properties properties 0 0 0 0 0 0 0 0 10 0 DT JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP IN O
TMP TMP 1 1 0 0 0 0 0 0 3 0 NNS IN NNP IN MD O
that that 0 0 0 0 0 0 0 0 4 0 IN NNP IN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NNP IN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 IN MD VB VBN IN O
exploited exploited 0 0 0 0 0 0 0 0 9 0 MD VB VBN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VB VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NN O
potential potential 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN IN O
option option 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN JJ NNP O
hepatic hepatic 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNP NONE O
fibrosis. fibrosis. 0 0 0 0 0 0 0 0 9 0 IN JJ NNP NONE NONE O
Unique Unique 1 0 0 0 0 0 0 0 6 0 NONE NONE NNP NN NNS O
solution solution 0 0 0 0 0 0 0 0 8 0 NONE NNP NN NNS IN O
properties properties 0 0 0 0 0 0 0 0 10 0 NNP NN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ JJ O
quaternized quaternized 0 0 0 0 0 0 0 0 11 0 NNS IN JJ JJ NNS O
oligomeric oligomeric 0 0 0 0 0 0 0 0 10 0 IN JJ JJ NNS VBD O
surfactants surfactants 0 0 0 0 0 0 0 0 11 0 JJ JJ NNS VBD IN O
derived derived 0 0 0 0 0 0 0 0 7 0 JJ NNS VBD IN NN O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NN CC O
ethylenediamine ethylenediamine 0 0 0 0 0 0 0 0 15 0 VBD IN NN CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 IN NN CC NNP RB O
G0 G0 1 1 0 0 0 0 0 1 2 0 NN CC NNP RB JJ O
poly poly 0 0 0 0 0 0 0 0 4 0 CC NNP RB JJ NNP O
(amidoamine) (amidoamine) 0 0 0 0 0 0 0 0 12 0 NNP RB JJ NNP NNP O
dendrimers. dendrimers. 0 0 0 0 0 0 0 0 11 0 RB JJ NNP NNP NNP O
Yoshimura Yoshimura 1 0 0 0 0 0 0 0 9 0 JJ NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Abe Abe 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Esumi Esumi 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
K. K. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Group Group 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Chemistry, Chemistry, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP IN O
Division Division 1 0 0 0 0 0 0 0 8 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Natural Natural 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
Science, Science, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP NNP O
Nara Nara 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Women's Women's 1 0 0 0 0 1 0 0 7 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Nara, Nara, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
Japan. Japan. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
yoshimura@cc.nara-wu.ac.jp yoshimura@cc.nara-wu.ac.jp 0 0 1 0 0 0 0 0 26 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBD O
New New 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP VBD JJ O
quaternized quaternized 0 0 0 0 0 0 0 0 11 0 NNP NNP VBD JJ NNS O
oligomeric oligomeric 0 0 0 0 0 0 0 0 10 0 NNP VBD JJ NNS VBG O
surfactants surfactants 0 0 0 0 0 0 0 0 11 0 VBD JJ NNS VBG CD O
containing containing 0 0 0 0 0 0 0 0 10 0 JJ NNS VBG CD CC O
4 4 0 0 0 0 0 0 1 1 1 0 NNS VBG CD CC CD O
or or 0 0 0 0 0 0 0 0 2 0 VBG CD CC CD NN O
8 8 0 0 0 0 0 0 1 1 1 0 CD CC CD NN NNS O
alkyl alkyl 0 0 0 0 0 0 0 0 5 0 CC CD NN NNS VBD O
chains chains 0 0 0 0 0 0 0 0 6 0 CD NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN VBG O
synthesized synthesized 0 0 0 0 0 0 0 0 11 0 NNS VBD VBN VBG NN O
using using 0 0 0 0 0 0 0 0 5 0 VBD VBN VBG NN CC O
ethylenediamine ethylenediamine 0 0 0 0 0 0 0 0 15 0 VBN VBG NN CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 VBG NN CC JJ NNS O
poly(amidoamine) poly(amidoamine) 0 0 0 0 0 0 0 0 16 0 NN CC JJ NNS IN O
dendrimers dendrimers 0 0 0 0 0 0 0 0 10 0 CC JJ NNS IN DT O
as as 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NNP O
central central 0 0 0 0 0 0 0 0 7 0 IN DT JJ NNP NNP O
scaffold. scaffold. 0 0 0 0 0 0 0 0 9 0 DT JJ NNP NNP NNP O
Electrical Electrical 1 0 0 0 0 0 0 0 10 0 JJ NNP NNP NNP NN O
conductivity, conductivity, 0 0 0 0 1 0 0 0 13 0 NNP NNP NNP NN -NONE- O
surface surface 0 0 0 0 0 0 0 0 7 0 NNP NNP NN -NONE- CC O
tension, tension, 0 0 0 0 1 0 0 0 8 0 NNP NN -NONE- CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC NN NN O
pyrene pyrene 0 0 0 0 0 0 0 0 6 0 -NONE- CC NN NN NN O
fluorescence fluorescence 0 0 0 0 0 0 0 0 12 0 CC NN NN NN IN O
measurements, measurements, 0 0 0 0 1 0 0 0 13 0 NN NN NN IN RB O
as as 0 0 0 0 0 0 0 0 2 0 NN NN IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NN IN RB IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN JJ JJ O
dynamic dynamic 0 0 0 0 0 0 0 0 7 0 RB IN JJ JJ NN O
light light 0 0 0 0 0 0 0 0 5 0 IN JJ JJ NN VBD O
scattering scattering 0 0 0 0 0 0 0 0 10 0 JJ JJ NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NN VBD VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB PRP$ O
characterize characterize 0 0 0 0 0 0 0 0 12 0 VBN TO VB PRP$ NNP O
their their 0 0 0 0 0 0 0 0 5 0 TO VB PRP$ NNP NNP O
properties. properties. 0 0 0 0 0 0 0 0 11 0 VB PRP$ NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 PRP$ NNP NNP NNP DT O
addition, addition, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
dependence dependence 0 0 0 0 0 0 0 0 10 0 NNP DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT NNS IN O
properties properties 0 0 0 0 0 0 0 0 10 0 IN DT NNS IN DT O
on on 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
alkyl alkyl 0 0 0 0 0 0 0 0 5 0 IN DT NN NN NN O
chain chain 0 0 0 0 0 0 0 0 5 0 DT NN NN NN NN O
length, length, 0 0 0 0 1 0 0 0 7 0 NN NN NN NN IN O
number number 0 0 0 0 0 0 0 0 6 0 NN NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP CC O
chains, chains, 0 0 0 0 1 0 0 0 7 0 NN IN NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NN NN O
dendrimer dendrimer 0 0 0 0 0 0 0 0 9 0 NNP CC NN NN VBD O
generation generation 0 0 0 0 0 0 0 0 10 0 CC NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
determined determined 0 0 0 0 0 0 0 0 10 0 NN VBD VBN IN NN O
through through 0 0 0 0 0 0 0 0 7 0 VBD VBN IN NN IN O
comparison comparison 0 0 0 0 0 0 0 0 10 0 VBN IN NN IN RB O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN RB VBN O
previously previously 0 0 0 0 0 0 0 0 10 0 NN IN RB VBN JJ O
reported reported 0 0 0 0 0 0 0 0 8 0 IN RB VBN JJ NNP O
oligomeric oligomeric 0 0 0 0 0 0 0 0 10 0 RB VBN JJ NNP NNP O
surfactants. surfactants. 0 0 0 0 0 0 0 0 12 0 VBN JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
relation relation 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN NN O
between between 0 0 0 0 0 0 0 0 7 0 NNP NN IN NN NN O
surface surface 0 0 0 0 0 0 0 0 7 0 NN IN NN NN CC O
tension tension 0 0 0 0 0 0 0 0 7 0 IN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
concentration concentration 0 0 0 0 0 0 0 0 13 0 NN CC NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 CC NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNS O
oligomeric oligomeric 0 0 0 0 0 0 0 0 10 0 IN DT JJ NNS VBN O
surfactants surfactants 0 0 0 0 0 0 0 0 11 0 DT JJ NNS VBN JJ O
exhibited exhibited 0 0 0 0 0 0 0 0 9 0 JJ NNS VBN JJ NN O
clear clear 0 0 0 0 0 0 0 0 5 0 NNS VBN JJ NN WDT O
breakpoints, breakpoints, 0 0 0 0 1 0 0 0 12 0 VBN JJ NN WDT NN O
which which 0 0 0 0 0 0 0 0 5 0 JJ NN WDT NN DT O
reflect reflect 0 0 0 0 0 0 0 0 7 0 NN WDT NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 WDT NN DT JJ NN O
critical critical 0 0 0 0 0 0 0 0 8 0 NN DT JJ NN NN O
micelle micelle 0 0 0 0 0 0 0 0 7 0 DT JJ NN NN NNP O
concentration concentration 0 0 0 0 0 0 0 0 13 0 JJ NN NN NNP NNP O
(cmc). (cmc). 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP NN O
Both Both 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NN CC O
cmc cmc 0 0 0 0 0 0 0 0 3 0 NNP NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN NN O
surface surface 0 0 0 0 0 0 0 0 7 0 NN CC NN NN VBD O
tension tension 0 0 0 0 0 0 0 0 7 0 CC NN NN VBD JJR O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD JJR IN O
lower lower 0 0 0 0 0 0 0 0 5 0 NN VBD JJR IN DT O
than than 0 0 0 0 0 0 0 0 4 0 VBD JJR IN DT IN O
those those 0 0 0 0 0 0 0 0 5 0 JJR IN DT IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN DT IN JJ NN O
monomeric monomeric 0 0 0 0 0 0 0 0 9 0 DT IN JJ NN NN O
alkyltrimethylammonium alkyltrimethylammonium 0 0 0 0 0 0 0 0 22 0 IN JJ NN NN NN O
bromide bromide 0 0 0 0 0 0 0 0 7 0 JJ NN NN NN VBG O
surfactants, surfactants, 0 0 0 0 1 0 0 0 12 0 NN NN NN VBG IN O
indicating indicating 0 0 0 0 0 0 0 0 10 0 NN NN VBG IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NN VBG IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBG IN DT JJ JJ O
synthesized synthesized 0 0 0 0 0 0 0 0 11 0 IN DT JJ JJ NNS O
oligomeric oligomeric 0 0 0 0 0 0 0 0 10 0 DT JJ JJ NNS VBP O
surfactants surfactants 0 0 0 0 0 0 0 0 11 0 JJ JJ NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 JJ NNS VBP VBN JJ O
excellent excellent 0 0 0 0 0 0 0 0 9 0 NNS VBP VBN JJ NN O
micelle-forming micelle-forming 0 0 1 0 0 0 0 0 15 0 VBP VBN JJ NN IN O
ability ability 0 0 0 0 0 0 0 0 7 0 VBN JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN CC O
solution solution 0 0 0 0 0 0 0 0 8 0 NN IN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 NN CC JJ NN NN O
adsorption adsorption 0 0 0 0 0 0 0 0 10 0 CC JJ NN NN IN O
ability ability 0 0 0 0 0 0 0 0 7 0 JJ NN NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
air/water air/water 0 0 0 1 0 0 0 0 9 0 IN DT JJ NN IN O
interface, interface, 0 0 0 0 1 0 0 0 10 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
spite spite 0 0 0 0 0 0 0 0 5 0 NN IN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
large large 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN NN O
bulky bulky 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN VBG O
structure structure 0 0 0 0 0 0 0 0 9 0 JJ NN NN VBG NN O
containing containing 0 0 0 0 0 0 0 0 10 0 NN NN VBG NN NN O
multiple multiple 0 0 0 0 0 0 0 0 8 0 NN VBG NN NN VBZ O
alkyl alkyl 0 0 0 0 0 0 0 0 5 0 VBG NN NN VBZ CC O
chains chains 0 0 0 0 0 0 0 0 6 0 NN NN VBZ CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NN VBZ CC NNS IN O
headgroups headgroups 0 0 0 0 0 0 0 0 10 0 VBZ CC NNS IN CD O
within within 0 0 0 0 0 0 0 0 6 0 CC NNS IN CD NNP O
one one 0 0 0 0 0 0 0 0 3 0 NNS IN CD NNP NNP O
molecule. molecule. 0 0 0 0 0 0 0 0 9 0 IN CD NNP NNP DT O
When When 1 0 0 0 0 0 0 0 4 0 CD NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
alkyl alkyl 0 0 0 0 0 0 0 0 5 0 NNP DT NN NN NN O
chain chain 0 0 0 0 0 0 0 0 5 0 DT NN NN NN CC O
length length 0 0 0 0 0 0 0 0 6 0 NN NN NN CC DT O
or or 0 0 0 0 0 0 0 0 2 0 NN NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN IN O
number number 0 0 0 0 0 0 0 0 6 0 CC DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS IN O
chains chains 0 0 0 0 0 0 0 0 6 0 NN IN NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NNS O
oligomeric oligomeric 0 0 0 0 0 0 0 0 10 0 IN DT JJ NNS VBD O
surfactants surfactants 0 0 0 0 0 0 0 0 11 0 DT JJ NNS VBD JJ O
was was 0 0 0 0 0 0 0 0 3 0 JJ NNS VBD JJ DT O
increased, increased, 0 0 0 0 1 0 0 0 10 0 NNS VBD JJ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBD JJ DT JJ NN O
unique unique 0 0 0 0 0 0 0 0 6 0 JJ DT JJ NN VBD O
behavior behavior 0 0 0 0 0 0 0 0 8 0 DT JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NN O
that that 0 0 0 0 0 0 0 0 4 0 VBN IN DT NN IN O
adsorption adsorption 0 0 0 0 0 0 0 0 10 0 IN DT NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
air/water air/water 0 0 0 1 0 0 0 0 9 0 IN DT JJ NN CC O
interface interface 0 0 0 0 0 0 0 0 9 0 DT JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NN O
solution solution 0 0 0 0 0 0 0 0 8 0 NN CC NN NN VBD O
aggregation aggregation 0 0 0 0 0 0 0 0 11 0 CC NN NN VBD RB O
occurred occurred 0 0 0 0 0 0 0 0 8 0 NN NN VBD RB IN O
simultaneously simultaneously 0 0 0 0 0 0 0 0 14 0 NN VBD RB IN DT O
at at 0 0 0 0 0 0 0 0 2 0 VBD RB IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 RB IN DT NN IN O
concentration concentration 0 0 0 0 0 0 0 0 13 0 IN DT NN IN NN O
below below 0 0 0 0 0 0 0 0 5 0 DT NN IN NN -NONE- O
cmc cmc 0 0 0 0 0 0 0 0 3 0 NN IN NN -NONE- VBD O
(as (as 0 0 0 0 0 0 0 0 3 0 IN NN -NONE- VBD IN O
determined determined 0 0 0 0 0 0 0 0 10 0 NN -NONE- VBD IN DT O
by by 0 0 0 0 0 0 0 0 2 0 -NONE- VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN NN O
surface surface 0 0 0 0 0 0 0 0 7 0 IN DT NN NN NNP O
tension tension 0 0 0 0 0 0 0 0 7 0 DT NN NN NNP NNP O
method). method). 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP VBZ O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP VBZ IN O
suggests suggests 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBZ IN JJ NN O
aggregate aggregate 0 0 0 0 0 0 0 0 9 0 VBZ IN JJ NN NNS O
formation formation 0 0 0 0 0 0 0 0 9 0 IN JJ NN NNS RB O
occurs occurs 0 0 0 0 0 0 0 0 6 0 JJ NN NNS RB IN O
readily readily 0 0 0 0 0 0 0 0 7 0 NN NNS RB IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNS RB IN NN IN O
solution solution 0 0 0 0 0 0 0 0 8 0 RB IN NN IN IN O
along along 0 0 0 0 0 0 0 0 5 0 IN NN IN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN IN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN IN DT NN IN O
adsorption adsorption 0 0 0 0 0 0 0 0 10 0 IN DT NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
interface interface 0 0 0 0 0 0 0 0 9 0 IN DT NN IN IN O
because because 0 0 0 0 0 0 0 0 7 0 DT NN IN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN IN IN JJ JJ O
strong strong 0 0 0 0 0 0 0 0 6 0 IN IN JJ JJ NNS O
attractive attractive 0 0 0 0 0 0 0 0 10 0 IN JJ JJ NNS IN O
interactions interactions 0 0 0 0 0 0 0 0 12 0 JJ JJ NNS IN NN O
between between 0 0 0 0 0 0 0 0 7 0 JJ NNS IN NN NN O
multiple multiple 0 0 0 0 0 0 0 0 8 0 NNS IN NN NN NNP O
alkyl alkyl 0 0 0 0 0 0 0 0 5 0 IN NN NN NNP NONE O
chains. chains. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NONE NONE O
Dentatin Dentatin 1 0 0 0 0 0 0 0 8 0 NONE NONE NNP VBD IN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 NONE NNP VBD IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NNP VBD IN NNP NN O
Clausena Clausena 1 0 0 0 0 0 0 0 8 0 VBD IN NNP NN NNS O
excavata excavata 0 0 0 0 0 0 0 0 8 0 IN NNP NN NNS VBZ O
induces induces 0 0 0 0 0 0 0 0 7 0 NNP NN NNS VBZ IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN NNS VBZ IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBZ IN NNP NNS O
MCF-7 MCF-7 1 1 1 0 0 0 0 1 5 0 VBZ IN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS IN DT O
through through 0 0 0 0 0 0 0 0 7 0 NNP NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
intrinsic intrinsic 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN IN O
pathway pathway 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN NN IN O
involvement involvement 0 0 0 0 0 0 0 0 11 0 NN IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NN O
NF-κB NF-κB 1 0 1 0 0 0 0 0 5 0 NN IN NNP NN CC O
signalling signalling 0 0 0 0 0 0 0 0 10 0 IN NNP NN CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC -NONE- NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NN CC -NONE- NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 CC -NONE- NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 -NONE- NN NN NN DT O
arrest: arrest: 0 0 0 0 0 0 0 0 7 0 NN NN NN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN NN DT JJ NNP O
bioassay-guided bioassay-guided 0 0 1 0 0 0 0 0 15 0 NN DT JJ NNP NNP O
approach. approach. 0 0 0 0 0 0 0 0 9 0 DT JJ NNP NNP NNP O
Arbab Arbab 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP NNP NNP O
IA, IA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abdul Abdul 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
AB, AB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Sukari Sukari 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
MA, MA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abdullah Abdullah 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Syam Syam 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kamalidehghan Kamalidehghan 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ibrahim Ibrahim 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
MY, MY, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Taha Taha 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
MM, MM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abdelwahab Abdelwahab 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
SI, SI, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Ali Ali 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
HM, HM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Mohan Mohan 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
S. S. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
UPM-MAKNA UPM-MAKNA 1 1 1 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Laboratory, Laboratory, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Bioscience, Bioscience, 1 0 0 0 1 0 0 0 11 0 NNP IN NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP NNP O
Putra Putra 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Malaysia, Malaysia, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Serdang, Serdang, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Selangor, Selangor, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Malaysia. Malaysia. 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
ETHNOPHARMACOLOGICAL ETHNOPHARMACOLOGICAL 1 1 0 0 0 0 0 0 20 0 NNP NNP NNP NNP NNP O
RELEVANCE: RELEVANCE: 1 1 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NN O
Clausena Clausena 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NN NNP O
excavata excavata 0 0 0 0 0 0 0 0 8 0 NNP NNP NN NNP NNP O
Burm. Burm. 1 0 0 0 0 0 0 0 5 0 NNP NN NNP NNP VBZ O
f. f. 0 0 0 0 0 0 0 0 2 0 NN NNP NNP VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP NNP VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBN VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 VBZ VBN VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN NN NNS O
folk folk 0 0 0 0 0 0 0 0 4 0 VBN IN NN NNS IN O
medicines medicines 0 0 0 0 0 0 0 0 9 0 IN NN NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NNP O
eastern eastern 0 0 0 0 0 0 0 0 7 0 NNS IN NN NNP IN O
Thailand Thailand 1 0 0 0 0 0 0 0 8 0 IN NN NNP IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNPS O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 NN IN NNP NNPS NNP O
MATERIALS MATERIALS 1 1 0 0 0 0 0 0 9 0 IN NNP NNPS NNP NNP O
AND AND 1 1 0 0 0 0 0 0 3 0 NNP NNPS NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 NNPS NNP NNP NNP VB O
To To 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VB DT O
investigate investigate 0 0 0 0 0 0 0 0 11 0 NNP NNP VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VB DT NN NN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 VB DT NN NN PRP O
mechanism, mechanism, 0 0 0 0 1 0 0 0 10 0 DT NN NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NN NN PRP VBD NN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 NN PRP VBD NN -NONE- O
dentatin dentatin 0 0 0 0 0 0 0 0 8 0 PRP VBD NN -NONE- IN O
(DTN) (DTN) 0 1 0 0 0 0 0 0 5 0 VBD NN -NONE- IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NN -NONE- IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 -NONE- IN DT NN VBG O
plant plant 0 0 0 0 0 0 0 0 5 0 IN DT NN VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 DT NN VBG DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBG DT JJ NNP O
bioassay-guided bioassay-guided 0 0 1 0 0 0 0 0 15 0 VBG DT JJ NNP JJ O
approach. approach. 0 0 0 0 0 0 0 0 9 0 DT JJ NNP JJ NN O
DTN-induced DTN-induced 1 0 1 0 0 0 0 0 11 0 JJ NNP JJ NN VBD O
cytotoxicity cytotoxicity 0 0 0 0 0 0 0 0 12 0 NNP JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NNP O
MTT MTT 1 1 0 0 0 0 0 0 3 0 IN DT NNP NNP NNP O
assay. assay. 0 0 0 0 0 0 0 0 6 0 DT NNP NNP NNP NNP O
Acridine Acridine 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
orange/propidium orange/propidium 0 0 0 1 0 0 0 0 16 0 NNP NNP NNP NN VBG O
iodide iodide 0 0 0 0 0 0 0 0 6 0 NNP NNP NN VBG VBD O
staining staining 0 0 0 0 0 0 0 0 8 0 NNP NN VBG VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN VBG VBD VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 VBG VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB NNS O
detect detect 0 0 0 0 0 0 0 0 6 0 VBN TO VB NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 TO VB NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VB NNS IN JJ NN O
early early 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NN CC O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 IN JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 NN CC JJ NN VBG O
content content 0 0 0 0 0 0 0 0 7 0 CC JJ NN VBG NN O
screening screening 0 0 0 0 0 0 0 0 9 0 JJ NN VBG NN TO O
(HCS) (HCS) 0 1 0 0 0 0 0 0 5 0 NN VBG NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBG NN TO VB JJ O
observe observe 0 0 0 0 0 0 0 0 7 0 NN TO VB JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 TO VB JJ NN NN O
condensation, condensation, 0 0 0 0 1 0 0 0 13 0 VB JJ NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NN O
permeability, permeability, 0 0 0 0 1 0 0 0 13 0 NN NN NN NN NN O
mitochondrial mitochondrial 0 0 0 0 0 0 0 0 13 0 NN NN NN NN NN O
membrane membrane 0 0 0 0 0 0 0 0 8 0 NN NN NN NN NN O
potential potential 0 0 0 0 0 0 0 0 9 0 NN NN NN NN CC O
(MMP) (MMP) 0 1 0 0 0 0 0 0 5 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
cytochrome cytochrome 0 0 0 0 0 0 0 0 10 0 NN CC NN NN NNP O
c c 0 0 0 0 0 0 0 0 1 0 CC NN NN NNP NNP O
release. release. 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP VBD O
Apoptosis Apoptosis 1 0 0 0 0 0 0 0 9 0 NN NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
confirmed confirmed 0 0 0 0 0 0 0 0 9 0 NNP VBD VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NN O
clonogenic clonogenic 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN NNP O
assay, assay, 0 0 0 0 1 0 0 0 6 0 DT JJ NN NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 JJ NN NNP NN CC O
laddering laddering 0 0 0 0 0 0 0 0 9 0 NN NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN CD O
caspase caspase 0 0 0 0 0 0 0 0 7 0 NN CC NN CD CC O
3/7 3/7 0 0 0 1 0 0 0 1 3 0 CC NN CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NN CD CC CD NNP O
9 9 0 0 0 0 0 0 1 1 1 0 CD CC CD NNP NNP O
assays. assays. 0 0 0 0 0 0 0 0 7 0 CC CD NNP NNP NN O
Reactive Reactive 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NN NNS O
oxygen oxygen 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NNS -NONE- O
species species 0 0 0 0 0 0 0 0 7 0 NNP NN NNS -NONE- -NONE- O
(ROS) (ROS) 0 1 0 0 0 0 0 0 5 0 NN NNS -NONE- -NONE- -NONE- O
formation, formation, 0 0 0 0 1 0 0 0 10 0 NNS -NONE- -NONE- -NONE- CC O
Bcl-2 Bcl-2 1 0 1 0 0 0 0 1 5 0 -NONE- -NONE- -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- CC NNP NNP O
Bax Bax 1 0 0 0 0 0 0 0 3 0 -NONE- CC NNP NNP CC O
expression, expression, 0 0 0 0 1 0 0 0 11 0 CC NNP NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP CC NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest CC NN NN NN VBD O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD RB NNP O
also also 0 0 0 0 0 0 0 0 4 0 NN VBD RB NNP NNP O
investigated. investigated. 0 0 0 0 0 0 0 0 13 0 VBD RB NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 RB NNP NNP NN IN O
involvement involvement 0 0 0 0 0 0 0 0 11 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN NNP O
factor-kappa factor-kappa 0 0 1 0 0 0 0 0 12 0 IN JJ NN NNP NNP O
B B 1 1 0 0 0 0 0 0 1 0 JJ NN NNP NNP VBD O
(NF-κB) (NF-κB) 0 0 1 0 0 0 0 0 7 0 NN NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
analysed analysed 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NNP O
HCS HCS 1 1 0 0 0 0 0 0 3 0 IN DT NNP NNP NNP O
assay. assay. 0 0 0 0 0 0 0 0 6 0 DT NNP NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNP JJ O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 NNP NNP JJ NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 NNP JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 NN IN NN NN IN O
condensation condensation 0 0 0 0 0 0 0 0 12 0 IN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBZ O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN VBZ VBD O
nucleus nucleus 0 0 0 0 0 0 0 0 7 0 DT NN VBZ VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN VBZ VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 VBZ VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN NNP O
fluorescence fluorescence 0 0 0 0 0 0 0 0 12 0 VBN IN NN NNP NNP O
analysis. analysis. 0 0 0 0 0 0 0 0 9 0 IN NN NNP NNP VBD O
Apoptosis Apoptosis 1 0 0 0 0 0 0 0 9 0 NN NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
confirmed confirmed 0 0 0 0 0 0 0 0 9 0 NNP VBD VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT VBN NN O
reduced reduced 0 0 0 0 0 0 0 0 7 0 IN DT VBN NN IN O
number number 0 0 0 0 0 0 0 0 6 0 DT VBN NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNS IN O
colonies colonies 0 0 0 0 0 0 0 0 8 0 NN IN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
clonogenic clonogenic 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN CC O
assay assay 0 0 0 0 0 0 0 0 5 0 DT JJ NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT VBN NN O
increased increased 0 0 0 0 0 0 0 0 9 0 CC DT VBN NN IN O
number number 0 0 0 0 0 0 0 0 6 0 DT VBN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN JJ NNP O
cellular cellular 0 0 0 0 0 0 0 0 8 0 NN IN JJ NNP VBZ O
DNA DNA 1 1 0 0 0 0 0 0 3 0 IN JJ NNP VBZ IN O
breaks breaks 0 0 0 0 0 0 0 0 6 0 JJ NNP VBZ IN VBN O
in in 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN VBN NNS O
treated treated 0 0 0 0 0 0 0 0 7 0 VBZ IN VBN NNS VBN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN VBN NNS VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 VBN NNS VBN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NNS VBN IN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 IN DT NNP NNP NNP O
ladder. ladder. 0 0 0 0 0 0 0 0 7 0 DT NNP NNP NNP IN O
Treatment Treatment 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNS O
MCF-7 MCF-7 1 1 1 0 0 0 0 1 5 0 NNP IN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNS IN NNP VBD O
DTN DTN 1 1 0 0 0 0 0 0 3 0 NNS IN NNP VBD NN O
encouraged encouraged 0 0 0 0 0 0 0 0 10 0 IN NNP VBD NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NNP VBD NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 VBD NN IN NN JJ O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN JJ NNS O
death-transducing death-transducing 0 0 1 0 0 0 0 0 17 0 IN NN JJ NNS WDT O
signals signals 0 0 0 0 0 0 0 0 7 0 NN JJ NNS WDT VBN O
that that 0 0 0 0 0 0 0 0 4 0 JJ NNS WDT VBN NNP O
reduced reduced 0 0 0 0 0 0 0 0 7 0 NNS WDT VBN NNP IN O
MMP MMP 1 1 0 0 0 0 0 0 3 0 WDT VBN NNP IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBN NNP IN NN IN O
down-regulation down-regulation 0 0 1 0 0 0 0 0 15 0 NNP IN NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN -NONE- CC O
Bcl-2 Bcl-2 1 0 1 0 0 0 0 1 5 0 NN IN -NONE- CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN -NONE- CC NN IN O
up-regulation up-regulation 0 0 1 0 0 0 0 0 13 0 -NONE- CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NN O
Bax, Bax, 1 0 0 0 1 0 0 0 4 0 NN IN NNP NN NN O
triggering triggering 0 0 0 0 0 0 0 0 10 0 IN NNP NN NN NN O
cytochrome cytochrome 0 0 0 0 0 0 0 0 10 0 NNP NN NN NN NN O
c c 0 0 0 0 0 0 0 0 1 0 NN NN NN NN IN O
release release 0 0 0 0 0 0 0 0 7 0 NN NN NN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN TO O
mitochondria mitochondria 0 0 0 0 0 0 0 0 12 0 IN DT NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT NNP NNP O
cytosol. cytosol. 0 0 0 0 0 0 0 0 8 0 TO DT NNP NNP VBD O
The The 1 0 0 0 0 0 0 0 3 0 DT NNP NNP VBD NN O
released released 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD NN NN O
cytochrome cytochrome 0 0 0 0 0 0 0 0 10 0 NNP VBD NN NN VBD O
c c 0 0 0 0 0 0 0 0 1 0 VBD NN NN VBD DT O
triggered triggered 0 0 0 0 0 0 0 0 9 0 NN NN VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBD DT NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 VBD DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN CD O
caspase caspase 0 0 0 0 0 0 0 0 7 0 NN IN NN CD VBN O
9 9 0 0 0 0 0 0 1 1 1 0 IN NN CD VBN IN O
followed followed 0 0 0 0 0 0 0 0 8 0 NN CD VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 CD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NN O
executioner executioner 0 0 0 0 0 0 0 0 11 0 IN DT NN NN CD O
caspase caspase 0 0 0 0 0 0 0 0 7 0 DT NN NN CD NNP O
3/7. 3/7. 0 0 0 1 0 0 0 1 4 0 NN NN CD NNP NN O
DTN DTN 1 1 0 0 0 0 0 0 3 0 NN CD NNP NN RB O
treatment treatment 0 0 0 0 0 0 0 0 9 0 CD NNP NN RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNP NN RB VBN -NONE- O
arrested arrested 0 0 0 0 0 0 0 0 8 0 NN RB VBN -NONE- NNS O
MCF-7 MCF-7 1 1 1 0 0 0 0 1 5 0 RB VBN -NONE- NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 VBN -NONE- NNS IN DT O
at at 0 0 0 0 0 0 0 0 2 0 -NONE- NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase IN DT NNP NN -NONE- B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NNP NN -NONE- CC O
(p<0.05) (p<0.05) 0 0 0 0 0 0 0 1 8 0 NNP NN -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC NNP VBD O
ROS ROS 1 1 0 0 0 0 0 0 3 0 -NONE- CC NNP VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 CC NNP VBD RB NNP O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNP VBD RB NNP NNP O
elevated. elevated. 0 0 0 0 0 0 0 0 9 0 VBD RB NNP NNP NNP O
Moreover, Moreover, 1 0 0 0 1 0 0 0 9 0 RB NNP NNP NNP RB O
DTN DTN 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP RB VBD O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNP NNP RB VBD DT O
blocked blocked 0 0 0 0 0 0 0 0 7 0 NNP RB VBD DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBD DT VBN NN O
induced induced 0 0 0 0 0 0 0 0 7 0 VBD DT VBN NN IN O
translocation translocation 0 0 0 0 0 0 0 0 13 0 DT VBN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNP IN O
NF-κB NF-κB 1 0 1 0 0 0 0 0 5 0 NN IN NNP IN NN O
from from 0 0 0 0 0 0 0 0 4 0 IN NNP IN NN TO O
cytoplasm cytoplasm 0 0 0 0 0 0 0 0 9 0 NNP IN NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO NNP NNP O
nucleus. nucleus. 0 0 0 0 0 0 0 0 8 0 NN TO NNP NNP NNP O
CONCLUSION: CONCLUSION: 1 1 0 0 0 0 0 0 11 0 TO NNP NNP NNP DT O
Together, Together, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNS VBD O
results results 0 0 0 0 0 0 0 0 7 0 NNP DT NNS VBD IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 DT NNS VBD IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NNP VBD O
DTN DTN 1 1 0 0 0 0 0 0 3 0 IN DT NNP VBD IN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 DT NNP VBD IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NNP VBD IN NNP NN O
Clausena Clausena 1 0 0 0 0 0 0 0 8 0 VBD IN NNP NN VBD O
excavata excavata 0 0 0 0 0 0 0 0 8 0 IN NNP NN VBD DT O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NNP NN VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBD DT NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VBD DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
MCF-7 MCF-7 1 1 1 0 0 0 0 1 5 0 NN IN NNP NNP VBG O
cells, cells, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP VBG TO O
leading leading 0 0 0 0 0 0 0 0 7 0 NNP NNP VBG TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBG TO VB NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBG TO VB NN JJS O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest TO VB NN JJS CC O
arrest arrest 0 0 0 0 0 0 0 0 6 0 VB NN JJS CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NN JJS CC VBD NN O
programmed programmed 0 0 0 0 0 0 0 0 10 0 JJS CC VBD NN -NONE- O
cell cell 0 0 0 0 0 0 0 0 4 0 CC VBD NN -NONE- WDT O
death, death, 0 0 0 0 1 0 0 0 6 0 VBD NN -NONE- WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 NN -NONE- WDT VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 -NONE- WDT VBD VBN TO O
confirmed confirmed 0 0 0 0 0 0 0 0 9 0 WDT VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB IN O
occur occur 0 0 0 0 0 0 0 0 5 0 VBN TO VB IN DT O
through through 0 0 0 0 0 0 0 0 7 0 TO VB IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VB IN DT JJ NN O
mitochondrial mitochondrial 0 0 0 0 0 0 0 0 13 0 IN DT JJ NN IN O
pathway pathway 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN NN IN O
involvement involvement 0 0 0 0 0 0 0 0 11 0 NN IN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
NF-κB NF-κB 1 0 1 0 0 0 0 0 5 0 IN DT JJ NN NNP O
signalling signalling 0 0 0 0 0 0 0 0 10 0 DT JJ NN NNP NONE O
pathway. pathway. 0 0 0 0 0 0 0 0 8 0 JJ NN NNP NONE NONE O
Lycorine Lycorine 1 0 0 0 0 0 0 0 8 0 NONE NONE NNP NNS JJ O
induces induces 0 0 0 0 0 0 0 0 7 0 NONE NNP NNS JJ NN O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 arrest NNP NNS JJ NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NNS JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase IN DT NN NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNS O
K562 K562 1 1 0 0 0 0 0 1 4 0 NN IN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS IN NNP O
via via 0 0 0 0 0 0 0 0 3 0 NNP NNS IN NNP NNP O
HDAC HDAC 1 1 0 0 0 0 0 0 4 0 NNS IN NNP NNP NNP O
inhibition. inhibition. 0 0 0 0 0 0 0 0 11 0 IN NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Dai Dai 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
HJ, HJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Ye Ye 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
SL, SL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Xiao Xiao 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
XJ, XJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Zheng Zheng 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
HY, HY, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Luo Luo 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
YH, YH, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Liu Liu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
J. J. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Biology Biology 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Center, Center, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biological Biological 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP CC O
Science Science 1 0 0 0 0 0 0 0 7 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Technology, Technology, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP NNP O
Central Central 1 0 0 0 0 0 0 0 7 0 CC NNP NNP NNP NNP O
South South 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Changsha, Changsha, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP CD O
Hunan Hunan 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP CD NNP O
410078, 410078, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
yemaocsu@hotmail.com. yemaocsu@hotmail.com. 0 0 0 0 0 0 0 0 21 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP DT O
Lycorine, Lycorine, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT JJ NN O
natural natural 0 0 0 0 0 0 0 0 7 0 NNP DT JJ NN VBD O
alkaloid alkaloid 0 0 0 0 0 0 0 0 8 0 DT JJ NN VBD IN O
extracted extracted 0 0 0 0 0 0 0 0 9 0 JJ NN VBD IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NN VBD IN NNP VBZ O
Amaryllidaceae, Amaryllidaceae, 1 0 0 0 1 0 0 0 15 0 VBD IN NNP VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 IN NNP VBZ VBN JJ O
shown shown 0 0 0 0 0 0 0 0 5 0 NNP VBZ VBN JJ JJ O
various various 0 0 0 0 0 0 0 0 7 0 VBZ VBN JJ JJ NNP O
pharmacological pharmacological 0 0 0 0 0 0 0 0 15 0 VBN JJ JJ NNP NNP O
effects. effects. 0 0 0 0 0 0 0 0 8 0 JJ JJ NNP NNP NNS O
Recent Recent 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP NNS VBP O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP VBN IN O
focused focused 0 0 0 0 0 0 0 0 7 0 NNS VBP VBN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 VBP VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NN O
potential potential 0 0 0 0 0 0 0 0 9 0 IN DT NN NN NN O
antitumor antitumor 0 0 0 0 0 0 0 0 9 0 DT NN NN NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NN NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
lycorine. lycorine. 0 0 0 0 0 0 0 0 9 0 NN IN NNP NNP PRP$ O
In In 1 0 0 0 0 0 0 0 2 0 IN NNP NNP PRP$ JJ O
our our 0 0 0 0 0 0 0 0 3 0 NNP NNP PRP$ JJ NN O
previous previous 0 0 0 0 0 0 0 0 8 0 NNP PRP$ JJ NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 PRP$ JJ NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 JJ NN PRP VBD IN O
found found 0 0 0 0 0 0 0 0 5 0 NN PRP VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBD IN NN NN O
lycorine lycorine 0 0 0 0 0 0 0 0 8 0 VBD IN NN NN DT O
decrease decrease 0 0 0 0 0 0 0 0 8 0 IN NN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN DT NN NN IN O
viability viability 0 0 0 0 0 0 0 0 9 0 DT NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN -NONE- O
leukemia leukemia 0 0 0 0 0 0 0 0 8 0 NN IN NN -NONE- VBZ O
HL-60 HL-60 1 1 1 0 0 0 0 1 5 0 IN NN -NONE- VBZ CC O
cells cells 0 0 0 0 0 0 0 0 5 0 NN -NONE- VBZ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- VBZ CC NN NN O
multiple multiple 0 0 0 0 0 0 0 0 8 0 VBZ CC NN NN NNP O
myeloma myeloma 0 0 0 0 0 0 0 0 7 0 CC NN NN NNP NNS O
KM3 KM3 1 1 0 0 0 0 0 1 3 0 NN NN NNP NNS CC O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NNP NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNS CC NNS VBP O
induces induces 0 0 0 0 0 0 0 0 7 0 NNS CC NNS VBP NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 CC NNS VBP NNP NNP O
apoptosis. apoptosis. 0 0 0 0 0 0 0 0 10 0 NNS VBP NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 VBP NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN CC O
effect effect 0 0 0 0 0 0 0 0 6 0 NNP DT NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 NN CC JJ NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 CC JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
lycorine lycorine 0 0 0 0 0 0 0 0 8 0 NN IN NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ JJ O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ JJ JJ O
chronic chronic 0 0 0 0 0 0 0 0 7 0 IN JJ JJ JJ NN O
myelocytic myelocytic 0 0 0 0 0 0 0 0 10 0 JJ JJ JJ NN NNS O
leukemia leukemia 0 0 0 0 0 0 0 0 8 0 JJ JJ NN NNS VBZ O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS VBZ RB O
has has 0 0 0 0 0 0 0 0 3 0 NN NNS VBZ RB TO O
yet yet 0 0 0 0 0 0 0 0 3 0 NNS VBZ RB TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ RB TO VB NNP O
be be 0 0 0 0 0 0 0 0 2 0 RB TO VB NNP NNP O
determined. determined. 0 0 0 0 0 0 0 0 11 0 TO VB NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 VB NNP NNP NNP JJ O
Human Human 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP JJ JJ O
chronic chronic 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ JJ NN O
myelocytic myelocytic 0 0 0 0 0 0 0 0 10 0 NNP JJ JJ NN NNS O
leukemia leukemia 0 0 0 0 0 0 0 0 8 0 JJ JJ NN NNS NNP O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS NNP VBD O
K562 K562 1 1 0 0 0 0 0 1 4 0 NN NNS NNP VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNS NNP VBD VBN IN O
treated treated 0 0 0 0 0 0 0 0 7 0 NNP VBD VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNP NNP O
lycorine. lycorine. 0 0 0 0 0 0 0 0 9 0 VBN IN NNP NNP NN O
Cell Cell 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NN VBD O
viability viability 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN VBG O
monitored monitored 0 0 0 0 0 0 0 0 9 0 NN VBD VBN VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 VBD VBN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN VBG DT NN IN O
method method 0 0 0 0 0 0 0 0 6 0 VBG DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
CCK-8. CCK-8. 1 1 1 0 0 0 0 1 6 0 NN IN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NN NN O
histone histone 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN NN O
deacetylase deacetylase 0 0 0 0 0 0 0 0 11 0 NNP NN NN NN JJ O
(HDAC) (HDAC) 0 1 0 0 0 0 0 0 6 0 NN NN NN JJ NN O
enzymatic enzymatic 0 0 0 0 0 0 0 0 9 0 NN NN JJ NN VBD O
activity activity 0 0 0 0 0 0 0 0 8 0 NN JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN IN O
detected detected 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP JJ O
HDAC HDAC 1 1 0 0 0 0 0 0 4 0 VBN IN NNP JJ NN O
colorimetric colorimetric 0 0 0 0 0 0 0 0 12 0 IN NNP JJ NN CC O
assay, assay, 0 0 0 0 1 0 0 0 6 0 NNP JJ NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 CC DT NN NN VBD O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
analyzed analyzed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN NNP O
flow flow 0 0 0 0 0 0 0 0 4 0 VBN IN NN NNP NNP O
cytometry. cytometry. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ JJ O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 0 NN IN JJ JJ NNS O
related related 0 0 0 0 0 0 0 0 7 0 IN JJ JJ NNS VBD O
proteins proteins 0 0 0 0 0 0 0 0 8 0 JJ JJ NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD VBN VBG O
identified identified 0 0 0 0 0 0 0 0 10 0 NNS VBD VBN VBG NNP O
using using 0 0 0 0 0 0 0 0 5 0 VBD VBN VBG NNP NNP O
Western Western 1 0 0 0 0 0 0 0 7 0 VBN VBG NNP NNP NNP O
blot. blot. 0 0 0 0 0 0 0 0 5 0 VBG NNP NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
present present 0 0 0 0 0 0 0 0 7 0 NNP DT NN NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 DT NN NN PRP RB O
we we 0 0 0 0 0 0 0 0 2 0 NN NN PRP RB VBD O
further further 0 0 0 0 0 0 0 0 7 0 NN PRP RB VBD IN O
revealed revealed 0 0 0 0 0 0 0 0 8 0 PRP RB VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 RB VBD IN NN MD O
lycorine lycorine 0 0 0 0 0 0 0 0 8 0 VBD IN NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 IN NN MD VB DT O
inhibit inhibit 0 0 0 0 0 0 0 0 7 0 NN MD VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VB DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
K562 K562 1 1 0 0 0 0 0 1 4 0 NN IN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP IN O
Analysis Analysis 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NN O
HDAC HDAC 1 1 0 0 0 0 0 0 4 0 NNP IN NNP NN VBD O
activity activity 0 0 0 0 0 0 0 0 8 0 IN NNP NN VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NN VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN NN NNS O
lycroine lycroine 0 0 0 0 0 0 0 0 8 0 VBD IN NN NNS NNP O
decreases decreases 0 0 0 0 0 0 0 0 9 0 IN NN NNS NNP JJ O
HDAC HDAC 1 1 0 0 0 0 0 0 4 0 NN NNS NNP JJ NNS O
enzymatic enzymatic 0 0 0 0 0 0 0 0 9 0 NNS NNP JJ NNS IN O
activities activities 0 0 0 0 0 0 0 0 10 0 NNP JJ NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NNS O
K562 K562 1 1 0 0 0 0 0 1 4 0 NNS IN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ NNP O
dose-dependent dose-dependent 0 0 1 0 0 0 0 0 14 0 IN DT JJ NNP NNP O
manner. manner. 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NNP IN O
Inhibition Inhibition 1 0 0 0 0 0 0 0 10 0 JJ NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NN O
HDAC HDAC 1 1 0 0 0 0 0 0 4 0 NNP IN NNP NN VBZ O
activity activity 0 0 0 0 0 0 0 0 8 0 IN NNP NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP NN VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 VBZ VBN VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBN VBN IN JJ NN O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 arrest VBN IN JJ NN CC O
arrest arrest 0 0 0 0 0 0 0 0 6 0 IN JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NNP O
growth growth 0 0 0 0 0 0 0 0 6 0 NN CC NN NNP NNP O
inhibition. inhibition. 0 0 0 0 0 0 0 0 11 0 CC NN NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBD DT O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBD DT NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN NN IN O
distribution distribution 0 0 0 0 0 0 0 0 12 0 NN NN NN IN NN O
after after 0 0 0 0 0 0 0 0 5 0 NN NN IN NN NN O
lycorine lycorine 0 0 0 0 0 0 0 0 8 0 NN IN NN NN CC O
treatment treatment 0 0 0 0 0 0 0 0 9 0 IN NN NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBD IN O
found found 0 0 0 0 0 0 0 0 5 0 NN CC VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 CC VBD IN NN NNS O
lycorine lycorine 0 0 0 0 0 0 0 0 8 0 VBD IN NN NNS JJ O
causes causes 0 0 0 0 0 0 0 0 6 0 IN NN NNS JJ NN O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 arrest NN NNS JJ NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NNS JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 IN DT NN NNP TO B_TIMEXCCP
phase. phase. 0 0 0 0 0 0 0 0 6 0 DT NN NNP TO VB O
To To 1 0 0 0 0 0 0 0 2 0 NN NNP TO VB DT O
investigate investigate 0 0 0 0 0 0 0 0 11 0 NNP TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 VB DT NN IN DT O
behind behind 0 0 0 0 0 0 0 0 6 0 DT NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN NN JJ O
arrest, arrest, 0 0 0 0 1 0 0 0 7 0 NN NN NN JJ NNS O
G1-related G1-related 1 0 1 0 0 0 0 1 10 0 NN NN JJ NNS VBD O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NN JJ NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD VBN IN O
assayed assayed 0 0 0 0 0 0 0 0 7 0 NNS VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
Western Western 1 0 0 0 0 0 0 0 7 0 VBN IN NNP NNP NNP O
blot. blot. 0 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NN O
After After 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NN -NONE- O
lycorine lycorine 0 0 0 0 0 0 0 0 8 0 NNP NNP NN -NONE- NN O
treatment, treatment, 0 0 0 0 1 0 0 0 10 0 NNP NN -NONE- NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN -NONE- NN NNP CC O
D1 D1 1 1 0 0 0 0 0 1 2 0 -NONE- NN NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC JJ NN O
cyclin-dependent cyclin-dependent 0 0 1 0 0 0 0 0 16 0 NNP CC JJ NN CD O
kinase kinase 0 0 0 0 0 0 0 0 6 0 CC JJ NN CD NNS O
4 4 0 0 0 0 0 0 1 1 1 0 JJ NN CD NNS VBD O
expressions expressions 0 0 0 0 0 0 0 0 11 0 NN CD NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 CD NNS VBD VBN CC O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VBD VBN CC NN NN O
retinoblastoma retinoblastoma 0 0 0 0 0 0 0 0 14 0 VBN CC NN NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 CC NN NN NN VBD O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 NN NN NN VBD NNP O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD NNP NNP O
reduced. reduced. 0 0 0 0 0 0 0 0 8 0 NN VBD NNP NNP NN O
Lycorine Lycorine 1 0 0 0 0 0 0 0 8 0 VBD NNP NNP NN RB O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NNP NNP NN RB RB O
also also 0 0 0 0 0 0 0 0 4 0 NNP NN RB RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NN RB RB VBN DT O
upregulated upregulated 0 0 0 0 0 0 0 0 11 0 RB RB VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBN DT NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 VBN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP CC O
p53 p53 0 0 0 0 0 0 0 1 3 0 NN IN NNP CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NNP CC PRP$ NN NN O
target target 0 0 0 0 0 0 0 0 6 0 CC PRP$ NN NN NN O
gene gene 0 0 0 0 0 0 0 0 4 0 PRP$ NN NN NN NNP O
product, product, 0 0 0 0 1 0 0 0 8 0 NN NN NN NNP NNP O
p21. p21. 0 0 0 0 0 0 0 1 4 0 NN NN NNP NNP NNP O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 NN NNP NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNP NNS VBP IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 VBP IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NN O
HDAC HDAC 1 1 0 0 0 0 0 0 4 0 NN IN NNP NN VBZ O
activity activity 0 0 0 0 0 0 0 0 8 0 IN NNP NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ JJ IN O
responsible responsible 0 0 0 0 0 0 0 0 11 0 NN VBZ JJ IN IN O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN IN JJS O
at at 0 0 0 0 0 0 0 0 2 0 JJ IN IN JJS NN O
least least 0 0 0 0 0 0 0 0 5 0 IN IN JJS NN IN O
part part 0 0 0 0 0 0 0 0 4 0 IN JJS NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJS NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 arrest NN IN JJ NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 IN JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase IN DT NN NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NN NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NN CC O
lycorine lycorine 0 0 0 0 0 0 0 0 8 0 NN IN NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VB DT O
provide provide 0 0 0 0 0 0 0 0 7 0 NN CC VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 CC VB DT JJ NN O
mechanistic mechanistic 0 0 0 0 0 0 0 0 11 0 VB DT JJ NN IN O
framework framework 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN JJ NN O
further further 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN DT O
exploring exploring 0 0 0 0 0 0 0 0 9 0 IN JJ NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NN IN O
use use 0 0 0 0 0 0 0 0 3 0 NN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
lycorine lycorine 0 0 0 0 0 0 0 0 8 0 NN IN NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 IN DT NN NN NNP O
antitumor antitumor 0 0 0 0 0 0 0 0 9 0 DT NN NN NNP NONE O
agent. agent. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NONE NONE O
Cell-cycle Cell-cycle 1 0 1 0 0 0 0 0 10 0 NONE NONE JJ NN CC O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NONE JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NN O
micronuclei micronuclei 0 0 0 0 0 0 0 0 11 0 NN CC NN NN NNS O
frequency frequency 0 0 0 0 0 0 0 0 9 0 CC NN NN NNS -NONE- O
reveals reveals 0 0 0 0 0 0 0 0 7 0 NN NN NNS -NONE- NNS O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NN NNS -NONE- NNS IN B_TIMEXCCP
blockers blockers 0 0 0 0 0 0 0 0 8 0 NNS -NONE- NNS IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 -NONE- NNS IN JJ NN O
weak weak 0 0 0 0 0 0 0 0 4 0 NNS IN JJ NN NNP O
micronuclei micronuclei 0 0 0 0 0 0 0 0 11 0 IN JJ NN NNP NNP O
inducers. inducers. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NNP NNP O
Krishnan Krishnan 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Gopinath Gopinath 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
VR, VR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Johnson Johnson 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Nair Nair 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
SA, SA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Pillai Pillai 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
MR. MR. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Research, Research, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Rajiv Rajiv 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Gandhi Gandhi 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Center Center 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNP O
Biotechnology, Biotechnology, 1 0 0 0 1 0 0 0 14 0 NNP IN NNP NNP NNP O
Thiruvananthapuram, Thiruvananthapuram, 1 0 0 0 1 0 0 0 19 0 IN NNP NNP NNP NNP O
India. India. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Micronuclei Micronuclei 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NN O
(MN) (MN) 0 1 0 0 0 0 0 0 4 0 NNP NNP NNP NN VBZ O
formation formation 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ RB VBN O
generally generally 0 0 0 0 0 0 0 0 9 0 NN VBZ RB VBN TO O
attributed attributed 0 0 0 0 0 0 0 0 10 0 VBZ RB VBN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 RB VBN TO NN IN O
error error 0 0 0 0 0 0 0 0 5 0 VBN TO NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 TO NN IN NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN IN NNP NN CC O
synthesis synthesis 0 0 0 0 0 0 0 0 9 0 IN NNP NN CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 NNP NN CC JJ WDT O
mitosis, mitosis, 0 0 0 0 1 0 0 0 8 0 NN CC JJ WDT VBP B_TIMEXCCP 
which which 0 0 0 0 0 0 0 0 5 0 CC JJ WDT VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 JJ WDT VBP VBN IN O
represented represented 0 0 0 0 0 0 0 0 11 0 WDT VBP VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBP VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP CC O
S S 1 1 0 0 0 0 0 0 1 0 IN DT NNP CC NNP B_TIMEXCCP
or or 0 0 0 0 0 0 0 0 2 0 DT NNP CC NNP NN O
G(2)/M G(2)/M 1 1 0 1 0 0 0 1 6 phase NNP CC NNP NN -NONE- B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 CC NNP NN -NONE- IN O
respectively, respectively, 0 0 0 0 1 0 0 0 13 0 NNP NN -NONE- IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN -NONE- IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- IN DT JJ NNP O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 0 IN DT JJ NNP NNP O
histogram. histogram. 0 0 0 0 0 0 0 0 10 0 DT JJ NNP NNP JJ O
Interestingly, Interestingly, 1 0 0 0 1 0 0 0 14 0 JJ NNP NNP JJ IN O
many many 0 0 0 0 0 0 0 0 4 0 NNP NNP JJ IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP JJ IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT VBN NN O
known known 0 0 0 0 0 0 0 0 5 0 IN DT VBN NN NNS O
anticancer anticancer 0 0 0 0 0 0 0 0 10 0 DT VBN NN NNS NN O
drugs drugs 0 0 0 0 0 0 0 0 5 0 VBN NN NNS NN DT O
target target 0 0 0 0 0 0 0 0 6 0 NN NNS NN DT JJ O
these these 0 0 0 0 0 0 0 0 5 0 NNS NN DT JJ NNS O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 phases NN DT JJ NNS TO O
phases phases 0 0 0 0 0 0 0 0 6 0 DT JJ NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO VB NNP O
elicit elicit 0 0 0 0 0 0 0 0 6 0 NNS TO VB NNP NNP O
cytotoxicity. cytotoxicity. 0 0 0 0 0 0 0 0 13 0 TO VB NNP NNP PRP O
Here, Here, 1 0 0 0 1 0 0 0 5 0 VB NNP NNP PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD TO O
attempted attempted 0 0 0 0 0 0 0 0 9 0 NNP PRP VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 PRP VBD TO VB IN O
identify identify 0 0 0 0 0 0 0 0 8 0 VBD TO VB IN DT O
whether whether 0 0 0 0 0 0 0 0 7 0 TO VB IN DT NN O
any any 0 0 0 0 0 0 0 0 3 0 VB IN DT NN NNS O
correlation correlation 0 0 0 0 0 0 0 0 11 0 IN DT NN NNS IN O
exists exists 0 0 0 0 0 0 0 0 6 0 DT NN NNS IN DT O
between between 0 0 0 0 0 0 0 0 7 0 NN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 0 IN DT JJ NN CC O
effect effect 0 0 0 0 0 0 0 0 6 0 DT JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP NN O
MN MN 1 1 0 0 0 0 0 0 2 0 NN CC NNP NN NN O
induction induction 0 0 0 0 0 0 0 0 9 0 CC NNP NN NN VBG O
potential potential 0 0 0 0 0 0 0 0 9 0 NNP NN NN VBG JJ O
using using 0 0 0 0 0 0 0 0 5 0 NN NN VBG JJ NNP O
various various 0 0 0 0 0 0 0 0 7 0 NN VBG JJ NNP NNP O
treatments. treatments. 0 0 0 0 0 0 0 0 11 0 VBG JJ NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NNP PRP O
addition, addition, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD RP O
tracked tracked 0 0 0 0 0 0 0 0 7 0 NNP PRP VBD RP NNP O
down down 0 0 0 0 0 0 0 0 4 0 PRP VBD RP NNP IN O
MN MN 1 1 0 0 0 0 0 0 2 0 VBD RP NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 RP NNP IN NN NNS O
cycling cycling 0 0 0 0 0 0 0 0 7 0 NNP IN NN NNS TO O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NN NNS TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO NN PRP$ O
assess assess 0 0 0 0 0 0 0 0 6 0 NNS TO NN PRP$ JJ O
its its 0 0 0 0 0 0 0 0 3 0 TO NN PRP$ JJ NNP O
final final 0 0 0 0 0 0 0 0 5 0 NN PRP$ JJ NNP NNP O
fate. fate. 0 0 0 0 0 0 0 0 5 0 PRP$ JJ NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP VBD NNP O
treated treated 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD NNP NNS O
SiHa SiHa 1 0 0 0 0 0 0 0 4 0 NNP VBD NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 VBD NNP NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNS IN JJ NN O
various various 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NN NNS O
known known 0 0 0 0 0 0 0 0 5 0 IN JJ NN NNS CC O
drugs drugs 0 0 0 0 0 0 0 0 5 0 JJ NN NNS CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC VBD PRP$ O
correlated correlated 0 0 0 0 0 0 0 0 10 0 NNS CC VBD PRP$ NNS O
their their 0 0 0 0 0 0 0 0 5 0 CC VBD PRP$ NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 VBD PRP$ NNS IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 PRP$ NNS IN JJ CC O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 0 NNS IN JJ CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC NNP NNP O
MN MN 1 1 0 0 0 0 0 0 2 0 JJ CC NNP NNP NNP O
frequency. frequency. 0 0 0 0 0 0 0 0 10 0 CC NNP NNP NNP NNS O
MN-tracking MN-tracking 1 0 1 0 0 0 0 0 11 0 NNP NNP NNP NNS VBD O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD VBN IN O
performed performed 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NN O
peripheral peripheral 0 0 0 0 0 0 0 0 10 0 VBN IN JJ NN CC O
mononuclear mononuclear 0 0 0 0 0 0 0 0 11 0 IN JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP NNS O
siHa siHa 0 0 0 0 0 0 0 0 4 0 NN CC NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 CC NNP NNS IN VBG O
upon upon 0 0 0 0 0 0 0 0 4 0 NNP NNS IN VBG IN O
staining staining 0 0 0 0 0 0 0 0 8 0 NNS IN VBG IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 IN VBG IN NNP CC O
Giemsa Giemsa 1 0 0 0 0 0 0 0 6 0 VBG IN NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NN NN O
ethidium ethidium 0 0 0 0 0 0 0 0 8 0 NNP CC NN NN NNP O
bromide bromide 0 0 0 0 0 0 0 0 7 0 CC NN NN NNP NNP O
respectively. respectively. 0 0 0 0 0 0 0 0 13 0 NN NN NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBD NNP O
observed observed 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD NNP NN O
MN MN 1 1 0 0 0 0 0 0 2 0 NNP VBD NNP NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 VBD NNP NN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT DT O
all all 0 0 0 0 0 0 0 0 3 0 NN IN DT DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 IN DT DT VBN NNS O
tested tested 0 0 0 0 0 0 0 0 6 0 DT DT VBN NNS VBP O
drugs drugs 0 0 0 0 0 0 0 0 5 0 DT VBN NNS VBP IN O
irrespective irrespective 0 0 0 0 0 0 0 0 12 0 VBN NNS VBP IN PRP$ O
of of 0 0 0 0 0 0 0 0 2 0 NNS VBP IN PRP$ JJ O
their their 0 0 0 0 0 0 0 0 5 0 VBP IN PRP$ JJ NN O
basic basic 0 0 0 0 0 0 0 0 5 0 IN PRP$ JJ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 PRP$ JJ NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NNP NNP O
cycle. cycle. 0 0 0 0 0 0 0 0 6 0 IN NN NNP NNP NNP O
However, However, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP NNP NN O
MN MN 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NN VBD O
induction induction 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBD JJR O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD JJR IN O
more more 0 0 0 0 0 0 0 0 4 0 NN VBD JJR IN NNS O
with with 0 0 0 0 0 0 0 0 4 0 VBD JJR IN NNS WDT O
drugs drugs 0 0 0 0 0 0 0 0 5 0 JJR IN NNS WDT RB O
which which 0 0 0 0 0 0 0 0 5 0 IN NNS WDT RB IN O
interfere interfere 0 0 0 0 0 0 0 0 9 0 NNS WDT RB IN DT O
with with 0 0 0 0 0 0 0 0 4 0 WDT RB IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NNP CC O
S S 1 1 0 0 0 0 0 0 1 0 IN DT NNP CC NNP B_TIMEXCCP
or or 0 0 0 0 0 0 0 0 2 0 DT NNP CC NNP IN O
G(2)/M G(2)/M 1 1 0 1 0 0 0 1 6 0 NNP CC NNP IN DT B_TIMEXCCP
than than 0 0 0 0 0 0 0 0 4 0 CC NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN NNP O
G(0)/G(1) G(0)/G(1) 1 1 0 1 0 0 0 1 9 0 IN DT NN NNP NNP B_TIMEXCCP
phase. phase. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP JJ O
indicate indicate 0 0 0 0 0 0 0 0 8 0 NNP NNS VBP JJ NNS O
G(0)/G(1) G(0)/G(1) 1 1 0 1 0 0 0 1 9 0 NNS VBP JJ NNS TO B_TIMEXCCP
blockers blockers 0 0 0 0 0 0 0 0 8 0 VBP JJ NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO VB RB O
be be 0 0 0 0 0 0 0 0 2 0 NNS TO VB RB JJR O
comparatively comparatively 0 0 0 0 0 0 0 0 13 0 TO VB RB JJR NNP O
safer safer 0 0 0 0 0 0 0 0 5 0 VB RB JJR NNP NNP O
drugs. drugs. 0 0 0 0 0 0 0 0 6 0 RB JJR NNP NNP PRP$ O
Additionally, Additionally, 1 0 0 0 1 0 0 0 13 0 JJR NNP NNP PRP$ NNS O
our our 0 0 0 0 0 0 0 0 3 0 NNP NNP PRP$ NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP PRP$ NNS VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 PRP$ NNS VBP IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NN IN O
expulsion expulsion 0 0 0 0 0 0 0 0 9 0 VBP IN NN IN IN O
out out 0 0 0 0 0 0 0 0 3 0 IN NN IN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NN IN IN NNS MD O
cells cells 0 0 0 0 0 0 0 0 5 0 IN IN NNS MD VB O
may may 0 0 0 0 0 0 0 0 3 0 IN NNS MD VB CD O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB CD IN O
one one 0 0 0 0 0 0 0 0 3 0 MD VB CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VB CD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT JJ NNS O
main main 0 0 0 0 0 0 0 0 4 0 IN DT JJ NNS IN O
fates fates 0 0 0 0 0 0 0 0 5 0 DT JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NNP O
drug-induced drug-induced 0 0 1 0 0 0 0 0 12 0 NNS IN JJ NNP NONE O
MN. MN. 1 1 0 0 0 0 0 0 3 0 IN JJ NNP NONE NONE O
Local Local 1 0 0 0 0 0 0 0 5 0 NONE NONE JJ NN IN O
injection injection 0 0 0 0 0 0 0 0 9 0 NONE JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNP O
lentivirus-delivered lentivirus-delivered 0 0 1 0 0 0 0 0 20 0 NN IN JJ NNP NNS O
livinshRNA livinshRNA 0 0 0 0 0 0 0 0 10 0 IN JJ NNP NNS VBP O
suppresses suppresses 0 0 0 0 0 0 0 0 10 0 JJ NNP NNS VBP NN O
lung lung 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP NN NN O
adenocarcinoma adenocarcinoma 0 0 0 0 0 0 0 0 14 0 NNS VBP NN NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 VBP NN NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NN DT O
inducing inducing 0 0 0 0 0 0 0 0 8 0 NN IN NN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 IN NN DT NN NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase NN DT NN NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN NNP O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NN NN NN NNP NNP O
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NNP NNP O
YS, YS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
HR, HR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Miao Miao 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
WY, WY, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
YT, YT, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
GQ, GQ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wu Wu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
ZC. ZC. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Respiratory Respiratory 1 0 0 0 0 0 0 0 11 0 NNP IN NNP NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Fujian Fujian 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Provincial Provincial 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Hospital, Hospital, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Fujian Fujian 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Fuzhou, Fuzhou, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Fujian, Fujian, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
P.R.China. P.R.China. 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
slyyywb@yahoo.com.cn slyyywb@yahoo.com.cn 0 0 0 0 0 0 0 0 20 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN IN NN NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 IN NN NN NN NNS O
(IAP) (IAP) 0 1 0 0 0 0 0 0 5 0 NN NN NN NNS DT O
plays plays 0 0 0 0 0 0 0 0 5 0 NN NN NNS DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN NNS DT JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 NNS DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN CC O
tumorigenesis tumorigenesis 0 0 0 0 0 0 0 0 13 0 NN IN NN CC MD O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN CC MD VB DT O
be be 0 0 0 0 0 0 0 0 2 0 CC MD VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT JJ NN O
potential potential 0 0 0 0 0 0 0 0 9 0 VB DT JJ NN IN O
target target 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP NNP O
therapy. therapy. 0 0 0 0 0 0 0 0 8 0 IN NN NNP NNP WDT O
Livin, Livin, 1 0 0 0 1 0 0 0 6 0 NN NNP NNP WDT NNS O
which which 0 0 0 0 0 0 0 0 5 0 NNP NNP WDT NNS TO O
belongs belongs 0 0 0 0 0 0 0 0 7 0 NNP WDT NNS TO DT O
to to 0 0 0 0 0 0 0 0 2 0 WDT NNS TO DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNS TO DT NN VBZ O
family, family, 0 0 0 0 1 0 0 0 7 0 TO DT NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ RB VBN O
highly highly 0 0 0 0 0 0 0 0 6 0 NN VBZ RB VBN IN O
expressed expressed 0 0 0 0 0 0 0 0 9 0 VBZ RB VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN JJ NNP O
various various 0 0 0 0 0 0 0 0 7 0 VBN IN JJ NNP NNP O
tumors. tumors. 0 0 0 0 0 0 0 0 7 0 IN JJ NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP JJ NN O
previous previous 0 0 0 0 0 0 0 0 8 0 NNP NNP JJ NN VBN O
study study 0 0 0 0 0 0 0 0 5 0 NNP JJ NN VBN IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 JJ NN VBN IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NN VBN IN NN NNP O
silencing silencing 0 0 0 0 0 0 0 0 9 0 VBN IN NN NNP NN O
Livin Livin 1 0 0 0 0 0 0 0 5 0 IN NN NNP NN VBD O
gene gene 0 0 0 0 0 0 0 0 4 0 NN NNP NN VBD JJ O
promoted promoted 0 0 0 0 0 0 0 0 8 0 NNP NN VBD JJ NN O
lung lung 0 0 0 0 0 0 0 0 4 0 NN VBD JJ NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 VBD JJ NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NN O
apoptosis; apoptosis; 0 0 0 0 0 0 0 0 10 0 NN NN NN NN DT O
however, however, 0 0 0 0 1 0 0 0 8 0 NN NN NN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 NN DT NNS IN NN O
on on 0 0 0 0 0 0 0 0 2 0 DT NNS IN NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NNS IN NN NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 IN NN NN NN IN O
suppression suppression 0 0 0 0 0 0 0 0 11 0 NN NN NN IN VBG O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN VBG DT O
targeting targeting 0 0 0 0 0 0 0 0 9 0 NN IN VBG DT NN O
this this 0 0 0 0 0 0 0 0 4 0 IN VBG DT NN IN O
gene gene 0 0 0 0 0 0 0 0 4 0 VBG DT NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP TO O
vivo, vivo, 0 0 0 0 1 0 0 0 5 0 NN IN NNP TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NNP TO VB NN O
thereby thereby 0 0 0 0 0 0 0 0 7 0 NNP TO VB NN DT O
determine determine 0 0 0 0 0 0 0 0 9 0 TO VB NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VB NN DT NN IN O
efficacy efficacy 0 0 0 0 0 0 0 0 8 0 NN DT NN IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN VBG NNP O
targeting targeting 0 0 0 0 0 0 0 0 9 0 NN IN VBG NNP IN O
Livin Livin 1 0 0 0 0 0 0 0 5 0 IN VBG NNP IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBG NNP IN NN NN O
patient patient 0 0 0 0 0 0 0 0 7 0 NNP IN NN NN VBP O
therapy, therapy, 0 0 0 0 1 0 0 0 8 0 IN NN NN VBP RB O
have have 0 0 0 0 0 0 0 0 4 0 NN NN VBP RB VBN O
not not 0 0 0 0 0 0 0 0 3 0 NN VBP RB VBN NNP O
been been 0 0 0 0 0 0 0 0 4 0 VBP RB VBN NNP NNP O
determined. determined. 0 0 0 0 0 0 0 0 11 0 RB VBN NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 VBN NNP NNP NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD JJ O
injected injected 0 0 0 0 0 0 0 0 8 0 NNP NN VBD JJ NNP O
lentivirus-delivered lentivirus-delivered 0 0 1 0 0 0 0 0 20 0 NN VBD JJ NNP IN O
livinshRNA livinshRNA 0 0 0 0 0 0 0 0 10 0 VBD JJ NNP IN JJ O
into into 0 0 0 0 0 0 0 0 4 0 JJ NNP IN JJ NN O
established established 0 0 0 0 0 0 0 0 11 0 NNP IN JJ NN NNS O
xenograft xenograft 0 0 0 0 0 0 0 0 9 0 IN JJ NN NNS VBD O
tumors tumors 0 0 0 0 0 0 0 0 6 0 JJ NN NNS VBD IN O
derived derived 0 0 0 0 0 0 0 0 7 0 NN NNS VBD IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN NN O
lung lung 0 0 0 0 0 0 0 0 4 0 IN DT NN NN NN O
adenocarcinoma adenocarcinoma 0 0 0 0 0 0 0 0 14 0 DT NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN -NONE- O
line line 0 0 0 0 0 0 0 0 4 0 NN NN NN -NONE- IN O
SPC-A-1 SPC-A-1 1 1 1 0 0 0 0 1 7 0 NN NN -NONE- IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN -NONE- IN JJ NN O
BALB/C BALB/C 1 1 0 1 0 0 0 0 6 0 -NONE- IN JJ NN NN O
nude nude 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN DT O
mice, mice, 0 0 0 0 1 0 0 0 5 0 JJ NN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NN VBD O
result result 0 0 0 0 0 0 0 0 6 0 NN DT NN VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 DT NN VBD IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN NNP JJ O
LivinshRNA LivinshRNA 1 0 0 0 0 0 0 0 10 0 VBD IN NNP JJ NNP O
down-regulated down-regulated 0 0 1 0 0 0 0 0 14 0 IN NNP JJ NNP NN O
Livin Livin 1 0 0 0 0 0 0 0 5 0 NNP JJ NNP NN -NONE- O
expression expression 0 0 0 0 0 0 0 0 10 0 JJ NNP NN -NONE- VBN O
effectively, effectively, 0 0 0 0 1 0 0 0 12 0 NNP NN -NONE- VBN NN O
induced induced 0 0 0 0 0 0 0 0 7 0 NN -NONE- VBN NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 -NONE- VBN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBN NN NN NN VBD O
apoptosis, apoptosis, 0 0 0 0 1 0 0 0 10 0 NN NN NN VBD NN O
reduced reduced 0 0 0 0 0 0 0 0 7 0 NN NN VBD NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NN VBD NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBD NN NN NN CC O
proliferation, proliferation, 0 0 0 0 1 0 0 0 14 0 NN NN NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBD NN O
suppressed suppressed 0 0 0 0 0 0 0 0 10 0 NN CC VBD NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 CC VBD NN NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 VBD NN NN NN IN O
dramatically, dramatically, 0 0 0 0 1 0 0 0 13 0 NN NN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 IN DT NN NN NN O
volume volume 0 0 0 0 0 0 0 0 6 0 DT NN NN NN NN O
inhibitory inhibitory 0 0 0 0 0 0 0 0 10 0 NN NN NN NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 NN NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN CC O
(58.65±4.82)% (58.65±4.82)% 0 0 0 0 0 0 0 1 13 0 NN IN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN CC DT NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 CC DT NN NN NN O
weight weight 0 0 0 0 0 0 0 0 6 0 DT NN NN NN NN O
inhibitory inhibitory 0 0 0 0 0 0 0 0 10 0 NN NN NN NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 NN NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP CC O
(47.44±1.64)%, (47.44±1.64)%, 0 0 0 0 1 0 0 1 14 0 NN IN NNP CC IN O
but but 0 0 0 0 0 0 0 0 3 0 IN NNP CC IN JJR O
with with 0 0 0 0 0 0 0 0 4 0 NNP CC IN JJR JJ O
less less 0 0 0 0 0 0 0 0 4 0 CC IN JJR JJ NN O
severe severe 0 0 0 0 0 0 0 0 6 0 IN JJR JJ NN NN O
adverse adverse 0 0 0 0 0 0 0 0 7 0 JJR JJ NN NN TO O
reaction reaction 0 0 0 0 0 0 0 0 8 0 JJ NN NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT NNP NNP O
mouse. mouse. 0 0 0 0 0 0 0 0 6 0 TO DT NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 DT NNP NNP NN RB O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN RB VBN O
further further 0 0 0 0 0 0 0 0 7 0 NNP NN RB VBN IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 NN RB VBN IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 RB VBN IN NNP NN O
Livin Livin 1 0 0 0 0 0 0 0 5 0 VBN IN NNP NN VBG O
gene gene 0 0 0 0 0 0 0 0 4 0 IN NNP NN VBG VBN O
silencing silencing 0 0 0 0 0 0 0 0 9 0 NNP NN VBG VBN DT O
induced induced 0 0 0 0 0 0 0 0 7 0 NN VBG VBN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBG VBN DT JJ NN O
G0/G1-phase G0/G1-phase 1 0 1 1 0 0 0 1 11 0 VBN DT JJ NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest JJ NN NN NN CC O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN CC NN NNP NNP O
D1 D1 1 1 0 0 0 0 0 1 2 0 CC NN NNP NNP WDT O
downregulation, downregulation, 0 0 0 0 1 0 0 0 15 0 NN NNP NNP WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NNP NNP WDT VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP WDT VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 WDT VBZ DT JJ NN O
key key 0 0 0 0 0 0 0 0 3 0 VBZ DT JJ NN IN O
regulator regulator 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ TO O
G0/G1- G0/G1- 1 1 1 1 0 0 0 1 6 0 IN DT JJ TO JJ 0
to to 0 0 0 0 0 0 0 0 2 0 DT JJ TO JJ NNP 0
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 JJ TO JJ NNP NNP 0
transition. transition. 0 0 0 0 0 0 0 0 11 0 TO JJ NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP NNS VBP O
findings findings 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNP NNS VBP IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NNP JJ O
LivinshRNA LivinshRNA 1 0 0 0 0 0 0 0 10 0 VBP IN NNP JJ NN O
local local 0 0 0 0 0 0 0 0 5 0 IN NNP JJ NN MD O
injection injection 0 0 0 0 0 0 0 0 9 0 NNP JJ NN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 JJ NN MD VB IN O
serve serve 0 0 0 0 0 0 0 0 5 0 NN MD VB IN DT O
as as 0 0 0 0 0 0 0 0 2 0 MD VB IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VB IN DT JJ NN O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 IN DT JJ NN IN O
method method 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN NN O
patient patient 0 0 0 0 0 0 0 0 7 0 NN IN NN NN CC O
treatment, treatment, 0 0 0 0 1 0 0 0 10 0 IN NN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NN CC IN NNP MD O
LivinshRNA LivinshRNA 1 0 0 0 0 0 0 0 10 0 CC IN NNP MD VB O
may may 0 0 0 0 0 0 0 0 3 0 IN NNP MD VB NN O
suppress suppress 0 0 0 0 0 0 0 0 8 0 NNP MD VB NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 MD VB NN NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 VB NN NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NN DT O
arresting arresting 0 0 0 0 0 0 0 0 9 0 NN IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN DT NN NN IN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NONE O
G0/G1-phase. G0/G1-phase. 1 0 1 1 0 0 0 1 12 0 IN DT NNP NONE NONE B_TIMEXCCP
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NN NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NONE DT NN NN NN O
switch switch 0 0 0 0 0 0 0 0 6 0 DT NN NN NN CD O
gene gene 0 0 0 0 0 0 0 0 4 0 NN NN NN CD NN O
2 2 0 0 0 0 0 0 1 1 1 0 NN NN CD NN VBG O
(G0S2): (G0S2): 0 1 0 0 0 0 0 1 7 0 NN CD NN VBG NN O
regulating regulating 0 0 0 0 0 0 0 0 10 0 CD NN VBG NN CC O
metabolism metabolism 0 0 0 0 0 0 0 0 10 0 NN VBG NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VBG NN CC NNP NNP O
beyond. beyond. 0 0 0 0 0 0 0 0 7 0 NN CC NNP NNP NNP O
Heckmann Heckmann 1 0 0 0 0 0 0 0 8 0 CC NNP NNP NNP NNP O
BL, BL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Xie Xie 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Liu Liu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
J. J. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Biochemistry Biochemistry 1 0 0 0 0 0 0 0 12 0 NNP IN NNP CC NNP O
& & 0 0 0 0 0 0 0 0 1 0 IN NNP CC NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP CC NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 CC NNP NNP NNP NNP O
Mayo Mayo 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Clinic, Clinic, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Scottsdale, Scottsdale, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP CD O
Arizona Arizona 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP CD NNP O
85259, 85259, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NNP NNP NNP NN NN O
switch switch 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NN CD O
gene gene 0 0 0 0 0 0 0 0 4 0 NNP NN NN CD NN O
2 2 0 0 0 0 0 0 1 1 1 0 NN NN CD NN VBD O
(G0S2) (G0S2) 0 1 0 0 0 0 0 1 6 0 NN CD NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 CD NN VBD RB VBD O
originally originally 0 0 0 0 0 0 0 0 10 0 NN VBD RB VBD IN O
identified identified 0 0 0 0 0 0 0 0 10 0 VBD RB VBD IN NN O
in in 0 0 0 0 0 0 0 0 2 0 RB VBD IN NN NN O
blood blood 0 0 0 0 0 0 0 0 5 0 VBD IN NN NN NNS O
mononuclear mononuclear 0 0 0 0 0 0 0 0 11 0 IN NN NN NNS VBG O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS VBG VBN O
following following 0 0 0 0 0 0 0 0 9 0 NN NNS VBG VBN NN O
induced induced 0 0 0 0 0 0 0 0 7 0 NNS VBG VBN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBG VBN NN NN NNP O
cycle cycle 0 0 0 0 0 0 0 0 5 0 VBN NN NN NNP NNP O
progression. progression. 0 0 0 0 0 0 0 0 12 0 NN NN NNP NNP IN O
Translation Translation 1 0 0 0 0 0 0 0 11 0 NN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNS O
G0S2 G0S2 1 1 0 0 0 0 0 1 4 0 NNP IN NNP NNS IN O
results results 0 0 0 0 0 0 0 0 7 0 IN NNP NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ JJ O
small small 0 0 0 0 0 0 0 0 5 0 IN DT JJ JJ NN O
basic basic 0 0 0 0 0 0 0 0 5 0 DT JJ JJ NN IN O
protein protein 0 0 0 0 0 0 0 0 7 0 JJ JJ NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN CD NN O
103 103 0 0 0 0 0 0 1 1 3 0 NN IN CD NN NNS O
amino amino 0 0 0 0 0 0 0 0 5 0 IN CD NN NNS IN O
acids acids 0 0 0 0 0 0 0 0 5 0 CD NN NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP NNP O
size. size. 0 0 0 0 0 0 0 0 5 0 NNS IN NNP NNP VBD O
It It 1 0 0 0 0 0 0 0 2 0 IN NNP NNP VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD RB VBN O
initially initially 0 0 0 0 0 0 0 0 9 0 NNP VBD RB VBN IN O
believed believed 0 0 0 0 0 0 0 0 8 0 VBD RB VBN IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 RB VBN IN NNP VBZ O
G0S2 G0S2 1 1 0 0 0 0 0 1 4 0 VBN IN NNP VBZ JJ O
mediates mediates 0 0 0 0 0 0 0 0 8 0 IN NNP VBZ JJ IN O
re-entry re-entry 0 0 1 0 0 0 0 0 8 0 NNP VBZ JJ IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 VBZ JJ IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ IN NNS IN DT O
from from 0 0 0 0 0 0 0 0 4 0 IN NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP TO O
G0 G0 1 1 0 0 0 0 0 1 2 0 IN DT NNP TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 DT NNP TO NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 phase NNP TO NNP NN IN O
phase phase 0 0 0 0 0 0 0 0 5 0 TO NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NNP NNP O
cycle. cycle. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP NNS O
Recent Recent 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NNS VBP O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP VBN TO O
begun begun 0 0 0 0 0 0 0 0 5 0 NNS VBP VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBP VBN TO VB DT O
reveal reveal 0 0 0 0 0 0 0 0 6 0 VBN TO VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJ NNS O
functional functional 0 0 0 0 0 0 0 0 10 0 VB DT JJ NNS IN O
aspects aspects 0 0 0 0 0 0 0 0 7 0 DT JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP CC O
G0S2 G0S2 1 1 0 0 0 0 0 1 4 0 NNS IN NNP CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NNP CC PRP$ NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 CC PRP$ NN NN IN O
product product 0 0 0 0 0 0 0 0 7 0 PRP$ NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
various various 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN NNP O
cellular cellular 0 0 0 0 0 0 0 0 8 0 IN JJ NN NNP TO O
settings. settings. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP TO NN O
To To 1 0 0 0 0 0 0 0 2 0 NN NNP TO NN DT O
date date 0 0 0 0 0 0 0 0 4 0 NNP TO NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO NN DT JJ NN O
best-known best-known 0 0 1 0 0 0 0 0 10 0 NN DT JJ NN IN O
function function 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP VBZ O
G0S2 G0S2 1 1 0 0 0 0 0 1 4 0 NN IN NNP VBZ PRP$ O
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ PRP$ JJ O
its its 0 0 0 0 0 0 0 0 3 0 NNP VBZ PRP$ JJ NN O
direct direct 0 0 0 0 0 0 0 0 6 0 VBZ PRP$ JJ NN NN O
inhibitory inhibitory 0 0 0 0 0 0 0 0 10 0 PRP$ JJ NN NN IN O
capacity capacity 0 0 0 0 0 0 0 0 8 0 JJ NN NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ JJ O
rate-limiting rate-limiting 0 0 1 0 0 0 0 0 13 0 IN DT JJ JJ NN O
lipolytic lipolytic 0 0 0 0 0 0 0 0 9 0 DT JJ JJ NN NN O
enzyme enzyme 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NN NN O
adipose adipose 0 0 0 0 0 0 0 0 7 0 JJ NN NN NN NN O
triglyceride triglyceride 0 0 0 0 0 0 0 0 12 0 NN NN NN NN NNP O
lipase lipase 0 0 0 0 0 0 0 0 6 0 NN NN NN NNP NNP O
(ATGL). (ATGL). 0 1 0 0 0 0 0 0 7 0 NN NN NNP NNP NNS O
Other Other 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNS VBP O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP VBN JJ O
illustrated illustrated 0 0 0 0 0 0 0 0 11 0 NNS VBP VBN JJ NNS O
key key 0 0 0 0 0 0 0 0 3 0 VBP VBN JJ NNS IN O
features features 0 0 0 0 0 0 0 0 8 0 VBN JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP VBG O
G0S2 G0S2 1 1 0 0 0 0 0 1 4 0 NNS IN NNP VBG JJ O
including including 0 0 0 0 0 0 0 0 9 0 IN NNP VBG JJ NN O
sub-cellular sub-cellular 0 0 1 0 0 0 0 0 12 0 NNP VBG JJ NN NN O
localization, localization, 0 0 0 0 1 0 0 0 13 0 VBG JJ NN NN NNS O
expression expression 0 0 0 0 0 0 0 0 10 0 JJ NN NN NNS CC O
profiles profiles 0 0 0 0 0 0 0 0 8 0 NN NN NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC JJ CC O
regulation, regulation, 0 0 0 0 1 0 0 0 11 0 NNS CC JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 CC JJ CC JJ NNS O
possible possible 0 0 0 0 0 0 0 0 8 0 JJ CC JJ NNS IN O
functions functions 0 0 0 0 0 0 0 0 9 0 CC JJ NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
cellular cellular 0 0 0 0 0 0 0 0 8 0 NNS IN JJ NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 IN JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP NNP O
differentiation. differentiation. 0 0 0 0 0 0 0 0 16 0 NN CC NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 CC NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
review review 0 0 0 0 0 0 0 0 6 0 NNP DT NN PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBP DT O
present present 0 0 0 0 0 0 0 0 7 0 NN PRP VBP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBP DT JJ NN O
current current 0 0 0 0 0 0 0 0 7 0 VBP DT JJ NN NN O
knowledge knowledge 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN VBG O
base base 0 0 0 0 0 0 0 0 4 0 JJ NN NN VBG DT O
regarding regarding 0 0 0 0 0 0 0 0 9 0 NN NN VBG DT NNS O
all all 0 0 0 0 0 0 0 0 3 0 NN VBG DT NNS IN O
facets facets 0 0 0 0 0 0 0 0 6 0 VBG DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ CC O
G0S2, G0S2, 1 1 0 0 1 0 0 1 5 0 NNS IN JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC NN DT O
pose pose 0 0 0 0 0 0 0 0 4 0 JJ CC NN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 CC NN DT NN IN O
variety variety 0 0 0 0 0 0 0 0 7 0 NN DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS CC O
questions questions 0 0 0 0 0 0 0 0 9 0 NN IN NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC NNS VBG O
hypotheses hypotheses 0 0 0 0 0 0 0 0 10 0 NNS CC NNS VBG TO O
pertaining pertaining 0 0 0 0 0 0 0 0 10 0 CC NNS VBG TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBG TO JJ NN O
future future 0 0 0 0 0 0 0 0 6 0 VBG TO JJ NN NNP O
research research 0 0 0 0 0 0 0 0 8 0 TO JJ NN NNP NONE O
directions. directions. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NN IN O
effectiveness effectiveness 0 0 0 0 0 0 0 0 13 0 NONE DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ JJ O
patient-controlled patient-controlled 0 0 1 0 0 0 0 0 18 0 NN IN JJ JJ NN O
epidural epidural 0 0 0 0 0 0 0 0 8 0 IN JJ JJ NN IN O
analgesia analgesia 0 0 0 0 0 0 0 0 9 0 JJ JJ NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN NN CD O
ropivacaine ropivacaine 0 0 0 0 0 0 0 0 11 0 NN IN NN CD IN O
0.165% 0.165% 0 0 0 0 0 0 0 1 6 0 IN NN CD IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NN CD IN NN CD O
fentanyl fentanyl 0 0 0 0 0 0 0 0 8 0 CD IN NN CD NN O
2.0 2.0 0 0 0 0 0 0 0 1 3 0 IN NN CD NN JJ O
miroc miroc 0 0 0 0 0 0 0 0 5 0 NN CD NN JJ CC O
g/ml g/ml 0 0 0 1 0 0 0 0 4 0 CD NN JJ CC NN O
or or 0 0 0 0 0 0 0 0 2 0 NN JJ CC NN CD O
levobupivacaine levobupivacaine 0 0 0 0 0 0 0 0 15 0 JJ CC NN CD IN O
0.125% 0.125% 0 0 0 0 0 0 0 1 6 0 CC NN CD IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NN CD IN NN CD O
fentanyl fentanyl 0 0 0 0 0 0 0 0 8 0 CD IN NN CD NN O
2.0 2.0 0 0 0 0 0 0 0 1 3 0 IN NN CD NN JJ O
micro micro 0 0 0 0 0 0 0 0 5 0 NN CD NN JJ IN O
g/ml g/ml 0 0 0 1 0 0 0 0 4 0 CD NN JJ IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NN JJ IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 JJ IN DT NN IN O
method method 0 0 0 0 0 0 0 0 6 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
postoperative postoperative 0 0 0 0 0 0 0 0 13 0 NN IN JJ NN IN O
analgesia analgesia 0 0 0 0 0 0 0 0 9 0 IN JJ NN IN JJ O
after after 0 0 0 0 0 0 0 0 5 0 JJ NN IN JJ NN O
major major 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NNP O
orthopaedic orthopaedic 0 0 0 0 0 0 0 0 11 0 IN JJ NN NNP NNP O
surgery. surgery. 0 0 0 0 0 0 0 0 8 0 JJ NN NNP NNP NNP O
Misiran Misiran 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NNP NNP O
KB, KB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Yahaya Yahaya 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
LS. LS. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Anaesthesia Anaesthesia 1 0 0 0 0 0 0 0 11 0 NNP IN NNP CC NNP O
& & 0 0 0 0 0 0 0 0 1 0 IN NNP CC NNP NNP O
Intensive Intensive 1 0 0 0 0 0 0 0 9 0 NNP CC NNP NNP NNP O
Care, Care, 1 0 0 0 1 0 0 0 5 0 CC NNP NNP NNP IN O
Faculty Faculty 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Universiti Universiti 1 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP NNP O
Teknologi Teknologi 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
MARA, MARA, 1 1 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
Sg Sg 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Buloh Buloh 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Campus, Campus, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Sg Sg 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Buloh, Buloh, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
Selangor. Selangor. 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Malaysia. Malaysia. 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
kariscarris@gmail.com kariscarris@gmail.com 0 0 0 0 0 0 0 0 21 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP JJ O
This This 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP JJ VBD O
prospective prospective 0 0 0 0 0 0 0 0 11 0 NNP NNP JJ VBD JJ O
randomized randomized 0 0 0 0 0 0 0 0 10 0 NNP JJ VBD JJ NN O
single-blinded single-blinded 0 0 1 0 0 0 0 0 14 0 JJ VBD JJ NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 VBD JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN TO O
conducted conducted 0 0 0 0 0 0 0 0 9 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB IN O
determine determine 0 0 0 0 0 0 0 0 9 0 VBN TO VB IN EX O
whether whether 0 0 0 0 0 0 0 0 7 0 TO VB IN EX VBD O
there there 0 0 0 0 0 0 0 0 5 0 VB IN EX VBD NNS O
were were 0 0 0 0 0 0 0 0 4 0 IN EX VBD NNS IN O
differences differences 0 0 0 0 0 0 0 0 11 0 EX VBD NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBD NNS IN NNP NN O
consumption, consumption, 0 0 0 0 1 0 0 0 12 0 NNS IN NNP NN VBG O
demand demand 0 0 0 0 0 0 0 0 6 0 IN NNP NN VBG CC O
dosing dosing 0 0 0 0 0 0 0 0 6 0 NNP NN VBG CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN VBG CC JJ NN O
postoperative postoperative 0 0 0 0 0 0 0 0 13 0 VBG CC JJ NN NN O
analgesia analgesia 0 0 0 0 0 0 0 0 9 0 CC JJ NN NN IN O
quality quality 0 0 0 0 0 0 0 0 7 0 JJ NN NN IN NNP O
between between 0 0 0 0 0 0 0 0 7 0 NN NN IN NNP VBG O
PCEA PCEA 1 1 0 0 0 0 0 0 4 0 NN IN NNP VBG NN O
using using 0 0 0 0 0 0 0 0 5 0 IN NNP VBG NN CC O
ropivacaine ropivacaine 0 0 0 0 0 0 0 0 11 0 NNP VBG NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VBG NN CC NNP NNP O
levobupivacaine. levobupivacaine. 0 0 0 0 0 0 0 0 16 0 NN CC NNP NNP NNS O
Seventy Seventy 1 0 0 0 0 0 0 0 7 0 CC NNP NNP NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNS IN NNP NN O
ASA ASA 1 1 0 0 0 0 0 0 3 0 NNS IN NNP NN PRP O
classification classification 0 0 0 0 0 0 0 0 14 0 IN NNP NN PRP CC O
I I 1 1 0 0 0 0 0 0 1 0 NNP NN PRP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN PRP CC NNP VBD O
II II 1 1 0 0 0 0 0 0 2 0 PRP CC NNP VBD CD O
aged aged 0 0 0 0 0 0 0 0 4 0 CC NNP VBD CD TO O
18 18 0 0 0 0 0 0 1 1 2 0 NNP VBD CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 VBD CD TO CD NNS O
80 80 0 0 0 0 0 0 1 1 2 0 CD TO CD NNS JJ O
years years 0 0 0 0 0 0 0 0 5 0 TO CD NNS JJ VBN O
old old 0 0 0 0 0 0 0 0 3 0 CD NNS JJ VBN IN O
scheduled scheduled 0 0 0 0 0 0 0 0 9 0 NNS JJ VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ VBN IN JJ JJ O
elective elective 0 0 0 0 0 0 0 0 8 0 VBN IN JJ JJ NN O
total total 0 0 0 0 0 0 0 0 5 0 IN JJ JJ NN NN O
knee knee 0 0 0 0 0 0 0 0 4 0 JJ JJ NN NN CC O
replacement replacement 0 0 0 0 0 0 0 0 11 0 JJ NN NN CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 NN NN CC JJ NN O
total total 0 0 0 0 0 0 0 0 5 0 NN CC JJ NN NN O
hip hip 0 0 0 0 0 0 0 0 3 0 CC JJ NN NN VBD O
replacement replacement 0 0 0 0 0 0 0 0 11 0 JJ NN NN VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD NNP NNP O
studied. studied. 0 0 0 0 0 0 0 0 8 0 NN VBD NNP NNP NNS O
All All 1 0 0 0 0 0 0 0 3 0 VBD NNP NNP NNS VBD O
patients patients 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBD NNP O
received received 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD NNP CC O
CSE CSE 1 1 0 0 0 0 0 0 3 0 NNS VBD NNP CC RB O
and and 0 0 0 0 0 0 0 0 3 0 VBD NNP CC RB VBD O
then then 0 0 0 0 0 0 0 0 4 0 NNP CC RB VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 CC RB VBD RB VBN O
randomly randomly 0 0 0 0 0 0 0 0 8 0 RB VBD RB VBN TO O
allocated allocated 0 0 0 0 0 0 0 0 9 0 VBD RB VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 RB VBN TO VB DT O
receive receive 0 0 0 0 0 0 0 0 7 0 VBN TO VB DT NN O
either either 0 0 0 0 0 0 0 0 6 0 TO VB DT NN CD O
ropivacaine ropivacaine 0 0 0 0 0 0 0 0 11 0 VB DT NN CD NN O
0.165% 0.165% 0 0 0 0 0 0 0 1 6 0 DT NN CD NN -NONE- O
(Group (Group 0 0 0 0 0 0 0 0 6 0 NN CD NN -NONE- CC O
A) A) 1 1 0 0 0 0 0 0 2 0 CD NN -NONE- CC NN O
or or 0 0 0 0 0 0 0 0 2 0 NN -NONE- CC NN CD O
levobupivacaine levobupivacaine 0 0 0 0 0 0 0 0 15 0 -NONE- CC NN CD NN O
0.125% 0.125% 0 0 0 0 0 0 0 1 6 0 CC NN CD NN -NONE- O
(Group (Group 0 0 0 0 0 0 0 0 6 0 NN CD NN -NONE- DT O
B) B) 1 1 0 0 0 0 0 0 2 0 CD NN -NONE- DT VBD O
both both 0 0 0 0 0 0 0 0 4 0 NN -NONE- DT VBD IN O
added added 0 0 0 0 0 0 0 0 5 0 -NONE- DT VBD IN NN O
with with 0 0 0 0 0 0 0 0 4 0 DT VBD IN NN CD O
fentanyl fentanyl 0 0 0 0 0 0 0 0 8 0 VBD IN NN CD NN O
2.0 2.0 0 0 0 0 0 0 0 1 3 0 IN NN CD NN JJ O
mcro mcro 0 0 0 0 0 0 0 0 4 0 NN CD NN JJ IN O
g/ml g/ml 0 0 0 1 0 0 0 0 4 0 CD NN JJ IN JJ O
via via 0 0 0 0 0 0 0 0 3 0 NN JJ IN JJ NNP O
epidural epidural 0 0 0 0 0 0 0 0 8 0 JJ IN JJ NNP NNP O
route. route. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP NN O
PCEA PCEA 1 1 0 0 0 0 0 0 4 0 JJ NNP NNP NN VBD O
regime regime 0 0 0 0 0 0 0 0 6 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
offered offered 0 0 0 0 0 0 0 0 7 0 NN VBD VBN IN CD O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN CD NNS O
48 48 0 0 0 0 0 0 1 1 2 0 VBN IN CD NNS IN O
hours hours 0 0 0 0 0 0 0 0 5 0 IN CD NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 CD NNS IN JJ JJ O
additional additional 0 0 0 0 0 0 0 0 10 0 NNS IN JJ JJ JJ O
standard standard 0 0 0 0 0 0 0 0 8 0 IN JJ JJ JJ NN O
orthopaedic orthopaedic 0 0 0 0 0 0 0 0 11 0 JJ JJ JJ NN IN O
practice practice 0 0 0 0 0 0 0 0 8 0 JJ JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
oral oral 0 0 0 0 0 0 0 0 4 0 NN IN JJ NN NN O
analgesia analgesia 0 0 0 0 0 0 0 0 9 0 IN JJ NN NN CD O
(etoricoxib (etoricoxib 0 0 0 0 0 0 0 0 11 0 JJ NN NN CD NN O
120 120 0 0 0 0 0 0 1 1 3 0 NN NN CD NN NNP O
mg mg 0 0 0 0 0 0 0 0 2 0 NN CD NN NNP CC O
OD OD 1 1 0 0 0 0 0 0 2 0 CD NN NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NN CD O
paracetamol paracetamol 0 0 0 0 0 0 0 0 11 0 NNP CC NN CD NN O
1.0 1.0 0 0 0 0 0 0 0 1 3 0 CC NN CD NN -NONE- O
gm gm 0 0 0 0 0 0 0 0 2 0 NN CD NN -NONE- IN O
QID) QID) 1 1 0 0 0 0 0 0 4 0 CD NN -NONE- IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NN -NONE- IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- IN DT JJ JJ O
second second 0 0 0 0 0 0 0 0 6 0 IN DT JJ JJ NNP O
postoperative postoperative 0 0 0 0 0 0 0 0 13 0 DT JJ JJ NNP NNP O
day. day. 0 0 0 0 0 0 0 0 4 0 JJ JJ NNP NNP NN O
Basal Basal 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP NN IN O
infusion infusion 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP VBD O
PCEA PCEA 1 1 0 0 0 0 0 0 4 0 NN IN NNP VBD IN O
was was 0 0 0 0 0 0 0 0 3 0 IN NNP VBD IN CD O
at at 0 0 0 0 0 0 0 0 2 0 NNP VBD IN CD JJ O
3.0 3.0 0 0 0 0 0 0 0 1 3 0 VBD IN CD JJ CC O
ml/hour ml/hour 0 0 0 1 0 0 0 0 7 0 IN CD JJ CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 CD JJ CC VBN IN O
discontinued discontinued 0 0 0 0 0 0 0 0 12 0 JJ CC VBN IN CD O
after after 0 0 0 0 0 0 0 0 5 0 CC VBN IN CD NNS O
24 24 0 0 0 0 0 0 1 1 2 0 VBN IN CD NNS VBG O
hours hours 0 0 0 0 0 0 0 0 5 0 IN CD NNS VBG VBN O
following following 0 0 0 0 0 0 0 0 9 0 CD NNS VBG VBN IN O
started started 0 0 0 0 0 0 0 0 7 0 NNS VBG VBN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBG VBN IN NNP NNP O
PCEA. PCEA. 1 1 0 0 0 0 0 0 5 0 VBN IN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NN IN O
consumption consumption 0 0 0 0 0 0 0 0 11 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NNS O
local local 0 0 0 0 0 0 0 0 5 0 NN IN JJ NNS VBN O
anaesthetics anaesthetics 0 0 0 0 0 0 0 0 12 0 IN JJ NNS VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 JJ NNS VBN IN DT O
within within 0 0 0 0 0 0 0 0 6 0 NNS VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ CD O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ CD NNS O
24 24 0 0 0 0 0 0 1 1 2 0 DT JJ CD NNS JJ O
hours hours 0 0 0 0 0 0 0 0 5 0 JJ CD NNS JJ NN O
(basal (basal 0 0 0 0 0 0 0 0 6 0 CD NNS JJ NN NN O
+ + 0 0 0 0 0 0 0 0 1 0 NNS JJ NN NN CC O
demand) demand) 0 0 0 0 0 0 0 0 7 0 JJ NN NN CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC CD NNS O
48 48 0 0 0 0 0 0 1 1 2 0 NN CC CD NNS JJ O
hours hours 0 0 0 0 0 0 0 0 5 0 CC CD NNS JJ NN O
(total (total 0 0 0 0 0 0 0 0 6 0 CD NNS JJ NN : O
basal basal 0 0 0 0 0 0 0 0 5 0 NNS JJ NN : JJ O
+ + 0 0 0 0 0 0 0 0 1 0 JJ NN : JJ NN O
total total 0 0 0 0 0 0 0 0 5 0 NN : JJ NN VBD O
demand) demand) 0 0 0 0 0 0 0 0 7 0 : JJ NN VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 JJ NN VBD NNP NNP O
recorded. recorded. 0 0 0 0 0 0 0 0 9 0 NN VBD NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 VBD NNP NNP NNP NN O
VAS VAS 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NN -NONE- O
pain pain 0 0 0 0 0 0 0 0 4 0 NNP NNP NN -NONE- NN O
score, score, 0 0 0 0 1 0 0 0 6 0 NNP NN -NONE- NN -NONE- O
sedation sedation 0 0 0 0 0 0 0 0 8 0 NN -NONE- NN -NONE- NN O
score, score, 0 0 0 0 1 0 0 0 6 0 -NONE- NN -NONE- NN NNS O
side side 0 0 0 0 0 0 0 0 4 0 NN -NONE- NN NNS CC O
effects effects 0 0 0 0 0 0 0 0 7 0 -NONE- NN NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC JJ NNS O
vital vital 0 0 0 0 0 0 0 0 5 0 NNS CC JJ NNS JJ O
signs signs 0 0 0 0 0 0 0 0 5 0 CC JJ NNS JJ NN O
(blood (blood 0 0 0 0 0 0 0 0 6 0 JJ NNS JJ NN NN O
pressure, pressure, 0 0 0 0 1 0 0 0 9 0 NNS JJ NN NN NN O
heart heart 0 0 0 0 0 0 0 0 5 0 JJ NN NN NN CC O
rate rate 0 0 0 0 0 0 0 0 4 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
respiratory respiratory 0 0 0 0 0 0 0 0 11 0 NN CC NN NN VBD O
rate) rate) 0 0 0 0 0 0 0 0 5 0 CC NN NN VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD RB VBN O
also also 0 0 0 0 0 0 0 0 4 0 NN VBD RB VBN DT O
recorded recorded 0 0 0 0 0 0 0 0 8 0 VBD RB VBN DT CD O
every every 0 0 0 0 0 0 0 0 5 0 RB VBN DT CD NNS O
four four 0 0 0 0 0 0 0 0 4 0 VBN DT CD NNS IN O
hours hours 0 0 0 0 0 0 0 0 5 0 DT CD NNS IN CD O
for for 0 0 0 0 0 0 0 0 3 0 CD NNS IN CD NNP O
48 48 0 0 0 0 0 0 1 1 2 0 NNS IN CD NNP NNP O
hours. hours. 0 0 0 0 0 0 0 0 6 0 IN CD NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 CD NNP NNP NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NN VBD IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT JJ NN O
total total 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN IN O
volume volume 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN VBN O
drug drug 0 0 0 0 0 0 0 0 4 0 NN IN NN VBN VBD O
used used 0 0 0 0 0 0 0 0 4 0 IN NN VBN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NN VBN VBD RB JJR O
significantly significantly 0 0 0 0 0 0 0 0 13 0 VBN VBD RB JJR IN O
higher higher 0 0 0 0 0 0 0 0 6 0 VBD RB JJR IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 RB JJR IN NNP DT O
Group Group 1 0 0 0 0 0 0 0 5 0 JJR IN NNP DT NN O
A A 1 1 0 0 0 0 0 0 1 0 IN NNP DT NN CD O
(163.31+/- (163.31+/- 0 0 1 1 0 0 0 1 10 0 NNP DT NN CD NN O
29.01 29.01 0 0 0 0 0 0 0 1 5 0 DT NN CD NN IN O
ml) ml) 0 0 0 0 0 0 0 0 3 0 NN CD NN IN NNP O
than than 0 0 0 0 0 0 0 0 4 0 CD NN IN NNP NNP O
Group Group 1 0 0 0 0 0 0 0 5 0 NN IN NNP NNP NNP O
B B 1 1 0 0 0 0 0 0 1 0 IN NNP NNP NNP : O
(142.69 (142.69 0 0 0 0 0 0 0 1 7 0 NNP NNP NNP : CD O
+/- +/- 0 0 1 1 0 0 0 0 3 0 NNP NNP : CD NNP O
30.93ml) 30.93ml) 0 0 0 0 0 0 0 1 8 0 NNP : CD NNP CD O
(p<0. (p<0. 0 0 0 0 0 0 0 1 5 0 : CD NNP CD NNP O
01). 01). 0 0 0 0 0 0 0 1 4 0 CD NNP CD NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NNP CD NNP JJ NN O
mean mean 0 0 0 0 0 0 0 0 4 0 CD NNP JJ NN IN O
dose dose 0 0 0 0 0 0 0 0 4 0 NNP JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP DT O
Group Group 1 0 0 0 0 0 0 0 5 0 NN IN NNP DT IN O
A A 1 1 0 0 0 0 0 0 1 0 IN NNP DT IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NNP DT IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 DT IN DT JJ CD O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ CD NNS O
48 48 0 0 0 0 0 0 1 1 2 0 DT JJ CD NNS IN O
hours hours 0 0 0 0 0 0 0 0 5 0 JJ CD NNS IN NN O
after after 0 0 0 0 0 0 0 0 5 0 CD NNS IN NN VBD O
surgery surgery 0 0 0 0 0 0 0 0 7 0 NNS IN NN VBD CD O
was was 0 0 0 0 0 0 0 0 3 0 IN NN VBD CD : O
251.43 251.43 0 0 0 0 0 0 0 1 6 0 NN VBD CD : CD O
+/- +/- 0 0 1 1 0 0 0 0 3 0 VBD CD : CD CC O
70.02mg 70.02mg 0 0 0 0 0 0 0 1 7 0 CD : CD CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 : CD CC VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 CD CC VBD RB JJR O
significantly significantly 0 0 0 0 0 0 0 0 13 0 CC VBD RB JJR IN O
greater greater 0 0 0 0 0 0 0 0 7 0 VBD RB JJR IN DT O
than than 0 0 0 0 0 0 0 0 4 0 RB JJR IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJR IN DT JJ NN O
mean mean 0 0 0 0 0 0 0 0 4 0 IN DT JJ NN IN O
dose dose 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
Group Group 1 0 0 0 0 0 0 0 5 0 NN IN NNP NNP -NONE- O
B B 1 1 0 0 0 0 0 0 1 0 IN NNP NNP -NONE- -NONE- O
(178.91 (178.91 0 0 0 0 0 0 0 1 7 0 NNP NNP -NONE- -NONE- -NONE- O
+/-42.33 +/-42.33 0 0 1 1 0 0 0 1 8 0 NNP -NONE- -NONE- -NONE- NNP O
mg) mg) 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- -NONE- NNP NNP O
(p<0.01). (p<0.01). 0 0 0 0 0 0 0 1 9 0 -NONE- -NONE- NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 -NONE- NNP NNP NNS IN O
numbers numbers 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NNP NNS O
PCEA PCEA 1 1 0 0 0 0 0 0 4 0 NNS IN NNP NNS VBD O
boluses boluses 0 0 0 0 0 0 0 0 7 0 IN NNP NNS VBD JJ O
delivered delivered 0 0 0 0 0 0 0 0 9 0 NNP NNS VBD JJ CC O
(D) (D) 0 1 0 0 0 0 0 0 3 0 NNS VBD JJ CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VBD JJ CC NNP VBZ O
PCEA PCEA 1 1 0 0 0 0 0 0 4 0 JJ CC NNP VBZ JJ O
attempts attempts 0 0 0 0 0 0 0 0 8 0 CC NNP VBZ JJ NN O
(A) (A) 0 1 0 0 0 0 0 0 3 0 NNP VBZ JJ NN JJR O
were were 0 0 0 0 0 0 0 0 4 0 VBZ JJ NN JJR IN O
higher higher 0 0 0 0 0 0 0 0 6 0 JJ NN JJR IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN JJR IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 JJR IN DT NNP DT O
Group Group 1 0 0 0 0 0 0 0 5 0 IN DT NNP DT NN O
A A 1 1 0 0 0 0 0 0 1 0 DT NNP DT NN -NONE- O
(22.37 (22.37 0 0 0 0 0 0 0 1 6 0 NNP DT NN -NONE- CC O
+/-7.32 +/-7.32 0 0 1 1 0 0 0 1 7 0 DT NN -NONE- CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC CD : O
27.66 27.66 0 0 0 0 0 0 0 1 5 0 -NONE- CC CD : CD O
+/- +/- 0 0 1 1 0 0 0 0 3 0 CC CD : CD IN O
9.12) 9.12) 0 0 0 0 0 0 0 1 5 0 CD : CD IN NN O
in in 0 0 0 0 0 0 0 0 2 0 : CD IN NN TO O
contrast contrast 0 0 0 0 0 0 0 0 8 0 CD IN NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO NNP NNP O
Group Group 1 0 0 0 0 0 0 0 5 0 NN TO NNP NNP NNP O
B B 1 1 0 0 0 0 0 0 1 0 TO NNP NNP NNP : O
(17.63 (17.63 0 0 0 0 0 0 0 1 6 0 NNP NNP NNP : CD O
+/- +/- 0 0 1 1 0 0 0 0 3 0 NNP NNP : CD CC O
7.71 7.71 0 0 0 0 0 0 0 1 4 0 NNP : CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 : CD CC CD : O
24.40 24.40 0 0 0 0 0 0 0 1 5 0 CD CC CD : CD O
+/- +/- 0 0 1 1 0 0 0 0 3 0 CC CD : CD CC O
11.51) 11.51) 0 0 0 0 0 0 0 1 6 0 CD : CD CC DT O
but but 0 0 0 0 0 0 0 0 3 0 : CD CC DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 CD CC DT NNS VBD O
differences differences 0 0 0 0 0 0 0 0 11 0 CC DT NNS VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 DT NNS VBD RB RB O
not not 0 0 0 0 0 0 0 0 3 0 NNS VBD RB RB NNP O
statistically statistically 0 0 0 0 0 0 0 0 13 0 VBD RB RB NNP NNP O
significant. significant. 0 0 0 0 0 0 0 0 12 0 RB RB NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 RB NNP NNP NN NNP O
ratio ratio 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NNP VBD O
D/A D/A 1 1 0 1 0 0 0 0 3 0 NNP NN NNP VBD RB O
showed showed 0 0 0 0 0 0 0 0 6 0 NN NNP VBD RB JJR O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNP VBD RB JJR IN O
higher higher 0 0 0 0 0 0 0 0 6 0 VBD RB JJR IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 RB JJR IN NNP DT O
Group Group 1 0 0 0 0 0 0 0 5 0 JJR IN NNP DT NN O
A A 1 1 0 0 0 0 0 0 1 0 IN NNP DT NN : O
(0.83 (0.83 0 0 0 0 0 0 0 1 5 0 NNP DT NN : CD O
+/- +/- 0 0 1 1 0 0 0 0 3 0 DT NN : CD IN O
0.13) 0.13) 0 0 0 0 0 0 0 1 5 0 NN : CD IN NNP O
than than 0 0 0 0 0 0 0 0 4 0 : CD IN NNP NNP O
Group Group 1 0 0 0 0 0 0 0 5 0 CD IN NNP NNP NNP O
B B 1 1 0 0 0 0 0 0 1 0 IN NNP NNP NNP : O
(0.74 (0.74 0 0 0 0 0 0 0 1 5 0 NNP NNP NNP : CD O
+/- +/- 0 0 1 1 0 0 0 0 3 0 NNP NNP : CD NNP O
0.15) 0.15) 0 0 0 0 0 0 0 1 5 0 NNP : CD NNP CD O
(p<0. (p<0. 0 0 0 0 0 0 0 1 5 0 : CD NNP CD NNP O
02). 02). 0 0 0 0 0 0 0 1 4 0 CD NNP CD NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP CD NNP NNP NN O
VAS VAS 1 1 0 0 0 0 0 0 3 0 CD NNP NNP NN NN O
pain pain 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN VBD O
score score 0 0 0 0 0 0 0 0 5 0 NNP NN NN VBD JJ O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD JJ IN O
similar similar 0 0 0 0 0 0 0 0 7 0 NN VBD JJ IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBD JJ IN DT NNP O
both both 0 0 0 0 0 0 0 0 4 0 JJ IN DT NNP CD O
groups. groups. 0 0 0 0 0 0 0 0 7 0 IN DT NNP CD NN O
One One 1 0 0 0 0 0 0 0 3 0 DT NNP CD NN IN O
patient patient 0 0 0 0 0 0 0 0 7 0 NNP CD NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN NNP NNP O
Group Group 1 0 0 0 0 0 0 0 5 0 NN IN NNP NNP VBD O
B B 1 1 0 0 0 0 0 0 1 0 IN NNP NNP VBD VBG O
had had 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBG CC O
vomiting vomiting 0 0 0 0 0 0 0 0 8 0 NNP VBD VBG CC EX O
and and 0 0 0 0 0 0 0 0 3 0 VBD VBG CC EX VBD O
there there 0 0 0 0 0 0 0 0 5 0 VBG CC EX VBD DT O
was was 0 0 0 0 0 0 0 0 3 0 CC EX VBD DT NN O
no no 0 0 0 0 0 0 0 0 2 0 EX VBD DT NN -NONE- O
sedation, sedation, 0 0 0 0 1 0 0 0 9 0 VBD DT NN -NONE- VBZ O
hypotension, hypotension, 0 0 0 0 1 0 0 0 12 0 DT NN -NONE- VBZ CC O
pruritus pruritus 0 0 0 0 0 0 0 0 8 0 NN -NONE- VBZ CC NN O
or or 0 0 0 0 0 0 0 0 2 0 -NONE- VBZ CC NN NN O
motor motor 0 0 0 0 0 0 0 0 5 0 VBZ CC NN NN VBD O
block block 0 0 0 0 0 0 0 0 5 0 CC NN NN VBD IN O
recorded recorded 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN VBD IN DT NNP O
both both 0 0 0 0 0 0 0 0 4 0 VBD IN DT NNP NNP O
groups. groups. 0 0 0 0 0 0 0 0 7 0 IN DT NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 DT NNP NNP NN DT O
conclusion conclusion 0 0 0 0 0 0 0 0 10 0 NNP NNP NN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NN DT NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NN DT NN VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 DT NN VBD IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN DT NNP O
both both 0 0 0 0 0 0 0 0 4 0 VBD IN DT NNP VBG O
PCEA PCEA 1 1 0 0 0 0 0 0 4 0 IN DT NNP VBG NN O
using using 0 0 0 0 0 0 0 0 5 0 DT NNP VBG NN CD O
ropivacaine ropivacaine 0 0 0 0 0 0 0 0 11 0 NNP VBG NN CD IN O
0.165% 0.165% 0 0 0 0 0 0 0 1 6 0 VBG NN CD IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NN CD IN NN CD O
fentanyl fentanyl 0 0 0 0 0 0 0 0 8 0 CD IN NN CD NN O
2.0 2.0 0 0 0 0 0 0 0 1 3 0 IN NN CD NN JJ O
micro micro 0 0 0 0 0 0 0 0 5 0 NN CD NN JJ CC O
g/ml g/ml 0 0 0 1 0 0 0 0 4 0 CD NN JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN JJ CC NN CD O
levobupivacaine levobupivacaine 0 0 0 0 0 0 0 0 15 0 JJ CC NN CD IN O
0.125% 0.125% 0 0 0 0 0 0 0 1 6 0 CC NN CD IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NN CD IN NN CD O
fentanyl fentanyl 0 0 0 0 0 0 0 0 8 0 CD IN NN CD NN O
2.0 2.0 0 0 0 0 0 0 0 1 3 0 IN NN CD NN JJ O
micro micro 0 0 0 0 0 0 0 0 5 0 NN CD NN JJ VBN O
g/ml g/ml 0 0 0 1 0 0 0 0 4 0 CD NN JJ VBN JJ O
provided provided 0 0 0 0 0 0 0 0 8 0 NN JJ VBN JJ JJ O
effective effective 0 0 0 0 0 0 0 0 9 0 JJ VBN JJ JJ NN O
postoperative postoperative 0 0 0 0 0 0 0 0 13 0 VBN JJ JJ NN IN O
analgesia analgesia 0 0 0 0 0 0 0 0 9 0 JJ JJ NN IN DT O
within within 0 0 0 0 0 0 0 0 6 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ CD O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ CD NNS O
48 48 0 0 0 0 0 0 1 1 2 0 DT JJ CD NNS IN O
hours hours 0 0 0 0 0 0 0 0 5 0 JJ CD NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN JJ JJR O
major major 0 0 0 0 0 0 0 0 5 0 NNS IN JJ JJR NN O
lower lower 0 0 0 0 0 0 0 0 5 0 IN JJ JJR NN JJ O
limb limb 0 0 0 0 0 0 0 0 4 0 JJ JJR NN JJ NN O
orthopaedic orthopaedic 0 0 0 0 0 0 0 0 11 0 JJR NN JJ NN IN O
surgery surgery 0 0 0 0 0 0 0 0 7 0 NN JJ NN IN RB O
despite despite 0 0 0 0 0 0 0 0 7 0 JJ NN IN RB JJ O
clinically clinically 0 0 0 0 0 0 0 0 10 0 NN IN RB JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 IN RB JJ NN NNP O
dose dose 0 0 0 0 0 0 0 0 4 0 RB JJ NN NNP NNP O
difference. difference. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP NNP VBD O
There There 1 0 0 0 0 0 0 0 5 0 NN NNP NNP VBD DT O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD DT NN O
no no 0 0 0 0 0 0 0 0 2 0 NNP VBD DT NN -NONE- O
hypotension, hypotension, 0 0 0 0 1 0 0 0 12 0 VBD DT NN -NONE- NN O
pruritus, pruritus, 0 0 0 0 1 0 0 0 9 0 DT NN -NONE- NN CC O
sedation sedation 0 0 0 0 0 0 0 0 8 0 NN -NONE- NN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 -NONE- NN CC NN NN O
motor motor 0 0 0 0 0 0 0 0 5 0 NN CC NN NN VBD O
block block 0 0 0 0 0 0 0 0 5 0 CC NN NN VBD IN O
recorded recorded 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN VBD IN DT NNP O
both both 0 0 0 0 0 0 0 0 4 0 VBD IN DT NNP NONE O
groups. groups. 0 0 0 0 0 0 0 0 7 0 IN DT NNP NONE NONE O
LY294002 LY294002 1 1 0 0 0 0 0 1 8 0 NONE NONE NNP NNS -NONE- O
induces induces 0 0 0 0 0 0 0 0 7 0 NONE NNP NNS -NONE- VBP O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NNP NNS -NONE- VBP NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 NNS -NONE- VBP NN JJS O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest -NONE- VBP NN JJS CC O
arrest arrest 0 0 0 0 0 0 0 0 6 0 VBP NN JJS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN JJS CC NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 JJS CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN JJ O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN IN NN JJ NNS O
stem-like stem-like 0 0 1 0 0 0 0 0 9 0 IN NN JJ NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN JJ NNS IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 JJ NNS IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NN IN O
osteosarcoma osteosarcoma 0 0 0 0 0 0 0 0 12 0 IN JJ NN IN NN O
via via 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN IN O
down-regulation down-regulation 0 0 1 0 0 0 0 0 15 0 NN IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNP O
PI3K PI3K 1 1 0 0 0 0 0 1 4 0 NN IN NNP NNP NNP O
activity. activity. 0 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP NNP O
Gong Gong 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Liao Liao 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lin Lin 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Qi Qi 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Qin Qin 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tian Tian 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
LQ, LQ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Guo Guo 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
FJ. FJ. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Orthopedics, Orthopedics, 1 0 0 0 1 0 0 0 12 0 NNP IN NNP NNP NNP O
Tongji Tongji 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
Hospital, Hospital, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Tongji Tongji 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
College, College, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Huazhong Huazhong 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Science Science 1 0 0 0 0 0 0 0 7 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Technology, Technology, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP NNP O
Wuhan, Wuhan, 1 0 0 0 1 0 0 0 6 0 CC NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP DT O
Osteosarcoma, Osteosarcoma, 1 0 0 0 1 0 0 0 13 0 NNP NNP NNP DT RBS O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT RBS JJ O
most most 0 0 0 0 0 0 0 0 4 0 NNP DT RBS JJ JJ O
common common 0 0 0 0 0 0 0 0 6 0 DT RBS JJ JJ JJ O
primary primary 0 0 0 0 0 0 0 0 7 0 RBS JJ JJ JJ NN O
mesenchymal mesenchymal 0 0 0 0 0 0 0 0 11 0 JJ JJ JJ NN NN O
malignant malignant 0 0 0 0 0 0 0 0 9 0 JJ JJ NN NN RB O
tumor, tumor, 0 0 0 0 1 0 0 0 6 0 JJ NN NN RB VBZ O
usually usually 0 0 0 0 0 0 0 0 7 0 NN NN RB VBZ JJ O
has has 0 0 0 0 0 0 0 0 3 0 NN RB VBZ JJ NN O
bad bad 0 0 0 0 0 0 0 0 3 0 RB VBZ JJ NN IN O
prognosis prognosis 0 0 0 0 0 0 0 0 9 0 VBZ JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP IN O
man, man, 0 0 0 0 1 0 0 0 4 0 NN IN NNP IN NN O
with with 0 0 0 0 0 0 0 0 4 0 IN NNP IN NN JJ O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NNP IN NN JJ NNS O
stem-like stem-like 0 0 1 0 0 0 0 0 9 0 IN NN JJ NNS -NONE- O
cells cells 0 0 0 0 0 0 0 0 5 0 NN JJ NNS -NONE- VBN O
(CSCs) (CSCs) 0 0 0 0 0 0 0 0 6 0 JJ NNS -NONE- VBN TO O
considered considered 0 0 0 0 0 0 0 0 10 0 NNS -NONE- VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 -NONE- VBN TO VB DT O
play play 0 0 0 0 0 0 0 0 4 0 VBN TO VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT JJ NN O
critical critical 0 0 0 0 0 0 0 0 8 0 VB DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN CC O
tumorigenesis tumorigenesis 0 0 0 0 0 0 0 0 13 0 NN IN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NNP NNP O
drug-resistance. drug-resistance. 0 0 1 0 0 0 0 0 16 0 NN CC NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 CC NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
known known 0 0 0 0 0 0 0 0 5 0 NNP VBZ VBN IN NN O
that that 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN NN CD O
phosphatidylinositol phosphatidylinositol 0 0 0 0 0 0 0 0 20 0 VBN IN NN CD NN O
3-kinase 3-kinase 0 0 1 0 0 0 0 1 8 0 IN NN CD NN VBZ O
(PI3K) (PI3K) 0 1 0 0 0 0 0 1 6 0 NN CD NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 CD NN VBZ VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 NN VBZ VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN NN IN O
regulation regulation 0 0 0 0 0 0 0 0 10 0 VBN IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NN IN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN NN NN NN JJ O
fates, fates, 0 0 0 0 1 0 0 0 6 0 NN NN NN JJ IN O
such such 0 0 0 0 0 0 0 0 4 0 NN NN JJ IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 NN JJ IN JJ NN O
proliferation, proliferation, 0 0 0 0 1 0 0 0 14 0 JJ IN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN NN O
cycling, cycling, 0 0 0 0 1 0 0 0 8 0 JJ NN NN NN CC O
survival survival 0 0 0 0 0 0 0 0 8 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
apoptosis. apoptosis. 0 0 0 0 0 0 0 0 10 0 NN CC NNP NNP CC O
Whether Whether 1 0 0 0 0 0 0 0 7 0 CC NNP NNP CC WRB O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC WRB NNP O
how how 0 0 0 0 0 0 0 0 3 0 NNP CC WRB NNP CC O
PI3K PI3K 1 1 0 0 0 0 0 1 4 0 CC WRB NNP CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 WRB NNP CC NNS MD O
inhibitors inhibitors 0 0 0 0 0 0 0 0 10 0 NNP CC NNS MD VB O
might might 0 0 0 0 0 0 0 0 5 0 CC NNS MD VB IN O
cooperate cooperate 0 0 0 0 0 0 0 0 9 0 NNS MD VB IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 MD VB IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 VB IN JJ NN NNP O
osteosarcoma osteosarcoma 0 0 0 0 0 0 0 0 12 0 IN JJ NN NNP VBZ O
CSCs CSCs 1 0 0 0 0 0 0 0 4 0 JJ NN NNP VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NN NNP VBZ RB NNP O
still still 0 0 0 0 0 0 0 0 5 0 NNP VBZ RB NNP NNP O
unknown. unknown. 0 0 0 0 0 0 0 0 8 0 VBZ RB NNP NNP RB O
We We 1 0 0 0 0 0 0 0 2 0 RB NNP NNP RB VBN O
therefore therefore 0 0 0 0 0 0 0 0 9 0 NNP NNP RB VBN DT O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 NNP RB VBN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 RB VBN DT NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 VBN DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ DT O
LY294002, LY294002, 1 1 0 0 1 0 0 1 9 0 NNS IN JJ DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 IN JJ DT NNP NNP O
PI3K PI3K 1 1 0 0 0 0 0 1 4 0 JJ DT NNP NNP IN O
inhibitor, inhibitor, 0 0 0 0 1 0 0 0 10 0 DT NNP NNP IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN CC O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NNP O
osteosarcoma osteosarcoma 0 0 0 0 0 0 0 0 12 0 NN IN NN NNP IN O
CSCs CSCs 1 0 0 0 0 0 0 0 4 0 IN NN NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NNP IN NNP NNP O
vitro. vitro. 0 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP VBD O
LY294002 LY294002 1 1 0 0 0 0 0 1 8 0 IN NNP NNP VBD NN O
prevented prevented 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 NNP VBD NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 NN IN NN NN NNP O
kinase kinase 0 0 0 0 0 0 0 0 6 0 IN NN NN NNP NNP O
B B 1 1 0 0 0 0 0 0 1 0 NN NN NNP NNP IN O
(PKB/Akt) (PKB/Akt) 0 0 0 1 0 0 0 0 9 0 NN NNP NNP IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 NNP IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NN O
PI3K PI3K 1 1 0 0 0 0 0 1 4 0 NN IN NNP NN -NONE- O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 IN NNP NN -NONE- RB O
activity, activity, 0 0 0 0 1 0 0 0 9 0 NNP NN -NONE- RB VBG O
thereby thereby 0 0 0 0 0 0 0 0 7 0 NN -NONE- RB VBG -NONE- O
inducing inducing 0 0 0 0 0 0 0 0 8 0 -NONE- RB VBG -NONE- NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 RB VBG -NONE- NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 VBG -NONE- NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest -NONE- NN NN NN CC O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN CC NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NNP O
osteosarcoma osteosarcoma 0 0 0 0 0 0 0 0 12 0 NN IN NN NNP NNP O
CSCs. CSCs. 1 0 0 0 0 0 0 0 5 0 IN NN NNP NNP NNS O
Further Further 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NNS RB O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS RB VBD O
also also 0 0 0 0 0 0 0 0 4 0 NNP NNS RB VBD IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 NNS RB VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 RB VBD IN NN NN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 VBD IN NN NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 IN NN NN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP VBZ O
LY294002 LY294002 1 1 0 0 0 0 0 1 8 0 NN IN NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ VBN IN O
accompanied accompanied 0 0 0 0 0 0 0 0 11 0 NNP VBZ VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 VBN IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP -NONE- O
caspase-9, caspase-9, 0 0 1 0 1 0 0 1 10 0 NN IN NNP -NONE- CC O
caspase-3 caspase-3 0 0 1 0 0 0 0 1 9 0 IN NNP -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP -NONE- CC NNP WDT O
PARP, PARP, 1 1 0 0 1 0 0 0 5 0 -NONE- CC NNP WDT VBP O
which which 0 0 0 0 0 0 0 0 5 0 CC NNP WDT VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NNP WDT VBP VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 WDT VBP VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBP VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
mitochondrial mitochondrial 0 0 0 0 0 0 0 0 13 0 IN DT JJ NN NNP O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 DT JJ NN NNP NNP O
pathway. pathway. 0 0 0 0 0 0 0 0 8 0 JJ NN NNP NNP PRP$ O
Therefore, Therefore, 1 0 0 0 1 0 0 0 10 0 NN NNP NNP PRP$ NNS O
our our 0 0 0 0 0 0 0 0 3 0 NNP NNP PRP$ NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP PRP$ NNS VBP NNP O
indicate indicate 0 0 0 0 0 0 0 0 8 0 PRP$ NNS VBP NNP NNS O
PI3K PI3K 1 1 0 0 0 0 0 1 4 0 NNS VBP NNP NNS MD O
inhibitors inhibitors 0 0 0 0 0 0 0 0 10 0 VBP NNP NNS MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NNP NNS MD VB DT O
represent represent 0 0 0 0 0 0 0 0 9 0 NNS MD VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT JJ NN O
potential potential 0 0 0 0 0 0 0 0 9 0 VB DT JJ NN IN O
strategy strategy 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN VBG O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN VBG NN O
managing managing 0 0 0 0 0 0 0 0 8 0 NN IN VBG NN NN O
human human 0 0 0 0 0 0 0 0 5 0 IN VBG NN NN IN O
osteosarcoma osteosarcoma 0 0 0 0 0 0 0 0 12 0 VBG NN NN IN VBG O
via via 0 0 0 0 0 0 0 0 3 0 NN NN IN VBG NNP O
affecting affecting 0 0 0 0 0 0 0 0 9 0 NN IN VBG NNP NONE O
CSCs. CSCs. 1 0 0 0 0 0 0 0 5 0 IN VBG NNP NONE NONE O
Overexpression Overexpression 1 0 0 0 0 0 0 0 14 0 NONE NONE NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NNP NNS O
ERα ERα 1 0 0 0 0 0 0 0 3 0 NN IN NNP NNS NN O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 IN NNP NNS NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NNP NNS NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNS NN CC NN IN O
invasion invasion 0 0 0 0 0 0 0 0 8 0 NN CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP JJ O
MKN28 MKN28 1 1 0 0 0 0 0 1 5 0 NN IN NNP JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 IN NNP JJ NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NNP JJ NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN VBG O
by by 0 0 0 0 0 0 0 0 2 0 NN NNS IN VBG NNP O
suppressing suppressing 0 0 0 0 0 0 0 0 11 0 NNS IN VBG NNP NNP O
β-catenin. β-catenin. 0 0 1 0 0 0 0 0 10 0 IN VBG NNP NNP NNP O
Zhou Zhou 1 0 0 0 0 0 0 0 4 0 VBG NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Teng Teng 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Xu Xu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Q, Q, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Guo Guo 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Xu Xu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Xie Xie 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Shen Shen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
L. L. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Surgical Surgical 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Oncology, Oncology, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Sir Sir 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Run Run 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Run Run 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Shaw Shaw 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Hospital, Hospital, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Zhejiang Zhejiang 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Hangzhou, Hangzhou, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP CD O
Zhejiang Zhejiang 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP CD NNP O
310016, 310016, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP NNP O
P.R. P.R. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
relationship relationship 0 0 0 0 0 0 0 0 12 0 NNP NNP NN IN NN O
between between 0 0 0 0 0 0 0 0 7 0 NNP NN IN NN NN O
estrogen estrogen 0 0 0 0 0 0 0 0 8 0 NN IN NN NN NN O
receptor receptor 0 0 0 0 0 0 0 0 8 0 IN NN NN NN CC O
(ER)α (ER)α 0 0 0 0 0 0 0 0 5 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
patient patient 0 0 0 0 0 0 0 0 7 0 NN CC NN NN VBZ O
prognosis prognosis 0 0 0 0 0 0 0 0 9 0 CC NN NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NN NN VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN VBN IN O
identified identified 0 0 0 0 0 0 0 0 10 0 VBZ VBN VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 VBN IN JJ NN NN O
cancer; cancer; 0 0 0 0 0 0 0 0 7 0 IN JJ NN NN DT O
however, however, 0 0 0 0 1 0 0 0 8 0 JJ NN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NN NN O
definite definite 0 0 0 0 0 0 0 0 8 0 NN DT NN NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP IN O
ERα ERα 1 0 0 0 0 0 0 0 3 0 NN IN NNP IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 NNP IN JJ NN VBZ O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN VBZ TO O
remains remains 0 0 0 0 0 0 0 0 7 0 JJ NN VBZ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBZ TO VB RB O
be be 0 0 0 0 0 0 0 0 2 0 VBZ TO VB RB NNP O
fully fully 0 0 0 0 0 0 0 0 5 0 TO VB RB NNP NNP O
elucidated. elucidated. 0 0 0 0 0 0 0 0 11 0 VB RB NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 RB NNP NNP NN IN O
aim aim 0 0 0 0 0 0 0 0 3 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
present present 0 0 0 0 0 0 0 0 7 0 IN DT NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
vitro vitro 0 0 0 0 0 0 0 0 5 0 NN IN NN NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 IN NN NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB DT O
investigate investigate 0 0 0 0 0 0 0 0 11 0 VBD TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
impact impact 0 0 0 0 0 0 0 0 6 0 VB DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ IN O
ERα ERα 1 0 0 0 0 0 0 0 3 0 NN IN JJ IN NN O
on on 0 0 0 0 0 0 0 0 2 0 IN JJ IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ IN NN NN NN O
proliferation, proliferation, 0 0 0 0 1 0 0 0 14 0 IN NN NN NN CC O
migration migration 0 0 0 0 0 0 0 0 9 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
invasion invasion 0 0 0 0 0 0 0 0 8 0 NN CC NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NNP NNP O
lines. lines. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBD DT O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NNP NNP VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT JJ NN O
biological biological 0 0 0 0 0 0 0 0 10 0 VBD DT JJ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
ERα ERα 1 0 0 0 0 0 0 0 3 0 NN IN NNP NN IN O
overexpression overexpression 0 0 0 0 0 0 0 0 14 0 IN NNP NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN NNP O
carcinoma carcinoma 0 0 0 0 0 0 0 0 9 0 IN JJ NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP NNP O
An An 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NNP JJ O
MKN28 MKN28 1 1 0 0 0 0 0 1 5 0 NNP NNP NNP JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NNP JJ NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN RB O
line line 0 0 0 0 0 0 0 0 4 0 NN NN NN RB VBG O
stably stably 0 0 0 0 0 0 0 0 6 0 NN NN RB VBG NN O
overexpressing overexpressing 0 0 0 0 0 0 0 0 14 0 NN RB VBG NN VBD O
ERα ERα 1 0 0 0 0 0 0 0 3 0 RB VBG NN VBD NNP O
was was 0 0 0 0 0 0 0 0 3 0 VBG NN VBD NNP NNP O
established. established. 0 0 0 0 0 0 0 0 12 0 NN VBD NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 VBD NNP NNP NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NN O
ERα ERα 1 0 0 0 0 0 0 0 3 0 NN IN NNP NN IN O
overexpression overexpression 0 0 0 0 0 0 0 0 14 0 IN NNP NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN VBD O
growth growth 0 0 0 0 0 0 0 0 6 0 IN NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
assessed assessed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN NN O
evaluating evaluating 0 0 0 0 0 0 0 0 10 0 VBN IN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN NN NN NN NN O
survival, survival, 0 0 0 0 1 0 0 0 9 0 NN NN NN NN NN O
colony colony 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NN O
formation, formation, 0 0 0 0 1 0 0 0 10 0 NN NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NN NN NN NN CC O
progression progression 0 0 0 0 0 0 0 0 11 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
apoptosis. apoptosis. 0 0 0 0 0 0 0 0 10 0 NN CC NNP NNP NN O
Cell Cell 1 0 0 0 0 0 0 0 4 0 CC NNP NNP NN CC O
migration migration 0 0 0 0 0 0 0 0 9 0 NNP NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN VBD O
invasion invasion 0 0 0 0 0 0 0 0 8 0 NN CC NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 CC NN VBD VBN IN O
detected detected 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
Transwell Transwell 1 0 0 0 0 0 0 0 9 0 VBN IN NNP NNP NNP O
migration/invasion migration/invasion 0 0 0 1 0 0 0 0 18 0 IN NNP NNP NNP NNP O
assays. assays. 0 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN NNS O
protein protein 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 NNP NN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ RB O
several several 0 0 0 0 0 0 0 0 7 0 NNS IN JJ RB VBN O
potentially potentially 0 0 0 0 0 0 0 0 11 0 IN JJ RB VBN NNS O
involved involved 0 0 0 0 0 0 0 0 8 0 JJ RB VBN NNS VBD O
genes genes 0 0 0 0 0 0 0 0 5 0 RB VBN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 VBN NNS VBD VBN IN O
determined determined 0 0 0 0 0 0 0 0 10 0 NNS VBD VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NN O
western western 0 0 0 0 0 0 0 0 7 0 VBN IN JJ NN TO O
blotting blotting 0 0 0 0 0 0 0 0 8 0 IN JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB DT O
elucidate elucidate 0 0 0 0 0 0 0 0 9 0 NN TO VB DT VBG O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT VBG JJ O
underlying underlying 0 0 0 0 0 0 0 0 10 0 VB DT VBG JJ NNP O
molecular molecular 0 0 0 0 0 0 0 0 9 0 DT VBG JJ NNP NNP O
mechanisms. mechanisms. 0 0 0 0 0 0 0 0 11 0 VBG JJ NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NNP NNP O
Student's Student's 1 0 0 0 0 1 0 0 9 0 NNP NNP NNP NNP VBD O
t-test t-test 0 0 1 0 0 0 0 0 6 0 NNP NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 NNP VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB DT O
determine determine 0 0 0 0 0 0 0 0 9 0 VBN TO VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJ NNS O
statistical statistical 0 0 0 0 0 0 0 0 11 0 VB DT JJ NNS IN O
differences differences 0 0 0 0 0 0 0 0 11 0 DT JJ NNS IN JJ O
between between 0 0 0 0 0 0 0 0 7 0 JJ NNS IN JJ NN O
various various 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NN CC O
experimental experimental 0 0 0 0 0 0 0 0 12 0 IN JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NN O
control control 0 0 0 0 0 0 0 0 7 0 NN CC NN NN CC O
groups, groups, 0 0 0 0 1 0 0 0 7 0 CC NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NNP O
one-way one-way 0 0 1 0 0 0 0 0 7 0 NN CC JJ NNP NN O
ANOVA ANOVA 1 1 0 0 0 0 0 0 5 0 CC JJ NNP NN VBD O
test test 0 0 0 0 0 0 0 0 4 0 JJ NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB DT O
determine determine 0 0 0 0 0 0 0 0 9 0 VBN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
difference difference 0 0 0 0 0 0 0 0 10 0 VB DT NN IN CD O
between between 0 0 0 0 0 0 0 0 7 0 DT NN IN CD CC O
three three 0 0 0 0 0 0 0 0 5 0 NN IN CD CC JJR O
or or 0 0 0 0 0 0 0 0 2 0 IN CD CC JJR NNP O
more more 0 0 0 0 0 0 0 0 4 0 CD CC JJR NNP NNP O
groups. groups. 0 0 0 0 0 0 0 0 7 0 CC JJR NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 JJR NNP NNP NNS VBD O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NNS VBD IN -NONE- O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN -NONE- NN O
ERα ERα 1 0 0 0 0 0 0 0 3 0 VBD IN -NONE- NN RB O
overexpression overexpression 0 0 0 0 0 0 0 0 14 0 IN -NONE- NN RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 -NONE- NN RB VBN NN O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NN RB VBN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 RB VBN NN NN CC O
growth growth 0 0 0 0 0 0 0 0 6 0 VBN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP VBD O
proliferation, proliferation, 0 0 0 0 1 0 0 0 14 0 NN CC NNP VBD NN O
blocked blocked 0 0 0 0 0 0 0 0 7 0 CC NNP VBD NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP VBD NN NN IN O
entry entry 0 0 0 0 0 0 0 0 5 0 VBD NN NN IN DT O
into into 0 0 0 0 0 0 0 0 4 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
G1/G0 G1/G0 1 1 0 1 0 0 0 1 5 phase IN DT JJ NN CC B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT JJ NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBD NN O
promoted promoted 0 0 0 0 0 0 0 0 8 0 NN CC VBD NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 CC VBD NN NNP NNP O
apoptosis. apoptosis. 0 0 0 0 0 0 0 0 10 0 VBD NN NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NNP NNP O
addition, addition, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP VBD O
ERα ERα 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP VBD DT O
reduced reduced 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN CC O
motility motility 0 0 0 0 0 0 0 0 8 0 VBD DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
invasion invasion 0 0 0 0 0 0 0 0 8 0 NN CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNS MD O
phenotypes phenotypes 0 0 0 0 0 0 0 0 10 0 NNP NNP NNS MD RB O
may may 0 0 0 0 0 0 0 0 3 0 NNP NNS MD RB VB O
partly partly 0 0 0 0 0 0 0 0 6 0 NNS MD RB VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 MD RB VB VBN IN O
explained explained 0 0 0 0 0 0 0 0 9 0 RB VB VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VB VBN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NN IN O
decrease decrease 0 0 0 0 0 0 0 0 8 0 IN DT NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
β-catenin β-catenin 0 0 1 0 0 0 0 0 9 0 NN IN JJ NN VBD O
expression expression 0 0 0 0 0 0 0 0 10 0 IN JJ NN VBD IN O
caused caused 0 0 0 0 0 0 0 0 6 0 JJ NN VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN NN NNP O
ERα ERα 1 0 0 0 0 0 0 0 3 0 VBD IN NN NNP NNP O
overexpression. overexpression. 0 0 0 0 0 0 0 0 15 0 IN NN NNP NNP NN O
ERα ERα 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN RB O
overexpression overexpression 0 0 0 0 0 0 0 0 14 0 NNP NNP NN RB VBN O
effectively effectively 0 0 0 0 0 0 0 0 11 0 NNP NN RB VBN NN O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NN RB VBN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 RB VBN NN NN CC O
growth growth 0 0 0 0 0 0 0 0 6 0 VBN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN CC NN NN IN O
progression progression 0 0 0 0 0 0 0 0 11 0 CC NN NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NN JJ O
suppressing suppressing 0 0 0 0 0 0 0 0 11 0 NN IN NN JJ IN O
β-catenin β-catenin 0 0 1 0 0 0 0 0 9 0 IN NN JJ IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN JJ IN JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 JJ IN JJ NN VBG O
cancer, cancer, 0 0 0 0 1 0 0 0 7 0 IN JJ NN VBG NN O
identifying identifying 0 0 0 0 0 0 0 0 11 0 JJ NN VBG NN IN O
ERα ERα 1 0 0 0 0 0 0 0 3 0 NN VBG NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VBG NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN NN O
promising promising 0 0 0 0 0 0 0 0 9 0 IN DT NN NN IN O
target target 0 0 0 0 0 0 0 0 6 0 DT NN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ JJ O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 NN IN JJ JJ IN O
potential potential 0 0 0 0 0 0 0 0 9 0 IN JJ JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ JJ IN NN IN O
development development 0 0 0 0 0 0 0 0 11 0 JJ IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NNS O
new new 0 0 0 0 0 0 0 0 3 0 NN IN JJ NNS TO O
approaches approaches 0 0 0 0 0 0 0 0 10 0 IN JJ NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO VB JJ O
treat treat 0 0 0 0 0 0 0 0 5 0 NNS TO VB JJ NNP O
gastric gastric 0 0 0 0 0 0 0 0 7 0 TO VB JJ NNP NONE O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 VB JJ NNP NONE NONE O
Steroidal Steroidal 1 0 0 0 0 0 0 0 9 0 NONE NONE NNP NN NNS O
aromatase aromatase 0 0 0 0 0 0 0 0 9 0 NONE NNP NN NNS NN O
inhibitors inhibitors 0 0 0 0 0 0 0 0 10 0 NNP NN NNS NN NN O
inhibit inhibit 0 0 0 0 0 0 0 0 7 0 NN NNS NN NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 NNS NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
hormone-dependent hormone-dependent 0 0 1 0 0 0 0 0 17 0 NN IN JJ NN NN O
breast breast 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 JJ NN NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS IN VBG O
by by 0 0 0 0 0 0 0 0 2 0 NN NNS IN VBG NN O
inducing inducing 0 0 0 0 0 0 0 0 8 0 NNS IN VBG NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN VBG NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest VBG NN NN NN CC O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
apoptosis. apoptosis. 0 0 0 0 0 0 0 0 10 0 NN CC NNP NNP NNP O
Amaral Amaral 1 0 0 0 0 0 0 0 6 0 CC NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Varela Varela 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Borges Borges 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NN O
Tavares Tavares 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NN NNP O
da da 0 0 0 0 0 0 0 0 2 0 NNP NNP NN NNP NNP O
Silva Silva 1 0 0 0 0 0 0 0 5 0 NNP NN NNP NNP NNP O
E, E, 1 1 0 0 1 0 0 0 2 0 NN NNP NNP NNP NNP O
Roleira Roleira 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
FM, FM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Correia-da-Silva Correia-da-Silva 1 0 1 0 0 0 0 0 16 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Teixeira Teixeira 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
N. N. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biochemistry, Biochemistry, 1 0 0 0 1 0 0 0 13 0 NNP IN NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biological Biological 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP IN O
Faculty Faculty 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pharmacy, Pharmacy, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Porto, Porto, 1 0 0 0 1 0 0 0 6 0 NNP IN NNP NNP NNP O
Rua Rua 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
Jorge Jorge 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Viterbo Viterbo 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Ferreira, Ferreira, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP CD O
no. no. 0 0 0 0 0 0 0 0 3 0 NNP NNP NNP CD CD O
228, 228, 0 0 0 0 1 0 0 1 4 0 NNP NNP CD CD JJ O
4050-313, 4050-313, 0 0 1 0 1 0 0 1 9 0 NNP CD CD JJ NNP O
Porto, Porto, 1 0 0 0 1 0 0 0 6 0 CD CD JJ NNP NNP O
Portugal. Portugal. 1 0 0 0 0 0 0 0 9 0 CD JJ NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP NNP JJ O
Different Different 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP JJ NNS O
hormonal hormonal 0 0 0 0 0 0 0 0 8 0 NNP NNP JJ NNS VBP O
therapies therapies 0 0 0 0 0 0 0 0 9 0 NNP JJ NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 JJ NNS VBP VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 NNS VBP VBN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBP VBN IN NN NN O
estrogen estrogen 0 0 0 0 0 0 0 0 8 0 VBN IN NN NN JJ O
receptor receptor 0 0 0 0 0 0 0 0 8 0 IN NN NN JJ NN O
positive positive 0 0 0 0 0 0 0 0 8 0 NN NN JJ NN NN O
(ER+) (ER+) 0 1 0 0 0 0 0 0 5 0 NN JJ NN NN NN O
breast breast 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN VBG O
cancers, cancers, 0 0 0 0 1 0 0 0 8 0 NN NN NN VBG DT O
being being 0 0 0 0 0 0 0 0 5 0 NN NN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT NN IN O
third-generation third-generation 0 0 1 0 0 0 0 0 16 0 VBG DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
aromatase aromatase 0 0 0 0 0 0 0 0 9 0 NN IN NN NNS -NONE- O
inhibitors inhibitors 0 0 0 0 0 0 0 0 10 0 IN NN NNS -NONE- DT O
(AIs), (AIs), 0 0 0 0 1 0 0 0 6 0 NN NNS -NONE- DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNS -NONE- DT JJ NN O
effective effective 0 0 0 0 0 0 0 0 9 0 -NONE- DT JJ NN TO O
alternative alternative 0 0 0 0 0 0 0 0 11 0 DT JJ NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT JJ NNP O
classical classical 0 0 0 0 0 0 0 0 9 0 TO DT JJ NNP NNP O
tamoxifen. tamoxifen. 0 0 0 0 0 0 0 0 10 0 DT JJ NNP NNP NN O
AIs AIs 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN DT O
inhibit inhibit 0 0 0 0 0 0 0 0 7 0 NNP NNP NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT NN NN O
enzyme enzyme 0 0 0 0 0 0 0 0 6 0 NN DT NN NN WDT O
aromatase, aromatase, 0 0 0 0 1 0 0 0 10 0 DT NN NN WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN WDT VBZ JJ IN O
responsible responsible 0 0 0 0 0 0 0 0 11 0 WDT VBZ JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN NN DT O
catalyzing catalyzing 0 0 0 0 0 0 0 0 10 0 JJ IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN IN O
conversion conversion 0 0 0 0 0 0 0 0 10 0 NN DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS TO O
androgens androgens 0 0 0 0 0 0 0 0 9 0 NN IN NNS TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 IN NNS TO NNP NNP O
estrogens. estrogens. 0 0 0 0 0 0 0 0 10 0 NNS TO NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 TO NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 NNP DT NN PRP VBD O
it it 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN PRP VBD VBN DT O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 PRP VBD VBN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 VBD VBN DT NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 VBN DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ JJ O
several several 0 0 0 0 0 0 0 0 7 0 NNS IN JJ JJ NN O
steroidal steroidal 0 0 0 0 0 0 0 0 9 0 IN JJ JJ NN RB O
AIs, AIs, 1 0 0 0 1 0 0 0 4 0 JJ JJ NN RB CD O
namely namely 0 0 0 0 0 0 0 0 6 0 JJ NN RB CD NN O
3β-hydroxyandrost-4-en-17-one 3β-hydroxyandrost-4-en-17-one 0 0 1 0 0 0 0 1 29 0 NN RB CD NN NN O
(1), (1), 0 0 0 0 1 0 0 1 4 0 RB CD NN NN NN O
androst-4-en-17-one androst-4-en-17-one 0 0 1 0 0 0 0 1 19 0 CD NN NN NN CD O
(12), (12), 0 0 0 0 1 0 0 1 5 0 NN NN NN CD NN O
4α,5α-epoxyandrostan-17-one 4α,5α-epoxyandrostan-17-one 0 0 1 0 1 0 0 1 27 0 NN NN CD NN CC O
(13a) (13a) 0 0 0 0 0 0 0 1 5 0 NN CD NN CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD NN CC CD NN O
5α-androst-2-en-17-one 5α-androst-2-en-17-one 0 0 1 0 0 0 0 1 22 0 NN CC CD NN IN O
(16), (16), 0 0 0 0 1 0 0 1 5 0 CC CD NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 CD NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN NN O
proliferation, proliferation, 0 0 0 0 1 0 0 0 14 0 IN NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NN NN NN NN CC O
progression progression 0 0 0 0 0 0 0 0 11 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN CC NN NN IN O
death death 0 0 0 0 0 0 0 0 5 0 CC NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT JJ JJ O
ER+ ER+ 1 1 0 0 0 0 0 0 3 0 IN DT JJ JJ NN O
aromatase-overexpressing aromatase-overexpressing 0 0 1 0 0 0 0 0 24 0 DT JJ JJ NN NN O
human human 0 0 0 0 0 0 0 0 5 0 JJ JJ NN NN NN O
breast breast 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN NNP O
line line 0 0 0 0 0 0 0 0 4 0 NN NN NN NNP NNP O
(MCF-7aro). (MCF-7aro). 0 0 1 0 0 0 0 1 11 0 NN NN NNP NNP NNP O
All All 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNP VBD O
AIs AIs 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP VBD DT O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBD DT NN IN O
decrease decrease 0 0 0 0 0 0 0 0 8 0 VBD DT NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 IN NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT JJ O
these these 0 0 0 0 0 0 0 0 5 0 NN CC DT JJ NNS O
anti-proliferative anti-proliferative 0 0 1 0 0 0 0 0 18 0 CC DT JJ NNS VBD O
effects effects 0 0 0 0 0 0 0 0 7 0 DT JJ NNS VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 NNS VBD JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBD JJ TO DT NN O
a a 0 0 0 0 0 0 0 0 1 0 JJ TO DT NN IN O
disruption disruption 0 0 0 0 0 0 0 0 10 0 TO DT NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN NN CC O
progression progression 0 0 0 0 0 0 0 0 11 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN CC NN NN IN O
death, death, 0 0 0 0 1 0 0 0 6 0 CC NN NN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
apoptosis. apoptosis. 0 0 0 0 0 0 0 0 10 0 NN IN NNP NNP CD O
AIs AIs 1 0 0 0 0 0 0 0 3 0 IN NNP NNP CD CC O
1 1 0 0 0 0 0 0 1 1 1 0 NNP NNP CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NNP CD CC CD VBD O
16 16 0 0 0 0 0 0 1 1 2 0 CD CC CD VBD NN O
caused caused 0 0 0 0 0 0 0 0 6 0 CC CD VBD NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 CD VBD NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest VBD NN NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP IN O
G0/G1, G0/G1, 1 1 0 1 1 0 0 1 6 0 NN IN NNP IN NNP B_TIMEXCCP
while while 0 0 0 0 0 0 0 0 5 0 IN NNP IN NNP CD O
AIs AIs 1 0 0 0 0 0 0 0 3 0 NNP IN NNP CD CC O
12 12 0 0 0 0 0 0 1 1 2 0 IN NNP CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NNP CD CC CD VBD O
13a 13a 0 0 0 0 0 0 0 1 3 0 CD CC CD VBD DT O
induced induced 0 0 0 0 0 0 0 0 7 0 CC CD VBD DT NN O
an an 0 0 0 0 0 0 0 0 2 arrest CD VBD DT NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 VBD DT NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
G2/M. G2/M. 1 1 0 1 0 0 0 1 5 0 NN IN NNP NNP PRP B_TIMEXCCP
Moreover, Moreover, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP PRP VBD O
it it 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP PRP VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 PRP VBD VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 VBD VBN IN DT NNP O
these these 0 0 0 0 0 0 0 0 5 0 VBN IN DT NNP VBD O
AIs AIs 1 0 0 0 0 0 0 0 3 0 IN DT NNP VBD NN O
induced induced 0 0 0 0 0 0 0 0 7 0 DT NNP VBD NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NNP VBD NN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBD NN IN JJ NN O
different different 0 0 0 0 0 0 0 0 9 0 NN IN JJ NN IN O
pathways, pathways, 0 0 0 0 1 0 0 0 9 0 IN JJ NN IN NNP O
since since 0 0 0 0 0 0 0 0 5 0 JJ NN IN NNP CD O
AIs AIs 1 0 0 0 0 0 0 0 3 0 NN IN NNP CD CD O
1, 1, 0 0 0 0 1 0 0 1 2 0 IN NNP CD CD CC O
12 12 0 0 0 0 0 0 1 1 2 0 NNP CD CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD CD CC CD VBD O
13a 13a 0 0 0 0 0 0 0 1 3 0 CD CC CD VBD DT O
activated activated 0 0 0 0 0 0 0 0 9 0 CC CD VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CD VBD DT JJ JJ O
apoptotic apoptotic 0 0 0 0 0 0 0 0 9 0 VBD DT JJ JJ NN O
mitochondrial mitochondrial 0 0 0 0 0 0 0 0 13 0 DT JJ JJ NN IN O
pathway, pathway, 0 0 0 0 1 0 0 0 8 0 JJ JJ NN IN NNP O
while while 0 0 0 0 0 0 0 0 5 0 JJ NN IN NNP CD O
AI AI 1 1 0 0 0 0 0 0 2 0 NN IN NNP CD VBD O
16 16 0 0 0 0 0 0 1 1 2 0 IN NNP CD VBD NN O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP CD VBD NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 CD VBD NN IN NN O
through through 0 0 0 0 0 0 0 0 7 0 VBD NN IN NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 NN IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNP O
caspase-8. caspase-8. 0 0 1 0 0 0 0 1 10 0 NN IN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNS VBP JJ IN O
important important 0 0 0 0 0 0 0 0 9 0 NNS VBP JJ IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBP JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN IN O
elucidation elucidation 0 0 0 0 0 0 0 0 11 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNS O
cellular cellular 0 0 0 0 0 0 0 0 8 0 IN DT JJ NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 DT JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NNP O
steroidal steroidal 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NNP IN O
AIs AIs 1 0 0 0 0 0 0 0 3 0 IN JJ NNP IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 JJ NNP IN JJ NN O
breast breast 0 0 0 0 0 0 0 0 6 0 NNP IN JJ NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNS CC O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS CC MD O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC MD RB O
will will 0 0 0 0 0 0 0 0 4 0 NNS CC MD RB VB O
also also 0 0 0 0 0 0 0 0 4 0 CC MD RB VB DT O
highlight highlight 0 0 0 0 0 0 0 0 9 0 MD RB VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VB DT NN IN O
importance importance 0 0 0 0 0 0 0 0 10 0 VB DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
AIs AIs 1 0 0 0 0 0 0 0 3 0 NN IN NNP IN NNS O
as as 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNS IN O
inducers inducers 0 0 0 0 0 0 0 0 8 0 NNP IN NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NNS IN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NN O
hormone-dependent hormone-dependent 0 0 1 0 0 0 0 0 17 0 NN IN JJ NN NNP O
breast breast 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
cancers. cancers. 0 0 0 0 0 0 0 0 8 0 JJ NN NNP NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NNP NNP O
DREAM DREAM 1 1 0 0 0 0 0 0 5 0 NONE DT NNP NNP NN O
complex: complex: 0 0 0 0 0 0 0 0 8 0 DT NNP NNP NN NN O
master master 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NN IN O
coordinator coordinator 0 0 0 0 0 0 0 0 11 0 NNP NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN JJ O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN JJ NN O
cycle-dependent cycle-dependent 0 0 1 0 0 0 0 0 15 0 IN NN JJ NN NNP O
gene gene 0 0 0 0 0 0 0 0 4 0 NN JJ NN NNP NNP O
expression. expression. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP NNP NNP O
Sadasivam Sadasivam 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Decaprio Decaprio 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
JA. JA. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNP O
Stem Stem 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP CC O
Biology Biology 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Regenerative Regenerative 1 0 0 0 0 0 0 0 12 0 NNP CC NNP NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 CC NNP NNP NNP NNP O
National National 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Centre Centre 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNPS O
Biological Biological 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNPS NNP O
Sciences Sciences 1 0 0 0 0 0 0 0 8 0 IN NNP NNPS NNP NNP O
(TIFR), (TIFR), 0 1 0 0 1 0 0 0 7 0 NNP NNPS NNP NNP NNP O
Bellary Bellary 1 0 0 0 0 0 0 0 7 0 NNPS NNP NNP NNP NNP O
Road, Road, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP CD O
Bangalore Bangalore 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP CD NNP O
560065, 560065, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP NNP O
India. India. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN -NONE- O
dimerization dimerization 0 0 0 0 0 0 0 0 12 0 NNP NNP NN -NONE- -NONE- O
partner, partner, 0 0 0 0 1 0 0 0 8 0 NNP NN -NONE- -NONE- NNP O
RB-like, RB-like, 1 0 1 0 1 0 0 0 8 0 NN -NONE- -NONE- NNP CC O
E2F E2F 1 1 0 0 0 0 0 1 3 0 -NONE- -NONE- NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NNP CC JJ NN O
multi-vulval multi-vulval 0 0 1 0 0 0 0 0 12 0 NNP CC JJ NN NNP O
class class 0 0 0 0 0 0 0 0 5 0 CC JJ NN NNP NNP O
B B 1 1 0 0 0 0 0 0 1 0 JJ NN NNP NNP NN O
(DREAM) (DREAM) 0 1 0 0 0 0 0 0 7 0 NN NNP NNP NN VBZ O
complex complex 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBZ DT O
provides provides 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ DT RB O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT RB VBN O
previously previously 0 0 0 0 0 0 0 0 10 0 VBZ DT RB VBN VBG O
unsuspected unsuspected 0 0 0 0 0 0 0 0 11 0 DT RB VBN VBG NN O
unifying unifying 0 0 0 0 0 0 0 0 8 0 RB VBN VBG NN IN O
role role 0 0 0 0 0 0 0 0 4 0 VBN VBG NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBG NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN IN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN IN RB O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN RB VBG O
directly directly 0 0 0 0 0 0 0 0 8 0 NN IN RB VBG NN O
linking linking 0 0 0 0 0 0 0 0 7 0 IN RB VBG NN -NONE- O
p130, p130, 0 0 0 0 1 0 0 1 5 0 RB VBG NN -NONE- -NONE- O
p107, p107, 0 0 0 0 1 0 0 1 5 0 VBG NN -NONE- -NONE- NNP O
E2F, E2F, 1 1 0 0 1 0 0 1 4 0 NN -NONE- -NONE- NNP CC O
BMYB BMYB 1 1 0 0 0 0 0 0 4 0 -NONE- -NONE- NNP CC VB O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NNP CC VB NN O
forkhead forkhead 0 0 0 0 0 0 0 0 8 0 NNP CC VB NN NN O
box box 0 0 0 0 0 0 0 0 3 0 CC VB NN NN NNP O
protein protein 0 0 0 0 0 0 0 0 7 0 VB NN NN NNP NNP O
M1. M1. 1 1 0 0 0 0 0 1 3 0 NN NN NNP NNP VBZ O
DREAM DREAM 1 1 0 0 0 0 0 0 5 0 NN NNP NNP VBZ NN O
mediates mediates 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ NN NN O
gene gene 0 0 0 0 0 0 0 0 4 0 NNP VBZ NN NN IN O
repression repression 0 0 0 0 0 0 0 0 10 0 VBZ NN NN IN DT O
during during 0 0 0 0 0 0 0 0 6 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
G0 G0 1 1 0 0 0 0 0 1 2 phase IN DT NNP NN CC O
phase phase 0 0 0 0 0 0 0 0 5 0 DT NNP NN CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC VBZ JJ O
coordinates coordinates 0 0 0 0 0 0 0 0 11 0 NN CC VBZ JJ NN O
periodic periodic 0 0 0 0 0 0 0 0 8 0 CC VBZ JJ NN NN O
gene gene 0 0 0 0 0 0 0 0 4 0 VBZ JJ NN NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 JJ NN NN IN NNS O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN NNS IN O
peaks peaks 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN DT O
during during 0 0 0 0 0 0 0 0 6 0 IN NNS IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNS CC O
G1/S G1/S 1 1 0 1 0 0 0 1 4 0 IN DT NNS CC JJ B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 DT NNS CC JJ NNP O
G2/M G2/M 1 1 0 1 0 0 0 1 4 0 NNS CC JJ NNP NNP B_TIMEXCCP
phases. phases. 0 0 0 0 0 0 0 0 7 0 CC JJ NNP NNP IN O
Perturbations Perturbations 1 0 0 0 0 0 0 0 13 0 JJ NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NN O
DREAM DREAM 1 1 0 0 0 0 0 0 5 0 NNP IN NNP NN NN O
complex complex 0 0 0 0 0 0 0 0 7 0 IN NNP NN NN NN O
regulation regulation 0 0 0 0 0 0 0 0 10 0 NNP NN NN NN DT O
shift shift 0 0 0 0 0 0 0 0 5 0 NN NN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NN IN O
balance balance 0 0 0 0 0 0 0 0 7 0 NN DT NN IN NN O
from from 0 0 0 0 0 0 0 0 4 0 DT NN IN NN NNS O
quiescence quiescence 0 0 0 0 0 0 0 0 10 0 NN IN NN NNS NN O
towards towards 0 0 0 0 0 0 0 0 7 0 IN NN NNS NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NN NNS NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNS NN CC NN TO O
contribute contribute 0 0 0 0 0 0 0 0 10 0 NN CC NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 CC NN TO DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT VBN JJ O
increased increased 0 0 0 0 0 0 0 0 9 0 TO DT VBN JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 DT VBN JJ NN NN O
gene gene 0 0 0 0 0 0 0 0 4 0 VBN JJ NN NN NNS O
expression expression 0 0 0 0 0 0 0 0 10 0 JJ NN NN NNS WDT O
levels levels 0 0 0 0 0 0 0 0 6 0 NN NN NNS WDT VBP O
that that 0 0 0 0 0 0 0 0 4 0 NN NNS WDT VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 NNS WDT VBP RB VBN O
frequently frequently 0 0 0 0 0 0 0 0 10 0 WDT VBP RB VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 VBP RB VBN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN NNS IN O
cancers cancers 0 0 0 0 0 0 0 0 7 0 VBN IN NNS IN DT O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ NNP O
poor poor 0 0 0 0 0 0 0 0 4 0 IN DT JJ NNP NONE O
prognosis. prognosis. 0 0 0 0 0 0 0 0 10 0 DT JJ NNP NONE NONE O
SHP1-mediated SHP1-mediated 1 0 1 0 0 0 0 1 13 0 NONE NONE JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NONE JJ NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 JJ NN NN NN NNS O
redistribution redistribution 0 0 0 0 0 0 0 0 14 0 NN NN NN NNS NN O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 NN NN NNS NN IN O
radiosensitivity radiosensitivity 0 0 0 0 0 0 0 0 16 0 NN NNS NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNS NN IN JJ NN O
non-small non-small 0 0 1 0 0 0 0 0 9 0 NN IN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN NNP O
lung lung 0 0 0 0 0 0 0 0 4 0 JJ NN NN NNP NNP O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP NNP O
Cao Cao 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ding Ding 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Q, Q, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Xue Xue 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zou Zou 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Huang Huang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Peng Peng 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
G. G. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Center Center 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Union Union 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Hospital, Hospital, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Tongji Tongji 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
College, College, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Huazhong Huazhong 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Science Science 1 0 0 0 0 0 0 0 7 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Technology, Technology, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP CD O
No, No, 1 0 0 0 1 0 0 0 3 0 CC NNP NNP CD NNP O
1227 1227 0 0 0 0 0 0 1 1 4 0 NNP NNP CD NNP NNP O
Jiefang Jiefang 1 0 0 0 0 0 0 0 7 0 NNP CD NNP NNP NNP O
Dadao, Dadao, 1 0 0 0 1 0 0 0 6 0 CD NNP NNP NNP CD O
Wuhan Wuhan 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP CD NNP O
430022, 430022, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
penggang1977@163.com. penggang1977@163.com. 0 0 0 0 0 0 0 1 21 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP VBZ O
Radioresistance Radioresistance 1 0 0 0 0 0 0 0 15 0 NNP NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT JJ NN O
common common 0 0 0 0 0 0 0 0 6 0 VBZ DT JJ NN IN O
cause cause 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN NN O
radiotherapy radiotherapy 0 0 0 0 0 0 0 0 12 0 NN IN NN NN IN O
failure failure 0 0 0 0 0 0 0 0 7 0 IN NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
non-small non-small 0 0 1 0 0 0 0 0 9 0 NN IN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN NN O
lung lung 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN NN NN NN CC O
(NSCLC), (NSCLC), 0 1 0 0 1 0 0 0 8 0 NN NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN IN O
degree degree 0 0 0 0 0 0 0 0 6 0 CC DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
radiosensitivity radiosensitivity 0 0 0 0 0 0 0 0 16 0 NN IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NNS O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NN IN NN NNS VBZ O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NN NNS VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN NNS VBZ JJ IN O
different different 0 0 0 0 0 0 0 0 9 0 NNS VBZ JJ IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 VBZ JJ IN JJ NN O
different different 0 0 0 0 0 0 0 0 9 0 JJ IN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN NNP O
cycle cycle 0 0 0 0 0 0 0 0 5 0 JJ NN NN NNP NNP O
phases. phases. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
objective objective 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
present present 0 0 0 0 0 0 0 0 7 0 IN DT NN NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 DT NN NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB DT O
investigate investigate 0 0 0 0 0 0 0 0 11 0 VBD TO VB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 VB DT NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN NN IN O
redistribution redistribution 0 0 0 0 0 0 0 0 14 0 NN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
establishment establishment 0 0 0 0 0 0 0 0 13 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
radioresistance radioresistance 0 0 0 0 0 0 0 0 15 0 NN IN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP IN O
NSCLC, NSCLC, 1 1 0 0 1 0 0 0 6 0 NN IN NNP IN RB O
as as 0 0 0 0 0 0 0 0 2 0 IN NNP IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NNP IN RB IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NN NN O
signaling signaling 0 0 0 0 0 0 0 0 9 0 IN DT NN NN IN O
pathway pathway 0 0 0 0 0 0 0 0 7 0 DT NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NN O
SH2 SH2 1 1 0 0 0 0 0 1 3 0 NN IN NNP NN NNP O
containing containing 0 0 0 0 0 0 0 0 10 0 IN NNP NN NNP NNP O
Tyrosine Tyrosine 1 0 0 0 0 0 0 0 8 0 NNP NN NNP NNP NNP O
Phosphatase Phosphatase 1 0 0 0 0 0 0 0 11 0 NN NNP NNP NNP NNP O
(SHP1). (SHP1). 0 1 0 0 0 0 0 1 7 0 NNP NNP NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NNP NN O
NSCLC NSCLC 1 1 0 0 0 0 0 0 5 0 NNP NNP NNP NN NN O
subtype subtype 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP NN NN NN NN O
line, line, 0 0 0 0 1 0 0 0 5 0 NN NN NN NN NNP O
radioresistant radioresistant 0 0 0 0 0 0 0 0 14 0 NN NN NN NNP NNP O
A549 A549 1 1 0 0 0 0 0 1 4 0 NN NN NNP NNP VBD O
(A549S1), (A549S1), 0 1 0 0 1 0 0 1 9 0 NN NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP VBD VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ VBN O
high-dose high-dose 0 0 1 0 0 0 0 0 9 0 VBN IN JJ VBN VBG O
hypofractionated hypofractionated 0 0 0 0 0 0 0 0 16 0 IN JJ VBN VBG NNP O
ionizing ionizing 0 0 0 0 0 0 0 0 8 0 JJ VBN VBG NNP JJ O
radiations. radiations. 0 0 0 0 0 0 0 0 11 0 VBN VBG NNP JJ NN O
Radiosensitivity-related Radiosensitivity-related 1 0 1 0 0 0 0 0 24 0 VBG NNP JJ NN NN O
parameters, parameters, 0 0 0 0 1 0 0 0 11 0 NNP JJ NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NN NN NN NN CC O
distribution distribution 0 0 0 0 0 0 0 0 12 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NN CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN JJ O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN JJ NNS O
cycle-related cycle-related 0 0 1 0 0 0 0 0 13 0 IN NN JJ NNS CC O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NN JJ NNS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC NNP VBD O
SHP1 SHP1 1 1 0 0 0 0 0 1 4 0 NNS CC NNP VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 CC NNP VBD NNP NNP O
investigated. investigated. 0 0 0 0 0 0 0 0 13 0 NNP VBD NNP NNP VBD O
siRNA siRNA 0 0 0 0 0 0 0 0 5 0 VBD NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN TO O
designed designed 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO JJ NNP O
down-regulate down-regulate 0 0 1 0 0 0 0 0 13 0 VBN TO JJ NNP NNP O
SHP1expression. SHP1expression. 1 0 0 0 0 0 0 1 15 0 TO JJ NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 JJ NNP NNP NNP IN O
Compared Compared 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNP IN JJ NNP O
native native 0 0 0 0 0 0 0 0 6 0 NNP IN JJ NNP NNP O
A549 A549 1 1 0 0 0 0 0 1 4 0 IN JJ NNP NNP DT O
cells, cells, 0 0 0 0 1 0 0 0 6 0 JJ NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
proportion proportion 0 0 0 0 0 0 0 0 10 0 NNP DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase IN DT NNP NN VBD O
phase phase 0 0 0 0 0 0 0 0 5 0 DT NNP NN VBD JJ O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD JJ CC O
increased, increased, 0 0 0 0 1 0 0 0 10 0 NN VBD JJ CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 VBD JJ CC NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ CC NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 CC NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase IN DT NN NN VBD B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NN NN VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD RB JJ O
consequently consequently 0 0 0 0 0 0 0 0 12 0 NN VBD RB JJ NN O
decreased, decreased, 0 0 0 0 1 0 0 0 10 0 VBD RB JJ NN DT O
however, however, 0 0 0 0 1 0 0 0 8 0 RB JJ NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NN IN O
proportion proportion 0 0 0 0 0 0 0 0 10 0 NN DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 phase IN DT NN NN VBD B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NN NN VBD RB O
did did 0 0 0 0 0 0 0 0 3 0 NN NN VBD RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NN VBD RB VB IN O
change change 0 0 0 0 0 0 0 0 6 0 VBD RB VB IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 RB VB IN NNP NNP O
A549S1 A549S1 1 1 0 0 0 0 0 1 6 0 VB IN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP DT O
Moreover, Moreover, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
SHP1, SHP1, 1 1 0 0 1 0 0 1 5 0 NN IN NNP NNP CC O
CDK4 CDK4 1 1 0 0 0 0 0 1 4 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP VBD O
CylinD1 CylinD1 1 0 0 0 0 0 0 1 7 0 NNP CC NNP VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 CC NNP VBD RB JJ O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNP VBD RB JJ IN O
increased, increased, 0 0 0 0 1 0 0 0 10 0 VBD RB JJ IN NNP O
while while 0 0 0 0 0 0 0 0 5 0 RB JJ IN NNP VBD O
p16 p16 0 0 0 0 0 0 0 1 3 0 JJ IN NNP VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 IN NNP VBD RB JJ O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNP VBD RB JJ IN O
down-regulated down-regulated 0 0 1 0 0 0 0 0 14 0 VBD RB JJ IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 RB JJ IN NNP NNS O
A549S1 A549S1 1 1 0 0 0 0 0 1 6 0 JJ IN NNP NNS VBN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS VBN IN O
compared compared 0 0 0 0 0 0 0 0 8 0 NNP NNS VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBN IN JJ NNP O
native native 0 0 0 0 0 0 0 0 6 0 VBN IN JJ NNP NNP O
A549 A549 1 1 0 0 0 0 0 1 4 0 IN JJ NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 JJ NNP NNP NNP NN O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 NNP NNP NNP NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP IN O
SHP1 SHP1 1 1 0 0 0 0 0 1 4 0 NN IN NNP IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP VBD O
siRNA siRNA 0 0 0 0 0 0 0 0 5 0 NNP IN NNP VBD DT O
increased increased 0 0 0 0 0 0 0 0 9 0 IN NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN IN O
radiosensitivity radiosensitivity 0 0 0 0 0 0 0 0 16 0 VBD DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
A549S1 A549S1 1 1 0 0 0 0 0 1 6 0 NN IN NNP NNP VBD O
cells, cells, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP VBD DT O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBD DT NN NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase VBD DT NN NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NN NN NN JJ O
arrest, arrest, 0 0 0 0 1 0 0 0 7 0 NN NN NN JJ NNP O
down-regulated down-regulated 0 0 1 0 0 0 0 0 14 0 NN NN JJ NNP CC O
CDK4 CDK4 1 1 0 0 0 0 0 1 4 0 NN JJ NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNP CC NNP CC O
CylinD1expressions, CylinD1expressions, 1 0 0 0 1 0 0 1 19 0 NNP CC NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC JJ NNP O
up-regulated up-regulated 0 0 1 0 0 0 0 0 12 0 NNP CC JJ NNP NNP O
p16 p16 0 0 0 0 0 0 0 1 3 0 CC JJ NNP NNP NNP O
expression. expression. 0 0 0 0 0 0 0 0 11 0 JJ NNP NNP NNP NNP O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 NNP NNP NNP NNP VBZ O
SHP1 SHP1 1 1 0 0 0 0 0 1 4 0 NNP NNP NNP VBZ DT O
decreases decreases 0 0 0 0 0 0 0 0 9 0 NNP NNP VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT NN IN O
radiosensitivity radiosensitivity 0 0 0 0 0 0 0 0 16 0 VBZ DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNS O
NSCLC NSCLC 1 1 0 0 0 0 0 0 5 0 NN IN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS IN VBG O
through through 0 0 0 0 0 0 0 0 7 0 NNP NNS IN VBG NN O
affecting affecting 0 0 0 0 0 0 0 0 9 0 NNS IN VBG NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN VBG NN NN NNP O
cycle cycle 0 0 0 0 0 0 0 0 5 0 VBG NN NN NNP NNP O
distribution. distribution. 0 0 0 0 0 0 0 0 13 0 NN NN NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NN MD O
finding finding 0 0 0 0 0 0 0 0 7 0 NNP NNP NN MD VB O
could could 0 0 0 0 0 0 0 0 5 0 NNP NN MD VB DT O
unravel unravel 0 0 0 0 0 0 0 0 7 0 NN MD VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 VB DT JJ NN VBN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 DT JJ NN VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 JJ NN VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN VBN IN NNP NNP O
NSCLC NSCLC 1 1 0 0 0 0 0 0 5 0 VBN IN NNP NNP NONE O
radioresistance. radioresistance. 0 0 0 0 0 0 0 0 16 0 IN NNP NNP NONE NONE O
Combination Combination 1 0 0 0 0 0 0 0 11 0 NONE NONE NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NNP CC O
Rituximab Rituximab 1 0 0 0 0 0 0 0 9 0 NN IN NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP CC DT NNP NN O
mTOR mTOR 0 0 0 0 0 0 0 0 4 0 CC DT NNP NN NNP O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 DT NNP NN NNP NNP O
Everolimus Everolimus 1 0 0 0 0 0 0 0 10 0 NNP NN NNP NNP IN O
(RAD001) (RAD001) 0 1 0 0 0 0 0 1 8 0 NN NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP JJ O
Diffuse Diffuse 1 0 0 0 0 0 0 0 7 0 NNP IN NNP JJ NNP O
large large 0 0 0 0 0 0 0 0 5 0 IN NNP JJ NNP NN O
B B 1 1 0 0 0 0 0 0 1 0 NNP JJ NNP NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NNP NN NNP NNP O
lymphoma. lymphoma. 0 0 0 0 0 0 0 0 9 0 NNP NN NNP NNP NNP O
Xu Xu 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NNP NNP O
ZZ, ZZ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
WF, WF, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Fu Fu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
WB, WB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
AH, AH, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Liu Liu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
ZY, ZY, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
LY, LY, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Guo Guo 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
JM. JM. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
ABSTRACT ABSTRACT 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBD DT O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 VBD DT NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP JJ O
anti-CD20 anti-CD20 0 0 1 0 0 0 0 1 9 0 IN DT NNP JJ NN O
monoclonal monoclonal 0 0 0 0 0 0 0 0 10 0 DT NNP JJ NN NN O
antibody antibody 0 0 0 0 0 0 0 0 8 0 NNP JJ NN NN IN O
rituximab rituximab 0 0 0 0 0 0 0 0 9 0 JJ NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN IN O
combination combination 0 0 0 0 0 0 0 0 11 0 NN IN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN IN O
target target 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
mTOR mTOR 0 0 0 0 0 0 0 0 4 0 NN IN NNP NN VBZ O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 IN NNP NN VBZ IN O
everolimus everolimus 0 0 0 0 0 0 0 0 10 0 NNP NN VBZ IN VBG O
for for 0 0 0 0 0 0 0 0 3 0 NN VBZ IN VBG NN O
treating treating 0 0 0 0 0 0 0 0 8 0 VBZ IN VBG NN JJ O
diffuse diffuse 0 0 0 0 0 0 0 0 7 0 IN VBG NN JJ NNP O
large large 0 0 0 0 0 0 0 0 5 0 VBG NN JJ NNP NN O
B B 1 1 0 0 0 0 0 0 1 0 NN JJ NNP NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NNP NN NN NNP O
lymphoma lymphoma 0 0 0 0 0 0 0 0 8 0 NNP NN NN NNP NNP O
(DLBCL). (DLBCL). 0 1 0 0 0 0 0 0 8 0 NN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
combination combination 0 0 0 0 0 0 0 0 11 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN CC O
rituximab rituximab 0 0 0 0 0 0 0 0 9 0 NN IN NN CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VBZ VBD O
everolimus everolimus 0 0 0 0 0 0 0 0 10 0 NN CC VBZ VBD JJR O
was was 0 0 0 0 0 0 0 0 3 0 CC VBZ VBD JJR JJ O
more more 0 0 0 0 0 0 0 0 4 0 VBZ VBD JJR JJ IN O
effective effective 0 0 0 0 0 0 0 0 9 0 VBD JJR JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJR JJ IN NN NN O
inhibiting inhibiting 0 0 0 0 0 0 0 0 10 0 JJ IN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN NN NN NN VBN O
growth growth 0 0 0 0 0 0 0 0 6 0 NN NN NN VBN IN O
compared compared 0 0 0 0 0 0 0 0 8 0 NN NN VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NNP O
single-agent single-agent 0 0 1 0 0 0 0 0 12 0 IN DT JJ NNP NNP O
therapy. therapy. 0 0 0 0 0 0 0 0 8 0 DT JJ NNP NNP NN O
An An 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NN IN NN NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 IN NN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest NN NN NN NN CC O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT VBN O
an an 0 0 0 0 0 0 0 0 2 0 NN CC DT VBN NN O
increased increased 0 0 0 0 0 0 0 0 9 0 CC DT VBN NN IN O
population population 0 0 0 0 0 0 0 0 10 0 DT VBN NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN NN VBD O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NNS IN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 IN NN VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NN O
combination combination 0 0 0 0 0 0 0 0 11 0 IN DT NN NN NNP O
treatment treatment 0 0 0 0 0 0 0 0 9 0 DT NN NN NNP NNP O
group. group. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP IN O
Addition Addition 1 0 0 0 0 0 0 0 8 0 NN NNP NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN VBN O
rituximab rituximab 0 0 0 0 0 0 0 0 9 0 NNP IN NN VBN DT O
reduced reduced 0 0 0 0 0 0 0 0 7 0 IN NN VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBN DT NN IN O
overexpression overexpression 0 0 0 0 0 0 0 0 14 0 VBN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ VBN O
p-AKT p-AKT 0 0 1 0 0 0 0 0 5 0 NN IN JJ VBN IN O
caused caused 0 0 0 0 0 0 0 0 6 0 IN JJ VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 JJ VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
negative negative 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN NN O
feedback feedback 0 0 0 0 0 0 0 0 8 0 DT JJ NN NN IN O
loop loop 0 0 0 0 0 0 0 0 4 0 JJ NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN CC O
everolimus everolimus 0 0 0 0 0 0 0 0 10 0 NN IN NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VBD DT O
had had 0 0 0 0 0 0 0 0 3 0 NN CC VBD DT VBN O
an an 0 0 0 0 0 0 0 0 2 0 CC VBD DT VBN NN O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 VBD DT VBN NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 DT VBN NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 VBN NN IN NN NNP O
inhibiting inhibiting 0 0 0 0 0 0 0 0 10 0 NN IN NN NNP NNP O
mTOR mTOR 0 0 0 0 0 0 0 0 4 0 IN NN NNP NNP RB O
signaling, signaling, 0 0 0 0 1 0 0 0 10 0 NN NNP NNP RB VBG O
thus thus 0 0 0 0 0 0 0 0 4 0 NNP NNP RB VBG DT O
providing providing 0 0 0 0 0 0 0 0 9 0 NNP RB VBG DT NN O
a a 0 0 0 0 0 0 0 0 1 0 RB VBG DT NN IN O
rationale rationale 0 0 0 0 0 0 0 0 9 0 VBG DT NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN DT JJ O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT JJ NNP O
synergistic synergistic 0 0 0 0 0 0 0 0 11 0 IN DT JJ NNP NNP O
effect. effect. 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NNP NN O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 JJ NNP NNP NN NN O
combination combination 0 0 0 0 0 0 0 0 11 0 NNP NNP NN NN VBD O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NNP NN NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD RB RBR O
also also 0 0 0 0 0 0 0 0 4 0 NN VBD RB RBR JJ O
more more 0 0 0 0 0 0 0 0 4 0 VBD RB RBR JJ IN O
effective effective 0 0 0 0 0 0 0 0 9 0 RB RBR JJ IN NN O
than than 0 0 0 0 0 0 0 0 4 0 RBR JJ IN NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 JJ IN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN DT NN O
either either 0 0 0 0 0 0 0 0 6 0 NN IN DT NN NN O
agent agent 0 0 0 0 0 0 0 0 5 0 IN DT NN NN IN O
alone alone 0 0 0 0 0 0 0 0 5 0 DT NN NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NN DT O
inhibiting inhibiting 0 0 0 0 0 0 0 0 10 0 NN IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 NN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
DLBCL DLBCL 1 1 0 0 0 0 0 0 5 0 NN IN NNP NNP NNP O
xenografts. xenografts. 0 0 0 0 0 0 0 0 11 0 IN NNP NNP NNP NN O
Our Our 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD JJ O
provided provided 0 0 0 0 0 0 0 0 8 0 NNP NN VBD JJ NN O
preclinical preclinical 0 0 0 0 0 0 0 0 11 0 NN VBD JJ NN CC O
evidence evidence 0 0 0 0 0 0 0 0 8 0 VBD JJ NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN CC DT JJ NN O
theoretical theoretical 0 0 0 0 0 0 0 0 11 0 CC DT JJ NN IN O
basis basis 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN NN O
combination combination 0 0 0 0 0 0 0 0 11 0 NN IN NN NN IN O
therapy therapy 0 0 0 0 0 0 0 0 7 0 IN NN NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NNP IN O
DLBCL DLBCL 1 1 0 0 0 0 0 0 5 0 NN IN NNP IN NN O
with with 0 0 0 0 0 0 0 0 4 0 IN NNP IN NN CC O
rituximab rituximab 0 0 0 0 0 0 0 0 9 0 NNP IN NN CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VBZ IN O
everolimus everolimus 0 0 0 0 0 0 0 0 10 0 NN CC VBZ IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CC VBZ IN NNP NONE O
DLBCL. DLBCL. 1 1 0 0 0 0 0 0 6 0 VBZ IN NNP NONE NONE O
Antiproliferative Antiproliferative 1 0 0 0 0 0 0 0 17 0 NONE NONE JJ NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 NONE JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
γ-secretase γ-secretase 0 0 1 0 0 0 0 0 11 0 NNS IN JJ NN DT O
inhibitor, inhibitor, 0 0 0 0 1 0 0 0 10 0 IN JJ NN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 JJ NN DT NNP NN O
Notch Notch 1 0 0 0 0 0 0 0 5 0 NN DT NNP NN -NONE- O
signalling signalling 0 0 0 0 0 0 0 0 10 0 DT NNP NN -NONE- IN O
inhibitor, inhibitor, 0 0 0 0 1 0 0 0 10 0 NNP NN -NONE- IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN -NONE- IN NN NN O
multiple multiple 0 0 0 0 0 0 0 0 8 0 -NONE- IN NN NN NNS O
myeloma myeloma 0 0 0 0 0 0 0 0 7 0 IN NN NN NNS CC O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC PRP$ JJ O
its its 0 0 0 0 0 0 0 0 3 0 NNS CC PRP$ JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 CC PRP$ JJ NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 PRP$ JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
action. action. 0 0 0 0 0 0 0 0 7 0 NN IN NNP NNP NNP O
Hu Hu 1 0 0 0 0 0 0 0 2 0 IN NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhu Zhu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lu Lu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Q. Q. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Haematology, Haematology, 1 0 0 0 1 0 0 0 12 0 NNP IN NNP NNP NNP O
First First 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP IN O
Hospital Hospital 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Quanzhou Quanzhou 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP TO O
Affiliated Affiliated 1 0 0 0 0 0 0 0 10 0 IN NNP NNP TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNP NNP TO NNP NNP O
Fujian Fujian 1 0 0 0 0 0 0 0 6 0 NNP TO NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 TO NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Quanzhou, Quanzhou, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
OBJECTIVES: OBJECTIVES: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP VB O
To To 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VB DT O
investigate investigate 0 0 0 0 0 0 0 0 11 0 NNP NNP VB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP VB DT NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 VB DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NN O
γ-secretase γ-secretase 0 0 1 0 0 0 0 0 11 0 NNS IN JJ NN NN O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 IN JJ NN NN DT O
(GSI), (GSI), 0 1 0 0 1 0 0 0 6 0 JJ NN NN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NN NN DT NNP NN O
Notch Notch 1 0 0 0 0 0 0 0 5 0 NN DT NNP NN -NONE- O
signalling signalling 0 0 0 0 0 0 0 0 10 0 DT NNP NN -NONE- IN O
inhibitor, inhibitor, 0 0 0 0 1 0 0 0 10 0 NNP NN -NONE- IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NN -NONE- IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- IN DT NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
multiple multiple 0 0 0 0 0 0 0 0 8 0 NN IN NN NN NNS O
myeloma myeloma 0 0 0 0 0 0 0 0 7 0 IN NN NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN CC O
vitro vitro 0 0 0 0 0 0 0 0 5 0 NNS IN NN CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC PRP$ JJ O
its its 0 0 0 0 0 0 0 0 3 0 NN CC PRP$ JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 CC PRP$ JJ NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 PRP$ JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
action. action. 0 0 0 0 0 0 0 0 7 0 NN IN NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 IN NNP NNP NNP CD O
RPMI RPMI 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP CD NNS O
8226 8226 0 0 0 0 0 0 1 1 4 0 NNP NNP CD NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP CD NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 CD NNS VBD VBN IN O
treated treated 0 0 0 0 0 0 0 0 7 0 NNS VBD VBN IN VBG O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN VBG NNS O
increasing increasing 0 0 0 0 0 0 0 0 10 0 VBN IN VBG NNS IN O
concentrations concentrations 0 0 0 0 0 0 0 0 14 0 IN VBG NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBG NNS IN NNP NNP O
GSI GSI 1 1 0 0 0 0 0 0 3 0 NNS IN NNP NNP NNP O
(0-20 (0-20 0 0 1 0 0 0 0 1 5 0 IN NNP NNP NNP IN O
µmol/l) µmol/l) 0 0 0 1 0 0 0 0 7 0 NNP NNP NNP IN CD O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN CD NNP O
24-72 24-72 0 0 1 0 0 0 0 1 5 0 NNP IN CD NNP NNP O
h. h. 0 0 0 0 0 0 0 0 2 0 IN CD NNP NNP VBD O
Proliferation Proliferation 1 0 0 0 0 0 0 0 13 0 CD NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN VBG O
measured measured 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 VBD VBN VBG DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN VBG DT JJ NN O
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide 0 0 1 0 1 0 0 1 59 0 VBG DT JJ NN NNP O
(MTT) (MTT) 0 1 0 0 0 0 0 0 5 0 DT JJ NN NNP NNP O
assay. assay. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP NN O
Cell-cycle Cell-cycle 1 0 1 0 0 0 0 0 10 0 NN NNP NNP NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
performed performed 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP CD O
RPMI RPMI 1 1 0 0 0 0 0 0 4 0 VBN IN NNP CD NNS O
8226 8226 0 0 0 0 0 0 1 1 4 0 IN NNP CD NNS VBN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP CD NNS VBN IN O
treated treated 0 0 0 0 0 0 0 0 7 0 CD NNS VBN IN CD O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBN IN CD JJ O
0-10 0-10 0 0 1 0 0 0 0 1 4 0 VBN IN CD JJ NNP O
µmol/l µmol/l 0 0 0 1 0 0 0 0 6 0 IN CD JJ NNP IN O
GSI GSI 1 1 0 0 0 0 0 0 3 0 CD JJ NNP IN CD O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNP IN CD NN O
48 48 0 0 0 0 0 0 1 1 2 0 NNP IN CD NN VBG O
h h 0 0 0 0 0 0 0 0 1 0 IN CD NN VBG NN O
using using 0 0 0 0 0 0 0 0 5 0 CD NN VBG NN NNP O
flow flow 0 0 0 0 0 0 0 0 4 0 NN VBG NN NNP NNP O
cytometry. cytometry. 0 0 0 0 0 0 0 0 10 0 VBG NN NNP NNP IN O
Expression Expression 1 0 0 0 0 0 0 0 10 0 NN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NN O
Notch Notch 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NN NNS O
signalling signalling 0 0 0 0 0 0 0 0 10 0 IN NNP NN NNS -NONE- O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NNP NN NNS -NONE- NNP O
(Notch1, (Notch1, 0 0 0 0 1 0 0 1 8 0 NN NNS -NONE- NNP CD O
Jagged Jagged 1 0 0 0 0 0 0 0 6 0 NNS -NONE- NNP CD CC O
1 1 0 0 0 0 0 0 1 1 1 0 -NONE- NNP CD CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP CD CC NNP CD O
Jagged Jagged 1 0 0 0 0 0 0 0 6 0 CD CC NNP CD -NONE- O
2), 2), 0 0 0 0 1 0 0 1 3 0 CC NNP CD -NONE- CC O
Bcl-2 Bcl-2 1 0 1 0 0 0 0 1 5 0 NNP CD -NONE- CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 CD -NONE- CC VBD NNP O
phosphorylated phosphorylated 0 0 0 0 0 0 0 0 14 0 -NONE- CC VBD NNP NNP O
Akt Akt 1 0 0 0 0 0 0 0 3 0 CC VBD NNP NNP VBD O
(p-Akt) (p-Akt) 0 0 1 0 0 0 0 0 7 0 VBD NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN VBG O
determined determined 0 0 0 0 0 0 0 0 10 0 NNP VBD VBN VBG NNP O
using using 0 0 0 0 0 0 0 0 5 0 VBD VBN VBG NNP NN O
Western Western 1 0 0 0 0 0 0 0 7 0 VBN VBG NNP NN IN O
blotting blotting 0 0 0 0 0 0 0 0 8 0 VBG NNP NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP CD O
RPMI RPMI 1 1 0 0 0 0 0 0 4 0 NN IN NNP CD NNS O
8226 8226 0 0 0 0 0 0 1 1 4 0 IN NNP CD NNS VBN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP CD NNS VBN IN O
treated treated 0 0 0 0 0 0 0 0 7 0 CD NNS VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBN IN JJ NNS O
various various 0 0 0 0 0 0 0 0 7 0 VBN IN JJ NNS IN O
concentrations concentrations 0 0 0 0 0 0 0 0 14 0 IN JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP IN O
GSI GSI 1 1 0 0 0 0 0 0 3 0 NNS IN NNP IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 IN NNP IN JJ NN O
various various 0 0 0 0 0 0 0 0 7 0 NNP IN JJ NN NNP O
time time 0 0 0 0 0 0 0 0 4 0 IN JJ NN NNP NNP O
periods. periods. 0 0 0 0 0 0 0 0 8 0 JJ NN NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 NN NNP NNP NNP VBD O
GSI GSI 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP VBD NN O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NNP VBD NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN NNP CD O
RPMI RPMI 1 1 0 0 0 0 0 0 4 0 NN IN NNP CD NNS O
8226 8226 0 0 0 0 0 0 1 1 4 0 IN NNP CD NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP CD NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 CD NNS IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT NN CC O
concentration- concentration- 0 0 1 0 0 0 0 0 14 0 IN DT NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC JJ NN O
time-dependent time-dependent 0 0 1 0 0 0 0 0 14 0 NN CC JJ NN IN O
manner manner 0 0 0 0 0 0 0 0 6 0 CC JJ NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN -NONE- O
inducing inducing 0 0 0 0 0 0 0 0 8 0 NN IN NN -NONE- JJ O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 IN NN -NONE- JJ NNP O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 0 NN -NONE- JJ NNP JJ O
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 -NONE- JJ NNP JJ JJ O
GSI-mediated GSI-mediated 1 0 1 0 0 0 0 0 12 0 JJ NNP JJ JJ NNS O
antiproliferative antiproliferative 0 0 0 0 0 0 0 0 17 0 NNP JJ JJ NNS VBD O
effects effects 0 0 0 0 0 0 0 0 7 0 JJ JJ NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NNS VBD VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN JJ NNS O
significant significant 0 0 0 0 0 0 0 0 11 0 VBN IN JJ NNS IN O
reductions reductions 0 0 0 0 0 0 0 0 10 0 IN JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
Notch1, Notch1, 1 0 0 0 1 0 0 1 7 0 NN IN NNP NNP NNP O
Jagged1, Jagged1, 1 0 0 0 1 0 0 1 8 0 IN NNP NNP NNP NNP O
Jagged2, Jagged2, 1 0 0 0 1 0 0 1 8 0 NNP NNP NNP NNP CC O
p-Akt p-Akt 0 0 1 0 0 0 0 0 5 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Bcl-2. Bcl-2. 1 0 1 0 0 0 0 1 6 0 NNP CC NNP NNP NNP O
CONCLUSION: CONCLUSION: 1 1 0 0 0 0 0 0 11 0 CC NNP NNP NNP IN O
Inhibition Inhibition 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP NN O
Notch Notch 1 0 0 0 0 0 0 0 5 0 IN DT NNP NN NN O
signalling signalling 0 0 0 0 0 0 0 0 10 0 DT NNP NN NN IN O
pathway pathway 0 0 0 0 0 0 0 0 7 0 NNP NN NN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP MD O
GSI GSI 1 1 0 0 0 0 0 0 3 0 NN IN NNP MD VB O
may may 0 0 0 0 0 0 0 0 3 0 IN NNP MD VB DT O
be be 0 0 0 0 0 0 0 0 2 0 NNP MD VB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT NN JJ O
promising promising 0 0 0 0 0 0 0 0 9 0 VB DT NN JJ NN O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 DT NN JJ NN IN O
approach approach 0 0 0 0 0 0 0 0 8 0 NN JJ NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNP O
multiple multiple 0 0 0 0 0 0 0 0 8 0 NN IN NN NNP NONE O
myeloma. myeloma. 0 0 0 0 0 0 0 0 8 0 IN NN NNP NONE NONE O
proNGF proNGF 0 0 0 0 0 0 0 0 6 0 NONE NONE NNP VBZ NN O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 NONE NNP VBZ NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NNP VBZ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VBZ NN CC NN IN O
oligodendrogenesis oligodendrogenesis 0 0 0 0 0 0 0 0 18 0 NN CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ JJ O
postnatal postnatal 0 0 0 0 0 0 0 0 9 0 NN IN JJ JJ JJ O
hippocampal hippocampal 0 0 0 0 0 0 0 0 11 0 IN JJ JJ JJ NN O
neural neural 0 0 0 0 0 0 0 0 6 0 JJ JJ JJ NN NNS O
stem/progenitor stem/progenitor 0 0 0 1 0 0 0 0 15 0 JJ JJ NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN NNP O
through through 0 0 0 0 0 0 0 0 7 0 NN NNS IN NNP IN O
p75NTR p75NTR 0 0 0 0 0 0 0 1 6 0 NNS IN NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NNP O
vitro. vitro. 0 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNP O
Guo Guo 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Liang Liang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yan Yan 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Liu Liu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Jiang Jiang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhou Zhou 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Liao Liao 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
H. H. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Neurobiology Neurobiology 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
Laboratory, Laboratory, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Jiangsu Jiangsu 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP IN O
Center Center 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNP O
Drug Drug 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP NNP O
Screening, Screening, 1 0 0 0 1 0 0 0 10 0 IN NNP NNP NNP NNP O
China China 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Pharmaceutical Pharmaceutical 1 0 0 0 0 0 0 0 14 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP CD O
Nanjing Nanjing 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP CD NNP O
210009, 210009, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NNP O
Neural Neural 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP VBZ O
stem/progenitor stem/progenitor 0 0 0 1 0 0 0 0 15 0 NNP NNP NNP VBZ JJ O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ JJ NN O
(NSCs) (NSCs) 0 0 0 0 0 0 0 0 6 0 NNP VBZ JJ NN CC O
proliferate proliferate 0 0 0 0 0 0 0 0 11 0 VBZ JJ NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VB IN O
differentiate differentiate 0 0 0 0 0 0 0 0 13 0 NN CC VB IN JJ O
under under 0 0 0 0 0 0 0 0 5 0 CC VB IN JJ NN O
tight tight 0 0 0 0 0 0 0 0 5 0 VB IN JJ NN IN O
regulation regulation 0 0 0 0 0 0 0 0 10 0 IN JJ NN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNS O
various various 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNS IN O
factors factors 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
stem stem 0 0 0 0 0 0 0 0 4 0 IN DT NN NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 DT NN NN NNP NNP O
niche. niche. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP NNS O
Recent Recent 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NNS VBP O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP VBN IN O
shown shown 0 0 0 0 0 0 0 0 5 0 NNS VBP VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 VBP VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
precursor precursor 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
nerve nerve 0 0 0 0 0 0 0 0 5 0 NN IN NN NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 IN NN NN NN NN O
factor factor 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NN O
(NGF), (NGF), 0 1 0 0 1 0 0 0 6 0 NN NN NN NN NNS O
proNGF, proNGF, 0 0 0 0 1 0 0 0 7 0 NN NN NN NNS IN O
abounds abounds 0 0 0 0 0 0 0 0 7 0 NN NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ JJ O
central central 0 0 0 0 0 0 0 0 7 0 IN DT JJ JJ NN O
nervous nervous 0 0 0 0 0 0 0 0 7 0 DT JJ JJ NN NN O
system system 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NN CC O
(CNS) (CNS) 0 1 0 0 0 0 0 0 5 0 JJ NN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC IN PRP$ O
that that 0 0 0 0 0 0 0 0 4 0 NN CC IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 CC IN PRP$ NN NN O
expression expression 0 0 0 0 0 0 0 0 10 0 IN PRP$ NN NN IN O
level level 0 0 0 0 0 0 0 0 5 0 PRP$ NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBZ O
brain brain 0 0 0 0 0 0 0 0 5 0 IN DT NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ RB VBN O
substantially substantially 0 0 0 0 0 0 0 0 13 0 NN VBZ RB VBN IN O
elevated elevated 0 0 0 0 0 0 0 0 8 0 VBZ RB VBN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN NN IN O
aging aging 0 0 0 0 0 0 0 0 5 0 VBN IN NN IN RB O
as as 0 0 0 0 0 0 0 0 2 0 IN NN IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NN IN RB IN IN O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 RB IN IN JJ NNS O
several several 0 0 0 0 0 0 0 0 7 0 IN IN JJ NNS IN O
types types 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NNP O
CNS CNS 1 1 0 0 0 0 0 0 3 0 NNS IN NNP NNP NNP O
disorders. disorders. 0 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 NNP DT NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBD IN O
found found 0 0 0 0 0 0 0 0 5 0 NN PRP VBD IN DT O
for for 0 0 0 0 0 0 0 0 3 0 PRP VBD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN WDT O
time time 0 0 0 0 0 0 0 0 4 0 DT JJ NN WDT NNP O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT NNP VBD O
proNGF proNGF 0 0 0 0 0 0 0 0 6 0 NN WDT NNP VBD DT O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 WDT NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VBD DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP VBD O
NSCs NSCs 1 0 0 0 0 0 0 0 4 0 NN IN NNP VBD IN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 IN NNP VBD IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NNP VBD IN JJ NN O
postnatal postnatal 0 0 0 0 0 0 0 0 9 0 VBD IN JJ NN NN O
mouse mouse 0 0 0 0 0 0 0 0 5 0 IN JJ NN NN CC O
hippocampus hippocampus 0 0 0 0 0 0 0 0 11 0 JJ NN NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBD NN O
caused caused 0 0 0 0 0 0 0 0 6 0 NN CC VBD NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 CC VBD NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest VBD NN NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase IN DT NN NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NN NN IN VBG O
without without 0 0 0 0 0 0 0 0 7 0 NN NN IN VBG NNP O
affecting affecting 0 0 0 0 0 0 0 0 9 0 NN IN VBG NNP NNP O
apoptosis. apoptosis. 0 0 0 0 0 0 0 0 10 0 IN VBG NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 VBG NNP NNP NNP NNP O
addition, addition, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP VBD O
proNGF proNGF 0 0 0 0 0 0 0 0 6 0 NNP NNP NNP VBD DT O
reduced reduced 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN IN O
differentiation differentiation 0 0 0 0 0 0 0 0 15 0 VBD DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP TO O
NSCs NSCs 1 0 0 0 0 0 0 0 4 0 NN IN NNP TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 IN NNP TO NNP DT O
oligodendrocytes. oligodendrocytes. 0 0 0 0 0 0 0 0 17 0 NNP TO NNP DT NNS O
The The 1 0 0 0 0 0 0 0 3 0 TO NNP DT NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 NNP DT NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NNP VBD O
proNGF proNGF 0 0 0 0 0 0 0 0 6 0 NNS IN NNP VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 IN NNP VBD VBN IN O
blocked blocked 0 0 0 0 0 0 0 0 7 0 NNP VBD VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NN O
fusion fusion 0 0 0 0 0 0 0 0 6 0 IN DT NN NN IN O
protein protein 0 0 0 0 0 0 0 0 7 0 DT NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP IN O
p75 p75 0 0 0 0 0 0 0 1 3 0 NN IN NNP IN NN O
neurotrophin neurotrophin 0 0 0 0 0 0 0 0 12 0 IN NNP IN NN NN O
receptor receptor 0 0 0 0 0 0 0 0 8 0 NNP IN NN NN NN O
extracellular extracellular 0 0 0 0 0 0 0 0 13 0 IN NN NN NN CC O
domain domain 0 0 0 0 0 0 0 0 6 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NNP O
human human 0 0 0 0 0 0 0 0 5 0 NN CC NN NNP NNP O
IgG IgG 1 0 0 0 0 0 0 0 3 0 CC NN NNP NNP NN O
Fc Fc 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NN -NONE- O
fragment fragment 0 0 0 0 0 0 0 0 8 0 NNP NNP NN -NONE- CC O
(p75NTR/Fc), (p75NTR/Fc), 0 0 0 1 1 0 0 1 12 0 NNP NN -NONE- CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 -NONE- CC IN NNP NNP O
p75NTR p75NTR 0 0 0 0 0 0 0 1 6 0 CC IN NNP NNP NN O
knockout, knockout, 0 0 0 0 1 0 0 0 9 0 IN NNP NNP NN WDT O
suggesting suggesting 0 0 0 0 0 0 0 0 10 0 NNP NNP NN WDT -NONE- O
that that 0 0 0 0 0 0 0 0 4 0 NNP NN WDT -NONE- NN O
proNGF/p75NTR proNGF/p75NTR 0 0 0 1 0 0 0 1 13 0 NN WDT -NONE- NN VBD O
interaction interaction 0 0 0 0 0 0 0 0 11 0 WDT -NONE- NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 -NONE- NN VBD VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 IN DT NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NNP IN O
proNGF proNGF 0 0 0 0 0 0 0 0 6 0 NNS IN NNP IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NN O
NSC NSC 1 1 0 0 0 0 0 0 3 0 NNP IN NNP NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 IN NNP NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NNP NNP O
differentiation. differentiation. 0 0 0 0 0 0 0 0 16 0 NN CC NNP NNP VBD O
proNGF proNGF 0 0 0 0 0 0 0 0 6 0 CC NNP NNP VBD DT O
decreased decreased 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN NN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 VBD DT NN NN IN O
level level 0 0 0 0 0 0 0 0 5 0 DT NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
extracellular extracellular 0 0 0 0 0 0 0 0 13 0 NN IN JJ NN NN O
signal signal 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN NN O
responsive responsive 0 0 0 0 0 0 0 0 10 0 JJ NN NN NN CD O
kinase kinase 0 0 0 0 0 0 0 0 6 0 NN NN NN CD NN O
1/2 1/2 0 0 0 1 0 0 0 1 3 0 NN NN CD NN CD O
(ERK (ERK 0 1 0 0 0 0 0 0 4 0 NN CD NN CD IN O
1/2) 1/2) 0 0 0 1 0 0 0 1 4 0 CD NN CD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN CD IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 CD IN DT JJ NN O
p75NTR-dependent p75NTR-dependent 0 0 1 0 0 0 0 1 16 0 IN DT JJ NN IN O
manner manner 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN DT O
under under 0 0 0 0 0 0 0 0 5 0 JJ NN IN DT JJ O
both both 0 0 0 0 0 0 0 0 4 0 NN IN DT JJ CC O
self-renewal self-renewal 0 0 1 0 0 0 0 0 12 0 IN DT JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC NN NNP O
differentiation differentiation 0 0 0 0 0 0 0 0 15 0 JJ CC NN NNP NNP O
conditions. conditions. 0 0 0 0 0 0 0 0 11 0 CC NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP CD O
ERK ERK 1 1 0 0 0 0 0 0 3 0 NN IN NNP CD NN O
1/2 1/2 0 0 0 1 0 0 0 1 3 0 IN NNP CD NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 NNP CD NN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 CD NN IN NNP RB O
U0126 U0126 1 1 0 0 0 0 0 1 5 0 NN IN NNP RB VBD O
significantly significantly 0 0 0 0 0 0 0 0 13 0 IN NNP RB VBD DT O
reduced reduced 0 0 0 0 0 0 0 0 7 0 NNP RB VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBD DT NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VBD DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
oligodendrogenesis oligodendrogenesis 0 0 0 0 0 0 0 0 18 0 NN CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NN O
NSCs, NSCs, 1 0 0 0 1 0 0 0 5 0 NN IN NNP NN WDT O
indicating indicating 0 0 0 0 0 0 0 0 10 0 IN NNP NN WDT NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNP NN WDT NNP CD O
ERK ERK 1 1 0 0 0 0 0 0 3 0 NN WDT NNP CD NN O
1/2 1/2 0 0 0 1 0 0 0 1 3 0 WDT NNP CD NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 NNP CD NN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 CD NN IN NNP RB O
proNGF proNGF 0 0 0 0 0 0 0 0 6 0 NN IN NNP RB VBZ O
partially partially 0 0 0 0 0 0 0 0 9 0 IN NNP RB VBZ PRP$ O
explains explains 0 0 0 0 0 0 0 0 8 0 NNP RB VBZ PRP$ NNS O
its its 0 0 0 0 0 0 0 0 3 0 RB VBZ PRP$ NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 VBZ PRP$ NNS IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 PRP$ NNS IN NNP NN O
NSC NSC 1 1 0 0 0 0 0 0 3 0 NNS IN NNP NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 IN NNP NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NNP NNP O
oligodendrogenesis. oligodendrogenesis. 0 0 0 0 0 0 0 0 19 0 NN CC NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 CC NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNP NNS VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT JJ NN O
proNGF/p75NTR proNGF/p75NTR 0 0 0 1 0 0 0 1 13 0 IN DT JJ NN NNS O
signal signal 0 0 0 0 0 0 0 0 6 0 DT JJ NN NNS DT O
plays plays 0 0 0 0 0 0 0 0 5 0 JJ NN NNS DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN NNS DT JJ NN O
key key 0 0 0 0 0 0 0 0 3 0 NNS DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
regulation regulation 0 0 0 0 0 0 0 0 10 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
NSCs' NSCs' 1 0 0 0 0 1 0 0 5 0 NN IN NNP NNP NONE O
behavior. behavior. 0 0 0 0 0 0 0 0 9 0 IN NNP NNP NONE NONE O
From From 1 0 0 0 0 0 0 0 4 0 NONE NONE IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NONE IN DT NN IN O
desk desk 0 0 0 0 0 0 0 0 4 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
Prof. Prof. 1 0 0 0 0 0 0 0 5 0 NN IN NNP NNP NNP O
Shadab Shadab 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
Mohammad Mohammad 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
(HOD (HOD 0 1 0 0 0 0 0 0 4 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Omfs) Omfs) 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
K K 1 1 0 0 0 0 0 0 1 0 IN NNP NNP NNP NNP O
G G 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Lucknow. Lucknow. 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Mohammad Mohammad 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
S. S. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Oral Oral 1 0 0 0 0 0 0 0 4 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Maxillofacial Maxillofacial 1 0 0 0 0 0 0 0 13 0 NNP CC NNP NNP NNP O
Surgery, Surgery, 1 0 0 0 1 0 0 0 8 0 CC NNP NNP NNP NNP O
Chhatrapati Chhatrapati 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
Shahuji Shahuji 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Maharaj Maharaj 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
(Erstwhile (Erstwhile 0 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
K.G.M.C.), K.G.M.C.), 1 1 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Lucknow, Lucknow, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Uttar Uttar 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Pradesh, Pradesh, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
India. India. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
E-mail: E-mail: 1 0 1 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Shadab31aug@yahoo.com. Shadab31aug@yahoo.com. 1 0 0 0 0 0 0 1 22 0 NNP NNP NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNP NNP NNP CD -NONE- O
23833483 23833483 0 0 0 0 0 0 1 1 8 0 NNP NNP CD -NONE- JJ O
[PubMed] [PubMed] 0 0 0 0 0 0 0 0 8 0 NNP CD -NONE- JJ NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 CD -NONE- JJ NNP NONE O
PMC3700142 PMC3700142 1 1 0 0 0 0 0 1 10 0 -NONE- JJ NNP NONE NONE O
Inhibition Inhibition 1 0 0 0 0 0 0 0 10 0 NONE NONE NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN JJ NNS O
leukemic leukemic 0 0 0 0 0 0 0 0 8 0 NN IN JJ NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
valproic valproic 0 0 0 0 0 0 0 0 8 0 NNS IN JJ NN DT O
acid, acid, 0 0 0 0 1 0 0 0 5 0 IN JJ NN DT NNP O
an an 0 0 0 0 0 0 0 0 2 0 JJ NN DT NNP NNP O
HDAC HDAC 1 1 0 0 0 0 0 0 4 0 NN DT NNP NNP IN O
inhibitor, inhibitor, 0 0 0 0 1 0 0 0 10 0 DT NNP NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN NNP O
xenograft xenograft 0 0 0 0 0 0 0 0 9 0 NNP IN NN NNP NNP O
tumors. tumors. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hao Hao 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Liu Liu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhao Zhao 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhu Zhu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tian Tian 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
X. X. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Hematology Hematology 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Department, Department, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Affiliated Affiliated 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP IN O
Hospital Hospital 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Chengde Chengde 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
College, College, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Chengde, Chengde, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Hebei Hebei 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Province, Province, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
People's People's 1 0 0 0 0 1 0 0 8 0 NNP NNP NNP NNP IN O
Republic Republic 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP JJ NN O
chimeric chimeric 0 0 0 0 0 0 0 0 8 0 NNP NNP JJ NN NN O
fusion fusion 0 0 0 0 0 0 0 0 6 0 NNP JJ NN NN NN O
protein, protein, 0 0 0 0 1 0 0 0 8 0 JJ NN NN NN VBD O
AML1-ETO, AML1-ETO, 1 1 1 0 1 0 0 1 9 0 NN NN NN VBD IN O
generated generated 0 0 0 0 0 0 0 0 9 0 NN NN VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN NN IN O
translocation translocation 0 0 0 0 0 0 0 0 13 0 VBD IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP RB O
t(8;21), t(8;21), 0 0 0 0 1 0 0 1 8 0 NN IN NNP RB VBZ O
abnormally abnormally 0 0 0 0 0 0 0 0 10 0 IN NNP RB VBZ NN O
recruits recruits 0 0 0 0 0 0 0 0 8 0 NNP RB VBZ NN NN O
histone histone 0 0 0 0 0 0 0 0 7 0 RB VBZ NN NN NN O
deacetylase deacetylase 0 0 0 0 0 0 0 0 11 0 VBZ NN NN NN TO O
(HDAC) (HDAC) 0 1 0 0 0 0 0 0 6 0 NN NN NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT NNS IN O
promoters promoters 0 0 0 0 0 0 0 0 9 0 TO DT NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NNP NN O
AML1 AML1 1 1 0 0 0 0 0 1 4 0 NNS IN NNP NN -NONE- O
target target 0 0 0 0 0 0 0 0 6 0 IN NNP NN -NONE- VBG O
genes, genes, 0 0 0 0 1 0 0 0 6 0 NNP NN -NONE- VBG IN O
resulting resulting 0 0 0 0 0 0 0 0 9 0 NN -NONE- VBG IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- VBG IN JJ NN O
transcriptional transcriptional 0 0 0 0 0 0 0 0 15 0 VBG IN JJ NN IN O
repression repression 0 0 0 0 0 0 0 0 10 0 IN JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNS O
target target 0 0 0 0 0 0 0 0 6 0 IN DT NN NNS CC O
genes genes 0 0 0 0 0 0 0 0 5 0 DT NN NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NN IN O
development development 0 0 0 0 0 0 0 0 11 0 NNS CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NN O
t(8;21) t(8;21) 0 0 0 0 0 0 0 1 7 0 NN IN NN NN VBD O
acute acute 0 0 0 0 0 0 0 0 5 0 IN NN NN VBD NNP O
myeloid myeloid 0 0 0 0 0 0 0 0 7 0 NN NN VBD NNP NNP O
leukemia. leukemia. 0 0 0 0 0 0 0 0 9 0 NN VBD NNP NNP NN O
Abnormal Abnormal 1 0 0 0 0 0 0 0 8 0 VBD NNP NNP NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
cyclin-dependent cyclin-dependent 0 0 1 0 0 0 0 0 16 0 NN IN JJ NN NN O
kinase kinase 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN RB O
inhibitors, inhibitors, 0 0 0 0 1 0 0 0 11 0 JJ NN NN RB JJ O
especially especially 0 0 0 0 0 0 0 0 10 0 NN NN RB JJ VBZ O
p21, p21, 0 0 0 0 1 0 0 1 4 0 NN RB JJ VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 RB JJ VBZ VBN DT O
considered considered 0 0 0 0 0 0 0 0 10 0 JJ VBZ VBN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBZ VBN DT JJ NN O
possible possible 0 0 0 0 0 0 0 0 8 0 VBN DT JJ NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT VBN NN O
arrested arrested 0 0 0 0 0 0 0 0 8 0 IN DT VBN NN CC O
maturation maturation 0 0 0 0 0 0 0 0 10 0 DT VBN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VBN NN CC NN IN O
differentiation differentiation 0 0 0 0 0 0 0 0 15 0 NN CC NN IN IN O
seen seen 0 0 0 0 0 0 0 0 4 0 CC NN IN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN IN IN NN NNP O
leukemia leukemia 0 0 0 0 0 0 0 0 8 0 IN IN NN NNP DT O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NN NNP DT JJ O
A A 1 1 0 0 0 0 0 0 1 0 NN NNP DT JJ NN O
new new 0 0 0 0 0 0 0 0 3 0 NNP DT JJ NN IN O
generation generation 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNS O
HDAC HDAC 1 1 0 0 0 0 0 0 4 0 NN IN NNP NNS VBZ O
inhibitors inhibitors 0 0 0 0 0 0 0 0 10 0 IN NNP NNS VBZ VBG O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNS VBZ VBG DT O
becoming becoming 0 0 0 0 0 0 0 0 8 0 NNS VBZ VBG DT VBG O
an an 0 0 0 0 0 0 0 0 2 0 VBZ VBG DT VBG NN O
increasing increasing 0 0 0 0 0 0 0 0 10 0 VBG DT VBG NN IN O
focus focus 0 0 0 0 0 0 0 0 5 0 DT VBG NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBG NN IN NN IN O
attention attention 0 0 0 0 0 0 0 0 9 0 NN IN NN IN PRP$ O
for for 0 0 0 0 0 0 0 0 3 0 IN NN IN PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 NN IN PRP$ NN TO O
ability ability 0 0 0 0 0 0 0 0 7 0 IN PRP$ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 PRP$ NN TO VB NN O
induce induce 0 0 0 0 0 0 0 0 6 0 NN TO VB NN CC O
differentiation differentiation 0 0 0 0 0 0 0 0 15 0 TO VB NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VB NN CC NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN CC NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NNS O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NN IN NN NNS CC O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NN NNS CC TO O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNS CC TO VB DT O
block block 0 0 0 0 0 0 0 0 5 0 CC TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 VB DT NN NNP NNP O
cycle. cycle. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP JJ O
Our Our 1 0 0 0 0 0 0 0 3 0 NN NNP NNP JJ NN O
previous previous 0 0 0 0 0 0 0 0 8 0 NNP NNP JJ NN VBD O
research research 0 0 0 0 0 0 0 0 8 0 NNP JJ NN VBD VBN O
had had 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 NN VBD VBN IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 VBD VBN IN JJ NN O
valproic valproic 0 0 0 0 0 0 0 0 8 0 VBN IN JJ NN NNS O
acid acid 0 0 0 0 0 0 0 0 4 0 IN JJ NN NNS -NONE- O
induces induces 0 0 0 0 0 0 0 0 7 0 JJ NN NNS -NONE- VBP O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 arrest NN NNS -NONE- VBP IN B_TIMEXCCP
arrest arrest 0 0 0 0 0 0 0 0 6 0 NNS -NONE- VBP IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 -NONE- VBP IN -NONE- VBZ O
Kasumi-1 Kasumi-1 1 0 1 0 0 0 0 1 8 0 VBP IN -NONE- VBZ IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN -NONE- VBZ IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- VBZ IN JJ NN O
t(8;21) t(8;21) 0 0 0 0 0 0 0 1 7 0 VBZ IN JJ NN VBD O
acute acute 0 0 0 0 0 0 0 0 5 0 IN JJ NN VBD NNP O
myeloid myeloid 0 0 0 0 0 0 0 0 7 0 JJ NN VBD NNP NNP O
leukemia. leukemia. 0 0 0 0 0 0 0 0 9 0 NN VBD NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 VBD NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 NNP DT NN PRP RB O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP RB VBD O
further further 0 0 0 0 0 0 0 0 7 0 NN PRP RB VBD IN O
confirmed confirmed 0 0 0 0 0 0 0 0 9 0 PRP RB VBD IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 RB VBD IN JJ NN O
valproic valproic 0 0 0 0 0 0 0 0 8 0 VBD IN JJ NN NNS O
acid acid 0 0 0 0 0 0 0 0 4 0 IN JJ NN NNS DT O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 JJ NN NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NNS DT NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 NNS DT NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN -NONE- VBZ O
Kasumi-1 Kasumi-1 1 0 1 0 0 0 0 1 8 0 NN IN -NONE- VBZ IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN -NONE- VBZ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- VBZ IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBZ IN DT NN NN O
murine murine 0 0 0 0 0 0 0 0 6 0 IN DT NN NN NN O
xenograft xenograft 0 0 0 0 0 0 0 0 9 0 DT NN NN NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NN NN NN NN CC O
model, model, 0 0 0 0 1 0 0 0 6 0 NN NN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NN CC IN DT NNS O
this this 0 0 0 0 0 0 0 0 4 0 CC IN DT NNS IN O
occurs occurs 0 0 0 0 0 0 0 0 6 0 IN DT NNS IN NN O
via via 0 0 0 0 0 0 0 0 3 0 DT NNS IN NN IN O
upregulation upregulation 0 0 0 0 0 0 0 0 12 0 NNS IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NN O
histone histone 0 0 0 0 0 0 0 0 7 0 NN IN NN NN IN O
acetylation acetylation 0 0 0 0 0 0 0 0 11 0 IN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
p21 p21 0 0 0 0 0 0 0 1 3 0 IN DT NNP NN -NONE- O
promoter promoter 0 0 0 0 0 0 0 0 8 0 DT NNP NN -NONE- NN O
region, region, 0 0 0 0 1 0 0 0 7 0 NNP NN -NONE- NN IN O
enhancement enhancement 0 0 0 0 0 0 0 0 11 0 NN -NONE- NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 -NONE- NN IN NNP NNP O
p21 p21 0 0 0 0 0 0 0 1 3 0 NN IN NNP NNP NN O
expression, expression, 0 0 0 0 1 0 0 0 11 0 IN NNP NNP NN IN O
suppression suppression 0 0 0 0 0 0 0 0 11 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 NN IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NN O
retinoblastoma retinoblastoma 0 0 0 0 0 0 0 0 14 0 NN IN NN NN VBG O
protein, protein, 0 0 0 0 1 0 0 0 8 0 IN NN NN VBG IN O
blocking blocking 0 0 0 0 0 0 0 0 8 0 NN NN VBG IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN VBG IN NN VBN O
transcription transcription 0 0 0 0 0 0 0 0 13 0 VBG IN NN VBN IN O
activated activated 0 0 0 0 0 0 0 0 9 0 IN NN VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN VBN IN NNP CC O
E2F, E2F, 1 1 0 0 1 0 0 1 4 0 VBN IN NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 NNP CC NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN -NONE- NNP O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NN IN -NONE- NNP NONE B_TIMEXCCP
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 IN -NONE- NNP NONE NONE O
TEMPORARY TEMPORARY 1 1 0 0 0 0 0 0 9 0 NONE NONE NNP NNP NNP O
REMOVAL: REMOVAL: 1 1 0 0 0 0 0 0 8 0 NONE NNP NNP NNP JJ O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP JJ NN O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 NNP NNP JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 NNP JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
K+-Cl- K+-Cl- 1 0 1 0 0 0 0 0 6 0 NN IN NNP NN IN O
cotransporter cotransporter 0 0 0 0 0 0 0 0 13 0 IN NNP NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN NN IN O
progression progression 0 0 0 0 0 0 0 0 11 0 NN NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
breast breast 0 0 0 0 0 0 0 0 6 0 NN IN JJ NN -NONE- O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN -NONE- NNP O
MDA-MB-231 MDA-MB-231 1 1 1 0 0 0 0 1 10 0 JJ NN -NONE- NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN -NONE- NNP NNP NNP O
Kitagawa Kitagawa 1 0 0 0 0 0 0 0 8 0 -NONE- NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Niisato Niisato 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Shiozaki Shiozaki 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ohta-Fujimoto Ohta-Fujimoto 1 0 1 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hosogi Hosogi 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Miyazaki Miyazaki 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ichikawa Ichikawa 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Otsuji Otsuji 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
E, E, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Marunaka Marunaka 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Y. Y. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Division Division 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Digestive Digestive 1 0 0 0 0 0 0 0 9 0 NNP IN NNP NNP NNP O
Surgery, Surgery, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Surgery, Surgery, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP NNP O
Kyoto Kyoto 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
Prefectural Prefectural 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Kajii-cho, Kajii-cho, 1 0 1 0 1 0 0 0 10 0 IN NNP NNP NNP NNP O
Kamigyo-ku, Kamigyo-ku, 1 0 1 0 1 0 0 0 11 0 NNP NNP NNP NNP CD O
Kyoto Kyoto 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP CD -NONE- O
602-8566, 602-8566, 0 0 1 0 1 0 0 1 9 0 NNP NNP CD -NONE- NNP O
Japan; Japan; 1 0 0 0 0 0 0 0 6 0 NNP CD -NONE- NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 CD -NONE- NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 -NONE- NNP IN NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP IN NNP NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNP O
Physiology, Physiology, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Kyoto Kyoto 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Prefectural Prefectural 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Kajii-cho, Kajii-cho, 1 0 1 0 1 0 0 0 10 0 IN NNP NNP NNP NNP O
Kamigyo-ku, Kamigyo-ku, 1 0 1 0 1 0 0 0 11 0 NNP NNP NNP NNP CD O
Kyoto Kyoto 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP CD NNP O
602-8566, 602-8566, 0 0 1 0 1 0 0 1 9 0 NNP NNP CD NNP NNP O
Japan. Japan. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN NNS O
publisher publisher 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NNS WDT O
regrets regrets 0 0 0 0 0 0 0 0 7 0 NNP NN NNS WDT DT O
that that 0 0 0 0 0 0 0 0 4 0 NN NNS WDT DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNS WDT DT NN VBZ O
article article 0 0 0 0 0 0 0 0 7 0 WDT DT NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 DT NN VBZ VBN RB O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN RB NNP O
temporarily temporarily 0 0 0 0 0 0 0 0 11 0 VBZ VBN RB NNP DT O
removed. removed. 0 0 0 0 0 0 0 0 8 0 VBN RB NNP DT NN O
A A 1 1 0 0 0 0 0 0 1 0 RB NNP DT NN MD O
replacement replacement 0 0 0 0 0 0 0 0 11 0 NNP DT NN MD VB O
will will 0 0 0 0 0 0 0 0 4 0 DT NN MD VB IN O
appear appear 0 0 0 0 0 0 0 0 6 0 NN MD VB IN RB O
as as 0 0 0 0 0 0 0 0 2 0 MD VB IN RB IN O
soon soon 0 0 0 0 0 0 0 0 4 0 VB IN RB IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN JJ IN O
possible possible 0 0 0 0 0 0 0 0 8 0 RB IN JJ IN WDT O
in in 0 0 0 0 0 0 0 0 2 0 IN JJ IN WDT DT O
which which 0 0 0 0 0 0 0 0 5 0 JJ IN WDT DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN WDT DT NN IN O
reason reason 0 0 0 0 0 0 0 0 6 0 WDT DT NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
removal removal 0 0 0 0 0 0 0 0 7 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN MD O
article article 0 0 0 0 0 0 0 0 7 0 IN DT NN MD VB O
will will 0 0 0 0 0 0 0 0 4 0 DT NN MD VB -NONE- O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB -NONE- CC O
specified, specified, 0 0 0 0 1 0 0 0 10 0 MD VB -NONE- CC DT O
or or 0 0 0 0 0 0 0 0 2 0 VB -NONE- CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- CC DT NN MD O
article article 0 0 0 0 0 0 0 0 7 0 CC DT NN MD VB O
will will 0 0 0 0 0 0 0 0 4 0 DT NN MD VB NNP O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB NNP NNP O
reinstated. reinstated. 0 0 0 0 0 0 0 0 11 0 MD VB NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 VB NNP NNP JJ NNP O
full full 0 0 0 0 0 0 0 0 4 0 NNP NNP JJ NNP NNP O
Elsevier Elsevier 1 0 0 0 0 0 0 0 8 0 NNP JJ NNP NNP IN O
Policy Policy 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Article Article 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP MD O
Withdrawal Withdrawal 1 0 0 0 0 0 0 0 10 0 IN NNP NNP MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NNP NNP MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NNP MD VB VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 MD VB VBN IN NNP O
at at 0 0 0 0 0 0 0 0 2 0 VB VBN IN NNP NONE O
http://www.elsevier.com/locate/withdrawalpolicy. http://www.elsevier.com/locate/withdrawalpolicy. 0 0 0 1 0 0 0 0 48 0 VBN IN NNP NONE NONE O
Integrin Integrin 1 0 0 0 0 0 0 0 8 0 NONE NONE NNP : CD O
α α 0 0 0 0 0 0 0 0 1 0 NONE NNP : CD NNS O
7 7 0 0 0 0 0 0 1 1 1 0 NNP : CD NNS NNP O
Binds Binds 1 0 0 0 0 0 0 0 5 0 : CD NNS NNP NNP O
Tissue Tissue 1 0 0 0 0 0 0 0 6 0 CD NNS NNP NNP IN O
Inhibitor Inhibitor 1 0 0 0 0 0 0 0 9 0 NNS NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CD O
Metalloproteinase Metalloproteinase 1 0 0 0 0 0 0 0 17 0 NNP IN NNP CD TO O
3 3 0 0 0 0 0 0 1 1 1 0 IN NNP CD TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNP CD TO NNP NNP O
Suppress Suppress 1 0 0 0 0 0 0 0 8 0 CD TO NNP NNP IN O
Growth Growth 1 0 0 0 0 0 0 0 6 0 TO NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Prostate Prostate 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
Cells. Cells. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Tan Tan 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
LZ, LZ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Song Song 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Nelson Nelson 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yu Yu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
YP, YP, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Luo Luo 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
JH. JH. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pathology, Pathology, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pittsburgh Pittsburgh 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Pittsburgh, Pittsburgh, 1 0 0 0 1 0 0 0 11 0 IN NNP NNP NNP NNP O
Pennsylvania. Pennsylvania. 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Integrin Integrin 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
α7 α7 0 0 0 0 0 0 0 1 2 0 NNP NNP NNP NNP VBZ O
(ITGA7) (ITGA7) 0 1 0 0 0 0 0 1 7 0 NNP NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT JJ NN O
tumor-suppressor tumor-suppressor 0 0 1 0 0 0 0 0 16 0 VBZ DT JJ NN WDT O
gene gene 0 0 0 0 0 0 0 0 4 0 DT JJ NN WDT VBZ O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN WDT VBZ JJ IN O
critical critical 0 0 0 0 0 0 0 0 8 0 WDT VBZ JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN NN DT O
suppressing suppressing 0 0 0 0 0 0 0 0 11 0 JJ IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 NN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
malignant malignant 0 0 0 0 0 0 0 0 9 0 NN IN JJ NN NN O
tumors; tumors; 0 0 0 0 0 0 0 0 7 0 IN JJ NN NN DT O
however, however, 0 0 0 0 1 0 0 0 8 0 JJ NN NN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NNS VBG O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 NN DT NNS VBG NNP O
allowing allowing 0 0 0 0 0 0 0 0 8 0 DT NNS VBG NNP TO O
ITGA7 ITGA7 1 1 0 0 0 0 0 1 5 0 NNS VBG NNP TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VBG NNP TO NN DT O
suppress suppress 0 0 0 0 0 0 0 0 8 0 NNP TO NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO NN DT NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 NN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN IN NN NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NN NNS VBP NNP O
remain remain 0 0 0 0 0 0 0 0 6 0 NN NNS VBP NNP NNP O
unclear. unclear. 0 0 0 0 0 0 0 0 8 0 NNS VBP NNP NNP PRP O
Herein, Herein, 1 0 0 0 1 0 0 0 7 0 VBP NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NNP PRP VBP IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN NNP NNS O
ITGA7 ITGA7 1 1 0 0 0 0 0 1 5 0 VBP IN NNP NNS TO O
binds binds 0 0 0 0 0 0 0 0 5 0 IN NNP NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNP NNS TO VB NN O
tissue tissue 0 0 0 0 0 0 0 0 6 0 NNS TO VB NN IN O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 TO VB NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VB NN IN NN CD O
metalloproteinase metalloproteinase 0 0 0 0 0 0 0 0 17 0 NN IN NN CD NN O
3 3 0 0 0 0 0 0 1 1 1 0 IN NN CD NN IN O
(TIMP3) (TIMP3) 0 1 0 0 0 0 0 1 7 0 NN CD NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN NN NN O
prostate prostate 0 0 0 0 0 0 0 0 8 0 NN IN NN NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN NN NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNP NN O
ITGA7-TIMP3 ITGA7-TIMP3 1 1 1 0 0 0 0 1 11 0 NNP NNP NNP NN VBD O
binding binding 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBD TO O
led led 0 0 0 0 0 0 0 0 3 0 NNP NN VBD TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO DT VBN O
a a 0 0 0 0 0 0 0 0 1 0 VBD TO DT VBN NN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 TO DT VBN NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 DT VBN NN NN IN O
level level 0 0 0 0 0 0 0 0 5 0 VBN NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NN IN NN NN NN O
necrosis necrosis 0 0 0 0 0 0 0 0 8 0 IN NN NN NN : O
factor factor 0 0 0 0 0 0 0 0 6 0 NN NN NN : JJ O
α, α, 0 0 0 0 1 0 0 0 2 0 NN NN : JJ NN O
cytoplasmic cytoplasmic 0 0 0 0 0 0 0 0 11 0 NN : JJ NN IN O
translocation translocation 0 0 0 0 0 0 0 0 13 0 : JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP CC O
NF-κB, NF-κB, 1 0 1 0 1 0 0 0 6 0 NN IN NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NN IN O
down-regulation down-regulation 0 0 1 0 0 0 0 0 15 0 NNP CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP NNP O
D1. D1. 1 1 0 0 0 0 0 1 3 0 IN NN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNS VBD O
changes changes 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD TO O
led led 0 0 0 0 0 0 0 0 3 0 NNP NNS VBD TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBD TO DT NN O
an an 0 0 0 0 0 0 0 0 2 0 VBD TO DT NN IN O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 TO DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN -NONE- O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN -NONE- CC O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NNS IN -NONE- CC DT B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 IN -NONE- CC DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- CC DT JJ NN O
dramatic dramatic 0 0 0 0 0 0 0 0 8 0 CC DT JJ NN IN O
suppression suppression 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NNP NNP O
growth. growth. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NNP IN O
Knocking Knocking 1 0 0 0 0 0 0 0 8 0 NN NNP NNP IN NNP O
down down 0 0 0 0 0 0 0 0 4 0 NNP NNP IN NNP CC O
TIMP3 TIMP3 1 1 0 0 0 0 0 1 5 0 NNP IN NNP CC -NONE- O
or or 0 0 0 0 0 0 0 0 2 0 IN NNP CC -NONE- VBG O
ITGA7/TIMP3 ITGA7/TIMP3 1 1 0 1 0 0 0 1 11 0 NNP CC -NONE- VBG NN O
binding binding 0 0 0 0 0 0 0 0 7 0 CC -NONE- VBG NN RB O
interference interference 0 0 0 0 0 0 0 0 12 0 -NONE- VBG NN RB VBN O
largely largely 0 0 0 0 0 0 0 0 7 0 VBG NN RB VBN DT O
abrogated abrogated 0 0 0 0 0 0 0 0 9 0 NN RB VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBN DT NN NNS O
signaling signaling 0 0 0 0 0 0 0 0 9 0 VBN DT NN NNS VBD O
changes changes 0 0 0 0 0 0 0 0 7 0 DT NN NNS VBD IN O
induced induced 0 0 0 0 0 0 0 0 7 0 NN NNS VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBD IN NN NNS O
ITGA7, ITGA7, 1 1 0 0 1 0 0 1 6 0 VBD IN NN NNS DT O
whereas whereas 0 0 0 0 0 0 0 0 7 0 IN NN NNS DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN NNS DT JJ NNP O
mutant mutant 0 0 0 0 0 0 0 0 6 0 NNS DT JJ NNP NN O
ITGA7 ITGA7 1 1 0 0 0 0 0 1 5 0 DT JJ NNP NN NNP O
lacking lacking 0 0 0 0 0 0 0 0 7 0 JJ NNP NN NNP NN O
TIMP3 TIMP3 1 1 0 0 0 0 0 1 5 0 NNP NN NNP NN NN O
binding binding 0 0 0 0 0 0 0 0 7 0 NN NNP NN NN VBD O
activity activity 0 0 0 0 0 0 0 0 8 0 NNP NN NN VBD DT O
had had 0 0 0 0 0 0 0 0 3 0 NN NN VBD DT NN O
no no 0 0 0 0 0 0 0 0 2 0 NN VBD DT NN NNP O
tumor-suppressor tumor-suppressor 0 0 1 0 0 0 0 0 16 0 VBD DT NN NNP NNP O
activity. activity. 0 0 0 0 0 0 0 0 9 0 DT NN NNP NNP NN O
Interestingly, Interestingly, 1 0 0 0 1 0 0 0 14 0 NN NNP NNP NN IN O
knocking knocking 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN NNP O
down down 0 0 0 0 0 0 0 0 4 0 NNP NN IN NNP NN O
ITGA7 ITGA7 1 1 0 0 0 0 0 1 5 0 NN IN NNP NN NN O
ligand ligand 0 0 0 0 0 0 0 0 6 0 IN NNP NN NN -NONE- O
laminin laminin 0 0 0 0 0 0 0 0 7 0 NNP NN NN -NONE- VBN O
β1 β1 0 0 0 0 0 0 0 1 2 0 NN NN -NONE- VBN -NONE- O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 NN -NONE- VBN -NONE- VBG O
ITGA7-TIMP3 ITGA7-TIMP3 1 1 1 0 0 0 0 1 11 0 -NONE- VBN -NONE- VBG CC O
signaling signaling 0 0 0 0 0 0 0 0 9 0 VBN -NONE- VBG CC DT O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- VBG CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBG CC DT NN NN O
downstream downstream 0 0 0 0 0 0 0 0 10 0 CC DT NN NN NN O
tumor-suppressor tumor-suppressor 0 0 1 0 0 0 0 0 16 0 DT NN NN NN VBG O
activity, activity, 0 0 0 0 1 0 0 0 9 0 NN NN NN VBG DT O
suggesting suggesting 0 0 0 0 0 0 0 0 10 0 NN NN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT NN IN O
existence existence 0 0 0 0 0 0 0 0 9 0 VBG DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN NN O
counterbalancing counterbalancing 0 0 0 0 0 0 0 0 16 0 IN DT NN NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT NN NN IN JJ O
between between 0 0 0 0 0 0 0 0 7 0 NN NN IN JJ NN O
extracellular extracellular 0 0 0 0 0 0 0 0 13 0 NN IN JJ NN CC O
matrix matrix 0 0 0 0 0 0 0 0 6 0 IN JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NNP O
integrin integrin 0 0 0 0 0 0 0 0 8 0 NN CC NN NNP NNP O
signaling. signaling. 0 0 0 0 0 0 0 0 10 0 CC NN NNP NNP DT O
As As 1 0 0 0 0 0 0 0 2 0 NN NNP NNP DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT NNP DT O
result, result, 0 0 0 0 1 0 0 0 7 0 NNP DT NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 DT NNP DT NN VBZ O
report report 0 0 0 0 0 0 0 0 6 0 NNP DT NN VBZ DT O
demonstrates demonstrates 0 0 0 0 0 0 0 0 12 0 DT NN VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT NN CC O
novel novel 0 0 0 0 0 0 0 0 5 0 VBZ DT NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC JJ NN O
critical critical 0 0 0 0 0 0 0 0 8 0 NN CC JJ NN NN O
signaling signaling 0 0 0 0 0 0 0 0 9 0 CC JJ NN NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 JJ NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP IN O
ITGA7, ITGA7, 1 1 0 0 1 0 0 1 6 0 NN IN NNP IN DT O
through through 0 0 0 0 0 0 0 0 7 0 IN NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ NNP O
TIMP3/NF-κB/cyclin TIMP3/NF-κB/cyclin 1 0 1 1 0 0 0 1 18 0 IN DT JJ NNP NNP O
D1 D1 1 1 0 0 0 0 0 1 2 0 DT JJ NNP NNP NONE O
pathway. pathway. 0 0 0 0 0 0 0 0 8 0 JJ NNP NNP NONE NONE O
Implication Implication 1 0 0 0 0 0 0 0 11 0 NONE NONE NN IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NONE NN IN JJ NN O
thyroid thyroid 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN VBG O
function function 0 0 0 0 0 0 0 0 8 0 IN JJ NN VBG IN O
decreasing decreasing 0 0 0 0 0 0 0 0 10 0 JJ NN VBG IN NN O
during during 0 0 0 0 0 0 0 0 6 0 NN VBG IN NN IN O
chemotherapy chemotherapy 0 0 0 0 0 0 0 0 12 0 VBG IN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NN O
breast breast 0 0 0 0 0 0 0 0 6 0 NN IN NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN NN NN NN NN O
patients: patients: 0 0 0 0 0 0 0 0 9 0 NN NN NN NN NN O
chemosensitization chemosensitization 0 0 0 0 0 0 0 0 18 0 NN NN NN NN IN O
role role 0 0 0 0 0 0 0 0 4 0 NN NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
triiodothyronine. triiodothyronine. 0 0 0 0 0 0 0 0 17 0 NN IN NNP NNP NNP O
Huang Huang 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Jin Jin 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ji Ji 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Xing Xing 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Xu Xu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Xiong Xiong 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wu Wu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ren Ren 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kong Kong 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
L. L. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Endocrine Endocrine 1 0 0 0 0 0 0 0 9 0 NNP IN NNP CC NNP O
& & 0 0 0 0 0 0 0 0 1 0 IN NNP CC NNP NNP O
Breast Breast 1 0 0 0 0 0 0 0 6 0 NNP CC NNP NNP DT O
Surgery, Surgery, 1 0 0 0 1 0 0 0 8 0 CC NNP NNP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNP NNP O
First First 1 0 0 0 0 0 0 0 5 0 NNP DT NNP NNP NNP O
Affiliated Affiliated 1 0 0 0 0 0 0 0 10 0 DT NNP NNP NNP IN O
Hospital Hospital 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Chongqing Chongqing 1 0 0 0 0 0 0 0 9 0 NNP IN NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
You You 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Yi Yi 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP CD O
Rd, Rd, 1 0 0 0 1 0 0 0 3 0 NNP NNP NNP CD -NONE- O
1, 1, 0 0 0 0 1 0 0 1 2 0 NNP NNP CD -NONE- VBZ O
Chongqing, Chongqing, 1 0 0 0 1 0 0 0 10 0 NNP CD -NONE- VBZ NNP O
People's People's 1 0 0 0 0 1 0 0 8 0 CD -NONE- VBZ NNP IN O
Republic Republic 1 0 0 0 0 0 0 0 8 0 -NONE- VBZ NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBZ NNP IN NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNP O
rgs726@163.com. rgs726@163.com. 0 0 0 0 0 0 0 1 15 0 IN NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP VBZ O
Thyroid Thyroid 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP VBZ VBP O
hormones hormones 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 VBZ VBP VBN VBN TO O
shown shown 0 0 0 0 0 0 0 0 5 0 VBP VBN VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO VB JJ O
regulate regulate 0 0 0 0 0 0 0 0 8 0 VBN TO VB JJ NN O
breast breast 0 0 0 0 0 0 0 0 6 0 TO VB JJ NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 VB JJ NN NNS -NONE- O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS -NONE- DT O
growth, growth, 0 0 0 0 1 0 0 0 7 0 NN NNS -NONE- DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS -NONE- DT NN CC O
absence absence 0 0 0 0 0 0 0 0 7 0 -NONE- DT NN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 DT NN CC NN IN O
reduction reduction 0 0 0 0 0 0 0 0 9 0 NN CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NNS O
thyroid thyroid 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNS IN O
hormones hormones 0 0 0 0 0 0 0 0 8 0 IN JJ NNS IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNS MD O
cells cells 0 0 0 0 0 0 0 0 5 0 NNS IN NNS MD VB O
could could 0 0 0 0 0 0 0 0 5 0 IN NNS MD VB DT O
provoke provoke 0 0 0 0 0 0 0 0 7 0 NNS MD VB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT NN NN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 arrest VB DT NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 DT NN NN IN -NONE- O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN -NONE- CC O
G0-G1 G0-G1 1 1 1 0 0 0 0 1 5 0 NN IN -NONE- CC JJ B_TIMEXCCP
or or 0 0 0 0 0 0 0 0 2 0 IN -NONE- CC JJ JJ O
weak weak 0 0 0 0 0 0 0 0 4 0 -NONE- CC JJ JJ NN O
mitochondrial mitochondrial 0 0 0 0 0 0 0 0 13 0 CC JJ JJ NN WDT O
activity, activity, 0 0 0 0 1 0 0 0 9 0 JJ JJ NN WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 JJ NN WDT VBZ NNS O
makes makes 0 0 0 0 0 0 0 0 5 0 NN WDT VBZ NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 WDT VBZ NNS VBP TO O
insensitive insensitive 0 0 0 0 0 0 0 0 11 0 VBZ NNS VBP TO NNS O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBP TO NNS IN O
therapies therapies 0 0 0 0 0 0 0 0 9 0 VBP TO NNS IN NNS O
for for 0 0 0 0 0 0 0 0 3 0 TO NNS IN NNS IN O
cancers cancers 0 0 0 0 0 0 0 0 7 0 NNS IN NNS IN VBG O
through through 0 0 0 0 0 0 0 0 7 0 IN NNS IN VBG IN O
transforming transforming 0 0 0 0 0 0 0 0 12 0 NNS IN VBG IN JJ O
into into 0 0 0 0 0 0 0 0 4 0 IN VBG IN JJ NN O
low low 0 0 0 0 0 0 0 0 3 0 VBG IN JJ NN NNP O
metabolism metabolism 0 0 0 0 0 0 0 0 10 0 IN JJ NN NNP NNP O
status. status. 0 0 0 0 0 0 0 0 7 0 JJ NN NNP NNP JJ O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP JJ NN O
biological biological 0 0 0 0 0 0 0 0 10 0 NNP NNP JJ NN MD O
phenomenon phenomenon 0 0 0 0 0 0 0 0 10 0 NNP JJ NN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 JJ NN MD VB VB O
help help 0 0 0 0 0 0 0 0 4 0 NN MD VB VB WRB O
explain explain 0 0 0 0 0 0 0 0 7 0 MD VB VB WRB NN O
why why 0 0 0 0 0 0 0 0 3 0 VB VB WRB NN NN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 VB WRB NN NN CC O
efficacy efficacy 0 0 0 0 0 0 0 0 8 0 WRB NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
prognosis prognosis 0 0 0 0 0 0 0 0 9 0 NN CC NN NN IN O
vary vary 0 0 0 0 0 0 0 0 4 0 CC NN NN IN JJ O
among among 0 0 0 0 0 0 0 0 5 0 NN NN IN JJ NN O
breast breast 0 0 0 0 0 0 0 0 6 0 NN IN JJ NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNS VBG O
patients patients 0 0 0 0 0 0 0 0 8 0 JJ NN NNS VBG NN O
having having 0 0 0 0 0 0 0 0 6 0 NN NNS VBG NN NN O
hypothyroid, hypothyroid, 0 0 0 0 1 0 0 0 12 0 NNS VBG NN NN CC O
hyperthyroid hyperthyroid 0 0 0 0 0 0 0 0 12 0 VBG NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NNP O
normal normal 0 0 0 0 0 0 0 0 6 0 NN CC JJ NNP NNP O
function. function. 0 0 0 0 0 0 0 0 9 0 CC JJ NNP NNP DT O
Nevertheless, Nevertheless, 1 0 0 0 1 0 0 0 13 0 JJ NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NN O
abnormal abnormal 0 0 0 0 0 0 0 0 8 0 NNP DT JJ NN NN O
thyroid thyroid 0 0 0 0 0 0 0 0 7 0 DT JJ NN NN IN O
function function 0 0 0 0 0 0 0 0 8 0 JJ NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
breast breast 0 0 0 0 0 0 0 0 6 0 NN IN NN NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN NN NN NNS VBZ O
patients patients 0 0 0 0 0 0 0 0 8 0 NN NN NNS VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NN NNS VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNS VBZ VBN VBN VBG O
considered considered 0 0 0 0 0 0 0 0 10 0 VBZ VBN VBN VBG RB O
being being 0 0 0 0 0 0 0 0 5 0 VBN VBN VBG RB VBN O
mainly mainly 0 0 0 0 0 0 0 0 6 0 VBN VBG RB VBN IN O
caused caused 0 0 0 0 0 0 0 0 6 0 VBG RB VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 RB VBN IN JJ NN O
thyroid thyroid 0 0 0 0 0 0 0 0 7 0 VBN IN JJ NN JJ O
diseases, diseases, 0 0 0 0 1 0 0 0 9 0 IN JJ NN JJ JJ O
few few 0 0 0 0 0 0 0 0 3 0 JJ NN JJ JJ NN O
studied studied 0 0 0 0 0 0 0 0 7 0 NN JJ JJ NN IN O
influence influence 0 0 0 0 0 0 0 0 9 0 JJ JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
chemotherapy chemotherapy 0 0 0 0 0 0 0 0 12 0 NN IN NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NN O
thyroid thyroid 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN CC O
function function 0 0 0 0 0 0 0 0 8 0 IN JJ NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC IN PRP$ O
whether whether 0 0 0 0 0 0 0 0 7 0 NN CC IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 CC IN PRP$ NN IN O
alteration alteration 0 0 0 0 0 0 0 0 10 0 IN PRP$ NN IN NN O
during during 0 0 0 0 0 0 0 0 6 0 PRP$ NN IN NN MD O
chemotherapy chemotherapy 0 0 0 0 0 0 0 0 12 0 NN IN NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 IN NN MD VB DT O
influence influence 0 0 0 0 0 0 0 0 9 0 NN MD VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NN TO O
respose respose 0 0 0 0 0 0 0 0 7 0 VB DT NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO VB VBZ O
chemotherapy chemotherapy 0 0 0 0 0 0 0 0 12 0 NN TO VB VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 TO VB VBZ RB NNP O
still still 0 0 0 0 0 0 0 0 5 0 VB VBZ RB NNP NNP O
unclear. unclear. 0 0 0 0 0 0 0 0 8 0 VBZ RB NNP NNP PRP O
So, So, 1 0 0 0 1 0 0 0 3 0 RB NNP NNP PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD TO O
aimed aimed 0 0 0 0 0 0 0 0 5 0 NNP PRP VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 PRP VBD TO VB DT O
find find 0 0 0 0 0 0 0 0 4 0 VBD TO VB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NNS IN O
alterations alterations 0 0 0 0 0 0 0 0 11 0 VB DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NN O
thyroid thyroid 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NN CC O
function function 0 0 0 0 0 0 0 0 8 0 IN JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NN O
non-thyroidal non-thyroidal 0 0 1 0 0 0 0 0 13 0 NN CC JJ NN NN O
illness illness 0 0 0 0 0 0 0 0 7 0 CC JJ NN NN NN O
syndrome syndrome 0 0 0 0 0 0 0 0 8 0 JJ NN NN NN NN O
(NTIS) (NTIS) 0 1 0 0 0 0 0 0 6 0 NN NN NN NN VBG O
prevalence prevalence 0 0 0 0 0 0 0 0 10 0 NN NN NN VBG NN O
druing druing 0 0 0 0 0 0 0 0 6 0 NN NN VBG NN IN O
chemotherapy chemotherapy 0 0 0 0 0 0 0 0 12 0 NN VBG NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBG NN IN NN NN O
breast breast 0 0 0 0 0 0 0 0 6 0 NN IN NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN NN NN NN CC O
patients, patients, 0 0 0 0 1 0 0 0 9 0 NN NN NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VB DT O
investigate investigate 0 0 0 0 0 0 0 0 11 0 NN CC VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC VB DT NN IN O
influence influence 0 0 0 0 0 0 0 0 9 0 VB DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
thyroid thyroid 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNS IN O
hormones hormones 0 0 0 0 0 0 0 0 8 0 IN JJ NNS IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NNP O
chemotherapeutic chemotherapeutic 0 0 0 0 0 0 0 0 16 0 NNS IN JJ NNP NNP O
efficacy. efficacy. 0 0 0 0 0 0 0 0 9 0 IN JJ NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 JJ NNP NNP NNP VBZ O
Thyroid Thyroid 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP VBZ CC O
hormones hormones 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP VBZ CC NNP NN O
NTIS NTIS 1 1 0 0 0 0 0 0 4 0 VBZ CC NNP NN IN O
prevalence prevalence 0 0 0 0 0 0 0 0 10 0 CC NNP NN IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NNS O
initial initial 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNS CC O
diagnosis diagnosis 0 0 0 0 0 0 0 0 9 0 IN JJ NNS CC IN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC IN NN O
during during 0 0 0 0 0 0 0 0 6 0 NNS CC IN NN VBD O
chemotherapy chemotherapy 0 0 0 0 0 0 0 0 12 0 CC IN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 IN NN VBD VBN IN O
analyzed analyzed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN CD NN O
685 685 0 0 0 0 0 0 1 1 3 0 VBN IN CD NN NNS O
breast breast 0 0 0 0 0 0 0 0 6 0 IN CD NN NNS NNS O
diseases diseases 0 0 0 0 0 0 0 0 8 0 CD NN NNS NNS -NONE- O
patients patients 0 0 0 0 0 0 0 0 8 0 NN NNS NNS -NONE- JJ O
(369 (369 0 0 0 0 0 0 0 1 4 0 NNS NNS -NONE- JJ NN O
breast breast 0 0 0 0 0 0 0 0 6 0 NNS -NONE- JJ NN CD O
cancer, cancer, 0 0 0 0 1 0 0 0 7 0 -NONE- JJ NN CD NN O
316 316 0 0 0 0 0 0 1 1 3 0 JJ NN CD NN NN O
breast breast 0 0 0 0 0 0 0 0 6 0 NN CD NN NN NNP O
benign benign 0 0 0 0 0 0 0 0 6 0 CD NN NN NNP NNP O
lesions). lesions). 0 0 0 0 0 0 0 0 9 0 NN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
influence influence 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NNS O
thyroid thyroid 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNS IN O
hormones hormones 0 0 0 0 0 0 0 0 8 0 IN JJ NNS IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
chemotherapeutic chemotherapeutic 0 0 0 0 0 0 0 0 16 0 NNS IN JJ NN VBD O
efficacy efficacy 0 0 0 0 0 0 0 0 8 0 IN JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN IN O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN -NONE- O
chemosensitization chemosensitization 0 0 0 0 0 0 0 0 18 0 VBN IN NN -NONE- TO O
test, test, 0 0 0 0 1 0 0 0 5 0 IN NN -NONE- TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN -NONE- TO VB JJ O
compare compare 0 0 0 0 0 0 0 0 7 0 -NONE- TO VB JJ NN O
chemotherapeutic chemotherapeutic 0 0 0 0 0 0 0 0 16 0 TO VB JJ NN IN O
efficacy efficacy 0 0 0 0 0 0 0 0 8 0 VB JJ NN IN JJ O
between between 0 0 0 0 0 0 0 0 7 0 JJ NN IN JJ NN O
breast breast 0 0 0 0 0 0 0 0 6 0 NN IN JJ NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN NNS O
with with 0 0 0 0 0 0 0 0 4 0 NN NNS IN NNS CC O
chemotherapeutics chemotherapeutics 0 0 0 0 0 0 0 0 17 0 NNS IN NNS CC NN O
plus plus 0 0 0 0 0 0 0 0 4 0 IN NNS CC NN NN O
triiodothyronine triiodothyronine 0 0 0 0 0 0 0 0 16 0 NNS CC NN NN CC O
(T3) (T3) 0 1 0 0 0 0 0 1 4 0 CC NN NN CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNS NNP O
chemotherapeutics chemotherapeutics 0 0 0 0 0 0 0 0 17 0 NN CC NNS NNP NNP O
only. only. 0 0 0 0 0 0 0 0 5 0 CC NNS NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 NNS NNP NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NN NN O
breast breast 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NN NNP O
cancer, cancer, 0 0 0 0 1 0 0 0 7 0 NNP NN NN NNP NN O
NTIS NTIS 1 1 0 0 0 0 0 0 4 0 NN NN NNP NN IN O
prevalence prevalence 0 0 0 0 0 0 0 0 10 0 NN NNP NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
initial initial 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN VBD O
diagnosis diagnosis 0 0 0 0 0 0 0 0 9 0 DT JJ NN VBD JJR O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD JJR CC O
higher higher 0 0 0 0 0 0 0 0 6 0 NN VBD JJR CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 VBD JJR CC VBN IN O
increased increased 0 0 0 0 0 0 0 0 9 0 JJR CC VBN IN NNP O
during during 0 0 0 0 0 0 0 0 6 0 CC VBN IN NNP CC O
chemotherapy, chemotherapy, 0 0 0 0 1 0 0 0 13 0 VBN IN NNP CC VBD O
but but 0 0 0 0 0 0 0 0 3 0 IN NNP CC VBD IN O
declined declined 0 0 0 0 0 0 0 0 8 0 NNP CC VBD IN DT O
before before 0 0 0 0 0 0 0 0 6 0 CC VBD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT JJ JJ O
next next 0 0 0 0 0 0 0 0 4 0 IN DT JJ JJ NNP O
chemotherapeutic chemotherapeutic 0 0 0 0 0 0 0 0 16 0 DT JJ JJ NNP NNP O
course. course. 0 0 0 0 0 0 0 0 7 0 JJ JJ NNP NNP VBZ O
Thyroid Thyroid 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP VBZ VBN O
hormones hormones 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ VBN RB O
decreased decreased 0 0 0 0 0 0 0 0 9 0 NNP VBZ VBN RB IN O
signigicantly signigicantly 0 0 0 0 0 0 0 0 13 0 VBZ VBN RB IN NNP O
during during 0 0 0 0 0 0 0 0 6 0 VBN RB IN NNP NNP O
chemotherapy. chemotherapy. 0 0 0 0 0 0 0 0 13 0 RB IN NNP NNP MD O
T3 T3 1 1 0 0 0 0 0 1 2 0 IN NNP NNP MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NNP NNP MD VB DT O
enhance enhance 0 0 0 0 0 0 0 0 7 0 NNP MD VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NN IN O
chemosensitivity chemosensitivity 0 0 0 0 0 0 0 0 16 0 VB DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP TO O
MCF-7 MCF-7 1 1 1 0 0 0 0 1 5 0 NN IN NNP TO CD O
to to 0 0 0 0 0 0 0 0 2 0 IN NNP TO CD CC O
5-Fu 5-Fu 0 0 1 0 0 0 0 1 4 0 NNP TO CD CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 TO CD CC JJ IN O
taxol, taxol, 0 0 0 0 1 0 0 0 6 0 CD CC JJ IN NN O
with with 0 0 0 0 0 0 0 0 4 0 CC JJ IN NN IN O
progression progression 0 0 0 0 0 0 0 0 11 0 JJ IN NN IN -NONE- O
from from 0 0 0 0 0 0 0 0 4 0 IN NN IN -NONE- NN O
G0-G1 G0-G1 1 1 1 0 0 0 0 1 5 phase NN IN -NONE- NN TO B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN -NONE- NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 -NONE- NN TO NNP NNP O
S S 1 1 0 0 0 0 0 0 1 0 NN TO NNP NNP NNP O
phase. phase. 0 0 0 0 0 0 0 0 6 0 TO NNP NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP JJ NN O
similar similar 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NN NN O
chemosensitization chemosensitization 0 0 0 0 0 0 0 0 18 0 NNP JJ NN NN IN O
role role 0 0 0 0 0 0 0 0 4 0 JJ NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP VBD O
T3 T3 1 1 0 0 0 0 0 1 2 0 NN IN NNP VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 IN NNP VBD VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 NNP VBD VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
MDA-MB-231. MDA-MB-231. 1 1 1 0 0 0 0 1 11 0 VBN IN NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 IN NNP NNP VBD JJ O
compared compared 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD JJ NN O
chemotherapeutic chemotherapeutic 0 0 0 0 0 0 0 0 16 0 NNP VBD JJ NN IN O
efficacy efficacy 0 0 0 0 0 0 0 0 8 0 VBD JJ NN IN NNS O
among among 0 0 0 0 0 0 0 0 5 0 JJ NN IN NNS IN O
groups groups 0 0 0 0 0 0 0 0 6 0 NN IN NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN JJ NN O
different different 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NN NNS O
usage usage 0 0 0 0 0 0 0 0 5 0 IN JJ NN NNS IN O
modes modes 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NN O
T3, T3, 1 1 0 0 1 0 0 1 3 0 NNS IN JJ NN NN O
finding finding 0 0 0 0 0 0 0 0 7 0 IN JJ NN NN IN O
pretreatment pretreatment 0 0 0 0 0 0 0 0 12 0 JJ NN NN IN JJR O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN JJR NN O
lower lower 0 0 0 0 0 0 0 0 5 0 NN IN JJR NN IN O
dose dose 0 0 0 0 0 0 0 0 4 0 IN JJR NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJR NN IN NNP VBG O
T3, T3, 1 1 0 0 1 0 0 1 3 0 NN IN NNP VBG JJR O
using using 0 0 0 0 0 0 0 0 5 0 IN NNP VBG JJR NN O
higher higher 0 0 0 0 0 0 0 0 6 0 NNP VBG JJR NN IN O
dose dose 0 0 0 0 0 0 0 0 4 0 VBG JJR NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJR NN IN NNP RB O
T3 T3 1 1 0 0 0 0 0 1 2 0 NN IN NNP RB IN O
together together 0 0 0 0 0 0 0 0 8 0 IN NNP RB IN CD O
with with 0 0 0 0 0 0 0 0 4 0 NNP RB IN CD CC O
5-Fu 5-Fu 0 0 1 0 0 0 0 1 4 0 RB IN CD CC IN O
or or 0 0 0 0 0 0 0 0 2 0 IN CD CC IN NN O
during during 0 0 0 0 0 0 0 0 6 0 CD CC IN NN IN O
chemotherapy chemotherapy 0 0 0 0 0 0 0 0 12 0 CC IN NN IN CD O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN CD VBD O
5-Fu 5-Fu 0 0 1 0 0 0 0 1 4 0 NN IN CD VBD DT O
were were 0 0 0 0 0 0 0 0 4 0 IN CD VBD DT JJ O
all all 0 0 0 0 0 0 0 0 3 0 CD VBD DT JJ TO O
available available 0 0 0 0 0 0 0 0 9 0 VBD DT JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT JJ TO VB JJ O
achieve achieve 0 0 0 0 0 0 0 0 7 0 JJ TO VB JJ CC O
chemosensitization, chemosensitization, 0 0 0 0 1 0 0 0 19 0 TO VB JJ CC NN O
but but 0 0 0 0 0 0 0 0 3 0 VB JJ CC NN IN O
pretreatment pretreatment 0 0 0 0 0 0 0 0 12 0 JJ CC NN IN JJR O
with with 0 0 0 0 0 0 0 0 4 0 CC NN IN JJR NN O
lower lower 0 0 0 0 0 0 0 0 5 0 NN IN JJR NN IN O
dose dose 0 0 0 0 0 0 0 0 4 0 IN JJR NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJR NN IN NNP IN O
T3 T3 1 1 0 0 0 0 0 1 2 0 NN IN NNP IN DT O
until until 0 0 0 0 0 0 0 0 5 0 IN NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN IN O
end end 0 0 0 0 0 0 0 0 3 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN MD O
chemotherapy chemotherapy 0 0 0 0 0 0 0 0 12 0 NN IN NN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 IN NN MD VB DT O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT NN CC O
safer safer 0 0 0 0 0 0 0 0 5 0 VB DT NN CC JJR O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC JJR JJ O
more more 0 0 0 0 0 0 0 0 4 0 NN CC JJR JJ NNP O
efficient efficient 0 0 0 0 0 0 0 0 9 0 CC JJR JJ NNP NNP O
therapy. therapy. 0 0 0 0 0 0 0 0 8 0 JJR JJ NNP NNP NNP O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 JJ NNP NNP NNP NNP O
Taken Taken 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP VBD O
together, together, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP VBD NNS O
thyroid thyroid 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD NNS VBG O
hormones hormones 0 0 0 0 0 0 0 0 8 0 NNP VBD NNS VBG IN O
decreasing decreasing 0 0 0 0 0 0 0 0 10 0 VBD NNS VBG IN NN O
during during 0 0 0 0 0 0 0 0 6 0 NNS VBG IN NN VBD O
chemotherapy chemotherapy 0 0 0 0 0 0 0 0 12 0 VBG IN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 IN NN VBD VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 NN VBD VBN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNS IN O
lots lots 0 0 0 0 0 0 0 0 4 0 VBN IN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN JJ NN O
breast breast 0 0 0 0 0 0 0 0 6 0 NNS IN JJ NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNP NNP O
patients. patients. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NNP DT O
On On 1 0 0 0 0 0 0 0 2 0 NN NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NN O
other other 0 0 0 0 0 0 0 0 5 0 NNP DT JJ NN VBD O
hand, hand, 0 0 0 0 1 0 0 0 5 0 DT JJ NN VBD NNS O
thyroid thyroid 0 0 0 0 0 0 0 0 7 0 JJ NN VBD NNS MD O
hormones hormones 0 0 0 0 0 0 0 0 8 0 NN VBD NNS MD VB O
can can 0 0 0 0 0 0 0 0 3 0 VBD NNS MD VB DT O
enhance enhance 0 0 0 0 0 0 0 0 7 0 NNS MD VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT JJ NN O
chemotherapeutic chemotherapeutic 0 0 0 0 0 0 0 0 16 0 VB DT JJ NN IN O
efficacy efficacy 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN VBG O
through through 0 0 0 0 0 0 0 0 7 0 JJ NN IN VBG NN O
gatherring gatherring 0 0 0 0 0 0 0 0 10 0 NN IN VBG NN NNS O
tumor tumor 0 0 0 0 0 0 0 0 5 0 IN VBG NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 VBG NN NNS IN RB O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN RB VBG O
actively actively 0 0 0 0 0 0 0 0 8 0 NNS IN RB VBG NN O
proliferating proliferating 0 0 0 0 0 0 0 0 13 0 IN RB VBG NN WDT O
stage, stage, 0 0 0 0 1 0 0 0 6 0 RB VBG NN WDT MD O
which which 0 0 0 0 0 0 0 0 5 0 VBG NN WDT MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN WDT MD VB DT O
provide provide 0 0 0 0 0 0 0 0 7 0 WDT MD VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT JJ NN O
new new 0 0 0 0 0 0 0 0 3 0 VB DT JJ NN NN O
adjuvant adjuvant 0 0 0 0 0 0 0 0 8 0 DT JJ NN NN IN O
therapy therapy 0 0 0 0 0 0 0 0 7 0 JJ NN NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NN NN O
breast breast 0 0 0 0 0 0 0 0 6 0 NN IN NN NN IN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP RB O
furture, furture, 0 0 0 0 1 0 0 0 8 0 NN IN NNP RB IN O
especially especially 0 0 0 0 0 0 0 0 10 0 IN NNP RB IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NNP RB IN DT VBP O
those those 0 0 0 0 0 0 0 0 5 0 RB IN DT VBP NN O
have have 0 0 0 0 0 0 0 0 4 0 IN DT VBP NN IN O
hypothyroidism hypothyroidism 0 0 0 0 0 0 0 0 14 0 DT VBP NN IN NNP O
during during 0 0 0 0 0 0 0 0 6 0 VBP NN IN NNP NONE O
chemotherapy. chemotherapy. 0 0 0 0 0 0 0 0 13 0 NN IN NNP NONE NONE O
Roles Roles 1 0 0 0 0 0 0 0 5 0 NONE NONE NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NONE NNS IN NN NN O
transient transient 0 0 0 0 0 0 0 0 9 0 NNS IN NN NN NN O
receptor receptor 0 0 0 0 0 0 0 0 8 0 IN NN NN NN JJ O
potential potential 0 0 0 0 0 0 0 0 9 0 NN NN NN JJ NN O
canonical canonical 0 0 0 0 0 0 0 0 9 0 NN NN JJ NN NNS O
(TRPC) (TRPC) 0 1 0 0 0 0 0 0 6 0 NN JJ NN NNS CC O
channels channels 0 0 0 0 0 0 0 0 8 0 JJ NN NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC JJ NN O
reverse-mode reverse-mode 0 0 1 0 0 0 0 0 12 0 NNS CC JJ NN NN O
Na+/Ca2+ Na+/Ca2+ 1 0 0 1 0 0 0 1 8 0 CC JJ NN NN IN O
exchanger exchanger 0 0 0 0 0 0 0 0 9 0 JJ NN NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 IN NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN NN NN NN O
cardiac cardiac 0 0 0 0 0 0 0 0 7 0 IN NN NN NN NNS O
fibroblasts: fibroblasts: 0 0 0 0 0 0 0 0 12 0 NN NN NN NNS IN O
Effects Effects 1 0 0 0 0 0 0 0 7 0 NN NN NNS IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN VBG NN O
transforming transforming 0 0 0 0 0 0 0 0 12 0 NNS IN VBG NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 IN VBG NN NN NNP O
factor factor 0 0 0 0 0 0 0 0 6 0 VBG NN NN NNP NNP O
β1. β1. 0 0 0 0 0 0 0 1 3 0 NN NN NNP NNP NNP O
Ikeda Ikeda 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Nakajima Nakajima 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yamamoto Yamamoto 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Takano Takano 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tanaka Tanaka 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kikuchi Kikuchi 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Oguri Oguri 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Morita Morita 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Nakamura Nakamura 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Komuro Komuro 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
I. I. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Cardiovascular Cardiovascular 1 0 0 0 0 0 0 0 14 0 NNP IN NNP NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Tokyo, Tokyo, 1 0 0 0 1 0 0 0 6 0 NNP IN NNP NNP CD O
Tokyo Tokyo 1 0 0 0 0 0 0 0 5 0 IN NNP NNP CD NNP O
113-8654, 113-8654, 0 0 1 0 1 0 0 1 9 0 NNP NNP CD NNP NNP O
Japan. Japan. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP IN O
Expression Expression 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN NN O
transient transient 0 0 0 0 0 0 0 0 9 0 NNP IN NN NN NN O
receptor receptor 0 0 0 0 0 0 0 0 8 0 IN NN NN NN JJ O
potential potential 0 0 0 0 0 0 0 0 9 0 NN NN NN JJ NNS O
canonical canonical 0 0 0 0 0 0 0 0 9 0 NN NN JJ NNS -NONE- O
channels channels 0 0 0 0 0 0 0 0 8 0 NN JJ NNS -NONE- CC O
(TRPC) (TRPC) 0 1 0 0 0 0 0 0 6 0 JJ NNS -NONE- CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- CC DT NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 CC DT NNS IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN VBG NN O
transforming transforming 0 0 0 0 0 0 0 0 12 0 NNS IN VBG NN -NONE- O
growth growth 0 0 0 0 0 0 0 0 6 0 IN VBG NN -NONE- JJ O
factor-β1 factor-β1 0 0 1 0 0 0 0 1 9 0 VBG NN -NONE- JJ IN O
(TGF-β1) (TGF-β1) 0 0 1 0 0 0 0 1 8 0 NN -NONE- JJ IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 -NONE- JJ IN JJ NNS O
Ca2+ Ca2+ 1 0 0 0 0 0 0 1 4 0 JJ IN JJ NNS CC O
signals signals 0 0 0 0 0 0 0 0 7 0 IN JJ NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC JJ NN O
fibroblast fibroblast 0 0 0 0 0 0 0 0 10 0 NNS CC JJ NN VBD O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 CC JJ NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NN VBD VBN IN O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NN VBD VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 VBN IN JJ NN NNP O
cardiac cardiac 0 0 0 0 0 0 0 0 7 0 IN JJ NN NNP NNP O
fibroblasts. fibroblasts. 0 0 0 0 0 0 0 0 12 0 JJ NN NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP JJ CC O
conventional conventional 0 0 0 0 0 0 0 0 12 0 NNP NNP JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP JJ CC JJ JJ O
quantitative quantitative 0 0 0 0 0 0 0 0 12 0 JJ CC JJ JJ NN O
real-time real-time 0 0 1 0 0 0 0 0 9 0 CC JJ JJ NN NN O
RT-PCR, RT-PCR, 1 1 1 0 1 0 0 0 7 0 JJ JJ NN NN NN O
western western 0 0 0 0 0 0 0 0 7 0 JJ NN NN NN JJ O
blot, blot, 0 0 0 0 1 0 0 0 5 0 NN NN NN JJ NN O
immunocytochemical immunocytochemical 0 0 0 0 0 0 0 0 18 0 NN NN JJ NN CC O
analysis, analysis, 0 0 0 0 1 0 0 0 9 0 NN JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NN O
intracellular intracellular 0 0 0 0 0 0 0 0 13 0 NN CC JJ NN NN O
Ca2+ Ca2+ 1 0 0 0 0 0 0 1 4 0 CC JJ NN NN NN O
concentration concentration 0 0 0 0 0 0 0 0 13 0 JJ NN NN NN NN O
[Ca2+]i [Ca2+]i 0 0 0 0 0 0 0 1 7 0 NN NN NN NN VBD O
measurement measurement 0 0 0 0 0 0 0 0 11 0 NN NN NN VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD NNP NNP O
applied. applied. 0 0 0 0 0 0 0 0 8 0 NN VBD NNP NNP NN O
Cell Cell 1 0 0 0 0 0 0 0 4 0 VBD NNP NNP NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NNP NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN CC NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 CC NN NN NN VBD O
progression progression 0 0 0 0 0 0 0 0 11 0 NN NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN VBG O
assessed assessed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN VBG NNP O
using using 0 0 0 0 0 0 0 0 5 0 VBD VBN VBG NNP NNS O
MTT MTT 1 1 0 0 0 0 0 0 3 0 VBN VBG NNP NNS CC O
assays assays 0 0 0 0 0 0 0 0 6 0 VBG NNP NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNS CC NN VBD O
fluorescence fluorescence 0 0 0 0 0 0 0 0 12 0 NNS CC NN VBD NN O
activated activated 0 0 0 0 0 0 0 0 9 0 CC NN VBD NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 NN VBD NN NNP NNP O
sorting. sorting. 0 0 0 0 0 0 0 0 8 0 VBD NN NNP NNP NN O
Human Human 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NN NNS O
cardiac cardiac 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NNS VBP O
fibroblasts fibroblasts 0 0 0 0 0 0 0 0 11 0 NNP NN NNS VBP DT O
have have 0 0 0 0 0 0 0 0 4 0 NN NNS VBP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBP DT NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 VBP DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
TRPC1,3,4,6 TRPC1,3,4,6 1 1 0 0 1 0 0 1 11 0 NN IN NNP NNP CC O
mRNA mRNA 0 0 0 0 0 0 0 0 4 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP CD O
proteins. proteins. 0 0 0 0 0 0 0 0 9 0 NNP CC NNP CD -NONE- O
1-oleoyl-2-acetyl-sn-glycerol 1-oleoyl-2-acetyl-sn-glycerol 0 0 1 0 0 0 0 1 29 0 CC NNP CD -NONE- CC O
(OAG) (OAG) 0 1 0 0 0 0 0 0 5 0 NNP CD -NONE- CC VB O
and and 0 0 0 0 0 0 0 0 3 0 CD -NONE- CC VB VBN O
thapsigargin thapsigargin 0 0 0 0 0 0 0 0 12 0 -NONE- CC VB VBN JJ O
induced induced 0 0 0 0 0 0 0 0 7 0 CC VB VBN JJ JJ O
extracellular extracellular 0 0 0 0 0 0 0 0 13 0 VB VBN JJ JJ NN O
Ca2+-mediated Ca2+-mediated 1 0 1 0 0 0 0 1 13 0 VBN JJ JJ NN NNP O
[Ca2+]i [Ca2+]i 0 0 0 0 0 0 0 1 7 0 JJ JJ NN NNP NNP O
rise. rise. 0 0 0 0 0 0 0 0 5 0 JJ NN NNP NNP IN O
siRNA siRNA 0 0 0 0 0 0 0 0 5 0 NN NNP NNP IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NN IN O
knock knock 0 0 0 0 0 0 0 0 5 0 NNP IN NN IN IN O
down down 0 0 0 0 0 0 0 0 4 0 IN NN IN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN IN IN NNP VBD O
TRPC6 TRPC6 1 1 0 0 0 0 0 1 5 0 IN IN NNP VBD JJ O
reduced reduced 0 0 0 0 0 0 0 0 7 0 IN NNP VBD JJ NN O
OAG-induced OAG-induced 1 0 1 0 0 0 0 0 11 0 NNP VBD JJ NN NNP O
Ca2+ Ca2+ 1 0 0 0 0 0 0 1 4 0 VBD JJ NN NNP NNP O
entry. entry. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP IN O
Hyperforin Hyperforin 1 0 0 0 0 0 0 0 10 0 NN NNP NNP IN RB O
as as 0 0 0 0 0 0 0 0 2 0 NNP NNP IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NNP IN RB IN NN O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN NN NNP O
angiotensin angiotensin 0 0 0 0 0 0 0 0 11 0 RB IN NN NNP JJ O
II II 1 1 0 0 0 0 0 0 2 0 IN NN NNP JJ NN O
(Ang (Ang 0 0 0 0 0 0 0 0 4 0 NN NNP JJ NN VBD O
II) II) 1 1 0 0 0 0 0 0 3 0 NNP JJ NN VBD JJ O
induced induced 0 0 0 0 0 0 0 0 7 0 JJ NN VBD JJ NNP O
Ca2+ Ca2+ 1 0 0 0 0 0 0 1 4 0 NN VBD JJ NNP NNP O
entry. entry. 0 0 0 0 0 0 0 0 6 0 VBD JJ NNP NNP DT O
KB-R7943, KB-R7943, 1 1 1 0 1 0 0 1 9 0 JJ NNP NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT JJ NN O
reverse-mode reverse-mode 0 0 1 0 0 0 0 0 12 0 NNP DT JJ NN NN O
Na+/Ca2+ Na+/Ca2+ 1 0 0 1 0 0 0 1 8 0 DT JJ NN NN NN O
exchanger exchanger 0 0 0 0 0 0 0 0 9 0 JJ NN NN NN NN O
(NCX) (NCX) 0 1 0 0 0 0 0 0 5 0 NN NN NN NN NN O
inhibitor, inhibitor, 0 0 0 0 1 0 0 0 10 0 NN NN NN NN NN O
and/or and/or 0 0 0 1 0 0 0 0 6 0 NN NN NN NN IN O
replacement replacement 0 0 0 0 0 0 0 0 11 0 NN NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP IN O
Na+ Na+ 1 0 0 0 0 0 0 0 3 0 NN IN NNP IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NNP IN JJ VBN O
NMDG+ NMDG+ 1 1 0 0 0 0 0 0 5 0 NNP IN JJ VBN -NONE- O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 IN JJ VBN -NONE- -NONE- O
thapsigargin-, thapsigargin-, 0 0 1 0 1 0 0 0 14 0 JJ VBN -NONE- -NONE- CC O
OAG- OAG- 1 1 1 0 0 0 0 0 4 0 VBN -NONE- -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- CC NNP JJ O
Ang Ang 1 0 0 0 0 0 0 0 3 0 -NONE- CC NNP JJ NN O
II-induced II-induced 1 0 1 0 0 0 0 0 10 0 CC NNP JJ NN NNP O
Ca2+ Ca2+ 1 0 0 0 0 0 0 1 4 0 NNP JJ NN NNP NNP O
entry. entry. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP IN O
Treatment Treatment 1 0 0 0 0 0 0 0 9 0 NN NNP NNP IN -NONE- O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNP IN -NONE- VBN O
TGF-β1 TGF-β1 1 0 1 0 0 0 0 1 6 0 NNP IN -NONE- VBN -NONE- O
increased increased 0 0 0 0 0 0 0 0 9 0 IN -NONE- VBN -NONE- -NONE- O
thapsigargin-, thapsigargin-, 0 0 1 0 1 0 0 0 14 0 -NONE- VBN -NONE- -NONE- CC O
OAG- OAG- 1 1 1 0 0 0 0 0 4 0 VBN -NONE- -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- CC NNP JJ O
Ang Ang 1 0 0 0 0 0 0 0 3 0 -NONE- CC NNP JJ NN O
II-induced II-induced 1 0 1 0 0 0 0 0 10 0 CC NNP JJ NN NN O
Ca2+ Ca2+ 1 0 0 0 0 0 0 1 4 0 NNP JJ NN NN IN O
entry entry 0 0 0 0 0 0 0 0 5 0 JJ NN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT NN IN O
enhancement enhancement 0 0 0 0 0 0 0 0 11 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NN O
TRPC1,6 TRPC1,6 1 1 0 0 1 0 0 1 7 0 NN IN NNP NN -NONE- O
protein protein 0 0 0 0 0 0 0 0 7 0 IN NNP NN -NONE- VBN O
expression, expression, 0 0 0 0 1 0 0 0 11 0 NNP NN -NONE- VBN IN O
suppressed suppressed 0 0 0 0 0 0 0 0 10 0 NN -NONE- VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 -NONE- VBN IN NNP NNP O
KB-R7943. KB-R7943. 1 1 1 0 0 0 0 1 9 0 VBN IN NNP NNP CC O
TGF-β1 TGF-β1 1 0 1 0 0 0 0 1 6 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP VBD O
AngII AngII 1 0 0 0 0 0 0 0 5 0 NNP CC NNP VBD NN O
promoted promoted 0 0 0 0 0 0 0 0 8 0 CC NNP VBD NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP VBD NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 VBD NN NN NN IN O
progression progression 0 0 0 0 0 0 0 0 11 0 NN NN NN IN -NONE- O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN -NONE- TO O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NN IN -NONE- TO JJ B_TIMEXCCP
to to 0 0 0 0 0 0 0 0 2 0 IN -NONE- TO JJ CC O
S/G2/M S/G2/M 1 1 0 1 0 0 0 1 6 0 -NONE- TO JJ CC NN B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 TO JJ CC NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ CC NN NNP DT O
proliferation. proliferation. 0 0 0 0 0 0 0 0 14 0 CC NN NNP DT NN O
A A 1 1 0 0 0 0 0 0 1 0 NN NNP DT NN IN O
decrease decrease 0 0 0 0 0 0 0 0 8 0 NNP DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
extracellular extracellular 0 0 0 0 0 0 0 0 13 0 IN DT JJ NN CC O
Ca2+ Ca2+ 1 0 0 0 0 0 0 1 4 0 DT JJ NN CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC -NONE- VBD O
KB-R7943 KB-R7943 1 1 1 0 0 0 0 1 8 0 NN CC -NONE- VBD NNP O
suppressed suppressed 0 0 0 0 0 0 0 0 10 0 CC -NONE- VBD NNP NNP O
it. it. 0 0 0 0 0 0 0 0 3 0 -NONE- VBD NNP NNP NN O
Human Human 1 0 0 0 0 0 0 0 5 0 VBD NNP NNP NN NNS O
cardiac cardiac 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NNS VBP O
fibroblasts fibroblasts 0 0 0 0 0 0 0 0 11 0 NNP NN NNS VBP JJ O
contain contain 0 0 0 0 0 0 0 0 7 0 NN NNS VBP JJ JJ O
several several 0 0 0 0 0 0 0 0 7 0 NNS VBP JJ JJ NN O
TRPC-mediated TRPC-mediated 1 0 1 0 0 0 0 0 13 0 VBP JJ JJ NN NN O
Ca2+ Ca2+ 1 0 0 0 0 0 0 1 4 0 JJ JJ NN NN NN O
influx influx 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN WDT O
pathways, pathways, 0 0 0 0 1 0 0 0 9 0 NN NN NN WDT NN O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT NN DT O
activate activate 0 0 0 0 0 0 0 0 8 0 NN WDT NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 WDT NN DT JJ NNP O
reverse-mode reverse-mode 0 0 1 0 0 0 0 0 12 0 NN DT JJ NNP NNP O
NCX. NCX. 1 1 0 0 0 0 0 0 4 0 DT JJ NNP NNP NNS O
TGF-β1 TGF-β1 1 0 1 0 0 0 0 1 6 0 JJ NNP NNP NNS DT O
enhances enhances 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNS DT NN NN O
Ca2+ Ca2+ 1 0 0 0 0 0 0 1 4 0 NNS DT NN NN NNS O
influx influx 0 0 0 0 0 0 0 0 6 0 DT NN NN NNS VBG O
pathways pathways 0 0 0 0 0 0 0 0 8 0 NN NN NNS VBG NN O
requiring requiring 0 0 0 0 0 0 0 0 9 0 NN NNS VBG NN NNS O
Ca2+ Ca2+ 1 0 0 0 0 0 0 1 4 0 NNS VBG NN NNS IN O
signals signals 0 0 0 0 0 0 0 0 7 0 VBG NN NNS IN PRP$ O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NNS IN PRP$ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 IN PRP$ NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 PRP$ NN IN NN NNP O
fibroblast fibroblast 0 0 0 0 0 0 0 0 10 0 NN IN NN NNP NONE O
proliferation. proliferation. 0 0 0 0 0 0 0 0 14 0 IN NN NNP NONE NONE O
MEK/ERK MEK/ERK 1 1 0 1 0 0 0 0 7 0 NONE NONE NN NNP NNP O
Dependent Dependent 1 0 0 0 0 0 0 0 9 0 NONE NN NNP NNP IN O
Activation Activation 1 0 0 0 0 0 0 0 10 0 NN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNPS O
STAT1 STAT1 1 1 0 0 0 0 0 1 5 0 NNP IN NNP NNPS JJ O
Mediates Mediates 1 0 0 0 0 0 0 0 8 0 IN NNP NNPS JJ NNP O
Dasatinib-Induced Dasatinib-Induced 1 0 1 0 0 0 0 0 17 0 NNP NNPS JJ NNP IN O
Differentiation Differentiation 1 0 0 0 0 0 0 0 15 0 NNPS JJ NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNP IN NNP NNP O
Acute Acute 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Myeloid Myeloid 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
Leukemia. Leukemia. 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Fang Fang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhong Zhong 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lin Lin 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhou Zhou 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Jing Jing 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ying Ying 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Luo Luo 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yang Yang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
He He 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Q. Q. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Pharmacology Pharmacology 1 0 0 0 0 0 0 0 12 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Toxicology, Toxicology, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pharmaceutical Pharmaceutical 1 0 0 0 0 0 0 0 14 0 NNP IN NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Zhejiang Zhejiang 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Hangzhou, Hangzhou, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Zhejiang, Zhejiang, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP : O
China China 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP : NNP O
; ; 0 0 0 0 0 0 0 0 1 0 NNP NNP : NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP : NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 : NNP IN NNP NNP O
Pathology, Pathology, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Michigan Michigan 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
School, School, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Ann Ann 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Arbor, Arbor, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
Michigan, Michigan, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNPS O
United United 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNPS IN O
States States 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
America. America. 1 0 0 0 0 0 0 0 8 0 NNPS IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
Dasatinib Dasatinib 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP VBZ O
(BMS-354825) (BMS-354825) 0 1 1 0 0 0 0 1 12 0 NNP NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT JJ VBN O
FDA-approved FDA-approved 1 0 1 0 0 0 0 0 12 0 VBZ DT JJ VBN NN O
multitargeted multitargeted 0 0 0 0 0 0 0 0 13 0 DT JJ VBN NN NN O
kinase kinase 0 0 0 0 0 0 0 0 6 0 JJ VBN NN NN IN O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 VBN NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ CC O
BCR/ABL BCR/ABL 1 1 0 1 0 0 0 0 7 0 NN IN JJ CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC NNP NNP O
Src Src 1 0 0 0 0 0 0 0 3 0 JJ CC NNP NNP NNP O
kinases. kinases. 0 0 0 0 0 0 0 0 8 0 CC NNP NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ RB VBN O
now now 0 0 0 0 0 0 0 0 3 0 NNP VBZ RB VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 VBZ RB VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ JJ O
chronic chronic 0 0 0 0 0 0 0 0 7 0 NN IN JJ JJ NN O
myelogenous myelogenous 0 0 0 0 0 0 0 0 11 0 IN JJ JJ NN NN O
leukemia leukemia 0 0 0 0 0 0 0 0 8 0 JJ JJ NN NN IN O
(CML) (CML) 0 1 0 0 0 0 0 0 5 0 JJ NN NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN NN CC O
resistance resistance 0 0 0 0 0 0 0 0 10 0 NN IN NN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 IN NN CC NN TO O
intolerance intolerance 0 0 0 0 0 0 0 0 11 0 NN CC NN TO RB O
to to 0 0 0 0 0 0 0 0 2 0 CC NN TO RB JJ O
prior prior 0 0 0 0 0 0 0 0 5 0 NN TO RB JJ NN O
therapies, therapies, 0 0 0 0 1 0 0 0 10 0 TO RB JJ NN NNP O
including including 0 0 0 0 0 0 0 0 9 0 RB JJ NN NNP NNP O
imatinib. imatinib. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NNP PRP O
Here Here 1 0 0 0 0 0 0 0 4 0 NN NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP DT O
report report 0 0 0 0 0 0 0 0 6 0 NNP PRP VBP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 PRP VBP DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 VBP DT NN NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 DT NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN IN O
dasatinib dasatinib 0 0 0 0 0 0 0 0 9 0 NN IN NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 IN NN IN NN DT O
inducing inducing 0 0 0 0 0 0 0 0 8 0 NN IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN IN O
differentiation differentiation 0 0 0 0 0 0 0 0 15 0 NN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN VBD O
acute acute 0 0 0 0 0 0 0 0 5 0 NN IN NN VBD NN O
myeloid myeloid 0 0 0 0 0 0 0 0 7 0 IN NN VBD NN -NONE- O
leukemia leukemia 0 0 0 0 0 0 0 0 8 0 NN VBD NN -NONE- VBZ O
(AML) (AML) 0 1 0 0 0 0 0 0 5 0 VBD NN -NONE- VBZ IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN -NONE- VBZ IN JJ O
through through 0 0 0 0 0 0 0 0 7 0 -NONE- VBZ IN JJ NN O
MEK/ERK-dependent MEK/ERK-dependent 1 0 1 1 0 0 0 0 17 0 VBZ IN JJ NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 IN JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
signal signal 0 0 0 0 0 0 0 0 6 0 NN IN JJ NN CC O
transducer transducer 0 0 0 0 0 0 0 0 10 0 IN JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN IN O
activator activator 0 0 0 0 0 0 0 0 9 0 NN CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN CD O
transcription transcription 0 0 0 0 0 0 0 0 13 0 NN IN NN CD NNP O
1 1 0 0 0 0 0 0 1 1 1 0 IN NN CD NNP NNP O
(STAT1). (STAT1). 0 1 0 0 0 0 0 1 8 0 NN CD NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 CD NNP NNP VBD IN O
found found 0 0 0 0 0 0 0 0 5 0 NNP NNP VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBD IN NN MD O
dasatinib dasatinib 0 0 0 0 0 0 0 0 9 0 VBD IN NN MD VB O
could could 0 0 0 0 0 0 0 0 5 0 IN NN MD VB DT O
induce induce 0 0 0 0 0 0 0 0 6 0 NN MD VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NN IN O
differentiation differentiation 0 0 0 0 0 0 0 0 15 0 VB DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNS O
AML AML 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS IN VBN O
as as 0 0 0 0 0 0 0 0 2 0 NNP NNS IN VBN IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 NNS IN VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 IN VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
differentiation differentiation 0 0 0 0 0 0 0 0 15 0 NN IN NN NN NN O
marker marker 0 0 0 0 0 0 0 0 6 0 IN NN NN NN -NONE- O
CD11b, CD11b, 1 0 0 0 1 0 0 1 6 0 NN NN NN -NONE- NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase NN NN -NONE- NN NN O
phase phase 0 0 0 0 0 0 0 0 5 arrest NN -NONE- NN NN CC O
arrest arrest 0 0 0 0 0 0 0 0 6 0 -NONE- NN NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBD NN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 NN CC VBD NN IN O
ratio ratio 0 0 0 0 0 0 0 0 5 0 CC VBD NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN NN TO O
nucleus nucleus 0 0 0 0 0 0 0 0 7 0 NN IN NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO NNP IN O
cytoplasm. cytoplasm. 0 0 0 0 0 0 0 0 10 0 NN TO NNP IN NNP O
Of Of 1 0 0 0 0 0 0 0 2 0 TO NNP IN NNP NN O
note, note, 0 0 0 0 1 0 0 0 5 0 NNP IN NNP NN VBD O
dasatinib dasatinib 0 0 0 0 0 0 0 0 9 0 IN NNP NN VBD RB O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP NN VBD RB NN O
robust robust 0 0 0 0 0 0 0 0 6 0 NN VBD RB NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 VBD RB NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 RB NN IN NNP DT O
STAT1 STAT1 1 1 0 0 0 0 0 1 5 0 NN IN NNP DT IN O
both both 0 0 0 0 0 0 0 0 4 0 IN NNP DT IN NNP O
at at 0 0 0 0 0 0 0 0 2 0 NNP DT IN NNP CC O
Tyr701 Tyr701 1 0 0 0 0 0 0 1 6 0 DT IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP IN O
Ser727 Ser727 1 0 0 0 0 0 0 1 6 0 NNP CC NNP IN RB O
as as 0 0 0 0 0 0 0 0 2 0 CC NNP IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NNP IN RB IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NN IN O
redistribution redistribution 0 0 0 0 0 0 0 0 14 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
STAT1 STAT1 1 1 0 0 0 0 0 1 5 0 NN IN NNP IN DT O
from from 0 0 0 0 0 0 0 0 4 0 IN NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN TO O
cytoplasm cytoplasm 0 0 0 0 0 0 0 0 9 0 IN DT NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT NN RB O
nucleus, nucleus, 0 0 0 0 1 0 0 0 8 0 TO DT NN RB VBG O
thus thus 0 0 0 0 0 0 0 0 4 0 DT NN RB VBG TO O
leading leading 0 0 0 0 0 0 0 0 7 0 NN RB VBG TO DT O
to to 0 0 0 0 0 0 0 0 2 0 RB VBG TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBG TO DT NN IN O
transcription transcription 0 0 0 0 0 0 0 0 13 0 TO DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
STAT1-targeted STAT1-targeted 1 0 1 0 0 0 0 1 14 0 NN IN JJ NNP NNP O
genes. genes. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP IN O
Knocking Knocking 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP IN NNP O
down down 0 0 0 0 0 0 0 0 4 0 NNP NNP IN NNP NN O
STAT1 STAT1 1 1 0 0 0 0 0 1 5 0 NNP IN NNP NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 IN NNP NN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP RB O
shRNA shRNA 0 0 0 0 0 0 0 0 5 0 NN IN NNP RB VBD O
significantly significantly 0 0 0 0 0 0 0 0 13 0 IN NNP RB VBD JJ O
attenuated attenuated 0 0 0 0 0 0 0 0 10 0 NNP RB VBD JJ NN O
dasatinib-induced dasatinib-induced 0 0 1 0 0 0 0 0 17 0 RB VBD JJ NN VBG O
differentiation, differentiation, 0 0 0 0 1 0 0 0 16 0 VBD JJ NN VBG DT O
indicating indicating 0 0 0 0 0 0 0 0 10 0 JJ NN VBG DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN VBG DT JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 VBG DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP IN O
STAT1 STAT1 1 1 0 0 0 0 0 1 5 0 NN IN NNP IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN JJ NNP O
myeloid myeloid 0 0 0 0 0 0 0 0 7 0 NNP IN JJ NNP NNP O
maturation. maturation. 0 0 0 0 0 0 0 0 11 0 IN JJ NNP NNP RB O
We We 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP RB VBD O
further further 0 0 0 0 0 0 0 0 7 0 NNP NNP RB VBD IN O
found found 0 0 0 0 0 0 0 0 5 0 NNP RB VBD IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 RB VBD IN JJ NN O
dasatinib-induced dasatinib-induced 0 0 1 0 0 0 0 0 17 0 VBD IN JJ NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 IN JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP VBD O
STAT1 STAT1 1 1 0 0 0 0 0 1 5 0 NN IN NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 IN NNP VBD VBN IN O
regulated regulated 0 0 0 0 0 0 0 0 9 0 NNP VBD VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNP O
MEK/ERK MEK/ERK 1 1 0 1 0 0 0 0 7 0 IN DT JJ NNP NNP O
kinases. kinases. 0 0 0 0 0 0 0 0 8 0 DT JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
phosporylation phosporylation 0 0 0 0 0 0 0 0 14 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP CC O
MEK MEK 1 1 0 0 0 0 0 0 3 0 NN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP VBD O
ERK ERK 1 1 0 0 0 0 0 0 3 0 NNP CC NNP VBD RB O
occurred occurred 0 0 0 0 0 0 0 0 8 0 CC NNP VBD RB IN O
rapidly rapidly 0 0 0 0 0 0 0 0 7 0 NNP VBD RB IN NN O
upon upon 0 0 0 0 0 0 0 0 4 0 VBD RB IN NN NN O
dasatinib dasatinib 0 0 0 0 0 0 0 0 9 0 RB IN NN NN CC O
treatment treatment 0 0 0 0 0 0 0 0 9 0 IN NN NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBD RB O
increased increased 0 0 0 0 0 0 0 0 9 0 NN CC VBD RB IN O
progressively progressively 0 0 0 0 0 0 0 0 13 0 CC VBD RB IN NN O
as as 0 0 0 0 0 0 0 0 2 0 VBD RB IN NN VBD O
differentiation differentiation 0 0 0 0 0 0 0 0 15 0 RB IN NN VBD NNP O
was was 0 0 0 0 0 0 0 0 3 0 IN NN VBD NNP NNP O
induced. induced. 0 0 0 0 0 0 0 0 8 0 NN VBD NNP NNP NNS O
MEK MEK 1 1 0 0 0 0 0 0 3 0 VBD NNP NNP NNS NNP O
inhibitors inhibitors 0 0 0 0 0 0 0 0 10 0 NNP NNP NNS NNP CC O
PD98059 PD98059 1 1 0 0 0 0 0 1 7 0 NNP NNS NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNS NNP CC NNP RB O
U0216 U0216 1 1 0 0 0 0 0 1 5 0 NNP CC NNP RB RB O
not not 0 0 0 0 0 0 0 0 3 0 CC NNP RB RB VBN O
only only 0 0 0 0 0 0 0 0 4 0 NNP RB RB VBN DT O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 RB RB VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBN DT NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 VBN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP CC O
STAT1, STAT1, 1 1 0 0 1 0 0 1 6 0 NN IN NNP CC RB O
but but 0 0 0 0 0 0 0 0 3 0 IN NNP CC RB VBD O
also also 0 0 0 0 0 0 0 0 4 0 NNP CC RB VBD JJ O
abrogated abrogated 0 0 0 0 0 0 0 0 9 0 CC RB VBD JJ NN O
dasatinib-induced dasatinib-induced 0 0 1 0 0 0 0 0 17 0 RB VBD JJ NN NN O
myeloid myeloid 0 0 0 0 0 0 0 0 7 0 VBD JJ NN NN VBG O
differentiation, differentiation, 0 0 0 0 1 0 0 0 16 0 JJ NN NN VBG IN O
suggesting suggesting 0 0 0 0 0 0 0 0 10 0 NN NN VBG IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NN VBG IN JJ NN O
MEK/ERK MEK/ERK 1 1 0 1 0 0 0 0 7 0 VBG IN JJ NN NN O
dependent dependent 0 0 0 0 0 0 0 0 9 0 IN JJ NN NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 JJ NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP MD O
STAT1 STAT1 1 1 0 0 0 0 0 1 5 0 NN IN NNP MD VB O
might might 0 0 0 0 0 0 0 0 5 0 IN NNP MD VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 NNP MD VB JJ IN O
indispensable indispensable 0 0 0 0 0 0 0 0 13 0 MD VB JJ IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VB JJ IN DT VBG O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT VBG NN O
differentiating differentiating 0 0 0 0 0 0 0 0 15 0 IN DT VBG NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 DT VBG NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBG NN IN NN IN O
dasatinib dasatinib 0 0 0 0 0 0 0 0 9 0 NN IN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNP O
AML AML 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
Taken Taken 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP PRP$ O
together, together, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP PRP$ NN O
our our 0 0 0 0 0 0 0 0 3 0 NNP NNP PRP$ NN VBZ O
study study 0 0 0 0 0 0 0 0 5 0 NNP PRP$ NN VBZ IN O
suggests suggests 0 0 0 0 0 0 0 0 8 0 PRP$ NN VBZ IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NN VBZ IN NNP VBZ O
STAT1 STAT1 1 1 0 0 0 0 0 1 5 0 VBZ IN NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNP VBZ DT JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ NN IN O
mediator mediator 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
dasatinib-induced dasatinib-induced 0 0 1 0 0 0 0 0 17 0 NN IN JJ NN IN O
differentiation differentiation 0 0 0 0 0 0 0 0 15 0 IN JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
AML AML 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNP WP$ O
cells, cells, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP WP$ NN O
whose whose 0 0 0 0 0 0 0 0 5 0 NNP NNP WP$ NN VBZ O
activation activation 0 0 0 0 0 0 0 0 10 0 NNP WP$ NN VBZ DT O
requires requires 0 0 0 0 0 0 0 0 8 0 WP$ NN VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 VBZ DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
MEK/ERK MEK/ERK 1 1 0 1 0 0 0 0 7 0 NN IN JJ NNP NONE O
cascades. cascades. 0 0 0 0 0 0 0 0 9 0 IN JJ NNP NONE NONE O
Comparative Comparative 1 0 0 0 0 0 0 0 11 0 NONE NONE JJ NN IN O
study study 0 0 0 0 0 0 0 0 5 0 NONE JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ CC O
physico-mechanical physico-mechanical 0 0 1 0 0 0 0 0 18 0 NN IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NNS O
antioxidant antioxidant 0 0 0 0 0 0 0 0 11 0 JJ CC JJ NNS IN O
properties properties 0 0 0 0 0 0 0 0 10 0 CC JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
edible edible 0 0 0 0 0 0 0 0 6 0 NNS IN JJ NN NNS O
gelatin gelatin 0 0 0 0 0 0 0 0 7 0 IN JJ NN NNS IN O
films films 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
skin skin 0 0 0 0 0 0 0 0 4 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
cuttlefish. cuttlefish. 0 0 0 0 0 0 0 0 11 0 NN IN NNP NNP NNP O
Jridi Jridi 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Souissi Souissi 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Mbarek Mbarek 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Chadeyron Chadeyron 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kammoun Kammoun 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Nasri Nasri 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
M. M. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Laboratoire Laboratoire 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Génie Génie 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NN O
Enzymatique Enzymatique 1 0 0 0 0 0 0 0 11 0 IN NNP NNP NN IN O
et et 0 0 0 0 0 0 0 0 2 0 NNP NNP NN IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP : O
Microbiologie Microbiologie 1 0 0 0 0 0 0 0 13 0 NN IN NNP : JJ O
- - 0 0 1 0 0 0 0 0 1 0 IN NNP : JJ NN O
Université Université 1 0 0 0 0 0 0 0 10 0 NNP : JJ NN NN O
de de 0 0 0 0 0 0 0 0 2 0 : JJ NN NN NNP O
Sfax, Sfax, 1 0 0 0 1 0 0 0 5 0 JJ NN NN NNP NNP O
Ecole Ecole 1 0 0 0 0 0 0 0 5 0 NN NN NNP NNP NNP O
Nationale Nationale 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP IN O
d'Ingénieurs d'Ingénieurs 0 0 0 0 0 1 0 0 12 0 NNP NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Sfax, Sfax, 1 0 0 0 1 0 0 0 5 0 NNP IN NNP NNP CD O
B.P. B.P. 1 1 0 0 0 0 0 0 4 0 IN NNP NNP CD CD O
1173, 1173, 0 0 0 0 1 0 0 1 5 0 NNP NNP CD CD JJ O
3038 3038 0 0 0 0 0 0 1 1 4 0 NNP CD CD JJ NNP O
Sfax, Sfax, 1 0 0 0 1 0 0 0 5 0 CD CD JJ NNP NNP O
Tunisia. Tunisia. 1 0 0 0 0 0 0 0 8 0 CD JJ NNP NNP NNP O
Electronic Electronic 1 0 0 0 0 0 0 0 10 0 JJ NNP NNP NNP NNP O
address: address: 0 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
jridimourad@gmail.com. jridimourad@gmail.com. 0 0 0 0 0 0 0 0 22 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
Physicochemical Physicochemical 1 0 0 0 0 0 0 0 15 0 NNP NNP NNP VBZ IN O
properties properties 0 0 0 0 0 0 0 0 10 0 NNP NNP VBZ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN JJ NNS O
edible edible 0 0 0 0 0 0 0 0 6 0 VBZ IN JJ NNS VBN O
films films 0 0 0 0 0 0 0 0 5 0 IN JJ NNS VBN IN O
based based 0 0 0 0 0 0 0 0 5 0 JJ NNS VBN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 NNS VBN IN JJ NN O
cuttlefish cuttlefish 0 0 0 0 0 0 0 0 10 0 VBN IN JJ NN NN O
skin skin 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN VBD O
gelatin gelatin 0 0 0 0 0 0 0 0 7 0 JJ NN NN VBD IN O
extracted extracted 0 0 0 0 0 0 0 0 9 0 NN NN VBD IN JJ O
without without 0 0 0 0 0 0 0 0 7 0 NN VBD IN JJ CC O
(G0) (G0) 0 1 0 0 0 0 0 1 4 0 VBD IN JJ CC IN O
or or 0 0 0 0 0 0 0 0 2 0 IN JJ CC IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 JJ CC IN JJ NNS O
different different 0 0 0 0 0 0 0 0 9 0 CC IN JJ NNS IN O
concentrations concentrations 0 0 0 0 0 0 0 0 14 0 IN JJ NNS IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNS -NONE- O
pepsins pepsins 0 0 0 0 0 0 0 0 7 0 NNS IN NNS -NONE- -NONE- O
(5 (5 0 0 0 0 0 0 0 1 2 0 IN NNS -NONE- -NONE- CD O
(G5), (G5), 0 1 0 0 1 0 0 1 5 0 NNS -NONE- -NONE- CD -NONE- O
10 10 0 0 0 0 0 0 1 1 2 0 -NONE- -NONE- CD -NONE- CC O
(G10) (G10) 0 1 0 0 0 0 0 1 5 0 -NONE- CD -NONE- CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD -NONE- CC CD NN O
15 15 0 0 0 0 0 0 1 1 2 0 -NONE- CC CD NN JJ O
(G15) (G15) 0 1 0 0 0 0 0 1 5 0 CC CD NN JJ IN O
U/g U/g 1 0 0 1 0 0 0 0 3 0 CD NN JJ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN JJ IN JJ VBD O
skin) skin) 0 0 0 0 0 0 0 0 5 0 JJ IN JJ VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 IN JJ VBD NNP NNP O
investigated. investigated. 0 0 0 0 0 0 0 0 13 0 JJ VBD NNP NNP VBZ O
Edible Edible 1 0 0 0 0 0 0 0 6 0 VBD NNP NNP VBZ VBN O
films films 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ VBN IN O
prepared prepared 0 0 0 0 0 0 0 0 8 0 NNP VBZ VBN IN RB O
with with 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN RB VBN O
partially partially 0 0 0 0 0 0 0 0 9 0 VBN IN RB VBN NNS O
hydrolyzed hydrolyzed 0 0 0 0 0 0 0 0 10 0 IN RB VBN NNS VBD O
gelatins gelatins 0 0 0 0 0 0 0 0 8 0 RB VBN NNS VBD JJR O
had had 0 0 0 0 0 0 0 0 3 0 VBN NNS VBD JJR NN O
lower lower 0 0 0 0 0 0 0 0 5 0 NNS VBD JJR NN NN O
tensile tensile 0 0 0 0 0 0 0 0 7 0 VBD JJR NN NN NN O
strength strength 0 0 0 0 0 0 0 0 8 0 JJR NN NN NN CC O
(TS) (TS) 0 1 0 0 0 0 0 0 4 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
elongation elongation 0 0 0 0 0 0 0 0 10 0 NN CC NN IN NN O
at at 0 0 0 0 0 0 0 0 2 0 CC NN IN NN -NONE- O
break break 0 0 0 0 0 0 0 0 5 0 NN IN NN -NONE- CC O
(EAB), (EAB), 0 1 0 0 1 0 0 0 6 0 IN NN -NONE- CC JJR O
but but 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC JJR NN O
higher higher 0 0 0 0 0 0 0 0 6 0 -NONE- CC JJR NN PRP$ O
water water 0 0 0 0 0 0 0 0 5 0 CC JJR NN PRP$ NN O
vapour vapour 0 0 0 0 0 0 0 0 6 0 JJR NN PRP$ NN NN O
permeability permeability 0 0 0 0 0 0 0 0 12 0 NN PRP$ NN NN CC O
(WVP) (WVP) 0 1 0 0 0 0 0 0 5 0 PRP$ NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
water water 0 0 0 0 0 0 0 0 5 0 NN CC NN NN IN O
solubility solubility 0 0 0 0 0 0 0 0 10 0 CC NN NN IN DT O
than than 0 0 0 0 0 0 0 0 4 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
control control 0 0 0 0 0 0 0 0 7 0 IN DT NN NNP NNP O
film. film. 0 0 0 0 0 0 0 0 5 0 DT NN NNP NNP NN O
FTIR FTIR 1 1 0 0 0 0 0 0 4 0 NN NNP NNP NN IN O
spectra spectra 0 0 0 0 0 0 0 0 7 0 NNP NNP NN IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN VBN NN O
obtained obtained 0 0 0 0 0 0 0 0 8 0 NN IN VBN NN NNS O
gelatin gelatin 0 0 0 0 0 0 0 0 7 0 IN VBN NN NNS VBD O
films films 0 0 0 0 0 0 0 0 5 0 VBN NN NNS VBD DT O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NN NNS VBD DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS VBD DT JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 VBD DT JJ NN IN O
loss loss 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 NN IN JJ NN IN O
order order 0 0 0 0 0 0 0 0 5 0 IN JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
triple triple 0 0 0 0 0 0 0 0 6 0 IN DT NN NNP NNP O
helix. helix. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NNP JJ O
addition, addition, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP JJ NN O
differential differential 0 0 0 0 0 0 0 0 12 0 NNP NNP JJ NN JJ O
scanning scanning 0 0 0 0 0 0 0 0 8 0 NNP JJ NN JJ NN O
calorimetric calorimetric 0 0 0 0 0 0 0 0 12 0 JJ NN JJ NN NN O
(DSC) (DSC) 0 1 0 0 0 0 0 0 5 0 NN JJ NN NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 JJ NN NN VBD IN O
indicated indicated 0 0 0 0 0 0 0 0 9 0 NN NN VBD IN RB O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN RB VBN O
partially partially 0 0 0 0 0 0 0 0 9 0 VBD IN RB VBN NN O
hydrolyzed hydrolyzed 0 0 0 0 0 0 0 0 10 0 IN RB VBN NN NNS O
gelatine gelatine 0 0 0 0 0 0 0 0 8 0 RB VBN NN NNS VBD O
films films 0 0 0 0 0 0 0 0 5 0 VBN NN NNS VBD JJR O
exhibited exhibited 0 0 0 0 0 0 0 0 9 0 NN NNS VBD JJR NN O
lower lower 0 0 0 0 0 0 0 0 5 0 NNS VBD JJR NN NN O
transition transition 0 0 0 0 0 0 0 0 10 0 VBD JJR NN NN CC O
temperature temperature 0 0 0 0 0 0 0 0 11 0 JJR NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN VBN O
enthalpy enthalpy 0 0 0 0 0 0 0 0 8 0 NN CC NN VBN IN O
compared compared 0 0 0 0 0 0 0 0 8 0 CC NN VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN VBN IN DT IN O
those those 0 0 0 0 0 0 0 0 5 0 VBN IN DT IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN DT IN NN NNP O
control control 0 0 0 0 0 0 0 0 7 0 DT IN NN NNP NNP O
film. film. 0 0 0 0 0 0 0 0 5 0 IN NN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS IN O
properties properties 0 0 0 0 0 0 0 0 10 0 NNP NNP NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNS VBD O
films films 0 0 0 0 0 0 0 0 5 0 IN DT NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 DT NNS VBD VBN TO O
related related 0 0 0 0 0 0 0 0 7 0 NNS VBD VBN TO PRP$ O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 VBN TO PRP$ NN WDT O
microstructure, microstructure, 0 0 0 0 1 0 0 0 15 0 TO PRP$ NN WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 PRP$ NN WDT VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN WDT VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 WDT VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN NN O
scanning scanning 0 0 0 0 0 0 0 0 8 0 VBN IN NN NN NNP O
electron electron 0 0 0 0 0 0 0 0 8 0 IN NN NN NNP NNP O
microscopy. microscopy. 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP IN O
Films Films 1 0 0 0 0 0 0 0 5 0 NN NNP NNP IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNP IN NNP CC O
G0 G0 1 1 0 0 0 0 0 1 2 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP VBD O
G5 G5 1 1 0 0 0 0 0 1 2 0 NNP CC NNP VBD DT O
had had 0 0 0 0 0 0 0 0 3 0 CC NNP VBD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBD DT NN NN O
smooth smooth 0 0 0 0 0 0 0 0 6 0 VBD DT NN NN CC O
surface surface 0 0 0 0 0 0 0 0 7 0 DT NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT RBR O
a a 0 0 0 0 0 0 0 0 1 0 NN CC DT RBR JJ O
more more 0 0 0 0 0 0 0 0 4 0 CC DT RBR JJ NN O
compact compact 0 0 0 0 0 0 0 0 7 0 DT RBR JJ NN IN O
structure, structure, 0 0 0 0 1 0 0 0 10 0 RBR JJ NN IN NNS O
while while 0 0 0 0 0 0 0 0 5 0 JJ NN IN NNS VBN O
films films 0 0 0 0 0 0 0 0 5 0 NN IN NNS VBN IN O
prepared prepared 0 0 0 0 0 0 0 0 8 0 IN NNS VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBN IN NNP CC O
G10 G10 1 1 0 0 0 0 0 1 3 0 VBN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP VBD O
G15 G15 1 1 0 0 0 0 0 1 3 0 NNP CC NNP VBD NN O
had had 0 0 0 0 0 0 0 0 3 0 CC NNP VBD NN NNP O
coarser coarser 0 0 0 0 0 0 0 0 7 0 NNP VBD NN NNP NNP O
surface. surface. 0 0 0 0 0 0 0 0 8 0 VBD NN NNP NNP DT O
Thus, Thus, 1 0 0 0 1 0 0 0 5 0 NN NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
chain chain 0 0 0 0 0 0 0 0 5 0 NNP DT NN NN IN O
length length 0 0 0 0 0 0 0 0 6 0 DT NN NN IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN VBN NN O
extracted extracted 0 0 0 0 0 0 0 0 9 0 NN IN VBN NN RB O
gelatin gelatin 0 0 0 0 0 0 0 0 7 0 IN VBN NN RB VBN O
directly directly 0 0 0 0 0 0 0 0 8 0 VBN NN RB VBN DT O
affected affected 0 0 0 0 0 0 0 0 8 0 NN RB VBN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 RB VBN DT NNS IN O
properties properties 0 0 0 0 0 0 0 0 10 0 VBN DT NNS IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN VBG NNP O
corresponding corresponding 0 0 0 0 0 0 0 0 13 0 NNS IN VBG NNP NONE O
films. films. 0 0 0 0 0 0 0 0 6 0 IN VBG NNP NONE NONE O
Characterization Characterization 1 0 0 0 0 0 0 0 16 0 NONE NONE NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NNP NN O
Lycium Lycium 1 0 0 0 0 0 0 0 6 0 NN IN NNP NN NN O
barbarum barbarum 0 0 0 0 0 0 0 0 8 0 IN NNP NN NN CC O
polysaccharide polysaccharide 0 0 0 0 0 0 0 0 14 0 NNP NN NN CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NN CC PRP$ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 CC PRP$ NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 PRP$ NN IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NNP O
hepatoma hepatoma 0 0 0 0 0 0 0 0 8 0 IN JJ NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tang Tang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Q, Q, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Z. Z. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Key Key 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP IN O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Food Food 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP CC O
Nutrition Nutrition 1 0 0 0 0 0 0 0 9 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Safety Safety 1 0 0 0 0 0 0 0 6 0 NNP CC NNP NNP NNP O
(Tianjin (Tianjin 0 0 0 0 0 0 0 0 8 0 CC NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Science Science 1 0 0 0 0 0 0 0 7 0 NNP IN NNP CC NNP O
& & 0 0 0 0 0 0 0 0 1 0 IN NNP CC NNP NNP O
Technology), Technology), 1 0 0 0 1 0 0 0 12 0 NNP CC NNP NNP IN O
Ministry Ministry 1 0 0 0 0 0 0 0 8 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Education, Education, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP CD O
Tianjin Tianjin 1 0 0 0 0 0 0 0 7 0 IN NNP NNP CD NNP O
300457, 300457, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
Electronic Electronic 1 0 0 0 0 0 0 0 10 0 CD NNP NNP NNP NNP O
address: address: 0 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
zm0102@sina.com. zm0102@sina.com. 0 0 0 0 0 0 0 1 16 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VB O
To To 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VB JJ O
investigate investigate 0 0 0 0 0 0 0 0 11 0 NNP NNP VB JJ NN O
structure-bioactivity structure-bioactivity 0 0 1 0 0 0 0 0 21 0 NNP VB JJ NN IN O
relationship relationship 0 0 0 0 0 0 0 0 12 0 VB JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
LBP, LBP, 1 1 0 0 1 0 0 0 4 0 NN IN NNP NNP NN O
Lycium Lycium 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NN NN O
barbarum barbarum 0 0 0 0 0 0 0 0 8 0 NNP NNP NN NN NN O
polysaccharide polysaccharide 0 0 0 0 0 0 0 0 14 0 NNP NN NN NN VBD O
(LBP) (LBP) 0 1 0 0 0 0 0 0 5 0 NN NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN CC O
extracted extracted 0 0 0 0 0 0 0 0 9 0 NN VBD VBN CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 VBD VBN CC VBN IN O
separated separated 0 0 0 0 0 0 0 0 9 0 VBN CC VBN IN CD O
into into 0 0 0 0 0 0 0 0 4 0 CC VBN IN CD NNS O
five five 0 0 0 0 0 0 0 0 4 0 VBN IN CD NNS VBG O
fractions fractions 0 0 0 0 0 0 0 0 9 0 IN CD NNS VBG NN O
using using 0 0 0 0 0 0 0 0 5 0 CD NNS VBG NN NN O
ultrafiltration ultrafiltration 0 0 0 0 0 0 0 0 15 0 NNS VBG NN NN NNP O
membrane membrane 0 0 0 0 0 0 0 0 8 0 VBG NN NN NNP NNP O
method. method. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP DT O
Then Then 1 0 0 0 0 0 0 0 4 0 NN NNP NNP DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 NNP DT NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT JJ O
these these 0 0 0 0 0 0 0 0 5 0 NNS IN DT JJ NNS O
polysaccharide polysaccharide 0 0 0 0 0 0 0 0 14 0 IN DT JJ NNS IN O
fractions fractions 0 0 0 0 0 0 0 0 9 0 DT JJ NNS IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NN NN O
liver liver 0 0 0 0 0 0 0 0 5 0 IN JJ NN NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 JJ NN NN NNS -NONE- O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS -NONE- VBD O
(SMMC-7721) (SMMC-7721) 0 1 1 0 0 0 0 1 11 0 NN NNS -NONE- VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNS -NONE- VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 -NONE- VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
MTT MTT 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NNP NNP O
assay, assay, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP NNP CC O
LSCM LSCM 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP CC O
FCM. FCM. 1 1 0 0 0 0 0 0 4 0 NNP CC NNP CC DT O
And And 1 0 0 0 0 0 0 0 3 0 CC NNP CC DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP CC DT NNP NN O
components, components, 0 0 0 0 1 0 0 0 11 0 CC DT NNP NN VBD O
molecular molecular 0 0 0 0 0 0 0 0 9 0 DT NNP NN VBD CC O
weight weight 0 0 0 0 0 0 0 0 6 0 NNP NN VBD CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN VBD CC NN IN O
conformation conformation 0 0 0 0 0 0 0 0 12 0 VBD CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NNS O
LBP LBP 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNS VBD O
fractions fractions 0 0 0 0 0 0 0 0 9 0 IN NNP NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD VBN IN O
analyzed analyzed 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
GC, GC, 1 1 0 0 1 0 0 0 3 0 VBN IN NNP NNP CC O
HPLC HPLC 1 1 0 0 0 0 0 0 4 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
AFM. AFM. 1 1 0 0 0 0 0 0 4 0 NNP CC NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 CC NNP NNP NNS VBD O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NNS VBD IN -NONE- O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN -NONE- -NONE- O
LBP-a8, LBP-a8, 1 0 1 0 1 0 0 1 7 0 VBD IN -NONE- -NONE- -NONE- O
LBP-a3, LBP-a3, 1 0 1 0 1 0 0 1 7 0 IN -NONE- -NONE- -NONE- CC O
LBP-a1 LBP-a1 1 0 1 0 0 0 0 1 6 0 -NONE- -NONE- -NONE- CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- CC -NONE- MD O
LBP-a4 LBP-a4 1 0 1 0 0 0 0 1 6 0 -NONE- CC -NONE- MD VB O
could could 0 0 0 0 0 0 0 0 5 0 CC -NONE- MD VB DT O
inhibit inhibit 0 0 0 0 0 0 0 0 7 0 -NONE- MD VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VB DT NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN -NONE- VBZ O
SMMC-7721 SMMC-7721 1 1 1 0 0 0 0 1 9 0 NN IN -NONE- VBZ IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN -NONE- VBZ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- VBZ IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBZ IN DT NN CC O
concentration concentration 0 0 0 0 0 0 0 0 13 0 IN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN NN O
time time 0 0 0 0 0 0 0 0 4 0 NN CC NN NN NNP O
dependent dependent 0 0 0 0 0 0 0 0 9 0 CC NN NN NNP CC O
manner. manner. 0 0 0 0 0 0 0 0 7 0 NN NN NNP CC -NONE- O
But But 1 0 0 0 0 0 0 0 3 0 NN NNP CC -NONE- MD O
LBP-p8 LBP-p8 1 0 1 0 0 0 0 1 6 0 NNP CC -NONE- MD VB O
could could 0 0 0 0 0 0 0 0 5 0 CC -NONE- MD VB DT O
promote promote 0 0 0 0 0 0 0 0 7 0 -NONE- MD VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 VB DT NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN -NONE- NNP O
SMMC-7721 SMMC-7721 1 1 1 0 0 0 0 1 9 0 NN IN -NONE- NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN -NONE- NNP NNP NNP O
LBP-a4 LBP-a4 1 0 1 0 0 0 0 1 6 0 -NONE- NNP NNP NNP WDT O
(10.2kDa), (10.2kDa), 0 0 0 0 1 0 0 1 10 0 NNP NNP NNP WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NNP NNP WDT VBZ IN O
consists consists 0 0 0 0 0 0 0 0 8 0 NNP WDT VBZ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 WDT VBZ IN JJ NN O
uronic uronic 0 0 0 0 0 0 0 0 6 0 VBZ IN JJ NN NN O
acid acid 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN NN O
(11.5%), (11.5%), 0 0 0 0 1 0 0 1 8 0 JJ NN NN NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 NN NN NN NN CC O
(0.34%) (0.34%) 0 0 0 0 0 0 0 1 7 0 NN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
neutral neutral 0 0 0 0 0 0 0 0 7 0 NN CC JJ NN NN O
sugar sugar 0 0 0 0 0 0 0 0 5 0 CC JJ NN NN MD O
(39.02%), (39.02%), 0 0 0 0 1 0 0 1 9 0 JJ NN NN MD VB O
could could 0 0 0 0 0 0 0 0 5 arrest NN NN MD VB -NONE- O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN MD VB -NONE- NNS O
SMMC-7721 SMMC-7721 1 1 1 0 0 0 0 1 9 0 MD VB -NONE- NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 VB -NONE- NNS IN -NONE- O
at at 0 0 0 0 0 0 0 0 2 0 -NONE- NNS IN -NONE- VB O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase NNS IN -NONE- VB CC O
phase phase 0 0 0 0 0 0 0 0 5 0 IN -NONE- VB CC NN O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- VB CC NN DT O
enhance enhance 0 0 0 0 0 0 0 0 7 0 VB CC NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CC NN DT JJ NN O
intracellular intracellular 0 0 0 0 0 0 0 0 13 0 NN DT JJ NN NN O
Ca2+ Ca2+ 1 0 0 0 0 0 0 1 4 0 DT JJ NN NN NNP O
concentration concentration 0 0 0 0 0 0 0 0 13 0 JJ NN NN NNP NNP O
significantly. significantly. 0 0 0 0 0 0 0 0 14 0 NN NN NNP NNP NNP O
Nevertheless, Nevertheless, 1 0 0 0 1 0 0 0 13 0 NN NNP NNP NNP NNP O
LBP-p8 LBP-p8 1 0 1 0 0 0 0 1 6 0 NNP NNP NNP NNP WDT O
(6.50×103kDa), (6.50×103kDa), 0 0 0 0 1 0 0 1 14 0 NNP NNP NNP WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NNP NNP WDT VBZ IN O
consists consists 0 0 0 0 0 0 0 0 8 0 NNP WDT VBZ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 WDT VBZ IN JJ NN O
uronic uronic 0 0 0 0 0 0 0 0 6 0 VBZ IN JJ NN NN O
acid acid 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN NN O
(13.4%), (13.4%), 0 0 0 0 1 0 0 1 8 0 JJ NN NN NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 NN NN NN NN CC O
(4.77%) (4.77%) 0 0 0 0 0 0 0 1 7 0 NN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
neutral neutral 0 0 0 0 0 0 0 0 7 0 NN CC JJ NN NN O
sugar sugar 0 0 0 0 0 0 0 0 5 0 CC JJ NN NN VBD O
(26.26%), (26.26%), 0 0 0 0 1 0 0 1 9 0 JJ NN NN VBD RB O
did did 0 0 0 0 0 0 0 0 3 0 NN NN VBD RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NN VBD RB VB DT O
change change 0 0 0 0 0 0 0 0 6 0 VBD RB VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VB DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VB DT NN NN CC O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NN O
Ca2+ Ca2+ 1 0 0 0 0 0 0 1 4 0 NN CC NNP NN IN O
concentration concentration 0 0 0 0 0 0 0 0 13 0 CC NNP NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NNP O
cytoplasm cytoplasm 0 0 0 0 0 0 0 0 9 0 NN IN NN NNP NNP O
significantly. significantly. 0 0 0 0 0 0 0 0 14 0 IN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NN IN O
conformation conformation 0 0 0 0 0 0 0 0 12 0 NNP NN NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN -NONE- CC O
LBP-a4 LBP-a4 1 0 1 0 0 0 0 1 6 0 NN IN -NONE- CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 IN -NONE- CC -NONE- VBD O
LBP-p8 LBP-p8 1 0 1 0 0 0 0 1 6 0 -NONE- CC -NONE- VBD JJ O
was was 0 0 0 0 0 0 0 0 3 0 CC -NONE- VBD JJ CC O
spherical spherical 0 0 0 0 0 0 0 0 9 0 -NONE- VBD JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VBD JJ CC NN NN O
flocculent flocculent 0 0 0 0 0 0 0 0 10 0 JJ CC NN NN NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 CC NN NN NN NN O
shape, shape, 0 0 0 0 1 0 0 0 6 0 NN NN NN NN VBG O
respectively, respectively, 0 0 0 0 1 0 0 0 13 0 NN NN NN VBG IN O
suggesting suggesting 0 0 0 0 0 0 0 0 10 0 NN NN VBG IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NN VBG IN JJ NN O
spherical spherical 0 0 0 0 0 0 0 0 9 0 VBG IN JJ NN NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 IN JJ NN NN VBD O
shape shape 0 0 0 0 0 0 0 0 5 0 JJ NN NN VBD NN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD NN TO O
benefit benefit 0 0 0 0 0 0 0 0 7 0 NN VBD NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 VBD NN TO NNP NN O
LBP's LBP's 1 0 0 0 0 1 0 0 5 0 NN TO NNP NN VBG O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 TO NNP NN VBG NN O
inducing inducing 0 0 0 0 0 0 0 0 8 0 NNP NN VBG NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NN VBG NN IN NN O
while while 0 0 0 0 0 0 0 0 5 0 VBG NN IN NN NN O
flocculent flocculent 0 0 0 0 0 0 0 0 10 0 NN IN NN NN NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 IN NN NN NN VBD O
shape shape 0 0 0 0 0 0 0 0 5 0 NN NN NN VBD RB O
did did 0 0 0 0 0 0 0 0 3 0 NN NN VBD RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NN VBD RB VB IN O
have have 0 0 0 0 0 0 0 0 4 0 VBD RB VB IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 RB VB IN NNP NONE O
function. function. 0 0 0 0 0 0 0 0 9 0 VB IN NNP NONE NONE O
Correction Correction 1 0 0 0 0 0 0 0 10 0 NONE NONE NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NONE NN IN NNP NN O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NN IN NNP NN -NONE- O
et et 0 0 0 0 0 0 0 0 2 0 IN NNP NN -NONE- NNP O
al., al., 0 0 0 0 1 0 0 0 4 0 NNP NN -NONE- NNP NN O
IKK IKK 1 1 0 0 0 0 0 0 3 0 NN -NONE- NNP NN NN O
epsilon epsilon 0 0 0 0 0 0 0 0 7 0 -NONE- NNP NN NN VBZ O
kinase kinase 0 0 0 0 0 0 0 0 6 0 NNP NN NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ JJ IN O
crucial crucial 0 0 0 0 0 0 0 0 7 0 NN VBZ JJ IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN JJ NNP O
viral viral 0 0 0 0 0 0 0 0 5 0 JJ IN JJ NNP JJ O
G G 1 1 0 0 0 0 0 0 1 0 IN JJ NNP JJ NN O
protein-coupled protein-coupled 0 0 1 0 0 0 0 0 15 0 JJ NNP JJ NN NNP O
receptor receptor 0 0 0 0 0 0 0 0 8 0 NNP JJ NN NNP NNP O
tumorigenesis. tumorigenesis. 0 0 0 0 0 0 0 0 14 0 JJ NN NNP NNP NNS O
[No [No 0 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS -NONE- O
authors authors 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS -NONE- -NONE- O
listed] listed] 0 0 0 0 0 0 0 0 7 0 NNP NNS -NONE- -NONE- CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNS -NONE- -NONE- CD JJ O
23832784 23832784 0 0 0 0 0 0 1 1 8 0 -NONE- -NONE- CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 -NONE- CD JJ : IN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ : IN JJ NONE O
process] process] 0 0 0 0 0 0 0 0 8 0 : IN JJ NONE NONE O
C/EBPα C/EBPα 1 0 0 1 0 0 0 0 6 0 NONE NONE NN NNS JJ O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 NONE NN NNS JJ NN O
hepatocellular hepatocellular 0 0 0 0 0 0 0 0 14 0 NN NNS JJ NN IN O
carcinoma carcinoma 0 0 0 0 0 0 0 0 9 0 NNS JJ NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN -NONE- O
reducing reducing 0 0 0 0 0 0 0 0 8 0 NN IN NN -NONE- NNP O
Notch3/Hes1/p27 Notch3/Hes1/p27 1 0 0 1 0 0 0 1 15 0 IN NN -NONE- NNP NNP O
cascades. cascades. 0 0 0 0 0 0 0 0 9 0 NN -NONE- NNP NNP NNP O
Shi Shi 1 0 0 0 0 0 0 0 3 0 -NONE- NNP NNP NNP NNP O
YC, YC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Zhao Zhao 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yin Yin 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zeng Zeng 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Q, Q, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Xu Xu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
WP, WP, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wei Wei 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Xie Xie 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
WF. WF. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Gastroenterology, Gastroenterology, 1 0 0 0 1 0 0 0 17 0 NNP IN NNP NNP NNP O
Changzheng Changzheng 1 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP NNP O
Hospital, Hospital, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Second Second 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Military Military 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Shanghai, Shanghai, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND BACKGROUND 1 1 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
AND AND 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
AIMS: AIMS: 1 1 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NN O
CCAAT/enhancer CCAAT/enhancer 1 0 0 1 0 0 0 0 14 0 NNP NNP NNP NN NN O
binding binding 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN : O
protein protein 0 0 0 0 0 0 0 0 7 0 NNP NN NN : VBZ O
α α 0 0 0 0 0 0 0 0 1 0 NN NN : VBZ CD O
is is 0 0 0 0 0 0 0 0 2 0 NN : VBZ CD IN O
one one 0 0 0 0 0 0 0 0 3 0 : VBZ CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBZ CD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT JJ NN O
key key 0 0 0 0 0 0 0 0 3 0 IN DT JJ NN NNS O
transcription transcription 0 0 0 0 0 0 0 0 13 0 DT JJ NN NNS IN O
factors factors 0 0 0 0 0 0 0 0 7 0 JJ NN NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
hepatocyte hepatocyte 0 0 0 0 0 0 0 0 10 0 IN DT NN NN NNS O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 DT NN NN NNS -NONE- O
factors factors 0 0 0 0 0 0 0 0 7 0 NN NN NNS -NONE- WDT O
family, family, 0 0 0 0 1 0 0 0 7 0 NN NNS -NONE- WDT NNS O
which which 0 0 0 0 0 0 0 0 5 0 NNS -NONE- WDT NNS DT O
plays plays 0 0 0 0 0 0 0 0 5 0 -NONE- WDT NNS DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 WDT NNS DT JJ NN O
critical critical 0 0 0 0 0 0 0 0 8 0 NNS DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
liver liver 0 0 0 0 0 0 0 0 5 0 NN IN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN NN NN NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
differentiation. differentiation. 0 0 0 0 0 0 0 0 16 0 NN CC NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 CC NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
role role 0 0 0 0 0 0 0 0 4 0 NNP DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN VBG O
CCAAT/enhancer CCAAT/enhancer 1 0 0 1 0 0 0 0 14 0 NN IN NN VBG NN O
binding binding 0 0 0 0 0 0 0 0 7 0 IN NN VBG NN : O
protein protein 0 0 0 0 0 0 0 0 7 0 NN VBG NN : IN O
α α 0 0 0 0 0 0 0 0 1 0 VBG NN : IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN : IN NN VBZ O
hepatocarcinogenesis hepatocarcinogenesis 0 0 0 0 0 0 0 0 20 0 : IN NN VBZ TO O
remains remains 0 0 0 0 0 0 0 0 7 0 IN NN VBZ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBZ TO VB NNP O
be be 0 0 0 0 0 0 0 0 2 0 VBZ TO VB NNP NNP O
defined. defined. 0 0 0 0 0 0 0 0 8 0 TO VB NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 VB NNP NNP NNP NN O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NN VBZ O
recombinant recombinant 0 0 0 0 0 0 0 0 11 0 NNP NNP NN VBZ VBG O
adenovirus adenovirus 0 0 0 0 0 0 0 0 10 0 NNP NN VBZ VBG DT O
carrying carrying 0 0 0 0 0 0 0 0 8 0 NN VBZ VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBZ VBG DT NN NN O
C/EBPα C/EBPα 1 0 0 1 0 0 0 0 6 0 VBG DT NN NN VBD O
gene gene 0 0 0 0 0 0 0 0 4 0 DT NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN TO O
constructed constructed 0 0 0 0 0 0 0 0 11 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB PRP$ O
determine determine 0 0 0 0 0 0 0 0 9 0 VBN TO VB PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 TO VB PRP$ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 VB PRP$ NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 PRP$ NN IN NN IN O
hepatocarcinogenesis hepatocarcinogenesis 0 0 0 0 0 0 0 0 20 0 NN IN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NN CC O
vitro vitro 0 0 0 0 0 0 0 0 5 0 NN IN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN CC IN NNP NNP O
vivo. vivo. 0 0 0 0 0 0 0 0 5 0 CC IN NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 IN NNP NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBD IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 NNP NNP VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBD IN NN IN O
overexpression overexpression 0 0 0 0 0 0 0 0 14 0 VBD IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN VBG O
CCAAT/enhancer CCAAT/enhancer 1 0 0 1 0 0 0 0 14 0 NN IN NN VBG NN O
binding binding 0 0 0 0 0 0 0 0 7 0 IN NN VBG NN : O
protein protein 0 0 0 0 0 0 0 0 7 0 NN VBG NN : VBN O
α α 0 0 0 0 0 0 0 0 1 0 VBG NN : VBN DT O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NN : VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 : VBN DT NN IN O
tumourigenicity tumourigenicity 0 0 0 0 0 0 0 0 15 0 VBN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
Huh7 Huh7 1 0 0 0 0 0 0 1 4 0 NN IN NNP NNP JJ O
cells, cells, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP JJ DT O
re-established re-established 0 0 1 0 0 0 0 0 14 0 NNP NNP JJ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP JJ DT NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 JJ DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ JJ O
certain certain 0 0 0 0 0 0 0 0 7 0 NN IN JJ JJ NNS O
liver-specific liver-specific 0 0 1 0 0 0 0 0 14 0 IN JJ JJ NNS CC O
genes genes 0 0 0 0 0 0 0 0 5 0 JJ JJ NNS CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC VBD -NONE- O
induced induced 0 0 0 0 0 0 0 0 7 0 NNS CC VBD -NONE- NNP O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 CC VBD -NONE- NNP NNP B_TIMEXCCP
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 VBD -NONE- NNP NNP IN O
Overexpression Overexpression 1 0 0 0 0 0 0 0 14 0 -NONE- NNP NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN VBG O
CCAAT/enhancer CCAAT/enhancer 1 0 0 1 0 0 0 0 14 0 NNP IN NN VBG NN O
binding binding 0 0 0 0 0 0 0 0 7 0 IN NN VBG NN : O
protein protein 0 0 0 0 0 0 0 0 7 0 NN VBG NN : RB O
α α 0 0 0 0 0 0 0 0 1 0 VBG NN : RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NN : RB VBN DT O
suppressed suppressed 0 0 0 0 0 0 0 0 10 0 : RB VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBN DT NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VBN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
primary primary 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN NNS O
hepatocarcinogenesis hepatocarcinogenesis 0 0 0 0 0 0 0 0 20 0 IN JJ NN NNS CC O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC PRP$ VBN O
tumour tumour 0 0 0 0 0 0 0 0 6 0 NNS CC PRP$ VBN NNS O
associated associated 0 0 0 0 0 0 0 0 10 0 CC PRP$ VBN NNS IN O
fibroblasts fibroblasts 0 0 0 0 0 0 0 0 11 0 PRP$ VBN NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBN NNS IN NNP NNP O
vitro. vitro. 0 0 0 0 0 0 0 0 6 0 NNS IN NNP NNP JJ O
Additionally, Additionally, 1 0 0 0 1 0 0 0 13 0 IN NNP NNP JJ NN O
intratumoural intratumoural 0 0 0 0 0 0 0 0 13 0 NNP NNP JJ NN IN O
injection injection 0 0 0 0 0 0 0 0 9 0 NNP JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN VBG O
adenovirus adenovirus 0 0 0 0 0 0 0 0 10 0 NN IN NN VBG DT O
carrying carrying 0 0 0 0 0 0 0 0 8 0 IN NN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT NN VBD O
C/EBPα C/EBPα 1 0 0 1 0 0 0 0 6 0 VBG DT NN VBD DT O
reduced reduced 0 0 0 0 0 0 0 0 7 0 DT NN VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBD DT NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 VBD DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
subcutaneous subcutaneous 0 0 0 0 0 0 0 0 12 0 NN IN JJ NN NNS O
hepatocarcinogenesis hepatocarcinogenesis 0 0 0 0 0 0 0 0 20 0 IN JJ NN NNS IN O
xenografts xenografts 0 0 0 0 0 0 0 0 10 0 JJ NN NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NNP O
nude nude 0 0 0 0 0 0 0 0 4 0 NNS IN NN NNP NNP O
mice. mice. 0 0 0 0 0 0 0 0 5 0 IN NN NNP NNP NN O
Systemic Systemic 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NN IN O
administration administration 0 0 0 0 0 0 0 0 14 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN VBG O
adenovirus adenovirus 0 0 0 0 0 0 0 0 10 0 NN IN NN VBG DT O
carrying carrying 0 0 0 0 0 0 0 0 8 0 IN NN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT NN VBD O
C/EBPα C/EBPα 1 0 0 1 0 0 0 0 6 0 VBG DT NN VBD IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 DT NN VBD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN IN O
eradication eradication 0 0 0 0 0 0 0 0 11 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
orthotopic orthotopic 0 0 0 0 0 0 0 0 10 0 NN IN JJ NN NN O
liver liver 0 0 0 0 0 0 0 0 5 0 IN JJ NN NN NNS O
hepatocarcinogenesis hepatocarcinogenesis 0 0 0 0 0 0 0 0 20 0 JJ NN NN NNS IN O
nodules nodules 0 0 0 0 0 0 0 0 7 0 NN NN NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NNP O
nude nude 0 0 0 0 0 0 0 0 4 0 NNS IN NN NNP NNP O
mice. mice. 0 0 0 0 0 0 0 0 5 0 IN NN NNP NNP NNP O
Further, Further, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP NNP IN O
up-regulation up-regulation 0 0 1 0 0 0 0 0 13 0 NNP NNP NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN VBG O
CCAAT/enhancer CCAAT/enhancer 1 0 0 1 0 0 0 0 14 0 NNP IN NN VBG NN O
binding binding 0 0 0 0 0 0 0 0 7 0 IN NN VBG NN : O
protein protein 0 0 0 0 0 0 0 0 7 0 NN VBG NN : VBN O
α α 0 0 0 0 0 0 0 0 1 0 VBG NN : VBN DT O
reduced reduced 0 0 0 0 0 0 0 0 7 0 NN : VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 : VBN DT NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 VBN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NN O
Notch3, Notch3, 1 0 0 0 1 0 0 1 7 0 NN IN NNP NN VBG O
thereby thereby 0 0 0 0 0 0 0 0 7 0 IN NNP NN VBG NNP O
suppressing suppressing 0 0 0 0 0 0 0 0 11 0 NNP NN VBG NNP NN O
Hes1 Hes1 1 0 0 0 0 0 0 1 4 0 NN VBG NNP NN NN O
transactivation transactivation 0 0 0 0 0 0 0 0 15 0 VBG NNP NN NN CC O
activity activity 0 0 0 0 0 0 0 0 8 0 NNP NN NN CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBG TO O
leading leading 0 0 0 0 0 0 0 0 7 0 NN CC VBG TO VBN O
to to 0 0 0 0 0 0 0 0 2 0 CC VBG TO VBN NNP O
decreased decreased 0 0 0 0 0 0 0 0 9 0 VBG TO VBN NNP NNP O
p27 p27 0 0 0 0 0 0 0 1 3 0 TO VBN NNP NNP NNP O
expression. expression. 0 0 0 0 0 0 0 0 11 0 VBN NNP NNP NNP IN O
Overexpression Overexpression 1 0 0 0 0 0 0 0 14 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP RB O
Hes1 Hes1 1 0 0 0 0 0 0 1 4 0 NNP IN NNP RB VBD O
partially partially 0 0 0 0 0 0 0 0 9 0 IN NNP RB VBD DT O
abolished abolished 0 0 0 0 0 0 0 0 9 0 NNP RB VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBD DT NN NN O
anti-proliferation anti-proliferation 0 0 1 0 0 0 0 0 18 0 VBD DT NN NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 DT NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN VBG O
CCAAT/enhancer CCAAT/enhancer 1 0 0 1 0 0 0 0 14 0 NN IN NN VBG NN O
binding binding 0 0 0 0 0 0 0 0 7 0 IN NN VBG NN : O
protein protein 0 0 0 0 0 0 0 0 7 0 NN VBG NN : IN O
α α 0 0 0 0 0 0 0 0 1 0 VBG NN : IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NN : IN NNP NNP O
Huh7 Huh7 1 0 0 0 0 0 0 1 4 0 : IN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
CONCLUSION: CONCLUSION: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNS VBD O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD IN O
suggested suggested 0 0 0 0 0 0 0 0 9 0 NNP NNS VBD IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN VBG O
CCAAT/enhancer CCAAT/enhancer 1 0 0 1 0 0 0 0 14 0 NN IN NN VBG NN O
binding binding 0 0 0 0 0 0 0 0 7 0 IN NN VBG NN : O
protein protein 0 0 0 0 0 0 0 0 7 0 NN VBG NN : IN O
α α 0 0 0 0 0 0 0 0 1 0 VBG NN : IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NN : IN NN VBZ O
hepatocarcinogenesis hepatocarcinogenesis 0 0 0 0 0 0 0 0 20 0 : IN NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 IN NN VBZ RB IN O
partially partially 0 0 0 0 0 0 0 0 9 0 NN VBZ RB IN IN O
through through 0 0 0 0 0 0 0 0 7 0 VBZ RB IN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 RB IN IN NN -NONE- O
reducing reducing 0 0 0 0 0 0 0 0 8 0 IN IN NN -NONE- VBZ O
Notch3/Hes1/p27 Notch3/Hes1/p27 1 0 0 1 0 0 0 1 15 0 IN NN -NONE- VBZ CC O
cascades cascades 0 0 0 0 0 0 0 0 8 0 NN -NONE- VBZ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- VBZ CC JJ NN O
CCAAT/enhancer CCAAT/enhancer 1 0 0 1 0 0 0 0 14 0 VBZ CC JJ NN NN O
binding binding 0 0 0 0 0 0 0 0 7 0 CC JJ NN NN : O
protein protein 0 0 0 0 0 0 0 0 7 0 JJ NN NN : MD O
α α 0 0 0 0 0 0 0 0 1 0 NN NN : MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN : MD VB DT O
possess possess 0 0 0 0 0 0 0 0 7 0 : MD VB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT NN JJ O
novel novel 0 0 0 0 0 0 0 0 5 0 VB DT NN JJ NN O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 DT NN JJ NN IN O
potential potential 0 0 0 0 0 0 0 0 9 0 NN JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN NNP O
human human 0 0 0 0 0 0 0 0 5 0 NN IN NN NNP NONE O
hepatocarcinogenesis. hepatocarcinogenesis. 0 0 0 0 0 0 0 0 21 0 IN NN NNP NONE NONE O
High High 1 0 0 0 0 0 0 0 4 0 NONE NONE JJ NN VBG O
resolution resolution 0 0 0 0 0 0 0 0 10 0 NONE JJ NN VBG NN O
melting melting 0 0 0 0 0 0 0 0 7 0 JJ NN VBG NN IN O
technique technique 0 0 0 0 0 0 0 0 9 0 NN VBG NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VBG NN IN JJ JJ O
molecular molecular 0 0 0 0 0 0 0 0 9 0 NN IN JJ JJ NNS O
epidemiological epidemiological 0 0 0 0 0 0 0 0 15 0 IN JJ JJ NNS IN O
studies studies 0 0 0 0 0 0 0 0 7 0 JJ JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
cystic cystic 0 0 0 0 0 0 0 0 6 0 NNS IN JJ NN VBG O
echinococcosis: echinococcosis: 0 0 0 0 0 0 0 0 15 0 IN JJ NN VBG NN O
differentiating differentiating 0 0 0 0 0 0 0 0 15 0 JJ NN VBG NN -NONE- O
G1, G1, 1 1 0 0 1 0 0 1 3 0 NN VBG NN -NONE- CC O
G3, G3, 1 1 0 0 1 0 0 1 3 0 VBG NN -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC NNP NNS O
G6 G6 1 1 0 0 0 0 0 1 2 0 -NONE- CC NNP NNS IN O
genotypes genotypes 0 0 0 0 0 0 0 0 9 0 CC NNP NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NNP NN O
Echinococcus Echinococcus 1 0 0 0 0 0 0 0 12 0 NNS IN NNP NN NN O
granulosus granulosus 0 0 0 0 0 0 0 0 10 0 IN NNP NN NN NNP O
sensu sensu 0 0 0 0 0 0 0 0 5 0 NNP NN NN NNP NNP O
lato. lato. 0 0 0 0 0 0 0 0 5 0 NN NN NNP NNP NNP O
Rostami Rostami 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Talebi Talebi 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Babaei Babaei 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sharbatkhori Sharbatkhori 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ziaali Ziaali 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Rostami Rostami 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Harandi Harandi 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
MF. MF. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Center Center 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Tropical Tropical 1 0 0 0 0 0 0 0 8 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Infectious Infectious 1 0 0 0 0 0 0 0 10 0 NNP CC NNP NNP NNP O
Diseases, Diseases, 1 0 0 0 1 0 0 0 9 0 CC NNP NNP NNP NNP O
Kerman Kerman 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Kerman, Kerman, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Iran. Iran. 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP CC O
Reliable Reliable 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC VBD VBG O
rapid rapid 0 0 0 0 0 0 0 0 5 0 NNP CC VBD VBG IN O
genotyping genotyping 0 0 0 0 0 0 0 0 10 0 CC VBD VBG IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBD VBG IN JJ NN O
large large 0 0 0 0 0 0 0 0 5 0 VBG IN JJ NN IN O
number number 0 0 0 0 0 0 0 0 6 0 IN JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
Echinococcus Echinococcus 1 0 0 0 0 0 0 0 12 0 NN IN NNP NN NN O
granulosus granulosus 0 0 0 0 0 0 0 0 10 0 IN NNP NN NN NN O
sensu sensu 0 0 0 0 0 0 0 0 5 0 NNP NN NN NN VBZ O
lato lato 0 0 0 0 0 0 0 0 4 0 NN NN NN VBZ VBZ O
isolates isolates 0 0 0 0 0 0 0 0 8 0 NN NN VBZ VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN VBZ VBZ JJ IN O
crucial crucial 0 0 0 0 0 0 0 0 7 0 VBZ VBZ JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN NN DT O
understanding understanding 0 0 0 0 0 0 0 0 13 0 JJ IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN CC O
epidemiology epidemiology 0 0 0 0 0 0 0 0 12 0 NN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
transmission transmission 0 0 0 0 0 0 0 0 12 0 NN CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NNP O
cystic cystic 0 0 0 0 0 0 0 0 6 0 NN IN JJ NNP NNP O
echinococcosis. echinococcosis. 0 0 0 0 0 0 0 0 15 0 IN JJ NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNP VBP VBN DT O
developed developed 0 0 0 0 0 0 0 0 9 0 NNP VBP VBN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBP VBN DT NN IN O
method method 0 0 0 0 0 0 0 0 6 0 VBN DT NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN NN CC O
distinguishing distinguishing 0 0 0 0 0 0 0 0 14 0 NN IN NN CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VBG JJ O
discriminating discriminating 0 0 0 0 0 0 0 0 14 0 NN CC VBG JJ NNS O
common common 0 0 0 0 0 0 0 0 6 0 CC VBG JJ NNS IN O
genotypes genotypes 0 0 0 0 0 0 0 0 9 0 VBG JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NN O
E. E. 1 1 0 0 0 0 0 0 2 0 NNS IN NNP NN NNP O
granulosus granulosus 0 0 0 0 0 0 0 0 10 0 IN NNP NN NNP NNP O
s.l. s.l. 0 0 0 0 0 0 0 0 4 0 NNP NN NNP NNP NNP O
(G1, (G1, 0 1 0 0 1 0 0 1 4 0 NN NNP NNP NNP CC O
G3, G3, 1 1 0 0 1 0 0 1 3 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP IN O
G6) G6) 1 1 0 0 0 0 0 1 3 0 NNP CC NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CC NNP IN NNP DT O
Iran. Iran. 1 0 0 0 0 0 0 0 5 0 NNP IN NNP DT NN O
This This 1 0 0 0 0 0 0 0 4 0 IN NNP DT NN VBZ O
method method 0 0 0 0 0 0 0 0 6 0 NNP DT NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ VBN IN O
based based 0 0 0 0 0 0 0 0 5 0 NN VBZ VBN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN NN NN O
polymerase polymerase 0 0 0 0 0 0 0 0 10 0 VBN IN NN NN NN O
chain chain 0 0 0 0 0 0 0 0 5 0 IN NN NN NN VBN O
reaction reaction 0 0 0 0 0 0 0 0 8 0 NN NN NN VBN IN O
coupled coupled 0 0 0 0 0 0 0 0 7 0 NN NN VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN VBN IN JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 VBN IN JJ NN VBG O
resolution resolution 0 0 0 0 0 0 0 0 10 0 IN JJ NN VBG NN O
melting melting 0 0 0 0 0 0 0 0 7 0 JJ NN VBG NN -NONE- O
curve curve 0 0 0 0 0 0 0 0 5 0 NN VBG NN -NONE- VBG O
(HRM), (HRM), 0 1 0 0 1 0 0 0 6 0 VBG NN -NONE- VBG IN O
ramping ramping 0 0 0 0 0 0 0 0 7 0 NN -NONE- VBG IN CD O
from from 0 0 0 0 0 0 0 0 4 0 -NONE- VBG IN CD TO O
70 70 0 0 0 0 0 0 1 1 2 0 VBG IN CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 IN CD TO CD JJ O
86 86 0 0 0 0 0 0 1 1 2 0 CD TO CD JJ IN O
°C °C 0 1 0 0 0 0 0 0 2 0 TO CD JJ IN NN O
with with 0 0 0 0 0 0 0 0 4 0 CD JJ IN NN NNS O
fluorescence fluorescence 0 0 0 0 0 0 0 0 12 0 JJ IN NN NNS NN O
data data 0 0 0 0 0 0 0 0 4 0 IN NN NNS NN NN O
acquisition acquisition 0 0 0 0 0 0 0 0 11 0 NN NNS NN NN IN O
set set 0 0 0 0 0 0 0 0 3 0 NNS NN NN IN CD O
at at 0 0 0 0 0 0 0 0 2 0 NN NN IN CD JJ O
0.1 0.1 0 0 0 0 0 0 0 1 3 0 NN IN CD JJ NNS O
°C °C 0 1 0 0 0 0 0 0 2 0 IN CD JJ NNS CC O
increments increments 0 0 0 0 0 0 0 0 10 0 CD JJ NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC JJ NN O
continuous continuous 0 0 0 0 0 0 0 0 10 0 NNS CC JJ NN NNP O
fluorescence fluorescence 0 0 0 0 0 0 0 0 12 0 CC JJ NN NNP NNP O
monitoring. monitoring. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP NNP IN O
Consistency Consistency 1 0 0 0 0 0 0 0 11 0 NN NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP IN DT NN VBD O
technique technique 0 0 0 0 0 0 0 0 9 0 IN DT NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD VBN IN O
assessed assessed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP CC O
inter- inter- 0 0 1 0 0 0 0 0 6 0 VBN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
intra-assays. intra-assays. 0 0 1 0 0 0 0 0 13 0 NNP CC NNP NNP IN O
Assessment Assessment 1 0 0 0 0 0 0 0 10 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
intra- intra- 0 0 1 0 0 0 0 0 6 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NN O
inter-assay inter-assay 0 0 1 0 0 0 0 0 11 0 NNP CC NNP NN VBD O
variability variability 0 0 0 0 0 0 0 0 11 0 CC NNP NN VBD JJ O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NN VBD JJ CC O
low low 0 0 0 0 0 0 0 0 3 0 NN VBD JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBD JJ CC JJ NN O
acceptable acceptable 0 0 0 0 0 0 0 0 10 0 JJ CC JJ NN IN O
coefficient coefficient 0 0 0 0 0 0 0 0 11 0 CC JJ NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS VBG O
variations variations 0 0 0 0 0 0 0 0 10 0 NN IN NNS VBG IN O
ranging ranging 0 0 0 0 0 0 0 0 7 0 IN NNS VBG IN CD O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBG IN CD TO O
0.09 0.09 0 0 0 0 0 0 0 1 4 0 VBG IN CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 IN CD TO CD : O
0.17 0.17 0 0 0 0 0 0 0 1 4 0 CD TO CD : CD O
%. %. 0 0 0 0 0 0 0 0 2 0 TO CD : CD CD O
Two Two 1 0 0 0 0 0 0 0 3 0 CD : CD CD CC O
hundred hundred 0 0 0 0 0 0 0 0 7 0 : CD CD CC NN O
and and 0 0 0 0 0 0 0 0 3 0 CD CD CC NN NNP O
eighty eighty 0 0 0 0 0 0 0 0 6 0 CD CC NN NNP NN O
E. E. 1 1 0 0 0 0 0 0 2 0 CC NN NNP NN NNP O
granulosus granulosus 0 0 0 0 0 0 0 0 10 0 NN NNP NN NNP VBZ O
s.l. s.l. 0 0 0 0 0 0 0 0 4 0 NNP NN NNP VBZ IN O
isolates isolates 0 0 0 0 0 0 0 0 8 0 NN NNP VBZ IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NNP VBZ IN NNP NNP O
sheep, sheep, 0 0 0 0 1 0 0 0 6 0 VBZ IN NNP NNP CC O
cattle, cattle, 0 0 0 0 1 0 0 0 7 0 IN NNP NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NN VBD O
camel camel 0 0 0 0 0 0 0 0 5 0 NNP CC NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 CC NN VBD VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB DT O
evaluate evaluate 0 0 0 0 0 0 0 0 8 0 VBN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN CC O
applicability applicability 0 0 0 0 0 0 0 0 13 0 VB DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
accuracy accuracy 0 0 0 0 0 0 0 0 8 0 NN CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
method. method. 0 0 0 0 0 0 0 0 7 0 IN DT NNP NNP VBZ O
The The 1 0 0 0 0 0 0 0 3 0 DT NNP NNP VBZ VBD O
isolates isolates 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBD VBN IN O
categorized categorized 0 0 0 0 0 0 0 0 11 0 VBZ VBD VBN IN NNP O
as as 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 VBN IN NNP NNP CD O
(93, (93, 0 0 0 0 1 0 0 1 4 0 IN NNP NNP CD CC O
94, 94, 0 0 0 0 1 0 0 1 3 0 NNP NNP CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NNP CD CC CD CD O
25 25 0 0 0 0 0 0 1 1 2 0 CD CC CD CD NNP O
%), %), 0 0 0 0 1 0 0 0 3 0 CC CD CD NNP NNP O
G3 G3 1 1 0 0 0 0 0 1 2 0 CD CD NNP NNP CD O
(7, (7, 0 0 0 0 1 0 0 1 3 0 CD NNP NNP CD CC O
4, 4, 0 0 0 0 1 0 0 1 2 0 NNP NNP CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NNP CD CC CD CD O
4 4 0 0 0 0 0 0 1 1 1 0 CD CC CD CD CC O
%), %), 0 0 0 0 1 0 0 0 3 0 CC CD CD CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 CD CD CC NNP NNP O
G6 G6 1 1 0 0 0 0 0 1 2 0 CD CC NNP NNP CD O
(0, (0, 0 0 0 0 1 0 0 1 3 0 CC NNP NNP CD CC O
2, 2, 0 0 0 0 1 0 0 1 2 0 NNP NNP CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NNP CD CC CD CD O
71 71 0 0 0 0 0 0 1 1 2 0 CD CC CD CD IN O
%) %) 0 0 0 0 0 0 0 0 2 0 CC CD CD IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 CD CD IN JJ NN O
sheep, sheep, 0 0 0 0 1 0 0 0 6 0 CD IN JJ NN CC O
cattle, cattle, 0 0 0 0 1 0 0 0 7 0 IN JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP NNP O
camel, camel, 0 0 0 0 1 0 0 0 6 0 NN CC NNP NNP NNP O
respectively. respectively. 0 0 0 0 0 0 0 0 13 0 CC NNP NNP NNP NNS O
HRM HRM 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNS VBD O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD RB JJ O
completely completely 0 0 0 0 0 0 0 0 10 0 NNS VBD RB JJ IN O
compatible compatible 0 0 0 0 0 0 0 0 10 0 VBD RB JJ IN DT O
with with 0 0 0 0 0 0 0 0 4 0 RB JJ IN DT VBN O
those those 0 0 0 0 0 0 0 0 5 0 JJ IN DT VBN IN O
obtained obtained 0 0 0 0 0 0 0 0 8 0 IN DT VBN IN VBG O
from from 0 0 0 0 0 0 0 0 4 0 DT VBN IN VBG CC O
sequencing sequencing 0 0 0 0 0 0 0 0 10 0 VBN IN VBG CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN VBG CC JJ NN O
rostellar rostellar 0 0 0 0 0 0 0 0 9 0 VBG CC JJ NN NNP O
hook hook 0 0 0 0 0 0 0 0 4 0 CC JJ NN NNP NNP O
measurement. measurement. 0 0 0 0 0 0 0 0 12 0 JJ NN NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NN VBD O
method method 0 0 0 0 0 0 0 0 6 0 NNP NNP NN VBD TO O
proved proved 0 0 0 0 0 0 0 0 6 0 NNP NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB DT O
be be 0 0 0 0 0 0 0 0 2 0 VBD TO VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT JJ NN O
valuable valuable 0 0 0 0 0 0 0 0 8 0 VB DT JJ NN NN O
screening screening 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN IN O
tool tool 0 0 0 0 0 0 0 0 4 0 JJ NN NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN JJ NN O
large-scale large-scale 0 0 1 0 0 0 0 0 11 0 NN IN JJ NN JJ O
molecular molecular 0 0 0 0 0 0 0 0 9 0 IN JJ NN JJ NNP O
epidemiological epidemiological 0 0 0 0 0 0 0 0 15 0 JJ NN JJ NNP NONE O
studies. studies. 0 0 0 0 0 0 0 0 8 0 NN JJ NNP NONE NONE O
miR-294/miR-302 miR-294/miR-302 0 0 1 1 0 0 0 1 15 0 NONE NONE -NONE- VBZ JJ O
Promotes Promotes 1 0 0 0 0 0 0 0 8 0 NONE -NONE- VBZ JJ NNS O
Proliferation, Proliferation, 1 0 0 0 1 0 0 0 14 0 -NONE- VBZ JJ NNS -NONE- O
Suppresses Suppresses 1 0 0 0 0 0 0 0 10 0 VBZ JJ NNS -NONE- NNP O
G1-S G1-S 1 1 1 0 0 0 0 1 4 0 JJ NNS -NONE- NNP NNP B_TIMEXCCP
Restriction Restriction 1 0 0 0 0 0 0 0 11 0 NNS -NONE- NNP NNP CC O
Point, Point, 1 0 0 0 1 0 0 0 6 0 -NONE- NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Inhibits Inhibits 1 0 0 0 0 0 0 0 8 0 NNP CC NNP NNP NNP O
ESC ESC 1 1 0 0 0 0 0 0 3 0 CC NNP NNP NNP IN O
Differentiation Differentiation 1 0 0 0 0 0 0 0 15 0 NNP NNP NNP IN NNP O
through through 0 0 0 0 0 0 0 0 7 0 NNP NNP IN NNP NNP O
Separable Separable 1 0 0 0 0 0 0 0 9 0 NNP IN NNP NNP NNP O
Mechanisms. Mechanisms. 1 0 0 0 0 0 0 0 11 0 IN NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Melton Melton 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
YP, YP, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Shenoy Shenoy 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
XX, XX, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Subramanyam Subramanyam 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Blelloch Blelloch 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
R. R. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Peking-Tsinghua Peking-Tsinghua 1 0 1 0 0 0 0 0 15 0 NNP NNP NNP NNP NNP O
Joint Joint 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP IN O
Center Center 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNP O
Life Life 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP IN NNP NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Peking Peking 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP CD O
Beijing Beijing 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP CD -NONE- O
100871, 100871, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD -NONE- NNP O
China; China; 1 0 0 0 0 0 0 0 6 0 NNP CD -NONE- NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 CD -NONE- NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 -NONE- NNP IN NNP NNP O
Urology, Urology, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP IN O
Center Center 1 0 0 0 0 0 0 0 6 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Reproductive Reproductive 1 0 0 0 0 0 0 0 12 0 NNP IN NNP NNP CC O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP CC DT NNP CC O
Eli Eli 1 0 0 0 0 0 0 0 3 0 CC DT NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC NNP NNP O
Edythe Edythe 1 0 0 0 0 0 0 0 6 0 NNP CC NNP NNP NNP O
Broad Broad 1 0 0 0 0 0 0 0 5 0 CC NNP NNP NNP IN O
Center Center 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNP O
Regeneration Regeneration 1 0 0 0 0 0 0 0 12 0 NNP IN NNP NNP CC O
Medicine Medicine 1 0 0 0 0 0 0 0 8 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Stem Stem 1 0 0 0 0 0 0 0 4 0 NNP CC NNP NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 CC NNP NNP NNP NNP O
Research, Research, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
California, California, 1 0 0 0 1 0 0 0 11 0 NNP IN NNP NNP NNP O
San San 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
Francisco, Francisco, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
San San 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Francisco, Francisco, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP CD O
CA CA 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
94143, 94143, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Electronic Electronic 1 0 0 0 0 0 0 0 10 0 CD NNP NNP NNP NNP O
address: address: 0 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
yangming.wang@pku.edu.cn. yangming.wang@pku.edu.cn. 0 0 0 0 0 0 0 0 25 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP CC O
miR-294 miR-294 0 0 1 0 0 0 0 1 7 0 NNP NNP NNP CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC -NONE- NNP O
miR-302 miR-302 0 0 1 0 0 0 0 1 7 0 NNP CC -NONE- NNP NN O
microRNAs microRNAs 0 0 0 0 0 0 0 0 9 0 CC -NONE- NNP NN DT O
promote promote 0 0 0 0 0 0 0 0 7 0 -NONE- NNP NN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT VBN NNP O
abbreviated abbreviated 0 0 0 0 0 0 0 0 11 0 NN DT VBN NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 phase DT VBN NNP NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 VBN NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
embryonic embryonic 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN NN O
stem stem 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NN O
(ESC) (ESC) 0 1 0 0 0 0 0 0 5 0 NN NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN CC O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
suppress suppress 0 0 0 0 0 0 0 0 8 0 NN CC NN NN VBD O
differentiation differentiation 0 0 0 0 0 0 0 0 15 0 CC NN NN VBD IN O
induced induced 0 0 0 0 0 0 0 0 7 0 NN NN VBD IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN NNP NNP O
let-7. let-7. 0 0 1 0 0 0 0 1 6 0 VBD IN NNP NNP PRP O
Here, Here, 1 0 0 0 1 0 0 0 5 0 IN NNP NNP PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD DT O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 NNP PRP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT NN IN O
role role 0 0 0 0 0 0 0 0 4 0 VBD DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
retinoblastoma retinoblastoma 0 0 0 0 0 0 0 0 14 0 IN DT NN NN NN O
(Rb) (Rb) 0 0 0 0 0 0 0 0 4 0 DT NN NN NN NNS O
family family 0 0 0 0 0 0 0 0 6 0 NN NN NN NNS IN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NN NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NNP O
these these 0 0 0 0 0 0 0 0 5 0 NNS IN DT NNP NNP O
settings. settings. 0 0 0 0 0 0 0 0 9 0 IN DT NNP NNP JJ O
Under Under 1 0 0 0 0 0 0 0 5 0 DT NNP NNP JJ NN O
normal normal 0 0 0 0 0 0 0 0 6 0 NNP NNP JJ NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 NNP JJ NN NN -NONE- O
conditions, conditions, 0 0 0 0 1 0 0 0 11 0 JJ NN NN -NONE- VBN O
miR-294 miR-294 0 0 1 0 0 0 0 1 7 0 NN NN -NONE- VBN DT O
promoted promoted 0 0 0 0 0 0 0 0 8 0 NN -NONE- VBN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- VBN DT JJ NNS O
rapid rapid 0 0 0 0 0 0 0 0 5 0 VBN DT JJ NNS NN O
G1-S G1-S 1 1 1 0 0 0 0 1 4 0 DT JJ NNS NN NN B_TIMEXCCP
transition transition 0 0 0 0 0 0 0 0 10 0 JJ NNS NN NN IN O
independent independent 0 0 0 0 0 0 0 0 11 0 NNS NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
Rb Rb 1 0 0 0 0 0 0 0 2 0 IN DT NNP NNP NNP O
family. family. 0 0 0 0 0 0 0 0 7 0 DT NNP NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
contrast, contrast, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP VBD O
miR-294 miR-294 0 0 1 0 0 0 0 1 7 0 NNP NNP NNP VBD DT O
suppressed suppressed 0 0 0 0 0 0 0 0 10 0 NNP NNP VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT JJ NN O
further further 0 0 0 0 0 0 0 0 7 0 VBD DT JJ NN IN O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 DT JJ NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN NNP IN O
G1 G1 1 1 0 0 0 0 0 1 2 0 NNS IN NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NN TO O
response response 0 0 0 0 0 0 0 0 8 0 NNP IN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB NN O
nutrient nutrient 0 0 0 0 0 0 0 0 8 0 NN TO VB NN CC O
deprivation deprivation 0 0 0 0 0 0 0 0 11 0 TO VB NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VB NN CC NNP NN O
cell-cell cell-cell 0 0 1 0 0 0 0 0 9 0 NN CC NNP NN IN O
contact contact 0 0 0 0 0 0 0 0 7 0 CC NNP NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT JJ NNP O
Rb-dependent Rb-dependent 1 0 1 0 0 0 0 0 12 0 IN DT JJ NNP NNP O
fashion. fashion. 0 0 0 0 0 0 0 0 8 0 DT JJ NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP VBD CD O
uncovered uncovered 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD CD JJ O
five five 0 0 0 0 0 0 0 0 4 0 NNP VBD CD JJ NNP O
additional additional 0 0 0 0 0 0 0 0 10 0 VBD CD JJ NNP NNP O
miRNAs miRNAs 0 0 0 0 0 0 0 0 6 0 CD JJ NNP NNP NNP O
(miR-26a, (miR-26a, 0 0 1 0 1 0 0 1 9 0 JJ NNP NNP NNP NNP O
miR-99b, miR-99b, 0 0 1 0 1 0 0 1 8 0 NNP NNP NNP NNP NNP O
miR-193, miR-193, 0 0 1 0 1 0 0 1 8 0 NNP NNP NNP NNP CC O
miR-199a-5p, miR-199a-5p, 0 0 1 0 1 0 0 1 12 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP IN O
miR-218) miR-218) 0 0 1 0 0 0 0 1 8 0 NNP CC NNP IN VBN O
that that 0 0 0 0 0 0 0 0 4 0 CC NNP IN VBN NNP O
silenced silenced 0 0 0 0 0 0 0 0 8 0 NNP IN VBN NNP NNP O
ESC ESC 1 1 0 0 0 0 0 0 3 0 IN VBN NNP NNP IN O
self-renewal self-renewal 0 0 1 0 0 0 0 0 12 0 VBN NNP NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN IN O
absence absence 0 0 0 0 0 0 0 0 7 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ JJ O
other other 0 0 0 0 0 0 0 0 5 0 NN IN JJ JJ DT O
miRNAs, miRNAs, 0 0 0 0 1 0 0 0 7 0 IN JJ JJ DT IN O
all all 0 0 0 0 0 0 0 0 3 0 JJ JJ DT IN WDT O
of of 0 0 0 0 0 0 0 0 2 0 JJ DT IN WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 DT IN WDT VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 IN WDT VBD VBN IN O
antagonized antagonized 0 0 0 0 0 0 0 0 11 0 WDT VBD VBN IN -NONE- O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN -NONE- CC O
miR-294 miR-294 0 0 1 0 0 0 0 1 7 0 VBN IN -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN -NONE- CC NNP NNP O
miR-302. miR-302. 0 0 1 0 0 0 0 1 8 0 -NONE- CC NNP NNP IN O
Four Four 1 0 0 0 0 0 0 0 4 0 CC NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT CD O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT CD JJ O
six six 0 0 0 0 0 0 0 0 3 0 IN DT CD JJ NNP O
differentiation-inducing differentiation-inducing 0 0 1 0 0 0 0 0 24 0 DT CD JJ NNP VBD O
miRNAs miRNAs 0 0 0 0 0 0 0 0 6 0 CD JJ NNP VBD DT O
induced induced 0 0 0 0 0 0 0 0 7 0 JJ NNP VBD DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNP VBD DT JJ NNP O
Rb-dependent Rb-dependent 1 0 1 0 0 0 0 0 12 0 VBD DT JJ NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 DT JJ NNP NNP NNP B_TIMEXCCP
accumulation. accumulation. 0 0 0 0 0 0 0 0 13 0 JJ NNP NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP DT CD O
all all 0 0 0 0 0 0 0 0 3 0 NNP NNP DT CD RB O
six six 0 0 0 0 0 0 0 0 3 0 NNP DT CD RB VBN O
still still 0 0 0 0 0 0 0 0 5 0 DT CD RB VBN JJ O
silenced silenced 0 0 0 0 0 0 0 0 8 0 CD RB VBN JJ IN O
self-renewal self-renewal 0 0 1 0 0 0 0 0 12 0 RB VBN JJ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBN JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN IN O
absence absence 0 0 0 0 0 0 0 0 7 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
Rb Rb 1 0 0 0 0 0 0 0 2 0 IN DT NNP NNP NNP O
proteins. proteins. 0 0 0 0 0 0 0 0 9 0 DT NNP NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NNP NN O
miR-294/miR-302 miR-294/miR-302 0 0 1 1 0 0 0 1 15 0 IN DT NNP NN VBZ O
family family 0 0 0 0 0 0 0 0 6 0 DT NNP NN VBZ IN O
acts acts 0 0 0 0 0 0 0 0 4 0 NNP NN VBZ IN JJ O
through through 0 0 0 0 0 0 0 0 7 0 NN VBZ IN JJ CC O
Rb-dependent Rb-dependent 1 0 1 0 0 0 0 0 12 0 VBZ IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NNS O
-independent -independent 0 0 1 0 0 0 0 0 12 0 JJ CC JJ NNS TO O
pathways pathways 0 0 0 0 0 0 0 0 8 0 CC JJ NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO VB DT O
regulate regulate 0 0 0 0 0 0 0 0 8 0 NNS TO VB DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 0 VB DT NNP NN NN B_TIMEXCCP
restriction restriction 0 0 0 0 0 0 0 0 11 0 DT NNP NN NN CC O
point point 0 0 0 0 0 0 0 0 5 0 NNP NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN IN O
silencing silencing 0 0 0 0 0 0 0 0 9 0 CC DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
self-renewal, self-renewal, 0 0 1 0 1 0 0 0 13 0 NN IN NNP NNP NONE O
respectively. respectively. 0 0 0 0 0 0 0 0 13 0 IN NNP NNP NONE NONE O
Biochemical Biochemical 1 0 0 0 0 0 0 0 11 0 NONE NONE JJ NNS IN O
insights insights 0 0 0 0 0 0 0 0 8 0 NONE JJ NNS IN DT O
into into 0 0 0 0 0 0 0 0 4 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
function function 0 0 0 0 0 0 0 0 8 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNP O
phage phage 0 0 0 0 0 0 0 0 5 0 NN IN NN NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 IN NN NNP NNP IN O
gp67 gp67 0 0 0 0 0 0 0 1 4 0 NN NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Staphylococcus Staphylococcus 1 0 0 0 0 0 0 0 14 0 NNP IN NNP NNP NNP O
aureus. aureus. 0 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
Osmundson Osmundson 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Darst Darst 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
SA. SA. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Rockefeller Rockefeller 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
University; University; 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
New New 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
York, York, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
NY NY 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Bacteriophage Bacteriophage 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP VBP O
(phage) (phage) 0 0 0 0 0 0 0 0 7 0 NNP NNP NNP VBP IN O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNP VBP IN DT O
among among 0 0 0 0 0 0 0 0 5 0 NNP VBP IN DT RBS O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT RBS JJ O
most most 0 0 0 0 0 0 0 0 4 0 IN DT RBS JJ CC O
diverse diverse 0 0 0 0 0 0 0 0 7 0 DT RBS JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 RBS JJ CC JJ NN O
abundant abundant 0 0 0 0 0 0 0 0 8 0 JJ CC JJ NN NNS O
life life 0 0 0 0 0 0 0 0 4 0 CC JJ NN NNS IN O
forms forms 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP NNP O
Earth. Earth. 1 0 0 0 0 0 0 0 6 0 NNS IN NNP NNP VBP O
Studies Studies 1 0 0 0 0 0 0 0 7 0 IN NNP NNP VBP RB O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNP VBP RB VBN O
recently recently 0 0 0 0 0 0 0 0 8 0 NNP VBP RB VBN NN O
used used 0 0 0 0 0 0 0 0 4 0 VBP RB VBN NN NN O
phage phage 0 0 0 0 0 0 0 0 5 0 RB VBN NN NN TO O
diversity diversity 0 0 0 0 0 0 0 0 9 0 VBN NN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO VB NN O
identify identify 0 0 0 0 0 0 0 0 8 0 NN TO VB NN JJ O
novel novel 0 0 0 0 0 0 0 0 5 0 TO VB NN JJ NNS O
antimicrobial antimicrobial 0 0 0 0 0 0 0 0 13 0 VB NN JJ NNS CC O
peptides peptides 0 0 0 0 0 0 0 0 8 0 NN JJ NNS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC NNP NNP O
proteins. proteins. 0 0 0 0 0 0 0 0 9 0 NNS CC NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 CC NNP NNP VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NNP VBD IN CD O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBD IN CD JJ O
one one 0 0 0 0 0 0 0 0 3 0 VBD IN CD JJ NN O
such such 0 0 0 0 0 0 0 0 4 0 IN CD JJ NN NN O
phage phage 0 0 0 0 0 0 0 0 5 0 CD JJ NN NN NNP O
protein, protein, 0 0 0 0 1 0 0 0 8 0 JJ NN NN NNP VBZ O
Staphylococcus Staphylococcus 1 0 0 0 0 0 0 0 14 0 NN NN NNP VBZ JJ O
aureus aureus 0 0 0 0 0 0 0 0 6 0 NN NNP VBZ JJ NN O
(Sau) (Sau) 0 0 0 0 0 0 0 0 5 0 NNP VBZ JJ NN NNP O
phage phage 0 0 0 0 0 0 0 0 5 0 VBZ JJ NN NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 JJ NN NNP NNP VBZ O
gp67, gp67, 0 0 0 0 1 0 0 1 5 0 NN NNP NNP VBZ NN O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP VBZ NN NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 VBZ NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP IN O
Sau Sau 1 0 0 0 0 0 0 0 3 0 NN IN NNP IN DT O
by by 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNP IN DT JJ NNP O
unusual unusual 0 0 0 0 0 0 0 0 7 0 IN DT JJ NNP NNP O
mechanism. mechanism. 0 0 0 0 0 0 0 0 10 0 DT JJ NNP NNP VBZ O
Gp67 Gp67 1 0 0 0 0 0 0 1 4 0 JJ NNP NNP VBZ TO O
binds binds 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBZ TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBZ TO DT NN NNP O
host host 0 0 0 0 0 0 0 0 4 0 TO DT NN NNP NN O
RNA RNA 1 1 0 0 0 0 0 0 3 0 DT NN NNP NN -NONE- O
polymerase polymerase 0 0 0 0 0 0 0 0 10 0 NN NNP NN -NONE- IN O
(RNAP) (RNAP) 0 1 0 0 0 0 0 0 6 0 NNP NN -NONE- IN DT O
through through 0 0 0 0 0 0 0 0 7 0 NN -NONE- IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 -NONE- IN DT NN IN O
interaction interaction 0 0 0 0 0 0 0 0 11 0 IN DT NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
promoter promoter 0 0 0 0 0 0 0 0 8 0 IN DT NN NN : O
specificity specificity 0 0 0 0 0 0 0 0 11 0 DT NN NN : JJ O
σ σ 0 0 0 0 0 0 0 0 1 0 NN NN : JJ CC O
subunit, subunit, 0 0 0 0 1 0 0 0 8 0 NN : JJ CC IN O
but but 0 0 0 0 0 0 0 0 3 0 : JJ CC IN JJ O
unlike unlike 0 0 0 0 0 0 0 0 6 0 JJ CC IN JJ JJ O
many many 0 0 0 0 0 0 0 0 4 0 CC IN JJ JJ JJ O
other other 0 0 0 0 0 0 0 0 5 0 IN JJ JJ JJ NN O
σ-binding σ-binding 0 0 1 0 0 0 0 0 9 0 JJ JJ JJ NN NN O
phage phage 0 0 0 0 0 0 0 0 5 0 JJ JJ NN NN NNP O
proteins, proteins, 0 0 0 0 1 0 0 0 9 0 JJ NN NN NNP VBZ O
gp67 gp67 0 0 0 0 0 0 0 1 4 0 NN NN NNP VBZ RB O
does does 0 0 0 0 0 0 0 0 4 0 NN NNP VBZ RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NNP VBZ RB VB NN O
disrupt disrupt 0 0 0 0 0 0 0 0 7 0 VBZ RB VB NN IN O
transcription transcription 0 0 0 0 0 0 0 0 13 0 RB VB NN IN JJS O
at at 0 0 0 0 0 0 0 0 2 0 VB NN IN JJS NNP O
most most 0 0 0 0 0 0 0 0 4 0 NN IN JJS NNP NNP O
promoters. promoters. 0 0 0 0 0 0 0 0 10 0 IN JJS NNP NNP NNP O
Rather, Rather, 1 0 0 0 1 0 0 0 7 0 JJS NNP NNP NNP VBZ O
gp67 gp67 0 0 0 0 0 0 0 1 4 0 NNP NNP NNP VBZ VBG O
prevents prevents 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ VBG IN O
binding binding 0 0 0 0 0 0 0 0 7 0 NNP VBZ VBG IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBZ VBG IN DT NNP O
another another 0 0 0 0 0 0 0 0 7 0 VBG IN DT NNP NNP O
RNAP RNAP 1 1 0 0 0 0 0 0 4 0 IN DT NNP NNP DT O
domain, domain, 0 0 0 0 1 0 0 0 7 0 DT NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NN O
α-C-terminal α-C-terminal 0 0 1 0 0 0 0 0 12 0 NNP DT JJ NN TO O
domain, domain, 0 0 0 0 1 0 0 0 7 0 DT JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB JJ O
upstream upstream 0 0 0 0 0 0 0 0 8 0 NN TO VB JJ NNS O
A/T-rich A/T-rich 1 0 1 1 0 0 0 0 8 0 TO VB JJ NNS VBN O
elements elements 0 0 0 0 0 0 0 0 8 0 VB JJ NNS VBN IN O
required required 0 0 0 0 0 0 0 0 8 0 JJ NNS VBN IN RB O
for for 0 0 0 0 0 0 0 0 3 0 NNS VBN IN RB NN O
robust robust 0 0 0 0 0 0 0 0 6 0 VBN IN RB NN IN O
transcription transcription 0 0 0 0 0 0 0 0 13 0 IN RB NN IN NNP O
at at 0 0 0 0 0 0 0 0 2 0 RB NN IN NNP NNP O
rRNA rRNA 0 0 0 0 0 0 0 0 4 0 NN IN NNP NNP NNP O
promoters. promoters. 0 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP PRP O
Here, Here, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP PRP VBZ O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBZ JJ O
discuss discuss 0 0 0 0 0 0 0 0 7 0 NNP PRP VBZ JJ JJ O
additional additional 0 0 0 0 0 0 0 0 10 0 PRP VBZ JJ JJ NNS O
biochemical biochemical 0 0 0 0 0 0 0 0 11 0 VBZ JJ JJ NNS IN O
insights insights 0 0 0 0 0 0 0 0 8 0 JJ JJ NNS IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ WRB O
gp67, gp67, 0 0 0 0 1 0 0 1 5 0 NNS IN JJ WRB NN O
how how 0 0 0 0 0 0 0 0 3 0 IN JJ WRB NN NNS O
phage phage 0 0 0 0 0 0 0 0 5 0 JJ WRB NN NNS NN O
promoters promoters 0 0 0 0 0 0 0 0 9 0 WRB NN NNS NN DT O
escape escape 0 0 0 0 0 0 0 0 6 0 NN NNS NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS NN DT NN NN O
inhibitory inhibitory 0 0 0 0 0 0 0 0 10 0 NN DT NN NN IN O
function function 0 0 0 0 0 0 0 0 8 0 DT NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP CC O
gp67, gp67, 0 0 0 0 1 0 0 1 5 0 NN IN NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC JJ NNS O
methodological methodological 0 0 0 0 0 0 0 0 14 0 NNP CC JJ NNS WDT O
advancements advancements 0 0 0 0 0 0 0 0 12 0 CC JJ NNS WDT VBD O
that that 0 0 0 0 0 0 0 0 4 0 JJ NNS WDT VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 NNS WDT VBD JJ TO O
foundational foundational 0 0 0 0 0 0 0 0 12 0 WDT VBD JJ TO PRP$ O
to to 0 0 0 0 0 0 0 0 2 0 VBD JJ TO PRP$ NNP O
our our 0 0 0 0 0 0 0 0 3 0 JJ TO PRP$ NNP NONE O
work. work. 0 0 0 0 0 0 0 0 5 0 TO PRP$ NNP NONE NONE O
Post-transcriptional Post-transcriptional 1 0 1 0 0 0 0 0 20 0 NONE NONE JJ NN IN O
regulation regulation 0 0 0 0 0 0 0 0 10 0 NONE JJ NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS -NONE- O
cyclins cyclins 0 0 0 0 0 0 0 0 7 0 NN IN NNS -NONE- NNP O
D1, D1, 1 1 0 0 1 0 0 1 3 0 IN NNS -NONE- NNP CC O
D3 D3 1 1 0 0 0 0 0 1 2 0 NNS -NONE- NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NNP CC NNP CC O
G1 G1 1 1 0 0 0 0 0 1 2 0 NNP CC NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NNP CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS VBP IN O
depend depend 0 0 0 0 0 0 0 0 6 0 NN NNS VBP IN -NONE- O
on on 0 0 0 0 0 0 0 0 2 0 NNS VBP IN -NONE- JJ O
IMP-3 IMP-3 1 1 1 0 0 0 0 1 5 0 VBP IN -NONE- JJ NNP O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 IN -NONE- JJ NNP NNP O
localization. localization. 0 0 0 0 0 0 0 0 13 0 -NONE- JJ NNP NNP NNP O
Rivera Rivera 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP NNP NNP O
Vargas Vargas 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Boudoukha Boudoukha 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Simon Simon 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Souidi Souidi 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Cuvellier Cuvellier 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Pinna Pinna 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Polesskaya Polesskaya 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
A. A. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP CD O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP CD NNP O
1] 1] 0 0 0 0 0 0 0 1 2 0 NNP NNP CD NNP NNP O
CNRS, CNRS, 1 1 0 0 1 0 0 0 5 0 NNP CD NNP NNP CD O
FRE FRE 1 1 0 0 0 0 0 0 3 0 CD NNP NNP CD -NONE- O
3377, 3377, 0 0 0 0 1 0 0 1 5 0 NNP NNP CD -NONE- NNP O
Gif-sur-Yvette, Gif-sur-Yvette, 1 0 1 0 1 0 0 0 15 0 NNP CD -NONE- NNP NNP O
France France 1 0 0 0 0 0 0 0 6 0 CD -NONE- NNP NNP NNP O
[2] [2] 0 0 0 0 0 0 0 1 3 0 -NONE- NNP NNP NNP NNP O
Univ Univ 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Paris-Sud, Paris-Sud, 1 0 1 0 1 0 0 0 10 0 NNP NNP NNP NNP CD O
FRE FRE 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP CD -NONE- O
3377, 3377, 0 0 0 0 1 0 0 1 5 0 NNP NNP CD -NONE- NNP O
Gif-sur-Yvette, Gif-sur-Yvette, 1 0 1 0 1 0 0 0 15 0 NNP CD -NONE- NNP NNP O
France France 1 0 0 0 0 0 0 0 6 0 CD -NONE- NNP NNP NNP O
[3] [3] 0 0 0 0 0 0 0 1 3 0 -NONE- NNP NNP NNP NNP O
CEA, CEA, 1 1 0 0 1 0 0 0 4 0 NNP NNP NNP NNP CD O
FRE FRE 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP CD -NONE- O
3377, 3377, 0 0 0 0 1 0 0 1 5 0 NNP NNP CD -NONE- NNP O
Gif-sur-Yvette, Gif-sur-Yvette, 1 0 1 0 1 0 0 0 15 0 NNP CD -NONE- NNP NNP O
France. France. 1 0 0 0 0 0 0 0 7 0 CD -NONE- NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 -NONE- NNP NNP NNP VBZ O
RNA-binding RNA-binding 1 0 1 0 0 0 0 0 11 0 NNP NNP NNP VBZ IN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBZ IN DT NNP NN O
IMP IMP 1 1 0 0 0 0 0 0 3 0 IN DT NNP NN NN O
family family 0 0 0 0 0 0 0 0 6 0 DT NNP NN NN NN O
(insulin-like (insulin-like 0 0 1 0 0 0 0 0 13 0 NNP NN NN NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 NN NN NN NN CD O
factor factor 0 0 0 0 0 0 0 0 6 0 NN NN NN CD NN O
2 2 0 0 0 0 0 0 1 1 1 0 NN NN CD NN JJ O
(IGF2) (IGF2) 0 1 0 0 0 0 0 1 6 0 NN CD NN JJ NNS O
mRNA-binding mRNA-binding 0 0 1 0 0 0 0 0 12 0 CD NN JJ NNS CD O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NN JJ NNS CD VBP O
1-3) 1-3) 0 0 1 0 0 0 0 1 4 0 JJ NNS CD VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNS CD VBP JJ JJ O
important important 0 0 0 0 0 0 0 0 9 0 CD VBP JJ JJ NNS O
post-transcriptional post-transcriptional 0 0 1 0 0 0 0 0 20 0 VBP JJ JJ NNS IN O
regulators regulators 0 0 0 0 0 0 0 0 10 0 JJ JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NNP O
gene gene 0 0 0 0 0 0 0 0 4 0 NNS IN NN NNP NNP O
expression. expression. 0 0 0 0 0 0 0 0 11 0 IN NN NNP NNP NNS O
Multiple Multiple 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NNS VBP O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP VBN JJ O
linked linked 0 0 0 0 0 0 0 0 6 0 NNS VBP VBN JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 VBP VBN JJ NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 VBN JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
IMP IMP 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNP CC O
proteins, proteins, 0 0 0 0 1 0 0 0 9 0 IN NNP NNP CC RB O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC RB IN O
especially especially 0 0 0 0 0 0 0 0 10 0 NNP CC RB IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC RB IN JJ TO O
IMP-3, IMP-3, 1 1 1 0 1 0 0 1 6 0 RB IN JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 IN JJ TO DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 JJ TO DT JJ NN O
unfavorable unfavorable 0 0 0 0 0 0 0 0 11 0 TO DT JJ NN IN O
prognosis prognosis 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNS O
numerous numerous 0 0 0 0 0 0 0 0 8 0 NN IN JJ NNS IN O
types types 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NNP O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 NNS IN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP NN O
specific specific 0 0 0 0 0 0 0 0 8 0 NNP NNP NNP NN IN O
importance importance 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN -NONE- IN O
IMP-3 IMP-3 1 1 1 0 0 0 0 1 5 0 NN IN -NONE- IN NN O
for for 0 0 0 0 0 0 0 0 3 0 IN -NONE- IN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 -NONE- IN NN NN VBZ O
transformation transformation 0 0 0 0 0 0 0 0 14 0 IN NN NN VBZ RB O
remains remains 0 0 0 0 0 0 0 0 7 0 NN NN VBZ RB NNP O
poorly poorly 0 0 0 0 0 0 0 0 6 0 NN VBZ RB NNP NNP O
understood. understood. 0 0 0 0 0 0 0 0 11 0 VBZ RB NNP NNP RB O
We We 1 0 0 0 0 0 0 0 2 0 RB NNP NNP RB VBP O
here here 0 0 0 0 0 0 0 0 4 0 NNP NNP RB VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NNP RB VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 RB VBP IN DT CD O
all all 0 0 0 0 0 0 0 0 3 0 VBP IN DT CD NNS O
three three 0 0 0 0 0 0 0 0 5 0 IN DT CD NNS MD O
IMPs IMPs 1 0 0 0 0 0 0 0 4 0 DT CD NNS MD RB O
can can 0 0 0 0 0 0 0 0 3 0 CD NNS MD RB VB O
directly directly 0 0 0 0 0 0 0 0 8 0 NNS MD RB VB DT O
bind bind 0 0 0 0 0 0 0 0 4 0 MD RB VB DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 RB VB DT NNP IN O
mRNAs mRNAs 0 0 0 0 0 0 0 0 5 0 VB DT NNP IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NNP IN NNS -NONE- O
cyclins cyclins 0 0 0 0 0 0 0 0 7 0 NNP IN NNS -NONE- NNP O
D1, D1, 1 1 0 0 1 0 0 1 3 0 IN NNS -NONE- NNP CC O
D3 D3 1 1 0 0 0 0 0 1 2 0 NNS -NONE- NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NNP CC NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 NNP CC NNP NNP NNP O
(CCND1, (CCND1, 0 1 0 0 1 0 0 1 7 0 CC NNP NNP NNP CC O
D3 D3 1 1 0 0 0 0 0 1 2 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP IN O
G1) G1) 1 1 0 0 0 0 0 1 3 0 NNP CC NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CC NNP IN NN CC O
vivo vivo 0 0 0 0 0 0 0 0 4 0 NNP IN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN CC IN NNP CC O
vitro, vitro, 0 0 0 0 1 0 0 0 6 0 CC IN NNP CC RB O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC RB RB O
yet yet 0 0 0 0 0 0 0 0 3 0 NNP CC RB RB -NONE- O
only only 0 0 0 0 0 0 0 0 4 0 CC RB RB -NONE- VBZ O
IMP-3 IMP-3 1 1 1 0 0 0 0 1 5 0 RB RB -NONE- VBZ DT O
regulates regulates 0 0 0 0 0 0 0 0 9 0 RB -NONE- VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- VBZ DT NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 VBZ DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT NNS IN O
cyclins cyclins 0 0 0 0 0 0 0 0 7 0 IN DT NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 IN DT JJ NN IN O
manner manner 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN CD NN O
six six 0 0 0 0 0 0 0 0 3 0 NN IN CD NN NN O
human human 0 0 0 0 0 0 0 0 5 0 IN CD NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 CD NN NN NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NNS IN O
lines lines 0 0 0 0 0 0 0 0 5 0 NN NN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NNP O
different different 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NNP NNP O
origins. origins. 0 0 0 0 0 0 0 0 8 0 IN JJ NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
absence absence 0 0 0 0 0 0 0 0 7 0 NNP DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP DT O
IMP-3, IMP-3, 1 1 1 0 1 0 0 1 6 0 NN IN NNP DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 IN NNP DT NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 NNP DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NNP O
CCND1, CCND1, 1 1 0 0 1 0 0 1 6 0 NNS IN JJ NNP CC O
D3 D3 1 1 0 0 0 0 0 1 2 0 IN JJ NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNP CC NNP NNS O
G1 G1 1 1 0 0 0 0 0 1 2 0 NNP CC NNP NNS VBP O
proteins proteins 0 0 0 0 0 0 0 0 8 0 CC NNP NNS VBP JJ O
fall fall 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP JJ CC O
dramatically, dramatically, 0 0 0 0 1 0 0 0 13 0 NNS VBP JJ CC DT O
and and 0 0 0 0 0 0 0 0 3 0 VBP JJ CC DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 JJ CC DT NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 CC DT NNS VBP IN O
accumulate accumulate 0 0 0 0 0 0 0 0 10 0 DT NNS VBP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 phase IN DT NNP NN IN O
phase phase 0 0 0 0 0 0 0 0 5 0 DT NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN VBG O
cycle, cycle, 0 0 0 0 1 0 0 0 6 0 DT NN NN VBG TO O
leading leading 0 0 0 0 0 0 0 0 7 0 NN NN VBG TO RB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBG TO RB JJ O
almost almost 0 0 0 0 0 0 0 0 6 0 VBG TO RB JJ NN O
complete complete 0 0 0 0 0 0 0 0 8 0 TO RB JJ NN NNP O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 RB JJ NN NNP NNP O
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 JJ NN NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP JJ O
show show 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP JJ VBN O
that, that, 0 0 0 0 1 0 0 0 5 0 NNS VBP JJ VBN IN O
compared compared 0 0 0 0 0 0 0 0 8 0 VBP JJ VBN IN -NONE- O
with with 0 0 0 0 0 0 0 0 4 0 JJ VBN IN -NONE- CC O
IMP-1 IMP-1 1 1 1 0 0 0 0 1 5 0 VBN IN -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN -NONE- CC NNP NNP O
IMP-2, IMP-2, 1 1 1 0 1 0 0 1 6 0 -NONE- CC NNP NNP VBZ O
IMP-3 IMP-3 1 1 1 0 0 0 0 1 5 0 CC NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
enriched enriched 0 0 0 0 0 0 0 0 8 0 NNP VBZ VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN WRB O
nucleus, nucleus, 0 0 0 0 1 0 0 0 8 0 IN DT NN WRB PRP O
where where 0 0 0 0 0 0 0 0 5 0 DT NN WRB PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NN WRB PRP VBZ DT O
binds binds 0 0 0 0 0 0 0 0 5 0 WRB PRP VBZ DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBZ DT NNS IN O
transcripts transcripts 0 0 0 0 0 0 0 0 11 0 VBZ DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NNP O
CCND1, CCND1, 1 1 0 0 1 0 0 1 6 0 NNS IN JJ NNP CC O
D3 D3 1 1 0 0 0 0 0 1 2 0 IN JJ NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNP CC NNP NNP O
G1. G1. 1 1 0 0 0 0 0 1 3 0 NNP CC NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 CC NNP NNP NN NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN IN O
localization localization 0 0 0 0 0 0 0 0 12 0 NNP NN NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN -NONE- VBZ O
IMP-3 IMP-3 1 1 1 0 0 0 0 1 5 0 NN IN -NONE- VBZ IN O
depends depends 0 0 0 0 0 0 0 0 7 0 IN -NONE- VBZ IN PRP$ O
on on 0 0 0 0 0 0 0 0 2 0 -NONE- VBZ IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 VBZ IN PRP$ NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 IN PRP$ NN NN NNP O
partner partner 0 0 0 0 0 0 0 0 7 0 PRP$ NN NN NNP CC O
HNRNPM HNRNPM 1 1 0 0 0 0 0 0 6 0 NN NN NNP CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP CC VBZ JJ IN O
indispensable indispensable 0 0 0 0 0 0 0 0 13 0 CC VBZ JJ IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT JJ NN O
post-transcriptional post-transcriptional 0 0 1 0 0 0 0 0 20 0 IN DT JJ NN IN O
regulation regulation 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NN IN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
cyclins. cyclins. 0 0 0 0 0 0 0 0 8 0 IN DT NNP NNP NN O
Cytoplasmic Cytoplasmic 1 0 0 0 0 0 0 0 11 0 DT NNP NNP NN IN O
retention retention 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN -NONE- CC O
IMP-3 IMP-3 1 1 1 0 0 0 0 1 5 0 NN IN -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN -NONE- CC NNP IN O
HNRNPM HNRNPM 1 1 0 0 0 0 0 0 6 0 -NONE- CC NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CC NNP IN NN NN O
human human 0 0 0 0 0 0 0 0 5 0 NNP IN NN NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN NN NN NNS NNS O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS NNS TO O
leads leads 0 0 0 0 0 0 0 0 5 0 NN NNS NNS TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NNS NNS TO JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 NNS TO JJ NN IN O
drop drop 0 0 0 0 0 0 0 0 4 0 TO JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
proliferation. proliferation. 0 0 0 0 0 0 0 0 14 0 NN IN NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 IN NNP NNP NNP DT O
conclusion, conclusion, 0 0 0 0 1 0 0 0 11 0 NNP NNP NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 NNP DT JJ NN NN O
IMP-3-HNRNPM IMP-3-HNRNPM 1 1 1 0 0 0 0 1 12 0 DT JJ NN NN VBZ O
complex complex 0 0 0 0 0 0 0 0 7 0 JJ NN NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ JJ IN O
important important 0 0 0 0 0 0 0 0 9 0 NN VBZ JJ IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN NN O
efficient efficient 0 0 0 0 0 0 0 0 9 0 IN DT NN NN IN O
synthesis synthesis 0 0 0 0 0 0 0 0 9 0 DT NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
CCND1, CCND1, 1 1 0 0 1 0 0 1 6 0 NN IN NNP NNP CC O
D3 D3 1 1 0 0 0 0 0 1 2 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP CC O
G1 G1 1 1 0 0 0 0 0 1 2 0 NNP CC NNP CC IN O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NNP CC IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC IN DT NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN NN O
cells.Oncogene cells.Oncogene 0 0 0 0 0 0 0 0 14 0 JJ NN NN NN NN O
advance advance 0 0 0 0 0 0 0 0 7 0 NN NN NN NN NN O
online online 0 0 0 0 0 0 0 0 6 0 NN NN NN NN CD O
publication, publication, 0 0 0 0 1 0 0 0 12 0 NN NN NN CD NNP O
1 1 0 0 0 0 0 0 1 1 1 0 NN NN CD NNP CD O
July July 1 0 0 0 0 0 0 0 4 0 NN CD NNP CD NNP O
2013; 2013; 0 0 0 0 0 0 0 1 5 0 CD NNP CD NNP NONE O
doi:10.1038/onc.2013.252. doi:10.1038/onc.2013.252. 0 0 0 1 0 0 0 1 25 0 NNP CD NNP NONE NONE O
Cyclin Cyclin 1 0 0 0 0 0 0 0 6 0 NONE NONE NNP NNP NNPS O
G1 G1 1 1 0 0 0 0 0 1 2 0 NONE NNP NNP NNPS NNP O
Expands Expands 1 0 0 0 0 0 0 0 7 0 NNP NNP NNPS NNP NNP O
Liver Liver 1 0 0 0 0 0 0 0 5 0 NNP NNPS NNP NNP NNP O
Tumor-Initiating Tumor-Initiating 1 0 1 0 0 0 0 0 16 0 NNPS NNP NNP NNP IN O
Cells Cells 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Sox2 Sox2 1 0 0 0 0 0 0 1 4 0 NNP IN NNP NNP IN O
Induction Induction 1 0 0 0 0 0 0 0 9 0 IN NNP NNP IN NNP O
via via 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNP O
Akt/mTOR Akt/mTOR 1 0 0 1 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Signaling. Signaling. 1 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP NNP O
Wen Wen 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
W, W, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Han Han 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Huang Huang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sun Sun 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
W, W, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
SZ, SZ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Xiang Xiang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
DM, DM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Tang Tang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Cao Cao 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Feng Feng 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
GS, GS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wu Wu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
MC, MC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Ding Ding 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
HY. HY. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP JJ O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP JJ NNP O
1International 1International 0 0 0 0 0 0 0 1 14 0 NNP NNP JJ NNP NNP O
Cooperation Cooperation 1 0 0 0 0 0 0 0 11 0 NNP JJ NNP NNP NNP O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 JJ NNP NNP NNP NNP O
on, on, 0 0 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Eastern Eastern 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Hepatobiliary Hepatobiliary 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
Surgery Surgery 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Institute. Institute. 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP CC O
Recurrence Recurrence 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NN IN O
chemo-resistance chemo-resistance 0 0 1 0 0 0 0 0 16 0 NNP CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NN O
liver liver 0 0 0 0 0 0 0 0 5 0 NN IN NN NN VBZ O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN NN NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NN NN VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN VBN TO O
attributed attributed 0 0 0 0 0 0 0 0 10 0 VBZ VBN VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN TO DT NN IN O
existence existence 0 0 0 0 0 0 0 0 9 0 TO DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN JJ O
liver liver 0 0 0 0 0 0 0 0 5 0 NN IN NN JJ NNS O
tumor-initiating tumor-initiating 0 0 1 0 0 0 0 0 16 0 IN NN JJ NNS NNP O
cells cells 0 0 0 0 0 0 0 0 5 0 NN JJ NNS NNP NNP O
(T-ICs). (T-ICs). 0 0 1 0 0 0 0 0 8 0 JJ NNS NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 NNS NNP NNP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ JJ TO O
important important 0 0 0 0 0 0 0 0 9 0 NNP VBZ JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO DT DT O
decipher decipher 0 0 0 0 0 0 0 0 8 0 JJ TO DT DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO DT DT JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 DT DT JJ NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN IN O
acquisition acquisition 0 0 0 0 0 0 0 0 11 0 NN IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ CC O
drug-resistance drug-resistance 0 0 1 0 0 0 0 0 15 0 NN IN JJ CC TO O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ CC TO VB JJ O
design design 0 0 0 0 0 0 0 0 6 0 CC TO VB JJ JJ O
combinatorial combinatorial 0 0 0 0 0 0 0 0 13 0 TO VB JJ JJ NNP O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 VB JJ JJ NNP NNP O
strategies. strategies. 0 0 0 0 0 0 0 0 11 0 JJ JJ NNP NNP NNP O
Cyclin Cyclin 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP NNP VBZ O
G1 G1 1 1 0 0 0 0 0 1 2 0 NNP NNP NNP VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP NNP VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBN VBN TO O
shown shown 0 0 0 0 0 0 0 0 5 0 VBZ VBN VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO VB DT O
play play 0 0 0 0 0 0 0 0 4 0 VBN TO VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT JJ NN O
pivotal pivotal 0 0 0 0 0 0 0 0 7 0 VB DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN CC O
initiation initiation 0 0 0 0 0 0 0 0 10 0 NN IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN IN O
metastasis metastasis 0 0 0 0 0 0 0 0 10 0 NN CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NNP O
HCC. HCC. 1 1 0 0 0 0 0 0 4 0 NN IN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 IN NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 NNP DT NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBD IN O
found found 0 0 0 0 0 0 0 0 5 0 NN PRP VBD IN VBN O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBD IN VBN NN O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 VBD IN VBN NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 IN VBN NN NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 0 VBN NN NNP NN VBD O
expression expression 0 0 0 0 0 0 0 0 10 0 NN NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NN VBD VBN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NN NN O
drug drug 0 0 0 0 0 0 0 0 4 0 VBN IN NN NN IN O
resistance resistance 0 0 0 0 0 0 0 0 10 0 IN NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NNS O
hepatoma hepatoma 0 0 0 0 0 0 0 0 8 0 NN IN NN NNS CC O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NN NNS CC JJR O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC JJR NN O
higher higher 0 0 0 0 0 0 0 0 6 0 NNS CC JJR NN NN O
recurrence recurrence 0 0 0 0 0 0 0 0 10 0 CC JJR NN NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 JJR NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
HCC HCC 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNP NNP O
patients. patients. 0 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP IN O
Expression Expression 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NNP IN NN NNP VBD O
G1 G1 1 1 0 0 0 0 0 1 2 0 IN NN NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NNP VBD VBN IN O
elevated elevated 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN NNS O
liver liver 0 0 0 0 0 0 0 0 5 0 VBN IN NN NNS CC O
T-ICs T-ICs 1 0 1 0 0 0 0 0 5 0 IN NN NNS CC RB O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC RB VBN O
closely closely 0 0 0 0 0 0 0 0 7 0 NNS CC RB VBN IN O
correlated correlated 0 0 0 0 0 0 0 0 10 0 CC RB VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN JJ O
liver liver 0 0 0 0 0 0 0 0 5 0 NN IN NN JJ NNP O
T-IC T-IC 1 1 1 0 0 0 0 0 4 0 IN NN JJ NNP NNP O
markers. markers. 0 0 0 0 0 0 0 0 8 0 NN JJ NNP NNP NN O
Forced Forced 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 0 NNP NN NNP NN RB O
expression expression 0 0 0 0 0 0 0 0 10 0 NN NNP NN RB VBN O
remarkably remarkably 0 0 0 0 0 0 0 0 10 0 NNP NN RB VBN JJ O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 NN RB VBN JJ CC O
self-renewal self-renewal 0 0 1 0 0 0 0 0 12 0 RB VBN JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VBN JJ CC NN IN O
tumorigenicity tumorigenicity 0 0 0 0 0 0 0 0 14 0 JJ CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NNP O
hepatoma hepatoma 0 0 0 0 0 0 0 0 8 0 NN IN NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NN NNP NNP NNP O
Cyclin Cyclin 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 0 NNP NNP NNP NN RB O
overexpression overexpression 0 0 0 0 0 0 0 0 14 0 NNP NNP NN RB JJ O
dramatically dramatically 0 0 0 0 0 0 0 0 12 0 NNP NN RB JJ DT O
up-regulated up-regulated 0 0 1 0 0 0 0 0 12 0 NN RB JJ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB JJ DT NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 JJ DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP DT O
Sox2 Sox2 1 0 0 0 0 0 0 1 4 0 NN IN NNP DT IN O
both both 0 0 0 0 0 0 0 0 4 0 IN NNP DT IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP DT IN NN CC O
vitro vitro 0 0 0 0 0 0 0 0 5 0 DT IN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN CC IN NNP WDT O
vivo, vivo, 0 0 0 0 1 0 0 0 5 0 CC IN NNP WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 IN NNP WDT VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP WDT VBD VBN IN O
impaired impaired 0 0 0 0 0 0 0 0 8 0 WDT VBD VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NNS O
chemical chemical 0 0 0 0 0 0 0 0 8 0 VBN IN JJ NNS IN O
inhibitors inhibitors 0 0 0 0 0 0 0 0 10 0 IN JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NNP O
Akt/mTOR Akt/mTOR 1 0 0 1 0 0 0 0 8 0 NNS IN NN NNP NNP O
signaling. signaling. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP NN O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 NN NNP NNP NN IN O
blockade blockade 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN VBG O
Akt/mTOR Akt/mTOR 1 0 0 1 0 0 0 0 8 0 NN IN NN VBG CC O
signaling signaling 0 0 0 0 0 0 0 0 9 0 IN NN VBG CC NN O
or or 0 0 0 0 0 0 0 0 2 0 NN VBG CC NN IN O
interference interference 0 0 0 0 0 0 0 0 12 0 VBG CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NN O
Sox2 Sox2 1 0 0 0 0 0 0 1 4 0 NN IN NNP NN VBD O
expression expression 0 0 0 0 0 0 0 0 10 0 IN NNP NN VBD NN O
suppressed suppressed 0 0 0 0 0 0 0 0 10 0 NNP NN VBD NN JJ O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN VBD NN JJ NN O
G1-enhanced G1-enhanced 1 0 1 0 0 0 0 1 11 0 VBD NN JJ NN NN O
self-renewal, self-renewal, 0 0 1 0 1 0 0 0 13 0 NN JJ NN NN CC O
chemo-resistance chemo-resistance 0 0 1 0 0 0 0 0 16 0 JJ NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
tumurigenicity tumurigenicity 0 0 0 0 0 0 0 0 14 0 NN CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NN O
hepatoma hepatoma 0 0 0 0 0 0 0 0 8 0 NN IN NN NN VBG O
cells, cells, 0 0 0 0 1 0 0 0 6 0 IN NN NN VBG IN O
indicating indicating 0 0 0 0 0 0 0 0 10 0 NN NN VBG IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NN VBG IN NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 VBG IN NN NNP VBZ O
G1 G1 1 1 0 0 0 0 0 1 2 0 IN NN NNP VBZ NN O
expands expands 0 0 0 0 0 0 0 0 7 0 NN NNP VBZ NN NNS O
liver liver 0 0 0 0 0 0 0 0 5 0 NNP VBZ NN NNS IN O
T-ICs T-ICs 1 0 1 0 0 0 0 0 5 0 VBZ NN NNS IN NNP O
through through 0 0 0 0 0 0 0 0 7 0 NN NNS IN NNP NN O
sox2 sox2 0 0 0 0 0 0 0 1 4 0 NNS IN NNP NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 IN NNP NN IN NN O
via via 0 0 0 0 0 0 0 0 3 0 NNP NN IN NN VBG O
Akt/mTOR Akt/mTOR 1 0 0 1 0 0 0 0 8 0 NN IN NN VBG NNP O
signaling signaling 0 0 0 0 0 0 0 0 9 0 IN NN VBG NNP NNP O
pathway. pathway. 0 0 0 0 0 0 0 0 8 0 NN VBG NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 VBG NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNP NNS VBP IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NNP JJ O
Cyclin Cyclin 1 0 0 0 0 0 0 0 6 0 VBP IN NNP JJ NN O
G1-induced G1-induced 1 0 1 0 0 0 0 1 10 0 IN NNP JJ NN JJ O
liver liver 0 0 0 0 0 0 0 0 5 0 NNP JJ NN JJ NN O
T-IC T-IC 1 1 1 0 0 0 0 0 4 0 JJ NN JJ NN NNS O
expansion expansion 0 0 0 0 0 0 0 0 9 0 NN JJ NN NNS TO O
contributes contributes 0 0 0 0 0 0 0 0 11 0 JJ NN NNS TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS TO DT NN CC O
recurrence recurrence 0 0 0 0 0 0 0 0 10 0 TO DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
chemo-resistance chemo-resistance 0 0 1 0 0 0 0 0 16 0 NN CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP CC O
hepatoma, hepatoma, 0 0 0 0 1 0 0 0 9 0 NN IN NNP CC VB O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC VB NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NNP CC VB NNP MD O
G1 G1 1 1 0 0 0 0 0 1 2 0 CC VB NNP MD VB O
may may 0 0 0 0 0 0 0 0 3 0 VB NNP MD VB DT O
be be 0 0 0 0 0 0 0 0 2 0 NNP MD VB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT NN NN O
promising promising 0 0 0 0 0 0 0 0 9 0 VB DT NN NN IN O
biomarker biomarker 0 0 0 0 0 0 0 0 9 0 DT NN NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN JJ NN O
individualized individualized 0 0 0 0 0 0 0 0 14 0 NN IN JJ NN IN O
therapy therapy 0 0 0 0 0 0 0 0 7 0 IN JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
HCC HCC 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNP NONE O
patients.` patients.` 0 0 0 0 0 0 0 0 10 0 IN NNP NNP NONE NONE O
A A 1 1 0 0 0 0 0 0 1 0 NONE NONE DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 NONE DT NN NN VBD O
flavonoid flavonoid 0 0 0 0 0 0 0 0 9 0 DT NN NN VBD IN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NN VBD IN NNP NNS O
Sophora Sophora 1 0 0 0 0 0 0 0 7 0 VBD IN NNP NNS VBD O
flavescens flavescens 0 0 0 0 0 0 0 0 10 0 IN NNP NNS VBD NN O
exhibited exhibited 0 0 0 0 0 0 0 0 9 0 NNP NNS VBD NN NN O
anti-angiogenesis anti-angiogenesis 0 0 1 0 0 0 0 0 17 0 NNS VBD NN NN VBD O
activity, activity, 0 0 0 0 1 0 0 0 9 0 VBD NN NN VBD NNP O
decreased decreased 0 0 0 0 0 0 0 0 9 0 NN NN VBD NNP NN O
VEGF VEGF 1 1 0 0 0 0 0 0 4 0 NN VBD NNP NN CC O
expression expression 0 0 0 0 0 0 0 0 10 0 VBD NNP NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC VBD -NONE- O
caused caused 0 0 0 0 0 0 0 0 6 0 NN CC VBD -NONE- NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 CC VBD -NONE- NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBD -NONE- NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest -NONE- NN NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
vitro. vitro. 0 0 0 0 0 0 0 0 6 0 NN IN NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
XL, XL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Cao Cao 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
MA, MA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Pu Pu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
LP, LP, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Huang Huang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
SS, SS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Gao Gao 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
QX, QX, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Yuan Yuan 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
CS, CS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
CM. CM. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Life Life 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Lanzhou Lanzhou 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Lanzhou, Lanzhou, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP DT O
Kushen, Kushen, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NN O
dried dried 0 0 0 0 0 0 0 0 5 0 NNP DT JJ NN IN O
root root 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNS O
Sophora Sophora 1 0 0 0 0 0 0 0 7 0 NN IN NNP NNS -NONE- O
flavescens flavescens 0 0 0 0 0 0 0 0 10 0 IN NNP NNS -NONE- VBZ O
Ait, Ait, 1 0 0 0 1 0 0 0 4 0 NNP NNS -NONE- VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNS -NONE- VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- VBZ DT JJ JJ O
traditional traditional 0 0 0 0 0 0 0 0 11 0 VBZ DT JJ JJ JJ O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 DT JJ JJ JJ NNP O
herbal herbal 0 0 0 0 0 0 0 0 6 0 JJ JJ JJ NNP NNP O
medicine. medicine. 0 0 0 0 0 0 0 0 9 0 JJ JJ NNP NNP NNS O
Kushen Kushen 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP NNS VBP O
alkaloids alkaloids 0 0 0 0 0 0 0 0 9 0 NNP NNP NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNS VBP VBN VBN IN O
developed developed 0 0 0 0 0 0 0 0 9 0 VBP VBN VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN NNP IN O
China China 1 0 0 0 0 0 0 0 5 0 VBN IN NNP IN NN O
as as 0 0 0 0 0 0 0 0 2 0 IN NNP IN NN NN O
anticancer anticancer 0 0 0 0 0 0 0 0 10 0 NNP IN NN NN CC O
drugs, drugs, 0 0 0 0 1 0 0 0 6 0 IN NN NN CC JJR O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJR NN O
more more 0 0 0 0 0 0 0 0 4 0 NN CC JJR NN NN O
potent potent 0 0 0 0 0 0 0 0 6 0 CC JJR NN NN NNS O
antitumor antitumor 0 0 0 0 0 0 0 0 9 0 JJR NN NN NNS VBP O
activities activities 0 0 0 0 0 0 0 0 10 0 NN NN NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NN NNS VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNS VBP VBN VBN IN O
identified identified 0 0 0 0 0 0 0 0 10 0 VBP VBN VBN IN WRB O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN WRB NNS O
kushen kushen 0 0 0 0 0 0 0 0 6 0 VBN IN WRB NNS IN O
flavonoids flavonoids 0 0 0 0 0 0 0 0 10 0 IN WRB NNS IN IN O
than than 0 0 0 0 0 0 0 0 4 0 WRB NNS IN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNS IN IN NN NNP O
kushen kushen 0 0 0 0 0 0 0 0 6 0 IN IN NN NNP NNP O
alkaloids. alkaloids. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN DT O
study, study, 0 0 0 0 1 0 0 0 6 0 NNP DT NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 DT NN DT JJ NNS O
anti-angiogenic anti-angiogenic 0 0 1 0 0 0 0 0 15 0 NN DT JJ NNS IN O
properties properties 0 0 0 0 0 0 0 0 10 0 DT JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
(2S)-7,2',4'-triihydroxy-5-methoxy-8-dimethylallyl (2S)-7,2',4'-triihydroxy-5-methoxy-8-dimethylallyl 0 0 1 0 1 1 0 1 50 0 NNS IN JJ NN NN O
flavanone flavanone 0 0 0 0 0 0 0 0 9 0 IN JJ NN NN CD O
(Compound (Compound 0 0 0 0 0 0 0 0 9 0 JJ NN NN CD DT O
1, 1, 0 0 0 0 1 0 0 1 2 0 NN NN CD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN CD DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 CD DT NN NN VBD O
flavonoid flavonoid 0 0 0 0 0 0 0 0 9 0 DT NN NN VBD IN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NN VBD IN NNP VBD O
Kushen), Kushen), 1 0 0 0 1 0 0 0 8 0 VBD IN NNP VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 IN NNP VBD VBN VBG O
examined examined 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 VBD VBN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN VBG DT NN JJ O
human human 0 0 0 0 0 0 0 0 5 0 VBG DT NN JJ NN O
umbilical umbilical 0 0 0 0 0 0 0 0 9 0 DT NN JJ NN JJ O
vein vein 0 0 0 0 0 0 0 0 4 0 NN JJ NN JJ NN O
endothelial endothelial 0 0 0 0 0 0 0 0 11 0 JJ NN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN JJ NN NN NN O
line line 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN IN O
(ECV304) (ECV304) 0 1 0 0 0 0 0 1 8 0 NN NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
vitro. vitro. 0 0 0 0 0 0 0 0 6 0 NN IN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNS VBD O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD IN O
indicated indicated 0 0 0 0 0 0 0 0 9 0 NNP NNS VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NN CD O
compound compound 0 0 0 0 0 0 0 0 8 0 VBD IN NN CD NNS O
1 1 0 0 0 0 0 0 1 1 1 0 IN NN CD NNS -NONE- O
shows shows 0 0 0 0 0 0 0 0 5 0 NN CD NNS -NONE- NN O
anti-angiogenesis anti-angiogenesis 0 0 1 0 0 0 0 0 17 0 CD NNS -NONE- NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NNS -NONE- NN IN NN O
via via 0 0 0 0 0 0 0 0 3 0 -NONE- NN IN NN NNS O
inhibitory inhibitory 0 0 0 0 0 0 0 0 10 0 NN IN NN NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 IN NN NNS IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN NN O
proliferation, proliferation, 0 0 0 0 1 0 0 0 14 0 IN NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN NN O
migration, migration, 0 0 0 0 1 0 0 0 10 0 NN NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN CC O
adhesion, adhesion, 0 0 0 0 1 0 0 0 9 0 NN NN NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VB NNP O
tube tube 0 0 0 0 0 0 0 0 4 0 NN CC VB NNP NNP O
formation. formation. 0 0 0 0 0 0 0 0 10 0 CC VB NNP NNP NNS O
Further Further 1 0 0 0 0 0 0 0 7 0 VB NNP NNP NNS VBD O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD IN O
indicated indicated 0 0 0 0 0 0 0 0 9 0 NNP NNS VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NN CD O
compound compound 0 0 0 0 0 0 0 0 8 0 VBD IN NN CD NNS O
1 1 0 0 0 0 0 0 1 1 1 0 IN NN CD NNS VBP O
blocks blocks 0 0 0 0 0 0 0 0 6 0 NN CD NNS VBP NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 CD NNS VBP NNS IN O
cycles cycles 0 0 0 0 0 0 0 0 6 0 NNS VBP NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBP NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase IN DT NN NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NN NN IN NN O
without without 0 0 0 0 0 0 0 0 7 0 NN NN IN NN -NONE- O
inducing inducing 0 0 0 0 0 0 0 0 8 0 NN IN NN -NONE- CC O
apoptosis, apoptosis, 0 0 0 0 1 0 0 0 10 0 IN NN -NONE- CC RB O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC RB VBZ O
down down 0 0 0 0 0 0 0 0 4 0 -NONE- CC RB VBZ JJ O
regulates regulates 0 0 0 0 0 0 0 0 9 0 CC RB VBZ JJ JJ O
vascular vascular 0 0 0 0 0 0 0 0 8 0 RB VBZ JJ JJ NN O
endothelial endothelial 0 0 0 0 0 0 0 0 11 0 VBZ JJ JJ NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NN NN O
factor factor 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN NNP O
(VEGF) (VEGF) 0 1 0 0 0 0 0 0 6 0 NN NN NN NNP NNP O
expression. expression. 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP JJ JJ O
free free 0 0 0 0 0 0 0 0 4 0 NNP NNP JJ JJ NN O
radical radical 0 0 0 0 0 0 0 0 7 0 NNP JJ JJ NN NN O
scavenging scavenging 0 0 0 0 0 0 0 0 10 0 JJ JJ NN NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 JJ NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN CD O
compound compound 0 0 0 0 0 0 0 0 8 0 NN IN NN CD VBD O
1 1 0 0 0 0 0 0 1 1 1 0 IN NN CD VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN CD VBD VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 CD VBD VBN IN CD O
through through 0 0 0 0 0 0 0 0 7 0 VBD VBN IN CD NN O
2',7'-dichlorofluorescin 2',7'-dichlorofluorescin 0 0 1 0 1 1 0 1 24 0 VBN IN CD NN -NONE- O
diacetate diacetate 0 0 0 0 0 0 0 0 9 0 IN CD NN -NONE- NN O
(DCFH-DA) (DCFH-DA) 0 1 1 0 0 0 0 0 9 0 CD NN -NONE- NN NN O
incubation incubation 0 0 0 0 0 0 0 0 10 0 NN -NONE- NN NN IN O
assay assay 0 0 0 0 0 0 0 0 5 0 -NONE- NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN IN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP VBZ O
anti-angiogenic anti-angiogenic 0 0 1 0 0 0 0 0 15 0 NNP NNP NNP VBZ IN O
properties properties 0 0 0 0 0 0 0 0 10 0 NNP NNP VBZ IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN NN CD O
compound compound 0 0 0 0 0 0 0 0 8 0 VBZ IN NN CD CC O
1 1 0 0 0 0 0 0 1 1 1 0 IN NN CD CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 NN CD CC PRP$ JJ O
its its 0 0 0 0 0 0 0 0 3 0 CD CC PRP$ JJ NN O
antiproliferative antiproliferative 0 0 0 0 0 0 0 0 17 0 CC PRP$ JJ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 PRP$ JJ NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNS O
endothelial endothelial 0 0 0 0 0 0 0 0 11 0 NN IN JJ NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN VBG O
without without 0 0 0 0 0 0 0 0 7 0 JJ NNS IN VBG NN O
causing causing 0 0 0 0 0 0 0 0 7 0 NNS IN VBG NN NN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 IN VBG NN NN PRP O
make make 0 0 0 0 0 0 0 0 4 0 VBG NN NN PRP DT O
it it 0 0 0 0 0 0 0 0 2 0 NN NN PRP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN PRP DT JJ NN O
good good 0 0 0 0 0 0 0 0 4 0 PRP DT JJ NN IN O
candidate candidate 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN IN O
development development 0 0 0 0 0 0 0 0 11 0 NN IN NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN IN O
agent agent 0 0 0 0 0 0 0 0 5 0 IN DT NN IN NN O
against against 0 0 0 0 0 0 0 0 7 0 DT NN IN NN IN O
development development 0 0 0 0 0 0 0 0 11 0 NN IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NONE O
tumors. tumors. 0 0 0 0 0 0 0 0 7 0 NN IN NNP NONE NONE O
Biochemical Biochemical 1 0 0 0 0 0 0 0 11 0 NONE NONE JJ JJ NN O
DSB-repair DSB-repair 1 0 1 0 0 0 0 0 10 0 NONE JJ JJ NN IN O
model model 0 0 0 0 0 0 0 0 5 0 JJ JJ NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN JJ NNS O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP CC O
G1 G1 1 1 0 0 0 0 0 1 2 0 NNS IN NNP CC RB O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC RB NNP O
early early 0 0 0 0 0 0 0 0 5 0 NNP CC RB NNP NNS O
S S 1 1 0 0 0 0 0 0 1 phases CC RB NNP NNS IN O
phases phases 0 0 0 0 0 0 0 0 6 0 RB NNP NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NNP NNP O
cycle. cycle. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP NNP O
Taleei Taleei 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Nikjoo Nikjoo 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
H. H. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Radiation Radiation 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Biophysics Biophysics 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Group, Group, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Oncology-Pathology, Oncology-Pathology, 1 0 1 0 1 0 0 0 19 0 NNP IN NNP NNP NNP O
Karolinska Karolinska 1 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP NNP O
Institute, Institute, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Stockholm Stockholm 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP CD O
SE171 SE171 1 1 0 0 0 0 0 1 5 0 NNP NNP NNP CD NNP O
76, 76, 0 0 0 0 1 0 0 1 3 0 NNP NNP CD NNP NNP O
Sweden. Sweden. 1 0 0 0 0 0 0 0 7 0 NNP CD NNP NNP NNP O
Electronic Electronic 1 0 0 0 0 0 0 0 10 0 CD NNP NNP NNP NNP O
address: address: 0 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
reza.taleei@ki.se. reza.taleei@ki.se. 0 0 0 0 0 0 0 0 18 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN NNS O
paper paper 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NNS DT O
presents presents 0 0 0 0 0 0 0 0 8 0 NNP NN NNS DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN NNS DT NN IN O
model model 0 0 0 0 0 0 0 0 5 0 NNS DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
double double 0 0 0 0 0 0 0 0 6 0 NN IN JJ NN NNS O
strand strand 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNS -NONE- O
breaks breaks 0 0 0 0 0 0 0 0 6 0 JJ NN NNS -NONE- NN O
(DSB) (DSB) 0 1 0 0 0 0 0 0 5 0 NN NNS -NONE- NN IN O
repair repair 0 0 0 0 0 0 0 0 6 0 NNS -NONE- NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- NN IN NNP CC O
G1 G1 1 1 0 0 0 0 0 1 2 0 NN IN NNP CC RB B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC RB NNP O
early early 0 0 0 0 0 0 0 0 5 0 NNP CC RB NNP NNS S
S S 1 1 0 0 0 0 0 0 1 phases CC RB NNP NNS IN S
phases phases 0 0 0 0 0 0 0 0 6 0 RB NNP NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NNP NNP O
cycle. cycle. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN VBZ O
model model 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ VBN IN O
based based 0 0 0 0 0 0 0 0 5 0 NN VBZ VBN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NN IN O
plethora plethora 0 0 0 0 0 0 0 0 8 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
published published 0 0 0 0 0 0 0 0 9 0 NN IN JJ NN IN O
information information 0 0 0 0 0 0 0 0 11 0 IN JJ NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
biochemical biochemical 0 0 0 0 0 0 0 0 11 0 NN IN JJ NN IN O
modification modification 0 0 0 0 0 0 0 0 12 0 IN JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP VBD O
DSB DSB 1 1 0 0 0 0 0 0 3 0 NN IN NNP VBD IN O
induced induced 0 0 0 0 0 0 0 0 7 0 IN NNP VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNP VBD IN NN NNP O
ionizing ionizing 0 0 0 0 0 0 0 0 8 0 VBD IN NN NNP NNP O
radiation. radiation. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP NNP O
So So 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NNP CD O
far, far, 0 0 0 0 1 0 0 0 4 0 NNP NNP NNP CD JJ O
three three 0 0 0 0 0 0 0 0 5 0 NNP NNP CD JJ NNP O
main main 0 0 0 0 0 0 0 0 4 0 NNP CD JJ NNP NN O
DSB DSB 1 1 0 0 0 0 0 0 3 0 CD JJ NNP NN VBZ O
repair repair 0 0 0 0 0 0 0 0 6 0 JJ NNP NN VBZ VB O
pathways pathways 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ VB VBN O
have have 0 0 0 0 0 0 0 0 4 0 NN VBZ VB VBN -NONE- O
been been 0 0 0 0 0 0 0 0 4 0 VBZ VB VBN -NONE- VBG O
identified, identified, 0 0 0 0 1 0 0 0 11 0 VB VBN -NONE- VBG JJ O
including including 0 0 0 0 0 0 0 0 9 0 VBN -NONE- VBG JJ JJ O
nonhomologous nonhomologous 0 0 0 0 0 0 0 0 13 0 -NONE- VBG JJ JJ NN O
end-joining end-joining 0 0 1 0 0 0 0 0 11 0 VBG JJ JJ NN JJ O
(NHEJ), (NHEJ), 0 1 0 0 1 0 0 0 7 0 JJ JJ NN JJ NN O
homologous homologous 0 0 0 0 0 0 0 0 10 0 JJ NN JJ NN NN O
recombination recombination 0 0 0 0 0 0 0 0 13 0 NN JJ NN NN CC O
(HR), (HR), 0 1 0 0 1 0 0 0 5 0 JJ NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ JJ O
microhomology-mediated microhomology-mediated 0 0 1 0 0 0 0 0 22 0 NN CC JJ JJ NNP O
end-joining end-joining 0 0 1 0 0 0 0 0 11 0 CC JJ JJ NNP NNP O
(MMEJ). (MMEJ). 0 1 0 0 0 0 0 0 7 0 JJ JJ NNP NNP NNP O
During During 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP NNP CC O
G1 G1 1 1 0 0 0 0 0 1 2 0 NNP NNP NNP CC RB B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC RB NNP O
early early 0 0 0 0 0 0 0 0 5 0 NNP CC RB NNP NNS S
S S 1 1 0 0 0 0 0 0 1 phases CC RB NNP NNS IN S
phases phases 0 0 0 0 0 0 0 0 6 0 RB NNP NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN NNP O
cycle, cycle, 0 0 0 0 1 0 0 0 6 0 DT NN NN NNP CC O
NHEJ NHEJ 1 1 0 0 0 0 0 0 4 0 NN NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP NN O
MMEJ MMEJ 1 1 0 0 0 0 0 0 4 0 NNP CC NNP NN VBZ O
repair repair 0 0 0 0 0 0 0 0 6 0 CC NNP NN VBZ VBP O
pathways pathways 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NN VBZ VBP VBN NN O
activated activated 0 0 0 0 0 0 0 0 9 0 VBZ VBP VBN NN IN O
dependent dependent 0 0 0 0 0 0 0 0 9 0 VBP VBN NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 VBN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
type type 0 0 0 0 0 0 0 0 4 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
double double 0 0 0 0 0 0 0 0 6 0 NN IN JJ NN NNP O
strand strand 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNP NNP O
breaks. breaks. 0 0 0 0 0 0 0 0 7 0 JJ NN NNP NNP NNP O
Simple Simple 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP VBP O
DSB DSB 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP VBP DT O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNP VBP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBP DT JJ IN O
substrate substrate 0 0 0 0 0 0 0 0 9 0 VBP DT JJ IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 DT JJ IN JJ IN O
NHEJ, NHEJ, 1 1 0 0 1 0 0 0 5 0 JJ IN JJ IN JJ O
while while 0 0 0 0 0 0 0 0 5 0 IN JJ IN JJ NNP O
complex complex 0 0 0 0 0 0 0 0 7 0 JJ IN JJ NNP CC O
DSB DSB 1 1 0 0 0 0 0 0 3 0 IN JJ NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNP CC NNP IN O
DSB DSB 1 1 0 0 0 0 0 0 3 0 NNP CC NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CC NNP IN NN NN O
heterochromatin heterochromatin 0 0 0 0 0 0 0 0 15 0 NNP IN NN NN RB O
require require 0 0 0 0 0 0 0 0 7 0 IN NN NN RB NN O
further further 0 0 0 0 0 0 0 0 7 0 NN NN RB NN NNP O
end end 0 0 0 0 0 0 0 0 3 0 NN RB NN NNP NNP O
processing. processing. 0 0 0 0 0 0 0 0 11 0 RB NN NNP NNP IN O
Repair Repair 1 0 0 0 0 0 0 0 6 0 NN NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NNP O
all all 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP NN O
DSB DSB 1 1 0 0 0 0 0 0 3 0 IN DT NNP NN IN O
start start 0 0 0 0 0 0 0 0 5 0 DT NNP NN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNP NN IN NNP JJ O
NHEJ NHEJ 1 1 0 0 0 0 0 0 4 0 NN IN NNP JJ NN O
presynaptic presynaptic 0 0 0 0 0 0 0 0 11 0 IN NNP JJ NN CC O
processes, processes, 0 0 0 0 1 0 0 0 10 0 NNP JJ NN CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBG IN O
depending depending 0 0 0 0 0 0 0 0 9 0 NN CC VBG IN DT O
on on 0 0 0 0 0 0 0 0 2 0 CC VBG IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBG IN DT NN IN O
type type 0 0 0 0 0 0 0 0 4 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NN O
DSB DSB 1 1 0 0 0 0 0 0 3 0 NN IN NNP NN NN O
pursue pursue 0 0 0 0 0 0 0 0 6 0 IN NNP NN NN NN O
simple simple 0 0 0 0 0 0 0 0 6 0 NNP NN NN NN RB O
ligation, ligation, 0 0 0 0 1 0 0 0 9 0 NN NN NN RB NN O
further further 0 0 0 0 0 0 0 0 7 0 NN NN RB NN NN O
end end 0 0 0 0 0 0 0 0 3 0 NN RB NN NN RB O
processing processing 0 0 0 0 0 0 0 0 10 0 RB NN NN RB TO O
prior prior 0 0 0 0 0 0 0 0 5 0 NN NN RB TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NN RB TO NNP CC O
ligation, ligation, 0 0 0 0 1 0 0 0 9 0 RB TO NNP CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 TO NNP CC NNP NNP O
resection. resection. 0 0 0 0 0 0 0 0 10 0 NNP CC NNP NNP NN O
Using Using 1 0 0 0 0 0 0 0 5 0 CC NNP NNP NN IN O
law law 0 0 0 0 0 0 0 0 3 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NN O
mass mass 0 0 0 0 0 0 0 0 4 0 NN IN NN NN DT O
action action 0 0 0 0 0 0 0 0 6 0 IN NN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NN VBZ O
model model 0 0 0 0 0 0 0 0 5 0 NN DT NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ VBN IN O
translated translated 0 0 0 0 0 0 0 0 10 0 NN VBZ VBN IN DT O
into into 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NNP O
mathematical mathematical 0 0 0 0 0 0 0 0 12 0 IN DT JJ NNP NNP O
formalism. formalism. 0 0 0 0 0 0 0 0 10 0 DT JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
solution solution 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBZ O
formalism formalism 0 0 0 0 0 0 0 0 9 0 IN DT NN VBZ DT O
provides provides 0 0 0 0 0 0 0 0 8 0 DT NN VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT NN IN O
step step 0 0 0 0 0 0 0 0 4 0 VBZ DT NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 DT NN IN NN CC O
step step 0 0 0 0 0 0 0 0 4 0 NN IN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC JJ NN O
overall overall 0 0 0 0 0 0 0 0 7 0 NN CC JJ NN NNP O
repair repair 0 0 0 0 0 0 0 0 6 0 CC JJ NN NNP NNP O
kinetics. kinetics. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP JJ NN O
overall overall 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NN NNS O
repair repair 0 0 0 0 0 0 0 0 6 0 NNP JJ NN NNS VBP O
kinetics kinetics 0 0 0 0 0 0 0 0 8 0 JJ NN NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NN NNS VBP VBN IN O
compared compared 0 0 0 0 0 0 0 0 8 0 NNS VBP VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBP VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
published published 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN NNP O
experimental experimental 0 0 0 0 0 0 0 0 12 0 DT JJ NN NNP NNP O
measurements. measurements. 0 0 0 0 0 0 0 0 13 0 JJ NN NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS VBP O
calculations calculations 0 0 0 0 0 0 0 0 12 0 NNP NNP NNS VBP IN O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNS VBP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBP IN NN IN O
agreement agreement 0 0 0 0 0 0 0 0 9 0 VBP IN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNS O
experimental experimental 0 0 0 0 0 0 0 0 12 0 IN DT JJ NNS CC O
results results 0 0 0 0 0 0 0 0 7 0 DT JJ NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC NN IN O
show show 0 0 0 0 0 0 0 0 4 0 NNS CC NN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 CC NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNS O
complex complex 0 0 0 0 0 0 0 0 7 0 IN DT NN NNS IN O
types types 0 0 0 0 0 0 0 0 5 0 DT NN NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP VBP O
DSBs DSBs 1 0 0 0 0 0 0 0 4 0 NNS IN NNP VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 IN NNP VBP VBN IN O
repaired repaired 0 0 0 0 0 0 0 0 8 0 NNP VBP VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBP VBN IN JJ NN O
slow slow 0 0 0 0 0 0 0 0 4 0 VBN IN JJ NN NNP O
repair repair 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNP NNP O
kinetics. kinetics. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNP CC O
G1 G1 1 1 0 0 0 0 0 1 2 0 NNP NNP NNP CC RB B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC RB NNP O
early early 0 0 0 0 0 0 0 0 5 0 NNP CC RB NNP NN S
S S 1 1 0 0 0 0 0 0 1 phase CC RB NNP NN NN S
phase phase 0 0 0 0 0 0 0 0 5 0 RB NNP NN NN MD O
model model 0 0 0 0 0 0 0 0 5 0 NNP NN NN MD VB O
could could 0 0 0 0 0 0 0 0 5 0 NN NN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB VBN TO O
employed employed 0 0 0 0 0 0 0 0 8 0 MD VB VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VB VBN TO VB DT O
predict predict 0 0 0 0 0 0 0 0 7 0 VBN TO VB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NNS IN O
kinetics kinetics 0 0 0 0 0 0 0 0 8 0 VB DT NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NNP NN O
DSB DSB 1 1 0 0 0 0 0 0 3 0 NNS IN NNP NN IN O
repair repair 0 0 0 0 0 0 0 0 6 0 IN NNP NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NNP NN IN NN VBD O
damage damage 0 0 0 0 0 0 0 0 6 0 NN IN NN VBD IN O
induced induced 0 0 0 0 0 0 0 0 7 0 IN NN VBD IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN JJ NNP O
high high 0 0 0 0 0 0 0 0 4 0 VBD IN JJ NNP NNP O
LET LET 1 1 0 0 0 0 0 0 3 0 IN JJ NNP NNP NONE O
radiation. radiation. 0 0 0 0 0 0 0 0 10 0 JJ NNP NNP NONE NONE O
CTLA-4 CTLA-4 1 1 1 0 0 0 0 1 6 0 NONE NONE -NONE- VBP NN O
gene gene 0 0 0 0 0 0 0 0 4 0 NONE -NONE- VBP NN IN O
polymorphism polymorphism 0 0 0 0 0 0 0 0 12 0 -NONE- VBP NN IN NN O
at at 0 0 0 0 0 0 0 0 2 0 VBP NN IN NN -NONE- O
position position 0 0 0 0 0 0 0 0 8 0 NN IN NN -NONE- JJ O
+49 +49 0 0 0 0 0 0 0 1 3 0 IN NN -NONE- JJ IN O
A>G A>G 1 1 0 0 0 0 0 0 3 0 NN -NONE- JJ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- JJ IN NN CD O
exon exon 0 0 0 0 0 0 0 0 4 0 JJ IN NN CD DT O
1: 1: 0 0 0 0 0 0 0 1 2 0 IN NN CD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN CD DT NN NN O
risk risk 0 0 0 0 0 0 0 0 4 0 CD DT NN NN IN O
factor factor 0 0 0 0 0 0 0 0 6 0 DT NN NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN JJ NN O
cervical cervical 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN IN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
Indian Indian 1 0 0 0 0 0 0 0 6 0 NN IN NNP NNP NNP O
women. women. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
Gokhale Gokhale 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kerkar Kerkar 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tongaonkar Tongaonkar 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Salvi Salvi 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
V, V, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Mania-Pramanik Mania-Pramanik 1 0 1 0 0 0 0 0 14 0 NNP NNP NNP NNP NNP O
J. J. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Infectious Infectious 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Diseases Diseases 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
National National 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP IN O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP IN NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NNP O
Reproductive Reproductive 1 0 0 0 0 0 0 0 12 0 NNP IN NNP NNP NNP O
Health, Health, 1 0 0 0 1 0 0 0 7 0 IN NNP NNP NNP NNP O
Mumbai, Mumbai, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
India. India. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
Single Single 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NN NNS O
nucleotide nucleotide 0 0 0 0 0 0 0 0 10 0 NNP NNP NN NNS -NONE- O
polymorphisms polymorphisms 0 0 0 0 0 0 0 0 13 0 NNP NN NNS -NONE- IN O
(SNPs) (SNPs) 0 0 0 0 0 0 0 0 6 0 NN NNS -NONE- IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNS -NONE- IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- IN DT NN NN O
CTLA-4 CTLA-4 1 1 1 0 0 0 0 1 6 0 IN DT NN NN NN O
gene gene 0 0 0 0 0 0 0 0 4 0 DT NN NN NN NN O
exert exert 0 0 0 0 0 0 0 0 5 0 NN NN NN NN NNS O
differential differential 0 0 0 0 0 0 0 0 12 0 NN NN NN NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 NN NN NNS IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP NN O
T-cell T-cell 1 0 1 0 0 0 0 0 6 0 NNS IN NNP NN TO O
response response 0 0 0 0 0 0 0 0 8 0 IN NNP NN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO JJ NNP O
viral viral 0 0 0 0 0 0 0 0 5 0 NN TO JJ NNP NNP O
infection. infection. 0 0 0 0 0 0 0 0 10 0 TO JJ NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP VBD TO O
aimed aimed 0 0 0 0 0 0 0 0 5 0 NNP NNP VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBD TO VB DT O
evaluate evaluate 0 0 0 0 0 0 0 0 8 0 VBD TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
association association 0 0 0 0 0 0 0 0 11 0 VB DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 NN IN CD NNS IN O
SNPs SNPs 1 0 0 0 0 0 0 0 4 0 IN CD NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
CTLA-4 CTLA-4 1 1 1 0 0 0 0 1 6 0 IN DT JJ NN IN O
gene gene 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN JJ NN O
cervical cervical 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN IN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
Indian Indian 1 0 0 0 0 0 0 0 6 0 NN IN NNP NNP NNP O
women. women. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP CD O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP CD JJ O
two two 0 0 0 0 0 0 0 0 3 0 NNP NNP CD JJ NN O
polymorphic polymorphic 0 0 0 0 0 0 0 0 11 0 NNP CD JJ NN CD O
loci, loci, 0 0 0 0 1 0 0 0 5 0 CD JJ NN CD IN O
one one 0 0 0 0 0 0 0 0 3 0 JJ NN CD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN CD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT NN NN O
promoter promoter 0 0 0 0 0 0 0 0 8 0 IN DT NN NN -NONE- O
region region 0 0 0 0 0 0 0 0 6 0 DT NN NN -NONE- JJ O
-318 -318 0 0 1 0 0 0 0 1 4 0 NN NN -NONE- JJ NNP O
C>T, C>T, 1 1 0 0 1 0 0 0 4 0 NN -NONE- JJ NNP NNP O
rs5742909 rs5742909 0 0 0 0 0 0 0 1 9 0 -NONE- JJ NNP NNP JJ O
(100 (100 0 0 0 0 0 0 0 1 4 0 JJ NNP NNP JJ NN O
cervical cervical 0 0 0 0 0 0 0 0 8 0 NNP NNP JJ NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NNP JJ NN NNS CC O
cases cases 0 0 0 0 0 0 0 0 5 0 JJ NN NNS CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC CD NN O
101 101 0 0 0 0 0 0 1 1 3 0 NNS CC CD NN CC O
controls) controls) 0 0 0 0 0 0 0 0 9 0 CC CD NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 CD NN CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT JJ IN O
other other 0 0 0 0 0 0 0 0 5 0 CC DT JJ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 DT JJ IN NN CD O
exon exon 0 0 0 0 0 0 0 0 4 0 JJ IN NN CD -NONE- O
1 1 0 0 0 0 0 0 1 1 1 0 IN NN CD -NONE- JJ O
+49 +49 0 0 0 0 0 0 0 1 3 0 NN CD -NONE- JJ NNP O
A>G, A>G, 1 1 0 0 1 0 0 0 4 0 CD -NONE- JJ NNP NNP O
rs231775 rs231775 0 0 0 0 0 0 0 1 8 0 -NONE- JJ NNP NNP JJ O
(104 (104 0 0 0 0 0 0 0 1 4 0 JJ NNP NNP JJ NN O
cervical cervical 0 0 0 0 0 0 0 0 8 0 NNP NNP JJ NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NNP JJ NN NNS CC O
cases cases 0 0 0 0 0 0 0 0 5 0 JJ NN NNS CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC CD NN O
162 162 0 0 0 0 0 0 1 1 3 0 NNS CC CD NN VBD O
controls) controls) 0 0 0 0 0 0 0 0 9 0 CC CD NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 CD NN VBD VBN VBG O
genotyped genotyped 0 0 0 0 0 0 0 0 9 0 NN VBD VBN VBG NN O
using using 0 0 0 0 0 0 0 0 5 0 VBD VBN VBG NN NN O
polymerase polymerase 0 0 0 0 0 0 0 0 10 0 VBN VBG NN NN NN O
chain chain 0 0 0 0 0 0 0 0 5 0 VBG NN NN NN NN O
reaction-restriction reaction-restriction 0 0 1 0 0 0 0 0 20 0 NN NN NN NN NN O
fragment fragment 0 0 0 0 0 0 0 0 8 0 NN NN NN NN NN O
length length 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NNP O
polymorphism polymorphism 0 0 0 0 0 0 0 0 12 0 NN NN NN NNP NNP O
methods. methods. 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP NN O
Haplotype Haplotype 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NN NN O
block block 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NN VBD O
structure structure 0 0 0 0 0 0 0 0 9 0 NNP NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN VBG O
determined determined 0 0 0 0 0 0 0 0 10 0 NN VBD VBN VBG NNP O
using using 0 0 0 0 0 0 0 0 5 0 VBD VBN VBG NNP NNP O
Haploview Haploview 1 0 0 0 0 0 0 0 9 0 VBN VBG NNP NNP NNP O
4.2. 4.2. 0 0 0 0 0 0 0 1 4 0 VBG NNP NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP JJ NNS O
statistical statistical 0 0 0 0 0 0 0 0 11 0 NNP NNP JJ NNS VBD O
analyses analyses 0 0 0 0 0 0 0 0 8 0 NNP JJ NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD VBN VBG O
performed performed 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 VBD VBN VBG DT RB O
a a 0 0 0 0 0 0 0 0 1 0 VBN VBG DT RB JJ O
commercially commercially 0 0 0 0 0 0 0 0 12 0 VBG DT RB JJ JJ O
available available 0 0 0 0 0 0 0 0 9 0 DT RB JJ JJ NN O
statistical statistical 0 0 0 0 0 0 0 0 11 0 RB JJ JJ NN NN O
software software 0 0 0 0 0 0 0 0 8 0 JJ JJ NN NN NNS O
package, package, 0 0 0 0 1 0 0 0 8 0 JJ NN NN NNS NNP O
whereas whereas 0 0 0 0 0 0 0 0 7 0 NN NN NNS NNP VBD O
PyPop PyPop 1 0 0 0 0 0 0 0 5 0 NN NNS NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNS NNP VBD VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 NNP VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB DT O
calculate calculate 0 0 0 0 0 0 0 0 9 0 VBN TO VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJ NNP O
haplotypic haplotypic 0 0 0 0 0 0 0 0 10 0 VB DT JJ NNP NNP O
frequencies. frequencies. 0 0 0 0 0 0 0 0 12 0 DT JJ NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN NN O
case-control case-control 0 0 1 0 0 0 0 0 12 0 NNP DT NN NN DT O
study, study, 0 0 0 0 1 0 0 0 6 0 DT NN NN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NNP NN O
A/A A/A 1 1 0 1 0 0 0 0 3 0 NN DT NNP NN NN O
genotype genotype 0 0 0 0 0 0 0 0 8 0 DT NNP NN NN NN O
frequency frequency 0 0 0 0 0 0 0 0 9 0 NNP NN NN NN NNP O
(30.76% (30.76% 0 0 0 0 0 0 0 1 7 0 NN NN NN NNP CD O
vs. vs. 0 0 0 0 0 0 0 0 3 0 NN NN NNP CD NNP O
17.6%, 17.6%, 0 0 0 0 1 0 0 1 6 0 NN NNP CD NNP NNP O
P P 1 1 0 0 0 0 0 0 1 0 NNP CD NNP NNP CD O
= = 0 0 0 0 0 0 0 0 1 0 CD NNP NNP CD IN O
0.01) 0.01) 0 0 0 0 0 0 0 1 5 0 NNP NNP CD IN RB O
as as 0 0 0 0 0 0 0 0 2 0 NNP CD IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 CD IN RB IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT JJ NN O
allelic allelic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN IN O
frequency frequency 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN DT NN O
A A 1 1 0 0 0 0 0 0 1 0 NN IN DT NN CC O
(52.8% (52.8% 0 0 0 0 0 0 0 1 6 0 IN DT NN CC CD O
vs. vs. 0 0 0 0 0 0 0 0 3 0 DT NN CC CD NNP O
43.5%, 43.5%, 0 0 0 0 1 0 0 1 6 0 NN CC CD NNP NNP O
P P 1 1 0 0 0 0 0 0 1 0 CC CD NNP NNP CD O
= = 0 0 0 0 0 0 0 0 1 0 CD NNP NNP CD VBD O
0.04) 0.04) 0 0 0 0 0 0 0 1 5 0 NNP NNP CD VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NNP CD VBD RB JJR O
significantly significantly 0 0 0 0 0 0 0 0 13 0 CD VBD RB JJR IN O
higher higher 0 0 0 0 0 0 0 0 6 0 VBD RB JJR IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 RB JJR IN NNS VBN O
cases cases 0 0 0 0 0 0 0 0 5 0 JJR IN NNS VBN TO O
compared compared 0 0 0 0 0 0 0 0 8 0 IN NNS VBN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBN TO NNP NNP O
controls. controls. 0 0 0 0 0 0 0 0 9 0 VBN TO NNP NNP JJ O
No No 1 0 0 0 0 0 0 0 2 0 TO NNP NNP JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 NNP NNP JJ NN VBD O
association association 0 0 0 0 0 0 0 0 11 0 NNP JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN IN O
seen seen 0 0 0 0 0 0 0 0 4 0 NN VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NN O
-318 -318 0 0 1 0 0 0 0 1 4 0 IN DT NN NN NNP O
C>T C>T 1 1 0 0 0 0 0 0 3 0 DT NN NN NNP NNP O
polymorphism. polymorphism. 0 0 0 0 0 0 0 0 13 0 NN NN NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NN NN O
forward forward 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN NN O
stepwise stepwise 0 0 0 0 0 0 0 0 8 0 NNP NN NN NN JJ O
binary binary 0 0 0 0 0 0 0 0 6 0 NN NN NN JJ NN O
logistic logistic 0 0 0 0 0 0 0 0 8 0 NN NN JJ NN NN O
regression regression 0 0 0 0 0 0 0 0 10 0 NN JJ NN NN VBG O
analysis analysis 0 0 0 0 0 0 0 0 8 0 JJ NN NN VBG NN O
considering considering 0 0 0 0 0 0 0 0 11 0 NN NN VBG NN CC O
age age 0 0 0 0 0 0 0 0 3 0 NN VBG NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VBG NN CC NN IN O
parity parity 0 0 0 0 0 0 0 0 6 0 NN CC NN IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NN O
potential potential 0 0 0 0 0 0 0 0 9 0 NN IN JJ NN JJ O
confounders, confounders, 0 0 0 0 1 0 0 0 12 0 IN JJ NN JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 JJ NN JJ NN VBD O
association association 0 0 0 0 0 0 0 0 11 0 NN JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 NN VBD VBN IN -NONE- O
between between 0 0 0 0 0 0 0 0 7 0 VBD VBN IN -NONE- NNP O
+49 +49 0 0 0 0 0 0 0 1 3 0 VBN IN -NONE- NNP CC O
A/A A/A 1 1 0 1 0 0 0 0 3 0 IN -NONE- NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NNP CC JJ NNP O
cervical cervical 0 0 0 0 0 0 0 0 8 0 NNP CC JJ NNP NNP O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 CC JJ NNP NNP NNP O
Most Most 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NNP DT O
likely, likely, 0 0 0 0 1 0 0 0 7 0 NNP NNP NNP DT VBZ O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP DT VBZ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 DT VBZ DT JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 VBZ DT JJ NN IN O
study study 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 JJ NN IN NNP TO O
India India 1 0 0 0 0 0 0 0 5 0 NN IN NNP TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NNP TO VB DT O
highlight highlight 0 0 0 0 0 0 0 0 9 0 NNP TO VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 VB DT JJ NN IN O
association association 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN DT O
between between 0 0 0 0 0 0 0 0 7 0 JJ NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
CTLA-4 CTLA-4 1 1 1 0 0 0 0 1 6 0 IN DT NNP NN -NONE- O
gene gene 0 0 0 0 0 0 0 0 4 0 DT NNP NN -NONE- NNP O
+49 +49 0 0 0 0 0 0 0 1 3 0 NNP NN -NONE- NNP NNP O
A/A A/A 1 1 0 1 0 0 0 0 3 0 NN -NONE- NNP NNP CC O
SNP SNP 1 1 0 0 0 0 0 0 3 0 -NONE- NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NN O
cervical cervical 0 0 0 0 0 0 0 0 8 0 NNP CC JJ NN RB O
cancer, cancer, 0 0 0 0 1 0 0 0 7 0 CC JJ NN RB VBG O
thus thus 0 0 0 0 0 0 0 0 4 0 JJ NN RB VBG TO O
adding adding 0 0 0 0 0 0 0 0 6 0 NN RB VBG TO DT O
to to 0 0 0 0 0 0 0 0 2 0 RB VBG TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBG TO DT JJ NN O
global global 0 0 0 0 0 0 0 0 6 0 TO DT JJ NN IN O
knowledge knowledge 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
association association 0 0 0 0 0 0 0 0 11 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NNP IN O
SNP SNP 1 1 0 0 0 0 0 0 3 0 IN DT NNP IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 DT NNP IN JJ NNP O
cervical cervical 0 0 0 0 0 0 0 0 8 0 NNP IN JJ NNP NNP O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 IN JJ NNP NNP NNP O
Copyright Copyright 1 0 0 0 0 0 0 0 9 0 JJ NNP NNP NNP CD O
© © 0 0 0 0 0 0 0 0 1 0 NNP NNP NNP CD NNP O
2013 2013 0 0 0 0 0 0 1 1 4 0 NNP NNP CD NNP NNP O
Elsevier Elsevier 1 0 0 0 0 0 0 0 8 0 NNP CD NNP NNP NNP O
Inc. Inc. 1 0 0 0 0 0 0 0 4 0 CD NNP NNP NNP NNS O
All All 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS NNP O
rights rights 0 0 0 0 0 0 0 0 6 0 NNP NNP NNS NNP NONE O
reserved. reserved. 0 0 0 0 0 0 0 0 9 0 NNP NNS NNP NONE NONE O
Bis(Monoacylglycero)Phosphate Bis(Monoacylglycero)Phosphate 1 0 0 0 0 0 0 0 29 0 NONE NONE JJ NN IN O
Accumulation Accumulation 1 0 0 0 0 0 0 0 12 0 NONE JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNPS O
Macrophages Macrophages 1 0 0 0 0 0 0 0 11 0 NN IN NNP NNPS NNP O
Induces Induces 1 0 0 0 0 0 0 0 7 0 IN NNP NNPS NNP NNP O
Intracellular Intracellular 1 0 0 0 0 0 0 0 13 0 NNP NNPS NNP NNP NNP O
Cholesterol Cholesterol 1 0 0 0 0 0 0 0 11 0 NNPS NNP NNP NNP NNP O
Redistribution, Redistribution, 1 0 0 0 1 0 0 0 15 0 NNP NNP NNP NNP NNP O
Attenuates Attenuates 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Liver-X Liver-X 1 0 1 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Receptor/ATP-Binding Receptor/ATP-Binding 1 0 1 1 0 0 0 0 20 0 NNP NNP NNP NNP NNP O
Cassette Cassette 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Transporter Transporter 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
A1/ATP-Binding A1/ATP-Binding 1 0 1 1 0 0 0 1 14 0 NNP NNP NNP NNP NNP O
Cassette Cassette 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Transporter Transporter 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 NNP NNP NNP NNP CC O
Pathway, Pathway, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Impairs Impairs 1 0 0 0 0 0 0 0 7 0 NNP CC NNP NNP NNP O
Cholesterol Cholesterol 1 0 0 0 0 0 0 0 11 0 CC NNP NNP NNP NNP O
Efflux. Efflux. 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Luquain-Costaz Luquain-Costaz 1 0 1 0 0 0 0 0 14 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lefai Lefai 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
E, E, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Arnal-Levron Arnal-Levron 1 0 1 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Markina Markina 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sakaï Sakaï 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Euthine Euthine 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
V, V, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Makino Makino 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Guichardant Guichardant 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yamashita Yamashita 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kobayashi Kobayashi 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lagarde Lagarde 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Moulin Moulin 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Delton-Vandenbroucke Delton-Vandenbroucke 1 0 1 0 0 0 0 0 20 0 NNP NNP NNP NNP NNP O
I. I. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP DT O
From From 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNP IN O
Université Université 1 0 0 0 0 0 0 0 10 0 NNP DT NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 DT NNP IN NNP NNP O
Lyon, Lyon, 1 0 0 0 1 0 0 0 5 0 NNP IN NNP NNP CD O
UMR UMR 1 1 0 0 0 0 0 0 3 0 IN NNP NNP CD NNP O
1060 1060 0 0 0 0 0 0 1 1 4 0 NNP NNP CD NNP NNP O
Inserm Inserm 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
(CarMeN), (CarMeN), 0 0 0 0 1 0 0 0 9 0 CD NNP NNP NNP NNP O
Institut Institut 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
National National 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP VBZ NNS O
des des 0 0 0 0 0 0 0 0 3 0 NNP NNP VBZ NNS -NONE- O
Sciences Sciences 1 0 0 0 0 0 0 0 8 0 NNP VBZ NNS -NONE- -NONE- O
Appliquées-Lyon, Appliquées-Lyon, 1 0 1 0 1 0 0 0 16 0 VBZ NNS -NONE- -NONE- NNP O
Villeurbanne, Villeurbanne, 1 0 0 0 1 0 0 0 13 0 NNS -NONE- -NONE- NNP NNP O
France France 1 0 0 0 0 0 0 0 6 0 -NONE- -NONE- NNP NNP NNP O
(C.L.-C., (C.L.-C., 0 1 1 0 1 0 0 0 9 0 -NONE- NNP NNP NNP NNP O
E.L., E.L., 1 1 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
M.A.-L., M.A.-L., 1 1 1 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
D.M., D.M., 1 1 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
V.E., V.E., 1 1 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
M.G., M.G., 1 1 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
M.L., M.L., 1 1 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
P.M., P.M., 1 1 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
I.D.-V.); I.D.-V.); 1 1 1 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Lipid Lipid 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Biology Biology 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Laboratory, Laboratory, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
RIKEN, RIKEN, 1 1 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
Saitama, Saitama, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Japan Japan 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
(S.S., (S.S., 0 1 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
A.M., A.M., 1 1 0 0 1 0 0 0 5 0 NNP NNP NNP NNP CC O
T.K.); T.K.); 1 1 0 0 0 0 0 0 6 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP CC NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NNP IN NNP NNP O
Cardiovascular Cardiovascular 1 0 0 0 0 0 0 0 14 0 NNP IN NNP NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Osaka Osaka 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Graduate Graduate 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Osaka, Osaka, 1 0 0 0 1 0 0 0 6 0 IN NNP NNP NNP NNP O
Japan Japan 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
(S.Y.). (S.Y.). 0 1 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
OBJECTIVE: OBJECTIVE: 1 1 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NN O
Endosomal Endosomal 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NN VBD O
signature signature 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBD JJ O
phospholipid phospholipid 0 0 0 0 0 0 0 0 12 0 NNP NN VBD JJ NN O
bis(monoacylglycero)phosphate bis(monoacylglycero)phosphate 0 0 0 0 0 0 0 0 29 0 NN VBD JJ NN VBZ O
(BMP) (BMP) 0 1 0 0 0 0 0 0 5 0 VBD JJ NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 JJ NN VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 VBZ VBN VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
regulation regulation 0 0 0 0 0 0 0 0 10 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
cellular cellular 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN NNP O
cholesterol cholesterol 0 0 0 0 0 0 0 0 11 0 IN JJ NN NNP NNP O
homeostasis. homeostasis. 0 0 0 0 0 0 0 0 12 0 JJ NN NNP NNP IN O
Accumulation Accumulation 1 0 0 0 0 0 0 0 12 0 NN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP VBZ O
BMP BMP 1 1 0 0 0 0 0 0 3 0 NNP IN NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT NN IN O
hallmark hallmark 0 0 0 0 0 0 0 0 8 0 VBZ DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
lipid lipid 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NNS O
storage storage 0 0 0 0 0 0 0 0 7 0 IN JJ NN NNS CC O
disorders disorders 0 0 0 0 0 0 0 0 9 0 JJ NN NNS CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NNS CC VBD RB VBN O
recently recently 0 0 0 0 0 0 0 0 8 0 CC VBD RB VBN IN O
reported reported 0 0 0 0 0 0 0 0 8 0 VBD RB VBN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 RB VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NN O
noticeable noticeable 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN IN O
feature feature 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
oxidized oxidized 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN JJ O
low-density low-density 0 0 1 0 0 0 0 0 11 0 IN JJ NN JJ NNP O
lipoprotein-laden lipoprotein-laden 0 0 1 0 0 0 0 0 17 0 JJ NN JJ NNP NNP O
macrophages. macrophages. 0 0 0 0 0 0 0 0 12 0 NN JJ NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN TO O
designed designed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB DT O
delineate delineate 0 0 0 0 0 0 0 0 9 0 VBN TO VB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NNS IN O
consequences consequences 0 0 0 0 0 0 0 0 12 0 VB DT NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NN NN O
macrophage macrophage 0 0 0 0 0 0 0 0 10 0 NNS IN NN NN NN O
BMP BMP 1 1 0 0 0 0 0 0 3 0 IN NN NN NN IN O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 NN NN NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
intracellular intracellular 0 0 0 0 0 0 0 0 13 0 NN IN JJ NN NN O
cholesterol cholesterol 0 0 0 0 0 0 0 0 11 0 IN JJ NN NN NN O
distribution, distribution, 0 0 0 0 1 0 0 0 13 0 JJ NN NN NN CC O
metabolism, metabolism, 0 0 0 0 1 0 0 0 11 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN CC O
efflux efflux 0 0 0 0 0 0 0 0 6 0 NN CC NN CC TO O
and and 0 0 0 0 0 0 0 0 3 0 CC NN CC TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN CC TO VB DT O
unravel unravel 0 0 0 0 0 0 0 0 7 0 CC TO VB DT VBG O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT VBG JJ O
underlying underlying 0 0 0 0 0 0 0 0 10 0 VB DT VBG JJ NNP O
molecular molecular 0 0 0 0 0 0 0 0 9 0 DT VBG JJ NNP NNP O
mechanisms. mechanisms. 0 0 0 0 0 0 0 0 11 0 VBG JJ NNP NNP NNP O
APPROACH APPROACH 1 1 0 0 0 0 0 0 8 0 JJ NNP NNP NNP NNP O
AND AND 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNP VBP VBN DT O
developed developed 0 0 0 0 0 0 0 0 9 0 NNP VBP VBN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 VBP VBN DT JJ NN O
experimental experimental 0 0 0 0 0 0 0 0 12 0 VBN DT JJ NN TO O
design design 0 0 0 0 0 0 0 0 6 0 DT JJ NN TO RB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO RB VB O
specifically specifically 0 0 0 0 0 0 0 0 12 0 NN TO RB VB NNP O
increase increase 0 0 0 0 0 0 0 0 8 0 TO RB VB NNP NN O
BMP BMP 1 1 0 0 0 0 0 0 3 0 RB VB NNP NN IN O
content content 0 0 0 0 0 0 0 0 7 0 VB NNP NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP CD O
RAW RAW 1 1 0 0 0 0 0 0 3 0 NN IN NNP CD NNP O
264.7 264.7 0 0 0 0 0 0 0 1 5 0 IN NNP CD NNP NNP O
macrophages. macrophages. 0 0 0 0 0 0 0 0 12 0 NNP CD NNP NNP NNP O
After After 1 0 0 0 0 0 0 0 5 0 CD NNP NNP NNP NNP O
BMP BMP 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NN O
accumulation, accumulation, 0 0 0 0 1 0 0 0 13 0 NNP NNP NNP NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN NN O
cholesterol cholesterol 0 0 0 0 0 0 0 0 11 0 NNP NN NN NN VBD O
distribution distribution 0 0 0 0 0 0 0 0 12 0 NN NN NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD RB -NONE- O
markedly markedly 0 0 0 0 0 0 0 0 8 0 NN VBD RB -NONE- IN O
altered, altered, 0 0 0 0 1 0 0 0 8 0 VBD RB -NONE- IN DT O
despite despite 0 0 0 0 0 0 0 0 7 0 RB -NONE- IN DT NN O
no no 0 0 0 0 0 0 0 0 2 0 -NONE- IN DT NN IN O
change change 0 0 0 0 0 0 0 0 6 0 IN DT NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
low-density low-density 0 0 1 0 0 0 0 0 11 0 NN IN NN NN NN O
lipoprotein lipoprotein 0 0 0 0 0 0 0 0 11 0 IN NN NN NN CC O
uptake uptake 0 0 0 0 0 0 0 0 6 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NN O
hydrolysis, hydrolysis, 0 0 0 0 1 0 0 0 11 0 NN CC NNP NN -NONE- O
cholesterol cholesterol 0 0 0 0 0 0 0 0 11 0 CC NNP NN -NONE- CC O
esterification, esterification, 0 0 0 0 1 0 0 0 15 0 NNP NN -NONE- CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 NN -NONE- CC JJ NN O
total total 0 0 0 0 0 0 0 0 5 0 -NONE- CC JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 CC JJ NN NN NNP O
cholesterol cholesterol 0 0 0 0 0 0 0 0 11 0 JJ NN NN NNP NNP O
content. content. 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NNS O
cholesterol-regulated cholesterol-regulated 0 0 1 0 0 0 0 0 21 0 NN IN JJ NNS NN O
genes genes 0 0 0 0 0 0 0 0 5 0 IN JJ NNS NN NN O
sterol sterol 0 0 0 0 0 0 0 0 6 0 JJ NNS NN NN NN O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 NNS NN NN NN NN O
element-binding element-binding 0 0 1 0 0 0 0 0 15 0 NN NN NN NN CD O
protein protein 0 0 0 0 0 0 0 0 7 0 NN NN NN CD CC O
2 2 0 0 0 0 0 0 1 1 1 0 NN NN CD CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN CD CC JJ DT O
hydroxymethylglutaryl-coenzyme hydroxymethylglutaryl-coenzyme 0 0 1 0 0 0 0 0 30 0 CD CC JJ DT NN O
A A 1 1 0 0 0 0 0 0 1 0 CC JJ DT NN VBD O
reductase reductase 0 0 0 0 0 0 0 0 9 0 JJ DT NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD VBN IN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN CD O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN CD JJ O
40%, 40%, 0 0 0 0 1 0 0 1 4 0 VBN IN CD JJ IN O
indicative indicative 0 0 0 0 0 0 0 0 10 0 IN CD JJ IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CD JJ IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 JJ IN DT NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ JJ O
endoplasmic endoplasmic 0 0 0 0 0 0 0 0 11 0 NN IN JJ JJ NNP O
reticulum-associated reticulum-associated 0 0 1 0 0 0 0 0 20 0 IN JJ JJ NNP NNP O
cholesterol. cholesterol. 0 0 0 0 0 0 0 0 12 0 JJ JJ NNP NNP NN O
Cholesterol Cholesterol 1 0 0 0 0 0 0 0 11 0 JJ NNP NNP NN TO O
delivery delivery 0 0 0 0 0 0 0 0 8 0 NNP NNP NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO VB NN O
plasma plasma 0 0 0 0 0 0 0 0 6 0 NN TO VB NN VBD O
membrane membrane 0 0 0 0 0 0 0 0 8 0 TO VB NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 VB NN VBD VBN IN O
reduced reduced 0 0 0 0 0 0 0 0 7 0 NN VBD VBN IN VBN O
as as 0 0 0 0 0 0 0 0 2 0 VBD VBN IN VBN IN O
evidenced evidenced 0 0 0 0 0 0 0 0 9 0 VBN IN VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 IN VBN IN DT CD O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT CD NN O
20% 20% 0 0 0 0 0 0 0 1 3 0 IN DT CD NN IN O
decrease decrease 0 0 0 0 0 0 0 0 8 0 DT CD NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN NN IN O
efflux efflux 0 0 0 0 0 0 0 0 6 0 NN IN NN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNP O
cyclodextrin. cyclodextrin. 0 0 0 0 0 0 0 0 13 0 NN IN NNP NNP NNP O
Functionally, Functionally, 1 0 0 0 1 0 0 0 13 0 IN NNP NNP NNP NN O
BMP BMP 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NN VBD O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 NNP NNP NN VBD NN O
reduced reduced 0 0 0 0 0 0 0 0 7 0 NNP NN VBD NN NN O
cholesterol cholesterol 0 0 0 0 0 0 0 0 11 0 NN VBD NN NN TO O
efflux efflux 0 0 0 0 0 0 0 0 6 0 VBD NN NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO DT NN O
both both 0 0 0 0 0 0 0 0 4 0 NN TO DT NN NNP O
apolipoprotein apolipoprotein 0 0 0 0 0 0 0 0 14 0 TO DT NN NNP CC O
A1 A1 1 1 0 0 0 0 0 1 2 0 DT NN NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NN NN O
high-density high-density 0 0 1 0 0 0 0 0 12 0 NNP CC NN NN IN O
lipoprotein lipoprotein 0 0 0 0 0 0 0 0 11 0 CC NN NN IN CD O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN CD CC O
40% 40% 0 0 0 0 0 0 0 1 3 0 NN IN CD CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 IN CD CC VBD IN O
correlated correlated 0 0 0 0 0 0 0 0 10 0 CD CC VBD IN DT O
with with 0 0 0 0 0 0 0 0 4 0 CC VBD IN DT CD O
a a 0 0 0 0 0 0 0 0 1 0 VBD IN DT CD NN O
40% 40% 0 0 0 0 0 0 0 1 3 0 IN DT CD NN IN O
decrease decrease 0 0 0 0 0 0 0 0 8 0 DT CD NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN NNP NNS O
mRNA mRNA 0 0 0 0 0 0 0 0 4 0 NN IN NNP NNS IN O
contents contents 0 0 0 0 0 0 0 0 8 0 IN NNP NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN JJ NN O
ATP-binding ATP-binding 1 0 1 0 0 0 0 0 11 0 NNS IN JJ NN NN O
cassette cassette 0 0 0 0 0 0 0 0 8 0 IN JJ NN NN NN O
transporter transporter 0 0 0 0 0 0 0 0 11 0 JJ NN NN NN NN O
A1, A1, 1 1 0 0 1 0 0 1 3 0 NN NN NN NN NN O
ATP-binding ATP-binding 1 0 1 0 0 0 0 0 11 0 NN NN NN NN NN O
cassette cassette 0 0 0 0 0 0 0 0 8 0 NN NN NN NN NN O
transporter transporter 0 0 0 0 0 0 0 0 11 0 NN NN NN NN CC O
G1, G1, 1 1 0 0 1 0 0 1 3 0 NN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
liver-X liver-X 0 0 1 0 0 0 0 0 7 0 NN CC JJ NN : O
receptor receptor 0 0 0 0 0 0 0 0 8 0 CC JJ NN : CC O
α α 0 0 0 0 0 0 0 0 1 0 JJ NN : CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN : CC NNP NNP O
β. β. 0 0 0 0 0 0 0 0 2 0 : CC NNP NNP NN O
Foam Foam 1 0 0 0 0 0 0 0 4 0 CC NNP NNP NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN VBD O
formation formation 0 0 0 0 0 0 0 0 9 0 NNP NN NN VBD IN O
induced induced 0 0 0 0 0 0 0 0 7 0 NN NN VBD IN VBN O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN VBN NN O
oxidized oxidized 0 0 0 0 0 0 0 0 8 0 VBD IN VBN NN NN O
low-density low-density 0 0 1 0 0 0 0 0 11 0 IN VBN NN NN NN O
lipoprotein lipoprotein 0 0 0 0 0 0 0 0 11 0 VBN NN NN NN VBD O
exposure exposure 0 0 0 0 0 0 0 0 8 0 NN NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
exacerbated exacerbated 0 0 0 0 0 0 0 0 11 0 NN VBD VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NNP O
BMP-enriched BMP-enriched 1 0 1 0 0 0 0 0 12 0 VBN IN JJ NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP NNP O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 JJ NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN NN O
present present 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN VBZ O
work work 0 0 0 0 0 0 0 0 4 0 NNP NN NN VBZ IN O
shows shows 0 0 0 0 0 0 0 0 5 0 NN NN VBZ IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN VBZ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBZ IN DT JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN DT O
time time 0 0 0 0 0 0 0 0 4 0 DT JJ NN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 JJ NN DT JJ JJ O
strong strong 0 0 0 0 0 0 0 0 6 0 NN DT JJ JJ NN O
functional functional 0 0 0 0 0 0 0 0 10 0 DT JJ JJ NN IN O
link link 0 0 0 0 0 0 0 0 4 0 JJ JJ NN IN NNP O
between between 0 0 0 0 0 0 0 0 7 0 JJ NN IN NNP CC O
BMP BMP 1 1 0 0 0 0 0 0 3 0 NN IN NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC JJ NNS O
cholesterol-regulating cholesterol-regulating 0 0 1 0 0 0 0 0 22 0 NNP CC JJ NNS VBN O
genes genes 0 0 0 0 0 0 0 0 5 0 CC JJ NNS VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 JJ NNS VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBN IN DT JJ O
both both 0 0 0 0 0 0 0 0 4 0 VBN IN DT JJ NN O
intracellular intracellular 0 0 0 0 0 0 0 0 13 0 IN DT JJ NN CC O
metabolism metabolism 0 0 0 0 0 0 0 0 10 0 DT JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP NNP O
efflux. efflux. 0 0 0 0 0 0 0 0 7 0 NN CC NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 CC NNP NNP VBP IN O
propose propose 0 0 0 0 0 0 0 0 7 0 NNP NNP VBP IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBP IN NN IN O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 VBP IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NN O
cellular cellular 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN MD O
BMP BMP 1 1 0 0 0 0 0 0 3 0 IN JJ NN MD VB O
might might 0 0 0 0 0 0 0 0 5 0 JJ NN MD VB TO O
contribute contribute 0 0 0 0 0 0 0 0 10 0 NN MD VB TO DT O
to to 0 0 0 0 0 0 0 0 2 0 MD VB TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VB TO DT NN IN O
deregulation deregulation 0 0 0 0 0 0 0 0 12 0 TO DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
cholesterol cholesterol 0 0 0 0 0 0 0 0 11 0 NN IN NN NN IN O
homeostasis homeostasis 0 0 0 0 0 0 0 0 11 0 IN NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNP O
atheromatous atheromatous 0 0 0 0 0 0 0 0 12 0 NN IN JJ NNP NONE O
macrophages. macrophages. 0 0 0 0 0 0 0 0 12 0 IN JJ NNP NONE NONE O
Immunoproteomics Immunoproteomics 1 0 0 0 0 0 0 0 16 0 NONE NONE NNS VBP IN O
approach approach 0 0 0 0 0 0 0 0 8 0 NONE NNS VBP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNS VBP IN NNP JJ O
EPC1 EPC1 1 1 0 0 0 0 0 1 4 0 VBP IN NNP JJ NN O
antigenic antigenic 0 0 0 0 0 0 0 0 9 0 IN NNP JJ NN NN O
epitope epitope 0 0 0 0 0 0 0 0 7 0 NNP JJ NN NN IN O
prediction prediction 0 0 0 0 0 0 0 0 10 0 JJ NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP CC O
G1 G1 1 1 0 0 0 0 0 1 2 0 NN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNS O
G6 G6 1 1 0 0 0 0 0 1 2 0 NNP CC NNP NNS IN O
strains strains 0 0 0 0 0 0 0 0 7 0 CC NNP NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NNP NNP O
Echinococcus Echinococcus 1 0 0 0 0 0 0 0 12 0 NNS IN NNP NNP NNP O
granulosus. granulosus. 0 0 0 0 0 0 0 0 11 0 IN NNP NNP NNP NNP O
Etebar Etebar 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Jalousian Jalousian 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hosseini Hosseini 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
SH, SH, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Kordafshari Kordafshari 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Najafi Najafi 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
A. A. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Parasitology, Parasitology, 1 0 0 0 1 0 0 0 13 0 NNP IN NNP NNP IN O
Faculty Faculty 1 0 0 0 0 0 0 0 7 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Veterinary Veterinary 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Tehran, Tehran, 1 0 0 0 1 0 0 0 7 0 NNP IN NNP NNP NNP O
Tehran, Tehran, 1 0 0 0 1 0 0 0 7 0 IN NNP NNP NNP NNP O
Iran. Iran. 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ JJ TO O
important important 0 0 0 0 0 0 0 0 9 0 NNP VBZ JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO VB DT O
establish establish 0 0 0 0 0 0 0 0 9 0 JJ TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
diagnosis diagnosis 0 0 0 0 0 0 0 0 9 0 VB DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
cystic cystic 0 0 0 0 0 0 0 0 6 0 NN IN JJ NN NN O
echinococcosis echinococcosis 0 0 0 0 0 0 0 0 14 0 IN JJ NN NN NN O
(CE) (CE) 0 1 0 0 0 0 0 0 4 0 JJ NN NN NN CC O
infection infection 0 0 0 0 0 0 0 0 9 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
begin begin 0 0 0 0 0 0 0 0 5 0 NN CC NN NN NNP O
control control 0 0 0 0 0 0 0 0 7 0 CC NN NN NNP NNP O
management. management. 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP PRP O
Currently, Currently, 1 0 0 0 1 0 0 0 10 0 NN NNP NNP PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP PRP VBZ JJ TO O
difficult difficult 0 0 0 0 0 0 0 0 9 0 PRP VBZ JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO VB DT O
make make 0 0 0 0 0 0 0 0 4 0 JJ TO VB DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 TO VB DT JJ NN O
accurate accurate 0 0 0 0 0 0 0 0 8 0 VB DT JJ NN IN O
diagnosis diagnosis 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP IN O
CE CE 1 1 0 0 0 0 0 0 2 0 NN IN NNP IN DT O
without without 0 0 0 0 0 0 0 0 7 0 IN NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN IN O
availability availability 0 0 0 0 0 0 0 0 12 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT JJ NN O
accurate accurate 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN WDT O
test, test, 0 0 0 0 1 0 0 0 5 0 DT JJ NN WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 JJ NN WDT VBZ DT O
requires requires 0 0 0 0 0 0 0 0 8 0 NN WDT VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 WDT VBZ DT NN IN O
use use 0 0 0 0 0 0 0 0 3 0 VBZ DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ CC O
sensitive sensitive 0 0 0 0 0 0 0 0 9 0 NN IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NNP O
specific specific 0 0 0 0 0 0 0 0 8 0 JJ CC JJ NNP NNP O
antigens. antigens. 0 0 0 0 0 0 0 0 9 0 CC JJ NNP NNP NN O
Using Using 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP NN VBZ O
recombinant recombinant 0 0 0 0 0 0 0 0 11 0 NNP NNP NN VBZ DT O
antigens antigens 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT NN CC O
sensitivity sensitivity 0 0 0 0 0 0 0 0 11 0 VBZ DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
specificity specificity 0 0 0 0 0 0 0 0 11 0 NN CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
CE CE 1 1 0 0 0 0 0 0 2 0 IN DT NNP NN VBZ O
serology serology 0 0 0 0 0 0 0 0 8 0 DT NNP NN VBZ MD O
assays assays 0 0 0 0 0 0 0 0 6 0 NNP NN VBZ MD VB O
could could 0 0 0 0 0 0 0 0 5 0 NN VBZ MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 VBZ MD VB VBN -NONE- O
improved improved 0 0 0 0 0 0 0 0 8 0 MD VB VBN -NONE- -NONE- O
considerably. considerably. 0 0 0 0 0 0 0 0 13 0 VB VBN -NONE- -NONE- DT O
Recently, Recently, 1 0 0 0 1 0 0 0 9 0 VBN -NONE- -NONE- DT RB O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- -NONE- DT RB JJ O
highly highly 0 0 0 0 0 0 0 0 6 0 -NONE- DT RB JJ NN O
antigenic antigenic 0 0 0 0 0 0 0 0 9 0 DT RB JJ NN VBD O
protein protein 0 0 0 0 0 0 0 0 7 0 RB JJ NN VBD NNP O
named named 0 0 0 0 0 0 0 0 5 0 JJ NN VBD NNP VBD O
EPC1was EPC1was 1 0 0 0 0 0 0 1 7 0 NN VBD NNP VBD CC O
characterized characterized 0 0 0 0 0 0 0 0 13 0 VBD NNP VBD CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 NNP VBD CC VBN IN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 VBD CC VBN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 CC VBN IN DT NNP O
an an 0 0 0 0 0 0 0 0 2 0 VBN IN DT NNP NN O
Echinococcus Echinococcus 1 0 0 0 0 0 0 0 12 0 IN DT NNP NN NNP O
granulosus granulosus 0 0 0 0 0 0 0 0 10 0 DT NNP NN NNP NNP O
protoscoleces. protoscoleces. 0 0 0 0 0 0 0 0 14 0 NNP NN NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP JJ NN O
current current 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NNP JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN TO O
designed designed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO NN DT O
assess assess 0 0 0 0 0 0 0 0 6 0 VBN TO NN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 TO NN DT NNS IN O
sequences sequences 0 0 0 0 0 0 0 0 9 0 NN DT NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NNP VBD O
EPC1 EPC1 1 1 0 0 0 0 0 1 4 0 NNS IN NNP VBD IN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 IN NNP VBD IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NNP VBD IN JJ JJ O
different different 0 0 0 0 0 0 0 0 9 0 VBD IN JJ JJ NNS O
intermediate intermediate 0 0 0 0 0 0 0 0 12 0 IN JJ JJ NNS IN O
hosts hosts 0 0 0 0 0 0 0 0 5 0 JJ JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NNP O
E. E. 1 1 0 0 0 0 0 0 2 0 NNS IN NNP NNP NNP O
granulosus. granulosus. 0 0 0 0 0 0 0 0 11 0 IN NNP NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NN O
addition, addition, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP NN IN O
identification identification 0 0 0 0 0 0 0 0 14 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT RB O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT RB JJ O
highly highly 0 0 0 0 0 0 0 0 6 0 IN DT RB JJ NN O
antigenic antigenic 0 0 0 0 0 0 0 0 9 0 DT RB JJ NN NNP O
linear linear 0 0 0 0 0 0 0 0 6 0 RB JJ NN NNP NN O
B B 1 1 0 0 0 0 0 0 1 0 JJ NN NNP NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NNP NN NN VBD O
epitope epitope 0 0 0 0 0 0 0 0 7 0 NNP NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 NN VBD VBN IN NNP O
within within 0 0 0 0 0 0 0 0 6 0 VBD VBN IN NNP NN O
EPC1 EPC1 1 1 0 0 0 0 0 1 4 0 VBN IN NNP NN NNP O
antigen antigen 0 0 0 0 0 0 0 0 7 0 IN NNP NN NNP NNP O
candidate. candidate. 0 0 0 0 0 0 0 0 10 0 NNP NN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNP NN O
EPC1 EPC1 1 1 0 0 0 0 0 1 4 0 NNP NNP NNP NN VBZ O
sequence sequence 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBZ VBG O
contains contains 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ VBG CC O
coding coding 0 0 0 0 0 0 0 0 6 0 NN VBZ VBG CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBZ VBG CC JJ NNS O
non-coding non-coding 0 0 1 0 0 0 0 0 10 0 VBG CC JJ NNS CC O
regions regions 0 0 0 0 0 0 0 0 7 0 CC JJ NNS CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNS CC VBD VBN IN O
compared compared 0 0 0 0 0 0 0 0 8 0 CC VBD VBN IN CD O
between between 0 0 0 0 0 0 0 0 7 0 VBD VBN IN CD JJ O
two two 0 0 0 0 0 0 0 0 3 0 VBN IN CD JJ NNS O
predominant predominant 0 0 0 0 0 0 0 0 11 0 IN CD JJ NNS -NONE- O
strains strains 0 0 0 0 0 0 0 0 7 0 CD JJ NNS -NONE- CC O
(G1 (G1 0 1 0 0 0 0 0 1 3 0 JJ NNS -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC NNP IN O
G6) G6) 1 1 0 0 0 0 0 1 3 0 -NONE- CC NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CC NNP IN NNP NNP O
Iran. Iran. 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NN O
Sequence Sequence 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NN VBD O
polymorphism polymorphism 0 0 0 0 0 0 0 0 12 0 NNP NNP NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD RB VBN O
not not 0 0 0 0 0 0 0 0 3 0 NN VBD RB VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 VBD RB VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN NN VBG O
protein protein 0 0 0 0 0 0 0 0 7 0 VBN IN NN VBG NN O
coding coding 0 0 0 0 0 0 0 0 6 0 IN NN VBG NN VBG O
regions, regions, 0 0 0 0 1 0 0 0 8 0 NN VBG NN VBG IN O
suggesting suggesting 0 0 0 0 0 0 0 0 10 0 VBG NN VBG IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NN VBG IN DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 VBG IN DT NNS MD O
regions regions 0 0 0 0 0 0 0 0 7 0 IN DT NNS MD VB O
may may 0 0 0 0 0 0 0 0 3 0 DT NNS MD VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB JJ IN O
useful useful 0 0 0 0 0 0 0 0 6 0 MD VB JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VB JJ IN NN IN O
identification identification 0 0 0 0 0 0 0 0 14 0 JJ IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 NN IN NN NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 IN NN NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT NNP NNP O
antigen. antigen. 0 0 0 0 0 0 0 0 8 0 IN DT NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 DT NNP NNP NN JJ O
average average 0 0 0 0 0 0 0 0 7 0 NNP NNP NN JJ NN O
antigenic antigenic 0 0 0 0 0 0 0 0 9 0 NNP NN JJ NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NN JJ NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
whole whole 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN VBZ O
protein protein 0 0 0 0 0 0 0 0 7 0 DT JJ NN VBZ IN O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ IN CD O
above above 0 0 0 0 0 0 0 0 5 0 NN VBZ IN CD CC O
1.1, 1.1, 0 0 0 0 1 0 0 1 4 0 VBZ IN CD CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN CD CC NN IN O
hydrophobicity hydrophobicity 0 0 0 0 0 0 0 0 14 0 CD CC NN IN -NONE- O
below below 0 0 0 0 0 0 0 0 5 0 CC NN IN -NONE- VBZ O
0 0 0 0 0 0 0 0 1 1 1 0 NN IN -NONE- VBZ IN O
indicates indicates 0 0 0 0 0 0 0 0 9 0 IN -NONE- VBZ IN PRP O
that that 0 0 0 0 0 0 0 0 4 0 -NONE- VBZ IN PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 VBZ IN PRP VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 IN PRP VBZ NNP NNP O
hydrophilic. hydrophilic. 0 0 0 0 0 0 0 0 12 0 PRP VBZ NNP NNP NN O
Structural Structural 1 0 0 0 0 0 0 0 10 0 VBZ NNP NNP NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBD NN O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NN VBD NN JJ O
alpha alpha 0 0 0 0 0 0 0 0 5 0 NN VBD NN JJ NNS O
helical helical 0 0 0 0 0 0 0 0 7 0 VBD NN JJ NNS IN O
regions regions 0 0 0 0 0 0 0 0 7 0 NN JJ NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NNS O
amino amino 0 0 0 0 0 0 0 0 5 0 NNS IN NN NNS CD O
acids acids 0 0 0 0 0 0 0 0 5 0 IN NN NNS CD CD O
6-25, 6-25, 0 0 1 0 1 0 0 1 5 0 NN NNS CD CD CD O
35-44, 35-44, 0 0 1 0 1 0 0 1 6 0 NNS CD CD CD CC O
52-62, 52-62, 0 0 1 0 1 0 0 1 6 0 CD CD CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD CD CC CD CD O
72-78. 72-78. 0 0 1 0 0 0 0 1 6 0 CD CC CD CD NNP O
Nine Nine 1 0 0 0 0 0 0 0 4 0 CC CD CD NNP NN O
B B 1 1 0 0 0 0 0 0 1 0 CD CD NNP NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 CD NNP NN NN NNS O
epitope epitope 0 0 0 0 0 0 0 0 7 0 NNP NN NN NNS VBD O
residues residues 0 0 0 0 0 0 0 0 8 0 NN NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN RP O
identified identified 0 0 0 0 0 0 0 0 10 0 NNS VBD VBN RP IN O
out out 0 0 0 0 0 0 0 0 3 0 VBD VBN RP IN CD O
of of 0 0 0 0 0 0 0 0 2 0 VBN RP IN CD JJ O
67 67 0 0 0 0 0 0 1 1 2 0 RP IN CD JJ NNP O
total total 0 0 0 0 0 0 0 0 5 0 IN CD JJ NNP NNP O
residues. residues. 0 0 0 0 0 0 0 0 9 0 CD JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
identity identity 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NN O
EPC1 EPC1 1 1 0 0 0 0 0 1 4 0 NN IN NNP NN IN O
sequence sequence 0 0 0 0 0 0 0 0 8 0 IN NNP NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NNP O
both both 0 0 0 0 0 0 0 0 4 0 NN IN DT NNP CC O
G1 G1 1 1 0 0 0 0 0 1 2 0 IN DT NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC NNP NNS O
G6 G6 1 1 0 0 0 0 0 1 2 0 NNP CC NNP NNS VBZ O
genotypes genotypes 0 0 0 0 0 0 0 0 9 0 CC NNP NNS VBZ DT O
affects affects 0 0 0 0 0 0 0 0 7 0 NNP NNS VBZ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBZ DT JJ NN O
antigenic antigenic 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ NN IN O
efficacy efficacy 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP VBZ O
EPC1and EPC1and 1 0 0 0 0 0 0 1 7 0 NN IN NNP VBZ DT O
suggests suggests 0 0 0 0 0 0 0 0 8 0 IN NNP VBZ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT JJ NN O
recombinant recombinant 0 0 0 0 0 0 0 0 11 0 VBZ DT JJ NN MD O
protein protein 0 0 0 0 0 0 0 0 7 0 DT JJ NN MD VB O
will will 0 0 0 0 0 0 0 0 4 0 JJ NN MD VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB JJ IN O
useful useful 0 0 0 0 0 0 0 0 6 0 MD VB JJ IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VB JJ IN JJ NNS O
serological serological 0 0 0 0 0 0 0 0 11 0 JJ IN JJ NNS IN O
assays assays 0 0 0 0 0 0 0 0 6 0 IN JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNS WRB O
regions regions 0 0 0 0 0 0 0 0 7 0 IN DT NNS WRB DT O
where where 0 0 0 0 0 0 0 0 5 0 DT NNS WRB DT CD O
the the 0 0 0 0 0 0 0 0 3 0 NNS WRB DT CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 WRB DT CD NNS VBP O
strains strains 0 0 0 0 0 0 0 0 7 0 DT CD NNS VBP NNP O
are are 0 0 0 0 0 0 0 0 3 0 CD NNS VBP NNP NONE O
prevalent. prevalent. 0 0 0 0 0 0 0 0 10 0 NNS VBP NNP NONE NONE O
Overexpression Overexpression 1 0 0 0 0 0 0 0 14 0 NONE NONE NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN JJ NNS O
DOC-1R DOC-1R 1 1 1 0 0 0 0 1 6 0 NN IN JJ NNS NNP O
Inhibits Inhibits 1 0 0 0 0 0 0 0 8 0 IN JJ NNS NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 JJ NNS NNP NNP NNP O
Cycle Cycle 1 0 0 0 0 0 0 0 5 0 NNS NNP NNP NNP NNP O
G1/S G1/S 1 1 0 1 0 0 0 1 4 0 NNP NNP NNP NNP IN B_TIMEXCCP
Transition Transition 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Repressing Repressing 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
CDK2 CDK2 1 1 0 0 0 0 0 1 4 0 IN NNP NNP NNP CC O
Expression Expression 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Activation. Activation. 1 0 0 0 0 0 0 0 11 0 NNP CC NNP NNP NNP O
Liu Liu 1 0 0 0 0 0 0 0 3 0 CC NNP NNP NNP NNP O
Q, Q, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Liu Liu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Gao Gao 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Shi Shi 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hu Hu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Luo Luo 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Y. Y. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Center Center 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
Genomics, Genomics, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
MOH MOH 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Key Key 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP IN O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP CC O
Biology Biology 1 0 0 0 0 0 0 0 7 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Key Key 1 0 0 0 0 0 0 0 3 0 NNP CC NNP NNP IN O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP IN O
Ministry Ministry 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Education, Education, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP NNP O
China China 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP CD O
Shenyang Shenyang 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP CD NNP O
110001, 110001, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NNP O
DOC-1R DOC-1R 1 1 1 0 0 0 0 1 6 0 NNP NNP NNP NNP IN O
(deleted (deleted 0 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ -NONE- O
oral oral 0 0 0 0 0 0 0 0 4 0 NNP IN JJ -NONE- JJ O
cancer-1 cancer-1 0 0 1 0 0 0 0 1 8 0 IN JJ -NONE- JJ VBZ O
related) related) 0 0 0 0 0 0 0 0 8 0 JJ -NONE- JJ VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 -NONE- JJ VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 JJ VBZ DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 VBZ DT NN NN NN O
putative putative 0 0 0 0 0 0 0 0 8 0 DT NN NN NN NNP O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NN NN NN NNP NNP O
suppressor. suppressor. 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD JJ O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NNP NN VBD JJ NN O
DOC-1R DOC-1R 1 1 1 0 0 0 0 1 6 0 NN VBD JJ NN NN O
antitumor antitumor 0 0 0 0 0 0 0 0 9 0 VBD JJ NN NN CC O
activity activity 0 0 0 0 0 0 0 0 8 0 JJ NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT VBG O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT VBG JJ O
underlying underlying 0 0 0 0 0 0 0 0 10 0 CC DT VBG JJ NNP O
molecular molecular 0 0 0 0 0 0 0 0 9 0 DT VBG JJ NNP NNP O
mechanisms. mechanisms. 0 0 0 0 0 0 0 0 11 0 VBG JJ NNP NNP VBZ O
Cell Cell 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP VBZ VBD O
phenotypes phenotypes 0 0 0 0 0 0 0 0 10 0 NNP NNP VBZ VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBD VBN VBG O
assessed assessed 0 0 0 0 0 0 0 0 8 0 VBZ VBD VBN VBG NN O
using using 0 0 0 0 0 0 0 0 5 0 VBD VBN VBG NN -NONE- O
flow flow 0 0 0 0 0 0 0 0 4 0 VBN VBG NN -NONE- NNP O
cytometry, cytometry, 0 0 0 0 1 0 0 0 10 0 VBG NN -NONE- NNP NN O
BrdU BrdU 1 0 0 0 0 0 0 0 4 0 NN -NONE- NNP NN CC O
incorporation incorporation 0 0 0 0 0 0 0 0 13 0 -NONE- NNP NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NNP NN O
CDK2 CDK2 1 1 0 0 0 0 0 1 4 0 NN CC NNP NN VBZ O
kinase kinase 0 0 0 0 0 0 0 0 6 0 CC NNP NN VBZ IN O
assays assays 0 0 0 0 0 0 0 0 6 0 NNP NN VBZ IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN VBZ IN JJ NN O
DOC-1R DOC-1R 1 1 1 0 0 0 0 1 6 0 VBZ IN JJ NN NNP O
overexpressing overexpressing 0 0 0 0 0 0 0 0 14 0 IN JJ NN NNP NNP O
HeLa HeLa 1 0 0 0 0 0 0 0 4 0 JJ NN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
addition, addition, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP CC O
RT-PCR RT-PCR 1 1 1 0 0 0 0 0 6 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NN O
Western Western 1 0 0 0 0 0 0 0 7 0 NNP CC NNP NN VBZ O
blot blot 0 0 0 0 0 0 0 0 4 0 CC NNP NN VBZ VBD O
assays assays 0 0 0 0 0 0 0 0 6 0 NNP NN VBZ VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN VBZ VBD VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 VBZ VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB JJ O
detect detect 0 0 0 0 0 0 0 0 6 0 VBN TO VB JJ JJ O
underlying underlying 0 0 0 0 0 0 0 0 10 0 TO VB JJ JJ NNS O
molecular molecular 0 0 0 0 0 0 0 0 9 0 VB JJ JJ NNS IN O
changes changes 0 0 0 0 0 0 0 0 7 0 JJ JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NNP O
these these 0 0 0 0 0 0 0 0 5 0 NNS IN DT NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN DT NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 DT NNP NNP NN IN O
interaction interaction 0 0 0 0 0 0 0 0 11 0 NNP NNP NN IN JJ O
between between 0 0 0 0 0 0 0 0 7 0 NNP NN IN JJ CC O
DOC-1R DOC-1R 1 1 1 0 0 0 0 1 6 0 NN IN JJ CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC NNP NNS O
CDK2 CDK2 1 1 0 0 0 0 0 1 4 0 JJ CC NNP NNS VBD O
proteins proteins 0 0 0 0 0 0 0 0 8 0 CC NNP NNS VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNS VBD VBN IN O
assayed assayed 0 0 0 0 0 0 0 0 7 0 NNS VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
GST GST 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NNP CC O
pull-down pull-down 0 0 1 0 0 0 0 0 9 0 IN NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NN O
immunoprecipitation-Western immunoprecipitation-Western 0 0 1 0 0 0 0 0 27 0 NNP CC JJ NN NNP O
blot blot 0 0 0 0 0 0 0 0 4 0 CC JJ NN NNP NNP O
assays. assays. 0 0 0 0 0 0 0 0 7 0 JJ NN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS VBD O
data data 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NNS VBD IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN JJ NN O
DOC-1R DOC-1R 1 1 1 0 0 0 0 1 6 0 VBD IN JJ NN VBD O
overexpression overexpression 0 0 0 0 0 0 0 0 14 0 IN JJ NN VBD NNS O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 JJ NN VBD NNS NN O
G1/S G1/S 1 1 0 1 0 0 0 1 4 phase NN VBD NNS NN -NONE- B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 VBD NNS NN -NONE- NNP O
transition, transition, 0 0 0 0 1 0 0 0 11 0 NNS NN -NONE- NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN -NONE- NNP NN CC O
replication replication 0 0 0 0 0 0 0 0 11 0 -NONE- NNP NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC VBD NNP O
suppressed suppressed 0 0 0 0 0 0 0 0 10 0 NN CC VBD NNP NNP O
CDK2 CDK2 1 1 0 0 0 0 0 1 4 0 CC VBD NNP NNP NNP O
activity. activity. 0 0 0 0 0 0 0 0 9 0 VBD NNP NNP NNP NNP O
Molecularly, Molecularly, 1 0 0 0 1 0 0 0 12 0 NNP NNP NNP NNP VBD O
DOC-1R DOC-1R 1 1 1 0 0 0 0 1 6 0 NNP NNP NNP VBD NNP O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD NNP NN O
CDK2 CDK2 1 1 0 0 0 0 0 1 4 0 NNP VBD NNP NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 VBD NNP NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP CC O
mRNA mRNA 0 0 0 0 0 0 0 0 4 0 IN DT NNP CC VB O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC VB JJ O
protein protein 0 0 0 0 0 0 0 0 7 0 NNP CC VB JJ CC O
levels, levels, 0 0 0 0 1 0 0 0 7 0 CC VB JJ CC EX O
and and 0 0 0 0 0 0 0 0 3 0 VB JJ CC EX VBD O
there there 0 0 0 0 0 0 0 0 5 0 JJ CC EX VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 CC EX VBD VBN NNS O
decreased decreased 0 0 0 0 0 0 0 0 9 0 EX VBD VBN NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 VBD VBN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBN NNS IN JJ NNS O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 NNS IN JJ NNS JJ O
cyclins cyclins 0 0 0 0 0 0 0 0 7 0 IN JJ NNS JJ NNP O
(cyclin (cyclin 0 0 0 0 0 0 0 0 7 0 JJ NNS JJ NNP CC O
D1 D1 1 1 0 0 0 0 0 1 2 0 NNS JJ NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNP CC NNP CC O
E) E) 1 1 0 0 0 0 0 0 2 0 NNP CC NNP CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC VBD NNS O
elevated elevated 0 0 0 0 0 0 0 0 8 0 NNP CC VBD NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 CC VBD NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBD NNS IN JJ NN O
p21, p21, 0 0 0 0 1 0 0 1 4 0 NNS IN JJ NN CC O
p27, p27, 0 0 0 0 1 0 0 1 4 0 IN JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP NNP O
p53 p53 0 0 0 0 0 0 0 1 3 0 NN CC NNP NNP NNP O
proteins. proteins. 0 0 0 0 0 0 0 0 9 0 CC NNP NNP NNP NNP O
Meanwhile, Meanwhile, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP VBD O
DOC-1R DOC-1R 1 1 1 0 0 0 0 1 6 0 NNP NNP NNP VBD IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NNP NNP VBD IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNP VBD IN NNP CC O
CDK2 CDK2 1 1 0 0 0 0 0 1 4 0 VBD IN NNP CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC VBD NNP O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NNP CC VBD NNP NN O
CDK2 CDK2 1 1 0 0 0 0 0 1 4 0 CC VBD NNP NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 VBD NNP NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN PRP$ O
obstructing obstructing 0 0 0 0 0 0 0 0 11 0 NN IN NN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 IN NN PRP$ NN IN O
association association 0 0 0 0 0 0 0 0 11 0 NN PRP$ NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 PRP$ NN IN NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP CC O
E E 1 1 0 0 0 0 0 0 1 0 IN NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP NNP O
A. A. 1 1 0 0 0 0 0 0 2 0 NNP CC NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 CC NNP NNP NNP DT O
conclusion, conclusion, 0 0 0 0 1 0 0 0 11 0 NNP NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NNS O
antitumor antitumor 0 0 0 0 0 0 0 0 9 0 NNP DT NN NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 DT NN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ MD O
DOC-1R DOC-1R 1 1 1 0 0 0 0 1 6 0 NNS IN JJ MD VB O
may may 0 0 0 0 0 0 0 0 3 0 IN JJ MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 JJ MD VB VBN IN O
mediated mediated 0 0 0 0 0 0 0 0 8 0 MD VB VBN IN RB O
by by 0 0 0 0 0 0 0 0 2 0 VB VBN IN RB VBG O
negatively negatively 0 0 0 0 0 0 0 0 10 0 VBN IN RB VBG NNP O
regulating regulating 0 0 0 0 0 0 0 0 10 0 IN RB VBG NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 phase RB VBG NNP NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 VBG NNP NN NN CC O
progression progression 0 0 0 0 0 0 0 0 11 0 NNP NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NN O
G1/S G1/S 1 1 0 1 0 0 0 1 4 0 NN CC NNP NN IN B_TIMEXCCP
transition transition 0 0 0 0 0 0 0 0 10 0 CC NNP NN IN VBG O
through through 0 0 0 0 0 0 0 0 7 0 NNP NN IN VBG NNP O
inhibiting inhibiting 0 0 0 0 0 0 0 0 10 0 NN IN VBG NNP NN O
CDK2 CDK2 1 1 0 0 0 0 0 1 4 0 IN VBG NNP NN CC O
expression expression 0 0 0 0 0 0 0 0 10 0 VBG NNP NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NNP NONE O
activation. activation. 0 0 0 0 0 0 0 0 11 0 NN CC NNP NONE NONE O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NONE NONE JJ NN IN O
basis basis 0 0 0 0 0 0 0 0 5 0 NONE JJ NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNS O
dissociation dissociation 0 0 0 0 0 0 0 0 12 0 IN DT NN NNS IN O
dynamics dynamics 0 0 0 0 0 0 0 0 8 0 DT NN NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN JJ O
protein protein 0 0 0 0 0 0 0 0 7 0 NNS IN NN JJ NNP O
a-immunoglobulin a-immunoglobulin 0 0 1 0 0 0 0 0 16 0 IN NN JJ NNP NNP O
g1 g1 0 0 0 0 0 0 0 1 2 0 NN JJ NNP NNP NNP O
complex. complex. 0 0 0 0 0 0 0 0 8 0 JJ NNP NNP NNP NNP O
Liu Liu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
FF, FF, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Huang Huang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Dong Dong 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
XY, XY, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Sun Sun 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Y. Y. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Key Key 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP IN O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNPS O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNPS NNP O
Systems Systems 1 0 0 0 0 0 0 0 7 0 NNP IN NNPS NNP IN O
Bioengineering Bioengineering 1 0 0 0 0 0 0 0 14 0 IN NNPS NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNPS NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP IN O
Ministry Ministry 1 0 0 0 0 0 0 0 8 0 IN DT NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNP IN NNP CC O
Education Education 1 0 0 0 0 0 0 0 9 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP CC NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NNP IN NNP NNP O
Biochemical Biochemical 1 0 0 0 0 0 0 0 11 0 NNP IN NNP NNP NNP O
Engineering, Engineering, 1 0 0 0 1 0 0 0 12 0 IN NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Chemical Chemical 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP CC O
Engineering Engineering 1 0 0 0 0 0 0 0 11 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Technology, Technology, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP NNP O
Tianjin Tianjin 1 0 0 0 0 0 0 0 7 0 CC NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Tianjin, Tianjin, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
Staphylococcus Staphylococcus 1 0 0 0 0 0 0 0 14 0 NNP NNP NNP VBZ NN O
aureus aureus 0 0 0 0 0 0 0 0 6 0 NNP NNP VBZ NN DT O
protein protein 0 0 0 0 0 0 0 0 7 0 NNP VBZ NN DT NN O
A A 1 1 0 0 0 0 0 0 1 0 VBZ NN DT NN VBZ O
(SpA) (SpA) 0 0 0 0 0 0 0 0 5 0 NN DT NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ DT RBS O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT RBS JJ O
most most 0 0 0 0 0 0 0 0 4 0 VBZ DT RBS JJ NN O
popular popular 0 0 0 0 0 0 0 0 7 0 DT RBS JJ NN NN O
affinity affinity 0 0 0 0 0 0 0 0 8 0 RBS JJ NN NN IN O
ligand ligand 0 0 0 0 0 0 0 0 6 0 JJ NN NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NN NNP O
immunoglobulin immunoglobulin 0 0 0 0 0 0 0 0 14 0 NN IN NN NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 IN NN NNP NNP NNP O
(IgG1). (IgG1). 0 0 0 0 0 0 0 1 7 0 NN NNP NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 NNP DT JJ NN IN O
basis basis 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNS O
dissociation dissociation 0 0 0 0 0 0 0 0 12 0 IN DT NN NNS IN O
dynamics dynamics 0 0 0 0 0 0 0 0 8 0 DT NN NNS IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN -NONE- JJ O
SpA-IgG1 SpA-IgG1 1 0 1 0 0 0 0 1 8 0 NNS IN -NONE- JJ VBZ O
complex complex 0 0 0 0 0 0 0 0 7 0 IN -NONE- JJ VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 -NONE- JJ VBZ NNP NNP O
unclear. unclear. 0 0 0 0 0 0 0 0 8 0 JJ VBZ NNP NNP NNP O
Herein, Herein, 1 0 0 0 1 0 0 0 7 0 VBZ NNP NNP NNP NNP O
coarse-grained coarse-grained 0 0 1 0 0 0 0 0 14 0 NNP NNP NNP NNP NN O
(CG) (CG) 0 1 0 0 0 0 0 0 4 0 NNP NNP NNP NN NNS O
molecular molecular 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NNS -NONE- O
dynamics dynamics 0 0 0 0 0 0 0 0 8 0 NNP NN NNS -NONE- NNS O
(MD) (MD) 0 1 0 0 0 0 0 0 4 0 NN NNS -NONE- NNS IN O
simulations simulations 0 0 0 0 0 0 0 0 11 0 NNS -NONE- NNS IN DT O
with with 0 0 0 0 0 0 0 0 4 0 -NONE- NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NN O
Martini Martini 1 0 0 0 0 0 0 0 7 0 IN DT NNP NN NN O
force force 0 0 0 0 0 0 0 0 5 0 DT NNP NN NN VBD O
field field 0 0 0 0 0 0 0 0 5 0 NNP NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 NN VBD VBN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO NN DT O
study study 0 0 0 0 0 0 0 0 5 0 VBN TO NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO NN DT NN NNS O
dissociation dissociation 0 0 0 0 0 0 0 0 12 0 NN DT NN NNS IN O
dynamics dynamics 0 0 0 0 0 0 0 0 8 0 DT NN NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NNP O
complex. complex. 0 0 0 0 0 0 0 0 8 0 IN DT NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 DT NNP NNP NNP NNS O
CG-MD CG-MD 1 1 1 0 0 0 0 0 5 0 NNP NNP NNP NNS VBD O
simulations simulations 0 0 0 0 0 0 0 0 11 0 NNP NNP NNS VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD RB VBN O
first first 0 0 0 0 0 0 0 0 5 0 NNS VBD RB VBN IN O
verified verified 0 0 0 0 0 0 0 0 8 0 VBD RB VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 RB VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
agreement agreement 0 0 0 0 0 0 0 0 9 0 IN DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ CC O
structural structural 0 0 0 0 0 0 0 0 10 0 IN DT JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC JJ NNS O
interactional interactional 0 0 0 0 0 0 0 0 13 0 JJ CC JJ NNS IN O
properties properties 0 0 0 0 0 0 0 0 10 0 CC JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP CC O
SpA SpA 1 0 0 0 0 0 0 0 3 0 NNS IN NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC JJ NNP O
human human 0 0 0 0 0 0 0 0 5 0 NNP CC JJ NNP NNP O
IgG1 IgG1 1 0 0 0 0 0 0 1 4 0 CC JJ NNP NNP IN O
(hIgG1) (hIgG1) 0 0 0 0 0 0 0 1 7 0 JJ NNP NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN NN O
association association 0 0 0 0 0 0 0 0 11 0 IN DT NN NN IN O
process process 0 0 0 0 0 0 0 0 7 0 DT NN NN IN DT O
between between 0 0 0 0 0 0 0 0 7 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ CC O
CG-MD CG-MD 1 1 1 0 0 0 0 0 5 0 IN DT JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC JJ NNP O
all-atom all-atom 0 0 1 0 0 0 0 0 8 0 JJ CC JJ NNP IN O
MD MD 1 1 0 0 0 0 0 0 2 0 CC JJ NNP IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 JJ NNP IN JJ NNP O
different different 0 0 0 0 0 0 0 0 9 0 NNP IN JJ NNP NNP O
NaCl NaCl 1 0 0 0 0 0 0 0 4 0 IN JJ NNP NNP NNP O
concentrations. concentrations. 0 0 0 0 0 0 0 0 15 0 JJ NNP NNP NNP DT O
Then, Then, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NN O
CG-MD CG-MD 1 1 1 0 0 0 0 0 5 0 NNP DT JJ NN NNS O
simulation simulation 0 0 0 0 0 0 0 0 10 0 DT JJ NN NNS VBD O
studies studies 0 0 0 0 0 0 0 0 7 0 JJ NN NNS VBD IN O
focused focused 0 0 0 0 0 0 0 0 7 0 NN NNS VBD IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NNS VBD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN IN O
insight insight 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN DT O
into into 0 0 0 0 0 0 0 0 4 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNS O
dissociation dissociation 0 0 0 0 0 0 0 0 12 0 IN DT NN NNS IN O
dynamics dynamics 0 0 0 0 0 0 0 0 8 0 DT NN NNS IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN -NONE- JJ O
SpA-hIgG1 SpA-hIgG1 1 0 1 0 0 0 0 1 9 0 NNS IN -NONE- JJ IN O
complex complex 0 0 0 0 0 0 0 0 7 0 IN -NONE- JJ IN NNP O
at at 0 0 0 0 0 0 0 0 2 0 -NONE- JJ IN NNP CD O
pH pH 0 0 0 0 0 0 0 0 2 0 JJ IN NNP CD PRP O
3.0. 3.0. 0 0 0 0 0 0 0 1 4 0 IN NNP CD PRP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 NNP CD PRP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 CD PRP VBZ VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 PRP VBZ VBN IN EX O
that that 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN EX VBP O
there there 0 0 0 0 0 0 0 0 5 0 VBN IN EX VBP CD O
are are 0 0 0 0 0 0 0 0 3 0 IN EX VBP CD NNS O
four four 0 0 0 0 0 0 0 0 4 0 EX VBP CD NNS IN O
steps steps 0 0 0 0 0 0 0 0 5 0 VBP CD NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 CD NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
dissociation dissociation 0 0 0 0 0 0 0 0 12 0 IN DT NN NN IN O
process process 0 0 0 0 0 0 0 0 7 0 DT NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
complex. complex. 0 0 0 0 0 0 0 0 8 0 IN DT NNP NNP RB O
First, First, 1 0 0 0 1 0 0 0 6 0 DT NNP NNP RB VBZ O
there there 0 0 0 0 0 0 0 0 5 0 NNP NNP RB VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP RB VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 RB VBZ DT NN JJ O
slight slight 0 0 0 0 0 0 0 0 6 0 VBZ DT NN JJ NN O
conformational conformational 0 0 0 0 0 0 0 0 14 0 DT NN JJ NN IN O
adjustment adjustment 0 0 0 0 0 0 0 0 10 0 NN JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNP O
helix helix 0 0 0 0 0 0 0 0 5 0 NN IN NN NNP IN O
II II 1 1 0 0 0 0 0 0 2 0 IN NN NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NNP IN NNP DT O
SpA. SpA. 1 0 0 0 0 0 0 0 4 0 NNP IN NNP DT VBZ O
This This 1 0 0 0 0 0 0 0 4 0 IN NNP DT VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP DT VBZ VBN IN O
followed followed 0 0 0 0 0 0 0 0 8 0 DT VBZ VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
phenomena phenomena 0 0 0 0 0 0 0 0 9 0 IN DT NN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNS O
electrostatic electrostatic 0 0 0 0 0 0 0 0 13 0 IN DT JJ NNS VBN O
interactions interactions 0 0 0 0 0 0 0 0 12 0 DT JJ NNS VBN IN O
provided provided 0 0 0 0 0 0 0 0 8 0 JJ NNS VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBN IN DT CD O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT CD JJ O
three three 0 0 0 0 0 0 0 0 5 0 IN DT CD JJ NNS O
hot hot 0 0 0 0 0 0 0 0 3 0 DT CD JJ NNS -NONE- O
spots spots 0 0 0 0 0 0 0 0 5 0 CD JJ NNS -NONE- NNP O
(Glu143, (Glu143, 0 0 0 0 1 0 0 1 8 0 JJ NNS -NONE- NNP CC O
Arg146 Arg146 1 0 0 0 0 0 0 1 6 0 NNS -NONE- NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NNP CC NNP IN O
Lys154) Lys154) 1 0 0 0 0 0 0 1 7 0 NNP CC NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NNP IN NN NNP O
helix helix 0 0 0 0 0 0 0 0 5 0 NNP IN NN NNP IN O
II II 1 1 0 0 0 0 0 0 2 0 IN NN NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NNP IN NNP NN O
SpA SpA 1 0 0 0 0 0 0 0 3 0 NNP IN NNP NN -NONE- O
break break 0 0 0 0 0 0 0 0 5 0 IN NNP NN -NONE- VBG O
up, up, 0 0 0 0 1 0 0 0 3 0 NNP NN -NONE- VBG TO O
leading leading 0 0 0 0 0 0 0 0 7 0 NN -NONE- VBG TO DT O
to to 0 0 0 0 0 0 0 0 2 0 -NONE- VBG TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBG TO DT NN IN O
dissociation dissociation 0 0 0 0 0 0 0 0 12 0 TO DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNP O
helix helix 0 0 0 0 0 0 0 0 5 0 NN IN NN NNP IN O
II II 1 1 0 0 0 0 0 0 2 0 IN NN NNP IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NN NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN NN O
binding binding 0 0 0 0 0 0 0 0 7 0 IN DT NN NN IN O
site site 0 0 0 0 0 0 0 0 4 0 DT NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
hIgG1. hIgG1. 0 0 0 0 0 0 0 1 6 0 NN IN NNP NNP NN O
Subsequently, Subsequently, 1 0 0 0 1 0 0 0 13 0 IN NNP NNP NN IN O
breakup breakup 0 0 0 0 0 0 0 0 7 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNS O
hydrophobic hydrophobic 0 0 0 0 0 0 0 0 11 0 IN DT JJ NNS IN O
interactions interactions 0 0 0 0 0 0 0 0 12 0 DT JJ NNS IN NN O
between between 0 0 0 0 0 0 0 0 7 0 JJ NNS IN NN PRP O
helix helix 0 0 0 0 0 0 0 0 5 0 NNS IN NN PRP VBP O
I I 1 1 0 0 0 0 0 0 1 0 IN NN PRP VBP NNP O
(Phe132, (Phe132, 0 0 0 0 1 0 0 1 8 0 NN PRP VBP NNP CC O
Tyr133 Tyr133 1 0 0 0 0 0 0 1 6 0 PRP VBP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VBP NNP CC NNP IN O
His137) His137) 1 0 0 0 0 0 0 1 7 0 NNP CC NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CC NNP IN NNP CC O
SpA SpA 1 0 0 0 0 0 0 0 3 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
hIgG1 hIgG1 0 0 0 0 0 0 0 1 5 0 NNP CC NNP NNP VBG O
occurs, occurs, 0 0 0 0 1 0 0 0 7 0 CC NNP NNP VBG IN O
resulting resulting 0 0 0 0 0 0 0 0 9 0 NNP NNP VBG IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP VBG IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBG IN DT NN IN O
disengagement disengagement 0 0 0 0 0 0 0 0 13 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN PRP O
helix helix 0 0 0 0 0 0 0 0 5 0 NN IN NN PRP IN O
I I 1 1 0 0 0 0 0 0 1 0 IN NN PRP IN PRP$ O
from from 0 0 0 0 0 0 0 0 4 0 NN PRP IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 PRP IN PRP$ NN NN O
binding binding 0 0 0 0 0 0 0 0 7 0 IN PRP$ NN NN IN O
site site 0 0 0 0 0 0 0 0 4 0 PRP$ NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
hIgG1. hIgG1. 0 0 0 0 0 0 0 1 6 0 NN IN NNP NNP DT O
Finally, Finally, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNP NNS O
non-specific non-specific 0 0 1 0 0 0 0 0 12 0 NNP DT NNP NNS IN O
interactions interactions 0 0 0 0 0 0 0 0 12 0 DT NNP NNS IN NNP O
between between 0 0 0 0 0 0 0 0 7 0 NNP NNS IN NNP CC O
SpA SpA 1 0 0 0 0 0 0 0 3 0 NNS IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NN O
hIgG1 hIgG1 0 0 0 0 0 0 0 1 5 0 NNP CC NNP NN RB O
decrease decrease 0 0 0 0 0 0 0 0 8 0 CC NNP NN RB RB O
slowly slowly 0 0 0 0 0 0 0 0 6 0 NNP NN RB RB JJ O
till till 0 0 0 0 0 0 0 0 4 0 NN RB RB JJ VBG O
disappearance, disappearance, 0 0 0 0 1 0 0 0 14 0 RB RB JJ VBG TO O
leading leading 0 0 0 0 0 0 0 0 7 0 RB JJ VBG TO DT O
to to 0 0 0 0 0 0 0 0 2 0 JJ VBG TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBG TO DT JJ NN O
complete complete 0 0 0 0 0 0 0 0 8 0 TO DT JJ NN IN O
dissociation dissociation 0 0 0 0 0 0 0 0 12 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
SpA-hIgG1 SpA-hIgG1 1 0 1 0 0 0 0 1 9 0 IN DT JJ NNP NNP O
complex. complex. 0 0 0 0 0 0 0 0 8 0 DT JJ NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NN VBZ O
work work 0 0 0 0 0 0 0 0 4 0 NNP NNP NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP NN VBZ VBN IN O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NN VBZ VBN IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN JJ VBN O
CG-MD CG-MD 1 1 1 0 0 0 0 0 5 0 VBN IN JJ VBN IN O
coupled coupled 0 0 0 0 0 0 0 0 7 0 IN JJ VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 JJ VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NN O
Martini Martini 1 0 0 0 0 0 0 0 7 0 IN DT NNP NN NN O
force force 0 0 0 0 0 0 0 0 5 0 DT NNP NN NN VBZ O
field field 0 0 0 0 0 0 0 0 5 0 NNP NN NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN VBZ DT JJ NN O
effective effective 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ NN IN O
method method 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN VBG O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN VBG DT O
studying studying 0 0 0 0 0 0 0 0 8 0 NN IN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN VBG DT NN NNS O
dissociation dissociation 0 0 0 0 0 0 0 0 12 0 VBG DT NN NNS IN O
dynamics dynamics 0 0 0 0 0 0 0 0 8 0 DT NN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NNP O
protein-protein protein-protein 0 0 1 0 0 0 0 0 15 0 NNS IN JJ NNP NONE O
complex. complex. 0 0 0 0 0 0 0 0 8 0 IN JJ NNP NONE NONE O
Phosphorylation-triggered Phosphorylation-triggered 1 0 1 0 0 0 0 0 25 0 NONE NONE JJ NNP NN O
CUEDC2 CUEDC2 1 1 0 0 0 0 0 1 6 0 NONE JJ NNP NN VBZ O
degradation degradation 0 0 0 0 0 0 0 0 11 0 JJ NNP NN VBZ JJ O
promotes promotes 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ JJ NNP O
UV-induced UV-induced 1 0 1 0 0 0 0 0 10 0 NN VBZ JJ NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 arrest VBZ JJ NNP NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 JJ NNP NN IN -NONE- O
through through 0 0 0 0 0 0 0 0 7 0 NNP NN IN -NONE- NNP O
APC/CCdh1 APC/CCdh1 1 0 0 1 0 0 0 1 9 0 NN IN -NONE- NNP NNP O
regulation. regulation. 0 0 0 0 0 0 0 0 11 0 IN -NONE- NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 -NONE- NNP NNP NNP NNP O
WN, WN, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Zhou Zhou 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhou Zhou 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
AL, AL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Xu Xu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
JJ, JJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Chang Chang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Man Man 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
JH, JH, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Pan Pan 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
WH, WH, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Mu Mu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Liang Liang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Jin Jin 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
BF, BF, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Xia Xia 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Q, Q, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Gong Gong 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
WL, WL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
XM, XM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
HY. HY. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Beijing Beijing 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biotechnology, Biotechnology, 1 0 0 0 1 0 0 0 14 0 NNP IN NNP NNP CD O
Beijing Beijing 1 0 0 0 0 0 0 0 7 0 IN NNP NNP CD NNP O
100071, 100071, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NN NNS O
damage damage 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NNS VBP O
triggers triggers 0 0 0 0 0 0 0 0 8 0 NNP NN NNS VBP NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NNS VBP NN JJS O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest NNS VBP NN JJS TO O
arrest arrest 0 0 0 0 0 0 0 0 6 0 VBP NN JJS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN JJS TO VB DT O
provide provide 0 0 0 0 0 0 0 0 7 0 JJS TO VB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT NN NN O
time time 0 0 0 0 0 0 0 0 4 0 VB DT NN NN IN O
window window 0 0 0 0 0 0 0 0 6 0 DT NN NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNP NNP O
repair. repair. 0 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP IN O
Failure Failure 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN JJS O
of of 0 0 0 0 0 0 0 0 2 arrest NNP NNP IN JJS MD O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NNP IN JJS MD VB O
could could 0 0 0 0 0 0 0 0 5 0 IN JJS MD VB TO O
lead lead 0 0 0 0 0 0 0 0 4 0 JJS MD VB TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 MD VB TO JJ NN O
genomic genomic 0 0 0 0 0 0 0 0 7 0 VB TO JJ NN CC O
instability instability 0 0 0 0 0 0 0 0 11 0 TO JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP NNP O
tumorigenesis. tumorigenesis. 0 0 0 0 0 0 0 0 14 0 NN CC NNP NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 CC NNP NNP NNP NNP O
damage-induced damage-induced 0 0 1 0 0 0 0 0 14 0 NNP NNP NNP NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 arrest NNP NNP NNP NN VBZ O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NNP NNP NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ RB VBN O
generally generally 0 0 0 0 0 0 0 0 9 0 NN VBZ RB VBN IN O
achieved achieved 0 0 0 0 0 0 0 0 8 0 VBZ RB VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 RB VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
Cyclin-dependent Cyclin-dependent 1 0 1 0 0 0 0 0 16 0 NN IN JJ NN NN O
kinase kinase 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN CD O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 JJ NN NN CD NNP O
1 1 0 0 0 0 0 0 1 1 1 0 NN NN CD NNP NNP O
(p21). (p21). 0 0 0 0 0 0 0 1 6 0 NN CD NNP NNP NNP O
However, However, 1 0 0 0 1 0 0 0 8 0 CD NNP NNP NNP VBZ O
p21 p21 0 0 0 0 0 0 0 1 3 0 NNP NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN CC O
degraded degraded 0 0 0 0 0 0 0 0 8 0 NNP VBZ VBN CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 VBZ VBN CC VBZ RB O
does does 0 0 0 0 0 0 0 0 4 0 VBN CC VBZ RB VB O
not not 0 0 0 0 0 0 0 0 3 0 CC VBZ RB VB DT O
play play 0 0 0 0 0 0 0 0 4 0 VBZ RB VB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 RB VB DT NN IN O
role role 0 0 0 0 0 0 0 0 4 0 VB DT NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
UV-induced UV-induced 1 0 1 0 0 0 0 0 10 0 NN IN JJ NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 IN JJ NNP NNP NNP B_TIMEXCCP
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 JJ NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NNP O
UV-induced UV-induced 1 0 1 0 0 0 0 0 10 0 NN IN JJ NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 arrest IN JJ NNP NN RB O
arrest arrest 0 0 0 0 0 0 0 0 6 0 JJ NNP NN RB VBZ O
thus thus 0 0 0 0 0 0 0 0 4 0 NNP NN RB VBZ NNP O
remains remains 0 0 0 0 0 0 0 0 7 0 NN RB VBZ NNP NNP O
elusive. elusive. 0 0 0 0 0 0 0 0 8 0 RB VBZ NNP NNP PRP O
Here, Here, 1 0 0 0 1 0 0 0 5 0 VBZ NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP PRP VBP VBN DT O
identified identified 0 0 0 0 0 0 0 0 10 0 PRP VBP VBN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBP VBN DT JJ NN O
critical critical 0 0 0 0 0 0 0 0 8 0 VBN DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NNP JJ O
CUE CUE 1 1 0 0 0 0 0 0 3 0 NN IN NNP JJ NN O
domain-containing domain-containing 0 0 1 0 0 0 0 0 17 0 IN NNP JJ NN CD O
protein protein 0 0 0 0 0 0 0 0 7 0 NNP JJ NN CD NN O
2 2 0 0 0 0 0 0 1 1 1 0 JJ NN CD NN IN O
(CUEDC2) (CUEDC2) 0 1 0 0 0 0 0 1 8 0 NN CD NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN DT NNP O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NNP NNP O
process. process. 0 0 0 0 0 0 0 0 8 0 IN DT NNP NNP VBZ O
CUEDC2 CUEDC2 1 1 0 0 0 0 0 1 6 0 DT NNP NNP VBZ TO O
binds binds 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ TO CC O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBZ TO CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 VBZ TO CC NNS JJ O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 TO CC NNS JJ -NONE- O
anaphase-promoting anaphase-promoting 0 0 1 0 0 0 0 0 18 0 CC NNS JJ -NONE- JJ O
complex/cyclosome-Cdh1 complex/cyclosome-Cdh1 0 0 1 1 0 0 0 1 22 0 NNS JJ -NONE- JJ DT O
(APC/C(Cdh1)), (APC/C(Cdh1)), 0 0 0 1 1 0 0 1 14 0 JJ -NONE- JJ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- JJ DT JJ NN O
critical critical 0 0 0 0 0 0 0 0 8 0 JJ DT JJ NN NN O
ubiquitin ubiquitin 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN IN O
ligase ligase 0 0 0 0 0 0 0 0 6 0 JJ NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 NN IN NNP NNP NN B_TIMEXCCP
phase, phase, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP NN VBG O
thereby thereby 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBG NNP O
stabilizing stabilizing 0 0 0 0 0 0 0 0 11 0 NNP NN VBG NNP DT O
Cyclin Cyclin 1 0 0 0 0 0 0 0 6 0 NN VBG NNP DT CC O
A A 1 1 0 0 0 0 0 0 1 0 VBG NNP DT CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 NNP DT CC VBG NNS O
promoting promoting 0 0 0 0 0 0 0 0 9 0 DT CC VBG NNS NNP O
G1-S G1-S 1 1 1 0 0 0 0 1 4 0 CC VBG NNS NNP NNP B_TIMEXCCP
transition. transition. 0 0 0 0 0 0 0 0 11 0 VBG NNS NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 NNS NNP NNP NN TO O
response response 0 0 0 0 0 0 0 0 8 0 NNP NNP NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO NNP NNP O
UV UV 1 1 0 0 0 0 0 0 2 0 NN TO NNP NNP NNP O
irradiation, irradiation, 0 0 0 0 1 0 0 0 12 0 TO NNP NNP NNP VBZ O
CUEDC2 CUEDC2 1 1 0 0 0 0 0 1 6 0 NNP NNP NNP VBZ JJ O
undergoes undergoes 0 0 0 0 0 0 0 0 9 0 NNP NNP VBZ JJ NN O
ERK1/2-dependent ERK1/2-dependent 1 0 1 1 0 0 0 1 16 0 NNP VBZ JJ NN CC O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 VBZ JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NN O
ubiquitin-dependent ubiquitin-dependent 0 0 1 0 0 0 0 0 19 0 NN CC JJ NN VBG O
degradation, degradation, 0 0 0 0 1 0 0 0 12 0 CC JJ NN VBG TO O
leading leading 0 0 0 0 0 0 0 0 7 0 JJ NN VBG TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NN VBG TO JJ NNP O
APC/C(Cdh1)-mediated APC/C(Cdh1)-mediated 1 0 1 1 0 0 0 1 20 0 VBG TO JJ NNP DT O
Cyclin Cyclin 1 0 0 0 0 0 0 0 6 0 TO JJ NNP DT NNP O
A A 1 1 0 0 0 0 0 0 1 0 JJ NNP DT NNP NNP O
destruction, destruction, 0 0 0 0 1 0 0 0 12 0 NNP DT NNP NNP NN O
Cyclin-dependent Cyclin-dependent 1 0 1 0 0 0 0 0 16 0 DT NNP NNP NN CD O
kinase kinase 0 0 0 0 0 0 0 0 6 0 NNP NNP NN CD NN O
2 2 0 0 0 0 0 0 1 1 1 0 NNP NN CD NN CC O
inactivation, inactivation, 0 0 0 0 1 0 0 0 13 0 NN CD NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 CD NN CC NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 NN CC NNP NNP NNP B_TIMEXCCP
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 CC NNP NNP NNP JJ O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP JJ NNP O
nonphosphorylatable nonphosphorylatable 0 0 0 0 0 0 0 0 19 0 NNP NNP JJ NNP NN O
CUEDC2 CUEDC2 1 1 0 0 0 0 0 1 6 0 NNP JJ NNP NN VBZ O
mutant mutant 0 0 0 0 0 0 0 0 6 0 JJ NNP NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ JJ TO O
resistant resistant 0 0 0 0 0 0 0 0 9 0 NN VBZ JJ TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO JJ NNP O
UV-induced UV-induced 1 0 1 0 0 0 0 0 10 0 JJ TO JJ NNP NNP O
degradation. degradation. 0 0 0 0 0 0 0 0 12 0 TO JJ NNP NNP IN O
Expression Expression 1 0 0 0 0 0 0 0 10 0 JJ NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP IN DT NN NN O
stable stable 0 0 0 0 0 0 0 0 6 0 IN DT NN NN RB O
mutant mutant 0 0 0 0 0 0 0 0 6 0 DT NN NN RB VBZ O
effectively effectively 0 0 0 0 0 0 0 0 11 0 NN NN RB VBZ JJ O
overrides overrides 0 0 0 0 0 0 0 0 9 0 NN RB VBZ JJ NNS O
UV-induced UV-induced 1 0 1 0 0 0 0 0 10 0 RB VBZ JJ NNS NNP O
G1-S G1-S 1 1 1 0 0 0 0 1 4 0 VBZ JJ NNS NNP NNP B_TIMEXCCP
block. block. 0 0 0 0 0 0 0 0 6 0 JJ NNS NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NNS NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP NNP O
establish establish 0 0 0 0 0 0 0 0 9 0 NNP NNS VBP NNP IN O
CUEDC2 CUEDC2 1 1 0 0 0 0 0 1 6 0 NNS VBP NNP IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VBP NNP IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NNP IN DT NN NN O
APC/C(Cdh1) APC/C(Cdh1) 1 0 0 1 0 0 0 1 11 0 IN DT NN NN CC O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 DT NN NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VB IN O
indicate indicate 0 0 0 0 0 0 0 0 8 0 NN CC VB IN VBN O
that that 0 0 0 0 0 0 0 0 4 0 CC VB IN VBN NNP O
regulated regulated 0 0 0 0 0 0 0 0 9 0 VB IN VBN NNP NN O
CUEDC2 CUEDC2 1 1 0 0 0 0 0 1 6 0 IN VBN NNP NN VBZ O
degradation degradation 0 0 0 0 0 0 0 0 11 0 VBN NNP NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ JJ IN O
critical critical 0 0 0 0 0 0 0 0 8 0 NN VBZ JJ IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN JJ NNP O
UV-induced UV-induced 1 0 1 0 0 0 0 0 10 0 JJ IN JJ NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 IN JJ NNP NNP NONE B_TIMEXCCP
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 JJ NNP NNP NONE NONE O
Immunoglobulin Immunoglobulin 1 0 0 0 0 0 0 0 14 0 NONE NONE NNP NNP CC O
G1 G1 1 1 0 0 0 0 0 1 2 0 NONE NNP NNP CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC VB NNP O
immunoglobulin immunoglobulin 0 0 0 0 0 0 0 0 14 0 NNP CC VB NNP NNS O
G4 G4 1 1 0 0 0 0 0 1 2 0 CC VB NNP NNS IN O
antibodies antibodies 0 0 0 0 0 0 0 0 10 0 VB NNP NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NN NN O
multiple multiple 0 0 0 0 0 0 0 0 8 0 NNS IN NN NN NNS O
sclerosis sclerosis 0 0 0 0 0 0 0 0 9 0 IN NN NN NNS VBD O
patients patients 0 0 0 0 0 0 0 0 8 0 NN NN NNS VBD IN O
treated treated 0 0 0 0 0 0 0 0 7 0 NN NNS VBD IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBD IN JJ NN O
IFNβ IFNβ 1 0 0 0 0 0 0 0 4 0 VBD IN JJ NN IN O
interact interact 0 0 0 0 0 0 0 0 8 0 IN JJ NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
endogenous endogenous 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN CC O
cytokine cytokine 0 0 0 0 0 0 0 0 8 0 DT JJ NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VB NNP O
activate activate 0 0 0 0 0 0 0 0 8 0 NN CC VB NNP NNP O
complement. complement. 0 0 0 0 0 0 0 0 11 0 CC VB NNP NNP NNP O
Sethu Sethu 1 0 0 0 0 0 0 0 5 0 VB NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Govindappa Govindappa 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Quinn Quinn 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wadhwa Wadhwa 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Stebbings Stebbings 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Boggild Boggild 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Naisbitt Naisbitt 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kimber Kimber 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
I, I, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Pirmohamed Pirmohamed 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Park Park 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sathish Sathish 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
J. J. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
MRC MRC 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP IN O
Centre Centre 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNP O
Drug Drug 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP NNP O
Safety Safety 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP CC O
Science Science 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP CC NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NNP IN NNP NNP O
Translational Translational 1 0 0 0 0 0 0 0 13 0 NNP IN NNP NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Clinical Clinical 1 0 0 0 0 0 0 0 8 0 NNP CC NNP NNP NNP O
Pharmacology, Pharmacology, 1 0 0 0 1 0 0 0 13 0 CC NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Liverpool, Liverpool, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP NNP O
Sherrington Sherrington 1 0 0 0 0 0 0 0 11 0 IN NNP NNP NNP NNP O
Buildings, Buildings, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Liverpool Liverpool 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP CD O
L69 L69 1 1 0 0 0 0 0 1 3 0 NNP NNP NNP CD NNP O
3GE, 3GE, 0 1 0 0 1 0 0 1 4 0 NNP NNP CD NNP NNP O
UK. UK. 1 1 0 0 0 0 0 0 3 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NN O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NN IN O
subset subset 0 0 0 0 0 0 0 0 6 0 NNP NNP NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 NN IN NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN JJ NNS O
relapsing-remitting relapsing-remitting 0 0 1 0 0 0 0 0 19 0 NNS IN JJ NNS VBZ O
multiple multiple 0 0 0 0 0 0 0 0 8 0 IN JJ NNS VBZ JJ O
sclerosis sclerosis 0 0 0 0 0 0 0 0 9 0 JJ NNS VBZ JJ IN O
(RRMS) (RRMS) 0 1 0 0 0 0 0 0 6 0 NNS VBZ JJ IN NN O
on on 0 0 0 0 0 0 0 0 2 0 VBZ JJ IN NN IN O
therapy therapy 0 0 0 0 0 0 0 0 7 0 JJ IN NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN NN NN O
interferon interferon 0 0 0 0 0 0 0 0 10 0 NN IN NN NN NN O
beta beta 0 0 0 0 0 0 0 0 4 0 IN NN NN NN NN O
(IFNβ) (IFNβ) 0 0 0 0 0 0 0 0 6 0 NN NN NN NN VBG O
develop develop 0 0 0 0 0 0 0 0 7 0 NN NN NN VBG JJ O
neutralising neutralising 0 0 0 0 0 0 0 0 12 0 NN NN VBG JJ NNS O
anti-drug anti-drug 0 0 1 0 0 0 0 0 9 0 NN VBG JJ NNS -NONE- O
antibodies antibodies 0 0 0 0 0 0 0 0 10 0 VBG JJ NNS -NONE- VBG O
(ADA) (ADA) 0 1 0 0 0 0 0 0 5 0 JJ NNS -NONE- VBG IN O
resulting resulting 0 0 0 0 0 0 0 0 9 0 NNS -NONE- VBG IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- VBG IN JJ CC O
reduced, reduced, 0 0 0 0 1 0 0 0 8 0 VBG IN JJ CC NN O
or or 0 0 0 0 0 0 0 0 2 0 IN JJ CC NN NN O
loss loss 0 0 0 0 0 0 0 0 4 0 JJ CC NN NN JJ O
of, of, 0 0 0 0 1 0 0 0 3 0 CC NN NN JJ NNP O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 NN NN JJ NNP NNP O
efficacy. efficacy. 0 0 0 0 0 0 0 0 9 0 NN JJ NNP NNP VBZ O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP VBZ VBD O
aims aims 0 0 0 0 0 0 0 0 4 0 NNP NNP VBZ VBD TO O
were were 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ VBD TO VB DT O
characterise characterise 0 0 0 0 0 0 0 0 12 0 VBD TO VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJ NNS O
relative relative 0 0 0 0 0 0 0 0 8 0 VB DT JJ NNS IN O
contributions contributions 0 0 0 0 0 0 0 0 13 0 DT JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
anti-IFNβ anti-IFNβ 0 0 1 0 0 0 0 0 9 0 NNS IN JJ NN NNS O
antibody antibody 0 0 0 0 0 0 0 0 8 0 IN JJ NN NNS TO O
isotypes isotypes 0 0 0 0 0 0 0 0 8 0 JJ NN NNS TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO NN NN O
drug drug 0 0 0 0 0 0 0 0 4 0 NNS TO NN NN NN O
neutralising neutralising 0 0 0 0 0 0 0 0 12 0 TO NN NN NN NN O
activity, activity, 0 0 0 0 1 0 0 0 9 0 NN NN NN NN IN O
ability ability 0 0 0 0 0 0 0 0 7 0 NN NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT NNS TO O
antibodies antibodies 0 0 0 0 0 0 0 0 10 0 IN DT NNS TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 DT NNS TO JJ IN O
cross-react cross-react 0 0 1 0 0 0 0 0 11 0 NNS TO JJ IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 TO JJ IN JJ NN O
endogenous endogenous 0 0 0 0 0 0 0 0 10 0 JJ IN JJ NN TO O
IFNβ, IFNβ, 1 0 0 0 1 0 0 0 5 0 IN JJ NN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO NN NN O
form form 0 0 0 0 0 0 0 0 4 0 NN TO NN NN NNS O
immune immune 0 0 0 0 0 0 0 0 6 0 TO NN NN NNS CC O
complexes complexes 0 0 0 0 0 0 0 0 9 0 NN NN NNS CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC VB NNP O
activate activate 0 0 0 0 0 0 0 0 8 0 NNS CC VB NNP NNP O
complement. complement. 0 0 0 0 0 0 0 0 11 0 CC VB NNP NNP NNP O
IFNβ-specific IFNβ-specific 1 0 1 0 0 0 0 0 13 0 VB NNP NNP NNP VBD O
ADA ADA 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD VBN IN O
measured measured 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN IN O
plasma plasma 0 0 0 0 0 0 0 0 6 0 VBN IN NN IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 IN NN IN NNP NNS O
RRMS RRMS 1 1 0 0 0 0 0 0 4 0 NN IN NNP NNS VBD O
patients patients 0 0 0 0 0 0 0 0 8 0 IN NNP NNS VBD IN O
treated treated 0 0 0 0 0 0 0 0 7 0 NNP NNS VBD IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBD IN JJ NNP O
IFNβ1a IFNβ1a 1 0 0 0 0 0 0 1 6 0 VBD IN JJ NNP NNP O
(Rebif(®)). (Rebif(®)). 0 0 0 0 0 0 0 0 11 0 IN JJ NNP NNP IN O
Neutralisation Neutralisation 1 0 0 0 0 0 0 0 14 0 JJ NNP NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ CC O
endogenous endogenous 0 0 0 0 0 0 0 0 10 0 NNP IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NN O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 JJ CC JJ NN IN O
IFNβ IFNβ 1 0 0 0 0 0 0 0 4 0 CC JJ NN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP VBD O
ADA ADA 1 1 0 0 0 0 0 0 3 0 NN IN NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 IN NNP VBD VBN IN O
determined determined 0 0 0 0 0 0 0 0 10 0 NNP VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
IFNβ IFNβ 1 0 0 0 0 0 0 0 4 0 VBN IN NNP NNP NNP O
bioassay. bioassay. 0 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP NN O
IFNβ-ADA IFNβ-ADA 1 0 1 0 0 0 0 0 8 0 NNP NNP NNP NN VBD O
profile profile 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD RB VBN O
predominantly predominantly 0 0 0 0 0 0 0 0 13 0 NN VBD RB VBN IN O
comprised comprised 0 0 0 0 0 0 0 0 9 0 VBD RB VBN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 RB VBN IN NNP CC O
IgG1 IgG1 1 0 0 0 0 0 0 1 4 0 VBN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NN O
IgG4 IgG4 1 0 0 0 0 0 0 1 4 0 NNP CC NNP NN NNP O
antibody antibody 0 0 0 0 0 0 0 0 8 0 CC NNP NN NNP NNP O
isotypes. isotypes. 0 0 0 0 0 0 0 0 9 0 NNP NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
contribution contribution 0 0 0 0 0 0 0 0 12 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NNS O
IgG4-ADA IgG4-ADA 1 0 1 0 0 0 0 1 8 0 NN IN NNP NNS VBG O
towards towards 0 0 0 0 0 0 0 0 7 0 IN NNP NNS VBG NN O
neutralising neutralising 0 0 0 0 0 0 0 0 12 0 NNP NNS VBG NN VBD O
activity activity 0 0 0 0 0 0 0 0 8 0 NNS VBG NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 VBG NN VBD VBN TO O
found found 0 0 0 0 0 0 0 0 5 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB NNP O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB NNP NNP O
minimal. minimal. 0 0 0 0 0 0 0 0 8 0 TO VB NNP NNP NNP O
Neutralising Neutralising 1 0 0 0 0 0 0 0 12 0 VB NNP NNP NNP VBZ O
IFNβ-ADA IFNβ-ADA 1 0 1 0 0 0 0 0 8 0 NNP NNP NNP VBZ JJ O
blocks blocks 0 0 0 0 0 0 0 0 6 0 NNP NNP VBZ JJ NN O
endogenous endogenous 0 0 0 0 0 0 0 0 10 0 NNP VBZ JJ NN NNP O
IFNβ IFNβ 1 0 0 0 0 0 0 0 4 0 VBZ JJ NN NNP NNP O
activity. activity. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NNP NN O
ADA ADA 1 1 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
interaction interaction 0 0 0 0 0 0 0 0 11 0 NNP NNP NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNP NN IN JJ NN O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 NN IN JJ NN NNS O
IFNβ IFNβ 1 0 0 0 0 0 0 0 4 0 IN JJ NN NNS IN O
results results 0 0 0 0 0 0 0 0 7 0 JJ NN NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NN O
immune immune 0 0 0 0 0 0 0 0 6 0 NNS IN NN NN NN O
complex complex 0 0 0 0 0 0 0 0 7 0 IN NN NN NN CC O
formation formation 0 0 0 0 0 0 0 0 9 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NNP O
complement complement 0 0 0 0 0 0 0 0 10 0 NN CC NN NNP NNP O
activation. activation. 0 0 0 0 0 0 0 0 11 0 CC NN NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NNP NNP O
summary, summary, 0 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP CC O
IgG1 IgG1 1 0 0 0 0 0 0 1 4 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
IgG4 IgG4 1 0 0 0 0 0 0 1 4 0 NNP CC NNP NNP VBP O
IFNβ-ADA IFNβ-ADA 1 0 1 0 0 0 0 0 8 0 CC NNP NNP VBP DT O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNP VBP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBP DT NN TO O
ability ability 0 0 0 0 0 0 0 0 7 0 VBP DT NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO VB JJ O
neutralise neutralise 0 0 0 0 0 0 0 0 10 0 NN TO VB JJ CC O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 TO VB JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VB JJ CC JJ NN O
endogenous endogenous 0 0 0 0 0 0 0 0 10 0 JJ CC JJ NN CC O
protein protein 0 0 0 0 0 0 0 0 7 0 CC JJ NN CC TO O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN CC TO VB NNP O
activate activate 0 0 0 0 0 0 0 0 8 0 CC TO VB NNP NONE O
complement. complement. 0 0 0 0 0 0 0 0 11 0 TO VB NNP NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NN NNP O
netrin netrin 0 0 0 0 0 0 0 0 6 0 NONE DT NN NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 0 DT NN NNP NN NNP O
gene gene 0 0 0 0 0 0 0 0 4 0 NN NNP NN NNP NN O
rs628117 rs628117 0 0 0 0 0 0 0 1 8 0 NNP NN NNP NN VBZ O
polymorphism polymorphism 0 0 0 0 0 0 0 0 12 0 NN NNP NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NN VBZ VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN JJ NNP O
ischemic ischemic 0 0 0 0 0 0 0 0 8 0 VBN IN JJ NNP NNP O
stroke. stroke. 0 0 0 0 0 0 0 0 7 0 IN JJ NNP NNP NNP O
Stepanyan Stepanyan 1 0 0 0 0 0 0 0 9 0 JJ NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zakharyan Zakharyan 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Boyajyan Boyajyan 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
A. A. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP IN NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP NNP O
National National 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Academy Academy 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNPS O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNPS IN O
Sciences Sciences 1 0 0 0 0 0 0 0 8 0 NNP IN NNPS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NNPS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNPS IN DT NNP IN O
Republic Republic 1 0 0 0 0 0 0 0 8 0 IN DT NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNP IN NNP NNP O
Armenia Armenia 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
(NAS (NAS 0 1 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNP O
RA), RA), 1 1 0 0 1 0 0 0 4 0 NNP NNP NNP NNP NNP O
Armenia. Armenia. 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNS O
Recent Recent 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNS VBD O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 NNP NNS VBD IN RB O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN RB VBG O
naturally naturally 0 0 0 0 0 0 0 0 9 0 VBD IN RB VBG JJ O
occurring occurring 0 0 0 0 0 0 0 0 9 0 IN RB VBG JJ NNS O
genetic genetic 0 0 0 0 0 0 0 0 7 0 RB VBG JJ NNS IN O
alterations alterations 0 0 0 0 0 0 0 0 11 0 VBG JJ NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ JJ O
synaptic synaptic 0 0 0 0 0 0 0 0 8 0 NNS IN JJ JJ NNS O
plasticity-related plasticity-related 0 0 1 0 0 0 0 0 18 0 IN JJ JJ NNS MD O
genes genes 0 0 0 0 0 0 0 0 5 0 JJ JJ NNS MD VB O
may may 0 0 0 0 0 0 0 0 3 0 JJ NNS MD VB DT O
influence influence 0 0 0 0 0 0 0 0 9 0 NNS MD VB DT NN O
both both 0 0 0 0 0 0 0 0 4 0 MD VB DT NN NN O
stroke stroke 0 0 0 0 0 0 0 0 6 0 VB DT NN NN CC O
progression progression 0 0 0 0 0 0 0 0 11 0 DT NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ JJ O
poor poor 0 0 0 0 0 0 0 0 4 0 NN CC JJ JJ NN O
functional functional 0 0 0 0 0 0 0 0 10 0 CC JJ JJ NN IN O
recovery recovery 0 0 0 0 0 0 0 0 8 0 JJ JJ NN IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 JJ NN IN NNP NNP O
stroke. stroke. 0 0 0 0 0 0 0 0 7 0 NN IN NNP NNP NNP O
Netrin Netrin 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP VBZ O
G1 G1 1 1 0 0 0 0 0 1 2 0 NNP NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNP VBZ DT JJ NN O
axonal axonal 0 0 0 0 0 0 0 0 6 0 VBZ DT JJ NN VBN O
protein protein 0 0 0 0 0 0 0 0 7 0 DT JJ NN VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 JJ NN VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN VBN IN JJ NNP O
synaptic synaptic 0 0 0 0 0 0 0 0 8 0 VBN IN JJ NNP NNP O
plasticity. plasticity. 0 0 0 0 0 0 0 0 11 0 IN JJ NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
present present 0 0 0 0 0 0 0 0 7 0 NNP DT NN NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 DT NN NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NN NN PRP VBD DT O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 NN PRP VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT JJ NN O
potential potential 0 0 0 0 0 0 0 0 9 0 VBD DT JJ NN IN O
association association 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
netrin netrin 0 0 0 0 0 0 0 0 6 0 IN DT NN NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 0 DT NN NNP NN NNP O
gene gene 0 0 0 0 0 0 0 0 4 0 NN NNP NN NNP JJ O
rs628117 rs628117 0 0 0 0 0 0 0 1 8 0 NNP NN NNP JJ NN O
single single 0 0 0 0 0 0 0 0 6 0 NN NNP JJ NN NN O
nucleotide nucleotide 0 0 0 0 0 0 0 0 10 0 NNP JJ NN NN IN O
polymorphism polymorphism 0 0 0 0 0 0 0 0 12 0 JJ NN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ NN O
ischemic ischemic 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN IN O
stroke stroke 0 0 0 0 0 0 0 0 6 0 IN JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT JJ NNP O
Armenian Armenian 1 0 0 0 0 0 0 0 8 0 IN DT JJ NNP NNP O
population. population. 0 0 0 0 0 0 0 0 11 0 DT JJ NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NNP CD O
total, total, 0 0 0 0 1 0 0 0 6 0 NNP NNP NNP CD NNS O
127 127 0 0 0 0 0 0 1 1 3 0 NNP NNP CD NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 NNP CD NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 CD NNS IN JJ NN O
ischemic ischemic 0 0 0 0 0 0 0 0 8 0 NNS IN JJ NN CC O
stroke stroke 0 0 0 0 0 0 0 0 6 0 IN JJ NN CC CD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC CD JJ O
128 128 0 0 0 0 0 0 1 1 3 0 NN CC CD JJ NNS O
healthy healthy 0 0 0 0 0 0 0 0 7 0 CC CD JJ NNS -NONE- O
subjects subjects 0 0 0 0 0 0 0 0 8 0 CD JJ NNS -NONE- VBD O
(controls) (controls) 0 0 0 0 0 0 0 0 10 0 JJ NNS -NONE- VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNS -NONE- VBD VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 -NONE- VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NNP O
this this 0 0 0 0 0 0 0 0 4 0 VBN IN DT NNP NNP O
study. study. 0 0 0 0 0 0 0 0 6 0 IN DT NNP NNP NNP O
Genomic Genomic 1 0 0 0 0 0 0 0 7 0 DT NNP NNP NNP VBZ O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP VBZ IN O
samples samples 0 0 0 0 0 0 0 0 7 0 NNP NNP VBZ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN JJ NN O
ischemic ischemic 0 0 0 0 0 0 0 0 8 0 VBZ IN JJ NN NNS O
stroke stroke 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNS CC O
patients patients 0 0 0 0 0 0 0 0 8 0 JJ NN NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NNS VBD O
controls controls 0 0 0 0 0 0 0 0 8 0 NNS CC NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 CC NNS VBD VBN IN O
genotyped genotyped 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN NN NNP O
netrin netrin 0 0 0 0 0 0 0 0 6 0 VBN IN NN NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 0 IN NN NNP NN -NONE- O
gene gene 0 0 0 0 0 0 0 0 4 0 NN NNP NN -NONE- NNP O
(NTNG1) (NTNG1) 0 1 0 0 0 0 0 1 7 0 NNP NN -NONE- NNP JJ O
rs628117 rs628117 0 0 0 0 0 0 0 1 8 0 NN -NONE- NNP JJ NN O
single single 0 0 0 0 0 0 0 0 6 0 -NONE- NNP JJ NN NN O
nucleotide nucleotide 0 0 0 0 0 0 0 0 10 0 NNP JJ NN NN VBG O
polymorphism polymorphism 0 0 0 0 0 0 0 0 12 0 JJ NN NN VBG NN O
using using 0 0 0 0 0 0 0 0 5 0 NN NN VBG NN NN O
polymerase polymerase 0 0 0 0 0 0 0 0 10 0 NN VBG NN NN NN O
chain chain 0 0 0 0 0 0 0 0 5 0 VBG NN NN NN IN O
reaction reaction 0 0 0 0 0 0 0 0 8 0 NN NN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ NNP O
sequence-specific sequence-specific 0 0 1 0 0 0 0 0 17 0 NN IN JJ NNP NNP O
primers. primers. 0 0 0 0 0 0 0 0 8 0 IN JJ NNP NNP VBD O
Data Data 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD VBN IN O
analyzed analyzed 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
Pearson's Pearson's 1 0 0 0 0 1 0 0 9 0 VBN IN NNP NNP NNP O
χ(2) χ(2) 0 0 0 0 0 0 0 1 4 0 IN NNP NNP NNP NNP O
test. test. 0 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS VBD O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD VBN O
obtained obtained 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD VBN NNP O
implicated implicated 0 0 0 0 0 0 0 0 10 0 NNS VBD VBN NNP JJ O
rs628117 rs628117 0 0 0 0 0 0 0 1 8 0 VBD VBN NNP JJ NN O
single single 0 0 0 0 0 0 0 0 6 0 VBN NNP JJ NN NN O
nucleotide nucleotide 0 0 0 0 0 0 0 0 10 0 NNP JJ NN NN IN O
polymorphism polymorphism 0 0 0 0 0 0 0 0 12 0 JJ NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP IN O
NTNG1 NTNG1 1 1 0 0 0 0 0 1 5 0 NN IN NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NN IN O
pathogenesis pathogenesis 0 0 0 0 0 0 0 0 12 0 NNP IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NNP O
ischemic ischemic 0 0 0 0 0 0 0 0 8 0 NN IN JJ NNP NNP O
stroke. stroke. 0 0 0 0 0 0 0 0 7 0 IN JJ NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NNP PRP O
particular, particular, 0 0 0 0 1 0 0 0 11 0 NNP NNP NNP PRP VBD O
it it 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP PRP VBD VBN IN O
shown shown 0 0 0 0 0 0 0 0 5 0 PRP VBD VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 VBD VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NNP O
NTNG1 NTNG1 1 1 0 0 0 0 0 1 5 0 IN DT NNP NNP NN O
rs628117*G rs628117*G 0 0 0 0 0 0 0 1 10 0 DT NNP NNP NN NN O
minor minor 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NN VBZ O
allele allele 0 0 0 0 0 0 0 0 6 0 NNP NN NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ RB VBN O
positively positively 0 0 0 0 0 0 0 0 10 0 NN VBZ RB VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 VBZ RB VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN JJ NN O
ischemic ischemic 0 0 0 0 0 0 0 0 8 0 VBN IN JJ NN CC O
stroke stroke 0 0 0 0 0 0 0 0 6 0 IN JJ NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NNS IN O
carriers carriers 0 0 0 0 0 0 0 0 8 0 CC DT NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNS IN DT NN VBD O
allele allele 0 0 0 0 0 0 0 0 6 0 IN DT NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 DT NN VBD VBN IN O
overrepresented overrepresented 0 0 0 0 0 0 0 0 15 0 NN VBD VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NN O
ischemic ischemic 0 0 0 0 0 0 0 0 8 0 VBN IN JJ NN NNS O
stroke stroke 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNS VBN O
patients patients 0 0 0 0 0 0 0 0 8 0 JJ NN NNS VBN IN O
compared compared 0 0 0 0 0 0 0 0 8 0 NN NNS VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBN IN NNP NNP O
controls. controls. 0 0 0 0 0 0 0 0 9 0 VBN IN NNP NNP NN O
Our Our 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NN VBZ O
finding finding 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBZ DT O
nominates nominates 0 0 0 0 0 0 0 0 9 0 NNP NN VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT NN NNP O
minor minor 0 0 0 0 0 0 0 0 5 0 VBZ DT NN NNP NN O
G G 1 1 0 0 0 0 0 0 1 0 DT NN NNP NN IN O
allele allele 0 0 0 0 0 0 0 0 6 0 NN NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
NTNG1 NTNG1 1 1 0 0 0 0 0 1 5 0 IN DT NNP NNP JJ O
rs628117 rs628117 0 0 0 0 0 0 0 1 8 0 DT NNP NNP JJ NN O
single single 0 0 0 0 0 0 0 0 6 0 NNP NNP JJ NN NN O
nucleotide nucleotide 0 0 0 0 0 0 0 0 10 0 NNP JJ NN NN IN O
polymorphism polymorphism 0 0 0 0 0 0 0 0 12 0 JJ NN NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN NN O
risk risk 0 0 0 0 0 0 0 0 4 0 IN DT NN NN IN O
factor factor 0 0 0 0 0 0 0 0 6 0 DT NN NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN JJ NN O
ischemic ischemic 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN IN O
stroke stroke 0 0 0 0 0 0 0 0 6 0 IN JJ NN IN JJS O
at at 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJS IN O
least least 0 0 0 0 0 0 0 0 5 0 NN IN JJS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN JJS IN NNP NNP O
Armenian Armenian 1 0 0 0 0 0 0 0 8 0 JJS IN NNP NNP NONE O
population. population. 0 0 0 0 0 0 0 0 11 0 IN NNP NNP NONE NONE O
MiR-7 MiR-7 1 0 1 0 0 0 0 1 5 0 NONE NONE NN NNS VBP O
triggers triggers 0 0 0 0 0 0 0 0 8 0 NONE NN NNS VBP NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NNS VBP NN JJS O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest NNS VBP NN JJS IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 VBP NN JJS IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NN JJS IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 JJS IN DT NNS NN O
G1/S G1/S 1 1 0 1 0 0 0 1 4 0 IN DT NNS NN IN B_TIMEXCCP
transition transition 0 0 0 0 0 0 0 0 10 0 DT NNS NN IN VBG O
by by 0 0 0 0 0 0 0 0 2 0 NNS NN IN VBG NN O
targeting targeting 0 0 0 0 0 0 0 0 9 0 NN IN VBG NN NNS O
multiple multiple 0 0 0 0 0 0 0 0 8 0 IN VBG NN NNS VBG O
genes genes 0 0 0 0 0 0 0 0 5 0 VBG NN NNS VBG NNP O
including including 0 0 0 0 0 0 0 0 9 0 NN NNS VBG NNP CC O
Skp2 Skp2 1 0 0 0 0 0 0 1 4 0 NNS VBG NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VBG NNP CC NNP NNP O
Psme3. Psme3. 1 0 0 0 0 0 0 1 6 0 NNP CC NNP NNP NNP O
Sanchez Sanchez 1 0 0 0 0 0 0 0 7 0 CC NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Gallagher Gallagher 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lao Lao 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Gallagher Gallagher 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Clarke Clarke 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Doolan Doolan 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Aherne Aherne 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Blanco Blanco 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Meleady Meleady 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Clynes Clynes 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Barron Barron 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
N. N. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
National National 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNP O
Cellular Cellular 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Biotechnology, Biotechnology, 1 0 0 0 1 0 0 0 14 0 IN NNP NNP NNP NNP O
Dublin Dublin 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
City City 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Dublin, Dublin, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Ireland. Ireland. 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
MiR-7 MiR-7 1 0 1 0 0 0 0 1 5 0 NNP NNP NNP VBZ IN O
acts acts 0 0 0 0 0 0 0 0 4 0 NNP NNP VBZ IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBZ IN DT NN NN O
tumour tumour 0 0 0 0 0 0 0 0 6 0 IN DT NN NN IN O
suppressor suppressor 0 0 0 0 0 0 0 0 10 0 DT NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNS O
many many 0 0 0 0 0 0 0 0 4 0 NN IN JJ NNS CC O
cancers cancers 0 0 0 0 0 0 0 0 7 0 IN JJ NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC NNS NN O
abrogates abrogates 0 0 0 0 0 0 0 0 9 0 NNS CC NNS NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 CC NNS NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNS NN IN NNP NNS O
CHO CHO 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NNP NNP O
culture. culture. 0 0 0 0 0 0 0 0 8 0 NNS IN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 IN NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
study study 0 0 0 0 0 0 0 0 5 0 NNP DT NN PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBP IN O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 NN PRP VBP IN -NONE- O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN -NONE- NNS O
miR-7 miR-7 0 0 1 0 0 0 0 1 5 0 VBP IN -NONE- NNS JJ O
targets targets 0 0 0 0 0 0 0 0 7 0 IN -NONE- NNS JJ NNS O
key key 0 0 0 0 0 0 0 0 3 0 -NONE- NNS JJ NNS IN O
regulators regulators 0 0 0 0 0 0 0 0 10 0 NNS JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP TO O
G1 G1 1 1 0 0 0 0 0 1 2 0 IN DT NNP TO NNP B_TIMEXCCP
to to 0 0 0 0 0 0 0 0 2 0 DT NNP TO NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase NNP TO NNP NN -NONE- B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 TO NNP NN -NONE- VBG O
transition, transition, 0 0 0 0 1 0 0 0 11 0 NNP NN -NONE- VBG NNP O
including including 0 0 0 0 0 0 0 0 9 0 NN -NONE- VBG NNP CC O
Skp2 Skp2 1 0 0 0 0 0 0 1 4 0 -NONE- VBG NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VBG NNP CC NNP TO O
Psme3, Psme3, 1 0 0 0 1 0 0 1 6 0 NNP CC NNP TO VB O
to to 0 0 0 0 0 0 0 0 2 0 CC NNP TO VB VBN O
promote promote 0 0 0 0 0 0 0 0 7 0 NNP TO VB VBN NNS O
increased increased 0 0 0 0 0 0 0 0 9 0 TO VB VBN NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 VB VBN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBN NNS IN JJ CC O
p27(KIP) p27(KIP) 0 0 0 0 0 0 0 1 8 0 NNS IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NN O
temporary temporary 0 0 0 0 0 0 0 0 9 0 JJ CC JJ NN NN O
growth growth 0 0 0 0 0 0 0 0 6 arrest CC JJ NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 JJ NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNS O
CHO CHO 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 IN DT NNP NNP NNP O
phase. phase. 0 0 0 0 0 0 0 0 6 0 DT NNP NNP NNP DT O
Simultaneously, Simultaneously, 1 0 0 0 1 0 0 0 15 0 NNP NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
down-regulation down-regulation 0 0 1 0 0 0 0 0 15 0 NNP DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNP VBZ O
repair-specific repair-specific 0 0 1 0 0 0 0 0 15 0 IN NNP NNP VBZ IN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ IN -NONE- O
via via 0 0 0 0 0 0 0 0 3 0 NNP VBZ IN -NONE- VBG O
miR-7 miR-7 0 0 1 0 0 0 0 1 5 0 VBZ IN -NONE- VBG NN O
including including 0 0 0 0 0 0 0 0 9 0 IN -NONE- VBG NN CC O
Rad54L, Rad54L, 1 0 0 0 1 0 0 1 7 0 -NONE- VBG NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBG NN CC JJ NNS O
pro-apoptotic pro-apoptotic 0 0 1 0 0 0 0 0 13 0 NN CC JJ NNS JJ O
regulators regulators 0 0 0 0 0 0 0 0 10 0 CC JJ NNS JJ IN O
such such 0 0 0 0 0 0 0 0 4 0 JJ NNS JJ IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 NNS JJ IN JJ VBN O
p53, p53, 0 0 0 0 1 0 0 1 4 0 JJ IN JJ VBN IN O
combined combined 0 0 0 0 0 0 0 0 8 0 IN JJ VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 JJ VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
up-regulation up-regulation 0 0 1 0 0 0 0 0 13 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
anti-apoptotic anti-apoptotic 0 0 1 0 0 0 0 0 14 0 NN IN JJ NNS IN O
factors factors 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN NN O
like like 0 0 0 0 0 0 0 0 4 0 JJ NNS IN NN VBN O
p-Akt, p-Akt, 0 0 1 0 1 0 0 0 6 0 NNS IN NN VBN NN O
promoted promoted 0 0 0 0 0 0 0 0 8 0 IN NN VBN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN VBN NN NN IN O
survival survival 0 0 0 0 0 0 0 0 8 0 VBN NN NN IN VBN O
while while 0 0 0 0 0 0 0 0 5 0 NN NN IN VBN IN O
arrested arrested 0 0 0 0 0 0 0 0 8 0 NN IN VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN VBN IN NNP NNP O
G1. G1. 1 1 0 0 0 0 0 1 3 0 VBN IN NNP NNP NNP B_TIMEXCCP
Thus Thus 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP MD O
miR-7 miR-7 0 0 1 0 0 0 0 1 5 0 NNP NNP NNP MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NNP NNP MD VB DT O
co-ordinate co-ordinate 0 0 1 0 0 0 0 0 11 0 NNP MD VB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 VB DT NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NN NNS O
multiple multiple 0 0 0 0 0 0 0 0 8 0 NNS IN NN NNS CC O
genes genes 0 0 0 0 0 0 0 0 5 0 IN NN NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NNS TO O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NNS CC NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 CC NNS TO VB NNP O
influence influence 0 0 0 0 0 0 0 0 9 0 NNS TO VB NNP TO O
G1 G1 1 1 0 0 0 0 0 1 2 0 TO VB NNP TO NNP B_TIMEXCCP
to to 0 0 0 0 0 0 0 0 2 0 VB NNP TO NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase NNP TO NNP NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 TO NNP NN NN CC O
transition transition 0 0 0 0 0 0 0 0 10 0 NNP NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT JJ NN O
apoptotic apoptotic 0 0 0 0 0 0 0 0 9 0 CC DT JJ NN IN O
response response 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN TO O
order order 0 0 0 0 0 0 0 0 5 0 NN IN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB JJ O
maintain maintain 0 0 0 0 0 0 0 0 8 0 NN TO VB JJ NNP O
cellular cellular 0 0 0 0 0 0 0 0 8 0 TO VB JJ NNP NNP O
homeostasis. homeostasis. 0 0 0 0 0 0 0 0 12 0 VB JJ NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NN VBZ O
work work 0 0 0 0 0 0 0 0 4 0 NNP NNP NN VBZ RB O
provides provides 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ RB JJ O
further further 0 0 0 0 0 0 0 0 7 0 NN VBZ RB JJ NN O
mechanistic mechanistic 0 0 0 0 0 0 0 0 11 0 VBZ RB JJ NN IN O
insight insight 0 0 0 0 0 0 0 0 7 0 RB JJ NN IN DT O
into into 0 0 0 0 0 0 0 0 4 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
role role 0 0 0 0 0 0 0 0 4 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
miR-7 miR-7 0 0 1 0 0 0 0 1 5 0 NN IN NNP IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT NN IN O
regulator regulator 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 IN NN NN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNS IN O
times times 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN JJ NNP O
cellular cellular 0 0 0 0 0 0 0 0 8 0 NNS IN JJ NNP NONE O
stress. stress. 0 0 0 0 0 0 0 0 7 0 IN JJ NNP NONE NONE O
Prenylated Prenylated 1 0 0 0 0 0 0 0 10 0 NONE NONE NNP NNP IN O
Flavonoids Flavonoids 1 0 0 0 0 0 0 0 10 0 NONE NNP NNP IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNP IN NNP NN O
Morus Morus 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NN NNP O
alba alba 0 0 0 0 0 0 0 0 4 0 IN NNP NN NNP NNP O
L. L. 1 1 0 0 0 0 0 0 2 0 NNP NN NNP NNP NNP O
Cause Cause 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP IN O
Inhibition Inhibition 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
G1/S G1/S 1 1 0 1 0 0 0 1 4 0 NNP IN NNP NNP IN B_TIMEXCCP
Transition Transition 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN -NONE- O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN -NONE- NNP O
THP-1 THP-1 1 1 1 0 0 0 0 1 5 0 NNP IN -NONE- NNP NNP O
Human Human 1 0 0 0 0 0 0 0 5 0 IN -NONE- NNP NNP NNP O
Leukemia Leukemia 1 0 0 0 0 0 0 0 8 0 -NONE- NNP NNP NNP CC O
Cells Cells 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP DT O
Prevent Prevent 1 0 0 0 0 0 0 0 7 0 NNP CC NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CC NNP DT JJ NNP O
Lipopolysaccharide-Induced Lipopolysaccharide-Induced 1 0 1 0 0 0 0 0 26 0 NNP DT JJ NNP NNP O
Inflammatory Inflammatory 1 0 0 0 0 0 0 0 12 0 DT JJ NNP NNP NNP O
Response. Response. 1 0 0 0 0 0 0 0 9 0 JJ NNP NNP NNP NNP O
Kollar Kollar 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Bárta Bárta 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hošek Hošek 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Souček Souček 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Závalová Závalová 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
VM, VM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Artinian Artinian 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Talhouk Talhouk 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Smejkal Smejkal 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Suchý Suchý 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
P P 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NNP NNP O
Jr, Jr, 1 0 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Hampl Hampl 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
A. A. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Human Human 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP CC O
Pharmacology Pharmacology 1 0 0 0 0 0 0 0 12 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Toxicology, Toxicology, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP IN O
Faculty Faculty 1 0 0 0 0 0 0 0 7 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pharmacy, Pharmacy, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Veterinary Veterinary 1 0 0 0 0 0 0 0 10 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNPS O
Pharmaceutical Pharmaceutical 1 0 0 0 0 0 0 0 14 0 NNP CC NNP NNPS NNP O
Sciences Sciences 1 0 0 0 0 0 0 0 8 0 CC NNP NNPS NNP NNP O
Brno, Brno, 1 0 0 0 1 0 0 0 5 0 NNP NNPS NNP NNP CD O
Palackého Palackého 1 0 0 0 0 0 0 0 9 0 NNPS NNP NNP CD CD O
1-3, 1-3, 0 0 1 0 1 0 0 1 4 0 NNP NNP CD CD CD O
612 612 0 0 0 0 0 0 1 1 3 0 NNP CD CD CD JJ O
42 42 0 0 0 0 0 0 1 1 2 0 CD CD CD JJ JJ O
Brno, Brno, 1 0 0 0 1 0 0 0 5 0 CD CD JJ JJ NNP O
Czech Czech 1 0 0 0 0 0 0 0 5 0 CD JJ JJ NNP NNP O
Republic. Republic. 1 0 0 0 0 0 0 0 9 0 JJ JJ NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP NNP NN O
Morus Morus 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NN NNP O
alba alba 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NNP NNP O
L. L. 1 1 0 0 0 0 0 0 2 0 NNP NN NNP NNP VBZ O
(MA) (MA) 0 1 0 0 0 0 0 0 4 0 NN NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT JJ NN O
natural natural 0 0 0 0 0 0 0 0 7 0 VBZ DT JJ NN IN O
source source 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNS O
many many 0 0 0 0 0 0 0 0 4 0 NN IN JJ NNS IN O
compounds compounds 0 0 0 0 0 0 0 0 9 0 IN JJ NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 JJ NNS IN JJ JJ O
different different 0 0 0 0 0 0 0 0 9 0 NNS IN JJ JJ NNP O
biological biological 0 0 0 0 0 0 0 0 10 0 IN JJ JJ NNP NNP O
effects. effects. 0 0 0 0 0 0 0 0 8 0 JJ JJ NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP NNP VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBN VBN TO O
described described 0 0 0 0 0 0 0 0 9 0 VBZ VBN VBN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO NN NN O
possess possess 0 0 0 0 0 0 0 0 7 0 VBN TO NN NN NN O
anti-inflammatory, anti-inflammatory, 0 0 1 0 1 0 0 0 18 0 TO NN NN NN CC O
antioxidant, antioxidant, 0 0 0 0 1 0 0 0 12 0 NN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NNP O
hepatoprotective hepatoprotective 0 0 0 0 0 0 0 0 16 0 NN CC JJ NNP NNP O
activities. activities. 0 0 0 0 0 0 0 0 11 0 CC JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
aim aim 0 0 0 0 0 0 0 0 3 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 IN DT NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB NN O
evaluate evaluate 0 0 0 0 0 0 0 0 8 0 VBD TO VB NN IN O
cytotoxicity cytotoxicity 0 0 0 0 0 0 0 0 12 0 TO VB NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 VB NN IN CD NNS O
three three 0 0 0 0 0 0 0 0 5 0 NN IN CD NNS VBN O
flavonoids flavonoids 0 0 0 0 0 0 0 0 10 0 IN CD NNS VBN IN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 CD NNS VBN IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBN IN NNP NNP O
MA MA 1 1 0 0 0 0 0 0 2 0 VBN IN NNP NNP NNP O
(kuwanon (kuwanon 0 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NN O
E, E, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NN -NONE- O
cudraflavone cudraflavone 0 0 0 0 0 0 0 0 12 0 NNP NNP NN -NONE- CC O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NN -NONE- CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC CD NN O
4'-O-methylkuwanon 4'-O-methylkuwanon 0 0 1 0 0 1 0 1 18 0 -NONE- CC CD NN CC O
E) E) 1 1 0 0 0 0 0 0 2 0 CC CD NN CC TO O
and and 0 0 0 0 0 0 0 0 3 0 CD NN CC TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN CC TO VB PRP$ O
determine determine 0 0 0 0 0 0 0 0 9 0 CC TO VB PRP$ NNS O
their their 0 0 0 0 0 0 0 0 5 0 TO VB PRP$ NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 VB PRP$ NNS IN NN O
on on 0 0 0 0 0 0 0 0 2 0 PRP$ NNS IN NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NNS IN NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN -NONE- JJ O
THP-1 THP-1 1 1 1 0 0 0 0 1 5 0 NN IN -NONE- JJ CC O
cells, cells, 0 0 0 0 1 0 0 0 6 0 IN -NONE- JJ CC IN O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- JJ CC IN NN O
on on 0 0 0 0 0 0 0 0 2 0 JJ CC IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 CC IN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN NN IN O
progression progression 0 0 0 0 0 0 0 0 11 0 NN NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NN NNP NNP VBZ O
Anti-inflammatory Anti-inflammatory 1 0 1 0 0 0 0 0 17 0 NN NNP NNP VBZ VBD O
effects effects 0 0 0 0 0 0 0 0 7 0 NNP NNP VBZ VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBD RB VBN O
also also 0 0 0 0 0 0 0 0 4 0 VBZ VBD RB VBN IN O
determined determined 0 0 0 0 0 0 0 0 10 0 VBD RB VBN IN PDT O
for for 0 0 0 0 0 0 0 0 3 0 RB VBN IN PDT CD O
all all 0 0 0 0 0 0 0 0 3 0 VBN IN PDT CD VBN O
three three 0 0 0 0 0 0 0 0 5 0 IN PDT CD VBN NNP O
given given 0 0 0 0 0 0 0 0 5 0 PDT CD VBN NNP NNP O
flavonoids. flavonoids. 0 0 0 0 0 0 0 0 11 0 CD VBN NNP NNP VBD O
Methods Methods 1 0 0 0 0 0 0 0 7 0 VBN NNP NNP VBD IN O
used used 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 IN DT NN VBD NN O
included included 0 0 0 0 0 0 0 0 8 0 DT NN VBD NN IN O
quantification quantification 0 0 0 0 0 0 0 0 14 0 NN VBD NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN NN O
by by 0 0 0 0 0 0 0 0 2 0 IN NNS IN NN CC O
hemocytometer hemocytometer 0 0 0 0 0 0 0 0 13 0 NNS IN NN CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC -NONE- JJ O
WST-1 WST-1 1 1 1 0 0 0 0 1 5 0 NN CC -NONE- JJ NN O
assays, assays, 0 0 0 0 1 0 0 0 7 0 CC -NONE- JJ NN NN O
flow flow 0 0 0 0 0 0 0 0 4 0 -NONE- JJ NN NN NN O
cytometry, cytometry, 0 0 0 0 1 0 0 0 10 0 JJ NN NN NN NN O
western western 0 0 0 0 0 0 0 0 7 0 NN NN NN NN NN O
blotting, blotting, 0 0 0 0 1 0 0 0 9 0 NN NN NN NN CC O
ELISA, ELISA, 1 1 0 0 1 0 0 0 6 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
zymography. zymography. 0 0 0 0 0 0 0 0 11 0 NN CC NNP NNP DT O
From From 1 0 0 0 0 0 0 0 4 0 CC NNP NNP DT CD O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT CD NNS O
three three 0 0 0 0 0 0 0 0 5 0 NNP DT CD NNS -NONE- O
compounds compounds 0 0 0 0 0 0 0 0 9 0 DT CD NNS -NONE- NN O
tested, tested, 0 0 0 0 1 0 0 0 7 0 CD NNS -NONE- NN NNP O
cudraflavone cudraflavone 0 0 0 0 0 0 0 0 12 0 NNS -NONE- NN NNP VBD O
B B 1 1 0 0 0 0 0 0 1 0 -NONE- NN NNP VBD DT O
showed showed 0 0 0 0 0 0 0 0 6 0 NN NNP VBD DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT JJS NNS O
strongest strongest 0 0 0 0 0 0 0 0 9 0 VBD DT JJS NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 DT JJS NNS IN NN O
on on 0 0 0 0 0 0 0 0 2 0 JJS NNS IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN NN CC O
progression progression 0 0 0 0 0 0 0 0 11 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
viability viability 0 0 0 0 0 0 0 0 9 0 NN CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NN IN NN NN VBD O
and/or and/or 0 0 0 1 0 0 0 0 6 0 IN NN NN VBD NNS O
immortalized immortalized 0 0 0 0 0 0 0 0 12 0 NN NN VBD NNS CC O
cells cells 0 0 0 0 0 0 0 0 5 0 NN VBD NNS CC RB O
and and 0 0 0 0 0 0 0 0 3 0 VBD NNS CC RB IN O
also also 0 0 0 0 0 0 0 0 4 0 NNS CC RB IN NN O
on on 0 0 0 0 0 0 0 0 2 0 CC RB IN NN NN O
inflammatory inflammatory 0 0 0 0 0 0 0 0 12 0 RB IN NN NN IN O
response response 0 0 0 0 0 0 0 0 8 0 IN NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNP O
macrophage-like macrophage-like 0 0 1 0 0 0 0 0 15 0 NN IN JJ NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP NNP O
Kuwanon Kuwanon 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP NNP CC O
E E 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC CD NNP O
4'-O-methylkuwanon 4'-O-methylkuwanon 0 0 1 0 0 1 0 1 18 0 NNP CC CD NNP VBD O
E E 1 1 0 0 0 0 0 0 1 0 CC CD NNP VBD JJR O
exerted exerted 0 0 0 0 0 0 0 0 7 0 CD NNP VBD JJR JJ O
more more 0 0 0 0 0 0 0 0 4 0 NNP VBD JJR JJ RB O
sophisticated sophisticated 0 0 0 0 0 0 0 0 13 0 VBD JJR JJ RB IN O
rather rather 0 0 0 0 0 0 0 0 6 0 JJR JJ RB IN JJ O
than than 0 0 0 0 0 0 0 0 4 0 JJ RB IN JJ JJ O
direct direct 0 0 0 0 0 0 0 0 6 0 RB IN JJ JJ NN O
toxic toxic 0 0 0 0 0 0 0 0 5 0 IN JJ JJ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 JJ JJ NN IN VBN O
on on 0 0 0 0 0 0 0 0 2 0 JJ NN IN VBN NN O
used used 0 0 0 0 0 0 0 0 4 0 NN IN VBN NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN VBN NN NNP NNP O
types. types. 0 0 0 0 0 0 0 0 6 0 VBN NN NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS VBP O
data data 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS VBP IN O
indicate indicate 0 0 0 0 0 0 0 0 8 0 NNP NNS VBP IN NNS O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NNS JJ O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 VBP IN NNS JJ IN O
different different 0 0 0 0 0 0 0 0 9 0 IN NNS JJ IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NNS JJ IN JJ CC O
stress-related stress-related 0 0 1 0 0 0 0 0 14 0 JJ IN JJ CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 IN JJ CC JJ NN O
apoptotic apoptotic 0 0 0 0 0 0 0 0 9 0 JJ CC JJ NN NNS O
signaling signaling 0 0 0 0 0 0 0 0 9 0 CC JJ NN NNS VBP O
pathways pathways 0 0 0 0 0 0 0 0 8 0 JJ NN NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NN NNS VBP VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 NNS VBP VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBP VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
action action 0 0 0 0 0 0 0 0 6 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT NNP NNP O
compounds. compounds. 0 0 0 0 0 0 0 0 10 0 IN DT NNP NNP RB O
Although Although 1 0 0 0 0 0 0 0 8 0 DT NNP NNP RB VBZ O
further further 0 0 0 0 0 0 0 0 7 0 NNP NNP RB VBZ VBP O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP RB VBZ VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 RB VBZ VBP VBN TO O
required required 0 0 0 0 0 0 0 0 8 0 VBZ VBP VBN TO RB O
to to 0 0 0 0 0 0 0 0 2 0 VBP VBN TO RB VB O
precisely precisely 0 0 0 0 0 0 0 0 9 0 VBN TO RB VB DT O
define define 0 0 0 0 0 0 0 0 6 0 TO RB VB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 RB VB DT NNS IN O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 VB DT NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NNP VBD O
MA MA 1 1 0 0 0 0 0 0 2 0 NNS IN NNP VBD NN O
flavonoid flavonoid 0 0 0 0 0 0 0 0 9 0 IN NNP VBD NN IN O
action action 0 0 0 0 0 0 0 0 6 0 NNP VBD NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBD NN IN NN NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN NN NN CC O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
macrophage-like macrophage-like 0 0 1 0 0 0 0 0 15 0 NN CC JJ NN RB O
cells, cells, 0 0 0 0 1 0 0 0 6 0 CC JJ NN RB PRP O
here here 0 0 0 0 0 0 0 0 4 0 JJ NN RB PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NN RB PRP VBP PRP$ O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 RB PRP VBP PRP$ NNS O
their their 0 0 0 0 0 0 0 0 5 0 PRP VBP PRP$ NNS VBG O
effects effects 0 0 0 0 0 0 0 0 7 0 VBP PRP$ NNS VBG JJ O
combining combining 0 0 0 0 0 0 0 0 9 0 PRP$ NNS VBG JJ CC O
antiproliferative antiproliferative 0 0 0 0 0 0 0 0 17 0 NNS VBG JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBG JJ CC JJ NN O
anti-inflammatory anti-inflammatory 0 0 1 0 0 0 0 0 17 0 JJ CC JJ NN NNP O
activities, activities, 0 0 0 0 1 0 0 0 11 0 CC JJ NN NNP NONE O
respectively. respectively. 0 0 0 0 0 0 0 0 13 0 JJ NN NNP NONE NONE O
MicroRNA-23b MicroRNA-23b 1 0 1 0 0 0 0 1 12 0 NONE NONE NN NNS IN O
Functions Functions 1 0 0 0 0 0 0 0 9 0 NONE NN NNS IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT NNP NNP O
Tumor Tumor 1 0 0 0 0 0 0 0 5 0 IN DT NNP NNP IN O
Suppressor Suppressor 1 0 0 0 0 0 0 0 10 0 DT NNP NNP IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Regulating Regulating 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP IN O
Zeb1 Zeb1 1 0 0 0 0 0 0 1 4 0 IN NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Bladder Bladder 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
Cancer. Cancer. 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
Majid Majid 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Dar Dar 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
AA, AA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Saini Saini 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Deng Deng 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Chang Chang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
I, I, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Greene Greene 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tanaka Tanaka 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Dahiya Dahiya 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yamamura Yamamura 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
S. S. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Urology, Urology, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP NNP O
VA VA 1 1 0 0 0 0 0 0 2 0 IN NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP CC O
Center Center 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
UCSF, UCSF, 1 1 0 0 1 0 0 0 5 0 NNP CC NNP NNP NNP O
San San 1 0 0 0 0 0 0 0 3 0 CC NNP NNP NNP NNP O
Francisco, Francisco, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
California, California, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNPS O
United United 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNPS IN O
States States 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
America. America. 1 0 0 0 0 0 0 0 8 0 NNPS IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
MicroRNAs MicroRNAs 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP VBP O
(miRNAs) (miRNAs) 0 0 0 0 0 0 0 0 8 0 NNP NNP NNP VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNP VBP JJ JJ O
small, small, 0 0 0 0 1 0 0 0 6 0 NNP VBP JJ JJ NNP O
non-coding non-coding 0 0 1 0 0 0 0 0 10 0 VBP JJ JJ NNP IN O
RNAs RNAs 1 0 0 0 0 0 0 0 4 0 JJ JJ NNP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 JJ NNP IN JJ NN O
regulate regulate 0 0 0 0 0 0 0 0 8 0 NNP IN JJ NN NN O
gene gene 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 JJ NN NN IN VBN O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN VBN NN O
targeted targeted 0 0 0 0 0 0 0 0 8 0 NN IN VBN NN IN O
repression repression 0 0 0 0 0 0 0 0 10 0 IN VBN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NN CC O
transcription transcription 0 0 0 0 0 0 0 0 13 0 NN IN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NNP NNP O
translation. translation. 0 0 0 0 0 0 0 0 12 0 NN CC NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 CC NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
study study 0 0 0 0 0 0 0 0 5 0 NNP DT NN PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NN PRP VBP IN -NONE- O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN -NONE- -NONE- O
miRNA-23b miRNA-23b 0 0 1 0 0 0 0 1 9 0 VBP IN -NONE- -NONE- VBZ O
(miR-23b) (miR-23b) 0 0 1 0 0 0 0 1 9 0 IN -NONE- -NONE- VBZ IN O
acts acts 0 0 0 0 0 0 0 0 4 0 -NONE- -NONE- VBZ IN DT O
as as 0 0 0 0 0 0 0 0 2 0 -NONE- VBZ IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBZ IN DT NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 IN DT NN NN IN O
suppressor suppressor 0 0 0 0 0 0 0 0 10 0 DT NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NNP O
bladder bladder 0 0 0 0 0 0 0 0 7 0 NN IN NN NNP NNP O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NNP NNP O
Quantitative Quantitative 1 0 0 0 0 0 0 0 12 0 NN NNP NNP NNP NNP O
real-time real-time 0 0 1 0 0 0 0 0 9 0 NNP NNP NNP NNP NN O
PCR PCR 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NN VBD IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN JJ VBZ O
miR-23b miR-23b 0 0 1 0 0 0 0 1 7 0 VBD IN JJ VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 IN JJ VBZ RB JJ O
significantly significantly 0 0 0 0 0 0 0 0 13 0 JJ VBZ RB JJ IN O
down-regulated down-regulated 0 0 1 0 0 0 0 0 14 0 VBZ RB JJ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 RB JJ IN NN NN O
bladder bladder 0 0 0 0 0 0 0 0 7 0 JJ IN NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN NN NN NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NNS CC O
lines lines 0 0 0 0 0 0 0 0 5 0 NN NN NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NN NNS O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NNS CC NN NNS VBN O
tissues tissues 0 0 0 0 0 0 0 0 7 0 CC NN NNS VBN TO O
compared compared 0 0 0 0 0 0 0 0 8 0 NN NNS VBN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBN TO JJ NNS O
non-malignant non-malignant 0 0 1 0 0 0 0 0 13 0 VBN TO JJ NNS CC O
cells cells 0 0 0 0 0 0 0 0 5 0 TO JJ NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC JJ NN O
normal normal 0 0 0 0 0 0 0 0 6 0 NNS CC JJ NN NNP O
tissue tissue 0 0 0 0 0 0 0 0 6 0 CC JJ NN NNP NNP O
samples. samples. 0 0 0 0 0 0 0 0 8 0 JJ NN NNP NNP RB O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP RB VBP O
also also 0 0 0 0 0 0 0 0 4 0 NNP NNP RB VBP IN O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 NNP RB VBP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 RB VBP IN JJ NN O
miR-23b miR-23b 0 0 1 0 0 0 0 1 7 0 VBP IN JJ NN VBZ O
expression expression 0 0 0 0 0 0 0 0 10 0 IN JJ NN VBZ DT O
has has 0 0 0 0 0 0 0 0 3 0 JJ NN VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT JJ TO O
potential potential 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT JJ TO VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 JJ TO VB JJ CC O
diagnostic diagnostic 0 0 0 0 0 0 0 0 10 0 TO VB JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VB JJ CC JJ NN O
prognostic prognostic 0 0 0 0 0 0 0 0 10 0 JJ CC JJ NN IN O
biomarker biomarker 0 0 0 0 0 0 0 0 9 0 CC JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNP O
bladder bladder 0 0 0 0 0 0 0 0 7 0 NN IN NN NNP NNP O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NNP NNP O
High High 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NNP NN O
miR-23b miR-23b 0 0 1 0 0 0 0 1 7 0 NNP NNP NNP NN VBZ O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP NNP NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ RB VBN O
positively positively 0 0 0 0 0 0 0 0 10 0 NN VBZ RB VBN IN O
correlated correlated 0 0 0 0 0 0 0 0 10 0 VBZ RB VBN IN JJR O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN JJR JJ O
higher higher 0 0 0 0 0 0 0 0 6 0 VBN IN JJR JJ NN O
overall overall 0 0 0 0 0 0 0 0 7 0 IN JJR JJ NN IN O
survival survival 0 0 0 0 0 0 0 0 8 0 JJR JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
bladder bladder 0 0 0 0 0 0 0 0 7 0 NN IN NN NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN NN NN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 NN NN NNS IN VBN O
as as 0 0 0 0 0 0 0 0 2 0 NN NNS IN VBN IN O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NNS IN VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 IN VBN IN JJ NNP O
Kaplan-Meier Kaplan-Meier 1 0 1 0 0 0 0 0 12 0 VBN IN JJ NNP NNP O
analysis. analysis. 0 0 0 0 0 0 0 0 9 0 IN JJ NNP NNP NN O
ROC ROC 1 1 0 0 0 0 0 0 3 0 JJ NNP NNP NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NN VBD IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN JJ NN O
miR-23b miR-23b 0 0 1 0 0 0 0 1 7 0 VBD IN JJ NN MD O
expression expression 0 0 0 0 0 0 0 0 10 0 IN JJ NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 JJ NN MD VB IN O
distinguish distinguish 0 0 0 0 0 0 0 0 11 0 NN MD VB IN JJ O
between between 0 0 0 0 0 0 0 0 7 0 MD VB IN JJ CC O
normal normal 0 0 0 0 0 0 0 0 6 0 VB IN JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC NN NN O
bladder bladder 0 0 0 0 0 0 0 0 7 0 JJ CC NN NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 CC NN NN NNP NNP O
tissues. tissues. 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP PRP O
Further Further 1 0 0 0 0 0 0 0 7 0 NN NNP NNP PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD DT O
elucidated elucidated 0 0 0 0 0 0 0 0 10 0 NNP PRP VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT JJ NN O
biological biological 0 0 0 0 0 0 0 0 10 0 VBD DT JJ NN IN O
significance significance 0 0 0 0 0 0 0 0 12 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP IN O
miR-23b miR-23b 0 0 1 0 0 0 0 1 7 0 NN IN NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NN NNP O
bladder bladder 0 0 0 0 0 0 0 0 7 0 NNP IN NN NNP NN O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NN IN O
Over-expression Over-expression 1 0 1 0 0 0 0 0 15 0 NN NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP IN O
miR-23b miR-23b 0 0 1 0 0 0 0 1 7 0 NN IN NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NN NN O
bladder bladder 0 0 0 0 0 0 0 0 7 0 NNP IN NN NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN NN NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS VBD NN O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NN NNS VBD NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNS VBD NN NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VBD NN NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBD NN O
impaired impaired 0 0 0 0 0 0 0 0 8 0 NN CC VBD NN NNP O
colony colony 0 0 0 0 0 0 0 0 6 0 CC VBD NN NNP NNP O
formation. formation. 0 0 0 0 0 0 0 0 10 0 VBD NN NNP NNP VBD O
Fluorescence Fluorescence 1 0 0 0 0 0 0 0 12 0 NN NNP NNP VBD NN O
activated activated 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP VBD NN NN NN O
sorting sorting 0 0 0 0 0 0 0 0 7 0 VBD NN NN NN NN O
(FACS) (FACS) 0 1 0 0 0 0 0 0 6 0 NN NN NN NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NN NN NN VBD IN O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN NN IN O
re-expression re-expression 0 0 1 0 0 0 0 0 13 0 VBD IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP IN O
miR-23b miR-23b 0 0 1 0 0 0 0 1 7 0 NN IN NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NN NN O
bladder bladder 0 0 0 0 0 0 0 0 7 0 NNP IN NN NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN NN NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS VBD -NONE- O
induced induced 0 0 0 0 0 0 0 0 7 0 NN NNS VBD -NONE- NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NNS VBD -NONE- NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 VBD -NONE- NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest -NONE- NN NN NN CC O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN CC NN IN VBG O
while while 0 0 0 0 0 0 0 0 5 0 CC NN IN VBG NN O
inhibiting inhibiting 0 0 0 0 0 0 0 0 10 0 NN IN VBG NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN VBG NN NN CC O
migration migration 0 0 0 0 0 0 0 0 9 0 VBG NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
invasion. invasion. 0 0 0 0 0 0 0 0 9 0 NN CC NNP NNP NN O
Luciferase Luciferase 1 0 0 0 0 0 0 0 10 0 CC NNP NNP NN VBZ O
reporter reporter 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBZ VBN O
assays assays 0 0 0 0 0 0 0 0 6 0 NNP NN VBZ VBN IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 NN VBZ VBN IN -NONE- O
that that 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN -NONE- DT O
Zeb1, Zeb1, 1 0 0 0 1 0 0 1 5 0 VBN IN -NONE- DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 IN -NONE- DT JJ NN O
crucial crucial 0 0 0 0 0 0 0 0 7 0 -NONE- DT JJ NN IN O
regulator regulator 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
epithelial-to-mesenchymal epithelial-to-mesenchymal 0 0 1 0 0 0 0 0 25 0 NN IN JJ NN NN O
transition transition 0 0 0 0 0 0 0 0 10 0 IN JJ NN NN VBZ O
(EMT), (EMT), 0 1 0 0 1 0 0 0 6 0 JJ NN NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT JJ NN O
direct direct 0 0 0 0 0 0 0 0 6 0 VBZ DT JJ NN IN O
target target 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ IN O
miR-23b miR-23b 0 0 1 0 0 0 0 1 7 0 NN IN JJ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN JJ IN NN NNP O
bladder bladder 0 0 0 0 0 0 0 0 7 0 JJ IN NN NNP NNP O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NN IN O
loss loss 0 0 0 0 0 0 0 0 4 0 VBP IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNS O
miR-23b miR-23b 0 0 1 0 0 0 0 1 7 0 NN IN NNP NNS DT O
confers confers 0 0 0 0 0 0 0 0 7 0 IN NNP NNS DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNS DT JJ NN O
proliferative proliferative 0 0 0 0 0 0 0 0 13 0 NNS DT JJ NN CC O
advantage advantage 0 0 0 0 0 0 0 0 9 0 DT JJ NN CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBZ NN O
promotes promotes 0 0 0 0 0 0 0 0 8 0 NN CC VBZ NN NN O
bladder bladder 0 0 0 0 0 0 0 0 7 0 CC VBZ NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 VBZ NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN CC O
migration migration 0 0 0 0 0 0 0 0 9 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
invasion. invasion. 0 0 0 0 0 0 0 0 9 0 NN CC NNP NNP NNP O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 CC NNP NNP NNP IN O
re-expression re-expression 0 0 1 0 0 0 0 0 13 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP MD O
miR-23b miR-23b 0 0 1 0 0 0 0 1 7 0 NNP IN NNP MD VB O
may may 0 0 0 0 0 0 0 0 3 0 IN NNP MD VB DT O
be be 0 0 0 0 0 0 0 0 2 0 NNP MD VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT JJ JJ O
beneficial beneficial 0 0 0 0 0 0 0 0 10 0 VB DT JJ JJ NN O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 DT JJ JJ NN IN O
strategy strategy 0 0 0 0 0 0 0 0 8 0 JJ JJ NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN NN NN NNP O
bladder bladder 0 0 0 0 0 0 0 0 7 0 IN NN NN NNP NONE O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NONE NONE O
Dabrafenib; Dabrafenib; 1 0 0 0 0 0 0 0 11 0 NONE NONE NN NNP NNP O
Preclinical Preclinical 1 0 0 0 0 0 0 0 11 0 NONE NN NNP NNP NNP O
Characterization, Characterization, 1 0 0 0 1 0 0 0 17 0 NN NNP NNP NNP NNP O
Increased Increased 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP WRB O
Efficacy Efficacy 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP WRB NNP O
when when 0 0 0 0 0 0 0 0 4 0 NNP NNP WRB NNP IN O
Combined Combined 1 0 0 0 0 0 0 0 8 0 NNP WRB NNP IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 WRB NNP IN JJ IN O
Trametinib, Trametinib, 1 0 0 0 1 0 0 0 11 0 NNP IN JJ IN JJ O
while while 0 0 0 0 0 0 0 0 5 0 IN JJ IN JJ NNP O
BRAF/MEK BRAF/MEK 1 1 0 1 0 0 0 0 8 0 JJ IN JJ NNP NNP O
Tool Tool 1 0 0 0 0 0 0 0 4 0 IN JJ NNP NNP NNP O
Combination Combination 1 0 0 0 0 0 0 0 11 0 JJ NNP NNP NNP NNP O
Reduced Reduced 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Skin Skin 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Lesions. Lesions. 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
King King 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
AJ, AJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Arnone Arnone 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
MR, MR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Bleam Bleam 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
MR, MR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Moss Moss 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
KG, KG, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Yang Yang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Fedorowicz Fedorowicz 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
KE, KE, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Smitheman Smitheman 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
KN, KN, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Erhardt Erhardt 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
JA, JA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Hughes-Earle Hughes-Earle 1 0 1 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kane-Carson Kane-Carson 1 0 1 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
LS, LS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Sinnamon Sinnamon 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
RH, RH, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Qi Qi 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Rheault Rheault 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
TR, TR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Uehling Uehling 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
DE, DE, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Laquerre Laquerre 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
SG. SG. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
GlaxoSmithKline GlaxoSmithKline 1 0 0 0 0 0 0 0 15 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Oncology Oncology 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP NNP O
Collegeville, Collegeville, 1 0 0 0 1 0 0 0 13 0 NNP NNP NNP NNP NNP O
Pennsylvania, Pennsylvania, 1 0 0 0 1 0 0 0 13 0 NNP NNP NNP NNP NNPS O
United United 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNPS IN O
States States 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
America. America. 1 0 0 0 0 0 0 0 8 0 NNPS IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
Mitogen-Activated Mitogen-Activated 1 0 1 0 0 0 0 0 17 0 NNP NNP NNP NNP NNP O
Protein Protein 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Kinase Kinase 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NN O
(MAPK) (MAPK) 0 1 0 0 0 0 0 0 6 0 NNP NNP NNP NN NN O
pathway pathway 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN VBZ O
activation activation 0 0 0 0 0 0 0 0 10 0 NNP NN NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NN NN VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN VBN IN O
implicated implicated 0 0 0 0 0 0 0 0 10 0 VBZ VBN VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN JJ NNS O
many many 0 0 0 0 0 0 0 0 4 0 VBN IN JJ NNS IN O
types types 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NNP O
human human 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NNP NNP O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 IN JJ NNP NNP NNS O
BRAF BRAF 1 1 0 0 0 0 0 0 4 0 JJ NNP NNP NNS WDT O
mutations mutations 0 0 0 0 0 0 0 0 9 0 NNP NNP NNS WDT RB O
that that 0 0 0 0 0 0 0 0 4 0 NNP NNS WDT RB VBP O
constitutively constitutively 0 0 0 0 0 0 0 0 14 0 NNS WDT RB VBP NNP O
activate activate 0 0 0 0 0 0 0 0 8 0 WDT RB VBP NNP NN O
MAPK MAPK 1 1 0 0 0 0 0 0 4 0 RB VBP NNP NN CC O
signalling signalling 0 0 0 0 0 0 0 0 10 0 VBP NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN DT O
bypass bypass 0 0 0 0 0 0 0 0 6 0 NN CC NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC NN DT NN IN O
need need 0 0 0 0 0 0 0 0 4 0 NN DT NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN NN NN O
upstream upstream 0 0 0 0 0 0 0 0 8 0 NN IN NN NN NN O
stimuli stimuli 0 0 0 0 0 0 0 0 7 0 IN NN NN NN IN O
occur occur 0 0 0 0 0 0 0 0 5 0 NN NN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 NN IN JJ NN IN O
prevalence prevalence 0 0 0 0 0 0 0 0 10 0 IN JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
melanoma, melanoma, 0 0 0 0 1 0 0 0 9 0 NN IN NNP NN -NONE- O
colorectal colorectal 0 0 0 0 0 0 0 0 10 0 IN NNP NN -NONE- JJ O
carcinoma, carcinoma, 0 0 0 0 1 0 0 0 10 0 NNP NN -NONE- JJ NN O
ovarian ovarian 0 0 0 0 0 0 0 0 7 0 NN -NONE- JJ NN NN O
cancer, cancer, 0 0 0 0 1 0 0 0 7 0 -NONE- JJ NN NN VBD O
papillary papillary 0 0 0 0 0 0 0 0 9 0 JJ NN NN VBD JJ O
thyroid thyroid 0 0 0 0 0 0 0 0 7 0 NN NN VBD JJ CC O
carcinoma, carcinoma, 0 0 0 0 1 0 0 0 10 0 NN VBD JJ CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VBD JJ CC NNP NNP O
cholangiocarcinoma. cholangiocarcinoma. 0 0 0 0 0 0 0 0 19 0 JJ CC NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 CC NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
report report 0 0 0 0 0 0 0 0 6 0 NNP DT NN PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBP DT O
characterize characterize 0 0 0 0 0 0 0 0 12 0 NN PRP VBP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBP DT NNP NNP O
novel, novel, 0 0 0 0 1 0 0 0 6 0 VBP DT NNP NNP CC O
potent, potent, 0 0 0 0 1 0 0 0 7 0 DT NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NNP O
selective selective 0 0 0 0 0 0 0 0 9 0 NNP CC JJ NNP NNP O
BRAF BRAF 1 1 0 0 0 0 0 0 4 0 CC JJ NNP NNP NN O
inhibitor, inhibitor, 0 0 0 0 1 0 0 0 10 0 JJ NNP NNP NN NNP O
dabrafenib dabrafenib 0 0 0 0 0 0 0 0 10 0 NNP NNP NN NNP NNP O
(GSK2118436). (GSK2118436). 0 1 0 0 0 0 0 1 13 0 NNP NN NNP NNP NN O
Cellular Cellular 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NN O
BRAF(V600E) BRAF(V600E) 1 1 0 0 0 0 0 1 11 0 NN IN NNP NN NN O
kinase kinase 0 0 0 0 0 0 0 0 6 0 IN NNP NN NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NNP NN NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NN VBD O
dabrafenib dabrafenib 0 0 0 0 0 0 0 0 10 0 NN IN NN VBD IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 IN NN VBD IN VBN O
in in 0 0 0 0 0 0 0 0 2 0 NN VBD IN VBN NNP O
decreased decreased 0 0 0 0 0 0 0 0 9 0 VBD IN VBN NNP CC O
MEK MEK 1 1 0 0 0 0 0 0 3 0 IN VBN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VBN NNP CC NNP NN O
ERK ERK 1 1 0 0 0 0 0 0 3 0 NNP CC NNP NN CC O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 CC NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 NN CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 IN NN NN IN DT O
through through 0 0 0 0 0 0 0 0 7 0 NN NN IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT JJ NNP O
initial initial 0 0 0 0 0 0 0 0 7 0 IN DT JJ NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 0 DT JJ NNP NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NNP NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NNP NN NN NN VBD O
arrest, arrest, 0 0 0 0 1 0 0 0 7 0 NN NN NN VBD IN O
followed followed 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 VBD IN NN NNP NNP O
death. death. 0 0 0 0 0 0 0 0 6 0 IN NN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT JJ NN O
BRAF(V600E)-containing BRAF(V600E)-containing 1 0 1 0 0 0 0 1 22 0 NNP DT JJ NN NN O
xenograft xenograft 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN IN O
model model 0 0 0 0 0 0 0 0 5 0 JJ NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN RB O
melanoma, melanoma, 0 0 0 0 1 0 0 0 9 0 IN JJ NN RB VBN O
orally orally 0 0 0 0 0 0 0 0 6 0 JJ NN RB VBN NN O
administered administered 0 0 0 0 0 0 0 0 12 0 NN RB VBN NN VBN O
dabrafenib dabrafenib 0 0 0 0 0 0 0 0 10 0 RB VBN NN VBN NNP O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 VBN NN VBN NNP NNP O
ERK ERK 1 1 0 0 0 0 0 0 3 0 NN VBN NNP NNP VBD O
activation, activation, 0 0 0 0 1 0 0 0 11 0 VBN NNP NNP VBD NNP O
downregulated downregulated 0 0 0 0 0 0 0 0 13 0 NNP NNP VBD NNP CC O
Ki67, Ki67, 1 0 0 0 1 0 0 1 5 0 NNP VBD NNP CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 VBD NNP CC VBD JJ O
upregulated upregulated 0 0 0 0 0 0 0 0 11 0 NNP CC VBD JJ NN O
p27, p27, 0 0 0 0 1 0 0 1 4 0 CC VBD JJ NN TO O
leading leading 0 0 0 0 0 0 0 0 7 0 VBD JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NN TO VB NN NNP O
growth growth 0 0 0 0 0 0 0 0 6 0 TO VB NN NNP NNP O
inhibition. inhibition. 0 0 0 0 0 0 0 0 11 0 VB NN NNP NNP IN O
However, However, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP IN VBD O
as as 0 0 0 0 0 0 0 0 2 0 NNP NNP IN VBD IN O
reported reported 0 0 0 0 0 0 0 0 8 0 NNP IN VBD IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 IN VBD IN JJ NNP O
other other 0 0 0 0 0 0 0 0 5 0 VBD IN JJ NNP NNP O
BRAF BRAF 1 1 0 0 0 0 0 0 4 0 IN JJ NNP NNP NN O
inhibitors, inhibitors, 0 0 0 0 1 0 0 0 11 0 JJ NNP NNP NN RB O
dabrafenib dabrafenib 0 0 0 0 0 0 0 0 10 0 NNP NNP NN RB VBD O
also also 0 0 0 0 0 0 0 0 4 0 NNP NN RB VBD NNP O
induced induced 0 0 0 0 0 0 0 0 7 0 NN RB VBD NNP NN O
MAPK MAPK 1 1 0 0 0 0 0 0 4 0 RB VBD NNP NN NN O
pathway pathway 0 0 0 0 0 0 0 0 7 0 VBD NNP NN NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 NNP NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NNP O
wild-type wild-type 0 0 1 0 0 0 0 0 9 0 NN IN NN NNP NNS O
BRAF BRAF 1 1 0 0 0 0 0 0 4 0 IN NN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NNP NNS IN NNP O
through through 0 0 0 0 0 0 0 0 7 0 NNP NNS IN NNP NNP O
CRAF CRAF 1 1 0 0 0 0 0 0 4 0 NNS IN NNP NNP NNP O
(RAF1) (RAF1) 0 1 0 0 0 0 0 1 6 0 IN NNP NNP NNP RB O
signalling, signalling, 0 0 0 0 1 0 0 0 11 0 NNP NNP NNP RB VBG O
potentially potentially 0 0 0 0 0 0 0 0 11 0 NNP NNP RB VBG DT O
explaining explaining 0 0 0 0 0 0 0 0 10 0 NNP RB VBG DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 RB VBG DT JJ NN O
squamous squamous 0 0 0 0 0 0 0 0 8 0 VBG DT JJ NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 DT JJ NN NNS CC O
carcinomas carcinomas 0 0 0 0 0 0 0 0 10 0 JJ NN NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NNS VBG O
keratoacanthomas keratoacanthomas 0 0 0 0 0 0 0 0 16 0 NNS CC NNS VBG IN O
arising arising 0 0 0 0 0 0 0 0 7 0 CC NNS VBG IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBG IN NNS VBN O
patients patients 0 0 0 0 0 0 0 0 8 0 VBG IN NNS VBN IN O
treated treated 0 0 0 0 0 0 0 0 7 0 IN NNS VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBN IN NNP NNP O
BRAF BRAF 1 1 0 0 0 0 0 0 4 0 VBN IN NNP NNP NNP O
inhibitors. inhibitors. 0 0 0 0 0 0 0 0 11 0 IN NNP NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NN DT O
addressing addressing 0 0 0 0 0 0 0 0 10 0 NNP NNP NN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NN DT NN PRP O
issue, issue, 0 0 0 0 1 0 0 0 6 0 NN DT NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NN PRP VBD IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBD IN JJ NN O
concomitant concomitant 0 0 0 0 0 0 0 0 11 0 VBD IN JJ NN IN O
administration administration 0 0 0 0 0 0 0 0 14 0 IN JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP CC O
BRAF BRAF 1 1 0 0 0 0 0 0 4 0 NN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNS O
MEK MEK 1 1 0 0 0 0 0 0 3 0 NNP CC NNP NNS VBD O
inhibitors inhibitors 0 0 0 0 0 0 0 0 10 0 CC NNP NNS VBD JJ O
abrogated abrogated 0 0 0 0 0 0 0 0 9 0 NNP NNS VBD JJ NNP O
paradoxical paradoxical 0 0 0 0 0 0 0 0 11 0 NNS VBD JJ NNP JJ O
BRAF BRAF 1 1 0 0 0 0 0 0 4 0 VBD JJ NNP JJ NNP O
inhibitor-induced inhibitor-induced 0 0 1 0 0 0 0 0 17 0 JJ NNP JJ NNP NN O
MAPK MAPK 1 1 0 0 0 0 0 0 4 0 NNP JJ NNP NN IN O
signalling signalling 0 0 0 0 0 0 0 0 10 0 JJ NNP NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP VBD O
cells, cells, 0 0 0 0 1 0 0 0 6 0 NN IN NNP VBD DT O
reduced reduced 0 0 0 0 0 0 0 0 7 0 IN NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN IN O
occurrence occurrence 0 0 0 0 0 0 0 0 10 0 VBD DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
skin skin 0 0 0 0 0 0 0 0 4 0 NN IN NN NNS IN O
lesions lesions 0 0 0 0 0 0 0 0 7 0 IN NN NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ CC O
rats, rats, 0 0 0 0 1 0 0 0 5 0 NNS IN JJ CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC VBD DT O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 JJ CC VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC VBD DT NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 VBD DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 IN JJ NN NN NN O
xenograft xenograft 0 0 0 0 0 0 0 0 9 0 JJ NN NN NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 NN NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NNP O
mouse mouse 0 0 0 0 0 0 0 0 5 0 NN IN NN NNP NNP O
models. models. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NNP NNP O
Taken Taken 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP PRP$ O
together, together, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP PRP$ NNS O
our our 0 0 0 0 0 0 0 0 3 0 NNP NNP PRP$ NNS VBP O
findings findings 0 0 0 0 0 0 0 0 8 0 NNP PRP$ NNS VBP JJ O
offer offer 0 0 0 0 0 0 0 0 5 0 PRP$ NNS VBP JJ IN O
preclinical preclinical 0 0 0 0 0 0 0 0 11 0 NNS VBP JJ IN IN O
proof proof 0 0 0 0 0 0 0 0 5 0 VBP JJ IN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ IN IN NN IN O
concept concept 0 0 0 0 0 0 0 0 7 0 IN IN NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 IN NN IN NN IN O
dabrafenib dabrafenib 0 0 0 0 0 0 0 0 10 0 NN IN NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ CC O
specific specific 0 0 0 0 0 0 0 0 8 0 IN DT JJ CC RB O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC RB JJ O
highly highly 0 0 0 0 0 0 0 0 6 0 JJ CC RB JJ NNP O
efficacious efficacious 0 0 0 0 0 0 0 0 11 0 CC RB JJ NNP NN O
BRAF BRAF 1 1 0 0 0 0 0 0 4 0 RB JJ NNP NN CC O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 JJ NNP NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC VB NN O
provide provide 0 0 0 0 0 0 0 0 7 0 NN CC VB NN IN O
evidence evidence 0 0 0 0 0 0 0 0 8 0 CC VB NN IN PRP$ O
for for 0 0 0 0 0 0 0 0 3 0 VB NN IN PRP$ JJ O
its its 0 0 0 0 0 0 0 0 3 0 NN IN PRP$ JJ JJ O
potential potential 0 0 0 0 0 0 0 0 9 0 IN PRP$ JJ JJ NNS O
clinical clinical 0 0 0 0 0 0 0 0 8 0 PRP$ JJ JJ NNS WRB O
benefits benefits 0 0 0 0 0 0 0 0 8 0 JJ JJ NNS WRB VBN O
when when 0 0 0 0 0 0 0 0 4 0 JJ NNS WRB VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 NNS WRB VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 WRB VBN IN NN IN O
combination combination 0 0 0 0 0 0 0 0 11 0 VBN IN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NNP NNP O
MEK MEK 1 1 0 0 0 0 0 0 3 0 IN DT NNP NNP NONE O
inhibitor. inhibitor. 0 0 0 0 0 0 0 0 10 0 DT NNP NNP NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NNP IN O
Role Role 1 0 0 0 0 0 0 0 4 0 NONE DT NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP NNP O
RACK1 RACK1 1 1 0 0 0 0 0 1 5 0 IN DT NNP NNP NNP O
Ortholog Ortholog 1 0 0 0 0 0 0 0 8 0 DT NNP NNP NNP IN O
Cpc2p Cpc2p 1 0 0 0 0 0 0 1 5 0 NNP NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP JJ O
Modulating Modulating 1 0 0 0 0 0 0 0 10 0 NNP IN NNP JJ NNP O
Pheromone-Induced Pheromone-Induced 1 0 1 0 0 0 0 0 17 0 IN NNP JJ NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NNP JJ NNP NNP NNP O
Cycle Cycle 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP NNP IN O
Arrest Arrest 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Fission Fission 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
Yeast. Yeast. 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
Mos Mos 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Esparza-Franco Esparza-Franco 1 0 1 0 0 0 0 0 14 0 NNP NNP NNP NNP NNP O
MA, MA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Godfrey Godfrey 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
EL, EL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Richardson Richardson 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Davey Davey 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ladds Ladds 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
G. G. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Division Division 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biomedical Biomedical 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Warwick Warwick 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
School, School, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Warwick, Warwick, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP NNP O
Coventry, Coventry, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
United United 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Kingdom. Kingdom. 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN CC O
detection detection 0 0 0 0 0 0 0 0 9 0 NNP NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN IN O
amplification amplification 0 0 0 0 0 0 0 0 13 0 NN CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NNS O
extracellular extracellular 0 0 0 0 0 0 0 0 13 0 NN IN JJ NNS VBZ O
signals signals 0 0 0 0 0 0 0 0 7 0 IN JJ NNS VBZ DT O
requires requires 0 0 0 0 0 0 0 0 8 0 JJ NNS VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBZ DT NN IN O
involvement involvement 0 0 0 0 0 0 0 0 11 0 VBZ DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
multiple multiple 0 0 0 0 0 0 0 0 8 0 NN IN NN NN NNP O
protein protein 0 0 0 0 0 0 0 0 7 0 IN NN NN NNP NNP O
components. components. 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NN NNS O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NNS DT O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NN NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NNS DT NN IN O
receptor receptor 0 0 0 0 0 0 0 0 8 0 NNS DT NN IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN VBN NNP O
activated activated 0 0 0 0 0 0 0 0 9 0 NN IN VBN NNP NN O
C C 1 1 0 0 0 0 0 0 1 0 IN VBN NNP NN -NONE- O
kinase kinase 0 0 0 0 0 0 0 0 6 0 VBN NNP NN -NONE- VBZ O
(RACK1) (RACK1) 0 1 0 0 0 0 0 1 7 0 NNP NN -NONE- VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN -NONE- VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 -NONE- VBZ DT JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ NN NN O
scaffolding scaffolding 0 0 0 0 0 0 0 0 11 0 DT JJ NN NN IN O
protein protein 0 0 0 0 0 0 0 0 7 0 JJ NN NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN JJ NN O
signal signal 0 0 0 0 0 0 0 0 6 0 NN IN JJ NN NNP O
transduction transduction 0 0 0 0 0 0 0 0 12 0 IN JJ NN NNP NNP O
networks. networks. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NNP PRP O
Further, Further, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP PRP RB O
it it 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP RB VBZ O
also also 0 0 0 0 0 0 0 0 4 0 NNP PRP RB VBZ DT O
performs performs 0 0 0 0 0 0 0 0 8 0 PRP RB VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 RB VBZ DT JJ NN O
critical critical 0 0 0 0 0 0 0 0 8 0 VBZ DT JJ NN IN O
function function 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN DT O
regulating regulating 0 0 0 0 0 0 0 0 10 0 NN IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN DT NN NN IN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NN DT O
modulating modulating 0 0 0 0 0 0 0 0 10 0 NN IN NN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NNP NNP O
G1/S G1/S 1 1 0 1 0 0 0 1 4 0 NN DT NNP NNP NNP B_TIMEXCCP
transition. transition. 0 0 0 0 0 0 0 0 11 0 DT NNP NNP NNP JJ O
Many Many 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP JJ NNS O
eukaryotic eukaryotic 0 0 0 0 0 0 0 0 10 0 NNP NNP JJ NNS NN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP JJ NNS NN NNP O
express express 0 0 0 0 0 0 0 0 7 0 JJ NNS NN NNP NNP O
RACK1 RACK1 1 1 0 0 0 0 0 1 5 0 NNS NN NNP NNP IN O
orthologs, orthologs, 0 0 0 0 1 0 0 0 10 0 NN NNP NNP IN CD O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNP IN CD NN O
one one 0 0 0 0 0 0 0 0 3 0 NNP IN CD NN VBG O
example example 0 0 0 0 0 0 0 0 7 0 IN CD NN VBG NNP O
being being 0 0 0 0 0 0 0 0 5 0 CD NN VBG NNP IN O
Cpc2p Cpc2p 1 0 0 0 0 0 0 1 5 0 NN VBG NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBG NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN NN O
fission fission 0 0 0 0 0 0 0 0 7 0 IN DT NN NN NNS O
yeast yeast 0 0 0 0 0 0 0 0 5 0 DT NN NN NNS NNP O
Schizosaccharomyces Schizosaccharomyces 1 0 0 0 0 0 0 0 19 0 NN NN NNS NNP NNP O
pombe. pombe. 0 0 0 0 0 0 0 0 6 0 NN NNS NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 NNS NNP NNP NN TO O
contrast contrast 0 0 0 0 0 0 0 0 8 0 NNP NNP NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO NNP NNP O
RACK1, RACK1, 1 1 0 0 1 0 0 1 6 0 NN TO NNP NNP VBZ O
Cpc2p Cpc2p 1 0 0 0 0 0 0 1 5 0 TO NNP NNP VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP NNP VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBN VBN TO O
described described 0 0 0 0 0 0 0 0 9 0 VBZ VBN VBN TO RB O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO RB JJ O
positively positively 0 0 0 0 0 0 0 0 10 0 VBN TO RB JJ IN O
regulate, regulate, 0 0 0 0 1 0 0 0 9 0 TO RB JJ IN DT O
at at 0 0 0 0 0 0 0 0 2 0 RB JJ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT JJ NN O
ribosomal ribosomal 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN NNS O
level, level, 0 0 0 0 1 0 0 0 6 0 DT JJ NN NNS NN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS NN IN O
entry entry 0 0 0 0 0 0 0 0 5 0 NN NNS NN IN NNP O
into into 0 0 0 0 0 0 0 0 4 0 NNS NN IN NNP NNP O
M M 1 1 0 0 0 0 0 0 1 0 NN IN NNP NNP NNP O
phase. phase. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
addition, addition, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNS O
Cpc2p Cpc2p 1 0 0 0 0 0 0 1 5 0 NNP NNP NNP NNS DT O
controls controls 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNS DT NN NN O
stress stress 0 0 0 0 0 0 0 0 6 0 NNS DT NN NN NNS O
response response 0 0 0 0 0 0 0 0 8 0 DT NN NN NNS IN O
pathways pathways 0 0 0 0 0 0 0 0 8 0 NN NN NNS IN DT O
through through 0 0 0 0 0 0 0 0 7 0 NN NNS IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NNS IN DT NN IN O
interaction interaction 0 0 0 0 0 0 0 0 11 0 IN DT NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 DT NN IN JJ CC O
Msa2p, Msa2p, 1 0 0 0 1 0 0 1 6 0 NN IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NN O
sexual sexual 0 0 0 0 0 0 0 0 6 0 JJ CC JJ NN IN O
development development 0 0 0 0 0 0 0 0 11 0 CC JJ NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNP O
modulating modulating 0 0 0 0 0 0 0 0 10 0 NN IN NN NNP NNP O
Ran1p/Pat1p. Ran1p/Pat1p. 1 0 0 1 0 0 0 1 12 0 IN NN NNP NNP PRP O
Here Here 1 0 0 0 0 0 0 0 4 0 NN NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP NNS O
describe describe 0 0 0 0 0 0 0 0 8 0 NNP PRP VBP NNS IN O
investigations investigations 0 0 0 0 0 0 0 0 14 0 PRP VBP NNS IN DT O
into into 0 0 0 0 0 0 0 0 4 0 VBP NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ WDT O
role, role, 0 0 0 0 1 0 0 0 5 0 IN DT JJ WDT NNP O
which which 0 0 0 0 0 0 0 0 5 0 DT JJ WDT NNP VBZ O
Cpc2p Cpc2p 1 0 0 0 0 0 0 1 5 0 JJ WDT NNP VBZ IN O
performs performs 0 0 0 0 0 0 0 0 8 0 WDT NNP VBZ IN VBG O
in in 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN VBG DT O
controlling controlling 0 0 0 0 0 0 0 0 11 0 VBZ IN VBG DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 IN VBG DT NNP NNP O
G G 1 1 0 0 0 0 0 0 1 0 VBG DT NNP NNP VBG O
protein-mediated protein-mediated 0 0 1 0 0 0 0 0 16 0 DT NNP NNP VBG NN O
mating mating 0 0 0 0 0 0 0 0 6 0 NNP NNP VBG NN NNP O
response response 0 0 0 0 0 0 0 0 8 0 NNP VBG NN NNP NNP O
pathway. pathway. 0 0 0 0 0 0 0 0 8 0 VBG NN NNP NNP JJ O
Despite Despite 1 0 0 0 0 0 0 0 7 0 NN NNP NNP JJ NN O
structural structural 0 0 0 0 0 0 0 0 10 0 NNP NNP JJ NN TO O
similarity similarity 0 0 0 0 0 0 0 0 10 0 NNP JJ NN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO JJ NN O
Gβ-like Gβ-like 1 0 1 0 0 0 0 0 7 0 NN TO JJ NN NNP O
subunits, subunits, 0 0 0 0 1 0 0 0 9 0 TO JJ NN NNP VBZ O
Cpc2p Cpc2p 1 0 0 0 0 0 0 1 5 0 JJ NN NNP VBZ RB O
appears appears 0 0 0 0 0 0 0 0 7 0 NN NNP VBZ RB TO O
not not 0 0 0 0 0 0 0 0 3 0 NNP VBZ RB TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VBZ RB TO NN IN O
function function 0 0 0 0 0 0 0 0 8 0 RB TO NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 TO NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
G G 1 1 0 0 0 0 0 0 1 0 IN DT NNP NN NNP O
protein protein 0 0 0 0 0 0 0 0 7 0 DT NNP NN NNP NNP O
level. level. 0 0 0 0 0 0 0 0 6 0 NNP NN NNP NNP IN O
However, However, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP IN NN O
upon upon 0 0 0 0 0 0 0 0 4 0 NNP NNP IN NN NN O
pheromone pheromone 0 0 0 0 0 0 0 0 9 0 NNP IN NN NN NNS O
stimulation, stimulation, 0 0 0 0 1 0 0 0 12 0 IN NN NN NNS VBG O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS VBG NNP O
overexpressing overexpressing 0 0 0 0 0 0 0 0 14 0 NN NNS VBG NNP NN O
Cpc2p Cpc2p 1 0 0 0 0 0 0 1 5 0 NNS VBG NNP NN JJ O
display display 0 0 0 0 0 0 0 0 7 0 VBG NNP NN JJ NN O
substantial substantial 0 0 0 0 0 0 0 0 11 0 NNP NN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN JJ NN NN NN O
morphology morphology 0 0 0 0 0 0 0 0 10 0 JJ NN NN NN NN O
defects, defects, 0 0 0 0 1 0 0 0 8 0 NN NN NN NN IN O
disorientation disorientation 0 0 0 0 0 0 0 0 14 0 NN NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
septum septum 0 0 0 0 0 0 0 0 6 0 NN IN NN NN CC O
formation formation 0 0 0 0 0 0 0 0 9 0 IN NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT RB O
a a 0 0 0 0 0 0 0 0 1 0 NN CC DT RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 CC DT RB VBN NNP O
protracted protracted 0 0 0 0 0 0 0 0 10 0 DT RB VBN NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 RB VBN NNP NNP NNP B_TIMEXCCP
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 VBN NNP NNP NNP VBZ O
Cpc2p Cpc2p 1 0 0 0 0 0 0 1 5 0 NNP NNP NNP VBZ DT O
has has 0 0 0 0 0 0 0 0 3 0 NNP NNP VBZ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT JJ TO O
potential potential 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ TO NN O
to to 0 0 0 0 0 0 0 0 2 0 DT JJ TO NN IN O
function function 0 0 0 0 0 0 0 0 8 0 JJ TO NN IN NN O
at at 0 0 0 0 0 0 0 0 2 0 TO NN IN NN NNS O
multiple multiple 0 0 0 0 0 0 0 0 8 0 NN IN NN NNS IN O
positions positions 0 0 0 0 0 0 0 0 9 0 IN NN NNS IN DT O
within within 0 0 0 0 0 0 0 0 6 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
pheromone pheromone 0 0 0 0 0 0 0 0 9 0 IN DT NN NN NNP O
response response 0 0 0 0 0 0 0 0 8 0 DT NN NN NNP NNP O
pathway. pathway. 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBP DT O
provide provide 0 0 0 0 0 0 0 0 7 0 NNP NNP VBP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBP DT JJ NN O
mechanistic mechanistic 0 0 0 0 0 0 0 0 11 0 VBP DT JJ NN IN O
interpretation interpretation 0 0 0 0 0 0 0 0 14 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN NNS O
novel novel 0 0 0 0 0 0 0 0 5 0 IN DT NN NNS IN O
data data 0 0 0 0 0 0 0 0 4 0 DT NN NNS IN VBG O
by by 0 0 0 0 0 0 0 0 2 0 NN NNS IN VBG NNP O
linking linking 0 0 0 0 0 0 0 0 7 0 NNS IN VBG NNP NNP O
Cpc2p Cpc2p 1 0 0 0 0 0 0 1 5 0 IN VBG NNP NNP IN O
function, function, 0 0 0 0 1 0 0 0 9 0 VBG NNP NNP IN DT O
during during 0 0 0 0 0 0 0 0 6 0 NNP NNP IN DT VBG O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT VBG NN O
mating mating 0 0 0 0 0 0 0 0 6 0 IN DT VBG NN IN O
response, response, 0 0 0 0 1 0 0 0 9 0 DT VBG NN IN PRP$ O
with with 0 0 0 0 0 0 0 0 4 0 VBG NN IN PRP$ JJ O
its its 0 0 0 0 0 0 0 0 3 0 NN IN PRP$ JJ VBN O
previous previous 0 0 0 0 0 0 0 0 8 0 IN PRP$ JJ VBN NNS O
described described 0 0 0 0 0 0 0 0 9 0 PRP$ JJ VBN NNS IN O
interactions interactions 0 0 0 0 0 0 0 0 12 0 JJ VBN NNS IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBN NNS IN NNP NNP O
Ran1p/Pat1p. Ran1p/Pat1p. 1 0 0 1 0 0 0 1 12 0 NNS IN NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 IN NNP NNP VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNP NNP VBP IN VBG O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBP IN VBG NNP O
overexpressing overexpressing 0 0 0 0 0 0 0 0 14 0 VBP IN VBG NNP NNS O
Cpc2p Cpc2p 1 0 0 0 0 0 0 1 5 0 IN VBG NNP NNS DT O
prolongs prolongs 0 0 0 0 0 0 0 0 8 0 VBG NNP NNS DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNS DT VBN NN O
stimulated stimulated 0 0 0 0 0 0 0 0 10 0 NNS DT VBN NN IN O
state state 0 0 0 0 0 0 0 0 5 0 DT VBN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN JJ NNS O
pheromone-induced pheromone-induced 0 0 1 0 0 0 0 0 17 0 NN IN JJ NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN VBG O
by by 0 0 0 0 0 0 0 0 2 0 JJ NNS IN VBG NNP O
increasing increasing 0 0 0 0 0 0 0 0 10 0 NNS IN VBG NNP NN O
ste11 ste11 0 0 0 0 0 0 0 1 5 0 IN VBG NNP NN NNP O
gene gene 0 0 0 0 0 0 0 0 4 0 VBG NNP NN NNP NNP O
expression. expression. 0 0 0 0 0 0 0 0 11 0 NNP NN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNS VBP O
data data 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS VBP IN O
indicate indicate 0 0 0 0 0 0 0 0 8 0 NNP NNS VBP IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NNP VBZ O
Cpc2p Cpc2p 1 0 0 0 0 0 0 1 5 0 VBP IN NNP VBZ DT O
regulates regulates 0 0 0 0 0 0 0 0 9 0 IN NNP VBZ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT JJ NN O
pheromone-induced pheromone-induced 0 0 1 0 0 0 0 0 17 0 VBZ DT JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest JJ NN NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
fission fission 0 0 0 0 0 0 0 0 7 0 NN IN NN NN IN O
yeast yeast 0 0 0 0 0 0 0 0 5 0 IN NN NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NNS O
delaying delaying 0 0 0 0 0 0 0 0 8 0 NN IN NN NNS NN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NN NNS NN IN O
entry entry 0 0 0 0 0 0 0 0 5 0 NN NNS NN IN NNP O
into into 0 0 0 0 0 0 0 0 4 0 NNS NN IN NNP NNP O
S S 1 1 0 0 0 0 0 0 1 0 NN IN NNP NNP NONE O
phase. phase. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NN NN O
inhibitory inhibitory 0 0 0 0 0 0 0 0 10 0 NONE DT NN NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 DT NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNP O
ellagic ellagic 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNP IN O
Acid Acid 1 0 0 0 0 0 0 0 4 0 IN JJ NNP IN NN O
on on 0 0 0 0 0 0 0 0 2 0 JJ NNP IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP IN NN NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 IN NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
ovarian ovarian 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN NNP O
carcinoma carcinoma 0 0 0 0 0 0 0 0 9 0 IN JJ NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP NNP O
Chung Chung 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP NNP O
YC, YC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Lu Lu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
LC, LC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Tsai Tsai 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
MH, MH, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
YJ, YJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
YY, YY, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Yao Yao 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
SP, SP, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Hsu Hsu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
CP. CP. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP JJ O
Surgery, Surgery, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP JJ NN O
Cheng-Ching Cheng-Ching 1 0 1 0 0 0 0 0 11 0 IN NNP JJ NN JJ O
Hospital, Hospital, 1 0 0 0 1 0 0 0 9 0 NNP JJ NN JJ NN O
Chung-Kang Chung-Kang 1 0 1 0 0 0 0 0 10 0 JJ NN JJ NN NN O
Branch, Branch, 1 0 0 0 1 0 0 0 7 0 NN JJ NN NN CD O
No. No. 1 0 0 0 0 0 0 0 3 0 JJ NN NN CD NN O
118, 118, 0 0 0 0 1 0 0 1 4 0 NN NN CD NN CD O
Section Section 1 0 0 0 0 0 0 0 7 0 NN CD NN CD NNP O
3, 3, 0 0 0 0 1 0 0 1 2 0 CD NN CD NNP NNP O
Chung Chung 1 0 0 0 0 0 0 0 5 0 NN CD NNP NNP NNP O
Kang Kang 1 0 0 0 0 0 0 0 4 0 CD NNP NNP NNP NNP O
Road, Road, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
Taichung Taichung 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP CD O
City City 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP CD NNP O
40764, 40764, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
Taiwan. Taiwan. 1 0 0 0 0 0 0 0 7 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP VBD O
Ellagic Ellagic 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP VBD NNP O
acid acid 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD NNP VBZ O
(EA) (EA) 0 1 0 0 0 0 0 0 4 0 NNP VBD NNP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 VBD NNP VBZ JJ TO O
able able 0 0 0 0 0 0 0 0 4 0 NNP VBZ JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO VB DT O
inhibit inhibit 0 0 0 0 0 0 0 0 7 0 JJ TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 VB DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
several several 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN -NONE- O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN -NONE- -NONE- O
cells; cells; 0 0 0 0 0 0 0 0 6 0 JJ NN -NONE- -NONE- PRP$ O
however, however, 0 0 0 0 1 0 0 0 8 0 NN -NONE- -NONE- PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- PRP$ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 -NONE- PRP$ NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 PRP$ NN IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NN O
ovarian ovarian 0 0 0 0 0 0 0 0 7 0 IN JJ NN NN NNS O
carcinoma carcinoma 0 0 0 0 0 0 0 0 9 0 JJ NN NN NNS VBZ O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS VBZ RB O
has has 0 0 0 0 0 0 0 0 3 0 NN NNS VBZ RB RB O
not not 0 0 0 0 0 0 0 0 3 0 NNS VBZ RB RB VBN O
yet yet 0 0 0 0 0 0 0 0 3 0 VBZ RB RB VBN NNP O
been been 0 0 0 0 0 0 0 0 4 0 RB RB VBN NNP NNP O
investigated. investigated. 0 0 0 0 0 0 0 0 13 0 RB VBN NNP NNP NN O
Ovarian Ovarian 1 0 0 0 0 0 0 0 7 0 VBN NNP NNP NN -NONE- O
carcinoma carcinoma 0 0 0 0 0 0 0 0 9 0 NNP NNP NN -NONE- CC O
ES-2 ES-2 1 1 1 0 0 0 0 1 4 0 NNP NN -NONE- CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC -NONE- NNS O
PA-1 PA-1 1 1 1 0 0 0 0 1 4 0 -NONE- CC -NONE- NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 CC -NONE- NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 -NONE- NNS VBD VBN IN O
treated treated 0 0 0 0 0 0 0 0 7 0 NNS VBD VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNP NNP O
EA EA 1 1 0 0 0 0 0 0 2 0 VBN IN NNP NNP NNP O
(10~100 (10~100 0 0 0 0 0 0 0 1 7 0 IN NNP NNP NNP NNP O
μ μ 0 0 0 0 0 0 0 0 1 0 NNP NNP NNP NNP CC O
M) M) 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC VBD IN O
assessed assessed 0 0 0 0 0 0 0 0 8 0 NNP CC VBD IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 CC VBD IN JJ NN O
viability, viability, 0 0 0 0 1 0 0 0 10 0 VBD IN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN NN O
cycle, cycle, 0 0 0 0 1 0 0 0 6 0 JJ NN NN NN NN O
apoptosis, apoptosis, 0 0 0 0 1 0 0 0 10 0 NN NN NN NN NN O
anoikis, anoikis, 0 0 0 0 1 0 0 0 8 0 NN NN NN NN CC O
autophagy, autophagy, 0 0 0 0 1 0 0 0 10 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN TO O
chemosensitivity chemosensitivity 0 0 0 0 0 0 0 0 16 0 NN CC NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 CC NN TO VB CC O
doxorubicin doxorubicin 0 0 0 0 0 0 0 0 11 0 NN TO VB CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 TO VB CC PRP$ JJ O
their their 0 0 0 0 0 0 0 0 5 0 VB CC PRP$ JJ NNP O
molecular molecular 0 0 0 0 0 0 0 0 9 0 CC PRP$ JJ NNP NNP O
mechanisms. mechanisms. 0 0 0 0 0 0 0 0 11 0 PRP$ JJ NNP NNP VBD O
EA EA 1 1 0 0 0 0 0 0 2 0 JJ NNP NNP VBD NN O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP VBD NN NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VBD NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN CC O
dose- dose- 0 0 1 0 0 0 0 0 5 0 IN DT NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC JJ NN O
time-dependent time-dependent 0 0 1 0 0 0 0 0 14 0 NN CC JJ NN IN O
manner manner 0 0 0 0 0 0 0 0 6 0 CC JJ NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN DT O
arresting arresting 0 0 0 0 0 0 0 0 9 0 NN IN NN DT NN O
both both 0 0 0 0 0 0 0 0 4 0 IN NN DT NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 NN DT NN NNS IN O
lines lines 0 0 0 0 0 0 0 0 5 0 DT NN NNS IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 phase IN DT NNP NN IN O
phase phase 0 0 0 0 0 0 0 0 5 0 DT NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN WDT O
cycle, cycle, 0 0 0 0 1 0 0 0 6 0 DT NN NN WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBD IN O
were were 0 0 0 0 0 0 0 0 4 0 NN WDT VBD IN VBG O
from from 0 0 0 0 0 0 0 0 4 0 WDT VBD IN VBG NNP O
elevating elevating 0 0 0 0 0 0 0 0 9 0 VBD IN VBG NNP CC O
p53 p53 0 0 0 0 0 0 0 1 3 0 IN VBG NNP CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 VBG NNP CC -NONE- CC O
Cip1/p21 Cip1/p21 1 0 0 1 0 0 0 1 8 0 NNP CC -NONE- CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 CC -NONE- CC VBG NN O
decreasing decreasing 0 0 0 0 0 0 0 0 10 0 -NONE- CC VBG NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 CC VBG NN NNP CC O
D1 D1 1 1 0 0 0 0 0 1 2 0 VBG NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP NNP O
E E 1 1 0 0 0 0 0 0 1 0 NNP CC NNP NNP NNP O
levels. levels. 0 0 0 0 0 0 0 0 7 0 CC NNP NNP NNP RB O
EA EA 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP RB VBD O
also also 0 0 0 0 0 0 0 0 4 0 NNP NNP RB VBD JJ O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP RB VBD JJ NN O
caspase-3-mediated caspase-3-mediated 0 0 1 0 0 0 0 1 18 0 RB VBD JJ NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 VBD JJ NN IN VBG O
by by 0 0 0 0 0 0 0 0 2 0 JJ NN IN VBG DT O
increasing increasing 0 0 0 0 0 0 0 0 10 0 NN IN VBG DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 IN VBG DT NNP : O
Bax Bax 1 0 0 0 0 0 0 0 3 0 VBG DT NNP : -NONE- O
: : 0 0 0 0 0 0 0 0 1 0 DT NNP : -NONE- NN O
Bcl-2 Bcl-2 1 0 1 0 0 0 0 1 5 0 NNP : -NONE- NN CC O
ratio ratio 0 0 0 0 0 0 0 0 5 0 : -NONE- NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NN CC VBD NNS O
restored restored 0 0 0 0 0 0 0 0 8 0 NN CC VBD NNS IN O
anoikis anoikis 0 0 0 0 0 0 0 0 7 0 CC VBD NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD NNS IN DT NN O
both both 0 0 0 0 0 0 0 0 4 0 NNS IN DT NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NNP NNP O
lines. lines. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
enhancement enhancement 0 0 0 0 0 0 0 0 11 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN IN NN NN NN O
and/or and/or 0 0 0 1 0 0 0 0 6 0 IN NN NN NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 NN NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN IN O
autophagy autophagy 0 0 0 0 0 0 0 0 9 0 NN IN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN DT NNS IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 DT NNS IN NNP VBD O
EA EA 1 1 0 0 0 0 0 0 2 0 NNS IN NNP VBD DT O
assisted assisted 0 0 0 0 0 0 0 0 8 0 IN NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN NNP O
chemotherapy chemotherapy 0 0 0 0 0 0 0 0 12 0 VBD DT NN NNP NNP O
efficacy. efficacy. 0 0 0 0 0 0 0 0 9 0 DT NN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS VBD O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD IN O
indicated indicated 0 0 0 0 0 0 0 0 9 0 NNP NNS VBD IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NNP VBZ O
EA EA 1 1 0 0 0 0 0 0 2 0 VBD IN NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT JJ NN O
potential potential 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN CC O
chemoprevention chemoprevention 0 0 0 0 0 0 0 0 15 0 JJ NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NN CC NN NN NN O
assistant assistant 0 0 0 0 0 0 0 0 9 0 CC NN NN NN IN O
agent agent 0 0 0 0 0 0 0 0 5 0 NN NN NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NN NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN NN NN NNP O
ovarian ovarian 0 0 0 0 0 0 0 0 7 0 IN NN NN NNP NONE O
carcinoma. carcinoma. 0 0 0 0 0 0 0 0 10 0 NN NN NNP NONE NONE O
C-Terminal C-Terminal 1 0 1 0 0 0 0 0 10 0 NONE NONE JJ NNP IN O
Peptide Peptide 1 0 0 0 0 0 0 0 7 0 NONE JJ NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNP IN JJ NNP O
γ-Enolase γ-Enolase 0 0 1 0 0 0 0 0 9 0 NNP IN JJ NNP JJ O
Impairs Impairs 1 0 0 0 0 0 0 0 7 0 IN JJ NNP JJ NNP O
Amyloid-β-Induced Amyloid-β-Induced 1 0 1 0 0 0 0 0 17 0 JJ NNP JJ NNP NNP O
Apoptosis Apoptosis 1 0 0 0 0 0 0 0 9 0 NNP JJ NNP NNP NNP O
Through Through 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP NNP NNP O
p75(NTR) p75(NTR) 0 0 0 0 0 0 0 1 8 0 NNP NNP NNP NNP JJ O
Signaling. Signaling. 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP JJ NN O
Pišlar Pišlar 1 0 0 0 0 0 0 0 6 0 NNP NNP JJ NN NNP O
AH, AH, 1 1 0 0 1 0 0 0 3 0 NNP JJ NN NNP NNP O
Kos Kos 1 0 0 0 0 0 0 0 3 0 JJ NN NNP NNP NNP O
J. J. 1 1 0 0 0 0 0 0 2 0 NN NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pharmaceutical Pharmaceutical 1 0 0 0 0 0 0 0 14 0 NNP IN NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP IN O
Faculty Faculty 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pharmacy, Pharmacy, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Ljubljana, Ljubljana, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP CD O
Askerceva Askerceva 1 0 0 0 0 0 0 0 9 0 IN NNP NNP CD CD O
7, 7, 0 0 0 0 1 0 0 1 2 0 NNP NNP CD CD JJ O
1000, 1000, 0 0 0 0 1 0 0 1 5 0 NNP CD CD JJ NN O
Ljubljana, Ljubljana, 1 0 0 0 1 0 0 0 10 0 CD CD JJ NN NNP O
Slovenia, Slovenia, 1 0 0 0 1 0 0 0 9 0 CD JJ NN NNP NNP O
anja.pislar@ffa.uni-lj.si. anja.pislar@ffa.uni-lj.si. 0 0 1 0 0 0 0 0 26 0 JJ NN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NNP VBZ O
γ-Enolase γ-Enolase 0 0 1 0 0 0 0 0 9 0 NNP NNP NNP VBZ IN O
acts acts 0 0 0 0 0 0 0 0 4 0 NNP NNP VBZ IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBZ IN DT JJ NN O
neurotrophic-like neurotrophic-like 0 0 1 0 0 0 0 0 17 0 IN DT JJ NN VBG O
factor factor 0 0 0 0 0 0 0 0 6 0 DT JJ NN VBG NN O
promoting promoting 0 0 0 0 0 0 0 0 9 0 JJ NN VBG NN -NONE- O
growth, growth, 0 0 0 0 1 0 0 0 7 0 NN VBG NN -NONE- NN O
differentiation, differentiation, 0 0 0 0 1 0 0 0 16 0 VBG NN -NONE- NN CC O
survival survival 0 0 0 0 0 0 0 0 8 0 NN -NONE- NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NN CC NN IN O
regeneration regeneration 0 0 0 0 0 0 0 0 12 0 NN CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NNP O
neurons. neurons. 0 0 0 0 0 0 0 0 8 0 NN IN NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 IN NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
shown shown 0 0 0 0 0 0 0 0 5 0 NNP VBZ VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 VBN IN DT NN TO O
study study 0 0 0 0 0 0 0 0 5 0 IN DT NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO VB DT O
exert exert 0 0 0 0 0 0 0 0 5 0 NN TO VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT JJ NN O
protective protective 0 0 0 0 0 0 0 0 10 0 VB DT JJ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN JJ O
against against 0 0 0 0 0 0 0 0 7 0 JJ NN IN JJ JJ O
amyloid-β-peptide amyloid-β-peptide 0 0 1 0 0 0 0 0 17 0 NN IN JJ JJ NN O
(Aβ)-induced (Aβ)-induced 0 0 1 0 0 0 0 0 12 0 IN JJ JJ NN IN O
neurotoxicity neurotoxicity 0 0 0 0 0 0 0 0 13 0 JJ JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
rat rat 0 0 0 0 0 0 0 0 3 0 NN IN NN NN NNP O
pheochromocytoma pheochromocytoma 0 0 0 0 0 0 0 0 16 0 IN NN NN NNP NNP O
PC12 PC12 1 1 0 0 0 0 0 1 4 0 NN NN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP NN O
Aβ-induced Aβ-induced 1 0 1 0 0 0 0 0 10 0 NNP NNP NNP NN VBD O
toxicity toxicity 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
abolished abolished 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
presence presence 0 0 0 0 0 0 0 0 8 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ JJ O
active active 0 0 0 0 0 0 0 0 6 0 IN DT JJ JJ NN O
C-terminal C-terminal 1 0 1 0 0 0 0 0 10 0 DT JJ JJ NN IN O
peptide peptide 0 0 0 0 0 0 0 0 7 0 JJ JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
γ-enolase γ-enolase 0 0 1 0 0 0 0 0 9 0 NN IN JJ NN IN O
(γ-Eno) (γ-Eno) 0 0 1 0 0 0 0 0 7 0 IN JJ NN IN VBN O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN VBN IN O
measured measured 0 0 0 0 0 0 0 0 8 0 NN IN VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 IN VBN IN NN -NONE- O
cell cell 0 0 0 0 0 0 0 0 4 0 VBN IN NN -NONE- JJ O
viability, viability, 0 0 0 0 1 0 0 0 10 0 IN NN -NONE- JJ NN O
lactate lactate 0 0 0 0 0 0 0 0 7 0 NN -NONE- JJ NN NN O
dehydrogenase dehydrogenase 0 0 0 0 0 0 0 0 13 0 -NONE- JJ NN NN -NONE- O
release, release, 0 0 0 0 1 0 0 0 8 0 JJ NN NN -NONE- NN O
sub-G1 sub-G1 0 0 1 0 0 0 0 1 6 0 NN NN -NONE- NN -NONE- O
cell cell 0 0 0 0 0 0 0 0 4 0 NN -NONE- NN -NONE- JJ O
population, population, 0 0 0 0 1 0 0 0 11 0 -NONE- NN -NONE- JJ JJ O
intracellular intracellular 0 0 0 0 0 0 0 0 13 0 NN -NONE- JJ JJ NN O
reactive reactive 0 0 0 0 0 0 0 0 8 0 -NONE- JJ JJ NN NN O
oxygen oxygen 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NN NN O
species, species, 0 0 0 0 1 0 0 0 8 0 JJ NN NN NN NNS O
mitochondrial mitochondrial 0 0 0 0 0 0 0 0 13 0 NN NN NN NNS CC O
functions functions 0 0 0 0 0 0 0 0 9 0 NN NN NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC JJ NNP O
apoptotic apoptotic 0 0 0 0 0 0 0 0 9 0 NNS CC JJ NNP NNP O
morphology. morphology. 0 0 0 0 0 0 0 0 11 0 CC JJ NNP NNP VBD O
γ-Eno γ-Eno 0 0 1 0 0 0 0 0 5 0 JJ NNP NNP VBD NN O
caused caused 0 0 0 0 0 0 0 0 6 0 NNP NNP VBD NN IN O
downregulation downregulation 0 0 0 0 0 0 0 0 14 0 NNP VBD NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
pro-apoptotic pro-apoptotic 0 0 1 0 0 0 0 0 13 0 IN DT JJ NN NNP O
protein protein 0 0 0 0 0 0 0 0 7 0 DT JJ NN NNP CC O
Bax Bax 1 0 0 0 0 0 0 0 3 0 JJ NN NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NN IN O
upregulation upregulation 0 0 0 0 0 0 0 0 12 0 NNP CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
anti-apoptotic anti-apoptotic 0 0 1 0 0 0 0 0 14 0 IN DT JJ NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 DT JJ NN NN IN O
Bcl-2, Bcl-2, 1 0 1 0 1 0 0 1 6 0 JJ NN NN IN RB O
as as 0 0 0 0 0 0 0 0 2 0 NN NN IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NN IN RB IN VBN O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN VBN -NONE- O
reduced reduced 0 0 0 0 0 0 0 0 7 0 RB IN VBN -NONE- NNP O
caspase-3 caspase-3 0 0 1 0 0 0 0 1 9 0 IN VBN -NONE- NNP NNP O
activation. activation. 0 0 0 0 0 0 0 0 11 0 VBN -NONE- NNP NNP TO O
Exposure Exposure 1 0 0 0 0 0 0 0 8 0 -NONE- NNP NNP TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNP NNP TO NNP VBD O
Aβ Aβ 1 0 0 0 0 0 0 0 2 0 NNP TO NNP VBD NN O
increased increased 0 0 0 0 0 0 0 0 9 0 TO NNP VBD NN NN O
surface surface 0 0 0 0 0 0 0 0 7 0 NNP VBD NN NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 VBD NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP IN O
p75 p75 0 0 0 0 0 0 0 1 3 0 NN IN NNP IN NN O
neurotrophin neurotrophin 0 0 0 0 0 0 0 0 12 0 IN NNP IN NN NN O
receptor receptor 0 0 0 0 0 0 0 0 8 0 NNP IN NN NN CC O
(p75(NTR)), (p75(NTR)), 0 0 0 0 1 0 0 1 11 0 IN NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN VBD O
increase increase 0 0 0 0 0 0 0 0 8 0 CC DT NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD VBN IN O
abolished abolished 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
presence presence 0 0 0 0 0 0 0 0 8 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
γ-Eno γ-Eno 0 0 1 0 0 0 0 0 5 0 NN IN NNP NNP NNP O
peptide. peptide. 0 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NN O
Further, Further, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NN IN O
pretreatment pretreatment 0 0 0 0 0 0 0 0 12 0 NNP NNP NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNP NN IN JJ VBN O
γ-Eno γ-Eno 0 0 1 0 0 0 0 0 5 0 NN IN JJ VBN DT O
suppressed suppressed 0 0 0 0 0 0 0 0 10 0 IN JJ VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ VBN DT NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 VBN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
mitogen-activated mitogen-activated 0 0 1 0 0 0 0 0 17 0 NN IN JJ NN NNS O
protein protein 0 0 0 0 0 0 0 0 7 0 IN JJ NN NNS NNP O
kinases kinases 0 0 0 0 0 0 0 0 7 0 JJ NN NNS NNP CC O
p38 p38 0 0 0 0 0 0 0 1 3 0 NN NNS NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNS NNP CC JJ NN O
Jun-N-terminal Jun-N-terminal 1 0 1 0 0 0 0 0 14 0 NNP CC JJ NN WDT O
kinase, kinase, 0 0 0 0 1 0 0 0 7 0 CC JJ NN WDT VBP O
which which 0 0 0 0 0 0 0 0 5 0 JJ NN WDT VBP -NONE- O
are are 0 0 0 0 0 0 0 0 3 0 NN WDT VBP -NONE- NN O
p75(NTR) p75(NTR) 0 0 0 0 0 0 0 1 8 0 WDT VBP -NONE- NN NNS O
downstream downstream 0 0 0 0 0 0 0 0 10 0 VBP -NONE- NN NNS IN O
effectors effectors 0 0 0 0 0 0 0 0 9 0 -NONE- NN NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NNP O
apoptotic apoptotic 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NNP NNP O
signaling. signaling. 0 0 0 0 0 0 0 0 10 0 IN JJ NNP NNP NNP O
Moreover, Moreover, 1 0 0 0 1 0 0 0 9 0 JJ NNP NNP NNP VBD O
Aβ Aβ 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBD JJ O
triggered triggered 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD JJ NN O
γ-enolase γ-enolase 0 0 1 0 0 0 0 0 9 0 NNP VBD JJ NN IN O
co-immunoprecipitation co-immunoprecipitation 0 0 1 0 0 0 0 0 22 0 VBD JJ NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN JJ IN O
p75(NTR) p75(NTR) 0 0 0 0 0 0 0 1 8 0 NN IN JJ IN RB O
as as 0 0 0 0 0 0 0 0 2 0 IN JJ IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 JJ IN RB IN PRP$ O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN PRP$ JJ O
their their 0 0 0 0 0 0 0 0 5 0 RB IN PRP$ JJ NN O
strong strong 0 0 0 0 0 0 0 0 6 0 IN PRP$ JJ NN IN O
association association 0 0 0 0 0 0 0 0 11 0 PRP$ JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
perimembrane perimembrane 0 0 0 0 0 0 0 0 12 0 IN DT NN NN IN O
region region 0 0 0 0 0 0 0 0 6 0 DT NN NN IN NN O
as as 0 0 0 0 0 0 0 0 2 0 NN NN IN NN IN O
shown shown 0 0 0 0 0 0 0 0 5 0 NN IN NN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NN O
confocal confocal 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN WDT O
microscopy, microscopy, 0 0 0 0 1 0 0 0 11 0 IN JJ NN WDT RB O
which which 0 0 0 0 0 0 0 0 5 0 JJ NN WDT RB VBZ O
further further 0 0 0 0 0 0 0 0 7 0 NN WDT RB VBZ DT O
supports supports 0 0 0 0 0 0 0 0 8 0 WDT RB VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBZ DT NN IN O
interaction interaction 0 0 0 0 0 0 0 0 11 0 VBZ DT NN IN DT O
between between 0 0 0 0 0 0 0 0 7 0 DT NN IN DT CD O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 IN DT CD NNS IN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 DT CD NNS IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 CD NNS IN NNS VBN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNS IN NNS VBN IN O
insulted insulted 0 0 0 0 0 0 0 0 8 0 IN NNS VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBN IN NNP NNP O
Aβ Aβ 1 0 0 0 0 0 0 0 2 0 VBN IN NNP NNP NNP O
peptide. peptide. 0 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP DT O
indicate indicate 0 0 0 0 0 0 0 0 8 0 NNP NNS VBP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBP DT JJ NN O
possible possible 0 0 0 0 0 0 0 0 8 0 VBP DT JJ NN IN O
use use 0 0 0 0 0 0 0 0 3 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN JJ O
γ-enolase γ-enolase 0 0 1 0 0 0 0 0 9 0 NN IN NN JJ NN O
C-terminal C-terminal 1 0 1 0 0 0 0 0 10 0 IN NN JJ NN IN O
peptide peptide 0 0 0 0 0 0 0 0 7 0 NN JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN CC O
treating treating 0 0 0 0 0 0 0 0 8 0 NN IN NN CC VBG O
or or 0 0 0 0 0 0 0 0 2 0 IN NN CC VBG JJ O
preventing preventing 0 0 0 0 0 0 0 0 10 0 NN CC VBG JJ NNP O
Alzheimer's Alzheimer's 1 0 0 0 0 1 0 0 11 0 CC VBG JJ NNP NONE O
disease. disease. 0 0 0 0 0 0 0 0 8 0 VBG JJ NNP NONE NONE O
Steroidal Steroidal 1 0 0 0 0 0 0 0 9 0 NONE NONE NNP NN NNS O
aromatase aromatase 0 0 0 0 0 0 0 0 9 0 NONE NNP NN NNS NN O
inhibitors inhibitors 0 0 0 0 0 0 0 0 10 0 NNP NN NNS NN NN O
inhibit inhibit 0 0 0 0 0 0 0 0 7 0 NN NNS NN NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 NNS NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
hormone-dependent hormone-dependent 0 0 1 0 0 0 0 0 17 0 NN IN JJ NN NN O
breast breast 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 JJ NN NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS IN VBG O
by by 0 0 0 0 0 0 0 0 2 0 NN NNS IN VBG NN O
inducing inducing 0 0 0 0 0 0 0 0 8 0 NNS IN VBG NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN VBG NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest VBG NN NN NN CC O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
apoptosis. apoptosis. 0 0 0 0 0 0 0 0 10 0 NN CC NNP NNP NNP O
Amaral Amaral 1 0 0 0 0 0 0 0 6 0 CC NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Varela Varela 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Borges Borges 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NN O
Tavares Tavares 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NN NNP O
da da 0 0 0 0 0 0 0 0 2 0 NNP NNP NN NNP NNP O
Silva Silva 1 0 0 0 0 0 0 0 5 0 NNP NN NNP NNP NNP O
E, E, 1 1 0 0 1 0 0 0 2 0 NN NNP NNP NNP NNP O
Roleira Roleira 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
FM, FM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Correia-da-Silva Correia-da-Silva 1 0 1 0 0 0 0 0 16 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Teixeira Teixeira 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
N. N. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biochemistry, Biochemistry, 1 0 0 0 1 0 0 0 13 0 NNP IN NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biological Biological 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP IN O
Faculty Faculty 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pharmacy, Pharmacy, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Porto, Porto, 1 0 0 0 1 0 0 0 6 0 NNP IN NNP NNP NNP O
Rua Rua 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
Jorge Jorge 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Viterbo Viterbo 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Ferreira, Ferreira, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP CD O
no. no. 0 0 0 0 0 0 0 0 3 0 NNP NNP NNP CD CD O
228, 228, 0 0 0 0 1 0 0 1 4 0 NNP NNP CD CD JJ O
4050-313, 4050-313, 0 0 1 0 1 0 0 1 9 0 NNP CD CD JJ NNP O
Porto, Porto, 1 0 0 0 1 0 0 0 6 0 CD CD JJ NNP NNP O
Portugal. Portugal. 1 0 0 0 0 0 0 0 9 0 CD JJ NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP NNP JJ O
Different Different 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP JJ NNS O
hormonal hormonal 0 0 0 0 0 0 0 0 8 0 NNP NNP JJ NNS VBP O
therapies therapies 0 0 0 0 0 0 0 0 9 0 NNP JJ NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 JJ NNS VBP VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 NNS VBP VBN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBP VBN IN NN NN O
estrogen estrogen 0 0 0 0 0 0 0 0 8 0 VBN IN NN NN JJ O
receptor receptor 0 0 0 0 0 0 0 0 8 0 IN NN NN JJ NN O
positive positive 0 0 0 0 0 0 0 0 8 0 NN NN JJ NN NN O
(ER+) (ER+) 0 1 0 0 0 0 0 0 5 0 NN JJ NN NN NN O
breast breast 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN VBG O
cancers, cancers, 0 0 0 0 1 0 0 0 8 0 NN NN NN VBG DT O
being being 0 0 0 0 0 0 0 0 5 0 NN NN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT NN IN O
third-generation third-generation 0 0 1 0 0 0 0 0 16 0 VBG DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
aromatase aromatase 0 0 0 0 0 0 0 0 9 0 NN IN NN NNS -NONE- O
inhibitors inhibitors 0 0 0 0 0 0 0 0 10 0 IN NN NNS -NONE- DT O
(AIs), (AIs), 0 0 0 0 1 0 0 0 6 0 NN NNS -NONE- DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNS -NONE- DT JJ NN O
effective effective 0 0 0 0 0 0 0 0 9 0 -NONE- DT JJ NN TO O
alternative alternative 0 0 0 0 0 0 0 0 11 0 DT JJ NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT JJ NNP O
classical classical 0 0 0 0 0 0 0 0 9 0 TO DT JJ NNP NNP O
tamoxifen. tamoxifen. 0 0 0 0 0 0 0 0 10 0 DT JJ NNP NNP NN O
AIs AIs 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN DT O
inhibit inhibit 0 0 0 0 0 0 0 0 7 0 NNP NNP NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT NN NN O
enzyme enzyme 0 0 0 0 0 0 0 0 6 0 NN DT NN NN WDT O
aromatase, aromatase, 0 0 0 0 1 0 0 0 10 0 DT NN NN WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN WDT VBZ JJ IN O
responsible responsible 0 0 0 0 0 0 0 0 11 0 WDT VBZ JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN NN DT O
catalyzing catalyzing 0 0 0 0 0 0 0 0 10 0 JJ IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN IN O
conversion conversion 0 0 0 0 0 0 0 0 10 0 NN DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS TO O
androgens androgens 0 0 0 0 0 0 0 0 9 0 NN IN NNS TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 IN NNS TO NNP NNP O
estrogens. estrogens. 0 0 0 0 0 0 0 0 10 0 NNS TO NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 TO NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 NNP DT NN PRP VBD O
it it 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN PRP VBD VBN DT O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 PRP VBD VBN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 VBD VBN DT NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 VBN DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ JJ O
several several 0 0 0 0 0 0 0 0 7 0 NNS IN JJ JJ NN O
steroidal steroidal 0 0 0 0 0 0 0 0 9 0 IN JJ JJ NN RB O
AIs, AIs, 1 0 0 0 1 0 0 0 4 0 JJ JJ NN RB CD O
namely namely 0 0 0 0 0 0 0 0 6 0 JJ NN RB CD NN O
3β-hydroxyandrost-4-en-17-one 3β-hydroxyandrost-4-en-17-one 0 0 1 0 0 0 0 1 29 0 NN RB CD NN NN O
(1), (1), 0 0 0 0 1 0 0 1 4 0 RB CD NN NN NN O
androst-4-en-17-one androst-4-en-17-one 0 0 1 0 0 0 0 1 19 0 CD NN NN NN CD O
(12), (12), 0 0 0 0 1 0 0 1 5 0 NN NN NN CD NN O
4α,5α-epoxyandrostan-17-one 4α,5α-epoxyandrostan-17-one 0 0 1 0 1 0 0 1 27 0 NN NN CD NN CC O
(13a) (13a) 0 0 0 0 0 0 0 1 5 0 NN CD NN CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD NN CC CD NN O
5α-androst-2-en-17-one 5α-androst-2-en-17-one 0 0 1 0 0 0 0 1 22 0 NN CC CD NN IN O
(16), (16), 0 0 0 0 1 0 0 1 5 0 CC CD NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 CD NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN NN O
proliferation, proliferation, 0 0 0 0 1 0 0 0 14 0 IN NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NN NN NN NN CC O
progression progression 0 0 0 0 0 0 0 0 11 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN CC NN NN IN O
death death 0 0 0 0 0 0 0 0 5 0 CC NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT JJ JJ O
ER+ ER+ 1 1 0 0 0 0 0 0 3 0 IN DT JJ JJ NN O
aromatase-overexpressing aromatase-overexpressing 0 0 1 0 0 0 0 0 24 0 DT JJ JJ NN NN O
human human 0 0 0 0 0 0 0 0 5 0 JJ JJ NN NN NN O
breast breast 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN NNP O
line line 0 0 0 0 0 0 0 0 4 0 NN NN NN NNP NNP O
(MCF-7aro). (MCF-7aro). 0 0 1 0 0 0 0 1 11 0 NN NN NNP NNP NNP O
All All 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNP VBD O
AIs AIs 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP VBD DT O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBD DT NN IN O
decrease decrease 0 0 0 0 0 0 0 0 8 0 VBD DT NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 IN NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT JJ O
these these 0 0 0 0 0 0 0 0 5 0 NN CC DT JJ NNS O
anti-proliferative anti-proliferative 0 0 1 0 0 0 0 0 18 0 CC DT JJ NNS VBD O
effects effects 0 0 0 0 0 0 0 0 7 0 DT JJ NNS VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 NNS VBD JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBD JJ TO DT NN O
a a 0 0 0 0 0 0 0 0 1 0 JJ TO DT NN IN O
disruption disruption 0 0 0 0 0 0 0 0 10 0 TO DT NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN NN CC O
progression progression 0 0 0 0 0 0 0 0 11 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN CC NN NN IN O
death, death, 0 0 0 0 1 0 0 0 6 0 CC NN NN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
apoptosis. apoptosis. 0 0 0 0 0 0 0 0 10 0 NN IN NNP NNP CD O
AIs AIs 1 0 0 0 0 0 0 0 3 0 IN NNP NNP CD CC O
1 1 0 0 0 0 0 0 1 1 1 0 NNP NNP CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NNP CD CC CD VBD O
16 16 0 0 0 0 0 0 1 1 2 0 CD CC CD VBD NN O
caused caused 0 0 0 0 0 0 0 0 6 0 CC CD VBD NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 CD VBD NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest VBD NN NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP IN O
G0/G1, G0/G1, 1 1 0 1 1 0 0 1 6 0 NN IN NNP IN NNP B_TIMEXCCP
while while 0 0 0 0 0 0 0 0 5 0 IN NNP IN NNP CD O
AIs AIs 1 0 0 0 0 0 0 0 3 0 NNP IN NNP CD CC O
12 12 0 0 0 0 0 0 1 1 2 0 IN NNP CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NNP CD CC CD VBD O
13a 13a 0 0 0 0 0 0 0 1 3 0 CD CC CD VBD DT O
induced induced 0 0 0 0 0 0 0 0 7 0 CC CD VBD DT NN O
an an 0 0 0 0 0 0 0 0 2 arrest CD VBD DT NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 VBD DT NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
G2/M. G2/M. 1 1 0 1 0 0 0 1 5 0 NN IN NNP NNP PRP B_TIMEXCCP
Moreover, Moreover, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP PRP VBD O
it it 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP PRP VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 PRP VBD VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 VBD VBN IN DT NNP O
these these 0 0 0 0 0 0 0 0 5 0 VBN IN DT NNP VBD O
AIs AIs 1 0 0 0 0 0 0 0 3 0 IN DT NNP VBD NN O
induced induced 0 0 0 0 0 0 0 0 7 0 DT NNP VBD NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NNP VBD NN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBD NN IN JJ NN O
different different 0 0 0 0 0 0 0 0 9 0 NN IN JJ NN IN O
pathways, pathways, 0 0 0 0 1 0 0 0 9 0 IN JJ NN IN NNP O
since since 0 0 0 0 0 0 0 0 5 0 JJ NN IN NNP CD O
AIs AIs 1 0 0 0 0 0 0 0 3 0 NN IN NNP CD CD O
1, 1, 0 0 0 0 1 0 0 1 2 0 IN NNP CD CD CC O
12 12 0 0 0 0 0 0 1 1 2 0 NNP CD CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD CD CC CD VBD O
13a 13a 0 0 0 0 0 0 0 1 3 0 CD CC CD VBD DT O
activated activated 0 0 0 0 0 0 0 0 9 0 CC CD VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CD VBD DT JJ JJ O
apoptotic apoptotic 0 0 0 0 0 0 0 0 9 0 VBD DT JJ JJ NN O
mitochondrial mitochondrial 0 0 0 0 0 0 0 0 13 0 DT JJ JJ NN IN O
pathway, pathway, 0 0 0 0 1 0 0 0 8 0 JJ JJ NN IN NNP O
while while 0 0 0 0 0 0 0 0 5 0 JJ NN IN NNP CD O
AI AI 1 1 0 0 0 0 0 0 2 0 NN IN NNP CD VBD O
16 16 0 0 0 0 0 0 1 1 2 0 IN NNP CD VBD NN O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP CD VBD NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 CD VBD NN IN NN O
through through 0 0 0 0 0 0 0 0 7 0 VBD NN IN NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 NN IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNP O
caspase-8. caspase-8. 0 0 1 0 0 0 0 1 10 0 NN IN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNS VBP JJ IN O
important important 0 0 0 0 0 0 0 0 9 0 NNS VBP JJ IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBP JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN IN O
elucidation elucidation 0 0 0 0 0 0 0 0 11 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNS O
cellular cellular 0 0 0 0 0 0 0 0 8 0 IN DT JJ NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 DT JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NNP O
steroidal steroidal 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NNP IN O
AIs AIs 1 0 0 0 0 0 0 0 3 0 IN JJ NNP IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 JJ NNP IN JJ NN O
breast breast 0 0 0 0 0 0 0 0 6 0 NNP IN JJ NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNS CC O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS CC MD O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC MD RB O
will will 0 0 0 0 0 0 0 0 4 0 NNS CC MD RB VB O
also also 0 0 0 0 0 0 0 0 4 0 CC MD RB VB DT O
highlight highlight 0 0 0 0 0 0 0 0 9 0 MD RB VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VB DT NN IN O
importance importance 0 0 0 0 0 0 0 0 10 0 VB DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
AIs AIs 1 0 0 0 0 0 0 0 3 0 NN IN NNP IN NNS O
as as 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNS IN O
inducers inducers 0 0 0 0 0 0 0 0 8 0 NNP IN NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NNS IN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NN O
hormone-dependent hormone-dependent 0 0 1 0 0 0 0 0 17 0 NN IN JJ NN NNP O
breast breast 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
cancers. cancers. 0 0 0 0 0 0 0 0 8 0 JJ NN NNP NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NNP NNP O
DREAM DREAM 1 1 0 0 0 0 0 0 5 0 NONE DT NNP NNP NN O
complex: complex: 0 0 0 0 0 0 0 0 8 0 DT NNP NNP NN NN O
master master 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NN IN O
coordinator coordinator 0 0 0 0 0 0 0 0 11 0 NNP NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN JJ O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN JJ NN O
cycle-dependent cycle-dependent 0 0 1 0 0 0 0 0 15 0 IN NN JJ NN NNP O
gene gene 0 0 0 0 0 0 0 0 4 0 NN JJ NN NNP NNP O
expression. expression. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP NNP NNP O
Sadasivam Sadasivam 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Decaprio Decaprio 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
JA. JA. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNP O
Stem Stem 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP CC O
Biology Biology 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Regenerative Regenerative 1 0 0 0 0 0 0 0 12 0 NNP CC NNP NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 CC NNP NNP NNP NNP O
National National 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Centre Centre 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNPS O
Biological Biological 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNPS NNP O
Sciences Sciences 1 0 0 0 0 0 0 0 8 0 IN NNP NNPS NNP NNP O
(TIFR), (TIFR), 0 1 0 0 1 0 0 0 7 0 NNP NNPS NNP NNP NNP O
Bellary Bellary 1 0 0 0 0 0 0 0 7 0 NNPS NNP NNP NNP NNP O
Road, Road, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP CD O
Bangalore Bangalore 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP CD NNP O
560065, 560065, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP NNP O
India. India. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN -NONE- O
dimerization dimerization 0 0 0 0 0 0 0 0 12 0 NNP NNP NN -NONE- -NONE- O
partner, partner, 0 0 0 0 1 0 0 0 8 0 NNP NN -NONE- -NONE- NNP O
RB-like, RB-like, 1 0 1 0 1 0 0 0 8 0 NN -NONE- -NONE- NNP CC O
E2F E2F 1 1 0 0 0 0 0 1 3 0 -NONE- -NONE- NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NNP CC JJ NN O
multi-vulval multi-vulval 0 0 1 0 0 0 0 0 12 0 NNP CC JJ NN NNP O
class class 0 0 0 0 0 0 0 0 5 0 CC JJ NN NNP NNP O
B B 1 1 0 0 0 0 0 0 1 0 JJ NN NNP NNP NN O
(DREAM) (DREAM) 0 1 0 0 0 0 0 0 7 0 NN NNP NNP NN VBZ O
complex complex 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBZ DT O
provides provides 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ DT RB O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT RB VBN O
previously previously 0 0 0 0 0 0 0 0 10 0 VBZ DT RB VBN VBG O
unsuspected unsuspected 0 0 0 0 0 0 0 0 11 0 DT RB VBN VBG NN O
unifying unifying 0 0 0 0 0 0 0 0 8 0 RB VBN VBG NN IN O
role role 0 0 0 0 0 0 0 0 4 0 VBN VBG NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBG NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN IN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN IN RB O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN RB VBG O
directly directly 0 0 0 0 0 0 0 0 8 0 NN IN RB VBG NN O
linking linking 0 0 0 0 0 0 0 0 7 0 IN RB VBG NN -NONE- O
p130, p130, 0 0 0 0 1 0 0 1 5 0 RB VBG NN -NONE- -NONE- O
p107, p107, 0 0 0 0 1 0 0 1 5 0 VBG NN -NONE- -NONE- NNP O
E2F, E2F, 1 1 0 0 1 0 0 1 4 0 NN -NONE- -NONE- NNP CC O
BMYB BMYB 1 1 0 0 0 0 0 0 4 0 -NONE- -NONE- NNP CC VB O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NNP CC VB NN O
forkhead forkhead 0 0 0 0 0 0 0 0 8 0 NNP CC VB NN NN O
box box 0 0 0 0 0 0 0 0 3 0 CC VB NN NN NNP O
protein protein 0 0 0 0 0 0 0 0 7 0 VB NN NN NNP NNP O
M1. M1. 1 1 0 0 0 0 0 1 3 0 NN NN NNP NNP VBZ O
DREAM DREAM 1 1 0 0 0 0 0 0 5 0 NN NNP NNP VBZ NN O
mediates mediates 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ NN NN O
gene gene 0 0 0 0 0 0 0 0 4 0 NNP VBZ NN NN IN O
repression repression 0 0 0 0 0 0 0 0 10 0 VBZ NN NN IN DT O
during during 0 0 0 0 0 0 0 0 6 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
G0 G0 1 1 0 0 0 0 0 1 2 phase IN DT NNP NN CC B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NNP NN CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC VBZ JJ O
coordinates coordinates 0 0 0 0 0 0 0 0 11 0 NN CC VBZ JJ NN O
periodic periodic 0 0 0 0 0 0 0 0 8 0 CC VBZ JJ NN NN O
gene gene 0 0 0 0 0 0 0 0 4 0 VBZ JJ NN NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 JJ NN NN IN NNS O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN NNS IN O
peaks peaks 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN DT O
during during 0 0 0 0 0 0 0 0 6 0 IN NNS IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNS CC O
G1/S G1/S 1 1 0 1 0 0 0 1 4 0 IN DT NNS CC JJ B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 DT NNS CC JJ NNP O
G2/M G2/M 1 1 0 1 0 0 0 1 4 0 NNS CC JJ NNP NNP B_TIMEXCCP
phases. phases. 0 0 0 0 0 0 0 0 7 0 CC JJ NNP NNP IN O
Perturbations Perturbations 1 0 0 0 0 0 0 0 13 0 JJ NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NN O
DREAM DREAM 1 1 0 0 0 0 0 0 5 0 NNP IN NNP NN NN O
complex complex 0 0 0 0 0 0 0 0 7 0 IN NNP NN NN NN O
regulation regulation 0 0 0 0 0 0 0 0 10 0 NNP NN NN NN DT O
shift shift 0 0 0 0 0 0 0 0 5 0 NN NN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NN IN O
balance balance 0 0 0 0 0 0 0 0 7 0 NN DT NN IN NN O
from from 0 0 0 0 0 0 0 0 4 0 DT NN IN NN NNS O
quiescence quiescence 0 0 0 0 0 0 0 0 10 0 NN IN NN NNS NN O
towards towards 0 0 0 0 0 0 0 0 7 0 IN NN NNS NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NN NNS NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNS NN CC NN TO O
contribute contribute 0 0 0 0 0 0 0 0 10 0 NN CC NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 CC NN TO DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT VBN JJ O
increased increased 0 0 0 0 0 0 0 0 9 0 TO DT VBN JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 DT VBN JJ NN NN O
gene gene 0 0 0 0 0 0 0 0 4 0 VBN JJ NN NN NNS O
expression expression 0 0 0 0 0 0 0 0 10 0 JJ NN NN NNS WDT O
levels levels 0 0 0 0 0 0 0 0 6 0 NN NN NNS WDT VBP O
that that 0 0 0 0 0 0 0 0 4 0 NN NNS WDT VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 NNS WDT VBP RB VBN O
frequently frequently 0 0 0 0 0 0 0 0 10 0 WDT VBP RB VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 VBP RB VBN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN NNS IN O
cancers cancers 0 0 0 0 0 0 0 0 7 0 VBN IN NNS IN DT O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ NNP O
poor poor 0 0 0 0 0 0 0 0 4 0 IN DT JJ NNP NONE O
prognosis. prognosis. 0 0 0 0 0 0 0 0 10 0 DT JJ NNP NONE NONE O
Assessment Assessment 1 0 0 0 0 0 0 0 10 0 NONE NONE NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NNP IN NNP NNP O
Patients' Patients' 1 0 0 0 0 1 0 0 9 0 NNP IN NNP NNP IN O
Dignity Dignity 1 0 0 0 0 0 0 0 7 0 IN NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNP O
Care: Care: 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
Preliminary Preliminary 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP IN O
Psychometrics Psychometrics 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP NNP O
German German 1 0 0 0 0 0 0 0 6 0 IN DT NNP NNP IN O
Version Version 1 0 0 0 0 0 0 0 7 0 DT NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP NNP O
Patient Patient 1 0 0 0 0 0 0 0 7 0 IN DT NNP NNP NNP O
Dignity Dignity 1 0 0 0 0 0 0 0 7 0 DT NNP NNP NNP NNP O
Inventory Inventory 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
(PDI-G). (PDI-G). 0 1 1 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Sautier Sautier 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
LP, LP, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Vehling Vehling 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Mehnert Mehnert 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
A. A. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
Psychology, Psychology, 1 0 0 0 1 0 0 0 11 0 IN NNP NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Center Center 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Hamburg-Eppendorf, Hamburg-Eppendorf, 1 0 1 0 1 0 0 0 18 0 NNP NNP NNP NNP NNP O
Hamburg, Hamburg, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Germany. Germany. 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Electronic Electronic 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
address: address: 0 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
l.sautier@uke.de. l.sautier@uke.de. 0 0 0 0 0 0 0 0 17 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
CONTEXT: CONTEXT: 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Patient Patient 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Dignity Dignity 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Inventory Inventory 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP VBZ O
(PDI) (PDI) 0 1 0 0 0 0 0 0 5 0 NNP NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT JJ CC O
valid valid 0 0 0 0 0 0 0 0 5 0 VBZ DT JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC JJ NN O
reliable reliable 0 0 0 0 0 0 0 0 8 0 JJ CC JJ NN VBN O
instrument instrument 0 0 0 0 0 0 0 0 10 0 CC JJ NN VBN TO O
designed designed 0 0 0 0 0 0 0 0 8 0 JJ NN VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBN TO VB JJ O
measure measure 0 0 0 0 0 0 0 0 7 0 VBN TO VB JJ NNS O
different different 0 0 0 0 0 0 0 0 9 0 TO VB JJ NNS IN O
sources sources 0 0 0 0 0 0 0 0 7 0 VB JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
dignity-related dignity-related 0 0 1 0 0 0 0 0 15 0 NNS IN JJ NN IN O
distress distress 0 0 0 0 0 0 0 0 8 0 IN JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN IN NN NNS VBG O
patients patients 0 0 0 0 0 0 0 0 8 0 IN NN NNS VBG JJ O
receiving receiving 0 0 0 0 0 0 0 0 9 0 NN NNS VBG JJ NNP O
palliative palliative 0 0 0 0 0 0 0 0 10 0 NNS VBG JJ NNP NNP O
care. care. 0 0 0 0 0 0 0 0 5 0 VBG JJ NNP NNP NNP O
OBJECTIVES: OBJECTIVES: 1 1 0 0 0 0 0 0 11 0 JJ NNP NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBD NN O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NNP NNP VBD NN -NONE- O
item item 0 0 0 0 0 0 0 0 4 0 NNP VBD NN -NONE- NN O
characteristics, characteristics, 0 0 0 0 1 0 0 0 16 0 VBD NN -NONE- NN -NONE- O
factor factor 0 0 0 0 0 0 0 0 6 0 NN -NONE- NN -NONE- JJ O
structure, structure, 0 0 0 0 1 0 0 0 10 0 -NONE- NN -NONE- JJ CC O
reliability, reliability, 0 0 0 0 1 0 0 0 12 0 NN -NONE- JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- JJ CC NN NN O
concurrent concurrent 0 0 0 0 0 0 0 0 10 0 JJ CC NN NN IN O
validity validity 0 0 0 0 0 0 0 0 8 0 CC NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
German German 1 0 0 0 0 0 0 0 6 0 IN DT NNP NN IN O
version version 0 0 0 0 0 0 0 0 7 0 DT NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
PDI PDI 1 1 0 0 0 0 0 0 3 0 IN DT NNP NNP IN O
(PDI-G) (PDI-G) 0 1 1 0 0 0 0 0 7 0 DT NNP NNP IN NNS O
among among 0 0 0 0 0 0 0 0 5 0 NNP NNP IN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 NNP IN NNS IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN NNP NNP O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 NNS IN NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 IN NNP NNP NNP VBD O
PDI PDI 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
translated translated 0 0 0 0 0 0 0 0 10 0 NNP VBD VBN IN DT O
into into 0 0 0 0 0 0 0 0 4 0 VBD VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NN O
German German 1 0 0 0 0 0 0 0 6 0 IN DT NNP NN VBG O
language language 0 0 0 0 0 0 0 0 8 0 DT NNP NN VBG NN O
following following 0 0 0 0 0 0 0 0 9 0 NNP NN VBG NN NNP O
state-of-the-art state-of-the-art 0 0 1 0 0 0 0 0 16 0 NN VBG NN NNP NNP O
criteria. criteria. 0 0 0 0 0 0 0 0 9 0 VBG NN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT NN IN O
sample sample 0 0 0 0 0 0 0 0 6 0 NNP DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD NNS O
112 112 0 0 0 0 0 0 1 1 3 0 NN IN CD NNS IN O
inpatients inpatients 0 0 0 0 0 0 0 0 10 0 IN CD NNS IN VBN O
with with 0 0 0 0 0 0 0 0 4 0 CD NNS IN VBN NN O
mixed mixed 0 0 0 0 0 0 0 0 5 0 NNS IN VBN NN -NONE- O
tumor tumor 0 0 0 0 0 0 0 0 5 0 IN VBN NN -NONE- NN O
types, types, 0 0 0 0 1 0 0 0 6 0 VBN NN -NONE- NN NN O
principal principal 0 0 0 0 0 0 0 0 9 0 NN -NONE- NN NN NN O
component component 0 0 0 0 0 0 0 0 9 0 -NONE- NN NN NN NN O
analysis, analysis, 0 0 0 0 1 0 0 0 9 0 NN NN NN NN NN O
reliability reliability 0 0 0 0 0 0 0 0 11 0 NN NN NN NN VBZ O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NN NN NN VBZ NN O
(Cronbach's (Cronbach's 0 0 0 0 0 1 0 0 11 0 NN NN VBZ NN -NONE- O
coefficient coefficient 0 0 0 0 0 0 0 0 11 0 NN VBZ NN -NONE- CC O
alpha), alpha), 0 0 0 0 1 0 0 0 7 0 VBZ NN -NONE- CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC NN NN O
correlation correlation 0 0 0 0 0 0 0 0 11 0 -NONE- CC NN NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 CC NN NN VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD NNP NNP O
performed. performed. 0 0 0 0 0 0 0 0 10 0 NN VBD NNP NNP NN O
Concurrent Concurrent 1 0 0 0 0 0 0 0 10 0 VBD NNP NNP NN VBD O
validity validity 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN VBN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN VBN NNS O
validated validated 0 0 0 0 0 0 0 0 9 0 VBN IN VBN NNS IN O
measures measures 0 0 0 0 0 0 0 0 8 0 IN VBN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBN NNS IN JJ NN O
distress, distress, 0 0 0 0 1 0 0 0 9 0 NNS IN JJ NN NN O
demoralization, demoralization, 0 0 0 0 1 0 0 0 15 0 IN JJ NN NN NN O
anxiety, anxiety, 0 0 0 0 1 0 0 0 8 0 JJ NN NN NN NN O
depression, depression, 0 0 0 0 1 0 0 0 11 0 NN NN NN NN NN O
hopelessness, hopelessness, 0 0 0 0 1 0 0 0 13 0 NN NN NN NN IN O
quality quality 0 0 0 0 0 0 0 0 7 0 NN NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NN O
life, life, 0 0 0 0 1 0 0 0 5 0 NN IN NNP NN IN O
sense sense 0 0 0 0 0 0 0 0 5 0 IN NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN CC O
meaning meaning 0 0 0 0 0 0 0 0 7 0 NN IN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NNP CC O
purpose, purpose, 0 0 0 0 1 0 0 0 8 0 NN CC NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC JJ NN O
supportive supportive 0 0 0 0 0 0 0 0 10 0 NNP CC JJ NN NNP O
care care 0 0 0 0 0 0 0 0 4 0 CC JJ NN NNP NNP O
needs. needs. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 NN NNP NNP NNP NN O
Cronbach's Cronbach's 1 0 0 0 0 1 0 0 10 0 NNP NNP NNP NN NN O
coefficient coefficient 0 0 0 0 0 0 0 0 11 0 NNP NNP NN NN IN O
alpha alpha 0 0 0 0 0 0 0 0 5 0 NNP NN NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN JJ VBD O
PDI-G PDI-G 1 1 1 0 0 0 0 0 5 0 NN IN JJ VBD CD O
was was 0 0 0 0 0 0 0 0 3 0 IN JJ VBD CD NN O
0.96; 0.96; 0 0 0 0 0 0 0 1 5 0 JJ VBD CD NN NN O
factor factor 0 0 0 0 0 0 0 0 6 0 VBD CD NN NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 CD NN NN VBD IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN VBD IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBD IN DT NN NN O
four-factor four-factor 0 0 1 0 0 0 0 0 11 0 IN DT NN NN VBG O
solution, solution, 0 0 0 0 1 0 0 0 9 0 DT NN NN VBG IN O
accounting accounting 0 0 0 0 0 0 0 0 10 0 NN NN VBG IN CD O
for for 0 0 0 0 0 0 0 0 3 0 NN VBG IN CD IN O
71% 71% 0 0 0 0 0 0 0 1 3 0 VBG IN CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN CD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT JJ NN O
overall overall 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN IN O
variance, variance, 0 0 0 0 1 0 0 0 9 0 DT JJ NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN NN NNS O
factor factor 0 0 0 0 0 0 0 0 6 0 NN IN NN NNS VBG O
loadings loadings 0 0 0 0 0 0 0 0 8 0 IN NN NNS VBG IN O
ranging ranging 0 0 0 0 0 0 0 0 7 0 NN NNS VBG IN CD O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBG IN CD TO O
0.49 0.49 0 0 0 0 0 0 0 1 4 0 VBG IN CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 IN CD TO CD NNP O
0.86. 0.86. 0 0 0 0 0 0 0 1 5 0 CD TO CD NNP NNS O
Factor Factor 1 0 0 0 0 0 0 0 6 0 TO CD NNP NNS VBP O
labels labels 0 0 0 0 0 0 0 0 6 0 CD NNP NNS VBP NNP O
include include 0 0 0 0 0 0 0 0 7 0 NNP NNS VBP NNP IN O
Loss Loss 1 0 0 0 0 0 0 0 4 0 NNS VBP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBP NNP IN NNP IN O
Sense Sense 1 0 0 0 0 0 0 0 5 0 NNP IN NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP CC O
Worth Worth 1 0 0 0 0 0 0 0 5 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Meaning, Meaning, 1 0 0 0 1 0 0 0 8 0 NNP CC NNP NNP CC O
Anxiety Anxiety 1 0 0 0 0 0 0 0 7 0 CC NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Uncertainty, Uncertainty, 1 0 0 0 1 0 0 0 12 0 NNP CC NNP NNP NNP O
Physical Physical 1 0 0 0 0 0 0 0 8 0 CC NNP NNP NNP NNP O
Symptom Symptom 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP CC O
Distress Distress 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Body Body 1 0 0 0 0 0 0 0 4 0 NNP CC NNP NNP CC O
Image, Image, 1 0 0 0 1 0 0 0 6 0 CC NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP IN O
Loss Loss 1 0 0 0 0 0 0 0 4 0 NNP CC NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NNP IN NNP NN O
Autonomy, Autonomy, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NN JJ O
showing showing 0 0 0 0 0 0 0 0 7 0 IN NNP NN JJ JJ O
high high 0 0 0 0 0 0 0 0 4 0 NNP NN JJ JJ NNS O
internal internal 0 0 0 0 0 0 0 0 8 0 NN JJ JJ NNS VBG O
consistencies consistencies 0 0 0 0 0 0 0 0 13 0 JJ JJ NNS VBG IN O
ranging ranging 0 0 0 0 0 0 0 0 7 0 JJ NNS VBG IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBG IN JJ NN O
Cronbach's Cronbach's 1 0 0 0 0 1 0 0 10 0 VBG IN JJ NN CD O
α α 0 0 0 0 0 0 0 0 1 0 IN JJ NN CD TO O
0.80 0.80 0 0 0 0 0 0 0 1 4 0 JJ NN CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 NN CD TO CD NNP O
0.95. 0.95. 0 0 0 0 0 0 0 1 5 0 CD TO CD NNP IN O
Evidence Evidence 1 0 0 0 0 0 0 0 8 0 TO CD NNP IN NN O
for for 0 0 0 0 0 0 0 0 3 0 CD NNP IN NN NN O
concurrent concurrent 0 0 0 0 0 0 0 0 10 0 NNP IN NN NN VBD O
validity validity 0 0 0 0 0 0 0 0 8 0 IN NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
established established 0 0 0 0 0 0 0 0 11 0 NN VBD VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NNS O
significant significant 0 0 0 0 0 0 0 0 11 0 VBN IN JJ NNS IN O
associations associations 0 0 0 0 0 0 0 0 12 0 IN JJ NNS IN JJ O
between between 0 0 0 0 0 0 0 0 7 0 JJ NNS IN JJ NNS O
PDI-G PDI-G 1 1 1 0 0 0 0 0 5 0 NNS IN JJ NNS CC O
scales scales 0 0 0 0 0 0 0 0 6 0 IN JJ NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC NN NNS O
concurrent concurrent 0 0 0 0 0 0 0 0 10 0 NNS CC NN NNS IN O
measures measures 0 0 0 0 0 0 0 0 8 0 CC NN NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP NNP O
distress. distress. 0 0 0 0 0 0 0 0 9 0 NNS IN NNP NNP NNP O
CONCLUSION: CONCLUSION: 1 1 0 0 0 0 0 0 11 0 IN NNP NNP NNP PRP O
Although Although 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 NNP PRP VBD JJ TO O
unable unable 0 0 0 0 0 0 0 0 6 0 PRP VBD JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD JJ TO VB DT O
replicate replicate 0 0 0 0 0 0 0 0 9 0 JJ TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN NN O
five-factor five-factor 0 0 1 0 0 0 0 0 11 0 VB DT NN NN VBD O
structure structure 0 0 0 0 0 0 0 0 9 0 DT NN NN VBD IN O
provided provided 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN NN DT O
Chochinov, Chochinov, 1 0 0 0 1 0 0 0 10 0 VBD IN NN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 IN NN DT NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NN DT NN VBD JJ O
gave gave 0 0 0 0 0 0 0 0 4 0 DT NN VBD JJ NN O
strong strong 0 0 0 0 0 0 0 0 6 0 NN VBD JJ NN TO O
support support 0 0 0 0 0 0 0 0 7 0 VBD JJ NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NN TO DT NN NN O
alternative alternative 0 0 0 0 0 0 0 0 11 0 TO DT NN NN NN O
four-factor four-factor 0 0 1 0 0 0 0 0 11 0 DT NN NN NN IN O
solution solution 0 0 0 0 0 0 0 0 8 0 NN NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NN O
PDI-G, PDI-G, 1 1 1 0 1 0 0 0 6 0 NN IN NNP NN DT O
capturing capturing 0 0 0 0 0 0 0 0 9 0 IN NNP NN DT CD O
all all 0 0 0 0 0 0 0 0 3 0 NNP NN DT CD NNP O
25 25 0 0 0 0 0 0 1 1 2 0 NN DT CD NNP NNP O
items. items. 0 0 0 0 0 0 0 0 6 0 DT CD NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 CD NNP NNP VBP IN O
conclude conclude 0 0 0 0 0 0 0 0 8 0 NNP NNP VBP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBP IN JJ VBZ O
PDI-G PDI-G 1 1 1 0 0 0 0 0 5 0 VBP IN JJ VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 IN JJ VBZ DT RB O
a a 0 0 0 0 0 0 0 0 1 0 JJ VBZ DT RB VBN O
psychometrically psychometrically 0 0 0 0 0 0 0 0 16 0 VBZ DT RB VBN NN O
sound sound 0 0 0 0 0 0 0 0 5 0 DT RB VBN NN NN O
instrument instrument 0 0 0 0 0 0 0 0 10 0 RB VBN NN NN DT O
assessing assessing 0 0 0 0 0 0 0 0 9 0 VBN NN NN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN NN DT JJ NN O
broad broad 0 0 0 0 0 0 0 0 5 0 NN DT JJ NN IN O
range range 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
dignity-related dignity-related 0 0 1 0 0 0 0 0 15 0 NN IN JJ NN NNS O
distress distress 0 0 0 0 0 0 0 0 8 0 IN JJ NN NNS IN O
issues issues 0 0 0 0 0 0 0 0 6 0 JJ NN NNS IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 NNS IN NNS IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN NNP NNP O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 NNS IN NNP NNP NNP O
Copyright Copyright 1 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP CD O
© © 0 0 0 0 0 0 0 0 1 0 NNP NNP NNP CD NNP O
2013 2013 0 0 0 0 0 0 1 1 4 0 NNP NNP CD NNP NNP O
U.S. U.S. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 CD NNP NNP NNP NNP O
Pain Pain 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Relief Relief 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Committee. Committee. 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP IN O
Published Published 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Elsevier Elsevier 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Inc. Inc. 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNS O
All All 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS NNP O
rights rights 0 0 0 0 0 0 0 0 6 0 NNP NNP NNS NNP NNP O
reserved. reserved. 0 0 0 0 0 0 0 0 9 0 NNP NNS NNP NNP NNP O
KEYWORDS: KEYWORDS: 1 1 0 0 0 0 0 0 9 0 NNS NNP NNP NNP NNP O
Dignity, Dignity, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Patient Patient 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Dignity Dignity 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Inventory, Inventory, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
cancer, cancer, 0 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
distress, distress, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP JJ O
measurement, measurement, 0 0 0 0 1 0 0 0 12 0 NNP NNP NNP JJ NN O
palliative palliative 0 0 0 0 0 0 0 0 10 0 NNP NNP JJ NN NONE O
care care 0 0 0 0 0 0 0 0 4 0 NNP JJ NN NONE NONE O
SHP1-mediated SHP1-mediated 1 0 1 0 0 0 0 1 13 0 NONE NONE JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NONE JJ NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 JJ NN NN NN NNS O
redistribution redistribution 0 0 0 0 0 0 0 0 14 0 NN NN NN NNS NN O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 NN NN NNS NN IN O
radiosensitivity radiosensitivity 0 0 0 0 0 0 0 0 16 0 NN NNS NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNS NN IN JJ NN O
non-small non-small 0 0 1 0 0 0 0 0 9 0 NN IN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN NNP O
lung lung 0 0 0 0 0 0 0 0 4 0 JJ NN NN NNP NNP O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP NNP O
Cao Cao 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ding Ding 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Q, Q, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Xue Xue 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zou Zou 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Huang Huang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Peng Peng 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
G. G. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Center Center 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Union Union 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Hospital, Hospital, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Tongji Tongji 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
College, College, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Huazhong Huazhong 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Science Science 1 0 0 0 0 0 0 0 7 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Technology, Technology, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP CD O
No, No, 1 0 0 0 1 0 0 0 3 0 CC NNP NNP CD NNP O
1227 1227 0 0 0 0 0 0 1 1 4 0 NNP NNP CD NNP NNP O
Jiefang Jiefang 1 0 0 0 0 0 0 0 7 0 NNP CD NNP NNP NNP O
Dadao, Dadao, 1 0 0 0 1 0 0 0 6 0 CD NNP NNP NNP CD O
Wuhan Wuhan 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP CD NNP O
430022, 430022, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
penggang1977@163.com. penggang1977@163.com. 0 0 0 0 0 0 0 1 21 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP VBZ O
Radioresistance Radioresistance 1 0 0 0 0 0 0 0 15 0 NNP NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT JJ NN O
common common 0 0 0 0 0 0 0 0 6 0 VBZ DT JJ NN IN O
cause cause 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN NN O
radiotherapy radiotherapy 0 0 0 0 0 0 0 0 12 0 NN IN NN NN IN O
failure failure 0 0 0 0 0 0 0 0 7 0 IN NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
non-small non-small 0 0 1 0 0 0 0 0 9 0 NN IN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN NN O
lung lung 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN NN NN NN CC O
(NSCLC), (NSCLC), 0 1 0 0 1 0 0 0 8 0 NN NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN IN O
degree degree 0 0 0 0 0 0 0 0 6 0 CC DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
radiosensitivity radiosensitivity 0 0 0 0 0 0 0 0 16 0 NN IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NNS O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NN IN NN NNS VBZ O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NN NNS VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN NNS VBZ JJ IN O
different different 0 0 0 0 0 0 0 0 9 0 NNS VBZ JJ IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 VBZ JJ IN JJ NN O
different different 0 0 0 0 0 0 0 0 9 0 JJ IN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN NNP O
cycle cycle 0 0 0 0 0 0 0 0 5 0 JJ NN NN NNP NNP O
phases. phases. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
objective objective 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
present present 0 0 0 0 0 0 0 0 7 0 IN DT NN NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 DT NN NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB DT O
investigate investigate 0 0 0 0 0 0 0 0 11 0 VBD TO VB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 VB DT NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN NN IN O
redistribution redistribution 0 0 0 0 0 0 0 0 14 0 NN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
establishment establishment 0 0 0 0 0 0 0 0 13 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
radioresistance radioresistance 0 0 0 0 0 0 0 0 15 0 NN IN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP IN O
NSCLC, NSCLC, 1 1 0 0 1 0 0 0 6 0 NN IN NNP IN RB O
as as 0 0 0 0 0 0 0 0 2 0 IN NNP IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NNP IN RB IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NN NN O
signaling signaling 0 0 0 0 0 0 0 0 9 0 IN DT NN NN IN O
pathway pathway 0 0 0 0 0 0 0 0 7 0 DT NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NN O
SH2 SH2 1 1 0 0 0 0 0 1 3 0 NN IN NNP NN NNP O
containing containing 0 0 0 0 0 0 0 0 10 0 IN NNP NN NNP NNP O
Tyrosine Tyrosine 1 0 0 0 0 0 0 0 8 0 NNP NN NNP NNP NNP O
Phosphatase Phosphatase 1 0 0 0 0 0 0 0 11 0 NN NNP NNP NNP NNP O
(SHP1). (SHP1). 0 1 0 0 0 0 0 1 7 0 NNP NNP NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NNP NN O
NSCLC NSCLC 1 1 0 0 0 0 0 0 5 0 NNP NNP NNP NN NN O
subtype subtype 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP NN NN NN NN O
line, line, 0 0 0 0 1 0 0 0 5 0 NN NN NN NN NNP O
radioresistant radioresistant 0 0 0 0 0 0 0 0 14 0 NN NN NN NNP NNP O
A549 A549 1 1 0 0 0 0 0 1 4 0 NN NN NNP NNP VBD O
(A549S1), (A549S1), 0 1 0 0 1 0 0 1 9 0 NN NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP VBD VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ VBN O
high-dose high-dose 0 0 1 0 0 0 0 0 9 0 VBN IN JJ VBN VBG O
hypofractionated hypofractionated 0 0 0 0 0 0 0 0 16 0 IN JJ VBN VBG NNP O
ionizing ionizing 0 0 0 0 0 0 0 0 8 0 JJ VBN VBG NNP JJ O
radiations. radiations. 0 0 0 0 0 0 0 0 11 0 VBN VBG NNP JJ NN O
Radiosensitivity-related Radiosensitivity-related 1 0 1 0 0 0 0 0 24 0 VBG NNP JJ NN NN O
parameters, parameters, 0 0 0 0 1 0 0 0 11 0 NNP JJ NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NN NN NN NN CC O
distribution distribution 0 0 0 0 0 0 0 0 12 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NN CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN JJ O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN JJ NNS O
cycle-related cycle-related 0 0 1 0 0 0 0 0 13 0 IN NN JJ NNS CC O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NN JJ NNS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC NNP VBD O
SHP1 SHP1 1 1 0 0 0 0 0 1 4 0 NNS CC NNP VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 CC NNP VBD NNP NNP O
investigated. investigated. 0 0 0 0 0 0 0 0 13 0 NNP VBD NNP NNP VBD O
siRNA siRNA 0 0 0 0 0 0 0 0 5 0 VBD NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN TO O
designed designed 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO JJ NNP O
down-regulate down-regulate 0 0 1 0 0 0 0 0 13 0 VBN TO JJ NNP NNP O
SHP1expression. SHP1expression. 1 0 0 0 0 0 0 1 15 0 TO JJ NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 JJ NNP NNP NNP IN O
Compared Compared 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNP IN JJ NNP O
native native 0 0 0 0 0 0 0 0 6 0 NNP IN JJ NNP NNP O
A549 A549 1 1 0 0 0 0 0 1 4 0 IN JJ NNP NNP DT O
cells, cells, 0 0 0 0 1 0 0 0 6 0 JJ NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
proportion proportion 0 0 0 0 0 0 0 0 10 0 NNP DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase IN DT NNP NN VBD B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NNP NN VBD JJ O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD JJ CC O
increased, increased, 0 0 0 0 1 0 0 0 10 0 NN VBD JJ CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 VBD JJ CC NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ CC NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 CC NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase IN DT NN NN VBD B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NN NN VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD RB JJ O
consequently consequently 0 0 0 0 0 0 0 0 12 0 NN VBD RB JJ NN O
decreased, decreased, 0 0 0 0 1 0 0 0 10 0 VBD RB JJ NN DT O
however, however, 0 0 0 0 1 0 0 0 8 0 RB JJ NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NN IN O
proportion proportion 0 0 0 0 0 0 0 0 10 0 NN DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 phase IN DT NN NN VBD B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NN NN VBD RB O
did did 0 0 0 0 0 0 0 0 3 0 NN NN VBD RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NN VBD RB VB IN O
change change 0 0 0 0 0 0 0 0 6 0 VBD RB VB IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 RB VB IN NNP NNP O
A549S1 A549S1 1 1 0 0 0 0 0 1 6 0 VB IN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP DT O
Moreover, Moreover, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
SHP1, SHP1, 1 1 0 0 1 0 0 1 5 0 NN IN NNP NNP CC O
CDK4 CDK4 1 1 0 0 0 0 0 1 4 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP VBD O
CylinD1 CylinD1 1 0 0 0 0 0 0 1 7 0 NNP CC NNP VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 CC NNP VBD RB JJ O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNP VBD RB JJ IN O
increased, increased, 0 0 0 0 1 0 0 0 10 0 VBD RB JJ IN NNP O
while while 0 0 0 0 0 0 0 0 5 0 RB JJ IN NNP VBD O
p16 p16 0 0 0 0 0 0 0 1 3 0 JJ IN NNP VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 IN NNP VBD RB JJ O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNP VBD RB JJ IN O
down-regulated down-regulated 0 0 1 0 0 0 0 0 14 0 VBD RB JJ IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 RB JJ IN NNP NNS O
A549S1 A549S1 1 1 0 0 0 0 0 1 6 0 JJ IN NNP NNS VBN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS VBN IN O
compared compared 0 0 0 0 0 0 0 0 8 0 NNP NNS VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBN IN JJ NNP O
native native 0 0 0 0 0 0 0 0 6 0 VBN IN JJ NNP NNP O
A549 A549 1 1 0 0 0 0 0 1 4 0 IN JJ NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 JJ NNP NNP NNP NN O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 NNP NNP NNP NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP IN O
SHP1 SHP1 1 1 0 0 0 0 0 1 4 0 NN IN NNP IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP VBD O
siRNA siRNA 0 0 0 0 0 0 0 0 5 0 NNP IN NNP VBD DT O
increased increased 0 0 0 0 0 0 0 0 9 0 IN NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN IN O
radiosensitivity radiosensitivity 0 0 0 0 0 0 0 0 16 0 VBD DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
A549S1 A549S1 1 1 0 0 0 0 0 1 6 0 NN IN NNP NNP VBD O
cells, cells, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP VBD DT O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBD DT NN NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase VBD DT NN NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NN NN NN JJ O
arrest, arrest, 0 0 0 0 1 0 0 0 7 0 NN NN NN JJ NNP O
down-regulated down-regulated 0 0 1 0 0 0 0 0 14 0 NN NN JJ NNP CC O
CDK4 CDK4 1 1 0 0 0 0 0 1 4 0 NN JJ NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNP CC NNP CC O
CylinD1expressions, CylinD1expressions, 1 0 0 0 1 0 0 1 19 0 NNP CC NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC JJ NNP O
up-regulated up-regulated 0 0 1 0 0 0 0 0 12 0 NNP CC JJ NNP NNP O
p16 p16 0 0 0 0 0 0 0 1 3 0 CC JJ NNP NNP NNP O
expression. expression. 0 0 0 0 0 0 0 0 11 0 JJ NNP NNP NNP NNP O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 NNP NNP NNP NNP VBZ O
SHP1 SHP1 1 1 0 0 0 0 0 1 4 0 NNP NNP NNP VBZ DT O
decreases decreases 0 0 0 0 0 0 0 0 9 0 NNP NNP VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT NN IN O
radiosensitivity radiosensitivity 0 0 0 0 0 0 0 0 16 0 VBZ DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNS O
NSCLC NSCLC 1 1 0 0 0 0 0 0 5 0 NN IN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS IN VBG O
through through 0 0 0 0 0 0 0 0 7 0 NNP NNS IN VBG NN O
affecting affecting 0 0 0 0 0 0 0 0 9 0 NNS IN VBG NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN VBG NN NN NNP O
cycle cycle 0 0 0 0 0 0 0 0 5 0 VBG NN NN NNP NNP O
distribution. distribution. 0 0 0 0 0 0 0 0 13 0 NN NN NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NN MD O
finding finding 0 0 0 0 0 0 0 0 7 0 NNP NNP NN MD VB O
could could 0 0 0 0 0 0 0 0 5 0 NNP NN MD VB DT O
unravel unravel 0 0 0 0 0 0 0 0 7 0 NN MD VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 VB DT JJ NN VBN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 DT JJ NN VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 JJ NN VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN VBN IN NNP NNP O
NSCLC NSCLC 1 1 0 0 0 0 0 0 5 0 VBN IN NNP NNP NONE O
radioresistance. radioresistance. 0 0 0 0 0 0 0 0 16 0 IN NNP NNP NONE NONE O
A A 1 1 0 0 0 0 0 0 1 0 NONE NONE DT CD NN O
3-plex 3-plex 0 0 1 0 0 0 0 1 6 0 NONE DT CD NN NN O
methylation methylation 0 0 0 0 0 0 0 0 11 0 DT CD NN NN VBN O
assay assay 0 0 0 0 0 0 0 0 5 0 CD NN NN VBN IN O
combined combined 0 0 0 0 0 0 0 0 8 0 NN NN VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NN O
FGFR3 FGFR3 1 1 0 0 0 0 0 1 5 0 IN DT NNP NN NN O
mutation mutation 0 0 0 0 0 0 0 0 8 0 DT NNP NN NN RB O
assay assay 0 0 0 0 0 0 0 0 5 0 NNP NN NN RB VBZ O
sensitively sensitively 0 0 0 0 0 0 0 0 11 0 NN NN RB VBZ NN O
detects detects 0 0 0 0 0 0 0 0 7 0 NN RB VBZ NN NN O
recurrent recurrent 0 0 0 0 0 0 0 0 9 0 RB VBZ NN NN NN O
bladder bladder 0 0 0 0 0 0 0 0 7 0 VBZ NN NN NN IN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNP O
voided voided 0 0 0 0 0 0 0 0 6 0 NN IN JJ NNP NNP O
urine. urine. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP NNP O
Kandimalla Kandimalla 1 0 0 0 0 0 0 0 10 0 JJ NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Masius Masius 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Beukers Beukers 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
W, W, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Bangma Bangma 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
CH, CH, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Orntoft Orntoft 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
TF, TF, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Dyrskjøt Dyrskjøt 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Leeuwen Leeuwen 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
NV, NV, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Lingsma Lingsma 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
HF, HF, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
van van 0 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Tilborg Tilborg 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
AA, AA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Zwarthoff Zwarthoff 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
EC. EC. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pathology, Pathology, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP NNP O
Erasmus Erasmus 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
MC. MC. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
PURPOSE: PURPOSE: 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NN VBZ O
methylation methylation 0 0 0 0 0 0 0 0 11 0 NNP NNP NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NN VBZ VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN NNP CC O
BC BC 1 1 0 0 0 0 0 0 2 0 VBN IN NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNP CC DT NNS MD O
modifications modifications 0 0 0 0 0 0 0 0 13 0 CC DT NNS MD VB O
could could 0 0 0 0 0 0 0 0 5 0 DT NNS MD VB IN O
serve serve 0 0 0 0 0 0 0 0 5 0 NNS MD VB IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 MD VB IN JJ NNP O
useful useful 0 0 0 0 0 0 0 0 6 0 VB IN JJ NNP NNP O
biomarkers. biomarkers. 0 0 0 0 0 0 0 0 11 0 IN JJ NNP NNP NNS O
FGFR3 FGFR3 1 1 0 0 0 0 0 1 5 0 JJ NNP NNP NNS VBP O
mutations mutations 0 0 0 0 0 0 0 0 9 0 NNP NNP NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNS VBP JJ IN O
present present 0 0 0 0 0 0 0 0 7 0 NNS VBP JJ IN CD O
in in 0 0 0 0 0 0 0 0 2 0 VBP JJ IN CD NN O
60-70 60-70 0 0 1 0 0 0 0 1 5 0 JJ IN CD NN IN O
% % 0 0 0 0 0 0 0 0 1 0 IN CD NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN NNP NNP O
NMIBC. NMIBC. 1 1 0 0 0 0 0 0 6 0 NN IN NNP NNP NN O
Low-grade Low-grade 1 0 1 0 0 0 0 0 9 0 IN NNP NNP NN NN O
bladder bladder 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NNP NN NN NNS IN O
recurs recurs 0 0 0 0 0 0 0 0 6 0 NN NN NNS IN IN O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN IN CD O
over over 0 0 0 0 0 0 0 0 4 0 NNS IN IN CD IN O
50% 50% 0 0 0 0 0 0 0 1 3 0 IN IN CD IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN CD IN NNP NNP O
patients. patients. 0 0 0 0 0 0 0 0 9 0 CD IN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NN IN O
aim aim 0 0 0 0 0 0 0 0 3 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN VBZ O
study study 0 0 0 0 0 0 0 0 5 0 IN DT NN VBZ TO O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBZ TO VB DT O
determine determine 0 0 0 0 0 0 0 0 9 0 VBZ TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN CC O
sensitivity sensitivity 0 0 0 0 0 0 0 0 11 0 VB DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
specificity specificity 0 0 0 0 0 0 0 0 11 0 NN CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN NN O
urine urine 0 0 0 0 0 0 0 0 5 0 IN DT NN NN IN O
assay assay 0 0 0 0 0 0 0 0 5 0 DT NN NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
diagnosis diagnosis 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS IN O
recurrences recurrences 0 0 0 0 0 0 0 0 11 0 NN IN NNS IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 NNS IN NNS IN DT O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ JJ O
previous previous 0 0 0 0 0 0 0 0 8 0 IN DT JJ JJ NNP O
primary primary 0 0 0 0 0 0 0 0 7 0 DT JJ JJ NNP NNP O
NMIBC NMIBC 1 1 0 0 0 0 0 0 5 0 JJ JJ NNP NNP IN O
G1/G2 G1/G2 1 1 0 1 0 0 0 1 5 0 JJ NNP NNP IN VBG O
by by 0 0 0 0 0 0 0 0 2 0 NNP NNP IN VBG NN O
using using 0 0 0 0 0 0 0 0 5 0 NNP IN VBG NN IN O
cystoscopy cystoscopy 0 0 0 0 0 0 0 0 10 0 IN VBG NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VBG NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
reference reference 0 0 0 0 0 0 0 0 9 0 IN DT NN NNP NNP O
standard. standard. 0 0 0 0 0 0 0 0 9 0 DT NN NNP NNP NNP O
EXPERIMENTAL EXPERIMENTAL 1 1 0 0 0 0 0 0 12 0 NN NNP NNP NNP NNP O
DESIGN: DESIGN: 1 1 0 0 0 0 0 0 7 0 NNP NNP NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBD CD O
selected selected 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD CD NNP O
eight eight 0 0 0 0 0 0 0 0 5 0 NNP VBD CD NNP VBD O
CGIs CGIs 1 0 0 0 0 0 0 0 4 0 VBD CD NNP VBD IN O
methylated methylated 0 0 0 0 0 0 0 0 10 0 CD NNP VBD IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP VBD IN NNP IN O
BC BC 1 1 0 0 0 0 0 0 2 0 VBD IN NNP IN PRP$ O
from from 0 0 0 0 0 0 0 0 4 0 IN NNP IN PRP$ JJR O
our our 0 0 0 0 0 0 0 0 3 0 NNP IN PRP$ JJR JJ O
earlier earlier 0 0 0 0 0 0 0 0 7 0 IN PRP$ JJR JJ NNP O
genome-wide genome-wide 0 0 1 0 0 0 0 0 11 0 PRP$ JJR JJ NNP NNP O
study. study. 0 0 0 0 0 0 0 0 6 0 JJR JJ NNP NNP IN O
Sensitivity Sensitivity 1 0 0 0 0 0 0 0 11 0 JJ NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP IN O
CGIs CGIs 1 0 0 0 0 0 0 0 4 0 IN DT NNP IN NNS O
for for 0 0 0 0 0 0 0 0 3 0 DT NNP IN NNS NN O
recurrences recurrences 0 0 0 0 0 0 0 0 11 0 NNP IN NNS NN VBD O
detection detection 0 0 0 0 0 0 0 0 9 0 IN NNS NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNS NN VBD VBN IN O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NN VBD VBN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NN NN O
test test 0 0 0 0 0 0 0 0 4 0 IN DT NN NN IN O
set set 0 0 0 0 0 0 0 0 3 0 DT NN NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN CD NNP O
101 101 0 0 0 0 0 0 1 1 3 0 NN IN CD NNP NNP O
preTUR preTUR 0 0 0 0 0 0 0 0 6 0 IN CD NNP NNP NNP O
urines. urines. 0 0 0 0 0 0 0 0 7 0 CD NNP NNP NNP VBD O
Specificity Specificity 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
determined determined 0 0 0 0 0 0 0 0 10 0 NNP VBD VBN IN CD O
on on 0 0 0 0 0 0 0 0 2 0 VBD VBN IN CD NNS O
70 70 0 0 0 0 0 0 1 1 2 0 VBN IN CD NNS IN O
urines urines 0 0 0 0 0 0 0 0 6 0 IN CD NNS IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 CD NNS IN JJ NNS O
healthy healthy 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NNS -NONE- O
males males 0 0 0 0 0 0 0 0 5 0 IN JJ NNS -NONE- NNP O
>50 >50 0 0 0 0 0 0 0 1 3 0 JJ NNS -NONE- NNP DT O
years. years. 0 0 0 0 0 0 0 0 6 0 NNS -NONE- NNP DT CD O
A A 1 1 0 0 0 0 0 0 1 0 -NONE- NNP DT CD NN O
3-plex 3-plex 0 0 1 0 0 0 0 1 6 0 NNP DT CD NN IN O
assay assay 0 0 0 0 0 0 0 0 5 0 DT CD NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 CD NN IN DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJS NN O
best best 0 0 0 0 0 0 0 0 4 0 IN DT JJS NN VBD O
combination combination 0 0 0 0 0 0 0 0 11 0 DT JJS NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJS NN VBD VBN CC O
developed developed 0 0 0 0 0 0 0 0 9 0 NN VBD VBN CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 VBD VBN CC VBN IN O
validated validated 0 0 0 0 0 0 0 0 9 0 VBN CC VBN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 CC VBN IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 VBN IN DT JJ NN O
independent independent 0 0 0 0 0 0 0 0 11 0 IN DT JJ NN IN O
set set 0 0 0 0 0 0 0 0 3 0 DT JJ NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN CD JJ O
95 95 0 0 0 0 0 0 1 1 2 0 NN IN CD JJ NN O
preTUR, preTUR, 0 0 0 0 1 0 0 0 7 0 IN CD JJ NN JJ O
recurrence recurrence 0 0 0 0 0 0 0 0 10 0 CD JJ NN JJ CC O
free free 0 0 0 0 0 0 0 0 4 0 JJ NN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN JJ CC JJ NNS O
non-malignant non-malignant 0 0 1 0 0 0 0 0 13 0 JJ CC JJ NNS NNP O
urines urines 0 0 0 0 0 0 0 0 6 0 CC JJ NNS NNP NNP O
(n=130). (n=130). 0 0 0 0 0 0 0 1 8 0 JJ NNS NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 NNS NNP NNP NNP CD O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP CD NN O
3-plex 3-plex 0 0 1 0 0 0 0 1 6 0 NNP NNP CD NN VBD O
assay assay 0 0 0 0 0 0 0 0 5 0 NNP CD NN VBD NN O
identified identified 0 0 0 0 0 0 0 0 10 0 CD NN VBD NN NNP O
recurrent recurrent 0 0 0 0 0 0 0 0 9 0 NN VBD NN NNP IN O
BC BC 1 1 0 0 0 0 0 0 2 0 VBD NN NNP IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NNP IN JJ NN O
voided voided 0 0 0 0 0 0 0 0 6 0 NNP IN JJ NN IN O
urine urine 0 0 0 0 0 0 0 0 5 0 IN JJ NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN IN O
sensitivity sensitivity 0 0 0 0 0 0 0 0 11 0 IN DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD IN O
74% 74% 0 0 0 0 0 0 0 1 3 0 NN IN CD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN CD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT NN NNP O
validation validation 0 0 0 0 0 0 0 0 10 0 IN DT NN NNP NNP O
set. set. 0 0 0 0 0 0 0 0 4 0 DT NN NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NN IN O
combination combination 0 0 0 0 0 0 0 0 11 0 NNP NNP NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NNP NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
FGFR3 FGFR3 1 1 0 0 0 0 0 1 5 0 IN DT NNP NN NN O
mutation mutation 0 0 0 0 0 0 0 0 8 0 DT NNP NN NN DT O
assay assay 0 0 0 0 0 0 0 0 5 0 NNP NN NN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN NN DT NN IN O
sensitivity sensitivity 0 0 0 0 0 0 0 0 11 0 NN DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD VBD O
79% 79% 0 0 0 0 0 0 0 1 3 0 NN IN CD VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 IN CD VBD VBN NN O
reached reached 0 0 0 0 0 0 0 0 7 0 CD VBD VBN NN IN O
(specificity (specificity 0 0 0 0 0 0 0 0 12 0 VBD VBN NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN CD NNP O
77%). 77%). 0 0 0 0 0 0 0 1 5 0 NN IN CD NNP IN O
Sensitivity Sensitivity 1 0 0 0 0 0 0 0 11 0 IN CD NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CD NNP IN NNP CC O
FGFR3 FGFR3 1 1 0 0 0 0 0 1 5 0 NNP IN NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NN VBD O
cytology cytology 0 0 0 0 0 0 0 0 8 0 NNP CC NN VBD CD O
was was 0 0 0 0 0 0 0 0 3 0 CC NN VBD CD CC O
52% 52% 0 0 0 0 0 0 0 1 3 0 NN VBD CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 VBD CD CC CD NNP O
57% 57% 0 0 0 0 0 0 0 1 3 0 CD CC CD NNP NNP O
respectively. respectively. 0 0 0 0 0 0 0 0 13 0 CC CD NNP NNP NNP O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 CD NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
combination combination 0 0 0 0 0 0 0 0 11 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN CC O
methylation methylation 0 0 0 0 0 0 0 0 11 0 NN IN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NNP NNS O
FGFR3 FGFR3 1 1 0 0 0 0 0 1 5 0 NN CC NNP NNS RB O
assays assays 0 0 0 0 0 0 0 0 6 0 CC NNP NNS RB VBZ O
efficiently efficiently 0 0 0 0 0 0 0 0 11 0 NNP NNS RB VBZ NN O
detects detects 0 0 0 0 0 0 0 0 7 0 NNS RB VBZ NN NNP O
recurrent recurrent 0 0 0 0 0 0 0 0 9 0 RB VBZ NN NNP IN O
BC BC 1 1 0 0 0 0 0 0 2 0 VBZ NN NNP IN DT O
without without 0 0 0 0 0 0 0 0 7 0 NN NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN IN O
need need 0 0 0 0 0 0 0 0 4 0 IN DT NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN NN IN O
stratification stratification 0 0 0 0 0 0 0 0 14 0 NN IN NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNS VBG O
patients patients 0 0 0 0 0 0 0 0 8 0 NN IN NNS VBG NN O
regarding regarding 0 0 0 0 0 0 0 0 9 0 IN NNS VBG NN NN O
methylation/mutation methylation/mutation 0 0 0 1 0 0 0 0 20 0 NNS VBG NN NN IN O
status status 0 0 0 0 0 0 0 0 6 0 VBG NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
primary primary 0 0 0 0 0 0 0 0 7 0 IN DT JJ NNP NNP O
tumor. tumor. 0 0 0 0 0 0 0 0 6 0 DT JJ NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP VBP IN O
conclude conclude 0 0 0 0 0 0 0 0 8 0 NNP NNP VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NN IN O
sensitivity sensitivity 0 0 0 0 0 0 0 0 11 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN VBZ O
combination combination 0 0 0 0 0 0 0 0 11 0 IN DT NN VBZ IN O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN VBZ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBZ IN DT JJ NN O
same same 0 0 0 0 0 0 0 0 4 0 IN DT JJ NN IN O
range range 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN NN O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN CC O
cystoscopy cystoscopy 0 0 0 0 0 0 0 0 10 0 NN IN NN CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NNS DT O
paves paves 0 0 0 0 0 0 0 0 5 0 NN CC NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC NNS DT NN IN O
way way 0 0 0 0 0 0 0 0 3 0 NNS DT NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
subsequent subsequent 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN WDT O
study study 0 0 0 0 0 0 0 0 5 0 DT JJ NN WDT VBZ O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT VBZ DT O
investigates investigates 0 0 0 0 0 0 0 0 12 0 NN WDT VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 WDT VBZ DT JJ NN O
modified modified 0 0 0 0 0 0 0 0 8 0 VBZ DT JJ NN NN O
surveillance surveillance 0 0 0 0 0 0 0 0 12 0 DT JJ NN NN VBG O
protocol protocol 0 0 0 0 0 0 0 0 8 0 JJ NN NN VBG IN O
consisting consisting 0 0 0 0 0 0 0 0 10 0 NN NN VBG IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN VBG IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBG IN DT NN NN O
urine urine 0 0 0 0 0 0 0 0 5 0 IN DT NN NN VBD O
test test 0 0 0 0 0 0 0 0 4 0 DT NN NN VBD IN O
followed followed 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN NN RB O
cystoscopy cystoscopy 0 0 0 0 0 0 0 0 10 0 VBD IN NN RB WRB O
only only 0 0 0 0 0 0 0 0 4 0 IN NN RB WRB DT O
when when 0 0 0 0 0 0 0 0 4 0 NN RB WRB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB WRB DT NN NN O
urine urine 0 0 0 0 0 0 0 0 5 0 WRB DT NN NN VBZ O
test test 0 0 0 0 0 0 0 0 4 0 DT NN NN VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ NNP NONE O
positive. positive. 0 0 0 0 0 0 0 0 9 0 NN VBZ NNP NONE NONE O
Evaluation Evaluation 1 0 0 0 0 0 0 0 10 0 NONE NONE NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NNP NNP O
Conjunctival Conjunctival 1 0 0 0 0 0 0 0 12 0 NN IN NNP NNP NNP O
Bleb Bleb 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNP O
Detection Detection 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
After After 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP IN O
Vitrectomy Vitrectomy 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Ultrasound Ultrasound 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Biomicroscopy, Biomicroscopy, 1 0 0 0 1 0 0 0 14 0 IN NNP NNP NNP NNP O
Optical Optical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Coherence Coherence 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP CC O
Tomography Tomography 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Direct Direct 1 0 0 0 0 0 0 0 6 0 NNP CC NNP NNP NNP O
Visualization. Visualization. 1 0 0 0 0 0 0 0 14 0 CC NNP NNP NNP NNP O
Benitez-Herreros Benitez-Herreros 1 0 1 0 0 0 0 0 16 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lopez-Guajardo Lopez-Guajardo 1 0 1 0 0 0 0 0 14 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Camara-Gonzalez Camara-Gonzalez 1 0 1 0 0 0 0 0 15 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Perez-Crespo Perez-Crespo 1 0 1 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Silva-Mato Silva-Mato 1 0 1 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Alvaro-Meca Alvaro-Meca 1 0 1 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Teus Teus 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
MA. MA. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Ophthalmology, Ophthalmology, 1 0 0 0 1 0 0 0 14 0 NNP IN NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP NNP O
Hospital Hospital 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Principe Principe 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Asturias, Asturias, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP IN O
Alcalá Alcalá 1 0 0 0 0 0 0 0 6 0 IN NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP , O
Henares Henares 1 0 0 0 0 0 0 0 7 0 NNP IN NNP , NNP O
, , 0 0 0 0 1 0 0 0 1 0 IN NNP , NNP , O
Madrid Madrid 1 0 0 0 0 0 0 0 6 0 NNP , NNP , NNP O
, , 0 0 0 0 1 0 0 0 1 0 , NNP , NNP . O
Spain Spain 1 0 0 0 0 0 0 0 5 0 NNP , NNP . NNP O
. . 0 0 0 0 0 0 0 0 1 0 , NNP . NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP . NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 . NNP NNP NNP NNP O
Purpose: Purpose: 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VB O
To To 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VB NN O
compare compare 0 0 0 0 0 0 0 0 7 0 NNP NNP VB NN NN O
ultrasound ultrasound 0 0 0 0 0 0 0 0 10 0 NNP VB NN NN NN O
biomicroscopy biomicroscopy 0 0 0 0 0 0 0 0 13 0 VB NN NN NN NN O
(UBM), (UBM), 0 1 0 0 1 0 0 0 6 0 NN NN NN NN JJ O
anterior-segment anterior-segment 0 0 1 0 0 0 0 0 16 0 NN NN NN JJ NN O
optical optical 0 0 0 0 0 0 0 0 7 0 NN NN JJ NN NN O
coherence coherence 0 0 0 0 0 0 0 0 9 0 NN JJ NN NN NN O
tomography tomography 0 0 0 0 0 0 0 0 10 0 JJ NN NN NN CC O
(AS-OCT), (AS-OCT), 0 1 1 0 1 0 0 0 9 0 NN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
direct direct 0 0 0 0 0 0 0 0 6 0 NN CC JJ NN IN O
visualization visualization 0 0 0 0 0 0 0 0 13 0 CC JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN NN O
detecting detecting 0 0 0 0 0 0 0 0 9 0 NN IN NN NN NNS O
conjunctival conjunctival 0 0 0 0 0 0 0 0 12 0 IN NN NN NNS IN O
blebs blebs 0 0 0 0 0 0 0 0 5 0 NN NN NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NNS O
sutureless sutureless 0 0 0 0 0 0 0 0 10 0 NNS IN NN NNS IN O
sclerotomies sclerotomies 0 0 0 0 0 0 0 0 12 0 IN NN NNS IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 NN NNS IN NNP NNP O
vitrectomy. vitrectomy. 0 0 0 0 0 0 0 0 11 0 NNS IN NNP NNP VBZ O
Conjunctival Conjunctival 1 0 0 0 0 0 0 0 12 0 IN NNP NNP VBZ VBP O
blebs blebs 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NNP VBZ VBP VBN IN O
formed formed 0 0 0 0 0 0 0 0 6 0 VBZ VBP VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBP VBN IN NN NN O
sclerotomy sclerotomy 0 0 0 0 0 0 0 0 10 0 VBN IN NN NN JJ O
leakage leakage 0 0 0 0 0 0 0 0 7 0 IN NN NN JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 NN NN JJ TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NN JJ TO NN NNP O
incompetent incompetent 0 0 0 0 0 0 0 0 11 0 JJ TO NN NNP NNP O
closure. closure. 0 0 0 0 0 0 0 0 8 0 TO NN NNP NNP NNP O
Methods: Methods: 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NNP NNP O
Experimental, Experimental, 1 0 0 0 1 0 0 0 13 0 NNP NNP NNP NNP CC O
randomized, randomized, 0 0 0 0 1 0 0 0 11 0 NNP NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NN O
observer-masked observer-masked 0 0 1 0 0 0 0 0 15 0 NNP CC JJ NN IN O
study study 0 0 0 0 0 0 0 0 5 0 CC JJ NN IN WDT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN WDT JJ O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT JJ NNS O
23-gauge 23-gauge 0 0 1 0 0 0 0 1 8 0 IN WDT JJ NNS VBD O
vitrectomies vitrectomies 0 0 0 0 0 0 0 0 12 0 WDT JJ NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD VBN IN O
performed performed 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NN O
cadaveric cadaveric 0 0 0 0 0 0 0 0 9 0 VBN IN JJ NN NNP O
pig pig 0 0 0 0 0 0 0 0 3 0 IN JJ NN NNP NNP O
eyes. eyes. 0 0 0 0 0 0 0 0 5 0 JJ NN NNP NNP NN O
Postoperative Postoperative 1 0 0 0 0 0 0 0 13 0 NN NNP NNP NN NNS O
conjunctival conjunctival 0 0 0 0 0 0 0 0 12 0 NNP NNP NN NNS VBD O
blebs blebs 0 0 0 0 0 0 0 0 5 0 NNP NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
assessed assessed 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
UBM, UBM, 1 1 0 0 1 0 0 0 4 0 VBN IN NNP NNP CC O
AS-OCT, AS-OCT, 1 1 1 0 1 0 0 0 7 0 IN NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NNP O
direct direct 0 0 0 0 0 0 0 0 6 0 NNP CC JJ NNP NNP O
visualization. visualization. 0 0 0 0 0 0 0 0 14 0 CC JJ NNP NNP NN O
No No 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NN VBZ O
conjunctival conjunctival 0 0 0 0 0 0 0 0 12 0 NNP NNP NN VBZ VBD O
blebs blebs 0 0 0 0 0 0 0 0 5 0 NNP NN VBZ VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN VBZ VBD VBN IN O
classified classified 0 0 0 0 0 0 0 0 10 0 VBZ VBD VBN IN NNP O
as as 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP -NONE- O
Grade Grade 1 0 0 0 0 0 0 0 5 0 VBN IN NNP -NONE- NNP O
0 0 0 0 0 0 0 0 1 1 1 0 IN NNP -NONE- NNP NN O
(G0), (G0), 0 1 0 0 1 0 0 1 5 0 NNP -NONE- NNP NN NNS O
thin thin 0 0 0 0 0 0 0 0 4 0 -NONE- NNP NN NNS JJ O
blebs blebs 0 0 0 0 0 0 0 0 5 0 NNP NN NNS JJ IN O
(less (less 0 0 0 0 0 0 0 0 5 0 NN NNS JJ IN CC O
than than 0 0 0 0 0 0 0 0 4 0 NNS JJ IN CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 JJ IN CC JJ TO O
equal equal 0 0 0 0 0 0 0 0 5 0 IN CC JJ TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 CC JJ TO JJ IN O
one-half one-half 0 0 1 0 0 0 0 0 8 0 JJ TO JJ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 TO JJ IN JJ NN O
scleral scleral 0 0 0 0 0 0 0 0 7 0 JJ IN JJ NN IN O
thickness) thickness) 0 0 0 0 0 0 0 0 10 0 IN JJ NN IN NNP O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP CD O
Grade Grade 1 0 0 0 0 0 0 0 5 0 NN IN NNP CD NNP O
1 1 0 0 0 0 0 0 1 1 1 0 IN NNP CD NNP CC O
(G1) (G1) 0 1 0 0 0 0 0 1 4 0 NNP CD NNP CC VB O
and and 0 0 0 0 0 0 0 0 3 0 CD NNP CC VB NNS O
thick thick 0 0 0 0 0 0 0 0 5 0 NNP CC VB NNS JJ O
blebs blebs 0 0 0 0 0 0 0 0 5 0 CC VB NNS JJ IN O
(greater (greater 0 0 0 0 0 0 0 0 8 0 VB NNS JJ IN JJ O
than than 0 0 0 0 0 0 0 0 4 0 NNS JJ IN JJ IN O
one-half one-half 0 0 1 0 0 0 0 0 8 0 JJ IN JJ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN JJ IN JJ NN O
scleral scleral 0 0 0 0 0 0 0 0 7 0 JJ IN JJ NN IN O
thickness) thickness) 0 0 0 0 0 0 0 0 10 0 IN JJ NN IN NNP O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP CD O
Grade Grade 1 0 0 0 0 0 0 0 5 0 NN IN NNP CD NNP O
2 2 0 0 0 0 0 0 1 1 1 0 IN NNP CD NNP NNP O
(G2). (G2). 0 1 0 0 0 0 0 1 5 0 NNP CD NNP NNP NNP O
Results: Results: 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NN O
Fifty Fifty 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NN VBZ O
pig pig 0 0 0 0 0 0 0 0 3 0 NNP NNP NN VBZ VBD O
eyes eyes 0 0 0 0 0 0 0 0 4 0 NNP NN VBZ VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 NN VBZ VBD NNP NNP O
included. included. 0 0 0 0 0 0 0 0 9 0 VBZ VBD NNP NNP VBZ O
Conjunctival Conjunctival 1 0 0 0 0 0 0 0 12 0 VBD NNP NNP VBZ VBD O
blebs blebs 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBD VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 VBZ VBD VBN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN CD NN O
13.3% 13.3% 0 0 0 0 0 0 0 1 5 0 VBN IN CD NN -NONE- O
(8% (8% 0 0 0 0 0 0 0 1 3 0 IN CD NN -NONE- CD O
G1, G1, 1 1 0 0 1 0 0 1 3 0 CD NN -NONE- CD -NONE- O
5.3% 5.3% 0 0 0 0 0 0 0 1 4 0 NN -NONE- CD -NONE- IN O
G2) G2) 1 1 0 0 0 0 0 1 3 0 -NONE- CD -NONE- IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CD -NONE- IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- IN DT NNS VBD O
incisions incisions 0 0 0 0 0 0 0 0 9 0 IN DT NNS VBD IN O
analyzed analyzed 0 0 0 0 0 0 0 0 8 0 DT NNS VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBD IN NN IN O
UBM, UBM, 1 1 0 0 1 0 0 0 4 0 VBD IN NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN CD NN O
20% 20% 0 0 0 0 0 0 0 1 3 0 NN IN CD NN -NONE- O
(14.7% (14.7% 0 0 0 0 0 0 0 1 6 0 IN CD NN -NONE- CD O
G1, G1, 1 1 0 0 1 0 0 1 3 0 CD NN -NONE- CD -NONE- O
5.3% 5.3% 0 0 0 0 0 0 0 1 4 0 NN -NONE- CD -NONE- IN O
G2) G2) 1 1 0 0 0 0 0 1 3 0 -NONE- CD -NONE- IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CD -NONE- IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- IN DT NNS VBD O
sclerotomies sclerotomies 0 0 0 0 0 0 0 0 12 0 IN DT NNS VBD IN O
studied studied 0 0 0 0 0 0 0 0 7 0 DT NNS VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBD IN NN CC O
AS-OCT, AS-OCT, 1 1 1 0 1 0 0 0 7 0 VBD IN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC IN CD O
in in 0 0 0 0 0 0 0 0 2 0 NN CC IN CD NN O
7.3% 7.3% 0 0 0 0 0 0 0 1 4 0 CC IN CD NN -NONE- O
(2% (2% 0 0 0 0 0 0 0 1 3 0 IN CD NN -NONE- CD O
G1, G1, 1 1 0 0 1 0 0 1 3 0 CD NN -NONE- CD -NONE- O
5.3% 5.3% 0 0 0 0 0 0 0 1 4 0 NN -NONE- CD -NONE- IN O
G2) G2) 1 1 0 0 0 0 0 1 3 0 -NONE- CD -NONE- IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CD -NONE- IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- IN DT NNS VBD O
wounds wounds 0 0 0 0 0 0 0 0 6 0 IN DT NNS VBD IN O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 DT NNS VBD IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBD IN JJ NNP O
direct direct 0 0 0 0 0 0 0 0 6 0 VBD IN JJ NNP JJ O
visualization. visualization. 0 0 0 0 0 0 0 0 14 0 IN JJ NNP JJ VBD O
AS-OCT AS-OCT 1 1 1 0 0 0 0 0 6 0 JJ NNP JJ VBD DT O
was was 0 0 0 0 0 0 0 0 3 0 NNP JJ VBD DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 JJ VBD DT JJS JJ O
most most 0 0 0 0 0 0 0 0 4 0 VBD DT JJS JJ NN O
sensitive sensitive 0 0 0 0 0 0 0 0 9 0 DT JJS JJ NN IN O
method method 0 0 0 0 0 0 0 0 6 0 JJS JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN NN O
identifying identifying 0 0 0 0 0 0 0 0 11 0 NN IN NN NN NNS O
conjunctival conjunctival 0 0 0 0 0 0 0 0 12 0 IN NN NN NNS WRB O
blebs blebs 0 0 0 0 0 0 0 0 5 0 NN NN NNS WRB VBN O
when when 0 0 0 0 0 0 0 0 4 0 NN NNS WRB VBN IN O
compared compared 0 0 0 0 0 0 0 0 8 0 NNS WRB VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 WRB VBN IN NNP CC O
UBM UBM 1 1 0 0 0 0 0 0 3 0 VBN IN NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC JJ NN O
direct direct 0 0 0 0 0 0 0 0 6 0 NNP CC JJ NN NN O
visualization visualization 0 0 0 0 0 0 0 0 13 0 CC JJ NN NN : O
(p (p 0 0 0 0 0 0 0 0 2 0 JJ NN NN : CD O
< < 0 0 0 0 0 0 0 0 1 0 NN NN : CD IN O
0.001). 0.001). 0 0 0 0 0 0 0 1 7 0 NN : CD IN JJ O
In In 1 0 0 0 0 0 0 0 2 0 : CD IN JJ NNP O
turn, turn, 0 0 0 0 1 0 0 0 5 0 CD IN JJ NNP VBD O
UBM UBM 1 1 0 0 0 0 0 0 3 0 IN JJ NNP VBD JJR O
was was 0 0 0 0 0 0 0 0 3 0 JJ NNP VBD JJR IN O
better better 0 0 0 0 0 0 0 0 6 0 NNP VBD JJR IN JJ O
than than 0 0 0 0 0 0 0 0 4 0 VBD JJR IN JJ NN O
direct direct 0 0 0 0 0 0 0 0 6 0 JJR IN JJ NN IN O
visualization visualization 0 0 0 0 0 0 0 0 13 0 IN JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN NN O
observing observing 0 0 0 0 0 0 0 0 9 0 NN IN NN NN NNS O
sclerotomy sclerotomy 0 0 0 0 0 0 0 0 10 0 IN NN NN NNS -NONE- O
blebs blebs 0 0 0 0 0 0 0 0 5 0 NN NN NNS -NONE- : O
(p (p 0 0 0 0 0 0 0 0 2 0 NN NNS -NONE- : CD O
= = 0 0 0 0 0 0 0 0 1 0 NNS -NONE- : CD NN O
0.004). 0.004). 0 0 0 0 0 0 0 1 7 0 -NONE- : CD NN JJ O
Conclusions: Conclusions: 1 0 0 0 0 0 0 0 12 0 : CD NN JJ VBZ O
AS-OCT AS-OCT 1 1 1 0 0 0 0 0 6 0 CD NN JJ VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN JJ VBZ DT RBS O
the the 0 0 0 0 0 0 0 0 3 0 JJ VBZ DT RBS JJ O
most most 0 0 0 0 0 0 0 0 4 0 VBZ DT RBS JJ NN O
sensitive sensitive 0 0 0 0 0 0 0 0 9 0 DT RBS JJ NN IN O
technique technique 0 0 0 0 0 0 0 0 9 0 RBS JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN JJ O
detecting detecting 0 0 0 0 0 0 0 0 9 0 NN IN NN JJ NNS O
subclinical subclinical 0 0 0 0 0 0 0 0 11 0 IN NN JJ NNS -NONE- O
blebs blebs 0 0 0 0 0 0 0 0 5 0 NN JJ NNS -NONE- CC O
(G1) (G1) 0 1 0 0 0 0 0 1 4 0 JJ NNS -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC NNP PRP O
thus, thus, 0 0 0 0 1 0 0 0 5 0 -NONE- CC NNP PRP MD O
it it 0 0 0 0 0 0 0 0 2 0 CC NNP PRP MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NNP PRP MD VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 PRP MD VB JJ IN O
useful useful 0 0 0 0 0 0 0 0 6 0 MD VB JJ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VB JJ IN NN IN O
research research 0 0 0 0 0 0 0 0 8 0 JJ IN NN IN VBG O
for for 0 0 0 0 0 0 0 0 3 0 IN NN IN VBG DT O
studying studying 0 0 0 0 0 0 0 0 8 0 NN IN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN VBG DT NN IN O
influence influence 0 0 0 0 0 0 0 0 9 0 VBG DT NN IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN JJ NNS O
surgical surgical 0 0 0 0 0 0 0 0 8 0 NN IN JJ NNS CC O
factors factors 0 0 0 0 0 0 0 0 7 0 IN JJ NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC NNS MD O
maneuvers maneuvers 0 0 0 0 0 0 0 0 9 0 NNS CC NNS MD VB O
may may 0 0 0 0 0 0 0 0 3 0 CC NNS MD VB IN O
exert exert 0 0 0 0 0 0 0 0 5 0 NNS MD VB IN NN O
on on 0 0 0 0 0 0 0 0 2 0 MD VB IN NN NN O
sclerotomy sclerotomy 0 0 0 0 0 0 0 0 10 0 VB IN NN NN NN O
closure closure 0 0 0 0 0 0 0 0 7 0 IN NN NN NN IN O
capacity capacity 0 0 0 0 0 0 0 0 8 0 NN NN NN IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 NN NN IN NNP NNP O
vitrectomy. vitrectomy. 0 0 0 0 0 0 0 0 11 0 NN IN NNP NNP NNP O
Direct Direct 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP IN O
visualization, visualization, 0 0 0 0 1 0 0 0 14 0 NNP NNP NNP IN VBZ O
that that 0 0 0 0 0 0 0 0 4 0 NNP NNP IN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP IN VBZ VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 IN VBZ VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN NN JJ O
routine routine 0 0 0 0 0 0 0 0 7 0 VBN IN NN JJ NN O
clinical clinical 0 0 0 0 0 0 0 0 8 0 IN NN JJ NN TO O
practice practice 0 0 0 0 0 0 0 0 8 0 NN JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB WDT O
determine determine 0 0 0 0 0 0 0 0 9 0 NN TO VB WDT NNS O
which which 0 0 0 0 0 0 0 0 5 0 TO VB WDT NNS MD O
sclerotomies sclerotomies 0 0 0 0 0 0 0 0 12 0 VB WDT NNS MD VB O
should should 0 0 0 0 0 0 0 0 6 0 WDT NNS MD VB -NONE- O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB -NONE- VBZ O
sutured, sutured, 0 0 0 0 1 0 0 0 8 0 MD VB -NONE- VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 VB -NONE- VBZ JJ RB O
useful useful 0 0 0 0 0 0 0 0 6 0 -NONE- VBZ JJ RB TO O
only only 0 0 0 0 0 0 0 0 4 0 VBZ JJ RB TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ RB TO VB NN O
identify identify 0 0 0 0 0 0 0 0 8 0 RB TO VB NN NNS O
thick thick 0 0 0 0 0 0 0 0 5 0 TO VB NN NNS -NONE- O
blebs blebs 0 0 0 0 0 0 0 0 5 0 VB NN NNS -NONE- IN O
(G2) (G2) 0 1 0 0 0 0 0 1 4 0 NN NNS -NONE- IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 NNS -NONE- IN NNP NONE O
vitrectomy. vitrectomy. 0 0 0 0 0 0 0 0 11 0 -NONE- IN NNP NONE NONE O
Combination Combination 1 0 0 0 0 0 0 0 11 0 NONE NONE NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NNP CC O
Rituximab Rituximab 1 0 0 0 0 0 0 0 9 0 NN IN NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP CC DT NNP NN O
mTOR mTOR 0 0 0 0 0 0 0 0 4 0 CC DT NNP NN NNP O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 DT NNP NN NNP NNP O
Everolimus Everolimus 1 0 0 0 0 0 0 0 10 0 NNP NN NNP NNP IN O
(RAD001) (RAD001) 0 1 0 0 0 0 0 1 8 0 NN NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP JJ O
Diffuse Diffuse 1 0 0 0 0 0 0 0 7 0 NNP IN NNP JJ NNP O
large large 0 0 0 0 0 0 0 0 5 0 IN NNP JJ NNP NN O
B B 1 1 0 0 0 0 0 0 1 0 NNP JJ NNP NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NNP NN NNP NNP O
lymphoma. lymphoma. 0 0 0 0 0 0 0 0 9 0 NNP NN NNP NNP NNP O
Xu Xu 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NNP NNP O
ZZ, ZZ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
WF, WF, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Fu Fu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
WB, WB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
AH, AH, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Liu Liu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
ZY, ZY, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
LY, LY, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Guo Guo 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
JM. JM. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
ABSTRACT ABSTRACT 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBD DT O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 VBD DT NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP JJ O
anti-CD20 anti-CD20 0 0 1 0 0 0 0 1 9 0 IN DT NNP JJ NN O
monoclonal monoclonal 0 0 0 0 0 0 0 0 10 0 DT NNP JJ NN NN O
antibody antibody 0 0 0 0 0 0 0 0 8 0 NNP JJ NN NN IN O
rituximab rituximab 0 0 0 0 0 0 0 0 9 0 JJ NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN IN O
combination combination 0 0 0 0 0 0 0 0 11 0 NN IN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN IN O
target target 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
mTOR mTOR 0 0 0 0 0 0 0 0 4 0 NN IN NNP NN VBZ O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 IN NNP NN VBZ IN O
everolimus everolimus 0 0 0 0 0 0 0 0 10 0 NNP NN VBZ IN VBG O
for for 0 0 0 0 0 0 0 0 3 0 NN VBZ IN VBG NN O
treating treating 0 0 0 0 0 0 0 0 8 0 VBZ IN VBG NN JJ O
diffuse diffuse 0 0 0 0 0 0 0 0 7 0 IN VBG NN JJ NNP O
large large 0 0 0 0 0 0 0 0 5 0 VBG NN JJ NNP NN O
B B 1 1 0 0 0 0 0 0 1 0 NN JJ NNP NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NNP NN NN NNP O
lymphoma lymphoma 0 0 0 0 0 0 0 0 8 0 NNP NN NN NNP NNP O
(DLBCL). (DLBCL). 0 1 0 0 0 0 0 0 8 0 NN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
combination combination 0 0 0 0 0 0 0 0 11 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN CC O
rituximab rituximab 0 0 0 0 0 0 0 0 9 0 NN IN NN CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VBZ VBD O
everolimus everolimus 0 0 0 0 0 0 0 0 10 0 NN CC VBZ VBD JJR O
was was 0 0 0 0 0 0 0 0 3 0 CC VBZ VBD JJR JJ O
more more 0 0 0 0 0 0 0 0 4 0 VBZ VBD JJR JJ IN O
effective effective 0 0 0 0 0 0 0 0 9 0 VBD JJR JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJR JJ IN NN NN O
inhibiting inhibiting 0 0 0 0 0 0 0 0 10 0 JJ IN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN NN NN NN VBN O
growth growth 0 0 0 0 0 0 0 0 6 0 NN NN NN VBN IN O
compared compared 0 0 0 0 0 0 0 0 8 0 NN NN VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NNP O
single-agent single-agent 0 0 1 0 0 0 0 0 12 0 IN DT JJ NNP NNP O
therapy. therapy. 0 0 0 0 0 0 0 0 8 0 DT JJ NNP NNP NN O
An An 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NN IN NN NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 IN NN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest NN NN NN NN CC O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT VBN O
an an 0 0 0 0 0 0 0 0 2 0 NN CC DT VBN NN O
increased increased 0 0 0 0 0 0 0 0 9 0 CC DT VBN NN IN O
population population 0 0 0 0 0 0 0 0 10 0 DT VBN NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN NN VBD O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NNS IN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 IN NN VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NN O
combination combination 0 0 0 0 0 0 0 0 11 0 IN DT NN NN NNP O
treatment treatment 0 0 0 0 0 0 0 0 9 0 DT NN NN NNP NNP O
group. group. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP IN O
Addition Addition 1 0 0 0 0 0 0 0 8 0 NN NNP NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN VBN O
rituximab rituximab 0 0 0 0 0 0 0 0 9 0 NNP IN NN VBN DT O
reduced reduced 0 0 0 0 0 0 0 0 7 0 IN NN VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBN DT NN IN O
overexpression overexpression 0 0 0 0 0 0 0 0 14 0 VBN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ VBN O
p-AKT p-AKT 0 0 1 0 0 0 0 0 5 0 NN IN JJ VBN IN O
caused caused 0 0 0 0 0 0 0 0 6 0 IN JJ VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 JJ VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
negative negative 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN NN O
feedback feedback 0 0 0 0 0 0 0 0 8 0 DT JJ NN NN IN O
loop loop 0 0 0 0 0 0 0 0 4 0 JJ NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN CC O
everolimus everolimus 0 0 0 0 0 0 0 0 10 0 NN IN NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VBD DT O
had had 0 0 0 0 0 0 0 0 3 0 NN CC VBD DT VBN O
an an 0 0 0 0 0 0 0 0 2 0 CC VBD DT VBN NN O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 VBD DT VBN NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 DT VBN NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 VBN NN IN NN NNP O
inhibiting inhibiting 0 0 0 0 0 0 0 0 10 0 NN IN NN NNP NNP O
mTOR mTOR 0 0 0 0 0 0 0 0 4 0 IN NN NNP NNP RB O
signaling, signaling, 0 0 0 0 1 0 0 0 10 0 NN NNP NNP RB VBG O
thus thus 0 0 0 0 0 0 0 0 4 0 NNP NNP RB VBG DT O
providing providing 0 0 0 0 0 0 0 0 9 0 NNP RB VBG DT NN O
a a 0 0 0 0 0 0 0 0 1 0 RB VBG DT NN IN O
rationale rationale 0 0 0 0 0 0 0 0 9 0 VBG DT NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN DT JJ O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT JJ NNP O
synergistic synergistic 0 0 0 0 0 0 0 0 11 0 IN DT JJ NNP NNP O
effect. effect. 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NNP NN O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 JJ NNP NNP NN NN O
combination combination 0 0 0 0 0 0 0 0 11 0 NNP NNP NN NN VBD O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NNP NN NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD RB RBR O
also also 0 0 0 0 0 0 0 0 4 0 NN VBD RB RBR JJ O
more more 0 0 0 0 0 0 0 0 4 0 VBD RB RBR JJ IN O
effective effective 0 0 0 0 0 0 0 0 9 0 RB RBR JJ IN NN O
than than 0 0 0 0 0 0 0 0 4 0 RBR JJ IN NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 JJ IN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN DT NN O
either either 0 0 0 0 0 0 0 0 6 0 NN IN DT NN NN O
agent agent 0 0 0 0 0 0 0 0 5 0 IN DT NN NN IN O
alone alone 0 0 0 0 0 0 0 0 5 0 DT NN NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NN DT O
inhibiting inhibiting 0 0 0 0 0 0 0 0 10 0 NN IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 NN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
DLBCL DLBCL 1 1 0 0 0 0 0 0 5 0 NN IN NNP NNP NNP O
xenografts. xenografts. 0 0 0 0 0 0 0 0 11 0 IN NNP NNP NNP NN O
Our Our 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD JJ O
provided provided 0 0 0 0 0 0 0 0 8 0 NNP NN VBD JJ NN O
preclinical preclinical 0 0 0 0 0 0 0 0 11 0 NN VBD JJ NN CC O
evidence evidence 0 0 0 0 0 0 0 0 8 0 VBD JJ NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN CC DT JJ NN O
theoretical theoretical 0 0 0 0 0 0 0 0 11 0 CC DT JJ NN IN O
basis basis 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN NN O
combination combination 0 0 0 0 0 0 0 0 11 0 NN IN NN NN IN O
therapy therapy 0 0 0 0 0 0 0 0 7 0 IN NN NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NNP IN O
DLBCL DLBCL 1 1 0 0 0 0 0 0 5 0 NN IN NNP IN NN O
with with 0 0 0 0 0 0 0 0 4 0 IN NNP IN NN CC O
rituximab rituximab 0 0 0 0 0 0 0 0 9 0 NNP IN NN CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VBZ IN O
everolimus everolimus 0 0 0 0 0 0 0 0 10 0 NN CC VBZ IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CC VBZ IN NNP NONE O
DLBCL. DLBCL. 1 1 0 0 0 0 0 0 6 0 VBZ IN NNP NONE NONE O
CDC25B CDC25B 1 1 0 0 0 0 0 1 6 0 NONE NONE NNP NNP NNP O
Overexpression Overexpression 1 0 0 0 0 0 0 0 14 0 NONE NNP NNP NNP NNP O
Stabilises Stabilises 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP CD O
Centrin Centrin 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP CD CC O
2 2 0 0 0 0 0 0 1 1 1 0 NNP NNP CD CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP CD CC NNP DT O
Promotes Promotes 1 0 0 0 0 0 0 0 8 0 CD CC NNP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 CC NNP DT NNP IN O
Formation Formation 1 0 0 0 0 0 0 0 9 0 NNP DT NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNP IN NNP NNP O
Excess Excess 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNP O
Centriolar Centriolar 1 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP NNP O
Foci. Foci. 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Boutros Boutros 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Mondesert Mondesert 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
O, O, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lorenzo Lorenzo 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Astuti Astuti 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
McArthur McArthur 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Chircop Chircop 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ducommun Ducommun 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Gabrielli Gabrielli 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
B. B. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Queensland Queensland 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Diamantina Diamantina 1 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP NNP O
Institute, Institute, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Princess Princess 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Alexandra Alexandra 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Hospital, Hospital, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Brisbane, Brisbane, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Queensland, Queensland, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP : O
Australia Australia 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP : NNP O
; ; 0 0 0 0 0 0 0 0 1 0 NNP NNP : NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NNP : NNP NNP NNP O
Cycle Cycle 1 0 0 0 0 0 0 0 5 0 : NNP NNP NNP NNP O
Unit, Unit, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
Children's Children's 1 0 0 0 0 1 0 0 10 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Institute, Institute, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Sydney, Sydney, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
New New 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
South South 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Wales, Wales, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
Australia. Australia. 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
CDK-cyclin CDK-cyclin 1 0 1 0 0 0 0 0 10 0 NNP NNP NNP VBZ JJ O
complexes complexes 0 0 0 0 0 0 0 0 9 0 NNP NNP VBZ JJ NN O
regulate regulate 0 0 0 0 0 0 0 0 8 0 NNP VBZ JJ NN NN O
centriole centriole 0 0 0 0 0 0 0 0 9 0 VBZ JJ NN NN CC O
duplication duplication 0 0 0 0 0 0 0 0 11 0 JJ NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
microtubule microtubule 0 0 0 0 0 0 0 0 11 0 NN CC NN NN IN O
nucleation nucleation 0 0 0 0 0 0 0 0 10 0 CC NN NN IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
specific specific 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 JJ NN NN NN IN O
stages, stages, 0 0 0 0 1 0 0 0 7 0 NN NN NN IN PRP$ O
although although 0 0 0 0 0 0 0 0 8 0 NN NN IN PRP$ JJ O
their their 0 0 0 0 0 0 0 0 5 0 NN IN PRP$ JJ NNS O
exact exact 0 0 0 0 0 0 0 0 5 0 IN PRP$ JJ NNS IN O
roles roles 0 0 0 0 0 0 0 0 5 0 PRP$ JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNS IN DT NNS VBP O
processes processes 0 0 0 0 0 0 0 0 9 0 IN DT NNS VBP NNP O
remain remain 0 0 0 0 0 0 0 0 6 0 DT NNS VBP NNP NNP O
unclear. unclear. 0 0 0 0 0 0 0 0 8 0 NNS VBP NNP NNP DT O
As As 1 0 0 0 0 0 0 0 2 0 VBP NNP NNP DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNS IN O
activities activities 0 0 0 0 0 0 0 0 10 0 NNP DT NNS IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NNS VBP O
CDK-cyclins CDK-cyclins 1 0 1 0 0 0 0 0 11 0 NNS IN NNS VBP PRP O
are are 0 0 0 0 0 0 0 0 3 0 IN NNS VBP PRP RB O
themselves themselves 0 0 0 0 0 0 0 0 10 0 NNS VBP PRP RB VBN O
positively positively 0 0 0 0 0 0 0 0 10 0 VBP PRP RB VBN IN O
regulated regulated 0 0 0 0 0 0 0 0 9 0 PRP RB VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 RB VBN IN NNP NNP O
CDC25 CDC25 1 1 0 0 0 0 0 1 5 0 VBN IN NNP NNP PRP O
phosphatases, phosphatases, 0 0 0 0 1 0 0 0 13 0 IN NNP NNP PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD DT O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NNP PRP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT NN IN O
role role 0 0 0 0 0 0 0 0 4 0 VBD DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
centrosomal centrosomal 0 0 0 0 0 0 0 0 11 0 NN IN JJ NNP IN O
CDC25B CDC25B 1 1 0 0 0 0 0 1 6 0 IN JJ NNP IN NNP O
during during 0 0 0 0 0 0 0 0 6 0 JJ NNP IN NNP NNP O
interphase. interphase. 0 0 0 0 0 0 0 0 11 0 NNP IN NNP NNP NN B_TIMEXCCP 
We We 1 0 0 0 0 0 0 0 2 0 IN NNP NNP NN WDT O
report report 0 0 0 0 0 0 0 0 6 0 NNP NNP NN WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 NNP NN WDT NN IN O
overexpression overexpression 0 0 0 0 0 0 0 0 14 0 NN WDT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 WDT NN IN NNP IN O
CDC25B, CDC25B, 1 1 0 0 1 0 0 1 7 0 NN IN NNP IN VBZ O
as as 0 0 0 0 0 0 0 0 2 0 IN NNP IN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP IN VBZ RB VBN O
commonly commonly 0 0 0 0 0 0 0 0 8 0 IN VBZ RB VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 VBZ RB VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 VBN IN JJ NN NNS O
cancer, cancer, 0 0 0 0 1 0 0 0 7 0 IN JJ NN NNS IN O
results results 0 0 0 0 0 0 0 0 7 0 JJ NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 IN DT JJ NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN CD O
centrin centrin 0 0 0 0 0 0 0 0 7 0 NN IN NN CD IN O
2 2 0 0 0 0 0 0 1 1 1 0 IN NN CD IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NN CD IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT NNS IN O
centrosomes centrosomes 0 0 0 0 0 0 0 0 11 0 IN DT NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NN NNP O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NNS IN NN NNP NNP B_TIMEXCCP 
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NN NNP NNP NNP O
Conversely, Conversely, 1 0 0 0 1 0 0 0 11 0 NN NNP NNP NNP NN O
CDC25B CDC25B 1 1 0 0 0 0 0 1 6 0 NNP NNP NNP NN NNS O
depletion depletion 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NNS DT O
causes causes 0 0 0 0 0 0 0 0 6 0 NNP NN NNS DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN NNS DT NN IN O
loss loss 0 0 0 0 0 0 0 0 4 0 NNS DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN CD O
centrin centrin 0 0 0 0 0 0 0 0 7 0 NN IN NN CD IN O
2 2 0 0 0 0 0 0 1 1 1 0 IN NN CD IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NN CD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT NN WDT O
centrosome, centrosome, 0 0 0 0 1 0 0 0 11 0 IN DT NN WDT MD O
which which 0 0 0 0 0 0 0 0 5 0 DT NN WDT MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN WDT MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 WDT MD VB VBN IN O
rescued rescued 0 0 0 0 0 0 0 0 7 0 MD VB VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VB VBN IN NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 VBN IN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
proteasome proteasome 0 0 0 0 0 0 0 0 10 0 IN DT NN NN NNP O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 DT NN NN NNP NNP O
MG132. MG132. 1 1 0 0 0 0 0 1 6 0 NN NN NNP NNP NN O
CDC25B CDC25B 1 1 0 0 0 0 0 1 6 0 NN NNP NNP NN RB O
overexpression overexpression 0 0 0 0 0 0 0 0 14 0 NNP NNP NN RB VBZ O
also also 0 0 0 0 0 0 0 0 4 0 NNP NN RB VBZ DT O
promotes promotes 0 0 0 0 0 0 0 0 8 0 NN RB VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBZ DT NN IN O
formation formation 0 0 0 0 0 0 0 0 9 0 VBZ DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
excess excess 0 0 0 0 0 0 0 0 6 0 NN IN NN NN CD O
centrin centrin 0 0 0 0 0 0 0 0 7 0 IN NN NN CD NNP O
2 2 0 0 0 0 0 0 1 1 1 0 NN NN CD NNP NNP O
"foci". "foci". 0 0 0 0 0 0 0 0 7 0 NN CD NNP NNP NN O
These These 1 0 0 0 0 0 0 0 5 0 CD NNP NNP NN MD O
foci foci 0 0 0 0 0 0 0 0 4 0 NNP NNP NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NNP NN MD VB JJ O
accumulate accumulate 0 0 0 0 0 0 0 0 10 0 NN MD VB JJ NN O
other other 0 0 0 0 0 0 0 0 5 0 MD VB JJ NN -NONE- O
centrosome centrosome 0 0 0 0 0 0 0 0 10 0 VB JJ NN -NONE- VBG O
proteins, proteins, 0 0 0 0 1 0 0 0 9 0 JJ NN -NONE- VBG NN O
including including 0 0 0 0 0 0 0 0 9 0 NN -NONE- VBG NN CC O
γ-tubulin γ-tubulin 0 0 1 0 0 0 0 0 9 0 -NONE- VBG NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VBG NN CC NNP CC O
PCM-1, PCM-1, 1 1 1 0 1 0 0 1 6 0 NN CC NNP CC MD O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NNP CC MD VB RB O
function function 0 0 0 0 0 0 0 0 8 0 CC MD VB RB JJ O
as as 0 0 0 0 0 0 0 0 2 0 MD VB RB JJ NN O
microtubule microtubule 0 0 0 0 0 0 0 0 11 0 VB RB JJ NN NN O
organising organising 0 0 0 0 0 0 0 0 10 0 RB JJ NN NN VBG O
centres, centres, 0 0 0 0 1 0 0 0 8 0 JJ NN NN VBG IN O
indicating indicating 0 0 0 0 0 0 0 0 10 0 NN NN VBG IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NN VBG IN DT NN O
these these 0 0 0 0 0 0 0 0 5 0 VBG IN DT NN JJ O
represent represent 0 0 0 0 0 0 0 0 9 0 IN DT NN JJ NNP O
functional functional 0 0 0 0 0 0 0 0 10 0 DT NN JJ NNP NNP O
centrosomes. centrosomes. 0 0 0 0 0 0 0 0 12 0 NN JJ NNP NNP IN O
Formation Formation 1 0 0 0 0 0 0 0 9 0 JJ NNP NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN CD O
centrin centrin 0 0 0 0 0 0 0 0 7 0 NNP IN NN CD NN O
2 2 0 0 0 0 0 0 1 1 1 0 IN NN CD NN MD O
foci foci 0 0 0 0 0 0 0 0 4 0 NN CD NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 CD NN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB VBN IN O
blocked blocked 0 0 0 0 0 0 0 0 7 0 MD VB VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VB VBN IN JJ NN O
specific specific 0 0 0 0 0 0 0 0 8 0 VBN IN JJ NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 IN JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP CC O
CDK2 CDK2 1 1 0 0 0 0 0 1 4 0 NN IN NNP CC RB O
but but 0 0 0 0 0 0 0 0 3 0 IN NNP CC RB NNP O
not not 0 0 0 0 0 0 0 0 3 0 NNP CC RB NNP JJ O
CDK1. CDK1. 1 1 0 0 0 0 0 1 5 0 CC RB NNP JJ NN O
CDK2-mediated CDK2-mediated 1 0 1 0 0 0 0 1 13 0 RB NNP JJ NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 NNP JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
Monopolar Monopolar 1 0 0 0 0 0 0 0 9 0 NN IN NNP NN CD O
spindle spindle 0 0 0 0 0 0 0 0 7 0 IN NNP NN CD NN O
1 1 0 0 0 0 0 0 1 1 1 0 NNP NN CD NN IN O
(Mps1) (Mps1) 0 0 0 0 0 0 0 1 6 0 NN CD NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 CD NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS NN O
G1/S G1/S 1 1 0 1 0 0 0 1 4 0 IN DT NNS NN VBZ B_TIMEXCCP
transition transition 0 0 0 0 0 0 0 0 10 0 DT NNS NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNS NN VBZ JJ IN O
essential essential 0 0 0 0 0 0 0 0 9 0 NN VBZ JJ IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN IN O
initiation initiation 0 0 0 0 0 0 0 0 10 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
centrosome centrosome 0 0 0 0 0 0 0 0 10 0 NN IN NN NN CC O
duplication, duplication, 0 0 0 0 1 0 0 0 12 0 IN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP VBZ O
Mps1 Mps1 1 0 0 0 0 0 0 1 4 0 NN CC NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 CC NNP VBZ VBN TO O
reported reported 0 0 0 0 0 0 0 0 8 0 NNP VBZ VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ VBN TO VB NN O
phosphorylate phosphorylate 0 0 0 0 0 0 0 0 13 0 VBN TO VB NN CD O
centrin centrin 0 0 0 0 0 0 0 0 7 0 TO VB NN CD NNP O
2. 2. 0 0 0 0 0 0 0 1 2 0 VB NN CD NNP IN O
Overexpression Overexpression 1 0 0 0 0 0 0 0 14 0 NN CD NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CD NNP IN JJ CC O
wild-type wild-type 0 0 1 0 0 0 0 0 9 0 NNP IN JJ CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 IN JJ CC JJ NNP O
non-degradable non-degradable 0 0 1 0 0 0 0 0 14 0 JJ CC JJ NNP VBD O
Mps1 Mps1 1 0 0 0 0 0 0 1 4 0 CC JJ NNP VBD DT O
exacerbated exacerbated 0 0 0 0 0 0 0 0 11 0 JJ NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN IN O
formation formation 0 0 0 0 0 0 0 0 9 0 VBD DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
excess excess 0 0 0 0 0 0 0 0 6 0 NN IN NN NN CD O
centrin centrin 0 0 0 0 0 0 0 0 7 0 IN NN NN CD NN O
2 2 0 0 0 0 0 0 1 1 1 0 NN NN CD NN VBD O
foci foci 0 0 0 0 0 0 0 0 4 0 NN CD NN VBD IN O
induced induced 0 0 0 0 0 0 0 0 7 0 CD NN VBD IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN NNP NNP O
CDC25B CDC25B 1 1 0 0 0 0 0 1 6 0 VBD IN NNP NNP IN O
overexpression, overexpression, 0 0 0 0 1 0 0 0 15 0 IN NNP NNP IN JJ O
while while 0 0 0 0 0 0 0 0 5 0 NNP NNP IN JJ NNP O
kinase-dead kinase-dead 0 0 1 0 0 0 0 0 11 0 NNP IN JJ NNP VBZ O
Mps1 Mps1 1 0 0 0 0 0 0 1 4 0 IN JJ NNP VBZ DT O
has has 0 0 0 0 0 0 0 0 3 0 JJ NNP VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT JJ NNP O
protective protective 0 0 0 0 0 0 0 0 10 0 VBZ DT JJ NNP NNP O
effect. effect. 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NNP PRP$ O
Together, Together, 1 0 0 0 1 0 0 0 9 0 JJ NNP NNP PRP$ NNS O
our our 0 0 0 0 0 0 0 0 3 0 NNP NNP PRP$ NNS VBP O
data data 0 0 0 0 0 0 0 0 4 0 NNP PRP$ NNS VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 PRP$ NNS VBP IN -NONE- O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN -NONE- IN O
CDC25B, CDC25B, 1 1 0 0 1 0 0 1 7 0 VBP IN -NONE- IN NN O
through through 0 0 0 0 0 0 0 0 7 0 IN -NONE- IN NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 -NONE- IN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
centrosomal centrosomal 0 0 0 0 0 0 0 0 11 0 IN DT JJ NN IN O
pool pool 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNS O
CDK2, CDK2, 1 1 0 0 1 0 0 1 5 0 NN IN NNP NNS DT O
stabilises stabilises 0 0 0 0 0 0 0 0 10 0 IN NNP NNS DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNS DT JJ NN O
local local 0 0 0 0 0 0 0 0 5 0 NNS DT JJ NN IN O
pool pool 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP WDT O
Mps1 Mps1 1 0 0 0 0 0 0 1 4 0 NN IN NNP WDT IN O
which which 0 0 0 0 0 0 0 0 5 0 IN NNP WDT IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP WDT IN NN NNS O
turn turn 0 0 0 0 0 0 0 0 4 0 WDT IN NN NNS DT O
regulates regulates 0 0 0 0 0 0 0 0 9 0 IN NN NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NNS DT NN IN O
level level 0 0 0 0 0 0 0 0 5 0 NNS DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN CD O
centrin centrin 0 0 0 0 0 0 0 0 7 0 NN IN NN CD IN O
2 2 0 0 0 0 0 0 1 1 1 0 IN NN CD IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NN CD IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT NNP NNP O
centrosome. centrosome. 0 0 0 0 0 0 0 0 11 0 IN DT NNP NNP IN O
Overexpression Overexpression 1 0 0 0 0 0 0 0 14 0 DT NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP MD O
CDC25B CDC25B 1 1 0 0 0 0 0 1 6 0 NNP IN NNP MD VB O
may may 0 0 0 0 0 0 0 0 3 0 IN NNP MD VB NN O
therefore therefore 0 0 0 0 0 0 0 0 9 0 NNP MD VB NN TO O
contribute contribute 0 0 0 0 0 0 0 0 10 0 MD VB NN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VB NN TO NN IN O
tumourigenesis tumourigenesis 0 0 0 0 0 0 0 0 14 0 NN TO NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 TO NN IN NN DT O
perturbing perturbing 0 0 0 0 0 0 0 0 10 0 NN IN NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT JJ NN O
natural natural 0 0 0 0 0 0 0 0 7 0 NN DT JJ NN IN O
turnover turnover 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNS O
centrosome centrosome 0 0 0 0 0 0 0 0 10 0 NN IN NN NNS JJ O
proteins proteins 0 0 0 0 0 0 0 0 8 0 IN NN NNS JJ IN O
such such 0 0 0 0 0 0 0 0 4 0 NN NNS JJ IN NNP O
as as 0 0 0 0 0 0 0 0 2 0 NNS JJ IN NNP CC O
Mps1 Mps1 1 0 0 0 0 0 0 1 4 0 JJ IN NNP CC VB O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC VB CD O
centrin centrin 0 0 0 0 0 0 0 0 7 0 NNP CC VB CD RB O
2, 2, 0 0 0 0 1 0 0 1 2 0 CC VB CD RB VBG O
thus thus 0 0 0 0 0 0 0 0 4 0 VB CD RB VBG IN O
resulting resulting 0 0 0 0 0 0 0 0 9 0 CD RB VBG IN DT O
in in 0 0 0 0 0 0 0 0 2 0 RB VBG IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBG IN DT NN NN O
de de 0 0 0 0 0 0 0 0 2 0 IN DT NN NN RB O
novo novo 0 0 0 0 0 0 0 0 4 0 DT NN NN RB IN O
assembly assembly 0 0 0 0 0 0 0 0 8 0 NN NN RB IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN RB IN JJ NNS O
extra-numerary extra-numerary 0 0 1 0 0 0 0 0 14 0 RB IN JJ NNS CC O
centrosomes centrosomes 0 0 0 0 0 0 0 0 11 0 IN JJ NNS CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC VBG NN O
potentiating potentiating 0 0 0 0 0 0 0 0 12 0 NNS CC VBG NN NNP O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 CC VBG NN NNP NONE O
instability. instability. 0 0 0 0 0 0 0 0 12 0 VBG NN NNP NONE NONE O
Overexpression Overexpression 1 0 0 0 0 0 0 0 14 0 NONE NONE NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NNP NNPS O
MTA3 MTA3 1 1 0 0 0 0 0 1 4 0 NN IN NNP NNPS IN O
Correlates Correlates 1 0 0 0 0 0 0 0 10 0 IN NNP NNPS IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNPS IN NNP NNP O
Tumor Tumor 1 0 0 0 0 0 0 0 5 0 NNPS IN NNP NNP IN O
Progression Progression 1 0 0 0 0 0 0 0 11 0 IN NNP NNP IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ NNP O
Non-Small Non-Small 1 0 1 0 0 0 0 0 9 0 NNP IN JJ NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 IN JJ NNP NNP NNP O
Lung Lung 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NNP NNP O
Cancer. Cancer. 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sun Sun 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Xu Xu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Luo Luo 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
W, W, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tang Tang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Qiu Qiu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
E. E. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pathology, Pathology, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP NNP O
First First 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
Affiliated Affiliated 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP CC O
Hospital Hospital 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP IN O
College College 1 0 0 0 0 0 0 0 7 0 NNP CC NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NNP IN NNP NNP O
Basic Basic 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
China China 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Shenyang, Shenyang, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Liaoning, Liaoning, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
objective objective 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
current current 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 DT JJ NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB DT O
investigate investigate 0 0 0 0 0 0 0 0 11 0 VBD TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN NN O
expression expression 0 0 0 0 0 0 0 0 10 0 VB DT NN NN CC O
pattern pattern 0 0 0 0 0 0 0 0 7 0 DT NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
clinicopathological clinicopathological 0 0 0 0 0 0 0 0 19 0 NN CC JJ NN IN O
significance significance 0 0 0 0 0 0 0 0 12 0 CC JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP IN O
MTA3 MTA3 1 1 0 0 0 0 0 1 4 0 NN IN NNP IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 NNP IN NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN JJ NN O
non-small non-small 0 0 1 0 0 0 0 0 9 0 NNS IN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN NN O
lung lung 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN NN NN NNP NNP O
(NSCLC). (NSCLC). 0 1 0 0 0 0 0 0 8 0 NN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN NN O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP NNP NN NN IN O
profile profile 0 0 0 0 0 0 0 0 7 0 NNP NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP IN O
MTA3 MTA3 1 1 0 0 0 0 0 1 4 0 NN IN NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NNS O
NSCLC NSCLC 1 1 0 0 0 0 0 0 5 0 NNP IN NNP NNS CC O
tissues tissues 0 0 0 0 0 0 0 0 7 0 IN NNP NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNS CC NN JJ O
adjacent adjacent 0 0 0 0 0 0 0 0 8 0 NNS CC NN JJ NN O
noncancerous noncancerous 0 0 0 0 0 0 0 0 12 0 CC NN JJ NN NNS O
lung lung 0 0 0 0 0 0 0 0 4 0 NN JJ NN NNS VBD O
tissues tissues 0 0 0 0 0 0 0 0 7 0 JJ NN NNS VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NNS VBD VBN IN O
detected detected 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
immunohistochemistry. immunohistochemistry. 0 0 0 0 0 0 0 0 21 0 VBN IN NNP NNP VBD O
MTA3 MTA3 1 1 0 0 0 0 0 1 4 0 IN NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
overexpressed overexpressed 0 0 0 0 0 0 0 0 13 0 NNP VBD VBN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN CD IN O
62 62 0 0 0 0 0 0 1 1 2 0 VBN IN CD IN CD O
of of 0 0 0 0 0 0 0 0 2 0 IN CD IN CD JJ O
108 108 0 0 0 0 0 0 1 1 3 0 CD IN CD JJ NN O
(57.4%) (57.4%) 0 0 0 0 0 0 0 1 7 0 IN CD JJ NN NN O
human human 0 0 0 0 0 0 0 0 5 0 CD JJ NN NN NN O
lung lung 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN NN NN NNS CC O
samples samples 0 0 0 0 0 0 0 0 7 0 NN NN NNS CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC VBD IN O
correlated correlated 0 0 0 0 0 0 0 0 10 0 NNS CC VBD IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 CC VBD IN JJ NN O
p-TNM p-TNM 0 0 1 0 0 0 0 0 5 0 VBD IN JJ NN NN O
stage stage 0 0 0 0 0 0 0 0 5 0 IN JJ NN NN NN O
(p<0.0001), (p<0.0001), 0 0 0 0 1 0 0 1 11 0 JJ NN NN NN NN O
nodal nodal 0 0 0 0 0 0 0 0 5 0 NN NN NN NN NN O
metastasis metastasis 0 0 0 0 0 0 0 0 10 0 NN NN NN NN : O
(p (p 0 0 0 0 0 0 0 0 2 0 NN NN NN : CD O
= = 0 0 0 0 0 0 0 0 1 0 NN NN : CD CC O
0.0009) 0.0009) 0 0 0 0 0 0 0 1 7 0 NN : CD CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 : CD CC JJ NN O
poor poor 0 0 0 0 0 0 0 0 4 0 CD CC JJ NN NNP O
prognosis prognosis 0 0 0 0 0 0 0 0 9 0 CC JJ NN NNP NNP O
(p<0.05). (p<0.05). 0 0 0 0 0 0 0 1 9 0 JJ NN NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NNP DT O
addition, addition, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
depletion depletion 0 0 0 0 0 0 0 0 9 0 NNP DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NN O
MTA3 MTA3 1 1 0 0 0 0 0 1 4 0 NN IN NNP NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 IN NNP NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNP NN IN JJ VBG O
small small 0 0 0 0 0 0 0 0 5 0 NN IN JJ VBG NNP O
interfering interfering 0 0 0 0 0 0 0 0 11 0 IN JJ VBG NNP VBD O
RNAs RNAs 1 0 0 0 0 0 0 0 4 0 JJ VBG NNP VBD NN O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 VBG NNP VBD NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP VBD NN NN CC O
growth growth 0 0 0 0 0 0 0 0 6 0 VBD NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
colony colony 0 0 0 0 0 0 0 0 6 0 NN CC NN NN IN O
formation formation 0 0 0 0 0 0 0 0 9 0 CC NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP CC O
A549 A549 1 1 0 0 0 0 0 1 4 0 IN DT NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC NNP NN O
H157 H157 1 1 0 0 0 0 0 1 4 0 NNP CC NNP NN NN O
lung lung 0 0 0 0 0 0 0 0 4 0 CC NNP NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NNP NN NN NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NNP NNP O
lines. lines. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP NNP O
Moreover, Moreover, 1 0 0 0 1 0 0 0 9 0 NN NNP NNP NNP NN O
MTA3 MTA3 1 1 0 0 0 0 0 1 4 0 NNP NNP NNP NN VBD O
depletion depletion 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBD NN O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP NN VBD NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN VBD NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest VBD NN NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS NNP O
G1/S G1/S 1 1 0 1 0 0 0 1 4 0 IN DT NNS NNP NNP B_TIMEXCCP
boundary. boundary. 0 0 0 0 0 0 0 0 9 0 DT NNS NNP NNP NN O
Western Western 1 0 0 0 0 0 0 0 7 0 NNS NNP NNP NN NN O
blotting blotting 0 0 0 0 0 0 0 0 8 0 NNP NNP NN NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NNP NN NN VBD IN O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN IN O
knockdown knockdown 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP VBD O
MTA3 MTA3 1 1 0 0 0 0 0 1 4 0 NN IN NNP VBD DT O
decreased decreased 0 0 0 0 0 0 0 0 9 0 IN NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN NNS O
protein protein 0 0 0 0 0 0 0 0 7 0 VBD DT NN NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 DT NN NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NN O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NNS IN NN NN NN O
A, A, 1 1 0 0 1 0 0 0 2 0 IN NN NN NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN NN NN NNP CC O
D1 D1 1 1 0 0 0 0 0 1 2 0 NN NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP NNP O
p-Rb. p-Rb. 0 0 1 0 0 0 0 0 5 0 NNP CC NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 CC NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
indicate indicate 0 0 0 0 0 0 0 0 8 0 NNP NNS VBP IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NNP NNS O
MTA3 MTA3 1 1 0 0 0 0 0 1 4 0 VBP IN NNP NNS DT O
plays plays 0 0 0 0 0 0 0 0 5 0 IN NNP NNS DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNP NNS DT JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 NNS DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
NSCLC NSCLC 1 1 0 0 0 0 0 0 5 0 NN IN NNP NNP NONE O
progression. progression. 0 0 0 0 0 0 0 0 12 0 IN NNP NNP NONE NONE O
Chemotherapeutic Chemotherapeutic 1 0 0 0 0 0 0 0 16 0 NONE NONE JJ JJ IN O
Potential Potential 1 0 0 0 0 0 0 0 9 0 NONE JJ JJ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ JJ IN JJ IN O
2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo(b)pyran 2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo(b)pyran 0 0 1 0 0 0 0 1 52 0 JJ IN JJ IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN JJ IN NNP NNP O
Estrogen Estrogen 1 0 0 0 0 0 0 0 8 0 JJ IN NNP NNP NNP O
Receptor- Receptor- 1 0 1 0 0 0 0 0 9 0 IN NNP NNP NNP NNP O
Negative Negative 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Breast Breast 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Cells: Cells: 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Action Action 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
via via 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP IN O
Prevention Prevention 1 0 0 0 0 0 0 0 10 0 NNP IN NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NNP O
EGFR EGFR 1 1 0 0 0 0 0 0 4 0 NNP IN NNP NNP CC O
Activation Activation 1 0 0 0 0 0 0 0 10 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Combined Combined 1 0 0 0 0 0 0 0 8 0 NNP CC NNP NNP IN O
Inhibition Inhibition 1 0 0 0 0 0 0 0 10 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
PI-3-K/Akt/FOXO PI-3-K/Akt/FOXO 1 0 1 1 0 0 0 1 15 0 NNP IN NNP CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC -NONE- NNP O
MEK/Erk/AP-1 MEK/Erk/AP-1 1 0 1 1 0 0 0 1 12 0 NNP CC -NONE- NNP NNP O
Pathways. Pathways. 1 0 0 0 0 0 0 0 9 0 CC -NONE- NNP NNP NNP O
Saxena Saxena 1 0 0 0 0 0 0 0 6 0 -NONE- NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Chandra Chandra 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
V, V, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Manohar Manohar 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hajela Hajela 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Debnath Debnath 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
U, U, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Prabhakar Prabhakar 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
YS, YS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Saini Saini 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
KS, KS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Konwar Konwar 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kumar Kumar 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Megu Megu 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Roy Roy 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
BG, BG, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Dwivedi Dwivedi 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
A. A. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Division Division 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP JJ O
Endocrinology, Endocrinology, 1 0 0 0 1 0 0 0 14 0 NNP IN NNP JJ NNP O
CSIR-Central CSIR-Central 1 0 1 0 0 0 0 0 12 0 IN NNP JJ NNP NNP O
Drug Drug 1 0 0 0 0 0 0 0 4 0 NNP JJ NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP NNP NNP O
Institute, Institute, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Lucknow, Lucknow, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Uttar Uttar 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Pradesh, Pradesh, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
India. India. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Inhibition Inhibition 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ NN O
epidermal epidermal 0 0 0 0 0 0 0 0 9 0 NNP IN JJ NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN NN O
factor factor 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN NN O
receptor receptor 0 0 0 0 0 0 0 0 8 0 NN NN NN NN VBG O
(EGFR) (EGFR) 0 1 0 0 0 0 0 0 6 0 NN NN NN VBG VBZ O
signaling signaling 0 0 0 0 0 0 0 0 9 0 NN NN VBG VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN VBG VBZ VBN TO O
considered considered 0 0 0 0 0 0 0 0 10 0 VBG VBZ VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ VBN TO VB DT O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT NN NN O
promising promising 0 0 0 0 0 0 0 0 9 0 VB DT NN NN NN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 DT NN NN NN IN O
strategy strategy 0 0 0 0 0 0 0 0 8 0 NN NN NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NN NN O
estrogen estrogen 0 0 0 0 0 0 0 0 8 0 NN IN NN NN JJ O
receptor receptor 0 0 0 0 0 0 0 0 8 0 IN NN NN JJ NN O
(ER)-negative (ER)-negative 0 0 1 0 0 0 0 0 13 0 NN NN JJ NN NNP O
breast breast 0 0 0 0 0 0 0 0 6 0 NN JJ NN NNP NNP O
tumors. tumors. 0 0 0 0 0 0 0 0 7 0 JJ NN NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNP VBP VBN RB O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NNP VBP VBN RB DT O
here here 0 0 0 0 0 0 0 0 4 0 VBP VBN RB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN RB DT JJ NN O
anti-breast anti-breast 0 0 1 0 0 0 0 0 11 0 RB DT JJ NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 DT JJ NN NNS IN O
properties properties 0 0 0 0 0 0 0 0 10 0 JJ NN NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT NN JJ O
novel novel 0 0 0 0 0 0 0 0 5 0 IN DT NN JJ NN O
anti-proliferative anti-proliferative 0 0 1 0 0 0 0 0 18 0 DT NN JJ NN NN O
benzopyran benzopyran 0 0 0 0 0 0 0 0 10 0 NN JJ NN NN NN O
compound compound 0 0 0 0 0 0 0 0 8 0 JJ NN NN NN CD O
namely, namely, 0 0 0 0 1 0 0 0 7 0 NN NN NN CD NN O
2-[piperidinoethoxyphenyl]-3-phenyl-2H-benzo(b)pyran 2-[piperidinoethoxyphenyl]-3-phenyl-2H-benzo(b)pyran 0 0 1 0 0 0 0 1 52 0 NN NN CD NN IN O
(CDRI-85/287) (CDRI-85/287) 0 1 1 1 0 0 0 1 13 0 NN CD NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN NNP JJ O
ER- ER- 1 1 1 0 0 0 0 0 3 0 NN IN NNP JJ CC O
negative negative 0 0 0 0 0 0 0 0 8 0 IN NNP JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP JJ CC JJ NN O
EGFR- EGFR- 1 1 1 0 0 0 0 0 5 0 JJ CC JJ NN NN O
overexpressing overexpressing 0 0 0 0 0 0 0 0 14 0 CC JJ NN NN NN O
breast breast 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN NN NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN VBD O
benzopyran benzopyran 0 0 0 0 0 0 0 0 10 0 NNP NNP NN VBD RB O
compound compound 0 0 0 0 0 0 0 0 8 0 NNP NN VBD RB VBN O
selectively selectively 0 0 0 0 0 0 0 0 11 0 NN VBD RB VBN DT O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 VBD RB VBN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 RB VBN DT JJ NN O
EGF-induced EGF-induced 1 0 1 0 0 0 0 0 11 0 VBN DT JJ NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ CD O
MDA-MB MDA-MB 1 1 1 0 0 0 0 0 6 0 NN IN JJ CD NNS O
231 231 0 0 0 0 0 0 1 1 3 0 IN JJ CD NNS CC O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ CD NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 CD NNS CC JJ JJ O
ER-negative ER-negative 1 0 1 0 0 0 0 0 11 0 NNS CC JJ JJ NN O
primary primary 0 0 0 0 0 0 0 0 7 0 CC JJ JJ NN NN O
breast breast 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NNP NNP O
culture. culture. 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN RB O
compound compound 0 0 0 0 0 0 0 0 8 0 NNP NNP NN RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNP NN RB VBN NN O
reduced reduced 0 0 0 0 0 0 0 0 7 0 NN RB VBN NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 RB VBN NN NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 VBN NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN IN O
xenograft xenograft 0 0 0 0 0 0 0 0 9 0 NN IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP CD O
MDA-MB MDA-MB 1 1 1 0 0 0 0 0 6 0 NN IN NNP CD NNS O
231 231 0 0 0 0 0 0 1 1 3 0 IN NNP CD NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP CD NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CD NNS IN NN NNP O
nude nude 0 0 0 0 0 0 0 0 4 0 NNS IN NN NNP NNP O
mice. mice. 0 0 0 0 0 0 0 0 5 0 IN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN VBD O
compound compound 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBD RBR O
displayed displayed 0 0 0 0 0 0 0 0 9 0 NNP NN VBD RBR VBG O
better better 0 0 0 0 0 0 0 0 6 0 NN VBD RBR VBG NN O
binding binding 0 0 0 0 0 0 0 0 7 0 VBD RBR VBG NN IN O
affinity affinity 0 0 0 0 0 0 0 0 8 0 RBR VBG NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 VBG NN IN NNP IN O
EGFR EGFR 1 1 0 0 0 0 0 0 4 0 NN IN NNP IN NN O
than than 0 0 0 0 0 0 0 0 4 0 IN NNP IN NN NNP O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 NNP IN NN NNP IN O
AG1478 AG1478 1 1 0 0 0 0 0 1 6 0 IN NN NNP IN VBN O
as as 0 0 0 0 0 0 0 0 2 0 NN NNP IN VBN IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 NNP IN VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 IN VBN IN JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 VBN IN JJ NN NNP O
docking docking 0 0 0 0 0 0 0 0 7 0 IN JJ NN NNP NNP O
studies. studies. 0 0 0 0 0 0 0 0 8 0 JJ NN NNP NNP RB O
CDRI-85/287 CDRI-85/287 1 1 1 1 0 0 0 1 11 0 NN NNP NNP RB VBD O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNP NNP RB VBD DT O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NNP RB VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBD DT NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 VBD DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP CC O
EGFR EGFR 1 1 0 0 0 0 0 0 4 0 NN IN NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NN NNS O
downstream downstream 0 0 0 0 0 0 0 0 10 0 NNP CC NN NNS -NONE- O
effectors effectors 0 0 0 0 0 0 0 0 9 0 CC NN NNS -NONE- CC O
MEK/Erk MEK/Erk 1 0 0 1 0 0 0 0 7 0 NN NNS -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC NNP NNP O
PI-3-K/Akt. PI-3-K/Akt. 1 0 1 1 0 0 0 1 11 0 -NONE- CC NNP NNP NN O
Subsequent Subsequent 1 0 0 0 0 0 0 0 10 0 CC NNP NNP NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN -NONE- JJR O
AP-1 AP-1 1 1 1 0 0 0 0 1 4 0 NN IN -NONE- JJR NN O
promoter promoter 0 0 0 0 0 0 0 0 8 0 IN -NONE- JJR NN VBD O
activity activity 0 0 0 0 0 0 0 0 8 0 -NONE- JJR NN VBD IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 JJR NN VBD IN VBN O
in in 0 0 0 0 0 0 0 0 2 0 NN VBD IN VBN NN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 VBD IN VBN NN NN O
transcription transcription 0 0 0 0 0 0 0 0 13 0 IN VBN NN NN CC O
activation activation 0 0 0 0 0 0 0 0 10 0 VBN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NN CC NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNS CC O
c-fos c-fos 0 0 1 0 0 0 0 0 5 0 NN IN NNS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC NNP NNP O
c-jun. c-jun. 0 0 1 0 0 0 0 0 6 0 NNS CC NNP NNP IN O
Dephosphorylation Dephosphorylation 1 0 0 0 0 0 0 0 17 0 CC NNP NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN NNS O
downstream downstream 0 0 0 0 0 0 0 0 10 0 NNP IN NN NNS -NONE- O
effectors effectors 0 0 0 0 0 0 0 0 9 0 IN NN NNS -NONE- CC O
FOXO-3a FOXO-3a 1 0 1 0 0 0 0 1 7 0 NN NNS -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC NNP VBD O
NF-κB NF-κB 1 0 1 0 0 0 0 0 5 0 -NONE- CC NNP VBD TO O
led led 0 0 0 0 0 0 0 0 3 0 CC NNP VBD TO VBN O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBD TO VBN NN O
increased increased 0 0 0 0 0 0 0 0 9 0 VBD TO VBN NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 TO VBN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNP CC O
p27 p27 0 0 0 0 0 0 0 1 3 0 NN IN NNP CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC VBD NN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 NNP CC VBD NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 CC VBD NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP WDT O
D1 D1 1 1 0 0 0 0 0 1 2 0 IN NN NNP WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 NN NNP WDT VBD JJ O
was was 0 0 0 0 0 0 0 0 3 0 NNP WDT VBD JJ IN O
responsible responsible 0 0 0 0 0 0 0 0 11 0 WDT VBD JJ IN VBN O
for for 0 0 0 0 0 0 0 0 3 0 VBD JJ IN VBN NN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 JJ IN VBN NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 IN VBN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNP CC O
Rb Rb 1 0 0 0 0 0 0 0 2 0 NN IN NNP CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC VBD DT O
prevented prevented 0 0 0 0 0 0 0 0 9 0 NNP CC VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC VBD DT NN IN O
transcription transcription 0 0 0 0 0 0 0 0 13 0 VBD DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NN O
E2F- E2F- 1 1 1 0 0 0 0 1 4 0 NN IN NNP NN NNS O
dependent dependent 0 0 0 0 0 0 0 0 9 0 IN NNP NN NNS VBD O
genes genes 0 0 0 0 0 0 0 0 5 0 NNP NN NNS VBD IN O
involved involved 0 0 0 0 0 0 0 0 8 0 NN NNS VBD IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBD IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBD IN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN NN IN O
progression progression 0 0 0 0 0 0 0 0 11 0 NN NN NN IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN NNP NNP O
G1/S G1/S 1 1 0 1 0 0 0 1 4 0 NN IN NNP NNP NNP B_TIMEXCCP
phase. phase. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN VBD O
compound compound 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBD NN O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP NN VBD NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN VBD NN IN JJ O
via via 0 0 0 0 0 0 0 0 3 0 VBD NN IN JJ NN O
mitochondrial mitochondrial 0 0 0 0 0 0 0 0 13 0 NN IN JJ NN CC O
pathway pathway 0 0 0 0 0 0 0 0 7 0 IN JJ NN CC PRP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC PRP RB O
it it 0 0 0 0 0 0 0 0 2 0 NN CC PRP RB VBD O
also also 0 0 0 0 0 0 0 0 4 0 CC PRP RB VBD JJ O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 PRP RB VBD JJ NN O
EGF-induced EGF-induced 1 0 1 0 0 0 0 0 11 0 RB VBD JJ NN IN O
invasion invasion 0 0 0 0 0 0 0 0 8 0 VBD JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP CD O
MDA-MB MDA-MB 1 1 1 0 0 0 0 0 6 0 NN IN NNP CD NNS O
231 231 0 0 0 0 0 0 1 1 3 0 IN NNP CD NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP CD NNS IN VBN O
as as 0 0 0 0 0 0 0 0 2 0 CD NNS IN VBN IN O
evidenced evidenced 0 0 0 0 0 0 0 0 9 0 NNS IN VBN IN VBN O
by by 0 0 0 0 0 0 0 0 2 0 IN VBN IN VBN NN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 VBN IN VBN NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 IN VBN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN JJ CC O
MMP-9 MMP-9 1 1 1 0 0 0 0 1 5 0 NN IN JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 JJ CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NNP O
CTGF. CTGF. 1 1 0 0 0 0 0 0 5 0 NN IN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
indicate indicate 0 0 0 0 0 0 0 0 8 0 NNP NNS VBP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN JJ NN O
benzopyran benzopyran 0 0 0 0 0 0 0 0 10 0 VBP IN JJ NN -NONE- O
compound compound 0 0 0 0 0 0 0 0 8 0 IN JJ NN -NONE- MD O
CDRI-85/287 CDRI-85/287 1 1 1 1 0 0 0 1 11 0 JJ NN -NONE- MD VB O
could could 0 0 0 0 0 0 0 0 5 0 NN -NONE- MD VB DT O
constitute constitute 0 0 0 0 0 0 0 0 10 0 -NONE- MD VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT JJ JJ O
powerful powerful 0 0 0 0 0 0 0 0 8 0 VB DT JJ JJ JJ O
new new 0 0 0 0 0 0 0 0 3 0 DT JJ JJ JJ NN O
chemotherapeutic chemotherapeutic 0 0 0 0 0 0 0 0 16 0 JJ JJ JJ NN IN O
agent agent 0 0 0 0 0 0 0 0 5 0 JJ JJ NN IN JJ O
against against 0 0 0 0 0 0 0 0 7 0 JJ NN IN JJ CC O
ER-negative ER-negative 1 0 1 0 0 0 0 0 11 0 NN IN JJ CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC NNP NNP O
EGFR EGFR 1 1 0 0 0 0 0 0 4 0 JJ CC NNP NNP NN O
over-expressing over-expressing 0 0 1 0 0 0 0 0 15 0 CC NNP NNP NN NNP O
breast breast 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NNP NONE O
tumors. tumors. 0 0 0 0 0 0 0 0 7 0 NNP NN NNP NONE NONE O
Cyclic Cyclic 1 0 0 0 0 0 0 0 6 0 NONE NONE NNP NN NNP O
AMP-Response AMP-Response 1 0 1 0 0 0 0 0 12 0 NONE NNP NN NNP NNP O
Element Element 1 0 0 0 0 0 0 0 7 0 NNP NN NNP NNP NNP O
Regulated Regulated 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Cycle Cycle 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP IN O
Arrests Arrests 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNP O
Cells. Cells. 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Huang Huang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ren Ren 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hehir Hehir 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Cai Cai 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
J. J. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Zhejiang Zhejiang 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Provincial Provincial 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Key Key 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP IN O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pathophysiology, Pathophysiology, 1 0 0 0 1 0 0 0 16 0 NNP IN NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
School, School, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Ningbo Ningbo 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Ningbo, Ningbo, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP PRP O
Recently, Recently, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP PRP VBP VBN IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 PRP VBP VBN IN IN O
that that 0 0 0 0 0 0 0 0 4 0 VBP VBN IN IN JJ O
trichosanthin trichosanthin 0 0 0 0 0 0 0 0 13 0 VBN IN IN JJ DT O
(TCS), (TCS), 0 1 0 0 1 0 0 0 6 0 IN IN JJ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 IN JJ DT NN NN O
promising promising 0 0 0 0 0 0 0 0 9 0 JJ DT NN NN IN O
agent agent 0 0 0 0 0 0 0 0 5 0 DT NN NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
cervical cervical 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN VBD O
adenocarcinoma, adenocarcinoma, 0 0 0 0 1 0 0 0 15 0 IN JJ NN VBD NNP O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 JJ NN VBD NNP NN O
HeLa HeLa 1 0 0 0 0 0 0 0 4 0 NN VBD NNP NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBD NNP NN NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NNP NN NN IN DT O
through through 0 0 0 0 0 0 0 0 7 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
PKC/MAPK/CREB PKC/MAPK/CREB 1 1 0 1 0 0 0 0 13 0 IN DT NNP NN NNP O
signal signal 0 0 0 0 0 0 0 0 6 0 DT NNP NN NNP NNP O
pathway. pathway. 0 0 0 0 0 0 0 0 8 0 NNP NN NNP NNP NNP O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 NN NNP NNP NNP NNP O
TCS TCS 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP -NONE- O
down-regulated down-regulated 0 0 1 0 0 0 0 0 14 0 NNP NNP NNP -NONE- NN O
Bcl-2 Bcl-2 1 0 1 0 0 0 0 1 5 0 NNP NNP -NONE- NN VBD O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP -NONE- NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 -NONE- NN VBD VBN IN O
abrogated abrogated 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NN NN O
decoy decoy 0 0 0 0 0 0 0 0 5 0 IN DT NN NN NN O
oligonucleotide oligonucleotide 0 0 0 0 0 0 0 0 15 0 DT NN NN NN TO O
(OGN) (OGN) 0 1 0 0 0 0 0 0 5 0 NN NN NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT JJ JJ O
cyclic cyclic 0 0 0 0 0 0 0 0 6 0 TO DT JJ JJ NN O
AMP-responsive AMP-responsive 1 0 1 0 0 0 0 0 14 0 DT JJ JJ NN NNP O
element element 0 0 0 0 0 0 0 0 7 0 JJ JJ NN NNP NNP O
(CRE). (CRE). 0 1 0 0 0 0 0 0 6 0 JJ NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN NNP O
decoy decoy 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NNP VBD O
OGN OGN 1 1 0 0 0 0 0 0 3 0 NNP NN NNP VBD DT O
blocked blocked 0 0 0 0 0 0 0 0 7 0 NN NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN IN O
binding binding 0 0 0 0 0 0 0 0 7 0 VBD DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
CRE-binding CRE-binding 1 0 1 0 0 0 0 0 11 0 NN IN JJ NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 IN JJ NN NN TO O
(CREB) (CREB) 0 1 0 0 0 0 0 0 6 0 JJ NN NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO NNP NNP O
Bcl-2. Bcl-2. 1 0 1 0 0 0 0 1 6 0 NN TO NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 TO NNP NNP NNS VBD O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD IN O
suggested suggested 0 0 0 0 0 0 0 0 9 0 NNP NNS VBD IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN JJ NN O
CRE-mediated CRE-mediated 1 0 1 0 0 0 0 0 12 0 VBD IN JJ NN NN O
gene gene 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN MD O
expression expression 0 0 0 0 0 0 0 0 10 0 JJ NN NN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN NN MD VB DT O
play play 0 0 0 0 0 0 0 0 4 0 NN MD VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT JJ NN O
pivotal pivotal 0 0 0 0 0 0 0 0 7 0 VB DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
HeLa HeLa 1 0 0 0 0 0 0 0 4 0 NN IN NNP NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN NNP NN NNP NNP O
proliferation. proliferation. 0 0 0 0 0 0 0 0 14 0 NNP NN NNP NNP RB O
However, However, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP RB VBZ O
little little 0 0 0 0 0 0 0 0 6 0 NNP NNP RB VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP RB VBZ VBN IN O
known known 0 0 0 0 0 0 0 0 5 0 RB VBZ VBN IN DT O
about about 0 0 0 0 0 0 0 0 5 0 VBZ VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
TCS TCS 1 1 0 0 0 0 0 0 3 0 NN IN NNP IN NN O
on on 0 0 0 0 0 0 0 0 2 0 IN NNP IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP IN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN NN NN O
arrests, arrests, 0 0 0 0 1 0 0 0 8 0 NN NN NN NN IN O
particularly, particularly, 0 0 0 0 1 0 0 0 13 0 NN NN NN IN DT O
whether whether 0 0 0 0 0 0 0 0 7 0 NN NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS VBD O
genes genes 0 0 0 0 0 0 0 0 5 0 IN DT NNS VBD IN O
involved involved 0 0 0 0 0 0 0 0 8 0 DT NNS VBD IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBD IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBD IN NN NN VBD O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN IN O
regulated regulated 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
CRE. CRE. 1 1 0 0 0 0 0 0 4 0 VBN IN NNP NNP NN O
Our Our 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NN NN O
present present 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN VBZ O
study study 0 0 0 0 0 0 0 0 5 0 NNP NN NN VBZ IN O
shows shows 0 0 0 0 0 0 0 0 5 0 NN NN VBZ IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NN VBZ IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 arrests VBZ IN DT NNS IN O
arrests arrests 0 0 0 0 0 0 0 0 7 0 IN DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNS IN JJ NNP CC B_TIMEXCCP
G1 G1 1 1 0 0 0 0 0 1 2 0 IN JJ NNP CC NNP B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 JJ NNP CC NNP NNS O
G2/M G2/M 1 1 0 1 0 0 0 1 4 phases NNP CC NNP NNS VBD B_TIMEXCCP
phases phases 0 0 0 0 0 0 0 0 6 0 CC NNP NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD VBN IN O
accompanied accompanied 0 0 0 0 0 0 0 0 11 0 NNS VBD VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 IN DT JJ NN IN O
down-regulation down-regulation 0 0 1 0 0 0 0 0 15 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN IN NN NN NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 IN NN NN NNP CC O
D1 D1 1 1 0 0 0 0 0 1 2 0 NN NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP CD O
CDK CDK 1 1 0 0 0 0 0 0 3 0 NNP CC NNP CD CD O
2, 2, 0 0 0 0 1 0 0 1 2 0 CC NNP CD CD IN O
4 4 0 0 0 0 0 0 1 1 1 0 NNP CD CD IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CD CD IN NNP NNP O
HeLa HeLa 1 0 0 0 0 0 0 0 4 0 CD IN NNP NNP NN O
cells, cells, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP NN -NONE- O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NNP NNP NN -NONE- NNP O
D1, D1, 1 1 0 0 1 0 0 1 3 0 NNP NN -NONE- NNP CC O
E E 1 1 0 0 0 0 0 0 1 0 NN -NONE- NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NNP CC NNP CD O
CDK CDK 1 1 0 0 0 0 0 0 3 0 NNP CC NNP CD CD O
2, 2, 0 0 0 0 1 0 0 1 2 0 CC NNP CD CD IN O
4 4 0 0 0 0 0 0 1 1 1 0 NNP CD CD IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CD CD IN NNP CC O
Caski Caski 1 0 0 0 0 0 0 0 5 0 CD IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
C33a C33a 1 0 0 0 0 0 0 1 4 0 NNP CC NNP NNP CC O
cells, cells, 0 0 0 0 1 0 0 0 6 0 CC NNP NNP CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC VB JJ O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NNP CC VB JJ NN O
A, A, 1 1 0 0 1 0 0 0 2 0 CC VB JJ NN NNP O
B1, B1, 1 1 0 0 1 0 0 1 3 0 VB JJ NN NNP CC O
E E 1 1 0 0 0 0 0 0 1 0 JJ NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP CD O
CDK CDK 1 1 0 0 0 0 0 0 3 0 NNP CC NNP CD IN O
2 2 0 0 0 0 0 0 1 1 1 0 CC NNP CD IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP CD IN NNP NNP O
SW1990 SW1990 1 1 0 0 0 0 0 1 6 0 CD IN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP DT NN NN NNS O
cycle cycle 0 0 0 0 0 0 0 0 5 arrests DT NN NN NNS VBD O
arrests arrests 0 0 0 0 0 0 0 0 7 0 NN NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
reversed reversed 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN DT O
via via 0 0 0 0 0 0 0 0 3 0 VBD VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 IN DT JJ NN IN O
up-regulation up-regulation 0 0 1 0 0 0 0 0 13 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN DT O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN IN NN DT CC O
A A 1 1 0 0 0 0 0 0 1 0 IN NN DT CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN DT CC NNP IN O
D1, D1, 1 1 0 0 1 0 0 1 3 0 DT CC NNP IN DT O
by by 0 0 0 0 0 0 0 0 2 0 CC NNP IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT VBN NN O
combined combined 0 0 0 0 0 0 0 0 8 0 IN DT VBN NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 DT VBN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNP CC O
TCS TCS 1 1 0 0 0 0 0 0 3 0 NN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
CRE. CRE. 1 1 0 0 0 0 0 0 4 0 NNP CC NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 CC NNP NNP NNP DT O
conclusion, conclusion, 0 0 0 0 1 0 0 0 11 0 NNP NNP NNP DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT NNS VBP O
data data 0 0 0 0 0 0 0 0 4 0 NNP DT NNS VBP IN O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 DT NNS VBP IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NNS VBP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN WDT O
time time 0 0 0 0 0 0 0 0 4 0 DT JJ NN WDT JJ O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT JJ NN O
specific specific 0 0 0 0 0 0 0 0 8 0 NN WDT JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 WDT JJ NN NN NNS O
cycle cycle 0 0 0 0 0 0 0 0 5 arrests JJ NN NN NNS IN O
arrests arrests 0 0 0 0 0 0 0 0 7 0 NN NN NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NNS IN NN NNS MD O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NN NNS MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN NNS MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB VBN IN O
induced induced 0 0 0 0 0 0 0 0 7 0 MD VB VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VB VBN IN NNP IN O
TCS TCS 1 1 0 0 0 0 0 0 3 0 VBN IN NNP IN NN O
by by 0 0 0 0 0 0 0 0 2 0 IN NNP IN NN DT O
inhibiting inhibiting 0 0 0 0 0 0 0 0 10 0 NNP IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN IN O
binding binding 0 0 0 0 0 0 0 0 7 0 NN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP TO O
CREB CREB 1 1 0 0 0 0 0 0 4 0 NN IN NNP TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 IN NNP TO NNP IN O
CRE CRE 1 1 0 0 0 0 0 0 3 0 NNP TO NNP IN NNS O
on on 0 0 0 0 0 0 0 0 2 0 TO NNP IN NNS VBN O
genes genes 0 0 0 0 0 0 0 0 5 0 NNP IN NNS VBN TO O
related related 0 0 0 0 0 0 0 0 7 0 IN NNS VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBN TO VB NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 VBN TO VB NNP NONE O
proliferation. proliferation. 0 0 0 0 0 0 0 0 14 0 TO VB NNP NONE NONE O
HLA-G HLA-G 1 1 1 0 0 0 0 0 5 0 NONE NONE JJ CD NNP O
5' 5' 0 0 0 0 0 1 0 1 2 0 NONE JJ CD NNP NNP O
URR URR 1 1 0 0 0 0 0 0 3 0 JJ CD NNP NNP CC O
SNPs SNPs 1 0 0 0 0 0 0 0 4 0 CD NNP NNP CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC CD NNP O
3' 3' 0 0 0 0 0 1 0 1 2 0 NNP CC CD NNP CD O
UTR UTR 1 1 0 0 0 0 0 0 3 0 CC CD NNP CD NN O
14-bp 14-bp 0 0 1 0 0 0 0 1 5 0 CD NNP CD NN NN O
insertion/deletion insertion/deletion 0 0 0 1 0 0 0 0 18 0 NNP CD NN NN IN O
polymorphism polymorphism 0 0 0 0 0 0 0 0 12 0 CD NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT JJ NN O
Afro-Brazilian Afro-Brazilian 1 0 1 0 0 0 0 0 14 0 IN DT JJ NN IN O
population population 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 JJ NN IN NNP NNP O
Paraná Paraná 1 0 0 0 0 0 0 0 6 0 NN IN NNP NNP NNP O
State. State. 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
Tureck Tureck 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
LV, LV, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Santos Santos 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
LC, LC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wowk Wowk 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
PF, PF, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Mattar Mattar 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
SB, SB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Silva Silva 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
JS, JS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Magalhães Magalhães 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
JC, JC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Roxo Roxo 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
VM, VM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Bicalho Bicalho 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
MG. MG. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Genetics, Genetics, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP IN O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Immunogenetics Immunogenetics 1 0 0 0 0 0 0 0 14 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Histocompatibility, Histocompatibility, 1 0 0 0 1 0 0 0 19 0 NNP CC NNP NNP NNP O
Universidade Universidade 1 0 0 0 0 0 0 0 12 0 CC NNP NNP NNP VBP O
Federal Federal 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP VBP -NONE- O
do do 0 0 0 0 0 0 0 0 2 0 NNP NNP VBP -NONE- -NONE- O
Paraná, Paraná, 1 0 0 0 1 0 0 0 7 0 NNP VBP -NONE- -NONE- NNP O
Curitiba, Curitiba, 1 0 0 0 1 0 0 0 9 0 VBP -NONE- -NONE- NNP NNP O
Brazil. Brazil. 1 0 0 0 0 0 0 0 7 0 -NONE- -NONE- NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 -NONE- NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN NN O
present present 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NNP NN NN VBD CD O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NN NN VBD CD NNP O
23 23 0 0 0 0 0 0 1 1 2 0 NN VBD CD NNP IN O
SNPs SNPs 1 0 0 0 0 0 0 0 4 0 VBD CD NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 CD NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ NN O
5'URR 5'URR 0 1 0 0 0 1 0 1 5 0 IN DT JJ NN NN O
promoter promoter 0 0 0 0 0 0 0 0 8 0 DT JJ NN NN CC O
region region 0 0 0 0 0 0 0 0 6 0 JJ NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT CD O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT CD NN O
14 14 0 0 0 0 0 0 1 1 2 0 CC DT CD NN JJ O
bp bp 0 0 0 0 0 0 0 0 2 0 DT CD NN JJ NN O
ins/del ins/del 0 0 0 1 0 0 0 0 7 0 CD NN JJ NN IN O
polymorphism polymorphism 0 0 0 0 0 0 0 0 12 0 NN JJ NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
3'UTR 3'UTR 0 1 0 0 0 1 0 1 5 0 IN DT JJ NN IN O
region region 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
HLA-G HLA-G 1 1 1 0 0 0 0 0 5 0 IN DT JJ NN IN O
gene gene 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN CD NNS O
150 150 0 0 0 0 0 0 1 1 3 0 NN IN CD NNS IN O
individuals individuals 0 0 0 0 0 0 0 0 11 0 IN CD NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 CD NNS IN JJ NNP O
Afro-Brazilian Afro-Brazilian 1 0 1 0 0 0 0 0 14 0 NNS IN JJ NNP NNP O
ancestry. ancestry. 0 0 0 0 0 0 0 0 9 0 IN JJ NNP NNP VBZ O
Three Three 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP VBZ VBD O
haplotypes haplotypes 0 0 0 0 0 0 0 0 10 0 NNP NNP VBZ VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBD VBN TO O
found found 0 0 0 0 0 0 0 0 5 0 VBZ VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB DT O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJS NNP O
most most 0 0 0 0 0 0 0 0 4 0 VB DT JJS NNP NNP O
frequent. frequent. 0 0 0 0 0 0 0 0 9 0 DT JJS NNP NNP DT O
Comparing Comparing 1 0 0 0 0 0 0 0 9 0 JJS NNP NNP DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT NNS IN O
polymorphisms polymorphisms 0 0 0 0 0 0 0 0 13 0 NNP DT NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NN O
other other 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NN PRP$ O
samples, samples, 0 0 0 0 1 0 0 0 8 0 IN JJ NN PRP$ NNS O
our our 0 0 0 0 0 0 0 0 3 0 JJ NN PRP$ NNS VBP O
data data 0 0 0 0 0 0 0 0 4 0 NN PRP$ NNS VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 PRP$ NNS VBP IN NNS O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NNS VBP O
Afro-Brazilians Afro-Brazilians 1 0 1 0 0 0 0 0 15 0 VBP IN NNS VBP RBR O
are are 0 0 0 0 0 0 0 0 3 0 IN NNS VBP RBR JJ O
more more 0 0 0 0 0 0 0 0 4 0 NNS VBP RBR JJ TO O
similar similar 0 0 0 0 0 0 0 0 7 0 VBP RBR JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 RBR JJ TO DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 JJ TO DT NNS IN O
Euro-Brazilians Euro-Brazilians 1 0 1 0 0 0 0 0 15 0 TO DT NNS IN TO O
than than 0 0 0 0 0 0 0 0 4 0 DT NNS IN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNS IN TO NNP NNP O
Hutterite Hutterite 1 0 0 0 0 0 0 0 9 0 IN TO NNP NNP NNP O
population. population. 0 0 0 0 0 0 0 0 11 0 TO NNP NNP NNP CD O
© © 0 0 0 0 0 0 0 0 1 0 NNP NNP NNP CD NNP O
2013 2013 0 0 0 0 0 0 1 1 4 0 NNP NNP CD NNP NNP O
John John 1 0 0 0 0 0 0 0 4 0 NNP CD NNP NNP CC O
Wiley Wiley 1 0 0 0 0 0 0 0 5 0 CD NNP NNP CC NNP O
& & 0 0 0 0 0 0 0 0 1 0 NNP NNP CC NNP NNP O
Sons Sons 1 0 0 0 0 0 0 0 4 0 NNP CC NNP NNP NONE O
Ltd. Ltd. 1 0 0 0 0 0 0 0 4 0 CC NNP NNP NONE NONE O
Cyclin Cyclin 1 0 0 0 0 0 0 0 6 0 NONE NONE NNP NNP VBZ O
D1 D1 1 1 0 0 0 0 0 1 2 0 NONE NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
required required 0 0 0 0 0 0 0 0 8 0 NNP VBZ VBN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBZ VBN IN NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VBN IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NN O
olig2-expressing olig2-expressing 0 0 1 0 0 0 0 1 16 0 NN IN JJ NN NNS O
progenitor progenitor 0 0 0 0 0 0 0 0 10 0 IN JJ NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT VBN JJ O
injured injured 0 0 0 0 0 0 0 0 7 0 IN DT VBN JJ NNP O
cerebral cerebral 0 0 0 0 0 0 0 0 8 0 DT VBN JJ NNP NNP O
cortex. cortex. 0 0 0 0 0 0 0 0 7 0 VBN JJ NNP NNP NNP O
Nobs Nobs 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Nestel Nestel 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kulik Kulik 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Nitsch Nitsch 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Atanasoski Atanasoski 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
S. S. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Physiology, Physiology, 1 0 0 0 1 0 0 0 11 0 NNP IN NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biomedicine, Biomedicine, 1 0 0 0 1 0 0 0 12 0 NNP IN NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Basel, Basel, 1 0 0 0 1 0 0 0 6 0 NNP IN NNP NNP NNP O
Basel, Basel, 1 0 0 0 1 0 0 0 6 0 IN NNP NNP NNP NNP O
Switzerland. Switzerland. 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
Little Little 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
known known 0 0 0 0 0 0 0 0 5 0 NNP VBZ VBN IN DT O
about about 0 0 0 0 0 0 0 0 5 0 VBZ VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNS O
molecular molecular 0 0 0 0 0 0 0 0 9 0 IN DT JJ NNS VBG O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 DT JJ NNS VBG NN O
driving driving 0 0 0 0 0 0 0 0 7 0 JJ NNS VBG NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NNS VBG NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBG NN IN JJ NNS O
glial glial 0 0 0 0 0 0 0 0 5 0 NN IN JJ NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN DT O
after after 0 0 0 0 0 0 0 0 5 0 JJ NNS IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NNS IN DT NN TO O
insult insult 0 0 0 0 0 0 0 0 6 0 IN DT NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT JJ JJ O
central central 0 0 0 0 0 0 0 0 7 0 TO DT JJ JJ NN O
nervous nervous 0 0 0 0 0 0 0 0 7 0 DT JJ JJ NN NNP O
system system 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NNP TO O
(CNS). (CNS). 0 1 0 0 0 0 0 0 6 0 JJ NN NNP TO NN O
To To 1 0 0 0 0 0 0 0 2 0 NN NNP TO NN DT O
test test 0 0 0 0 0 0 0 0 4 0 NNP TO NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO NN DT NN IN O
hypothesis hypothesis 0 0 0 0 0 0 0 0 10 0 NN DT NN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 0 IN DT NNP NN NN O
regulator regulator 0 0 0 0 0 0 0 0 9 0 DT NNP NN NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NNP NN NN NNP VBZ O
D1 D1 1 1 0 0 0 0 0 1 2 0 NN NN NNP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN NNP VBZ JJ IN O
critical critical 0 0 0 0 0 0 0 0 8 0 NNP VBZ JJ IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN JJ NN O
injury-induced injury-induced 0 0 1 0 0 0 0 0 14 0 JJ IN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN IN O
division division 0 0 0 0 0 0 0 0 8 0 JJ NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
glial glial 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN PRP O
cells, cells, 0 0 0 0 1 0 0 0 6 0 IN JJ NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 JJ NN PRP VBD DT O
applied applied 0 0 0 0 0 0 0 0 7 0 NN PRP VBD DT NN O
an an 0 0 0 0 0 0 0 0 2 0 PRP VBD DT NN NN O
injury injury 0 0 0 0 0 0 0 0 6 0 VBD DT NN NN WDT O
model model 0 0 0 0 0 0 0 0 5 0 DT NN NN WDT VBZ O
that that 0 0 0 0 0 0 0 0 4 0 NN NN WDT VBZ NN O
causes causes 0 0 0 0 0 0 0 0 6 0 NN WDT VBZ NN NN O
brain brain 0 0 0 0 0 0 0 0 5 0 WDT VBZ NN NN IN O
damage damage 0 0 0 0 0 0 0 0 6 0 VBZ NN NN IN DT O
within within 0 0 0 0 0 0 0 0 6 0 NN NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NNP O
well-defined well-defined 0 0 1 0 0 0 0 0 12 0 IN DT JJ NNP NNP O
region. region. 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NNP NNP O
For For 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NNP PRP O
this, this, 0 0 0 0 1 0 0 0 5 0 NNP NNP NNP PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD DT O
injected injected 0 0 0 0 0 0 0 0 8 0 NNP PRP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT NN NN O
neurotoxin neurotoxin 0 0 0 0 0 0 0 0 10 0 VBD DT NN NN NN O
ibotenic ibotenic 0 0 0 0 0 0 0 0 8 0 DT NN NN NN IN O
acid acid 0 0 0 0 0 0 0 0 4 0 NN NN NN IN DT O
into into 0 0 0 0 0 0 0 0 4 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
prefrontal prefrontal 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN IN O
cortex cortex 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
adult adult 0 0 0 0 0 0 0 0 5 0 NN IN NN NN WDT O
mice, mice, 0 0 0 0 1 0 0 0 5 0 IN NN NN WDT NNS O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT NNS TO O
leads leads 0 0 0 0 0 0 0 0 5 0 NN WDT NNS TO DT O
to to 0 0 0 0 0 0 0 0 2 0 WDT NNS TO DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS TO DT JJ NN O
local local 0 0 0 0 0 0 0 0 5 0 TO DT JJ NN NN O
nerve nerve 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN CC O
loss loss 0 0 0 0 0 0 0 0 4 0 NN NN NN CC VBZ O
but but 0 0 0 0 0 0 0 0 3 0 NN NN CC VBZ RB O
does does 0 0 0 0 0 0 0 0 4 0 NN CC VBZ RB VB O
not not 0 0 0 0 0 0 0 0 3 0 CC VBZ RB VB DT O
affect affect 0 0 0 0 0 0 0 0 6 0 VBZ RB VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VB DT NN IN O
survival survival 0 0 0 0 0 0 0 0 8 0 VB DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
glial glial 0 0 0 0 0 0 0 0 5 0 NN IN JJ NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP PRP O
Here, Here, 1 0 0 0 1 0 0 0 5 0 JJ NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NNP PRP VBP IN NN O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 VBP IN NN NNP NN O
D1 D1 1 1 0 0 0 0 0 1 2 0 IN NN NNP NN NNS O
immunoreativity immunoreativity 0 0 0 0 0 0 0 0 15 0 NN NNP NN NNS RB O
increases increases 0 0 0 0 0 0 0 0 9 0 NNP NN NNS RB IN O
drastically drastically 0 0 0 0 0 0 0 0 11 0 NN NNS RB IN NN O
after after 0 0 0 0 0 0 0 0 5 0 NNS RB IN NN NNP O
neurotoxin neurotoxin 0 0 0 0 0 0 0 0 10 0 RB IN NN NNP NNP O
injection. injection. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBP IN O
find find 0 0 0 0 0 0 0 0 4 0 NNP NNP VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NN JJ O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 IN DT NN JJ NN O
D1-immunopositive D1-immunopositive 1 0 1 0 0 0 0 1 17 0 DT NN JJ NN NN O
(cyclin (cyclin 0 0 0 0 0 0 0 0 7 0 NN JJ NN NN NN O
D1+) D1+) 1 1 0 0 0 0 0 1 4 0 JJ NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN IN O
population population 0 0 0 0 0 0 0 0 10 0 NN NN NN IN DT O
within within 0 0 0 0 0 0 0 0 6 0 NN NN IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT VBN NN O
lesioned lesioned 0 0 0 0 0 0 0 0 8 0 IN DT VBN NN NNS O
area area 0 0 0 0 0 0 0 0 4 0 DT VBN NN NNS TO O
consists consists 0 0 0 0 0 0 0 0 8 0 VBN NN NNS TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS TO DT JJ NN O
large large 0 0 0 0 0 0 0 0 5 0 TO DT JJ NN IN O
extent extent 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
Olig2+ Olig2+ 1 0 0 0 0 0 0 1 6 0 NN IN NNP NN NN O
oligodendrocyte oligodendrocyte 0 0 0 0 0 0 0 0 15 0 IN NNP NN NN NNP O
progenitor progenitor 0 0 0 0 0 0 0 0 10 0 NNP NN NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP IN O
Analysis Analysis 1 0 0 0 0 0 0 0 8 0 NN NNP NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN JJ O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NNP IN NN JJ NN O
D1-deficient D1-deficient 1 0 1 0 0 0 0 1 12 0 IN NN JJ NN NNS O
mice mice 0 0 0 0 0 0 0 0 4 0 NN JJ NN NNS WDT O
demonstrates demonstrates 0 0 0 0 0 0 0 0 12 0 JJ NN NNS WDT DT O
that that 0 0 0 0 0 0 0 0 4 0 NN NNS WDT DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS WDT DT NN NN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 WDT DT NN NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 DT NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNS O
Olig2+ Olig2+ 1 0 0 0 0 0 0 1 6 0 NN IN NNP NNS VBZ O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS VBZ IN O
diminishes diminishes 0 0 0 0 0 0 0 0 10 0 NNP NNS VBZ IN NN O
upon upon 0 0 0 0 0 0 0 0 4 0 NNS VBZ IN NN IN O
loss loss 0 0 0 0 0 0 0 0 4 0 VBZ IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP NNP O
D1. D1. 1 1 0 0 0 0 0 1 3 0 IN NN NNP NNP PRP O
Further, Further, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NNP PRP VBP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN JJ NN O
cyclin-dependent cyclin-dependent 0 0 1 0 0 0 0 0 16 0 VBP IN JJ NN NN O
kinase kinase 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN CD O
(cdk) (cdk) 0 0 0 0 0 0 0 0 5 0 JJ NN NN CD CC O
4, 4, 0 0 0 0 1 0 0 1 2 0 NN NN CD CC RB O
but but 0 0 0 0 0 0 0 0 3 0 NN CD CC RB NNP O
not not 0 0 0 0 0 0 0 0 3 0 CD CC RB NNP CC O
cdk6 cdk6 0 0 0 0 0 0 0 1 4 0 CC RB NNP CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 RB NNP CC NNP VBZ O
cdk2, cdk2, 0 0 0 0 1 0 0 1 5 0 NNP CC NNP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 CC NNP VBZ JJ IN O
essential essential 0 0 0 0 0 0 0 0 9 0 NNP VBZ JJ IN VBG O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN VBG NN O
driving driving 0 0 0 0 0 0 0 0 7 0 JJ IN VBG NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN VBG NN NN IN O
division division 0 0 0 0 0 0 0 0 8 0 VBG NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNS O
Olig2-expressing Olig2-expressing 1 0 1 0 0 0 0 1 16 0 NN IN JJ NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN PRP$ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN PRP$ NN O
our our 0 0 0 0 0 0 0 0 3 0 NNS IN PRP$ NN NNP O
injury injury 0 0 0 0 0 0 0 0 6 0 IN PRP$ NN NNP NNP O
model. model. 0 0 0 0 0 0 0 0 6 0 PRP$ NN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNS VBP O
data data 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNP NNS VBP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN JJ NN O
distinct distinct 0 0 0 0 0 0 0 0 8 0 VBP IN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN NNS O
cycle cycle 0 0 0 0 0 0 0 0 5 0 JJ NN NN NNS VBP O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NN NN NNS VBP NN O
regulate regulate 0 0 0 0 0 0 0 0 8 0 NN NNS VBP NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NNS VBP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBP NN IN NNP NN O
Olig2+ Olig2+ 1 0 0 0 0 0 0 1 6 0 NN IN NNP NN NNS O
progenitor progenitor 0 0 0 0 0 0 0 0 10 0 IN NNP NN NNS VBG O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NN NNS VBG DT O
following following 0 0 0 0 0 0 0 0 9 0 NN NNS VBG DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NNS VBG DT NNP NNP O
CNS CNS 1 1 0 0 0 0 0 0 3 0 VBG DT NNP NNP NONE O
insult. insult. 0 0 0 0 0 0 0 0 7 0 DT NNP NNP NONE NONE O
Generation Generation 1 0 0 0 0 0 0 0 10 0 NONE NONE NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN JJ NN O
reactive reactive 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN NNS O
oxygen oxygen 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNS IN O
species species 0 0 0 0 0 0 0 0 7 0 JJ NN NNS IN NNS O
by by 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNS NNS O
polyenylpyrroles polyenylpyrroles 0 0 0 0 0 0 0 0 16 0 NNS IN NNS NNS NNS O
derivatives derivatives 0 0 0 0 0 0 0 0 11 0 IN NNS NNS NNS NNP O
causes causes 0 0 0 0 0 0 0 0 6 0 NNS NNS NNS NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NNS NNS NNP NN VBG O
damage damage 0 0 0 0 0 0 0 0 6 0 NNS NNP NN VBG TO O
leading leading 0 0 0 0 0 0 0 0 7 0 NNP NN VBG TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NN VBG TO JJ NN O
g2/m g2/m 0 0 0 1 0 0 0 1 4 arrest VBG TO JJ NN CC B_TIMEXCCP
arrest arrest 0 0 0 0 0 0 0 0 6 0 TO JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN CC NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CC NN IN NN JJ O
human human 0 0 0 0 0 0 0 0 5 0 NN IN NN JJ JJ O
oral oral 0 0 0 0 0 0 0 0 4 0 IN NN JJ JJ NN O
squamous squamous 0 0 0 0 0 0 0 0 8 0 NN JJ JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ JJ NN NN NNP O
carcinoma carcinoma 0 0 0 0 0 0 0 0 9 0 JJ NN NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP NNP O
Hua Hua 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNP NNP O
KF, KF, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Liao Liao 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
PC, PC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Fang Fang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yang Yang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
FL, FL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Yang Yang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
YL, YL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
YL, YL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Chiu Chiu 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
YC, YC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Liu Liu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
ML, ML, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Lam Lam 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wu Wu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
SH. SH. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Biotechnology Biotechnology 1 0 0 0 0 0 0 0 13 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Animal Animal 1 0 0 0 0 0 0 0 6 0 NNP CC NNP NNP NNP O
Science, Science, 1 0 0 0 1 0 0 0 8 0 CC NNP NNP NNP NNP O
National National 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Ilan Ilan 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Ilan, Ilan, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
Taiwan. Taiwan. 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP JJ O
Oral Oral 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP JJ NN O
squamous squamous 0 0 0 0 0 0 0 0 8 0 NNP NNP JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP JJ NN NN NN O
carcinoma carcinoma 0 0 0 0 0 0 0 0 9 0 JJ NN NN NN NNS O
(OSCC) (OSCC) 0 1 0 0 0 0 0 0 6 0 NN NN NN NNS IN O
accounts accounts 0 0 0 0 0 0 0 0 8 0 NN NN NNS IN CD O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN CD IN O
5.8% 5.8% 0 0 0 0 0 0 0 1 4 0 NNS IN CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN CD IN DT NNS O
all all 0 0 0 0 0 0 0 0 3 0 CD IN DT NNS IN O
malignancies malignancies 0 0 0 0 0 0 0 0 12 0 IN DT NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 DT NNS IN NNP CC O
Taiwan Taiwan 1 0 0 0 0 0 0 0 6 0 NNS IN NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP CC DT NN IN O
incidence incidence 0 0 0 0 0 0 0 0 9 0 CC DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP VBZ O
OSCC OSCC 1 1 0 0 0 0 0 0 4 0 NN IN NNP VBZ IN O
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBZ IN DT NNP NNP O
rise. rise. 0 0 0 0 0 0 0 0 5 0 IN DT NNP NNP VBZ O
OSCC OSCC 1 1 0 0 0 0 0 0 4 0 DT NNP NNP VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ RB DT O
also also 0 0 0 0 0 0 0 0 4 0 NNP VBZ RB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBZ RB DT JJ NN O
common common 0 0 0 0 0 0 0 0 6 0 RB DT JJ NN NN O
malignancy malignancy 0 0 0 0 0 0 0 0 10 0 DT JJ NN NN CC O
worldwide worldwide 0 0 0 0 0 0 0 0 9 0 JJ NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT JJ NN O
five-year five-year 0 0 1 0 0 0 0 0 9 0 CC DT JJ NN NN O
survival survival 0 0 0 0 0 0 0 0 8 0 DT JJ NN NN VBZ O
rate rate 0 0 0 0 0 0 0 0 4 0 JJ NN NN VBZ NNP O
remains remains 0 0 0 0 0 0 0 0 7 0 NN NN VBZ NNP NNP O
poor. poor. 0 0 0 0 0 0 0 0 5 0 NN VBZ NNP NNP JJ O
Therefore, Therefore, 1 0 0 0 1 0 0 0 10 0 VBZ NNP NNP JJ CC O
new new 0 0 0 0 0 0 0 0 3 0 NNP NNP JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP JJ CC JJ NNS O
effective effective 0 0 0 0 0 0 0 0 9 0 JJ CC JJ NNS VBP O
treatments treatments 0 0 0 0 0 0 0 0 10 0 CC JJ NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 JJ NNS VBP VBN TO O
needed needed 0 0 0 0 0 0 0 0 6 0 NNS VBP VBN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VBP VBN TO NN NNP O
control control 0 0 0 0 0 0 0 0 7 0 VBN TO NN NNP NNP O
OSCC. OSCC. 1 1 0 0 0 0 0 0 5 0 TO NN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
present present 0 0 0 0 0 0 0 0 7 0 NNP DT NN NN PRP O
study study 0 0 0 0 0 0 0 0 5 0 DT NN NN PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NN NN PRP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NN PRP VBP VBN DT O
investigated investigated 0 0 0 0 0 0 0 0 12 0 PRP VBP VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP VBN DT NN CC O
efficacy efficacy 0 0 0 0 0 0 0 0 8 0 VBN DT NN CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC VBN NNS O
associated associated 0 0 0 0 0 0 0 0 10 0 NN CC VBN NNS IN O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 CC VBN NNS IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 VBN NNS IN NNS CC O
polyenylpyrroles polyenylpyrroles 0 0 0 0 0 0 0 0 16 0 NNS IN NNS CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC PRP$ NNS O
their their 0 0 0 0 0 0 0 0 5 0 NNS CC PRP$ NNS IN O
analogs analogs 0 0 0 0 0 0 0 0 7 0 CC PRP$ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 PRP$ NNS IN DT IN O
both both 0 0 0 0 0 0 0 0 4 0 NNS IN DT IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN DT IN NN NN O
vitro vitro 0 0 0 0 0 0 0 0 5 0 DT IN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN NN NN NN CC O
culture culture 0 0 0 0 0 0 0 0 7 0 NN NN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN CC IN NN NN O
vivo vivo 0 0 0 0 0 0 0 0 4 0 CC IN NN NN NN O
nude nude 0 0 0 0 0 0 0 0 4 0 IN NN NN NN NNP O
mice mice 0 0 0 0 0 0 0 0 4 0 NN NN NN NNP NNP O
xenografts. xenografts. 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP NNP O
Auxarconjugatin Auxarconjugatin 1 0 0 0 0 0 0 0 15 0 NN NNP NNP NNP NNP O
B B 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NNP CD O
(compound (compound 0 0 0 0 0 0 0 0 9 0 NNP NNP NNP CD VBD O
1a) 1a) 0 0 0 0 0 0 0 1 3 0 NNP NNP CD VBD IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 NNP CD VBD IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CD VBD IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBD IN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest IN NN NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 phase IN DT NN NN CC B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
caspase-dependent caspase-dependent 0 0 1 0 0 0 0 0 17 0 NN CC JJ NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 CC JJ NN IN -NONE- O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN -NONE- CC O
OEC-M1 OEC-M1 1 1 1 0 0 0 0 1 6 0 NN IN -NONE- CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 IN -NONE- CC -NONE- NNS O
HSC-3 HSC-3 1 1 1 0 0 0 0 1 5 0 -NONE- CC -NONE- NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 CC -NONE- NNS IN VBG O
by by 0 0 0 0 0 0 0 0 2 0 -NONE- NNS IN VBG NNP O
activating activating 0 0 0 0 0 0 0 0 10 0 NNS IN VBG NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 IN VBG NNP NN CC O
damage damage 0 0 0 0 0 0 0 0 6 0 VBG NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN NN O
mitochondria mitochondria 0 0 0 0 0 0 0 0 12 0 NN CC NN NN IN O
dysfunction dysfunction 0 0 0 0 0 0 0 0 11 0 CC NN NN IN DT O
through through 0 0 0 0 0 0 0 0 7 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
loss loss 0 0 0 0 0 0 0 0 4 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
mitochondrial mitochondrial 0 0 0 0 0 0 0 0 13 0 NN IN JJ NN NN O
membrane membrane 0 0 0 0 0 0 0 0 8 0 IN JJ NN NN NN O
potential, potential, 0 0 0 0 1 0 0 0 10 0 JJ NN NN NN IN O
release release 0 0 0 0 0 0 0 0 7 0 NN NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
cytochrome cytochrome 0 0 0 0 0 0 0 0 10 0 NN IN NN NN NN O
c, c, 0 0 0 0 1 0 0 0 2 0 IN NN NN NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 NN NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP JJ O
B-cell B-cell 1 0 1 0 0 0 0 0 6 0 NN IN NNP JJ NNP O
lymphoma-2-associated lymphoma-2-associated 0 0 1 0 0 0 0 1 21 0 IN NNP JJ NNP NN O
X X 1 1 0 0 0 0 0 0 1 0 NNP JJ NNP NN -NONE- O
protein protein 0 0 0 0 0 0 0 0 7 0 JJ NNP NN -NONE- CC O
level, level, 0 0 0 0 1 0 0 0 6 0 NNP NN -NONE- CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC VB IN O
decrease decrease 0 0 0 0 0 0 0 0 8 0 -NONE- CC VB IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CC VB IN NNP -NONE- O
B-cell B-cell 1 0 1 0 0 0 0 0 6 0 VB IN NNP -NONE- NNP O
lymphoma-2 lymphoma-2 0 0 1 0 0 0 0 1 10 0 IN NNP -NONE- NNP NNP O
level. level. 0 0 0 0 0 0 0 0 6 0 NNP -NONE- NNP NNP CD O
Compound Compound 1 0 0 0 0 0 0 0 8 0 -NONE- NNP NNP CD NN O
1a-induced 1a-induced 0 0 1 0 0 0 0 1 10 0 NNP NNP CD NN IN O
generation generation 0 0 0 0 0 0 0 0 10 0 NNP CD NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN JJ JJ O
intracellular intracellular 0 0 0 0 0 0 0 0 13 0 NN IN JJ JJ NN O
reactive reactive 0 0 0 0 0 0 0 0 8 0 IN JJ JJ NN NNS O
oxygen oxygen 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NNS IN O
species species 0 0 0 0 0 0 0 0 7 0 JJ NN NNS IN NN O
through through 0 0 0 0 0 0 0 0 7 0 NN NNS IN NN NNP O
cytochrome cytochrome 0 0 0 0 0 0 0 0 10 0 NNS IN NN NNP CD O
P450 P450 1 1 0 0 0 0 0 1 4 0 IN NN NNP CD VBD O
1A1 1A1 0 1 0 0 0 0 0 1 3 0 NN NNP CD VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP CD VBD VBN IN O
identified identified 0 0 0 0 0 0 0 0 10 0 CD VBD VBN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NN O
major major 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN PRP$ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NN IN PRP$ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 IN PRP$ NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 PRP$ NN IN NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNP NN O
damage, damage, 0 0 0 0 1 0 0 0 7 0 IN NNP NNP NN NN O
mitochondria mitochondria 0 0 0 0 0 0 0 0 12 0 NNP NNP NN NN CC O
dysfunction dysfunction 0 0 0 0 0 0 0 0 11 0 NNP NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP WDT O
apoptosis, apoptosis, 0 0 0 0 1 0 0 0 10 0 NN CC NNP WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 CC NNP WDT VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP WDT VBD VBN IN O
reversed reversed 0 0 0 0 0 0 0 0 8 0 WDT VBD VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ JJ O
antioxidant antioxidant 0 0 0 0 0 0 0 0 11 0 VBN IN JJ JJ IN O
N-acetylcysteine N-acetylcysteine 1 0 1 0 0 0 0 0 16 0 IN JJ JJ IN RB O
as as 0 0 0 0 0 0 0 0 2 0 JJ JJ IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 JJ IN RB IN NN O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN NN NNP O
cytochrome cytochrome 0 0 0 0 0 0 0 0 10 0 RB IN NN NNP CD O
P450 P450 1 1 0 0 0 0 0 1 4 0 IN NN NNP CD NN O
1A1 1A1 0 1 0 0 0 0 0 1 3 0 NN NNP CD NN CC O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 NNP CD NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 CD NN CC JJ NNP O
specific specific 0 0 0 0 0 0 0 0 8 0 NN CC JJ NNP NNP O
siRNA. siRNA. 0 0 0 0 0 0 0 0 6 0 CC JJ NNP NNP NN O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 JJ NNP NNP NN VBD O
compound compound 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBD NN O
1a-treated 1a-treated 0 0 1 0 0 0 0 1 10 0 NNP NN VBD NN NN O
nude nude 0 0 0 0 0 0 0 0 4 0 NN VBD NN NN VBD O
mice mice 0 0 0 0 0 0 0 0 4 0 VBD NN NN VBD DT O
showed showed 0 0 0 0 0 0 0 0 6 0 NN NN VBD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN VBD DT NN IN O
reduction reduction 0 0 0 0 0 0 0 0 9 0 VBD DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
OEC-M1 OEC-M1 1 1 1 0 0 0 0 1 6 0 IN DT NN NN NN O
xenograft xenograft 0 0 0 0 0 0 0 0 9 0 DT NN NN NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NN NN NN NN CC O
growth growth 0 0 0 0 0 0 0 0 6 0 NN NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NN CC DT NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 CC DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
caspase-3 caspase-3 0 0 1 0 0 0 0 1 9 0 IN DT NN NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 DT NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NNP O
xenograft xenograft 0 0 0 0 0 0 0 0 9 0 NN IN NN NNP NNP O
tissue. tissue. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNS VB O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VB JJ O
provide provide 0 0 0 0 0 0 0 0 7 0 NNP NNS VB JJ NNS O
promising promising 0 0 0 0 0 0 0 0 9 0 NNS VB JJ NNS IN O
insights insights 0 0 0 0 0 0 0 0 8 0 VB JJ NNS IN TO O
as as 0 0 0 0 0 0 0 0 2 0 JJ NNS IN TO WRB O
to to 0 0 0 0 0 0 0 0 2 0 NNS IN TO WRB NN O
how how 0 0 0 0 0 0 0 0 3 0 IN TO WRB NN CD O
compound compound 0 0 0 0 0 0 0 0 8 0 TO WRB NN CD NNS O
1a 1a 0 0 0 0 0 0 0 1 2 0 WRB NN CD NNS NN O
mediates mediates 0 0 0 0 0 0 0 0 8 0 NN CD NNS NN CC O
cytotoxicity cytotoxicity 0 0 0 0 0 0 0 0 12 0 CD NNS NN CC MD O
and and 0 0 0 0 0 0 0 0 3 0 NNS NN CC MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN CC MD VB TO O
prove prove 0 0 0 0 0 0 0 0 5 0 CC MD VB TO VB O
to to 0 0 0 0 0 0 0 0 2 0 MD VB TO VB DT O
be be 0 0 0 0 0 0 0 0 2 0 VB TO VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 VB DT JJ NN IN O
rationale rationale 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN PRP$ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NN IN PRP$ NN IN O
translation translation 0 0 0 0 0 0 0 0 11 0 IN PRP$ NN IN DT O
into into 0 0 0 0 0 0 0 0 4 0 PRP$ NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ JJ O
potential potential 0 0 0 0 0 0 0 0 9 0 IN DT JJ JJ IN O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 DT JJ JJ IN NNP O
against against 0 0 0 0 0 0 0 0 7 0 JJ JJ IN NNP NONE O
OSCC. OSCC. 1 1 0 0 0 0 0 0 5 0 JJ IN NNP NONE NONE O
Apoptosis Apoptosis 1 0 0 0 0 0 0 0 9 0 NONE NONE NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NONE NNP CC NNP NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 arrest NNP CC NNP NN VBD B_TIMEXCCP
arrest arrest 0 0 0 0 0 0 0 0 6 0 CC NNP NN VBD IN O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP NN VBD IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN NNP NN O
Allium Allium 1 0 0 0 0 0 0 0 6 0 VBD IN NNP NN -NONE- O
ursinum ursinum 0 0 0 0 0 0 0 0 7 0 IN NNP NN -NONE- NN O
(ramson) (ramson) 0 0 0 0 0 0 0 0 8 0 NNP NN -NONE- NN NN O
watery watery 0 0 0 0 0 0 0 0 6 0 NN -NONE- NN NN IN O
extract extract 0 0 0 0 0 0 0 0 7 0 -NONE- NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT NNP JJ O
AGS AGS 1 1 0 0 0 0 0 0 3 0 IN DT NNP JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 DT NNP JJ NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NNP JJ NN NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NNP NNP O
line. line. 0 0 0 0 0 0 0 0 5 0 NN NN NNP NNP NNP O
Xu Xu 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NNP NNP O
XY, XY, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Song Song 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
GQ, GQ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Yu Yu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
YQ, YQ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Ma Ma 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
HY, HY, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Ma Ma 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Jin Jin 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
YN. YN. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pathophysiology, Pathophysiology, 1 0 0 0 1 0 0 0 16 0 NNP IN NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Pathology Pathology 1 0 0 0 0 0 0 0 9 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Pathophysiology, Pathophysiology, 1 0 0 0 1 0 0 0 16 0 NNP CC NNP NNP IN O
College College 1 0 0 0 0 0 0 0 7 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Basic Basic 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
China China 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
University. University. 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN NN O
present present 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NNP NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN TO O
designed designed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB IN O
determine determine 0 0 0 0 0 0 0 0 9 0 VBN TO VB IN NNP O
whether whether 0 0 0 0 0 0 0 0 7 0 TO VB IN NNP NN O
Allium Allium 1 0 0 0 0 0 0 0 6 0 VB IN NNP NN NNP O
ursinum ursinum 0 0 0 0 0 0 0 0 7 0 IN NNP NN NNP NNP O
L L 1 1 0 0 0 0 0 0 1 0 NNP NN NNP NNP MD O
(ramson) (ramson) 0 0 0 0 0 0 0 0 8 0 NN NNP NNP MD VB O
could could 0 0 0 0 0 0 0 0 5 0 NNP NNP MD VB DT O
inhibit inhibit 0 0 0 0 0 0 0 0 7 0 NNP MD VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VB DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ NNS JJ O
AGS AGS 1 1 0 0 0 0 0 0 3 0 IN JJ NNS JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 JJ NNS JJ NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NNS JJ NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP PRP O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 NN NNP NNP PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD TO O
attempted attempted 0 0 0 0 0 0 0 0 9 0 NNP PRP VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 PRP VBD TO VB IN O
determine determine 0 0 0 0 0 0 0 0 9 0 VBD TO VB IN DT O
whether whether 0 0 0 0 0 0 0 0 7 0 TO VB IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 VB IN DT NN MD O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 IN DT NN MD VB O
could could 0 0 0 0 0 0 0 0 5 0 DT NN MD VB IN O
occur occur 0 0 0 0 0 0 0 0 5 0 NN MD VB IN VBG O
by by 0 0 0 0 0 0 0 0 2 0 MD VB IN VBG JJ O
targeting targeting 0 0 0 0 0 0 0 0 9 0 VB IN VBG JJ NNS O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 IN VBG JJ NNS IN O
elements elements 0 0 0 0 0 0 0 0 8 0 VBG JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NNP NNP O
cycle. cycle. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 NN NNP NNP NNP NN O
Flow Flow 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NN VBD O
cytometry cytometry 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB NN O
observe observe 0 0 0 0 0 0 0 0 7 0 VBN TO VB NN CC O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 TO VB NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 VB NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 CC DT NN NN IN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NN O
AGS AGS 1 1 0 0 0 0 0 0 3 0 NN IN NNP NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 IN NNP NN NNS VBD O
lines lines 0 0 0 0 0 0 0 0 5 0 NNP NN NNS VBD CC O
treated treated 0 0 0 0 0 0 0 0 7 0 NN NNS VBD CC RB O
or or 0 0 0 0 0 0 0 0 2 0 NNS VBD CC RB VBN O
not not 0 0 0 0 0 0 0 0 3 0 VBD CC RB VBN IN O
treated treated 0 0 0 0 0 0 0 0 7 0 CC RB VBN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN NN NN O
ramson ramson 0 0 0 0 0 0 0 0 6 0 VBN IN NN NN NNP O
watery watery 0 0 0 0 0 0 0 0 6 0 IN NN NN NNP NNP O
extract. extract. 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP VBD O
Proteins Proteins 1 0 0 0 0 0 0 0 8 0 NN NNP NNP VBD TO O
related related 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBD TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD TO DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 TO DT NN NN VBD O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN IN O
detected detected 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
Western Western 1 0 0 0 0 0 0 0 7 0 VBN IN NNP NNP NNP O
blotting. blotting. 0 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP NN O
Caspase Caspase 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NN VBD O
activity activity 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN VBG O
measured measured 0 0 0 0 0 0 0 0 8 0 NN VBD VBN VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 VBD VBN VBG DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN VBG DT JJ NN O
colorimetric colorimetric 0 0 0 0 0 0 0 0 12 0 VBG DT JJ NN NN O
assay assay 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN VBG O
kit kit 0 0 0 0 0 0 0 0 3 0 JJ NN NN VBG TO O
according according 0 0 0 0 0 0 0 0 9 0 NN NN VBG TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN VBG TO DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 VBG TO DT NNS NNP O
manufacturer's manufacturer's 0 0 0 0 0 1 0 0 14 0 TO DT NNS NNP NNP O
instructions. instructions. 0 0 0 0 0 0 0 0 13 0 DT NNS NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 NNS NNP NNP NNP NN O
Ramson Ramson 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NN NN O
watery watery 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NN VBD O
extract extract 0 0 0 0 0 0 0 0 7 0 NNP NN NN VBD NN O
induced induced 0 0 0 0 0 0 0 0 7 0 NN NN VBD NN CC O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN VBD NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBD NN CC JJ NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 phase NN CC JJ NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 arrest CC JJ NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 JJ NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
AGS AGS 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NN O
Western Western 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NN VBD O
blotting blotting 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NN VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 VBD IN NN NNP VBD O
B B 1 1 0 0 0 0 0 0 1 0 IN NN NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NNP VBD VBN IN O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NNP VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN NN O
ramson ramson 0 0 0 0 0 0 0 0 6 0 VBN IN NN NN NNP O
watery watery 0 0 0 0 0 0 0 0 6 0 IN NN NN NNP NNP O
extract. extract. 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP NNP O
However, However, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 NNP NNP NNP NNP VBZ B_TIMEXCCP
phase-related phase-related 0 0 1 0 0 0 0 0 13 0 NNP NNP NNP VBZ NN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ NN JJ O
remain remain 0 0 0 0 0 0 0 0 6 0 NNP VBZ NN JJ IN O
unchanged unchanged 0 0 0 0 0 0 0 0 9 0 VBZ NN JJ IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 NN JJ IN NNP NNP O
treatment. treatment. 0 0 0 0 0 0 0 0 10 0 JJ IN NNP NNP NNP O
CONCLUSION: CONCLUSION: 1 1 0 0 0 0 0 0 11 0 IN NNP NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
indicate indicate 0 0 0 0 0 0 0 0 8 0 NNP NNS VBP IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NN RB O
ramson ramson 0 0 0 0 0 0 0 0 6 0 VBP IN NN RB VB O
effectively effectively 0 0 0 0 0 0 0 0 11 0 IN NN RB VB VBN O
sup sup 0 0 0 0 0 0 0 0 3 0 NN RB VB VBN NN O
pressed pressed 0 0 0 0 0 0 0 0 7 0 RB VB VBN NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VB VBN NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 VBN NN CC VBD NN O
induced induced 0 0 0 0 0 0 0 0 7 0 NN CC VBD NN CC O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 CC VBD NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBD NN CC JJ NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 arrest NN CC JJ NN IN B_TIMEXCCP
arrest arrest 0 0 0 0 0 0 0 0 6 0 CC JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNS O
AGS AGS 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS IN VBG O
by by 0 0 0 0 0 0 0 0 2 0 NNP NNS IN VBG NNS O
regulating regulating 0 0 0 0 0 0 0 0 10 0 NNS IN VBG NNS IN O
elements elements 0 0 0 0 0 0 0 0 8 0 IN VBG NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBG NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NNP NONE O
cycle. cycle. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NONE NONE O
Role Role 1 0 0 0 0 0 0 0 4 0 NONE NONE NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NONE NNP IN JJ NN O
helicase-like helicase-like 0 0 1 0 0 0 0 0 13 0 NNP IN JJ NN NN O
transcription transcription 0 0 0 0 0 0 0 0 13 0 IN JJ NN NN NN O
factor factor 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN IN O
(hltf) (hltf) 0 0 0 0 0 0 0 0 6 0 NN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
g2/m g2/m 0 0 0 1 0 0 0 1 4 0 IN DT NN NN CC B_TIMEXCCP
transition transition 0 0 0 0 0 0 0 0 10 0 DT NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN CC NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NNP O
brain. brain. 0 0 0 0 0 0 0 0 6 0 NN IN NNP NNP NNP O
Helmer Helmer 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
RA, RA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Foreman Foreman 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
O, O, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Dertien Dertien 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
JS, JS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Panchoo Panchoo 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Bhakta Bhakta 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
SM, SM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Chilton Chilton 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
BS. BS. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP CC O
Biology Biology 1 0 0 0 0 0 0 0 7 0 IN NNP NNP CC NNP O
& & 0 0 0 0 0 0 0 0 1 0 NNP NNP CC NNP NNP O
Biochemistry, Biochemistry, 1 0 0 0 1 0 0 0 13 0 NNP CC NNP NNP NNP O
Texas Texas 1 0 0 0 0 0 0 0 5 0 CC NNP NNP NNP NNP O
Tech Tech 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNPS O
Health Health 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNPS NNP O
Sciences Sciences 1 0 0 0 0 0 0 0 8 0 NNP NNP NNPS NNP NNP O
Center, Center, 1 0 0 0 1 0 0 0 7 0 NNP NNPS NNP NNP NNP O
Lubbock, Lubbock, 1 0 0 0 1 0 0 0 8 0 NNPS NNP NNP NNP NNP O
Texas, Texas, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNPS O
United United 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNPS IN O
States States 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
America. America. 1 0 0 0 0 0 0 0 8 0 NNPS IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP VBZ O
HLTF HLTF 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP VBZ IN O
participates participates 0 0 0 0 0 0 0 0 12 0 NNP NNP VBZ IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN JJ NN O
transcription, transcription, 0 0 0 0 1 0 0 0 14 0 VBZ IN JJ NN NN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 IN JJ NN NN NNP O
remodeling, remodeling, 0 0 0 0 1 0 0 0 11 0 JJ NN NN NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN NN NNP NN -NONE- O
damage damage 0 0 0 0 0 0 0 0 6 0 NN NNP NN -NONE- CC O
repair, repair, 0 0 0 0 1 0 0 0 7 0 NNP NN -NONE- CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC NN NNP O
tumor tumor 0 0 0 0 0 0 0 0 5 0 -NONE- CC NN NNP NNP O
suppression. suppression. 0 0 0 0 0 0 0 0 12 0 CC NN NNP NNP IN O
Aside Aside 1 0 0 0 0 0 0 0 5 0 NN NNP NNP IN VBG O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNP IN VBG VBN O
being being 0 0 0 0 0 0 0 0 5 0 NNP IN VBG VBN IN O
expressed expressed 0 0 0 0 0 0 0 0 9 0 IN VBG VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBG VBN IN NN NN O
mouse mouse 0 0 0 0 0 0 0 0 5 0 VBN IN NN NN IN O
brain brain 0 0 0 0 0 0 0 0 5 0 IN NN NN IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 NN NN IN JJ CC O
embryonic embryonic 0 0 0 0 0 0 0 0 9 0 NN IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NN O
postnatal postnatal 0 0 0 0 0 0 0 0 9 0 JJ CC JJ NN RB O
development, development, 0 0 0 0 1 0 0 0 12 0 CC JJ NN RB VBZ O
little little 0 0 0 0 0 0 0 0 6 0 JJ NN RB VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN RB VBZ VBN IN O
known known 0 0 0 0 0 0 0 0 5 0 RB VBZ VBN IN NNP O
about about 0 0 0 0 0 0 0 0 5 0 VBZ VBN IN NNP JJ O
Hltf's Hltf's 1 0 0 0 0 1 0 0 6 0 VBN IN NNP JJ NNP O
functional functional 0 0 0 0 0 0 0 0 10 0 IN NNP JJ NNP NNP O
importance. importance. 0 0 0 0 0 0 0 0 11 0 NNP JJ NNP NNP NN O
Splice Splice 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP NN NN O
variant variant 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN IN O
quantification quantification 0 0 0 0 0 0 0 0 14 0 NNP NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ JJ O
wild-type wild-type 0 0 1 0 0 0 0 0 9 0 NN IN JJ JJ NN O
neonatal neonatal 0 0 0 0 0 0 0 0 8 0 IN JJ JJ NN NN O
(6-8 (6-8 0 0 1 0 0 0 0 1 4 0 JJ JJ NN NN NN O
hour hour 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NN O
postpartum) postpartum) 0 0 0 0 0 0 0 0 11 0 NN NN NN NN VBD O
brain brain 0 0 0 0 0 0 0 0 5 0 NN NN NN VBD DT O
gave gave 0 0 0 0 0 0 0 0 4 0 NN NN VBD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN VBD DT NN IN O
ratio ratio 0 0 0 0 0 0 0 0 5 0 VBD DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD IN O
5:1 5:1 0 0 0 0 0 0 0 1 3 0 NN IN CD IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 IN CD IN NNP NN O
Hltf Hltf 1 0 0 0 0 0 0 0 4 0 CD IN NNP NN CD O
isoform isoform 0 0 0 0 0 0 0 0 7 0 IN NNP NN CD NNS O
1 1 0 0 0 0 0 0 1 1 1 0 NNP NN CD NNS CD O
(exons (exons 0 0 0 0 0 0 0 0 6 0 NN CD NNS CD TO O
1-25) 1-25) 0 0 1 0 0 0 0 1 5 0 CD NNS CD TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NNS CD TO NN CD O
isoform isoform 0 0 0 0 0 0 0 0 7 0 CD TO NN CD NNS O
2 2 0 0 0 0 0 0 1 1 1 0 TO NN CD NNS CD O
(exons (exons 0 0 0 0 0 0 0 0 6 0 NN CD NNS CD IN O
1-21 1-21 0 0 1 0 0 0 0 1 4 0 CD NNS CD IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NNS CD IN NN CD O
exon exon 0 0 0 0 0 0 0 0 4 0 CD IN NN CD VBD O
21 21 0 0 0 0 0 0 1 1 2 0 IN NN CD VBD IN O
extended extended 0 0 0 0 0 0 0 0 8 0 NN CD VBD IN DT O
via via 0 0 0 0 0 0 0 0 3 0 CD VBD IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBD IN DT JJ NN O
partial partial 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN NN O
intron intron 0 0 0 0 0 0 0 0 6 0 DT JJ NN NN NNP O
retention retention 0 0 0 0 0 0 0 0 9 0 JJ NN NN NNP NNP O
event). event). 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP NN O
Western Western 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBD DT O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NN VBD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN VBD DT NN NN O
close close 0 0 0 0 0 0 0 0 5 0 VBD DT NN NN IN O
correlation correlation 0 0 0 0 0 0 0 0 11 0 DT NN NN IN NNP O
between between 0 0 0 0 0 0 0 0 7 0 NN NN IN NNP CC O
mRNA mRNA 0 0 0 0 0 0 0 0 4 0 NN IN NNP CC VB O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC VB NNP O
protein protein 0 0 0 0 0 0 0 0 7 0 NNP CC VB NNP NNP O
expression. expression. 0 0 0 0 0 0 0 0 11 0 CC VB NNP NNP NN O
Complete Complete 1 0 0 0 0 0 0 0 8 0 VB NNP NNP NN IN O
loss loss 0 0 0 0 0 0 0 0 4 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP VBD O
Hltf Hltf 1 0 0 0 0 0 0 0 4 0 NN IN NNP VBD NN O
caused caused 0 0 0 0 0 0 0 0 6 0 IN NNP VBD NN IN O
encephalomalacia encephalomalacia 0 0 0 0 0 0 0 0 16 0 NNP VBD NN IN VBN O
with with 0 0 0 0 0 0 0 0 4 0 VBD NN IN VBN -NONE- O
increased increased 0 0 0 0 0 0 0 0 9 0 NN IN VBN -NONE- CC O
apoptosis, apoptosis, 0 0 0 0 1 0 0 0 10 0 IN VBN -NONE- CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 VBN -NONE- CC VBD NNP O
reduced reduced 0 0 0 0 0 0 0 0 7 0 -NONE- CC VBD NNP JJ O
viability. viability. 0 0 0 0 0 0 0 0 10 0 CC VBD NNP JJ NN O
Sixty-four Sixty-four 1 0 1 0 0 0 0 0 10 0 VBD NNP JJ NN IN O
percent percent 0 0 0 0 0 0 0 0 7 0 NNP JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
Hltf Hltf 1 0 0 0 0 0 0 0 4 0 NN IN NNP NN NN O
null null 0 0 0 0 0 0 0 0 4 0 IN NNP NN NN NN O
mice mice 0 0 0 0 0 0 0 0 4 0 NNP NN NN NN CD O
died, died, 0 0 0 0 1 0 0 0 5 0 NN NN NN CD IN O
48% 48% 0 0 0 0 0 0 0 1 3 0 NN NN CD IN CD O
within within 0 0 0 0 0 0 0 0 6 0 NN CD IN CD NNS O
12-24 12-24 0 0 1 0 0 0 0 1 5 0 CD IN CD NNS IN O
hours hours 0 0 0 0 0 0 0 0 5 0 IN CD NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN NNP NNP O
birth. birth. 0 0 0 0 0 0 0 0 6 0 NNS IN NNP NNP NNP O
An An 1 0 0 0 0 0 0 0 2 0 IN NNP NNP NNP NN O
RNA-Seq RNA-Seq 1 0 1 0 0 0 0 0 7 0 NNP NNP NNP NN IN O
snapshot snapshot 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
neonatal neonatal 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN NN O
brain brain 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN VBD O
transcriptome transcriptome 0 0 0 0 0 0 0 0 13 0 JJ NN NN VBD CD O
showed showed 0 0 0 0 0 0 0 0 6 0 NN NN VBD CD IN O
341 341 0 0 0 0 0 0 1 1 3 0 NN VBD CD IN CD O
of of 0 0 0 0 0 0 0 0 2 0 VBD CD IN CD NNS O
20,000 20,000 0 0 0 0 1 0 0 1 6 0 CD IN CD NNS VBD O
transcripts transcripts 0 0 0 0 0 0 0 0 11 0 IN CD NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 CD NNS VBD VBN -NONE- O
altered altered 0 0 0 0 0 0 0 0 7 0 NNS VBD VBN -NONE- : O
(p (p 0 0 0 0 0 0 0 0 2 0 VBD VBN -NONE- : CD O
< < 0 0 0 0 0 0 0 0 1 0 VBN -NONE- : CD : O
0.05) 0.05) 0 0 0 0 0 0 0 1 5 0 -NONE- : CD : CD O
- - 0 0 1 0 0 0 0 0 1 0 : CD : CD RP O
95 95 0 0 0 0 0 0 1 1 2 0 CD : CD RP VBN O
up up 0 0 0 0 0 0 0 0 2 0 : CD RP VBN CC O
regulated regulated 0 0 0 0 0 0 0 0 9 0 CD RP VBN CC CD O
and and 0 0 0 0 0 0 0 0 3 0 RP VBN CC CD IN O
246 246 0 0 0 0 0 0 1 1 3 0 VBN CC CD IN NNP O
down down 0 0 0 0 0 0 0 0 4 0 CC CD IN NNP NNP O
regulated. regulated. 0 0 0 0 0 0 0 0 10 0 CD IN NNP NNP NN O
MetaCore(TM) MetaCore(TM) 1 0 0 0 0 0 0 0 12 0 IN NNP NNP NN NN O
enrichment enrichment 0 0 0 0 0 0 0 0 10 0 NNP NNP NN NN NN O
pathway pathway 0 0 0 0 0 0 0 0 7 0 NNP NN NN NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NN NN NN VBD NNP O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NN NN VBD NNP NNS O
Hltf Hltf 1 0 0 0 0 0 0 0 4 0 NN VBD NNP NNS VBP O
regulates regulates 0 0 0 0 0 0 0 0 9 0 VBD NNP NNS VBP JJ O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP JJ NN O
cycle, cycle, 0 0 0 0 1 0 0 0 6 0 NNS VBP JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBP JJ NN NN CC O
adhesion, adhesion, 0 0 0 0 1 0 0 0 9 0 JJ NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NN O
TGF-beta TGF-beta 1 0 1 0 0 0 0 0 8 0 NN CC NNP NN NNP O
receptor receptor 0 0 0 0 0 0 0 0 8 0 CC NNP NN NNP NNP O
signaling. signaling. 0 0 0 0 0 0 0 0 10 0 NNP NN NNP NNP RBS O
Hltf's Hltf's 1 0 0 0 0 1 0 0 6 0 NN NNP NNP RBS JJ O
most most 0 0 0 0 0 0 0 0 4 0 NNP NNP RBS JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 NNP RBS JJ NN VBZ O
role role 0 0 0 0 0 0 0 0 4 0 RBS JJ NN VBZ IN O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN VBZ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBZ IN DT NN NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 0 IN DT NN NN IN B_TIMEXCCP
transition transition 0 0 0 0 0 0 0 0 10 0 DT NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN NN : O
(p (p 0 0 0 0 0 0 0 0 2 0 NN NN NN : CD O
= = 0 0 0 0 0 0 0 0 1 0 NN NN : CD IN O
4.672e-7) 4.672e-7) 0 0 1 0 0 0 0 1 9 0 NN : CD IN DT O
with with 0 0 0 0 0 0 0 0 4 0 : CD IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 CD IN DT NN IN O
emphasis emphasis 0 0 0 0 0 0 0 0 8 0 IN DT NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
transcript transcript 0 0 0 0 0 0 0 0 10 0 NN IN NN NN IN O
availability availability 0 0 0 0 0 0 0 0 12 0 IN NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNS O
major major 0 0 0 0 0 0 0 0 5 0 NN IN JJ NNS IN O
components components 0 0 0 0 0 0 0 0 10 0 IN JJ NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NNS IN NN NN CC O
cohesion cohesion 0 0 0 0 0 0 0 0 8 0 IN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
condensation. condensation. 0 0 0 0 0 0 0 0 13 0 NN CC NNP NNP NN O
Hltf Hltf 1 0 0 0 0 0 0 0 4 0 CC NNP NNP NN VBZ O
null null 0 0 0 0 0 0 0 0 4 0 NNP NNP NN VBZ VB O
brains brains 0 0 0 0 0 0 0 0 6 0 NNP NN VBZ VB VBN O
have have 0 0 0 0 0 0 0 0 4 0 NN VBZ VB VBN NN O
reduced reduced 0 0 0 0 0 0 0 0 7 0 VBZ VB VBN NN NNS O
transcript transcript 0 0 0 0 0 0 0 0 10 0 VB VBN NN NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 VBN NN NNS IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN JJ NN O
Rad21/Scc1, Rad21/Scc1, 1 0 0 1 1 0 0 1 11 0 NNS IN JJ NN NN O
histone histone 0 0 0 0 0 0 0 0 7 0 IN JJ NN NN NN O
H3.3, H3.3, 1 1 0 0 1 0 0 1 5 0 JJ NN NN NN NN O
Cap-E/Smc2, Cap-E/Smc2, 1 0 1 1 1 0 0 1 11 0 NN NN NN NN CC O
Cap-G/G2, Cap-G/G2, 1 0 1 1 1 0 0 1 9 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
Aurora Aurora 1 0 0 0 0 0 0 0 6 0 NN CC NNP NNP NNP O
B B 1 1 0 0 0 0 0 0 1 0 CC NNP NNP NNP NNP O
kinase. kinase. 0 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
loss loss 0 0 0 0 0 0 0 0 4 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP IN O
Hltf Hltf 1 0 0 0 0 0 0 0 4 0 NN IN NNP IN PRP$ O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NNP IN PRP$ NN JJ O
yeast yeast 0 0 0 0 0 0 0 0 5 0 IN PRP$ NN JJ NN O
Rad5-like Rad5-like 1 0 1 0 0 0 0 1 9 0 PRP$ NN JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 NN JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN IN NNP NN NN O
damage damage 0 0 0 0 0 0 0 0 6 0 IN NNP NN NN VBZ O
repair repair 0 0 0 0 0 0 0 0 6 0 NNP NN NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ VBN IN O
accompanied accompanied 0 0 0 0 0 0 0 0 11 0 NN VBZ VBN IN RB O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN RB NN O
down down 0 0 0 0 0 0 0 0 4 0 VBN IN RB NN IN O
regulation regulation 0 0 0 0 0 0 0 0 10 0 IN RB NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 RB NN IN NNP DT O
Cflar, Cflar, 1 0 0 0 1 0 0 0 6 0 NN IN NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 IN NNP DT JJ NN O
critical critical 0 0 0 0 0 0 0 0 8 0 NNP DT JJ NN IN O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
TNFRSF6-mediated TNFRSF6-mediated 1 0 1 0 0 0 0 1 16 0 NN IN JJ NN CC O
apoptosis, apoptosis, 0 0 0 0 1 0 0 0 10 0 IN JJ NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBD NNP O
increased increased 0 0 0 0 0 0 0 0 9 0 NN CC VBD NNP JJ O
(p<0.0001) (p<0.0001) 0 0 0 0 0 0 0 1 10 0 CC VBD NNP JJ NN O
active active 0 0 0 0 0 0 0 0 6 0 VBD NNP JJ NN DT O
caspase-3, caspase-3, 0 0 1 0 1 0 0 1 10 0 NNP JJ NN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 JJ NN DT NN IN O
indicator indicator 0 0 0 0 0 0 0 0 9 0 NN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
intrinsic intrinsic 0 0 0 0 0 0 0 0 9 0 NN IN JJ NN IN O
triggering triggering 0 0 0 0 0 0 0 0 10 0 IN JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN IN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NNP O
null null 0 0 0 0 0 0 0 0 4 0 NN IN NN NNP NNP O
brains. brains. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NNP RB O
Hltf Hltf 1 0 0 0 0 0 0 0 4 0 NN NNP NNP RB VBZ O
also also 0 0 0 0 0 0 0 0 4 0 NNP NNP RB VBZ JJ O
regulates regulates 0 0 0 0 0 0 0 0 9 0 NNP RB VBZ JJ NN O
Smad7/Bambi/Tgf-beta/Bmp5/Wnt10b Smad7/Bambi/Tgf-beta/Bmp5/Wnt10b 1 0 1 1 0 0 0 1 32 0 RB VBZ JJ NN IN O
signaling signaling 0 0 0 0 0 0 0 0 9 0 VBZ JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
brain. brain. 0 0 0 0 0 0 0 0 6 0 NN IN NNP NNP VBD O
ChIP ChIP 1 0 0 0 0 0 0 0 4 0 IN NNP NNP VBD NNP O
confirmed confirmed 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD NNP NN O
Hltf Hltf 1 0 0 0 0 0 0 0 4 0 NNP VBD NNP NN TO O
binding binding 0 0 0 0 0 0 0 0 7 0 VBD NNP NN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO NN NNS O
consensus consensus 0 0 0 0 0 0 0 0 9 0 NN TO NN NNS IN O
sequences sequences 0 0 0 0 0 0 0 0 9 0 TO NN NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NN O
predicted predicted 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NN NNP O
(promoter (promoter 0 0 0 0 0 0 0 0 9 0 IN JJ NN NNP NNP O
Scgb3a1 Scgb3a1 1 0 0 0 0 0 0 1 7 0 JJ NN NNP NNP CC O
gene) gene) 0 0 0 0 0 0 0 0 5 0 NN NNP NNP CC RB O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC RB VBD O
previously previously 0 0 0 0 0 0 0 0 10 0 NNP CC RB VBD JJ O
unidentified unidentified 0 0 0 0 0 0 0 0 12 0 CC RB VBD JJ IN O
(P-element (P-element 0 0 1 0 0 0 0 0 10 0 RB VBD JJ IN NN O
on on 0 0 0 0 0 0 0 0 2 0 VBD JJ IN NN CD O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 JJ IN NN CD NNP O
7) 7) 0 0 0 0 0 0 0 1 2 0 IN NN CD NNP NNP O
targets. targets. 0 0 0 0 0 0 0 0 8 0 NN CD NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 CD NNP NNP NN VBZ O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT JJ TO O
first first 0 0 0 0 0 0 0 0 5 0 VBZ DT JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT JJ TO VB DT O
provide provide 0 0 0 0 0 0 0 0 7 0 JJ TO VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT JJ NN O
comprehensive comprehensive 0 0 0 0 0 0 0 0 13 0 VB DT JJ NN IN O
view view 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNS O
Hltf Hltf 1 0 0 0 0 0 0 0 4 0 NN IN NNP NNS IN O
targets targets 0 0 0 0 0 0 0 0 7 0 IN NNP NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NNP NNP O
brain. brain. 0 0 0 0 0 0 0 0 6 0 NNS IN NNP NNP PRP O
Moreover, Moreover, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBZ WRB O
reveals reveals 0 0 0 0 0 0 0 0 7 0 NNP PRP VBZ WRB VBG O
how how 0 0 0 0 0 0 0 0 3 0 PRP VBZ WRB VBG NNP O
silencing silencing 0 0 0 0 0 0 0 0 9 0 VBZ WRB VBG NNP NNS O
Hltf Hltf 1 0 0 0 0 0 0 0 4 0 WRB VBG NNP NNS VBP O
disrupts disrupts 0 0 0 0 0 0 0 0 8 0 VBG NNP NNS VBP NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP NN -NONE- O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NNS VBP NN -NONE- CC O
progression, progression, 0 0 0 0 1 0 0 0 12 0 VBP NN -NONE- CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC VBZ NNP O
attenuates attenuates 0 0 0 0 0 0 0 0 10 0 -NONE- CC VBZ NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 CC VBZ NNP NN NNP O
damage damage 0 0 0 0 0 0 0 0 6 0 VBZ NNP NN NNP NONE O
repair. repair. 0 0 0 0 0 0 0 0 7 0 NNP NN NNP NONE NONE O
Intrinsic Intrinsic 1 0 0 0 0 0 0 0 9 0 NONE NONE NNP JJ NN O
apoptotic apoptotic 0 0 0 0 0 0 0 0 9 0 NONE NNP JJ NN CC O
pathway pathway 0 0 0 0 0 0 0 0 7 0 NNP JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 0 NN CC JJ NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 CC JJ NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest JJ NN NN NN VBN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 NN NN VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN VBN IN NN JJ O
tubeimoside tubeimoside 0 0 0 0 0 0 0 0 11 0 VBN IN NN JJ NNP O
I-induced I-induced 1 0 1 0 0 0 0 0 9 0 IN NN JJ NNP NN O
EC109 EC109 1 1 0 0 0 0 0 1 5 0 NN JJ NNP NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NNP NN NNP NNP O
death. death. 0 0 0 0 0 0 0 0 6 0 NNP NN NNP NNP NNP O
Xu Xu 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Q, Q, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lin Lin 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zeng Zeng 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Luo Luo 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Q, Q, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Liu Liu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sun Sun 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
C. C. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pharmaceutical Pharmaceutical 1 0 0 0 0 0 0 0 14 0 NNP IN NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Xiamen Xiamen 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP CD O
Xiamen Xiamen 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP CD NNP O
361005, 361005, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NNP O
OBJECTIVE: OBJECTIVE: 1 1 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NN O
Squamous Squamous 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NN NN O
esophageal esophageal 0 0 0 0 0 0 0 0 10 0 NNP NNP NN NN VBZ O
carcinoma carcinoma 0 0 0 0 0 0 0 0 9 0 NNP NN NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ RB JJ O
highly highly 0 0 0 0 0 0 0 0 6 0 NN VBZ RB JJ IN O
prevalent prevalent 0 0 0 0 0 0 0 0 9 0 VBZ RB JJ IN VBG O
in in 0 0 0 0 0 0 0 0 2 0 RB JJ IN VBG NN O
developing developing 0 0 0 0 0 0 0 0 10 0 JJ IN VBG NN RB O
countries, countries, 0 0 0 0 1 0 0 0 10 0 IN VBG NN RB IN O
especially especially 0 0 0 0 0 0 0 0 10 0 VBG NN RB IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN RB IN NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 RB IN NNP NNP NNP O
Tu Tu 1 0 0 0 0 0 0 0 2 0 IN NNP NNP NNP NNP O
Bei Bei 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Mu Mu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP DT O
(TBM), (TBM), 0 1 0 0 1 0 0 0 6 0 NNP NNP NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT JJ NN O
traditional traditional 0 0 0 0 0 0 0 0 11 0 NNP DT JJ NN NN O
folk folk 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN VBZ O
medicine, medicine, 0 0 0 0 1 0 0 0 9 0 JJ NN NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NN NN VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 VBZ VBN VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO VB JJ O
treat treat 0 0 0 0 0 0 0 0 5 0 VBN TO VB JJ JJ O
esophageal esophageal 0 0 0 0 0 0 0 0 10 0 TO VB JJ JJ NN O
squamous squamous 0 0 0 0 0 0 0 0 8 0 VB JJ JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ JJ NN NN NN O
carcinoma carcinoma 0 0 0 0 0 0 0 0 9 0 JJ NN NN NN IN O
(ESCC) (ESCC) 0 1 0 0 0 0 0 0 6 0 NN NN NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NNP O
long long 0 0 0 0 0 0 0 0 4 0 IN DT JJ NNP NN O
term. term. 0 0 0 0 0 0 0 0 5 0 DT JJ NNP NN PRP O
tubeimoside tubeimoside 0 0 0 0 0 0 0 0 11 0 JJ NNP NN PRP VBP O
I I 1 1 0 0 0 0 0 0 1 0 NNP NN PRP VBP VBZ O
(TBMS1) (TBMS1) 0 1 0 0 0 0 0 1 7 0 NN PRP VBP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 PRP VBP VBZ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBP VBZ DT JJ NN O
main main 0 0 0 0 0 0 0 0 4 0 VBZ DT JJ NN IN O
component component 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
TBM, TBM, 1 1 0 0 1 0 0 0 4 0 NN IN NNP NN NN O
exhibiting exhibiting 0 0 0 0 0 0 0 0 10 0 IN NNP NN NN NN O
great great 0 0 0 0 0 0 0 0 5 0 NNP NN NN NN NNP O
anticancer anticancer 0 0 0 0 0 0 0 0 10 0 NN NN NN NNP NNP O
potential. potential. 0 0 0 0 0 0 0 0 10 0 NN NN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 NNP DT NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBD DT O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NN PRP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 VBD DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP JJ O
TBMS1 TBMS1 1 1 0 0 0 0 0 1 5 0 NN IN NNP JJ NN O
cytotoxic cytotoxic 0 0 0 0 0 0 0 0 9 0 IN NNP JJ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 NNP JJ NN IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
EC109 EC109 1 1 0 0 0 0 0 1 5 0 NN IN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
Comparative Comparative 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NN JJ O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 NNP NNP NN JJ NN O
proteomic proteomic 0 0 0 0 0 0 0 0 9 0 NNP NN JJ NN VBD O
approach approach 0 0 0 0 0 0 0 0 8 0 NN JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN IN O
applied applied 0 0 0 0 0 0 0 0 7 0 NN VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
current current 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN CC O
study study 0 0 0 0 0 0 0 0 5 0 DT JJ NN CC PRP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NN CC PRP VBD JJ O
identified identified 0 0 0 0 0 0 0 0 10 0 CC PRP VBD JJ VBN O
several several 0 0 0 0 0 0 0 0 7 0 PRP VBD JJ VBN NN O
altered altered 0 0 0 0 0 0 0 0 7 0 VBD JJ VBN NN NNP O
protein protein 0 0 0 0 0 0 0 0 7 0 JJ VBN NN NNP NNP O
spots. spots. 0 0 0 0 0 0 0 0 6 0 VBN NN NNP NNP JJ O
Further Further 1 0 0 0 0 0 0 0 7 0 NN NNP NNP JJ NNS O
biochemical biochemical 0 0 0 0 0 0 0 0 11 0 NNP NNP JJ NNS VBD O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP JJ NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD VBN RP O
carried carried 0 0 0 0 0 0 0 0 7 0 NNS VBD VBN RP TO O
out out 0 0 0 0 0 0 0 0 3 0 VBD VBN RP TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN RP TO VB DT O
detect detect 0 0 0 0 0 0 0 0 6 0 RP TO VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJ NN O
mitochondrial mitochondrial 0 0 0 0 0 0 0 0 13 0 VB DT JJ NN NN O
membrane membrane 0 0 0 0 0 0 0 0 8 0 DT JJ NN NN NN O
potential, potential, 0 0 0 0 1 0 0 0 10 0 JJ NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN CC O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NN NN NN CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBG NN O
corresponding corresponding 0 0 0 0 0 0 0 0 13 0 NN CC VBG NN NN O
proteins' proteins' 0 0 0 0 0 1 0 0 9 0 CC VBG NN NN CC O
expression expression 0 0 0 0 0 0 0 0 10 0 VBG NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
location. location. 0 0 0 0 0 0 0 0 9 0 NN CC NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 CC NNP NNP NNP JJ O
Subcellular Subcellular 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP JJ NN O
proteomic proteomic 0 0 0 0 0 0 0 0 9 0 NNP NNP JJ NN IN O
study study 0 0 0 0 0 0 0 0 5 0 NNP JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
nucleus nucleus 0 0 0 0 0 0 0 0 7 0 IN DT NN IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 DT NN IN NNP NNS O
EC109 EC109 1 1 0 0 0 0 0 1 5 0 NN IN NNP NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS VBD IN O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD IN VBN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN VBN NNS O
altered altered 0 0 0 0 0 0 0 0 7 0 VBD IN VBN NNS VBD O
proteins proteins 0 0 0 0 0 0 0 0 8 0 IN VBN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 VBN NNS VBD VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NNS VBD VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN JJ NN O
mitochondrial mitochondrial 0 0 0 0 0 0 0 0 13 0 VBN IN JJ NN CC O
function function 0 0 0 0 0 0 0 0 8 0 IN JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 NN CC NN NNP NNP O
proliferation. proliferation. 0 0 0 0 0 0 0 0 14 0 CC NN NNP NNP JJ O
Further Further 1 0 0 0 0 0 0 0 7 0 NN NNP NNP JJ NNS O
biochemical biochemical 0 0 0 0 0 0 0 0 11 0 NNP NNP JJ NNS VBD O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP JJ NNS VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 JJ NNS VBD IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN JJ NN O
TBMS1-induced TBMS1-induced 1 0 1 0 0 0 0 1 13 0 VBD IN JJ NN NNS O
molecular molecular 0 0 0 0 0 0 0 0 9 0 IN JJ NN NNS VBD O
events events 0 0 0 0 0 0 0 0 6 0 JJ NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN TO O
related related 0 0 0 0 0 0 0 0 7 0 NNS VBD VBN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO JJ JJ O
mitochondria-induced mitochondria-induced 0 0 1 0 0 0 0 0 20 0 VBN TO JJ JJ NN O
intrinsic intrinsic 0 0 0 0 0 0 0 0 9 0 TO JJ JJ NN CC O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 JJ JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ -NONE- O
P21-cyclin P21-cyclin 1 0 1 0 0 0 0 1 10 0 NN CC JJ -NONE- JJ O
B1/cdc2 B1/cdc2 1 0 0 1 0 0 0 1 7 0 CC JJ -NONE- JJ NN O
complex-related complex-related 0 0 1 0 0 0 0 0 15 0 JJ -NONE- JJ NN NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 0 -NONE- JJ NN NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NNP O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NN NN NN NNP NNP O
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP NNP O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 NN NNP NNP NNP DT O
Considering Considering 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NN O
conventional conventional 0 0 0 0 0 0 0 0 12 0 NNP DT JJ NN IN O
application application 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP IN O
TBM TBM 1 1 0 0 0 0 0 0 3 0 NN IN NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NN NN O
esophageal esophageal 0 0 0 0 0 0 0 0 10 0 NNP IN NN NN NNP O
cancer, cancer, 0 0 0 0 1 0 0 0 7 0 IN NN NN NNP RB O
TBMS1 TBMS1 1 1 0 0 0 0 0 1 5 0 NN NN NNP RB MD O
therefore therefore 0 0 0 0 0 0 0 0 9 0 NN NNP RB MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NNP RB MD VB DT O
have have 0 0 0 0 0 0 0 0 4 0 RB MD VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT JJ NN O
great great 0 0 0 0 0 0 0 0 5 0 VB DT JJ NN IN O
potential potential 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
chemotherapeutic chemotherapeutic 0 0 0 0 0 0 0 0 16 0 IN DT JJ NN NN O
drug drug 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN IN O
candidate candidate 0 0 0 0 0 0 0 0 9 0 JJ NN NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NNP NONE O
ESCC. ESCC. 1 1 0 0 0 0 0 0 5 0 NN IN NNP NONE NONE O
AdHu5-apoptin AdHu5-apoptin 1 0 1 0 0 0 0 1 13 0 NONE NONE JJ NNS JJ O
induces induces 0 0 0 0 0 0 0 0 7 0 NONE JJ NNS JJ NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 arrest JJ NNS JJ NN CC B_TIMEXCCP
arrest arrest 0 0 0 0 0 0 0 0 6 0 NNS JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN CC NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NN O
p53-mutated p53-mutated 0 0 1 0 0 0 0 1 11 0 NN IN JJ NN JJ O
human human 0 0 0 0 0 0 0 0 5 0 IN JJ NN JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 JJ NN JJ NN -NONE- O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN JJ NN -NONE- NNP O
SGC-7901 SGC-7901 1 1 1 0 0 0 0 1 8 0 JJ NN -NONE- NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN -NONE- NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 -NONE- NNP NNP NNP NNP O
Q, Q, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tan Tan 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Peng Peng 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
W, W, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ren Ren 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Jia Jia 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
He He 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhou Zhou 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Xiang Xiang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
T. T. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP CC O
Oncology Oncology 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Epigenetics Epigenetics 1 0 0 0 0 0 0 0 11 0 NNP CC NNP NNP NNP O
Laboratory, Laboratory, 1 0 0 0 1 0 0 0 11 0 CC NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
First First 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Affiliated Affiliated 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP IN O
Hospital Hospital 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Chongqing Chongqing 1 0 0 0 0 0 0 0 9 0 NNP IN NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Chongqing, Chongqing, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
use use 0 0 0 0 0 0 0 0 3 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN JJ O
anticancer anticancer 0 0 0 0 0 0 0 0 10 0 NN IN NN JJ NNS O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 IN NN JJ NNS VBZ O
agents agents 0 0 0 0 0 0 0 0 6 0 NN JJ NNS VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 JJ NNS VBZ VBN RB O
limited limited 0 0 0 0 0 0 0 0 7 0 NNS VBZ VBN RB IN O
largely largely 0 0 0 0 0 0 0 0 7 0 VBZ VBN RB IN PRP$ O
by by 0 0 0 0 0 0 0 0 2 0 VBN RB IN PRP$ JJ O
their their 0 0 0 0 0 0 0 0 5 0 RB IN PRP$ JJ NN O
severe severe 0 0 0 0 0 0 0 0 6 0 IN PRP$ JJ NN TO O
toxicity toxicity 0 0 0 0 0 0 0 0 8 0 PRP$ JJ NN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO JJ NNP O
normal normal 0 0 0 0 0 0 0 0 6 0 NN TO JJ NNP NNP O
tissues. tissues. 0 0 0 0 0 0 0 0 8 0 TO JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
development development 0 0 0 0 0 0 0 0 11 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NNS O
novel novel 0 0 0 0 0 0 0 0 5 0 NN IN NN NNS IN O
agents agents 0 0 0 0 0 0 0 0 6 0 IN NN NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN NNS IN JJ JJ O
tumor-specific tumor-specific 0 0 1 0 0 0 0 0 14 0 NNS IN JJ JJ CC O
cell-killing cell-killing 0 0 1 0 0 0 0 0 12 0 IN JJ JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ JJ CC JJ NN O
effective effective 0 0 0 0 0 0 0 0 9 0 JJ CC JJ NN NN O
gene gene 0 0 0 0 0 0 0 0 4 0 CC JJ NN NN NNS O
delivery delivery 0 0 0 0 0 0 0 0 8 0 JJ NN NN NNS VBZ O
properties properties 0 0 0 0 0 0 0 0 10 0 NN NN NNS VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NN NNS VBZ RB RB O
thus thus 0 0 0 0 0 0 0 0 4 0 NNS VBZ RB RB NNP O
very very 0 0 0 0 0 0 0 0 4 0 VBZ RB RB NNP NNP O
desirable. desirable. 0 0 0 0 0 0 0 0 10 0 RB RB NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 RB NNP NNP VBD JJ O
used used 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NNP VBD JJ NN NN O
adenovirus adenovirus 0 0 0 0 0 0 0 0 10 0 VBD JJ NN NN CD O
serotype serotype 0 0 0 0 0 0 0 0 8 0 JJ NN NN CD NN O
5 5 0 0 0 0 0 0 1 1 1 0 NN NN CD NN IN O
(AdHu5) (AdHu5) 0 0 0 0 0 0 0 1 7 0 NN CD NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 CD NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN TO O
vehicle vehicle 0 0 0 0 0 0 0 0 7 0 IN DT NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO VB DT O
deliver deliver 0 0 0 0 0 0 0 0 7 0 NN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN NN O
apoptin apoptin 0 0 0 0 0 0 0 0 7 0 VB DT NN NN TO O
gene gene 0 0 0 0 0 0 0 0 4 0 DT NN NN TO RB O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO RB VB O
specifically specifically 0 0 0 0 0 0 0 0 12 0 NN TO RB VB JJ O
target target 0 0 0 0 0 0 0 0 6 0 TO RB VB JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 RB VB JJ NN IN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 VB JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
recombinant recombinant 0 0 0 0 0 0 0 0 11 0 IN DT JJ NN NN O
gene gene 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN NNP O
delivery delivery 0 0 0 0 0 0 0 0 8 0 JJ NN NN NNP NNP O
approach. approach. 0 0 0 0 0 0 0 0 9 0 NN NN NNP NNP VBZ O
AdHu5-apoptin AdHu5-apoptin 1 0 1 0 0 0 0 1 13 0 NN NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT NN CC O
safe safe 0 0 0 0 0 0 0 0 4 0 VBZ DT NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC JJ NN O
efficacious efficacious 0 0 0 0 0 0 0 0 11 0 NN CC JJ NN IN O
agent agent 0 0 0 0 0 0 0 0 5 0 CC JJ NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNP NNP O
(GC). (GC). 0 1 0 0 0 0 0 0 5 0 JJ NN NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NN NN O
apoptin apoptin 0 0 0 0 0 0 0 0 7 0 VBP IN NN NN VBD O
protein protein 0 0 0 0 0 0 0 0 7 0 IN NN NN VBD IN O
encoded encoded 0 0 0 0 0 0 0 0 7 0 NN NN VBD IN DT O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN NN O
apoptin apoptin 0 0 0 0 0 0 0 0 7 0 IN DT NN NN VBD O
gene gene 0 0 0 0 0 0 0 0 4 0 DT NN NN VBD IN O
delivered delivered 0 0 0 0 0 0 0 0 9 0 NN NN VBD IN NNP O
via via 0 0 0 0 0 0 0 0 3 0 NN VBD IN NNP RB O
AdHu5 AdHu5 1 0 0 0 0 0 0 1 5 0 VBD IN NNP RB VBD O
significantly significantly 0 0 0 0 0 0 0 0 13 0 IN NNP RB VBD DT O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NNP RB VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBD DT NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VBD DT NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN -NONE- NNP O
SGC-7901 SGC-7901 1 1 1 0 0 0 0 1 8 0 NN IN -NONE- NNP NNP O
GC GC 1 1 0 0 0 0 0 0 2 0 IN -NONE- NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 -NONE- NNP NNP NNP VBD O
Apoptin Apoptin 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP VBD DT O
reduced reduced 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN NN O
clone clone 0 0 0 0 0 0 0 0 5 0 VBD DT NN NN IN O
number number 0 0 0 0 0 0 0 0 6 0 DT NN NN IN RBR O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN RBR IN O
more more 0 0 0 0 0 0 0 0 4 0 NN IN RBR IN CD O
than than 0 0 0 0 0 0 0 0 4 0 IN RBR IN CD NN O
75 75 0 0 0 0 0 0 1 1 2 0 RBR IN CD NN CC O
% % 0 0 0 0 0 0 0 0 1 0 IN CD NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 CD NN CC VBD IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 NN CC VBD IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CC VBD IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBD IN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest IN NN NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 phase IN DT NN NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NN NN IN CD O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN CD NN O
48 48 0 0 0 0 0 0 1 1 2 0 NN IN CD NN IN O
% % 0 0 0 0 0 0 0 0 1 0 IN CD NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
GC GC 1 1 0 0 0 0 0 0 2 0 IN DT NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 DT NNP NNP NNP RB O
It It 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP RB VBD O
also also 0 0 0 0 0 0 0 0 4 0 NNP NNP RB VBD NN O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP RB VBD NN IN O
cleavage cleavage 0 0 0 0 0 0 0 0 8 0 RB VBD NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN NNP NNP O
caspase-3, caspase-3, 0 0 1 0 1 0 0 1 10 0 NN IN NNP NNP CC O
caspase-7, caspase-7, 0 0 1 0 1 0 0 1 10 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP IN O
caspase-9 caspase-9 0 0 1 0 0 0 0 1 9 0 NNP CC NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 CC NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP NNP O
GC GC 1 1 0 0 0 0 0 0 2 0 IN DT NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 DT NNP NNP NNP CC O
Intratumoral Intratumoral 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ IN O
peritumoral peritumoral 0 0 0 0 0 0 0 0 11 0 NNP CC JJ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CC JJ IN NN NN O
vivo vivo 0 0 0 0 0 0 0 0 4 0 JJ IN NN NN IN O
injection injection 0 0 0 0 0 0 0 0 9 0 IN NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ RB O
AdHu5-apoptin AdHu5-apoptin 1 0 1 0 0 0 0 1 13 0 NN IN JJ RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 IN JJ RB VBN NN O
suppressed suppressed 0 0 0 0 0 0 0 0 10 0 JJ RB VBN NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 RB VBN NN NN CC O
growth growth 0 0 0 0 0 0 0 0 6 0 VBN NN NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBD NN O
induced induced 0 0 0 0 0 0 0 0 7 0 NN CC VBD NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 CC VBD NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBD NN IN JJ NNS O
xenogeneic xenogeneic 0 0 0 0 0 0 0 0 10 0 NN IN JJ NNS IN O
tumors tumors 0 0 0 0 0 0 0 0 6 0 IN JJ NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NNP O
mice. mice. 0 0 0 0 0 0 0 0 5 0 NNS IN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NN VBD O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBD IN O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP NN VBD IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN JJ VBD O
AdHu5-apoptin AdHu5-apoptin 1 0 1 0 0 0 0 1 13 0 VBD IN JJ VBD JJ O
was was 0 0 0 0 0 0 0 0 3 0 IN JJ VBD JJ IN O
independent independent 0 0 0 0 0 0 0 0 11 0 JJ VBD JJ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBD JJ IN JJ -NONE- O
anti-apoptotic anti-apoptotic 0 0 1 0 0 0 0 0 14 0 JJ IN JJ -NONE- CC O
Bcl-2 Bcl-2 1 0 1 0 0 0 0 1 5 0 IN JJ -NONE- CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ -NONE- CC JJ NNS O
Bcl-xL Bcl-xL 1 0 1 0 0 0 0 0 6 0 -NONE- CC JJ NNS CC O
proteins proteins 0 0 0 0 0 0 0 0 8 0 CC JJ NNS CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS CC DT NNP NNP O
p53 p53 0 0 0 0 0 0 0 1 3 0 CC DT NNP NNP NNP O
pathway. pathway. 0 0 0 0 0 0 0 0 8 0 DT NNP NNP NNP NNP O
Taken Taken 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP PRP$ O
together, together, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP PRP$ NNS O
our our 0 0 0 0 0 0 0 0 3 0 NNP NNP PRP$ NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP PRP$ NNS VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 PRP$ NNS VBP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN JJ VBZ O
AdHu5-apoptin AdHu5-apoptin 1 0 1 0 0 0 0 1 13 0 VBP IN JJ VBZ JJ O
has has 0 0 0 0 0 0 0 0 3 0 IN JJ VBZ JJ JJ O
great great 0 0 0 0 0 0 0 0 5 0 JJ VBZ JJ JJ IN O
potential potential 0 0 0 0 0 0 0 0 9 0 VBZ JJ JJ IN DT O
as as 0 0 0 0 0 0 0 0 2 0 JJ JJ IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 JJ IN DT JJ NN O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 IN DT JJ NN IN O
agent agent 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN JJ NN O
effective effective 0 0 0 0 0 0 0 0 9 0 NN IN JJ NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 IN JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNP O
gastric gastric 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNP NONE O
tumors. tumors. 0 0 0 0 0 0 0 0 7 0 IN JJ NNP NONE NONE O
Fisetin Fisetin 1 0 0 0 0 0 0 0 7 0 NONE NONE NNP VBZ JJ O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 NONE NNP VBZ JJ NNS O
growth, growth, 0 0 0 0 1 0 0 0 7 0 NNP VBZ JJ NNS NNP O
induces induces 0 0 0 0 0 0 0 0 7 0 VBZ JJ NNS NNP NNP O
G2 G2 1 1 0 0 0 0 0 1 2 0 JJ NNS NNP NNP NN G2/M
/M /M 0 1 0 1 0 0 0 0 2 arrest NNS NNP NNP NN CC G2/M
arrest arrest 0 0 0 0 0 0 0 0 6 0 NNP NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NN O
epidermoid epidermoid 0 0 0 0 0 0 0 0 10 0 IN JJ NN NN NNP O
carcinoma carcinoma 0 0 0 0 0 0 0 0 9 0 JJ NN NN NNP NNP O
A431 A431 1 1 0 0 0 0 0 1 4 0 NN NN NNP NNP NN O
cells: cells: 0 0 0 0 0 0 0 0 6 0 NN NNP NNP NN IN O
role role 0 0 0 0 0 0 0 0 4 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
mitochondrial mitochondrial 0 0 0 0 0 0 0 0 13 0 NN IN JJ NN NN O
membrane membrane 0 0 0 0 0 0 0 0 8 0 IN JJ NN NN NN O
potential potential 0 0 0 0 0 0 0 0 9 0 JJ NN NN NN CC O
disruption disruption 0 0 0 0 0 0 0 0 10 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NNS O
consequent consequent 0 0 0 0 0 0 0 0 10 0 NN CC NN NNS NNP O
caspases caspases 0 0 0 0 0 0 0 0 8 0 CC NN NNS NNP NNP O
activation. activation. 0 0 0 0 0 0 0 0 11 0 NN NNS NNP NNP NNP O
Pal Pal 1 0 0 0 0 0 0 0 3 0 NNS NNP NNP NNP NNP O
HC, HC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Sharma Sharma 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNPS O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNPS NNP O
Elmets Elmets 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS NNP NNP O
CA, CA, 1 1 0 0 1 0 0 0 3 0 NNP NNPS NNP NNP NNP O
Athar Athar 1 0 0 0 0 0 0 0 5 0 NNPS NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Afaq Afaq 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
F. F. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Dermatology, Dermatology, 1 0 0 0 1 0 0 0 12 0 NNP IN NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP IN O
Alabama Alabama 1 0 0 0 0 0 0 0 7 0 NNP IN NNP IN NNP O
at at 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NNP O
Birmingham, Birmingham, 1 0 0 0 1 0 0 0 11 0 NNP IN NNP NNP NNP O
Birmingham, Birmingham, 1 0 0 0 1 0 0 0 11 0 IN NNP NNP NNP NNP O
AL, AL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
Non-melanoma Non-melanoma 1 0 1 0 0 0 0 0 12 0 NNP NNP NNP NN NNS O
skin skin 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NNS -NONE- O
cancers cancers 0 0 0 0 0 0 0 0 7 0 NNP NN NNS -NONE- CD O
(NMSCs), (NMSCs), 0 0 0 0 1 0 0 0 8 0 NN NNS -NONE- CD IN O
one one 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 -NONE- CD IN DT RBS O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT RBS JJ O
most most 0 0 0 0 0 0 0 0 4 0 IN DT RBS JJ NN O
common common 0 0 0 0 0 0 0 0 6 0 DT RBS JJ NN NN O
neoplasms, neoplasms, 0 0 0 0 1 0 0 0 10 0 RBS JJ NN NN JJ O
cause cause 0 0 0 0 0 0 0 0 5 0 JJ NN NN JJ NN O
serious serious 0 0 0 0 0 0 0 0 7 0 NN NN JJ NN CC O
morbidity morbidity 0 0 0 0 0 0 0 0 9 0 NN JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP NNP O
mortality. mortality. 0 0 0 0 0 0 0 0 10 0 NN CC NNP NNP NN O
Therefore, Therefore, 1 0 0 0 1 0 0 0 10 0 CC NNP NNP NN IN O
identification identification 0 0 0 0 0 0 0 0 14 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NNS O
non-toxic non-toxic 0 0 1 0 0 0 0 0 9 0 NN IN JJ NNS IN O
phytochemicals phytochemicals 0 0 0 0 0 0 0 0 14 0 IN JJ NNS IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN JJ IN O
prevention/treatment prevention/treatment 0 0 0 1 0 0 0 0 20 0 NNS IN JJ IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN JJ IN NNP VBZ O
NMSCs NMSCs 1 0 0 0 0 0 0 0 5 0 JJ IN NNP VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ RB NNP O
highly highly 0 0 0 0 0 0 0 0 6 0 NNP VBZ RB NNP NNP O
desirable. desirable. 0 0 0 0 0 0 0 0 10 0 VBZ RB NNP NNP NNP O
Fisetin Fisetin 1 0 0 0 0 0 0 0 7 0 RB NNP NNP NNP DT O
(3,3',4',7-tetrahydroxyflavone), (3,3',4',7-tetrahydroxyflavone), 0 0 1 0 1 1 0 1 32 0 NNP NNP NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT JJ NN O
dietary dietary 0 0 0 0 0 0 0 0 7 0 NNP DT JJ NN NN O
flavonoid, flavonoid, 0 0 0 0 1 0 0 0 10 0 DT JJ NN NN IN O
present present 0 0 0 0 0 0 0 0 7 0 JJ NN NN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNS CC O
fruits fruits 0 0 0 0 0 0 0 0 6 0 NN IN NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC NNS NNS O
vegetables vegetables 0 0 0 0 0 0 0 0 10 0 NNS CC NNS NNS JJ O
possesses possesses 0 0 0 0 0 0 0 0 9 0 CC NNS NNS JJ CC O
anti-oxidant anti-oxidant 0 0 1 0 0 0 0 0 12 0 NNS NNS JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNS JJ CC JJ NNP O
antiproliferative antiproliferative 0 0 0 0 0 0 0 0 17 0 JJ CC JJ NNP NNP O
properties. properties. 0 0 0 0 0 0 0 0 11 0 CC JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
aim aim 0 0 0 0 0 0 0 0 3 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 IN DT NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB DT O
investigate investigate 0 0 0 0 0 0 0 0 11 0 VBD TO VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJ NN O
chemotherapeutic chemotherapeutic 0 0 0 0 0 0 0 0 16 0 VB DT JJ NN IN O
potential potential 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
fisetin fisetin 0 0 0 0 0 0 0 0 7 0 NN IN NN IN VBN O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN VBN NN O
cultured cultured 0 0 0 0 0 0 0 0 8 0 NN IN VBN NN VBD O
human human 0 0 0 0 0 0 0 0 5 0 IN VBN NN VBD NN O
epidermoid epidermoid 0 0 0 0 0 0 0 0 10 0 VBN NN VBD NN NNP O
carcinoma carcinoma 0 0 0 0 0 0 0 0 9 0 NN VBD NN NNP NNP O
A431 A431 1 1 0 0 0 0 0 1 4 0 VBD NN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP IN O
Treatment Treatment 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNS O
A431 A431 1 1 0 0 0 0 0 1 4 0 NNP IN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNS IN NN -NONE- O
fisetin fisetin 0 0 0 0 0 0 0 0 7 0 NNS IN NN -NONE- -NONE- O
(5-80 (5-80 0 0 1 0 0 0 0 1 5 0 IN NN -NONE- -NONE- VBN O
μm) μm) 0 0 0 0 0 0 0 0 3 0 NN -NONE- -NONE- VBN IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 -NONE- -NONE- VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 IN DT JJ NN IN O
decrease decrease 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN IN O
viability viability 0 0 0 0 0 0 0 0 9 0 IN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN CC O
dose- dose- 0 0 1 0 0 0 0 0 5 0 IN DT NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC JJ NNP O
time-dependent time-dependent 0 0 1 0 0 0 0 0 14 0 NN CC JJ NNP NNP O
manner. manner. 0 0 0 0 0 0 0 0 7 0 CC JJ NNP NNP JJ O
Employing Employing 1 0 0 0 0 0 0 0 9 0 JJ NNP NNP JJ NN O
clonogenic clonogenic 0 0 0 0 0 0 0 0 10 0 NNP NNP JJ NN PRP O
assay, assay, 0 0 0 0 1 0 0 0 6 0 NNP JJ NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 JJ NN PRP VBD IN O
found found 0 0 0 0 0 0 0 0 5 0 NN PRP VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBD IN NN NN O
fisetin fisetin 0 0 0 0 0 0 0 0 7 0 VBD IN NN NN RB O
treatment treatment 0 0 0 0 0 0 0 0 9 0 IN NN NN RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NN NN RB VBN NN O
reduced reduced 0 0 0 0 0 0 0 0 7 0 NN RB VBN NN NN O
colony colony 0 0 0 0 0 0 0 0 6 0 RB VBN NN NN IN O
formation formation 0 0 0 0 0 0 0 0 9 0 VBN NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
A431 A431 1 1 0 0 0 0 0 1 4 0 NN IN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NN O
Fisetin Fisetin 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NNS O
A431 A431 1 1 0 0 0 0 0 1 4 0 NN IN NNP NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS VBD IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBD IN NNP NNP O
G2 G2 1 1 0 0 0 0 0 1 2 0 VBD IN NNP NNP NN G2/M
/M /M 0 1 0 1 0 0 0 0 2 arrest IN NNP NNP NN CC G2/M
arrest arrest 0 0 0 0 0 0 0 0 6 0 NNP NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 NN CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NNP O
apoptosis. apoptosis. 0 0 0 0 0 0 0 0 10 0 NN IN NNP NNP NN O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 IN NNP NNP NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NNS O
A431 A431 1 1 0 0 0 0 0 1 4 0 NN IN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNS IN NN VBN O
fisetin fisetin 0 0 0 0 0 0 0 0 7 0 NNS IN NN VBN IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 IN NN VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN VBN IN NNP VBD O
(i) (i) 0 0 0 0 0 0 0 0 3 0 VBN IN NNP VBD NN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 IN NNP VBD NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP VBD NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN JJ NNS O
anti-apoptotic anti-apoptotic 0 0 1 0 0 0 0 0 14 0 NN IN JJ NNS -NONE- O
proteins proteins 0 0 0 0 0 0 0 0 8 0 IN JJ NNS -NONE- JJ O
(Bcl2; (Bcl2; 0 0 0 0 0 0 0 1 6 0 JJ NNS -NONE- JJ CC O
Bcl-xL Bcl-xL 1 0 1 0 0 0 0 0 6 0 NNS -NONE- JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- JJ CC JJ NN O
Mcl-1); Mcl-1); 1 0 1 0 0 0 0 1 7 0 JJ CC JJ NN VBD O
(ii) (ii) 0 0 0 0 0 0 0 0 4 0 CC JJ NN VBD NN O
increased increased 0 0 0 0 0 0 0 0 9 0 JJ NN VBD NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NN VBD NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN JJ NNS O
pro-apoptotic pro-apoptotic 0 0 1 0 0 0 0 0 13 0 NN IN JJ NNS -NONE- O
proteins proteins 0 0 0 0 0 0 0 0 8 0 IN JJ NNS -NONE- NNP O
(Bax, (Bax, 0 0 0 0 1 0 0 0 5 0 JJ NNS -NONE- NNP CC O
Bak Bak 1 0 0 0 0 0 0 0 3 0 NNS -NONE- NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NNP CC NNP NNP O
Bad); Bad); 1 0 0 0 0 0 0 0 5 0 NNP CC NNP NNP NN O
(iii) (iii) 0 0 0 0 0 0 0 0 5 0 CC NNP NNP NN IN O
disruption disruption 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
mitochondrial mitochondrial 0 0 0 0 0 0 0 0 13 0 NN IN JJ NN NN O
potential; potential; 0 0 0 0 0 0 0 0 10 0 IN JJ NN NN NN O
(iv) (iv) 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN IN O
release release 0 0 0 0 0 0 0 0 7 0 NN NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
cytochrome cytochrome 0 0 0 0 0 0 0 0 10 0 NN IN NN NN CC O
c c 0 0 0 0 0 0 0 0 1 0 IN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP IN O
Smac/DIABLO Smac/DIABLO 1 0 0 1 0 0 0 0 11 0 NN CC NNP IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 CC NNP IN NNP NNP O
mitochondria; mitochondria; 0 0 0 0 0 0 0 0 13 0 NNP IN NNP NNP NN O
(v) (v) 0 0 0 0 0 0 0 0 3 0 IN NNP NNP NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP CC O
caspases; caspases; 0 0 0 0 0 0 0 0 9 0 NN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NN O
(vi) (vi) 0 0 0 0 0 0 0 0 4 0 NNP CC NNP NN IN O
cleavage cleavage 0 0 0 0 0 0 0 0 8 0 CC NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NN O
Poly(ADP-ribose) Poly(ADP-ribose) 1 0 1 0 0 0 0 0 16 0 NN IN NNP NN -NONE- O
polymerase polymerase 0 0 0 0 0 0 0 0 10 0 IN NNP NN -NONE- NNP O
(PARP) (PARP) 0 1 0 0 0 0 0 0 6 0 NNP NN -NONE- NNP NNP O
protein. protein. 0 0 0 0 0 0 0 0 8 0 NN -NONE- NNP NNP IN O
Pretreatment Pretreatment 1 0 0 0 0 0 0 0 12 0 -NONE- NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNS O
A431 A431 1 1 0 0 0 0 0 1 4 0 NNP IN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
pan-caspase pan-caspase 0 0 1 0 0 0 0 0 11 0 IN DT JJ NN NN O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN VBD O
(Z-VAD-FMK) (Z-VAD-FMK) 0 1 1 0 0 0 0 0 11 0 JJ NN NN VBD JJ O
blocked blocked 0 0 0 0 0 0 0 0 7 0 NN NN VBD JJ NN O
fisetin-induced fisetin-induced 0 0 1 0 0 0 0 0 15 0 NN VBD JJ NN IN O
cleavage cleavage 0 0 0 0 0 0 0 0 8 0 VBD JJ NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS CC O
caspases caspases 0 0 0 0 0 0 0 0 8 0 NN IN NNS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC NNP NNP O
PARP. PARP. 1 1 0 0 0 0 0 0 5 0 NNS CC NNP NNP NNP O
Taken Taken 1 0 0 0 0 0 0 0 5 0 CC NNP NNP NNP DT O
together, together, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT NNS VBP O
data data 0 0 0 0 0 0 0 0 4 0 NNP DT NNS VBP NN O
provide provide 0 0 0 0 0 0 0 0 7 0 DT NNS VBP NN IN O
evidence evidence 0 0 0 0 0 0 0 0 8 0 NNS VBP NN IN NN O
that that 0 0 0 0 0 0 0 0 4 0 VBP NN IN NN NNS O
fisetin fisetin 0 0 0 0 0 0 0 0 7 0 NN IN NN NNS JJ O
possesses possesses 0 0 0 0 0 0 0 0 9 0 IN NN NNS JJ NN O
chemotherapeutic chemotherapeutic 0 0 0 0 0 0 0 0 16 0 NN NNS JJ NN IN O
potential potential 0 0 0 0 0 0 0 0 9 0 NNS JJ NN IN JJ O
against against 0 0 0 0 0 0 0 0 7 0 JJ NN IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NN O
epidermoid epidermoid 0 0 0 0 0 0 0 0 10 0 IN JJ NN NN NNP O
carcinoma carcinoma 0 0 0 0 0 0 0 0 9 0 JJ NN NN NNP NNP O
A431 A431 1 1 0 0 0 0 0 1 4 0 NN NN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP DT O
Overall, Overall, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP DT NNS VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 DT NNS VBP IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NN MD O
fisetin fisetin 0 0 0 0 0 0 0 0 7 0 VBP IN NN MD VB O
could could 0 0 0 0 0 0 0 0 5 0 IN NN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB VBN IN O
developed developed 0 0 0 0 0 0 0 0 9 0 MD VB VBN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VB VBN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NN JJ O
novel novel 0 0 0 0 0 0 0 0 5 0 IN DT NN JJ NN O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 DT NN JJ NN IN O
agent agent 0 0 0 0 0 0 0 0 5 0 NN JJ NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
management management 0 0 0 0 0 0 0 0 10 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NONE O
NMSCs. NMSCs. 1 0 0 0 0 0 0 0 6 0 NN IN NNP NONE NONE O
Sulforaphane Sulforaphane 1 0 0 0 0 0 0 0 12 0 NONE NONE NNP VBD NN O
induced induced 0 0 0 0 0 0 0 0 7 0 NONE NNP VBD NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP VBD NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest VBD NN NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 phase IN DT NN NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NN NN IN DT O
via via 0 0 0 0 0 0 0 0 3 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
blockade blockade 0 0 0 0 0 0 0 0 8 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN -NONE- O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN IN NN -NONE- IN O
B1/CDC2 B1/CDC2 1 1 0 1 0 0 0 1 7 0 IN NN -NONE- IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN -NONE- IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 -NONE- IN JJ NN NN O
ovarian ovarian 0 0 0 0 0 0 0 0 7 0 IN JJ NN NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 JJ NN NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP NNP O
Chang Chang 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP NNP O
CC, CC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Hung Hung 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
CM, CM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Yang Yang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
YR, YR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Lee Lee 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
MJ, MJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Hsu Hsu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
YC. YC. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNS O
Malignant Malignant 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNS VBP O
tumors tumors 0 0 0 0 0 0 0 0 6 0 NNP NNP NNS VBP DT O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNS VBP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBP DT JJ JJS O
single single 0 0 0 0 0 0 0 0 6 0 VBP DT JJ JJS JJ O
most most 0 0 0 0 0 0 0 0 4 0 DT JJ JJS JJ NN O
common common 0 0 0 0 0 0 0 0 6 0 JJ JJS JJ NN IN O
cause cause 0 0 0 0 0 0 0 0 5 0 JJS JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN CC O
death death 0 0 0 0 0 0 0 0 5 0 NN IN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN NN O
mortality mortality 0 0 0 0 0 0 0 0 9 0 CC DT NN NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 DT NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
ovarian ovarian 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN VBZ O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT JJS IN O
highest highest 0 0 0 0 0 0 0 0 7 0 VBZ DT JJS IN JJ O
among among 0 0 0 0 0 0 0 0 5 0 DT JJS IN JJ NNP O
gynecological gynecological 0 0 0 0 0 0 0 0 13 0 JJS IN JJ NNP NNP O
disorders. disorders. 0 0 0 0 0 0 0 0 10 0 IN JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
excision excision 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NNS O
benign benign 0 0 0 0 0 0 0 0 6 0 NN IN NN NNS VBZ O
tumors tumors 0 0 0 0 0 0 0 0 6 0 IN NN NNS VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NN NNS VBZ RB VBN O
generally generally 0 0 0 0 0 0 0 0 9 0 NNS VBZ RB VBN IN O
followed followed 0 0 0 0 0 0 0 0 8 0 VBZ RB VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 RB VBN IN JJ NN O
complete complete 0 0 0 0 0 0 0 0 8 0 VBN IN JJ NN NN O
recovery; recovery; 0 0 0 0 0 0 0 0 9 0 IN JJ NN NN DT O
however, however, 0 0 0 0 1 0 0 0 8 0 JJ NN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN IN NN NNS RB O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NN NNS RB NNS O
often often 0 0 0 0 0 0 0 0 5 0 NN NNS RB NNS IN O
results results 0 0 0 0 0 0 0 0 7 0 NNS RB NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 RB NNS IN JJ NN O
rapid rapid 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NN RB O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 IN JJ NN RB IN O
even even 0 0 0 0 0 0 0 0 4 0 JJ NN RB IN DT O
after after 0 0 0 0 0 0 0 0 5 0 NN RB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NN VBZ O
tumor tumor 0 0 0 0 0 0 0 0 5 0 IN DT NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 DT NN VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN VBN NNP O
excised excised 0 0 0 0 0 0 0 0 7 0 VBZ VBN VBN NNP NNP O
completely. completely. 0 0 0 0 0 0 0 0 11 0 VBN VBN NNP NNP JJ O
Thus, Thus, 1 0 0 0 1 0 0 0 5 0 VBN NNP NNP JJ NN O
clinical clinical 0 0 0 0 0 0 0 0 8 0 NNP NNP JJ NN MD O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NNP JJ NN MD VB O
must must 0 0 0 0 0 0 0 0 4 0 JJ NN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB VBN IN O
supplemented supplemented 0 0 0 0 0 0 0 0 12 0 MD VB VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VB VBN IN JJ NN O
auxiliary auxiliary 0 0 0 0 0 0 0 0 9 0 VBN IN JJ NN CC O
chemotherapy chemotherapy 0 0 0 0 0 0 0 0 12 0 IN JJ NN CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 JJ NN CC NNP NNP O
radiotherapy. radiotherapy. 0 0 0 0 0 0 0 0 13 0 NN CC NNP NNP NNP O
Sulforaphane Sulforaphane 1 0 0 0 0 0 0 0 12 0 CC NNP NNP NNP VBZ O
(SFN) (SFN) 0 1 0 0 0 0 0 0 5 0 NNP NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NNP VBZ DT NN IN O
extract extract 0 0 0 0 0 0 0 0 7 0 VBZ DT NN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
mustard mustard 0 0 0 0 0 0 0 0 7 0 IN DT NN NN VBD O
family family 0 0 0 0 0 0 0 0 6 0 DT NN NN VBD IN O
recognized recognized 0 0 0 0 0 0 0 0 10 0 NN NN VBD IN PRP$ O
for for 0 0 0 0 0 0 0 0 3 0 NN VBD IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 VBD IN PRP$ NN NN O
anti-oxidation anti-oxidation 0 0 1 0 0 0 0 0 14 0 IN PRP$ NN NN NN O
abilities, abilities, 0 0 0 0 1 0 0 0 10 phase PRP$ NN NN NN CD O
phase phase 0 0 0 0 0 0 0 0 5 0 NN NN NN CD NN O
2 2 0 0 0 0 0 0 1 1 1 0 NN NN CD NN -NONE- O
enzyme enzyme 0 0 0 0 0 0 0 0 6 0 NN CD NN -NONE- CC O
induction, induction, 0 0 0 0 1 0 0 0 10 0 CD NN -NONE- CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC JJ NNP O
anti-tumor anti-tumor 0 0 1 0 0 0 0 0 10 0 -NONE- CC JJ NNP NNP O
activity. activity. 0 0 0 0 0 0 0 0 9 0 CC JJ NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 JJ NNP NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD DT O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NNP NN VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBD DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBD DT NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest DT NN NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ IN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 0 NN IN JJ IN NNP B_TIMEXCCP
by by 0 0 0 0 0 0 0 0 2 0 IN JJ IN NNP CC O
SFN SFN 1 1 0 0 0 0 0 0 3 0 JJ IN NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP CC DT NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 CC DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN IN NN NN NN O
B1, B1, 1 1 0 0 1 0 0 1 3 0 IN NN NN NN CC O
Cdc2, Cdc2, 1 0 0 0 1 0 0 1 5 0 NN NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN -NONE- O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 CC DT NN -NONE- JJ O
B1/CDC2 B1/CDC2 1 1 0 1 0 0 0 1 7 0 DT NN -NONE- JJ IN O
complex complex 0 0 0 0 0 0 0 0 7 0 NN -NONE- JJ IN -NONE- O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- JJ IN -NONE- NNS O
PA-1 PA-1 1 1 1 0 0 0 0 1 4 0 JJ IN -NONE- NNS VBG O
cells cells 0 0 0 0 0 0 0 0 5 0 IN -NONE- NNS VBG NN O
using using 0 0 0 0 0 0 0 0 5 0 -NONE- NNS VBG NN VBG O
western western 0 0 0 0 0 0 0 0 7 0 NNS VBG NN VBG CC O
blotting blotting 0 0 0 0 0 0 0 0 8 0 VBG NN VBG CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN VBG CC JJ NN O
co-IP co-IP 0 0 1 0 0 0 0 0 5 0 VBG CC JJ NN NNP O
western western 0 0 0 0 0 0 0 0 7 0 CC JJ NN NNP NNP O
blotting. blotting. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 NN NNP NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD DT O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NNP NN VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBD DT NN NNS O
anticancer anticancer 0 0 0 0 0 0 0 0 10 0 VBD DT NN NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 DT NN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NN O
dietary dietary 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NN NNP O
isothiocyanate isothiocyanate 0 0 0 0 0 0 0 0 14 0 IN JJ NN NNP IN O
SFN SFN 1 1 0 0 0 0 0 0 3 0 JJ NN NNP IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 NN NNP IN JJ NN O
ovarian ovarian 0 0 0 0 0 0 0 0 7 0 NNP IN JJ NN VBG O
cancer, cancer, 0 0 0 0 1 0 0 0 7 0 IN JJ NN VBG NN O
using using 0 0 0 0 0 0 0 0 5 0 JJ NN VBG NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN VBG NN NNS NN O
cells cells 0 0 0 0 0 0 0 0 5 0 VBG NN NNS NN NNP O
line line 0 0 0 0 0 0 0 0 4 0 NN NNS NN NNP JJ O
PA-1. PA-1. 1 1 1 0 0 0 0 1 5 0 NNS NN NNP JJ NNS O
SFN-treated SFN-treated 1 0 1 0 0 0 0 0 11 0 NN NNP JJ NNS VBN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP JJ NNS VBN IN O
accumulated accumulated 0 0 0 0 0 0 0 0 11 0 JJ NNS VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBN IN NN IN O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 VBN IN NN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNP O
CDC2 CDC2 1 1 0 0 0 0 0 1 4 0 NN IN NNP NNP CC O
down-regulation down-regulation 0 0 1 0 0 0 0 0 15 0 IN NNP NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NN IN O
dissociation dissociation 0 0 0 0 0 0 0 0 12 0 NNP CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN -NONE- O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 IN DT NN -NONE- NNP O
B1/CDC2 B1/CDC2 1 1 0 1 0 0 0 1 7 0 DT NN -NONE- NNP NNP O
complex. complex. 0 0 0 0 0 0 0 0 8 0 NN -NONE- NNP NNP NNP O
CONCLUSION: CONCLUSION: 1 1 0 0 0 0 0 0 11 0 -NONE- NNP NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS VBP O
findings findings 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBP JJ O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNP NNS VBP JJ IN O
that, that, 0 0 0 0 1 0 0 0 5 0 NNS VBP JJ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBP JJ IN NN TO O
addition addition 0 0 0 0 0 0 0 0 8 0 JJ IN NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT NN NNS O
known known 0 0 0 0 0 0 0 0 5 0 TO DT NN NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 DT NN NNS IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NNS IN NN NN NNP O
prevention, prevention, 0 0 0 0 1 0 0 0 11 0 IN NN NN NNP MD O
SFN SFN 1 1 0 0 0 0 0 0 3 0 NN NN NNP MD RB O
may may 0 0 0 0 0 0 0 0 3 0 NN NNP MD RB VB O
also also 0 0 0 0 0 0 0 0 4 0 NNP MD RB VB JJ O
provide provide 0 0 0 0 0 0 0 0 7 0 MD RB VB JJ NN O
antitumor antitumor 0 0 0 0 0 0 0 0 9 0 RB VB JJ NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 VB JJ NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
established established 0 0 0 0 0 0 0 0 11 0 NN IN JJ NN NNP O
ovarian ovarian 0 0 0 0 0 0 0 0 7 0 IN JJ NN NNP NONE O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 JJ NN NNP NONE NONE O
Synthesis Synthesis 1 0 0 0 0 0 0 0 9 0 NONE NONE NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NONE NNP CC NN IN O
characterization characterization 0 0 0 0 0 0 0 0 16 0 NNP CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
hybrid hybrid 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN JJ O
(chitosan-g-glycidyl (chitosan-g-glycidyl 0 0 1 0 0 0 0 0 20 0 DT JJ NN JJ NNP O
methacrylate)-xanthan methacrylate)-xanthan 0 0 1 0 0 0 0 0 21 0 JJ NN JJ NNP NNP O
hydrogel. hydrogel. 0 0 0 0 0 0 0 0 9 0 NN JJ NNP NNP NNP O
Elizalde-Peña Elizalde-Peña 1 0 1 0 0 0 0 0 13 0 JJ NNP NNP NNP NNP O
EA, EA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Zarate-Triviño Zarate-Triviño 1 0 1 0 0 0 0 0 14 0 NNP NNP NNP NNP NNP O
DG, DG, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Nuño-Donlucas Nuño-Donlucas 1 0 1 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
SM, SM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Medina-Torres Medina-Torres 1 0 1 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Gough Gough 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
JE, JE, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Sanchez Sanchez 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
IC, IC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Villaseñor Villaseñor 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Luna-Barcenas Luna-Barcenas 1 0 1 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
G. G. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP DT O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT NNP NNP O
CINVESTAV, CINVESTAV, 1 1 0 0 1 0 0 0 10 0 NNP DT NNP NNP NNP O
Unidad Unidad 1 0 0 0 0 0 0 0 6 0 DT NNP NNP NNP , O
Querétaro Querétaro 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP , NNP O
, , 0 0 0 0 1 0 0 0 1 0 NNP NNP , NNP NNP O
Libramiento Libramiento 1 0 0 0 0 0 0 0 11 0 NNP , NNP NNP NNP O
Norponiente Norponiente 1 0 0 0 0 0 0 0 11 0 , NNP NNP NNP CD O
No. No. 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP CD NNP O
2000, 2000, 0 0 0 0 1 0 0 1 5 0 NNP NNP CD NNP NNP O
Frac. Frac. 1 0 0 0 0 0 0 0 5 0 NNP CD NNP NNP IN O
Real Real 1 0 0 0 0 0 0 0 4 0 CD NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP , O
Juriquilla Juriquilla 1 0 0 0 0 0 0 0 10 0 NNP IN NNP , NNP O
, , 0 0 0 0 1 0 0 0 1 0 IN NNP , NNP , O
Querétaro Querétaro 1 0 0 0 0 0 0 0 9 0 NNP , NNP , NNP O
, , 0 0 0 0 1 0 0 0 1 0 , NNP , NNP CD O
Qro. Qro. 1 0 0 0 0 0 0 0 4 0 NNP , NNP CD , O
76230 76230 0 0 0 0 0 0 1 1 5 0 , NNP CD , NNP O
, , 0 0 0 0 1 0 0 0 1 0 NNP CD , NNP NNP O
Mexico. Mexico. 1 0 0 0 0 0 0 0 7 0 CD , NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 , NNP NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NN VBZ O
work work 0 0 0 0 0 0 0 0 4 0 NNP NNP NN VBZ DT O
reports reports 0 0 0 0 0 0 0 0 7 0 NNP NN VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT NN CC O
synthesis synthesis 0 0 0 0 0 0 0 0 9 0 VBZ DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
characterization characterization 0 0 0 0 0 0 0 0 16 0 NN CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
new new 0 0 0 0 0 0 0 0 3 0 IN DT JJ NN VBD O
material material 0 0 0 0 0 0 0 0 8 0 DT JJ NN VBD IN O
obtained obtained 0 0 0 0 0 0 0 0 8 0 JJ NN VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN NN DT O
mixing mixing 0 0 0 0 0 0 0 0 6 0 VBD IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN JJ O
hybrid hybrid 0 0 0 0 0 0 0 0 6 0 NN DT NN JJ NN O
natural-synthetic natural-synthetic 0 0 1 0 0 0 0 0 17 0 DT NN JJ NN NN O
chitosan-g-glycidyl chitosan-g-glycidyl 0 0 1 0 0 0 0 0 19 0 NN JJ NN NN NN O
methacrylate methacrylate 0 0 0 0 0 0 0 0 12 0 JJ NN NN NN NN O
(CTS-g-GMA) (CTS-g-GMA) 0 0 1 0 0 0 0 0 11 0 NN NN NN NN CC O
biopolymer biopolymer 0 0 0 0 0 0 0 0 10 0 NN NN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC IN NN O
xanthan xanthan 0 0 0 0 0 0 0 0 7 0 NN CC IN NN NNP O
gum gum 0 0 0 0 0 0 0 0 3 0 CC IN NN NNP NNP O
(X). (X). 0 1 0 0 0 0 0 0 4 0 IN NN NNP NNP NNS O
All All 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS VBD O
materials materials 0 0 0 0 0 0 0 0 9 0 NNP NNP NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD VBN IN O
characterized characterized 0 0 0 0 0 0 0 0 13 0 NNS VBD VBN IN VBN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN VBN NN O
infrared infrared 0 0 0 0 0 0 0 0 8 0 VBN IN VBN NN -NONE- O
spectroscopy spectroscopy 0 0 0 0 0 0 0 0 12 0 IN VBN NN -NONE- NNP O
(FTIR), (FTIR), 0 1 0 0 1 0 0 0 7 0 VBN NN -NONE- NNP NNP O
X-ray X-ray 1 0 1 0 0 0 0 0 5 0 NN -NONE- NNP NNP CC O
diffraction, diffraction, 0 0 0 0 1 0 0 0 12 0 -NONE- NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NN O
thermal thermal 0 0 0 0 0 0 0 0 7 0 NNP CC JJ NN NN O
analysis analysis 0 0 0 0 0 0 0 0 8 0 CC JJ NN NN CC O
(DSC (DSC 0 1 0 0 0 0 0 0 4 0 JJ NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP CC O
TGA) TGA) 1 1 0 0 0 0 0 0 4 0 NN CC NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP CC DT NNS VBD O
results results 0 0 0 0 0 0 0 0 7 0 CC DT NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 DT NNS VBD VBN IN O
contrasted contrasted 0 0 0 0 0 0 0 0 10 0 NNS VBD VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN DT IN O
those those 0 0 0 0 0 0 0 0 5 0 VBN IN DT IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN DT IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 DT IN DT NN NNP O
precursor precursor 0 0 0 0 0 0 0 0 9 0 IN DT NN NNP NNP O
materials. materials. 0 0 0 0 0 0 0 0 10 0 DT NN NNP NNP VBG O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP VBG NN O
swelling swelling 0 0 0 0 0 0 0 0 8 0 NNP NNP VBG NN IN O
index index 0 0 0 0 0 0 0 0 5 0 NNP VBG NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBG NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS VBZ O
hydrogels hydrogels 0 0 0 0 0 0 0 0 9 0 IN DT NNS VBZ WRB O
decreases decreases 0 0 0 0 0 0 0 0 9 0 DT NNS VBZ WRB DT O
when when 0 0 0 0 0 0 0 0 4 0 NNS VBZ WRB DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBZ WRB DT NNP NN O
GMA GMA 1 1 0 0 0 0 0 0 3 0 WRB DT NNP NN NN O
mass mass 0 0 0 0 0 0 0 0 4 0 DT NNP NN NN NNP O
percentage percentage 0 0 0 0 0 0 0 0 10 0 NNP NN NN NNP NNP O
increases. increases. 0 0 0 0 0 0 0 0 10 0 NN NN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNP NN O
X-ray X-ray 1 0 1 0 0 0 0 0 5 0 NNP NNP NNP NN NNS O
diffraction diffraction 0 0 0 0 0 0 0 0 11 0 NNP NNP NN NNS VBP O
patterns patterns 0 0 0 0 0 0 0 0 8 0 NNP NN NNS VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NN NNS VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NN NNS O
hybrid hybrid 0 0 0 0 0 0 0 0 6 0 IN DT NN NNS VBP O
hydrogels hydrogels 0 0 0 0 0 0 0 0 9 0 DT NN NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NN NNS VBP JJ IN O
amorphous amorphous 0 0 0 0 0 0 0 0 9 0 NNS VBP JJ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBP JJ IN NN TO O
contrast contrast 0 0 0 0 0 0 0 0 8 0 JJ IN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB JJ O
chitosan chitosan 0 0 0 0 0 0 0 0 8 0 NN TO VB JJ WDT O
(CTS), (CTS), 0 1 0 0 1 0 0 0 6 0 TO VB JJ WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 VB JJ WDT VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 JJ WDT VBZ NNP NNP O
semi-crystalline. semi-crystalline. 0 0 1 0 0 0 0 0 17 0 WDT VBZ NNP NNP NN O
FTIR FTIR 1 1 0 0 0 0 0 0 4 0 VBZ NNP NNP NN VBZ O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBZ DT O
confirms confirms 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT NN IN O
existence existence 0 0 0 0 0 0 0 0 9 0 VBZ DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
physical physical 0 0 0 0 0 0 0 0 8 0 NN IN JJ NNS IN O
interactions interactions 0 0 0 0 0 0 0 0 12 0 IN JJ NNS IN NNP O
among among 0 0 0 0 0 0 0 0 5 0 JJ NNS IN NNP NNP O
constituents. constituents. 0 0 0 0 0 0 0 0 13 0 NNS IN NNP NNP NNP O
Rheological Rheological 1 0 0 0 0 0 0 0 11 0 IN NNP NNP NNP , O
properties, properties, 0 0 0 0 1 0 0 0 11 0 NNP NNP NNP , NNP O
η, η, 0 0 0 0 1 0 0 0 2 0 NNP NNP , NNP CC O
G', G', 1 1 0 0 1 1 0 0 3 0 NNP , NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 , NNP CC NNP VBD O
G″, G″, 1 1 0 0 1 0 0 0 3 0 NNP CC NNP VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 CC NNP VBD VBN IN O
determined determined 0 0 0 0 0 0 0 0 10 0 NNP VBD VBN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NN IN O
function function 0 0 0 0 0 0 0 0 8 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN VBG O
flow flow 0 0 0 0 0 0 0 0 4 0 NN IN NN VBG CD O
allowing allowing 0 0 0 0 0 0 0 0 8 0 IN NN VBG CD TO O
one one 0 0 0 0 0 0 0 0 3 0 NN VBG CD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBG CD TO VB IN O
conclude conclude 0 0 0 0 0 0 0 0 8 0 CD TO VB IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 TO VB IN JJ NNS O
(CTS-g-GMA)-X (CTS-g-GMA)-X 0 0 1 0 0 0 0 0 13 0 VB IN JJ NNS IN O
behaves behaves 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NNP O
physical physical 0 0 0 0 0 0 0 0 8 0 NNS IN JJ NNP NNP O
hydrogel. hydrogel. 0 0 0 0 0 0 0 0 9 0 IN JJ NNP NNP PRP O
Additionally, Additionally, 1 0 0 0 1 0 0 0 13 0 JJ NNP NNP PRP NN O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP NN NN O
report report 0 0 0 0 0 0 0 0 6 0 NNP PRP NN NN IN O
viability viability 0 0 0 0 0 0 0 0 9 0 PRP NN NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNS WRB O
fibroblasts fibroblasts 0 0 0 0 0 0 0 0 11 0 NN IN NNS WRB VBN O
when when 0 0 0 0 0 0 0 0 4 0 IN NNS WRB VBN IN O
cultured cultured 0 0 0 0 0 0 0 0 8 0 NNS WRB VBN IN DT O
onto onto 0 0 0 0 0 0 0 0 4 0 WRB VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNP O
synthesized synthesized 0 0 0 0 0 0 0 0 11 0 IN DT JJ NNP NNP O
hydrogels. hydrogels. 0 0 0 0 0 0 0 0 10 0 DT JJ NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NN VBZ O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ IN O
shows shows 0 0 0 0 0 0 0 0 5 0 NNP NN VBZ IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NN VBZ IN DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 VBZ IN DT NNS NN O
hydrogels hydrogels 0 0 0 0 0 0 0 0 9 0 IN DT NNS NN NN O
support support 0 0 0 0 0 0 0 0 7 0 DT NNS NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNS NN NN NN CC O
viability viability 0 0 0 0 0 0 0 0 9 0 NN NN NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VB JJ O
have have 0 0 0 0 0 0 0 0 4 0 NN CC VB JJ IN O
potential potential 0 0 0 0 0 0 0 0 9 0 CC VB JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VB JJ IN NN IN O
use use 0 0 0 0 0 0 0 0 3 0 JJ IN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NN O
biomedical biomedical 0 0 0 0 0 0 0 0 10 0 NN IN JJ NN NNP O
engineering engineering 0 0 0 0 0 0 0 0 11 0 IN JJ NN NNP NONE O
applications. applications. 0 0 0 0 0 0 0 0 13 0 JJ NN NNP NONE NONE O
Sesquiterpene Sesquiterpene 1 0 0 0 0 0 0 0 13 0 NONE NONE NNP NNS VBP O
lactones lactones 0 0 0 0 0 0 0 0 8 0 NONE NNP NNS VBP JJ O
downregulate downregulate 0 0 0 0 0 0 0 0 12 0 NNP NNS VBP JJ NN O
g2/m g2/m 0 0 0 1 0 0 0 1 4 0 NNS VBP JJ NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 VBP JJ NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 JJ NN NN NN NNS O
regulator regulator 0 0 0 0 0 0 0 0 9 0 NN NN NN NNS CC O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NN NN NNS CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC VB DT O
affect affect 0 0 0 0 0 0 0 0 6 0 NNS CC VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CC VB DT JJ NN O
invasive invasive 0 0 0 0 0 0 0 0 8 0 VB DT JJ NN IN O
potential potential 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN NN NN NN O
soft soft 0 0 0 0 0 0 0 0 4 0 IN NN NN NN NN O
tissue tissue 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NNP O
sarcoma sarcoma 0 0 0 0 0 0 0 0 7 0 NN NN NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP NNP O
Lohberger Lohberger 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Rinner Rinner 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Stuendl Stuendl 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kaltenegger Kaltenegger 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Steinecker-Frohnwieser Steinecker-Frohnwieser 1 0 1 0 0 0 0 0 22 0 NNP NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Bernhart Bernhart 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
E, E, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Rad Rad 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
EB, EB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Weinberg Weinberg 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
AM, AM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Leithner Leithner 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Bauer Bauer 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kretschmer Kretschmer 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
N. N. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Orthopedic Orthopedic 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Surgery, Surgery, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Graz, Graz, 1 0 0 0 1 0 0 0 5 0 NNP IN NNP NNP NNP O
Graz, Graz, 1 0 0 0 1 0 0 0 5 0 IN NNP NNP NNP NNP O
Austria. Austria. 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
Soft Soft 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NN VBZ O
tissue tissue 0 0 0 0 0 0 0 0 6 0 NNP NNP NN VBZ JJ O
sarcomas sarcomas 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ JJ NN O
(STS) (STS) 0 1 0 0 0 0 0 0 5 0 NN VBZ JJ NN DT O
represent represent 0 0 0 0 0 0 0 0 9 0 VBZ JJ NN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 JJ NN DT NN NN O
rare rare 0 0 0 0 0 0 0 0 4 0 NN DT NN NN IN O
group group 0 0 0 0 0 0 0 0 5 0 DT NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNS O
malignant malignant 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNS WDT O
tumors tumors 0 0 0 0 0 0 0 0 6 0 IN JJ NNS WDT RB O
that that 0 0 0 0 0 0 0 0 4 0 JJ NNS WDT RB VBP O
frequently frequently 0 0 0 0 0 0 0 0 10 0 NNS WDT RB VBP JJ O
exhibit exhibit 0 0 0 0 0 0 0 0 7 0 WDT RB VBP JJ NN O
chemotherapeutic chemotherapeutic 0 0 0 0 0 0 0 0 16 0 RB VBP JJ NN CC O
resistance resistance 0 0 0 0 0 0 0 0 10 0 VBP JJ NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBD JJ O
increased increased 0 0 0 0 0 0 0 0 9 0 NN CC VBD JJ NNP O
metastatic metastatic 0 0 0 0 0 0 0 0 10 0 CC VBD JJ NNP NNP O
potential. potential. 0 0 0 0 0 0 0 0 10 0 VBD JJ NNP NNP VBZ O
Many Many 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP VBZ VBP O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP NNP VBZ VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBP VBN DT O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 VBZ VBP VBN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBP VBN DT JJ NN O
great great 0 0 0 0 0 0 0 0 5 0 VBN DT JJ NN IN O
potential potential 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNS O
plant-derived plant-derived 0 0 1 0 0 0 0 0 13 0 NN IN JJ NNS IN O
agents agents 0 0 0 0 0 0 0 0 6 0 IN JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
various various 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN NNP O
malignant malignant 0 0 0 0 0 0 0 0 9 0 IN JJ NN NNP NNP O
entities. entities. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN NN O
present present 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN VBZ O
study study 0 0 0 0 0 0 0 0 5 0 NNP NN NN VBZ DT O
investigates investigates 0 0 0 0 0 0 0 0 12 0 NN NN VBZ DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 VBZ DT NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NNS O
sesquiterpene sesquiterpene 0 0 0 0 0 0 0 0 13 0 IN DT NN NNS VBP O
lactones lactones 0 0 0 0 0 0 0 0 8 0 DT NN NNS VBP CC O
costunolide costunolide 0 0 0 0 0 0 0 0 11 0 NN NNS VBP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNS VBP CC NN NN O
dehydrocostus dehydrocostus 0 0 0 0 0 0 0 0 13 0 VBP CC NN NN IN O
lactone lactone 0 0 0 0 0 0 0 0 7 0 CC NN NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN NNP O
cycle, cycle, 0 0 0 0 1 0 0 0 6 0 IN NN NN NNP NNP O
MMP MMP 1 1 0 0 0 0 0 0 3 0 NN NN NNP NNP CC O
expression, expression, 0 0 0 0 1 0 0 0 11 0 NN NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ JJ O
invasive invasive 0 0 0 0 0 0 0 0 8 0 NNP CC JJ JJ IN O
potential potential 0 0 0 0 0 0 0 0 9 0 CC JJ JJ IN CD O
of of 0 0 0 0 0 0 0 0 2 0 JJ JJ IN CD JJ O
three three 0 0 0 0 0 0 0 0 5 0 JJ IN CD JJ NNS O
human human 0 0 0 0 0 0 0 0 5 0 IN CD JJ NNS VBP O
STS STS 1 1 0 0 0 0 0 0 3 0 CD JJ NNS VBP NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NNS VBP NNS IN O
lines lines 0 0 0 0 0 0 0 0 5 0 NNS VBP NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBP NNS IN JJ NNP O
various various 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NNP NNP O
origins. origins. 0 0 0 0 0 0 0 0 8 0 IN JJ NNP NNP NNS O
Both Both 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NNS VBD O
compounds compounds 0 0 0 0 0 0 0 0 9 0 NNP NNP NNS VBD NN O
reduced reduced 0 0 0 0 0 0 0 0 7 0 NNP NNS VBD NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNS VBD NN NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VBD NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN CC O
time- time- 0 0 1 0 0 0 0 0 5 0 IN DT NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC JJ NNP O
dose-dependent dose-dependent 0 0 1 0 0 0 0 0 14 0 NN CC JJ NNP NNP O
manner. manner. 0 0 0 0 0 0 0 0 7 0 CC JJ NNP NNP NN O
Dehydrocostus Dehydrocostus 1 0 0 0 0 0 0 0 13 0 JJ NNP NNP NN RB O
lactone lactone 0 0 0 0 0 0 0 0 7 0 NNP NNP NN RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNP NN RB VBN NN O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NN RB VBN NN -NONE- O
cell cell 0 0 0 0 0 0 0 0 4 0 RB VBN NN -NONE- VBN O
proliferation, proliferation, 0 0 0 0 1 0 0 0 14 0 VBN NN -NONE- VBN DT O
arrested arrested 0 0 0 0 0 0 0 0 8 0 NN -NONE- VBN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- VBN DT NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 VBN DT NNS IN DT O
at at 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 0 IN DT JJ NN CC B_TIMEXCCP
interface interface 0 0 0 0 0 0 0 0 9 0 DT JJ NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBD DT O
caused caused 0 0 0 0 0 0 0 0 6 0 NN CC VBD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 CC VBD DT NN IN O
decrease decrease 0 0 0 0 0 0 0 0 8 0 VBD DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
cyclin-dependent cyclin-dependent 0 0 1 0 0 0 0 0 16 0 IN DT JJ NN NNP O
kinase kinase 0 0 0 0 0 0 0 0 6 0 DT JJ NN NNP CC O
CDK2 CDK2 1 1 0 0 0 0 0 1 4 0 JJ NN NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP CC DT JJ NN O
cyclin-dependent cyclin-dependent 0 0 1 0 0 0 0 0 16 0 CC DT JJ NN NN O
kinase kinase 0 0 0 0 0 0 0 0 6 0 DT JJ NN NN NNP O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 JJ NN NN NNP NNP O
p27(Kip1). p27(Kip1). 0 0 0 0 0 0 0 1 10 0 NN NN NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NNP NN O
addition, addition, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP NN IN O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 NNP NNP NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN DT O
at at 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 phase IN DT JJ NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN NN O
transition transition 0 0 0 0 0 0 0 0 10 0 JJ NN NN NN VBD O
interface interface 0 0 0 0 0 0 0 0 9 0 NN NN NN VBD IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN VBD IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBD IN DT JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 IN DT JJ NN IN O
decrease decrease 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
cdc2 cdc2 0 0 0 0 0 0 0 1 4 0 NN IN NNP NNP RB O
(CDK1) (CDK1) 0 1 0 0 0 0 0 1 6 0 IN NNP NNP RB IN O
together together 0 0 0 0 0 0 0 0 8 0 NNP NNP RB IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NNP RB IN NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 RB IN NN NNP NNP O
B1. B1. 1 1 0 0 0 0 0 1 3 0 IN NN NNP NNP VBD O
Costunolide Costunolide 1 0 0 0 0 0 0 0 11 0 NN NNP NNP VBD DT O
had had 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD DT NN O
no no 0 0 0 0 0 0 0 0 2 0 NNP VBD DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 VBD DT NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NNP NNP O
cycle. cycle. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP IN O
Based Based 1 0 0 0 0 0 0 0 5 0 NN NNP NNP IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN IN O
fact fact 0 0 0 0 0 0 0 0 4 0 IN DT NN IN NNPS O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN NNPS VBP O
STS STS 1 1 0 0 0 0 0 0 3 0 NN IN NNPS VBP TO O
tend tend 0 0 0 0 0 0 0 0 4 0 IN NNPS VBP TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NNPS VBP TO NN NN O
form form 0 0 0 0 0 0 0 0 4 0 VBP TO NN NN NN O
daughter daughter 0 0 0 0 0 0 0 0 8 0 TO NN NN NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NNS CC O
nests nests 0 0 0 0 0 0 0 0 5 0 NN NN NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC JJ DT O
metastasize, metastasize, 0 0 0 0 1 0 0 0 12 0 NNS CC JJ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC JJ DT NN NNS O
expression expression 0 0 0 0 0 0 0 0 10 0 JJ DT NN NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 DT NN NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NNS O
matrix matrix 0 0 0 0 0 0 0 0 6 0 NNS IN NN NNS -NONE- O
metalloproteinases metalloproteinases 0 0 0 0 0 0 0 0 18 0 IN NN NNS -NONE- WDT O
(MMPs), (MMPs), 0 0 0 0 1 0 0 0 7 0 NN NNS -NONE- WDT NN O
which which 0 0 0 0 0 0 0 0 5 0 NNS -NONE- WDT NN DT O
play play 0 0 0 0 0 0 0 0 4 0 -NONE- WDT NN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 WDT NN DT JJ NN O
crucial crucial 0 0 0 0 0 0 0 0 7 0 NN DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
extracellular extracellular 0 0 0 0 0 0 0 0 13 0 NN IN JJ NN NN O
matrix matrix 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN CC O
degradation degradation 0 0 0 0 0 0 0 0 11 0 JJ NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP VBD O
metastasis, metastasis, 0 0 0 0 1 0 0 0 11 0 NN CC NNP VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 CC NNP VBD VBN IN O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NNP VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NN O
Luminex® Luminex® 1 0 0 0 0 0 0 0 8 0 VBN IN NNP NN CC O
technology technology 0 0 0 0 0 0 0 0 10 0 IN NNP NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC JJ NNP O
real-time real-time 0 0 1 0 0 0 0 0 9 0 NN CC JJ NNP NNP O
RT-PCR. RT-PCR. 1 1 1 0 0 0 0 0 7 0 CC JJ NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
presence presence 0 0 0 0 0 0 0 0 8 0 NNP DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN -NONE- O
costunolide, costunolide, 0 0 0 0 1 0 0 0 12 0 NN IN NN -NONE- CC O
MMP-2 MMP-2 1 1 1 0 0 0 0 1 5 0 IN NN -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC NNP NNS O
-9 -9 0 0 1 0 0 0 0 1 2 0 -NONE- CC NNP NNS VBD O
levels levels 0 0 0 0 0 0 0 0 6 0 CC NNP NNS VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNS VBD RB VBN IN O
increased increased 0 0 0 0 0 0 0 0 9 0 VBD RB VBN IN -NONE- O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN -NONE- CC O
SW-982 SW-982 1 1 1 0 0 0 0 1 6 0 VBN IN -NONE- CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 IN -NONE- CC -NONE- NNP O
TE-671 TE-671 1 1 1 0 0 0 0 1 6 0 -NONE- CC -NONE- NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 CC -NONE- NNP NNP NN O
Dehydrocostus Dehydrocostus 1 0 0 0 0 0 0 0 13 0 -NONE- NNP NNP NN NN O
lactone lactone 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN RB O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NNP NN NN RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NN NN RB VBN -NONE- O
reduced reduced 0 0 0 0 0 0 0 0 7 0 NN RB VBN -NONE- CC O
MMP-2 MMP-2 1 1 1 0 0 0 0 1 5 0 RB VBN -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VBN -NONE- CC NNP NN O
-9 -9 0 0 1 0 0 0 0 1 2 0 -NONE- CC NNP NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 CC NNP NN IN -NONE- O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN -NONE- JJ O
TE-671 TE-671 1 1 1 0 0 0 0 1 6 0 NN IN -NONE- JJ CC O
cells, cells, 0 0 0 0 1 0 0 0 6 0 IN -NONE- JJ CC VBN O
but but 0 0 0 0 0 0 0 0 3 0 -NONE- JJ CC VBN -NONE- O
increased increased 0 0 0 0 0 0 0 0 9 0 JJ CC VBN -NONE- NN O
MMP-9 MMP-9 1 1 1 0 0 0 0 1 5 0 CC VBN -NONE- NN IN O
level level 0 0 0 0 0 0 0 0 5 0 VBN -NONE- NN IN -NONE- O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- NN IN -NONE- NNP O
SW-982 SW-982 1 1 1 0 0 0 0 1 6 0 NN IN -NONE- NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN -NONE- NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 -NONE- NNP NNP NNP DT O
addition, addition, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
invasion invasion 0 0 0 0 0 0 0 0 8 0 NNP DT NN NN VBD O
potential potential 0 0 0 0 0 0 0 0 9 0 DT NN NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NN VBD RB VBN IN O
reduced reduced 0 0 0 0 0 0 0 0 7 0 VBD RB VBN IN NN O
after after 0 0 0 0 0 0 0 0 5 0 RB VBN IN NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 VBN IN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN DT NN O
both both 0 0 0 0 0 0 0 0 4 0 NN IN DT NN NNS O
sesquiterpene sesquiterpene 0 0 0 0 0 0 0 0 13 0 IN DT NN NNS IN O
lactones lactones 0 0 0 0 0 0 0 0 8 0 DT NN NNS IN VBN O
as as 0 0 0 0 0 0 0 0 2 0 NN NNS IN VBN IN O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NNS IN VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 IN VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NNP O
HTS HTS 1 1 0 0 0 0 0 0 3 0 IN DT NNP NNP NN O
FluoroBlock™ FluoroBlock™ 1 0 0 0 0 0 0 0 12 0 DT NNP NNP NN NNP O
insert insert 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NNP NONE O
system. system. 0 0 0 0 0 0 0 0 7 0 NNP NN NNP NONE NONE O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NONE NONE NNP NN VBD O
damage damage 0 0 0 0 0 0 0 0 6 0 NONE NNP NN VBD IN O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP NN VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN NN NNS O
oridonin oridonin 0 0 0 0 0 0 0 0 8 0 VBD IN NN NNS VBP O
involves involves 0 0 0 0 0 0 0 0 8 0 IN NN NNS VBP NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NNS VBP NN JJS O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest NNS VBP NN JJS IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 VBP NN JJS IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 NN JJS IN JJ NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 phase JJS IN JJ NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN -NONE- O
human human 0 0 0 0 0 0 0 0 5 0 NN IN NN -NONE- NNP O
MCF-7 MCF-7 1 1 1 0 0 0 0 1 5 0 IN NN -NONE- NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN -NONE- NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 -NONE- NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tan Tan 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhao Zhao 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Liu Liu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Z. Z. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Central Central 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP DT O
Laboratory, Laboratory, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNP NNP O
First First 1 0 0 0 0 0 0 0 5 0 NNP DT NNP NNP NNP O
Affiliated Affiliated 1 0 0 0 0 0 0 0 10 0 DT NNP NNP NNP IN O
Hospital Hospital 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Jilin Jilin 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 IN NNP NNP NNP NNP O
Changchun, Changchun, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP : O
China China 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP : NNP O
; ; 0 0 0 0 0 0 0 0 1 0 NNP NNP : NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP : NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 : NNP IN NNP NNP O
Basic Basic 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Jiamusi Jiamusi 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP CD O
No. No. 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP CD NNP O
148 148 0 0 0 0 0 0 1 1 3 0 NNP NNP CD NNP NNP O
Xuefu Xuefu 1 0 0 0 0 0 0 0 5 0 NNP CD NNP NNP NNP O
Street, Street, 1 0 0 0 1 0 0 0 7 0 CD NNP NNP NNP NNP O
Jiamusi Jiamusi 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
City, City, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
Heilongjiang Heilongjiang 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
Province, Province, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
AIM AIM 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
OF OF 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
THE THE 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
STUDY: STUDY: 1 1 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NN O
To To 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NN DT O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT NNS IN O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 NN DT NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 NNS IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN CC O
growth growth 0 0 0 0 0 0 0 0 6 0 IN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 NN CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN IN NNP NN IN O
damage damage 0 0 0 0 0 0 0 0 6 0 IN NNP NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
oridonin-treated oridonin-treated 0 0 1 0 0 0 0 0 16 0 NN IN JJ NN NN O
MCF-7 MCF-7 1 1 1 0 0 0 0 1 5 0 IN JJ NN NN NN O
human human 0 0 0 0 0 0 0 0 5 0 JJ NN NN NN NN O
breast breast 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN NN NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP NNP O
MATERIAL MATERIAL 1 1 0 0 0 0 0 0 8 0 NN NNP NNP NNP NNP O
AND AND 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
cytotoxicity cytotoxicity 0 0 0 0 0 0 0 0 12 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
oridonin-treated oridonin-treated 0 0 1 0 0 0 0 0 16 0 NN IN JJ NN NNS O
MCF-7 MCF-7 1 1 1 0 0 0 0 1 5 0 IN JJ NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NNS VBD VBN IN O
measured measured 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
MTT MTT 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NNP NNP O
assay. assay. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NN O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 phase NNP NNP NN NN NN O
phase phase 0 0 0 0 0 0 0 0 5 0 NNP NN NN NN VBD O
distribution distribution 0 0 0 0 0 0 0 0 12 0 NN NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
analyzed analyzed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN NNP O
flow flow 0 0 0 0 0 0 0 0 4 0 VBN IN NN NNP NNP O
cytometry. cytometry. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP NNP O
P-ATM, P-ATM, 1 1 1 0 1 0 0 0 6 0 NN NNP NNP NNP NNP O
P-CHK2, P-CHK2, 1 1 1 0 1 0 0 1 7 0 NNP NNP NNP NNP CC O
γH2AX γH2AX 0 0 0 0 0 0 0 1 5 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NN O
P-P53 P-P53 1 1 1 0 0 0 0 1 5 0 NNP CC NNP NN NNS O
protein protein 0 0 0 0 0 0 0 0 7 0 CC NNP NN NNS VBD O
expressions expressions 0 0 0 0 0 0 0 0 11 0 NNP NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
detected detected 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NN O
Western Western 1 0 0 0 0 0 0 0 7 0 VBN IN NNP NN NNP O
blot blot 0 0 0 0 0 0 0 0 4 0 IN NNP NN NNP NNP O
analysis. analysis. 0 0 0 0 0 0 0 0 9 0 NNP NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ CC O
r-h2ax r-h2ax 0 0 1 0 0 0 0 1 6 0 NN IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ VBD O
P-ATM P-ATM 1 1 1 0 0 0 0 0 5 0 JJ CC JJ VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 CC JJ VBD RB VBN O
also also 0 0 0 0 0 0 0 0 4 0 JJ VBD RB VBN IN O
detected detected 0 0 0 0 0 0 0 0 8 0 VBD RB VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 RB VBN IN NN NNP O
immunofluorescence immunofluorescence 0 0 0 0 0 0 0 0 18 0 VBN IN NN NNP NNP O
staining. staining. 0 0 0 0 0 0 0 0 9 0 IN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
degree degree 0 0 0 0 0 0 0 0 6 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
cellular cellular 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN IN O
damage damage 0 0 0 0 0 0 0 0 6 0 IN JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
oridonin-induced oridonin-induced 0 0 1 0 0 0 0 0 16 0 NN IN JJ NN NN O
MCF-7 MCF-7 1 1 1 0 0 0 0 1 5 0 IN JJ NN NN NN O
human human 0 0 0 0 0 0 0 0 5 0 JJ NN NN NN NN O
breast breast 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN NN NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NNS VBD VBN IN O
confirmed confirmed 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NN O
comet comet 0 0 0 0 0 0 0 0 5 0 IN DT NN NN NN O
assay assay 0 0 0 0 0 0 0 0 5 0 DT NN NN NN IN O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NN NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNP NNP O
fragmentation. fragmentation. 0 0 0 0 0 0 0 0 14 0 IN NNP NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBD O
Oridonin Oridonin 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP VBD NN O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP VBD NN NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 VBD NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN CC O
time- time- 0 0 1 0 0 0 0 0 5 0 IN DT NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC JJ NNP O
dose-dependent dose-dependent 0 0 1 0 0 0 0 0 14 0 NN CC JJ NNP NNP O
manner. manner. 0 0 0 0 0 0 0 0 7 0 CC JJ NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NNP VBZ O
IC50 IC50 1 1 0 0 0 0 0 1 4 0 NNP NNP NNP VBZ IN O
values values 0 0 0 0 0 0 0 0 6 0 NNP NNP VBZ IN CD O
at at 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN CD CC O
48 48 0 0 0 0 0 0 1 1 2 0 VBZ IN CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 IN CD CC CD NNS O
72 72 0 0 0 0 0 0 1 1 2 0 CD CC CD NNS VBD O
hours hours 0 0 0 0 0 0 0 0 5 0 CC CD NNS VBD CD O
were were 0 0 0 0 0 0 0 0 4 0 CD NNS VBD CD CC O
78.3 78.3 0 0 0 0 0 0 0 1 4 0 NNS VBD CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 VBD CD CC CD NN O
31.62 31.62 0 0 0 0 0 0 0 1 5 0 CD CC CD NN NNP O
µmol/l, µmol/l, 0 0 0 1 1 0 0 0 7 0 CC CD NN NNP NNP O
respectively. respectively. 0 0 0 0 0 0 0 0 13 0 CD NN NNP NNP VBD O
Oridonin Oridonin 1 0 0 0 0 0 0 0 8 0 NN NNP NNP VBD JJ O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD JJ NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 phase NNP VBD JJ NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 arrest VBD JJ NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 JJ NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
MCF-7 MCF-7 1 1 1 0 0 0 0 1 5 0 NN IN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP VBZ O
MCF-7 MCF-7 1 1 1 0 0 0 0 1 5 0 NNP NNP NNP VBZ VBN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ VBN IN O
treated treated 0 0 0 0 0 0 0 0 7 0 NNP VBZ VBN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN NN VBD O
oridonin oridonin 0 0 0 0 0 0 0 0 8 0 VBN IN NN VBD JJ O
showed showed 0 0 0 0 0 0 0 0 6 0 IN NN VBD JJ NNP O
significant significant 0 0 0 0 0 0 0 0 11 0 NN VBD JJ NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 VBD JJ NNP NN IN O
damage damage 0 0 0 0 0 0 0 0 6 0 JJ NNP NN IN NN O
as as 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN IN O
shown shown 0 0 0 0 0 0 0 0 5 0 NN IN NN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 IN DT NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
olive olive 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NN O
tail tail 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN NNP O
moment moment 0 0 0 0 0 0 0 0 6 0 JJ NN NN NNP NNP O
(OTM). (OTM). 0 1 0 0 0 0 0 0 6 0 NN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN NNS O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP NN NN NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 NN NN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NN O
P-ATM, P-ATM, 1 1 1 0 1 0 0 0 6 0 NNS IN JJ NN NN O
P-CHK2, P-CHK2, 1 1 1 0 1 0 0 1 7 0 IN JJ NN NN CC O
γH2AX γH2AX 0 0 0 0 0 0 0 1 5 0 JJ NN NN CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC -NONE- VBD O
P-P53 P-P53 1 1 1 0 0 0 0 1 5 0 NN CC -NONE- VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 CC -NONE- VBD VBN RB O
increased increased 0 0 0 0 0 0 0 0 9 0 -NONE- VBD VBN RB IN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 VBD VBN RB IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBN RB IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 RB IN DT JJ NNP O
dose-dependent dose-dependent 0 0 1 0 0 0 0 0 14 0 IN DT JJ NNP NNP O
manner. manner. 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NNP NNP O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 JJ NNP NNP NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NN VBZ O
damage damage 0 0 0 0 0 0 0 0 6 0 NNP NNP NN VBZ JJ O
provokes provokes 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ JJ NN O
p53-mediated p53-mediated 0 0 1 0 0 0 0 1 12 0 NN VBZ JJ NN NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 0 VBZ JJ NN NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest NN NN NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
oridonin-induced oridonin-induced 0 0 1 0 0 0 0 0 16 0 NN IN JJ NN NNS O
MCF-7 MCF-7 1 1 1 0 0 0 0 1 5 0 IN JJ NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN DT O
through through 0 0 0 0 0 0 0 0 7 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NN O
CHK2 CHK2 1 1 0 0 0 0 0 1 4 0 NN IN NNP NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 IN NNP NN IN VBN O
by by 0 0 0 0 0 0 0 0 2 0 NNP NN IN VBN NNP O
activated activated 0 0 0 0 0 0 0 0 9 0 NN IN VBN NNP NN O
ATM ATM 1 1 0 0 0 0 0 0 3 0 IN VBN NNP NN -NONE- O
protein protein 0 0 0 0 0 0 0 0 7 0 VBN NNP NN -NONE- WDT O
kinase, kinase, 0 0 0 0 1 0 0 0 7 0 NNP NN -NONE- WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN -NONE- WDT VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 -NONE- WDT VBZ VBN IN O
induced induced 0 0 0 0 0 0 0 0 7 0 WDT VBZ VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN NNP NONE O
oridonin. oridonin. 0 0 0 0 0 0 0 0 9 0 VBN IN NNP NONE NONE O
Gadolinium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic Gadolinium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 1 0 1 0 1 0 0 1 62 0 NONE NONE JJ NN -NONE- O
acid acid 0 0 0 0 0 0 0 0 4 0 NONE JJ NN -NONE- JJ O
monoamide-G2 monoamide-G2 0 0 1 0 0 0 0 1 12 0 JJ NN -NONE- JJ NNP O
nanoglobule-CGLIIQKNEC nanoglobule-CGLIIQKNEC 0 0 1 0 0 0 0 0 22 0 NN -NONE- JJ NNP NNP O
(CLT1)-Cy5. (CLT1)-Cy5. 0 0 1 0 0 0 0 1 11 0 -NONE- JJ NNP NNP NNP O
Authors Authors 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP NNP NNP O
Leung Leung 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
K. K. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
SourceMolecular SourceMolecular 1 0 0 0 0 0 0 0 15 0 NNP NNP NNP NNP CC O
Imaging Imaging 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Contrast Contrast 1 0 0 0 0 0 0 0 8 0 NNP CC NNP NNP NNP O
Agent Agent 1 0 0 0 0 0 0 0 5 0 CC NNP NNP NNP NNP O
Database Database 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
(MICAD) (MICAD) 0 1 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
[Internet]. [Internet]. 0 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
Bethesda Bethesda 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
(MD): (MD): 0 1 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
National National 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Center Center 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNP O
Biotechnology Biotechnology 1 0 0 0 0 0 0 0 13 0 NNP IN NNP NNP NNP O
Information Information 1 0 0 0 0 0 0 0 11 0 IN NNP NNP NNP NNP O
(US); (US); 0 1 0 0 0 0 0 0 5 0 NNP NNP NNP NNP CD O
2004-2013. 2004-2013. 0 0 1 0 0 0 0 1 10 0 NNP NNP NNP CD NNP O
2013 2013 0 0 0 0 0 0 1 1 4 0 NNP NNP CD NNP CD O
Apr Apr 1 0 0 0 0 0 0 0 3 0 NNP CD NNP CD JJ O
21 21 0 0 0 0 0 0 1 1 2 0 CD NNP CD JJ CD O
[updated [updated 0 0 0 0 0 0 0 0 8 0 NNP CD JJ CD NNP O
2013 2013 0 0 0 0 0 0 1 1 4 0 CD JJ CD NNP CD O
Jun Jun 1 0 0 0 0 0 0 0 3 0 JJ CD NNP CD NNP O
13]. 13]. 0 0 0 0 0 0 0 1 4 0 CD NNP CD NNP NNP O
Excerpt Excerpt 1 0 0 0 0 0 0 0 7 0 NNP CD NNP NNP NN O
Extracellular Extracellular 1 0 0 0 0 0 0 0 13 0 CD NNP NNP NN NN O
matrix matrix 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NN NNS O
adhesion adhesion 0 0 0 0 0 0 0 0 8 0 NNP NN NN NNS VBP O
molecules molecules 0 0 0 0 0 0 0 0 9 0 NN NN NNS VBP IN O
consist consist 0 0 0 0 0 0 0 0 7 0 NN NNS VBP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNS VBP IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBP IN DT JJ NN O
complex complex 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN IN O
network network 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
fibronectins, fibronectins, 0 0 0 0 1 0 0 0 13 0 NN IN NNP NNP NNP O
collagens, collagens, 0 0 0 0 1 0 0 0 10 0 IN NNP NNP NNP NNP O
chondroitins, chondroitins, 0 0 0 0 1 0 0 0 13 0 NNP NNP NNP NNP NNP O
laminins, laminins, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NN O
glycoproteins, glycoproteins, 0 0 0 0 1 0 0 0 14 0 NNP NNP NNP NN -NONE- O
heparin heparin 0 0 0 0 0 0 0 0 7 0 NNP NNP NN -NONE- -NONE- O
sulfate, sulfate, 0 0 0 0 1 0 0 0 8 0 NNP NN -NONE- -NONE- CC O
tenascins, tenascins, 0 0 0 0 1 0 0 0 10 0 NN -NONE- -NONE- CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- CC NNS WDT O
proteoglycans proteoglycans 0 0 0 0 0 0 0 0 13 0 -NONE- CC NNS WDT IN O
that that 0 0 0 0 0 0 0 0 4 0 CC NNS WDT IN JJ O
surround surround 0 0 0 0 0 0 0 0 8 0 NNS WDT IN JJ NN O
connective connective 0 0 0 0 0 0 0 0 10 0 WDT IN JJ NN NN O
tissue tissue 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN CC O
cells, cells, 0 0 0 0 1 0 0 0 6 0 JJ NN NN CC PRP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC PRP VBP O
they they 0 0 0 0 0 0 0 0 4 0 NN CC PRP VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 CC PRP VBP RB VBN O
mainly mainly 0 0 0 0 0 0 0 0 6 0 PRP VBP RB VBN IN O
secreted secreted 0 0 0 0 0 0 0 0 8 0 VBP RB VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 RB VBN IN NNP NNP O
fibroblasts, fibroblasts, 0 0 0 0 1 0 0 0 12 0 VBN IN NNP NNP CC O
chondroblasts, chondroblasts, 0 0 0 0 1 0 0 0 14 0 IN NNP NNP CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNS NNP O
osteoblasts osteoblasts 0 0 0 0 0 0 0 0 11 0 NNP CC NNS NNP NNP O
(1). (1). 0 0 0 0 0 0 0 1 4 0 CC NNS NNP NNP NN O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NNS NNP NNP NN NN O
substrate substrate 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NN NNS O
adhesion adhesion 0 0 0 0 0 0 0 0 8 0 NNP NN NN NNS VBP O
molecules molecules 0 0 0 0 0 0 0 0 9 0 NN NN NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NN NNS VBP VBN JJ O
considered considered 0 0 0 0 0 0 0 0 10 0 NNS VBP VBN JJ NNS O
essential essential 0 0 0 0 0 0 0 0 9 0 VBP VBN JJ NNS IN O
regulators regulators 0 0 0 0 0 0 0 0 10 0 VBN JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN NN O
migration, migration, 0 0 0 0 1 0 0 0 10 0 IN NN NN NN CC O
differentiation, differentiation, 0 0 0 0 1 0 0 0 16 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
tissue tissue 0 0 0 0 0 0 0 0 6 0 NN CC NN NN CC O
integrity integrity 0 0 0 0 0 0 0 0 9 0 CC NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
remodeling. remodeling. 0 0 0 0 0 0 0 0 11 0 NN CC NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 CC NNP NNP NNS VBP O
molecules molecules 0 0 0 0 0 0 0 0 9 0 NNP NNP NNS VBP DT O
play play 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNS VBP DT NN IN O
role role 0 0 0 0 0 0 0 0 4 0 VBP DT NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NN CC O
inflammation inflammation 0 0 0 0 0 0 0 0 12 0 NN IN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NNP CC O
atherogenesis, atherogenesis, 0 0 0 0 1 0 0 0 14 0 NN CC NNP CC PRP O
but but 0 0 0 0 0 0 0 0 3 0 CC NNP CC PRP RB O
they they 0 0 0 0 0 0 0 0 4 0 NNP CC PRP RB VBP O
also also 0 0 0 0 0 0 0 0 4 0 CC PRP RB VBP IN O
participate participate 0 0 0 0 0 0 0 0 11 0 PRP RB VBP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 RB VBP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NN IN O
process process 0 0 0 0 0 0 0 0 7 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN CC O
invasion invasion 0 0 0 0 0 0 0 0 8 0 NN IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN IN O
metastasis metastasis 0 0 0 0 0 0 0 0 10 0 NN CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NNS O
malignant malignant 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
host host 0 0 0 0 0 0 0 0 4 0 IN DT NN NN NNP O
tissue tissue 0 0 0 0 0 0 0 0 6 0 DT NN NN NNP DT O
(2). (2). 0 0 0 0 0 0 0 1 4 0 NN NN NNP DT NN O
A A 1 1 0 0 0 0 0 0 1 0 NN NNP DT NN IN O
meshwork meshwork 0 0 0 0 0 0 0 0 8 0 NNP DT NN IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN VBN NN O
clotted clotted 0 0 0 0 0 0 0 0 7 0 NN IN VBN NN NN O
plasma plasma 0 0 0 0 0 0 0 0 6 0 IN VBN NN NN VBZ O
protein protein 0 0 0 0 0 0 0 0 7 0 VBN NN NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ JJ IN O
present present 0 0 0 0 0 0 0 0 7 0 NN VBZ JJ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBZ JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 IN DT NN NN CC O
stroma stroma 0 0 0 0 0 0 0 0 6 0 DT NN NN CC RB O
but but 0 0 0 0 0 0 0 0 3 0 NN NN CC RB IN O
not not 0 0 0 0 0 0 0 0 3 0 NN CC RB IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 CC RB IN JJ NN O
normal normal 0 0 0 0 0 0 0 0 6 0 RB IN JJ NN VBG O
tissues, tissues, 0 0 0 0 1 0 0 0 8 0 IN JJ NN VBG DT O
providing providing 0 0 0 0 0 0 0 0 9 0 JJ NN VBG DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBG DT JJ NN O
functional functional 0 0 0 0 0 0 0 0 10 0 VBG DT JJ NN IN O
matrix matrix 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN NN O
angiogenesis, angiogenesis, 0 0 0 0 1 0 0 0 13 0 NN IN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN NN NN NN CC O
migration, migration, 0 0 0 0 1 0 0 0 10 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NN CC NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 CC NN NN NN NNP O
invasion invasion 0 0 0 0 0 0 0 0 8 0 NN NN NN NNP NNP O
(3). (3). 0 0 0 0 0 0 0 1 4 0 NN NN NNP NNP VBP O
There There 1 0 0 0 0 0 0 0 5 0 NN NNP NNP VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNP VBP JJ NNS O
high high 0 0 0 0 0 0 0 0 4 0 NNP VBP JJ NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 VBP JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
collagens, collagens, 0 0 0 0 1 0 0 0 10 0 NNS IN JJ NN CC O
fibronectin, fibronectin, 0 0 0 0 1 0 0 0 12 0 IN JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN IN O
fibrin fibrin 0 0 0 0 0 0 0 0 6 0 NN CC NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 CC NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 IN DT NN NN NNP O
connective connective 0 0 0 0 0 0 0 0 10 0 DT NN NN NNP NNP O
tissues. tissues. 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP NNP O
Gadolinium Gadolinium 1 0 0 0 0 0 0 0 10 0 NN NNP NNP NNP DT O
(Gd), (Gd), 0 0 0 0 1 0 0 0 5 0 NNP NNP NNP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT NN NN O
lanthanide lanthanide 0 0 0 0 0 0 0 0 10 0 NNP DT NN NN NN O
metal metal 0 0 0 0 0 0 0 0 5 0 DT NN NN NN IN O
ion ion 0 0 0 0 0 0 0 0 3 0 NN NN NN IN CD O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN CD VBN O
seven seven 0 0 0 0 0 0 0 0 5 0 NN IN CD VBN -NONE- O
unpaired unpaired 0 0 0 0 0 0 0 0 8 0 IN CD VBN -NONE- VBZ O
electrons, electrons, 0 0 0 0 1 0 0 0 10 0 CD VBN -NONE- VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 VBN -NONE- VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 -NONE- VBZ VBN VBN TO O
shown shown 0 0 0 0 0 0 0 0 5 0 VBZ VBN VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO VB RB O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB RB JJ O
very very 0 0 0 0 0 0 0 0 4 0 TO VB RB JJ IN O
effective effective 0 0 0 0 0 0 0 0 9 0 VB RB JJ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 RB JJ IN NN NN O
enhancing enhancing 0 0 0 0 0 0 0 0 9 0 JJ IN NN NN NN O
proton proton 0 0 0 0 0 0 0 0 6 0 IN NN NN NN IN O
relaxation relaxation 0 0 0 0 0 0 0 0 10 0 NN NN NN IN IN O
because because 0 0 0 0 0 0 0 0 7 0 NN NN IN IN PRP$ O
of of 0 0 0 0 0 0 0 0 2 0 NN IN IN PRP$ JJ O
its its 0 0 0 0 0 0 0 0 3 0 IN IN PRP$ JJ JJ O
high high 0 0 0 0 0 0 0 0 4 0 IN PRP$ JJ JJ NN O
magnetic magnetic 0 0 0 0 0 0 0 0 8 0 PRP$ JJ JJ NN CC O
moment moment 0 0 0 0 0 0 0 0 6 0 JJ JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NN O
water water 0 0 0 0 0 0 0 0 5 0 NN CC NN NN NN O
coordination coordination 0 0 0 0 0 0 0 0 12 0 CC NN NN NN CD O
(4, (4, 0 0 0 0 1 0 0 1 3 0 NN NN NN CD JJ O
5). 5). 0 0 0 0 0 0 0 1 3 0 NN NN CD JJ JJ O
Gd-Diethylenetriamine Gd-Diethylenetriamine 1 0 1 0 0 0 0 0 21 0 NN CD JJ JJ NN O
pentaacetic pentaacetic 0 0 0 0 0 0 0 0 11 0 CD JJ JJ NN NN O
acid acid 0 0 0 0 0 0 0 0 4 0 JJ JJ NN NN VBD O
(Gd-DTPA) (Gd-DTPA) 0 0 1 0 0 0 0 0 9 0 JJ NN NN VBD DT O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN VBD DT JJ JJ O
first first 0 0 0 0 0 0 0 0 5 0 VBD DT JJ JJ JJ O
intravenous intravenous 0 0 0 0 0 0 0 0 11 0 DT JJ JJ JJ NN O
magnetic magnetic 0 0 0 0 0 0 0 0 8 0 JJ JJ JJ NN VBG O
resonance resonance 0 0 0 0 0 0 0 0 9 0 JJ JJ NN VBG NN O
imaging imaging 0 0 0 0 0 0 0 0 7 0 JJ NN VBG NN NN O
(MRI) (MRI) 0 1 0 0 0 0 0 0 5 0 NN VBG NN NN NN O
contrast contrast 0 0 0 0 0 0 0 0 8 0 VBG NN NN NN TO O
agent agent 0 0 0 0 0 0 0 0 5 0 NN NN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN TO VB VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 TO VB VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VB VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN CC O
clinic, clinic, 0 0 0 0 1 0 0 0 7 0 IN DT NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN CC DT NN IN O
number number 0 0 0 0 0 0 0 0 6 0 CC DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
similar similar 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNP VBZ O
Gd Gd 1 0 0 0 0 0 0 0 2 0 IN JJ NNP VBZ VBP O
chelates chelates 0 0 0 0 0 0 0 0 8 0 JJ NNP VBZ VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 VBZ VBP VBN VBN IN O
developed developed 0 0 0 0 0 0 0 0 9 0 VBP VBN VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 VBN IN DT NN TO O
effort effort 0 0 0 0 0 0 0 0 6 0 IN DT NN TO RBR O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO RBR VB O
further further 0 0 0 0 0 0 0 0 7 0 NN TO RBR VB JJ O
improve improve 0 0 0 0 0 0 0 0 7 0 TO RBR VB JJ NNP O
clinical clinical 0 0 0 0 0 0 0 0 8 0 RBR VB JJ NNP NNP O
use. use. 0 0 0 0 0 0 0 0 4 0 VB JJ NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 JJ NNP NNP DT JJ O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT JJ NN O
low low 0 0 0 0 0 0 0 0 3 0 NNP DT JJ NN NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN NNP O
weight weight 0 0 0 0 0 0 0 0 6 0 JJ NN NN NNP VBZ O
Gd Gd 1 0 0 0 0 0 0 0 2 0 NN NN NNP VBZ VBP O
chelates chelates 0 0 0 0 0 0 0 0 8 0 NN NNP VBZ VBP JJ O
have have 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBP JJ NN O
short short 0 0 0 0 0 0 0 0 5 0 VBZ VBP JJ NN CC O
blood blood 0 0 0 0 0 0 0 0 5 0 VBP JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NN O
tissue tissue 0 0 0 0 0 0 0 0 6 0 NN CC NN NN NN O
retention retention 0 0 0 0 0 0 0 0 9 0 CC NN NN NN WDT O
times, times, 0 0 0 0 1 0 0 0 6 0 NN NN NN WDT NN O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT NN PRP$ O
limit limit 0 0 0 0 0 0 0 0 5 0 NN WDT NN PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 WDT NN PRP$ NN IN O
use use 0 0 0 0 0 0 0 0 3 0 NN PRP$ NN IN NN O
as as 0 0 0 0 0 0 0 0 2 0 PRP$ NN IN NN NNS O
imaging imaging 0 0 0 0 0 0 0 0 7 0 NN IN NN NNS IN O
agents agents 0 0 0 0 0 0 0 0 6 0 IN NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN CC O
vasculature vasculature 0 0 0 0 0 0 0 0 11 0 IN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN NNS O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NN CC NN NNS NNP O
tissues tissues 0 0 0 0 0 0 0 0 7 0 CC NN NNS NNP NNP O
(6). (6). 0 0 0 0 0 0 0 1 4 0 NN NNS NNP NNP DT O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 NNS NNP NNP DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT NNS VBP O
agents agents 0 0 0 0 0 0 0 0 6 0 NNP DT NNS VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 DT NNS VBP RB NNP O
largely largely 0 0 0 0 0 0 0 0 7 0 NNS VBP RB NNP NNP O
nonspecific. nonspecific. 0 0 0 0 0 0 0 0 12 0 VBP RB NNP NNP NNP O
CGLIIQKNEC CGLIIQKNEC 1 1 0 0 0 0 0 0 10 0 RB NNP NNP NNP DT O
(CLT1), (CLT1), 0 1 0 0 1 0 0 1 7 0 NNP NNP NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT JJ JJ O
fibronectin-fibrin–binding fibronectin-fibrin–binding 0 0 1 0 0 0 0 0 26 0 NNP DT JJ JJ NN O
cyclic cyclic 0 0 0 0 0 0 0 0 6 0 DT JJ JJ NN VBD O
peptide, peptide, 0 0 0 0 1 0 0 0 8 0 JJ JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN IN O
identified identified 0 0 0 0 0 0 0 0 10 0 NN VBD VBN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NN NN O
phage phage 0 0 0 0 0 0 0 0 5 0 VBN IN NN NN VBG O
display display 0 0 0 0 0 0 0 0 7 0 IN NN NN VBG NNP O
screening screening 0 0 0 0 0 0 0 0 9 0 NN NN VBG NNP NNP O
(3). (3). 0 0 0 0 0 0 0 1 4 0 NN VBG NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 VBG NNP NNP NN VBD O
peptide peptide 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
conjugated conjugated 0 0 0 0 0 0 0 0 10 0 NN VBD VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNP TO O
Gd-DTPA Gd-DTPA 1 0 1 0 0 0 0 0 7 0 VBN IN NNP TO NN O
to to 0 0 0 0 0 0 0 0 2 0 IN NNP TO NN -NONE- O
form form 0 0 0 0 0 0 0 0 4 0 NNP TO NN -NONE- IN O
Gd-DTPA-CLT1 Gd-DTPA-CLT1 1 0 1 0 0 0 0 1 12 0 TO NN -NONE- IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NN -NONE- IN NN IN O
use use 0 0 0 0 0 0 0 0 3 0 -NONE- IN NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN NN IN O
imaging imaging 0 0 0 0 0 0 0 0 7 0 NN IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NNS O
fibronectin-fibrin fibronectin-fibrin 0 0 1 0 0 0 0 0 18 0 NN IN JJ NNS IN O
complexes complexes 0 0 0 0 0 0 0 0 9 0 IN JJ NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NNS IN NN NN CC O
tissues, tissues, 0 0 0 0 1 0 0 0 8 0 IN NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN CC DT NN VBD O
agent agent 0 0 0 0 0 0 0 0 5 0 CC DT NN VBD JJ O
exhibited exhibited 0 0 0 0 0 0 0 0 9 0 DT NN VBD JJ NN O
specific specific 0 0 0 0 0 0 0 0 8 0 NN VBD JJ NN IN O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 VBD JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS NNP O
tumors tumors 0 0 0 0 0 0 0 0 6 0 IN DT NNS NNP NNP O
(7). (7). 0 0 0 0 0 0 0 1 4 0 DT NNS NNP NNP NN O
Tan Tan 1 0 0 0 0 0 0 0 3 0 NNS NNP NNP NN NNP O
et et 0 0 0 0 0 0 0 0 2 0 NNP NNP NN NNP NNP O
al. al. 0 0 0 0 0 0 0 0 3 0 NNP NN NNP NNP VBD O
(8) (8) 0 0 0 0 0 0 0 1 3 0 NN NNP NNP VBD NNP O
prepared prepared 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD NNP DT O
Gd-DOTA-G3-CLT1, Gd-DOTA-G3-CLT1, 1 0 1 0 1 0 0 1 16 0 NNP VBD NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBD NNP DT JJ NN O
CLT1-targeted CLT1-targeted 1 0 1 0 0 0 0 1 13 0 NNP DT JJ NN NN O
contrast contrast 0 0 0 0 0 0 0 0 8 0 DT JJ NN NN IN O
agent agent 0 0 0 0 0 0 0 0 5 0 JJ NN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ NN O
Gd-tetraazacyclododecane-1,4,7,10-tetraacetic Gd-tetraazacyclododecane-1,4,7,10-tetraacetic 1 0 1 0 1 0 0 1 45 0 NN IN JJ NN -NONE- O
acid acid 0 0 0 0 0 0 0 0 4 0 IN JJ NN -NONE- VBP O
(GD-DOTA)43 (GD-DOTA)43 0 1 1 0 0 0 0 1 11 0 JJ NN -NONE- VBP NNS O
monoamide monoamide 0 0 0 0 0 0 0 0 9 0 NN -NONE- VBP NNS CC O
chelates chelates 0 0 0 0 0 0 0 0 8 0 -NONE- VBP NNS CC CD O
and and 0 0 0 0 0 0 0 0 3 0 VBP NNS CC CD NNP O
three three 0 0 0 0 0 0 0 0 5 0 NNS CC CD NNP NNS O
CLT1 CLT1 1 1 0 0 0 0 0 1 4 0 CC CD NNP NNS VBD O
molecules molecules 0 0 0 0 0 0 0 0 9 0 CD NNP NNS VBD TO O
conjugated conjugated 0 0 0 0 0 0 0 0 10 0 NNP NNS VBD TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBD TO DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBD TO DT NN CD O
generation generation 0 0 0 0 0 0 0 0 10 0 TO DT NN CD NN O
3 3 0 0 0 0 0 0 1 1 1 0 DT NN CD NN NN O
(G3) (G3) 0 1 0 0 0 0 0 1 4 0 NN CD NN NN NN O
polylysine polylysine 0 0 0 0 0 0 0 0 10 0 CD NN NN NN IN O
dendrimer dendrimer 0 0 0 0 0 0 0 0 9 0 NN NN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
cubic cubic 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN NNP O
silsesquioxane silsesquioxane 0 0 0 0 0 0 0 0 14 0 DT JJ NN NNP NNP O
core. core. 0 0 0 0 0 0 0 0 5 0 JJ NN NNP NNP VBD O
Gd-DOTA-G3-CLT1 Gd-DOTA-G3-CLT1 1 0 1 0 0 0 0 1 15 0 NN NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 NNP VBD VBN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NNP NN O
MRI MRI 1 1 0 0 0 0 0 0 3 0 IN DT NNP NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 DT NNP NN NN NN O
contrast contrast 0 0 0 0 0 0 0 0 8 0 NNP NN NN NN IN O
agent agent 0 0 0 0 0 0 0 0 5 0 NN NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
nude nude 0 0 0 0 0 0 0 0 4 0 NN IN NN NN VBG O
mice mice 0 0 0 0 0 0 0 0 4 0 IN NN NN VBG -NONE- O
bearing bearing 0 0 0 0 0 0 0 0 7 0 NN NN VBG -NONE- JJ O
MDA-MB-231 MDA-MB-231 1 1 1 0 0 0 0 1 10 0 NN VBG -NONE- JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 VBG -NONE- JJ NN NN O
breast breast 0 0 0 0 0 0 0 0 6 0 -NONE- JJ NN NN NNP O
carcinoma carcinoma 0 0 0 0 0 0 0 0 9 0 JJ NN NN NNP NNP O
xenografts. xenografts. 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP NNP O
Subsequently, Subsequently, 1 0 0 0 1 0 0 0 13 0 NN NNP NNP NNP NN O
Tan Tan 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN NNP O
et et 0 0 0 0 0 0 0 0 2 0 NNP NNP NN NNP NNP O
al. al. 0 0 0 0 0 0 0 0 3 0 NNP NN NNP NNP VBD O
(9) (9) 0 0 0 0 0 0 0 1 3 0 NN NNP NNP VBD NNP O
prepared prepared 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD NNP DT O
CLT1-G2-(Gd-DOTA-MA)-Cy5, CLT1-G2-(Gd-DOTA-MA)-Cy5, 1 0 1 0 1 0 0 1 25 0 NNP VBD NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBD NNP DT JJ NNP O
CLT1-targeted CLT1-targeted 1 0 1 0 0 0 0 1 13 0 NNP DT JJ NNP NN O
G2 G2 1 1 0 0 0 0 0 1 2 0 DT JJ NNP NN NNP O
nanoglobular nanoglobular 0 0 0 0 0 0 0 0 12 0 JJ NNP NN NNP NN O
Gd-DOTA Gd-DOTA 1 0 1 0 0 0 0 0 7 0 NNP NN NNP NN CC O
monoamide monoamide 0 0 0 0 0 0 0 0 9 0 NN NNP NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NNP NN O
Cy5 Cy5 1 0 0 0 0 0 0 1 3 0 NN CC NNP NN IN O
conjugate conjugate 0 0 0 0 0 0 0 0 9 0 CC NNP NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NNP NN IN NN IN O
use use 0 0 0 0 0 0 0 0 3 0 NN IN NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN NN -NONE- O
multimodality multimodality 0 0 0 0 0 0 0 0 13 0 NN IN NN -NONE- CC O
(MRI (MRI 0 1 0 0 0 0 0 0 4 0 IN NN -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC NNP NN O
optical) optical) 0 0 0 0 0 0 0 0 8 0 -NONE- CC NNP NN IN O
imaging imaging 0 0 0 0 0 0 0 0 7 0 CC NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NNP O
prostate prostate 0 0 0 0 0 0 0 0 8 0 NN IN NN NNP NONE O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NONE NONE O
Gas Gas 1 0 0 0 0 0 0 0 3 0 NONE NONE NNP VBD NNP O
cloud cloud 0 0 0 0 0 0 0 0 5 0 NONE NNP VBD NNP MD O
g2 g2 0 0 0 0 0 0 0 1 2 0 NNP VBD NNP MD VB O
can can 0 0 0 0 0 0 0 0 3 0 VBD NNP MD VB DT O
illuminate illuminate 0 0 0 0 0 0 0 0 10 0 NNP MD VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT JJ NN O
black black 0 0 0 0 0 0 0 0 5 0 VB DT JJ NN NN O
hole hole 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN IN O
population population 0 0 0 0 0 0 0 0 10 0 JJ NN NN IN DT O
near near 0 0 0 0 0 0 0 0 4 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
galactic galactic 0 0 0 0 0 0 0 0 8 0 IN DT JJ NNP NNP O
center. center. 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NNP NNP O
Bartos Bartos 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP NNP NNP O
I, I, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Haiman Haiman 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kocsis Kocsis 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Márka Márka 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
S. S. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Physics, Physics, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP NNP O
Columbia Columbia 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
New New 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
York, York, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
New New 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP CD O
York York 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP CD NNP O
10027, 10027, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP CC O
USA USA 1 1 0 0 0 0 0 0 3 0 NNP CD NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 CD NNP CC NNP NNP O
Columbia Columbia 1 0 0 0 0 0 0 0 8 0 NNP CC NNP NNP NNP O
Astrophysics Astrophysics 1 0 0 0 0 0 0 0 12 0 CC NNP NNP NNP NNP O
Laboratory, Laboratory, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Columbia Columbia 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
New New 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
York, York, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
New New 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP CD O
York York 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP CD NNP O
10027, 10027, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NN O
Galactic Galactic 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NN VBP O
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 NNP NNP NN VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NNP NN VBP VBN TO O
expected expected 0 0 0 0 0 0 0 0 8 0 NN VBP VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBP VBN TO VB RB O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB RB VBN O
densely densely 0 0 0 0 0 0 0 0 7 0 TO VB RB VBN IN O
populated populated 0 0 0 0 0 0 0 0 9 0 VB RB VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN JJ CC O
stellar- stellar- 0 0 1 0 0 0 0 0 8 0 VBN IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NN O
intermediate-mass intermediate-mass 0 0 1 0 0 0 0 0 17 0 JJ CC JJ NN NNP O
black black 0 0 0 0 0 0 0 0 5 0 CC JJ NN NNP NNP O
holes. holes. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP DT O
Exploring Exploring 1 0 0 0 0 0 0 0 9 0 NN NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN MD O
population population 0 0 0 0 0 0 0 0 10 0 NNP DT NN MD VB O
will will 0 0 0 0 0 0 0 0 4 0 DT NN MD VB JJ O
have have 0 0 0 0 0 0 0 0 4 0 NN MD VB JJ NNS O
important important 0 0 0 0 0 0 0 0 9 0 MD VB JJ NNS IN O
consequences consequences 0 0 0 0 0 0 0 0 12 0 VB JJ NNS IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NNS O
observation observation 0 0 0 0 0 0 0 0 11 0 IN DT NN NNS IN O
prospects prospects 0 0 0 0 0 0 0 0 9 0 DT NN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NNS O
gravitational gravitational 0 0 0 0 0 0 0 0 13 0 NNS IN JJ NNS IN O
waves waves 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN RB O
as as 0 0 0 0 0 0 0 0 2 0 JJ NNS IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NNS IN RB IN NN O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN NN JJ O
understanding understanding 0 0 0 0 0 0 0 0 13 0 RB IN NN JJ NNP O
galactic galactic 0 0 0 0 0 0 0 0 8 0 IN NN JJ NNP NNP O
evolution. evolution. 0 0 0 0 0 0 0 0 10 0 NN JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN VBD O
gas gas 0 0 0 0 0 0 0 0 3 0 NNP NNP NN VBD NNP O
cloud cloud 0 0 0 0 0 0 0 0 5 0 NNP NN VBD NNP RB O
G2 G2 1 1 0 0 0 0 0 1 2 0 NN VBD NNP RB VBG O
currently currently 0 0 0 0 0 0 0 0 9 0 VBD NNP RB VBG NNP O
approaching approaching 0 0 0 0 0 0 0 0 11 0 NNP RB VBG NNP -NONE- O
Sgr Sgr 1 0 0 0 0 0 0 0 3 0 RB VBG NNP -NONE- VBZ O
A* A* 1 1 0 0 0 0 0 0 2 0 VBG NNP -NONE- VBZ DT O
provides provides 0 0 0 0 0 0 0 0 8 0 NNP -NONE- VBZ DT VBN O
an an 0 0 0 0 0 0 0 0 2 0 -NONE- VBZ DT VBN NN O
unprecedented unprecedented 0 0 0 0 0 0 0 0 13 0 VBZ DT VBN NN TO O
opportunity opportunity 0 0 0 0 0 0 0 0 11 0 DT VBN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN NN TO VB DT O
probe probe 0 0 0 0 0 0 0 0 5 0 NN TO VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJ NN O
black black 0 0 0 0 0 0 0 0 5 0 VB DT JJ NN CC O
hole hole 0 0 0 0 0 0 0 0 4 0 DT JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NN O
neutron neutron 0 0 0 0 0 0 0 0 7 0 NN CC NN NN NN O
star star 0 0 0 0 0 0 0 0 4 0 CC NN NN NN IN O
population population 0 0 0 0 0 0 0 0 10 0 NN NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
Galactic Galactic 1 0 0 0 0 0 0 0 8 0 IN DT NNP NNP NNP O
nucleus. nucleus. 0 0 0 0 0 0 0 0 8 0 DT NNP NNP NNP NN O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NN DT O
examine examine 0 0 0 0 0 0 0 0 7 0 NNP NNP NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT NN IN O
possibility possibility 0 0 0 0 0 0 0 0 11 0 NN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
G2-cloud-black-hole G2-cloud-black-hole 1 0 1 0 0 0 0 1 19 0 IN DT JJ NN CC O
encounter encounter 0 0 0 0 0 0 0 0 9 0 DT JJ NN CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NN CC PRP$ NN IN O
detectability detectability 0 0 0 0 0 0 0 0 13 0 CC PRP$ NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 PRP$ NN IN JJ JJ O
current current 0 0 0 0 0 0 0 0 7 0 NN IN JJ JJ NN O
x-ray x-ray 0 0 1 0 0 0 0 0 5 0 IN JJ JJ NN JJ O
satellites, satellites, 0 0 0 0 1 0 0 0 11 0 JJ JJ NN JJ IN O
such such 0 0 0 0 0 0 0 0 4 0 JJ NN JJ IN NNP O
as as 0 0 0 0 0 0 0 0 2 0 NN JJ IN NNP CC O
Chandra Chandra 1 0 0 0 0 0 0 0 7 0 JJ IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
NuSTAR. NuSTAR. 1 0 0 0 0 0 0 0 7 0 NNP CC NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 CC NNP NNP VBP IN O
find find 0 0 0 0 0 0 0 0 4 0 NNP NNP VBP IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBP IN NN NNS O
multiple multiple 0 0 0 0 0 0 0 0 8 0 VBP IN NN NNS VBP O
encounters encounters 0 0 0 0 0 0 0 0 10 0 IN NN NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NN NNS VBP JJ TO O
likely likely 0 0 0 0 0 0 0 0 6 0 NNS VBP JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBP JJ TO VB JJ O
occur occur 0 0 0 0 0 0 0 0 5 0 JJ TO VB JJ TO O
close close 0 0 0 0 0 0 0 0 5 0 TO VB JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VB JJ TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ TO DT NN WDT O
pericenter, pericenter, 0 0 0 0 1 0 0 0 11 0 TO DT NN WDT MD O
which which 0 0 0 0 0 0 0 0 5 0 DT NN WDT MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN WDT MD VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 WDT MD VB JJ IN O
detectable detectable 0 0 0 0 0 0 0 0 10 0 MD VB JJ IN JJ O
upon upon 0 0 0 0 0 0 0 0 4 0 VB JJ IN JJ NNP O
favorable favorable 0 0 0 0 0 0 0 0 9 0 JJ IN JJ NNP NNP O
circumstances. circumstances. 0 0 0 0 0 0 0 0 14 0 IN JJ NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NN VBZ O
opportunity opportunity 0 0 0 0 0 0 0 0 11 0 NNP NNP NN VBZ DT O
provides provides 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN VBZ DT JJ JJ O
additional additional 0 0 0 0 0 0 0 0 10 0 VBZ DT JJ JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 DT JJ JJ NN NN O
science science 0 0 0 0 0 0 0 0 7 0 JJ JJ NN NN IN O
case case 0 0 0 0 0 0 0 0 4 0 JJ NN NN IN VBG O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN VBG JJ O
leading leading 0 0 0 0 0 0 0 0 7 0 NN IN VBG JJ NNS O
x-ray x-ray 0 0 1 0 0 0 0 0 5 0 IN VBG JJ NNS TO O
observatories observatories 0 0 0 0 0 0 0 0 13 0 VBG JJ NNS TO RB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO RB VB O
closely closely 0 0 0 0 0 0 0 0 7 0 NNS TO RB VB NNP O
follow follow 0 0 0 0 0 0 0 0 6 0 TO RB VB NNP IN O
G2 G2 1 1 0 0 0 0 0 1 2 0 RB VB NNP IN PRP$ O
on on 0 0 0 0 0 0 0 0 2 0 VB NNP IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NNP IN PRP$ NN TO O
way way 0 0 0 0 0 0 0 0 3 0 IN PRP$ NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 PRP$ NN TO DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT NNP NONE O
nucleus. nucleus. 0 0 0 0 0 0 0 0 8 0 TO DT NNP NONE NONE O
Flavokawain Flavokawain 1 0 0 0 0 0 0 0 11 0 NONE NONE NNP NNP DT O
B, B, 1 1 0 0 1 0 0 0 2 0 NONE NNP NNP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT NN NN O
kava kava 0 0 0 0 0 0 0 0 4 0 NNP DT NN NN NNS O
chalcone, chalcone, 0 0 0 0 1 0 0 0 9 0 DT NN NN NNS NN O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 NN NN NNS NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 NN NNS NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNS NN IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NNS O
osteosarcoma osteosarcoma 0 0 0 0 0 0 0 0 12 0 IN JJ NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN JJ O
through through 0 0 0 0 0 0 0 0 7 0 NN NNS IN JJ NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 0 NNS IN JJ NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest JJ NN NN NN CC O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
apoptosis. apoptosis. 0 0 0 0 0 0 0 0 10 0 NN CC NNP NNP NNP O
Ji Ji 1 0 0 0 0 0 0 0 2 0 CC NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lin Lin 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Krill Krill 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
LS, LS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Eskander Eskander 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Guo Guo 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zi Zi 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hoang Hoang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
BH. BH. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Orthopaedic Orthopaedic 1 0 0 0 0 0 0 0 11 0 NNP IN NNP NNP NNP O
Surgery, Surgery, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP NNP O
UC UC 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Irvine Irvine 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Multidisciplinary Multidisciplinary 1 0 0 0 0 0 0 0 17 0 NNP NNP NNP NNP NNP O
Sarcoma Sarcoma 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Center, Center, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Chao Chao 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Family Family 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Comprehensive Comprehensive 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Center, Center, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
California, California, 1 0 0 0 1 0 0 0 11 0 NNP IN NNP NNP NNP O
Irvine, Irvine, 1 0 0 0 1 0 0 0 7 0 IN NNP NNP NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
bhhoang@uci.edu. bhhoang@uci.edu. 0 0 0 0 0 0 0 0 16 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
Osteosarcoma Osteosarcoma 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP VBZ O
(OS) (OS) 0 1 0 0 0 0 0 0 4 0 NNP NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT RBS O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT RBS JJ O
most most 0 0 0 0 0 0 0 0 4 0 VBZ DT RBS JJ JJ O
common common 0 0 0 0 0 0 0 0 6 0 DT RBS JJ JJ NN O
primary primary 0 0 0 0 0 0 0 0 7 0 RBS JJ JJ NN NN O
bone bone 0 0 0 0 0 0 0 0 4 0 JJ JJ NN NN IN O
malignancy malignancy 0 0 0 0 0 0 0 0 10 0 JJ NN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 IN DT JJ NN IN O
propensity propensity 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN JJ NN O
local local 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN CC O
invasion invasion 0 0 0 0 0 0 0 0 8 0 IN JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NNP O
distant distant 0 0 0 0 0 0 0 0 7 0 NN CC JJ NNP NNP O
metastasis. metastasis. 0 0 0 0 0 0 0 0 11 0 CC JJ NNP NNP IN O
Limited Limited 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP IN DT O
by by 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ NN O
severe severe 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN IN O
toxicity toxicity 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
conventional conventional 0 0 0 0 0 0 0 0 12 0 NN IN JJ NN DT O
agents, agents, 0 0 0 0 1 0 0 0 7 0 IN JJ NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT JJ NN O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 NN DT JJ NN IN O
bottleneck bottleneck 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN RB O
osteosarcoma osteosarcoma 0 0 0 0 0 0 0 0 12 0 NN IN NN RB VBZ O
still still 0 0 0 0 0 0 0 0 5 0 IN NN RB VBZ NNP O
remains remains 0 0 0 0 0 0 0 0 7 0 NN RB VBZ NNP NNP O
unconquered. unconquered. 0 0 0 0 0 0 0 0 12 0 RB VBZ NNP NNP NNP O
Flavokawain Flavokawain 1 0 0 0 0 0 0 0 11 0 VBZ NNP NNP NNP NNP O
B B 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NNP DT O
(FKB), (FKB), 0 1 0 0 1 0 0 0 6 0 NNP NNP NNP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT NN NN O
kava kava 0 0 0 0 0 0 0 0 4 0 NNP DT NN NN VBZ O
extract, extract, 0 0 0 0 1 0 0 0 8 0 DT NN NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NN NN VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN VBN TO O
reported reported 0 0 0 0 0 0 0 0 8 0 VBZ VBN VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO VB JJ O
have have 0 0 0 0 0 0 0 0 4 0 VBN TO VB JJ JJ O
significant significant 0 0 0 0 0 0 0 0 11 0 TO VB JJ JJ NNS O
anti-tumor anti-tumor 0 0 1 0 0 0 0 0 10 0 VB JJ JJ NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 JJ JJ NNS IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
several several 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NN NN O
carcinoma carcinoma 0 0 0 0 0 0 0 0 9 0 IN JJ NN NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NNS DT O
lines lines 0 0 0 0 0 0 0 0 5 0 NN NN NNS DT IN O
both both 0 0 0 0 0 0 0 0 4 0 NN NNS DT IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNS DT IN NN CC O
vitro vitro 0 0 0 0 0 0 0 0 5 0 DT IN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN CC IN NNP NNP O
vivo. vivo. 0 0 0 0 0 0 0 0 5 0 CC IN NNP NNP NN O
Its Its 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NN CC O
efficacy efficacy 0 0 0 0 0 0 0 0 8 0 NNP NNP NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC JJ NN O
low low 0 0 0 0 0 0 0 0 3 0 NN CC JJ NN NN O
toxicity toxicity 0 0 0 0 0 0 0 0 8 0 CC JJ NN NN VB O
profile profile 0 0 0 0 0 0 0 0 7 0 JJ NN NN VB NNP O
make make 0 0 0 0 0 0 0 0 4 0 NN NN VB NNP DT O
FKB FKB 1 1 0 0 0 0 0 0 3 0 NN VB NNP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VB NNP DT NN NN O
promising promising 0 0 0 0 0 0 0 0 9 0 NNP DT NN NN IN O
agent agent 0 0 0 0 0 0 0 0 5 0 DT NN NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NN IN O
use use 0 0 0 0 0 0 0 0 3 0 NN IN NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN JJ O
novel novel 0 0 0 0 0 0 0 0 5 0 IN DT NN JJ NNP O
chemotherapeutic chemotherapeutic 0 0 0 0 0 0 0 0 16 0 DT NN JJ NNP NNP O
agent. agent. 0 0 0 0 0 0 0 0 6 0 NN JJ NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 JJ NNP NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NN O
current current 0 0 0 0 0 0 0 0 7 0 NNP DT JJ NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 DT JJ NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 JJ NN PRP VBD DT O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NN PRP VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT JJ CC O
anti-proliferative anti-proliferative 0 0 1 0 0 0 0 0 18 0 VBD DT JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC JJ NNS O
apoptotic apoptotic 0 0 0 0 0 0 0 0 9 0 JJ CC JJ NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 CC JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP IN O
FKB FKB 1 1 0 0 0 0 0 0 3 0 NNS IN NNP IN JJ O
against against 0 0 0 0 0 0 0 0 7 0 IN NNP IN JJ NNP O
human human 0 0 0 0 0 0 0 0 5 0 NNP IN JJ NNP NNP O
osteosarcomas. osteosarcomas. 0 0 0 0 0 0 0 0 14 0 IN JJ NNP NNP IN O
Exposure Exposure 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNS O
OS OS 1 1 0 0 0 0 0 0 2 0 NNP IN NNP NNS TO O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNP NNS TO NNP VBD O
FKB FKB 1 1 0 0 0 0 0 0 3 0 NNS TO NNP VBD IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 TO NNP VBD IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP VBD IN NNP VBD O
apoptosis, apoptosis, 0 0 0 0 1 0 0 0 10 0 VBD IN NNP VBD IN O
evidenced evidenced 0 0 0 0 0 0 0 0 9 0 IN NNP VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNP VBD IN NN IN O
loss loss 0 0 0 0 0 0 0 0 4 0 VBD IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN JJ O
viability, viability, 0 0 0 0 1 0 0 0 10 0 IN NN NN JJ NNS O
morphological morphological 0 0 0 0 0 0 0 0 13 0 NN NN JJ NNS CC O
changes changes 0 0 0 0 0 0 0 0 7 0 NN JJ NNS CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS CC DT NN IN O
externalization externalization 0 0 0 0 0 0 0 0 15 0 CC DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
phosphatidylserine. phosphatidylserine. 0 0 0 0 0 0 0 0 19 0 NN IN NNP NNP VBD O
Apoptosis Apoptosis 1 0 0 0 0 0 0 0 9 0 IN NNP NNP VBD IN O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NNP VBD IN NNP VBD O
FKB FKB 1 1 0 0 0 0 0 0 3 0 VBD IN NNP VBD IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 IN NNP VBD IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP VBD IN NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 VBD IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNP O
Caspase-3/7, Caspase-3/7, 1 0 1 1 1 0 0 1 12 0 NN IN NNP NNP CC O
-8 -8 0 0 1 0 0 0 0 1 2 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP IN O
-9 -9 0 0 1 0 0 0 0 1 2 0 NNP CC NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CC NNP IN NNP NN O
OS OS 1 1 0 0 0 0 0 0 2 0 NNP IN NNP NN -NONE- O
cell cell 0 0 0 0 0 0 0 0 4 0 IN NNP NN -NONE- CD O
lines, lines, 0 0 0 0 1 0 0 0 6 0 NNP NN -NONE- CD CC O
143B 143B 0 1 0 0 0 0 0 1 4 0 NN -NONE- CD CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- CD CC NNP NNP O
Saos-2. Saos-2. 1 0 1 0 0 0 0 1 7 0 CD CC NNP NNP RB O
FKB FKB 1 1 0 0 0 0 0 0 3 0 CC NNP NNP RB JJ O
also also 0 0 0 0 0 0 0 0 4 0 NNP NNP RB JJ NN O
down-regulated down-regulated 0 0 1 0 0 0 0 0 14 0 NNP RB JJ NN JJ O
inhibitory inhibitory 0 0 0 0 0 0 0 0 10 0 RB JJ NN JJ NN O
apoptotic apoptotic 0 0 0 0 0 0 0 0 9 0 JJ NN JJ NN VBG O
markers, markers, 0 0 0 0 1 0 0 0 8 0 NN JJ NN VBG -NONE- O
including including 0 0 0 0 0 0 0 0 9 0 JJ NN VBG -NONE- CC O
Bcl-2 Bcl-2 1 0 1 0 0 0 0 1 5 0 NN VBG -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VBG -NONE- CC NNP CC O
Survivin Survivin 1 0 0 0 0 0 0 0 8 0 -NONE- CC NNP CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC VBD TO O
led led 0 0 0 0 0 0 0 0 3 0 NNP CC VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 CC VBD TO VB NNS O
concomitant concomitant 0 0 0 0 0 0 0 0 11 0 VBD TO VB NNS IN O
increases increases 0 0 0 0 0 0 0 0 9 0 TO VB NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VB NNS IN JJ NN O
apoptotic apoptotic 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NN NN O
proteins, proteins, 0 0 0 0 1 0 0 0 9 0 IN JJ NN NN NNP O
Bax, Bax, 1 0 0 0 1 0 0 0 4 0 JJ NN NN NNP CC O
Puma Puma 1 0 0 0 0 0 0 0 4 0 NN NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP NNP O
Fas. Fas. 1 0 0 0 0 0 0 0 4 0 NNP CC NNP NNP DT O
Therefore, Therefore, 1 0 0 0 1 0 0 0 10 0 CC NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 NNP DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN IN NN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP VBD O
FKB FKB 1 1 0 0 0 0 0 0 3 0 NN IN NNP VBD DT O
involved involved 0 0 0 0 0 0 0 0 8 0 IN NNP VBD DT JJ O
both both 0 0 0 0 0 0 0 0 4 0 NNP VBD DT JJ CC O
extrinsic extrinsic 0 0 0 0 0 0 0 0 9 0 VBD DT JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC JJ NNP O
intrinsic intrinsic 0 0 0 0 0 0 0 0 9 0 JJ CC JJ NNP NNP O
pathways. pathways. 0 0 0 0 0 0 0 0 9 0 CC JJ NNP NNP RB O
FKB FKB 1 1 0 0 0 0 0 0 3 0 JJ NNP NNP RB VBD O
also also 0 0 0 0 0 0 0 0 4 0 NNP NNP RB VBD JJ O
caused caused 0 0 0 0 0 0 0 0 6 0 NNP RB VBD JJ NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 phase RB VBD JJ NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 VBD JJ NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NN NN NN NN WDT O
arrest, arrest, 0 0 0 0 1 0 0 0 7 0 NN NN NN WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN WDT VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 WDT VBD VBN IN NNS O
through through 0 0 0 0 0 0 0 0 7 0 VBD VBN IN NNS IN O
reductions reductions 0 0 0 0 0 0 0 0 10 0 VBN IN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 IN DT NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NN NN O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NNS IN NN NN NNP O
B1, B1, 1 1 0 0 1 0 0 1 3 0 IN NN NN NNP CC O
cdc2 cdc2 0 0 0 0 0 0 0 1 4 0 NN NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP CC O
cdc25c cdc25c 0 0 0 0 0 0 0 1 6 0 NNP CC NNP CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC NNS IN O
increases increases 0 0 0 0 0 0 0 0 9 0 NNP CC NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CC NNS IN NNP NNP O
Myt1 Myt1 1 0 0 0 0 0 0 1 4 0 NNS IN NNP NNP NNP O
levels. levels. 0 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NN O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 NNP NNP NNP NN CC O
migration migration 0 0 0 0 0 0 0 0 9 0 NNP NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN NN O
invasion invasion 0 0 0 0 0 0 0 0 8 0 NN CC NN NN VBD O
ability ability 0 0 0 0 0 0 0 0 7 0 CC NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP IN O
FKB FKB 1 1 0 0 0 0 0 0 3 0 VBN IN NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT JJ NNP O
dose-dependent dose-dependent 0 0 1 0 0 0 0 0 14 0 IN DT JJ NNP NNP O
manner. manner. 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN NN O
cytotoxicity cytotoxicity 0 0 0 0 0 0 0 0 12 0 NNP NNP NN NN VBD O
profile profile 0 0 0 0 0 0 0 0 7 0 NNP NN NN VBD NNP O
showed showed 0 0 0 0 0 0 0 0 6 0 NN NN VBD NNP VBD O
FKB FKB 1 1 0 0 0 0 0 0 3 0 NN VBD NNP VBD JJ O
had had 0 0 0 0 0 0 0 0 3 0 VBD NNP VBD JJ JJR O
significant significant 0 0 0 0 0 0 0 0 11 0 NNP VBD JJ JJR NN O
lower lower 0 0 0 0 0 0 0 0 5 0 VBD JJ JJR NN NNS O
side side 0 0 0 0 0 0 0 0 4 0 JJ JJR NN NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 JJR NN NNS IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NN O
bone bone 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN NNS O
marrow marrow 0 0 0 0 0 0 0 0 6 0 IN NN NN NNS CC O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC JJ JJ O
small small 0 0 0 0 0 0 0 0 5 0 NNS CC JJ JJ JJ O
intestinal intestinal 0 0 0 0 0 0 0 0 10 0 CC JJ JJ JJ NNS O
epithelial epithelial 0 0 0 0 0 0 0 0 10 0 JJ JJ JJ NNS VBN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ JJ NNS VBN IN O
compared compared 0 0 0 0 0 0 0 0 8 0 JJ NNS VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBN IN NNP NNP O
Adriamycin. Adriamycin. 1 0 0 0 0 0 0 0 11 0 VBN IN NNP NNP NNP O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 IN NNP NNP NNP NNP O
Taken Taken 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP PRP$ O
together, together, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP PRP$ NN O
our our 0 0 0 0 0 0 0 0 3 0 NNP NNP PRP$ NN IN O
evidence evidence 0 0 0 0 0 0 0 0 8 0 NNP PRP$ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 PRP$ NN IN NN CC O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN CC NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest CC NN NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NN O
FKB FKB 1 1 0 0 0 0 0 0 3 0 NN IN NNP NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 IN NNP NN IN JJR O
with with 0 0 0 0 0 0 0 0 4 0 NNP NN IN JJR NN O
less less 0 0 0 0 0 0 0 0 4 0 NN IN JJR NN IN O
toxicity toxicity 0 0 0 0 0 0 0 0 8 0 IN JJR NN IN DT O
than than 0 0 0 0 0 0 0 0 4 0 JJR NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNS O
standard standard 0 0 0 0 0 0 0 0 8 0 IN DT JJ NNS VBZ O
treatments treatments 0 0 0 0 0 0 0 0 10 0 DT JJ NNS VBZ DT O
provides provides 0 0 0 0 0 0 0 0 8 0 JJ NNS VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNS VBZ DT JJ NN O
innovative innovative 0 0 0 0 0 0 0 0 10 0 VBZ DT JJ NN IN O
argument argument 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
use use 0 0 0 0 0 0 0 0 3 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
FKB FKB 1 1 0 0 0 0 0 0 3 0 NN IN NNP IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT JJ CC O
chemotherapeutic chemotherapeutic 0 0 0 0 0 0 0 0 16 0 IN DT JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC JJ NNP O
chemopreventive chemopreventive 0 0 0 0 0 0 0 0 15 0 JJ CC JJ NNP NNP O
compound. compound. 0 0 0 0 0 0 0 0 9 0 CC JJ NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NN NNS O
vivo vivo 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NNS VBG O
experiments experiments 0 0 0 0 0 0 0 0 11 0 NNP NN NNS VBG NNP O
utilizing utilizing 0 0 0 0 0 0 0 0 9 0 NN NNS VBG NNP TO O
FKB FKB 1 1 0 0 0 0 0 0 3 0 NNS VBG NNP TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBG NNP TO VB NN O
reduce reduce 0 0 0 0 0 0 0 0 6 0 NNP TO VB NN CC O
tumorigenesis tumorigenesis 0 0 0 0 0 0 0 0 13 0 TO VB NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VB NN CC JJ JJ O
metastatic metastatic 0 0 0 0 0 0 0 0 10 0 NN CC JJ JJ MD O
potential potential 0 0 0 0 0 0 0 0 9 0 CC JJ JJ MD VB O
will will 0 0 0 0 0 0 0 0 4 0 JJ JJ MD VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 JJ MD VB JJ TO O
crucial crucial 0 0 0 0 0 0 0 0 7 0 MD VB JJ TO RBR O
to to 0 0 0 0 0 0 0 0 2 0 VB JJ TO RBR JJ O
further further 0 0 0 0 0 0 0 0 7 0 JJ TO RBR JJ JJ O
justify justify 0 0 0 0 0 0 0 0 7 0 TO RBR JJ JJ NNP O
clinical clinical 0 0 0 0 0 0 0 0 8 0 RBR JJ JJ NNP NONE O
application. application. 0 0 0 0 0 0 0 0 12 0 JJ JJ NNP NONE NONE O
Wentilactone Wentilactone 1 0 0 0 0 0 0 0 12 0 NONE NONE NNP NNP NNS O
B B 1 1 0 0 0 0 0 0 1 0 NONE NNP NNP NNS -NONE- O
induces induces 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS -NONE- VB O
G2/M G2/M 1 1 0 1 0 0 0 1 4 phase NNP NNS -NONE- VB JJS B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 arrest NNS -NONE- VB JJS CC O
arrest arrest 0 0 0 0 0 0 0 0 6 0 -NONE- VB JJS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VB JJS CC NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 JJS CC NN IN DT O
via via 0 0 0 0 0 0 0 0 3 0 CC NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
Ras/Raf/MAPK Ras/Raf/MAPK 1 0 0 1 0 0 0 0 12 0 IN DT JJ NN NN O
signaling signaling 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN IN O
pathway pathway 0 0 0 0 0 0 0 0 7 0 JJ NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN NN NN -NONE- O
hepatoma hepatoma 0 0 0 0 0 0 0 0 8 0 IN NN NN -NONE- NNP O
SMMC-7721 SMMC-7721 1 1 1 0 0 0 0 1 9 0 NN NN -NONE- NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN -NONE- NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 -NONE- NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Miao Miao 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lv Lv 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sun Sun 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wei Wei 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Huang Huang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Jiao Jiao 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
B. B. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Biochemistry Biochemistry 1 0 0 0 0 0 0 0 12 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP CC NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 CC NNP NNP NNP IN O
Faculty Faculty 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Basic Basic 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Second Second 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Military Military 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Shanghai, Shanghai, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
Hepatocellular Hepatocellular 1 0 0 0 0 0 0 0 14 0 NNP NNP NNP NN -NONE- O
carcinoma carcinoma 0 0 0 0 0 0 0 0 9 0 NNP NNP NN -NONE- VBZ O
(HCC) (HCC) 0 1 0 0 0 0 0 0 5 0 NNP NN -NONE- VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NN -NONE- VBZ RB VBN O
generally generally 0 0 0 0 0 0 0 0 9 0 -NONE- VBZ RB VBN IN O
acknowledged acknowledged 0 0 0 0 0 0 0 0 12 0 VBZ RB VBN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 RB VBN IN DT RBS O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT RBS JJ O
most most 0 0 0 0 0 0 0 0 4 0 IN DT RBS JJ JJ O
common common 0 0 0 0 0 0 0 0 6 0 DT RBS JJ JJ NN O
primary primary 0 0 0 0 0 0 0 0 7 0 RBS JJ JJ NN NN O
malignant malignant 0 0 0 0 0 0 0 0 9 0 JJ JJ NN NN CC O
tumor, tumor, 0 0 0 0 1 0 0 0 6 0 JJ NN NN CC PRP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NN CC PRP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 CC PRP VBZ VBN TO O
known known 0 0 0 0 0 0 0 0 5 0 PRP VBZ VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ VBN TO VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB JJ TO O
resistant resistant 0 0 0 0 0 0 0 0 9 0 TO VB JJ TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 VB JJ TO JJ NNP O
conventional conventional 0 0 0 0 0 0 0 0 12 0 JJ TO JJ NNP NNP O
chemotherapy. chemotherapy. 0 0 0 0 0 0 0 0 13 0 TO JJ NNP NNP NNP O
Wentilactone Wentilactone 1 0 0 0 0 0 0 0 12 0 JJ NNP NNP NNP NNP O
B B 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NNP DT O
(WB), (WB), 0 1 0 0 1 0 0 0 5 0 NNP NNP NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT JJ JJ O
tetranorditerpenoid tetranorditerpenoid 0 0 0 0 0 0 0 0 19 0 NNP DT JJ JJ JJ O
derivative derivative 0 0 0 0 0 0 0 0 10 0 DT JJ JJ JJ IN O
extracted extracted 0 0 0 0 0 0 0 0 9 0 JJ JJ JJ IN DT O
from from 0 0 0 0 0 0 0 0 4 0 JJ JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN JJ O
marine marine 0 0 0 0 0 0 0 0 6 0 IN DT NN JJ JJ O
algae-derived algae-derived 0 0 1 0 0 0 0 0 13 0 DT NN JJ JJ NN O
endophytic endophytic 0 0 0 0 0 0 0 0 10 0 NN JJ JJ NN NNP O
fungus fungus 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NNP NN O
Aspergillus Aspergillus 1 0 0 0 0 0 0 0 11 0 JJ NN NNP NN -NONE- O
wentii wentii 0 0 0 0 0 0 0 0 6 0 NN NNP NN -NONE- VBZ O
EN-48, EN-48, 1 1 1 0 1 0 0 1 6 0 NNP NN -NONE- VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NN -NONE- VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 -NONE- VBZ VBN VBN TO O
shown shown 0 0 0 0 0 0 0 0 5 0 VBZ VBN VBN TO JJR O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO JJR NN O
trigger trigger 0 0 0 0 0 0 0 0 7 0 VBN TO JJR NN CC O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 TO JJR NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJR NN CC NN NN O
inhibit inhibit 0 0 0 0 0 0 0 0 7 0 NN CC NN NN IN O
metastasis metastasis 0 0 0 0 0 0 0 0 10 0 CC NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NN O
HCC HCC 1 1 0 0 0 0 0 0 3 0 NN IN NNP NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN NNP NN NNP NNP O
lines. lines. 0 0 0 0 0 0 0 0 6 0 NNP NN NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNS IN O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 NNP DT NNS IN PRP$ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NNS IN PRP$ NN NN O
antitumor antitumor 0 0 0 0 0 0 0 0 9 0 IN PRP$ NN NN NN O
activity activity 0 0 0 0 0 0 0 0 8 0 PRP$ NN NN NN TO O
remain remain 0 0 0 0 0 0 0 0 6 0 NN NN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO VB NNP O
be be 0 0 0 0 0 0 0 0 2 0 NN TO VB NNP NNP O
elucidated. elucidated. 0 0 0 0 0 0 0 0 11 0 TO VB NNP NNP NN O
We We 1 0 0 0 0 0 0 0 2 0 VB NNP NNP NN RB O
report report 0 0 0 0 0 0 0 0 6 0 NNP NNP NN RB IN O
here here 0 0 0 0 0 0 0 0 4 0 NNP NN RB IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NN RB IN NNP MD O
WB WB 1 1 0 0 0 0 0 0 2 0 RB IN NNP MD RB O
could could 0 0 0 0 0 0 0 0 5 0 IN NNP MD RB VB O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNP MD RB VB NN O
induce induce 0 0 0 0 0 0 0 0 6 0 MD RB VB NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 RB VB NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest VB NN NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN IN NNP O
at at 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NN O
G2 G2 1 1 0 0 0 0 0 1 2 phase NN IN NNP NN CC B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN NNP NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC JJ NN O
mitochondrial-related mitochondrial-related 0 0 1 0 0 0 0 0 21 0 NN CC JJ NN VBG O
apoptosis, apoptosis, 0 0 0 0 1 0 0 0 10 0 CC JJ NN VBG DT O
accompanying accompanying 0 0 0 0 0 0 0 0 12 0 JJ NN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT NN IN O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 VBG DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
reactive reactive 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN NNS O
oxygen oxygen 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNS NNP O
species species 0 0 0 0 0 0 0 0 7 0 JJ NN NNS NNP NNP O
(ROS). (ROS). 0 1 0 0 0 0 0 0 6 0 NN NNS NNP NNP NN O
Additionally, Additionally, 1 0 0 0 1 0 0 0 13 0 NNS NNP NNP NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNP NN IN NNP VBD O
WB WB 1 1 0 0 0 0 0 0 2 0 NN IN NNP VBD NN O
induced induced 0 0 0 0 0 0 0 0 7 0 IN NNP VBD NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 NNP VBD NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN JJ JJ O
extracellular extracellular 0 0 0 0 0 0 0 0 13 0 NN IN JJ JJ NN O
signal-regulated signal-regulated 0 0 1 0 0 0 0 0 16 0 IN JJ JJ NN NN O
kinase kinase 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NN NN O
(ERK), (ERK), 0 1 0 0 1 0 0 0 6 0 JJ NN NN NN JJ O
c-Jun c-Jun 0 0 1 0 0 0 0 0 5 0 NN NN NN JJ NN O
N-terminal N-terminal 1 0 1 0 0 0 0 0 10 0 NN NN JJ NN NN O
kinase kinase 0 0 0 0 0 0 0 0 6 0 NN JJ NN NN CC O
(JNK), (JNK), 0 1 0 0 1 0 0 0 6 0 JJ NN NN CC RB O
but but 0 0 0 0 0 0 0 0 3 0 NN NN CC RB NNP O
not not 0 0 0 0 0 0 0 0 3 0 NN CC RB NNP NNP O
p38 p38 0 0 0 0 0 0 0 1 3 0 CC RB NNP NNP NNP O
MAP MAP 1 1 0 0 0 0 0 0 3 0 RB NNP NNP NNP NNP O
kinase. kinase. 0 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP DT O
Among Among 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NNS O
pathway pathway 0 0 0 0 0 0 0 0 7 0 NNP DT NN NNS -NONE- O
inhibitors inhibitors 0 0 0 0 0 0 0 0 10 0 DT NN NNS -NONE- RB O
examined, examined, 0 0 0 0 1 0 0 0 9 0 NN NNS -NONE- RB NNP O
only only 0 0 0 0 0 0 0 0 4 0 NNS -NONE- RB NNP NNP O
SP600125 SP600125 1 1 0 0 0 0 0 1 8 0 -NONE- RB NNP NNP NNP O
(JNK (JNK 0 1 0 0 0 0 0 0 4 0 RB NNP NNP NNP RB O
inhibitor) inhibitor) 0 0 0 0 0 0 0 0 10 0 NNP NNP NNP RB JJ O
markedly markedly 0 0 0 0 0 0 0 0 8 0 NNP NNP RB JJ NN O
reversedWB-induced reversedWB-induced 0 0 1 0 0 0 0 0 18 0 NNP RB JJ NN CC O
apoptosis, apoptosis, 0 0 0 0 1 0 0 0 10 0 RB JJ NN CC RB O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC RB NNP O
only only 0 0 0 0 0 0 0 0 4 0 NN CC RB NNP NNP O
U0126 U0126 1 1 0 0 0 0 0 1 5 0 CC RB NNP NNP NNP O
(ERK (ERK 0 1 0 0 0 0 0 0 4 0 RB NNP NNP NNP RB O
inhibitor) inhibitor) 0 0 0 0 0 0 0 0 10 0 NNP NNP NNP RB VBD O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNP NNP RB VBD JJ O
blocked blocked 0 0 0 0 0 0 0 0 7 0 NNP RB VBD JJ NNP O
WB-triggered WB-triggered 1 0 1 0 0 0 0 0 12 0 RB VBD JJ NNP NN O
G2 G2 1 1 0 0 0 0 0 1 2 phase VBD JJ NNP NN NNP B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 JJ NNP NN NNP NNP O
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 NNP NN NNP NNP RB O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP RB VBD O
also also 0 0 0 0 0 0 0 0 4 0 NNP NNP RB VBD IN O
found found 0 0 0 0 0 0 0 0 5 0 NNP RB VBD IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 RB VBD IN NNP NN O
WB WB 1 1 0 0 0 0 0 0 2 0 VBD IN NNP NN VBD O
treatment treatment 0 0 0 0 0 0 0 0 9 0 IN NNP NN VBD DT O
increased increased 0 0 0 0 0 0 0 0 9 0 NNP NN VBD DT NNP O
both both 0 0 0 0 0 0 0 0 4 0 NN VBD DT NNP CC O
Ras Ras 1 0 0 0 0 0 0 0 3 0 VBD DT NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC NNP NNP O
Raf Raf 1 0 0 0 0 0 0 0 3 0 NNP CC NNP NNP CC O
activation, activation, 0 0 0 0 1 0 0 0 11 0 CC NNP NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NN IN O
transfection transfection 0 0 0 0 0 0 0 0 12 0 NNP CC NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN JJ NNS O
dominant-negative dominant-negative 0 0 1 0 0 0 0 0 17 0 NNS IN JJ NNS -NONE- O
Ras Ras 1 0 0 0 0 0 0 0 3 0 IN JJ NNS -NONE- JJ O
(RasN17) (RasN17) 0 0 0 0 0 0 0 1 8 0 JJ NNS -NONE- JJ NN O
abolishedWB-induced abolishedWB-induced 0 0 1 0 0 0 0 0 19 0 NNS -NONE- JJ NN CC O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 -NONE- JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP NN O
G2 G2 1 1 0 0 0 0 0 1 2 phase NN CC NNP NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 arrest CC NNP NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NNP NN NN IN -NONE- O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN -NONE- NNP O
SMMC-7721 SMMC-7721 1 1 1 0 0 0 0 1 9 0 NN IN -NONE- NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN -NONE- NNP NNP DT O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 -NONE- NNP NNP DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNS IN O
results results 0 0 0 0 0 0 0 0 7 0 NNP DT NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NN VBG O
inverse inverse 0 0 0 0 0 0 0 0 7 0 NNS IN NN VBG NN O
docking docking 0 0 0 0 0 0 0 0 7 0 IN NN VBG NN NN O
(INVDOCK) (INVDOCK) 0 1 0 0 0 0 0 0 9 0 NN VBG NN NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 VBG NN NN VBD IN O
suggested suggested 0 0 0 0 0 0 0 0 9 0 NN NN VBD IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN NNP MD O
WB WB 1 1 0 0 0 0 0 0 2 0 VBD IN NNP MD VB O
could could 0 0 0 0 0 0 0 0 5 0 IN NNP MD VB TO O
bind bind 0 0 0 0 0 0 0 0 4 0 NNP MD VB TO VB O
to to 0 0 0 0 0 0 0 0 2 0 MD VB TO VB CC O
Ras-GTP, Ras-GTP, 1 0 1 0 1 0 0 0 8 0 VB TO VB CC DT O
and and 0 0 0 0 0 0 0 0 3 0 TO VB CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VB CC DT JJ NN O
direct direct 0 0 0 0 0 0 0 0 6 0 CC DT JJ NN NN O
binding binding 0 0 0 0 0 0 0 0 7 0 DT JJ NN NN VBD O
affinity affinity 0 0 0 0 0 0 0 0 8 0 JJ NN NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD RB VBN O
also also 0 0 0 0 0 0 0 0 4 0 NN VBD RB VBN IN O
confirmed confirmed 0 0 0 0 0 0 0 0 9 0 VBD RB VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 RB VBN IN NN NN O
surface surface 0 0 0 0 0 0 0 0 7 0 VBN IN NN NN NN O
plasmon plasmon 0 0 0 0 0 0 0 0 7 0 IN NN NN NN NNP O
resonance resonance 0 0 0 0 0 0 0 0 9 0 NN NN NN NNP NNP O
(SPR). (SPR). 0 1 0 0 0 0 0 0 6 0 NN NN NNP NNP IN O
Finally, Finally, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
vivo, vivo, 0 0 0 0 1 0 0 0 5 0 NNP IN NNP NNP VBD O
WB WB 1 1 0 0 0 0 0 0 2 0 IN NNP NNP VBD NN O
suppressed suppressed 0 0 0 0 0 0 0 0 10 0 NNP NNP VBD NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NNP VBD NN NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 VBD NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
mouse mouse 0 0 0 0 0 0 0 0 5 0 NN IN NN NN NNP O
xenograft xenograft 0 0 0 0 0 0 0 0 9 0 IN NN NN NNP NNP O
models. models. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP NNP O
Taken Taken 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP DT O
together, together, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP DT NNS VBP IN O
indicate indicate 0 0 0 0 0 0 0 0 8 0 DT NNS VBP IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NNP VBD O
WB WB 1 1 0 0 0 0 0 0 2 0 VBP IN NNP VBD JJ O
induced induced 0 0 0 0 0 0 0 0 7 0 IN NNP VBD JJ NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 phase NNP VBD JJ NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 arrest VBD JJ NN NN CC O
arrest arrest 0 0 0 0 0 0 0 0 6 0 JJ NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN CC NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN NN NN -NONE- O
hepatoma hepatoma 0 0 0 0 0 0 0 0 8 0 IN NN NN -NONE- VBZ O
SMMC-7721 SMMC-7721 1 1 1 0 0 0 0 1 9 0 NN NN -NONE- VBZ IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN -NONE- VBZ IN DT O
via via 0 0 0 0 0 0 0 0 3 0 -NONE- VBZ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBZ IN DT JJ CC O
Ras/Raf/ERK Ras/Raf/ERK 1 0 0 1 0 0 0 0 11 0 IN DT JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC JJ NN O
Ras/Raf/JNK Ras/Raf/JNK 1 0 0 1 0 0 0 0 11 0 JJ CC JJ NN NN O
signaling signaling 0 0 0 0 0 0 0 0 9 0 CC JJ NN NN CC O
pathways, pathways, 0 0 0 0 1 0 0 0 9 0 JJ NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN CC DT NN MD O
agent agent 0 0 0 0 0 0 0 0 5 0 CC DT NN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 DT NN MD VB DT O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB DT RB O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT RB JJ O
potentially potentially 0 0 0 0 0 0 0 0 11 0 VB DT RB JJ NN O
useful useful 0 0 0 0 0 0 0 0 6 0 DT RB JJ NN IN O
compound compound 0 0 0 0 0 0 0 0 8 0 RB JJ NN IN VBG O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN VBG NN O
developing developing 0 0 0 0 0 0 0 0 10 0 NN IN VBG NN NNS O
anticancer anticancer 0 0 0 0 0 0 0 0 10 0 IN VBG NN NNS IN O
agents agents 0 0 0 0 0 0 0 0 6 0 VBG NN NNS IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN NNP NONE O
HCC. HCC. 1 1 0 0 0 0 0 0 4 0 NNS IN NNP NONE NONE O
Brain-derived Brain-derived 1 0 1 0 0 0 0 0 13 0 NONE NONE JJ JJ JJ O
neurotrophic neurotrophic 0 0 0 0 0 0 0 0 12 0 NONE JJ JJ JJ NNP O
factor-dependent factor-dependent 0 0 1 0 0 0 0 0 16 0 JJ JJ JJ NNP NN O
cdk1 cdk1 0 0 0 0 0 0 0 1 4 0 JJ JJ NNP NN VBZ O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 JJ NNP NN VBZ JJ O
prevents prevents 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ JJ NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 0 NN VBZ JJ NN IN B_TIMEXCCP
progression progression 0 0 0 0 0 0 0 0 11 0 VBZ JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN VBD O
differentiating differentiating 0 0 0 0 0 0 0 0 15 0 NN IN NN VBD NNP O
tetraploid tetraploid 0 0 0 0 0 0 0 0 10 0 IN NN VBD NNP NNP O
neurons. neurons. 0 0 0 0 0 0 0 0 8 0 NN VBD NNP NNP NNP O
Ovejero-Benito Ovejero-Benito 1 0 1 0 0 0 0 0 14 0 VBD NNP NNP NNP NNP O
MC, MC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Frade Frade 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
JM. JM. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Molecular, Molecular, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP CC O
Cellular, Cellular, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Developmental Developmental 1 0 0 0 0 0 0 0 13 0 NNP CC NNP NNP NNP O
Neurobiology, Neurobiology, 1 0 0 0 1 0 0 0 13 0 CC NNP NNP NNP NNP O
Instituto Instituto 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Cajal, Cajal, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
Consejo Consejo 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP IN O
Superior Superior 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Investigaciones Investigaciones 1 0 0 0 0 0 0 0 15 0 NNP IN NNP NNP NNP O
Científicas, Científicas, 1 0 0 0 1 0 0 0 12 0 IN NNP NNP NNP NNP O
Madrid, Madrid, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Spain. Spain. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
Neurodegeneration Neurodegeneration 1 0 0 0 0 0 0 0 17 0 NNP NNP NNP VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ RB VBN O
often often 0 0 0 0 0 0 0 0 5 0 NNP VBZ RB VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 VBZ RB VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NN IN O
synthesis synthesis 0 0 0 0 0 0 0 0 9 0 IN NNP NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP DT O
neurons, neurons, 0 0 0 0 1 0 0 0 8 0 NN IN NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NNP DT NN RB O
latter latter 0 0 0 0 0 0 0 0 6 0 NNP DT NN RB VBG O
usually usually 0 0 0 0 0 0 0 0 7 0 DT NN RB VBG IN O
remaining remaining 0 0 0 0 0 0 0 0 9 0 NN RB VBG IN DT O
for for 0 0 0 0 0 0 0 0 3 0 RB VBG IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBG IN DT JJ NN O
long long 0 0 0 0 0 0 0 0 4 0 IN DT JJ NN IN O
time time 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNS O
tetraploid tetraploid 0 0 0 0 0 0 0 0 10 0 NN IN JJ NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN VBG O
before before 0 0 0 0 0 0 0 0 6 0 JJ NNS IN VBG IN O
dying dying 0 0 0 0 0 0 0 0 5 0 NNS IN VBG IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 IN VBG IN NNP NNP O
apoptosis. apoptosis. 0 0 0 0 0 0 0 0 10 0 VBG IN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NN NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NN VBG O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 NNP NN NN VBG NN O
preventing preventing 0 0 0 0 0 0 0 0 10 0 NN NN VBG NN NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 0 NN VBG NN NN IN B_TIMEXCCP
transition transition 0 0 0 0 0 0 0 0 10 0 VBG NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT NNS VBZ O
neurons neurons 0 0 0 0 0 0 0 0 7 0 IN DT NNS VBZ JJ O
remains remains 0 0 0 0 0 0 0 0 7 0 DT NNS VBZ JJ CC O
unknown, unknown, 0 0 0 0 1 0 0 0 8 0 NNS VBZ JJ CC PRP O
but but 0 0 0 0 0 0 0 0 3 0 VBZ JJ CC PRP MD O
it it 0 0 0 0 0 0 0 0 2 0 JJ CC PRP MD VB O
may may 0 0 0 0 0 0 0 0 3 0 CC PRP MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 PRP MD VB VBN IN O
reminiscent reminiscent 0 0 0 0 0 0 0 0 11 0 MD VB VBN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VB VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NNS O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN NNS VBD O
maintains maintains 0 0 0 0 0 0 0 0 9 0 NN IN NNS VBD JJ O
tetraploid tetraploid 0 0 0 0 0 0 0 0 10 0 IN NNS VBD JJ NN O
retinal retinal 0 0 0 0 0 0 0 0 7 0 NNS VBD JJ NN NNS O
ganglion ganglion 0 0 0 0 0 0 0 0 8 0 VBD JJ NN NNS -NONE- O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS -NONE- IN O
(RGCs) (RGCs) 0 0 0 0 0 0 0 0 6 0 NN NNS -NONE- IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNS -NONE- IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- IN DT JJ NN O
G2-like G2-like 1 0 1 0 0 0 0 1 7 0 IN DT JJ NN IN O
state state 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 JJ NN IN JJ NN O
normal normal 0 0 0 0 0 0 0 0 6 0 NN IN JJ NN RB O
development, development, 0 0 0 0 1 0 0 0 12 0 IN JJ NN RB VBG O
thus thus 0 0 0 0 0 0 0 0 4 0 JJ NN RB VBG PRP$ O
preventing preventing 0 0 0 0 0 0 0 0 10 0 NN RB VBG PRP$ NNP O
their their 0 0 0 0 0 0 0 0 5 0 RB VBG PRP$ NNP NNP O
death. death. 0 0 0 0 0 0 0 0 6 0 VBG PRP$ NNP NNP PRP O
Here Here 1 0 0 0 0 0 0 0 4 0 PRP$ NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NNP PRP VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 VBP IN DT NN NN O
latter latter 0 0 0 0 0 0 0 0 6 0 IN DT NN NN VBN O
process, process, 0 0 0 0 1 0 0 0 8 0 DT NN NN VBN TO O
known known 0 0 0 0 0 0 0 0 5 0 NN NN VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBN TO VB IN O
depend depend 0 0 0 0 0 0 0 0 6 0 VBN TO VB IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 TO VB IN JJ JJ O
brain-derived brain-derived 0 0 1 0 0 0 0 0 13 0 VB IN JJ JJ NN O
neurotrophic neurotrophic 0 0 0 0 0 0 0 0 12 0 IN JJ JJ NN NN O
factor factor 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NN VBZ O
(BDNF), (BDNF), 0 1 0 0 1 0 0 0 7 0 JJ NN NN VBZ DT O
requires requires 0 0 0 0 0 0 0 0 8 0 NN NN VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 VBZ DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
cdk1 cdk1 0 0 0 0 0 0 0 1 4 0 NN IN NNP IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NNP O
TrkB. TrkB. 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NN O
We We 1 0 0 0 0 0 0 0 2 0 IN NNP NNP NN WDT O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 NNP NNP NN WDT DT O
that that 0 0 0 0 0 0 0 0 4 0 NNP NN WDT DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN WDT DT NN IN O
subpopulation subpopulation 0 0 0 0 0 0 0 0 13 0 WDT DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNP O
chick chick 0 0 0 0 0 0 0 0 5 0 NN IN NN NNP RB O
RGCs RGCs 1 0 0 0 0 0 0 0 4 0 IN NN NNP RB JJ O
previously previously 0 0 0 0 0 0 0 0 10 0 NN NNP RB JJ TO O
shown shown 0 0 0 0 0 0 0 0 5 0 NNP RB JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 RB JJ TO VB JJ O
become become 0 0 0 0 0 0 0 0 6 0 JJ TO VB JJ NNS O
tetraploid tetraploid 0 0 0 0 0 0 0 0 10 0 TO VB JJ NNS NNP O
co-expresses co-expresses 0 0 1 0 0 0 0 0 12 0 VB JJ NNS NNP CC O
TrkB TrkB 1 0 0 0 0 0 0 0 4 0 JJ NNS NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNS NNP CC NNP IN O
cdk1 cdk1 0 0 0 0 0 0 0 1 4 0 NNP CC NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CC NNP IN NNP NNP O
vivo. vivo. 0 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NN O
By By 1 0 0 0 0 0 0 0 2 0 IN NNP NNP NN DT O
using using 0 0 0 0 0 0 0 0 5 0 NNP NNP NN DT IN O
an an 0 0 0 0 0 0 0 0 2 0 NNP NN DT IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN DT IN NN NN O
vitro vitro 0 0 0 0 0 0 0 0 5 0 DT IN NN NN WDT O
system system 0 0 0 0 0 0 0 0 6 0 IN NN NN WDT VBZ O
that that 0 0 0 0 0 0 0 0 4 0 NN NN WDT VBZ NN O
recapitulates recapitulates 0 0 0 0 0 0 0 0 13 0 NN WDT VBZ NN CC O
differentiation differentiation 0 0 0 0 0 0 0 0 15 0 WDT VBZ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VBZ NN CC NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN CC NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 CC NN NN NN IN O
re-entry re-entry 0 0 1 0 0 0 0 0 8 0 NN NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN JJ O
chick chick 0 0 0 0 0 0 0 0 5 0 NN IN NN JJ NNS O
retinal retinal 0 0 0 0 0 0 0 0 7 0 IN NN JJ NNS PRP O
neurons neurons 0 0 0 0 0 0 0 0 7 0 NN JJ NNS PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 JJ NNS PRP VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NNS PRP VBP IN -NONE- O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN -NONE- VBN O
BDNF, BDNF, 1 1 0 0 1 0 0 0 5 0 VBP IN -NONE- VBN IN O
employed employed 0 0 0 0 0 0 0 0 8 0 IN -NONE- VBN IN NNS O
at at 0 0 0 0 0 0 0 0 2 0 -NONE- VBN IN NNS JJ O
concentrations concentrations 0 0 0 0 0 0 0 0 14 0 VBN IN NNS JJ IN O
specific specific 0 0 0 0 0 0 0 0 8 0 IN NNS JJ IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NNS JJ IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NNP NNP O
TrkB TrkB 1 0 0 0 0 0 0 0 4 0 IN DT NNP NNP NNS O
receptor, receptor, 0 0 0 0 1 0 0 0 9 0 DT NNP NNP NNS DT O
reduces reduces 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNS DT NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NNS DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
cdk1 cdk1 0 0 0 0 0 0 0 1 4 0 NN IN NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NN O
TrkB-positive, TrkB-positive, 1 0 1 0 1 0 0 0 14 0 NNP IN NNP NN NNP O
differentiating differentiating 0 0 0 0 0 0 0 0 15 0 IN NNP NN NNP NNP O
neurons. neurons. 0 0 0 0 0 0 0 0 8 0 NNP NN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN NNP O
system, system, 0 0 0 0 1 0 0 0 7 0 NNP DT NN NNP RB O
BDNF BDNF 1 1 0 0 0 0 0 0 4 0 DT NN NNP RB VBZ O
also also 0 0 0 0 0 0 0 0 4 0 NN NNP RB VBZ DT O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 NNP RB VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBZ DT NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 VBZ DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
both both 0 0 0 0 0 0 0 0 4 0 NN IN DT JJ NNP O
endogenous endogenous 0 0 0 0 0 0 0 0 10 0 IN DT JJ NNP CC O
cdk1 cdk1 0 0 0 0 0 0 0 1 4 0 DT JJ NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNP CC JJ NN O
exogenously-expressed exogenously-expressed 0 0 1 0 0 0 0 0 21 0 NNP CC JJ NN NNP O
cdk1/cyclin cdk1/cyclin 0 0 0 1 0 0 0 1 11 0 CC JJ NN NNP NNP O
B1 B1 1 1 0 0 0 0 0 1 2 0 JJ NN NNP NNP NNP O
complex. complex. 0 0 0 0 0 0 0 0 8 0 NN NNP NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NN VBZ O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 NNP NNP NN VBZ IN O
correlates correlates 0 0 0 0 0 0 0 0 10 0 NNP NN VBZ IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN VBZ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBZ IN DT NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
cdk1 cdk1 0 0 0 0 0 0 0 1 4 0 NN IN NNP IN NNP O
at at 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP DT O
Tyr15, Tyr15, 1 0 0 0 1 0 0 1 6 0 NNP IN NNP DT NN O
an an 0 0 0 0 0 0 0 0 2 0 IN NNP DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 NNP DT NN IN MD O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN IN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 IN MD VB VBN IN O
prevented prevented 0 0 0 0 0 0 0 0 9 0 MD VB VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VB VBN IN JJ DT O
K252a, K252a, 1 0 0 0 1 0 0 1 6 0 VBN IN JJ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 IN JJ DT NN NN O
tyrosine tyrosine 0 0 0 0 0 0 0 0 8 0 JJ DT NN NN NN O
kinase kinase 0 0 0 0 0 0 0 0 6 0 DT NN NN NN RB O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 NN NN NN RB VBN O
commonly commonly 0 0 0 0 0 0 0 0 8 0 NN NN RB VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 NN RB VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 RB VBN TO VB DT O
prevent prevent 0 0 0 0 0 0 0 0 7 0 VBN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 VB DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS IN O
neurotrophins neurotrophins 0 0 0 0 0 0 0 0 13 0 NN IN NNS IN PRP$ O
through through 0 0 0 0 0 0 0 0 7 0 IN NNS IN PRP$ NNP O
their their 0 0 0 0 0 0 0 0 5 0 NNS IN PRP$ NNP NNP O
Trk Trk 1 0 0 0 0 0 0 0 3 0 IN PRP$ NNP NNP NNP O
receptors. receptors. 0 0 0 0 0 0 0 0 10 0 PRP$ NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP IN O
BDNF BDNF 1 1 0 0 0 0 0 0 4 0 NN IN NNP IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NN O
cdk1 cdk1 0 0 0 0 0 0 0 1 4 0 NNP IN NNP NN VBZ O
activity activity 0 0 0 0 0 0 0 0 8 0 IN NNP NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ JJ IN O
Tyr15-specific Tyr15-specific 1 0 1 0 0 0 0 1 14 0 NN VBZ JJ IN NNP O
since since 0 0 0 0 0 0 0 0 5 0 VBZ JJ IN NNP RB O
BDNF BDNF 1 1 0 0 0 0 0 0 4 0 JJ IN NNP RB JJ O
cannot cannot 0 0 0 0 0 0 0 0 6 0 IN NNP RB JJ DT O
prevent prevent 0 0 0 0 0 0 0 0 7 0 NNP RB JJ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB JJ DT NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 JJ DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT RB O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT RB JJ O
constitutively constitutively 0 0 0 0 0 0 0 0 14 0 IN DT RB JJ NN O
active active 0 0 0 0 0 0 0 0 6 0 DT RB JJ NN IN O
form form 0 0 0 0 0 0 0 0 4 0 RB JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
cdk1 cdk1 0 0 0 0 0 0 0 1 4 0 NN IN NNP NNP WRB O
(Tyr15Phe) (Tyr15Phe) 0 0 0 0 0 0 0 1 10 0 IN NNP NNP WRB VBN O
when when 0 0 0 0 0 0 0 0 4 0 NNP NNP WRB VBN IN O
expressed expressed 0 0 0 0 0 0 0 0 9 0 NNP WRB VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 WRB VBN IN NN JJ O
differentiating differentiating 0 0 0 0 0 0 0 0 15 0 VBN IN NN JJ NNP O
retinal retinal 0 0 0 0 0 0 0 0 7 0 IN NN JJ NNP NNP O
neurons. neurons. 0 0 0 0 0 0 0 0 8 0 NN JJ NNP NNP RB O
We We 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP RB VBP O
also also 0 0 0 0 0 0 0 0 4 0 NNP NNP RB VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NNP RB VBP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 RB VBP IN JJ NN O
BDNF-dependent BDNF-dependent 1 0 1 0 0 0 0 0 14 0 VBP IN JJ NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 IN JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP IN O
cdk1 cdk1 0 0 0 0 0 0 0 1 4 0 NN IN NNP IN NNP O
at at 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP MD O
Tyr15 Tyr15 1 0 0 0 0 0 0 1 5 0 NNP IN NNP MD RB O
could could 0 0 0 0 0 0 0 0 5 0 IN NNP MD RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NNP MD RB VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 MD RB VB VBN IN O
blocked blocked 0 0 0 0 0 0 0 0 7 0 RB VB VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VB VBN IN JJ DT O
MK-1775, MK-1775, 1 1 1 0 1 0 0 1 8 0 VBN IN JJ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 IN JJ DT JJ NN O
Wee1-selective Wee1-selective 1 0 1 0 0 0 0 1 14 0 JJ DT JJ NN VBG O
inhibitor, inhibitor, 0 0 0 0 1 0 0 0 10 0 DT JJ NN VBG IN O
indicating indicating 0 0 0 0 0 0 0 0 10 0 JJ NN VBG IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NN VBG IN NNP NN O
Tyr15 Tyr15 1 0 0 0 0 0 0 1 5 0 VBG IN NNP NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 IN NNP NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP VBZ O
cdk1 cdk1 0 0 0 0 0 0 0 1 4 0 NN IN NNP VBZ RB O
does does 0 0 0 0 0 0 0 0 4 0 IN NNP VBZ RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NNP VBZ RB VB TO O
seem seem 0 0 0 0 0 0 0 0 4 0 VBZ RB VB TO VB O
to to 0 0 0 0 0 0 0 0 2 0 RB VB TO VB IN O
occur occur 0 0 0 0 0 0 0 0 5 0 VB TO VB IN DT O
through through 0 0 0 0 0 0 0 0 7 0 TO VB IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VB IN DT JJ NN O
canonical canonical 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN VBN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 DT JJ NN VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 JJ NN VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN VBN IN NN NNP O
proliferating proliferating 0 0 0 0 0 0 0 0 13 0 VBN IN NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NN NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBP IN O
conclude conclude 0 0 0 0 0 0 0 0 8 0 NNP NNP VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
both both 0 0 0 0 0 0 0 0 4 0 NN IN DT NN CC O
expression expression 0 0 0 0 0 0 0 0 10 0 IN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NN CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP IN O
cdk1 cdk1 0 0 0 0 0 0 0 1 4 0 NN IN NNP IN DT O
through through 0 0 0 0 0 0 0 0 7 0 IN NNP IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT JJ NN O
BDNF-dependent BDNF-dependent 1 0 1 0 0 0 0 0 14 0 IN DT JJ NN NNS O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 DT JJ NN NNS TO O
contributes contributes 0 0 0 0 0 0 0 0 11 0 JJ NN NNS TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS TO DT NN IN O
maintenance maintenance 0 0 0 0 0 0 0 0 11 0 TO DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
tetraploid tetraploid 0 0 0 0 0 0 0 0 10 0 NN IN JJ NNS IN O
RGCs RGCs 1 0 0 0 0 0 0 0 4 0 IN JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ NNP O
G2-like G2-like 1 0 1 0 0 0 0 1 7 0 IN DT JJ NNP NONE B_TIMEXCCP
state. state. 0 0 0 0 0 0 0 0 6 0 DT JJ NNP NONE NONE O
4-Hydroxynonenal 4-Hydroxynonenal 0 0 1 0 0 0 0 1 16 0 NONE NONE JJ NNS JJ O
Induces Induces 1 0 0 0 0 0 0 0 7 0 NONE JJ NNS JJ NNP O
G2/M G2/M 1 1 0 1 0 0 0 1 4 0 JJ NNS JJ NNP NNP B_TIMEXCCP
Phase Phase 1 0 0 0 0 0 0 0 5 0 NNS JJ NNP NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NNP NNP O
Cycle Cycle 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP IN O
Arrest Arrest 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP IN O
Activation Activation 1 0 0 0 0 0 0 0 10 0 NNP IN NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP NNP O
Ataxia Ataxia 1 0 0 0 0 0 0 0 6 0 IN DT NNP NNP NNP O
Telangiectasia Telangiectasia 1 0 0 0 0 0 0 0 14 0 DT NNP NNP NNP CC O
Mutated Mutated 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NNP O
Rad3-related Rad3-related 1 0 1 0 0 0 0 1 12 0 NNP CC JJ NNP JJ O
Protein Protein 1 0 0 0 0 0 0 0 7 0 CC JJ NNP JJ NNP O
(ATR)/Checkpoint (ATR)/Checkpoint 0 0 0 1 0 0 0 0 16 0 JJ NNP JJ NNP CD O
Kinase Kinase 1 0 0 0 0 0 0 0 6 0 NNP JJ NNP CD NNP O
1 1 0 0 0 0 0 0 1 1 1 0 JJ NNP CD NNP NNP O
(Chk1) (Chk1) 0 0 0 0 0 0 0 1 6 0 NNP CD NNP NNP NNP O
Signaling Signaling 1 0 0 0 0 0 0 0 9 0 CD NNP NNP NNP NNP O
Pathway. Pathway. 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Chaudhary Chaudhary 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sharma Sharma 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sahu Sahu 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Vishwanatha Vishwanatha 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
JK, JK, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Awasthi Awasthi 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Awasthi Awasthi 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
YC. YC. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP DT O
From From 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP DT NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNP IN NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP IN NNP NNP CC O
Biology Biology 1 0 0 0 0 0 0 0 7 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP CC O
Immunology Immunology 1 0 0 0 0 0 0 0 10 0 NNP CC NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP CC NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 CC NNP IN NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNP O
Research, Research, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
North North 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Texas Texas 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
Health Health 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Science Science 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Center, Center, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Fort Fort 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Worth, Worth, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP CD O
Texas Texas 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP CD NNP O
76107 76107 0 0 0 0 0 0 1 1 5 0 NNP NNP CD NNP NNP O
and. and. 0 0 0 0 0 0 0 0 4 0 NNP CD NNP NNP JJ O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP JJ NN O
4-Hydroxynonenal 4-Hydroxynonenal 0 0 1 0 0 0 0 1 16 0 NNP NNP JJ NN VBZ O
(HNE) (HNE) 0 1 0 0 0 0 0 0 5 0 NNP JJ NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 JJ NN VBZ VBN RB O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN RB VBN O
widely widely 0 0 0 0 0 0 0 0 6 0 VBZ VBN RB VBN IN O
implicated implicated 0 0 0 0 0 0 0 0 10 0 VBN RB VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNS IN O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 IN DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NN O
oxidant-induced oxidant-induced 0 0 1 0 0 0 0 0 15 0 NNS IN JJ NN CC O
toxicity, toxicity, 0 0 0 0 1 0 0 0 9 0 IN JJ NN CC DT O
but but 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT JJ NNS O
detrimental detrimental 0 0 0 0 0 0 0 0 11 0 CC DT JJ NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 DT JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP VBD O
HNE HNE 1 1 0 0 0 0 0 0 3 0 NNS IN NNP VBD IN O
associated associated 0 0 0 0 0 0 0 0 10 0 IN NNP VBD IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNP VBD IN NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 VBD IN NNP NN CC O
damage damage 0 0 0 0 0 0 0 0 6 0 IN NNP NN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 NNP NN CC NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN CC NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest CC NN NN NN VBP O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN VBP RB O
have have 0 0 0 0 0 0 0 0 4 0 NN NN VBP RB VBN O
not not 0 0 0 0 0 0 0 0 3 0 NN VBP RB VBN RB O
been been 0 0 0 0 0 0 0 0 4 0 VBP RB VBN RB NNP O
thoroughly thoroughly 0 0 0 0 0 0 0 0 10 0 RB VBN RB NNP NNP O
studied. studied. 0 0 0 0 0 0 0 0 8 0 VBN RB NNP NNP PRP O
Here Here 1 0 0 0 0 0 0 0 4 0 RB NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP IN O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 NNP PRP VBP IN DT O
for for 0 0 0 0 0 0 0 0 3 0 PRP VBP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN WDT O
time time 0 0 0 0 0 0 0 0 4 0 DT JJ NN WDT NNP O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT NNP VBD O
HNE HNE 1 1 0 0 0 0 0 0 3 0 NN WDT NNP VBD JJ O
caused caused 0 0 0 0 0 0 0 0 6 0 WDT NNP VBD JJ NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 0 NNP VBD JJ NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 VBD JJ NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest JJ NN NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
hepatocellular hepatocellular 0 0 0 0 0 0 0 0 14 0 NN IN JJ NN NNP O
carcinoma carcinoma 0 0 0 0 0 0 0 0 9 0 IN JJ NN NNP NNP O
HepG2 HepG2 1 0 0 0 0 0 0 1 5 0 JJ NN NNP NNP VBD O
(p53 (p53 0 0 0 0 0 0 0 1 4 0 NN NNP NNP VBD NNP O
wild wild 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD NNP CC O
type) type) 0 0 0 0 0 0 0 0 5 0 NNP VBD NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VBD NNP CC NNP NNP O
Hep3B Hep3B 1 0 0 0 0 0 0 1 5 0 NNP CC NNP NNP NNP O
(p53 (p53 0 0 0 0 0 0 0 1 4 0 CC NNP NNP NNP VBZ O
null) null) 0 0 0 0 0 0 0 0 5 0 NNP NNP NNP VBZ IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ IN VBD O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBZ IN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 VBZ IN VBD VBN IN O
accompanied accompanied 0 0 0 0 0 0 0 0 11 0 IN VBD VBN IN VBN O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN VBN NN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 VBN IN VBN NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 IN VBN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNP CC O
CDK1 CDK1 1 1 0 0 0 0 0 1 4 0 NN IN NNP CC VB O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC VB NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NNP CC VB NNP CC O
B1 B1 1 1 0 0 0 0 0 1 2 0 CC VB NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VB NNP CC NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 NNP CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP IN O
p21 p21 0 0 0 0 0 0 0 1 3 0 NN IN NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT JJ NNP O
p53-independent p53-independent 0 0 1 0 0 0 0 1 15 0 IN DT JJ NNP NNP O
manner. manner. 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NNP NN O
HNE HNE 1 1 0 0 0 0 0 0 3 0 JJ NNP NNP NN VBD O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBD DT O
suppressed suppressed 0 0 0 0 0 0 0 0 10 0 NNP NN VBD DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN VBD DT NNP NNP O
Cdc25C Cdc25C 1 0 0 0 0 0 0 1 6 0 VBD DT NNP NNP WDT O
level, level, 0 0 0 0 1 0 0 0 6 0 DT NNP NNP WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 NNP NNP WDT VBD TO O
led led 0 0 0 0 0 0 0 0 3 0 NNP WDT VBD TO NN O
to to 0 0 0 0 0 0 0 0 2 0 WDT VBD TO NN IN O
inactivation inactivation 0 0 0 0 0 0 0 0 12 0 VBD TO NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 TO NN IN NNP JJ O
CDK1. CDK1. 1 1 0 0 0 0 0 1 5 0 NN IN NNP JJ NN O
HNE-induced HNE-induced 1 0 1 0 0 0 0 0 11 0 IN NNP JJ NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 NNP JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP IN O
Cdc25C Cdc25C 1 0 0 0 0 0 0 1 6 0 NN IN NNP IN NNP O
at at 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP VBD O
Ser-216 Ser-216 1 0 1 0 0 0 0 1 7 0 NNP IN NNP VBD IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 IN NNP VBD IN PRP$ O
in in 0 0 0 0 0 0 0 0 2 0 NNP VBD IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 VBD IN PRP$ NN IN O
translocation translocation 0 0 0 0 0 0 0 0 13 0 IN PRP$ NN IN NN O
from from 0 0 0 0 0 0 0 0 4 0 PRP$ NN IN NN TO O
nucleus nucleus 0 0 0 0 0 0 0 0 7 0 NN IN NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO NNP NN O
cytoplasm, cytoplasm, 0 0 0 0 1 0 0 0 10 0 NN TO NNP NN VBG O
thereby thereby 0 0 0 0 0 0 0 0 7 0 TO NNP NN VBG PRP$ O
facilitating facilitating 0 0 0 0 0 0 0 0 12 0 NNP NN VBG PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NN VBG PRP$ NN IN O
degradation degradation 0 0 0 0 0 0 0 0 11 0 VBG PRP$ NN IN DT O
via via 0 0 0 0 0 0 0 0 3 0 PRP$ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ JJ O
ubiquitin-mediated ubiquitin-mediated 0 0 1 0 0 0 0 0 18 0 IN DT JJ JJ NNP O
proteasomal proteasomal 0 0 0 0 0 0 0 0 11 0 DT JJ JJ NNP NNP O
pathway. pathway. 0 0 0 0 0 0 0 0 8 0 JJ JJ NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP VBD O
Cdc25C Cdc25C 1 0 0 0 0 0 0 1 6 0 NN IN NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 IN NNP VBD VBN IN O
regulated regulated 0 0 0 0 0 0 0 0 9 0 NNP VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 VBN IN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
ataxia ataxia 0 0 0 0 0 0 0 0 6 0 IN DT NN NN CC O
telangiectasia telangiectasia 0 0 0 0 0 0 0 0 14 0 DT NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
Rad3-related Rad3-related 1 0 1 0 0 0 0 1 12 0 NN CC JJ NN JJ O
protein protein 0 0 0 0 0 0 0 0 7 0 CC JJ NN JJ NN O
(ATR)/checkpoint (ATR)/checkpoint 0 0 0 1 0 0 0 0 16 0 JJ NN JJ NN CD I_TIMEXCCP
kinase kinase 0 0 0 0 0 0 0 0 6 0 NN JJ NN CD NN O
1 1 0 0 0 0 0 0 1 1 1 0 JJ NN CD NN NNP O
(Chk1) (Chk1) 0 0 0 0 0 0 0 1 6 0 NN CD NN NNP NNP O
pathway. pathway. 0 0 0 0 0 0 0 0 8 0 CD NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
role role 0 0 0 0 0 0 0 0 4 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP IN O
HNE HNE 1 1 0 0 0 0 0 0 3 0 NN IN NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP JJ O
DNA DNA 1 1 0 0 0 0 0 0 3 0 IN DT NNP JJ NN O
double double 0 0 0 0 0 0 0 0 6 0 DT NNP JJ NN NN O
strand strand 0 0 0 0 0 0 0 0 6 0 NNP JJ NN NN VBD O
break break 0 0 0 0 0 0 0 0 5 0 JJ NN NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD RB VBN O
strongly strongly 0 0 0 0 0 0 0 0 8 0 NN VBD RB VBN IN O
suggested suggested 0 0 0 0 0 0 0 0 9 0 VBD RB VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 RB VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NN O
remarkable remarkable 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
comet comet 0 0 0 0 0 0 0 0 5 0 NN IN NN NN NN O
tail tail 0 0 0 0 0 0 0 0 4 0 IN NN NN NN CC O
formation formation 0 0 0 0 0 0 0 0 9 0 NN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
H2A.X H2A.X 1 1 0 0 0 0 0 1 5 0 NN CC JJ NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 CC JJ NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNS O
HNE-treated HNE-treated 1 0 1 0 0 0 0 0 11 0 NN IN JJ NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP DT O
vitro. vitro. 0 0 0 0 0 0 0 0 6 0 NNS IN NNP DT VBD O
This This 1 0 0 0 0 0 0 0 4 0 IN NNP DT VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP DT VBD VBN IN O
supported supported 0 0 0 0 0 0 0 0 9 0 DT VBD VBN IN VBN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN VBN IN O
increased increased 0 0 0 0 0 0 0 0 9 0 VBN IN VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN VBN IN NN NN O
vivo vivo 0 0 0 0 0 0 0 0 4 0 VBN IN NN NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 IN NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ IN O
H2A.X H2A.X 1 1 0 0 0 0 0 1 5 0 NN IN JJ IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN JJ IN NNP NN O
mGsta4 mGsta4 0 0 0 0 0 0 0 1 6 0 JJ IN NNP NN NN O
null null 0 0 0 0 0 0 0 0 4 0 IN NNP NN NN WDT O
mice mice 0 0 0 0 0 0 0 0 4 0 NNP NN NN WDT VBP O
that that 0 0 0 0 0 0 0 0 4 0 NN NN WDT VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NN WDT VBP VBN NNP O
impaired impaired 0 0 0 0 0 0 0 0 8 0 WDT VBP VBN NNP NN O
HNE HNE 1 1 0 0 0 0 0 0 3 0 VBP VBN NNP NN CC O
metabolism metabolism 0 0 0 0 0 0 0 0 10 0 VBN NNP NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC VBD NNP O
increased increased 0 0 0 0 0 0 0 0 9 0 NN CC VBD NNP NNS O
HNE HNE 1 1 0 0 0 0 0 0 3 0 CC VBD NNP NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 VBD NNP NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NNP JJ O
tissues. tissues. 0 0 0 0 0 0 0 0 8 0 NNS IN NNP JJ -NONE- O
HNE-mediated HNE-mediated 1 0 1 0 0 0 0 0 12 0 IN NNP JJ -NONE- VBG O
ATR/Chk1 ATR/Chk1 1 0 0 1 0 0 0 1 8 0 NNP JJ -NONE- VBG VBD O
signaling signaling 0 0 0 0 0 0 0 0 9 0 JJ -NONE- VBG VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 -NONE- VBG VBD VBN IN O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 VBG VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NN O
ATR ATR 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NN NN O
kinase kinase 0 0 0 0 0 0 0 0 6 0 IN NNP NN NN NNP O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 NNP NN NN NNP NNP O
(caffeine). (caffeine). 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP RBS O
Additionally, Additionally, 1 0 0 0 1 0 0 0 13 0 NN NNP NNP RBS IN O
most most 0 0 0 0 0 0 0 0 4 0 NNP NNP RBS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP RBS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RBS IN DT NN NNS O
signaling signaling 0 0 0 0 0 0 0 0 9 0 IN DT NN NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 DT NN NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP IN O
HNE HNE 1 1 0 0 0 0 0 0 3 0 NNS IN NNP IN NN O
on on 0 0 0 0 0 0 0 0 2 0 IN NNP IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP IN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest IN NN NN NN VBD O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN IN O
attenuated attenuated 0 0 0 0 0 0 0 0 10 0 NN VBD VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP VBD O
hGSTA4 hGSTA4 0 0 0 0 0 0 0 1 6 0 VBN IN NNP VBD NNP O
transfected transfected 0 0 0 0 0 0 0 0 11 0 IN NNP VBD NNP NN O
cells, cells, 0 0 0 0 1 0 0 0 6 0 NNP VBD NNP NN VBG O
thereby thereby 0 0 0 0 0 0 0 0 7 0 VBD NNP NN VBG DT O
indicating indicating 0 0 0 0 0 0 0 0 10 0 NNP NN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT NN IN O
involvement involvement 0 0 0 0 0 0 0 0 11 0 VBG DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
HNE HNE 1 1 0 0 0 0 0 0 3 0 NN IN NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT NNP O
these these 0 0 0 0 0 0 0 0 5 0 NNP IN DT NNP DT O
events. events. 0 0 0 0 0 0 0 0 7 0 IN DT NNP DT NN O
A A 1 1 0 0 0 0 0 0 1 0 DT NNP DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 NNP DT NN NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT NN NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN -NONE- IN O
GSTA4-4 GSTA4-4 1 1 1 0 0 0 0 1 7 0 NN IN -NONE- IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN -NONE- IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- IN DT NN IN O
maintenance maintenance 0 0 0 0 0 0 0 0 11 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
genomic genomic 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN VBZ O
integrity integrity 0 0 0 0 0 0 0 0 9 0 IN JJ NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ RB NNP O
also also 0 0 0 0 0 0 0 0 4 0 NN VBZ RB NNP NONE O
suggested. suggested. 0 0 0 0 0 0 0 0 10 0 VBZ RB NNP NONE NONE O
Rephrasing Rephrasing 1 0 0 0 0 0 0 0 10 0 NONE NONE VBG NN NN O
anaphase: anaphase: 0 0 0 0 0 0 0 0 9 0 NONE VBG NN NN NNS B_TIMEXCCP
separase separase 0 0 0 0 0 0 0 0 8 0 VBG NN NN NNS NNP O
FEARs FEARs 1 0 0 0 0 0 0 0 5 0 NN NN NNS NNP NNP O
shugoshin. shugoshin. 0 0 0 0 0 0 0 0 10 0 NN NNS NNP NNP NNP O
Stemmann Stemmann 1 0 0 0 0 0 0 0 8 0 NNS NNP NNP NNP NNP O
O, O, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Boos Boos 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Gorr Gorr 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
IH. IH. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP IN NNP NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Max Max 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Planck Planck 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biochemistry, Biochemistry, 1 0 0 0 1 0 0 0 13 0 NNP IN NNP NNP NNP O
Am Am 1 0 0 0 0 0 0 0 2 0 IN NNP NNP NNP CD O
Klopferspitz Klopferspitz 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP CD CD O
18, 18, 0 0 0 0 1 0 0 1 3 0 NNP NNP CD CD JJ O
82152, 82152, 0 0 0 0 1 0 0 1 6 0 NNP CD CD JJ NNP O
Martinsried, Martinsried, 1 0 0 0 1 0 0 0 12 0 CD CD JJ NNP NNP O
Germany. Germany. 1 0 0 0 0 0 0 0 8 0 CD JJ NNP NNP NNP O
stemmann@biochem.mpg.de stemmann@biochem.mpg.de 0 0 0 0 0 0 0 0 23 0 JJ NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Cleavage Cleavage 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ NN O
ring-like ring-like 0 0 1 0 0 0 0 0 9 0 IN DT JJ NN NN O
cohesin cohesin 0 0 0 0 0 0 0 0 7 0 DT JJ NN NN IN O
complex complex 0 0 0 0 0 0 0 0 7 0 JJ NN NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NNS O
separase separase 0 0 0 0 0 0 0 0 8 0 NN IN NN NNS NN O
triggers triggers 0 0 0 0 0 0 0 0 8 0 IN NN NNS NN IN O
segregation segregation 0 0 0 0 0 0 0 0 11 0 NN NNS NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNS NN IN NN NNS O
sister sister 0 0 0 0 0 0 0 0 6 0 NN IN NN NNS IN O
chromatids chromatids 0 0 0 0 0 0 0 0 10 0 IN NN NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP DT O
anaphase. anaphase. 0 0 0 0 0 0 0 0 9 0 NNS IN NNP DT JJ B_TIMEXCCP
This This 1 0 0 0 0 0 0 0 4 0 IN NNP DT JJ NN O
simplistic simplistic 0 0 0 0 0 0 0 0 10 0 NNP DT JJ NN VBZ O
model model 0 0 0 0 0 0 0 0 5 0 DT JJ NN VBZ RB O
has has 0 0 0 0 0 0 0 0 3 0 JJ NN VBZ RB VBN O
recently recently 0 0 0 0 0 0 0 0 8 0 NN VBZ RB VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 VBZ RB VBN VBN IN O
extended extended 0 0 0 0 0 0 0 0 8 0 RB VBN VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBN VBN IN JJ NNS O
exciting exciting 0 0 0 0 0 0 0 0 8 0 VBN IN JJ NNS IN O
discoveries discoveries 0 0 0 0 0 0 0 0 11 0 IN JJ NNS IN CD O
on on 0 0 0 0 0 0 0 0 2 0 JJ NNS IN CD JJ O
three three 0 0 0 0 0 0 0 0 5 0 NNS IN CD JJ NN O
levels: levels: 0 0 0 0 0 0 0 0 7 0 IN CD JJ NN IN O
regulation regulation 0 0 0 0 0 0 0 0 10 0 CD JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 NN IN NN IN JJ B_TIMEXCCP
by by 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NNS O
posttranslational posttranslational 0 0 0 0 0 0 0 0 17 0 NN IN JJ NNS CC O
modifications modifications 0 0 0 0 0 0 0 0 13 0 IN JJ NNS CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS CC DT NN NN O
cohesin cohesin 0 0 0 0 0 0 0 0 7 0 CC DT NN NN NN O
protector protector 0 0 0 0 0 0 0 0 9 0 DT NN NN NN JJ O
shugoshin; shugoshin; 0 0 0 0 0 0 0 0 10 0 NN NN NN JJ NNS O
non-proteolytic non-proteolytic 0 0 1 0 0 0 0 0 15 0 NN NN JJ NNS IN O
roles roles 0 0 0 0 0 0 0 0 5 0 NN JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ CC O
separase; separase; 0 0 0 0 0 0 0 0 9 0 NNS IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NN O
cohesin-independent cohesin-independent 0 0 1 0 0 0 0 0 19 0 JJ CC JJ NN IN O
linkage linkage 0 0 0 0 0 0 0 0 7 0 CC JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNP O
sister sister 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP NNP O
chromatids. chromatids. 0 0 0 0 0 0 0 0 11 0 IN NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
15703941 15703941 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NN NNP O
pachytene pachytene 0 0 0 0 0 0 0 0 9 0 NONE DT NN NNP NNP O
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 DT NN NNP NNP NNP B_TIMEXCCP
Roeder Roeder 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP NNP O
GS, GS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Bailis Bailis 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
JM. JM. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Howard Howard 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Hughes Hughes 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Institute, Institute, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Yale Yale 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
PO PO 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP CD O
Box Box 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP CD NNP O
208103, 208103, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP NNP O
New New 1 0 0 0 0 0 0 0 3 0 NNP CD NNP NNP NNP O
Haven, Haven, 1 0 0 0 1 0 0 0 6 0 CD NNP NNP NNP CD O
CT CT 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
06520-8103, 06520-8103, 0 0 1 0 1 0 0 1 11 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
shirleen.roeder@yale.edu shirleen.roeder@yale.edu 0 0 0 0 0 0 0 0 24 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN NN O
pachytene pachytene 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NN NNS O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NNP NN NN NNS JJ B_TIMEXCCP
prevents prevents 0 0 0 0 0 0 0 0 8 0 NN NN NNS JJ JJ O
meiotic meiotic 0 0 0 0 0 0 0 0 7 0 NN NNS JJ JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 NNS JJ JJ NN IN O
division division 0 0 0 0 0 0 0 0 8 0 JJ JJ NN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS WDT O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 IN NNS WDT NN TO O
fail fail 0 0 0 0 0 0 0 0 4 0 NNS WDT NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 WDT NN TO VB JJ O
complete complete 0 0 0 0 0 0 0 0 8 0 NN TO VB JJ NN O
meiotic meiotic 0 0 0 0 0 0 0 0 7 0 TO VB JJ NN CC O
recombination recombination 0 0 0 0 0 0 0 0 13 0 VB JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NNP O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NN CC NN NNP NNP O
synapsis. synapsis. 0 0 0 0 0 0 0 0 9 0 CC NN NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NN NN O
control control 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN NNS O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 NNP NN NN NNS VBP O
prevents prevents 0 0 0 0 0 0 0 0 8 0 NN NN NNS VBP NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NN NNS VBP NN IN O
missegregation missegregation 0 0 0 0 0 0 0 0 14 0 NNS VBP NN IN MD O
that that 0 0 0 0 0 0 0 0 4 0 VBP NN IN MD VB O
would would 0 0 0 0 0 0 0 0 5 0 NN IN MD VB TO O
lead lead 0 0 0 0 0 0 0 0 4 0 IN MD VB TO DT O
to to 0 0 0 0 0 0 0 0 2 0 MD VB TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VB TO DT NN IN O
production production 0 0 0 0 0 0 0 0 10 0 TO DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
aneuploid aneuploid 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNP NNP O
gametes. gametes. 0 0 0 0 0 0 0 0 8 0 IN JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN NN O
pachytene pachytene 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NN VBZ O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NNP NN NN VBZ DT B_TIMEXCCP
requires requires 0 0 0 0 0 0 0 0 8 0 NN NN VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT NN IN O
subset subset 0 0 0 0 0 0 0 0 6 0 VBZ DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS WDT O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NN IN NNS WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 IN NNS WDT NN IN O
function function 0 0 0 0 0 0 0 0 8 0 NNS WDT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 WDT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 DT JJ NNP NN NNP O
damage damage 0 0 0 0 0 0 0 0 6 0 JJ NNP NN NNP NNP O
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 NNP NN NNP NNP NN B_TIMEXCCP
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NN NN O
budding budding 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN DT O
yeast, yeast, 0 0 0 0 1 0 0 0 6 0 NNP NN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NN NN O
pachytene pachytene 0 0 0 0 0 0 0 0 9 0 NN DT NN NN RB O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 DT NN NN RB VBZ B_TIMEXCCP
also also 0 0 0 0 0 0 0 0 4 0 NN NN RB VBZ JJ O
requires requires 0 0 0 0 0 0 0 0 8 0 NN RB VBZ JJ JJ O
meiosis-specific meiosis-specific 0 0 1 0 0 0 0 0 16 0 RB VBZ JJ JJ NNS O
chromosomal chromosomal 0 0 0 0 0 0 0 0 11 0 VBZ JJ JJ NNS -NONE- O
proteins proteins 0 0 0 0 0 0 0 0 8 0 JJ JJ NNS -NONE- -NONE- O
and, and, 0 0 0 0 1 0 0 0 4 0 JJ NNS -NONE- -NONE- VBZ O
unexpectedly, unexpectedly, 0 0 0 0 1 0 0 0 13 0 NNS -NONE- -NONE- VBZ VBN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 -NONE- -NONE- VBZ VBN IN O
concentrated concentrated 0 0 0 0 0 0 0 0 12 0 -NONE- VBZ VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NNP O
nucleolus. nucleolus. 0 0 0 0 0 0 0 0 10 0 IN DT NNP NNP VBZ O
Progress Progress 1 0 0 0 0 0 0 0 8 0 DT NNP NNP VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP NNP VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBN VBN IN O
made made 0 0 0 0 0 0 0 0 4 0 VBZ VBN VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN NN NNS O
identifying identifying 0 0 0 0 0 0 0 0 11 0 VBN IN NN NNS IN O
components components 0 0 0 0 0 0 0 0 10 0 IN NN NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 0 IN DT JJ NN WDT O
machinery machinery 0 0 0 0 0 0 0 0 9 0 DT JJ NN WDT VBP O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NN WDT VBP VBN IN O
impacted impacted 0 0 0 0 0 0 0 0 8 0 WDT VBP VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBP VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NNP O
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 IN DT NNP NNP CD B_TIMEXCCP
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 DT NNP NNP CD JJ O
10973068 10973068 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
On On 1 0 0 0 0 0 0 0 2 0 NONE NONE IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NONE IN DT NN IN O
proposal proposal 0 0 0 0 0 0 0 0 8 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NNP NN O
G0 G0 1 1 0 0 0 0 0 1 2 phase IN DT NNP NN CC B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NNP NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN NNP O
restriction restriction 0 0 0 0 0 0 0 0 11 0 CC DT NN NNP NNP O
point. point. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP NNP O
Cooper Cooper 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP NNP O
S. S. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Microbiology Microbiology 1 0 0 0 0 0 0 0 12 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Immunology, Immunology, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Michigan Michigan 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
School, School, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Ann Ann 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP CD O
Arbor Arbor 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP CD NNP O
49109-0620, 49109-0620, 0 0 1 0 1 0 0 1 11 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
cooper@umich.edu cooper@umich.edu 0 0 0 0 0 0 0 0 16 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP CC O
Zetterberg Zetterberg 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP VBD O
Larsson Larsson 1 0 0 0 0 0 0 0 7 0 NNP CC NNP VBD IN O
proposed proposed 0 0 0 0 0 0 0 0 8 0 CC NNP VBD IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN NN O
restriction restriction 0 0 0 0 0 0 0 0 11 0 IN DT NN NN VBZ O
point point 0 0 0 0 0 0 0 0 5 0 DT NN NN VBZ DT O
divides divides 0 0 0 0 0 0 0 0 7 0 NN NN VBZ DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 phase VBZ DT NNP NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NNP NN IN CD O
into into 0 0 0 0 0 0 0 0 4 0 NNP NN IN CD NNP O
two two 0 0 0 0 0 0 0 0 3 0 NN IN CD NNP NNP O
parts. parts. 0 0 0 0 0 0 0 0 6 0 IN CD NNP NNP IN O
Cells Cells 1 0 0 0 0 0 0 0 5 0 CD NNP NNP IN DT O
before before 0 0 0 0 0 0 0 0 6 0 NNP NNP IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP IN DT NN VBP O
point point 0 0 0 0 0 0 0 0 5 0 IN DT NN VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 DT NN VBP JJ TO O
able able 0 0 0 0 0 0 0 0 4 0 NN VBP JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBP JJ TO VB DT O
leave leave 0 0 0 0 0 0 0 0 5 0 JJ TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN NN O
division division 0 0 0 0 0 0 0 0 8 0 VB DT NN NN CC O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 enter NN NN CC NN DT O
enter enter 0 0 0 0 0 0 0 0 5 0 NN CC NN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 CC NN DT NNP NNP O
G0 G0 1 1 0 0 0 0 0 1 2 0 NN DT NNP NNP VBZ B_TIMEXCCP
phase; phase; 0 0 0 0 0 0 0 0 6 0 DT NNP NNP VBZ JJ O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ JJ DT O
past past 0 0 0 0 0 0 0 0 4 0 NNP VBZ JJ DT NN O
this this 0 0 0 0 0 0 0 0 4 0 VBZ JJ DT NN VBP O
point point 0 0 0 0 0 0 0 0 5 0 JJ DT NN VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 DT NN VBP VBN IN O
unaffected unaffected 0 0 0 0 0 0 0 0 10 0 NN VBP VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBP VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NN O
short short 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN IN O
period period 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNP O
low low 0 0 0 0 0 0 0 0 3 0 NN IN JJ NNP NNP O
serum. serum. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP NNS O
Additional Additional 1 0 0 0 0 0 0 0 10 0 JJ NNP NNP NNS IN O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NNP CC O
Zetterberg Zetterberg 1 0 0 0 0 0 0 0 10 0 NNS IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NN O
Larsson--1) Larsson--1) 1 0 1 0 0 0 0 1 11 0 NNP CC NNP NN NN O
cycloheximide cycloheximide 0 0 0 0 0 0 0 0 13 0 CC NNP NN NN NNS O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NNP NN NN NNS NNS O
affects affects 0 0 0 0 0 0 0 0 7 0 NN NN NNS NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NNS NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNS NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
same same 0 0 0 0 0 0 0 0 4 0 IN DT JJ NN IN O
way way 0 0 0 0 0 0 0 0 3 0 DT JJ NN IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
low low 0 0 0 0 0 0 0 0 3 0 NN IN JJ NN CC O
serum, serum, 0 0 0 0 1 0 0 0 6 0 IN JJ NN CC CD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC CD DT O
2) 2) 0 0 0 0 0 0 0 1 2 0 NN CC CD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 CC CD DT NN IN O
delay delay 0 0 0 0 0 0 0 0 5 0 CD DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
second second 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN IN O
division division 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NN O
after after 0 0 0 0 0 0 0 0 5 0 JJ NN IN NN NN O
serum serum 0 0 0 0 0 0 0 0 5 0 NN IN NN NN IN O
starvation starvation 0 0 0 0 0 0 0 0 10 0 IN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS RB O
cells cells 0 0 0 0 0 0 0 0 5 0 IN DT NNS RB RB O
not not 0 0 0 0 0 0 0 0 3 0 DT NNS RB RB VBN O
initially initially 0 0 0 0 0 0 0 0 9 0 NNS RB RB VBN IN O
affected affected 0 0 0 0 0 0 0 0 8 0 RB RB VBN IN PRP$ O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN PRP$ JJ O
their their 0 0 0 0 0 0 0 0 5 0 VBN IN PRP$ JJ JJ O
first first 0 0 0 0 0 0 0 0 5 0 IN PRP$ JJ JJ IN O
division--indicate division--indicate 0 0 1 0 0 0 0 0 18 0 PRP$ JJ JJ IN PRP$ O
that that 0 0 0 0 0 0 0 0 4 0 JJ JJ IN PRP$ NNS O
their their 0 0 0 0 0 0 0 0 5 0 JJ IN PRP$ NNS VBP O
experiments experiments 0 0 0 0 0 0 0 0 11 0 IN PRP$ NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 PRP$ NNS VBP JJ IN O
consistent consistent 0 0 0 0 0 0 0 0 10 0 NNS VBP JJ IN NN O
with with 0 0 0 0 0 0 0 0 4 0 VBP JJ IN NN NN O
serum serum 0 0 0 0 0 0 0 0 5 0 JJ IN NN NN VBG O
removal removal 0 0 0 0 0 0 0 0 7 0 IN NN NN VBG NNS O
affecting affecting 0 0 0 0 0 0 0 0 9 0 NN NN VBG NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN VBG NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBG NNS IN DT NNS O
all all 0 0 0 0 0 0 0 0 3 phases NNS IN DT NNS IN O
phases phases 0 0 0 0 0 0 0 0 6 0 IN DT NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN NNP O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN NNP NNP O
equally. equally. 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP NNS O
Their Their 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNS VBP O
experiments experiments 0 0 0 0 0 0 0 0 11 0 NNP NNP NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNS VBP JJ IN O
consistent consistent 0 0 0 0 0 0 0 0 10 0 NNS VBP JJ IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBP JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN NN O
continuum continuum 0 0 0 0 0 0 0 0 9 0 IN DT NN NN IN O
model model 0 0 0 0 0 0 0 0 5 0 DT NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN NNP O
division division 0 0 0 0 0 0 0 0 8 0 DT JJ NN NNP NNP O
cycle. cycle. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP VBZ O
There There 1 0 0 0 0 0 0 0 5 0 NN NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT NN O
no no 0 0 0 0 0 0 0 0 2 0 NNP VBZ DT NN TO O
need need 0 0 0 0 0 0 0 0 4 0 VBZ DT NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO VB DT O
postulate postulate 0 0 0 0 0 0 0 0 9 0 NN TO VB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT NN NN O
restriction restriction 0 0 0 0 0 0 0 0 11 0 VB DT NN NN CC O
point point 0 0 0 0 0 0 0 0 5 0 DT NN NN CC DT O
or or 0 0 0 0 0 0 0 0 2 0 NN NN CC DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NN CC DT NNP NN O
G0 G0 1 1 0 0 0 0 0 1 2 phase CC DT NNP NN TO B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NNP NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO VB DT O
explain explain 0 0 0 0 0 0 0 0 7 0 NN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN NN O
serum serum 0 0 0 0 0 0 0 0 5 0 VB DT NN NN NNP O
starvation starvation 0 0 0 0 0 0 0 0 10 0 DT NN NN NNP NNP O
results. results. 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
9506481 9506481 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NONE NONE JJ NN IN O
cloning cloning 0 0 0 0 0 0 0 0 7 0 NONE JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 phase NN IN NNP NN NNP B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN NNP NN NNP IN O
mRNAs mRNAs 0 0 0 0 0 0 0 0 5 0 NNP NN NNP IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NN NNP IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT JJ NNP O
subtractive subtractive 0 0 0 0 0 0 0 0 11 0 IN DT JJ NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 phase DT JJ NNP NN NNP B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 JJ NNP NN NNP NNP O
cDNA cDNA 0 0 0 0 0 0 0 0 4 0 NNP NN NNP NNP NNP O
library. library. 0 0 0 0 0 0 0 0 8 0 NN NNP NNP NNP NNP O
Wu Wu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Su Su 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kung Kung 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
TY, TY, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Bird Bird 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
RC. RC. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pathobiology, Pathobiology, 1 0 0 0 1 0 0 0 13 0 NNP IN NNP NNP NNP O
Auburn Auburn 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
AL AL 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
36849-5519. 36849-5519. 0 0 1 0 0 0 0 1 11 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Many Many 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
G1-phase-specific G1-phase-specific 1 0 1 0 0 0 0 1 17 0 NNP NNP NNP NNP VBP B_TIMEXCCP
mRNAs mRNAs 0 0 0 0 0 0 0 0 5 0 NNP NNP NNP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNP VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNP VBP VBN VBN IN O
identified identified 0 0 0 0 0 0 0 0 10 0 VBP VBN VBN IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 VBN VBN IN JJ JJ O
various various 0 0 0 0 0 0 0 0 7 0 VBN IN JJ JJ CC O
normal normal 0 0 0 0 0 0 0 0 6 0 IN JJ JJ CC VBN O
or or 0 0 0 0 0 0 0 0 2 0 JJ JJ CC VBN NNS O
transformed transformed 0 0 0 0 0 0 0 0 11 0 JJ CC VBN NNS VBN O
cells cells 0 0 0 0 0 0 0 0 5 0 CC VBN NNS VBN IN O
based based 0 0 0 0 0 0 0 0 5 0 VBN NNS VBN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NNS VBN IN NN NN O
serum serum 0 0 0 0 0 0 0 0 5 0 VBN IN NN NN CC O
induction induction 0 0 0 0 0 0 0 0 9 0 IN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ IN O
re-entry re-entry 0 0 1 0 0 0 0 0 8 0 NN CC JJ IN DT O
into into 0 0 0 0 0 0 0 0 4 0 CC JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN IN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN NNP NNP O
quiescence. quiescence. 0 0 0 0 0 0 0 0 11 0 NN IN NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP DT NNP O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT NNP MD O
mRNAs mRNAs 0 0 0 0 0 0 0 0 5 0 NNP DT NNP MD RB O
may may 0 0 0 0 0 0 0 0 3 0 DT NNP MD RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NNP MD RB VB DT O
represent represent 0 0 0 0 0 0 0 0 9 0 MD RB VB DT JJ O
some some 0 0 0 0 0 0 0 0 4 0 RB VB DT JJ NNS O
important important 0 0 0 0 0 0 0 0 9 0 VB DT JJ NNS VBN O
genes genes 0 0 0 0 0 0 0 0 5 0 DT JJ NNS VBN IN O
expressed expressed 0 0 0 0 0 0 0 0 9 0 JJ NNS VBN IN NNP O
during during 0 0 0 0 0 0 0 0 6 0 NNS VBN IN NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 phase VBN IN NNP NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN NNP NN IN RB O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN RB VBG O
continuously continuously 0 0 0 0 0 0 0 0 12 0 NN IN RB VBG NNP O
cycling cycling 0 0 0 0 0 0 0 0 7 0 IN RB VBG NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 RB VBG NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 VBG NNP NNP JJ NN O
eukaryotic eukaryotic 0 0 0 0 0 0 0 0 10 0 NNP NNP JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP JJ NN NN NNS O
cycle cycle 0 0 0 0 0 0 0 0 5 0 JJ NN NN NNS CD O
possesses possesses 0 0 0 0 0 0 0 0 9 0 NN NN NNS CD NN O
two two 0 0 0 0 0 0 0 0 3 0 NN NNS CD NN JJ O
cdk cdk 0 0 0 0 0 0 0 0 3 0 NNS CD NN JJ NN O
(cyclin-dependent (cyclin-dependent 0 0 1 0 0 0 0 0 17 0 CD NN JJ NN NN O
kinase) kinase) 0 0 0 0 0 0 0 0 7 0 NN JJ NN NN NN O
dependent dependent 0 0 0 0 0 0 0 0 9 0 JJ NN NN NN VBZ O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 NN NN NN VBZ IN O
gates gates 0 0 0 0 0 0 0 0 5 0 NN NN VBZ IN WDT O
through through 0 0 0 0 0 0 0 0 7 0 NN VBZ IN WDT NNS O
which which 0 0 0 0 0 0 0 0 5 0 VBZ IN WDT NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 IN WDT NNS VBP IN O
pass pass 0 0 0 0 0 0 0 0 4 0 WDT NNS VBP IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 NNS VBP IN JJ NNP O
late late 0 0 0 0 0 0 0 0 4 0 VBP IN JJ NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 phase IN JJ NNP NN CC B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 JJ NNP NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NNP NN O
G2 G2 1 1 0 0 0 0 0 1 2 phase NN CC NNP NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 CC NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NNP O
each each 0 0 0 0 0 0 0 0 4 0 NN IN DT NNP NNP O
cycle. cycle. 0 0 0 0 0 0 0 0 6 0 IN DT NNP NNP NN O
Subtractive Subtractive 1 0 0 0 0 0 0 0 11 0 DT NNP NNP NN VBD O
hybridization hybridization 0 0 0 0 0 0 0 0 13 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN TO O
employed employed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB DT O
synthesize synthesize 0 0 0 0 0 0 0 0 10 0 VBN TO VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT JJ NNP O
high high 0 0 0 0 0 0 0 0 4 0 VB DT JJ NNP NN O
R0t R0t 1 0 0 0 0 0 0 1 3 0 DT JJ NNP NN NNP O
fraction fraction 0 0 0 0 0 0 0 0 8 0 JJ NNP NN NNP NN O
cDNA cDNA 0 0 0 0 0 0 0 0 4 0 NNP NN NNP NN VBD O
library library 0 0 0 0 0 0 0 0 7 0 NN NNP NN VBD IN O
enriched enriched 0 0 0 0 0 0 0 0 8 0 NNP NN VBD IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 NN VBD IN NNS VBN O
sequences sequences 0 0 0 0 0 0 0 0 9 0 VBD IN NNS VBN IN O
expressed expressed 0 0 0 0 0 0 0 0 9 0 IN NNS VBN IN NNP O
during during 0 0 0 0 0 0 0 0 6 0 NNS VBN IN NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 phase VBN IN NNP NN RB B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN NNP NN RB TO O
prior prior 0 0 0 0 0 0 0 0 5 0 NNP NN RB TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN RB TO VB IN O
passage passage 0 0 0 0 0 0 0 0 7 0 RB TO VB IN DT O
through through 0 0 0 0 0 0 0 0 7 0 TO VB IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VB IN DT JJ NNP O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 IN DT JJ NNP NNP B_TIMEXCCP
gate. gate. 0 0 0 0 0 0 0 0 5 0 DT JJ NNP NNP NN O
To To 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NN NN O
prepare prepare 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN NNS O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 NNP NN NN NNS IN B_TIMEXCCP
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS IN RB O
from from 0 0 0 0 0 0 0 0 4 0 NN NNS IN RB VBG O
continuously continuously 0 0 0 0 0 0 0 0 12 0 NNS IN RB VBG NN O
cycling cycling 0 0 0 0 0 0 0 0 7 0 IN RB VBG NN -NONE- O
cell cell 0 0 0 0 0 0 0 0 4 0 RB VBG NN -NONE- JJ O
populations, populations, 0 0 0 0 1 0 0 0 12 0 VBG NN -NONE- JJ NNP O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 NN -NONE- JJ NNP NNS B_TIMEXCCP
HeLa HeLa 1 0 0 0 0 0 0 0 4 0 -NONE- JJ NNP NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NNP NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD VBN IN O
collected collected 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NN O
centrifugal centrifugal 0 0 0 0 0 0 0 0 11 0 VBN IN JJ NN CC O
elutriation elutriation 0 0 0 0 0 0 0 0 11 0 IN JJ NN CC RB O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC RB JJ O
highly highly 0 0 0 0 0 0 0 0 6 0 NN CC RB JJ NNP O
synchronous synchronous 0 0 0 0 0 0 0 0 11 0 CC RB JJ NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase RB JJ NNP NN NNS B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 JJ NNP NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
obtained obtained 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NN O
double double 0 0 0 0 0 0 0 0 6 0 VBN IN JJ NN NN O
thymidine thymidine 0 0 0 0 0 0 0 0 9 0 IN JJ NN NN VBD O
block block 0 0 0 0 0 0 0 0 5 0 JJ NN NN VBD IN O
followed followed 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN JJ NNP O
centrifugal centrifugal 0 0 0 0 0 0 0 0 11 0 VBD IN JJ NNP DT O
elutriation. elutriation. 0 0 0 0 0 0 0 0 12 0 IN JJ NNP DT NN O
A A 1 1 0 0 0 0 0 0 1 0 JJ NNP DT NN NN O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 NNP DT NN NN NNP B_TIMEXCCP
subtractive subtractive 0 0 0 0 0 0 0 0 11 0 DT NN NN NNP NN O
cDNA cDNA 0 0 0 0 0 0 0 0 4 0 NN NN NNP NN VBD O
library library 0 0 0 0 0 0 0 0 7 0 NN NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
prepared prepared 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN NN O
subtracting subtracting 0 0 0 0 0 0 0 0 11 0 VBN IN NN NN NNP O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 IN NN NN NNP IN B_TIMEXCCP
cDNA cDNA 0 0 0 0 0 0 0 0 4 0 NN NN NNP IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN NNP IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT JJ NN O
10-fold 10-fold 0 0 1 0 0 0 0 1 7 0 IN DT JJ NN IN O
excess excess 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNP O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 NN IN JJ NNP NNP B_TIMEXCCP
mRNA. mRNA. 0 0 0 0 0 0 0 0 5 0 IN JJ NNP NNP NNP O
Single-stranded, Single-stranded, 1 0 1 0 1 0 0 0 16 0 JJ NNP NNP NNP NNP O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 NNP NNP NNP NNP VBD B_TIMEXCCP
cDNAs cDNAs 0 0 0 0 0 0 0 0 5 0 NNP NNP NNP VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD VBN IN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
oligo(dA) oligo(dA) 0 0 0 0 0 0 0 0 9 0 VBN IN NNP NNP NNP O
chromatography. chromatography. 0 0 0 0 0 0 0 0 15 0 IN NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN VBD O
library library 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
screened screened 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NNP O
high high 0 0 0 0 0 0 0 0 4 0 IN DT JJ NNP NN O
R0t R0t 1 0 0 0 0 0 0 1 3 0 DT JJ NNP NN JJ O
fraction fraction 0 0 0 0 0 0 0 0 8 0 JJ NNP NN JJ NN O
subtractive subtractive 0 0 0 0 0 0 0 0 11 0 NNP NN JJ NN NNP O
probe probe 0 0 0 0 0 0 0 0 5 0 NN JJ NN NNP NNP O
population. population. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP NNP CD O
Following Following 1 0 0 0 0 0 0 0 9 0 NN NNP NNP CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 NNP NNP CD NNS IN O
rounds rounds 0 0 0 0 0 0 0 0 6 0 NNP CD NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN JJ CD O
screening, screening, 0 0 0 0 1 0 0 0 10 0 NNS IN JJ CD JJ O
20 20 0 0 0 0 0 0 1 1 2 0 IN JJ CD JJ NNS O
positive positive 0 0 0 0 0 0 0 0 8 0 JJ CD JJ NNS VBD O
clones clones 0 0 0 0 0 0 0 0 6 0 CD JJ NNS VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD NNP NNP O
obtained. obtained. 0 0 0 0 0 0 0 0 9 0 NNS VBD NNP NNP NN O
Northern Northern 1 0 0 0 0 0 0 0 8 0 VBD NNP NNP NN NN O
blot blot 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NNP NN NN VBD IN O
indicated indicated 0 0 0 0 0 0 0 0 9 0 NN NN VBD IN CD O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN CD IN O
six six 0 0 0 0 0 0 0 0 3 0 VBD IN CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN CD IN DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 CD IN DT NNS VBD O
clones clones 0 0 0 0 0 0 0 0 6 0 IN DT NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 DT NNS VBD VBN IN O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN NN O
expression expression 0 0 0 0 0 0 0 0 10 0 VBN IN NN NN IN O
level level 0 0 0 0 0 0 0 0 5 0 IN NN NN IN NNP O
during during 0 0 0 0 0 0 0 0 6 0 NN NN IN NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 phase NN IN NNP NN WRB B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN NNP NN WRB VBN O
when when 0 0 0 0 0 0 0 0 4 0 NNP NN WRB VBN IN O
compared compared 0 0 0 0 0 0 0 0 8 0 NN WRB VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 WRB VBN IN NNP NNP O
S S 1 1 0 0 0 0 0 0 1 0 VBN IN NNP NNP NNP B_TIMEXCCP
phase. phase. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NN O
Nucleotide Nucleotide 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NN NN O
sequence sequence 0 0 0 0 0 0 0 0 8 0 NNP NNP NN NN IN O
comparison comparison 0 0 0 0 0 0 0 0 10 0 NNP NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
each each 0 0 0 0 0 0 0 0 4 0 NN IN DT NN IN O
clone clone 0 0 0 0 0 0 0 0 5 0 IN DT NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 DT NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNS O
GenBank GenBank 1 0 0 0 0 0 0 0 7 0 IN DT NNP NNS NN O
data data 0 0 0 0 0 0 0 0 4 0 DT NNP NNS NN VBD O
base base 0 0 0 0 0 0 0 0 4 0 NNP NNS NN VBD IN O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NNS NN VBD IN -NONE- O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN -NONE- VBD O
hG1.11 hG1.11 0 0 0 0 0 0 0 1 6 0 VBD IN -NONE- VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 IN -NONE- VBD RB JJ O
highly highly 0 0 0 0 0 0 0 0 6 0 -NONE- VBD RB JJ NN O
homologous homologous 0 0 0 0 0 0 0 0 10 0 VBD RB JJ NN TO O
(99%) (99%) 0 0 0 0 0 0 0 1 5 0 RB JJ NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT NN NN O
apoferritin apoferritin 0 0 0 0 0 0 0 0 11 0 TO DT NN NN NN O
light light 0 0 0 0 0 0 0 0 5 0 DT NN NN NN NN O
chain chain 0 0 0 0 0 0 0 0 5 0 NN NN NN NN CC O
gene gene 0 0 0 0 0 0 0 0 4 0 NN NN NN CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNS -NONE- O
clones clones 0 0 0 0 0 0 0 0 6 0 NN CC NNS -NONE- -NONE- O
hG1.6, hG1.6, 0 0 0 0 1 0 0 1 6 0 CC NNS -NONE- -NONE- -NONE- O
hG1.10, hG1.10, 0 0 0 0 1 0 0 1 7 0 NNS -NONE- -NONE- -NONE- CC O
hG1.17, hG1.17, 0 0 0 0 1 0 0 1 7 0 -NONE- -NONE- -NONE- CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- CC -NONE- VBD O
hG1.18 hG1.18 0 0 0 0 0 0 0 1 6 0 -NONE- CC -NONE- VBD JJ O
represented represented 0 0 0 0 0 0 0 0 11 0 CC -NONE- VBD JJ JJ O
new new 0 0 0 0 0 0 0 0 3 0 -NONE- VBD JJ JJ NNS O
G1-phase-enriched G1-phase-enriched 1 0 1 0 0 0 0 1 17 0 VBD JJ JJ NNS IN B_TIMEXCCP
members members 0 0 0 0 0 0 0 0 7 0 JJ JJ NNS IN CD O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN CD JJ O
four four 0 0 0 0 0 0 0 0 4 0 NNS IN CD JJ JJ O
human human 0 0 0 0 0 0 0 0 5 0 IN CD JJ JJ NN O
ribosomal ribosomal 0 0 0 0 0 0 0 0 9 0 CD JJ JJ NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 JJ JJ NN NN NNS O
gene gene 0 0 0 0 0 0 0 0 4 0 JJ NN NN NNS -NONE- O
families families 0 0 0 0 0 0 0 0 8 0 NN NN NNS -NONE- NNP O
(71-95% (71-95% 0 0 1 0 0 0 0 1 7 0 NN NNS -NONE- NNP NNP O
homology). homology). 0 0 0 0 0 0 0 0 10 0 NNS -NONE- NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 -NONE- NNP NNP JJ NN O
last last 0 0 0 0 0 0 0 0 4 0 NNP NNP JJ NN NN O
clone, clone, 0 0 0 0 1 0 0 0 6 0 NNP JJ NN NN VBD O
hG1.1, hG1.1, 0 0 0 0 1 0 0 1 6 0 JJ NN NN VBD DT O
encoded encoded 0 0 0 0 0 0 0 0 7 0 NN NN VBD DT RB O
a a 0 0 0 0 0 0 0 0 1 0 NN VBD DT RB VBN O
highly highly 0 0 0 0 0 0 0 0 6 0 VBD DT RB VBN NN O
charged charged 0 0 0 0 0 0 0 0 7 0 DT RB VBN NN RB O
polypeptide polypeptide 0 0 0 0 0 0 0 0 11 0 RB VBN NN RB RB O
not not 0 0 0 0 0 0 0 0 3 0 VBN NN RB RB NNP O
previously previously 0 0 0 0 0 0 0 0 10 0 NN RB RB NNP NNP O
identified. identified. 0 0 0 0 0 0 0 0 11 0 RB RB NNP NNP NN O
Additional Additional 1 0 0 0 0 0 0 0 10 0 RB NNP NNP NN IN O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT JJ NNP O
G1-phase-enriched G1-phase-enriched 1 0 1 0 0 0 0 1 17 0 IN DT JJ NNP MD B_TIMEXCCP
mRNAs mRNAs 0 0 0 0 0 0 0 0 5 0 DT JJ NNP MD VB O
will will 0 0 0 0 0 0 0 0 4 0 JJ NNP MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NNP MD VB VBN TO O
required required 0 0 0 0 0 0 0 0 8 0 MD VB VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VB VBN TO VB PRP$ O
determine determine 0 0 0 0 0 0 0 0 9 0 VBN TO VB PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 TO VB PRP$ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 VB PRP$ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 PRP$ NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN NN CC O
progression progression 0 0 0 0 0 0 0 0 11 0 NN NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN NN O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 CC DT NN NN IN B_TIMEXCCP
gateway gateway 0 0 0 0 0 0 0 0 7 0 DT NN NN IN WDT O
through through 0 0 0 0 0 0 0 0 7 0 NN NN IN WDT NNS O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 IN WDT NNS VBP RB O
transit transit 0 0 0 0 0 0 0 0 7 0 WDT NNS VBP RB PRP O
as as 0 0 0 0 0 0 0 0 2 0 NNS VBP RB PRP VBP O
they they 0 0 0 0 0 0 0 0 4 0 VBP RB PRP VBP IN O
proceed proceed 0 0 0 0 0 0 0 0 7 0 RB PRP VBP IN DT O
through through 0 0 0 0 0 0 0 0 7 0 PRP VBP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NNP NNP O
cycle. cycle. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
8123253 8123253 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 NONE DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NN O
G2-phase G2-phase 1 0 1 0 0 0 0 1 8 0 NNS IN JJ NN CC B_TIMEXCCP
enrichment enrichment 0 0 0 0 0 0 0 0 10 0 IN JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NN O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NN CC NN NN IN B_TIMEXCCP
abrogation abrogation 0 0 0 0 0 0 0 0 10 0 CC NN NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNP O
low-dose low-dose 0 0 1 0 0 0 0 0 8 0 NN IN JJ NNP NNP O
hyper-radiosensitivity. hyper-radiosensitivity. 0 0 1 0 0 0 0 0 23 0 IN JJ NNP NNP NNP O
Krueger Krueger 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP NNP NNP O
SA, SA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wilson Wilson 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
GD, GD, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Piasentin Piasentin 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
E, E, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Joiner Joiner 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
MC, MC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Marples Marples 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
B. B. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Radiation Radiation 1 0 0 0 0 0 0 0 9 0 NNP IN NNP NNP NNP O
Oncology, Oncology, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
William William 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Beaumont Beaumont 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Hospital, Hospital, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Royal Royal 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Oak, Oak, 1 0 0 0 1 0 0 0 4 0 NNP NNP NNP NNP CD O
Michigan Michigan 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP CD NNP O
48073, 48073, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NNP O
PURPOSE: PURPOSE: 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
An An 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NN IN O
association association 0 0 0 0 0 0 0 0 11 0 NNP NNP NN IN JJ O
between between 0 0 0 0 0 0 0 0 7 0 NNP NN IN JJ NN O
low-dose low-dose 0 0 1 0 0 0 0 0 8 0 NN IN JJ NN NN O
hyper-radiosensitivity hyper-radiosensitivity 0 0 1 0 0 0 0 0 22 0 IN JJ NN NN CC O
(HRS) (HRS) 0 1 0 0 0 0 0 0 5 0 JJ NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NNP NNP O
"early" "early" 0 0 0 0 0 0 0 0 7 0 CC DT NNP NNP NN early
G2/M G2/M 1 1 0 1 0 0 0 1 4 0 DT NNP NNP NN VBZ early
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NNP NNP NN VBZ VBN early
has has 0 0 0 0 0 0 0 0 3 0 NNP NN VBZ VBN NNP O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN NNP NNP O
established. established. 0 0 0 0 0 0 0 0 12 0 VBZ VBN NNP NNP VBD O
An An 1 0 0 0 0 0 0 0 2 0 VBN NNP NNP VBD JJ O
improved improved 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 NNP VBD JJ NN IN O
understanding understanding 0 0 0 0 0 0 0 0 13 0 VBD JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNS O
temporal temporal 0 0 0 0 0 0 0 0 8 0 IN DT JJ NNS IN O
dynamics dynamics 0 0 0 0 0 0 0 0 8 0 DT JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNS IN DT NN VBZ O
relationship relationship 0 0 0 0 0 0 0 0 12 0 IN DT NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ VBN IN O
needed needed 0 0 0 0 0 0 0 0 6 0 NN VBZ VBN IN JJ O
before before 0 0 0 0 0 0 0 0 6 0 VBZ VBN IN JJ NN O
clinical clinical 0 0 0 0 0 0 0 0 8 0 VBN IN JJ NN MD O
translation translation 0 0 0 0 0 0 0 0 11 0 IN JJ NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 JJ NN MD VB NNP O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB NNP NNP O
considered. considered. 0 0 0 0 0 0 0 0 11 0 MD VB NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 VB NNP NNP NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN TO O
conducted conducted 0 0 0 0 0 0 0 0 9 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB DT O
characterize characterize 0 0 0 0 0 0 0 0 12 0 VBN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN NN O
dose dose 0 0 0 0 0 0 0 0 4 0 VB DT NN NN IN O
response response 0 0 0 0 0 0 0 0 8 0 DT NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
early early 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN NN 0
G2/M G2/M 1 1 0 1 0 0 0 1 4 0 DT JJ NN NN CC early
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 JJ NN NN CC RB early
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC RB VB O
then then 0 0 0 0 0 0 0 0 4 0 NN CC RB VB IN O
determine determine 0 0 0 0 0 0 0 0 9 0 CC RB VB IN JJ O
whether whether 0 0 0 0 0 0 0 0 7 0 RB VB IN JJ NN O
low-dose low-dose 0 0 1 0 0 0 0 0 8 0 VB IN JJ NN NN O
radiation radiation 0 0 0 0 0 0 0 0 9 0 IN JJ NN NN MD O
sensitivity sensitivity 0 0 0 0 0 0 0 0 11 0 JJ NN NN MD VB O
could could 0 0 0 0 0 0 0 0 5 0 NN NN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB VBN IN O
increased increased 0 0 0 0 0 0 0 0 9 0 MD VB VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VB VBN IN NN CC O
synchronization synchronization 0 0 0 0 0 0 0 0 15 0 VBN IN NN CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 IN NN CC JJ NN O
chemical chemical 0 0 0 0 0 0 0 0 8 0 NN CC JJ NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 CC JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NNP NNP O
cycle. cycle. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP NNP O
METHODS METHODS 1 1 0 0 0 0 0 0 7 0 NN NNP NNP NNP NNP O
AND AND 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
MATERIALS: MATERIALS: 1 1 0 0 0 0 0 0 10 0 NNP NNP NNP NNP VBD O
Two Two 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP VBD NN O
related related 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP VBD NN NNS IN O
lines lines 0 0 0 0 0 0 0 0 5 0 VBD NN NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN NNS IN JJ NNS O
disparate disparate 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NNS NN O
HRS HRS 1 1 0 0 0 0 0 0 3 0 IN JJ NNS NN VBD O
status status 0 0 0 0 0 0 0 0 6 0 JJ NNS NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNS NN VBD VBN -NONE- O
used used 0 0 0 0 0 0 0 0 4 0 NN VBD VBN -NONE- CC O
(MR4 (MR4 0 1 0 0 0 0 0 1 4 0 VBD VBN -NONE- CC CD O
and and 0 0 0 0 0 0 0 0 3 0 VBN -NONE- CC CD NNP O
3.7 3.7 0 0 0 0 0 0 0 1 3 0 -NONE- CC CD NNP NNP O
cells). cells). 0 0 0 0 0 0 0 0 7 0 CC CD NNP NNP NNP O
A A 1 1 0 0 0 0 0 0 1 0 CD NNP NNP NNP NN O
double-thymidine double-thymidine 0 0 1 0 0 0 0 0 16 0 NNP NNP NNP NN NN O
block block 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NN VBD O
technique technique 0 0 0 0 0 0 0 0 9 0 NNP NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN TO O
developed developed 0 0 0 0 0 0 0 0 9 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB DT O
enrich enrich 0 0 0 0 0 0 0 0 6 0 VBN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN NNP O
G2-phase G2-phase 1 0 1 0 0 0 0 1 8 0 VB DT NN NNP NNP B_TIMEXCCP
population. population. 0 0 0 0 0 0 0 0 11 0 DT NN NNP NNP NN O
Clonogenic Clonogenic 1 0 0 0 0 0 0 0 10 0 NN NNP NNP NN -NONE- O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP NNP NN -NONE- JJ O
survival, survival, 0 0 0 0 1 0 0 0 9 0 NNP NN -NONE- JJ NN O
radiation-induced radiation-induced 0 0 1 0 0 0 0 0 17 0 NN -NONE- JJ NN NN O
G2-phase G2-phase 1 0 1 0 0 0 0 1 8 0 -NONE- JJ NN NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NN NN NN NN CC O
arrest, arrest, 0 0 0 0 1 0 0 0 7 0 NN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
deoxyribonucleic deoxyribonucleic 0 0 0 0 0 0 0 0 16 0 NN CC JJ NN NN O
acid acid 0 0 0 0 0 0 0 0 4 0 CC JJ NN NN NN O
double-strand double-strand 0 0 1 0 0 0 0 0 13 0 JJ NN NN NN NN O
break break 0 0 0 0 0 0 0 0 5 0 NN NN NN NN VBD O
repair repair 0 0 0 0 0 0 0 0 6 0 NN NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN IN O
measured measured 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN CC O
presence presence 0 0 0 0 0 0 0 0 8 0 IN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
absence absence 0 0 0 0 0 0 0 0 7 0 NN CC NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNS TO O
inhibitors inhibitors 0 0 0 0 0 0 0 0 10 0 NN IN NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NNS TO VB NN O
G2-phase G2-phase 1 0 1 0 0 0 0 1 8 0 NNS TO VB NN NNP G2
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 TO VB NN NNP NNP G2
proteins. proteins. 0 0 0 0 0 0 0 0 9 0 VB NN NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 NN NNP NNP NNP NNP O
For For 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
MR4 MR4 1 1 0 0 0 0 0 1 3 0 NNP NNP NNP NNP DT O
cells, cells, 0 0 0 0 1 0 0 0 6 0 NNP NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN VBN O
dose dose 0 0 0 0 0 0 0 0 4 0 NNP DT NN VBN TO O
required required 0 0 0 0 0 0 0 0 8 0 DT NN VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBN TO VB DT O
overcome overcome 0 0 0 0 0 0 0 0 8 0 VBN TO VB DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NNP NN O
HRS HRS 1 1 0 0 0 0 0 0 3 0 VB DT NNP NN RB O
response response 0 0 0 0 0 0 0 0 8 0 DT NNP NN RB CD O
(approximately (approximately 0 0 0 0 0 0 0 0 14 0 NNP NN RB CD -NONE- O
0.2 0.2 0 0 0 0 0 0 0 1 3 0 NN RB CD -NONE- VBN O
Gy) Gy) 1 0 0 0 0 0 0 0 3 0 RB CD -NONE- VBN IN O
corresponded corresponded 0 0 0 0 0 0 0 0 12 0 CD -NONE- VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 -NONE- VBN IN DT VBN O
that that 0 0 0 0 0 0 0 0 4 0 VBN IN DT VBN IN O
needed needed 0 0 0 0 0 0 0 0 6 0 IN DT VBN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 DT VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
early early 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN NNP 0
G2/M G2/M 1 1 0 1 0 0 0 1 4 0 DT JJ NN NNP NNP early
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP NNP NNP early
As As 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NNP NN O
hypothesized, hypothesized, 0 0 0 0 1 0 0 0 13 0 NNP NNP NNP NN DT O
enriching enriching 0 0 0 0 0 0 0 0 9 0 NNP NNP NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT NN IN O
number number 0 0 0 0 0 0 0 0 6 0 NN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
G2-phase G2-phase 1 0 1 0 0 0 0 1 8 0 NN IN JJ NNS IN B_TIMEXCCP
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN VBD O
population population 0 0 0 0 0 0 0 0 10 0 IN DT NN VBD IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 DT NN VBD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN VBD IN DT VBN O
an an 0 0 0 0 0 0 0 0 2 0 VBD IN DT VBN NNP O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 IN DT VBN NNP NNP O
HRS HRS 1 1 0 0 0 0 0 0 3 0 DT VBN NNP NNP IN O
response, response, 0 0 0 0 1 0 0 0 9 0 VBN NNP NNP IN DT O
because because 0 0 0 0 0 0 0 0 7 0 NNP NNP IN DT JJR O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT JJR NN O
greater greater 0 0 0 0 0 0 0 0 7 0 IN DT JJR NN IN O
proportion proportion 0 0 0 0 0 0 0 0 10 0 DT JJR NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJR NN IN JJ NNS O
radiation-damaged radiation-damaged 0 0 1 0 0 0 0 0 17 0 NN IN JJ NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS VBD DT O
evaded evaded 0 0 0 0 0 0 0 0 6 0 JJ NNS VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBD DT JJ NN O
early early 0 0 0 0 0 0 0 0 5 0 VBD DT JJ NN NN 0
G2/M G2/M 1 1 0 1 0 0 0 1 4 0 DT JJ NN NN CC early
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 JJ NN NN CC VBD early
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBD NN O
entered entered 0 0 0 0 0 0 0 0 7 0 NN CC VBD NN IN O
mitosis mitosis 0 0 0 0 0 0 0 0 7 0 CC VBD NN IN JJ B_TIMEXCCP 
with with 0 0 0 0 0 0 0 0 4 0 VBD NN IN JJ JJ O
unrepaired unrepaired 0 0 0 0 0 0 0 0 10 0 NN IN JJ JJ NN O
deoxyribonucleic deoxyribonucleic 0 0 0 0 0 0 0 0 16 0 IN JJ JJ NN NN O
acid acid 0 0 0 0 0 0 0 0 4 0 JJ JJ NN NN NNP O
double-strand double-strand 0 0 1 0 0 0 0 0 13 0 JJ NN NN NNP NNP O
breaks. breaks. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP NN O
Likewise, Likewise, 1 0 0 0 1 0 0 0 9 0 NN NNP NNP NN IN O
abrogation abrogation 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 IN DT NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 NN IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP CC O
Chk1 Chk1 1 0 0 0 0 0 0 1 4 0 NN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP RB O
Chk2 Chk2 1 0 0 0 0 0 0 1 4 0 NNP CC NNP RB VBD O
also also 0 0 0 0 0 0 0 0 4 0 CC NNP RB VBD JJ O
increased increased 0 0 0 0 0 0 0 0 9 0 NNP RB VBD JJ NNP O
low-dose low-dose 0 0 1 0 0 0 0 0 8 0 RB VBD JJ NNP NNP O
radiosensitivity. radiosensitivity. 0 0 0 0 0 0 0 0 17 0 VBD JJ NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP NNS VBD O
effects effects 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD RB JJ O
not not 0 0 0 0 0 0 0 0 3 0 NNS VBD RB JJ IN O
evident evident 0 0 0 0 0 0 0 0 7 0 VBD RB JJ IN CD O
in in 0 0 0 0 0 0 0 0 2 0 RB JJ IN CD NNP O
3.7 3.7 0 0 0 0 0 0 0 1 3 0 JJ IN CD NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN CD NNP NNP NNP O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 CD NNP NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS NN O
data data 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS NN IN O
confirm confirm 0 0 0 0 0 0 0 0 7 0 NNP NNS NN IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNS NN IN NNP VBZ O
HRS HRS 1 1 0 0 0 0 0 0 3 0 NN IN NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ VBN TO O
linked linked 0 0 0 0 0 0 0 0 6 0 NNP VBZ VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBZ VBN TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN TO DT JJ NN O
early early 0 0 0 0 0 0 0 0 5 0 TO DT JJ NN NN 0
G2/M G2/M 1 1 0 1 0 0 0 1 4 0 DT JJ NN NN IN early
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 JJ NN NN IN DT early
through through 0 0 0 0 0 0 0 0 7 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
damage damage 0 0 0 0 0 0 0 0 6 0 IN DT NN NN IN O
response response 0 0 0 0 0 0 0 0 8 0 DT NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNP O
G2-phase G2-phase 1 0 1 0 0 0 0 1 8 0 NN IN JJ NNP NNP B_TIMEXCCP
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP NN O
Low-dose Low-dose 1 0 1 0 0 0 0 0 8 0 JJ NNP NNP NN MD O
radiosensitivity radiosensitivity 0 0 0 0 0 0 0 0 16 0 NNP NNP NN MD VB O
could could 0 0 0 0 0 0 0 0 5 0 NNP NN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB VBN IN O
increased increased 0 0 0 0 0 0 0 0 9 0 MD VB VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VB VBN IN NN DT O
manipulating manipulating 0 0 0 0 0 0 0 0 12 0 VBN IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN IN O
transition transition 0 0 0 0 0 0 0 0 10 0 NN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
radiation-damaged radiation-damaged 0 0 1 0 0 0 0 0 17 0 NN IN JJ NN NNS O
G2-phase G2-phase 1 0 1 0 0 0 0 1 8 0 IN JJ NN NNS IN B_TIMEXCCP
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN NNP O
into into 0 0 0 0 0 0 0 0 4 0 NN NNS IN NNP NNP O
mitosis. mitosis. 0 0 0 0 0 0 0 0 8 0 NNS IN NNP NNP VBZ O
This This 1 0 0 0 0 0 0 0 4 0 IN NNP NNP VBZ DT O
provides provides 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT NN IN O
rationale rationale 0 0 0 0 0 0 0 0 9 0 VBZ DT NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN NN JJ O
combining combining 0 0 0 0 0 0 0 0 9 0 NN IN NN JJ NN O
low-dose low-dose 0 0 1 0 0 0 0 0 8 0 IN NN JJ NN NN O
radiation radiation 0 0 0 0 0 0 0 0 9 0 NN JJ NN NN IN O
therapy therapy 0 0 0 0 0 0 0 0 7 0 JJ NN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ NN O
chemical chemical 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN NNS O
synchronization synchronization 0 0 0 0 0 0 0 0 15 0 IN JJ NN NNS TO O
techniques techniques 0 0 0 0 0 0 0 0 10 0 JJ NN NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO VB VBN O
improve improve 0 0 0 0 0 0 0 0 7 0 NNS TO VB VBN NNP O
increased increased 0 0 0 0 0 0 0 0 9 0 TO VB VBN NNP NNP O
radiosensitivity. radiosensitivity. 0 0 0 0 0 0 0 0 17 0 VB VBN NNP NNP CD O
Copyright Copyright 1 0 0 0 0 0 0 0 9 0 VBN NNP NNP CD NNP O
2010 2010 0 0 0 0 0 0 1 1 4 0 NNP NNP CD NNP NNP O
Elsevier Elsevier 1 0 0 0 0 0 0 0 8 0 NNP CD NNP NNP NNP O
Inc. Inc. 1 0 0 0 0 0 0 0 4 0 CD NNP NNP NNP NNS O
All All 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS NNP O
rights rights 0 0 0 0 0 0 0 0 6 0 NNP NNP NNS NNP NNP O
reserved. reserved. 0 0 0 0 0 0 0 0 9 0 NNP NNS NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNS NNP NNP CD JJ O
20637979 20637979 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Visualizing Visualizing 1 0 0 0 0 0 0 0 11 0 NONE NONE VBG NN NNS O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 NONE VBG NN NNS IN O
dynamics dynamics 0 0 0 0 0 0 0 0 8 0 VBG NN NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NNP O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NNS IN NN NNP NNP B_TIMEXCCP
nuclei. nuclei. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NNP NNP O
Gasser Gasser 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP NNP O
SM. SM. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP IN NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Geneva, Geneva, 1 0 0 0 1 0 0 0 7 0 NNP IN NNP NNP NNP O
Quai Quai 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP CD O
Ernest-Ansermet Ernest-Ansermet 1 0 1 0 0 0 0 0 15 0 NNP NNP NNP CD -NONE- O
30, 30, 0 0 0 0 1 0 0 1 3 0 NNP NNP CD -NONE- JJ O
CH-1211 CH-1211 1 1 1 0 0 0 0 1 7 0 NNP CD -NONE- JJ NNP O
Geneva, Geneva, 1 0 0 0 1 0 0 0 7 0 CD -NONE- JJ NNP JJ O
Switzerland. Switzerland. 1 0 0 0 0 0 0 0 12 0 -NONE- JJ NNP JJ JJ O
susan.gasser@molbio.unige.ch susan.gasser@molbio.unige.ch 0 0 0 0 0 0 0 0 28 0 JJ NNP JJ JJ NN O
Real-time Real-time 1 0 1 0 0 0 0 0 9 0 NNP JJ JJ NN NN O
fluorescence fluorescence 0 0 0 0 0 0 0 0 12 0 JJ JJ NN NN VBZ O
microscopy microscopy 0 0 0 0 0 0 0 0 10 0 JJ NN NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NN NN VBZ VBN IN O
emerged emerged 0 0 0 0 0 0 0 0 7 0 NN VBZ VBN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NN O
powerful powerful 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN IN O
tool tool 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN NN O
examining examining 0 0 0 0 0 0 0 0 9 0 NN IN NN NN NNP O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 IN NN NN NNP NNP O
dynamics. dynamics. 0 0 0 0 0 0 0 0 9 0 NN NN NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP JJ NN O
initial initial 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NN VBZ O
lesson lesson 0 0 0 0 0 0 0 0 6 0 NNP JJ NN VBZ IN O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NN VBZ IN JJ IN O
much much 0 0 0 0 0 0 0 0 4 0 VBZ IN JJ IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN JJ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT JJ RB O
genome, genome, 0 0 0 0 1 0 0 0 7 0 IN DT JJ RB IN O
particularly particularly 0 0 0 0 0 0 0 0 12 0 DT JJ RB IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ RB IN NNP VBZ O
yeast, yeast, 0 0 0 0 1 0 0 0 6 0 RB IN NNP VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ RB NNP O
highly highly 0 0 0 0 0 0 0 0 6 0 NNP VBZ RB NNP NNP O
dynamic. dynamic. 0 0 0 0 0 0 0 0 8 0 VBZ RB NNP NNP NN O
Its Its 1 0 0 0 0 0 0 0 3 0 RB NNP NNP NN IN O
movement movement 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN DT O
within within 0 0 0 0 0 0 0 0 6 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBZ O
interphase interphase 0 0 0 0 0 0 0 0 10 0 IN DT NN VBZ VBZ B_TIMEXCCP 
nucleus nucleus 0 0 0 0 0 0 0 0 7 0 DT NN VBZ VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN VBZ VBZ VBN IN O
correlated correlated 0 0 0 0 0 0 0 0 10 0 VBZ VBZ VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN JJ NNP O
metabolic metabolic 0 0 0 0 0 0 0 0 9 0 VBN IN JJ NNP NNP O
activity. activity. 0 0 0 0 0 0 0 0 9 0 IN JJ NNP NNP DT O
Nonetheless, Nonetheless, 1 0 0 0 1 0 0 0 12 0 JJ NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN VBZ O
nucleus nucleus 0 0 0 0 0 0 0 0 7 0 NNP DT NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NN VBZ DT NN IN O
organelle organelle 0 0 0 0 0 0 0 0 9 0 VBZ DT NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 DT NN IN JJ NNS O
conserved conserved 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNS IN O
rules rules 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NNP O
organization. organization. 0 0 0 0 0 0 0 0 13 0 NNS IN NNP NNP DT O
Determining Determining 1 0 0 0 0 0 0 0 11 0 IN NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN CC O
distribution distribution 0 0 0 0 0 0 0 0 12 0 NNP DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
regulation regulation 0 0 0 0 0 0 0 0 10 0 NN CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NNS O
mobile mobile 0 0 0 0 0 0 0 0 6 0 NN IN JJ NNS IN O
domains domains 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NN O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NNS IN NN NN CC B_TIMEXCCP 
chromosomes, chromosomes, 0 0 0 0 1 0 0 0 12 0 IN NN NN CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBG NNS O
characterizing characterizing 0 0 0 0 0 0 0 0 14 0 NN CC VBG NNS IN O
sites sites 0 0 0 0 0 0 0 0 5 0 CC VBG NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBG NNS IN JJ NN O
anchorage, anchorage, 0 0 0 0 1 0 0 0 10 0 NNS IN JJ NN RB O
will will 0 0 0 0 0 0 0 0 4 0 IN JJ NN RB VBD O
undoubtedly undoubtedly 0 0 0 0 0 0 0 0 11 0 JJ NN RB VBD JJ O
shed shed 0 0 0 0 0 0 0 0 4 0 NN RB VBD JJ NN O
new new 0 0 0 0 0 0 0 0 3 0 RB VBD JJ NN IN O
light light 0 0 0 0 0 0 0 0 5 0 VBD JJ NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
function function 0 0 0 0 0 0 0 0 8 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNP NNP O
order. order. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
12029120 12029120 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Mitosis. Mitosis. 1 0 0 0 0 0 0 0 8 0 NONE NONE NNP NNP NNP B_TIMEXCCP
Earnshaw Earnshaw 1 0 0 0 0 0 0 0 8 0 NONE NNP NNP NNP NNP O
WC, WC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Pluta Pluta 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
AF. AF. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP CC O
Biology Biology 1 0 0 0 0 0 0 0 7 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Anatomy, Anatomy, 1 0 0 0 1 0 0 0 8 0 NNP CC NNP NNP NNP O
Johns Johns 1 0 0 0 0 0 0 0 5 0 CC NNP NNP NNP NNP O
Hopkins Hopkins 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Baltimore, Baltimore, 1 0 0 0 1 0 0 0 10 0 IN NNP NNP NNP NNP O
MD MD 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
21205. 21205. 0 0 0 0 0 0 0 1 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP DT O
Within Within 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NN O
last last 0 0 0 0 0 0 0 0 4 0 NNP DT JJ NN DT O
decade, decade, 0 0 0 0 1 0 0 0 7 0 DT JJ NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NN IN O
study study 0 0 0 0 0 0 0 0 5 0 NN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN VBZ O
mitosis mitosis 0 0 0 0 0 0 0 0 7 0 NN IN NN VBZ VBN B_TIMEXCCP
has has 0 0 0 0 0 0 0 0 3 0 IN NN VBZ VBN IN O
evolved evolved 0 0 0 0 0 0 0 0 7 0 NN VBZ VBN IN DT O
into into 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NN O
multidisciplinary multidisciplinary 0 0 0 0 0 0 0 0 17 0 IN DT JJ NN IN O
science science 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN WDT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN WDT NNS O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT NNS IN O
findings findings 0 0 0 0 0 0 0 0 8 0 IN WDT NNS IN NNS O
from from 0 0 0 0 0 0 0 0 4 0 WDT NNS IN NNS IN O
fields fields 0 0 0 0 0 0 0 0 6 0 NNS IN NNS IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 IN NNS IN JJ IN O
diverse diverse 0 0 0 0 0 0 0 0 7 0 NNS IN JJ IN NN O
as as 0 0 0 0 0 0 0 0 2 0 IN JJ IN NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 JJ IN NN NN CC O
biology biology 0 0 0 0 0 0 0 0 7 0 IN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
cytoskeletal cytoskeletal 0 0 0 0 0 0 0 0 12 0 NN CC JJ NN VBP O
architecture architecture 0 0 0 0 0 0 0 0 12 0 CC JJ NN VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 JJ NN VBP VBN TO O
converged converged 0 0 0 0 0 0 0 0 9 0 NN VBP VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBP VBN TO VB DT O
present present 0 0 0 0 0 0 0 0 7 0 VBN TO VB DT RBR O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT RBR JJ O
more more 0 0 0 0 0 0 0 0 4 0 VB DT RBR JJ NN O
cohesive cohesive 0 0 0 0 0 0 0 0 8 0 DT RBR JJ NN IN O
understanding understanding 0 0 0 0 0 0 0 0 13 0 RBR JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNS O
complex complex 0 0 0 0 0 0 0 0 7 0 IN DT JJ NNS WDT O
events events 0 0 0 0 0 0 0 0 6 0 DT JJ NNS WDT VBP O
that that 0 0 0 0 0 0 0 0 4 0 JJ NNS WDT VBP WRB O
occur occur 0 0 0 0 0 0 0 0 5 0 NNS WDT VBP WRB NNS O
when when 0 0 0 0 0 0 0 0 4 0 WDT VBP WRB NNS NNP O
cells cells 0 0 0 0 0 0 0 0 5 0 VBP WRB NNS NNP NNP O
divide. divide. 0 0 0 0 0 0 0 0 7 0 WRB NNS NNP NNP JJS O
The The 1 0 0 0 0 0 0 0 3 0 NNS NNP NNP JJS NNS O
largest largest 0 0 0 0 0 0 0 0 7 0 NNP NNP JJS NNS VBP O
strides strides 0 0 0 0 0 0 0 0 7 0 NNP JJS NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 JJS NNS VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNS VBP VBN VBN IN O
made made 0 0 0 0 0 0 0 0 4 0 VBP VBN VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN CC O
identification identification 0 0 0 0 0 0 0 0 14 0 IN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
characterization characterization 0 0 0 0 0 0 0 0 16 0 NN CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NNS O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 NN IN JJ NNS NNS O
enzymes enzymes 0 0 0 0 0 0 0 0 7 0 IN JJ NNS NNS CC O
(kinases (kinases 0 0 0 0 0 0 0 0 8 0 JJ NNS NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNS NNS CC JJ IN O
phosphatases) phosphatases) 0 0 0 0 0 0 0 0 13 0 NNS CC JJ IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 CC JJ IN JJ JJ O
modulate modulate 0 0 0 0 0 0 0 0 8 0 JJ IN JJ JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 IN JJ JJ NN IN B_TIMEXCCP
activity, activity, 0 0 0 0 1 0 0 0 9 0 JJ JJ NN IN RB O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NN IN RB IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 RB IN DT NN IN O
number number 0 0 0 0 0 0 0 0 6 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS CC O
proteins proteins 0 0 0 0 0 0 0 0 8 0 IN DT NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT NNS CC JJ NNS O
structural structural 0 0 0 0 0 0 0 0 10 0 NNS CC JJ NNS -NONE- O
components components 0 0 0 0 0 0 0 0 10 0 CC JJ NNS -NONE- -NONE- O
(spindle, (spindle, 0 0 0 0 1 0 0 0 9 0 JJ NNS -NONE- -NONE- JJ O
chromosomes, chromosomes, 0 0 0 0 1 0 0 0 12 0 NNS -NONE- -NONE- JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 -NONE- -NONE- JJ NN WDT O
envelope) envelope) 0 0 0 0 0 0 0 0 9 0 -NONE- JJ NN WDT NN O
which which 0 0 0 0 0 0 0 0 5 0 JJ NN WDT NN RP O
carry carry 0 0 0 0 0 0 0 0 5 0 NN WDT NN RP DT O
out out 0 0 0 0 0 0 0 0 3 0 WDT NN RP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN RP DT JJ NNP O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 RP DT JJ NNP CD B_TIMEXCCP
instructions. instructions. 0 0 0 0 0 0 0 0 13 0 DT JJ NNP CD VBG O
One One 1 0 0 0 0 0 0 0 3 0 JJ NNP CD VBG NN O
emerging emerging 0 0 0 0 0 0 0 0 8 0 NNP CD VBG NN VBZ O
theme theme 0 0 0 0 0 0 0 0 5 0 CD VBG NN VBZ TO O
appears appears 0 0 0 0 0 0 0 0 7 0 VBG NN VBZ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBZ TO VB IN O
be be 0 0 0 0 0 0 0 0 2 0 VBZ TO VB IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 TO VB IN JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 VB IN JJ NN WDT O
signalling, signalling, 0 0 0 0 1 0 0 0 11 0 IN JJ NN WDT MD O
which which 0 0 0 0 0 0 0 0 5 0 JJ NN WDT MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN WDT MD VB NN O
involve involve 0 0 0 0 0 0 0 0 7 0 WDT MD VB NN IN O
modification modification 0 0 0 0 0 0 0 0 12 0 MD VB NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 VB NN IN NNS JJ O
components components 0 0 0 0 0 0 0 0 10 0 NN IN NNS JJ IN O
(such (such 0 0 0 0 0 0 0 0 5 0 IN NNS JJ IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 NNS JJ IN JJ CC O
phosphorylation) phosphorylation) 0 0 0 0 0 0 0 0 16 0 JJ IN JJ CC RB O
or or 0 0 0 0 0 0 0 0 2 0 IN JJ CC RB PRP$ O
even even 0 0 0 0 0 0 0 0 4 0 JJ CC RB PRP$ JJ O
their their 0 0 0 0 0 0 0 0 5 0 CC RB PRP$ JJ NN O
specific specific 0 0 0 0 0 0 0 0 8 0 RB PRP$ JJ NN NNS O
destruction, destruction, 0 0 0 0 1 0 0 0 12 0 PRP$ JJ NN NNS DT O
monitors monitors 0 0 0 0 0 0 0 0 8 0 JJ NN NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NNS DT NN IN O
state state 0 0 0 0 0 0 0 0 5 0 NNS DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN IN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNP O
all all 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP CD O
stages. stages. 0 0 0 0 0 0 0 0 7 0 IN DT NNP CD IN O
One One 1 0 0 0 0 0 0 0 3 0 DT NNP CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP CD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT JJ NNS O
major major 0 0 0 0 0 0 0 0 5 0 IN DT JJ NNS IN O
challenges challenges 0 0 0 0 0 0 0 0 10 0 DT JJ NNS IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN MD O
future future 0 0 0 0 0 0 0 0 6 0 IN DT NN MD VB O
will will 0 0 0 0 0 0 0 0 4 0 DT NN MD VB DT O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NN IN O
identification identification 0 0 0 0 0 0 0 0 14 0 VB DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
additional additional 0 0 0 0 0 0 0 0 10 0 NN IN JJ NNS IN O
targets targets 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
signalling signalling 0 0 0 0 0 0 0 0 10 0 IN DT NN NN IN O
machinery, machinery, 0 0 0 0 1 0 0 0 10 0 DT NN NN IN RB O
as as 0 0 0 0 0 0 0 0 2 0 NN NN IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NN IN RB IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN JJ JJ O
new new 0 0 0 0 0 0 0 0 3 0 RB IN JJ JJ NNS O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 IN JJ JJ NNS CC O
components components 0 0 0 0 0 0 0 0 10 0 JJ JJ NNS CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC PRP$ NNS O
their their 0 0 0 0 0 0 0 0 5 0 NNS CC PRP$ NNS IN O
targets targets 0 0 0 0 0 0 0 0 7 0 CC PRP$ NNS IN DT O
on on 0 0 0 0 0 0 0 0 2 0 PRP$ NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP IN O
chromosomes, chromosomes, 0 0 0 0 1 0 0 0 12 0 IN DT NNP IN DT O
on on 0 0 0 0 0 0 0 0 2 0 DT NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP CC O
spindle, spindle, 0 0 0 0 1 0 0 0 8 0 IN DT NNP CC IN O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NNP CC IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC IN DT NN NNP O
cleavage cleavage 0 0 0 0 0 0 0 0 8 0 IN DT NN NNP NNP O
furrow. furrow. 0 0 0 0 0 0 0 0 7 0 DT NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
7980489 7980489 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Photographic Photographic 1 0 0 0 0 0 0 0 12 0 NONE NONE NNP NN IN O
equidensitometry equidensitometry 0 0 0 0 0 0 0 0 16 0 NONE NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NNP O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 NN IN NN NNP NNP B_TIMEXCCP
chromosomes. chromosomes. 0 0 0 0 0 0 0 0 12 0 IN NN NNP NNP NNP O
Stockert Stockert 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NNP NNP O
JC. JC. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Photographic Photographic 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP WDT O
equidensitometry, equidensitometry, 0 0 0 0 1 0 0 0 17 0 NNP NNP NNP WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NNP NNP WDT VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP WDT VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 WDT VBZ DT NN TO O
procedure procedure 0 0 0 0 0 0 0 0 9 0 VBZ DT NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO VB JJ O
obtain obtain 0 0 0 0 0 0 0 0 6 0 NN TO VB JJ NNS O
specific specific 0 0 0 0 0 0 0 0 8 0 TO VB JJ NNS CC O
lines lines 0 0 0 0 0 0 0 0 5 0 VB JJ NNS CC NNS O
or or 0 0 0 0 0 0 0 0 2 0 JJ NNS CC NNS IN O
symbols symbols 0 0 0 0 0 0 0 0 7 0 NNS CC NNS IN NNS O
for for 0 0 0 0 0 0 0 0 3 0 CC NNS IN NNS IN O
points points 0 0 0 0 0 0 0 0 6 0 NNS IN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN JJ JJ O
equal equal 0 0 0 0 0 0 0 0 5 0 NNS IN JJ JJ NN O
optical optical 0 0 0 0 0 0 0 0 7 0 IN JJ JJ NN VBZ O
density, density, 0 0 0 0 1 0 0 0 8 0 JJ JJ NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 JJ NN VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN VBN IN O
utilized utilized 0 0 0 0 0 0 0 0 8 0 VBZ VBN VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
study study 0 0 0 0 0 0 0 0 5 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNP O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NN IN NN NNP NNP O
images. images. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NNP NNP O
Equidensitometric Equidensitometric 1 0 0 0 0 0 0 0 17 0 NN NNP NNP NNP VBG O
techniques, techniques, 0 0 0 0 1 0 0 0 11 0 NNP NNP NNP VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 NNP NNP VBG DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBG DT JJ NN O
special special 0 0 0 0 0 0 0 0 7 0 VBG DT JJ NN NN O
contour contour 0 0 0 0 0 0 0 0 7 0 DT JJ NN NN VBD O
film, film, 0 0 0 0 1 0 0 0 5 0 JJ NN NN VBD CD O
permitted permitted 0 0 0 0 0 0 0 0 9 0 NN NN VBD CD JJ O
three three 0 0 0 0 0 0 0 0 5 0 NN VBD CD JJ NN O
approaches, approaches, 0 0 0 0 1 0 0 0 11 0 VBD CD JJ NN NN O
namely, namely, 0 0 0 0 1 0 0 0 7 0 CD JJ NN NN IN O
production production 0 0 0 0 0 0 0 0 10 0 JJ NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NNS O
line line 0 0 0 0 0 0 0 0 4 0 NN IN NN NNS JJ O
equidensities equidensities 0 0 0 0 0 0 0 0 13 0 IN NN NNS JJ DT O
(in (in 0 0 0 0 0 0 0 0 3 0 NN NNS JJ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS JJ DT NN IN O
form form 0 0 0 0 0 0 0 0 4 0 JJ DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNS O
families, families, 0 0 0 0 1 0 0 0 9 0 NN IN NNP NNS CC O
sequences sequences 0 0 0 0 0 0 0 0 9 0 IN NNP NNS CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNS CC PRP$ NN O
contour contour 0 0 0 0 0 0 0 0 7 0 NNS CC PRP$ NN NN O
maps), maps), 0 0 0 0 1 0 0 0 6 0 CC PRP$ NN NN NNS O
color color 0 0 0 0 0 0 0 0 5 0 PRP$ NN NN NNS JJ O
equidensifies equidensifies 0 0 0 0 0 0 0 0 13 0 NN NN NNS JJ NN O
(color (color 0 0 0 0 0 0 0 0 6 0 NN NNS JJ NN IN O
conversion conversion 0 0 0 0 0 0 0 0 10 0 NNS JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
line line 0 0 0 0 0 0 0 0 4 0 NN IN NN NN CC O
sequences), sequences), 0 0 0 0 1 0 0 0 11 0 IN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NNS O
screen screen 0 0 0 0 0 0 0 0 6 0 NN CC NN NNS JJ O
equidensities equidensities 0 0 0 0 0 0 0 0 13 0 CC NN NNS JJ JJ O
(substituting (substituting 0 0 0 0 0 0 0 0 13 0 NN NNS JJ JJ NNS O
characteristic characteristic 0 0 0 0 0 0 0 0 14 0 NNS JJ JJ NNS IN O
symbols symbols 0 0 0 0 0 0 0 0 7 0 JJ JJ NNS IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN NNP NNP O
densities). densities). 0 0 0 0 0 0 0 0 11 0 NNS IN NNP NNP DT O
All All 1 0 0 0 0 0 0 0 3 0 IN NNP NNP DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT NNS VBP O
techniques techniques 0 0 0 0 0 0 0 0 10 0 NNP DT NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 DT NNS VBP VBN RB O
proved proved 0 0 0 0 0 0 0 0 6 0 NNS VBP VBN RB JJ O
very very 0 0 0 0 0 0 0 0 4 0 VBP VBN RB JJ TO O
useful useful 0 0 0 0 0 0 0 0 6 0 VBN RB JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 RB JJ TO VB NNS O
analyze analyze 0 0 0 0 0 0 0 0 7 0 JJ TO VB NNS IN O
images images 0 0 0 0 0 0 0 0 6 0 TO VB NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VB NNS IN NN NNS O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 NNS IN NN NNS CC B_TIMEXCCP
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 IN NN NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NN IN O
occurrence occurrence 0 0 0 0 0 0 0 0 10 0 NNS CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NN O
spontaneous spontaneous 0 0 0 0 0 0 0 0 11 0 NN IN JJ NN NN O
banding banding 0 0 0 0 0 0 0 0 7 0 IN JJ NN NN IN O
patterns, patterns, 0 0 0 0 1 0 0 0 9 0 JJ NN NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NN DT O
showing showing 0 0 0 0 0 0 0 0 7 0 NN IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN NN O
precise precise 0 0 0 0 0 0 0 0 7 0 NN DT NN NN CC O
distribution distribution 0 0 0 0 0 0 0 0 12 0 DT NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NNS O
relative relative 0 0 0 0 0 0 0 0 8 0 NN CC JJ NNS IN O
values values 0 0 0 0 0 0 0 0 6 0 CC JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NNP O
grey grey 0 0 0 0 0 0 0 0 4 0 IN DT NN NNP NNP O
gradient. gradient. 0 0 0 0 0 0 0 0 9 0 DT NN NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NN VBZ O
report report 0 0 0 0 0 0 0 0 6 0 NNP NNP NN VBZ DT O
demonstrates demonstrates 0 0 0 0 0 0 0 0 12 0 NNP NN VBZ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT JJ IN O
potential potential 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT JJ IN JJ JJ O
photograhic photograhic 0 0 0 0 0 0 0 0 11 0 JJ IN JJ JJ NNS O
equidensitometrical equidensitometrical 0 0 0 0 0 0 0 0 19 0 IN JJ JJ NNS IN O
procedures procedures 0 0 0 0 0 0 0 0 10 0 JJ JJ NNS IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN NN -NONE- O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NNS IN NN -NONE- WDT O
studies, studies, 0 0 0 0 1 0 0 0 8 0 IN NN -NONE- WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN -NONE- WDT VBZ DT O
obviates obviates 0 0 0 0 0 0 0 0 8 0 -NONE- WDT VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 WDT VBZ DT NN TO O
need need 0 0 0 0 0 0 0 0 4 0 VBZ DT NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO VB JJ O
purchase purchase 0 0 0 0 0 0 0 0 8 0 NN TO VB JJ NNP O
elaborate elaborate 0 0 0 0 0 0 0 0 9 0 TO VB JJ NNP NNP O
equipment. equipment. 0 0 0 0 0 0 0 0 10 0 VB JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
7399971 7399971 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NN IN O
nucleolus nucleolus 0 0 0 0 0 0 0 0 9 0 NONE DT NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NN O
telophase, telophase, 0 0 0 0 1 0 0 0 10 0 NN IN NNP NN CC B_TIMEXCCP
interphase interphase 0 0 0 0 0 0 0 0 10 0 IN NNP NN CC NNP B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NNP NNP O
prophase. prophase. 0 0 0 0 0 0 0 0 9 0 NN CC NNP NNP NNP B_TIMEXCCP
Ashraf Ashraf 1 0 0 0 0 0 0 0 6 0 CC NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Godward Godward 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
MB. MB. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
ultrastructure ultrastructure 0 0 0 0 0 0 0 0 14 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN TO O
telophase telophase 0 0 0 0 0 0 0 0 9 0 NN IN NN TO VB B_TIMEXCCP
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB VBZ O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NN TO VB VBZ VBN B_TIMEXCCP
has has 0 0 0 0 0 0 0 0 3 0 TO VB VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 VB VBZ VBN VBN IN O
followed followed 0 0 0 0 0 0 0 0 8 0 VBZ VBN VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NN O
green green 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN NNP O
alga, alga, 0 0 0 0 1 0 0 0 5 0 DT JJ NN NNP NNP O
Spirogyra Spirogyra 1 0 0 0 0 0 0 0 9 0 JJ NN NNP NNP NNP O
submargaritata. submargaritata. 0 0 0 0 0 0 0 0 15 0 NN NNP NNP NNP NN O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NN IN O
series series 0 0 0 0 0 0 0 0 6 0 NNP NNP NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNS JJ O
changes changes 0 0 0 0 0 0 0 0 7 0 NN IN NNS JJ IN O
transitional transitional 0 0 0 0 0 0 0 0 12 0 IN NNS JJ IN DT O
between between 0 0 0 0 0 0 0 0 7 0 NNS JJ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT JJ NN O
late late 0 0 0 0 0 0 0 0 4 0 IN DT JJ NN NN anaphase
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 DT JJ NN NN DT anaphase
chromatid, chromatid, 0 0 0 0 1 0 0 0 10 0 JJ NN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NN VBD O
decondensing decondensing 0 0 0 0 0 0 0 0 12 0 NN DT NN VBD IN O
chromatid chromatid 0 0 0 0 0 0 0 0 9 0 DT NN VBD IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN VBD IN JJ CC O
telophase, telophase, 0 0 0 0 1 0 0 0 10 0 VBD IN JJ CC DT B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ CC DT JJ NN O
'pale 'pale 0 0 0 0 0 1 0 0 5 0 CC DT JJ NN NN O
fibrillar fibrillar 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN VBG O
material' material' 0 0 0 0 0 1 0 0 9 0 JJ NN NN VBG NNS O
occupying occupying 0 0 0 0 0 0 0 0 9 0 NN NN VBG NNS IN O
channels channels 0 0 0 0 0 0 0 0 8 0 NN VBG NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBG NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
nucleolus nucleolus 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NN O
at at 0 0 0 0 0 0 0 0 2 0 DT NN IN NN VBP O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NN IN NN VBP VBN B_TIMEXCCP
have have 0 0 0 0 0 0 0 0 4 0 IN NN VBP VBN NNP O
been been 0 0 0 0 0 0 0 0 4 0 NN VBP VBN NNP NNP O
demonstrated. demonstrated. 0 0 0 0 0 0 0 0 13 0 VBP VBN NNP NNP NNS O
Early Early 1 0 0 0 0 0 0 0 5 0 VBN NNP NNP NNS IN O
stages stages 0 0 0 0 0 0 0 0 6 0 NNP NNP NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
regeneration regeneration 0 0 0 0 0 0 0 0 12 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBP O
nucleolus nucleolus 0 0 0 0 0 0 0 0 9 0 IN DT NN VBP NNP O
are are 0 0 0 0 0 0 0 0 3 0 DT NN VBP NNP NNP O
described. described. 0 0 0 0 0 0 0 0 10 0 NN VBP NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 VBP NNP NNP VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP NNP VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBN VBN IN O
shown shown 0 0 0 0 0 0 0 0 5 0 VBZ VBN VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 VBN VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NN O
pale pale 0 0 0 0 0 0 0 0 4 0 IN DT NN NN NN O
fibrillar fibrillar 0 0 0 0 0 0 0 0 9 0 DT NN NN NN IN O
material material 0 0 0 0 0 0 0 0 8 0 NN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBZ O
nucleolus nucleolus 0 0 0 0 0 0 0 0 9 0 IN DT NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ VBN -NONE- O
attached attached 0 0 0 0 0 0 0 0 8 0 NN VBZ VBN -NONE- CC O
to, to, 0 0 0 0 1 0 0 0 3 0 VBZ VBN -NONE- CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBN -NONE- CC JJ NN O
continuous continuous 0 0 0 0 0 0 0 0 10 0 -NONE- CC JJ NN DT O
with, with, 0 0 0 0 1 0 0 0 5 0 CC JJ NN DT RB O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT RB VBN O
fully fully 0 0 0 0 0 0 0 0 5 0 NN DT RB VBN -NONE- O
condensed condensed 0 0 0 0 0 0 0 0 9 0 DT RB VBN -NONE- NN O
(chromocentric) (chromocentric) 0 0 0 0 0 0 0 0 15 0 RB VBN -NONE- NN IN O
part part 0 0 0 0 0 0 0 0 4 0 VBN -NONE- NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 -NONE- NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
nucleolar-organizing nucleolar-organizing 0 0 1 0 0 0 0 0 20 0 IN DT JJ NN IN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN NNP O
at at 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
interphase. interphase. 0 0 0 0 0 0 0 0 11 0 NN IN NNP NNP VBZ B_TIMEXCCP
It It 1 0 0 0 0 0 0 0 2 0 IN NNP NNP VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ RB VBN O
also also 0 0 0 0 0 0 0 0 4 0 NNP VBZ RB VBN IN O
shown shown 0 0 0 0 0 0 0 0 5 0 VBZ RB VBN IN IN O
that that 0 0 0 0 0 0 0 0 4 0 RB VBN IN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBN IN IN JJ NN O
early early 0 0 0 0 0 0 0 0 5 0 IN IN JJ NN DT prophase
prophase, prophase, 0 0 0 0 1 0 0 0 9 0 IN JJ NN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NNS IN O
channels channels 0 0 0 0 0 0 0 0 8 0 NN DT NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
nucleolonema nucleolonema 0 0 0 0 0 0 0 0 12 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBP O
nucleolus nucleolus 0 0 0 0 0 0 0 0 9 0 IN DT NN VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 DT NN VBP RB RBR O
no no 0 0 0 0 0 0 0 0 2 0 NN VBP RB RBR VBN O
longer longer 0 0 0 0 0 0 0 0 6 0 VBP RB RBR VBN IN O
occupied occupied 0 0 0 0 0 0 0 0 8 0 RB RBR VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 RBR VBN IN NN NN O
pale pale 0 0 0 0 0 0 0 0 4 0 VBN IN NN NN NN O
fibrillar fibrillar 0 0 0 0 0 0 0 0 9 0 IN NN NN NN CC O
material, material, 0 0 0 0 1 0 0 0 9 0 NN NN NN CC RB O
but but 0 0 0 0 0 0 0 0 3 0 NN NN CC RB DT O
instead instead 0 0 0 0 0 0 0 0 7 0 NN CC RB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 CC RB DT JJ NN O
long long 0 0 0 0 0 0 0 0 4 0 RB DT JJ NN IN O
section section 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN VBN NN O
condensed condensed 0 0 0 0 0 0 0 0 9 0 NN IN VBN NN VBZ O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 IN VBN NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 VBN NN VBZ JJ NN O
present, present, 0 0 0 0 1 0 0 0 8 0 NN VBZ JJ NN DT O
traversing traversing 0 0 0 0 0 0 0 0 10 0 VBZ JJ NN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NNP NNP O
nucleolonema. nucleolonema. 0 0 0 0 0 0 0 0 13 0 NN DT NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 DT NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
contended contended 0 0 0 0 0 0 0 0 9 0 NNP VBZ VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 VBN IN DT NNS VBN O
observations observations 0 0 0 0 0 0 0 0 12 0 IN DT NNS VBN RB O
taken taken 0 0 0 0 0 0 0 0 5 0 DT NNS VBN RB JJ O
together together 0 0 0 0 0 0 0 0 8 0 NNS VBN RB JJ NN O
constitute constitute 0 0 0 0 0 0 0 0 10 0 VBN RB JJ NN IN O
evidence evidence 0 0 0 0 0 0 0 0 8 0 RB JJ NN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
pale pale 0 0 0 0 0 0 0 0 4 0 IN DT NN NN NN O
fibrillar fibrillar 0 0 0 0 0 0 0 0 9 0 DT NN NN NN IN O
material material 0 0 0 0 0 0 0 0 8 0 NN NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBZ O
nucleolus nucleolus 0 0 0 0 0 0 0 0 9 0 IN DT NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT NN IN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 VBZ DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
nucleolar-organizing nucleolar-organizing 0 0 1 0 0 0 0 0 20 0 IN DT JJ NN IN O
region region 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ VBD O
chromosome, chromosome, 0 0 0 0 1 0 0 0 11 0 IN DT JJ VBD IN O
expanded expanded 0 0 0 0 0 0 0 0 8 0 DT JJ VBD IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 JJ VBD IN NNP DT O
transcription. transcription. 0 0 0 0 0 0 0 0 14 0 VBD IN NNP DT NN O
A A 1 1 0 0 0 0 0 0 1 0 IN NNP DT NN IN O
model model 0 0 0 0 0 0 0 0 5 0 NNP DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
nucleolus nucleolus 0 0 0 0 0 0 0 0 9 0 IN DT NN IN PRP O
as as 0 0 0 0 0 0 0 0 2 0 DT NN IN PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NN IN PRP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 IN PRP VBZ VBN IN O
seen seen 0 0 0 0 0 0 0 0 4 0 PRP VBZ VBN IN JJS O
in in 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN JJS JJ O
most most 0 0 0 0 0 0 0 0 4 0 VBN IN JJS JJ NN O
electron-microscope electron-microscope 0 0 1 0 0 0 0 0 19 0 IN JJS JJ NN CC O
sections, sections, 0 0 0 0 1 0 0 0 9 0 JJS JJ NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC IN PRP O
as as 0 0 0 0 0 0 0 0 2 0 NN CC IN PRP MD O
it it 0 0 0 0 0 0 0 0 2 0 CC IN PRP MD VB O
can can 0 0 0 0 0 0 0 0 3 0 IN PRP MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 PRP MD VB VBN IN O
interpreted interpreted 0 0 0 0 0 0 0 0 11 0 MD VB VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VB VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ IN O
light light 0 0 0 0 0 0 0 0 5 0 IN DT JJ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT JJ IN JJ NN O
present-day present-day 0 0 1 0 0 0 0 0 11 0 JJ IN JJ NN IN O
knowledge knowledge 0 0 0 0 0 0 0 0 9 0 IN JJ NN IN JJ O
about about 0 0 0 0 0 0 0 0 5 0 JJ NN IN JJ VBZ O
it, it, 0 0 0 0 1 0 0 0 3 0 NN IN JJ VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 IN JJ VBZ NNP DT O
presented. presented. 0 0 0 0 0 0 0 0 10 0 JJ VBZ NNP DT JJ O
A A 1 1 0 0 0 0 0 0 1 0 VBZ NNP DT JJ NN O
brief brief 0 0 0 0 0 0 0 0 5 0 NNP DT JJ NN IN O
review review 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
relevant relevant 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN NNS O
literature literature 0 0 0 0 0 0 0 0 10 0 DT JJ NN NNS DT O
considers considers 0 0 0 0 0 0 0 0 9 0 JJ NN NNS DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN NNS DT NNS VBG O
views views 0 0 0 0 0 0 0 0 5 0 NNS DT NNS VBG DT O
supporting supporting 0 0 0 0 0 0 0 0 10 0 DT NNS VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBG DT NN CC O
mode, mode, 0 0 0 0 1 0 0 0 5 0 VBG DT NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN NN O
contrary contrary 0 0 0 0 0 0 0 0 8 0 CC DT NN NN VBG O
views, views, 0 0 0 0 1 0 0 0 6 0 DT NN NN VBG DT O
implicating implicating 0 0 0 0 0 0 0 0 11 0 NN NN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT NN IN O
use use 0 0 0 0 0 0 0 0 3 0 VBG DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN JJ O
term term 0 0 0 0 0 0 0 0 4 0 IN DT NN JJ NN O
'nucleolar 'nucleolar 0 0 0 0 0 1 0 0 10 0 DT NN JJ NN WDT O
organizer', organizer', 0 0 0 0 1 1 0 0 11 0 NN JJ NN WDT VBP O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 NN WDT VBP RB JJ O
still still 0 0 0 0 0 0 0 0 5 0 WDT VBP RB JJ IN O
current current 0 0 0 0 0 0 0 0 7 0 VBP RB JJ IN DT O
at at 0 0 0 0 0 0 0 0 2 0 RB JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN NNP O
present present 0 0 0 0 0 0 0 0 7 0 IN DT NN NNP NNP O
time. time. 0 0 0 0 0 0 0 0 5 0 DT NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
7364886 7364886 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NN NN O
limiting limiting 0 0 0 0 0 0 0 0 8 0 NONE DT NN NN IN O
radiosensitisation radiosensitisation 0 0 0 0 0 0 0 0 18 0 DT NN NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNS IN O
tumours tumours 0 0 0 0 0 0 0 0 7 0 NN IN NNS IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 IN NNS IN JJ NNP O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 NNS IN JJ NNP NNP B_TIMEXCCP
sensitisers. sensitisers. 0 0 0 0 0 0 0 0 12 0 IN JJ NNP NNP NNP O
Fowler Fowler 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP NNP NNP O
JF, JF, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Kinsella Kinsella 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
TJ. TJ. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Oncology Oncology 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Department, Department, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Hospital Hospital 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Gasthuisberg, Gasthuisberg, 1 0 0 0 1 0 0 0 13 0 NNP NNP NNP NNP NNP O
Leuven, Leuven, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Belgium. Belgium. 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
aim aim 0 0 0 0 0 0 0 0 3 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 IN DT NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB JJ O
improve improve 0 0 0 0 0 0 0 0 7 0 VBD TO VB JJ NN O
local local 0 0 0 0 0 0 0 0 5 0 TO VB JJ NN CC O
control control 0 0 0 0 0 0 0 0 7 0 VB JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN IN O
survival survival 0 0 0 0 0 0 0 0 8 0 NN CC NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 NN IN NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN JJ NNS O
radioresistant radioresistant 0 0 0 0 0 0 0 0 14 0 NNS IN JJ NNS IN O
tumours tumours 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN VBG O
by by 0 0 0 0 0 0 0 0 2 0 JJ NNS IN VBG VBG O
sensitising sensitising 0 0 0 0 0 0 0 0 11 0 NNS IN VBG VBG NNS O
proliferating proliferating 0 0 0 0 0 0 0 0 13 0 IN VBG VBG NNS VBG O
cells cells 0 0 0 0 0 0 0 0 5 0 VBG VBG NNS VBG VBN O
using using 0 0 0 0 0 0 0 0 5 0 VBG NNS VBG VBN NNS O
halogenated halogenated 0 0 0 0 0 0 0 0 11 0 NNS VBG VBN NNS IN O
analogues analogues 0 0 0 0 0 0 0 0 9 0 VBG VBN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBN NNS IN JJ IN O
thymidine, thymidine, 0 0 0 0 1 0 0 0 10 0 NNS IN JJ IN NN O
with with 0 0 0 0 0 0 0 0 4 0 IN JJ IN NN IN O
emphasis emphasis 0 0 0 0 0 0 0 0 8 0 JJ IN NN IN VBG O
on on 0 0 0 0 0 0 0 0 2 0 IN NN IN VBG DT O
increasing increasing 0 0 0 0 0 0 0 0 10 0 NN IN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN VBG DT NN IN O
proportion proportion 0 0 0 0 0 0 0 0 10 0 VBG DT NN IN PRP$ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN PRP$ NNS O
tumour tumour 0 0 0 0 0 0 0 0 6 0 NN IN PRP$ NNS WDT O
cells cells 0 0 0 0 0 0 0 0 5 0 IN PRP$ NNS WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 PRP$ NNS WDT NN DT O
incorporate incorporate 0 0 0 0 0 0 0 0 11 0 NNS WDT NN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 WDT NN DT NNP NNP O
sensitiser. sensitiser. 0 0 0 0 0 0 0 0 11 0 NN DT NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 DT NNP NNP VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP NNP VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBN VBN RB O
found found 0 0 0 0 0 0 0 0 5 0 VBZ VBN VBN RB IN O
clinically clinically 0 0 0 0 0 0 0 0 10 0 VBN VBN RB IN CD O
that that 0 0 0 0 0 0 0 0 4 0 VBN RB IN CD NNS O
2 2 0 0 0 0 0 0 1 1 1 0 RB IN CD NNS IN O
weeks weeks 0 0 0 0 0 0 0 0 5 0 IN CD NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN JJ NN O
continuous continuous 0 0 0 0 0 0 0 0 10 0 NNS IN JJ NN IN O
infusion infusion 0 0 0 0 0 0 0 0 8 0 IN JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP IN O
IUdR IUdR 1 0 0 0 0 0 0 0 4 0 NN IN NNP IN CD O
at at 0 0 0 0 0 0 0 0 2 0 IN NNP IN CD NN O
1000 1000 0 0 0 0 0 0 1 1 4 0 NNP IN CD NN -NONE- O
mg mg 0 0 0 0 0 0 0 0 2 0 IN CD NN -NONE- IN O
m-2 m-2 0 0 1 0 0 0 0 1 3 0 CD NN -NONE- IN NN O
per per 0 0 0 0 0 0 0 0 3 0 NN -NONE- IN NN MD O
day day 0 0 0 0 0 0 0 0 3 0 -NONE- IN NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 IN NN MD VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB JJ VBN O
tolerated, tolerated, 0 0 0 0 1 0 0 0 10 0 MD VB JJ VBN IN O
followed followed 0 0 0 0 0 0 0 0 8 0 VB JJ VBN IN DT O
after after 0 0 0 0 0 0 0 0 5 0 JJ VBN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NN IN O
gap gap 0 0 0 0 0 0 0 0 3 0 IN DT NN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
third third 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN IN O
week week 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
same. same. 0 0 0 0 0 0 0 0 5 0 IN DT NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 DT NNP NNP NN VBD O
sensitising sensitising 0 0 0 0 0 0 0 0 11 0 NNP NNP NN VBD VBZ O
compound compound 0 0 0 0 0 0 0 0 8 0 NNP NN VBD VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN VBD VBZ VBN RP O
taken taken 0 0 0 0 0 0 0 0 5 0 VBD VBZ VBN RP RB O
up up 0 0 0 0 0 0 0 0 2 0 VBZ VBN RP RB IN O
only only 0 0 0 0 0 0 0 0 4 0 VBN RP RB IN DT O
into into 0 0 0 0 0 0 0 0 4 0 RP RB IN DT NNS O
those those 0 0 0 0 0 0 0 0 5 0 RB IN DT NNS WDT O
cells cells 0 0 0 0 0 0 0 0 5 0 IN DT NNS WDT VBP O
which which 0 0 0 0 0 0 0 0 5 0 DT NNS WDT VBP IN O
are are 0 0 0 0 0 0 0 0 3 0 NNS WDT VBP IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 WDT VBP IN JJ IN O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 VBP IN JJ IN DT B_TIMEXCCP
at at 0 0 0 0 0 0 0 0 2 0 IN JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN IN O
time time 0 0 0 0 0 0 0 0 4 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
administration. administration. 0 0 0 0 0 0 0 0 15 0 NN IN NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 IN NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
assumed assumed 0 0 0 0 0 0 0 0 7 0 NNP VBZ VBN IN IN O
that that 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN IN DT O
if if 0 0 0 0 0 0 0 0 2 0 VBN IN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 IN IN DT JJ NN O
same same 0 0 0 0 0 0 0 0 4 0 IN DT JJ NN NN O
total total 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN IN O
dose dose 0 0 0 0 0 0 0 0 4 0 JJ NN NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN CD NN O
3 3 0 0 0 0 0 0 1 1 1 0 NN IN CD NN -NONE- O
g g 0 0 0 0 0 0 0 0 1 0 IN CD NN -NONE- VBD O
m-2 m-2 0 0 1 0 0 0 0 1 3 0 CD NN -NONE- VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN -NONE- VBD VBN NN O
administered administered 0 0 0 0 0 0 0 0 12 0 -NONE- VBD VBN NN RB O
spread spread 0 0 0 0 0 0 0 0 6 0 VBD VBN NN RB IN O
evenly evenly 0 0 0 0 0 0 0 0 6 0 VBN NN RB IN DT O
over over 0 0 0 0 0 0 0 0 4 0 NN RB IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 RB IN DT NN NN O
longer longer 0 0 0 0 0 0 0 0 6 0 IN DT NN NN PRP O
period, period, 0 0 0 0 1 0 0 0 7 0 DT NN NN PRP MD O
it it 0 0 0 0 0 0 0 0 2 0 NN NN PRP MD VB O
would would 0 0 0 0 0 0 0 0 5 0 NN PRP MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 PRP MD VB VBN IN O
tolerated tolerated 0 0 0 0 0 0 0 0 9 0 MD VB VBN IN JJS O
at at 0 0 0 0 0 0 0 0 2 0 VB VBN IN JJS IN O
least least 0 0 0 0 0 0 0 0 5 0 VBN IN JJS IN NN O
as as 0 0 0 0 0 0 0 0 2 0 IN JJS IN NN CC O
well, well, 0 0 0 0 1 0 0 0 5 0 JJS IN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC DT JJR O
a a 0 0 0 0 0 0 0 0 1 0 NN CC DT JJR NN O
higher higher 0 0 0 0 0 0 0 0 6 0 CC DT JJR NN IN O
proportion proportion 0 0 0 0 0 0 0 0 10 0 DT JJR NN IN PRP$ O
of of 0 0 0 0 0 0 0 0 2 0 JJR NN IN PRP$ NNS O
tumour tumour 0 0 0 0 0 0 0 0 6 0 NN IN PRP$ NNS MD O
cells cells 0 0 0 0 0 0 0 0 5 0 IN PRP$ NNS MD VB O
would would 0 0 0 0 0 0 0 0 5 0 PRP$ NNS MD VB VBN O
become become 0 0 0 0 0 0 0 0 6 0 NNS MD VB VBN JJ O
sensitised sensitised 0 0 0 0 0 0 0 0 10 0 MD VB VBN JJ IN O
(labelled (labelled 0 0 0 0 0 0 0 0 9 0 VB VBN JJ IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBN JJ IN NNP NNP O
IUdR). IUdR). 1 0 0 0 0 0 0 0 6 0 JJ IN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NN RB O
question question 0 0 0 0 0 0 0 0 8 0 NNP NNP NN RB JJ O
then then 0 0 0 0 0 0 0 0 4 0 NNP NN RB JJ VBZ O
arises: arises: 0 0 0 0 0 0 0 0 7 0 NN RB JJ VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 RB JJ VBZ DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 JJ VBZ DT VBN NN O
reduced reduced 0 0 0 0 0 0 0 0 7 0 VBZ DT VBN NN IN O
concentration concentration 0 0 0 0 0 0 0 0 13 0 DT VBN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNP RB O
IUdR IUdR 1 0 0 0 0 0 0 0 4 0 NN IN NNP RB TO O
enough enough 0 0 0 0 0 0 0 0 6 0 IN NNP RB TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNP RB TO VB JJ O
cause cause 0 0 0 0 0 0 0 0 5 0 RB TO VB JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 TO VB JJ NN DT O
radiosensitisation? radiosensitisation? 0 0 0 0 0 0 0 0 19 0 VB JJ NN DT NN O
This This 1 0 0 0 0 0 0 0 4 0 JJ NN DT NN VBD O
question question 0 0 0 0 0 0 0 0 8 0 NN DT NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD VBN IN O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NN VBD VBN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN CD VBG O
two two 0 0 0 0 0 0 0 0 3 0 VBN IN CD VBG NNS O
contrasting contrasting 0 0 0 0 0 0 0 0 11 0 IN CD VBG NNS IN O
lines lines 0 0 0 0 0 0 0 0 5 0 CD VBG NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBG NNS IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NN NN O
colon colon 0 0 0 0 0 0 0 0 5 0 IN JJ NN NN IN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 JJ NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
vitro. vitro. 0 0 0 0 0 0 0 0 6 0 NN IN NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 IN NNP NNP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ JJ IN O
essential essential 0 0 0 0 0 0 0 0 9 0 NNP VBZ JJ IN IN O
that that 0 0 0 0 0 0 0 0 4 0 VBZ JJ IN IN JJS O
at at 0 0 0 0 0 0 0 0 2 0 JJ IN IN JJS CD O
least least 0 0 0 0 0 0 0 0 5 0 IN IN JJS CD IN O
90% 90% 0 0 0 0 0 0 0 1 3 0 IN JJS CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJS CD IN DT JJ O
all all 0 0 0 0 0 0 0 0 3 0 CD IN DT JJ NN O
clonogenic clonogenic 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN NNS O
tumour tumour 0 0 0 0 0 0 0 0 6 0 DT JJ NN NNS MD O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS MD VB O
should should 0 0 0 0 0 0 0 0 6 0 NN NNS MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB VBN IN O
labelled labelled 0 0 0 0 0 0 0 0 8 0 MD VB VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VB VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NNP O
IUdR IUdR 1 0 0 0 0 0 0 0 4 0 IN DT NNP NNP VBZ O
(that (that 0 0 0 0 0 0 0 0 5 0 DT NNP NNP VBZ CD O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ CD -NONE- O
1 1 0 0 0 0 0 0 1 1 1 0 NNP VBZ CD -NONE- CC O
log), log), 0 0 0 0 1 0 0 0 5 0 VBZ CD -NONE- CC VB O
or or 0 0 0 0 0 0 0 0 2 0 CD -NONE- CC VB DT O
else else 0 0 0 0 0 0 0 0 4 0 -NONE- CC VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC VB DT NN NN O
sensitiser sensitiser 0 0 0 0 0 0 0 0 10 0 VB DT NN NN NN O
enhancement enhancement 0 0 0 0 0 0 0 0 11 0 DT NN NN NN NN O
ratio ratio 0 0 0 0 0 0 0 0 5 0 NN NN NN NN RB O
(SER) (SER) 0 1 0 0 0 0 0 0 5 0 NN NN NN RB VB O
cannot cannot 0 0 0 0 0 0 0 0 6 0 NN NN RB VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN RB VB VBN TO O
expected expected 0 0 0 0 0 0 0 0 8 0 RB VB VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VB VBN TO VB CD O
exceed exceed 0 0 0 0 0 0 0 0 6 0 VBN TO VB CD -NONE- O
1.1. 1.1. 0 0 0 0 0 0 0 1 4 0 TO VB CD -NONE- TO O
Similarly, Similarly, 1 0 0 0 1 0 0 0 10 0 VB CD -NONE- TO VB O
to to 0 0 0 0 0 0 0 0 2 0 CD -NONE- TO VB DT O
reach reach 0 0 0 0 0 0 0 0 5 0 -NONE- TO VB DT NNP O
an an 0 0 0 0 0 0 0 0 2 0 TO VB DT NNP IN O
SER SER 1 1 0 0 0 0 0 0 3 0 VB DT NNP IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NNP IN CD PRP O
1.2, 1.2, 0 0 0 0 1 0 0 1 4 0 NNP IN CD PRP MD O
we we 0 0 0 0 0 0 0 0 2 0 IN CD PRP MD VB O
should should 0 0 0 0 0 0 0 0 6 0 CD PRP MD VB CD O
label label 0 0 0 0 0 0 0 0 5 0 PRP MD VB CD IN O
99% 99% 0 0 0 0 0 0 0 1 3 0 MD VB CD IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 VB CD IN NNS -NONE- O
cells cells 0 0 0 0 0 0 0 0 5 0 CD IN NNS -NONE- NNS O
(2 (2 0 0 0 0 0 0 0 1 2 0 IN NNS -NONE- NNS NNP O
logs logs 0 0 0 0 0 0 0 0 4 0 NNS -NONE- NNS NNP TO O
labelled). labelled). 0 0 0 0 0 0 0 0 10 0 -NONE- NNS NNP TO VB O
To To 1 0 0 0 0 0 0 0 2 0 NNS NNP TO VB JJ O
achieve achieve 0 0 0 0 0 0 0 0 7 0 NNP TO VB JJ NNS O
such such 0 0 0 0 0 0 0 0 4 0 TO VB JJ NNS -NONE- O
proportions proportions 0 0 0 0 0 0 0 0 11 0 VB JJ NNS -NONE- NNS O
labelled, labelled, 0 0 0 0 1 0 0 0 9 0 JJ NNS -NONE- NNS MD O
infusions infusions 0 0 0 0 0 0 0 0 9 0 NNS -NONE- NNS MD VB O
would would 0 0 0 0 0 0 0 0 5 0 -NONE- NNS MD VB TO O
have have 0 0 0 0 0 0 0 0 4 0 NNS MD VB TO VB O
to to 0 0 0 0 0 0 0 0 2 0 MD VB TO VB CD O
be be 0 0 0 0 0 0 0 0 2 0 VB TO VB CD CC O
5 5 0 0 0 0 0 0 1 1 1 0 TO VB CD CC CD O
or or 0 0 0 0 0 0 0 0 2 0 VB CD CC CD NNS O
10 10 0 0 0 0 0 0 1 1 2 0 CD CC CD NNS JJR O
times times 0 0 0 0 0 0 0 0 5 0 CC CD NNS JJR IN O
longer longer 0 0 0 0 0 0 0 0 6 0 CD NNS JJR IN DT O
than than 0 0 0 0 0 0 0 0 4 0 NNS JJR IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJR IN DT NN VBG O
population population 0 0 0 0 0 0 0 0 10 0 IN DT NN VBG NN O
doubling doubling 0 0 0 0 0 0 0 0 8 0 DT NN VBG NN IN O
time time 0 0 0 0 0 0 0 0 4 0 NN VBG NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBG NN IN JJ NNS O
clonogenic clonogenic 0 0 0 0 0 0 0 0 10 0 NN IN JJ NNS NNP O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS NNP IN O
Tpot Tpot 1 0 0 0 0 0 0 0 4 0 JJ NNS NNP IN VBZ O
that that 0 0 0 0 0 0 0 0 4 0 NNS NNP IN VBZ IN O
is is 0 0 0 0 0 0 0 0 2 0 NNP IN VBZ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN VBZ IN JJ NNS O
several several 0 0 0 0 0 0 0 0 7 0 VBZ IN JJ NNS NNP O
weeks weeks 0 0 0 0 0 0 0 0 5 0 IN JJ NNS NNP NNP O
duration. duration. 0 0 0 0 0 0 0 0 9 0 JJ NNS NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNS NNP NNP NN MD O
infusion infusion 0 0 0 0 0 0 0 0 8 0 NNP NNP NN MD VB O
should should 0 0 0 0 0 0 0 0 6 0 NNP NN MD VB RB O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB RB JJ O
either either 0 0 0 0 0 0 0 0 6 0 MD VB RB JJ CC O
continuous continuous 0 0 0 0 0 0 0 0 10 0 VB RB JJ CC RB O
or or 0 0 0 0 0 0 0 0 2 0 RB JJ CC RB JJ O
perhaps perhaps 0 0 0 0 0 0 0 0 7 0 JJ CC RB JJ VBN O
better-by better-by 0 0 1 0 0 0 0 0 9 0 CC RB JJ VBN JJ O
repeated repeated 0 0 0 0 0 0 0 0 8 0 RB JJ VBN JJ NNS O
small small 0 0 0 0 0 0 0 0 5 0 JJ VBN JJ NNS IN O
boluses boluses 0 0 0 0 0 0 0 0 7 0 VBN JJ NNS IN NNS O
at at 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNS IN O
intervals intervals 0 0 0 0 0 0 0 0 9 0 NNS IN NNS IN JJR O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN JJR IN O
less less 0 0 0 0 0 0 0 0 4 0 NNS IN JJR IN NNP O
than than 0 0 0 0 0 0 0 0 4 0 IN JJR IN NNP NN O
T T 1 1 0 0 0 0 0 0 1 0 JJR IN NNP NN IN O
(duration (duration 0 0 0 0 0 0 0 0 9 0 IN NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNP RB O
synthesis), synthesis), 0 0 0 0 1 0 0 0 11 0 IN NNP NNP RB IN O
so so 0 0 0 0 0 0 0 0 2 0 NNP NNP RB IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNP RB IN DT NN O
no no 0 0 0 0 0 0 0 0 2 0 RB IN DT NN NNS O
proliferating proliferating 0 0 0 0 0 0 0 0 13 0 IN DT NN NNS NN O
cells cells 0 0 0 0 0 0 0 0 5 0 DT NN NNS NN VBG O
escape escape 0 0 0 0 0 0 0 0 6 0 NN NNS NN VBG VBN O
being being 0 0 0 0 0 0 0 0 5 0 NNS NN VBG VBN TO O
exposed exposed 0 0 0 0 0 0 0 0 7 0 NN VBG VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBG VBN TO DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN TO DT NNP NNP O
IUdR. IUdR. 1 0 0 0 0 0 0 0 5 0 TO DT NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 DT NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
shown shown 0 0 0 0 0 0 0 0 5 0 NNP VBZ VBN IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN NNP NNP O
LIs LIs 1 0 0 0 0 0 0 0 3 0 VBN IN NNP NNP NNP O
(labelling (labelling 0 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP IN O
indices) indices) 0 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN CD MD O
94% 94% 0 0 0 0 0 0 0 1 3 0 NNP IN CD MD VB O
can can 0 0 0 0 0 0 0 0 3 0 IN CD MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 CD MD VB VBN IN O
obtained obtained 0 0 0 0 0 0 0 0 8 0 MD VB VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VB VBN IN NNP VBG O
SERs SERs 1 0 0 0 0 0 0 0 4 0 VBN IN NNP VBG IN O
ranging ranging 0 0 0 0 0 0 0 0 7 0 IN NNP VBG IN CD O
from from 0 0 0 0 0 0 0 0 4 0 NNP VBG IN CD TO O
1.5 1.5 0 0 0 0 0 0 0 1 3 0 VBG IN CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 IN CD TO CD CC O
3.0 3.0 0 0 0 0 0 0 0 1 3 0 CD TO CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 TO CD CC CD IN O
99% 99% 0 0 0 0 0 0 0 1 3 0 CD CC CD IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 CC CD IN NNP IN O
SERs SERs 1 0 0 0 0 0 0 0 4 0 CD IN NNP IN CD O
from from 0 0 0 0 0 0 0 0 4 0 IN NNP IN CD TO O
1.2 1.2 0 0 0 0 0 0 0 1 3 0 NNP IN CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 IN CD TO CD IN O
2.4, 2.4, 0 0 0 0 1 0 0 1 4 0 CD TO CD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 TO CD IN DT CD O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT CD JJS O
two two 0 0 0 0 0 0 0 0 3 0 IN DT CD JJS VBG O
most most 0 0 0 0 0 0 0 0 4 0 DT CD JJS VBG NN O
contrasting contrasting 0 0 0 0 0 0 0 0 11 0 CD JJS VBG NN NN O
human human 0 0 0 0 0 0 0 0 5 0 JJS VBG NN NN NN O
colon colon 0 0 0 0 0 0 0 0 5 0 VBG NN NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NNS IN O
lines lines 0 0 0 0 0 0 0 0 5 0 NN NN NNS IN WDT O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN WDT NNS O
which which 0 0 0 0 0 0 0 0 5 0 NNS IN WDT NNS VBP O
data data 0 0 0 0 0 0 0 0 4 0 IN WDT NNS VBP NNP O
are are 0 0 0 0 0 0 0 0 3 0 WDT NNS VBP NNP NNP O
available. available. 0 0 0 0 0 0 0 0 10 0 NNS VBP NNP NNP JJR O
Longer, Longer, 1 0 0 0 1 0 0 0 7 0 VBP NNP NNP JJR NN O
lower lower 0 0 0 0 0 0 0 0 5 0 NNP NNP JJR NN NNS O
dose dose 0 0 0 0 0 0 0 0 4 0 NNP JJR NN NNS IN O
infusions infusions 0 0 0 0 0 0 0 0 9 0 JJR NN NNS IN RB O
than than 0 0 0 0 0 0 0 0 4 0 NN NNS IN RB VBN O
previously previously 0 0 0 0 0 0 0 0 10 0 NNS IN RB VBN MD O
used used 0 0 0 0 0 0 0 0 4 0 IN RB VBN MD VB O
should should 0 0 0 0 0 0 0 0 6 0 RB VBN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 VBN MD VB VBN RB O
considered considered 0 0 0 0 0 0 0 0 10 0 MD VB VBN RB IN O
so so 0 0 0 0 0 0 0 0 2 0 VB VBN RB IN TO O
as as 0 0 0 0 0 0 0 0 2 0 VBN RB IN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 RB IN TO VB DT O
emphasise emphasise 0 0 0 0 0 0 0 0 9 0 IN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
importance importance 0 0 0 0 0 0 0 0 10 0 VB DT NN IN RB O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN RB VBG O
not not 0 0 0 0 0 0 0 0 3 0 NN IN RB VBG DT O
allowing allowing 0 0 0 0 0 0 0 0 8 0 IN RB VBG DT RB O
any any 0 0 0 0 0 0 0 0 3 0 RB VBG DT RB JJ O
potentially potentially 0 0 0 0 0 0 0 0 11 0 VBG DT RB JJ NN O
clonogenic clonogenic 0 0 0 0 0 0 0 0 10 0 DT RB JJ NN NNS O
tumour tumour 0 0 0 0 0 0 0 0 6 0 RB JJ NN NNS TO O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO VB IN O
pass pass 0 0 0 0 0 0 0 0 4 0 NNS TO VB IN JJ O
through through 0 0 0 0 0 0 0 0 7 0 TO VB IN JJ IN O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 VB IN JJ IN NNP B_TIMEXCCP
without without 0 0 0 0 0 0 0 0 7 0 IN JJ IN NNP NNP O
labelling. labelling. 0 0 0 0 0 0 0 0 10 0 JJ IN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 IN NNP NNP CD JJ O
8763900 8763900 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NN O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NN NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
PMC2150020 PMC2150020 1 1 0 0 0 0 0 1 10 0 JJ NN NNP NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NN IN O
nucleolus nucleolus 0 0 0 0 0 0 0 0 9 0 NONE DT NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NN O
telophase, telophase, 0 0 0 0 1 0 0 0 10 0 NN IN NNP NN CC B_TIMEXCCP
interphase interphase 0 0 0 0 0 0 0 0 10 0 IN NNP NN CC NNP B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NNP NNP O
prophase. prophase. 0 0 0 0 0 0 0 0 9 0 NN CC NNP NNP NNP B_TIMEXCCP
Ashraf Ashraf 1 0 0 0 0 0 0 0 6 0 CC NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Godward Godward 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
MB. MB. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
ultrastructure ultrastructure 0 0 0 0 0 0 0 0 14 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN TO O
telophase telophase 0 0 0 0 0 0 0 0 9 0 NN IN NN TO VB B_TIMEXCCP
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB VBZ O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NN TO VB VBZ VBN B_TIMEXCCP
has has 0 0 0 0 0 0 0 0 3 0 TO VB VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 VB VBZ VBN VBN IN O
followed followed 0 0 0 0 0 0 0 0 8 0 VBZ VBN VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NN O
green green 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN NNP O
alga, alga, 0 0 0 0 1 0 0 0 5 0 DT JJ NN NNP NNP O
Spirogyra Spirogyra 1 0 0 0 0 0 0 0 9 0 JJ NN NNP NNP NNP O
submargaritata. submargaritata. 0 0 0 0 0 0 0 0 15 0 NN NNP NNP NNP NN O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NN IN O
series series 0 0 0 0 0 0 0 0 6 0 NNP NNP NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNS JJ O
changes changes 0 0 0 0 0 0 0 0 7 0 NN IN NNS JJ IN O
transitional transitional 0 0 0 0 0 0 0 0 12 0 IN NNS JJ IN DT O
between between 0 0 0 0 0 0 0 0 7 0 NNS JJ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT JJ NN O
late late 0 0 0 0 0 0 0 0 4 0 IN DT JJ NN NN anaphase
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 DT JJ NN NN DT anaphase
chromatid, chromatid, 0 0 0 0 1 0 0 0 10 0 JJ NN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NN VBD O
decondensing decondensing 0 0 0 0 0 0 0 0 12 0 NN DT NN VBD IN O
chromatid chromatid 0 0 0 0 0 0 0 0 9 0 DT NN VBD IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN VBD IN JJ CC O
telophase, telophase, 0 0 0 0 1 0 0 0 10 0 VBD IN JJ CC DT B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ CC DT JJ NN O
'pale 'pale 0 0 0 0 0 1 0 0 5 0 CC DT JJ NN NN O
fibrillar fibrillar 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN VBG O
material' material' 0 0 0 0 0 1 0 0 9 0 JJ NN NN VBG NNS O
occupying occupying 0 0 0 0 0 0 0 0 9 0 NN NN VBG NNS IN O
channels channels 0 0 0 0 0 0 0 0 8 0 NN VBG NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBG NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
nucleolus nucleolus 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NN O
at at 0 0 0 0 0 0 0 0 2 0 DT NN IN NN VBP O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NN IN NN VBP VBN B_TIMEXCCP
have have 0 0 0 0 0 0 0 0 4 0 IN NN VBP VBN NNP O
been been 0 0 0 0 0 0 0 0 4 0 NN VBP VBN NNP NNP O
demonstrated. demonstrated. 0 0 0 0 0 0 0 0 13 0 VBP VBN NNP NNP NNS O
Early Early 1 0 0 0 0 0 0 0 5 0 VBN NNP NNP NNS IN O
stages stages 0 0 0 0 0 0 0 0 6 0 NNP NNP NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
regeneration regeneration 0 0 0 0 0 0 0 0 12 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBP O
nucleolus nucleolus 0 0 0 0 0 0 0 0 9 0 IN DT NN VBP NNP O
are are 0 0 0 0 0 0 0 0 3 0 DT NN VBP NNP NNP O
described. described. 0 0 0 0 0 0 0 0 10 0 NN VBP NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 VBP NNP NNP VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP NNP VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBN VBN IN O
shown shown 0 0 0 0 0 0 0 0 5 0 VBZ VBN VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 VBN VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NN O
pale pale 0 0 0 0 0 0 0 0 4 0 IN DT NN NN NN O
fibrillar fibrillar 0 0 0 0 0 0 0 0 9 0 DT NN NN NN IN O
material material 0 0 0 0 0 0 0 0 8 0 NN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBZ O
nucleolus nucleolus 0 0 0 0 0 0 0 0 9 0 IN DT NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ VBN -NONE- O
attached attached 0 0 0 0 0 0 0 0 8 0 NN VBZ VBN -NONE- CC O
to, to, 0 0 0 0 1 0 0 0 3 0 VBZ VBN -NONE- CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBN -NONE- CC JJ NN O
continuous continuous 0 0 0 0 0 0 0 0 10 0 -NONE- CC JJ NN DT O
with, with, 0 0 0 0 1 0 0 0 5 0 CC JJ NN DT RB O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT RB VBN O
fully fully 0 0 0 0 0 0 0 0 5 0 NN DT RB VBN -NONE- O
condensed condensed 0 0 0 0 0 0 0 0 9 0 DT RB VBN -NONE- NN O
(chromocentric) (chromocentric) 0 0 0 0 0 0 0 0 15 0 RB VBN -NONE- NN IN O
part part 0 0 0 0 0 0 0 0 4 0 VBN -NONE- NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 -NONE- NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
nucleolar-organizing nucleolar-organizing 0 0 1 0 0 0 0 0 20 0 IN DT JJ NN IN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN NNP O
at at 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
interphase. interphase. 0 0 0 0 0 0 0 0 11 0 NN IN NNP NNP VBZ B_TIMEXCCP
It It 1 0 0 0 0 0 0 0 2 0 IN NNP NNP VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ RB VBN O
also also 0 0 0 0 0 0 0 0 4 0 NNP VBZ RB VBN IN O
shown shown 0 0 0 0 0 0 0 0 5 0 VBZ RB VBN IN IN O
that that 0 0 0 0 0 0 0 0 4 0 RB VBN IN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBN IN IN JJ NN O
early early 0 0 0 0 0 0 0 0 5 0 IN IN JJ NN DT prophase
prophase, prophase, 0 0 0 0 1 0 0 0 9 0 IN JJ NN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NNS IN O
channels channels 0 0 0 0 0 0 0 0 8 0 NN DT NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
nucleolonema nucleolonema 0 0 0 0 0 0 0 0 12 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBP O
nucleolus nucleolus 0 0 0 0 0 0 0 0 9 0 IN DT NN VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 DT NN VBP RB RBR O
no no 0 0 0 0 0 0 0 0 2 0 NN VBP RB RBR VBN O
longer longer 0 0 0 0 0 0 0 0 6 0 VBP RB RBR VBN IN O
occupied occupied 0 0 0 0 0 0 0 0 8 0 RB RBR VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 RBR VBN IN NN NN O
pale pale 0 0 0 0 0 0 0 0 4 0 VBN IN NN NN NN O
fibrillar fibrillar 0 0 0 0 0 0 0 0 9 0 IN NN NN NN CC O
material, material, 0 0 0 0 1 0 0 0 9 0 NN NN NN CC RB O
but but 0 0 0 0 0 0 0 0 3 0 NN NN CC RB DT O
instead instead 0 0 0 0 0 0 0 0 7 0 NN CC RB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 CC RB DT JJ NN O
long long 0 0 0 0 0 0 0 0 4 0 RB DT JJ NN IN O
section section 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN VBN NN O
condensed condensed 0 0 0 0 0 0 0 0 9 0 NN IN VBN NN VBZ O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 IN VBN NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 VBN NN VBZ JJ NN O
present, present, 0 0 0 0 1 0 0 0 8 0 NN VBZ JJ NN DT O
traversing traversing 0 0 0 0 0 0 0 0 10 0 VBZ JJ NN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NNP NNP O
nucleolonema. nucleolonema. 0 0 0 0 0 0 0 0 13 0 NN DT NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 DT NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
contended contended 0 0 0 0 0 0 0 0 9 0 NNP VBZ VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 VBN IN DT NNS VBN O
observations observations 0 0 0 0 0 0 0 0 12 0 IN DT NNS VBN RB O
taken taken 0 0 0 0 0 0 0 0 5 0 DT NNS VBN RB JJ O
together together 0 0 0 0 0 0 0 0 8 0 NNS VBN RB JJ NN O
constitute constitute 0 0 0 0 0 0 0 0 10 0 VBN RB JJ NN IN O
evidence evidence 0 0 0 0 0 0 0 0 8 0 RB JJ NN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
pale pale 0 0 0 0 0 0 0 0 4 0 IN DT NN NN NN O
fibrillar fibrillar 0 0 0 0 0 0 0 0 9 0 DT NN NN NN IN O
material material 0 0 0 0 0 0 0 0 8 0 NN NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBZ O
nucleolus nucleolus 0 0 0 0 0 0 0 0 9 0 IN DT NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT NN IN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 VBZ DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
nucleolar-organizing nucleolar-organizing 0 0 1 0 0 0 0 0 20 0 IN DT JJ NN IN O
region region 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ VBD O
chromosome, chromosome, 0 0 0 0 1 0 0 0 11 0 IN DT JJ VBD IN O
expanded expanded 0 0 0 0 0 0 0 0 8 0 DT JJ VBD IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 JJ VBD IN NNP DT O
transcription. transcription. 0 0 0 0 0 0 0 0 14 0 VBD IN NNP DT NN O
A A 1 1 0 0 0 0 0 0 1 0 IN NNP DT NN IN O
model model 0 0 0 0 0 0 0 0 5 0 NNP DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
nucleolus nucleolus 0 0 0 0 0 0 0 0 9 0 IN DT NN IN PRP O
as as 0 0 0 0 0 0 0 0 2 0 DT NN IN PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NN IN PRP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 IN PRP VBZ VBN IN O
seen seen 0 0 0 0 0 0 0 0 4 0 PRP VBZ VBN IN JJS O
in in 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN JJS JJ O
most most 0 0 0 0 0 0 0 0 4 0 VBN IN JJS JJ NN O
electron-microscope electron-microscope 0 0 1 0 0 0 0 0 19 0 IN JJS JJ NN CC O
sections, sections, 0 0 0 0 1 0 0 0 9 0 JJS JJ NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC IN PRP O
as as 0 0 0 0 0 0 0 0 2 0 NN CC IN PRP MD O
it it 0 0 0 0 0 0 0 0 2 0 CC IN PRP MD VB O
can can 0 0 0 0 0 0 0 0 3 0 IN PRP MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 PRP MD VB VBN IN O
interpreted interpreted 0 0 0 0 0 0 0 0 11 0 MD VB VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VB VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ IN O
light light 0 0 0 0 0 0 0 0 5 0 IN DT JJ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT JJ IN JJ NN O
present-day present-day 0 0 1 0 0 0 0 0 11 0 JJ IN JJ NN IN O
knowledge knowledge 0 0 0 0 0 0 0 0 9 0 IN JJ NN IN JJ O
about about 0 0 0 0 0 0 0 0 5 0 JJ NN IN JJ VBZ O
it, it, 0 0 0 0 1 0 0 0 3 0 NN IN JJ VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 IN JJ VBZ NNP DT O
presented. presented. 0 0 0 0 0 0 0 0 10 0 JJ VBZ NNP DT JJ O
A A 1 1 0 0 0 0 0 0 1 0 VBZ NNP DT JJ NN O
brief brief 0 0 0 0 0 0 0 0 5 0 NNP DT JJ NN IN O
review review 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
relevant relevant 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN NNS O
literature literature 0 0 0 0 0 0 0 0 10 0 DT JJ NN NNS DT O
considers considers 0 0 0 0 0 0 0 0 9 0 JJ NN NNS DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN NNS DT NNS VBG O
views views 0 0 0 0 0 0 0 0 5 0 NNS DT NNS VBG DT O
supporting supporting 0 0 0 0 0 0 0 0 10 0 DT NNS VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBG DT NN CC O
mode, mode, 0 0 0 0 1 0 0 0 5 0 VBG DT NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN NN O
contrary contrary 0 0 0 0 0 0 0 0 8 0 CC DT NN NN VBG O
views, views, 0 0 0 0 1 0 0 0 6 0 DT NN NN VBG DT O
implicating implicating 0 0 0 0 0 0 0 0 11 0 NN NN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT NN IN O
use use 0 0 0 0 0 0 0 0 3 0 VBG DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN JJ O
term term 0 0 0 0 0 0 0 0 4 0 IN DT NN JJ NN O
'nucleolar 'nucleolar 0 0 0 0 0 1 0 0 10 0 DT NN JJ NN WDT O
organizer', organizer', 0 0 0 0 1 1 0 0 11 0 NN JJ NN WDT VBP O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 NN WDT VBP RB JJ O
still still 0 0 0 0 0 0 0 0 5 0 WDT VBP RB JJ IN O
current current 0 0 0 0 0 0 0 0 7 0 VBP RB JJ IN DT O
at at 0 0 0 0 0 0 0 0 2 0 RB JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN NNP O
present present 0 0 0 0 0 0 0 0 7 0 IN DT NN NNP NNP O
time. time. 0 0 0 0 0 0 0 0 5 0 DT NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
7364886 7364886 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Dynamical Dynamical 1 0 0 0 0 0 0 0 9 0 NONE NONE JJ NN IN O
account account 0 0 0 0 0 0 0 0 7 0 NONE JJ NN IN WRB O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN WRB JJ O
how how 0 0 0 0 0 0 0 0 3 0 NN IN WRB JJ NN O
/b, /b, 0 0 0 1 1 0 0 0 3 0 IN WRB JJ NN NN O
d, d, 0 0 0 0 1 0 0 0 2 0 WRB JJ NN NN NN O
g/ g/ 0 0 0 1 0 0 0 0 2 0 JJ NN NN NN IN O
differ differ 0 0 0 0 0 0 0 0 6 0 NN NN NN IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN NNP NNP O
/p, /p, 0 0 0 1 1 0 0 0 3 0 NN IN NNP NNP NNP O
t, t, 0 0 0 0 1 0 0 0 2 0 IN NNP NNP NNP IN O
k/ k/ 0 0 0 1 0 0 0 0 2 0 NNP NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Spanish: Spanish: 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP IN O
Evidence Evidence 1 0 0 0 0 0 0 0 8 0 IN NNP NNP IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNP IN NNP NNP O
labials. labials. 0 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Parrell Parrell 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
B. B. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Linguistics, Linguistics, 1 0 0 0 1 0 0 0 12 0 NNP IN NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Southern Southern 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
California. California. 1 0 0 0 0 0 0 0 11 0 IN NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NN VBZ O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ NN O
examines examines 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ NN NN O
articulatory articulatory 0 0 0 0 0 0 0 0 12 0 NN VBZ NN NN IN O
lenition lenition 0 0 0 0 0 0 0 0 8 0 VBZ NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNS O
intervocalic intervocalic 0 0 0 0 0 0 0 0 12 0 NN IN JJ NNS IN O
stops stops 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP CC O
Spanish Spanish 1 0 0 0 0 0 0 0 7 0 NNS IN NNP CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNS DT O
tests tests 0 0 0 0 0 0 0 0 5 0 NNP CC NNS DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 CC NNS DT NNS WDT O
theories theories 0 0 0 0 0 0 0 0 8 0 NNS DT NNS WDT CD O
that that 0 0 0 0 0 0 0 0 4 0 DT NNS WDT CD -NONE- O
1) 1) 0 0 0 0 0 0 0 1 2 0 NNS WDT CD -NONE- JJ O
/b, /b, 0 0 0 1 1 0 0 0 3 0 WDT CD -NONE- JJ NN O
d, d, 0 0 0 0 1 0 0 0 2 0 CD -NONE- JJ NN VBP O
g/ g/ 0 0 0 1 0 0 0 0 2 0 -NONE- JJ NN VBP DT O
have have 0 0 0 0 0 0 0 0 4 0 JJ NN VBP DT VBN O
an an 0 0 0 0 0 0 0 0 2 0 NN VBP DT VBN NN O
intended intended 0 0 0 0 0 0 0 0 8 0 VBP DT VBN NN IN O
target target 0 0 0 0 0 0 0 0 6 0 DT VBN NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBN NN IN NN JJ O
closure closure 0 0 0 0 0 0 0 0 7 0 NN IN NN JJ TO O
equal equal 0 0 0 0 0 0 0 0 5 0 IN NN JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN JJ TO DT IN O
that that 0 0 0 0 0 0 0 0 4 0 JJ TO DT IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 TO DT IN NNP NNP O
/p, /p, 0 0 0 1 1 0 0 0 3 0 DT IN NNP NNP NNP O
t, t, 0 0 0 0 1 0 0 0 2 0 IN NNP NNP NNP CC O
k/ k/ 0 0 0 1 0 0 0 0 2 0 NNP NNP NNP CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC CD NN O
2) 2) 0 0 0 0 0 0 0 1 2 0 NNP CC CD NN IN O
spirantization spirantization 0 0 0 0 0 0 0 0 14 0 CC CD NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN NNP NNP O
/b, /b, 0 0 0 1 1 0 0 0 3 0 NN IN NNP NNP NNP O
d, d, 0 0 0 0 1 0 0 0 2 0 IN NNP NNP NNP VBZ O
g/ g/ 0 0 0 1 0 0 0 0 2 0 NNP NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
caused caused 0 0 0 0 0 0 0 0 6 0 NNP VBZ VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN NN JJ O
undershoot undershoot 0 0 0 0 0 0 0 0 10 0 VBN IN NN JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 IN NN JJ TO PRP$ O
to to 0 0 0 0 0 0 0 0 2 0 NN JJ TO PRP$ JJ O
their their 0 0 0 0 0 0 0 0 5 0 JJ TO PRP$ JJ NN O
short short 0 0 0 0 0 0 0 0 5 0 TO PRP$ JJ NN NN O
duration duration 0 0 0 0 0 0 0 0 8 0 PRP$ JJ NN NN NNP O
phrase phrase 0 0 0 0 0 0 0 0 6 0 JJ NN NN NNP NNP O
medially. medially. 0 0 0 0 0 0 0 0 9 0 NN NN NNP NNP IN O
Consistent Consistent 1 0 0 0 0 0 0 0 10 0 NN NNP NNP IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNP IN JJ JJ O
past past 0 0 0 0 0 0 0 0 4 0 NNP IN JJ JJ NN O
acoustic acoustic 0 0 0 0 0 0 0 0 8 0 IN JJ JJ NN NNS O
studies, studies, 0 0 0 0 1 0 0 0 8 0 JJ JJ NN NNS VBP O
subjects subjects 0 0 0 0 0 0 0 0 8 0 JJ NN NNS VBP JJ O
produce produce 0 0 0 0 0 0 0 0 7 0 NN NNS VBP JJ IN O
/b/ /b/ 0 0 0 1 0 0 0 0 3 0 NNS VBP JJ IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBP JJ IN JJ NN O
incomplete incomplete 0 0 0 0 0 0 0 0 10 0 JJ IN JJ NN NN O
closure closure 0 0 0 0 0 0 0 0 7 0 IN JJ NN NN RB O
phrase phrase 0 0 0 0 0 0 0 0 6 0 JJ NN NN RB CC O
medially medially 0 0 0 0 0 0 0 0 8 0 NN NN RB CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN RB CC JJ NN O
complete complete 0 0 0 0 0 0 0 0 8 0 RB CC JJ NN NN O
closure closure 0 0 0 0 0 0 0 0 7 0 CC JJ NN NN NNP O
phrase phrase 0 0 0 0 0 0 0 0 6 0 JJ NN NN NNP NNP O
initially. initially. 0 0 0 0 0 0 0 0 10 0 NN NN NNP NNP NNP O
Additionally, Additionally, 1 0 0 0 1 0 0 0 13 0 NN NNP NNP NNP VBZ O
/b/ /b/ 0 0 0 1 0 0 0 0 3 0 NNP NNP NNP VBZ JJR O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ JJR IN O
shorter shorter 0 0 0 0 0 0 0 0 7 0 NNP VBZ JJR IN JJ O
than than 0 0 0 0 0 0 0 0 4 0 VBZ JJR IN JJ NN O
/p/ /p/ 0 0 0 1 0 0 0 0 3 0 JJR IN JJ NN RB O
phrase phrase 0 0 0 0 0 0 0 0 6 0 IN JJ NN RB IN O
medially medially 0 0 0 0 0 0 0 0 8 0 JJ NN RB IN RB O
though though 0 0 0 0 0 0 0 0 6 0 NN RB IN RB NNP O
not not 0 0 0 0 0 0 0 0 3 0 RB IN RB NNP NNP O
initially. initially. 0 0 0 0 0 0 0 0 10 0 IN RB NNP NNP NNP O
For For 1 0 0 0 0 0 0 0 3 0 RB NNP NNP NNP IN O
/b/, /b/, 0 0 0 1 1 0 0 0 4 0 NNP NNP NNP IN RB O
though though 0 0 0 0 0 0 0 0 6 0 NNP NNP IN RB IN O
not not 0 0 0 0 0 0 0 0 3 0 NNP IN RB IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 IN RB IN JJ EX O
/p/, /p/, 0 0 0 1 1 0 0 0 4 0 RB IN JJ EX VBZ O
there there 0 0 0 0 0 0 0 0 5 0 IN JJ EX VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 JJ EX VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 EX VBZ DT NN IN O
correlation correlation 0 0 0 0 0 0 0 0 11 0 VBZ DT NN IN NN O
between between 0 0 0 0 0 0 0 0 7 0 DT NN IN NN NN O
constriction constriction 0 0 0 0 0 0 0 0 12 0 NN IN NN NN CC O
degree degree 0 0 0 0 0 0 0 0 6 0 IN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NN O
duration, duration, 0 0 0 0 1 0 0 0 9 0 NN CC NNP NN IN O
consistent consistent 0 0 0 0 0 0 0 0 10 0 CC NNP NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
theory theory 0 0 0 0 0 0 0 0 6 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
dynamical dynamical 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNP NNP O
undershoot. undershoot. 0 0 0 0 0 0 0 0 11 0 IN JJ NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NNS IN O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN VBP O
study study 0 0 0 0 0 0 0 0 5 0 IN DT NN VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 DT NN VBP RB VBN O
accurately accurately 0 0 0 0 0 0 0 0 10 0 NN VBP RB VBN IN O
modeled modeled 0 0 0 0 0 0 0 0 7 0 VBP RB VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NN O
virtual virtual 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN IN O
target target 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN JJ RB O
/b/ /b/ 0 0 0 1 0 0 0 0 3 0 NN IN JJ RB IN O
slightly slightly 0 0 0 0 0 0 0 0 8 0 IN JJ RB IN DT O
beyond beyond 0 0 0 0 0 0 0 0 6 0 JJ RB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NN IN O
point point 0 0 0 0 0 0 0 0 5 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNP O
articulator articulator 0 0 0 0 0 0 0 0 11 0 NN IN NN NNP NNP O
contact. contact. 0 0 0 0 0 0 0 0 8 0 IN NN NNP NNP DT O
Such Such 1 0 0 0 0 0 0 0 4 0 NN NNP NNP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT NN NNS O
target target 0 0 0 0 0 0 0 0 6 0 NNP DT NN NNS IN O
results results 0 0 0 0 0 0 0 0 7 0 DT NN NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NN O
full full 0 0 0 0 0 0 0 0 4 0 NNS IN JJ NN IN O
closure closure 0 0 0 0 0 0 0 0 7 0 IN JJ NN IN RB O
at at 0 0 0 0 0 0 0 0 2 0 JJ NN IN RB NNS O
long long 0 0 0 0 0 0 0 0 4 0 NN IN RB NNS JJ O
durations durations 0 0 0 0 0 0 0 0 9 0 IN RB NNS JJ IN O
(such (such 0 0 0 0 0 0 0 0 5 0 RB NNS JJ IN NN O
as as 0 0 0 0 0 0 0 0 2 0 NNS JJ IN NN NN O
found found 0 0 0 0 0 0 0 0 5 0 JJ IN NN NN NN O
phrase phrase 0 0 0 0 0 0 0 0 6 0 IN NN NN NN CC O
initially) initially) 0 0 0 0 0 0 0 0 10 0 NN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
incomplete incomplete 0 0 0 0 0 0 0 0 10 0 NN CC JJ NN IN O
closure closure 0 0 0 0 0 0 0 0 7 0 CC JJ NN IN NN O
at at 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNP O
shorter shorter 0 0 0 0 0 0 0 0 7 0 NN IN NN NNP NNP O
durations. durations. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP IN O
Based Based 1 0 0 0 0 0 0 0 5 0 NN NNP NNP IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP IN DT NN PRP O
evidence, evidence, 0 0 0 0 1 0 0 0 9 0 IN DT NN PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN PRP VBZ VBN IN O
proposed proposed 0 0 0 0 0 0 0 0 8 0 PRP VBZ VBN IN -NONE- O
that that 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN -NONE- -NONE- O
/b, /b, 0 0 0 1 1 0 0 0 3 0 VBN IN -NONE- -NONE- -NONE- O
d, d, 0 0 0 0 1 0 0 0 2 0 IN -NONE- -NONE- -NONE- VBP O
g/ g/ 0 0 0 1 0 0 0 0 2 0 -NONE- -NONE- -NONE- VBP IN O
differ differ 0 0 0 0 0 0 0 0 6 0 -NONE- -NONE- VBP IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 -NONE- VBP IN NNP NNP O
/p, /p, 0 0 0 1 1 0 0 0 3 0 VBP IN NNP NNP NNP O
t, t, 0 0 0 0 1 0 0 0 2 0 IN NNP NNP NNP IN O
k/ k/ 0 0 0 1 0 0 0 0 2 0 NNP NNP NNP IN CD O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN CD JJ O
three three 0 0 0 0 0 0 0 0 5 0 NNP IN CD JJ PRP O
ways: ways: 0 0 0 0 0 0 0 0 5 0 IN CD JJ PRP VBP O
they they 0 0 0 0 0 0 0 0 4 0 CD JJ PRP VBP -NONE- O
are are 0 0 0 0 0 0 0 0 3 0 JJ PRP VBP -NONE- VBP O
shorter, shorter, 0 0 0 0 1 0 0 0 8 0 PRP VBP -NONE- VBP DT O
lack lack 0 0 0 0 0 0 0 0 4 0 VBP -NONE- VBP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- VBP DT NN NN O
devoicing devoicing 0 0 0 0 0 0 0 0 9 0 VBP DT NN NN CC O
gesture, gesture, 0 0 0 0 1 0 0 0 8 0 DT NN NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VB DT O
have have 0 0 0 0 0 0 0 0 4 0 NN CC VB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 CC VB DT NN NN O
target target 0 0 0 0 0 0 0 0 6 0 VB DT NN NN TO O
closer closer 0 0 0 0 0 0 0 0 6 0 DT NN NN TO : O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO : CC O
- - 0 0 1 0 0 0 0 0 1 0 NN TO : CC RB O
but but 0 0 0 0 0 0 0 0 3 0 TO : CC RB IN O
still still 0 0 0 0 0 0 0 0 5 0 : CC RB IN : O
beyond beyond 0 0 0 0 0 0 0 0 6 0 CC RB IN : DT O
- - 0 0 1 0 0 0 0 0 1 0 RB IN : DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN : DT NN IN O
point point 0 0 0 0 0 0 0 0 5 0 : DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNP O
articulator articulator 0 0 0 0 0 0 0 0 11 0 NN IN NN NNP NNP O
contact. contact. 0 0 0 0 0 0 0 0 8 0 IN NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD -NONE- O
23843928 23843928 0 0 0 0 0 0 1 1 8 0 NNP NNP CD -NONE- JJ O
[PubMed] [PubMed] 0 0 0 0 0 0 0 0 8 0 NNP CD -NONE- JJ NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 CD -NONE- JJ NNP NNP O
PMC3703669 PMC3703669 1 1 0 0 0 0 0 1 10 0 -NONE- JJ NNP NNP NNP O
Free Free 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NNP NNP O
PMC PMC 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NONE O
Article Article 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NONE NONE O
Novel Novel 1 0 0 0 0 0 0 0 5 0 NONE NONE NNP NNP NNP O
c.191C>G c.191C>G 0 0 0 0 0 0 0 1 8 0 NONE NNP NNP NNP NNP O
(p.Pro64Arg) (p.Pro64Arg) 0 0 0 0 0 0 0 1 12 0 NNP NNP NNP NNP NN O
MPV17 MPV17 1 1 0 0 0 0 0 1 5 0 NNP NNP NNP NN VBD O
mutation mutation 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBD IN O
identified identified 0 0 0 0 0 0 0 0 10 0 NNP NN VBD IN CD O
in in 0 0 0 0 0 0 0 0 2 0 NN VBD IN CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 VBD IN CD NNS IN O
pairs pairs 0 0 0 0 0 0 0 0 5 0 IN CD NNS IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN VBN JJ O
unrelated unrelated 0 0 0 0 0 0 0 0 9 0 NNS IN VBN JJ NNS O
Polish Polish 1 0 0 0 0 0 0 0 6 0 IN VBN JJ NNS IN O
siblings siblings 0 0 0 0 0 0 0 0 8 0 VBN JJ NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 JJ NNS IN JJ NNP O
mitochondrial mitochondrial 0 0 0 0 0 0 0 0 13 0 NNS IN JJ NNP NNP O
hepatoencephalopathy. hepatoencephalopathy. 0 0 0 0 0 0 0 0 21 0 IN JJ NNP NNP NNP O
Piekutowska-Abramczuk Piekutowska-Abramczuk 1 0 1 0 0 0 0 0 21 0 JJ NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Pronicki Pronicki 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Strawa Strawa 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Karkucińska-Więckowska Karkucińska-Więckowska 1 0 1 0 0 0 0 0 22 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Szymańska-Dębińska Szymańska-Dębińska 1 0 1 0 0 0 0 0 18 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Fidziańska Fidziańska 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Więckowski Więckowski 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Jurkiewicz Jurkiewicz 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ciara Ciara 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
E, E, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Jankowska Jankowska 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
I, I, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sykut-Cegielska Sykut-Cegielska 1 0 1 0 0 0 0 0 15 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Krajewska-Walasek Krajewska-Walasek 1 0 1 0 0 0 0 0 17 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Płoski Płoski 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Pronicka Pronicka 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
E. E. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
Genetics. Genetics. 1 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NN VBZ O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ JJ O
reports reports 0 0 0 0 0 0 0 0 7 0 NNP NN VBZ JJ JJ O
clinical, clinical, 0 0 0 0 1 0 0 0 9 0 NN VBZ JJ JJ CC O
biochemical biochemical 0 0 0 0 0 0 0 0 11 0 VBZ JJ JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ JJ CC JJ NNS O
histopathological histopathological 0 0 0 0 0 0 0 0 17 0 JJ CC JJ NNS VBN O
findings findings 0 0 0 0 0 0 0 0 8 0 CC JJ NNS VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 JJ NNS VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NN JJ O
novel novel 0 0 0 0 0 0 0 0 5 0 IN DT NN JJ NNP O
homozygous homozygous 0 0 0 0 0 0 0 0 10 0 DT NN JJ NNP NN O
MPV17 MPV17 1 1 0 0 0 0 0 1 5 0 NN JJ NNP NN IN O
mutation mutation 0 0 0 0 0 0 0 0 8 0 JJ NNP NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN CD NNS O
four four 0 0 0 0 0 0 0 0 4 0 NN IN CD NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 IN CD NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 CD NNS IN JJ NN O
mitochondrial mitochondrial 0 0 0 0 0 0 0 0 13 0 NNS IN JJ NN NNP O
depletion depletion 0 0 0 0 0 0 0 0 9 0 IN JJ NN NNP NNP O
syndrome. syndrome. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP JJ NN O
severe severe 0 0 0 0 0 0 0 0 6 0 NNP NNP JJ NN IN O
course course 0 0 0 0 0 0 0 0 6 0 NNP JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ WDT O
disease, disease, 0 0 0 0 1 0 0 0 8 0 IN DT JJ WDT VBN O
which which 0 0 0 0 0 0 0 0 5 0 DT JJ WDT VBN IN O
started started 0 0 0 0 0 0 0 0 7 0 JJ WDT VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 WDT VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNS O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ NNS IN O
weeks weeks 0 0 0 0 0 0 0 0 5 0 DT JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ VBD O
life, life, 0 0 0 0 1 0 0 0 5 0 NNS IN JJ VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 IN JJ VBD VBN IN O
dominated dominated 0 0 0 0 0 0 0 0 9 0 JJ VBD VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NN TO O
failure failure 0 0 0 0 0 0 0 0 7 0 IN DT NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO NNP NN O
thrive, thrive, 0 0 0 0 1 0 0 0 7 0 NN TO NNP NN CC O
hypotonia hypotonia 0 0 0 0 0 0 0 0 9 0 TO NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN NN O
liver liver 0 0 0 0 0 0 0 0 5 0 NN CC NN NN IN O
dysfunction, dysfunction, 0 0 0 0 1 0 0 0 12 0 CC NN NN IN RB O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN RB JJ O
relatively relatively 0 0 0 0 0 0 0 0 10 0 NN IN RB JJ JJ O
mild mild 0 0 0 0 0 0 0 0 4 0 IN RB JJ JJ NNP O
neurological neurological 0 0 0 0 0 0 0 0 12 0 RB JJ JJ NNP NNP O
involvement. involvement. 0 0 0 0 0 0 0 0 12 0 JJ JJ NNP NNP VBD O
All All 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP VBD NNS O
affected affected 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD NNS VBN O
infants infants 0 0 0 0 0 0 0 0 7 0 NNP VBD NNS VBN IN O
died died 0 0 0 0 0 0 0 0 4 0 VBD NNS VBN IN CD O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBN IN CD NN O
1 1 0 0 0 0 0 0 1 1 1 0 VBN IN CD NN IN O
year year 0 0 0 0 0 0 0 0 4 0 IN CD NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN NNP NNP O
age. age. 0 0 0 0 0 0 0 0 4 0 NN IN NNP NNP NNS O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 IN NNP NNP NNS VBD O
findings findings 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBD JJ O
included included 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD JJ NN O
progressive progressive 0 0 0 0 0 0 0 0 11 0 NNS VBD JJ NN NN O
liver liver 0 0 0 0 0 0 0 0 5 0 VBD JJ NN NN NN O
failure failure 0 0 0 0 0 0 0 0 7 0 JJ NN NN NN NN O
(hypertransaminasaemia, (hypertransaminasaemia, 0 0 0 0 1 0 0 0 23 0 NN NN NN NN CC O
icterus, icterus, 0 0 0 0 1 0 0 0 8 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NN O
coagulopathy), coagulopathy), 0 0 0 0 1 0 0 0 14 0 NN CC NNP NN -NONE- O
recurrent recurrent 0 0 0 0 0 0 0 0 9 0 CC NNP NN -NONE- JJ O
hypoglycaemia, hypoglycaemia, 0 0 0 0 1 0 0 0 14 0 NNP NN -NONE- JJ NN O
lactic lactic 0 0 0 0 0 0 0 0 6 0 NN -NONE- JJ NN NN O
acidaemia, acidaemia, 0 0 0 0 1 0 0 0 10 0 -NONE- JJ NN NN CC O
hyperferritinaemia, hyperferritinaemia, 0 0 0 0 1 0 0 0 19 0 JJ NN NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBD NN O
increased increased 0 0 0 0 0 0 0 0 9 0 NN CC VBD NN NNP O
transferrin transferrin 0 0 0 0 0 0 0 0 11 0 CC VBD NN NNP NNP O
saturation. saturation. 0 0 0 0 0 0 0 0 11 0 VBD NN NNP NNP CC O
Histological Histological 1 0 0 0 0 0 0 0 12 0 NN NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NNS O
ultrastructural ultrastructural 0 0 0 0 0 0 0 0 15 0 NNP CC JJ NNS VBN O
analyses analyses 0 0 0 0 0 0 0 0 8 0 CC JJ NNS VBN JJ O
uncovered uncovered 0 0 0 0 0 0 0 0 9 0 JJ NNS VBN JJ JJ O
significant significant 0 0 0 0 0 0 0 0 11 0 NNS VBN JJ JJ NN O
lipid lipid 0 0 0 0 0 0 0 0 5 0 VBN JJ JJ NN IN O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 JJ JJ NN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS CC O
hepatocytes hepatocytes 0 0 0 0 0 0 0 0 11 0 NN IN NNS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC NNP DT O
myocytes. myocytes. 0 0 0 0 0 0 0 0 9 0 NNS CC NNP DT JJ O
A A 1 1 0 0 0 0 0 0 1 0 CC NNP DT JJ NN O
severe severe 0 0 0 0 0 0 0 0 6 0 NNP DT JJ NN IN O
decrease decrease 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
mitochondrial/nuclear mitochondrial/nuclear 0 0 0 1 0 0 0 0 21 0 IN DT JJ NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 DT JJ NNP NNP NN O
(mtDNA/nDNA) (mtDNA/nDNA) 0 0 0 1 0 0 0 0 12 0 JJ NNP NNP NN VBD O
ratio ratio 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN -NONE- O
found found 0 0 0 0 0 0 0 0 5 0 NN VBD VBN -NONE- IN O
post-mortem post-mortem 0 0 1 0 0 0 0 0 11 0 VBD VBN -NONE- IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBN -NONE- IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- IN DT NNS VBP O
livers livers 0 0 0 0 0 0 0 0 6 0 IN DT NNS VBP IN O
(and (and 0 0 0 0 0 0 0 0 4 0 DT NNS VBP IN CD O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBP IN CD NN O
one one 0 0 0 0 0 0 0 0 3 0 VBP IN CD NN -NONE- O
muscle muscle 0 0 0 0 0 0 0 0 6 0 IN CD NN -NONE- IN O
specimen) specimen) 0 0 0 0 0 0 0 0 9 0 CD NN -NONE- IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN -NONE- IN DT VBN O
both both 0 0 0 0 0 0 0 0 4 0 -NONE- IN DT VBN NNP O
examined examined 0 0 0 0 0 0 0 0 8 0 IN DT VBN NNP NNP O
patients. patients. 0 0 0 0 0 0 0 0 9 0 DT VBN NNP NNP NN O
Oxidative Oxidative 1 0 0 0 0 0 0 0 9 0 VBN NNP NNP NN NN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 NNP NNP NN NN NN O
system system 0 0 0 0 0 0 0 0 6 0 NNP NN NN NN NNP O
(OXPHOS) (OXPHOS) 0 1 0 0 0 0 0 0 8 0 NN NN NN NNP NN O
Western Western 1 0 0 0 0 0 0 0 7 0 NN NN NNP NN VBD O
blotting blotting 0 0 0 0 0 0 0 0 8 0 NN NNP NN VBD JJ O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NNP NN VBD JJ NNS O
low low 0 0 0 0 0 0 0 0 3 0 NN VBD JJ NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 VBD JJ NNS IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNS -NONE- O
complexes complexes 0 0 0 0 0 0 0 0 9 0 NNS IN NNS -NONE- NNP O
I, I, 1 1 0 0 1 0 0 0 2 0 IN NNS -NONE- NNP CC O
III III 1 1 0 0 0 0 0 0 3 0 NNS -NONE- NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NNP CC NNP NNP O
IV IV 1 1 0 0 0 0 0 0 2 0 NNP CC NNP NNP NNP O
subunits. subunits. 0 0 0 0 0 0 0 0 9 0 CC NNP NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS IN O
highlights highlights 0 0 0 0 0 0 0 0 10 0 NNP NNP NNS IN PRP$ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN PRP$ NNS O
our our 0 0 0 0 0 0 0 0 3 0 NNS IN PRP$ NNS VBP O
findings findings 0 0 0 0 0 0 0 0 8 0 IN PRP$ NNS VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 PRP$ NNS VBP RB JJ O
as as 0 0 0 0 0 0 0 0 2 0 NNS VBP RB JJ NN O
follows: follows: 0 0 0 0 0 0 0 0 8 0 VBP RB JJ NN DT O
(i) (i) 0 0 0 0 0 0 0 0 3 0 RB JJ NN DT NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NN DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 NN DT NN NN NN O
p.Pro64Arg p.Pro64Arg 0 0 0 0 0 0 0 1 10 0 DT NN NN NN VBZ O
mutation mutation 0 0 0 0 0 0 0 0 8 0 NN NN NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT JJ NN O
second second 0 0 0 0 0 0 0 0 6 0 VBZ DT JJ NN NNP O
recurrent recurrent 0 0 0 0 0 0 0 0 9 0 DT JJ NN NNP NN O
MPV17 MPV17 1 1 0 0 0 0 0 1 5 0 JJ NN NNP NN NNP O
mutation mutation 0 0 0 0 0 0 0 0 8 0 NN NNP NN NNP NNP O
reported. reported. 0 0 0 0 0 0 0 0 9 0 NNP NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN VBD O
phenotype phenotype 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBD IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NNP NN VBD IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN VBD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT JJ NN O
p.Pro64Arg p.Pro64Arg 0 0 0 0 0 0 0 1 10 0 IN DT JJ NN NNS O
mutation mutation 0 0 0 0 0 0 0 0 8 0 DT JJ NN NNS IN O
differs differs 0 0 0 0 0 0 0 0 7 0 JJ NN NNS IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
phenotype phenotype 0 0 0 0 0 0 0 0 9 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT RB O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT RB JJ O
relatively relatively 0 0 0 0 0 0 0 0 10 0 IN DT RB JJ JJ O
common common 0 0 0 0 0 0 0 0 6 0 DT RB JJ JJ NN O
p.Arg50Gln p.Arg50Gln 0 0 0 0 0 0 0 1 10 0 RB JJ JJ NN VBG O
mutation, mutation, 0 0 0 0 1 0 0 0 9 0 JJ JJ NN VBG DT O
suggesting suggesting 0 0 0 0 0 0 0 0 10 0 JJ NN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT NN IN O
existence existence 0 0 0 0 0 0 0 0 9 0 VBG DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NNP O
genotype-phenotype genotype-phenotype 0 0 1 0 0 0 0 0 18 0 IN DT JJ NNP NNP O
correlation. correlation. 0 0 0 0 0 0 0 0 12 0 DT JJ NNP NNP NNP O
(ii) (ii) 0 0 0 0 0 0 0 0 4 0 JJ NNP NNP NNP VBD O
Tissues Tissues 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP VBD IN O
collected collected 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD IN NNS O
from from 0 0 0 0 0 0 0 0 4 0 NNP VBD IN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 VBD IN NNS IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 IN NNS IN JJ MD O
autopsy autopsy 0 0 0 0 0 0 0 0 7 0 NNS IN JJ MD VB O
may may 0 0 0 0 0 0 0 0 3 0 IN JJ MD VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 JJ MD VB JJ IN O
useful useful 0 0 0 0 0 0 0 0 6 0 MD VB JJ IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VB JJ IN DT JJ O
both both 0 0 0 0 0 0 0 0 4 0 JJ IN DT JJ NN O
mtDNA/nDNA mtDNA/nDNA 0 0 0 1 0 0 0 0 10 0 IN DT JJ NN NN O
ratio ratio 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN CC O
assessment assessment 0 0 0 0 0 0 0 0 10 0 JJ NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
OXPHOS OXPHOS 1 1 0 0 0 0 0 0 6 0 NN CC NNP NNP NNP O
Western Western 1 0 0 0 0 0 0 0 7 0 CC NNP NNP NNP NONE O
blotting. blotting. 0 0 0 0 0 0 0 0 9 0 NNP NNP NNP NONE NONE O
Assessing Assessing 1 0 0 0 0 0 0 0 9 0 NONE NONE VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NONE VBG DT NN IN O
amount amount 0 0 0 0 0 0 0 0 6 0 VBG DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
quadruplex quadruplex 0 0 0 0 0 0 0 0 10 0 NN IN NN NNS NN O
structures structures 0 0 0 0 0 0 0 0 10 0 IN NN NNS NN IN O
present present 0 0 0 0 0 0 0 0 7 0 NN NNS NN IN JJ O
within within 0 0 0 0 0 0 0 0 6 0 NNS NN IN JJ JJ O
G₂-tract G₂-tract 1 0 1 0 0 0 0 1 8 0 NN IN JJ JJ NN O
synthetic synthetic 0 0 0 0 0 0 0 0 9 0 IN JJ JJ NN NNP O
random-sequence random-sequence 0 0 1 0 0 0 0 0 15 0 JJ JJ NN NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 JJ NN NNP NNP NNP O
libraries. libraries. 0 0 0 0 0 0 0 0 10 0 NN NNP NNP NNP NNP O
McManus McManus 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
SA, SA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Y. Y. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Biochemistry Biochemistry 1 0 0 0 0 0 0 0 12 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Biomedical Biomedical 1 0 0 0 0 0 0 0 10 0 NNP CC NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 CC NNP NNP NNP NNP O
McMaster McMaster 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Hamilton, Hamilton, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Ontario, Ontario, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Canada. Canada. 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
process process 0 0 0 0 0 0 0 0 7 0 NNP NNP NN IN IN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN IN IN NN NN O
vitro vitro 0 0 0 0 0 0 0 0 5 0 IN IN NN NN VBZ O
selection selection 0 0 0 0 0 0 0 0 9 0 IN NN NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NN NN VBZ VBN TO O
led led 0 0 0 0 0 0 0 0 3 0 NN VBZ VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBZ VBN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN TO DT NN IN O
discovery discovery 0 0 0 0 0 0 0 0 9 0 TO DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
many many 0 0 0 0 0 0 0 0 4 0 NN IN JJ NNS IN O
aptamers aptamers 0 0 0 0 0 0 0 0 8 0 IN JJ NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 JJ NNS IN JJ TO O
potential potential 0 0 0 0 0 0 0 0 9 0 NNS IN JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN JJ TO VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 JJ TO VB VBN IN O
developed developed 0 0 0 0 0 0 0 0 9 0 TO VB VBN IN NNS O
into into 0 0 0 0 0 0 0 0 4 0 VB VBN IN NNS CC O
inhibitors inhibitors 0 0 0 0 0 0 0 0 10 0 VBN IN NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC JJ CC O
biosensors, biosensors, 0 0 0 0 1 0 0 0 11 0 NNS CC JJ CC NNS O
but but 0 0 0 0 0 0 0 0 3 0 CC JJ CC NNS IN O
problems problems 0 0 0 0 0 0 0 0 8 0 JJ CC NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CC NNS IN NN NNS O
isolating isolating 0 0 0 0 0 0 0 0 9 0 NNS IN NN NNS IN O
aptamers aptamers 0 0 0 0 0 0 0 0 8 0 IN NN NNS IN JJ O
against against 0 0 0 0 0 0 0 0 7 0 NN NNS IN JJ NNS O
certain certain 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NNS IN O
targets targets 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 JJ NNS IN JJ NN O
desired desired 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NN CC O
affinity affinity 0 0 0 0 0 0 0 0 8 0 IN JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN RB O
specificity specificity 0 0 0 0 0 0 0 0 11 0 NN CC NN RB NNP O
still still 0 0 0 0 0 0 0 0 5 0 CC NN RB NNP CD O
remain. remain. 0 0 0 0 0 0 0 0 7 0 NN RB NNP CD JJ O
One One 1 0 0 0 0 0 0 0 3 0 RB NNP CD JJ NN O
possible possible 0 0 0 0 0 0 0 0 8 0 NNP CD JJ NN VBZ O
improvement improvement 0 0 0 0 0 0 0 0 11 0 CD JJ NN VBZ TO O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBZ TO VB NNS O
use use 0 0 0 0 0 0 0 0 3 0 VBZ TO VB NNS VBN O
libraries libraries 0 0 0 0 0 0 0 0 9 0 TO VB NNS VBN IN O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 VB NNS VBN IN NNS O
for for 0 0 0 0 0 0 0 0 3 0 NNS VBN IN NNS RB O
motifs motifs 0 0 0 0 0 0 0 0 6 0 VBN IN NNS RB VBN O
repeatedly repeatedly 0 0 0 0 0 0 0 0 10 0 IN NNS RB VBN IN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 NNS RB VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN NN NNP O
aptamer aptamer 0 0 0 0 0 0 0 0 7 0 VBN IN NN NNP CD O
molecules. molecules. 0 0 0 0 0 0 0 0 10 0 IN NN NNP CD JJ O
One One 1 0 0 0 0 0 0 0 3 0 NN NNP CD JJ RB O
such such 0 0 0 0 0 0 0 0 4 0 NNP CD JJ RB VBN O
frequently frequently 0 0 0 0 0 0 0 0 10 0 CD JJ RB VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 JJ RB VBN IN VBZ O
motif motif 0 0 0 0 0 0 0 0 5 0 RB VBN IN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 VBN IN VBZ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 IN VBZ DT JJ NN O
two-tiered two-tiered 0 0 1 0 0 0 0 0 10 0 VBZ DT JJ NN NNP O
guanine guanine 0 0 0 0 0 0 0 0 7 0 DT JJ NN NNP NNP O
quadruplex. quadruplex. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
study study 0 0 0 0 0 0 0 0 5 0 NNP DT NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBD IN O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NN PRP VBD IN NNP O
whether whether 0 0 0 0 0 0 0 0 7 0 PRP VBD IN NNP NNS O
DNA DNA 1 1 0 0 0 0 0 0 3 0 VBD IN NNP NNS MD O
libraries libraries 0 0 0 0 0 0 0 0 9 0 IN NNP NNS MD VB O
could could 0 0 0 0 0 0 0 0 5 0 NNP NNS MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB VBN TO O
designed designed 0 0 0 0 0 0 0 0 8 0 MD VB VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VB VBN TO VB DT O
contain contain 0 0 0 0 0 0 0 0 7 0 VBN TO VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT JJ NN O
large large 0 0 0 0 0 0 0 0 5 0 VB DT JJ NN IN O
fraction fraction 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS JJ O
molecules molecules 0 0 0 0 0 0 0 0 9 0 NN IN NNS JJ IN O
capable capable 0 0 0 0 0 0 0 0 7 0 IN NNS JJ IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNS JJ IN NN IN O
folding folding 0 0 0 0 0 0 0 0 7 0 JJ IN NN IN JJ O
into into 0 0 0 0 0 0 0 0 4 0 IN NN IN JJ NN O
two-tiered two-tiered 0 0 1 0 0 0 0 0 10 0 NN IN JJ NN NNP O
guanine guanine 0 0 0 0 0 0 0 0 7 0 IN JJ NN NNP NNP O
quadruplexes. quadruplexes. 0 0 0 0 0 0 0 0 13 0 JJ NN NNP NNP JJ O
Using Using 1 0 0 0 0 0 0 0 5 0 NN NNP NNP JJ NN O
comprehensive comprehensive 0 0 0 0 0 0 0 0 13 0 NNP NNP JJ NN NN O
circular circular 0 0 0 0 0 0 0 0 8 0 NNP JJ NN NN NN O
dichroism dichroism 0 0 0 0 0 0 0 0 9 0 JJ NN NN NN PRP O
analysis, analysis, 0 0 0 0 1 0 0 0 9 0 NN NN NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NN NN PRP VBD IN O
found found 0 0 0 0 0 0 0 0 5 0 NN PRP VBD IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBD IN NNP NNS O
DNA DNA 1 1 0 0 0 0 0 0 3 0 VBD IN NNP NNS MD O
libraries libraries 0 0 0 0 0 0 0 0 9 0 IN NNP NNS MD VB O
could could 0 0 0 0 0 0 0 0 5 0 NNP NNS MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB VBN TO O
designed designed 0 0 0 0 0 0 0 0 8 0 MD VB VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VB VBN TO VB DT O
contain contain 0 0 0 0 0 0 0 0 7 0 VBN TO VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT JJ NN O
large large 0 0 0 0 0 0 0 0 5 0 VB DT JJ NN IN O
proportion proportion 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS WDT O
sequences sequences 0 0 0 0 0 0 0 0 9 0 NN IN NNS WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 IN NNS WDT NN NN O
adopt adopt 0 0 0 0 0 0 0 0 5 0 NNS WDT NN NN NN O
guanine guanine 0 0 0 0 0 0 0 0 7 0 WDT NN NN NN NNP O
quadruplex quadruplex 0 0 0 0 0 0 0 0 10 0 NN NN NN NNP NNP O
structures. structures. 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP IN O
Analysis Analysis 1 0 0 0 0 0 0 0 8 0 NN NNP NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ NNS O
individual individual 0 0 0 0 0 0 0 0 10 0 NNP IN JJ NNS IN O
sequences sequences 0 0 0 0 0 0 0 0 9 0 IN JJ NNS IN DT O
from from 0 0 0 0 0 0 0 0 4 0 JJ NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ NN O
small small 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN VBD O
library library 0 0 0 0 0 0 0 0 7 0 DT JJ NN VBD DT O
revealed revealed 0 0 0 0 0 0 0 0 8 0 JJ NN VBD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN VBD DT NN IN O
mixture mixture 0 0 0 0 0 0 0 0 7 0 VBD DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS IN O
quadruplexes quadruplexes 0 0 0 0 0 0 0 0 12 0 NN IN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN JJ NNS O
different different 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NNS VBG O
topologies topologies 0 0 0 0 0 0 0 0 10 0 IN JJ NNS VBG DT O
providing providing 0 0 0 0 0 0 0 0 9 0 JJ NNS VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBG DT NN VBD O
diversity diversity 0 0 0 0 0 0 0 0 9 0 VBG DT NN VBD IN O
desired desired 0 0 0 0 0 0 0 0 7 0 DT NN VBD IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN VBD IN DT IN O
an an 0 0 0 0 0 0 0 0 2 0 VBD IN DT IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN DT IN NN NNP O
vitro vitro 0 0 0 0 0 0 0 0 5 0 DT IN NN NNP NNP O
selection. selection. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP RB O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP RB VBD O
also also 0 0 0 0 0 0 0 0 4 0 NNP NNP RB VBD IN O
found found 0 0 0 0 0 0 0 0 5 0 NNP RB VBD IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 RB VBD IN JJ NNS O
primer-binding primer-binding 0 0 1 0 0 0 0 0 14 0 VBD IN JJ NNS VBP O
sites sites 0 0 0 0 0 0 0 0 5 0 IN JJ NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 JJ NNS VBP JJ TO O
detrimental detrimental 0 0 0 0 0 0 0 0 11 0 NNS VBP JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBP JJ TO VB NN O
quadruplex quadruplex 0 0 0 0 0 0 0 0 10 0 JJ TO VB NN CC O
formation formation 0 0 0 0 0 0 0 0 9 0 TO VB NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 VB NN CC VBD DT O
devised devised 0 0 0 0 0 0 0 0 7 0 NN CC VBD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 CC VBD DT NN IN O
method method 0 0 0 0 0 0 0 0 6 0 VBD DT NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN NN NN O
post-selection post-selection 0 0 1 0 0 0 0 0 14 0 NN IN NN NN IN O
amplification amplification 0 0 0 0 0 0 0 0 13 0 IN NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
primer-less primer-less 0 0 1 0 0 0 0 0 11 0 NN IN JJ NN NNP O
quadruplex quadruplex 0 0 0 0 0 0 0 0 10 0 IN JJ NN NNP NNP O
libraries. libraries. 0 0 0 0 0 0 0 0 10 0 JJ NN NNP NNP DT O
With With 1 0 0 0 0 0 0 0 4 0 NN NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
development development 0 0 0 0 0 0 0 0 11 0 NNP DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
guanine guanine 0 0 0 0 0 0 0 0 7 0 NN IN NN NN VBD O
quadruplex quadruplex 0 0 0 0 0 0 0 0 10 0 IN NN NN VBD NNP O
enriched enriched 0 0 0 0 0 0 0 0 8 0 NN NN VBD NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN VBD NNP NNP PRP O
libraries, libraries, 0 0 0 0 1 0 0 0 10 0 VBD NNP NNP PRP MD O
it it 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP MD VB O
should should 0 0 0 0 0 0 0 0 6 0 NNP PRP MD VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 PRP MD VB JJ TO O
possible possible 0 0 0 0 0 0 0 0 8 0 MD VB JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VB JJ TO VB DT O
improve improve 0 0 0 0 0 0 0 0 7 0 JJ TO VB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NNS IN O
chances chances 0 0 0 0 0 0 0 0 7 0 VB DT NNS IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN VBG NNS O
isolating isolating 0 0 0 0 0 0 0 0 9 0 NNS IN VBG NNS WDT O
aptamers aptamers 0 0 0 0 0 0 0 0 8 0 IN VBG NNS WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 VBG NNS WDT NN DT O
utilize utilize 0 0 0 0 0 0 0 0 7 0 NNS WDT NN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 WDT NN DT NN NN O
quadruplex quadruplex 0 0 0 0 0 0 0 0 10 0 NN DT NN NN CC O
scaffold scaffold 0 0 0 0 0 0 0 0 8 0 DT NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN DT O
enhance enhance 0 0 0 0 0 0 0 0 7 0 NN CC NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC NN DT NN IN O
success success 0 0 0 0 0 0 0 0 7 0 NN DT NN IN IN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN IN IN NN NN O
vitro vitro 0 0 0 0 0 0 0 0 5 0 IN IN NN NN NNP O
selection selection 0 0 0 0 0 0 0 0 9 0 IN NN NN NNP NONE O
experiments. experiments. 0 0 0 0 0 0 0 0 12 0 NN NN NNP NONE NONE O
Bounds Bounds 1 0 0 0 0 0 0 0 6 0 NONE NONE NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NONE NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
spectral spectral 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN CC O
radius radius 0 0 0 0 0 0 0 0 6 0 DT JJ NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN NN O
nordhaus-gaddum nordhaus-gaddum 0 0 1 0 0 0 0 0 15 0 CC DT NN NN IN O
type type 0 0 0 0 0 0 0 0 4 0 DT NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
graphs. graphs. 0 0 0 0 0 0 0 0 7 0 IN DT NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 DT NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Jia Jia 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sun Sun 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
F. F. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Mathematics Mathematics 1 0 0 0 0 0 0 0 11 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Information Information 1 0 0 0 0 0 0 0 11 0 NNP CC NNP NNP NNP O
Science, Science, 1 0 0 0 1 0 0 0 8 0 CC NNP NNP NNP NNP O
Leshan Leshan 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Normal Normal 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP CD O
Leshan Leshan 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP CD NNP O
614004, 614004, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NN O
Laplacian Laplacian 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NN VBP O
spectra spectra 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBP DT O
are are 0 0 0 0 0 0 0 0 3 0 NNP NN VBP DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN VBP DT NNS IN O
eigenvalues eigenvalues 0 0 0 0 0 0 0 0 11 0 VBP DT NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NNP CD O
Laplacian Laplacian 1 0 0 0 0 0 0 0 9 0 NNS IN NNP CD -NONE- O
matrix matrix 0 0 0 0 0 0 0 0 6 0 IN NNP CD -NONE- : O
L(G) L(G) 1 1 0 0 0 0 0 0 4 0 NNP CD -NONE- : JJ O
= = 0 0 0 0 0 0 0 0 1 0 CD -NONE- : JJ : O
D(G) D(G) 1 1 0 0 0 0 0 0 4 0 -NONE- : JJ : JJ O
- - 0 0 1 0 0 0 0 0 1 0 : JJ : JJ WRB O
A(G), A(G), 1 1 0 0 1 0 0 0 5 0 JJ : JJ WRB JJ O
where where 0 0 0 0 0 0 0 0 5 0 : JJ WRB JJ CC O
D(G) D(G) 1 1 0 0 0 0 0 0 4 0 JJ WRB JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 WRB JJ CC JJ VBP O
A(G) A(G) 1 1 0 0 0 0 0 0 4 0 JJ CC JJ VBP DT O
are are 0 0 0 0 0 0 0 0 3 0 CC JJ VBP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ VBP DT JJ NN O
diagonal diagonal 0 0 0 0 0 0 0 0 8 0 VBP DT JJ NN IN O
matrix matrix 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNS O
vertex vertex 0 0 0 0 0 0 0 0 6 0 NN IN NN NNS CC O
degrees degrees 0 0 0 0 0 0 0 0 7 0 IN NN NNS CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS CC DT NN NN O
adjacency adjacency 0 0 0 0 0 0 0 0 9 0 CC DT NN NN IN O
matrix matrix 0 0 0 0 0 0 0 0 6 0 DT NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN NN O
graph graph 0 0 0 0 0 0 0 0 5 0 IN DT NN NN NN O
G, G, 1 1 0 0 1 0 0 0 2 0 DT NN NN NN CC O
respectively, respectively, 0 0 0 0 1 0 0 0 13 0 NN NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT JJ NN O
spectral spectral 0 0 0 0 0 0 0 0 8 0 CC DT JJ NN IN O
radius radius 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN NNP O
graph graph 0 0 0 0 0 0 0 0 5 0 IN DT NN NNP VBZ O
G G 1 1 0 0 0 0 0 0 1 0 DT NN NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN NNP VBZ DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT JJS NN O
largest largest 0 0 0 0 0 0 0 0 7 0 VBZ DT JJS NN IN O
eigenvalue eigenvalue 0 0 0 0 0 0 0 0 10 0 DT JJS NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJS NN IN NNP NNP O
A(G). A(G). 1 1 0 0 0 0 0 0 5 0 NN IN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP IN O
spectra spectra 0 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN CC O
graph graph 0 0 0 0 0 0 0 0 5 0 IN DT NN CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC VBG NNS O
corresponding corresponding 0 0 0 0 0 0 0 0 13 0 NN CC VBG NNS VBP O
eigenvalues eigenvalues 0 0 0 0 0 0 0 0 11 0 CC VBG NNS VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 VBG NNS VBP RB VBN O
closely closely 0 0 0 0 0 0 0 0 7 0 NNS VBP RB VBN TO O
linked linked 0 0 0 0 0 0 0 0 6 0 VBP RB VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 RB VBN TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN TO DT JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 TO DT JJ NN CC O
stability stability 0 0 0 0 0 0 0 0 9 0 DT JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NN O
related related 0 0 0 0 0 0 0 0 7 0 NN CC JJ NN NNP O
chemical chemical 0 0 0 0 0 0 0 0 8 0 CC JJ NN NNP NNP O
properties. properties. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NN NN O
quantum quantum 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN JJ O
chemistry, chemistry, 0 0 0 0 1 0 0 0 10 0 NNP NN NN JJ NN O
spectral spectral 0 0 0 0 0 0 0 0 8 0 NN NN JJ NN IN O
radius radius 0 0 0 0 0 0 0 0 6 0 NN JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN VBZ O
graph graph 0 0 0 0 0 0 0 0 5 0 IN DT NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT NN NN O
maximum maximum 0 0 0 0 0 0 0 0 7 0 VBZ DT NN NN NN O
energy energy 0 0 0 0 0 0 0 0 6 0 DT NN NN NN IN O
level level 0 0 0 0 0 0 0 0 5 0 NN NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
molecules. molecules. 0 0 0 0 0 0 0 0 10 0 NN IN NNP NNP VBD O
Therefore, Therefore, 1 0 0 0 1 0 0 0 10 0 IN NNP NNP VBD NN O
good good 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD NN NNS O
upper upper 0 0 0 0 0 0 0 0 5 0 NNP VBD NN NNS IN O
bounds bounds 0 0 0 0 0 0 0 0 6 0 VBD NN NNS IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
spectral spectral 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN VBP O
radius radius 0 0 0 0 0 0 0 0 6 0 DT JJ NN VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 JJ NN VBP JJ TO O
conducive conducive 0 0 0 0 0 0 0 0 9 0 NN VBP JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBP JJ TO VB DT O
evaluate evaluate 0 0 0 0 0 0 0 0 8 0 JJ TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
energy energy 0 0 0 0 0 0 0 0 6 0 VB DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
molecules. molecules. 0 0 0 0 0 0 0 0 10 0 NN IN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 IN NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
paper, paper, 0 0 0 0 1 0 0 0 6 0 NNP DT NN PRP RB O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP RB VBP O
first first 0 0 0 0 0 0 0 0 5 0 NN PRP RB VBP JJ O
give give 0 0 0 0 0 0 0 0 4 0 PRP RB VBP JJ JJ O
several several 0 0 0 0 0 0 0 0 7 0 RB VBP JJ JJ NN O
sharp sharp 0 0 0 0 0 0 0 0 5 0 VBP JJ JJ NN NNS O
upper upper 0 0 0 0 0 0 0 0 5 0 JJ JJ NN NNS IN O
bounds bounds 0 0 0 0 0 0 0 0 6 0 JJ NN NNS IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN JJ O
adjacency adjacency 0 0 0 0 0 0 0 0 9 0 IN DT NN JJ NN O
spectral spectral 0 0 0 0 0 0 0 0 8 0 DT NN JJ NN IN O
radius radius 0 0 0 0 0 0 0 0 6 0 NN JJ NN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS IN O
terms terms 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT NNS O
some some 0 0 0 0 0 0 0 0 4 0 NNS IN DT NNS IN O
invariants invariants 0 0 0 0 0 0 0 0 10 0 IN DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ JJ O
graphs, graphs, 0 0 0 0 1 0 0 0 7 0 NNS IN JJ JJ IN O
such such 0 0 0 0 0 0 0 0 4 0 IN JJ JJ IN DT O
as as 0 0 0 0 0 0 0 0 2 0 JJ JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN NN O
vertex vertex 0 0 0 0 0 0 0 0 6 0 IN DT NN NN DT O
degree, degree, 0 0 0 0 1 0 0 0 7 0 DT NN NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT JJ CD O
average average 0 0 0 0 0 0 0 0 7 0 NN DT JJ CD CC O
2-degree, 2-degree, 0 0 1 0 1 0 0 1 9 0 DT JJ CD CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ CD CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CD CC DT NN IN O
number number 0 0 0 0 0 0 0 0 6 0 CC DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
triangles. triangles. 0 0 0 0 0 0 0 0 10 0 IN DT NNP NNP PRP O
Then, Then, 1 0 0 0 1 0 0 0 5 0 DT NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP DT O
give give 0 0 0 0 0 0 0 0 4 0 NNP PRP VBP DT JJ O
some some 0 0 0 0 0 0 0 0 4 0 PRP VBP DT JJ NNS O
numerical numerical 0 0 0 0 0 0 0 0 9 0 VBP DT JJ NNS WDT O
examples examples 0 0 0 0 0 0 0 0 8 0 DT JJ NNS WDT VBP O
which which 0 0 0 0 0 0 0 0 5 0 JJ NNS WDT VBP IN O
indicate indicate 0 0 0 0 0 0 0 0 8 0 NNS WDT VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 WDT VBP IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 IN DT NNS VBP RBR O
are are 0 0 0 0 0 0 0 0 3 0 DT NNS VBP RBR IN O
better better 0 0 0 0 0 0 0 0 6 0 NNS VBP RBR IN DT O
than than 0 0 0 0 0 0 0 0 4 0 VBP RBR IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 RBR IN DT VBN NN O
mentioned mentioned 0 0 0 0 0 0 0 0 9 0 IN DT VBN NN NNS O
upper upper 0 0 0 0 0 0 0 0 5 0 DT VBN NN NNS IN O
bounds bounds 0 0 0 0 0 0 0 0 6 0 VBN NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NNP O
some some 0 0 0 0 0 0 0 0 4 0 NNS IN DT NNP NNP O
sense. sense. 0 0 0 0 0 0 0 0 6 0 IN DT NNP NNP DT O
Finally, Finally, 1 0 0 0 1 0 0 0 8 0 DT NNP NNP DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNP NNP DT JJ NN O
upper upper 0 0 0 0 0 0 0 0 5 0 NNP DT JJ NN IN O
bound bound 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
Nordhaus-Gaddum Nordhaus-Gaddum 1 0 1 0 0 0 0 0 15 0 IN DT NN NN VBZ O
type type 0 0 0 0 0 0 0 0 4 0 DT NN NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ VBN IN O
obtained obtained 0 0 0 0 0 0 0 0 8 0 NN VBZ VBN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBZ VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
sum sum 0 0 0 0 0 0 0 0 3 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP JJ O
Laplacian Laplacian 1 0 0 0 0 0 0 0 9 0 NN IN NNP JJ NN O
spectral spectral 0 0 0 0 0 0 0 0 8 0 IN NNP JJ NN IN O
radius radius 0 0 0 0 0 0 0 0 6 0 NNP JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT VBN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT VBN NN O
connected connected 0 0 0 0 0 0 0 0 9 0 IN DT VBN NN CC O
graph graph 0 0 0 0 0 0 0 0 5 0 DT VBN NN CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 VBN NN CC PRP$ NNP O
its its 0 0 0 0 0 0 0 0 3 0 NN CC PRP$ NNP NNP O
complement. complement. 0 0 0 0 0 0 0 0 11 0 CC PRP$ NNP NNP DT O
Moreover, Moreover, 1 0 0 0 1 0 0 0 9 0 PRP$ NNP NNP DT NNS O
some some 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NNS VBP O
examples examples 0 0 0 0 0 0 0 0 8 0 NNP DT NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 DT NNS VBP VBN TO O
applied applied 0 0 0 0 0 0 0 0 7 0 NNS VBP VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBP VBN TO VB IN O
illustrate illustrate 0 0 0 0 0 0 0 0 10 0 VBN TO VB IN PRP$ O
that that 0 0 0 0 0 0 0 0 4 0 TO VB IN PRP$ NN O
our our 0 0 0 0 0 0 0 0 3 0 VB IN PRP$ NN VBZ O
result result 0 0 0 0 0 0 0 0 6 0 IN PRP$ NN VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 PRP$ NN VBZ NNP NONE O
valuable. valuable. 0 0 0 0 0 0 0 0 9 0 NN VBZ NNP NONE NONE O
New New 1 0 0 0 0 0 0 0 3 0 NONE NONE NNP NNS IN O
records records 0 0 0 0 0 0 0 0 7 0 NONE NNP NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NN NN O
lake lake 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN NN O
baikal baikal 0 0 0 0 0 0 0 0 6 0 IN NN NN NN NN O
leech leech 0 0 0 0 0 0 0 0 5 0 NN NN NN NN NNS O
fauna: fauna: 0 0 0 0 0 0 0 0 6 0 NN NN NN NNS NN O
species species 0 0 0 0 0 0 0 0 7 0 NN NN NNS NN CC O
diversity diversity 0 0 0 0 0 0 0 0 9 0 NN NNS NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNS NN CC JJ NN O
spatial spatial 0 0 0 0 0 0 0 0 7 0 NN CC JJ NN IN O
distribution distribution 0 0 0 0 0 0 0 0 12 0 CC JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNP O
chivyrkuy chivyrkuy 0 0 0 0 0 0 0 0 9 0 NN IN NN NNP NNP O
gulf. gulf. 0 0 0 0 0 0 0 0 5 0 IN NN NNP NNP NNP O
Kaygorodova Kaygorodova 1 0 0 0 0 0 0 0 11 0 NN NNP NNP NNP NNP O
IA, IA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Pronin Pronin 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
NM. NM. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Limnological Limnological 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Siberian Siberian 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP IN O
Branch Branch 1 0 0 0 0 0 0 0 6 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Russian Russian 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP IN O
Academy Academy 1 0 0 0 0 0 0 0 7 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CD O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP CD NNP O
3 3 0 0 0 0 0 0 1 1 1 0 IN NNP CD NNP NNP O
Ulan-Batorskaja Ulan-Batorskaja 1 0 1 0 0 0 0 0 15 0 NNP CD NNP NNP NNP O
Street, Street, 1 0 0 0 1 0 0 0 7 0 CD NNP NNP NNP CD O
Irkutsk Irkutsk 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP CD NNP O
664033, 664033, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP NNP O
Russia. Russia. 1 0 0 0 0 0 0 0 7 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NNP O
several several 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNP NNP O
Lake Lake 1 0 0 0 0 0 0 0 4 0 IN JJ NNP NNP NN O
Baikal Baikal 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP NN NNS O
leech leech 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NNS VBD O
collections collections 0 0 0 0 0 0 0 0 11 0 NNP NN NNS VBD PRP O
offered offered 0 0 0 0 0 0 0 0 7 0 NN NNS VBD PRP DT O
us us 0 0 0 0 0 0 0 0 2 0 NNS VBD PRP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD PRP DT NN TO O
possibility possibility 0 0 0 0 0 0 0 0 11 0 PRP DT NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO VB NNS O
determine determine 0 0 0 0 0 0 0 0 9 0 NN TO VB NNS NN O
species species 0 0 0 0 0 0 0 0 7 0 TO VB NNS NN IN O
diversity diversity 0 0 0 0 0 0 0 0 9 0 VB NNS NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNS NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
Chivyrkuy Chivyrkuy 1 0 0 0 0 0 0 0 9 0 IN DT NNP NNP DT O
Gulf, Gulf, 1 0 0 0 1 0 0 0 5 0 DT NNP NNP DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJS CD O
biggest biggest 0 0 0 0 0 0 0 0 7 0 NNP DT JJS CD IN O
one one 0 0 0 0 0 0 0 0 3 0 DT JJS CD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJS CD IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT NNP NNP O
lake. lake. 0 0 0 0 0 0 0 0 5 0 IN DT NNP NNP DT O
As As 1 0 0 0 0 0 0 0 2 0 DT NNP NNP DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT NNP DT O
result, result, 0 0 0 0 1 0 0 0 7 0 NNP DT NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 DT NNP DT JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 NNP DT JJ NN IN O
information information 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
Chivyrkuy Chivyrkuy 1 0 0 0 0 0 0 0 9 0 IN DT NNP NNP NN O
Hirudinea Hirudinea 1 0 0 0 0 0 0 0 9 0 DT NNP NNP NN -NONE- O
fauna fauna 0 0 0 0 0 0 0 0 5 0 NNP NNP NN -NONE- -NONE- O
(Annelida, (Annelida, 0 0 0 0 1 0 0 0 10 0 NNP NN -NONE- -NONE- VBZ O
Clitellata) Clitellata) 1 0 0 0 0 0 0 0 11 0 NN -NONE- -NONE- VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- VBZ VBN NNP O
been been 0 0 0 0 0 0 0 0 4 0 -NONE- VBZ VBN NNP NNP O
revealed. revealed. 0 0 0 0 0 0 0 0 9 0 VBZ VBN NNP NNP VBP O
There There 1 0 0 0 0 0 0 0 5 0 VBN NNP NNP VBP CD O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNP VBP CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 NNP VBP CD NNS CC O
orders orders 0 0 0 0 0 0 0 0 6 0 VBP CD NNS CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD NNS CC CD NNS O
four four 0 0 0 0 0 0 0 0 4 0 NNS CC CD NNS IN O
families families 0 0 0 0 0 0 0 0 8 0 CC CD NNS IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN NNS IN O
leeches leeches 0 0 0 0 0 0 0 0 7 0 NNS IN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NNP O
Chivyrkuy Chivyrkuy 1 0 0 0 0 0 0 0 9 0 IN DT NNP NNP NN O
Gulf: Gulf: 1 0 0 0 0 0 0 0 5 0 DT NNP NNP NN NNP O
order order 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NNP NNP O
Rhynchobdellida Rhynchobdellida 1 0 0 0 0 0 0 0 15 0 NNP NN NNP NNP NNP O
(families (families 0 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP CC O
Glossiphoniidae Glossiphoniidae 1 0 0 0 0 0 0 0 15 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP CC O
Piscicolidae) Piscicolidae) 1 0 0 0 0 0 0 0 13 0 NNP CC NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC NN NNP O
order order 0 0 0 0 0 0 0 0 5 0 NNP CC NN NNP NNP O
Arhynchobdellida Arhynchobdellida 1 0 0 0 0 0 0 0 16 0 CC NN NNP NNP NNP O
(families (families 0 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP CC O
Erpobdellidae Erpobdellidae 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Haemopidae). Haemopidae). 1 0 0 0 0 0 0 0 12 0 NNP CC NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 CC NNP NNP NNP CD O
total, total, 0 0 0 0 1 0 0 0 6 0 NNP NNP NNP CD NN O
22 22 0 0 0 0 0 0 1 1 2 0 NNP NNP CD NN NNS O
leech leech 0 0 0 0 0 0 0 0 5 0 NNP CD NN NNS CC O
species species 0 0 0 0 0 0 0 0 7 0 CD NN NNS CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC CD NNS O
2 2 0 0 0 0 0 0 1 1 1 0 NNS CC CD NNS VBG O
subspecies subspecies 0 0 0 0 0 0 0 0 10 0 CC CD NNS VBG TO O
belonging belonging 0 0 0 0 0 0 0 0 9 0 CD NNS VBG TO CD O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBG TO CD NN O
11 11 0 0 0 0 0 0 1 1 2 0 VBG TO CD NN VBD O
genera genera 0 0 0 0 0 0 0 0 6 0 TO CD NN VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 CD NN VBD NNP IN O
identified. identified. 0 0 0 0 0 0 0 0 11 0 NN VBD NNP IN NNP O
Of Of 1 0 0 0 0 0 0 0 2 0 VBD NNP IN NNP CD O
these, these, 0 0 0 0 1 0 0 0 6 0 NNP IN NNP CD NN O
4 4 0 0 0 0 0 0 1 1 1 0 IN NNP CD NN IN O
taxa taxa 0 0 0 0 0 0 0 0 4 0 NNP CD NN IN TO O
belong belong 0 0 0 0 0 0 0 0 6 0 CD NN IN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN IN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN TO DT NN NNP O
family family 0 0 0 0 0 0 0 0 6 0 TO DT NN NNP NNP O
Glossiphoniidae Glossiphoniidae 1 0 0 0 0 0 0 0 15 0 DT NN NNP NNP NNP O
(G. (G. 0 1 0 0 0 0 0 0 3 0 NN NNP NNP NNP NNP O
concolor, concolor, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
A. A. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
hyalina, hyalina, 0 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NN O
A. A. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NN NNP O
heteroclita heteroclita 0 0 0 0 0 0 0 0 11 0 NNP NNP NN NNP NNP O
f. f. 0 0 0 0 0 0 0 0 2 0 NNP NN NNP NNP CC O
papillosa, papillosa, 0 0 0 0 1 0 0 0 10 0 NN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NN O
A. A. 1 1 0 0 0 0 0 0 2 0 NNP CC NNP NN NNP O
heteroclita heteroclita 0 0 0 0 0 0 0 0 11 0 CC NNP NN NNP NNP O
f. f. 0 0 0 0 0 0 0 0 2 0 NNP NN NNP NNP VBD O
striata) striata) 0 0 0 0 0 0 0 0 8 0 NN NNP NNP VBD IN O
recorded recorded 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP VBD IN NNP IN O
Baikal Baikal 1 0 0 0 0 0 0 0 6 0 VBD IN NNP IN DT O
for for 0 0 0 0 0 0 0 0 3 0 IN NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ NNP O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ NNP NNP O
time. time. 0 0 0 0 0 0 0 0 5 0 DT JJ NNP NNP IN O
Representatives Representatives 1 0 0 0 0 0 0 0 15 0 JJ NNP NNP IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN CD VBN O
8 8 0 0 0 0 0 0 1 1 1 0 NNP IN CD VBN NNS O
unidentified unidentified 0 0 0 0 0 0 0 0 12 0 IN CD VBN NNS -NONE- O
species species 0 0 0 0 0 0 0 0 7 0 CD VBN NNS -NONE- -NONE- O
(Glossophinia (Glossophinia 0 0 0 0 0 0 0 0 13 0 VBN NNS -NONE- -NONE- NNP O
sp., sp., 0 0 0 0 1 0 0 0 4 0 NNS -NONE- -NONE- NNP NNP O
Baicaloclepsis Baicaloclepsis 1 0 0 0 0 0 0 0 14 0 -NONE- -NONE- NNP NNP NNP O
sp., sp., 0 0 0 0 1 0 0 0 4 0 -NONE- NNP NNP NNP NNP O
Baicalobdella Baicalobdella 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
sp., sp., 0 0 0 0 1 0 0 0 4 0 NNP NNP NNP NNP NNP O
Piscicola Piscicola 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP CD O
sp. sp. 0 0 0 0 0 0 0 0 3 0 NNP NNP NNP CD NNP O
1, 1, 0 0 0 0 1 0 0 1 2 0 NNP NNP CD NNP NNP O
Piscicola Piscicola 1 0 0 0 0 0 0 0 9 0 NNP CD NNP NNP CD O
sp. sp. 0 0 0 0 0 0 0 0 3 0 CD NNP NNP CD NNP O
2, 2, 0 0 0 0 1 0 0 1 2 0 NNP NNP CD NNP NNP O
Erpobdella Erpobdella 1 0 0 0 0 0 0 0 10 0 NNP CD NNP NNP CD O
sp. sp. 0 0 0 0 0 0 0 0 3 0 CD NNP NNP CD NNP O
1, 1, 0 0 0 0 1 0 0 1 2 0 NNP NNP CD NNP NNP O
Erpobdella Erpobdella 1 0 0 0 0 0 0 0 10 0 NNP CD NNP NNP CD O
sp. sp. 0 0 0 0 0 0 0 0 3 0 CD NNP NNP CD CC O
2, 2, 0 0 0 0 1 0 0 1 2 0 NNP NNP CD CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP CD CC NNP NNP O
Erpobdella Erpobdella 1 0 0 0 0 0 0 0 10 0 CD CC NNP NNP CD O
sp. sp. 0 0 0 0 0 0 0 0 3 0 CC NNP NNP CD VBP O
3) 3) 0 0 0 0 0 0 0 1 2 0 NNP NNP CD VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP CD VBP VBN RB O
been been 0 0 0 0 0 0 0 0 4 0 CD VBP VBN RB NNP O
also also 0 0 0 0 0 0 0 0 4 0 VBP VBN RB NNP NNP O
recorded. recorded. 0 0 0 0 0 0 0 0 9 0 VBN RB NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 RB NNP NNP NN VBZ O
checklist checklist 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBZ DT O
gives gives 0 0 0 0 0 0 0 0 5 0 NNP NN VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT JJ NN O
contemporary contemporary 0 0 0 0 0 0 0 0 12 0 VBZ DT JJ NN IN O
overview overview 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS NN O
species species 0 0 0 0 0 0 0 0 7 0 IN DT NNS NN IN O
composition composition 0 0 0 0 0 0 0 0 11 0 DT NNS NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNS NN IN NN NN O
leech leech 0 0 0 0 0 0 0 0 5 0 NN IN NN NN PRP$ O
parasites, parasites, 0 0 0 0 1 0 0 0 10 0 IN NN NN PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 NN NN PRP$ NN CC O
hosts, hosts, 0 0 0 0 1 0 0 0 6 0 NN PRP$ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 PRP$ NN CC NN IN O
distribution distribution 0 0 0 0 0 0 0 0 12 0 NN CC NN IN DT O
within within 0 0 0 0 0 0 0 0 6 0 CC NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
Chivyrkuy Chivyrkuy 1 0 0 0 0 0 0 0 9 0 IN DT NNP NNP NNP O
Gulf. Gulf. 1 0 0 0 0 0 0 0 5 0 DT NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
spatial spatial 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN VBZ O
distribution distribution 0 0 0 0 0 0 0 0 12 0 IN JJ NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 JJ NN VBZ VBN IN O
shown shown 0 0 0 0 0 0 0 0 5 0 NN VBZ VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NNS O
leech leech 0 0 0 0 0 0 0 0 5 0 IN DT NN NNS NN O
species species 0 0 0 0 0 0 0 0 7 0 DT NN NNS NN VBZ O
diversity diversity 0 0 0 0 0 0 0 0 9 0 NN NNS NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNS NN VBZ VBN IN O
correlated correlated 0 0 0 0 0 0 0 0 10 0 NN VBZ VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
biological biological 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN IN O
productivity productivity 0 0 0 0 0 0 0 0 12 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
bay. bay. 0 0 0 0 0 0 0 0 4 0 IN DT NNP NNP RBS O
The The 1 0 0 0 0 0 0 0 3 0 DT NNP NNP RBS JJ O
most most 0 0 0 0 0 0 0 0 4 0 NNP NNP RBS JJ NN O
diverse diverse 0 0 0 0 0 0 0 0 7 0 NNP RBS JJ NN IN O
community community 0 0 0 0 0 0 0 0 9 0 RBS JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNS O
leech leech 0 0 0 0 0 0 0 0 5 0 NN IN NN NNS VBZ O
species species 0 0 0 0 0 0 0 0 7 0 IN NN NNS VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN NNS VBZ VBN IN O
detected detected 0 0 0 0 0 0 0 0 8 0 NNS VBZ VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
eutrophic eutrophic 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN IN O
zone zone 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NONE O
lake. lake. 0 0 0 0 0 0 0 0 5 0 IN DT NNP NONE NONE O
Metabolic Metabolic 1 0 0 0 0 0 0 0 9 0 NONE NONE NNP NNP IN O
Disturbance Disturbance 1 0 0 0 0 0 0 0 11 0 NONE NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
PCOS: PCOS: 1 1 0 0 0 0 0 0 5 0 NNP IN NNP NNP CC O
Clinical Clinical 1 0 0 0 0 0 0 0 8 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNPS O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP CC NNP NNPS IN O
Effects Effects 1 0 0 0 0 0 0 0 7 0 CC NNP NNPS IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
Skeletal Skeletal 1 0 0 0 0 0 0 0 8 0 NNPS IN NNP NNP NNP O
Muscle Muscle 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
Tissue. Tissue. 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Silva Silva 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Dantas Dantas 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
W, W, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Gualano Gualano 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Patrocínio Patrocínio 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Rocha Rocha 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Roberto Roberto 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Grimaldi Grimaldi 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Barcellos Barcellos 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Dos Dos 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Reis Reis 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Vieira Vieira 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Yance Yance 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
V, V, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Miguel Miguel 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Marcondes Marcondes 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
JA. JA. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Physical Physical 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP CC O
Education Education 1 0 0 0 0 0 0 0 9 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Sport, Sport, 1 0 0 0 1 0 0 0 6 0 NNP CC NNP NNP IN O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Applied Applied 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP CC O
Nutrition Nutrition 1 0 0 0 0 0 0 0 9 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Metabolism, Metabolism, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
São São 1 0 0 0 0 0 0 0 3 0 NNP IN NNP NNP CD O
Paulo, Paulo, 1 0 0 0 1 0 0 0 6 0 IN NNP NNP CD NNP O
05508-030 05508-030 0 0 1 0 0 0 0 1 9 0 NNP NNP CD NNP NNP O
São São 1 0 0 0 0 0 0 0 3 0 NNP CD NNP NNP NNP O
Paulo, Paulo, 1 0 0 0 1 0 0 0 6 0 CD NNP NNP NNP NNP O
SP, SP, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Brazil. Brazil. 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
Polycystic Polycystic 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NN NN O
ovary ovary 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NN VBZ O
syndrome syndrome 0 0 0 0 0 0 0 0 8 0 NNP NN NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT JJ JJ O
complex complex 0 0 0 0 0 0 0 0 7 0 VBZ DT JJ JJ NN O
hormonal hormonal 0 0 0 0 0 0 0 0 8 0 DT JJ JJ NN VBG O
disorder disorder 0 0 0 0 0 0 0 0 8 0 JJ JJ NN VBG DT O
affecting affecting 0 0 0 0 0 0 0 0 9 0 JJ NN VBG DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT JJ CC O
reproductive reproductive 0 0 0 0 0 0 0 0 12 0 VBG DT JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC JJ NNS O
metabolic metabolic 0 0 0 0 0 0 0 0 9 0 JJ CC JJ NNS IN O
systems systems 0 0 0 0 0 0 0 0 7 0 CC JJ NNS IN NNS O
with with 0 0 0 0 0 0 0 0 4 0 JJ NNS IN NNS CC O
signs signs 0 0 0 0 0 0 0 0 5 0 NNS IN NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC NNS VBN O
symptoms symptoms 0 0 0 0 0 0 0 0 8 0 NNS CC NNS VBN TO O
related related 0 0 0 0 0 0 0 0 7 0 CC NNS VBN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBN TO NNP NNP O
anovulation, anovulation, 0 0 0 0 1 0 0 0 12 0 VBN TO NNP NNP JJ O
infertility, infertility, 0 0 0 0 1 0 0 0 12 0 TO NNP NNP JJ NN O
menstrual menstrual 0 0 0 0 0 0 0 0 9 0 NNP NNP JJ NN CC O
irregularity irregularity 0 0 0 0 0 0 0 0 12 0 NNP JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP NNP O
hirsutism. hirsutism. 0 0 0 0 0 0 0 0 10 0 NN CC NNP NNP NN O
Skeletal Skeletal 1 0 0 0 0 0 0 0 8 0 CC NNP NNP NN VBZ O
muscle muscle 0 0 0 0 0 0 0 0 6 0 NNP NNP NN VBZ DT O
plays plays 0 0 0 0 0 0 0 0 5 0 NNP NN VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT JJ NN O
vital vital 0 0 0 0 0 0 0 0 5 0 VBZ DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
peripheral peripheral 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN NNP O
glucose glucose 0 0 0 0 0 0 0 0 7 0 DT JJ NN NNP NNP O
uptake. uptake. 0 0 0 0 0 0 0 0 7 0 JJ NN NNP NNP NNP O
Since Since 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP VBZ O
PCOS PCOS 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NNP VBZ VBN IN NNS O
with with 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN NNS IN O
defects defects 0 0 0 0 0 0 0 0 7 0 VBN IN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN CC O
activation activation 0 0 0 0 0 0 0 0 10 0 IN DT NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC JJ NN O
pancreatic pancreatic 0 0 0 0 0 0 0 0 10 0 NN CC JJ NN IN O
dysfunction dysfunction 0 0 0 0 0 0 0 0 11 0 CC JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
β-cell β-cell 0 0 1 0 0 0 0 0 6 0 NN IN NNP NNP PRP O
insulin, insulin, 0 0 0 0 1 0 0 0 8 0 IN NNP NNP PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP PRP VBZ JJ TO O
important important 0 0 0 0 0 0 0 0 9 0 PRP VBZ JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO VB DT O
understand understand 0 0 0 0 0 0 0 0 10 0 JJ TO VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJ NNS O
molecular molecular 0 0 0 0 0 0 0 0 9 0 VB DT JJ NNS IN O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 DT JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NN O
insulin insulin 0 0 0 0 0 0 0 0 7 0 NNS IN NN NN IN O
resistance resistance 0 0 0 0 0 0 0 0 10 0 IN NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNPS O
PCOS. PCOS. 1 1 0 0 0 0 0 0 5 0 NN IN NNP NNPS IN O
Studies Studies 1 0 0 0 0 0 0 0 7 0 IN NNP NNPS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NN NN O
muscle muscle 0 0 0 0 0 0 0 0 6 0 NNPS IN NN NN IN O
tissue tissue 0 0 0 0 0 0 0 0 6 0 IN NN NN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 NN IN NNS IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN NNP NN O
PCOS PCOS 1 1 0 0 0 0 0 0 4 0 NNS IN NNP NN NNS O
reveal reveal 0 0 0 0 0 0 0 0 6 0 IN NNP NN NNS IN O
defects defects 0 0 0 0 0 0 0 0 7 0 NNP NN NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NNP O
insulin insulin 0 0 0 0 0 0 0 0 7 0 NNS IN NN NNP NNP O
signaling. signaling. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP VBZ O
Muscle Muscle 1 0 0 0 0 0 0 0 6 0 NN NNP NNP VBZ VBN O
biopsies biopsies 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ VBN IN O
performed performed 0 0 0 0 0 0 0 0 9 0 NNP VBZ VBN IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 VBZ VBN IN JJ JJ O
euglycemic euglycemic 0 0 0 0 0 0 0 0 10 0 VBN IN JJ JJ NN O
hyperinsulinemic hyperinsulinemic 0 0 0 0 0 0 0 0 16 0 IN JJ JJ NN VBD O
clamp clamp 0 0 0 0 0 0 0 0 5 0 JJ JJ NN VBD DT O
showed showed 0 0 0 0 0 0 0 0 6 0 JJ NN VBD DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBD DT JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 VBD DT JJ NN IN O
reduction reduction 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
glucose glucose 0 0 0 0 0 0 0 0 7 0 NN IN NN NN CC O
uptake, uptake, 0 0 0 0 1 0 0 0 7 0 IN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ -NONE- O
insulin-mediated insulin-mediated 0 0 1 0 0 0 0 0 16 0 NN CC JJ -NONE- VBN O
IRS-2 IRS-2 1 1 1 0 0 0 0 1 5 0 CC JJ -NONE- VBN RB O
increased increased 0 0 0 0 0 0 0 0 9 0 JJ -NONE- VBN RB IN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 -NONE- VBN RB IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBN RB IN JJ NNP O
skeletal skeletal 0 0 0 0 0 0 0 0 8 0 RB IN JJ NNP NNP O
muscle. muscle. 0 0 0 0 0 0 0 0 7 0 IN JJ NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
recognized recognized 0 0 0 0 0 0 0 0 10 0 NNP VBZ VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
etiology etiology 0 0 0 0 0 0 0 0 8 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
insulin insulin 0 0 0 0 0 0 0 0 7 0 NN IN NN NN IN O
resistance resistance 0 0 0 0 0 0 0 0 10 0 IN NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP VBZ O
PCOS PCOS 1 1 0 0 0 0 0 0 4 0 NN IN NNP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ JJ TO O
likely likely 0 0 0 0 0 0 0 0 6 0 NNP VBZ JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO VB RB O
be be 0 0 0 0 0 0 0 0 2 0 JJ TO VB RB VBN O
as as 0 0 0 0 0 0 0 0 2 0 TO VB RB VBN IN O
complicated complicated 0 0 0 0 0 0 0 0 11 0 VB RB VBN IN IN O
as as 0 0 0 0 0 0 0 0 2 0 RB VBN IN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBN IN IN NN CD O
type type 0 0 0 0 0 0 0 0 4 0 IN IN NN CD NNS O
2 2 0 0 0 0 0 0 1 1 1 0 IN NN CD NNS CC O
diabetes diabetes 0 0 0 0 0 0 0 0 8 0 NN CD NNS CC PRP O
and and 0 0 0 0 0 0 0 0 3 0 CD NNS CC PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NNS CC PRP VBZ DT O
has has 0 0 0 0 0 0 0 0 3 0 CC PRP VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 PRP VBZ DT JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ CC O
metabolic metabolic 0 0 0 0 0 0 0 0 9 0 NN IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NNS O
reproductive reproductive 0 0 0 0 0 0 0 0 12 0 JJ CC JJ NNS IN O
phenotypes phenotypes 0 0 0 0 0 0 0 0 10 0 CC JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NNP O
this this 0 0 0 0 0 0 0 0 4 0 NNS IN DT NNP NNP O
syndrome. syndrome. 0 0 0 0 0 0 0 0 9 0 IN DT NNP NNP RB O
Thus, Thus, 1 0 0 0 1 0 0 0 5 0 DT NNP NNP RB NN O
further further 0 0 0 0 0 0 0 0 7 0 NNP NNP RB NN VBG O
evidence evidence 0 0 0 0 0 0 0 0 8 0 NNP RB NN VBG DT O
regarding regarding 0 0 0 0 0 0 0 0 9 0 RB NN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 VBG DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
nonpharmacological nonpharmacological 0 0 0 0 0 0 0 0 18 0 NN IN JJ NNS -NONE- O
approaches approaches 0 0 0 0 0 0 0 0 10 0 IN JJ NNS -NONE- JJ O
(e.g., (e.g., 0 0 0 0 1 0 0 0 6 0 JJ NNS -NONE- JJ NN O
physical physical 0 0 0 0 0 0 0 0 8 0 NNS -NONE- JJ NN IN O
exercise) exercise) 0 0 0 0 0 0 0 0 9 0 -NONE- JJ NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
skeletal skeletal 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN IN O
muscle muscle 0 0 0 0 0 0 0 0 6 0 IN JJ NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS IN O
women women 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN NNP VBZ O
PCOS PCOS 1 1 0 0 0 0 0 0 4 0 NNS IN NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ VBN IN O
required required 0 0 0 0 0 0 0 0 8 0 NNP VBZ VBN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBZ VBN IN DT JJR O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJR JJ O
better better 0 0 0 0 0 0 0 0 6 0 IN DT JJR JJ NN O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 DT JJR JJ NN IN O
approach approach 0 0 0 0 0 0 0 0 8 0 JJR JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
management management 0 0 0 0 0 0 0 0 10 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ JJ O
various various 0 0 0 0 0 0 0 0 7 0 NN IN JJ JJ CC O
metabolic metabolic 0 0 0 0 0 0 0 0 9 0 IN JJ JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ JJ CC JJ NNS O
reproductive reproductive 0 0 0 0 0 0 0 0 12 0 JJ CC JJ NNS VBN O
problems problems 0 0 0 0 0 0 0 0 8 0 CC JJ NNS VBN IN O
caused caused 0 0 0 0 0 0 0 0 6 0 JJ NNS VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBN IN DT NNP O
this this 0 0 0 0 0 0 0 0 4 0 VBN IN DT NNP NONE O
syndrome. syndrome. 0 0 0 0 0 0 0 0 9 0 IN DT NNP NONE NONE O
Effects Effects 1 0 0 0 0 0 0 0 7 0 NONE NONE NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NNS IN NNP IN O
Chitosan Chitosan 1 0 0 0 0 0 0 0 8 0 NNS IN NNP IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NNP O
Candida Candida 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
albicans: albicans: 0 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP IN O
Conditions Conditions 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNPS O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNPS NNP O
Its Its 1 0 0 0 0 0 0 0 3 0 NNP IN NNPS NNP NNP O
Antifungal Antifungal 1 0 0 0 0 0 0 0 10 0 IN NNPS NNP NNP NNP O
Activity. Activity. 1 0 0 0 0 0 0 0 9 0 NNPS NNP NNP NNP NNP O
Peña Peña 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sánchez Sánchez 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
NS, NS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Calahorra Calahorra 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
M. M. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Departamento Departamento 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Genética Genética 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Molecular, Molecular, 1 0 0 0 1 0 0 0 10 0 IN NNP NNP NNP IN O
Instituto Instituto 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Fisiología Fisiología 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Celular, Celular, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP NNP O
Universidad Universidad 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
Nacional Nacional 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Autónoma Autónoma 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
México, México, 1 0 0 0 1 0 0 0 7 0 NNP IN NNP NNP NNP O
Circuito Circuito 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
Exterior Exterior 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
s/n, s/n, 0 0 0 1 1 0 0 0 4 0 NNP NNP NNP NNP NNP O
Ciudad Ciudad 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP CD O
Universitaria, Universitaria, 1 0 0 0 1 0 0 0 14 0 NNP NNP NNP CD -NONE- O
04510 04510 0 0 0 0 0 0 1 1 5 0 NNP NNP CD -NONE- JJ O
México, México, 1 0 0 0 1 0 0 0 7 0 NNP CD -NONE- JJ NNP O
DF, DF, 1 1 0 0 1 0 0 0 3 0 CD -NONE- JJ NNP NNP O
Mexico. Mexico. 1 0 0 0 0 0 0 0 7 0 -NONE- JJ NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN JJ NN O
low low 0 0 0 0 0 0 0 0 3 0 NNS IN JJ NN NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 IN JJ NN NN -NONE- O
weight weight 0 0 0 0 0 0 0 0 6 0 JJ NN NN -NONE- -NONE- O
(96.5 (96.5 0 0 0 0 0 0 0 1 5 0 NN NN -NONE- -NONE- JJ O
KDa) KDa) 1 0 0 0 0 0 0 0 4 0 NN -NONE- -NONE- JJ IN O
chitosan chitosan 0 0 0 0 0 0 0 0 8 0 -NONE- -NONE- JJ IN DT O
on on 0 0 0 0 0 0 0 0 2 0 -NONE- JJ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT JJ NN O
pathogenic pathogenic 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN NNP O
yeast yeast 0 0 0 0 0 0 0 0 5 0 DT JJ NN NNP NNS O
Candida Candida 1 0 0 0 0 0 0 0 7 0 JJ NN NNP NNS VBD O
albicans albicans 0 0 0 0 0 0 0 0 8 0 NN NNP NNS VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD NNP NNP O
studied. studied. 0 0 0 0 0 0 0 0 8 0 NNS VBD NNP NNP NNS O
Low Low 1 0 0 0 0 0 0 0 3 0 VBD NNP NNP NNS IN O
concentrations concentrations 0 0 0 0 0 0 0 0 14 0 NNP NNP NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN JJ IN O
chitosan, chitosan, 0 0 0 0 1 0 0 0 9 0 NNS IN JJ IN CD O
around around 0 0 0 0 0 0 0 0 6 0 IN JJ IN CD TO O
2.5 2.5 0 0 0 0 0 0 0 1 3 0 JJ IN CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 IN CD TO CD CD O
10 10 0 0 0 0 0 0 1 1 2 0 CD TO CD CD JJ O
μ μ 0 0 0 0 0 0 0 0 1 0 TO CD CD JJ VBN O
g·mL(-1) g·mL(-1) 0 0 1 0 0 0 0 1 8 0 CD CD JJ VBN -NONE- O
produced produced 0 0 0 0 0 0 0 0 8 0 CD JJ VBN -NONE- DT O
(a) (a) 0 0 0 0 0 0 0 0 3 0 JJ VBN -NONE- DT NN O
an an 0 0 0 0 0 0 0 0 2 0 VBN -NONE- DT NN IN O
efflux efflux 0 0 0 0 0 0 0 0 6 0 -NONE- DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP CC O
K(+) K(+) 1 1 0 0 0 0 0 0 4 0 NN IN NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NN IN O
stimulation stimulation 0 0 0 0 0 0 0 0 11 0 NNP CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NN O
extracellular extracellular 0 0 0 0 0 0 0 0 13 0 NN IN JJ NN NN O
acidification, acidification, 0 0 0 0 1 0 0 0 14 0 IN JJ NN NN DT O
(b) (b) 0 0 0 0 0 0 0 0 3 0 JJ NN NN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NN NN DT NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 NN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
Rb(+) Rb(+) 1 0 0 0 0 0 0 0 5 0 NN IN NNP NNP NNP O
uptake, uptake, 0 0 0 0 1 0 0 0 7 0 IN NNP NNP NNP DT O
(c) (c) 0 0 0 0 0 0 0 0 3 0 NNP NNP NNP DT VBN O
an an 0 0 0 0 0 0 0 0 2 0 NNP NNP DT VBN NN O
increased increased 0 0 0 0 0 0 0 0 9 0 NNP DT VBN NN NN O
transmembrane transmembrane 0 0 0 0 0 0 0 0 13 0 DT VBN NN NN NN O
potential potential 0 0 0 0 0 0 0 0 9 0 VBN NN NN NN IN O
difference difference 0 0 0 0 0 0 0 0 10 0 NN NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ CC O
cells, cells, 0 0 0 0 1 0 0 0 6 0 IN DT JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC JJ DT O
(d) (d) 0 0 0 0 0 0 0 0 3 0 JJ CC JJ DT VBN O
an an 0 0 0 0 0 0 0 0 2 0 CC JJ DT VBN NN O
increased increased 0 0 0 0 0 0 0 0 9 0 JJ DT VBN NN IN O
uptake uptake 0 0 0 0 0 0 0 0 6 0 DT VBN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNP NNP O
Ca(2+). Ca(2+). 1 0 0 0 0 0 0 1 7 0 NN IN NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 IN NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
proposed proposed 0 0 0 0 0 0 0 0 8 0 NNP VBZ VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 VBN IN DT NNS VBP O
effects effects 0 0 0 0 0 0 0 0 7 0 IN DT NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 DT NNS VBP JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 NNS VBP JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBP JJ TO DT NN O
a a 0 0 0 0 0 0 0 0 1 0 JJ TO DT NN IN O
decrease decrease 0 0 0 0 0 0 0 0 8 0 TO DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
negative negative 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN NN O
surface surface 0 0 0 0 0 0 0 0 7 0 DT JJ NN NN IN O
charge charge 0 0 0 0 0 0 0 0 6 0 JJ NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS VBG O
cells cells 0 0 0 0 0 0 0 0 5 0 IN DT NNS VBG IN O
resulting resulting 0 0 0 0 0 0 0 0 9 0 DT NNS VBG IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBG IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBG IN DT JJ NN O
strong strong 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN IN O
binding binding 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN TO O
polymer polymer 0 0 0 0 0 0 0 0 7 0 IN DT NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 TO DT NNP NNP JJR O
At At 1 0 0 0 0 0 0 0 2 0 DT NNP NNP JJR JJ O
higher higher 0 0 0 0 0 0 0 0 6 0 NNP NNP JJR JJ NNS O
concentrations, concentrations, 0 0 0 0 1 0 0 0 15 0 NNP JJR JJ NNS DT O
besides besides 0 0 0 0 0 0 0 0 7 0 JJR JJ NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ NNS DT NN IN O
efflux efflux 0 0 0 0 0 0 0 0 6 0 NNS DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP PRP O
K(+), K(+), 1 1 0 0 1 0 0 0 5 0 NN IN NNP PRP VBD O
it it 0 0 0 0 0 0 0 0 2 0 IN NNP PRP VBD -NONE- O
produced produced 0 0 0 0 0 0 0 0 8 0 NNP PRP VBD -NONE- DT O
(a) (a) 0 0 0 0 0 0 0 0 3 0 PRP VBD -NONE- DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBD -NONE- DT JJ NN O
large large 0 0 0 0 0 0 0 0 5 0 -NONE- DT JJ NN IN O
efflux efflux 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS CC O
phosphates phosphates 0 0 0 0 0 0 0 0 10 0 NN IN NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC NN VBG O
material material 0 0 0 0 0 0 0 0 8 0 NNS CC NN VBG IN O
absorbing absorbing 0 0 0 0 0 0 0 0 9 0 CC NN VBG IN CD O
at at 0 0 0 0 0 0 0 0 2 0 NN VBG IN CD JJ O
260 260 0 0 0 0 0 0 1 1 3 0 VBG IN CD JJ NN O
nm, nm, 0 0 0 0 1 0 0 0 3 0 IN CD JJ NN DT O
(b) (b) 0 0 0 0 0 0 0 0 3 0 CD JJ NN DT VBN O
a a 0 0 0 0 0 0 0 0 1 0 JJ NN DT VBN NN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 NN DT VBN NN IN O
uptake uptake 0 0 0 0 0 0 0 0 6 0 DT VBN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNP NNP O
Ca(2+), Ca(2+), 1 0 0 0 1 0 0 1 7 0 NN IN NNP NNP DT O
(c) (c) 0 0 0 0 0 0 0 0 3 0 IN NNP NNP DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NNP NNP DT NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 NNP DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN CC O
fermentation fermentation 0 0 0 0 0 0 0 0 12 0 NN IN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NNP CC O
respiration, respiration, 0 0 0 0 1 0 0 0 12 0 NN CC NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC NNP DT O
(d) (d) 0 0 0 0 0 0 0 0 3 0 NNP CC NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC NNP DT NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 NNP DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
growth. growth. 0 0 0 0 0 0 0 0 7 0 NN IN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNS VBP O
effects effects 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
depend depend 0 0 0 0 0 0 0 0 6 0 NNP NNS VBP IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NNS VBP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NN VBD O
medium medium 0 0 0 0 0 0 0 0 6 0 IN DT NN VBD CC O
used used 0 0 0 0 0 0 0 0 4 0 DT NN VBD CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN VBD CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD CC DT NN IN O
amount amount 0 0 0 0 0 0 0 0 6 0 CC DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN CC O
cells, cells, 0 0 0 0 1 0 0 0 6 0 NN IN NN CC IN O
but but 0 0 0 0 0 0 0 0 3 0 IN NN CC IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN CC IN NNP JJ O
YPD YPD 1 1 0 0 0 0 0 0 3 0 CC IN NNP JJ NNS O
high high 0 0 0 0 0 0 0 0 4 0 IN NNP JJ NNS JJ O
concentrations concentrations 0 0 0 0 0 0 0 0 14 0 NNP JJ NNS JJ TO O
close close 0 0 0 0 0 0 0 0 5 0 JJ NNS JJ TO CD O
to to 0 0 0 0 0 0 0 0 2 0 NNS JJ TO CD NN O
1 1 0 0 0 0 0 0 1 1 1 0 JJ TO CD NN VBP O
mg·mL(-1) mg·mL(-1) 0 0 1 0 0 0 0 1 9 0 TO CD NN VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 CD NN VBP VBN TO O
required required 0 0 0 0 0 0 0 0 8 0 NN VBP VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBP VBN TO VB DT O
produce produce 0 0 0 0 0 0 0 0 7 0 VBN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
disruption disruption 0 0 0 0 0 0 0 0 10 0 VB DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN DT O
membrane, membrane, 0 0 0 0 1 0 0 0 9 0 DT NN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NN IN O
efflux efflux 0 0 0 0 0 0 0 0 6 0 NN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP CC O
protein, protein, 0 0 0 0 1 0 0 0 8 0 NN IN NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP CC DT NN NNP O
growth growth 0 0 0 0 0 0 0 0 6 0 CC DT NN NNP NNP O
inhibition. inhibition. 0 0 0 0 0 0 0 0 11 0 DT NN NNP NNP DT O
Besides Besides 1 0 0 0 0 0 0 0 7 0 NN NNP NNP DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNS IN O
findings findings 0 0 0 0 0 0 0 0 8 0 NNP DT NNS IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NN O
low low 0 0 0 0 0 0 0 0 3 0 NNS IN JJ NN NN O
chitosan chitosan 0 0 0 0 0 0 0 0 8 0 IN JJ NN NN DT O
concentrations, concentrations, 0 0 0 0 1 0 0 0 15 0 JJ NN NN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN NN DT NN VBZ O
work work 0 0 0 0 0 0 0 0 4 0 NN DT NN VBZ DT O
provides provides 0 0 0 0 0 0 0 0 8 0 DT NN VBZ DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NN VBZ DT NN IN O
insight insight 0 0 0 0 0 0 0 0 7 0 VBZ DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS VBN O
conditions conditions 0 0 0 0 0 0 0 0 10 0 IN DT NNS VBN IN O
required required 0 0 0 0 0 0 0 0 8 0 DT NNS VBN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NNS VBN IN NN TO O
chitosan chitosan 0 0 0 0 0 0 0 0 8 0 VBN IN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB IN O
act act 0 0 0 0 0 0 0 0 3 0 NN TO VB IN DT O
as as 0 0 0 0 0 0 0 0 2 0 TO VB IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VB IN DT JJ CC O
fungistatic fungistatic 0 0 0 0 0 0 0 0 11 0 IN DT JJ CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 DT JJ CC JJ CC O
antifungal antifungal 0 0 0 0 0 0 0 0 10 0 JJ CC JJ CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 CC JJ CC NNS DT O
proposes proposes 0 0 0 0 0 0 0 0 8 0 JJ CC NNS DT NN O
a a 0 0 0 0 0 0 0 0 1 0 CC NNS DT NN IN O
method method 0 0 0 0 0 0 0 0 6 0 NNS DT NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
permeabilization permeabilization 0 0 0 0 0 0 0 0 16 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
yeast yeast 0 0 0 0 0 0 0 0 5 0 NN IN JJ NNP NONE O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NONE NONE O
Regulatory Regulatory 1 0 0 0 0 0 0 0 10 0 NONE NONE JJ NNS IN O
systems systems 0 0 0 0 0 0 0 0 7 0 NONE JJ NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NN O
bone bone 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN IN O
marrow marrow 0 0 0 0 0 0 0 0 6 0 IN NN NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN JJ NN O
hematopoietic hematopoietic 0 0 0 0 0 0 0 0 13 0 NN IN JJ NN NNS O
stem/progenitor stem/progenitor 0 0 0 1 0 0 0 0 15 0 IN JJ NN NNS NN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS NN CC O
mobilization mobilization 0 0 0 0 0 0 0 0 12 0 NN NNS NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNS NN CC NNP NNP O
homing. homing. 0 0 0 0 0 0 0 0 7 0 NN CC NNP NNP NNP O
Alvarez Alvarez 1 0 0 0 0 0 0 0 7 0 CC NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Carrillo Carrillo 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
E, E, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Vélez Vélez 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hita-Contreras Hita-Contreras 1 0 1 0 0 0 0 0 14 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Martínez-Amat Martínez-Amat 1 0 1 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Rodríguez-Serrano Rodríguez-Serrano 1 0 1 0 0 0 0 0 17 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Boulaiz Boulaiz 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ortiz Ortiz 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Melguizo Melguizo 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Prados Prados 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Aránega Aránega 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
A. A. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Biopathology Biopathology 1 0 0 0 0 0 0 0 12 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Regenerative Regenerative 1 0 0 0 0 0 0 0 12 0 NNP CC NNP NNP NNP O
Medicine Medicine 1 0 0 0 0 0 0 0 8 0 CC NNP NNP NNP NNP O
(IBIMER), (IBIMER), 0 1 0 0 1 0 0 0 9 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CD O
Granada, Granada, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP CD -NONE- O
18100 18100 0 0 0 0 0 0 1 1 5 0 IN NNP CD -NONE- NNP O
Granada, Granada, 1 0 0 0 1 0 0 0 8 0 NNP CD -NONE- NNP : O
Spain Spain 1 0 0 0 0 0 0 0 5 0 CD -NONE- NNP : NNP O
; ; 0 0 0 0 0 0 0 0 1 0 -NONE- NNP : NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP : NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 : NNP IN NNP NNP O
Human Human 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP CC O
Anatomy Anatomy 1 0 0 0 0 0 0 0 7 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Embryology, Embryology, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CD O
Granada, Granada, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP CD -NONE- O
18071 18071 0 0 0 0 0 0 1 1 5 0 IN NNP CD -NONE- NNP O
Granada, Granada, 1 0 0 0 1 0 0 0 8 0 NNP CD -NONE- NNP NNP O
Spain. Spain. 1 0 0 0 0 0 0 0 6 0 CD -NONE- NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 -NONE- NNP NNP NNP IN O
Regulation Regulation 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ NN O
hematopoietic hematopoietic 0 0 0 0 0 0 0 0 13 0 NNP IN JJ NN NN O
stem stem 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NN O
release, release, 0 0 0 0 1 0 0 0 8 0 NN NN NN NN CC O
migration, migration, 0 0 0 0 1 0 0 0 10 0 NN NN NN CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBG IN O
homing homing 0 0 0 0 0 0 0 0 6 0 NN CC VBG IN DT O
from from 0 0 0 0 0 0 0 0 4 0 CC VBG IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBG IN DT NN NN O
bone bone 0 0 0 0 0 0 0 0 4 0 IN DT NN NN NN O
marrow marrow 0 0 0 0 0 0 0 0 6 0 DT NN NN NN CC O
(BM) (BM) 0 1 0 0 0 0 0 0 4 0 NN NN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN CC IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC IN DT NN NN O
mobilization mobilization 0 0 0 0 0 0 0 0 12 0 IN DT NN NN VBZ O
pathway pathway 0 0 0 0 0 0 0 0 7 0 DT NN NN VBZ DT O
involves involves 0 0 0 0 0 0 0 0 8 0 NN NN VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT JJ NN O
complex complex 0 0 0 0 0 0 0 0 7 0 VBZ DT JJ NN IN O
interaction interaction 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN NN O
among among 0 0 0 0 0 0 0 0 5 0 JJ NN IN NN -NONE- O
adhesion adhesion 0 0 0 0 0 0 0 0 8 0 NN IN NN -NONE- -NONE- O
molecules, molecules, 0 0 0 0 1 0 0 0 10 0 IN NN -NONE- -NONE- JJ O
cytokines, cytokines, 0 0 0 0 1 0 0 0 10 0 NN -NONE- -NONE- JJ NN O
proteolytic proteolytic 0 0 0 0 0 0 0 0 11 0 -NONE- -NONE- JJ NN JJ O
enzymes, enzymes, 0 0 0 0 1 0 0 0 8 0 -NONE- JJ NN JJ NN O
stromal stromal 0 0 0 0 0 0 0 0 7 0 JJ NN JJ NN CC O
cells, cells, 0 0 0 0 1 0 0 0 6 0 NN JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NNP O
hematopoietic hematopoietic 0 0 0 0 0 0 0 0 13 0 NN CC JJ NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 CC JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
identification identification 0 0 0 0 0 0 0 0 14 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NNS O
new new 0 0 0 0 0 0 0 0 3 0 NN IN JJ NNS WDT O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 IN JJ NNS WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 JJ NNS WDT NN DT O
regulate regulate 0 0 0 0 0 0 0 0 8 0 NNS WDT NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 WDT NN DT NN IN O
trafficking trafficking 0 0 0 0 0 0 0 0 11 0 NN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
hematopoietic hematopoietic 0 0 0 0 0 0 0 0 13 0 NN IN JJ NN NNS O
stem/progenitor stem/progenitor 0 0 0 1 0 0 0 0 15 0 IN JJ NN NNS -NONE- O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS -NONE- NNS O
(HSPCs) (HSPCs) 0 0 0 0 0 0 0 0 7 0 NN NNS -NONE- NNS VBZ O
cells cells 0 0 0 0 0 0 0 0 5 0 NNS -NONE- NNS VBZ JJ O
has has 0 0 0 0 0 0 0 0 3 0 -NONE- NNS VBZ JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 NNS VBZ JJ NN RB O
implications, implications, 0 0 0 0 1 0 0 0 13 0 VBZ JJ NN RB RB O
not not 0 0 0 0 0 0 0 0 3 0 JJ NN RB RB IN O
only only 0 0 0 0 0 0 0 0 4 0 NN RB RB IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 RB RB IN JJ NN O
hematopoietic hematopoietic 0 0 0 0 0 0 0 0 13 0 RB IN JJ NN CC O
transplantation transplantation 0 0 0 0 0 0 0 0 15 0 IN JJ NN CC RB O
but but 0 0 0 0 0 0 0 0 3 0 JJ NN CC RB IN O
also also 0 0 0 0 0 0 0 0 4 0 NN CC RB IN NN O
for for 0 0 0 0 0 0 0 0 3 0 CC RB IN NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 RB IN NN NNS IN O
therapies therapies 0 0 0 0 0 0 0 0 9 0 IN NN NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NN O
regenerative regenerative 0 0 0 0 0 0 0 0 12 0 NNS IN JJ NN IN O
medicine medicine 0 0 0 0 0 0 0 0 8 0 IN JJ NN IN NNS O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 NN IN NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN JJ JJ O
acute acute 0 0 0 0 0 0 0 0 5 0 NNS IN JJ JJ NN O
myocardial myocardial 0 0 0 0 0 0 0 0 10 0 IN JJ JJ NN JJ O
infarction, infarction, 0 0 0 0 1 0 0 0 11 0 JJ JJ NN JJ NN O
spinal spinal 0 0 0 0 0 0 0 0 6 0 JJ NN JJ NN NN O
cord cord 0 0 0 0 0 0 0 0 4 0 NN JJ NN NN CC O
injury, injury, 0 0 0 0 1 0 0 0 7 0 JJ NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP IN O
stroke, stroke, 0 0 0 0 1 0 0 0 7 0 NN CC NNP IN NNP O
among among 0 0 0 0 0 0 0 0 5 0 CC NNP IN NNP NNP O
others. others. 0 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NN VBZ O
paper paper 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ DT O
reviews reviews 0 0 0 0 0 0 0 0 7 0 NNP NN VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT NN NNS O
regulation regulation 0 0 0 0 0 0 0 0 10 0 VBZ DT NN NNS VBG O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 DT NN NNS VBG DT O
underlying underlying 0 0 0 0 0 0 0 0 10 0 NN NNS VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBG DT NN CC O
homing homing 0 0 0 0 0 0 0 0 6 0 VBG DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
mobilization mobilization 0 0 0 0 0 0 0 0 12 0 NN CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP JJ O
BM BM 1 1 0 0 0 0 0 0 2 0 NN IN NNP JJ NN O
hematopoietic hematopoietic 0 0 0 0 0 0 0 0 13 0 IN NNP JJ NN NN O
stem/progenitor stem/progenitor 0 0 0 1 0 0 0 0 15 0 NNP JJ NN NN VBG O
cells, cells, 0 0 0 0 1 0 0 0 6 0 JJ NN NN VBG DT O
investigating investigating 0 0 0 0 0 0 0 0 13 0 NN NN VBG DT VBG O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT VBG NN O
following following 0 0 0 0 0 0 0 0 9 0 VBG DT VBG NN NN O
issues: issues: 0 0 0 0 0 0 0 0 7 0 DT VBG NN NN DT O
(a) (a) 0 0 0 0 0 0 0 0 3 0 VBG NN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NN IN O
role role 0 0 0 0 0 0 0 0 4 0 NN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
different different 0 0 0 0 0 0 0 0 9 0 NN IN JJ NN JJ O
factors, factors, 0 0 0 0 1 0 0 0 8 0 IN JJ NN JJ IN O
such such 0 0 0 0 0 0 0 0 4 0 JJ NN JJ IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 NN JJ IN JJ NN O
stromal stromal 0 0 0 0 0 0 0 0 7 0 JJ IN JJ NN VBD O
cell cell 0 0 0 0 0 0 0 0 4 0 IN JJ NN VBD -NONE- O
derived derived 0 0 0 0 0 0 0 0 7 0 JJ NN VBD -NONE- -NONE- O
factor-1 factor-1 0 0 1 0 0 0 0 1 8 0 NN VBD -NONE- -NONE- VB O
(SDF-1), (SDF-1), 0 1 1 0 1 0 0 1 8 0 VBD -NONE- -NONE- VB JJ O
granulocyte granulocyte 0 0 0 0 0 0 0 0 11 0 -NONE- -NONE- VB JJ NN O
colony-stimulating colony-stimulating 0 0 1 0 0 0 0 0 18 0 -NONE- VB JJ NN NN O
factor factor 0 0 0 0 0 0 0 0 6 0 VB JJ NN NN CC O
(G-CSF), (G-CSF), 0 1 1 0 1 0 0 0 8 0 JJ NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
vascular vascular 0 0 0 0 0 0 0 0 8 0 NN CC JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 CC JJ NN NN -NONE- O
adhesion adhesion 0 0 0 0 0 0 0 0 8 0 JJ NN NN -NONE- -NONE- O
molecule-1 molecule-1 0 0 1 0 0 0 0 1 10 0 NN NN -NONE- -NONE- IN O
(VCAM-1), (VCAM-1), 0 1 1 0 1 0 0 1 9 0 NN -NONE- -NONE- IN JJ O
among among 0 0 0 0 0 0 0 0 5 0 -NONE- -NONE- IN JJ JJ O
other other 0 0 0 0 0 0 0 0 5 0 -NONE- IN JJ JJ NN O
ligands; ligands; 0 0 0 0 0 0 0 0 8 0 IN JJ JJ NN DT O
(b) (b) 0 0 0 0 0 0 0 0 3 0 JJ JJ NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NN NN O
stem stem 0 0 0 0 0 0 0 0 4 0 NN DT NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 DT NN NN NN IN O
count count 0 0 0 0 0 0 0 0 5 0 NN NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
peripheral peripheral 0 0 0 0 0 0 0 0 10 0 NN IN JJ NN CC O
blood blood 0 0 0 0 0 0 0 0 5 0 IN JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP CC O
BM BM 1 1 0 0 0 0 0 0 2 0 NN CC NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC JJ NN O
influential influential 0 0 0 0 0 0 0 0 11 0 NNP CC JJ NN NN O
factors; factors; 0 0 0 0 0 0 0 0 8 0 CC JJ NN NN DT O
(c) (c) 0 0 0 0 0 0 0 0 3 0 JJ NN NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT JJ NN O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 NN DT JJ NN IN O
utilization utilization 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN IN O
phenomenon phenomenon 0 0 0 0 0 0 0 0 10 0 IN DT NN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS IN O
lesions lesions 0 0 0 0 0 0 0 0 7 0 NN IN NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN JJ NN O
different different 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NN VBG O
tissues, tissues, 0 0 0 0 1 0 0 0 8 0 IN JJ NN VBG DT O
examining examining 0 0 0 0 0 0 0 0 9 0 JJ NN VBG DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT NNS VBD O
agents agents 0 0 0 0 0 0 0 0 6 0 VBG DT NNS VBD IN O
involved involved 0 0 0 0 0 0 0 0 8 0 DT NNS VBD IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBD IN NNP NNP O
HSPCs HSPCs 1 0 0 0 0 0 0 0 5 0 VBD IN NNP NNP JJ O
mobilization, mobilization, 0 0 0 0 1 0 0 0 13 0 IN NNP NNP JJ IN O
such such 0 0 0 0 0 0 0 0 4 0 NNP NNP JJ IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NNP JJ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT JJ NNS O
different different 0 0 0 0 0 0 0 0 9 0 IN DT JJ NNS IN O
forms forms 0 0 0 0 0 0 0 0 5 0 DT JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
G-CSF, G-CSF, 1 1 1 0 1 0 0 0 6 0 NNS IN JJ NN CC O
plerixafor, plerixafor, 0 0 0 0 1 0 0 0 11 0 IN JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP CC O
natalizumab; natalizumab; 0 0 0 0 0 0 0 0 12 0 NN CC NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC NNP DT O
(d) (d) 0 0 0 0 0 0 0 0 3 0 NNP CC NNP DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 CC NNP DT NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 NNP DT NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNS IN DT NN IN O
mobilization mobilization 0 0 0 0 0 0 0 0 12 0 IN DT NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
BM-derived BM-derived 1 0 1 0 0 0 0 0 10 0 NN IN JJ NN NNS O
stem/progenitor stem/progenitor 0 0 0 1 0 0 0 0 15 0 IN JJ NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NNS O
clinical clinical 0 0 0 0 0 0 0 0 8 0 NNS IN JJ NNS IN O
trials trials 0 0 0 0 0 0 0 0 6 0 IN JJ NNS IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 NNS IN NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN JJ NNP O
different different 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NNP NONE O
diseases. diseases. 0 0 0 0 0 0 0 0 9 0 IN JJ NNP NONE NONE O
Multiple Multiple 1 0 0 0 0 0 0 0 8 0 NONE NONE NNP VBZ IN O
regimes regimes 0 0 0 0 0 0 0 0 7 0 NONE NNP VBZ IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN NN IN O
operation operation 0 0 0 0 0 0 0 0 9 0 VBZ IN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NN O
bimodal bimodal 0 0 0 0 0 0 0 0 7 0 NN IN NN NN NN O
AFM: AFM: 1 1 0 0 0 0 0 0 4 0 IN NN NN NN DT O
understanding understanding 0 0 0 0 0 0 0 0 13 0 NN NN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NN IN O
energy energy 0 0 0 0 0 0 0 0 6 0 NN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNP O
cantilever cantilever 0 0 0 0 0 0 0 0 10 0 NN IN NN NNP NNP O
eigenmodes. eigenmodes. 0 0 0 0 0 0 0 0 11 0 IN NN NNP NNP NNP O
Kiracofe Kiracofe 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Raman Raman 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yablon Yablon 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
D. D. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Purdue Purdue 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Mechanical Mechanical 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Engineering, Engineering, 1 0 0 0 1 0 0 0 12 0 IN NNP NNP NNP NNP O
West West 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Lafayette, Lafayette, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
IN, IN, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP : O
USA USA 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP : NNP O
; ; 0 0 0 0 0 0 0 0 1 0 NNP NNP : NNP NNP O
ExxonMobil ExxonMobil 1 0 0 0 0 0 0 0 10 0 NNP : NNP NNP CC O
Research Research 1 0 0 0 0 0 0 0 8 0 : NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Engineering Engineering 1 0 0 0 0 0 0 0 11 0 NNP CC NNP NNP NNP O
Co., Co., 1 0 0 0 1 0 0 0 4 0 CC NNP NNP NNP NNP O
Annandale, Annandale, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
NJ, NJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP NNP CD O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP CD IN O
One One 1 0 0 0 0 0 0 0 3 0 NNP NNP CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP CD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT JJ NNS O
key key 0 0 0 0 0 0 0 0 3 0 IN DT JJ NNS IN O
goals goals 0 0 0 0 0 0 0 0 5 0 DT JJ NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
atomic atomic 0 0 0 0 0 0 0 0 6 0 NNS IN JJ NN NN O
force force 0 0 0 0 0 0 0 0 5 0 IN JJ NN NN NN O
microscopy microscopy 0 0 0 0 0 0 0 0 10 0 JJ NN NN NN VBG O
(AFM) (AFM) 0 1 0 0 0 0 0 0 5 0 NN NN NN VBG VBZ O
imaging imaging 0 0 0 0 0 0 0 0 7 0 NN NN VBG VBZ TO O
is is 0 0 0 0 0 0 0 0 2 0 NN VBG VBZ TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VBG VBZ TO NN NN O
enhance enhance 0 0 0 0 0 0 0 0 7 0 VBZ TO NN NN NN O
material material 0 0 0 0 0 0 0 0 8 0 TO NN NN NN NN O
property property 0 0 0 0 0 0 0 0 8 0 NN NN NN NN IN O
contrast contrast 0 0 0 0 0 0 0 0 8 0 NN NN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ NNP O
high high 0 0 0 0 0 0 0 0 4 0 NN IN JJ NNP NNP O
resolution. resolution. 0 0 0 0 0 0 0 0 11 0 IN JJ NNP NNP NNP O
Bimodal Bimodal 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP NNP WRB O
AFM, AFM, 1 1 0 0 1 0 0 0 4 0 NNP NNP NNP WRB CD O
where where 0 0 0 0 0 0 0 0 5 0 NNP NNP WRB CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 NNP WRB CD NNS VBP O
eigenmodes eigenmodes 0 0 0 0 0 0 0 0 10 0 WRB CD NNS VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 CD NNS VBP RB JJ O
simultaneously simultaneously 0 0 0 0 0 0 0 0 14 0 NNS VBP RB JJ NNS O
excited, excited, 0 0 0 0 1 0 0 0 8 0 VBP RB JJ NNS JJ O
confers confers 0 0 0 0 0 0 0 0 7 0 RB JJ NNS JJ NNS O
significant significant 0 0 0 0 0 0 0 0 11 0 JJ NNS JJ NNS IN O
advantages advantages 0 0 0 0 0 0 0 0 10 0 NNS JJ NNS IN JJ O
over over 0 0 0 0 0 0 0 0 4 0 JJ NNS IN JJ NN O
conventional conventional 0 0 0 0 0 0 0 0 12 0 NNS IN JJ NN VBG O
single-frequency single-frequency 0 0 1 0 0 0 0 0 16 0 IN JJ NN VBG NN O
tapping tapping 0 0 0 0 0 0 0 0 7 0 JJ NN VBG NN NNP O
mode mode 0 0 0 0 0 0 0 0 4 0 NN VBG NN NNP JJ O
AFM AFM 1 1 0 0 0 0 0 0 3 0 VBG NN NNP JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 NN NNP JJ TO PRP$ O
to to 0 0 0 0 0 0 0 0 2 0 NNP JJ TO PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 JJ TO PRP$ NN TO O
ability ability 0 0 0 0 0 0 0 0 7 0 TO PRP$ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 PRP$ NN TO VB JJ O
provide provide 0 0 0 0 0 0 0 0 7 0 NN TO VB JJ IN O
contrast contrast 0 0 0 0 0 0 0 0 8 0 TO VB JJ IN NNS O
between between 0 0 0 0 0 0 0 0 7 0 VB JJ IN NNS IN O
regions regions 0 0 0 0 0 0 0 0 7 0 JJ IN NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN JJ NN O
different different 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NN NNS O
material material 0 0 0 0 0 0 0 0 8 0 IN JJ NN NNS IN O
properties properties 0 0 0 0 0 0 0 0 10 0 JJ NN NNS IN JJ O
under under 0 0 0 0 0 0 0 0 5 0 NN NNS IN JJ NN O
gentle gentle 0 0 0 0 0 0 0 0 6 0 NNS IN JJ NN NNP O
imaging imaging 0 0 0 0 0 0 0 0 7 0 IN JJ NN NNP NNP O
conditions. conditions. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP NNP NNP O
Bimodal Bimodal 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NNP RB O
AFM AFM 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP RB VBZ O
traditionally traditionally 0 0 0 0 0 0 0 0 13 0 NNP NNP RB VBZ DT O
uses uses 0 0 0 0 0 0 0 0 4 0 NNP RB VBZ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 RB VBZ DT JJ CD O
first first 0 0 0 0 0 0 0 0 5 0 VBZ DT JJ CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 DT JJ CD NNS IN O
eigenmodes eigenmodes 0 0 0 0 0 0 0 0 10 0 JJ CD NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NNP O
AFM AFM 1 1 0 0 0 0 0 0 3 0 IN DT NNP NNP NNP O
cantilever. cantilever. 0 0 0 0 0 0 0 0 11 0 DT NNP NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN DT O
work, work, 0 0 0 0 1 0 0 0 5 0 NNP DT NN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 DT NN DT NNS VBP O
authors authors 0 0 0 0 0 0 0 0 7 0 NN DT NNS VBP DT O
explore explore 0 0 0 0 0 0 0 0 7 0 DT NNS VBP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBP DT NN IN O
use use 0 0 0 0 0 0 0 0 3 0 VBP DT NN IN JJR O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJR NNS O
higher higher 0 0 0 0 0 0 0 0 6 0 NN IN JJR NNS IN O
eigenmodes eigenmodes 0 0 0 0 0 0 0 0 10 0 IN JJR NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJR NNS IN JJ NNP O
bimodal bimodal 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NNP NNP O
AFM AFM 1 1 0 0 0 0 0 0 3 0 IN JJ NNP NNP NN O
(e.g., (e.g., 0 0 0 0 1 0 0 0 6 0 JJ NNP NNP NN DT O
exciting exciting 0 0 0 0 0 0 0 0 8 0 NNP NNP NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT JJ CC O
first first 0 0 0 0 0 0 0 0 5 0 NN DT JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC JJ NNP O
fourth fourth 0 0 0 0 0 0 0 0 6 0 JJ CC JJ NNP NNP O
eigenmodes). eigenmodes). 0 0 0 0 0 0 0 0 12 0 CC JJ NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 NNP VBZ VBN IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN JJ NN O
such such 0 0 0 0 0 0 0 0 4 0 VBN IN JJ NN NNS O
operation operation 0 0 0 0 0 0 0 0 9 0 IN JJ NN NNS TO O
leads leads 0 0 0 0 0 0 0 0 5 0 JJ NN NNS TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO JJ NN O
interesting interesting 0 0 0 0 0 0 0 0 11 0 NNS TO JJ NN NNS O
contrast contrast 0 0 0 0 0 0 0 0 8 0 TO JJ NN NNS VBN O
reversals reversals 0 0 0 0 0 0 0 0 9 0 JJ NN NNS VBN TO O
compared compared 0 0 0 0 0 0 0 0 8 0 NN NNS VBN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBN TO JJ NN O
traditional traditional 0 0 0 0 0 0 0 0 11 0 VBN TO JJ NN NNP O
bimodal bimodal 0 0 0 0 0 0 0 0 7 0 TO JJ NN NNP DT O
AFM. AFM. 1 1 0 0 0 0 0 0 4 0 JJ NN NNP DT NN O
A A 1 1 0 0 0 0 0 0 1 0 NN NNP DT NN IN O
series series 0 0 0 0 0 0 0 0 6 0 NNP DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS CC O
experiments experiments 0 0 0 0 0 0 0 0 11 0 NN IN NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC JJ NNS O
numerical numerical 0 0 0 0 0 0 0 0 9 0 NNS CC JJ NNS VBZ O
simulations simulations 0 0 0 0 0 0 0 0 11 0 CC JJ NNS VBZ IN O
shows shows 0 0 0 0 0 0 0 0 5 0 JJ NNS VBZ IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBZ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBZ IN DT JJ NN O
primary primary 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN IN O
cause cause 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNS O
contrast contrast 0 0 0 0 0 0 0 0 8 0 IN DT NN NNS VBZ O
reversals reversals 0 0 0 0 0 0 0 0 9 0 DT NN NNS VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NN NNS VBZ RB DT O
not not 0 0 0 0 0 0 0 0 3 0 NNS VBZ RB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBZ RB DT NN IN O
choice choice 0 0 0 0 0 0 0 0 6 0 RB DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN PRP O
eigenmode eigenmode 0 0 0 0 0 0 0 0 9 0 NN IN NN PRP -NONE- O
itself itself 0 0 0 0 0 0 0 0 6 0 IN NN PRP -NONE- JJ O
(e.g., (e.g., 0 0 0 0 1 0 0 0 6 0 NN PRP -NONE- JJ NN O
second second 0 0 0 0 0 0 0 0 6 0 PRP -NONE- JJ NN NN O
versus versus 0 0 0 0 0 0 0 0 6 0 -NONE- JJ NN NN CC O
fourth), fourth), 0 0 0 0 1 0 0 0 8 0 JJ NN NN CC RB O
but but 0 0 0 0 0 0 0 0 3 0 NN NN CC RB DT O
rather rather 0 0 0 0 0 0 0 0 6 0 NN CC RB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CC RB DT JJ JJ O
relative relative 0 0 0 0 0 0 0 0 8 0 RB DT JJ JJ NN O
kinetic kinetic 0 0 0 0 0 0 0 0 7 0 DT JJ JJ NN IN O
energy energy 0 0 0 0 0 0 0 0 6 0 JJ JJ NN IN DT O
between between 0 0 0 0 0 0 0 0 7 0 JJ NN IN DT JJR O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJR NN O
higher higher 0 0 0 0 0 0 0 0 6 0 IN DT JJR NN CC O
eigenmode eigenmode 0 0 0 0 0 0 0 0 9 0 DT JJR NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJR NN CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT JJ NNP O
first first 0 0 0 0 0 0 0 0 5 0 CC DT JJ NNP NNP O
eigenmode. eigenmode. 0 0 0 0 0 0 0 0 10 0 DT JJ NNP NNP VBZ O
This This 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP VBZ TO O
leads leads 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBZ TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBZ TO DT NN IN O
identification identification 0 0 0 0 0 0 0 0 14 0 TO DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD JJ O
three three 0 0 0 0 0 0 0 0 5 0 NN IN CD JJ NN O
distinct distinct 0 0 0 0 0 0 0 0 8 0 IN CD JJ NN VBZ O
imaging imaging 0 0 0 0 0 0 0 0 7 0 CD JJ NN VBZ IN O
regimes regimes 0 0 0 0 0 0 0 0 7 0 JJ NN VBZ IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN VBZ IN JJ NNP O
bimodal bimodal 0 0 0 0 0 0 0 0 7 0 VBZ IN JJ NNP NNP O
AFM. AFM. 1 1 0 0 0 0 0 0 4 0 IN JJ NNP NNP NNP O
This This 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NNP WDT O
result, result, 0 0 0 0 1 0 0 0 7 0 NNP NNP NNP WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NNP NNP WDT VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP WDT VBZ JJ RB O
applicable applicable 0 0 0 0 0 0 0 0 10 0 WDT VBZ JJ RB TO O
even even 0 0 0 0 0 0 0 0 4 0 VBZ JJ RB TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 JJ RB TO JJ NN O
traditional traditional 0 0 0 0 0 0 0 0 11 0 RB TO JJ NN NN O
bimodal bimodal 0 0 0 0 0 0 0 0 7 0 TO JJ NN NN MD O
AFM, AFM, 1 1 0 0 1 0 0 0 4 0 JJ NN NN MD VB O
should should 0 0 0 0 0 0 0 0 6 0 NN NN MD VB NNS O
allow allow 0 0 0 0 0 0 0 0 5 0 NN MD VB NNS TO O
researchers researchers 0 0 0 0 0 0 0 0 11 0 MD VB NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VB NNS TO VB NN O
choose choose 0 0 0 0 0 0 0 0 6 0 NNS TO VB NN CC O
cantilever cantilever 0 0 0 0 0 0 0 0 10 0 TO VB NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VB NN CC NN NNS O
operating operating 0 0 0 0 0 0 0 0 9 0 NN CC NN NNS IN O
parameters parameters 0 0 0 0 0 0 0 0 10 0 CC NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT RBR O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT RBR JJ O
more more 0 0 0 0 0 0 0 0 4 0 IN DT RBR JJ NN O
rational rational 0 0 0 0 0 0 0 0 8 0 DT RBR JJ NN IN O
manner manner 0 0 0 0 0 0 0 0 6 0 RBR JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN TO O
order order 0 0 0 0 0 0 0 0 5 0 NN IN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB NN O
optimize optimize 0 0 0 0 0 0 0 0 8 0 NN TO VB NN CC O
resolution resolution 0 0 0 0 0 0 0 0 10 0 TO VB NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VB NN CC NN IN O
contrast contrast 0 0 0 0 0 0 0 0 8 0 NN CC NN IN NN O
during during 0 0 0 0 0 0 0 0 6 0 CC NN IN NN VBG O
nanoscale nanoscale 0 0 0 0 0 0 0 0 9 0 NN IN NN VBG IN O
imaging imaging 0 0 0 0 0 0 0 0 7 0 IN NN VBG IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN VBG IN NNP NONE O
materials. materials. 0 0 0 0 0 0 0 0 10 0 VBG IN NNP NONE NONE O
Ferromagnetic Ferromagnetic 1 0 0 0 0 0 0 0 13 0 NONE NONE JJ PRP$ IN O
behaviour behaviour 0 0 0 0 0 0 0 0 9 0 NONE JJ PRP$ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ PRP$ IN JJ NNP O
Fe-doped Fe-doped 1 0 1 0 0 0 0 0 8 0 PRP$ IN JJ NNP VBD O
ZnO ZnO 1 0 0 0 0 0 0 0 3 0 IN JJ NNP VBD NNP O
nanograined nanograined 0 0 0 0 0 0 0 0 11 0 JJ NNP VBD NNP NNP O
films. films. 0 0 0 0 0 0 0 0 6 0 NNP VBD NNP NNP NNP O
Straumal Straumal 1 0 0 0 0 0 0 0 8 0 VBD NNP NNP NNP NNP O
BB, BB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Protasova Protasova 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
SG, SG, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Mazilkin Mazilkin 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
AA, AA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Tietze Tietze 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Goering Goering 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
E, E, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Schütz Schütz 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Straumal Straumal 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
PB, PB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Baretzky Baretzky 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
B. B. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Karlsruher Karlsruher 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Institut Institut 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
für für 0 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Technologie, Technologie, 1 0 0 0 1 0 0 0 12 0 NNP NNP NNP NNP NNP O
Institut Institut 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
für für 0 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Nanotechnologie, Nanotechnologie, 1 0 0 0 1 0 0 0 16 0 NNP NNP NNP NNP CD O
Hermann-von-Helmholtz-Platz Hermann-von-Helmholtz-Platz 1 0 1 0 0 0 0 0 27 0 NNP NNP NNP CD CD O
1, 1, 0 0 0 0 1 0 0 1 2 0 NNP NNP CD CD JJ O
76344 76344 0 0 0 0 0 0 1 1 5 0 NNP CD CD JJ NNP O
Eggenstein-Leopoldshafen, Eggenstein-Leopoldshafen, 1 0 1 0 1 0 0 0 25 0 CD CD JJ NNP : O
Germany Germany 1 0 0 0 0 0 0 0 7 0 CD JJ NNP : NNP O
; ; 0 0 0 0 0 0 0 0 1 0 JJ NNP : NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP : NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 : NNP IN NNP NNP O
Solid Solid 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
State State 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
Physics, Physics, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Russian Russian 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP IN O
Academy Academy 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Ac. Ac. 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
Ossipyan Ossipyan 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP CD O
str. str. 0 0 0 0 0 0 0 0 4 0 NNP NNP NNP CD CD O
2, 2, 0 0 0 0 1 0 0 1 2 0 NNP NNP CD CD JJ O
142432 142432 0 0 0 0 0 0 1 1 6 0 NNP CD CD JJ NNP O
Chernogolovka, Chernogolovka, 1 0 0 0 1 0 0 0 14 0 CD CD JJ NNP : O
Russia Russia 1 0 0 0 0 0 0 0 6 0 CD JJ NNP : JJ O
; ; 0 0 0 0 0 0 0 0 1 0 JJ NNP : JJ NN O
Max-Planck-Institut Max-Planck-Institut 1 0 1 0 0 0 0 0 19 0 NNP : JJ NN NNP O
für für 0 0 0 0 0 0 0 0 3 0 : JJ NN NNP NNP O
Intelligente Intelligente 1 0 0 0 0 0 0 0 12 0 JJ NN NNP NNP NNP O
Systeme, Systeme, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP NNP CD O
Heisenbergstrasse Heisenbergstrasse 1 0 0 0 0 0 0 0 17 0 NNP NNP NNP CD CD O
3, 3, 0 0 0 0 1 0 0 1 2 0 NNP NNP CD CD JJ O
70569 70569 0 0 0 0 0 0 1 1 5 0 NNP CD CD JJ NNP O
Stuttgart, Stuttgart, 1 0 0 0 1 0 0 0 10 0 CD CD JJ NNP : O
Germany Germany 1 0 0 0 0 0 0 0 7 0 CD JJ NNP : NNP O
; ; 0 0 0 0 0 0 0 0 1 0 JJ NNP : NNP NNP O
National National 1 0 0 0 0 0 0 0 8 0 NNP : NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 : NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP CC O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Technology Technology 1 0 0 0 0 0 0 0 10 0 NNP CC NNP NNP NNP O
"MISiS", "MISiS", 0 0 0 0 1 0 0 0 8 0 CC NNP NNP NNP NN O
Leninsky Leninsky 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NN CD O
prospect prospect 0 0 0 0 0 0 0 0 8 0 NNP NNP NN CD CD O
4, 4, 0 0 0 0 1 0 0 1 2 0 NNP NN CD CD JJ O
119991 119991 0 0 0 0 0 0 1 1 6 0 NN CD CD JJ NNP O
Moscow, Moscow, 1 0 0 0 1 0 0 0 7 0 CD CD JJ NNP NNP O
Russia. Russia. 1 0 0 0 0 0 0 0 7 0 CD JJ NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
influence influence 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
grain grain 0 0 0 0 0 0 0 0 5 0 IN DT NN NN NN O
boundary boundary 0 0 0 0 0 0 0 0 8 0 DT NN NN NN NN O
(GB) (GB) 0 1 0 0 0 0 0 0 4 0 NN NN NN NN NN O
specific specific 0 0 0 0 0 0 0 0 8 0 NN NN NN NN NNS O
area area 0 0 0 0 0 0 0 0 4 0 NN NN NN NNS NNP O
s s 0 0 0 0 0 0 0 0 1 0 NN NN NNS NNP IN O
GB GB 1 1 0 0 0 0 0 0 2 0 NN NNS NNP IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NNS NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN IN O
appearance appearance 0 0 0 0 0 0 0 0 10 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
ferromagnetism ferromagnetism 0 0 0 0 0 0 0 0 14 0 NN IN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NNP O
Fe-doped Fe-doped 1 0 1 0 0 0 0 0 8 0 NN IN JJ NNP VBZ O
ZnO ZnO 1 0 0 0 0 0 0 0 3 0 IN JJ NNP VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 JJ NNP VBZ VBN NNP O
been been 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBN NNP NNP O
analysed. analysed. 0 0 0 0 0 0 0 0 9 0 VBZ VBN NNP NNP NN O
A A 1 1 0 0 0 0 0 0 1 0 VBN NNP NNP NN IN O
review review 0 0 0 0 0 0 0 0 6 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
numerous numerous 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN NNS O
research research 0 0 0 0 0 0 0 0 8 0 IN JJ NN NNS IN O
contributions contributions 0 0 0 0 0 0 0 0 13 0 JJ NN NNS IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
literature literature 0 0 0 0 0 0 0 0 10 0 IN DT NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
origin origin 0 0 0 0 0 0 0 0 6 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
ferromagnetic ferromagnetic 0 0 0 0 0 0 0 0 13 0 IN DT JJ NN IN O
behaviour behaviour 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNP O
Fe-doped Fe-doped 1 0 1 0 0 0 0 0 8 0 NN IN JJ NNP VBZ O
ZnO ZnO 1 0 0 0 0 0 0 0 3 0 IN JJ NNP VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 JJ NNP VBZ NNP NNP O
given. given. 0 0 0 0 0 0 0 0 6 0 NNP VBZ NNP NNP JJ O
An An 1 0 0 0 0 0 0 0 2 0 VBZ NNP NNP JJ NN O
empirical empirical 0 0 0 0 0 0 0 0 9 0 NNP NNP JJ NN VBZ O
correlation correlation 0 0 0 0 0 0 0 0 11 0 NNP JJ NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 JJ NN VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 VBZ VBN VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 VBN VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
value value 0 0 0 0 0 0 0 0 5 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
specific specific 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN NN O
grain grain 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN NN O
boundary boundary 0 0 0 0 0 0 0 0 8 0 JJ NN NN NN NNS O
area area 0 0 0 0 0 0 0 0 4 0 NN NN NN NNS NNP O
s s 0 0 0 0 0 0 0 0 1 0 NN NN NNS NNP VBZ O
GB GB 1 1 0 0 0 0 0 0 2 0 NN NNS NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNS NNP VBZ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT JJ NN O
main main 0 0 0 0 0 0 0 0 4 0 VBZ DT JJ NN VBG O
factor factor 0 0 0 0 0 0 0 0 6 0 DT JJ NN VBG JJ O
controlling controlling 0 0 0 0 0 0 0 0 11 0 JJ NN VBG JJ NNP O
such such 0 0 0 0 0 0 0 0 4 0 NN VBG JJ NNP NNP O
behaviour. behaviour. 0 0 0 0 0 0 0 0 10 0 VBG JJ NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NNP NNP O
Fe-doped Fe-doped 1 0 1 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
ZnO ZnO 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP VBZ JJ O
becomes becomes 0 0 0 0 0 0 0 0 7 0 NNP NNP VBZ JJ RB O
ferromagnetic ferromagnetic 0 0 0 0 0 0 0 0 13 0 NNP VBZ JJ RB IN O
only only 0 0 0 0 0 0 0 0 4 0 VBZ JJ RB IN PRP O
if if 0 0 0 0 0 0 0 0 2 0 JJ RB IN PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 RB IN PRP VBZ RB O
contains contains 0 0 0 0 0 0 0 0 8 0 IN PRP VBZ RB JJ O
enough enough 0 0 0 0 0 0 0 0 6 0 PRP VBZ RB JJ NN O
GBs, GBs, 1 0 0 0 1 0 0 0 4 0 VBZ RB JJ NN IN O
i.e., i.e., 0 0 0 0 1 0 0 0 5 0 RB JJ NN IN NNS O
if if 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS NNP O
s s 0 0 0 0 0 0 0 0 1 0 NN IN NNS NNP VBZ O
GB GB 1 1 0 0 0 0 0 0 2 0 IN NNS NNP VBZ JJR O
is is 0 0 0 0 0 0 0 0 2 0 NNS NNP VBZ JJR IN O
higher higher 0 0 0 0 0 0 0 0 6 0 NNP VBZ JJR IN DT O
than than 0 0 0 0 0 0 0 0 4 0 VBZ JJR IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 JJR IN DT JJ NN O
certain certain 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN NN O
threshold threshold 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN NNS O
value value 0 0 0 0 0 0 0 0 5 0 JJ NN NN NNS IN O
s s 0 0 0 0 0 0 0 0 1 0 NN NN NNS IN CD O
th th 0 0 0 0 0 0 0 0 2 0 NN NNS IN CD CD O
= = 0 0 0 0 0 0 0 0 1 0 NNS IN CD CD CD O
5 5 0 0 0 0 0 0 1 1 1 0 IN CD CD CD CD O
× × 0 0 0 0 0 0 0 0 1 0 CD CD CD CD NNP O
10(4) 10(4) 0 0 0 0 0 0 0 1 5 0 CD CD CD NNP NNP O
m(2)/m(3). m(2)/m(3). 0 0 0 1 0 0 0 1 10 0 CD CD NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 CD NNP NNP VBZ TO O
corresponds corresponds 0 0 0 0 0 0 0 0 11 0 NNP NNP VBZ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBZ TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBZ TO DT JJ NN O
effective effective 0 0 0 0 0 0 0 0 9 0 TO DT JJ NN NN O
grain grain 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN IN O
size size 0 0 0 0 0 0 0 0 4 0 JJ NN NN IN RB O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN RB CD O
about about 0 0 0 0 0 0 0 0 5 0 NN IN RB CD JJ O
40 40 0 0 0 0 0 0 1 1 2 0 IN RB CD JJ NN O
μm μm 0 0 0 0 0 0 0 0 2 0 RB CD JJ NN DT O
assuming assuming 0 0 0 0 0 0 0 0 8 0 CD JJ NN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 JJ NN DT NN NN O
full, full, 0 0 0 0 1 0 0 0 5 0 NN DT NN NN NN O
dense dense 0 0 0 0 0 0 0 0 5 0 DT NN NN NN CC O
material material 0 0 0 0 0 0 0 0 8 0 NN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NNP O
equiaxial equiaxial 0 0 0 0 0 0 0 0 9 0 NN CC JJ NNP NNP O
grains. grains. 0 0 0 0 0 0 0 0 7 0 CC JJ NNP NNP VBZ O
Magnetic Magnetic 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP VBZ IN O
properties properties 0 0 0 0 0 0 0 0 10 0 NNP NNP VBZ IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN NNP NN O
ZnO ZnO 1 0 0 0 0 0 0 0 3 0 VBZ IN NNP NN VBD O
dense dense 0 0 0 0 0 0 0 0 5 0 IN NNP NN VBD JJ O
nanograined nanograined 0 0 0 0 0 0 0 0 11 0 NNP NN VBD JJ NNS O
thin thin 0 0 0 0 0 0 0 0 4 0 NN VBD JJ NNS VBD O
films films 0 0 0 0 0 0 0 0 5 0 VBD JJ NNS VBD IN O
doped doped 0 0 0 0 0 0 0 0 5 0 JJ NNS VBD IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NN -NONE- O
iron iron 0 0 0 0 0 0 0 0 4 0 VBD IN NN -NONE- TO O
(0 (0 0 0 0 0 0 0 0 1 2 0 IN NN -NONE- TO CD O
to to 0 0 0 0 0 0 0 0 2 0 NN -NONE- TO CD NN O
40 40 0 0 0 0 0 0 1 1 2 0 -NONE- TO CD NN : O
atom atom 0 0 0 0 0 0 0 0 4 0 TO CD NN : VBP O
%) %) 0 0 0 0 0 0 0 0 2 0 CD NN : VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NN : VBP VBN NNP O
been been 0 0 0 0 0 0 0 0 4 0 : VBP VBN NNP NNP O
investigated. investigated. 0 0 0 0 0 0 0 0 13 0 VBP VBN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 VBN NNP NNP NNS VBD O
films films 0 0 0 0 0 0 0 0 5 0 NNP NNP NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD VBN IN O
deposited deposited 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN DT O
using using 0 0 0 0 0 0 0 0 5 0 VBN IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN NN O
wet wet 0 0 0 0 0 0 0 0 3 0 NN DT NN NN JJ O
chemistry chemistry 0 0 0 0 0 0 0 0 9 0 DT NN NN JJ NN O
"liquid "liquid 0 0 0 0 0 0 0 0 7 0 NN NN JJ NN NNP O
ceramics" ceramics" 0 0 0 0 0 0 0 0 9 0 NN JJ NN NNP NNP O
method. method. 0 0 0 0 0 0 0 0 7 0 JJ NN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS VBP O
samples samples 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP JJ O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 NNP NNS VBP JJ NN O
ferromagnetic ferromagnetic 0 0 0 0 0 0 0 0 13 0 NNS VBP JJ NN IN O
behaviour behaviour 0 0 0 0 0 0 0 0 9 0 VBP JJ NN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN NNP NNS O
J J 1 1 0 0 0 0 0 0 1 0 NN IN NNP NNS IN O
s s 0 0 0 0 0 0 0 0 1 0 IN NNP NNS IN TO O
up up 0 0 0 0 0 0 0 0 2 0 NNP NNS IN TO CD O
to to 0 0 0 0 0 0 0 0 2 0 NNS IN TO CD JJ O
0.10 0.10 0 0 0 0 0 0 0 1 4 0 IN TO CD JJ NN O
emu/g emu/g 0 0 0 1 0 0 0 0 5 0 TO CD JJ NN NN O
(0.025 (0.025 0 0 0 0 0 0 0 1 6 0 CD JJ NN NN CC O
μB/f.u.ZnO) μB/f.u.ZnO) 0 0 0 1 0 0 0 0 11 0 JJ NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NNP O
coercivity coercivity 0 0 0 0 0 0 0 0 10 0 NN CC NN NNP NN O
H H 1 1 0 0 0 0 0 0 1 0 CC NN NNP NN : O
c c 0 0 0 0 0 0 0 0 1 0 NN NNP NN : CD O
≈ ≈ 0 0 0 0 0 0 0 0 1 0 NNP NN : CD NNP O
0.03 0.03 0 0 0 0 0 0 0 1 4 0 NN : CD NNP NNP O
T. T. 1 1 0 0 0 0 0 0 2 0 : CD NNP NNP NN O
Saturation Saturation 1 0 0 0 0 0 0 0 10 0 CD NNP NNP NN VBZ O
magnetisation magnetisation 0 0 0 0 0 0 0 0 13 0 NNP NNP NN VBZ RB O
depends depends 0 0 0 0 0 0 0 0 7 0 NNP NN VBZ RB IN O
nonmonotonically nonmonotonically 0 0 0 0 0 0 0 0 16 0 NN VBZ RB IN DT O
on on 0 0 0 0 0 0 0 0 2 0 VBZ RB IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NNP NNP O
Fe Fe 1 0 0 0 0 0 0 0 2 0 IN DT NNP NNP NNP O
concentration. concentration. 0 0 0 0 0 0 0 0 14 0 DT NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
dependence dependence 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NN O
Fe Fe 1 0 0 0 0 0 0 0 2 0 NN IN NNP NN MD O
content content 0 0 0 0 0 0 0 0 7 0 IN NNP NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NNP NN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB VBN IN O
explained explained 0 0 0 0 0 0 0 0 9 0 MD VB VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VB VBN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNS IN O
changes changes 0 0 0 0 0 0 0 0 7 0 IN DT NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN CC O
structure structure 0 0 0 0 0 0 0 0 9 0 IN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
contiguity contiguity 0 0 0 0 0 0 0 0 10 0 NN CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
ferromagnetic ferromagnetic 0 0 0 0 0 0 0 0 13 0 IN DT JJ NN NN O
"grain "grain 0 0 0 0 0 0 0 0 6 0 DT JJ NN NN NN O
boundary boundary 0 0 0 0 0 0 0 0 8 0 JJ NN NN NN JJ O
foam" foam" 0 0 0 0 0 0 0 0 5 0 NN NN NN JJ IN O
responsible responsible 0 0 0 0 0 0 0 0 11 0 NN NN JJ IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN JJ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT JJ NNS O
magnetic magnetic 0 0 0 0 0 0 0 0 8 0 IN DT JJ NNS IN O
properties properties 0 0 0 0 0 0 0 0 10 0 DT JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN CC O
pure pure 0 0 0 0 0 0 0 0 4 0 NNS IN NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VBD NNP O
doped doped 0 0 0 0 0 0 0 0 5 0 NN CC VBD NNP NONE O
ZnO. ZnO. 1 0 0 0 0 0 0 0 4 0 CC VBD NNP NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT JJ NNS O
many many 0 0 0 0 0 0 0 0 4 phases NONE DT JJ NNS IN O
phases phases 0 0 0 0 0 0 0 0 6 0 DT JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP IN O
anaphase. anaphase. 0 0 0 0 0 0 0 0 9 0 NNS IN NNP IN NNP B_TIMEXCCP
de de 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NNP O
Gramont Gramont 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 IN NNP NNP NNP NNP O
Cohen-Fix Cohen-Fix 1 0 1 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
O. O. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP IN O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Cellular Cellular 1 0 0 0 0 0 0 0 8 0 NNP CC NNP NNP DT O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 CC NNP NNP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNP NNP O
National National 1 0 0 0 0 0 0 0 8 0 NNP DT NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 DT NNP NNP IN NNPS O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNPS CC O
Diabetes Diabetes 1 0 0 0 0 0 0 0 8 0 NNP IN NNPS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNPS CC NNP CC O
Digestive Digestive 1 0 0 0 0 0 0 0 9 0 NNPS CC NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC NNP NNP O
Kidney Kidney 1 0 0 0 0 0 0 0 6 0 NNP CC NNP NNP NNP O
Diseases Diseases 1 0 0 0 0 0 0 0 8 0 CC NNP NNP NNP DT O
(NIDDK), (NIDDK), 0 1 0 0 1 0 0 0 8 0 NNP NNP NNP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNP NNPS O
National National 1 0 0 0 0 0 0 0 8 0 NNP DT NNP NNPS IN O
Institutes Institutes 1 0 0 0 0 0 0 0 10 0 DT NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
Health, Health, 1 0 0 0 1 0 0 0 7 0 NNPS IN NNP NNP NNP O
Bethesda, Bethesda, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP CD O
MD MD 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
20892, 20892, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
degramonta@niddk.nih.gov degramonta@niddk.nih.gov 0 0 0 0 0 0 0 0 24 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
Anaphase Anaphase 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP VBZ DT B_TIMEXCCP
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT NN IN O
stage stage 0 0 0 0 0 0 0 0 5 0 VBZ DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN IN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN IN WDT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN WDT VBN O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT VBN VBZ O
duplicated duplicated 0 0 0 0 0 0 0 0 10 0 IN WDT VBN VBZ JJ O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 WDT VBN VBZ JJ CC O
separate separate 0 0 0 0 0 0 0 0 8 0 VBN VBZ JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VBZ JJ CC NN NNS O
move move 0 0 0 0 0 0 0 0 4 0 JJ CC NN NNS VBP O
towards towards 0 0 0 0 0 0 0 0 7 0 CC NN NNS VBP NNS O
opposite opposite 0 0 0 0 0 0 0 0 8 0 NN NNS VBP NNS IN O
poles poles 0 0 0 0 0 0 0 0 5 0 NNS VBP NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBP NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NNP O
cell. cell. 0 0 0 0 0 0 0 0 5 0 IN DT NNP NNP PRP$ O
Although Although 1 0 0 0 0 0 0 0 8 0 DT NNP NNP PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NNP NNP PRP$ NN NNS O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NNP PRP$ NN NNS VBP O
movements movements 0 0 0 0 0 0 0 0 9 0 PRP$ NN NNS VBP RB O
have have 0 0 0 0 0 0 0 0 4 0 NN NNS VBP RB VBN O
always always 0 0 0 0 0 0 0 0 6 0 NNS VBP RB VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 VBP RB VBN VBN IN O
viewed viewed 0 0 0 0 0 0 0 0 6 0 RB VBN VBN IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 VBN VBN IN JJ IN O
majestic, majestic, 0 0 0 0 1 0 0 0 9 0 VBN IN JJ IN RB O
until until 0 0 0 0 0 0 0 0 5 0 IN JJ IN RB NN O
recently recently 0 0 0 0 0 0 0 0 8 0 JJ IN RB NN VBD O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 IN RB NN VBD JJ B_TIMEXCCP
lacked lacked 0 0 0 0 0 0 0 0 6 0 RB NN VBD JJ NNS O
obvious obvious 0 0 0 0 0 0 0 0 7 0 NN VBD JJ NNS IN O
landmarks landmarks 0 0 0 0 0 0 0 0 9 0 VBD JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NNP O
regulation. regulation. 0 0 0 0 0 0 0 0 11 0 NNS IN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NN VBZ O
picture picture 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP NN VBZ VBN IN O
changed changed 0 0 0 0 0 0 0 0 7 0 NN VBZ VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN JJ JJ O
numerous numerous 0 0 0 0 0 0 0 0 8 0 VBN IN JJ JJ NNS O
recent recent 0 0 0 0 0 0 0 0 6 0 IN JJ JJ NNS WDT O
studies studies 0 0 0 0 0 0 0 0 7 0 JJ JJ NNS WDT VBP O
that that 0 0 0 0 0 0 0 0 4 0 JJ NNS WDT VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNS WDT VBP VBN DT O
highlighted highlighted 0 0 0 0 0 0 0 0 11 0 WDT VBP VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP VBN DT NN NN O
raison raison 0 0 0 0 0 0 0 0 6 0 VBN DT NN NN IN O
d'être d'être 0 0 0 0 0 1 0 0 6 0 DT NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
anaphase. anaphase. 0 0 0 0 0 0 0 0 9 0 NN IN NNP NNP VBZ B_TIMEXCCP
It It 1 0 0 0 0 0 0 0 2 0 IN NNP NNP VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ RB VBN O
now now 0 0 0 0 0 0 0 0 3 0 NNP VBZ RB VBN TO O
known known 0 0 0 0 0 0 0 0 5 0 VBZ RB VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 RB VBN TO VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 TO VB VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VB VBN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NN IN O
series series 0 0 0 0 0 0 0 0 6 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 NN IN JJ NNS WDT O
pathways pathways 0 0 0 0 0 0 0 0 8 0 IN JJ NNS WDT VBP O
that that 0 0 0 0 0 0 0 0 4 0 JJ NNS WDT VBP DT O
promote promote 0 0 0 0 0 0 0 0 7 0 NNS WDT VBP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 WDT VBP DT NN IN O
switch switch 0 0 0 0 0 0 0 0 6 0 VBP DT NN IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 DT NN IN JJ TO O
high high 0 0 0 0 0 0 0 0 4 0 NN IN JJ TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 IN JJ TO JJ NN O
low low 0 0 0 0 0 0 0 0 3 0 JJ TO JJ NN NN O
cyclin-dependent cyclin-dependent 0 0 1 0 0 0 0 0 16 0 TO JJ NN NN JJ O
kinase kinase 0 0 0 0 0 0 0 0 6 0 JJ NN NN JJ JJ O
activity--an activity--an 0 0 1 0 0 0 0 0 12 0 NN NN JJ JJ NN O
essential essential 0 0 0 0 0 0 0 0 9 0 NN JJ JJ NN IN O
feature feature 0 0 0 0 0 0 0 0 7 0 JJ JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN JJ O
proper proper 0 0 0 0 0 0 0 0 6 0 NN IN NN JJ NNP O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 IN NN JJ NNP NNP B_TIMEXCCP
exit. exit. 0 0 0 0 0 0 0 0 5 0 NN JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
balance balance 0 0 0 0 0 0 0 0 7 0 NNP NNP NN IN NN O
between between 0 0 0 0 0 0 0 0 7 0 NNP NN IN NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 NN IN NN NN CC O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 IN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 NN CC NN NN NNS O
dephosphorylation dephosphorylation 0 0 0 0 0 0 0 0 17 0 CC NN NN NNS CC O
drives drives 0 0 0 0 0 0 0 0 6 0 NN NN NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NNS VBP O
coordinates coordinates 0 0 0 0 0 0 0 0 11 0 NNS CC NNS VBP NNS O
diverse diverse 0 0 0 0 0 0 0 0 7 0 CC NNS VBP NNS JJ O
processes processes 0 0 0 0 0 0 0 0 9 0 NNS VBP NNS JJ IN O
such such 0 0 0 0 0 0 0 0 4 0 VBP NNS JJ IN NN O
as as 0 0 0 0 0 0 0 0 2 0 NNS JJ IN NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 JJ IN NN NN NN O
movement, movement, 0 0 0 0 1 0 0 0 9 0 IN NN NN NN NNS O
spindle spindle 0 0 0 0 0 0 0 0 7 0 NN NN NN NNS CC O
dynamics dynamics 0 0 0 0 0 0 0 0 8 0 NN NN NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NN NN O
cleavage cleavage 0 0 0 0 0 0 0 0 8 0 NNS CC NN NN NNP O
furrow furrow 0 0 0 0 0 0 0 0 6 0 CC NN NN NNP NNP O
formation. formation. 0 0 0 0 0 0 0 0 10 0 NN NN NNP NNP NNP O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NNP NN O
well-ordered well-ordered 0 0 1 0 0 0 0 0 12 0 NNP NNP NNP NN IN O
sequence sequence 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNS VBZ O
events events 0 0 0 0 0 0 0 0 6 0 NN IN NNS VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 IN NNS VBZ JJ TO O
central central 0 0 0 0 0 0 0 0 7 0 NNS VBZ JJ TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO JJ NNP O
successful successful 0 0 0 0 0 0 0 0 10 0 JJ TO JJ NNP NNP O
mitosis. mitosis. 0 0 0 0 0 0 0 0 8 0 TO JJ NNP NNP CD B_TIMEXCCP
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
16126387 16126387 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NN NNP O
spindle spindle 0 0 0 0 0 0 0 0 7 0 NONE DT NN NNP NNP O
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 DT NN NNP NNP NNP B_TIMEXCCP
Amon Amon 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NNP NNP O
A. A. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Whitehead Whitehead 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNP O
Biomedical Biomedical 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP CD O
Research, Research, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP CD NNP O
9 9 0 0 0 0 0 0 1 1 1 0 NNP NNP CD NNP NNP O
Cambridge Cambridge 1 0 0 0 0 0 0 0 9 0 NNP CD NNP NNP NNP O
Center, Center, 1 0 0 0 1 0 0 0 7 0 CD NNP NNP NNP NNP O
Cambridge, Cambridge, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP CD O
Massachusetts Massachusetts 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP CD NNP O
02142, 02142, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Weis-Amon@wi.mit.edu Weis-Amon@wi.mit.edu 1 0 1 0 0 0 0 0 20 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP TO O
Prior Prior 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NNP NNP TO JJ NN O
sister-chromatid sister-chromatid 0 0 1 0 0 0 0 0 16 0 NNP TO JJ NN DT O
separation, separation, 0 0 0 0 1 0 0 0 11 0 TO JJ NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NN NN O
spindle spindle 0 0 0 0 0 0 0 0 7 0 NN DT NN NN NNS O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 DT NN NN NNS JJ B_TIMEXCCP
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 NN NN NNS JJ NN O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 0 NN NNS JJ NN IN O
progression progression 0 0 0 0 0 0 0 0 11 0 NNS JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN TO O
response response 0 0 0 0 0 0 0 0 8 0 NN IN NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN TO DT NN VBN O
signal signal 0 0 0 0 0 0 0 0 6 0 TO DT NN VBN IN O
generated generated 0 0 0 0 0 0 0 0 9 0 DT NN VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NN VBN IN JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 VBN IN JJ NN NN O
spindle spindle 0 0 0 0 0 0 0 0 7 0 IN JJ NN NN CC O
damage damage 0 0 0 0 0 0 0 0 6 0 JJ NN NN CC IN O
or or 0 0 0 0 0 0 0 0 2 0 NN NN CC IN NNS O
by by 0 0 0 0 0 0 0 0 2 0 NN CC IN NNS IN O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 CC IN NNS IN VBP O
that that 0 0 0 0 0 0 0 0 4 0 IN NNS IN VBP RB O
have have 0 0 0 0 0 0 0 0 4 0 NNS IN VBP RB VBN O
not not 0 0 0 0 0 0 0 0 3 0 IN VBP RB VBN TO O
attached attached 0 0 0 0 0 0 0 0 8 0 VBP RB VBN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 RB VBN TO NNP NNP O
microtubules. microtubules. 0 0 0 0 0 0 0 0 13 0 VBN TO NNP NNP NN O
Recent Recent 1 0 0 0 0 0 0 0 6 0 TO NNP NNP NN VBZ O
work work 0 0 0 0 0 0 0 0 4 0 NNP NNP NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP NN VBZ VBN IN O
shown shown 0 0 0 0 0 0 0 0 5 0 NN VBZ VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NN O
spindle spindle 0 0 0 0 0 0 0 0 7 0 IN DT NN NN NNS O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 DT NN NN NNS JJ B_TIMEXCCP
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 NN NN NNS JJ NN O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 0 NN NNS JJ NN IN O
progression progression 0 0 0 0 0 0 0 0 11 0 NNS JJ NN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
direct direct 0 0 0 0 0 0 0 0 6 0 NN IN JJ NN IN O
binding binding 0 0 0 0 0 0 0 0 7 0 IN JJ NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS IN O
components components 0 0 0 0 0 0 0 0 10 0 NN IN NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
spindle spindle 0 0 0 0 0 0 0 0 7 0 IN DT NN NN NN O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 DT NN NN NN TO B_TIMEXCCP
pathway pathway 0 0 0 0 0 0 0 0 7 0 NN NN NN TO NNS O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO NNS IN O
components components 0 0 0 0 0 0 0 0 10 0 NN TO NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 TO NNS IN DT VBN O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT VBN JJ O
specialized specialized 0 0 0 0 0 0 0 0 11 0 IN DT VBN JJ NN O
ubiquitin-conjugating ubiquitin-conjugating 0 0 1 0 0 0 0 0 21 0 DT VBN JJ NN WDT O
system system 0 0 0 0 0 0 0 0 6 0 VBN JJ NN WDT VBZ O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN WDT VBZ JJ IN O
responsible responsible 0 0 0 0 0 0 0 0 11 0 WDT VBZ JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN NN JJ O
triggering triggering 0 0 0 0 0 0 0 0 10 0 JJ IN NN JJ NNP O
sister-chromatid sister-chromatid 0 0 1 0 0 0 0 0 16 0 IN NN JJ NNP NNP O
separation. separation. 0 0 0 0 0 0 0 0 11 0 NN JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
10072359 10072359 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
SPRR1B SPRR1B 1 1 0 0 0 0 0 1 6 0 NONE NONE NNP NN NNS O
overexpression overexpression 0 0 0 0 0 0 0 0 14 0 NONE NNP NN NNS NN O
enhances enhances 0 0 0 0 0 0 0 0 8 0 NNP NN NNS NN IN O
entry entry 0 0 0 0 0 0 0 0 5 0 NN NNS NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NNS NN IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN DT O
into into 0 0 0 0 0 0 0 0 4 0 IN NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NN O
G0 G0 1 1 0 0 0 0 0 1 2 phase IN DT NNP NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NNP NNP O
cycle. cycle. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP NNP O
Tesfaigzi Tesfaigzi 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wright Wright 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
PS, PS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Belinsky Belinsky 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
SA. SA. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Lovelace Lovelace 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Respiratory Respiratory 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP CD O
Inst., Inst., 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP CD NNP O
2425 2425 0 0 0 0 0 0 1 1 4 0 NNP NNP CD NNP NNP O
Ridgecrest Ridgecrest 1 0 0 0 0 0 0 0 10 0 NNP CD NNP NNP NNP O
Dr., Dr., 1 0 0 0 1 0 0 0 4 0 CD NNP NNP NNP NNP O
SE, SE, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Albuquerque, Albuquerque, 1 0 0 0 1 0 0 0 12 0 NNP NNP NNP NNP CD O
NM NM 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
87108, 87108, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
ytesfaig@lrri.org ytesfaig@lrri.org 0 0 0 0 0 0 0 0 17 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
Many Many 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP VBZ VBP O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP NNP VBZ VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBP VBN DT O
established established 0 0 0 0 0 0 0 0 11 0 VBZ VBP VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP VBN DT NN IN O
role role 0 0 0 0 0 0 0 0 4 0 VBN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
SPRR1B SPRR1B 1 1 0 0 0 0 0 1 6 0 NN IN NNP IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 IN NNP IN JJ NN O
squamous squamous 0 0 0 0 0 0 0 0 8 0 NNP IN JJ NN IN O
differentiation differentiation 0 0 0 0 0 0 0 0 15 0 IN JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN CC O
skin skin 0 0 0 0 0 0 0 0 4 0 NN IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN NN O
respiratory respiratory 0 0 0 0 0 0 0 0 11 0 NN CC NN NN NNP O
epithelial epithelial 0 0 0 0 0 0 0 0 10 0 CC NN NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP PRP$ O
However, However, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NNP NNP PRP$ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 NNP PRP$ NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 PRP$ NN IN JJ NNS O
nonsquamous nonsquamous 0 0 0 0 0 0 0 0 11 0 NN IN JJ NNS VBZ O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 JJ NNS VBZ RB NNP O
largely largely 0 0 0 0 0 0 0 0 7 0 NNS VBZ RB NNP NNP O
unknown. unknown. 0 0 0 0 0 0 0 0 8 0 VBZ RB NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 RB NNP NNP VBD IN O
reported reported 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBD IN NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 VBD IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP IN O
SPRR1B SPRR1B 1 1 0 0 0 0 0 1 6 0 NN IN NNP IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN JJ NN O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 NNP IN JJ NN NN O
hamster hamster 0 0 0 0 0 0 0 0 7 0 IN JJ NN NN NN O
ovary ovary 0 0 0 0 0 0 0 0 5 0 JJ NN NN NN NNS O
(CHO) (CHO) 0 1 0 0 0 0 0 0 5 0 NN NN NN NNS VBZ O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN NNS VBZ VBN RB O
increased increased 0 0 0 0 0 0 0 0 9 0 NNS VBZ VBN RB PRP O
as as 0 0 0 0 0 0 0 0 2 0 VBZ VBN RB PRP VBP O
they they 0 0 0 0 0 0 0 0 4 enter VBN RB PRP VBP DT O
enter enter 0 0 0 0 0 0 0 0 5 0 RB PRP VBP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBP DT NNP NN O
G0 G0 1 1 0 0 0 0 0 1 2 phase VBP DT NNP NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NNP NNP O
cycle. cycle. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
purpose purpose 0 0 0 0 0 0 0 0 7 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 IN DT NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD TO RBR O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO RBR JJ O
further further 0 0 0 0 0 0 0 0 7 0 VBD TO RBR JJ DT O
investigate investigate 0 0 0 0 0 0 0 0 11 0 TO RBR JJ DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 RBR JJ DT NNP NN O
SPRR1B SPRR1B 1 1 0 0 0 0 0 1 6 0 JJ DT NNP NN NN O
expression expression 0 0 0 0 0 0 0 0 10 0 DT NNP NN NN IN O
pattern pattern 0 0 0 0 0 0 0 0 7 0 NNP NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNS O
nonsquamous nonsquamous 0 0 0 0 0 0 0 0 11 0 NN IN JJ NNS CC O
tumors tumors 0 0 0 0 0 0 0 0 6 0 IN JJ NNS CC TO O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NNS CC TO NN PRP$ O
study study 0 0 0 0 0 0 0 0 5 0 CC TO NN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 TO NN PRP$ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 NN PRP$ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 PRP$ NN IN DT NNP O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN DT NNP NNP IN O
Expression Expression 1 0 0 0 0 0 0 0 10 0 DT NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP VBD O
SPRR1B SPRR1B 1 1 0 0 0 0 0 1 6 0 NNP IN NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 IN NNP VBD VBN IN O
detected detected 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NN O
Northern Northern 1 0 0 0 0 0 0 0 8 0 VBN IN NNP NN IN O
blotting blotting 0 0 0 0 0 0 0 0 8 0 IN NNP NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJR O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJR NN O
higher higher 0 0 0 0 0 0 0 0 6 0 IN DT JJR NN IN O
percentage percentage 0 0 0 0 0 0 0 0 10 0 DT JJR NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJR NN IN JJ VBN O
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced 0 0 1 0 0 0 0 1 54 0 NN IN JJ VBN IN O
compared compared 0 0 0 0 0 0 0 0 8 0 IN JJ VBN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 JJ VBN IN NN JJ O
beryllium beryllium 0 0 0 0 0 0 0 0 9 0 VBN IN NN JJ NN O
metal-induced metal-induced 0 0 1 0 0 0 0 0 13 0 IN NN JJ NN NN O
rat rat 0 0 0 0 0 0 0 0 3 0 NN JJ NN NN NNP O
lung lung 0 0 0 0 0 0 0 0 4 0 JJ NN NN NNP NNP O
adenocarcinomas. adenocarcinomas. 0 0 0 0 0 0 0 0 16 0 NN NN NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NN NNS O
situ situ 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NNS VBD O
hybridizations hybridizations 0 0 0 0 0 0 0 0 14 0 NNP NN NNS VBD IN O
confirmed confirmed 0 0 0 0 0 0 0 0 9 0 NN NNS VBD IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NNP VBZ O
SPRR1B SPRR1B 1 1 0 0 0 0 0 1 6 0 VBD IN NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ VBN IN O
expressed expressed 0 0 0 0 0 0 0 0 9 0 NNP VBZ VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN JJ CC O
individual individual 0 0 0 0 0 0 0 0 10 0 VBN IN JJ CC NNS O
or or 0 0 0 0 0 0 0 0 2 0 IN JJ CC NNS IN O
clusters clusters 0 0 0 0 0 0 0 0 8 0 JJ CC NNS IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 CC NNS IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNS IN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN JJ NNS O
nonsquamous nonsquamous 0 0 0 0 0 0 0 0 11 0 NNS IN JJ NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 JJ NNS IN NNP NNP O
mouse, mouse, 0 0 0 0 1 0 0 0 6 0 NNS IN NNP NNP CC O
rat, rat, 0 0 0 0 1 0 0 0 4 0 IN NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NNP O
human human 0 0 0 0 0 0 0 0 5 0 NNP CC JJ NNP NNP O
adenocarcinomas. adenocarcinomas. 0 0 0 0 0 0 0 0 16 0 CC JJ NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP JJ NN O
same same 0 0 0 0 0 0 0 0 4 0 NNP NNP JJ NN IN O
pattern pattern 0 0 0 0 0 0 0 0 7 0 NNP JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN VBD O
expression expression 0 0 0 0 0 0 0 0 10 0 NN IN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 IN NN VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNS VBN O
adenocarcinomas adenocarcinomas 0 0 0 0 0 0 0 0 15 0 VBN IN NNS VBN IN O
formed formed 0 0 0 0 0 0 0 0 6 0 IN NNS VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBN IN NN NN O
nude nude 0 0 0 0 0 0 0 0 4 0 VBN IN NN NN IN O
mice mice 0 0 0 0 0 0 0 0 4 0 IN NN NN IN NN O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NNS VBD O
lines lines 0 0 0 0 0 0 0 0 5 0 IN NN NNS VBD IN O
established established 0 0 0 0 0 0 0 0 11 0 NN NNS VBD IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NNP NNP O
adenocarcinomas. adenocarcinomas. 0 0 0 0 0 0 0 0 16 0 VBD IN NNP NNP NN O
SPRR1B SPRR1B 1 1 0 0 0 0 0 1 6 0 IN NNP NNP NN VBD O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
downregulated downregulated 0 0 0 0 0 0 0 0 13 0 NN VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NNS VBD O
lines lines 0 0 0 0 0 0 0 0 5 0 DT NN NNS VBD IN O
derived derived 0 0 0 0 0 0 0 0 7 0 NN NNS VBD IN NN O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NN WRB O
adenocarcinoma adenocarcinoma 0 0 0 0 0 0 0 0 14 0 VBD IN NN WRB NNS O
when when 0 0 0 0 0 0 0 0 4 0 IN NN WRB NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NN WRB NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 WRB NNS VBD VBN IN O
enriched enriched 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP IN O
G0 G0 1 1 0 0 0 0 0 1 2 0 VBN IN NNP IN JJ B_TIMEXCCP
at at 0 0 0 0 0 0 0 0 2 0 IN NNP IN JJ NNP O
low low 0 0 0 0 0 0 0 0 3 0 NNP IN JJ NNP NNP O
confluence. confluence. 0 0 0 0 0 0 0 0 11 0 IN JJ NNP NNP VBD O
Tetraploidy Tetraploidy 1 0 0 0 0 0 0 0 11 0 JJ NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP VBD VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
CHO, CHO, 1 1 0 0 1 0 0 0 4 0 VBN IN NNP NNP CC O
mouse, mouse, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NNP CC JJ NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 CC JJ NN NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NNS IN O
lines lines 0 0 0 0 0 0 0 0 5 0 NN NN NNS IN RB O
by by 0 0 0 0 0 0 0 0 2 0 NN NNS IN RB VBG O
stably stably 0 0 0 0 0 0 0 0 6 0 NNS IN RB VBG NN O
overexpressing overexpressing 0 0 0 0 0 0 0 0 14 0 IN RB VBG NN NNS O
SPRR1B, SPRR1B, 1 1 0 0 1 0 0 1 7 0 RB VBG NN NNS NN O
whereas whereas 0 0 0 0 0 0 0 0 7 0 VBG NN NNS NN NNS O
control control 0 0 0 0 0 0 0 0 7 0 NN NNS NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NNS NN NNS VBD DT O
showed showed 0 0 0 0 0 0 0 0 6 0 NN NNS VBD DT NN O
no no 0 0 0 0 0 0 0 0 2 0 NNS VBD DT NN IN O
change change 0 0 0 0 0 0 0 0 6 0 VBD DT NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
ploidy. ploidy. 0 0 0 0 0 0 0 0 7 0 NN IN NNP NNP NN O
Inducible Inducible 1 0 0 0 0 0 0 0 9 0 IN NNP NNP NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN IN O
protein protein 0 0 0 0 0 0 0 0 7 0 IN DT NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN NN NNS O
shorter shorter 0 0 0 0 0 0 0 0 7 0 NN IN NN NNS VBG O
periods periods 0 0 0 0 0 0 0 0 7 0 IN NN NNS VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 NN NNS VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBG DT NN NN O
ecdyson ecdyson 0 0 0 0 0 0 0 0 7 0 VBG DT NN NN VBD O
system system 0 0 0 0 0 0 0 0 6 0 DT NN NN VBD RB O
did did 0 0 0 0 0 0 0 0 3 0 NN NN VBD RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NN VBD RB VB NN O
affect affect 0 0 0 0 0 0 0 0 6 0 VBD RB VB NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 RB VB NN NN CC O
rate rate 0 0 0 0 0 0 0 0 4 0 VB NN NN CC DT O
or or 0 0 0 0 0 0 0 0 2 0 NN NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN IN O
ploidy ploidy 0 0 0 0 0 0 0 0 6 0 CC DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNS O
CHO CHO 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNS CC O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS CC VBD O
but but 0 0 0 0 0 0 0 0 3 0 NNP NNS CC VBD NN O
accelerated accelerated 0 0 0 0 0 0 0 0 11 0 NNS CC VBD NN IN O
entry entry 0 0 0 0 0 0 0 0 5 0 CC VBD NN IN -NONE- O
into into 0 0 0 0 0 0 0 0 4 0 VBD NN IN -NONE- VBN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NN IN -NONE- VBN IN B_TIMEXCCP
compared compared 0 0 0 0 0 0 0 0 8 0 IN -NONE- VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 -NONE- VBN IN NNP NNP O
controls. controls. 0 0 0 0 0 0 0 0 9 0 VBN IN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNS VBP O
findings findings 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBP IN O
indicate indicate 0 0 0 0 0 0 0 0 8 0 NNP NNS VBP IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NNP VBZ O
SPRR1B SPRR1B 1 1 0 0 0 0 0 1 6 0 VBP IN NNP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ JJ VBN O
likely likely 0 0 0 0 0 0 0 0 6 0 NNP VBZ JJ VBN RB O
coupled coupled 0 0 0 0 0 0 0 0 7 0 VBZ JJ VBN RB TO O
primarily primarily 0 0 0 0 0 0 0 0 9 0 JJ VBN RB TO NNS O
to to 0 0 0 0 0 0 0 0 2 0 VBN RB TO NNS JJ O
signals signals 0 0 0 0 0 0 0 0 7 0 RB TO NNS JJ IN O
responsible responsible 0 0 0 0 0 0 0 0 11 0 TO NNS JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NNS JJ IN NN IN O
withdrawal withdrawal 0 0 0 0 0 0 0 0 10 0 JJ IN NN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 IN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
proliferative proliferative 0 0 0 0 0 0 0 0 13 0 IN DT JJ NN RB O
state state 0 0 0 0 0 0 0 0 5 0 DT JJ NN RB IN O
rather rather 0 0 0 0 0 0 0 0 6 0 JJ NN RB IN DT O
than than 0 0 0 0 0 0 0 0 4 0 NN RB IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT JJ NNS O
final final 0 0 0 0 0 0 0 0 5 0 IN DT JJ NNS IN O
stages stages 0 0 0 0 0 0 0 0 6 0 DT JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
cellular cellular 0 0 0 0 0 0 0 0 8 0 NNS IN JJ NN CC O
quiescence quiescence 0 0 0 0 0 0 0 0 10 0 IN JJ NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC IN PRP$ O
that that 0 0 0 0 0 0 0 0 4 0 NN CC IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 CC IN PRP$ NN IN O
overexpression overexpression 0 0 0 0 0 0 0 0 14 0 IN PRP$ NN IN VBN O
for for 0 0 0 0 0 0 0 0 3 0 PRP$ NN IN VBN NNS O
prolonged prolonged 0 0 0 0 0 0 0 0 9 0 NN IN VBN NNS MD O
periods periods 0 0 0 0 0 0 0 0 7 0 IN VBN NNS MD VB O
may may 0 0 0 0 0 0 0 0 3 0 VBN NNS MD VB DT O
disrupt disrupt 0 0 0 0 0 0 0 0 7 0 NNS MD VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT JJ NN O
normal normal 0 0 0 0 0 0 0 0 6 0 VB DT JJ NN IN O
progression progression 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
mitosis. mitosis. 0 0 0 0 0 0 0 0 8 0 NN IN NNP NNP CD B_TIMEXCCP
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 IN NNP NNP CD JJ O
12832281 12832281 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Signal Signal 1 0 0 0 0 0 0 0 6 0 NONE NONE NNP NN CC O
transduction transduction 0 0 0 0 0 0 0 0 12 0 NONE NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN IN O
actin actin 0 0 0 0 0 0 0 0 5 0 NN CC NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 CC NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
regulation regulation 0 0 0 0 0 0 0 0 10 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 NN IN JJ NNP NNP B_TIMEXCCP
progression. progression. 0 0 0 0 0 0 0 0 12 0 IN JJ NNP NNP NNP O
Boonstra Boonstra 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Moes Moes 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
MJ. MJ. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP CC O
Architecture Architecture 1 0 0 0 0 0 0 0 12 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Dynamics, Dynamics, 1 0 0 0 1 0 0 0 9 0 NNP CC NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biomembranes, Biomembranes, 1 0 0 0 1 0 0 0 13 0 NNP IN NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Utrecht, Utrecht, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
Netherlands. Netherlands. 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
J.Boonstra@bio.uu.nl J.Boonstra@bio.uu.nl 1 0 0 0 0 0 0 0 20 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Regulation Regulation 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP IN NN NN VBZ O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 IN NN NN VBZ NN O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ NN IN O
dependent dependent 0 0 0 0 0 0 0 0 9 0 NN VBZ NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 VBZ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
integration integration 0 0 0 0 0 0 0 0 11 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
signal signal 0 0 0 0 0 0 0 0 6 0 NN IN JJ NN NNS O
transduction transduction 0 0 0 0 0 0 0 0 12 0 IN JJ NN NNS WDT O
systems systems 0 0 0 0 0 0 0 0 7 0 JJ NN NNS WDT VBP O
that that 0 0 0 0 0 0 0 0 4 0 NN NNS WDT VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NNS WDT VBP VBN IN O
activated activated 0 0 0 0 0 0 0 0 9 0 WDT VBP VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBP VBN IN JJ NN O
external external 0 0 0 0 0 0 0 0 8 0 VBN IN JJ NN NN O
signal signal 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN JJ O
molecules, molecules, 0 0 0 0 1 0 0 0 10 0 JJ NN NN JJ IN O
such such 0 0 0 0 0 0 0 0 4 0 NN NN JJ IN NN O
as as 0 0 0 0 0 0 0 0 2 0 NN JJ IN NN NNS O
growth growth 0 0 0 0 0 0 0 0 6 0 JJ IN NN NNS CC O
factors factors 0 0 0 0 0 0 0 0 7 0 IN NN NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC JJ NN O
extracellular extracellular 0 0 0 0 0 0 0 0 13 0 NNS CC JJ NN NNP O
matrix matrix 0 0 0 0 0 0 0 0 6 0 CC JJ NN NNP NNP O
components. components. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP NNP IN O
Dependent Dependent 1 0 0 0 0 0 0 0 9 0 NN NNP NNP IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT JJ O
these these 0 0 0 0 0 0 0 0 5 0 NNP IN DT JJ NN O
signal signal 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN NN O
transduction transduction 0 0 0 0 0 0 0 0 12 0 DT JJ NN NN DT O
networks, networks, 0 0 0 0 1 0 0 0 9 0 JJ NN NN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 NN DT NNS VBP IN O
decide decide 0 0 0 0 0 0 0 0 6 0 DT NNS VBP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 phase IN DT NNP NN TO B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NNP NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO VB NN O
continue continue 0 0 0 0 0 0 0 0 8 0 NN TO VB NN -NONE- O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 TO VB NN -NONE- -NONE- O
or, or, 0 0 0 0 1 0 0 0 3 0 VB NN -NONE- -NONE- TO O
alternatively, alternatively, 0 0 0 0 1 0 0 0 14 0 NN -NONE- -NONE- TO VB O
to to 0 0 0 0 0 0 0 0 2 0 -NONE- -NONE- TO VB JJ O
stop stop 0 0 0 0 0 0 0 0 4 0 -NONE- TO VB JJ NN O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 0 TO VB JJ NN CC O
progression progression 0 0 0 0 0 0 0 0 11 0 VB JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NN O
undergo undergo 0 0 0 0 0 0 0 0 7 0 NN CC NN NN NN O
apoptosis, apoptosis, 0 0 0 0 1 0 0 0 10 0 CC NN NN NN CC O
differentiation, differentiation, 0 0 0 0 1 0 0 0 16 0 NN NN NN CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 NN NN CC NNP NNP O
quiescence. quiescence. 0 0 0 0 0 0 0 0 11 0 NN CC NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 CC NNP NNP NNP NN O
MAP MAP 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NN CC O
kinase kinase 0 0 0 0 0 0 0 0 6 0 NNP NNP NN CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC -NONE- VB O
PI-3 PI-3 1 1 1 0 0 0 0 1 4 0 NN CC -NONE- VB NNS O
kinase kinase 0 0 0 0 0 0 0 0 6 0 CC -NONE- VB NNS VBP O
pathways pathways 0 0 0 0 0 0 0 0 8 0 -NONE- VB NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 VB NNS VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNS VBP VBN VBN TO O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 VBP VBN VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO VB DT O
play play 0 0 0 0 0 0 0 0 4 0 VBN TO VB DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 TO VB DT JJ NN O
essential essential 0 0 0 0 0 0 0 0 9 0 VB DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT JJ NNP O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 IN DT JJ NNP NNP B_TIMEXCCP
decisions. decisions. 0 0 0 0 0 0 0 0 10 0 DT JJ NNP NNP NN O
Interestingly, Interestingly, 1 0 0 0 1 0 0 0 14 0 JJ NNP NNP NN VBZ O
actin actin 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP NN VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN VBN TO O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 VBZ VBN VBN TO RB O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO RB RB O
mutually mutually 0 0 0 0 0 0 0 0 8 0 VBN TO RB RB IN O
interfere interfere 0 0 0 0 0 0 0 0 9 0 TO RB RB IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 RB RB IN JJ NNP O
signal signal 0 0 0 0 0 0 0 0 6 0 RB IN JJ NNP NNP O
transduction. transduction. 0 0 0 0 0 0 0 0 13 0 IN JJ NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NNP PRP O
addition, addition, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP PRP VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 PRP VBZ VBN VBN IN O
indicated indicated 0 0 0 0 0 0 0 0 9 0 VBZ VBN VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 VBN VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NN O
FOXO FOXO 1 1 0 0 0 0 0 0 4 0 IN DT NNP NN NNS O
transcription transcription 0 0 0 0 0 0 0 0 13 0 DT NNP NN NNS VBP O
factors factors 0 0 0 0 0 0 0 0 7 0 NNP NN NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NN NNS VBP VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 NNS VBP VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBP VBN IN DT JJ O
these these 0 0 0 0 0 0 0 0 5 0 VBN IN DT JJ IN O
decisions, decisions, 0 0 0 0 1 0 0 0 10 0 IN DT JJ IN NNP O
as as 0 0 0 0 0 0 0 0 2 0 DT JJ IN NNP NNP O
well. well. 0 0 0 0 0 0 0 0 5 0 JJ IN NNP NNP VBZ O
Actin Actin 1 0 0 0 0 0 0 0 5 0 IN NNP NNP VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP NNP VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBN VBN TO O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 VBZ VBN VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO VB DT O
play play 0 0 0 0 0 0 0 0 4 0 VBN TO VB DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 TO VB DT JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 VB DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
regulation regulation 0 0 0 0 0 0 0 0 10 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 NN IN JJ NNP NNP B_TIMEXCCP
progression. progression. 0 0 0 0 0 0 0 0 12 0 IN JJ NNP NNP IN O
Because Because 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP IN PRP$ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN PRP$ NNS O
its its 0 0 0 0 0 0 0 0 3 0 NNP IN PRP$ NNS IN O
properties properties 0 0 0 0 0 0 0 0 10 0 IN PRP$ NNS IN DT O
as as 0 0 0 0 0 0 0 0 2 0 PRP$ NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ NN O
structural structural 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN NN O
protein, protein, 0 0 0 0 1 0 0 0 8 0 DT JJ NN NN VBZ O
actin actin 0 0 0 0 0 0 0 0 5 0 JJ NN NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ JJ IN O
essential essential 0 0 0 0 0 0 0 0 9 0 NN VBZ JJ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBZ JJ IN NN CC O
cytokinesis cytokinesis 0 0 0 0 0 0 0 0 11 0 JJ IN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN CC IN NN VBG O
cell cell 0 0 0 0 0 0 0 0 4 0 CC IN NN VBG NN O
spreading spreading 0 0 0 0 0 0 0 0 9 0 IN NN VBG NN -NONE- O
and, and, 0 0 0 0 1 0 0 0 4 0 NN VBG NN -NONE- VBZ O
thus, thus, 0 0 0 0 1 0 0 0 5 0 VBG NN -NONE- VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN -NONE- VBZ VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 -NONE- VBZ VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN JJ NNP O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 VBN IN JJ NNP NNP B_TIMEXCCP
progression. progression. 0 0 0 0 0 0 0 0 12 0 IN JJ NNP NNP DT O
As As 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNP NNP DT JJ NN O
intermediate intermediate 0 0 0 0 0 0 0 0 12 0 NNP DT JJ NN IN O
factor factor 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
signal signal 0 0 0 0 0 0 0 0 6 0 NN IN JJ NN NN O
transduction, transduction, 0 0 0 0 1 0 0 0 13 0 IN JJ NN NN VBZ O
actin actin 0 0 0 0 0 0 0 0 5 0 JJ NN NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ JJ TO O
likely likely 0 0 0 0 0 0 0 0 6 0 NN VBZ JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 JJ TO VB VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 TO VB VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VB VBN IN JJ NN O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 0 VBN IN JJ NN VBD O
regulation regulation 0 0 0 0 0 0 0 0 10 0 IN JJ NN VBD IN O
induced induced 0 0 0 0 0 0 0 0 7 0 JJ NN VBD IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN JJ NN O
external external 0 0 0 0 0 0 0 0 8 0 VBD IN JJ NN NNP O
signal signal 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNP NNP O
molecules. molecules. 0 0 0 0 0 0 0 0 10 0 JJ NN NNP NNP NNP O
And, And, 1 0 0 0 1 0 0 0 4 0 NN NNP NNP NNP NN O
finally, finally, 0 0 0 0 1 0 0 0 8 0 NNP NNP NNP NN VBZ O
actin actin 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP NN VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN VBN TO O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 VBZ VBN VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO VB DT O
play play 0 0 0 0 0 0 0 0 4 0 VBN TO VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT JJ NN O
direct direct 0 0 0 0 0 0 0 0 6 0 VB DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
transcription. transcription. 0 0 0 0 0 0 0 0 14 0 NN IN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNS VBP O
observations observations 0 0 0 0 0 0 0 0 12 0 NNP NNP NNS VBP DT O
indicate indicate 0 0 0 0 0 0 0 0 8 0 NNP NNS VBP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNS VBP DT NN NN O
prominent prominent 0 0 0 0 0 0 0 0 9 0 VBP DT NN NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN IN O
actin actin 0 0 0 0 0 0 0 0 5 0 NN IN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
regulation regulation 0 0 0 0 0 0 0 0 10 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 NN IN JJ NNP NNP B_TIMEXCCP
progression. progression. 0 0 0 0 0 0 0 0 12 0 IN JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
16390321 16390321 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Cyclin Cyclin 1 0 0 0 0 0 0 0 6 0 NONE NONE NNP NN CC O
expression expression 0 0 0 0 0 0 0 0 10 0 NONE NNP NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC JJ NN O
G2-phase G2-phase 1 0 1 0 0 0 0 1 8 0 NN CC JJ NN IN B_TIMEXCCP
delay delay 0 0 0 0 0 0 0 0 5 0 CC JJ NN IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 JJ NN IN NNP NNP O
irradiation. irradiation. 0 0 0 0 0 0 0 0 12 0 NN IN NNP NNP NNP O
Bernhard Bernhard 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
EJ, EJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
McKenna McKenna 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
WG, WG, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Muschel Muschel 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
RJ. RJ. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Radiation Radiation 1 0 0 0 0 0 0 0 9 0 NNP IN NNP NNP NNP O
Oncology, Oncology, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pennsylvania, Pennsylvania, 1 0 0 0 1 0 0 0 13 0 NNP IN NNP NNP NNP O
Philadelphia Philadelphia 1 0 0 0 0 0 0 0 12 0 IN NNP NNP NNP NNP O
19104. 19104. 0 0 0 0 0 0 0 1 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
Many Many 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP VBZ VBP O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP NNP VBZ VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBP VBN DT O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 VBZ VBP VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP VBN DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 VBN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
oncogene oncogene 0 0 0 0 0 0 0 0 8 0 NN IN NN NN IN O
transfection transfection 0 0 0 0 0 0 0 0 12 0 IN NN NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
radiation radiation 0 0 0 0 0 0 0 0 9 0 IN DT NN NN IN O
sensitivity sensitivity 0 0 0 0 0 0 0 0 11 0 DT NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
primary primary 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN NN O
rat rat 0 0 0 0 0 0 0 0 3 0 IN JJ NN NN NNP O
embryo embryo 0 0 0 0 0 0 0 0 6 0 JJ NN NN NNP NNP O
fibroblasts. fibroblasts. 0 0 0 0 0 0 0 0 12 0 NN NN NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
indicate indicate 0 0 0 0 0 0 0 0 8 0 NNP NNS VBP IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NN IN O
transformation transformation 0 0 0 0 0 0 0 0 14 0 VBP IN NN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ CC O
H-ras H-ras 1 0 1 0 0 0 0 0 5 0 NN IN JJ CC JJ O
plus plus 0 0 0 0 0 0 0 0 4 0 IN JJ CC JJ NNS O
v-myc v-myc 0 0 1 0 0 0 0 0 5 0 JJ CC JJ NNS NNS O
oncogenes oncogenes 0 0 0 0 0 0 0 0 9 0 CC JJ NNS NNS NN O
confers confers 0 0 0 0 0 0 0 0 7 0 JJ NNS NNS NN NN O
radiation radiation 0 0 0 0 0 0 0 0 9 0 NNS NNS NN NN TO O
resistance resistance 0 0 0 0 0 0 0 0 10 0 NNS NN NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO DT RB O
a a 0 0 0 0 0 0 0 0 1 0 NN TO DT RB JJR O
much much 0 0 0 0 0 0 0 0 4 0 TO DT RB JJR NN O
greater greater 0 0 0 0 0 0 0 0 7 0 DT RB JJR NN IN O
extent extent 0 0 0 0 0 0 0 0 6 0 RB JJR NN IN NN O
than than 0 0 0 0 0 0 0 0 4 0 JJR NN IN NN IN O
transformation transformation 0 0 0 0 0 0 0 0 14 0 NN IN NN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NN O
either either 0 0 0 0 0 0 0 0 6 0 NN IN DT NN NNP O
gene gene 0 0 0 0 0 0 0 0 4 0 IN DT NN NNP NNP O
alone. alone. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBP JJ O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNP VBP JJ NN O
further further 0 0 0 0 0 0 0 0 7 0 NNP VBP JJ NN WDT O
shown shown 0 0 0 0 0 0 0 0 5 0 VBP JJ NN WDT DT O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN WDT DT NN NN O
radioresistant radioresistant 0 0 0 0 0 0 0 0 14 0 WDT DT NN NN VBZ O
phenotype phenotype 0 0 0 0 0 0 0 0 9 0 DT NN NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ VBN IN O
accompanied accompanied 0 0 0 0 0 0 0 0 11 0 NN VBZ VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NN O
prolonged prolonged 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN NNP O
G2-phase G2-phase 1 0 1 0 0 0 0 1 8 0 DT JJ NN NNP NNP B_TIMEXCCP
delay. delay. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP VBZ O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP VBZ NN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ NN IN O
consistent consistent 0 0 0 0 0 0 0 0 10 0 NNP VBZ NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBZ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
hypothesis hypothesis 0 0 0 0 0 0 0 0 10 0 IN DT NN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
extent extent 0 0 0 0 0 0 0 0 6 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN VBZ O
delay delay 0 0 0 0 0 0 0 0 5 0 IN DT NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN VBZ DT JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ NN IN O
determinant determinant 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNP O
radiation radiation 0 0 0 0 0 0 0 0 9 0 NN IN NN NNP NNP O
sensitivity. sensitivity. 0 0 0 0 0 0 0 0 12 0 IN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NN O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN IN NN NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 IN NN NN IN DT O
during during 0 0 0 0 0 0 0 0 6 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
progression progression 0 0 0 0 0 0 0 0 11 0 IN DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN NNP O
through through 0 0 0 0 0 0 0 0 7 0 IN NNS IN NNP CC O
G2 G2 1 1 0 0 0 0 0 1 2 0 NNS IN NNP CC NNP B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NN O
M M 1 1 0 0 0 0 0 0 1 phase NNP CC NNP NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 CC NNP NN IN NN O
after after 0 0 0 0 0 0 0 0 5 0 NNP NN IN NN VBZ O
irradiation irradiation 0 0 0 0 0 0 0 0 11 0 NN IN NN VBZ RB O
has has 0 0 0 0 0 0 0 0 3 0 IN NN VBZ RB VBN O
also also 0 0 0 0 0 0 0 0 4 0 NN VBZ RB VBN JJ O
revealed revealed 0 0 0 0 0 0 0 0 8 0 VBZ RB VBN JJ JJ O
several several 0 0 0 0 0 0 0 0 7 0 RB VBN JJ JJ NNS O
possible possible 0 0 0 0 0 0 0 0 8 0 VBN JJ JJ NNS IN O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 JJ JJ NNS IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 NNS IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NNP O
G2-phase G2-phase 1 0 1 0 0 0 0 1 8 0 NN IN JJ NNP NNP B_TIMEXCCP
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 IN JJ NNP NNP IN O
Control Control 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NNP IN NN NNP NNS O
B B 1 1 0 0 0 0 0 0 1 0 IN NN NNP NNS VBD O
levels levels 0 0 0 0 0 0 0 0 6 0 NN NNP NNS VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNS VBD VBN DT O
seen seen 0 0 0 0 0 0 0 0 4 0 NNS VBD VBN DT IN O
both both 0 0 0 0 0 0 0 0 4 0 VBD VBN DT IN DT O
at at 0 0 0 0 0 0 0 0 2 0 VBN DT IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 DT IN DT NNP NN O
mRNA mRNA 0 0 0 0 0 0 0 0 4 0 IN DT NNP NN IN O
level level 0 0 0 0 0 0 0 0 5 0 DT NNP NN IN VBN O
as as 0 0 0 0 0 0 0 0 2 0 NNP NN IN VBN IN O
evidenced evidenced 0 0 0 0 0 0 0 0 9 0 NN IN VBN IN VBN O
by by 0 0 0 0 0 0 0 0 2 0 IN VBN IN VBN NN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 VBN IN VBN NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 IN VBN NN NNP NNP O
B B 1 1 0 0 0 0 0 0 1 0 VBN NN NNP NNP NN O
mRNA mRNA 0 0 0 0 0 0 0 0 4 0 NN NNP NNP NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN NN O
after after 0 0 0 0 0 0 0 0 5 0 NNP NN IN NN IN O
irradiation irradiation 0 0 0 0 0 0 0 0 11 0 NN IN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
S S 1 1 0 0 0 0 0 0 1 0 IN DT NNP NNP CC B_TIMEXCCP
phase, phase, 0 0 0 0 1 0 0 0 6 0 DT NNP NNP CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NNP CC IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC IN DT NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 IN DT NN NN IN O
level level 0 0 0 0 0 0 0 0 5 0 DT NN NN IN VBN O
as as 0 0 0 0 0 0 0 0 2 0 NN NN IN VBN IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 NN IN VBN IN NN O
after after 0 0 0 0 0 0 0 0 5 0 IN VBN IN NN IN O
irradiation irradiation 0 0 0 0 0 0 0 0 11 0 VBN IN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNP O
G2 G2 1 1 0 0 0 0 0 1 2 0 NN IN NNP NNP NNP B_TIMEXCCP
phase. phase. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBZ TO O
remains remains 0 0 0 0 0 0 0 0 7 0 NNP NNP VBZ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBZ TO VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 VBZ TO VB VBN WRB O
determined determined 0 0 0 0 0 0 0 0 10 0 TO VB VBN WRB DT O
how how 0 0 0 0 0 0 0 0 3 0 VB VBN WRB DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 VBN WRB DT NNS MD O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 WRB DT NNS MD VB O
might might 0 0 0 0 0 0 0 0 5 0 DT NNS MD VB RB O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB RB VBN O
differentially differentially 0 0 0 0 0 0 0 0 14 0 MD VB RB VBN IN O
regulated regulated 0 0 0 0 0 0 0 0 9 0 VB RB VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN JJ CC O
radioresistant radioresistant 0 0 0 0 0 0 0 0 14 0 VBN IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NNP O
sensitive sensitive 0 0 0 0 0 0 0 0 9 0 JJ CC JJ NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 CC JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
8146330 8146330 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Visualization Visualization 1 0 0 0 0 0 0 0 13 0 NONE NONE NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NN NNP O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NN IN NN NNP NNP B_TIMEXCCP
chromosomes. chromosomes. 0 0 0 0 0 0 0 0 12 0 IN NN NNP NNP NNP O
Stack Stack 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP NNP O
SM, SM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Brown Brown 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
DB, DB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Dewey Dewey 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
WC. WC. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP DT O
Using Using 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT JJ JJ O
modified modified 0 0 0 0 0 0 0 0 8 0 NNP DT JJ JJ NN O
Giemsa-banding Giemsa-banding 1 0 1 0 0 0 0 0 14 0 DT JJ JJ NN PRP O
technique technique 0 0 0 0 0 0 0 0 9 0 JJ JJ NN PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 JJ NN PRP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NN PRP VBP VBN WP O
observed observed 0 0 0 0 0 0 0 0 8 0 PRP VBP VBN WP JJ O
what what 0 0 0 0 0 0 0 0 4 0 VBP VBN WP JJ TO O
appear appear 0 0 0 0 0 0 0 0 6 0 VBN WP JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 WP JJ TO VB NNS O
be be 0 0 0 0 0 0 0 0 2 0 JJ TO VB NNS IN O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 TO VB NNS IN NN O
during during 0 0 0 0 0 0 0 0 6 0 VB NNS IN NN IN O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NNS IN NN IN NN B_TIMEXCCP
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NN IN O
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 NN IN NN IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 IN NN IN NNP NN O
Allium Allium 1 0 0 0 0 0 0 0 6 0 NN IN NNP NN NN O
cepa cepa 0 0 0 0 0 0 0 0 4 0 IN NNP NN NN NNS O
root root 0 0 0 0 0 0 0 0 4 0 NNP NN NN NNS CC O
tips tips 0 0 0 0 0 0 0 0 4 0 NN NN NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC JJ NN O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 NNS CC JJ NN NNS O
hamster hamster 0 0 0 0 0 0 0 0 7 0 CC JJ NN NNS -NONE- O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS -NONE- NNP O
(CHO (CHO 0 1 0 0 0 0 0 0 4 0 NN NNS -NONE- NNP NNP O
line). line). 0 0 0 0 0 0 0 0 6 0 NNS -NONE- NNP NNP NN O
During During 1 0 0 0 0 0 0 0 6 0 -NONE- NNP NNP NN IN O
telophase telophase 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN NNP B_TIMEXCCP
through through 0 0 0 0 0 0 0 0 7 0 NNP NN IN NNP NNS O
G1 G1 1 1 0 0 0 0 0 1 2 0 NN IN NNP NNS RB B_TIMEXCCP
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 IN NNP NNS RB NN O
progressively progressively 0 0 0 0 0 0 0 0 13 0 NNP NNS RB NN CC O
uncoil uncoil 0 0 0 0 0 0 0 0 6 0 NNS RB NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 RB NN CC NNP NNP O
decondense. decondense. 0 0 0 0 0 0 0 0 11 0 NN CC NNP NNP NNP O
During During 1 0 0 0 0 0 0 0 6 0 CC NNP NNP NNP VBZ O
S S 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP VBZ VBP B_TIMEXCCP
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 NNP NNP VBZ VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 NNP VBZ VBP RB JJ O
comparatively comparatively 0 0 0 0 0 0 0 0 13 0 VBZ VBP RB JJ CC O
decondensed, decondensed, 0 0 0 0 1 0 0 0 12 0 VBP RB JJ CC DT O
but but 0 0 0 0 0 0 0 0 3 0 RB JJ CC DT NNS O
some some 0 0 0 0 0 0 0 0 4 0 JJ CC DT NNS VBP O
segments segments 0 0 0 0 0 0 0 0 8 0 CC DT NNS VBP NN O
have have 0 0 0 0 0 0 0 0 4 0 DT NNS VBP NN JJ O
structure structure 0 0 0 0 0 0 0 0 9 0 NNS VBP NN JJ TO O
similar similar 0 0 0 0 0 0 0 0 7 0 VBP NN JJ TO NNS O
to to 0 0 0 0 0 0 0 0 2 0 NN JJ TO NNS IN O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 JJ TO NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 TO NNS IN NNP CC O
G1 G1 1 1 0 0 0 0 0 1 2 0 NNS IN NNP CC NNP B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
G2. G2. 1 1 0 0 0 0 0 1 3 0 NNP CC NNP NNP NNP B_TIMEXCCP
During During 1 0 0 0 0 0 0 0 6 0 CC NNP NNP NNP DT O
G2 G2 1 1 0 0 0 0 0 1 2 0 NNP NNP NNP DT NNS B_TIMEXCCP
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNS RB O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 NNP DT NNS RB VBP O
progressively progressively 0 0 0 0 0 0 0 0 13 0 DT NNS RB VBP CC O
recondense recondense 0 0 0 0 0 0 0 0 10 0 NNS RB VBP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 RB VBP CC NN IN O
coil coil 0 0 0 0 0 0 0 0 4 0 VBP CC NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NN O
apparent apparent 0 0 0 0 0 0 0 0 8 0 NN IN NN NN IN O
preparation preparation 0 0 0 0 0 0 0 0 11 0 IN NN NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NNP NNP O
prophase. prophase. 0 0 0 0 0 0 0 0 9 0 NN IN NNP NNP NNP B_TIMEXCCP
Although Although 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP JJ O
specific specific 0 0 0 0 0 0 0 0 8 0 NNP NNP NNP JJ NNS O
structural structural 0 0 0 0 0 0 0 0 10 0 NNP NNP JJ NNS IN O
modifications modifications 0 0 0 0 0 0 0 0 13 0 NNP JJ NNS IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNS VBP O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 NNS IN NNS VBP IN O
occur occur 0 0 0 0 0 0 0 0 5 0 IN NNS VBP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBP IN NNP NNP O
G1, G1, 1 1 0 0 1 0 0 1 3 0 VBP IN NNP NNP NNP B_TIMEXCCP
Sand Sand 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNP O
G2 G2 1 1 0 0 0 0 0 1 2 0 NNP NNP NNP NNP VBZ B_TIMEXCCP
nuclei, nuclei, 0 0 0 0 1 0 0 0 7 0 NNP NNP NNP VBZ JJ O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 NNP NNP VBZ JJ RB O
appear appear 0 0 0 0 0 0 0 0 6 0 NNP VBZ JJ RB TO O
never never 0 0 0 0 0 0 0 0 5 0 VBZ JJ RB TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ RB TO VB TO O
decondense decondense 0 0 0 0 0 0 0 0 10 0 RB TO VB TO DT O
to to 0 0 0 0 0 0 0 0 2 0 TO VB TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VB TO DT NN IN O
point point 0 0 0 0 0 0 0 0 5 0 TO DT NN IN PRP O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN PRP VBP O
they they 0 0 0 0 0 0 0 0 4 0 NN IN PRP VBP PRP$ O
lose lose 0 0 0 0 0 0 0 0 4 0 IN PRP VBP PRP$ JJ O
their their 0 0 0 0 0 0 0 0 5 0 PRP VBP PRP$ JJ NN O
3-dimensional 3-dimensional 0 0 1 0 0 0 0 1 13 0 VBP PRP$ JJ NN CC O
integrity, integrity, 0 0 0 0 1 0 0 0 10 0 PRP$ JJ NN CC NN O
but but 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN IN O
remain remain 0 0 0 0 0 0 0 0 6 0 NN CC NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NNS O
distinct distinct 0 0 0 0 0 0 0 0 8 0 NN IN NN NNS IN O
domains domains 0 0 0 0 0 0 0 0 7 0 IN NN NNS IN NNP O
throughout throughout 0 0 0 0 0 0 0 0 10 0 NN NNS IN NNP NNP O
interphase. interphase. 0 0 0 0 0 0 0 0 11 0 NNS IN NNP NNP CD B_TIMEXCCP
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 IN NNP NNP CD JJ O
562895 562895 0 0 0 0 0 0 1 1 6 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Brinkley-fest Brinkley-fest 1 0 1 0 0 0 0 0 13 0 NONE NONE JJ IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE JJ IN NNP NNP O
mitosis. mitosis. 0 0 0 0 0 0 0 0 8 0 JJ IN NNP NNP NNP B_TIMEXCCP
Heald Heald 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
R. R. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP CC O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NNP CC NNP NNP NNP O
Biology Biology 1 0 0 0 0 0 0 0 7 0 CC NNP NNP NNP NNP O
Department, Department, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
California, California, 1 0 0 0 1 0 0 0 11 0 NNP IN NNP NNP NNP O
Berkeley, Berkeley, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Berkeley, Berkeley, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP CD O
CA CA 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
94720, 94720, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
bheald@berkeley.edu bheald@berkeley.edu 0 0 0 0 0 0 0 0 19 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
"Mitosis: "Mitosis: 0 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP B_TIMEXCCP 
Spindle Spindle 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP CC O
Assembly Assembly 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP DT O
Function," Function," 1 0 0 0 1 0 0 0 10 0 NNP CC NNP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 CC NNP DT NN IN O
conference conference 0 0 0 0 0 0 0 0 10 0 NNP DT NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
honor honor 0 0 0 0 0 0 0 0 5 0 NN IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNP O
Dr. Dr. 1 0 0 0 0 0 0 0 3 0 NN IN NNP NNP NNP O
Bill Bill 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNP O
R. R. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP VBD O
Brinkley, Brinkley, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP VBD RP O
brought brought 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD RP JJ O
together together 0 0 0 0 0 0 0 0 8 0 NNP VBD RP JJ NNS O
many many 0 0 0 0 0 0 0 0 4 0 VBD RP JJ NNS TO O
researchers researchers 0 0 0 0 0 0 0 0 11 0 RP JJ NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO VB NN O
discuss discuss 0 0 0 0 0 0 0 0 7 0 NNS TO VB NN IN O
progress progress 0 0 0 0 0 0 0 0 8 0 TO VB NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VB NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN CC O
field field 0 0 0 0 0 0 0 0 5 0 IN DT NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC VB DT O
celebrate celebrate 0 0 0 0 0 0 0 0 9 0 NN CC VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CC VB DT JJ NNS O
many many 0 0 0 0 0 0 0 0 4 0 VB DT JJ NNS WDT O
contributions contributions 0 0 0 0 0 0 0 0 13 0 DT JJ NNS WDT NNP O
that that 0 0 0 0 0 0 0 0 4 0 JJ NNS WDT NNP NNP O
Dr. Dr. 1 0 0 0 0 0 0 0 3 0 NNS WDT NNP NNP VBZ O
Brinkley Brinkley 1 0 0 0 0 0 0 0 8 0 WDT NNP NNP VBZ NNP O
has has 0 0 0 0 0 0 0 0 3 0 NNP NNP VBZ NNP NNP O
made. made. 0 0 0 0 0 0 0 0 5 0 NNP VBZ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 VBZ NNP NNP CD JJ O
17681129 17681129 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Immunoelectronmicroscopy Immunoelectronmicroscopy 1 0 0 0 0 0 0 0 24 0 NONE NONE NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NONE NNP IN NN NNP O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 NNP IN NN NNP NNP B_TIMEXCCP
chromosomes. chromosomes. 0 0 0 0 0 0 0 0 12 0 IN NN NNP NNP NNP O
Bosman Bosman 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP NNP O
FT, FT, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Nakane Nakane 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
PK. PK. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NN IN O
method method 0 0 0 0 0 0 0 0 6 0 NNP NNP NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
preparation preparation 0 0 0 0 0 0 0 0 11 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
ultrathin ultrathin 0 0 0 0 0 0 0 0 9 0 NN IN NN NNS IN O
sections sections 0 0 0 0 0 0 0 0 8 0 IN NN NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NNS O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 NNS IN NN NNS VBZ B_TIMEXCCP
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 IN NN NNS VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 NN NNS VBZ NNP DT O
described. described. 0 0 0 0 0 0 0 0 10 0 NNS VBZ NNP DT NN O
This This 1 0 0 0 0 0 0 0 4 0 VBZ NNP DT NN VBD O
method method 0 0 0 0 0 0 0 0 6 0 NNP DT NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD VBN TO O
applied applied 0 0 0 0 0 0 0 0 7 0 NN VBD VBN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 VBN TO JJ NN NN O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 TO JJ NN NN WDT B_TIMEXCCP
chromosomes, chromosomes, 0 0 0 0 1 0 0 0 12 0 JJ NN NN WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NN WDT VBD RB VBN O
immunocytochemically immunocytochemically 0 0 0 0 0 0 0 0 20 0 WDT VBD RB VBN IN O
stained stained 0 0 0 0 0 0 0 0 7 0 VBD RB VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN JJ CC O
anti-DNA anti-DNA 0 0 1 0 0 0 0 0 8 0 VBN IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NN O
anti-ribonucleoprotein anti-ribonucleoprotein 0 0 1 0 0 0 0 0 22 0 JJ CC JJ NN VBD O
antibodies, antibodies, 0 0 0 0 1 0 0 0 11 0 CC JJ NN VBD IN O
derived derived 0 0 0 0 0 0 0 0 7 0 JJ NN VBD IN NNS O
from from 0 0 0 0 0 0 0 0 4 0 NN VBD IN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 VBD IN NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN JJ NNP O
auto-immune auto-immune 0 0 1 0 0 0 0 0 11 0 NNS IN JJ NNP NNP O
disease. disease. 0 0 0 0 0 0 0 0 8 0 IN JJ NNP NNP VBD O
Conventionally Conventionally 1 0 0 0 0 0 0 0 14 0 JJ NNP NNP VBD NN O
prepared prepared 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD NN NNS O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 NNP VBD NN NNS IN B_TIMEXCCP
spreads spreads 0 0 0 0 0 0 0 0 7 0 VBD NN NNS IN RB O
as as 0 0 0 0 0 0 0 0 2 0 NN NNS IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NNS IN RB IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN JJ NNS O
cytocentrifuge cytocentrifuge 0 0 0 0 0 0 0 0 14 0 RB IN JJ NNS IN O
preparations preparations 0 0 0 0 0 0 0 0 12 0 IN JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NNS O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NNS IN NN NNS VBD O
suspensions suspensions 0 0 0 0 0 0 0 0 11 0 IN NN NNS VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD NNP NNP O
studied. studied. 0 0 0 0 0 0 0 0 8 0 NNS VBD NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 VBD NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
indicate indicate 0 0 0 0 0 0 0 0 8 0 NNP NNS VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NN IN O
ultrastructure ultrastructure 0 0 0 0 0 0 0 0 14 0 IN DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS CC O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 NN IN NNS CC DT O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS CC DT NN IN O
immunoreactivity immunoreactivity 0 0 0 0 0 0 0 0 16 0 CC DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
chromosomal chromosomal 0 0 0 0 0 0 0 0 11 0 NN IN JJ NNS VBP O
constituents constituents 0 0 0 0 0 0 0 0 12 0 IN JJ NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 JJ NNS VBP VBN IN O
influenced influenced 0 0 0 0 0 0 0 0 10 0 NNS VBP VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBP VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
applied applied 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN NNP O
preparation preparation 0 0 0 0 0 0 0 0 11 0 DT JJ NN NNP NNP O
methods. methods. 0 0 0 0 0 0 0 0 8 0 JJ NN NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NN IN O
comparison comparison 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNP NN IN JJ NN O
whole whole 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NN O
mount mount 0 0 0 0 0 0 0 0 5 0 IN JJ NN NN NN O
preparations, preparations, 0 0 0 0 1 0 0 0 13 0 JJ NN NN NN NNS O
ultrathin ultrathin 0 0 0 0 0 0 0 0 9 0 NN NN NN NNS IN O
sections sections 0 0 0 0 0 0 0 0 8 0 NN NN NNS IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN VBN NNS O
immunostained immunostained 0 0 0 0 0 0 0 0 13 0 NNS IN VBN NNS VBP O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 IN VBN NNS VBP JJR O
allow allow 0 0 0 0 0 0 0 0 5 0 VBN NNS VBP JJR NN O
higher higher 0 0 0 0 0 0 0 0 6 0 NNS VBP JJR NN CC O
resolution resolution 0 0 0 0 0 0 0 0 10 0 VBP JJR NN CC JJR O
and and 0 0 0 0 0 0 0 0 3 0 JJR NN CC JJR NN O
more more 0 0 0 0 0 0 0 0 4 0 NN CC JJR NN NN O
precise precise 0 0 0 0 0 0 0 0 7 0 CC JJR NN NN IN O
localization localization 0 0 0 0 0 0 0 0 12 0 JJR NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNS O
immunoreactive immunoreactive 0 0 0 0 0 0 0 0 14 0 NN IN JJ NNS IN O
sites sites 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN DT O
within within 0 0 0 0 0 0 0 0 6 0 JJ NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NNP O
chromosomal chromosomal 0 0 0 0 0 0 0 0 11 0 IN DT JJ NNP NNP O
structure. structure. 0 0 0 0 0 0 0 0 10 0 DT JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
6179900 6179900 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
[Dynamics [Dynamics 0 0 0 0 0 0 0 0 9 0 NONE NONE NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NONE NNS IN NN NNS O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NNS IN NN NNS IN O
rearrangements rearrangements 0 0 0 0 0 0 0 0 14 0 IN NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
meiotic meiotic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN IN O
prophase prophase 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NN B_TIMEXCCP
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNP O
human human 0 0 0 0 0 0 0 0 5 0 NN IN NN NNP NNP O
oogenesis]. oogenesis]. 0 0 0 0 0 0 0 0 11 0 IN NN NNP NNP IN O
[Article [Article 0 0 0 0 0 0 0 0 8 0 NN NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Russian] Russian] 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Kurilo Kurilo 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
LF. LF. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP JJ O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP JJ NN O
quantitative quantitative 0 0 0 0 0 0 0 0 12 0 NNP NNP JJ NN IN O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NNP JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
germ germ 0 0 0 0 0 0 0 0 4 0 NN IN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN NN NN NN NN O
population population 0 0 0 0 0 0 0 0 10 0 NN NN NN NN IN O
development development 0 0 0 0 0 0 0 0 11 0 NN NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN NN NN NN O
female female 0 0 0 0 0 0 0 0 6 0 IN NN NN NN NNS O
embryonic embryonic 0 0 0 0 0 0 0 0 9 0 NN NN NN NNS VBZ O
gonads gonads 0 0 0 0 0 0 0 0 6 0 NN NN NNS VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NN NNS VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNS VBZ VBN VBN -NONE- O
carried carried 0 0 0 0 0 0 0 0 7 0 VBZ VBN VBN -NONE- IN O
out, out, 0 0 0 0 1 0 0 0 4 0 VBN VBN -NONE- IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBN -NONE- IN JJ NN O
special special 0 0 0 0 0 0 0 0 7 0 -NONE- IN JJ NN VBG O
attention attention 0 0 0 0 0 0 0 0 9 0 IN JJ NN VBG VBN O
being being 0 0 0 0 0 0 0 0 5 0 JJ NN VBG VBN TO O
paid paid 0 0 0 0 0 0 0 0 4 0 NN VBG VBN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 VBG VBN TO JJ NNS O
chromosomal chromosomal 0 0 0 0 0 0 0 0 11 0 VBN TO JJ NNS IN O
changes changes 0 0 0 0 0 0 0 0 7 0 TO JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
prophase prophase 0 0 0 0 0 0 0 0 8 0 IN DT NN IN DT B_TIMEXCCP
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ JJ O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ JJ NNP O
meiotic meiotic 0 0 0 0 0 0 0 0 7 0 DT JJ JJ NNP CD O
division. division. 0 0 0 0 0 0 0 0 9 0 JJ JJ NNP CD NNS O
97 97 0 0 0 0 0 0 1 1 2 0 JJ NNP CD NNS IN O
embryos embryos 0 0 0 0 0 0 0 0 7 0 NNP CD NNS IN DT O
at at 0 0 0 0 0 0 0 0 2 0 CD NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
age age 0 0 0 0 0 0 0 0 3 0 IN DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD TO O
6 6 0 0 0 0 0 0 1 1 1 0 NN IN CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 IN CD TO CD NNS O
40 40 0 0 0 0 0 0 1 1 2 0 CD TO CD NNS VBD O
weeks weeks 0 0 0 0 0 0 0 0 5 0 TO CD NNS VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 CD NNS VBD NNP NNP O
investigated. investigated. 0 0 0 0 0 0 0 0 13 0 NNS VBD NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 VBD NNP NNP NN IN O
morphology morphology 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN IN O
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 NN IN NN IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NN O
different different 0 0 0 0 0 0 0 0 9 0 NN IN JJ NN NNS O
prophase prophase 0 0 0 0 0 0 0 0 8 0 IN JJ NN NNS VBZ B_TIMEXCCP
stages stages 0 0 0 0 0 0 0 0 6 0 JJ NN NNS VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN NNS VBZ JJ JJ O
described, described, 0 0 0 0 1 0 0 0 10 0 NNS VBZ JJ JJ NNS O
temporal temporal 0 0 0 0 0 0 0 0 8 0 VBZ JJ JJ NNS IN O
dynamics dynamics 0 0 0 0 0 0 0 0 8 0 JJ JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT DT O
all all 0 0 0 0 0 0 0 0 3 0 NNS IN DT DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 IN DT DT NNS VBZ O
stages stages 0 0 0 0 0 0 0 0 6 0 DT DT NNS VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 DT NNS VBZ JJ NNS O
presented, presented, 0 0 0 0 1 0 0 0 10 0 NNS VBZ JJ NNS IN O
dynamics dynamics 0 0 0 0 0 0 0 0 8 0 VBZ JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NN O
germ germ 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN NN NN NN VBZ O
degeneration degeneration 0 0 0 0 0 0 0 0 12 0 NN NN NN VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ NNP NNP O
outlined. outlined. 0 0 0 0 0 0 0 0 9 0 NN VBZ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 VBZ NNP NNP CD JJ O
7385359 7385359 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NN NN O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 NONE DT NN NN IN B_TIMEXCCP
cytotoxicity cytotoxicity 0 0 0 0 0 0 0 0 12 0 DT NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
camptothecin. camptothecin. 0 0 0 0 0 0 0 0 13 0 NN IN NNP NNP NNP O
Del Del 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
Bino Bino 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lassota Lassota 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Darzynkiewicz Darzynkiewicz 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
Z. Z. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Institute, Institute, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
New New 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
York York 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
College, College, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Elmsford Elmsford 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
10523. 10523. 0 0 0 0 0 0 0 1 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NN PRP O
topoisomerase topoisomerase 0 0 0 0 0 0 0 0 13 0 NNP NNP NN PRP NN O
I I 1 1 0 0 0 0 0 0 1 0 NNP NN PRP NN NN O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 NN PRP NN NN NN O
camptothecin camptothecin 0 0 0 0 0 0 0 0 12 0 PRP NN NN NN VBZ O
(CAM) (CAM) 0 1 0 0 0 0 0 0 5 0 NN NN NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ RB JJ O
selectively selectively 0 0 0 0 0 0 0 0 11 0 NN VBZ RB JJ TO O
cytotoxic cytotoxic 0 0 0 0 0 0 0 0 9 0 VBZ RB JJ TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 RB JJ TO JJ NNS O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 JJ TO JJ NNS IN B_TIMEXCCP
cells cells 0 0 0 0 0 0 0 0 5 0 TO JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ CC O
HL-60, HL-60, 1 1 1 0 1 0 0 1 6 0 NNS IN JJ CC DT O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC DT JJ O
some some 0 0 0 0 0 0 0 0 4 0 JJ CC DT JJ JJ O
other other 0 0 0 0 0 0 0 0 5 0 CC DT JJ JJ JJ O
myelogenous myelogenous 0 0 0 0 0 0 0 0 11 0 DT JJ JJ JJ NNP O
leukemic leukemic 0 0 0 0 0 0 0 0 8 0 JJ JJ JJ NNP NNP O
lines. lines. 0 0 0 0 0 0 0 0 6 0 JJ JJ NNP NNP RB O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP RB VBZ O
early early 0 0 0 0 0 0 0 0 5 0 NNP NNP RB VBZ IN O
effects effects 0 0 0 0 0 0 0 0 7 0 NNP RB VBZ IN NN O
of of 0 0 0 0 0 0 0 0 2 0 RB VBZ IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBZ IN NN NN TO O
exposure exposure 0 0 0 0 0 0 0 0 8 0 IN NN NN TO CD O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO CD JJ O
0.05-0.2 0.05-0.2 0 0 1 0 0 0 0 1 8 0 NN TO CD JJ NNP O
micrograms/ml micrograms/ml 0 0 0 1 0 0 0 0 13 0 TO CD JJ NNP VBP O
CAM CAM 1 1 0 0 0 0 0 0 3 0 CD JJ NNP VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 JJ NNP VBP VBN IN O
seen seen 0 0 0 0 0 0 0 0 4 0 NNP VBP VBN IN CD O
after after 0 0 0 0 0 0 0 0 5 0 VBP VBN IN CD NN O
2 2 0 0 0 0 0 0 1 1 1 0 VBN IN CD NN IN O
h; h; 0 0 0 0 0 0 0 0 2 0 IN CD NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 CD NN IN DT NN O
that that 0 0 0 0 0 0 0 0 4 0 NN IN DT NN DT O
time time 0 0 0 0 0 0 0 0 4 0 IN DT NN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 DT NN DT JJ NN O
progressive progressive 0 0 0 0 0 0 0 0 11 0 NN DT JJ NN IN O
degradation degradation 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP IN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN IN NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN IN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 NN IN JJ NNS VBZ B_TIMEXCCP
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 JJ NNS VBZ NNP DT O
initiated. initiated. 0 0 0 0 0 0 0 0 10 0 NNS VBZ NNP DT NN O
The The 1 0 0 0 0 0 0 0 3 0 VBZ NNP DT NN NNS O
degradation degradation 0 0 0 0 0 0 0 0 11 0 NNP DT NN NNS IN O
manifests manifests 0 0 0 0 0 0 0 0 9 0 DT NN NNS IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ IN O
"pulverization" "pulverization" 0 0 0 0 0 0 0 0 15 0 NNS IN JJ IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN JJ IN NN VBN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 JJ IN NN VBN IN O
followed followed 0 0 0 0 0 0 0 0 8 0 IN NN VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN VBN IN NN IN O
coalescence coalescence 0 0 0 0 0 0 0 0 11 0 VBN IN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNS O
fine fine 0 0 0 0 0 0 0 0 4 0 IN DT NN NNS CC O
granules granules 0 0 0 0 0 0 0 0 8 0 DT NN NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC JJ NNP O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 NNS CC JJ NNP NNP O
disintegration. disintegration. 0 0 0 0 0 0 0 0 15 0 CC JJ NNP NNP CD O
Between Between 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP CD CC O
2 2 0 0 0 0 0 0 1 1 1 0 NNP NNP CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NNP CD CC CD NN O
6 6 0 0 0 0 0 0 1 1 1 0 CD CC CD NN IN O
h h 0 0 0 0 0 0 0 0 1 0 CC CD NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN NNP DT O
treatment, treatment, 0 0 0 0 1 0 0 0 10 0 NN IN NNP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 IN NNP DT NN IN O
loss loss 0 0 0 0 0 0 0 0 4 0 NNP DT NN IN RB O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN RB CD O
about about 0 0 0 0 0 0 0 0 5 0 NN IN RB CD IN O
30-70% 30-70% 0 0 1 0 0 0 0 1 6 0 IN RB CD IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 RB CD IN NNP IN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 CD IN NNP IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 IN NNP IN JJ NN O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 NNP IN JJ NN VBZ B_TIMEXCCP
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 IN JJ NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ VBN IN O
detected detected 0 0 0 0 0 0 0 0 8 0 NN VBZ VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN NN NNP O
flow flow 0 0 0 0 0 0 0 0 4 0 VBN IN NN NNP DT O
cytometry. cytometry. 0 0 0 0 0 0 0 0 10 0 IN NN NNP DT CD O
A A 1 1 0 0 0 0 0 0 1 0 NN NNP DT CD NN O
10-min 10-min 0 0 1 0 0 0 0 1 6 0 NNP DT CD NN IN O
pulse pulse 0 0 0 0 0 0 0 0 5 0 DT CD NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN NNP VBZ O
CAM CAM 1 1 0 0 0 0 0 0 3 0 NN IN NNP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ JJ TO O
adequate adequate 0 0 0 0 0 0 0 0 8 0 NNP VBZ JJ TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO NN NN O
trigger trigger 0 0 0 0 0 0 0 0 7 0 JJ TO NN NN NNP O
subsequent subsequent 0 0 0 0 0 0 0 0 10 0 TO NN NN NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN NN NNP NNP NNP O
degradation. degradation. 0 0 0 0 0 0 0 0 12 0 NN NNP NNP NNP NN O
Agarose Agarose 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NN NN O
gel gel 0 0 0 0 0 0 0 0 3 0 NNP NNP NN NN IN O
electrophoresis electrophoresis 0 0 0 0 0 0 0 0 15 0 NNP NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP IN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN IN NNP IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 IN NNP IN JJ NNS O
CAM-treated CAM-treated 1 0 1 0 0 0 0 0 11 0 NNP IN JJ NNS NNS O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS NNS DT O
reveals reveals 0 0 0 0 0 0 0 0 7 0 JJ NNS NNS DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS NNS DT JJ NN O
typical typical 0 0 0 0 0 0 0 0 7 0 NNS DT JJ NN NN O
nucleosome nucleosome 0 0 0 0 0 0 0 0 10 0 DT JJ NN NN NNS O
core core 0 0 0 0 0 0 0 0 4 0 JJ NN NN NNS -NONE- O
particles particles 0 0 0 0 0 0 0 0 9 0 NN NN NNS -NONE- JJ O
"ladder," "ladder," 0 0 0 0 1 0 0 0 9 0 NN NNS -NONE- JJ IN O
suggestive suggestive 0 0 0 0 0 0 0 0 10 0 NNS -NONE- JJ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 -NONE- JJ IN JJ NN O
preferential preferential 0 0 0 0 0 0 0 0 12 0 JJ IN JJ NN IN O
degradation degradation 0 0 0 0 0 0 0 0 11 0 IN JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNP O
spacer spacer 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP NNP O
DNA. DNA. 1 1 0 0 0 0 0 0 4 0 IN NN NNP NNP JJ O
Despite Despite 1 0 0 0 0 0 0 0 7 0 NN NNP NNP JJ NN O
extensive extensive 0 0 0 0 0 0 0 0 9 0 NNP NNP JJ NN IN O
loss loss 0 0 0 0 0 0 0 0 4 0 NNP JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP CC O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN IN NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 NNP CC JJ NN DT O
disintegration, disintegration, 0 0 0 0 1 0 0 0 15 0 CC JJ NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN DT NN NN IN O
membrane membrane 0 0 0 0 0 0 0 0 8 0 DT NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
CAM-treated CAM-treated 1 0 1 0 0 0 0 0 11 0 NN IN JJ NN NNS O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 IN JJ NN NNS VBZ B_TIMEXCCP
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS VBZ NN O
remains remains 0 0 0 0 0 0 0 0 7 0 NN NNS VBZ NN IN O
intact intact 0 0 0 0 0 0 0 0 6 0 NNS VBZ NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VBZ NN IN JJ JJ O
several several 0 0 0 0 0 0 0 0 7 0 NN IN JJ JJ NN O
hours, hours, 0 0 0 0 1 0 0 0 6 0 IN JJ JJ NN NN O
excluding excluding 0 0 0 0 0 0 0 0 9 0 JJ JJ NN NN NN O
trypan trypan 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN CC O
blue blue 0 0 0 0 0 0 0 0 4 0 NN NN NN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 NN NN CC NN NNP O
propidium propidium 0 0 0 0 0 0 0 0 9 0 NN CC NN NNP NNP O
iodide. iodide. 0 0 0 0 0 0 0 0 7 0 CC NN NNP NNP VBD O
Mitochondria, Mitochondria, 1 0 0 0 1 0 0 0 13 0 NN NNP NNP VBD IN O
assayed assayed 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD IN PRP$ O
for for 0 0 0 0 0 0 0 0 3 0 NNP VBD IN PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 VBD IN PRP$ NN TO O
ability ability 0 0 0 0 0 0 0 0 7 0 IN PRP$ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 PRP$ NN TO VB DT O
maintain maintain 0 0 0 0 0 0 0 0 8 0 NN TO VB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT NN NN O
transmembrane transmembrane 0 0 0 0 0 0 0 0 13 0 VB DT NN NN NN O
potential potential 0 0 0 0 0 0 0 0 9 0 DT NN NN NN CD O
(rhodamine (rhodamine 0 0 0 0 0 0 0 0 10 0 NN NN NN CD NN O
123 123 0 0 0 0 0 0 1 1 3 0 NN NN CD NN IN O
retention), retention), 0 0 0 0 1 0 0 0 11 0 NN CD NN IN RB O
as as 0 0 0 0 0 0 0 0 2 0 CD NN IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NN IN RB IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT JJ NN O
lysosomal lysosomal 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN NN O
proton proton 0 0 0 0 0 0 0 0 6 0 DT JJ NN NN JJ O
pump pump 0 0 0 0 0 0 0 0 4 0 JJ NN NN JJ IN O
(probed (probed 0 0 0 0 0 0 0 0 7 0 NN NN JJ IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NN JJ IN JJ NN O
supravital supravital 0 0 0 0 0 0 0 0 10 0 JJ IN JJ NN IN O
uptake uptake 0 0 0 0 0 0 0 0 6 0 IN JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
acridine acridine 0 0 0 0 0 0 0 0 8 0 NN IN NN NN RB O
orange) orange) 0 0 0 0 0 0 0 0 7 0 IN NN NN RB VB O
also also 0 0 0 0 0 0 0 0 4 0 NN NN RB VB JJ O
remain remain 0 0 0 0 0 0 0 0 6 0 NN RB VB JJ IN O
unchanged unchanged 0 0 0 0 0 0 0 0 9 0 RB VB JJ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VB JJ IN DT NNP O
these these 0 0 0 0 0 0 0 0 5 0 JJ IN DT NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN DT NNP NNP VBZ O
G1 G1 1 1 0 0 0 0 0 1 2 0 DT NNP NNP VBZ VBP B_TIMEXCCP
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNP VBZ VBP JJ TO O
refractory refractory 0 0 0 0 0 0 0 0 10 0 VBZ VBP JJ TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 VBP JJ TO NNP IN O
CAM CAM 1 1 0 0 0 0 0 0 3 0 JJ TO NNP IN DT O
under under 0 0 0 0 0 0 0 0 5 0 TO NNP IN DT NNP O
these these 0 0 0 0 0 0 0 0 5 0 NNP IN DT NNP NNP O
conditions. conditions. 0 0 0 0 0 0 0 0 11 0 IN DT NNP NNP IN O
Synchronization Synchronization 1 0 0 0 0 0 0 0 15 0 DT NNP NNP IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP IN NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase NNS IN NNP NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN NNP NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NNS O
aphidicolin aphidicolin 0 0 0 0 0 0 0 0 11 0 NN IN NN NNS DT O
increases increases 0 0 0 0 0 0 0 0 9 0 IN NN NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NNS DT NN IN O
sensitivity sensitivity 0 0 0 0 0 0 0 0 11 0 NNS DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
whole whole 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN TO O
population population 0 0 0 0 0 0 0 0 10 0 JJ NN NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO NNP DT O
CAM. CAM. 1 1 0 0 0 0 0 0 4 0 NN TO NNP DT NNS O
The The 1 0 0 0 0 0 0 0 3 0 TO NNP DT NNS VBP O
data data 0 0 0 0 0 0 0 0 4 0 NNP DT NNS VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 DT NNS VBP IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NNP CC O
CAM CAM 1 1 0 0 0 0 0 0 3 0 VBP IN NNP CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 IN NNP CC JJ NN O
other other 0 0 0 0 0 0 0 0 5 0 NNP CC JJ NN PRP O
topoisomerase topoisomerase 0 0 0 0 0 0 0 0 13 0 CC JJ NN PRP VBZ O
I I 1 1 0 0 0 0 0 0 1 0 JJ NN PRP VBZ MD O
inhibitors inhibitors 0 0 0 0 0 0 0 0 10 0 NN PRP VBZ MD VB O
may may 0 0 0 0 0 0 0 0 3 0 PRP VBZ MD VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 VBZ MD VB JJ IN O
effective effective 0 0 0 0 0 0 0 0 9 0 MD VB JJ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VB JJ IN DT JJ O
some some 0 0 0 0 0 0 0 0 4 0 JJ IN DT JJ NN O
myelogenous myelogenous 0 0 0 0 0 0 0 0 11 0 IN DT JJ NN RB O
leukemias, leukemias, 0 0 0 0 1 0 0 0 10 0 DT JJ NN RB IN O
especially especially 0 0 0 0 0 0 0 0 10 0 JJ NN RB IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN RB IN NN IN O
combination combination 0 0 0 0 0 0 0 0 11 0 RB IN NN IN NNS O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN NNS VBG O
treatments treatments 0 0 0 0 0 0 0 0 10 0 NN IN NNS VBG NNS O
synchronizing synchronizing 0 0 0 0 0 0 0 0 13 0 IN NNS VBG NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNS VBG NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBG NNS IN NNP NNP O
S S 1 1 0 0 0 0 0 0 1 0 NNS IN NNP NNP NNP B_TIMEXCCP
phase. phase. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNP NNP NNP CD JJ O
1995300 1995300 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Asymmetric Asymmetric 1 0 0 0 0 0 0 0 10 0 NONE NONE NNP NN IN O
division division 0 0 0 0 0 0 0 0 8 0 NONE NNP NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NNS O
fucoid fucoid 0 0 0 0 0 0 0 0 6 0 NN IN NN NNS VBZ O
zygotes zygotes 0 0 0 0 0 0 0 0 7 0 IN NN NNS VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN NNS VBZ VBN IN O
positioned positioned 0 0 0 0 0 0 0 0 10 0 NNS VBZ VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN NN NNP O
telophase telophase 0 0 0 0 0 0 0 0 9 0 VBN IN NN NNP NNP B_TIMEXCCP
nuclei. nuclei. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NNP NNP O
Bisgrove Bisgrove 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NNP NNP O
SR, SR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Henderson Henderson 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
DC, DC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Kropf Kropf 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
DL. DL. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Utah, Utah, 1 0 0 0 1 0 0 0 5 0 NNP IN NNP NNP NNP O
Salt Salt 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNP O
Lake Lake 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
City, City, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP CD O
Utah Utah 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP CD NNP O
84112-0840, 84112-0840, 0 0 1 0 1 0 0 1 11 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
bisgrove@biology.utah.edu bisgrove@biology.utah.edu 0 0 0 0 0 0 0 0 25 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP JJ NNS O
relative relative 0 0 0 0 0 0 0 0 8 0 NNP NNP JJ NNS IN O
contributions contributions 0 0 0 0 0 0 0 0 13 0 NNP JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN CC O
polarity polarity 0 0 0 0 0 0 0 0 8 0 IN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 NN CC JJ NN IN O
position position 0 0 0 0 0 0 0 0 8 0 CC JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN DT O
specifying specifying 0 0 0 0 0 0 0 0 10 0 NN IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN IN O
plane plane 0 0 0 0 0 0 0 0 5 0 NN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
asymmetric asymmetric 0 0 0 0 0 0 0 0 10 0 NN IN JJ NN IN O
division division 0 0 0 0 0 0 0 0 8 0 IN JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNS O
fucoid fucoid 0 0 0 0 0 0 0 0 6 0 NN IN NN NNS VBD O
zygotes zygotes 0 0 0 0 0 0 0 0 7 0 IN NN NNS VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD NNP NNP O
investigated. investigated. 0 0 0 0 0 0 0 0 13 0 NNS VBD NNP NNP VBZ O
In In 1 0 0 0 0 0 0 0 2 0 VBD NNP NNP VBZ VBG O
zygotes zygotes 0 0 0 0 0 0 0 0 7 0 NNP NNP VBZ VBG NN O
developing developing 0 0 0 0 0 0 0 0 10 0 NNP VBZ VBG NN NN O
normally, normally, 0 0 0 0 1 0 0 0 9 0 VBZ VBG NN NN NN O
telophase telophase 0 0 0 0 0 0 0 0 9 0 VBG NN NN NN VBD B_TIMEXCCP
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 NN NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN JJ O
positioned positioned 0 0 0 0 0 0 0 0 10 0 NN VBD VBN JJ TO O
parallel parallel 0 0 0 0 0 0 0 0 8 0 VBD VBN JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBN JJ TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ TO DT JJ NN O
polar polar 0 0 0 0 0 0 0 0 5 0 TO DT JJ NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 DT JJ NN NN CC O
axis, axis, 0 0 0 0 1 0 0 0 5 0 JJ NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN NN O
division division 0 0 0 0 0 0 0 0 8 0 CC DT NN NN VBD O
plane plane 0 0 0 0 0 0 0 0 5 0 DT NN NN VBD DT O
bisected bisected 0 0 0 0 0 0 0 0 8 0 NN NN VBD DT NNP O
both both 0 0 0 0 0 0 0 0 4 0 NN VBD DT NNP NNP O
axes. axes. 0 0 0 0 0 0 0 0 5 0 VBD DT NNP NNP NN O
To To 1 0 0 0 0 0 0 0 2 0 DT NNP NNP NN NN O
assess assess 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NN NN O
division division 0 0 0 0 0 0 0 0 8 0 NNP NN NN NN NN O
plane plane 0 0 0 0 0 0 0 0 5 0 NN NN NN NN DT O
specification, specification, 0 0 0 0 1 0 0 0 14 0 NN NN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NN IN O
colinearity colinearity 0 0 0 0 0 0 0 0 11 0 NN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ CC O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 IN DT JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC NN NNS O
growth growth 0 0 0 0 0 0 0 0 6 0 JJ CC NN NNS VBD O
axes axes 0 0 0 0 0 0 0 0 4 0 CC NN NNS VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NNS VBD VBN IN O
uncoupled uncoupled 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 VBN IN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN JJ NNP O
pharmacological pharmacological 0 0 0 0 0 0 0 0 15 0 NN IN JJ NNP NNP O
agents. agents. 0 0 0 0 0 0 0 0 7 0 IN JJ NNP NNP NNS O
Spatial Spatial 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP NNS IN O
correlations correlations 0 0 0 0 0 0 0 0 12 0 NNP NNP NNS IN DT O
between between 0 0 0 0 0 0 0 0 7 0 NNP NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 IN DT NN NN NN O
axis, axis, 0 0 0 0 1 0 0 0 5 0 DT NN NN NN NN O
telophase telophase 0 0 0 0 0 0 0 0 9 0 NN NN NN NN CC B_TIMEXCCP
nuclei, nuclei, 0 0 0 0 1 0 0 0 7 0 NN NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN NN O
division division 0 0 0 0 0 0 0 0 8 0 CC DT NN NN VBD O
plane plane 0 0 0 0 0 0 0 0 5 0 DT NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN IN O
analyzed analyzed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT VBN NNP O
treated treated 0 0 0 0 0 0 0 0 7 0 IN DT VBN NNP NNP O
zygotes. zygotes. 0 0 0 0 0 0 0 0 8 0 DT VBN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 VBN NNP NNP DT NNP O
all all 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNP NN O
cases, cases, 0 0 0 0 1 0 0 0 6 0 NNP DT NNP NN VBD O
cytokinesis cytokinesis 0 0 0 0 0 0 0 0 11 0 DT NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN NN O
oriented oriented 0 0 0 0 0 0 0 0 8 0 NN VBD VBN NN TO O
transverse transverse 0 0 0 0 0 0 0 0 10 0 VBD VBN NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBN NN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT NN JJ O
telophase telophase 0 0 0 0 0 0 0 0 9 0 TO DT NN JJ NN telophase
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 DT NN JJ NN CC telophase
array array 0 0 0 0 0 0 0 0 5 0 NN JJ NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBD JJR O
was was 0 0 0 0 0 0 0 0 3 0 NN CC VBD JJR RB O
less less 0 0 0 0 0 0 0 0 4 0 CC VBD JJR RB VBN O
well well 0 0 0 0 0 0 0 0 4 0 VBD JJR RB VBN IN O
aligned aligned 0 0 0 0 0 0 0 0 7 0 JJR RB VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NNP O
growth growth 0 0 0 0 0 0 0 0 6 0 IN DT NN NNP NNP O
axis. axis. 0 0 0 0 0 0 0 0 5 0 DT NN NNP NNP NN O
Telophase Telophase 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NN RB B_TIMEXCCP
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 NNP NNP NN RB VBN O
also also 0 0 0 0 0 0 0 0 4 0 NNP NN RB VBN DT O
played played 0 0 0 0 0 0 0 0 6 0 NN RB VBN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 RB VBN DT JJ NN O
predominant predominant 0 0 0 0 0 0 0 0 11 0 VBN DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN DT O
positioning positioning 0 0 0 0 0 0 0 0 11 0 NN IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN NN O
division division 0 0 0 0 0 0 0 0 8 0 NN DT NN NN IN O
plane plane 0 0 0 0 0 0 0 0 5 0 DT NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNP O
polyspermic polyspermic 0 0 0 0 0 0 0 0 11 0 NN IN JJ NNP NNP O
zygotes. zygotes. 0 0 0 0 0 0 0 0 8 0 IN JJ NNP NNP IN O
Microtubules Microtubules 1 0 0 0 0 0 0 0 12 0 JJ NNP NNP IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN NN O
telophase telophase 0 0 0 0 0 0 0 0 9 0 IN DT NN NN VBD B_TIMEXCCP
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 DT NN NN VBD IN O
interdigitated interdigitated 0 0 0 0 0 0 0 0 14 0 NN NN VBD IN DT O
throughout throughout 0 0 0 0 0 0 0 0 10 0 NN VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN IN O
plane plane 0 0 0 0 0 0 0 0 5 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
subsequent subsequent 0 0 0 0 0 0 0 0 10 0 NN IN NN NN CC O
cytokinesis, cytokinesis, 0 0 0 0 1 0 0 0 12 0 IN NN NN CC PRP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NN CC PRP VBP IN O
speculate speculate 0 0 0 0 0 0 0 0 9 0 CC PRP VBP IN PRP O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN PRP VBP O
they they 0 0 0 0 0 0 0 0 4 0 VBP IN PRP VBP DT O
specify specify 0 0 0 0 0 0 0 0 7 0 IN PRP VBP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBP DT NN NNP O
division division 0 0 0 0 0 0 0 0 8 0 VBP DT NN NNP NNP O
plane. plane. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP NNS O
Morphological Morphological 1 0 0 0 0 0 0 0 13 0 NN NNP NNP NNS IN O
markers markers 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
division division 0 0 0 0 0 0 0 0 8 0 IN DT NN NN VBD O
plane plane 0 0 0 0 0 0 0 0 5 0 DT NN NN VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD RB VBN O
not not 0 0 0 0 0 0 0 0 3 0 NN VBD RB VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 VBD RB VBN IN NNP O
before before 0 0 0 0 0 0 0 0 6 0 RB VBN IN NNP DT telophase
telophase; telophase; 0 0 0 0 0 0 0 0 10 0 VBN IN NNP DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 IN NNP DT JJS NN O
earliest earliest 0 0 0 0 0 0 0 0 8 0 NNP DT JJS NN NN O
division division 0 0 0 0 0 0 0 0 8 0 DT JJS NN NN VBD O
marker marker 0 0 0 0 0 0 0 0 6 0 JJS NN NN VBD VBD O
detected detected 0 0 0 0 0 0 0 0 8 0 NN NN VBD VBD DT O
was was 0 0 0 0 0 0 0 0 3 0 NN VBD VBD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBD VBD DT NN IN O
plate plate 0 0 0 0 0 0 0 0 5 0 VBD DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
actin actin 0 0 0 0 0 0 0 0 5 0 NN IN NN IN VBN O
that that 0 0 0 0 0 0 0 0 4 0 IN NN IN VBN IN O
assembled assembled 0 0 0 0 0 0 0 0 9 0 NN IN VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
zone zone 0 0 0 0 0 0 0 0 4 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
microtubule microtubule 0 0 0 0 0 0 0 0 11 0 NN IN NN NN RB O
overlap overlap 0 0 0 0 0 0 0 0 7 0 IN NN NN RB IN O
late late 0 0 0 0 0 0 0 0 4 0 NN NN RB IN NNP 0
in in 0 0 0 0 0 0 0 0 2 0 NN RB IN NNP NNP late
telophase. telophase. 0 0 0 0 0 0 0 0 10 0 RB IN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNS VBP O
findings findings 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNS VBP JJ IN O
consistent consistent 0 0 0 0 0 0 0 0 10 0 NNS VBP JJ IN NN O
with with 0 0 0 0 0 0 0 0 4 0 VBP JJ IN NN NN O
division division 0 0 0 0 0 0 0 0 8 0 JJ IN NN NN NN O
plane plane 0 0 0 0 0 0 0 0 5 0 IN NN NN NN IN O
specification specification 0 0 0 0 0 0 0 0 13 0 NN NN NN IN NN O
at at 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NNP O
cytoplast cytoplast 0 0 0 0 0 0 0 0 9 0 NN IN NN NNP NNP O
boundaries. boundaries. 0 0 0 0 0 0 0 0 11 0 IN NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
12671082 12671082 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NN O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NN NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
PMC152334 PMC152334 1 1 0 0 0 0 0 1 9 0 JJ NN NNP NONE NONE O
Role Role 1 0 0 0 0 0 0 0 4 0 NONE NONE NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NONE NNP IN NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 NNP IN NN NN NNP O
kinase kinase 0 0 0 0 0 0 0 0 6 0 IN NN NN NNP IN O
G G 1 1 0 0 0 0 0 0 1 0 NN NN NNP IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NN NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ JJ O
post-shock post-shock 0 0 1 0 0 0 0 0 10 0 IN DT JJ JJ NN O
mesenteric mesenteric 0 0 0 0 0 0 0 0 10 0 DT JJ JJ NN NN O
lymph lymph 0 0 0 0 0 0 0 0 5 0 JJ JJ NN NN VBG O
blockage blockage 0 0 0 0 0 0 0 0 8 0 JJ NN NN VBG JJ O
ameliorating ameliorating 0 0 0 0 0 0 0 0 12 0 NN NN VBG JJ NN O
vascular vascular 0 0 0 0 0 0 0 0 8 0 NN VBG JJ NN NNP O
calcium calcium 0 0 0 0 0 0 0 0 7 0 VBG JJ NN NNP NNP O
sensitivity. sensitivity. 0 0 0 0 0 0 0 0 12 0 JJ NN NNP NNP NNP O
Zhao Zhao 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NNP NNP O
ZG, ZG, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wei Wei 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
YL, YL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Niu Niu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
CY, CY, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
YP, YP, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
LM, LM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Jiang Jiang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
LN. LN. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
PURPOSE: PURPOSE: 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VB O
To To 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VB DT O
investigate investigate 0 0 0 0 0 0 0 0 11 0 NNP NNP VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VB DT NN IN O
role role 0 0 0 0 0 0 0 0 4 0 VB DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 NN IN NN NN NNP O
kinase kinase 0 0 0 0 0 0 0 0 6 0 IN NN NN NNP NNP O
G G 1 1 0 0 0 0 0 0 1 0 NN NN NNP NNP IN O
(PKG) (PKG) 0 1 0 0 0 0 0 0 5 0 NN NNP NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN NN O
blocking blocking 0 0 0 0 0 0 0 0 8 0 NNP IN NN NN JJ O
post-shock post-shock 0 0 1 0 0 0 0 0 10 0 IN NN NN JJ NN O
mesenteric mesenteric 0 0 0 0 0 0 0 0 10 0 NN NN JJ NN NN O
lymph lymph 0 0 0 0 0 0 0 0 5 0 NN JJ NN NN NN O
(PSML) (PSML) 0 1 0 0 0 0 0 0 6 0 JJ NN NN NN VBG O
return return 0 0 0 0 0 0 0 0 6 0 NN NN NN VBG DT O
ameliorating ameliorating 0 0 0 0 0 0 0 0 12 0 NN NN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT NN NN O
calcium calcium 0 0 0 0 0 0 0 0 7 0 VBG DT NN NN IN O
sensitivity sensitivity 0 0 0 0 0 0 0 0 11 0 DT NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
hemorrhagic hemorrhagic 0 0 0 0 0 0 0 0 11 0 NN IN JJ NN NNP O
shock shock 0 0 0 0 0 0 0 0 5 0 IN JJ NN NNP NNP O
rats. rats. 0 0 0 0 0 0 0 0 5 0 JJ NN NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 NN NNP NNP NNP NNP O
Male Male 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP VBZ O
Wistar Wistar 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP VBZ VBD O
rats rats 0 0 0 0 0 0 0 0 4 0 NNP NNP VBZ VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBD RB VBN O
randomly randomly 0 0 0 0 0 0 0 0 8 0 VBZ VBD RB VBN IN O
divided divided 0 0 0 0 0 0 0 0 7 0 VBD RB VBN IN JJ O
into into 0 0 0 0 0 0 0 0 4 0 RB VBN IN JJ JJ O
sham, sham, 0 0 0 0 1 0 0 0 5 0 VBN IN JJ JJ NN O
shock, shock, 0 0 0 0 1 0 0 0 6 0 IN JJ JJ NN NN O
shock+ligation shock+ligation 0 0 0 0 0 0 0 0 14 0 JJ JJ NN NN CC O
(shock (shock 0 0 0 0 0 0 0 0 6 0 JJ NN NN CC JJ O
plus plus 0 0 0 0 0 0 0 0 4 0 NN NN CC JJ NN O
mesenteric mesenteric 0 0 0 0 0 0 0 0 10 0 NN CC JJ NN NN O
lymph lymph 0 0 0 0 0 0 0 0 5 0 CC JJ NN NN NN O
duct duct 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NN O
ligation ligation 0 0 0 0 0 0 0 0 8 0 NN NN NN NN NN O
(MLDL)), (MLDL)), 0 1 0 0 1 0 0 0 8 0 NN NN NN NN NN O
shock+drainage shock+drainage 0 0 0 0 0 0 0 0 14 0 NN NN NN NN CC O
(shock (shock 0 0 0 0 0 0 0 0 6 0 NN NN NN CC NNP O
plus plus 0 0 0 0 0 0 0 0 4 0 NN NN CC NNP NNP O
PSML PSML 1 1 0 0 0 0 0 0 4 0 NN CC NNP NNP NNP O
drainage) drainage) 0 0 0 0 0 0 0 0 9 0 CC NNP NNP NNP NNP O
groups. groups. 0 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NN O
After After 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NN NN O
shock shock 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NN CD O
(hypotension (hypotension 0 0 0 0 0 0 0 0 12 0 NNP NN NN CD IN O
40mmHg) 40mmHg) 0 0 0 0 0 0 0 1 7 0 NN NN CD IN CD O
for for 0 0 0 0 0 0 0 0 3 0 NN CD IN CD NNS O
three three 0 0 0 0 0 0 0 0 5 0 CD IN CD NNS CC O
hours hours 0 0 0 0 0 0 0 0 5 0 IN CD NNS CC VBG O
or or 0 0 0 0 0 0 0 0 2 0 CD NNS CC VBG JJ O
corresponding corresponding 0 0 0 0 0 0 0 0 13 0 NNS CC VBG JJ DT O
times, times, 0 0 0 0 1 0 0 0 6 0 CC VBG JJ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBG JJ DT JJ JJ O
superior superior 0 0 0 0 0 0 0 0 8 0 JJ DT JJ JJ NN O
mesenteric mesenteric 0 0 0 0 0 0 0 0 10 0 DT JJ JJ NN NN O
artery artery 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NN VBD O
(SMA) (SMA) 0 1 0 0 0 0 0 0 5 0 JJ NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN RP O
taken taken 0 0 0 0 0 0 0 0 5 0 NN VBD VBN RP IN O
out out 0 0 0 0 0 0 0 0 3 0 VBD VBN RP IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBN RP IN NN DT O
detecting detecting 0 0 0 0 0 0 0 0 9 0 RP IN NN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NNP CC O
PKG PKG 1 1 0 0 0 0 0 0 3 0 NN DT NNP CC WP O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC WP NNP O
phospho phospho 0 0 0 0 0 0 0 0 7 0 NNP CC WP NNP NNP O
PKG PKG 1 1 0 0 0 0 0 0 3 0 CC WP NNP NNP NNP O
(p-PKG) (p-PKG) 0 0 1 0 0 0 0 0 7 0 WP NNP NNP NNP CC O
contents, contents, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP CC DT JJ NNS O
vascular vascular 0 0 0 0 0 0 0 0 8 0 CC DT JJ NNS IN O
rings rings 0 0 0 0 0 0 0 0 5 0 DT JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP VBD O
SMA SMA 1 1 0 0 0 0 0 0 3 0 NNS IN NNP VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 IN NNP VBD VBN IN O
prepared prepared 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN NN DT O
assaying assaying 0 0 0 0 0 0 0 0 8 0 VBN IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN NN O
calcium calcium 0 0 0 0 0 0 0 0 7 0 NN DT NN NN VBG O
sensitivity sensitivity 0 0 0 0 0 0 0 0 11 0 DT NN NN VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 NN NN VBG DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN VBG DT JJ NN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 VBG DT JJ NN NN O
organ organ 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN NNP O
perfusion perfusion 0 0 0 0 0 0 0 0 9 0 JJ NN NN NNP NNP O
system. system. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 NN NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP CC O
PKG PKG 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NNS O
p-PKG p-PKG 0 0 1 0 0 0 0 0 5 0 NNP CC JJ NNS IN O
contents contents 0 0 0 0 0 0 0 0 8 0 CC JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP IN O
SMA SMA 1 1 0 0 0 0 0 0 3 0 NNS IN NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NN NN O
shock shock 0 0 0 0 0 0 0 0 5 0 NNP IN NN NN VBD O
group group 0 0 0 0 0 0 0 0 5 0 IN NN NN VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NN VBD RB VBN IN O
increased increased 0 0 0 0 0 0 0 0 9 0 VBD RB VBN IN DT O
than than 0 0 0 0 0 0 0 0 4 0 RB VBN IN DT IN O
that that 0 0 0 0 0 0 0 0 4 0 VBN IN DT IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN DT IN NN NN O
sham sham 0 0 0 0 0 0 0 0 4 0 DT IN NN NN CC O
group, group, 0 0 0 0 1 0 0 0 6 0 IN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP CC O
MLDL MLDL 1 1 0 0 0 0 0 0 4 0 NN CC NNP CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 CC NNP CC NNP NN O
PSML PSML 1 1 0 0 0 0 0 0 4 0 NNP CC NNP NN VBG O
drainage drainage 0 0 0 0 0 0 0 0 8 0 CC NNP NN VBG DT O
reducing reducing 0 0 0 0 0 0 0 0 8 0 NNP NN VBG DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 VBG DT NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NNP CC O
PKG PKG 1 1 0 0 0 0 0 0 3 0 NNS IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
p-PKG. p-PKG. 0 0 1 0 0 0 0 0 6 0 NNP CC NNP NNP DT O
Meanwhile, Meanwhile, 1 0 0 0 1 0 0 0 10 0 CC NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NN O
vascular vascular 0 0 0 0 0 0 0 0 8 0 NNP DT JJ NN NN O
calcium calcium 0 0 0 0 0 0 0 0 7 0 DT JJ NN NN IN O
sensitivity sensitivity 0 0 0 0 0 0 0 0 11 0 JJ NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
shock shock 0 0 0 0 0 0 0 0 5 0 NN IN NN NN VBD O
group group 0 0 0 0 0 0 0 0 5 0 IN NN NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD RB JJR O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NN VBD RB JJR IN O
lower lower 0 0 0 0 0 0 0 0 5 0 VBD RB JJR IN DT O
than than 0 0 0 0 0 0 0 0 4 0 RB JJR IN DT IN O
that that 0 0 0 0 0 0 0 0 4 0 JJR IN DT IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN DT IN NN NN O
sham sham 0 0 0 0 0 0 0 0 4 0 DT IN NN NN NNP O
group, group, 0 0 0 0 1 0 0 0 6 0 IN NN NN NNP CC O
MLDL MLDL 1 1 0 0 0 0 0 0 4 0 NN NN NNP CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 NN NNP CC NNP NN O
PSML PSML 1 1 0 0 0 0 0 0 4 0 NNP CC NNP NN VBD O
drainage drainage 0 0 0 0 0 0 0 0 8 0 CC NNP NN VBD DT O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 NNP NN VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBD DT NN NNP O
calcium calcium 0 0 0 0 0 0 0 0 7 0 VBD DT NN NNP NNP O
sensitivity. sensitivity. 0 0 0 0 0 0 0 0 12 0 DT NN NNP NNP NN O
After After 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NN IN O
incubating incubating 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNP NN IN NNP NNS O
PKG PKG 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNS IN O
regulators regulators 0 0 0 0 0 0 0 0 10 0 IN NNP NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NN CC O
shock+ligation shock+ligation 0 0 0 0 0 0 0 0 14 0 NNS IN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC JJ NN O
shock+drainage shock+drainage 0 0 0 0 0 0 0 0 14 0 NN CC JJ NN DT O
groups, groups, 0 0 0 0 1 0 0 0 7 0 CC JJ NN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NNP NN O
PKG PKG 1 1 0 0 0 0 0 0 3 0 NN DT NNP NN CD O
agonist agonist 0 0 0 0 0 0 0 0 7 0 DT NNP NN CD VBN O
8Br-cGMP 8Br-cGMP 0 0 1 0 0 0 0 1 8 0 NNP NN CD VBN DT O
reduced reduced 0 0 0 0 0 0 0 0 7 0 NN CD VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CD VBN DT NN IN O
contractility contractility 0 0 0 0 0 0 0 0 13 0 VBN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
vascular vascular 0 0 0 0 0 0 0 0 8 0 NN IN JJ NNS TO O
rings rings 0 0 0 0 0 0 0 0 5 0 IN JJ NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO VB NN O
gradient gradient 0 0 0 0 0 0 0 0 8 0 NNS TO VB NN NNS O
calcium calcium 0 0 0 0 0 0 0 0 7 0 TO VB NN NNS CC O
ions ions 0 0 0 0 0 0 0 0 4 0 VB NN NNS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NNP CC O
Emax Emax 1 0 0 0 0 0 0 0 4 0 NNS CC NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP CC DT NNP NN O
PKG PKG 1 1 0 0 0 0 0 0 3 0 CC DT NNP NN NN O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 DT NNP NN NN NNP O
agonist agonist 0 0 0 0 0 0 0 0 7 0 NNP NN NN NNP VBD O
KT5823 KT5823 1 1 0 0 0 0 0 1 6 0 NN NN NNP VBD DT O
elevated elevated 0 0 0 0 0 0 0 0 8 0 NN NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN NN O
calcium calcium 0 0 0 0 0 0 0 0 7 0 VBD DT NN NN NNP O
sensitivity sensitivity 0 0 0 0 0 0 0 0 11 0 DT NN NN NNP NNP O
significantly. significantly. 0 0 0 0 0 0 0 0 14 0 NN NN NNP NNP NNP O
CONCLUSION: CONCLUSION: 1 1 0 0 0 0 0 0 11 0 NN NNP NNP NNP NN O
Protein Protein 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NN NNP O
kinase kinase 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NNP VBZ O
G G 1 1 0 0 0 0 0 0 1 0 NNP NN NNP VBZ DT O
plays plays 0 0 0 0 0 0 0 0 5 0 NN NNP VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNP VBZ DT JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN JJ O
post-shock post-shock 0 0 1 0 0 0 0 0 10 0 NN IN NN JJ NN O
mesenteric mesenteric 0 0 0 0 0 0 0 0 10 0 IN NN JJ NN NN O
lymph lymph 0 0 0 0 0 0 0 0 5 0 NN JJ NN NN VBG O
blockage blockage 0 0 0 0 0 0 0 0 8 0 JJ NN NN VBG NN O
improving improving 0 0 0 0 0 0 0 0 9 0 NN NN VBG NN NN O
vascular vascular 0 0 0 0 0 0 0 0 8 0 NN VBG NN NN NNP O
calcium calcium 0 0 0 0 0 0 0 0 7 0 VBG NN NN NNP NNP O
sensitivity. sensitivity. 0 0 0 0 0 0 0 0 12 0 NN NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
23842936 23842936 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : IN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ : IN JJ NONE O
process] process] 0 0 0 0 0 0 0 0 8 0 : IN JJ NONE NONE O
Factors Factors 1 0 0 0 0 0 0 0 7 0 NONE NONE NNS VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NONE NNS VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ VBG O
recent recent 0 0 0 0 0 0 0 0 6 0 IN DT JJ VBG NN O
increasing increasing 0 0 0 0 0 0 0 0 10 0 DT JJ VBG NN NN O
cesarean cesarean 0 0 0 0 0 0 0 0 8 0 JJ VBG NN NN NN O
delivery delivery 0 0 0 0 0 0 0 0 8 0 VBG NN NN NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 NN NN NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
Japanese Japanese 1 0 0 0 0 0 0 0 8 0 IN DT JJ NN NNP O
perinatal perinatal 0 0 0 0 0 0 0 0 9 0 DT JJ NN NNP NNP O
center. center. 0 0 0 0 0 0 0 0 7 0 JJ NN NNP NNP NNP O
Suzuki Suzuki 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Nakata Nakata 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
M. M. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Obstetrics Obstetrics 1 0 0 0 0 0 0 0 10 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Gynecology, Gynecology, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP NNP O
Japanese Japanese 1 0 0 0 0 0 0 0 8 0 CC NNP NNP NNP NNP O
Red Red 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Cross Cross 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Katsushika Katsushika 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Maternity Maternity 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP CD O
Hospital, Hospital, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP CD -NONE- O
5-11-12 5-11-12 0 0 1 0 0 0 0 1 7 0 NNP NNP CD -NONE- JJ O
Tateishi, Tateishi, 1 0 0 0 1 0 0 0 9 0 NNP CD -NONE- JJ NNP O
Katsushika-ku, Katsushika-ku, 1 0 1 0 1 0 0 0 14 0 CD -NONE- JJ NNP CD O
Tokyo Tokyo 1 0 0 0 0 0 0 0 5 0 -NONE- JJ NNP CD NNP O
124-0012, 124-0012, 0 0 1 0 1 0 0 1 9 0 JJ NNP CD NNP NNP O
Japan. Japan. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NNP O
Objective. Objective. 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBD WDT O
examined examined 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD WDT JJ O
which which 0 0 0 0 0 0 0 0 5 0 NNP VBD WDT JJ NNS O
specific specific 0 0 0 0 0 0 0 0 8 0 VBD WDT JJ NNS VBD O
factors factors 0 0 0 0 0 0 0 0 7 0 WDT JJ NNS VBD TO O
contributed contributed 0 0 0 0 0 0 0 0 11 0 JJ NNS VBD TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBD TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD TO DT NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 TO DT NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NN O
Cesarean Cesarean 1 0 0 0 0 0 0 0 8 0 NN IN NNP NN NN O
delivery delivery 0 0 0 0 0 0 0 0 8 0 IN NNP NN NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 NNP NN NN IN PRP$ O
at at 0 0 0 0 0 0 0 0 2 0 NN NN IN PRP$ JJ O
our our 0 0 0 0 0 0 0 0 3 0 NN IN PRP$ JJ IN O
hospital hospital 0 0 0 0 0 0 0 0 8 0 IN PRP$ JJ IN DT O
over over 0 0 0 0 0 0 0 0 4 0 PRP$ JJ IN DT CD O
a a 0 0 0 0 0 0 0 0 1 0 JJ IN DT CD NNP O
10-year 10-year 0 0 1 0 0 0 0 1 7 0 IN DT CD NNP NNP O
period. period. 0 0 0 0 0 0 0 0 7 0 DT CD NNP NNP NNP O
Methods. Methods. 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NNP O
From From 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP CD O
January January 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP CD TO O
2002 2002 0 0 0 0 0 0 1 1 4 0 NNP NNP CD TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNP CD TO NNP CD O
December December 1 0 0 0 0 0 0 0 8 0 CD TO NNP CD NNS O
2012, 2012, 0 0 0 0 1 0 0 1 5 0 TO NNP CD NNS IN O
data data 0 0 0 0 0 0 0 0 4 0 NNP CD NNS IN DT O
on on 0 0 0 0 0 0 0 0 2 0 CD NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
Japanese Japanese 1 0 0 0 0 0 0 0 8 0 IN DT JJ NN NNS O
singleton singleton 0 0 0 0 0 0 0 0 9 0 DT JJ NN NNS IN O
deliveries deliveries 0 0 0 0 0 0 0 0 10 0 JJ NN NNS IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NN O
≥22-week ≥22-week 0 0 1 0 0 0 0 1 8 0 NNS IN JJ NN VBN O
gestation gestation 0 0 0 0 0 0 0 0 9 0 IN JJ NN VBN IN O
managed managed 0 0 0 0 0 0 0 0 7 0 JJ NN VBN IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 NN VBN IN JJ NNP O
Japanese Japanese 1 0 0 0 0 0 0 0 8 0 VBN IN JJ NNP NNP O
Red Red 1 0 0 0 0 0 0 0 3 0 IN JJ NNP NNP NNP O
Cross Cross 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP NNP NNP O
Katsushika Katsushika 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Maternity Maternity 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP VBD O
Hospital Hospital 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD NNP NNP O
collected. collected. 0 0 0 0 0 0 0 0 10 0 NNP VBD NNP NNP NNS O
Potential Potential 1 0 0 0 0 0 0 0 9 0 VBD NNP NNP NNS VBN O
factors factors 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NNP NNS VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBN IN DT VBG O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT VBG NNP O
increasing increasing 0 0 0 0 0 0 0 0 10 0 IN DT VBG NNP NN O
Cesarean Cesarean 1 0 0 0 0 0 0 0 8 0 DT VBG NNP NN NN O
delivery delivery 0 0 0 0 0 0 0 0 8 0 VBG NNP NN NN VBD O
rate rate 0 0 0 0 0 0 0 0 4 0 NNP NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN VBG O
selected selected 0 0 0 0 0 0 0 0 8 0 NN VBD VBN VBG TO O
according according 0 0 0 0 0 0 0 0 9 0 VBD VBN VBG TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBG TO JJ NNP O
previous previous 0 0 0 0 0 0 0 0 8 0 VBG TO JJ NNP NNP O
studies. studies. 0 0 0 0 0 0 0 0 8 0 TO JJ NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN DT O
study, study, 0 0 0 0 1 0 0 0 6 0 NNP DT NN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 DT NN DT NNS IN O
incidences incidences 0 0 0 0 0 0 0 0 10 0 NN DT NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NN JJ O
intrauterine intrauterine 0 0 0 0 0 0 0 0 12 0 NNS IN NN JJ NN O
fetal fetal 0 0 0 0 0 0 0 0 5 0 IN NN JJ NN JJ O
demise, demise, 0 0 0 0 1 0 0 0 7 0 NN JJ NN JJ NN O
umbilical umbilical 0 0 0 0 0 0 0 0 9 0 JJ NN JJ NN NNP O
artery artery 0 0 0 0 0 0 0 0 6 0 NN JJ NN NNP NNP O
pH pH 0 0 0 0 0 0 0 0 2 0 JJ NN NNP NNP CC O
<7.1, <7.1, 0 0 0 0 1 0 0 1 5 0 NN NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NN O
severe severe 0 0 0 0 0 0 0 0 6 0 NNP CC JJ NN NN O
perineal perineal 0 0 0 0 0 0 0 0 8 0 CC JJ NN NN VBD O
laceration laceration 0 0 0 0 0 0 0 0 10 0 JJ NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN IN O
calculated calculated 0 0 0 0 0 0 0 0 10 0 NN VBD VBN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN DT NNP O
each each 0 0 0 0 0 0 0 0 4 0 VBN IN DT NNP NNP O
year. year. 0 0 0 0 0 0 0 0 5 0 IN DT NNP NNP NNP O
Results. Results. 1 0 0 0 0 0 0 0 8 0 DT NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NN O
Cesarean Cesarean 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NN NN O
delivery delivery 0 0 0 0 0 0 0 0 8 0 NNP NNP NN NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 NNP NN NN IN PRP$ O
at at 0 0 0 0 0 0 0 0 2 0 NN NN IN PRP$ NN O
our our 0 0 0 0 0 0 0 0 3 0 NN IN PRP$ NN VBD O
institution institution 0 0 0 0 0 0 0 0 11 0 IN PRP$ NN VBD RB O
increased increased 0 0 0 0 0 0 0 0 9 0 PRP$ NN VBD RB IN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NN VBD RB IN DT O
during during 0 0 0 0 0 0 0 0 6 0 VBD RB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NN NN O
study study 0 0 0 0 0 0 0 0 5 0 IN DT NN NN NN O
period period 0 0 0 0 0 0 0 0 6 0 DT NN NN NN IN O
(17.3% (17.3% 0 0 0 0 0 0 0 1 6 0 NN NN NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN CD NN O
2002 2002 0 0 0 0 0 0 1 1 4 0 NN IN CD NN CD O
versus versus 0 0 0 0 0 0 0 0 6 0 IN CD NN CD IN O
23.4% 23.4% 0 0 0 0 0 0 0 1 5 0 CD NN CD IN CD O
in in 0 0 0 0 0 0 0 0 2 0 NN CD IN CD NNP O
2012, 2012, 0 0 0 0 1 0 0 1 5 0 CD IN CD NNP NNP O
P P 1 1 0 0 0 0 0 0 1 0 IN CD NNP NNP NNP O
< < 0 0 0 0 0 0 0 0 1 0 CD NNP NNP NNP NNP O
0.01). 0.01). 0 0 0 0 0 0 0 1 6 0 NNP NNP NNP NNP DT O
During During 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
study study 0 0 0 0 0 0 0 0 5 0 NNP DT NN NN DT O
period, period, 0 0 0 0 1 0 0 0 7 0 DT NN NN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NNP NN O
Cesarean Cesarean 1 0 0 0 0 0 0 0 8 0 NN DT NNP NN NNS O
delivery delivery 0 0 0 0 0 0 0 0 8 0 DT NNP NN NNS IN O
rates rates 0 0 0 0 0 0 0 0 5 0 NNP NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNS IN O
cases cases 0 0 0 0 0 0 0 0 5 0 IN DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NN O
nulliparity, nulliparity, 0 0 0 0 1 0 0 0 12 0 NNS IN JJ NN NN O
preterm preterm 0 0 0 0 0 0 0 0 7 0 IN JJ NN NN JJ O
delivery, delivery, 0 0 0 0 1 0 0 0 9 0 JJ NN NN JJ NN O
low low 0 0 0 0 0 0 0 0 3 0 NN NN JJ NN NN O
birth birth 0 0 0 0 0 0 0 0 5 0 NN JJ NN NN -NONE- O
weight weight 0 0 0 0 0 0 0 0 6 0 JJ NN NN -NONE- -NONE- O
(<2,500 (<2,500 0 0 0 0 1 0 0 1 7 0 NN NN -NONE- -NONE- JJ O
g), g), 0 0 0 0 1 0 0 0 3 0 NN -NONE- -NONE- JJ NNP O
previous previous 0 0 0 0 0 0 0 0 8 0 -NONE- -NONE- JJ NNP NNS O
Cesarean Cesarean 1 0 0 0 0 0 0 0 8 0 -NONE- JJ NNP NNS CC O
deliveries deliveries 0 0 0 0 0 0 0 0 10 0 JJ NNP NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNS CC NN NN O
breech breech 0 0 0 0 0 0 0 0 6 0 NNS CC NN NN VBD O
presentation presentation 0 0 0 0 0 0 0 0 12 0 CC NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN NNP O
increased increased 0 0 0 0 0 0 0 0 9 0 NN VBD VBN NNP NNP O
significantly. significantly. 0 0 0 0 0 0 0 0 14 0 VBD VBN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 VBN NNP NNP NN IN O
incidence incidence 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN JJ O
intrauterine intrauterine 0 0 0 0 0 0 0 0 12 0 NN IN NN JJ NN O
fetal fetal 0 0 0 0 0 0 0 0 5 0 IN NN JJ NN CC O
demise demise 0 0 0 0 0 0 0 0 6 0 NN JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ JJ O
low low 0 0 0 0 0 0 0 0 3 0 NN CC JJ JJ NN O
umbilical umbilical 0 0 0 0 0 0 0 0 9 0 CC JJ JJ NN NNP O
artery artery 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NNP VBD O
pH pH 0 0 0 0 0 0 0 0 2 0 JJ NN NNP VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NN NNP VBD RB -NONE- O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNP VBD RB -NONE- CC O
decreased, decreased, 0 0 0 0 1 0 0 0 10 0 VBD RB -NONE- CC DT O
and and 0 0 0 0 0 0 0 0 3 0 RB -NONE- CC DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- CC DT JJ NN O
negative negative 0 0 0 0 0 0 0 0 8 0 CC DT JJ NN VBD O
correlation correlation 0 0 0 0 0 0 0 0 11 0 DT JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 NN VBD VBN IN DT O
between between 0 0 0 0 0 0 0 0 7 0 VBD VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NN O
Cesarean Cesarean 1 0 0 0 0 0 0 0 8 0 IN DT NNP NN NN O
delivery delivery 0 0 0 0 0 0 0 0 8 0 DT NNP NN NN CC O
rate rate 0 0 0 0 0 0 0 0 4 0 NNP NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN IN O
incidence incidence 0 0 0 0 0 0 0 0 9 0 CC DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ JJ O
low low 0 0 0 0 0 0 0 0 3 0 NN IN JJ JJ NN O
umbilical umbilical 0 0 0 0 0 0 0 0 9 0 IN JJ JJ NN NNP O
artery artery 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NNP IN O
pH pH 0 0 0 0 0 0 0 0 2 0 JJ NN NNP IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN NNP IN DT NN O
each each 0 0 0 0 0 0 0 0 4 0 NNP IN DT NN JJ O
year year 0 0 0 0 0 0 0 0 4 0 IN DT NN JJ NN O
(r (r 0 0 0 0 0 0 0 0 2 0 DT NN JJ NN NN O
= = 0 0 0 0 0 0 0 0 1 0 NN JJ NN NN NNP O
-0.92, -0.92, 0 0 1 0 1 0 0 1 6 0 JJ NN NN NNP NNP O
P P 1 1 0 0 0 0 0 0 1 0 NN NN NNP NNP NNP O
< < 0 0 0 0 0 0 0 0 1 0 NN NNP NNP NNP NNP O
0.01). 0.01). 0 0 0 0 0 0 0 1 6 0 NNP NNP NNP NNP NNP O
Conclusion. Conclusion. 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP PRP$ O
At At 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP PRP$ NNP O
our our 0 0 0 0 0 0 0 0 3 0 NNP NNP PRP$ NNP DT O
institute, institute, 0 0 0 0 1 0 0 0 10 0 NNP PRP$ NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 PRP$ NNP DT JJ NNS O
neonatal neonatal 0 0 0 0 0 0 0 0 8 0 NNP DT JJ NNS VBD O
outcomes outcomes 0 0 0 0 0 0 0 0 8 0 DT JJ NNS VBD TO O
seemed seemed 0 0 0 0 0 0 0 0 6 0 JJ NNS VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBD TO VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 VBD TO VB VBN VBN O
improved improved 0 0 0 0 0 0 0 0 8 0 TO VB VBN VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 VB VBN VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBN VBN IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT VBN NNP O
increased increased 0 0 0 0 0 0 0 0 9 0 IN DT VBN NNP NN O
Cesarean Cesarean 1 0 0 0 0 0 0 0 8 0 DT VBN NNP NN NN O
delivery delivery 0 0 0 0 0 0 0 0 8 0 VBN NNP NN NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 NNP NN NN IN CD O
between between 0 0 0 0 0 0 0 0 7 0 NN NN IN CD CC O
2002 2002 0 0 0 0 0 0 1 1 4 0 NN IN CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 IN CD CC CD NONE O
2012. 2012. 0 0 0 0 0 0 0 1 5 0 CD CC CD NONE NONE O
Malondialdehyde Malondialdehyde 1 0 0 0 0 0 0 0 15 0 NONE NONE NNP NN TO O
adduct adduct 0 0 0 0 0 0 0 0 6 0 NONE NNP NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO NNP DT O
hemoglobin: hemoglobin: 0 0 0 0 0 0 0 0 11 0 NN TO NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 TO NNP DT JJ NN O
new new 0 0 0 0 0 0 0 0 3 0 NNP DT JJ NN IN O
marker marker 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
oxidative oxidative 0 0 0 0 0 0 0 0 9 0 NN IN JJ NN JJ O
stress stress 0 0 0 0 0 0 0 0 6 0 IN JJ NN JJ IN O
suitable suitable 0 0 0 0 0 0 0 0 8 0 JJ NN JJ IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NN JJ IN JJ CC O
full-term full-term 0 0 1 0 0 0 0 0 9 0 JJ IN JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC NN NNP O
preterm preterm 0 0 0 0 0 0 0 0 7 0 JJ CC NN NNP NNP O
neonates. neonates. 0 0 0 0 0 0 0 0 9 0 CC NN NNP NNP NNP O
Cipierre Cipierre 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Haÿs Haÿs 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Maucort-Boulch Maucort-Boulch 1 0 1 0 0 0 0 0 14 0 NNP NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Steghens Steghens 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
JP, JP, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Picaud Picaud 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
JC. JC. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Département Département 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Néonatologie, Néonatologie, 1 0 0 0 1 0 0 0 13 0 NNP IN NNP NNP NNP O
CHU CHU 1 1 0 0 0 0 0 0 3 0 IN NNP NNP NNP CD O
Angers, Angers, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP CD NN O
4 4 0 0 0 0 0 0 1 1 1 0 NNP NNP CD NN -NONE- O
rue rue 0 0 0 0 0 0 0 0 3 0 NNP CD NN -NONE- CD O
Larrey, Larrey, 1 0 0 0 1 0 0 0 7 0 CD NN -NONE- CD -NONE- O
49100 49100 0 0 0 0 0 0 1 1 5 0 NN -NONE- CD -NONE- NNP O
Angers, Angers, 1 0 0 0 1 0 0 0 7 0 -NONE- CD -NONE- NNP : O
France France 1 0 0 0 0 0 0 0 6 0 CD -NONE- NNP : JJ O
; ; 0 0 0 0 0 0 0 0 1 0 -NONE- NNP : JJ NN O
Département Département 1 0 0 0 0 0 0 0 11 0 NNP : JJ NN NN O
de de 0 0 0 0 0 0 0 0 2 0 : JJ NN NN JJ O
Néonatologie, Néonatologie, 1 0 0 0 1 0 0 0 13 0 JJ NN NN JJ NN O
Hôpital Hôpital 1 0 0 0 0 0 0 0 7 0 NN NN JJ NN NN O
de de 0 0 0 0 0 0 0 0 2 0 NN JJ NN NN NNP O
la la 0 0 0 0 0 0 0 0 2 0 JJ NN NN NNP NNP O
Croix Croix 1 0 0 0 0 0 0 0 5 0 NN NN NNP NNP NNPS O
Rousse, Rousse, 1 0 0 0 1 0 0 0 7 0 NN NNP NNP NNPS NNP O
Hospices Hospices 1 0 0 0 0 0 0 0 8 0 NNP NNP NNPS NNP IN O
Civils Civils 1 0 0 0 0 0 0 0 6 0 NNP NNPS NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNPS NNP IN NNP CD O
Lyon, Lyon, 1 0 0 0 1 0 0 0 5 0 NNP IN NNP CD -NONE- O
69004 69004 0 0 0 0 0 0 1 1 5 0 IN NNP CD -NONE- NNP O
Lyon, Lyon, 1 0 0 0 1 0 0 0 5 0 NNP CD -NONE- NNP NNP O
France. France. 1 0 0 0 0 0 0 0 7 0 CD -NONE- NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 -NONE- NNP NNP NNP NN O
Oxidative Oxidative 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NN MD O
stress stress 0 0 0 0 0 0 0 0 6 0 NNP NNP NN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NNP NN MD VB DT O
play play 0 0 0 0 0 0 0 0 4 0 NN MD VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT JJ NN O
central central 0 0 0 0 0 0 0 0 7 0 VB DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
onset onset 0 0 0 0 0 0 0 0 5 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
many many 0 0 0 0 0 0 0 0 4 0 NN IN JJ NNS IN O
diseases diseases 0 0 0 0 0 0 0 0 8 0 IN JJ NNS IN DT O
during during 0 0 0 0 0 0 0 0 6 0 JJ NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NNP O
neonatal neonatal 0 0 0 0 0 0 0 0 8 0 IN DT JJ NNP NNP O
period. period. 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NNP NNP O
Malondialdehyde Malondialdehyde 1 0 0 0 0 0 0 0 15 0 JJ NNP NNP NNP VBZ O
(MDA) (MDA) 0 1 0 0 0 0 0 0 5 0 NNP NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT NN IN O
marker marker 0 0 0 0 0 0 0 0 6 0 VBZ DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
lipid lipid 0 0 0 0 0 0 0 0 5 0 NN IN JJ NNP NNP O
peroxidation. peroxidation. 0 0 0 0 0 0 0 0 13 0 IN JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
aim aim 0 0 0 0 0 0 0 0 3 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 IN DT NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB DT O
evaluate evaluate 0 0 0 0 0 0 0 0 8 0 VBD TO VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT JJ NN O
new new 0 0 0 0 0 0 0 0 3 0 VB DT JJ NN DT O
marker, marker, 0 0 0 0 1 0 0 0 7 0 DT JJ NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NN NN O
malondialdehyde malondialdehyde 0 0 0 0 0 0 0 0 15 0 NN DT NN NN TO O
adduct adduct 0 0 0 0 0 0 0 0 6 0 DT NN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO VB JJ O
hemoglobin hemoglobin 0 0 0 0 0 0 0 0 10 0 NN TO VB JJ WDT O
(MDA-Hb), (MDA-Hb), 0 0 1 0 1 0 0 0 9 0 TO VB JJ WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 VB JJ WDT VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 JJ WDT VBZ VBN IN O
measured measured 0 0 0 0 0 0 0 0 8 0 WDT VBZ VBN IN VBN O
in in 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN VBN NN O
red red 0 0 0 0 0 0 0 0 3 0 VBN IN VBN NN NNS O
blood blood 0 0 0 0 0 0 0 0 5 0 IN VBN NN NNS -NONE- O
cells cells 0 0 0 0 0 0 0 0 5 0 VBN NN NNS -NONE- CC O
(RBCs) (RBCs) 0 0 0 0 0 0 0 0 6 0 NN NNS -NONE- CC RB O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC RB VBZ O
thus thus 0 0 0 0 0 0 0 0 4 0 -NONE- CC RB VBZ RB O
does does 0 0 0 0 0 0 0 0 4 0 CC RB VBZ RB VB O
not not 0 0 0 0 0 0 0 0 3 0 RB VBZ RB VB IN O
require require 0 0 0 0 0 0 0 0 7 0 VBZ RB VB IN DT O
that that 0 0 0 0 0 0 0 0 4 0 RB VB IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 VB IN DT JJ NN O
additional additional 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN NN O
blood blood 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN VB O
sample sample 0 0 0 0 0 0 0 0 6 0 JJ NN NN VB NNP O
be be 0 0 0 0 0 0 0 0 2 0 NN NN VB NNP NNP O
drawn. drawn. 0 0 0 0 0 0 0 0 6 0 NN VB NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 VB NNP NNP DT JJ O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT JJ NN O
prospective prospective 0 0 0 0 0 0 0 0 11 0 NNP DT JJ NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 DT JJ NN PRP RB O
we we 0 0 0 0 0 0 0 0 2 0 JJ NN PRP RB VBD O
first first 0 0 0 0 0 0 0 0 5 0 NN PRP RB VBD DT O
adapted adapted 0 0 0 0 0 0 0 0 7 0 PRP RB VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBD DT NN NN O
measurement measurement 0 0 0 0 0 0 0 0 11 0 VBD DT NN NN RB O
method method 0 0 0 0 0 0 0 0 6 0 DT NN NN RB VBD O
previously previously 0 0 0 0 0 0 0 0 10 0 NN NN RB VBD TO O
described described 0 0 0 0 0 0 0 0 9 0 NN RB VBD TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 RB VBD TO NNP NNS O
Hb Hb 1 0 0 0 0 0 0 0 2 0 VBD TO NNP NNS VBD O
solutions solutions 0 0 0 0 0 0 0 0 9 0 TO NNP NNS VBD IN O
obtained obtained 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD IN VBN O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBD IN VBN NNS O
washed washed 0 0 0 0 0 0 0 0 6 0 VBD IN VBN NNS CC O
RBCs RBCs 1 0 0 0 0 0 0 0 4 0 IN VBN NNS CC RB O
and and 0 0 0 0 0 0 0 0 3 0 VBN NNS CC RB VBD O
then then 0 0 0 0 0 0 0 0 4 0 NNS CC RB VBD DT O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 CC RB VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBD DT NN IN O
suitability suitability 0 0 0 0 0 0 0 0 11 0 VBD DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
method method 0 0 0 0 0 0 0 0 6 0 IN DT NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN NN IN O
use use 0 0 0 0 0 0 0 0 3 0 NN IN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNP O
neonates. neonates. 0 0 0 0 0 0 0 0 9 0 NN IN NNP NNP NNS O
MDA-Hb MDA-Hb 1 0 1 0 0 0 0 0 6 0 IN NNP NNP NNS VBD O
concentrations concentrations 0 0 0 0 0 0 0 0 14 0 NNP NNP NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD VBN IN O
measured measured 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN NN O
liquid liquid 0 0 0 0 0 0 0 0 6 0 VBN IN NN NN NNP O
chromatography-mass chromatography-mass 0 0 1 0 0 0 0 0 19 0 IN NN NN NNP NNP O
spectrometry. spectrometry. 0 0 0 0 0 0 0 0 13 0 NN NN NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBD DT O
compared compared 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NNS IN O
concentrations concentrations 0 0 0 0 0 0 0 0 14 0 VBD DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ IN O
MDA-Hb MDA-Hb 1 0 1 0 0 0 0 0 6 0 NNS IN JJ IN NN O
between between 0 0 0 0 0 0 0 0 7 0 IN JJ IN NN CC O
preterm preterm 0 0 0 0 0 0 0 0 7 0 JJ IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN NNP O
term term 0 0 0 0 0 0 0 0 4 0 NN CC NN NNP NNP O
neonates. neonates. 0 0 0 0 0 0 0 0 9 0 CC NN NNP NNP VBZ O
Erythrocyte Erythrocyte 1 0 0 0 0 0 0 0 11 0 NN NNP NNP VBZ VBD O
samples samples 0 0 0 0 0 0 0 0 7 0 NNP NNP VBZ VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBD VBN IN O
collected collected 0 0 0 0 0 0 0 0 9 0 VBZ VBD VBN IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ IN O
birth birth 0 0 0 0 0 0 0 0 5 0 VBN IN JJ IN CD O
from from 0 0 0 0 0 0 0 0 4 0 IN JJ IN CD JJ O
60 60 0 0 0 0 0 0 1 1 2 0 JJ IN CD JJ NNS O
healthy healthy 0 0 0 0 0 0 0 0 7 0 IN CD JJ NNS -NONE- O
neonates neonates 0 0 0 0 0 0 0 0 8 0 CD JJ NNS -NONE- JJ O
(29 (29 0 0 0 0 0 0 0 1 3 0 JJ NNS -NONE- JJ CC O
full-term full-term 0 0 1 0 0 0 0 0 9 0 NNS -NONE- JJ CC CD O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- JJ CC CD NN O
31 31 0 0 0 0 0 0 1 1 2 0 JJ CC CD NN IN O
preterm), preterm), 0 0 0 0 1 0 0 0 9 0 CC CD NN IN RB O
as as 0 0 0 0 0 0 0 0 2 0 CD NN IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NN IN RB IN IN O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN IN CD O
from from 0 0 0 0 0 0 0 0 4 0 RB IN IN CD NN O
50 50 0 0 0 0 0 0 1 1 2 0 IN IN CD NN VBZ O
preterm preterm 0 0 0 0 0 0 0 0 7 0 IN CD NN VBZ IN O
neonates neonates 0 0 0 0 0 0 0 0 8 0 CD NN VBZ IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN VBZ IN JJ JJ O
uncomplicated uncomplicated 0 0 0 0 0 0 0 0 13 0 VBZ IN JJ JJ NN O
postnatal postnatal 0 0 0 0 0 0 0 0 9 0 IN JJ JJ NN IN O
evolution evolution 0 0 0 0 0 0 0 0 9 0 JJ JJ NN IN DT O
during during 0 0 0 0 0 0 0 0 6 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNS O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ NNS IN O
months months 0 0 0 0 0 0 0 0 6 0 DT JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NNP O
life. life. 0 0 0 0 0 0 0 0 5 0 NNS IN NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 IN NNP NNP VBD DT O
found found 0 0 0 0 0 0 0 0 5 0 NNP NNP VBD DT RB O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBD DT RB JJR O
significantly significantly 0 0 0 0 0 0 0 0 13 0 VBD DT RB JJR JJ O
higher higher 0 0 0 0 0 0 0 0 6 0 DT RB JJR JJ NN O
MDA-Hb MDA-Hb 1 0 1 0 0 0 0 0 6 0 RB JJR JJ NN IN O
concentration concentration 0 0 0 0 0 0 0 0 13 0 JJR JJ NN IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ IN O
birth birth 0 0 0 0 0 0 0 0 5 0 NN IN JJ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN JJ IN NN NNS O
preterm preterm 0 0 0 0 0 0 0 0 7 0 JJ IN NN NNS -NONE- O
neonates neonates 0 0 0 0 0 0 0 0 8 0 IN NN NNS -NONE- : O
(P (P 0 1 0 0 0 0 0 0 2 0 NN NNS -NONE- : CD O
= = 0 0 0 0 0 0 0 0 1 0 NNS -NONE- : CD NNP O
0.002). 0.002). 0 0 0 0 0 0 0 1 7 0 -NONE- : CD NNP DT O
During During 1 0 0 0 0 0 0 0 6 0 : CD NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CD NNP DT JJ NNS O
first first 0 0 0 0 0 0 0 0 5 0 NNP DT JJ NNS IN O
months months 0 0 0 0 0 0 0 0 6 0 DT JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NN O
life, life, 0 0 0 0 1 0 0 0 5 0 NNS IN NN NN NNS O
MDA-Hb MDA-Hb 1 0 1 0 0 0 0 0 6 0 IN NN NN NNS VBD O
concentrations concentrations 0 0 0 0 0 0 0 0 14 0 NN NN NNS VBD CD O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD CD JJ O
9.4 9.4 0 0 0 0 0 0 0 1 3 0 NNS VBD CD JJ NNP O
nanomol/g nanomol/g 0 0 0 1 0 0 0 0 9 0 VBD CD JJ NNP IN O
Hb Hb 1 0 0 0 0 0 0 0 2 0 CD JJ NNP IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNP IN JJ NN O
hospitalized hospitalized 0 0 0 0 0 0 0 0 12 0 NNP IN JJ NN NNP O
preterm preterm 0 0 0 0 0 0 0 0 7 0 IN JJ NN NNP NNP O
neonates. neonates. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NNP MD O
MDA-Hb MDA-Hb 1 0 1 0 0 0 0 0 6 0 NN NNP NNP MD VB O
could could 0 0 0 0 0 0 0 0 5 0 NNP NNP MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NNP MD VB VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 MD VB VBN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VB VBN TO NN VB O
assess assess 0 0 0 0 0 0 0 0 6 0 VBN TO NN VB NN O
oxidative oxidative 0 0 0 0 0 0 0 0 9 0 TO NN VB NN IN O
stress stress 0 0 0 0 0 0 0 0 6 0 NN VB NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VB NN IN NN NNP O
preterm preterm 0 0 0 0 0 0 0 0 7 0 NN IN NN NNP NNP O
neonates. neonates. 0 0 0 0 0 0 0 0 9 0 IN NN NNP NNP IN O
Together Together 1 0 0 0 0 0 0 0 8 0 NN NNP NNP IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNP IN JJ NN O
clinical clinical 0 0 0 0 0 0 0 0 8 0 NNP IN JJ NN PRP O
variables, variables, 0 0 0 0 1 0 0 0 10 0 IN JJ NN PRP MD O
it it 0 0 0 0 0 0 0 0 2 0 JJ NN PRP MD VB O
could could 0 0 0 0 0 0 0 0 5 0 NN PRP MD VB DT O
be be 0 0 0 0 0 0 0 0 2 0 PRP MD VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT JJ NN O
useful useful 0 0 0 0 0 0 0 0 6 0 VB DT JJ NN IN O
marker marker 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN JJ NN O
oxidative oxidative 0 0 0 0 0 0 0 0 9 0 NN IN JJ NN NN O
stress stress 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN IN O
exposition exposition 0 0 0 0 0 0 0 0 10 0 JJ NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJR O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT JJR NN O
higher higher 0 0 0 0 0 0 0 0 6 0 IN DT JJR NN NNP O
risk risk 0 0 0 0 0 0 0 0 4 0 DT JJR NN NNP NONE O
patients. patients. 0 0 0 0 0 0 0 0 9 0 JJR NN NNP NONE NONE O
Sodium Sodium 1 0 0 0 0 0 0 0 6 0 NONE NONE NN NN NNP O
Concentration Concentration 1 0 0 0 0 0 0 0 13 0 NONE NN NN NNP IN O
Measurement Measurement 1 0 0 0 0 0 0 0 11 0 NN NN NNP IN NNP O
during during 0 0 0 0 0 0 0 0 6 0 NN NNP IN NNP IN O
Hemodialysis Hemodialysis 1 0 0 0 0 0 0 0 12 0 NNP IN NNP IN JJ O
through through 0 0 0 0 0 0 0 0 7 0 IN NNP IN JJ NNP O
Ion-Exchange Ion-Exchange 1 0 1 0 0 0 0 0 12 0 NNP IN JJ NNP CC O
Resin Resin 1 0 0 0 0 0 0 0 5 0 IN JJ NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNP CC NNP NNP O
Conductivity Conductivity 1 0 0 0 0 0 0 0 12 0 NNP CC NNP NNP NNP O
Measure Measure 1 0 0 0 0 0 0 0 7 0 CC NNP NNP NNP NNP O
Approach: Approach: 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Vitro Vitro 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Experiments. Experiments. 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
Tura Tura 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sbrignadello Sbrignadello 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Mambelli Mambelli 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
E, E, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ravazzani Ravazzani 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Santoro Santoro 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Pacini Pacini 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
G. G. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biomedical Biomedical 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Engineering, Engineering, 1 0 0 0 1 0 0 0 12 0 IN NNP NNP NNP NNP O
National National 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Council, Council, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Padova, Padova, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Italy. Italy. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
Sodium Sodium 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NN IN O
measurement measurement 0 0 0 0 0 0 0 0 11 0 NNP NNP NN IN NN O
during during 0 0 0 0 0 0 0 0 6 0 NNP NN IN NN NN O
hemodialysis hemodialysis 0 0 0 0 0 0 0 0 12 0 NN IN NN NN VBZ O
treatment treatment 0 0 0 0 0 0 0 0 9 0 IN NN NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ JJ TO O
important important 0 0 0 0 0 0 0 0 9 0 NN VBZ JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO VB DT O
preserve preserve 0 0 0 0 0 0 0 0 8 0 JJ TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
patient patient 0 0 0 0 0 0 0 0 7 0 VB DT NN IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 DT NN IN JJ NNS O
clinical clinical 0 0 0 0 0 0 0 0 8 0 NN IN JJ NNS VBN O
events events 0 0 0 0 0 0 0 0 6 0 IN JJ NNS VBN TO O
related related 0 0 0 0 0 0 0 0 7 0 JJ NNS VBN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBN TO NNP CC O
hypo- hypo- 0 0 1 0 0 0 0 0 5 0 VBN TO NNP CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 TO NNP CC NNP NNP O
hyper-natremia hyper-natremia 0 0 1 0 0 0 0 0 14 0 NNP CC NNP NNP NN O
Usually, Usually, 1 0 0 0 1 0 0 0 8 0 CC NNP NNP NN NN O
sodium sodium 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NN VBZ O
measurement measurement 0 0 0 0 0 0 0 0 11 0 NNP NN NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ VBN IN O
performed performed 0 0 0 0 0 0 0 0 9 0 NN VBZ VBN IN NN O
through through 0 0 0 0 0 0 0 0 7 0 VBZ VBN IN NN NN O
laboratory laboratory 0 0 0 0 0 0 0 0 10 0 VBN IN NN NN WDT O
equipment equipment 0 0 0 0 0 0 0 0 9 0 IN NN NN WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NN WDT VBZ RB -NONE- O
typically typically 0 0 0 0 0 0 0 0 9 0 WDT VBZ RB -NONE- CC O
expensive, expensive, 0 0 0 0 1 0 0 0 10 0 VBZ RB -NONE- CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 RB -NONE- CC VBZ JJ O
requires requires 0 0 0 0 0 0 0 0 8 0 -NONE- CC VBZ JJ NNP O
manual manual 0 0 0 0 0 0 0 0 6 0 CC VBZ JJ NNP NNP O
intervention. intervention. 0 0 0 0 0 0 0 0 13 0 VBZ JJ NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP VBP DT O
propose propose 0 0 0 0 0 0 0 0 7 0 NNP NNP VBP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBP DT JJ NN O
new new 0 0 0 0 0 0 0 0 3 0 VBP DT JJ NN VBN O
method, method, 0 0 0 0 1 0 0 0 7 0 DT JJ NN VBN IN O
based based 0 0 0 0 0 0 0 0 5 0 JJ NN VBN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NN VBN IN NN NN O
conductivity conductivity 0 0 0 0 0 0 0 0 12 0 VBN IN NN NN IN O
measurement measurement 0 0 0 0 0 0 0 0 11 0 IN NN NN IN NN O
after after 0 0 0 0 0 0 0 0 5 0 NN NN IN NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NN IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NN O
dialysate dialysate 0 0 0 0 0 0 0 0 9 0 NN IN NN NN IN O
solution solution 0 0 0 0 0 0 0 0 8 0 IN NN NN IN JJ O
through through 0 0 0 0 0 0 0 0 7 0 NN NN IN JJ NNP O
ion-exchange ion-exchange 0 0 1 0 0 0 0 0 12 0 NN IN JJ NNP NNP O
resin. resin. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP NN O
To To 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NN DT O
test test 0 0 0 0 0 0 0 0 4 0 NNP NNP NN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NN DT NN PRP O
method, method, 0 0 0 0 1 0 0 0 7 0 NN DT NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBD IN O
performed performed 0 0 0 0 0 0 0 0 9 0 NN PRP VBD IN NN O
in in 0 0 0 0 0 0 0 0 2 0 PRP VBD IN NN NNP O
vitro vitro 0 0 0 0 0 0 0 0 5 0 VBD IN NN NNP NNP O
experiments. experiments. 0 0 0 0 0 0 0 0 12 0 IN NN NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBD CD O
prepared prepared 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD CD NN O
40 40 0 0 0 0 0 0 1 1 2 0 NNP VBD CD NN NN O
ml ml 0 0 0 0 0 0 0 0 2 0 VBD CD NN NN NN O
sodium sodium 0 0 0 0 0 0 0 0 6 0 CD NN NN NN NN O
chloride chloride 0 0 0 0 0 0 0 0 8 0 NN NN NN NN NNS O
(NaCl) (NaCl) 0 0 0 0 0 0 0 0 6 0 NN NN NN NNS IN O
samples samples 0 0 0 0 0 0 0 0 7 0 NN NN NNS IN CD O
at at 0 0 0 0 0 0 0 0 2 0 NN NNS IN CD CD O
280, 280, 0 0 0 0 1 0 0 1 4 0 NNS IN CD CD CD O
140, 140, 0 0 0 0 1 0 0 1 4 0 IN CD CD CD CD O
70, 70, 0 0 0 0 1 0 0 1 3 0 CD CD CD CD CD O
35, 35, 0 0 0 0 1 0 0 1 3 0 CD CD CD CD CD O
17.5, 17.5, 0 0 0 0 1 0 0 1 5 0 CD CD CD CD CD O
8.75, 8.75, 0 0 0 0 1 0 0 1 5 0 CD CD CD CD JJ O
4.375 4.375 0 0 0 0 0 0 0 1 5 0 CD CD CD JJ CC O
mEq/l, mEq/l, 0 0 0 1 1 0 0 0 6 0 CD CD JJ CC DT O
and and 0 0 0 0 0 0 0 0 3 0 CD JJ CC DT JJ O
some some 0 0 0 0 0 0 0 0 4 0 JJ CC DT JJ NN O
"mixed "mixed 0 0 0 0 0 0 0 0 6 0 CC DT JJ NN NN O
samples", samples", 0 0 0 0 1 0 0 0 9 0 DT JJ NN NN IN O
i.e., i.e., 0 0 0 0 1 0 0 0 5 0 JJ NN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ NN O
added added 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NN O
potassium potassium 0 0 0 0 0 0 0 0 9 0 IN JJ NN NN NN O
chloride chloride 0 0 0 0 0 0 0 0 8 0 JJ NN NN NN IN O
(KCl) (KCl) 0 0 0 0 0 0 0 0 5 0 NN NN NN IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNS O
different different 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNS -NONE- O
concentrations concentrations 0 0 0 0 0 0 0 0 14 0 IN JJ NNS -NONE- -NONE- O
(4.375-17.5 (4.375-17.5 0 0 1 0 0 0 0 1 11 0 JJ NNS -NONE- -NONE- TO O
mEq/l), mEq/l), 0 0 0 1 1 0 0 0 7 0 NNS -NONE- -NONE- TO VB O
to to 0 0 0 0 0 0 0 0 2 0 -NONE- -NONE- TO VB DT O
simulate simulate 0 0 0 0 0 0 0 0 8 0 -NONE- TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN NNS O
confounding confounding 0 0 0 0 0 0 0 0 11 0 VB DT NN NNS IN O
factors factors 0 0 0 0 0 0 0 0 7 0 DT NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ NN O
conductivity-based conductivity-based 0 0 1 0 0 0 0 0 18 0 IN DT JJ NN NNP O
sodium sodium 0 0 0 0 0 0 0 0 6 0 DT JJ NN NNP NNP O
measurement. measurement. 0 0 0 0 0 0 0 0 12 0 JJ NN NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBD DT O
measured measured 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN IN O
conductivity conductivity 0 0 0 0 0 0 0 0 12 0 VBD DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
all all 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
samples. samples. 0 0 0 0 0 0 0 0 8 0 IN DT NNP NNP DT O
Afterwards, Afterwards, 1 0 0 0 1 0 0 0 11 0 DT NNP NNP DT NN O
each each 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN VBD O
sample sample 0 0 0 0 0 0 0 0 6 0 NNP DT NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD VBN IN O
treated treated 0 0 0 0 0 0 0 0 7 0 NN VBD VBN IN CD O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN CD NN O
1 1 0 0 0 0 0 0 1 1 1 0 VBN IN CD NN IN O
min min 0 0 0 0 0 0 0 0 3 0 IN CD NN IN CD O
with with 0 0 0 0 0 0 0 0 4 0 CD NN IN CD NN O
1 1 0 0 0 0 0 0 1 1 1 0 NN IN CD NN IN O
g g 0 0 0 0 0 0 0 0 1 0 IN CD NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN NNP NNP O
Dowex Dowex 1 0 0 0 0 0 0 0 5 0 NN IN NNP NNP NNP O
G-26 G-26 1 1 1 0 0 0 0 1 4 0 IN NNP NNP NNP CC O
resin, resin, 0 0 0 0 1 0 0 0 6 0 NNP NNP NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NN VBD O
conductivity conductivity 0 0 0 0 0 0 0 0 12 0 NNP CC NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 CC NN VBD VBN NNP O
measured measured 0 0 0 0 0 0 0 0 8 0 NN VBD VBN NNP NNP O
again. again. 0 0 0 0 0 0 0 0 6 0 VBD VBN NNP NNP NNP O
On On 1 0 0 0 0 0 0 0 2 0 VBN NNP NNP NNP DT O
average, average, 0 0 0 0 1 0 0 0 8 0 NNP NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
difference difference 0 0 0 0 0 0 0 0 10 0 NNP DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
conductivity conductivity 0 0 0 0 0 0 0 0 12 0 IN DT NN IN VBN O
between between 0 0 0 0 0 0 0 0 7 0 DT NN IN VBN NNS O
mixed mixed 0 0 0 0 0 0 0 0 5 0 NN IN VBN NNS CC O
samples samples 0 0 0 0 0 0 0 0 7 0 IN VBN NNS CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 VBN NNS CC VBG NN O
corresponding corresponding 0 0 0 0 0 0 0 0 13 0 NNS CC VBG NN NNP O
pure pure 0 0 0 0 0 0 0 0 4 0 CC VBG NN NNP NNS O
NaCl NaCl 1 0 0 0 0 0 0 0 4 0 VBG NN NNP NNS JJ O
samples samples 0 0 0 0 0 0 0 0 7 0 NN NNP NNS JJ DT O
(at (at 0 0 0 0 0 0 0 0 3 0 NNP NNS JJ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS JJ DT JJ NNP O
same same 0 0 0 0 0 0 0 0 4 0 JJ DT JJ NNP NNP O
NaCl NaCl 1 0 0 0 0 0 0 0 4 0 DT JJ NNP NNP VBD O
concentration) concentration) 0 0 0 0 0 0 0 0 14 0 JJ NNP NNP VBD CD O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD CD NNP O
20.9%. 20.9%. 0 0 0 0 0 0 0 1 6 0 NNP VBD CD NNP NN O
After After 1 0 0 0 0 0 0 0 5 0 VBD CD NNP NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 CD NNP NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
exchange exchange 0 0 0 0 0 0 0 0 8 0 IN DT NN NN PRP O
resin, resin, 0 0 0 0 1 0 0 0 6 0 DT NN NN PRP VBD O
it it 0 0 0 0 0 0 0 0 2 0 NN NN PRP VBD CD O
was was 0 0 0 0 0 0 0 0 3 0 NN PRP VBD CD -NONE- O
14.7%, 14.7%, 0 0 0 0 1 0 0 1 6 0 PRP VBD CD -NONE- CD O
i.e., i.e., 0 0 0 0 1 0 0 0 5 0 VBD CD -NONE- CD NNP O
42% 42% 0 0 0 0 0 0 0 1 3 0 CD -NONE- CD NNP NNP O
lower. lower. 0 0 0 0 0 0 0 0 6 0 -NONE- CD NNP NNP NNS O
Similar Similar 1 0 0 0 0 0 0 0 7 0 CD NNP NNP NNS VBD O
experiments experiments 0 0 0 0 0 0 0 0 11 0 NNP NNP NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD VBN IN O
performed performed 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NN NN O
calcium calcium 0 0 0 0 0 0 0 0 7 0 VBN IN NN NN CC O
chloride chloride 0 0 0 0 0 0 0 0 8 0 IN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
magnesium magnesium 0 0 0 0 0 0 0 0 9 0 NN CC NN NN IN O
chloride chloride 0 0 0 0 0 0 0 0 8 0 CC NN NN IN NN O
as as 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
confounding confounding 0 0 0 0 0 0 0 0 11 0 NN IN NN NN IN O
factors, factors, 0 0 0 0 1 0 0 0 8 0 IN NN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ NNP O
similar similar 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNP NNP O
results. results. 0 0 0 0 0 0 0 0 8 0 IN JJ NNP NNP RB O
We We 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP RB VBD O
also also 0 0 0 0 0 0 0 0 4 0 NNP NNP RB VBD DT O
performed performed 0 0 0 0 0 0 0 0 9 0 NNP RB VBD DT NNS O
some some 0 0 0 0 0 0 0 0 4 0 RB VBD DT NNS IN O
experiments experiments 0 0 0 0 0 0 0 0 11 0 VBD DT NNS IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NN O
actual actual 0 0 0 0 0 0 0 0 6 0 NNS IN JJ NN NN O
dialysate dialysate 0 0 0 0 0 0 0 0 9 0 IN JJ NN NN IN O
solution solution 0 0 0 0 0 0 0 0 8 0 JJ NN NN IN NN O
during during 0 0 0 0 0 0 0 0 6 0 NN NN IN NN NNS O
hemodialysis hemodialysis 0 0 0 0 0 0 0 0 12 0 NN IN NN NNS IN O
sessions sessions 0 0 0 0 0 0 0 0 8 0 IN NN NNS IN CD O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN CD NN O
15 15 0 0 0 0 0 0 1 1 2 0 NNS IN CD NN CC O
patients, patients, 0 0 0 0 1 0 0 0 9 0 IN CD NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 CD NN CC VBD IN O
found found 0 0 0 0 0 0 0 0 5 0 NN CC VBD IN DT O
that that 0 0 0 0 0 0 0 0 4 0 CC VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN IN O
correlation correlation 0 0 0 0 0 0 0 0 11 0 IN DT NN IN NN O
between between 0 0 0 0 0 0 0 0 7 0 DT NN IN NN NNS O
conductivity conductivity 0 0 0 0 0 0 0 0 12 0 NN IN NN NNS CC O
measures measures 0 0 0 0 0 0 0 0 8 0 IN NN NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NN NN O
sodium sodium 0 0 0 0 0 0 0 0 6 0 NNS CC NN NN VBN O
concentration concentration 0 0 0 0 0 0 0 0 13 0 CC NN NN VBN IN O
improved improved 0 0 0 0 0 0 0 0 8 0 NN NN VBN IN NN O
after after 0 0 0 0 0 0 0 0 5 0 NN VBN IN NN NN O
resin resin 0 0 0 0 0 0 0 0 5 0 VBN IN NN NN -NONE- O
treatment treatment 0 0 0 0 0 0 0 0 9 0 IN NN NN -NONE- IN O
(R=0.839 (R=0.839 0 1 0 0 0 0 0 1 8 0 NN NN -NONE- IN JJ O
before before 0 0 0 0 0 0 0 0 6 0 NN -NONE- IN JJ NN O
treatment, treatment, 0 0 0 0 1 0 0 0 10 0 -NONE- IN JJ NN IN O
R=0.924 R=0.924 1 1 0 0 0 0 0 1 7 0 IN JJ NN IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 JJ NN IN NNP NNP O
treatment, treatment, 0 0 0 0 1 0 0 0 10 0 NN IN NNP NNP NNP O
P<0.0001). P<0.0001). 1 1 0 0 0 0 0 1 10 0 IN NNP NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBP IN O
conclude conclude 0 0 0 0 0 0 0 0 8 0 NNP NNP VBP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBP IN JJ NN O
ion-exchange ion-exchange 0 0 1 0 0 0 0 0 12 0 VBP IN JJ NN NN O
resin resin 0 0 0 0 0 0 0 0 5 0 IN JJ NN NN VBN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 JJ NN NN VBN IN O
coupled coupled 0 0 0 0 0 0 0 0 7 0 NN NN VBN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NN VBN IN NN NNS O
conductivity conductivity 0 0 0 0 0 0 0 0 12 0 VBN IN NN NNS MD O
measures measures 0 0 0 0 0 0 0 0 8 0 IN NN NNS MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN NNS MD VB DT O
improve improve 0 0 0 0 0 0 0 0 7 0 NNS MD VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NN IN O
measurement measurement 0 0 0 0 0 0 0 0 11 0 VB DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN VBN O
sodium sodium 0 0 0 0 0 0 0 0 6 0 NN IN NN VBN TO O
compared compared 0 0 0 0 0 0 0 0 8 0 IN NN VBN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NN VBN TO NN NNS O
conductivity conductivity 0 0 0 0 0 0 0 0 12 0 VBN TO NN NNS -NONE- O
measures measures 0 0 0 0 0 0 0 0 8 0 TO NN NNS -NONE- CC O
alone, alone, 0 0 0 0 1 0 0 0 6 0 NN NNS -NONE- CC MD O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC MD VB O
may may 0 0 0 0 0 0 0 0 3 0 -NONE- CC MD VB DT O
become become 0 0 0 0 0 0 0 0 6 0 CC MD VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT JJ NN O
possible possible 0 0 0 0 0 0 0 0 8 0 VB DT JJ NN NN O
simple simple 0 0 0 0 0 0 0 0 6 0 DT JJ NN NN IN O
approach approach 0 0 0 0 0 0 0 0 8 0 JJ NN NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN JJ CC O
continuous continuous 0 0 0 0 0 0 0 0 10 0 NN IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NN O
automatic automatic 0 0 0 0 0 0 0 0 9 0 JJ CC JJ NN NN O
sodium sodium 0 0 0 0 0 0 0 0 6 0 CC JJ NN NN IN O
measurement measurement 0 0 0 0 0 0 0 0 11 0 JJ NN NN IN NNP O
during during 0 0 0 0 0 0 0 0 6 0 NN NN IN NNP NONE O
hemodialysis. hemodialysis. 0 0 0 0 0 0 0 0 13 0 NN IN NNP NONE NONE O
ortical ortical 0 0 0 0 0 0 0 0 7 0 NONE NONE JJ NN NN O
hand hand 0 0 0 0 0 0 0 0 4 0 NONE JJ NN NN NN O
bone bone 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN CC O
porosity porosity 0 0 0 0 0 0 0 0 8 0 NN NN NN CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NN CC PRP$ NN IN O
association association 0 0 0 0 0 0 0 0 11 0 CC PRP$ NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 PRP$ NN IN JJ NNS O
distal distal 0 0 0 0 0 0 0 0 6 0 NN IN JJ NNS NN O
radius radius 0 0 0 0 0 0 0 0 6 0 IN JJ NNS NN IN O
fracture fracture 0 0 0 0 0 0 0 0 8 0 JJ NNS NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNS NN IN NN VBD O
middle middle 0 0 0 0 0 0 0 0 6 0 NN IN NN VBD CC O
aged aged 0 0 0 0 0 0 0 0 4 0 IN NN VBD CC RB O
and and 0 0 0 0 0 0 0 0 3 0 NN VBD CC RB NNP O
elderly elderly 0 0 0 0 0 0 0 0 7 0 VBD CC RB NNP NNP O
women. women. 0 0 0 0 0 0 0 0 6 0 CC RB NNP NNP NNP O
Dhainaut Dhainaut 1 0 0 0 0 0 0 0 8 0 RB NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hoff Hoff 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Syversen Syversen 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
U, U, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Haugeberg Haugeberg 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
G. G. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Neuroscience, Neuroscience, 1 0 0 0 1 0 0 0 13 0 NNP IN NNP NNP IN O
Division Division 1 0 0 0 0 0 0 0 8 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Rheumatology, Rheumatology, 1 0 0 0 1 0 0 0 13 0 NNP IN NNP NNP NNP O
Norwegian Norwegian 1 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Science Science 1 0 0 0 0 0 0 0 7 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Technology, Technology, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP NNP O
Trondheim, Trondheim, 1 0 0 0 1 0 0 0 10 0 CC NNP NNP NNP NNP O
Norway. Norway. 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
OBJECTIVE: OBJECTIVE: 1 1 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NN O
Reduced Reduced 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NN JJ O
bone bone 0 0 0 0 0 0 0 0 4 0 NNP NNP NN JJ NN O
mineral mineral 0 0 0 0 0 0 0 0 7 0 NNP NN JJ NN NN O
density density 0 0 0 0 0 0 0 0 7 0 NN JJ NN NN VBD O
(BMD), (BMD), 0 1 0 0 1 0 0 0 6 0 JJ NN NN VBD IN O
assessed assessed 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN NNP NNP O
Dual Dual 1 0 0 0 0 0 0 0 4 0 VBD IN NNP NNP NNP O
Energy Energy 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NN O
X-ray X-ray 1 0 1 0 0 0 0 0 5 0 NNP NNP NNP NN -NONE- O
absorptiometry absorptiometry 0 0 0 0 0 0 0 0 14 0 NNP NNP NN -NONE- VBZ O
(DXA), (DXA), 0 1 0 0 1 0 0 0 6 0 NNP NN -NONE- VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN -NONE- VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- VBZ DT JJ NN O
well-known well-known 0 0 1 0 0 0 0 0 10 0 VBZ DT JJ NN NN O
risk risk 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN IN O
factor factor 0 0 0 0 0 0 0 0 6 0 JJ NN NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NN NNP O
fragility fragility 0 0 0 0 0 0 0 0 9 0 NN IN NN NNP DT O
fracture. fracture. 0 0 0 0 0 0 0 0 9 0 IN NN NNP DT JJ O
A A 1 1 0 0 0 0 0 0 1 0 NN NNP DT JJ NN O
large large 0 0 0 0 0 0 0 0 5 0 NNP DT JJ NN IN O
proportion proportion 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 NN IN NNS IN NN O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN NN VBP O
fracture fracture 0 0 0 0 0 0 0 0 8 0 NNS IN NN VBP RB O
have have 0 0 0 0 0 0 0 0 4 0 IN NN VBP RB RB O
only only 0 0 0 0 0 0 0 0 4 0 NN VBP RB RB VBN O
slightly slightly 0 0 0 0 0 0 0 0 8 0 VBP RB RB VBN NNP O
reduced reduced 0 0 0 0 0 0 0 0 7 0 RB RB VBN NNP NNP O
BMD. BMD. 1 1 0 0 0 0 0 0 4 0 RB VBN NNP NNP IN O
Assessment Assessment 1 0 0 0 0 0 0 0 10 0 VBN NNP NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ NN O
other other 0 0 0 0 0 0 0 0 5 0 NNP IN JJ NN NN O
bone bone 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN NNS O
structure structure 0 0 0 0 0 0 0 0 9 0 JJ NN NN NNS IN O
features features 0 0 0 0 0 0 0 0 8 0 NN NN NNS IN NNP O
than than 0 0 0 0 0 0 0 0 4 0 NN NNS IN NNP MD O
BMD BMD 1 1 0 0 0 0 0 0 3 0 NNS IN NNP MD VB O
may may 0 0 0 0 0 0 0 0 3 0 IN NNP MD VB NN O
improve improve 0 0 0 0 0 0 0 0 7 0 NNP MD VB NN IN O
identification identification 0 0 0 0 0 0 0 0 14 0 MD VB NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 VB NN IN NNS IN O
individuals individuals 0 0 0 0 0 0 0 0 11 0 NN IN NNS IN VBN O
at at 0 0 0 0 0 0 0 0 2 0 IN NNS IN VBN NN O
increased increased 0 0 0 0 0 0 0 0 9 0 NNS IN VBN NN NNP O
fracture fracture 0 0 0 0 0 0 0 0 8 0 IN VBN NN NNP NNP O
risk. risk. 0 0 0 0 0 0 0 0 5 0 VBN NN NNP NNP NNP O
Digital Digital 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NNP NN O
X-ray X-ray 1 0 1 0 0 0 0 0 5 0 NNP NNP NNP NN -NONE- O
radiogrammetry radiogrammetry 0 0 0 0 0 0 0 0 14 0 NNP NNP NN -NONE- WDT O
(DXR), (DXR), 0 1 0 0 1 0 0 0 6 0 NNP NN -NONE- WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN -NONE- WDT VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 -NONE- WDT VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 WDT VBZ DT JJ NN O
feasible feasible 0 0 0 0 0 0 0 0 8 0 VBZ DT JJ NN IN O
tool tool 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN IN O
measurement measurement 0 0 0 0 0 0 0 0 11 0 NN IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ JJ O
metacarpal metacarpal 0 0 0 0 0 0 0 0 10 0 NN IN JJ JJ NN O
cortical cortical 0 0 0 0 0 0 0 0 8 0 IN JJ JJ NN NN O
bone bone 0 0 0 0 0 0 0 0 4 0 JJ JJ NN NN RB O
density, density, 0 0 0 0 1 0 0 0 8 0 JJ NN NN RB VBZ O
also also 0 0 0 0 0 0 0 0 4 0 NN NN RB VBZ DT O
gives gives 0 0 0 0 0 0 0 0 5 0 NN RB VBZ DT NN O
an an 0 0 0 0 0 0 0 0 2 0 RB VBZ DT NN IN O
estimate estimate 0 0 0 0 0 0 0 0 8 0 VBZ DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
cortical cortical 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN NNP O
bone bone 0 0 0 0 0 0 0 0 4 0 IN JJ NN NNP NNP O
porosity. porosity. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NNP JJ O
Our Our 1 0 0 0 0 0 0 0 3 0 NN NNP NNP JJ NN O
primary primary 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NN VBD O
aim aim 0 0 0 0 0 0 0 0 3 0 NNP JJ NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB DT O
explore explore 0 0 0 0 0 0 0 0 7 0 VBD TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
association association 0 0 0 0 0 0 0 0 11 0 VB DT NN IN JJ O
between between 0 0 0 0 0 0 0 0 7 0 DT NN IN JJ NN O
cortical cortical 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN IN O
porosity porosity 0 0 0 0 0 0 0 0 8 0 IN JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBD O
hand hand 0 0 0 0 0 0 0 0 4 0 IN DT NN VBD IN O
assessed assessed 0 0 0 0 0 0 0 0 8 0 DT NN VBD IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN NNP CC O
DXR DXR 1 1 0 0 0 0 0 0 3 0 VBD IN NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC JJ NN O
distal distal 0 0 0 0 0 0 0 0 6 0 NNP CC JJ NN NNP O
radius radius 0 0 0 0 0 0 0 0 6 0 CC JJ NN NNP NNP O
fracture. fracture. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 NN NNP NNP NNP NNP O
This This 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NN O
case-control case-control 0 0 1 0 0 0 0 0 12 0 NNP NNP NNP NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD CD O
included included 0 0 0 0 0 0 0 0 8 0 NNP NN VBD CD NNS O
123 123 0 0 0 0 0 0 1 1 3 0 NN VBD CD NNS -NONE- O
women women 0 0 0 0 0 0 0 0 5 0 VBD CD NNS -NONE- NNS O
>50 >50 0 0 0 0 0 0 0 1 3 0 CD NNS -NONE- NNS IN O
years years 0 0 0 0 0 0 0 0 5 0 NNS -NONE- NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 -NONE- NNS IN JJ NNS O
distal distal 0 0 0 0 0 0 0 0 6 0 NNS IN JJ NNS -NONE- O
radius radius 0 0 0 0 0 0 0 0 6 0 IN JJ NNS -NONE- CC O
fracture, fracture, 0 0 0 0 1 0 0 0 9 0 JJ NNS -NONE- CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC CD NNP O
170 170 0 0 0 0 0 0 1 1 3 0 -NONE- CC CD NNP NNP O
controls. controls. 0 0 0 0 0 0 0 0 9 0 CC CD NNP NNP VBD O
DXR DXR 1 1 0 0 0 0 0 0 3 0 CD NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 NNP VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB JJ O
measure measure 0 0 0 0 0 0 0 0 7 0 VBN TO VB JJ NNP O
metacarpal metacarpal 0 0 0 0 0 0 0 0 10 0 TO VB JJ NNP NNP O
BMD BMD 1 1 0 0 0 0 0 0 3 0 VB JJ NNP NNP JJ O
(DXR-BMD), (DXR-BMD), 0 1 1 0 1 0 0 0 10 0 JJ NNP NNP JJ NN O
cortical cortical 0 0 0 0 0 0 0 0 8 0 NNP NNP JJ NN NN O
porosity porosity 0 0 0 0 0 0 0 0 8 0 NNP JJ NN NN NN O
(DXR-porosity), (DXR-porosity), 0 0 1 0 1 0 0 0 15 0 JJ NN NN NN NN O
thickness thickness 0 0 0 0 0 0 0 0 9 0 NN NN NN NN CC O
(DXR-CT) (DXR-CT) 0 1 1 0 0 0 0 0 8 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
bone bone 0 0 0 0 0 0 0 0 4 0 NN CC NN NN NN O
width width 0 0 0 0 0 0 0 0 5 0 CC NN NN NN IN O
(DXR-W) (DXR-W) 0 1 1 0 0 0 0 0 7 0 NN NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
hand. hand. 0 0 0 0 0 0 0 0 5 0 IN DT NNP NNP NN O
Femoral Femoral 1 0 0 0 0 0 0 0 7 0 DT NNP NNP NN NNP O
neck neck 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NNP VBD O
BMD BMD 1 1 0 0 0 0 0 0 3 0 NNP NN NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NNP VBD VBN IN O
measured measured 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
DXA. DXA. 1 1 0 0 0 0 0 0 4 0 VBN IN NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 IN NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN NN O
fracture fracture 0 0 0 0 0 0 0 0 8 0 NNP NNP NN NN VBD O
group group 0 0 0 0 0 0 0 0 5 0 NNP NN NN VBD DT O
had had 0 0 0 0 0 0 0 0 3 0 NN NN VBD DT RB O
a a 0 0 0 0 0 0 0 0 1 0 NN VBD DT RB JJ O
statistically statistically 0 0 0 0 0 0 0 0 13 0 VBD DT RB JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 DT RB JJ NN JJ O
lower lower 0 0 0 0 0 0 0 0 5 0 RB JJ NN JJ -NONE- O
DXR-BMD DXR-BMD 1 1 1 0 0 0 0 0 7 0 JJ NN JJ -NONE- NNP O
(0.492 (0.492 0 0 0 0 0 0 0 1 6 0 NN JJ -NONE- NNP CD O
vs. vs. 0 0 0 0 0 0 0 0 3 0 JJ -NONE- NNP CD -NONE- O
0.524 0.524 0 0 0 0 0 0 0 1 5 0 -NONE- NNP CD -NONE- JJ O
g/cm(2) g/cm(2) 0 0 0 1 0 0 0 1 7 0 NNP CD -NONE- JJ JJR O
p<0.001), p<0.001), 0 0 0 0 1 0 0 1 9 0 CD -NONE- JJ JJR JJ O
higher higher 0 0 0 0 0 0 0 0 6 0 -NONE- JJ JJR JJ NN O
cortical cortical 0 0 0 0 0 0 0 0 8 0 JJ JJR JJ NN -NONE- O
DXR-porosity DXR-porosity 1 0 1 0 0 0 0 0 12 0 JJR JJ NN -NONE- NNP O
(0.01256 (0.01256 0 0 0 0 0 0 0 1 8 0 JJ NN -NONE- NNP CD O
vs. vs. 0 0 0 0 0 0 0 0 3 0 NN -NONE- NNP CD -NONE- O
0.01093, 0.01093, 0 0 0 0 1 0 0 1 8 0 -NONE- NNP CD -NONE- JJR O
p<0.001), p<0.001), 0 0 0 0 1 0 0 1 9 0 NNP CD -NONE- JJR JJ O
less less 0 0 0 0 0 0 0 0 4 0 CD -NONE- JJR JJ NN O
DXR-CT DXR-CT 1 1 1 0 0 0 0 0 6 0 -NONE- JJR JJ NN NNP O
(0.148 (0.148 0 0 0 0 0 0 0 1 6 0 JJR JJ NN NNP CD O
vs. vs. 0 0 0 0 0 0 0 0 3 0 JJ NN NNP CD -NONE- O
0.161cm, 0.161cm, 0 0 0 0 1 0 0 1 8 0 NN NNP CD -NONE- CC O
p<0.001) p<0.001) 0 0 0 0 0 0 0 1 8 0 NNP CD -NONE- CC JJR O
and and 0 0 0 0 0 0 0 0 3 0 CD -NONE- CC JJR JJ O
lower lower 0 0 0 0 0 0 0 0 5 0 -NONE- CC JJR JJ NN O
femoral femoral 0 0 0 0 0 0 0 0 7 0 CC JJR JJ NN JJ O
neck neck 0 0 0 0 0 0 0 0 4 0 JJR JJ NN JJ NN O
DXA-BMD DXA-BMD 1 1 1 0 0 0 0 0 7 0 JJ NN JJ NN NNP O
(0.789 (0.789 0 0 0 0 0 0 0 1 6 0 NN JJ NN NNP CD O
vs. vs. 0 0 0 0 0 0 0 0 3 0 JJ NN NNP CD -NONE- O
0.844 0.844 0 0 0 0 0 0 0 1 5 0 NN NNP CD -NONE- NN O
g/cm(2), g/cm(2), 0 0 0 1 1 0 0 1 8 0 NNP CD -NONE- NN : O
p p 0 0 0 0 0 0 0 0 1 0 CD -NONE- NN : CD O
= = 0 0 0 0 0 0 0 0 1 0 -NONE- NN : CD IN O
0.001) 0.001) 0 0 0 0 0 0 0 1 6 0 NN : CD IN DT O
than than 0 0 0 0 0 0 0 0 4 0 : CD IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT NNP NNP O
controls. controls. 0 0 0 0 0 0 0 0 9 0 IN DT NNP NNP JJ O
In In 1 0 0 0 0 0 0 0 2 0 DT NNP NNP JJ NN O
logistic logistic 0 0 0 0 0 0 0 0 8 0 NNP NNP JJ NN NN O
regression regression 0 0 0 0 0 0 0 0 10 0 NNP JJ NN NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 JJ NN NN VBD IN O
adjusted adjusted 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NN VBD IN JJ DT O
age, age, 0 0 0 0 1 0 0 0 4 0 VBD IN JJ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 IN JJ DT JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 JJ DT JJ NN IN O
association association 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN JJ NNS O
distal distal 0 0 0 0 0 0 0 0 6 0 NN IN JJ NNS NN O
radius radius 0 0 0 0 0 0 0 0 6 0 IN JJ NNS NN NN O
fracture fracture 0 0 0 0 0 0 0 0 8 0 JJ NNS NN NN CD O
(OR, (OR, 0 1 0 0 1 0 0 0 4 0 NNS NN NN CD NN O
95% 95% 0 0 0 0 0 0 0 1 3 0 NN NN CD NN VBD O
CI) CI) 1 1 0 0 0 0 0 0 3 0 NN CD NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 CD NN VBD VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 NN VBD VBN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN NN NN O
body body 0 0 0 0 0 0 0 0 4 0 VBN IN NN NN NN O
mass mass 0 0 0 0 0 0 0 0 4 0 IN NN NN NN NN O
index index 0 0 0 0 0 0 0 0 5 0 NN NN NN NN CD O
(0.930, (0.930, 0 0 0 0 1 0 0 1 7 0 NN NN NN CD JJ O
0.880-0.983), 0.880-0.983), 0 0 1 0 1 0 0 1 13 0 NN NN CD JJ NN O
DXA-BMD DXA-BMD 1 1 1 0 0 0 0 0 7 0 NN CD JJ NN CD O
(0.996, (0.996, 0 0 0 0 1 0 0 1 7 0 CD JJ NN CD JJ O
0.995-0.999), 0.995-0.999), 0 0 1 0 1 0 0 1 13 0 JJ NN CD JJ NN O
DXR-BMD DXR-BMD 1 1 1 0 0 0 0 0 7 0 NN CD JJ NN CD O
(0.990, (0.990, 0 0 0 0 1 0 0 1 7 0 CD JJ NN CD NN O
0.985-0.998), 0.985-0.998), 0 0 1 0 1 0 0 1 13 0 JJ NN CD NN -NONE- O
DXR-porosity DXR-porosity 1 0 1 0 0 0 0 0 12 0 NN CD NN -NONE- CD O
(1.468, (1.468, 0 0 0 0 1 0 0 1 7 0 CD NN -NONE- CD CC O
1.278-1.687) 1.278-1.687) 0 0 1 0 0 0 0 1 12 0 NN -NONE- CD CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- CD CC JJ NN O
DXR-CT DXR-CT 1 1 1 0 0 0 0 0 6 0 CD CC JJ NN CD O
(0.997, (0.997, 0 0 0 0 1 0 0 1 7 0 CC JJ NN CD NNP O
0.996-0.999). 0.996-0.999). 0 0 1 0 0 0 0 1 13 0 JJ NN CD NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NN CD NNP DT VBN O
an an 0 0 0 0 0 0 0 0 2 0 CD NNP DT VBN -NONE- O
adjusted adjusted 0 0 0 0 0 0 0 0 8 0 NNP DT VBN -NONE- JJ O
model, model, 0 0 0 0 1 0 0 0 6 0 DT VBN -NONE- JJ VBN O
DXR-porosity DXR-porosity 1 0 1 0 0 0 0 0 12 0 VBN -NONE- JJ VBN DT O
remained remained 0 0 0 0 0 0 0 0 8 0 -NONE- JJ VBN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ VBN DT JJ JJ O
only only 0 0 0 0 0 0 0 0 4 0 VBN DT JJ JJ VBN O
variable variable 0 0 0 0 0 0 0 0 8 0 DT JJ JJ VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 JJ JJ VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 JJ VBN IN JJ NNS O
distal distal 0 0 0 0 0 0 0 0 6 0 VBN IN JJ NNS NN O
radius radius 0 0 0 0 0 0 0 0 6 0 IN JJ NNS NN NN O
fracture fracture 0 0 0 0 0 0 0 0 8 0 JJ NNS NN NN CD O
(1.415, (1.415, 0 0 0 0 1 0 0 1 7 0 NNS NN NN CD NN O
1.194-1.677). 1.194-1.677). 0 0 1 0 0 0 0 1 13 0 NN NN CD NN NNP O
CONCLUSION: CONCLUSION: 1 1 0 0 0 0 0 0 11 0 NN CD NN NNP VBD O
DXR DXR 1 1 0 0 0 0 0 0 3 0 CD NN NNP VBD NN O
derived derived 0 0 0 0 0 0 0 0 7 0 NN NNP VBD NN VBZ O
porosity porosity 0 0 0 0 0 0 0 0 8 0 NNP VBD NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 VBD NN VBZ VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NN VBZ VBN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN NN IN O
fracture fracture 0 0 0 0 0 0 0 0 8 0 VBN IN NN IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NNS O
distal distal 0 0 0 0 0 0 0 0 6 0 NN IN JJ NNS CC O
radius radius 0 0 0 0 0 0 0 0 6 0 IN JJ NNS CC MD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC MD VB O
might might 0 0 0 0 0 0 0 0 5 0 NNS CC MD VB DT O
be be 0 0 0 0 0 0 0 0 2 0 CC MD VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT JJ NN O
sensitive sensitive 0 0 0 0 0 0 0 0 9 0 VB DT JJ NN IN O
marker marker 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN JJ NNP O
skeletal skeletal 0 0 0 0 0 0 0 0 8 0 NN IN JJ NNP NONE O
fragility. fragility. 0 0 0 0 0 0 0 0 10 0 IN JJ NNP NONE NONE O
Optimization Optimization 1 0 0 0 0 0 0 0 12 0 NONE NONE NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN -NONE- CC O
CDT-1 CDT-1 1 1 1 0 0 0 0 1 5 0 NN IN -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN -NONE- CC NNP NNP O
XYL1 XYL1 1 1 0 0 0 0 0 1 4 0 -NONE- CC NNP NNP IN O
Expression Expression 1 0 0 0 0 0 0 0 10 0 CC NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NN O
Balanced Balanced 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NN IN O
Co-Production Co-Production 1 0 1 0 0 0 0 0 13 0 IN NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP CC O
Ethanol Ethanol 1 0 0 0 0 0 0 0 7 0 NN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP IN O
Xylitol Xylitol 1 0 0 0 0 0 0 0 7 0 NNP CC NNP IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 CC NNP IN NNP CC O
Cellobiose Cellobiose 1 0 0 0 0 0 0 0 10 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP IN O
Xylose Xylose 1 0 0 0 0 0 0 0 6 0 NNP CC NNP IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 CC NNP IN NNP NNPS O
Engineered Engineered 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNPS NNP O
Saccharomyces Saccharomyces 1 0 0 0 0 0 0 0 13 0 IN NNP NNPS NNP NNP O
cerevisiae. cerevisiae. 0 0 0 0 0 0 0 0 11 0 NNP NNPS NNP NNP NNP O
Zha Zha 1 0 0 0 0 0 0 0 3 0 NNPS NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
BZ, BZ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Shen Shen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
MH, MH, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Hu Hu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
ML, ML, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Song Song 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yuan Yuan 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
YJ. YJ. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Key Key 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP IN O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNPS O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNPS NNP O
Systems Systems 1 0 0 0 0 0 0 0 7 0 NNP IN NNPS NNP NNP O
Bioengineering Bioengineering 1 0 0 0 0 0 0 0 14 0 IN NNPS NNP NNP NNP O
(Tianjin (Tianjin 0 0 0 0 0 0 0 0 8 0 NNPS NNP NNP NNP NNP O
University), University), 1 0 0 0 1 0 0 0 12 0 NNP NNP NNP NNP IN O
Ministry Ministry 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Education, Education, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pharmaceutical Pharmaceutical 1 0 0 0 0 0 0 0 14 0 NNP IN NNP NNP NNP O
Engineering, Engineering, 1 0 0 0 1 0 0 0 12 0 IN NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Chemical Chemical 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP CC O
Engineering Engineering 1 0 0 0 0 0 0 0 11 0 IN NNP NNP CC NNP O
& & 0 0 0 0 0 0 0 0 1 0 NNP NNP CC NNP NNP O
Technology, Technology, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP NNP O
Tianjin Tianjin 1 0 0 0 0 0 0 0 7 0 CC NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Tianjin, Tianjin, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
P. P. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
R. R. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Production Production 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN CC O
ethanol ethanol 0 0 0 0 0 0 0 0 7 0 NNP IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN IN O
xylitol xylitol 0 0 0 0 0 0 0 0 7 0 NN CC NN IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 CC NN IN JJ NNS O
lignocellulosic lignocellulosic 0 0 0 0 0 0 0 0 15 0 NN IN JJ NNS VBZ O
hydrolysates hydrolysates 0 0 0 0 0 0 0 0 12 0 IN JJ NNS VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 JJ NNS VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNS VBZ DT JJ TO O
alternative alternative 0 0 0 0 0 0 0 0 11 0 VBZ DT JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 DT JJ TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ TO DT JJ NN O
traditional traditional 0 0 0 0 0 0 0 0 11 0 TO DT JJ NN IN O
production production 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
ethanol ethanol 0 0 0 0 0 0 0 0 7 0 NN IN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NNP O
utilizing utilizing 0 0 0 0 0 0 0 0 9 0 NN IN NN NNP NNP O
biomass. biomass. 0 0 0 0 0 0 0 0 8 0 IN NN NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
conversion conversion 0 0 0 0 0 0 0 0 10 0 NNP DT NN NN IN O
efficiency efficiency 0 0 0 0 0 0 0 0 10 0 DT NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN TO O
xylose xylose 0 0 0 0 0 0 0 0 6 0 NN IN NN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO NN VBZ O
xylitol xylitol 0 0 0 0 0 0 0 0 7 0 NN TO NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 TO NN VBZ VBN IN O
restricted restricted 0 0 0 0 0 0 0 0 10 0 NN VBZ VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN NN -NONE- O
glucose glucose 0 0 0 0 0 0 0 0 7 0 VBN IN NN -NONE- VBG O
repression, repression, 0 0 0 0 1 0 0 0 11 0 IN NN -NONE- VBG DT O
causing causing 0 0 0 0 0 0 0 0 7 0 NN -NONE- VBG DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- VBG DT JJ NN O
low low 0 0 0 0 0 0 0 0 3 0 VBG DT JJ NN NNP O
xylitol xylitol 0 0 0 0 0 0 0 0 7 0 DT JJ NN NNP TO O
titer. titer. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP TO DT O
To To 1 0 0 0 0 0 0 0 2 0 NN NNP TO DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP TO DT NN PRP O
end, end, 0 0 0 0 1 0 0 0 4 0 TO DT NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBD NNS O
cloned cloned 0 0 0 0 0 0 0 0 6 0 NN PRP VBD NNS -NONE- O
genes genes 0 0 0 0 0 0 0 0 5 0 PRP VBD NNS -NONE- JJ O
CDT-1 CDT-1 1 1 1 0 0 0 0 1 5 0 VBD NNS -NONE- JJ DT O
(encoding (encoding 0 0 0 0 0 0 0 0 9 0 NNS -NONE- JJ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- JJ DT NN NN O
cellodextrin cellodextrin 0 0 0 0 0 0 0 0 12 0 JJ DT NN NN CC O
transporter) transporter) 0 0 0 0 0 0 0 0 12 0 DT NN NN CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC -NONE- JJ O
gh1-1 gh1-1 0 0 1 0 0 0 0 1 5 0 NN CC -NONE- JJ DT O
(encoding (encoding 0 0 0 0 0 0 0 0 9 0 CC -NONE- JJ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 -NONE- JJ DT JJ NN O
intracellular intracellular 0 0 0 0 0 0 0 0 13 0 JJ DT JJ NN IN O
β-glucosidase) β-glucosidase) 0 0 1 0 0 0 0 0 14 0 DT JJ NN IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 JJ NN IN NNP NN O
Neurospora Neurospora 1 0 0 0 0 0 0 0 10 0 NN IN NNP NN CC O
crassa crassa 0 0 0 0 0 0 0 0 6 0 IN NNP NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NNP NNP O
XYL1 XYL1 1 1 0 0 0 0 0 1 4 0 NN CC NNP NNP DT O
(encoding (encoding 0 0 0 0 0 0 0 0 9 0 CC NNP NNP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT NN NN O
xylose xylose 0 0 0 0 0 0 0 0 6 0 NNP DT NN NN WDT O
reductase reductase 0 0 0 0 0 0 0 0 9 0 DT NN NN WDT VBZ O
that that 0 0 0 0 0 0 0 0 4 0 NN NN WDT VBZ VBP O
converts converts 0 0 0 0 0 0 0 0 8 0 NN WDT VBZ VBP IN O
xylose xylose 0 0 0 0 0 0 0 0 6 0 WDT VBZ VBP IN JJ O
into into 0 0 0 0 0 0 0 0 4 0 VBZ VBP IN JJ IN O
xylitol) xylitol) 0 0 0 0 0 0 0 0 8 0 VBP IN JJ IN NNPS O
from from 0 0 0 0 0 0 0 0 4 0 IN JJ IN NNPS NNS O
Scheffersomyces Scheffersomyces 1 0 0 0 0 0 0 0 15 0 JJ IN NNPS NNS IN O
stipitis stipitis 0 0 0 0 0 0 0 0 8 0 IN NNPS NNS IN NNS O
into into 0 0 0 0 0 0 0 0 4 0 NNPS NNS IN NNS -NONE- O
Saccharomyces Saccharomyces 1 0 0 0 0 0 0 0 13 0 NNS IN NNS -NONE- VBG O
cerevisiae, cerevisiae, 0 0 0 0 1 0 0 0 11 0 IN NNS -NONE- VBG JJ O
enabling enabling 0 0 0 0 0 0 0 0 8 0 NNS -NONE- VBG JJ NN O
simultaneous simultaneous 0 0 0 0 0 0 0 0 12 0 -NONE- VBG JJ NN IN O
production production 0 0 0 0 0 0 0 0 10 0 VBG JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN CC O
ethanol ethanol 0 0 0 0 0 0 0 0 7 0 NN IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN IN O
xylitol xylitol 0 0 0 0 0 0 0 0 7 0 NN CC NN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 CC NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN IN O
mixture mixture 0 0 0 0 0 0 0 0 7 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN CC O
cellobiose cellobiose 0 0 0 0 0 0 0 0 10 0 NN IN NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VB JJ O
xylose xylose 0 0 0 0 0 0 0 0 6 0 NN CC VB JJ NNS O
(main (main 0 0 0 0 0 0 0 0 5 0 CC VB JJ NNS IN O
components components 0 0 0 0 0 0 0 0 10 0 VB JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NNP O
lignocellulosic lignocellulosic 0 0 0 0 0 0 0 0 15 0 NNS IN JJ NNP NNP O
hydrolysates). hydrolysates). 0 0 0 0 0 0 0 0 14 0 IN JJ NNP NNP RB O
We We 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP RB VBD O
further further 0 0 0 0 0 0 0 0 7 0 NNP NNP RB VBD DT O
optimized optimized 0 0 0 0 0 0 0 0 9 0 NNP RB VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBD DT NN NNS O
expression expression 0 0 0 0 0 0 0 0 10 0 VBD DT NN NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 DT NN NNS IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN -NONE- CC O
CDT-1 CDT-1 1 1 1 0 0 0 0 1 5 0 NNS IN -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN -NONE- CC NNP IN O
XYL1 XYL1 1 1 0 0 0 0 0 1 4 0 -NONE- CC NNP IN NN O
by by 0 0 0 0 0 0 0 0 2 0 CC NNP IN NN PRP$ O
manipulating manipulating 0 0 0 0 0 0 0 0 12 0 NNP IN NN PRP$ NNS O
their their 0 0 0 0 0 0 0 0 5 0 IN NN PRP$ NNS CC O
promoters promoters 0 0 0 0 0 0 0 0 9 0 NN PRP$ NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 PRP$ NNS CC JJ CC O
copy-numbers, copy-numbers, 0 0 1 0 1 0 0 0 13 0 NNS CC JJ CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 CC JJ CC VBD DT O
constructed constructed 0 0 0 0 0 0 0 0 11 0 JJ CC VBD DT VBN O
an an 0 0 0 0 0 0 0 0 2 0 CC VBD DT VBN NNP O
engineered engineered 0 0 0 0 0 0 0 0 10 0 VBD DT VBN NNP NN O
S. S. 1 1 0 0 0 0 0 0 2 0 DT VBN NNP NN NN O
cerevisiae cerevisiae 0 0 0 0 0 0 0 0 10 0 VBN NNP NN NN NN O
strain strain 0 0 0 0 0 0 0 0 6 0 NNP NN NN NN CD O
(carrying (carrying 0 0 0 0 0 0 0 0 9 0 NN NN NN CD NN O
one one 0 0 0 0 0 0 0 0 3 0 NN NN CD NN IN O
copy copy 0 0 0 0 0 0 0 0 4 0 NN CD NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN -NONE- CC O
PGK1p-CDT1 PGK1p-CDT1 1 0 1 0 0 0 0 1 10 0 NN IN -NONE- CC CD O
and and 0 0 0 0 0 0 0 0 3 0 IN -NONE- CC CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 -NONE- CC CD NNS IN O
copies copies 0 0 0 0 0 0 0 0 6 0 CC CD NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN JJ WDT O
TDH3p-XYL1), TDH3p-XYL1), 1 0 1 0 1 0 0 1 12 0 NNS IN JJ WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 IN JJ WDT VBD DT O
showed showed 0 0 0 0 0 0 0 0 6 0 JJ WDT VBD DT CD O
an an 0 0 0 0 0 0 0 0 2 0 WDT VBD DT CD NN O
85.7% 85.7% 0 0 0 0 0 0 0 1 5 0 VBD DT CD NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 DT CD NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN NN NN O
xylitol xylitol 0 0 0 0 0 0 0 0 7 0 NN IN NN NN IN O
production production 0 0 0 0 0 0 0 0 10 0 IN NN NN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
mixture mixture 0 0 0 0 0 0 0 0 7 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN CC O
cellobiose cellobiose 0 0 0 0 0 0 0 0 10 0 NN IN NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VB IN O
xylose xylose 0 0 0 0 0 0 0 0 6 0 NN CC VB IN DT O
than than 0 0 0 0 0 0 0 0 4 0 CC VB IN DT IN O
that that 0 0 0 0 0 0 0 0 4 0 VB IN DT IN DT O
from from 0 0 0 0 0 0 0 0 4 0 IN DT IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 DT IN DT NN IN O
mixture mixture 0 0 0 0 0 0 0 0 7 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN CC O
glucose glucose 0 0 0 0 0 0 0 0 7 0 NN IN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NNP NNP O
xylose. xylose. 0 0 0 0 0 0 0 0 7 0 NN CC NNP NNP PRP O
Thus, Thus, 1 0 0 0 1 0 0 0 5 0 CC NNP NNP PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD DT O
achieved achieved 0 0 0 0 0 0 0 0 8 0 NNP PRP VBD DT VBN O
a a 0 0 0 0 0 0 0 0 1 0 PRP VBD DT VBN NN O
balanced balanced 0 0 0 0 0 0 0 0 8 0 VBD DT VBN NN IN O
co-fermentation co-fermentation 0 0 1 0 0 0 0 0 15 0 DT VBN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NN -NONE- O
cellobiose cellobiose 0 0 0 0 0 0 0 0 10 0 NN IN NN -NONE- -NONE- O
(0.165 (0.165 0 0 0 0 0 0 0 1 6 0 IN NN -NONE- -NONE- CC O
g/L/h) g/L/h) 0 0 0 1 0 0 0 0 6 0 NN -NONE- -NONE- CC VB O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- CC VB -NONE- O
xylose xylose 0 0 0 0 0 0 0 0 6 0 -NONE- CC VB -NONE- -NONE- O
(0.162 (0.162 0 0 0 0 0 0 0 1 6 0 CC VB -NONE- -NONE- IN O
g/L/h) g/L/h) 0 0 0 1 0 0 0 0 6 0 VB -NONE- -NONE- IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 -NONE- -NONE- IN JJ NNS O
similar similar 0 0 0 0 0 0 0 0 7 0 -NONE- IN JJ NNS TO O
rates rates 0 0 0 0 0 0 0 0 5 0 IN JJ NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO VB NN O
co-produce co-produce 0 0 1 0 0 0 0 0 10 0 NNS TO VB NN -NONE- O
ethanol ethanol 0 0 0 0 0 0 0 0 7 0 TO VB NN -NONE- -NONE- O
(0.36 (0.36 0 0 0 0 0 0 0 1 5 0 VB NN -NONE- -NONE- CC O
g/g) g/g) 0 0 0 1 0 0 0 0 4 0 NN -NONE- -NONE- CC NN O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- CC NN -NONE- O
xylitol xylitol 0 0 0 0 0 0 0 0 7 0 -NONE- CC NN -NONE- NNP O
(1.00 (1.00 0 0 0 0 0 0 0 1 5 0 CC NN -NONE- NNP NONE O
g/g). g/g). 0 0 0 1 0 0 0 0 5 0 NN -NONE- NNP NONE NONE O
Bidirectional Bidirectional 1 0 0 0 0 0 0 0 13 0 NONE NONE NNP NNP IN O
Transfer Transfer 1 0 0 0 0 0 0 0 8 0 NONE NNP NNP IN NNP O
between between 0 0 0 0 0 0 0 0 7 0 NNP NNP IN NNP NNP O
Metaphorical Metaphorical 1 0 0 0 0 0 0 0 12 0 NNP IN NNP NNP NNP O
Related Related 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP IN O
Domains Domains 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Implicit Implicit 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP IN O
Learning Learning 1 0 0 0 0 0 0 0 8 0 IN NNP NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ NNP O
Form-Meaning Form-Meaning 1 0 1 0 0 0 0 0 12 0 NNP IN JJ NNP NNP O
Connections. Connections. 1 0 0 0 0 0 0 0 12 0 IN JJ NNP NNP NNP O
Guo Guo 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yang Yang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Dienes Dienes 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Z. Z. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Shanghai Shanghai 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Key Key 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP IN O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Magnetic Magnetic 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP CC O
Resonance Resonance 1 0 0 0 0 0 0 0 9 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP CC NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NNP IN NNP CC O
Psychology Psychology 1 0 0 0 0 0 0 0 10 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Cognitive Cognitive 1 0 0 0 0 0 0 0 9 0 NNP CC NNP NNP NNP O
Science, Science, 1 0 0 0 1 0 0 0 8 0 CC NNP NNP NNP NNP O
East East 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
China China 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Normal Normal 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Shanghai, Shanghai, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP MD O
People People 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP MD RB O
can can 0 0 0 0 0 0 0 0 3 0 NNP NNP MD RB VB O
implicitly implicitly 0 0 0 0 0 0 0 0 10 0 NNP MD RB VB DT O
learn learn 0 0 0 0 0 0 0 0 5 0 MD RB VB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 RB VB DT NN IN O
connection connection 0 0 0 0 0 0 0 0 10 0 VB DT NN IN JJ O
between between 0 0 0 0 0 0 0 0 7 0 DT NN IN JJ NNS O
linguistic linguistic 0 0 0 0 0 0 0 0 10 0 NN IN JJ NNS CC O
forms forms 0 0 0 0 0 0 0 0 5 0 IN JJ NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC JJ IN O
meanings, meanings, 0 0 0 0 1 0 0 0 9 0 NNS CC JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 CC JJ IN NN IN O
example example 0 0 0 0 0 0 0 0 7 0 JJ IN NN IN JJ O
between between 0 0 0 0 0 0 0 0 7 0 IN NN IN JJ NNS O
specific specific 0 0 0 0 0 0 0 0 8 0 NN IN JJ NNS NNP O
determiners determiners 0 0 0 0 0 0 0 0 11 0 IN JJ NNS NNP NNP O
(e.g. (e.g. 0 0 0 0 0 0 0 0 5 0 JJ NNS NNP NNP NNP O
this, this, 0 0 0 0 1 0 0 0 5 0 NNS NNP NNP NNP CC O
that…) that…) 0 0 0 0 0 0 0 0 6 0 NNP NNP NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP CC DT NN IN O
type type 0 0 0 0 0 0 0 0 4 0 CC DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS TO O
nouns nouns 0 0 0 0 0 0 0 0 5 0 NN IN NNS TO WDT O
to to 0 0 0 0 0 0 0 0 2 0 IN NNS TO WDT PRP O
which which 0 0 0 0 0 0 0 0 5 0 NNS TO WDT PRP VBP O
they they 0 0 0 0 0 0 0 0 4 0 TO WDT PRP VBP NNP O
apply. apply. 0 0 0 0 0 0 0 0 6 0 WDT PRP VBP NNP NN O
Li Li 1 0 0 0 0 0 0 0 2 0 PRP VBP NNP NN NN O
et et 0 0 0 0 0 0 0 0 2 0 VBP NNP NN NN NN O
al al 0 0 0 0 0 0 0 0 2 0 NNP NN NN NN RB O
(2013) (2013) 0 0 0 0 0 0 0 1 6 0 NN NN NN RB VBD O
recently recently 0 0 0 0 0 0 0 0 8 0 NN NN RB VBD IN O
found found 0 0 0 0 0 0 0 0 5 0 NN RB VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 RB VBD IN NN IN O
transfer transfer 0 0 0 0 0 0 0 0 8 0 VBD IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NNS O
form-meaning form-meaning 0 0 1 0 0 0 0 0 12 0 NN IN JJ NNS IN O
connections connections 0 0 0 0 0 0 0 0 11 0 IN JJ NNS IN DT O
from from 0 0 0 0 0 0 0 0 4 0 JJ NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ NN O
concrete concrete 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN NN O
domain domain 0 0 0 0 0 0 0 0 6 0 DT JJ NN NN TO O
(height) (height) 0 0 0 0 0 0 0 0 8 0 JJ NN NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NN TO DT NN NN O
abstract abstract 0 0 0 0 0 0 0 0 8 0 TO DT NN NN NN O
domain domain 0 0 0 0 0 0 0 0 6 0 DT NN NN NN VBD O
(power) (power) 0 0 0 0 0 0 0 0 7 0 NN NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
achieved achieved 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NN O
metaphor-consistent metaphor-consistent 0 0 1 0 0 0 0 0 19 0 IN DT JJ NN IN O
way way 0 0 0 0 0 0 0 0 3 0 DT JJ NN IN NN O
without without 0 0 0 0 0 0 0 0 7 0 JJ NN IN NN VBG O
awareness, awareness, 0 0 0 0 1 0 0 0 10 0 NN IN NN VBG IN O
showing showing 0 0 0 0 0 0 0 0 7 0 IN NN VBG IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NN VBG IN JJ NN O
unconscious unconscious 0 0 0 0 0 0 0 0 11 0 VBG IN JJ NN MD O
knowledge knowledge 0 0 0 0 0 0 0 0 9 0 IN JJ NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 JJ NN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB VBN CC O
abstract abstract 0 0 0 0 0 0 0 0 8 0 MD VB VBN CC RB O
and and 0 0 0 0 0 0 0 0 3 0 VB VBN CC RB NNP O
flexibly flexibly 0 0 0 0 0 0 0 0 8 0 VBN CC RB NNP NNP O
deployed. deployed. 0 0 0 0 0 0 0 0 9 0 CC RB NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 RB NNP NNP JJ NN O
current current 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NN NNS O
study study 0 0 0 0 0 0 0 0 5 0 NNP JJ NN NNS TO O
aims aims 0 0 0 0 0 0 0 0 4 0 JJ NN NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO VB IN O
determine determine 0 0 0 0 0 0 0 0 9 0 NNS TO VB IN NNS O
whether whether 0 0 0 0 0 0 0 0 7 0 TO VB IN NNS VBP O
people people 0 0 0 0 0 0 0 0 6 0 VB IN NNS VBP NN O
transfer transfer 0 0 0 0 0 0 0 0 8 0 IN NNS VBP NN IN O
knowledge knowledge 0 0 0 0 0 0 0 0 9 0 NNS VBP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBP NN IN JJ NNS O
form-meaning form-meaning 0 0 1 0 0 0 0 0 12 0 NN IN JJ NNS RB O
connections connections 0 0 0 0 0 0 0 0 11 0 IN JJ NNS RB RB O
not not 0 0 0 0 0 0 0 0 3 0 JJ NNS RB RB IN O
only only 0 0 0 0 0 0 0 0 4 0 NNS RB RB IN DT O
from from 0 0 0 0 0 0 0 0 4 0 RB RB IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 RB IN DT JJ NN O
concrete concrete 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN TO O
domain domain 0 0 0 0 0 0 0 0 6 0 DT JJ NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NN TO DT NN NN O
abstract abstract 0 0 0 0 0 0 0 0 8 0 TO DT NN NN CC O
one, one, 0 0 0 0 1 0 0 0 4 0 DT NN NN CC RB O
but but 0 0 0 0 0 0 0 0 3 0 NN NN CC RB NN O
also also 0 0 0 0 0 0 0 0 4 0 NN CC RB NN -NONE- O
vice vice 0 0 0 0 0 0 0 0 4 0 CC RB NN -NONE- NN O
versa, versa, 0 0 0 0 1 0 0 0 6 0 RB NN -NONE- NN IN O
consistent consistent 0 0 0 0 0 0 0 0 10 0 NN -NONE- NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 -NONE- NN IN NN NN O
metaphor metaphor 0 0 0 0 0 0 0 0 8 0 NN IN NN NN VBG O
representation representation 0 0 0 0 0 0 0 0 14 0 IN NN NN VBG NNP O
being being 0 0 0 0 0 0 0 0 5 0 NN NN VBG NNP NNP O
bi-directional. bi-directional. 0 0 1 0 0 0 0 0 15 0 NN VBG NNP NNP DT O
With With 1 0 0 0 0 0 0 0 4 0 VBG NNP NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT JJ NN O
similar similar 0 0 0 0 0 0 0 0 7 0 NNP DT JJ NN IN O
paradigm paradigm 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN VBN O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 NN IN VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 IN VBN IN NNP NN O
Li Li 1 0 0 0 0 0 0 0 2 0 VBN IN NNP NN -NONE- O
et et 0 0 0 0 0 0 0 0 2 0 IN NNP NN -NONE- NNS O
al, al, 0 0 0 0 1 0 0 0 3 0 NNP NN -NONE- NNS VBP O
participants participants 0 0 0 0 0 0 0 0 12 0 NN -NONE- NNS VBP JJ O
learnt learnt 0 0 0 0 0 0 0 0 6 0 -NONE- NNS VBP JJ NN O
form- form- 0 0 1 0 0 0 0 0 5 0 NNS VBP JJ NN NNS O
meaning meaning 0 0 0 0 0 0 0 0 7 0 VBP JJ NN NNS IN O
connections connections 0 0 0 0 0 0 0 0 11 0 JJ NN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NNS O
different different 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NNS JJ O
domains domains 0 0 0 0 0 0 0 0 7 0 IN JJ NNS JJ NNP O
(concrete (concrete 0 0 0 0 0 0 0 0 9 0 JJ NNS JJ NNP NNP O
vs. vs. 0 0 0 0 0 0 0 0 3 0 NNS JJ NNP NNP CC O
abstract) abstract) 0 0 0 0 0 0 0 0 9 0 JJ NNP NNP CC RB O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC RB VBD O
then then 0 0 0 0 0 0 0 0 4 0 NNP CC RB VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 CC RB VBD VBN IN O
tested tested 0 0 0 0 0 0 0 0 6 0 RB VBD VBN IN CD O
on on 0 0 0 0 0 0 0 0 2 0 VBD VBN IN CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 VBN IN CD NNS IN O
kinds kinds 0 0 0 0 0 0 0 0 5 0 IN CD NNS IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN NNS JJ O
generalizations generalizations 0 0 0 0 0 0 0 0 15 0 NNS IN NNS JJ CC O
(same (same 0 0 0 0 0 0 0 0 5 0 IN NNS JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNS JJ CC JJ NN O
different different 0 0 0 0 0 0 0 0 9 0 JJ CC JJ NN NNP O
domain domain 0 0 0 0 0 0 0 0 6 0 CC JJ NN NNP NNP O
generalization). generalization). 0 0 0 0 0 0 0 0 16 0 JJ NN NNP NNP NNP O
As As 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NNP NN O
predicted, predicted, 0 0 0 0 1 0 0 0 10 0 NNP NNP NNP NN IN O
transfer transfer 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NNS O
form-meaning form-meaning 0 0 1 0 0 0 0 0 12 0 NN IN JJ NNS VBD O
connections connections 0 0 0 0 0 0 0 0 11 0 IN JJ NNS VBD RB O
occurred occurred 0 0 0 0 0 0 0 0 8 0 JJ NNS VBD RB WRB O
bidirectionally bidirectionally 0 0 0 0 0 0 0 0 15 0 NNS VBD RB WRB JJ O
when when 0 0 0 0 0 0 0 0 4 0 VBD RB WRB JJ NN O
structural structural 0 0 0 0 0 0 0 0 10 0 RB WRB JJ NN VBD O
knowledge knowledge 0 0 0 0 0 0 0 0 9 0 WRB JJ NN VBD NNP O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD NNP NNP O
unconscious. unconscious. 0 0 0 0 0 0 0 0 12 0 NN VBD NNP NNP DT O
Moreover, Moreover, 1 0 0 0 1 0 0 0 9 0 VBD NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
present present 0 0 0 0 0 0 0 0 7 0 NNP DT NN NN RB O
study study 0 0 0 0 0 0 0 0 5 0 DT NN NN RB VBD O
also also 0 0 0 0 0 0 0 0 4 0 NN NN RB VBD IN O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NN RB VBD IN JJR O
that that 0 0 0 0 0 0 0 0 4 0 RB VBD IN JJR NN O
more more 0 0 0 0 0 0 0 0 4 0 VBD IN JJR NN VBD O
transfer transfer 0 0 0 0 0 0 0 0 8 0 IN JJR NN VBD IN O
occurred occurred 0 0 0 0 0 0 0 0 8 0 JJR NN VBD IN RB O
between between 0 0 0 0 0 0 0 0 7 0 NN VBD IN RB VBN O
metaphorically metaphorically 0 0 0 0 0 0 0 0 14 0 VBD IN RB VBN NNS O
related related 0 0 0 0 0 0 0 0 7 0 IN RB VBN NNS WRB O
domains domains 0 0 0 0 0 0 0 0 7 0 RB VBN NNS WRB NN O
when when 0 0 0 0 0 0 0 0 4 0 VBN NNS WRB NN NN O
judgment judgment 0 0 0 0 0 0 0 0 8 0 NNS WRB NN NN VBD O
knowledge knowledge 0 0 0 0 0 0 0 0 9 0 WRB NN NN VBD JJ O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD JJ NN O
conscious conscious 0 0 0 0 0 0 0 0 9 0 NN VBD JJ NN RB O
(intuition) (intuition) 0 0 0 0 0 0 0 0 11 0 VBD JJ NN RB IN O
rather rather 0 0 0 0 0 0 0 0 6 0 JJ NN RB IN JJ O
than than 0 0 0 0 0 0 0 0 4 0 NN RB IN JJ NNP O
unconscious unconscious 0 0 0 0 0 0 0 0 11 0 RB IN JJ NNP NNP O
(guess). (guess). 0 0 0 0 0 0 0 0 8 0 IN JJ NNP NNP CC O
Conscious Conscious 1 0 0 0 0 0 0 0 9 0 JJ NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NN O
unconscious unconscious 0 0 0 0 0 0 0 0 11 0 NNP CC JJ NN NN O
judgment judgment 0 0 0 0 0 0 0 0 8 0 CC JJ NN NN MD O
knowledge knowledge 0 0 0 0 0 0 0 0 9 0 JJ NN NN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN NN MD VB JJ O
have have 0 0 0 0 0 0 0 0 4 0 NN MD VB JJ JJ O
different different 0 0 0 0 0 0 0 0 9 0 MD VB JJ JJ NNP O
functional functional 0 0 0 0 0 0 0 0 10 0 VB JJ JJ NNP NONE O
properties. properties. 0 0 0 0 0 0 0 0 11 0 JJ JJ NNP NONE NONE O
Sildenafil Sildenafil 1 0 0 0 0 0 0 0 10 0 NONE NONE NNP JJ NNP O
Citrate-Restored Citrate-Restored 1 0 1 0 0 0 0 0 16 0 NONE NNP JJ NNP CC O
eNOS eNOS 0 0 0 0 0 0 0 0 4 0 NNP JJ NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNP CC NNP NNP O
PDE5 PDE5 1 1 0 0 0 0 0 1 4 0 NNP CC NNP NNP IN O
Regulation Regulation 1 0 0 0 0 0 0 0 10 0 CC NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Sickle Sickle 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNP O
Mouse Mouse 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Penis Penis 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Prevents Prevents 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Priapism Priapism 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Via Via 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP IN O
Control Control 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ NNP O
Oxidative/Nitrosative Oxidative/Nitrosative 1 0 0 1 0 0 0 0 21 0 NNP IN JJ NNP NNP O
Stress. Stress. 1 0 0 0 0 0 0 0 7 0 IN JJ NNP NNP NNP O
Bivalacqua Bivalacqua 1 0 0 0 0 0 0 0 10 0 JJ NNP NNP NNP NNP O
TJ, TJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Musicki Musicki 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hsu Hsu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
LL, LL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Berkowitz Berkowitz 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
DE, DE, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Champion Champion 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
HC, HC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Burnett Burnett 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
AL. AL. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
James James 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Buchanan Buchanan 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Brady Brady 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Urological Urological 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Institute, Institute, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Johns Johns 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Hopkins Hopkins 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Institutions, Institutions, 1 0 0 0 1 0 0 0 13 0 NNP NNP NNP NNP NNP O
Baltimore, Baltimore, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Maryland, Maryland, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNPS O
United United 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNPS IN O
States States 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
America. America. 1 0 0 0 0 0 0 0 8 0 NNPS IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NN O
Sildenafil Sildenafil 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NN VBD O
citrate citrate 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBD DT O
revolutionized revolutionized 0 0 0 0 0 0 0 0 14 0 NNP NN VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBD DT NN IN O
practice practice 0 0 0 0 0 0 0 0 8 0 VBD DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
sexual sexual 0 0 0 0 0 0 0 0 6 0 NN IN JJ NN IN O
medicine medicine 0 0 0 0 0 0 0 0 8 0 IN JJ NN IN PRP$ O
upon upon 0 0 0 0 0 0 0 0 4 0 JJ NN IN PRP$ JJ O
its its 0 0 0 0 0 0 0 0 3 0 NN IN PRP$ JJ JJ O
federal federal 0 0 0 0 0 0 0 0 7 0 IN PRP$ JJ JJ NN O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 PRP$ JJ JJ NN NN O
agency agency 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NN RB O
approval approval 0 0 0 0 0 0 0 0 8 0 JJ NN NN RB CD O
approximately approximately 0 0 0 0 0 0 0 0 13 0 NN NN RB CD NNS O
15 15 0 0 0 0 0 0 1 1 2 0 NN RB CD NNS IN O
years years 0 0 0 0 0 0 0 0 5 0 RB CD NNS IN IN O
ago ago 0 0 0 0 0 0 0 0 3 0 CD NNS IN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NNS IN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 IN IN DT JJ NN O
prototypical prototypical 0 0 0 0 0 0 0 0 12 0 IN DT JJ NN NN O
phosphodiesterase phosphodiesterase 0 0 0 0 0 0 0 0 17 0 DT JJ NN NN CD O
type type 0 0 0 0 0 0 0 0 4 0 JJ NN NN CD NN O
5 5 0 0 0 0 0 0 1 1 1 0 NN NN CD NN VBD O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 NN CD NN VBD IN O
indicated indicated 0 0 0 0 0 0 0 0 9 0 CD NN VBD IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
male male 0 0 0 0 0 0 0 0 4 0 NN IN JJ NN NNP O
erectile erectile 0 0 0 0 0 0 0 0 8 0 IN JJ NN NNP NNP O
dysfunction. dysfunction. 0 0 0 0 0 0 0 0 12 0 JJ NN NNP NNP RB O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP RB VB O
now now 0 0 0 0 0 0 0 0 3 0 NNP NNP RB VB JJ O
provide provide 0 0 0 0 0 0 0 0 7 0 NNP RB VB JJ NN O
scientific scientific 0 0 0 0 0 0 0 0 10 0 RB VB JJ NN IN O
support support 0 0 0 0 0 0 0 0 7 0 VB JJ NN IN PRP$ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NN IN PRP$ NN NN O
alternative alternative 0 0 0 0 0 0 0 0 11 0 IN PRP$ NN NN IN O
use use 0 0 0 0 0 0 0 0 3 0 PRP$ NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
management management 0 0 0 0 0 0 0 0 10 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP DT O
priapism, priapism, 0 0 0 0 1 0 0 0 9 0 NN IN NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 IN NNP DT JJ NN O
clinical clinical 0 0 0 0 0 0 0 0 8 0 NNP DT JJ NN IN O
disorder disorder 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN VBN CC O
prolonged prolonged 0 0 0 0 0 0 0 0 9 0 NN IN VBN CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 IN VBN CC VBN NN O
uncontrolled uncontrolled 0 0 0 0 0 0 0 0 12 0 VBN CC VBN NN NNP O
penile penile 0 0 0 0 0 0 0 0 6 0 CC VBN NN NNP NNP O
erection. erection. 0 0 0 0 0 0 0 0 9 0 VBN NN NNP NNP VBD O
Sildenafil Sildenafil 1 0 0 0 0 0 0 0 10 0 NN NNP NNP VBD RB O
administered administered 0 0 0 0 0 0 0 0 12 0 NNP NNP VBD RB TO O
continuously continuously 0 0 0 0 0 0 0 0 12 0 NNP VBD RB TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD RB TO VB NN O
sickle sickle 0 0 0 0 0 0 0 0 6 0 RB TO VB NN -NONE- O
cell cell 0 0 0 0 0 0 0 0 4 0 TO VB NN -NONE- WDT O
mice, mice, 0 0 0 0 1 0 0 0 5 0 VB NN -NONE- WDT NN O
which which 0 0 0 0 0 0 0 0 5 0 NN -NONE- WDT NN DT O
show show 0 0 0 0 0 0 0 0 4 0 -NONE- WDT NN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 WDT NN DT NN NN O
priapism priapism 0 0 0 0 0 0 0 0 8 0 NN DT NN NN NNS O
phenotype, phenotype, 0 0 0 0 1 0 0 0 10 0 DT NN NN NNS JJ O
reverses reverses 0 0 0 0 0 0 0 0 8 0 NN NN NNS JJ NN O
oxidative/nitrosative oxidative/nitrosative 0 0 0 1 0 0 0 0 21 0 NN NNS JJ NN NNS O
stress stress 0 0 0 0 0 0 0 0 6 0 NNS JJ NN NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 JJ NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN RB O
penis, penis, 0 0 0 0 1 0 0 0 6 0 IN DT NN RB IN O
mainly mainly 0 0 0 0 0 0 0 0 6 0 DT NN RB IN NN O
via via 0 0 0 0 0 0 0 0 3 0 NN RB IN NN IN O
reversion reversion 0 0 0 0 0 0 0 0 9 0 RB IN NN IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN VBN JJ O
uncoupled uncoupled 0 0 0 0 0 0 0 0 9 0 NN IN VBN JJ JJ O
endothelial endothelial 0 0 0 0 0 0 0 0 11 0 IN VBN JJ JJ NN O
nitric nitric 0 0 0 0 0 0 0 0 6 0 VBN JJ JJ NN NN O
oxide oxide 0 0 0 0 0 0 0 0 5 0 JJ JJ NN NN TO O
synthase synthase 0 0 0 0 0 0 0 0 8 0 JJ NN NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT JJ VBN O
functional functional 0 0 0 0 0 0 0 0 10 0 TO DT JJ VBN NN O
coupled coupled 0 0 0 0 0 0 0 0 7 0 DT JJ VBN NN IN O
state state 0 0 0 0 0 0 0 0 5 0 JJ VBN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ WDT O
enzyme, enzyme, 0 0 0 0 1 0 0 0 7 0 IN DT JJ WDT IN O
which which 0 0 0 0 0 0 0 0 5 0 DT JJ WDT IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ WDT IN NN NNS O
turn turn 0 0 0 0 0 0 0 0 4 0 WDT IN NN NNS VBP O
corrects corrects 0 0 0 0 0 0 0 0 8 0 IN NN NNS VBP VBG O
aberrant aberrant 0 0 0 0 0 0 0 0 8 0 NN NNS VBP VBG CC O
signaling signaling 0 0 0 0 0 0 0 0 9 0 NNS VBP VBG CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VBP VBG CC NN IN O
function function 0 0 0 0 0 0 0 0 8 0 VBG CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ JJ O
nitric nitric 0 0 0 0 0 0 0 0 6 0 IN DT JJ JJ JJ O
oxide/cyclic oxide/cyclic 0 0 0 1 0 0 0 0 12 0 DT JJ JJ JJ NN O
GMP/protein GMP/protein 1 0 0 1 0 0 0 0 11 0 JJ JJ JJ NN NN O
kinase kinase 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NN NN O
G/phosphodiesterase G/phosphodiesterase 1 0 0 1 0 0 0 0 19 0 JJ NN NN NN CD O
type type 0 0 0 0 0 0 0 0 4 0 NN NN NN CD NNP O
5 5 0 0 0 0 0 0 1 1 1 0 NN NN CD NNP NNP O
cascade. cascade. 0 0 0 0 0 0 0 0 8 0 NN CD NNP NNP VBZ O
Priapism Priapism 1 0 0 0 0 0 0 0 8 0 CD NNP NNP VBZ IN O
tendencies tendencies 0 0 0 0 0 0 0 0 10 0 NNP NNP VBZ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN DT NN O
these these 0 0 0 0 0 0 0 0 5 0 VBZ IN DT NN VBP O
mice mice 0 0 0 0 0 0 0 0 4 0 IN DT NN VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 DT NN VBP VBN RB O
reverted reverted 0 0 0 0 0 0 0 0 8 0 NN VBP VBN RB IN O
partially partially 0 0 0 0 0 0 0 0 9 0 VBP VBN RB IN JJ O
toward toward 0 0 0 0 0 0 0 0 6 0 VBN RB IN JJ VBN O
normal normal 0 0 0 0 0 0 0 0 6 0 RB IN JJ VBN NN O
neurostimulated neurostimulated 0 0 0 0 0 0 0 0 15 0 IN JJ VBN NN NNS O
erection erection 0 0 0 0 0 0 0 0 8 0 JJ VBN NN NNS CC O
frequencies frequencies 0 0 0 0 0 0 0 0 11 0 VBN NN NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NNS IN O
durations durations 0 0 0 0 0 0 0 0 9 0 NNS CC NNS IN NN O
after after 0 0 0 0 0 0 0 0 5 0 CC NNS IN NN NN O
sildenafil sildenafil 0 0 0 0 0 0 0 0 10 0 NNS IN NN NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 IN NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN IN O
association association 0 0 0 0 0 0 0 0 11 0 NN IN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN JJ JJ O
normalized normalized 0 0 0 0 0 0 0 0 10 0 NN IN JJ JJ NNP O
cyclic cyclic 0 0 0 0 0 0 0 0 6 0 IN JJ JJ NNP NNP O
GMP GMP 1 1 0 0 0 0 0 0 3 0 JJ JJ NNP NNP NN O
concentration, concentration, 0 0 0 0 1 0 0 0 14 0 JJ NNP NNP NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN NNP O
kinase kinase 0 0 0 0 0 0 0 0 6 0 NNP NN NN NNP NN O
G G 1 1 0 0 0 0 0 0 1 0 NN NN NNP NN CC O
activity activity 0 0 0 0 0 0 0 0 8 0 NN NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN NN O
phosphodiesterase phosphodiesterase 0 0 0 0 0 0 0 0 17 0 NN CC NN NN CD O
type type 0 0 0 0 0 0 0 0 4 0 CC NN NN CD NN O
5 5 0 0 0 0 0 0 1 1 1 0 NN NN CD NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NN CD NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
penis. penis. 0 0 0 0 0 0 0 0 6 0 IN DT NNP NNP NN O
Thus, Thus, 1 0 0 0 1 0 0 0 5 0 DT NNP NNP NN NNS O
sildenafil sildenafil 0 0 0 0 0 0 0 0 10 0 NNP NNP NN NNS JJ O
exerts exerts 0 0 0 0 0 0 0 0 6 0 NNP NN NNS JJ NNS O
pleiotropic pleiotropic 0 0 0 0 0 0 0 0 11 0 NN NNS JJ NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 NNS JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
penis penis 0 0 0 0 0 0 0 0 5 0 IN DT NN IN NN O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN NN TO O
extend extend 0 0 0 0 0 0 0 0 6 0 NN IN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB NN O
diverse diverse 0 0 0 0 0 0 0 0 7 0 NN TO VB NN NNP O
erection erection 0 0 0 0 0 0 0 0 8 0 TO VB NN NNP NONE O
disorders. disorders. 0 0 0 0 0 0 0 0 10 0 VB NN NNP NONE NONE O
History History 1 0 0 0 0 0 0 0 7 0 NONE NONE NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NNP NNP O
Childhood Childhood 1 0 0 0 0 0 0 0 9 0 NN IN NNP NNP NNP O
Abuse, Abuse, 1 0 0 0 1 0 0 0 6 0 IN NNP NNP NNP NNP O
Sensation Sensation 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP CC O
Seeking, Seeking, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Intimate Intimate 1 0 0 0 0 0 0 0 8 0 NNP CC NNP NNP NNP O
Partner Partner 1 0 0 0 0 0 0 0 7 0 CC NNP NNP NNP NNP O
Violence Violence 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
under/Not under/Not 0 0 0 1 0 0 0 0 9 0 NNP NNP NNP IN DT O
under under 0 0 0 0 0 0 0 0 5 0 NNP NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP IN O
Influence Influence 1 0 0 0 0 0 0 0 9 0 IN DT NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NNP IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT JJ DT O
Substance: Substance: 1 0 0 0 0 0 0 0 10 0 IN DT JJ DT JJ O
A A 1 1 0 0 0 0 0 0 1 0 DT JJ DT JJ NNP O
Cross-Sectional Cross-Sectional 1 0 1 0 0 0 0 0 15 0 JJ DT JJ NNP IN O
Study Study 1 0 0 0 0 0 0 0 5 0 DT JJ NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNP IN NNP NNP O
Russia. Russia. 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
Zhan Zhan 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNP O
W, W, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Shaboltas Shaboltas 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
AV, AV, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Skochilov Skochilov 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
RV, RV, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Krasnoselskikh Krasnoselskikh 1 0 0 0 0 0 0 0 14 0 NNP NNP NNP NNP NNP O
TV, TV, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abdala Abdala 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
N. N. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Center Center 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNP O
Interdisciplinary Interdisciplinary 1 0 0 0 0 0 0 0 17 0 NNP IN NNP NNP IN O
Research Research 1 0 0 0 0 0 0 0 8 0 IN NNP NNP IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
AIDS, AIDS, 1 1 0 0 1 0 0 0 5 0 NNP IN NNP NNP NNP O
Yale Yale 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Public Public 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNP O
Health, Health, 1 0 0 0 1 0 0 0 7 0 IN NNP NNP NNP NNP O
New New 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Haven, Haven, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
Connecticut, Connecticut, 1 0 0 0 1 0 0 0 12 0 NNP NNP NNP NNP NNPS O
United United 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNPS IN O
States States 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
America. America. 1 0 0 0 0 0 0 0 8 0 NNPS IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
OBJECTIVES: OBJECTIVES: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NN O
To To 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NN VBZ O
examine examine 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBZ IN O
correlates correlates 0 0 0 0 0 0 0 0 10 0 NNP NN VBZ IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN VBZ IN NN CC O
perpetration perpetration 0 0 0 0 0 0 0 0 12 0 VBZ IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN IN O
victimization victimization 0 0 0 0 0 0 0 0 13 0 NN CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NN O
intimate intimate 0 0 0 0 0 0 0 0 8 0 NN IN NN NN NN O
partner partner 0 0 0 0 0 0 0 0 7 0 IN NN NN NN NN O
violence violence 0 0 0 0 0 0 0 0 8 0 NN NN NN NN IN O
(IPV) (IPV) 0 1 0 0 0 0 0 0 5 0 NN NN NN IN CC O
under under 0 0 0 0 0 0 0 0 5 0 NN NN IN CC RB O
and and 0 0 0 0 0 0 0 0 3 0 NN IN CC RB IN O
not not 0 0 0 0 0 0 0 0 3 0 IN CC RB IN DT O
under under 0 0 0 0 0 0 0 0 5 0 CC RB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NN IN O
influence influence 0 0 0 0 0 0 0 0 9 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ PRP O
substance, substance, 0 0 0 0 1 0 0 0 10 0 IN DT JJ PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 DT JJ PRP VBD DT O
conducted conducted 0 0 0 0 0 0 0 0 9 0 JJ PRP VBD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 PRP VBD DT NN IN O
study study 0 0 0 0 0 0 0 0 5 0 VBD DT NN IN NNS O
among among 0 0 0 0 0 0 0 0 5 0 DT NN IN NNS IN O
women women 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN NNP NNP O
Russia. Russia. 1 0 0 0 0 0 0 0 7 0 NNS IN NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 IN NNP NNP NNP CD O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP CD DT O
2011, 2011, 0 0 0 0 1 0 0 1 5 0 NNP NNP CD DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP CD DT JJ NN O
cross-sectional cross-sectional 0 0 1 0 0 0 0 0 15 0 CD DT JJ NN VBD O
survey survey 0 0 0 0 0 0 0 0 6 0 DT JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN IN O
conducted conducted 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN NNS O
among among 0 0 0 0 0 0 0 0 5 0 VBD VBN IN NNS VBG O
patients patients 0 0 0 0 0 0 0 0 8 0 VBN IN NNS VBG NNS O
receiving receiving 0 0 0 0 0 0 0 0 9 0 IN NNS VBG NNS IN O
services services 0 0 0 0 0 0 0 0 8 0 NNS VBG NNS IN DT O
at at 0 0 0 0 0 0 0 0 2 0 VBG NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ IN O
clinic clinic 0 0 0 0 0 0 0 0 6 0 IN DT JJ IN RB O
for for 0 0 0 0 0 0 0 0 3 0 DT JJ IN RB VBN O
sexually sexually 0 0 0 0 0 0 0 0 8 0 JJ IN RB VBN NNS O
transmitted transmitted 0 0 0 0 0 0 0 0 11 0 IN RB VBN NNS IN O
infections infections 0 0 0 0 0 0 0 0 10 0 RB VBN NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBN NNS IN NNP NNP O
St. St. 1 0 0 0 0 0 0 0 3 0 NNS IN NNP NNP NNP O
Petersburg, Petersburg, 1 0 0 0 1 0 0 0 11 0 IN NNP NNP NNP NNP O
Russia. Russia. 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP JJ O
Multinomial Multinomial 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP JJ NN O
logistic logistic 0 0 0 0 0 0 0 0 8 0 NNP NNP JJ NN VBD O
regression regression 0 0 0 0 0 0 0 0 10 0 NNP JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 NN VBD VBN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN NNP NNP O
analysis. analysis. 0 0 0 0 0 0 0 0 9 0 VBN IN NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 IN NNP NNP NNP CD O
Of Of 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP CD -NONE- O
299 299 0 0 0 0 0 0 1 1 3 0 NNP NNP CD -NONE- CD O
women, women, 0 0 0 0 1 0 0 0 6 0 NNP CD -NONE- CD -NONE- O
104 104 0 0 0 0 0 0 1 1 3 0 CD -NONE- CD -NONE- CC O
(34.8%) (34.8%) 0 0 0 0 0 0 0 1 7 0 -NONE- CD -NONE- CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD -NONE- CC CD NN O
113 113 0 0 0 0 0 0 1 1 3 0 -NONE- CC CD NN VBD O
(37.8%) (37.8%) 0 0 0 0 0 0 0 1 7 0 CC CD NN VBD DT O
reported reported 0 0 0 0 0 0 0 0 8 0 CD NN VBD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN VBD DT NN IN O
history history 0 0 0 0 0 0 0 0 7 0 VBD DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NN O
IPV IPV 1 1 0 0 0 0 0 0 3 0 NN IN NNP NN CC O
perpetration perpetration 0 0 0 0 0 0 0 0 12 0 IN NNP NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NNP NNP O
victimization, victimization, 0 0 0 0 1 0 0 0 14 0 NN CC NNP NNP NNP O
respectively. respectively. 0 0 0 0 0 0 0 0 13 0 CC NNP NNP NNP NN O
Nearly Nearly 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NN -NONE- O
half half 0 0 0 0 0 0 0 0 4 0 NNP NNP NN -NONE- IN O
(47.1%) (47.1%) 0 0 0 0 0 0 0 1 7 0 NNP NN -NONE- IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NN -NONE- IN NNS CC O
perpetrators perpetrators 0 0 0 0 0 0 0 0 12 0 -NONE- IN NNS CC CD O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC CD IN O
61.1% 61.1% 0 0 0 0 0 0 0 1 5 0 NNS CC CD IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 CC CD IN NNS VBD O
victims victims 0 0 0 0 0 0 0 0 7 0 CD IN NNS VBD IN O
reported reported 0 0 0 0 0 0 0 0 8 0 IN NNS VBD IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT JJS NNP O
latest latest 0 0 0 0 0 0 0 0 6 0 IN DT JJS NNP NN O
IPV IPV 1 1 0 0 0 0 0 0 3 0 DT JJS NNP NN NN O
event event 0 0 0 0 0 0 0 0 5 0 JJS NNP NN NN CC O
(perpetration (perpetration 0 0 0 0 0 0 0 0 13 0 NNP NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
victimization, victimization, 0 0 0 0 1 0 0 0 14 0 NN CC NNP NNP VBD O
respectively) respectively) 0 0 0 0 0 0 0 0 13 0 CC NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
experienced experienced 0 0 0 0 0 0 0 0 11 0 NNP VBD VBN IN DT O
under under 0 0 0 0 0 0 0 0 5 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
influence influence 0 0 0 0 0 0 0 0 9 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NNP NNP O
substance. substance. 0 0 0 0 0 0 0 0 10 0 IN DT NNP NNP RB O
Factors Factors 1 0 0 0 0 0 0 0 7 0 DT NNP NNP RB VBN O
independently independently 0 0 0 0 0 0 0 0 13 0 NNP NNP RB VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NNP RB VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN NNP NN O
IPV IPV 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NN IN O
victimization victimization 0 0 0 0 0 0 0 0 13 0 IN NNP NN IN DT O
under under 0 0 0 0 0 0 0 0 5 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
influence influence 0 0 0 0 0 0 0 0 9 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN VBD O
substance substance 0 0 0 0 0 0 0 0 9 0 IN DT NN VBD NN O
were were 0 0 0 0 0 0 0 0 4 0 DT NN VBD NN NN O
alcohol alcohol 0 0 0 0 0 0 0 0 7 0 NN VBD NN NN CC O
misuse misuse 0 0 0 0 0 0 0 0 6 0 VBD NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT JJR O
a a 0 0 0 0 0 0 0 0 1 0 NN CC DT JJR NN O
higher higher 0 0 0 0 0 0 0 0 6 0 CC DT JJR NN IN O
number number 0 0 0 0 0 0 0 0 6 0 DT JJR NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJR NN IN NN NN O
lifetime lifetime 0 0 0 0 0 0 0 0 8 0 NN IN NN NN NN O
sex sex 0 0 0 0 0 0 0 0 3 0 IN NN NN NN NNS O
partners, partners, 0 0 0 0 1 0 0 0 9 0 NN NN NN NNS RB O
whereas whereas 0 0 0 0 0 0 0 0 7 0 NN NN NNS RB VBP O
only only 0 0 0 0 0 0 0 0 4 0 NN NNS RB VBP IN O
experience experience 0 0 0 0 0 0 0 0 10 0 NNS RB VBP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 RB VBP IN NN NN O
childhood childhood 0 0 0 0 0 0 0 0 9 0 VBP IN NN NN JJ O
abuse abuse 0 0 0 0 0 0 0 0 5 0 IN NN NN JJ CC O
(emotional (emotional 0 0 0 0 0 0 0 0 10 0 NN NN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN JJ CC JJ NN O
physical physical 0 0 0 0 0 0 0 0 8 0 JJ CC JJ NN VBD O
abuse) abuse) 0 0 0 0 0 0 0 0 6 0 CC JJ NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD RB VBN O
independently independently 0 0 0 0 0 0 0 0 13 0 NN VBD RB VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 VBD RB VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN NNP NN O
IPV IPV 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NN WDT O
victimization victimization 0 0 0 0 0 0 0 0 13 0 IN NNP NN WDT VBD O
that that 0 0 0 0 0 0 0 0 4 0 NNP NN WDT VBD RB O
did did 0 0 0 0 0 0 0 0 3 0 NN WDT VBD RB VB O
not not 0 0 0 0 0 0 0 0 3 0 WDT VBD RB VB IN O
occur occur 0 0 0 0 0 0 0 0 5 0 VBD RB VB IN DT O
under under 0 0 0 0 0 0 0 0 5 0 RB VB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VB IN DT NN IN O
influence influence 0 0 0 0 0 0 0 0 9 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NNP NNP O
substance. substance. 0 0 0 0 0 0 0 0 10 0 IN DT NNP NNP JJ O
Childhood Childhood 1 0 0 0 0 0 0 0 9 0 DT NNP NNP JJ NN O
physical physical 0 0 0 0 0 0 0 0 8 0 NNP NNP JJ NN JJR O
abuse, abuse, 0 0 0 0 1 0 0 0 6 0 NNP JJ NN JJR NN O
lower lower 0 0 0 0 0 0 0 0 5 0 JJ NN JJR NN IN O
age age 0 0 0 0 0 0 0 0 3 0 NN JJR NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJR NN IN JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NN O
sex, sex, 0 0 0 0 1 0 0 0 4 0 IN JJ NN NN NN O
sensation sensation 0 0 0 0 0 0 0 0 9 0 JJ NN NN NN CC O
seeking, seeking, 0 0 0 0 1 0 0 0 8 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
alcohol alcohol 0 0 0 0 0 0 0 0 7 0 NN CC NN NN VBD O
misuse misuse 0 0 0 0 0 0 0 0 6 0 CC NN NN VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD RB VBN O
independently independently 0 0 0 0 0 0 0 0 13 0 NN VBD RB VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 VBD RB VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN NNP NN O
IPV IPV 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NN IN O
perpetration perpetration 0 0 0 0 0 0 0 0 12 0 IN NNP NN IN DT O
under under 0 0 0 0 0 0 0 0 5 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
influence influence 0 0 0 0 0 0 0 0 9 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
substance, substance, 0 0 0 0 1 0 0 0 10 0 IN DT JJ NN RB O
while while 0 0 0 0 0 0 0 0 5 0 DT JJ NN RB VBD O
only only 0 0 0 0 0 0 0 0 4 0 JJ NN RB VBD NN O
childhood childhood 0 0 0 0 0 0 0 0 9 0 NN RB VBD NN JJ O
abuse abuse 0 0 0 0 0 0 0 0 5 0 RB VBD NN JJ CC O
(emotional (emotional 0 0 0 0 0 0 0 0 10 0 VBD NN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN JJ CC JJ NN O
physical physical 0 0 0 0 0 0 0 0 8 0 JJ CC JJ NN VBD O
abuse) abuse) 0 0 0 0 0 0 0 0 6 0 CC JJ NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD RB VBN O
independently independently 0 0 0 0 0 0 0 0 13 0 NN VBD RB VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 VBD RB VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN NNP NN O
IPV IPV 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NN WDT O
perpetration perpetration 0 0 0 0 0 0 0 0 12 0 IN NNP NN WDT VBD O
that that 0 0 0 0 0 0 0 0 4 0 NNP NN WDT VBD RB O
did did 0 0 0 0 0 0 0 0 3 0 NN WDT VBD RB VB O
not not 0 0 0 0 0 0 0 0 3 0 WDT VBD RB VB IN O
occur occur 0 0 0 0 0 0 0 0 5 0 VBD RB VB IN DT O
under under 0 0 0 0 0 0 0 0 5 0 RB VB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VB IN DT NN IN O
influence influence 0 0 0 0 0 0 0 0 9 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NNP NNP O
substance. substance. 0 0 0 0 0 0 0 0 10 0 IN DT NNP NNP NNP O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 DT NNP NNP NNP IN O
IPV IPV 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP IN CC O
under under 0 0 0 0 0 0 0 0 5 0 NNP NNP IN CC RB O
and and 0 0 0 0 0 0 0 0 3 0 NNP IN CC RB IN O
not not 0 0 0 0 0 0 0 0 3 0 IN CC RB IN DT O
under under 0 0 0 0 0 0 0 0 5 0 CC RB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NN IN O
influence influence 0 0 0 0 0 0 0 0 9 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN VBD O
substance substance 0 0 0 0 0 0 0 0 9 0 IN DT NN VBD JJ O
had had 0 0 0 0 0 0 0 0 3 0 DT NN VBD JJ NNS O
different different 0 0 0 0 0 0 0 0 9 0 NN VBD JJ NNS -NONE- O
correlates correlates 0 0 0 0 0 0 0 0 10 0 VBD JJ NNS -NONE- NN O
(e.g., (e.g., 0 0 0 0 1 0 0 0 6 0 JJ NNS -NONE- NN NN O
alcohol alcohol 0 0 0 0 0 0 0 0 7 0 NNS -NONE- NN NN CC O
misuse misuse 0 0 0 0 0 0 0 0 6 0 -NONE- NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NNP O
sensation sensation 0 0 0 0 0 0 0 0 9 0 NN CC NN NNP NNP O
seeking). seeking). 0 0 0 0 0 0 0 0 9 0 CC NN NNP NNP DT O
Despite Despite 1 0 0 0 0 0 0 0 7 0 NN NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NN O
strong strong 0 0 0 0 0 0 0 0 6 0 NNP DT JJ NN IN O
association association 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN NN O
between between 0 0 0 0 0 0 0 0 7 0 JJ NN IN NN NN O
substance substance 0 0 0 0 0 0 0 0 9 0 NN IN NN NN CC O
use use 0 0 0 0 0 0 0 0 3 0 IN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NN O
IPV, IPV, 1 1 0 0 1 0 0 0 4 0 NN CC NNP NN IN O
experience experience 0 0 0 0 0 0 0 0 10 0 CC NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NN O
childhood childhood 0 0 0 0 0 0 0 0 9 0 NN IN NN NN VBZ O
abuse abuse 0 0 0 0 0 0 0 0 5 0 IN NN NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN VBZ DT JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ NN IN O
predictor predictor 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
IPV IPV 1 1 0 0 0 0 0 0 3 0 NN IN NNP NN CC O
perpetration perpetration 0 0 0 0 0 0 0 0 12 0 IN NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN IN O
victimization victimization 0 0 0 0 0 0 0 0 13 0 NN CC NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP IN O
Russia, Russia, 1 0 0 0 1 0 0 0 7 0 NN IN NNP IN CC O
above above 0 0 0 0 0 0 0 0 5 0 IN NNP IN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NNP IN CC IN NN O
beyond beyond 0 0 0 0 0 0 0 0 6 0 IN CC IN NN NNP O
substance substance 0 0 0 0 0 0 0 0 9 0 CC IN NN NNP NONE O
use. use. 0 0 0 0 0 0 0 0 4 0 IN NN NNP NONE NONE O
Chromosome Chromosome 1 0 0 0 0 0 0 0 10 0 NONE NONE NNP NNS VBD O
tips tips 0 0 0 0 0 0 0 0 4 0 NONE NNP NNS VBD IN O
damaged damaged 0 0 0 0 0 0 0 0 7 0 NNP NNS VBD IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBD IN NN NN O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 VBD IN NN NN NNP B_TIMEXCCP
inhibit inhibit 0 0 0 0 0 0 0 0 7 0 IN NN NN NNP NNP O
cytokinesis. cytokinesis. 0 0 0 0 0 0 0 0 12 0 NN NN NNP NNP NNP O
Baker Baker 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP NNP O
NM, NM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Zeitlin Zeitlin 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
SG, SG, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Shi Shi 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
LZ, LZ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Shah Shah 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Berns Berns 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
MW. MW. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Electrical Electrical 1 0 0 0 0 0 0 0 10 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Computer Computer 1 0 0 0 0 0 0 0 8 0 NNP CC NNP NNP NNP O
Engineering, Engineering, 1 0 0 0 1 0 0 0 12 0 CC NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
California California 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
San San 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
Diego, Diego, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
La La 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Jolla, Jolla, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
California, California, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNPS O
United United 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNPS IN O
States States 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
America. America. 1 0 0 0 0 0 0 0 8 0 NNPS IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NN O
Genome Genome 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NN VBZ O
maintenance maintenance 0 0 0 0 0 0 0 0 11 0 NNP NNP NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ VBN IN O
ensured ensured 0 0 0 0 0 0 0 0 7 0 NN VBZ VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NN IN O
variety variety 0 0 0 0 0 0 0 0 7 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
biochemical biochemical 0 0 0 0 0 0 0 0 11 0 NN IN JJ NNS CC O
sensors sensors 0 0 0 0 0 0 0 0 7 0 IN JJ NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC NNS WDT O
pathways pathways 0 0 0 0 0 0 0 0 8 0 NNS CC NNS WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 CC NNS WDT NN VBD O
repair repair 0 0 0 0 0 0 0 0 6 0 NNS WDT NN VBD NNP O
accumulated accumulated 0 0 0 0 0 0 0 0 11 0 WDT NN VBD NNP NNP O
damage. damage. 0 0 0 0 0 0 0 0 7 0 NN VBD NNP NNP NNP O
During During 1 0 0 0 0 0 0 0 6 0 VBD NNP NNP NNP DT O
mitosis, mitosis, 0 0 0 0 1 0 0 0 8 0 NNP NNP NNP DT NNS B_TIMEXCCP
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNS WDT O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 NNP DT NNS WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 DT NNS WDT NN CC O
sense sense 0 0 0 0 0 0 0 0 5 0 NNS WDT NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 WDT NN CC VB NNP O
resolve resolve 0 0 0 0 0 0 0 0 7 0 NN CC VB NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 CC VB NNP NN NN O
damage damage 0 0 0 0 0 0 0 0 6 0 VB NNP NN NN NNP O
remain remain 0 0 0 0 0 0 0 0 6 0 NNP NN NN NNP NNP O
elusive. elusive. 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP VBP O
Studies Studies 1 0 0 0 0 0 0 0 7 0 NN NNP NNP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNP VBP VBN IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 NNP VBP VBN IN NN O
that that 0 0 0 0 0 0 0 0 4 0 VBP VBN IN NN VBD O
damage damage 0 0 0 0 0 0 0 0 6 0 VBN IN NN VBD IN O
accumulated accumulated 0 0 0 0 0 0 0 0 11 0 IN NN VBD IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NN VBD IN NN NNS O
lagging lagging 0 0 0 0 0 0 0 0 7 0 VBD IN NN NNS MD O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 IN NN NNS MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN NNS MD VB DT O
activate activate 0 0 0 0 0 0 0 0 8 0 NNS MD VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NN RB O
spindle spindle 0 0 0 0 0 0 0 0 7 0 VB DT NN RB NNP O
assembly assembly 0 0 0 0 0 0 0 0 8 0 DT NN RB NNP NNP O
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 NN RB NNP NNP RB B_TIMEXCCP
However, However, 1 0 0 0 1 0 0 0 8 0 RB NNP NNP RB VBZ O
there there 0 0 0 0 0 0 0 0 5 0 NNP NNP RB VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP RB VBZ RB VBN O
little little 0 0 0 0 0 0 0 0 6 0 RB VBZ RB VBN VBG O
known known 0 0 0 0 0 0 0 0 5 0 VBZ RB VBN VBG NN O
regarding regarding 0 0 0 0 0 0 0 0 9 0 RB VBN VBG NN TO O
damage damage 0 0 0 0 0 0 0 0 6 0 VBN VBG NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 VBG NN TO NNP IN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN TO NNP IN NN O
after after 0 0 0 0 0 0 0 0 5 0 TO NNP IN NN NNP anaphase
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 NNP IN NN NNP NNP anaphase
onset. onset. 0 0 0 0 0 0 0 0 6 0 IN NN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 NNP DT NN PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBP IN O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 NN PRP VBP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN JJ NN O
laser-induced laser-induced 0 0 1 0 0 0 0 0 13 0 VBP IN JJ NN TO O
damage damage 0 0 0 0 0 0 0 0 6 0 IN JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB NNS O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NN TO VB NNS JJ O
tips tips 0 0 0 0 0 0 0 0 4 0 TO VB NNS JJ NN O
(presumptive (presumptive 0 0 0 0 0 0 0 0 12 0 VB NNS JJ NN IN O
telomeres) telomeres) 0 0 0 0 0 0 0 0 10 0 NNS JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 NN IN NN IN NNP B_TIMEXCCP
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP VBZ O
Potorous Potorous 1 0 0 0 0 0 0 0 8 0 NN IN NNP VBZ NNS O
tridactylis tridactylis 0 0 0 0 0 0 0 0 11 0 IN NNP VBZ NNS -NONE- O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP VBZ NNS -NONE- VBZ O
(PtK2) (PtK2) 0 0 0 0 0 0 0 1 6 0 VBZ NNS -NONE- VBZ NNP O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 NNS -NONE- VBZ NNP NNP O
cytokinesis. cytokinesis. 0 0 0 0 0 0 0 0 12 0 -NONE- VBZ NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 VBZ NNP NNP NNP NN O
contrast, contrast, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP NN NN O
equivalent equivalent 0 0 0 0 0 0 0 0 10 0 NNP NNP NN NN IN O
irradiation irradiation 0 0 0 0 0 0 0 0 11 0 NNP NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
non-telomeric non-telomeric 0 0 1 0 0 0 0 0 13 0 NN IN JJ NN NNS O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 IN JJ NN NNS CC O
regions regions 0 0 0 0 0 0 0 0 7 0 JJ NN NNS CC NN O
or or 0 0 0 0 0 0 0 0 2 0 NN NNS CC NN NNS O
control control 0 0 0 0 0 0 0 0 7 0 NNS CC NN NNS IN O
irradiations irradiations 0 0 0 0 0 0 0 0 12 0 CC NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT DT O
either either 0 0 0 0 0 0 0 0 6 0 NNS IN DT DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN DT DT NN NN O
adjacent adjacent 0 0 0 0 0 0 0 0 8 0 DT DT NN NN CC O
cytoplasm cytoplasm 0 0 0 0 0 0 0 0 9 0 DT NN NN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 NN NN CC NN TO O
adjacent adjacent 0 0 0 0 0 0 0 0 8 0 NN CC NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 CC NN TO VB NNS O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NN TO VB NNS IN O
tips tips 0 0 0 0 0 0 0 0 4 0 TO VB NNS IN DT O
near near 0 0 0 0 0 0 0 0 4 0 VB NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
spindle spindle 0 0 0 0 0 0 0 0 7 0 IN DT NN NN IN O
midzone midzone 0 0 0 0 0 0 0 0 7 0 DT NN NN IN NN O
during during 0 0 0 0 0 0 0 0 6 0 NN NN IN NN VBD O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 NN IN NN VBD DT B_TIMEXCCP
caused caused 0 0 0 0 0 0 0 0 6 0 IN NN VBD DT NN O
no no 0 0 0 0 0 0 0 0 2 0 NN VBD DT NN IN O
change change 0 0 0 0 0 0 0 0 6 0 VBD DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
eventual eventual 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN IN O
completion completion 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
cytokinesis. cytokinesis. 0 0 0 0 0 0 0 0 12 0 NN IN NNP NNP TO O
Damage Damage 1 0 0 0 0 0 0 0 6 0 IN NNP NNP TO RB O
to to 0 0 0 0 0 0 0 0 2 0 NNP NNP TO RB CD O
only only 0 0 0 0 0 0 0 0 4 0 NNP TO RB CD NN O
one one 0 0 0 0 0 0 0 0 3 0 TO RB CD NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 RB CD NN NN VBD O
tip tip 0 0 0 0 0 0 0 0 3 0 CD NN NN VBD DT O
caused caused 0 0 0 0 0 0 0 0 6 0 NN NN VBD DT JJ O
either either 0 0 0 0 0 0 0 0 6 0 NN VBD DT JJ NN O
complete complete 0 0 0 0 0 0 0 0 8 0 VBD DT JJ NN IN O
absence absence 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
furrow furrow 0 0 0 0 0 0 0 0 6 0 NN IN NN NN DT O
formation, formation, 0 0 0 0 1 0 0 0 10 0 IN NN NN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN NN DT JJ NN O
prolonged prolonged 0 0 0 0 0 0 0 0 9 0 NN DT JJ NN IN O
delay delay 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
furrow furrow 0 0 0 0 0 0 0 0 6 0 NN IN NN NN CC O
formation, formation, 0 0 0 0 1 0 0 0 10 0 IN NN NN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 NN NN CC NN NNP O
furrow furrow 0 0 0 0 0 0 0 0 6 0 NN CC NN NNP NNP O
regression. regression. 0 0 0 0 0 0 0 0 11 0 CC NN NNP NNP NN O
When When 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NN NN O
multiple multiple 0 0 0 0 0 0 0 0 8 0 NNP NNP NN NN NNS O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NNP NN NN NNS VBD O
tips tips 0 0 0 0 0 0 0 0 4 0 NN NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
irradiated irradiated 0 0 0 0 0 0 0 0 10 0 NNS VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
same same 0 0 0 0 0 0 0 0 4 0 IN DT JJ NN DT O
cell, cell, 0 0 0 0 1 0 0 0 5 0 DT JJ NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NN NNS O
cytokinesis cytokinesis 0 0 0 0 0 0 0 0 11 0 NN DT NN NNS -NONE- O
defects defects 0 0 0 0 0 0 0 0 7 0 DT NN NNS -NONE- VBG O
increased, increased, 0 0 0 0 1 0 0 0 10 0 NN NNS -NONE- VBG DT O
suggesting suggesting 0 0 0 0 0 0 0 0 10 0 NNS -NONE- VBG DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- VBG DT JJ NN O
potential potential 0 0 0 0 0 0 0 0 9 0 VBG DT JJ NN NNP O
dose-dependent dose-dependent 0 0 1 0 0 0 0 0 14 0 DT JJ NN NNP NNP O
mechanism. mechanism. 0 0 0 0 0 0 0 0 10 0 JJ NN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP DT O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNP NNS VBP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNS VBP DT NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 VBP DT NN IN WDT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN WDT JJ O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT JJ NNS O
dysfunctional dysfunctional 0 0 0 0 0 0 0 0 13 0 IN WDT JJ NNS NN O
telomeres telomeres 0 0 0 0 0 0 0 0 9 0 WDT JJ NNS NN JJ O
inhibit inhibit 0 0 0 0 0 0 0 0 7 0 JJ NNS NN JJ NNP O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 NNS NN JJ NNP NNP B_TIMEXCCP
exit. exit. 0 0 0 0 0 0 0 0 5 0 NN JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
20811641 20811641 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NN O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NN NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
PMC2928297 PMC2928297 1 1 0 0 0 0 0 1 10 0 JJ NN NNP NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NONE DT JJ NN NNP O
decatenation decatenation 0 0 0 0 0 0 0 0 12 0 DT JJ NN NNP NNP O
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP NNP NNP B_TIMEXCCP
Deming Deming 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP NNP O
PB, PB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Cistulli Cistulli 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
CA, CA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Zhao Zhao 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Graves Graves 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
PR, PR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Piwnica-Worms Piwnica-Worms 1 0 1 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Paules Paules 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
RS, RS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Downes Downes 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
CS, CS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Kaufmann Kaufmann 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
WK. WK. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Pathology Pathology 1 0 0 0 0 0 0 0 9 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 NNP CC NNP NNP CC O
Medicine Medicine 1 0 0 0 0 0 0 0 8 0 CC NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Lineberger Lineberger 1 0 0 0 0 0 0 0 10 0 NNP CC NNP NNP NNP O
Comprehensive Comprehensive 1 0 0 0 0 0 0 0 13 0 CC NNP NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Center, Center, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
North North 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Carolina, Carolina, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Chapel Chapel 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Hill, Hill, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP CD O
NC NC 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
27599, 27599, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NN O
Chromatid Chromatid 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NN VBZ O
catenation catenation 0 0 0 0 0 0 0 0 10 0 NNP NNP NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ RB VBN O
actively actively 0 0 0 0 0 0 0 0 8 0 NN VBZ RB VBN IN O
monitored monitored 0 0 0 0 0 0 0 0 9 0 VBZ RB VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 VBN IN JJ NN IN O
cells, cells, 0 0 0 0 1 0 0 0 6 0 IN JJ NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN NN IN O
progression progression 0 0 0 0 0 0 0 0 11 0 NN IN NN IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 IN NN IN NNP TO O
G(2) G(2) 1 1 0 0 0 0 0 1 4 0 NN IN NNP TO NN B_TIMEXCCP
to to 0 0 0 0 0 0 0 0 2 0 IN NNP TO NN VBG O
mitosis mitosis 0 0 0 0 0 0 0 0 7 0 NNP TO NN VBG VBN B_TIMEXCCP
being being 0 0 0 0 0 0 0 0 5 0 TO NN VBG VBN WRB O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NN VBG VBN WRB NNS O
when when 0 0 0 0 0 0 0 0 4 0 VBG VBN WRB NNS VBP O
chromatids chromatids 0 0 0 0 0 0 0 0 10 0 VBN WRB NNS VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 WRB NNS VBP RB NNP O
insufficiently insufficiently 0 0 0 0 0 0 0 0 14 0 NNS VBP RB NNP NNP O
decatenated. decatenated. 0 0 0 0 0 0 0 0 12 0 VBP RB NNP NNP NN O
Mitotic Mitotic 1 0 0 0 0 0 0 0 7 0 RB NNP NNP NN VBD B_TIMEXCCP
delay delay 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
quantified quantified 0 0 0 0 0 0 0 0 10 0 NN VBD VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ CC O
normal normal 0 0 0 0 0 0 0 0 6 0 VBN IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NN O
checkpoint-deficient checkpoint-deficient 0 0 1 0 0 0 0 0 20 0 JJ CC JJ NN NNS B_TIMEXCCP
human human 0 0 0 0 0 0 0 0 5 0 CC JJ NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN NN O
during during 0 0 0 0 0 0 0 0 6 0 NN NNS IN NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NNS IN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN JJ DT O
ICRF-193, ICRF-193, 1 1 1 0 1 0 0 1 9 0 NN IN JJ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 IN JJ DT NN NNP O
topoisomerase topoisomerase 0 0 0 0 0 0 0 0 13 0 JJ DT NN NNP JJ O
II II 1 1 0 0 0 0 0 0 2 0 DT NN NNP JJ NN O
catalytic catalytic 0 0 0 0 0 0 0 0 9 0 NN NNP JJ NN WDT O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 NNP JJ NN WDT VBZ O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT VBZ JJ O
prevents prevents 0 0 0 0 0 0 0 0 8 0 NN WDT VBZ JJ NN O
chromatid chromatid 0 0 0 0 0 0 0 0 9 0 WDT VBZ JJ NN IN O
decatenation decatenation 0 0 0 0 0 0 0 0 12 0 VBZ JJ NN IN VBG O
without without 0 0 0 0 0 0 0 0 7 0 JJ NN IN VBG JJ O
producing producing 0 0 0 0 0 0 0 0 9 0 NN IN VBG JJ NNP O
topoisomerase-associated topoisomerase-associated 0 0 1 0 0 0 0 0 24 0 IN VBG JJ NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 VBG JJ NNP NN NNP O
strand strand 0 0 0 0 0 0 0 0 6 0 JJ NNP NN NNP NNP O
breaks. breaks. 0 0 0 0 0 0 0 0 7 0 NNP NN NNP NNP NN O
Ataxia Ataxia 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NN -NONE- O
telangiectasia telangiectasia 0 0 0 0 0 0 0 0 14 0 NNP NNP NN -NONE- -NONE- O
(A-T) (A-T) 0 1 1 0 0 0 0 0 5 0 NNP NN -NONE- -NONE- JJ O
cells, cells, 0 0 0 0 1 0 0 0 6 0 NN -NONE- -NONE- JJ IN O
defective defective 0 0 0 0 0 0 0 0 9 0 -NONE- -NONE- JJ IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- JJ IN NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 JJ IN NNP NN -NONE- O
damage damage 0 0 0 0 0 0 0 0 6 0 IN NNP NN -NONE- VBD O
checkpoints, checkpoints, 0 0 0 0 1 0 0 0 12 0 NNP NN -NONE- VBD JJ B_TIMEXCCP
showed showed 0 0 0 0 0 0 0 0 6 0 NN -NONE- VBD JJ JJ O
normal normal 0 0 0 0 0 0 0 0 6 0 -NONE- VBD JJ JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 VBD JJ JJ NN WRB B_TIMEXCCP
delay delay 0 0 0 0 0 0 0 0 5 0 JJ JJ NN WRB VBN O
when when 0 0 0 0 0 0 0 0 4 0 JJ NN WRB VBN IN O
treated treated 0 0 0 0 0 0 0 0 7 0 NN WRB VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 WRB VBN IN NNP NNP O
ICRF-193. ICRF-193. 1 1 1 0 0 0 0 1 9 0 VBN IN NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NN IN O
delay delay 0 0 0 0 0 0 0 0 5 0 NNP JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN TO O
response response 0 0 0 0 0 0 0 0 8 0 NN IN NN TO -NONE- O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO -NONE- VBD O
ICRF-193 ICRF-193 1 1 1 0 0 0 0 1 8 0 NN TO -NONE- VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 TO -NONE- VBD VBN IN O
ablated ablated 0 0 0 0 0 0 0 0 7 0 -NONE- VBD VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NNS O
human human 0 0 0 0 0 0 0 0 5 0 VBN IN JJ NNS VBG O
fibroblasts fibroblasts 0 0 0 0 0 0 0 0 11 0 IN JJ NNS VBG DT O
expressing expressing 0 0 0 0 0 0 0 0 10 0 JJ NNS VBG DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NNS VBG DT NN NN O
ataxia ataxia 0 0 0 0 0 0 0 0 6 0 VBG DT NN NN NN O
telangiectasia telangiectasia 0 0 0 0 0 0 0 0 14 0 DT NN NN NN CC O
mutated- mutated- 0 0 1 0 0 0 0 0 8 0 NN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
rad3-related rad3-related 0 0 1 0 0 0 0 1 12 0 NN CC JJ NN JJ O
(ATR) (ATR) 0 1 0 0 0 0 0 0 5 0 CC JJ NN JJ NNP O
kinase-inactive kinase-inactive 0 0 1 0 0 0 0 0 15 0 JJ NN JJ NNP NN O
ATR ATR 1 1 0 0 0 0 0 0 3 0 NN JJ NNP NN NNP O
allele allele 0 0 0 0 0 0 0 0 6 0 JJ NNP NN NNP JJ O
(ATR(ki)). (ATR(ki)). 0 0 0 0 0 0 0 0 10 0 NNP NN NNP JJ NNP O
BRCA1-mutant BRCA1-mutant 1 0 1 0 0 0 0 1 12 0 NN NNP JJ NNP NNS O
HCC1937 HCC1937 1 1 0 0 0 0 0 1 7 0 NNP JJ NNP NNS RB O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NNP NNS RB VBD O
also also 0 0 0 0 0 0 0 0 4 0 NNP NNS RB VBD DT O
displayed displayed 0 0 0 0 0 0 0 0 9 0 NNS RB VBD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 RB VBD DT NN IN O
defect defect 0 0 0 0 0 0 0 0 6 0 VBD DT NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ JJ O
ICRF-193-induced ICRF-193-induced 1 0 1 0 0 0 0 1 16 0 NN IN JJ JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 IN JJ JJ NN WDT B_TIMEXCCP
delay, delay, 0 0 0 0 1 0 0 0 6 0 JJ JJ NN WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 JJ NN WDT VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN WDT VBD VBN IN O
corrected corrected 0 0 0 0 0 0 0 0 9 0 WDT VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 VBN IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NNP O
wild-type wild-type 0 0 1 0 0 0 0 0 9 0 NN IN JJ NNP NNP O
BRCA1. BRCA1. 1 1 0 0 0 0 0 1 6 0 IN JJ NNP NNP IN O
Phosphorylations Phosphorylations 1 0 0 0 0 0 0 0 16 0 JJ NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
hCds1 hCds1 0 0 0 0 0 0 0 1 5 0 NNP IN NNP CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 IN NNP CC NNP CC O
Chk1 Chk1 1 0 0 0 0 0 0 1 4 0 NNP CC NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 NNP CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NN O
Cdk1 Cdk1 1 0 0 0 0 0 0 1 4 0 NN IN NNP NN -NONE- O
kinase kinase 0 0 0 0 0 0 0 0 6 0 IN NNP NN -NONE- WDT O
activity, activity, 0 0 0 0 1 0 0 0 9 0 NNP NN -NONE- WDT VBP O
which which 0 0 0 0 0 0 0 0 5 0 NN -NONE- WDT VBP NNS O
are are 0 0 0 0 0 0 0 0 3 0 -NONE- WDT VBP NNS IN O
elements elements 0 0 0 0 0 0 0 0 8 0 WDT VBP NNS IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 VBP NNS IN NNS VBN O
checkpoints checkpoints 0 0 0 0 0 0 0 0 11 0 NNS IN NNS VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 IN NNS VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBN IN NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NN CC O
damage damage 0 0 0 0 0 0 0 0 6 0 IN NNP NN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 NNP NN CC NN VBD O
replication, replication, 0 0 0 0 1 0 0 0 12 0 NN CC NN VBD RB O
did did 0 0 0 0 0 0 0 0 3 0 CC NN VBD RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NN VBD RB VB IN O
occur occur 0 0 0 0 0 0 0 0 5 0 VBD RB VB IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 RB VB IN JJ JJ O
ICRF-193-induced ICRF-193-induced 1 0 1 0 0 0 0 1 16 0 VB IN JJ JJ NNP O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 IN JJ JJ NNP NN O
delay. delay. 0 0 0 0 0 0 0 0 6 0 JJ JJ NNP NN IN O
Over-expression Over-expression 1 0 1 0 0 0 0 0 15 0 JJ NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP NN O
B1 B1 1 1 0 0 0 0 0 1 2 0 IN NN NNP NN DT O
containing containing 0 0 0 0 0 0 0 0 10 0 NN NNP NN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NN DT JJ JJ O
dominant dominant 0 0 0 0 0 0 0 0 8 0 NN DT JJ JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 DT JJ JJ NN NN O
localization localization 0 0 0 0 0 0 0 0 12 0 JJ JJ NN NN CC O
signal, signal, 0 0 0 0 1 0 0 0 7 0 JJ NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 NN CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ JJ O
Crm1-mediated Crm1-mediated 1 0 1 0 0 0 0 1 13 0 NN IN JJ JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 IN JJ JJ NN VBD O
export, export, 0 0 0 0 1 0 0 0 7 0 JJ JJ NN VBD JJ O
reversed reversed 0 0 0 0 0 0 0 0 8 0 JJ NN VBD JJ JJ O
ICRF-193-induced ICRF-193-induced 1 0 1 0 0 0 0 1 16 0 NN VBD JJ JJ NNP O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 VBD JJ JJ NNP NNP B_TIMEXCCP
delay. delay. 0 0 0 0 0 0 0 0 6 0 JJ JJ NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NNP DT O
combination, combination, 0 0 0 0 1 0 0 0 12 0 NNP NNP NNP DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP DT NNS VBP IN O
imply imply 0 0 0 0 0 0 0 0 5 0 DT NNS VBP IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NNP CC O
ATR ATR 1 1 0 0 0 0 0 0 3 0 VBP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NN O
BRCA1 BRCA1 1 1 0 0 0 0 0 1 5 0 NNP CC NNP NN DT O
enforce enforce 0 0 0 0 0 0 0 0 7 0 CC NNP NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT NN NN O
decatenation decatenation 0 0 0 0 0 0 0 0 12 0 NN DT NN NN NN O
G(2) G(2) 1 1 0 0 0 0 0 1 4 0 DT NN NN NN WDT O
checkpoint, checkpoint, 0 0 0 0 1 0 0 0 11 0 NN NN NN WDT MD O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN WDT MD VB TO O
act act 0 0 0 0 0 0 0 0 3 0 WDT MD VB TO VB O
to to 0 0 0 0 0 0 0 0 2 0 MD VB TO VB NN O
exclude exclude 0 0 0 0 0 0 0 0 7 0 VB TO VB NN -NONE- O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 TO VB NN -NONE- VBZ O
B1/Cdk1 B1/Cdk1 1 0 0 1 0 0 0 1 7 0 VB NN -NONE- VBZ IN O
complexes complexes 0 0 0 0 0 0 0 0 9 0 NN -NONE- VBZ IN DT O
from from 0 0 0 0 0 0 0 0 4 0 -NONE- VBZ IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBZ IN DT NNP NNP O
nucleus. nucleus. 0 0 0 0 0 0 0 0 8 0 IN DT NNP NNP NN O
Moreover, Moreover, 1 0 0 0 1 0 0 0 9 0 DT NNP NNP NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP VBN O
ATR(ki) ATR(ki) 1 0 0 0 0 0 0 0 7 0 NN IN NNP VBN DT O
produced produced 0 0 0 0 0 0 0 0 8 0 IN NNP VBN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBN DT JJ NN O
10-fold 10-fold 0 0 1 0 0 0 0 1 7 0 VBN DT JJ NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
chromosomal chromosomal 0 0 0 0 0 0 0 0 11 0 NN IN JJ NN RB O
aberrations, aberrations, 0 0 0 0 1 0 0 0 12 0 IN JJ NN RB VBG O
further further 0 0 0 0 0 0 0 0 7 0 JJ NN RB VBG DT O
emphasizing emphasizing 0 0 0 0 0 0 0 0 11 0 NN RB VBG DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 RB VBG DT JJ NN O
vital vital 0 0 0 0 0 0 0 0 5 0 VBG DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NNP IN O
ATR ATR 1 1 0 0 0 0 0 0 3 0 NN IN NNP IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN JJ NNP O
genetic genetic 0 0 0 0 0 0 0 0 7 0 NNP IN JJ NNP NNP O
stability. stability. 0 0 0 0 0 0 0 0 10 0 IN JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
11593014 11593014 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NN O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NN NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
PMC59764 PMC59764 1 1 0 0 0 0 0 1 8 0 JJ NN NNP NONE NONE O
Early Early 1 0 0 0 0 0 0 0 5 0 NONE NONE RB NN IN O
development development 0 0 0 0 0 0 0 0 11 0 NONE RB NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 RB NN IN NN IN O
utero utero 0 0 0 0 0 0 0 0 5 0 NN IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN JJ O
bovine bovine 0 0 0 0 0 0 0 0 6 0 NN IN NN JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 IN NN JJ NN NNS O
transfer transfer 0 0 0 0 0 0 0 0 8 0 NN JJ NN NNS VBG O
embryos embryos 0 0 0 0 0 0 0 0 7 0 JJ NN NNS VBG RB O
using using 0 0 0 0 0 0 0 0 5 0 NN NNS VBG RB NNP O
early early 0 0 0 0 0 0 0 0 5 0 NNS VBG RB NNP CC G1
G1 G1 1 1 0 0 0 0 0 1 2 0 VBG RB NNP CC NNP G1
and and 0 0 0 0 0 0 0 0 3 0 RB NNP CC NNP NN O
G0 G0 1 1 0 0 0 0 0 1 2 phase NNP CC NNP NN NNP B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 CC NNP NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NNP NN NNP NNP NNP O
Ideta Ideta 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Urakawa Urakawa 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Aoyagi Aoyagi 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Saeki Saeki 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
K. K. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Zen-noh Zen-noh 1 0 1 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Embryo Embryo 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Transfer Transfer 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Center, Center, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Kamishihoro, Kamishihoro, 1 0 0 0 1 0 0 0 12 0 NNP NNP NNP NNP NNP O
Katogun, Katogun, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Hokkaido, Hokkaido, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Japan. Japan. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
ideta-atsushi@zennoh.or.jp ideta-atsushi@zennoh.or.jp 0 0 1 0 0 0 0 0 26 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP JJ O
Bovine Bovine 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP JJ NN O
somatic somatic 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP JJ NN NN NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 JJ NN NN NN NN O
transfer transfer 0 0 0 0 0 0 0 0 8 0 NN NN NN NN NNS O
(NT) (NT) 0 1 0 0 0 0 0 0 4 0 NN NN NN NNS MD O
embryos embryos 0 0 0 0 0 0 0 0 7 0 NN NN NNS MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN NNS MD VB TO O
develop develop 0 0 0 0 0 0 0 0 7 0 NNS MD VB TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 MD VB TO JJ NN O
normal normal 0 0 0 0 0 0 0 0 6 0 VB TO JJ NN CC O
calves, calves, 0 0 0 0 1 0 0 0 7 0 TO JJ NN CC DT O
but but 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN NNS O
success success 0 0 0 0 0 0 0 0 7 0 CC DT NN NNS VBP O
rates rates 0 0 0 0 0 0 0 0 5 0 DT NN NNS VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 NN NNS VBP RB RB O
still still 0 0 0 0 0 0 0 0 5 0 NNS VBP RB RB NNP O
quite quite 0 0 0 0 0 0 0 0 5 0 VBP RB RB NNP NNP O
low. low. 0 0 0 0 0 0 0 0 4 0 RB RB NNP NNP VBD O
Recently, Recently, 1 0 0 0 1 0 0 0 9 0 RB NNP NNP VBD NN O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD NN IN O
development development 0 0 0 0 0 0 0 0 11 0 NNP VBD NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN NN NNP O
bovine bovine 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP NNS O
NT NT 1 1 0 0 0 0 0 0 2 0 IN NN NNP NNS TO O
embryos embryos 0 0 0 0 0 0 0 0 7 0 NN NNP NNS TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NNP NNS TO JJ NN O
full full 0 0 0 0 0 0 0 0 4 0 NNS TO JJ NN VBZ O
term term 0 0 0 0 0 0 0 0 4 0 TO JJ NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 JJ NN VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN VBN VBG O
achieved achieved 0 0 0 0 0 0 0 0 8 0 VBZ VBN VBN VBG NNS O
using using 0 0 0 0 0 0 0 0 5 0 VBN VBN VBG NNS IN O
fibroblasts fibroblasts 0 0 0 0 0 0 0 0 11 0 VBN VBG NNS IN DT O
at at 0 0 0 0 0 0 0 0 2 0 VBG NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NNP O
early early 0 0 0 0 0 0 0 0 5 0 IN DT JJ NNP NN G1
G1 G1 1 1 0 0 0 0 0 1 2 phase DT JJ NNP NN RB G1
phase phase 0 0 0 0 0 0 0 0 5 0 JJ NNP NN RB IN O
instead instead 0 0 0 0 0 0 0 0 7 0 NNP NN RB IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NN RB IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 RB IN NNS IN DT O
at at 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
quiescent quiescent 0 0 0 0 0 0 0 0 9 0 IN DT NN NN NNP O
(G0) (G0) 0 1 0 0 0 0 0 1 4 0 DT NN NN NNP NNP B_TIMEXCCP
phase. phase. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
present present 0 0 0 0 0 0 0 0 7 0 NNP DT NN NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 DT NN NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NN NN PRP VBD DT O
examined examined 0 0 0 0 0 0 0 0 8 0 NN PRP VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT JJ NN O
morphological morphological 0 0 0 0 0 0 0 0 13 0 VBD DT JJ NN IN O
development development 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
utero utero 0 0 0 0 0 0 0 0 5 0 NN IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNS O
NT NT 1 1 0 0 0 0 0 0 2 0 NN IN NNP NNS VBG O
embryos embryos 0 0 0 0 0 0 0 0 7 0 IN NNP NNS VBG RB O
using using 0 0 0 0 0 0 0 0 5 0 NNP NNS VBG RB NNP O
early early 0 0 0 0 0 0 0 0 5 0 NNS VBG RB NNP NN G1
G1 G1 1 1 0 0 0 0 0 1 2 phase VBG RB NNP NN NNS G1
phase phase 0 0 0 0 0 0 0 0 5 0 RB NNP NN NNS JJ O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NN NNS JJ NN O
(eG1-NT (eG1-NT 0 0 1 0 0 0 0 1 7 0 NN NNS JJ NN CC O
embryos) embryos) 0 0 0 0 0 0 0 0 8 0 NNS JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP NN O
G0 G0 1 1 0 0 0 0 0 1 2 phase NN CC NNP NN NNS B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 CC NNP NN NNS JJ O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NN NNS JJ NNP O
(G0-NT (G0-NT 0 1 1 0 0 0 0 1 6 0 NN NNS JJ NNP NNP O
embryos). embryos). 0 0 0 0 0 0 0 0 9 0 NNS JJ NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP VBD NNP O
produced produced 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD NNP CC O
eG1- eG1- 0 0 1 0 0 0 0 1 4 0 NNP VBD NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBD NNP CC JJ NN O
G0-NT G0-NT 1 1 1 0 0 0 0 1 5 0 NNP CC JJ NN CC O
blastocysts, blastocysts, 0 0 0 0 1 0 0 0 12 0 CC JJ NN CC RB O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC RB PRP O
then then 0 0 0 0 0 0 0 0 4 0 NN CC RB PRP VBD O
they they 0 0 0 0 0 0 0 0 4 0 CC RB PRP VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 RB PRP VBD VBN TO O
transferred transferred 0 0 0 0 0 0 0 0 11 0 PRP VBD VBN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO JJ NNS O
recipient recipient 0 0 0 0 0 0 0 0 9 0 VBN TO JJ NNS IN O
heifers heifers 0 0 0 0 0 0 0 0 7 0 TO JJ NNS IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN NN NN O
transient transient 0 0 0 0 0 0 0 0 9 0 NNS IN NN NN IN O
development development 0 0 0 0 0 0 0 0 11 0 IN NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN IN O
utero utero 0 0 0 0 0 0 0 0 5 0 NN IN NN IN TO O
up up 0 0 0 0 0 0 0 0 2 0 IN NN IN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NN IN TO NN CD O
day day 0 0 0 0 0 0 0 0 3 0 IN TO NN CD IN O
14 14 0 0 0 0 0 0 1 1 2 0 TO NN CD IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN CD IN NNP NNP O
gestation. gestation. 0 0 0 0 0 0 0 0 10 0 CD IN NNP NNP JJ O
In In 1 0 0 0 0 0 0 0 2 0 IN NNP NNP JJ NN O
vitro-fertilized vitro-fertilized 0 0 1 0 0 0 0 0 16 0 NNP NNP JJ NN JJ O
(IVF), (IVF), 0 1 0 0 1 0 0 0 6 0 NNP JJ NN JJ CC O
parthenogenetic parthenogenetic 0 0 0 0 0 0 0 0 15 0 JJ NN JJ CC RB O
and and 0 0 0 0 0 0 0 0 3 0 NN JJ CC RB VBN O
artificially artificially 0 0 0 0 0 0 0 0 12 0 JJ CC RB VBN -NONE- O
inseminated inseminated 0 0 0 0 0 0 0 0 11 0 CC RB VBN -NONE- VBZ O
(AI) (AI) 0 1 0 0 0 0 0 0 4 0 RB VBN -NONE- VBZ RB O
embryos embryos 0 0 0 0 0 0 0 0 7 0 VBN -NONE- VBZ RB VBN O
were were 0 0 0 0 0 0 0 0 4 0 -NONE- VBZ RB VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 VBZ RB VBN IN NNP O
as as 0 0 0 0 0 0 0 0 2 0 RB VBN IN NNP NNP O
controls. controls. 0 0 0 0 0 0 0 0 9 0 VBN IN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN IN O
formation formation 0 0 0 0 0 0 0 0 9 0 NN IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NNS O
embryonic embryonic 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNS IN O
disks disks 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT VBN NNS O
recovered recovered 0 0 0 0 0 0 0 0 9 0 IN DT VBN NNS VBD O
embryos embryos 0 0 0 0 0 0 0 0 7 0 DT VBN NNS VBD DT O
was was 0 0 0 0 0 0 0 0 3 0 VBN NNS VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBD DT JJ IN O
same same 0 0 0 0 0 0 0 0 4 0 VBD DT JJ IN DT O
among among 0 0 0 0 0 0 0 0 5 0 DT JJ IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NNS IN O
groups groups 0 0 0 0 0 0 0 0 6 0 IN DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NN O
eG1-NT, eG1-NT, 0 0 1 0 1 0 0 1 7 0 NNS IN JJ NN CC O
IVF, IVF, 1 1 0 0 1 0 0 0 4 0 IN JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP NNS O
AI AI 1 1 0 0 0 0 0 0 2 0 NN CC NNP NNS NNP O
embryos embryos 0 0 0 0 0 0 0 0 7 0 CC NNP NNS NNP NNP O
(p>0.05). (p>0.05). 0 0 0 0 0 0 0 1 9 0 NNP NNS NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNS NNP NNP NN NN O
formation formation 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 NNP NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNS O
eG1-NT eG1-NT 0 0 1 0 0 0 0 1 6 0 NN IN JJ NNS VBD O
embryos embryos 0 0 0 0 0 0 0 0 7 0 IN JJ NNS VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 JJ NNS VBD RB JJR O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNS VBD RB JJR IN O
higher higher 0 0 0 0 0 0 0 0 6 0 VBD RB JJR IN DT O
than than 0 0 0 0 0 0 0 0 4 0 RB JJR IN DT IN O
that that 0 0 0 0 0 0 0 0 4 0 JJR IN DT IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN DT IN JJ NNS O
G0-NT G0-NT 1 1 1 0 0 0 0 1 5 0 DT IN JJ NNS NNP O
embryos embryos 0 0 0 0 0 0 0 0 7 0 IN JJ NNS NNP NNP O
(p<0.05). (p<0.05). 0 0 0 0 0 0 0 1 9 0 JJ NNS NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NNS NNP NNP NNS IN O
lengths lengths 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN JJ NNS O
eG1-NT eG1-NT 0 0 1 0 0 0 0 1 6 0 NNS IN JJ NNS VBD O
embryos embryos 0 0 0 0 0 0 0 0 7 0 IN JJ NNS VBD DT O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBD DT JJ IN O
same same 0 0 0 0 0 0 0 0 4 0 VBD DT JJ IN DT O
as as 0 0 0 0 0 0 0 0 2 0 DT JJ IN DT IN O
those those 0 0 0 0 0 0 0 0 5 0 JJ IN DT IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN DT IN NNP NNP O
IVF, IVF, 1 1 0 0 1 0 0 0 4 0 DT IN NNP NNP CC O
parthenogenetic, parthenogenetic, 0 0 0 0 1 0 0 0 16 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNS O
AI AI 1 1 0 0 0 0 0 0 2 0 NNP CC NNP NNS -NONE- O
embryos embryos 0 0 0 0 0 0 0 0 7 0 CC NNP NNS -NONE- CC O
(p>0.05), (p>0.05), 0 0 0 0 1 0 0 1 9 0 NNP NNS -NONE- CC RB O
but but 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC RB JJR O
significantly significantly 0 0 0 0 0 0 0 0 13 0 -NONE- CC RB JJR IN O
shorter shorter 0 0 0 0 0 0 0 0 7 0 CC RB JJR IN DT O
than than 0 0 0 0 0 0 0 0 4 0 RB JJR IN DT IN O
those those 0 0 0 0 0 0 0 0 5 0 JJR IN DT IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN DT IN JJ NNS O
G0-NT G0-NT 1 1 1 0 0 0 0 1 5 0 DT IN JJ NNS NNP O
embryos embryos 0 0 0 0 0 0 0 0 7 0 IN JJ NNS NNP NNP O
(p<0.01). (p<0.01). 0 0 0 0 0 0 0 1 9 0 JJ NNS NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 NNS NNP NNP VBP IN O
conclude conclude 0 0 0 0 0 0 0 0 8 0 NNP NNP VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT JJ NN O
morphological morphological 0 0 0 0 0 0 0 0 13 0 IN DT JJ NN IN O
development development 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN CD O
day day 0 0 0 0 0 0 0 0 3 0 NN IN NN CD NNS O
14 14 0 0 0 0 0 0 1 1 2 0 IN NN CD NNS VBD O
embryos embryos 0 0 0 0 0 0 0 0 7 0 NN CD NNS VBD IN O
derived derived 0 0 0 0 0 0 0 0 7 0 CD NNS VBD IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBD IN JJ NNS O
eG1-NT eG1-NT 0 0 1 0 0 0 0 1 6 0 VBD IN JJ NNS VBD O
embryos embryos 0 0 0 0 0 0 0 0 7 0 IN JJ NNS VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 JJ NNS VBD RB JJ O
mostly mostly 0 0 0 0 0 0 0 0 6 0 NNS VBD RB JJ TO O
similar similar 0 0 0 0 0 0 0 0 7 0 VBD RB JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 RB JJ TO DT IN O
that that 0 0 0 0 0 0 0 0 4 0 JJ TO DT IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 TO DT IN NNP NNP O
AI AI 1 1 0 0 0 0 0 0 2 0 DT IN NNP NNP CC O
embryos, embryos, 0 0 0 0 1 0 0 0 8 0 IN NNP NNP CC IN O
but but 0 0 0 0 0 0 0 0 3 0 NNP NNP CC IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNP CC IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CC IN DT JJ NN O
morphological morphological 0 0 0 0 0 0 0 0 13 0 IN DT JJ NN IN O
development development 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNS O
G0-NT G0-NT 1 1 1 0 0 0 0 1 5 0 NN IN JJ NNS VBD O
embryos embryos 0 0 0 0 0 0 0 0 7 0 IN JJ NNS VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 JJ NNS VBD RB JJ O
abnormally abnormally 0 0 0 0 0 0 0 0 10 0 NNS VBD RB JJ CC O
large large 0 0 0 0 0 0 0 0 5 0 VBD RB JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 RB JJ CC JJ IN O
different different 0 0 0 0 0 0 0 0 9 0 JJ CC JJ IN DT O
from from 0 0 0 0 0 0 0 0 4 0 CC JJ IN DT IN O
that that 0 0 0 0 0 0 0 0 4 0 JJ IN DT IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN DT IN NNP CC O
AI AI 1 1 0 0 0 0 0 0 2 0 DT IN NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC JJ NNP O
eG1-NT eG1-NT 0 0 1 0 0 0 0 1 6 0 NNP CC JJ NNP NNP O
embryos. embryos. 0 0 0 0 0 0 0 0 8 0 CC JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
18154517 18154517 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Cytogenetic Cytogenetic 1 0 0 0 0 0 0 0 11 0 NONE NONE JJ NN CC O
damage damage 0 0 0 0 0 0 0 0 6 0 NONE JJ NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT JJ NN O
radiation-induced radiation-induced 0 0 1 0 0 0 0 0 17 0 CC DT JJ NN NNP O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 DT JJ NN NNP NNP G1
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP NNP NNP G1
Gupta Gupta 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Vij Vij 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Haas-Kogan Haas-Kogan 1 0 1 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
DA, DA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Israel Israel 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
MA, MA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Deen Deen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
DF, DF, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Morgan Morgan 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
WF. WF. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Brain Brain 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Tumor Tumor 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Center Center 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 IN DT NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNP IN NNP NNP O
Neurological Neurological 1 0 0 0 0 0 0 0 12 0 NNP IN NNP NNP NNP O
Surgery, Surgery, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
California California 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
San San 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP CD O
Francisco Francisco 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP CD NNP O
94143, 94143, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
proposed proposed 0 0 0 0 0 0 0 0 8 0 NNP VBZ VBN IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN JJ NN O
genomic genomic 0 0 0 0 0 0 0 0 7 0 VBN IN JJ NN VBZ O
integrity integrity 0 0 0 0 0 0 0 0 9 0 IN JJ NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ VBN IN O
preserved preserved 0 0 0 0 0 0 0 0 9 0 NN VBZ VBN IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 VBZ VBN IN NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NN IN O
damage damage 0 0 0 0 0 0 0 0 6 0 IN NNP NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN IN O
variety variety 0 0 0 0 0 0 0 0 7 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
ways. ways. 0 0 0 0 0 0 0 0 5 0 NN IN NNP NNP NN O
X X 1 1 0 0 0 0 0 0 1 0 IN NNP NNP NN NNS O
irradiation irradiation 0 0 0 0 0 0 0 0 11 0 NNP NNP NN NNS DT O
induces induces 0 0 0 0 0 0 0 0 7 0 NNP NN NNS DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN NNS DT JJ NN O
p53-dependent p53-dependent 0 0 1 0 0 0 0 1 13 0 NNS DT JJ NN NN O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 DT JJ NN NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NN NN NN NN WDT O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NN NN NN WDT RB B_TIMEXCCP
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT RB VBZ O
putatively putatively 0 0 0 0 0 0 0 0 10 0 NN WDT RB VBZ NN O
allows allows 0 0 0 0 0 0 0 0 6 0 WDT RB VBZ NN IN O
time time 0 0 0 0 0 0 0 0 4 0 RB VBZ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBZ NN IN NN IN O
repair repair 0 0 0 0 0 0 0 0 6 0 NN IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNP NNP O
damage. damage. 0 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NN O
p53 p53 0 0 0 0 0 0 0 1 3 0 NNP NNP NNP NN VBZ O
protein protein 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ RB VBN O
also also 0 0 0 0 0 0 0 0 4 0 NN VBZ RB VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 VBZ RB VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
initiation initiation 0 0 0 0 0 0 0 0 10 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN IN NN IN JJ O
after after 0 0 0 0 0 0 0 0 5 0 IN NN IN JJ NNP O
radiation-induced radiation-induced 0 0 1 0 0 0 0 0 17 0 NN IN JJ NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 IN JJ NNP NNP RB O
damage, damage, 0 0 0 0 1 0 0 0 7 0 JJ NNP NNP RB VBG O
presumably presumably 0 0 0 0 0 0 0 0 10 0 NNP NNP RB VBG TO O
leading leading 0 0 0 0 0 0 0 0 7 0 NNP RB VBG TO DT O
to to 0 0 0 0 0 0 0 0 2 0 RB VBG TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBG TO DT NN IN O
elimination elimination 0 0 0 0 0 0 0 0 11 0 TO DT NN IN RB O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN RB VBN O
lethally lethally 0 0 0 0 0 0 0 0 8 0 NN IN RB VBN NNS O
damaged damaged 0 0 0 0 0 0 0 0 7 0 IN RB VBN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 RB VBN NNS IN DT O
from from 0 0 0 0 0 0 0 0 4 0 VBN NNS IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT VBN NNP O
irradiated irradiated 0 0 0 0 0 0 0 0 10 0 IN DT VBN NNP NNP O
population. population. 0 0 0 0 0 0 0 0 11 0 DT VBN NNP NNP NN O
To To 1 0 0 0 0 0 0 0 2 0 VBN NNP NNP NN DT O
test test 0 0 0 0 0 0 0 0 4 0 NNP NNP NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT NN IN O
hypothesis hypothesis 0 0 0 0 0 0 0 0 10 0 NN DT NN IN NN O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN NN NNS O
repair repair 0 0 0 0 0 0 0 0 6 0 NN IN NN NNS IN O
occurs occurs 0 0 0 0 0 0 0 0 6 0 IN NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
additional additional 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN VBN O
time time 0 0 0 0 0 0 0 0 4 0 DT JJ NN VBN IN O
provided provided 0 0 0 0 0 0 0 0 8 0 JJ NN VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 NN VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 IN DT JJ NN PRP G1
checkpoint, checkpoint, 0 0 0 0 1 0 0 0 11 0 DT JJ NN PRP VBD G1
we we 0 0 0 0 0 0 0 0 2 0 JJ NN PRP VBD IN O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NN PRP VBD IN DT O
whether whether 0 0 0 0 0 0 0 0 7 0 PRP VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN IN O
presence presence 0 0 0 0 0 0 0 0 8 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 arrest IN DT JJ NN VBD B_TIMEXCCP
arrest arrest 0 0 0 0 0 0 0 0 6 0 DT JJ NN VBD DT O
modified modified 0 0 0 0 0 0 0 0 8 0 JJ NN VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBD DT NN CC O
frequency frequency 0 0 0 0 0 0 0 0 9 0 VBD DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
type type 0 0 0 0 0 0 0 0 4 0 NN CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NNS O
chromosomal chromosomal 0 0 0 0 0 0 0 0 11 0 NN IN JJ NNS IN O
rearrangements rearrangements 0 0 0 0 0 0 0 0 14 0 IN JJ NNS IN DT O
at at 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN IN O
mitosis mitosis 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN NNP B_TIMEXCCP
after after 0 0 0 0 0 0 0 0 5 0 JJ NN IN NNP NNP O
irradiation. irradiation. 0 0 0 0 0 0 0 0 12 0 NN IN NNP NNP NN O
Isogenic Isogenic 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NNS VBD O
lines lines 0 0 0 0 0 0 0 0 5 0 NNP NN NNS VBD IN O
derived derived 0 0 0 0 0 0 0 0 7 0 NN NNS VBD IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT JJ NN O
same same 0 0 0 0 0 0 0 0 4 0 IN DT JJ NN NN O
human human 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN NN O
glioma glioma 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN CC O
line, line, 0 0 0 0 1 0 0 0 5 0 NN NN NN CC VBG O
but but 0 0 0 0 0 0 0 0 3 0 NN NN CC VBG IN O
differing differing 0 0 0 0 0 0 0 0 9 0 NN CC VBG IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CC VBG IN NNP NNP O
p53 p53 0 0 0 0 0 0 0 1 3 0 VBG IN NNP NNP VBD O
status, status, 0 0 0 0 1 0 0 0 7 0 IN NNP NNP VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD NNP NNP O
used. used. 0 0 0 0 0 0 0 0 5 0 NNP VBD NNP NNP NNP O
Purified Purified 1 0 0 0 0 0 0 0 8 0 VBD NNP NNP NNP NNP O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 NNP NNP NNP NNP VBD B_TIMEXCCP
cells, cells, 0 0 0 0 1 0 0 0 6 0 NNP NNP NNP VBD IN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NNP VBD IN JJ NN O
centrifugal centrifugal 0 0 0 0 0 0 0 0 11 0 VBD IN JJ NN CC O
elutriation elutriation 0 0 0 0 0 0 0 0 11 0 IN JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP VBD O
X-irradiated, X-irradiated, 1 0 1 0 1 0 0 0 13 0 NN CC NNP VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 CC NNP VBD NNP NNP O
studied. studied. 0 0 0 0 0 0 0 0 8 0 NNP VBD NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 VBD NNP NNP NNP NNP O
wild-type wild-type 0 0 1 0 0 0 0 0 9 0 NNP NNP NNP NNP NN O
p53 p53 0 0 0 0 0 0 0 1 3 0 NNP NNP NNP NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN VBD O
line line 0 0 0 0 0 0 0 0 4 0 NNP NN NN VBD DT O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 NN NN VBD DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBD DT JJ NN O
dose-dependent dose-dependent 0 0 1 0 0 0 0 0 14 arrest VBD DT JJ NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NNP O
during during 0 0 0 0 0 0 0 0 6 0 JJ NN IN NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 NN IN NNP NNP IN B_TIMEXCCP
phase, phase, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP IN VBN O
as as 0 0 0 0 0 0 0 0 2 0 NNP NNP IN VBN IN O
determined determined 0 0 0 0 0 0 0 0 10 0 NNP IN VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 IN VBN IN NN NNP O
flow flow 0 0 0 0 0 0 0 0 4 0 VBN IN NN NNP NNP O
cytometry. cytometry. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP NNS VBD IN O
remained remained 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBD IN JJ IN O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 VBD IN JJ IN RB B_TIMEXCCP
as as 0 0 0 0 0 0 0 0 2 0 IN JJ IN RB IN O
long long 0 0 0 0 0 0 0 0 4 0 JJ IN RB IN CD O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN CD NN O
48 48 0 0 0 0 0 0 1 1 2 0 RB IN CD NN IN O
h h 0 0 0 0 0 0 0 0 1 0 IN CD NN IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 CD NN IN NNP NNP O
irradiation. irradiation. 0 0 0 0 0 0 0 0 12 0 NN IN NNP NNP NN O
Cells Cells 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NN DT O
expressing expressing 0 0 0 0 0 0 0 0 10 0 NNP NNP NN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NN DT JJ NNP O
dominant-negative dominant-negative 0 0 1 0 0 0 0 0 17 0 NN DT JJ NNP NN O
p53 p53 0 0 0 0 0 0 0 1 3 0 DT JJ NNP NN VBD O
mutation mutation 0 0 0 0 0 0 0 0 8 0 JJ NNP NN VBD TO O
accumulated accumulated 0 0 0 0 0 0 0 0 11 0 NNP NN VBD TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO DT RB O
a a 0 0 0 0 0 0 0 0 1 0 VBD TO DT RB RBR O
much much 0 0 0 0 0 0 0 0 4 0 TO DT RB RBR NN O
lesser lesser 0 0 0 0 0 0 0 0 6 0 DT RB RBR NN IN O
extent extent 0 0 0 0 0 0 0 0 6 0 RB RBR NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 RBR NN IN NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 phase NN IN NNP NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN NNP NN IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 NNP NN IN NNP NNP O
irradiation. irradiation. 0 0 0 0 0 0 0 0 12 0 NN IN NNP NNP NN O
Cells Cells 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NN DT O
lacking lacking 0 0 0 0 0 0 0 0 7 0 NNP NNP NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT NN NN O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 NN DT NN NN VBD G1
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 DT NN NN VBD VBN G1
showed showed 0 0 0 0 0 0 0 0 6 0 NN NN VBD VBN NN O
increased increased 0 0 0 0 0 0 0 0 9 0 NN VBD VBN NN IN O
survival survival 0 0 0 0 0 0 0 0 8 0 VBD VBN NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 VBN NN IN DT NN O
all all 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
radiation radiation 0 0 0 0 0 0 0 0 9 0 IN DT NN NNP NNP O
doses. doses. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP VBD O
There There 1 0 0 0 0 0 0 0 5 0 NN NNP NNP VBD DT O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD DT JJ O
no no 0 0 0 0 0 0 0 0 2 0 NNP VBD DT JJ NNS O
significant significant 0 0 0 0 0 0 0 0 11 0 VBD DT JJ NNS IN O
differences differences 0 0 0 0 0 0 0 0 11 0 DT JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN CC O
type type 0 0 0 0 0 0 0 0 4 0 IN DT NN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 DT NN CC NN IN O
frequency frequency 0 0 0 0 0 0 0 0 9 0 NN CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ JJ O
total total 0 0 0 0 0 0 0 0 5 0 NN IN JJ JJ NNS O
chromosomal chromosomal 0 0 0 0 0 0 0 0 11 0 IN JJ JJ NNS IN O
aberrations aberrations 0 0 0 0 0 0 0 0 11 0 JJ JJ NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NNS O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN DT O
from from 0 0 0 0 0 0 0 0 4 0 JJ NNS IN DT NN O
either either 0 0 0 0 0 0 0 0 6 0 NNS IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN IN O
line line 0 0 0 0 0 0 0 0 4 0 DT NN NN IN CD O
after after 0 0 0 0 0 0 0 0 5 0 NN NN IN CD CC O
1,2,4 1,2,4 0 0 0 0 1 0 0 1 5 0 NN IN CD CC CD O
or or 0 0 0 0 0 0 0 0 2 0 IN CD CC CD NNP O
6 6 0 0 0 0 0 0 1 1 1 0 CD CC CD NNP NNP O
Gy Gy 1 0 0 0 0 0 0 0 2 0 CC CD NNP NNP NNP O
X X 1 1 0 0 0 0 0 0 1 0 CD NNP NNP NNP IN O
rays, rays, 0 0 0 0 1 0 0 0 5 0 NNP NNP NNP IN VBN O
as as 0 0 0 0 0 0 0 0 2 0 NNP NNP IN VBN IN O
measured measured 0 0 0 0 0 0 0 0 8 0 NNP IN VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 IN VBN IN JJ JJ O
conventional conventional 0 0 0 0 0 0 0 0 12 0 VBN IN JJ JJ NNP O
cytogenetic cytogenetic 0 0 0 0 0 0 0 0 11 0 IN JJ JJ NNP NNP O
analysis. analysis. 0 0 0 0 0 0 0 0 9 0 JJ JJ NNP NNP VBD O
There There 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP VBD DT O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNP VBD DT JJ NN O
increase, increase, 0 0 0 0 1 0 0 0 9 0 VBD DT JJ NN IN O
however, however, 0 0 0 0 1 0 0 0 8 0 DT JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
number number 0 0 0 0 0 0 0 0 6 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
reciprocal reciprocal 0 0 0 0 0 0 0 0 10 0 NN IN JJ NNS IN O
translocations translocations 0 0 0 0 0 0 0 0 14 0 IN JJ NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NNS O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NNS IN B_TIMEXCCP
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 JJ NNS IN JJ NNP O
mutant mutant 0 0 0 0 0 0 0 0 6 0 NNS IN JJ NNP JJ O
p53 p53 0 0 0 0 0 0 0 1 3 0 IN JJ NNP JJ DT O
(lacking (lacking 0 0 0 0 0 0 0 0 8 0 JJ NNP JJ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP JJ DT JJ NN O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 JJ DT JJ NN IN G1
checkpoint), checkpoint), 0 0 0 0 1 0 0 0 12 0 DT JJ NN IN VBN G1
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN VBN IN O
measured measured 0 0 0 0 0 0 0 0 8 0 NN IN VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 IN VBN IN NN IN O
fluorescence fluorescence 0 0 0 0 0 0 0 0 12 0 VBN IN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NN O
situ situ 0 0 0 0 0 0 0 0 4 0 NN IN NN NN IN O
hybridization hybridization 0 0 0 0 0 0 0 0 13 0 IN NN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN JJ O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 IN DT NN JJ NNP O
4-specific 4-specific 0 0 1 0 0 0 0 1 10 0 DT NN JJ NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN JJ NNP NNP CC O
library, library, 0 0 0 0 1 0 0 0 8 0 JJ NNP NNP CC RB O
but but 0 0 0 0 0 0 0 0 3 0 NNP NNP CC RB IN O
only only 0 0 0 0 0 0 0 0 4 0 NNP CC RB IN CD O
after after 0 0 0 0 0 0 0 0 5 0 CC RB IN CD NNP O
6 6 0 0 0 0 0 0 1 1 1 0 RB IN CD NNP NNP O
Gy. Gy. 1 0 0 0 0 0 0 0 3 0 IN CD NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 CD NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNP NNS VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NN IN O
presence presence 0 0 0 0 0 0 0 0 8 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ JJ O
well-defined well-defined 0 0 1 0 0 0 0 0 12 0 IN DT JJ JJ NN O
p53-dependent p53-dependent 0 0 1 0 0 0 0 1 13 0 DT JJ JJ NN NN O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 arrest JJ JJ NN NN VBZ B_TIMEXCCP
arrest arrest 0 0 0 0 0 0 0 0 6 0 JJ NN NN VBZ RB O
does does 0 0 0 0 0 0 0 0 4 0 NN NN VBZ RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NN VBZ RB VB JJ O
reduce reduce 0 0 0 0 0 0 0 0 6 0 VBZ RB VB JJ NNS O
chromosomal chromosomal 0 0 0 0 0 0 0 0 11 0 RB VB JJ NNS VBN O
aberrations aberrations 0 0 0 0 0 0 0 0 11 0 VB JJ NNS VBN IN O
caused caused 0 0 0 0 0 0 0 0 6 0 JJ NNS VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBN IN JJ NNS O
low low 0 0 0 0 0 0 0 0 3 0 VBN IN JJ NNS IN O
doses doses 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN VBG NN O
ionizing ionizing 0 0 0 0 0 0 0 0 8 0 NNS IN VBG NN -NONE- O
radiation radiation 0 0 0 0 0 0 0 0 9 0 IN VBG NN -NONE- CC O
markedly, markedly, 0 0 0 0 1 0 0 0 9 0 VBG NN -NONE- CC MD O
but but 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC MD VB O
may may 0 0 0 0 0 0 0 0 3 0 -NONE- CC MD VB DT O
reduce reduce 0 0 0 0 0 0 0 0 6 0 CC MD VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT JJ NN O
overall overall 0 0 0 0 0 0 0 0 7 0 VB DT JJ NN IN O
degree degree 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
survival survival 0 0 0 0 0 0 0 0 8 0 NN IN NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 IN NN IN NN JJ O
triggering triggering 0 0 0 0 0 0 0 0 10 0 NN IN NN JJ NN O
other other 0 0 0 0 0 0 0 0 5 0 IN NN JJ NN NNP O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 NN JJ NN NNP NNP B_TIMEXCCP
events. events. 0 0 0 0 0 0 0 0 7 0 JJ NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
8927696 8927696 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
G2 G2 1 1 0 0 0 0 0 1 2 phase NONE NONE NNP NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 NONE NNP NN NN VBZ O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 NNP NN NN VBZ NNS O
lacks lacks 0 0 0 0 0 0 0 0 5 0 NN NN VBZ NNS IN O
determinants determinants 0 0 0 0 0 0 0 0 12 0 NN VBZ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBZ NNS IN NN NNP O
replication replication 0 0 0 0 0 0 0 0 11 0 NNS IN NN NNP NNP O
timing. timing. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NNP NNP O
Lu Lu 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Murphy Murphy 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
CS, CS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Davidson Davidson 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
MW, MW, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Gilbert Gilbert 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
DM. DM. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biological Biological 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Science, Science, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP NNP O
Florida Florida 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
State State 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Tallahassee, Tallahassee, 1 0 0 0 1 0 0 0 12 0 NNP NNP NNP NNP CD O
FL FL 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
32306, 32306, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
replication replication 0 0 0 0 0 0 0 0 11 0 NNP NNP NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NNS O
all all 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS VBZ O
eukaryotes eukaryotes 0 0 0 0 0 0 0 0 10 0 IN DT NNS VBZ DT O
follows follows 0 0 0 0 0 0 0 0 7 0 DT NNS VBZ DT VBN O
a a 0 0 0 0 0 0 0 0 1 0 NNS VBZ DT VBN NN O
defined defined 0 0 0 0 0 0 0 0 7 0 VBZ DT VBN NN NN O
replication replication 0 0 0 0 0 0 0 0 11 0 DT VBN NN NN NN O
timing timing 0 0 0 0 0 0 0 0 6 0 VBN NN NN NN DT O
program, program, 0 0 0 0 1 0 0 0 8 0 NN NN NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 NN DT JJ NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN WDT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT VBZ NNP O
remains remains 0 0 0 0 0 0 0 0 7 0 IN WDT VBZ NNP NNP O
elusive. elusive. 0 0 0 0 0 0 0 0 8 0 WDT VBZ NNP NNP DT O
Using Using 1 0 0 0 0 0 0 0 5 0 VBZ NNP NNP DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT NNP NN O
Xenopus Xenopus 1 0 0 0 0 0 0 0 7 0 NNP DT NNP NN NN O
laevis laevis 0 0 0 0 0 0 0 0 6 0 DT NNP NN NN NN O
egg egg 0 0 0 0 0 0 0 0 3 0 NNP NN NN NN NN O
extract extract 0 0 0 0 0 0 0 0 7 0 NN NN NN NN NN O
replication replication 0 0 0 0 0 0 0 0 11 0 NN NN NN NN PRP O
system, system, 0 0 0 0 1 0 0 0 7 0 NN NN NN PRP RB O
we we 0 0 0 0 0 0 0 0 2 0 NN NN PRP RB VBD O
previously previously 0 0 0 0 0 0 0 0 10 0 NN PRP RB VBD IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 PRP RB VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 RB VBD IN NN VBG O
replication replication 0 0 0 0 0 0 0 0 11 0 VBD IN NN VBG VBZ O
timing timing 0 0 0 0 0 0 0 0 6 0 IN NN VBG VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN VBG VBZ VBN IN O
established established 0 0 0 0 0 0 0 0 11 0 VBG VBZ VBN IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 VBZ VBN IN JJ NNP O
early early 0 0 0 0 0 0 0 0 5 0 VBN IN JJ NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 phase IN JJ NNP NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 JJ NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN NN NN O
(timing (timing 0 0 0 0 0 0 0 0 7 0 NN NN NN NN NN O
decision decision 0 0 0 0 0 0 0 0 8 0 NN NN NN NN -NONE- O
point point 0 0 0 0 0 0 0 0 5 0 NN NN NN -NONE- WDT O
[TDP]), [TDP]), 0 1 0 0 1 0 0 0 7 0 NN NN -NONE- WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN -NONE- WDT VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 -NONE- WDT VBZ JJ IN O
coincident coincident 0 0 0 0 0 0 0 0 10 0 WDT VBZ JJ IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBZ JJ IN DT VBG O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT VBG CC O
repositioning repositioning 0 0 0 0 0 0 0 0 13 0 IN DT VBG CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT VBG CC NN IN O
anchorage anchorage 0 0 0 0 0 0 0 0 9 0 VBG CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN IN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 NN IN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN DT RB O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT RB VBN O
newly newly 0 0 0 0 0 0 0 0 5 0 IN DT RB VBN NNP O
formed formed 0 0 0 0 0 0 0 0 6 0 DT RB VBN NNP NNP O
nucleus. nucleus. 0 0 0 0 0 0 0 0 8 0 RB VBN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 VBN NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 NNP DT NN PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBP DT O
use use 0 0 0 0 0 0 0 0 3 0 NN PRP VBP DT JJ O
this this 0 0 0 0 0 0 0 0 4 0 PRP VBP DT JJ NN O
same same 0 0 0 0 0 0 0 0 4 0 VBP DT JJ NN TO O
system system 0 0 0 0 0 0 0 0 6 0 DT JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB IN O
show show 0 0 0 0 0 0 0 0 4 0 NN TO VB IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 TO VB IN NNP NN O
G2 G2 1 1 0 0 0 0 0 1 2 phase VB IN NNP NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN NNP NN NN VBZ O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 NNP NN NN VBZ NNS O
lacks lacks 0 0 0 0 0 0 0 0 5 0 NN NN VBZ NNS IN O
determinants determinants 0 0 0 0 0 0 0 0 12 0 NN VBZ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBZ NNS IN NN VBG O
replication replication 0 0 0 0 0 0 0 0 11 0 NNS IN NN VBG CC O
timing timing 0 0 0 0 0 0 0 0 6 0 IN NN VBG CC NNS O
but but 0 0 0 0 0 0 0 0 3 0 NN VBG CC NNS DT O
maintains maintains 0 0 0 0 0 0 0 0 9 0 VBG CC NNS DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CC NNS DT JJ JJ O
overall overall 0 0 0 0 0 0 0 0 7 0 NNS DT JJ JJ NN O
spatial spatial 0 0 0 0 0 0 0 0 7 0 DT JJ JJ NN IN O
organization organization 0 0 0 0 0 0 0 0 12 0 JJ JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 NN IN NN NN CC O
domains, domains, 0 0 0 0 1 0 0 0 8 0 IN NN NN CC PRP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NN CC PRP VBP DT O
confirm confirm 0 0 0 0 0 0 0 0 7 0 CC PRP VBP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 PRP VBP DT NN IN O
finding finding 0 0 0 0 0 0 0 0 7 0 VBP DT NN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
genome-wide genome-wide 0 0 1 0 0 0 0 0 11 0 NN IN JJ NN IN O
analysis analysis 0 0 0 0 0 0 0 0 8 0 IN JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
rereplication rereplication 0 0 0 0 0 0 0 0 13 0 NN IN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNP O
vivo. vivo. 0 0 0 0 0 0 0 0 5 0 NN IN NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 IN NNP NNP NNP NN O
contrast, contrast, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP NN IN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN NN O
from from 0 0 0 0 0 0 0 0 4 0 NNP NN IN NN NNS O
quiescent quiescent 0 0 0 0 0 0 0 0 9 0 NN IN NN NNS VBZ O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NN NNS VBZ NN O
retains retains 0 0 0 0 0 0 0 0 7 0 NN NNS VBZ NN VBG O
replication replication 0 0 0 0 0 0 0 0 11 0 NNS VBZ NN VBG CC O
timing timing 0 0 0 0 0 0 0 0 6 0 VBZ NN VBG CC NNS O
but but 0 0 0 0 0 0 0 0 3 0 NN VBG CC NNS VBD O
exhibits exhibits 0 0 0 0 0 0 0 0 8 0 VBG CC NNS VBD JJ O
disrupted disrupted 0 0 0 0 0 0 0 0 9 0 CC NNS VBD JJ NNP O
spatial spatial 0 0 0 0 0 0 0 0 7 0 NNS VBD JJ NNP NNP O
organization. organization. 0 0 0 0 0 0 0 0 13 0 VBD JJ NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP NNS NN O
data data 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS NN DT O
support support 0 0 0 0 0 0 0 0 7 0 NNP NNS NN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNS NN DT NN IN O
model model 0 0 0 0 0 0 0 0 5 0 NN DT NN IN WDT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN WDT NNS O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT NNS IN O
events events 0 0 0 0 0 0 0 0 6 0 IN WDT NNS IN DT O
at at 0 0 0 0 0 0 0 0 2 0 WDT NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP VBD O
TDP, TDP, 1 1 0 0 1 0 0 0 4 0 IN DT NNP VBD IN O
facilitated facilitated 0 0 0 0 0 0 0 0 11 0 DT NNP VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNP VBD IN NN JJ O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 VBD IN NN JJ NN O
spatial spatial 0 0 0 0 0 0 0 0 7 0 IN NN JJ NN NN O
organization, organization, 0 0 0 0 1 0 0 0 13 0 NN JJ NN NN NNS O
establish establish 0 0 0 0 0 0 0 0 9 0 JJ NN NN NNS IN O
determinants determinants 0 0 0 0 0 0 0 0 12 0 NN NN NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN VBG O
replication replication 0 0 0 0 0 0 0 0 11 0 NNS IN NN VBG IN O
timing timing 0 0 0 0 0 0 0 0 6 0 IN NN VBG IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NN VBG IN NN NN O
persist persist 0 0 0 0 0 0 0 0 7 0 VBG IN NN NN IN O
independent independent 0 0 0 0 0 0 0 0 11 0 IN NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
spatial spatial 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN IN O
organization organization 0 0 0 0 0 0 0 0 12 0 IN JJ NN IN DT O
until until 0 0 0 0 0 0 0 0 5 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
process process 0 0 0 0 0 0 0 0 7 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 NN IN NN NN IN O
replication replication 0 0 0 0 0 0 0 0 11 0 IN NN NN IN NNP O
during during 0 0 0 0 0 0 0 0 6 0 NN NN IN NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase NN IN NNP NN NNS B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN NNP NN NNS DT O
erases erases 0 0 0 0 0 0 0 0 6 0 NNP NN NNS DT NNP O
those those 0 0 0 0 0 0 0 0 5 0 NN NNS DT NNP NNP O
determinants. determinants. 0 0 0 0 0 0 0 0 13 0 NNS DT NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 DT NNP NNP CD JJ O
20530209 20530209 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NN O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NN NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
PMC2886351 PMC2886351 1 1 0 0 0 0 0 1 10 0 JJ NN NNP NONE NONE O
Structure Structure 1 0 0 0 0 0 0 0 9 0 NONE NONE NN CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NONE NN CC NNS IN O
dynamics dynamics 0 0 0 0 0 0 0 0 8 0 NN CC NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NNS IN NN NNP O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NNS IN NN NNP NNP B_TIMEXCCP
chromosomes. chromosomes. 0 0 0 0 0 0 0 0 12 0 IN NN NNP NNP NNP O
Rosa Rosa 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Everaers Everaers 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
R. R. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Max-Planck-Institut Max-Planck-Institut 1 0 1 0 0 0 0 0 19 0 NNP NNP NNP NNP NNP O
für für 0 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Physik Physik 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Komplexer Komplexer 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Systeme, Systeme, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Dresden, Dresden, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Germany. Germany. 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
anrosa@unizar.es anrosa@unizar.es 0 0 0 0 0 0 0 0 16 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
During During 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NN VBZ O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NNP NNP NN VBZ JJ B_TIMEXCCP 
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 NNP NN VBZ JJ CC O
decondense, decondense, 0 0 0 0 1 0 0 0 11 0 NN VBZ JJ CC NN O
but but 0 0 0 0 0 0 0 0 3 0 VBZ JJ CC NN IN O
fluorescent fluorescent 0 0 0 0 0 0 0 0 11 0 JJ CC NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NN O
situ situ 0 0 0 0 0 0 0 0 4 0 NN IN NN NN NNS O
hybridization hybridization 0 0 0 0 0 0 0 0 13 0 IN NN NN NNS VBP O
experiments experiments 0 0 0 0 0 0 0 0 11 0 NN NN NNS VBP DT O
reveal reveal 0 0 0 0 0 0 0 0 6 0 NN NNS VBP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBP DT NN IN O
existence existence 0 0 0 0 0 0 0 0 9 0 VBP DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
distinct distinct 0 0 0 0 0 0 0 0 8 0 NN IN NN NNS VBD O
territories territories 0 0 0 0 0 0 0 0 11 0 IN NN NNS VBD IN O
occupied occupied 0 0 0 0 0 0 0 0 8 0 NN NNS VBD IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBD IN JJ NNS O
individual individual 0 0 0 0 0 0 0 0 10 0 VBD IN JJ NNS VBP O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 IN JJ NNS VBP DT O
inside inside 0 0 0 0 0 0 0 0 6 0 JJ NNS VBP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBP DT NN IN O
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 VBP DT NN IN JJS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJS JJ O
most most 0 0 0 0 0 0 0 0 4 0 NN IN JJS JJ NNP O
eukaryotic eukaryotic 0 0 0 0 0 0 0 0 10 0 IN JJS JJ NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 JJS JJ NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP VBP NN O
use use 0 0 0 0 0 0 0 0 3 0 NNP NNP VBP NN NNS O
computer computer 0 0 0 0 0 0 0 0 8 0 NNP VBP NN NNS TO O
simulations simulations 0 0 0 0 0 0 0 0 11 0 VBP NN NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO VB IN O
show show 0 0 0 0 0 0 0 0 4 0 NNS TO VB IN DT O
that that 0 0 0 0 0 0 0 0 4 0 TO VB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VB IN DT NN CC O
existence existence 0 0 0 0 0 0 0 0 9 0 IN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
stability stability 0 0 0 0 0 0 0 0 9 0 NN CC NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNS VBZ O
territories territories 0 0 0 0 0 0 0 0 11 0 NN IN NNS VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 IN NNS VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS VBZ DT JJ NN O
kinetic kinetic 0 0 0 0 0 0 0 0 7 0 VBZ DT JJ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN MD O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN IN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN IN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 IN MD VB VBN IN O
explained explained 0 0 0 0 0 0 0 0 9 0 MD VB VBN IN NN O
without without 0 0 0 0 0 0 0 0 7 0 VB VBN IN NN DT O
invoking invoking 0 0 0 0 0 0 0 0 8 0 VBN IN NN DT VBG O
an an 0 0 0 0 0 0 0 0 2 0 IN NN DT VBG JJ O
underlying underlying 0 0 0 0 0 0 0 0 10 0 NN DT VBG JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 DT VBG JJ NN CC O
scaffold scaffold 0 0 0 0 0 0 0 0 8 0 VBG JJ NN CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 JJ NN CC JJ NNS O
protein-mediated protein-mediated 0 0 1 0 0 0 0 0 16 0 NN CC JJ NNS IN O
interactions interactions 0 0 0 0 0 0 0 0 12 0 CC JJ NNS IN NNP O
between between 0 0 0 0 0 0 0 0 7 0 JJ NNS IN NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NNS IN NNP NNP NNP O
sequences. sequences. 0 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP PRP O
particular, particular, 0 0 0 0 1 0 0 0 11 0 NNP NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NNP PRP VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN DT RB O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT RB VBN O
experimentally experimentally 0 0 0 0 0 0 0 0 14 0 IN DT RB VBN NN O
observed observed 0 0 0 0 0 0 0 0 8 0 DT RB VBN NN NNS O
territory territory 0 0 0 0 0 0 0 0 9 0 RB VBN NN NNS CC O
shapes shapes 0 0 0 0 0 0 0 0 6 0 VBN NN NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC JJ NNS O
spatial spatial 0 0 0 0 0 0 0 0 7 0 NNS CC JJ NNS IN O
distances distances 0 0 0 0 0 0 0 0 9 0 CC JJ NNS IN VBN O
between between 0 0 0 0 0 0 0 0 7 0 JJ NNS IN VBN NN O
marked marked 0 0 0 0 0 0 0 0 6 0 NNS IN VBN NN NNS O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 IN VBN NN NNS IN O
sites sites 0 0 0 0 0 0 0 0 5 0 VBN NN NNS IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN JJ NN O
human, human, 0 0 0 0 1 0 0 0 6 0 NNS IN JJ NN CC O
Drosophila, Drosophila, 1 0 0 0 1 0 0 0 11 0 IN JJ NN CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBG NN O
budding budding 0 0 0 0 0 0 0 0 7 0 NN CC VBG NN NNS O
yeast yeast 0 0 0 0 0 0 0 0 5 0 CC VBG NN NNS MD O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 VBG NN NNS MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN NNS MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB VBN IN O
reproduced reproduced 0 0 0 0 0 0 0 0 10 0 MD VB VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VB VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ JJ O
parameter-free parameter-free 0 0 1 0 0 0 0 0 14 0 IN DT JJ JJ NN O
minimal minimal 0 0 0 0 0 0 0 0 7 0 DT JJ JJ NN IN O
model model 0 0 0 0 0 0 0 0 5 0 JJ JJ NN IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN VBG NNP O
decondensing decondensing 0 0 0 0 0 0 0 0 12 0 NN IN VBG NNP NNP O
chromosomes. chromosomes. 0 0 0 0 0 0 0 0 12 0 IN VBG NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 VBG NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNP NNS VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT VBN NN O
observed observed 0 0 0 0 0 0 0 0 8 0 IN DT VBN NN NN O
interphase interphase 0 0 0 0 0 0 0 0 10 0 DT VBN NN NN CC B_TIMEXCCP 
structure structure 0 0 0 0 0 0 0 0 9 0 VBN NN NN CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNS VBP O
dynamics dynamics 0 0 0 0 0 0 0 0 8 0 NN CC NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 CC NNS VBP JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 NNS VBP JJ TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 VBP JJ TO JJ NN O
generic generic 0 0 0 0 0 0 0 0 7 0 JJ TO JJ NN NN O
polymer polymer 0 0 0 0 0 0 0 0 7 0 TO JJ NN NN VBD O
effects: effects: 0 0 0 0 0 0 0 0 8 0 JJ NN NN VBD NNP O
confined confined 0 0 0 0 0 0 0 0 8 0 NN NN VBD NNP NN O
Brownian Brownian 1 0 0 0 0 0 0 0 8 0 NN VBD NNP NN VBG O
motion motion 0 0 0 0 0 0 0 0 6 0 VBD NNP NN VBG DT O
conserving conserving 0 0 0 0 0 0 0 0 10 0 NNP NN VBG DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT JJ JJ O
local local 0 0 0 0 0 0 0 0 5 0 VBG DT JJ JJ NN O
topological topological 0 0 0 0 0 0 0 0 11 0 DT JJ JJ NN IN O
state state 0 0 0 0 0 0 0 0 5 0 JJ JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
long long 0 0 0 0 0 0 0 0 4 0 NN IN JJ NN NNS O
chain chain 0 0 0 0 0 0 0 0 5 0 IN JJ NN NNS CC O
molecules molecules 0 0 0 0 0 0 0 0 9 0 JJ NN NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NN IN O
segregation segregation 0 0 0 0 0 0 0 0 11 0 NNS CC NN IN RB O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN RB VBN O
mutually mutually 0 0 0 0 0 0 0 0 8 0 NN IN RB VBN NNS O
unentangled unentangled 0 0 0 0 0 0 0 0 11 0 IN RB VBN NNS JJ O
chains chains 0 0 0 0 0 0 0 0 6 0 RB VBN NNS JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 VBN NNS JJ TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NNS JJ TO JJ NNP O
topological topological 0 0 0 0 0 0 0 0 11 0 JJ TO JJ NNP NNP O
constraints. constraints. 0 0 0 0 0 0 0 0 12 0 TO JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
18725929 18725929 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NN O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NN NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
PMC2515109 PMC2515109 1 1 0 0 0 0 0 1 10 0 JJ NN NNP NONE NONE O
Modeling Modeling 1 0 0 0 0 0 0 0 8 0 NONE NONE VBG NNP NNP O
mitosis. mitosis. 0 0 0 0 0 0 0 0 8 0 NONE VBG NNP NNP NNP B_TIMEXCCP
Mogilner Mogilner 1 0 0 0 0 0 0 0 8 0 VBG NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wollman Wollman 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Civelekoglu-Scholey Civelekoglu-Scholey 1 0 1 0 0 0 0 0 19 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Scholey Scholey 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
J. J. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Computational Computational 1 0 0 0 0 0 0 0 13 0 NNP CC NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 CC NNP NNP NNP IN O
Center Center 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP CC O
Genetics Genetics 1 0 0 0 0 0 0 0 8 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Development, Development, 1 0 0 0 1 0 0 0 12 0 NNP CC NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
California, California, 1 0 0 0 1 0 0 0 11 0 NNP IN NNP NNP NNP O
Davis, Davis, 1 0 0 0 1 0 0 0 6 0 IN NNP NNP NNP CD O
CA CA 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
95616, 95616, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
mogilner@math.ucdavis.edu mogilner@math.ucdavis.edu 0 0 0 0 0 0 0 0 25 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NN VBZ B_TIMEXCCP
spindle spindle 0 0 0 0 0 0 0 0 7 0 NNP JJ NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT NN NN O
fascinating fascinating 0 0 0 0 0 0 0 0 11 0 VBZ DT NN NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 DT NN NN NN WDT O
machine machine 0 0 0 0 0 0 0 0 7 0 NN NN NN WDT VBZ O
that that 0 0 0 0 0 0 0 0 4 0 NN NN WDT VBZ JJ O
uses uses 0 0 0 0 0 0 0 0 4 0 NN WDT VBZ JJ NNS O
bipolar bipolar 0 0 0 0 0 0 0 0 7 0 WDT VBZ JJ NNS IN O
arrays arrays 0 0 0 0 0 0 0 0 6 0 VBZ JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NNS O
dynamic dynamic 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NNS CC O
microtubules microtubules 0 0 0 0 0 0 0 0 12 0 IN JJ NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC JJ JJ O
many many 0 0 0 0 0 0 0 0 4 0 NNS CC JJ JJ NNS O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 CC JJ JJ NNS TO B_TIMEXCCP
motors motors 0 0 0 0 0 0 0 0 6 0 JJ JJ NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO VB DT O
coordinate coordinate 0 0 0 0 0 0 0 0 10 0 NNS TO VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJ NN O
accurate accurate 0 0 0 0 0 0 0 0 8 0 VB DT JJ NN IN O
segregation segregation 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNP O
sister sister 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP NNP O
chromatids. chromatids. 0 0 0 0 0 0 0 0 11 0 IN NN NNP NNP PRP O
Here Here 1 0 0 0 0 0 0 0 4 0 NN NNP NNP PRP VBZ O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBZ JJ O
discuss discuss 0 0 0 0 0 0 0 0 7 0 NNP PRP VBZ JJ JJ O
recent recent 0 0 0 0 0 0 0 0 6 0 PRP VBZ JJ JJ NNS O
mathematical mathematical 0 0 0 0 0 0 0 0 12 0 VBZ JJ JJ NNS CC O
models models 0 0 0 0 0 0 0 0 6 0 JJ JJ NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC NN NNS O
computer computer 0 0 0 0 0 0 0 0 8 0 NNS CC NN NNS -NONE- O
simulations simulations 0 0 0 0 0 0 0 0 11 0 CC NN NNS -NONE- IN O
that, that, 0 0 0 0 1 0 0 0 5 0 NN NNS -NONE- IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNS -NONE- IN NN IN O
concert concert 0 0 0 0 0 0 0 0 7 0 -NONE- IN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN JJ NN O
experimental experimental 0 0 0 0 0 0 0 0 12 0 NN IN JJ NN NN O
studies, studies, 0 0 0 0 1 0 0 0 8 0 IN JJ NN NN VB O
help help 0 0 0 0 0 0 0 0 4 0 JJ NN NN VB DT O
explain explain 0 0 0 0 0 0 0 0 7 0 NN NN VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN VB DT JJ NNS O
molecular molecular 0 0 0 0 0 0 0 0 9 0 VB DT JJ NNS IN O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 DT JJ NNS IN WDT O
by by 0 0 0 0 0 0 0 0 2 0 JJ NNS IN WDT DT O
which which 0 0 0 0 0 0 0 0 5 0 NNS IN WDT DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN WDT DT NN NN O
spindle spindle 0 0 0 0 0 0 0 0 7 0 WDT DT NN NN NNS O
machinery machinery 0 0 0 0 0 0 0 0 9 0 DT NN NN NNS PRP$ O
performs performs 0 0 0 0 0 0 0 0 8 0 NN NN NNS PRP$ JJ O
its its 0 0 0 0 0 0 0 0 3 0 NN NNS PRP$ JJ NNP O
crucial crucial 0 0 0 0 0 0 0 0 7 0 NNS PRP$ JJ NNP NNP O
functions. functions. 0 0 0 0 0 0 0 0 10 0 PRP$ JJ NNP NNP NN O
We We 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NN JJ O
review review 0 0 0 0 0 0 0 0 6 0 NNP NNP NN JJ NNS O
current current 0 0 0 0 0 0 0 0 7 0 NNP NN JJ NNS IN O
models models 0 0 0 0 0 0 0 0 6 0 NN JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NN O
spindle spindle 0 0 0 0 0 0 0 0 7 0 NNS IN NN NN NN O
assembly, assembly, 0 0 0 0 1 0 0 0 9 0 IN NN NN NN NN O
positioning, positioning, 0 0 0 0 1 0 0 0 12 0 NN NN NN NN CC O
maintenance maintenance 0 0 0 0 0 0 0 0 11 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
elongation; elongation; 0 0 0 0 0 0 0 0 11 0 NN CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NN IN NN NN CC O
capture capture 0 0 0 0 0 0 0 0 7 0 IN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP CC O
congression; congression; 0 0 0 0 0 0 0 0 12 0 NN CC NNP CC IN O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP CC IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC IN DT NN RB O
spindle spindle 0 0 0 0 0 0 0 0 7 0 IN DT NN RB NNP O
assembly assembly 0 0 0 0 0 0 0 0 8 0 DT NN RB NNP NNP O
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 NN RB NNP NNP NN B_TIMEXCCP
We We 1 0 0 0 0 0 0 0 2 0 RB NNP NNP NN DT O
discuss discuss 0 0 0 0 0 0 0 0 7 0 NNP NNP NN DT NNS O
some some 0 0 0 0 0 0 0 0 4 0 NNP NN DT NNS IN O
limitations limitations 0 0 0 0 0 0 0 0 11 0 NN DT NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
application application 0 0 0 0 0 0 0 0 11 0 IN DT NN IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN VBG TO O
modeling modeling 0 0 0 0 0 0 0 0 8 0 NN IN VBG TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 IN VBG TO JJ NNS O
other other 0 0 0 0 0 0 0 0 5 0 VBG TO JJ NNS IN O
aspects aspects 0 0 0 0 0 0 0 0 7 0 TO JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN CC O
mitosis mitosis 0 0 0 0 0 0 0 0 7 0 NNS IN NN CC DT B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN IN O
feasibility feasibility 0 0 0 0 0 0 0 0 11 0 CC DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN JJR O
building building 0 0 0 0 0 0 0 0 8 0 NN IN NN JJR JJ O
more more 0 0 0 0 0 0 0 0 4 0 IN NN JJR JJ JJ O
comprehensive comprehensive 0 0 0 0 0 0 0 0 13 0 NN JJR JJ JJ NNP O
system-level system-level 0 0 1 0 0 0 0 0 12 0 JJR JJ JJ NNP NNP O
models. models. 0 0 0 0 0 0 0 0 7 0 JJ JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
16406522 16406522 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Nucleosomes Nucleosomes 1 0 0 0 0 0 0 0 11 0 NONE NONE NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NONE NNP IN NN NNP O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 NNP IN NN NNP NNP B_TIMEXCCP
chromosomes. chromosomes. 0 0 0 0 0 0 0 0 12 0 IN NN NNP NNP NNP O
Wigler Wigler 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP NNP O
MH, MH, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Axel Axel 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
R. R. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNS O
Previous Previous 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNS IN O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
structure structure 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 NN IN NN NNS VBP B_TIMEXCCP
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 IN NN NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NN NNS VBP VBN RB O
relied relied 0 0 0 0 0 0 0 0 6 0 NNS VBP VBN RB IN O
heavily heavily 0 0 0 0 0 0 0 0 7 0 VBP VBN RB IN NN O
on on 0 0 0 0 0 0 0 0 2 0 VBN RB IN NN NN O
electron electron 0 0 0 0 0 0 0 0 8 0 RB IN NN NN CC O
micrography micrography 0 0 0 0 0 0 0 0 11 0 IN NN NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VB VBN O
have have 0 0 0 0 0 0 0 0 4 0 NN CC VB VBN DT O
revealed revealed 0 0 0 0 0 0 0 0 8 0 CC VB VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VB VBN DT NN IN O
existence existence 0 0 0 0 0 0 0 0 9 0 VBN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT CD O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT CD NN O
10-nm 10-nm 0 0 1 0 0 0 0 1 5 0 IN DT CD NN NN O
unit unit 0 0 0 0 0 0 0 0 4 0 DT CD NN NN IN O
fiber fiber 0 0 0 0 0 0 0 0 5 0 CD NN NN IN VBZ O
that that 0 0 0 0 0 0 0 0 4 0 NN NN IN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN IN VBZ VBN TO O
thought thought 0 0 0 0 0 0 0 0 7 0 IN VBZ VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ VBN TO VB DT O
generate generate 0 0 0 0 0 0 0 0 8 0 VBN TO VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJ CD O
native native 0 0 0 0 0 0 0 0 6 0 VB DT JJ CD NN O
23-30-nm 23-30-nm 0 0 1 0 0 0 0 1 8 0 DT JJ CD NN IN O
fiber fiber 0 0 0 0 0 0 0 0 5 0 JJ CD NN IN JJR O
by by 0 0 0 0 0 0 0 0 2 0 CD NN IN JJR NN O
higher higher 0 0 0 0 0 0 0 0 6 0 NN IN JJR NN NNP O
order order 0 0 0 0 0 0 0 0 5 0 IN JJR NN NNP NNP O
folding. folding. 0 0 0 0 0 0 0 0 8 0 JJR NN NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP JJ NN O
structural structural 0 0 0 0 0 0 0 0 10 0 NNP NNP JJ NN IN O
relationship relationship 0 0 0 0 0 0 0 0 12 0 NNP JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT NN NNS O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 IN DT NN NNS TO B_TIMEXCCP
fibers fibers 0 0 0 0 0 0 0 0 6 0 DT NN NNS TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS TO DT NN NN O
interphase interphase 0 0 0 0 0 0 0 0 10 0 TO DT NN NN VBZ B_TIMEXCCP
fiber fiber 0 0 0 0 0 0 0 0 5 0 DT NN NN VBZ NNP O
remains remains 0 0 0 0 0 0 0 0 7 0 NN NN VBZ NNP NNP O
obscure. obscure. 0 0 0 0 0 0 0 0 8 0 NN VBZ NNP NNP NNS O
Recent Recent 1 0 0 0 0 0 0 0 6 0 VBZ NNP NNP NNS IN O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
digestion digestion 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NN IN NN NN VBP B_TIMEXCCP
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 IN NN NN VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NN NN VBP VBN DT O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NN VBP VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP VBN DT NN IN O
existence existence 0 0 0 0 0 0 0 0 9 0 VBN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT RB O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT RB VBG O
regularly regularly 0 0 0 0 0 0 0 0 9 0 IN DT RB VBG NN O
repeating repeating 0 0 0 0 0 0 0 0 9 0 DT RB VBG NN IN O
subunit subunit 0 0 0 0 0 0 0 0 7 0 RB VBG NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBG NN IN NNP CC O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP DT O
histone, histone, 0 0 0 0 1 0 0 0 8 0 NNP CC NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC NNP DT NN IN O
nucleosome nucleosome 0 0 0 0 0 0 0 0 10 0 NNP DT NN IN NNS O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN NNS DT O
generates generates 0 0 0 0 0 0 0 0 9 0 NN IN NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NNS DT NN IN O
appearance appearance 0 0 0 0 0 0 0 0 10 0 NNS DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD NNS O
10-nm 10-nm 0 0 1 0 0 0 0 1 5 0 NN IN CD NNS VBN O
beads beads 0 0 0 0 0 0 0 0 5 0 IN CD NNS VBN IN O
connected connected 0 0 0 0 0 0 0 0 9 0 CD NNS VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NN O
short short 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN IN O
fiber fiber 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP IN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN IN NNP IN IN O
seen seen 0 0 0 0 0 0 0 0 4 0 IN NNP IN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NNP IN IN NN NNP O
electron electron 0 0 0 0 0 0 0 0 8 0 IN IN NN NNP NNP O
micrographs. micrographs. 0 0 0 0 0 0 0 0 12 0 IN NN NNP NNP VBD O
It It 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD RB IN O
therefore therefore 0 0 0 0 0 0 0 0 9 0 NNP VBD RB IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBD RB IN NN TO O
interest interest 0 0 0 0 0 0 0 0 8 0 RB IN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB DT O
probe probe 0 0 0 0 0 0 0 0 5 0 NN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
structure structure 0 0 0 0 0 0 0 0 9 0 VB DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 IN DT NN NN IN B_TIMEXCCP
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 DT NN NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
presence presence 0 0 0 0 0 0 0 0 8 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
nucleosomal nucleosomal 0 0 0 0 0 0 0 0 11 0 NN IN JJ NNP NNP O
subunits. subunits. 0 0 0 0 0 0 0 0 9 0 IN JJ NNP NNP DT O
To To 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN NN O
end end 0 0 0 0 0 0 0 0 3 0 NNP DT NN NN VBZ O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 DT NN NN VBZ VBD B_TIMEXCCP
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 NN NN VBZ VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN VBZ VBD VBN IN O
prepared prepared 0 0 0 0 0 0 0 0 8 0 VBZ VBD VBN IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 VBD VBN IN JJ NNS O
colchicine-arrested colchicine-arrested 0 0 1 0 0 0 0 0 19 0 VBN IN JJ NNS IN O
cultures cultures 0 0 0 0 0 0 0 0 8 0 IN JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NNS O
mouse mouse 0 0 0 0 0 0 0 0 5 0 NNS IN NN NNS CC O
L-cells L-cells 1 0 1 0 0 0 0 0 7 0 IN NN NNS CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNS CC VBD VBN TO O
subjected subjected 0 0 0 0 0 0 0 0 9 0 CC VBD VBN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO NN IN O
digestion digestion 0 0 0 0 0 0 0 0 9 0 VBN TO NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 TO NN IN JJ NNP O
stayphylococcal stayphylococcal 0 0 0 0 0 0 0 0 15 0 NN IN JJ NNP NNP O
nuclease. nuclease. 0 0 0 0 0 0 0 0 9 0 IN JJ NNP NNP IN O
Comparison Comparison 1 0 0 0 0 0 0 0 10 0 JJ NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ CC O
early early 0 0 0 0 0 0 0 0 5 0 IN DT JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC NN NN O
limit limit 0 0 0 0 0 0 0 0 5 0 JJ CC NN NN NNS O
digestion digestion 0 0 0 0 0 0 0 0 9 0 CC NN NN NNS IN O
products products 0 0 0 0 0 0 0 0 8 0 NN NN NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NNS O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 NNS IN NN NNS IN B_TIMEXCCP
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 IN NN NNS IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN NNS IN DT VBN O
those those 0 0 0 0 0 0 0 0 5 0 NNS IN DT VBN IN O
obtained obtained 0 0 0 0 0 0 0 0 8 0 IN DT VBN IN NN O
from from 0 0 0 0 0 0 0 0 4 0 DT VBN IN NN NN O
interphase interphase 0 0 0 0 0 0 0 0 10 0 VBN IN NN NN VBZ B_TIMEXCCP
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 IN NN NN VBZ IN O
indicates indicates 0 0 0 0 0 0 0 0 9 0 NN NN VBZ IN IN O
that that 0 0 0 0 0 0 0 0 4 0 NN VBZ IN IN JJ O
although although 0 0 0 0 0 0 0 0 8 0 VBZ IN IN JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 IN IN JJ NN NNS O
morphologic morphologic 0 0 0 0 0 0 0 0 11 0 IN JJ NN NNS VBP O
changes changes 0 0 0 0 0 0 0 0 7 0 JJ NN NNS VBP IN O
occur occur 0 0 0 0 0 0 0 0 5 0 NN NNS VBP IN DT O
within within 0 0 0 0 0 0 0 0 6 0 NNS VBP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NN NN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 IN DT NN NN IN O
fiber fiber 0 0 0 0 0 0 0 0 5 0 DT NN NN IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 NN NN IN JJ DT O
mitosis, mitosis, 0 0 0 0 1 0 0 0 8 0 NN IN JJ DT JJ B_TIMEXCCP
the the 0 0 0 0 0 0 0 0 3 0 IN JJ DT JJ NN O
basic basic 0 0 0 0 0 0 0 0 5 0 JJ DT JJ NN NN O
subunit subunit 0 0 0 0 0 0 0 0 7 0 DT JJ NN NN IN O
structure structure 0 0 0 0 0 0 0 0 9 0 JJ NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 IN DT NN NN VBZ O
fiber fiber 0 0 0 0 0 0 0 0 5 0 DT NN NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ VBN IN O
retained retained 0 0 0 0 0 0 0 0 8 0 NN VBZ VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNP O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NNP NNP B_TIMEXCCP
chromosome. chromosome. 0 0 0 0 0 0 0 0 11 0 DT JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
958895 958895 0 0 0 0 0 0 1 1 6 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NN O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NN NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
PMC343005 PMC343005 1 1 0 0 0 0 0 1 9 0 JJ NN NNP NONE NONE O
Functional Functional 1 0 0 0 0 0 0 0 10 0 NONE NONE NNP NNS IN O
dynamics dynamics 0 0 0 0 0 0 0 0 8 0 NONE NNP NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NNP NN O
H3K9 H3K9 1 1 0 0 0 0 0 1 4 0 NNS IN NNP NN IN O
methylation methylation 0 0 0 0 0 0 0 0 11 0 IN NNP NN IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 NNP NN IN JJ NN O
meiotic meiotic 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN NNP O
prophase prophase 0 0 0 0 0 0 0 0 8 0 IN JJ NN NNP NNP B_TIMEXCCP
progression. progression. 0 0 0 0 0 0 0 0 12 0 JJ NN NNP NNP NNP O
Tachibana Tachibana 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Nozaki Nozaki 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Takeda Takeda 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Shinkai Shinkai 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Y. Y. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Experimental Experimental 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Center Center 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNP O
Infectious Infectious 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Diseases, Diseases, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNP O
Virus Virus 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Research, Research, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Kyoto Kyoto 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Sakyo-ku, Sakyo-ku, 1 0 1 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Kyoto, Kyoto, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
Japan. Japan. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
mtachiba@virus.kyoto-u.ac.jp mtachiba@virus.kyoto-u.ac.jp 0 0 1 0 0 0 0 0 28 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Histone Histone 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NN O
H3 H3 1 1 0 0 0 0 0 1 2 0 NNP NNP NNP NN CD O
lysine lysine 0 0 0 0 0 0 0 0 6 0 NNP NNP NN CD NN O
9 9 0 0 0 0 0 0 1 1 1 0 NNP NN CD NN NN O
(H3K9) (H3K9) 0 1 0 0 0 0 0 1 6 0 NN CD NN NN VBZ O
methylation methylation 0 0 0 0 0 0 0 0 11 0 CD NN NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT JJ JJ O
crucial crucial 0 0 0 0 0 0 0 0 7 0 VBZ DT JJ JJ NN O
epigenetic epigenetic 0 0 0 0 0 0 0 0 10 0 DT JJ JJ NN IN O
mark mark 0 0 0 0 0 0 0 0 4 0 JJ JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
heterochromatin heterochromatin 0 0 0 0 0 0 0 0 15 0 NN IN NN NN CC O
formation formation 0 0 0 0 0 0 0 0 9 0 IN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NNP O
transcriptional transcriptional 0 0 0 0 0 0 0 0 15 0 NN CC JJ NNP NNP O
silencing. silencing. 0 0 0 0 0 0 0 0 10 0 CC JJ NNP NNP VBZ O
G9a G9a 1 0 0 0 0 0 0 1 3 0 JJ NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT JJ NN O
major major 0 0 0 0 0 0 0 0 5 0 VBZ DT JJ NN NNP O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 DT JJ NN NNP NN O
H3K9 H3K9 1 1 0 0 0 0 0 1 4 0 JJ NN NNP NN IN O
methyltransferase methyltransferase 0 0 0 0 0 0 0 0 17 0 NN NNP NN IN NN O
at at 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN CC O
euchromatin euchromatin 0 0 0 0 0 0 0 0 11 0 NN IN NN CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN CC VBZ JJ IN O
essential essential 0 0 0 0 0 0 0 0 9 0 CC VBZ JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN NN NNP O
mouse mouse 0 0 0 0 0 0 0 0 5 0 JJ IN NN NNP NNP O
embryogenesis. embryogenesis. 0 0 0 0 0 0 0 0 14 0 IN NN NNP NNP PRP O
Here Here 1 0 0 0 0 0 0 0 4 0 NN NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP DT O
describe describe 0 0 0 0 0 0 0 0 8 0 NNP PRP VBP DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBP DT NNS IN O
roles roles 0 0 0 0 0 0 0 0 5 0 VBP DT NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NNP IN O
G9a G9a 1 0 0 0 0 0 0 1 3 0 NNS IN NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NN NN O
germ germ 0 0 0 0 0 0 0 0 4 0 NNP IN NN NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN NN NN NNP NNP O
development. development. 0 0 0 0 0 0 0 0 12 0 NN NN NNP NNP NN O
Mutant Mutant 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NN IN O
mice mice 0 0 0 0 0 0 0 0 4 0 NNP NNP NN IN WDT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN WDT NNP O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT NNP VBZ O
G9a G9a 1 0 0 0 0 0 0 1 3 0 IN WDT NNP VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 WDT NNP VBZ RB VBN O
specifically specifically 0 0 0 0 0 0 0 0 12 0 NNP VBZ RB VBN IN O
inactivated inactivated 0 0 0 0 0 0 0 0 11 0 VBZ RB VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN VBD O
germ-lineage germ-lineage 0 0 1 0 0 0 0 0 12 0 IN DT NN VBD NN O
displayed displayed 0 0 0 0 0 0 0 0 9 0 DT NN VBD NN JJ O
sterility sterility 0 0 0 0 0 0 0 0 9 0 NN VBD NN JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 VBD NN JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN JJ TO DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 JJ TO DT JJ NN O
drastic drastic 0 0 0 0 0 0 0 0 7 0 TO DT JJ NN IN O
loss loss 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNP O
mature mature 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP NNP O
gametes. gametes. 0 0 0 0 0 0 0 0 8 0 IN NN NNP NNP NN O
G9a-deficient G9a-deficient 1 0 1 0 0 0 0 1 13 0 NN NNP NNP NN NNS O
germ germ 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NN NNS VBD NN O
exhibited exhibited 0 0 0 0 0 0 0 0 9 0 NN NNS VBD NN IN O
perturbation perturbation 0 0 0 0 0 0 0 0 12 0 NNS VBD NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN JJ NN O
synchronous synchronous 0 0 0 0 0 0 0 0 11 0 NN IN JJ NN IN O
synapsis synapsis 0 0 0 0 0 0 0 0 8 0 IN JJ NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNP O
meiotic meiotic 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNP NNP O
prophase. prophase. 0 0 0 0 0 0 0 0 9 0 IN JJ NNP NNP NNP B_TIMEXCCP
Importantly, Importantly, 1 0 0 0 1 0 0 0 12 0 JJ NNP NNP NNP CC O
mono- mono- 0 0 1 0 0 0 0 0 5 0 NNP NNP NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NN IN O
di-methylation di-methylation 0 0 1 0 0 0 0 0 14 0 NNP CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NNP O
H3K9 H3K9 1 1 0 0 0 0 0 1 4 0 NN IN NNP NNP CC O
(H3K9me1 (H3K9me1 0 0 0 0 0 0 0 1 8 0 IN NNP NNP CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC CD IN O
2) 2) 0 0 0 0 0 0 0 1 2 0 NNP CC CD IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 CC CD IN JJ NN O
G9a-deficient G9a-deficient 1 0 1 0 0 0 0 1 13 0 CD IN JJ NN NNS O
germ germ 0 0 0 0 0 0 0 0 4 0 IN JJ NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNS VBD RB VBN CC O
reduced reduced 0 0 0 0 0 0 0 0 7 0 VBD RB VBN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 RB VBN CC JJ NNS O
G9a-regulated G9a-regulated 1 0 1 0 0 0 0 1 13 0 VBN CC JJ NNS VBD O
genes genes 0 0 0 0 0 0 0 0 5 0 CC JJ NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD VBN IN O
overexpressed overexpressed 0 0 0 0 0 0 0 0 13 0 NNS VBD VBN IN NNP O
during during 0 0 0 0 0 0 0 0 6 0 VBD VBN IN NNP NN O
meiosis, meiosis, 0 0 0 0 1 0 0 0 8 0 VBN IN NNP NN WDT O
suggesting suggesting 0 0 0 0 0 0 0 0 10 0 IN NNP NN WDT JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNP NN WDT JJ JJ O
G9a-mediated G9a-mediated 1 0 1 0 0 0 0 1 12 0 NN WDT JJ JJ NN O
epigenetic epigenetic 0 0 0 0 0 0 0 0 10 0 WDT JJ JJ NN VBG O
gene gene 0 0 0 0 0 0 0 0 4 0 JJ JJ NN VBG VBZ O
silencing silencing 0 0 0 0 0 0 0 0 9 0 JJ NN VBG VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN VBG VBZ JJ IN O
crucial crucial 0 0 0 0 0 0 0 0 7 0 VBG VBZ JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN NN JJ O
proper proper 0 0 0 0 0 0 0 0 6 0 JJ IN NN JJ NN O
meiotic meiotic 0 0 0 0 0 0 0 0 7 0 IN NN JJ NN NNP O
prophase prophase 0 0 0 0 0 0 0 0 8 0 NN JJ NN NNP NNP B_TIMEXCCP
progression. progression. 0 0 0 0 0 0 0 0 12 0 JJ NN NNP NNP PRP O
Finally, Finally, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NNP PRP VBP IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN NNP CC O
H3K9me1 H3K9me1 1 0 0 0 0 0 0 1 7 0 VBP IN NNP CC CD O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC CD VBP O
2 2 0 0 0 0 0 0 1 1 1 0 NNP CC CD VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 CC CD VBP RB CC O
dynamically dynamically 0 0 0 0 0 0 0 0 11 0 CD VBP RB CC RB O
and and 0 0 0 0 0 0 0 0 3 0 VBP RB CC RB VBN O
sex-differentially sex-differentially 0 0 1 0 0 0 0 0 18 0 RB CC RB VBN IN O
regulated regulated 0 0 0 0 0 0 0 0 9 0 CC RB VBN IN DT O
during during 0 0 0 0 0 0 0 0 6 0 RB VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNP O
meiotic meiotic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NNP NNP O
prophase. prophase. 0 0 0 0 0 0 0 0 9 0 DT JJ NNP NNP JJ B_TIMEXCCP
This This 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP JJ CC O
genetic genetic 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP JJ CC JJ NN O
biochemical biochemical 0 0 0 0 0 0 0 0 11 0 JJ CC JJ NN RB O
evidence evidence 0 0 0 0 0 0 0 0 8 0 CC JJ NN RB VBZ O
strongly strongly 0 0 0 0 0 0 0 0 8 0 JJ NN RB VBZ IN O
suggests suggests 0 0 0 0 0 0 0 0 8 0 NN RB VBZ IN DT O
that that 0 0 0 0 0 0 0 0 4 0 RB VBZ IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBZ IN DT JJ NN O
specific specific 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN IN O
set set 0 0 0 0 0 0 0 0 3 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
H3K9 H3K9 1 1 0 0 0 0 0 1 4 0 NN IN NNP NNP CC O
methyltransferase(s) methyltransferase(s) 0 0 0 0 0 0 0 0 20 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP RB O
demethylase(s) demethylase(s) 0 0 0 0 0 0 0 0 14 0 NNP CC NNP RB JJ O
coordinately coordinately 0 0 0 0 0 0 0 0 12 0 CC NNP RB JJ NNP O
regulate regulate 0 0 0 0 0 0 0 0 8 0 NNP RB JJ NNP NNP O
gametogenesis. gametogenesis. 0 0 0 0 0 0 0 0 14 0 RB JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
17599069 17599069 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NN O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NN NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
PMC1933398 PMC1933398 1 1 0 0 0 0 0 1 10 0 JJ NN NNP NONE NONE O
Reactivation Reactivation 1 0 0 0 0 0 0 0 12 0 NONE NONE NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NNP NN O
G0 G0 1 1 0 0 0 0 0 1 2 0 NN IN NNP NN IN B_TIMEXCCP
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 IN NNP NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NNP O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 NN IN NN NNP NNP B_TIMEXCCP
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NN NNP NNP NNP O
Floros Floros 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Baserga Baserga 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
R. R. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
tsAF8 tsAF8 0 0 0 0 0 0 0 1 5 0 NNP NNP NNP VBZ VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ VBP DT O
are are 0 0 0 0 0 0 0 0 3 0 NNP VBZ VBP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBZ VBP DT NN JJ O
temperature temperature 0 0 0 0 0 0 0 0 11 0 VBP DT NN JJ NN O
sensitive sensitive 0 0 0 0 0 0 0 0 9 0 DT NN JJ NN NN O
(ts) (ts) 0 0 0 0 0 0 0 0 4 0 NN JJ NN NN IN O
mutant mutant 0 0 0 0 0 0 0 0 6 0 JJ NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP IN O
BHK BHK 1 1 0 0 0 0 0 0 3 0 NN IN NNP IN JJS O
that that 0 0 0 0 0 0 0 0 4 arrest IN NNP IN JJS IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NNP IN JJS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN JJS IN NNP IN O
G1 G1 1 1 0 0 0 0 0 1 2 0 JJS IN NNP IN DT B_TIMEXCCP
at at 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ NN O
nonpermissive nonpermissive 0 0 0 0 0 0 0 0 13 0 IN DT JJ NN CC O
temperature temperature 0 0 0 0 0 0 0 0 11 0 DT JJ NN CC IN O
or or 0 0 0 0 0 0 0 0 2 0 JJ NN CC IN NN O
after after 0 0 0 0 0 0 0 0 5 0 NN CC IN NN NNP O
serum serum 0 0 0 0 0 0 0 0 5 0 CC IN NN NNP NNP O
deprivation. deprivation. 0 0 0 0 0 0 0 0 12 0 IN NN NNP NNP NNP O
G0 G0 1 1 0 0 0 0 0 1 2 0 NN NNP NNP NNP VBD O
tsAF8 tsAF8 0 0 0 0 0 0 0 1 5 0 NNP NNP NNP VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD VBN IN O
fused fused 0 0 0 0 0 0 0 0 5 0 NNP VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN NN O
polyethylene polyethylene 0 0 0 0 0 0 0 0 12 0 VBN IN NN NN IN O
glycol glycol 0 0 0 0 0 0 0 0 6 0 IN NN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ NNP O
other other 0 0 0 0 0 0 0 0 5 0 NN IN JJ NNP NNP O
G0 G0 1 1 0 0 0 0 0 1 2 0 IN JJ NNP NNP NNP O
tsAF8 tsAF8 0 0 0 0 0 0 0 1 5 0 JJ NNP NNP NNP CC O
cells, cells, 0 0 0 0 1 0 0 0 6 0 NNP NNP NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP CC DT NN NNS O
fusion fusion 0 0 0 0 0 0 0 0 6 0 CC DT NN NNS VBD O
products products 0 0 0 0 0 0 0 0 8 0 DT NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
incubated incubated 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNP O
nonpermissive nonpermissive 0 0 0 0 0 0 0 0 13 0 IN DT JJ NNP NNP O
temperature. temperature. 0 0 0 0 0 0 0 0 12 0 DT JJ NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NNS VBD O
homokaryons homokaryons 0 0 0 0 0 0 0 0 11 0 NNP NNP NNS VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD JJ IN O
incapable incapable 0 0 0 0 0 0 0 0 9 0 NNS VBD JJ IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBD JJ IN NN NNP O
entering entering 0 0 0 0 0 0 0 0 8 0 JJ IN NN NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase IN NN NNP NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 NN NNP NN IN DT O
under under 0 0 0 0 0 0 0 0 5 0 NNP NN IN DT NNP O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT NNP NNP O
conditions. conditions. 0 0 0 0 0 0 0 0 11 0 IN DT NNP NNP WRB O
However, However, 1 0 0 0 1 0 0 0 8 0 DT NNP NNP WRB NNP O
when when 0 0 0 0 0 0 0 0 4 0 NNP NNP WRB NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase NNP WRB NNP NN NNP B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 WRB NNP NN NNP NNS O
tsAF8 tsAF8 0 0 0 0 0 0 0 1 5 0 NNP NN NNP NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NNP NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD VBN IN O
fused fused 0 0 0 0 0 0 0 0 5 0 NNS VBD VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNP NNP O
G0 G0 1 1 0 0 0 0 0 1 2 0 VBN IN NNP NNP NNP B_TIMEXCCP
tsAF8 tsAF8 0 0 0 0 0 0 0 1 5 0 IN NNP NNP NNP DT O
cells, cells, 0 0 0 0 1 0 0 0 6 0 NNP NNP NNP DT NN O
both both 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN IN O
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 NNP DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS VBD O
homokaryons homokaryons 0 0 0 0 0 0 0 0 11 0 IN DT NNS VBD NNP O
entered entered 0 0 0 0 0 0 0 0 7 0 DT NNS VBD NNP NNP O
S S 1 1 0 0 0 0 0 0 1 0 NNS VBD NNP NNP RB B_TIMEXCCP
phase, phase, 0 0 0 0 1 0 0 0 6 0 VBD NNP NNP RB WRB O
even even 0 0 0 0 0 0 0 0 4 0 NNP NNP RB WRB DT O
when when 0 0 0 0 0 0 0 0 4 0 NNP RB WRB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB WRB DT NN NNS O
fusion fusion 0 0 0 0 0 0 0 0 6 0 WRB DT NN NNS VBD O
products products 0 0 0 0 0 0 0 0 8 0 DT NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
incubated incubated 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNP O
nonpermissive nonpermissive 0 0 0 0 0 0 0 0 13 0 IN DT JJ NNP NNP O
temperature. temperature. 0 0 0 0 0 0 0 0 12 0 DT JJ NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NN NNP O
addition addition 0 0 0 0 0 0 0 0 8 0 NNP NNP NN NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase NNP NN NNP NN NNP B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 NN NNP NN NNP NNP O
tsAF8 tsAF8 0 0 0 0 0 0 0 1 5 0 NNP NN NNP NNP IN O
cells, cells, 0 0 0 0 1 0 0 0 6 0 NN NNP NNP IN VBN O
if if 0 0 0 0 0 0 0 0 2 0 NNP NNP IN VBN IN O
fused fused 0 0 0 0 0 0 0 0 5 0 NNP IN VBN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 IN VBN IN NN -NONE- O
chick chick 0 0 0 0 0 0 0 0 5 0 VBN IN NN -NONE- MD O
erythrocytes, erythrocytes, 0 0 0 0 1 0 0 0 13 0 IN NN -NONE- MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN -NONE- MD VB DT O
reactivate reactivate 0 0 0 0 0 0 0 0 10 0 -NONE- MD VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NN NN O
chick chick 0 0 0 0 0 0 0 0 5 0 VB DT NN NN RB O
nucleus, nucleus, 0 0 0 0 1 0 0 0 8 0 DT NN NN RB IN O
even even 0 0 0 0 0 0 0 0 4 0 NN NN RB IN DT O
if if 0 0 0 0 0 0 0 0 2 0 NN RB IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NNS VBP O
heterokaryons heterokaryons 0 0 0 0 0 0 0 0 13 0 IN DT NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 DT NNS VBP VBN IN O
placed placed 0 0 0 0 0 0 0 0 6 0 NNS VBP VBN IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 VBP VBN IN JJ NNP O
nonpermissive nonpermissive 0 0 0 0 0 0 0 0 13 0 VBN IN JJ NNP NNP O
temperature. temperature. 0 0 0 0 0 0 0 0 12 0 IN JJ NNP NNP NNP O
Therefore Therefore 1 0 0 0 0 0 0 0 9 0 JJ NNP NNP NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase NNP NNP NNP NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NN IN O
information information 0 0 0 0 0 0 0 0 11 0 NNP NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP MD O
tsAF8 tsAF8 0 0 0 0 0 0 0 1 5 0 NN IN NNP MD VB O
can can 0 0 0 0 0 0 0 0 3 0 IN NNP MD VB NNP O
induce induce 0 0 0 0 0 0 0 0 6 0 NNP MD VB NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 MD VB NNP NNP IN O
synthesis, synthesis, 0 0 0 0 1 0 0 0 10 0 VB NNP NNP IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 NNP NNP IN NNP IN O
fusion, fusion, 0 0 0 0 1 0 0 0 7 0 NNP IN NNP IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN JJ NNP O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 NNP IN JJ NNP NNP O
G0 G0 1 1 0 0 0 0 0 1 2 0 IN JJ NNP NNP VBZ B_TIMEXCCP
AF8 AF8 1 1 0 0 0 0 0 1 3 0 JJ NNP NNP VBZ CC O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP VBZ CC NN NNS O
chick chick 0 0 0 0 0 0 0 0 5 0 VBZ CC NN NNS RB O
erythrocytes erythrocytes 0 0 0 0 0 0 0 0 12 0 CC NN NNS RB WRB O
even even 0 0 0 0 0 0 0 0 4 0 NN NNS RB WRB DT O
when when 0 0 0 0 0 0 0 0 4 0 NNS RB WRB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 RB WRB DT NNS CC O
homokaryons homokaryons 0 0 0 0 0 0 0 0 11 0 WRB DT NNS CC NNS O
or or 0 0 0 0 0 0 0 0 2 0 DT NNS CC NNS VBP O
heterokaryons heterokaryons 0 0 0 0 0 0 0 0 13 0 NNS CC NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 CC NNS VBP VBN IN O
incubated incubated 0 0 0 0 0 0 0 0 9 0 NNS VBP VBN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 VBP VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNP O
nonpermissive nonpermissive 0 0 0 0 0 0 0 0 13 0 IN DT JJ NNP NNP O
temperature. temperature. 0 0 0 0 0 0 0 0 12 0 DT JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
7388961 7388961 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Interzone Interzone 1 0 0 0 0 0 0 0 9 0 NONE NONE NNP NN NN O
microtubule microtubule 0 0 0 0 0 0 0 0 11 0 NONE NNP NN NN IN O
behavior behavior 0 0 0 0 0 0 0 0 8 0 NNP NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
late late 0 0 0 0 0 0 0 0 4 0 NN IN JJ NN CC anaphase
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 IN JJ NN CC NN anaphase
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NNP O
telophase telophase 0 0 0 0 0 0 0 0 9 0 NN CC NN NNP NNP B_TIMEXCCP
spindles. spindles. 0 0 0 0 0 0 0 0 9 0 CC NN NNP NNP NNP O
Saxton Saxton 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP NNP O
WM, WM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
McIntosh McIntosh 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
JR. JR. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNP VBP VBN NN O
studied studied 0 0 0 0 0 0 0 0 7 0 NNP VBP VBN NN NN O
microtubule microtubule 0 0 0 0 0 0 0 0 11 0 VBP VBN NN NN IN O
behavior behavior 0 0 0 0 0 0 0 0 8 0 VBN NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
late late 0 0 0 0 0 0 0 0 4 0 NN IN JJ NN CC anaphase
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 IN JJ NN CC NN anaphase
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NNS O
telophase telophase 0 0 0 0 0 0 0 0 9 0 NN CC NN NNS IN B_TIMEXCCP
spindles spindles 0 0 0 0 0 0 0 0 8 0 CC NN NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP NNP O
PtK1 PtK1 1 0 0 0 0 0 0 1 4 0 NNS IN NNP NNP VBG O
cells, cells, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP VBG VBN O
using using 0 0 0 0 0 0 0 0 5 0 NNP NNP VBG VBN NN O
fluoresceinated fluoresceinated 0 0 0 0 0 0 0 0 15 0 NNP VBG VBN NN -NONE- O
tubulin tubulin 0 0 0 0 0 0 0 0 7 0 VBG VBN NN -NONE- -NONE- O
(DTAF-tubulin), (DTAF-tubulin), 0 0 1 0 1 0 0 0 15 0 VBN NN -NONE- -NONE- CC O
microinjection, microinjection, 0 0 0 0 1 0 0 0 15 0 NN -NONE- -NONE- CC NN O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- CC NN NN O
laser laser 0 0 0 0 0 0 0 0 5 0 -NONE- CC NN NN NNP O
microbeam microbeam 0 0 0 0 0 0 0 0 9 0 CC NN NN NNP NNP O
photobleaching. photobleaching. 0 0 0 0 0 0 0 0 15 0 NN NN NNP NNP NN O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NN DT O
present present 0 0 0 0 0 0 0 0 7 0 NNP NNP NN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT NNS IN O
results results 0 0 0 0 0 0 0 0 7 0 NN DT NNS IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN CD NN O
two two 0 0 0 0 0 0 0 0 3 0 NNS IN CD NN NNS O
novel novel 0 0 0 0 0 0 0 0 5 0 IN CD NN NNS WDT O
tests tests 0 0 0 0 0 0 0 0 5 0 CD NN NNS WDT JJ O
which which 0 0 0 0 0 0 0 0 5 0 NN NNS WDT JJ TO O
add add 0 0 0 0 0 0 0 0 3 0 NNS WDT JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 WDT JJ TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ TO DT NN IN O
evidence evidence 0 0 0 0 0 0 0 0 8 0 TO DT NN IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN JJ RB O
DTAF-tubulin DTAF-tubulin 1 0 1 0 0 0 0 0 12 0 NN IN JJ RB NNS O
closely closely 0 0 0 0 0 0 0 0 7 0 IN JJ RB NNS DT O
mimics mimics 0 0 0 0 0 0 0 0 6 0 JJ RB NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB NNS DT NN IN O
behavior behavior 0 0 0 0 0 0 0 0 8 0 NNS DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
native native 0 0 0 0 0 0 0 0 6 0 NN IN JJ NN IN O
tubulin tubulin 0 0 0 0 0 0 0 0 7 0 IN JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
vivo. vivo. 0 0 0 0 0 0 0 0 5 0 NN IN NNP NNP NNP O
(a) (a) 0 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
Microinjected Microinjected 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP VBD O
DTAF-tubulin DTAF-tubulin 1 0 1 0 0 0 0 0 12 0 NNP NNP NNP VBD IN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 NNP VBD IN JJ IN O
effective effective 0 0 0 0 0 0 0 0 9 0 VBD IN JJ IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 IN JJ IN JJ JJ O
injected injected 0 0 0 0 0 0 0 0 8 0 JJ IN JJ JJ NN O
native native 0 0 0 0 0 0 0 0 6 0 IN JJ JJ NN IN O
tubulin tubulin 0 0 0 0 0 0 0 0 7 0 JJ JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
promoting promoting 0 0 0 0 0 0 0 0 9 0 NN IN NN NN IN O
division division 0 0 0 0 0 0 0 0 8 0 IN NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ JJ O
taxol-dependent taxol-dependent 0 0 1 0 0 0 0 0 15 0 NN IN JJ JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 IN JJ JJ NN NNS O
mutant mutant 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NNS WDT O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS WDT VBD O
that that 0 0 0 0 0 0 0 0 4 0 NN NNS WDT VBD VBN O
had had 0 0 0 0 0 0 0 0 3 0 NNS WDT VBD VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 WDT VBD VBN VBN IN O
deprived deprived 0 0 0 0 0 0 0 0 8 0 VBD VBN VBN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBN VBN IN NNP NNP O
taxol. taxol. 0 0 0 0 0 0 0 0 6 0 VBN IN NNP NNP NNP O
(b) (b) 0 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
Microinjected Microinjected 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP NN O
colchicine-DTAF-tubulin colchicine-DTAF-tubulin 0 0 1 0 0 0 0 0 23 0 NNP NNP NNP NN VBD O
complex complex 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBD JJ O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD JJ TO O
similar similar 0 0 0 0 0 0 0 0 7 0 NN VBD JJ TO VBN O
to to 0 0 0 0 0 0 0 0 2 0 VBD JJ TO VBN JJ O
injected injected 0 0 0 0 0 0 0 0 8 0 JJ TO VBN JJ NN O
colchicine-native colchicine-native 0 0 1 0 0 0 0 0 17 0 TO VBN JJ NN NN O
tubulin tubulin 0 0 0 0 0 0 0 0 7 0 VBN JJ NN NN IN O
complex complex 0 0 0 0 0 0 0 0 7 0 JJ NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
causing causing 0 0 0 0 0 0 0 0 7 0 NN IN NN NN IN O
depolymerization depolymerization 0 0 0 0 0 0 0 0 16 0 IN NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
spindles. spindles. 0 0 0 0 0 0 0 0 9 0 NN IN NNP NNP IN O
Immediately Immediately 1 0 0 0 0 0 0 0 11 0 IN NNP NNP IN NN O
after after 0 0 0 0 0 0 0 0 5 0 NNP NNP IN NN IN O
microinjection microinjection 0 0 0 0 0 0 0 0 14 0 NNP IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ IN O
DTAF-tubulin DTAF-tubulin 1 0 1 0 0 0 0 0 12 0 NN IN JJ IN JJ O
into into 0 0 0 0 0 0 0 0 4 0 IN JJ IN JJ NNS O
wild-type wild-type 0 0 1 0 0 0 0 0 9 0 JJ IN JJ NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 JJ NNS IN JJ NN O
late late 0 0 0 0 0 0 0 0 4 0 NNS IN JJ NN CC anaphase
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 IN JJ NN CC JJ anaphase
or or 0 0 0 0 0 0 0 0 2 0 JJ NN CC JJ NN O
telophase, telophase, 0 0 0 0 1 0 0 0 10 0 NN CC JJ NN NN B_TIMEXCCP
fluorescence fluorescence 0 0 0 0 0 0 0 0 12 0 CC JJ NN NN IN O
incorporation incorporation 0 0 0 0 0 0 0 0 13 0 JJ NN NN IN NNS O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NNS VBD O
microtubules microtubules 0 0 0 0 0 0 0 0 12 0 NN IN NNS VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 IN NNS VBD VBN IN O
seen seen 0 0 0 0 0 0 0 0 4 0 NNS VBD VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NNS O
chromosomal chromosomal 0 0 0 0 0 0 0 0 11 0 VBN IN JJ NNS CC O
half-spindles half-spindles 0 0 1 0 0 0 0 0 13 0 IN JJ NNS CC RB O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC RB IN O
just just 0 0 0 0 0 0 0 0 4 0 NNS CC RB IN DT O
behind behind 0 0 0 0 0 0 0 0 6 0 CC RB IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NNP CC O
chromosomes, chromosomes, 0 0 0 0 1 0 0 0 12 0 IN DT NNP CC EX O
but but 0 0 0 0 0 0 0 0 3 0 DT NNP CC EX VBD O
there there 0 0 0 0 0 0 0 0 5 0 NNP CC EX VBD DT O
was was 0 0 0 0 0 0 0 0 3 0 CC EX VBD DT NN O
no no 0 0 0 0 0 0 0 0 2 0 EX VBD DT NN NN O
fluorescence fluorescence 0 0 0 0 0 0 0 0 12 0 VBD DT NN NN IN O
incorporation incorporation 0 0 0 0 0 0 0 0 13 0 DT NN NN IN DT O
near near 0 0 0 0 0 0 0 0 4 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
middle middle 0 0 0 0 0 0 0 0 6 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
interzone. interzone. 0 0 0 0 0 0 0 0 10 0 IN DT NNP NNP DT O
Over Over 1 0 0 0 0 0 0 0 4 0 DT NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ JJ O
next next 0 0 0 0 0 0 0 0 4 0 NNP DT JJ JJ JJ O
few few 0 0 0 0 0 0 0 0 3 0 DT JJ JJ JJ NN O
minutes, minutes, 0 0 0 0 1 0 0 0 8 0 JJ JJ JJ NN NN O
tubulin tubulin 0 0 0 0 0 0 0 0 7 0 JJ JJ NN NN VBD O
fluorescence fluorescence 0 0 0 0 0 0 0 0 12 0 JJ NN NN VBD IN O
accumulated accumulated 0 0 0 0 0 0 0 0 11 0 NN NN VBD IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NN VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN IN O
center center 0 0 0 0 0 0 0 0 6 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN DT O
interzone interzone 0 0 0 0 0 0 0 0 9 0 IN DT NN DT NN O
(the (the 0 0 0 0 0 0 0 0 4 0 DT NN DT NN VBG O
equator), equator), 0 0 0 0 1 0 0 0 9 0 NN DT NN VBG RB O
becoming becoming 0 0 0 0 0 0 0 0 8 0 DT NN VBG RB JJR O
progressively progressively 0 0 0 0 0 0 0 0 13 0 NN VBG RB JJR NNP O
more more 0 0 0 0 0 0 0 0 4 0 VBG RB JJR NNP NNP O
intense. intense. 0 0 0 0 0 0 0 0 8 0 RB JJR NNP NNP JJ O
In In 1 0 0 0 0 0 0 0 2 0 JJR NNP NNP JJ NN O
other other 0 0 0 0 0 0 0 0 5 0 NNP NNP JJ NN NNS O
experiments, experiments, 0 0 0 0 1 0 0 0 12 0 NNP JJ NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
microinjected microinjected 0 0 0 0 0 0 0 0 13 0 NNS VBD VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN JJ IN O
DTAF-tubulin DTAF-tubulin 1 0 1 0 0 0 0 0 12 0 VBN IN JJ IN NN O
at at 0 0 0 0 0 0 0 0 2 0 IN JJ IN NN CC O
prophase prophase 0 0 0 0 0 0 0 0 8 0 JJ IN NN CC VBD B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VBD TO O
allowed allowed 0 0 0 0 0 0 0 0 7 0 NN CC VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 CC VBD TO VB IN O
equilibrate equilibrate 0 0 0 0 0 0 0 0 11 0 VBD TO VB IN CD O
for for 0 0 0 0 0 0 0 0 3 0 TO VB IN CD NNP O
30 30 0 0 0 0 0 0 1 1 2 0 VB IN CD NNP NNP O
min. min. 0 0 0 0 0 0 0 0 4 0 IN CD NNP NNP IN O
Cells Cells 1 0 0 0 0 0 0 0 5 0 CD NNP NNP IN VBD O
that that 0 0 0 0 0 0 0 0 4 0 NNP NNP IN VBD VBN O
had had 0 0 0 0 0 0 0 0 3 0 NNP IN VBD VBN TO O
progressed progressed 0 0 0 0 0 0 0 0 10 0 IN VBD VBN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO JJ NN O
late late 0 0 0 0 0 0 0 0 4 0 VBN TO JJ NN VBD anaphase
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 TO JJ NN VBD RB anaphase
were were 0 0 0 0 0 0 0 0 4 0 JJ NN VBD RB VBN O
then then 0 0 0 0 0 0 0 0 4 0 NN VBD RB VBN TO O
photobleached photobleached 0 0 0 0 0 0 0 0 13 0 VBD RB VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 RB VBN TO VB DT O
reduce reduce 0 0 0 0 0 0 0 0 6 0 VBN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
fluorescence fluorescence 0 0 0 0 0 0 0 0 12 0 VB DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
central central 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN IN O
portion portion 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
interzone. interzone. 0 0 0 0 0 0 0 0 10 0 IN DT NNP NNP DT O
Over Over 1 0 0 0 0 0 0 0 4 0 DT NNP NNP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT NN IN O
period period 0 0 0 0 0 0 0 0 6 0 NNP DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ JJ O
several several 0 0 0 0 0 0 0 0 7 0 NN IN JJ JJ DT O
minutes, minutes, 0 0 0 0 1 0 0 0 8 0 IN JJ JJ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ JJ DT JJ JJ O
only only 0 0 0 0 0 0 0 0 4 0 JJ DT JJ JJ NN O
substantial substantial 0 0 0 0 0 0 0 0 11 0 DT JJ JJ NN IN O
redistribution redistribution 0 0 0 0 0 0 0 0 14 0 JJ JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN VBD O
fluorescence fluorescence 0 0 0 0 0 0 0 0 12 0 NN IN NN VBD DT O
was was 0 0 0 0 0 0 0 0 3 0 IN NN VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBD DT NN IN O
appearance appearance 0 0 0 0 0 0 0 0 10 0 VBD DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
bright bright 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN IN O
area area 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
equator equator 0 0 0 0 0 0 0 0 7 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
interzone. interzone. 0 0 0 0 0 0 0 0 10 0 IN DT NNP NNP DT O
Both Both 1 0 0 0 0 0 0 0 4 0 DT NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
site site 0 0 0 0 0 0 0 0 4 0 NNP DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
fluorescence fluorescence 0 0 0 0 0 0 0 0 12 0 NN IN NN NN CC O
incorporation incorporation 0 0 0 0 0 0 0 0 13 0 IN NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN NNS O
photobleaching photobleaching 0 0 0 0 0 0 0 0 14 0 CC DT NN NNS VBP O
data data 0 0 0 0 0 0 0 0 4 0 DT NN NNS VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NN NNS VBP IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NN VBZ O
tubulin tubulin 0 0 0 0 0 0 0 0 7 0 VBP IN NN VBZ TO O
adds adds 0 0 0 0 0 0 0 0 4 0 IN NN VBZ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN VBZ TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBZ TO DT NN NN O
elongating elongating 0 0 0 0 0 0 0 0 10 0 TO DT NN NN NN O
spindle spindle 0 0 0 0 0 0 0 0 7 0 DT NN NN NN IN O
interzone interzone 0 0 0 0 0 0 0 0 9 0 NN NN NN IN DT O
near near 0 0 0 0 0 0 0 0 4 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN WRB O
equator equator 0 0 0 0 0 0 0 0 7 0 IN DT NN WRB DT O
where where 0 0 0 0 0 0 0 0 5 0 DT NN WRB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN WRB DT NN VBZ O
plus plus 0 0 0 0 0 0 0 0 4 0 WRB DT NN VBZ IN O
ends ends 0 0 0 0 0 0 0 0 4 0 DT NN VBZ IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN VBZ IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 VBZ IN DT VBN NNS O
interdigitated interdigitated 0 0 0 0 0 0 0 0 14 0 IN DT VBN NNS VBP O
microtubules microtubules 0 0 0 0 0 0 0 0 12 0 DT VBN NNS VBP NNP O
are are 0 0 0 0 0 0 0 0 3 0 VBN NNS VBP NNP NNP O
located. located. 0 0 0 0 0 0 0 0 8 0 NNS VBP NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 VBP NNP NNP NN -NONE- O
further further 0 0 0 0 0 0 0 0 7 0 NNP NNP NN -NONE- JJ O
experiments, experiments, 0 0 0 0 1 0 0 0 12 0 NNP NN -NONE- JJ NN O
several several 0 0 0 0 0 0 0 0 7 0 NN -NONE- JJ NN NNS O
dark dark 0 0 0 0 0 0 0 0 4 0 -NONE- JJ NN NNS VBD O
lines lines 0 0 0 0 0 0 0 0 5 0 JJ NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN JJ O
photobleached photobleached 0 0 0 0 0 0 0 0 13 0 NNS VBD VBN JJ TO O
perpendicular perpendicular 0 0 0 0 0 0 0 0 13 0 VBD VBN JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBN JJ TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ TO DT JJ NNS O
pole-to-pole pole-to-pole 0 0 1 0 0 0 0 0 12 0 TO DT JJ NNS IN O
axis axis 0 0 0 0 0 0 0 0 4 0 DT JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NN O
fluorescent fluorescent 0 0 0 0 0 0 0 0 11 0 NNS IN NN NN NNP O
anaphase-telophase anaphase-telophase 0 0 1 0 0 0 0 0 18 0 IN NN NN NNP NNP B_TIMEXCCP
spindles. spindles. 0 0 0 0 0 0 0 0 9 0 NN NN NNP NNP NNS O
Time-dependent Time-dependent 1 0 1 0 0 0 0 0 14 0 NN NNP NNP NNS IN O
changes changes 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNS IN O
spacings spacings 0 0 0 0 0 0 0 0 8 0 IN DT NNS IN DT O
between between 0 0 0 0 0 0 0 0 7 0 DT NNS IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNS VBD O
lines lines 0 0 0 0 0 0 0 0 5 0 IN DT NNS VBD IN O
indicated indicated 0 0 0 0 0 0 0 0 9 0 DT NNS VBD IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN DT CD O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 IN DT CD NNS IN O
halves halves 0 0 0 0 0 0 0 0 6 0 DT CD NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN VBG O
interzone interzone 0 0 0 0 0 0 0 0 9 0 IN DT NN VBG IN O
lying lying 0 0 0 0 0 0 0 0 5 0 DT NN VBG IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 NN VBG IN JJ NNS O
opposite opposite 0 0 0 0 0 0 0 0 8 0 VBG IN JJ NNS IN O
sides sides 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
spindle spindle 0 0 0 0 0 0 0 0 7 0 IN DT NN NN VBD O
equator equator 0 0 0 0 0 0 0 0 7 0 DT NN NN VBD RB O
moved moved 0 0 0 0 0 0 0 0 5 0 NN NN VBD RB IN O
away away 0 0 0 0 0 0 0 0 4 0 NN VBD RB IN CD O
from from 0 0 0 0 0 0 0 0 4 0 VBD RB IN CD NNP O
one one 0 0 0 0 0 0 0 0 3 0 RB IN CD NNP NNP O
another. another. 0 0 0 0 0 0 0 0 8 0 IN CD NNP NNP VBZ O
This This 1 0 0 0 0 0 0 0 4 0 CD NNP NNP VBZ IN O
shows shows 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBZ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBZ IN DT JJ NN O
interdigitated interdigitated 0 0 0 0 0 0 0 0 14 0 IN DT JJ NN WDT O
microtubules, microtubules, 0 0 0 0 1 0 0 0 13 0 DT JJ NN WDT VB O
which which 0 0 0 0 0 0 0 0 5 0 JJ NN WDT VB RP O
make make 0 0 0 0 0 0 0 0 4 0 NN WDT VB RP JJS O
up up 0 0 0 0 0 0 0 0 2 0 WDT VB RP JJS IN O
most most 0 0 0 0 0 0 0 0 4 0 VB RP JJS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 RP JJS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJS IN DT JJ NN O
interzone, interzone, 0 0 0 0 1 0 0 0 10 0 IN DT JJ NN NN O
can can 0 0 0 0 0 0 0 0 3 0 DT JJ NN NN NN O
undergo undergo 0 0 0 0 0 0 0 0 7 0 JJ NN NN NN NNP O
antiparallel antiparallel 0 0 0 0 0 0 0 0 12 0 NN NN NN NNP NNP O
sliding. sliding. 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS NN O
data data 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS NN DT O
support support 0 0 0 0 0 0 0 0 7 0 NNP NNS NN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNS NN DT NN IN O
model model 0 0 0 0 0 0 0 0 5 0 NN DT NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN NN NNP O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 NN IN NN NNP IN O
B B 1 1 0 0 0 0 0 0 1 0 IN NN NNP IN WDT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNP IN WDT CC O
which which 0 0 0 0 0 0 0 0 5 0 NNP IN WDT CC VBP O
plus plus 0 0 0 0 0 0 0 0 4 0 IN WDT CC VBP NN O
end end 0 0 0 0 0 0 0 0 3 0 WDT CC VBP NN IN O
elongation elongation 0 0 0 0 0 0 0 0 10 0 CC VBP NN IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 VBP NN IN VBN NNS O
interdigitated interdigitated 0 0 0 0 0 0 0 0 14 0 NN IN VBN NNS CC O
microtubules microtubules 0 0 0 0 0 0 0 0 12 0 IN VBN NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VBN NNS CC NN VBG O
antiparallel antiparallel 0 0 0 0 0 0 0 0 12 0 NNS CC NN VBG NN O
sliding sliding 0 0 0 0 0 0 0 0 7 0 CC NN VBG NN TO O
contribute contribute 0 0 0 0 0 0 0 0 10 0 NN VBG NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBG NN TO VB NNP O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NN TO VB NNP NNP O
separation. separation. 0 0 0 0 0 0 0 0 11 0 TO VB NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 VB NNP NNP CD JJ O
3305523 3305523 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NN O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NN NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
PMC2114759 PMC2114759 1 1 0 0 0 0 0 1 10 0 JJ NN NNP NONE NONE O
HLA-G/C, HLA-G/C, 1 1 1 1 1 0 0 0 8 0 NONE NONE NN NN CC O
miRNAs, miRNAs, 0 0 0 0 1 0 0 0 7 0 NONE NN NN CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 NN CC PRP$ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 CC PRP$ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 PRP$ NN IN NNP NN O
HIV HIV 1 1 0 0 0 0 0 0 3 0 NN IN NNP NN CC O
infection infection 0 0 0 0 0 0 0 0 9 0 IN NNP NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NNP NNP O
replication. replication. 0 0 0 0 0 0 0 0 12 0 NN CC NNP NNP NNP O
Celsi Celsi 1 0 0 0 0 0 0 0 5 0 CC NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Catamo Catamo 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
E, E, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kleiner Kleiner 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tricarico Tricarico 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
PM, PM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Vuch Vuch 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Crovella Crovella 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
S. S. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP CC O
Maternal Maternal 1 0 0 0 0 0 0 0 8 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Child Child 1 0 0 0 0 0 0 0 5 0 NNP CC NNP NNP NNP O
Health, Health, 1 0 0 0 1 0 0 0 7 0 CC NNP NNP NNP NNP O
IRCCS IRCCS 1 1 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Burlo Burlo 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP CD O
Garofolo, Garofolo, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP CD -NONE- O
34137 34137 0 0 0 0 0 0 1 1 5 0 NNP NNP CD -NONE- NNP O
Trieste, Trieste, 1 0 0 0 1 0 0 0 8 0 NNP CD -NONE- NNP NN O
Italy. Italy. 1 0 0 0 0 0 0 0 6 0 CD -NONE- NNP NN NNP O
celsi@burlo.trieste.it celsi@burlo.trieste.it 0 0 0 0 0 0 0 0 22 0 -NONE- NNP NN NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NN NNP NNP JJ O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP JJ NN O
recent recent 0 0 0 0 0 0 0 0 6 0 NNP NNP JJ NN DT O
years, years, 0 0 0 0 1 0 0 0 6 0 NNP JJ NN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 JJ NN DT NN IN O
number number 0 0 0 0 0 0 0 0 6 0 NN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
different different 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNS VBG O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 IN JJ NNS VBG NN O
regulating regulating 0 0 0 0 0 0 0 0 10 0 JJ NNS VBG NN -NONE- O
gene gene 0 0 0 0 0 0 0 0 4 0 NNS VBG NN -NONE- DT O
expressions, expressions, 0 0 0 0 1 0 0 0 12 0 VBG NN -NONE- DT IN O
either either 0 0 0 0 0 0 0 0 6 0 NN -NONE- DT IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- DT IN JJ CC O
normal normal 0 0 0 0 0 0 0 0 6 0 DT IN JJ CC IN O
or or 0 0 0 0 0 0 0 0 2 0 IN JJ CC IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ CC IN JJ NN O
pathological pathological 0 0 0 0 0 0 0 0 12 0 CC IN JJ NN VBP O
conditions, conditions, 0 0 0 0 1 0 0 0 11 0 IN JJ NN VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 JJ NN VBP VBN NNP O
been been 0 0 0 0 0 0 0 0 4 0 NN VBP VBN NNP NNP O
discovered. discovered. 0 0 0 0 0 0 0 0 11 0 VBP VBN NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 VBN NNP NNP NN VBZ O
review review 0 0 0 0 0 0 0 0 6 0 NNP NNP NN VBZ TO O
aims aims 0 0 0 0 0 0 0 0 4 0 NNP NN VBZ TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NN VBZ TO NN DT O
highlight highlight 0 0 0 0 0 0 0 0 9 0 VBZ TO NN DT IN O
some some 0 0 0 0 0 0 0 0 4 0 TO NN DT IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN DT IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 DT IN DT JJ NNS O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 IN DT JJ NNS VBN O
pathways pathways 0 0 0 0 0 0 0 0 8 0 DT JJ NNS VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 JJ NNS VBN IN DT O
during during 0 0 0 0 0 0 0 0 6 0 NNS VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NN O
HIV-1 HIV-1 1 1 1 0 0 0 0 1 5 0 IN DT NN NN CC O
infection infection 0 0 0 0 0 0 0 0 9 0 DT NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
disease disease 0 0 0 0 0 0 0 0 7 0 NN CC NN NN VBG O
progression, progression, 0 0 0 0 1 0 0 0 12 0 CC NN NN VBG IN O
focusing focusing 0 0 0 0 0 0 0 0 8 0 NN NN VBG IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NN VBG IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBG IN DT NN VBD O
novel novel 0 0 0 0 0 0 0 0 5 0 IN DT NN VBD NNP O
discovered discovered 0 0 0 0 0 0 0 0 10 0 DT NN VBD NNP NNP O
microRNAs microRNAs 0 0 0 0 0 0 0 0 9 0 NN VBD NNP NNP CC O
(miRNAs) (miRNAs) 0 0 0 0 0 0 0 0 8 0 VBD NNP NNP CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 NNP CC PRP$ NN IN O
relation relation 0 0 0 0 0 0 0 0 8 0 CC PRP$ NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 PRP$ NN IN NN NNS O
immune immune 0 0 0 0 0 0 0 0 6 0 NN IN NN NNS NNP O
system's system's 0 0 0 0 0 1 0 0 8 0 IN NN NNS NNP NNP O
agents. agents. 0 0 0 0 0 0 0 0 7 0 NN NNS NNP NNP NN O
Human Human 1 0 0 0 0 0 0 0 5 0 NNS NNP NNP NN NN O
leukocyte leukocyte 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NN NN O
antigen antigen 0 0 0 0 0 0 0 0 7 0 NNP NN NN NN NN O
(HLA) (HLA) 0 1 0 0 0 0 0 0 5 0 NN NN NN NN IN O
family family 0 0 0 0 0 0 0 0 6 0 NN NN NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNS NNS O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NN IN NNS NNS DT O
plays plays 0 0 0 0 0 0 0 0 5 0 IN NNS NNS DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS NNS DT JJ NN O
key key 0 0 0 0 0 0 0 0 3 0 NNS DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN PRP O
because because 0 0 0 0 0 0 0 0 7 0 JJ NN IN PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NN IN PRP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 IN PRP VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 PRP VBZ DT JJ NN O
crucial crucial 0 0 0 0 0 0 0 0 7 0 VBZ DT JJ NN IN O
modulator modulator 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
immune immune 0 0 0 0 0 0 0 0 6 0 IN DT NN NN RB O
response; response; 0 0 0 0 0 0 0 0 9 0 DT NN NN RB PRP O
here here 0 0 0 0 0 0 0 0 4 0 NN NN RB PRP MD O
we we 0 0 0 0 0 0 0 0 2 0 NN RB PRP MD VB O
will will 0 0 0 0 0 0 0 0 4 0 RB PRP MD VB JJ O
examine examine 0 0 0 0 0 0 0 0 7 0 PRP MD VB JJ NN O
recent recent 0 0 0 0 0 0 0 0 6 0 MD VB JJ NN NN O
findings, findings, 0 0 0 0 1 0 0 0 9 0 VB JJ NN NN RB O
centering centering 0 0 0 0 0 0 0 0 9 0 JJ NN NN RB IN O
especially especially 0 0 0 0 0 0 0 0 10 0 NN NN RB IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 NN RB IN JJ CC O
HLA-C HLA-C 1 1 1 0 0 0 0 0 5 0 RB IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NN O
-G, -G, 0 1 1 0 1 0 0 0 3 0 JJ CC JJ NN NNS O
novel novel 0 0 0 0 0 0 0 0 5 0 CC JJ NN NNS RB O
players players 0 0 0 0 0 0 0 0 7 0 JJ NN NNS RB VBN O
lately lately 0 0 0 0 0 0 0 0 6 0 NN NNS RB VBN TO O
discovered discovered 0 0 0 0 0 0 0 0 10 0 NNS RB VBN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 RB VBN TO NN IN O
engage engage 0 0 0 0 0 0 0 0 6 0 VBN TO NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 TO NN IN NN IN O
modulation modulation 0 0 0 0 0 0 0 0 10 0 NN IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NNP O
immune immune 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP NNP O
system. system. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NNP NN O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NN TO O
hope hope 0 0 0 0 0 0 0 0 4 0 NNP NNP NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO VB NN O
provide provide 0 0 0 0 0 0 0 0 7 0 NN TO VB NN NNS O
novel novel 0 0 0 0 0 0 0 0 5 0 TO VB NN NNS JJ O
perspectives perspectives 0 0 0 0 0 0 0 0 12 0 VB NN NNS JJ TO O
useful useful 0 0 0 0 0 0 0 0 6 0 NN NNS JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNS JJ TO VB RP O
find find 0 0 0 0 0 0 0 0 4 0 JJ TO VB RP JJ O
out out 0 0 0 0 0 0 0 0 3 0 TO VB RP JJ JJ O
original original 0 0 0 0 0 0 0 0 8 0 VB RP JJ JJ NNS O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 RP JJ JJ NNS IN O
roads roads 0 0 0 0 0 0 0 0 5 0 JJ JJ NNS IN -NONE- O
against against 0 0 0 0 0 0 0 0 7 0 JJ NNS IN -NONE- NN O
HIV-1 HIV-1 1 1 1 0 0 0 0 1 5 0 NNS IN -NONE- NN CC O
infection infection 0 0 0 0 0 0 0 0 9 0 IN -NONE- NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NN CC NNP NNP O
AIDS AIDS 1 1 0 0 0 0 0 0 4 0 NN CC NNP NNP NNP O
progression. progression. 0 0 0 0 0 0 0 0 12 0 CC NNP NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNP NNP NNP CD JJ O
23841087 23841087 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : IN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ : IN JJ NN O
process] process] 0 0 0 0 0 0 0 0 8 0 : IN JJ NN NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
PMC3697138 PMC3697138 1 1 0 0 0 0 0 1 10 0 JJ NN NNP NONE NONE O
Estimating Estimating 1 0 0 0 0 0 0 0 10 0 NONE NONE VBG NN CC O
bat bat 0 0 0 0 0 0 0 0 3 0 NONE VBG NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBG NN CC JJ NN O
bird bird 0 0 0 0 0 0 0 0 4 0 NN CC JJ NN VBG O
mortality mortality 0 0 0 0 0 0 0 0 9 0 CC JJ NN VBG IN O
occurring occurring 0 0 0 0 0 0 0 0 9 0 JJ NN VBG IN NN O
at at 0 0 0 0 0 0 0 0 2 0 NN VBG IN NN NN O
wind wind 0 0 0 0 0 0 0 0 4 0 VBG IN NN NN NNS O
energy energy 0 0 0 0 0 0 0 0 6 0 IN NN NN NNS IN O
turbines turbines 0 0 0 0 0 0 0 0 8 0 NN NN NNS IN NNS O
from from 0 0 0 0 0 0 0 0 4 0 NN NNS IN NNS CC O
covariates covariates 0 0 0 0 0 0 0 0 10 0 NNS IN NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC NN NNS O
carcass carcass 0 0 0 0 0 0 0 0 7 0 NNS CC NN NNS VBG O
searches searches 0 0 0 0 0 0 0 0 8 0 CC NN NNS VBG NN O
using using 0 0 0 0 0 0 0 0 5 0 NN NNS VBG NN NNP O
mixture mixture 0 0 0 0 0 0 0 0 7 0 NNS VBG NN NNP NNP O
models. models. 0 0 0 0 0 0 0 0 7 0 VBG NN NNP NNP NNP O
Korner-Nievergelt Korner-Nievergelt 1 0 1 0 0 0 0 0 17 0 NN NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Brinkmann Brinkmann 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Niermann Niermann 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
I, I, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Behr Behr 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
O. O. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NN O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NN -NONE- O
oikostat oikostat 0 0 0 0 0 0 0 0 8 0 NNP NNP NN -NONE- -NONE- O
GmbH, GmbH, 1 0 0 0 1 0 0 0 5 0 NNP NN -NONE- -NONE- NNP O
Ettiswil, Ettiswil, 1 0 0 0 1 0 0 0 9 0 NN -NONE- -NONE- NNP : O
Switzerland Switzerland 1 0 0 0 0 0 0 0 11 0 -NONE- -NONE- NNP : NNP O
; ; 0 0 0 0 0 0 0 0 1 0 -NONE- NNP : NNP NNP O
Swiss Swiss 1 0 0 0 0 0 0 0 5 0 NNP : NNP NNP NNP O
Ornithological Ornithological 1 0 0 0 0 0 0 0 14 0 : NNP NNP NNP NNP O
Institute, Institute, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Sempach, Sempach, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Switzerland. Switzerland. 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
Environmental Environmental 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP VBZ IN O
impacts impacts 0 0 0 0 0 0 0 0 7 0 NNP NNP VBZ IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN NN NN O
wind wind 0 0 0 0 0 0 0 0 4 0 VBZ IN NN NN NNS O
energy energy 0 0 0 0 0 0 0 0 6 0 IN NN NN NNS RB O
facilities facilities 0 0 0 0 0 0 0 0 10 0 NN NN NNS RB VB O
increasingly increasingly 0 0 0 0 0 0 0 0 12 0 NN NNS RB VB JJ O
cause cause 0 0 0 0 0 0 0 0 5 0 NNS RB VB JJ DT O
concern, concern, 0 0 0 0 1 0 0 0 8 0 RB VB JJ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VB JJ DT JJ NN O
central central 0 0 0 0 0 0 0 0 7 0 JJ DT JJ NN VBG O
issue issue 0 0 0 0 0 0 0 0 5 0 DT JJ NN VBG NNS O
being being 0 0 0 0 0 0 0 0 5 0 JJ NN VBG NNS CC O
bats bats 0 0 0 0 0 0 0 0 4 0 NN VBG NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 VBG NNS CC NNS VBD O
birds birds 0 0 0 0 0 0 0 0 5 0 NNS CC NNS VBD IN O
killed killed 0 0 0 0 0 0 0 0 6 0 CC NNS VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBD IN NN NNP O
rotor rotor 0 0 0 0 0 0 0 0 5 0 VBD IN NN NNP NNP O
blades. blades. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NNP VBZ O
Two Two 1 0 0 0 0 0 0 0 3 0 NN NNP NNP VBZ VBP O
approaches approaches 0 0 0 0 0 0 0 0 10 0 NNP NNP VBZ VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 VBZ VBP VBN VBN TO O
employed employed 0 0 0 0 0 0 0 0 8 0 VBP VBN VBN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO NN NN O
assess assess 0 0 0 0 0 0 0 0 6 0 VBN TO NN NN NN O
collision collision 0 0 0 0 0 0 0 0 9 0 TO NN NN NN NN O
rates: rates: 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NNS O
carcass carcass 0 0 0 0 0 0 0 0 7 0 NN NN NN NNS CC O
searches searches 0 0 0 0 0 0 0 0 8 0 NN NN NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NNS IN O
surveys surveys 0 0 0 0 0 0 0 0 7 0 NNS CC NNS IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 CC NNS IN NNS VBP O
animals animals 0 0 0 0 0 0 0 0 7 0 NNS IN NNS VBP TO O
prone prone 0 0 0 0 0 0 0 0 5 0 IN NNS VBP TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBP TO NNP NNP O
collisions. collisions. 0 0 0 0 0 0 0 0 11 0 VBP TO NNP NNP VBZ O
Carcass Carcass 1 0 0 0 0 0 0 0 7 0 TO NNP NNP VBZ MD O
searches searches 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NNP VBZ MD VB DT O
provide provide 0 0 0 0 0 0 0 0 7 0 VBZ MD VB DT NN O
an an 0 0 0 0 0 0 0 0 2 0 MD VB DT NN IN O
estimate estimate 0 0 0 0 0 0 0 0 8 0 VB DT NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
actual actual 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN IN O
number number 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS VBG O
animals animals 0 0 0 0 0 0 0 0 7 0 NN IN NNS VBG VBN O
being being 0 0 0 0 0 0 0 0 5 0 IN NNS VBG VBN CC O
killed killed 0 0 0 0 0 0 0 0 6 0 NNS VBG VBN CC PRP O
but but 0 0 0 0 0 0 0 0 3 0 VBG VBN CC PRP VBP O
they they 0 0 0 0 0 0 0 0 4 0 VBN CC PRP VBP JJ O
offer offer 0 0 0 0 0 0 0 0 5 0 CC PRP VBP JJ NN O
little little 0 0 0 0 0 0 0 0 6 0 PRP VBP JJ NN IN O
information information 0 0 0 0 0 0 0 0 11 0 VBP JJ NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
relation relation 0 0 0 0 0 0 0 0 8 0 IN DT NN IN NN O
between between 0 0 0 0 0 0 0 0 7 0 DT NN IN NN NNS O
collision collision 0 0 0 0 0 0 0 0 9 0 NN IN NN NNS -NONE- O
rates rates 0 0 0 0 0 0 0 0 5 0 IN NN NNS -NONE- IN O
and, and, 0 0 0 0 1 0 0 0 4 0 NN NNS -NONE- IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NNS -NONE- IN JJ NN O
example, example, 0 0 0 0 1 0 0 0 8 0 -NONE- IN JJ NN NNS O
weather weather 0 0 0 0 0 0 0 0 7 0 IN JJ NN NNS JJ O
parameters parameters 0 0 0 0 0 0 0 0 10 0 JJ NN NNS JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 NN NNS JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNS JJ TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ TO DT NN IN O
time time 0 0 0 0 0 0 0 0 4 0 TO DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN RB O
death death 0 0 0 0 0 0 0 0 5 0 NN IN NN RB VBG O
not not 0 0 0 0 0 0 0 0 3 0 IN NN RB VBG RB O
being being 0 0 0 0 0 0 0 0 5 0 NN RB VBG RB NNP O
precisely precisely 0 0 0 0 0 0 0 0 9 0 RB VBG RB NNP NNP O
known. known. 0 0 0 0 0 0 0 0 6 0 VBG RB NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 RB NNP NNP NNP DT O
contrast, contrast, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT NN NN O
density density 0 0 0 0 0 0 0 0 7 0 NNP DT NN NN IN O
index index 0 0 0 0 0 0 0 0 5 0 DT NN NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNS VBN O
animals animals 0 0 0 0 0 0 0 0 7 0 NN IN NNS VBN TO O
exposed exposed 0 0 0 0 0 0 0 0 7 0 IN NNS VBN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBN TO NN VBZ O
collision collision 0 0 0 0 0 0 0 0 9 0 VBN TO NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 TO NN VBZ JJ TO O
sufficient sufficient 0 0 0 0 0 0 0 0 10 0 NN VBZ JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO VB DT O
analyse analyse 0 0 0 0 0 0 0 0 7 0 JJ TO VB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NNS VBG O
parameters parameters 0 0 0 0 0 0 0 0 10 0 VB DT NNS VBG DT O
influencing influencing 0 0 0 0 0 0 0 0 11 0 DT NNS VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBG DT NN NNP O
collision collision 0 0 0 0 0 0 0 0 9 0 VBG DT NN NNP NNP O
rate. rate. 0 0 0 0 0 0 0 0 5 0 DT NN NNP NNP NN O
However, However, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP NN IN O
quantification quantification 0 0 0 0 0 0 0 0 14 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
collision collision 0 0 0 0 0 0 0 0 9 0 IN DT NN NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 DT NN NN IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ NN O
animal animal 0 0 0 0 0 0 0 0 6 0 NN IN JJ NN NNS O
density density 0 0 0 0 0 0 0 0 7 0 IN JJ NN NNS NNP O
indices indices 0 0 0 0 0 0 0 0 7 0 JJ NN NNS NNP JJ O
(e.g. (e.g. 0 0 0 0 0 0 0 0 5 0 NN NNS NNP JJ NN O
acoustic acoustic 0 0 0 0 0 0 0 0 8 0 NNS NNP JJ NN NN O
bat bat 0 0 0 0 0 0 0 0 3 0 NNP JJ NN NN CC O
activity activity 0 0 0 0 0 0 0 0 8 0 JJ NN NN CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 NN NN CC JJ NN O
bird bird 0 0 0 0 0 0 0 0 4 0 NN CC JJ NN NN O
migration migration 0 0 0 0 0 0 0 0 9 0 CC JJ NN NN NN O
traffic traffic 0 0 0 0 0 0 0 0 7 0 JJ NN NN NN VBZ O
rates) rates) 0 0 0 0 0 0 0 0 6 0 NN NN NN VBZ NNP O
remains remains 0 0 0 0 0 0 0 0 7 0 NN NN VBZ NNP NNP O
difficult. difficult. 0 0 0 0 0 0 0 0 10 0 NN VBZ NNP NNP NN O
We We 1 0 0 0 0 0 0 0 2 0 VBZ NNP NNP NN NN O
combine combine 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN NN O
carcass carcass 0 0 0 0 0 0 0 0 7 0 NNP NN NN NN NNS O
search search 0 0 0 0 0 0 0 0 6 0 NN NN NN NNS IN O
data data 0 0 0 0 0 0 0 0 4 0 NN NN NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN NNS IN JJ NN O
animal animal 0 0 0 0 0 0 0 0 6 0 NNS IN JJ NN NNS O
density density 0 0 0 0 0 0 0 0 7 0 IN JJ NN NNS IN O
indices indices 0 0 0 0 0 0 0 0 7 0 JJ NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT NN NN O
mixture mixture 0 0 0 0 0 0 0 0 7 0 IN DT NN NN TO O
model model 0 0 0 0 0 0 0 0 5 0 DT NN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO VB NN O
investigate investigate 0 0 0 0 0 0 0 0 11 0 NN TO VB NN NNP O
collision collision 0 0 0 0 0 0 0 0 9 0 TO VB NN NNP NNP O
rates. rates. 0 0 0 0 0 0 0 0 6 0 VB NN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT NN NN O
simulation simulation 0 0 0 0 0 0 0 0 10 0 NNP DT NN NN PRP O
study study 0 0 0 0 0 0 0 0 5 0 DT NN NN PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NN NN PRP VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NN PRP VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NN NNS O
collision collision 0 0 0 0 0 0 0 0 9 0 IN DT NN NNS VBD O
rates rates 0 0 0 0 0 0 0 0 5 0 DT NN NNS VBD IN O
estimated estimated 0 0 0 0 0 0 0 0 9 0 NN NNS VBD IN PRP$ O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBD IN PRP$ NN O
our our 0 0 0 0 0 0 0 0 3 0 VBD IN PRP$ NN VBD O
model model 0 0 0 0 0 0 0 0 5 0 IN PRP$ NN VBD IN O
were were 0 0 0 0 0 0 0 0 4 0 PRP$ NN VBD IN JJS O
at at 0 0 0 0 0 0 0 0 2 0 NN VBD IN JJS IN O
least least 0 0 0 0 0 0 0 0 5 0 VBD IN JJS IN NN O
as as 0 0 0 0 0 0 0 0 2 0 IN JJS IN NN IN O
precise precise 0 0 0 0 0 0 0 0 7 0 JJS IN NN IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NNS O
conventional conventional 0 0 0 0 0 0 0 0 12 0 NN IN JJ NNS VBN O
estimates estimates 0 0 0 0 0 0 0 0 9 0 IN JJ NNS VBN RB O
based based 0 0 0 0 0 0 0 0 5 0 JJ NNS VBN RB IN O
solely solely 0 0 0 0 0 0 0 0 6 0 NNS VBN RB IN NN O
on on 0 0 0 0 0 0 0 0 2 0 VBN RB IN NN NN O
carcass carcass 0 0 0 0 0 0 0 0 7 0 RB IN NN NN NNP O
search search 0 0 0 0 0 0 0 0 6 0 IN NN NN NNP NNP O
data. data. 0 0 0 0 0 0 0 0 5 0 NN NN NNP NNP IN O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 NN NNP NNP IN JJ O
if if 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ NNS O
certain certain 0 0 0 0 0 0 0 0 7 0 NNP IN JJ NNS VBP O
conditions conditions 0 0 0 0 0 0 0 0 10 0 IN JJ NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 JJ NNS VBP JJ DT O
met, met, 0 0 0 0 1 0 0 0 4 0 NNS VBP JJ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP JJ DT NN MD O
model model 0 0 0 0 0 0 0 0 5 0 JJ DT NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 DT NN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 MD VB VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VB VBN TO VB DT O
predict predict 0 0 0 0 0 0 0 0 7 0 VBN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN NN O
collision collision 0 0 0 0 0 0 0 0 9 0 VB DT NN NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 DT NN NN IN NN O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN NN NNS O
density density 0 0 0 0 0 0 0 0 7 0 NN IN NN NNS -NONE- O
indices indices 0 0 0 0 0 0 0 0 7 0 IN NN NNS -NONE- IN O
alone, alone, 0 0 0 0 1 0 0 0 6 0 NN NNS -NONE- IN NNS O
without without 0 0 0 0 0 0 0 0 7 0 NNS -NONE- IN NNS IN O
data data 0 0 0 0 0 0 0 0 4 0 -NONE- IN NNS IN NN O
from from 0 0 0 0 0 0 0 0 4 0 IN NNS IN NN NNP O
carcass carcass 0 0 0 0 0 0 0 0 7 0 NNS IN NN NNP NNP O
searches. searches. 0 0 0 0 0 0 0 0 9 0 IN NN NNP NNP MD O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NNP NNP MD VB DT O
reduce reduce 0 0 0 0 0 0 0 0 6 0 NNP MD VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NN CC O
time time 0 0 0 0 0 0 0 0 4 0 VB DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN VBD O
effort effort 0 0 0 0 0 0 0 0 6 0 NN CC NN VBD TO O
required required 0 0 0 0 0 0 0 0 8 0 CC NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB NN O
estimate estimate 0 0 0 0 0 0 0 0 8 0 VBD TO VB NN NNP O
collision collision 0 0 0 0 0 0 0 0 9 0 TO VB NN NNP NNP O
rates. rates. 0 0 0 0 0 0 0 0 6 0 VB NN NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBD DT O
applied applied 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN TO O
model model 0 0 0 0 0 0 0 0 5 0 VBD DT NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO VB NN O
bat bat 0 0 0 0 0 0 0 0 3 0 NN TO VB NN NN O
carcass carcass 0 0 0 0 0 0 0 0 7 0 TO VB NN NN NNS O
search search 0 0 0 0 0 0 0 0 6 0 VB NN NN NNS VBD O
data data 0 0 0 0 0 0 0 0 4 0 NN NN NNS VBD IN O
obtained obtained 0 0 0 0 0 0 0 0 8 0 NN NNS VBD IN CD O
at at 0 0 0 0 0 0 0 0 2 0 NNS VBD IN CD NN O
30 30 0 0 0 0 0 0 1 1 2 0 VBD IN CD NN NNS O
wind wind 0 0 0 0 0 0 0 0 4 0 IN CD NN NNS IN O
turbines turbines 0 0 0 0 0 0 0 0 8 0 CD NN NNS IN CD O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN CD NN O
15 15 0 0 0 0 0 0 1 1 2 0 NNS IN CD NN NNS O
wind wind 0 0 0 0 0 0 0 0 4 0 IN CD NN NNS IN O
facilities facilities 0 0 0 0 0 0 0 0 10 0 CD NN NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP NNP O
Germany. Germany. 1 0 0 0 0 0 0 0 8 0 NNS IN NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 IN NNP NNP VBD JJ O
used used 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD JJ NN O
acoustic acoustic 0 0 0 0 0 0 0 0 8 0 NNP VBD JJ NN NN O
bat bat 0 0 0 0 0 0 0 0 3 0 VBD JJ NN NN CC O
activity activity 0 0 0 0 0 0 0 0 8 0 JJ NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
wind wind 0 0 0 0 0 0 0 0 4 0 NN CC NN NN IN O
speed speed 0 0 0 0 0 0 0 0 5 0 CC NN NN IN NNS O
as as 0 0 0 0 0 0 0 0 2 0 NN NN IN NNS IN O
predictors predictors 0 0 0 0 0 0 0 0 10 0 NN IN NNS IN DT O
for for 0 0 0 0 0 0 0 0 3 0 IN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NNP O
collision collision 0 0 0 0 0 0 0 0 9 0 IN DT NN NNP NNP O
rate. rate. 0 0 0 0 0 0 0 0 5 0 DT NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN VBZ O
model model 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ VBN O
estimates estimates 0 0 0 0 0 0 0 0 9 0 NNP NN VBZ VBN RB O
correlated correlated 0 0 0 0 0 0 0 0 10 0 NN VBZ VBN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 VBZ VBN RB IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBN RB IN JJ NNP O
conventional conventional 0 0 0 0 0 0 0 0 12 0 RB IN JJ NNP NNP O
estimators. estimators. 0 0 0 0 0 0 0 0 11 0 IN JJ NNP NNP NN O
Our Our 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN MD O
model model 0 0 0 0 0 0 0 0 5 0 NNP NNP NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NNP NN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 MD VB VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VB VBN TO VB DT O
predict predict 0 0 0 0 0 0 0 0 7 0 VBN TO VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJ NN O
average average 0 0 0 0 0 0 0 0 7 0 VB DT JJ NN NNP O
collision collision 0 0 0 0 0 0 0 0 9 0 DT JJ NN NNP NNP O
rate. rate. 0 0 0 0 0 0 0 0 5 0 JJ NN NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBZ DT O
enables enables 0 0 0 0 0 0 0 0 7 0 NNP NNP VBZ DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NNP VBZ DT NN IN O
analysis analysis 0 0 0 0 0 0 0 0 8 0 VBZ DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 IN DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS JJ O
parameters parameters 0 0 0 0 0 0 0 0 10 0 NN IN NNS JJ IN O
such such 0 0 0 0 0 0 0 0 4 0 IN NNS JJ IN NN O
as as 0 0 0 0 0 0 0 0 2 0 NNS JJ IN NN NN O
rotor rotor 0 0 0 0 0 0 0 0 5 0 JJ IN NN NN CC O
diameter diameter 0 0 0 0 0 0 0 0 8 0 IN NN NN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 NN NN CC NN NN O
turbine turbine 0 0 0 0 0 0 0 0 7 0 NN CC NN NN IN O
type type 0 0 0 0 0 0 0 0 4 0 CC NN NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
collision collision 0 0 0 0 0 0 0 0 9 0 IN DT NN NNP NNP O
rate. rate. 0 0 0 0 0 0 0 0 5 0 DT NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN MD O
model model 0 0 0 0 0 0 0 0 5 0 NNP NNP NN MD RB O
can can 0 0 0 0 0 0 0 0 3 0 NNP NN MD RB VB O
also also 0 0 0 0 0 0 0 0 4 0 NN MD RB VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 MD RB VB VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 RB VB VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VB VBN IN NNP NN O
turbine-specific turbine-specific 0 0 1 0 0 0 0 0 16 0 VBN IN NNP NN NNS O
curtailment curtailment 0 0 0 0 0 0 0 0 11 0 IN NNP NN NNS WDT O
algorithms algorithms 0 0 0 0 0 0 0 0 10 0 NNP NN NNS WDT VBP O
that that 0 0 0 0 0 0 0 0 4 0 NN NNS WDT VBP DT O
predict predict 0 0 0 0 0 0 0 0 7 0 NNS WDT VBP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 WDT VBP DT NN NN O
collision collision 0 0 0 0 0 0 0 0 9 0 VBP DT NN NN CC O
rate rate 0 0 0 0 0 0 0 0 4 0 DT NN NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VB DT O
reduce reduce 0 0 0 0 0 0 0 0 6 0 NN CC VB DT NN O
this this 0 0 0 0 0 0 0 0 4 0 CC VB DT NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 VB DT NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 DT NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
minimal minimal 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN IN O
loss loss 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNP O
energy energy 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP NONE O
production. production. 0 0 0 0 0 0 0 0 11 0 IN NN NNP NONE NONE O
S-nitroso-N-acetylcysteine S-nitroso-N-acetylcysteine 1 0 1 0 0 0 0 0 26 0 NONE NONE JJ NNS RB O
attenuates attenuates 0 0 0 0 0 0 0 0 10 0 NONE JJ NNS RB VBZ O
liver liver 0 0 0 0 0 0 0 0 5 0 JJ NNS RB VBZ IN O
fibrosis fibrosis 0 0 0 0 0 0 0 0 8 0 NNS RB VBZ IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 RB VBZ IN JJ JJ O
experimental experimental 0 0 0 0 0 0 0 0 12 0 VBZ IN JJ JJ NNP O
nonalcoholic nonalcoholic 0 0 0 0 0 0 0 0 12 0 IN JJ JJ NNP NNP O
steatohepatitis. steatohepatitis. 0 0 0 0 0 0 0 0 16 0 JJ JJ NNP NNP NNP O
Mazo Mazo 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NNP IN O
DF, DF, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Oliveira Oliveira 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
MG, MG, 1 1 0 0 1 0 0 0 3 0 IN NNP NNP NNP NNP O
Pereira Pereira 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
IV, IV, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Cogliati Cogliati 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Stefano Stefano 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP IN O
JT, JT, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Souza Souza 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
GF, GF, 1 1 0 0 1 0 0 0 3 0 IN NNP NNP NNP NNP O
Rabelo Rabelo 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lima Lima 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
FR, FR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Ferreira Ferreira 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Alves Alves 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
VA, VA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Carrilho Carrilho 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
FJ, FJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Oliveira Oliveira 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
CP. CP. 1 1 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
São São 1 0 0 0 0 0 0 0 3 0 NNP IN NNP NNP NNP O
Paulo Paulo 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Gastroenterology, Gastroenterology, 1 0 0 0 1 0 0 0 17 0 NNP IN NNP NNP NNP O
Clinical Clinical 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
Division, Division, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Hepatology Hepatology 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Branch Branch 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
(LIM-07), (LIM-07), 0 1 1 0 1 0 0 1 9 0 NNP NNP NNP NNP NNP O
Sao Sao 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Paulo, Paulo, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
Brazil. Brazil. 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
S-Nitroso-N-acetylcysteine S-Nitroso-N-acetylcysteine 1 0 1 0 0 0 0 0 26 0 NNP NNP NNP NNP VBZ O
(SNAC) (SNAC) 0 1 0 0 0 0 0 0 6 0 NNP NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT NN JJ O
water water 0 0 0 0 0 0 0 0 5 0 VBZ DT NN JJ JJ O
soluble soluble 0 0 0 0 0 0 0 0 7 0 DT NN JJ JJ NN O
primary primary 0 0 0 0 0 0 0 0 7 0 NN JJ JJ NN JJ O
S-nitrosothiol S-nitrosothiol 1 0 1 0 0 0 0 0 14 0 JJ JJ NN JJ IN O
capable capable 0 0 0 0 0 0 0 0 7 0 JJ NN JJ IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN JJ IN NN CC O
transferring transferring 0 0 0 0 0 0 0 0 12 0 JJ IN NN CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VBG JJ O
releasing releasing 0 0 0 0 0 0 0 0 9 0 NN CC VBG JJ NN O
nitric nitric 0 0 0 0 0 0 0 0 6 0 CC VBG JJ NN CC O
oxide oxide 0 0 0 0 0 0 0 0 5 0 VBG JJ NN CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBG JJ O
inducing inducing 0 0 0 0 0 0 0 0 8 0 NN CC VBG JJ JJ O
several several 0 0 0 0 0 0 0 0 7 0 CC VBG JJ JJ NN O
biochemical biochemical 0 0 0 0 0 0 0 0 11 0 VBG JJ JJ NN VBG O
activities, activities, 0 0 0 0 1 0 0 0 11 0 JJ JJ NN VBG NN O
including including 0 0 0 0 0 0 0 0 9 0 JJ NN VBG NN IN O
modulation modulation 0 0 0 0 0 0 0 0 10 0 NN VBG NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBG NN IN JJ NN O
hepatic hepatic 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN NN O
stellate stellate 0 0 0 0 0 0 0 0 8 0 IN JJ NN NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NNP NNP O
activation. activation. 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 NNP DT NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBD DT O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 NN PRP VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT JJ NN O
antifibrotic antifibrotic 0 0 0 0 0 0 0 0 12 0 VBD DT JJ NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP IN O
SNAC SNAC 1 1 0 0 0 0 0 0 4 0 NN IN NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNP IN DT JJ NN O
animal animal 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN IN O
model model 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNS O
nonalcoholic nonalcoholic 0 0 0 0 0 0 0 0 12 0 NN IN JJ NNS -NONE- O
steatohepatitis steatohepatitis 0 0 0 0 0 0 0 0 15 0 IN JJ NNS -NONE- VBN O
(NASH) (NASH) 0 1 0 0 0 0 0 0 6 0 JJ NNS -NONE- VBN IN O
induced induced 0 0 0 0 0 0 0 0 7 0 NNS -NONE- VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- VBN IN NNP NNS O
Sprague-Dawley Sprague-Dawley 1 0 1 0 0 0 0 0 14 0 VBN IN NNP NNS VBD O
rats rats 0 0 0 0 0 0 0 0 4 0 IN NNP NNS VBD IN O
fed fed 0 0 0 0 0 0 0 0 3 0 NNP NNS VBD IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBD IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBD IN DT JJ NN O
choline-deficient, choline-deficient, 0 0 1 0 1 0 0 0 18 0 IN DT JJ NN NNS O
high high 0 0 0 0 0 0 0 0 4 0 DT JJ NN NNS JJ O
trans trans 0 0 0 0 0 0 0 0 5 0 JJ NN NNS JJ NN O
fat fat 0 0 0 0 0 0 0 0 3 0 NN NNS JJ NN CC O
diet diet 0 0 0 0 0 0 0 0 4 0 NNS JJ NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBD TO O
exposed exposed 0 0 0 0 0 0 0 0 7 0 NN CC VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 CC VBD TO VB IN O
diethylnitrosamine diethylnitrosamine 0 0 0 0 0 0 0 0 18 0 VBD TO VB IN CD O
for for 0 0 0 0 0 0 0 0 3 0 TO VB IN CD NNP O
8 8 0 0 0 0 0 0 1 1 1 0 VB IN CD NNP NNP O
weeks. weeks. 0 0 0 0 0 0 0 0 6 0 IN CD NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 CD NNP NNP NNS VBD O
rats rats 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD VBN IN O
divided divided 0 0 0 0 0 0 0 0 7 0 NNS VBD VBN IN CD O
into into 0 0 0 0 0 0 0 0 4 0 VBD VBN IN CD JJ O
three three 0 0 0 0 0 0 0 0 5 0 VBN IN CD JJ NN O
groups: groups: 0 0 0 0 0 0 0 0 7 0 IN CD JJ NN WDT O
SNAC, SNAC, 1 1 0 0 1 0 0 0 5 0 CD JJ NN WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 JJ NN WDT VBD JJ O
received received 0 0 0 0 0 0 0 0 8 0 NN WDT VBD JJ NNP O
oral oral 0 0 0 0 0 0 0 0 4 0 WDT VBD JJ NNP NN O
SNAC SNAC 1 1 0 0 0 0 0 0 4 0 VBD JJ NNP NN -NONE- O
solution solution 0 0 0 0 0 0 0 0 8 0 JJ NNP NN -NONE- -NONE- O
daily; daily; 0 0 0 0 0 0 0 0 6 0 NNP NN -NONE- -NONE- WDT O
NASH, NASH, 1 1 0 0 1 0 0 0 5 0 NN -NONE- -NONE- WDT VBN O
which which 0 0 0 0 0 0 0 0 5 0 -NONE- -NONE- WDT VBN DT O
received received 0 0 0 0 0 0 0 0 8 0 -NONE- WDT VBN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 WDT VBN DT NNP CC O
vehicle; vehicle; 0 0 0 0 0 0 0 0 8 0 VBN DT NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC NNP WDT O
control, control, 0 0 0 0 1 0 0 0 8 0 NNP CC NNP WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 CC NNP WDT VBD JJ O
received received 0 0 0 0 0 0 0 0 8 0 NNP WDT VBD JJ NN O
standard standard 0 0 0 0 0 0 0 0 8 0 WDT VBD JJ NN CC O
diet diet 0 0 0 0 0 0 0 0 4 0 VBD JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP NNP O
vehicle. vehicle. 0 0 0 0 0 0 0 0 8 0 NN CC NNP NNP VBD O
Genes Genes 1 0 0 0 0 0 0 0 5 0 CC NNP NNP VBD TO O
related related 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBD TO NN CD O
fibrosis fibrosis 0 0 0 0 0 0 0 0 8 0 VBD TO NN CD NNS O
(matrix (matrix 0 0 0 0 0 0 0 0 7 0 TO NN CD NNS -NONE- O
metalloproteinases metalloproteinases 0 0 0 0 0 0 0 0 18 0 NN CD NNS -NONE- -NONE- O
[MMP]-13, [MMP]-13, 0 1 1 0 1 0 0 1 9 0 CD NNS -NONE- -NONE- CC O
-9, -9, 0 0 1 0 1 0 0 1 3 0 NNS -NONE- -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- CC NNP NN O
-2), -2), 0 0 1 0 1 0 0 1 4 0 -NONE- CC NNP NN NN O
transforming transforming 0 0 0 0 0 0 0 0 12 0 CC NNP NN NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 NNP NN NN NN -NONE- O
factor factor 0 0 0 0 0 0 0 0 6 0 NN NN NN -NONE- JJ O
β-1 β-1 0 0 1 0 0 0 0 1 3 0 NN NN -NONE- JJ NN O
[TGFβ-1], [TGFβ-1], 0 0 1 0 1 0 0 1 9 0 NN -NONE- JJ NN CC O
collagen-1α, collagen-1α, 0 0 1 0 1 0 0 1 12 0 -NONE- JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NNS O
tissue tissue 0 0 0 0 0 0 0 0 6 0 NN CC NN NNS IN O
inhibitors inhibitors 0 0 0 0 0 0 0 0 10 0 CC NN NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN -NONE- O
metalloproteinase metalloproteinase 0 0 0 0 0 0 0 0 17 0 NNS IN NN -NONE- CC O
[TIMP-1 [TIMP-1 0 1 1 0 0 0 0 1 7 0 IN NN -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC NNP CC O
-2] -2] 0 0 1 0 0 0 0 1 3 0 -NONE- CC NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC JJ NN O
oxidative oxidative 0 0 0 0 0 0 0 0 9 0 NNP CC JJ NN NN O
stress stress 0 0 0 0 0 0 0 0 6 0 CC JJ NN NN NNS O
(heat-shock (heat-shock 0 0 1 0 0 0 0 0 11 0 JJ NN NN NNS -NONE- O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NN NN NNS -NONE- CC O
[HSP]-60 [HSP]-60 0 1 1 0 0 0 0 1 8 0 NN NNS -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC NNP VBD O
-90) -90) 0 0 1 0 0 0 0 1 4 0 -NONE- CC NNP VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 CC NNP VBD NNP NNP O
evaluated. evaluated. 0 0 0 0 0 0 0 0 10 0 NNP VBD NNP NNP VBD O
SNAC SNAC 1 1 0 0 0 0 0 0 4 0 VBD NNP NNP VBD TO O
led led 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBD TO DT CD O
a a 0 0 0 0 0 0 0 0 1 0 VBD TO DT CD NN O
34.4% 34.4% 0 0 0 0 0 0 0 1 5 0 TO DT CD NN IN O
reduction reduction 0 0 0 0 0 0 0 0 9 0 DT CD NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBD O
collagen collagen 0 0 0 0 0 0 0 0 8 0 IN DT NN VBD NN O
occupied occupied 0 0 0 0 0 0 0 0 8 0 DT NN VBD NN VBN O
area area 0 0 0 0 0 0 0 0 4 0 NN VBD NN VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 VBD NN VBN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NN VBN IN NN IN O
upregulation upregulation 0 0 0 0 0 0 0 0 12 0 VBN IN NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN -NONE- CC O
MMP-13 MMP-13 1 1 1 0 0 0 0 1 6 0 NN IN -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN -NONE- CC NNP CC O
-9 -9 0 0 1 0 0 0 0 1 2 0 -NONE- CC NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC NN IN O
downregulation downregulation 0 0 0 0 0 0 0 0 14 0 NNP CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NNP O
HSP-60, HSP-60, 1 1 1 0 1 0 0 1 7 0 NN IN NNP NNP NNP O
TIMP-2, TIMP-2, 1 1 1 0 1 0 0 1 7 0 IN NNP NNP NNP CC O
TGFβ-1, TGFβ-1, 1 0 1 0 1 0 0 1 7 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
collagen-1α. collagen-1α. 0 0 1 0 0 0 0 1 12 0 NNP CC NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 CC NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
indicate indicate 0 0 0 0 0 0 0 0 8 0 NNP NNS VBP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN JJ NNP O
oral oral 0 0 0 0 0 0 0 0 4 0 VBP IN JJ NNP NN O
SNAC SNAC 1 1 0 0 0 0 0 0 4 0 IN JJ NNP NN MD O
administration administration 0 0 0 0 0 0 0 0 14 0 JJ NNP NN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NNP NN MD VB DT O
represent represent 0 0 0 0 0 0 0 0 9 0 NN MD VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT JJ JJ O
potential potential 0 0 0 0 0 0 0 0 9 0 VB DT JJ JJ NN O
antifibrotic antifibrotic 0 0 0 0 0 0 0 0 12 0 DT JJ JJ NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 JJ JJ NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NNP NONE O
NASH. NASH. 1 1 0 0 0 0 0 0 5 0 NN IN NNP NONE NONE O
Appropriate Appropriate 1 0 0 0 0 0 0 0 11 0 NONE NONE NNP NN IN O
implementation implementation 0 0 0 0 0 0 0 0 14 0 NONE NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NN O
severity severity 0 0 0 0 0 0 0 0 8 0 NN IN NN NN NN O
ratings, ratings, 0 0 0 0 1 0 0 0 8 0 IN NN NN NN CC O
regulations, regulations, 0 0 0 0 1 0 0 0 12 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
state state 0 0 0 0 0 0 0 0 5 0 NN CC NN NN DT O
guidance: guidance: 0 0 0 0 0 0 0 0 9 0 CC NN NN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN NN DT NN TO O
response response 0 0 0 0 0 0 0 0 8 0 NN DT NN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO JJ JJ O
"using "using 0 0 0 0 0 0 0 0 6 0 NN TO JJ JJ NNS O
norm-referenced norm-referenced 0 0 1 0 0 0 0 0 15 0 TO JJ JJ NNS TO O
tests tests 0 0 0 0 0 0 0 0 5 0 JJ JJ NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO VB NN O
determine determine 0 0 0 0 0 0 0 0 9 0 NNS TO VB NN IN O
severity severity 0 0 0 0 0 0 0 0 8 0 TO VB NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VB NN IN NN NN O
language language 0 0 0 0 0 0 0 0 8 0 NN IN NN NN IN O
impairment impairment 0 0 0 0 0 0 0 0 10 0 IN NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NN O
children: children: 0 0 0 0 0 0 0 0 9 0 NN IN NNP NN IN O
disconnect disconnect 0 0 0 0 0 0 0 0 10 0 IN NNP NN IN NNP O
between between 0 0 0 0 0 0 0 0 7 0 NNP NN IN NNP NNP O
u.s. u.s. 0 0 0 0 0 0 0 0 4 0 NN IN NNP NNP NNS O
Policy Policy 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNS CC O
makers makers 0 0 0 0 0 0 0 0 6 0 NNP NNP NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNS CC NN NN O
test test 0 0 0 0 0 0 0 0 4 0 NNS CC NN NN IN O
developers" developers" 0 0 0 0 0 0 0 0 11 0 CC NN NN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
spaulding, spaulding, 0 0 0 0 1 0 0 0 10 0 NN IN NNP NNP CC O
szulga, szulga, 0 0 0 0 1 0 0 0 7 0 IN NNP NNP CC NNP O
& & 0 0 0 0 0 0 0 0 1 0 NNP NNP CC NNP NNP O
figueria figueria 0 0 0 0 0 0 0 0 8 0 NNP CC NNP NNP NNP O
(2012). (2012). 0 0 0 0 0 0 0 1 7 0 CC NNP NNP NNP NNP O
Ireland Ireland 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hall-Mills Hall-Mills 1 0 1 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Millikin Millikin 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
C. C. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP TO O
Correspondence Correspondence 1 0 0 0 0 0 0 0 14 0 NNP NNP NNP TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNP NNP TO NNP NNP O
Marie Marie 1 0 0 0 0 0 0 0 5 0 NNP TO NNP NNP NNP O
Ireland: Ireland: 1 0 0 0 0 0 0 0 8 0 TO NNP NNP NNP NONE O
marie.ireland@doe.virginia.gov. marie.ireland@doe.virginia.gov. 0 0 0 0 0 0 0 0 31 0 NNP NNP NNP NONE NONE O
A A 1 1 0 0 0 0 0 0 1 0 NONE NONE DT NN TO O
correction correction 0 0 0 0 0 0 0 0 10 0 NONE DT NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT NN NN O
research research 0 0 0 0 0 0 0 0 8 0 TO DT NN NN NN O
article article 0 0 0 0 0 0 0 0 7 0 DT NN NN NN NN O
titled: titled: 0 0 0 0 0 0 0 0 7 0 NN NN NN NN NN O
"lineage "lineage 0 0 0 0 0 0 0 0 8 0 NN NN NN NN IN O
structure structure 0 0 0 0 0 0 0 0 9 0 NN NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN NN O
antibody antibody 0 0 0 0 0 0 0 0 8 0 DT JJ NN NN IN O
repertoire repertoire 0 0 0 0 0 0 0 0 10 0 JJ NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN TO O
response response 0 0 0 0 0 0 0 0 8 0 NN IN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB JJ O
influenza influenza 0 0 0 0 0 0 0 0 9 0 NN TO VB JJ IN O
vaccination" vaccination" 0 0 0 0 0 0 0 0 12 0 TO VB JJ IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VB JJ IN NNP NNP O
N. N. 1 1 0 0 0 0 0 0 2 0 JJ IN NNP NNP NNP O
Jiang, Jiang, 1 0 0 0 1 0 0 0 6 0 IN NNP NNP NNP NNP O
j. j. 0 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
He, He, 1 0 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
j. j. 0 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
A. A. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Weinstein, Weinstein, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
L. L. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Penland, Penland, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
s. s. 0 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sasaki, Sasaki, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
x.-S. x.-S. 0 0 1 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
He, He, 1 0 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
C. C. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
L. L. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Dekker, Dekker, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
N.-Y. N.-Y. 1 1 1 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Zheng, Zheng, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
m. m. 0 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Huang, Huang, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
m. m. 0 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sullivan, Sullivan, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
p. p. 0 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
C. C. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wilson, Wilson, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
h. h. 0 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
B. B. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Greenberg, Greenberg, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
m. m. 0 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
M. M. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Davis, Davis, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
d. d. 0 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
S. S. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Fisher, Fisher, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
s. s. 0 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
R. R. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Quake. Quake. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNS O
[No [No 0 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS -NONE- O
authors authors 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS -NONE- -NONE- O
listed] listed] 0 0 0 0 0 0 0 0 7 0 NNP NNS -NONE- -NONE- CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNS -NONE- -NONE- CD JJ O
23843446 23843446 0 0 0 0 0 0 1 1 8 0 -NONE- -NONE- CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 -NONE- CD JJ : IN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ : IN JJ NONE O
process] process] 0 0 0 0 0 0 0 0 8 0 : IN JJ NONE NONE O
A A 1 1 0 0 0 0 0 0 1 0 NONE NONE DT JJ NN O
pedoprosthetic pedoprosthetic 0 0 0 0 0 0 0 0 14 0 NONE DT JJ NN IN O
rehabilitation rehabilitation 0 0 0 0 0 0 0 0 14 0 DT JJ NN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 NN IN NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN JJ JJ O
severe severe 0 0 0 0 0 0 0 0 6 0 NNS IN JJ JJ NN O
early early 0 0 0 0 0 0 0 0 5 0 IN JJ JJ NN NNS O
childhood childhood 0 0 0 0 0 0 0 0 9 0 JJ JJ NN NNS NNP O
caries caries 0 0 0 0 0 0 0 0 6 0 JJ NN NNS NNP NNP O
(S-ECC). (S-ECC). 0 1 1 0 0 0 0 0 8 0 NN NNS NNP NNP NNP O
Mishra Mishra 1 0 0 0 0 0 0 0 6 0 NNS NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Pandey Pandey 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Pandey Pandey 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Jain Jain 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
E. E. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Pedodontics Pedodontics 1 0 0 0 0 0 0 0 11 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Preventive Preventive 1 0 0 0 0 0 0 0 10 0 NNP CC NNP NNP NNP O
Dentistry, Dentistry, 1 0 0 0 1 0 0 0 10 0 CC NNP NNP NNP NNP O
King King 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
George George 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Lucknow, Lucknow, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Uttar Uttar 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Pradesh, Pradesh, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
India. India. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
Early Early 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NN NNS O
childhood childhood 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NNS -NONE- O
caries caries 0 0 0 0 0 0 0 0 6 0 NNP NN NNS -NONE- VBZ O
(ECC) (ECC) 0 1 0 0 0 0 0 0 5 0 NN NNS -NONE- VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNS -NONE- VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- VBZ DT JJ NN O
rapid rapid 0 0 0 0 0 0 0 0 5 0 VBZ DT JJ NN IN O
form form 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNP O
dental dental 0 0 0 0 0 0 0 0 6 0 NN IN JJ NNP NNP O
caries. caries. 0 0 0 0 0 0 0 0 7 0 IN JJ NNP NNP VBZ O
ECC ECC 1 1 0 0 0 0 0 0 3 0 JJ NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT RBS O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT RBS JJ O
most most 0 0 0 0 0 0 0 0 4 0 VBZ DT RBS JJ JJ O
common common 0 0 0 0 0 0 0 0 6 0 DT RBS JJ JJ NN O
chronic chronic 0 0 0 0 0 0 0 0 7 0 RBS JJ JJ NN NN O
childhood childhood 0 0 0 0 0 0 0 0 9 0 JJ JJ NN NN WDT O
disease disease 0 0 0 0 0 0 0 0 7 0 JJ NN NN WDT MD O
that that 0 0 0 0 0 0 0 0 4 0 NN NN WDT MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN WDT MD VB DT O
compromise compromise 0 0 0 0 0 0 0 0 10 0 WDT MD VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT JJ NN O
child's child's 0 0 0 0 0 1 0 0 7 0 VB DT JJ NN JJ O
self-esteem, self-esteem, 0 0 1 0 1 0 0 0 12 0 DT JJ NN JJ NN O
nutritional nutritional 0 0 0 0 0 0 0 0 11 0 JJ NN JJ NN JJ O
intake, intake, 0 0 0 0 1 0 0 0 7 0 NN JJ NN JJ NN O
oral oral 0 0 0 0 0 0 0 0 4 0 JJ NN JJ NN CC O
development development 0 0 0 0 0 0 0 0 11 0 NN JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN IN O
quality quality 0 0 0 0 0 0 0 0 7 0 NN CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP RB O
life, life, 0 0 0 0 1 0 0 0 5 0 NN IN NNP RB VBG O
subsequently subsequently 0 0 0 0 0 0 0 0 12 0 IN NNP RB VBG TO O
leading leading 0 0 0 0 0 0 0 0 7 0 NNP RB VBG TO NN O
to to 0 0 0 0 0 0 0 0 2 0 RB VBG TO NN CC O
malocclusion malocclusion 0 0 0 0 0 0 0 0 12 0 VBG TO NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 TO NN CC JJ NNP O
psychological psychological 0 0 0 0 0 0 0 0 13 0 NN CC JJ NNP NNP O
problems. problems. 0 0 0 0 0 0 0 0 9 0 CC JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
restoration restoration 0 0 0 0 0 0 0 0 11 0 NNP NNP NN IN RB O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN RB VBN O
severely severely 0 0 0 0 0 0 0 0 8 0 NN IN RB VBN JJ O
decayed decayed 0 0 0 0 0 0 0 0 7 0 IN RB VBN JJ NN O
primary primary 0 0 0 0 0 0 0 0 7 0 RB VBN JJ NN VBZ O
teeth teeth 0 0 0 0 0 0 0 0 5 0 VBN JJ NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ RB DT O
often often 0 0 0 0 0 0 0 0 5 0 NN VBZ RB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBZ RB DT JJ NN O
difficult difficult 0 0 0 0 0 0 0 0 9 0 RB DT JJ NN WDT O
procedure procedure 0 0 0 0 0 0 0 0 9 0 DT JJ NN WDT VBZ O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT VBZ DT O
offers offers 0 0 0 0 0 0 0 0 6 0 NN WDT VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 WDT VBZ DT JJ NN O
great great 0 0 0 0 0 0 0 0 5 0 VBZ DT JJ NN TO O
challenge challenge 0 0 0 0 0 0 0 0 9 0 DT JJ NN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO JJ NNP O
paediatric paediatric 0 0 0 0 0 0 0 0 10 0 NN TO JJ NNP NNP O
dentists. dentists. 0 0 0 0 0 0 0 0 9 0 TO JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN NN O
present present 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN NN O
case case 0 0 0 0 0 0 0 0 4 0 NNP NN NN NN NN O
series series 0 0 0 0 0 0 0 0 6 0 NN NN NN NN DT O
document document 0 0 0 0 0 0 0 0 8 0 NN NN NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT JJ NN O
clinical clinical 0 0 0 0 0 0 0 0 8 0 NN DT JJ NN IN O
management management 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS VBG O
patients patients 0 0 0 0 0 0 0 0 8 0 NN IN NNS VBG IN O
suffering suffering 0 0 0 0 0 0 0 0 9 0 IN NNS VBG IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBG IN JJ JJ O
severe severe 0 0 0 0 0 0 0 0 6 0 VBG IN JJ JJ NN O
early early 0 0 0 0 0 0 0 0 5 0 IN JJ JJ NN NNS O
childhood childhood 0 0 0 0 0 0 0 0 9 0 JJ JJ NN NNS VBG O
caries caries 0 0 0 0 0 0 0 0 6 0 JJ NN NNS VBG JJ O
using using 0 0 0 0 0 0 0 0 5 0 NN NNS VBG JJ JJ O
removable removable 0 0 0 0 0 0 0 0 9 0 NNS VBG JJ JJ NN O
partial partial 0 0 0 0 0 0 0 0 7 0 VBG JJ JJ NN VBG O
prosthesis prosthesis 0 0 0 0 0 0 0 0 10 0 JJ JJ NN VBG PRP$ O
restoring restoring 0 0 0 0 0 0 0 0 9 0 JJ NN VBG PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 NN VBG PRP$ NN NN O
masticatory masticatory 0 0 0 0 0 0 0 0 11 0 VBG PRP$ NN NN CC O
function function 0 0 0 0 0 0 0 0 8 0 PRP$ NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
aesthestics. aesthestics. 0 0 0 0 0 0 0 0 12 0 NN CC NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 CC NNP NNP JJ NN O
ultimate ultimate 0 0 0 0 0 0 0 0 8 0 NNP NNP JJ NN IN O
aim aim 0 0 0 0 0 0 0 0 3 0 NNP JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBD O
treatment treatment 0 0 0 0 0 0 0 0 9 0 IN DT NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB JJ O
improve improve 0 0 0 0 0 0 0 0 7 0 VBD TO VB JJ CC O
psychological psychological 0 0 0 0 0 0 0 0 13 0 TO VB JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VB JJ CC JJ NN O
physiological physiological 0 0 0 0 0 0 0 0 13 0 JJ CC JJ NN VBG O
development development 0 0 0 0 0 0 0 0 11 0 CC JJ NN VBG TO O
leading leading 0 0 0 0 0 0 0 0 7 0 JJ NN VBG TO JJR O
to to 0 0 0 0 0 0 0 0 2 0 NN VBG TO JJR NN O
better better 0 0 0 0 0 0 0 0 6 0 VBG TO JJR NN IN O
functioning functioning 0 0 0 0 0 0 0 0 11 0 TO JJR NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJR NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
stomatognathic stomatognathic 0 0 0 0 0 0 0 0 14 0 IN DT JJ NNP NONE O
system. system. 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NONE NONE O
Low Low 1 0 0 0 0 0 0 0 3 0 NONE NONE NNP NN NN O
temperature temperature 0 0 0 0 0 0 0 0 11 0 NONE NNP NN NN NNS O
rate rate 0 0 0 0 0 0 0 0 4 0 NNP NN NN NNS IN O
constants constants 0 0 0 0 0 0 0 0 9 0 NN NN NNS IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN : O
N((4)S) N((4)S) 1 1 0 0 0 0 0 1 7 0 IN DT NN : JJ O
+ + 0 0 0 0 0 0 0 0 1 0 DT NN : JJ NNP O
CH(X(2)Πr) CH(X(2)Πr) 1 0 0 0 0 0 0 1 10 0 NN : JJ NNP NNP O
reaction. reaction. 0 0 0 0 0 0 0 0 9 0 : JJ NNP NNP IN O
Implications Implications 1 0 0 0 0 0 0 0 12 0 JJ NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NN O
N2 N2 1 1 0 0 0 0 0 1 2 0 NNP IN NNP NN NNS O
formation formation 0 0 0 0 0 0 0 0 9 0 IN NNP NN NNS IN O
cycles cycles 0 0 0 0 0 0 0 0 6 0 NNP NN NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NN O
dense dense 0 0 0 0 0 0 0 0 5 0 NNS IN NN NN NNP O
interstellar interstellar 0 0 0 0 0 0 0 0 12 0 IN NN NN NNP NNP O
clouds. clouds. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP NNP O
Daranlot Daranlot 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hu Hu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Xie Xie 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Loison Loison 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
JC, JC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Caubet Caubet 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Costes Costes 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wakelam Wakelam 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
V, V, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Xie Xie 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Guo Guo 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hickson Hickson 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
KM. KM. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Université Université 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Bordeaux, Bordeaux, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP VBZ O
Institut Institut 1 0 0 0 0 0 0 0 8 0 IN NNP NNP VBZ NNS O
des des 0 0 0 0 0 0 0 0 3 0 NNP NNP VBZ NNS -NONE- O
Sciences Sciences 1 0 0 0 0 0 0 0 8 0 NNP VBZ NNS -NONE- NNP O
Moléculaires, Moléculaires, 1 0 0 0 1 0 0 0 13 0 VBZ NNS -NONE- NNP NNP O
CNRS CNRS 1 1 0 0 0 0 0 0 4 0 NNS -NONE- NNP NNP CD O
UMR UMR 1 1 0 0 0 0 0 0 3 0 -NONE- NNP NNP CD -NONE- O
5255, 5255, 0 0 0 0 1 0 0 1 5 0 NNP NNP CD -NONE- JJ O
F-33400 F-33400 1 1 1 0 0 0 0 1 7 0 NNP CD -NONE- JJ NNP O
Talence, Talence, 1 0 0 0 1 0 0 0 8 0 CD -NONE- JJ NNP NNP O
France. France. 1 0 0 0 0 0 0 0 7 0 -NONE- JJ NNP NNP NNP O
km.hickson@ism.u-bordeaux1.fr. km.hickson@ism.u-bordeaux1.fr. 0 0 1 0 0 0 0 1 30 0 JJ NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
Rate Rate 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP VBZ IN O
constants constants 0 0 0 0 0 0 0 0 9 0 NNP NNP VBZ IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NNP VBZ IN DT RB O
the the 0 0 0 0 0 0 0 0 3 0 VBZ IN DT RB JJ O
potentially potentially 0 0 0 0 0 0 0 0 11 0 IN DT RB JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 DT RB JJ NN NN O
interstellar interstellar 0 0 0 0 0 0 0 0 12 0 RB JJ NN NN : O
N((4)S) N((4)S) 1 1 0 0 0 0 0 1 7 0 JJ NN NN : JJ O
+ + 0 0 0 0 0 0 0 0 1 0 NN NN : JJ NN O
CH(X(2)Πr) CH(X(2)Πr) 1 0 0 0 0 0 0 1 10 0 NN : JJ NN VBP O
reaction reaction 0 0 0 0 0 0 0 0 8 0 : JJ NN VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 JJ NN VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBP VBN VBN IN O
measured measured 0 0 0 0 0 0 0 0 8 0 VBP VBN VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ JJ O
continuous continuous 0 0 0 0 0 0 0 0 10 0 IN DT JJ JJ NN O
supersonic supersonic 0 0 0 0 0 0 0 0 10 0 DT JJ JJ NN NN O
flow flow 0 0 0 0 0 0 0 0 4 0 JJ JJ NN NN IN O
reactor reactor 0 0 0 0 0 0 0 0 7 0 JJ NN NN IN DT O
over over 0 0 0 0 0 0 0 0 4 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN CD O
range range 0 0 0 0 0 0 0 0 5 0 IN DT NN CD NNP O
56 56 0 0 0 0 0 0 1 1 2 0 DT NN CD NNP NNP O
K K 1 1 0 0 0 0 0 0 1 0 NN CD NNP NNP CD O
≤T≤ ≤T≤ 0 1 0 0 0 0 0 0 3 0 CD NNP NNP CD NNP O
296 296 0 0 0 0 0 0 1 1 3 0 NNP NNP CD NNP NN O
K K 1 1 0 0 0 0 0 0 1 0 NNP CD NNP NN DT O
using using 0 0 0 0 0 0 0 0 5 0 CD NNP NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT JJ NN O
relative relative 0 0 0 0 0 0 0 0 8 0 NN DT JJ NN NN O
rate rate 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN VBG O
technique technique 0 0 0 0 0 0 0 0 9 0 JJ NN NN VBG DT O
employing employing 0 0 0 0 0 0 0 0 9 0 NN NN VBG DT DT O
both both 0 0 0 0 0 0 0 0 4 0 NN VBG DT DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBG DT DT NNP NNP O
N((4)S) N((4)S) 1 1 0 0 0 0 0 1 7 0 DT DT NNP NNP NNP O
+ + 0 0 0 0 0 0 0 0 1 0 DT NNP NNP NNP CC O
OH(X(2)Πi) OH(X(2)Πi) 1 0 0 0 0 0 0 1 10 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
N((4)S) N((4)S) 1 1 0 0 0 0 0 1 7 0 NNP CC NNP NNP NNP O
+ + 0 0 0 0 0 0 0 0 1 0 CC NNP NNP NNP NNS O
CN(X(2)Σ(+)) CN(X(2)Σ(+)) 1 1 0 0 0 0 0 1 12 0 NNP NNP NNP NNS IN O
reactions reactions 0 0 0 0 0 0 0 0 9 0 NNP NNP NNS IN NNP O
as as 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NNP NNP O
references. references. 0 0 0 0 0 0 0 0 11 0 NNS IN NNP NNP NNS O
Excess Excess 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNS IN O
concentrations concentrations 0 0 0 0 0 0 0 0 14 0 NNP NNP NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN JJ NN O
atomic atomic 0 0 0 0 0 0 0 0 6 0 NNS IN JJ NN VBD O
nitrogen nitrogen 0 0 0 0 0 0 0 0 8 0 IN JJ NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NN VBD VBN IN O
produced produced 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NN O
microwave microwave 0 0 0 0 0 0 0 0 9 0 IN DT NN NN NN O
discharge discharge 0 0 0 0 0 0 0 0 9 0 DT NN NN NN NN O
method method 0 0 0 0 0 0 0 0 6 0 NN NN NN NN IN O
upstream upstream 0 0 0 0 0 0 0 0 8 0 NN NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
Laval Laval 1 0 0 0 0 0 0 0 5 0 IN DT NNP NN CC O
nozzle nozzle 0 0 0 0 0 0 0 0 6 0 DT NNP NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NNP CC O
CH CH 1 1 0 0 0 0 0 0 2 0 NN CC NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC NNP NNS O
OH OH 1 1 0 0 0 0 0 0 2 0 NNP CC NNP NNS VBD O
radicals radicals 0 0 0 0 0 0 0 0 8 0 CC NNP NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD VBN IN O
created created 0 0 0 0 0 0 0 0 7 0 NNS VBD VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT IN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN DT IN NN VBN O
situ situ 0 0 0 0 0 0 0 0 4 0 DT IN NN VBN NN O
pulsed pulsed 0 0 0 0 0 0 0 0 6 0 IN NN VBN NN NN O
laser laser 0 0 0 0 0 0 0 0 5 0 NN VBN NN NN IN O
photolysis photolysis 0 0 0 0 0 0 0 0 10 0 VBN NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
suitable suitable 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN NNP O
precursor precursor 0 0 0 0 0 0 0 0 9 0 IN JJ NN NNP NNP O
molecules. molecules. 0 0 0 0 0 0 0 0 10 0 JJ NN NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NNP NN O
parallel, parallel, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP NN NNS O
quantum quantum 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NNS NNS O
dynamics dynamics 0 0 0 0 0 0 0 0 8 0 NNP NN NNS NNS IN O
calculations calculations 0 0 0 0 0 0 0 0 12 0 NN NNS NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNS NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
title title 0 0 0 0 0 0 0 0 5 0 IN DT NN NN VBP O
reaction reaction 0 0 0 0 0 0 0 0 8 0 DT NN NN VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NN NN VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBP VBN VBN VBN O
performed performed 0 0 0 0 0 0 0 0 9 0 VBP VBN VBN VBN IN O
based based 0 0 0 0 0 0 0 0 5 0 VBN VBN VBN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 VBN VBN IN JJ JJ O
accurate accurate 0 0 0 0 0 0 0 0 8 0 VBN IN JJ JJ JJ O
global global 0 0 0 0 0 0 0 0 6 0 IN JJ JJ JJ NN O
potential potential 0 0 0 0 0 0 0 0 9 0 JJ JJ JJ NN NNS O
energy energy 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NNS IN O
surfaces surfaces 0 0 0 0 0 0 0 0 8 0 JJ NN NNS IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN DT CD O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT CD CC O
1(3)A' 1(3)A' 0 1 0 0 0 1 0 1 6 0 IN DT CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 DT CD CC CD NNS O
1(3)A'' 1(3)A'' 0 1 0 0 0 1 0 1 7 0 CD CC CD NNS IN O
states states 0 0 0 0 0 0 0 0 6 0 CC CD NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN NNP CC O
HCN HCN 1 1 0 0 0 0 0 0 3 0 NNS IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP VBD O
HNC, HNC, 1 1 0 0 1 0 0 0 4 0 NNP CC NNP VBD IN O
brought brought 0 0 0 0 0 0 0 0 7 0 CC NNP VBD IN IN O
about about 0 0 0 0 0 0 0 0 5 0 NNP VBD IN IN DT O
through through 0 0 0 0 0 0 0 0 7 0 VBD IN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 IN IN DT JJ NN O
hierarchical hierarchical 0 0 0 0 0 0 0 0 12 0 IN DT JJ NN NNP O
construction construction 0 0 0 0 0 0 0 0 12 0 DT JJ NN NNP NNP O
scheme. scheme. 0 0 0 0 0 0 0 0 7 0 JJ NN NNP NNP JJ O
Both Both 1 0 0 0 0 0 0 0 4 0 NN NNP NNP JJ JJ O
adiabatic adiabatic 0 0 0 0 0 0 0 0 9 0 NNP NNP JJ JJ NN O
potential potential 0 0 0 0 0 0 0 0 9 0 NNP JJ JJ NN NNS O
energy energy 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NNS VBP O
surfaces surfaces 0 0 0 0 0 0 0 0 8 0 JJ NN NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NN NNS VBP JJ DT O
barrierless, barrierless, 0 0 0 0 1 0 0 0 12 0 NNS VBP JJ DT CD O
each each 0 0 0 0 0 0 0 0 4 0 VBP JJ DT CD VBG O
one one 0 0 0 0 0 0 0 0 3 0 JJ DT CD VBG CD O
having having 0 0 0 0 0 0 0 0 6 0 DT CD VBG CD JJ O
two two 0 0 0 0 0 0 0 0 3 0 CD VBG CD JJ JJ O
deep deep 0 0 0 0 0 0 0 0 4 0 VBG CD JJ JJ NNS O
potential potential 0 0 0 0 0 0 0 0 9 0 CD JJ JJ NNS VBG O
wells wells 0 0 0 0 0 0 0 0 5 0 JJ JJ NNS VBG IN O
suggesting suggesting 0 0 0 0 0 0 0 0 10 0 JJ NNS VBG IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBG IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 VBG IN DT NN VBZ O
reaction reaction 0 0 0 0 0 0 0 0 8 0 IN DT NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ VBN IN O
dominated dominated 0 0 0 0 0 0 0 0 9 0 NN VBZ VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NNP O
complex-forming complex-forming 0 0 1 0 0 0 0 0 15 0 IN DT JJ NNP NNP O
mechanism. mechanism. 0 0 0 0 0 0 0 0 10 0 DT JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN CC O
experimental experimental 0 0 0 0 0 0 0 0 12 0 NNP NNP NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC JJ NN O
theoretical theoretical 0 0 0 0 0 0 0 0 11 0 NN CC JJ NN VBP O
work work 0 0 0 0 0 0 0 0 4 0 CC JJ NN VBP IN O
are are 0 0 0 0 0 0 0 0 3 0 JJ NN VBP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN VBP IN NN NN O
excellent excellent 0 0 0 0 0 0 0 0 9 0 VBP IN NN NN VBG O
agreement, agreement, 0 0 0 0 1 0 0 0 10 0 IN NN NN VBG DT O
predicting predicting 0 0 0 0 0 0 0 0 10 0 NN NN VBG DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBG DT JJ NN O
positive positive 0 0 0 0 0 0 0 0 8 0 VBG DT JJ NN NN O
temperature temperature 0 0 0 0 0 0 0 0 11 0 DT JJ NN NN IN O
dependence dependence 0 0 0 0 0 0 0 0 10 0 JJ NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
rate rate 0 0 0 0 0 0 0 0 4 0 IN DT NN NN IN O
constant, constant, 0 0 0 0 1 0 0 0 9 0 DT NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN TO O
contrast contrast 0 0 0 0 0 0 0 0 8 0 NN IN NN TO JJR O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO JJR JJ O
earlier earlier 0 0 0 0 0 0 0 0 7 0 NN TO JJR JJ NN O
experimental experimental 0 0 0 0 0 0 0 0 12 0 TO JJR JJ NN IN O
work work 0 0 0 0 0 0 0 0 4 0 JJR JJ NN IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNP O
low low 0 0 0 0 0 0 0 0 3 0 NN IN JJ NNP NNP O
temperature. temperature. 0 0 0 0 0 0 0 0 12 0 IN JJ NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ JJ O
new new 0 0 0 0 0 0 0 0 3 0 IN DT JJ JJ NN O
low low 0 0 0 0 0 0 0 0 3 0 DT JJ JJ NN NN O
temperature temperature 0 0 0 0 0 0 0 0 11 0 JJ JJ NN NN NNS O
rate rate 0 0 0 0 0 0 0 0 4 0 JJ NN NN NNS IN O
constants constants 0 0 0 0 0 0 0 0 9 0 NN NN NNS IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NNP O
interstellar interstellar 0 0 0 0 0 0 0 0 12 0 NNS IN JJ NNP NN O
N2 N2 1 1 0 0 0 0 0 1 2 0 IN JJ NNP NN VBP O
formation formation 0 0 0 0 0 0 0 0 9 0 JJ NNP NN VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NNP NN VBP VBN VBG O
tested tested 0 0 0 0 0 0 0 0 6 0 NN VBP VBN VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 VBP VBN VBG DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN VBG DT NN NN O
dense dense 0 0 0 0 0 0 0 0 5 0 VBG DT NN NN NN O
cloud cloud 0 0 0 0 0 0 0 0 5 0 DT NN NN NN NN O
model, model, 0 0 0 0 1 0 0 0 6 0 NN NN NN NN NNP O
yielding yielding 0 0 0 0 0 0 0 0 8 0 NN NN NN NNP NNS O
N2 N2 1 1 0 0 0 0 0 1 2 0 NN NN NNP NNS CD O
abundances abundances 0 0 0 0 0 0 0 0 10 0 NN NNP NNS CD JJR O
10-20% 10-20% 0 0 1 0 0 0 0 1 6 0 NNP NNS CD JJR IN O
lower lower 0 0 0 0 0 0 0 0 5 0 NNS CD JJR IN RB O
than than 0 0 0 0 0 0 0 0 4 0 CD JJR IN RB NNP O
previously previously 0 0 0 0 0 0 0 0 10 0 JJR IN RB NNP NONE O
predicted. predicted. 0 0 0 0 0 0 0 0 10 0 IN RB NNP NONE NONE O
A A 1 1 0 0 0 0 0 0 1 0 NONE NONE DT NNP NNP O
Glutamate Glutamate 1 0 0 0 0 0 0 0 9 0 NONE DT NNP NNP NNP O
Receptor Receptor 1 0 0 0 0 0 0 0 8 0 DT NNP NNP NNP NNP O
Antagonist, Antagonist, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
S-4-Carboxyphenylglycine S-4-Carboxyphenylglycine 1 0 1 0 0 0 0 1 24 0 NNP NNP NNP NNP NNP O
(S-4-CPG), (S-4-CPG), 0 1 1 0 1 0 0 1 10 0 NNP NNP NNP NNP NNP O
Inhibits Inhibits 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Vasospasm Vasospasm 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
After After 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Subarachnoid Subarachnoid 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP IN O
Hemorrhage Hemorrhage 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CD O
Haptoglobin Haptoglobin 1 0 0 0 0 0 0 0 11 0 NNP IN NNP CD NNP O
2-2 2-2 0 0 1 0 0 0 0 1 3 0 IN NNP CD NNP NNP O
Mice. Mice. 1 0 0 0 0 0 0 0 5 0 NNP CD NNP NNP NNP O
Garzon-Muvdi Garzon-Muvdi 1 0 1 0 0 0 0 0 12 0 CD NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Pradilla Pradilla 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ruzevick Ruzevick 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
JJ, JJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Bender Bender 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Edwards Edwards 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Grossman Grossman 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhao Zhao 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Rudek Rudek 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
MA, MA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Riggins Riggins 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Levy Levy 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tamargo Tamargo 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
RJ. RJ. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP JJ O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP JJ IN O
1Department 1Department 0 0 0 0 0 0 0 1 11 0 NNP NNP JJ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP JJ IN JJ CD O
Neurosurgery, Neurosurgery, 1 0 0 0 1 0 0 0 13 0 JJ IN JJ CD JJ O
2Oncology 2Oncology 0 0 0 0 0 0 0 1 9 0 IN JJ CD JJ NN O
Center-Chemical Center-Chemical 1 0 1 0 0 0 0 0 15 0 JJ CD JJ NN DT O
Therapeutics, Therapeutics, 1 0 0 0 1 0 0 0 13 0 CD JJ NN DT NNP O
The The 1 0 0 0 0 0 0 0 3 0 JJ NN DT NNP NNP O
Johns Johns 1 0 0 0 0 0 0 0 5 0 NN DT NNP NNP NNP O
Hopkins Hopkins 1 0 0 0 0 0 0 0 7 0 DT NNP NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Baltimore, Baltimore, 1 0 0 0 1 0 0 0 10 0 IN NNP NNP NNP CD O
MD MD 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
3Technion 3Technion 0 0 0 0 0 0 0 1 9 0 NNP NNP CD NNP IN O
Faculty Faculty 1 0 0 0 0 0 0 0 7 0 NNP CD NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CD NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Technion-Israel Technion-Israel 1 0 1 0 0 0 0 0 15 0 IN NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Technology, Technology, 1 0 0 0 1 0 0 0 11 0 NNP IN NNP NNP NNP O
Haifa, Haifa, 1 0 0 0 1 0 0 0 6 0 IN NNP NNP NNP NNP O
Israel. Israel. 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND:: BACKGROUND:: 1 1 0 0 0 0 0 0 12 0 NNP NNP NNP NNP VBZ O
Vasospasm Vasospasm 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP VBZ TO O
contributes contributes 0 0 0 0 0 0 0 0 11 0 NNP NNP VBZ TO VBN O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBZ TO VBN JJ O
delayed delayed 0 0 0 0 0 0 0 0 7 0 VBZ TO VBN JJ NN O
cerebral cerebral 0 0 0 0 0 0 0 0 8 0 TO VBN JJ NN IN O
ischemia ischemia 0 0 0 0 0 0 0 0 8 0 VBN JJ NN IN JJ O
after after 0 0 0 0 0 0 0 0 5 0 JJ NN IN JJ NN O
aneurysmal aneurysmal 0 0 0 0 0 0 0 0 10 0 NN IN JJ NN NN O
subarachnoid subarachnoid 0 0 0 0 0 0 0 0 12 0 IN JJ NN NN NNP O
hemorrhage hemorrhage 0 0 0 0 0 0 0 0 10 0 JJ NN NN NNP NNP O
(aSAH). (aSAH). 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP NNS O
Glutamate Glutamate 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NNS VB O
concentrations concentrations 0 0 0 0 0 0 0 0 14 0 NNP NNP NNS VB IN O
increase increase 0 0 0 0 0 0 0 0 8 0 NNP NNS VB IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 NNS VB IN NNP CC O
aSAH aSAH 0 0 0 0 0 0 0 0 4 0 VB IN NNP CC VB O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC VB IN O
correlate correlate 0 0 0 0 0 0 0 0 9 0 NNP CC VB IN NN O
with with 0 0 0 0 0 0 0 0 4 0 CC VB IN NN IN O
vasospasm vasospasm 0 0 0 0 0 0 0 0 9 0 VB IN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NNP O
experimental experimental 0 0 0 0 0 0 0 0 12 0 NN IN JJ NNP NNP O
SAH. SAH. 1 1 0 0 0 0 0 0 4 0 IN JJ NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NNP NN O
Hp2-2 Hp2-2 1 0 1 0 0 0 0 1 5 0 NNP NNP NNP NN VBZ O
genotype genotype 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NN VBZ VBN IN JJR O
with with 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN JJR NN O
higher higher 0 0 0 0 0 0 0 0 6 0 VBN IN JJR NN IN O
risk risk 0 0 0 0 0 0 0 0 4 0 IN JJR NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJR NN IN NN IN O
vasospasm vasospasm 0 0 0 0 0 0 0 0 9 0 NN IN NN IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 IN NN IN NNP NNP O
SAH. SAH. 1 1 0 0 0 0 0 0 4 0 NN IN NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 IN NNP NNP VBD DT O
tested tested 0 0 0 0 0 0 0 0 6 0 NNP NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN IN O
efficacy efficacy 0 0 0 0 0 0 0 0 8 0 VBD DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP DT O
S-4-CPG, S-4-CPG, 1 1 1 0 1 0 0 1 8 0 NN IN NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 IN NNP DT JJ NN O
metabotropic metabotropic 0 0 0 0 0 0 0 0 12 0 NNP DT JJ NN NN O
glutamate glutamate 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN NN O
receptor receptor 0 0 0 0 0 0 0 0 8 0 JJ NN NN NN IN O
inhibitor, inhibitor, 0 0 0 0 1 0 0 0 10 0 NN NN NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NN IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN IN O
vasospasm vasospasm 0 0 0 0 0 0 0 0 9 0 NN IN NN IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 IN NN IN NNP IN O
SAH SAH 1 1 0 0 0 0 0 0 3 0 NN IN NNP IN -NONE- O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN -NONE- CC O
Hp2-2 Hp2-2 1 0 1 0 0 0 0 1 5 0 NNP IN -NONE- CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 IN -NONE- CC -NONE- NNP O
Hp1-1 Hp1-1 1 0 1 0 0 0 0 1 5 0 -NONE- CC -NONE- NNP NNP O
mice. mice. 0 0 0 0 0 0 0 0 5 0 CC -NONE- NNP NNP NNP O
OBJECTIVE:: OBJECTIVE:: 1 1 0 0 0 0 0 0 11 0 -NONE- NNP NNP NNP VB O
To To 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VB DT O
evaluate evaluate 0 0 0 0 0 0 0 0 8 0 NNP NNP VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VB DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 VB DT NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 DT NN IN NN CC O
vasospasm vasospasm 0 0 0 0 0 0 0 0 9 0 NN IN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC JJ NNS O
neurobehavioral neurobehavioral 0 0 0 0 0 0 0 0 15 0 NN CC JJ NNS IN O
scores scores 0 0 0 0 0 0 0 0 6 0 CC JJ NNS IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 JJ NNS IN NNP IN O
SAH SAH 1 1 0 0 0 0 0 0 3 0 NNS IN NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NNP IN JJ NN O
systemic systemic 0 0 0 0 0 0 0 0 8 0 NNP IN JJ NN IN O
S-4-CPG, S-4-CPG, 1 1 1 0 1 0 0 1 8 0 IN JJ NN IN RB O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NN IN RB IN PRP$ O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN PRP$ NNP O
its its 0 0 0 0 0 0 0 0 3 0 RB IN PRP$ NNP CC O
toxicity, toxicity, 0 0 0 0 1 0 0 0 9 0 IN PRP$ NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 PRP$ NNP CC NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 NNP CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NN O
vasodilator-stimulated vasodilator-stimulated 0 0 1 0 0 0 0 0 22 0 NN IN JJ NN NN O
phosphoprotein phosphoprotein 0 0 0 0 0 0 0 0 14 0 IN JJ NN NN IN O
(VASP) (VASP) 0 1 0 0 0 0 0 0 6 0 JJ NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP CD O
Hp Hp 1 0 0 0 0 0 0 0 2 0 NN IN NNP CD NNP O
2-2 2-2 0 0 1 0 0 0 0 1 3 0 IN NNP CD NNP NNP O
mice. mice. 0 0 0 0 0 0 0 0 5 0 NNP CD NNP NNP NNP O
METHODS:: METHODS:: 1 1 0 0 0 0 0 0 9 0 CD NNP NNP NNP NN O
Western Western 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NN VBD O
blot blot 0 0 0 0 0 0 0 0 4 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 NN VBD VBN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO NN NNS O
assess assess 0 0 0 0 0 0 0 0 6 0 VBN TO NN NNS IN O
changes changes 0 0 0 0 0 0 0 0 7 0 TO NN NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP NN O
VASP VASP 1 1 0 0 0 0 0 0 4 0 NNS IN NNP NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 IN NNP NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN TO O
response response 0 0 0 0 0 0 0 0 8 0 NN IN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB IN O
glutamate glutamate 0 0 0 0 0 0 0 0 9 0 NN TO VB IN CC O
with with 0 0 0 0 0 0 0 0 4 0 TO VB IN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 VB IN CC IN NNP O
without without 0 0 0 0 0 0 0 0 7 0 IN CC IN NNP DT O
S-4-CPG. S-4-CPG. 1 1 1 0 0 0 0 1 8 0 CC IN NNP DT NN O
A A 1 1 0 0 0 0 0 0 1 0 IN NNP DT NN NN O
pharmacokinetics pharmacokinetics 0 0 0 0 0 0 0 0 16 0 NNP DT NN NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 DT NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN TO O
done done 0 0 0 0 0 0 0 0 4 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB JJ O
evaluate evaluate 0 0 0 0 0 0 0 0 8 0 VBN TO VB JJ NN O
S-4-CPG S-4-CPG 1 1 1 0 0 0 0 1 7 0 TO VB JJ NN IN O
penetration penetration 0 0 0 0 0 0 0 0 11 0 VB JJ NN IN DT O
through through 0 0 0 0 0 0 0 0 7 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
blood blood 0 0 0 0 0 0 0 0 5 0 IN DT NN NN NN O
brain brain 0 0 0 0 0 0 0 0 5 0 DT NN NN NN NN O
barrier barrier 0 0 0 0 0 0 0 0 7 0 NN NN NN NN IN O
(BBB) (BBB) 0 1 0 0 0 0 0 0 5 0 NN NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
vivo. vivo. 0 0 0 0 0 0 0 0 5 0 NN IN NNP NNP VBD O
Toxicity Toxicity 1 0 0 0 0 0 0 0 8 0 IN NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
assessed assessed 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN VBG O
administering administering 0 0 0 0 0 0 0 0 13 0 VBN IN NN VBG JJ O
escalating escalating 0 0 0 0 0 0 0 0 10 0 IN NN VBG JJ NNP O
S-4-CPG S-4-CPG 1 1 1 0 0 0 0 1 7 0 NN VBG JJ NNP NNP O
doses. doses. 0 0 0 0 0 0 0 0 6 0 VBG JJ NNP NNP IN O
Efficacy Efficacy 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ VBN O
S-4-CPG S-4-CPG 1 1 1 0 0 0 0 1 7 0 NNP IN JJ VBN DT O
assessed assessed 0 0 0 0 0 0 0 0 8 0 IN JJ VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ VBN DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 VBN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ IN O
S-4-CPG S-4-CPG 1 1 1 0 0 0 0 1 7 0 NN IN JJ IN NNS O
on on 0 0 0 0 0 0 0 0 2 0 IN JJ IN NNS NN O
lumen lumen 0 0 0 0 0 0 0 0 5 0 JJ IN NNS NN IN O
patency patency 0 0 0 0 0 0 0 0 7 0 IN NNS NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNS NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
basilar basilar 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN CC O
artery artery 0 0 0 0 0 0 0 0 6 0 DT JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NN O
animal animal 0 0 0 0 0 0 0 0 6 0 NN CC JJ NN IN O
behavior behavior 0 0 0 0 0 0 0 0 8 0 CC JJ NN IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 JJ NN IN NNP IN O
SAH SAH 1 1 0 0 0 0 0 0 3 0 NN IN NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP CD O
Hp Hp 1 0 0 0 0 0 0 0 2 0 NNP IN NNP CD CC O
1-1 1-1 0 0 1 0 0 0 0 1 3 0 IN NNP CD CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP CD CC NNP CD O
Hp Hp 1 0 0 0 0 0 0 0 2 0 CD CC NNP CD NNP O
2-2 2-2 0 0 1 0 0 0 0 1 3 0 CC NNP CD NNP NNP O
mice. mice. 0 0 0 0 0 0 0 0 5 0 NNP CD NNP NNP VBD O
Immunohistochemistry Immunohistochemistry 1 0 0 0 0 0 0 0 20 0 CD NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 NNP VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB DT O
evaluate evaluate 0 0 0 0 0 0 0 0 8 0 VBN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
presence presence 0 0 0 0 0 0 0 0 8 0 VB DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS VBG O
neutrophils neutrophils 0 0 0 0 0 0 0 0 11 0 NN IN NNS VBG DT O
surrounding surrounding 0 0 0 0 0 0 0 0 11 0 IN NNS VBG DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBG DT JJ NN O
basilar basilar 0 0 0 0 0 0 0 0 7 0 VBG DT JJ NN IN O
artery artery 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 JJ NN IN NNP NNP O
SAH. SAH. 1 1 0 0 0 0 0 0 4 0 NN IN NNP NNP NNP O
RESULTS:: RESULTS:: 1 1 0 0 0 0 0 0 9 0 IN NNP NNP NNP IN O
Exposure Exposure 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NNP IN JJ NN NN O
brain brain 0 0 0 0 0 0 0 0 5 0 IN JJ NN NN NN O
microvascular microvascular 0 0 0 0 0 0 0 0 13 0 JJ NN NN NN NNS O
endothelial endothelial 0 0 0 0 0 0 0 0 11 0 NN NN NN NNS TO O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO VB VBN O
glutamate glutamate 0 0 0 0 0 0 0 0 9 0 NNS TO VB VBN NN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 TO VB VBN NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 VB VBN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNP NNP O
VASP VASP 1 1 0 0 0 0 0 0 4 0 NN IN NNP NNP CC O
(p-VASP), (p-VASP), 0 0 1 0 1 0 0 0 9 0 IN NNP NNP CC JJ O
but but 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NN O
glutamate glutamate 0 0 0 0 0 0 0 0 9 0 NNP CC JJ NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 CC JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
presence presence 0 0 0 0 0 0 0 0 8 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
S-4-CPG S-4-CPG 1 1 1 0 0 0 0 1 7 0 NN IN JJ NNS NNP O
maintains maintains 0 0 0 0 0 0 0 0 9 0 IN JJ NNS NNP NNP O
p-VASP. p-VASP. 0 0 1 0 0 0 0 0 7 0 JJ NNS NNP NNP VBZ O
S-4-CPG S-4-CPG 1 1 1 0 0 0 0 1 7 0 NNS NNP NNP VBZ DT O
crosses crosses 0 0 0 0 0 0 0 0 7 0 NNP NNP VBZ DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT NNP CC O
BBB BBB 1 1 0 0 0 0 0 0 3 0 VBZ DT NNP CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NNP CC VBD RB JJ O
not not 0 0 0 0 0 0 0 0 3 0 CC VBD RB JJ TO O
toxic toxic 0 0 0 0 0 0 0 0 5 0 VBD RB JJ TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 RB JJ TO NNP NNP O
mice. mice. 0 0 0 0 0 0 0 0 5 0 JJ TO NNP NNP NN O
S-4-CPG S-4-CPG 1 1 1 0 0 0 0 1 7 0 TO NNP NNP NN RB O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NNP NNP NN RB VBZ O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNP NN RB VBZ NN O
prevents prevents 0 0 0 0 0 0 0 0 8 0 NN RB VBZ NN IN O
vasospasm vasospasm 0 0 0 0 0 0 0 0 9 0 RB VBZ NN IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 VBZ NN IN NNP NNP O
SAH. SAH. 1 1 0 0 0 0 0 0 4 0 NN IN NNP NNP VBD O
S-4-CPG S-4-CPG 1 1 1 0 0 0 0 1 7 0 IN NNP NNP VBD IN O
administered administered 0 0 0 0 0 0 0 0 12 0 NNP NNP VBD IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 NNP VBD IN NNP VBD O
SAH SAH 1 1 0 0 0 0 0 0 3 0 VBD IN NNP VBD IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 IN NNP VBD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP VBD IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBD IN DT NN NNS O
trend trend 0 0 0 0 0 0 0 0 5 0 IN DT NN NNS NN O
towards towards 0 0 0 0 0 0 0 0 7 0 DT NN NNS NN IN O
improvement improvement 0 0 0 0 0 0 0 0 11 0 NN NNS NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNS NN IN JJ NNP O
animal animal 0 0 0 0 0 0 0 0 6 0 NN IN JJ NNP NNP O
behavior. behavior. 0 0 0 0 0 0 0 0 9 0 IN JJ NNP NNP NNP O
CONCLUSION:: CONCLUSION:: 1 1 0 0 0 0 0 0 12 0 JJ NNP NNP NNP VBZ O
S-4-CPG S-4-CPG 1 1 1 0 0 0 0 1 7 0 NNP NNP NNP VBZ NN O
prevents prevents 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ NN IN O
vasospasm vasospasm 0 0 0 0 0 0 0 0 9 0 NNP VBZ NN IN JJ O
after after 0 0 0 0 0 0 0 0 5 0 VBZ NN IN JJ NNP O
experimental experimental 0 0 0 0 0 0 0 0 12 0 NN IN JJ NNP IN O
SAH SAH 1 1 0 0 0 0 0 0 3 0 IN JJ NNP IN -NONE- O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNP IN -NONE- NNP O
Hp2-2 Hp2-2 1 0 1 0 0 0 0 1 5 0 NNP IN -NONE- NNP NNP O
mice. mice. 0 0 0 0 0 0 0 0 5 0 IN -NONE- NNP NNP VBD O
S-4-CPG S-4-CPG 1 1 1 0 0 0 0 1 7 0 -NONE- NNP NNP VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD RB JJ O
not not 0 0 0 0 0 0 0 0 3 0 NNP VBD RB JJ CC O
toxic toxic 0 0 0 0 0 0 0 0 5 0 VBD RB JJ CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 RB JJ CC VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 JJ CC VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 CC VBZ DT JJ JJ O
potential potential 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ JJ NN O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 DT JJ JJ NN IN O
agent agent 0 0 0 0 0 0 0 0 5 0 JJ JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN IN O
vasospasm vasospasm 0 0 0 0 0 0 0 0 9 0 NN IN NN IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 IN NN IN NNP NONE O
SAH. SAH. 1 1 0 0 0 0 0 0 4 0 NN IN NNP NONE NONE O
Transmission Transmission 1 0 0 0 0 0 0 0 12 0 NONE NONE NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN CD CD O
8 8 0 0 0 0 0 0 1 1 1 0 NN IN CD CD CD O
× × 0 0 0 0 0 0 0 0 1 0 IN CD CD CD JJ O
480-Gb/s 480-Gb/s 0 0 1 1 0 0 0 1 8 0 CD CD CD JJ CD O
super-Nyquist-filtering super-Nyquist-filtering 0 0 1 0 0 0 0 0 23 0 CD CD JJ CD JJ O
9-QAM-like 9-QAM-like 0 0 1 0 0 0 0 1 10 0 CD JJ CD JJ IN O
signal signal 0 0 0 0 0 0 0 0 6 0 JJ CD JJ IN CD O
at at 0 0 0 0 0 0 0 0 2 0 CD JJ IN CD JJ O
100 100 0 0 0 0 0 0 1 1 3 0 JJ IN CD JJ IN O
GHz-grid GHz-grid 1 0 1 0 0 0 0 0 8 0 IN CD JJ IN CD O
over over 0 0 0 0 0 0 0 0 4 0 CD JJ IN CD -NONE- O
5000-km 5000-km 0 0 1 0 0 0 0 1 7 0 JJ IN CD -NONE- CC O
SMF-28 SMF-28 1 1 1 0 0 0 0 1 6 0 IN CD -NONE- CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 CD -NONE- CC JJ CD O
twenty-five twenty-five 0 0 1 0 0 0 0 0 11 0 -NONE- CC JJ CD JJ O
100 100 0 0 0 0 0 0 1 1 3 0 CC JJ CD JJ NNP O
GHz-grid GHz-grid 1 0 1 0 0 0 0 0 8 0 JJ CD JJ NNP NNP O
ROADMs. ROADMs. 1 0 0 0 0 0 0 0 7 0 CD JJ NNP NNP NNP O
Yu Yu 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Dong Dong 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Jia Jia 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Chien Chien 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
HC, HC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Cai Cai 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Xiao Xiao 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
X. X. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP RB O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP RB JJ O
experimentally experimentally 0 0 0 0 0 0 0 0 14 0 NNP NNP RB JJ DT O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 NNP RB JJ DT RB O
a a 0 0 0 0 0 0 0 0 1 0 RB JJ DT RB JJ O
highly highly 0 0 0 0 0 0 0 0 6 0 JJ DT RB JJ JJ O
filtering-tolerant filtering-tolerant 0 0 1 0 0 0 0 0 18 0 DT RB JJ JJ NN O
multi-modulus multi-modulus 0 0 1 0 0 0 0 0 13 0 RB JJ JJ NN NN O
equalization equalization 0 0 0 0 0 0 0 0 12 0 JJ JJ NN NN NN O
(MMEQ) (MMEQ) 0 1 0 0 0 0 0 0 6 0 JJ NN NN NN IN O
process process 0 0 0 0 0 0 0 0 7 0 NN NN NN IN RB O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN RB RB O
very very 0 0 0 0 0 0 0 0 4 0 NN IN RB RB JJ O
aggressively aggressively 0 0 0 0 0 0 0 0 12 0 IN RB RB JJ JJ O
spectrum-shaped spectrum-shaped 0 0 1 0 0 0 0 0 15 0 RB RB JJ JJ NN O
9-ary 9-ary 0 0 1 0 0 0 0 1 5 0 RB JJ JJ NN JJ O
quadrature-amplitude-modulation quadrature-amplitude-modulation 0 0 1 0 0 0 0 0 31 0 JJ JJ NN JJ NN O
(9-QAM)-like (9-QAM)-like 0 0 1 0 0 0 0 1 12 0 JJ NN JJ NN NN O
polarization polarization 0 0 0 0 0 0 0 0 12 0 NN JJ NN NN VBG O
division division 0 0 0 0 0 0 0 0 8 0 JJ NN NN VBG NN O
multiplexing multiplexing 0 0 0 0 0 0 0 0 12 0 NN NN VBG NN NN O
quadrature quadrature 0 0 0 0 0 0 0 0 10 phase NN VBG NN NN NN O
phase phase 0 0 0 0 0 0 0 0 5 0 VBG NN NN NN VBG O
shift shift 0 0 0 0 0 0 0 0 5 0 NN NN NN VBG NN O
keying keying 0 0 0 0 0 0 0 0 6 0 NN NN VBG NN NN O
(PDM-QPSK) (PDM-QPSK) 0 1 1 0 0 0 0 0 10 0 NN VBG NN NN TO O
signal signal 0 0 0 0 0 0 0 0 6 0 VBG NN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO VB CD O
achieve achieve 0 0 0 0 0 0 0 0 7 0 NN TO VB CD JJ O
400-Gb/s 400-Gb/s 0 0 1 1 0 0 0 1 8 0 TO VB CD JJ NN O
wavelength-division-multiplexing wavelength-division-multiplexing 0 0 1 0 0 0 0 0 32 0 VB CD JJ NN NNS O
(WDM) (WDM) 0 1 0 0 0 0 0 0 5 0 CD JJ NN NNS IN O
channels channels 0 0 0 0 0 0 0 0 8 0 JJ NN NNS IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT CD O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT CD NN O
100-GHz 100-GHz 0 0 1 0 0 0 0 1 7 0 IN DT CD NN IN O
grid grid 0 0 0 0 0 0 0 0 4 0 DT CD NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 CD NN IN JJ NN O
ultra-long-haul ultra-long-haul 0 0 1 0 0 0 0 0 15 0 NN IN JJ NN CC O
reach reach 0 0 0 0 0 0 0 0 5 0 IN JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 NN CC JJ NN IN O
tolerance tolerance 0 0 0 0 0 0 0 0 9 0 CC JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBG O
filter filter 0 0 0 0 0 0 0 0 6 0 IN DT NN VBG NN O
narrowing narrowing 0 0 0 0 0 0 0 0 9 0 DT NN VBG NN VBD O
effect effect 0 0 0 0 0 0 0 0 6 0 NN VBG NN VBD IN O
caused caused 0 0 0 0 0 0 0 0 6 0 VBG NN VBD IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN JJ JJ O
reconfigurable reconfigurable 0 0 0 0 0 0 0 0 14 0 VBD IN JJ JJ NN O
optical optical 0 0 0 0 0 0 0 0 7 0 IN JJ JJ NN NNS O
add-drop add-drop 0 0 1 0 0 0 0 0 8 0 JJ JJ NN NNS NNP O
multiplexers multiplexers 0 0 0 0 0 0 0 0 12 0 JJ NN NNS NNP NNP O
(ROADMs). (ROADMs). 0 0 0 0 0 0 0 0 9 0 NN NNS NNP NNP RB O
We We 1 0 0 0 0 0 0 0 2 0 NNS NNP NNP RB VBN O
successfully successfully 0 0 0 0 0 0 0 0 12 0 NNP NNP RB VBN CD O
transmitted transmitted 0 0 0 0 0 0 0 0 11 0 NNP RB VBN CD NNS O
8 8 0 0 0 0 0 0 1 1 1 0 RB VBN CD NNS CD O
channels channels 0 0 0 0 0 0 0 0 8 0 VBN CD NNS CD JJ O
480-Gb/s 480-Gb/s 0 0 1 1 0 0 0 1 8 0 CD NNS CD JJ JJ O
super-Nyquist super-Nyquist 0 0 1 0 0 0 0 0 13 0 NNS CD JJ JJ NN O
(channel (channel 0 0 0 0 0 0 0 0 8 0 CD JJ JJ NN RB O
occupancy occupancy 0 0 0 0 0 0 0 0 9 0 JJ JJ NN RB JJR O
much much 0 0 0 0 0 0 0 0 4 0 JJ NN RB JJR IN O
less less 0 0 0 0 0 0 0 0 4 0 NN RB JJR IN JJ O
than than 0 0 0 0 0 0 0 0 4 0 RB JJR IN JJ NN O
signal signal 0 0 0 0 0 0 0 0 6 0 JJR IN JJ NN NN O
baud baud 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN NNP O
rate) rate) 0 0 0 0 0 0 0 0 5 0 JJ NN NN NNP NNS O
WDM WDM 1 1 0 0 0 0 0 0 3 0 NN NN NNP NNS IN O
signals signals 0 0 0 0 0 0 0 0 7 0 NN NNP NNS IN CD O
at at 0 0 0 0 0 0 0 0 2 0 NNP NNS IN CD JJ O
100-GHz 100-GHz 0 0 1 0 0 0 0 1 7 0 NNS IN CD JJ IN O
grid grid 0 0 0 0 0 0 0 0 4 0 IN CD JJ IN CD O
over over 0 0 0 0 0 0 0 0 4 0 CD JJ IN CD CD O
25 25 0 0 0 0 0 0 1 1 2 0 JJ IN CD CD CD O
× × 0 0 0 0 0 0 0 0 1 0 IN CD CD CD NN O
200 200 0 0 0 0 0 0 1 1 3 0 CD CD CD NN JJ O
km km 0 0 0 0 0 0 0 0 2 0 CD CD NN JJ NN O
conventional conventional 0 0 0 0 0 0 0 0 12 0 CD NN JJ NN -NONE- O
single-mode single-mode 0 0 1 0 0 0 0 0 11 0 NN JJ NN -NONE- -NONE- O
fiber-28 fiber-28 0 0 1 0 0 0 0 1 8 0 JJ NN -NONE- -NONE- IN O
(SMF-28) (SMF-28) 0 1 1 0 0 0 0 1 8 0 NN -NONE- -NONE- IN NN O
with with 0 0 0 0 0 0 0 0 4 0 -NONE- -NONE- IN NN NNP O
post post 0 0 0 0 0 0 0 0 4 0 -NONE- IN NN NNP NN O
Raman Raman 1 0 0 0 0 0 0 0 5 0 IN NN NNP NN CC O
amplification amplification 0 0 0 0 0 0 0 0 13 0 NN NNP NN CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC CD NNP O
25 25 0 0 0 0 0 0 1 1 2 0 NN CC CD NNP IN O
ROADMs ROADMs 1 0 0 0 0 0 0 0 6 0 CC CD NNP IN DT O
at at 0 0 0 0 0 0 0 0 2 0 CD NNP IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT JJ JJ O
net net 0 0 0 0 0 0 0 0 3 0 IN DT JJ JJ NN O
spectral spectral 0 0 0 0 0 0 0 0 8 0 DT JJ JJ NN NN O
efficiency efficiency 0 0 0 0 0 0 0 0 10 0 JJ JJ NN NN IN O
(SE) (SE) 0 1 0 0 0 0 0 0 4 0 JJ NN NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN CD IN O
4b/s/Hz, 4b/s/Hz, 0 0 0 1 1 0 0 1 8 0 NN IN CD IN VBG O
after after 0 0 0 0 0 0 0 0 5 0 IN CD IN VBG DT O
excluding excluding 0 0 0 0 0 0 0 0 9 0 CD IN VBG DT CD O
the the 0 0 0 0 0 0 0 0 3 0 IN VBG DT CD NN O
20% 20% 0 0 0 0 0 0 0 1 3 0 VBG DT CD NN NN O
soft-decision soft-decision 0 0 1 0 0 0 0 0 13 0 DT CD NN NN NN O
forward-error-correction forward-error-correction 0 0 1 0 0 0 0 0 24 0 CD NN NN NN NNP O
(FEC) (FEC) 0 1 0 0 0 0 0 0 5 0 NN NN NN NNP NNP O
overhead. overhead. 0 0 0 0 0 0 0 0 9 0 NN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN NN O
system system 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NN VBZ O
performance performance 0 0 0 0 0 0 0 0 11 0 NNP NN NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NN VBZ RB VBN IN O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 VBZ RB VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 RB VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP VBN O
MMEQ MMEQ 1 1 0 0 0 0 0 0 4 0 IN DT NNP VBN IN O
based based 0 0 0 0 0 0 0 0 5 0 DT NNP VBN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 NNP VBN IN JJ NNS O
9-QAM-like 9-QAM-like 0 0 1 0 0 0 0 1 10 0 VBN IN JJ NNS VBN O
constellations constellations 0 0 0 0 0 0 0 0 14 0 IN JJ NNS VBN TO O
compared compared 0 0 0 0 0 0 0 0 8 0 JJ NNS VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBN TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN TO DT JJ CD O
conventional conventional 0 0 0 0 0 0 0 0 12 0 TO DT JJ CD NN O
4 4 0 0 0 0 0 0 1 1 1 0 DT JJ CD NN NNP O
point point 0 0 0 0 0 0 0 0 5 0 JJ CD NN NNP NNP O
QPSK QPSK 1 1 0 0 0 0 0 0 4 0 CD NN NNP NNP NNP O
constellation. constellation. 0 0 0 0 0 0 0 0 14 0 NN NNP NNP NNP NN O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NN NN O
record record 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NN NN O
transmission transmission 0 0 0 0 0 0 0 0 12 0 NNP NN NN NN IN O
distance distance 0 0 0 0 0 0 0 0 8 0 NN NN NN IN JJ O
over over 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ NN O
conventional conventional 0 0 0 0 0 0 0 0 12 0 NN IN JJ NN IN O
SMF-28 SMF-28 1 1 1 0 0 0 0 1 6 0 IN JJ NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
large large 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN IN O
number number 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP VBZ O
ROADMs ROADMs 1 0 0 0 0 0 0 0 6 0 NN IN NNP VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ RB VBN O
firstly firstly 0 0 0 0 0 0 0 0 7 0 NNP VBZ RB VBN IN O
reported reported 0 0 0 0 0 0 0 0 8 0 VBZ RB VBN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 RB VBN IN DT CD O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT CD NNS O
400-Gb/s 400-Gb/s 0 0 1 1 0 0 0 1 8 0 IN DT CD NNS IN O
channels channels 0 0 0 0 0 0 0 0 8 0 DT CD NNS IN CD O
at at 0 0 0 0 0 0 0 0 2 0 CD NNS IN CD NNP O
100-GHz 100-GHz 0 0 1 0 0 0 0 1 7 0 NNS IN CD NNP NONE O
grid. grid. 0 0 0 0 0 0 0 0 5 0 IN CD NNP NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 NONE DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 NN IN NN NN NNP B_TIMEXCCP
spindle spindle 0 0 0 0 0 0 0 0 7 0 IN NN NN NNP NNP O
elongation. elongation. 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP NNP O
Cande Cande 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP NNP O
WZ, WZ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Hogan Hogan 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
CJ. CJ. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
At At 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NN VBZ O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBZ NN B_TIMEXCCP
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 NNP NN VBZ NN TO O
move move 0 0 0 0 0 0 0 0 4 0 NN VBZ NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBZ NN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT NN NNS O
spindle spindle 0 0 0 0 0 0 0 0 7 0 TO DT NN NNS JJ O
poles poles 0 0 0 0 0 0 0 0 5 0 DT NN NNS JJ NN O
(anaphase (anaphase 0 0 0 0 0 0 0 0 9 0 NN NNS JJ NN CC O
A) A) 1 1 0 0 0 0 0 0 2 0 NNS JJ NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN NNS O
spindle spindle 0 0 0 0 0 0 0 0 7 0 CC DT NN NNS VB O
poles poles 0 0 0 0 0 0 0 0 5 0 DT NN NNS VB NN O
move move 0 0 0 0 0 0 0 0 4 0 NN NNS VB NN NN O
apart apart 0 0 0 0 0 0 0 0 5 0 NNS VB NN NN NNP O
(anaphase (anaphase 0 0 0 0 0 0 0 0 9 0 VB NN NN NNP NNP O
B). B). 1 1 0 0 0 0 0 0 3 0 NN NN NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NN NNS O
vitro vitro 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NNS VBG O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP NN NNS VBG VBN O
using using 0 0 0 0 0 0 0 0 5 0 NN NNS VBG VBN NN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 NNS VBG VBN NN NNS O
diatom diatom 0 0 0 0 0 0 0 0 6 0 VBG VBN NN NNS VBP O
spindles spindles 0 0 0 0 0 0 0 0 8 0 VBN NN NNS VBP IN O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 NN NNS VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT JJ JJ O
primary primary 0 0 0 0 0 0 0 0 7 0 IN DT JJ JJ NN O
mechanochemical mechanochemical 0 0 0 0 0 0 0 0 15 0 DT JJ JJ NN JJ O
event event 0 0 0 0 0 0 0 0 5 0 JJ JJ NN JJ IN O
responsible responsible 0 0 0 0 0 0 0 0 11 0 JJ NN JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NN JJ IN NN NN O
spindle spindle 0 0 0 0 0 0 0 0 7 0 JJ IN NN NN VBZ O
elongation elongation 0 0 0 0 0 0 0 0 10 0 IN NN NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT NN NN O
sliding sliding 0 0 0 0 0 0 0 0 7 0 VBZ DT NN NN IN O
apart apart 0 0 0 0 0 0 0 0 5 0 DT NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNP O
half-spindle half-spindle 0 0 1 0 0 0 0 0 12 0 NN IN JJ NNP NNP O
microtubules. microtubules. 0 0 0 0 0 0 0 0 13 0 IN JJ NNP NNP DT O
Further, Further, 1 0 0 0 1 0 0 0 8 0 JJ NNP NNP DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT NNS VBP O
forces forces 0 0 0 0 0 0 0 0 6 0 NNP DT NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 DT NNS VBP VBN IN O
generated generated 0 0 0 0 0 0 0 0 9 0 NNS VBP VBN IN DT O
within within 0 0 0 0 0 0 0 0 6 0 VBP VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
zone zone 0 0 0 0 0 0 0 0 4 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
microtubule microtubule 0 0 0 0 0 0 0 0 11 0 NN IN NN NN IN O
overlap overlap 0 0 0 0 0 0 0 0 7 0 IN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
spindle spindle 0 0 0 0 0 0 0 0 7 0 IN DT NN NNP NNP O
mid-zone. mid-zone. 0 0 1 0 0 0 0 0 9 0 DT NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
2673231 2673231 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT JJ NNS O
structural structural 0 0 0 0 0 0 0 0 10 0 NONE DT JJ NNS IN O
determinants determinants 0 0 0 0 0 0 0 0 12 0 DT JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NNP O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NNS IN NN NNP NNP B_TIMEXCCP
activation. activation. 0 0 0 0 0 0 0 0 11 0 IN NN NNP NNP NNP O
MacDougall MacDougall 1 0 0 0 0 0 0 0 10 0 NN NNP NNP NNP NNP O
CA, CA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Byun Byun 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
TS, TS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Van Van 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yee Yee 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
MC, MC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Cimprich Cimprich 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
KA. KA. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Chemical Chemical 1 0 0 0 0 0 0 0 8 0 NNP IN NNP CC NNPS O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNPS NNP O
Systems Systems 1 0 0 0 0 0 0 0 7 0 NNP CC NNPS NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 CC NNPS NNP NNP NNP O
Stanford Stanford 1 0 0 0 0 0 0 0 8 0 NNPS NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Stanford, Stanford, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP CD O
California California 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP CD NNP O
94305, 94305, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP PRP O
Here, Here, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP IN O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 NNP PRP VBP IN -NONE- O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN -NONE- JJ O
primed, primed, 0 0 0 0 1 0 0 0 7 0 VBP IN -NONE- JJ NNP O
single-stranded single-stranded 0 0 1 0 0 0 0 0 15 0 IN -NONE- JJ NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 -NONE- JJ NNP NNP VBZ O
(ssDNA) (ssDNA) 0 0 0 0 0 0 0 0 7 0 JJ NNP NNP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ JJ IN O
sufficient sufficient 0 0 0 0 0 0 0 0 10 0 NNP VBZ JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 JJ IN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
ATR-dependent ATR-dependent 1 0 1 0 0 0 0 0 13 0 IN DT JJ NN NN O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 DT JJ NN NN IN B_TIMEXCCP
pathway pathway 0 0 0 0 0 0 0 0 7 0 JJ NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NN O
Xenopus Xenopus 1 0 0 0 0 0 0 0 7 0 NN IN NNP NN NNP O
egg egg 0 0 0 0 0 0 0 0 3 0 IN NNP NN NNP NNP O
extracts. extracts. 0 0 0 0 0 0 0 0 9 0 NNP NN NNP NNP DT O
Using Using 1 0 0 0 0 0 0 0 5 0 NN NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
structure, structure, 0 0 0 0 1 0 0 0 10 0 NNP DT NN PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBP DT O
define define 0 0 0 0 0 0 0 0 6 0 NN PRP VBP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBP DT NN IN O
contribution contribution 0 0 0 0 0 0 0 0 12 0 VBP DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT CD O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT CD CC O
5'- 5'- 0 0 1 0 0 1 0 1 3 0 IN DT CD CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT CD CC JJ NNS O
3'-primer 3'-primer 0 0 1 0 0 1 0 1 9 0 CD CC JJ NNS TO O
ends ends 0 0 0 0 0 0 0 0 4 0 CC JJ NNS TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO NNP NN O
Chk1 Chk1 1 0 0 0 0 0 0 1 4 0 NNS TO NNP NN WRB O
activation activation 0 0 0 0 0 0 0 0 10 0 TO NNP NN WRB NN O
when when 0 0 0 0 0 0 0 0 4 0 NNP NN WRB NN VBZ O
replication replication 0 0 0 0 0 0 0 0 11 0 NN WRB NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 WRB NN VBZ VBN CC O
blocked blocked 0 0 0 0 0 0 0 0 7 0 NN VBZ VBN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VBZ VBN CC NNP NNP O
ongoing. ongoing. 0 0 0 0 0 0 0 0 8 0 VBN CC NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 CC NNP NNP NNP PRP O
addition, addition, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NNP PRP VBP IN IN O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN IN NNP O
although although 0 0 0 0 0 0 0 0 8 0 VBP IN IN NNP VBZ O
ssDNA ssDNA 0 0 0 0 0 0 0 0 5 0 IN IN NNP VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ RB JJ O
not not 0 0 0 0 0 0 0 0 3 0 NNP VBZ RB JJ IN O
sufficient sufficient 0 0 0 0 0 0 0 0 10 0 VBZ RB JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 RB JJ IN NN -NONE- O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 JJ IN NN -NONE- DT B_TIMEXCCP
activation, activation, 0 0 0 0 1 0 0 0 11 0 IN NN -NONE- DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN -NONE- DT NN IN O
amount amount 0 0 0 0 0 0 0 0 6 0 -NONE- DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NN O
ssDNA ssDNA 0 0 0 0 0 0 0 0 5 0 NN IN NNP NN TO O
adjacent adjacent 0 0 0 0 0 0 0 0 8 0 IN NNP NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT NN NNS O
primer primer 0 0 0 0 0 0 0 0 6 0 TO DT NN NNS DT O
influences influences 0 0 0 0 0 0 0 0 10 0 DT NN NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NNS DT NN IN O
level level 0 0 0 0 0 0 0 0 5 0 NNS DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
Chk1 Chk1 1 0 0 0 0 0 0 1 4 0 NN IN NNP NNP NNP O
phosphorylation. phosphorylation. 0 0 0 0 0 0 0 0 16 0 IN NNP NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNS VBP O
observations observations 0 0 0 0 0 0 0 0 12 0 NNP NNP NNS VBP DT O
define define 0 0 0 0 0 0 0 0 6 0 NNP NNS VBP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBP DT JJ NNP O
minimal minimal 0 0 0 0 0 0 0 0 7 0 VBP DT JJ NNP NNS O
DNA DNA 1 1 0 0 0 0 0 0 3 0 DT JJ NNP NNS IN O
requirements requirements 0 0 0 0 0 0 0 0 12 0 JJ NNP NNS IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNS IN NN NN O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NNS IN NN NN CC B_TIMEXCCP
activation activation 0 0 0 0 0 0 0 0 10 0 IN NN NN CC VBP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NN CC VBP IN VBN O
that that 0 0 0 0 0 0 0 0 4 0 CC VBP IN VBN NNP O
primed primed 0 0 0 0 0 0 0 0 6 0 VBP IN VBN NNP NNS O
ssDNA ssDNA 0 0 0 0 0 0 0 0 5 0 IN VBN NNP NNS DT O
represents represents 0 0 0 0 0 0 0 0 10 0 VBN NNP NNS DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNS DT JJ NN O
common common 0 0 0 0 0 0 0 0 6 0 NNS DT JJ NN NN O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 DT JJ NN NN VBN B_TIMEXCCP
activating-structure activating-structure 0 0 1 0 0 0 0 0 20 0 JJ NN NN VBN VBG O
formed formed 0 0 0 0 0 0 0 0 6 0 NN NN VBN VBG JJ O
following following 0 0 0 0 0 0 0 0 9 0 NN VBN VBG JJ NNS O
many many 0 0 0 0 0 0 0 0 4 0 VBN VBG JJ NNS IN O
types types 0 0 0 0 0 0 0 0 5 0 VBG JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NNP O
damage. damage. 0 0 0 0 0 0 0 0 7 0 NNS IN NNP NNP IN O
Comment Comment 1 0 0 0 0 0 0 0 7 0 IN NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Single- Single- 1 0 1 0 0 0 0 0 7 0 NNP IN NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC JJ NN O
double-stranded double-stranded 0 0 1 0 0 0 0 0 15 0 NNP CC JJ NN NN O
DNA: DNA: 1 1 0 0 0 0 0 0 4 0 CC JJ NN NN DT O
building building 0 0 0 0 0 0 0 0 8 0 JJ NN NN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN NN DT NN IN O
trigger trigger 0 0 0 0 0 0 0 0 7 0 NN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
ATR-mediated ATR-mediated 1 0 1 0 0 0 0 0 12 0 NN IN JJ NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 IN JJ NNP NN NNP O
damage damage 0 0 0 0 0 0 0 0 6 0 JJ NNP NN NNP NONE O
response. response. 0 0 0 0 0 0 0 0 9 0 NNP NN NNP NONE NONE O
[Selective [Selective 0 0 0 0 0 0 0 0 10 0 NONE NONE JJ NN IN O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 NONE JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
alkaline alkaline 0 0 0 0 0 0 0 0 8 0 NN IN NN NN IN O
phosphatase phosphatase 0 0 0 0 0 0 0 0 11 0 IN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS IN O
microsomes microsomes 0 0 0 0 0 0 0 0 10 0 IN DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NNS O
human human 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NNS VBN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS VBN IN O
cultured cultured 0 0 0 0 0 0 0 0 8 0 JJ NNS VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
G0-phase G0-phase 1 0 1 0 0 0 0 1 8 0 IN DT NN IN DT B_TIMEXCCP
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NNP NNP O
cycle]. cycle]. 0 0 0 0 0 0 0 0 7 0 DT NN NNP NNP IN O
[Article [Article 0 0 0 0 0 0 0 0 8 0 NN NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Russian] Russian] 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Zgurskiĭ Zgurskiĭ 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
AA, AA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Alekseev Alekseev 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
SB, SB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Stepanova Stepanova 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
LG. LG. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN NN O
subcellular subcellular 0 0 0 0 0 0 0 0 11 0 NNP NNP NN NN IN O
distribution distribution 0 0 0 0 0 0 0 0 12 0 NNP NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
alkaline alkaline 0 0 0 0 0 0 0 0 8 0 NN IN NN NN IN O
phosphatase phosphatase 0 0 0 0 0 0 0 0 11 0 IN NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ CC O
normal normal 0 0 0 0 0 0 0 0 6 0 NN IN JJ CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC VBD VBN O
transformed transformed 0 0 0 0 0 0 0 0 11 0 JJ CC VBD VBN NN O
cultivated cultivated 0 0 0 0 0 0 0 0 10 0 CC VBD VBN NN NNS O
human human 0 0 0 0 0 0 0 0 5 0 VBD VBN NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 VBN NN NNS VBD NNP O
was was 0 0 0 0 0 0 0 0 3 0 NN NNS VBD NNP NNP O
investigated. investigated. 0 0 0 0 0 0 0 0 13 0 NNS VBD NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 VBD NNP NNP JJ NN O
total total 0 0 0 0 0 0 0 0 5 0 NNP NNP JJ NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NNP JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
alkaline alkaline 0 0 0 0 0 0 0 0 8 0 NN IN NN NN IN O
phosphatase phosphatase 0 0 0 0 0 0 0 0 11 0 IN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT VBN NNS O
transformed transformed 0 0 0 0 0 0 0 0 11 0 IN DT VBN NNS NNS O
cells cells 0 0 0 0 0 0 0 0 5 0 DT VBN NNS NNS WDT O
exceeds exceeds 0 0 0 0 0 0 0 0 7 0 VBN NNS NNS WDT IN O
that that 0 0 0 0 0 0 0 0 4 0 NNS NNS WDT IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNS WDT IN JJ NNS O
normal normal 0 0 0 0 0 0 0 0 6 0 WDT IN JJ NNS CD O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS CD JJ O
10- 10- 0 0 1 0 0 0 0 1 3 0 JJ NNS CD JJ NN O
(or (or 0 0 0 0 0 0 0 0 3 0 NNS CD JJ NN NN O
more) more) 0 0 0 0 0 0 0 0 5 0 CD JJ NN NN CC O
fold fold 0 0 0 0 0 0 0 0 4 0 JJ NN NN CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NN CC VBZ RB VBN O
sharply sharply 0 0 0 0 0 0 0 0 7 0 CC VBZ RB VBN IN O
increased increased 0 0 0 0 0 0 0 0 9 0 VBZ RB VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NN IN O
rise rise 0 0 0 0 0 0 0 0 4 0 IN DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN NNP O
population population 0 0 0 0 0 0 0 0 10 0 DT NN NN NNP NNP O
density. density. 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN NNS O
proliferating proliferating 0 0 0 0 0 0 0 0 13 0 NNP NNP NN NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NN NNS VBP DT O
have have 0 0 0 0 0 0 0 0 4 0 NN NNS VBP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBP DT JJ NN O
same same 0 0 0 0 0 0 0 0 4 0 VBP DT JJ NN NN O
specific specific 0 0 0 0 0 0 0 0 8 0 DT JJ NN NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 JJ NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
alkaline alkaline 0 0 0 0 0 0 0 0 8 0 NN IN NN NN IN O
phosphatase phosphatase 0 0 0 0 0 0 0 0 11 0 IN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ CC O
mitochondrial-lysosomal mitochondrial-lysosomal 0 0 1 0 0 0 0 0 23 0 IN DT JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC JJ NNP O
microsomal microsomal 0 0 0 0 0 0 0 0 10 0 JJ CC JJ NNP NNP O
fractions. fractions. 0 0 0 0 0 0 0 0 10 0 CC JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
transition transition 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NNS O
normal normal 0 0 0 0 0 0 0 0 6 0 NN IN JJ NNS TO O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS TO DT O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS TO DT NN IN O
G0-phase G0-phase 1 0 1 0 0 0 0 1 8 0 TO DT NN IN DT B_TIMEXCCP
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN VBZ O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ VBN IN O
accompanied accompanied 0 0 0 0 0 0 0 0 11 0 NN VBZ VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 VBN IN DT NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 IN DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
total total 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN NN O
enzyme enzyme 0 0 0 0 0 0 0 0 6 0 DT JJ NN NN CC O
activity activity 0 0 0 0 0 0 0 0 8 0 JJ NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
selective selective 0 0 0 0 0 0 0 0 9 0 NN CC JJ NN IN O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 CC JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
alkaline alkaline 0 0 0 0 0 0 0 0 8 0 NN IN NN NN IN O
phosphatase phosphatase 0 0 0 0 0 0 0 0 11 0 IN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
microsomes. microsomes. 0 0 0 0 0 0 0 0 11 0 IN DT NNP NNP NN O
An An 1 0 0 0 0 0 0 0 2 0 DT NNP NNP NN IN O
addition addition 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
exogenous exogenous 0 0 0 0 0 0 0 0 9 0 NN IN JJ NN NN O
alkaline alkaline 0 0 0 0 0 0 0 0 8 0 IN JJ NN NN TO O
phosphatase phosphatase 0 0 0 0 0 0 0 0 11 0 JJ NN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO VB NNS O
intact intact 0 0 0 0 0 0 0 0 6 0 NN TO VB NNS NNS O
cells cells 0 0 0 0 0 0 0 0 5 0 TO VB NNS NNS TO O
leads leads 0 0 0 0 0 0 0 0 5 0 VB NNS NNS TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNS NNS TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS TO DT NN IN O
stimulation stimulation 0 0 0 0 0 0 0 0 11 0 TO DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN IN NNP NN CC O
synthesis synthesis 0 0 0 0 0 0 0 0 9 0 IN NNP NN CC TO O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC TO NNS O
to to 0 0 0 0 0 0 0 0 2 0 NN CC TO NNS IN O
changes changes 0 0 0 0 0 0 0 0 7 0 CC TO NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 TO NNS IN NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 NNS IN NN NNP NNP O
morphology. morphology. 0 0 0 0 0 0 0 0 11 0 IN NN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS VBD O
data data 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS VBD VBP O
obtained obtained 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNS VBD VBP IN NN O
that that 0 0 0 0 0 0 0 0 4 0 VBD VBP IN NN NN O
alkaline alkaline 0 0 0 0 0 0 0 0 8 0 VBP IN NN NN MD O
phosphatase phosphatase 0 0 0 0 0 0 0 0 11 0 IN NN NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN NN MD VB IN O
participate participate 0 0 0 0 0 0 0 0 11 0 NN MD VB IN DT O
in in 0 0 0 0 0 0 0 0 2 0 MD VB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VB IN DT NN IN O
destabilization destabilization 0 0 0 0 0 0 0 0 15 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN CC O
cytoskeleton cytoskeleton 0 0 0 0 0 0 0 0 12 0 IN DT NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC VB NN O
stimulate stimulate 0 0 0 0 0 0 0 0 9 0 NN CC VB NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 CC VB NN NNP NNP O
proliferation. proliferation. 0 0 0 0 0 0 0 0 14 0 VB NN NNP NNP IN O
However, However, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ NNS O
normal normal 0 0 0 0 0 0 0 0 6 0 NNP IN JJ NNS DT O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ NNS DT JJ NN O
selective selective 0 0 0 0 0 0 0 0 9 0 NNS DT JJ NN IN O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
enzyme enzyme 0 0 0 0 0 0 0 0 6 0 IN DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS MD O
membranes membranes 0 0 0 0 0 0 0 0 9 0 IN DT NNS MD VB O
may may 0 0 0 0 0 0 0 0 3 0 DT NNS MD VB PRP$ O
hamper hamper 0 0 0 0 0 0 0 0 6 0 NNS MD VB PRP$ NNP O
its its 0 0 0 0 0 0 0 0 3 0 MD VB PRP$ NNP DT O
biosynthesis. biosynthesis. 0 0 0 0 0 0 0 0 13 0 VB PRP$ NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP$ NNP DT NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NNP DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
alkaline alkaline 0 0 0 0 0 0 0 0 8 0 NN IN NN NN RB O
phosphatase phosphatase 0 0 0 0 0 0 0 0 11 0 IN NN NN RB VBZ O
thus thus 0 0 0 0 0 0 0 0 4 0 NN NN RB VBZ RB O
does does 0 0 0 0 0 0 0 0 4 0 NN RB VBZ RB VB O
not not 0 0 0 0 0 0 0 0 3 0 RB VBZ RB VB DT O
reach reach 0 0 0 0 0 0 0 0 5 0 VBZ RB VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VB DT NN NN O
level level 0 0 0 0 0 0 0 0 5 0 VB DT NN NN IN O
sufficient sufficient 0 0 0 0 0 0 0 0 10 0 DT NN NN IN VBN O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN VBN NN O
unrestricted unrestricted 0 0 0 0 0 0 0 0 12 0 NN IN VBN NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN VBN NN NNP NNP O
growth. growth. 0 0 0 0 0 0 0 0 7 0 VBN NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
6518183 6518183 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Yeast Yeast 1 0 0 0 0 0 0 0 5 0 NONE NONE NNP NNP VBZ O
G1 G1 1 1 0 0 0 0 0 1 2 0 NONE NNP NNP VBZ VBP B_TIMEXCCP
cyclins cyclins 0 0 0 0 0 0 0 0 7 0 NNP NNP VBZ VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNP VBZ VBP JJ IN O
unstable unstable 0 0 0 0 0 0 0 0 8 0 VBZ VBP JJ IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBP JJ IN NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 JJ IN NNP NNP NNP B_TIMEXCCP
phase. phase. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
Schneider Schneider 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
BL, BL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Patton Patton 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
EE, EE, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Lanker Lanker 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Mendenhall Mendenhall 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
MD, MD, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wittenberg Wittenberg 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Futcher Futcher 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tyers Tyers 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
M. M. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Cold Cold 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Spring Spring 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Harbor Harbor 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Laboratory, Laboratory, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
New New 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP CD O
York York 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP CD NNP O
11724, 11724, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP JJS O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP JJS JJ O
most most 0 0 0 0 0 0 0 0 4 0 NNP NNP JJS JJ NN O
eukaryotes, eukaryotes, 0 0 0 0 1 0 0 0 11 0 NNP JJS JJ NN TO O
commitment commitment 0 0 0 0 0 0 0 0 10 0 JJS JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN TO VB NN NNS O
division division 0 0 0 0 0 0 0 0 8 0 TO VB NN NNS IN O
occurs occurs 0 0 0 0 0 0 0 0 6 0 VB NN NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NNP O
late late 0 0 0 0 0 0 0 0 4 0 NNS IN JJ NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 phase IN JJ NNP NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 JJ NNP NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT NN VBN O
event event 0 0 0 0 0 0 0 0 5 0 IN DT NN VBN NNP O
called called 0 0 0 0 0 0 0 0 6 0 DT NN VBN NNP IN O
Start Start 1 0 0 0 0 0 0 0 5 0 NN VBN NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBN NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN NNS O
yeast yeast 0 0 0 0 0 0 0 0 5 0 IN DT NN NNS -NONE- O
Saccharomyces Saccharomyces 1 0 0 0 0 0 0 0 13 0 DT NN NNS -NONE- CC O
cerevisiae, cerevisiae, 0 0 0 0 1 0 0 0 11 0 NN NNS -NONE- CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC VBN DT O
called called 0 0 0 0 0 0 0 0 6 0 -NONE- CC VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC VBN DT NN NN O
restriction restriction 0 0 0 0 0 0 0 0 11 0 VBN DT NN NN IN O
point point 0 0 0 0 0 0 0 0 5 0 DT NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNP O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP VBZ O
Start Start 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
triggered triggered 0 0 0 0 0 0 0 0 9 0 NNP VBZ VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
cyclin-dependent cyclin-dependent 0 0 1 0 0 0 0 0 16 0 IN DT JJ NN NNP O
kinase kinase 0 0 0 0 0 0 0 0 6 0 DT JJ NN NNP CC O
Cdc28 Cdc28 1 0 0 0 0 0 0 1 5 0 JJ NN NNP CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC CD JJ O
three three 0 0 0 0 0 0 0 0 5 0 NNP CC CD JJ NN O
rate-limiting rate-limiting 0 0 1 0 0 0 0 0 13 0 CC CD JJ NN DT O
activators, activators, 0 0 0 0 1 0 0 0 11 0 CD JJ NN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NNP VBZ O
G1 G1 1 1 0 0 0 0 0 1 2 0 NN DT NNP VBZ JJ B_TIMEXCCP
cyclins cyclins 0 0 0 0 0 0 0 0 7 0 DT NNP VBZ JJ NNP O
Cln1, Cln1, 1 0 0 0 1 0 0 1 5 0 NNP VBZ JJ NNP CC O
Cln2 Cln2 1 0 0 0 0 0 0 1 4 0 VBZ JJ NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNP CC NNP NNP O
Cln3. Cln3. 1 0 0 0 0 0 0 1 5 0 NNP CC NNP NNP NN O
Cyclin Cyclin 1 0 0 0 0 0 0 0 6 0 CC NNP NNP NN IN O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 NNP NNP NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP VBZ O
G1 G1 1 1 0 0 0 0 0 1 2 0 NN IN NNP VBZ VBN B_TIMEXCCP
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ VBN IN O
driven driven 0 0 0 0 0 0 0 0 6 0 NNP VBZ VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN NN IN O
part part 0 0 0 0 0 0 0 0 4 0 VBN IN NN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 IN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
cell-cycle-regulated cell-cycle-regulated 0 0 1 0 0 0 0 0 20 0 IN DT JJ NN IN O
transcription transcription 0 0 0 0 0 0 0 0 13 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP CC O
CLN1 CLN1 1 1 0 0 0 0 0 1 4 0 NN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP WDT O
CLN2, CLN2, 1 1 0 0 1 0 0 1 5 0 NNP CC NNP WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 CC NNP WDT VBZ IN O
peaks peaks 0 0 0 0 0 0 0 0 5 0 NNP WDT VBZ IN NNP O
at at 0 0 0 0 0 0 0 0 2 0 WDT VBZ IN NNP NNP O
Start. Start. 1 0 0 0 0 0 0 0 6 0 VBZ IN NNP NNP NN O
CLN CLN 1 1 0 0 0 0 0 0 3 0 IN NNP NNP NN VBZ O
transcription transcription 0 0 0 0 0 0 0 0 13 0 NNP NNP NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ VBN IN O
modulated modulated 0 0 0 0 0 0 0 0 9 0 NN VBZ VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN JJ NNS O
physiological physiological 0 0 0 0 0 0 0 0 13 0 VBN IN JJ NNS WDT O
signals signals 0 0 0 0 0 0 0 0 7 0 IN JJ NNS WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 JJ NNS WDT NN NNP O
regulate regulate 0 0 0 0 0 0 0 0 8 0 NNS WDT NN NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 WDT NN NNP NNP CC B_TIMEXCCP
progression, progression, 0 0 0 0 1 0 0 0 12 0 NN NNP NNP CC PRP O
but but 0 0 0 0 0 0 0 0 3 0 NNP NNP CC PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NNP CC PRP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 CC PRP VBZ JJ IN O
unclear unclear 0 0 0 0 0 0 0 0 7 0 PRP VBZ JJ IN NNP O
whether whether 0 0 0 0 0 0 0 0 7 0 VBZ JJ IN NNP NN O
Cln Cln 1 0 0 0 0 0 0 0 3 0 JJ IN NNP NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 IN NNP NN NN VBZ O
stability stability 0 0 0 0 0 0 0 0 9 0 NNP NN NN VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ NNP NNP O
cell-cycle-regulated. cell-cycle-regulated. 0 0 1 0 0 0 0 0 21 0 NN VBZ NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 VBZ NNP NNP VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP NNP VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBN VBN IN O
suggested suggested 0 0 0 0 0 0 0 0 9 0 VBZ VBN VBN IN RB O
that that 0 0 0 0 0 0 0 0 4 0 VBN VBN IN RB VBZ O
once once 0 0 0 0 0 0 0 0 4 0 VBN IN RB VBZ NN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN RB VBZ NN -NONE- O
pass pass 0 0 0 0 0 0 0 0 4 0 RB VBZ NN -NONE- NNP O
Start, Start, 1 0 0 0 1 0 0 0 6 0 VBZ NN -NONE- NNP NN O
Cln Cln 1 0 0 0 0 0 0 0 3 0 NN -NONE- NNP NN VBZ O
proteolysis proteolysis 0 0 0 0 0 0 0 0 11 0 -NONE- NNP NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ VBN IN O
triggered triggered 0 0 0 0 0 0 0 0 9 0 NN VBZ VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNS O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NNS -NONE- O
cyclins cyclins 0 0 0 0 0 0 0 0 7 0 DT JJ NNS -NONE- CD O
Clb1, Clb1, 1 0 0 0 1 0 0 1 5 0 JJ NNS -NONE- CD CD O
2, 2, 0 0 0 0 1 0 0 1 2 0 NNS -NONE- CD CD CC O
3 3 0 0 0 0 0 0 1 1 1 0 -NONE- CD CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD CD CC CD CC O
4. 4. 0 0 0 0 0 0 0 1 2 0 CD CC CD CC RB O
But But 1 0 0 0 0 0 0 0 3 0 CC CD CC RB PRP O
here here 0 0 0 0 0 0 0 0 4 0 CD CC RB PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 CC RB PRP VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 RB PRP VBP IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN NNP VBZ O
G1 G1 1 1 0 0 0 0 0 1 2 0 VBP IN NNP VBZ VBP B_TIMEXCCP
cyclins cyclins 0 0 0 0 0 0 0 0 7 0 IN NNP VBZ VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNP VBZ VBP JJ IN O
unstable unstable 0 0 0 0 0 0 0 0 8 0 VBZ VBP JJ IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBP JJ IN NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 JJ IN NNP NNP CC B_TIMEXCCP
phase, phase, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC IN -NONE- O
that that 0 0 0 0 0 0 0 0 4 0 NNP CC IN -NONE- NN O
Clb-Cdc28 Clb-Cdc28 1 0 1 0 0 0 0 1 9 0 CC IN -NONE- NN VBZ O
activity activity 0 0 0 0 0 0 0 0 8 0 IN -NONE- NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 -NONE- NN VBZ RB VBN O
not not 0 0 0 0 0 0 0 0 3 0 NN VBZ RB VBN NN O
needed needed 0 0 0 0 0 0 0 0 6 0 VBZ RB VBN NN NNP O
fgr fgr 0 0 0 0 0 0 0 0 3 0 RB VBN NN NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 0 VBN NN NNP NN NNP B_TIMEXCCP
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN NNP NN NNP NNP O
turnover. turnover. 0 0 0 0 0 0 0 0 9 0 NNP NN NNP NNP NN O
Cln Cln 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN RB O
instability instability 0 0 0 0 0 0 0 0 11 0 NNP NNP NN RB VBZ O
thus thus 0 0 0 0 0 0 0 0 4 0 NNP NN RB VBZ DT O
provides provides 0 0 0 0 0 0 0 0 8 0 NN RB VBZ DT VBZ O
a a 0 0 0 0 0 0 0 0 1 0 RB VBZ DT VBZ TO O
means means 0 0 0 0 0 0 0 0 5 0 VBZ DT VBZ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT VBZ TO VB -NONE- O
couple couple 0 0 0 0 0 0 0 0 6 0 VBZ TO VB -NONE- NN O
Cln-Cdc28 Cln-Cdc28 1 0 1 0 0 0 0 1 9 0 TO VB -NONE- NN TO O
activity activity 0 0 0 0 0 0 0 0 8 0 VB -NONE- NN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 -NONE- NN TO JJ NN O
transcriptional transcriptional 0 0 0 0 0 0 0 0 15 0 NN TO JJ NN CC O
regulation regulation 0 0 0 0 0 0 0 0 10 0 TO JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN JJ O
protein protein 0 0 0 0 0 0 0 0 7 0 NN CC NN JJ NN O
synthetic synthetic 0 0 0 0 0 0 0 0 9 0 CC NN JJ NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 NN JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNP O
pre-Start pre-Start 0 0 1 0 0 0 0 0 9 0 NN IN NN NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 IN NN NNP NNP NNP B_TIMEXCCP
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNP NNP NNP CD JJ O
9738503 9738503 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
G2 G2 1 1 0 0 0 0 0 1 2 0 NONE NONE NNP NNP VBZ B_TIMEXCCP
phase-specific phase-specific 0 0 1 0 0 0 0 0 14 0 NONE NNP NNP VBZ IN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN NNP NNP O
HeLa HeLa 1 0 0 0 0 0 0 0 4 0 VBZ IN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
Al-Bader Al-Bader 1 0 1 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
AA, AA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Orengo Orengo 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Rao Rao 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
PN. PN. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
objective objective 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 IN DT NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB IN O
determine determine 0 0 0 0 0 0 0 0 9 0 VBD TO VB IN NNP O
if if 0 0 0 0 0 0 0 0 2 0 TO VB IN NNP NNS O
HeLa HeLa 1 0 0 0 0 0 0 0 4 0 VB IN NNP NNS RB O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS RB VBN O
irreversibly irreversibly 0 0 0 0 0 0 0 0 12 0 NNP NNS RB VBN IN O
arrested arrested 0 0 0 0 0 0 0 0 8 0 NNS RB VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN NNP NN O
G2 G2 1 1 0 0 0 0 0 1 2 phase VBN IN NNP NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN IN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
brief brief 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN TO O
exposure exposure 0 0 0 0 0 0 0 0 8 0 DT JJ NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN TO DT NN NN O
nitrosourea nitrosourea 0 0 0 0 0 0 0 0 11 0 TO DT NN NN VBD O
compound compound 0 0 0 0 0 0 0 0 8 0 DT NN NN VBD NN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD NN IN O
deficient deficient 0 0 0 0 0 0 0 0 9 0 NN VBD NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBD NN IN JJ NNS O
certain certain 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNS WRB O
proteins proteins 0 0 0 0 0 0 0 0 8 0 IN JJ NNS WRB VBN O
when when 0 0 0 0 0 0 0 0 4 0 JJ NNS WRB VBN IN O
compared compared 0 0 0 0 0 0 0 0 8 0 NNS WRB VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 WRB VBN IN JJ NNP O
G2-synchronized G2-synchronized 1 0 1 0 0 0 0 1 15 0 VBN IN JJ NNP NNP B_TIMEXCCP
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP NN O
Total Total 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP NN VBZ O
cellular cellular 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBZ IN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN VBZ IN JJ NN O
G2-synchronized, G2-synchronized, 1 0 1 0 1 0 0 1 16 0 VBZ IN JJ NN CC B_TIMEXCCP
G2-arrested, G2-arrested, 1 0 1 0 1 0 0 1 12 0 IN JJ NN CC NNP B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP JJ O
S S 1 1 0 0 0 0 0 0 1 0 NN CC NNP JJ NNS B_TIMEXCCP
phase-synchronized phase-synchronized 0 0 1 0 0 0 0 0 18 0 CC NNP JJ NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP JJ NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD VBN IN O
compared compared 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NN O
two-dimensional two-dimensional 0 0 1 0 0 0 0 0 15 0 VBN IN JJ NN NN O
polyacrylamide polyacrylamide 0 0 0 0 0 0 0 0 14 0 IN JJ NN NN NNP O
gel gel 0 0 0 0 0 0 0 0 3 0 JJ NN NN NNP NNP O
electrophoresis. electrophoresis. 0 0 0 0 0 0 0 0 16 0 NN NN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase NNP NNP NNP NN NNS B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NN NNS VBD IN O
differed differed 0 0 0 0 0 0 0 0 8 0 NN NNS VBD IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT JJ CC O
G2-synchronized G2-synchronized 1 0 1 0 0 0 0 1 15 0 IN DT JJ CC JJ B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC JJ NNS O
G2-arrested G2-arrested 1 0 1 0 0 0 0 1 11 0 JJ CC JJ NNS IN B_TIMEXCCP
cells cells 0 0 0 0 0 0 0 0 5 0 CC JJ NNS IN DT O
by by 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
absence absence 0 0 0 0 0 0 0 0 7 0 IN DT NN IN RB O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN RB CD O
about about 0 0 0 0 0 0 0 0 5 0 NN IN RB CD CC O
35 35 0 0 0 0 0 0 1 1 2 0 IN RB CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 RB CD CC CD NN O
25 25 0 0 0 0 0 0 1 1 2 0 CD CC CD NN -NONE- O
protein protein 0 0 0 0 0 0 0 0 7 0 CC CD NN -NONE- -NONE- O
spots, spots, 0 0 0 0 1 0 0 0 6 0 CD NN -NONE- -NONE- IN O
respectively, respectively, 0 0 0 0 1 0 0 0 13 0 NN -NONE- -NONE- IN DT O
of of 0 0 0 0 0 0 0 0 2 0 -NONE- -NONE- IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- IN DT JJ IN O
total total 0 0 0 0 0 0 0 0 5 0 IN DT JJ IN RB O
of of 0 0 0 0 0 0 0 0 2 0 DT JJ IN RB CD O
nearly nearly 0 0 0 0 0 0 0 0 6 0 JJ IN RB CD IN O
150. 150. 0 0 0 0 0 0 0 1 4 0 IN RB CD IN JJS O
At At 1 0 0 0 0 0 0 0 2 0 RB CD IN JJS CD O
least least 0 0 0 0 0 0 0 0 5 0 CD IN JJS CD NN O
nine nine 0 0 0 0 0 0 0 0 4 0 IN JJS CD NN NNS O
protein protein 0 0 0 0 0 0 0 0 7 0 JJS CD NN NNS IN O
spots spots 0 0 0 0 0 0 0 0 5 0 CD NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN NN O
weight weight 0 0 0 0 0 0 0 0 6 0 DT JJ NN NN IN O
range range 0 0 0 0 0 0 0 0 5 0 JJ NN NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN CD NNP O
4--5 4--5 0 0 1 0 0 0 0 1 4 0 NN IN CD NNP CD O
X X 1 1 0 0 0 0 0 0 1 0 IN CD NNP CD WDT O
10(4) 10(4) 0 0 0 0 0 0 0 1 5 0 CD NNP CD WDT VBD O
that that 0 0 0 0 0 0 0 0 4 0 NNP CD WDT VBD NN O
were were 0 0 0 0 0 0 0 0 4 0 CD WDT VBD NN IN O
present present 0 0 0 0 0 0 0 0 7 0 WDT VBD NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNS O
G2-synchronized G2-synchronized 1 0 1 0 0 0 0 1 15 0 IN DT JJ NNS VBD B_TIMEXCCP
cells cells 0 0 0 0 0 0 0 0 5 0 DT JJ NNS VBD NN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD NN IN O
absent absent 0 0 0 0 0 0 0 0 6 0 NNS VBD NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD NN IN DT DT O
both both 0 0 0 0 0 0 0 0 4 0 NN IN DT DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 IN DT DT JJ CC O
G2-arrested G2-arrested 1 0 1 0 0 0 0 1 11 0 DT DT JJ CC DT B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 JJ CC DT NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase CC DT NNP NN NNP B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NNP NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NNP NN NNP NNP DT O
Thus, Thus, 1 0 0 0 1 0 0 0 5 0 NN NNP NNP DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT NNS VBP O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP DT NNS VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 DT NNS VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NN NNS O
missing missing 0 0 0 0 0 0 0 0 7 0 IN DT NN NNS VBP O
proteins proteins 0 0 0 0 0 0 0 0 8 0 DT NN NNS VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 NN NNS VBP RB JJ O
probably probably 0 0 0 0 0 0 0 0 8 0 NNS VBP RB JJ IN O
necessary necessary 0 0 0 0 0 0 0 0 9 0 VBP RB JJ IN DT O
for for 0 0 0 0 0 0 0 0 3 0 RB JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN IN O
transition transition 0 0 0 0 0 0 0 0 10 0 IN DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 IN NNS IN NNP NN O
G2 G2 1 1 0 0 0 0 0 1 2 phase NNS IN NNP NN TO B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN NNP NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO NNP NNP O
mitosis. mitosis. 0 0 0 0 0 0 0 0 8 0 NN TO NNP NNP DT B_TIMEXCCP
Supplying Supplying 1 0 0 0 0 0 0 0 9 0 TO NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NNS O
missing missing 0 0 0 0 0 0 0 0 7 0 NNP DT NN NNS TO O
proteins proteins 0 0 0 0 0 0 0 0 8 0 DT NN NNS TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS TO DT JJ NNS O
G2-arrested G2-arrested 1 0 1 0 0 0 0 1 11 0 TO DT JJ NNS IN B_TIMEXCCP
cells cells 0 0 0 0 0 0 0 0 5 0 DT JJ NNS IN NN O
by by 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN IN O
fusion fusion 0 0 0 0 0 0 0 0 6 0 NNS IN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN JJ NNS O
G2-synchronized G2-synchronized 1 0 1 0 0 0 0 1 15 0 NN IN JJ NNS VBN B_TIMEXCCP
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS VBN DT O
facilitated facilitated 0 0 0 0 0 0 0 0 11 0 JJ NNS VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBN DT NN IN O
entry entry 0 0 0 0 0 0 0 0 5 0 VBN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ IN O
former former 0 0 0 0 0 0 0 0 6 0 IN DT JJ IN NNP O
into into 0 0 0 0 0 0 0 0 4 0 DT JJ IN NNP NNP O
mitosis. mitosis. 0 0 0 0 0 0 0 0 8 0 JJ IN NNP NNP CD B_TIMEXCCP 
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 IN NNP NNP CD JJ O
282623 282623 0 0 0 0 0 0 1 1 6 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NN O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NN NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
PMC393118 PMC393118 1 1 0 0 0 0 0 1 9 0 JJ NN NNP NONE NONE O
On On 1 0 0 0 0 0 0 0 2 0 NONE NONE IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NONE IN DT NN IN O
fusion fusion 0 0 0 0 0 0 0 0 6 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
nucleoli nucleoli 0 0 0 0 0 0 0 0 8 0 NN IN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNP O
interphase. interphase. 0 0 0 0 0 0 0 0 11 0 NN IN NNP NNP NNP B_TIMEXCCP
Wachtler Wachtler 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Schwarzacher Schwarzacher 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
HG, HG, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Smetana Smetana 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
K. K. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
By By 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NN VBD O
comparing comparing 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBD CC O
unstimulated unstimulated 0 0 0 0 0 0 0 0 12 0 NNP NN VBD CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN VBD CC NN JJ O
phytohaemagglutinine phytohaemagglutinine 0 0 0 0 0 0 0 0 20 0 VBD CC NN JJ NN O
(PHA)-stimulated (PHA)-stimulated 0 0 1 0 0 0 0 0 16 0 CC NN JJ NN NNS O
human human 0 0 0 0 0 0 0 0 5 0 NN JJ NN NNS IN O
lymphocytes lymphocytes 0 0 0 0 0 0 0 0 11 0 JJ NN NNS IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NN NNS IN JJ NN O
peripheral peripheral 0 0 0 0 0 0 0 0 10 0 NNS IN JJ NN PRP O
blood blood 0 0 0 0 0 0 0 0 5 0 IN JJ NN PRP VBD O
it it 0 0 0 0 0 0 0 0 2 0 JJ NN PRP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN PRP VBD VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 PRP VBD VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
fusion fusion 0 0 0 0 0 0 0 0 6 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
nucleoli nucleoli 0 0 0 0 0 0 0 0 8 0 NN IN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NN VBZ O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NN IN NN VBZ RB B_TIMEXCCP
is is 0 0 0 0 0 0 0 0 2 0 IN NN VBZ RB RB O
not not 0 0 0 0 0 0 0 0 3 0 NN VBZ RB RB DT O
merely merely 0 0 0 0 0 0 0 0 6 0 VBZ RB RB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 RB RB DT JJ NN O
passive passive 0 0 0 0 0 0 0 0 7 0 RB DT JJ NN CC O
phenomenon phenomenon 0 0 0 0 0 0 0 0 10 0 DT JJ NN CC VBZ O
but but 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NN CC VBZ RB VBN O
strongly strongly 0 0 0 0 0 0 0 0 8 0 CC VBZ RB VBN TO O
correlated correlated 0 0 0 0 0 0 0 0 10 0 VBZ RB VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 RB VBN TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN TO DT JJ NN O
metabolic metabolic 0 0 0 0 0 0 0 0 9 0 TO DT JJ NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN IN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NN VBZ O
fusion fusion 0 0 0 0 0 0 0 0 6 0 NNP NNP NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ JJ IN O
independent independent 0 0 0 0 0 0 0 0 11 0 NN VBZ JJ IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBZ JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN NN NNP O
(DNA-replication (DNA-replication 0 0 1 0 0 0 0 0 16 0 NN NN NN NNP NNP O
cycle). cycle). 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
6734627 6734627 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Biophysics Biophysics 1 0 0 0 0 0 0 0 10 0 NONE NONE NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NNS IN NNP NNP O
mitosis. mitosis. 0 0 0 0 0 0 0 0 8 0 NNS IN NNP NNP NNP B_TIMEXCCP
McIntosh McIntosh 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
JR, JR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Molodtsov Molodtsov 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
MI, MI, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Ataullakhanov Ataullakhanov 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
FI. FI. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Molecular, Molecular, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP CC O
Cellular, Cellular, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Developmental Developmental 1 0 0 0 0 0 0 0 13 0 NNP CC NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 CC NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Colorado, Colorado, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Boulder, Boulder, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP CD O
CO CO 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
80309, 80309, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
richard.mcintosh@colorado.edu richard.mcintosh@colorado.edu 0 0 0 0 0 0 0 0 29 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
Mitosis Mitosis 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP VBZ DT B_TIMEXCCP
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT NN IN O
process process 0 0 0 0 0 0 0 0 7 0 VBZ DT NN IN WDT O
by by 0 0 0 0 0 0 0 0 2 0 DT NN IN WDT JJ O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT JJ NNS O
eukaryotic eukaryotic 0 0 0 0 0 0 0 0 10 0 IN WDT JJ NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 WDT JJ NNS VBP CC O
organize organize 0 0 0 0 0 0 0 0 8 0 JJ NNS VBP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNS VBP CC JJ PRP$ O
segregate segregate 0 0 0 0 0 0 0 0 9 0 VBP CC JJ PRP$ NNS O
their their 0 0 0 0 0 0 0 0 5 0 CC JJ PRP$ NNS IN O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 JJ PRP$ NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 PRP$ NNS IN NN IN O
preparation preparation 0 0 0 0 0 0 0 0 11 0 NNS IN NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 IN NN IN NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NNP NNP O
division. division. 0 0 0 0 0 0 0 0 9 0 IN NN NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
accomplished accomplished 0 0 0 0 0 0 0 0 12 0 NNP VBZ VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NN O
cellular cellular 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN VBD O
machine machine 0 0 0 0 0 0 0 0 7 0 DT JJ NN VBD RB O
composed composed 0 0 0 0 0 0 0 0 8 0 JJ NN VBD RB IN O
largely largely 0 0 0 0 0 0 0 0 7 0 NN VBD RB IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 VBD RB IN NNS -NONE- O
microtubules microtubules 0 0 0 0 0 0 0 0 12 0 RB IN NNS -NONE- CC O
(MTs) (MTs) 0 0 0 0 0 0 0 0 5 0 IN NNS -NONE- CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC PRP$ VBN O
their their 0 0 0 0 0 0 0 0 5 0 -NONE- CC PRP$ VBN NNP O
associated associated 0 0 0 0 0 0 0 0 10 0 CC PRP$ VBN NNP NNP O
proteins. proteins. 0 0 0 0 0 0 0 0 9 0 PRP$ VBN NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 VBN NNP NNP NN VBZ O
article article 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBZ NN O
reviews reviews 0 0 0 0 0 0 0 0 7 0 NNP NN VBZ NN IN O
literature literature 0 0 0 0 0 0 0 0 10 0 NN VBZ NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 VBZ NN IN NN IN O
mitosis mitosis 0 0 0 0 0 0 0 0 7 0 NN IN NN IN DT B_TIMEXCCP
from from 0 0 0 0 0 0 0 0 4 0 IN NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
biophysical biophysical 0 0 0 0 0 0 0 0 11 0 IN DT JJ NN IN O
point point 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
view, view, 0 0 0 0 1 0 0 0 5 0 NN IN JJ NN NN O
drawing drawing 0 0 0 0 0 0 0 0 7 0 IN JJ NN NN TO O
attention attention 0 0 0 0 0 0 0 0 9 0 JJ NN NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO DT RB O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT RB CC O
assembly assembly 0 0 0 0 0 0 0 0 8 0 TO DT RB CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT RB CC NN NNS O
motility motility 0 0 0 0 0 0 0 0 8 0 RB CC NN NNS VBN O
processes processes 0 0 0 0 0 0 0 0 9 0 CC NN NNS VBN TO O
required required 0 0 0 0 0 0 0 0 8 0 NN NNS VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBN TO VB DT O
do do 0 0 0 0 0 0 0 0 2 0 VBN TO VB DT NN O
this this 0 0 0 0 0 0 0 0 4 0 TO VB DT NN NN O
complex complex 0 0 0 0 0 0 0 0 7 0 VB DT NN NN IN O
job job 0 0 0 0 0 0 0 0 3 0 DT NN NN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN NNP NNP O
precision. precision. 0 0 0 0 0 0 0 0 10 0 NN IN NNP NNP IN O
Work Work 1 0 0 0 0 0 0 0 4 0 IN NNP NNP IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNP IN DT DT O
both both 0 0 0 0 0 0 0 0 4 0 NNP IN DT DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 IN DT DT JJ CC O
recent recent 0 0 0 0 0 0 0 0 6 0 DT DT JJ CC DT O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ CC DT NN NN O
older older 0 0 0 0 0 0 0 0 5 0 CC DT NN NN VBZ O
literature literature 0 0 0 0 0 0 0 0 10 0 DT NN NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ VBN IN O
integrated integrated 0 0 0 0 0 0 0 0 10 0 NN VBZ VBN IN DT O
into into 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NN IN O
description description 0 0 0 0 0 0 0 0 11 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ JJ O
relevant relevant 0 0 0 0 0 0 0 0 8 0 NN IN JJ JJ NNS O
biological biological 0 0 0 0 0 0 0 0 10 0 IN JJ JJ NNS CC O
events events 0 0 0 0 0 0 0 0 6 0 JJ JJ NNS CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNS CC DT NNS WDT O
experiments experiments 0 0 0 0 0 0 0 0 11 0 CC DT NNS WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 DT NNS WDT NN PRP$ O
probe probe 0 0 0 0 0 0 0 0 5 0 NNS WDT NN PRP$ NNP O
their their 0 0 0 0 0 0 0 0 5 0 WDT NN PRP$ NNP NNP O
mechanisms. mechanisms. 0 0 0 0 0 0 0 0 11 0 NN PRP$ NNP NNP NN O
Theoretical Theoretical 1 0 0 0 0 0 0 0 11 0 PRP$ NNP NNP NN IN O
work work 0 0 0 0 0 0 0 0 4 0 NNP NNP NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NNS O
specific specific 0 0 0 0 0 0 0 0 8 0 NN IN JJ NNS VBZ O
subprocesses subprocesses 0 0 0 0 0 0 0 0 12 0 IN JJ NNS VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 JJ NNS VBZ RB NNP O
also also 0 0 0 0 0 0 0 0 4 0 NNS VBZ RB NNP NNP O
reviewed. reviewed. 0 0 0 0 0 0 0 0 9 0 VBZ RB NNP NNP NN O
Our Our 1 0 0 0 0 0 0 0 3 0 RB NNP NNP NN VBZ O
goal goal 0 0 0 0 0 0 0 0 4 0 NNP NNP NN VBZ TO O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBZ TO VB DT O
provide provide 0 0 0 0 0 0 0 0 7 0 VBZ TO VB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT NN WDT O
document document 0 0 0 0 0 0 0 0 8 0 VB DT NN WDT MD O
that that 0 0 0 0 0 0 0 0 4 0 DT NN WDT MD VB O
will will 0 0 0 0 0 0 0 0 4 0 NN WDT MD VB NNS O
expose expose 0 0 0 0 0 0 0 0 6 0 WDT MD VB NNS TO O
biophysicists biophysicists 0 0 0 0 0 0 0 0 13 0 MD VB NNS TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VB NNS TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS TO DT NN IN O
fascination fascination 0 0 0 0 0 0 0 0 11 0 TO DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN VBG O
quite quite 0 0 0 0 0 0 0 0 5 0 IN DT NN VBG NN O
amazing amazing 0 0 0 0 0 0 0 0 7 0 DT NN VBG NN CC O
process process 0 0 0 0 0 0 0 0 7 0 NN VBG NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 VBG NN CC VB PRP O
provide provide 0 0 0 0 0 0 0 0 7 0 NN CC VB PRP IN O
them them 0 0 0 0 0 0 0 0 4 0 CC VB PRP IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VB PRP IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 PRP IN DT JJ NN O
good good 0 0 0 0 0 0 0 0 4 0 IN DT JJ NN IN O
background background 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN WDT O
from from 0 0 0 0 0 0 0 0 4 0 JJ NN IN WDT PRP O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT PRP MD O
they they 0 0 0 0 0 0 0 0 4 0 IN WDT PRP MD VB O
can can 0 0 0 0 0 0 0 0 3 0 WDT PRP MD VB PRP$ O
pursue pursue 0 0 0 0 0 0 0 0 6 0 PRP MD VB PRP$ JJ O
their their 0 0 0 0 0 0 0 0 5 0 MD VB PRP$ JJ NN O
own own 0 0 0 0 0 0 0 0 3 0 VB PRP$ JJ NN NNS O
research research 0 0 0 0 0 0 0 0 8 0 PRP$ JJ NN NNS IN O
interests interests 0 0 0 0 0 0 0 0 9 0 JJ NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NNP O
subject. subject. 0 0 0 0 0 0 0 0 8 0 IN DT NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 DT NNP NNP CD JJ O
22321376 22321376 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Evolution Evolution 1 0 0 0 0 0 0 0 9 0 NONE NONE NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NONE NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN IN O
meaning meaning 0 0 0 0 0 0 0 0 7 0 CC DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
metaphase. metaphase. 0 0 0 0 0 0 0 0 10 0 NN IN NNP NNP NNP B_TIMEXCCP
Nicklas Nicklas 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
RB, RB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Arana Arana 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
P. P. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Zoology, Zoology, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP NNP O
Duke Duke 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Durham, Durham, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
NC NC 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
27706. 27706. 0 0 0 0 0 0 0 1 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBD DT O
used used 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNP VBD DT JJ NN O
evolutionary evolutionary 0 0 0 0 0 0 0 0 12 0 VBD DT JJ NN TO O
test test 0 0 0 0 0 0 0 0 4 0 DT JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB IN O
ask ask 0 0 0 0 0 0 0 0 3 0 NN TO VB IN DT O
whether whether 0 0 0 0 0 0 0 0 7 0 TO VB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VB IN DT NN IN O
congression congression 0 0 0 0 0 0 0 0 11 0 IN DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS TO O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 NN IN NNS TO DT O
to to 0 0 0 0 0 0 0 0 2 0 IN NNS TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS TO DT NN NN O
spindle spindle 0 0 0 0 0 0 0 0 7 0 TO DT NN NN VBZ O
equator equator 0 0 0 0 0 0 0 0 7 0 DT NN NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ JJ IN O
important important 0 0 0 0 0 0 0 0 9 0 NN VBZ JJ IN PRP O
in in 0 0 0 0 0 0 0 0 2 0 VBZ JJ IN PRP CC O
itself itself 0 0 0 0 0 0 0 0 6 0 JJ IN PRP CC RB O
or or 0 0 0 0 0 0 0 0 2 0 IN PRP CC RB DT O
just just 0 0 0 0 0 0 0 0 4 0 PRP CC RB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 CC RB DT JJ NNP O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 RB DT JJ NNP NNP B_TIMEXCCP
happenstance. happenstance. 0 0 0 0 0 0 0 0 13 0 DT JJ NNP NNP NN O
If If 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NN -NONE- O
congression congression 0 0 0 0 0 0 0 0 11 0 NNP NNP NN -NONE- RB O
matters, matters, 0 0 0 0 1 0 0 0 8 0 NNP NN -NONE- RB PRP O
then then 0 0 0 0 0 0 0 0 4 0 NN -NONE- RB PRP MD O
it it 0 0 0 0 0 0 0 0 2 0 -NONE- RB PRP MD VB O
might might 0 0 0 0 0 0 0 0 5 0 RB PRP MD VB IN O
evolve evolve 0 0 0 0 0 0 0 0 6 0 PRP MD VB IN NN O
if if 0 0 0 0 0 0 0 0 2 0 MD VB IN NN NNP O
absent absent 0 0 0 0 0 0 0 0 6 0 VB IN NN NNP NNP O
initially. initially. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP NNS O
Previous Previous 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NNS VBD O
workers workers 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD IN O
established established 0 0 0 0 0 0 0 0 11 0 NNP NNS VBD IN RB O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN RB VBN O
newly newly 0 0 0 0 0 0 0 0 5 0 VBD IN RB VBN -NONE- O
made made 0 0 0 0 0 0 0 0 4 0 IN RB VBN -NONE- JJ O
trivalents, trivalents, 0 0 0 0 1 0 0 0 11 0 RB VBN -NONE- JJ NNS O
meiotic meiotic 0 0 0 0 0 0 0 0 7 0 VBN -NONE- JJ NNS IN O
units units 0 0 0 0 0 0 0 0 5 0 -NONE- JJ NNS IN CD O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN CD JJ O
three three 0 0 0 0 0 0 0 0 5 0 NNS IN CD JJ RB O
chromosomes, chromosomes, 0 0 0 0 1 0 0 0 12 0 IN CD JJ RB VBP O
generally generally 0 0 0 0 0 0 0 0 9 0 CD JJ RB VBP RB O
do do 0 0 0 0 0 0 0 0 2 0 JJ RB VBP RB VB O
not not 0 0 0 0 0 0 0 0 3 0 RB VBP RB VB TO O
congress congress 0 0 0 0 0 0 0 0 8 0 VBP RB VB TO DT O
to to 0 0 0 0 0 0 0 0 2 0 RB VB TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VB TO DT NN NNP O
spindle spindle 0 0 0 0 0 0 0 0 7 0 TO DT NN NNP NNP O
equator. equator. 0 0 0 0 0 0 0 0 8 0 DT NN NNP NNP DT O
Instead, Instead, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP DT JJ O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT JJ NNS O
young young 0 0 0 0 0 0 0 0 5 0 NNP DT JJ NNS VBP O
trivalents trivalents 0 0 0 0 0 0 0 0 10 0 DT JJ NNS VBP JJ O
lie lie 0 0 0 0 0 0 0 0 3 0 JJ NNS VBP JJ TO O
close close 0 0 0 0 0 0 0 0 5 0 NNS VBP JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBP JJ TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ TO DT NN TO O
pole pole 0 0 0 0 0 0 0 0 4 0 TO DT NN TO WDT O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO WDT CD O
which which 0 0 0 0 0 0 0 0 5 0 NN TO WDT CD IN O
two two 0 0 0 0 0 0 0 0 3 0 TO WDT CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 WDT CD IN DT CD O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT CD NNS O
three three 0 0 0 0 0 0 0 0 5 0 IN DT CD NNS VBP O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 DT CD NNS VBP NNP O
are are 0 0 0 0 0 0 0 0 3 0 CD NNS VBP NNP NNP O
oriented. oriented. 0 0 0 0 0 0 0 0 9 0 NNS VBP NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 VBP NNP NNP VBD JJ O
studied studied 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD JJ NN O
ancient ancient 0 0 0 0 0 0 0 0 7 0 NNP VBD JJ NN NNS O
sex-chromosome sex-chromosome 0 0 1 0 0 0 0 0 14 0 VBD JJ NN NNS WDT O
trivalents trivalents 0 0 0 0 0 0 0 0 10 0 JJ NN NNS WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 NN NNS WDT NN VBZ O
arose arose 0 0 0 0 0 0 0 0 5 0 NNS WDT NN VBZ IN O
hundreds hundreds 0 0 0 0 0 0 0 0 8 0 WDT NN VBZ IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NN VBZ IN NNS TO O
thousands thousands 0 0 0 0 0 0 0 0 9 0 VBZ IN NNS TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 IN NNS TO JJ CD O
several several 0 0 0 0 0 0 0 0 7 0 NNS TO JJ CD NNS O
million million 0 0 0 0 0 0 0 0 7 0 TO JJ CD NNS IN O
years years 0 0 0 0 0 0 0 0 5 0 JJ CD NNS IN IN O
ago ago 0 0 0 0 0 0 0 0 3 0 CD NNS IN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNS IN IN JJ NNS O
several several 0 0 0 0 0 0 0 0 7 0 IN IN JJ NNS IN O
species species 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN VBG NNS O
praying praying 0 0 0 0 0 0 0 0 7 0 NNS IN VBG NNS CC O
mantids mantids 0 0 0 0 0 0 0 0 7 0 IN VBG NNS CC CD O
and and 0 0 0 0 0 0 0 0 3 0 VBG NNS CC CD NNP O
one one 0 0 0 0 0 0 0 0 3 0 NNS CC CD NNP NNP O
grasshopper. grasshopper. 0 0 0 0 0 0 0 0 12 0 CC CD NNP NNP DT O
All All 1 0 0 0 0 0 0 0 3 0 CD NNP NNP DT JJ O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT JJ NNS O
old old 0 0 0 0 0 0 0 0 3 0 NNP DT JJ NNS VBP O
trivalents trivalents 0 0 0 0 0 0 0 0 10 0 DT JJ NNS VBP IN O
lie lie 0 0 0 0 0 0 0 0 3 0 JJ NNS VBP IN DT O
near near 0 0 0 0 0 0 0 0 4 0 NNS VBP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NN NN O
spindle spindle 0 0 0 0 0 0 0 0 7 0 IN DT NN NN IN O
equator equator 0 0 0 0 0 0 0 0 7 0 DT NN NN IN NN O
at at 0 0 0 0 0 0 0 0 2 0 NN NN IN NN DT O
metaphase; metaphase; 0 0 0 0 0 0 0 0 10 0 NN IN NN DT IN B_TIMEXCCP
some some 0 0 0 0 0 0 0 0 4 0 IN NN DT IN PRP O
of of 0 0 0 0 0 0 0 0 2 0 NN DT IN PRP VBZ O
them them 0 0 0 0 0 0 0 0 4 0 DT IN PRP VBZ IN O
congress congress 0 0 0 0 0 0 0 0 8 0 IN PRP VBZ IN RB O
as as 0 0 0 0 0 0 0 0 2 0 PRP VBZ IN RB TO O
precisely precisely 0 0 0 0 0 0 0 0 9 0 VBZ IN RB TO DT O
to to 0 0 0 0 0 0 0 0 2 0 IN RB TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB TO DT NN IN O
equator equator 0 0 0 0 0 0 0 0 7 0 TO DT NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNS O
ordinary ordinary 0 0 0 0 0 0 0 0 8 0 IN DT JJ NNS IN O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 DT JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NNP O
same same 0 0 0 0 0 0 0 0 4 0 IN DT JJ NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 DT JJ NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP VBP IN O
conclude conclude 0 0 0 0 0 0 0 0 8 0 NNP NNP VBP IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBP IN NN VBD O
congression congression 0 0 0 0 0 0 0 0 11 0 VBP IN NN VBD RB O
evolved evolved 0 0 0 0 0 0 0 0 7 0 IN NN VBD RB CD O
independently independently 0 0 0 0 0 0 0 0 13 0 NN VBD RB CD CC O
two two 0 0 0 0 0 0 0 0 3 0 VBD RB CD CC CD O
or or 0 0 0 0 0 0 0 0 2 0 RB CD CC CD NNS O
three three 0 0 0 0 0 0 0 0 5 0 CD CC CD NNS IN O
times times 0 0 0 0 0 0 0 0 5 0 CC CD NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 CD NNS IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNS NNP O
materials materials 0 0 0 0 0 0 0 0 9 0 IN DT NNS NNP NNP O
studied. studied. 0 0 0 0 0 0 0 0 8 0 DT NNS NNP NNP DT O
Therefore, Therefore, 1 0 0 0 1 0 0 0 10 0 NNS NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 NNP DT NN NN IN B_TIMEXCCP
position position 0 0 0 0 0 0 0 0 8 0 DT NN NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNS VBP O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 NN IN NNS VBP IN O
midway midway 0 0 0 0 0 0 0 0 6 0 IN NNS VBP IN DT O
between between 0 0 0 0 0 0 0 0 7 0 NNS VBP IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NNS VBZ O
poles poles 0 0 0 0 0 0 0 0 5 0 IN DT NNS VBZ TO O
appears appears 0 0 0 0 0 0 0 0 7 0 DT NNS VBZ TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBZ TO JJ CC O
matter, matter, 0 0 0 0 1 0 0 0 7 0 VBZ TO JJ CC NNP O
but but 0 0 0 0 0 0 0 0 3 0 TO JJ CC NNP NNP O
why? why? 0 0 0 0 0 0 0 0 4 0 JJ CC NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 CC NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
praying praying 0 0 0 0 0 0 0 0 7 0 NNP DT NN NN DT O
mantids, mantids, 0 0 0 0 1 0 0 0 8 0 DT NN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NN NN O
evident evident 0 0 0 0 0 0 0 0 7 0 NN DT NN NN VBZ O
answer answer 0 0 0 0 0 0 0 0 6 0 DT NN NN VBZ IN O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NN VBZ IN NN VBZ O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 VBZ IN NN VBZ DT B_TIMEXCCP
is is 0 0 0 0 0 0 0 0 2 0 IN NN VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT JJ NNP O
quality-control quality-control 0 0 1 0 0 0 0 0 15 0 VBZ DT JJ NNP NNP O
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 DT JJ NNP NNP DT B_TIMEXCCP
Sometimes Sometimes 1 0 0 0 0 0 0 0 9 0 JJ NNP NNP DT CD O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT CD NNS O
three three 0 0 0 0 0 0 0 0 5 0 NNP DT CD NNS VBP O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 DT CD NNS VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 CD NNS VBP RB VBN O
not not 0 0 0 0 0 0 0 0 3 0 NNS VBP RB VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 VBP RB VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NN CC O
trivalent trivalent 0 0 0 0 0 0 0 0 9 0 IN DT NN CC RB O
but but 0 0 0 0 0 0 0 0 3 0 DT NN CC RB VBP O
rather rather 0 0 0 0 0 0 0 0 6 0 NN CC RB VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 CC RB VBP JJ IN O
present present 0 0 0 0 0 0 0 0 7 0 RB VBP JJ IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VBP JJ IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 JJ IN DT NN CC O
bivalent bivalent 0 0 0 0 0 0 0 0 8 0 IN DT NN CC DT O
plus plus 0 0 0 0 0 0 0 0 4 0 DT NN CC DT VBN O
an an 0 0 0 0 0 0 0 0 2 0 NN CC DT VBN -NONE- O
unpaired unpaired 0 0 0 0 0 0 0 0 8 0 CC DT VBN -NONE- WDT O
chromosome, chromosome, 0 0 0 0 1 0 0 0 11 0 DT VBN -NONE- WDT NNS O
which which 0 0 0 0 0 0 0 0 5 0 VBN -NONE- WDT NNS VBP O
lies lies 0 0 0 0 0 0 0 0 4 0 -NONE- WDT NNS VBP CD O
near near 0 0 0 0 0 0 0 0 4 0 WDT NNS VBP CD NNP O
one one 0 0 0 0 0 0 0 0 3 0 NNS VBP CD NNP NNP O
pole. pole. 0 0 0 0 0 0 0 0 5 0 VBP CD NNP NNP NNS O
Earlier Earlier 1 0 0 0 0 0 0 0 7 0 CD NNP NNP NNS VBD O
workers workers 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NNS VBD IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN JJ NNS O
such such 0 0 0 0 0 0 0 0 4 0 VBD IN JJ NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 JJ NNS VBP VBN IN O
blocked blocked 0 0 0 0 0 0 0 0 7 0 NNS VBP VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBP VBN IN NN CC O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 VBN IN NN CC RB B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC RB JJ O
eventually eventually 0 0 0 0 0 0 0 0 10 0 NN CC RB JJ DT O
degenerate; degenerate; 0 0 0 0 0 0 0 0 11 0 CC RB JJ DT NNS O
this this 0 0 0 0 0 0 0 0 4 0 RB JJ DT NNS DT O
prevents prevents 0 0 0 0 0 0 0 0 8 0 JJ DT NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 DT NNS DT NN IN O
formation formation 0 0 0 0 0 0 0 0 9 0 NNS DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
sperm sperm 0 0 0 0 0 0 0 0 5 0 NN IN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN JJ NNS O
abnormal abnormal 0 0 0 0 0 0 0 0 8 0 NN IN JJ NNS IN O
combinations combinations 0 0 0 0 0 0 0 0 12 0 IN JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NNP O
sex sex 0 0 0 0 0 0 0 0 3 0 NNS IN NN NNP NNP O
chromosomes. chromosomes. 0 0 0 0 0 0 0 0 12 0 IN NN NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNP NNP VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NN NN O
quality-control quality-control 0 0 1 0 0 0 0 0 15 0 IN DT NN NN MD O
system system 0 0 0 0 0 0 0 0 6 0 DT NN NN MD VB O
would would 0 0 0 0 0 0 0 0 5 0 NN NN MD VB JJ O
have have 0 0 0 0 0 0 0 0 4 0 NN MD VB JJ NN O
trouble trouble 0 0 0 0 0 0 0 0 7 0 MD VB JJ NN DT O
distinguishing distinguishing 0 0 0 0 0 0 0 0 14 0 VB JJ NN DT VBN O
an an 0 0 0 0 0 0 0 0 2 0 JJ NN DT VBN NN O
unpaired unpaired 0 0 0 0 0 0 0 0 8 0 NN DT VBN NN IN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 DT VBN NN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 VBN NN IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT JJ RB O
uncongressed, uncongressed, 0 0 0 0 1 0 0 0 13 0 IN DT JJ RB VBN O
newly newly 0 0 0 0 0 0 0 0 5 0 DT JJ RB VBN -NONE- O
arisen arisen 0 0 0 0 0 0 0 0 6 0 JJ RB VBN -NONE- DT O
trivalent, trivalent, 0 0 0 0 1 0 0 0 10 0 RB VBN -NONE- DT IN O
both both 0 0 0 0 0 0 0 0 4 0 VBN -NONE- DT IN WDT O
of of 0 0 0 0 0 0 0 0 2 0 -NONE- DT IN WDT MD O
which which 0 0 0 0 0 0 0 0 5 0 DT IN WDT MD VB O
would would 0 0 0 0 0 0 0 0 5 0 IN WDT MD VB IN O
lie lie 0 0 0 0 0 0 0 0 3 0 WDT MD VB IN DT O
near near 0 0 0 0 0 0 0 0 4 0 MD VB IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VB IN DT NN NNP O
spindle spindle 0 0 0 0 0 0 0 0 7 0 IN DT NN NNP NNP O
pole. pole. 0 0 0 0 0 0 0 0 5 0 DT NN NNP NNP NNP O
If If 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NNP DT O
so, so, 0 0 0 0 1 0 0 0 3 0 NNP NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NN O
confused confused 0 0 0 0 0 0 0 0 8 0 NNP DT JJ NN NN O
quality-control quality-control 0 0 1 0 0 0 0 0 15 0 DT JJ NN NN MD O
system system 0 0 0 0 0 0 0 0 6 0 JJ NN NN MD VB O
would would 0 0 0 0 0 0 0 0 5 0 NN NN MD VB NN O
block block 0 0 0 0 0 0 0 0 5 0 NN MD VB NN -NONE- O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 MD VB NN -NONE- VBG B_TIMEXCCP
imprudently, imprudently, 0 0 0 0 1 0 0 0 12 0 VB NN -NONE- VBG DT O
causing causing 0 0 0 0 0 0 0 0 7 0 NN -NONE- VBG DT NN O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- VBG DT NN IN O
loss loss 0 0 0 0 0 0 0 0 4 0 VBG DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS WDT O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS WDT MD O
that that 0 0 0 0 0 0 0 0 4 0 IN NNS WDT MD VB O
would would 0 0 0 0 0 0 0 0 5 0 NNS WDT MD VB VBN O
have have 0 0 0 0 0 0 0 0 4 0 WDT MD VB VBN JJ O
produced produced 0 0 0 0 0 0 0 0 8 0 MD VB VBN JJ NNP O
normal normal 0 0 0 0 0 0 0 0 6 0 VB VBN JJ NNP NNP O
sperm. sperm. 0 0 0 0 0 0 0 0 6 0 VBN JJ NNP NNP PRP O
Hence, Hence, 1 0 0 0 1 0 0 0 6 0 JJ NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP IN O
conclude conclude 0 0 0 0 0 0 0 0 8 0 NNP PRP VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NN IN O
congression congression 0 0 0 0 0 0 0 0 11 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN TO O
trivalent trivalent 0 0 0 0 0 0 0 0 9 0 IN DT NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT NN RB O
equator equator 0 0 0 0 0 0 0 0 7 0 TO DT NN RB VBD O
probably probably 0 0 0 0 0 0 0 0 8 0 DT NN RB VBD IN O
evolved evolved 0 0 0 0 0 0 0 0 7 0 NN RB VBD IN IN O
along along 0 0 0 0 0 0 0 0 5 0 RB VBD IN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBD IN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN IN DT NN NN O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 IN DT NN NN NNP B_TIMEXCCP
quality-control quality-control 0 0 1 0 0 0 0 0 15 0 DT NN NN NNP NNP O
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP NN B_TIMEXCCP
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN IN O
congression congression 0 0 0 0 0 0 0 0 11 0 NN IN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NNS O
old old 0 0 0 0 0 0 0 0 3 0 NN IN JJ NNS VBZ O
trivalents trivalents 0 0 0 0 0 0 0 0 10 0 IN JJ NNS VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 JJ NNS VBZ JJ CC O
uncertain, uncertain, 0 0 0 0 1 0 0 0 10 0 NNS VBZ JJ CC RB O
but but 0 0 0 0 0 0 0 0 3 0 VBZ JJ CC RB VBZ O
probably probably 0 0 0 0 0 0 0 0 8 0 JJ CC RB VBZ DT O
involves involves 0 0 0 0 0 0 0 0 8 0 CC RB VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 RB VBZ DT JJ JJ O
interesting interesting 0 0 0 0 0 0 0 0 11 0 VBZ DT JJ JJ NN O
force-sensitive force-sensitive 0 0 1 0 0 0 0 0 15 0 DT JJ JJ NN IN O
regulation regulation 0 0 0 0 0 0 0 0 10 0 JJ JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS VBN O
motors motors 0 0 0 0 0 0 0 0 6 0 IN DT NNS VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 DT NNS VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBN IN JJ NNP O
particular particular 0 0 0 0 0 0 0 0 10 0 VBN IN JJ NNP NNP O
chromosomes. chromosomes. 0 0 0 0 0 0 0 0 12 0 IN JJ NNP NNP RB O
We We 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP RB VBD O
also also 0 0 0 0 0 0 0 0 4 0 NNP NNP RB VBD DT O
examined examined 0 0 0 0 0 0 0 0 8 0 NNP RB VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBD DT NN IN O
congression congression 0 0 0 0 0 0 0 0 11 0 VBD DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD RB O
two two 0 0 0 0 0 0 0 0 3 0 NN IN CD RB VBN O
newly newly 0 0 0 0 0 0 0 0 5 0 IN CD RB VBN NNS O
made made 0 0 0 0 0 0 0 0 4 0 CD RB VBN NNS WRB O
quadrivalents quadrivalents 0 0 0 0 0 0 0 0 13 0 RB VBN NNS WRB PRP O
when when 0 0 0 0 0 0 0 0 4 0 VBN NNS WRB PRP VBP O
they they 0 0 0 0 0 0 0 0 4 0 NNS WRB PRP VBP IN O
orient orient 0 0 0 0 0 0 0 0 6 0 WRB PRP VBP IN CD O
with with 0 0 0 0 0 0 0 0 4 0 PRP VBP IN CD NNS O
three three 0 0 0 0 0 0 0 0 5 0 VBP IN CD NNS TO O
kinetochores kinetochores 0 0 0 0 0 0 0 0 12 0 IN CD NNS TO CD O
to to 0 0 0 0 0 0 0 0 2 0 CD NNS TO CD NN O
one one 0 0 0 0 0 0 0 0 3 0 NNS TO CD NN CC O
pole pole 0 0 0 0 0 0 0 0 4 0 TO CD NN CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD NN CC CD TO O
one one 0 0 0 0 0 0 0 0 3 0 NN CC CD TO DT O
to to 0 0 0 0 0 0 0 0 2 0 CC CD TO DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 CD TO DT NNP NNP O
other. other. 0 0 0 0 0 0 0 0 6 0 TO DT NNP NNP NNS O
As As 1 0 0 0 0 0 0 0 2 0 DT NNP NNP NNS VBP O
others others 0 0 0 0 0 0 0 0 6 0 NNP NNP NNS VBP JJ O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP JJ CD O
described, described, 0 0 0 0 1 0 0 0 10 0 NNS VBP JJ CD IN O
one one 0 0 0 0 0 0 0 0 3 0 VBP JJ CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ CD IN DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 CD IN DT NNS VBZ O
quadrivalents quadrivalents 0 0 0 0 0 0 0 0 13 0 IN DT NNS VBZ RB O
does does 0 0 0 0 0 0 0 0 4 0 DT NNS VBZ RB JJ O
not not 0 0 0 0 0 0 0 0 3 0 NNS VBZ RB JJ IN O
congress, congress, 0 0 0 0 1 0 0 0 9 0 VBZ RB JJ IN DT O
while while 0 0 0 0 0 0 0 0 5 0 RB JJ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT JJ NN O
other other 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN VBZ O
quadrivalent quadrivalent 0 0 0 0 0 0 0 0 12 0 DT JJ NN VBZ JJR O
comes comes 0 0 0 0 0 0 0 0 5 0 JJ NN VBZ JJR IN O
closer closer 0 0 0 0 0 0 0 0 6 0 NN VBZ JJR IN VBN O
than than 0 0 0 0 0 0 0 0 4 0 VBZ JJR IN VBN TO O
expected expected 0 0 0 0 0 0 0 0 8 0 JJR IN VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 IN VBN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN TO DT NN NNP O
spindle spindle 0 0 0 0 0 0 0 0 7 0 TO DT NN NNP NNP O
equator. equator. 0 0 0 0 0 0 0 0 8 0 DT NN NNP NNP NN O
Such Such 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NN IN O
variation variation 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
extent extent 0 0 0 0 0 0 0 0 6 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN MD O
congression congression 0 0 0 0 0 0 0 0 11 0 NN IN NN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 IN NN MD VB NNS O
provide provide 0 0 0 0 0 0 0 0 7 0 NN MD VB NNS IN O
materials materials 0 0 0 0 0 0 0 0 9 0 MD VB NNS IN WDT O
on on 0 0 0 0 0 0 0 0 2 0 VB NNS IN WDT JJ O
which which 0 0 0 0 0 0 0 0 5 0 NNS IN WDT JJ NN O
natural natural 0 0 0 0 0 0 0 0 7 0 IN WDT JJ NN MD O
selection selection 0 0 0 0 0 0 0 0 9 0 WDT JJ NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 JJ NN MD VB VBG O
act, act, 0 0 0 0 1 0 0 0 4 0 NN MD VB VBG TO O
leading leading 0 0 0 0 0 0 0 0 7 0 MD VB VBG TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VB VBG TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBG TO DT NN IN O
evolution evolution 0 0 0 0 0 0 0 0 9 0 TO DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
congression. congression. 0 0 0 0 0 0 0 0 12 0 NN IN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNS IN O
trivalents trivalents 0 0 0 0 0 0 0 0 10 0 NNP NNP NNS IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN VBG NNS O
praying praying 0 0 0 0 0 0 0 0 7 0 NNS IN VBG NNS VBP O
mantids mantids 0 0 0 0 0 0 0 0 7 0 IN VBG NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 VBG NNS VBP JJ NNS O
attractive attractive 0 0 0 0 0 0 0 0 10 0 NNS VBP JJ NNS IN O
materials materials 0 0 0 0 0 0 0 0 9 0 VBP JJ NNS IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN JJ NNS O
further further 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NNS IN O
studies studies 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN CC O
congression congression 0 0 0 0 0 0 0 0 11 0 NN IN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN CC IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC IN DT NN IN O
idea idea 0 0 0 0 0 0 0 0 4 0 IN DT NN IN NN O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN NN VBZ O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 NN IN NN VBZ DT B_TIMEXCCP
is is 0 0 0 0 0 0 0 0 2 0 IN NN VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT NN IN O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 VBZ DT NN IN NN B_TIMEXCCP
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN NN IN O
progression progression 0 0 0 0 0 0 0 0 11 0 NN IN NN IN DT O
through through 0 0 0 0 0 0 0 0 7 0 IN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NNP NNP O
cycle. cycle. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
1429886 1429886 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
[Nucleolar [Nucleolar 0 0 0 0 0 0 0 0 10 0 NONE NONE JJ NN IN O
structure structure 0 0 0 0 0 0 0 0 9 0 NONE JJ NN IN DT O
during during 0 0 0 0 0 0 0 0 6 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
prophase prophase 0 0 0 0 0 0 0 0 8 0 IN DT NN IN NNP B_TIMEXCCP
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
Physarum Physarum 1 0 0 0 0 0 0 0 8 0 NN IN NNP NNP NNP O
polycephalum]. polycephalum]. 0 0 0 0 0 0 0 0 14 0 IN NNP NNP NNP IN O
[Article [Article 0 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
French] French] 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
Ploton Ploton 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Gontcharoff Gontcharoff 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
M. M. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
With With 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NN O
Sugihara's Sugihara's 1 0 0 0 0 1 0 0 10 0 NNP NNP NNP NN -NONE- O
fixation fixation 0 0 0 0 0 0 0 0 8 0 NNP NNP NN -NONE- NN O
technique, technique, 0 0 0 0 1 0 0 0 10 0 NNP NN -NONE- NN JJ O
electron electron 0 0 0 0 0 0 0 0 8 0 NN -NONE- NN JJ NN O
microscopic microscopic 0 0 0 0 0 0 0 0 11 0 -NONE- NN JJ NN IN O
study study 0 0 0 0 0 0 0 0 5 0 NN JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
early-prophase early-prophase 0 0 1 0 0 0 0 0 14 0 NN IN JJ NN IN B_TIMEXCCP
nucleolus nucleolus 0 0 0 0 0 0 0 0 9 0 IN JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
Physarm Physarm 1 0 0 0 0 0 0 0 7 0 IN DT NNP NN VBD O
polycephalum polycephalum 0 0 0 0 0 0 0 0 12 0 DT NNP NN VBD DT O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NN VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBD DT NN IN O
existence existence 0 0 0 0 0 0 0 0 9 0 VBD DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
particular particular 0 0 0 0 0 0 0 0 10 0 NN IN JJ NN NNP O
fibrillar fibrillar 0 0 0 0 0 0 0 0 9 0 IN JJ NN NNP NNP O
structures. structures. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP JJ NN O
characteristic characteristic 0 0 0 0 0 0 0 0 14 0 NNP NNP JJ NN IN O
feature feature 0 0 0 0 0 0 0 0 7 0 NNP JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT JJ NNS O
spherical spherical 0 0 0 0 0 0 0 0 9 0 IN DT JJ NNS VBZ O
structures structures 0 0 0 0 0 0 0 0 10 0 DT JJ NNS VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 JJ NNS VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNS VBZ DT JJ NN O
electron-lucid electron-lucid 0 0 1 0 0 0 0 0 14 0 VBZ DT JJ NN VBD O
center center 0 0 0 0 0 0 0 0 6 0 DT JJ NN VBD IN O
surrounded surrounded 0 0 0 0 0 0 0 0 10 0 JJ NN VBD IN DT O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBD IN DT NN NN O
dense dense 0 0 0 0 0 0 0 0 5 0 IN DT NN NN NNP O
fibrillar fibrillar 0 0 0 0 0 0 0 0 9 0 DT NN NN NNP NNP O
component. component. 0 0 0 0 0 0 0 0 10 0 NN NN NNP NNP NNS O
Their Their 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNS IN O
relationships relationships 0 0 0 0 0 0 0 0 13 0 NNP NNP NNS IN DT O
between between 0 0 0 0 0 0 0 0 7 0 NNP NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
"fibrillar "fibrillar 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN CC O
centers" centers" 0 0 0 0 0 0 0 0 8 0 DT JJ NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC IN DT O
between between 0 0 0 0 0 0 0 0 7 0 NN CC IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC IN DT NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
ribosomal ribosomal 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNP NN O
RNA RNA 1 1 0 0 0 0 0 0 3 0 IN JJ NNP NN VBP O
synthesis synthesis 0 0 0 0 0 0 0 0 9 0 JJ NNP NN VBP NNP O
are are 0 0 0 0 0 0 0 0 3 0 NNP NN VBP NNP NNP O
studied. studied. 0 0 0 0 0 0 0 0 8 0 NN VBP NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 VBP NNP NNP CD JJ O
413663 413663 0 0 0 0 0 0 1 1 6 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 NONE NONE NN NN IN B_TIMEXCCP
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 NONE NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NNP O
lamin lamin 0 0 0 0 0 0 0 0 5 0 NN IN NN NNP NNP O
B2. B2. 1 1 0 0 0 0 0 1 3 0 IN NN NNP NNP NNP O
Kill Kill 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NNP NNP O
IR, IR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Hutchison Hutchison 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
CJ. CJ. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biological Biological 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Dundee, Dundee, 1 0 0 0 1 0 0 0 7 0 NNP IN NNP NNP NNP O
Scotland, Scotland, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
UK. UK. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Lamin Lamin 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NN O
B2 B2 1 1 0 0 0 0 0 1 2 0 NNP NNP NNP NN IN O
modification modification 0 0 0 0 0 0 0 0 12 0 NNP NNP NN IN RB O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN RB VBG O
synchronously synchronously 0 0 0 0 0 0 0 0 13 0 NN IN RB VBG NNS O
dividing dividing 0 0 0 0 0 0 0 0 8 0 IN RB VBG NNS IN O
populations populations 0 0 0 0 0 0 0 0 11 0 RB VBG NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBG NNS IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NN NNS O
diploid diploid 0 0 0 0 0 0 0 0 7 0 IN JJ NN NNS VBD O
fibroblasts fibroblasts 0 0 0 0 0 0 0 0 11 0 JJ NN NNS VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NNS VBD VBN IN O
determined determined 0 0 0 0 0 0 0 0 10 0 NNS VBD VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NN O
2-dimensional 2-dimensional 0 0 1 0 0 0 0 1 13 0 VBN IN JJ NN NN O
gel gel 0 0 0 0 0 0 0 0 3 0 IN JJ NN NN CC O
electrophoresis electrophoresis 0 0 0 0 0 0 0 0 15 0 JJ NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NNP O
[32P]orthophosphate [32P]orthophosphate 0 0 0 0 0 0 0 1 19 0 NN CC JJ NNP NNP O
labelling. labelling. 0 0 0 0 0 0 0 0 10 0 CC JJ NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NN NN O
quiescent quiescent 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NN CC O
(G0) (G0) 0 1 0 0 0 0 0 1 4 0 NNP NN NN CC NNP B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNS O
G1 G1 1 1 0 0 0 0 0 1 2 0 NN CC NNP NNS IN B_TIMEXCCP
cultures cultures 0 0 0 0 0 0 0 0 8 0 CC NNP NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN JJ NN O
HDF, HDF, 1 1 0 0 1 0 0 0 4 0 NNS IN JJ NN NNP O
lamin lamin 0 0 0 0 0 0 0 0 5 0 IN JJ NN NNP VBD O
B2 B2 1 1 0 0 0 0 0 1 2 0 JJ NN NNP VBD IN O
migrated migrated 0 0 0 0 0 0 0 0 8 0 NN NNP VBD IN CD O
as as 0 0 0 0 0 0 0 0 2 0 NNP VBD IN CD NNS O
2 2 0 0 0 0 0 0 1 1 1 0 VBD IN CD NNS IN O
spots spots 0 0 0 0 0 0 0 0 5 0 IN CD NNS IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 CD NNS IN JJ NNP O
2-dimensional 2-dimensional 0 0 1 0 0 0 0 1 13 0 NNS IN JJ NNP NNP O
gels. gels. 0 0 0 0 0 0 0 0 5 0 IN JJ NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NNP IN O
contrast, contrast, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ NNS O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 NNP IN JJ NNS IN B_TIMEXCCP
populations populations 0 0 0 0 0 0 0 0 11 0 IN JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NN O
HDF HDF 1 1 0 0 0 0 0 0 3 0 NNS IN NNP NN NNP O
lamin lamin 0 0 0 0 0 0 0 0 5 0 IN NNP NN NNP VBD O
B2 B2 1 1 0 0 0 0 0 1 2 0 NNP NN NNP VBD IN O
migrated migrated 0 0 0 0 0 0 0 0 8 0 NN NNP VBD IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NNP VBD IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBD IN DT JJ JJ O
single single 0 0 0 0 0 0 0 0 6 0 IN DT JJ JJ NNP O
basic basic 0 0 0 0 0 0 0 0 5 0 DT JJ JJ NNP NNP O
species. species. 0 0 0 0 0 0 0 0 8 0 JJ JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
level level 0 0 0 0 0 0 0 0 5 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NNP O
lamin lamin 0 0 0 0 0 0 0 0 5 0 NN IN NN NNP NN O
B2 B2 1 1 0 0 0 0 0 1 2 0 IN NN NNP NN VBD O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 NN NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
determined determined 0 0 0 0 0 0 0 0 10 0 NN VBD VBN IN NN O
after after 0 0 0 0 0 0 0 0 5 0 VBD VBN IN NN IN O
immunoisolation immunoisolation 0 0 0 0 0 0 0 0 15 0 VBN IN NN IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 IN NN IN JJ VBN O
[32P]orthophosphate [32P]orthophosphate 0 0 0 0 0 0 0 1 19 0 NN IN JJ VBN NNP O
labelled labelled 0 0 0 0 0 0 0 0 8 0 IN JJ VBN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 JJ VBN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 VBN NNP NNP NNS IN O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNS IN DT NNS VBD O
experiments experiments 0 0 0 0 0 0 0 0 11 0 IN DT NNS VBD DT O
indicated indicated 0 0 0 0 0 0 0 0 9 0 DT NNS VBD DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS VBD DT JJ NN O
2-3-fold 2-3-fold 0 0 1 0 0 0 0 1 8 0 VBD DT JJ NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
steady steady 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN NN O
state state 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN IN O
level level 0 0 0 0 0 0 0 0 5 0 JJ NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NNP O
lamin lamin 0 0 0 0 0 0 0 0 5 0 NN IN NN NNP NN O
B2 B2 1 1 0 0 0 0 0 1 2 0 IN NN NNP NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 NN NNP NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NNP O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 NN IN NN NNP VBD B_TIMEXCCP
HDF HDF 1 1 0 0 0 0 0 0 3 0 IN NN NNP VBD IN O
compared compared 0 0 0 0 0 0 0 0 8 0 NN NNP VBD IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNP VBD IN NNP NNP O
G0 G0 1 1 0 0 0 0 0 1 2 0 VBD IN NNP NNP NNP O
HDF. HDF. 1 1 0 0 0 0 0 0 4 0 IN NNP NNP NNP IN O
Consistent Consistent 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNP IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP IN DT NN JJ O
evidence, evidence, 0 0 0 0 1 0 0 0 9 0 IN DT NN JJ NN O
tryptic tryptic 0 0 0 0 0 0 0 0 7 0 DT NN JJ NN NNS O
peptide peptide 0 0 0 0 0 0 0 0 7 0 NN JJ NN NNS VBD O
maps maps 0 0 0 0 0 0 0 0 4 0 JJ NN NNS VBD DT O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NN NNS VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBD DT NN IN O
presence presence 0 0 0 0 0 0 0 0 8 0 VBD DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN IN O
phosphopeptide phosphopeptide 0 0 0 0 0 0 0 0 14 0 IN DT NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 NN IN NN NN NNP B_TIMEXCCP
lamin lamin 0 0 0 0 0 0 0 0 5 0 IN NN NN NNP WDT O
B2 B2 1 1 0 0 0 0 0 1 2 0 NN NN NNP WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 NN NNP WDT VBD JJ O
was was 0 0 0 0 0 0 0 0 3 0 NNP WDT VBD JJ IN O
absent absent 0 0 0 0 0 0 0 0 6 0 WDT VBD JJ IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 VBD JJ IN NNP NN O
G0 G0 1 1 0 0 0 0 0 1 2 0 JJ IN NNP NN NNP B_TIMEXCCP
lamin lamin 0 0 0 0 0 0 0 0 5 0 IN NNP NN NNP NNP O
B2. B2. 1 1 0 0 0 0 0 1 3 0 NNP NN NNP NNP DT O
Since Since 1 0 0 0 0 0 0 0 5 0 NN NNP NNP DT IN O
all all 0 0 0 0 0 0 0 0 3 0 NNP NNP DT IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP DT IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 DT IN DT NN VBD O
phosphate phosphate 0 0 0 0 0 0 0 0 9 0 IN DT NN VBD IN O
incorporated incorporated 0 0 0 0 0 0 0 0 12 0 DT NN VBD IN JJ O
into into 0 0 0 0 0 0 0 0 4 0 NN VBD IN JJ CC O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 VBD IN JJ CC NNP B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC NNP NN O
G0 G0 1 1 0 0 0 0 0 1 2 0 JJ CC NNP NN NNP B_TIMEXCCP
lamin lamin 0 0 0 0 0 0 0 0 5 0 CC NNP NN NNP VBD O
B2 B2 1 1 0 0 0 0 0 1 2 0 NNP NN NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NNP VBD VBN IN O
recovered recovered 0 0 0 0 0 0 0 0 9 0 NNP VBD VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN NNS O
serine serine 0 0 0 0 0 0 0 0 6 0 VBN IN NN NNS PRP O
residues residues 0 0 0 0 0 0 0 0 8 0 IN NN NNS PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NN NNS PRP VBP IN O
conclude conclude 0 0 0 0 0 0 0 0 8 0 NNS PRP VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NN NN O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 IN DT NN NN NN B_TIMEXCCP
specific specific 0 0 0 0 0 0 0 0 8 0 DT NN NN NN VBD O
phosphopeptide phosphopeptide 0 0 0 0 0 0 0 0 14 0 NN NN NN VBD RB O
did did 0 0 0 0 0 0 0 0 3 0 NN NN VBD RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NN VBD RB VB DT O
represent represent 0 0 0 0 0 0 0 0 9 0 VBD RB VB DT IN O
either either 0 0 0 0 0 0 0 0 6 0 RB VB DT IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VB DT IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 DT IN DT NNP VBZ O
cdc2 cdc2 0 0 0 0 0 0 0 1 4 0 IN DT NNP VBZ VBN O
sites sites 0 0 0 0 0 0 0 0 5 0 DT NNP VBZ VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NNP VBZ VBN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN NN JJ O
entry entry 0 0 0 0 0 0 0 0 5 0 VBN IN NN JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 IN NN JJ NN NNP O
lamina lamina 0 0 0 0 0 0 0 0 6 0 NN JJ NN NNP NNP O
breakdown. breakdown. 0 0 0 0 0 0 0 0 10 0 JJ NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
8543011 8543011 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Mammalian Mammalian 1 0 0 0 0 0 0 0 9 0 NONE NONE JJ NN NN O
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 NONE JJ NN NN VBD O
become become 0 0 0 0 0 0 0 0 6 0 JJ NN NN VBD IN O
licensed licensed 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NN VBD IN NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 VBD IN NNP NN IN O
replication replication 0 0 0 0 0 0 0 0 11 0 IN NNP NN IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 NNP NN IN JJ NNP O
late late 0 0 0 0 0 0 0 0 4 0 NN IN JJ NNP NNP telophase
telophase. telophase. 0 0 0 0 0 0 0 0 10 0 IN JJ NNP NNP NNP O
Dimitrova Dimitrova 1 0 0 0 0 0 0 0 9 0 JJ NNP NNP NNP NNP O
DS, DS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Prokhorova Prokhorova 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
TA, TA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Blow Blow 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
JJ, JJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Todorov Todorov 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
IT, IT, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Gilbert Gilbert 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
DM. DM. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Biochemistry Biochemistry 1 0 0 0 0 0 0 0 12 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP CC NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 CC NNP NNP NNP NNP O
SUNY SUNY 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Upstate Upstate 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP CD O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP CD NNP O
750 750 0 0 0 0 0 0 1 1 3 0 NNP NNP CD NNP NNP O
East East 1 0 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Adams Adams 1 0 0 0 0 0 0 0 5 0 CD NNP NNP NNP NNP O
Street, Street, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Syracuse, Syracuse, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP CD O
NY NY 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
13210, 13210, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
dsd7@acsu.buffalo.edu dsd7@acsu.buffalo.edu 0 0 0 0 0 0 0 1 21 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP CD O
Mcm Mcm 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP CD VBP O
2-7 2-7 0 0 1 0 0 0 0 1 3 0 NNP NNP CD VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNP CD VBP JJ NN O
essential essential 0 0 0 0 0 0 0 0 9 0 CD VBP JJ NN NNS O
replication replication 0 0 0 0 0 0 0 0 11 0 VBP JJ NN NNS WDT O
proteins proteins 0 0 0 0 0 0 0 0 8 0 JJ NN NNS WDT IN O
that that 0 0 0 0 0 0 0 0 4 0 NN NNS WDT IN TO O
bind bind 0 0 0 0 0 0 0 0 4 0 NNS WDT IN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 WDT IN TO VB IN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 IN TO VB IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 TO VB IN JJ NN O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 VB IN JJ NN IN O
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 IN JJ NN IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 JJ NN IN JJ NNP O
late late 0 0 0 0 0 0 0 0 4 0 NN IN JJ NNP NNP telophase
telophase. telophase. 0 0 0 0 0 0 0 0 10 0 IN JJ NNP NNP PRP O
Here, Here, 1 0 0 0 1 0 0 0 5 0 JJ NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP PRP VBP VBN DT O
investigated investigated 0 0 0 0 0 0 0 0 12 0 PRP VBP VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP VBN DT NN IN O
relationship relationship 0 0 0 0 0 0 0 0 12 0 VBN DT NN IN NNP O
between between 0 0 0 0 0 0 0 0 7 0 DT NN IN NNP NNP O
Mcm Mcm 1 0 0 0 0 0 0 0 3 0 NN IN NNP NNP NN O
binding, binding, 0 0 0 0 1 0 0 0 8 0 IN NNP NNP NN IN O
licensing licensing 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN IN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 NN IN NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 IN NN IN NN CC O
replication, replication, 0 0 0 0 1 0 0 0 12 0 NN IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN IN O
specification specification 0 0 0 0 0 0 0 0 13 0 NN CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
dihydrofolate dihydrofolate 0 0 0 0 0 0 0 0 13 0 IN DT NN NN NN O
reductase reductase 0 0 0 0 0 0 0 0 9 0 DT NN NN NN NN O
(DHFR) (DHFR) 0 1 0 0 0 0 0 0 6 0 NN NN NN NN NNP O
replication replication 0 0 0 0 0 0 0 0 11 0 NN NN NN NNP NNP O
origin. origin. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP CD O
Approximately Approximately 1 0 0 0 0 0 0 0 13 0 NN NNP NNP CD IN O
20% 20% 0 0 0 0 0 0 0 1 3 0 NNP NNP CD IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP CD IN JJ NNP O
total total 0 0 0 0 0 0 0 0 5 0 CD IN JJ NNP NN O
Mcm3 Mcm3 1 0 0 0 0 0 0 1 4 0 IN JJ NNP NN VBD O
protein protein 0 0 0 0 0 0 0 0 7 0 JJ NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN TO O
bound bound 0 0 0 0 0 0 0 0 5 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB IN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 VBN TO VB IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 TO VB IN JJ NN O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 VB IN JJ NN NN O
hamster hamster 0 0 0 0 0 0 0 0 7 0 IN JJ NN NN NN O
ovary ovary 0 0 0 0 0 0 0 0 5 0 JJ NN NN NN NNS O
(CHO) (CHO) 0 1 0 0 0 0 0 0 5 0 NN NN NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 NN NNS IN JJ IN O
telophase, telophase, 0 0 0 0 1 0 0 0 10 0 NNS IN JJ IN DT B_TIMEXCCP
while while 0 0 0 0 0 0 0 0 5 0 IN JJ IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 JJ IN DT JJ CD O
additional additional 0 0 0 0 0 0 0 0 10 0 IN DT JJ CD NN O
25% 25% 0 0 0 0 0 0 0 1 3 0 DT JJ CD NN RB O
bound bound 0 0 0 0 0 0 0 0 5 0 JJ CD NN RB CC O
gradually gradually 0 0 0 0 0 0 0 0 9 0 CD NN RB CC RB O
and and 0 0 0 0 0 0 0 0 3 0 NN RB CC RB IN O
cumulatively cumulatively 0 0 0 0 0 0 0 0 12 0 RB CC RB IN NNP O
throughout throughout 0 0 0 0 0 0 0 0 10 0 CC RB IN NNP NNP O
G1-phase. G1-phase. 1 0 1 0 0 0 0 1 9 0 RB IN NNP NNP VB O
To To 1 0 0 0 0 0 0 0 2 0 IN NNP NNP VB DT O
investigate investigate 0 0 0 0 0 0 0 0 11 0 NNP NNP VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP VB DT JJ NN O
functional functional 0 0 0 0 0 0 0 0 10 0 VB DT JJ NN IN O
significance significance 0 0 0 0 0 0 0 0 12 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN NN O
binding, binding, 0 0 0 0 1 0 0 0 8 0 IN DT NN NN VBN O
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 DT NN NN VBN IN O
prepared prepared 0 0 0 0 0 0 0 0 8 0 NN NN VBN IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NN VBN IN NNP NNS O
CHO CHO 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS VBD IN O
synchronized synchronized 0 0 0 0 0 0 0 0 12 0 NNP NNS VBD IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 NNS VBD IN JJ NNS O
various various 0 0 0 0 0 0 0 0 7 0 VBD IN JJ NNS IN O
times times 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN NN O
after after 0 0 0 0 0 0 0 0 5 0 JJ NNS IN NN VBD O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 NNS IN NN VBD VBN B_TIMEXCCP
were were 0 0 0 0 0 0 0 0 4 0 IN NN VBD VBN IN O
introduced introduced 0 0 0 0 0 0 0 0 10 0 NN VBD VBN IN NNP O
into into 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNP NN O
Xenopus Xenopus 1 0 0 0 0 0 0 0 7 0 VBN IN NNP NN -NONE- O
egg egg 0 0 0 0 0 0 0 0 3 0 IN NNP NN -NONE- WDT O
extracts, extracts, 0 0 0 0 1 0 0 0 9 0 NNP NN -NONE- WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 NN -NONE- WDT VBD DT O
were were 0 0 0 0 0 0 0 0 4 0 -NONE- WDT VBD DT VBN O
either either 0 0 0 0 0 0 0 0 6 0 WDT VBD DT VBN IN O
immunodepleted immunodepleted 0 0 0 0 0 0 0 0 14 0 VBD DT VBN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT VBN IN NNP NNS O
Mcm Mcm 1 0 0 0 0 0 0 0 3 0 VBN IN NNP NNS CC O
proteins proteins 0 0 0 0 0 0 0 0 8 0 IN NNP NNS CC VBN O
or or 0 0 0 0 0 0 0 0 2 0 NNP NNS CC VBN IN O
supplemented supplemented 0 0 0 0 0 0 0 0 12 0 NNS CC VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 CC VBN IN JJ DT O
geminin, geminin, 0 0 0 0 1 0 0 0 8 0 VBN IN JJ DT NN O
an an 0 0 0 0 0 0 0 0 2 0 IN JJ DT NN IN O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 JJ DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
Mcm-loading Mcm-loading 1 0 1 0 0 0 0 0 11 0 IN DT JJ NN NNP O
protein protein 0 0 0 0 0 0 0 0 7 0 DT JJ NN NNP NNP O
Cdt1. Cdt1. 1 0 0 0 0 0 0 1 5 0 JJ NN NNP NNP CD O
Within Within 1 0 0 0 0 0 0 0 6 0 NN NNP NNP CD NN O
1 1 0 0 0 0 0 0 1 1 1 0 NNP NNP CD NN IN O
hour hour 0 0 0 0 0 0 0 0 4 0 NNP CD NN IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 CD NN IN NNP NN O
metaphase, metaphase, 0 0 0 0 1 0 0 0 10 0 NN IN NNP NN IN B_TIMEXCCP
coincident coincident 0 0 0 0 0 0 0 0 10 0 IN NNP NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NNP NN IN NN IN O
completion completion 0 0 0 0 0 0 0 0 10 0 NN IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN NN O
envelope envelope 0 0 0 0 0 0 0 0 8 0 IN JJ NN NN NNP O
formation, formation, 0 0 0 0 1 0 0 0 10 0 JJ NN NN NNP NN O
CHO CHO 1 1 0 0 0 0 0 0 3 0 NN NN NNP NN VBD O
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 NN NNP NN VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NNP NN VBD RB JJ O
fully fully 0 0 0 0 0 0 0 0 5 0 NN VBD RB JJ TO O
competent competent 0 0 0 0 0 0 0 0 9 0 VBD RB JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 RB JJ TO VB IN O
replicate replicate 0 0 0 0 0 0 0 0 9 0 JJ TO VB IN DT O
in in 0 0 0 0 0 0 0 0 2 0 TO VB IN DT IN O
both both 0 0 0 0 0 0 0 0 4 0 VB IN DT IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN DT IN DT JJ O
these these 0 0 0 0 0 0 0 0 5 0 DT IN DT JJ NNP O
licensing-defective licensing-defective 0 0 1 0 0 0 0 0 19 0 IN DT JJ NNP NNP O
extracts. extracts. 0 0 0 0 0 0 0 0 9 0 DT JJ NNP NNP VBZ O
However, However, 1 0 0 0 1 0 0 0 8 0 JJ NNP NNP VBZ IN O
sites sites 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN NN IN O
initiation initiation 0 0 0 0 0 0 0 0 10 0 VBZ IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN IN O
replication replication 0 0 0 0 0 0 0 0 11 0 NN IN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN DT IN O
each each 0 0 0 0 0 0 0 0 4 0 NN IN DT IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN DT IN DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 DT IN DT NNS VBD O
extracts extracts 0 0 0 0 0 0 0 0 8 0 IN DT NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 DT NNS VBD VBN TO O
found found 0 0 0 0 0 0 0 0 5 0 NNS VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB VBN IN O
dispersed dispersed 0 0 0 0 0 0 0 0 9 0 TO VB VBN IN DT O
throughout throughout 0 0 0 0 0 0 0 0 10 0 VB VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP VBZ O
DHFR DHFR 1 1 0 0 0 0 0 0 4 0 IN DT NNP VBZ IN O
locus locus 0 0 0 0 0 0 0 0 5 0 DT NNP VBZ IN NN O
within within 0 0 0 0 0 0 0 0 6 0 NNP VBZ IN NN VBN O
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 VBZ IN NN VBN IN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 IN NN VBN IN CD O
between between 0 0 0 0 0 0 0 0 7 0 NN VBN IN CD TO O
1 1 0 0 0 0 0 0 1 1 1 0 VBN IN CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 IN CD TO CD NNS O
5 5 0 0 0 0 0 0 1 1 1 0 CD TO CD NNS IN O
hours hours 0 0 0 0 0 0 0 0 5 0 TO CD NNS IN JJ O
after after 0 0 0 0 0 0 0 0 5 0 CD NNS IN JJ CC O
metaphase, metaphase, 0 0 0 0 1 0 0 0 10 0 NNS IN JJ CC VBD B_TIMEXCCP
but but 0 0 0 0 0 0 0 0 3 0 IN JJ CC VBD VBN O
became became 0 0 0 0 0 0 0 0 6 0 JJ CC VBD VBN TO O
focused focused 0 0 0 0 0 0 0 0 7 0 CC VBD VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN TO DT NNP NN O
DHFR DHFR 1 1 0 0 0 0 0 0 4 0 TO DT NNP NN IN O
origin origin 0 0 0 0 0 0 0 0 6 0 DT NNP NN IN NN O
within within 0 0 0 0 0 0 0 0 6 0 NNP NN IN NN VBN O
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 NN IN NN VBN IN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 IN NN VBN IN CD O
after after 0 0 0 0 0 0 0 0 5 0 NN VBN IN CD NNS O
5 5 0 0 0 0 0 0 1 1 1 0 VBN IN CD NNS NNP O
hours hours 0 0 0 0 0 0 0 0 5 0 IN CD NNS NNP NNP O
post-metaphase. post-metaphase. 0 0 1 0 0 0 0 0 15 0 CD NNS NNP NNP NN O
Importantly, Importantly, 1 0 0 0 1 0 0 0 12 0 NNS NNP NNP NN IN O
introduction introduction 0 0 0 0 0 0 0 0 12 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
permeabilized permeabilized 0 0 0 0 0 0 0 0 13 0 NN IN JJ NN CC O
post-ODP, post-ODP, 0 0 1 0 1 0 0 0 9 0 IN JJ NN CC RB O
but but 0 0 0 0 0 0 0 0 3 0 JJ NN CC RB JJ O
not not 0 0 0 0 0 0 0 0 3 0 NN CC RB JJ NNP O
pre-ODP, pre-ODP, 0 0 1 0 1 0 0 0 8 0 CC RB JJ NNP NN O
CHO CHO 1 1 0 0 0 0 0 0 3 0 RB JJ NNP NN IN O
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 JJ NNP NN IN JJ O
into into 0 0 0 0 0 0 0 0 4 0 NNP NN IN JJ NNP O
licensing-deficient licensing-deficient 0 0 1 0 0 0 0 0 19 0 NN IN JJ NNP NN O
Xenopus Xenopus 1 0 0 0 0 0 0 0 7 0 IN JJ NNP NN NNS O
egg egg 0 0 0 0 0 0 0 0 3 0 JJ NNP NN NNS VBD O
extracts extracts 0 0 0 0 0 0 0 0 8 0 NNP NN NNS VBD IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 NN NNS VBD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN IN O
preservation preservation 0 0 0 0 0 0 0 0 12 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 IN DT JJ NN IN O
degree degree 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
DHFR DHFR 1 1 0 0 0 0 0 0 4 0 NN IN NNP NN -NONE- O
origin origin 0 0 0 0 0 0 0 0 6 0 IN NNP NN -NONE- VBG O
specificity, specificity, 0 0 0 0 1 0 0 0 12 0 NNP NN -NONE- VBG IN O
implying implying 0 0 0 0 0 0 0 0 8 0 NN -NONE- VBG IN DT O
that that 0 0 0 0 0 0 0 0 4 0 -NONE- VBG IN DT RB O
the the 0 0 0 0 0 0 0 0 3 0 VBG IN DT RB VBD O
previously previously 0 0 0 0 0 0 0 0 10 0 IN DT RB VBD NN O
documented documented 0 0 0 0 0 0 0 0 10 0 DT RB VBD NN IN O
lack lack 0 0 0 0 0 0 0 0 4 0 RB VBD NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN JJ NN O
specific specific 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN NN O
origin origin 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN IN O
selection selection 0 0 0 0 0 0 0 0 9 0 JJ NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
permeabilized permeabilized 0 0 0 0 0 0 0 0 13 0 NN IN JJ NN VBZ O
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 IN JJ NN VBZ IN O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ IN JJS O
at at 0 0 0 0 0 0 0 0 2 0 NN VBZ IN JJS RB O
least least 0 0 0 0 0 0 0 0 5 0 VBZ IN JJS RB JJ O
partially partially 0 0 0 0 0 0 0 0 9 0 IN JJS RB JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 JJS RB JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 RB JJ TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ TO DT NN IN O
licensing licensing 0 0 0 0 0 0 0 0 9 0 TO DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
new new 0 0 0 0 0 0 0 0 3 0 NN IN JJ NN NNS O
initiation initiation 0 0 0 0 0 0 0 0 10 0 IN JJ NN NNS IN O
sites sites 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN NNS O
by by 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNS IN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NNS IN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NN O
Xenopus Xenopus 1 0 0 0 0 0 0 0 7 0 IN DT NNP NN NNP O
egg egg 0 0 0 0 0 0 0 0 3 0 DT NNP NN NNP NNP O
extracts. extracts. 0 0 0 0 0 0 0 0 9 0 NNP NN NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBP IN O
conclude conclude 0 0 0 0 0 0 0 0 8 0 NNP NNP VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT JJ NN O
functional functional 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN IN O
association association 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNS O
Mcm Mcm 1 0 0 0 0 0 0 0 3 0 NN IN NNP NNS IN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 IN NNP NNS IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNS IN NN NNP O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 NNS IN NN NNP NN O
(i.e. (i.e. 0 0 0 0 0 0 0 0 5 0 IN NN NNP NN -NONE- O
replication replication 0 0 0 0 0 0 0 0 11 0 NN NNP NN -NONE- IN O
licensing) licensing) 0 0 0 0 0 0 0 0 10 0 NNP NN -NONE- IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN -NONE- IN NNP NNS O
CHO CHO 1 1 0 0 0 0 0 0 3 0 -NONE- IN NNP NNS VBZ O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS VBZ NN O
takes takes 0 0 0 0 0 0 0 0 5 0 NNP NNS VBZ NN IN O
place place 0 0 0 0 0 0 0 0 5 0 NNS VBZ NN IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 VBZ NN IN JJ JJ O
telophase, telophase, 0 0 0 0 1 0 0 0 10 0 NN IN JJ JJ NNS B_TIMEXCCP
several several 0 0 0 0 0 0 0 0 7 0 IN JJ JJ NNS RB O
hours hours 0 0 0 0 0 0 0 0 5 0 JJ JJ NNS RB TO O
prior prior 0 0 0 0 0 0 0 0 5 0 JJ NNS RB TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNS RB TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB TO DT NN IN O
specification specification 0 0 0 0 0 0 0 0 13 0 TO DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
replication replication 0 0 0 0 0 0 0 0 11 0 NN IN NN NNS IN O
origins origins 0 0 0 0 0 0 0 0 7 0 IN NN NNS IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NNP O
DHFR DHFR 1 1 0 0 0 0 0 0 4 0 IN DT NNP NNP NNP O
locus. locus. 0 0 0 0 0 0 0 0 6 0 DT NNP NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNP NNP NNP CD JJ O
11801723 11801723 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NN O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NN NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
PMC1255924 PMC1255924 1 1 0 0 0 0 0 1 10 0 JJ NN NNP NONE NONE O
Buffalo Buffalo 1 0 0 0 0 0 0 0 7 0 NONE NONE NNP NNP NNP O
Colostrum Colostrum 1 0 0 0 0 0 0 0 9 0 NONE NNP NNP NNP NNP O
β-lactoglobulin β-lactoglobulin 0 0 1 0 0 0 0 0 15 0 NNP NNP NNP NNP NNP O
Inhibits Inhibits 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
VEGF-Induced VEGF-Induced 1 0 1 0 0 0 0 0 12 0 NNP NNP NNP NNP IN O
Angiogenesis Angiogenesis 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP IN O
Interacting Interacting 1 0 0 0 0 0 0 0 11 0 NNP IN NNP IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 IN NNP IN NNP JJ O
G G 1 1 0 0 0 0 0 0 1 0 NNP IN NNP JJ NNP O
protein-Coupled protein-Coupled 0 0 1 0 0 0 0 0 15 0 IN NNP JJ NNP NNP O
Receptor Receptor 1 0 0 0 0 0 0 0 8 0 NNP JJ NNP NNP NNP O
Kinase. Kinase. 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP NNP NNP O
Chougule Chougule 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
RA, RA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
P P 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Salimath Salimath 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BP, BP, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Sosalegowda Sosalegowda 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
AH. AH. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNPS O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNPS IN O
Studies Studies 1 0 0 0 0 0 0 0 7 0 NNP IN NNPS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NNPS IN NNP NNP O
Biotechnology, Biotechnology, 1 0 0 0 1 0 0 0 14 0 NNPS IN NNP NNP NNP O
Manasagangotri, Manasagangotri, 1 0 0 0 1 0 0 0 15 0 IN NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Mysore, Mysore, 1 0 0 0 1 0 0 0 7 0 NNP IN NNP NNP CD O
Mysore, Mysore, 1 0 0 0 1 0 0 0 7 0 IN NNP NNP CD CD O
570 570 0 0 0 0 0 0 1 1 3 0 NNP NNP CD CD NNP O
006, 006, 0 0 0 0 1 0 0 1 4 0 NNP CD CD NNP NNP O
India. India. 1 0 0 0 0 0 0 0 6 0 CD CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NNP O
β-lactoglobulin β-lactoglobulin 0 0 1 0 0 0 0 0 15 0 NNP NNP NNP NNP DT O
(β-lg), (β-lg), 0 0 1 0 1 0 0 0 7 0 NNP NNP NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT JJ NN O
major major 0 0 0 0 0 0 0 0 5 0 NNP DT JJ NN NN O
whey whey 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN VBD O
protein protein 0 0 0 0 0 0 0 0 7 0 JJ NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN CC O
purified purified 0 0 0 0 0 0 0 0 8 0 NN VBD VBN CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 VBD VBN CC VBN IN O
characterised characterised 0 0 0 0 0 0 0 0 13 0 VBN CC VBN IN NN O
from from 0 0 0 0 0 0 0 0 4 0 CC VBN IN NN NNP O
buffalo buffalo 0 0 0 0 0 0 0 0 7 0 VBN IN NN NNP NNP O
colostrum. colostrum. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP IN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN NN O
silico silico 0 0 0 0 0 0 0 0 6 0 NNP IN NN NN IN O
analysis analysis 0 0 0 0 0 0 0 0 8 0 IN NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNS O
tryptic tryptic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NNS VBN O
peptides peptides 0 0 0 0 0 0 0 0 8 0 DT JJ NNS VBN IN O
based based 0 0 0 0 0 0 0 0 5 0 JJ NNS VBN IN NNS O
on on 0 0 0 0 0 0 0 0 2 0 NNS VBN IN NNS VBN O
LC-CID-MS/MS LC-CID-MS/MS 1 1 1 1 0 0 0 0 12 0 VBN IN NNS VBN DT O
facilitated facilitated 0 0 0 0 0 0 0 0 11 0 IN NNS VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBN DT NN IN O
identification identification 0 0 0 0 0 0 0 0 14 0 VBN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
protein protein 0 0 0 0 0 0 0 0 7 0 NN IN NN IN NNP O
as as 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNP O
β-lg. β-lg. 0 0 1 0 0 0 0 0 5 0 NN IN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNS NNP O
sequences sequences 0 0 0 0 0 0 0 0 9 0 NNP NNP NNS NNP NNP O
IIVTQ IIVTQ 1 1 0 0 0 0 0 0 5 0 NNP NNS NNP NNP CC O
f[1-5] f[1-5] 0 0 1 0 0 0 0 1 6 0 NNS NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
LSFNPTQLEEQCHV LSFNPTQLEEQCHV 1 1 0 0 0 0 0 0 14 0 NNP CC NNP NNP IN O
f(149-162) f(149-162) 0 0 1 0 0 0 0 1 10 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CD O
m/z m/z 0 0 0 1 0 0 0 0 3 0 NNP IN NNP CD CC O
933+ 933+ 0 0 0 0 0 0 0 1 4 0 IN NNP CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NNP CD CC CD VBD O
8512+ 8512+ 0 0 0 0 0 0 0 1 5 0 CD CC CD VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 CC CD VBD VBN TO O
found found 0 0 0 0 0 0 0 0 5 0 CD VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB JJ O
match match 0 0 0 0 0 0 0 0 5 0 VBN TO VB JJ CC O
N- N- 1 1 1 0 0 0 0 0 2 0 TO VB JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VB JJ CC JJ IN O
C-extreme C-extreme 1 0 1 0 0 0 0 0 9 0 JJ CC JJ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC JJ IN JJ IN O
β-lg β-lg 0 0 1 0 0 0 0 0 4 0 JJ IN JJ IN NNP O
while while 0 0 0 0 0 0 0 0 5 0 IN JJ IN NNP NNP O
IDALNENK IDALNENK 1 1 0 0 0 0 0 0 8 0 JJ IN NNP NNP CC O
f(84-91) f(84-91) 0 0 1 0 0 0 0 1 8 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
TPEVDDEALEKFDK TPEVDDEALEKFDK 1 1 0 0 0 0 0 0 14 0 NNP CC NNP NNP NNS O
f(125-138) f(125-138) 0 0 1 0 0 0 0 1 10 0 CC NNP NNP NNS VBD O
sequences sequences 0 0 0 0 0 0 0 0 9 0 NNP NNP NNS VBD IN O
deduced deduced 0 0 0 0 0 0 0 0 7 0 NNP NNS VBD IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NNS VBD IN JJ CD O
m/z m/z 0 0 0 1 0 0 0 0 3 0 VBD IN JJ CD CC O
916+ 916+ 0 0 0 0 0 0 0 1 4 0 IN JJ CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 JJ CD CC CD VBD O
8182+ 8182+ 0 0 0 0 0 0 0 1 5 0 CD CC CD VBD IN O
were were 0 0 0 0 0 0 0 0 4 0 CC CD VBD IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CD VBD IN NN TO O
compliance compliance 0 0 0 0 0 0 0 0 10 0 VBD IN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB NN O
buffalo buffalo 0 0 0 0 0 0 0 0 7 0 NN TO VB NN NNP O
milk milk 0 0 0 0 0 0 0 0 4 0 TO VB NN NNP NNP O
β-lg. β-lg. 0 0 1 0 0 0 0 0 5 0 VB NN NNP NNP DT O
Considering Considering 1 0 0 0 0 0 0 0 11 0 NN NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
sequence sequence 0 0 0 0 0 0 0 0 8 0 NNP DT NN NN IN O
similarity similarity 0 0 0 0 0 0 0 0 10 0 DT NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ TO O
β-lg β-lg 0 0 1 0 0 0 0 0 4 0 NN IN JJ TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 IN JJ TO NNP DT O
glycodelin, glycodelin, 0 0 0 0 1 0 0 0 11 0 JJ TO NNP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 TO NNP DT NN NN O
proven proven 0 0 0 0 0 0 0 0 6 0 NNP DT NN NN NN O
angiogenic angiogenic 0 0 0 0 0 0 0 0 10 0 DT NN NN NN JJ O
protein, protein, 0 0 0 0 1 0 0 0 8 0 NN NN NN JJ NN O
similar similar 0 0 0 0 0 0 0 0 7 0 NN NN JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 NN JJ NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN JJ IN O
β-lg β-lg 0 0 1 0 0 0 0 0 4 0 NN IN JJ IN NN O
from from 0 0 0 0 0 0 0 0 4 0 IN JJ IN NN NN O
buffalo buffalo 0 0 0 0 0 0 0 0 7 0 JJ IN NN NN NN O
colostrum colostrum 0 0 0 0 0 0 0 0 9 0 IN NN NN NN VBD O
(BLG-col) (BLG-col) 0 0 1 0 0 0 0 0 9 0 NN NN NN VBD NNP O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD NNP NNP O
examined. examined. 0 0 0 0 0 0 0 0 9 0 NN VBD NNP NNP NNP O
Interestingly, Interestingly, 1 0 0 0 1 0 0 0 14 0 VBD NNP NNP NNP VBD O
BLG-col BLG-col 1 0 1 0 0 0 0 0 7 0 NNP NNP NNP VBD JJ O
exhibited exhibited 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD JJ NN O
anti-angiogenic anti-angiogenic 0 0 1 0 0 0 0 0 15 0 NNP VBD JJ NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 VBD JJ NN IN RB O
by by 0 0 0 0 0 0 0 0 2 0 JJ NN IN RB VBG O
potently potently 0 0 0 0 0 0 0 0 8 0 NN IN RB VBG NN O
inhibiting inhibiting 0 0 0 0 0 0 0 0 10 0 IN RB VBG NN -NONE- O
cell cell 0 0 0 0 0 0 0 0 4 0 RB VBG NN -NONE- JJ O
proliferation, proliferation, 0 0 0 0 1 0 0 0 14 0 VBG NN -NONE- JJ NN O
micro-vessel micro-vessel 0 0 1 0 0 0 0 0 12 0 NN -NONE- JJ NN NN O
sprouting, sprouting, 0 0 0 0 1 0 0 0 10 0 -NONE- JJ NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN CC O
migration migration 0 0 0 0 0 0 0 0 9 0 NN NN NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VB NN O
tube tube 0 0 0 0 0 0 0 0 4 0 NN CC VB NN IN O
formation formation 0 0 0 0 0 0 0 0 9 0 CC VB NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VB NN IN JJ JJ O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ JJ NN O
umbilical umbilical 0 0 0 0 0 0 0 0 9 0 IN JJ JJ NN JJ O
vein vein 0 0 0 0 0 0 0 0 4 0 JJ JJ NN JJ NNS O
endothelial endothelial 0 0 0 0 0 0 0 0 11 0 JJ NN JJ NNS -NONE- O
cells cells 0 0 0 0 0 0 0 0 5 0 NN JJ NNS -NONE- IN O
(HUVECs) (HUVECs) 0 0 0 0 0 0 0 0 8 0 JJ NNS -NONE- IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNS -NONE- IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- IN DT JJ NN O
dose-dependent dose-dependent 0 0 1 0 0 0 0 0 14 0 IN DT JJ NN CC O
manner manner 0 0 0 0 0 0 0 0 6 0 DT JJ NN CC VBG O
but but 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBG VBN O
having having 0 0 0 0 0 0 0 0 6 0 NN CC VBG VBN NN O
varied varied 0 0 0 0 0 0 0 0 6 0 CC VBG VBN NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 VBG VBN NN IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNP VBZ O
Ehrlich Ehrlich 1 0 0 0 0 0 0 0 7 0 NN IN NNP VBZ NN O
ascites ascites 0 0 0 0 0 0 0 0 7 0 IN NNP VBZ NN -NONE- O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NNP VBZ NN -NONE- -NONE- O
cells, cells, 0 0 0 0 1 0 0 0 6 0 VBZ NN -NONE- -NONE- JJ O
MCF-7, MCF-7, 1 1 1 0 1 0 0 1 6 0 NN -NONE- -NONE- JJ CD O
MDA-MB MDA-MB 1 1 1 0 0 0 0 0 6 0 -NONE- -NONE- JJ CD CC O
435 435 0 0 0 0 0 0 1 1 3 0 -NONE- JJ CD CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ CD CC JJ CD O
MDA-MB MDA-MB 1 1 1 0 0 0 0 0 6 0 CD CC JJ CD NN O
231 231 0 0 0 0 0 0 1 1 3 0 CC JJ CD NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ CD NN NNP NNP O
lines. lines. 0 0 0 0 0 0 0 0 6 0 CD NN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNP NN O
anti-angiogenic anti-angiogenic 0 0 1 0 0 0 0 0 15 0 NNP NNP NNP NN IN O
potential potential 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ VBD O
BLG-col BLG-col 1 0 1 0 0 0 0 0 7 0 NN IN JJ VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 IN JJ VBD VBN TO O
found found 0 0 0 0 0 0 0 0 5 0 JJ VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB JJ JJ O
vascular vascular 0 0 0 0 0 0 0 0 8 0 TO VB JJ JJ NN O
endothelial endothelial 0 0 0 0 0 0 0 0 11 0 VB JJ JJ NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NN NNP O
factor factor 0 0 0 0 0 0 0 0 6 0 JJ NN NN NNP NNP O
mediated. mediated. 0 0 0 0 0 0 0 0 9 0 NN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
immunolocalisation immunolocalisation 0 0 0 0 0 0 0 0 18 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ IN O
BLG-col BLG-col 1 0 1 0 0 0 0 0 7 0 NN IN JJ IN DT O
on on 0 0 0 0 0 0 0 0 2 0 IN JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN IN O
surface surface 0 0 0 0 0 0 0 0 7 0 DT NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP VBD O
HUVECs HUVECs 1 0 0 0 0 0 0 0 6 0 NN IN NNP VBD VBG O
evidenced evidenced 0 0 0 0 0 0 0 0 9 0 IN NNP VBD VBG JJ O
using using 0 0 0 0 0 0 0 0 5 0 NNP VBD VBG JJ JJ O
FITC-labelled FITC-labelled 1 0 1 0 0 0 0 0 13 0 VBD VBG JJ JJ NN O
β-lg β-lg 0 0 1 0 0 0 0 0 4 0 VBG JJ JJ NN VBD O
antibody antibody 0 0 0 0 0 0 0 0 8 0 JJ JJ NN VBD PRP$ O
indicated indicated 0 0 0 0 0 0 0 0 9 0 JJ NN VBD PRP$ JJ O
its its 0 0 0 0 0 0 0 0 3 0 NN VBD PRP$ JJ NNP O
extra-cellular extra-cellular 0 0 1 0 0 0 0 0 14 0 VBD PRP$ JJ NNP NNP O
binding. binding. 0 0 0 0 0 0 0 0 8 0 PRP$ JJ NNP NNP NNP O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 JJ NNP NNP NNP NN O
BLG-col BLG-col 1 0 1 0 0 0 0 0 7 0 NNP NNP NNP NN NNP O
interacting interacting 0 0 0 0 0 0 0 0 11 0 NNP NNP NN NNP NN O
HUVEC HUVEC 1 1 0 0 0 0 0 0 5 0 NNP NN NNP NN NN O
membrane membrane 0 0 0 0 0 0 0 0 8 0 NN NNP NN NN -NONE- O
protein protein 0 0 0 0 0 0 0 0 7 0 NNP NN NN -NONE- -NONE- O
(64 (64 0 0 0 0 0 0 0 1 3 0 NN NN -NONE- -NONE- VBD O
kDa) kDa) 0 0 0 0 0 0 0 0 4 0 NN -NONE- -NONE- VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- VBD VBN IN O
detected detected 0 0 0 0 0 0 0 0 8 0 -NONE- VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN CC O
immunoblot immunoblot 0 0 0 0 0 0 0 0 10 0 VBN IN NN CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NN CC PRP$ NN VBD O
identity identity 0 0 0 0 0 0 0 0 8 0 CC PRP$ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 PRP$ NN VBD VBN IN O
established established 0 0 0 0 0 0 0 0 11 0 NN VBD VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NN O
matrix-assisted matrix-assisted 0 0 1 0 0 0 0 0 15 0 VBN IN JJ NN NN O
laser laser 0 0 0 0 0 0 0 0 5 0 IN JJ NN NN JJ O
desorption/ionisation desorption/ionisation 0 0 0 1 0 0 0 0 21 0 JJ NN NN JJ NN O
time-of-flight time-of-flight 0 0 1 0 0 0 0 0 14 0 NN NN JJ NN NN O
mass mass 0 0 0 0 0 0 0 0 4 0 NN JJ NN NN NN O
spectrometry spectrometry 0 0 0 0 0 0 0 0 12 0 JJ NN NN NN WDT O
analysis, analysis, 0 0 0 0 1 0 0 0 9 0 NN NN NN WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBD VBP O
showed showed 0 0 0 0 0 0 0 0 6 0 NN WDT VBD VBP NN O
peptide peptide 0 0 0 0 0 0 0 0 7 0 WDT VBD VBP NN NN O
sequence sequence 0 0 0 0 0 0 0 0 8 0 VBD VBP NN NN TO O
homology homology 0 0 0 0 0 0 0 0 8 0 VBP NN NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO NNP JJ O
G G 1 1 0 0 0 0 0 0 1 0 NN TO NNP JJ NN O
protein-coupled protein-coupled 0 0 1 0 0 0 0 0 15 0 TO NNP JJ NN NN O
receptor receptor 0 0 0 0 0 0 0 0 8 0 NNP JJ NN NN CD O
kinase kinase 0 0 0 0 0 0 0 0 6 0 JJ NN NN CD NONE O
4. 4. 0 0 0 0 0 0 0 1 2 0 NN NN CD NONE NONE O
U.S. U.S. 1 1 0 0 0 0 0 0 4 0 NONE NONE NNP NNS IN O
hospitalizations hospitalizations 0 0 0 0 0 0 0 0 16 0 NONE NNP NNS IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNS IN NN IN O
pneumonia pneumonia 0 0 0 0 0 0 0 0 9 0 NNS IN NN IN DT O
after after 0 0 0 0 0 0 0 0 5 0 IN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN IN O
decade decade 0 0 0 0 0 0 0 0 6 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
pneumococcal pneumococcal 0 0 0 0 0 0 0 0 12 0 NN IN JJ NNP NNP O
vaccination. vaccination. 0 0 0 0 0 0 0 0 12 0 IN JJ NNP NNP NNP O
Griffin Griffin 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP NNP NNP O
MR, MR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Zhu Zhu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Moore Moore 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
MR, MR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Whitney Whitney 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
CG, CG, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Grijalva Grijalva 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
CG. CG. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Preventive Preventive 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Vanderbilt Vanderbilt 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Nashville, Nashville, 1 0 0 0 1 0 0 0 10 0 IN NNP NNP NNP CD O
TN TN 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
37212, 37212, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
marie.griffin@vanderbilt.edu marie.griffin@vanderbilt.edu 0 0 0 0 0 0 0 0 28 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
introduction introduction 0 0 0 0 0 0 0 0 12 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ JJ O
7-valent 7-valent 0 0 1 0 0 0 0 1 8 0 NN IN JJ JJ NN O
pneumococcal pneumococcal 0 0 0 0 0 0 0 0 12 0 IN JJ JJ NN NN O
conjugate conjugate 0 0 0 0 0 0 0 0 9 0 JJ JJ NN NN NN O
vaccine vaccine 0 0 0 0 0 0 0 0 7 0 JJ NN NN NN IN O
(PCV7) (PCV7) 0 1 0 0 0 0 0 1 6 0 NN NN NN IN DT O
into into 0 0 0 0 0 0 0 0 4 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
U.S. U.S. 1 1 0 0 0 0 0 0 4 0 IN DT NNP NN NN O
childhood childhood 0 0 0 0 0 0 0 0 9 0 DT NNP NN NN NN O
immunization immunization 0 0 0 0 0 0 0 0 12 0 NNP NN NN NN IN O
schedule schedule 0 0 0 0 0 0 0 0 8 0 NN NN NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN CD VBZ O
2000 2000 0 0 0 0 0 0 1 1 4 0 NN IN CD VBZ RB O
has has 0 0 0 0 0 0 0 0 3 0 IN CD VBZ RB VBN O
substantially substantially 0 0 0 0 0 0 0 0 13 0 CD VBZ RB VBN DT O
reduced reduced 0 0 0 0 0 0 0 0 7 0 VBZ RB VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBN DT NN IN O
incidence incidence 0 0 0 0 0 0 0 0 9 0 VBN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ JJ O
vaccine-serotype vaccine-serotype 0 0 1 0 0 0 0 0 16 0 NN IN JJ JJ JJ O
invasive invasive 0 0 0 0 0 0 0 0 8 0 IN JJ JJ JJ NN O
pneumococcal pneumococcal 0 0 0 0 0 0 0 0 12 0 JJ JJ JJ NN IN O
disease disease 0 0 0 0 0 0 0 0 7 0 JJ JJ NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNS O
young young 0 0 0 0 0 0 0 0 5 0 NN IN JJ NNS CC O
children children 0 0 0 0 0 0 0 0 8 0 IN JJ NNS CC IN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNS CC IN JJ NN O
unvaccinated unvaccinated 0 0 0 0 0 0 0 0 12 0 CC IN JJ NN NNS O
older older 0 0 0 0 0 0 0 0 5 0 IN JJ NN NNS CC O
children children 0 0 0 0 0 0 0 0 8 0 JJ NN NNS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NNP NNP O
adults. adults. 0 0 0 0 0 0 0 0 7 0 NNS CC NNP NNP CD O
By By 1 0 0 0 0 0 0 0 2 0 CC NNP NNP CD NNS O
2004, 2004, 0 0 0 0 1 0 0 1 5 0 NNP NNP CD NNS VBN O
hospitalizations hospitalizations 0 0 0 0 0 0 0 0 16 0 NNP CD NNS VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 CD NNS VBN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBN IN NN IN O
pneumonia pneumonia 0 0 0 0 0 0 0 0 9 0 VBN IN NN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 IN NN IN DT NN O
any any 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBD O
cause cause 0 0 0 0 0 0 0 0 5 0 IN DT NN VBD RB O
had had 0 0 0 0 0 0 0 0 3 0 DT NN VBD RB VBN O
also also 0 0 0 0 0 0 0 0 4 0 NN VBD RB VBN RB O
declined declined 0 0 0 0 0 0 0 0 8 0 VBD RB VBN RB IN O
markedly markedly 0 0 0 0 0 0 0 0 8 0 RB VBN RB IN JJ O
among among 0 0 0 0 0 0 0 0 5 0 VBN RB IN JJ NNP O
young young 0 0 0 0 0 0 0 0 5 0 RB IN JJ NNP NNP O
children. children. 0 0 0 0 0 0 0 0 9 0 IN JJ NNP NNP IN O
Because Because 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNS IN O
concerns concerns 0 0 0 0 0 0 0 0 8 0 NNP IN NNS IN NNS O
about about 0 0 0 0 0 0 0 0 5 0 IN NNS IN NNS IN O
increases increases 0 0 0 0 0 0 0 0 9 0 NNS IN NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN NN VBN O
disease disease 0 0 0 0 0 0 0 0 7 0 NNS IN NN VBN IN O
caused caused 0 0 0 0 0 0 0 0 6 0 IN NN VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN VBN IN NN -NONE- O
nonvaccine nonvaccine 0 0 0 0 0 0 0 0 10 0 VBN IN NN -NONE- PRP O
serotypes, serotypes, 0 0 0 0 1 0 0 0 10 0 IN NN -NONE- PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NN -NONE- PRP VBD TO O
wanted wanted 0 0 0 0 0 0 0 0 6 0 -NONE- PRP VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 PRP VBD TO VB IN O
determine determine 0 0 0 0 0 0 0 0 9 0 VBD TO VB IN DT O
whether whether 0 0 0 0 0 0 0 0 7 0 TO VB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VB IN DT NN IN O
reduction reduction 0 0 0 0 0 0 0 0 9 0 IN DT NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
pneumonia-related pneumonia-related 0 0 1 0 0 0 0 0 17 0 NN IN JJ NNS IN O
hospitalizations hospitalizations 0 0 0 0 0 0 0 0 16 0 IN JJ NNS IN JJ O
among among 0 0 0 0 0 0 0 0 5 0 JJ NNS IN JJ NNS O
young young 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NNS VBD O
children children 0 0 0 0 0 0 0 0 8 0 IN JJ NNS VBD VBN O
had had 0 0 0 0 0 0 0 0 3 0 JJ NNS VBD VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNS VBD VBN VBN IN O
sustained sustained 0 0 0 0 0 0 0 0 9 0 VBD VBN VBN IN CD O
through through 0 0 0 0 0 0 0 0 7 0 VBN VBN IN CD CC O
2009 2009 0 0 0 0 0 0 1 1 4 0 VBN IN CD CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN CD CC IN JJ O
whether whether 0 0 0 0 0 0 0 0 7 0 CD CC IN JJ NNS O
such such 0 0 0 0 0 0 0 0 4 0 CC IN JJ NNS IN O
hospitalizations hospitalizations 0 0 0 0 0 0 0 0 16 0 IN JJ NNS IN JJR O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJR NN O
older older 0 0 0 0 0 0 0 0 5 0 NNS IN JJR NN NNS O
age age 0 0 0 0 0 0 0 0 3 0 IN JJR NN NNS VBD O
groups groups 0 0 0 0 0 0 0 0 6 0 JJR NN NNS VBD RB O
had had 0 0 0 0 0 0 0 0 3 0 NN NNS VBD RB NNP O
also also 0 0 0 0 0 0 0 0 4 0 NNS VBD RB NNP NNP O
declined. declined. 0 0 0 0 0 0 0 0 9 0 VBD RB NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 RB NNP NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBD JJ O
estimated estimated 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD JJ NNS O
annual annual 0 0 0 0 0 0 0 0 6 0 NNP VBD JJ NNS IN O
rates rates 0 0 0 0 0 0 0 0 5 0 VBD JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN IN O
hospitalization hospitalization 0 0 0 0 0 0 0 0 15 0 NNS IN NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 IN NN IN NN IN O
pneumonia pneumonia 0 0 0 0 0 0 0 0 9 0 NN IN NN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 IN NN IN DT NN O
any any 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBG O
cause cause 0 0 0 0 0 0 0 0 5 0 IN DT NN VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 DT NN VBG DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT NNP NNP O
Nationwide Nationwide 1 0 0 0 0 0 0 0 10 0 VBG DT NNP NNP NNP O
Inpatient Inpatient 1 0 0 0 0 0 0 0 9 0 DT NNP NNP NNP NNP O
Sample Sample 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
database. database. 0 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
reason reason 0 0 0 0 0 0 0 0 6 0 NNP NNP NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NNP NN IN NN VBD O
hospitalization hospitalization 0 0 0 0 0 0 0 0 15 0 NN IN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 IN NN VBD VBN IN O
classified classified 0 0 0 0 0 0 0 0 10 0 NN VBD VBN IN NN O
as as 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN IN O
pneumonia pneumonia 0 0 0 0 0 0 0 0 9 0 VBN IN NN IN NN O
if if 0 0 0 0 0 0 0 0 2 0 IN NN IN NN VBD O
pneumonia pneumonia 0 0 0 0 0 0 0 0 9 0 NN IN NN VBD DT O
was was 0 0 0 0 0 0 0 0 3 0 IN NN VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN VBD DT JJ VBN O
first first 0 0 0 0 0 0 0 0 5 0 VBD DT JJ VBN NN O
listed listed 0 0 0 0 0 0 0 0 6 0 DT JJ VBN NN CC O
diagnosis diagnosis 0 0 0 0 0 0 0 0 9 0 JJ VBN NN CC IN O
or or 0 0 0 0 0 0 0 0 2 0 VBN NN CC IN PRP O
if if 0 0 0 0 0 0 0 0 2 0 NN CC IN PRP VBD O
it it 0 0 0 0 0 0 0 0 2 0 CC IN PRP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 IN PRP VBD VBN IN O
listed listed 0 0 0 0 0 0 0 0 6 0 PRP VBD VBN IN DT O
after after 0 0 0 0 0 0 0 0 5 0 VBD VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN IN O
diagnosis diagnosis 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
sepsis, sepsis, 0 0 0 0 1 0 0 0 7 0 NN IN NNP NNP CC O
meningitis, meningitis, 0 0 0 0 1 0 0 0 11 0 IN NNP NNP CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 NNP NNP CC NNP NNP O
empyema. empyema. 0 0 0 0 0 0 0 0 8 0 NNP CC NNP NNP JJ O
Average Average 1 0 0 0 0 0 0 0 7 0 CC NNP NNP JJ NNS O
annual annual 0 0 0 0 0 0 0 0 6 0 NNP NNP JJ NNS IN O
rates rates 0 0 0 0 0 0 0 0 5 0 NNP JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NNS O
pneumonia-related pneumonia-related 0 0 1 0 0 0 0 0 17 0 NNS IN JJ NNS IN O
hospitalizations hospitalizations 0 0 0 0 0 0 0 0 16 0 IN JJ NNS IN CD O
from from 0 0 0 0 0 0 0 0 4 0 JJ NNS IN CD IN O
1997 1997 0 0 0 0 0 0 1 1 4 0 NNS IN CD IN CD O
through through 0 0 0 0 0 0 0 0 7 0 IN CD IN CD JJ O
1999 1999 0 0 0 0 0 0 1 1 4 0 CD IN CD JJ DT O
(before (before 0 0 0 0 0 0 0 0 7 0 IN CD JJ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CD JJ DT NN IN O
introduction introduction 0 0 0 0 0 0 0 0 12 0 JJ DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ CC O
PCV7) PCV7) 1 1 0 0 0 0 0 1 5 0 NN IN JJ CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC IN CD O
from from 0 0 0 0 0 0 0 0 4 0 JJ CC IN CD IN O
2007 2007 0 0 0 0 0 0 1 1 4 0 CC IN CD IN CD O
through through 0 0 0 0 0 0 0 0 7 0 IN CD IN CD JJ O
2009 2009 0 0 0 0 0 0 1 1 4 0 CD IN CD JJ IN O
(well (well 0 0 0 0 0 0 0 0 5 0 IN CD JJ IN PRP$ O
after after 0 0 0 0 0 0 0 0 5 0 CD JJ IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 JJ IN PRP$ NN VBD O
introduction) introduction) 0 0 0 0 0 0 0 0 13 0 IN PRP$ NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 PRP$ NN VBD VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB JJ O
estimate estimate 0 0 0 0 0 0 0 0 8 0 VBN TO VB JJ NNS O
annual annual 0 0 0 0 0 0 0 0 6 0 TO VB JJ NNS IN O
declines declines 0 0 0 0 0 0 0 0 8 0 VB JJ NNS IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNS JJ O
hospitalizations hospitalizations 0 0 0 0 0 0 0 0 16 0 NNS IN NNS JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 IN NNS JJ TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNS JJ TO NNP NNP O
pneumonia. pneumonia. 0 0 0 0 0 0 0 0 10 0 JJ TO NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 TO NNP NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP JJ NN O
annual annual 0 0 0 0 0 0 0 0 6 0 NNP NNP JJ NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 NNP JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
hospitalization hospitalization 0 0 0 0 0 0 0 0 15 0 NN IN NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 IN NN IN NN IN O
pneumonia pneumonia 0 0 0 0 0 0 0 0 9 0 NN IN NN IN NNS O
among among 0 0 0 0 0 0 0 0 5 0 IN NN IN NNS JJR O
children children 0 0 0 0 0 0 0 0 8 0 NN IN NNS JJR IN O
younger younger 0 0 0 0 0 0 0 0 7 0 IN NNS JJR IN CD O
than than 0 0 0 0 0 0 0 0 4 0 NNS JJR IN CD NNS O
2 2 0 0 0 0 0 0 1 1 1 0 JJR IN CD NNS IN O
years years 0 0 0 0 0 0 0 0 5 0 IN CD NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN NN VBD O
age age 0 0 0 0 0 0 0 0 3 0 NNS IN NN VBD IN O
declined declined 0 0 0 0 0 0 0 0 8 0 IN NN VBD IN CD O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN CD IN O
551.1 551.1 0 0 0 0 0 0 0 1 5 0 VBD IN CD IN CD O
per per 0 0 0 0 0 0 0 0 3 0 IN CD IN CD NNS O
100,000 100,000 0 0 0 0 1 0 0 1 7 0 CD IN CD NNS -NONE- O
children children 0 0 0 0 0 0 0 0 8 0 IN CD NNS -NONE- NN O
(95% (95% 0 0 0 0 0 0 0 1 4 0 CD NNS -NONE- NN NN O
confidence confidence 0 0 0 0 0 0 0 0 10 0 NNS -NONE- NN NN NN O
interval interval 0 0 0 0 0 0 0 0 8 0 -NONE- NN NN NN CD O
[CI], [CI], 0 1 0 0 1 0 0 0 5 0 NN NN NN CD TO O
445.1 445.1 0 0 0 0 0 0 0 1 5 0 NN NN CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 NN CD TO CD WDT O
657.1), 657.1), 0 0 0 0 1 0 0 1 7 0 CD TO CD WDT NNS O
which which 0 0 0 0 0 0 0 0 5 0 TO CD WDT NNS TO O
translates translates 0 0 0 0 0 0 0 0 10 0 CD WDT NNS TO CD O
to to 0 0 0 0 0 0 0 0 2 0 WDT NNS TO CD JJR O
47,000 47,000 0 0 0 0 1 0 0 1 6 0 NNS TO CD JJR NNS O
fewer fewer 0 0 0 0 0 0 0 0 5 0 TO CD JJR NNS RB O
hospitalizations hospitalizations 0 0 0 0 0 0 0 0 16 0 CD JJR NNS RB IN O
annually annually 0 0 0 0 0 0 0 0 8 0 JJR NNS RB IN VBN O
than than 0 0 0 0 0 0 0 0 4 0 NNS RB IN VBN IN O
expected expected 0 0 0 0 0 0 0 0 8 0 RB IN VBN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 IN VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
basis basis 0 0 0 0 0 0 0 0 5 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS IN O
rates rates 0 0 0 0 0 0 0 0 5 0 IN DT NNS IN NNP O
before before 0 0 0 0 0 0 0 0 6 0 DT NNS IN NNP VBD O
PCV7 PCV7 1 1 0 0 0 0 0 1 4 0 NNS IN NNP VBD NNP O
was was 0 0 0 0 0 0 0 0 3 0 IN NNP VBD NNP NNP O
introduced. introduced. 0 0 0 0 0 0 0 0 11 0 NNP VBD NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 VBD NNP NNP NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 NNP NNP NN IN NNS O
for for 0 0 0 0 0 0 0 0 3 0 NNP NN IN NNS CD O
adults adults 0 0 0 0 0 0 0 0 6 0 NN IN NNS CD NNS O
85 85 0 0 0 0 0 0 1 1 2 0 IN NNS CD NNS IN O
years years 0 0 0 0 0 0 0 0 5 0 NNS CD NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN NN CC O
age age 0 0 0 0 0 0 0 0 3 0 NNS IN NN CC JJR O
or or 0 0 0 0 0 0 0 0 2 0 IN NN CC JJR VBD O
older older 0 0 0 0 0 0 0 0 5 0 NN CC JJR VBD IN O
declined declined 0 0 0 0 0 0 0 0 8 0 CC JJR VBD IN CD O
by by 0 0 0 0 0 0 0 0 2 0 JJR VBD IN CD IN O
1300.8 1300.8 0 0 0 0 0 0 0 1 6 0 VBD IN CD IN CD O
per per 0 0 0 0 0 0 0 0 3 0 IN CD IN CD NN O
100,000 100,000 0 0 0 0 1 0 0 1 7 0 CD IN CD NN -NONE- O
(95% (95% 0 0 0 0 0 0 0 1 4 0 IN CD NN -NONE- CD O
CI, CI, 1 1 0 0 1 0 0 0 3 0 CD NN -NONE- CD TO O
984.0 984.0 0 0 0 0 0 0 0 1 5 0 NN -NONE- CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 -NONE- CD TO CD WDT O
1617.6), 1617.6), 0 0 0 0 1 0 0 1 8 0 CD TO CD WDT NNS O
which which 0 0 0 0 0 0 0 0 5 0 TO CD WDT NNS TO O
translates translates 0 0 0 0 0 0 0 0 10 0 CD WDT NNS TO CD O
to to 0 0 0 0 0 0 0 0 2 0 WDT NNS TO CD JJR O
73,000 73,000 0 0 0 0 1 0 0 1 6 0 NNS TO CD JJR NNS O
fewer fewer 0 0 0 0 0 0 0 0 5 0 TO CD JJR NNS NNP O
hospitalizations hospitalizations 0 0 0 0 0 0 0 0 16 0 CD JJR NNS NNP NNP O
annually. annually. 0 0 0 0 0 0 0 0 9 0 JJR NNS NNP NNP DT O
For For 1 0 0 0 0 0 0 0 3 0 NNS NNP NNP DT CD O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT CD NN O
three three 0 0 0 0 0 0 0 0 5 0 NNP DT CD NN NNS O
age age 0 0 0 0 0 0 0 0 3 0 DT CD NN NNS IN O
groups groups 0 0 0 0 0 0 0 0 6 0 CD NN NNS IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN CD TO O
18 18 0 0 0 0 0 0 1 1 2 0 NNS IN CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 IN CD TO CD NN O
39 39 0 0 0 0 0 0 1 1 2 0 CD TO CD NN CD O
years, years, 0 0 0 0 1 0 0 0 6 0 TO CD NN CD TO O
65 65 0 0 0 0 0 0 1 1 2 0 CD NN CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 NN CD TO CD NN O
74 74 0 0 0 0 0 0 1 1 2 0 CD TO CD NN CC O
years, years, 0 0 0 0 1 0 0 0 6 0 TO CD NN CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD NN CC CD TO O
75 75 0 0 0 0 0 0 1 1 2 0 NN CC CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 CC CD TO CD NN O
84 84 0 0 0 0 0 0 1 1 2 0 CD TO CD NN DT O
years, years, 0 0 0 0 1 0 0 0 6 0 TO CD NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CD NN DT JJ NN O
annual annual 0 0 0 0 0 0 0 0 6 0 NN DT JJ NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
hospitalization hospitalization 0 0 0 0 0 0 0 0 15 0 NN IN NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 IN NN IN NN VBD O
pneumonia pneumonia 0 0 0 0 0 0 0 0 9 0 NN IN NN VBD IN O
declined declined 0 0 0 0 0 0 0 0 8 0 IN NN VBD IN CD O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN CD IN O
8.4 8.4 0 0 0 0 0 0 0 1 3 0 VBD IN CD IN CD O
per per 0 0 0 0 0 0 0 0 3 0 IN CD IN CD NN O
100,000 100,000 0 0 0 0 1 0 0 1 7 0 CD IN CD NN -NONE- O
(95% (95% 0 0 0 0 0 0 0 1 4 0 IN CD NN -NONE- CD O
CI, CI, 1 1 0 0 1 0 0 0 3 0 CD NN -NONE- CD TO O
0.6 0.6 0 0 0 0 0 0 0 1 3 0 NN -NONE- CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 -NONE- CD TO CD CD O
16.2), 16.2), 0 0 0 0 1 0 0 1 6 0 CD TO CD CD IN O
85.3 85.3 0 0 0 0 0 0 0 1 4 0 TO CD CD IN CD O
per per 0 0 0 0 0 0 0 0 3 0 CD CD IN CD NN O
100,000 100,000 0 0 0 0 1 0 0 1 7 0 CD IN CD NN -NONE- O
(95% (95% 0 0 0 0 0 0 0 1 4 0 IN CD NN -NONE- CD O
CI, CI, 1 1 0 0 1 0 0 0 3 0 CD NN -NONE- CD TO O
7.0 7.0 0 0 0 0 0 0 0 1 3 0 NN -NONE- CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 -NONE- CD TO CD CC O
163.6), 163.6), 0 0 0 0 1 0 0 1 7 0 CD TO CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 TO CD CC CD IN O
359.8 359.8 0 0 0 0 0 0 0 1 5 0 CD CC CD IN CD O
per per 0 0 0 0 0 0 0 0 3 0 CC CD IN CD NN O
100,000 100,000 0 0 0 0 1 0 0 1 7 0 CD IN CD NN -NONE- O
(95% (95% 0 0 0 0 0 0 0 1 4 0 IN CD NN -NONE- CD O
CI, CI, 1 1 0 0 1 0 0 0 3 0 CD NN -NONE- CD TO O
199.6 199.6 0 0 0 0 0 0 0 1 5 0 NN -NONE- CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 -NONE- CD TO CD NNP O
520.0), 520.0), 0 0 0 0 1 0 0 1 7 0 CD TO CD NNP NNP O
respectively. respectively. 0 0 0 0 0 0 0 0 13 0 TO CD NNP NNP PRP O
Overall, Overall, 1 0 0 0 1 0 0 0 8 0 CD NNP NNP PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD DT O
estimated estimated 0 0 0 0 0 0 0 0 9 0 NNP PRP VBD DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 PRP VBD DT JJ JJ O
age-adjusted age-adjusted 0 0 1 0 0 0 0 0 12 0 VBD DT JJ JJ NN O
annual annual 0 0 0 0 0 0 0 0 6 0 DT JJ JJ NN IN O
reduction reduction 0 0 0 0 0 0 0 0 9 0 JJ JJ NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN CD IN O
54.8 54.8 0 0 0 0 0 0 0 1 4 0 NN IN CD IN CD O
per per 0 0 0 0 0 0 0 0 3 0 IN CD IN CD NN O
100,000 100,000 0 0 0 0 1 0 0 1 7 0 CD IN CD NN -NONE- O
(95% (95% 0 0 0 0 0 0 0 1 4 0 IN CD NN -NONE- CD O
CI, CI, 1 1 0 0 1 0 0 0 3 0 CD NN -NONE- CD TO O
41.0 41.0 0 0 0 0 0 0 0 1 4 0 NN -NONE- CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 -NONE- CD TO CD CC O
68.5), 68.5), 0 0 0 0 1 0 0 1 6 0 CD TO CD CC CD O
or or 0 0 0 0 0 0 0 0 2 0 TO CD CC CD JJR O
168,000 168,000 0 0 0 0 1 0 0 1 7 0 CD CC CD JJR NNS O
fewer fewer 0 0 0 0 0 0 0 0 5 0 CC CD JJR NNS IN O
hospitalizations hospitalizations 0 0 0 0 0 0 0 0 16 0 CD JJR NNS IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJR NNS IN NN NNP O
pneumonia pneumonia 0 0 0 0 0 0 0 0 9 0 NNS IN NN NNP NNP O
annually. annually. 0 0 0 0 0 0 0 0 9 0 IN NN NNP NNP NNP O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 NN NNP NNP NNP IN O
Declines Declines 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNS IN O
hospitalizations hospitalizations 0 0 0 0 0 0 0 0 16 0 NNP IN NNS IN NN O
for for 0 0 0 0 0 0 0 0 3 0 IN NNS IN NN NN O
childhood childhood 0 0 0 0 0 0 0 0 9 0 NNS IN NN NN VBD O
pneumonia pneumonia 0 0 0 0 0 0 0 0 9 0 IN NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN IN O
sustained sustained 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN DT O
during during 0 0 0 0 0 0 0 0 6 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
decade decade 0 0 0 0 0 0 0 0 6 0 IN DT NN IN DT O
after after 0 0 0 0 0 0 0 0 5 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
introduction introduction 0 0 0 0 0 0 0 0 12 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
PCV7. PCV7. 1 1 0 0 0 0 0 1 5 0 NN IN NNP NNP NNS O
Substantial Substantial 1 0 0 0 0 0 0 0 11 0 IN NNP NNP NNS IN O
reductions reductions 0 0 0 0 0 0 0 0 10 0 NNP NNP NNS IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NNS IN O
hospitalizations hospitalizations 0 0 0 0 0 0 0 0 16 0 NNS IN NNS IN NN O
for for 0 0 0 0 0 0 0 0 3 0 IN NNS IN NN IN O
pneumonia pneumonia 0 0 0 0 0 0 0 0 9 0 NNS IN NN IN NNS O
among among 0 0 0 0 0 0 0 0 5 0 IN NN IN NNS VBD O
adults adults 0 0 0 0 0 0 0 0 6 0 NN IN NNS VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 IN NNS VBD RB NNP O
also also 0 0 0 0 0 0 0 0 4 0 NNS VBD RB NNP JJ O
observed. observed. 0 0 0 0 0 0 0 0 9 0 VBD RB NNP JJ IN O
(Funded (Funded 0 0 0 0 0 0 0 0 7 0 RB NNP JJ IN DT O
by by 0 0 0 0 0 0 0 0 2 0 NNP JJ IN DT NNPS O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NNPS IN O
Centers Centers 1 0 0 0 0 0 0 0 7 0 IN DT NNPS IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 DT NNPS IN NNP NNP O
Disease Disease 1 0 0 0 0 0 0 0 7 0 NNPS IN NNP NNP CC O
Control Control 1 0 0 0 0 0 0 0 7 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NONE O
Prevention.). Prevention.). 1 0 0 0 0 0 0 0 13 0 NNP CC NNP NONE NONE O
Decreased Decreased 1 0 0 0 0 0 0 0 9 0 NONE NONE VBN NN NN O
tissue tissue 0 0 0 0 0 0 0 0 6 0 NONE VBN NN NN NN O
factor factor 0 0 0 0 0 0 0 0 6 0 VBN NN NN NN NN O
pathway pathway 0 0 0 0 0 0 0 0 7 0 NN NN NN NN NN O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 NN NN NN NN NN O
(TFPI)-dependent (TFPI)-dependent 0 0 1 0 0 0 0 0 16 0 NN NN NN NN NN O
anticoagulant anticoagulant 0 0 0 0 0 0 0 0 13 0 NN NN NN NN IN O
capacity capacity 0 0 0 0 0 0 0 0 8 0 NN NN NN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 NN IN NNS IN NN O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN NN WP O
cirrhosis cirrhosis 0 0 0 0 0 0 0 0 9 0 NNS IN NN WP VBP O
who who 0 0 0 0 0 0 0 0 3 0 IN NN WP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NN WP VBP VBN NN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 WP VBP VBN NN NNP O
protein protein 0 0 0 0 0 0 0 0 7 0 VBP VBN NN NNP CC O
S S 1 1 0 0 0 0 0 0 1 0 VBN NN NNP CC JJ O
but but 0 0 0 0 0 0 0 0 3 0 NN NNP CC JJ NNP O
normal normal 0 0 0 0 0 0 0 0 6 0 NNP CC JJ NNP NN O
TFPI TFPI 1 1 0 0 0 0 0 0 4 0 CC JJ NNP NN NNP O
plasma plasma 0 0 0 0 0 0 0 0 6 0 JJ NNP NN NNP NNP O
levels. levels. 0 0 0 0 0 0 0 0 7 0 NNP NN NNP NNP NNP O
Potze Potze 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP NNP O
W, W, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Arshad Arshad 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Adelmeijer Adelmeijer 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Blokzijl Blokzijl 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NN O
van van 0 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN NNP O
den den 0 0 0 0 0 0 0 0 3 0 NNP NNP NN NNP NNP O
Berg Berg 1 0 0 0 0 0 0 0 4 0 NNP NN NNP NNP NNP O
AP, AP, 1 1 0 0 1 0 0 0 3 0 NN NNP NNP NNP NNP O
Meijers Meijers 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
JC, JC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Porte Porte 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
RJ, RJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Lisman Lisman 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
T. T. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Surgical Surgical 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Laboratory, Laboratory, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Groningen, Groningen, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Centre Centre 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Groningen, Groningen, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Groningen, Groningen, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Netherlands. Netherlands. 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Protein Protein 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP VBZ O
S S 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP VBZ IN O
acts acts 0 0 0 0 0 0 0 0 4 0 NNP NNP VBZ IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBZ IN DT NN IN O
cofactor cofactor 0 0 0 0 0 0 0 0 8 0 IN DT NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN NN NN O
tissue tissue 0 0 0 0 0 0 0 0 6 0 NN IN NN NN NN O
factor factor 0 0 0 0 0 0 0 0 6 0 IN NN NN NN NN O
pathway pathway 0 0 0 0 0 0 0 0 7 0 NN NN NN NN NN O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 NN NN NN NN IN O
(TFPI) (TFPI) 0 1 0 0 0 0 0 0 6 0 NN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
down down 0 0 0 0 0 0 0 0 4 0 IN DT NN NN IN O
regulation regulation 0 0 0 0 0 0 0 0 10 0 DT NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
thrombin thrombin 0 0 0 0 0 0 0 0 8 0 NN IN NN NN CC O
generation, generation, 0 0 0 0 1 0 0 0 11 0 IN NN NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBD CC O
acquired acquired 0 0 0 0 0 0 0 0 8 0 NN CC VBD CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 CC VBD CC JJ NN O
congenital congenital 0 0 0 0 0 0 0 0 10 0 VBD CC JJ NN NNP O
protein protein 0 0 0 0 0 0 0 0 7 0 CC JJ NN NNP NNS O
S S 1 1 0 0 0 0 0 0 1 0 JJ NN NNP NNS VBP O
deficiencies deficiencies 0 0 0 0 0 0 0 0 12 0 NN NNP NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNS VBP VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NNS VBP VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBP VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NNP O
concomitant concomitant 0 0 0 0 0 0 0 0 11 0 IN DT JJ NNP NNP O
TFPI TFPI 1 1 0 0 0 0 0 0 4 0 DT JJ NNP NNP NNP O
deficiency. deficiency. 0 0 0 0 0 0 0 0 11 0 JJ NNP NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP IN O
contrast, contrast, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 NNP IN NNS IN NN O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN NN -NONE- O
liver liver 0 0 0 0 0 0 0 0 5 0 NNS IN NN -NONE- VBN O
diseases, diseases, 0 0 0 0 1 0 0 0 9 0 IN NN -NONE- VBN NN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 NN -NONE- VBN NN -NONE- O
protein protein 0 0 0 0 0 0 0 0 7 0 -NONE- VBN NN -NONE- CC O
S, S, 1 1 0 0 1 0 0 0 2 0 VBN NN -NONE- CC JJ O
but but 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC JJ CC O
normal normal 0 0 0 0 0 0 0 0 6 0 -NONE- CC JJ CC VBN O
or or 0 0 0 0 0 0 0 0 2 0 CC JJ CC VBN NNS O
increased increased 0 0 0 0 0 0 0 0 9 0 JJ CC VBN NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 CC VBN NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBN NNS IN NNP VBP O
TFPI TFPI 1 1 0 0 0 0 0 0 4 0 NNS IN NNP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 IN NNP VBP VBN NNP O
been been 0 0 0 0 0 0 0 0 4 0 NNP VBP VBN NNP NNP O
reported. reported. 0 0 0 0 0 0 0 0 9 0 VBP VBN NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 VBN NNP NNP VBD NNP O
compared compared 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD NNP CC O
TFPI TFPI 1 1 0 0 0 0 0 0 4 0 NNP VBD NNP CC VB O
and and 0 0 0 0 0 0 0 0 3 0 VBD NNP CC VB NNP O
protein protein 0 0 0 0 0 0 0 0 7 0 NNP CC VB NNP NN O
S S 1 1 0 0 0 0 0 0 1 0 CC VB NNP NN NNS O
plasma plasma 0 0 0 0 0 0 0 0 6 0 VB NNP NN NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 NNP NN NNS IN CD O
between between 0 0 0 0 0 0 0 0 7 0 NN NNS IN CD NNS O
26 26 0 0 0 0 0 0 1 1 2 0 NNS IN CD NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 IN CD NNS IN NN O
with with 0 0 0 0 0 0 0 0 4 0 CD NNS IN NN CC O
cirrhosis cirrhosis 0 0 0 0 0 0 0 0 9 0 NNS IN NN CC CD O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC CD JJ O
20 20 0 0 0 0 0 0 1 1 2 0 NN CC CD JJ NNS O
healthy healthy 0 0 0 0 0 0 0 0 7 0 CC CD JJ NNS CC O
controls controls 0 0 0 0 0 0 0 0 8 0 CD JJ NNS CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 NNS CC VBN IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 CC VBN IN NNP NNS O
TFPI TFPI 1 1 0 0 0 0 0 0 4 0 VBN IN NNP NNS VBD O
levels levels 0 0 0 0 0 0 0 0 6 0 IN NNP NNS VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD JJ IN O
comparable comparable 0 0 0 0 0 0 0 0 10 0 NNS VBD JJ IN NNS O
between between 0 0 0 0 0 0 0 0 7 0 VBD JJ IN NNS -NONE- O
patients patients 0 0 0 0 0 0 0 0 8 0 JJ IN NNS -NONE- : O
(111 (111 0 0 0 0 0 0 0 1 4 0 IN NNS -NONE- : CD O
± ± 0 0 0 0 0 0 0 0 1 0 NNS -NONE- : CD CC O
38%) 38%) 0 0 0 0 0 0 0 1 4 0 -NONE- : CD CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 : CD CC NNS -NONE- O
controls controls 0 0 0 0 0 0 0 0 8 0 CD CC NNS -NONE- : O
(108 (108 0 0 0 0 0 0 0 1 4 0 CC NNS -NONE- : CD O
± ± 0 0 0 0 0 0 0 0 1 0 NNS -NONE- : CD IN O
27%), 27%), 0 0 0 0 1 0 0 1 5 0 -NONE- : CD IN VBN O
despite despite 0 0 0 0 0 0 0 0 7 0 : CD IN VBN NN O
reduced reduced 0 0 0 0 0 0 0 0 7 0 CD IN VBN NN NNP O
protein protein 0 0 0 0 0 0 0 0 7 0 IN VBN NN NNP NNS O
S S 1 1 0 0 0 0 0 0 1 0 VBN NN NNP NNS -NONE- O
levels levels 0 0 0 0 0 0 0 0 6 0 NN NNP NNS -NONE- : O
(74 (74 0 0 0 0 0 0 0 1 3 0 NNP NNS -NONE- : CD O
± ± 0 0 0 0 0 0 0 0 1 0 NNS -NONE- : CD IN O
23% 23% 0 0 0 0 0 0 0 1 3 0 -NONE- : CD IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 : CD IN NNS CC O
patients patients 0 0 0 0 0 0 0 0 8 0 CD IN NNS CC CD O
vs. vs. 0 0 0 0 0 0 0 0 3 0 IN NNS CC CD CD O
98 98 0 0 0 0 0 0 1 1 2 0 NNS CC CD CD CD O
± ± 0 0 0 0 0 0 0 0 1 0 CC CD CD CD IN O
10% 10% 0 0 0 0 0 0 0 1 3 0 CD CD CD IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CD CD IN NNP NNP O
controls). controls). 0 0 0 0 0 0 0 0 10 0 CD IN NNP NNP PRP O
Subsequently, Subsequently, 1 0 0 0 1 0 0 0 13 0 IN NNP NNP PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD DT O
quantified quantified 0 0 0 0 0 0 0 0 10 0 NNP PRP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 VBD DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
TFPI-protein TFPI-protein 1 0 1 0 0 0 0 0 12 0 IN DT JJ NNP NN O
S S 1 1 0 0 0 0 0 0 1 0 DT JJ NNP NN IN O
system system 0 0 0 0 0 0 0 0 6 0 JJ NNP NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NN O
measuring measuring 0 0 0 0 0 0 0 0 9 0 NN IN NN NN NN O
thrombin thrombin 0 0 0 0 0 0 0 0 8 0 IN NN NN NN IN O
generation generation 0 0 0 0 0 0 0 0 10 0 NN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN CC O
absence absence 0 0 0 0 0 0 0 0 7 0 IN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
presence presence 0 0 0 0 0 0 0 0 8 0 NN CC NN IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN VBG NNS O
neutralizing neutralizing 0 0 0 0 0 0 0 0 12 0 NN IN VBG NNS TO O
antibodies antibodies 0 0 0 0 0 0 0 0 10 0 IN VBG NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBG NNS TO VB NNP O
protein protein 0 0 0 0 0 0 0 0 7 0 NNS TO VB NNP CC O
S S 1 1 0 0 0 0 0 0 1 0 TO VB NNP CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 VB NNP CC NNP NNP O
TFPI. TFPI. 1 1 0 0 0 0 0 0 5 0 NNP CC NNP NNP IN O
Ratios Ratios 1 0 0 0 0 0 0 0 6 0 CC NNP NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN NN O
peak peak 0 0 0 0 0 0 0 0 4 0 NNP IN NN NN NN O
thrombin thrombin 0 0 0 0 0 0 0 0 8 0 IN NN NN NN IN O
generation generation 0 0 0 0 0 0 0 0 10 0 NN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN CC O
absence absence 0 0 0 0 0 0 0 0 7 0 IN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
presence presence 0 0 0 0 0 0 0 0 8 0 NN CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT NNS VBD O
antibodies antibodies 0 0 0 0 0 0 0 0 10 0 IN DT NNS VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 DT NNS VBD NNP NNP O
calculated. calculated. 0 0 0 0 0 0 0 0 11 0 NNS VBD NNP NNP DT O
Both Both 1 0 0 0 0 0 0 0 4 0 VBD NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NNP O
protein protein 0 0 0 0 0 0 0 0 7 0 NNP DT NN NNP CC O
S S 1 1 0 0 0 0 0 0 1 0 DT NN NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP CC DT NNP VBZ O
TFPI TFPI 1 1 0 0 0 0 0 0 4 0 CC DT NNP VBZ VBD O
ratios ratios 0 0 0 0 0 0 0 0 6 0 DT NNP VBZ VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBD VBN IN O
increased increased 0 0 0 0 0 0 0 0 9 0 VBZ VBD VBN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 VBN IN NNS IN NN O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN NN VBN O
cirrhosis cirrhosis 0 0 0 0 0 0 0 0 9 0 NNS IN NN VBN TO O
compared compared 0 0 0 0 0 0 0 0 8 0 IN NN VBN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NN VBN TO NNP NNP O
controls. controls. 0 0 0 0 0 0 0 0 9 0 VBN TO NNP NNP NNP O
Protein Protein 1 0 0 0 0 0 0 0 7 0 TO NNP NNP NNP VBZ O
S S 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP VBZ VBD O
ratios ratios 0 0 0 0 0 0 0 0 6 0 NNP NNP VBZ VBD -NONE- O
were were 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBD -NONE- -NONE- O
(0·62 (0·62 0 0 0 0 0 0 0 1 5 0 VBZ VBD -NONE- -NONE- IN O
[0·08-0·93] [0·08-0·93] 0 0 1 0 0 0 0 1 11 0 VBD -NONE- -NONE- IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- -NONE- IN NNS CC O
patients patients 0 0 0 0 0 0 0 0 8 0 -NONE- IN NNS CC CD O
vs. vs. 0 0 0 0 0 0 0 0 3 0 IN NNS CC CD NN O
0·32 0·32 0 0 0 0 0 0 0 1 4 0 NNS CC CD NN IN O
[0·20-0·54] [0·20-0·54] 0 0 1 0 0 0 0 1 11 0 CC CD NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN NNP NNP O
controls; controls; 0 0 0 0 0 0 0 0 9 0 NN IN NNP NNP VBZ O
TFPI TFPI 1 1 0 0 0 0 0 0 4 0 IN NNP NNP VBZ VBD O
ratios ratios 0 0 0 0 0 0 0 0 6 0 NNP NNP VBZ VBD CD O
were were 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBD CD -NONE- O
0·50 0·50 0 0 0 0 0 0 0 1 4 0 VBZ VBD CD -NONE- IN O
[0·05-0·90] [0·05-0·90] 0 0 1 0 0 0 0 1 11 0 VBD CD -NONE- IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 CD -NONE- IN NNS CC O
patients patients 0 0 0 0 0 0 0 0 8 0 -NONE- IN NNS CC CD O
vs. vs. 0 0 0 0 0 0 0 0 3 0 IN NNS CC CD NN O
0·18 0·18 0 0 0 0 0 0 0 1 4 0 NNS CC CD NN IN O
[0·11-0·49] [0·11-0·49] 0 0 1 0 0 0 0 1 11 0 CC CD NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN NNP NNP O
controls). controls). 0 0 0 0 0 0 0 0 10 0 NN IN NNP NNP IN O
Thus, Thus, 1 0 0 0 1 0 0 0 5 0 IN NNP NNP IN DT O
although although 0 0 0 0 0 0 0 0 8 0 NNP NNP IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT VBN NN O
acquired acquired 0 0 0 0 0 0 0 0 8 0 IN DT VBN NN NNP O
protein protein 0 0 0 0 0 0 0 0 7 0 DT VBN NN NNP NN O
S S 1 1 0 0 0 0 0 0 1 0 VBN NN NNP NN IN O
deficiency deficiency 0 0 0 0 0 0 0 0 10 0 NN NNP NN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 NN IN NNS IN NN O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN NN VBZ O
cirrhosis cirrhosis 0 0 0 0 0 0 0 0 9 0 NNS IN NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 IN NN VBZ RB VBN O
not not 0 0 0 0 0 0 0 0 3 0 NN VBZ RB VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 VBZ RB VBN IN VBN O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN VBN NNP O
decreased decreased 0 0 0 0 0 0 0 0 9 0 VBN IN VBN NNP NNP O
TFPI TFPI 1 1 0 0 0 0 0 0 4 0 IN VBN NNP NNP DT O
levels, levels, 0 0 0 0 1 0 0 0 7 0 VBN NNP NNP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNP NNP O
TFPI/protein TFPI/protein 1 0 0 1 0 0 0 0 12 0 NNP DT NNP NNP NN O
S S 1 1 0 0 0 0 0 0 1 0 DT NNP NNP NN NN O
anticoagulant anticoagulant 0 0 0 0 0 0 0 0 13 0 NNP NNP NN NN VBZ O
system system 0 0 0 0 0 0 0 0 6 0 NNP NN NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ RB NNP O
functionally functionally 0 0 0 0 0 0 0 0 12 0 NN VBZ RB NNP NONE O
impaired. impaired. 0 0 0 0 0 0 0 0 9 0 VBZ RB NNP NONE NONE O
A A 1 1 0 0 0 0 0 0 1 0 NONE NONE DT NNP IN O
Study Study 1 0 0 0 0 0 0 0 5 0 NONE DT NNP IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 DT NNP IN NNP IN O
Course Course 1 0 0 0 0 0 0 0 6 0 NNP IN NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP CC O
Infection Infection 1 0 0 0 0 0 0 0 9 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNPS O
Haematological Haematological 1 0 0 0 0 0 0 0 14 0 NNP CC NNP NNPS IN O
Changes Changes 1 0 0 0 0 0 0 0 7 0 CC NNP NNPS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN JJ IN O
falciparum-Infected falciparum-Infected 0 0 1 0 0 0 0 0 19 0 NNPS IN JJ IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN JJ IN NNP IN O
Comparison Comparison 1 0 0 0 0 0 0 0 10 0 JJ IN NNP IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NNP IN JJ NNP O
Artemisinin(s)-Treated Artemisinin(s)-Treated 1 0 1 0 0 0 0 0 22 0 NNP IN JJ NNP NNP O
Mice. Mice. 1 0 0 0 0 0 0 0 5 0 IN JJ NNP NNP NNP O
Kuthala Kuthala 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP NNP NNP O
KK, KK, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Meka Meka 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kanikaram Kanikaram 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
S. S. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Zoology Zoology 1 0 0 0 0 0 0 0 7 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Aquaculture, Aquaculture, 1 0 0 0 1 0 0 0 12 0 NNP CC NNP NNP NNP O
Acharya Acharya 1 0 0 0 0 0 0 0 7 0 CC NNP NNP NNP NNP O
Nagarjuna Nagarjuna 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Nagarjunanagar, Nagarjunanagar, 1 0 0 0 1 0 0 0 15 0 NNP NNP NNP NNP NNP O
Guntur, Guntur, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Andhra Andhra 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP CD O
Pradesh Pradesh 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP CD CD O
522 522 0 0 0 0 0 0 1 1 3 0 NNP NNP CD CD NNP O
510, 510, 0 0 0 0 1 0 0 1 4 0 NNP CD CD NNP NNP O
India. India. 1 0 0 0 0 0 0 0 6 0 CD CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP VB O
To To 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VB RP O
find find 0 0 0 0 0 0 0 0 4 0 NNP NNP VB RP DT O
out out 0 0 0 0 0 0 0 0 3 0 NNP VB RP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VB RP DT NN CC O
efficacy efficacy 0 0 0 0 0 0 0 0 8 0 RP DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 NN CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NNS O
artemisinin artemisinin 0 0 0 0 0 0 0 0 11 0 NN IN NN NNS IN O
derivatives derivatives 0 0 0 0 0 0 0 0 11 0 IN NN NNS IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NN O
haematological haematological 0 0 0 0 0 0 0 0 14 0 NNS IN JJ NN NN O
indices, indices, 0 0 0 0 1 0 0 0 8 0 IN JJ NN NN NN O
C57BL/6J C57BL/6J 1 1 0 1 0 0 0 1 8 0 JJ NN NN NN VBD O
mice mice 0 0 0 0 0 0 0 0 4 0 NN NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN IN O
challenged challenged 0 0 0 0 0 0 0 0 10 0 NN VBD VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNP NN O
Plasmodium Plasmodium 1 0 0 0 0 0 0 0 10 0 VBN IN NNP NN CC O
falciparum falciparum 0 0 0 0 0 0 0 0 10 0 IN NNP NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC VBD IN O
treated treated 0 0 0 0 0 0 0 0 7 0 NN CC VBD IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 CC VBD IN JJ NNS O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 VBD IN JJ NNS IN O
doses doses 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
AS, AS, 1 1 0 0 1 0 0 0 3 0 NNS IN JJ NN CC O
AE, AE, 1 1 0 0 1 0 0 0 3 0 IN JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP NNP O
AL. AL. 1 1 0 0 0 0 0 0 3 0 NN CC NNP NNP IN O
Course Course 1 0 0 0 0 0 0 0 6 0 CC NNP NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN VBD O
infection infection 0 0 0 0 0 0 0 0 9 0 NNP IN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 IN NN VBD VBN IN O
studied studied 0 0 0 0 0 0 0 0 7 0 NN VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT VBN CC O
infected infected 0 0 0 0 0 0 0 0 8 0 IN DT VBN CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 DT VBN CC VBN NNS O
treated treated 0 0 0 0 0 0 0 0 7 0 VBN CC VBN NNS RP O
groups groups 0 0 0 0 0 0 0 0 6 0 CC VBN NNS RP TO O
up up 0 0 0 0 0 0 0 0 2 0 VBN NNS RP TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NNS RP TO NN CD O
day day 0 0 0 0 0 0 0 0 3 0 RP TO NN CD NNP O
42. 42. 0 0 0 0 0 0 0 1 3 0 TO NN CD NNP NN O
Peak Peak 1 0 0 0 0 0 0 0 4 0 NN CD NNP NN IN O
level level 0 0 0 0 0 0 0 0 5 0 CD NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NN O
parasitaemia parasitaemia 0 0 0 0 0 0 0 0 12 0 NN IN NN NN VBD O
(38%) (38%) 0 0 0 0 0 0 0 1 5 0 IN NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN CD O
day day 0 0 0 0 0 0 0 0 3 0 VBN IN NN CD IN O
11 11 0 0 0 0 0 0 1 1 2 0 IN NN CD IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN CD IN JJ NNP O
infected infected 0 0 0 0 0 0 0 0 8 0 CD IN JJ NNP NNP O
group. group. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP NNS O
Haematological Haematological 1 0 0 0 0 0 0 0 14 0 JJ NNP NNP NNS VBD O
indices indices 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD JJ O
indicated indicated 0 0 0 0 0 0 0 0 9 0 NNP NNS VBD JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 NNS VBD JJ NN : O
(P (P 0 1 0 0 0 0 0 0 2 0 VBD JJ NN : CD O
< < 0 0 0 0 0 0 0 0 1 0 JJ NN : CD NN O
0.05) 0.05) 0 0 0 0 0 0 0 1 5 0 NN : CD NN IN O
decrease decrease 0 0 0 0 0 0 0 0 8 0 : CD NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN NNP NNP O
RBC, RBC, 1 1 0 0 1 0 0 0 4 0 NN IN NNP NNP NNP O
WBC, WBC, 1 1 0 0 1 0 0 0 4 0 IN NNP NNP NNP VBD O
haemoglobin, haemoglobin, 0 0 0 0 1 0 0 0 12 0 NNP NNP NNP VBD NN O
packed packed 0 0 0 0 0 0 0 0 6 0 NNP NNP VBD NN -NONE- O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP VBD NN -NONE- JJ O
volume, volume, 0 0 0 0 1 0 0 0 7 0 VBD NN -NONE- JJ NN O
mean mean 0 0 0 0 0 0 0 0 4 0 NN -NONE- JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 -NONE- JJ NN NN CC O
volume, volume, 0 0 0 0 1 0 0 0 7 0 JJ NN NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VB NNS O
platelet platelet 0 0 0 0 0 0 0 0 8 0 NN CC VB NNS IN O
counts counts 0 0 0 0 0 0 0 0 6 0 CC VB NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VB NNS IN JJ NNP O
infected infected 0 0 0 0 0 0 0 0 8 0 NNS IN JJ NNP CC O
mice. mice. 0 0 0 0 0 0 0 0 5 0 IN JJ NNP CC DT O
But But 1 0 0 0 0 0 0 0 3 0 JJ NNP CC DT DT O
all all 0 0 0 0 0 0 0 0 3 0 NNP CC DT DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 CC DT DT NNS VBD O
parameters parameters 0 0 0 0 0 0 0 0 10 0 DT DT NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 DT NNS VBD VBN TO O
restored restored 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO JJ NN O
normal normal 0 0 0 0 0 0 0 0 6 0 VBN TO JJ NN CC O
values, values, 0 0 0 0 1 0 0 0 7 0 TO JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 NN CC JJ NN : O
(P (P 0 1 0 0 0 0 0 0 2 0 CC JJ NN : CD O
< < 0 0 0 0 0 0 0 0 1 0 JJ NN : CD NNS O
0.05) 0.05) 0 0 0 0 0 0 0 1 5 0 NN : CD NNS VBD O
changes changes 0 0 0 0 0 0 0 0 7 0 : CD NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 CD NNS VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT JJ O
all all 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNP O
drug-treated drug-treated 0 0 1 0 0 0 0 0 12 0 IN DT JJ NNP NNP O
groups. groups. 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NNP NNS O
Insignificant Insignificant 1 0 0 0 0 0 0 0 13 0 JJ NNP NNP NNS VBD O
changes changes 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN NNP NNP O
MCHC MCHC 1 1 0 0 0 0 0 0 4 0 VBN IN NNP NNP NNP O
(P (P 0 1 0 0 0 0 0 0 2 0 IN NNP NNP NNP CD O
> > 0 0 0 0 0 0 0 0 1 0 NNP NNP NNP CD IN O
0.05) 0.05) 0 0 0 0 0 0 0 1 5 0 NNP NNP CD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP CD IN DT JJ O
all all 0 0 0 0 0 0 0 0 3 0 CD IN DT JJ NNP O
drug-treated drug-treated 0 0 1 0 0 0 0 0 12 0 IN DT JJ NNP NNP O
groups. groups. 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NNP IN O
Percent Percent 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN NN O
peak peak 0 0 0 0 0 0 0 0 4 0 NNP IN NN NN VBD O
parasitaemia parasitaemia 0 0 0 0 0 0 0 0 12 0 IN NN NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD RB VBN O
much much 0 0 0 0 0 0 0 0 4 0 NN VBD RB VBN IN O
reduced reduced 0 0 0 0 0 0 0 0 7 0 VBD RB VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN NNP NNP O
AL- AL- 1 1 1 0 0 0 0 0 3 0 VBN IN NNP NNP IN O
(3.2% (3.2% 0 0 0 0 0 0 0 1 5 0 IN NNP NNP IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN CD O
day day 0 0 0 0 0 0 0 0 3 0 NNP IN NN CD VBN O
3) 3) 0 0 0 0 0 0 0 1 2 0 IN NN CD VBN NN O
treated treated 0 0 0 0 0 0 0 0 7 0 NN CD VBN NN IN O
group group 0 0 0 0 0 0 0 0 5 0 CD VBN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBN NN IN NN IN O
comparison comparison 0 0 0 0 0 0 0 0 10 0 NN IN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN JJ NN O
AE- AE- 1 1 1 0 0 0 0 0 3 0 NN IN JJ NN IN O
(2.4% (2.4% 0 0 0 0 0 0 0 1 5 0 IN JJ NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN CD O
day day 0 0 0 0 0 0 0 0 3 0 NN IN NN CD CC O
4) 4) 0 0 0 0 0 0 0 1 2 0 IN NN CD CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN CD CC JJ NN O
AS- AS- 1 1 1 0 0 0 0 0 3 0 CD CC JJ NN IN O
(4% (4% 0 0 0 0 0 0 0 1 3 0 CC JJ NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN CD O
day day 0 0 0 0 0 0 0 0 3 0 NN IN NN CD VBN O
2) 2) 0 0 0 0 0 0 0 1 2 0 IN NN CD VBN NNP O
treated treated 0 0 0 0 0 0 0 0 7 0 NN CD VBN NNP NNP O
groups. groups. 0 0 0 0 0 0 0 0 7 0 CD VBN NNP NNP VBD O
Parasites Parasites 1 0 0 0 0 0 0 0 9 0 VBN NNP NNP VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD RB VBN O
completely completely 0 0 0 0 0 0 0 0 10 0 NNP VBD RB VBN IN O
cleared cleared 0 0 0 0 0 0 0 0 7 0 VBD RB VBN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 RB VBN IN NN CD O
day day 0 0 0 0 0 0 0 0 3 0 VBN IN NN CD IN O
6 6 0 0 0 0 0 0 1 1 1 0 IN NN CD IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN CD IN NNP NNP O
AS AS 1 1 0 0 0 0 0 0 2 0 CD IN NNP NNP NN O
group, group, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP NN CD O
day day 0 0 0 0 0 0 0 0 3 0 NNP NNP NN CD IN O
5 5 0 0 0 0 0 0 1 1 1 0 NNP NN CD IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN CD IN NNP NNP O
AE AE 1 1 0 0 0 0 0 0 2 0 CD IN NNP NNP CC O
group, group, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NN CD O
day day 0 0 0 0 0 0 0 0 3 0 NNP CC NN CD IN O
4 4 0 0 0 0 0 0 1 1 1 0 CC NN CD IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN CD IN NNP NNP O
AL AL 1 1 0 0 0 0 0 0 2 0 CD IN NNP NNP NNP O
group. group. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP PRP$ O
Hence, Hence, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP PRP$ NNS O
our our 0 0 0 0 0 0 0 0 3 0 NNP NNP PRP$ NNS RB O
results results 0 0 0 0 0 0 0 0 7 0 NNP PRP$ NNS RB NN O
strongly strongly 0 0 0 0 0 0 0 0 8 0 PRP$ NNS RB NN IN O
support support 0 0 0 0 0 0 0 0 7 0 NNS RB NN IN NN O
that that 0 0 0 0 0 0 0 0 4 0 RB NN IN NN NN O
combination combination 0 0 0 0 0 0 0 0 11 0 NN IN NN NN VBZ O
therapy therapy 0 0 0 0 0 0 0 0 7 0 IN NN NN VBZ JJ O
has has 0 0 0 0 0 0 0 0 3 0 NN NN VBZ JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 NN VBZ JJ NN NNS O
efficacy efficacy 0 0 0 0 0 0 0 0 8 0 VBZ JJ NN NNS IN O
rates rates 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN NNP O
than than 0 0 0 0 0 0 0 0 4 0 NN NNS IN NNP NNP O
monotherapy. monotherapy. 0 0 0 0 0 0 0 0 12 0 NNS IN NNP NNP NN O
No No 1 0 0 0 0 0 0 0 2 0 IN NNP NNP NN VBZ O
adverse adverse 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBZ VBD O
effects effects 0 0 0 0 0 0 0 0 7 0 NNP NN VBZ VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN VBZ VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 VBZ VBD VBN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NNS O
haematological haematological 0 0 0 0 0 0 0 0 14 0 VBN IN JJ NNS WRB O
parameters parameters 0 0 0 0 0 0 0 0 10 0 IN JJ NNS WRB NNS O
when when 0 0 0 0 0 0 0 0 4 0 JJ NNS WRB NNS VBD O
animals animals 0 0 0 0 0 0 0 0 7 0 NNS WRB NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 WRB NNS VBD VBN IN O
treated treated 0 0 0 0 0 0 0 0 7 0 NNS VBD VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN JJ NNP O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 VBN IN JJ NNP NONE O
dosages. dosages. 0 0 0 0 0 0 0 0 8 0 IN JJ NNP NONE NONE O
Hybrid Hybrid 1 0 0 0 0 0 0 0 6 0 NONE NONE NNP NNP IN O
Technique Technique 1 0 0 0 0 0 0 0 9 0 NONE NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Lamellar Lamellar 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Keratoplasty Keratoplasty 1 0 0 0 0 0 0 0 12 0 IN NNP NNP NNP NNP O
(DMEK-S). (DMEK-S). 0 1 1 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Studeny Studeny 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sivekova Sivekova 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Liehneova Liehneova 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Vokrojova Vokrojova 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kuchynka Kuchynka 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
P. P. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Ophthalmology Ophthalmology 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
Department, Department, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP IN O
Faculty Faculty 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Charles Charles 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP CC O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Teaching Teaching 1 0 0 0 0 0 0 0 8 0 NNP CC NNP NNP NNP O
Hospital Hospital 1 0 0 0 0 0 0 0 8 0 CC NNP NNP NNP NNP O
Kralovske Kralovske 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Vinohrady, Vinohrady, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP CD O
Srobarova Srobarova 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP CD NNP O
50, 50, 0 0 0 0 1 0 0 1 3 0 NNP NNP CD NNP CD O
Prague Prague 1 0 0 0 0 0 0 0 6 0 NNP CD NNP CD CD O
100 100 0 0 0 0 0 0 1 1 3 0 CD NNP CD CD NNP O
34, 34, 0 0 0 0 1 0 0 1 3 0 NNP CD CD NNP NNP O
Czech Czech 1 0 0 0 0 0 0 0 5 0 CD CD NNP NNP NNP O
Republic. Republic. 1 0 0 0 0 0 0 0 9 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Purpose: Purpose: 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VB O
To To 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VB DT O
evaluate evaluate 0 0 0 0 0 0 0 0 8 0 NNP NNP VB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP VB DT NNS IN O
outcomes outcomes 0 0 0 0 0 0 0 0 8 0 VB DT NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
hybrid hybrid 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN IN O
technique technique 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ JJ O
posterior posterior 0 0 0 0 0 0 0 0 9 0 NN IN JJ JJ NN O
lamellar lamellar 0 0 0 0 0 0 0 0 8 0 IN JJ JJ NN NNP O
keratoplasty keratoplasty 0 0 0 0 0 0 0 0 12 0 JJ JJ NN NNP NNPS O
(DMEK-S). (DMEK-S). 0 1 1 0 0 0 0 0 9 0 JJ NN NNP NNPS CC O
Materials Materials 1 0 0 0 0 0 0 0 9 0 NN NNP NNPS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNPS CC NNP CD O
Methods: Methods: 1 0 0 0 0 0 0 0 8 0 NNPS CC NNP CD NNS O
71 71 0 0 0 0 0 0 1 1 2 0 CC NNP CD NNS IN O
eyes eyes 0 0 0 0 0 0 0 0 4 0 NNP CD NNS IN CD O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN CD NNS O
55 55 0 0 0 0 0 0 1 1 2 0 NNS IN CD NNS VBD O
patients patients 0 0 0 0 0 0 0 0 8 0 IN CD NNS VBD IN O
enrolled enrolled 0 0 0 0 0 0 0 0 8 0 CD NNS VBD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBD IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBD IN DT JJ NN O
single-center single-center 0 0 1 0 0 0 0 0 13 0 IN DT JJ NN NN O
study study 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN NN O
underwent underwent 0 0 0 0 0 0 0 0 9 0 JJ NN NN NN NN O
posterior posterior 0 0 0 0 0 0 0 0 9 0 NN NN NN NN NN O
lamellar lamellar 0 0 0 0 0 0 0 0 8 0 NN NN NN NN IN O
keratoplasty keratoplasty 0 0 0 0 0 0 0 0 12 0 NN NN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
hybrid hybrid 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN NNS O
lamella lamella 0 0 0 0 0 0 0 0 7 0 DT JJ NN NNS VBD O
DMEK-S DMEK-S 1 1 1 0 0 0 0 0 6 0 JJ NN NNS VBD VBG O
implanted implanted 0 0 0 0 0 0 0 0 9 0 NN NNS VBD VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 NNS VBD VBG DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBD VBG DT NN NN O
solution solution 0 0 0 0 0 0 0 0 8 0 VBG DT NN NN NN O
implantation implantation 0 0 0 0 0 0 0 0 12 0 DT NN NN NN VBG O
technique, technique, 0 0 0 0 1 0 0 0 10 0 NN NN NN VBG TO O
owing owing 0 0 0 0 0 0 0 0 5 0 NN NN VBG TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NN VBG TO JJ NNP O
endothelial endothelial 0 0 0 0 0 0 0 0 11 0 VBG TO JJ NNP NNP O
dysfunction. dysfunction. 0 0 0 0 0 0 0 0 12 0 TO JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN VBZ O
outcome outcome 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBZ VBN O
measures measures 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ VBN VBD O
studied studied 0 0 0 0 0 0 0 0 7 0 NN VBZ VBN VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 VBZ VBN VBD JJ NN O
visual visual 0 0 0 0 0 0 0 0 6 0 VBN VBD JJ NN CC O
acuity acuity 0 0 0 0 0 0 0 0 6 0 VBD JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NN O
endothelial endothelial 0 0 0 0 0 0 0 0 11 0 NN CC JJ NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 CC JJ NN NNP NNP O
density. density. 0 0 0 0 0 0 0 0 8 0 JJ NN NNP NNP NNP O
Results: Results: 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
endothelial endothelial 0 0 0 0 0 0 0 0 11 0 NN IN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN VBD O
loss loss 0 0 0 0 0 0 0 0 4 0 JJ NN NN VBD IN O
caused caused 0 0 0 0 0 0 0 0 6 0 NN NN VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN NN VBD O
surgery surgery 0 0 0 0 0 0 0 0 7 0 VBD IN NN VBD CD O
was was 0 0 0 0 0 0 0 0 3 0 IN NN VBD CD NNP O
43.8%. 43.8%. 0 0 0 0 0 0 0 1 6 0 NN VBD CD NNP NNP O
During During 1 0 0 0 0 0 0 0 6 0 VBD CD NNP NNP PRP O
followups, followups, 0 0 0 0 1 0 0 0 10 0 CD NNP NNP PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD DT O
observed observed 0 0 0 0 0 0 0 0 8 0 NNP PRP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT NN IN O
stabilization stabilization 0 0 0 0 0 0 0 0 13 0 VBD DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
postoperative postoperative 0 0 0 0 0 0 0 0 13 0 NN IN JJ NN CC O
findings, findings, 0 0 0 0 1 0 0 0 9 0 IN JJ NN CC IN O
or or 0 0 0 0 0 0 0 0 2 0 JJ NN CC IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 NN CC IN JJ DT O
minimum minimum 0 0 0 0 0 0 0 0 7 0 CC IN JJ DT RB O
a a 0 0 0 0 0 0 0 0 1 0 IN JJ DT RB JJ O
very very 0 0 0 0 0 0 0 0 4 0 JJ DT RB JJ NN O
low low 0 0 0 0 0 0 0 0 3 0 DT RB JJ NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 RB JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN JJ O
corneal corneal 0 0 0 0 0 0 0 0 7 0 NN IN NN JJ NN O
endothelial endothelial 0 0 0 0 0 0 0 0 11 0 IN NN JJ NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 NN JJ NN NNP NNP O
loss. loss. 0 0 0 0 0 0 0 0 5 0 JJ NN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNP CC O
UCDVA UCDVA 1 1 0 0 0 0 0 0 5 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP RB O
BCDVA BCDVA 1 1 0 0 0 0 0 0 5 0 NNP CC NNP RB VBN O
dramatically dramatically 0 0 0 0 0 0 0 0 12 0 CC NNP RB VBN NNP O
improved improved 0 0 0 0 0 0 0 0 8 0 NNP RB VBN NNP NNP O
postoperatively. postoperatively. 0 0 0 0 0 0 0 0 16 0 RB VBN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 VBN NNP NNP NN NN O
rebubbling rebubbling 0 0 0 0 0 0 0 0 10 0 NNP NNP NN NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 NNP NN NN IN PRP$ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN PRP$ NN O
our our 0 0 0 0 0 0 0 0 3 0 NN IN PRP$ NN IN O
group group 0 0 0 0 0 0 0 0 5 0 IN PRP$ NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 PRP$ NN IN NNS VBD O
patients patients 0 0 0 0 0 0 0 0 8 0 NN IN NNS VBD CD O
was was 0 0 0 0 0 0 0 0 3 0 IN NNS VBD CD PRP O
61.9%. 61.9%. 0 0 0 0 0 0 0 1 6 0 NNS VBD CD PRP VBD O
We We 1 0 0 0 0 0 0 0 2 0 VBD CD PRP VBD DT O
replaced replaced 0 0 0 0 0 0 0 0 8 0 CD PRP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT NN JJ O
lamella lamella 0 0 0 0 0 0 0 0 7 0 VBD DT NN JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 DT NN JJ TO PRP$ O
to to 0 0 0 0 0 0 0 0 2 0 NN JJ TO PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 JJ TO PRP$ NN CC O
failure failure 0 0 0 0 0 0 0 0 7 0 TO PRP$ NN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 PRP$ NN CC NN IN O
malfunction malfunction 0 0 0 0 0 0 0 0 11 0 NN CC NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 CC NN IN CD NNS O
17 17 0 0 0 0 0 0 1 1 2 0 NN IN CD NNS NNP O
patients patients 0 0 0 0 0 0 0 0 8 0 IN CD NNS NNP NNP O
(23.9%). (23.9%). 0 0 0 0 0 0 0 1 8 0 CD NNS NNP NNP NNP O
Conclusion: Conclusion: 1 0 0 0 0 0 0 0 11 0 NNS NNP NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
summary, summary, 0 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP VBZ O
DMEK-S DMEK-S 1 1 1 0 0 0 0 0 6 0 NNP NNP NNP VBZ DT O
combines combines 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT NNS IN O
advantages advantages 0 0 0 0 0 0 0 0 10 0 VBZ DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ CC O
DSEK/DSAEK DSEK/DSAEK 1 1 0 1 0 0 0 0 10 0 NNS IN JJ CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC NNP NNP O
DMEK. DMEK. 1 1 0 0 0 0 0 0 5 0 JJ CC NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 CC NNP NNP JJ NN O
central central 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NN IN O
zone zone 0 0 0 0 0 0 0 0 4 0 NNP JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNS O
bare bare 0 0 0 0 0 0 0 0 4 0 NN IN NN NNS VBP O
Descemet's Descemet's 1 0 0 0 0 1 0 0 10 0 IN NN NNS VBP CC O
membrane membrane 0 0 0 0 0 0 0 0 8 0 NN NNS VBP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNS VBP CC NN VBZ O
endothelium endothelium 0 0 0 0 0 0 0 0 11 0 VBP CC NN VBZ IN O
allows allows 0 0 0 0 0 0 0 0 6 0 CC NN VBZ IN RB O
for for 0 0 0 0 0 0 0 0 3 0 NN VBZ IN RB JJ O
very very 0 0 0 0 0 0 0 0 4 0 VBZ IN RB JJ JJ O
good good 0 0 0 0 0 0 0 0 4 0 IN RB JJ JJ NN O
visual visual 0 0 0 0 0 0 0 0 6 0 RB JJ JJ NN CC O
outcomes, outcomes, 0 0 0 0 1 0 0 0 9 0 JJ JJ NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT JJ NN O
peripheral peripheral 0 0 0 0 0 0 0 0 10 0 CC DT JJ NN VBZ O
rim rim 0 0 0 0 0 0 0 0 3 0 DT JJ NN VBZ IN O
allows allows 0 0 0 0 0 0 0 0 6 0 JJ NN VBZ IN JJR O
for for 0 0 0 0 0 0 0 0 3 0 NN VBZ IN JJR NN O
better better 0 0 0 0 0 0 0 0 6 0 VBZ IN JJR NN IN O
manipulation manipulation 0 0 0 0 0 0 0 0 12 0 IN JJR NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJR NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
lamella lamella 0 0 0 0 0 0 0 0 7 0 IN DT NN IN NNP O
during during 0 0 0 0 0 0 0 0 6 0 DT NN IN NNP NNP O
implantation. implantation. 0 0 0 0 0 0 0 0 13 0 NN IN NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 IN NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNP VBZ DT JJ NN O
effective effective 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ NN IN O
method method 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN VBG DT O
treating treating 0 0 0 0 0 0 0 0 8 0 NN IN VBG DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 IN VBG DT JJ NN O
endothelial endothelial 0 0 0 0 0 0 0 0 11 0 VBG DT JJ NN IN O
dysfunction dysfunction 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
various various 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN CC O
etiologies, etiologies, 0 0 0 0 1 0 0 0 11 0 IN JJ NN CC DT O
but but 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 CC DT JJ NN NN O
complication complication 0 0 0 0 0 0 0 0 12 0 DT JJ NN NN VBZ O
rate rate 0 0 0 0 0 0 0 0 4 0 JJ NN NN VBZ TO O
needs needs 0 0 0 0 0 0 0 0 5 0 NN NN VBZ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBZ TO VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 VBZ TO VB VBN IN O
addressed addressed 0 0 0 0 0 0 0 0 9 0 TO VB VBN IN JJ O
before before 0 0 0 0 0 0 0 0 6 0 VB VBN IN JJ NN O
widespread widespread 0 0 0 0 0 0 0 0 10 0 VBN IN JJ NN IN O
implementation implementation 0 0 0 0 0 0 0 0 14 0 IN JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
technique technique 0 0 0 0 0 0 0 0 9 0 IN DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NONE O
future. future. 0 0 0 0 0 0 0 0 7 0 IN DT NNP NONE NONE O
haracterization haracterization 0 0 0 0 0 0 0 0 15 0 NONE NONE NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NNP NNP O
Novel Novel 1 0 0 0 0 0 0 0 5 0 IN DT NNP NNP NNP O
Putative Putative 1 0 0 0 0 0 0 0 8 0 DT NNP NNP NNP NNP O
S-Adenosylmethionine S-Adenosylmethionine 1 0 1 0 0 0 0 0 20 0 NNP NNP NNP NNP NNP O
Decarboxylase-Like Decarboxylase-Like 1 0 1 0 0 0 0 0 18 0 NNP NNP NNP NNP IN O
Protein Protein 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNP IN NNP NNP O
Leishmania Leishmania 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
donovani. donovani. 0 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP NNP O
Singh Singh 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
SP, SP, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Agnihotri Agnihotri 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Pratap Pratap 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
JV. JV. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP CC O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP CC NNP O
& & 0 0 0 0 0 0 0 0 1 0 NNP NNP CC NNP NNP O
Structural Structural 1 0 0 0 0 0 0 0 10 0 NNP CC NNP NNP NNP O
Biology Biology 1 0 0 0 0 0 0 0 7 0 CC NNP NNP NNP NNP O
Division, Division, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Central Central 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Drug Drug 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Institute, Institute, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Chattar Chattar 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Manzil, Manzil, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Mahatma Mahatma 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Gandhi Gandhi 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Marg, Marg, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
Lucknow, Lucknow, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Uttar Uttar 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Pradesh, Pradesh, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
India. India. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NN TO O
addition addition 0 0 0 0 0 0 0 0 8 0 NNP NNP NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT JJ NN O
S-adenosylmethionine S-adenosylmethionine 1 0 1 0 0 0 0 0 20 0 TO DT JJ NN NN O
decarboxylase decarboxylase 0 0 0 0 0 0 0 0 13 0 DT JJ NN NN NN O
(AD) (AD) 0 1 0 0 0 0 0 0 4 0 JJ NN NN NN IN O
present present 0 0 0 0 0 0 0 0 7 0 NN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
all all 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNS O
organisms, organisms, 0 0 0 0 1 0 0 0 10 0 IN DT JJ NNS VBG O
trypanosomatids trypanosomatids 0 0 0 0 0 0 0 0 15 0 DT JJ NNS VBG NNP O
including including 0 0 0 0 0 0 0 0 9 0 JJ NNS VBG NNP NNP O
Leishmania Leishmania 1 0 0 0 0 0 0 0 10 0 NNS VBG NNP NNP NN O
spp. spp. 0 0 0 0 0 0 0 0 4 0 VBG NNP NNP NN DT O
possess possess 0 0 0 0 0 0 0 0 7 0 NNP NNP NN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNP NN DT JJ NN O
additional additional 0 0 0 0 0 0 0 0 10 0 NN DT JJ NN VBD O
copy, copy, 0 0 0 0 1 0 0 0 5 0 DT JJ NN VBD IN O
annotated annotated 0 0 0 0 0 0 0 0 9 0 JJ NN VBD IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NN VBD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT JJ NN O
putative putative 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN JJ O
S-adenosylmethionine S-adenosylmethionine 1 0 1 0 0 0 0 0 20 0 DT JJ NN JJ NN O
decarboxylase-like decarboxylase-like 0 0 1 0 0 0 0 0 18 0 JJ NN JJ NN NNP O
proenzyme proenzyme 0 0 0 0 0 0 0 0 9 0 NN JJ NN NNP NNP O
(ADL). (ADL). 0 1 0 0 0 0 0 0 6 0 JJ NN NNP NNP NN O
Phylogenetic Phylogenetic 1 0 0 0 0 0 0 0 12 0 NN NNP NNP NN VBZ O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBZ IN O
confirms confirms 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NN VBZ IN NNP VBZ O
ADL ADL 1 1 0 0 0 0 0 0 3 0 VBZ IN NNP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ JJ TO O
unique unique 0 0 0 0 0 0 0 0 6 0 NNP VBZ JJ TO NNS O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO NNS CC O
trypanosomatids trypanosomatids 0 0 0 0 0 0 0 0 15 0 JJ TO NNS CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 TO NNS CC VBZ JJ O
has has 0 0 0 0 0 0 0 0 3 0 NNS CC VBZ JJ JJ O
several several 0 0 0 0 0 0 0 0 7 0 CC VBZ JJ JJ NNS O
unique unique 0 0 0 0 0 0 0 0 6 0 VBZ JJ JJ NNS JJ O
features features 0 0 0 0 0 0 0 0 8 0 JJ JJ NNS JJ IN O
such such 0 0 0 0 0 0 0 0 4 0 JJ NNS JJ IN NN O
as as 0 0 0 0 0 0 0 0 2 0 NNS JJ IN NN IN O
lack lack 0 0 0 0 0 0 0 0 4 0 JJ IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NN O
autocatalytic autocatalytic 0 0 0 0 0 0 0 0 13 0 NN IN JJ NN CC O
cleavage cleavage 0 0 0 0 0 0 0 0 8 0 IN JJ NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN CC DT JJ NN O
distinct distinct 0 0 0 0 0 0 0 0 8 0 CC DT JJ NN NN O
evolutionary evolutionary 0 0 0 0 0 0 0 0 12 0 DT JJ NN NN RB O
lineage, lineage, 0 0 0 0 1 0 0 0 8 0 JJ NN NN RB IN O
even even 0 0 0 0 0 0 0 0 4 0 NN NN RB IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NN RB IN JJ NNP O
trypanosomatid trypanosomatid 0 0 0 0 0 0 0 0 14 0 RB IN JJ NNP NNP O
ADs. ADs. 1 0 0 0 0 0 0 0 4 0 IN JJ NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NNP NNP O
Trypanosoma Trypanosoma 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP VBD O
ADL ADL 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN TO O
found found 0 0 0 0 0 0 0 0 5 0 NNP VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB RB O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB RB JJ O
enzymaticaly enzymaticaly 0 0 0 0 0 0 0 0 12 0 TO VB RB JJ CC O
dead dead 0 0 0 0 0 0 0 0 4 0 VB RB JJ CC VBZ O
but but 0 0 0 0 0 0 0 0 3 0 RB JJ CC VBZ DT O
plays plays 0 0 0 0 0 0 0 0 5 0 JJ CC VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 CC VBZ DT JJ JJ O
essential essential 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ JJ NN O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 DT JJ JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 JJ JJ NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN DT O
forming forming 0 0 0 0 0 0 0 0 7 0 NN IN NN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 IN NN DT NN NN O
heterodimer heterodimer 0 0 0 0 0 0 0 0 11 0 NN DT NN NN IN O
complex complex 0 0 0 0 0 0 0 0 7 0 DT NN NN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN NNP NNP O
AD. AD. 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP DT JJ O
no no 0 0 0 0 0 0 0 0 2 0 NNP NNP DT JJ CC O
structural structural 0 0 0 0 0 0 0 0 10 0 NNP DT JJ CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 DT JJ CC JJ NN O
functional functional 0 0 0 0 0 0 0 0 10 0 JJ CC JJ NN VBZ O
information information 0 0 0 0 0 0 0 0 11 0 CC JJ NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ JJ IN O
available available 0 0 0 0 0 0 0 0 9 0 NN VBZ JJ IN NNP O
about about 0 0 0 0 0 0 0 0 5 0 VBZ JJ IN NNP IN O
ADL ADL 1 1 0 0 0 0 0 0 3 0 JJ IN NNP IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 IN NNP IN NNP NNP O
Leishmania Leishmania 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
spp. spp. 0 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP IN O
Here, Here, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP IN DT NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 IN DT NN PRP NN O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP NN DT O
report report 0 0 0 0 0 0 0 0 6 0 NN PRP NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP NN DT NN NN O
cloning, cloning, 0 0 0 0 1 0 0 0 8 0 NN DT NN NN NN O
expression, expression, 0 0 0 0 1 0 0 0 11 0 DT NN NN NN JJ O
purification, purification, 0 0 0 0 1 0 0 0 13 0 NN NN NN JJ CC O
structural structural 0 0 0 0 0 0 0 0 10 0 NN NN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN JJ CC JJ NN O
functional functional 0 0 0 0 0 0 0 0 10 0 JJ CC JJ NN IN O
characterization characterization 0 0 0 0 0 0 0 0 16 0 CC JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
Leishmania Leishmania 1 0 0 0 0 0 0 0 10 0 NN IN NNP NN NNP O
donovani donovani 0 0 0 0 0 0 0 0 8 0 IN NNP NN NNP NNP O
(L. (L. 0 1 0 0 0 0 0 0 3 0 NNP NN NNP NNP NNP O
donovani) donovani) 0 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP VBG O
ADL ADL 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP VBG NN O
using using 0 0 0 0 0 0 0 0 5 0 NNP NNP VBG NN JJ O
biophysical, biophysical, 0 0 0 0 1 0 0 0 12 0 NNP VBG NN JJ CC O
biochemical biochemical 0 0 0 0 0 0 0 0 11 0 VBG NN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN JJ CC JJ NNP O
computational computational 0 0 0 0 0 0 0 0 13 0 JJ CC JJ NNP NNP O
techniques. techniques. 0 0 0 0 0 0 0 0 11 0 CC JJ NNP NNP NNS O
Biophysical Biophysical 1 0 0 0 0 0 0 0 11 0 JJ NNP NNP NNS VBP O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP JJ O
show show 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP JJ NNP O
that, that, 0 0 0 0 1 0 0 0 5 0 NNS VBP JJ NNP NN O
L. L. 1 1 0 0 0 0 0 0 2 0 VBP JJ NNP NN NNP O
donovani donovani 0 0 0 0 0 0 0 0 8 0 JJ NNP NN NNP NNS O
ADL ADL 1 1 0 0 0 0 0 0 3 0 NNP NN NNP NNS JJ O
binds binds 0 0 0 0 0 0 0 0 5 0 NN NNP NNS JJ NN O
S-adenosylmethionine S-adenosylmethionine 1 0 1 0 0 0 0 0 20 0 NNP NNS JJ NN CC O
(SAM) (SAM) 0 1 0 0 0 0 0 0 5 0 NNS JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN WDT O
putrescine putrescine 0 0 0 0 0 0 0 0 10 0 NN CC NN WDT VBP O
which which 0 0 0 0 0 0 0 0 5 0 CC NN WDT VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NN WDT VBP JJ NNS O
natural natural 0 0 0 0 0 0 0 0 7 0 WDT VBP JJ NNS IN O
substrates substrates 0 0 0 0 0 0 0 0 10 0 VBP JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NNP O
AD. AD. 1 1 0 0 0 0 0 0 3 0 NNS IN NNP NNP NN O
Computational Computational 1 0 0 0 0 0 0 0 13 0 IN NNP NNP NN CC O
modeling modeling 0 0 0 0 0 0 0 0 8 0 NNP NNP NN CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC VBG NNS O
docking docking 0 0 0 0 0 0 0 0 7 0 NN CC VBG NNS VBD O
studies studies 0 0 0 0 0 0 0 0 7 0 CC VBG NNS VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 VBG NNS VBD IN IN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBD IN IN NN TO O
comparison comparison 0 0 0 0 0 0 0 0 10 0 IN IN NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT NNS IN O
ADs ADs 1 0 0 0 0 0 0 0 3 0 TO DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NNS O
other other 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NNS VBG O
organisms organisms 0 0 0 0 0 0 0 0 9 0 IN JJ NNS VBG NN O
including including 0 0 0 0 0 0 0 0 9 0 JJ NNS VBG NN NNS O
human, human, 0 0 0 0 1 0 0 0 6 0 NNS VBG NN NNS VBD O
residues residues 0 0 0 0 0 0 0 0 8 0 VBG NN NNS VBD IN O
involved involved 0 0 0 0 0 0 0 0 8 0 NN NNS VBD IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBD IN NN VBG O
putrescine putrescine 0 0 0 0 0 0 0 0 10 0 VBD IN NN VBG VBP O
binding binding 0 0 0 0 0 0 0 0 7 0 IN NN VBG VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 NN VBG VBP RB VBN O
partially partially 0 0 0 0 0 0 0 0 9 0 VBG VBP RB VBN IN O
conserved conserved 0 0 0 0 0 0 0 0 9 0 VBP RB VBN IN DT O
while while 0 0 0 0 0 0 0 0 5 0 RB VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NN O
SAM SAM 1 1 0 0 0 0 0 0 3 0 IN DT NNP NN NNS O
binding binding 0 0 0 0 0 0 0 0 7 0 DT NNP NN NNS VBP O
residues residues 0 0 0 0 0 0 0 0 8 0 NNP NN NNS VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 NN NNS VBP RB NNP O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNS VBP RB NNP NNP O
different. different. 0 0 0 0 0 0 0 0 10 0 VBP RB NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 RB NNP NNP NN NN O
silico silico 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NN NN O
protein-protein protein-protein 0 0 1 0 0 0 0 0 15 0 NNP NN NN NN NN O
interaction interaction 0 0 0 0 0 0 0 0 11 0 NN NN NN NN NNS O
study study 0 0 0 0 0 0 0 0 5 0 NN NN NN NNS WDT O
reveals reveals 0 0 0 0 0 0 0 0 7 0 NN NN NNS WDT -NONE- O
that that 0 0 0 0 0 0 0 0 4 0 NN NNS WDT -NONE- VBP O
L. L. 1 1 0 0 0 0 0 0 2 0 NNS WDT -NONE- VBP NNP O
donovani donovani 0 0 0 0 0 0 0 0 8 0 WDT -NONE- VBP NNP MD O
ADL ADL 1 1 0 0 0 0 0 0 3 0 -NONE- VBP NNP MD VB O
can can 0 0 0 0 0 0 0 0 3 0 VBP NNP MD VB IN O
interact interact 0 0 0 0 0 0 0 0 8 0 NNP MD VB IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 MD VB IN NNP NNP O
AD. AD. 1 1 0 0 0 0 0 0 3 0 VB IN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
indicate indicate 0 0 0 0 0 0 0 0 8 0 NNP NNS VBP IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NNP NN O
L. L. 1 1 0 0 0 0 0 0 2 0 VBP IN NNP NN NNP O
donovani donovani 0 0 0 0 0 0 0 0 8 0 IN NNP NN NNP NNS O
ADL ADL 1 1 0 0 0 0 0 0 3 0 NNP NN NNP NNS DT O
posses posses 0 0 0 0 0 0 0 0 6 0 NN NNP NNS DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNS DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 NNS DT NN NN VBG O
substrate substrate 0 0 0 0 0 0 0 0 9 0 DT NN NN VBG NN O
binding binding 0 0 0 0 0 0 0 0 7 0 NN NN VBG NN CC O
property property 0 0 0 0 0 0 0 0 8 0 NN VBG NN CC MD O
and and 0 0 0 0 0 0 0 0 3 0 VBG NN CC MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN CC MD VB DT O
play play 0 0 0 0 0 0 0 0 4 0 CC MD VB DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 MD VB DT JJ NN O
essential essential 0 0 0 0 0 0 0 0 9 0 VB DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
polyamine polyamine 0 0 0 0 0 0 0 0 9 0 NN IN NN NN IN O
biosynthesis biosynthesis 0 0 0 0 0 0 0 0 12 0 IN NN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
different different 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN IN O
mode mode 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
function function 0 0 0 0 0 0 0 0 8 0 NN IN NN IN VBN O
from from 0 0 0 0 0 0 0 0 4 0 IN NN IN VBN NNS O
known known 0 0 0 0 0 0 0 0 5 0 NN IN VBN NNS IN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 IN VBN NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
S-adenosylmethionine S-adenosylmethionine 1 0 1 0 0 0 0 0 20 0 IN DT JJ NN NN O
decarboxylase decarboxylase 0 0 0 0 0 0 0 0 13 0 DT JJ NN NN NNP O
super super 0 0 0 0 0 0 0 0 5 0 JJ NN NN NNP NONE O
family. family. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NONE NONE O
Secondary Secondary 1 0 0 0 0 0 0 0 9 0 NONE NONE NNP NN IN O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NONE NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
electronic electronic 0 0 0 0 0 0 0 0 10 0 NN IN JJ NN NNS O
databases: databases: 0 0 0 0 0 0 0 0 10 0 IN JJ NN NNS CC O
potentials potentials 0 0 0 0 0 0 0 0 10 0 JJ NN NNS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NNP NNP O
limitations. limitations. 0 0 0 0 0 0 0 0 12 0 NNS CC NNP NNP TO O
Reply Reply 1 0 0 0 0 0 0 0 5 0 CC NNP NNP TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNP NNP TO NNP NNP O
Asghari Asghari 1 0 0 0 0 0 0 0 7 0 NNP TO NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 TO NNP NNP NNP NNP O
Mahdavian Mahdavian 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
M M 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NNP NNP O
[letter]. [letter]. 0 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Kostev Kostev 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Rathmann Rathmann 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
W. W. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
IMS IMS 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Health, Health, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Epidemiology, Epidemiology, 1 0 0 0 1 0 0 0 13 0 NNP NNP NNP NNP NNP O
Darmstädter Darmstädter 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP CD O
Landstraße Landstraße 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP CD CD O
108, 108, 0 0 0 0 1 0 0 1 4 0 NNP NNP CD CD NNP O
60598, 60598, 0 0 0 0 1 0 0 1 6 0 NNP CD CD NNP NN O
Frankfurt Frankfurt 1 0 0 0 0 0 0 0 9 0 CD CD NNP NN -NONE- O
am am 0 0 0 0 0 0 0 0 2 0 CD NNP NN -NONE- -NONE- O
Main, Main, 1 0 0 0 1 0 0 0 5 0 NNP NN -NONE- -NONE- NNP O
Germany, Germany, 1 0 0 0 1 0 0 0 8 0 NN -NONE- -NONE- NNP NONE O
kkostev@de.imshealth.com. kkostev@de.imshealth.com. 0 0 0 0 0 0 0 0 25 0 -NONE- -NONE- NNP NONE NONE O
Neoadjuvant Neoadjuvant 1 0 0 0 0 0 0 0 11 0 NONE NONE NNP NNP IN O
Chemotherapy Chemotherapy 1 0 0 0 0 0 0 0 12 0 NONE NNP NNP IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNP IN NNP CC O
Gemcitabine Gemcitabine 1 0 0 0 0 0 0 0 11 0 NNP IN NNP CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC -NONE- IN O
S-1 S-1 1 1 1 0 0 0 0 1 3 0 NNP CC -NONE- IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 CC -NONE- IN NNP CC O
Resectable Resectable 1 0 0 0 0 0 0 0 10 0 -NONE- IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Borderline Borderline 1 0 0 0 0 0 0 0 10 0 NNP CC NNP NNP NNP O
Pancreatic Pancreatic 1 0 0 0 0 0 0 0 10 0 CC NNP NNP NNP NNP O
Ductal Ductal 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Adenocarcinoma: Adenocarcinoma: 1 0 0 0 0 0 0 0 15 0 NNP NNP NNP NNP IN O
Results Results 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNP IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT JJ JJ O
Prospective Prospective 1 0 0 0 0 0 0 0 11 0 IN DT JJ JJ NNP O
Multi-institutional Multi-institutional 1 0 1 0 0 0 0 0 19 0 DT JJ JJ NNP CD O
Phase Phase 1 0 0 0 0 0 0 0 5 0 JJ JJ NNP CD NNP O
2 2 0 0 0 0 0 0 1 1 1 0 JJ NNP CD NNP NNP O
Trial. Trial. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
Motoi Motoi 1 0 0 0 0 0 0 0 5 0 CD NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ishida Ishida 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Fujishima Fujishima 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ottomo Ottomo 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Oikawa Oikawa 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Okada Okada 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Shimamura Shimamura 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Takemura Takemura 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ono Ono 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Akada Akada 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Nakagawa Nakagawa 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Katayose Katayose 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Egawa Egawa 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Unno Unno 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
M. M. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Division Division 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Gastroenterological Gastroenterological 1 0 0 0 0 0 0 0 19 0 NNP IN NNP NNP NNP O
Surgery, Surgery, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Surgery, Surgery, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP NNP O
Graduate Graduate 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Tohoku Tohoku 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Sendai, Sendai, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Japan, Japan, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
fmotoi@surg1.med.tohoku.ac.jp. fmotoi@surg1.med.tohoku.ac.jp. 0 0 0 0 0 0 0 1 30 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NN O
Surgical Surgical 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NN VBZ O
resection resection 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT JJ JJ O
only only 0 0 0 0 0 0 0 0 4 0 VBZ DT JJ JJ NN O
curative curative 0 0 0 0 0 0 0 0 8 0 DT JJ JJ NN IN O
strategy strategy 0 0 0 0 0 0 0 0 8 0 JJ JJ NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN JJ NN O
pancreatic pancreatic 0 0 0 0 0 0 0 0 10 0 NN IN JJ NN NN O
ductal ductal 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN NN O
adenocarcinoma adenocarcinoma 0 0 0 0 0 0 0 0 14 0 JJ NN NN NN CC O
(PDAC), (PDAC), 0 1 0 0 1 0 0 0 7 0 NN NN NN CC NN O
but but 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NNS O
recurrence recurrence 0 0 0 0 0 0 0 0 10 0 NN CC NN NNS VBP O
rates rates 0 0 0 0 0 0 0 0 5 0 CC NN NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NN NNS VBP JJ RB O
high high 0 0 0 0 0 0 0 0 4 0 NNS VBP JJ RB IN O
even even 0 0 0 0 0 0 0 0 4 0 VBP JJ RB IN VBN O
after after 0 0 0 0 0 0 0 0 5 0 JJ RB IN VBN JJ O
purported purported 0 0 0 0 0 0 0 0 9 0 RB IN VBN JJ NNP O
curative curative 0 0 0 0 0 0 0 0 8 0 IN VBN JJ NNP NNP O
resection. resection. 0 0 0 0 0 0 0 0 10 0 VBN JJ NNP NNP NN O
First-line First-line 1 0 1 0 0 0 0 0 10 0 JJ NNP NNP NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NNP NN IN NN CC O
gemcitabine gemcitabine 0 0 0 0 0 0 0 0 11 0 NN IN NN CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC -NONE- JJ O
S-1 S-1 1 1 1 0 0 0 0 1 3 0 NN CC -NONE- JJ VBZ O
(GS) (GS) 0 1 0 0 0 0 0 0 4 0 CC -NONE- JJ VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 -NONE- JJ VBZ VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 JJ VBZ VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN JJ NN O
promising promising 0 0 0 0 0 0 0 0 9 0 VBN IN JJ NN NN O
antitumor antitumor 0 0 0 0 0 0 0 0 9 0 IN JJ NN NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 JJ NN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 IN DT JJ NN NNP O
response response 0 0 0 0 0 0 0 0 8 0 DT JJ NN NNP NNP O
rate. rate. 0 0 0 0 0 0 0 0 5 0 JJ NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
aim aim 0 0 0 0 0 0 0 0 3 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 IN DT NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO NN DT O
assess assess 0 0 0 0 0 0 0 0 6 0 VBD TO NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO NN DT NN CC O
feasibility feasibility 0 0 0 0 0 0 0 0 11 0 NN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
efficacy efficacy 0 0 0 0 0 0 0 0 8 0 NN CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP IN O
GS GS 1 1 0 0 0 0 0 0 2 0 NN IN NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN NNP O
neoadjuvant neoadjuvant 0 0 0 0 0 0 0 0 11 0 IN DT NN NNP NNP O
setting. setting. 0 0 0 0 0 0 0 0 8 0 DT NN NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 NN NNP NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT JJ NN O
multi-institutional multi-institutional 0 0 1 0 0 0 0 0 19 0 NNP DT JJ NN NN O
single-arm single-arm 0 0 1 0 0 0 0 0 10 phase DT JJ NN NN CD O
phase phase 0 0 0 0 0 0 0 0 5 0 JJ NN NN CD NN O
2 2 0 0 0 0 0 0 1 1 1 0 NN NN CD NN NN O
study, study, 0 0 0 0 1 0 0 0 6 0 NN CD NN NN NN O
neoadjuvant neoadjuvant 0 0 0 0 0 0 0 0 11 0 CD NN NN NN NN O
chemotherapy chemotherapy 0 0 0 0 0 0 0 0 12 0 NN NN NN NN IN O
(NAC) (NAC) 0 1 0 0 0 0 0 0 5 0 NN NN NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN NN CC O
gemcitabine gemcitabine 0 0 0 0 0 0 0 0 11 0 NN IN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NNP VBD O
S-1, S-1, 1 1 1 0 1 0 0 1 4 0 NN CC NNP VBD DT O
repeated repeated 0 0 0 0 0 0 0 0 8 0 CC NNP VBD DT CD O
every every 0 0 0 0 0 0 0 0 5 0 NNP VBD DT CD NN O
21 21 0 0 0 0 0 0 1 1 2 0 VBD DT CD NN VBD O
days, days, 0 0 0 0 1 0 0 0 5 0 DT CD NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 CD NN VBD VBN IN O
administered administered 0 0 0 0 0 0 0 0 12 0 NN VBD VBN IN CD O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 VBN IN CD NNS -NONE- O
cycles cycles 0 0 0 0 0 0 0 0 6 0 IN CD NNS -NONE- TO O
(NAC-GS) (NAC-GS) 0 1 1 0 0 0 0 0 8 0 CD NNS -NONE- TO NNS O
to to 0 0 0 0 0 0 0 0 2 0 NNS -NONE- TO NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 -NONE- TO NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 TO NNS IN JJ CC O
resectable resectable 0 0 0 0 0 0 0 0 10 0 NNS IN JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC NN NNP O
borderline borderline 0 0 0 0 0 0 0 0 10 0 JJ CC NN NNP NNP O
PDAC. PDAC. 1 1 0 0 0 0 0 0 5 0 CC NN NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP JJ NN O
primary primary 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NN NN O
end end 0 0 0 0 0 0 0 0 3 0 NNP JJ NN NN VBD O
point point 0 0 0 0 0 0 0 0 5 0 JJ NN NN VBD DT O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN VBD DT JJ NN O
2-year 2-year 0 0 1 0 0 0 0 1 6 0 VBD DT JJ NN NNP O
survival survival 0 0 0 0 0 0 0 0 8 0 DT JJ NN NNP NNP O
rate. rate. 0 0 0 0 0 0 0 0 5 0 JJ NN NNP NNP NN O
Secondary Secondary 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NN NNS O
end end 0 0 0 0 0 0 0 0 3 0 NNP NNP NN NNS VBD O
points points 0 0 0 0 0 0 0 0 6 0 NNP NN NNS VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD JJ NN O
feasibility, feasibility, 0 0 0 0 1 0 0 0 12 0 NNS VBD JJ NN NN O
resection resection 0 0 0 0 0 0 0 0 9 0 VBD JJ NN NN JJ O
rate, rate, 0 0 0 0 1 0 0 0 5 0 JJ NN NN JJ NN O
pathological pathological 0 0 0 0 0 0 0 0 12 0 NN NN JJ NN JJ O
effect, effect, 0 0 0 0 1 0 0 0 7 0 NN JJ NN JJ NN O
recurrence-free recurrence-free 0 0 1 0 0 0 0 0 15 0 JJ NN JJ NN CC O
survival, survival, 0 0 0 0 1 0 0 0 9 0 NN JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NN CC NN NN NNP O
marker marker 0 0 0 0 0 0 0 0 6 0 CC NN NN NNP NNP O
status. status. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 NN NNP NNP NNP CD O
Of Of 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNS O
36 36 0 0 0 0 0 0 1 1 2 0 NNP NNP CD NNS -NONE- O
patients patients 0 0 0 0 0 0 0 0 8 0 NNP CD NNS -NONE- CD O
enrolled, enrolled, 0 0 0 0 1 0 0 0 9 0 CD NNS -NONE- CD VBD O
35 35 0 0 0 0 0 0 1 1 2 0 NNS -NONE- CD VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 -NONE- CD VBD JJ IN O
eligible eligible 0 0 0 0 0 0 0 0 8 0 CD VBD JJ IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBD JJ IN DT JJ O
this this 0 0 0 0 0 0 0 0 4 0 JJ IN DT JJ NN O
clinical clinical 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN VBD O
trial trial 0 0 0 0 0 0 0 0 5 0 DT JJ NN VBD IN O
conducted conducted 0 0 0 0 0 0 0 0 9 0 JJ NN VBD IN CD O
between between 0 0 0 0 0 0 0 0 7 0 NN VBD IN CD CC O
2008 2008 0 0 0 0 0 0 1 1 4 0 VBD IN CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 IN CD CC CD DT O
2010. 2010. 0 0 0 0 0 0 0 1 5 0 CD CC CD DT RBS O
The The 1 0 0 0 0 0 0 0 3 0 CC CD DT RBS JJ O
most most 0 0 0 0 0 0 0 0 4 0 CD DT RBS JJ NN O
common common 0 0 0 0 0 0 0 0 6 0 DT RBS JJ NN VBD O
toxicity toxicity 0 0 0 0 0 0 0 0 8 0 RBS JJ NN VBD NNS O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD NNS IN O
neutropenia neutropenia 0 0 0 0 0 0 0 0 11 0 NN VBD NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBD NNS IN NN TO O
response response 0 0 0 0 0 0 0 0 8 0 NNS IN NN TO CD O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO CD NN O
90 90 0 0 0 0 0 0 1 1 2 0 NN TO CD NN IN O
% % 0 0 0 0 0 0 0 0 1 0 TO CD NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
relative relative 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN NNP O
dose dose 0 0 0 0 0 0 0 0 4 0 DT JJ NN NNP NNP O
intensity. intensity. 0 0 0 0 0 0 0 0 10 0 JJ NN NNP NNP TO O
Responses Responses 1 0 0 0 0 0 0 0 9 0 NN NNP NNP TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNP NNP TO NNP VBD O
NAC NAC 1 1 0 0 0 0 0 0 3 0 NNP TO NNP VBD JJ O
included included 0 0 0 0 0 0 0 0 8 0 TO NNP VBD JJ NN O
radiological radiological 0 0 0 0 0 0 0 0 12 0 NNP VBD JJ NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 VBD JJ NN NN -NONE- O
shrinkage shrinkage 0 0 0 0 0 0 0 0 9 0 JJ NN NN -NONE- . O
(69 (69 0 0 0 0 0 0 0 1 3 0 NN NN -NONE- . CC O
%) %) 0 0 0 0 0 0 0 0 2 0 NN -NONE- . CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- . CC NNS IN O
decreases decreases 0 0 0 0 0 0 0 0 9 0 . CC NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 CC NNS IN JJ NNS O
CA19-9 CA19-9 1 1 1 0 0 0 0 1 6 0 NNS IN JJ NNS -NONE- O
levels levels 0 0 0 0 0 0 0 0 6 0 IN JJ NNS -NONE- . O
(89 (89 0 0 0 0 0 0 0 1 3 0 JJ NNS -NONE- . NNP O
%). %). 0 0 0 0 0 0 0 0 3 0 NNS -NONE- . NNP NN O
R0 R0 1 1 0 0 0 0 0 1 2 0 -NONE- . NNP NN VBD O
resection resection 0 0 0 0 0 0 0 0 9 0 . NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
performed performed 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN CD O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN CD NN O
87 87 0 0 0 0 0 0 1 1 2 0 VBN IN CD NN IN O
% % 0 0 0 0 0 0 0 0 1 0 IN CD NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN NNP CC O
resection, resection, 0 0 0 0 1 0 0 0 10 0 NN IN NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP CC DT NN NN O
morbidity morbidity 0 0 0 0 0 0 0 0 9 0 CC DT NN NN -NONE- O
rate rate 0 0 0 0 0 0 0 0 4 0 DT NN NN -NONE- . O
(40 (40 0 0 0 0 0 0 0 1 3 0 NN NN -NONE- . VBD O
%) %) 0 0 0 0 0 0 0 0 2 0 NN -NONE- . VBD NNP O
was was 0 0 0 0 0 0 0 0 3 0 -NONE- . VBD NNP NNP O
acceptable. acceptable. 0 0 0 0 0 0 0 0 11 0 . VBD NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 VBD NNP NNP JJ NN O
2-year 2-year 0 0 1 0 0 0 0 1 6 0 NNP NNP JJ NN NN O
survival survival 0 0 0 0 0 0 0 0 8 0 NNP JJ NN NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 JJ NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
total total 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN VBD O
cohort cohort 0 0 0 0 0 0 0 0 6 0 DT JJ NN VBD CD O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD CD NNP O
45.7 45.7 0 0 0 0 0 0 0 1 4 0 NN VBD CD NNP NNP O
%. %. 0 0 0 0 0 0 0 0 2 0 VBD CD NNP NNP WP O
Patients Patients 1 0 0 0 0 0 0 0 8 0 CD NNP NNP WP NN O
who who 0 0 0 0 0 0 0 0 3 0 NNP NNP WP NN NN O
underwent underwent 0 0 0 0 0 0 0 0 9 0 NNP WP NN NN IN O
resection resection 0 0 0 0 0 0 0 0 9 0 WP NN NN IN NNS O
without without 0 0 0 0 0 0 0 0 7 0 NN NN IN NNS IN O
metastases metastases 0 0 0 0 0 0 0 0 10 0 NN IN NNS IN NNS O
after after 0 0 0 0 0 0 0 0 5 0 IN NNS IN NNS -NONE- O
NAC-GS NAC-GS 1 1 1 0 0 0 0 0 6 0 NNS IN NNS -NONE- : O
(n (n 0 0 0 0 0 0 0 0 2 0 IN NNS -NONE- : CD O
= = 0 0 0 0 0 0 0 0 1 0 NNS -NONE- : CD VBD O
27) 27) 0 0 0 0 0 0 0 1 3 0 -NONE- : CD VBD DT O
had had 0 0 0 0 0 0 0 0 3 0 : CD VBD DT VBN O
an an 0 0 0 0 0 0 0 0 2 0 CD VBD DT VBN JJ O
increased increased 0 0 0 0 0 0 0 0 9 0 VBD DT VBN JJ JJ O
median median 0 0 0 0 0 0 0 0 6 0 DT VBN JJ JJ NN O
overall overall 0 0 0 0 0 0 0 0 7 0 VBN JJ JJ NN -NONE- O
survival survival 0 0 0 0 0 0 0 0 8 0 JJ JJ NN -NONE- -NONE- O
(34.7 (34.7 0 0 0 0 0 0 0 1 5 0 JJ NN -NONE- -NONE- VBN O
months) months) 0 0 0 0 0 0 0 0 7 0 NN -NONE- -NONE- VBN IN O
compared compared 0 0 0 0 0 0 0 0 8 0 -NONE- -NONE- VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 -NONE- VBN IN DT WP O
those those 0 0 0 0 0 0 0 0 5 0 VBN IN DT WP VBD O
who who 0 0 0 0 0 0 0 0 3 0 IN DT WP VBD RB O
did did 0 0 0 0 0 0 0 0 3 0 DT WP VBD RB VB O
not not 0 0 0 0 0 0 0 0 3 0 WP VBD RB VB NN O
undergo undergo 0 0 0 0 0 0 0 0 7 0 VBD RB VB NN -NONE- O
resection resection 0 0 0 0 0 0 0 0 9 0 RB VB NN -NONE- . O
(P (P 0 1 0 0 0 0 0 0 2 0 VB NN -NONE- . CD O
= = 0 0 0 0 0 0 0 0 1 0 NN -NONE- . CD NN O
0.0017). 0.0017). 0 0 0 0 0 0 0 1 8 0 -NONE- . CD NN NNS O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 . CD NN NNS VBD O
NAC-GS NAC-GS 1 1 1 0 0 0 0 0 6 0 CD NN NNS VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NN NNS VBD RB VBN O
well well 0 0 0 0 0 0 0 0 4 0 NNS VBD RB VBN CC O
tolerated tolerated 0 0 0 0 0 0 0 0 9 0 VBD RB VBN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 RB VBN CC JJ WRB O
safe safe 0 0 0 0 0 0 0 0 4 0 VBN CC JJ WRB VBN O
when when 0 0 0 0 0 0 0 0 4 0 CC JJ WRB VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 JJ WRB VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 WRB VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NNP O
multi-institutional multi-institutional 0 0 1 0 0 0 0 0 19 0 IN DT JJ NNP NNP O
setting. setting. 0 0 0 0 0 0 0 0 8 0 DT JJ NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NNP NN O
R0 R0 1 1 0 0 0 0 0 1 2 0 NNP NNP NNP NN NN O
resection resection 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NN CC O
rate rate 0 0 0 0 0 0 0 0 4 0 NNP NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT JJ NN O
2-year 2-year 0 0 1 0 0 0 0 1 6 0 CC DT JJ NN NN O
survival survival 0 0 0 0 0 0 0 0 8 0 DT JJ NN NN NN O
rate rate 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN VBP O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NN NN NN VBP VBG O
are are 0 0 0 0 0 0 0 0 3 0 NN NN VBP VBG IN O
encouraging encouraging 0 0 0 0 0 0 0 0 11 0 NN VBP VBG IN NNS O
for for 0 0 0 0 0 0 0 0 3 0 VBP VBG IN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 VBG IN NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN JJ CC O
resectable resectable 0 0 0 0 0 0 0 0 10 0 NNS IN JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC NN NNP O
borderline borderline 0 0 0 0 0 0 0 0 10 0 JJ CC NN NNP NONE O
PDAC. PDAC. 1 1 0 0 0 0 0 0 5 0 CC NN NNP NONE NONE O
Evaluation Evaluation 1 0 0 0 0 0 0 0 10 0 NONE NONE NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
wound wound 0 0 0 0 0 0 0 0 5 0 IN DT NN NN NN O
healing healing 0 0 0 0 0 0 0 0 7 0 DT NN NN NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NN NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
Shorea Shorea 1 0 0 0 0 0 0 0 6 0 NN IN NNP NNP DT O
robusta, robusta, 0 0 0 0 1 0 0 0 8 0 IN NNP NNP DT NNP O
an an 0 0 0 0 0 0 0 0 2 0 NNP NNP DT NNP NNP O
Indian Indian 1 0 0 0 0 0 0 0 6 0 NNP DT NNP NNP CC O
ethnomedicine, ethnomedicine, 0 0 0 0 1 0 0 0 14 0 DT NNP NNP CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC PRP$ VBN O
its its 0 0 0 0 0 0 0 0 3 0 NNP CC PRP$ VBN -NONE- O
isolated isolated 0 0 0 0 0 0 0 0 8 0 CC PRP$ VBN -NONE- IN O
constituent(s) constituent(s) 0 0 0 0 0 0 0 0 14 0 PRP$ VBN -NONE- IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBN -NONE- IN JJ NNP O
topical topical 0 0 0 0 0 0 0 0 7 0 -NONE- IN JJ NNP NNP O
formulation. formulation. 0 0 0 0 0 0 0 0 12 0 IN JJ NNP NNP NNP O
Mukherjee Mukherjee 1 0 0 0 0 0 0 0 9 0 JJ NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ojha Ojha 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Bharitkar Bharitkar 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
YP, YP, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Ghosh Ghosh 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Mondal Mondal 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kaity Kaity 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Dutta Dutta 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Samanta Samanta 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Chatterjee Chatterjee 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
TK, TK, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Chakrabarti Chakrabarti 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Mondal Mondal 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
NB, NB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Chattopadhyay Chattopadhyay 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
D. D. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
ICMR ICMR 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Virus Virus 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Unit, Unit, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP CC O
ID ID 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CC NNP O
& & 0 0 0 0 0 0 0 0 1 0 NNP NNP CC NNP NNP O
BG BG 1 1 0 0 0 0 0 0 2 0 NNP CC NNP NNP NNP O
Hospital, Hospital, 1 0 0 0 1 0 0 0 9 0 CC NNP NNP NNP NNP O
GB-4, GB-4, 1 1 1 0 1 0 0 1 5 0 NNP NNP NNP NNP NNP O
First First 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP CD O
Floor, Floor, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP CD NNP O
57 57 0 0 0 0 0 0 1 1 2 0 NNP NNP CD NNP NNP O
Dr Dr 1 0 0 0 0 0 0 0 2 0 NNP CD NNP NNP NNP O
Suresh Suresh 1 0 0 0 0 0 0 0 6 0 CD NNP NNP NNP NNP O
C C 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NNP NNP O
Banerjee Banerjee 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Road, Road, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
Beliaghata, Beliaghata, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Kolkata-700010, Kolkata-700010, 1 0 1 0 1 0 0 1 15 0 NNP NNP NNP NNP NNP O
West West 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Bengal, Bengal, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
India. India. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
ETHNOPHARMACOLOGICAL ETHNOPHARMACOLOGICAL 1 1 0 0 0 0 0 0 20 0 NNP NNP NNP NNP NNP O
RELEVANCE: RELEVANCE: 1 1 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNS O
Different Different 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNS IN O
parts parts 0 0 0 0 0 0 0 0 5 0 NNP NNP NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NNP JJ O
Indian Indian 1 0 0 0 0 0 0 0 6 0 NNS IN NNP JJ NN O
ethnomedicinal ethnomedicinal 0 0 0 0 0 0 0 0 14 0 IN NNP JJ NN NNP O
plant plant 0 0 0 0 0 0 0 0 5 0 NNP JJ NN NNP NN O
Shorea Shorea 1 0 0 0 0 0 0 0 6 0 JJ NN NNP NN VBZ O
robusta robusta 0 0 0 0 0 0 0 0 7 0 NN NNP NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ RB VBN O
traditionally traditionally 0 0 0 0 0 0 0 0 13 0 NN VBZ RB VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 VBZ RB VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 RB VBN IN JJ NNS O
several several 0 0 0 0 0 0 0 0 7 0 VBN IN JJ NNS VBG O
ailments ailments 0 0 0 0 0 0 0 0 8 0 IN JJ NNS VBG NNS O
including including 0 0 0 0 0 0 0 0 9 0 JJ NNS VBG NNS CC O
wounds wounds 0 0 0 0 0 0 0 0 6 0 NNS VBG NNS CC VBP O
and and 0 0 0 0 0 0 0 0 3 0 VBG NNS CC VBP IN O
burn burn 0 0 0 0 0 0 0 0 4 0 NNS CC VBP IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 CC VBP IN JJ JJ O
different different 0 0 0 0 0 0 0 0 9 0 VBP IN JJ JJ NN O
tribal tribal 0 0 0 0 0 0 0 0 6 0 IN JJ JJ NN IN O
groups, groups, 0 0 0 0 1 0 0 0 7 0 JJ JJ NN IN NNP O
since since 0 0 0 0 0 0 0 0 5 0 JJ NN IN NNP NNP O
ages. ages. 0 0 0 0 0 0 0 0 5 0 NN IN NNP NNP PRP O
Here Here 1 0 0 0 0 0 0 0 4 0 IN NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP -NONE- O
have have 0 0 0 0 0 0 0 0 4 0 NNP PRP VBP -NONE- IN O
validated, validated, 0 0 0 0 1 0 0 0 10 0 PRP VBP -NONE- IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBP -NONE- IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- IN DT JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN DT O
time, time, 0 0 0 0 1 0 0 0 5 0 DT JJ NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NN CC O
effectiveness effectiveness 0 0 0 0 0 0 0 0 13 0 NN DT NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT JJ NN O
possible possible 0 0 0 0 0 0 0 0 8 0 CC DT JJ NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
action action 0 0 0 0 0 0 0 0 6 0 NN IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NN O
young young 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NNS O
leaf leaf 0 0 0 0 0 0 0 0 4 0 IN JJ NN NNS IN O
extracts extracts 0 0 0 0 0 0 0 0 8 0 JJ NN NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP NNP O
Shorea Shorea 1 0 0 0 0 0 0 0 6 0 NNS IN NNP NNP VBD O
robusta, robusta, 0 0 0 0 1 0 0 0 8 0 IN NNP NNP VBD IN O
used used 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD IN CD O
by by 0 0 0 0 0 0 0 0 2 0 NNP VBD IN CD JJ O
two two 0 0 0 0 0 0 0 0 3 0 VBD IN CD JJ NNS O
distinct distinct 0 0 0 0 0 0 0 0 8 0 IN CD JJ NNS IN O
tribes tribes 0 0 0 0 0 0 0 0 6 0 CD JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ CC O
India, India, 1 0 0 0 1 0 0 0 6 0 NNS IN JJ CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC PRP$ VBN O
its its 0 0 0 0 0 0 0 0 3 0 JJ CC PRP$ VBN NNS O
isolated isolated 0 0 0 0 0 0 0 0 8 0 CC PRP$ VBN NNS IN O
compounds compounds 0 0 0 0 0 0 0 0 9 0 PRP$ VBN NNS IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VBN NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ NN O
topical topical 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN IN O
formulation formulation 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN CD NN O
three three 0 0 0 0 0 0 0 0 5 0 NN IN CD NN NNS O
wound wound 0 0 0 0 0 0 0 0 5 0 IN CD NN NNS IN O
models models 0 0 0 0 0 0 0 0 6 0 CD NN NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP NNPS O
rats. rats. 0 0 0 0 0 0 0 0 5 0 NNS IN NNP NNPS NNP O
MATERIALS MATERIALS 1 1 0 0 0 0 0 0 9 0 IN NNP NNPS NNP NNP O
AND AND 1 1 0 0 0 0 0 0 3 0 NNP NNPS NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 NNPS NNP NNP NNP NN O
Bioactivity-guided Bioactivity-guided 1 0 1 0 0 0 0 0 18 0 NNP NNP NNP NN IN O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
active active 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN VBD O
extract extract 0 0 0 0 0 0 0 0 7 0 DT JJ NN VBD IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 JJ NN VBD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN IN O
isolation isolation 0 0 0 0 0 0 0 0 9 0 IN DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD VBN O
two two 0 0 0 0 0 0 0 0 3 0 NN IN CD VBN NNP O
known known 0 0 0 0 0 0 0 0 5 0 IN CD VBN NNP NNP O
compounds. compounds. 0 0 0 0 0 0 0 0 10 0 CD VBN NNP NNP VBD O
The The 1 0 0 0 0 0 0 0 3 0 VBN NNP NNP VBD NN O
prepared prepared 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD NN VBG O
ointment ointment 0 0 0 0 0 0 0 0 8 0 NNP VBD NN VBG NNS O
containing containing 0 0 0 0 0 0 0 0 10 0 VBD NN VBG NNS -NONE- O
extracts extracts 0 0 0 0 0 0 0 0 8 0 NN VBG NNS -NONE- CC O
(2.5 (2.5 0 0 0 0 0 0 0 1 4 0 VBG NNS -NONE- CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC CD NN O
5%, 5%, 0 0 0 0 1 0 0 1 3 0 -NONE- CC CD NN NNS O
w/w), w/w), 0 0 0 1 1 0 0 0 5 0 CC CD NN NNS -NONE- O
fractions fractions 0 0 0 0 0 0 0 0 9 0 CD NN NNS -NONE- -NONE- O
(5% (5% 0 0 0 0 0 0 0 1 3 0 NN NNS -NONE- -NONE- CC O
w/w) w/w) 0 0 0 1 0 0 0 0 4 0 NNS -NONE- -NONE- CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- CC VBD NNS O
isolated isolated 0 0 0 0 0 0 0 0 8 0 -NONE- CC VBD NNS -NONE- O
compounds compounds 0 0 0 0 0 0 0 0 9 0 CC VBD NNS -NONE- -NONE- O
(0.25% (0.25% 0 0 0 0 0 0 0 1 6 0 VBD NNS -NONE- -NONE- VBD O
w/w) w/w) 0 0 0 1 0 0 0 0 4 0 NNS -NONE- -NONE- VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 -NONE- -NONE- VBD VBN IN O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 -NONE- VBD VBN IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NN O
excision, excision, 0 0 0 0 1 0 0 0 9 0 VBN IN NNP NN CC O
incision incision 0 0 0 0 0 0 0 0 8 0 IN NNP NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC JJ NN O
dead dead 0 0 0 0 0 0 0 0 4 0 NN CC JJ NN NN O
space space 0 0 0 0 0 0 0 0 5 0 CC JJ NN NN NNS O
wound wound 0 0 0 0 0 0 0 0 5 0 JJ NN NN NNS IN O
models models 0 0 0 0 0 0 0 0 6 0 NN NN NNS IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNS IN O
rats rats 0 0 0 0 0 0 0 0 4 0 NNS IN NNS IN DT O
by by 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
wound wound 0 0 0 0 0 0 0 0 5 0 NN IN NN NN NN O
closure, closure, 0 0 0 0 1 0 0 0 8 0 IN NN NN NN IN O
period period 0 0 0 0 0 0 0 0 6 0 NN NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP IN O
epithelialisation, epithelialisation, 0 0 0 0 1 0 0 0 18 0 NN IN NNP IN NNP O
tensile tensile 0 0 0 0 0 0 0 0 7 0 IN NNP IN NNP NN O
strength, strength, 0 0 0 0 1 0 0 0 9 0 NNP IN NNP NN NN O
granulation granulation 0 0 0 0 0 0 0 0 11 0 IN NNP NN NN NN O
tissue tissue 0 0 0 0 0 0 0 0 6 0 NNP NN NN NN NN O
weight, weight, 0 0 0 0 1 0 0 0 7 0 NN NN NN NN NN O
hydroxyproline hydroxyproline 0 0 0 0 0 0 0 0 14 0 NN NN NN NN CC O
content content 0 0 0 0 0 0 0 0 7 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
histopathology. histopathology. 0 0 0 0 0 0 0 0 15 0 NN CC NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 CC NNP NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS VBD O
animals animals 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD IN O
treated treated 0 0 0 0 0 0 0 0 7 0 NNP NNS VBD IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBD IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NNS CC O
extracts extracts 0 0 0 0 0 0 0 0 8 0 IN DT NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 DT NNS CC NNS -NONE- O
fractions fractions 0 0 0 0 0 0 0 0 9 0 NNS CC NNS -NONE- VBD O
(5%) (5%) 0 0 0 0 0 0 0 1 4 0 CC NNS -NONE- VBD JJ O
showed showed 0 0 0 0 0 0 0 0 6 0 NNS -NONE- VBD JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 -NONE- VBD JJ NN IN O
reduction reduction 0 0 0 0 0 0 0 0 9 0 VBD JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
wound wound 0 0 0 0 0 0 0 0 5 0 NN IN NN NN CD O
area area 0 0 0 0 0 0 0 0 4 0 IN NN NN CD CC O
96.55 96.55 0 0 0 0 0 0 0 1 5 0 NN NN CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NN CD CC CD IN O
96.41% 96.41% 0 0 0 0 0 0 0 1 6 0 CD CC CD IN JJR O
with with 0 0 0 0 0 0 0 0 4 0 CC CD IN JJR NN O
faster faster 0 0 0 0 0 0 0 0 6 0 CD IN JJR NN -NONE- O
epithelialisation epithelialisation 0 0 0 0 0 0 0 0 17 0 IN JJR NN -NONE- CC O
(17.50 (17.50 0 0 0 0 0 0 0 1 6 0 JJR NN -NONE- CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC CD IN O
17.86), 17.86), 0 0 0 0 1 0 0 1 7 0 -NONE- CC CD IN DT O
while while 0 0 0 0 0 0 0 0 5 0 CC CD IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT VBN NNS O
isolated isolated 0 0 0 0 0 0 0 0 8 0 IN DT VBN NNS IN O
compounds compounds 0 0 0 0 0 0 0 0 9 0 DT VBN NNS IN CC O
bergenin bergenin 0 0 0 0 0 0 0 0 8 0 VBN NNS IN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNS IN CC JJ NN O
ursolic ursolic 0 0 0 0 0 0 0 0 7 0 IN CC JJ NN NN O
acid acid 0 0 0 0 0 0 0 0 4 0 CC JJ NN NN DT O
heal heal 0 0 0 0 0 0 0 0 4 0 JJ NN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NN NN O
wound wound 0 0 0 0 0 0 0 0 5 0 NN DT NN NN CC O
faster, faster, 0 0 0 0 1 0 0 0 7 0 DT NN NN CC JJ O
but but 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
complete complete 0 0 0 0 0 0 0 0 8 0 NN CC JJ NN IN O
epithelialisation epithelialisation 0 0 0 0 0 0 0 0 17 0 CC JJ NN IN CD O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN CD NN O
100% 100% 0 0 0 0 0 0 0 1 4 0 NN IN CD NN NN O
wound wound 0 0 0 0 0 0 0 0 5 0 IN CD NN NN VBD O
contraction contraction 0 0 0 0 0 0 0 0 11 0 CD NN NN VBD JJ O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD JJ IN O
evident evident 0 0 0 0 0 0 0 0 7 0 NN VBD JJ IN CD O
with with 0 0 0 0 0 0 0 0 4 0 VBD JJ IN CD JJ O
5% 5% 0 0 0 0 0 0 0 1 2 0 JJ IN CD JJ NN O
povidone-iodine povidone-iodine 0 0 1 0 0 0 0 0 15 0 IN CD JJ NN IN O
group group 0 0 0 0 0 0 0 0 5 0 CD JJ NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ JJ O
18th 18th 0 0 0 0 0 0 0 1 4 0 NN IN JJ JJ NNP O
post-wounding post-wounding 0 0 1 0 0 0 0 0 13 0 IN JJ JJ NNP NNP O
day. day. 0 0 0 0 0 0 0 0 4 0 JJ JJ NNP NNP DT O
Moreover, Moreover, 1 0 0 0 1 0 0 0 9 0 JJ NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
tensile tensile 0 0 0 0 0 0 0 0 7 0 NNP DT NN NN IN O
strength strength 0 0 0 0 0 0 0 0 8 0 DT NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
incision incision 0 0 0 0 0 0 0 0 8 0 NN IN NN NN NN O
wound, wound, 0 0 0 0 1 0 0 0 6 0 IN NN NN NN NN O
granuloma granuloma 0 0 0 0 0 0 0 0 9 0 NN NN NN NN NN O
tissue tissue 0 0 0 0 0 0 0 0 6 0 NN NN NN NN CC O
weight, weight, 0 0 0 0 1 0 0 0 7 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
hydroxyproline hydroxyproline 0 0 0 0 0 0 0 0 14 0 NN CC NN NN VBD O
content content 0 0 0 0 0 0 0 0 7 0 CC NN NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NN VBD RB VBN IN O
increased increased 0 0 0 0 0 0 0 0 9 0 VBD RB VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN DT DT O
both both 0 0 0 0 0 0 0 0 4 0 VBN IN DT DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN DT DT NN CC O
extract extract 0 0 0 0 0 0 0 0 7 0 DT DT NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NNP VBD O
compound(s) compound(s) 0 0 0 0 0 0 0 0 11 0 NN CC NNP VBD NNP O
treated treated 0 0 0 0 0 0 0 0 7 0 CC NNP VBD NNP NNP O
animals. animals. 0 0 0 0 0 0 0 0 8 0 NNP VBD NNP NNP DT O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 VBD NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
tissue tissue 0 0 0 0 0 0 0 0 6 0 NNP DT NN NN IN O
histology histology 0 0 0 0 0 0 0 0 9 0 DT NN NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNS VBN O
animals animals 0 0 0 0 0 0 0 0 7 0 NN IN NNS VBN IN O
treated treated 0 0 0 0 0 0 0 0 7 0 IN NNS VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBN IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT VBN -NONE- O
isolated isolated 0 0 0 0 0 0 0 0 8 0 IN DT VBN -NONE- VBD O
compound(s) compound(s) 0 0 0 0 0 0 0 0 11 0 DT VBN -NONE- VBD JJ O
showed showed 0 0 0 0 0 0 0 0 6 0 VBN -NONE- VBD JJ NN O
complete complete 0 0 0 0 0 0 0 0 8 0 -NONE- VBD JJ NN IN O
epithelialisation epithelialisation 0 0 0 0 0 0 0 0 17 0 VBD JJ NN IN VBN O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN VBN -NONE- O
increased increased 0 0 0 0 0 0 0 0 9 0 NN IN VBN -NONE- JJ O
collagenation, collagenation, 0 0 0 0 1 0 0 0 14 0 IN VBN -NONE- JJ TO O
similar similar 0 0 0 0 0 0 0 0 7 0 VBN -NONE- JJ TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 -NONE- JJ TO JJ NNP O
povidone-iodine povidone-iodine 0 0 1 0 0 0 0 0 15 0 JJ TO JJ NNP NNP O
group. group. 0 0 0 0 0 0 0 0 6 0 TO JJ NNP NNP NNP O
CONCLUSION: CONCLUSION: 1 1 0 0 0 0 0 0 11 0 JJ NNP NNP NNP PRP$ O
Thus, Thus, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP PRP$ NNS O
our our 0 0 0 0 0 0 0 0 3 0 NNP NNP PRP$ NNS VBD O
results results 0 0 0 0 0 0 0 0 7 0 NNP PRP$ NNS VBD DT O
validated validated 0 0 0 0 0 0 0 0 9 0 PRP$ NNS VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBD DT JJ NN O
traditional traditional 0 0 0 0 0 0 0 0 11 0 VBD DT JJ NN IN O
use use 0 0 0 0 0 0 0 0 3 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
Shorea Shorea 1 0 0 0 0 0 0 0 6 0 NN IN NNP NN NN O
robusta robusta 0 0 0 0 0 0 0 0 7 0 IN NNP NN NN VBZ O
young young 0 0 0 0 0 0 0 0 5 0 NNP NN NN VBZ IN O
leaves leaves 0 0 0 0 0 0 0 0 6 0 NN NN VBZ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN VBZ IN NN NNP O
wound wound 0 0 0 0 0 0 0 0 5 0 VBZ IN NN NNP NNP O
management. management. 0 0 0 0 0 0 0 0 11 0 IN NN NNP NNP NNP O
Copyright Copyright 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP CD O
© © 0 0 0 0 0 0 0 0 1 0 NNP NNP NNP CD NNP O
2013 2013 0 0 0 0 0 0 1 1 4 0 NNP NNP CD NNP NNP O
Elsevier Elsevier 1 0 0 0 0 0 0 0 8 0 NNP CD NNP NNP NNP O
Ireland Ireland 1 0 0 0 0 0 0 0 7 0 CD NNP NNP NNP NNP O
Ltd. Ltd. 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNS O
All All 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS NNP O
rights rights 0 0 0 0 0 0 0 0 6 0 NNP NNP NNS NNP NNP O
reserved. reserved. 0 0 0 0 0 0 0 0 9 0 NNP NNS NNP NNP NNP O
KEYWORDS: KEYWORDS: 1 1 0 0 0 0 0 0 9 0 NNS NNP NNP NNP CD O
(3-(4, (3-(4, 0 0 1 0 1 0 0 1 6 0 NNP NNP NNP CD CD O
5-Dimethylthiazol-2-yl)-2, 5-Dimethylthiazol-2-yl)-2, 0 0 1 0 1 0 0 1 26 0 NNP NNP CD CD JJ O
5-diphenyltetrazolium 5-diphenyltetrazolium 0 0 1 0 0 0 0 1 21 0 NNP CD CD JJ NN O
bromide, bromide, 0 0 0 0 1 0 0 0 8 0 CD CD JJ NN NNP O
AE, AE, 1 1 0 0 1 0 0 0 3 0 CD JJ NN NNP NNP O
Aqueous Aqueous 1 0 0 0 0 0 0 0 7 0 JJ NN NNP NNP NNP O
extract, extract, 0 0 0 0 1 0 0 0 8 0 NN NNP NNP NNP NNP O
BP, BP, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
British British 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Pharmacopoeia, Pharmacopoeia, 1 0 0 0 1 0 0 0 14 0 NNP NNP NNP NNP NNP O
COX, COX, 1 1 0 0 1 0 0 0 4 0 NNP NNP NNP NNP NNP O
Cyclooxygenase, Cyclooxygenase, 1 0 0 0 1 0 0 0 15 0 NNP NNP NNP NNP NNP O
DMSO, DMSO, 1 1 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
Dimethyl Dimethyl 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
sulfoxide, sulfoxide, 0 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Epithelialisation, Epithelialisation, 1 0 0 0 1 0 0 0 18 0 NNP NNP NNP NNP NNP O
Ethnomedicine, Ethnomedicine, 1 0 0 0 1 0 0 0 14 0 NNP NNP NNP NNP NNP O
FBS, FBS, 1 1 0 0 1 0 0 0 4 0 NNP NNP NNP NNP NNP O
FTIR, FTIR, 1 1 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NN O
Fetal Fetal 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NN -NONE- O
bovine bovine 0 0 0 0 0 0 0 0 6 0 NNP NNP NN -NONE- NNP O
serum, serum, 0 0 0 0 1 0 0 0 6 0 NNP NN -NONE- NNP NN O
Fourier Fourier 1 0 0 0 0 0 0 0 7 0 NN -NONE- NNP NN VBD O
transform transform 0 0 0 0 0 0 0 0 9 0 -NONE- NNP NN VBD JJ O
infrared infrared 0 0 0 0 0 0 0 0 8 0 NNP NN VBD JJ NN O
spectroscopy, spectroscopy, 0 0 0 0 1 0 0 0 13 0 NN VBD JJ NN NN O
Hb, Hb, 1 0 0 0 1 0 0 0 3 0 VBD JJ NN NN NNP O
Hemoglobin, Hemoglobin, 1 0 0 0 1 0 0 0 11 0 JJ NN NN NNP NN O
Human Human 1 0 0 0 0 0 0 0 5 0 NN NN NNP NN JJ O
acute acute 0 0 0 0 0 0 0 0 5 0 NN NNP NN JJ NN O
monocytic monocytic 0 0 0 0 0 0 0 0 9 0 NNP NN JJ NN NN O
leukemia leukemia 0 0 0 0 0 0 0 0 8 0 NN JJ NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NN O
line, line, 0 0 0 0 1 0 0 0 5 0 NN NN NN NN NN O
IFN-γ, IFN-γ, 1 0 1 0 1 0 0 0 6 0 NN NN NN NN NN O
IL, IL, 1 1 0 0 1 0 0 0 3 0 NN NN NN NN NNP O
IR, IR, 1 1 0 0 1 0 0 0 3 0 NN NN NN NNP JJ O
Inducible Inducible 1 0 0 0 0 0 0 0 9 0 NN NN NNP JJ NN O
nitric nitric 0 0 0 0 0 0 0 0 6 0 NN NNP JJ NN NN O
oxide oxide 0 0 0 0 0 0 0 0 5 0 NNP JJ NN NN NN O
synthase, synthase, 0 0 0 0 1 0 0 0 9 0 JJ NN NN NN NN O
Infrared, Infrared, 1 0 0 0 1 0 0 0 9 0 NN NN NN NN : O
Interferon- Interferon- 1 0 1 0 0 0 0 0 11 0 NN NN NN : JJ O
γ, γ, 0 0 0 0 1 0 0 0 2 0 NN NN : JJ NN O
Interleukin, Interleukin, 1 0 0 0 1 0 0 0 12 0 NN : JJ NN NN O
LPS, LPS, 1 1 0 0 1 0 0 0 4 0 : JJ NN NN NN O
Lipopolysaccharide, Lipopolysaccharide, 1 0 0 0 1 0 0 0 19 0 JJ NN NN NN NN O
ME, ME, 1 1 0 0 1 0 0 0 3 0 NN NN NN NN NN O
MS, MS, 1 1 0 0 1 0 0 0 3 0 NN NN NN NN NNP O
MTT, MTT, 1 1 0 0 1 0 0 0 4 0 NN NN NN NNP NNP O
Mass Mass 1 0 0 0 0 0 0 0 4 0 NN NN NNP NNP NNP O
spectrometry, spectrometry, 0 0 0 0 1 0 0 0 13 0 NN NNP NNP NNP NNP O
Methanol Methanol 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
extract, extract, 0 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide, N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide, 1 0 1 0 1 0 0 1 55 0 NNP NNP NNP NNP NNP O
NMR, NMR, 1 1 0 0 1 0 0 0 4 0 NNP NNP NNP NNP NNP O
NO, NO, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
NS-398, NS-398, 1 1 1 0 1 0 0 1 7 0 NNP NNP NNP NNP NNP O
Nitric Nitric 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
oxide, oxide, 0 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
PGE, PGE, 1 1 0 0 1 0 0 0 4 0 NNP NNP NNP NNP NNP O
PMA, PMA, 1 1 0 0 1 0 0 0 4 0 NNP NNP NNP NNP JJ O
Phorbol Phorbol 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP JJ CD O
12-myristate 12-myristate 0 0 1 0 0 0 0 1 12 0 NNP NNP JJ CD NN O
13-acetate, 13-acetate, 0 0 1 0 1 0 0 1 11 0 NNP JJ CD NN -NONE- O
Prostaglandin, Prostaglandin, 1 0 0 0 1 0 0 0 14 0 JJ CD NN -NONE- -NONE- O
RBC, RBC, 1 1 0 0 1 0 0 0 4 0 CD NN -NONE- -NONE- NNP O
RPMI, RPMI, 1 1 0 0 1 0 0 0 5 0 NN -NONE- -NONE- NNP NN O
Red Red 1 0 0 0 0 0 0 0 3 0 -NONE- -NONE- NNP NN -NONE- O
blood blood 0 0 0 0 0 0 0 0 5 0 -NONE- NNP NN -NONE- NNP O
corpuscles, corpuscles, 0 0 0 0 1 0 0 0 11 0 NNP NN -NONE- NNP NN O
Roswell Roswell 1 0 0 0 0 0 0 0 7 0 NN -NONE- NNP NN NN O
park park 0 0 0 0 0 0 0 0 4 0 -NONE- NNP NN NN NN O
memorial memorial 0 0 0 0 0 0 0 0 8 0 NNP NN NN NN NN O
institute institute 0 0 0 0 0 0 0 0 9 0 NN NN NN NN NNP O
medium, medium, 0 0 0 0 1 0 0 0 7 0 NN NN NN NNP NNP O
Shorea Shorea 1 0 0 0 0 0 0 0 6 0 NN NN NNP NNP NNP O
robusta, robusta, 0 0 0 0 1 0 0 0 8 0 NN NNP NNP NNP NNP O
T T 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NNP NNP O
helper, helper, 0 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
THP, THP, 1 1 0 0 1 0 0 0 4 0 NNP NNP NNP NNP NNP O
TLC, TLC, 1 1 0 0 1 0 0 0 4 0 NNP NNP NNP NNP NNP O
TNF-α, TNF-α, 1 0 1 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
Tensile Tensile 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
strength, strength, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Th, Th, 1 0 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NN O
Thin Thin 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NN -NONE- O
layer layer 0 0 0 0 0 0 0 0 5 0 NNP NNP NN -NONE- NNP O
chromatography, chromatography, 0 0 0 0 1 0 0 0 15 0 NNP NN -NONE- NNP NN O
Tumour Tumour 1 0 0 0 0 0 0 0 6 0 NN -NONE- NNP NN -NONE- O
necrosis necrosis 0 0 0 0 0 0 0 0 8 0 -NONE- NNP NN -NONE- -NONE- O
factor-α, factor-α, 0 0 1 0 1 0 0 0 9 0 NNP NN -NONE- -NONE- NNP O
USP, USP, 1 1 0 0 1 0 0 0 4 0 NN -NONE- -NONE- NNP NNP O
United United 1 0 0 0 0 0 0 0 6 0 -NONE- -NONE- NNP NNP NNP O
State State 1 0 0 0 0 0 0 0 5 0 -NONE- NNP NNP NNP NNP O
Pharmacopoeia, Pharmacopoeia, 1 0 0 0 1 0 0 0 14 0 NNP NNP NNP NNP NNP O
WBC, WBC, 1 1 0 0 1 0 0 0 4 0 NNP NNP NNP NNP NN O
White White 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NN -NONE- O
blood blood 0 0 0 0 0 0 0 0 5 0 NNP NNP NN -NONE- NNP O
corpuscles, corpuscles, 0 0 0 0 1 0 0 0 11 0 NNP NN -NONE- NNP NNP O
Wound Wound 1 0 0 0 0 0 0 0 5 0 NN -NONE- NNP NNP NNP O
healing, healing, 0 0 0 0 1 0 0 0 8 0 -NONE- NNP NNP NNP NN O
iNOS, iNOS, 0 0 0 0 1 0 0 0 5 0 NNP NNP NNP NN JJ O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 NNP NNP NN JJ NN O
magnetic magnetic 0 0 0 0 0 0 0 0 8 0 NNP NN JJ NN NONE O
resonance resonance 0 0 0 0 0 0 0 0 9 0 NN JJ NN NONE NONE O
Evidence Evidence 1 0 0 0 0 0 0 0 8 0 NONE NONE NN IN RB O
for for 0 0 0 0 0 0 0 0 3 0 NONE NN IN RB VBN O
fully fully 0 0 0 0 0 0 0 0 5 0 NN IN RB VBN JJ O
gapped gapped 0 0 0 0 0 0 0 0 6 0 IN RB VBN JJ NN O
strong strong 0 0 0 0 0 0 0 0 6 0 RB VBN JJ NN JJ O
coupling coupling 0 0 0 0 0 0 0 0 8 0 VBN JJ NN JJ NN O
s-wave s-wave 0 0 1 0 0 0 0 0 6 0 JJ NN JJ NN IN O
superconductivity superconductivity 0 0 0 0 0 0 0 0 17 0 NN JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
Bi4O4S3. Bi4O4S3. 1 0 0 0 0 0 0 1 8 0 NN IN NNP NNP NNP O
Shruti, Shruti, 1 0 0 0 1 0 0 0 7 0 IN NNP NNP NNP NNP O
Srivastava Srivastava 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Patnaik Patnaik 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
S. S. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Physical Physical 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Jawaharlal Jawaharlal 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Nehru Nehru 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
New New 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Delhi-110067, Delhi-110067, 1 0 1 0 1 0 0 1 13 0 NNP NNP NNP NNP NNP O
India. India. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NN IN O
report report 0 0 0 0 0 0 0 0 6 0 NNP NNP NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
superconducting superconducting 0 0 0 0 0 0 0 0 15 0 IN DT NN NN CC O
gap gap 0 0 0 0 0 0 0 0 3 0 DT NN NN CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBG NN O
pairing pairing 0 0 0 0 0 0 0 0 7 0 NN CC VBG NN IN O
symmetry symmetry 0 0 0 0 0 0 0 0 8 0 CC VBG NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBG NN IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT VBN NN O
layered layered 0 0 0 0 0 0 0 0 7 0 IN DT VBN NN NNP O
superconductor superconductor 0 0 0 0 0 0 0 0 14 0 DT VBN NN NNP NNP O
Bi4O4S3. Bi4O4S3. 1 0 0 0 0 0 0 1 8 0 VBN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
measurement measurement 0 0 0 0 0 0 0 0 11 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NN O
temperature temperature 0 0 0 0 0 0 0 0 11 0 NN IN NN NN IN O
dependence dependence 0 0 0 0 0 0 0 0 10 0 IN NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
magnetic magnetic 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN NN O
penetration penetration 0 0 0 0 0 0 0 0 11 0 IN JJ NN NN VBD O
depth depth 0 0 0 0 0 0 0 0 5 0 JJ NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN RP O
carried carried 0 0 0 0 0 0 0 0 7 0 NN VBD VBN RP VBG O
out out 0 0 0 0 0 0 0 0 3 0 VBD VBN RP VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 VBN RP VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RP VBG DT NN NN O
tunnel tunnel 0 0 0 0 0 0 0 0 6 0 VBG DT NN NN NN O
diode diode 0 0 0 0 0 0 0 0 5 0 DT NN NN NN NNP O
oscillator oscillator 0 0 0 0 0 0 0 0 10 0 NN NN NN NNP NNP O
technique. technique. 0 0 0 0 0 0 0 0 10 0 NN NN NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 NNP VBZ VBN IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN NNP VBZ O
Bi4O4S3 Bi4O4S3 1 0 0 0 0 0 0 1 7 0 VBN IN NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT JJ JJ O
conventional conventional 0 0 0 0 0 0 0 0 12 0 VBZ DT JJ JJ NN O
s-wave s-wave 0 0 1 0 0 0 0 0 6 0 DT JJ JJ NN NN O
type type 0 0 0 0 0 0 0 0 4 0 JJ JJ NN NN IN O
superconductor superconductor 0 0 0 0 0 0 0 0 14 0 JJ NN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN DT RB O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT RB VBN O
fully fully 0 0 0 0 0 0 0 0 5 0 IN DT RB VBN NNP O
developed developed 0 0 0 0 0 0 0 0 9 0 DT RB VBN NNP NNP O
gap. gap. 0 0 0 0 0 0 0 0 4 0 RB VBN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 VBN NNP NNP NNP NN O
zero-temperature zero-temperature 0 0 1 0 0 0 0 0 16 0 NNP NNP NNP NN IN O
value value 0 0 0 0 0 0 0 0 5 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
superconducting superconducting 0 0 0 0 0 0 0 0 15 0 IN DT NN NN NN O
energy energy 0 0 0 0 0 0 0 0 6 0 DT NN NN NN -NONE- O
gap gap 0 0 0 0 0 0 0 0 3 0 NN NN NN -NONE- VBD O
Δ0 Δ0 1 1 0 0 0 0 0 1 2 0 NN NN -NONE- VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN -NONE- VBD VBN TO O
found found 0 0 0 0 0 0 0 0 5 0 -NONE- VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB CD O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB CD -NONE- O
1.54 1.54 0 0 0 0 0 0 0 1 4 0 TO VB CD -NONE- VBG O
meV, meV, 0 0 0 0 1 0 0 0 4 0 VB CD -NONE- VBG TO O
corresponding corresponding 0 0 0 0 0 0 0 0 13 0 CD -NONE- VBG TO DT O
to to 0 0 0 0 0 0 0 0 2 0 -NONE- VBG TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBG TO DT NN CD O
ratio ratio 0 0 0 0 0 0 0 0 5 0 TO DT NN CD CD O
2Δ0/kBTc 2Δ0/kBTc 0 0 0 1 0 0 0 1 8 0 DT NN CD CD CD O
= = 0 0 0 0 0 0 0 0 1 0 NN CD CD CD WDT O
7.2 7.2 0 0 0 0 0 0 0 1 3 0 CD CD CD WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 CD CD WDT VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 CD WDT VBZ RB JJR O
much much 0 0 0 0 0 0 0 0 4 0 WDT VBZ RB JJR IN O
higher higher 0 0 0 0 0 0 0 0 6 0 VBZ RB JJR IN DT O
than than 0 0 0 0 0 0 0 0 4 0 RB JJR IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 JJR IN DT NNP NN O
BCS BCS 1 1 0 0 0 0 0 0 3 0 IN DT NNP NN IN O
value value 0 0 0 0 0 0 0 0 5 0 DT NNP NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN CD IN O
3.53. 3.53. 0 0 0 0 0 0 0 1 5 0 NN IN CD IN DT O
In In 1 0 0 0 0 0 0 0 2 0 IN CD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT NN NN O
superconducting superconducting 0 0 0 0 0 0 0 0 15 0 IN DT NN NN VBD O
range, range, 0 0 0 0 1 0 0 0 6 0 DT NN NN VBD NN O
superfluid superfluid 0 0 0 0 0 0 0 0 10 0 NN NN VBD NN VBZ O
density density 0 0 0 0 0 0 0 0 7 0 NN VBD NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 VBD NN VBZ RB RB O
very very 0 0 0 0 0 0 0 0 4 0 NN VBZ RB RB VBN O
well well 0 0 0 0 0 0 0 0 4 0 VBZ RB RB VBN IN O
described described 0 0 0 0 0 0 0 0 9 0 RB RB VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 RB VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
single single 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN JJ O
gap gap 0 0 0 0 0 0 0 0 3 0 DT JJ NN JJ NNP O
s-wave s-wave 0 0 1 0 0 0 0 0 6 0 JJ NN JJ NNP NONE O
model. model. 0 0 0 0 0 0 0 0 6 0 NN JJ NNP NONE NONE O
Ferromagnetic Ferromagnetic 1 0 0 0 0 0 0 0 13 0 NONE NONE JJ PRP$ IN O
behaviour behaviour 0 0 0 0 0 0 0 0 9 0 NONE JJ PRP$ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ PRP$ IN JJ NNP O
Fe-doped Fe-doped 1 0 1 0 0 0 0 0 8 0 PRP$ IN JJ NNP VBD O
ZnO ZnO 1 0 0 0 0 0 0 0 3 0 IN JJ NNP VBD NNP O
nanograined nanograined 0 0 0 0 0 0 0 0 11 0 JJ NNP VBD NNP NNP O
films. films. 0 0 0 0 0 0 0 0 6 0 NNP VBD NNP NNP NNP O
Straumal Straumal 1 0 0 0 0 0 0 0 8 0 VBD NNP NNP NNP NNP O
BB, BB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Protasova Protasova 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
SG, SG, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Mazilkin Mazilkin 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
AA, AA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Tietze Tietze 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Goering Goering 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
E, E, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Schütz Schütz 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Straumal Straumal 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
PB, PB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Baretzky Baretzky 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
B. B. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Karlsruher Karlsruher 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Institut Institut 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
für für 0 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Technologie, Technologie, 1 0 0 0 1 0 0 0 12 0 NNP NNP NNP NNP NNP O
Institut Institut 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
für für 0 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Nanotechnologie, Nanotechnologie, 1 0 0 0 1 0 0 0 16 0 NNP NNP NNP NNP CD O
Hermann-von-Helmholtz-Platz Hermann-von-Helmholtz-Platz 1 0 1 0 0 0 0 0 27 0 NNP NNP NNP CD CD O
1, 1, 0 0 0 0 1 0 0 1 2 0 NNP NNP CD CD JJ O
76344 76344 0 0 0 0 0 0 1 1 5 0 NNP CD CD JJ NNP O
Eggenstein-Leopoldshafen, Eggenstein-Leopoldshafen, 1 0 1 0 1 0 0 0 25 0 CD CD JJ NNP : O
Germany Germany 1 0 0 0 0 0 0 0 7 0 CD JJ NNP : NNP O
; ; 0 0 0 0 0 0 0 0 1 0 JJ NNP : NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP : NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 : NNP IN NNP NNP O
Solid Solid 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
State State 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
Physics, Physics, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Russian Russian 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP IN O
Academy Academy 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Ac. Ac. 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
Ossipyan Ossipyan 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP CD O
str. str. 0 0 0 0 0 0 0 0 4 0 NNP NNP NNP CD CD O
2, 2, 0 0 0 0 1 0 0 1 2 0 NNP NNP CD CD JJ O
142432 142432 0 0 0 0 0 0 1 1 6 0 NNP CD CD JJ NNP O
Chernogolovka, Chernogolovka, 1 0 0 0 1 0 0 0 14 0 CD CD JJ NNP : O
Russia Russia 1 0 0 0 0 0 0 0 6 0 CD JJ NNP : JJ O
; ; 0 0 0 0 0 0 0 0 1 0 JJ NNP : JJ NN O
Max-Planck-Institut Max-Planck-Institut 1 0 1 0 0 0 0 0 19 0 NNP : JJ NN NNP O
für für 0 0 0 0 0 0 0 0 3 0 : JJ NN NNP NNP O
Intelligente Intelligente 1 0 0 0 0 0 0 0 12 0 JJ NN NNP NNP NNP O
Systeme, Systeme, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP NNP CD O
Heisenbergstrasse Heisenbergstrasse 1 0 0 0 0 0 0 0 17 0 NNP NNP NNP CD CD O
3, 3, 0 0 0 0 1 0 0 1 2 0 NNP NNP CD CD JJ O
70569 70569 0 0 0 0 0 0 1 1 5 0 NNP CD CD JJ NNP O
Stuttgart, Stuttgart, 1 0 0 0 1 0 0 0 10 0 CD CD JJ NNP : O
Germany Germany 1 0 0 0 0 0 0 0 7 0 CD JJ NNP : NNP O
; ; 0 0 0 0 0 0 0 0 1 0 JJ NNP : NNP NNP O
National National 1 0 0 0 0 0 0 0 8 0 NNP : NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 : NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP CC O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Technology Technology 1 0 0 0 0 0 0 0 10 0 NNP CC NNP NNP NNP O
"MISiS", "MISiS", 0 0 0 0 1 0 0 0 8 0 CC NNP NNP NNP NN O
Leninsky Leninsky 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NN CD O
prospect prospect 0 0 0 0 0 0 0 0 8 0 NNP NNP NN CD CD O
4, 4, 0 0 0 0 1 0 0 1 2 0 NNP NN CD CD JJ O
119991 119991 0 0 0 0 0 0 1 1 6 0 NN CD CD JJ NNP O
Moscow, Moscow, 1 0 0 0 1 0 0 0 7 0 CD CD JJ NNP NNP O
Russia. Russia. 1 0 0 0 0 0 0 0 7 0 CD JJ NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
influence influence 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
grain grain 0 0 0 0 0 0 0 0 5 0 IN DT NN NN NN O
boundary boundary 0 0 0 0 0 0 0 0 8 0 DT NN NN NN NN O
(GB) (GB) 0 1 0 0 0 0 0 0 4 0 NN NN NN NN NN O
specific specific 0 0 0 0 0 0 0 0 8 0 NN NN NN NN NNS O
area area 0 0 0 0 0 0 0 0 4 0 NN NN NN NNS NNP O
s s 0 0 0 0 0 0 0 0 1 0 NN NN NNS NNP IN O
GB GB 1 1 0 0 0 0 0 0 2 0 NN NNS NNP IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NNS NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN IN O
appearance appearance 0 0 0 0 0 0 0 0 10 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
ferromagnetism ferromagnetism 0 0 0 0 0 0 0 0 14 0 NN IN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NNP O
Fe-doped Fe-doped 1 0 1 0 0 0 0 0 8 0 NN IN JJ NNP VBZ O
ZnO ZnO 1 0 0 0 0 0 0 0 3 0 IN JJ NNP VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 JJ NNP VBZ VBN NNP O
been been 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBN NNP NNP O
analysed. analysed. 0 0 0 0 0 0 0 0 9 0 VBZ VBN NNP NNP NN O
A A 1 1 0 0 0 0 0 0 1 0 VBN NNP NNP NN IN O
review review 0 0 0 0 0 0 0 0 6 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
numerous numerous 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN NNS O
research research 0 0 0 0 0 0 0 0 8 0 IN JJ NN NNS IN O
contributions contributions 0 0 0 0 0 0 0 0 13 0 JJ NN NNS IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
literature literature 0 0 0 0 0 0 0 0 10 0 IN DT NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
origin origin 0 0 0 0 0 0 0 0 6 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
ferromagnetic ferromagnetic 0 0 0 0 0 0 0 0 13 0 IN DT JJ NN IN O
behaviour behaviour 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNP O
Fe-doped Fe-doped 1 0 1 0 0 0 0 0 8 0 NN IN JJ NNP VBZ O
ZnO ZnO 1 0 0 0 0 0 0 0 3 0 IN JJ NNP VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 JJ NNP VBZ NNP NNP O
given. given. 0 0 0 0 0 0 0 0 6 0 NNP VBZ NNP NNP JJ O
An An 1 0 0 0 0 0 0 0 2 0 VBZ NNP NNP JJ NN O
empirical empirical 0 0 0 0 0 0 0 0 9 0 NNP NNP JJ NN VBZ O
correlation correlation 0 0 0 0 0 0 0 0 11 0 NNP JJ NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 JJ NN VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 VBZ VBN VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 VBN VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
value value 0 0 0 0 0 0 0 0 5 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
specific specific 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN NN O
grain grain 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN NN O
boundary boundary 0 0 0 0 0 0 0 0 8 0 JJ NN NN NN NNS O
area area 0 0 0 0 0 0 0 0 4 0 NN NN NN NNS NNP O
s s 0 0 0 0 0 0 0 0 1 0 NN NN NNS NNP VBZ O
GB GB 1 1 0 0 0 0 0 0 2 0 NN NNS NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNS NNP VBZ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT JJ NN O
main main 0 0 0 0 0 0 0 0 4 0 VBZ DT JJ NN VBG O
factor factor 0 0 0 0 0 0 0 0 6 0 DT JJ NN VBG JJ O
controlling controlling 0 0 0 0 0 0 0 0 11 0 JJ NN VBG JJ NNP O
such such 0 0 0 0 0 0 0 0 4 0 NN VBG JJ NNP NNP O
behaviour. behaviour. 0 0 0 0 0 0 0 0 10 0 VBG JJ NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NNP NNP O
Fe-doped Fe-doped 1 0 1 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
ZnO ZnO 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP VBZ JJ O
becomes becomes 0 0 0 0 0 0 0 0 7 0 NNP NNP VBZ JJ RB O
ferromagnetic ferromagnetic 0 0 0 0 0 0 0 0 13 0 NNP VBZ JJ RB IN O
only only 0 0 0 0 0 0 0 0 4 0 VBZ JJ RB IN PRP O
if if 0 0 0 0 0 0 0 0 2 0 JJ RB IN PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 RB IN PRP VBZ RB O
contains contains 0 0 0 0 0 0 0 0 8 0 IN PRP VBZ RB JJ O
enough enough 0 0 0 0 0 0 0 0 6 0 PRP VBZ RB JJ NN O
GBs, GBs, 1 0 0 0 1 0 0 0 4 0 VBZ RB JJ NN IN O
i.e., i.e., 0 0 0 0 1 0 0 0 5 0 RB JJ NN IN NNS O
if if 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS NNP O
s s 0 0 0 0 0 0 0 0 1 0 NN IN NNS NNP VBZ O
GB GB 1 1 0 0 0 0 0 0 2 0 IN NNS NNP VBZ JJR O
is is 0 0 0 0 0 0 0 0 2 0 NNS NNP VBZ JJR IN O
higher higher 0 0 0 0 0 0 0 0 6 0 NNP VBZ JJR IN DT O
than than 0 0 0 0 0 0 0 0 4 0 VBZ JJR IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 JJR IN DT JJ NN O
certain certain 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN NN O
threshold threshold 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN NNS O
value value 0 0 0 0 0 0 0 0 5 0 JJ NN NN NNS IN O
s s 0 0 0 0 0 0 0 0 1 0 NN NN NNS IN CD O
th th 0 0 0 0 0 0 0 0 2 0 NN NNS IN CD CD O
= = 0 0 0 0 0 0 0 0 1 0 NNS IN CD CD CD O
5 5 0 0 0 0 0 0 1 1 1 0 IN CD CD CD CD O
× × 0 0 0 0 0 0 0 0 1 0 CD CD CD CD NNP O
10(4) 10(4) 0 0 0 0 0 0 0 1 5 0 CD CD CD NNP NNP O
m(2)/m(3). m(2)/m(3). 0 0 0 1 0 0 0 1 10 0 CD CD NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 CD NNP NNP VBZ TO O
corresponds corresponds 0 0 0 0 0 0 0 0 11 0 NNP NNP VBZ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBZ TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBZ TO DT JJ NN O
effective effective 0 0 0 0 0 0 0 0 9 0 TO DT JJ NN NN O
grain grain 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN IN O
size size 0 0 0 0 0 0 0 0 4 0 JJ NN NN IN RB O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN RB CD O
about about 0 0 0 0 0 0 0 0 5 0 NN IN RB CD JJ O
40 40 0 0 0 0 0 0 1 1 2 0 IN RB CD JJ NN O
μm μm 0 0 0 0 0 0 0 0 2 0 RB CD JJ NN DT O
assuming assuming 0 0 0 0 0 0 0 0 8 0 CD JJ NN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 JJ NN DT NN NN O
full, full, 0 0 0 0 1 0 0 0 5 0 NN DT NN NN NN O
dense dense 0 0 0 0 0 0 0 0 5 0 DT NN NN NN CC O
material material 0 0 0 0 0 0 0 0 8 0 NN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NNP O
equiaxial equiaxial 0 0 0 0 0 0 0 0 9 0 NN CC JJ NNP NNP O
grains. grains. 0 0 0 0 0 0 0 0 7 0 CC JJ NNP NNP VBZ O
Magnetic Magnetic 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP VBZ IN O
properties properties 0 0 0 0 0 0 0 0 10 0 NNP NNP VBZ IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN NNP NN O
ZnO ZnO 1 0 0 0 0 0 0 0 3 0 VBZ IN NNP NN VBD O
dense dense 0 0 0 0 0 0 0 0 5 0 IN NNP NN VBD JJ O
nanograined nanograined 0 0 0 0 0 0 0 0 11 0 NNP NN VBD JJ NNS O
thin thin 0 0 0 0 0 0 0 0 4 0 NN VBD JJ NNS VBD O
films films 0 0 0 0 0 0 0 0 5 0 VBD JJ NNS VBD IN O
doped doped 0 0 0 0 0 0 0 0 5 0 JJ NNS VBD IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NN -NONE- O
iron iron 0 0 0 0 0 0 0 0 4 0 VBD IN NN -NONE- TO O
(0 (0 0 0 0 0 0 0 0 1 2 0 IN NN -NONE- TO CD O
to to 0 0 0 0 0 0 0 0 2 0 NN -NONE- TO CD NN O
40 40 0 0 0 0 0 0 1 1 2 0 -NONE- TO CD NN : O
atom atom 0 0 0 0 0 0 0 0 4 0 TO CD NN : VBP O
%) %) 0 0 0 0 0 0 0 0 2 0 CD NN : VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NN : VBP VBN NNP O
been been 0 0 0 0 0 0 0 0 4 0 : VBP VBN NNP NNP O
investigated. investigated. 0 0 0 0 0 0 0 0 13 0 VBP VBN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 VBN NNP NNP NNS VBD O
films films 0 0 0 0 0 0 0 0 5 0 NNP NNP NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD VBN IN O
deposited deposited 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN DT O
using using 0 0 0 0 0 0 0 0 5 0 VBN IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN NN O
wet wet 0 0 0 0 0 0 0 0 3 0 NN DT NN NN JJ O
chemistry chemistry 0 0 0 0 0 0 0 0 9 0 DT NN NN JJ NN O
"liquid "liquid 0 0 0 0 0 0 0 0 7 0 NN NN JJ NN NNP O
ceramics" ceramics" 0 0 0 0 0 0 0 0 9 0 NN JJ NN NNP NNP O
method. method. 0 0 0 0 0 0 0 0 7 0 JJ NN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS VBP O
samples samples 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP JJ O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 NNP NNS VBP JJ NN O
ferromagnetic ferromagnetic 0 0 0 0 0 0 0 0 13 0 NNS VBP JJ NN IN O
behaviour behaviour 0 0 0 0 0 0 0 0 9 0 VBP JJ NN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN NNP NNS O
J J 1 1 0 0 0 0 0 0 1 0 NN IN NNP NNS IN O
s s 0 0 0 0 0 0 0 0 1 0 IN NNP NNS IN TO O
up up 0 0 0 0 0 0 0 0 2 0 NNP NNS IN TO CD O
to to 0 0 0 0 0 0 0 0 2 0 NNS IN TO CD JJ O
0.10 0.10 0 0 0 0 0 0 0 1 4 0 IN TO CD JJ NN O
emu/g emu/g 0 0 0 1 0 0 0 0 5 0 TO CD JJ NN NN O
(0.025 (0.025 0 0 0 0 0 0 0 1 6 0 CD JJ NN NN CC O
μB/f.u.ZnO) μB/f.u.ZnO) 0 0 0 1 0 0 0 0 11 0 JJ NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NNP O
coercivity coercivity 0 0 0 0 0 0 0 0 10 0 NN CC NN NNP NN O
H H 1 1 0 0 0 0 0 0 1 0 CC NN NNP NN : O
c c 0 0 0 0 0 0 0 0 1 0 NN NNP NN : CD O
≈ ≈ 0 0 0 0 0 0 0 0 1 0 NNP NN : CD NNP O
0.03 0.03 0 0 0 0 0 0 0 1 4 0 NN : CD NNP NNP O
T. T. 1 1 0 0 0 0 0 0 2 0 : CD NNP NNP NN O
Saturation Saturation 1 0 0 0 0 0 0 0 10 0 CD NNP NNP NN VBZ O
magnetisation magnetisation 0 0 0 0 0 0 0 0 13 0 NNP NNP NN VBZ RB O
depends depends 0 0 0 0 0 0 0 0 7 0 NNP NN VBZ RB IN O
nonmonotonically nonmonotonically 0 0 0 0 0 0 0 0 16 0 NN VBZ RB IN DT O
on on 0 0 0 0 0 0 0 0 2 0 VBZ RB IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NNP NNP O
Fe Fe 1 0 0 0 0 0 0 0 2 0 IN DT NNP NNP NNP O
concentration. concentration. 0 0 0 0 0 0 0 0 14 0 DT NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
dependence dependence 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NN O
Fe Fe 1 0 0 0 0 0 0 0 2 0 NN IN NNP NN MD O
content content 0 0 0 0 0 0 0 0 7 0 IN NNP NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NNP NN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB VBN IN O
explained explained 0 0 0 0 0 0 0 0 9 0 MD VB VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VB VBN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNS IN O
changes changes 0 0 0 0 0 0 0 0 7 0 IN DT NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN CC O
structure structure 0 0 0 0 0 0 0 0 9 0 IN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
contiguity contiguity 0 0 0 0 0 0 0 0 10 0 NN CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
ferromagnetic ferromagnetic 0 0 0 0 0 0 0 0 13 0 IN DT JJ NN NN O
"grain "grain 0 0 0 0 0 0 0 0 6 0 DT JJ NN NN NN O
boundary boundary 0 0 0 0 0 0 0 0 8 0 JJ NN NN NN JJ O
foam" foam" 0 0 0 0 0 0 0 0 5 0 NN NN NN JJ IN O
responsible responsible 0 0 0 0 0 0 0 0 11 0 NN NN JJ IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN JJ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT JJ NNS O
magnetic magnetic 0 0 0 0 0 0 0 0 8 0 IN DT JJ NNS IN O
properties properties 0 0 0 0 0 0 0 0 10 0 DT JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN CC O
pure pure 0 0 0 0 0 0 0 0 4 0 NNS IN NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VBD NNP O
doped doped 0 0 0 0 0 0 0 0 5 0 NN CC VBD NNP NONE O
ZnO. ZnO. 1 0 0 0 0 0 0 0 4 0 CC VBD NNP NONE NONE O
Association Association 1 0 0 0 0 0 0 0 11 0 NONE NONE NN IN JJ O
between between 0 0 0 0 0 0 0 0 7 0 NONE NN IN JJ NNS O
spinocerebellar spinocerebellar 0 0 0 0 0 0 0 0 15 0 NN IN JJ NNS VBN O
ataxias ataxias 0 0 0 0 0 0 0 0 7 0 IN JJ NNS VBN IN O
caused caused 0 0 0 0 0 0 0 0 6 0 JJ NNS VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBN IN NN NN O
glutamine glutamine 0 0 0 0 0 0 0 0 9 0 VBN IN NN NN CC O
expansion expansion 0 0 0 0 0 0 0 0 9 0 IN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ CC O
psychiatric psychiatric 0 0 0 0 0 0 0 0 11 0 NN CC JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 CC JJ CC JJ NNS O
neuropsychological neuropsychological 0 0 0 0 0 0 0 0 18 0 JJ CC JJ NNS : O
signals signals 0 0 0 0 0 0 0 0 7 0 CC JJ NNS : DT O
- - 0 0 1 0 0 0 0 0 1 0 JJ NNS : DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNS : DT NN NNP O
literature literature 0 0 0 0 0 0 0 0 10 0 : DT NN NNP NNP O
review. review. 0 0 0 0 0 0 0 0 7 0 DT NN NNP NNP NNP O
Almeida-Silva Almeida-Silva 1 0 1 0 0 0 0 0 13 0 NN NNP NNP NNP NNP O
UC, UC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Hallak Hallak 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
JE, JE, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Júnior Júnior 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
WM, WM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Osório Osório 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Fde Fde 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
L. L. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNPS O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNPS CC O
Neurosciences Neurosciences 1 0 0 0 0 0 0 0 13 0 NNP IN NNPS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNPS CC NNP NNP O
Behavior, Behavior, 1 0 0 0 1 0 0 0 9 0 NNPS CC NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 CC NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Ribeirão Ribeirão 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Preto, Preto, 1 0 0 0 1 0 0 0 6 0 IN NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
São São 1 0 0 0 0 0 0 0 3 0 NNP IN NNP NNP NNP O
Paulo Paulo 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
Brazil. Brazil. 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP JJ NN O
autosomal autosomal 0 0 0 0 0 0 0 0 9 0 NNP NNP JJ NN NN O
dominant dominant 0 0 0 0 0 0 0 0 8 0 NNP JJ NN NN NN O
cerebellar cerebellar 0 0 0 0 0 0 0 0 10 0 JJ NN NN NN RB O
ataxias, ataxias, 0 0 0 0 1 0 0 0 8 0 NN NN NN RB VBN O
also also 0 0 0 0 0 0 0 0 4 0 NN NN RB VBN IN O
known known 0 0 0 0 0 0 0 0 5 0 NN RB VBN IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 RB VBN IN JJ NNS O
spinocerebellar spinocerebellar 0 0 0 0 0 0 0 0 15 0 VBN IN JJ NNS -NONE- O
ataxias ataxias 0 0 0 0 0 0 0 0 7 0 IN JJ NNS -NONE- VBP O
(SCA), (SCA), 0 1 0 0 1 0 0 0 6 0 JJ NNS -NONE- VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NNS -NONE- VBP VBN IN O
characterized characterized 0 0 0 0 0 0 0 0 13 0 -NONE- VBP VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBP VBN IN JJ NN O
cerebellar cerebellar 0 0 0 0 0 0 0 0 10 0 VBN IN JJ NN CC O
degeneration degeneration 0 0 0 0 0 0 0 0 12 0 IN JJ NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC IN PRP$ O
by by 0 0 0 0 0 0 0 0 2 0 NN CC IN PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 CC IN PRP$ NN CC O
afferent afferent 0 0 0 0 0 0 0 0 8 0 IN PRP$ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 PRP$ NN CC NN NNP O
efferent efferent 0 0 0 0 0 0 0 0 8 0 NN CC NN NNP NNP O
connections. connections. 0 0 0 0 0 0 0 0 12 0 CC NN NNP NNP IN O
Currently, Currently, 1 0 0 0 1 0 0 0 10 0 NN NNP NNP IN JJS O
at at 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJS CD O
least least 0 0 0 0 0 0 0 0 5 0 NNP IN JJS CD NNS O
31 31 0 0 0 0 0 0 1 1 2 0 IN JJS CD NNS IN O
types types 0 0 0 0 0 0 0 0 5 0 JJS CD NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN NNP VBP O
SCA SCA 1 1 0 0 0 0 0 0 3 0 NNS IN NNP VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 IN NNP VBP JJ IN O
described, described, 0 0 0 0 1 0 0 0 10 0 NNP VBP JJ IN WDT O
among among 0 0 0 0 0 0 0 0 5 0 VBP JJ IN WDT DT O
which which 0 0 0 0 0 0 0 0 5 0 JJ IN WDT DT NN O
a a 0 0 0 0 0 0 0 0 1 0 IN WDT DT NN VBG O
subset, subset, 0 0 0 0 1 0 0 0 7 0 WDT DT NN VBG NNS O
comprising comprising 0 0 0 0 0 0 0 0 10 0 DT NN VBG NNS CD O
types types 0 0 0 0 0 0 0 0 5 0 NN VBG NNS CD CD O
1, 1, 0 0 0 0 1 0 0 1 2 0 VBG NNS CD CD CD O
2, 2, 0 0 0 0 1 0 0 1 2 0 NNS CD CD CD CD O
3, 3, 0 0 0 0 1 0 0 1 2 0 CD CD CD CD CD O
6, 6, 0 0 0 0 1 0 0 1 2 0 CD CD CD CD CD O
7, 7, 0 0 0 0 1 0 0 1 2 0 CD CD CD CD IN O
17 17 0 0 0 0 0 0 1 1 2 0 CD CD CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CD CD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT JJ VBZ O
disease, disease, 0 0 0 0 1 0 0 0 8 0 IN DT JJ VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 DT JJ VBZ VBN JJ O
distinguished distinguished 0 0 0 0 0 0 0 0 13 0 JJ VBZ VBN JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 VBZ VBN JJ TO VBG O
to to 0 0 0 0 0 0 0 0 2 0 VBN JJ TO VBG DT O
sharing sharing 0 0 0 0 0 0 0 0 7 0 JJ TO VBG DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VBG DT JJ NN O
same same 0 0 0 0 0 0 0 0 4 0 VBG DT JJ NN IN O
form form 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN VBG O
mutation mutation 0 0 0 0 0 0 0 0 8 0 NN IN NN VBG DT O
involving involving 0 0 0 0 0 0 0 0 9 0 IN NN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT NN IN O
repetition repetition 0 0 0 0 0 0 0 0 10 0 VBG DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
series series 0 0 0 0 0 0 0 0 6 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
CAG CAG 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNP NN O
triplets, triplets, 0 0 0 0 1 0 0 0 9 0 IN NNP NNP NN IN O
known known 0 0 0 0 0 0 0 0 5 0 NNP NNP NN IN NN O
as as 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NNS O
polyglutamine polyglutamine 0 0 0 0 0 0 0 0 13 0 NN IN NN NNS NNP O
diseases diseases 0 0 0 0 0 0 0 0 8 0 IN NN NNS NNP NNP O
(SCApolyQ). (SCApolyQ). 0 0 0 0 0 0 0 0 11 0 NN NNS NNP NNP DT O
Through Through 1 0 0 0 0 0 0 0 7 0 NNS NNP NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT JJ NN O
systematic systematic 0 0 0 0 0 0 0 0 10 0 NNP DT JJ NN NN O
literature literature 0 0 0 0 0 0 0 0 10 0 DT JJ NN NN VBG O
review review 0 0 0 0 0 0 0 0 6 0 JJ NN NN VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 NN NN VBG DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT NNP NNP O
Pubmed, Pubmed, 1 0 0 0 1 0 0 0 7 0 VBG DT NNP NNP NNP O
PsycoINFO, PsycoINFO, 1 0 0 0 1 0 0 0 10 0 DT NNP NNP NNP CC O
LILACS LILACS 1 1 0 0 0 0 0 0 6 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNS O
SciELO SciELO 1 0 0 0 0 0 0 0 6 0 NNP CC NNP NNS CC O
databases databases 0 0 0 0 0 0 0 0 9 0 CC NNP NNS CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNS CC DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNS CC DT NNS NNP O
keywords keywords 0 0 0 0 0 0 0 0 8 0 CC DT NNS NNP NNP O
Spinocerebellar Spinocerebellar 1 0 0 0 0 0 0 0 15 0 DT NNS NNP NNP IN O
Ataxia Ataxia 1 0 0 0 0 0 0 0 6 0 NNS NNP NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN IN O
association association 0 0 0 0 0 0 0 0 11 0 NNP IN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS -NONE- O
words words 0 0 0 0 0 0 0 0 5 0 IN DT NNS -NONE- -NONE- O
neuropsychiatric, neuropsychiatric, 0 0 0 0 1 0 0 0 17 0 DT NNS -NONE- -NONE- JJ O
psychological, psychological, 0 0 0 0 1 0 0 0 14 0 NNS -NONE- -NONE- JJ NN O
cognitive cognitive 0 0 0 0 0 0 0 0 9 0 -NONE- -NONE- JJ NN CC O
impairment(s) impairment(s) 0 0 0 0 0 0 0 0 13 0 -NONE- JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NNS O
psychiatric psychiatric 0 0 0 0 0 0 0 0 11 0 NN CC JJ NNS DT O
comorbidities comorbidities 0 0 0 0 0 0 0 0 13 0 CC JJ NNS DT NN O
this this 0 0 0 0 0 0 0 0 4 0 JJ NNS DT NN VBN O
study study 0 0 0 0 0 0 0 0 5 0 NNS DT NN VBN TO O
aimed aimed 0 0 0 0 0 0 0 0 5 0 DT NN VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBN TO VB DT O
identify identify 0 0 0 0 0 0 0 0 8 0 VBN TO VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJ NNS O
possible possible 0 0 0 0 0 0 0 0 8 0 VB DT JJ NNS IN O
associations associations 0 0 0 0 0 0 0 0 12 0 DT JJ NNS IN NNP O
between between 0 0 0 0 0 0 0 0 7 0 JJ NNS IN NNP CC O
SCApolyQ SCApolyQ 1 0 0 0 0 0 0 0 8 0 NNS IN NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC JJ CC O
neuropsychological neuropsychological 0 0 0 0 0 0 0 0 18 0 NNP CC JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 CC JJ CC JJ NNP O
psychiatric psychiatric 0 0 0 0 0 0 0 0 11 0 JJ CC JJ NNP DT O
symptoms/disorders. symptoms/disorders. 0 0 0 1 0 0 0 0 19 0 CC JJ NNP DT JJR O
A A 1 1 0 0 0 0 0 0 1 0 JJ NNP DT JJR NN O
greater greater 0 0 0 0 0 0 0 0 7 0 NNP DT JJR NN IN O
presence presence 0 0 0 0 0 0 0 0 8 0 DT JJR NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJR NN IN NNS IN O
symptoms symptoms 0 0 0 0 0 0 0 0 8 0 NN IN NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN NN CC O
depression depression 0 0 0 0 0 0 0 0 10 0 NNS IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN VBD O
anxiety anxiety 0 0 0 0 0 0 0 0 7 0 NN CC NN VBD JJ O
was was 0 0 0 0 0 0 0 0 3 0 CC NN VBD JJ IN O
evidenced, evidenced, 0 0 0 0 1 0 0 0 10 0 NN VBD JJ IN RB O
as as 0 0 0 0 0 0 0 0 2 0 VBD JJ IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 JJ IN RB IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NN IN O
existence existence 0 0 0 0 0 0 0 0 9 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
cognitive cognitive 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNS IN O
impairments impairments 0 0 0 0 0 0 0 0 11 0 IN JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 IN DT NNS IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 DT NNS IN NNP WRB O
SCApolyQ SCApolyQ 1 0 0 0 0 0 0 0 8 0 NNS IN NNP WRB VBN O
when when 0 0 0 0 0 0 0 0 4 0 IN NNP WRB VBN IN O
compared compared 0 0 0 0 0 0 0 0 8 0 NNP WRB VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 WRB VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
general general 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN IN O
population, population, 0 0 0 0 1 0 0 0 11 0 DT JJ NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN JJ NNS O
important important 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNS IN O
differences differences 0 0 0 0 0 0 0 0 11 0 IN JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
profile profile 0 0 0 0 0 0 0 0 7 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT NNS IN O
impairments impairments 0 0 0 0 0 0 0 0 11 0 IN DT NNS IN DT O
among among 0 0 0 0 0 0 0 0 5 0 DT NNS IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNS IN O
types types 0 0 0 0 0 0 0 0 5 0 IN DT NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NNP NNP O
SCA. SCA. 1 1 0 0 0 0 0 0 4 0 NNS IN NNP NNP VBD O
It It 1 0 0 0 0 0 0 0 2 0 IN NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 VBD VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP IN O
findings, findings, 0 0 0 0 1 0 0 0 9 0 IN DT NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 DT NNP IN NNP VBD O
general, general, 0 0 0 0 1 0 0 0 8 0 NNP IN NNP VBD JJR O
indicated indicated 0 0 0 0 0 0 0 0 9 0 IN NNP VBD JJR NN O
greater greater 0 0 0 0 0 0 0 0 7 0 NNP VBD JJR NN IN O
impairment impairment 0 0 0 0 0 0 0 0 10 0 VBD JJR NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJR NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
executive executive 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN JJ O
functions, functions, 0 0 0 0 1 0 0 0 10 0 DT JJ NN JJ NN O
verbal verbal 0 0 0 0 0 0 0 0 6 0 JJ NN JJ NN CC O
fluency fluency 0 0 0 0 0 0 0 0 7 0 NN JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NN O
verbal verbal 0 0 0 0 0 0 0 0 6 0 NN CC JJ NN CC O
memory memory 0 0 0 0 0 0 0 0 6 0 CC JJ NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC IN EX O
that that 0 0 0 0 0 0 0 0 4 0 NN CC IN EX VBD O
there there 0 0 0 0 0 0 0 0 5 0 CC IN EX VBD DT O
was was 0 0 0 0 0 0 0 0 3 0 IN EX VBD DT JJR O
a a 0 0 0 0 0 0 0 0 1 0 EX VBD DT JJR NN O
higher higher 0 0 0 0 0 0 0 0 6 0 VBD DT JJR NN IN O
concentration concentration 0 0 0 0 0 0 0 0 13 0 DT JJR NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJR NN IN NNS IN O
studies studies 0 0 0 0 0 0 0 0 7 0 NN IN NNS IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 IN NNS IN NNP CC O
SCA2 SCA2 1 1 0 0 0 0 0 1 4 0 NNS IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
SCA3. SCA3. 1 1 0 0 0 0 0 1 5 0 NNP CC NNP NNP RB O
However, However, 1 0 0 0 1 0 0 0 8 0 CC NNP NNP RB VBZ O
there there 0 0 0 0 0 0 0 0 5 0 NNP NNP RB VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP RB VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 RB VBZ DT NN IN O
need need 0 0 0 0 0 0 0 0 4 0 VBZ DT NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN DT JJR O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJR NN O
greater greater 0 0 0 0 0 0 0 0 7 0 IN DT JJR NN IN O
number number 0 0 0 0 0 0 0 0 6 0 DT JJR NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJR NN IN NNS VBG O
studies studies 0 0 0 0 0 0 0 0 7 0 NN IN NNS VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 IN NNS VBG DT JJR O
a a 0 0 0 0 0 0 0 0 1 0 NNS VBG DT JJR JJ O
more more 0 0 0 0 0 0 0 0 4 0 VBG DT JJR JJ NN O
homogeneous homogeneous 0 0 0 0 0 0 0 0 11 0 DT JJR JJ NN WDT O
methodology, methodology, 0 0 0 0 1 0 0 0 12 0 JJR JJ NN WDT NN O
which which 0 0 0 0 0 0 0 0 5 0 JJ NN WDT NN VBP O
perform perform 0 0 0 0 0 0 0 0 7 0 NN WDT NN VBP NNS O
direct direct 0 0 0 0 0 0 0 0 6 0 WDT NN VBP NNS IN O
comparisons comparisons 0 0 0 0 0 0 0 0 11 0 NN VBP NNS IN DT O
between between 0 0 0 0 0 0 0 0 7 0 VBP NNS IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNS IN O
types types 0 0 0 0 0 0 0 0 5 0 IN DT NNS IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NNS CC O
ataxias ataxias 0 0 0 0 0 0 0 0 7 0 NNS IN NNS CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS CC IN NN DT O
explore explore 0 0 0 0 0 0 0 0 7 0 CC IN NN DT IN O
some some 0 0 0 0 0 0 0 0 4 0 IN NN DT IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN DT IN DT RB O
the the 0 0 0 0 0 0 0 0 3 0 DT IN DT RB JJ O
still still 0 0 0 0 0 0 0 0 5 0 IN DT RB JJ VBN O
little little 0 0 0 0 0 0 0 0 6 0 DT RB JJ VBN JJ O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 RB JJ VBN JJ NNS O
neuropsychological neuropsychological 0 0 0 0 0 0 0 0 18 0 JJ VBN JJ NNS CC O
functions functions 0 0 0 0 0 0 0 0 9 0 VBN JJ NNS CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS CC DT JJ JJ O
different different 0 0 0 0 0 0 0 0 9 0 CC DT JJ JJ NNS O
psychiatric psychiatric 0 0 0 0 0 0 0 0 11 0 DT JJ JJ NNS IN O
disorders disorders 0 0 0 0 0 0 0 0 9 0 JJ JJ NNS IN PRP$ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN PRP$ NNP O
their their 0 0 0 0 0 0 0 0 5 0 NNS IN PRP$ NNP NONE O
amplitude. amplitude. 0 0 0 0 0 0 0 0 10 0 IN PRP$ NNP NONE NONE O
Flow-Volume Flow-Volume 1 0 1 0 0 0 0 0 11 0 NONE NONE NN NNS IN O
Parameters Parameters 1 0 0 0 0 0 0 0 10 0 NONE NN NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP NNP O
COPD COPD 1 1 0 0 0 0 0 0 4 0 NNS IN NNP NNP TO O
Related Related 1 0 0 0 0 0 0 0 7 0 IN NNP NNP TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNP NNP TO NNP NNP O
Extended Extended 1 0 0 0 0 0 0 0 8 0 NNP TO NNP NNP IN O
Measurements Measurements 1 0 0 0 0 0 0 0 12 0 TO NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Lung Lung 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP NNP O
Volume, Volume, 1 0 0 0 1 0 0 0 7 0 IN NNP NNP NNP CC O
Diffusion, Diffusion, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Resistance. Resistance. 1 0 0 0 0 0 0 0 11 0 NNP CC NNP NNP NNP O
Jarenbäck Jarenbäck 1 0 0 0 0 0 0 0 9 0 CC NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ankerst Ankerst 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Bjermer Bjermer 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tufvesson Tufvesson 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
E. E. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Clinical Clinical 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Respiratory Respiratory 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP CC O
Medicine Medicine 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Allergology, Allergology, 1 0 0 0 1 0 0 0 12 0 NNP CC NNP NNP NNP O
Lund Lund 1 0 0 0 0 0 0 0 4 0 CC NNP NNP NNP CD O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP CD CD O
221 221 0 0 0 0 0 0 1 1 3 0 NNP NNP CD CD JJ O
84 84 0 0 0 0 0 0 1 1 2 0 NNP CD CD JJ NNP O
Lund, Lund, 1 0 0 0 1 0 0 0 5 0 CD CD JJ NNP NNP O
Sweden. Sweden. 1 0 0 0 0 0 0 0 7 0 CD JJ NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP NNP IN O
Classification Classification 1 0 0 0 0 0 0 0 14 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP IN O
COPD COPD 1 1 0 0 0 0 0 0 4 0 NNP IN NNP IN JJ O
into into 0 0 0 0 0 0 0 0 4 0 IN NNP IN JJ NNP O
different different 0 0 0 0 0 0 0 0 9 0 NNP IN JJ NNP NNS O
GOLD GOLD 1 1 0 0 0 0 0 0 4 0 IN JJ NNP NNS VBZ O
stages stages 0 0 0 0 0 0 0 0 6 0 JJ NNP NNS VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNS VBZ VBN IN O
based based 0 0 0 0 0 0 0 0 5 0 NNS VBZ VBN IN VBN O
on on 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN VBN NN O
forced forced 0 0 0 0 0 0 0 0 6 0 VBN IN VBN NN NN O
expiratory expiratory 0 0 0 0 0 0 0 0 10 0 IN VBN NN NN IN O
volume volume 0 0 0 0 0 0 0 0 6 0 VBN NN NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN CD NNS O
1 1 0 0 0 0 0 0 1 1 1 0 NN IN CD NNS -NONE- O
s s 0 0 0 0 0 0 0 0 1 0 IN CD NNS -NONE- CC O
(FEV1) (FEV1) 0 1 0 0 0 0 0 1 6 0 CD NNS -NONE- CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC VBD JJ O
forced forced 0 0 0 0 0 0 0 0 6 0 -NONE- CC VBD JJ NN O
vital vital 0 0 0 0 0 0 0 0 5 0 CC VBD JJ NN NN O
capacity capacity 0 0 0 0 0 0 0 0 8 0 VBD JJ NN NN CC O
(FVC) (FVC) 0 1 0 0 0 0 0 0 5 0 JJ NN NN CC VBZ O
but but 0 0 0 0 0 0 0 0 3 0 NN NN CC VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NN CC VBZ VBN TO O
shown shown 0 0 0 0 0 0 0 0 5 0 CC VBZ VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ VBN TO VB IN O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 TO VB IN VBN NNP O
limited limited 0 0 0 0 0 0 0 0 7 0 VB IN VBN NNP NNP O
value. value. 0 0 0 0 0 0 0 0 6 0 IN VBN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 VBN NNP NNP NN IN O
aim aim 0 0 0 0 0 0 0 0 3 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 IN DT NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB NN O
relate relate 0 0 0 0 0 0 0 0 6 0 VBD TO VB NN NNS O
spirometry spirometry 0 0 0 0 0 0 0 0 10 0 TO VB NN NNS TO O
values values 0 0 0 0 0 0 0 0 6 0 VB NN NNS TO JJR O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO JJR JJ O
more more 0 0 0 0 0 0 0 0 4 0 NNS TO JJR JJ NNS O
advanced advanced 0 0 0 0 0 0 0 0 8 0 TO JJR JJ NNS IN O
measures measures 0 0 0 0 0 0 0 0 8 0 JJR JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
lung lung 0 0 0 0 0 0 0 0 4 0 NNS IN JJ NN IN O
function function 0 0 0 0 0 0 0 0 8 0 IN JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNS O
COPD COPD 1 1 0 0 0 0 0 0 4 0 NN IN NNP NNS VBN O
patients patients 0 0 0 0 0 0 0 0 8 0 IN NNP NNS VBN TO O
compared compared 0 0 0 0 0 0 0 0 8 0 NNP NNS VBN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBN TO JJ NNP O
healthy healthy 0 0 0 0 0 0 0 0 7 0 VBN TO JJ NNP NNP O
smokers. smokers. 0 0 0 0 0 0 0 0 8 0 TO JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN NN O
lung lung 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN IN O
function function 0 0 0 0 0 0 0 0 8 0 NNP NN NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN CD NNP O
65 65 0 0 0 0 0 0 1 1 2 0 NN IN CD NNP NNS O
COPD COPD 1 1 0 0 0 0 0 0 4 0 IN CD NNP NNS CC O
patients patients 0 0 0 0 0 0 0 0 8 0 CD NNP NNS CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNS CC CD JJ O
34 34 0 0 0 0 0 0 1 1 2 0 NNS CC CD JJ NNS O
healthy healthy 0 0 0 0 0 0 0 0 7 0 CC CD JJ NNS VBD O
smokers smokers 0 0 0 0 0 0 0 0 7 0 CD JJ NNS VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NNS VBD VBN VBG O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NNS VBD VBN VBG JJ O
using using 0 0 0 0 0 0 0 0 5 0 VBD VBN VBG JJ NN O
flow-volume flow-volume 0 0 1 0 0 0 0 0 11 0 VBN VBG JJ NN NN O
spirometry, spirometry, 0 0 0 0 1 0 0 0 11 0 VBG JJ NN NN NN O
body body 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NN O
plethysmography, plethysmography, 0 0 0 0 1 0 0 0 16 0 NN NN NN NN NN O
single single 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NN O
breath breath 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NN O
helium helium 0 0 0 0 0 0 0 0 6 0 NN NN NN NN IN O
dilution dilution 0 0 0 0 0 0 0 0 8 0 NN NN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ CC O
CO-diffusion, CO-diffusion, 1 0 1 0 1 0 0 0 13 0 NN IN JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC NN NNP O
impulse impulse 0 0 0 0 0 0 0 0 7 0 JJ CC NN NNP NNP O
oscillometry. oscillometry. 0 0 0 0 0 0 0 0 13 0 CC NN NNP NNP NN O
All All 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN NN O
lung lung 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN NN O
function function 0 0 0 0 0 0 0 0 8 0 NNP NN NN NN VBD O
parameters, parameters, 0 0 0 0 1 0 0 0 11 0 NN NN NN VBD IN O
measured measured 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN NN -NONE- O
body body 0 0 0 0 0 0 0 0 4 0 VBD IN NN -NONE- -NONE- O
plethysmography, plethysmography, 0 0 0 0 1 0 0 0 16 0 IN NN -NONE- -NONE- CC O
CO-diffusion, CO-diffusion, 1 0 1 0 1 0 0 0 13 0 NN -NONE- -NONE- CC VB O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- CC VB JJ O
impulse impulse 0 0 0 0 0 0 0 0 7 0 -NONE- CC VB JJ NN O
oscillometry, oscillometry, 0 0 0 0 1 0 0 0 13 0 CC VB JJ NN RB O
were were 0 0 0 0 0 0 0 0 4 0 VB JJ NN RB VBN O
increasingly increasingly 0 0 0 0 0 0 0 0 12 0 JJ NN RB VBN IN O
affected affected 0 0 0 0 0 0 0 0 8 0 NN RB VBN IN VBG O
through through 0 0 0 0 0 0 0 0 7 0 RB VBN IN VBG NNP O
increasing increasing 0 0 0 0 0 0 0 0 10 0 VBN IN VBG NNP NN O
GOLD GOLD 1 1 0 0 0 0 0 0 4 0 IN VBG NNP NN CC O
stage stage 0 0 0 0 0 0 0 0 5 0 VBG NNP NN CC VBD O
but but 0 0 0 0 0 0 0 0 3 0 NNP NN CC VBD RB O
did did 0 0 0 0 0 0 0 0 3 0 NN CC VBD RB VB O
not not 0 0 0 0 0 0 0 0 3 0 CC VBD RB VB IN O
correlate correlate 0 0 0 0 0 0 0 0 9 0 VBD RB VB IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 RB VB IN NNP IN O
FEV1 FEV1 1 1 0 0 0 0 0 1 4 0 VB IN NNP IN DT O
within within 0 0 0 0 0 0 0 0 6 0 IN NNP IN DT NNP O
any any 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP NNP O
GOLD GOLD 1 1 0 0 0 0 0 0 4 0 IN DT NNP NNP NNP O
stage. stage. 0 0 0 0 0 0 0 0 6 0 DT NNP NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP PRP O
contrast, contrast, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP PRP VBD O
they they 0 0 0 0 0 0 0 0 4 0 NNP NNP PRP VBD RB O
correlated correlated 0 0 0 0 0 0 0 0 10 0 NNP PRP VBD RB RB O
fairly fairly 0 0 0 0 0 0 0 0 6 0 PRP VBD RB RB IN O
well well 0 0 0 0 0 0 0 0 4 0 VBD RB RB IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 RB RB IN JJ NN O
FVC%p, FVC%p, 1 0 0 0 1 0 0 0 6 0 RB IN JJ NN CC O
FEV1/FVC, FEV1/FVC, 1 1 0 1 1 0 0 1 9 0 IN JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NNP O
inspiratory inspiratory 0 0 0 0 0 0 0 0 11 0 NN CC NN NNP NNP O
capacity. capacity. 0 0 0 0 0 0 0 0 9 0 CC NN NNP NNP NN O
Residual Residual 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NN -NONE- O
volume volume 0 0 0 0 0 0 0 0 6 0 NNP NNP NN -NONE- VBN O
(RV) (RV) 0 1 0 0 0 0 0 0 4 0 NNP NN -NONE- VBN IN O
measured measured 0 0 0 0 0 0 0 0 8 0 NN -NONE- VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 -NONE- VBN IN NN NN O
body body 0 0 0 0 0 0 0 0 4 0 VBN IN NN NN VBD O
plethysmography plethysmography 0 0 0 0 0 0 0 0 15 0 IN NN NN VBD IN O
increased increased 0 0 0 0 0 0 0 0 9 0 NN NN VBD IN NNP O
through through 0 0 0 0 0 0 0 0 7 0 NN VBD IN NNP NNP O
GOLD GOLD 1 1 0 0 0 0 0 0 4 0 VBD IN NNP NNP IN O
stages, stages, 0 0 0 0 1 0 0 0 7 0 IN NNP NNP IN NNP O
while while 0 0 0 0 0 0 0 0 5 0 NNP NNP IN NNP VBD O
RV RV 1 1 0 0 0 0 0 0 2 0 NNP IN NNP VBD IN O
measured measured 0 0 0 0 0 0 0 0 8 0 IN NNP VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNP VBD IN NN NN O
helium helium 0 0 0 0 0 0 0 0 6 0 VBD IN NN NN NNP O
dilution dilution 0 0 0 0 0 0 0 0 8 0 IN NN NN NNP NNP O
decreased. decreased. 0 0 0 0 0 0 0 0 10 0 NN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
difference difference 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN DT O
between between 0 0 0 0 0 0 0 0 7 0 NNP NN IN DT NNP O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT NNP VBD O
RV RV 1 1 0 0 0 0 0 0 2 0 IN DT NNP VBD JJ O
provided provided 0 0 0 0 0 0 0 0 8 0 DT NNP VBD JJ JJ O
valuable valuable 0 0 0 0 0 0 0 0 8 0 NNP VBD JJ JJ NN O
additional additional 0 0 0 0 0 0 0 0 10 0 VBD JJ JJ NN CC O
information information 0 0 0 0 0 0 0 0 11 0 JJ JJ NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBD IN O
correlated correlated 0 0 0 0 0 0 0 0 10 0 NN CC VBD IN JJS O
with with 0 0 0 0 0 0 0 0 4 0 CC VBD IN JJS JJ O
most most 0 0 0 0 0 0 0 0 4 0 VBD IN JJS JJ NN O
other other 0 0 0 0 0 0 0 0 5 0 IN JJS JJ NN NN O
lung lung 0 0 0 0 0 0 0 0 4 0 JJS JJ NN NN NNS O
function function 0 0 0 0 0 0 0 0 8 0 JJ NN NN NNS VBD O
parameters parameters 0 0 0 0 0 0 0 0 10 0 NN NN NNS VBD IN O
measured measured 0 0 0 0 0 0 0 0 8 0 NN NNS VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBD IN NN NN O
body body 0 0 0 0 0 0 0 0 4 0 VBD IN NN NN CC O
plethysmography plethysmography 0 0 0 0 0 0 0 0 15 0 IN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
CO-diffusion. CO-diffusion. 1 0 1 0 0 0 0 0 13 0 NN CC NNP NNP NN O
Airway Airway 1 0 0 0 0 0 0 0 6 0 CC NNP NNP NN VBD O
resistance resistance 0 0 0 0 0 0 0 0 10 0 NNP NNP NN VBD IN O
measured measured 0 0 0 0 0 0 0 0 8 0 NNP NN VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN NN NN O
body body 0 0 0 0 0 0 0 0 4 0 VBD IN NN NN CC O
plethysmography plethysmography 0 0 0 0 0 0 0 0 15 0 IN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
impulse impulse 0 0 0 0 0 0 0 0 7 0 NN CC NN NN VBD O
oscillometry oscillometry 0 0 0 0 0 0 0 0 12 0 CC NN NN VBD IN O
correlated correlated 0 0 0 0 0 0 0 0 10 0 NN NN VBD IN NNP O
within within 0 0 0 0 0 0 0 0 6 0 NN VBD IN NNP NNP O
COPD COPD 1 1 0 0 0 0 0 0 4 0 VBD IN NNP NNP NNP O
stages. stages. 0 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NN O
Different Different 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NN NN O
lung lung 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN NNS O
function function 0 0 0 0 0 0 0 0 8 0 NNP NN NN NNS VBP O
parameters parameters 0 0 0 0 0 0 0 0 10 0 NN NN NNS VBP IN O
are are 0 0 0 0 0 0 0 0 3 0 NN NNS VBP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNS VBP IN NN IN O
importance importance 0 0 0 0 0 0 0 0 10 0 VBP IN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP CC O
COPD, COPD, 1 1 0 0 1 0 0 0 5 0 NN IN NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP CC DT JJ NN O
thorough thorough 0 0 0 0 0 0 0 0 8 0 CC DT JJ NN NN O
patient patient 0 0 0 0 0 0 0 0 7 0 DT JJ NN NN VBZ O
characterization characterization 0 0 0 0 0 0 0 0 16 0 JJ NN NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ JJ TO O
important important 0 0 0 0 0 0 0 0 9 0 NN VBZ JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO VB DT O
understand understand 0 0 0 0 0 0 0 0 10 0 JJ TO VB DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NNP NONE O
disease. disease. 0 0 0 0 0 0 0 0 8 0 VB DT NNP NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NN NN O
power power 0 0 0 0 0 0 0 0 5 0 NONE DT NN NN IN O
combination combination 0 0 0 0 0 0 0 0 11 0 DT NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNS O
blood-pressure blood-pressure 0 0 1 0 0 0 0 0 14 0 NN IN JJ NNS TO O
parameters parameters 0 0 0 0 0 0 0 0 10 0 IN JJ NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO VB DT O
predict predict 0 0 0 0 0 0 0 0 7 0 NNS TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
incidence incidence 0 0 0 0 0 0 0 0 9 0 VB DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
plaque plaque 0 0 0 0 0 0 0 0 6 0 NN IN NN NN IN O
formation formation 0 0 0 0 0 0 0 0 9 0 IN NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NNS O
carotid carotid 0 0 0 0 0 0 0 0 7 0 NN IN NN NNS IN O
arteries arteries 0 0 0 0 0 0 0 0 8 0 IN NN NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP NNP O
elderly. elderly. 0 0 0 0 0 0 0 0 8 0 NNS IN NNP NNP NNP O
Hao Hao 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
CN, CN, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Shi Shi 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
YQ, YQ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Huang Huang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
JJ, JJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
HY, HY, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Huang Huang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
ZH, ZH, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Cheng Cheng 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
XW, XW, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Lu Lu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
W, W, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Duan Duan 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
JL. JL. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
gerontology, gerontology, 0 0 0 0 1 0 0 0 12 0 NNP IN NNP NNP NNP O
Xinhua Xinhua 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
hospital, hospital, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Shanghai Shanghai 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Jiaotong Jiaotong 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Kongjiang Kongjiang 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP CD O
Road Road 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP CD NNP O
1665, 1665, 0 0 0 0 1 0 0 1 5 0 NNP NNP CD NNP CD O
Shanghai Shanghai 1 0 0 0 0 0 0 0 8 0 NNP CD NNP CD NNP O
200092, 200092, 0 0 0 0 1 0 0 1 7 0 CD NNP CD NNP : O
China China 1 0 0 0 0 0 0 0 5 0 NNP CD NNP : NNP O
; ; 0 0 0 0 0 0 0 0 1 0 CD NNP : NNP CC O
Cardiology Cardiology 1 0 0 0 0 0 0 0 10 0 NNP : NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 : NNP CC NNP NNP O
nephrology, nephrology, 0 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP NNP O
Nagoya Nagoya 1 0 0 0 0 0 0 0 6 0 CC NNP NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Graduate Graduate 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CD O
Medicine Medicine 1 0 0 0 0 0 0 0 8 0 NNP IN NNP CD -NONE- O
65 65 0 0 0 0 0 0 1 1 2 0 IN NNP CD -NONE- JJ O
Tsuruma-cho, Tsuruma-cho, 1 0 1 0 1 0 0 0 12 0 NNP CD -NONE- JJ NNP O
Showa-ku, Showa-ku, 1 0 1 0 1 0 0 0 9 0 CD -NONE- JJ NNP CD O
Nagoya Nagoya 1 0 0 0 0 0 0 0 6 0 -NONE- JJ NNP CD NNP O
466-8550, 466-8550, 0 0 1 0 1 0 0 1 9 0 JJ NNP CD NNP NNP O
Japan. Japan. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP VBZ O
Hypertension Hypertension 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN RB O
considered considered 0 0 0 0 0 0 0 0 10 0 NNP VBZ VBN RB CD O
as as 0 0 0 0 0 0 0 0 2 0 VBZ VBN RB CD IN O
one one 0 0 0 0 0 0 0 0 3 0 VBN RB CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 RB CD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT JJ NN O
major major 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN NNS O
risk risk 0 0 0 0 0 0 0 0 4 0 DT JJ NN NNS IN O
factors factors 0 0 0 0 0 0 0 0 7 0 JJ NN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ RB O
atherosclerosis, atherosclerosis, 0 0 0 0 1 0 0 0 16 0 NNS IN JJ RB IN O
especially especially 0 0 0 0 0 0 0 0 10 0 IN JJ RB IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ RB IN JJ NN O
carotid carotid 0 0 0 0 0 0 0 0 7 0 RB IN JJ NN NN O
artery artery 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN WDT O
plaque, plaque, 0 0 0 0 1 0 0 0 7 0 JJ NN NN WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN WDT VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 WDT VBZ DT NN IN O
sign sign 0 0 0 0 0 0 0 0 4 0 VBZ DT NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN JJ NN O
cardiovascular cardiovascular 0 0 0 0 0 0 0 0 14 0 NN IN JJ NN CC O
incapacity incapacity 0 0 0 0 0 0 0 0 10 0 IN JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NNP O
cerebral cerebral 0 0 0 0 0 0 0 0 8 0 NN CC JJ NNP NNP O
infarction. infarction. 0 0 0 0 0 0 0 0 11 0 CC JJ NNP NNP NN O
As As 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NN -NONE- O
adult adult 0 0 0 0 0 0 0 0 5 0 NNP NNP NN -NONE- JJ O
age, age, 0 0 0 0 1 0 0 0 4 0 NNP NN -NONE- JJ NN O
systolic systolic 0 0 0 0 0 0 0 0 8 0 NN -NONE- JJ NN NN O
blood blood 0 0 0 0 0 0 0 0 5 0 -NONE- JJ NN NN NN O
pressure pressure 0 0 0 0 0 0 0 0 8 0 JJ NN NN NN CC O
(SBP (SBP 0 1 0 0 0 0 0 0 4 0 NN NN NN CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 NN NN CC JJ NNS O
S) S) 1 1 0 0 0 0 0 0 2 0 NN CC JJ NNS TO O
tends tends 0 0 0 0 0 0 0 0 5 0 CC JJ NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO VB CC O
rise rise 0 0 0 0 0 0 0 0 4 0 NNS TO VB CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 TO VB CC JJ NN O
diastolic diastolic 0 0 0 0 0 0 0 0 9 0 VB CC JJ NN NN O
blood blood 0 0 0 0 0 0 0 0 5 0 CC JJ NN NN NN O
pressure pressure 0 0 0 0 0 0 0 0 8 0 JJ NN NN NN CC O
(DBP (DBP 0 1 0 0 0 0 0 0 4 0 NN NN NN CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 NN NN CC JJ NNS O
D) D) 1 1 0 0 0 0 0 0 2 0 NN CC JJ NNS TO O
tends tends 0 0 0 0 0 0 0 0 5 0 CC JJ NNS TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO NNP RB O
fall, fall, 0 0 0 0 1 0 0 0 5 0 NNS TO NNP RB DT O
thus thus 0 0 0 0 0 0 0 0 4 0 TO NNP RB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP RB DT NN NN O
pulse pulse 0 0 0 0 0 0 0 0 5 0 RB DT NN NN NN O
pressure pressure 0 0 0 0 0 0 0 0 8 0 DT NN NN NN MD O
(PP) (PP) 0 1 0 0 0 0 0 0 4 0 NN NN NN MD NNP O
will will 0 0 0 0 0 0 0 0 4 0 NN NN MD NNP NNP O
increase. increase. 0 0 0 0 0 0 0 0 9 0 NN MD NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 MD NNP NNP NN NN O
vascular vascular 0 0 0 0 0 0 0 0 8 0 NNP NNP NN NN VBD O
injury injury 0 0 0 0 0 0 0 0 6 0 NNP NN NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD RB JJ O
directly directly 0 0 0 0 0 0 0 0 8 0 NN VBD RB JJ TO O
proportional proportional 0 0 0 0 0 0 0 0 12 0 VBD RB JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 RB JJ TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ TO DT NN IN O
level level 0 0 0 0 0 0 0 0 5 0 TO DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP CC O
SBP, SBP, 1 1 0 0 1 0 0 0 4 0 NN IN NNP CC RB O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC RB JJ O
inversely inversely 0 0 0 0 0 0 0 0 9 0 NNP CC RB JJ TO O
proportional proportional 0 0 0 0 0 0 0 0 12 0 CC RB JJ TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 RB JJ TO NNP CC O
DBP. DBP. 1 1 0 0 0 0 0 0 4 0 JJ TO NNP CC RB O
But But 1 0 0 0 0 0 0 0 3 0 TO NNP CC RB JJ O
so so 0 0 0 0 0 0 0 0 2 0 NNP CC RB JJ NNS O
far, far, 0 0 0 0 1 0 0 0 4 0 CC RB JJ NNS IN O
studies studies 0 0 0 0 0 0 0 0 7 0 RB JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
vascular vascular 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN VBN O
injury injury 0 0 0 0 0 0 0 0 6 0 DT JJ NN VBN IN O
based based 0 0 0 0 0 0 0 0 5 0 JJ NN VBN IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NN VBN IN NNP CC O
SBP SBP 1 1 0 0 0 0 0 0 3 0 VBN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NN O
DBP DBP 1 1 0 0 0 0 0 0 3 0 NNP CC NNP NN VBD O
measurement measurement 0 0 0 0 0 0 0 0 11 0 CC NNP NN VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NNP NN VBD RB NNP O
mostly mostly 0 0 0 0 0 0 0 0 6 0 NN VBD RB NNP NNP O
qualitative. qualitative. 0 0 0 0 0 0 0 0 12 0 VBD RB NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 RB NNP NNP NN NN O
exact exact 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NN IN O
contribution contribution 0 0 0 0 0 0 0 0 12 0 NNP NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
each each 0 0 0 0 0 0 0 0 4 0 NN IN DT NN TO O
parameter parameter 0 0 0 0 0 0 0 0 9 0 IN DT NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT JJ NN O
vascular vascular 0 0 0 0 0 0 0 0 8 0 TO DT JJ NN VBZ O
injury injury 0 0 0 0 0 0 0 0 6 0 DT JJ NN VBZ RB O
has has 0 0 0 0 0 0 0 0 3 0 JJ NN VBZ RB VBN O
not not 0 0 0 0 0 0 0 0 3 0 NN VBZ RB VBN RB O
been been 0 0 0 0 0 0 0 0 4 0 VBZ RB VBN RB NNP O
quantitatively quantitatively 0 0 0 0 0 0 0 0 14 0 RB VBN RB NNP NNP O
identified. identified. 0 0 0 0 0 0 0 0 11 0 VBN RB NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 RB NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 NNP DT NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBD DT O
employed employed 0 0 0 0 0 0 0 0 8 0 NN PRP VBD DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 PRP VBD DT JJ NN O
mathematical mathematical 0 0 0 0 0 0 0 0 12 0 VBD DT JJ NN TO O
model model 0 0 0 0 0 0 0 0 5 0 DT JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB DT O
predict predict 0 0 0 0 0 0 0 0 7 0 NN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
risk risk 0 0 0 0 0 0 0 0 4 0 VB DT NN IN NNS O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN NNS IN O
plaques plaques 0 0 0 0 0 0 0 0 7 0 NN IN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN JJ NNS O
carotid carotid 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NNS IN O
arteries arteries 0 0 0 0 0 0 0 0 8 0 IN JJ NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NNS O
aged aged 0 0 0 0 0 0 0 0 4 0 NNS IN JJ NNS CC O
people people 0 0 0 0 0 0 0 0 6 0 IN JJ NNS CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC VBD DT O
combined combined 0 0 0 0 0 0 0 0 8 0 NNS CC VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC VBD DT NN NNP O
SBP, SBP, 1 1 0 0 1 0 0 0 4 0 VBD DT NN NNP CC O
DBP DBP 1 1 0 0 0 0 0 0 3 0 DT NN NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NN NN O
heart heart 0 0 0 0 0 0 0 0 5 0 NNP CC NN NN NN O
rate rate 0 0 0 0 0 0 0 0 4 0 CC NN NN NN TO O
(HR) (HR) 0 1 0 0 0 0 0 0 4 0 NN NN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO VB DT O
perform perform 0 0 0 0 0 0 0 0 7 0 NN TO VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT JJ NNP O
quantitative quantitative 0 0 0 0 0 0 0 0 12 0 VB DT JJ NNP NNP O
analysis. analysis. 0 0 0 0 0 0 0 0 9 0 DT JJ NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP VBD CD O
analyzed analyzed 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD CD NNS O
1672 1672 0 0 0 0 0 0 1 1 4 0 NNP VBD CD NNS WP O
males males 0 0 0 0 0 0 0 0 5 0 VBD CD NNS WP VBD O
who who 0 0 0 0 0 0 0 0 3 0 CD NNS WP VBD IN O
were were 0 0 0 0 0 0 0 0 4 0 NNS WP VBD IN JJ O
over over 0 0 0 0 0 0 0 0 4 0 WP VBD IN JJ CC O
60-year-old 60-year-old 0 0 1 0 0 0 0 1 11 0 VBD IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ JJ O
hospitalized hospitalized 0 0 0 0 0 0 0 0 12 0 JJ CC JJ JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 CC JJ JJ TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 JJ JJ TO JJ NNS O
atherosclerosis-related atherosclerosis-related 0 0 1 0 0 0 0 0 23 0 JJ TO JJ NNS CC O
diseases diseases 0 0 0 0 0 0 0 0 8 0 TO JJ NNS CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC VBD DT O
received received 0 0 0 0 0 0 0 0 8 0 NNS CC VBD DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 CC VBD DT JJ JJ O
24-h 24-h 0 0 1 0 0 0 0 1 4 0 VBD DT JJ JJ NN O
arterial arterial 0 0 0 0 0 0 0 0 8 0 DT JJ JJ NN NN O
blood blood 0 0 0 0 0 0 0 0 5 0 JJ JJ NN NN VBG O
pressure pressure 0 0 0 0 0 0 0 0 8 0 JJ NN NN VBG NN O
monitoring monitoring 0 0 0 0 0 0 0 0 10 0 NN NN VBG NN NNP O
(ABPM) (ABPM) 0 1 0 0 0 0 0 0 6 0 NN VBG NN NNP NNP O
examination. examination. 0 0 0 0 0 0 0 0 12 0 VBG NN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNS VBD O
patients patients 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD VBN IN O
divided divided 0 0 0 0 0 0 0 0 7 0 NNS VBD VBN IN CD O
into into 0 0 0 0 0 0 0 0 4 0 VBD VBN IN CD NNS O
19 19 0 0 0 0 0 0 1 1 2 0 VBN IN CD NNS VBG O
subgroups subgroups 0 0 0 0 0 0 0 0 9 0 IN CD NNS VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 CD NNS VBG DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBG DT NNP NNP O
ABPM ABPM 1 1 0 0 0 0 0 0 4 0 VBG DT NNP NNP CD O
data, data, 0 0 0 0 1 0 0 0 5 0 DT NNP NNP CD JJ O
24-h 24-h 0 0 1 0 0 0 0 1 4 0 NNP NNP CD JJ NN O
average average 0 0 0 0 0 0 0 0 7 0 NNP CD JJ NN NNP O
SBP, SBP, 1 1 0 0 1 0 0 0 4 0 CD JJ NN NNP CC O
DBP DBP 1 1 0 0 0 0 0 0 3 0 JJ NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP IN O
HR HR 1 1 0 0 0 0 0 0 2 0 NNP CC NNP IN NNS O
as as 0 0 0 0 0 0 0 0 2 0 CC NNP IN NNS VBN O
variables variables 0 0 0 0 0 0 0 0 9 0 NNP IN NNS VBN IN O
based based 0 0 0 0 0 0 0 0 5 0 IN NNS VBN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NNS VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NN O
ascending ascending 0 0 0 0 0 0 0 0 9 0 IN DT NN NN IN O
order order 0 0 0 0 0 0 0 0 5 0 DT NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
magnitude magnitude 0 0 0 0 0 0 0 0 9 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
each each 0 0 0 0 0 0 0 0 4 0 NN IN DT NNP NNP O
element. element. 0 0 0 0 0 0 0 0 8 0 IN DT NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 DT NNP NNP VBD DT O
developed developed 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBD DT JJ NN O
new new 0 0 0 0 0 0 0 0 3 0 VBD DT JJ NN RB O
index, index, 0 0 0 0 1 0 0 0 6 0 DT JJ NN RB DT O
namely namely 0 0 0 0 0 0 0 0 6 0 JJ NN RB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN RB DT JJ NN O
dynamic dynamic 0 0 0 0 0 0 0 0 7 0 RB DT JJ NN NN O
level level 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN WDT O
(DL) (DL) 0 1 0 0 0 0 0 0 4 0 JJ NN NN WDT VBN O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBN JJS O
correlated correlated 0 0 0 0 0 0 0 0 10 0 NN WDT VBN JJS IN O
best best 0 0 0 0 0 0 0 0 4 0 WDT VBN JJS IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBN JJS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJS IN DT NN NN O
plaque plaque 0 0 0 0 0 0 0 0 6 0 IN DT NN NN IN O
formation formation 0 0 0 0 0 0 0 0 9 0 DT NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNS O
carotid carotid 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNS IN O
arteries arteries 0 0 0 0 0 0 0 0 8 0 IN JJ NNS IN DT O
among among 0 0 0 0 0 0 0 0 5 0 JJ NNS IN DT DT O
all all 0 0 0 0 0 0 0 0 3 0 NNS IN DT DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 IN DT DT JJ NNS O
well-established well-established 0 0 1 0 0 0 0 0 16 0 DT DT JJ NNS IN O
indexes indexes 0 0 0 0 0 0 0 0 7 0 DT JJ NNS IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN NN NNP O
blood blood 0 0 0 0 0 0 0 0 5 0 NNS IN NN NNP NNP O
pressure. pressure. 0 0 0 0 0 0 0 0 9 0 IN NN NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBD IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 NNP NNP VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBD IN NN NNP O
index index 0 0 0 0 0 0 0 0 5 0 VBD IN NN NNP VBZ O
DL DL 1 1 0 0 0 0 0 0 2 0 IN NN NNP VBZ JJR O
has has 0 0 0 0 0 0 0 0 3 0 NN NNP VBZ JJR NN O
better better 0 0 0 0 0 0 0 0 6 0 NNP VBZ JJR NN TO O
correlation correlation 0 0 0 0 0 0 0 0 11 0 VBZ JJR NN TO NNS O
to to 0 0 0 0 0 0 0 0 2 0 JJR NN TO NNS NN O
plaques plaques 0 0 0 0 0 0 0 0 7 0 NN TO NNS NN NN O
incidence incidence 0 0 0 0 0 0 0 0 9 0 TO NNS NN NN NN O
tendency tendency 0 0 0 0 0 0 0 0 8 0 NNS NN NN NN : O
(p (p 0 0 0 0 0 0 0 0 2 0 NN NN NN : CD O
< < 0 0 0 0 0 0 0 0 1 0 NN NN : CD WRB O
0.0001) 0.0001) 0 0 0 0 0 0 0 1 7 0 NN : CD WRB VBN O
when when 0 0 0 0 0 0 0 0 4 0 : CD WRB VBN TO O
compared compared 0 0 0 0 0 0 0 0 8 0 CD WRB VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 WRB VBN TO DT NNP O
either either 0 0 0 0 0 0 0 0 6 0 VBN TO DT NNP NNP O
SBP SBP 1 1 0 0 0 0 0 0 3 0 TO DT NNP NNP NNP O
(P (P 0 1 0 0 0 0 0 0 2 0 DT NNP NNP NNP CD O
< < 0 0 0 0 0 0 0 0 1 0 NNP NNP NNP CD CC O
0.05) 0.05) 0 0 0 0 0 0 0 1 5 0 NNP NNP CD CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 NNP CD CC NNP NNP O
PP PP 1 1 0 0 0 0 0 0 2 0 CD CC NNP NNP NNP O
(P (P 0 1 0 0 0 0 0 0 2 0 CC NNP NNP NNP CD O
< < 0 0 0 0 0 0 0 0 1 0 NNP NNP NNP CD NNP O
0.001) 0.001) 0 0 0 0 0 0 0 1 6 0 NNP NNP CD NNP NNP O
alone. alone. 0 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 CD NNP NNP NN IN O
risk risk 0 0 0 0 0 0 0 0 4 0 NNP NNP NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN IN O
incidence incidence 0 0 0 0 0 0 0 0 9 0 NN IN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS IN O
plaques plaques 0 0 0 0 0 0 0 0 7 0 IN DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NNS O
carotid carotid 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NNS VBZ O
arteries arteries 0 0 0 0 0 0 0 0 8 0 IN JJ NNS VBZ JJ O
has has 0 0 0 0 0 0 0 0 3 0 JJ NNS VBZ JJ NN O
positive positive 0 0 0 0 0 0 0 0 8 0 NNS VBZ JJ NN IN O
correlation correlation 0 0 0 0 0 0 0 0 11 0 VBZ JJ NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN IN O
power power 0 0 0 0 0 0 0 0 5 0 IN JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP CC O
SBP SBP 1 1 0 0 0 0 0 0 3 0 NN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NN O
-0.8 -0.8 0 0 1 0 0 0 0 1 4 0 NNP CC NNP NN IN O
power power 0 0 0 0 0 0 0 0 5 0 CC NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NNP O
DBP. DBP. 1 1 0 0 0 0 0 0 4 0 NN IN NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NN MD O
model model 0 0 0 0 0 0 0 0 5 0 NNP NNP NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NNP NN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB VBN RB O
used used 0 0 0 0 0 0 0 0 4 0 MD VB VBN RB TO O
clinically clinically 0 0 0 0 0 0 0 0 10 0 VB VBN RB TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN RB TO VB DT O
predict predict 0 0 0 0 0 0 0 0 7 0 RB TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
occurrence occurrence 0 0 0 0 0 0 0 0 10 0 VB DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNP O
plaque plaque 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP NONE O
formation. formation. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NONE NONE O
Incidence Incidence 1 0 0 0 0 0 0 0 9 0 NONE NONE NN NN IN O
Survey Survey 1 0 0 0 0 0 0 0 6 0 NONE NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
Acute Acute 1 0 0 0 0 0 0 0 5 0 NN IN NNP NNP NNP O
Otitis Otitis 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP IN O
Media Media 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP IN O
Children Children 1 0 0 0 0 0 0 0 8 0 NNP IN NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NNP O
Sado Sado 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP NNP O
Island, Island, 1 0 0 0 1 0 0 0 7 0 IN NNP NNP NNP NNP O
Japan-Sado Japan-Sado 1 0 1 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Otitis Otitis 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Media Media 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Study Study 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
(SADOMS). (SADOMS). 0 1 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Otsuka Otsuka 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kitami Kitami 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
O, O, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kondo Kondo 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ota Ota 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Oshima Oshima 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tsuchiya Tsuchiya 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Shirai Shirai 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Fujii Fujii 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Nakamure Nakamure 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Shoji Shoji 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Nakamura Nakamura 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Masuda Masuda 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Komiyama Komiyama 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yoshida Yoshida 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ishikawa Ishikawa 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Iwaya Iwaya 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Takahashi Takahashi 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Okazaki Okazaki 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hotomi Hotomi 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yamanaka Yamanaka 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
N. N. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pediatrics, Pediatrics, 1 0 0 0 1 0 0 0 11 0 NNP IN NNP NNP NNP O
Sado Sado 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNP O
General General 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Hospital, Hospital, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Sado, Sado, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
Niigata, Niigata, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Japan. Japan. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP VBZ O
Acute Acute 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP VBZ NNS O
otitis otitis 0 0 0 0 0 0 0 0 6 0 NNP NNP VBZ NNS -NONE- O
media media 0 0 0 0 0 0 0 0 5 0 NNP VBZ NNS -NONE- VBZ O
(AOM) (AOM) 0 1 0 0 0 0 0 0 5 0 VBZ NNS -NONE- VBZ CD O
is is 0 0 0 0 0 0 0 0 2 0 NNS -NONE- VBZ CD IN O
one one 0 0 0 0 0 0 0 0 3 0 -NONE- VBZ CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBZ CD IN DT RBS O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT RBS JJ O
most most 0 0 0 0 0 0 0 0 4 0 IN DT RBS JJ NNS O
common common 0 0 0 0 0 0 0 0 6 0 DT RBS JJ NNS IN O
forms forms 0 0 0 0 0 0 0 0 5 0 RBS JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
bacterial bacterial 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NN CC O
infection infection 0 0 0 0 0 0 0 0 9 0 IN JJ NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VB IN O
cause cause 0 0 0 0 0 0 0 0 5 0 NN CC VB IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 CC VB IN JJ NNS O
clinic clinic 0 0 0 0 0 0 0 0 6 0 VB IN JJ NNS IN O
visits visits 0 0 0 0 0 0 0 0 6 0 IN JJ NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NNP O
children. children. 0 0 0 0 0 0 0 0 9 0 NNS IN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NN IN O
incidence incidence 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP VBD O
AOM AOM 1 1 0 0 0 0 0 0 3 0 NN IN NNP VBD CD O
was was 0 0 0 0 0 0 0 0 3 0 IN NNP VBD CD NNS O
0.9-1.2 0.9-1.2 0 0 1 0 0 0 0 1 7 0 NNP VBD CD NNS IN O
episodes episodes 0 0 0 0 0 0 0 0 8 0 VBD CD NNS IN JJ O
per per 0 0 0 0 0 0 0 0 3 0 CD NNS IN JJ IN O
person-year person-year 0 0 1 0 0 0 0 0 11 0 NNS IN JJ IN DT O
during during 0 0 0 0 0 0 0 0 6 0 IN JJ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT JJ CD O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ CD NNS O
2 2 0 0 0 0 0 0 1 1 1 0 DT JJ CD NNS IN O
years years 0 0 0 0 0 0 0 0 5 0 JJ CD NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN NN IN O
life life 0 0 0 0 0 0 0 0 4 0 NNS IN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NNS O
previous previous 0 0 0 0 0 0 0 0 8 0 NN IN JJ NNS VBN O
reports reports 0 0 0 0 0 0 0 0 7 0 IN JJ NNS VBN IN O
conducted conducted 0 0 0 0 0 0 0 0 9 0 JJ NNS VBN IN CD O
before before 0 0 0 0 0 0 0 0 6 0 NNS VBN IN CD DT O
2000. 2000. 0 0 0 0 0 0 0 1 5 0 VBN IN CD DT NN O
The The 1 0 0 0 0 0 0 0 3 0 IN CD DT NN IN O
aim aim 0 0 0 0 0 0 0 0 3 0 CD DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 IN DT NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO CD NN O
1) 1) 0 0 0 0 0 0 0 1 2 0 VBD TO CD NN DT O
evaluate evaluate 0 0 0 0 0 0 0 0 8 0 TO CD NN DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 CD NN DT JJS NNP O
latest latest 0 0 0 0 0 0 0 0 6 0 NN DT JJS NNP NN O
AOM AOM 1 1 0 0 0 0 0 0 3 0 DT JJS NNP NN IN O
incidence incidence 0 0 0 0 0 0 0 0 9 0 JJS NNP NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NNS O
pediatric pediatric 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNS CC O
outpatients outpatients 0 0 0 0 0 0 0 0 11 0 IN JJ NNS CC CD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC CD NN O
2) 2) 0 0 0 0 0 0 0 1 2 0 NNS CC CD NN DT O
identify identify 0 0 0 0 0 0 0 0 8 0 CC CD NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CD NN DT JJ NNS O
bacterial bacterial 0 0 0 0 0 0 0 0 9 0 NN DT JJ NNS IN O
pathogens pathogens 0 0 0 0 0 0 0 0 9 0 DT JJ NNS IN DT O
from from 0 0 0 0 0 0 0 0 4 0 JJ NNS IN DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNS IN DT NNS CC O
patients patients 0 0 0 0 0 0 0 0 8 0 IN DT NNS CC VB O
and and 0 0 0 0 0 0 0 0 3 0 DT NNS CC VB PRP$ O
ascertain ascertain 0 0 0 0 0 0 0 0 9 0 NNS CC VB PRP$ NNS O
their their 0 0 0 0 0 0 0 0 5 0 CC VB PRP$ NNS CC O
serotypes serotypes 0 0 0 0 0 0 0 0 9 0 VB PRP$ NNS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 PRP$ NNS CC NNP NNP O
resistance. resistance. 0 0 0 0 0 0 0 0 11 0 NNS CC NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 CC NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
conducted conducted 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT VBN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT VBN -NONE- O
closed closed 0 0 0 0 0 0 0 0 6 0 IN DT VBN -NONE- VBG O
population, population, 0 0 0 0 1 0 0 0 11 0 DT VBN -NONE- VBG DT O
involving involving 0 0 0 0 0 0 0 0 9 0 VBN -NONE- VBG DT NNS O
all all 0 0 0 0 0 0 0 0 3 0 -NONE- VBG DT NNS CC O
pediatricians pediatricians 0 0 0 0 0 0 0 0 13 0 VBG DT NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 DT NNS CC NNS IN O
otolaryngologists otolaryngologists 0 0 0 0 0 0 0 0 17 0 NNS CC NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CC NNS IN NNP NNP O
Sado Sado 1 0 0 0 0 0 0 0 4 0 NNS IN NNP NNP NN O
Island Island 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NN NN O
allowing allowing 0 0 0 0 0 0 0 0 8 0 NNP NNP NN NN NN O
accurate accurate 0 0 0 0 0 0 0 0 8 0 NNP NN NN NN IN O
determination determination 0 0 0 0 0 0 0 0 13 0 NN NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
AOM AOM 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNP NNP O
incidence. incidence. 0 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP DT NN O
each each 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN CD O
month, month, 0 0 0 0 1 0 0 0 6 0 NNP DT NN CD NN O
one one 0 0 0 0 0 0 0 0 3 0 DT NN CD NN VBD O
week week 0 0 0 0 0 0 0 0 4 0 NN CD NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 CD NN VBD VBN IN O
assigned assigned 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NN O
"surveillance "surveillance 0 0 0 0 0 0 0 0 13 0 VBN IN JJ NN CC O
week", week", 0 0 0 0 1 0 0 0 6 0 IN JJ NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT NNS O
all all 0 0 0 0 0 0 0 0 3 0 NN CC DT NNS IN O
outpatients outpatients 0 0 0 0 0 0 0 0 11 0 CC DT NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 DT NNS IN JJ NN O
acute acute 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NN VBD O
illness illness 0 0 0 0 0 0 0 0 7 0 IN JJ NN VBD CD O
aged aged 0 0 0 0 0 0 0 0 4 0 JJ NN VBD CD NNS O
0-18 0-18 0 0 1 0 0 0 0 1 4 0 NN VBD CD NNS VBN O
years years 0 0 0 0 0 0 0 0 5 0 VBD CD NNS VBN IN O
examined examined 0 0 0 0 0 0 0 0 8 0 CD NNS VBN IN DT O
during during 0 0 0 0 0 0 0 0 6 0 NNS VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NNS O
surveillance surveillance 0 0 0 0 0 0 0 0 12 0 IN DT NN NNS VBD O
weeks weeks 0 0 0 0 0 0 0 0 5 0 DT NN NNS VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD NNP NNP O
enrolled. enrolled. 0 0 0 0 0 0 0 0 9 0 NNS VBD NNP NNP VBD O
AOM AOM 1 1 0 0 0 0 0 0 3 0 VBD NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
diagnosed diagnosed 0 0 0 0 0 0 0 0 9 0 NNP VBD VBN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
basis basis 0 0 0 0 0 0 0 0 5 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
otoscopic otoscopic 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNS CC O
findings findings 0 0 0 0 0 0 0 0 8 0 IN JJ NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC JJ NNS O
clinical clinical 0 0 0 0 0 0 0 0 8 0 NNS CC JJ NNS VBD O
symptoms symptoms 0 0 0 0 0 0 0 0 8 0 CC JJ NNS VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD NNP NNP O
recorded. recorded. 0 0 0 0 0 0 0 0 9 0 NNS VBD NNP NNP VBD O
Specimens Specimens 1 0 0 0 0 0 0 0 9 0 VBD NNP NNP VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD VBN IN O
collected collected 0 0 0 0 0 0 0 0 9 0 NNP VBD VBN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN CC O
nasopharynx nasopharynx 0 0 0 0 0 0 0 0 11 0 IN DT NN CC VB O
or or 0 0 0 0 0 0 0 0 2 0 DT NN CC VB JJ O
middle middle 0 0 0 0 0 0 0 0 6 0 NN CC VB JJ NN O
ear ear 0 0 0 0 0 0 0 0 3 0 CC VB JJ NN IN O
cavity cavity 0 0 0 0 0 0 0 0 6 0 VB JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNS O
AOM AOM 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNS CC O
patients patients 0 0 0 0 0 0 0 0 8 0 IN NNP NNS CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNS CC VBD IN O
examined examined 0 0 0 0 0 0 0 0 8 0 NNS CC VBD IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 CC VBD IN NNP NNP O
bacteria. bacteria. 0 0 0 0 0 0 0 0 9 0 VBD IN NNP NNP NNP O
Antimicrobial Antimicrobial 1 0 0 0 0 0 0 0 13 0 IN NNP NNP NNP NNP O
susceptibilities, susceptibilities, 0 0 0 0 1 0 0 0 17 0 NNP NNP NNP NNP CC O
serotypes, serotypes, 0 0 0 0 1 0 0 0 10 0 NNP NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 NNP CC JJ NN IN O
typing typing 0 0 0 0 0 0 0 0 6 0 CC JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN VBD O
resistance resistance 0 0 0 0 0 0 0 0 10 0 NN IN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 IN NN VBD VBN IN O
determined determined 0 0 0 0 0 0 0 0 10 0 NN VBD VBN IN NNP O
among among 0 0 0 0 0 0 0 0 5 0 VBD VBN IN NNP NN O
Streptococcus Streptococcus 1 0 0 0 0 0 0 0 13 0 VBN IN NNP NN CC O
pneumoniae pneumoniae 0 0 0 0 0 0 0 0 10 0 IN NNP NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NNP NNP O
Haemophilus Haemophilus 1 0 0 0 0 0 0 0 11 0 NN CC NNP NNP NNP O
influenzae. influenzae. 0 0 0 0 0 0 0 0 11 0 CC NNP NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP CD O
total, total, 0 0 0 0 1 0 0 0 6 0 NNP NNP NNP CD JJ O
8,283 8,283 0 0 0 0 1 0 0 1 5 0 NNP NNP CD JJ NNS O
clinic clinic 0 0 0 0 0 0 0 0 6 0 NNP CD JJ NNS VBD O
visits visits 0 0 0 0 0 0 0 0 6 0 CD JJ NNS VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD JJ CC O
conducted, conducted, 0 0 0 0 1 0 0 0 10 0 NNS VBD JJ CC CD O
and and 0 0 0 0 0 0 0 0 3 0 VBD JJ CC CD NNS O
354 354 0 0 0 0 0 0 1 1 3 0 JJ CC CD NNS -NONE- O
episodes episodes 0 0 0 0 0 0 0 0 8 0 CC CD NNS -NONE- CD O
(4.3%, (4.3%, 0 0 0 0 1 0 0 1 6 0 CD NNS -NONE- CD -NONE- O
95% 95% 0 0 0 0 0 0 0 1 3 0 NNS -NONE- CD -NONE- CD O
CI: CI: 1 1 0 0 0 0 0 0 3 0 -NONE- CD -NONE- CD IN O
3.9-4.7%) 3.9-4.7%) 0 0 1 0 0 0 0 1 9 0 CD -NONE- CD IN CD O
among among 0 0 0 0 0 0 0 0 5 0 -NONE- CD IN CD NNS O
312 312 0 0 0 0 0 0 1 1 3 0 CD IN CD NNS VBD O
children children 0 0 0 0 0 0 0 0 8 0 IN CD NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 CD NNS VBD VBN IN O
diagnosed diagnosed 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN NNP O
as as 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
AOM. AOM. 1 1 0 0 0 0 0 0 4 0 VBN IN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NN IN O
incidence incidence 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP VBD O
AOM AOM 1 1 0 0 0 0 0 0 3 0 NN IN NNP VBD JJS O
was was 0 0 0 0 0 0 0 0 3 0 IN NNP VBD JJS IN O
highest highest 0 0 0 0 0 0 0 0 7 0 NNP VBD JJS IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 VBD JJS IN NNS IN O
children children 0 0 0 0 0 0 0 0 8 0 JJS IN NNS IN CD O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN CD NN O
1 1 0 0 0 0 0 0 1 1 1 0 NNS IN CD NN IN O
year year 0 0 0 0 0 0 0 0 4 0 IN CD NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN NN -NONE- O
age age 0 0 0 0 0 0 0 0 3 0 NN IN NN -NONE- -NONE- O
(0.54 (0.54 0 0 0 0 0 0 0 1 5 0 IN NN -NONE- -NONE- CD O
episodes/child/year, episodes/child/year, 0 0 0 1 1 0 0 0 20 0 NN -NONE- -NONE- CD -NONE- O
95% 95% 0 0 0 0 0 0 0 1 3 0 -NONE- -NONE- CD -NONE- CD O
CI: CI: 1 1 0 0 0 0 0 0 3 0 -NONE- CD -NONE- CD NNP O
0.44-0.64). 0.44-0.64). 0 0 1 0 0 0 0 1 11 0 CD -NONE- CD NNP NN O
Serotype Serotype 1 0 0 0 0 0 0 0 8 0 -NONE- CD NNP NN IN O
coverage coverage 0 0 0 0 0 0 0 0 8 0 CD NNP NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN CD CC O
7- 7- 0 0 1 0 0 0 0 1 2 0 NN IN CD CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN CD CC JJ JJ O
13-valent 13-valent 0 0 1 0 0 0 0 1 9 0 CD CC JJ JJ NN O
pneumococcal pneumococcal 0 0 0 0 0 0 0 0 12 0 CC JJ JJ NN NNS O
conjugate conjugate 0 0 0 0 0 0 0 0 9 0 JJ JJ NN NNS IN O
vaccines vaccines 0 0 0 0 0 0 0 0 8 0 JJ NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNS IN DT NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 IN DT NN VBD CD O
were were 0 0 0 0 0 0 0 0 4 0 DT NN VBD CD -NONE- O
38.0% 38.0% 0 0 0 0 0 0 0 1 5 0 NN VBD CD -NONE- JJ O
(95% (95% 0 0 0 0 0 0 0 1 4 0 VBD CD -NONE- JJ CD O
CI: CI: 1 1 0 0 0 0 0 0 3 0 CD -NONE- JJ CD CC O
29.3-47.3) 29.3-47.3) 0 0 1 0 0 0 0 1 10 0 -NONE- JJ CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 JJ CD CC CD NN O
62.8% 62.8% 0 0 0 0 0 0 0 1 5 0 CD CC CD NN -NONE- O
(95% (95% 0 0 0 0 0 0 0 1 4 0 CC CD NN -NONE- CD O
CI: CI: 1 1 0 0 0 0 0 0 3 0 CD NN -NONE- CD NNP O
53.6-71.4), 53.6-71.4), 0 0 1 0 1 0 0 1 11 0 NN -NONE- CD NNP NNP O
respectively. respectively. 0 0 0 0 0 0 0 0 13 0 -NONE- CD NNP NNP CD O
Of Of 1 0 0 0 0 0 0 0 2 0 CD NNP NNP CD JJ O
122 122 0 0 0 0 0 0 1 1 3 0 NNP NNP CD JJ NNS O
H.influenzae H.influenzae 1 0 0 0 0 0 0 0 12 0 NNP CD JJ NNS JJ O
isolates isolates 0 0 0 0 0 0 0 0 8 0 CD JJ NNS JJ IN O
available available 0 0 0 0 0 0 0 0 9 0 JJ NNS JJ IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NNS JJ IN JJ CD O
typing, typing, 0 0 0 0 1 0 0 0 7 0 JJ IN JJ CD VBD O
120 120 0 0 0 0 0 0 1 1 3 0 IN JJ CD VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 JJ CD VBD JJ CC O
nontypeable nontypeable 0 0 0 0 0 0 0 0 11 0 CD VBD JJ CC CD O
and and 0 0 0 0 0 0 0 0 3 0 VBD JJ CC CD VBD O
2 2 0 0 0 0 0 0 1 1 1 0 JJ CC CD VBD NN O
were were 0 0 0 0 0 0 0 0 4 0 CC CD VBD NN NNP O
type type 0 0 0 0 0 0 0 0 4 0 CD VBD NN NNP DT O
b. b. 0 0 0 0 0 0 0 0 2 0 VBD NN NNP DT JJ O
A A 1 1 0 0 0 0 0 0 1 0 NN NNP DT JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 NNP DT JJ NN IN O
proportion proportion 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
S. S. 1 1 0 0 0 0 0 0 2 0 NN IN NNP NN VBZ O
pneumoniae pneumoniae 0 0 0 0 0 0 0 0 10 0 IN NNP NN VBZ JJ O
isolates isolates 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ JJ VBN O
(46%) (46%) 0 0 0 0 0 0 0 1 5 0 NN VBZ JJ VBN NN O
showed showed 0 0 0 0 0 0 0 0 6 0 VBZ JJ VBN NN TO O
resistance resistance 0 0 0 0 0 0 0 0 10 0 JJ VBN NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 VBN NN TO NNP NNP O
penicillin. penicillin. 0 0 0 0 0 0 0 0 11 0 NN TO NNP NNP NN O
Approximately Approximately 1 0 0 0 0 0 0 0 13 0 TO NNP NNP NN IN O
half half 0 0 0 0 0 0 0 0 4 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NN O
H. H. 1 1 0 0 0 0 0 0 2 0 NN IN NNP NN VBZ O
influenzae influenzae 0 0 0 0 0 0 0 0 10 0 IN NNP NN VBZ VBN O
isolates isolates 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ VBN JJ O
had had 0 0 0 0 0 0 0 0 3 0 NN VBZ VBN JJ NNS O
genetic genetic 0 0 0 0 0 0 0 0 7 0 VBZ VBN JJ NNS IN O
markers markers 0 0 0 0 0 0 0 0 7 0 VBN JJ NNS IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN JJ NNP O
beta-lactamase-negative beta-lactamase-negative 0 0 1 0 0 0 0 0 23 0 NNS IN JJ NNP NNP O
ampicillin-resistance. ampicillin-resistance. 0 0 1 0 0 0 0 0 22 0 IN JJ NNP NNP NNP O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 JJ NNP NNP NNP CD O
Approximately Approximately 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP CD IN O
4-5% 4-5% 0 0 1 0 0 0 0 1 4 0 NNP NNP CD IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP CD IN JJ NN O
pediatric pediatric 0 0 0 0 0 0 0 0 9 0 CD IN JJ NN RB O
outpatients, outpatients, 0 0 0 0 1 0 0 0 12 0 IN JJ NN RB IN O
even even 0 0 0 0 0 0 0 0 4 0 JJ NN RB IN JJ O
without without 0 0 0 0 0 0 0 0 7 0 NN RB IN JJ NN O
AOM-related AOM-related 1 0 1 0 0 0 0 0 11 0 RB IN JJ NN VBD O
symptoms, symptoms, 0 0 0 0 1 0 0 0 9 0 IN JJ NN VBD NNP O
had had 0 0 0 0 0 0 0 0 3 0 JJ NN VBD NNP IN O
AOM AOM 1 1 0 0 0 0 0 0 3 0 NN VBD NNP IN PRP$ O
in in 0 0 0 0 0 0 0 0 2 0 VBD NNP IN PRP$ NNP O
our our 0 0 0 0 0 0 0 0 3 0 NNP IN PRP$ NNP NNP O
study. study. 0 0 0 0 0 0 0 0 6 0 IN PRP$ NNP NNP IN O
Pediatricians Pediatricians 1 0 0 0 0 0 0 0 13 0 PRP$ NNP NNP IN RB O
as as 0 0 0 0 0 0 0 0 2 0 NNP NNP IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NNP IN RB IN NNS O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN NNS MD O
otolaryngologists otolaryngologists 0 0 0 0 0 0 0 0 17 0 RB IN NNS MD VB O
should should 0 0 0 0 0 0 0 0 6 0 IN NNS MD VB DT O
check check 0 0 0 0 0 0 0 0 5 0 NNS MD VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT JJ NN O
tympanic tympanic 0 0 0 0 0 0 0 0 8 0 VB DT JJ NN NNS O
membrane membrane 0 0 0 0 0 0 0 0 8 0 DT JJ NN NNS IN O
findings findings 0 0 0 0 0 0 0 0 8 0 JJ NN NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT JJ O
all all 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NNP O
pediatric pediatric 0 0 0 0 0 0 0 0 9 0 IN DT JJ NNP NONE O
outpatients. outpatients. 0 0 0 0 0 0 0 0 12 0 DT JJ NNP NONE NONE O
Henryin, Henryin, 1 0 0 0 1 0 0 0 8 0 NONE NONE NN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NONE NN DT JJ NN O
ent-kaurane ent-kaurane 0 0 1 0 0 0 0 0 11 0 NN DT JJ NN NNS O
Diterpenoid, Diterpenoid, 1 0 0 0 1 0 0 0 12 0 DT JJ NN NNS NNP O
Inhibits Inhibits 1 0 0 0 0 0 0 0 8 0 JJ NN NNS NNP NNP O
Wnt Wnt 1 0 0 0 0 0 0 0 3 0 NN NNS NNP NNP IN O
Signaling Signaling 1 0 0 0 0 0 0 0 9 0 NNS NNP NNP IN NNP O
through through 0 0 0 0 0 0 0 0 7 0 NNP NNP IN NNP IN O
Interference Interference 1 0 0 0 0 0 0 0 12 0 NNP IN NNP IN -NONE- O
with with 0 0 0 0 0 0 0 0 4 0 IN NNP IN -NONE- NNP O
β-Catenin/TCF4 β-Catenin/TCF4 0 0 1 1 0 0 0 1 14 0 NNP IN -NONE- NNP IN O
Interaction Interaction 1 0 0 0 0 0 0 0 11 0 IN -NONE- NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- NNP IN NNP NNP O
Colorectal Colorectal 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
Cells. Cells. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Pu Pu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Jiang Jiang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Su Su 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kong Kong 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Mao Mao 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sun Sun 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Y. Y. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
State State 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Key Key 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP IN O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Phytochemistry Phytochemistry 1 0 0 0 0 0 0 0 14 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNPS O
Plant Plant 1 0 0 0 0 0 0 0 5 0 NNP CC NNP NNPS IN O
Resources Resources 1 0 0 0 0 0 0 0 9 0 CC NNP NNPS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
West West 1 0 0 0 0 0 0 0 4 0 NNPS IN NNP NNP NNP O
China, China, 1 0 0 0 1 0 0 0 6 0 IN NNP NNP NNP NNP O
Kunming Kunming 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Botany, Botany, 1 0 0 0 1 0 0 0 7 0 NNP IN NNP NNP NNP O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP IN O
Academy Academy 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Kunming, Kunming, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP : O
China China 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP : NNP O
; ; 0 0 0 0 0 0 0 0 1 0 NNP NNP : NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP : NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 : NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP NNP O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 IN DT NNP NNP IN O
Academy Academy 1 0 0 0 0 0 0 0 7 0 DT NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Beijing, Beijing, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Aberrant Aberrant 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBG O
Wnt/β-catenin Wnt/β-catenin 1 0 1 1 0 0 0 0 13 0 NNP NNP NNP VBG VBZ O
signaling signaling 0 0 0 0 0 0 0 0 9 0 NNP NNP VBG VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP VBG VBZ VBN RB O
been been 0 0 0 0 0 0 0 0 4 0 VBG VBZ VBN RB VBN O
strongly strongly 0 0 0 0 0 0 0 0 8 0 VBZ VBN RB VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 VBN RB VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
tumorigenesis tumorigenesis 0 0 0 0 0 0 0 0 13 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ JJ O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ JJ NNP O
colorectal colorectal 0 0 0 0 0 0 0 0 10 0 IN JJ JJ NNP NNP O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 JJ JJ NNP NNP IN O
Inhibitors Inhibitors 1 0 0 0 0 0 0 0 10 0 JJ NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP IN DT NN MD O
pathway pathway 0 0 0 0 0 0 0 0 7 0 IN DT NN MD RB O
may may 0 0 0 0 0 0 0 0 3 0 DT NN MD RB VB O
then then 0 0 0 0 0 0 0 0 4 0 NN MD RB VB JJ O
offer offer 0 0 0 0 0 0 0 0 5 0 MD RB VB JJ NNS O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 RB VB JJ NNS IN O
strategies strategies 0 0 0 0 0 0 0 0 10 0 VB JJ NNS IN RB O
as as 0 0 0 0 0 0 0 0 2 0 JJ NNS IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NNS IN RB IN NN O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN NN IN O
chemoprevention chemoprevention 0 0 0 0 0 0 0 0 15 0 RB IN NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 IN NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN NNP O
malignant malignant 0 0 0 0 0 0 0 0 9 0 IN DT NN NNP NNP O
disease. disease. 0 0 0 0 0 0 0 0 8 0 DT NN NNP NNP VBZ O
Henryin Henryin 1 0 0 0 0 0 0 0 7 0 NN NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNP VBZ DT JJ NN O
ent-kaurane ent-kaurane 0 0 1 0 0 0 0 0 11 0 VBZ DT JJ NN VBD O
diterpenoid diterpenoid 0 0 0 0 0 0 0 0 11 0 DT JJ NN VBD IN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 JJ NN VBD IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NN VBD IN NNP NNP O
Isodonrubescens Isodonrubescens 1 0 0 0 0 0 0 0 15 0 VBD IN NNP NNP NNP O
var. var. 0 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP DT O
lushanensis, lushanensis, 0 0 0 0 1 0 0 0 12 0 NNP NNP NNP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT NN RB O
plant plant 0 0 0 0 0 0 0 0 5 0 NNP DT NN RB VBN O
long long 0 0 0 0 0 0 0 0 4 0 DT NN RB VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN RB VBN VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 RB VBN VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN NN NN O
folk folk 0 0 0 0 0 0 0 0 4 0 VBN IN NN NN TO O
medicine medicine 0 0 0 0 0 0 0 0 8 0 IN NN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO VB NN O
prevent prevent 0 0 0 0 0 0 0 0 7 0 NN TO VB NN CC O
inflammation inflammation 0 0 0 0 0 0 0 0 12 0 TO VB NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VB NN CC JJ NNP O
gastrointestinal gastrointestinal 0 0 0 0 0 0 0 0 16 0 NN CC JJ NNP NNP O
disease. disease. 0 0 0 0 0 0 0 0 8 0 CC JJ NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
present present 0 0 0 0 0 0 0 0 7 0 NNP DT NN NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 DT NN NN PRP NN O
we we 0 0 0 0 0 0 0 0 2 0 NN NN PRP NN WDT O
report report 0 0 0 0 0 0 0 0 6 0 NN PRP NN WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 PRP NN WDT NN RB O
henryin henryin 0 0 0 0 0 0 0 0 7 0 NN WDT NN RB VBZ O
selectively selectively 0 0 0 0 0 0 0 0 11 0 WDT NN RB VBZ DT O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 NN RB VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBZ DT NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VBZ DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ JJ O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ JJ NN O
colorectal colorectal 0 0 0 0 0 0 0 0 10 0 IN JJ JJ NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN NNS IN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT NNP NN O
GI50 GI50 1 1 0 0 0 0 0 1 4 0 IN DT NNP NN IN O
value value 0 0 0 0 0 0 0 0 5 0 DT NNP NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
nano-molar nano-molar 0 0 1 0 0 0 0 0 10 0 IN DT JJ NNP NNP O
range. range. 0 0 0 0 0 0 0 0 6 0 DT JJ NNP NNP NN O
Microarray Microarray 1 0 0 0 0 0 0 0 10 0 JJ NNP NNP NN CC O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NNP NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN NNS O
reporter reporter 0 0 0 0 0 0 0 0 8 0 NN CC NN NNS VBD O
assays assays 0 0 0 0 0 0 0 0 6 0 CC NN NNS VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NN NNS VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NN VBD O
henryin henryin 0 0 0 0 0 0 0 0 7 0 VBD IN NN VBD IN O
worked worked 0 0 0 0 0 0 0 0 6 0 IN NN VBD IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NN VBD IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBD IN DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 IN DT NN NN IN O
antagonist antagonist 0 0 0 0 0 0 0 0 10 0 DT NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NN O
Wnt Wnt 1 0 0 0 0 0 0 0 3 0 NN IN NNP NN NNP O
signaling signaling 0 0 0 0 0 0 0 0 9 0 IN NNP NN NNP NNP O
pathway. pathway. 0 0 0 0 0 0 0 0 8 0 NNP NN NNP NNP VBD O
Henryin Henryin 1 0 0 0 0 0 0 0 7 0 NN NNP NNP VBD DT O
reduced reduced 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 VBD DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
Cyclin Cyclin 1 0 0 0 0 0 0 0 6 0 NN IN NNP NNP CC O
D1 D1 1 1 0 0 0 0 0 1 2 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP CC O
C-myc, C-myc, 1 0 1 0 1 0 0 0 6 0 NNP CC NNP CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC VBD NNS O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP CC VBD NNS NN O
G1/S G1/S 1 1 0 1 0 0 0 1 4 phase CC VBD NNS NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 arrest VBD NNS NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NNS NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
HCT116 HCT116 1 1 0 0 0 0 0 1 6 0 NN IN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NN O
Concurrently, Concurrently, 1 0 0 0 1 0 0 0 13 0 NNP NNP NNP NN VBD O
henryin henryin 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBD RB O
did did 0 0 0 0 0 0 0 0 3 0 NNP NN VBD RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NN VBD RB VB DT O
affect affect 0 0 0 0 0 0 0 0 6 0 VBD RB VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 RB VB DT JJ NN O
cytosol-nuclear cytosol-nuclear 0 0 1 0 0 0 0 0 15 0 VB DT JJ NN IN O
distribution distribution 0 0 0 0 0 0 0 0 12 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
soluble soluble 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN CC O
β-catenin, β-catenin, 0 0 1 0 1 0 0 0 10 0 IN JJ NN CC VBD O
but but 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBD DT O
impaired impaired 0 0 0 0 0 0 0 0 8 0 NN CC VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC VBD DT NN IN O
association association 0 0 0 0 0 0 0 0 11 0 VBD DT NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN -NONE- JJ O
β-catenin/TCF4 β-catenin/TCF4 0 0 1 1 0 0 0 1 14 0 NN IN -NONE- JJ NN O
transcriptional transcriptional 0 0 0 0 0 0 0 0 15 0 IN -NONE- JJ NN JJ O
complex complex 0 0 0 0 0 0 0 0 7 0 -NONE- JJ NN JJ IN O
likely likely 0 0 0 0 0 0 0 0 6 0 JJ NN JJ IN RB O
through through 0 0 0 0 0 0 0 0 7 0 NN JJ IN RB VBG O
directly directly 0 0 0 0 0 0 0 0 8 0 JJ IN RB VBG DT O
blocking blocking 0 0 0 0 0 0 0 0 8 0 IN RB VBG DT VBG O
the the 0 0 0 0 0 0 0 0 3 0 RB VBG DT VBG IN O
binding binding 0 0 0 0 0 0 0 0 7 0 VBG DT VBG IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT VBG IN JJ TO O
β-catenin β-catenin 0 0 1 0 0 0 0 0 9 0 VBG IN JJ TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 IN JJ TO NNP NNP O
TCF4. TCF4. 1 1 0 0 0 0 0 1 5 0 JJ TO NNP NNP RB O
We We 1 0 0 0 0 0 0 0 2 0 TO NNP NNP RB RB O
also also 0 0 0 0 0 0 0 0 4 0 NNP NNP RB RB VBN O
then then 0 0 0 0 0 0 0 0 4 0 NNP RB RB VBN DT O
analyzed analyzed 0 0 0 0 0 0 0 0 8 0 RB RB VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBN DT NN NN O
structure-activity structure-activity 0 0 1 0 0 0 0 0 18 0 VBN DT NN NN IN O
relationship relationship 0 0 0 0 0 0 0 0 12 0 DT NN NN IN DT O
among among 0 0 0 0 0 0 0 0 5 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
ent-kaurane ent-kaurane 0 0 1 0 0 0 0 0 11 0 IN DT JJ NN NNP O
type type 0 0 0 0 0 0 0 0 4 0 DT JJ NN NNP NNP O
diterpenoids. diterpenoids. 0 0 0 0 0 0 0 0 13 0 JJ NN NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS VBZ O
data data 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS VBZ IN O
suggests suggests 0 0 0 0 0 0 0 0 8 0 NNP NNS VBZ IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBZ IN JJ IN O
henryin, henryin, 0 0 0 0 1 0 0 0 8 0 VBZ IN JJ IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN JJ IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 JJ IN DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 IN DT NN NN IN O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 DT NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
Wnt Wnt 1 0 0 0 0 0 0 0 3 0 NN IN NNP NNP MD O
signaling, signaling, 0 0 0 0 1 0 0 0 10 0 IN NNP NNP MD VB O
could could 0 0 0 0 0 0 0 0 5 0 NNP NNP MD VB DT O
be be 0 0 0 0 0 0 0 0 2 0 NNP MD VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT JJ NN O
potential potential 0 0 0 0 0 0 0 0 9 0 VB DT JJ NN IN O
candidate candidate 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN JJ JJ O
further further 0 0 0 0 0 0 0 0 7 0 NN IN JJ JJ NN O
preclinical preclinical 0 0 0 0 0 0 0 0 11 0 IN JJ JJ NN IN O
evaluation evaluation 0 0 0 0 0 0 0 0 10 0 JJ JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN NN O
colon colon 0 0 0 0 0 0 0 0 5 0 NN IN NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN NN NN NN CC O
treatment, treatment, 0 0 0 0 1 0 0 0 10 0 NN NN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 NN CC IN JJ NNS O
such such 0 0 0 0 0 0 0 0 4 0 CC IN JJ NNS RBR O
warrants warrants 0 0 0 0 0 0 0 0 8 0 IN JJ NNS RBR NNP O
further further 0 0 0 0 0 0 0 0 7 0 JJ NNS RBR NNP NONE O
exploration. exploration. 0 0 0 0 0 0 0 0 12 0 NNS RBR NNP NONE NONE O
Modulation-specific Modulation-specific 1 0 1 0 0 0 0 0 19 0 NONE NONE JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NONE JJ CC JJ NNS O
laminar-dependent laminar-dependent 0 0 1 0 0 0 0 0 17 0 JJ CC JJ NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 CC JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN IN O
acetylcholine acetylcholine 0 0 0 0 0 0 0 0 13 0 NNS IN NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NNS O
visual visual 0 0 0 0 0 0 0 0 6 0 NN IN JJ NNS IN O
responses responses 0 0 0 0 0 0 0 0 9 0 IN JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
rat rat 0 0 0 0 0 0 0 0 3 0 IN DT NN NN JJ O
primary primary 0 0 0 0 0 0 0 0 7 0 DT NN NN JJ NNP O
visual visual 0 0 0 0 0 0 0 0 6 0 NN NN JJ NNP NNP O
cortex. cortex. 0 0 0 0 0 0 0 0 7 0 NN JJ NNP NNP NNP O
Soma Soma 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Shimegi Shimegi 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Suematsu Suematsu 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tamura Tamura 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sato Sato 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
H. H. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Graduate Graduate 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Frontier Frontier 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Biosciences, Biosciences, 1 0 0 0 1 0 0 0 12 0 IN NNP NNP NNP NNP O
Osaka Osaka 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Toyonaka, Toyonaka, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Osaka, Osaka, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
Japan. Japan. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Acetylcholine Acetylcholine 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP VBZ O
(ACh) (ACh) 0 0 0 0 0 0 0 0 5 0 NNP NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
secreted secreted 0 0 0 0 0 0 0 0 8 0 NNP VBZ VBN IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN JJ NNS O
cholinergic cholinergic 0 0 0 0 0 0 0 0 11 0 VBN IN JJ NNS IN O
neurons neurons 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
basal basal 0 0 0 0 0 0 0 0 5 0 IN DT NN NN TO O
forebrain forebrain 0 0 0 0 0 0 0 0 9 0 DT NN NN TO NNS O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO NNS IN O
regions regions 0 0 0 0 0 0 0 0 7 0 NN TO NNS IN DT O
throughout throughout 0 0 0 0 0 0 0 0 10 0 TO NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
cerebral cerebral 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN VBG O
cortex, cortex, 0 0 0 0 1 0 0 0 7 0 DT JJ NN VBG DT O
including including 0 0 0 0 0 0 0 0 9 0 JJ NN VBG DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT JJ JJ O
primary primary 0 0 0 0 0 0 0 0 7 0 VBG DT JJ JJ NN O
visual visual 0 0 0 0 0 0 0 0 6 0 DT JJ JJ NN NN O
cortex cortex 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NN CC O
(V1), (V1), 0 1 0 0 1 0 0 1 5 0 JJ NN NN CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNS JJ O
influences influences 0 0 0 0 0 0 0 0 10 0 NN CC NNS JJ NNS O
neuronal neuronal 0 0 0 0 0 0 0 0 8 0 CC NNS JJ NNS IN O
activities activities 0 0 0 0 0 0 0 0 10 0 NNS JJ NNS IN DT O
across across 0 0 0 0 0 0 0 0 6 0 JJ NNS IN DT CD O
all all 0 0 0 0 0 0 0 0 3 0 NNS IN DT CD NNS O
six six 0 0 0 0 0 0 0 0 3 0 IN DT CD NNS IN O
layers layers 0 0 0 0 0 0 0 0 6 0 DT CD NNS IN DT O
via via 0 0 0 0 0 0 0 0 3 0 CD NNS IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT NN IN O
form form 0 0 0 0 0 0 0 0 4 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN JJ O
diffuse diffuse 0 0 0 0 0 0 0 0 7 0 NN IN NN JJ NN O
extrasynaptic extrasynaptic 0 0 0 0 0 0 0 0 13 0 IN NN JJ NN VBD O
modulation modulation 0 0 0 0 0 0 0 0 10 0 NN JJ NN VBD NN O
termed termed 0 0 0 0 0 0 0 0 6 0 JJ NN VBD NN NNP O
volume volume 0 0 0 0 0 0 0 0 6 0 NN VBD NN NNP TO O
transmission. transmission. 0 0 0 0 0 0 0 0 13 0 VBD NN NNP TO VB O
To To 1 0 0 0 0 0 0 0 2 0 NN NNP TO VB DT O
understand understand 0 0 0 0 0 0 0 0 10 0 NNP TO VB DT NN O
this this 0 0 0 0 0 0 0 0 4 0 TO VB DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 VB DT NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP PRP O
V1, V1, 1 1 0 0 1 0 0 1 3 0 NN IN NNP PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 IN NNP PRP VBD JJ O
performed performed 0 0 0 0 0 0 0 0 9 0 NNP PRP VBD JJ JJ O
extracellular extracellular 0 0 0 0 0 0 0 0 13 0 PRP VBD JJ JJ NNS O
multi-point multi-point 0 0 1 0 0 0 0 0 11 0 VBD JJ JJ NNS IN O
recordings recordings 0 0 0 0 0 0 0 0 10 0 JJ JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NNS O
neuronal neuronal 0 0 0 0 0 0 0 0 8 0 NNS IN JJ NNS TO O
responses responses 0 0 0 0 0 0 0 0 9 0 IN JJ NNS TO VBG O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO VBG NN O
drifting drifting 0 0 0 0 0 0 0 0 8 0 NNS TO VBG NN VBG O
sinusoidal sinusoidal 0 0 0 0 0 0 0 0 10 0 TO VBG NN VBG NN O
grating grating 0 0 0 0 0 0 0 0 7 0 VBG NN VBG NN IN O
stimuli stimuli 0 0 0 0 0 0 0 0 7 0 NN VBG NN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 VBG NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNS O
cortical cortical 0 0 0 0 0 0 0 0 8 0 IN DT JJ NNS IN O
layers layers 0 0 0 0 0 0 0 0 6 0 DT JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP IN O
V1 V1 1 1 0 0 0 0 0 1 2 0 NNS IN NNP IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN JJ NNS O
anesthetized anesthetized 0 0 0 0 0 0 0 0 12 0 NNP IN JJ NNS CC O
rats rats 0 0 0 0 0 0 0 0 4 0 IN JJ NNS CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC VBD DT O
examined examined 0 0 0 0 0 0 0 0 8 0 NNS CC VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC VBD DT NN NNS O
modulatory modulatory 0 0 0 0 0 0 0 0 10 0 VBD DT NN NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 DT NN NNS IN RB O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN RB VBN O
topically topically 0 0 0 0 0 0 0 0 9 0 NNS IN RB VBN NNP O
administered administered 0 0 0 0 0 0 0 0 12 0 IN RB VBN NNP NNP O
ACh. ACh. 1 0 0 0 0 0 0 0 4 0 RB VBN NNP NNP VBD O
ACh ACh 1 0 0 0 0 0 0 0 3 0 VBN NNP NNP VBD CC O
facilitated facilitated 0 0 0 0 0 0 0 0 11 0 NNP NNP VBD CC VBN O
or or 0 0 0 0 0 0 0 0 2 0 NNP VBD CC VBN DT O
suppressed suppressed 0 0 0 0 0 0 0 0 10 0 VBD CC VBN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CC VBN DT JJ NNS O
visual visual 0 0 0 0 0 0 0 0 6 0 VBN DT JJ NNS IN O
responses responses 0 0 0 0 0 0 0 0 9 0 DT JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NNS O
individual individual 0 0 0 0 0 0 0 0 10 0 NNS IN JJ NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN DT O
with with 0 0 0 0 0 0 0 0 4 0 JJ NNS IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT NN NN O
laminar laminar 0 0 0 0 0 0 0 0 7 0 IN DT NN NN NN O
bias: bias: 0 0 0 0 0 0 0 0 5 0 DT NN NN NN NN O
response response 0 0 0 0 0 0 0 0 8 0 NN NN NN NN VBD O
suppression suppression 0 0 0 0 0 0 0 0 11 0 NN NN NN VBD IN O
prevailed prevailed 0 0 0 0 0 0 0 0 9 0 NN NN VBD IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 NN VBD IN NNS CD O
layers layers 0 0 0 0 0 0 0 0 6 0 VBD IN NNS CD NNS O
2/3, 2/3, 0 0 0 1 1 0 0 1 4 0 IN NNS CD NNS NN O
whereas whereas 0 0 0 0 0 0 0 0 7 0 NNS CD NNS NN NN O
response response 0 0 0 0 0 0 0 0 8 0 CD NNS NN NN VBD O
facilitation facilitation 0 0 0 0 0 0 0 0 12 0 NNS NN NN VBD IN O
prevailed prevailed 0 0 0 0 0 0 0 0 9 0 NN NN VBD IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN VBD IN NN CD O
layer layer 0 0 0 0 0 0 0 0 5 0 VBD IN NN CD NNP O
5. 5. 0 0 0 0 0 0 0 1 2 0 IN NN CD NNP NNS O
ACh ACh 1 0 0 0 0 0 0 0 3 0 NN CD NNP NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 CD NNP NNS IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
stimulus stimulus 0 0 0 0 0 0 0 0 8 0 IN DT NN NN NN O
contrast-response contrast-response 0 0 1 0 0 0 0 0 17 0 DT NN NN NN VBD O
function function 0 0 0 0 0 0 0 0 8 0 NN NN NN VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NN NN VBD IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN NNP NNS O
ACh ACh 1 0 0 0 0 0 0 0 3 0 VBD IN NNP NNS DT O
changes changes 0 0 0 0 0 0 0 0 7 0 IN NNP NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNS DT NN NN O
response response 0 0 0 0 0 0 0 0 8 0 NNS DT NN NN NN O
gain gain 0 0 0 0 0 0 0 0 4 0 DT NN NN NN CC O
upward upward 0 0 0 0 0 0 0 0 6 0 NN NN NN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 NN NN CC NN IN O
downward downward 0 0 0 0 0 0 0 0 8 0 NN CC NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ CC O
facilitated facilitated 0 0 0 0 0 0 0 0 11 0 NN IN JJ CC VBN O
or or 0 0 0 0 0 0 0 0 2 0 IN JJ CC VBN -NONE- O
suppressed suppressed 0 0 0 0 0 0 0 0 10 0 JJ CC VBN -NONE- NNP O
cells, cells, 0 0 0 0 1 0 0 0 6 0 CC VBN -NONE- NNP NNP O
respectively. respectively. 0 0 0 0 0 0 0 0 13 0 VBN -NONE- NNP NNP NNP O
Next, Next, 1 0 0 0 1 0 0 0 5 0 -NONE- NNP NNP NNP VBZ O
ACh ACh 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP VBZ IN O
effects effects 0 0 0 0 0 0 0 0 7 0 NNP NNP VBZ IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBZ IN DT JJ NN O
signal-to-noise signal-to-noise 0 0 1 0 0 0 0 0 15 0 IN DT JJ NN NN O
(S/N) (S/N) 0 1 0 1 0 0 0 0 5 0 DT JJ NN NN CC O
ratio ratio 0 0 0 0 0 0 0 0 5 0 JJ NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN NN O
grating-phase grating-phase 0 0 1 0 0 0 0 0 13 0 CC DT NN NN VBD O
information information 0 0 0 0 0 0 0 0 11 0 DT NN NN VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD NNP NNP O
tested. tested. 0 0 0 0 0 0 0 0 7 0 NN VBD NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 VBD NNP NNP NNP NN O
grating-phase grating-phase 0 0 1 0 0 0 0 0 13 0 NNP NNP NNP NN VBD O
information information 0 0 0 0 0 0 0 0 11 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
calculated calculated 0 0 0 0 0 0 0 0 10 0 NN VBD VBN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NNP O
F1/F0 F1/F0 1 1 0 1 0 0 0 1 5 0 IN DT NNP NNP WDT O
ratio, ratio, 0 0 0 0 1 0 0 0 6 0 DT NNP NNP WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NNP NNP WDT VBZ DT O
represents represents 0 0 0 0 0 0 0 0 10 0 NNP WDT VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 WDT VBZ DT NN IN O
amount amount 0 0 0 0 0 0 0 0 6 0 VBZ DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
temporal temporal 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN NN O
response response 0 0 0 0 0 0 0 0 8 0 IN JJ NN NN IN O
modulation modulation 0 0 0 0 0 0 0 0 10 0 JJ NN NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
fundamental fundamental 0 0 0 0 0 0 0 0 11 0 IN DT JJ NN NN O
frequency frequency 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN IN O
(F1) (F1) 0 1 0 0 0 0 0 1 4 0 JJ NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN VBG O
drifting drifting 0 0 0 0 0 0 0 0 8 0 IN DT NN VBG JJ O
grating grating 0 0 0 0 0 0 0 0 7 0 DT NN VBG JJ TO O
relative relative 0 0 0 0 0 0 0 0 8 0 NN VBG JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBG JJ TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ TO DT JJ VBN O
mean mean 0 0 0 0 0 0 0 0 4 0 TO DT JJ VBN NN O
evoked evoked 0 0 0 0 0 0 0 0 6 0 DT JJ VBN NN NNP O
response response 0 0 0 0 0 0 0 0 8 0 JJ VBN NN NNP NNP O
(F0). (F0). 0 1 0 0 0 0 0 1 5 0 VBN NN NNP NNP VBD O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBD NNP O
facilitated facilitated 0 0 0 0 0 0 0 0 11 0 NNP NNP VBD NNP NNP O
cells, cells, 0 0 0 0 1 0 0 0 6 0 NNP VBD NNP NNP VBD O
ACh ACh 1 0 0 0 0 0 0 0 3 0 VBD NNP NNP VBD DT O
improved improved 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT JJ NN O
S/N S/N 1 1 0 1 0 0 0 0 3 0 VBD DT JJ NN IN O
ratio, ratio, 0 0 0 0 1 0 0 0 6 0 DT JJ NN IN IN O
while while 0 0 0 0 0 0 0 0 5 0 JJ NN IN IN VBN O
in in 0 0 0 0 0 0 0 0 2 0 NN IN IN VBN NNS O
suppressed suppressed 0 0 0 0 0 0 0 0 10 0 IN IN VBN NNS PRP O
cells cells 0 0 0 0 0 0 0 0 5 0 IN VBN NNS PRP VBD O
it it 0 0 0 0 0 0 0 0 2 0 VBN NNS PRP VBD DT O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 NNS PRP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT NN NN O
F1/F0 F1/F0 1 1 0 1 0 0 0 1 5 0 VBD DT NN NN IN O
ratio ratio 0 0 0 0 0 0 0 0 5 0 DT NN NN IN DT O
without without 0 0 0 0 0 0 0 0 7 0 NN NN IN DT NN O
any any 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
concurrent concurrent 0 0 0 0 0 0 0 0 10 0 IN DT NN NN IN O
reduction reduction 0 0 0 0 0 0 0 0 9 0 DT NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
S/N S/N 1 1 0 1 0 0 0 0 3 0 IN DT JJ NNP NNP O
ratio. ratio. 0 0 0 0 0 0 0 0 6 0 DT JJ NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP NNS VBD O
effects effects 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD RB VBN O
predominantly predominantly 0 0 0 0 0 0 0 0 13 0 NNS VBD RB VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 VBD RB VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN JJ NN O
regular-spiking regular-spiking 0 0 1 0 0 0 0 0 15 0 VBN IN JJ NN CC O
cells, cells, 0 0 0 0 1 0 0 0 6 0 IN JJ NN CC RB O
but but 0 0 0 0 0 0 0 0 3 0 JJ NN CC RB IN O
not not 0 0 0 0 0 0 0 0 3 0 NN CC RB IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 CC RB IN JJ NNP O
fast-spiking fast-spiking 0 0 1 0 0 0 0 0 12 0 RB IN JJ NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP CC O
Electrophysiological Electrophysiological 1 0 0 0 0 0 0 0 20 0 JJ NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NNS O
histological histological 0 0 0 0 0 0 0 0 12 0 NNP CC JJ NNS VBP O
findings findings 0 0 0 0 0 0 0 0 8 0 CC JJ NNS VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 JJ NNS VBP IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NNP VBZ O
ACh ACh 1 0 0 0 0 0 0 0 3 0 VBP IN NNP VBZ DT O
promotes promotes 0 0 0 0 0 0 0 0 8 0 IN NNP VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT NN IN O
signaling signaling 0 0 0 0 0 0 0 0 9 0 VBZ DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
grating-phase grating-phase 0 0 1 0 0 0 0 0 13 0 NN IN JJ NN TO O
information information 0 0 0 0 0 0 0 0 11 0 IN JJ NN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO JJ NNS O
higher-order higher-order 0 0 1 0 0 0 0 0 12 0 NN TO JJ NNS IN O
areas areas 0 0 0 0 0 0 0 0 5 0 TO JJ NNS IN DT O
by by 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ NN O
suppressive suppressive 0 0 0 0 0 0 0 0 11 0 IN DT JJ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNS O
supragranular supragranular 0 0 0 0 0 0 0 0 13 0 NN IN JJ NNS CC O
layers layers 0 0 0 0 0 0 0 0 6 0 IN JJ NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC NNS VBP O
enhances enhances 0 0 0 0 0 0 0 0 8 0 NNS CC NNS VBP NNS O
feedback feedback 0 0 0 0 0 0 0 0 8 0 CC NNS VBP NNS IN O
signals signals 0 0 0 0 0 0 0 0 7 0 NNS VBP NNS IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBP NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ JJ O
high high 0 0 0 0 0 0 0 0 4 0 IN DT JJ JJ NN O
S/N S/N 1 1 0 1 0 0 0 0 3 0 DT JJ JJ NN TO O
ratio ratio 0 0 0 0 0 0 0 0 5 0 JJ JJ NN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO JJ NNS O
subcortical subcortical 0 0 0 0 0 0 0 0 11 0 NN TO JJ NNS IN O
areas areas 0 0 0 0 0 0 0 0 5 0 TO JJ NNS IN DT O
by by 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT NN NN O
facilitatory facilitatory 0 0 0 0 0 0 0 0 12 0 IN DT NN NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 DT NN NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNP O
infragranular infragranular 0 0 0 0 0 0 0 0 13 0 NN IN JJ NNP NNP O
layers. layers. 0 0 0 0 0 0 0 0 7 0 IN JJ NNP NNP NNP O
Thus, Thus, 1 0 0 0 1 0 0 0 5 0 JJ NNP NNP NNP RB O
ACh ACh 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP RB CC O
distinctly distinctly 0 0 0 0 0 0 0 0 10 0 NNP NNP RB CC RB O
and and 0 0 0 0 0 0 0 0 3 0 NNP RB CC RB NNS O
finely finely 0 0 0 0 0 0 0 0 6 0 RB CC RB NNS JJ O
controls controls 0 0 0 0 0 0 0 0 8 0 CC RB NNS JJ NN O
visual visual 0 0 0 0 0 0 0 0 6 0 RB NNS JJ NN NN O
information information 0 0 0 0 0 0 0 0 11 0 NNS JJ NN NN IN O
processing processing 0 0 0 0 0 0 0 0 10 0 JJ NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN WDT O
manner manner 0 0 0 0 0 0 0 0 6 0 IN DT NN WDT VBZ O
that that 0 0 0 0 0 0 0 0 4 0 DT NN WDT VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN WDT VBZ JJ IN O
specific specific 0 0 0 0 0 0 0 0 8 0 WDT VBZ JJ IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN CC O
modulation modulation 0 0 0 0 0 0 0 0 10 0 IN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN CC NN NN CC O
type type 0 0 0 0 0 0 0 0 4 0 CC NN NN CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NN CC VBZ RB RB O
also also 0 0 0 0 0 0 0 0 4 0 CC VBZ RB RB NNP O
laminar laminar 0 0 0 0 0 0 0 0 7 0 VBZ RB RB NNP NONE O
dependent. dependent. 0 0 0 0 0 0 0 0 10 0 RB RB NNP NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NN VBG O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 NONE DT NN VBG NNP B_TIMEXCCP
promoting promoting 0 0 0 0 0 0 0 0 9 0 DT NN VBG NNP NNP O
complex. complex. 0 0 0 0 0 0 0 0 8 0 NN VBG NNP NNP NNP O
Page Page 1 0 0 0 0 0 0 0 4 0 VBG NNP NNP NNP NNP O
AM, AM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Hieter Hieter 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
P. P. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP IN NNP NNP CC O
Biology Biology 1 0 0 0 0 0 0 0 7 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Genetics, Genetics, 1 0 0 0 1 0 0 0 9 0 NNP CC NNP NNP NNP O
Johns Johns 1 0 0 0 0 0 0 0 5 0 CC NNP NNP NNP NNP O
Hopkins Hopkins 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Baltimore, Baltimore, 1 0 0 0 1 0 0 0 10 0 IN NNP NNP NNP CD O
MD MD 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
21205, 21205, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNP VBP VBN DT O
proposed proposed 0 0 0 0 0 0 0 0 8 0 NNP VBP VBN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBP VBN DT JJ NN O
preliminary preliminary 0 0 0 0 0 0 0 0 11 0 VBN DT JJ NN IN O
model model 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN WRB O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN WRB DT O
how how 0 0 0 0 0 0 0 0 3 0 NN IN WRB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN WRB DT NN VBG O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 WRB DT NN VBG NN B_TIMEXCCP
promoting promoting 0 0 0 0 0 0 0 0 9 0 DT NN VBG NN NNS O
complex complex 0 0 0 0 0 0 0 0 7 0 NN VBG NN NNS IN O
functions functions 0 0 0 0 0 0 0 0 9 0 VBG NN NNS IN DT O
throughout throughout 0 0 0 0 0 0 0 0 10 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN CC O
cycle, cycle, 0 0 0 0 1 0 0 0 6 0 DT NN NN CC IN O
but but 0 0 0 0 0 0 0 0 3 0 NN NN CC IN DT O
despite despite 0 0 0 0 0 0 0 0 7 0 NN CC IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC IN DT NN IN O
flurry flurry 0 0 0 0 0 0 0 0 6 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
recent recent 0 0 0 0 0 0 0 0 6 0 NN IN JJ NNS VBG O
publications publications 0 0 0 0 0 0 0 0 12 0 IN JJ NNS VBG DT O
characterizing characterizing 0 0 0 0 0 0 0 0 14 0 JJ NNS VBG DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBG DT NNS -NONE- O
APC--its APC--its 1 0 1 0 0 0 0 0 8 0 VBG DT NNS -NONE- NN O
components, components, 0 0 0 0 1 0 0 0 11 0 DT NNS -NONE- NN CC O
regulation regulation 0 0 0 0 0 0 0 0 10 0 NNS -NONE- NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NN CC VB JJ O
substrate substrate 0 0 0 0 0 0 0 0 9 0 NN CC VB JJ JJ O
specificity--many specificity--many 0 0 1 0 0 0 0 0 17 0 CC VB JJ JJ NNS O
fundamental fundamental 0 0 0 0 0 0 0 0 11 0 VB JJ JJ NNS VBP O
questions questions 0 0 0 0 0 0 0 0 9 0 JJ JJ NNS VBP TO O
remain remain 0 0 0 0 0 0 0 0 6 0 JJ NNS VBP TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBP TO VB NNP O
be be 0 0 0 0 0 0 0 0 2 0 VBP TO VB NNP NNP O
answered. answered. 0 0 0 0 0 0 0 0 9 0 TO VB NNP NNP DT O
Firstly, Firstly, 1 0 0 0 1 0 0 0 8 0 VB NNP NNP DT VBG O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT VBG NNS O
remaining remaining 0 0 0 0 0 0 0 0 9 0 NNP DT VBG NNS IN O
components components 0 0 0 0 0 0 0 0 10 0 DT VBG NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBG NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP VBP O
APC APC 1 1 0 0 0 0 0 0 3 0 IN DT NNP VBP TO O
need need 0 0 0 0 0 0 0 0 4 0 DT NNP VBP TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBP TO VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 VBP TO VB VBN CC O
identified identified 0 0 0 0 0 0 0 0 10 0 TO VB VBN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VB VBN CC NNP NNP O
characterized. characterized. 0 0 0 0 0 0 0 0 14 0 VBN CC NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 CC NNP NNP VBP RB O
do do 0 0 0 0 0 0 0 0 2 0 NNP NNP VBP RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NNP VBP RB VB IN O
know know 0 0 0 0 0 0 0 0 4 0 VBP RB VB IN PDT O
if if 0 0 0 0 0 0 0 0 2 0 RB VB IN PDT DT O
all all 0 0 0 0 0 0 0 0 3 0 VB IN PDT DT NNS O
cyclosome cyclosome 0 0 0 0 0 0 0 0 9 0 IN PDT DT NNS VBP O
components components 0 0 0 0 0 0 0 0 10 0 PDT DT NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 DT NNS VBP VBN IN O
conserved conserved 0 0 0 0 0 0 0 0 9 0 NNS VBP VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBP VBN IN DT JJ O
all all 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ CC O
eukaryotes, eukaryotes, 0 0 0 0 1 0 0 0 11 0 IN DT JJ CC IN O
or or 0 0 0 0 0 0 0 0 2 0 DT JJ CC IN JJR O
if if 0 0 0 0 0 0 0 0 2 0 JJ CC IN JJR JJ O
higher higher 0 0 0 0 0 0 0 0 6 0 CC IN JJR JJ NN O
eukaryotes, eukaryotes, 0 0 0 0 1 0 0 0 11 0 IN JJR JJ NN DT O
having having 0 0 0 0 0 0 0 0 6 0 JJR JJ NN DT RBR O
a a 0 0 0 0 0 0 0 0 1 0 JJ NN DT RBR JJ O
more more 0 0 0 0 0 0 0 0 4 0 NN DT RBR JJ NN O
complicated complicated 0 0 0 0 0 0 0 0 11 0 DT RBR JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 RBR JJ NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 JJ NN NN NN NN O
machinery, machinery, 0 0 0 0 1 0 0 0 10 0 NN NN NN NN JJ O
maintain maintain 0 0 0 0 0 0 0 0 8 0 NN NN NN JJ NNS O
additional additional 0 0 0 0 0 0 0 0 10 0 NN NN JJ NNS IN O
subunits subunits 0 0 0 0 0 0 0 0 8 0 NN JJ NNS IN JJR O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN JJR JJ O
more more 0 0 0 0 0 0 0 0 4 0 NNS IN JJR JJ JJ O
sophisticated sophisticated 0 0 0 0 0 0 0 0 13 0 IN JJR JJ JJ CC O
functional functional 0 0 0 0 0 0 0 0 10 0 JJR JJ JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ JJ CC JJ NNP O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 JJ CC JJ NNP NNP O
control. control. 0 0 0 0 0 0 0 0 8 0 CC JJ NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NNP PRP O
addition, addition, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP TO O
need need 0 0 0 0 0 0 0 0 4 0 NNP PRP VBP TO VB O
to to 0 0 0 0 0 0 0 0 2 0 PRP VBP TO VB DT O
determine determine 0 0 0 0 0 0 0 0 9 0 VBP TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
identity identity 0 0 0 0 0 0 0 0 8 0 VB DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNS O
various various 0 0 0 0 0 0 0 0 7 0 IN DT JJ NNS CC O
kinases kinases 0 0 0 0 0 0 0 0 7 0 DT JJ NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC NNS WDT O
phosphatases phosphatases 0 0 0 0 0 0 0 0 12 0 NNS CC NNS WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 CC NNS WDT NN DT O
regulate regulate 0 0 0 0 0 0 0 0 8 0 NNS WDT NN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 WDT NN DT NNP NNP O
APC APC 1 1 0 0 0 0 0 0 3 0 NN DT NNP NNP NNP O
itself. itself. 0 0 0 0 0 0 0 0 7 0 DT NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
biochemistry biochemistry 0 0 0 0 0 0 0 0 12 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NNP O
individual individual 0 0 0 0 0 0 0 0 10 0 NN IN JJ NNP NNS O
APC APC 1 1 0 0 0 0 0 0 3 0 IN JJ NNP NNS VBZ O
components components 0 0 0 0 0 0 0 0 10 0 JJ NNP NNS VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNS VBZ RB DT O
also also 0 0 0 0 0 0 0 0 4 0 NNS VBZ RB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBZ RB DT JJ CC O
mystery, mystery, 0 0 0 0 1 0 0 0 8 0 RB DT JJ CC DT O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 JJ CC DT JJ JJ O
specific specific 0 0 0 0 0 0 0 0 8 0 CC DT JJ JJ NN O
biochemical biochemical 0 0 0 0 0 0 0 0 11 0 DT JJ JJ NN VBZ O
function function 0 0 0 0 0 0 0 0 8 0 JJ JJ NN VBZ RB O
has has 0 0 0 0 0 0 0 0 3 0 JJ NN VBZ RB VBN O
not not 0 0 0 0 0 0 0 0 3 0 NN VBZ RB VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 VBZ RB VBN VBN TO O
assigned assigned 0 0 0 0 0 0 0 0 8 0 RB VBN VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO DT NN O
any any 0 0 0 0 0 0 0 0 3 0 VBN TO DT NN NNS O
known known 0 0 0 0 0 0 0 0 5 0 TO DT NN NNS IN O
members members 0 0 0 0 0 0 0 0 7 0 DT NN NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NNP O
complex. complex. 0 0 0 0 0 0 0 0 8 0 IN DT NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 DT NNP NNP VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ RB IN O
not not 0 0 0 0 0 0 0 0 3 0 NNP VBZ RB IN DT O
at at 0 0 0 0 0 0 0 0 2 0 VBZ RB IN DT JJ O
all all 0 0 0 0 0 0 0 0 3 0 RB IN DT JJ WDT O
clear clear 0 0 0 0 0 0 0 0 5 0 IN DT JJ WDT -NONE- O
which which 0 0 0 0 0 0 0 0 5 0 DT JJ WDT -NONE- IN O
subunit(s) subunit(s) 0 0 0 0 0 0 0 0 10 0 JJ WDT -NONE- IN DT O
of of 0 0 0 0 0 0 0 0 2 0 WDT -NONE- IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- IN DT JJ RB O
complex complex 0 0 0 0 0 0 0 0 7 0 IN DT JJ RB VBZ O
actually actually 0 0 0 0 0 0 0 0 8 0 DT JJ RB VBZ DT O
recognizes recognizes 0 0 0 0 0 0 0 0 10 0 JJ RB VBZ DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 RB VBZ DT NNP NN O
E2 E2 1 1 0 0 0 0 0 1 2 0 VBZ DT NNP NN CC O
enzyme enzyme 0 0 0 0 0 0 0 0 6 0 DT NNP NN CC WDT O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC WDT -NONE- O
which which 0 0 0 0 0 0 0 0 5 0 NN CC WDT -NONE- VBZ O
subunit(s) subunit(s) 0 0 0 0 0 0 0 0 10 0 CC WDT -NONE- VBZ DT O
recognizes recognizes 0 0 0 0 0 0 0 0 10 0 WDT -NONE- VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- VBZ DT NN NN O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 VBZ DT NN NN NNP O
destruction destruction 0 0 0 0 0 0 0 0 11 0 DT NN NN NNP NNP O
box. box. 0 0 0 0 0 0 0 0 4 0 NN NN NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ JJ IN O
likely likely 0 0 0 0 0 0 0 0 6 0 NNP VBZ JJ IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 VBZ JJ IN JJ NN O
many many 0 0 0 0 0 0 0 0 4 0 JJ IN JJ NN NNS O
cyclosome cyclosome 0 0 0 0 0 0 0 0 9 0 IN JJ NN NNS VBP O
substrates substrates 0 0 0 0 0 0 0 0 10 0 JJ NN NNS VBP TO O
remain remain 0 0 0 0 0 0 0 0 6 0 NN NNS VBP TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBP TO VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 VBP TO VB JJ CC O
identified, identified, 0 0 0 0 1 0 0 0 11 0 TO VB JJ CC PRP O
and and 0 0 0 0 0 0 0 0 3 0 VB JJ CC PRP MD O
it it 0 0 0 0 0 0 0 0 2 0 JJ CC PRP MD VB O
will will 0 0 0 0 0 0 0 0 4 0 CC PRP MD VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 PRP MD VB JJ TO O
interesting interesting 0 0 0 0 0 0 0 0 11 0 MD VB JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VB JJ TO VB IN O
determine determine 0 0 0 0 0 0 0 0 9 0 JJ TO VB IN DT O
whether whether 0 0 0 0 0 0 0 0 7 0 TO VB IN DT NN O
all all 0 0 0 0 0 0 0 0 3 0 VB IN DT NN NNS O
cyclosome cyclosome 0 0 0 0 0 0 0 0 9 0 IN DT NN NNS VBP O
substrates substrates 0 0 0 0 0 0 0 0 10 0 DT NN NNS VBP DT O
require require 0 0 0 0 0 0 0 0 7 0 NN NNS VBP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNS VBP DT NN NN O
destruction destruction 0 0 0 0 0 0 0 0 11 0 VBP DT NN NN IN O
box box 0 0 0 0 0 0 0 0 3 0 DT NN NN IN PRP$ O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 NN IN PRP$ NN CC O
degradation degradation 0 0 0 0 0 0 0 0 11 0 IN PRP$ NN CC IN O
or or 0 0 0 0 0 0 0 0 2 0 PRP$ NN CC IN DT O
whether whether 0 0 0 0 0 0 0 0 7 0 NN CC IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 CC IN DT NNP VBZ O
APC APC 1 1 0 0 0 0 0 0 3 0 IN DT NNP VBZ JJ O
recognizes recognizes 0 0 0 0 0 0 0 0 10 0 DT NNP VBZ JJ NNS O
other other 0 0 0 0 0 0 0 0 5 0 NNP VBZ JJ NNS IN O
determinants determinants 0 0 0 0 0 0 0 0 12 0 VBZ JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NNP O
protein protein 0 0 0 0 0 0 0 0 7 0 NNS IN NN NNP NNP O
instability. instability. 0 0 0 0 0 0 0 0 12 0 IN NN NNP NNP PRP O
Finally, Finally, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP IN O
assume assume 0 0 0 0 0 0 0 0 6 0 NNP PRP VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NNP VBZ O
APC APC 1 1 0 0 0 0 0 0 3 0 IN DT NNP VBZ JJ O
degrades degrades 0 0 0 0 0 0 0 0 8 0 DT NNP VBZ JJ NNS O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 NNP VBZ JJ NNS IN B_TIMEXCCP
cyclins cyclins 0 0 0 0 0 0 0 0 7 0 VBZ JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT VBG O
all all 0 0 0 0 0 0 0 0 3 0 NNS IN DT VBG JJ O
proliferating proliferating 0 0 0 0 0 0 0 0 13 0 IN DT VBG JJ CC O
cells, cells, 0 0 0 0 1 0 0 0 6 0 DT VBG JJ CC IN O
but but 0 0 0 0 0 0 0 0 3 0 VBG JJ CC IN PRP O
whether whether 0 0 0 0 0 0 0 0 7 0 JJ CC IN PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 CC IN PRP VBZ JJ O
degrades degrades 0 0 0 0 0 0 0 0 8 0 IN PRP VBZ JJ NN O
unique unique 0 0 0 0 0 0 0 0 6 0 PRP VBZ JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBZ JJ NN NN VBD O
cycle cycle 0 0 0 0 0 0 0 0 5 0 JJ NN NN VBD NNS O
related related 0 0 0 0 0 0 0 0 7 0 NN NN VBD NNS IN O
substrates substrates 0 0 0 0 0 0 0 0 10 0 NN VBD NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBD NNS IN JJ NNS O
specific specific 0 0 0 0 0 0 0 0 8 0 NNS IN JJ NNS VBZ O
tissues tissues 0 0 0 0 0 0 0 0 7 0 IN JJ NNS VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 JJ NNS VBZ NNP NNP O
unclear. unclear. 0 0 0 0 0 0 0 0 8 0 NNS VBZ NNP NNP NN O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 VBZ NNP NNP NN VBZ O
nothing nothing 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ VBN IN O
known known 0 0 0 0 0 0 0 0 5 0 NN VBZ VBN IN NNP O
about about 0 0 0 0 0 0 0 0 5 0 VBZ VBN IN NNP NN O
APC APC 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NN IN O
function function 0 0 0 0 0 0 0 0 8 0 IN NNP NN IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 NNP NN IN JJ CC O
meiosis, meiosis, 0 0 0 0 1 0 0 0 8 0 NN IN JJ CC IN O
or or 0 0 0 0 0 0 0 0 2 0 IN JJ CC IN DT O
whether whether 0 0 0 0 0 0 0 0 7 0 JJ CC IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 CC IN DT NNP VBZ O
APC APC 1 1 0 0 0 0 0 0 3 0 IN DT NNP VBZ JJ O
degrades degrades 0 0 0 0 0 0 0 0 8 0 DT NNP VBZ JJ NNS O
other other 0 0 0 0 0 0 0 0 5 0 NNP VBZ JJ NNS IN O
substrates substrates 0 0 0 0 0 0 0 0 10 0 VBZ JJ NNS IN VBP O
that that 0 0 0 0 0 0 0 0 4 0 JJ NNS IN VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 NNS IN VBP RB VBN O
not not 0 0 0 0 0 0 0 0 3 0 IN VBP RB VBN TO O
related related 0 0 0 0 0 0 0 0 7 0 VBP RB VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 RB VBN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN TO DT NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 TO DT NN NNP NNP O
cycle. cycle. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP VBZ O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNP VBZ DT JJ CC O
exciting exciting 0 0 0 0 0 0 0 0 8 0 VBZ DT JJ CC RB O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC RB VBG O
rapidly rapidly 0 0 0 0 0 0 0 0 7 0 JJ CC RB VBG NN O
developing developing 0 0 0 0 0 0 0 0 10 0 CC RB VBG NN IN O
field field 0 0 0 0 0 0 0 0 5 0 RB VBG NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBG NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
exciting exciting 0 0 0 0 0 0 0 0 8 0 IN DT NN NN IN O
world world 0 0 0 0 0 0 0 0 5 0 DT NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN NNP O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN NNP NNP O
biology. biology. 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBP IN O
expect expect 0 0 0 0 0 0 0 0 6 0 NNP NNP VBP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBP IN JJ NNS O
new new 0 0 0 0 0 0 0 0 3 0 VBP IN JJ NNS MD O
findings findings 0 0 0 0 0 0 0 0 8 0 IN JJ NNS MD RB O
will will 0 0 0 0 0 0 0 0 4 0 JJ NNS MD RB VB O
surely surely 0 0 0 0 0 0 0 0 6 0 NNS MD RB VB JJ O
reveal reveal 0 0 0 0 0 0 0 0 6 0 MD RB VB JJ JJ O
many many 0 0 0 0 0 0 0 0 4 0 RB VB JJ JJ NNS O
interesting interesting 0 0 0 0 0 0 0 0 11 0 VB JJ JJ NNS IN O
surprises surprises 0 0 0 0 0 0 0 0 9 0 JJ JJ NNS IN DT O
about about 0 0 0 0 0 0 0 0 5 0 JJ NNS IN DT JJ O
this this 0 0 0 0 0 0 0 0 4 0 NNS IN DT JJ NN O
essential essential 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN NNP O
protein protein 0 0 0 0 0 0 0 0 7 0 DT JJ NN NNP NNP O
complex. complex. 0 0 0 0 0 0 0 0 8 0 JJ NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
9338100 9338100 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Topoisomerase Topoisomerase 1 0 0 0 0 0 0 0 13 0 NONE NONE NN NNP NNS O
IIalpha IIalpha 1 0 0 0 0 0 0 0 7 0 NONE NN NNP NNS DT O
controls controls 0 0 0 0 0 0 0 0 8 0 NN NNP NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNS DT NN NNP O
decatenation decatenation 0 0 0 0 0 0 0 0 12 0 NNS DT NN NNP NNP O
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 DT NN NNP NNP NNP B_TIMEXCCP
Luo Luo 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yuan Yuan 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lou Lou 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Z. Z. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Division Division 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Oncology Oncology 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Research, Research, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Oncology, Oncology, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Mayo Mayo 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNP O
Clinic, Clinic, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Rochester, Rochester, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP CD O
MN MN 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
55905, 55905, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NNP O
Topoisomerase Topoisomerase 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
II II 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
(Topo (Topo 0 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP VBZ O
II) II) 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN TO O
required required 0 0 0 0 0 0 0 0 8 0 NNP VBZ VBN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 VBZ VBN TO JJ VBN O
separate separate 0 0 0 0 0 0 0 0 8 0 VBN TO JJ VBN NN O
intertwined intertwined 0 0 0 0 0 0 0 0 11 0 TO JJ VBN NN NNS O
sister sister 0 0 0 0 0 0 0 0 6 0 JJ VBN NN NNS IN O
chromatids chromatids 0 0 0 0 0 0 0 0 10 0 VBN NN NNS IN NN O
before before 0 0 0 0 0 0 0 0 6 0 NN NNS IN NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NNS IN NN NN MD O
segregation segregation 0 0 0 0 0 0 0 0 11 0 IN NN NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN NN MD VB IN O
occur occur 0 0 0 0 0 0 0 0 5 0 NN MD VB IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 MD VB IN NNP NNP O
mitosis. mitosis. 0 0 0 0 0 0 0 0 8 0 VB IN NNP NNP PRP B_TIMEXCCP
However, However, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBZ TO O
remains remains 0 0 0 0 0 0 0 0 7 0 NNP PRP VBZ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 PRP VBZ TO VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 VBZ TO VB VBN IN O
resolved resolved 0 0 0 0 0 0 0 0 8 0 TO VB VBN IN NNP O
whether whether 0 0 0 0 0 0 0 0 7 0 VB VBN IN NNP NNP O
Topo Topo 1 0 0 0 0 0 0 0 4 0 VBN IN NNP NNP VBZ O
II II 1 1 0 0 0 0 0 0 2 0 IN NNP NNP VBZ DT O
has has 0 0 0 0 0 0 0 0 3 0 NNP NNP VBZ DT NN O
any any 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT NN IN O
role role 0 0 0 0 0 0 0 0 4 0 VBZ DT NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNP O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NN IN NN NNP NNP B_TIMEXCCP
control. control. 0 0 0 0 0 0 0 0 8 0 IN NN NNP NNP PRP O
Here Here 1 0 0 0 0 0 0 0 4 0 NN NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP IN O
report report 0 0 0 0 0 0 0 0 6 0 NNP PRP VBP IN WRB O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN WRB JJ O
when when 0 0 0 0 0 0 0 0 4 0 VBP IN WRB JJ NNP O
phosphorylated, phosphorylated, 0 0 0 0 1 0 0 0 15 0 IN WRB JJ NNP CD O
Ser Ser 1 0 0 0 0 0 0 0 3 0 WRB JJ NNP CD IN O
1524 1524 0 0 0 0 0 0 1 1 4 0 JJ NNP CD IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP CD IN NNP NNP O
Topo Topo 1 0 0 0 0 0 0 0 4 0 CD IN NNP NNP VBZ O
IIalpha IIalpha 1 0 0 0 0 0 0 0 7 0 IN NNP NNP VBZ IN O
acts acts 0 0 0 0 0 0 0 0 4 0 NNP NNP VBZ IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBZ IN DT NN NN O
binding binding 0 0 0 0 0 0 0 0 7 0 IN DT NN NN IN O
site site 0 0 0 0 0 0 0 0 4 0 DT NN NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
BRCT BRCT 1 1 0 0 0 0 0 0 4 0 IN DT NNP NN IN O
domain domain 0 0 0 0 0 0 0 0 6 0 DT NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NNP O
MDC1 MDC1 1 1 0 0 0 0 0 1 4 0 NN IN NNP NNP IN O
(mediator (mediator 0 0 0 0 0 0 0 0 9 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NNP IN NNP NN NN O
damage damage 0 0 0 0 0 0 0 0 6 0 IN NNP NN NN NN O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NNP NN NN NN NN B_TIMEXCCP
protein-1), protein-1), 0 0 1 0 1 0 0 1 11 0 NN NN NN NN VBG O
thereby thereby 0 0 0 0 0 0 0 0 7 0 NN NN NN VBG NNP O
recruiting recruiting 0 0 0 0 0 0 0 0 10 0 NN NN VBG NNP TO O
MDC1 MDC1 1 1 0 0 0 0 0 1 4 0 NN VBG NNP TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 VBG NNP TO NNP NNP O
chromatin. chromatin. 0 0 0 0 0 0 0 0 10 0 NNP TO NNP NNP NNP O
Although Although 1 0 0 0 0 0 0 0 8 0 TO NNP NNP NNP NNP O
Topo Topo 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NN O
IIalpha-MDC1 IIalpha-MDC1 1 0 1 0 0 0 0 1 12 0 NNP NNP NNP NN VBZ O
interaction interaction 0 0 0 0 0 0 0 0 11 0 NNP NNP NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ RB VBN O
not not 0 0 0 0 0 0 0 0 3 0 NN VBZ RB VBN IN O
required required 0 0 0 0 0 0 0 0 8 0 VBZ RB VBN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 RB VBN IN NN NN O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 VBN IN NN NN VBD O
activation activation 0 0 0 0 0 0 0 0 10 0 IN NN NN VBD IN O
induced induced 0 0 0 0 0 0 0 0 7 0 NN NN VBD IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 VBD IN NNP NNP PRP O
damage, damage, 0 0 0 0 1 0 0 0 7 0 IN NNP NNP PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP PRP VBZ VBN IN O
required required 0 0 0 0 0 0 0 0 8 0 PRP VBZ VBN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBZ VBN IN NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 VBN IN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
decatenation decatenation 0 0 0 0 0 0 0 0 12 0 IN DT NN NNP NNP O
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 DT NN NNP NNP IN B_TIMEXCCP
Mutation Mutation 1 0 0 0 0 0 0 0 8 0 NN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CD O
Ser Ser 1 0 0 0 0 0 0 0 3 0 NNP IN NNP CD NNS O
1524 1524 0 0 0 0 0 0 1 1 4 0 IN NNP CD NNS IN O
results results 0 0 0 0 0 0 0 0 7 0 NNP CD NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 CD NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ NN O
defective defective 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN NNP O
decatenation decatenation 0 0 0 0 0 0 0 0 12 0 DT JJ NN NNP NNP O
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP NNP NNS B_TIMEXCCP
These These 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP DT O
reveal reveal 0 0 0 0 0 0 0 0 6 0 NNP NNS VBP DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNS VBP DT JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 VBP DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
Topo Topo 1 0 0 0 0 0 0 0 4 0 NN IN NNP NNP IN O
II II 1 1 0 0 0 0 0 0 2 0 IN NNP NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN NN O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NNP IN NN NN CC O
activation activation 0 0 0 0 0 0 0 0 10 0 IN NN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN CC IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC IN DT NN IN O
maintenance maintenance 0 0 0 0 0 0 0 0 11 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
genomic genomic 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNP NNP O
stability. stability. 0 0 0 0 0 0 0 0 10 0 IN JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
19098900 19098900 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NN O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NN NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
PMC2712943 PMC2712943 1 1 0 0 0 0 0 1 10 0 JJ NN NNP NONE NONE O
Biotinylation Biotinylation 1 0 0 0 0 0 0 0 13 0 NONE NONE NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NN CC O
transducin transducin 0 0 0 0 0 0 0 0 10 0 NN IN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NNP IN O
G0 G0 1 1 0 0 0 0 0 1 2 0 NN CC NNP IN NN O
from from 0 0 0 0 0 0 0 0 4 0 CC NNP IN NN NNP O
bovine bovine 0 0 0 0 0 0 0 0 6 0 NNP IN NN NNP NNP O
brain. brain. 0 0 0 0 0 0 0 0 6 0 IN NN NNP NNP NNP O
Heller Heller 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hucho Hucho 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
F. F. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Institut Institut 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
für für 0 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Biochemie, Biochemie, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Freie Freie 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Universität Universität 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
Berlin. Berlin. 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NN VBZ O
method method 0 0 0 0 0 0 0 0 6 0 NNP NNP NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ VBN IN O
described described 0 0 0 0 0 0 0 0 9 0 NN VBZ VBN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBZ VBN IN NN NNP O
modifying modifying 0 0 0 0 0 0 0 0 9 0 VBN IN NN NNP NNS O
G G 1 1 0 0 0 0 0 0 1 0 IN NN NNP NNS IN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NN NNP NNS IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNS IN NNP NNP O
biotin. biotin. 0 0 0 0 0 0 0 0 7 0 NNS IN NNP NNP NNP O
With With 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP JJR O
transducin, transducin, 0 0 0 0 1 0 0 0 11 0 NNP NNP NNP JJR NNS O
better better 0 0 0 0 0 0 0 0 6 0 NNP NNP JJR NNS VBD O
results results 0 0 0 0 0 0 0 0 7 0 NNP JJR NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJR NNS VBD VBN IN O
obtained obtained 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NNP O
amino amino 0 0 0 0 0 0 0 0 5 0 IN DT NN NNP JJ O
group-specific group-specific 0 0 1 0 0 0 0 0 14 0 DT NN NNP JJ NNP O
derivative derivative 0 0 0 0 0 0 0 0 10 0 NN NNP JJ NNP JJ O
BXNHS BXNHS 1 1 0 0 0 0 0 0 5 0 NNP JJ NNP JJ NN O
(biotinyl-epsilon-aminocaproic (biotinyl-epsilon-aminocaproic 0 0 1 0 0 0 0 0 30 0 JJ NNP JJ NN JJ O
acid acid 0 0 0 0 0 0 0 0 4 0 NNP JJ NN JJ NN O
N-hydroxysuccinimide N-hydroxysuccinimide 1 0 1 0 0 0 0 0 20 0 JJ NN JJ NN IN O
ester) ester) 0 0 0 0 0 0 0 0 6 0 NN JJ NN IN VBN O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN VBN TO O
compared compared 0 0 0 0 0 0 0 0 8 0 NN IN VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 IN VBN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN TO DT NN NN O
-SH-group -SH-group 0 0 1 0 0 0 0 0 9 0 TO DT NN NN NN O
specific specific 0 0 0 0 0 0 0 0 8 0 DT NN NN NN NNP O
reagent reagent 0 0 0 0 0 0 0 0 7 0 NN NN NN NNP NNP O
MBB MBB 1 1 0 0 0 0 0 0 3 0 NN NN NNP NNP NNP O
(maleimidobutyrylbiocytin). (maleimidobutyrylbiocytin). 0 0 0 0 0 0 0 0 27 0 NN NNP NNP NNP VBD O
Modification Modification 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP VBD IN O
occurred occurred 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD IN NNS O
under under 0 0 0 0 0 0 0 0 5 0 NNP VBD IN NNS VBG O
conditions conditions 0 0 0 0 0 0 0 0 10 0 VBD IN NNS VBG JJ O
preserving preserving 0 0 0 0 0 0 0 0 10 0 IN NNS VBG JJ NN O
functional functional 0 0 0 0 0 0 0 0 10 0 NNS VBG JJ NN NNP O
activity: activity: 0 0 0 0 0 0 0 0 9 0 VBG JJ NN NNP IN O
Interaction Interaction 1 0 0 0 0 0 0 0 11 0 JJ NN NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NNP IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT VBN NN O
biotinylated biotinylated 0 0 0 0 0 0 0 0 12 0 IN DT VBN NN IN O
transducin transducin 0 0 0 0 0 0 0 0 10 0 DT VBN NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 VBN NN IN NN NN O
rod rod 0 0 0 0 0 0 0 0 3 0 NN IN NN NN NN O
outer outer 0 0 0 0 0 0 0 0 5 0 IN NN NN NN NNS O
segment segment 0 0 0 0 0 0 0 0 7 0 NN NN NN NNS VBD O
membranes membranes 0 0 0 0 0 0 0 0 9 0 NN NN NNS VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NNS VBD VBN IN O
shown shown 0 0 0 0 0 0 0 0 5 0 NNS VBD VBN IN PRP$ O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN PRP$ JJ O
its its 0 0 0 0 0 0 0 0 3 0 VBN IN PRP$ JJ NN O
light-dependent light-dependent 0 0 1 0 0 0 0 0 15 0 IN PRP$ JJ NN CC O
association association 0 0 0 0 0 0 0 0 11 0 PRP$ JJ NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC IN DT O
by by 0 0 0 0 0 0 0 0 2 0 NN CC IN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 CC IN DT NNP NN O
GTP GTP 1 1 0 0 0 0 0 0 3 0 IN DT NNP NN NN O
gamma gamma 0 0 0 0 0 0 0 0 5 0 DT NNP NN NN NNP O
S-binding S-binding 1 0 1 0 0 0 0 0 9 0 NNP NN NN NNP NNP O
assay. assay. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP IN O
G0 G0 1 1 0 0 0 0 0 1 2 0 NN NNP NNP IN NN O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNP IN NN NN O
bovine bovine 0 0 0 0 0 0 0 0 6 0 NNP IN NN NN VBD O
brain brain 0 0 0 0 0 0 0 0 5 0 IN NN NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD RB VBN O
also also 0 0 0 0 0 0 0 0 4 0 NN VBD RB VBN IN O
biotinylated biotinylated 0 0 0 0 0 0 0 0 12 0 VBD RB VBN IN NNS O
under under 0 0 0 0 0 0 0 0 5 0 RB VBN IN NNS VBG O
conditions conditions 0 0 0 0 0 0 0 0 10 0 VBN IN NNS VBG PRP$ O
preserving preserving 0 0 0 0 0 0 0 0 10 0 IN NNS VBG PRP$ NNP O
its its 0 0 0 0 0 0 0 0 3 0 NNS VBG PRP$ NNP NNP O
activity. activity. 0 0 0 0 0 0 0 0 9 0 VBG PRP$ NNP NNP -NONE- O
Biotinyl-alpha Biotinyl-alpha 1 0 1 0 0 0 0 0 14 0 PRP$ NNP NNP -NONE- VBD O
0 0 0 0 0 0 0 0 1 1 1 0 NNP NNP -NONE- VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP -NONE- VBD VBN TO O
shown shown 0 0 0 0 0 0 0 0 5 0 -NONE- VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB TO O
bind bind 0 0 0 0 0 0 0 0 4 0 VBN TO VB TO DT O
to to 0 0 0 0 0 0 0 0 2 0 TO VB TO DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VB TO DT NN NNP O
streptavidin streptavidin 0 0 0 0 0 0 0 0 12 0 TO DT NN NNP NNP O
Sepharose Sepharose 1 0 0 0 0 0 0 0 9 0 DT NN NNP NNP NNP O
matrix. matrix. 0 0 0 0 0 0 0 0 7 0 NN NNP NNP NNP NNP O
Biotinyl-G Biotinyl-G 1 0 1 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
proteins, proteins, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP VBP O
therefore, therefore, 0 0 0 0 1 0 0 0 10 0 NNP NNP NNP VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNP VBP VBN IN O
proposed proposed 0 0 0 0 0 0 0 0 8 0 NNP VBP VBN IN NNS O
as as 0 0 0 0 0 0 0 0 2 0 VBP VBN IN NNS IN O
tools tools 0 0 0 0 0 0 0 0 5 0 VBN IN NNS IN VBG O
for for 0 0 0 0 0 0 0 0 3 0 IN NNS IN VBG NNS O
extracting extracting 0 0 0 0 0 0 0 0 10 0 NNS IN VBG NNS NNS O
proteins proteins 0 0 0 0 0 0 0 0 8 0 IN VBG NNS NNS CC O
(receptors (receptors 0 0 0 0 0 0 0 0 10 0 VBG NNS NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNS NNS CC NN NN O
effector effector 0 0 0 0 0 0 0 0 8 0 NNS CC NN NN WDT O
systems), systems), 0 0 0 0 1 0 0 0 9 0 CC NN NN WDT NN O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT NN IN O
interact interact 0 0 0 0 0 0 0 0 8 0 NN WDT NN IN JJ O
under under 0 0 0 0 0 0 0 0 5 0 WDT NN IN JJ NNS O
specific specific 0 0 0 0 0 0 0 0 8 0 NN IN JJ NNS IN O
conditions conditions 0 0 0 0 0 0 0 0 10 0 IN JJ NNS IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 JJ NNS IN NNP NNP O
G G 1 1 0 0 0 0 0 0 1 0 NNS IN NNP NNP NNP O
proteins. proteins. 0 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNP NNP NNP CD JJ O
1910464 1910464 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Yeast Yeast 1 0 0 0 0 0 0 0 5 0 NONE NONE NNP NNP VBZ O
G1 G1 1 1 0 0 0 0 0 1 2 0 NONE NNP NNP VBZ VBP B_TIMEXCCP
cyclins cyclins 0 0 0 0 0 0 0 0 7 0 NNP NNP VBZ VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNP VBZ VBP JJ IN O
unstable unstable 0 0 0 0 0 0 0 0 8 0 VBZ VBP JJ IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBP JJ IN NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 JJ IN NNP NNP NNP B_TIMEXCCP
phase. phase. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
Schneider Schneider 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
BL, BL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Patton Patton 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
EE, EE, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Lanker Lanker 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Mendenhall Mendenhall 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
MD, MD, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wittenberg Wittenberg 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Futcher Futcher 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tyers Tyers 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
M. M. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Cold Cold 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Spring Spring 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Harbor Harbor 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Laboratory, Laboratory, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
New New 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP CD O
York York 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP CD NNP O
11724, 11724, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP JJS O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP JJS JJ O
most most 0 0 0 0 0 0 0 0 4 0 NNP NNP JJS JJ NN O
eukaryotes, eukaryotes, 0 0 0 0 1 0 0 0 11 0 NNP JJS JJ NN TO O
commitment commitment 0 0 0 0 0 0 0 0 10 0 JJS JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN TO VB NN NNS O
division division 0 0 0 0 0 0 0 0 8 0 TO VB NN NNS IN O
occurs occurs 0 0 0 0 0 0 0 0 6 0 VB NN NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NNP O
late late 0 0 0 0 0 0 0 0 4 0 NNS IN JJ NNP NN G1
G1 G1 1 1 0 0 0 0 0 1 2 phase IN JJ NNP NN IN G1
phase phase 0 0 0 0 0 0 0 0 5 0 JJ NNP NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT NN VBN O
event event 0 0 0 0 0 0 0 0 5 0 IN DT NN VBN NNP O
called called 0 0 0 0 0 0 0 0 6 0 DT NN VBN NNP IN O
Start Start 1 0 0 0 0 0 0 0 5 0 NN VBN NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBN NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN NNS O
yeast yeast 0 0 0 0 0 0 0 0 5 0 IN DT NN NNS -NONE- O
Saccharomyces Saccharomyces 1 0 0 0 0 0 0 0 13 0 DT NN NNS -NONE- CC O
cerevisiae, cerevisiae, 0 0 0 0 1 0 0 0 11 0 NN NNS -NONE- CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC VBN DT O
called called 0 0 0 0 0 0 0 0 6 0 -NONE- CC VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC VBN DT NN NN O
restriction restriction 0 0 0 0 0 0 0 0 11 0 VBN DT NN NN IN O
point point 0 0 0 0 0 0 0 0 5 0 DT NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNP O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP VBZ O
Start Start 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
triggered triggered 0 0 0 0 0 0 0 0 9 0 NNP VBZ VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
cyclin-dependent cyclin-dependent 0 0 1 0 0 0 0 0 16 0 IN DT JJ NN NNP O
kinase kinase 0 0 0 0 0 0 0 0 6 0 DT JJ NN NNP CC O
Cdc28 Cdc28 1 0 0 0 0 0 0 1 5 0 JJ NN NNP CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC CD JJ O
three three 0 0 0 0 0 0 0 0 5 0 NNP CC CD JJ NN O
rate-limiting rate-limiting 0 0 1 0 0 0 0 0 13 0 CC CD JJ NN DT O
activators, activators, 0 0 0 0 1 0 0 0 11 0 CD JJ NN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NNP VBZ O
G1 G1 1 1 0 0 0 0 0 1 2 0 NN DT NNP VBZ JJ B_TIMEXCCP
cyclins cyclins 0 0 0 0 0 0 0 0 7 0 DT NNP VBZ JJ NNP O
Cln1, Cln1, 1 0 0 0 1 0 0 1 5 0 NNP VBZ JJ NNP CC O
Cln2 Cln2 1 0 0 0 0 0 0 1 4 0 VBZ JJ NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNP CC NNP NNP O
Cln3. Cln3. 1 0 0 0 0 0 0 1 5 0 NNP CC NNP NNP NN O
Cyclin Cyclin 1 0 0 0 0 0 0 0 6 0 CC NNP NNP NN IN O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 NNP NNP NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP VBZ O
G1 G1 1 1 0 0 0 0 0 1 2 0 NN IN NNP VBZ VBN B_TIMEXCCP
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ VBN IN O
driven driven 0 0 0 0 0 0 0 0 6 0 NNP VBZ VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN NN IN O
part part 0 0 0 0 0 0 0 0 4 0 VBN IN NN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 IN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
cell-cycle-regulated cell-cycle-regulated 0 0 1 0 0 0 0 0 20 0 IN DT JJ NN IN O
transcription transcription 0 0 0 0 0 0 0 0 13 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP CC O
CLN1 CLN1 1 1 0 0 0 0 0 1 4 0 NN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP WDT O
CLN2, CLN2, 1 1 0 0 1 0 0 1 5 0 NNP CC NNP WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 CC NNP WDT VBZ IN O
peaks peaks 0 0 0 0 0 0 0 0 5 0 NNP WDT VBZ IN NNP O
at at 0 0 0 0 0 0 0 0 2 0 WDT VBZ IN NNP NNP O
Start. Start. 1 0 0 0 0 0 0 0 6 0 VBZ IN NNP NNP NN O
CLN CLN 1 1 0 0 0 0 0 0 3 0 IN NNP NNP NN VBZ O
transcription transcription 0 0 0 0 0 0 0 0 13 0 NNP NNP NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ VBN IN O
modulated modulated 0 0 0 0 0 0 0 0 9 0 NN VBZ VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN JJ NNS O
physiological physiological 0 0 0 0 0 0 0 0 13 0 VBN IN JJ NNS WDT O
signals signals 0 0 0 0 0 0 0 0 7 0 IN JJ NNS WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 JJ NNS WDT NN NNP O
regulate regulate 0 0 0 0 0 0 0 0 8 0 NNS WDT NN NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 WDT NN NNP NNP CC B_TIMEXCCP
progression, progression, 0 0 0 0 1 0 0 0 12 0 NN NNP NNP CC PRP O
but but 0 0 0 0 0 0 0 0 3 0 NNP NNP CC PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NNP CC PRP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 CC PRP VBZ JJ IN O
unclear unclear 0 0 0 0 0 0 0 0 7 0 PRP VBZ JJ IN NNP O
whether whether 0 0 0 0 0 0 0 0 7 0 VBZ JJ IN NNP NN O
Cln Cln 1 0 0 0 0 0 0 0 3 0 JJ IN NNP NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 IN NNP NN NN VBZ O
stability stability 0 0 0 0 0 0 0 0 9 0 NNP NN NN VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ NNP NNP O
cell-cycle-regulated. cell-cycle-regulated. 0 0 1 0 0 0 0 0 21 0 NN VBZ NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 VBZ NNP NNP VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP NNP VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBN VBN IN O
suggested suggested 0 0 0 0 0 0 0 0 9 0 VBZ VBN VBN IN RB O
that that 0 0 0 0 0 0 0 0 4 0 VBN VBN IN RB VBZ O
once once 0 0 0 0 0 0 0 0 4 0 VBN IN RB VBZ NN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN RB VBZ NN -NONE- O
pass pass 0 0 0 0 0 0 0 0 4 0 RB VBZ NN -NONE- NNP O
Start, Start, 1 0 0 0 1 0 0 0 6 0 VBZ NN -NONE- NNP NN O
Cln Cln 1 0 0 0 0 0 0 0 3 0 NN -NONE- NNP NN VBZ O
proteolysis proteolysis 0 0 0 0 0 0 0 0 11 0 -NONE- NNP NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ VBN IN O
triggered triggered 0 0 0 0 0 0 0 0 9 0 NN VBZ VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNS O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NNS -NONE- O
cyclins cyclins 0 0 0 0 0 0 0 0 7 0 DT JJ NNS -NONE- CD O
Clb1, Clb1, 1 0 0 0 1 0 0 1 5 0 JJ NNS -NONE- CD CD O
2, 2, 0 0 0 0 1 0 0 1 2 0 NNS -NONE- CD CD CC O
3 3 0 0 0 0 0 0 1 1 1 0 -NONE- CD CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD CD CC CD CC O
4. 4. 0 0 0 0 0 0 0 1 2 0 CD CC CD CC RB O
But But 1 0 0 0 0 0 0 0 3 0 CC CD CC RB PRP O
here here 0 0 0 0 0 0 0 0 4 0 CD CC RB PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 CC RB PRP VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 RB PRP VBP IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN NNP VBZ O
G1 G1 1 1 0 0 0 0 0 1 2 0 VBP IN NNP VBZ VBP B_TIMEXCCP
cyclins cyclins 0 0 0 0 0 0 0 0 7 0 IN NNP VBZ VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNP VBZ VBP JJ IN O
unstable unstable 0 0 0 0 0 0 0 0 8 0 VBZ VBP JJ IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBP JJ IN NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 JJ IN NNP NNP CC B_TIMEXCCP
phase, phase, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC IN -NONE- O
that that 0 0 0 0 0 0 0 0 4 0 NNP CC IN -NONE- NN O
Clb-Cdc28 Clb-Cdc28 1 0 1 0 0 0 0 1 9 0 CC IN -NONE- NN VBZ O
activity activity 0 0 0 0 0 0 0 0 8 0 IN -NONE- NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 -NONE- NN VBZ RB VBN O
not not 0 0 0 0 0 0 0 0 3 0 NN VBZ RB VBN NN O
needed needed 0 0 0 0 0 0 0 0 6 0 VBZ RB VBN NN NNP O
fgr fgr 0 0 0 0 0 0 0 0 3 0 RB VBN NN NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 0 VBN NN NNP NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN NNP NN NNP NNP O
turnover. turnover. 0 0 0 0 0 0 0 0 9 0 NNP NN NNP NNP NN O
Cln Cln 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN RB O
instability instability 0 0 0 0 0 0 0 0 11 0 NNP NNP NN RB VBZ O
thus thus 0 0 0 0 0 0 0 0 4 0 NNP NN RB VBZ DT O
provides provides 0 0 0 0 0 0 0 0 8 0 NN RB VBZ DT VBZ O
a a 0 0 0 0 0 0 0 0 1 0 RB VBZ DT VBZ TO O
means means 0 0 0 0 0 0 0 0 5 0 VBZ DT VBZ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT VBZ TO VB -NONE- O
couple couple 0 0 0 0 0 0 0 0 6 0 VBZ TO VB -NONE- NN O
Cln-Cdc28 Cln-Cdc28 1 0 1 0 0 0 0 1 9 0 TO VB -NONE- NN TO O
activity activity 0 0 0 0 0 0 0 0 8 0 VB -NONE- NN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 -NONE- NN TO JJ NN O
transcriptional transcriptional 0 0 0 0 0 0 0 0 15 0 NN TO JJ NN CC O
regulation regulation 0 0 0 0 0 0 0 0 10 0 TO JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN JJ O
protein protein 0 0 0 0 0 0 0 0 7 0 NN CC NN JJ NN O
synthetic synthetic 0 0 0 0 0 0 0 0 9 0 CC NN JJ NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 NN JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNP O
pre-Start pre-Start 0 0 1 0 0 0 0 0 9 0 NN IN NN NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 IN NN NNP NNP NNP B_TIMEXCCP
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNP NNP NNP CD JJ O
9738503 9738503 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
G2 G2 1 1 0 0 0 0 0 1 2 0 NONE NONE NNP VBD NNS G2
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NONE NNP VBD NNS IN G2
abrogators abrogators 0 0 0 0 0 0 0 0 10 0 NNP VBD NNS IN NN O
as as 0 0 0 0 0 0 0 0 2 0 VBD NNS IN NN NNP O
anticancer anticancer 0 0 0 0 0 0 0 0 10 0 NNS IN NN NNP NNP O
drugs. drugs. 0 0 0 0 0 0 0 0 6 0 IN NN NNP NNP NNP O
Kawabe Kawabe 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP NNP O
T. T. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
CanBas CanBas 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Co. Co. 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Ltd., Ltd., 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
Numazu, Numazu, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Japan. Japan. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
takumi@canbas.co.jp takumi@canbas.co.jp 0 0 0 0 0 0 0 0 19 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP JJ O
Many Many 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP JJ NN O
conventional conventional 0 0 0 0 0 0 0 0 12 0 NNP NNP JJ NN NNS O
anticancer anticancer 0 0 0 0 0 0 0 0 10 0 NNP JJ NN NNS VBP O
treatments treatments 0 0 0 0 0 0 0 0 10 0 JJ NN NNS VBP NNS O
kill kill 0 0 0 0 0 0 0 0 4 0 NN NNS VBP NNS JJ O
cells cells 0 0 0 0 0 0 0 0 5 0 NNS VBP NNS JJ IN O
irrespective irrespective 0 0 0 0 0 0 0 0 12 0 VBP NNS JJ IN IN O
of of 0 0 0 0 0 0 0 0 2 0 NNS JJ IN IN PRP O
whether whether 0 0 0 0 0 0 0 0 7 0 JJ IN IN PRP VBP O
they they 0 0 0 0 0 0 0 0 4 0 IN IN PRP VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 IN PRP VBP JJ CC O
normal normal 0 0 0 0 0 0 0 0 6 0 PRP VBP JJ CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 VBP JJ CC JJ IN O
cancerous, cancerous, 0 0 0 0 1 0 0 0 10 0 JJ CC JJ IN NNS O
so so 0 0 0 0 0 0 0 0 2 0 CC JJ IN NNS VBP O
patients patients 0 0 0 0 0 0 0 0 8 0 JJ IN NNS VBP IN O
suffer suffer 0 0 0 0 0 0 0 0 6 0 IN NNS VBP IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBP IN JJ NN O
adverse adverse 0 0 0 0 0 0 0 0 7 0 VBP IN JJ NN NNS O
side side 0 0 0 0 0 0 0 0 4 0 IN JJ NN NNS JJ O
effects effects 0 0 0 0 0 0 0 0 7 0 JJ NN NNS JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 NN NNS JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNS JJ TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ TO DT NN IN O
loss loss 0 0 0 0 0 0 0 0 4 0 TO DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
healthy healthy 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP NNS O
Anticancer Anticancer 1 0 0 0 0 0 0 0 10 0 JJ NNP NNP NNS VBD O
insights insights 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBD IN O
derived derived 0 0 0 0 0 0 0 0 7 0 NNP NNS VBD IN NN O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBD IN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN NN VBZ O
research research 0 0 0 0 0 0 0 0 8 0 NN NN NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NN NN VBZ VBN JJ O
given given 0 0 0 0 0 0 0 0 5 0 NN VBZ VBN JJ TO O
birth birth 0 0 0 0 0 0 0 0 5 0 VBZ VBN JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBN JJ TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ TO DT NN IN O
idea idea 0 0 0 0 0 0 0 0 4 0 TO DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN NNP O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN NNP NN O
G2 G2 1 1 0 0 0 0 0 1 2 0 NN NN NNP NN NN G2
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NN NNP NN NN IN G2
abrogation abrogation 0 0 0 0 0 0 0 0 10 0 NNP NN NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN DT NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 DT NN NN NN NN O
specific specific 0 0 0 0 0 0 0 0 8 0 NN NN NN NN VBN O
therapy, therapy, 0 0 0 0 1 0 0 0 8 0 NN NN NN VBN IN O
based based 0 0 0 0 0 0 0 0 5 0 NN NN VBN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NN VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
discovery discovery 0 0 0 0 0 0 0 0 9 0 IN DT NN IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN JJ NN O
many many 0 0 0 0 0 0 0 0 4 0 NN IN JJ NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS VBP DT O
have have 0 0 0 0 0 0 0 0 4 0 NN NNS VBP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS VBP DT JJ NNP O
defective defective 0 0 0 0 0 0 0 0 9 0 VBP DT JJ NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 0 DT JJ NNP NN VBG G1
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 JJ NNP NN VBG IN G1
resulting resulting 0 0 0 0 0 0 0 0 9 0 NNP NN VBG IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN VBG IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBG IN DT NN IN O
dependence dependence 0 0 0 0 0 0 0 0 10 0 IN DT NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
G2 G2 1 1 0 0 0 0 0 1 2 0 IN DT NNP NN IN G2
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 DT NNP NN IN NN G2
during during 0 0 0 0 0 0 0 0 6 0 NNP NN IN NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NNP NNP O
replication. replication. 0 0 0 0 0 0 0 0 12 0 IN NN NNP NNP NNP O
Damaged Damaged 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NNP IN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNS VBZ O
humans humans 0 0 0 0 0 0 0 0 6 0 NNP IN NNS VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 IN NNS VBZ VBN IN O
detected detected 0 0 0 0 0 0 0 0 8 0 NNS VBZ VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN NN NNS O
sensor sensor 0 0 0 0 0 0 0 0 6 0 VBN IN NN NNS JJ O
proteins proteins 0 0 0 0 0 0 0 0 8 0 IN NN NNS JJ IN O
(such (such 0 0 0 0 0 0 0 0 5 0 NN NNS JJ IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 NNS JJ IN JJ NN O
hHUS1, hHUS1, 0 0 0 0 1 0 0 1 6 0 JJ IN JJ NN NN O
hRAD1, hRAD1, 0 0 0 0 1 0 0 1 6 0 IN JJ NN NN NN O
hRAD9, hRAD9, 0 0 0 0 1 0 0 1 6 0 JJ NN NN NN CC O
hRAD17, hRAD17, 0 0 0 0 1 0 0 1 7 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP IN O
hRAD26) hRAD26) 0 0 0 0 0 0 0 1 7 0 NN CC NNP IN NN O
that that 0 0 0 0 0 0 0 0 4 0 CC NNP IN NN DT O
transmit transmit 0 0 0 0 0 0 0 0 8 0 NNP IN NN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 IN NN DT NN IN O
signal signal 0 0 0 0 0 0 0 0 6 0 NN DT NN IN NNP O
via via 0 0 0 0 0 0 0 0 3 0 DT NN IN NNP TO O
ATR ATR 1 1 0 0 0 0 0 0 3 0 NN IN NNP TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 IN NNP TO NNP CC O
CHK1, CHK1, 1 1 0 0 1 0 0 1 5 0 NNP TO NNP CC IN O
or or 0 0 0 0 0 0 0 0 2 0 TO NNP CC IN DT O
by by 0 0 0 0 0 0 0 0 2 0 NNP CC IN DT NN O
another another 0 0 0 0 0 0 0 0 7 0 CC IN DT NN NN O
sensor sensor 0 0 0 0 0 0 0 0 6 0 IN DT NN NN WDT O
complex complex 0 0 0 0 0 0 0 0 7 0 DT NN NN WDT MD O
(that (that 0 0 0 0 0 0 0 0 5 0 NN NN WDT MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN WDT MD VB -NONE- O
include include 0 0 0 0 0 0 0 0 7 0 WDT MD VB -NONE- CD O
gammaH2AX, gammaH2AX, 0 0 0 0 1 0 0 1 10 0 MD VB -NONE- CD -NONE- O
53BP1, 53BP1, 0 1 0 0 1 0 0 1 6 0 VB -NONE- CD -NONE- JJ O
BRCA1, BRCA1, 1 1 0 0 1 0 0 1 6 0 -NONE- CD -NONE- JJ NN O
NBS1, NBS1, 1 1 0 0 1 0 0 1 5 0 CD -NONE- JJ NN CC O
hMRE11, hMRE11, 0 0 0 0 1 0 0 1 7 0 -NONE- JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP DT O
hRAD50), hRAD50), 0 0 0 0 1 0 0 1 8 0 NN CC NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC NNP DT NN IN O
signal signal 0 0 0 0 0 0 0 0 6 0 NNP DT NN IN WDT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 IN WDT VBZ VBN IN O
relayed relayed 0 0 0 0 0 0 0 0 7 0 WDT VBZ VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN NNP TO O
ATM ATM 1 1 0 0 0 0 0 0 3 0 VBN IN NNP TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 IN NNP TO NNP NNP O
CHK2. CHK2. 1 1 0 0 0 0 0 1 5 0 NNP TO NNP NNP IN O
Most Most 1 0 0 0 0 0 0 0 4 0 TO NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN VBZ O
damage damage 0 0 0 0 0 0 0 0 6 0 IN DT NN VBZ VBN O
signals signals 0 0 0 0 0 0 0 0 7 0 DT NN VBZ VBN IN O
originated originated 0 0 0 0 0 0 0 0 10 0 NN VBZ VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NNS O
sensor sensor 0 0 0 0 0 0 0 0 6 0 IN DT NN NNS IN O
complexes complexes 0 0 0 0 0 0 0 0 9 0 DT NN NNS IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NN O
G2 G2 1 1 0 0 0 0 0 1 2 0 IN DT NNP NN VBP G2
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 DT NNP NN VBP VBN G2
are are 0 0 0 0 0 0 0 0 3 0 NNP NN VBP VBN TO O
conducted conducted 0 0 0 0 0 0 0 0 9 0 NN VBP VBN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 VBP VBN TO NNP DT O
CDC25C, CDC25C, 1 1 0 0 1 0 0 1 7 0 VBN TO NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO NNP DT NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NNP DT NN IN WDT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 IN WDT VBZ VBN IN O
modulated modulated 0 0 0 0 0 0 0 0 9 0 WDT VBZ VBN IN CD O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN CD EX O
14-3-3. 14-3-3. 0 0 1 0 0 0 0 1 7 0 VBN IN CD EX VBP O
There There 1 0 0 0 0 0 0 0 5 0 IN CD EX VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 CD EX VBP RB RBR O
also also 0 0 0 0 0 0 0 0 4 0 EX VBP RB RBR RB O
less less 0 0 0 0 0 0 0 0 4 0 VBP RB RBR RB VBN O
extensively extensively 0 0 0 0 0 0 0 0 11 0 RB RBR RB VBN NNS O
explored explored 0 0 0 0 0 0 0 0 8 0 RBR RB VBN NNS VBG O
pathways pathways 0 0 0 0 0 0 0 0 8 0 RB VBN NNS VBG NN O
involving involving 0 0 0 0 0 0 0 0 9 0 VBN NNS VBG NN NN O
p53, p53, 0 0 0 0 1 0 0 1 4 0 NNS VBG NN NN NN O
p38, p38, 0 0 0 0 1 0 0 1 4 0 VBG NN NN NN NN O
PCNA, PCNA, 1 1 0 0 1 0 0 0 5 0 NN NN NN NN NN O
HDAC, HDAC, 1 1 0 0 1 0 0 0 5 0 NN NN NN NN NN O
PP2A, PP2A, 1 1 0 0 1 0 0 1 5 0 NN NN NN NN NN O
PLK1, PLK1, 1 1 0 0 1 0 0 1 5 0 NN NN NN NN NN O
WEE1, WEE1, 1 1 0 0 1 0 0 1 5 0 NN NN NN NN CC O
CDC25B, CDC25B, 1 1 0 0 1 0 0 1 7 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
CDC25A. CDC25A. 1 1 0 0 0 0 0 1 7 0 NN CC NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 CC NNP NNP NN MD O
review review 0 0 0 0 0 0 0 0 6 0 NNP NNP NN MD VB O
will will 0 0 0 0 0 0 0 0 4 0 NNP NN MD VB DT O
examine examine 0 0 0 0 0 0 0 0 7 0 NN MD VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT JJ NNS O
available available 0 0 0 0 0 0 0 0 9 0 VB DT JJ NNS IN O
inhibitors inhibitors 0 0 0 0 0 0 0 0 10 0 DT JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NNP O
CHK1 CHK1 1 1 0 0 0 0 0 1 4 0 NNS IN NNP NNP NNP O
(Staurosporin, (Staurosporin, 0 0 0 0 1 0 0 0 14 0 IN NNP NNP NNP NNP O
UCN-01, UCN-01, 1 1 1 0 1 0 0 1 7 0 NNP NNP NNP NNP NNP O
Go6976, Go6976, 1 0 0 0 1 0 0 1 7 0 NNP NNP NNP NNP NNP O
SB-218078, SB-218078, 1 1 1 0 1 0 0 1 10 0 NNP NNP NNP NNP CC O
ICP-1, ICP-1, 1 1 1 0 1 0 0 1 6 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP DT O
CEP-3891), CEP-3891), 1 1 1 0 1 0 0 1 10 0 NNP CC NNP DT NNP O
both both 0 0 0 0 0 0 0 0 4 0 CC NNP DT NNP CC O
CHK1 CHK1 1 1 0 0 0 0 0 1 4 0 NNP DT NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC NNP NNP O
CHK2 CHK2 1 1 0 0 0 0 0 1 4 0 NNP CC NNP NNP CC O
(TAT-S216A (TAT-S216A 0 1 1 0 0 0 0 1 10 0 CC NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
debromohymenialdisine), debromohymenialdisine), 0 0 0 0 1 0 0 0 23 0 NNP CC NNP NNP NNP O
CHK2 CHK2 1 1 0 0 0 0 0 1 4 0 CC NNP NNP NNP NNP O
(CEP-6367), (CEP-6367), 0 1 1 0 1 0 0 1 11 0 NNP NNP NNP NNP NNP O
WEE1 WEE1 1 1 0 0 0 0 0 1 4 0 NNP NNP NNP NNP CC O
(PD0166285), (PD0166285), 0 1 0 0 1 0 0 1 12 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
PP2A PP2A 1 1 0 0 0 0 0 1 4 0 NNP CC NNP NNP VBD O
(okadaic (okadaic 0 0 0 0 0 0 0 0 8 0 CC NNP NNP VBD CC O
acid acid 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP VBD CC JJ IN O
fostriecin), fostriecin), 0 0 0 0 1 0 0 0 12 0 VBD CC JJ IN RB O
as as 0 0 0 0 0 0 0 0 2 0 CC JJ IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 JJ IN RB IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NN NN O
unknown unknown 0 0 0 0 0 0 0 0 7 0 IN DT NN NN NNS O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 DT NN NN NNS CD O
inhibitors inhibitors 0 0 0 0 0 0 0 0 10 0 NN NN NNS CD CC O
13-hydroxy-15-ozoapathin 13-hydroxy-15-ozoapathin 0 0 1 0 0 0 0 1 24 0 NN NNS CD CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NNS CD CC DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 CD CC DT NNP NNP O
isogranulatimides. isogranulatimides. 0 0 0 0 0 0 0 0 18 0 CC DT NNP NNP DT O
Among Among 1 0 0 0 0 0 0 0 5 0 DT NNP NNP DT JJ O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT JJ NNP O
targets, targets, 0 0 0 0 1 0 0 0 8 0 NNP DT JJ NNP VBZ O
CHK1 CHK1 1 1 0 0 0 0 0 1 4 0 DT JJ NNP VBZ TO O
seems seems 0 0 0 0 0 0 0 0 5 0 JJ NNP VBZ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBZ TO VB DT O
be be 0 0 0 0 0 0 0 0 2 0 VBZ TO VB DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJS JJ O
most most 0 0 0 0 0 0 0 0 4 0 VB DT JJS JJ NN O
suitable suitable 0 0 0 0 0 0 0 0 8 0 DT JJS JJ NN IN O
target target 0 0 0 0 0 0 0 0 6 0 JJS JJ NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN JJ NNP O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 NN IN JJ NNP NN O
G2 G2 1 1 0 0 0 0 0 1 2 0 IN JJ NNP NN TO B_TIMEXCCP
abrogation abrogation 0 0 0 0 0 0 0 0 10 0 JJ NNP NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO NNP IN O
date, date, 0 0 0 0 1 0 0 0 5 0 NN TO NNP IN DT O
although although 0 0 0 0 0 0 0 0 8 0 TO NNP IN DT VBN O
an an 0 0 0 0 0 0 0 0 2 0 NNP IN DT VBN NN O
unexplored unexplored 0 0 0 0 0 0 0 0 10 0 IN DT VBN NN JJ O
target target 0 0 0 0 0 0 0 0 6 0 DT VBN NN JJ IN O
such such 0 0 0 0 0 0 0 0 4 0 VBN NN JJ IN CD O
as as 0 0 0 0 0 0 0 0 2 0 NN JJ IN CD CC O
14-3-3 14-3-3 0 0 1 0 0 0 0 1 6 0 JJ IN CD CC DT O
or or 0 0 0 0 0 0 0 0 2 0 IN CD CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CD CC DT NN IN O
strategy strategy 0 0 0 0 0 0 0 0 8 0 CC DT NN IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN VBG NN O
targeting targeting 0 0 0 0 0 0 0 0 9 0 NN IN VBG NN NNS O
multiple multiple 0 0 0 0 0 0 0 0 8 0 IN VBG NN NNS IN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 VBG NN NNS IN RB O
at at 0 0 0 0 0 0 0 0 2 0 NN NNS IN RB MD O
once once 0 0 0 0 0 0 0 0 4 0 NNS IN RB MD VB O
may may 0 0 0 0 0 0 0 0 3 0 IN RB MD VB IN O
be be 0 0 0 0 0 0 0 0 2 0 RB MD VB IN NN O
of of 0 0 0 0 0 0 0 0 2 0 MD VB IN NN IN O
interest interest 0 0 0 0 0 0 0 0 8 0 VB IN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
future. future. 0 0 0 0 0 0 0 0 7 0 IN DT NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 DT NNP NNP CD JJ O
15078995 15078995 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Microtubule Microtubule 1 0 0 0 0 0 0 0 11 0 NONE NONE NNP NNS JJR O
dynamics dynamics 0 0 0 0 0 0 0 0 8 0 NONE NNP NNS JJR DT O
alter alter 0 0 0 0 0 0 0 0 5 0 NNP NNS JJR DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS JJR DT NN NNP O
interphase interphase 0 0 0 0 0 0 0 0 10 0 JJR DT NN NNP NNP B_TIMEXCCP
nucleus. nucleus. 0 0 0 0 0 0 0 0 8 0 DT NN NNP NNP NNP O
Gerlitz Gerlitz 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Reiner Reiner 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
O, O, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Bustin Bustin 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
M. M. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Protein Protein 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Section, Section, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP IN O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Metabolism, Metabolism, 1 0 0 0 1 0 0 0 11 0 NNP IN NNP NNP NNP O
National National 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Institute, Institute, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
US US 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNPS O
National National 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNPS IN O
Institutes Institutes 1 0 0 0 0 0 0 0 10 0 NNP NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
Health, Health, 1 0 0 0 1 0 0 0 7 0 NNPS IN NNP NNP NNP O
Bethesda, Bethesda, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP CD O
MD MD 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
20892, 20892, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
gabi.gerlitz@gmail.com gabi.gerlitz@gmail.com 0 0 0 0 0 0 0 0 22 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBP O
Microtubules Microtubules 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNP VBP VBN TO O
known known 0 0 0 0 0 0 0 0 5 0 NNP VBP VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBP VBN TO VB NN O
drive drive 0 0 0 0 0 0 0 0 5 0 VBN TO VB NN NNS O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 TO VB NN NNS CC O
movements movements 0 0 0 0 0 0 0 0 9 0 VB NN NNS CC TO O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNS CC TO VB JJ O
induce induce 0 0 0 0 0 0 0 0 6 0 CC TO VB JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 TO VB JJ NN NN O
envelope envelope 0 0 0 0 0 0 0 0 8 0 VB JJ NN NN IN O
breakdown breakdown 0 0 0 0 0 0 0 0 9 0 JJ NN NN IN NN O
during during 0 0 0 0 0 0 0 0 6 0 NN NN IN NN CC O
mitosis mitosis 0 0 0 0 0 0 0 0 7 0 NN IN NN CC NNP B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NNP NNP O
meiosis. meiosis. 0 0 0 0 0 0 0 0 8 0 NN CC NNP NNP PRP O
Here Here 1 0 0 0 0 0 0 0 4 0 CC NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NNP PRP VBP IN NNS O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN NNS MD O
microtubules microtubules 0 0 0 0 0 0 0 0 12 0 VBP IN NNS MD VB O
can can 0 0 0 0 0 0 0 0 3 0 IN NNS MD VB JJ O
enforce enforce 0 0 0 0 0 0 0 0 7 0 NNS MD VB JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 MD VB JJ NN VBG O
envelope envelope 0 0 0 0 0 0 0 0 8 0 VB JJ NN VBG CC O
folding folding 0 0 0 0 0 0 0 0 7 0 JJ NN VBG CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN VBG CC NN DT O
alter alter 0 0 0 0 0 0 0 0 5 0 VBG CC NN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 CC NN DT NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 NN DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ JJ O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 NNS IN JJ JJ NN O
envelope-associated envelope-associated 0 0 1 0 0 0 0 0 19 0 IN JJ JJ NN IN O
heterochromatin heterochromatin 0 0 0 0 0 0 0 0 15 0 JJ JJ NN IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 JJ NN IN JJ WRB O
interphase, interphase, 0 0 0 0 1 0 0 0 11 0 NN IN JJ WRB DT B_TIMEXCCP
when when 0 0 0 0 0 0 0 0 4 0 IN JJ WRB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ WRB DT JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 WRB DT JJ NN VBZ O
envelope envelope 0 0 0 0 0 0 0 0 8 0 DT JJ NN VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ NNP NNP O
intact. intact. 0 0 0 0 0 0 0 0 7 0 NN VBZ NNP NNP NNP O
Microtubule Microtubule 1 0 0 0 0 0 0 0 11 0 VBZ NNP NNP NNP IN O
reassembly, reassembly, 0 0 0 0 1 0 0 0 11 0 NNP NNP NNP IN RB O
after after 0 0 0 0 0 0 0 0 5 0 NNP NNP IN RB VBN O
chemically chemically 0 0 0 0 0 0 0 0 10 0 NNP IN RB VBN NN O
induced induced 0 0 0 0 0 0 0 0 7 0 IN RB VBN NN VBN O
depolymerization depolymerization 0 0 0 0 0 0 0 0 16 0 RB VBN NN VBN TO O
led led 0 0 0 0 0 0 0 0 3 0 VBN NN VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBN TO VB IN O
folding folding 0 0 0 0 0 0 0 0 7 0 VBN TO VB IN DT O
of of 0 0 0 0 0 0 0 0 2 0 TO VB IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VB IN DT JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN CC O
envelope envelope 0 0 0 0 0 0 0 0 8 0 DT JJ NN CC TO O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN CC TO DT NN O
a a 0 0 0 0 0 0 0 0 1 0 CC TO DT NN NN O
transient transient 0 0 0 0 0 0 0 0 9 0 TO DT NN NN IN O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 DT NN NN IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN VBN NN O
condensed condensed 0 0 0 0 0 0 0 0 9 0 NN IN VBN NN IN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 IN VBN NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 VBN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
site site 0 0 0 0 0 0 0 0 4 0 IN DT JJ NN DT O
nearest nearest 0 0 0 0 0 0 0 0 7 0 DT JJ NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NN VBG O
microtubule microtubule 0 0 0 0 0 0 0 0 11 0 NN DT NN VBG NN O
organizing organizing 0 0 0 0 0 0 0 0 10 0 DT NN VBG NN NNP O
center center 0 0 0 0 0 0 0 0 6 0 NN VBG NN NNP NNP O
(MTOC). (MTOC). 0 1 0 0 0 0 0 0 7 0 VBG NN NNP NNP NNP O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NNP NN O
microtubule-dependent microtubule-dependent 0 0 1 0 0 0 0 0 21 0 NNP NNP NNP NN NN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NN IN O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 NNP NN NN IN TO O
next next 0 0 0 0 0 0 0 0 4 0 NN NN IN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN IN TO DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 IN TO DT NNP VBZ O
MTOC MTOC 1 1 0 0 0 0 0 0 4 0 TO DT NNP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 DT NNP VBZ JJ IN O
dependent dependent 0 0 0 0 0 0 0 0 9 0 NNP VBZ JJ IN DT O
on on 0 0 0 0 0 0 0 0 2 0 VBZ JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN IN O
composition composition 0 0 0 0 0 0 0 0 11 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN CC O
lamina lamina 0 0 0 0 0 0 0 0 6 0 DT JJ NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 CC DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
dynein dynein 0 0 0 0 0 0 0 0 6 0 IN DT NN NN NNP O
motor motor 0 0 0 0 0 0 0 0 5 0 DT NN NN NNP NNP O
protein. protein. 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNP NNP VBP IN NNS O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBP IN NNS VBG O
forces forces 0 0 0 0 0 0 0 0 6 0 VBP IN NNS VBG IN O
originating originating 0 0 0 0 0 0 0 0 11 0 IN NNS VBG IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBG IN JJ NN O
simultaneous simultaneous 0 0 0 0 0 0 0 0 12 0 VBG IN JJ NN IN O
polymerization polymerization 0 0 0 0 0 0 0 0 14 0 IN JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNS O
microtubule microtubule 0 0 0 0 0 0 0 0 11 0 NN IN NN NNS NN O
fibers fibers 0 0 0 0 0 0 0 0 6 0 IN NN NNS NN DT O
deform deform 0 0 0 0 0 0 0 0 6 0 NN NNS NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS NN DT JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 NN DT JJ NN CC O
membrane membrane 0 0 0 0 0 0 0 0 8 0 DT JJ NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT VBG O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT VBG NNP O
underlying underlying 0 0 0 0 0 0 0 0 10 0 CC DT VBG NNP NNP O
lamina. lamina. 0 0 0 0 0 0 0 0 7 0 DT VBG NNP NNP NN O
Whereas Whereas 1 0 0 0 0 0 0 0 7 0 VBG NNP NNP NN NN O
dynein dynein 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NN NNS O
motor motor 0 0 0 0 0 0 0 0 5 0 NNP NN NN NNS VBD O
complexes complexes 0 0 0 0 0 0 0 0 9 0 NN NN NNS VBD TO O
localized localized 0 0 0 0 0 0 0 0 9 0 NN NNS VBD TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBD TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBD TO DT JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 TO DT JJ NN WDT O
envelope envelope 0 0 0 0 0 0 0 0 8 0 DT JJ NN WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT NN IN O
slide slide 0 0 0 0 0 0 0 0 5 0 NN WDT NN IN DT O
along along 0 0 0 0 0 0 0 0 5 0 WDT NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS VBP O
microtubules microtubules 0 0 0 0 0 0 0 0 12 0 IN DT NNS VBP NNS O
transfer transfer 0 0 0 0 0 0 0 0 8 0 DT NNS VBP NNS -NONE- O
forces forces 0 0 0 0 0 0 0 0 6 0 NNS VBP NNS -NONE- NNS O
and/or and/or 0 0 0 1 0 0 0 0 6 0 VBP NNS -NONE- NNS IN O
signals signals 0 0 0 0 0 0 0 0 7 0 NNS -NONE- NNS IN DT O
into into 0 0 0 0 0 0 0 0 4 0 -NONE- NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ TO O
nucleus nucleus 0 0 0 0 0 0 0 0 7 0 IN DT JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT JJ TO VB NN O
induce induce 0 0 0 0 0 0 0 0 6 0 JJ TO VB NN NN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 TO VB NN NN CC O
reorganization reorganization 0 0 0 0 0 0 0 0 14 0 VB NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 NN CC NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 CC NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN NNP O
membrane membrane 0 0 0 0 0 0 0 0 8 0 DT JJ NN NNP NNP O
folds. folds. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP PRP$ O
Thus, Thus, 1 0 0 0 1 0 0 0 5 0 NN NNP NNP PRP$ NN O
our our 0 0 0 0 0 0 0 0 3 0 NNP NNP PRP$ NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NNP PRP$ NN VBD DT O
identified identified 0 0 0 0 0 0 0 0 10 0 PRP$ NN VBD DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBD DT JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 VBD DT JJ NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN WDT O
by by 0 0 0 0 0 0 0 0 2 0 JJ NN IN WDT JJ O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT JJ NNS O
mechanical mechanical 0 0 0 0 0 0 0 0 10 0 IN WDT JJ NNS VBN O
forces forces 0 0 0 0 0 0 0 0 6 0 WDT JJ NNS VBN IN O
generated generated 0 0 0 0 0 0 0 0 9 0 JJ NNS VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NN O
cytoplasm cytoplasm 0 0 0 0 0 0 0 0 9 0 IN DT NN NN DT O
reshape reshape 0 0 0 0 0 0 0 0 7 0 DT NN NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 NN DT JJ NN NN O
envelope, envelope, 0 0 0 0 1 0 0 0 9 0 DT JJ NN NN DT O
alter alter 0 0 0 0 0 0 0 0 5 0 JJ NN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NN NN O
intranuclear intranuclear 0 0 0 0 0 0 0 0 12 0 NN DT NN NN IN O
organization organization 0 0 0 0 0 0 0 0 12 0 DT NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP CC O
chromatin, chromatin, 0 0 0 0 1 0 0 0 10 0 NN IN NNP CC VB O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC VB DT O
affect affect 0 0 0 0 0 0 0 0 6 0 NNP CC VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC VB DT NN IN O
architecture architecture 0 0 0 0 0 0 0 0 12 0 VB DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
interphase interphase 0 0 0 0 0 0 0 0 10 0 IN DT NN NNP NNP B_TIMEXCCP
nucleus. nucleus. 0 0 0 0 0 0 0 0 8 0 DT NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
23117601 23117601 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Mitosis Mitosis 1 0 0 0 0 0 0 0 7 0 NONE NONE NNP NNS DT B_TIMEXCCP
controls controls 0 0 0 0 0 0 0 0 8 0 NONE NNP NNS DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNS DT NNP CC O
Golgi Golgi 1 0 0 0 0 0 0 0 5 0 NNS DT NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP CC DT NNP NNS O
Golgi Golgi 1 0 0 0 0 0 0 0 5 0 CC DT NNP NNS NNP O
controls controls 0 0 0 0 0 0 0 0 8 0 DT NNP NNS NNP NNP O
mitosis. mitosis. 0 0 0 0 0 0 0 0 8 0 NNP NNS NNP NNP NNP B_TIMEXCCP
Colanzi Colanzi 1 0 0 0 0 0 0 0 7 0 NNS NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Corda Corda 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
D. D. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP CC O
Biology Biology 1 0 0 0 0 0 0 0 7 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Oncology, Oncology, 1 0 0 0 1 0 0 0 9 0 NNP CC NNP NNP NNP O
Consorzio Consorzio 1 0 0 0 0 0 0 0 9 0 CC NNP NNP NNP NNP O
Mario Mario 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Negri Negri 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP CD O
Sud, Sud, 1 0 0 0 1 0 0 0 4 0 NNP NNP NNP CD NNP O
66030 66030 0 0 0 0 0 0 1 1 5 0 NNP NNP CD NNP NNP O
Santa Santa 1 0 0 0 0 0 0 0 5 0 NNP CD NNP NNP NNP O
Maria Maria 1 0 0 0 0 0 0 0 5 0 CD NNP NNP NNP NNP O
Imbaro, Imbaro, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Chieti, Chieti, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Italy. Italy. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP DT O
mammals, mammals, 0 0 0 0 1 0 0 0 8 0 NNP NNP NNP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNP NN O
Golgi Golgi 1 0 0 0 0 0 0 0 5 0 NNP DT NNP NN VBZ O
complex complex 0 0 0 0 0 0 0 0 7 0 DT NNP NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ VBN IN O
structured structured 0 0 0 0 0 0 0 0 10 0 NN VBZ VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
form form 0 0 0 0 0 0 0 0 4 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ JJ O
continuous continuous 0 0 0 0 0 0 0 0 10 0 IN DT JJ JJ NN O
membranous membranous 0 0 0 0 0 0 0 0 10 0 DT JJ JJ NN VBD O
system system 0 0 0 0 0 0 0 0 6 0 JJ JJ NN VBD IN O
composed composed 0 0 0 0 0 0 0 0 8 0 JJ NN VBD IN IN O
of of 0 0 0 0 0 0 0 0 2 0 NN VBD IN IN TO O
up up 0 0 0 0 0 0 0 0 2 0 VBD IN IN TO CD O
to to 0 0 0 0 0 0 0 0 2 0 IN IN TO CD NNS O
100 100 0 0 0 0 0 0 1 1 3 0 IN TO CD NNS VBN O
stacks stacks 0 0 0 0 0 0 0 0 6 0 TO CD NNS VBN IN O
connected connected 0 0 0 0 0 0 0 0 9 0 CD NNS VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBN IN JJ NN O
tubular tubular 0 0 0 0 0 0 0 0 7 0 VBN IN JJ NN DT O
bridges, bridges, 0 0 0 0 1 0 0 0 8 0 IN JJ NN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NNP NNP O
'Golgi 'Golgi 0 0 0 0 0 1 0 0 6 0 NN DT NNP NNP NNP O
ribbon'. ribbon'. 0 0 0 0 0 1 0 0 8 0 DT NNP NNP NNP NNP O
During During 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP DT O
mitosis, mitosis, 0 0 0 0 1 0 0 0 8 0 NNP NNP NNP DT NNP B_TIMEXCCP
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNP VBZ O
Golgi Golgi 1 0 0 0 0 0 0 0 5 0 NNP DT NNP VBZ JJ O
undergoes undergoes 0 0 0 0 0 0 0 0 9 0 DT NNP VBZ JJ NN O
extensive extensive 0 0 0 0 0 0 0 0 9 0 NNP VBZ JJ NN IN O
fragmentation fragmentation 0 0 0 0 0 0 0 0 13 0 VBZ JJ NN IN DT O
through through 0 0 0 0 0 0 0 0 7 0 JJ NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN NN O
multistage multistage 0 0 0 0 0 0 0 0 10 0 IN DT NN NN WDT O
process process 0 0 0 0 0 0 0 0 7 0 DT NN NN WDT VBZ O
that that 0 0 0 0 0 0 0 0 4 0 NN NN WDT VBZ PRP$ O
allows allows 0 0 0 0 0 0 0 0 6 0 NN WDT VBZ PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 WDT VBZ PRP$ NN VBG O
correct correct 0 0 0 0 0 0 0 0 7 0 VBZ PRP$ NN VBG CC O
partitioning partitioning 0 0 0 0 0 0 0 0 12 0 PRP$ NN VBG CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN VBG CC NN IN O
inheritance inheritance 0 0 0 0 0 0 0 0 11 0 VBG CC NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NNP O
daughter daughter 0 0 0 0 0 0 0 0 8 0 NN IN NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NN NNP NNP DT O
Strikingly, Strikingly, 1 0 0 0 1 0 0 0 11 0 NN NNP NNP DT NNP O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NNP NN O
Golgi Golgi 1 0 0 0 0 0 0 0 5 0 NNP DT NNP NN VBZ O
fragmentation fragmentation 0 0 0 0 0 0 0 0 13 0 DT NNP NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ VBN RB O
required required 0 0 0 0 0 0 0 0 8 0 NN VBZ VBN RB RB O
not not 0 0 0 0 0 0 0 0 3 0 VBZ VBN RB RB IN O
only only 0 0 0 0 0 0 0 0 4 0 VBN RB RB IN NN O
for for 0 0 0 0 0 0 0 0 3 0 RB RB IN NN CC O
inheritance inheritance 0 0 0 0 0 0 0 0 11 0 RB IN NN CC RB O
but but 0 0 0 0 0 0 0 0 3 0 IN NN CC RB IN O
also also 0 0 0 0 0 0 0 0 4 0 NN CC RB IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 CC RB IN JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 RB IN JJ NN NN B_TIMEXCCP
entrance entrance 0 0 0 0 0 0 0 0 8 0 IN JJ NN NN IN O
itself, itself, 0 0 0 0 1 0 0 0 7 0 JJ NN NN IN PRP$ O
since since 0 0 0 0 0 0 0 0 5 0 NN NN IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NN IN PRP$ NN NNS O
block block 0 0 0 0 0 0 0 0 5 0 IN PRP$ NN NNS IN O
results results 0 0 0 0 0 0 0 0 7 0 PRP$ NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 arrest NNS IN DT NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN IN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP DT O
G2. G2. 1 1 0 0 0 0 0 1 3 0 NN IN NNP DT VBZ B_TIMEXCCP
This This 1 0 0 0 0 0 0 0 4 0 IN NNP DT VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP DT VBZ VBN DT O
called called 0 0 0 0 0 0 0 0 6 0 DT VBZ VBN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBZ VBN DT NNP JJ O
'Golgi 'Golgi 0 0 0 0 0 1 0 0 6 0 VBN DT NNP JJ NNP O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 DT NNP JJ NNP NNP M
checkpoint'. checkpoint'. 0 0 0 0 0 1 0 0 12 0 NNP JJ NNP NNP NNS O
Recent Recent 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP NNS VBP O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP VBN DT O
identified identified 0 0 0 0 0 0 0 0 10 0 NNS VBP VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP VBN DT NN IN O
severing severing 0 0 0 0 0 0 0 0 8 0 VBN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
ribbon ribbon 0 0 0 0 0 0 0 0 6 0 IN DT NN IN PRP$ O
into into 0 0 0 0 0 0 0 0 4 0 DT NN IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NN IN PRP$ NN NNS O
constituent constituent 0 0 0 0 0 0 0 0 11 0 IN PRP$ NN NNS IN O
stacks stacks 0 0 0 0 0 0 0 0 6 0 PRP$ NN NNS IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 NN NNS IN JJ NNP O
early early 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NNP IN G2
G2 G2 1 1 0 0 0 0 0 1 2 0 IN JJ NNP IN DT G2
as as 0 0 0 0 0 0 0 0 2 0 JJ NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN NN O
precise precise 0 0 0 0 0 0 0 0 7 0 IN DT NN NN IN O
stage stage 0 0 0 0 0 0 0 0 5 0 DT NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NN O
Golgi Golgi 1 0 0 0 0 0 0 0 5 0 NN IN NNP NN WDT O
fragmentation fragmentation 0 0 0 0 0 0 0 0 13 0 IN NNP NN WDT VBZ O
that that 0 0 0 0 0 0 0 0 4 0 NNP NN WDT VBZ JJ O
controls controls 0 0 0 0 0 0 0 0 8 0 NN WDT VBZ JJ NNP O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 WDT VBZ JJ NNP NNP B_TIMEXCCP
entry. entry. 0 0 0 0 0 0 0 0 6 0 VBZ JJ NNP NNP VBZ O
This This 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP VBZ JJ O
opens opens 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ JJ NNS O
new new 0 0 0 0 0 0 0 0 3 0 NNP VBZ JJ NNS TO O
ways ways 0 0 0 0 0 0 0 0 4 0 VBZ JJ NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO VB DT O
elucidate elucidate 0 0 0 0 0 0 0 0 9 0 NNS TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 VB DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
Golgi Golgi 1 0 0 0 0 0 0 0 5 0 IN DT NNP NNP NNP O
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 DT NNP NNP NNP CD B_TIMEXCCP
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNP NNP NNP CD JJ O
17689238 17689238 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NN IN O
structure structure 0 0 0 0 0 0 0 0 9 0 NONE DT NN IN RB O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN RB VBN O
partly partly 0 0 0 0 0 0 0 0 6 0 NN IN RB VBN NN O
decondensed decondensed 0 0 0 0 0 0 0 0 11 0 IN RB VBN NN NNP O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 RB VBN NN NNP NNP B_TIMEXCCP
chromosomes. chromosomes. 0 0 0 0 0 0 0 0 12 0 VBN NN NNP NNP NNP O
Nasedkina Nasedkina 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP NNP O
TV, TV, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Slesinger Slesinger 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
SI. SI. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
technique technique 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ VBD O
freeze-drying freeze-drying 0 0 1 0 0 0 0 0 13 0 NN IN JJ VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 IN JJ VBD VBN TO O
applied applied 0 0 0 0 0 0 0 0 7 0 JJ VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB DT O
examine examine 0 0 0 0 0 0 0 0 7 0 VBN TO VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJ NN O
submicroscopic submicroscopic 0 0 0 0 0 0 0 0 14 0 VB DT JJ NN IN O
organisation organisation 0 0 0 0 0 0 0 0 12 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNS O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 NN IN NN NNS IN B_TIMEXCCP
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 IN NN NNS IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NN NNS IN JJ NN O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 NNS IN JJ NN IN O
hamster hamster 0 0 0 0 0 0 0 0 7 0 IN JJ NN IN NN O
after after 0 0 0 0 0 0 0 0 5 0 JJ NN IN NN IN O
removal removal 0 0 0 0 0 0 0 0 7 0 NN IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NNS O
bivalent bivalent 0 0 0 0 0 0 0 0 8 0 NN IN NN NNS IN O
cations cations 0 0 0 0 0 0 0 0 7 0 IN NN NNS IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NN NNS IN NNP CC O
EDTA EDTA 1 1 0 0 0 0 0 0 4 0 NNS IN NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NN IN O
removal removal 0 0 0 0 0 0 0 0 7 0 NNP CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NNP O
histone histone 0 0 0 0 0 0 0 0 7 0 NN IN NN NNP IN O
HI HI 1 1 0 0 0 0 0 0 2 0 IN NN NNP IN CD O
with with 0 0 0 0 0 0 0 0 4 0 NN NNP IN CD NNP O
0,6 0,6 0 0 0 0 1 0 0 1 3 0 NNP IN CD NNP NNP O
M M 1 1 0 0 0 0 0 0 1 0 IN CD NNP NNP NNP O
NaCl. NaCl. 1 0 0 0 0 0 0 0 5 0 CD NNP NNP NNP VBZ O
Treated Treated 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP VBZ VBN O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 NNP NNP VBZ VBN IN O
increased increased 0 0 0 0 0 0 0 0 9 0 NNP VBZ VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN NNP CC O
size, size, 0 0 0 0 1 0 0 0 5 0 VBN IN NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC JJ NNS O
nucleosomal nucleosomal 0 0 0 0 0 0 0 0 11 0 NNP CC JJ NNS VBD O
filaments filaments 0 0 0 0 0 0 0 0 9 0 CC JJ NNS VBD IN O
appeared appeared 0 0 0 0 0 0 0 0 8 0 JJ NNS VBD IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NNS VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN IN O
periphery periphery 0 0 0 0 0 0 0 0 9 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
chromosomes. chromosomes. 0 0 0 0 0 0 0 0 12 0 IN DT NNP NNP IN O
Removal Removal 1 0 0 0 0 0 0 0 7 0 DT NNP NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN NNS O
bivalent bivalent 0 0 0 0 0 0 0 0 8 0 NNP IN NN NNS VBZ O
cations cations 0 0 0 0 0 0 0 0 7 0 IN NN NNS VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN NNS VBZ VBN IN O
accompanied accompanied 0 0 0 0 0 0 0 0 11 0 NNS VBZ VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
appearance appearance 0 0 0 0 0 0 0 0 10 0 IN DT NN IN RB O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN RB VBN O
regularly regularly 0 0 0 0 0 0 0 0 9 0 NN IN RB VBN NNS O
organized organized 0 0 0 0 0 0 0 0 9 0 IN RB VBN NNS IN O
structures structures 0 0 0 0 0 0 0 0 10 0 RB VBN NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NNP O
"beads-on-a-string" "beads-on-a-string" 0 0 1 0 0 0 0 0 19 0 IN DT JJ NNP NNP O
type. type. 0 0 0 0 0 0 0 0 5 0 DT JJ NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP JJ NN O
regular regular 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NN IN O
organization organization 0 0 0 0 0 0 0 0 12 0 NNP JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS VBZ O
fibers fibers 0 0 0 0 0 0 0 0 6 0 IN DT NNS VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 DT NNS VBZ VBN RB O
damaged damaged 0 0 0 0 0 0 0 0 7 0 NNS VBZ VBN RB RB O
as as 0 0 0 0 0 0 0 0 2 0 VBZ VBN RB RB IN O
soon soon 0 0 0 0 0 0 0 0 4 0 VBN RB RB IN NN O
as as 0 0 0 0 0 0 0 0 2 0 RB RB IN NN NNP O
histone histone 0 0 0 0 0 0 0 0 7 0 RB IN NN NNP VBZ O
H1 H1 1 1 0 0 0 0 0 1 2 0 IN NN NNP VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 NN NNP VBZ NNP NNP O
removed. removed. 0 0 0 0 0 0 0 0 8 0 NNP VBZ NNP NNP NN O
After After 1 0 0 0 0 0 0 0 5 0 VBZ NNP NNP NN IN O
decondensation decondensation 0 0 0 0 0 0 0 0 14 0 NNP NNP NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT CD O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT CD NNP O
0.6 0.6 0 0 0 0 0 0 0 1 3 0 IN DT CD NNP NNP O
M M 1 1 0 0 0 0 0 0 1 0 DT CD NNP NNP NN O
NaCl NaCl 1 0 0 0 0 0 0 0 4 0 CD NNP NNP NN DT O
solution solution 0 0 0 0 0 0 0 0 8 0 NNP NNP NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT NN VBZ O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 NN DT NN VBZ VBD B_TIMEXCCP
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 DT NN VBZ VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN VBZ VBD VBN IN O
treated treated 0 0 0 0 0 0 0 0 7 0 VBZ VBD VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN JJ NN O
staphylococcal staphylococcal 0 0 0 0 0 0 0 0 14 0 VBN IN JJ NN IN O
nuclease nuclease 0 0 0 0 0 0 0 0 8 0 IN JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
situ situ 0 0 0 0 0 0 0 0 4 0 NN IN NN IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNS O
EM EM 1 1 0 0 0 0 0 0 2 0 NN IN NNP NNS VBP O
grids grids 0 0 0 0 0 0 0 0 5 0 IN NNP NNS VBP DT O
nd nd 0 0 0 0 0 0 0 0 2 0 NNP NNS VBP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBP DT JJ NNS O
residual residual 0 0 0 0 0 0 0 0 8 0 VBP DT JJ NNS VBN O
structures structures 0 0 0 0 0 0 0 0 10 0 DT JJ NNS VBN VBG O
analysed analysed 0 0 0 0 0 0 0 0 8 0 JJ NNS VBN VBG NN O
using using 0 0 0 0 0 0 0 0 5 0 NNS VBN VBG NN NNP O
electron electron 0 0 0 0 0 0 0 0 8 0 VBN VBG NN NNP NNP O
microscopy. microscopy. 0 0 0 0 0 0 0 0 11 0 VBG NN NNP NNP NNS O
Nucleohistone Nucleohistone 1 0 0 0 0 0 0 0 13 0 NN NNP NNP NNS JJR O
fibers fibers 0 0 0 0 0 0 0 0 6 0 NNP NNP NNS JJR JJ O
wer wer 0 0 0 0 0 0 0 0 3 0 NNP NNS JJR JJ IN O
visible visible 0 0 0 0 0 0 0 0 7 0 NNS JJR JJ IN DT O
at at 0 0 0 0 0 0 0 0 2 0 JJR JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN IN O
periphery periphery 0 0 0 0 0 0 0 0 9 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS IN O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 IN DT NNS IN DT O
at at 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
beginning beginning 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
digestion. digestion. 0 0 0 0 0 0 0 0 10 0 NN IN NNP NNP JJ O
After After 1 0 0 0 0 0 0 0 5 0 IN NNP NNP JJ NN O
complete complete 0 0 0 0 0 0 0 0 8 0 NNP NNP JJ NN IN O
elimination elimination 0 0 0 0 0 0 0 0 11 0 NNP JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNS O
nucleohistone nucleohistone 0 0 0 0 0 0 0 0 13 0 IN DT NN NNS IN O
fibers fibers 0 0 0 0 0 0 0 0 6 0 DT NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
course course 0 0 0 0 0 0 0 0 6 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN DT O
digestion digestion 0 0 0 0 0 0 0 0 9 0 NN IN NN DT VBG O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT VBG JJ O
remaining remaining 0 0 0 0 0 0 0 0 9 0 NN DT VBG JJ NN O
proteinaceous proteinaceous 0 0 0 0 0 0 0 0 13 0 DT VBG JJ NN VBD O
material material 0 0 0 0 0 0 0 0 8 0 VBG JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN IN O
represented represented 0 0 0 0 0 0 0 0 11 0 NN VBD VBN IN NNS O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNS IN O
aggregates aggregates 0 0 0 0 0 0 0 0 10 0 VBN IN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN JJ NN O
irregular irregular 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NN CC O
shape shape 0 0 0 0 0 0 0 0 5 0 IN JJ NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 NN CC IN VBG NNP O
varying varying 0 0 0 0 0 0 0 0 7 0 CC IN VBG NNP NNP O
size. size. 0 0 0 0 0 0 0 0 5 0 IN VBG NNP NNP VBD O
These These 1 0 0 0 0 0 0 0 5 0 VBG NNP NNP VBD DT O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD DT VBN O
either either 0 0 0 0 0 0 0 0 6 0 NNP VBD DT VBN IN O
concentrated concentrated 0 0 0 0 0 0 0 0 12 0 VBD DT VBN IN DT O
along along 0 0 0 0 0 0 0 0 5 0 DT VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNS O
central central 0 0 0 0 0 0 0 0 7 0 IN DT JJ NNS IN O
axis axis 0 0 0 0 0 0 0 0 4 0 DT JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNS -NONE- O
chromatids chromatids 0 0 0 0 0 0 0 0 10 0 IN DT NNS -NONE- IN O
or, or, 0 0 0 0 1 0 0 0 3 0 DT NNS -NONE- IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NNS -NONE- IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- IN DT JJ NN O
final final 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN IN O
step step 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ VBN O
digestion, digestion, 0 0 0 0 1 0 0 0 10 0 NN IN JJ VBN RB O
scattered scattered 0 0 0 0 0 0 0 0 9 0 IN JJ VBN RB IN O
evenly evenly 0 0 0 0 0 0 0 0 6 0 JJ VBN RB IN DT O
over over 0 0 0 0 0 0 0 0 4 0 VBN RB IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT JJ NN O
entire entire 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN WDT O
area area 0 0 0 0 0 0 0 0 4 0 DT JJ NN WDT VBD O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT VBD VBN O
had had 0 0 0 0 0 0 0 0 3 0 NN WDT VBD VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 WDT VBD VBN VBN IN O
occupied occupied 0 0 0 0 0 0 0 0 8 0 VBD VBN VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBN VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NNP O
chromosome. chromosome. 0 0 0 0 0 0 0 0 11 0 IN DT NNP NNP IN O
Presumably, Presumably, 1 0 0 0 1 0 0 0 11 0 DT NNP NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN RB O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 IN DT NN RB TO O
prior prior 0 0 0 0 0 0 0 0 5 0 DT NN RB TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NN RB TO NNP DT O
digestion, digestion, 0 0 0 0 1 0 0 0 10 0 RB TO NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO NNP DT NN VBD O
material material 0 0 0 0 0 0 0 0 8 0 NNP DT NN VBD RB O
did did 0 0 0 0 0 0 0 0 3 0 DT NN VBD RB NN O
not not 0 0 0 0 0 0 0 0 3 0 NN VBD RB NN DT O
form form 0 0 0 0 0 0 0 0 4 0 VBD RB NN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 RB NN DT JJ NN O
integral integral 0 0 0 0 0 0 0 0 8 0 NN DT JJ NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 DT JJ NN NN JJ O
structure structure 0 0 0 0 0 0 0 0 9 0 JJ NN NN JJ TO O
similar similar 0 0 0 0 0 0 0 0 7 0 NN NN JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN JJ TO DT NN O
a a 0 0 0 0 0 0 0 0 1 0 JJ TO DT NN IN O
scaffold scaffold 0 0 0 0 0 0 0 0 8 0 TO DT NN IN VBN O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN VBN CC O
dehistonised dehistonised 0 0 0 0 0 0 0 0 12 0 NN IN VBN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN VBN CC NN NNP O
spread spread 0 0 0 0 0 0 0 0 6 0 VBN CC NN NNP NNP O
chromosomes. chromosomes. 0 0 0 0 0 0 0 0 12 0 CC NN NNP NNP NN O
An An 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NN NN O
alternative alternative 0 0 0 0 0 0 0 0 11 0 NNP NNP NN NN IN O
interpretation interpretation 0 0 0 0 0 0 0 0 14 0 NNP NN NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
fragmentation fragmentation 0 0 0 0 0 0 0 0 13 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 NN IN NN NN IN O
material material 0 0 0 0 0 0 0 0 8 0 IN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNS O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 IN DT NN NNS JJ O
considers considers 0 0 0 0 0 0 0 0 9 0 DT NN NNS JJ NN O
possible possible 0 0 0 0 0 0 0 0 8 0 NN NNS JJ NN IN O
degradation degradation 0 0 0 0 0 0 0 0 11 0 NNS JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBD O
protein protein 0 0 0 0 0 0 0 0 7 0 IN DT NN VBD IN O
scaffold scaffold 0 0 0 0 0 0 0 0 8 0 DT NN VBD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN IN O
course course 0 0 0 0 0 0 0 0 6 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
digestion. digestion. 0 0 0 0 0 0 0 0 10 0 NN IN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 IN NNP NNP CD JJ O
6183061 6183061 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Characterization Characterization 1 0 0 0 0 0 0 0 16 0 NONE NONE NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NN NN O
vertebrate vertebrate 0 0 0 0 0 0 0 0 10 0 NN IN NN NN NNS O
cohesin cohesin 0 0 0 0 0 0 0 0 7 0 IN NN NN NNS CC O
complexes complexes 0 0 0 0 0 0 0 0 9 0 NN NN NNS CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 NNS CC PRP$ NN IN O
regulation regulation 0 0 0 0 0 0 0 0 10 0 CC PRP$ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 PRP$ NN IN NNP NNP O
prophase. prophase. 0 0 0 0 0 0 0 0 9 0 NN IN NNP NNP NNP B_TIMEXCCP
Sumara Sumara 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
I, I, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Vorlaufer Vorlaufer 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
E, E, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Gieffers Gieffers 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Peters Peters 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
BH, BH, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Peters Peters 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
JM. JM. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP IN NNP NNP NNP O
Pathology Pathology 1 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP NNP O
(IMP), (IMP), 0 1 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
A-1030 A-1030 1 1 1 0 0 0 0 1 6 0 NNP NNP NNP NNP NNP O
Vienna, Vienna, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Austria. Austria. 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NN O
eukaryotes, eukaryotes, 0 0 0 0 1 0 0 0 11 0 NNP NNP NNP NN NNS O
sister sister 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NNS VBP O
chromatids chromatids 0 0 0 0 0 0 0 0 10 0 NNP NN NNS VBP VBN O
remain remain 0 0 0 0 0 0 0 0 6 0 NN NNS VBP VBN IN O
connected connected 0 0 0 0 0 0 0 0 9 0 NNS VBP VBN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 VBP VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
time time 0 0 0 0 0 0 0 0 4 0 IN DT NN IN PRP$ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 NN IN PRP$ NN IN O
synthesis synthesis 0 0 0 0 0 0 0 0 9 0 IN PRP$ NN IN PRP O
until until 0 0 0 0 0 0 0 0 5 0 PRP$ NN IN PRP VBP O
they they 0 0 0 0 0 0 0 0 4 0 NN IN PRP VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 IN PRP VBP VBN IN O
separated separated 0 0 0 0 0 0 0 0 9 0 PRP VBP VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBP VBN IN NNP DT O
anaphase. anaphase. 0 0 0 0 0 0 0 0 9 0 VBN IN NNP DT NN B_TIMEXCCP
This This 1 0 0 0 0 0 0 0 4 0 IN NNP DT NN VBZ O
cohesion cohesion 0 0 0 0 0 0 0 0 8 0 NNP DT NN VBZ IN O
depends depends 0 0 0 0 0 0 0 0 7 0 DT NN VBZ IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NN VBZ IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBZ IN DT JJ IN O
complex complex 0 0 0 0 0 0 0 0 7 0 IN DT JJ IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT JJ IN NNS VBN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 JJ IN NNS VBN NNP O
called called 0 0 0 0 0 0 0 0 6 0 IN NNS VBN NNP NNP O
cohesins. cohesins. 0 0 0 0 0 0 0 0 9 0 NNS VBN NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 VBN NNP NNP NN NN O
budding budding 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN DT O
yeast, yeast, 0 0 0 0 1 0 0 0 6 0 NNP NN NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT JJ NN O
anaphase-promoting anaphase-promoting 0 0 1 0 0 0 0 0 18 0 NN DT JJ NN NN O
complex complex 0 0 0 0 0 0 0 0 7 0 DT JJ NN NN NN O
(APC) (APC) 0 1 0 0 0 0 0 0 5 0 JJ NN NN NN VBZ O
pathway pathway 0 0 0 0 0 0 0 0 7 0 NN NN NN VBZ NN O
initiates initiates 0 0 0 0 0 0 0 0 9 0 NN NN VBZ NN IN O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 NN VBZ NN IN NN B_TIMEXCCP
by by 0 0 0 0 0 0 0 0 2 0 VBZ NN IN NN NNS O
removing removing 0 0 0 0 0 0 0 0 8 0 NN IN NN NNS IN O
cohesins cohesins 0 0 0 0 0 0 0 0 8 0 IN NN NNS IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NN NNS IN NNP NNP O
chromosomes. chromosomes. 0 0 0 0 0 0 0 0 12 0 NNS IN NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 IN NNP NNP NNP VBZ O
vertebrates, vertebrates, 0 0 0 0 1 0 0 0 12 0 NNP NNP NNP VBZ JJ O
cohesins cohesins 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ JJ IN O
dissociate dissociate 0 0 0 0 0 0 0 0 10 0 NNP VBZ JJ IN NNS O
from from 0 0 0 0 0 0 0 0 4 0 VBZ JJ IN NNS RB O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 JJ IN NNS RB IN O
already already 0 0 0 0 0 0 0 0 7 0 IN NNS RB IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNS RB IN NNP TO O
prophase. prophase. 0 0 0 0 0 0 0 0 9 0 RB IN NNP TO VB B_TIMEXCCP
To To 1 0 0 0 0 0 0 0 2 0 IN NNP TO VB PRP$ O
study study 0 0 0 0 0 0 0 0 5 0 NNP TO VB PRP$ JJ O
their their 0 0 0 0 0 0 0 0 5 0 TO VB PRP$ JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 VB PRP$ JJ NN PRP O
regulation regulation 0 0 0 0 0 0 0 0 10 0 PRP$ JJ NN PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 JJ NN PRP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NN PRP VBP VBN CD O
purified purified 0 0 0 0 0 0 0 0 8 0 PRP VBP VBN CD CD O
two two 0 0 0 0 0 0 0 0 3 0 VBP VBN CD CD NN O
14S 14S 0 1 0 0 0 0 0 1 3 0 VBN CD CD NN NNS O
cohesin cohesin 0 0 0 0 0 0 0 0 7 0 CD CD NN NNS IN O
complexes complexes 0 0 0 0 0 0 0 0 9 0 CD NN NNS IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NN NNS IN JJ NNP O
human human 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP NNS O
Both Both 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NNS VBP O
complexes complexes 0 0 0 0 0 0 0 0 9 0 NNP NNP NNS VBP JJ O
contain contain 0 0 0 0 0 0 0 0 7 0 NNP NNS VBP JJ NN O
SMC1, SMC1, 1 1 0 0 1 0 0 1 5 0 NNS VBP JJ NN NN O
SMC3, SMC3, 1 1 0 0 1 0 0 1 5 0 VBP JJ NN NN CC O
SCC1, SCC1, 1 1 0 0 1 0 0 1 5 0 JJ NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT CD O
either either 0 0 0 0 0 0 0 0 6 0 NN CC DT CD IN O
one one 0 0 0 0 0 0 0 0 3 0 CC DT CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT CD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT JJ NNP O
yeast yeast 0 0 0 0 0 0 0 0 5 0 IN DT JJ NNP NNS O
Scc3p Scc3p 1 0 0 0 0 0 0 1 5 0 DT JJ NNP NNS NNP O
orthologs orthologs 0 0 0 0 0 0 0 0 9 0 JJ NNP NNS NNP CC O
SA1 SA1 1 1 0 0 0 0 0 1 3 0 NNP NNS NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNS NNP CC NNP NNP O
SA2. SA2. 1 1 0 0 0 0 0 1 4 0 NNP CC NNP NNP VBZ O
SA1 SA1 1 1 0 0 0 0 0 1 3 0 CC NNP NNP VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ RB DT O
also also 0 0 0 0 0 0 0 0 4 0 NNP VBZ RB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBZ RB DT NN IN O
subunit subunit 0 0 0 0 0 0 0 0 7 0 RB DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD NN O
14S 14S 0 1 0 0 0 0 0 1 3 0 NN IN CD NN IN O
cohesin cohesin 0 0 0 0 0 0 0 0 7 0 IN CD NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN NNP NNP O
Xenopus. Xenopus. 1 0 0 0 0 0 0 0 8 0 NN IN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNS VBP O
complexes complexes 0 0 0 0 0 0 0 0 9 0 NNP NNP NNS VBP IN O
interact interact 0 0 0 0 0 0 0 0 8 0 NNP NNS VBP IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBP IN JJ DT O
PDS5, PDS5, 1 1 0 0 1 0 0 1 5 0 VBP IN JJ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 IN JJ DT NN WP$ O
protein protein 0 0 0 0 0 0 0 0 7 0 JJ DT NN WP$ JJ O
whose whose 0 0 0 0 0 0 0 0 5 0 DT NN WP$ JJ NNS O
fungal fungal 0 0 0 0 0 0 0 0 6 0 NN WP$ JJ NNS VBP O
orthologs orthologs 0 0 0 0 0 0 0 0 9 0 WP$ JJ NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 JJ NNS VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNS VBP VBN VBN IN O
implicated implicated 0 0 0 0 0 0 0 0 10 0 VBP VBN VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 VBN IN NN NN NN O
cohesion, cohesion, 0 0 0 0 1 0 0 0 9 0 IN NN NN NN CC O
condensation, condensation, 0 0 0 0 1 0 0 0 13 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
recombination. recombination. 0 0 0 0 0 0 0 0 14 0 NN CC NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 CC NNP NNP NN IN O
bulk bulk 0 0 0 0 0 0 0 0 4 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP CC O
SA1- SA1- 1 1 1 0 0 0 0 1 4 0 NN IN NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC JJ NNS O
SA2-containing SA2-containing 1 0 1 0 0 0 0 1 14 0 NNP CC JJ NNS CC O
complexes complexes 0 0 0 0 0 0 0 0 9 0 CC JJ NNS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC NNP VBP O
PDS5 PDS5 1 1 0 0 0 0 0 1 4 0 NNS CC NNP VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 CC NNP VBP JJ IN O
chromatin-associated chromatin-associated 0 0 1 0 0 0 0 0 20 0 NNP VBP JJ IN PRP O
until until 0 0 0 0 0 0 0 0 5 0 VBP JJ IN PRP VBP O
they they 0 0 0 0 0 0 0 0 4 0 JJ IN PRP VBP JJ O
become become 0 0 0 0 0 0 0 0 6 0 IN PRP VBP JJ IN O
soluble soluble 0 0 0 0 0 0 0 0 7 0 PRP VBP JJ IN NN O
from from 0 0 0 0 0 0 0 0 4 0 VBP JJ IN NN TO O
prophase prophase 0 0 0 0 0 0 0 0 8 0 JJ IN NN TO NNP B_TIMEXCCP
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO NNP NNP O
telophase. telophase. 0 0 0 0 0 0 0 0 10 0 NN TO NNP NNP IN B_TIMEXCCP
Reconstitution Reconstitution 1 0 0 0 0 0 0 0 14 0 TO NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP IN DT NN IN O
process process 0 0 0 0 0 0 0 0 7 0 IN DT NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNP NNS O
Xenopus Xenopus 1 0 0 0 0 0 0 0 7 0 IN JJ NNP NNS VBZ O
extracts extracts 0 0 0 0 0 0 0 0 8 0 JJ NNP NNS VBZ IN O
shows shows 0 0 0 0 0 0 0 0 5 0 NNP NNS VBZ IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBZ IN NN NN O
cohesin cohesin 0 0 0 0 0 0 0 0 7 0 VBZ IN NN NN VBZ O
dissociation dissociation 0 0 0 0 0 0 0 0 12 0 IN NN NN VBZ DT O
does does 0 0 0 0 0 0 0 0 4 0 NN NN VBZ DT NN O
neither neither 0 0 0 0 0 0 0 0 7 0 NN VBZ DT NN IN O
depend depend 0 0 0 0 0 0 0 0 6 0 VBZ DT NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP NN O
B B 1 1 0 0 0 0 0 0 1 0 IN NN NNP NN CC O
proteolysis proteolysis 0 0 0 0 0 0 0 0 11 0 NN NNP NN CC IN O
nor nor 0 0 0 0 0 0 0 0 3 0 NNP NN CC IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NN CC IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC IN DT NN IN O
presence presence 0 0 0 0 0 0 0 0 8 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
APC. APC. 1 1 0 0 0 0 0 0 4 0 IN DT NNP NNP MD O
Cohesins Cohesins 1 0 0 0 0 0 0 0 8 0 DT NNP NNP MD RB O
can can 0 0 0 0 0 0 0 0 3 0 NNP NNP MD RB VB O
also also 0 0 0 0 0 0 0 0 4 0 NNP MD RB VB IN O
dissociate dissociate 0 0 0 0 0 0 0 0 10 0 MD RB VB IN NN O
from from 0 0 0 0 0 0 0 0 4 0 RB VB IN NN IN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 VB IN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
absence absence 0 0 0 0 0 0 0 0 7 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
cyclin-dependent cyclin-dependent 0 0 1 0 0 0 0 0 16 0 NN IN JJ NN CD O
kinase kinase 0 0 0 0 0 0 0 0 6 0 IN JJ NN CD NNP O
1 1 0 0 0 0 0 0 1 1 1 0 JJ NN CD NNP NNP O
activity. activity. 0 0 0 0 0 0 0 0 9 0 NN CD NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 CD NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNP NNS VBP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN JJ NNS O
vertebrate vertebrate 0 0 0 0 0 0 0 0 10 0 VBP IN JJ NNS VBP O
cohesins cohesins 0 0 0 0 0 0 0 0 8 0 IN JJ NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 JJ NNS VBP VBN IN O
regulated regulated 0 0 0 0 0 0 0 0 9 0 NNS VBP VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBP VBN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 IN DT NN NN NN O
prophase prophase 0 0 0 0 0 0 0 0 8 0 DT NN NN NN WDT B_TIMEXCCP
pathway pathway 0 0 0 0 0 0 0 0 7 0 NN NN NN WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN WDT VBZ JJ IN O
distinct distinct 0 0 0 0 0 0 0 0 8 0 WDT VBZ JJ IN DT O
from from 0 0 0 0 0 0 0 0 4 0 VBZ JJ IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NNP NN O
APC APC 1 1 0 0 0 0 0 0 3 0 IN DT NNP NN WDT O
pathway pathway 0 0 0 0 0 0 0 0 7 0 DT NNP NN WDT VBZ O
that that 0 0 0 0 0 0 0 0 4 0 NNP NN WDT VBZ VBZ O
controls controls 0 0 0 0 0 0 0 0 8 0 NN WDT VBZ VBZ IN O
cohesins cohesins 0 0 0 0 0 0 0 0 8 0 WDT VBZ VBZ IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBZ VBZ IN NNP NNP O
yeast. yeast. 0 0 0 0 0 0 0 0 6 0 VBZ IN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 IN NNP NNP CD JJ O
11076961 11076961 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NN O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NN NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
PMC2169443 PMC2169443 1 1 0 0 0 0 0 1 10 0 JJ NN NNP NONE NONE O
Multiparametric Multiparametric 1 0 0 0 0 0 0 0 15 0 NONE NONE NNP NN IN O
evaluation evaluation 0 0 0 0 0 0 0 0 10 0 NONE NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN JJ O
flow flow 0 0 0 0 0 0 0 0 4 0 NN IN NN JJ NN O
cytometric cytometric 0 0 0 0 0 0 0 0 10 0 IN NN JJ NN NN O
synthesis synthesis 0 0 0 0 0 0 0 0 9 phase NN JJ NN NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 JJ NN NN NN NN O
fraction fraction 0 0 0 0 0 0 0 0 8 0 NN NN NN NN IN O
determination determination 0 0 0 0 0 0 0 0 13 0 NN NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
dual-labelled dual-labelled 0 0 1 0 0 0 0 0 13 0 NN IN JJ NN NNP O
breast breast 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNP NNP O
carcinomas. carcinomas. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP NNP NNP O
Visscher Visscher 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NNP NNP O
DW, DW, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wykes Wykes 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zarbo Zarbo 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
RJ, RJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Crissman Crissman 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
JD. JD. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pathology, Pathology, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP NNP O
Henry Henry 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
Ford Ford 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Hospital, Hospital, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Detroit, Detroit, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Michigan Michigan 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
48202. 48202. 0 0 0 0 0 0 0 1 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Multiparametric, Multiparametric, 1 0 0 0 1 0 0 0 16 0 NNP NNP NNP NNP NNP O
two-color two-color 0 0 1 0 0 0 0 0 9 0 NNP NNP NNP NNP CC O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP CC NN NN NNS O
cycle cycle 0 0 0 0 0 0 0 0 5 0 CC NN NN NNS VBD O
analyses analyses 0 0 0 0 0 0 0 0 8 0 NN NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
performed performed 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN CD O
on on 0 0 0 0 0 0 0 0 2 0 VBD VBN IN CD JJ O
112 112 0 0 0 0 0 0 1 1 3 0 VBN IN CD JJ RB O
consecutive consecutive 0 0 0 0 0 0 0 0 11 0 IN CD JJ RB JJ O
mechanically mechanically 0 0 0 0 0 0 0 0 12 0 CD JJ RB JJ JJ O
dissociated, dissociated, 0 0 0 0 1 0 0 0 12 0 JJ RB JJ JJ NN O
ethanol-fixed ethanol-fixed 0 0 1 0 0 0 0 0 13 0 RB JJ JJ NN NNS O
breast breast 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NNS VBG O
carcinomas carcinomas 0 0 0 0 0 0 0 0 10 0 JJ NN NNS VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 NN NNS VBG DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NNS VBG DT NNP NN O
dual-label dual-label 0 0 1 0 0 0 0 0 10 0 VBG DT NNP NN IN O
method method 0 0 0 0 0 0 0 0 6 0 DT NNP NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNP NN IN JJ NNS O
monoclonal monoclonal 0 0 0 0 0 0 0 0 10 0 NN IN JJ NNS JJ O
antibodies antibodies 0 0 0 0 0 0 0 0 10 0 IN JJ NNS JJ CD O
(CAM (CAM 0 1 0 0 0 0 0 0 4 0 JJ NNS JJ CD TO O
5.2) 5.2) 0 0 0 0 0 0 0 1 4 0 NNS JJ CD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ CD TO VB JJ O
cytokeratin cytokeratin 0 0 0 0 0 0 0 0 11 0 CD TO VB JJ CC O
(CK) (CK) 0 1 0 0 0 0 0 0 4 0 TO VB JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VB JJ CC JJ JJ O
leukocyte leukocyte 0 0 0 0 0 0 0 0 9 0 JJ CC JJ JJ NN O
common common 0 0 0 0 0 0 0 0 6 0 CC JJ JJ NN NN O
antigen antigen 0 0 0 0 0 0 0 0 7 0 JJ JJ NN NN IN O
(LCA) (LCA) 0 1 0 0 0 0 0 0 5 0 JJ NN NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN NN NN O
propidium propidium 0 0 0 0 0 0 0 0 9 0 NN IN NN NN NN O
iodide iodide 0 0 0 0 0 0 0 0 6 0 IN NN NN NN NNP O
(PI) (PI) 0 1 0 0 0 0 0 0 4 0 NN NN NN NNP NNP O
staining. staining. 0 0 0 0 0 0 0 0 9 0 NN NN NNP NNP VBD O
There There 1 0 0 0 0 0 0 0 5 0 NN NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN JJ O
marked marked 0 0 0 0 0 0 0 0 6 0 NNP VBD VBN JJ NN O
intertumoral intertumoral 0 0 0 0 0 0 0 0 12 0 VBD VBN JJ NN IN O
variation variation 0 0 0 0 0 0 0 0 9 0 VBN JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
CK-positive CK-positive 1 0 1 0 0 0 0 0 11 0 NN IN JJ NN CD O
(range, (range, 0 0 0 0 1 0 0 0 7 0 IN JJ NN CD NN O
3-87%; 3-87%; 0 0 1 0 0 0 0 1 6 0 JJ NN CD NN CD O
mean, mean, 0 0 0 0 1 0 0 0 5 0 NN CD NN CD CC O
40%) 40%) 0 0 0 0 0 0 0 1 4 0 CD NN CD CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN CD CC JJ NN O
LCA-positive LCA-positive 1 0 1 0 0 0 0 0 12 0 CD CC JJ NN CD O
(range, (range, 0 0 0 0 1 0 0 0 7 0 CC JJ NN CD NN O
1-28%; 1-28%; 0 0 1 0 0 0 0 1 6 0 JJ NN CD NN CD O
mean, mean, 0 0 0 0 1 0 0 0 5 0 NN CD NN CD NNS O
6.5%) 6.5%) 0 0 0 0 0 0 0 1 5 0 CD NN CD NNS IN O
events events 0 0 0 0 0 0 0 0 6 0 NN CD NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CD NNS IN NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NNS IN NNP NNP NNP O
histograms. histograms. 0 0 0 0 0 0 0 0 11 0 IN NNP NNP NNP CD O
Approximately Approximately 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP CD IN O
70% 70% 0 0 0 0 0 0 0 1 3 0 NNP NNP CD IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP CD IN NNP VBD O
DNA DNA 1 1 0 0 0 0 0 0 3 0 CD IN NNP VBD NNS O
aneuploid aneuploid 0 0 0 0 0 0 0 0 9 0 IN NNP VBD NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP VBD NNS VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 VBD NNS VBD NNP NNP O
CK CK 1 1 0 0 0 0 0 0 2 0 NNS VBD NNP NNP NNP O
positive. positive. 0 0 0 0 0 0 0 0 9 0 VBD NNP NNP NNP CD O
CAM CAM 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP CD NNP O
5.2-stained 5.2-stained 0 0 1 0 0 0 0 1 11 0 NNP NNP CD NNP NNP O
(avidin-biotin (avidin-biotin 0 0 1 0 0 0 0 0 14 0 NNP CD NNP NNP NNP O
technique) technique) 0 0 0 0 0 0 0 0 10 0 CD NNP NNP NNP NNS O
Cytospin Cytospin 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNS VBD O
preparations preparations 0 0 0 0 0 0 0 0 12 0 NNP NNP NNS VBD IN O
correlated correlated 0 0 0 0 0 0 0 0 10 0 NNP NNS VBD IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NN JJ O
flow flow 0 0 0 0 0 0 0 0 4 0 VBD IN NN JJ NN O
cytometric cytometric 0 0 0 0 0 0 0 0 10 0 IN NN JJ NN NN O
(FCM) (FCM) 0 1 0 0 0 0 0 0 5 0 NN JJ NN NN IN O
detection detection 0 0 0 0 0 0 0 0 9 0 JJ NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNS O
CK-positive CK-positive 1 0 1 0 0 0 0 0 11 0 NN IN JJ NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN CD O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN CD NN O
15/21 15/21 0 0 0 1 0 0 0 1 5 0 NNS IN CD NN NNP O
(71%) (71%) 0 0 0 0 0 0 0 1 5 0 IN CD NN NNP NNP O
cases. cases. 0 0 0 0 0 0 0 0 6 0 CD NN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP DT NN O
each each 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN NN O
discrepant discrepant 0 0 0 0 0 0 0 0 10 0 NNP DT NN NN NNP O
case, case, 0 0 0 0 1 0 0 0 5 0 DT NN NN NNP VBD O
FCM FCM 1 1 0 0 0 0 0 0 3 0 NN NN NNP VBD JJR O
detected detected 0 0 0 0 0 0 0 0 8 0 NN NNP VBD JJR NNS O
greater greater 0 0 0 0 0 0 0 0 7 0 NNP VBD JJR NNS IN O
numbers numbers 0 0 0 0 0 0 0 0 7 0 VBD JJR NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJR NNS IN JJ NNP O
CK-positive CK-positive 1 0 1 0 0 0 0 0 11 0 NNS IN JJ NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP NNS O
Cytospin Cytospin 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP NNS IN O
controls controls 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NN NNS O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NNS IN NN NNS VBD O
suspensions suspensions 0 0 0 0 0 0 0 0 11 0 IN NN NNS VBD IN O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NN NNS VBD IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN JJ NN O
cytoplasmic cytoplasmic 0 0 0 0 0 0 0 0 11 0 VBD IN JJ NN VBD O
loss loss 0 0 0 0 0 0 0 0 4 0 IN JJ NN VBD DT O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN VBD DT JJ NN O
major major 0 0 0 0 0 0 0 0 5 0 VBD DT JJ NN IN O
cause cause 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN VBN NNP O
decreased decreased 0 0 0 0 0 0 0 0 9 0 NN IN VBN NNP NNP O
CK CK 1 1 0 0 0 0 0 0 2 0 IN VBN NNP NNP NNP O
staining. staining. 0 0 0 0 0 0 0 0 9 0 VBN NNP NNP NNP NN O
Synthesis Synthesis 1 0 0 0 0 0 0 0 9 phase NNP NNP NNP NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NN NN O
fraction fraction 0 0 0 0 0 0 0 0 8 0 NNP NN NN NN NN O
(SPF) (SPF) 0 1 0 0 0 0 0 0 5 0 NN NN NN NN IN O
calculation calculation 0 0 0 0 0 0 0 0 11 0 NN NN NN IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ NNS O
CK-gated CK-gated 1 0 1 0 0 0 0 0 8 0 NN IN JJ NNS VBN O
histograms histograms 0 0 0 0 0 0 0 0 10 0 IN JJ NNS VBN IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 JJ NNS VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBN IN JJ NNS O
kinetic kinetic 0 0 0 0 0 0 0 0 7 0 VBN IN JJ NNS JJ O
indices indices 0 0 0 0 0 0 0 0 7 0 IN JJ NNS JJ NN O
(mean (mean 0 0 0 0 0 0 0 0 5 0 JJ NNS JJ NN CD O
ungated, ungated, 0 0 0 0 1 0 0 0 8 0 NNS JJ NN CD NNP O
12.3%, 12.3%, 0 0 0 0 1 0 0 1 6 0 JJ NN CD NNP NN O
vs. vs. 0 0 0 0 0 0 0 0 3 0 NN CD NNP NN -NONE- O
mean mean 0 0 0 0 0 0 0 0 4 0 CD NNP NN -NONE- CD O
CK-gated, CK-gated, 1 0 1 0 1 0 0 0 9 0 NNP NN -NONE- CD NNP O
16.8%; 16.8%; 0 0 0 0 0 0 0 1 6 0 NN -NONE- CD NNP RBR O
P P 1 1 0 0 0 0 0 0 1 0 -NONE- CD NNP RBR IN O
less less 0 0 0 0 0 0 0 0 4 0 CD NNP RBR IN NNP O
than than 0 0 0 0 0 0 0 0 4 0 NNP RBR IN NNP IN O
.01) .01) 0 0 0 0 0 0 0 1 4 0 RBR IN NNP IN VBN O
with with 0 0 0 0 0 0 0 0 4 0 IN NNP IN VBN JJ O
improved improved 0 0 0 0 0 0 0 0 8 0 NNP IN VBN JJ NNS O
statistical statistical 0 0 0 0 0 0 0 0 11 0 IN VBN JJ NNS IN O
correlations correlations 0 0 0 0 0 0 0 0 12 0 VBN JJ NNS IN NN O
with with 0 0 0 0 0 0 0 0 4 0 JJ NNS IN NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NNS IN NN NN CC O
grade grade 0 0 0 0 0 0 0 0 5 0 IN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
estrogen estrogen 0 0 0 0 0 0 0 0 8 0 NN CC NN NN NN O
receptor receptor 0 0 0 0 0 0 0 0 8 0 CC NN NN NN NNP O
(ER) (ER) 0 1 0 0 0 0 0 0 4 0 NN NN NN NNP NNP O
status. status. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP IN O
Differences Differences 1 0 0 0 0 0 0 0 11 0 NN NNP NNP IN VBN O
between between 0 0 0 0 0 0 0 0 7 0 NNP NNP IN VBN NNP O
ungated ungated 0 0 0 0 0 0 0 0 7 0 NNP IN VBN NNP JJ O
vs. vs. 0 0 0 0 0 0 0 0 3 0 IN VBN NNP JJ NNP O
CK-gated CK-gated 1 0 1 0 0 0 0 0 8 0 VBN NNP JJ NNP VBD O
SPF SPF 1 1 0 0 0 0 0 0 3 0 NNP JJ NNP VBD JJS O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNP VBD JJS IN O
greatest greatest 0 0 0 0 0 0 0 0 8 0 NNP VBD JJS IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 VBD JJS IN NNS VBG O
cases cases 0 0 0 0 0 0 0 0 5 0 JJS IN NNS VBG JJR O
having having 0 0 0 0 0 0 0 0 6 0 IN NNS VBG JJR IN O
less less 0 0 0 0 0 0 0 0 4 0 NNS VBG JJR IN CD O
than than 0 0 0 0 0 0 0 0 4 0 VBG JJR IN CD JJ O
20% 20% 0 0 0 0 0 0 0 1 3 0 JJR IN CD JJ NNS O
CK-positive CK-positive 1 0 1 0 0 0 0 0 11 0 IN CD JJ NNS -NONE- O
events events 0 0 0 0 0 0 0 0 6 0 CD JJ NNS -NONE- JJR O
(P (P 0 1 0 0 0 0 0 0 2 0 JJ NNS -NONE- JJR IN O
less less 0 0 0 0 0 0 0 0 4 0 NNS -NONE- JJR IN NNP O
than than 0 0 0 0 0 0 0 0 4 0 -NONE- JJR IN NNP NNP O
.05). .05). 0 0 0 0 0 0 0 1 5 0 JJR IN NNP NNP IN O
Cases Cases 1 0 0 0 0 0 0 0 5 0 IN NNP NNP IN JJR O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNP IN JJR NNP O
lower lower 0 0 0 0 0 0 0 0 5 0 NNP IN JJR NNP NN O
CK CK 1 1 0 0 0 0 0 0 2 0 IN JJR NNP NN NNS O
staining staining 0 0 0 0 0 0 0 0 8 0 JJR NNP NN NNS RB O
events events 0 0 0 0 0 0 0 0 6 0 NNP NN NNS RB VBD O
generally generally 0 0 0 0 0 0 0 0 9 0 NN NNS RB VBD JJR O
had had 0 0 0 0 0 0 0 0 3 0 NNS RB VBD JJR NNP O
higher higher 0 0 0 0 0 0 0 0 6 0 RB VBD JJR NNP CC O
SPF SPF 1 1 0 0 0 0 0 0 3 0 VBD JJR NNP CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 JJR NNP CC VBD RBR O
were were 0 0 0 0 0 0 0 0 4 0 NNP CC VBD RBR RB O
more more 0 0 0 0 0 0 0 0 4 0 CC VBD RBR RB JJ O
often often 0 0 0 0 0 0 0 0 5 0 VBD RBR RB JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 RBR RB JJ NN JJ O
grade grade 0 0 0 0 0 0 0 0 5 0 RB JJ NN JJ NN O
(below (below 0 0 0 0 0 0 0 0 6 0 JJ NN JJ NN NNP O
median median 0 0 0 0 0 0 0 0 6 0 NN JJ NN NNP NNP O
CK CK 1 1 0 0 0 0 0 0 2 0 JJ NN NNP NNP CD O
staining, staining, 0 0 0 0 1 0 0 0 9 0 NN NNP NNP CD JJ O
61% 61% 0 0 0 0 0 0 0 1 3 0 NNP NNP CD JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 NNP CD JJ NN NNP O
grade, grade, 0 0 0 0 1 0 0 0 6 0 CD JJ NN NNP IN O
vs. vs. 0 0 0 0 0 0 0 0 3 0 JJ NN NNP IN JJ O
above above 0 0 0 0 0 0 0 0 5 0 NN NNP IN JJ NNP O
median median 0 0 0 0 0 0 0 0 6 0 NNP IN JJ NNP NNP O
CK CK 1 1 0 0 0 0 0 0 2 0 IN JJ NNP NNP CD O
staining, staining, 0 0 0 0 1 0 0 0 9 0 JJ NNP NNP CD JJ O
31% 31% 0 0 0 0 0 0 0 1 3 0 NNP NNP CD JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 NNP CD JJ NN CC O
grade) grade) 0 0 0 0 0 0 0 0 6 0 CD JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ JJ O
ER-negative ER-negative 1 0 1 0 0 0 0 0 11 0 NN CC JJ JJ NN O
(below (below 0 0 0 0 0 0 0 0 6 0 CC JJ JJ NN NNP O
median median 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NNP NNP O
CK CK 1 1 0 0 0 0 0 0 2 0 JJ NN NNP NNP CD O
staining, staining, 0 0 0 0 1 0 0 0 9 0 NN NNP NNP CD NNP O
55% 55% 0 0 0 0 0 0 0 1 3 0 NNP NNP CD NNP NNP O
ER ER 1 1 0 0 0 0 0 0 2 0 NNP CD NNP NNP NNP O
negative, negative, 0 0 0 0 1 0 0 0 9 0 CD NNP NNP NNP IN O
vs. vs. 0 0 0 0 0 0 0 0 3 0 NNP NNP NNP IN JJ O
above above 0 0 0 0 0 0 0 0 5 0 NNP NNP IN JJ NNP O
median median 0 0 0 0 0 0 0 0 6 0 NNP IN JJ NNP NNP O
CK CK 1 1 0 0 0 0 0 0 2 0 IN JJ NNP NNP CD O
staining, staining, 0 0 0 0 1 0 0 0 9 0 JJ NNP NNP CD NNP O
12% 12% 0 0 0 0 0 0 0 1 3 0 NNP NNP CD NNP JJ O
ER ER 1 1 0 0 0 0 0 0 2 0 NNP CD NNP JJ NNP O
negative).(ABSTRACT negative).(ABSTRACT 0 0 0 0 0 0 0 0 19 0 CD NNP JJ NNP NNP O
TRUNCATED TRUNCATED 1 1 0 0 0 0 0 0 9 0 NNP JJ NNP NNP CD O
AT AT 1 1 0 0 0 0 0 0 2 0 JJ NNP NNP CD NN O
250 250 0 0 0 0 0 0 1 1 3 0 NNP NNP CD NN -NONE- O
WORDS) WORDS) 1 1 0 0 0 0 0 0 6 0 NNP CD NN -NONE- CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 CD NN -NONE- CD JJ O
1718294 1718294 0 0 0 0 0 0 1 1 7 0 NN -NONE- CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 -NONE- CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
[The [The 0 0 0 0 0 0 0 0 4 0 NONE NONE DT JJ NN O
centriolar centriolar 0 0 0 0 0 0 0 0 10 0 NONE DT JJ NN IN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS VBG O
polykaryons polykaryons 0 0 0 0 0 0 0 0 11 0 NN IN NNS VBG RB O
containing containing 0 0 0 0 0 0 0 0 10 0 IN NNS VBG RB VBN O
prematurely prematurely 0 0 0 0 0 0 0 0 11 0 NNS VBG RB VBN NNS O
condensed condensed 0 0 0 0 0 0 0 0 9 0 VBG RB VBN NNS CC O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 RB VBN NNS CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 VBN NNS CC JJ NNP O
telophase-like telophase-like 0 0 1 0 0 0 0 0 14 0 NNS CC JJ NNP NNP B_TIMEXCCP
nuclei]. nuclei]. 0 0 0 0 0 0 0 0 8 0 CC JJ NNP NNP IN O
[Article [Article 0 0 0 0 0 0 0 0 8 0 JJ NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Russian] Russian] 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Manandkhar Manandkhar 1 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Onishchenko Onishchenko 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
GE. GE. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBD O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBD JJ O
fused fused 0 0 0 0 0 0 0 0 5 0 NNP NNP VBD JJ NN O
interphase-mitotic interphase-mitotic 0 0 1 0 0 0 0 0 18 0 NNP VBD JJ NN DT B_TIMEXCCP
cells, cells, 0 0 0 0 1 0 0 0 6 0 VBD JJ NN DT NN O
either either 0 0 0 0 0 0 0 0 6 0 JJ NN DT NN NN O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NN DT NN NN VBP B_TIMEXCCP
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 DT NN NN VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NN NN VBP VBN TO O
induced induced 0 0 0 0 0 0 0 0 7 0 NN VBP VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBP VBN TO VB NN O
premature premature 0 0 0 0 0 0 0 0 9 0 VBN TO VB NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 TO VB NN NN NN O
condensation condensation 0 0 0 0 0 0 0 0 12 0 VB NN NN NN CC O
(PCC) (PCC) 0 1 0 0 0 0 0 0 5 0 NN NN NN CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 NN NN CC JJ NNS O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 NN CC JJ NNS VBP B_TIMEXCCP
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 CC JJ NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 JJ NNS VBP VBN TO O
induced induced 0 0 0 0 0 0 0 0 7 0 NNS VBP VBN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 VBP VBN TO JJ NN O
telophase-like telophase-like 0 0 1 0 0 0 0 0 14 0 VBN TO JJ NN NN B_TIMEXCCP
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 TO JJ NN NN NNP O
(TLN) (TLN) 0 1 0 0 0 0 0 0 5 0 JJ NN NN NNP NNP O
formation. formation. 0 0 0 0 0 0 0 0 10 0 NN NN NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NN NNS O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NNS JJ O
concerns concerns 0 0 0 0 0 0 0 0 8 0 NNP NN NNS JJ CC O
structural structural 0 0 0 0 0 0 0 0 10 0 NN NNS JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNS JJ CC JJ NNS O
functional functional 0 0 0 0 0 0 0 0 10 0 JJ CC JJ NNS IN O
changes changes 0 0 0 0 0 0 0 0 7 0 CC JJ NNS IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNS IN O
centrioles centrioles 0 0 0 0 0 0 0 0 10 0 NNS IN NNS IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN VBN NNS O
fused fused 0 0 0 0 0 0 0 0 5 0 NNS IN VBN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN VBN NNS IN WDT O
in in 0 0 0 0 0 0 0 0 2 0 VBN NNS IN WDT NNP O
which which 0 0 0 0 0 0 0 0 5 0 NNS IN WDT NNP CC O
PCC PCC 1 1 0 0 0 0 0 0 3 0 IN WDT NNP CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 WDT NNP CC NNP VBP O
TLN TLN 1 1 0 0 0 0 0 0 3 0 NNP CC NNP VBP NNP O
are are 0 0 0 0 0 0 0 0 3 0 CC NNP VBP NNP NNP O
induced. induced. 0 0 0 0 0 0 0 0 8 0 NNP VBP NNP NNP NN O
Embryonic Embryonic 1 0 0 0 0 0 0 0 9 0 VBP NNP NNP NN NN O
pig pig 0 0 0 0 0 0 0 0 3 0 NNP NNP NN NN NNS O
kidney kidney 0 0 0 0 0 0 0 0 6 0 NNP NN NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN VBG O
fused fused 0 0 0 0 0 0 0 0 5 0 NNS VBD VBN VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 VBD VBN VBG DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN VBG DT JJ NN O
modified modified 0 0 0 0 0 0 0 0 8 0 VBG DT JJ NN NNP O
PEG-DMSO-serum PEG-DMSO-serum 1 0 1 0 0 0 0 0 14 0 DT JJ NN NNP NNP O
method. method. 0 0 0 0 0 0 0 0 7 0 JJ NN NNP NNP NN O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NN IN O
period period 0 0 0 0 0 0 0 0 6 0 NNP NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBD O
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 IN DT NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD VBN IN O
determined determined 0 0 0 0 0 0 0 0 10 0 NN VBD VBN IN NN O
before before 0 0 0 0 0 0 0 0 6 0 VBD VBN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBN IN NN NN VBG O
fusion fusion 0 0 0 0 0 0 0 0 6 0 IN NN NN VBG JJ O
using using 0 0 0 0 0 0 0 0 5 0 NN NN VBG JJ NNP O
double-labeling double-labeling 0 0 1 0 0 0 0 0 15 0 NN VBG JJ NNP NNP O
autoradiography. autoradiography. 0 0 0 0 0 0 0 0 16 0 VBG JJ NNP NNP NN O
Polykaryons Polykaryons 1 0 0 0 0 0 0 0 11 0 JJ NNP NNP NN JJ O
containing containing 0 0 0 0 0 0 0 0 10 0 NNP NNP NN JJ NN O
desirable desirable 0 0 0 0 0 0 0 0 9 0 NNP NN JJ NN IN O
type type 0 0 0 0 0 0 0 0 4 0 NN JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP CC O
PCC PCC 1 1 0 0 0 0 0 0 3 0 NN IN NNP CC VB O
or or 0 0 0 0 0 0 0 0 2 0 IN NNP CC VB JJ O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NNP CC VB JJ NN B_TIMEXCCP
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 CC VB JJ NN IN O
combination combination 0 0 0 0 0 0 0 0 11 0 VB JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP VBD O
TLN TLN 1 1 0 0 0 0 0 0 3 0 NN IN NNP VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 IN NNP VBD VBN IN O
selected selected 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
basis basis 0 0 0 0 0 0 0 0 5 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN VBG O
isotope isotope 0 0 0 0 0 0 0 0 7 0 NN IN NN VBG IN O
labeling labeling 0 0 0 0 0 0 0 0 8 0 IN NN VBG IN VBG O
after after 0 0 0 0 0 0 0 0 5 0 NN VBG IN VBG VBN O
being being 0 0 0 0 0 0 0 0 5 0 VBG IN VBG VBN IN O
embedded embedded 0 0 0 0 0 0 0 0 8 0 IN VBG VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBG VBN IN NNP NNP O
epon. epon. 0 0 0 0 0 0 0 0 5 0 VBN IN NNP NNP VBZ O
Selected Selected 1 0 0 0 0 0 0 0 8 0 IN NNP NNP VBZ VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBD VBN IN O
cut cut 0 0 0 0 0 0 0 0 3 0 VBZ VBD VBN IN JJ O
into into 0 0 0 0 0 0 0 0 4 0 VBD VBN IN JJ NNS O
serial serial 0 0 0 0 0 0 0 0 6 0 VBN IN JJ NNS CC O
sections sections 0 0 0 0 0 0 0 0 8 0 IN JJ NNS CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC VBD IN O
studied studied 0 0 0 0 0 0 0 0 7 0 NNS CC VBD IN NN O
under under 0 0 0 0 0 0 0 0 5 0 CC VBD IN NN NNP O
electron electron 0 0 0 0 0 0 0 0 8 0 VBD IN NN NNP NNP O
microscope. microscope. 0 0 0 0 0 0 0 0 11 0 IN NN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS VBD O
data data 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS VBD VBN O
obtained obtained 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD VBN IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NNS VBD VBN IN NNS O
that that 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNS IN O
centrioles centrioles 0 0 0 0 0 0 0 0 10 0 VBN IN NNS IN DT O
at at 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT NN O
every every 0 0 0 0 0 0 0 0 5 0 NNS IN DT NN NN O
interphase interphase 0 0 0 0 0 0 0 0 10 0 IN DT NN NN NN B_TIMEXCCP
period period 0 0 0 0 0 0 0 0 6 0 DT NN NN NN JJ O
undergo undergo 0 0 0 0 0 0 0 0 7 0 NN NN NN JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 NN NN JJ NN WRB B_TIMEXCCP
activation activation 0 0 0 0 0 0 0 0 10 0 NN JJ NN WRB PRP$ O
when when 0 0 0 0 0 0 0 0 4 0 JJ NN WRB PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 NN WRB PRP$ NN VBP O
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 WRB PRP$ NN VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 PRP$ NN VBP VBN TO O
induced induced 0 0 0 0 0 0 0 0 7 0 NN VBP VBN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 VBP VBN TO NNP NNP O
PCC. PCC. 1 1 0 0 0 0 0 0 4 0 VBN TO NNP NNP VBP O
They They 1 0 0 0 0 0 0 0 4 0 TO NNP NNP VBP JJ O
acquire acquire 0 0 0 0 0 0 0 0 7 0 NNP NNP VBP JJ NN O
fibrillar fibrillar 0 0 0 0 0 0 0 0 9 0 NNP VBP JJ NN CC O
halo halo 0 0 0 0 0 0 0 0 4 0 VBP JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NNP O
form form 0 0 0 0 0 0 0 0 4 0 NN CC NN NNP NNP O
half-spindles. half-spindles. 0 0 1 0 0 0 0 0 14 0 CC NN NNP NNP VBZ O
Daughter Daughter 1 0 0 0 0 0 0 0 8 0 NN NNP NNP VBZ IN O
centrioles centrioles 0 0 0 0 0 0 0 0 10 0 NNP NNP VBZ IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN JJ NNS O
G1, G1, 1 1 0 0 1 0 0 1 3 0 VBZ IN JJ NNS CC B_TIMEXCCP
S S 1 1 0 0 0 0 0 0 1 0 IN JJ NNS CC NNP B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC NNP NNS O
G2 G2 1 1 0 0 0 0 0 1 2 0 NNS CC NNP NNS VBP B_TIMEXCCP
periods periods 0 0 0 0 0 0 0 0 7 0 CC NNP NNS VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNS VBP RB JJ O
also also 0 0 0 0 0 0 0 0 4 0 NNS VBP RB JJ IN O
capable capable 0 0 0 0 0 0 0 0 7 0 VBP RB JJ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 RB JJ IN JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 JJ IN JJ NN WRB B_TIMEXCCP
activation activation 0 0 0 0 0 0 0 0 10 0 IN JJ NN WRB VBN O
when when 0 0 0 0 0 0 0 0 4 0 JJ NN WRB VBN IN O
separated separated 0 0 0 0 0 0 0 0 9 0 NN WRB VBN IN PRP$ O
from from 0 0 0 0 0 0 0 0 4 0 WRB VBN IN PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 VBN IN PRP$ NN NNP O
mother mother 0 0 0 0 0 0 0 0 6 0 IN PRP$ NN NNP NNP O
centriole. centriole. 0 0 0 0 0 0 0 0 10 0 PRP$ NN NNP NNP VBZ O
Inert Inert 1 0 0 0 0 0 0 0 5 0 NN NNP NNP VBZ VBD O
centrioles centrioles 0 0 0 0 0 0 0 0 10 0 NNP NNP VBZ VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBD VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 VBZ VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NNS O
some some 0 0 0 0 0 0 0 0 4 0 VBN IN DT NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN DT NNS IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 DT NNS IN NNP NNP O
G1-PCC. G1-PCC. 1 1 1 0 0 0 0 1 7 0 NNS IN NNP NNP JJ O
When When 1 0 0 0 0 0 0 0 4 0 IN NNP NNP JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NN VBP B_TIMEXCCP
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 NNP JJ NN VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 JJ NN VBP VBN TO O
induced induced 0 0 0 0 0 0 0 0 7 0 NN VBP VBN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 VBP VBN TO NNP NNP O
TLN TLN 1 1 0 0 0 0 0 0 3 0 VBN TO NNP NNP PRP$ O
formation, formation, 0 0 0 0 1 0 0 0 10 0 TO NNP NNP PRP$ NNS O
their their 0 0 0 0 0 0 0 0 5 0 NNP NNP PRP$ NNS RB O
centrioles centrioles 0 0 0 0 0 0 0 0 10 0 NNP PRP$ NNS RB VB O
also also 0 0 0 0 0 0 0 0 4 0 PRP$ NNS RB VB NNP O
become become 0 0 0 0 0 0 0 0 6 0 NNS RB VB NNP NNP O
inactivated. inactivated. 0 0 0 0 0 0 0 0 12 0 RB VB NNP NNP VBP O
They They 1 0 0 0 0 0 0 0 4 0 VB NNP NNP VBP JJ O
lose lose 0 0 0 0 0 0 0 0 4 0 NNP NNP VBP JJ NN O
fibrillar fibrillar 0 0 0 0 0 0 0 0 9 0 NNP VBP JJ NN CC O
halo halo 0 0 0 0 0 0 0 0 4 0 VBP JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NNS O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 NN CC JJ NNS VBP O
spindles spindles 0 0 0 0 0 0 0 0 8 0 CC JJ NNS VBP NNP O
break break 0 0 0 0 0 0 0 0 5 0 JJ NNS VBP NNP NNP O
down. down. 0 0 0 0 0 0 0 0 5 0 NNS VBP NNP NNP JJ O
Some Some 1 0 0 0 0 0 0 0 4 0 VBP NNP NNP JJ NNS O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NNS VB B_TIMEXCCP
centrioles centrioles 0 0 0 0 0 0 0 0 10 0 NNP JJ NNS VB NNS O
develop develop 0 0 0 0 0 0 0 0 7 0 JJ NNS VB NNS JJ O
features features 0 0 0 0 0 0 0 0 8 0 NNS VB NNS JJ IN O
characteristic characteristic 0 0 0 0 0 0 0 0 14 0 VB NNS JJ IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNS JJ IN NN NN O
interphase interphase 0 0 0 0 0 0 0 0 10 0 JJ IN NN NN JJ B_TIMEXCCP
period period 0 0 0 0 0 0 0 0 6 0 IN NN NN JJ IN O
such such 0 0 0 0 0 0 0 0 4 0 NN NN JJ IN NNS O
as as 0 0 0 0 0 0 0 0 2 0 NN JJ IN NNS CC O
satellites satellites 0 0 0 0 0 0 0 0 10 0 JJ IN NNS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC NNP NNP O
vacuoles. vacuoles. 0 0 0 0 0 0 0 0 9 0 NNS CC NNP NNP NN O
Induced Induced 1 0 0 0 0 0 0 0 7 0 CC NNP NNP NN CC O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 NNP NNP NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC JJ NNS O
centriolar centriolar 0 0 0 0 0 0 0 0 10 0 NN CC JJ NNS VBP O
changes changes 0 0 0 0 0 0 0 0 7 0 CC JJ NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 JJ NNS VBP JJ CC O
simultaneous simultaneous 0 0 0 0 0 0 0 0 12 0 NNS VBP JJ CC MD O
and and 0 0 0 0 0 0 0 0 3 0 VBP JJ CC MD VB O
may may 0 0 0 0 0 0 0 0 3 0 JJ CC MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 CC MD VB VBN IN O
controlled controlled 0 0 0 0 0 0 0 0 10 0 MD VB VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VB VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNP O
same same 0 0 0 0 0 0 0 0 4 0 IN DT JJ NNP NNP O
factor. factor. 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NNP NN O
Mitotic Mitotic 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP NN IN B_TIMEXCCP
factor factor 0 0 0 0 0 0 0 0 6 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN WDT O
partner partner 0 0 0 0 0 0 0 0 7 0 JJ NN NN WDT NNS O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT NNS NNP O
induces induces 0 0 0 0 0 0 0 0 7 0 NN WDT NNS NNP MD O
PCC PCC 1 1 0 0 0 0 0 0 3 0 WDT NNS NNP MD RB O
may may 0 0 0 0 0 0 0 0 3 0 NNS NNP MD RB VB O
also also 0 0 0 0 0 0 0 0 4 0 NNP MD RB VB NN O
induce induce 0 0 0 0 0 0 0 0 6 0 MD RB VB NN NNS O
interphase interphase 0 0 0 0 0 0 0 0 10 0 RB VB NN NNS TO B_TIMEXCCP 
centrioles centrioles 0 0 0 0 0 0 0 0 10 0 VB NN NNS TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO JJ NNP O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 NNS TO JJ NNP NNP B_TIMEXCCP
activation. activation. 0 0 0 0 0 0 0 0 11 0 TO JJ NNP NNP IN O
Degradation Degradation 1 0 0 0 0 0 0 0 11 0 JJ NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN VBG B_TIMEXCCP
factor factor 0 0 0 0 0 0 0 0 6 0 DT JJ NN VBG TO O
leading leading 0 0 0 0 0 0 0 0 7 0 JJ NN VBG TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NN VBG TO NNP NN O
TLN TLN 1 1 0 0 0 0 0 0 3 0 VBG TO NNP NN MD O
formation formation 0 0 0 0 0 0 0 0 9 0 TO NNP NN MD RB O
may may 0 0 0 0 0 0 0 0 3 0 NNP NN MD RB VB O
also also 0 0 0 0 0 0 0 0 4 0 NN MD RB VB DT O
cause cause 0 0 0 0 0 0 0 0 5 0 MD RB VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VB DT NN IN O
loss loss 0 0 0 0 0 0 0 0 4 0 VB DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS CC O
centrioles centrioles 0 0 0 0 0 0 0 0 10 0 NN IN NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC NN IN O
disorganization disorganization 0 0 0 0 0 0 0 0 15 0 NNS CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NNP O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNP NNP B_TIMEXCCP
spindles. spindles. 0 0 0 0 0 0 0 0 9 0 IN JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
1294931 1294931 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Ligands Ligands 1 0 0 0 0 0 0 0 7 0 NONE NONE NNS VBP DT O
raise raise 0 0 0 0 0 0 0 0 5 0 NONE NNS VBP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBP DT NN IN O
constraint constraint 0 0 0 0 0 0 0 0 10 0 VBP DT NN IN NNS O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN NNS VBP O
limits limits 0 0 0 0 0 0 0 0 6 0 NN IN NNS VBP NN O
constitutive constitutive 0 0 0 0 0 0 0 0 12 0 IN NNS VBP NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 NNS VBP NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBP NN IN NNP JJ O
G G 1 1 0 0 0 0 0 0 1 0 NN IN NNP JJ NN O
protein-coupled protein-coupled 0 0 1 0 0 0 0 0 15 0 IN NNP JJ NN NNP O
opioid opioid 0 0 0 0 0 0 0 0 6 0 NNP JJ NN NNP NNP O
receptors. receptors. 0 0 0 0 0 0 0 0 10 0 JJ NN NNP NNP NNP O
Vezzi Vezzi 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP NNP O
V, V, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Onaran Onaran 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
HO, HO, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Molinari Molinari 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Guerrini Guerrini 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Balboni Balboni 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Calo' Calo' 1 0 0 0 0 1 0 0 5 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Costa Costa 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
T. T. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Istituto Istituto 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
Superiore Superiore 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NN -NONE- O
di di 0 0 0 0 0 0 0 0 2 0 NNP NNP NN -NONE- -NONE- O
Sanita', Sanita', 1 0 0 0 1 1 0 0 8 0 NNP NN -NONE- -NONE- NNP O
Italy; Italy; 1 0 0 0 0 0 0 0 6 0 NN -NONE- -NONE- NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 -NONE- -NONE- NNP NNP DT O
Using Using 1 0 0 0 0 0 0 0 5 0 -NONE- NNP NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT JJ NN O
cell-free cell-free 0 0 1 0 0 0 0 0 9 0 NNP DT JJ NN NN O
bioluminescence bioluminescence 0 0 0 0 0 0 0 0 15 0 DT JJ NN NN NN O
resonance resonance 0 0 0 0 0 0 0 0 9 0 JJ NN NN NN NN O
energy energy 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NN O
transfer transfer 0 0 0 0 0 0 0 0 8 0 NN NN NN NN PRP O
strategy strategy 0 0 0 0 0 0 0 0 8 0 NN NN NN PRP VBN O
we we 0 0 0 0 0 0 0 0 2 0 NN NN PRP VBN DT O
compared compared 0 0 0 0 0 0 0 0 8 0 NN PRP VBN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBN DT NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 VBN DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ CC O
spontaneous spontaneous 0 0 0 0 0 0 0 0 11 0 NNS IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ JJ O
ligand-induced ligand-induced 0 0 1 0 0 0 0 0 14 0 JJ CC JJ JJ NN O
receptor-G receptor-G 0 0 1 0 0 0 0 0 10 0 CC JJ JJ NN VBG O
protein protein 0 0 0 0 0 0 0 0 7 0 JJ JJ NN VBG IN O
coupling coupling 0 0 0 0 0 0 0 0 8 0 JJ NN VBG IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN VBG IN NNP NNP O
δ δ 0 0 0 0 0 0 0 0 1 0 VBG IN NNP NNP CC O
(DOP) (DOP) 0 1 0 0 0 0 0 0 5 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
μ μ 0 0 0 0 0 0 0 0 1 0 NNP CC NNP NNP VBD O
(MOP) (MOP) 0 1 0 0 0 0 0 0 5 0 CC NNP NNP VBD NNP O
opioid opioid 0 0 0 0 0 0 0 0 6 0 NNP NNP VBD NNP NNP O
receptors. receptors. 0 0 0 0 0 0 0 0 10 0 NNP VBD NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 VBD NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN NNP O
assay assay 0 0 0 0 0 0 0 0 5 0 NNP DT NN NNP MD O
GDP GDP 1 1 0 0 0 0 0 0 3 0 DT NN NNP MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN NNP MD VB JJ O
suppress suppress 0 0 0 0 0 0 0 0 8 0 NNP MD VB JJ NN O
spontaneous spontaneous 0 0 0 0 0 0 0 0 11 0 MD VB JJ NN RB O
coupling coupling 0 0 0 0 0 0 0 0 8 0 VB JJ NN RB VBG O
thus thus 0 0 0 0 0 0 0 0 4 0 JJ NN RB VBG PRP$ O
allowing allowing 0 0 0 0 0 0 0 0 8 0 NN RB VBG PRP$ NNP O
its its 0 0 0 0 0 0 0 0 3 0 RB VBG PRP$ NNP NNP O
quantification. quantification. 0 0 0 0 0 0 0 0 15 0 VBG PRP$ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 PRP$ NNP NNP NN IN O
level level 0 0 0 0 0 0 0 0 5 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
constitutive constitutive 0 0 0 0 0 0 0 0 12 0 NN IN JJ NN VBD O
activity activity 0 0 0 0 0 0 0 0 8 0 IN JJ NN VBD CD O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD CD NNS O
4-5 4-5 0 0 1 0 0 0 0 1 3 0 NN VBD CD NNS JJR O
times times 0 0 0 0 0 0 0 0 5 0 VBD CD NNS JJR IN O
greater greater 0 0 0 0 0 0 0 0 7 0 CD NNS JJR IN NNP O
at at 0 0 0 0 0 0 0 0 2 0 NNS JJR IN NNP IN O
DOP DOP 1 1 0 0 0 0 0 0 3 0 JJR IN NNP IN IN O
than than 0 0 0 0 0 0 0 0 4 0 IN NNP IN IN NNP O
at at 0 0 0 0 0 0 0 0 2 0 NNP IN IN NNP NNP O
MOP MOP 1 1 0 0 0 0 0 0 3 0 IN IN NNP NNP NNP O
receptor. receptor. 0 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP NN O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NN IN O
series series 0 0 0 0 0 0 0 0 6 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NNS O
opioid opioid 0 0 0 0 0 0 0 0 6 0 NN IN JJ NNS IN O
analogs analogs 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN DT O
with with 0 0 0 0 0 0 0 0 4 0 JJ NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ JJ O
common common 0 0 0 0 0 0 0 0 6 0 IN DT JJ JJ NN O
peptidomimetic peptidomimetic 0 0 0 0 0 0 0 0 14 0 DT JJ JJ NN VBN O
scaffold scaffold 0 0 0 0 0 0 0 0 8 0 JJ JJ NN VBN JJ O
displayed displayed 0 0 0 0 0 0 0 0 9 0 JJ NN VBN JJ NNS O
remarkable remarkable 0 0 0 0 0 0 0 0 10 0 NN VBN JJ NNS IN O
inversions inversions 0 0 0 0 0 0 0 0 10 0 VBN JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN IN O
efficacy efficacy 0 0 0 0 0 0 0 0 8 0 NNS IN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN DT CD O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT CD NNP O
two two 0 0 0 0 0 0 0 0 3 0 IN DT CD NNP NNP O
receptors. receptors. 0 0 0 0 0 0 0 0 10 0 DT CD NNP NNP IN O
Agonists Agonists 1 0 0 0 0 0 0 0 8 0 CD NNP NNP IN VBN O
that that 0 0 0 0 0 0 0 0 4 0 NNP NNP IN VBN VBG O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 NNP IN VBN VBG IN O
coupling coupling 0 0 0 0 0 0 0 0 8 0 IN VBN VBG IN DT O
above above 0 0 0 0 0 0 0 0 5 0 VBN VBG IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBG IN DT JJ NN O
low low 0 0 0 0 0 0 0 0 3 0 IN DT JJ NN NN O
intrinsic intrinsic 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN IN O
level level 0 0 0 0 0 0 0 0 5 0 JJ NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NN O
MOP MOP 1 1 0 0 0 0 0 0 3 0 NN IN NNP NN VBD O
receptor receptor 0 0 0 0 0 0 0 0 8 0 IN NNP NN VBD NN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NN VBD NN NNS O
inverse inverse 0 0 0 0 0 0 0 0 7 0 NN VBD NN NNS IN O
agonists agonists 0 0 0 0 0 0 0 0 8 0 VBD NN NNS IN VBG O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN VBG DT O
reducing reducing 0 0 0 0 0 0 0 0 8 0 NNS IN VBG DT JJR O
the the 0 0 0 0 0 0 0 0 3 0 IN VBG DT JJR NN O
greater greater 0 0 0 0 0 0 0 0 7 0 VBG DT JJR NN IN O
level level 0 0 0 0 0 0 0 0 5 0 DT JJR NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJR NN IN JJ NN O
constitutive constitutive 0 0 0 0 0 0 0 0 12 0 NN IN JJ NN IN O
coupling coupling 0 0 0 0 0 0 0 0 8 0 IN JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
DOP DOP 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNP NNP O
receptor. receptor. 0 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP DT O
Yet Yet 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NNS O
intrinsic intrinsic 0 0 0 0 0 0 0 0 9 0 NNP DT JJ NNS IN O
activities activities 0 0 0 0 0 0 0 0 10 0 DT JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NNS O
such such 0 0 0 0 0 0 0 0 4 0 NNS IN JJ NNS VBP O
ligands ligands 0 0 0 0 0 0 0 0 7 0 IN JJ NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 JJ NNS VBP JJ WRB O
identical identical 0 0 0 0 0 0 0 0 9 0 NNS VBP JJ WRB VBN O
when when 0 0 0 0 0 0 0 0 4 0 VBP JJ WRB VBN IN O
scaled scaled 0 0 0 0 0 0 0 0 6 0 JJ WRB VBN IN DT O
over over 0 0 0 0 0 0 0 0 4 0 WRB VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NN O
GDP GDP 1 1 0 0 0 0 0 0 3 0 IN DT NNP NN IN O
baseline baseline 0 0 0 0 0 0 0 0 8 0 DT NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NNP O
both both 0 0 0 0 0 0 0 0 4 0 NN IN DT NNP NNP O
receptors. receptors. 0 0 0 0 0 0 0 0 10 0 IN DT NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 DT NNP NNP NN VBZ O
pattern pattern 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBZ IN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN VBZ IN NN IN O
conflict conflict 0 0 0 0 0 0 0 0 8 0 VBZ IN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS IN O
predictions predictions 0 0 0 0 0 0 0 0 11 0 IN DT NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
ternary ternary 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN NN O
complex complex 0 0 0 0 0 0 0 0 7 0 DT JJ NN NN CC O
model model 0 0 0 0 0 0 0 0 5 0 JJ NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NNP NNP O
"two-state" "two-state" 0 0 1 0 0 0 0 0 11 0 CC DT NNP NNP NNP O
extensions. extensions. 0 0 0 0 0 0 0 0 11 0 DT NNP NNP NNP TO O
According According 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNP NNP TO DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP TO DT NN DT O
theory, theory, 0 0 0 0 1 0 0 0 7 0 TO DT NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 DT NN DT NN IN O
order order 0 0 0 0 0 0 0 0 5 0 NN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ CC O
spontaneous spontaneous 0 0 0 0 0 0 0 0 11 0 NN IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NN O
ligand-induced ligand-induced 0 0 1 0 0 0 0 0 14 0 JJ CC JJ NN NN O
coupling coupling 0 0 0 0 0 0 0 0 8 0 CC JJ NN NN VB O
cannot cannot 0 0 0 0 0 0 0 0 6 0 JJ NN NN VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN NN VB VBN IN O
reversed reversed 0 0 0 0 0 0 0 0 8 0 NN VB VBN IN DT O
if if 0 0 0 0 0 0 0 0 2 0 VB VBN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NN IN O
shift shift 0 0 0 0 0 0 0 0 5 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
equilibrium equilibrium 0 0 0 0 0 0 0 0 11 0 IN DT NN IN JJ O
between between 0 0 0 0 0 0 0 0 7 0 DT NN IN JJ CC O
active active 0 0 0 0 0 0 0 0 6 0 NN IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NNS O
inactive inactive 0 0 0 0 0 0 0 0 8 0 JJ CC JJ NNS VBZ O
forms forms 0 0 0 0 0 0 0 0 5 0 CC JJ NNS VBZ JJ O
raises raises 0 0 0 0 0 0 0 0 6 0 JJ NNS VBZ JJ NN O
constitutive constitutive 0 0 0 0 0 0 0 0 12 0 NNS VBZ JJ NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 VBZ JJ NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN CD NN O
one one 0 0 0 0 0 0 0 0 3 0 NN IN CD NN NNP O
receptor receptor 0 0 0 0 0 0 0 0 8 0 IN CD NN NNP NNP O
type. type. 0 0 0 0 0 0 0 0 5 0 CD NN NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBP IN O
propose propose 0 0 0 0 0 0 0 0 7 0 NNP NNP VBP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBP IN JJ NN O
constitutive constitutive 0 0 0 0 0 0 0 0 12 0 VBP IN JJ NN NNS O
activation activation 0 0 0 0 0 0 0 0 10 0 IN JJ NN NNS IN O
results results 0 0 0 0 0 0 0 0 7 0 JJ NN NNS IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NN NNS IN DT VBN O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT VBN JJ O
lessened lessened 0 0 0 0 0 0 0 0 8 0 IN DT VBN JJ NN O
intrinsic intrinsic 0 0 0 0 0 0 0 0 9 0 DT VBN JJ NN WDT O
barrier barrier 0 0 0 0 0 0 0 0 7 0 VBN JJ NN WDT VBZ O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT VBZ JJ O
restrains restrains 0 0 0 0 0 0 0 0 9 0 NN WDT VBZ JJ NNP O
spontaneous spontaneous 0 0 0 0 0 0 0 0 11 0 WDT VBZ JJ NNP NNP O
coupling. coupling. 0 0 0 0 0 0 0 0 9 0 VBZ JJ NNP NNP NN O
Any Any 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN NN O
ligand ligand 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NN IN O
regardless regardless 0 0 0 0 0 0 0 0 10 0 NNP NN NN IN PRP$ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NN IN PRP$ NN MD O
efficacy efficacy 0 0 0 0 0 0 0 0 8 0 IN PRP$ NN MD VB O
must must 0 0 0 0 0 0 0 0 4 0 PRP$ NN MD VB DT O
enhance enhance 0 0 0 0 0 0 0 0 7 0 NN MD VB DT NN O
this this 0 0 0 0 0 0 0 0 4 0 MD VB DT NN TO O
constraint constraint 0 0 0 0 0 0 0 0 10 0 VB DT NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO VB DT O
stabilize stabilize 0 0 0 0 0 0 0 0 9 0 NN TO VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJ VBN O
ligand-bound ligand-bound 0 0 1 0 0 0 0 0 12 0 VB DT JJ VBN NNP O
complexed complexed 0 0 0 0 0 0 0 0 9 0 DT JJ VBN NNP NNP O
form. form. 0 0 0 0 0 0 0 0 5 0 JJ VBN NNP NNP NNP O
KEYWORDS: KEYWORDS: 1 1 0 0 0 0 0 0 9 0 VBN NNP NNP NNP NN O
Bioluminescence Bioluminescence 1 0 0 0 0 0 0 0 15 0 NNP NNP NNP NN NN O
resonance resonance 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NN NN O
energy energy 0 0 0 0 0 0 0 0 6 0 NNP NN NN NN NN O
transfer transfer 0 0 0 0 0 0 0 0 8 0 NN NN NN NN NNP O
(bret), (bret), 0 0 0 0 1 0 0 0 7 0 NN NN NN NNP NN O
Constitutive Constitutive 1 0 0 0 0 0 0 0 12 0 NN NN NNP NN -NONE- O
receptor receptor 0 0 0 0 0 0 0 0 8 0 NN NNP NN -NONE- -NONE- O
activation, activation, 0 0 0 0 1 0 0 0 11 0 NNP NN -NONE- -NONE- NNP O
Cooperativity, Cooperativity, 1 0 0 0 1 0 0 0 14 0 NN -NONE- -NONE- NNP NN O
G G 1 1 0 0 0 0 0 0 1 0 -NONE- -NONE- NNP NN VBD O
protein protein 0 0 0 0 0 0 0 0 7 0 -NONE- NNP NN VBD NNS O
coupled coupled 0 0 0 0 0 0 0 0 7 0 NNP NN VBD NNS -NONE- O
receptors receptors 0 0 0 0 0 0 0 0 9 0 NN VBD NNS -NONE- NNP O
(GPCR), (GPCR), 0 1 0 0 1 0 0 0 7 0 VBD NNS -NONE- NNP NNP O
G G 1 1 0 0 0 0 0 0 1 0 NNS -NONE- NNP NNP NNP O
proteins, proteins, 0 0 0 0 1 0 0 0 9 0 -NONE- NNP NNP NNP NNP O
Opiate Opiate 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NN O
opioid, opioid, 0 0 0 0 1 0 0 0 7 0 NNP NNP NNP NN NN O
inverse inverse 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN NN O
agonism agonism 0 0 0 0 0 0 0 0 7 0 NNP NN NN NN CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NN NN CD JJ O
23836900 23836900 0 0 0 0 0 0 1 1 8 0 NN NN CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NN CD JJ : IN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 JJ : IN JJ IN O
supplied supplied 0 0 0 0 0 0 0 0 8 0 : IN JJ IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 IN JJ IN JJ NONE O
publisher] publisher] 0 0 0 0 0 0 0 0 10 0 JJ IN JJ NONE NONE O
Optimization Optimization 1 0 0 0 0 0 0 0 12 0 NONE NONE NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN -NONE- CC O
CDT-1 CDT-1 1 1 1 0 0 0 0 1 5 0 NN IN -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN -NONE- CC NNP NNP O
XYL1 XYL1 1 1 0 0 0 0 0 1 4 0 -NONE- CC NNP NNP IN O
Expression Expression 1 0 0 0 0 0 0 0 10 0 CC NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NN O
Balanced Balanced 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NN IN O
Co-Production Co-Production 1 0 1 0 0 0 0 0 13 0 IN NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP CC O
Ethanol Ethanol 1 0 0 0 0 0 0 0 7 0 NN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP IN O
Xylitol Xylitol 1 0 0 0 0 0 0 0 7 0 NNP CC NNP IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 CC NNP IN NNP CC O
Cellobiose Cellobiose 1 0 0 0 0 0 0 0 10 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP IN O
Xylose Xylose 1 0 0 0 0 0 0 0 6 0 NNP CC NNP IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 CC NNP IN NNP NNPS O
Engineered Engineered 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNPS NNP O
Saccharomyces Saccharomyces 1 0 0 0 0 0 0 0 13 0 IN NNP NNPS NNP NNP O
cerevisiae. cerevisiae. 0 0 0 0 0 0 0 0 11 0 NNP NNPS NNP NNP NNP O
Zha Zha 1 0 0 0 0 0 0 0 3 0 NNPS NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
BZ, BZ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Shen Shen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
MH, MH, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Hu Hu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
ML, ML, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Song Song 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yuan Yuan 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
YJ. YJ. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Key Key 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP IN O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNPS O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNPS NNP O
Systems Systems 1 0 0 0 0 0 0 0 7 0 NNP IN NNPS NNP NNP O
Bioengineering Bioengineering 1 0 0 0 0 0 0 0 14 0 IN NNPS NNP NNP NNP O
(Tianjin (Tianjin 0 0 0 0 0 0 0 0 8 0 NNPS NNP NNP NNP NNP O
University), University), 1 0 0 0 1 0 0 0 12 0 NNP NNP NNP NNP IN O
Ministry Ministry 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Education, Education, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pharmaceutical Pharmaceutical 1 0 0 0 0 0 0 0 14 0 NNP IN NNP NNP NNP O
Engineering, Engineering, 1 0 0 0 1 0 0 0 12 0 IN NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Chemical Chemical 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP CC O
Engineering Engineering 1 0 0 0 0 0 0 0 11 0 IN NNP NNP CC NNP O
& & 0 0 0 0 0 0 0 0 1 0 NNP NNP CC NNP NNP O
Technology, Technology, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP NNP O
Tianjin Tianjin 1 0 0 0 0 0 0 0 7 0 CC NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Tianjin, Tianjin, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
P. P. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
R. R. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Production Production 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN CC O
ethanol ethanol 0 0 0 0 0 0 0 0 7 0 NNP IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN IN O
xylitol xylitol 0 0 0 0 0 0 0 0 7 0 NN CC NN IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 CC NN IN JJ NNS O
lignocellulosic lignocellulosic 0 0 0 0 0 0 0 0 15 0 NN IN JJ NNS VBZ O
hydrolysates hydrolysates 0 0 0 0 0 0 0 0 12 0 IN JJ NNS VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 JJ NNS VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNS VBZ DT JJ TO O
alternative alternative 0 0 0 0 0 0 0 0 11 0 VBZ DT JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 DT JJ TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ TO DT JJ NN O
traditional traditional 0 0 0 0 0 0 0 0 11 0 TO DT JJ NN IN O
production production 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
ethanol ethanol 0 0 0 0 0 0 0 0 7 0 NN IN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NNP O
utilizing utilizing 0 0 0 0 0 0 0 0 9 0 NN IN NN NNP NNP O
biomass. biomass. 0 0 0 0 0 0 0 0 8 0 IN NN NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
conversion conversion 0 0 0 0 0 0 0 0 10 0 NNP DT NN NN IN O
efficiency efficiency 0 0 0 0 0 0 0 0 10 0 DT NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN TO O
xylose xylose 0 0 0 0 0 0 0 0 6 0 NN IN NN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO NN VBZ O
xylitol xylitol 0 0 0 0 0 0 0 0 7 0 NN TO NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 TO NN VBZ VBN IN O
restricted restricted 0 0 0 0 0 0 0 0 10 0 NN VBZ VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN NN -NONE- O
glucose glucose 0 0 0 0 0 0 0 0 7 0 VBN IN NN -NONE- VBG O
repression, repression, 0 0 0 0 1 0 0 0 11 0 IN NN -NONE- VBG DT O
causing causing 0 0 0 0 0 0 0 0 7 0 NN -NONE- VBG DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- VBG DT JJ NN O
low low 0 0 0 0 0 0 0 0 3 0 VBG DT JJ NN NNP O
xylitol xylitol 0 0 0 0 0 0 0 0 7 0 DT JJ NN NNP TO O
titer. titer. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP TO DT O
To To 1 0 0 0 0 0 0 0 2 0 NN NNP TO DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP TO DT NN PRP O
end, end, 0 0 0 0 1 0 0 0 4 0 TO DT NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBD NNS O
cloned cloned 0 0 0 0 0 0 0 0 6 0 NN PRP VBD NNS -NONE- O
genes genes 0 0 0 0 0 0 0 0 5 0 PRP VBD NNS -NONE- JJ O
CDT-1 CDT-1 1 1 1 0 0 0 0 1 5 0 VBD NNS -NONE- JJ DT O
(encoding (encoding 0 0 0 0 0 0 0 0 9 0 NNS -NONE- JJ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- JJ DT NN NN O
cellodextrin cellodextrin 0 0 0 0 0 0 0 0 12 0 JJ DT NN NN CC O
transporter) transporter) 0 0 0 0 0 0 0 0 12 0 DT NN NN CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC -NONE- JJ O
gh1-1 gh1-1 0 0 1 0 0 0 0 1 5 0 NN CC -NONE- JJ DT O
(encoding (encoding 0 0 0 0 0 0 0 0 9 0 CC -NONE- JJ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 -NONE- JJ DT JJ NN O
intracellular intracellular 0 0 0 0 0 0 0 0 13 0 JJ DT JJ NN IN O
β-glucosidase) β-glucosidase) 0 0 1 0 0 0 0 0 14 0 DT JJ NN IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 JJ NN IN NNP NN O
Neurospora Neurospora 1 0 0 0 0 0 0 0 10 0 NN IN NNP NN CC O
crassa crassa 0 0 0 0 0 0 0 0 6 0 IN NNP NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NNP NNP O
XYL1 XYL1 1 1 0 0 0 0 0 1 4 0 NN CC NNP NNP DT O
(encoding (encoding 0 0 0 0 0 0 0 0 9 0 CC NNP NNP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT NN NN O
xylose xylose 0 0 0 0 0 0 0 0 6 0 NNP DT NN NN WDT O
reductase reductase 0 0 0 0 0 0 0 0 9 0 DT NN NN WDT VBZ O
that that 0 0 0 0 0 0 0 0 4 0 NN NN WDT VBZ VBP O
converts converts 0 0 0 0 0 0 0 0 8 0 NN WDT VBZ VBP IN O
xylose xylose 0 0 0 0 0 0 0 0 6 0 WDT VBZ VBP IN JJ O
into into 0 0 0 0 0 0 0 0 4 0 VBZ VBP IN JJ IN O
xylitol) xylitol) 0 0 0 0 0 0 0 0 8 0 VBP IN JJ IN NNPS O
from from 0 0 0 0 0 0 0 0 4 0 IN JJ IN NNPS NNS O
Scheffersomyces Scheffersomyces 1 0 0 0 0 0 0 0 15 0 JJ IN NNPS NNS IN O
stipitis stipitis 0 0 0 0 0 0 0 0 8 0 IN NNPS NNS IN NNS O
into into 0 0 0 0 0 0 0 0 4 0 NNPS NNS IN NNS -NONE- O
Saccharomyces Saccharomyces 1 0 0 0 0 0 0 0 13 0 NNS IN NNS -NONE- VBG O
cerevisiae, cerevisiae, 0 0 0 0 1 0 0 0 11 0 IN NNS -NONE- VBG JJ O
enabling enabling 0 0 0 0 0 0 0 0 8 0 NNS -NONE- VBG JJ NN O
simultaneous simultaneous 0 0 0 0 0 0 0 0 12 0 -NONE- VBG JJ NN IN O
production production 0 0 0 0 0 0 0 0 10 0 VBG JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN CC O
ethanol ethanol 0 0 0 0 0 0 0 0 7 0 NN IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN IN O
xylitol xylitol 0 0 0 0 0 0 0 0 7 0 NN CC NN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 CC NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN IN O
mixture mixture 0 0 0 0 0 0 0 0 7 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN CC O
cellobiose cellobiose 0 0 0 0 0 0 0 0 10 0 NN IN NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VB JJ O
xylose xylose 0 0 0 0 0 0 0 0 6 0 NN CC VB JJ NNS O
(main (main 0 0 0 0 0 0 0 0 5 0 CC VB JJ NNS IN O
components components 0 0 0 0 0 0 0 0 10 0 VB JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NNP O
lignocellulosic lignocellulosic 0 0 0 0 0 0 0 0 15 0 NNS IN JJ NNP NNP O
hydrolysates). hydrolysates). 0 0 0 0 0 0 0 0 14 0 IN JJ NNP NNP RB O
We We 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP RB VBD O
further further 0 0 0 0 0 0 0 0 7 0 NNP NNP RB VBD DT O
optimized optimized 0 0 0 0 0 0 0 0 9 0 NNP RB VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBD DT NN NNS O
expression expression 0 0 0 0 0 0 0 0 10 0 VBD DT NN NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 DT NN NNS IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN -NONE- CC O
CDT-1 CDT-1 1 1 1 0 0 0 0 1 5 0 NNS IN -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN -NONE- CC NNP IN O
XYL1 XYL1 1 1 0 0 0 0 0 1 4 0 -NONE- CC NNP IN NN O
by by 0 0 0 0 0 0 0 0 2 0 CC NNP IN NN PRP$ O
manipulating manipulating 0 0 0 0 0 0 0 0 12 0 NNP IN NN PRP$ NNS O
their their 0 0 0 0 0 0 0 0 5 0 IN NN PRP$ NNS CC O
promoters promoters 0 0 0 0 0 0 0 0 9 0 NN PRP$ NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 PRP$ NNS CC JJ CC O
copy-numbers, copy-numbers, 0 0 1 0 1 0 0 0 13 0 NNS CC JJ CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 CC JJ CC VBD DT O
constructed constructed 0 0 0 0 0 0 0 0 11 0 JJ CC VBD DT VBN O
an an 0 0 0 0 0 0 0 0 2 0 CC VBD DT VBN NNP O
engineered engineered 0 0 0 0 0 0 0 0 10 0 VBD DT VBN NNP NN O
S. S. 1 1 0 0 0 0 0 0 2 0 DT VBN NNP NN NN O
cerevisiae cerevisiae 0 0 0 0 0 0 0 0 10 0 VBN NNP NN NN NN O
strain strain 0 0 0 0 0 0 0 0 6 0 NNP NN NN NN CD O
(carrying (carrying 0 0 0 0 0 0 0 0 9 0 NN NN NN CD NN O
one one 0 0 0 0 0 0 0 0 3 0 NN NN CD NN IN O
copy copy 0 0 0 0 0 0 0 0 4 0 NN CD NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN -NONE- CC O
PGK1p-CDT1 PGK1p-CDT1 1 0 1 0 0 0 0 1 10 0 NN IN -NONE- CC CD O
and and 0 0 0 0 0 0 0 0 3 0 IN -NONE- CC CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 -NONE- CC CD NNS IN O
copies copies 0 0 0 0 0 0 0 0 6 0 CC CD NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN JJ WDT O
TDH3p-XYL1), TDH3p-XYL1), 1 0 1 0 1 0 0 1 12 0 NNS IN JJ WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 IN JJ WDT VBD DT O
showed showed 0 0 0 0 0 0 0 0 6 0 JJ WDT VBD DT CD O
an an 0 0 0 0 0 0 0 0 2 0 WDT VBD DT CD NN O
85.7% 85.7% 0 0 0 0 0 0 0 1 5 0 VBD DT CD NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 DT CD NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN NN NN O
xylitol xylitol 0 0 0 0 0 0 0 0 7 0 NN IN NN NN IN O
production production 0 0 0 0 0 0 0 0 10 0 IN NN NN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
mixture mixture 0 0 0 0 0 0 0 0 7 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN CC O
cellobiose cellobiose 0 0 0 0 0 0 0 0 10 0 NN IN NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VB IN O
xylose xylose 0 0 0 0 0 0 0 0 6 0 NN CC VB IN DT O
than than 0 0 0 0 0 0 0 0 4 0 CC VB IN DT IN O
that that 0 0 0 0 0 0 0 0 4 0 VB IN DT IN DT O
from from 0 0 0 0 0 0 0 0 4 0 IN DT IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 DT IN DT NN IN O
mixture mixture 0 0 0 0 0 0 0 0 7 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN CC O
glucose glucose 0 0 0 0 0 0 0 0 7 0 NN IN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NNP NNP O
xylose. xylose. 0 0 0 0 0 0 0 0 7 0 NN CC NNP NNP PRP O
Thus, Thus, 1 0 0 0 1 0 0 0 5 0 CC NNP NNP PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD DT O
achieved achieved 0 0 0 0 0 0 0 0 8 0 NNP PRP VBD DT VBN O
a a 0 0 0 0 0 0 0 0 1 0 PRP VBD DT VBN NN O
balanced balanced 0 0 0 0 0 0 0 0 8 0 VBD DT VBN NN IN O
co-fermentation co-fermentation 0 0 1 0 0 0 0 0 15 0 DT VBN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NN -NONE- O
cellobiose cellobiose 0 0 0 0 0 0 0 0 10 0 NN IN NN -NONE- -NONE- O
(0.165 (0.165 0 0 0 0 0 0 0 1 6 0 IN NN -NONE- -NONE- CC O
g/L/h) g/L/h) 0 0 0 1 0 0 0 0 6 0 NN -NONE- -NONE- CC VB O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- CC VB -NONE- O
xylose xylose 0 0 0 0 0 0 0 0 6 0 -NONE- CC VB -NONE- -NONE- O
(0.162 (0.162 0 0 0 0 0 0 0 1 6 0 CC VB -NONE- -NONE- IN O
g/L/h) g/L/h) 0 0 0 1 0 0 0 0 6 0 VB -NONE- -NONE- IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 -NONE- -NONE- IN JJ NNS O
similar similar 0 0 0 0 0 0 0 0 7 0 -NONE- IN JJ NNS TO O
rates rates 0 0 0 0 0 0 0 0 5 0 IN JJ NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO VB NN O
co-produce co-produce 0 0 1 0 0 0 0 0 10 0 NNS TO VB NN -NONE- O
ethanol ethanol 0 0 0 0 0 0 0 0 7 0 TO VB NN -NONE- -NONE- O
(0.36 (0.36 0 0 0 0 0 0 0 1 5 0 VB NN -NONE- -NONE- CC O
g/g) g/g) 0 0 0 1 0 0 0 0 4 0 NN -NONE- -NONE- CC NN O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- CC NN -NONE- O
xylitol xylitol 0 0 0 0 0 0 0 0 7 0 -NONE- CC NN -NONE- NNP O
(1.00 (1.00 0 0 0 0 0 0 0 1 5 0 CC NN -NONE- NNP NONE O
g/g). g/g). 0 0 0 1 0 0 0 0 5 0 NN -NONE- NNP NONE NONE O
ZrFsy1, ZrFsy1, 1 0 0 0 1 0 0 1 7 0 NONE NONE NN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NONE NN DT NN NN O
High-Affinity High-Affinity 1 0 1 0 0 0 0 0 13 0 NN DT NN NN NNP O
Fructose/H(+) Fructose/H(+) 1 0 0 1 0 0 0 0 13 0 DT NN NN NNP IN O
Symporter Symporter 1 0 0 0 0 0 0 0 9 0 NN NN NNP IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NN NNP IN NNP NNP O
Fructophilic Fructophilic 1 0 0 0 0 0 0 0 12 0 NNP IN NNP NNP NNPS O
Yeast Yeast 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNPS NNP O
Zygosaccharomyces Zygosaccharomyces 1 0 0 0 0 0 0 0 17 0 NNP NNP NNPS NNP NNP O
rouxii. rouxii. 0 0 0 0 0 0 0 0 7 0 NNP NNPS NNP NNP NNP O
Leandro Leandro 1 0 0 0 0 0 0 0 7 0 NNPS NNP NNP NNP NNP O
MJ, MJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Sychrová Sychrová 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Prista Prista 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Loureiro-Dias Loureiro-Dias 1 0 1 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
MC. MC. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
CBAA, CBAA, 1 1 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
Instituto Instituto 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP IN O
Superior Superior 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Agronomia, Agronomia, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP NNP O
Universidade Universidade 1 0 0 0 0 0 0 0 12 0 IN NNP NNP NNP IN O
Técnica Técnica 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Lisboa, Lisboa, 1 0 0 0 1 0 0 0 7 0 NNP IN NNP NNP NNP O
Lisbon, Lisbon, 1 0 0 0 1 0 0 0 7 0 IN NNP NNP NNP : O
Portugal Portugal 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP : NNP O
; ; 0 0 0 0 0 0 0 0 1 0 NNP NNP : NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP : NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 : NNP IN NNP NNP O
Membrane Membrane 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Transport, Transport, 1 0 0 0 1 0 0 0 10 0 IN NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Physiology Physiology 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
AS AS 1 1 0 0 0 0 0 0 2 0 IN NNP NNP NNP NNP O
CR, CR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
v.v.i., v.v.i., 0 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Prague, Prague, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Czech Czech 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Republic. Republic. 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNPS O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNPS NN O
Zygosaccharomyces Zygosaccharomyces 1 0 0 0 0 0 0 0 17 0 NNP NNP NNPS NN VBZ O
rouxii rouxii 0 0 0 0 0 0 0 0 6 0 NNP NNPS NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNPS NN VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT JJ NN O
fructophilic fructophilic 0 0 0 0 0 0 0 0 12 0 VBZ DT JJ NN IN O
yeast yeast 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN MD O
than than 0 0 0 0 0 0 0 0 4 0 JJ NN IN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN IN MD VB IN O
grow grow 0 0 0 0 0 0 0 0 4 0 IN MD VB IN RB O
at at 0 0 0 0 0 0 0 0 2 0 MD VB IN RB JJ O
very very 0 0 0 0 0 0 0 0 4 0 VB IN RB JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 IN RB JJ NN NNP O
sugar sugar 0 0 0 0 0 0 0 0 5 0 RB JJ NN NNP NNP O
concentrations. concentrations. 0 0 0 0 0 0 0 0 15 0 JJ NN NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNP VBP VBN DT O
identified identified 0 0 0 0 0 0 0 0 10 0 NNP VBP VBN DT NNP O
an an 0 0 0 0 0 0 0 0 2 0 VBP VBN DT NNP NN O
ORF ORF 1 1 0 0 0 0 0 0 3 0 VBN DT NNP NN DT O
encoding encoding 0 0 0 0 0 0 0 0 8 0 DT NNP NN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NN DT JJ NN O
putative putative 0 0 0 0 0 0 0 0 8 0 NN DT JJ NN NN O
fructose/H(+) fructose/H(+) 0 0 0 1 0 0 0 0 13 0 DT JJ NN NN IN O
symporter symporter 0 0 0 0 0 0 0 0 9 0 JJ NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
Z. Z. 1 1 0 0 0 0 0 0 2 0 IN DT NNP NN NNP O
rouxii rouxii 0 0 0 0 0 0 0 0 6 0 DT NNP NN NNP CD O
CBS CBS 1 1 0 0 0 0 0 0 3 0 NNP NN NNP CD NN O
732 732 0 0 0 0 0 0 1 1 3 0 NN NNP CD NN NNP O
genome genome 0 0 0 0 0 0 0 0 6 0 NNP CD NN NNP NNP O
database. database. 0 0 0 0 0 0 0 0 9 0 CD NN NNP NNP NN O
Heterologous Heterologous 1 0 0 0 0 0 0 0 12 0 NN NNP NNP NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NNP O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NNP IN O
ORF ORF 1 1 0 0 0 0 0 0 3 0 IN DT NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NNP IN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT NNP NN O
S. S. 1 1 0 0 0 0 0 0 2 0 IN DT NNP NN NN O
cerevisiae cerevisiae 0 0 0 0 0 0 0 0 10 0 DT NNP NN NN VBG O
strain strain 0 0 0 0 0 0 0 0 6 0 NNP NN NN VBG PRP$ O
lacking lacking 0 0 0 0 0 0 0 0 7 0 NN NN VBG PRP$ JJ O
its its 0 0 0 0 0 0 0 0 3 0 NN VBG PRP$ JJ NN O
own own 0 0 0 0 0 0 0 0 3 0 VBG PRP$ JJ NN NNS O
hexose hexose 0 0 0 0 0 0 0 0 6 0 PRP$ JJ NN NNS -NONE- O
transporters transporters 0 0 0 0 0 0 0 0 12 0 JJ NN NNS -NONE- CC O
(hxt-null) (hxt-null) 0 0 1 0 0 0 0 0 10 0 NN NNS -NONE- CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC JJ JJ O
subsequent subsequent 0 0 0 0 0 0 0 0 10 0 -NONE- CC JJ JJ NN O
kinetic kinetic 0 0 0 0 0 0 0 0 7 0 CC JJ JJ NN IN O
characterization characterization 0 0 0 0 0 0 0 0 16 0 JJ JJ NN IN PRP$ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NN IN PRP$ NN NN O
sugar sugar 0 0 0 0 0 0 0 0 5 0 IN PRP$ NN NN NN O
transport transport 0 0 0 0 0 0 0 0 9 0 PRP$ NN NN NN VBD O
activity activity 0 0 0 0 0 0 0 0 8 0 NN NN NN VBD PRP O
showed showed 0 0 0 0 0 0 0 0 6 0 NN NN VBD PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NN VBD PRP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 VBD PRP VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 PRP VBZ DT NN NN O
high-affinity high-affinity 0 0 1 0 0 0 0 0 13 0 VBZ DT NN NN NN O
low-capacity low-capacity 0 0 1 0 0 0 0 0 12 0 DT NN NN NN NN O
fructose/H(+) fructose/H(+) 0 0 0 1 0 0 0 0 13 0 NN NN NN NN IN O
symporter, symporter, 0 0 0 0 1 0 0 0 10 0 NN NN NN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN NNP CD O
Km Km 1 0 0 0 0 0 0 0 2 0 NN IN NNP CD NNP O
0.45±0.07 0.45±0.07 0 0 0 0 0 0 0 1 9 0 IN NNP CD NNP CC O
mM mM 0 0 0 0 0 0 0 0 2 0 NNP CD NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 CD NNP CC NNP CD O
Vmax Vmax 1 0 0 0 0 0 0 0 4 0 NNP CC NNP CD NN O
0.57±0.02 0.57±0.02 0 0 0 0 0 0 0 1 9 0 CC NNP CD NN -NONE- O
mmol mmol 0 0 0 0 0 0 0 0 4 0 NNP CD NN -NONE- -NONE- O
h(-1) h(-1) 0 0 1 0 0 0 0 1 5 0 CD NN -NONE- -NONE- NNP O
(gdw) (gdw) 0 0 0 0 0 0 0 0 5 0 NN -NONE- -NONE- NNP NNP O
(-1). (-1). 0 0 1 0 0 0 0 1 5 0 -NONE- -NONE- NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 -NONE- NNP NNP VBD PRP O
named named 0 0 0 0 0 0 0 0 5 0 NNP NNP VBD PRP NNP O
it it 0 0 0 0 0 0 0 0 2 0 NNP VBD PRP NNP NNP O
ZrFsy1. ZrFsy1. 1 0 0 0 0 0 0 1 7 0 VBD PRP NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 PRP NNP NNP NN RB O
protein protein 0 0 0 0 0 0 0 0 7 0 NNP NNP NN RB RB O
also also 0 0 0 0 0 0 0 0 4 0 NNP NN RB RB NNS O
weakly weakly 0 0 0 0 0 0 0 0 6 0 NN RB RB NNS NN O
transports transports 0 0 0 0 0 0 0 0 10 0 RB RB NNS NN CC O
xylitol xylitol 0 0 0 0 0 0 0 0 7 0 RB NNS NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNS NN CC NNP CC O
sorbose, sorbose, 0 0 0 0 1 0 0 0 8 0 NN CC NNP CC RB O
but but 0 0 0 0 0 0 0 0 3 0 CC NNP CC RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NNP CC RB VB CC O
glucose glucose 0 0 0 0 0 0 0 0 7 0 CC RB VB CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 RB VB CC JJ NNP O
other other 0 0 0 0 0 0 0 0 5 0 VB CC JJ NNP NNP O
hexoses. hexoses. 0 0 0 0 0 0 0 0 8 0 CC JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP IN O
ZrFSY1 ZrFSY1 1 0 0 0 0 0 0 1 6 0 NN IN NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NN O
Z. Z. 1 1 0 0 0 0 0 0 2 0 NNP IN NNP NN VBZ O
rouxii rouxii 0 0 0 0 0 0 0 0 6 0 IN NNP NN VBZ JJR O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ JJR WRB O
higher higher 0 0 0 0 0 0 0 0 6 0 NN VBZ JJR WRB DT O
when when 0 0 0 0 0 0 0 0 4 0 VBZ JJR WRB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 JJR WRB DT NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 WRB DT NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 DT NNS VBP VBN IN O
cultivated cultivated 0 0 0 0 0 0 0 0 10 0 NNS VBP VBN IN RB O
at at 0 0 0 0 0 0 0 0 2 0 VBP VBN IN RB JJ O
extremely extremely 0 0 0 0 0 0 0 0 9 0 VBN IN RB JJ NN O
low low 0 0 0 0 0 0 0 0 3 0 IN RB JJ NN NNS O
fructose fructose 0 0 0 0 0 0 0 0 8 0 RB JJ NN NNS -NONE- O
concentrations concentrations 0 0 0 0 0 0 0 0 14 0 JJ NN NNS -NONE- CC O
(<0.2%) (<0.2%) 0 0 0 0 0 0 0 1 7 0 NN NNS -NONE- CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 -NONE- CC IN JJ NN O
non-fermentable non-fermentable 0 0 1 0 0 0 0 0 15 0 CC IN JJ NN NNS O
carbon carbon 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNS JJ O
sources sources 0 0 0 0 0 0 0 0 7 0 JJ NN NNS JJ IN O
such such 0 0 0 0 0 0 0 0 4 0 NN NNS JJ IN NN O
as as 0 0 0 0 0 0 0 0 2 0 NNS JJ IN NN CC O
mannitol mannitol 0 0 0 0 0 0 0 0 8 0 JJ IN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NNP WRB O
xylitol, xylitol, 0 0 0 0 1 0 0 0 8 0 NN CC NNP WRB DT O
where where 0 0 0 0 0 0 0 0 5 0 CC NNP WRB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP WRB DT NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 WRB DT NNS VBP DT O
have have 0 0 0 0 0 0 0 0 4 0 DT NNS VBP DT VBN O
a a 0 0 0 0 0 0 0 0 1 0 NNS VBP DT VBN NN O
prolonged prolonged 0 0 0 0 0 0 0 0 9 0 VBP DT VBN NN -NONE- O
lag lag 0 0 0 0 0 0 0 0 3 0 DT VBN NN -NONE- JJR O
phase, phase, 0 0 0 0 1 0 0 0 6 0 VBN NN -NONE- JJR NN O
longer longer 0 0 0 0 0 0 0 0 6 0 NN -NONE- JJR NN NNS O
duplication duplication 0 0 0 0 0 0 0 0 11 0 -NONE- JJR NN NNS CC O
times times 0 0 0 0 0 0 0 0 5 0 JJR NN NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NN PRP$ O
change change 0 0 0 0 0 0 0 0 6 0 NNS CC NN PRP$ JJ O
their their 0 0 0 0 0 0 0 0 5 0 CC NN PRP$ JJ NNP O
microscopic microscopic 0 0 0 0 0 0 0 0 11 0 NN PRP$ JJ NNP DT O
morphology. morphology. 0 0 0 0 0 0 0 0 11 0 PRP$ JJ NNP DT JJ O
A A 1 1 0 0 0 0 0 0 1 0 JJ NNP DT JJ NN O
clear clear 0 0 0 0 0 0 0 0 5 0 NNP DT JJ NN VBD O
phenotype phenotype 0 0 0 0 0 0 0 0 9 0 DT JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN IN O
determined determined 0 0 0 0 0 0 0 0 10 0 NN VBD VBN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN IN O
time time 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
deletion deletion 0 0 0 0 0 0 0 0 8 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
fructose/H(+) fructose/H(+) 0 0 0 1 0 0 0 0 13 0 IN DT JJ NN IN O
symporter symporter 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN WRB O
genome genome 0 0 0 0 0 0 0 0 6 0 IN DT NN WRB PRP O
where where 0 0 0 0 0 0 0 0 5 0 DT NN WRB PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NN WRB PRP VBZ NNP O
occurs occurs 0 0 0 0 0 0 0 0 6 0 WRB PRP VBZ NNP NNP O
naturally. naturally. 0 0 0 0 0 0 0 0 10 0 PRP VBZ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 VBZ NNP NNP NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
deletion deletion 0 0 0 0 0 0 0 0 8 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
ZrFSY1 ZrFSY1 1 0 0 0 0 0 0 1 6 0 NN IN NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NN O
Z. Z. 1 1 0 0 0 0 0 0 2 0 NNP IN NNP NN NNS O
rouxii rouxii 0 0 0 0 0 0 0 0 6 0 IN NNP NN NNS VBZ O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NN NNS VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NN NNS VBZ RB JJ O
only only 0 0 0 0 0 0 0 0 4 0 NNS VBZ RB JJ WRB O
evident evident 0 0 0 0 0 0 0 0 7 0 VBZ RB JJ WRB DT O
when when 0 0 0 0 0 0 0 0 4 0 RB JJ WRB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 JJ WRB DT NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 WRB DT NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 DT NNS VBP VBN IN O
cultivated cultivated 0 0 0 0 0 0 0 0 10 0 NNS VBP VBN IN RB O
at at 0 0 0 0 0 0 0 0 2 0 VBP VBN IN RB JJ O
very very 0 0 0 0 0 0 0 0 4 0 VBN IN RB JJ NN O
low low 0 0 0 0 0 0 0 0 3 0 IN RB JJ NN NN O
fructose fructose 0 0 0 0 0 0 0 0 8 0 RB JJ NN NN WRB O
concentrations, concentrations, 0 0 0 0 1 0 0 0 15 0 JJ NN NN WRB DT O
when when 0 0 0 0 0 0 0 0 4 0 NN NN WRB DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN WRB DT NNP NN O
ZrFsy1 ZrFsy1 1 0 0 0 0 0 0 1 6 0 WRB DT NNP NN NN O
fructose fructose 0 0 0 0 0 0 0 0 8 0 DT NNP NN NN VBZ O
symporter symporter 0 0 0 0 0 0 0 0 9 0 NNP NN NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT JJ JJ O
main main 0 0 0 0 0 0 0 0 4 0 VBZ DT JJ JJ NN O
active active 0 0 0 0 0 0 0 0 6 0 DT JJ JJ NN NN O
fructose fructose 0 0 0 0 0 0 0 0 8 0 JJ JJ NN NN NNP O
transporter transporter 0 0 0 0 0 0 0 0 11 0 JJ NN NN NNP NONE O
system. system. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NONE NONE O
Field Field 1 0 0 0 0 0 0 0 5 0 NONE NONE NNP NNS IN O
tests tests 0 0 0 0 0 0 0 0 5 0 NONE NNP NNS IN VBG O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNS IN VBG DT O
evaluating evaluating 0 0 0 0 0 0 0 0 10 0 NNS IN VBG DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 IN VBG DT JJ NN O
aerobic aerobic 0 0 0 0 0 0 0 0 7 0 VBG DT JJ NN NN O
work work 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN IN O
capacity capacity 0 0 0 0 0 0 0 0 8 0 JJ NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
firefighters. firefighters. 0 0 0 0 0 0 0 0 13 0 NN IN NNP NNP NNP O
Lindberg Lindberg 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
AS, AS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Oksa Oksa 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Gavhed Gavhed 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Malm Malm 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
C. C. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Sports Sports 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Medicine Medicine 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Unit, Unit, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
Umeå Umeå 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP : O
Sweden Sweden 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP : NNP O
; ; 0 0 0 0 0 0 0 0 1 0 NNP NNP : NNP NNP O
Winternet, Winternet, 1 0 0 0 1 0 0 0 10 0 NNP : NNP NNP NNP O
Boden, Boden, 1 0 0 0 1 0 0 0 6 0 : NNP NNP NNP NNP O
Sweden. Sweden. 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Working Working 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT NN VBZ O
firefighter firefighter 0 0 0 0 0 0 0 0 11 0 IN DT NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ RB -NONE- O
physically physically 0 0 0 0 0 0 0 0 10 0 NN VBZ RB -NONE- CC O
strenuous, strenuous, 0 0 0 0 1 0 0 0 10 0 VBZ RB -NONE- CC DT O
and and 0 0 0 0 0 0 0 0 3 0 RB -NONE- CC DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- CC DT JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 CC DT JJ NN IN O
level level 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
physical physical 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN NNS O
fitness fitness 0 0 0 0 0 0 0 0 7 0 IN JJ NN NNS DT O
increases increases 0 0 0 0 0 0 0 0 9 0 JJ NN NNS DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN NNS DT JJ NN O
firefighter's firefighter's 0 0 0 0 0 1 0 0 13 0 NNS DT JJ NN TO O
ability ability 0 0 0 0 0 0 0 0 7 0 DT JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB IN O
cope cope 0 0 0 0 0 0 0 0 4 0 NN TO VB IN DT O
with with 0 0 0 0 0 0 0 0 4 0 TO VB IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VB IN DT JJ NN O
physical physical 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN IN O
stress stress 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN PRP$ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN PRP$ NNP O
their their 0 0 0 0 0 0 0 0 5 0 NN IN PRP$ NNP NNP O
profession. profession. 0 0 0 0 0 0 0 0 11 0 IN PRP$ NNP NNP NNS O
Direct Direct 1 0 0 0 0 0 0 0 6 0 PRP$ NNP NNP NNS IN O
measurements measurements 0 0 0 0 0 0 0 0 12 0 NNP NNP NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN JJ NN O
aerobic aerobic 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NN NN O
capacity, capacity, 0 0 0 0 1 0 0 0 9 0 IN JJ NN NN VBP O
however, however, 0 0 0 0 1 0 0 0 8 0 JJ NN NN VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 NN NN VBP RB JJ O
often often 0 0 0 0 0 0 0 0 5 0 NN VBP RB JJ NN O
complicated, complicated, 0 0 0 0 1 0 0 0 12 0 VBP RB JJ NN NN O
time time 0 0 0 0 0 0 0 0 4 0 RB JJ NN NN CC O
consuming, consuming, 0 0 0 0 1 0 0 0 10 0 JJ NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
expensive. expensive. 0 0 0 0 0 0 0 0 10 0 NN CC NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 CC NNP NNP JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 NNP NNP JJ NN IN O
aim aim 0 0 0 0 0 0 0 0 3 0 NNP JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
present present 0 0 0 0 0 0 0 0 7 0 IN DT NN NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 DT NN NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB DT O
evaluate evaluate 0 0 0 0 0 0 0 0 8 0 VBD TO VB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NNS IN O
correlations correlations 0 0 0 0 0 0 0 0 12 0 VB DT NNS IN JJ O
between between 0 0 0 0 0 0 0 0 7 0 DT NNS IN JJ NN O
direct direct 0 0 0 0 0 0 0 0 6 0 NNS IN JJ NN CC O
(laboratory) (laboratory) 0 0 0 0 0 0 0 0 12 0 IN JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NN O
indirect indirect 0 0 0 0 0 0 0 0 8 0 NN CC JJ NN JJ O
(field) (field) 0 0 0 0 0 0 0 0 7 0 CC JJ NN JJ NN O
aerobic aerobic 0 0 0 0 0 0 0 0 7 0 JJ NN JJ NN NNS O
capacity capacity 0 0 0 0 0 0 0 0 8 0 NN JJ NN NNS IN O
tests tests 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN NNS IN JJ CC O
common common 0 0 0 0 0 0 0 0 6 0 NNS IN JJ CC RB O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC RB VBG O
physically physically 0 0 0 0 0 0 0 0 10 0 JJ CC RB VBG VBG O
demanding demanding 0 0 0 0 0 0 0 0 9 0 CC RB VBG VBG NNP O
firefighting firefighting 0 0 0 0 0 0 0 0 12 0 RB VBG VBG NNP NNP O
tasks. tasks. 0 0 0 0 0 0 0 0 6 0 VBG VBG NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 VBG NNP NNP JJ NN O
second second 0 0 0 0 0 0 0 0 6 0 NNP NNP JJ NN VBD O
aim aim 0 0 0 0 0 0 0 0 3 0 NNP JJ NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB NNS O
give give 0 0 0 0 0 0 0 0 4 0 VBD TO VB NNS IN O
recommendations recommendations 0 0 0 0 0 0 0 0 15 0 TO VB NNS IN TO O
as as 0 0 0 0 0 0 0 0 2 0 VB NNS IN TO WDT O
to to 0 0 0 0 0 0 0 0 2 0 NNS IN TO WDT NN O
which which 0 0 0 0 0 0 0 0 5 0 IN TO WDT NN NNS O
field field 0 0 0 0 0 0 0 0 5 0 TO WDT NN NNS MD O
tests tests 0 0 0 0 0 0 0 0 5 0 WDT NN NNS MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN NNS MD VB DT O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT JJS JJ O
most most 0 0 0 0 0 0 0 0 4 0 VB DT JJS JJ IN O
useful useful 0 0 0 0 0 0 0 0 6 0 DT JJS JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJS JJ IN NN -NONE- O
evaluating evaluating 0 0 0 0 0 0 0 0 10 0 JJ IN NN -NONE- JJ O
firefighters' firefighters' 0 0 0 0 0 1 0 0 13 0 IN NN -NONE- JJ NN O
aerobic aerobic 0 0 0 0 0 0 0 0 7 0 NN -NONE- JJ NN NNP O
work work 0 0 0 0 0 0 0 0 4 0 -NONE- JJ NN NNP DT O
capacity. capacity. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP DT NN O
A A 1 1 0 0 0 0 0 0 1 0 NN NNP DT NN IN O
total total 0 0 0 0 0 0 0 0 5 0 NNP DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD NNS O
38 38 0 0 0 0 0 0 1 1 2 0 NN IN CD NNS -NONE- O
subjects subjects 0 0 0 0 0 0 0 0 8 0 IN CD NNS -NONE- NNS O
(26 (26 0 0 0 0 0 0 0 1 3 0 CD NNS -NONE- NNS CC O
men men 0 0 0 0 0 0 0 0 3 0 NNS -NONE- NNS CC CD O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NNS CC CD NN O
12 12 0 0 0 0 0 0 1 1 2 0 NNS CC CD NN VBD O
women) women) 0 0 0 0 0 0 0 0 6 0 CC CD NN VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 CD NN VBD NNP NNP O
included. included. 0 0 0 0 0 0 0 0 9 0 NN VBD NNP NNP JJ O
Two Two 1 0 0 0 0 0 0 0 3 0 VBD NNP NNP JJ NN O
aerobic aerobic 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NN NN O
capacity capacity 0 0 0 0 0 0 0 0 8 0 NNP JJ NN NN CD O
tests, tests, 0 0 0 0 1 0 0 0 6 0 JJ NN NN CD NN O
six six 0 0 0 0 0 0 0 0 3 0 NN NN CD NN -NONE- O
field field 0 0 0 0 0 0 0 0 5 0 NN CD NN -NONE- CC O
tests, tests, 0 0 0 0 1 0 0 0 6 0 CD NN -NONE- CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC CD VBG O
seven seven 0 0 0 0 0 0 0 0 5 0 -NONE- CC CD VBG NNS O
firefighting firefighting 0 0 0 0 0 0 0 0 12 0 CC CD VBG NNS VBD O
tasks tasks 0 0 0 0 0 0 0 0 5 0 CD VBG NNS VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 VBG NNS VBD NNP NNP O
performed. performed. 0 0 0 0 0 0 0 0 10 0 NNS VBD NNP NNP VBD O
Lactate Lactate 1 0 0 0 0 0 0 0 7 0 VBD NNP NNP VBD CC O
threshold threshold 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP VBD CC NN IN O
onset onset 0 0 0 0 0 0 0 0 5 0 VBD CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NN O
blood blood 0 0 0 0 0 0 0 0 5 0 NN IN NN NN NN O
lactate lactate 0 0 0 0 0 0 0 0 7 0 IN NN NN NN VBD O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 NN NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN TO O
found found 0 0 0 0 0 0 0 0 5 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB VBN TO O
correlated correlated 0 0 0 0 0 0 0 0 10 0 TO VB VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VB VBN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN TO DT NN IN O
performance performance 0 0 0 0 0 0 0 0 11 0 TO DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD NN O
one one 0 0 0 0 0 0 0 0 3 0 NN IN CD NN NN O
work work 0 0 0 0 0 0 0 0 4 0 IN CD NN NN NNS O
task task 0 0 0 0 0 0 0 0 4 0 CD NN NN NNS : O
(rs (rs 0 0 0 0 0 0 0 0 3 0 NN NN NNS : -NONE- O
= = 0 0 0 0 0 0 0 0 1 0 NN NNS : -NONE- CC O
-0.65 -0.65 0 0 1 0 0 0 0 1 5 0 NNS : -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 : -NONE- CC NNP NNP O
-0.63, -0.63, 0 0 1 0 1 0 0 1 6 0 -NONE- CC NNP NNP NNP O
p<0.01, p<0.01, 0 0 0 0 1 0 0 1 7 0 CC NNP NNP NNP NNP O
respectively). respectively). 0 0 0 0 0 0 0 0 14 0 NNP NNP NNP NNP NNP O
Absolute Absolute 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP CC O
(mL·min(-1)) (mL·min(-1)) 0 0 1 0 0 0 0 1 12 0 NNP NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NN O
relative relative 0 0 0 0 0 0 0 0 8 0 NNP CC JJ NN JJ O
(mL·kg(-1)·min(-1)) (mL·kg(-1)·min(-1)) 0 0 1 0 0 0 0 1 19 0 CC JJ NN JJ JJ O
maximal maximal 0 0 0 0 0 0 0 0 7 0 JJ NN JJ JJ NN O
aerobic aerobic 0 0 0 0 0 0 0 0 7 0 NN JJ JJ NN VBD O
capacity capacity 0 0 0 0 0 0 0 0 8 0 JJ JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN TO O
correlated correlated 0 0 0 0 0 0 0 0 10 0 NN VBD VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO DT CC O
all all 0 0 0 0 0 0 0 0 3 0 VBN TO DT CC CD O
but but 0 0 0 0 0 0 0 0 3 0 TO DT CC CD IN O
one one 0 0 0 0 0 0 0 0 3 0 DT CC CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC CD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT NN VBZ O
work work 0 0 0 0 0 0 0 0 4 0 IN DT NN VBZ NNS O
tasks tasks 0 0 0 0 0 0 0 0 5 0 DT NN VBZ NNS : O
(rs (rs 0 0 0 0 0 0 0 0 3 0 NN VBZ NNS : -NONE- O
= = 0 0 0 0 0 0 0 0 1 0 VBZ NNS : -NONE- TO O
-0.79 -0.79 0 0 1 0 0 0 0 1 5 0 NNS : -NONE- TO CD O
to to 0 0 0 0 0 0 0 0 2 0 : -NONE- TO CD CC O
0.55 0.55 0 0 0 0 0 0 0 1 4 0 -NONE- TO CD CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 TO CD CC -NONE- TO O
-0.74 -0.74 0 0 1 0 0 0 0 1 5 0 CD CC -NONE- TO CD O
to to 0 0 0 0 0 0 0 0 2 0 CC -NONE- TO CD NN O
0.47, 0.47, 0 0 0 0 1 0 0 1 5 0 -NONE- TO CD NN NNP O
p<0.01, p<0.01, 0 0 0 0 1 0 0 1 7 0 TO CD NN NNP NNP O
respectively). respectively). 0 0 0 0 0 0 0 0 14 0 CD NN NNP NNP NN O
Aerobic Aerobic 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NN VBZ O
capacity capacity 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ JJ IN O
important important 0 0 0 0 0 0 0 0 9 0 NN VBZ JJ IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN JJ NN O
firefighters' firefighters' 0 0 0 0 0 1 0 0 13 0 JJ IN JJ NN NN O
work work 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN CC O
performance, performance, 0 0 0 0 1 0 0 0 12 0 JJ NN NN CC PRP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NN CC PRP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 CC PRP VBP VBN IN O
concluded concluded 0 0 0 0 0 0 0 0 9 0 PRP VBP VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 VBP VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN TO O
time time 0 0 0 0 0 0 0 0 4 0 IN DT NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO VB CD O
row row 0 0 0 0 0 0 0 0 3 0 NN TO VB CD -NONE- O
500 500 0 0 0 0 0 0 1 1 3 0 TO VB CD -NONE- DT O
m, m, 0 0 0 0 1 0 0 0 2 0 VB CD -NONE- DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CD -NONE- DT NN TO O
time time 0 0 0 0 0 0 0 0 4 0 -NONE- DT NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO VB CD O
run run 0 0 0 0 0 0 0 0 3 0 NN TO VB CD NN O
3000 3000 0 0 0 0 0 0 1 1 4 0 TO VB CD NN JJ O
m m 0 0 0 0 0 0 0 0 1 0 VB CD NN JJ TO O
relative relative 0 0 0 0 0 0 0 0 8 0 CD NN JJ TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NN JJ TO NN NN O
body body 0 0 0 0 0 0 0 0 4 0 JJ TO NN NN NN O
weight weight 0 0 0 0 0 0 0 0 6 0 TO NN NN NN CC O
(s·kg(-1)), (s·kg(-1)), 0 0 1 0 1 0 0 1 11 0 NN NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN IN O
percent percent 0 0 0 0 0 0 0 0 7 0 CC DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
maximal maximal 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN NN O
heart heart 0 0 0 0 0 0 0 0 5 0 IN JJ NN NN VBD O
rate rate 0 0 0 0 0 0 0 0 4 0 JJ NN NN VBD IN O
achieved achieved 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN NN O
during during 0 0 0 0 0 0 0 0 6 0 NN VBD IN NN VBG O
treadmill treadmill 0 0 0 0 0 0 0 0 9 0 VBD IN NN VBG VBP O
walking walking 0 0 0 0 0 0 0 0 7 0 IN NN VBG VBP DT O
are are 0 0 0 0 0 0 0 0 3 0 NN VBG VBP DT RBS O
the the 0 0 0 0 0 0 0 0 3 0 VBG VBP DT RBS JJ O
most most 0 0 0 0 0 0 0 0 4 0 VBP DT RBS JJ NN O
valid valid 0 0 0 0 0 0 0 0 5 0 DT RBS JJ NN NNS O
field field 0 0 0 0 0 0 0 0 5 0 RBS JJ NN NNS IN O
tests tests 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN VBG O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN VBG DT O
evaluating evaluating 0 0 0 0 0 0 0 0 10 0 NNS IN VBG DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 IN VBG DT JJ JJ O
firefighter's firefighter's 0 0 0 0 0 1 0 0 13 0 VBG DT JJ JJ NN O
aerobic aerobic 0 0 0 0 0 0 0 0 7 0 DT JJ JJ NN NNP O
work work 0 0 0 0 0 0 0 0 4 0 JJ JJ NN NNP NONE O
capacity. capacity. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NONE NONE O
DJ-1-Dependent DJ-1-Dependent 1 0 1 0 0 0 0 1 14 0 NONE NONE JJ NN IN O
Regulation Regulation 1 0 0 0 0 0 0 0 10 0 NONE JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
Oxidative Oxidative 1 0 0 0 0 0 0 0 9 0 NN IN NNP NNP IN O
Stress Stress 1 0 0 0 0 0 0 0 6 0 IN NNP NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP NNP O
Retinal Retinal 1 0 0 0 0 0 0 0 7 0 IN DT NNP NNP NNP O
Pigment Pigment 1 0 0 0 0 0 0 0 7 0 DT NNP NNP NNP NNP O
Epithelium Epithelium 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
(RPE). (RPE). 0 1 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Shadrach Shadrach 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
KG, KG, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Rayborn Rayborn 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
ME, ME, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Hollyfield Hollyfield 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
JG, JG, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Bonilha Bonilha 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
VL. VL. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Ophthalmic Ophthalmic 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Research, Research, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Cole Cole 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Eye Eye 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Institute, Institute, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Cleveland Cleveland 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Clinic Clinic 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Lerner Lerner 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
College College 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Cleveland, Cleveland, 1 0 0 0 1 0 0 0 10 0 IN NNP NNP NNP NNP O
Ohio, Ohio, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNPS O
United United 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNPS IN O
States States 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
America. America. 1 0 0 0 0 0 0 0 8 0 NNPS IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP -NONE- O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP -NONE- VBZ O
DJ-1 DJ-1 1 1 1 0 0 0 0 1 4 0 NNP NNP -NONE- VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP -NONE- VBZ VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 -NONE- VBZ VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN JJ NN O
many many 0 0 0 0 0 0 0 0 4 0 VBN IN JJ NN VBG O
tissues, tissues, 0 0 0 0 1 0 0 0 8 0 IN JJ NN VBG DT O
including including 0 0 0 0 0 0 0 0 9 0 JJ NN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT NN WRB O
brain, brain, 0 0 0 0 1 0 0 0 6 0 VBG DT NN WRB PRP O
where where 0 0 0 0 0 0 0 0 5 0 DT NN WRB PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NN WRB PRP VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 WRB PRP VBZ VBN RB O
been been 0 0 0 0 0 0 0 0 4 0 PRP VBZ VBN RB VBN O
extensively extensively 0 0 0 0 0 0 0 0 11 0 VBZ VBN RB VBN JJ O
studied studied 0 0 0 0 0 0 0 0 7 0 VBN RB VBN JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 RB VBN JJ TO PRP$ O
to to 0 0 0 0 0 0 0 0 2 0 VBN JJ TO PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 JJ TO PRP$ NN IN O
association association 0 0 0 0 0 0 0 0 11 0 TO PRP$ NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 PRP$ NN IN JJ NNP O
Parkinson's Parkinson's 1 0 0 0 0 1 0 0 11 0 NN IN JJ NNP -NONE- O
disease. disease. 0 0 0 0 0 0 0 0 8 0 IN JJ NNP -NONE- NNS O
DJ-1 DJ-1 1 1 1 0 0 0 0 1 4 0 JJ NNP -NONE- NNS IN O
functions functions 0 0 0 0 0 0 0 0 9 0 NNP -NONE- NNS IN DT O
as as 0 0 0 0 0 0 0 0 2 0 -NONE- NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ NN O
redox-sensitive redox-sensitive 0 0 1 0 0 0 0 0 15 0 IN DT JJ NN NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN CC O
chaperone chaperone 0 0 0 0 0 0 0 0 9 0 JJ NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
transcription transcription 0 0 0 0 0 0 0 0 13 0 NN CC NN NN WDT O
regulator regulator 0 0 0 0 0 0 0 0 9 0 CC NN NN WDT RB O
that that 0 0 0 0 0 0 0 0 4 0 NN NN WDT RB VBZ O
robustly robustly 0 0 0 0 0 0 0 0 8 0 NN WDT RB VBZ NNS O
protects protects 0 0 0 0 0 0 0 0 8 0 WDT RB VBZ NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 RB VBZ NNS IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 VBZ NNS IN JJ NNP O
oxidative oxidative 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NNP NNP O
stress. stress. 0 0 0 0 0 0 0 0 7 0 IN JJ NNP NNP NNP O
METHODOLOGY: METHODOLOGY: 1 1 0 0 0 0 0 0 12 0 JJ NNP NNP NNP NN O
Retinal Retinal 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NN NN O
pigment pigment 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN NN O
epithelial epithelial 0 0 0 0 0 0 0 0 10 0 NNP NN NN NN NNS O
(RPE) (RPE) 0 1 0 0 0 0 0 0 5 0 NN NN NN NNS VBD O
cultures cultures 0 0 0 0 0 0 0 0 8 0 NN NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
treated treated 0 0 0 0 0 0 0 0 7 0 NNS VBD VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNP IN O
H2O2 H2O2 1 1 0 0 0 0 0 1 4 0 VBN IN NNP IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 IN NNP IN JJ NNS O
various various 0 0 0 0 0 0 0 0 7 0 NNP IN JJ NNS VBN O
times times 0 0 0 0 0 0 0 0 5 0 IN JJ NNS VBN IN O
followed followed 0 0 0 0 0 0 0 0 8 0 JJ NNS VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBN IN JJ CC O
biochemical biochemical 0 0 0 0 0 0 0 0 11 0 VBN IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NNP O
immunohistological immunohistological 0 0 0 0 0 0 0 0 18 0 JJ CC JJ NNP NNP O
analysis. analysis. 0 0 0 0 0 0 0 0 9 0 CC JJ NNP NNP VBD O
Cells Cells 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD VBN IN O
transfected transfected 0 0 0 0 0 0 0 0 11 0 NNP VBD VBN IN NNS O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNS VBG O
adenoviruses adenoviruses 0 0 0 0 0 0 0 0 12 0 VBN IN NNS VBG DT O
carrying carrying 0 0 0 0 0 0 0 0 8 0 IN NNS VBG DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBG DT JJ NN O
full-length full-length 0 0 1 0 0 0 0 0 11 0 VBG DT JJ NN -NONE- O
human human 0 0 0 0 0 0 0 0 5 0 DT JJ NN -NONE- NNP O
DJ-1 DJ-1 1 1 1 0 0 0 0 1 4 0 JJ NN -NONE- NNP CC O
cDNA cDNA 0 0 0 0 0 0 0 0 4 0 NN -NONE- NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NNP CC DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP CC DT NN NN O
mutant mutant 0 0 0 0 0 0 0 0 6 0 CC DT NN NN WDT O
construct, construct, 0 0 0 0 1 0 0 0 10 0 DT NN NN WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBZ DT O
has has 0 0 0 0 0 0 0 0 3 0 NN WDT VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 WDT VBZ DT NN VBZ O
cysteine cysteine 0 0 0 0 0 0 0 0 8 0 VBZ DT NN VBZ IN O
residues residues 0 0 0 0 0 0 0 0 8 0 DT NN VBZ IN NN O
at at 0 0 0 0 0 0 0 0 2 0 NN VBZ IN NN NN O
amino amino 0 0 0 0 0 0 0 0 5 0 VBZ IN NN NN CD O
acid acid 0 0 0 0 0 0 0 0 4 0 IN NN NN CD CD O
46, 46, 0 0 0 0 1 0 0 1 3 0 NN NN CD CD CC O
53 53 0 0 0 0 0 0 1 1 2 0 NN CD CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD CD CC CD VBD O
106 106 0 0 0 0 0 0 1 1 3 0 CD CC CD VBD TO O
mutated mutated 0 0 0 0 0 0 0 0 7 0 CC CD VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 CD VBD TO VB JJ O
serine serine 0 0 0 0 0 0 0 0 6 0 VBD TO VB JJ TO O
(C (C 0 1 0 0 0 0 0 0 2 0 TO VB JJ TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 VB JJ TO NNP RB O
S) S) 1 1 0 0 0 0 0 0 2 0 JJ TO NNP RB TO O
prior prior 0 0 0 0 0 0 0 0 5 0 TO NNP RB TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NNP RB TO NN NNP O
stress stress 0 0 0 0 0 0 0 0 6 0 RB TO NN NNP -NONE- O
experiments. experiments. 0 0 0 0 0 0 0 0 12 0 TO NN NNP -NONE- -NONE- O
DJ-1 DJ-1 1 1 1 0 0 0 0 1 4 0 NN NNP -NONE- -NONE- NNS O
localization, localization, 0 0 0 0 1 0 0 0 13 0 NNP -NONE- -NONE- NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 -NONE- -NONE- NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 -NONE- NNS IN NN CC O
expression expression 0 0 0 0 0 0 0 0 10 0 NNS IN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC JJ NN O
reactive reactive 0 0 0 0 0 0 0 0 8 0 NN CC JJ NN NNS O
oxygen oxygen 0 0 0 0 0 0 0 0 6 0 CC JJ NN NNS -NONE- O
species species 0 0 0 0 0 0 0 0 7 0 JJ NN NNS -NONE- NN O
(ROS) (ROS) 0 1 0 0 0 0 0 0 5 0 NN NNS -NONE- NN VBD O
generation generation 0 0 0 0 0 0 0 0 10 0 NNS -NONE- NN VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 -NONE- NN VBD RB VBN O
also also 0 0 0 0 0 0 0 0 4 0 NN VBD RB VBN IN O
analyzed analyzed 0 0 0 0 0 0 0 0 8 0 VBD RB VBN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN NNS VBG O
cells cells 0 0 0 0 0 0 0 0 5 0 VBN IN NNS VBG JJ O
expressing expressing 0 0 0 0 0 0 0 0 10 0 IN NNS VBG JJ -NONE- O
exogenous exogenous 0 0 0 0 0 0 0 0 9 0 NNS VBG JJ -NONE- IN O
DJ-1 DJ-1 1 1 1 0 0 0 0 1 4 0 VBG JJ -NONE- IN NN O
under under 0 0 0 0 0 0 0 0 5 0 JJ -NONE- IN NN CC O
baseline baseline 0 0 0 0 0 0 0 0 8 0 -NONE- IN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC JJ NN O
oxidative oxidative 0 0 0 0 0 0 0 0 9 0 NN CC JJ NN NNP O
stress stress 0 0 0 0 0 0 0 0 6 0 CC JJ NN NNP NNP O
conditions. conditions. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
presence presence 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN -NONE- CC O
DJ-1 DJ-1 1 1 1 0 0 0 0 1 4 0 NN IN -NONE- CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 IN -NONE- CC VBD -NONE- O
oxidized oxidized 0 0 0 0 0 0 0 0 8 0 -NONE- CC VBD -NONE- VBD O
DJ-1 DJ-1 1 1 1 0 0 0 0 1 4 0 CC VBD -NONE- VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 VBD -NONE- VBD VBN IN O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 -NONE- VBD VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 VBN IN JJ NN NN O
RPE RPE 1 1 0 0 0 0 0 0 3 0 IN JJ NN NN NNP O
total total 0 0 0 0 0 0 0 0 5 0 JJ NN NN NNP NNP O
lysates. lysates. 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
distribution distribution 0 0 0 0 0 0 0 0 12 0 NNP NNP NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN -NONE- VBD O
DJ-1 DJ-1 1 1 1 0 0 0 0 1 4 0 NN IN -NONE- VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 IN -NONE- VBD VBN IN O
assessed assessed 0 0 0 0 0 0 0 0 8 0 -NONE- VBD VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP CC O
AMD AMD 1 1 0 0 0 0 0 0 3 0 VBN IN NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC JJ NN O
non-AMD non-AMD 0 0 1 0 0 0 0 0 7 0 NNP CC JJ NN CC O
cryosectionss cryosectionss 0 0 0 0 0 0 0 0 13 0 CC JJ NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN CC IN JJ NN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 CC IN JJ NN NNS O
human human 0 0 0 0 0 0 0 0 5 0 IN JJ NN NNS VBP O
Bruch's Bruch's 1 0 0 0 0 1 0 0 7 0 JJ NN NNS VBP JJ O
membrane membrane 0 0 0 0 0 0 0 0 8 0 NN NNS VBP JJ IN O
(BM)/choroid (BM)/choroid 0 0 0 1 0 0 0 0 12 0 NNS VBP JJ IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 VBP JJ IN NNP NNP O
AMD AMD 1 1 0 0 0 0 0 0 3 0 JJ IN NNP NNP NNP O
eyes. eyes. 0 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
PRINCIPAL PRINCIPAL 1 1 0 0 0 0 0 0 9 0 NNP NNP NNP NNP -NONE- O
FINDINGS: FINDINGS: 1 1 0 0 0 0 0 0 9 0 NNP NNP NNP -NONE- IN O
DJ-1 DJ-1 1 1 1 0 0 0 0 1 4 0 NNP NNP -NONE- IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP -NONE- IN NNP NNS O
RPE RPE 1 1 0 0 0 0 0 0 3 0 -NONE- IN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS IN NN O
under under 0 0 0 0 0 0 0 0 5 0 NNP NNS IN NN NN O
baseline baseline 0 0 0 0 0 0 0 0 8 0 NNS IN NN NN NNS O
conditions, conditions, 0 0 0 0 1 0 0 0 11 0 IN NN NN NNS DT O
displays displays 0 0 0 0 0 0 0 0 8 0 NN NN NNS DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN NNS DT NN JJ O
diffuse diffuse 0 0 0 0 0 0 0 0 7 0 NNS DT NN JJ CC O
cytoplasmic cytoplasmic 0 0 0 0 0 0 0 0 11 0 DT NN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN JJ CC JJ NNP O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 JJ CC JJ NNP NNP O
staining. staining. 0 0 0 0 0 0 0 0 9 0 CC JJ NNP NNP JJ O
After After 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP JJ NN O
oxidative oxidative 0 0 0 0 0 0 0 0 9 0 NNP NNP JJ NN RBR O
challenge, challenge, 0 0 0 0 1 0 0 0 10 0 NNP JJ NN RBR -NONE- O
more more 0 0 0 0 0 0 0 0 4 0 JJ NN RBR -NONE- VBD O
DJ-1 DJ-1 1 1 1 0 0 0 0 1 4 0 NN RBR -NONE- VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 RBR -NONE- VBD VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 -NONE- VBD VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNP NNP O
mitochondria. mitochondria. 0 0 0 0 0 0 0 0 13 0 VBN IN NNP NNP NNS O
Increasing Increasing 1 0 0 0 0 0 0 0 10 0 IN NNP NNP NNS IN O
concentrations concentrations 0 0 0 0 0 0 0 0 14 0 NNP NNP NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NNP VBD O
H2O2 H2O2 1 1 0 0 0 0 0 1 4 0 NNS IN NNP VBD IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 IN NNP VBD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP VBD IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBD IN DT JJ NN O
dose-dependent dose-dependent 0 0 1 0 0 0 0 0 14 0 IN DT JJ NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
DJ-1. DJ-1. 1 1 1 0 0 0 0 1 5 0 NN IN NNP NNP IN O
Overexpression Overexpression 1 0 0 0 0 0 0 0 14 0 IN NNP NNP IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN -NONE- CC O
DJ-1 DJ-1 1 1 1 0 0 0 0 1 4 0 NNP IN -NONE- CC RB O
but but 0 0 0 0 0 0 0 0 3 0 IN -NONE- CC RB DT O
not not 0 0 0 0 0 0 0 0 3 0 -NONE- CC RB DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 CC RB DT NNP TO O
C C 1 1 0 0 0 0 0 0 1 0 RB DT NNP TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 DT NNP TO NNP NN O
S S 1 1 0 0 0 0 0 0 1 0 NNP TO NNP NN RB O
mutant mutant 0 0 0 0 0 0 0 0 6 0 TO NNP NN RB TO O
prior prior 0 0 0 0 0 0 0 0 5 0 NNP NN RB TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN RB TO VB TO O
exposure exposure 0 0 0 0 0 0 0 0 8 0 RB TO VB TO VB O
to to 0 0 0 0 0 0 0 0 2 0 TO VB TO VB NN O
oxidative oxidative 0 0 0 0 0 0 0 0 9 0 VB TO VB NN VBN O
stress stress 0 0 0 0 0 0 0 0 6 0 TO VB NN VBN TO O
led led 0 0 0 0 0 0 0 0 3 0 VB NN VBN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NN VBN TO JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 VBN TO JJ NN IN O
decrease decrease 0 0 0 0 0 0 0 0 8 0 TO JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
generation generation 0 0 0 0 0 0 0 0 10 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP -NONE- O
ROS. ROS. 1 1 0 0 0 0 0 0 4 0 NN IN NNP -NONE- CC O
DJ-1 DJ-1 1 1 1 0 0 0 0 1 4 0 IN NNP -NONE- CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 NNP -NONE- CC -NONE- NN O
oxDJ-1 oxDJ-1 0 0 1 0 0 0 0 1 6 0 -NONE- CC -NONE- NN IN O
intensity intensity 0 0 0 0 0 0 0 0 9 0 CC -NONE- NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 -NONE- NN IN NN VBD O
immunoreactivity immunoreactivity 0 0 0 0 0 0 0 0 16 0 NN IN NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 IN NN VBD RB JJR O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NN VBD RB JJR IN O
higher higher 0 0 0 0 0 0 0 0 6 0 VBD RB JJR IN DT O
in in 0 0 0 0 0 0 0 0 2 0 RB JJR IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 JJR IN DT NNP VBZ O
RPE RPE 1 1 0 0 0 0 0 0 3 0 IN DT NNP VBZ IN O
lysates lysates 0 0 0 0 0 0 0 0 7 0 DT NNP VBZ IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NNP VBZ IN NNP NNP O
AMD AMD 1 1 0 0 0 0 0 0 3 0 VBZ IN NNP NNP NNP O
eyes. eyes. 0 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP -NONE- O
More More 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP -NONE- VBD O
DJ-1 DJ-1 1 1 1 0 0 0 0 1 4 0 NNP NNP -NONE- VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP -NONE- VBD VBN TO O
localized localized 0 0 0 0 0 0 0 0 9 0 -NONE- VBD VBN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO NNP NNS O
RPE RPE 1 1 0 0 0 0 0 0 3 0 VBN TO NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 TO NNP NNS IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNS IN NNP NNS O
AMD AMD 1 1 0 0 0 0 0 0 3 0 NNS IN NNP NNS IN O
donors donors 0 0 0 0 0 0 0 0 6 0 IN NNP NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNS IN JJ NN O
geographic geographic 0 0 0 0 0 0 0 0 10 0 NNS IN JJ NN CC O
atrophy atrophy 0 0 0 0 0 0 0 0 7 0 IN JJ NN CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC -NONE- VBD O
DJ-1 DJ-1 1 1 1 0 0 0 0 1 4 0 NN CC -NONE- VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 CC -NONE- VBD RB JJ O
also also 0 0 0 0 0 0 0 0 4 0 -NONE- VBD RB JJ IN O
present present 0 0 0 0 0 0 0 0 7 0 VBD RB JJ IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 RB JJ IN JJ NN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 JJ IN JJ NN JJ O
human human 0 0 0 0 0 0 0 0 5 0 IN JJ NN JJ IN O
BM/choroid BM/choroid 1 0 0 1 0 0 0 0 10 0 JJ NN JJ IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NN JJ IN NNP NNP O
AMD AMD 1 1 0 0 0 0 0 0 3 0 JJ IN NNP NNP NNP O
eyes. eyes. 0 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP -NONE- O
CONCLUSIONS/SIGNIFICANCE: CONCLUSIONS/SIGNIFICANCE: 1 1 0 1 0 0 0 0 25 0 NNP NNP NNP -NONE- VBZ O
DJ-1 DJ-1 1 1 1 0 0 0 0 1 4 0 NNP NNP -NONE- VBZ NNP O
regulates regulates 0 0 0 0 0 0 0 0 9 0 NNP -NONE- VBZ NNP NNS O
RPE RPE 1 1 0 0 0 0 0 0 3 0 -NONE- VBZ NNP NNS TO O
responses responses 0 0 0 0 0 0 0 0 9 0 VBZ NNP NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNP NNS TO VB NNP O
oxidative oxidative 0 0 0 0 0 0 0 0 9 0 NNS TO VB NNP NNP O
stress. stress. 0 0 0 0 0 0 0 0 7 0 TO VB NNP NNP NNP O
Most Most 1 0 0 0 0 0 0 0 4 0 VB NNP NNP NNP VBD O
importantly, importantly, 0 0 0 0 1 0 0 0 12 0 NNP NNP NNP VBD -NONE- O
increased increased 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD -NONE- NN O
DJ-1 DJ-1 1 1 1 0 0 0 0 1 4 0 NNP VBD -NONE- NN RB O
expression expression 0 0 0 0 0 0 0 0 10 0 VBD -NONE- NN RB TO O
prior prior 0 0 0 0 0 0 0 0 5 0 -NONE- NN RB TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN RB TO VB NN O
oxidative oxidative 0 0 0 0 0 0 0 0 9 0 RB TO VB NN NNS O
stress stress 0 0 0 0 0 0 0 0 6 0 TO VB NN NNS TO O
leads leads 0 0 0 0 0 0 0 0 5 0 VB NN NNS TO VBN O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO VBN NN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 NNS TO VBN NN IN O
generation generation 0 0 0 0 0 0 0 0 10 0 TO VBN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNP WDT O
ROS, ROS, 1 1 0 0 1 0 0 0 4 0 NN IN NNP WDT MD O
which which 0 0 0 0 0 0 0 0 5 0 IN NNP WDT MD VB O
will will 0 0 0 0 0 0 0 0 4 0 NNP WDT MD VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 WDT MD VB JJ IN O
relevant relevant 0 0 0 0 0 0 0 0 8 0 MD VB JJ IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VB JJ IN JJ NNS O
future future 0 0 0 0 0 0 0 0 6 0 JJ IN JJ NNS IN O
studies studies 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP IN O
AMD AMD 1 1 0 0 0 0 0 0 3 0 NNS IN NNP IN JJ O
since since 0 0 0 0 0 0 0 0 5 0 IN NNP IN JJ NN O
oxidative oxidative 0 0 0 0 0 0 0 0 9 0 NNP IN JJ NN VBZ O
stress stress 0 0 0 0 0 0 0 0 6 0 IN JJ NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ DT VBN O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT VBN NN O
known known 0 0 0 0 0 0 0 0 5 0 VBZ DT VBN NN NN O
factor factor 0 0 0 0 0 0 0 0 6 0 DT VBN NN NN DT O
affecting affecting 0 0 0 0 0 0 0 0 9 0 VBN NN NN DT NNP O
this this 0 0 0 0 0 0 0 0 4 0 NN NN DT NNP NONE O
disease. disease. 0 0 0 0 0 0 0 0 8 0 NN DT NNP NONE NONE O
TLR5 TLR5 1 1 0 0 0 0 0 1 4 0 NONE NONE NNP NNP NNPS O
Signaling Signaling 1 0 0 0 0 0 0 0 9 0 NONE NNP NNP NNPS DT O
Enhances Enhances 1 0 0 0 0 0 0 0 8 0 NNP NNP NNPS DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNPS DT NNP IN O
Proliferation Proliferation 1 0 0 0 0 0 0 0 13 0 NNPS DT NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNP IN NNP NNP O
Human Human 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Allogeneic Allogeneic 1 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP NNP O
CD40-Activated CD40-Activated 1 0 1 0 0 0 0 1 14 0 NNP NNP NNP NNP NNP O
B B 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Induced Induced 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
CD4(hi)CD25(+) CD4(hi)CD25(+) 1 0 0 0 0 0 0 1 14 0 NNP NNP NNP NNP NNP O
Regulatory Regulatory 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
T T 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NNP NNP O
Cells. Cells. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Chan Chan 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
PL, PL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Zheng Zheng 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Liu Liu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lam Lam 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
KT, KT, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Xiang Xiang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Mao Mao 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Liu Liu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Qin Qin 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lau Lau 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
YL, YL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Tu Tu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
W. W. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Paediatrics Paediatrics 1 0 0 0 0 0 0 0 11 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Adolescent Adolescent 1 0 0 0 0 0 0 0 10 0 NNP CC NNP NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 CC NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ka Ka 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Shing Shing 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP IN O
Faculty Faculty 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Hong Hong 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP NNP O
Kong. Kong. 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
Hong Hong 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Kong Kong 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
SAR, SAR, 1 1 0 0 1 0 0 0 4 0 NNP NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
Although Although 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NN NNS O
diverse diverse 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NNS IN O
functions functions 0 0 0 0 0 0 0 0 9 0 NNP NN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ JJ O
different different 0 0 0 0 0 0 0 0 9 0 NNS IN JJ JJ NNS O
toll-like toll-like 0 0 1 0 0 0 0 0 9 0 IN JJ JJ NNS -NONE- O
receptors receptors 0 0 0 0 0 0 0 0 9 0 JJ JJ NNS -NONE- IN O
(TLR) (TLR) 0 1 0 0 0 0 0 0 5 0 JJ NNS -NONE- IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 NNS -NONE- IN JJ JJ O
human human 0 0 0 0 0 0 0 0 5 0 -NONE- IN JJ JJ JJ O
natural natural 0 0 0 0 0 0 0 0 7 0 IN JJ JJ JJ NNP O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 JJ JJ JJ NNP NNS O
T T 1 1 0 0 0 0 0 0 1 0 JJ JJ NNP NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NNP NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNS VBP VBN VBN -NONE- O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 VBP VBN VBN -NONE- DT O
recently, recently, 0 0 0 0 1 0 0 0 9 0 VBN VBN -NONE- DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN -NONE- DT NN IN O
role role 0 0 0 0 0 0 0 0 4 0 -NONE- DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
TLR-related TLR-related 1 0 1 0 0 0 0 0 11 0 NN IN JJ NNS IN O
signals signals 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ VBN O
human human 0 0 0 0 0 0 0 0 5 0 NNS IN JJ VBN JJ O
induced induced 0 0 0 0 0 0 0 0 7 0 IN JJ VBN JJ NNP O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 JJ VBN JJ NNP NNS O
T T 1 1 0 0 0 0 0 0 1 0 VBN JJ NNP NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NNP NNS VBP NNP O
remain remain 0 0 0 0 0 0 0 0 6 0 NNP NNS VBP NNP NNP O
elusive. elusive. 0 0 0 0 0 0 0 0 8 0 NNS VBP NNP NNP PRP$ O
Previously Previously 1 0 0 0 0 0 0 0 10 0 VBP NNP NNP PRP$ NN O
our our 0 0 0 0 0 0 0 0 3 0 NNP NNP PRP$ NN VBD O
group group 0 0 0 0 0 0 0 0 5 0 NNP PRP$ NN VBD DT O
developed developed 0 0 0 0 0 0 0 0 9 0 PRP$ NN VBD DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NN VBD DT NN NN O
ex ex 0 0 0 0 0 0 0 0 2 0 VBD DT NN NN NN O
vivo vivo 0 0 0 0 0 0 0 0 4 0 DT NN NN NN NN O
high-efficient high-efficient 0 0 1 0 0 0 0 0 14 0 NN NN NN NN IN O
system system 0 0 0 0 0 0 0 0 6 0 NN NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
generating generating 0 0 0 0 0 0 0 0 10 0 NN IN NN NN JJ O
human human 0 0 0 0 0 0 0 0 5 0 IN NN NN JJ NN O
alloantigen-specific alloantigen-specific 0 0 1 0 0 0 0 0 20 0 NN NN JJ NN NN O
CD4(hi)CD25(+) CD4(hi)CD25(+) 1 0 0 0 0 0 0 1 14 0 NN JJ NN NN NNP O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 JJ NN NN NNP NNS O
T T 1 1 0 0 0 0 0 0 1 0 NN NN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NNP NNS IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNS IN JJ NN O
naïve naïve 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NN NNP O
CD4(+)CD25(-) CD4(+)CD25(-) 1 1 1 0 0 0 0 1 13 0 IN JJ NN NNP NNS O
T T 1 1 0 0 0 0 0 0 1 0 JJ NN NNP NNS VBG O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NNP NNS VBG JJ O
using using 0 0 0 0 0 0 0 0 5 0 NNP NNS VBG JJ JJ O
allogeneic allogeneic 0 0 0 0 0 0 0 0 10 0 NNS VBG JJ JJ NNP O
CD40-activated CD40-activated 1 0 1 0 0 0 0 1 14 0 VBG JJ JJ NNP NNS O
B B 1 1 0 0 0 0 0 0 1 0 JJ JJ NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NNP NNS IN NNP O
as as 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NNP NNP O
stimulators. stimulators. 0 0 0 0 0 0 0 0 12 0 NNS IN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 IN NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 NNP DT NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBD DT O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NN PRP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT NN IN O
role role 0 0 0 0 0 0 0 0 4 0 VBD DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
TLR5-related TLR5-related 1 0 1 0 0 0 0 1 12 0 NN IN JJ NNS IN O
signals signals 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN DT O
on on 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN CC O
generation generation 0 0 0 0 0 0 0 0 10 0 IN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
function function 0 0 0 0 0 0 0 0 8 0 NN CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT NN O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 IN DT NN NN NN O
CD4(hi)CD25(+) CD4(hi)CD25(+) 1 0 0 0 0 0 0 1 14 0 DT NN NN NN NNP O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 NN NN NN NNP NNP O
T T 1 1 0 0 0 0 0 0 1 0 NN NN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP VBD O
It It 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 NNP VBD VBN IN VBN O
that that 0 0 0 0 0 0 0 0 4 0 VBD VBN IN VBN -NONE- O
induced induced 0 0 0 0 0 0 0 0 7 0 VBN IN VBN -NONE- JJ O
CD4(hi)CD25(+) CD4(hi)CD25(+) 1 0 0 0 0 0 0 1 14 0 IN VBN -NONE- JJ NNP O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 VBN -NONE- JJ NNP NNS O
T T 1 1 0 0 0 0 0 0 1 0 -NONE- JJ NNP NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NNP NNS VBD DT O
expressed expressed 0 0 0 0 0 0 0 0 9 0 NNP NNS VBD DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNS VBD DT JJ NN O
up-regulated up-regulated 0 0 1 0 0 0 0 0 12 0 VBD DT JJ NN IN O
level level 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP VBN O
TLR5 TLR5 1 1 0 0 0 0 0 1 4 0 NN IN NNP VBN TO O
compared compared 0 0 0 0 0 0 0 0 8 0 IN NNP VBN TO PRP$ O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBN TO PRP$ NNP O
their their 0 0 0 0 0 0 0 0 5 0 VBN TO PRP$ NNP NNP O
precursors. precursors. 0 0 0 0 0 0 0 0 11 0 TO PRP$ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 PRP$ NNP NNP NN IN O
blockade blockade 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP VBG O
TLR5 TLR5 1 1 0 0 0 0 0 1 4 0 NN IN NNP VBG -NONE- O
using using 0 0 0 0 0 0 0 0 5 0 IN NNP VBG -NONE- NNS O
anti-TLR5 anti-TLR5 0 0 1 0 0 0 0 1 9 0 NNP VBG -NONE- NNS IN O
antibodies antibodies 0 0 0 0 0 0 0 0 10 0 VBG -NONE- NNS IN DT O
during during 0 0 0 0 0 0 0 0 6 0 -NONE- NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ VBN O
co-culture co-culture 0 0 1 0 0 0 0 0 10 0 IN DT JJ VBN -NONE- O
decreased decreased 0 0 0 0 0 0 0 0 9 0 DT JJ VBN -NONE- JJ O
CD4(hi)CD25(+) CD4(hi)CD25(+) 1 0 0 0 0 0 0 1 14 0 JJ VBN -NONE- JJ NNP O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 VBN -NONE- JJ NNP NNS O
T T 1 1 0 0 0 0 0 0 1 0 -NONE- JJ NNP NNS NN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NNP NNS NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NNP NNS NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNS NN IN NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 NN IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase NN IN NNP NN NNP O
phase phase 0 0 0 0 0 0 0 0 5 0 IN NNP NN NNP NNP O
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 NNP NN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase NNP NNP NNP NN NN O
phase phase 0 0 0 0 0 0 0 0 5 arrest NNP NNP NN NN VBD O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NNP NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NN VBD VBN IN VBN O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN VBN -NONE- O
reduced reduced 0 0 0 0 0 0 0 0 7 0 VBN IN VBN -NONE- NNP O
ERK1/2 ERK1/2 1 1 0 1 0 0 0 1 6 0 IN VBN -NONE- NNP NNP O
phosphorylation. phosphorylation. 0 0 0 0 0 0 0 0 16 0 VBN -NONE- NNP NNP NNP O
However, However, 1 0 0 0 1 0 0 0 8 0 -NONE- NNP NNP NNP NN O
TLR5 TLR5 1 1 0 0 0 0 0 1 4 0 NNP NNP NNP NN VBD O
blockade blockade 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBD RB O
did did 0 0 0 0 0 0 0 0 3 0 NNP NN VBD RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NN VBD RB VB DT O
decrease decrease 0 0 0 0 0 0 0 0 8 0 VBD RB VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VB DT NN NNP O
CTLA-4, CTLA-4, 1 1 1 0 1 0 0 1 7 0 VB DT NN NNP CC O
GITR GITR 1 1 0 0 0 0 0 0 4 0 DT NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP NNP O
FOXP3 FOXP3 1 1 0 0 0 0 0 1 5 0 NNP CC NNP NNP CC O
expressions, expressions, 0 0 0 0 1 0 0 0 12 0 CC NNP NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP CC DT JJ NN O
suppressive suppressive 0 0 0 0 0 0 0 0 11 0 CC DT JJ NN IN O
function function 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP JJ O
CD4(hi)CD25(+) CD4(hi)CD25(+) 1 0 0 0 0 0 0 1 14 0 NN IN NNP JJ NNP O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 IN NNP JJ NNP NNP O
T T 1 1 0 0 0 0 0 0 1 0 NNP JJ NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 JJ NNP NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP PRP O
conclusion, conclusion, 0 0 0 0 1 0 0 0 11 0 NNP NNP NNP PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD DT O
discovered discovered 0 0 0 0 0 0 0 0 10 0 NNP PRP VBD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 PRP VBD DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 VBD DT NN NN IN O
function function 0 0 0 0 0 0 0 0 8 0 DT NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
TLR5-related TLR5-related 1 0 1 0 0 0 0 1 12 0 NN IN JJ NN IN O
signaling signaling 0 0 0 0 0 0 0 0 9 0 IN JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN DT O
enhancing enhancing 0 0 0 0 0 0 0 0 9 0 NN IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP JJ O
CD4(hi)CD25(+) CD4(hi)CD25(+) 1 0 0 0 0 0 0 1 14 0 NN IN NNP JJ NNP O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 IN NNP JJ NNP NNS O
T T 1 1 0 0 0 0 0 0 1 0 NNP JJ NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NNP NNS IN VBG O
by by 0 0 0 0 0 0 0 0 2 0 NNP NNS IN VBG NNP O
promoting promoting 0 0 0 0 0 0 0 0 9 0 NNS IN VBG NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase IN VBG NNP NN NN O
phase phase 0 0 0 0 0 0 0 0 5 0 VBG NNP NN NN CC O
progress progress 0 0 0 0 0 0 0 0 8 0 NNP NN NN CC RB O
but but 0 0 0 0 0 0 0 0 3 0 NN NN CC RB VBN O
not not 0 0 0 0 0 0 0 0 3 0 NN CC RB VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 CC RB VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
suppressive suppressive 0 0 0 0 0 0 0 0 11 0 IN DT JJ NN IN O
function function 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ JJ O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ JJ NNP O
CD40-activated CD40-activated 1 0 1 0 0 0 0 1 14 0 IN JJ JJ NNP JJ O
B B 1 1 0 0 0 0 0 0 1 0 JJ JJ NNP JJ NN O
cell-induced cell-induced 0 0 1 0 0 0 0 0 12 0 JJ NNP JJ NN NN O
CD4(hi)CD25(+) CD4(hi)CD25(+) 1 0 0 0 0 0 0 1 14 0 NNP JJ NN NN NNP O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 JJ NN NN NNP NNP O
T T 1 1 0 0 0 0 0 0 1 0 NN NN NNP NNP NN O
cells, cells, 0 0 0 0 1 0 0 0 6 0 NN NNP NNP NN DT O
suggesting suggesting 0 0 0 0 0 0 0 0 10 0 NNP NNP NN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP NN DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 NN DT NN NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNS O
TLR5-related TLR5-related 1 0 1 0 0 0 0 1 12 0 NN IN JJ NNS IN O
signals signals 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
generation generation 0 0 0 0 0 0 0 0 10 0 IN DT NN IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN VBN JJ O
induced induced 0 0 0 0 0 0 0 0 7 0 NN IN VBN JJ NNP O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 IN VBN JJ NNP NNP O
T T 1 1 0 0 0 0 0 0 1 0 VBN JJ NNP NNP NONE O
cells. cells. 0 0 0 0 0 0 0 0 6 0 JJ NNP NNP NONE NONE O
Identification Identification 1 0 0 0 0 0 0 0 14 0 NONE NONE NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NNP IN O
QTLs QTLs 1 0 0 0 0 0 0 0 4 0 NN IN NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 IN NNP IN NNP TO O
Resistance Resistance 1 0 0 0 0 0 0 0 10 0 NNP IN NNP TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 IN NNP TO NNP NNP O
Sclerotinia Sclerotinia 1 0 0 0 0 0 0 0 11 0 NNP TO NNP NNP NNP O
Stem Stem 1 0 0 0 0 0 0 0 4 0 TO NNP NNP NNP CC O
Rot Rot 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP IN O
BnaC.IGMT5.a BnaC.IGMT5.a 1 0 0 0 0 0 0 1 12 0 NNP CC NNP IN DT O
as as 0 0 0 0 0 0 0 0 2 0 CC NNP IN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT NNP NNP O
Candidate Candidate 1 0 0 0 0 0 0 0 9 0 IN DT NNP NNP IN O
Gene Gene 1 0 0 0 0 0 0 0 4 0 DT NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP NNP O
Major Major 1 0 0 0 0 0 0 0 5 0 IN DT NNP NNP NNP O
Resistant Resistant 1 0 0 0 0 0 0 0 9 0 DT NNP NNP NNP NNP O
QTL QTL 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP IN O
SRC6 SRC6 1 1 0 0 0 0 0 1 4 0 NNP NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Brassica Brassica 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
napus. napus. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
Wu Wu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Cai Cai 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tu Tu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Liu Liu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Luo Luo 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhou Zhou 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Fan Fan 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhou Zhou 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Y. Y. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
National National 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Key Key 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP IN O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Crop Crop 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP NNP O
Genetic Genetic 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
Improvement, Improvement, 1 0 0 0 1 0 0 0 12 0 NNP NNP NNP NNP NNP O
Huazhong Huazhong 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Agricultural Agricultural 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Wuhan, Wuhan, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBD O
Stem Stem 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP VBD VBN O
rot rot 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
caused caused 0 0 0 0 0 0 0 0 6 0 NNP VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NN O
Sclerotinia Sclerotinia 1 0 0 0 0 0 0 0 11 0 VBN IN NNP NN IN O
sclerotiorum sclerotiorum 0 0 0 0 0 0 0 0 12 0 IN NNP NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ JJ O
many many 0 0 0 0 0 0 0 0 4 0 NN IN JJ JJ JJ O
important important 0 0 0 0 0 0 0 0 9 0 IN JJ JJ JJ NN O
dicotyledonous dicotyledonous 0 0 0 0 0 0 0 0 14 0 JJ JJ JJ NN VBG O
crops, crops, 0 0 0 0 1 0 0 0 6 0 JJ JJ NN VBG NN O
including including 0 0 0 0 0 0 0 0 9 0 JJ NN VBG NN NN O
oilseed oilseed 0 0 0 0 0 0 0 0 7 0 NN VBG NN NN NN O
rape rape 0 0 0 0 0 0 0 0 4 0 VBG NN NN NN NN O
(Brassica (Brassica 0 0 0 0 0 0 0 0 9 0 NN NN NN NN VBZ O
napus), napus), 0 0 0 0 1 0 0 0 7 0 NN NN NN VBZ CD O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ CD IN O
one one 0 0 0 0 0 0 0 0 3 0 NN VBZ CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBZ CD IN DT RBS O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT RBS JJ O
most most 0 0 0 0 0 0 0 0 4 0 IN DT RBS JJ NN O
devastating devastating 0 0 0 0 0 0 0 0 11 0 DT RBS JJ NN NNS O
fungal fungal 0 0 0 0 0 0 0 0 6 0 RBS JJ NN NNS CC O
diseases diseases 0 0 0 0 0 0 0 0 8 0 JJ NN NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NNS JJ O
imposes imposes 0 0 0 0 0 0 0 0 7 0 NNS CC NNS JJ NN O
huge huge 0 0 0 0 0 0 0 0 4 0 CC NNS JJ NN NN O
yield yield 0 0 0 0 0 0 0 0 5 0 NNS JJ NN NN DT O
loss loss 0 0 0 0 0 0 0 0 4 0 JJ NN NN DT NN O
each each 0 0 0 0 0 0 0 0 4 0 NN NN DT NN NNP O
year year 0 0 0 0 0 0 0 0 4 0 NN DT NN NNP NNP O
worldwide. worldwide. 0 0 0 0 0 0 0 0 10 0 DT NN NNP NNP NN O
Currently, Currently, 1 0 0 0 1 0 0 0 10 0 NN NNP NNP NN IN O
breeding breeding 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NN IN NNP NN O
Sclerotinia Sclerotinia 1 0 0 0 0 0 0 0 11 0 NN IN NNP NN IN O
resistance resistance 0 0 0 0 0 0 0 0 10 0 IN NNP NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NNP O
B. B. 1 1 0 0 0 0 0 0 2 0 NN IN NNP NNP IN O
napus, napus, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP IN IN O
as as 0 0 0 0 0 0 0 0 2 0 NNP NNP IN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNP IN IN JJ NN O
other other 0 0 0 0 0 0 0 0 5 0 IN IN JJ NN MD O
crops, crops, 0 0 0 0 1 0 0 0 6 0 IN JJ NN MD RB O
can can 0 0 0 0 0 0 0 0 3 0 JJ NN MD RB RB O
only only 0 0 0 0 0 0 0 0 4 0 NN MD RB RB IN O
rely rely 0 0 0 0 0 0 0 0 4 0 MD RB RB IN NNS O
on on 0 0 0 0 0 0 0 0 2 0 RB RB IN NNS IN O
germplasms germplasms 0 0 0 0 0 0 0 0 10 0 RB IN NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN JJ NN O
quantitative quantitative 0 0 0 0 0 0 0 0 12 0 NNS IN JJ NN NNP O
resistance resistance 0 0 0 0 0 0 0 0 10 0 IN JJ NN NNP NNP O
genes. genes. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP DT O
Thus, Thus, 1 0 0 0 1 0 0 0 5 0 NN NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
identification identification 0 0 0 0 0 0 0 0 14 0 NNP DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
quantitative quantitative 0 0 0 0 0 0 0 0 12 0 NN IN JJ NN NN O
trait trait 0 0 0 0 0 0 0 0 5 0 IN JJ NN NN NN O
locus locus 0 0 0 0 0 0 0 0 5 0 JJ NN NN NN IN O
(QTL) (QTL) 0 1 0 0 0 0 0 0 5 0 NN NN NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NNP NN O
S. S. 1 1 0 0 0 0 0 0 2 0 NN IN NNP NN NN O
sclerotiorum sclerotiorum 0 0 0 0 0 0 0 0 12 0 IN NNP NN NN IN O
resistance/tolerance resistance/tolerance 0 0 0 1 0 0 0 0 20 0 NNP NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN VBZ O
crop crop 0 0 0 0 0 0 0 0 4 0 IN DT NN VBZ JJ O
holds holds 0 0 0 0 0 0 0 0 5 0 DT NN VBZ JJ NN O
immediate immediate 0 0 0 0 0 0 0 0 9 0 NN VBZ JJ NN IN O
promise promise 0 0 0 0 0 0 0 0 7 0 VBZ JJ NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
genetic genetic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN IN O
improvement improvement 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
disease disease 0 0 0 0 0 0 0 0 7 0 IN DT NN NNP NNP O
resistance. resistance. 0 0 0 0 0 0 0 0 11 0 DT NN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN NN O
study, study, 0 0 0 0 1 0 0 0 6 0 NNP DT NN NN NNS O
ten ten 0 0 0 0 0 0 0 0 3 0 DT NN NN NNS IN O
QTLs QTLs 1 0 0 0 0 0 0 0 4 0 NN NN NNS IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN NN NN O
stem stem 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN NN O
resistance resistance 0 0 0 0 0 0 0 0 10 0 IN NN NN NN IN O
(SR) (SR) 0 1 0 0 0 0 0 0 4 0 NN NN NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
mature mature 0 0 0 0 0 0 0 0 6 0 IN DT NN NN NN O
plant plant 0 0 0 0 0 0 0 0 5 0 DT NN NN NN CC O
stage stage 0 0 0 0 0 0 0 0 5 0 NN NN NN CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC CD NNS O
three three 0 0 0 0 0 0 0 0 5 0 NN CC CD NNS IN O
QTLs QTLs 1 0 0 0 0 0 0 0 4 0 CC CD NNS IN NN O
for for 0 0 0 0 0 0 0 0 3 0 CD NNS IN NN NN O
leaf leaf 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN NN O
resistance resistance 0 0 0 0 0 0 0 0 10 0 IN NN NN NN IN O
(LR) (LR) 0 1 0 0 0 0 0 0 4 0 NN NN NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
seedling seedling 0 0 0 0 0 0 0 0 8 0 IN DT NN NN IN O
stage stage 0 0 0 0 0 0 0 0 5 0 DT NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NNS O
multiple multiple 0 0 0 0 0 0 0 0 8 0 NN IN NN NNS VBD O
environments environments 0 0 0 0 0 0 0 0 12 0 IN NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
mapped mapped 0 0 0 0 0 0 0 0 6 0 NNS VBD VBN IN CD O
on on 0 0 0 0 0 0 0 0 2 0 VBD VBN IN CD NN O
nine nine 0 0 0 0 0 0 0 0 4 0 VBN IN CD NN NNS O
linkage linkage 0 0 0 0 0 0 0 0 7 0 IN CD NN NNS -NONE- O
groups groups 0 0 0 0 0 0 0 0 6 0 CD NN NNS -NONE- IN O
(LGs) (LGs) 0 0 0 0 0 0 0 0 5 0 NN NNS -NONE- IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNS -NONE- IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- IN DT JJ NN O
whole whole 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN NN O
genome genome 0 0 0 0 0 0 0 0 6 0 DT JJ NN NN IN O
map map 0 0 0 0 0 0 0 0 3 0 JJ NN NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NNP NN O
B. B. 1 1 0 0 0 0 0 0 2 0 NN IN NNP NN VBD O
napus napus 0 0 0 0 0 0 0 0 5 0 IN NNP NN VBD IN O
constructed constructed 0 0 0 0 0 0 0 0 11 0 NNP NN VBD IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NN VBD IN NNP NNP O
SSR SSR 1 1 0 0 0 0 0 0 3 0 VBD IN NNP NNP NNP O
markers. markers. 0 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP JJ O
Two Two 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP JJ NN O
major major 0 0 0 0 0 0 0 0 5 0 NNP NNP JJ NN NNP O
QTLs, QTLs, 1 0 0 0 1 0 0 0 5 0 NNP JJ NN NNP IN O
LRA9 LRA9 1 1 0 0 0 0 0 1 4 0 JJ NN NNP IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NN NNP IN NNP NNP O
LG LG 1 1 0 0 0 0 0 0 2 0 NNP IN NNP NNP CC O
A9 A9 1 1 0 0 0 0 0 1 2 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP IN O
SRC6 SRC6 1 1 0 0 0 0 0 1 4 0 NNP CC NNP IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 CC NNP IN NNP NNP O
LG LG 1 1 0 0 0 0 0 0 2 0 NNP IN NNP NNP VBD O
C6, C6, 1 1 0 0 1 0 0 1 3 0 IN NNP NNP VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD RB VBN O
repeatedly repeatedly 0 0 0 0 0 0 0 0 10 0 NNP VBD RB VBN IN O
detected detected 0 0 0 0 0 0 0 0 8 0 VBD RB VBN IN DT O
across across 0 0 0 0 0 0 0 0 6 0 RB VBN IN DT NNS O
all all 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNS CC O
environments environments 0 0 0 0 0 0 0 0 12 0 IN DT NNS CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 DT NNS CC VBD CD O
explained explained 0 0 0 0 0 0 0 0 9 0 NNS CC VBD CD CC O
8.54-15.86% 8.54-15.86% 0 0 1 0 0 0 0 1 11 0 CC VBD CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 VBD CD CC CD IN O
29.01%-32.61% 29.01%-32.61% 0 0 1 0 0 0 0 1 13 0 CD CC CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC CD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT JJ NN O
phenotypic phenotypic 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN NNP O
variations, variations, 0 0 0 0 1 0 0 0 11 0 DT JJ NN NNP NNP O
respectively. respectively. 0 0 0 0 0 0 0 0 13 0 JJ NN NNP NNP NN O
Genotypes Genotypes 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NN NN O
containing containing 0 0 0 0 0 0 0 0 10 0 NNP NNP NN NN NNP O
resistant resistant 0 0 0 0 0 0 0 0 9 0 NNP NN NN NNP CC O
SRC6 SRC6 1 1 0 0 0 0 0 1 4 0 NN NN NNP CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 NN NNP CC NNP NN O
LRA9 LRA9 1 1 0 0 0 0 0 1 4 0 NNP CC NNP NN VBD O
allele allele 0 0 0 0 0 0 0 0 6 0 CC NNP NN VBD DT O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NN VBD DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBD DT JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 VBD DT JJ NN IN O
reduction reduction 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
disease disease 0 0 0 0 0 0 0 0 7 0 NN IN NN NN IN O
lesion lesion 0 0 0 0 0 0 0 0 6 0 IN NN NN IN NN O
after after 0 0 0 0 0 0 0 0 5 0 NN NN IN NN NNP O
pathogen pathogen 0 0 0 0 0 0 0 0 8 0 NN IN NN NNP NNP O
infection. infection. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP NN O
Comparative Comparative 1 0 0 0 0 0 0 0 11 0 NN NNP NNP NN IN O
mapping mapping 0 0 0 0 0 0 0 0 7 0 NNP NNP NN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNP NN IN NNP CC O
Arabidopsis Arabidopsis 1 0 0 0 0 0 0 0 11 0 NN IN NNP CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNS VBG O
data data 0 0 0 0 0 0 0 0 4 0 NNP CC NNS VBG IN O
mining mining 0 0 0 0 0 0 0 0 6 0 CC NNS VBG IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBG IN JJ NN O
previous previous 0 0 0 0 0 0 0 0 8 0 VBG IN JJ NN VBG O
gene gene 0 0 0 0 0 0 0 0 4 0 IN JJ NN VBG NNS O
profiling profiling 0 0 0 0 0 0 0 0 9 0 JJ NN VBG NNS VBD O
experiments experiments 0 0 0 0 0 0 0 0 11 0 NN VBG NNS VBD IN O
identified identified 0 0 0 0 0 0 0 0 10 0 VBG NNS VBD IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NNP JJ O
Arabidopsis Arabidopsis 1 0 0 0 0 0 0 0 11 0 IN DT NNP JJ NN O
homologous homologous 0 0 0 0 0 0 0 0 10 0 DT NNP JJ NN IN O
gene gene 0 0 0 0 0 0 0 0 4 0 NNP JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
IGMT5 IGMT5 1 1 0 0 0 0 0 1 5 0 NN IN NNP NNP VBD O
(At1g76790) (At1g76790) 0 0 0 0 0 0 0 1 11 0 IN NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN TO O
related related 0 0 0 0 0 0 0 0 7 0 NNP VBD VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN TO DT NNP NNP O
SRC6 SRC6 1 1 0 0 0 0 0 1 4 0 TO DT NNP NNP NNP O
locus. locus. 0 0 0 0 0 0 0 0 6 0 DT NNP NNP NNP NNS O
Four Four 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNS IN O
copies copies 0 0 0 0 0 0 0 0 6 0 NNP NNP NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NN O
IGMT5 IGMT5 1 1 0 0 0 0 0 1 5 0 IN DT NNP NN IN O
gene gene 0 0 0 0 0 0 0 0 4 0 DT NNP NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NN O
B. B. 1 1 0 0 0 0 0 0 2 0 NN IN NNP NN VBD O
napus napus 0 0 0 0 0 0 0 0 5 0 IN NNP NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NN VBD VBN IN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN JJ O
through through 0 0 0 0 0 0 0 0 7 0 VBD VBN IN JJ NN O
homologous homologous 0 0 0 0 0 0 0 0 10 0 VBN IN JJ NN IN O
cloning, cloning, 0 0 0 0 1 0 0 0 8 0 IN JJ NN IN NNP O
among among 0 0 0 0 0 0 0 0 5 0 JJ NN IN NNP RB O
which, which, 0 0 0 0 1 0 0 0 6 0 NN IN NNP RB NNP O
only only 0 0 0 0 0 0 0 0 4 0 IN NNP RB NNP VBD O
BnaC.IGMT5.a BnaC.IGMT5.a 1 0 0 0 0 0 0 1 12 0 NNP RB NNP VBD DT O
showed showed 0 0 0 0 0 0 0 0 6 0 RB NNP VBD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBD DT NN IN O
polymorphism polymorphism 0 0 0 0 0 0 0 0 12 0 VBD DT NN IN JJ O
between between 0 0 0 0 0 0 0 0 7 0 DT NN IN JJ NNS O
parental parental 0 0 0 0 0 0 0 0 8 0 NN IN JJ NNS CC O
lines lines 0 0 0 0 0 0 0 0 5 0 IN JJ NNS CC MD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NNS CC MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 CC MD VB VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 MD VB VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VB VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NNP O
SRC6. SRC6. 1 1 0 0 0 0 0 1 5 0 IN DT NNP NNP CD O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 DT NNP NNP CD JJ O
two two 0 0 0 0 0 0 0 0 3 0 NNP NNP CD JJ NNS O
parental parental 0 0 0 0 0 0 0 0 8 0 NNP CD JJ NNS VBN O
lines lines 0 0 0 0 0 0 0 0 5 0 CD JJ NNS VBN DT O
exhibited exhibited 0 0 0 0 0 0 0 0 9 0 JJ NNS VBN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS VBN DT JJ NN O
differential differential 0 0 0 0 0 0 0 0 12 0 VBN DT JJ NN NN O
expression expression 0 0 0 0 0 0 0 0 10 0 DT JJ NN NN IN O
pattern pattern 0 0 0 0 0 0 0 0 7 0 JJ NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
BnaC.IGMT5.a BnaC.IGMT5.a 1 0 0 0 0 0 0 1 12 0 IN DT NNP NN IN O
gene gene 0 0 0 0 0 0 0 0 4 0 DT NNP NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN TO O
responding responding 0 0 0 0 0 0 0 0 10 0 NN IN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB NNP O
pathogen pathogen 0 0 0 0 0 0 0 0 8 0 NN TO VB NNP NNP O
inoculation. inoculation. 0 0 0 0 0 0 0 0 12 0 TO VB NNP NNP PRP$ O
Thus, Thus, 1 0 0 0 1 0 0 0 5 0 VB NNP NNP PRP$ NNS O
our our 0 0 0 0 0 0 0 0 3 0 NNP NNP PRP$ NNS VBD O
data data 0 0 0 0 0 0 0 0 4 0 NNP PRP$ NNS VBD IN O
suggested suggested 0 0 0 0 0 0 0 0 9 0 PRP$ NNS VBD IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NNP VBD O
BnaC.IGMT5.a BnaC.IGMT5.a 1 0 0 0 0 0 0 1 12 0 VBD IN NNP VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 IN NNP VBD RB JJ O
very very 0 0 0 0 0 0 0 0 4 0 NNP VBD RB JJ DT O
likely likely 0 0 0 0 0 0 0 0 6 0 VBD RB JJ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 RB JJ DT NN NN O
candidate candidate 0 0 0 0 0 0 0 0 9 0 JJ DT NN NN IN O
gene gene 0 0 0 0 0 0 0 0 4 0 DT NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT JJ NN O
major major 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN NNP O
resistance resistance 0 0 0 0 0 0 0 0 10 0 DT JJ NN NNP NONE O
QTL. QTL. 1 1 0 0 0 0 0 0 4 0 JJ NN NNP NONE NONE O
Livestock-Associated Livestock-Associated 1 0 1 0 0 0 0 0 20 0 NONE NONE JJ NNP CC O
Methicillin Methicillin 1 0 0 0 0 0 0 0 11 0 NONE JJ NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNP CC NNP NNP O
Multidrug Multidrug 1 0 0 0 0 0 0 0 9 0 NNP CC NNP NNP NNP O
Resistant Resistant 1 0 0 0 0 0 0 0 9 0 CC NNP NNP NNP VBZ O
Staphylococcus Staphylococcus 1 0 0 0 0 0 0 0 14 0 NNP NNP NNP VBZ NNP O
aureus aureus 0 0 0 0 0 0 0 0 6 0 NNP NNP VBZ NNP NNP O
Is Is 1 0 0 0 0 0 0 0 2 0 NNP VBZ NNP NNP IN O
Present Present 1 0 0 0 0 0 0 0 7 0 VBZ NNP NNP IN NNP O
among among 0 0 0 0 0 0 0 0 5 0 NNP NNP IN NNP NNP O
Industrial, Industrial, 1 0 0 0 1 0 0 0 11 0 NNP IN NNP NNP NNP O
Not Not 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
Antibiotic-Free Antibiotic-Free 1 0 1 0 0 0 0 0 15 0 NNP NNP NNP NNP NNP O
Livestock Livestock 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Operation Operation 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP IN O
Workers Workers 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
North North 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Carolina. Carolina. 1 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP NNP O
Rinsky Rinsky 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
JL, JL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Nadimpalli Nadimpalli 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wing Wing 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hall Hall 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Baron Baron 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Price Price 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
LB, LB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Larsen Larsen 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Stegger Stegger 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Stewart Stewart 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Heaney Heaney 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
CD. CD. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Epidemiology, Epidemiology, 1 0 0 0 1 0 0 0 13 0 NNP IN NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
North North 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Carolina, Carolina, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Chapel Chapel 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Hill, Hill, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
North North 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Carolina, Carolina, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNPS O
United United 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNPS IN O
States States 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
America. America. 1 0 0 0 0 0 0 0 8 0 NNPS IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
OBJECTIVES: OBJECTIVES: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP IN O
Administration Administration 1 0 0 0 0 0 0 0 14 0 NNP NNP NNP IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNS TO O
antibiotics antibiotics 0 0 0 0 0 0 0 0 11 0 NNP IN NNS TO NN O
to to 0 0 0 0 0 0 0 0 2 0 IN NNS TO NN NNS O
food food 0 0 0 0 0 0 0 0 4 0 NNS TO NN NNS MD O
animals animals 0 0 0 0 0 0 0 0 7 0 TO NN NNS MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN NNS MD VB IN O
select select 0 0 0 0 0 0 0 0 6 0 NNS MD VB IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 MD VB IN JJ NNS O
drug-resistant drug-resistant 0 0 1 0 0 0 0 0 14 0 VB IN JJ NNS IN O
pathogens pathogens 0 0 0 0 0 0 0 0 9 0 IN JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
clinical clinical 0 0 0 0 0 0 0 0 8 0 NNS IN JJ NN JJ O
significance, significance, 0 0 0 0 1 0 0 0 13 0 IN JJ NN JJ IN O
such such 0 0 0 0 0 0 0 0 4 0 JJ NN JJ IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 NN JJ IN JJ NNP O
methicillin-resistant methicillin-resistant 0 0 1 0 0 0 0 0 21 0 JJ IN JJ NNP NN O
Staphylococcus Staphylococcus 1 0 0 0 0 0 0 0 14 0 IN JJ NNP NN NNP O
aureus aureus 0 0 0 0 0 0 0 0 6 0 JJ NNP NN NNP NNP O
(MRSA). (MRSA). 0 1 0 0 0 0 0 0 7 0 NNP NN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNP NNP O
United United 1 0 0 0 0 0 0 0 6 0 NNP DT NNP NNP NNS O
States, States, 1 0 0 0 1 0 0 0 7 0 DT NNP NNP NNS VBP O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP VBN NN O
examined examined 0 0 0 0 0 0 0 0 8 0 NNS VBP VBN NN IN O
prevalence prevalence 0 0 0 0 0 0 0 0 10 0 VBP VBN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNP NN O
MRSA MRSA 1 1 0 0 0 0 0 0 4 0 NN IN NNP NN IN O
carriage carriage 0 0 0 0 0 0 0 0 8 0 IN NNP NN IN NNS O
among among 0 0 0 0 0 0 0 0 5 0 NNP NN IN NNS VBN O
individuals individuals 0 0 0 0 0 0 0 0 11 0 NN IN NNS VBN TO O
exposed exposed 0 0 0 0 0 0 0 0 7 0 IN NNS VBN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBN TO NNP CC O
livestock, livestock, 0 0 0 0 1 0 0 0 10 0 VBN TO NNP CC NN O
but but 0 0 0 0 0 0 0 0 3 0 TO NNP CC NN IN O
prevalence prevalence 0 0 0 0 0 0 0 0 10 0 NNP CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NNP O
multidrug-resistant multidrug-resistant 0 0 1 0 0 0 0 0 19 0 NN IN JJ NNP NN O
S. S. 1 1 0 0 0 0 0 0 2 0 IN JJ NNP NN -NONE- O
aureus aureus 0 0 0 0 0 0 0 0 6 0 JJ NNP NN -NONE- NN O
(MDRSA) (MDRSA) 0 1 0 0 0 0 0 0 7 0 NNP NN -NONE- NN CC O
carriage carriage 0 0 0 0 0 0 0 0 8 0 NN -NONE- NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN IN O
association association 0 0 0 0 0 0 0 0 11 0 CC DT NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 DT NN IN NN VBD O
livestock livestock 0 0 0 0 0 0 0 0 9 0 NN IN NN VBD IN O
raised raised 0 0 0 0 0 0 0 0 6 0 IN NN VBD IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NN VBD IN NN IN O
versus versus 0 0 0 0 0 0 0 0 6 0 VBD IN NN IN JJ O
without without 0 0 0 0 0 0 0 0 7 0 IN NN IN JJ JJ O
antibiotic antibiotic 0 0 0 0 0 0 0 0 10 0 NN IN JJ JJ NN O
selective selective 0 0 0 0 0 0 0 0 9 0 IN JJ JJ NN VBZ O
pressure pressure 0 0 0 0 0 0 0 0 8 0 JJ JJ NN VBZ NNP O
remains remains 0 0 0 0 0 0 0 0 7 0 JJ NN VBZ NNP NNP O
unclear. unclear. 0 0 0 0 0 0 0 0 8 0 NN VBZ NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 VBZ NNP NNP VBD TO O
aimed aimed 0 0 0 0 0 0 0 0 5 0 NNP NNP VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBD TO VB JJ O
examine examine 0 0 0 0 0 0 0 0 7 0 VBD TO VB JJ JJ O
prevalence, prevalence, 0 0 0 0 1 0 0 0 11 0 TO VB JJ JJ NN O
antibiotic antibiotic 0 0 0 0 0 0 0 0 10 0 VB JJ JJ NN CC O
susceptibility, susceptibility, 0 0 0 0 1 0 0 0 15 0 JJ JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NNS O
molecular molecular 0 0 0 0 0 0 0 0 9 0 NN CC JJ NNS IN O
characteristics characteristics 0 0 0 0 0 0 0 0 15 0 CC JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NN O
S. S. 1 1 0 0 0 0 0 0 2 0 NNS IN NNP NN IN O
aureus aureus 0 0 0 0 0 0 0 0 6 0 IN NNP NN IN JJ O
among among 0 0 0 0 0 0 0 0 5 0 NNP NN IN JJ NN O
industrial industrial 0 0 0 0 0 0 0 0 10 0 NN IN JJ NN NN O
livestock livestock 0 0 0 0 0 0 0 0 9 0 IN JJ NN NN NN O
operation operation 0 0 0 0 0 0 0 0 9 0 JJ NN NN NN CC O
(ILO) (ILO) 0 1 0 0 0 0 0 0 5 0 NN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
antibiotic-free antibiotic-free 0 0 1 0 0 0 0 0 15 0 NN CC JJ NN NN O
livestock livestock 0 0 0 0 0 0 0 0 9 0 CC JJ NN NN NN O
operation operation 0 0 0 0 0 0 0 0 9 0 JJ NN NN NN NNS O
(AFLO) (AFLO) 0 1 0 0 0 0 0 0 6 0 NN NN NN NNS CC O
workers workers 0 0 0 0 0 0 0 0 7 0 NN NN NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NN NNS O
household household 0 0 0 0 0 0 0 0 9 0 NNS CC NN NNS IN O
members members 0 0 0 0 0 0 0 0 7 0 CC NN NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP NNP O
North North 1 0 0 0 0 0 0 0 5 0 NNS IN NNP NNP NNP O
Carolina. Carolina. 1 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Participants Participants 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT JJ O
this this 0 0 0 0 0 0 0 0 4 0 NNP IN DT JJ NN O
cross-sectional cross-sectional 0 0 1 0 0 0 0 0 15 0 IN DT JJ NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 DT JJ NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NN VBD VBN CC O
interviewed interviewed 0 0 0 0 0 0 0 0 11 0 NN VBD VBN CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 VBD VBN CC VBN DT O
provided provided 0 0 0 0 0 0 0 0 8 0 VBN CC VBN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 CC VBN DT NN NN O
nasal nasal 0 0 0 0 0 0 0 0 5 0 VBN DT NN NN IN O
swab swab 0 0 0 0 0 0 0 0 4 0 DT NN NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NNP NN O
S. S. 1 1 0 0 0 0 0 0 2 0 NN IN NNP NN NNP O
aureus aureus 0 0 0 0 0 0 0 0 6 0 IN NNP NN NNP NNP O
analysis. analysis. 0 0 0 0 0 0 0 0 9 0 NNP NN NNP NNP NNP O
Resulting Resulting 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP VBZ O
S. S. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP VBZ NNS O
aureus aureus 0 0 0 0 0 0 0 0 6 0 NNP NNP VBZ NNS VBD O
isolates isolates 0 0 0 0 0 0 0 0 8 0 NNP VBZ NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 VBZ NNS VBD VBN IN O
assessed assessed 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN JJ NN O
antibiotic antibiotic 0 0 0 0 0 0 0 0 10 0 VBN IN JJ NN JJ O
susceptibility, susceptibility, 0 0 0 0 1 0 0 0 15 0 IN JJ NN JJ NN O
multi-locus multi-locus 0 0 1 0 0 0 0 0 11 0 JJ NN JJ NN NN O
sequence sequence 0 0 0 0 0 0 0 0 8 0 NN JJ NN NN CC O
type, type, 0 0 0 0 1 0 0 0 5 0 JJ NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
absence absence 0 0 0 0 0 0 0 0 7 0 NN CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
scn scn 0 0 0 0 0 0 0 0 3 0 IN DT NN NN NN O
gene gene 0 0 0 0 0 0 0 0 4 0 DT NN NN NN NN O
(a (a 0 0 0 0 0 0 0 0 2 0 NN NN NN NN IN O
marker marker 0 0 0 0 0 0 0 0 6 0 NN NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NNP O
livestock livestock 0 0 0 0 0 0 0 0 9 0 NN IN NN NNP NNP O
association). association). 0 0 0 0 0 0 0 0 13 0 IN NN NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 NN NNP NNP NNP CD O
Among Among 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP CD NNP O
99 99 0 0 0 0 0 0 1 1 2 0 NNP NNP CD NNP CC O
ILO ILO 1 1 0 0 0 0 0 0 3 0 NNP CD NNP CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD NNP CC CD NNP O
105 105 0 0 0 0 0 0 1 1 3 0 NNP CC CD NNP NNP O
AFLO AFLO 1 1 0 0 0 0 0 0 4 0 CC CD NNP NNP NNP O
participants, participants, 0 0 0 0 1 0 0 0 13 0 CD NNP NNP NNP VBZ O
S. S. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP VBZ NN O
aureus aureus 0 0 0 0 0 0 0 0 6 0 NNP NNP VBZ NN NN O
nasal nasal 0 0 0 0 0 0 0 0 5 0 NNP VBZ NN NN NN O
carriage carriage 0 0 0 0 0 0 0 0 8 0 VBZ NN NN NN VBD O
prevalence prevalence 0 0 0 0 0 0 0 0 10 0 NN NN NN VBD CD O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD CD CC O
41% 41% 0 0 0 0 0 0 0 1 3 0 NN VBD CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 VBD CD CC CD NNP O
40%, 40%, 0 0 0 0 1 0 0 1 4 0 CD CC CD NNP NNP O
respectively. respectively. 0 0 0 0 0 0 0 0 13 0 CC CD NNP NNP NNP O
Among Among 1 0 0 0 0 0 0 0 5 0 CD NNP NNP NNP CC O
ILO ILO 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
AFLO AFLO 1 1 0 0 0 0 0 0 4 0 NNP CC NNP NNP VBZ O
S. S. 1 1 0 0 0 0 0 0 2 0 CC NNP NNP VBZ JJ O
aureus aureus 0 0 0 0 0 0 0 0 6 0 NNP NNP VBZ JJ NNP O
carriers, carriers, 0 0 0 0 1 0 0 0 9 0 NNP VBZ JJ NNP VBD O
MRSA MRSA 1 1 0 0 0 0 0 0 4 0 VBZ JJ NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NNP VBD VBN IN O
detected detected 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN CD NN O
7% 7% 0 0 0 0 0 0 0 1 2 0 VBN IN CD NN CC O
(3/41) (3/41) 0 0 0 1 0 0 0 1 6 0 IN CD NN CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD NN CC CD NN O
7% 7% 0 0 0 0 0 0 0 1 2 0 NN CC CD NN NNP O
(3/42), (3/42), 0 0 0 1 1 0 0 1 7 0 CC CD NN NNP NNP O
respectively. respectively. 0 0 0 0 0 0 0 0 13 0 CD NN NNP NNP CD O
Thirty Thirty 1 0 0 0 0 0 0 0 6 0 NN NNP NNP CD NN O
seven seven 0 0 0 0 0 0 0 0 5 0 NNP NNP CD NN IN O
percent percent 0 0 0 0 0 0 0 0 7 0 NNP CD NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN CD NNP O
41 41 0 0 0 0 0 0 1 1 2 0 NN IN CD NNP CC O
ILO ILO 1 1 0 0 0 0 0 0 3 0 IN CD NNP CC CD O
versus versus 0 0 0 0 0 0 0 0 6 0 CD NNP CC CD IN O
19% 19% 0 0 0 0 0 0 0 1 3 0 NNP CC CD IN CD O
of of 0 0 0 0 0 0 0 0 2 0 CC CD IN CD NNP O
42 42 0 0 0 0 0 0 1 1 2 0 CD IN CD NNP NNP O
AFLO AFLO 1 1 0 0 0 0 0 0 4 0 IN CD NNP NNP JJ O
S. S. 1 1 0 0 0 0 0 0 2 0 CD NNP NNP JJ NNS O
aureus-positive aureus-positive 0 0 1 0 0 0 0 0 15 0 NNP NNP JJ NNS VBN O
participants participants 0 0 0 0 0 0 0 0 12 0 NNP JJ NNS VBN NNP O
carried carried 0 0 0 0 0 0 0 0 7 0 JJ NNS VBN NNP NNP O
MDRSA. MDRSA. 1 1 0 0 0 0 0 0 6 0 NNS VBN NNP NNP VBZ O
S. S. 1 1 0 0 0 0 0 0 2 0 VBN NNP NNP VBZ JJ O
aureus aureus 0 0 0 0 0 0 0 0 6 0 NNP NNP VBZ JJ NN O
clonal clonal 0 0 0 0 0 0 0 0 6 0 NNP VBZ JJ NN NN O
complex complex 0 0 0 0 0 0 0 0 7 0 VBZ JJ NN NN CD O
(CC) (CC) 0 1 0 0 0 0 0 0 4 0 JJ NN NN CD VBD O
398 398 0 0 0 0 0 0 1 1 3 0 NN NN CD VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN CD VBD VBN RB O
observed observed 0 0 0 0 0 0 0 0 8 0 CD VBD VBN RB IN O
only only 0 0 0 0 0 0 0 0 4 0 VBD VBN RB IN NNS O
among among 0 0 0 0 0 0 0 0 5 0 VBN RB IN NNS CC O
workers workers 0 0 0 0 0 0 0 0 7 0 RB IN NNS CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC VBD IN O
predominated predominated 0 0 0 0 0 0 0 0 12 0 NNS CC VBD IN NNP O
among among 0 0 0 0 0 0 0 0 5 0 CC VBD IN NNP NNP O
ILO ILO 1 1 0 0 0 0 0 0 3 0 VBD IN NNP NNP VBD O
(13/34) (13/34) 0 0 0 1 0 0 0 1 7 0 IN NNP NNP VBD IN O
compared compared 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNP VBD IN NNP NNP O
AFLO AFLO 1 1 0 0 0 0 0 0 4 0 VBD IN NNP NNP NNP O
(1/35) (1/35) 0 0 0 1 0 0 0 1 6 0 IN NNP NNP NNP JJ O
S. S. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP JJ NNP O
aureus-positive aureus-positive 0 0 1 0 0 0 0 0 15 0 NNP NNP JJ NNP NNP O
workers. workers. 0 0 0 0 0 0 0 0 8 0 NNP JJ NNP NNP NNP O
Only Only 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NNP NNS O
ILO ILO 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNS VBD O
workers workers 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD JJ O
carried carried 0 0 0 0 0 0 0 0 7 0 NNP NNS VBD JJ NNP O
scn-negative scn-negative 0 0 1 0 0 0 0 0 12 0 NNS VBD JJ NNP NNP O
MRSA MRSA 1 1 0 0 0 0 0 0 4 0 VBD JJ NNP NNP NNP O
CC398 CC398 1 1 0 0 0 0 0 1 5 0 JJ NNP NNP NNP CC O
(2/34) (2/34) 0 0 0 1 0 0 0 1 6 0 NNP NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NNP O
scn-negative scn-negative 0 0 1 0 0 0 0 0 12 0 NNP CC JJ NNP NNP O
MDRSA MDRSA 1 1 0 0 0 0 0 0 5 0 CC JJ NNP NNP NNP O
CC398 CC398 1 1 0 0 0 0 0 1 5 0 JJ NNP NNP NNP CC O
(6/34), (6/34), 0 0 0 1 1 0 0 1 7 0 NNP NNP NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC DT IN O
all all 0 0 0 0 0 0 0 0 3 0 NNP CC DT IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC DT IN DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 DT IN DT NNS VBD O
isolates isolates 0 0 0 0 0 0 0 0 8 0 IN DT NNS VBD NN O
were were 0 0 0 0 0 0 0 0 4 0 DT NNS VBD NN NNP O
tetracycline tetracycline 0 0 0 0 0 0 0 0 12 0 NNS VBD NN NNP NNP O
resistant. resistant. 0 0 0 0 0 0 0 0 10 0 VBD NN NNP NNP NNP O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 NN NNP NNP NNP JJ O
Despite Despite 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP JJ NNP O
similar similar 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NNP NN O
S. S. 1 1 0 0 0 0 0 0 2 0 NNP JJ NNP NN CC O
aureus aureus 0 0 0 0 0 0 0 0 6 0 JJ NNP NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NNP NN O
MRSA MRSA 1 1 0 0 0 0 0 0 4 0 NN CC NNP NN IN O
prevalence prevalence 0 0 0 0 0 0 0 0 10 0 CC NNP NN IN NNP O
among among 0 0 0 0 0 0 0 0 5 0 NNP NN IN NNP CC O
ILO ILO 1 1 0 0 0 0 0 0 3 0 NN IN NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC JJ NN O
AFLO-exposed AFLO-exposed 1 0 1 0 0 0 0 0 12 0 NNP CC JJ NN JJ O
individuals, individuals, 0 0 0 0 1 0 0 0 12 0 CC JJ NN JJ NNP O
livestock-associated livestock-associated 0 0 1 0 0 0 0 0 20 0 JJ NN JJ NNP CC O
MRSA MRSA 1 1 0 0 0 0 0 0 4 0 NN JJ NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNP CC NNP NNP O
MDRSA MDRSA 1 1 0 0 0 0 0 0 5 0 NNP CC NNP NNP NNP O
(tetracycline-resistant, (tetracycline-resistant, 0 0 1 0 1 0 0 0 24 0 CC NNP NNP NNP NNP O
CC398, CC398, 1 1 0 0 1 0 0 1 6 0 NNP NNP NNP NNP VBD O
scn-negative) scn-negative) 0 0 1 0 0 0 0 0 13 0 NNP NNP NNP VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD RB JJ O
only only 0 0 0 0 0 0 0 0 4 0 NNP VBD RB JJ IN O
present present 0 0 0 0 0 0 0 0 7 0 VBD RB JJ IN JJ O
among among 0 0 0 0 0 0 0 0 5 0 RB JJ IN JJ NNP O
ILO-exposed ILO-exposed 1 0 1 0 0 0 0 0 11 0 JJ IN JJ NNP NNP O
individuals. individuals. 0 0 0 0 0 0 0 0 12 0 IN JJ NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP NNS NN O
findings findings 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS NN VBG O
support support 0 0 0 0 0 0 0 0 7 0 NNP NNS NN VBG NN O
growing growing 0 0 0 0 0 0 0 0 7 0 NNS NN VBG NN IN O
concern concern 0 0 0 0 0 0 0 0 7 0 NN VBG NN IN NNS O
about about 0 0 0 0 0 0 0 0 5 0 VBG NN IN NNS VBP O
antibiotics antibiotics 0 0 0 0 0 0 0 0 11 0 NN IN NNS VBP CC O
use use 0 0 0 0 0 0 0 0 3 0 IN NNS VBP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNS VBP CC NN IN O
confinement confinement 0 0 0 0 0 0 0 0 11 0 VBP CC NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NN O
livestock livestock 0 0 0 0 0 0 0 0 9 0 NN IN NN NN VBG O
production, production, 0 0 0 0 1 0 0 0 11 0 IN NN NN VBG NNS O
raising raising 0 0 0 0 0 0 0 0 7 0 NN NN VBG NNS IN O
questions questions 0 0 0 0 0 0 0 0 9 0 NN VBG NNS IN DT O
about about 0 0 0 0 0 0 0 0 5 0 VBG NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
potential potential 0 0 0 0 0 0 0 0 9 0 IN DT NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN JJ NN O
occupational occupational 0 0 0 0 0 0 0 0 12 0 NN IN JJ NN TO O
exposure exposure 0 0 0 0 0 0 0 0 8 0 IN JJ NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN TO DT JJ CC O
opportunistic opportunistic 0 0 0 0 0 0 0 0 13 0 TO DT JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC JJ NN O
drug-resistant drug-resistant 0 0 1 0 0 0 0 0 14 0 JJ CC JJ NN WDT O
pathogen, pathogen, 0 0 0 0 1 0 0 0 9 0 CC JJ NN WDT IN O
which which 0 0 0 0 0 0 0 0 5 0 JJ NN WDT IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN WDT IN JJ NNS O
other other 0 0 0 0 0 0 0 0 5 0 WDT IN JJ NNS VBG O
settings settings 0 0 0 0 0 0 0 0 8 0 IN JJ NNS VBG NNS O
including including 0 0 0 0 0 0 0 0 9 0 JJ NNS VBG NNS CC O
hospitals hospitals 0 0 0 0 0 0 0 0 9 0 NNS VBG NNS CC DT O
and and 0 0 0 0 0 0 0 0 3 0 VBG NNS CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS CC DT NN VBZ O
community community 0 0 0 0 0 0 0 0 9 0 CC DT NN VBZ IN O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN VBZ IN JJ JJ O
broad broad 0 0 0 0 0 0 0 0 5 0 VBZ IN JJ JJ NN O
public public 0 0 0 0 0 0 0 0 6 0 IN JJ JJ NN NNP O
health health 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NNP NONE O
importance. importance. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP NONE NONE O
Intracellular Intracellular 1 0 0 0 0 0 0 0 13 0 NONE NONE JJ NN NN O
water water 0 0 0 0 0 0 0 0 5 0 NONE JJ NN NN IN O
exchange exchange 0 0 0 0 0 0 0 0 8 0 JJ NN NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NN DT O
measuring measuring 0 0 0 0 0 0 0 0 9 0 NN IN NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT JJ NN O
dry dry 0 0 0 0 0 0 0 0 3 0 NN DT JJ NN NN O
mass, mass, 0 0 0 0 1 0 0 0 5 0 DT JJ NN NN NN O
water water 0 0 0 0 0 0 0 0 5 0 JJ NN NN NN CC O
mass mass 0 0 0 0 0 0 0 0 4 0 NN NN NN CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNS IN O
changes changes 0 0 0 0 0 0 0 0 7 0 NN CC NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 CC NNS IN JJ NN O
chemical chemical 0 0 0 0 0 0 0 0 8 0 NNS IN JJ NN IN O
composition composition 0 0 0 0 0 0 0 0 11 0 IN JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNP O
living living 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NN NNP NNP NNP O
Feijó Feijó 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP NNP O
Delgado Delgado 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Cermak Cermak 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hecht Hecht 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
VC, VC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Son Son 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Knudsen Knudsen 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
SM, SM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Olcum Olcum 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Higgins Higgins 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
JM, JM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Grover Grover 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
WH, WH, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Manalis Manalis 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
SR. SR. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biological Biological 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Engineering, Engineering, 1 0 0 0 1 0 0 0 12 0 IN NNP NNP NNP NNP O
Massachusetts Massachusetts 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Technology, Technology, 1 0 0 0 1 0 0 0 11 0 NNP IN NNP NNP NNP O
Cambridge, Cambridge, 1 0 0 0 1 0 0 0 10 0 IN NNP NNP NNP NNP O
Massachusetts, Massachusetts, 1 0 0 0 1 0 0 0 14 0 NNP NNP NNP NNP NNPS O
United United 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNPS IN O
States States 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
America. America. 1 0 0 0 0 0 0 0 8 0 NNPS IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NN O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NN DT O
present present 0 0 0 0 0 0 0 0 7 0 NNP NNP NN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP NN DT NN IN O
method method 0 0 0 0 0 0 0 0 6 0 NN DT NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN JJ JJ O
direct direct 0 0 0 0 0 0 0 0 6 0 NN IN JJ JJ NN O
non-optical non-optical 0 0 1 0 0 0 0 0 11 0 IN JJ JJ NN IN O
quantification quantification 0 0 0 0 0 0 0 0 14 0 JJ JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
dry dry 0 0 0 0 0 0 0 0 3 0 NN IN JJ NN NN O
mass, mass, 0 0 0 0 1 0 0 0 5 0 IN JJ NN NN NN O
dry dry 0 0 0 0 0 0 0 0 3 0 JJ NN NN NN CC O
density density 0 0 0 0 0 0 0 0 7 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
water water 0 0 0 0 0 0 0 0 5 0 NN CC NN NN IN O
mass mass 0 0 0 0 0 0 0 0 4 0 CC NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
single single 0 0 0 0 0 0 0 0 6 0 NN IN JJ NN NNS O
living living 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP NNP O
suspension. suspension. 0 0 0 0 0 0 0 0 11 0 NNS IN NNP NNP NN O
Dry Dry 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NN CC O
mass mass 0 0 0 0 0 0 0 0 4 0 NNP NNP NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC JJ NN O
dry dry 0 0 0 0 0 0 0 0 3 0 NN CC JJ NN VBP O
density density 0 0 0 0 0 0 0 0 7 0 CC JJ NN VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 JJ NN VBP VBN RB O
obtained obtained 0 0 0 0 0 0 0 0 8 0 NN VBP VBN RB IN O
simultaneously simultaneously 0 0 0 0 0 0 0 0 14 0 VBP VBN RB IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBN RB IN NN DT O
measuring measuring 0 0 0 0 0 0 0 0 9 0 RB IN NN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 IN NN DT JJ NN O
cell's cell's 0 0 0 0 0 1 0 0 6 0 NN DT JJ NN NN O
buoyant buoyant 0 0 0 0 0 0 0 0 7 0 DT JJ NN NN RB O
mass mass 0 0 0 0 0 0 0 0 4 0 JJ NN NN RB IN O
sequentially sequentially 0 0 0 0 0 0 0 0 12 0 NN NN RB IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN RB IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 RB IN DT JJ NN O
H2O-based H2O-based 1 0 1 0 0 0 0 1 9 0 IN DT JJ NN CC O
fluid fluid 0 0 0 0 0 0 0 0 5 0 DT JJ NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN CC DT JJ NNP O
D2O-based D2O-based 1 0 1 0 0 0 0 1 9 0 CC DT JJ NNP NNP O
fluid. fluid. 0 0 0 0 0 0 0 0 6 0 DT JJ NNP NNP NN O
Rapid Rapid 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP NN IN O
exchange exchange 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NNP O
intracellular intracellular 0 0 0 0 0 0 0 0 13 0 NN IN JJ NNP IN O
H2O H2O 1 1 0 0 0 0 0 1 3 0 IN JJ NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNP IN NNP NNS O
D2O D2O 1 1 0 0 0 0 0 1 3 0 NNP IN NNP NNS DT O
renders renders 0 0 0 0 0 0 0 0 7 0 IN NNP NNS DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNS DT NNS NN O
cell's cell's 0 0 0 0 0 1 0 0 6 0 NNS DT NNS NN NN O
water water 0 0 0 0 0 0 0 0 5 0 DT NNS NN NN RB O
content content 0 0 0 0 0 0 0 0 7 0 NNS NN NN RB JJ O
neutrally neutrally 0 0 0 0 0 0 0 0 9 0 NN NN RB JJ IN O
buoyant buoyant 0 0 0 0 0 0 0 0 7 0 NN RB JJ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 RB JJ IN DT NN O
both both 0 0 0 0 0 0 0 0 4 0 JJ IN DT NN CC O
measurements, measurements, 0 0 0 0 1 0 0 0 13 0 IN DT NN CC RB O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC RB DT O
thus thus 0 0 0 0 0 0 0 0 4 0 NN CC RB DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 CC RB DT VBN NNS O
paired paired 0 0 0 0 0 0 0 0 6 0 RB DT VBN NNS NN O
measurements measurements 0 0 0 0 0 0 0 0 12 0 DT VBN NNS NN DT O
yield yield 0 0 0 0 0 0 0 0 5 0 VBN NNS NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS NN DT NN CC O
mass mass 0 0 0 0 0 0 0 0 4 0 NN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
density density 0 0 0 0 0 0 0 0 7 0 NN CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
cell's cell's 0 0 0 0 0 1 0 0 6 0 IN DT JJ NN NN O
dry dry 0 0 0 0 0 0 0 0 3 0 DT JJ NN NN NNP O
material material 0 0 0 0 0 0 0 0 8 0 JJ NN NN NNP NNP O
alone. alone. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP DT O
Utilizing Utilizing 1 0 0 0 0 0 0 0 9 0 NN NNP NNP DT JJ O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT JJ NN O
same same 0 0 0 0 0 0 0 0 4 0 NNP DT JJ NN IN O
property property 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
rapid rapid 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NN O
water water 0 0 0 0 0 0 0 0 5 0 IN JJ NN NN PRP O
exchange, exchange, 0 0 0 0 1 0 0 0 9 0 JJ NN NN PRP RB O
we we 0 0 0 0 0 0 0 0 2 0 NN NN PRP RB VBP O
also also 0 0 0 0 0 0 0 0 4 0 NN PRP RB VBP DT O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 PRP RB VBP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBP DT NN IN O
quantification quantification 0 0 0 0 0 0 0 0 14 0 VBP DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
intracellular intracellular 0 0 0 0 0 0 0 0 13 0 NN IN JJ NN NNP O
water water 0 0 0 0 0 0 0 0 5 0 IN JJ NN NNP NNP O
mass. mass. 0 0 0 0 0 0 0 0 5 0 JJ NN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT NN IN O
population population 0 0 0 0 0 0 0 0 10 0 NNP DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
E. E. 1 1 0 0 0 0 0 0 2 0 NN IN NNP NNP PRP O
coli, coli, 0 0 0 0 1 0 0 0 5 0 IN NNP NNP PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD DT O
paired paired 0 0 0 0 0 0 0 0 6 0 NNP PRP VBD DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 PRP VBD DT NNS TO O
measurements measurements 0 0 0 0 0 0 0 0 12 0 VBD DT NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT NNS TO VB DT O
estimate estimate 0 0 0 0 0 0 0 0 8 0 NNS TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN NN O
percent percent 0 0 0 0 0 0 0 0 7 0 VB DT NN NN NN O
dry dry 0 0 0 0 0 0 0 0 3 0 DT NN NN NN IN O
weight weight 0 0 0 0 0 0 0 0 6 0 NN NN NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NN CC O
mass mass 0 0 0 0 0 0 0 0 4 0 NN IN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NNP NNP O
volume. volume. 0 0 0 0 0 0 0 0 7 0 NN CC NNP NNP RB O
We We 1 0 0 0 0 0 0 0 2 0 CC NNP NNP RB VBD O
then then 0 0 0 0 0 0 0 0 4 0 NNP NNP RB VBD IN O
focused focused 0 0 0 0 0 0 0 0 7 0 NNP RB VBD IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 RB VBD IN JJ JJ O
cellular cellular 0 0 0 0 0 0 0 0 8 0 VBD IN JJ JJ NN O
dry dry 0 0 0 0 0 0 0 0 3 0 IN JJ JJ NN : O
density density 0 0 0 0 0 0 0 0 7 0 JJ JJ NN : DT O
- - 0 0 1 0 0 0 0 0 1 0 JJ NN : DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN : DT JJ NN O
average average 0 0 0 0 0 0 0 0 7 0 : DT JJ NN IN O
density density 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
all all 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
cellular cellular 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN VBD O
biomolecules, biomolecules, 0 0 0 0 1 0 0 0 13 0 DT JJ NN VBD IN O
weighted weighted 0 0 0 0 0 0 0 0 8 0 JJ NN VBD IN PRP$ O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN PRP$ JJ O
their their 0 0 0 0 0 0 0 0 5 0 VBD IN PRP$ JJ NNP O
relative relative 0 0 0 0 0 0 0 0 8 0 IN PRP$ JJ NNP NNP O
abundances. abundances. 0 0 0 0 0 0 0 0 11 0 PRP$ JJ NNP NNP IN O
Given Given 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP IN NNS O
that that 0 0 0 0 0 0 0 0 4 0 NNP NNP IN NNS VBP O
densities densities 0 0 0 0 0 0 0 0 9 0 NNP IN NNS VBP IN O
vary vary 0 0 0 0 0 0 0 0 4 0 IN NNS VBP IN NN O
across across 0 0 0 0 0 0 0 0 6 0 NNS VBP IN NN NNS O
biomolecule biomolecule 0 0 0 0 0 0 0 0 11 0 VBP IN NN NNS -NONE- O
types types 0 0 0 0 0 0 0 0 5 0 IN NN NNS -NONE- -NONE- O
(RNA, (RNA, 0 1 0 0 1 0 0 0 5 0 NN NNS -NONE- -NONE- -NONE- O
DNA, DNA, 1 1 0 0 1 0 0 0 4 0 NNS -NONE- -NONE- -NONE- PRP O
protein), protein), 0 0 0 0 1 0 0 0 9 0 -NONE- -NONE- -NONE- PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 -NONE- -NONE- PRP VBD IN O
investigated investigated 0 0 0 0 0 0 0 0 12 0 -NONE- PRP VBD IN PRP O
whether whether 0 0 0 0 0 0 0 0 7 0 PRP VBD IN PRP MD O
we we 0 0 0 0 0 0 0 0 2 0 VBD IN PRP MD VB O
could could 0 0 0 0 0 0 0 0 5 0 IN PRP MD VB NNS O
detect detect 0 0 0 0 0 0 0 0 6 0 PRP MD VB NNS IN O
changes changes 0 0 0 0 0 0 0 0 7 0 MD VB NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VB NNS IN JJ NN O
biomolecular biomolecular 0 0 0 0 0 0 0 0 12 0 NNS IN JJ NN IN O
composition composition 0 0 0 0 0 0 0 0 11 0 IN JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
bacteria, bacteria, 0 0 0 0 1 0 0 0 9 0 NN IN NNP NNP CC O
fungi, fungi, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NNP O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 NNP CC JJ NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 CC JJ NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NNP NNP O
E. E. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP CC O
coli, coli, 0 0 0 0 1 0 0 0 5 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
S. S. 1 1 0 0 0 0 0 0 2 0 NNP CC NNP NNP NN O
cerevisiae, cerevisiae, 0 0 0 0 1 0 0 0 11 0 CC NNP NNP NN NN O
dry dry 0 0 0 0 0 0 0 0 3 0 NNP NNP NN NN NNS O
density density 0 0 0 0 0 0 0 0 7 0 NNP NN NN NNS IN O
increases increases 0 0 0 0 0 0 0 0 9 0 NN NN NNS IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NN NNS IN JJ TO O
stationary stationary 0 0 0 0 0 0 0 0 10 0 NNS IN JJ TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 IN JJ TO JJ NN O
exponential exponential 0 0 0 0 0 0 0 0 11 0 JJ TO JJ NN NN O
phase, phase, 0 0 0 0 1 0 0 0 6 0 TO JJ NN NN IN O
consistent consistent 0 0 0 0 0 0 0 0 10 0 JJ NN NN IN RB O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN RB VBN O
previously previously 0 0 0 0 0 0 0 0 10 0 NN IN RB VBN NNS O
known known 0 0 0 0 0 0 0 0 5 0 IN RB VBN NNS IN O
increases increases 0 0 0 0 0 0 0 0 9 0 RB VBN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
RNA/protein RNA/protein 1 0 0 1 0 0 0 0 11 0 IN DT JJ NN IN O
ratio ratio 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 JJ NN IN JJ NN O
up-regulated up-regulated 0 0 1 0 0 0 0 0 12 0 NN IN JJ NN NNP O
ribosome ribosome 0 0 0 0 0 0 0 0 8 0 IN JJ NN NNP NNP O
production. production. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP NNP NN O
For For 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN -NONE- O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 NNP NNP NN -NONE- NNS O
cells, cells, 0 0 0 0 1 0 0 0 6 0 NNP NN -NONE- NNS IN O
changes changes 0 0 0 0 0 0 0 0 7 0 NN -NONE- NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- NNS IN NN NNS O
growth growth 0 0 0 0 0 0 0 0 6 0 NNS IN NN NNS VBP O
conditions conditions 0 0 0 0 0 0 0 0 10 0 IN NN NNS VBP JJ O
cause cause 0 0 0 0 0 0 0 0 5 0 NN NNS VBP JJ NNS O
substantial substantial 0 0 0 0 0 0 0 0 11 0 NNS VBP JJ NNS IN O
shifts shifts 0 0 0 0 0 0 0 0 6 0 VBP JJ NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
dry dry 0 0 0 0 0 0 0 0 3 0 NNS IN JJ NN VBG O
density, density, 0 0 0 0 1 0 0 0 8 0 IN JJ NN VBG NN O
suggesting suggesting 0 0 0 0 0 0 0 0 10 0 JJ NN VBG NN NNS O
concurrent concurrent 0 0 0 0 0 0 0 0 10 0 NN VBG NN NNS IN O
changes changes 0 0 0 0 0 0 0 0 7 0 VBG NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
protein, protein, 0 0 0 0 1 0 0 0 8 0 IN DT NN NN NN O
nucleic nucleic 0 0 0 0 0 0 0 0 7 0 DT NN NN NN CC O
acid acid 0 0 0 0 0 0 0 0 4 0 NN NN NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBD NN O
lipid lipid 0 0 0 0 0 0 0 0 5 0 NN CC VBD NN IN O
content content 0 0 0 0 0 0 0 0 7 0 CC VBD NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NONE O
cell. cell. 0 0 0 0 0 0 0 0 5 0 IN DT NNP NONE NONE O
Meiosis: Meiosis: 1 0 0 0 0 0 0 0 8 0 NONE NONE NN NN NNS O
mouse mouse 0 0 0 0 0 0 0 0 5 0 NONE NN NN NNS VBP O
eggs eggs 0 0 0 0 0 0 0 0 4 0 NN NN NNS VBP PRP$ O
do do 0 0 0 0 0 0 0 0 2 0 NN NNS VBP PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 NNS VBP PRP$ NN NNP O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 VBP PRP$ NN NNP NNP B_TIMEXCCP
topsy-turvy. topsy-turvy. 0 0 1 0 0 0 0 0 12 0 PRP$ NN NNP NNP NNP O
Jones Jones 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP NNP O
KT. KT. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNPS O
Biomedical Biomedical 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNPS CC O
Sciences Sciences 1 0 0 0 0 0 0 0 8 0 IN NNP NNPS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNPS CC NNP NNP O
Pharmacy, Pharmacy, 1 0 0 0 1 0 0 0 9 0 NNPS CC NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Newcastle, Newcastle, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP NNP O
Callaghan Callaghan 1 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP CD O
NSW NSW 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP CD NNP O
2308, 2308, 0 0 0 0 1 0 0 1 5 0 NNP NNP CD NNP NNP O
Australia. Australia. 1 0 0 0 0 0 0 0 10 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP JJ NN O
meiotic meiotic 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NN IN O
separation separation 0 0 0 0 0 0 0 0 10 0 NNP JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNS O
sister sister 0 0 0 0 0 0 0 0 6 0 NN IN NN NNS IN O
chromatids chromatids 0 0 0 0 0 0 0 0 10 0 IN NN NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NN O
mature mature 0 0 0 0 0 0 0 0 6 0 NNS IN NN NN NNP O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 IN NN NN NNP NN B_TIMEXCCP
II II 1 1 0 0 0 0 0 0 2 0 NN NN NNP NN NNS O
mouse mouse 0 0 0 0 0 0 0 0 5 0 NN NNP NN NNS VBZ O
eggs eggs 0 0 0 0 0 0 0 0 4 0 NNP NN NNS VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN NNS VBZ VBN TO O
observed observed 0 0 0 0 0 0 0 0 8 0 NNS VBZ VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ VBN TO VB RB O
depend depend 0 0 0 0 0 0 0 0 6 0 VBN TO VB RB IN O
initially initially 0 0 0 0 0 0 0 0 9 0 TO VB RB IN NN O
on on 0 0 0 0 0 0 0 0 2 0 VB RB IN NN VBG O
spindle spindle 0 0 0 0 0 0 0 0 7 0 RB IN NN VBG NN O
lengthening lengthening 0 0 0 0 0 0 0 0 11 0 IN NN VBG NN -NONE- O
(Anaphase (Anaphase 0 0 0 0 0 0 0 0 9 0 NN VBG NN -NONE- RB O
B), B), 1 1 0 0 1 0 0 0 3 0 VBG NN -NONE- RB IN O
then then 0 0 0 0 0 0 0 0 4 0 NN -NONE- RB IN NN O
on on 0 0 0 0 0 0 0 0 2 0 -NONE- RB IN NN VBG O
microtubule microtubule 0 0 0 0 0 0 0 0 11 0 RB IN NN VBG NN O
shortening shortening 0 0 0 0 0 0 0 0 10 0 IN NN VBG NN NNP O
(Anaphase (Anaphase 0 0 0 0 0 0 0 0 9 0 NN VBG NN NNP NNP I_TIMEXCCP
A). A). 1 1 0 0 0 0 0 0 3 0 VBG NN NNP NNP NNP O
Having Having 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP NNP O
Anaphase Anaphase 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN B_TIMEXCCP
B B 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NN NNP O
precede precede 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NNP DT O
Anaphase Anaphase 1 0 0 0 0 0 0 0 8 0 NNP NN NNP DT MD B_TIMEXCCP
A A 1 1 0 0 0 0 0 0 1 0 NN NNP DT MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NNP DT MD VB DT O
be be 0 0 0 0 0 0 0 0 2 0 DT MD VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 VB DT NN IN WDT O
by by 0 0 0 0 0 0 0 0 2 0 DT NN IN WDT JJ O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT JJ NNS O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 IN WDT JJ NNS MD O
eggs eggs 0 0 0 0 0 0 0 0 4 0 WDT JJ NNS MD VB O
can can 0 0 0 0 0 0 0 0 3 0 JJ NNS MD VB DT O
generate generate 0 0 0 0 0 0 0 0 8 0 NNS MD VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT JJ NN O
haploid haploid 0 0 0 0 0 0 0 0 7 0 VB DT JJ NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 DT JJ NN NN CC O
number number 0 0 0 0 0 0 0 0 6 0 JJ NN NN CC IN O
but but 0 0 0 0 0 0 0 0 3 0 NN NN CC IN DT O
without without 0 0 0 0 0 0 0 0 7 0 NN CC IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC IN DT NN IN O
loss loss 0 0 0 0 0 0 0 0 4 0 IN DT NN IN RB O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN RB JJ O
too too 0 0 0 0 0 0 0 0 3 0 NN IN RB JJ NNP O
much much 0 0 0 0 0 0 0 0 4 0 IN RB JJ NNP NNP O
cytoplasm. cytoplasm. 0 0 0 0 0 0 0 0 10 0 RB JJ NNP NNP NNP O
Copyright Copyright 1 0 0 0 0 0 0 0 9 0 JJ NNP NNP NNP CD O
Â© Â© 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
2012 2012 0 0 0 0 0 0 1 1 4 0 NNP NNP CD NNP NNP O
Elsevier Elsevier 1 0 0 0 0 0 0 0 8 0 NNP CD NNP NNP NNP O
Ltd. Ltd. 1 0 0 0 0 0 0 0 4 0 CD NNP NNP NNP NNS O
All All 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS NNP O
rights rights 0 0 0 0 0 0 0 0 6 0 NNP NNP NNS NNP NNP O
reserved. reserved. 0 0 0 0 0 0 0 0 9 0 NNP NNS NNP NNP IN O
Comment Comment 1 0 0 0 0 0 0 0 7 0 NNS NNP NNP IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Anaphase Anaphase 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP VBZ O
B B 1 1 0 0 0 0 0 0 1 0 IN NNP NNP VBZ NN O
precedes precedes 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ NN DT O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 NNP VBZ NN DT IN O
A A 1 1 0 0 0 0 0 0 1 0 VBZ NN DT IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN DT IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 DT IN DT NN NNP O
mouse mouse 0 0 0 0 0 0 0 0 5 0 IN DT NN NNP NNP O
egg. egg. 0 0 0 0 0 0 0 0 4 0 DT NN NNP NNP NNP O
[Curr [Curr 0 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP CD O
Biol. Biol. 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP CD -NONE- O
2012] 2012] 0 0 0 0 0 0 0 1 5 0 NNP NNP CD -NONE- CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNP CD -NONE- CD JJ O
22401893 22401893 0 0 0 0 0 0 1 1 8 0 CD -NONE- CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 -NONE- CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Spindle Spindle 1 0 0 0 0 0 0 0 7 0 NONE NONE NNP VBD NN O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NONE NNP VBD NN NNS B_TIMEXCCP
maintenance maintenance 0 0 0 0 0 0 0 0 11 0 NNP VBD NN NNS NNP O
requires requires 0 0 0 0 0 0 0 0 8 0 VBD NN NNS NNP CC O
Ame1 Ame1 1 0 0 0 0 0 0 1 4 0 NN NNS NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNS NNP CC NNP NNP O
Okp1. Okp1. 1 0 0 0 0 0 0 1 5 0 NNP CC NNP NNP NNP O
Pot Pot 1 0 0 0 0 0 0 0 3 0 CC NNP NNP NNP NNP O
I, I, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Knockleby Knockleby 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Aneliunas Aneliunas 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
V, V, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Nguyen Nguyen 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ah-Kye Ah-Kye 1 0 1 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Liszt Liszt 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Snyder Snyder 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hieter Hieter 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Vogel Vogel 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
J. J. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Biochemistry Biochemistry 1 0 0 0 0 0 0 0 12 0 NNP IN NNP CC NNP O
& & 0 0 0 0 0 0 0 0 1 0 IN NNP CC NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP CC NNP NNP CC O
Biology Biology 1 0 0 0 0 0 0 0 7 0 CC NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP IN O
Centre Centre 1 0 0 0 0 0 0 0 6 0 NNP CC NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 CC NNP IN NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP IN NNP NNP CC O
Medicine Medicine 1 0 0 0 0 0 0 0 8 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Therapeutics, Therapeutics, 1 0 0 0 1 0 0 0 13 0 NNP CC NNP NNP NNP O
Michael Michael 1 0 0 0 0 0 0 0 7 0 CC NNP NNP NNP NNP O
Smith Smith 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Laboratories, Laboratories, 1 0 0 0 1 0 0 0 13 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
British British 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
Columbia, Columbia, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Vancouver, Vancouver, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
British British 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Columbia, Columbia, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Canada. Canada. 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
Kinetochore Kinetochore 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP VBZ VBP O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NNP VBZ VBP VBN IN O
required required 0 0 0 0 0 0 0 0 8 0 VBZ VBP VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VBP VBN IN JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 VBN IN JJ NN NN O
fidelity fidelity 0 0 0 0 0 0 0 0 8 0 IN JJ NN NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 JJ NN NN NN CC O
segregation segregation 0 0 0 0 0 0 0 0 11 0 NN NN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NN CC IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 CC IN DT NN IN O
platform platform 0 0 0 0 0 0 0 0 8 0 IN DT NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN NN NNP O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NN IN NN NNP NNP B_TIMEXCCP
signaling. signaling. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP VBZ O
Ame1 Ame1 1 0 0 0 0 0 0 1 4 0 NN NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNP VBZ DT JJ NN O
essential essential 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ NN IN O
component component 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
COMA COMA 1 1 0 0 0 0 0 0 4 0 IN DT NNP NNP NNP O
(Ctf19, (Ctf19, 0 0 0 0 1 0 0 1 7 0 DT NNP NNP NNP NNP O
Okp1, Okp1, 1 0 0 0 1 0 0 1 5 0 NNP NNP NNP NNP NNP O
Mcm21, Mcm21, 1 0 0 0 1 0 0 1 6 0 NNP NNP NNP NNP NNP O
Ame1) Ame1) 1 0 0 0 0 0 0 1 5 0 NNP NNP NNP NNP IN O
sub-complex sub-complex 0 0 1 0 0 0 0 0 11 0 NNP NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ NN O
central central 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN IN O
kinetochore kinetochore 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN VBG NNP O
budding budding 0 0 0 0 0 0 0 0 7 0 NN IN VBG NNP NNP O
yeast. yeast. 0 0 0 0 0 0 0 0 6 0 IN VBG NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 VBG NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 NNP DT NN PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBP DT O
describe describe 0 0 0 0 0 0 0 0 8 0 NN PRP VBP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBP DT NN CC O
isolation isolation 0 0 0 0 0 0 0 0 9 0 VBP DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
characterization characterization 0 0 0 0 0 0 0 0 16 0 NN CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT NNP O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT NNP JJ O
Ame1 Ame1 1 0 0 0 0 0 0 1 4 0 IN DT NNP JJ NN O
conditional conditional 0 0 0 0 0 0 0 0 11 0 DT NNP JJ NN NNP O
mutant, mutant, 0 0 0 0 1 0 0 0 7 0 NNP JJ NN NNP -NONE- O
ame1-4. ame1-4. 0 0 1 0 0 0 0 1 7 0 JJ NN NNP -NONE- VBZ O
ame1-4 ame1-4 0 0 1 0 0 0 0 1 6 0 NN NNP -NONE- VBZ NN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP -NONE- VBZ NN NN O
exhibit exhibit 0 0 0 0 0 0 0 0 7 0 -NONE- VBZ NN NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 VBZ NN NN NN NNS O
segregation segregation 0 0 0 0 0 0 0 0 11 0 NN NN NN NNS CC O
defects defects 0 0 0 0 0 0 0 0 7 0 NN NN NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC JJ NN O
Mad2-dependent Mad2-dependent 1 0 1 0 0 0 0 1 14 0 NNS CC JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 CC JJ NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 JJ NN NN NN JJ O
delay delay 0 0 0 0 0 0 0 0 5 0 NN NN NN JJ TO O
similar similar 0 0 0 0 0 0 0 0 7 0 NN NN JJ TO -NONE- O
to to 0 0 0 0 0 0 0 0 2 0 NN JJ TO -NONE- NNP O
okp1-5 okp1-5 0 0 1 0 0 0 0 1 6 0 JJ TO -NONE- NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 TO -NONE- NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 -NONE- NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
viability viability 0 0 0 0 0 0 0 0 9 0 NNP DT NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN -NONE- VBZ O
ame1-4 ame1-4 0 0 1 0 0 0 0 1 6 0 NN IN -NONE- VBZ VBZ O
cells cells 0 0 0 0 0 0 0 0 5 0 IN -NONE- VBZ VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 -NONE- VBZ VBZ RB VBN O
markedly markedly 0 0 0 0 0 0 0 0 8 0 VBZ VBZ RB VBN JJ O
reduced reduced 0 0 0 0 0 0 0 0 7 0 VBZ RB VBN JJ TO O
relative relative 0 0 0 0 0 0 0 0 8 0 RB VBN JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN JJ TO VB NN O
wild wild 0 0 0 0 0 0 0 0 4 0 JJ TO VB NN CC O
type type 0 0 0 0 0 0 0 0 4 0 TO VB NN CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 VB NN CC -NONE- NNS O
okp1-5 okp1-5 0 0 1 0 0 0 0 1 6 0 NN CC -NONE- NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 CC -NONE- NNS IN CD O
after after 0 0 0 0 0 0 0 0 5 0 -NONE- NNS IN CD NNS O
three three 0 0 0 0 0 0 0 0 5 0 NNS IN CD NNS IN O
hours hours 0 0 0 0 0 0 0 0 5 0 IN CD NNS IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 CD NNS IN JJ NNP O
restrictive restrictive 0 0 0 0 0 0 0 0 11 0 NNS IN JJ NNP NNP O
temperature. temperature. 0 0 0 0 0 0 0 0 12 0 IN JJ NNP NNP NN O
To To 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NN IN O
determine determine 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN -NONE- O
if if 0 0 0 0 0 0 0 0 2 0 NNP NN IN -NONE- VBZ O
ame1-4 ame1-4 0 0 1 0 0 0 0 1 6 0 NN IN -NONE- VBZ NN O
cells cells 0 0 0 0 0 0 0 0 5 enter IN -NONE- VBZ NN NN O
enter enter 0 0 0 0 0 0 0 0 5 0 -NONE- VBZ NN NN IN O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 VBZ NN NN IN JJ B_TIMEXCCP
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ NN O
mis-segregated mis-segregated 0 0 1 0 0 0 0 0 14 0 NN IN JJ NN PRP O
chromosomes, chromosomes, 0 0 0 0 1 0 0 0 12 0 IN JJ NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 JJ NN PRP VBD DT O
monitored monitored 0 0 0 0 0 0 0 0 9 0 NN PRP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT NN IN O
localization localization 0 0 0 0 0 0 0 0 12 0 VBD DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ IN O
Bub3:VFP Bub3:VFP 1 0 0 0 0 0 0 1 8 0 NN IN JJ IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN JJ IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 JJ IN DT NN IN O
marker marker 0 0 0 0 0 0 0 0 6 0 IN DT NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN NN NNP O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 NN IN NN NNP -NONE- B_TIMEXCCP
onset. onset. 0 0 0 0 0 0 0 0 6 0 IN NN NNP -NONE- VBZ O
ame1-4 ame1-4 0 0 1 0 0 0 0 1 6 0 NN NNP -NONE- VBZ VBG O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP -NONE- VBZ VBG JJ O
containing containing 0 0 0 0 0 0 0 0 10 0 -NONE- VBZ VBG JJ NN O
mis-segregated mis-segregated 0 0 1 0 0 0 0 0 14 0 VBZ VBG JJ NN NNS O
sister sister 0 0 0 0 0 0 0 0 6 0 VBG JJ NN NNS RB O
chromatids chromatids 0 0 0 0 0 0 0 0 10 0 JJ NN NNS RB JJ O
initially initially 0 0 0 0 0 0 0 0 9 0 NN NNS RB JJ NN O
accumulate accumulate 0 0 0 0 0 0 0 0 10 0 NNS RB JJ NN IN O
Bub3:VFP Bub3:VFP 1 0 0 0 0 0 0 1 8 0 RB JJ NN IN NN O
at at 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN VBG O
kinetochores, kinetochores, 0 0 0 0 1 0 0 0 13 0 NN IN NN VBG NN O
indicating indicating 0 0 0 0 0 0 0 0 10 0 IN NN VBG NN NN O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NN VBG NN NN CC B_TIMEXCCP
activation activation 0 0 0 0 0 0 0 0 10 0 VBG NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN CC DT NN NNP O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 CC DT NN NNP NNP B_TIMEXCCP
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 DT NN NNP NNP NNP O
Subsequently, Subsequently, 1 0 0 0 1 0 0 0 13 0 NN NNP NNP NNP NNP O
Bub3:VFP Bub3:VFP 1 0 0 0 0 0 0 1 8 0 NNP NNP NNP NNP CC O
de-localizes de-localizes 0 0 1 0 0 0 0 0 12 0 NNP NNP NNP CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP CC NNS VBP NNP O
reinitiate reinitiate 0 0 0 0 0 0 0 0 10 0 CC NNS VBP NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NNS VBP NNP NN CC O
duplication duplication 0 0 0 0 0 0 0 0 11 0 VBP NNP NN CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC VBG IN O
budding budding 0 0 0 0 0 0 0 0 7 0 NN CC VBG IN NN O
without without 0 0 0 0 0 0 0 0 7 0 CC VBG IN NN IN O
cytokinesis cytokinesis 0 0 0 0 0 0 0 0 11 0 VBG IN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
presence presence 0 0 0 0 0 0 0 0 8 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
un-segregated un-segregated 0 0 1 0 0 0 0 0 13 0 NN IN JJ NNP NNP O
chromosomes. chromosomes. 0 0 0 0 0 0 0 0 12 0 IN JJ NNP NNP IN O
Overexpression Overexpression 1 0 0 0 0 0 0 0 14 0 JJ NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP IN O
OKP1 OKP1 1 1 0 0 0 0 0 1 4 0 NNP IN NNP IN -NONE- O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN -NONE- NNS O
ame1-4 ame1-4 0 0 1 0 0 0 0 1 6 0 NNP IN -NONE- NNS NNS O
cells cells 0 0 0 0 0 0 0 0 5 0 IN -NONE- NNS NNS -NONE- O
restores restores 0 0 0 0 0 0 0 0 8 0 -NONE- NNS NNS -NONE- VBP O
ame1-4 ame1-4 0 0 1 0 0 0 0 1 6 0 NNS NNS -NONE- VBP NN O
protein protein 0 0 0 0 0 0 0 0 7 0 NNS -NONE- VBP NN CC O
localization localization 0 0 0 0 0 0 0 0 12 0 -NONE- VBP NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 VBP NN CC DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN CC DT NN NNP O
stable stable 0 0 0 0 0 0 0 0 6 0 CC DT NN NNP NNP O
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 DT NN NNP NNP IN O
Based Based 1 0 0 0 0 0 0 0 5 0 NN NNP NNP IN PRP$ O
on on 0 0 0 0 0 0 0 0 2 0 NNP NNP IN PRP$ JJ O
our our 0 0 0 0 0 0 0 0 3 0 NNP IN PRP$ JJ PRP O
results, results, 0 0 0 0 1 0 0 0 8 0 IN PRP$ JJ PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 PRP$ JJ PRP VBP IN O
propose propose 0 0 0 0 0 0 0 0 7 0 JJ PRP VBP IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN NNP CC O
Ame1 Ame1 1 0 0 0 0 0 0 1 4 0 VBP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP VBP O
Okp1 Okp1 1 0 0 0 0 0 0 1 4 0 NNP CC NNP VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 CC NNP VBP VBN IN O
required required 0 0 0 0 0 0 0 0 8 0 NNP VBP VBN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBP VBN IN DT VBN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT VBN NN O
sustained sustained 0 0 0 0 0 0 0 0 9 0 IN DT VBN NN NN O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 arrest DT VBN NN NN IN B_TIMEXCCP
arrest arrest 0 0 0 0 0 0 0 0 6 0 VBN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
presence presence 0 0 0 0 0 0 0 0 8 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
mis-segregated mis-segregated 0 0 1 0 0 0 0 0 14 0 NN IN JJ NNP NNP O
chromosomes. chromosomes. 0 0 0 0 0 0 0 0 12 0 IN JJ NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNP NNS VBP IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NN NN O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 VBP IN NN NN MD B_TIMEXCCP
response response 0 0 0 0 0 0 0 0 8 0 IN NN NN MD VB O
might might 0 0 0 0 0 0 0 0 5 0 NN NN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB VBN RB O
controlled controlled 0 0 0 0 0 0 0 0 10 0 MD VB VBN RB RB O
not not 0 0 0 0 0 0 0 0 3 0 VB VBN RB RB IN O
only only 0 0 0 0 0 0 0 0 4 0 VBN RB RB IN DT O
at at 0 0 0 0 0 0 0 0 2 0 RB RB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NN IN O
level level 0 0 0 0 0 0 0 0 5 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN CC O
activation activation 0 0 0 0 0 0 0 0 10 0 NN IN NN CC RB O
but but 0 0 0 0 0 0 0 0 3 0 IN NN CC RB IN O
also also 0 0 0 0 0 0 0 0 4 0 NN CC RB IN NNS O
via via 0 0 0 0 0 0 0 0 3 0 CC RB IN NNS WDT O
signals signals 0 0 0 0 0 0 0 0 7 0 RB IN NNS WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 IN NNS WDT NN NN O
ensure ensure 0 0 0 0 0 0 0 0 6 0 NNS WDT NN NN IN O
maintenance maintenance 0 0 0 0 0 0 0 0 11 0 WDT NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
response. response. 0 0 0 0 0 0 0 0 9 0 IN DT NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 DT NNP NNP CD JJ O
16177574 16177574 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
G0 G0 1 1 0 0 0 0 0 1 2 0 NONE NONE NNP JJ NN O
chromosomal chromosomal 0 0 0 0 0 0 0 0 11 0 NONE NNP JJ NN IN O
radiosensitivity radiosensitivity 0 0 0 0 0 0 0 0 16 0 NNP JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
ataxia ataxia 0 0 0 0 0 0 0 0 6 0 NN IN NN NN NNP O
telangiectasia telangiectasia 0 0 0 0 0 0 0 0 14 0 IN NN NN NNP NNP O
lymphocytes. lymphocytes. 0 0 0 0 0 0 0 0 12 0 NN NN NNP NNP NNP O
Bender Bender 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP NNP O
MA, MA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Rary Rary 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
JM, JM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Kale Kale 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
RP. RP. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP TO O
Contrary Contrary 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNP NNP TO DT JJR O
an an 0 0 0 0 0 0 0 0 2 0 NNP TO DT JJR JJ O
earlier earlier 0 0 0 0 0 0 0 0 7 0 TO DT JJR JJ JJ O
report, report, 0 0 0 0 1 0 0 0 7 0 DT JJR JJ JJ NNS O
peripheral peripheral 0 0 0 0 0 0 0 0 10 0 JJR JJ JJ NNS IN O
lymphocytes lymphocytes 0 0 0 0 0 0 0 0 11 0 JJ JJ NNS IN CD O
from from 0 0 0 0 0 0 0 0 4 0 JJ NNS IN CD IN O
4 4 0 0 0 0 0 0 1 1 1 0 NNS IN CD IN NNS O
AT AT 1 1 0 0 0 0 0 0 2 0 IN CD IN NNS VBD O
patients patients 0 0 0 0 0 0 0 0 8 0 CD IN NNS VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 IN NNS VBD RB VBN O
not not 0 0 0 0 0 0 0 0 3 0 NNS VBD RB VBN TO O
found found 0 0 0 0 0 0 0 0 5 0 VBD RB VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 RB VBN TO VB JJR O
exhibit exhibit 0 0 0 0 0 0 0 0 7 0 VBN TO VB JJR NNS O
higher higher 0 0 0 0 0 0 0 0 6 0 TO VB JJR NNS IN O
yields yields 0 0 0 0 0 0 0 0 6 0 VB JJR NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJR NNS IN JJ NN O
unequivocal unequivocal 0 0 0 0 0 0 0 0 11 0 NNS IN JJ NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 IN JJ NN NN NNS O
type type 0 0 0 0 0 0 0 0 4 0 JJ NN NN NNS VBG O
aberrations aberrations 0 0 0 0 0 0 0 0 11 0 NN NN NNS VBG NN O
following following 0 0 0 0 0 0 0 0 9 0 NN NNS VBG NN IN O
irradiation irradiation 0 0 0 0 0 0 0 0 11 0 NNS VBG NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBG NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
G0 G0 1 1 0 0 0 0 0 1 2 phase IN DT NNP NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN VBG O
cycle, cycle, 0 0 0 0 1 0 0 0 6 0 DT NN NN VBG IN O
providing providing 0 0 0 0 0 0 0 0 9 0 NN NN VBG IN RB O
that that 0 0 0 0 0 0 0 0 4 0 NN VBG IN RB JJ O
only only 0 0 0 0 0 0 0 0 4 0 VBG IN RB JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 IN RB JJ NN NNS O
post-irradiation post-irradiation 0 0 1 0 0 0 0 0 16 0 RB JJ NN NNS VBD O
metaphases metaphases 0 0 0 0 0 0 0 0 10 0 JJ NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
included included 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNS JJ O
samples samples 0 0 0 0 0 0 0 0 7 0 IN DT NNS JJ IN O
(ensured (ensured 0 0 0 0 0 0 0 0 8 0 DT NNS JJ IN CD O
by by 0 0 0 0 0 0 0 0 2 0 NNS JJ IN CD JJ O
5-bromodeoxyuridine 5-bromodeoxyuridine 0 0 1 0 0 0 0 1 19 0 JJ IN CD JJ NN O
(BrdU) (BrdU) 0 0 0 0 0 0 0 0 6 0 IN CD JJ NN CC O
incorporation incorporation 0 0 0 0 0 0 0 0 13 0 CD JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NN O
differential differential 0 0 0 0 0 0 0 0 12 0 NN CC JJ NN CC O
fluorescence fluorescence 0 0 0 0 0 0 0 0 12 0 CC JJ NN CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 JJ NN CC NNP NNP O
Giemsa Giemsa 1 0 0 0 0 0 0 0 6 0 NN CC NNP NNP NNP O
staining). staining). 0 0 0 0 0 0 0 0 10 0 CC NNP NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD NNP NNP O
able, able, 0 0 0 0 1 0 0 0 5 0 NNP VBD NNP NNP TO O
however, however, 0 0 0 0 1 0 0 0 8 0 VBD NNP NNP TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNP NNP TO VB DT O
confirm confirm 0 0 0 0 0 0 0 0 7 0 NNP TO VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJ NN O
earlier-reported earlier-reported 0 0 1 0 0 0 0 0 16 0 VB DT JJ NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNS O
chromatid-type chromatid-type 0 0 1 0 0 0 0 0 14 0 NN IN NN NNS IN O
aberrations aberrations 0 0 0 0 0 0 0 0 11 0 IN NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NNP O
G0-irradiated G0-irradiated 1 0 1 0 0 0 0 1 13 0 IN DT JJ NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 DT JJ NNP NNP VBZ O
AT AT 1 1 0 0 0 0 0 0 2 0 JJ NNP NNP VBZ VBD O
lymphocytes lymphocytes 0 0 0 0 0 0 0 0 11 0 NNP NNP VBZ VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBD VBN TO O
found found 0 0 0 0 0 0 0 0 5 0 VBZ VBD VBN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO NN JJR O
experience experience 0 0 0 0 0 0 0 0 10 0 VBN TO NN JJR JJ O
more more 0 0 0 0 0 0 0 0 4 0 TO NN JJR JJ NN O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 0 NN JJR JJ NN VBG O
delay delay 0 0 0 0 0 0 0 0 5 0 JJR JJ NN VBG NNP O
following following 0 0 0 0 0 0 0 0 9 0 JJ NN VBG NNP NN O
G0 G0 1 1 0 0 0 0 0 1 2 0 NN VBG NNP NN IN O
irradiation irradiation 0 0 0 0 0 0 0 0 11 0 VBG NNP NN IN JJ O
than than 0 0 0 0 0 0 0 0 4 0 NNP NN IN JJ NNP O
normal normal 0 0 0 0 0 0 0 0 6 0 NN IN JJ NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP NNS VBP O
observations observations 0 0 0 0 0 0 0 0 12 0 NNP NNP NNS VBP JJ O
appear appear 0 0 0 0 0 0 0 0 6 0 NNP NNS VBP JJ IN O
consistent consistent 0 0 0 0 0 0 0 0 10 0 NNS VBP JJ IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBP JJ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT JJ NN O
damaged damaged 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN NN O
base base 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN JJ O
excision excision 0 0 0 0 0 0 0 0 8 0 JJ NN NN JJ NN O
DNA-repair DNA-repair 1 0 1 0 0 0 0 0 10 0 NN NN JJ NN VBD O
defect defect 0 0 0 0 0 0 0 0 6 0 NN JJ NN VBD IN O
reported reported 0 0 0 0 0 0 0 0 8 0 JJ NN VBD IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NN VBD IN NNP NNP O
AT AT 1 1 0 0 0 0 0 0 2 0 VBD IN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNP NNP NNP CD JJ O
4000160 4000160 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Mammalian Mammalian 1 0 0 0 0 0 0 0 9 0 NONE NONE JJ NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 NONE JJ NNP NNP NNP B_TIMEXCCP
cyclins. cyclins. 0 0 0 0 0 0 0 0 8 0 JJ NNP NNP NNP NNP O
Draetta Draetta 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
GF. GF. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Mitotix Mitotix 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Incorporated, Incorporated, 1 0 0 0 1 0 0 0 13 0 NNP NNP NNP NNP NNP O
Cambridge. Cambridge. 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP CC O
D- D- 1 1 1 0 0 0 0 0 2 0 NNP NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NNS O
E-type E-type 1 0 1 0 0 0 0 0 6 0 NNP CC JJ NNS VBP O
cyclins cyclins 0 0 0 0 0 0 0 0 7 0 CC JJ NNS VBP DT O
regulate regulate 0 0 0 0 0 0 0 0 8 0 JJ NNS VBP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBP DT NN IN O
progression progression 0 0 0 0 0 0 0 0 11 0 VBP DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN DT O
through through 0 0 0 0 0 0 0 0 7 0 JJ NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 phase IN DT NNP NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NNP NNP O
cycle. cycle. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS JJ O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 NNP NNP NNS JJ IN O
responsible responsible 0 0 0 0 0 0 0 0 11 0 NNP NNS JJ IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NNS JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN CC O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 IN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 NN CC NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNS VBP O
kinases kinases 0 0 0 0 0 0 0 0 7 0 NN IN NNS VBP IN O
dependent dependent 0 0 0 0 0 0 0 0 9 0 IN NNS VBP IN NNS O
on on 0 0 0 0 0 0 0 0 2 0 NNS VBP IN NNS NNP O
cyclins cyclins 0 0 0 0 0 0 0 0 7 0 VBP IN NNS NNP CC O
D D 1 1 0 0 0 0 0 0 1 0 IN NNS NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNS NNP CC NNP IN O
E E 1 1 0 0 0 0 0 0 1 0 NNP CC NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 CC NNP IN DT JJ O
both both 0 0 0 0 0 0 0 0 4 0 NNP IN DT JJ CC O
normal normal 0 0 0 0 0 0 0 0 6 0 IN DT JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC JJ NNS O
cancerous cancerous 0 0 0 0 0 0 0 0 9 0 JJ CC JJ NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 CC JJ NNS VBP RB O
have have 0 0 0 0 0 0 0 0 4 0 JJ NNS VBP RB VBN O
recently recently 0 0 0 0 0 0 0 0 8 0 NNS VBP RB VBN NNP O
been been 0 0 0 0 0 0 0 0 4 0 VBP RB VBN NNP NNP O
uncovered. uncovered. 0 0 0 0 0 0 0 0 10 0 RB VBN NNP NNP IN O
Overexpression Overexpression 1 0 0 0 0 0 0 0 14 0 VBN NNP NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NNP IN NN NNP NN O
D1 D1 1 1 0 0 0 0 0 1 2 0 IN NN NNP NN IN O
protein protein 0 0 0 0 0 0 0 0 7 0 NN NNP NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN IN O
consequence consequence 0 0 0 0 0 0 0 0 11 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
genetic genetic 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN CC O
rearrangements, rearrangements, 0 0 0 0 1 0 0 0 15 0 IN JJ NN CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNS CC O
deletions deletions 0 0 0 0 0 0 0 0 9 0 NN CC NNS CC NNS O
or or 0 0 0 0 0 0 0 0 2 0 CC NNS CC NNS IN O
mutations mutations 0 0 0 0 0 0 0 0 9 0 NNS CC NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NN O
p16INK4 p16INK4 0 0 0 0 0 0 0 1 7 0 IN DT NNP NN VBP O
gene gene 0 0 0 0 0 0 0 0 4 0 DT NNP NN VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NN VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBP VBN VBN IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 VBP VBN VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NN O
large large 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN IN O
variety variety 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN NN NN VBG O
cancers, cancers, 0 0 0 0 1 0 0 0 8 0 IN NN NN VBG NN O
including including 0 0 0 0 0 0 0 0 9 0 NN NN VBG NN CC O
breast breast 0 0 0 0 0 0 0 0 6 0 NN VBG NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VBG NN CC NN NN O
esophageal esophageal 0 0 0 0 0 0 0 0 10 0 NN CC NN NN NN O
carcinomas, carcinomas, 0 0 0 0 1 0 0 0 11 0 CC NN NN NN NN O
lymphomas, lymphomas, 0 0 0 0 1 0 0 0 10 0 NN NN NN NN NN O
bladder bladder 0 0 0 0 0 0 0 0 7 0 NN NN NN NN JJ O
carcinoma, carcinoma, 0 0 0 0 1 0 0 0 10 0 NN NN NN JJ NN O
pancreatic pancreatic 0 0 0 0 0 0 0 0 10 0 NN NN JJ NN CC O
adenocarcinoma adenocarcinoma 0 0 0 0 0 0 0 0 14 0 NN JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NNP O
familial familial 0 0 0 0 0 0 0 0 8 0 NN CC JJ NNP NNP O
melanoma. melanoma. 0 0 0 0 0 0 0 0 9 0 CC JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
7880531 7880531 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
G2 G2 1 1 0 0 0 0 0 1 2 0 NONE NONE NNP JJ NN O
chromosomal chromosomal 0 0 0 0 0 0 0 0 11 0 NONE NNP JJ NN IN O
radiosensitivity radiosensitivity 0 0 0 0 0 0 0 0 16 0 NNP JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
ataxia-telangiectasia ataxia-telangiectasia 0 0 1 0 0 0 0 0 21 0 NN IN NNP NNP NNP O
heterozygotes. heterozygotes. 0 0 0 0 0 0 0 0 14 0 IN NNP NNP NNP NNP O
Parshad Parshad 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sanford Sanford 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
KK, KK, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Jones Jones 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
GM, GM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Tarone Tarone 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
RE. RE. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNS O
Five Five 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNS IN O
lines lines 0 0 0 0 0 0 0 0 5 0 NNP NNP NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NN NNS O
skin skin 0 0 0 0 0 0 0 0 4 0 NNS IN NN NNS IN O
fibroblasts fibroblasts 0 0 0 0 0 0 0 0 11 0 IN NN NNS IN NNS O
from from 0 0 0 0 0 0 0 0 4 0 NN NNS IN NNS JJ O
individuals individuals 0 0 0 0 0 0 0 0 11 0 NNS IN NNS JJ IN O
heterozygous heterozygous 0 0 0 0 0 0 0 0 12 0 IN NNS JJ IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNS JJ IN NNP NNP O
ataxia-telangiectasia ataxia-telangiectasia 0 0 1 0 0 0 0 0 21 0 JJ IN NNP NNP VBD O
(A-T), (A-T), 0 1 1 0 1 0 0 0 6 0 IN NNP NNP VBD IN O
compared compared 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD IN CD O
with with 0 0 0 0 0 0 0 0 4 0 NNP VBD IN CD NN O
six six 0 0 0 0 0 0 0 0 3 0 VBD IN CD NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 IN CD NN NNS IN O
lines lines 0 0 0 0 0 0 0 0 5 0 CD NN NNS IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NN NNS IN JJ JJ O
age-matched age-matched 0 0 1 0 0 0 0 0 11 0 NNS IN JJ JJ NN O
normal normal 0 0 0 0 0 0 0 0 6 0 IN JJ JJ NN NN O
controls, controls, 0 0 0 0 1 0 0 0 9 0 JJ JJ NN NN DT O
show show 0 0 0 0 0 0 0 0 4 0 JJ NN NN DT RB O
a a 0 0 0 0 0 0 0 0 1 0 NN NN DT RB JJR O
much much 0 0 0 0 0 0 0 0 4 0 NN DT RB JJR NN O
higher higher 0 0 0 0 0 0 0 0 6 0 DT RB JJR NN IN O
frequency frequency 0 0 0 0 0 0 0 0 9 0 RB JJR NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJR NN IN JJ NNS O
chromatid chromatid 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNS CC O
breaks breaks 0 0 0 0 0 0 0 0 6 0 IN JJ NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC NNS VBG O
gaps gaps 0 0 0 0 0 0 0 0 4 0 NNS CC NNS VBG NN O
following following 0 0 0 0 0 0 0 0 9 0 CC NNS VBG NN IN O
x-irradiation x-irradiation 0 0 1 0 0 0 0 0 13 0 NNS VBG NN IN DT O
during during 0 0 0 0 0 0 0 0 6 0 VBG NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
G2 G2 1 1 0 0 0 0 0 1 2 phase IN DT NNP NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NNP NNP O
cycle. cycle. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
magnitude magnitude 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN VBZ O
difference difference 0 0 0 0 0 0 0 0 10 0 IN DT NN VBZ IN O
suggests suggests 0 0 0 0 0 0 0 0 8 0 DT NN VBZ IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NN VBZ IN NNP VBD O
G2 G2 1 1 0 0 0 0 0 1 2 0 VBZ IN NNP VBD NN O
chromatid chromatid 0 0 0 0 0 0 0 0 9 0 IN NNP VBD NN MD O
radiosensitivity radiosensitivity 0 0 0 0 0 0 0 0 16 0 NNP VBD NN MD VB O
could could 0 0 0 0 0 0 0 0 5 0 VBD NN MD VB DT O
provide provide 0 0 0 0 0 0 0 0 7 0 NN MD VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NN IN O
basis basis 0 0 0 0 0 0 0 0 5 0 VB DT NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT NN TO O
assay assay 0 0 0 0 0 0 0 0 5 0 IN DT NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO VB JJ O
detect detect 0 0 0 0 0 0 0 0 6 0 NN TO VB JJ NNP O
A-T A-T 1 1 1 0 0 0 0 0 3 0 TO VB JJ NNP NNP O
heterozygotes. heterozygotes. 0 0 0 0 0 0 0 0 14 0 VB JJ NNP NNP RB O
Though Though 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP RB NNP O
clinically clinically 0 0 0 0 0 0 0 0 10 0 NNP NNP RB NNP NNP O
normal, normal, 0 0 0 0 1 0 0 0 7 0 NNP RB NNP NNP VBZ O
A-T A-T 1 1 1 0 0 0 0 0 3 0 RB NNP NNP VBZ NN O
heterozygotes heterozygotes 0 0 0 0 0 0 0 0 13 0 NNP NNP VBZ NN DT O
share share 0 0 0 0 0 0 0 0 5 0 NNP VBZ NN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBZ NN DT JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 NN DT JJ NN IN O
risk risk 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN IN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN JJ NNS O
A-T A-T 1 1 1 0 0 0 0 0 3 0 NN IN JJ NNS CC O
homozygotes homozygotes 0 0 0 0 0 0 0 0 11 0 IN JJ NNS CC VB O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC VB RB O
constitute constitute 0 0 0 0 0 0 0 0 10 0 NNS CC VB RB CD O
approximately approximately 0 0 0 0 0 0 0 0 13 0 CC VB RB CD IN O
1% 1% 0 0 0 0 0 0 0 1 2 0 VB RB CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 RB CD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT JJ NNP O
human human 0 0 0 0 0 0 0 0 5 0 IN DT JJ NNP NNP O
population. population. 0 0 0 0 0 0 0 0 11 0 DT JJ NNP NNP PRP O
Further, Further, 1 0 0 0 1 0 0 0 8 0 JJ NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP IN O
propose propose 0 0 0 0 0 0 0 0 7 0 NNP PRP VBP IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN NNP JJ O
G2 G2 1 1 0 0 0 0 0 1 2 0 VBP IN NNP JJ NN O
chromosomal chromosomal 0 0 0 0 0 0 0 0 11 0 IN NNP JJ NN WDT O
radiosensitivity, radiosensitivity, 0 0 0 0 1 0 0 0 17 0 NNP JJ NN WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 JJ NN WDT VBZ TO O
appears appears 0 0 0 0 0 0 0 0 7 0 NN WDT VBZ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 WDT VBZ TO VB IN O
result result 0 0 0 0 0 0 0 0 6 0 VBZ TO VB IN DT O
from from 0 0 0 0 0 0 0 0 4 0 TO VB IN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 VB IN DT NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 IN DT NNP NN -NONE- O
repair repair 0 0 0 0 0 0 0 0 6 0 DT NNP NN -NONE- MD O
deficiency, deficiency, 0 0 0 0 1 0 0 0 11 0 NNP NN -NONE- MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN -NONE- MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 -NONE- MD VB VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 MD VB VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VB VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NN O
genetic genetic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN TO O
predisposition predisposition 0 0 0 0 0 0 0 0 14 0 DT JJ NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO NNP NNP O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 NN TO NNP NNP IN O
Comment Comment 1 0 0 0 0 0 0 0 7 0 TO NNP NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
A A 1 1 0 0 0 0 0 0 1 0 NNP IN DT NN IN O
procedure procedure 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN NN NN O
carrier carrier 0 0 0 0 0 0 0 0 7 0 NN IN NN NN IN O
detection detection 0 0 0 0 0 0 0 0 9 0 IN NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NN O
ataxia-telangiectasia. ataxia-telangiectasia. 0 0 1 0 0 0 0 0 22 0 NN IN NNP NN NNP O
[Cancer [Cancer 0 0 0 0 0 0 0 0 7 0 IN NNP NN NNP NNP O
Genet Genet 1 0 0 0 0 0 0 0 5 0 NNP NN NNP NNP CD O
Cytogenet. Cytogenet. 1 0 0 0 0 0 0 0 10 0 NN NNP NNP CD NONE O
1990] 1990] 0 0 0 0 0 0 0 1 5 0 NNP NNP CD NONE NONE O
Nucleocytoplasmic Nucleocytoplasmic 1 0 0 0 0 0 0 0 17 0 NONE NONE JJ NNS IN O
exchanges exchanges 0 0 0 0 0 0 0 0 9 0 NONE JJ NNS IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 JJ NNS IN JJ NNP O
early early 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NNP NNP B_TIMEXCCP
interphase. interphase. 0 0 0 0 0 0 0 0 11 0 IN JJ NNP NNP NNP I_TIMEXCCP
Feldherr Feldherr 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP NNP NNP O
CM. CM. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
Colloidal Colloidal 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NN VBD O
gold gold 0 0 0 0 0 0 0 0 4 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
injected injected 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN DT O
into into 0 0 0 0 0 0 0 0 4 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
cytoplasm cytoplasm 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
amebae amebae 0 0 0 0 0 0 0 0 6 0 NN IN NN NN NN O
(Amoeba (Amoeba 0 0 0 0 0 0 0 0 7 0 IN NN NN NN RB O
proteus) proteus) 0 0 0 0 0 0 0 0 8 0 NN NN NN RB CD O
approximately approximately 0 0 0 0 0 0 0 0 13 0 NN NN RB CD NN O
5 5 0 0 0 0 0 0 1 1 1 0 NN RB CD NN CD O
min, min, 0 0 0 0 1 0 0 0 4 0 RB CD NN CD NN O
1 1 0 0 0 0 0 0 1 1 1 0 CD NN CD NN CC O
hr, hr, 0 0 0 0 1 0 0 0 3 0 NN CD NN CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD NN CC CD NN O
2 2 0 0 0 0 0 0 1 1 1 0 NN CC CD NN IN O
hr hr 0 0 0 0 0 0 0 0 2 0 CC CD NN IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 CD NN IN NNP NNP O
cytokinesis. cytokinesis. 0 0 0 0 0 0 0 0 12 0 NN IN NNP NNP NN O
Later, Later, 1 0 0 0 1 0 0 0 6 0 IN NNP NNP NN NNS O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NNP NNP NN NNS VBD B_TIMEXCCP
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NN NNS VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD RB NNP O
similarly similarly 0 0 0 0 0 0 0 0 9 0 NNS VBD RB NNP NNP O
treated. treated. 0 0 0 0 0 0 0 0 8 0 VBD RB NNP NNP IN O
All All 1 0 0 0 0 0 0 0 3 0 RB NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN VBD O
amebae amebae 0 0 0 0 0 0 0 0 6 0 IN DT NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 DT NN VBD VBN IN O
fixed fixed 0 0 0 0 0 0 0 0 5 0 NN VBD VBN IN CD O
about about 0 0 0 0 0 0 0 0 5 0 VBD VBN IN CD NN O
50 50 0 0 0 0 0 0 1 1 2 0 VBN IN CD NN IN O
min min 0 0 0 0 0 0 0 0 3 0 IN CD NN IN NN O
after after 0 0 0 0 0 0 0 0 5 0 CD NN IN NN CC O
injection injection 0 0 0 0 0 0 0 0 9 0 NN IN NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN CC VBD VBN IN O
examined examined 0 0 0 0 0 0 0 0 8 0 CC VBD VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NN O
electron electron 0 0 0 0 0 0 0 0 8 0 IN DT NN NN IN O
microscope microscope 0 0 0 0 0 0 0 0 10 0 DT NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN TO O
order order 0 0 0 0 0 0 0 0 5 0 NN IN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB DT O
determine determine 0 0 0 0 0 0 0 0 9 0 NN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
distribution distribution 0 0 0 0 0 0 0 0 12 0 VB DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
gold. gold. 0 0 0 0 0 0 0 0 5 0 IN DT NNP NNP VBD O
It It 1 0 0 0 0 0 0 0 2 0 DT NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 NNP VBD VBN IN IN O
that that 0 0 0 0 0 0 0 0 4 0 VBD VBN IN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBN IN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 IN IN DT NN IN O
period period 0 0 0 0 0 0 0 0 6 0 IN DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD NN O
2 2 0 0 0 0 0 0 1 1 1 0 NN IN CD NN IN O
hr hr 0 0 0 0 0 0 0 0 2 0 IN CD NN IN NN O
after after 0 0 0 0 0 0 0 0 5 0 CD NN IN NN DT O
division division 0 0 0 0 0 0 0 0 8 0 NN IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN IN O
uptake uptake 0 0 0 0 0 0 0 0 6 0 NN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
gold gold 0 0 0 0 0 0 0 0 4 0 NN IN NN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBD O
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 IN DT NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD RB JJR O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NN VBD RB JJR IN O
greater greater 0 0 0 0 0 0 0 0 7 0 VBD RB JJR IN DT O
than than 0 0 0 0 0 0 0 0 4 0 RB JJR IN DT IN O
that that 0 0 0 0 0 0 0 0 4 0 JJR IN DT IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 IN DT IN JJ NNP O
late late 0 0 0 0 0 0 0 0 4 0 DT IN JJ NNP NNP B_TIMEXCCP
interphase. interphase. 0 0 0 0 0 0 0 0 11 0 IN JJ NNP NNP IN I_TIMEXCCP
Correlation Correlation 1 0 0 0 0 0 0 0 11 0 JJ NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN NN O
gold gold 0 0 0 0 0 0 0 0 4 0 IN DT NN NN IN O
distribution distribution 0 0 0 0 0 0 0 0 12 0 DT NN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
morphology morphology 0 0 0 0 0 0 0 0 10 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN VBD O
envelope envelope 0 0 0 0 0 0 0 0 8 0 DT JJ NN VBD IN O
indicated indicated 0 0 0 0 0 0 0 0 9 0 JJ NN VBD IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 VBD IN DT NN NN O
inverse inverse 0 0 0 0 0 0 0 0 7 0 IN DT NN NN NNS O
relationship relationship 0 0 0 0 0 0 0 0 12 0 DT NN NN NNS IN O
exists exists 0 0 0 0 0 0 0 0 6 0 NN NN NNS IN DT O
between between 0 0 0 0 0 0 0 0 7 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
incorporation incorporation 0 0 0 0 0 0 0 0 13 0 NN IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ IN O
colloid colloid 0 0 0 0 0 0 0 0 7 0 NN IN JJ IN DT O
into into 0 0 0 0 0 0 0 0 4 0 IN JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN CC O
nucleoplasm nucleoplasm 0 0 0 0 0 0 0 0 11 0 IN DT NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN IN O
degree degree 0 0 0 0 0 0 0 0 6 0 CC DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
reconstitution reconstitution 0 0 0 0 0 0 0 0 14 0 NN IN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
fibrous fibrous 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN NN O
lamina lamina 0 0 0 0 0 0 0 0 6 0 DT JJ NN NN NNP O
("honeycomb" ("honeycomb" 0 0 0 0 0 0 0 0 12 0 JJ NN NN NNP NNP O
structure). structure). 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNS NN O
data data 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS NN DT O
support support 0 0 0 0 0 0 0 0 7 0 NNP NNS NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS NN DT NN IN O
view view 0 0 0 0 0 0 0 0 4 0 NN DT NN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
fibrous fibrous 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN NNS O
lamina lamina 0 0 0 0 0 0 0 0 6 0 DT JJ NN NNS IN O
functions functions 0 0 0 0 0 0 0 0 9 0 JJ NN NNS IN VBG O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN VBG JJ O
regulating regulating 0 0 0 0 0 0 0 0 10 0 NNS IN VBG JJ NNP O
nucleocytoplasmic nucleocytoplasmic 0 0 0 0 0 0 0 0 17 0 IN VBG JJ NNP NNP O
exchanges. exchanges. 0 0 0 0 0 0 0 0 10 0 VBG JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
5678450 5678450 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NN O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NN NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
PMC2107511 PMC2107511 1 1 0 0 0 0 0 1 10 0 JJ NN NNP NONE NONE O
Rheostat-ing Rheostat-ing 1 0 1 0 0 0 0 0 12 0 NONE NONE JJ NNP NNP O
mitosis. mitosis. 0 0 0 0 0 0 0 0 8 0 NONE JJ NNP NNP NNP B_TIMEXCCP
Eyers Eyers 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP NNP NNP O
PA. PA. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Oncology, Oncology, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
CR-UK/YCR CR-UK/YCR 1 1 1 1 0 0 0 0 9 0 IN NNP NNP NNP NNP O
Sheffield Sheffield 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Centre, Centre, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Sheffield, Sheffield, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP NNP O
Sheffield Sheffield 1 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP CD O
S10 S10 1 1 0 0 0 0 0 1 3 0 NNP NNP NNP CD NNP O
2RX, 2RX, 0 1 0 0 1 0 0 1 4 0 NNP NNP CD NNP NNP O
UK. UK. 1 1 0 0 0 0 0 0 3 0 NNP CD NNP NNP NNP O
p.eyers@sheffield.ac.uk p.eyers@sheffield.ac.uk 0 0 0 0 0 0 0 0 23 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP DT O
Ark1, Ark1, 1 0 0 0 1 0 0 1 5 0 NNP NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NNP O
unique unique 0 0 0 0 0 0 0 0 6 0 NNP DT JJ NNP NN O
Aurora Aurora 1 0 0 0 0 0 0 0 6 0 DT JJ NNP NN IN O
kinase kinase 0 0 0 0 0 0 0 0 6 0 JJ NNP NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NNP O
Schizosaccharomyces Schizosaccharomyces 1 0 0 0 0 0 0 0 19 0 NN IN NNP NNP VBZ O
pombe, pombe, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP VBZ NN O
regulates regulates 0 0 0 0 0 0 0 0 9 0 NNP NNP VBZ NN NNS O
multiple multiple 0 0 0 0 0 0 0 0 8 0 NNP VBZ NN NNS IN O
aspects aspects 0 0 0 0 0 0 0 0 7 0 VBZ NN NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP NNP O
mitosis. mitosis. 0 0 0 0 0 0 0 0 8 0 NNS IN NNP NNP DT B_TIMEXCCP
In In 1 0 0 0 0 0 0 0 2 0 IN NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN IN O
issue issue 0 0 0 0 0 0 0 0 5 0 NNP DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP CC O
Chemistry Chemistry 1 0 0 0 0 0 0 0 9 0 NN IN NNP CC NNP O
& & 0 0 0 0 0 0 0 0 1 0 IN NNP CC NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 NNP CC NNP NNP CC O
Kawashima Kawashima 1 0 0 0 0 0 0 0 9 0 CC NNP NNP CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNS NN O
colleagues colleagues 0 0 0 0 0 0 0 0 10 0 NNP CC NNS NN DT O
report report 0 0 0 0 0 0 0 0 6 0 CC NNS NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS NN DT NN CC O
discovery discovery 0 0 0 0 0 0 0 0 9 0 NN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
validation validation 0 0 0 0 0 0 0 0 10 0 NN CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NNP O
fungal fungal 0 0 0 0 0 0 0 0 6 0 IN DT JJ NNP NNP O
Ark1 Ark1 1 0 0 0 0 0 0 1 4 0 DT JJ NNP NNP WDT O
inhibitor, inhibitor, 0 0 0 0 1 0 0 0 10 0 JJ NNP NNP WDT PRP O
which which 0 0 0 0 0 0 0 0 5 0 NNP NNP WDT PRP VBP O
they they 0 0 0 0 0 0 0 0 4 0 NNP WDT PRP VBP TO O
employ employ 0 0 0 0 0 0 0 0 6 0 WDT PRP VBP TO VB O
to to 0 0 0 0 0 0 0 0 2 0 PRP VBP TO VB DT O
evaluate evaluate 0 0 0 0 0 0 0 0 8 0 VBP TO VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJ NNS O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 VB DT JJ NNS IN B_TIMEXCCP
outputs outputs 0 0 0 0 0 0 0 0 7 0 DT JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NNP O
endogenous endogenous 0 0 0 0 0 0 0 0 10 0 NNS IN JJ NNP NNP O
Ark1 Ark1 1 0 0 0 0 0 0 1 4 0 IN JJ NNP NNP NNP O
signaling. signaling. 0 0 0 0 0 0 0 0 10 0 JJ NNP NNP NNP NNP O
Copyright Copyright 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP CD O
© © 0 0 0 0 0 0 0 0 1 0 NNP NNP NNP CD NNP O
2013 2013 0 0 0 0 0 0 1 1 4 0 NNP NNP CD NNP NNP O
Elsevier Elsevier 1 0 0 0 0 0 0 0 8 0 NNP CD NNP NNP NNP O
Ltd. Ltd. 1 0 0 0 0 0 0 0 4 0 CD NNP NNP NNP NNS O
All All 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS NNP O
rights rights 0 0 0 0 0 0 0 0 6 0 NNP NNP NNS NNP NNP O
reserved. reserved. 0 0 0 0 0 0 0 0 9 0 NNP NNS NNP NNP IN O
Comment Comment 1 0 0 0 0 0 0 0 7 0 NNS NNP NNP IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT JJ O
A A 1 1 0 0 0 0 0 0 1 0 NNP IN DT JJ NN O
chemical chemical 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN NN O
biology biology 0 0 0 0 0 0 0 0 7 0 DT JJ NN NN TO O
strategy strategy 0 0 0 0 0 0 0 0 8 0 JJ NN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO VB JJ O
analyze analyze 0 0 0 0 0 0 0 0 7 0 NN TO VB JJ NN O
rheostat-like rheostat-like 0 0 1 0 0 0 0 0 13 0 TO VB JJ NN JJ O
protein protein 0 0 0 0 0 0 0 0 7 0 VB JJ NN JJ NNP O
kinase-dependent kinase-dependent 0 0 1 0 0 0 0 0 16 0 JJ NN JJ NNP NNP O
regulation. regulation. 0 0 0 0 0 0 0 0 11 0 NN JJ NNP NNP NNP O
[Chem [Chem 0 0 0 0 0 0 0 0 5 0 JJ NNP NNP NNP CD O
Biol. Biol. 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP CD NONE O
2013] 2013] 0 0 0 0 0 0 0 1 5 0 NNP NNP CD NONE NONE O
Metaphase Metaphase 1 0 0 0 0 0 0 0 9 0 NONE NONE NN VBD NNS B_TIMEXCCP
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NONE NN VBD NNS CC O
folds folds 0 0 0 0 0 0 0 0 5 0 NN VBD NNS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VBD NNS CC NNP NNP O
X-inactivation. X-inactivation. 1 0 1 0 0 0 0 0 15 0 NNS CC NNP NNP NNP O
Butler Butler 1 0 0 0 0 0 0 0 6 0 CC NNP NNP NNP NNP O
MG, MG, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Joseph Joseph 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
GM, GM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Dev Dev 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
VG. VG. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VB O
To To 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VB DT O
evaluate evaluate 0 0 0 0 0 0 0 0 8 0 NNP NNP VB DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VB DT VBN NN O
suggested suggested 0 0 0 0 0 0 0 0 9 0 VB DT VBN NN NN O
nonrandom nonrandom 0 0 0 0 0 0 0 0 9 0 DT VBN NN NN IN O
folding folding 0 0 0 0 0 0 0 0 7 0 VBN NN NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN -NONE- JJ O
Xq13-q21 Xq13-q21 1 0 1 0 0 0 0 1 8 0 NN IN -NONE- JJ IN O
(center (center 0 0 0 0 0 0 0 0 7 0 IN -NONE- JJ IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 -NONE- JJ IN NNP NN O
Barr Barr 1 0 0 0 0 0 0 0 4 0 JJ IN NNP NN -NONE- O
body body 0 0 0 0 0 0 0 0 4 0 IN NNP NN -NONE- IN O
condensation) condensation) 0 0 0 0 0 0 0 0 13 0 NNP NN -NONE- IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN -NONE- IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- IN DT VBN NNP O
inactivated inactivated 0 0 0 0 0 0 0 0 11 0 IN DT VBN NNP NNP O
X X 1 1 0 0 0 0 0 0 1 0 DT VBN NNP NNP VBZ O
chromosomes, chromosomes, 0 0 0 0 1 0 0 0 12 0 VBN NNP NNP VBZ IN O
metaphases metaphases 0 0 0 0 0 0 0 0 10 0 NNP NNP VBZ IN CD B_TIMEXCCP
from from 0 0 0 0 0 0 0 0 4 0 NNP VBZ IN CD NNS O
nine nine 0 0 0 0 0 0 0 0 4 0 VBZ IN CD NNS IN O
subjects subjects 0 0 0 0 0 0 0 0 8 0 IN CD NNS IN CC O
with with 0 0 0 0 0 0 0 0 4 0 CD NNS IN CC IN O
or or 0 0 0 0 0 0 0 0 2 0 NNS IN CC IN NNP O
without without 0 0 0 0 0 0 0 0 7 0 IN CC IN NNP NN O
X X 1 1 0 0 0 0 0 0 1 0 CC IN NNP NN NNS O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 IN NNP NN NNS JJ O
abnormalities abnormalities 0 0 0 0 0 0 0 0 13 0 NNP NN NNS JJ NNS O
(eight (eight 0 0 0 0 0 0 0 0 6 0 NN NNS JJ NNS CC O
females females 0 0 0 0 0 0 0 0 7 0 NNS JJ NNS CC CD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC CD NN O
one one 0 0 0 0 0 0 0 0 3 0 NNS CC CD NN VBD O
male) male) 0 0 0 0 0 0 0 0 5 0 CC CD NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 CD NN VBD VBN IN O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NN VBD VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNP DT O
RBG-staining. RBG-staining. 1 0 1 0 0 0 0 0 13 0 VBN IN NNP DT JJ O
A A 1 1 0 0 0 0 0 0 1 0 IN NNP DT JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 NNP DT JJ NN NN O
increase increase 0 0 0 0 0 0 0 0 8 0 DT JJ NN NN RBR O
(p (p 0 0 0 0 0 0 0 0 2 0 JJ NN NN RBR IN O
less less 0 0 0 0 0 0 0 0 4 0 NN NN RBR IN NNP O
than than 0 0 0 0 0 0 0 0 4 0 NN RBR IN NNP IN O
.05) .05) 0 0 0 0 0 0 0 1 4 0 RBR IN NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN IN O
number number 0 0 0 0 0 0 0 0 6 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
arm arm 0 0 0 0 0 0 0 0 3 0 NN IN NN NNS -NONE- O
folds folds 0 0 0 0 0 0 0 0 5 0 IN NN NNS -NONE- IN O
(Xq13-q21) (Xq13-q21) 0 0 1 0 0 0 0 1 10 0 NN NNS -NONE- IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNS -NONE- IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- IN DT JJ NNP O
late-replicating late-replicating 0 0 1 0 0 0 0 0 16 0 IN DT JJ NNP NNP O
X X 1 1 0 0 0 0 0 0 1 0 DT JJ NNP NNP RB O
chromosome, chromosome, 0 0 0 0 1 0 0 0 11 0 JJ NNP NNP RB IN O
particularly particularly 0 0 0 0 0 0 0 0 12 0 NNP NNP RB IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNP RB IN JJ TO O
early early 0 0 0 0 0 0 0 0 5 0 RB IN JJ TO NNP 0
to to 0 0 0 0 0 0 0 0 2 0 IN JJ TO NNP VBD early-mid
mid-metaphase, mid-metaphase, 0 0 1 0 1 0 0 0 14 0 JJ TO NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 TO NNP VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN CD IN O
four four 0 0 0 0 0 0 0 0 4 0 VBN IN CD IN CD O
of of 0 0 0 0 0 0 0 0 2 0 IN CD IN CD NNP O
eight eight 0 0 0 0 0 0 0 0 5 0 CD IN CD NNP NNP O
females. females. 0 0 0 0 0 0 0 0 8 0 IN CD NNP NNP DT O
Therefore, Therefore, 1 0 0 0 1 0 0 0 10 0 CD NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
stage stage 0 0 0 0 0 0 0 0 5 0 NNP DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NN IN NN NN VBD O
contraction contraction 0 0 0 0 0 0 0 0 11 0 IN NN NN VBD DT O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN VBD DT JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 VBD DT JJ NN IN O
factor factor 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN JJR O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN JJR NNS O
more more 0 0 0 0 0 0 0 0 4 0 NN IN JJR NNS VBN O
folds folds 0 0 0 0 0 0 0 0 5 0 IN JJR NNS VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 JJR NNS VBN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NNS VBN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNS CC O
centromeres centromeres 0 0 0 0 0 0 0 0 11 0 IN DT NNS CC IN O
and and 0 0 0 0 0 0 0 0 3 0 DT NNS CC IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNS CC IN NN NNS O
longer longer 0 0 0 0 0 0 0 0 6 0 CC IN NN NNS IN O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 IN NN NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NN O
early early 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NN VBN metaphase
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 IN JJ NN VBN IN metaphase
compared compared 0 0 0 0 0 0 0 0 8 0 JJ NN VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN VBN IN JJ TO O
mid- mid- 0 0 1 0 0 0 0 0 4 0 VBN IN JJ TO JJ metaphase
to to 0 0 0 0 0 0 0 0 2 0 IN JJ TO JJ NNP metaphase
late late 0 0 0 0 0 0 0 0 4 0 JJ TO JJ NNP NNP metaphase
metaphase. metaphase. 0 0 0 0 0 0 0 0 10 0 TO JJ NNP NNP NN O
X X 1 1 0 0 0 0 0 0 1 0 JJ NNP NNP NN NNS O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NNP NNP NN NNS VBD O
folds folds 0 0 0 0 0 0 0 0 5 0 NNP NN NNS VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD JJ IN O
present present 0 0 0 0 0 0 0 0 7 0 NNS VBD JJ IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 VBD JJ IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ IN NNS IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN NNS VBN O
subjects subjects 0 0 0 0 0 0 0 0 8 0 NNS IN NNS VBN IN O
treated treated 0 0 0 0 0 0 0 0 7 0 IN NNS VBN IN CC O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBN IN CC IN O
or or 0 0 0 0 0 0 0 0 2 0 VBN IN CC IN NNP O
without without 0 0 0 0 0 0 0 0 7 0 IN CC IN NNP NNP O
bromodeoxyuridine. bromodeoxyuridine. 0 0 0 0 0 0 0 0 18 0 CC IN NNP NNP PRP$ O
While While 1 0 0 0 0 0 0 0 5 0 IN NNP NNP PRP$ NN O
our our 0 0 0 0 0 0 0 0 3 0 NNP NNP PRP$ NN NNS O
study study 0 0 0 0 0 0 0 0 5 0 NNP PRP$ NN NNS IN O
agrees agrees 0 0 0 0 0 0 0 0 6 0 PRP$ NN NNS IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
relationship relationship 0 0 0 0 0 0 0 0 12 0 IN DT NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN -NONE- JJ O
Xq13-q21 Xq13-q21 1 0 1 0 0 0 0 1 8 0 NN IN -NONE- JJ IN O
fold fold 0 0 0 0 0 0 0 0 4 0 IN -NONE- JJ IN DT O
with with 0 0 0 0 0 0 0 0 4 0 -NONE- JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN NN O
X-inactivation X-inactivation 1 0 1 0 0 0 0 0 14 0 IN DT NN NN DT O
center, center, 0 0 0 0 1 0 0 0 7 0 DT NN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NN IN O
correlation correlation 0 0 0 0 0 0 0 0 11 0 NN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
extended extended 0 0 0 0 0 0 0 0 8 0 NN IN JJ NNS CC O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 IN JJ NNS CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC VBG NNS O
folding folding 0 0 0 0 0 0 0 0 7 0 NNS CC VBG NNS DT O
limits limits 0 0 0 0 0 0 0 0 6 0 CC VBG NNS DT NN O
this this 0 0 0 0 0 0 0 0 4 0 VBG NNS DT NN IN O
method method 0 0 0 0 0 0 0 0 6 0 NNS DT NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
sole sole 0 0 0 0 0 0 0 0 4 0 IN DT JJ NN IN O
indicator indicator 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
X-inactivation X-inactivation 1 0 1 0 0 0 0 0 14 0 NN IN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NN O
routine routine 0 0 0 0 0 0 0 0 7 0 NN IN NN NN CC O
mid-metaphase, mid-metaphase, 0 0 1 0 1 0 0 0 14 0 IN NN NN CC VBZ O
but but 0 0 0 0 0 0 0 0 3 0 NN NN CC VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN CC VBZ JJ IN O
useful useful 0 0 0 0 0 0 0 0 6 0 CC VBZ JJ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBZ JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN IN O
analysis analysis 0 0 0 0 0 0 0 0 8 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
early early 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NNP metaphase
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 IN JJ NN NNP NNP metaphase
chromosomes. chromosomes. 0 0 0 0 0 0 0 0 12 0 JJ NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
3565471 3565471 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Effect Effect 1 0 0 0 0 0 0 0 6 0 NONE NONE NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN JJ JJ O
inspiratory-phase inspiratory-phase 0 0 1 0 0 0 0 0 17 0 NN IN JJ JJ NN O
negative negative 0 0 0 0 0 0 0 0 8 0 IN JJ JJ NN VBG O
pressure pressure 0 0 0 0 0 0 0 0 8 0 JJ JJ NN VBG IN O
breathing breathing 0 0 0 0 0 0 0 0 9 0 JJ NN VBG IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NN VBG IN NN NN O
urine urine 0 0 0 0 0 0 0 0 5 0 VBG IN NN NN IN O
flow flow 0 0 0 0 0 0 0 0 4 0 IN NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
man. man. 0 0 0 0 0 0 0 0 4 0 NN IN NNP NNP NNP O
Hebden Hebden 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
RA, RA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Freund Freund 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
BJ, BJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Claybaugh Claybaugh 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
JR, JR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Ichimura Ichimura 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
WM, WM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Hashiro Hashiro 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
GM. GM. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Clinical Clinical 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Investigation, Investigation, 1 0 0 0 1 0 0 0 14 0 IN NNP NNP NNP NNP O
Tripler Tripler 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Army Army 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Center, Center, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
HI HI 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
96859-5000. 96859-5000. 0 0 1 0 0 0 0 1 11 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBD DT O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NNP NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 VBD DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
negative negative 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN VBG O
pressure pressure 0 0 0 0 0 0 0 0 8 0 IN JJ NN VBG IN O
breathing breathing 0 0 0 0 0 0 0 0 9 0 JJ NN VBG IN DT O
during during 0 0 0 0 0 0 0 0 6 0 NN VBG IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBG IN DT NN NN O
inspiratory inspiratory 0 0 0 0 0 0 0 0 11 phase IN DT NN NN RB O
phase phase 0 0 0 0 0 0 0 0 5 0 DT NN NN RB JJ O
only only 0 0 0 0 0 0 0 0 4 0 NN NN RB JJ NN O
(intermittent (intermittent 0 0 0 0 0 0 0 0 13 0 NN RB JJ NN IN O
NPB) NPB) 1 1 0 0 0 0 0 0 4 0 RB JJ NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN CD JJ O
9 9 0 0 0 0 0 0 1 1 1 0 NN IN CD JJ JJ O
healthy healthy 0 0 0 0 0 0 0 0 7 0 IN CD JJ JJ NNS O
male male 0 0 0 0 0 0 0 0 4 0 CD JJ JJ NNS WP O
subjects subjects 0 0 0 0 0 0 0 0 8 0 JJ JJ NNS WP VBD O
who who 0 0 0 0 0 0 0 0 3 0 JJ NNS WP VBD IN O
were were 0 0 0 0 0 0 0 0 4 0 NNS WP VBD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 WP VBD IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBD IN DT NN NN O
sitting sitting 0 0 0 0 0 0 0 0 7 0 IN DT NN NN CC O
position position 0 0 0 0 0 0 0 0 8 0 DT NN NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBD DT O
had had 0 0 0 0 0 0 0 0 3 0 NN CC VBD DT NN O
no no 0 0 0 0 0 0 0 0 2 0 CC VBD DT NN CC O
food food 0 0 0 0 0 0 0 0 4 0 VBD DT NN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 DT NN CC NN NN O
fluid fluid 0 0 0 0 0 0 0 0 5 0 NN CC NN NN IN O
intake intake 0 0 0 0 0 0 0 0 6 0 CC NN NN IN CD O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN CD NN O
12 12 0 0 0 0 0 0 1 1 2 0 NN IN CD NN IN O
h h 0 0 0 0 0 0 0 0 1 0 IN CD NN IN DT O
before before 0 0 0 0 0 0 0 0 6 0 CD NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
study. study. 0 0 0 0 0 0 0 0 6 0 IN DT NNP NNP NNP O
Intermittent Intermittent 1 0 0 0 0 0 0 0 12 0 DT NNP NNP NNP VBD O
NPB NPB 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP VBD IN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD IN NN O
without without 0 0 0 0 0 0 0 0 7 0 NNP VBD IN NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 VBD IN NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NN O
urine urine 0 0 0 0 0 0 0 0 5 0 NN IN NN NN CC O
flow flow 0 0 0 0 0 0 0 0 4 0 IN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
urinary urinary 0 0 0 0 0 0 0 0 7 0 NN CC JJ NN NN O
sodium sodium 0 0 0 0 0 0 0 0 6 0 CC JJ NN NN CC O
excretion excretion 0 0 0 0 0 0 0 0 9 0 JJ NN NN CC VBD O
but but 0 0 0 0 0 0 0 0 3 0 NN NN CC VBD DT O
caused caused 0 0 0 0 0 0 0 0 6 0 NN CC VBD DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 CC VBD DT JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 VBD DT JJ NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNP O
creatinine creatinine 0 0 0 0 0 0 0 0 10 0 NN IN NN NNP NNP O
clearance. clearance. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP NN O
Plasma Plasma 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NN NN O
renin renin 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NN VBD O
activity activity 0 0 0 0 0 0 0 0 8 0 NNP NN NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD RB -NONE- O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NN VBD RB -NONE- RB O
reduced, reduced, 0 0 0 0 1 0 0 0 8 0 VBD RB -NONE- RB VB O
whereas whereas 0 0 0 0 0 0 0 0 7 0 RB -NONE- RB VB JJ O
plasma plasma 0 0 0 0 0 0 0 0 6 0 -NONE- RB VB JJ NN O
antidiuretic antidiuretic 0 0 0 0 0 0 0 0 12 0 RB VB JJ NN NN O
hormone hormone 0 0 0 0 0 0 0 0 7 0 VB JJ NN NN NN O
(ADH), (ADH), 0 1 0 0 1 0 0 0 6 0 JJ NN NN NN JJ O
atrial atrial 0 0 0 0 0 0 0 0 6 0 NN NN NN JJ NN O
natriuretic natriuretic 0 0 0 0 0 0 0 0 11 0 NN NN JJ NN NN O
factor factor 0 0 0 0 0 0 0 0 6 0 NN JJ NN NN CC O
(ANF), (ANF), 0 1 0 0 1 0 0 0 6 0 JJ NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NNS O
aldosterone aldosterone 0 0 0 0 0 0 0 0 11 0 NN CC NN NNS VBD O
levels levels 0 0 0 0 0 0 0 0 6 0 CC NN NNS VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD NNP TO O
unaffected. unaffected. 0 0 0 0 0 0 0 0 11 0 NNS VBD NNP TO VB O
To To 1 0 0 0 0 0 0 0 2 0 VBD NNP TO VB IN O
determine determine 0 0 0 0 0 0 0 0 9 0 NNP TO VB IN DT O
whether whether 0 0 0 0 0 0 0 0 7 0 TO VB IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 VB IN DT VBN JJ O
blunted blunted 0 0 0 0 0 0 0 0 7 0 IN DT VBN JJ NN O
urinary urinary 0 0 0 0 0 0 0 0 7 0 DT VBN JJ NN TO O
response response 0 0 0 0 0 0 0 0 8 0 VBN JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB NNP O
intermittent intermittent 0 0 0 0 0 0 0 0 12 0 NN TO VB NNP VBD O
NPB NPB 1 1 0 0 0 0 0 0 3 0 TO VB NNP VBD DT O
was was 0 0 0 0 0 0 0 0 3 0 VB NNP VBD DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBD DT JJ NN O
postural postural 0 0 0 0 0 0 0 0 8 0 VBD DT JJ NN DT O
phenomenon, phenomenon, 0 0 0 0 1 0 0 0 11 0 DT JJ NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NN DT NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD VBN IN O
repeated repeated 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN CD IN O
6 6 0 0 0 0 0 0 1 1 1 0 VBN IN CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN CD IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT NNS IN O
subjects subjects 0 0 0 0 0 0 0 0 8 0 IN DT NNS IN NNP O
while while 0 0 0 0 0 0 0 0 5 0 DT NNS IN NNP NNP O
supine. supine. 0 0 0 0 0 0 0 0 7 0 NNS IN NNP NNP DT O
Under Under 1 0 0 0 0 0 0 0 5 0 IN NNP NNP DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT NNS RB O
conditions conditions 0 0 0 0 0 0 0 0 10 0 NNP DT NNS RB VBD O
there there 0 0 0 0 0 0 0 0 5 0 DT NNS RB VBD DT O
was was 0 0 0 0 0 0 0 0 3 0 NNS RB VBD DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 RB VBD DT JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 VBD DT JJ NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
urine urine 0 0 0 0 0 0 0 0 5 0 NN IN NN NN CC O
flow flow 0 0 0 0 0 0 0 0 4 0 IN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NNP O
plasma plasma 0 0 0 0 0 0 0 0 6 0 NN CC NN NNP NNP O
ANF ANF 1 1 0 0 0 0 0 0 3 0 CC NN NNP NNP CC O
levels, levels, 0 0 0 0 1 0 0 0 7 0 NN NNP NNP CC DT O
but but 0 0 0 0 0 0 0 0 3 0 NNP NNP CC DT NN O
no no 0 0 0 0 0 0 0 0 2 0 NNP CC DT NN IN O
change change 0 0 0 0 0 0 0 0 6 0 CC DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
all all 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ VBN O
other other 0 0 0 0 0 0 0 0 5 0 IN DT JJ VBN NNP O
measured measured 0 0 0 0 0 0 0 0 8 0 DT JJ VBN NNP NNP O
variables. variables. 0 0 0 0 0 0 0 0 10 0 JJ VBN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 VBN NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNS VBP JJ IN O
consistent consistent 0 0 0 0 0 0 0 0 10 0 NNS VBP JJ IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBP JJ IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 JJ IN DT NN IN O
role role 0 0 0 0 0 0 0 0 4 0 IN DT NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN NN CC O
ANF, ANF, 1 1 0 0 1 0 0 0 4 0 NN IN NN CC RB O
but but 0 0 0 0 0 0 0 0 3 0 IN NN CC RB JJ O
not not 0 0 0 0 0 0 0 0 3 0 NN CC RB JJ IN O
ADH, ADH, 1 1 0 0 1 0 0 0 4 0 CC RB JJ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 RB JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN VBN O
diuresis diuresis 0 0 0 0 0 0 0 0 8 0 IN DT NN VBN IN O
seen seen 0 0 0 0 0 0 0 0 4 0 DT NN VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN VBN IN NN NNS O
supine supine 0 0 0 0 0 0 0 0 6 0 VBN IN NN NNS IN O
subjects subjects 0 0 0 0 0 0 0 0 8 0 IN NN NNS IN NNP O
during during 0 0 0 0 0 0 0 0 6 0 NN NNS IN NNP NNP O
NPB. NPB. 1 1 0 0 0 0 0 0 4 0 NNS IN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 IN NNP NNP CD JJ O
1531561 1531561 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Bone Bone 1 0 0 0 0 0 0 0 4 0 NONE NONE NN NN NNS O
marrow marrow 0 0 0 0 0 0 0 0 6 0 NONE NN NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
DNA-synthesis-phase DNA-synthesis-phase 1 0 1 0 0 0 0 0 19 0 IN DT NN IN DT B_TIMEXCCP
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
myelodysplastic myelodysplastic 0 0 0 0 0 0 0 0 15 0 IN DT JJ NN CC O
syndrome syndrome 0 0 0 0 0 0 0 0 8 0 DT JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP NNP O
lymphome. lymphome. 0 0 0 0 0 0 0 0 9 0 NN CC NNP NNP NNP O
Wenthzel Wenthzel 1 0 0 0 0 0 0 0 8 0 CC NNP NNP NNP NNP O
AM, AM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Porwit Porwit 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lindahl Lindahl 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Widell Widell 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Reizenstein Reizenstein 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
P. P. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Hematology Hematology 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Laboratory, Laboratory, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Karolinska Karolinska 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Hospital, Hospital, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Stockholm, Stockholm, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Sweden. Sweden. 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN -NONE- O
bromodeoxyuridine bromodeoxyuridine 0 0 0 0 0 0 0 0 17 0 NNP NNP NN -NONE- VBG O
(BRDU) (BRDU) 0 1 0 0 0 0 0 0 6 0 NNP NN -NONE- VBG IN O
labelling labelling 0 0 0 0 0 0 0 0 9 0 NN -NONE- VBG IN NN O
of of 0 0 0 0 0 0 0 0 2 0 -NONE- VBG IN NN NN O
bone bone 0 0 0 0 0 0 0 0 4 0 VBG IN NN NN NNS O
marrow marrow 0 0 0 0 0 0 0 0 6 0 IN NN NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NNS VBD VBN IN O
studied studied 0 0 0 0 0 0 0 0 7 0 NNS VBD VBN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN CD NNP O
46 46 0 0 0 0 0 0 1 1 2 0 VBN IN CD NNP NNP O
subjects. subjects. 0 0 0 0 0 0 0 0 9 0 IN CD NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 CD NNP NNP NN IN O
labelling labelling 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN CD NN O
14 14 0 0 0 0 0 0 1 1 2 0 NN IN CD NN RB O
patients, patients, 0 0 0 0 1 0 0 0 9 0 IN CD NN RB JJ O
mostly mostly 0 0 0 0 0 0 0 0 6 0 CD NN RB JJ IN O
untreated, untreated, 0 0 0 0 1 0 0 0 10 0 NN RB JJ IN DT O
with with 0 0 0 0 0 0 0 0 4 0 RB JJ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT JJ NN O
myelodysplastic myelodysplastic 0 0 0 0 0 0 0 0 15 0 IN DT JJ NN NN O
syndrome syndrome 0 0 0 0 0 0 0 0 8 0 DT JJ NN NN CC O
(MDS) (MDS) 0 1 0 0 0 0 0 0 5 0 JJ NN NN CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC CD NN O
four four 0 0 0 0 0 0 0 0 4 0 NN CC CD NN NNS O
lymphoma lymphoma 0 0 0 0 0 0 0 0 8 0 CC CD NN NNS VBD O
patients patients 0 0 0 0 0 0 0 0 8 0 CD NN NNS VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NN NNS VBD RB JJ O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNS VBD RB JJ NN O
(p (p 0 0 0 0 0 0 0 0 2 0 VBD RB JJ NN CD O
= = 0 0 0 0 0 0 0 0 1 0 RB JJ NN CD JJR O
0.043) 0.043) 0 0 0 0 0 0 0 1 6 0 JJ NN CD JJR -NONE- O
higher higher 0 0 0 0 0 0 0 0 6 0 NN CD JJR -NONE- : O
(11.38 (11.38 0 0 0 0 0 0 0 1 6 0 CD JJR -NONE- : NNP O
+/- +/- 0 0 1 1 0 0 0 0 3 0 JJR -NONE- : NNP CD O
SE SE 1 1 0 0 0 0 0 0 2 0 -NONE- : NNP CD NN O
2.3% 2.3% 0 0 0 0 0 0 0 1 4 0 : NNP CD NN -NONE- O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 NNP CD NN -NONE- IN O
cells) cells) 0 0 0 0 0 0 0 0 6 0 CD NN -NONE- IN DT O
than than 0 0 0 0 0 0 0 0 4 0 NN -NONE- IN DT IN O
that that 0 0 0 0 0 0 0 0 4 0 -NONE- IN DT IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN DT IN NN NNS O
marrow marrow 0 0 0 0 0 0 0 0 6 0 DT IN NN NNS -NONE- O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NN NNS -NONE- : O
(7.18 (7.18 0 0 0 0 0 0 0 1 5 0 NN NNS -NONE- : NNP O
+/- +/- 0 0 1 1 0 0 0 0 3 0 NNS -NONE- : NNP CD O
SE SE 1 1 0 0 0 0 0 0 2 0 -NONE- : NNP CD IN O
1.04%) 1.04%) 0 0 0 0 0 0 0 1 6 0 : NNP CD IN CD O
from from 0 0 0 0 0 0 0 0 4 0 NNP CD IN CD RB O
14 14 0 0 0 0 0 0 1 1 2 0 CD IN CD RB JJ O
apparently apparently 0 0 0 0 0 0 0 0 10 0 IN CD RB JJ JJ O
healthy healthy 0 0 0 0 0 0 0 0 7 0 CD RB JJ JJ NNS O
normal normal 0 0 0 0 0 0 0 0 6 0 RB JJ JJ NNS CC O
controls controls 0 0 0 0 0 0 0 0 8 0 JJ JJ NNS CC IN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC IN CD O
from from 0 0 0 0 0 0 0 0 4 0 NNS CC IN CD NNS O
nine nine 0 0 0 0 0 0 0 0 4 0 CC IN CD NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 IN CD NNS IN NN O
with with 0 0 0 0 0 0 0 0 4 0 CD NNS IN NN NN O
non non 0 0 0 0 0 0 0 0 3 0 NNS IN NN NN NNP O
hematologic hematologic 0 0 0 0 0 0 0 0 11 0 IN NN NN NNP NNP O
disease. disease. 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP NN O
Six Six 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN NN O
iron iron 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN VBD O
deficiency deficiency 0 0 0 0 0 0 0 0 10 0 NNP NN NN VBD RB O
had had 0 0 0 0 0 0 0 0 3 0 NN NN VBD RB CC O
numerically numerically 0 0 0 0 0 0 0 0 11 0 NN VBD RB CC RB O
but but 0 0 0 0 0 0 0 0 3 0 VBD RB CC RB RB O
not not 0 0 0 0 0 0 0 0 3 0 RB CC RB RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 CC RB RB VBN NNP O
increased increased 0 0 0 0 0 0 0 0 9 0 RB RB VBN NNP NNP O
values. values. 0 0 0 0 0 0 0 0 7 0 RB VBN NNP NNP NN O
Bone Bone 1 0 0 0 0 0 0 0 4 0 VBN NNP NNP NN NNS O
marrow marrow 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NNS IN O
samples samples 0 0 0 0 0 0 0 0 7 0 NNP NN NNS IN NNS O
from from 0 0 0 0 0 0 0 0 4 0 NN NNS IN NNS VBG O
MDS-patients MDS-patients 1 0 1 0 0 0 0 0 12 0 NNS IN NNS VBG DT O
showing showing 0 0 0 0 0 0 0 0 7 0 IN NNS VBG DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBG DT JJS NNS O
highest highest 0 0 0 0 0 0 0 0 7 0 VBG DT JJS NNS IN O
numbers numbers 0 0 0 0 0 0 0 0 7 0 DT JJS NNS IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJS NNS IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNS IN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
DNA-synthesis DNA-synthesis 1 0 1 0 0 0 0 0 13 phase IN DT NN NN VBD B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NN NN VBD DT O
had had 0 0 0 0 0 0 0 0 3 0 NN NN VBD DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 NN VBD DT JJS NNS O
lowest lowest 0 0 0 0 0 0 0 0 6 0 VBD DT JJS NNS IN O
numbers numbers 0 0 0 0 0 0 0 0 7 0 DT JJS NNS IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJS NNS IN NNS CC O
colonies colonies 0 0 0 0 0 0 0 0 8 0 NNS IN NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC NNS IN O
clusters clusters 0 0 0 0 0 0 0 0 8 0 NNS CC NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 CC NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
CFU-C CFU-C 1 1 1 0 0 0 0 0 5 0 IN DT JJ NN NN O
assay assay 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN : O
(p (p 0 0 0 0 0 0 0 0 2 0 JJ NN NN : CD O
< < 0 0 0 0 0 0 0 0 1 0 NN NN : CD DT O
0.03). 0.03). 0 0 0 0 0 0 0 1 6 0 NN : CD DT NNS O
The The 1 0 0 0 0 0 0 0 3 0 : CD DT NNS VBP O
data data 0 0 0 0 0 0 0 0 4 0 CD DT NNS VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 DT NNS VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NN NN O
DNA-synthesis DNA-synthesis 1 0 1 0 0 0 0 0 13 0 IN DT NN NN VBZ B_TIMEXCCP
period period 0 0 0 0 0 0 0 0 6 0 DT NN NN VBZ JJR O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ JJR IN O
longer longer 0 0 0 0 0 0 0 0 6 0 NN VBZ JJR IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBZ JJR IN NNP IN O
MDS MDS 1 1 0 0 0 0 0 0 3 0 JJR IN NNP IN IN O
than than 0 0 0 0 0 0 0 0 4 0 IN NNP IN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP IN IN NNP NNP O
controls. controls. 0 0 0 0 0 0 0 0 9 0 IN IN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 IN NNP NNP CD JJ O
1341321 1341321 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Genotoxicity Genotoxicity 1 0 0 0 0 0 0 0 12 0 NONE NONE NN VBG IN O
screening screening 0 0 0 0 0 0 0 0 9 0 NONE NN VBG IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN VBG IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBG IN DT NN NNP O
river river 0 0 0 0 0 0 0 0 5 0 IN DT NN NNP IN O
Rasina Rasina 1 0 0 0 0 0 0 0 6 0 DT NN NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NNP IN NNP NN O
Serbia Serbia 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NN DT O
using using 0 0 0 0 0 0 0 0 5 0 IN NNP NN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT NNP NNP O
Allium Allium 1 0 0 0 0 0 0 0 6 0 NN DT NNP NNP NNP O
anaphase-telophase anaphase-telophase 0 0 1 0 0 0 0 0 18 0 DT NNP NNP NNP NNP B_TIMEXCCP
test. test. 0 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Vujosević Vujosević 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Andelković Andelković 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Savić Savić 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Blagojević Blagojević 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
J. J. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Genetic Genetic 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
Research, Research, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNP O
Biological Biological 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
Sinisa Sinisa 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP CD O
Stanković, Stanković, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP CD -NONE- O
11060, 11060, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD -NONE- NNP O
Belgrade, Belgrade, 1 0 0 0 1 0 0 0 9 0 NNP CD -NONE- NNP NNP O
Serbia. Serbia. 1 0 0 0 0 0 0 0 7 0 CD -NONE- NNP NNP NNP O
mladenvu@ibiss.bg.ac.yu mladenvu@ibiss.bg.ac.yu 0 0 0 0 0 0 0 0 23 0 -NONE- NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Evaluation Evaluation 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN IN O
presence presence 0 0 0 0 0 0 0 0 8 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
genotoxic genotoxic 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNS VBZ O
substances substances 0 0 0 0 0 0 0 0 10 0 IN JJ NNS VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 JJ NNS VBZ RB JJ O
especially especially 0 0 0 0 0 0 0 0 10 0 NNS VBZ RB JJ IN O
important important 0 0 0 0 0 0 0 0 9 0 VBZ RB JJ IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 RB JJ IN NNS WDT O
rivers rivers 0 0 0 0 0 0 0 0 6 0 JJ IN NNS WDT VB O
that that 0 0 0 0 0 0 0 0 4 0 IN NNS WDT VB IN O
serve serve 0 0 0 0 0 0 0 0 5 0 NNS WDT VB IN DT O
as as 0 0 0 0 0 0 0 0 2 0 WDT VB IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VB IN DT NN IN O
source source 0 0 0 0 0 0 0 0 6 0 IN DT NN IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN VBG NNP O
drinking drinking 0 0 0 0 0 0 0 0 8 0 NN IN VBG NNP NNP O
water. water. 0 0 0 0 0 0 0 0 6 0 IN VBG NNP NNP NN O
Nine Nine 1 0 0 0 0 0 0 0 4 0 VBG NNP NNP NN NNS O
water water 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NNS VBN O
samples samples 0 0 0 0 0 0 0 0 7 0 NNP NN NNS VBN IN O
collected collected 0 0 0 0 0 0 0 0 9 0 NN NNS VBN IN DT O
along along 0 0 0 0 0 0 0 0 5 0 NNS VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NNP O
river river 0 0 0 0 0 0 0 0 5 0 IN DT NN NNP IN O
Rasina Rasina 1 0 0 0 0 0 0 0 6 0 DT NN NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NNP IN NNP VBD O
Serbia Serbia 1 0 0 0 0 0 0 0 6 0 NNP IN NNP VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 IN NNP VBD VBN IN O
analyzed analyzed 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN JJ JJ O
potential potential 0 0 0 0 0 0 0 0 9 0 VBN IN JJ JJ CC O
toxic toxic 0 0 0 0 0 0 0 0 5 0 IN JJ JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ JJ CC JJ NNS O
genotoxic genotoxic 0 0 0 0 0 0 0 0 9 0 JJ CC JJ NNS VBG O
effects effects 0 0 0 0 0 0 0 0 7 0 CC JJ NNS VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 JJ NNS VBG DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBG DT NNP NNP O
Allium Allium 1 0 0 0 0 0 0 0 6 0 VBG DT NNP NNP NNP O
anaphase-telophase anaphase-telophase 0 0 1 0 0 0 0 0 18 0 DT NNP NNP NNP NNP B_TIMEXCCP
test. test. 0 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP IN O
Inhibition Inhibition 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN NN O
root root 0 0 0 0 0 0 0 0 4 0 NNP IN NN NN JJ O
growth growth 0 0 0 0 0 0 0 0 6 0 IN NN NN JJ TO O
relative relative 0 0 0 0 0 0 0 0 8 0 NN NN JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN JJ TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ TO DT JJ NN O
negative negative 0 0 0 0 0 0 0 0 8 0 TO DT JJ NN JJ O
control control 0 0 0 0 0 0 0 0 7 0 DT JJ NN JJ NN O
(synthetic (synthetic 0 0 0 0 0 0 0 0 10 0 JJ NN JJ NN VBD O
water) water) 0 0 0 0 0 0 0 0 6 0 NN JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NNP O
all all 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NNP O
samples. samples. 0 0 0 0 0 0 0 0 8 0 IN DT NNP NNP IN O
Analysis Analysis 1 0 0 0 0 0 0 0 8 0 DT NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ NN O
genotoxic genotoxic 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN IN O
potential, potential, 0 0 0 0 1 0 0 0 10 0 DT JJ NN IN VBG O
through through 0 0 0 0 0 0 0 0 7 0 JJ NN IN VBG NN O
scoring scoring 0 0 0 0 0 0 0 0 7 0 NN IN VBG NN CC O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 IN VBG NN CC NN B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 VBG NN CC NN NN O
telophase telophase 0 0 0 0 0 0 0 0 9 0 NN CC NN NN VBD B_TIMEXCCP
aberrations, aberrations, 0 0 0 0 1 0 0 0 12 0 CC NN NN VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NN NN VBD IN IN O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 VBD IN IN CD IN O
seven seven 0 0 0 0 0 0 0 0 5 0 IN IN CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN CD IN DT CD O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT CD NNS O
nine nine 0 0 0 0 0 0 0 0 4 0 IN DT CD NNS DT O
samples samples 0 0 0 0 0 0 0 0 7 0 DT CD NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CD NNS DT NN IN O
level level 0 0 0 0 0 0 0 0 5 0 NNS DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS VBD O
aberrations aberrations 0 0 0 0 0 0 0 0 11 0 NN IN NNS VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 IN NNS VBD RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNS VBD RB VBN JJ O
increased increased 0 0 0 0 0 0 0 0 9 0 VBD RB VBN JJ TO O
relative relative 0 0 0 0 0 0 0 0 8 0 RB VBN JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBN JJ TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ TO DT JJ NN O
negative negative 0 0 0 0 0 0 0 0 8 0 TO DT JJ NN CC O
control control 0 0 0 0 0 0 0 0 7 0 DT JJ NN CC VBD O
but but 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBD JJR O
was was 0 0 0 0 0 0 0 0 3 0 NN CC VBD JJR IN O
lower lower 0 0 0 0 0 0 0 0 5 0 CC VBD JJR IN DT O
than than 0 0 0 0 0 0 0 0 4 0 VBD JJR IN DT VBN O
that that 0 0 0 0 0 0 0 0 4 0 JJR IN DT VBN IN O
obtained obtained 0 0 0 0 0 0 0 0 8 0 IN DT VBN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 DT VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
positive positive 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN NN O
control control 0 0 0 0 0 0 0 0 7 0 DT JJ NN NN NNP O
(methyl (methyl 0 0 0 0 0 0 0 0 7 0 JJ NN NN NNP NNP O
methanesulfonate). methanesulfonate). 0 0 0 0 0 0 0 0 18 0 NN NN NNP NNP IN O
Changes Changes 1 0 0 0 0 0 0 0 7 0 NN NNP NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN IN O
relation relation 0 0 0 0 0 0 0 0 8 0 IN DT NN IN NN O
between between 0 0 0 0 0 0 0 0 7 0 DT NN IN NN CC O
spindle spindle 0 0 0 0 0 0 0 0 7 0 NN IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN NNS O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NN CC NN NNS IN O
types types 0 0 0 0 0 0 0 0 5 0 CC NN NNS IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNS VBD O
aberrations aberrations 0 0 0 0 0 0 0 0 11 0 NNS IN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 IN NNS VBD VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 NNS VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT JJ O
some some 0 0 0 0 0 0 0 0 4 0 VBN IN DT JJ NN O
samples, samples, 0 0 0 0 1 0 0 0 8 0 IN DT JJ NN NNS O
indicating indicating 0 0 0 0 0 0 0 0 10 0 DT JJ NN NNS IN O
differences differences 0 0 0 0 0 0 0 0 11 0 JJ NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
potential potential 0 0 0 0 0 0 0 0 9 0 IN DT NN NN NNS O
genotoxic genotoxic 0 0 0 0 0 0 0 0 9 0 DT NN NN NNS NN O
substances substances 0 0 0 0 0 0 0 0 10 0 NN NN NNS NN IN O
present present 0 0 0 0 0 0 0 0 7 0 NN NNS NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NNS NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
analyzed analyzed 0 0 0 0 0 0 0 0 8 0 IN DT JJ NNP NNP O
sites. sites. 0 0 0 0 0 0 0 0 6 0 DT JJ NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NNP WDT O
data, data, 0 0 0 0 1 0 0 0 5 0 NNP NNP NNP WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 NNP NNP WDT VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP WDT VBD VBN IN O
obtained obtained 0 0 0 0 0 0 0 0 8 0 WDT VBD VBN IN NNS O
from from 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNS VBN O
samples samples 0 0 0 0 0 0 0 0 7 0 VBN IN NNS VBN IN O
collected collected 0 0 0 0 0 0 0 0 9 0 IN NNS VBN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NNS VBN IN DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJS NN O
highest highest 0 0 0 0 0 0 0 0 7 0 IN DT JJS NN IN O
level level 0 0 0 0 0 0 0 0 5 0 DT JJS NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJS NN IN NN -NONE- O
river river 0 0 0 0 0 0 0 0 5 0 NN IN NN -NONE- NN O
water, water, 0 0 0 0 1 0 0 0 6 0 IN NN -NONE- NN WDT O
warn warn 0 0 0 0 0 0 0 0 4 0 NN -NONE- NN WDT IN O
that that 0 0 0 0 0 0 0 0 4 0 -NONE- NN WDT IN NNS O
during during 0 0 0 0 0 0 0 0 6 0 NN WDT IN NNS IN O
periods periods 0 0 0 0 0 0 0 0 7 0 WDT IN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN JJ NN O
low low 0 0 0 0 0 0 0 0 3 0 NNS IN JJ NN DT O
flow flow 0 0 0 0 0 0 0 0 4 0 IN JJ NN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NNS MD O
values values 0 0 0 0 0 0 0 0 6 0 NN DT NNS MD VB O
could could 0 0 0 0 0 0 0 0 5 0 DT NNS MD VB JJ O
reach reach 0 0 0 0 0 0 0 0 5 0 NNS MD VB JJ NNP O
genotoxic genotoxic 0 0 0 0 0 0 0 0 9 0 MD VB JJ NNP NNP O
activity. activity. 0 0 0 0 0 0 0 0 9 0 VB JJ NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NNP NNP O
Allium Allium 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NN O
anaphase-telophase anaphase-telophase 0 0 1 0 0 0 0 0 18 0 NNP NNP NNP NN MD B_TIMEXCCP
test test 0 0 0 0 0 0 0 0 4 0 NNP NNP NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NNP NN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB VBN IN O
recommended recommended 0 0 0 0 0 0 0 0 11 0 MD VB VBN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VB VBN IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 VBN IN DT NN NN O
monitoring monitoring 0 0 0 0 0 0 0 0 10 0 IN DT NN NN WDT O
system, system, 0 0 0 0 1 0 0 0 7 0 DT NN NN WDT MD O
that that 0 0 0 0 0 0 0 0 4 0 NN NN WDT MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN WDT MD VB IN O
serve serve 0 0 0 0 0 0 0 0 5 0 WDT MD VB IN DT O
as as 0 0 0 0 0 0 0 0 2 0 MD VB IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VB IN DT JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN IN O
alert alert 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
presence presence 0 0 0 0 0 0 0 0 8 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ JJ O
genotoxic genotoxic 0 0 0 0 0 0 0 0 9 0 NN IN JJ JJ NNP O
environmental environmental 0 0 0 0 0 0 0 0 13 0 IN JJ JJ NNP NNP O
pollutants. pollutants. 0 0 0 0 0 0 0 0 11 0 JJ JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
18080777 18080777 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Aggressive Aggressive 1 0 0 0 0 0 0 0 10 0 NONE NONE JJ PRP$ CC O
behaviour behaviour 0 0 0 0 0 0 0 0 9 0 NONE JJ PRP$ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ PRP$ CC JJ NNS O
physiological physiological 0 0 0 0 0 0 0 0 13 0 PRP$ CC JJ NNS TO O
responses responses 0 0 0 0 0 0 0 0 9 0 CC JJ NNS TO NNS O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO NNS VBP O
pheromones pheromones 0 0 0 0 0 0 0 0 10 0 NNS TO NNS VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 TO NNS VBP RB VBN O
strongly strongly 0 0 0 0 0 0 0 0 8 0 NNS VBP RB VBN IN O
impaired impaired 0 0 0 0 0 0 0 0 8 0 VBP RB VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN NN NN O
mice mice 0 0 0 0 0 0 0 0 4 0 VBN IN NN NN IN O
deficient deficient 0 0 0 0 0 0 0 0 9 0 IN NN NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
olfactory olfactory 0 0 0 0 0 0 0 0 9 0 IN DT NN NN NN O
G-protein G-protein 1 0 1 0 0 0 0 0 9 0 DT NN NN NN NNP O
γ-subunit, γ-subunit, 0 0 1 0 1 0 0 0 10 0 NN NN NN NNP NNP O
Gγ8. Gγ8. 1 0 0 0 0 0 0 1 4 0 NN NN NNP NNP NNP O
Montani Montani 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tonelli Tonelli 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sanghez Sanghez 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
V, V, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ferrari Ferrari 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
PF, PF, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Palanza Palanza 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zimmer Zimmer 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tirindelli Tirindelli 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
R. R. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Parma; Parma; 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
Heterotrimeric Heterotrimeric 1 0 0 0 0 0 0 0 14 0 NNP NNP NNP NNP VBP O
G-proteins G-proteins 1 0 1 0 0 0 0 0 10 0 NNP NNP NNP VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNP VBP JJ NNS O
critical critical 0 0 0 0 0 0 0 0 8 0 NNP VBP JJ NNS IN O
players players 0 0 0 0 0 0 0 0 7 0 VBP JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NNS O
transduction transduction 0 0 0 0 0 0 0 0 12 0 IN DT NN NNS VBG O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 DT NN NNS VBG JJ O
underlying underlying 0 0 0 0 0 0 0 0 10 0 NN NNS VBG JJ CC O
odorant odorant 0 0 0 0 0 0 0 0 7 0 NNS VBG JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBG JJ CC JJ NNP O
pheromonal pheromonal 0 0 0 0 0 0 0 0 10 0 JJ CC JJ NNP NNP O
signaling. signaling. 0 0 0 0 0 0 0 0 10 0 CC JJ NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN VBD O
vomeronasal vomeronasal 0 0 0 0 0 0 0 0 11 0 NNP DT NN VBD IN O
organ organ 0 0 0 0 0 0 0 0 5 0 DT NN VBD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN NN O
adult adult 0 0 0 0 0 0 0 0 5 0 IN DT NN NN CD O
mouse, mouse, 0 0 0 0 1 0 0 0 6 0 DT NN NN CD JJ O
two two 0 0 0 0 0 0 0 0 3 0 NN NN CD JJ JJ O
different different 0 0 0 0 0 0 0 0 9 0 NN CD JJ JJ NNS O
G-protein G-protein 1 0 1 0 0 0 0 0 9 0 CD JJ JJ NNS VBP O
complexes complexes 0 0 0 0 0 0 0 0 9 0 JJ JJ NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 JJ NNS VBP VBN NNP O
been been 0 0 0 0 0 0 0 0 4 0 NNS VBP VBN NNP -NONE- O
identified. identified. 0 0 0 0 0 0 0 0 11 0 VBP VBN NNP -NONE- VBZ O
Gαoβ2γ8 Gαoβ2γ8 1 0 0 0 0 0 0 1 7 0 VBN NNP -NONE- VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP -NONE- VBZ RB VBN O
preferentially preferentially 0 0 0 0 0 0 0 0 14 0 -NONE- VBZ RB VBN IN O
expressed expressed 0 0 0 0 0 0 0 0 9 0 VBZ RB VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NNS O
basal basal 0 0 0 0 0 0 0 0 5 0 IN DT NN NNS CC O
neurons neurons 0 0 0 0 0 0 0 0 7 0 DT NN NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NNS IN O
coexpresses coexpresses 0 0 0 0 0 0 0 0 11 0 NNS CC NNS IN -NONE- O
with with 0 0 0 0 0 0 0 0 4 0 CC NNS IN -NONE- JJ O
type-2 type-2 0 0 1 0 0 0 0 1 6 0 NNS IN -NONE- JJ NN O
vomeronasal vomeronasal 0 0 0 0 0 0 0 0 11 0 IN -NONE- JJ NN NNS O
pheromone pheromone 0 0 0 0 0 0 0 0 9 0 -NONE- JJ NN NNS -NONE- O
receptors receptors 0 0 0 0 0 0 0 0 9 0 JJ NN NNS -NONE- IN O
(V2Rs) (V2Rs) 0 0 0 0 0 0 0 1 6 0 NN NNS -NONE- IN -NONE- O
whereas whereas 0 0 0 0 0 0 0 0 7 0 NNS -NONE- IN -NONE- VBZ O
Gαi2β2γ2 Gαi2β2γ2 1 0 0 0 0 0 0 1 8 0 -NONE- IN -NONE- VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 IN -NONE- VBZ VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 -NONE- VBZ VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNS O
apical apical 0 0 0 0 0 0 0 0 6 0 IN DT JJ NNS CC O
neurons neurons 0 0 0 0 0 0 0 0 7 0 DT JJ NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC NNS IN O
coexpresses coexpresses 0 0 0 0 0 0 0 0 11 0 NNS CC NNS IN -NONE- O
with with 0 0 0 0 0 0 0 0 4 0 CC NNS IN -NONE- JJ O
type-1 type-1 0 0 1 0 0 0 0 1 6 0 NNS IN -NONE- JJ NN O
vomeronasal vomeronasal 0 0 0 0 0 0 0 0 11 0 IN -NONE- JJ NN NNS O
pheromone pheromone 0 0 0 0 0 0 0 0 9 0 -NONE- JJ NN NNS NNP O
receptors receptors 0 0 0 0 0 0 0 0 9 0 JJ NN NNS NNP JJ O
(V1Rs). (V1Rs). 0 0 0 0 0 0 0 1 7 0 NN NNS NNP JJ NNS O
V2R-expressing V2R-expressing 1 0 1 0 0 0 0 1 14 0 NNS NNP JJ NNS VBP O
neurons neurons 0 0 0 0 0 0 0 0 7 0 NNP JJ NNS VBP TO O
project project 0 0 0 0 0 0 0 0 7 0 JJ NNS VBP TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBP TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP TO DT NN NN O
posterior posterior 0 0 0 0 0 0 0 0 9 0 TO DT NN NN NN O
accessory accessory 0 0 0 0 0 0 0 0 9 0 DT NN NN NN NN O
olfactory olfactory 0 0 0 0 0 0 0 0 9 0 NN NN NN NN NN O
bulb bulb 0 0 0 0 0 0 0 0 4 0 NN NN NN NN NNS O
(AOB) (AOB) 0 1 0 0 0 0 0 0 5 0 NN NN NN NNS NNS O
whereas whereas 0 0 0 0 0 0 0 0 7 0 NN NN NNS NNS VBG O
neurons neurons 0 0 0 0 0 0 0 0 7 0 NN NNS NNS VBG NNS O
expressing expressing 0 0 0 0 0 0 0 0 10 0 NNS NNS VBG NNS VBP O
V1Rs V1Rs 1 0 0 0 0 0 0 1 4 0 NNS VBG NNS VBP PRP$ O
send send 0 0 0 0 0 0 0 0 4 0 VBG NNS VBP PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 NNS VBP PRP$ NN TO O
axon axon 0 0 0 0 0 0 0 0 4 0 VBP PRP$ NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 PRP$ NN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT NN NNP O
anterior anterior 0 0 0 0 0 0 0 0 8 0 TO DT NN NNP NNP O
AOB. AOB. 1 1 0 0 0 0 0 0 4 0 DT NN NNP NNP VBZ O
Gγ8 Gγ8 1 0 0 0 0 0 0 1 3 0 NN NNP NNP VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ RB VBN O
also also 0 0 0 0 0 0 0 0 4 0 NNP VBZ RB VBN IN O
expressed expressed 0 0 0 0 0 0 0 0 9 0 VBZ RB VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN NN NN O
developing developing 0 0 0 0 0 0 0 0 10 0 VBN IN NN NN NNS O
olfactory olfactory 0 0 0 0 0 0 0 0 9 0 IN NN NN NNS WRB O
neurons neurons 0 0 0 0 0 0 0 0 7 0 NN NN NNS WRB DT O
where where 0 0 0 0 0 0 0 0 5 0 NN NNS WRB DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNS WRB DT NN VBZ O
protein protein 0 0 0 0 0 0 0 0 7 0 WRB DT NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ RB VBN O
probably probably 0 0 0 0 0 0 0 0 8 0 NN VBZ RB VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 VBZ RB VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN NNP NNP O
Go. Go. 1 0 0 0 0 0 0 0 3 0 VBN IN NNP NNP PRP O
Here, Here, 1 0 0 0 1 0 0 0 5 0 IN NNP NNP PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD NN O
generated generated 0 0 0 0 0 0 0 0 9 0 NNP PRP VBD NN IN O
mice mice 0 0 0 0 0 0 0 0 4 0 PRP VBD NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBD NN IN DT VBN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT VBN NN O
targeted targeted 0 0 0 0 0 0 0 0 8 0 IN DT VBN NN IN O
deletion deletion 0 0 0 0 0 0 0 0 8 0 DT VBN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
Gγ8 Gγ8 1 0 0 0 0 0 0 1 3 0 IN DT JJ NN CC O
gene gene 0 0 0 0 0 0 0 0 4 0 DT JJ NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBD DT O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NN CC VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CC VBD DT JJ NNS O
behavioural behavioural 0 0 0 0 0 0 0 0 11 0 VBD DT JJ NNS CC O
effects effects 0 0 0 0 0 0 0 0 7 0 DT JJ NNS CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS CC DT JJ NNS O
physiological physiological 0 0 0 0 0 0 0 0 13 0 CC DT JJ NNS IN O
consequences consequences 0 0 0 0 0 0 0 0 12 0 DT JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NNP O
this this 0 0 0 0 0 0 0 0 4 0 NNS IN DT NNP NNP O
mutation. mutation. 0 0 0 0 0 0 0 0 9 0 IN DT NNP NNP NN O
Gγ8-/- Gγ8-/- 1 0 1 1 0 0 0 1 6 0 DT NNP NNP NN NN O
mice mice 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN DT O
show show 0 0 0 0 0 0 0 0 4 0 NNP NN NN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN NN DT JJ NN O
normal normal 0 0 0 0 0 0 0 0 6 0 NN DT JJ NN IN O
development development 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
main main 0 0 0 0 0 0 0 0 4 0 IN DT JJ NN NN O
olfactory olfactory 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN NN O
epithelium; epithelium; 0 0 0 0 0 0 0 0 11 0 JJ NN NN NN PRP O
moreover, moreover, 0 0 0 0 1 0 0 0 9 0 NN NN NN PRP VBP O
they they 0 0 0 0 0 0 0 0 4 0 NN NN PRP VBP RB O
do do 0 0 0 0 0 0 0 0 2 0 NN PRP VBP RB VB O
not not 0 0 0 0 0 0 0 0 3 0 PRP VBP RB VB JJ O
display display 0 0 0 0 0 0 0 0 7 0 VBP RB VB JJ NNS O
major major 0 0 0 0 0 0 0 0 5 0 RB VB JJ NNS IN O
deficits deficits 0 0 0 0 0 0 0 0 8 0 VB JJ NNS IN PRP$ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN PRP$ NNP O
odour odour 0 0 0 0 0 0 0 0 5 0 NNS IN PRP$ NNP NNP O
perception. perception. 0 0 0 0 0 0 0 0 11 0 IN PRP$ NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 PRP$ NNP NNP NNP DT O
contrast, contrast, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN VBD O
vomeronasal vomeronasal 0 0 0 0 0 0 0 0 11 0 NNP DT NN VBD VBZ O
organ organ 0 0 0 0 0 0 0 0 5 0 DT NN VBD VBZ DT O
undergoes undergoes 0 0 0 0 0 0 0 0 9 0 NN VBD VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBD VBZ DT JJ CC O
slow slow 0 0 0 0 0 0 0 0 4 0 VBZ DT JJ CC JJ O
but but 0 0 0 0 0 0 0 0 3 0 DT JJ CC JJ NN O
remarkable remarkable 0 0 0 0 0 0 0 0 10 0 JJ CC JJ NN IN O
loss loss 0 0 0 0 0 0 0 0 4 0 CC JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNS O
basal basal 0 0 0 0 0 0 0 0 5 0 NN IN NN NNS VBG O
neurons neurons 0 0 0 0 0 0 0 0 7 0 IN NN NNS VBG IN O
starting starting 0 0 0 0 0 0 0 0 8 0 NN NNS VBG IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBG IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBG IN DT JJ NN O
fourth fourth 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN NN O
postnatal postnatal 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN IN O
week, week, 0 0 0 0 1 0 0 0 5 0 JJ NN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN DT CD O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT CD NN O
40% 40% 0 0 0 0 0 0 0 1 3 0 IN DT CD NN IN O
reduction reduction 0 0 0 0 0 0 0 0 9 0 DT CD NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN CD O
at at 0 0 0 0 0 0 0 0 2 0 IN NNS IN CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 NNS IN CD NNS CC O
months months 0 0 0 0 0 0 0 0 6 0 IN CD NNS CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD NNS CC CD IN O
70% 70% 0 0 0 0 0 0 0 1 3 0 NNS CC CD IN CD O
at at 0 0 0 0 0 0 0 0 2 0 CC CD IN CD NNP O
one one 0 0 0 0 0 0 0 0 3 0 CD IN CD NNP NNP O
year. year. 0 0 0 0 0 0 0 0 5 0 IN CD NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 CD NNP NNP NN VBZ O
loss loss 0 0 0 0 0 0 0 0 4 0 NNP NNP NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NN VBZ VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN DT VBN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT VBN JJ O
reduced reduced 0 0 0 0 0 0 0 0 7 0 IN DT VBN JJ NN O
early-gene early-gene 0 0 1 0 0 0 0 0 10 0 DT VBN JJ NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 VBN JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
posterior posterior 0 0 0 0 0 0 0 0 9 0 IN DT NN NNP IN O
AOB AOB 1 1 0 0 0 0 0 0 3 0 DT NN NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NNP IN NN VBN O
mice mice 0 0 0 0 0 0 0 0 4 0 NNP IN NN VBN IN O
stimulated stimulated 0 0 0 0 0 0 0 0 10 0 IN NN VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NN VBN IN NNP NNP O
pheromones. pheromones. 0 0 0 0 0 0 0 0 11 0 VBN IN NNP NNP NNP O
More More 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP DT O
interestingly, interestingly, 0 0 0 0 1 0 0 0 14 0 NNP NNP NNP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNP NN O
Gγ8 Gγ8 1 0 0 0 0 0 0 1 3 0 NNP DT NNP NN RB O
deletion deletion 0 0 0 0 0 0 0 0 8 0 DT NNP NN RB VBZ O
specifically specifically 0 0 0 0 0 0 0 0 12 0 NNP NN RB VBZ TO O
leads leads 0 0 0 0 0 0 0 0 5 0 NN RB VBZ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 RB VBZ TO DT VBN O
a a 0 0 0 0 0 0 0 0 1 0 VBZ TO DT VBN JJ O
reduced reduced 0 0 0 0 0 0 0 0 7 0 TO DT VBN JJ NN O
pheromone-mediated pheromone-mediated 0 0 1 0 0 0 0 0 18 0 DT VBN JJ NN IN O
aggressiveness aggressiveness 0 0 0 0 0 0 0 0 14 0 VBN JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNS O
both both 0 0 0 0 0 0 0 0 4 0 NN IN DT NNS CC O
males males 0 0 0 0 0 0 0 0 5 0 IN DT NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 DT NNS CC NNS VBG O
females females 0 0 0 0 0 0 0 0 7 0 NNS CC NNS VBG VBN O
leaving leaving 0 0 0 0 0 0 0 0 7 0 CC NNS VBG VBN DT O
unaltered unaltered 0 0 0 0 0 0 0 0 9 0 NNS VBG VBN DT JJ O
all all 0 0 0 0 0 0 0 0 3 0 VBG VBN DT JJ JJ O
other other 0 0 0 0 0 0 0 0 5 0 VBN DT JJ JJ NNP O
socio-sexual socio-sexual 0 0 1 0 0 0 0 0 12 0 DT JJ JJ NNP NNP O
behaviours. behaviours. 0 0 0 0 0 0 0 0 11 0 JJ JJ NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NN VBZ O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ DT O
defines defines 0 0 0 0 0 0 0 0 7 0 NNP NN VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT JJ NN O
specific specific 0 0 0 0 0 0 0 0 8 0 VBZ DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN -NONE- O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN -NONE- IN O
Gγ8 Gγ8 1 0 0 0 0 0 0 1 3 0 NN IN -NONE- IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN -NONE- IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- IN DT NN IN O
maintenance maintenance 0 0 0 0 0 0 0 0 11 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
neuronal neuronal 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN IN O
population population 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP CC O
VNO VNO 1 1 0 0 0 0 0 0 3 0 IN DT NNP CC IN O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP CC IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 CC IN DT NNS IN O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 IN DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NN O
pheromonal pheromonal 0 0 0 0 0 0 0 0 10 0 NNS IN JJ NN WDT O
signalling signalling 0 0 0 0 0 0 0 0 10 0 IN JJ NN WDT VB O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT VB DT O
involve involve 0 0 0 0 0 0 0 0 7 0 NN WDT VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 WDT VB DT JJ NN O
aggressive aggressive 0 0 0 0 0 0 0 0 10 0 VB DT JJ NN NNS O
behaviour behaviour 0 0 0 0 0 0 0 0 9 0 DT JJ NN NNS NNP O
towards towards 0 0 0 0 0 0 0 0 7 0 JJ NN NNS NNP NNP O
conspecifics. conspecifics. 0 0 0 0 0 0 0 0 13 0 NN NNS NNP NNP NNP O
KEYWORDS: KEYWORDS: 1 1 0 0 0 0 0 0 9 0 NNS NNP NNP NNP JJ O
G-protein, G-protein, 1 0 1 0 1 0 0 0 10 0 NNP NNP NNP JJ NN O
aggressive aggressive 0 0 0 0 0 0 0 0 10 0 NNP NNP JJ NN NN O
behaviour, behaviour, 0 0 0 0 1 0 0 0 10 0 NNP JJ NN NN NONE O
vomeronasal vomeronasal 0 0 0 0 0 0 0 0 11 0 JJ NN NN NONE NONE O
Mesenchymal Mesenchymal 1 0 0 0 0 0 0 0 11 0 NONE NONE NNP NN NNS O
stem stem 0 0 0 0 0 0 0 0 4 0 NONE NNP NN NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NN NNS VBP JJ O
improve improve 0 0 0 0 0 0 0 0 7 0 NN NNS VBP JJ NN O
medullary medullary 0 0 0 0 0 0 0 0 9 0 NNS VBP JJ NN CC O
inflammation inflammation 0 0 0 0 0 0 0 0 12 0 VBP JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN IN O
fibrosis fibrosis 0 0 0 0 0 0 0 0 8 0 NN CC NN IN NN O
after after 0 0 0 0 0 0 0 0 5 0 CC NN IN NN IN O
revascularization revascularization 0 0 0 0 0 0 0 0 17 0 NN IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP JJ O
Swine Swine 1 0 0 0 0 0 0 0 5 0 NN IN NNP JJ JJ O
atherosclerotic atherosclerotic 0 0 0 0 0 0 0 0 15 0 IN NNP JJ JJ NN O
renal renal 0 0 0 0 0 0 0 0 5 0 NNP JJ JJ NN NNP O
artery artery 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NNP NNP O
stenosis. stenosis. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NNP NNP O
Ebrahimi Ebrahimi 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Eirin Eirin 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhu Zhu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
XY, XY, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lerman Lerman 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Textor Textor 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
SC, SC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Lerman Lerman 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
LO. LO. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Division Division 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Nephrology Nephrology 1 0 0 0 0 0 0 0 10 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Hypertension, Hypertension, 1 0 0 0 1 0 0 0 13 0 NNP CC NNP NNP NNP O
Mayo Mayo 1 0 0 0 0 0 0 0 4 0 CC NNP NNP NNP NNP O
Clinic, Clinic, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Rochester, Rochester, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Minnesota, Minnesota, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNPS O
United United 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNPS IN O
States States 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
America. America. 1 0 0 0 0 0 0 0 8 0 NNPS IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP JJ O
Atherosclerotic Atherosclerotic 1 0 0 0 0 0 0 0 15 0 NNP NNP NNP JJ NN O
renal renal 0 0 0 0 0 0 0 0 5 0 NNP NNP JJ NN NN O
artery artery 0 0 0 0 0 0 0 0 6 0 NNP JJ NN NN NN O
stenosis stenosis 0 0 0 0 0 0 0 0 8 0 JJ NN NN NN VBZ O
(ARAS) (ARAS) 0 1 0 0 0 0 0 0 6 0 NN NN NN VBZ NN O
raises raises 0 0 0 0 0 0 0 0 6 0 NN NN VBZ NN NN O
blood blood 0 0 0 0 0 0 0 0 5 0 NN VBZ NN NN CC O
pressure pressure 0 0 0 0 0 0 0 0 8 0 VBZ NN NN CC MD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN CC MD VB NN O
reduce reduce 0 0 0 0 0 0 0 0 6 0 CC MD VB NN NNP O
kidney kidney 0 0 0 0 0 0 0 0 6 0 MD VB NN NNP NNP O
function. function. 0 0 0 0 0 0 0 0 9 0 VB NN NNP NNP IN O
Revascularization Revascularization 1 0 0 0 0 0 0 0 17 0 NN NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ JJ O
stenotic stenotic 0 0 0 0 0 0 0 0 8 0 IN DT JJ JJ NN O
renal renal 0 0 0 0 0 0 0 0 5 0 DT JJ JJ NN NN O
artery artery 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NN VBZ O
alone alone 0 0 0 0 0 0 0 0 5 0 JJ NN NN VBZ RB O
does does 0 0 0 0 0 0 0 0 4 0 NN NN VBZ RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NN VBZ RB VB JJ O
restore restore 0 0 0 0 0 0 0 0 7 0 VBZ RB VB JJ NN O
renal renal 0 0 0 0 0 0 0 0 5 0 RB VB JJ NN NN O
medullary medullary 0 0 0 0 0 0 0 0 9 0 VB JJ NN NN CC O
structure structure 0 0 0 0 0 0 0 0 9 0 JJ NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
function. function. 0 0 0 0 0 0 0 0 9 0 NN CC NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 CC NNP NNP NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD DT O
tested tested 0 0 0 0 0 0 0 0 6 0 NNP NN VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBD DT NN IN O
hypothesis hypothesis 0 0 0 0 0 0 0 0 10 0 VBD DT NN IN NN O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN NN IN O
addition addition 0 0 0 0 0 0 0 0 8 0 NN IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NN O
mesenchymal mesenchymal 0 0 0 0 0 0 0 0 11 0 NN IN JJ NN NNS O
stem stem 0 0 0 0 0 0 0 0 4 0 IN JJ NN NNS -NONE- O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS -NONE- TO O
(MSC) (MSC) 0 1 0 0 0 0 0 0 5 0 NN NNS -NONE- TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NNS -NONE- TO JJ JJ O
percutaneous percutaneous 0 0 0 0 0 0 0 0 12 0 -NONE- TO JJ JJ JJ O
transluminal transluminal 0 0 0 0 0 0 0 0 12 0 TO JJ JJ JJ NN O
renal renal 0 0 0 0 0 0 0 0 5 0 JJ JJ JJ NN NN O
angioplasty angioplasty 0 0 0 0 0 0 0 0 11 0 JJ JJ NN NN MD O
(PTRA) (PTRA) 0 1 0 0 0 0 0 0 6 0 JJ NN NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN NN MD VB JJ O
restore restore 0 0 0 0 0 0 0 0 7 0 NN MD VB JJ NN O
stenotic-kidney stenotic-kidney 0 0 1 0 0 0 0 0 15 0 MD VB JJ NN JJ O
medullary medullary 0 0 0 0 0 0 0 0 9 0 VB JJ NN JJ NN O
tubular tubular 0 0 0 0 0 0 0 0 7 0 JJ NN JJ NN NN O
transport transport 0 0 0 0 0 0 0 0 9 0 NN JJ NN NN CC O
function function 0 0 0 0 0 0 0 0 8 0 JJ NN NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VB PRP$ O
attenuate attenuate 0 0 0 0 0 0 0 0 9 0 NN CC VB PRP$ NNP O
its its 0 0 0 0 0 0 0 0 3 0 CC VB PRP$ NNP NNP O
remodeling. remodeling. 0 0 0 0 0 0 0 0 11 0 VB PRP$ NNP NNP NN O
Twenty-seven Twenty-seven 1 0 1 0 0 0 0 0 12 0 PRP$ NNP NNP NN VBD O
swine swine 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NN VBD VBN IN O
divided divided 0 0 0 0 0 0 0 0 7 0 NN VBD VBN IN CD O
into into 0 0 0 0 0 0 0 0 4 0 VBD VBN IN CD NNP O
three three 0 0 0 0 0 0 0 0 5 0 VBN IN CD NNP NNP O
ARAS ARAS 1 1 0 0 0 0 0 0 4 0 IN CD NNP NNP NN O
(high-cholesterol (high-cholesterol 0 0 1 0 0 0 0 0 17 0 CD NNP NNP NN CC O
diet diet 0 0 0 0 0 0 0 0 4 0 NNP NNP NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC JJ NN O
renal renal 0 0 0 0 0 0 0 0 5 0 NN CC JJ NN NN O
artery artery 0 0 0 0 0 0 0 0 6 0 CC JJ NN NN CC O
stenosis) stenosis) 0 0 0 0 0 0 0 0 9 0 JJ NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN CC DT JJ NN O
normal normal 0 0 0 0 0 0 0 0 6 0 CC DT JJ NN NNP O
control control 0 0 0 0 0 0 0 0 7 0 DT JJ NN NNP NNP O
group. group. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP VBZ O
Six Six 1 0 0 0 0 0 0 0 3 0 NN NNP NNP VBZ IN O
weeks weeks 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 NNP VBZ IN NNP NNP O
ARAS ARAS 1 1 0 0 0 0 0 0 4 0 VBZ IN NNP NNP CD O
induction, induction, 0 0 0 0 1 0 0 0 10 0 IN NNP NNP CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 NNP NNP CD NNS VBD O
groups groups 0 0 0 0 0 0 0 0 6 0 NNP CD NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 CD NNS VBD VBN IN O
treated treated 0 0 0 0 0 0 0 0 7 0 NNS VBD VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNP RB O
PTRA PTRA 1 1 0 0 0 0 0 0 4 0 VBN IN NNP RB CC O
alone alone 0 0 0 0 0 0 0 0 5 0 IN NNP RB CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 NNP RB CC NNP VBD O
PTRA PTRA 1 1 0 0 0 0 0 0 4 0 RB CC NNP VBD IN O
supplemented supplemented 0 0 0 0 0 0 0 0 12 0 CC NNP VBD IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNP VBD IN JJ NNP O
adipose-tissue-derived adipose-tissue-derived 0 0 1 0 0 0 0 0 22 0 VBD IN JJ NNP NNP O
MSC MSC 1 1 0 0 0 0 0 0 3 0 IN JJ NNP NNP VBZ O
(10×10(6) (10×10(6) 0 0 0 0 0 0 0 1 9 0 JJ NNP NNP VBZ NNP O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ NNP NNP O
intra-renal). intra-renal). 0 0 1 0 0 0 0 0 13 0 NNP VBZ NNP NNP VBD O
Multi-detector Multi-detector 1 0 1 0 0 0 0 0 14 0 VBZ NNP NNP VBD NN O
computed computed 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD NN CC O
tomography tomography 0 0 0 0 0 0 0 0 10 0 NNP VBD NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBD NN CC JJ NN O
blood-oxygenation-level-dependent blood-oxygenation-level-dependent 0 0 1 0 0 0 0 0 33 0 NN CC JJ NN NNP O
(BOLD) (BOLD) 0 1 0 0 0 0 0 0 6 0 CC JJ NN NNP NNS O
MRI MRI 1 1 0 0 0 0 0 0 3 0 JJ NN NNP NNS VBD O
studies studies 0 0 0 0 0 0 0 0 7 0 NN NNP NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD VBN CD O
performed performed 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN CD NNS O
4 4 0 0 0 0 0 0 1 1 1 0 VBD VBN CD NNS JJ O
weeks weeks 0 0 0 0 0 0 0 0 5 0 VBN CD NNS JJ TO O
later later 0 0 0 0 0 0 0 0 5 0 CD NNS JJ TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NNS JJ TO NN NN O
assess assess 0 0 0 0 0 0 0 0 6 0 JJ TO NN NN NNS O
kidney kidney 0 0 0 0 0 0 0 0 6 0 TO NN NN NNS CC O
hemodynamics hemodynamics 0 0 0 0 0 0 0 0 12 0 NN NN NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC JJ CC O
function, function, 0 0 0 0 1 0 0 0 9 0 NNS CC JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 CC JJ CC NN VBD O
tissue tissue 0 0 0 0 0 0 0 0 6 0 JJ CC NN VBD DT O
collected collected 0 0 0 0 0 0 0 0 9 0 CC NN VBD DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBD DT JJ NNS O
few few 0 0 0 0 0 0 0 0 3 0 VBD DT JJ NNS JJ O
days days 0 0 0 0 0 0 0 0 4 0 DT JJ NNS JJ IN O
later later 0 0 0 0 0 0 0 0 5 0 JJ NNS JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NNS JJ IN NN CC O
histology histology 0 0 0 0 0 0 0 0 9 0 JJ IN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC JJ NNP O
micro-CT micro-CT 0 0 1 0 0 0 0 0 8 0 NN CC JJ NNP NNP O
imaging. imaging. 0 0 0 0 0 0 0 0 8 0 CC JJ NNP NNP RB O
PTRA PTRA 1 1 0 0 0 0 0 0 4 0 JJ NNP NNP RB VBD O
effectively effectively 0 0 0 0 0 0 0 0 11 0 NNP NNP RB VBD NN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 NNP RB VBD NN NN O
blood blood 0 0 0 0 0 0 0 0 5 0 RB VBD NN NN RB O
pressure, pressure, 0 0 0 0 1 0 0 0 9 0 VBD NN NN RB JJ O
yet yet 0 0 0 0 0 0 0 0 3 0 NN NN RB JJ NN O
medullary medullary 0 0 0 0 0 0 0 0 9 0 NN RB JJ NN NN O
vascular vascular 0 0 0 0 0 0 0 0 8 0 RB JJ NN NN VBD O
density density 0 0 0 0 0 0 0 0 7 0 JJ NN NN VBD NNP O
remained remained 0 0 0 0 0 0 0 0 8 0 NN NN VBD NNP NNP O
low. low. 0 0 0 0 0 0 0 0 4 0 NN VBD NNP NNP IN O
Addition Addition 1 0 0 0 0 0 0 0 8 0 VBD NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP VBD O
MSC MSC 1 1 0 0 0 0 0 0 3 0 NNP IN NNP VBD JJ O
improved improved 0 0 0 0 0 0 0 0 8 0 IN NNP VBD JJ NN O
medullary medullary 0 0 0 0 0 0 0 0 9 0 NNP VBD JJ NN IN O
vascularization vascularization 0 0 0 0 0 0 0 0 15 0 VBD JJ NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ CC O
ARAS+PTRA+MSC ARAS+PTRA+MSC 1 1 0 0 0 0 0 0 13 0 NN IN JJ CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC VBN JJ O
increased increased 0 0 0 0 0 0 0 0 9 0 JJ CC VBN JJ NN O
angiogenic angiogenic 0 0 0 0 0 0 0 0 10 0 CC VBN JJ NN VBG O
signaling, signaling, 0 0 0 0 1 0 0 0 10 0 VBN JJ NN VBG NN O
including including 0 0 0 0 0 0 0 0 9 0 JJ NN VBG NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 NN VBG NN NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 VBG NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ JJ O
vascular vascular 0 0 0 0 0 0 0 0 8 0 NN IN JJ JJ NN O
endothelial endothelial 0 0 0 0 0 0 0 0 11 0 IN JJ JJ NN PRP$ O
growth-factor, growth-factor, 0 0 1 0 1 0 0 0 14 0 JJ JJ NN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 JJ NN PRP$ NN NN O
receptor receptor 0 0 0 0 0 0 0 0 8 0 NN PRP$ NN NN CC O
(FLK-1), (FLK-1), 0 1 1 0 1 0 0 1 8 0 PRP$ NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NNP O
hypoxia-inducible hypoxia-inducible 0 0 1 0 0 0 0 0 17 0 NN CC JJ NNP NNP O
factor-1α. factor-1α. 0 0 1 0 0 0 0 1 10 0 CC JJ NNP NNP RB O
ARAS+PTRA+MSC ARAS+PTRA+MSC 1 1 0 0 0 0 0 0 13 0 JJ NNP NNP RB VBD O
also also 0 0 0 0 0 0 0 0 4 0 NNP NNP RB VBD VBN O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP RB VBD VBN -NONE- O
attenuated attenuated 0 0 0 0 0 0 0 0 10 0 RB VBD VBN -NONE- IN O
inflammation, inflammation, 0 0 0 0 1 0 0 0 13 0 VBD VBN -NONE- IN JJ O
although although 0 0 0 0 0 0 0 0 8 0 VBN -NONE- IN JJ VBN O
oxidative-stress oxidative-stress 0 0 1 0 0 0 0 0 16 0 -NONE- IN JJ VBN NNP O
remained remained 0 0 0 0 0 0 0 0 8 0 IN JJ VBN NNP NNP O
elevated. elevated. 0 0 0 0 0 0 0 0 9 0 JJ VBN NNP NNP VBD O
BOLD-MRI BOLD-MRI 1 1 1 0 0 0 0 0 8 0 VBN NNP NNP VBD IN O
indicated indicated 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBD IN NNP VBD O
MSC MSC 1 1 0 0 0 0 0 0 3 0 VBD IN NNP VBD JJ O
normalized normalized 0 0 0 0 0 0 0 0 10 0 IN NNP VBD JJ JJ O
oxygen-dependent oxygen-dependent 0 0 1 0 0 0 0 0 16 0 NNP VBD JJ JJ NN O
tubular tubular 0 0 0 0 0 0 0 0 7 0 VBD JJ JJ NN TO O
response response 0 0 0 0 0 0 0 0 8 0 JJ JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB JJ O
furosemide furosemide 0 0 0 0 0 0 0 0 10 0 NN TO VB JJ NN O
(-4.3±0.9, (-4.3±0.9, 0 0 1 0 1 0 0 1 10 0 TO VB JJ NN -NONE- O
-0.1±0.4, -0.1±0.4, 0 0 1 0 1 0 0 1 9 0 VB JJ NN -NONE- CC O
-1.6±0.9 -1.6±0.9 0 0 1 0 0 0 0 1 8 0 JJ NN -NONE- CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC -NONE- JJ O
-3.6±1.0 -3.6±1.0 0 0 1 0 0 0 0 1 8 0 -NONE- CC -NONE- JJ IN O
s(-1) s(-1) 0 0 1 0 0 0 0 1 5 0 CC -NONE- JJ IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- JJ IN JJ NN O
Normal, Normal, 1 0 0 0 1 0 0 0 7 0 JJ IN JJ NN NNP O
ARAS, ARAS, 1 1 0 0 1 0 0 0 5 0 IN JJ NN NNP CC O
ARAS+PTRA ARAS+PTRA 1 1 0 0 0 0 0 0 9 0 JJ NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP NNP O
ARAS+PTRA+MSC, ARAS+PTRA+MSC, 1 1 0 0 1 0 0 0 14 0 NNP CC NNP NNP NNP O
respectively, respectively, 0 0 0 0 1 0 0 0 13 0 CC NNP NNP NNP WDT O
p<0.05), p<0.05), 0 0 0 0 1 0 0 1 8 0 NNP NNP NNP WDT VBN O
which which 0 0 0 0 0 0 0 0 5 0 NNP NNP WDT VBN IN O
correlated correlated 0 0 0 0 0 0 0 0 10 0 NNP WDT VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 WDT VBN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NN IN O
decrease decrease 0 0 0 0 0 0 0 0 8 0 IN DT NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ JJ O
medullary medullary 0 0 0 0 0 0 0 0 9 0 NN IN JJ JJ NN O
tubular tubular 0 0 0 0 0 0 0 0 7 0 IN JJ JJ NN NN O
injury injury 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NN NN O
score score 0 0 0 0 0 0 0 0 5 0 JJ NN NN NN : O
(R(2) (R(2) 0 1 0 0 0 0 0 1 5 0 NN NN NN : CD O
= = 0 0 0 0 0 0 0 0 1 0 NN NN : CD NN O
0.33, 0.33, 0 0 0 0 1 0 0 1 5 0 NN : CD NN : O
p p 0 0 0 0 0 0 0 0 1 0 : CD NN : CD O
= = 0 0 0 0 0 0 0 0 1 0 CD NN : CD NN O
0.02). 0.02). 0 0 0 0 0 0 0 1 6 0 NN : CD NN JJ O
Therefore, Therefore, 1 0 0 0 1 0 0 0 10 0 : CD NN JJ NNP O
adjunctive adjunctive 0 0 0 0 0 0 0 0 10 0 CD NN JJ NNP NN O
MSC MSC 1 1 0 0 0 0 0 0 3 0 NN JJ NNP NN IN O
delivery delivery 0 0 0 0 0 0 0 0 8 0 JJ NNP NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN TO O
addition addition 0 0 0 0 0 0 0 0 8 0 NN IN NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO NNP NNS O
PTRA PTRA 1 1 0 0 0 0 0 0 4 0 NN TO NNP NNS -NONE- O
reduces reduces 0 0 0 0 0 0 0 0 7 0 TO NNP NNS -NONE- VBZ O
inflammation, inflammation, 0 0 0 0 1 0 0 0 13 0 NNP NNS -NONE- VBZ CC O
fibrogenesis fibrogenesis 0 0 0 0 0 0 0 0 12 0 NNS -NONE- VBZ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- VBZ CC JJ NN O
vascular vascular 0 0 0 0 0 0 0 0 8 0 VBZ CC JJ NN CC O
remodeling, remodeling, 0 0 0 0 1 0 0 0 11 0 CC JJ NN CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNS JJ O
restores restores 0 0 0 0 0 0 0 0 8 0 NN CC NNS JJ JJ O
oxygen-dependent oxygen-dependent 0 0 1 0 0 0 0 0 16 0 CC NNS JJ JJ NN O
tubular tubular 0 0 0 0 0 0 0 0 7 0 NNS JJ JJ NN IN O
function function 0 0 0 0 0 0 0 0 8 0 JJ JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
stenotic-kidney stenotic-kidney 0 0 1 0 0 0 0 0 15 0 IN DT NN NN IN O
medulla, medulla, 0 0 0 0 1 0 0 0 8 0 DT NN NN IN JJ O
although although 0 0 0 0 0 0 0 0 8 0 NN NN IN JJ NNS O
additional additional 0 0 0 0 0 0 0 0 10 0 NN IN JJ NNS MD O
interventions interventions 0 0 0 0 0 0 0 0 13 0 IN JJ NNS MD VB O
might might 0 0 0 0 0 0 0 0 5 0 JJ NNS MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB VBN TO O
required required 0 0 0 0 0 0 0 0 8 0 MD VB VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VB VBN TO VB NNP O
reduce reduce 0 0 0 0 0 0 0 0 6 0 VBN TO VB NNP NNP O
oxidative-stress. oxidative-stress. 0 0 1 0 0 0 0 0 17 0 TO VB NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 VB NNP NNP NN VBZ O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ NN O
supports supports 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ NN IN O
development development 0 0 0 0 0 0 0 0 11 0 NN VBZ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBZ NN IN JJ NNS O
cell-based cell-based 0 0 1 0 0 0 0 0 10 0 NN IN JJ NNS IN O
strategies strategies 0 0 0 0 0 0 0 0 10 0 IN JJ NNS IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN JJ NN O
renal renal 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NN IN O
protection protection 0 0 0 0 0 0 0 0 10 0 IN JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NONE O
ARAS. ARAS. 1 1 0 0 0 0 0 0 5 0 NN IN NNP NONE NONE O
3D 3D 0 1 0 0 0 0 0 1 2 0 NONE NONE JJ VBN JJ O
pulsed pulsed 0 0 0 0 0 0 0 0 6 0 NONE JJ VBN JJ JJ O
laser-triggered laser-triggered 0 0 1 0 0 0 0 0 15 0 JJ VBN JJ JJ JJ O
high-speed high-speed 0 0 1 0 0 0 0 0 10 0 VBN JJ JJ JJ JJ O
microfluidic microfluidic 0 0 0 0 0 0 0 0 12 0 JJ JJ JJ JJ NN O
fluorescence-activated fluorescence-activated 0 0 1 0 0 0 0 0 22 0 JJ JJ JJ NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ JJ NN NNP NNP O
sorter. sorter. 0 0 0 0 0 0 0 0 7 0 JJ NN NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wu Wu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
TH, TH, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Kung Kung 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
YC, YC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Teitell Teitell 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
MA, MA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Chiou Chiou 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
PY. PY. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Mechanical Mechanical 1 0 0 0 0 0 0 0 10 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Aerospace Aerospace 1 0 0 0 0 0 0 0 9 0 NNP CC NNP NNP NNP O
Engineering, Engineering, 1 0 0 0 1 0 0 0 12 0 CC NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP IN O
California California 1 0 0 0 0 0 0 0 10 0 NNP IN NNP IN NNP O
at at 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NNP O
Los Los 1 0 0 0 0 0 0 0 3 0 NNP IN NNP NNP NNP O
Angeles Angeles 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP CD O
(UCLA), (UCLA), 0 1 0 0 1 0 0 0 7 0 NNP NNP NNP CD NNP O
43-147 43-147 0 0 1 0 0 0 0 1 6 0 NNP NNP CD NNP NNP O
Eng. Eng. 1 0 0 0 0 0 0 0 4 0 NNP CD NNP NNP CD O
IV, IV, 1 1 0 0 1 0 0 0 3 0 CD NNP NNP CD NNP O
420 420 0 0 0 0 0 0 1 1 3 0 NNP NNP CD NNP NNP O
Westwood Westwood 1 0 0 0 0 0 0 0 8 0 NNP CD NNP NNP NNP O
Plaza, Plaza, 1 0 0 0 1 0 0 0 6 0 CD NNP NNP NNP NNP O
Los Los 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Angeles, Angeles, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP CD O
CA CA 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
90095-1597, 90095-1597, 0 0 1 0 1 0 0 1 11 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
pychiou@seas.ucla.edu pychiou@seas.ucla.edu 0 0 0 0 0 0 0 0 21 0 CD NNP NNP NNP NNP O
katechen@ucla.edu. katechen@ucla.edu. 0 0 0 0 0 0 0 0 18 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NN DT O
report report 0 0 0 0 0 0 0 0 6 0 NNP NNP NN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NN DT JJ JJ O
3D 3D 0 1 0 0 0 0 0 1 2 0 NN DT JJ JJ VBN O
microfluidic microfluidic 0 0 0 0 0 0 0 0 12 0 DT JJ JJ VBN JJ O
pulsed pulsed 0 0 0 0 0 0 0 0 6 0 JJ JJ VBN JJ JJ O
laser-triggered laser-triggered 0 0 1 0 0 0 0 0 15 0 JJ VBN JJ JJ NN O
fluorescence-activated fluorescence-activated 0 0 1 0 0 0 0 0 22 0 VBN JJ JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ JJ NN NN JJ O
sorter sorter 0 0 0 0 0 0 0 0 6 0 JJ NN NN JJ IN O
capable capable 0 0 0 0 0 0 0 0 7 0 NN NN JJ IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN JJ IN NN IN O
sorting sorting 0 0 0 0 0 0 0 0 7 0 JJ IN NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN IN O
throughput throughput 0 0 0 0 0 0 0 0 10 0 IN DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD CD O
23 23 0 0 0 0 0 0 1 1 2 0 NN IN CD CD NNS O
000 000 0 0 0 0 0 0 1 1 3 0 IN CD CD NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 CD CD NNS IN NNS O
per per 0 0 0 0 0 0 0 0 3 0 CD NNS IN NNS IN O
s s 0 0 0 0 0 0 0 0 1 0 NNS IN NNS IN CD O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN CD NN O
90% 90% 0 0 0 0 0 0 0 1 3 0 NNS IN CD NN IN O
purity purity 0 0 0 0 0 0 0 0 6 0 IN CD NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN NN NN O
high-purity high-purity 0 0 1 0 0 0 0 0 11 0 NN IN NN NN CC O
mode mode 0 0 0 0 0 0 0 0 4 0 IN NN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NN CC IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 CC IN DT NN IN O
throughput throughput 0 0 0 0 0 0 0 0 10 0 IN DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD CD O
45 45 0 0 0 0 0 0 1 1 2 0 NN IN CD CD NNS O
000 000 0 0 0 0 0 0 1 1 3 0 IN CD CD NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 CD CD NNS IN NNS O
per per 0 0 0 0 0 0 0 0 3 0 CD NNS IN NNS IN O
s s 0 0 0 0 0 0 0 0 1 0 NNS IN NNS IN CD O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN CD NN O
45% 45% 0 0 0 0 0 0 0 1 3 0 NNS IN CD NN IN O
purity purity 0 0 0 0 0 0 0 0 6 0 IN CD NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN NN NN O
enrichment enrichment 0 0 0 0 0 0 0 0 10 0 NN IN NN NN IN O
mode mode 0 0 0 0 0 0 0 0 4 0 IN NN NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN CD NN O
one one 0 0 0 0 0 0 0 0 3 0 NN IN CD NN CC O
stage stage 0 0 0 0 0 0 0 0 5 0 IN CD NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 CD NN CC IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN CC IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 CC IN DT JJ NNP O
single single 0 0 0 0 0 0 0 0 6 0 IN DT JJ NNP NNP O
channel. channel. 0 0 0 0 0 0 0 0 8 0 DT JJ NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NN VBZ O
performance performance 0 0 0 0 0 0 0 0 11 0 NNP NNP NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ VBN IN O
realized realized 0 0 0 0 0 0 0 0 8 0 NN VBZ VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN JJ JJ O
exciting exciting 0 0 0 0 0 0 0 0 8 0 VBN IN JJ JJ NN O
laser-induced laser-induced 0 0 1 0 0 0 0 0 13 0 IN JJ JJ NN NNS O
cavitation cavitation 0 0 0 0 0 0 0 0 10 0 JJ JJ NN NNS IN O
bubbles bubbles 0 0 0 0 0 0 0 0 7 0 JJ NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ NNP O
3D 3D 0 1 0 0 0 0 0 1 2 0 IN DT JJ NNP JJ O
PDMS PDMS 1 1 0 0 0 0 0 0 4 0 DT JJ NNP JJ NN O
microfluidic microfluidic 0 0 0 0 0 0 0 0 12 0 JJ NNP JJ NN TO O
channel channel 0 0 0 0 0 0 0 0 7 0 NNP JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB JJ O
generate generate 0 0 0 0 0 0 0 0 8 0 NN TO VB JJ NN O
high-speed high-speed 0 0 1 0 0 0 0 0 10 0 TO VB JJ NN NNS O
liquid liquid 0 0 0 0 0 0 0 0 6 0 VB JJ NN NNS WDT O
jets jets 0 0 0 0 0 0 0 0 4 0 JJ NN NNS WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 NN NNS WDT NN VBD O
deflect deflect 0 0 0 0 0 0 0 0 7 0 NNS WDT NN VBD NN O
detected detected 0 0 0 0 0 0 0 0 8 0 WDT NN VBD NN NNS O
fluorescent fluorescent 0 0 0 0 0 0 0 0 11 0 NN VBD NN NNS CC O
cells cells 0 0 0 0 0 0 0 0 5 0 VBD NN NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NNS VBD O
particles particles 0 0 0 0 0 0 0 0 9 0 NNS CC NNS VBD IN O
focused focused 0 0 0 0 0 0 0 0 7 0 CC NNS VBD IN CD O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBD IN CD NN O
3D 3D 0 1 0 0 0 0 0 1 2 0 VBD IN CD NN NNP O
sheath sheath 0 0 0 0 0 0 0 0 6 0 IN CD NN NNP NNP O
flows. flows. 0 0 0 0 0 0 0 0 6 0 CD NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN VBG O
ultrafast ultrafast 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBG NN O
switching switching 0 0 0 0 0 0 0 0 9 0 NNP NN VBG NN -NONE- O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 NN VBG NN -NONE- VBZ O
(20 (20 0 0 0 0 0 0 0 1 3 0 VBG NN -NONE- VBZ JJ O
μs μs 0 0 0 0 0 0 0 0 2 0 NN -NONE- VBZ JJ NN O
complete complete 0 0 0 0 0 0 0 0 8 0 -NONE- VBZ JJ NN NN O
on-off on-off 0 0 1 0 0 0 0 0 6 0 VBZ JJ NN NN JJ O
cycle), cycle), 0 0 0 0 1 0 0 0 7 0 JJ NN NN JJ NN O
small small 0 0 0 0 0 0 0 0 5 0 NN NN JJ NN NN O
liquid liquid 0 0 0 0 0 0 0 0 6 0 NN JJ NN NN NN O
jet jet 0 0 0 0 0 0 0 0 3 0 JJ NN NN NN NN O
perturbation perturbation 0 0 0 0 0 0 0 0 12 0 NN NN NN NN CC O
volume, volume, 0 0 0 0 1 0 0 0 7 0 NN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
three-dimensional three-dimensional 0 0 1 0 0 0 0 0 17 0 NN CC JJ NN NN O
sheath sheath 0 0 0 0 0 0 0 0 6 0 CC JJ NN NN VBG O
flow flow 0 0 0 0 0 0 0 0 4 0 JJ NN NN VBG IN O
focusing focusing 0 0 0 0 0 0 0 0 8 0 NN NN VBG IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NN VBG IN JJ NN O
accurate accurate 0 0 0 0 0 0 0 0 8 0 VBG IN JJ NN NN O
timing timing 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN IN O
control control 0 0 0 0 0 0 0 0 7 0 JJ NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
fast fast 0 0 0 0 0 0 0 0 4 0 NN IN JJ NN NN O
(1.5 (1.5 0 0 0 0 0 0 0 1 4 0 IN JJ NN NN NN O
m m 0 0 0 0 0 0 0 0 1 0 JJ NN NN NN VBG O
s-1) s-1) 0 0 1 0 0 0 0 1 4 0 NN NN NN VBG NNS O
passing passing 0 0 0 0 0 0 0 0 7 0 NN NN VBG NNS CC O
cells cells 0 0 0 0 0 0 0 0 5 0 NN VBG NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 VBG NNS CC NNS VBP O
particles particles 0 0 0 0 0 0 0 0 9 0 NNS CC NNS VBP CD O
are are 0 0 0 0 0 0 0 0 3 0 CC NNS VBP CD JJ O
three three 0 0 0 0 0 0 0 0 5 0 NNS VBP CD JJ NNS O
critical critical 0 0 0 0 0 0 0 0 8 0 VBP CD JJ NNS VBG O
factors factors 0 0 0 0 0 0 0 0 7 0 CD JJ NNS VBG NN O
enabling enabling 0 0 0 0 0 0 0 0 8 0 JJ NNS VBG NN VBG O
high-purity high-purity 0 0 1 0 0 0 0 0 11 0 NNS VBG NN VBG IN O
sorting sorting 0 0 0 0 0 0 0 0 7 0 VBG NN VBG IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 NN VBG IN JJ IN O
high-throughput high-throughput 0 0 1 0 0 0 0 0 15 0 VBG IN JJ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN JJ IN DT NNP O
this this 0 0 0 0 0 0 0 0 4 0 JJ IN DT NNP NONE O
sorter. sorter. 0 0 0 0 0 0 0 0 7 0 IN DT NNP NONE NONE O
Reproductive Reproductive 1 0 0 0 0 0 0 0 12 0 NONE NONE JJ NNP IN O
Cycle Cycle 1 0 0 0 0 0 0 0 5 0 NONE JJ NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNP IN NNP NN O
Marphysa Marphysa 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NN -NONE- O
sanguinea sanguinea 0 0 0 0 0 0 0 0 9 0 IN NNP NN -NONE- CD O
(Montagu, (Montagu, 0 0 0 0 1 0 0 0 9 0 NNP NN -NONE- CD -NONE- O
1815) 1815) 0 0 0 0 0 0 0 1 5 0 NN -NONE- CD -NONE- JJ O
(Polychaeta: (Polychaeta: 0 0 0 0 0 0 0 0 12 0 -NONE- CD -NONE- JJ IN O
Eunicidae) Eunicidae) 1 0 0 0 0 0 0 0 10 0 CD -NONE- JJ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- JJ IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NNP IN O
Lagoon Lagoon 1 0 0 0 0 0 0 0 6 0 IN DT NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNP IN NNP NNP O
Tunis. Tunis. 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNP O
El El 1 0 0 0 0 0 0 0 2 0 IN NNP NNP NNP NNP O
Barhoumi Barhoumi 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Scaps Scaps 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zghal Zghal 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
F. F. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Laboratoire Laboratoire 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP IN O
Biologie Biologie 1 0 0 0 0 0 0 0 8 0 NNP IN NNP IN DT O
de de 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT NNP O
la la 0 0 0 0 0 0 0 0 2 0 NNP IN DT NNP NN O
Reproduction Reproduction 1 0 0 0 0 0 0 0 12 0 IN DT NNP NN NN O
et et 0 0 0 0 0 0 0 0 2 0 DT NNP NN NN NN O
du du 0 0 0 0 0 0 0 0 2 0 NNP NN NN NN NN O
Développement Développement 1 0 0 0 0 0 0 0 13 0 NN NN NN NN NN O
Animal, Animal, 1 0 0 0 1 0 0 0 7 0 NN NN NN NN VBZ O
Faculté Faculté 1 0 0 0 0 0 0 0 7 0 NN NN NN VBZ NNS O
des des 0 0 0 0 0 0 0 0 3 0 NN NN VBZ NNS IN O
Sciences Sciences 1 0 0 0 0 0 0 0 8 0 NN VBZ NNS IN JJ O
de de 0 0 0 0 0 0 0 0 2 0 VBZ NNS IN JJ NNP O
Tunis, Tunis, 1 0 0 0 1 0 0 0 6 0 NNS IN JJ NNP NNP O
Campus Campus 1 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP NNP O
Universitaire, Universitaire, 1 0 0 0 1 0 0 0 14 0 JJ NNP NNP NNP NNP O
El El 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP CD O
Manar Manar 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP CD -NONE- O
2092 2092 0 0 0 0 0 0 1 1 4 0 NNP NNP CD -NONE- NNP O
Tunis, Tunis, 1 0 0 0 1 0 0 0 6 0 NNP CD -NONE- NNP NNP O
Tunisia. Tunisia. 1 0 0 0 0 0 0 0 8 0 CD -NONE- NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 -NONE- NNP NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP JJ NN O
reproductive reproductive 0 0 0 0 0 0 0 0 12 0 NNP NNP JJ NN IN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NNP JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
Marphysa Marphysa 1 0 0 0 0 0 0 0 8 0 NN IN NNP NN -NONE- O
sanguinea sanguinea 0 0 0 0 0 0 0 0 9 0 IN NNP NN -NONE- -NONE- O
(Polychaeta: (Polychaeta: 0 0 0 0 0 0 0 0 12 0 NNP NN -NONE- -NONE- VBD O
Eunicidae) Eunicidae) 1 0 0 0 0 0 0 0 10 0 NN -NONE- -NONE- VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- VBD VBN IN O
studied studied 0 0 0 0 0 0 0 0 7 0 -NONE- VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP IN O
Lagoon Lagoon 1 0 0 0 0 0 0 0 6 0 IN DT NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNP IN NNP IN O
Tunis Tunis 1 0 0 0 0 0 0 0 5 0 NNP IN NNP IN NNP O
between between 0 0 0 0 0 0 0 0 7 0 IN NNP IN NNP CD O
May May 1 0 0 0 0 0 0 0 3 0 NNP IN NNP CD CC O
2006 2006 0 0 0 0 0 0 1 1 4 0 IN NNP CD CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP CD CC NNP CD O
May May 1 0 0 0 0 0 0 0 3 0 CD CC NNP CD NNP O
2007. 2007. 0 0 0 0 0 0 0 1 5 0 CC NNP CD NNP NN O
M. M. 1 1 0 0 0 0 0 0 2 0 NNP CD NNP NN VBZ O
sanguinea sanguinea 0 0 0 0 0 0 0 0 9 0 CD NNP NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT JJ NNP O
gonochoric gonochoric 0 0 0 0 0 0 0 0 10 0 VBZ DT JJ NNP NNP O
species. species. 0 0 0 0 0 0 0 0 8 0 DT JJ NNP NNP VBD O
There There 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP VBD DT O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD DT JJ O
no no 0 0 0 0 0 0 0 0 2 0 NNP VBD DT JJ NNS O
morphological morphological 0 0 0 0 0 0 0 0 13 0 VBD DT JJ NNS IN O
differences differences 0 0 0 0 0 0 0 0 11 0 DT JJ NNS IN NNS O
between between 0 0 0 0 0 0 0 0 7 0 JJ NNS IN NNS CC O
males males 0 0 0 0 0 0 0 0 5 0 NNS IN NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC JJ CC O
females, females, 0 0 0 0 1 0 0 0 8 0 NNS CC JJ CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 CC JJ CC VBG VBN O
spawning spawning 0 0 0 0 0 0 0 0 8 0 JJ CC VBG VBN IN O
occurred occurred 0 0 0 0 0 0 0 0 8 0 CC VBG VBN IN JJ O
without without 0 0 0 0 0 0 0 0 7 0 VBG VBN IN JJ NNP O
epitokal epitokal 0 0 0 0 0 0 0 0 8 0 VBN IN JJ NNP NNP O
metamorphosis. metamorphosis. 0 0 0 0 0 0 0 0 14 0 IN JJ NNP NNP VBP O
Gonads Gonads 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNP VBP RB RB O
not not 0 0 0 0 0 0 0 0 3 0 NNP VBP RB RB VBN O
well well 0 0 0 0 0 0 0 0 4 0 VBP RB RB VBN IN O
defined defined 0 0 0 0 0 0 0 0 7 0 RB RB VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN DT NNP O
either either 0 0 0 0 0 0 0 0 6 0 VBN IN DT NNP NNP O
sex. sex. 0 0 0 0 0 0 0 0 4 0 IN DT NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 DT NNP NNP NN IN O
process process 0 0 0 0 0 0 0 0 7 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN VBZ O
spermatogenesis spermatogenesis 0 0 0 0 0 0 0 0 15 0 NN IN NN VBZ NN O
takes takes 0 0 0 0 0 0 0 0 5 0 IN NN VBZ NN IN O
place place 0 0 0 0 0 0 0 0 5 0 NN VBZ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBZ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
coelomic coelomic 0 0 0 0 0 0 0 0 8 0 IN DT JJ NNP NNP O
cavity. cavity. 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NNP VBZ O
Mature Mature 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP VBZ NN O
males males 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ NN DT O
show show 0 0 0 0 0 0 0 0 4 0 NNP VBZ NN DT NNS O
all all 0 0 0 0 0 0 0 0 3 0 VBZ NN DT NNS IN O
stages stages 0 0 0 0 0 0 0 0 6 0 NN DT NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NN IN O
spermiogenesis spermiogenesis 0 0 0 0 0 0 0 0 14 0 NNS IN NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 IN NN IN DT CD O
any any 0 0 0 0 0 0 0 0 3 0 NN IN DT CD NNP O
one one 0 0 0 0 0 0 0 0 3 0 IN DT CD NNP NNP O
time. time. 0 0 0 0 0 0 0 0 5 0 DT CD NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 CD NNP NNP NNS IN O
ovaries ovaries 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NNP NN O
M. M. 1 1 0 0 0 0 0 0 2 0 NNS IN NNP NN NN O
sanguinea sanguinea 0 0 0 0 0 0 0 0 9 0 IN NNP NN NN IN O
consist consist 0 0 0 0 0 0 0 0 7 0 NNP NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ JJ O
coelomic coelomic 0 0 0 0 0 0 0 0 8 0 NN IN JJ JJ NNS O
germ-cell germ-cell 0 0 1 0 0 0 0 0 9 0 IN JJ JJ NNS VBD O
clusters clusters 0 0 0 0 0 0 0 0 8 0 JJ JJ NNS VBD IN O
surrounded surrounded 0 0 0 0 0 0 0 0 10 0 JJ NNS VBD IN DT O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBD IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBD IN DT JJ NN O
thin thin 0 0 0 0 0 0 0 0 4 0 IN DT JJ NN IN O
envelope envelope 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNS O
follicle follicle 0 0 0 0 0 0 0 0 8 0 NN IN NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NN NNS VBD IN O
derived derived 0 0 0 0 0 0 0 0 7 0 NN NNS VBD IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBD IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NNP NNP O
peritoneum. peritoneum. 0 0 0 0 0 0 0 0 11 0 IN DT NNP NNP VBZ O
Germ Germ 1 0 0 0 0 0 0 0 4 0 DT NNP NNP VBZ IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN JJ CC O
premeiotic premeiotic 0 0 0 0 0 0 0 0 10 0 VBZ IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NNS O
previtellogenic previtellogenic 0 0 0 0 0 0 0 0 15 phases JJ CC JJ NNS VBP O
phases phases 0 0 0 0 0 0 0 0 6 0 CC JJ NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 JJ NNS VBP VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 NNS VBP VBN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 VBP VBN IN CD NNP O
one one 0 0 0 0 0 0 0 0 3 0 VBN IN CD NNP NNP O
cluster. cluster. 0 0 0 0 0 0 0 0 8 0 IN CD NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 CD NNP NNP DT NN O
each each 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN DT O
cluster cluster 0 0 0 0 0 0 0 0 7 0 NNP DT NN DT RBR O
the the 0 0 0 0 0 0 0 0 3 0 DT NN DT RBR JJ O
more more 0 0 0 0 0 0 0 0 4 0 NN DT RBR JJ NNS O
differentiated differentiated 0 0 0 0 0 0 0 0 14 0 DT RBR JJ NNS VBP O
oocytes oocytes 0 0 0 0 0 0 0 0 7 0 RBR JJ NNS VBP CC O
detach detach 0 0 0 0 0 0 0 0 6 0 JJ NNS VBP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNS VBP CC JJ JJ O
float float 0 0 0 0 0 0 0 0 5 0 VBP CC JJ JJ IN O
free free 0 0 0 0 0 0 0 0 4 0 CC JJ JJ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ JJ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT JJ NN O
coelomic coelomic 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN WRB O
cavity cavity 0 0 0 0 0 0 0 0 6 0 DT JJ NN WRB PRP O
where where 0 0 0 0 0 0 0 0 5 0 JJ NN WRB PRP VBP O
they they 0 0 0 0 0 0 0 0 4 0 NN WRB PRP VBP NNS O
undergo undergo 0 0 0 0 0 0 0 0 7 0 WRB PRP VBP NNS IN O
vitellogenesis vitellogenesis 0 0 0 0 0 0 0 0 14 0 PRP VBP NNS IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 VBP NNS IN JJ NNP O
solitary solitary 0 0 0 0 0 0 0 0 8 0 NNS IN JJ NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP JJ NN O
cytoplasmic cytoplasmic 0 0 0 0 0 0 0 0 11 0 NNP NNP JJ NN IN O
material material 0 0 0 0 0 0 0 0 8 0 NNP JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBZ O
mature mature 0 0 0 0 0 0 0 0 6 0 IN DT NN VBZ JJ O
oocytes oocytes 0 0 0 0 0 0 0 0 7 0 DT NN VBZ JJ NN O
(diameter (diameter 0 0 0 0 0 0 0 0 9 0 NN VBZ JJ NN TO O
superior superior 0 0 0 0 0 0 0 0 8 0 VBZ JJ NN TO CD O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO CD CD O
200 200 0 0 0 0 0 0 1 1 3 0 NN TO CD CD JJ O
μ μ 0 0 0 0 0 0 0 0 1 0 TO CD CD JJ VBZ O
m) m) 0 0 0 0 0 0 0 0 2 0 CD CD JJ VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 CD JJ VBZ RB -NONE- O
asymmetrically asymmetrically 0 0 0 0 0 0 0 0 14 0 JJ VBZ RB -NONE- JJ O
distributed; distributed; 0 0 0 0 0 0 0 0 12 0 VBZ RB -NONE- JJ NN O
large large 0 0 0 0 0 0 0 0 5 0 RB -NONE- JJ NN NNS O
lipid lipid 0 0 0 0 0 0 0 0 5 0 -NONE- JJ NN NNS CC O
droplets droplets 0 0 0 0 0 0 0 0 8 0 JJ NN NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC JJ NN O
large large 0 0 0 0 0 0 0 0 5 0 NNS CC JJ NN NNS O
yolk yolk 0 0 0 0 0 0 0 0 4 0 CC JJ NN NNS VBP O
spheres spheres 0 0 0 0 0 0 0 0 7 0 JJ NN NNS VBP DT O
occupy occupy 0 0 0 0 0 0 0 0 6 0 NN NNS VBP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBP DT JJ NN O
vegetal vegetal 0 0 0 0 0 0 0 0 7 0 VBP DT JJ NN IN O
pole pole 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
oocyte oocyte 0 0 0 0 0 0 0 0 6 0 IN DT NN IN JJR O
while while 0 0 0 0 0 0 0 0 5 0 DT NN IN JJR NN O
smaller smaller 0 0 0 0 0 0 0 0 7 0 NN IN JJR NN NNS O
yolk yolk 0 0 0 0 0 0 0 0 4 0 IN JJR NN NNS VBP O
spheres spheres 0 0 0 0 0 0 0 0 7 0 JJR NN NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NN NNS VBP VBN IN O
situated situated 0 0 0 0 0 0 0 0 8 0 NNS VBP VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBP VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNP O
animal animal 0 0 0 0 0 0 0 0 6 0 IN DT JJ NNP NNP O
hemisphere. hemisphere. 0 0 0 0 0 0 0 0 11 0 DT JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN JJ O
female female 0 0 0 0 0 0 0 0 6 0 NNP NNP NN JJ NN O
coelomic coelomic 0 0 0 0 0 0 0 0 8 0 NNP NN JJ NN VBZ O
puncture puncture 0 0 0 0 0 0 0 0 8 0 NN JJ NN VBZ DT O
has has 0 0 0 0 0 0 0 0 3 0 JJ NN VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT JJ NN O
heterogeneous heterogeneous 0 0 0 0 0 0 0 0 13 0 VBZ DT JJ NN CC O
aspect aspect 0 0 0 0 0 0 0 0 6 0 DT JJ NN CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBZ JJ O
shows shows 0 0 0 0 0 0 0 0 5 0 NN CC VBZ JJ NN O
different different 0 0 0 0 0 0 0 0 9 0 CC VBZ JJ NN NNP O
oocyte oocyte 0 0 0 0 0 0 0 0 6 0 VBZ JJ NN NNP NNP O
diameters. diameters. 0 0 0 0 0 0 0 0 10 0 JJ NN NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP JJ NN O
reproductive reproductive 0 0 0 0 0 0 0 0 12 0 NNP NNP JJ NN VBZ O
period period 0 0 0 0 0 0 0 0 6 0 NNP JJ NN VBZ RBR O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ RBR JJ O
more more 0 0 0 0 0 0 0 0 4 0 NN VBZ RBR JJ IN O
intense intense 0 0 0 0 0 0 0 0 7 0 VBZ RBR JJ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 RBR JJ IN NN NN O
winter winter 0 0 0 0 0 0 0 0 6 0 JJ IN NN NN IN O
period period 0 0 0 0 0 0 0 0 6 0 IN NN NN IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN NNP TO O
January January 1 0 0 0 0 0 0 0 7 0 NN IN NNP TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 IN NNP TO NNP NNP O
March. March. 1 0 0 0 0 0 0 0 6 0 NNP TO NNP NNP VBZ O
Spawning Spawning 1 0 0 0 0 0 0 0 8 0 TO NNP NNP VBZ RB O
occurs occurs 0 0 0 0 0 0 0 0 6 0 NNP NNP VBZ RB IN O
mainly mainly 0 0 0 0 0 0 0 0 6 0 NNP VBZ RB IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBZ RB IN NNP NONE O
April. April. 1 0 0 0 0 0 0 0 6 0 RB IN NNP NONE NONE O
Formation Formation 1 0 0 0 0 0 0 0 9 0 NONE NONE NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NNP NNPS O
Humic Humic 1 0 0 0 0 0 0 0 5 0 NN IN NNP NNPS IN O
Substances Substances 1 0 0 0 0 0 0 0 10 0 IN NNP NNPS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
Weathered Weathered 1 0 0 0 0 0 0 0 9 0 NNPS IN NNP NNP NNP O
MSWI MSWI 1 1 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNP O
Bottom Bottom 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Ash. Ash. 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Shimaoka Shimaoka 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
T. T. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Urban Urban 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Construction, Construction, 1 0 0 0 1 0 0 0 13 0 IN NNP NNP NNP NNP O
Hebei Hebei 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Engineering, Engineering, 1 0 0 0 1 0 0 0 12 0 NNP IN NNP NNP CD O
Handan Handan 1 0 0 0 0 0 0 0 6 0 IN NNP NNP CD NNP O
056038, 056038, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD IN O
aimed aimed 0 0 0 0 0 0 0 0 5 0 NNP NN VBD IN NN O
at at 0 0 0 0 0 0 0 0 2 0 NN VBD IN NN DT O
evaluating evaluating 0 0 0 0 0 0 0 0 10 0 VBD IN NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT JJ NNS O
humic humic 0 0 0 0 0 0 0 0 5 0 NN DT JJ NNS -NONE- O
substances substances 0 0 0 0 0 0 0 0 10 0 DT JJ NNS -NONE- NN O
(HSs) (HSs) 0 0 0 0 0 0 0 0 5 0 JJ NNS -NONE- NN IN O
content content 0 0 0 0 0 0 0 0 7 0 NNS -NONE- NN IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 -NONE- NN IN JJ JJ O
municipal municipal 0 0 0 0 0 0 0 0 9 0 NN IN JJ JJ NN O
solid solid 0 0 0 0 0 0 0 0 5 0 IN JJ JJ NN NN O
waste waste 0 0 0 0 0 0 0 0 5 0 JJ JJ NN NN NN O
incinerator incinerator 0 0 0 0 0 0 0 0 11 0 JJ NN NN NN NN O
(MSWI) (MSWI) 0 1 0 0 0 0 0 0 6 0 NN NN NN NN NN O
bottom bottom 0 0 0 0 0 0 0 0 6 0 NN NN NN NN CC O
ash ash 0 0 0 0 0 0 0 0 3 0 NN NN NN CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NN CC PRP$ NN IN O
variation variation 0 0 0 0 0 0 0 0 9 0 CC PRP$ NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 PRP$ NN IN NN CC O
time time 0 0 0 0 0 0 0 0 4 0 NN IN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 CC DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
temperature temperature 0 0 0 0 0 0 0 0 11 0 NN IN NN IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNP O
HSs HSs 1 0 0 0 0 0 0 0 3 0 NN IN NNP NNP NNP O
formation. formation. 0 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN VBD O
process process 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBD IN O
suggested suggested 0 0 0 0 0 0 0 0 9 0 NNP NN VBD IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN NNP VBD O
IHSS IHSS 1 1 0 0 0 0 0 0 4 0 VBD IN NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 IN NNP VBD VBN TO O
applied applied 0 0 0 0 0 0 0 0 7 0 NNP VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB NNP O
extract extract 0 0 0 0 0 0 0 0 7 0 VBN TO VB NNP IN O
HSs HSs 1 0 0 0 0 0 0 0 3 0 TO VB NNP IN CD O
from from 0 0 0 0 0 0 0 0 4 0 VB NNP IN CD JJ O
two two 0 0 0 0 0 0 0 0 3 0 NNP IN CD JJ NN O
different different 0 0 0 0 0 0 0 0 9 0 IN CD JJ NN NN O
bottom bottom 0 0 0 0 0 0 0 0 6 0 CD JJ NN NN NN O
ash ash 0 0 0 0 0 0 0 0 3 0 JJ NN NN NN CC O
samples, samples, 0 0 0 0 1 0 0 0 8 0 NN NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT JJ NN O
extracted extracted 0 0 0 0 0 0 0 0 9 0 CC DT JJ NN IN O
efficiency efficiency 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN NNP CC O
NaOH NaOH 1 0 0 0 0 0 0 0 4 0 NN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP VBD O
Na4P2O7 Na4P2O7 1 0 0 0 0 0 0 1 7 0 NNP CC NNP VBD NNP O
was was 0 0 0 0 0 0 0 0 3 0 CC NNP VBD NNP NNP O
compared. compared. 0 0 0 0 0 0 0 0 9 0 NNP VBD NNP NNP NN O
MSWI MSWI 1 1 0 0 0 0 0 0 4 0 VBD NNP NNP NN NN O
bottom bottom 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NN NNS O
ash ash 0 0 0 0 0 0 0 0 3 0 NNP NN NN NNS VBD O
samples samples 0 0 0 0 0 0 0 0 7 0 NN NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
incubated incubated 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN CD O
at at 0 0 0 0 0 0 0 0 2 0 VBD VBN IN CD CC O
37°C 37°C 0 1 0 0 0 0 0 1 4 0 VBN IN CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 IN CD CC CD IN O
50°C 50°C 0 1 0 0 0 0 0 1 4 0 CD CC CD IN CD O
for for 0 0 0 0 0 0 0 0 3 0 CC CD IN CD NNP O
1 1 0 0 0 0 0 0 1 1 1 0 CD IN CD NNP NNP O
year. year. 0 0 0 0 0 0 0 0 5 0 IN CD NNP NNP CC O
HSs HSs 1 0 0 0 0 0 0 0 3 0 CD NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NNS O
nonhumic nonhumic 0 0 0 0 0 0 0 0 8 0 NNP CC JJ NNS VBD O
substances substances 0 0 0 0 0 0 0 0 10 0 CC JJ NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD VBN IN O
extracted extracted 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NN O
bottom bottom 0 0 0 0 0 0 0 0 6 0 IN DT NN NN NN O
ash ash 0 0 0 0 0 0 0 0 3 0 DT NN NN NN IN O
sample sample 0 0 0 0 0 0 0 0 6 0 NN NN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ VBN O
different different 0 0 0 0 0 0 0 0 9 0 NN IN JJ VBN NN O
incubated incubated 0 0 0 0 0 0 0 0 9 0 IN JJ VBN NN IN O
period period 0 0 0 0 0 0 0 0 6 0 JJ VBN NN IN CD O
by by 0 0 0 0 0 0 0 0 2 0 VBN NN IN CD NNP O
0.1 0.1 0 0 0 0 0 0 0 1 3 0 NN IN CD NNP NNP O
M M 1 1 0 0 0 0 0 0 1 0 IN CD NNP NNP NNP O
NaOH/Na4P2O7. NaOH/Na4P2O7. 1 0 0 1 0 0 0 1 13 0 CD NNP NNP NNP NN O
Results Results 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NN WDT O
show show 0 0 0 0 0 0 0 0 4 0 NNP NNP NN WDT DT O
that that 0 0 0 0 0 0 0 0 4 0 NNP NN WDT DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN WDT DT NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 WDT DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
humic humic 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NN O
acid acid 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN VBD O
formation formation 0 0 0 0 0 0 0 0 9 0 JJ NN NN VBD RB O
increased increased 0 0 0 0 0 0 0 0 9 0 NN NN VBD RB IN O
originally originally 0 0 0 0 0 0 0 0 10 0 NN VBD RB IN NN O
with with 0 0 0 0 0 0 0 0 4 0 VBD RB IN NN -NONE- O
incubation incubation 0 0 0 0 0 0 0 0 10 0 RB IN NN -NONE- VBD O
time, time, 0 0 0 0 1 0 0 0 5 0 IN NN -NONE- VBD DT O
reached reached 0 0 0 0 0 0 0 0 7 0 NN -NONE- VBD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- VBD DT NN IN O
maximum maximum 0 0 0 0 0 0 0 0 7 0 VBD DT NN IN CD O
at at 0 0 0 0 0 0 0 0 2 0 DT NN IN CD NN O
12th 12th 0 0 0 0 0 0 0 1 4 0 NN IN CD NN IN O
week week 0 0 0 0 0 0 0 0 4 0 IN CD NN IN CD O
under under 0 0 0 0 0 0 0 0 5 0 CD NN IN CD CC O
37°C 37°C 0 1 0 0 0 0 0 1 4 0 NN IN CD CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN CD CC IN CD O
at at 0 0 0 0 0 0 0 0 2 0 CD CC IN CD NN O
18th 18th 0 0 0 0 0 0 0 1 4 0 CC IN CD NN IN O
week week 0 0 0 0 0 0 0 0 4 0 IN CD NN IN CD O
under under 0 0 0 0 0 0 0 0 5 0 CD NN IN CD CC O
50°C, 50°C, 0 1 0 0 1 0 0 1 5 0 NN IN CD CC RB O
and and 0 0 0 0 0 0 0 0 3 0 IN CD CC RB VBD O
then then 0 0 0 0 0 0 0 0 4 0 CD CC RB VBD IN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 CC RB VBD IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 RB VBD IN NNP NNP O
time. time. 0 0 0 0 0 0 0 0 5 0 VBD IN NNP NNP JJ O
More More 1 0 0 0 0 0 0 0 4 0 IN NNP NNP JJ NN O
humic humic 0 0 0 0 0 0 0 0 5 0 NNP NNP JJ NN IN O
acid acid 0 0 0 0 0 0 0 0 4 0 NNP JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
MSWI MSWI 1 1 0 0 0 0 0 0 4 0 NN IN NNP NN NN O
bottom bottom 0 0 0 0 0 0 0 0 6 0 IN NNP NN NN VBD O
ash ash 0 0 0 0 0 0 0 0 3 0 NNP NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
formed formed 0 0 0 0 0 0 0 0 6 0 NN VBD VBN IN CD O
under under 0 0 0 0 0 0 0 0 5 0 VBD VBN IN CD VBN O
50°C 50°C 0 1 0 0 0 0 0 1 4 0 VBN IN CD VBN NN O
incubated incubated 0 0 0 0 0 0 0 0 9 0 IN CD VBN NN VBN O
condition condition 0 0 0 0 0 0 0 0 9 0 CD VBN NN VBN IN O
compared compared 0 0 0 0 0 0 0 0 8 0 VBN NN VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN VBN IN DT VBN O
that that 0 0 0 0 0 0 0 0 4 0 VBN IN DT VBN IN O
incubated incubated 0 0 0 0 0 0 0 0 9 0 IN DT VBN IN CD O
under under 0 0 0 0 0 0 0 0 5 0 DT VBN IN CD NN O
37°C. 37°C. 0 1 0 0 0 0 0 1 5 0 VBN IN CD NN DT O
Also, Also, 1 0 0 0 1 0 0 0 5 0 IN CD NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CD NN DT JJ NNS O
elemental elemental 0 0 0 0 0 0 0 0 9 0 NN DT JJ NNS IN O
compositions compositions 0 0 0 0 0 0 0 0 12 0 DT JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP VBD O
HSs HSs 1 0 0 0 0 0 0 0 3 0 NNS IN NNP VBD IN O
extracted extracted 0 0 0 0 0 0 0 0 9 0 IN NNP VBD IN NN O
from from 0 0 0 0 0 0 0 0 4 0 NNP VBD IN NN NN O
bottom bottom 0 0 0 0 0 0 0 0 6 0 VBD IN NN NN VBP O
ash ash 0 0 0 0 0 0 0 0 3 0 IN NN NN VBP NNP O
are are 0 0 0 0 0 0 0 0 3 0 NN NN VBP NNP NONE O
reported. reported. 0 0 0 0 0 0 0 0 9 0 NN VBP NNP NONE NONE O
Ionospheric Ionospheric 1 0 0 0 0 0 0 0 11 0 NONE NONE NNP NNS VBD O
anomalies anomalies 0 0 0 0 0 0 0 0 9 0 NONE NNP NNS VBD TO O
related related 0 0 0 0 0 0 0 0 7 0 NNP NNS VBD TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBD TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD TO DT NN : O
(m (m 0 0 0 0 0 0 0 0 2 0 TO DT NN : CD O
= = 0 0 0 0 0 0 0 0 1 0 DT NN : CD NN O
7.3), 7.3), 0 0 0 0 1 0 0 1 5 0 NN : CD NN CD O
august august 0 0 0 0 0 0 0 0 6 0 : CD NN CD CD O
27, 27, 0 0 0 0 1 0 0 1 3 0 CD NN CD CD NN O
2012, 2012, 0 0 0 0 1 0 0 1 5 0 NN CD CD NN -NONE- O
puerto puerto 0 0 0 0 0 0 0 0 6 0 CD CD NN -NONE- JJ O
earthquake, earthquake, 0 0 0 0 1 0 0 0 11 0 CD NN -NONE- JJ NN O
(m (m 0 0 0 0 0 0 0 0 2 0 NN -NONE- JJ NN CD O
= = 0 0 0 0 0 0 0 0 1 0 -NONE- JJ NN CD NN O
6.8), 6.8), 0 0 0 0 1 0 0 1 5 0 JJ NN CD NN CD O
august august 0 0 0 0 0 0 0 0 6 0 NN CD NN CD CD O
30, 30, 0 0 0 0 1 0 0 1 3 0 CD NN CD CD NN O
2012 2012 0 0 0 0 0 0 1 1 4 0 NN CD CD NN NN O
jan jan 0 0 0 0 0 0 0 0 3 0 CD CD NN NN NN O
mayen mayen 0 0 0 0 0 0 0 0 5 0 CD NN NN NN NN O
island island 0 0 0 0 0 0 0 0 6 0 NN NN NN NN CC O
earthquake, earthquake, 0 0 0 0 1 0 0 0 11 0 NN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
(m (m 0 0 0 0 0 0 0 0 2 0 NN CC JJ NN CD O
= = 0 0 0 0 0 0 0 0 1 0 CC JJ NN CD NN O
7.6), 7.6), 0 0 0 0 1 0 0 1 5 0 JJ NN CD NN CD O
august august 0 0 0 0 0 0 0 0 6 0 NN CD NN CD CD O
31, 31, 0 0 0 0 1 0 0 1 3 0 CD NN CD CD NNS O
2012, 2012, 0 0 0 0 1 0 0 1 5 0 NN CD CD NNS -NONE- O
Philippines Philippines 1 0 0 0 0 0 0 0 11 0 CD CD NNS -NONE- JJ O
earthquake: earthquake: 0 0 0 0 0 0 0 0 11 0 CD NNS -NONE- JJ NN O
two-dimensional two-dimensional 0 0 1 0 0 0 0 0 15 0 NNS -NONE- JJ NN NN O
principal principal 0 0 0 0 0 0 0 0 9 0 -NONE- JJ NN NN NNP O
component component 0 0 0 0 0 0 0 0 9 0 JJ NN NN NNP NNP O
analysis. analysis. 0 0 0 0 0 0 0 0 9 0 NN NN NNP NNP NNP O
Lin Lin 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNP NNP O
JW. JW. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Earth Earth 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Science, Science, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP NNP O
National National 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Cheng Cheng 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Kung Kung 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP CD O
No. No. 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP CD NNP O
1 1 0 0 0 0 0 0 1 1 1 0 NNP NNP CD NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 NNP CD NNP NNP NNP O
Road, Road, 1 0 0 0 1 0 0 0 5 0 CD NNP NNP NNP CD O
Tainan Tainan 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP CD NNP O
701, 701, 0 0 0 0 1 0 0 1 4 0 NNP NNP CD NNP NNP O
Taiwan. Taiwan. 1 0 0 0 0 0 0 0 7 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NN O
Two-dimensional Two-dimensional 1 0 1 0 0 0 0 0 15 0 NNP NNP NNP NN NN O
principal principal 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NN NN O
component component 0 0 0 0 0 0 0 0 9 0 NNP NN NN NN NN O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NN NN NN NN CC O
(2DPCA) (2DPCA) 0 1 0 0 0 0 0 1 7 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
principal principal 0 0 0 0 0 0 0 0 9 0 NN CC NN NN NN O
component component 0 0 0 0 0 0 0 0 9 0 CC NN NN NN NN O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NN NN NN NN VBP O
(PCA) (PCA) 0 1 0 0 0 0 0 0 5 0 NN NN NN VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NN NN VBP VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 NN VBP VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBP VBN TO VB DT O
examine examine 0 0 0 0 0 0 0 0 7 0 VBN TO VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJ NN O
ionospheric ionospheric 0 0 0 0 0 0 0 0 11 0 VB DT JJ NN NN O
total total 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN NN O
electron electron 0 0 0 0 0 0 0 0 8 0 JJ NN NN NN NN O
content content 0 0 0 0 0 0 0 0 7 0 NN NN NN NN NNS O
(TEC) (TEC) 0 1 0 0 0 0 0 0 5 0 NN NN NN NNS IN O
data data 0 0 0 0 0 0 0 0 4 0 NN NN NNS IN DT O
during during 0 0 0 0 0 0 0 0 6 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
time time 0 0 0 0 0 0 0 0 4 0 IN DT NN NN IN O
period period 0 0 0 0 0 0 0 0 6 0 DT NN NN IN CD O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN CD IN O
00:00 00:00 0 0 0 0 0 0 0 1 5 0 NN IN CD IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 IN CD IN NNP CD O
August August 1 0 0 0 0 0 0 0 6 0 CD IN NNP CD TO O
21 21 0 0 0 0 0 0 1 1 2 0 IN NNP CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 NNP CD TO CD CD O
12: 12: 0 0 0 0 0 0 0 1 3 0 CD TO CD CD IN O
45 45 0 0 0 0 0 0 1 1 2 0 TO CD CD IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 CD CD IN NNP CD O
August August 1 0 0 0 0 0 0 0 6 0 CD IN NNP CD JJ O
31 31 0 0 0 0 0 0 1 1 2 0 IN NNP CD JJ WDT O
(UT), (UT), 0 1 0 0 1 0 0 0 5 0 NNP CD JJ WDT VBP O
which which 0 0 0 0 0 0 0 0 5 0 CD JJ WDT VBP CD O
are are 0 0 0 0 0 0 0 0 3 0 JJ WDT VBP CD NNS O
10 10 0 0 0 0 0 0 1 1 2 0 WDT VBP CD NNS IN O
days days 0 0 0 0 0 0 0 0 4 0 VBP CD NNS IN DT O
before before 0 0 0 0 0 0 0 0 6 0 CD NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NNP O
M M 1 1 0 0 0 0 0 0 1 0 IN DT NNP NNP CD O
= = 0 0 0 0 0 0 0 0 1 0 DT NNP NNP CD NNP O
7.6 7.6 0 0 0 0 0 0 0 1 3 0 NNP NNP CD NNP NN O
Philippines Philippines 1 0 0 0 0 0 0 0 11 0 NNP CD NNP NN IN O
earthquake earthquake 0 0 0 0 0 0 0 0 10 0 CD NNP NN IN CD O
at at 0 0 0 0 0 0 0 0 2 0 NNP NN IN CD IN O
12:47:34 12:47:34 0 0 0 0 0 0 0 1 8 0 NN IN CD IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 IN CD IN NNP CD O
August August 1 0 0 0 0 0 0 0 6 0 CD IN NNP CD CD O
31, 31, 0 0 0 0 1 0 0 1 3 0 IN NNP CD CD JJ O
2012 2012 0 0 0 0 0 0 1 1 4 0 NNP CD CD JJ IN O
(UT) (UT) 0 1 0 0 0 0 0 0 4 0 CD CD JJ IN DT O
with with 0 0 0 0 0 0 0 0 4 0 CD JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN IN O
depth depth 0 0 0 0 0 0 0 0 5 0 IN DT NN IN CD O
at at 0 0 0 0 0 0 0 0 2 0 DT NN IN CD NNP O
34.9 34.9 0 0 0 0 0 0 0 1 4 0 NN IN CD NNP NNP O
km. km. 0 0 0 0 0 0 0 0 3 0 IN CD NNP NNP DT O
From From 1 0 0 0 0 0 0 0 4 0 CD NNP NNP DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNS IN O
results results 0 0 0 0 0 0 0 0 7 0 NNP DT NNS IN VBG O
by by 0 0 0 0 0 0 0 0 2 0 DT NNS IN VBG CD O
using using 0 0 0 0 0 0 0 0 5 0 NNS IN VBG CD DT O
2DPCA, 2DPCA, 0 1 0 0 1 0 0 1 6 0 IN VBG CD DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 VBG CD DT NNP NN O
TEC TEC 1 1 0 0 0 0 0 0 3 0 CD DT NNP NN IN O
precursor precursor 0 0 0 0 0 0 0 0 9 0 DT NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NN O
Philippines Philippines 1 0 0 0 0 0 0 0 11 0 NN IN NNP NN VBZ O
earthquake earthquake 0 0 0 0 0 0 0 0 10 0 IN NNP NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 NN VBZ VBN IN DT O
during during 0 0 0 0 0 0 0 0 6 0 VBZ VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NN O
time time 0 0 0 0 0 0 0 0 4 0 IN DT NN NN IN O
period period 0 0 0 0 0 0 0 0 6 0 DT NN NN IN CD O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN CD TO O
4:25 4:25 0 0 0 0 0 0 0 1 4 0 NN IN CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 IN CD TO CD IN O
4:40 4:40 0 0 0 0 0 0 0 1 4 0 CD TO CD IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 TO CD IN NNP CD O
August August 1 0 0 0 0 0 0 0 6 0 CD IN NNP CD CD O
28, 28, 0 0 0 0 1 0 0 1 3 0 IN NNP CD CD JJ O
2012 2012 0 0 0 0 0 0 1 1 4 0 NNP CD CD JJ IN O
(UT) (UT) 0 1 0 0 0 0 0 0 4 0 CD CD JJ IN DT O
with with 0 0 0 0 0 0 0 0 4 0 CD JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN NN O
duration duration 0 0 0 0 0 0 0 0 8 0 IN DT NN NN IN O
time time 0 0 0 0 0 0 0 0 4 0 DT NN NN IN IN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN IN JJS O
at at 0 0 0 0 0 0 0 0 2 0 NN IN IN JJS CD O
least least 0 0 0 0 0 0 0 0 5 0 IN IN JJS CD NNP O
15 15 0 0 0 0 0 0 1 1 2 0 IN JJS CD NNP NNP O
minutes. minutes. 0 0 0 0 0 0 0 0 8 0 JJS CD NNP NNP NNP O
Another Another 1 0 0 0 0 0 0 0 7 0 CD NNP NNP NNP NNP O
earthquake-related earthquake-related 0 0 1 0 0 0 0 0 18 0 NNP NNP NNP NNP RB O
TEC TEC 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP RB VBZ O
anomaly anomaly 0 0 0 0 0 0 0 0 7 0 NNP NNP RB VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP RB VBZ JJ IN O
detectable detectable 0 0 0 0 0 0 0 0 10 0 RB VBZ JJ IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN NN O
time time 0 0 0 0 0 0 0 0 4 0 IN DT NN NN IN O
period period 0 0 0 0 0 0 0 0 6 0 DT NN NN IN CD O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN CD TO O
04:35 04:35 0 0 0 0 0 0 0 1 5 0 NN IN CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 IN CD TO CD IN O
04:40 04:40 0 0 0 0 0 0 0 1 5 0 CD TO CD IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 TO CD IN NNP CD O
August August 1 0 0 0 0 0 0 0 6 0 CD IN NNP CD CD O
27, 27, 0 0 0 0 1 0 0 1 3 0 IN NNP CD CD JJ O
2012 2012 0 0 0 0 0 0 1 1 4 0 NNP CD CD JJ IN O
(UT) (UT) 0 1 0 0 0 0 0 0 4 0 CD CD JJ IN DT O
with with 0 0 0 0 0 0 0 0 4 0 CD JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN NN O
duration duration 0 0 0 0 0 0 0 0 8 0 IN DT NN NN IN O
time time 0 0 0 0 0 0 0 0 4 0 DT NN NN IN IN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN IN JJS O
at at 0 0 0 0 0 0 0 0 2 0 NN IN IN JJS CD O
least least 0 0 0 0 0 0 0 0 5 0 IN IN JJS CD NNS O
5 5 0 0 0 0 0 0 1 1 1 0 IN JJS CD NNS IN O
minutes minutes 0 0 0 0 0 0 0 0 7 0 JJS CD NNS IN DT O
during during 0 0 0 0 0 0 0 0 6 0 CD NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NN O
Puerto Puerto 1 0 0 0 0 0 0 0 6 0 IN DT NNP NN IN O
earthquake earthquake 0 0 0 0 0 0 0 0 10 0 DT NNP NN IN CD O
at at 0 0 0 0 0 0 0 0 2 0 NNP NN IN CD CD O
04: 04: 0 0 0 0 0 0 0 1 3 0 NN IN CD CD IN O
37:20 37:20 0 0 0 0 0 0 0 1 5 0 IN CD CD IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 CD CD IN NNP CD O
August August 1 0 0 0 0 0 0 0 6 0 CD IN NNP CD CD O
27, 27, 0 0 0 0 1 0 0 1 3 0 IN NNP CD CD JJ O
2012 2012 0 0 0 0 0 0 1 1 4 0 NNP CD CD JJ NN O
(UT) (UT) 0 1 0 0 0 0 0 0 4 0 CD CD JJ NN NN O
(M (M 0 1 0 0 0 0 0 0 2 0 CD JJ NN NN : O
w w 0 0 0 0 0 0 0 0 1 0 JJ NN NN : CD O
= = 0 0 0 0 0 0 0 0 1 0 NN NN : CD IN O
7.3) 7.3) 0 0 0 0 0 0 0 1 4 0 NN : CD IN DT O
with with 0 0 0 0 0 0 0 0 4 0 : CD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT NN IN O
depth depth 0 0 0 0 0 0 0 0 5 0 IN DT NN IN CD O
at at 0 0 0 0 0 0 0 0 2 0 DT NN IN CD NNP O
20.3 20.3 0 0 0 0 0 0 0 1 4 0 NN IN CD NNP NNP O
km. km. 0 0 0 0 0 0 0 0 3 0 IN CD NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 CD NNP NNP NN IN O
precursor precursor 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
Puerto Puerto 1 0 0 0 0 0 0 0 6 0 IN DT NNP NN VBZ O
earthquake earthquake 0 0 0 0 0 0 0 0 10 0 DT NNP NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ RB NNP O
not not 0 0 0 0 0 0 0 0 3 0 NN VBZ RB NNP NNP O
detectable. detectable. 0 0 0 0 0 0 0 0 11 0 VBZ RB NNP NNP RB O
TEC TEC 1 1 0 0 0 0 0 0 3 0 RB NNP NNP RB VBZ O
anomaly anomaly 0 0 0 0 0 0 0 0 7 0 NNP NNP RB VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP RB VBZ RB TO O
not not 0 0 0 0 0 0 0 0 3 0 RB VBZ RB TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ RB TO VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 RB TO VB VBN VBN O
found found 0 0 0 0 0 0 0 0 5 0 TO VB VBN VBN TO O
related related 0 0 0 0 0 0 0 0 7 0 VB VBN VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN TO DT NNP NNP O
Jan Jan 1 0 0 0 0 0 0 0 3 0 TO DT NNP NNP NNP O
Mayen Mayen 1 0 0 0 0 0 0 0 5 0 DT NNP NNP NNP NN O
Island Island 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NN NN O
earthquake earthquake 0 0 0 0 0 0 0 0 10 0 NNP NNP NN NN NN O
(M (M 0 1 0 0 0 0 0 0 2 0 NNP NN NN NN : O
w w 0 0 0 0 0 0 0 0 1 0 NN NN NN : CD O
= = 0 0 0 0 0 0 0 0 1 0 NN NN : CD IN O
6.8) 6.8) 0 0 0 0 0 0 0 1 4 0 NN : CD IN CD O
at at 0 0 0 0 0 0 0 0 2 0 : CD IN CD IN O
13:43:24 13:43:24 0 0 0 0 0 0 0 1 8 0 CD IN CD IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 IN CD IN NNP CD O
August August 1 0 0 0 0 0 0 0 6 0 CD IN NNP CD CD O
30, 30, 0 0 0 0 1 0 0 1 3 0 IN NNP CD CD NNP O
2012 2012 0 0 0 0 0 0 1 1 4 0 NNP CD CD NNP NNP O
(UT). (UT). 0 1 0 0 0 0 0 0 5 0 CD CD NNP NNP JJ O
These These 1 0 0 0 0 0 0 0 5 0 CD NNP NNP JJ NNP O
earthquake-related earthquake-related 0 0 1 0 0 0 0 0 18 0 NNP NNP JJ NNP NNS O
TEC TEC 1 1 0 0 0 0 0 0 3 0 NNP JJ NNP NNS VBP O
anomalies anomalies 0 0 0 0 0 0 0 0 9 0 JJ NNP NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNS VBP JJ IN O
detectable detectable 0 0 0 0 0 0 0 0 10 0 NNS VBP JJ IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBP JJ IN NN CD O
using using 0 0 0 0 0 0 0 0 5 0 JJ IN NN CD RB O
2DPCA 2DPCA 0 1 0 0 0 0 0 1 5 0 IN NN CD RB IN O
rather rather 0 0 0 0 0 0 0 0 6 0 NN CD RB IN NNP O
than than 0 0 0 0 0 0 0 0 4 0 CD RB IN NNP NNP O
PCA. PCA. 1 1 0 0 0 0 0 0 4 0 RB IN NNP NNP VBP O
They They 1 0 0 0 0 0 0 0 4 0 IN NNP NNP VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNP VBP VBN JJ O
localized localized 0 0 0 0 0 0 0 0 9 0 NNP VBP VBN JJ DT O
nearby nearby 0 0 0 0 0 0 0 0 6 0 VBP VBN JJ DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 VBN JJ DT NNS IN O
epicenters epicenters 0 0 0 0 0 0 0 0 10 0 JJ DT NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT NNPS O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNPS CC O
Philippines Philippines 1 0 0 0 0 0 0 0 11 0 IN DT NNPS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 DT NNPS CC NNP NNP O
Puerto Puerto 1 0 0 0 0 0 0 0 6 0 NNPS CC NNP NNP NONE O
earthquakes. earthquakes. 0 0 0 0 0 0 0 0 12 0 CC NNP NNP NONE NONE O
Norepinephrine Norepinephrine 1 0 0 0 0 0 0 0 14 0 NONE NONE NNP NNP NNP O
Inhibits Inhibits 1 0 0 0 0 0 0 0 8 0 NONE NNP NNP NNP NNP O
Macrophage Macrophage 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP IN O
Migration Migration 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Decreasing Decreasing 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
CCR2 CCR2 1 1 0 0 0 0 0 1 4 0 IN NNP NNP NNP NNP O
Expression. Expression. 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
Xiu Xiu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Stanojcic Stanojcic 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Jeschke Jeschke 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
MG. MG. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Ross Ross 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Tilley Tilley 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Burn Burn 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Centre, Centre, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Sunnybrook Sunnybrook 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Health Health 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Science Science 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Centre, Centre, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Sunnybrook Sunnybrook 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Institute, Institute, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP IN O
Division Division 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Plastic Plastic 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
Surgery, Surgery, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Surgery, Surgery, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Immunology, Immunology, 1 0 0 0 1 0 0 0 11 0 NNP IN NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Toronto, Toronto, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP NNP O
Toronto, Toronto, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP NNP O
Ontario, Ontario, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Canada. Canada. 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNS O
Increased Increased 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNS IN O
incidences incidences 0 0 0 0 0 0 0 0 10 0 NNP NNP NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN JJ CC O
infectious infectious 0 0 0 0 0 0 0 0 10 0 NNS IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NNS O
septic septic 0 0 0 0 0 0 0 0 6 0 JJ CC JJ NNS IN O
complications complications 0 0 0 0 0 0 0 0 13 0 CC JJ NNS IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 JJ NNS IN JJ NNS O
post-burn post-burn 0 0 1 0 0 0 0 0 9 0 NNS IN JJ NNS VBP O
courses courses 0 0 0 0 0 0 0 0 7 0 IN JJ NNS VBP DT O
represent represent 0 0 0 0 0 0 0 0 9 0 JJ NNS VBP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBP DT JJ NN O
main main 0 0 0 0 0 0 0 0 4 0 VBP DT JJ NN TO O
contributor contributor 0 0 0 0 0 0 0 0 11 0 DT JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB NN O
burn burn 0 0 0 0 0 0 0 0 4 0 NN TO VB NN NNP O
injury injury 0 0 0 0 0 0 0 0 6 0 TO VB NN NNP NNP O
mortality. mortality. 0 0 0 0 0 0 0 0 10 0 VB NN NNP NNP VBZ O
Sustained Sustained 1 0 0 0 0 0 0 0 9 0 NN NNP NNP VBZ IN O
increases increases 0 0 0 0 0 0 0 0 9 0 NNP NNP VBZ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN NN NN O
catecholamine catecholamine 0 0 0 0 0 0 0 0 13 0 VBZ IN NN NN RB O
levels, levels, 0 0 0 0 1 0 0 0 7 0 IN NN NN RB JJ O
especially especially 0 0 0 0 0 0 0 0 10 0 NN NN RB JJ NN O
norepinephrine norepinephrine 0 0 0 0 0 0 0 0 14 0 NN RB JJ NN NN O
(NE), (NE), 0 1 0 0 1 0 0 0 5 0 RB JJ NN NN TO O
contribute contribute 0 0 0 0 0 0 0 0 10 0 JJ NN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO VB NNS O
immune immune 0 0 0 0 0 0 0 0 6 0 NN TO VB NNS IN O
disturbances disturbances 0 0 0 0 0 0 0 0 12 0 TO VB NNS IN RB O
in in 0 0 0 0 0 0 0 0 2 0 VB NNS IN RB VBN O
severely severely 0 0 0 0 0 0 0 0 8 0 NNS IN RB VBN NNP O
burned burned 0 0 0 0 0 0 0 0 6 0 IN RB VBN NNP NNP O
patients. patients. 0 0 0 0 0 0 0 0 9 0 RB VBN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 VBN NNP NNP NN NNS O
precise precise 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NNS VBG O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 NNP NN NNS VBG JJ O
underlying underlying 0 0 0 0 0 0 0 0 10 0 NN NNS VBG JJ NN O
NE-mediated NE-mediated 1 0 1 0 0 0 0 0 11 0 NNS VBG JJ NN VBP O
immunoregulation immunoregulation 0 0 0 0 0 0 0 0 16 0 VBG JJ NN VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 JJ NN VBP RB RB O
not not 0 0 0 0 0 0 0 0 3 0 NN VBP RB RB NNP O
fully fully 0 0 0 0 0 0 0 0 5 0 VBP RB RB NNP NNP O
understood. understood. 0 0 0 0 0 0 0 0 11 0 RB RB NNP NNP PRP O
Here Here 1 0 0 0 0 0 0 0 4 0 RB NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP IN O
hypothesize hypothesize 0 0 0 0 0 0 0 0 11 0 NNP PRP VBP IN RB O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN RB VBN O
persistently persistently 0 0 0 0 0 0 0 0 12 0 VBP IN RB VBN NNP O
elevated elevated 0 0 0 0 0 0 0 0 8 0 IN RB VBN NNP NNS O
NE NE 1 1 0 0 0 0 0 0 2 0 RB VBN NNP NNS VBP O
levels levels 0 0 0 0 0 0 0 0 6 0 VBN NNP NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNS VBP VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NNS VBP VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBP VBN IN NNP NNP O
immunodysfunctions. immunodysfunctions. 0 0 0 0 0 0 0 0 19 0 VBN IN NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 IN NNP NNP VBD DT O
examined examined 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 VBD DT NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NNP IN O
NE NE 1 1 0 0 0 0 0 0 2 0 NNS IN NNP IN DT O
on on 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN CC O
phenotype phenotype 0 0 0 0 0 0 0 0 9 0 IN DT NN CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NNS IN O
functions functions 0 0 0 0 0 0 0 0 9 0 NN CC NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NNS IN NN JJ O
bone bone 0 0 0 0 0 0 0 0 4 0 NNS IN NN JJ NNS O
marrow-derived marrow-derived 0 0 1 0 0 0 0 0 14 0 IN NN JJ NNS NNP O
macrophages macrophages 0 0 0 0 0 0 0 0 11 0 NN JJ NNS NNP NNP O
(BMMs). (BMMs). 0 0 0 0 0 0 0 0 7 0 JJ NNS NNP NNP NN O
Whole Whole 1 0 0 0 0 0 0 0 5 0 NNS NNP NNP NN NN O
mouse mouse 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NN NN O
bone bone 0 0 0 0 0 0 0 0 4 0 NNP NN NN NN NNS O
marrow marrow 0 0 0 0 0 0 0 0 6 0 NN NN NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
treated treated 0 0 0 0 0 0 0 0 7 0 NNS VBD VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN IN O
vitro vitro 0 0 0 0 0 0 0 0 5 0 VBN IN NN IN CD O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN CD JJ O
40 40 0 0 0 0 0 0 1 1 2 0 NN IN CD JJ IN O
ng/mL ng/mL 0 0 0 1 0 0 0 0 5 0 IN CD JJ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CD JJ IN JJ CC O
M-CSF M-CSF 1 1 1 0 0 0 0 0 5 0 JJ IN JJ CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC IN CD O
with with 0 0 0 0 0 0 0 0 4 0 JJ CC IN CD NN O
1 1 0 0 0 0 0 0 1 1 1 0 CC IN CD NN CD O
x x 0 0 0 0 0 0 0 0 1 0 IN CD NN CD NNP O
10(-6) 10(-6) 0 0 1 0 0 0 0 1 6 0 CD NN CD NNP CC O
M M 1 1 0 0 0 0 0 0 1 0 NN CD NNP CC CD O
or or 0 0 0 0 0 0 0 0 2 0 CD NNP CC CD NN O
1 1 0 0 0 0 0 0 1 1 1 0 NNP CC CD NN CD O
x x 0 0 0 0 0 0 0 0 1 0 CC CD NN CD NNP O
10(-8) 10(-8) 0 0 1 0 0 0 0 1 6 0 CD NN CD NNP IN O
M M 1 1 0 0 0 0 0 0 1 0 NN CD NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CD NNP IN NNP CC O
NE NE 1 1 0 0 0 0 0 0 2 0 NNP IN NNP CC IN O
or or 0 0 0 0 0 0 0 0 2 0 IN NNP CC IN NNP O
without without 0 0 0 0 0 0 0 0 7 0 NNP CC IN NNP IN O
NE NE 1 1 0 0 0 0 0 0 2 0 CC IN NNP IN CD O
for for 0 0 0 0 0 0 0 0 3 0 IN NNP IN CD NN O
7 7 0 0 0 0 0 0 1 1 1 0 NNP IN CD NN NNS O
days; days; 0 0 0 0 0 0 0 0 5 0 IN CD NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 CD NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN CC O
collected collected 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 VBD VBN CC VBN IN O
stained stained 0 0 0 0 0 0 0 0 7 0 VBN CC VBN IN NNS O
with with 0 0 0 0 0 0 0 0 4 0 CC VBN IN NNS IN O
antibodies antibodies 0 0 0 0 0 0 0 0 10 0 VBN IN NNS IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 IN NNS IN JJ NN O
CD11b, CD11b, 1 0 0 0 1 0 0 1 6 0 NNS IN JJ NN NNP O
F4/80, F4/80, 1 1 0 1 1 0 0 1 6 0 IN JJ NN NNP NNP O
MHC MHC 1 1 0 0 0 0 0 0 3 0 JJ NN NNP NNP CC O
II II 1 1 0 0 0 0 0 0 2 0 NN NNP NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP CC DT NN NNP O
inflammatory inflammatory 0 0 0 0 0 0 0 0 12 0 CC DT NN NNP NN O
CC CC 1 1 0 0 0 0 0 0 2 0 DT NN NNP NN NN O
chemokine chemokine 0 0 0 0 0 0 0 0 9 0 NN NNP NN NN CD O
receptor receptor 0 0 0 0 0 0 0 0 8 0 NNP NN NN CD NNP O
2 2 0 0 0 0 0 0 1 1 1 0 NN NN CD NNP NNP O
(CCR2). (CCR2). 0 1 0 0 0 0 0 1 7 0 NN CD NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 CD NNP NNP VBD CD O
found found 0 0 0 0 0 0 0 0 5 0 NNP NNP VBD CD NN O
1 1 0 0 0 0 0 0 1 1 1 0 NNP VBD CD NN CD O
x x 0 0 0 0 0 0 0 0 1 0 VBD CD NN CD NNP O
10(-6) 10(-6) 0 0 1 0 0 0 0 1 6 0 CD NN CD NNP IN O
M M 1 1 0 0 0 0 0 0 1 0 NN CD NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CD NNP IN NNP VBD O
NE NE 1 1 0 0 0 0 0 0 2 0 NNP IN NNP VBD NNP O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 IN NNP VBD NNP NNP O
MHC MHC 1 1 0 0 0 0 0 0 3 0 NNP VBD NNP NNP CC O
II II 1 1 0 0 0 0 0 0 2 0 VBD NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NN O
CCR2 CCR2 1 1 0 0 0 0 0 1 4 0 NNP CC NNP NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 CC NNP NN IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NNP O
CD11b(+)/F4/80(+) CD11b(+)/F4/80(+) 1 0 0 1 0 0 0 1 17 0 NN IN NNP NNP NNP O
BMM BMM 1 1 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP RB O
It It 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP RB VBD O
also also 0 0 0 0 0 0 0 0 4 0 NNP NNP RB VBD NNP O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NNP RB VBD NNP NN O
BMM BMM 1 1 0 0 0 0 0 0 3 0 RB VBD NNP NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VBD NNP NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN JJ O
inhibiting inhibiting 0 0 0 0 0 0 0 0 10 0 NN IN NN JJ NNP O
CSF-1R CSF-1R 1 1 1 0 0 0 0 1 6 0 IN NN JJ NNP NNP O
expression. expression. 0 0 0 0 0 0 0 0 11 0 NN JJ NNP NNP DT O
On On 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNP CD O
contrary, contrary, 0 0 0 0 1 0 0 0 9 0 NNP DT NNP CD NN O
1 1 0 0 0 0 0 0 1 1 1 0 DT NNP CD NN CD O
x x 0 0 0 0 0 0 0 0 1 0 NNP CD NN CD NNP O
10(-8) 10(-8) 0 0 1 0 0 0 0 1 6 0 CD NN CD NNP IN O
M M 1 1 0 0 0 0 0 0 1 0 NN CD NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CD NNP IN NNP RB O
NE NE 1 1 0 0 0 0 0 0 2 0 NNP IN NNP RB VBD O
slightly slightly 0 0 0 0 0 0 0 0 8 0 IN NNP RB VBD DT O
increased increased 0 0 0 0 0 0 0 0 9 0 NNP RB VBD DT NNP O
both both 0 0 0 0 0 0 0 0 4 0 RB VBD DT NNP NNP O
MHC MHC 1 1 0 0 0 0 0 0 3 0 VBD DT NNP NNP CC O
II II 1 1 0 0 0 0 0 0 2 0 DT NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NN O
CCR2 CCR2 1 1 0 0 0 0 0 1 4 0 NNP CC NNP NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 CC NNP NN IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NNP O
CD11b(+)/F4/80(+) CD11b(+)/F4/80(+) 1 0 0 1 0 0 0 1 17 0 NN IN NNP NNP VBZ O
BMM BMM 1 1 0 0 0 0 0 0 3 0 IN NNP NNP VBZ CC O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ CC VBN O
but but 0 0 0 0 0 0 0 0 3 0 NNP VBZ CC VBN -NONE- O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 VBZ CC VBN -NONE- NNP O
CD11b(+)/F4/80(+) CD11b(+)/F4/80(+) 1 0 0 1 0 0 0 1 17 0 CC VBN -NONE- NNP NNP O
BMM BMM 1 1 0 0 0 0 0 0 3 0 VBN -NONE- NNP NNP -NONE- O
proliferation. proliferation. 0 0 0 0 0 0 0 0 14 0 -NONE- NNP NNP -NONE- VBN O
MCP-1 MCP-1 1 1 1 0 0 0 0 1 5 0 NNP NNP -NONE- VBN NN O
based based 0 0 0 0 0 0 0 0 5 0 NNP -NONE- VBN NN NN O
migration migration 0 0 0 0 0 0 0 0 9 0 -NONE- VBN NN NN VBD O
assay assay 0 0 0 0 0 0 0 0 5 0 VBN NN NN VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NN NN VBD IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN IN O
migration migration 0 0 0 0 0 0 0 0 9 0 IN DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD NN O
1 1 0 0 0 0 0 0 1 1 1 0 NN IN CD NN CD O
x x 0 0 0 0 0 0 0 0 1 0 IN CD NN CD NNP O
10(-6) 10(-6) 0 0 1 0 0 0 0 1 6 0 CD NN CD NNP IN O
M M 1 1 0 0 0 0 0 0 1 0 NN CD NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CD NNP IN JJ NNP O
NE-treated NE-treated 1 0 1 0 0 0 0 0 10 0 NNP IN JJ NNP IN O
BMM BMM 1 1 0 0 0 0 0 0 3 0 IN JJ NNP IN -NONE- O
toward toward 0 0 0 0 0 0 0 0 6 0 JJ NNP IN -NONE- VBD O
MCP-1 MCP-1 1 1 1 0 0 0 0 1 5 0 NNP IN -NONE- VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 IN -NONE- VBD RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 -NONE- VBD RB VBN VBN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 VBD RB VBN VBN TO O
compared compared 0 0 0 0 0 0 0 0 8 0 RB VBN VBN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO NNP IN O
BMM BMM 1 1 0 0 0 0 0 0 3 0 VBN TO NNP IN NNP O
without without 0 0 0 0 0 0 0 0 7 0 TO NNP IN NNP NNP O
NE NE 1 1 0 0 0 0 0 0 2 0 NNP IN NNP NNP NNP O
treatment. treatment. 0 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP CD O
Both Both 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP CD NN O
1 1 0 0 0 0 0 0 1 1 1 0 NNP NNP CD NN CD O
x x 0 0 0 0 0 0 0 0 1 0 NNP CD NN CD NNP O
10(-8) 10(-8) 0 0 1 0 0 0 0 1 6 0 CD NN CD NNP CC O
M M 1 1 0 0 0 0 0 0 1 0 NN CD NNP CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD NNP CC CD NN O
1 1 0 0 0 0 0 0 1 1 1 0 NNP CC CD NN CD O
x x 0 0 0 0 0 0 0 0 1 0 CC CD NN CD NNP O
10(-6) 10(-6) 0 0 1 0 0 0 0 1 6 0 CD NN CD NNP IN O
M M 1 1 0 0 0 0 0 0 1 0 NN CD NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CD NNP IN NNP VBD O
NE NE 1 1 0 0 0 0 0 0 2 0 NNP IN NNP VBD NNP O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 IN NNP VBD NNP NN O
TNF-α TNF-α 1 0 1 0 0 0 0 0 5 0 NNP VBD NNP NN CC O
production production 0 0 0 0 0 0 0 0 10 0 VBD NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN IN O
phagocytosis phagocytosis 0 0 0 0 0 0 0 0 12 0 NN CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NNP O
FITC-Dextran. FITC-Dextran. 1 0 1 0 0 0 0 0 13 0 NN IN NNP NNP NN O
Intracellular Intracellular 1 0 0 0 0 0 0 0 13 0 IN NNP NNP NN IN O
staining staining 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
transcriptional transcriptional 0 0 0 0 0 0 0 0 15 0 NN IN JJ NN NNP O
factor factor 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNP VBD O
MafB MafB 1 0 0 0 0 0 0 0 4 0 JJ NN NNP VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NN NNP VBD IN CD O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBD IN CD NN O
1 1 0 0 0 0 0 0 1 1 1 0 VBD IN CD NN CD O
x x 0 0 0 0 0 0 0 0 1 0 IN CD NN CD NNP O
10(-6) 10(-6) 0 0 1 0 0 0 0 1 6 0 CD NN CD NNP IN O
M M 1 1 0 0 0 0 0 0 1 0 NN CD NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CD NNP IN NNP NN O
NE NE 1 1 0 0 0 0 0 0 2 0 NNP IN NNP NN VBD O
treatment treatment 0 0 0 0 0 0 0 0 9 0 IN NNP NN VBD PRP$ O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 NNP NN VBD PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NN VBD PRP$ NN NNS O
expression, expression, 0 0 0 0 1 0 0 0 11 0 VBD PRP$ NN NNS CD O
whereas whereas 0 0 0 0 0 0 0 0 7 0 PRP$ NN NNS CD NN O
1 1 0 0 0 0 0 0 1 1 1 0 NN NNS CD NN CD O
x x 0 0 0 0 0 0 0 0 1 0 NNS CD NN CD NNP O
10(-8) 10(-8) 0 0 1 0 0 0 0 1 6 0 CD NN CD NNP IN O
M M 1 1 0 0 0 0 0 0 1 0 NN CD NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CD NNP IN NNP VBD O
NE NE 1 1 0 0 0 0 0 0 2 0 NNP IN NNP VBD NNP O
decreased decreased 0 0 0 0 0 0 0 0 9 0 IN NNP VBD NNP NNP O
expression. expression. 0 0 0 0 0 0 0 0 11 0 NNP VBD NNP NNP IN O
Stimulation Stimulation 1 0 0 0 0 0 0 0 11 0 VBD NNP NNP IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNP IN NNP IN O
LPS LPS 1 1 0 0 0 0 0 0 3 0 NNP IN NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ NNS O
last last 0 0 0 0 0 0 0 0 4 0 IN DT JJ NNS IN O
24-hours 24-hours 0 0 1 0 0 0 0 1 8 0 DT JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NN O
BMM BMM 1 1 0 0 0 0 0 0 3 0 NNS IN NNP NN RB O
culture culture 0 0 0 0 0 0 0 0 7 0 IN NNP NN RB VBN O
further further 0 0 0 0 0 0 0 0 7 0 NNP NN RB VBN NNP O
decreased decreased 0 0 0 0 0 0 0 0 9 0 NN RB VBN NNP CC O
CCR2 CCR2 1 1 0 0 0 0 0 1 4 0 RB VBN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VBN NNP CC NNP NNP O
MHC MHC 1 1 0 0 0 0 0 0 3 0 NNP CC NNP NNP NN O
II II 1 1 0 0 0 0 0 0 2 0 CC NNP NNP NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT JJ NN O
BMM, BMM, 1 1 0 0 1 0 0 0 4 0 IN DT JJ NN DT O
suggesting suggesting 0 0 0 0 0 0 0 0 10 0 DT JJ NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT JJ NN O
synergistic synergistic 0 0 0 0 0 0 0 0 11 0 NN DT JJ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP CC O
LPS LPS 1 1 0 0 0 0 0 0 3 0 NN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP IN O
NE NE 1 1 0 0 0 0 0 0 2 0 NNP CC NNP IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 CC NNP IN NNP NNP O
macrophage. macrophage. 0 0 0 0 0 0 0 0 11 0 NNP IN NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 NNP NNS VBP IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NNP VBZ O
NE NE 1 1 0 0 0 0 0 0 2 0 VBP IN NNP VBZ NN O
regulates regulates 0 0 0 0 0 0 0 0 9 0 IN NNP VBZ NN -NONE- O
macrophage macrophage 0 0 0 0 0 0 0 0 10 0 NNP VBZ NN -NONE- NN O
differentiation, differentiation, 0 0 0 0 1 0 0 0 16 0 VBZ NN -NONE- NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NN -NONE- NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NN CC NNP CC O
function, function, 0 0 0 0 1 0 0 0 9 0 NN CC NNP CC MD O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NNP CC MD VB DT O
play play 0 0 0 0 0 0 0 0 4 0 CC MD VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT JJ NN O
critical critical 0 0 0 0 0 0 0 0 8 0 VB DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
dysfunctional dysfunctional 0 0 0 0 0 0 0 0 13 0 IN DT JJ NN NN O
immune immune 0 0 0 0 0 0 0 0 6 0 DT JJ NN NN NNP O
response response 0 0 0 0 0 0 0 0 8 0 JJ NN NN NNP NONE O
post-burn. post-burn. 0 0 1 0 0 0 0 0 10 0 NN NN NNP NONE NONE O
Aging Aging 1 0 0 0 0 0 0 0 5 0 NONE NONE VBG CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NONE VBG CC NN NN O
curvature curvature 0 0 0 0 0 0 0 0 9 0 VBG CC NN NN IN O
discrimination discrimination 0 0 0 0 0 0 0 0 14 0 CC NN NN IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ CC O
static static 0 0 0 0 0 0 0 0 6 0 NN IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NNP O
dynamic dynamic 0 0 0 0 0 0 0 0 7 0 JJ CC JJ NNP NNP O
touch. touch. 0 0 0 0 0 0 0 0 6 0 CC JJ NNP NNP NNP O
Norman Norman 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP NNP NNP O
JF, JF, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Kappers Kappers 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
AM, AM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Cheeseman Cheeseman 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
JR, JR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Ronning Ronning 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Thomason Thomason 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
KE, KE, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Baxter Baxter 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
MW, MW, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Calloway Calloway 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
AB, AB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Lamirande Lamirande 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
DN. DN. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Psychology, Psychology, 1 0 0 0 1 0 0 0 11 0 NNP IN NNP NNP NNP O
Western Western 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
Kentucky Kentucky 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Bowling Bowling 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Green, Green, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
Kentucky, Kentucky, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNPS O
United United 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNPS IN O
States States 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP : O
America America 1 0 0 0 0 0 0 0 7 0 NNPS IN NNP : NNP O
; ; 0 0 0 0 0 0 0 0 1 0 IN NNP : NNP IN O
Center Center 1 0 0 0 0 0 0 0 6 0 NNP : NNP IN DT O
for for 0 0 0 0 0 0 0 0 3 0 : NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP IN O
Study Study 1 0 0 0 0 0 0 0 5 0 IN DT NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNP IN NNP NNP O
Lifespan Lifespan 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Development, Development, 1 0 0 0 1 0 0 0 12 0 IN NNP NNP NNP NNP O
Western Western 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Kentucky Kentucky 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Bowling Bowling 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Green, Green, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
Kentucky, Kentucky, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNPS O
United United 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNPS IN O
States States 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
America. America. 1 0 0 0 0 0 0 0 8 0 NNPS IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNS O
Two Two 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS VBD O
experiments experiments 0 0 0 0 0 0 0 0 11 0 NNP NNP NNS VBD DT O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 NNP NNS VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBD DT NN IN O
ability ability 0 0 0 0 0 0 0 0 7 0 VBD DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD JJR O
30 30 0 0 0 0 0 0 1 1 2 0 NN IN CD JJR CC O
older older 0 0 0 0 0 0 0 0 5 0 IN CD JJR CC JJR O
and and 0 0 0 0 0 0 0 0 3 0 CD JJR CC JJR NNS O
younger younger 0 0 0 0 0 0 0 0 7 0 JJR CC JJR NNS TO O
adults adults 0 0 0 0 0 0 0 0 6 0 CC JJR NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJR NNS TO VB DT O
discriminate discriminate 0 0 0 0 0 0 0 0 12 0 NNS TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
curvature curvature 0 0 0 0 0 0 0 0 9 0 VB DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
simple simple 0 0 0 0 0 0 0 0 6 0 NN IN JJ NN NNS O
object object 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNS IN O
surfaces surfaces 0 0 0 0 0 0 0 0 8 0 JJ NN NNS IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NN NNS IN JJ CC O
static static 0 0 0 0 0 0 0 0 6 0 NNS IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NNP O
dynamic dynamic 0 0 0 0 0 0 0 0 7 0 JJ CC JJ NNP NNP O
touch. touch. 0 0 0 0 0 0 0 0 6 0 CC JJ NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NNS IN O
ages ages 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NNS O
older older 0 0 0 0 0 0 0 0 5 0 IN DT NN NNS VBD O
adults adults 0 0 0 0 0 0 0 0 6 0 DT NN NNS VBD IN O
ranged ranged 0 0 0 0 0 0 0 0 6 0 NN NNS VBD IN CD O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBD IN CD TO O
66 66 0 0 0 0 0 0 1 1 2 0 VBD IN CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 IN CD TO CD NN O
85 85 0 0 0 0 0 0 1 1 2 0 CD TO CD NN IN O
years, years, 0 0 0 0 1 0 0 0 6 0 TO CD NN IN DT O
while while 0 0 0 0 0 0 0 0 5 0 CD NN IN DT IN O
those those 0 0 0 0 0 0 0 0 5 0 NN IN DT IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN DT IN DT JJR O
the the 0 0 0 0 0 0 0 0 3 0 DT IN DT JJR NNS O
younger younger 0 0 0 0 0 0 0 0 7 0 IN DT JJR NNS VBD O
adults adults 0 0 0 0 0 0 0 0 6 0 DT JJR NNS VBD IN O
ranged ranged 0 0 0 0 0 0 0 0 6 0 JJR NNS VBD IN CD O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBD IN CD TO O
20 20 0 0 0 0 0 0 1 1 2 0 VBD IN CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 IN CD TO CD NNP O
29 29 0 0 0 0 0 0 1 1 2 0 CD TO CD NNP NNP O
years. years. 0 0 0 0 0 0 0 0 6 0 TO CD NNP NNP DT O
For For 1 0 0 0 0 0 0 0 3 0 CD NNP NNP DT NN O
each each 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN IN O
participant participant 0 0 0 0 0 0 0 0 11 0 NNP DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
both both 0 0 0 0 0 0 0 0 4 0 NN IN DT NN DT O
experiments, experiments, 0 0 0 0 1 0 0 0 12 0 IN DT NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 DT NN DT JJ NN O
minimum minimum 0 0 0 0 0 0 0 0 7 0 NN DT JJ NN NN O
curvature curvature 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN VBN O
magnitude magnitude 0 0 0 0 0 0 0 0 9 0 JJ NN NN VBN TO O
needed needed 0 0 0 0 0 0 0 0 6 0 NN NN VBN TO RB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBN TO RB VB O
reliably reliably 0 0 0 0 0 0 0 0 8 0 VBN TO RB VB IN O
discriminate discriminate 0 0 0 0 0 0 0 0 12 0 TO RB VB IN NN O
between between 0 0 0 0 0 0 0 0 7 0 RB VB IN NN CC O
convex convex 0 0 0 0 0 0 0 0 6 0 VB IN NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VB NNS O
concave concave 0 0 0 0 0 0 0 0 7 0 NN CC VB NNS VBD O
surfaces surfaces 0 0 0 0 0 0 0 0 8 0 CC VB NNS VBD NNP O
was was 0 0 0 0 0 0 0 0 3 0 VB NNS VBD NNP NNP O
determined. determined. 0 0 0 0 0 0 0 0 11 0 NNS VBD NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 VBD NNP NNP NNP CD O
Experiment Experiment 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP CD NNS O
1, 1, 0 0 0 0 1 0 0 1 2 0 NNP NNP CD NNS VBN O
participants participants 0 0 0 0 0 0 0 0 12 0 NNP CD NNS VBN JJ O
used used 0 0 0 0 0 0 0 0 4 0 CD NNS VBN JJ NN O
static static 0 0 0 0 0 0 0 0 6 0 NNS VBN JJ NN TO O
touch touch 0 0 0 0 0 0 0 0 5 0 VBN JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB PRP$ O
make make 0 0 0 0 0 0 0 0 4 0 NN TO VB PRP$ NNS O
their their 0 0 0 0 0 0 0 0 5 0 TO VB PRP$ NNS IN O
judgments judgments 0 0 0 0 0 0 0 0 9 0 VB PRP$ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 PRP$ NNS IN JJ IN O
curvature, curvature, 0 0 0 0 1 0 0 0 10 0 NNS IN JJ IN JJ O
while while 0 0 0 0 0 0 0 0 5 0 IN JJ IN JJ NN O
dynamic dynamic 0 0 0 0 0 0 0 0 7 0 JJ IN JJ NN VBD O
touch touch 0 0 0 0 0 0 0 0 5 0 IN JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 NN VBD VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP CD O
Experiment Experiment 1 0 0 0 0 0 0 0 10 0 VBN IN NNP CD WRB O
2. 2. 0 0 0 0 0 0 0 1 2 0 IN NNP CD WRB JJ O
When When 1 0 0 0 0 0 0 0 4 0 NNP CD WRB JJ NN O
static static 0 0 0 0 0 0 0 0 6 0 CD WRB JJ NN VBD O
touch touch 0 0 0 0 0 0 0 0 5 0 WRB JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB JJ O
discriminate discriminate 0 0 0 0 0 0 0 0 12 0 VBN TO VB JJ DT O
curvature, curvature, 0 0 0 0 1 0 0 0 10 0 TO VB JJ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VB JJ DT JJ NN O
large large 0 0 0 0 0 0 0 0 5 0 JJ DT JJ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN VBD O
age age 0 0 0 0 0 0 0 0 3 0 NN IN NN VBD NNP O
occurred occurred 0 0 0 0 0 0 0 0 8 0 IN NN VBD NNP NNS O
(the (the 0 0 0 0 0 0 0 0 4 0 NN VBD NNP NNS VBD O
thresholds thresholds 0 0 0 0 0 0 0 0 10 0 VBD NNP NNS VBD CD O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD CD CC O
0.67 0.67 0 0 0 0 0 0 0 1 4 0 NNS VBD CD CC CD O
& & 0 0 0 0 0 0 0 0 1 0 VBD CD CC CD IN O
1.11/m 1.11/m 0 0 0 1 0 0 0 1 6 0 CD CC CD IN DT O
for for 0 0 0 0 0 0 0 0 3 0 CC CD IN DT JJR O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT JJR CC O
younger younger 0 0 0 0 0 0 0 0 7 0 IN DT JJR CC JJR O
and and 0 0 0 0 0 0 0 0 3 0 DT JJR CC JJR NN O
older older 0 0 0 0 0 0 0 0 5 0 JJR CC JJR NN NNP O
participants, participants, 0 0 0 0 1 0 0 0 13 0 CC JJR NN NNP NNP O
respectively). respectively). 0 0 0 0 0 0 0 0 14 0 JJR NN NNP NNP WRB O
However, However, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP WRB NNS O
when when 0 0 0 0 0 0 0 0 4 0 NNP NNP WRB NNS VBN O
participants participants 0 0 0 0 0 0 0 0 12 0 NNP WRB NNS VBN JJ O
used used 0 0 0 0 0 0 0 0 4 0 WRB NNS VBN JJ NN O
dynamic dynamic 0 0 0 0 0 0 0 0 7 0 NNS VBN JJ NN EX O
touch, touch, 0 0 0 0 1 0 0 0 6 0 VBN JJ NN EX VBD O
there there 0 0 0 0 0 0 0 0 5 0 JJ NN EX VBD DT O
was was 0 0 0 0 0 0 0 0 3 0 NN EX VBD DT JJ O
no no 0 0 0 0 0 0 0 0 2 0 EX VBD DT JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 VBD DT JJ NN IN O
difference difference 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN DT O
between between 0 0 0 0 0 0 0 0 7 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
ability ability 0 0 0 0 0 0 0 0 7 0 IN DT NN IN JJR O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJR CC O
younger younger 0 0 0 0 0 0 0 0 7 0 NN IN JJR CC JJR O
and and 0 0 0 0 0 0 0 0 3 0 IN JJR CC JJR NNS O
older older 0 0 0 0 0 0 0 0 5 0 JJR CC JJR NNS TO O
participants participants 0 0 0 0 0 0 0 0 12 0 CC JJR NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJR NNS TO VB NN O
discriminate discriminate 0 0 0 0 0 0 0 0 12 0 NNS TO VB NN DT O
curvature curvature 0 0 0 0 0 0 0 0 9 0 TO VB NN DT NNS O
(the (the 0 0 0 0 0 0 0 0 4 0 VB NN DT NNS VBD O
thresholds thresholds 0 0 0 0 0 0 0 0 10 0 NN DT NNS VBD CD O
were were 0 0 0 0 0 0 0 0 4 0 DT NNS VBD CD CC O
0.58 0.58 0 0 0 0 0 0 0 1 4 0 NNS VBD CD CC CD O
& & 0 0 0 0 0 0 0 0 1 0 VBD CD CC CD IN O
0.59/m 0.59/m 0 0 0 1 0 0 0 1 6 0 CD CC CD IN DT O
for for 0 0 0 0 0 0 0 0 3 0 CC CD IN DT JJR O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT JJR CC O
younger younger 0 0 0 0 0 0 0 0 7 0 IN DT JJR CC JJR O
and and 0 0 0 0 0 0 0 0 3 0 DT JJR CC JJR NN O
older older 0 0 0 0 0 0 0 0 5 0 JJR CC JJR NN NNP O
participants, participants, 0 0 0 0 1 0 0 0 13 0 CC JJR NN NNP NNP O
respectively). respectively). 0 0 0 0 0 0 0 0 14 0 JJR NN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS IN O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
current current 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN NN O
study study 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN WDT O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 JJ NN NN WDT IN O
that that 0 0 0 0 0 0 0 0 4 0 NN NN WDT IN JJR O
while while 0 0 0 0 0 0 0 0 5 0 NN WDT IN JJR NNS O
older older 0 0 0 0 0 0 0 0 5 0 WDT IN JJR NNS MD O
adults adults 0 0 0 0 0 0 0 0 6 0 IN JJR NNS MD RB O
can can 0 0 0 0 0 0 0 0 3 0 JJR NNS MD RB VB O
accurately accurately 0 0 0 0 0 0 0 0 10 0 NNS MD RB VB NN O
discriminate discriminate 0 0 0 0 0 0 0 0 12 0 MD RB VB NN NN O
surface surface 0 0 0 0 0 0 0 0 7 0 RB VB NN NN IN O
curvature curvature 0 0 0 0 0 0 0 0 9 0 VB NN NN IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ NN O
dynamic dynamic 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN PRP O
touch, touch, 0 0 0 0 1 0 0 0 6 0 IN JJ NN PRP VBP O
they they 0 0 0 0 0 0 0 0 4 0 JJ NN PRP VBP JJ O
possess possess 0 0 0 0 0 0 0 0 7 0 NN PRP VBP JJ NNS O
significant significant 0 0 0 0 0 0 0 0 11 0 PRP VBP JJ NNS IN O
impairments impairments 0 0 0 0 0 0 0 0 11 0 VBP JJ NNS IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN JJ NNP O
static static 0 0 0 0 0 0 0 0 6 0 NNS IN JJ NNP NONE O
touch. touch. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NONE NONE O
RNA-Seq-Based RNA-Seq-Based 1 0 1 0 0 0 0 0 13 0 NONE NONE JJ NNP IN O
Analysis Analysis 1 0 0 0 0 0 0 0 8 0 NONE JJ NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP NNP O
Physiologic Physiologic 1 0 0 0 0 0 0 0 11 0 IN DT NNP NNP NNP O
Cold Cold 1 0 0 0 0 0 0 0 4 0 DT NNP NNP NNP NNP O
Shock-Induced Shock-Induced 1 0 1 0 0 0 0 0 13 0 NNP NNP NNP NNP IN O
Changes Changes 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NN O
Moraxella Moraxella 1 0 0 0 0 0 0 0 9 0 NNP IN NNP NN NNP O
catarrhalis catarrhalis 0 0 0 0 0 0 0 0 11 0 IN NNP NN NNP NNP O
Gene Gene 1 0 0 0 0 0 0 0 4 0 NNP NN NNP NNP NNP O
Expression. Expression. 1 0 0 0 0 0 0 0 11 0 NN NNP NNP NNP NNP O
Spaniol Spaniol 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
V, V, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wyder Wyder 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Aebi Aebi 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
C. C. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNP O
Infectious Infectious 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Diseases, Diseases, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Bern, Bern, 1 0 0 0 1 0 0 0 5 0 NNP IN NNP NNP NNP O
Bern, Bern, 1 0 0 0 1 0 0 0 5 0 IN NNP NNP NNP NNP O
Switzerland. Switzerland. 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
Moraxella Moraxella 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP DT O
catarrhalis, catarrhalis, 0 0 0 0 1 0 0 0 12 0 NNP NNP NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT JJ NN O
major major 0 0 0 0 0 0 0 0 5 0 NNP DT JJ NN NN O
nasopharyngeal nasopharyngeal 0 0 0 0 0 0 0 0 14 0 DT JJ NN NN IN O
pathogen pathogen 0 0 0 0 0 0 0 0 8 0 JJ NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN NN O
respiratory respiratory 0 0 0 0 0 0 0 0 11 0 DT JJ NN NN VBZ O
tract, tract, 0 0 0 0 1 0 0 0 6 0 JJ NN NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ VBN TO O
exposed exposed 0 0 0 0 0 0 0 0 7 0 NN VBZ VBN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 VBZ VBN TO JJ NNS O
rapid rapid 0 0 0 0 0 0 0 0 5 0 VBN TO JJ NNS IN O
downshifts downshifts 0 0 0 0 0 0 0 0 10 0 TO JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
environmental environmental 0 0 0 0 0 0 0 0 13 0 NNS IN JJ NN WRB O
temperature temperature 0 0 0 0 0 0 0 0 11 0 IN JJ NN WRB NNS O
when when 0 0 0 0 0 0 0 0 4 0 JJ NN WRB NNS VBP O
humans humans 0 0 0 0 0 0 0 0 6 0 NN WRB NNS VBP JJ O
breathe breathe 0 0 0 0 0 0 0 0 7 0 WRB NNS VBP JJ NNP O
cold cold 0 0 0 0 0 0 0 0 4 0 NNS VBP JJ NNP NNP O
air. air. 0 0 0 0 0 0 0 0 4 0 VBP JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
prevalence prevalence 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NN O
pharyngeal pharyngeal 0 0 0 0 0 0 0 0 10 0 NN IN NN NN CC O
colonization colonization 0 0 0 0 0 0 0 0 12 0 IN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
respiratory respiratory 0 0 0 0 0 0 0 0 11 0 NN CC NN NN NNS O
tract tract 0 0 0 0 0 0 0 0 5 0 CC NN NN NNS VBN O
infections infections 0 0 0 0 0 0 0 0 10 0 NN NN NNS VBN IN O
caused caused 0 0 0 0 0 0 0 0 6 0 NN NNS VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBN IN NNP NNS O
M. M. 1 1 0 0 0 0 0 0 2 0 VBN IN NNP NNS VBZ O
catarrhalis catarrhalis 0 0 0 0 0 0 0 0 11 0 IN NNP NNS VBZ JJS O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNS VBZ JJS IN O
greatest greatest 0 0 0 0 0 0 0 0 8 0 NNS VBZ JJS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBZ JJS IN NNP NNP O
winter. winter. 0 0 0 0 0 0 0 0 7 0 JJS IN NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 IN NNP NNP VBD WRB O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NNP NNP VBD WRB NNP O
how how 0 0 0 0 0 0 0 0 3 0 NNP VBD WRB NNP VBZ O
M. M. 1 1 0 0 0 0 0 0 2 0 VBD WRB NNP VBZ NNS O
catarrhalis catarrhalis 0 0 0 0 0 0 0 0 11 0 WRB NNP VBZ NNS DT O
uses uses 0 0 0 0 0 0 0 0 4 0 NNP VBZ NNS DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBZ NNS DT JJ NN O
physiologic physiologic 0 0 0 0 0 0 0 0 11 0 NNS DT JJ NN TO O
exposure exposure 0 0 0 0 0 0 0 0 8 0 DT JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB NN O
cold cold 0 0 0 0 0 0 0 0 4 0 NN TO VB NN TO O
air air 0 0 0 0 0 0 0 0 3 0 TO VB NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VB NN TO VB JJ O
regulate regulate 0 0 0 0 0 0 0 0 8 0 NN TO VB JJ NN O
pivotal pivotal 0 0 0 0 0 0 0 0 7 0 TO VB JJ NN NNS O
survival survival 0 0 0 0 0 0 0 0 8 0 VB JJ NN NNS WDT O
systems systems 0 0 0 0 0 0 0 0 7 0 JJ NN NNS WDT MD O
that that 0 0 0 0 0 0 0 0 4 0 NN NNS WDT MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NNS WDT MD VB TO O
contribute contribute 0 0 0 0 0 0 0 0 10 0 WDT MD VB TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 MD VB TO NNP NN O
M. M. 1 1 0 0 0 0 0 0 2 0 VB TO NNP NN NNP O
catarrhalis catarrhalis 0 0 0 0 0 0 0 0 11 0 TO NNP NN NNP NNP O
virulence. virulence. 0 0 0 0 0 0 0 0 10 0 NNP NN NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 NN NNP NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
study study 0 0 0 0 0 0 0 0 5 0 NNP DT NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBD DT O
used used 0 0 0 0 0 0 0 0 4 0 NN PRP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT NN NNS O
RNA-seq RNA-seq 1 0 1 0 0 0 0 0 7 0 VBD DT NN NNS TO O
techniques techniques 0 0 0 0 0 0 0 0 10 0 DT NN NNS TO RB O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO RB VB O
quantitatively quantitatively 0 0 0 0 0 0 0 0 14 0 NNS TO RB VB DT O
catalogue catalogue 0 0 0 0 0 0 0 0 9 0 TO RB VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VB DT NN IN O
transcriptome transcriptome 0 0 0 0 0 0 0 0 13 0 VB DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP VBZ O
M. M. 1 1 0 0 0 0 0 0 2 0 NN IN NNP VBZ VBN O
catarrhalis catarrhalis 0 0 0 0 0 0 0 0 11 0 IN NNP VBZ VBN TO O
exposed exposed 0 0 0 0 0 0 0 0 7 0 NNP VBZ VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBZ VBN TO DT CD O
a a 0 0 0 0 0 0 0 0 1 0 VBN TO DT CD JJ O
26°C 26°C 0 1 0 0 0 0 0 1 4 0 TO DT CD JJ NN O
cold cold 0 0 0 0 0 0 0 0 4 0 DT CD JJ NN CC O
shock shock 0 0 0 0 0 0 0 0 5 0 CD JJ NN CC TO O
or or 0 0 0 0 0 0 0 0 2 0 JJ NN CC TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NN CC TO JJ NN O
continuous continuous 0 0 0 0 0 0 0 0 10 0 CC TO JJ NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 TO JJ NN IN CD O
at at 0 0 0 0 0 0 0 0 2 0 JJ NN IN CD NNP O
37°C. 37°C. 0 1 0 0 0 0 0 1 5 0 NN IN CD NNP IN O
Validation Validation 1 0 0 0 0 0 0 0 10 0 IN CD NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CD NNP IN NNP NNS O
RNA-seq RNA-seq 1 0 1 0 0 0 0 0 7 0 NNP IN NNP NNS VBG O
data data 0 0 0 0 0 0 0 0 4 0 IN NNP NNS VBG JJ O
using using 0 0 0 0 0 0 0 0 5 0 NNP NNS VBG JJ NN O
quantitative quantitative 0 0 0 0 0 0 0 0 12 0 NNS VBG JJ NN NN O
RT-PCR RT-PCR 1 1 1 0 0 0 0 0 6 0 VBG JJ NN NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 JJ NN NN VBD DT O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 NN NN VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBD DT NN NNS O
RNA-seq RNA-seq 1 0 1 0 0 0 0 0 7 0 VBD DT NN NNS TO O
results results 0 0 0 0 0 0 0 0 7 0 DT NN NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO VB RB O
be be 0 0 0 0 0 0 0 0 2 0 NNS TO VB RB NNP O
highly highly 0 0 0 0 0 0 0 0 6 0 TO VB RB NNP NNP O
reliable. reliable. 0 0 0 0 0 0 0 0 9 0 VB RB NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 RB NNP NNP VBD IN O
observed observed 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBD IN DT CD O
a a 0 0 0 0 0 0 0 0 1 0 VBD IN DT CD JJ O
26°C 26°C 0 1 0 0 0 0 0 1 4 0 IN DT CD JJ NN O
cold cold 0 0 0 0 0 0 0 0 4 0 DT CD JJ NN NNS O
shock shock 0 0 0 0 0 0 0 0 5 0 CD JJ NN NNS DT O
induces induces 0 0 0 0 0 0 0 0 7 0 JJ NN NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NNS DT NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NNS DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS WDT O
genes genes 0 0 0 0 0 0 0 0 5 0 NN IN NNS WDT IN O
that that 0 0 0 0 0 0 0 0 4 0 IN NNS WDT IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNS WDT IN JJ NN O
other other 0 0 0 0 0 0 0 0 5 0 WDT IN JJ NN VBP O
bacteria bacteria 0 0 0 0 0 0 0 0 8 0 IN JJ NN VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 JJ NN VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBP VBN VBN TO O
related related 0 0 0 0 0 0 0 0 7 0 VBP VBN VBN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO NN DT O
virulence virulence 0 0 0 0 0 0 0 0 9 0 VBN TO NN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 TO NN DT JJ NN O
strong strong 0 0 0 0 0 0 0 0 6 0 NN DT JJ NN VBD O
induction induction 0 0 0 0 0 0 0 0 9 0 DT JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN NNS O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN NNS VBN O
genes genes 0 0 0 0 0 0 0 0 5 0 VBN IN NNS VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 IN NNS VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBN IN JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 VBN IN JJ NN NN O
affinity affinity 0 0 0 0 0 0 0 0 8 0 IN JJ NN NN NN O
phosphate phosphate 0 0 0 0 0 0 0 0 9 0 JJ NN NN NN CC O
transport transport 0 0 0 0 0 0 0 0 9 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
iron iron 0 0 0 0 0 0 0 0 4 0 NN CC NN NN VBG O
acquisition, acquisition, 0 0 0 0 1 0 0 0 12 0 CC NN NN VBG IN O
indicating indicating 0 0 0 0 0 0 0 0 10 0 NN NN VBG IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NN VBG IN NNP VBZ O
M. M. 1 1 0 0 0 0 0 0 2 0 VBG IN NNP VBZ VBZ O
catarrhalis catarrhalis 0 0 0 0 0 0 0 0 11 0 IN NNP VBZ VBZ DT O
makes makes 0 0 0 0 0 0 0 0 5 0 NNP VBZ VBZ DT JJR O
a a 0 0 0 0 0 0 0 0 1 0 VBZ VBZ DT JJR NN O
better better 0 0 0 0 0 0 0 0 6 0 VBZ DT JJR NN IN O
use use 0 0 0 0 0 0 0 0 3 0 DT JJR NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJR NN IN DT NN O
both both 0 0 0 0 0 0 0 0 4 0 NN IN DT NN CC O
phosphate phosphate 0 0 0 0 0 0 0 0 9 0 IN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN NNS O
iron iron 0 0 0 0 0 0 0 0 4 0 NN CC NN NNS IN O
resources resources 0 0 0 0 0 0 0 0 9 0 CC NN NNS IN NN O
after after 0 0 0 0 0 0 0 0 5 0 NN NNS IN NN TO O
exposure exposure 0 0 0 0 0 0 0 0 8 0 NNS IN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB NNP O
cold cold 0 0 0 0 0 0 0 0 4 0 NN TO VB NNP NNP O
shock. shock. 0 0 0 0 0 0 0 0 6 0 TO VB NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 VB NNP NNP VBD DT O
detected detected 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 VBD DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS VBN O
genes genes 0 0 0 0 0 0 0 0 5 0 NN IN NNS VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 IN NNS VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBN IN NN NN O
nitrogen nitrogen 0 0 0 0 0 0 0 0 8 0 VBN IN NN NN IN O
metabolism, metabolism, 0 0 0 0 1 0 0 0 11 0 IN NN NN IN RB O
as as 0 0 0 0 0 0 0 0 2 0 NN NN IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NN IN RB IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN JJ NN O
several several 0 0 0 0 0 0 0 0 7 0 RB IN JJ NN NN O
outer outer 0 0 0 0 0 0 0 0 5 0 IN JJ NN NN NN O
membrane membrane 0 0 0 0 0 0 0 0 8 0 JJ NN NN NN VBG O
proteins, proteins, 0 0 0 0 1 0 0 0 9 0 NN NN NN VBG NN O
including including 0 0 0 0 0 0 0 0 9 0 NN NN VBG NN JJ O
ompA, ompA, 0 0 0 0 1 0 0 0 5 0 NN VBG NN JJ NN O
m35-like m35-like 0 0 1 0 0 0 0 1 8 0 VBG NN JJ NN CC O
porin porin 0 0 0 0 0 0 0 0 5 0 NN JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NN O
multidrug multidrug 0 0 0 0 0 0 0 0 9 0 NN CC NN NN NN O
efflux efflux 0 0 0 0 0 0 0 0 6 0 CC NN NN NN NN O
pump pump 0 0 0 0 0 0 0 0 4 0 NN NN NN NN VBG O
(acrAB) (acrAB) 0 0 0 0 0 0 0 0 7 0 NN NN NN VBG IN O
indicating indicating 0 0 0 0 0 0 0 0 10 0 NN NN VBG IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NN VBG IN NNP VBZ O
M. M. 1 1 0 0 0 0 0 0 2 0 VBG IN NNP VBZ NNS O
catarrhalis catarrhalis 0 0 0 0 0 0 0 0 11 0 IN NNP VBZ NNS PRP$ O
remodels remodels 0 0 0 0 0 0 0 0 8 0 NNP VBZ NNS PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 VBZ NNS PRP$ NN NNS O
membrane membrane 0 0 0 0 0 0 0 0 8 0 NNS PRP$ NN NNS IN O
components components 0 0 0 0 0 0 0 0 10 0 PRP$ NN NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN TO O
response response 0 0 0 0 0 0 0 0 8 0 NNS IN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB IN O
downshift downshift 0 0 0 0 0 0 0 0 9 0 NN TO VB IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 TO VB IN NNP NNP O
temperature. temperature. 0 0 0 0 0 0 0 0 12 0 VB IN NNP NNP PRP O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 IN NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP IN O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 NNP PRP VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN DT CD O
a a 0 0 0 0 0 0 0 0 1 0 VBP IN DT CD JJ O
26°C 26°C 0 1 0 0 0 0 0 1 4 0 IN DT CD JJ NN O
cold cold 0 0 0 0 0 0 0 0 4 0 DT CD JJ NN NNS O
shock shock 0 0 0 0 0 0 0 0 5 0 CD JJ NN NNS DT O
enhances enhances 0 0 0 0 0 0 0 0 8 0 JJ NN NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NNS DT NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 NNS DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS VBG O
genes genes 0 0 0 0 0 0 0 0 5 0 NN IN NNS VBG DT O
encoding encoding 0 0 0 0 0 0 0 0 8 0 IN NNS VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBG DT NN NNP O
type type 0 0 0 0 0 0 0 0 4 0 VBG DT NN NNP NN O
IV IV 1 1 0 0 0 0 0 0 2 0 DT NN NNP NN WDT O
pili pili 0 0 0 0 0 0 0 0 4 0 NN NNP NN WDT VBP O
that that 0 0 0 0 0 0 0 0 4 0 NNP NN WDT VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NN WDT VBP JJ IN O
essential essential 0 0 0 0 0 0 0 0 9 0 WDT VBP JJ IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VBP JJ IN JJ NN O
natural natural 0 0 0 0 0 0 0 0 7 0 JJ IN JJ NN CC O
transformation, transformation, 0 0 0 0 1 0 0 0 15 0 IN JJ NN CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBZ DT O
increases increases 0 0 0 0 0 0 0 0 9 0 NN CC VBZ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CC VBZ DT JJ NN O
genetic genetic 0 0 0 0 0 0 0 0 7 0 VBZ DT JJ NN IN O
competence competence 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
M. M. 1 1 0 0 0 0 0 0 2 0 NN IN NNP NNP WDT O
catarrhalis, catarrhalis, 0 0 0 0 1 0 0 0 12 0 IN NNP NNP WDT MD O
which which 0 0 0 0 0 0 0 0 5 0 NNP NNP WDT MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NNP WDT MD VB DT O
facilitate facilitate 0 0 0 0 0 0 0 0 10 0 WDT MD VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT JJ NN O
rapid rapid 0 0 0 0 0 0 0 0 5 0 VB DT JJ NN CC O
spread spread 0 0 0 0 0 0 0 0 6 0 DT JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN IN O
acquisition acquisition 0 0 0 0 0 0 0 0 11 0 NN CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN JJ O
novel novel 0 0 0 0 0 0 0 0 5 0 NN IN NN JJ NNP O
virulence-associated virulence-associated 0 0 1 0 0 0 0 0 20 0 IN NN JJ NNP NNP O
genes. genes. 0 0 0 0 0 0 0 0 6 0 NN JJ NNP NNP NNP O
CONCLUSION: CONCLUSION: 1 1 0 0 0 0 0 0 11 0 JJ NNP NNP NNP NN O
Cold Cold 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NN IN O
shock shock 0 0 0 0 0 0 0 0 5 0 NNP NNP NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT RB O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT RB JJ O
physiologically physiologically 0 0 0 0 0 0 0 0 15 0 IN DT RB JJ NN O
relevant relevant 0 0 0 0 0 0 0 0 8 0 DT RB JJ NN IN O
temperature temperature 0 0 0 0 0 0 0 0 11 0 RB JJ NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN CD NNS O
26°C 26°C 0 1 0 0 0 0 0 1 4 0 NN IN CD NNS IN O
induces induces 0 0 0 0 0 0 0 0 7 0 IN CD NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CD NNS IN NNP NN O
M. M. 1 1 0 0 0 0 0 0 2 0 NNS IN NNP NN DT O
catarrhalis catarrhalis 0 0 0 0 0 0 0 0 11 0 IN NNP NN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NN DT JJ IN O
complex complex 0 0 0 0 0 0 0 0 7 0 NN DT JJ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT JJ IN JJ NNS O
adaptive adaptive 0 0 0 0 0 0 0 0 8 0 JJ IN JJ NNS WDT O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 IN JJ NNS WDT MD O
that that 0 0 0 0 0 0 0 0 4 0 JJ NNS WDT MD VB O
could could 0 0 0 0 0 0 0 0 5 0 NNS WDT MD VB NN O
convey convey 0 0 0 0 0 0 0 0 6 0 WDT MD VB NN JJ O
novel novel 0 0 0 0 0 0 0 0 5 0 MD VB NN JJ NNS O
pathogenic pathogenic 0 0 0 0 0 0 0 0 10 0 VB NN JJ NNS CC O
functions functions 0 0 0 0 0 0 0 0 9 0 NN JJ NNS CC MD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NNS CC MD VB TO O
contribute contribute 0 0 0 0 0 0 0 0 10 0 CC MD VB TO VBN O
to to 0 0 0 0 0 0 0 0 2 0 MD VB TO VBN NN O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 VB TO VBN NN CC O
colonization colonization 0 0 0 0 0 0 0 0 12 0 TO VBN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VBN NN CC NNP NONE O
virulence. virulence. 0 0 0 0 0 0 0 0 10 0 NN CC NNP NONE NONE O
Inducing Inducing 1 0 0 0 0 0 0 0 8 0 NONE NONE VBG JJ NN O
precocious precocious 0 0 0 0 0 0 0 0 10 0 NONE VBG JJ NN IN O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 VBG JJ NN IN VBN B_TIMEXCCP
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN VBN JJ O
cultured cultured 0 0 0 0 0 0 0 0 8 0 NN IN VBN JJ NNP O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 IN VBN JJ NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 VBN JJ NNP NNP NNP O
Canman Canman 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP NNP NNP O
JC, JC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Salmon Salmon 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
ED, ED, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Fang Fang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
G. G. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
North North 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Carolina, Carolina, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CD O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP CD NNP O
607 607 0 0 0 0 0 0 1 1 3 0 IN NNP CD NNP NNP O
Fordham Fordham 1 0 0 0 0 0 0 0 7 0 NNP CD NNP NNP NNP O
Hall, Hall, 1 0 0 0 1 0 0 0 5 0 CD NNP NNP NNP CD O
CB# CB# 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP CD NNP O
3280, 3280, 0 0 0 0 1 0 0 1 5 0 NNP NNP CD NNP NNP O
Chapel Chapel 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
Hill, Hill, 1 0 0 0 1 0 0 0 5 0 CD NNP NNP NNP CD O
NC NC 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
27599-3280, 27599-3280, 0 0 1 0 1 0 0 1 11 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
jccanman@email.unc.edu jccanman@email.unc.edu 0 0 0 0 0 0 0 0 22 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN -NONE- O
spindle spindle 0 0 0 0 0 0 0 0 7 0 NNP NNP NN -NONE- WDT O
checkpoint, checkpoint, 0 0 0 0 1 0 0 0 11 0 NNP NN -NONE- WDT NNS O
which which 0 0 0 0 0 0 0 0 5 0 NN -NONE- WDT NNS VBP O
prevents prevents 0 0 0 0 0 0 0 0 8 0 -NONE- WDT NNS VBP VBN O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 WDT NNS VBP VBN IN B_TIMEXCCP
onset onset 0 0 0 0 0 0 0 0 5 0 NNS VBP VBN IN NN O
upon upon 0 0 0 0 0 0 0 0 4 0 VBP VBN IN NN NN O
spindle spindle 0 0 0 0 0 0 0 0 7 0 VBN IN NN NN CC O
damage damage 0 0 0 0 0 0 0 0 6 0 IN NN NN CC VB O
or or 0 0 0 0 0 0 0 0 2 0 NN NN CC VB JJ O
incorrect incorrect 0 0 0 0 0 0 0 0 9 0 NN CC VB JJ NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 CC VB JJ NN NNS O
alignment, alignment, 0 0 0 0 1 0 0 0 10 0 VB JJ NN NNS DT O
presents presents 0 0 0 0 0 0 0 0 8 0 JJ NN NNS DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN NNS DT NN IN O
problem problem 0 0 0 0 0 0 0 0 7 0 NNS DT NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN JJ NN O
experimental experimental 0 0 0 0 0 0 0 0 12 0 NN IN JJ NN IN O
analysis analysis 0 0 0 0 0 0 0 0 8 0 IN JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 NN IN NN NN IN O
function function 0 0 0 0 0 0 0 0 8 0 IN NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN CC O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 NN IN NN CC NNP B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NNP NNP O
cytokinesis. cytokinesis. 0 0 0 0 0 0 0 0 12 0 NN CC NNP NNP VBZ O
This This 1 0 0 0 0 0 0 0 4 0 CC NNP NNP VBZ IN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ IN DT O
because because 0 0 0 0 0 0 0 0 7 0 NNP VBZ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBZ IN DT JJ NN O
functional functional 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN IN O
disruption disruption 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNS O
many many 0 0 0 0 0 0 0 0 4 0 NN IN JJ NNS IN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 IN JJ NNS IN NN O
before before 0 0 0 0 0 0 0 0 6 0 JJ NNS IN NN NN O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 NNS IN NN NN MD B_TIMEXCCP
onset onset 0 0 0 0 0 0 0 0 5 0 IN NN NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN NN MD VB DT O
activate activate 0 0 0 0 0 0 0 0 8 0 NN MD VB DT NN O
this this 0 0 0 0 0 0 0 0 4 0 MD VB DT NN VBG O
checkpoint, checkpoint, 0 0 0 0 1 0 0 0 11 0 VB DT NN VBG NN O
preventing preventing 0 0 0 0 0 0 0 0 10 0 DT NN VBG NN CC O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 NN VBG NN CC NN B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 VBG NN CC NN NN O
subsequent subsequent 0 0 0 0 0 0 0 0 10 0 NN CC NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 CC NN NN NN NNP O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NN NN NN NNP NNP O
events. events. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NN VBZ O
paper paper 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ JJ O
compares compares 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ JJ CC O
new new 0 0 0 0 0 0 0 0 3 0 NN VBZ JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBZ JJ CC JJ NNS O
old old 0 0 0 0 0 0 0 0 3 0 JJ CC JJ NNS IN O
methods methods 0 0 0 0 0 0 0 0 7 0 CC JJ NNS IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN VBG DT O
overriding overriding 0 0 0 0 0 0 0 0 10 0 NNS IN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN VBG DT NN NN O
spindle spindle 0 0 0 0 0 0 0 0 7 0 VBG DT NN NN IN O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 DT NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
prometaphase prometaphase 0 0 0 0 0 0 0 0 12 0 NN IN NN NN NN O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 IN NN NN NN NN O
tissue tissue 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NNP O
culture culture 0 0 0 0 0 0 0 0 7 0 NN NN NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP CD O
Copyright Copyright 1 0 0 0 0 0 0 0 9 0 NN NNP NNP CD -NONE- O
2002 2002 0 0 0 0 0 0 1 1 4 0 NNP NNP CD -NONE- NNP O
Wiley-Liss, Wiley-Liss, 1 0 1 0 1 0 0 0 11 0 NNP CD -NONE- NNP NNP O
Inc. Inc. 1 0 0 0 0 0 0 0 4 0 CD -NONE- NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 -NONE- NNP NNP CD JJ O
12112148 12112148 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NN NN O
G2-phase G2-phase 1 0 1 0 0 0 0 1 8 0 NONE DT NN NN NNP B_TIMEXCCP
DNA-damage DNA-damage 1 0 1 0 0 0 0 0 10 0 DT NN NN NNP NNP O
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP NNP B_TIMEXCCP
O'Connell O'Connell 1 0 0 0 0 1 0 0 9 0 NN NNP NNP NNP NNP O
MJ, MJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Walworth Walworth 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
NC, NC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Carr Carr 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
AM. AM. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Trescowthick Trescowthick 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Laboratories, Laboratories, 1 0 0 0 1 0 0 0 13 0 NNP NNP NNP NNP NNP O
Peter Peter 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
MacCallum MacCallum 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Institute, Institute, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Locked Locked 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP CD O
Bag Bag 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP CD JJ O
1, 1, 0 0 0 0 1 0 0 1 2 0 NNP NNP CD JJ NN O
A'Beckett A'Beckett 1 0 0 0 0 1 0 0 9 0 NNP CD JJ NN NN O
Street, Street, 1 0 0 0 1 0 0 0 7 0 CD JJ NN NN NNP O
Melbourne, Melbourne, 1 0 0 0 1 0 0 0 10 0 JJ NN NN NNP CD O
Victoria Victoria 1 0 0 0 0 0 0 0 8 0 NN NN NNP CD NNP O
8006, 8006, 0 0 0 0 1 0 0 1 5 0 NN NNP CD NNP NNP O
Australia. Australia. 1 0 0 0 0 0 0 0 10 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NN NNS O
damage damage 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NNS JJ O
causes causes 0 0 0 0 0 0 0 0 6 0 NNP NN NNS JJ NN O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 0 NN NNS JJ NN IN O
delay delay 0 0 0 0 0 0 0 0 5 0 NNS JJ NN IN NNP O
before before 0 0 0 0 0 0 0 0 6 0 JJ NN IN NNP NNP O
S S 1 1 0 0 0 0 0 0 1 0 NN IN NNP NNP IN B_TIMEXCCP
phase, phase, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP IN NN O
during during 0 0 0 0 0 0 0 0 6 0 NNP NNP IN NN CC O
replication replication 0 0 0 0 0 0 0 0 11 0 NNP IN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC IN NNP O
before before 0 0 0 0 0 0 0 0 6 0 NN CC IN NNP NNP O
mitosis. mitosis. 0 0 0 0 0 0 0 0 8 0 CC IN NNP NNP VBZ B_TIMEXCCP
This This 1 0 0 0 0 0 0 0 4 0 IN NNP NNP VBZ DT O
involves involves 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT NN IN O
number number 0 0 0 0 0 0 0 0 6 0 VBZ DT NN IN RB O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN RB VBN O
highly highly 0 0 0 0 0 0 0 0 6 0 NN IN RB VBN NNS O
conserved conserved 0 0 0 0 0 0 0 0 9 0 IN RB VBN NNS IN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 RB VBN NNS IN NN O
that that 0 0 0 0 0 0 0 0 4 0 VBN NNS IN NN NNP O
sense sense 0 0 0 0 0 0 0 0 5 0 NNS IN NN NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 IN NN NNP NN CC O
damage damage 0 0 0 0 0 0 0 0 6 0 NN NNP NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC JJ DT O
signal signal 0 0 0 0 0 0 0 0 6 0 NN CC JJ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CC JJ DT JJ NNP O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 0 JJ DT JJ NNP NNP O
machinery. machinery. 0 0 0 0 0 0 0 0 10 0 DT JJ NNP NNP IN O
Kinases Kinases 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP IN VBD O
that that 0 0 0 0 0 0 0 0 4 0 NNP NNP IN VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NNP IN VBD RB VBN O
initially initially 0 0 0 0 0 0 0 0 9 0 IN VBD RB VBN IN O
discovered discovered 0 0 0 0 0 0 0 0 10 0 VBD RB VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN NN NN O
yeast yeast 0 0 0 0 0 0 0 0 5 0 VBN IN NN NN NNS O
model model 0 0 0 0 0 0 0 0 5 0 IN NN NN NNS VBP O
systems systems 0 0 0 0 0 0 0 0 7 0 NN NN NNS VBP RB O
have have 0 0 0 0 0 0 0 0 4 0 NN NNS VBP RB VBN O
recently recently 0 0 0 0 0 0 0 0 8 0 NNS VBP RB VBN RP O
been been 0 0 0 0 0 0 0 0 4 0 VBP RB VBN RP TO O
shown shown 0 0 0 0 0 0 0 0 5 0 RB VBN RP TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN RP TO VB DT O
regulate regulate 0 0 0 0 0 0 0 0 8 0 RP TO VB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NNS IN O
regulators regulators 0 0 0 0 0 0 0 0 10 0 VB DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NNS O
cyclin-dependent cyclin-dependent 0 0 1 0 0 0 0 0 16 0 NNS IN JJ NNS CC O
kinases kinases 0 0 0 0 0 0 0 0 7 0 IN JJ NNS CC TO O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NNS CC TO NN DT O
control control 0 0 0 0 0 0 0 0 7 0 CC TO NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO NN DT NN IN O
stability stability 0 0 0 0 0 0 0 0 9 0 NN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
p53. p53. 0 0 0 0 0 0 0 1 4 0 NN IN NNP NNP VBZ O
This This 1 0 0 0 0 0 0 0 4 0 IN NNP NNP VBZ DT O
shows shows 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT NN IN O
importance importance 0 0 0 0 0 0 0 0 10 0 VBZ DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NN IN NN NNS IN B_TIMEXCCP
proteins proteins 0 0 0 0 0 0 0 0 8 0 IN NN NNS IN VBG O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN VBG NN O
maintaining maintaining 0 0 0 0 0 0 0 0 11 0 NNS IN VBG NN NNP O
genome genome 0 0 0 0 0 0 0 0 6 0 IN VBG NN NNP NNP O
stability. stability. 0 0 0 0 0 0 0 0 10 0 VBG NN NNP NNP PRP O
Here, Here, 1 0 0 0 1 0 0 0 5 0 NN NNP NNP PRP VBZ O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBZ JJ O
discuss discuss 0 0 0 0 0 0 0 0 7 0 NNP PRP VBZ JJ NNS O
recent recent 0 0 0 0 0 0 0 0 6 0 PRP VBZ JJ NNS IN O
data data 0 0 0 0 0 0 0 0 4 0 VBZ JJ NNS IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 JJ NNS IN JJ CC O
yeast yeast 0 0 0 0 0 0 0 0 5 0 NNS IN JJ CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC NNS WDT O
metazoans metazoans 0 0 0 0 0 0 0 0 9 0 JJ CC NNS WDT VBP O
that that 0 0 0 0 0 0 0 0 4 0 CC NNS WDT VBP DT O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNS WDT VBP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 WDT VBP DT JJ NN O
remarkable remarkable 0 0 0 0 0 0 0 0 10 0 VBP DT JJ NN IN O
conservation conservation 0 0 0 0 0 0 0 0 12 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
organization organization 0 0 0 0 0 0 0 0 12 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
G2 G2 1 1 0 0 0 0 0 1 2 0 IN DT NNP NNP NN B_TIMEXCCP
DNA-damage DNA-damage 1 0 1 0 0 0 0 0 10 0 DT NNP NNP NN NNP O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NNP NNP NN NNP NNP B_TIMEXCCP
pathway. pathway. 0 0 0 0 0 0 0 0 8 0 NNP NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
10856933 10856933 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Regulation Regulation 1 0 0 0 0 0 0 0 10 0 NONE NONE NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NNP NN O
G0 G0 1 1 0 0 0 0 0 1 2 0 NN IN NNP NN IN B_TIMEXCCP
entry entry 0 0 0 0 0 0 0 0 5 0 IN NNP NN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
Pho80-Pho85 Pho80-Pho85 1 0 1 0 0 0 0 1 11 0 IN DT NNP NNP NNP O
cyclin-CDK cyclin-CDK 0 0 1 0 0 0 0 0 10 0 DT NNP NNP NNP NNP O
complex. complex. 0 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Wanke Wanke 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
V, V, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Pedruzzi Pedruzzi 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
I, I, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Cameroni Cameroni 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
E, E, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Dubouloz Dubouloz 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
De De 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Virgilio Virgilio 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
C. C. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Microbiology Microbiology 1 0 0 0 0 0 0 0 12 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP CC NNP NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 CC NNP NNP NNP NNP O
CMU, CMU, 1 1 0 0 1 0 0 0 4 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Geneva, Geneva, 1 0 0 0 1 0 0 0 7 0 NNP IN NNP NNP NNP O
Geneva, Geneva, 1 0 0 0 1 0 0 0 7 0 IN NNP NNP NNP NNP O
Switzerland. Switzerland. 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
Eukaryotic Eukaryotic 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN VBZ O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NNP NN NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ VBN IN O
controlled controlled 0 0 0 0 0 0 0 0 10 0 NN VBZ VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN NN NNS O
growth growth 0 0 0 0 0 0 0 0 6 0 VBN IN NN NNS CC O
factors factors 0 0 0 0 0 0 0 0 7 0 IN NN NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC JJ NNP O
essential essential 0 0 0 0 0 0 0 0 9 0 NNS CC JJ NNP NNP O
nutrients. nutrients. 0 0 0 0 0 0 0 0 10 0 CC JJ NNP NNP PRP$ O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 NNP NNP PRP$ NN NNS O
absence, absence, 0 0 0 0 1 0 0 0 8 0 NNP PRP$ NN NNS MD O
cells cells 0 0 0 0 0 0 0 0 5 0 PRP$ NN NNS MD VB O
may may 0 0 0 0 0 0 0 0 3 enter NN NNS MD VB IN O
enter enter 0 0 0 0 0 0 0 0 5 0 NNS MD VB IN DT O
into into 0 0 0 0 0 0 0 0 4 0 MD VB IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VB IN DT NN NN O
quiescent quiescent 0 0 0 0 0 0 0 0 9 0 IN DT NN NN NNP O
state state 0 0 0 0 0 0 0 0 5 0 DT NN NN NNP NNP O
(G0). (G0). 0 1 0 0 0 0 0 1 5 0 NN NN NNP NNP NNP B_TIMEXCCP
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NNP NNP O
Saccharomyces Saccharomyces 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP DT O
cerevisiae, cerevisiae, 0 0 0 0 1 0 0 0 11 0 NNP NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NN O
conserved conserved 0 0 0 0 0 0 0 0 9 0 NNP DT JJ NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 DT JJ NN NN DT O
kinase kinase 0 0 0 0 0 0 0 0 6 0 JJ NN NN DT NN O
A A 1 1 0 0 0 0 0 0 1 0 NN NN DT NN CC O
(PKA) (PKA) 0 1 0 0 0 0 0 0 5 0 NN DT NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC JJ NNP O
rapamycin-sensitive rapamycin-sensitive 0 0 1 0 0 0 0 0 19 0 NN CC JJ NNP NNP O
TOR TOR 1 1 0 0 0 0 0 0 3 0 CC JJ NNP NNP VBZ O
(TORC1) (TORC1) 0 1 0 0 0 0 0 1 7 0 JJ NNP NNP VBZ NN O
pathways pathways 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ NN NNP O
antagonize antagonize 0 0 0 0 0 0 0 0 10 0 NNP VBZ NN NNP NN O
G0 G0 1 1 0 0 0 0 0 1 2 0 VBZ NN NNP NN IN B_TIMEXCCP
entry entry 0 0 0 0 0 0 0 0 5 0 NN NNP NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN TO O
response response 0 0 0 0 0 0 0 0 8 0 NN IN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB JJ O
carbon carbon 0 0 0 0 0 0 0 0 6 0 NN TO VB JJ NN O
and/or and/or 0 0 0 1 0 0 0 0 6 0 TO VB JJ NN NN O
nitrogen nitrogen 0 0 0 0 0 0 0 0 8 0 VB JJ NN NN RB O
availability availability 0 0 0 0 0 0 0 0 12 0 JJ NN NN RB IN O
primarily primarily 0 0 0 0 0 0 0 0 9 0 NN NN RB IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN RB IN NN DT O
inhibiting inhibiting 0 0 0 0 0 0 0 0 10 0 RB IN NN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NNP NN O
PAS PAS 1 1 0 0 0 0 0 0 3 0 NN DT NNP NN NNP O
kinase kinase 0 0 0 0 0 0 0 0 6 0 DT NNP NN NNP NNP O
Rim15 Rim15 1 0 0 0 0 0 0 1 5 0 NNP NN NNP NNP NNP O
function. function. 0 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP PRP O
Here, Here, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NNP PRP VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT JJ NN O
phosphate-sensing phosphate-sensing 0 0 1 0 0 0 0 0 17 0 IN DT JJ NN JJ O
Pho80-Pho85 Pho80-Pho85 1 0 1 0 0 0 0 1 11 0 DT JJ NN JJ NN O
cyclin-cyclin-dependent cyclin-cyclin-dependent 0 0 1 0 0 0 0 0 23 0 JJ NN JJ NN NN O
kinase kinase 0 0 0 0 0 0 0 0 6 0 NN JJ NN NN NN O
(CDK) (CDK) 0 1 0 0 0 0 0 0 5 0 JJ NN NN NN RB O
complex complex 0 0 0 0 0 0 0 0 7 0 NN NN NN RB VBZ O
also also 0 0 0 0 0 0 0 0 4 0 NN NN RB VBZ IN O
participates participates 0 0 0 0 0 0 0 0 12 0 NN RB VBZ IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 RB VBZ IN NNP NN O
Rim15 Rim15 1 0 0 0 0 0 0 1 5 0 VBZ IN NNP NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 IN NNP NN IN JJ O
through through 0 0 0 0 0 0 0 0 7 0 NNP NN IN JJ NN O
direct direct 0 0 0 0 0 0 0 0 6 0 NN IN JJ NN NN O
phosphorylation, phosphorylation, 0 0 0 0 1 0 0 0 16 0 IN JJ NN NN RB O
thereby thereby 0 0 0 0 0 0 0 0 7 0 JJ NN NN RB VBG O
effectively effectively 0 0 0 0 0 0 0 0 11 0 NN NN RB VBG NNP O
sequestering sequestering 0 0 0 0 0 0 0 0 12 0 NN RB VBG NNP IN O
Rim15 Rim15 1 0 0 0 0 0 0 1 5 0 RB VBG NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBG NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN IN O
cytoplasm cytoplasm 0 0 0 0 0 0 0 0 9 0 IN DT NN IN PRP$ O
via via 0 0 0 0 0 0 0 0 3 0 DT NN IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NN IN PRP$ NN IN O
association association 0 0 0 0 0 0 0 0 11 0 IN PRP$ NN IN CD O
with with 0 0 0 0 0 0 0 0 4 0 PRP$ NN IN CD NNP O
14-3-3 14-3-3 0 0 1 0 0 0 0 1 6 0 NN IN CD NNP NNP O
proteins. proteins. 0 0 0 0 0 0 0 0 9 0 IN CD NNP NNP IN O
Inactivation Inactivation 1 0 0 0 0 0 0 0 12 0 CD NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT JJ O
either either 0 0 0 0 0 0 0 0 6 0 NNP IN DT JJ CC O
Pho80-Pho85 Pho80-Pho85 1 0 1 0 0 0 0 1 11 0 IN DT JJ CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 DT JJ CC NNP NNS O
TORC1 TORC1 1 1 0 0 0 0 0 1 5 0 JJ CC NNP NNS NN O
causes causes 0 0 0 0 0 0 0 0 6 0 CC NNP NNS NN IN O
dephosphorylation dephosphorylation 0 0 0 0 0 0 0 0 17 0 NNP NNS NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNS NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
14-3-3-binding 14-3-3-binding 0 0 1 0 0 0 0 1 14 0 IN DT JJ NN IN O
site site 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP RB O
Rim15, Rim15, 1 0 0 0 1 0 0 1 6 0 NN IN NNP RB VBG O
thus thus 0 0 0 0 0 0 0 0 4 0 IN NNP RB VBG JJ O
enabling enabling 0 0 0 0 0 0 0 0 8 0 NNP RB VBG JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 RB VBG JJ NN IN O
import import 0 0 0 0 0 0 0 0 6 0 VBG JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP CC O
Rim15 Rim15 1 0 0 0 0 0 0 1 5 0 NN IN NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 NNP CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
Rim15-controlled Rim15-controlled 1 0 1 0 0 0 0 1 16 0 IN DT JJ NNP NNP O
G0 G0 1 1 0 0 0 0 0 1 2 0 DT JJ NNP NNP NNP B_TIMEXCCP
program. program. 0 0 0 0 0 0 0 0 8 0 JJ NNP NNP NNP PRP O
Importantly, Importantly, 1 0 0 0 1 0 0 0 12 0 NNP NNP NNP PRP RB O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP RB VBP O
also also 0 0 0 0 0 0 0 0 4 0 NNP PRP RB VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 PRP RB VBP IN -NONE- O
that that 0 0 0 0 0 0 0 0 4 0 RB VBP IN -NONE- CC O
Pho80-Pho85 Pho80-Pho85 1 0 1 0 0 0 0 1 11 0 VBP IN -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN -NONE- CC NNP NN O
TORC1 TORC1 1 1 0 0 0 0 0 1 5 0 -NONE- CC NNP NN IN O
converge converge 0 0 0 0 0 0 0 0 8 0 CC NNP NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
single single 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN NN O
amino amino 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN IN O
acid acid 0 0 0 0 0 0 0 0 4 0 JJ NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
Rim15. Rim15. 1 0 0 0 0 0 0 1 6 0 NN IN NNP NNP NNP O
Thus, Thus, 1 0 0 0 1 0 0 0 5 0 IN NNP NNP NNP VBZ O
Rim15 Rim15 1 0 0 0 0 0 0 1 5 0 NNP NNP NNP VBZ DT O
plays plays 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT JJ NN O
key key 0 0 0 0 0 0 0 0 3 0 VBZ DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
G0 G0 1 1 0 0 0 0 0 1 2 0 NN IN NNP NN IN B_TIMEXCCP
entry entry 0 0 0 0 0 0 0 0 5 0 IN NNP NN IN PRP$ O
through through 0 0 0 0 0 0 0 0 7 0 NNP NN IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NN IN PRP$ NN TO O
ability ability 0 0 0 0 0 0 0 0 7 0 IN PRP$ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 PRP$ NN TO VB VBG O
integrate integrate 0 0 0 0 0 0 0 0 9 0 NN TO VB VBG IN O
signaling signaling 0 0 0 0 0 0 0 0 9 0 TO VB VBG IN DT O
from from 0 0 0 0 0 0 0 0 4 0 VB VBG IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBG IN DT NN NN O
PKA, PKA, 1 1 0 0 1 0 0 0 4 0 IN DT NN NN CC O
TORC1, TORC1, 1 1 0 0 1 0 0 1 6 0 DT NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
Pho80-Pho85 Pho80-Pho85 1 0 1 0 0 0 0 1 11 0 NN CC NNP NNP NNP O
pathways. pathways. 0 0 0 0 0 0 0 0 9 0 CC NNP NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNP NNP NNP CD JJ O
16308562 16308562 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NN O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NN NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
PMC1356330 PMC1356330 1 1 0 0 0 0 0 1 10 0 JJ NN NNP NONE NONE O
G1 G1 1 1 0 0 0 0 0 1 2 0 NONE NONE NNP NNP NNP B_TIMEXCCP
phase: phase: 0 0 0 0 0 0 0 0 6 0 NONE NNP NNP NNP NNP O
components, components, 0 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
conundrums, conundrums, 0 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
context. context. 0 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Moeller Moeller 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
SJ, SJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Sheaff Sheaff 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
RJ. RJ. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Corporate Corporate 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNPS O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNPS NNP O
Materials Materials 1 0 0 0 0 0 0 0 9 0 NNP NNP NNPS NNP NNP O
Laboratory, Laboratory, 1 0 0 0 1 0 0 0 11 0 NNP NNPS NNP NNP NNP O
St. St. 1 0 0 0 0 0 0 0 3 0 NNPS NNP NNP NNP NNP O
Paul, Paul, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP CD O
MN MN 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
55144-1000, 55144-1000, 0 0 1 0 1 0 0 1 11 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP JJ O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP JJ NN O
eukaryotic eukaryotic 0 0 0 0 0 0 0 0 10 0 NNP NNP JJ NN MD O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP JJ NN MD VB O
must must 0 0 0 0 0 0 0 0 4 0 JJ NN MD VB NNP O
coordinate coordinate 0 0 0 0 0 0 0 0 10 0 NN MD VB NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 MD VB NNP NN CC O
synthesis synthesis 0 0 0 0 0 0 0 0 9 0 VB NNP NN CC JJ B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC JJ NN O
chromosomal chromosomal 0 0 0 0 0 0 0 0 11 0 NN CC JJ NN TO O
segregation segregation 0 0 0 0 0 0 0 0 11 0 CC JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB DT O
generate generate 0 0 0 0 0 0 0 0 8 0 NN TO VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT JJ NN O
faithful faithful 0 0 0 0 0 0 0 0 8 0 VB DT JJ NN IN O
replica replica 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
itself. itself. 0 0 0 0 0 0 0 0 7 0 NN IN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNS VBP O
events events 0 0 0 0 0 0 0 0 6 0 NNP NNP NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNS VBP VBN TO O
confined confined 0 0 0 0 0 0 0 0 8 0 NNS VBP VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBP VBN TO VB NNS O
discrete discrete 0 0 0 0 0 0 0 0 8 0 VBN TO VB NNS VBN O
periods periods 0 0 0 0 0 0 0 0 7 0 TO VB NNS VBN NN O
designated designated 0 0 0 0 0 0 0 0 10 0 VB NNS VBN NN -NONE- O
synthesis synthesis 0 0 0 0 0 0 0 0 9 0 NNS VBN NN -NONE- CC S
(S) (S) 0 1 0 0 0 0 0 0 3 0 VBN NN -NONE- CC NN S
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC NN NN O
mitosis mitosis 0 0 0 0 0 0 0 0 7 0 -NONE- CC NN NN CC B_TIMEXCCP 
(M), (M), 0 1 0 0 1 0 0 0 4 0 CC NN NN CC VBP B_TIMEXCCP 
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NN CC VBP VBN IN O
separated separated 0 0 0 0 0 0 0 0 9 0 CC VBP VBN IN CD O
by by 0 0 0 0 0 0 0 0 2 0 VBP VBN IN CD NN O
two two 0 0 0 0 0 0 0 0 3 0 VBN IN CD NN NNS O
gap gap 0 0 0 0 0 0 0 0 3 0 IN CD NN NNS JJ O
periods periods 0 0 0 0 0 0 0 0 7 0 CD NN NNS JJ CC O
(Gl (Gl 0 0 0 0 0 0 0 0 3 0 NN NNS JJ CC NNP I_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 NNS JJ CC NNP DT O
G2). G2). 1 1 0 0 0 0 0 1 4 0 JJ CC NNP DT JJ B_TIMEXCCP
A A 1 1 0 0 0 0 0 0 1 0 CC NNP DT JJ JJ O
complete complete 0 0 0 0 0 0 0 0 8 0 NNP DT JJ JJ NN O
proliferative proliferative 0 0 0 0 0 0 0 0 13 0 DT JJ JJ NN NNS O
cycle cycle 0 0 0 0 0 0 0 0 5 0 JJ JJ NN NNS JJ O
entails entails 0 0 0 0 0 0 0 0 7 0 JJ NN NNS JJ CC O
sequential sequential 0 0 0 0 0 0 0 0 10 0 NN NNS JJ CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 NNS JJ CC VBN NN O
regulated regulated 0 0 0 0 0 0 0 0 9 0 JJ CC VBN NN IN O
progression progression 0 0 0 0 0 0 0 0 11 0 CC VBN NN IN JJ O
through through 0 0 0 0 0 0 0 0 7 0 VBN NN IN JJ NN O
G1, G1, 1 1 0 0 1 0 0 1 3 0 NN IN JJ NN NN B_TIMEXCCP
S, S, 1 1 0 0 1 0 0 0 2 0 IN JJ NN NN CC B_TIMEXCCP
G2, G2, 1 1 0 0 1 0 0 1 3 0 JJ NN NN CC NNP B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
M M 1 1 0 0 0 0 0 0 1 0 NN CC NNP NNP NNP B_TIMEXCCP
phases. phases. 0 0 0 0 0 0 0 0 7 0 CC NNP NNP NNP NNP O
During During 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP VBZ O
G1, G1, 1 1 0 0 1 0 0 1 3 0 NNP NNP NNP VBZ JJ B_TIMEXCCP
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ JJ NN O
receive receive 0 0 0 0 0 0 0 0 7 0 NNP VBZ JJ NN IN O
information information 0 0 0 0 0 0 0 0 11 0 VBZ JJ NN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
extracellular extracellular 0 0 0 0 0 0 0 0 13 0 IN DT JJ NN CC O
environment environment 0 0 0 0 0 0 0 0 11 0 DT JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN IN O
determine determine 0 0 0 0 0 0 0 0 9 0 NN CC NN IN TO O
whether whether 0 0 0 0 0 0 0 0 7 0 CC NN IN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN IN TO VB CC O
proliferate proliferate 0 0 0 0 0 0 0 0 11 0 IN TO VB CC TO O
or or 0 0 0 0 0 0 0 0 2 0 TO VB CC TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VB CC TO VB DT O
adopt adopt 0 0 0 0 0 0 0 0 5 0 CC TO VB DT NN O
an an 0 0 0 0 0 0 0 0 2 0 TO VB DT NN NNP O
alternate alternate 0 0 0 0 0 0 0 0 9 0 VB DT NN NNP NNP O
fate. fate. 0 0 0 0 0 0 0 0 5 0 DT NN NNP NNP IN O
Work Work 1 0 0 0 0 0 0 0 4 0 NN NNP NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN CC O
yeast yeast 0 0 0 0 0 0 0 0 5 0 NNP IN NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VBD JJ O
cultured cultured 0 0 0 0 0 0 0 0 8 0 NN CC VBD JJ NNS O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 CC VBD JJ NNS VBZ O
cells cells 0 0 0 0 0 0 0 0 5 0 VBD JJ NNS VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 JJ NNS VBZ VBN NN O
implicated implicated 0 0 0 0 0 0 0 0 10 0 NNS VBZ VBN NN NN O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 VBZ VBN NN NN NNS O
dependent dependent 0 0 0 0 0 0 0 0 9 0 VBN NN NN NNS -NONE- O
kinases kinases 0 0 0 0 0 0 0 0 7 0 NN NN NNS -NONE- CC O
(Cdks) (Cdks) 0 0 0 0 0 0 0 0 6 0 NN NNS -NONE- CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 -NONE- CC PRP$ NN NN O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 CC PRP$ NN NN NNS O
regulatory regulatory 0 0 0 0 0 0 0 0 10 0 PRP$ NN NN NNS IN O
partners partners 0 0 0 0 0 0 0 0 8 0 NN NN NNS IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NNS O
key key 0 0 0 0 0 0 0 0 3 0 NNS IN JJ NNS VBG O
components components 0 0 0 0 0 0 0 0 10 0 IN JJ NNS VBG NNP O
controlling controlling 0 0 0 0 0 0 0 0 11 0 JJ NNS VBG NNP NNP O
G1. G1. 1 1 0 0 0 0 0 1 3 0 NNS VBG NNP NNP NNP B_TIMEXCCP
Unique Unique 1 0 0 0 0 0 0 0 6 0 VBG NNP NNP NNP VBZ O
cyclin/Cdk cyclin/Cdk 0 0 0 1 0 0 0 0 10 0 NNP NNP NNP VBZ VBP O
complexes complexes 0 0 0 0 0 0 0 0 9 0 NNP NNP VBZ VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 NNP VBZ VBP RB VBN O
temporally temporally 0 0 0 0 0 0 0 0 10 0 VBZ VBP RB VBN IN O
expressed expressed 0 0 0 0 0 0 0 0 9 0 VBP RB VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN NN TO O
response response 0 0 0 0 0 0 0 0 8 0 VBN IN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB JJ O
extracellular extracellular 0 0 0 0 0 0 0 0 13 0 NN TO VB JJ NN O
signaling, signaling, 0 0 0 0 1 0 0 0 10 0 TO VB JJ NN PRP O
whereupon whereupon 0 0 0 0 0 0 0 0 9 0 VB JJ NN PRP VBP O
they they 0 0 0 0 0 0 0 0 4 0 JJ NN PRP VBP JJ O
phosphorylate phosphorylate 0 0 0 0 0 0 0 0 13 0 NN PRP VBP JJ NNS O
specific specific 0 0 0 0 0 0 0 0 8 0 PRP VBP JJ NNS TO O
targets targets 0 0 0 0 0 0 0 0 7 0 VBP JJ NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO VB VBN O
promote promote 0 0 0 0 0 0 0 0 7 0 NNS TO VB VBN NNP O
ordered ordered 0 0 0 0 0 0 0 0 7 0 TO VB VBN NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 0 VB VBN NNP NN CC B_TIMEXCCP
progression progression 0 0 0 0 0 0 0 0 11 0 VBN NNP NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase NN CC NNP NN NNP B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 CC NNP NN NNP NNP O
entry. entry. 0 0 0 0 0 0 0 0 6 0 NNP NN NNP NNP CC O
Cyclins Cyclins 1 0 0 0 0 0 0 0 7 0 NN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP VBP O
Cdks Cdks 1 0 0 0 0 0 0 0 4 0 NNP CC NNP VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 CC NNP VBP VBN TO O
thought thought 0 0 0 0 0 0 0 0 7 0 NNP VBP VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBP VBN TO VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB VBN CC O
required required 0 0 0 0 0 0 0 0 8 0 TO VB VBN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VB VBN CC JJ IN O
rate-limiting rate-limiting 0 0 1 0 0 0 0 0 13 0 VBN CC JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 CC JJ IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ IN NN NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 IN NN NN IN VBG O
because because 0 0 0 0 0 0 0 0 7 0 NN NN IN VBG PRP$ O
manipulating manipulating 0 0 0 0 0 0 0 0 12 0 NN IN VBG PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 IN VBG PRP$ NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 VBG PRP$ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 PRP$ NN IN NN CC O
yeast yeast 0 0 0 0 0 0 0 0 5 0 NN IN NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VBD JJ O
cultured cultured 0 0 0 0 0 0 0 0 8 0 NN CC VBD JJ NNS O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 CC VBD JJ NNS NNS O
cells cells 0 0 0 0 0 0 0 0 5 0 VBD JJ NNS NNS NNP O
alters alters 0 0 0 0 0 0 0 0 6 0 JJ NNS NNS NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 NNS NNS NNP NNP NNP B_TIMEXCCP
progression. progression. 0 0 0 0 0 0 0 0 12 0 NNS NNP NNP NNP JJ O
However, However, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP JJ NN O
recent recent 0 0 0 0 0 0 0 0 6 0 NNP NNP JJ NN VBZ O
evidence evidence 0 0 0 0 0 0 0 0 8 0 NNP JJ NN VBZ IN O
suggests suggests 0 0 0 0 0 0 0 0 8 0 JJ NN VBZ IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NN VBZ IN DT JJ O
these these 0 0 0 0 0 0 0 0 5 0 VBZ IN DT JJ NNS O
same same 0 0 0 0 0 0 0 0 4 0 IN DT JJ NNS VBP O
components components 0 0 0 0 0 0 0 0 10 0 DT JJ NNS VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 JJ NNS VBP RB RB O
not not 0 0 0 0 0 0 0 0 3 0 NNS VBP RB RB VBN O
necessarily necessarily 0 0 0 0 0 0 0 0 11 0 VBP RB RB VBN IN O
required required 0 0 0 0 0 0 0 0 8 0 RB RB VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN NN NN O
developing developing 0 0 0 0 0 0 0 0 10 0 VBN IN NN NN NNS O
mouse mouse 0 0 0 0 0 0 0 0 5 0 IN NN NN NNS CC O
embryos embryos 0 0 0 0 0 0 0 0 7 0 NN NN NNS CC NNS O
or or 0 0 0 0 0 0 0 0 2 0 NN NNS CC NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NNS CC NNS VBD IN O
derived derived 0 0 0 0 0 0 0 0 7 0 CC NNS VBD IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NNP NNP O
them. them. 0 0 0 0 0 0 0 0 5 0 VBD IN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNS IN O
implications implications 0 0 0 0 0 0 0 0 12 0 NNP NNP NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT JJ O
these these 0 0 0 0 0 0 0 0 5 0 NNS IN DT JJ NNS O
intriguing intriguing 0 0 0 0 0 0 0 0 10 0 IN DT JJ NNS IN O
observations observations 0 0 0 0 0 0 0 0 12 0 DT JJ NNS IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN NN NNP O
understanding understanding 0 0 0 0 0 0 0 0 13 0 NNS IN NN NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 0 IN NN NNP NN CC B_TIMEXCCP
progression progression 0 0 0 0 0 0 0 0 11 0 NN NNP NN CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NN CC PRP$ NN VBP O
regulation regulation 0 0 0 0 0 0 0 0 10 0 CC PRP$ NN VBP NNP O
are are 0 0 0 0 0 0 0 0 3 0 PRP$ NN VBP NNP NNP O
discussed. discussed. 0 0 0 0 0 0 0 0 10 0 NN VBP NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 VBP NNP NNP CD JJ O
16903206 16903206 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NNP JJ O
G2 G2 1 1 0 0 0 0 0 1 2 0 NONE DT NNP JJ NN O
chromosomal chromosomal 0 0 0 0 0 0 0 0 11 0 DT NNP JJ NN NNP O
radiosensitivity radiosensitivity 0 0 0 0 0 0 0 0 16 0 NNP JJ NN NNP NNP O
assay. assay. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP NNP O
Bryant Bryant 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP NNP O
PE, PE, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Gray Gray 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Riches Riches 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
AC, AC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Steel Steel 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
CM, CM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Finnon Finnon 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Howe Howe 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
O, O, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kesterton Kesterton 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
I, I, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Vral Vral 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Curwen Curwen 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
GB, GB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Smart Smart 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
V, V, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tawn Tawn 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
EJ, EJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Whitehouse Whitehouse 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
CA. CA. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
St St 1 0 0 0 0 0 0 0 2 0 NNP IN NNP NNP NNP O
Andrews, Andrews, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP NNP O
Scotland, Scotland, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
UK. UK. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
peb@st-and.ac.uk peb@st-and.ac.uk 0 0 1 0 0 0 0 0 16 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBG O
Although Although 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP VBG NN O
requiring requiring 0 0 0 0 0 0 0 0 9 0 NNP NNP VBG NN NN O
stringent stringent 0 0 0 0 0 0 0 0 9 0 NNP VBG NN NN NNS O
experimental experimental 0 0 0 0 0 0 0 0 12 0 VBG NN NN NNS TO O
conditions conditions 0 0 0 0 0 0 0 0 10 0 NN NN NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO VB JJ O
achieve achieve 0 0 0 0 0 0 0 0 7 0 NNS TO VB JJ NN O
good good 0 0 0 0 0 0 0 0 4 0 TO VB JJ NN DT O
reproducibility, reproducibility, 0 0 0 0 1 0 0 0 16 0 VB JJ NN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NNP NN O
G2 G2 1 1 0 0 0 0 0 1 2 0 NN DT NNP NN VBZ O
assay assay 0 0 0 0 0 0 0 0 5 0 DT NNP NN VBZ JJ O
has has 0 0 0 0 0 0 0 0 3 0 NNP NN VBZ JJ IN O
potential potential 0 0 0 0 0 0 0 0 9 0 NN VBZ JJ IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VBZ JJ IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 JJ IN DT JJ NN O
sensitive sensitive 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN IN O
marker marker 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN IN NN NN CC O
susceptibility, susceptibility, 0 0 0 0 1 0 0 0 15 0 IN NN NN CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NN CC VBZ RB JJ O
particularly particularly 0 0 0 0 0 0 0 0 12 0 CC VBZ RB JJ IN O
useful useful 0 0 0 0 0 0 0 0 6 0 VBZ RB JJ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 RB JJ IN NN NNP O
population population 0 0 0 0 0 0 0 0 10 0 JJ IN NN NNP NNP O
studies. studies. 0 0 0 0 0 0 0 0 8 0 IN NN NNP NNP NN O
Immediate Immediate 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NN IN O
culture culture 0 0 0 0 0 0 0 0 7 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN VBZ O
blood blood 0 0 0 0 0 0 0 0 5 0 NN IN NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 IN NN VBZ JJ CC O
preferable, preferable, 0 0 0 0 1 0 0 0 11 0 NN VBZ JJ CC JJ O
but but 0 0 0 0 0 0 0 0 3 0 VBZ JJ CC JJ NN O
overnight overnight 0 0 0 0 0 0 0 0 9 0 JJ CC JJ NN IN O
storage storage 0 0 0 0 0 0 0 0 7 0 CC JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN DT O
blood blood 0 0 0 0 0 0 0 0 5 0 NN IN NN DT IN O
either either 0 0 0 0 0 0 0 0 6 0 IN NN DT IN NN O
at at 0 0 0 0 0 0 0 0 2 0 NN DT IN NN NN O
ambient ambient 0 0 0 0 0 0 0 0 7 0 DT IN NN NN CC O
temperature temperature 0 0 0 0 0 0 0 0 11 0 IN NN NN CC IN O
or or 0 0 0 0 0 0 0 0 2 0 NN NN CC IN CD O
at at 0 0 0 0 0 0 0 0 2 0 NN CC IN CD NNS O
4 4 0 0 0 0 0 0 1 1 1 0 CC IN CD NNS NNP O
degrees degrees 0 0 0 0 0 0 0 0 7 0 IN CD NNS NNP VBZ O
C C 1 1 0 0 0 0 0 0 1 0 CD NNS NNP VBZ RB O
does does 0 0 0 0 0 0 0 0 4 0 NNS NNP VBZ RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NNP VBZ RB VB RB O
appear appear 0 0 0 0 0 0 0 0 6 0 VBZ RB VB RB TO O
significantly significantly 0 0 0 0 0 0 0 0 13 0 RB VB RB TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VB RB TO VB NNP O
affect affect 0 0 0 0 0 0 0 0 6 0 RB TO VB NNP NNP O
G2 G2 1 1 0 0 0 0 0 1 2 0 TO VB NNP NNP NNP O
scores. scores. 0 0 0 0 0 0 0 0 7 0 VB NNP NNP NNP IN O
Transport Transport 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN MD O
blood blood 0 0 0 0 0 0 0 0 5 0 NNP IN NN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 IN NN MD VB TO O
lead lead 0 0 0 0 0 0 0 0 4 0 NN MD VB TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 MD VB TO JJ NN O
additional additional 0 0 0 0 0 0 0 0 10 0 VB TO JJ NN IN O
variability variability 0 0 0 0 0 0 0 0 11 0 TO JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNS O
assay assay 0 0 0 0 0 0 0 0 5 0 NN IN NN NNS CC O
results results 0 0 0 0 0 0 0 0 7 0 IN NN NNS CC MD O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC MD VB O
should should 0 0 0 0 0 0 0 0 6 0 NNS CC MD VB RB O
be be 0 0 0 0 0 0 0 0 2 0 CC MD VB RB NNP O
well well 0 0 0 0 0 0 0 0 4 0 MD VB RB NNP NNP O
controlled. controlled. 0 0 0 0 0 0 0 0 11 0 VB RB NNP NNP NN O
Although Although 1 0 0 0 0 0 0 0 8 0 RB NNP NNP NN VBZ O
reproducibility reproducibility 0 0 0 0 0 0 0 0 15 0 NNP NNP NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ RB -NONE- O
generally generally 0 0 0 0 0 0 0 0 9 0 NN VBZ RB -NONE- NNP O
good, good, 0 0 0 0 1 0 0 0 5 0 VBZ RB -NONE- NNP NNS O
G2 G2 1 1 0 0 0 0 0 1 2 0 RB -NONE- NNP NNS IN O
scores scores 0 0 0 0 0 0 0 0 6 0 -NONE- NNP NNS IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NN IN O
blood blood 0 0 0 0 0 0 0 0 5 0 NNS IN NN IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 IN NN IN JJ NNS O
certain certain 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNS VBP O
individuals individuals 0 0 0 0 0 0 0 0 11 0 IN JJ NNS VBP TO O
appear appear 0 0 0 0 0 0 0 0 6 0 JJ NNS VBP TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBP TO VB JJ O
show show 0 0 0 0 0 0 0 0 4 0 VBP TO VB JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 TO VB JJ NN IN O
variability variability 0 0 0 0 0 0 0 0 11 0 VB JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNP O
repeat repeat 0 0 0 0 0 0 0 0 6 0 NN IN NN NNP NNP O
samples. samples. 0 0 0 0 0 0 0 0 8 0 IN NN NNP NNP NN O
Thus, Thus, 1 0 0 0 1 0 0 0 5 0 NN NNP NNP NN IN O
determination determination 0 0 0 0 0 0 0 0 13 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT JJ NN O
individual's individual's 0 0 0 0 0 1 0 0 12 0 IN DT JJ NN MD O
radiosensitivity radiosensitivity 0 0 0 0 0 0 0 0 16 0 DT JJ NN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 JJ NN MD VB NN O
require require 0 0 0 0 0 0 0 0 7 0 NN MD VB NN NNS O
multiple multiple 0 0 0 0 0 0 0 0 8 0 MD VB NN NNS IN O
assays assays 0 0 0 0 0 0 0 0 6 0 VB NN NNS IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NNP O
different different 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NNP NNP O
occasions. occasions. 0 0 0 0 0 0 0 0 10 0 IN JJ NNP NNP PRP O
While While 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP PRP VBZ VBN IN O
recognized recognized 0 0 0 0 0 0 0 0 10 0 PRP VBZ VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
distinction distinction 0 0 0 0 0 0 0 0 11 0 IN DT NN IN VBN O
between between 0 0 0 0 0 0 0 0 7 0 DT NN IN VBN CC O
aligned aligned 0 0 0 0 0 0 0 0 7 0 NN IN VBN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN VBN CC JJ NNS O
mis-aligned mis-aligned 0 0 1 0 0 0 0 0 11 0 VBN CC JJ NNS VBZ O
discontinuities discontinuities 0 0 0 0 0 0 0 0 15 0 CC JJ NNS VBZ DT O
has has 0 0 0 0 0 0 0 0 3 0 JJ NNS VBZ DT JJ O
no no 0 0 0 0 0 0 0 0 2 0 NNS VBZ DT JJ NN O
scientific scientific 0 0 0 0 0 0 0 0 10 0 VBZ DT JJ NN DT O
basis, basis, 0 0 0 0 1 0 0 0 6 0 DT JJ NN DT NNS O
some some 0 0 0 0 0 0 0 0 4 0 JJ NN DT NNS VBP O
laboratories laboratories 0 0 0 0 0 0 0 0 12 0 NN DT NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 DT NNS VBP VBN IN O
decided decided 0 0 0 0 0 0 0 0 7 0 NNS VBP VBN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBP VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
purpose purpose 0 0 0 0 0 0 0 0 7 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ TO O
record-keeping record-keeping 0 0 1 0 0 0 0 0 14 0 NN IN JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN JJ TO VB DT O
score score 0 0 0 0 0 0 0 0 5 0 JJ TO VB DT VBN O
all all 0 0 0 0 0 0 0 0 3 0 TO VB DT VBN NNS O
aligned aligned 0 0 0 0 0 0 0 0 7 0 VB DT VBN NNS IN O
discontinuities discontinuities 0 0 0 0 0 0 0 0 15 0 DT VBN NNS IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 VBN NNS IN JJ CC O
gaps, gaps, 0 0 0 0 1 0 0 0 5 0 NNS IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NNS O
mis-aligned mis-aligned 0 0 1 0 0 0 0 0 11 0 JJ CC JJ NNS IN O
discontinuities discontinuities 0 0 0 0 0 0 0 0 15 0 CC JJ NNS IN NNP O
as as 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NNP O
breaks. breaks. 0 0 0 0 0 0 0 0 7 0 NNS IN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 IN NNP NNP DT NNS O
all all 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNS DT O
cases cases 0 0 0 0 0 0 0 0 5 0 NNP DT NNS DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 DT NNS DT JJ NNP O
final final 0 0 0 0 0 0 0 0 5 0 NNS DT JJ NNP NN O
G2 G2 1 1 0 0 0 0 0 1 2 0 DT JJ NNP NN MD O
score score 0 0 0 0 0 0 0 0 5 0 JJ NNP NN MD VB O
should should 0 0 0 0 0 0 0 0 6 0 NNP NN MD VB DT O
comprise comprise 0 0 0 0 0 0 0 0 8 0 NN MD VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NN IN O
sum sum 0 0 0 0 0 0 0 0 3 0 VB DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNS O
all all 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS CC O
gaps gaps 0 0 0 0 0 0 0 0 4 0 IN DT NNS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 DT NNS CC NNP NNP O
breaks. breaks. 0 0 0 0 0 0 0 0 7 0 NNS CC NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 CC NNP NNP CD JJ O
12428927 12428927 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Quantitative Quantitative 1 0 0 0 0 0 0 0 12 0 NONE NONE JJ NN NNS O
misorientation misorientation 0 0 0 0 0 0 0 0 14 0 NONE JJ NN NNS IN O
characteristics characteristics 0 0 0 0 0 0 0 0 15 0 JJ NN NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NNS O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NNS IN NN NNS IN B_TIMEXCCP
boundaries boundaries 0 0 0 0 0 0 0 0 10 0 IN NN NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP NNP O
composites. composites. 0 0 0 0 0 0 0 0 11 0 NNS IN NNP NNP NNP O
Sztwiertnia Sztwiertnia 1 0 0 0 0 0 0 0 11 0 IN NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Faryna Faryna 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sawina Sawina 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
G. G. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Polish Polish 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Academy Academy 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Metallurgy Metallurgy 1 0 0 0 0 0 0 0 10 0 NNP IN NNP CC NNPS O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNPS NNP O
Materials Materials 1 0 0 0 0 0 0 0 9 0 NNP CC NNPS NNP CD O
Science, Science, 1 0 0 0 1 0 0 0 8 0 CC NNPS NNP CD NNP O
25 25 0 0 0 0 0 0 1 1 2 0 NNPS NNP CD NNP NNP O
Reymonta Reymonta 1 0 0 0 0 0 0 0 8 0 NNP CD NNP NNP CD O
Street, Street, 1 0 0 0 1 0 0 0 7 0 CD NNP NNP CD -NONE- O
30-059 30-059 0 0 1 0 0 0 0 1 6 0 NNP NNP CD -NONE- NNP O
Krakow, Krakow, 1 0 0 0 1 0 0 0 7 0 NNP CD -NONE- NNP NNP O
Poland. Poland. 1 0 0 0 0 0 0 0 7 0 CD -NONE- NNP NNP NNP O
nmsztwie@imim-pan.krakow.pl nmsztwie@imim-pan.krakow.pl 0 0 1 0 0 0 0 0 27 0 -NONE- NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP JJ O
Specific Specific 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP JJ NNS O
crystallographic crystallographic 0 0 0 0 0 0 0 0 16 0 NNP NNP JJ NNS IN O
correlations correlations 0 0 0 0 0 0 0 0 12 0 NNP JJ NNS IN VBG O
between between 0 0 0 0 0 0 0 0 7 0 JJ NNS IN VBG NNS O
neighbouring neighbouring 0 0 0 0 0 0 0 0 12 0 NNS IN VBG NNS IN O
grains grains 0 0 0 0 0 0 0 0 6 0 IN VBG NNS IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 VBG NNS IN NNS VBD O
composites composites 0 0 0 0 0 0 0 0 10 0 NNS IN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 IN NNS VBD VBN IN O
established established 0 0 0 0 0 0 0 0 11 0 NNS VBD VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
use use 0 0 0 0 0 0 0 0 3 0 IN DT NN IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN VBN NN O
selected selected 0 0 0 0 0 0 0 0 8 0 NN IN VBN NN NN O
area area 0 0 0 0 0 0 0 0 4 0 IN VBN NN NN NN O
electron electron 0 0 0 0 0 0 0 0 8 0 VBN NN NN NN IN O
diffraction diffraction 0 0 0 0 0 0 0 0 11 0 NN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
transmission transmission 0 0 0 0 0 0 0 0 12 0 IN DT NN NN NNP O
electron electron 0 0 0 0 0 0 0 0 8 0 DT NN NN NNP NNP O
microscope. microscope. 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP PRP O
However, However, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP PRP VBD O
it it 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD DT O
was was 0 0 0 0 0 0 0 0 3 0 NNP PRP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT NN IN O
development development 0 0 0 0 0 0 0 0 11 0 VBD DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN VBG O
orientation orientation 0 0 0 0 0 0 0 0 11 0 NN IN NN VBG NNS O
mapping mapping 0 0 0 0 0 0 0 0 7 0 IN NN VBG NNS WDT O
techniques techniques 0 0 0 0 0 0 0 0 10 0 NN VBG NNS WDT VBN O
that that 0 0 0 0 0 0 0 0 4 0 VBG NNS WDT VBN PRP O
made made 0 0 0 0 0 0 0 0 4 0 NNS WDT VBN PRP JJ O
it it 0 0 0 0 0 0 0 0 2 0 WDT VBN PRP JJ TO O
possible possible 0 0 0 0 0 0 0 0 8 0 VBN PRP JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 PRP JJ TO VB DT O
obtain obtain 0 0 0 0 0 0 0 0 6 0 JJ TO VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT JJ NN O
quantitative quantitative 0 0 0 0 0 0 0 0 12 0 VB DT JJ NN IN O
description description 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
distribution distribution 0 0 0 0 0 0 0 0 12 0 IN DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS IN O
boundaries boundaries 0 0 0 0 0 0 0 0 10 0 NN IN NNS IN DT O
between between 0 0 0 0 0 0 0 0 7 0 IN NNS IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNS IN O
grains grains 0 0 0 0 0 0 0 0 6 0 IN DT NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT DT O
both both 0 0 0 0 0 0 0 0 4 0 NNS IN DT DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 IN DT DT JJ NN O
same same 0 0 0 0 0 0 0 0 4 phase DT DT JJ NN CC O
phase phase 0 0 0 0 0 0 0 0 5 0 DT JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NNP O
different different 0 0 0 0 0 0 0 0 9 0 NN CC JJ NNP NNP O
phases. phases. 0 0 0 0 0 0 0 0 7 0 CC JJ NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NN VBZ O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ IN O
shows shows 0 0 0 0 0 0 0 0 5 0 NNP NN VBZ IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NN VBZ IN NN NN O
orientation orientation 0 0 0 0 0 0 0 0 11 0 VBZ IN NN NN NNS O
topography topography 0 0 0 0 0 0 0 0 10 0 IN NN NN NNS VBN O
measurements measurements 0 0 0 0 0 0 0 0 12 0 NN NN NNS VBN IN O
made made 0 0 0 0 0 0 0 0 4 0 NN NNS VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBN IN NN NN O
electron electron 0 0 0 0 0 0 0 0 8 0 VBN IN NN NN NN O
backscatter backscatter 0 0 0 0 0 0 0 0 11 0 IN NN NN NN IN O
diffraction diffraction 0 0 0 0 0 0 0 0 11 0 NN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
scanning scanning 0 0 0 0 0 0 0 0 8 0 IN DT NN NN NN O
electron electron 0 0 0 0 0 0 0 0 8 0 DT NN NN NN VBD O
microscope microscope 0 0 0 0 0 0 0 0 10 0 NN NN NN VBD NN O
allowed allowed 0 0 0 0 0 0 0 0 7 0 NN NN VBD NN IN O
determination determination 0 0 0 0 0 0 0 0 13 0 NN VBD NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNS O
crystallographic crystallographic 0 0 0 0 0 0 0 0 16 0 IN DT JJ NNS IN O
relationships relationships 0 0 0 0 0 0 0 0 13 0 DT JJ NNS IN NNS O
between between 0 0 0 0 0 0 0 0 7 0 JJ NNS IN NNS IN O
grains grains 0 0 0 0 0 0 0 0 6 0 NNS IN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN JJ NNP O
different different 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NNP NNP O
phases. phases. 0 0 0 0 0 0 0 0 7 0 IN JJ NNP NNP JJ O
An An 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP JJ JJ O
alumina-based alumina-based 0 0 1 0 0 0 0 0 13 0 NNP NNP JJ JJ IN O
composite composite 0 0 0 0 0 0 0 0 9 0 NNP JJ JJ IN DT O
with with 0 0 0 0 0 0 0 0 4 0 JJ JJ IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 JJ IN DT NN IN O
content content 0 0 0 0 0 0 0 0 7 0 IN DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD NN O
10 10 0 0 0 0 0 0 1 1 2 0 NN IN CD NN RB O
vol% vol% 0 0 0 0 0 0 0 0 4 0 IN CD NN RB VB O
tungsten tungsten 0 0 0 0 0 0 0 0 8 0 CD NN RB VB VBD O
carbide carbide 0 0 0 0 0 0 0 0 7 0 NN RB VB VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 RB VB VBD VBN IN O
chosen chosen 0 0 0 0 0 0 0 0 6 0 VB VBD VBN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN NNP NNP O
investigations. investigations. 0 0 0 0 0 0 0 0 15 0 VBN IN NNP NNP NN O
Misorientation Misorientation 1 0 0 0 0 0 0 0 14 0 IN NNP NNP NN NNS O
distribution distribution 0 0 0 0 0 0 0 0 12 0 NNP NNP NN NNS VBD O
functions functions 0 0 0 0 0 0 0 0 9 0 NNP NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN TO O
calculated calculated 0 0 0 0 0 0 0 0 10 0 NNS VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB DT O
describe describe 0 0 0 0 0 0 0 0 8 0 VBN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN NN O
distribution distribution 0 0 0 0 0 0 0 0 12 0 VB DT NN NN IN O
density density 0 0 0 0 0 0 0 0 7 0 DT NN NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNS IN O
misorientations misorientations 0 0 0 0 0 0 0 0 15 0 NN IN NNS IN NN O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN NN TO O
respect respect 0 0 0 0 0 0 0 0 7 0 NNS IN NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT JJS VBG O
nearest nearest 0 0 0 0 0 0 0 0 7 0 TO DT JJS VBG VBN O
neighbouring neighbouring 0 0 0 0 0 0 0 0 12 0 DT JJS VBG VBN NN O
measured measured 0 0 0 0 0 0 0 0 8 0 JJS VBG VBN NN VBN O
point point 0 0 0 0 0 0 0 0 5 0 VBG VBN NN VBN IN O
located located 0 0 0 0 0 0 0 0 7 0 VBN NN VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
grain grain 0 0 0 0 0 0 0 0 5 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
second second 0 0 0 0 0 0 0 0 6 0 IN DT JJ NNP NNP O
phase. phase. 0 0 0 0 0 0 0 0 6 0 DT JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NN O
misorientation misorientation 0 0 0 0 0 0 0 0 14 0 NN IN NN NN NNS O
distribution distribution 0 0 0 0 0 0 0 0 12 0 IN NN NN NNS VBD O
functions functions 0 0 0 0 0 0 0 0 9 0 NN NN NNS VBD DT O
permitted permitted 0 0 0 0 0 0 0 0 9 0 NN NNS VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBD DT NN IN O
evaluation evaluation 0 0 0 0 0 0 0 0 10 0 VBD DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS IN O
preferences preferences 0 0 0 0 0 0 0 0 11 0 NN IN NNS IN DT O
for for 0 0 0 0 0 0 0 0 3 0 IN NNS IN DT JJ O
some some 0 0 0 0 0 0 0 0 4 0 NNS IN DT JJ JJ O
special special 0 0 0 0 0 0 0 0 7 0 IN DT JJ JJ NNS O
crystallographic crystallographic 0 0 0 0 0 0 0 0 16 0 DT JJ JJ NNS IN O
correlations correlations 0 0 0 0 0 0 0 0 12 0 JJ JJ NNS IN DT O
between between 0 0 0 0 0 0 0 0 7 0 JJ NNS IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNS IN O
grains grains 0 0 0 0 0 0 0 0 6 0 IN DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NN O
composite composite 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NN CC O
matrix matrix 0 0 0 0 0 0 0 0 6 0 IN JJ NN CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNS IN O
inclusions inclusions 0 0 0 0 0 0 0 0 10 0 NN CC NNS IN RB O
as as 0 0 0 0 0 0 0 0 2 0 CC NNS IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NNS IN RB IN NNS O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN NNS IN O
shares shares 0 0 0 0 0 0 0 0 6 0 RB IN NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN NN NNS O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NNS IN NN NNS VBD B_TIMEXCCP
boundaries boundaries 0 0 0 0 0 0 0 0 10 0 IN NN NNS VBD IN O
characterized characterized 0 0 0 0 0 0 0 0 13 0 NN NNS VBD IN DT O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBD IN DT NNP O
those those 0 0 0 0 0 0 0 0 5 0 VBD IN DT NNP NNP O
correlations. correlations. 0 0 0 0 0 0 0 0 13 0 IN DT NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 DT NNP NNP CD -NONE- O
17100892 17100892 0 0 0 0 0 0 1 1 8 0 NNP NNP CD -NONE- NONE O
[PubMed] [PubMed] 0 0 0 0 0 0 0 0 8 0 NNP CD -NONE- NONE NONE O
Spotlight Spotlight 1 0 0 0 0 0 0 0 9 0 NONE NONE NNP IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NONE NNP IN NNP NNP O
mitosis: mitosis: 0 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP B_TIMEXCCP
introduction. introduction. 0 0 0 0 0 0 0 0 13 0 IN NNP NNP NNP NNP O
Clarke Clarke 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
DJ. DJ. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Genetics, Genetics, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP CC O
Biology Biology 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Development, Development, 1 0 0 0 1 0 0 0 12 0 NNP CC NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Minnesota Minnesota 1 0 0 0 0 0 0 0 9 0 NNP IN NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP CD O
School, School, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP CD NNP O
420 420 0 0 0 0 0 0 1 1 3 0 NNP NNP CD NNP NNP O
Washington Washington 1 0 0 0 0 0 0 0 10 0 NNP CD NNP NNP NNP O
Ave., Ave., 1 0 0 0 1 0 0 0 5 0 CD NNP NNP NNP NNP O
Minneapolis, Minneapolis, 1 0 0 0 1 0 0 0 12 0 NNP NNP NNP NNP CD O
Minnesota Minnesota 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP CD NNP O
55455, 55455, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Duncan.J.Clarke-2@umn.edu Duncan.J.Clarke-2@umn.edu 1 0 1 0 0 0 0 1 25 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Even Even 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP IN JJ O
before before 0 0 0 0 0 0 0 0 6 0 NNP NNP IN JJ CC O
biochemical biochemical 0 0 0 0 0 0 0 0 11 0 NNP IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NNS O
genetic genetic 0 0 0 0 0 0 0 0 7 0 JJ CC JJ NNS VBD O
approaches approaches 0 0 0 0 0 0 0 0 10 0 CC JJ NNS VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD JJ JJ O
employed, employed, 0 0 0 0 1 0 0 0 9 0 NNS VBD JJ JJ NNS O
many many 0 0 0 0 0 0 0 0 4 0 VBD JJ JJ NNS VBD O
researchers researchers 0 0 0 0 0 0 0 0 11 0 JJ JJ NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD VBN CC O
captivated captivated 0 0 0 0 0 0 0 0 10 0 NNS VBD VBN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 VBD VBN CC VBD IN O
astounded astounded 0 0 0 0 0 0 0 0 9 0 VBN CC VBD IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 CC VBD IN NNP NNP O
mitosis. mitosis. 0 0 0 0 0 0 0 0 8 0 VBD IN NNP NNP VBZ B_TIMEXCCP
Cell Cell 1 0 0 0 0 0 0 0 4 0 IN NNP NNP VBZ VBP O
biologists biologists 0 0 0 0 0 0 0 0 10 0 NNP NNP VBZ VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 VBZ VBP VBN VBN IN O
enthralled enthralled 0 0 0 0 0 0 0 0 10 0 VBP VBN VBN IN PRP$ O
by by 0 0 0 0 0 0 0 0 2 0 VBN VBN IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 VBN IN PRP$ NN NN O
sheer sheer 0 0 0 0 0 0 0 0 5 0 IN PRP$ NN NN IN O
beauty beauty 0 0 0 0 0 0 0 0 6 0 PRP$ NN NN IN JJR O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN JJR IN O
more more 0 0 0 0 0 0 0 0 4 0 NN IN JJR IN DT O
than than 0 0 0 0 0 0 0 0 4 0 IN JJR IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 JJR IN DT NN NNP O
century century 0 0 0 0 0 0 0 0 7 0 IN DT NN NNP CD O
(Fig. (Fig. 0 0 0 0 0 0 0 0 5 0 DT NN NNP CD -NONE- O
1). 1). 0 0 0 0 0 0 0 1 3 0 NN NNP CD -NONE- WP O
Yanagida, Yanagida, 1 0 0 0 1 0 0 0 9 0 NNP CD -NONE- WP RB O
who who 0 0 0 0 0 0 0 0 3 0 CD -NONE- WP RB VBD O
probably probably 0 0 0 0 0 0 0 0 8 0 -NONE- WP RB VBD JJR O
contributed contributed 0 0 0 0 0 0 0 0 11 0 WP RB VBD JJR TO O
more more 0 0 0 0 0 0 0 0 4 0 RB VBD JJR TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBD JJR TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJR TO DT JJ NN O
genetic genetic 0 0 0 0 0 0 0 0 7 0 TO DT JJ NN IN O
dissection dissection 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNS O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNS IN B_TIMEXCCP
processes processes 0 0 0 0 0 0 0 0 9 0 IN JJ NNS IN DT O
than than 0 0 0 0 0 0 0 0 4 0 JJ NNS IN DT JJ O
any any 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
other other 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN VBD O
scientist, scientist, 0 0 0 0 1 0 0 0 10 0 DT JJ NN VBD PRP O
described described 0 0 0 0 0 0 0 0 9 0 JJ NN VBD PRP IN O
it it 0 0 0 0 0 0 0 0 2 0 NN VBD PRP IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VBD PRP IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 PRP IN DT JJ NN O
"cellular "cellular 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN RB O
festival", festival", 0 0 0 0 1 0 0 0 10 0 DT JJ NN RB JJ O
dramatically dramatically 0 0 0 0 0 0 0 0 12 0 JJ NN RB JJ IN O
thrust thrust 0 0 0 0 0 0 0 0 6 0 NN RB JJ IN DT O
between between 0 0 0 0 0 0 0 0 7 0 RB JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN NNS O
humdrum humdrum 0 0 0 0 0 0 0 0 7 0 IN DT NN NNS IN O
chores chores 0 0 0 0 0 0 0 0 6 0 DT NN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NNP O
daily daily 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NNP NNP O
life. life. 0 0 0 0 0 0 0 0 5 0 IN JJ NNP NNP NNP O
True True 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NNP IN O
enough; enough; 0 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN DT O
if if 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN VBD O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN VBD DT O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBD DT JJ NN O
theatrical theatrical 0 0 0 0 0 0 0 0 10 0 VBD DT JJ NN NN O
performance, performance, 0 0 0 0 1 0 0 0 12 0 DT JJ NN NN MD O
mitosis mitosis 0 0 0 0 0 0 0 0 7 0 JJ NN NN MD VB B_TIMEXCCP 
would would 0 0 0 0 0 0 0 0 5 0 NN NN MD VB DT O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT JJ JJ O
final final 0 0 0 0 0 0 0 0 5 0 VB DT JJ JJ NNP O
climatic climatic 0 0 0 0 0 0 0 0 8 0 DT JJ JJ NNP NNP O
act. act. 0 0 0 0 0 0 0 0 4 0 JJ JJ NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN DT O
Spotlight, Spotlight, 1 0 0 0 1 0 0 0 10 0 NNP DT NN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 DT NN DT JJ IN O
few few 0 0 0 0 0 0 0 0 3 0 NN DT JJ IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN VBZ O
exciting exciting 0 0 0 0 0 0 0 0 8 0 IN DT NN VBZ IN O
aspects aspects 0 0 0 0 0 0 0 0 7 0 DT NN VBZ IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN VBZ IN NN VBP O
mitosis mitosis 0 0 0 0 0 0 0 0 7 0 VBZ IN NN VBP NNP B_TIMEXCCP 
are are 0 0 0 0 0 0 0 0 3 0 IN NN VBP NNP NNP O
reviewed. reviewed. 0 0 0 0 0 0 0 0 9 0 NN VBP NNP NNP IN O
Comment Comment 1 0 0 0 0 0 0 0 7 0 VBP NNP NNP IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NN O
Spindle Spindle 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NN IN O
polarity polarity 0 0 0 0 0 0 0 0 8 0 IN NNP NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NNP O
S. S. 1 1 0 0 0 0 0 0 2 0 NN IN NNP NNP NNP O
cerevisiae: cerevisiae: 0 0 0 0 0 0 0 0 11 0 IN NNP NNP NNP MD O
MEN MEN 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP MD NNP O
can can 0 0 0 0 0 0 0 0 3 0 NNP NNP MD NNP NNP O
tell. tell. 0 0 0 0 0 0 0 0 5 0 NNP MD NNP NNP NNP O
[Cell [Cell 0 0 0 0 0 0 0 0 5 0 MD NNP NNP NNP CD O
Cycle. Cycle. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP CD NNP O
2002] 2002] 0 0 0 0 0 0 0 1 5 0 NNP NNP CD NNP NNS O
Recent Recent 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNS IN O
glimpses glimpses 0 0 0 0 0 0 0 0 8 0 CD NNP NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
elusive elusive 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN NNP O
spindle spindle 0 0 0 0 0 0 0 0 7 0 DT JJ NN NNP NNP O
matrix. matrix. 0 0 0 0 0 0 0 0 7 0 JJ NN NNP NNP NNP O
[Cell [Cell 0 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP CD O
Cycle. Cycle. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP CD NNP O
2002] 2002] 0 0 0 0 0 0 0 1 5 0 NNP NNP CD NNP IN O
Complexity Complexity 1 0 0 0 0 0 0 0 10 0 NNP CD NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CD NNP IN JJ NNP O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 NNP IN JJ NNP NNP O
exit. exit. 0 0 0 0 0 0 0 0 5 0 IN JJ NNP NNP NNP O
[Cell [Cell 0 0 0 0 0 0 0 0 5 0 JJ NNP NNP NNP CD O
Cycle. Cycle. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP CD NNP O
2002] 2002] 0 0 0 0 0 0 0 1 5 0 NNP NNP CD NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP CD NNP NNP NNP O
FEAR FEAR 1 1 0 0 0 0 0 0 4 0 CD NNP NNP NNP NNP O
Before Before 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP VBZ O
MEN: MEN: 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP VBZ IN O
networks networks 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN JJ NNP O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 VBZ IN JJ NNP NNP O
exit. exit. 0 0 0 0 0 0 0 0 5 0 IN JJ NNP NNP NNP O
[Cell [Cell 0 0 0 0 0 0 0 0 5 0 JJ NNP NNP NNP CD O
Cycle. Cycle. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP CD -NONE- O
2002] 2002] 0 0 0 0 0 0 0 1 5 0 NNP NNP CD -NONE- CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNP CD -NONE- CD JJ O
12461286 12461286 0 0 0 0 0 0 1 1 8 0 CD -NONE- CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 -NONE- CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Reactivity Reactivity 1 0 0 0 0 0 0 0 10 0 NONE NONE NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NN NN O
anti anti 0 0 0 0 0 0 0 0 4 0 NN IN NN NN NNS O
nucleoside nucleoside 0 0 0 0 0 0 0 0 10 0 IN NN NN NNS IN O
antibodies antibodies 0 0 0 0 0 0 0 0 10 0 NN NN NNS IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NN NNS IN NN NNP O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 NNS IN NN NNP NNP B_TIMEXCCP
chromosomes. chromosomes. 0 0 0 0 0 0 0 0 12 0 IN NN NNP NNP NNP O
Morin Morin 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Marcollet Marcollet 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Leng Leng 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
M. M. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
shown shown 0 0 0 0 0 0 0 0 5 0 NNP VBZ VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
binding binding 0 0 0 0 0 0 0 0 7 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
anti-nucleoside anti-nucleoside 0 0 1 0 0 0 0 0 15 0 NN IN JJ NNS TO O
antibodies antibodies 0 0 0 0 0 0 0 0 10 0 IN JJ NNS TO VBN O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO VBN NN O
fixed fixed 0 0 0 0 0 0 0 0 5 0 NNS TO VBN NN NN O
human human 0 0 0 0 0 0 0 0 5 0 TO VBN NN NN VBZ O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 VBN NN NN VBZ MD B_TIMEXCCP
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 NN NN VBZ MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN VBZ MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 VBZ MD VB VBN VBG O
revealed revealed 0 0 0 0 0 0 0 0 8 0 MD VB VBN VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 VB VBN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN VBG DT NN NN O
immunoperoxidase immunoperoxidase 0 0 0 0 0 0 0 0 16 0 VBG DT NN NN IN O
procedure procedure 0 0 0 0 0 0 0 0 9 0 DT NN NN IN IN O
while while 0 0 0 0 0 0 0 0 5 0 NN NN IN IN DT O
under under 0 0 0 0 0 0 0 0 5 0 NN IN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 IN IN DT JJ NNS O
same same 0 0 0 0 0 0 0 0 4 0 IN DT JJ NNS DT O
conditions conditions 0 0 0 0 0 0 0 0 10 0 DT JJ NNS DT NN O
no no 0 0 0 0 0 0 0 0 2 0 JJ NNS DT NN VBG O
antibody antibody 0 0 0 0 0 0 0 0 8 0 NNS DT NN VBG VBZ O
binding binding 0 0 0 0 0 0 0 0 7 0 DT NN VBG VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN VBG VBZ VBN VBG O
revealed revealed 0 0 0 0 0 0 0 0 8 0 VBG VBZ VBN VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 VBZ VBN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN VBG DT NN NNP O
immunofluorescence immunofluorescence 0 0 0 0 0 0 0 0 18 0 VBG DT NN NNP NNP O
procedure. procedure. 0 0 0 0 0 0 0 0 10 0 DT NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
391289 391289 0 0 0 0 0 0 1 1 6 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Coordinating Coordinating 1 0 0 0 0 0 0 0 12 0 NONE NONE VBG DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NONE VBG DT NNS IN O
events events 0 0 0 0 0 0 0 0 6 0 VBG DT NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NNP O
meiotic meiotic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NNP NNP O
prophase. prophase. 0 0 0 0 0 0 0 0 9 0 DT JJ NNP NNP NNP B_TIMEXCCP
Pawlowski Pawlowski 1 0 0 0 0 0 0 0 9 0 JJ NNP NNP NNP NNP O
WP, WP, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Cande Cande 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
WZ. WZ. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Plant Plant 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP CC O
Breeding Breeding 1 0 0 0 0 0 0 0 8 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Genetics, Genetics, 1 0 0 0 1 0 0 0 9 0 NNP CC NNP NNP NNP O
Cornell Cornell 1 0 0 0 0 0 0 0 7 0 CC NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Ithaca, Ithaca, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP CD O
NY NY 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
14853, 14853, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
wp45@cornell.edu wp45@cornell.edu 0 0 0 0 0 0 0 1 16 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
Meiosis Meiosis 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT VBN O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT VBN NN O
specialized specialized 0 0 0 0 0 0 0 0 11 0 VBZ DT VBN NN IN O
type type 0 0 0 0 0 0 0 0 4 0 DT VBN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN VBG O
division division 0 0 0 0 0 0 0 0 8 0 IN NN NN VBG TO O
leading leading 0 0 0 0 0 0 0 0 7 0 NN NN VBG TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN VBG TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBG TO DT NN IN O
production production 0 0 0 0 0 0 0 0 10 0 TO DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
gametes. gametes. 0 0 0 0 0 0 0 0 8 0 NN IN NNP NNP JJ O
During During 1 0 0 0 0 0 0 0 6 0 IN NNP NNP JJ NN O
meiotic meiotic 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NN NN O
prophase prophase 0 0 0 0 0 0 0 0 8 0 NNP JJ NN NN JJ B_TIMEXCCP
I, I, 1 1 0 0 1 0 0 0 2 0 JJ NN NN JJ NNS O
homologous homologous 0 0 0 0 0 0 0 0 10 0 NN NN JJ NNS VBP O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 NN JJ NNS VBP IN O
interact interact 0 0 0 0 0 0 0 0 8 0 JJ NNS VBP IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBP IN DT JJ O
each each 0 0 0 0 0 0 0 0 4 0 VBP IN DT JJ CC O
other other 0 0 0 0 0 0 0 0 5 0 IN DT JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC NN NNS O
form form 0 0 0 0 0 0 0 0 4 0 JJ CC NN NNS NNS O
bivalents bivalents 0 0 0 0 0 0 0 0 9 0 CC NN NNS NNS IN O
(pairs (pairs 0 0 0 0 0 0 0 0 6 0 NN NNS NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNS NNS IN JJ NNP O
homologous homologous 0 0 0 0 0 0 0 0 10 0 NNS IN JJ NNP NNP O
chromosomes). chromosomes). 0 0 0 0 0 0 0 0 13 0 IN JJ NNP NNP JJ O
Three Three 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP JJ JJ O
major major 0 0 0 0 0 0 0 0 5 0 NNP NNP JJ JJ JJ O
meiotic meiotic 0 0 0 0 0 0 0 0 7 0 NNP JJ JJ JJ NN O
processes--chromosome processes--chromosome 0 0 1 0 0 0 0 0 21 0 JJ JJ JJ NN NN O
pairing, pairing, 0 0 0 0 1 0 0 0 8 0 JJ JJ NN NN CC O
synapsis synapsis 0 0 0 0 0 0 0 0 8 0 JJ NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ VBN O
recombination--are recombination--are 0 0 1 0 0 0 0 0 18 0 NN CC JJ VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 CC JJ VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
formation formation 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
bivalents. bivalents. 0 0 0 0 0 0 0 0 10 0 NN IN NNP NNP JJ O
Many Many 1 0 0 0 0 0 0 0 4 0 IN NNP NNP JJ NNS O
recent recent 0 0 0 0 0 0 0 0 6 0 NNP NNP JJ NNS VBP O
reports reports 0 0 0 0 0 0 0 0 7 0 NNP JJ NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 JJ NNS VBP VBN JJ O
uncovered uncovered 0 0 0 0 0 0 0 0 9 0 NNS VBP VBN JJ NNS O
complex complex 0 0 0 0 0 0 0 0 7 0 VBP VBN JJ NNS IN O
networks networks 0 0 0 0 0 0 0 0 8 0 VBN JJ NNS IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNS IN O
interactions interactions 0 0 0 0 0 0 0 0 12 0 NNS IN NNS IN DT O
between between 0 0 0 0 0 0 0 0 7 0 IN NNS IN DT NNP O
these these 0 0 0 0 0 0 0 0 5 0 NNS IN DT NNP NNP O
processes. processes. 0 0 0 0 0 0 0 0 10 0 IN DT NNP NNP NN O
Chromosome Chromosome 1 0 0 0 0 0 0 0 10 0 DT NNP NNP NN VBZ O
pairing pairing 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ RB JJ O
largely largely 0 0 0 0 0 0 0 0 7 0 NN VBZ RB JJ IN O
dependent dependent 0 0 0 0 0 0 0 0 9 0 VBZ RB JJ IN DT O
on on 0 0 0 0 0 0 0 0 2 0 RB JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN CC O
initiation initiation 0 0 0 0 0 0 0 0 10 0 IN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
progression progression 0 0 0 0 0 0 0 0 11 0 NN CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN IN O
recombination recombination 0 0 0 0 0 0 0 0 13 0 NN IN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNS O
fungi, fungi, 0 0 0 0 1 0 0 0 6 0 NN IN NNP NNS CC O
mammals mammals 0 0 0 0 0 0 0 0 7 0 IN NNP NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNS CC JJ CC O
plants, plants, 0 0 0 0 1 0 0 0 7 0 NNS CC JJ CC RB O
but but 0 0 0 0 0 0 0 0 3 0 CC JJ CC RB IN O
not not 0 0 0 0 0 0 0 0 3 0 JJ CC RB IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CC RB IN NNP NNS O
Caenorhabditis Caenorhabditis 1 0 0 0 0 0 0 0 14 0 RB IN NNP NNS CC O
elegans elegans 0 0 0 0 0 0 0 0 7 0 IN NNP NNS CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 NNP NNS CC NNP NNP O
Drosophila. Drosophila. 1 0 0 0 0 0 0 0 11 0 NNS CC NNP NNP CC O
Synapsis Synapsis 1 0 0 0 0 0 0 0 8 0 CC NNP NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NN VBP O
recombination recombination 0 0 0 0 0 0 0 0 13 0 NNP CC NN VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 CC NN VBP RB RB O
also also 0 0 0 0 0 0 0 0 4 0 NN VBP RB RB NNP O
tightly tightly 0 0 0 0 0 0 0 0 7 0 VBP RB RB NNP NNP O
linked. linked. 0 0 0 0 0 0 0 0 7 0 RB RB NNP NNP DT O
Understanding Understanding 1 0 0 0 0 0 0 0 13 0 RB NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
coordination coordination 0 0 0 0 0 0 0 0 12 0 NNP DT NN IN NN O
between between 0 0 0 0 0 0 0 0 7 0 DT NN IN NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NN IN NN NN NN O
pairing, pairing, 0 0 0 0 1 0 0 0 8 0 IN NN NN NN CC O
synapsis synapsis 0 0 0 0 0 0 0 0 8 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NNS O
recombination recombination 0 0 0 0 0 0 0 0 13 0 NN CC NN NNS VBD O
lends lends 0 0 0 0 0 0 0 0 5 0 CC NN NNS VBD IN O
insight insight 0 0 0 0 0 0 0 0 7 0 NN NNS VBD IN JJ O
into into 0 0 0 0 0 0 0 0 4 0 NNS VBD IN JJ RB O
many many 0 0 0 0 0 0 0 0 4 0 VBD IN JJ RB VBN O
poorly poorly 0 0 0 0 0 0 0 0 6 0 IN JJ RB VBN NNS O
explained explained 0 0 0 0 0 0 0 0 9 0 JJ RB VBN NNS IN O
aspects aspects 0 0 0 0 0 0 0 0 7 0 RB VBN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBN NNS IN JJ JJ O
meiosis, meiosis, 0 0 0 0 1 0 0 0 8 0 NNS IN JJ JJ IN O
such such 0 0 0 0 0 0 0 0 4 0 IN JJ JJ IN DT O
as as 0 0 0 0 0 0 0 0 2 0 JJ JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN IN O
nature nature 0 0 0 0 0 0 0 0 6 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NN IN NN NN NNP O
homology homology 0 0 0 0 0 0 0 0 8 0 IN NN NN NNP NNP O
recognition. recognition. 0 0 0 0 0 0 0 0 12 0 NN NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
16257210 16257210 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Mutation Mutation 1 0 0 0 0 0 0 0 8 0 NONE NONE NN NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 NONE NN NN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP CD O
high-density, high-density, 0 0 1 0 1 0 0 0 13 0 NN IN NNP CD JJ O
50-Hz 50-Hz 0 0 1 0 0 0 0 1 5 0 IN NNP CD JJ NNS O
magnetic magnetic 0 0 0 0 0 0 0 0 8 0 NNP CD JJ NNS IN O
fields fields 0 0 0 0 0 0 0 0 6 0 CD JJ NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NNP O
human human 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NNP NNS O
MeWo MeWo 1 0 0 0 0 0 0 0 4 0 IN JJ NNP NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NNP NNS VBD IN O
exposed exposed 0 0 0 0 0 0 0 0 7 0 NNP NNS VBD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBD IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 IN DT NNP NN NNP O
synthesis synthesis 0 0 0 0 0 0 0 0 9 0 DT NNP NN NNP NNP B_TIMEXCCP
phase. phase. 0 0 0 0 0 0 0 0 6 0 NNP NN NNP NNP NNP O
Miyakoshi Miyakoshi 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kitagawa Kitagawa 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Takebe Takebe 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
H. H. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Radiation Radiation 1 0 0 0 0 0 0 0 9 0 NNP IN NNP NNP NNP O
Genetics, Genetics, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP IN O
Faculty Faculty 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Kyoto Kyoto 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Japan. Japan. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Exposure Exposure 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN VBN JJ O
cultured cultured 0 0 0 0 0 0 0 0 8 0 NNP IN VBN JJ NNP O
human human 0 0 0 0 0 0 0 0 5 0 IN VBN JJ NNP NNS O
MeWo MeWo 1 0 0 0 0 0 0 0 4 0 VBN JJ NNP NNS TO O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NNP NNS TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NNP NNS TO NN -NONE- O
high-density high-density 0 0 1 0 0 0 0 0 12 0 NNS TO NN -NONE- NNP O
(400 (400 0 0 0 0 0 0 0 1 4 0 TO NN -NONE- NNP IN O
mT mT 0 0 0 0 0 0 0 0 2 0 NN -NONE- NNP IN CD O
at at 0 0 0 0 0 0 0 0 2 0 -NONE- NNP IN CD JJ O
50 50 0 0 0 0 0 0 1 1 2 0 NNP IN CD JJ RB O
Hz) Hz) 1 0 0 0 0 0 0 0 3 0 IN CD JJ RB JJ O
extremely extremely 0 0 0 0 0 0 0 0 9 0 CD JJ RB JJ NN O
low low 0 0 0 0 0 0 0 0 3 0 JJ RB JJ NN JJ O
frequency frequency 0 0 0 0 0 0 0 0 9 0 RB JJ NN JJ NNS O
magnetic magnetic 0 0 0 0 0 0 0 0 8 0 JJ NN JJ NNS -NONE- O
fields fields 0 0 0 0 0 0 0 0 6 0 NN JJ NNS -NONE- VBN O
(ELF-MF) (ELF-MF) 0 1 1 0 0 0 0 0 8 0 JJ NNS -NONE- VBN NNS O
induced induced 0 0 0 0 0 0 0 0 7 0 NNS -NONE- VBN NNS IN O
mutations mutations 0 0 0 0 0 0 0 0 9 0 -NONE- VBN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
hypoxanthine-guanine hypoxanthine-guanine 0 0 1 0 0 0 0 0 20 0 IN DT JJ NN NN O
phosphoribosyl phosphoribosyl 0 0 0 0 0 0 0 0 14 0 DT JJ NN NN NNP O
transferase transferase 0 0 0 0 0 0 0 0 11 0 JJ NN NN NNP NNP O
gene. gene. 0 0 0 0 0 0 0 0 5 0 NN NN NNP NNP VBD O
Mutation Mutation 1 0 0 0 0 0 0 0 8 0 NN NNP NNP VBD IN O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD IN DT O
by by 0 0 0 0 0 0 0 0 2 0 NNP VBD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT JJ VBN O
ELF-MF ELF-MF 1 1 1 0 0 0 0 0 6 0 IN DT JJ VBN IN O
increased increased 0 0 0 0 0 0 0 0 9 0 DT JJ VBN IN DT O
during during 0 0 0 0 0 0 0 0 6 0 JJ VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NN O
DNA-synthesis DNA-synthesis 1 0 1 0 0 0 0 0 13 phase IN DT NN NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NN NN IN RB O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN RB VBG O
synchronously synchronously 0 0 0 0 0 0 0 0 13 0 NN IN RB VBG NNP O
growing growing 0 0 0 0 0 0 0 0 7 0 IN RB VBG NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 RB VBG NNP NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 VBG NNP NNP NN NNS O
replication replication 0 0 0 0 0 0 0 0 11 0 NNP NNP NN NNS JJ O
errors errors 0 0 0 0 0 0 0 0 6 0 NNP NN NNS JJ NN O
and/or and/or 0 0 0 1 0 0 0 0 6 0 NN NNS JJ NN IN O
disturbance disturbance 0 0 0 0 0 0 0 0 11 0 NNS JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
mismatch mismatch 0 0 0 0 0 0 0 0 8 0 IN DT NN NN NNS O
repair repair 0 0 0 0 0 0 0 0 6 0 DT NN NN NNS VBN O
systems systems 0 0 0 0 0 0 0 0 7 0 NN NN NNS VBN IN O
caused caused 0 0 0 0 0 0 0 0 6 0 NN NNS VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBN IN NN TO O
exposure exposure 0 0 0 0 0 0 0 0 8 0 VBN IN NN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO JJ NN O
ELF-MF ELF-MF 1 1 1 0 0 0 0 0 6 0 NN TO JJ NN VB O
may may 0 0 0 0 0 0 0 0 3 0 TO JJ NN VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 JJ NN VB VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 NN VB VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VB VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNP O
mutagenic mutagenic 0 0 0 0 0 0 0 0 9 0 IN DT JJ NNP NNP O
effect. effect. 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
9020966 9020966 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Telophase Telophase 1 0 0 0 0 0 0 0 9 0 NONE NONE NN NN DT B_TIMEXCCP
enucleation: enucleation: 0 0 0 0 0 0 0 0 12 0 NONE NN NN DT VBN O
an an 0 0 0 0 0 0 0 0 2 0 NN NN DT VBN NN O
improved improved 0 0 0 0 0 0 0 0 8 0 NN DT VBN NN TO O
method method 0 0 0 0 0 0 0 0 6 0 DT VBN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN NN TO VB JJ O
prepare prepare 0 0 0 0 0 0 0 0 7 0 NN TO VB JJ NNS O
recipient recipient 0 0 0 0 0 0 0 0 9 0 TO VB JJ NNS IN O
cytoplasts cytoplasts 0 0 0 0 0 0 0 0 10 0 VB JJ NNS IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN NN IN O
use use 0 0 0 0 0 0 0 0 3 0 NNS IN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NN O
bovine bovine 0 0 0 0 0 0 0 0 6 0 NN IN NN NN NNP O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 IN NN NN NNP NNP O
transfer. transfer. 0 0 0 0 0 0 0 0 9 0 NN NN NNP NNP NNP O
Bordignon Bordignon 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP NNP O
V, V, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Smith Smith 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
LC. LC. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Centre Centre 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN PRP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN PRP VBP O
recherche recherche 0 0 0 0 0 0 0 0 9 0 NNP IN PRP VBP NN O
en en 0 0 0 0 0 0 0 0 2 0 IN PRP VBP NN -NONE- O
reproduction reproduction 0 0 0 0 0 0 0 0 12 0 PRP VBP NN -NONE- NNP O
animale, animale, 0 0 0 0 1 0 0 0 8 0 VBP NN -NONE- NNP IN O
Faculte Faculte 1 0 0 0 0 0 0 0 7 0 NN -NONE- NNP IN JJ O
de de 0 0 0 0 0 0 0 0 2 0 -NONE- NNP IN JJ NN O
médecine médecine 0 0 0 0 0 0 0 0 8 0 NNP IN JJ NN NN O
vétérinaire, vétérinaire, 0 0 0 0 1 0 0 0 12 0 IN JJ NN NN IN O
Université Université 1 0 0 0 0 0 0 0 10 0 JJ NN NN IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
Montréal, Montréal, 1 0 0 0 1 0 0 0 9 0 NN IN NNP NNP NNP O
Saint-Hyacinthe, Saint-Hyacinthe, 1 0 1 0 1 0 0 0 16 0 IN NNP NNP NNP NNP O
Quebec, Quebec, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Canada. Canada. 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
enucleation enucleation 0 0 0 0 0 0 0 0 11 0 NNP NNP NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNS TO O
oocytes oocytes 0 0 0 0 0 0 0 0 7 0 NN IN NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NNS TO VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NNS TO VB VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 TO VB VBN IN NN O
as as 0 0 0 0 0 0 0 0 2 0 VB VBN IN NN NNS O
host host 0 0 0 0 0 0 0 0 4 0 VBN IN NN NNS IN O
cytoplasts cytoplasts 0 0 0 0 0 0 0 0 10 0 IN NN NNS IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN NN NN O
embryo embryo 0 0 0 0 0 0 0 0 6 0 NNS IN NN NN IN O
reconstruction reconstruction 0 0 0 0 0 0 0 0 14 0 IN NN NN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN VBZ O
transfer transfer 0 0 0 0 0 0 0 0 8 0 IN JJ NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN VBZ DT JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ NN NN O
limiting limiting 0 0 0 0 0 0 0 0 8 0 DT JJ NN NN WRB O
step step 0 0 0 0 0 0 0 0 4 0 JJ NN NN WRB VBG O
when when 0 0 0 0 0 0 0 0 4 0 NN NN WRB VBG NNP O
cloning cloning 0 0 0 0 0 0 0 0 7 0 NN WRB VBG NNP NNP O
mammals. mammals. 0 0 0 0 0 0 0 0 8 0 WRB VBG NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 VBG NNP NNP VBP DT O
propose propose 0 0 0 0 0 0 0 0 7 0 NNP NNP VBP DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NNP VBP DT NN NN O
enucleation enucleation 0 0 0 0 0 0 0 0 11 0 VBP DT NN NN VBN O
technique technique 0 0 0 0 0 0 0 0 9 0 DT NN NN VBN IN O
based based 0 0 0 0 0 0 0 0 5 0 NN NN VBN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NN VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
removal removal 0 0 0 0 0 0 0 0 7 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 NN IN NN IN NN O
after after 0 0 0 0 0 0 0 0 5 0 IN NN IN NN -NONE- O
oocyte oocyte 0 0 0 0 0 0 0 0 6 0 NN IN NN -NONE- IN O
activation, activation, 0 0 0 0 1 0 0 0 11 0 IN NN -NONE- IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NN -NONE- IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- IN DT NN NN O
telophase telophase 0 0 0 0 0 0 0 0 9 0 IN DT NN NN IN B_TIMEXCCP
stage, stage, 0 0 0 0 1 0 0 0 6 0 DT NN NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NN DT O
aspirating aspirating 0 0 0 0 0 0 0 0 10 0 NN IN NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT JJ NN O
second second 0 0 0 0 0 0 0 0 6 0 NN DT JJ NN NN O
polar polar 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN CC O
body body 0 0 0 0 0 0 0 0 4 0 JJ NN NN CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBG NNP O
surrounding surrounding 0 0 0 0 0 0 0 0 11 0 NN CC VBG NNP NNP O
cytoplasm. cytoplasm. 0 0 0 0 0 0 0 0 10 0 CC VBG NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 VBG NNP NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT JJ NN O
preliminary preliminary 0 0 0 0 0 0 0 0 11 0 NNP DT JJ NN TO O
experiment experiment 0 0 0 0 0 0 0 0 10 0 DT JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB DT O
determine determine 0 0 0 0 0 0 0 0 9 0 NN TO VB DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 TO VB DT JJ NN O
optimal optimal 0 0 0 0 0 0 0 0 7 0 VB DT JJ NN NN O
activation activation 0 0 0 0 0 0 0 0 10 0 DT JJ NN NN VBZ O
protocol, protocol, 0 0 0 0 1 0 0 0 9 0 JJ NN NN VBZ VBD O
oocytes oocytes 0 0 0 0 0 0 0 0 7 0 NN NN VBZ VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN VBZ VBD VBN IN O
matured matured 0 0 0 0 0 0 0 0 7 0 VBZ VBD VBN IN CD O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN CD CC O
26 26 0 0 0 0 0 0 1 1 2 0 VBN IN CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 IN CD CC CD NN O
30 30 0 0 0 0 0 0 1 1 2 0 CD CC CD NN CC O
hr hr 0 0 0 0 0 0 0 0 2 0 CC CD NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 CD NN CC VBD IN O
exposed exposed 0 0 0 0 0 0 0 0 7 0 NN CC VBD IN CD O
for for 0 0 0 0 0 0 0 0 3 0 CC VBD IN CD NN O
5 5 0 0 0 0 0 0 1 1 1 0 VBD IN CD NN TO O
min min 0 0 0 0 0 0 0 0 3 0 IN CD NN TO CD O
to to 0 0 0 0 0 0 0 0 2 0 CD NN TO CD NN O
7% 7% 0 0 0 0 0 0 0 1 2 0 NN TO CD NN JJ O
ethanol ethanol 0 0 0 0 0 0 0 0 7 0 TO CD NN JJ IN O
and/or and/or 0 0 0 1 0 0 0 0 6 0 CD NN JJ IN CD O
for for 0 0 0 0 0 0 0 0 3 0 NN JJ IN CD NN O
3 3 0 0 0 0 0 0 1 1 1 0 JJ IN CD NN IN O
hr hr 0 0 0 0 0 0 0 0 2 0 IN CD NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 CD NN IN DT CD O
either either 0 0 0 0 0 0 0 0 6 0 NN IN DT CD CC O
25 25 0 0 0 0 0 0 1 1 2 0 IN DT CD CC CD O
or or 0 0 0 0 0 0 0 0 2 0 DT CD CC CD NNS O
4 4 0 0 0 0 0 0 1 1 1 0 CD CC CD NNS NNP O
degrees degrees 0 0 0 0 0 0 0 0 7 0 CC CD NNS NNP NNP O
C. C. 1 1 0 0 0 0 0 0 2 0 CD NNS NNP NNP TO O
Relative Relative 1 0 0 0 0 0 0 0 8 0 NNS NNP NNP TO RBS O
to to 0 0 0 0 0 0 0 0 2 0 NNP NNP TO RBS NN O
most most 0 0 0 0 0 0 0 0 4 0 NNP TO RBS NN NNS O
activation activation 0 0 0 0 0 0 0 0 10 0 TO RBS NN NNS -NONE- O
treatments treatments 0 0 0 0 0 0 0 0 10 0 RBS NN NNS -NONE- VBZ O
tested, tested, 0 0 0 0 1 0 0 0 7 0 NN NNS -NONE- VBZ VBN O
oocytes oocytes 0 0 0 0 0 0 0 0 7 0 NNS -NONE- VBZ VBN IN O
matured matured 0 0 0 0 0 0 0 0 7 0 -NONE- VBZ VBN IN CD O
for for 0 0 0 0 0 0 0 0 3 0 VBZ VBN IN CD NN O
30 30 0 0 0 0 0 0 1 1 2 0 VBN IN CD NN CC O
hr hr 0 0 0 0 0 0 0 0 2 0 IN CD NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 CD NN CC VBD TO O
exposed exposed 0 0 0 0 0 0 0 0 7 0 NN CC VBD TO NN O
to to 0 0 0 0 0 0 0 0 2 0 CC VBD TO NN RB O
ethanol ethanol 0 0 0 0 0 0 0 0 7 0 VBD TO NN RB VBD O
alone alone 0 0 0 0 0 0 0 0 5 0 TO NN RB VBD JJS O
showed showed 0 0 0 0 0 0 0 0 6 0 NN RB VBD JJS NN O
highest highest 0 0 0 0 0 0 0 0 7 0 RB VBD JJS NN NN O
activation activation 0 0 0 0 0 0 0 0 10 0 VBD JJS NN NN IN O
rates, rates, 0 0 0 0 1 0 0 0 6 0 JJS NN NN IN VBN O
as as 0 0 0 0 0 0 0 0 2 0 NN NN IN VBN IN O
determined determined 0 0 0 0 0 0 0 0 10 0 NN IN VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 IN VBN IN JJ NNS O
low low 0 0 0 0 0 0 0 0 3 0 VBN IN JJ NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 IN JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NN O
H1 H1 1 1 0 0 0 0 0 1 2 0 NNS IN NNP NN NN O
kinase kinase 0 0 0 0 0 0 0 0 6 0 IN NNP NN NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NNP NN NN IN CD O
within within 0 0 0 0 0 0 0 0 6 0 NN NN IN CD NN O
90 90 0 0 0 0 0 0 1 1 2 0 NN IN CD NN IN O
min min 0 0 0 0 0 0 0 0 3 0 IN CD NN IN NN O
from from 0 0 0 0 0 0 0 0 4 0 CD NN IN NN CC O
exposure exposure 0 0 0 0 0 0 0 0 8 0 NN IN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 NN CC JJ NN NN O
pronuclear pronuclear 0 0 0 0 0 0 0 0 10 0 CC JJ NN NN NN O
formation formation 0 0 0 0 0 0 0 0 9 0 JJ NN NN NN IN O
(82%) (82%) 0 0 0 0 0 0 0 1 5 0 NN NN NN IN CD O
after after 0 0 0 0 0 0 0 0 5 0 NN NN IN CD NN O
12 12 0 0 0 0 0 0 1 1 2 0 NN IN CD NN IN O
hr hr 0 0 0 0 0 0 0 0 2 0 IN CD NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN NNP NNP O
culture. culture. 0 0 0 0 0 0 0 0 8 0 NN IN NNP NNP JJ O
No No 1 0 0 0 0 0 0 0 2 0 IN NNP NNP JJ NN O
synergistic synergistic 0 0 0 0 0 0 0 0 11 0 NNP NNP JJ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 NNP JJ NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNS O
activation activation 0 0 0 0 0 0 0 0 10 0 NN IN NN NNS VBD O
rates rates 0 0 0 0 0 0 0 0 5 0 IN NN NNS VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NNS VBD VBN WRB O
observed observed 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN WRB NNS O
when when 0 0 0 0 0 0 0 0 4 0 VBD VBN WRB NNS RB O
oocytes oocytes 0 0 0 0 0 0 0 0 7 0 VBN WRB NNS RB VBD O
also also 0 0 0 0 0 0 0 0 4 0 WRB NNS RB VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNS RB VBD VBN TO O
exposed exposed 0 0 0 0 0 0 0 0 7 0 RB VBD VBN TO VBN O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VBN NN O
reduced reduced 0 0 0 0 0 0 0 0 7 0 VBN TO VBN NN IN O
temperature temperature 0 0 0 0 0 0 0 0 11 0 TO VBN NN IN NN O
after after 0 0 0 0 0 0 0 0 5 0 VBN NN IN NN NNP O
ethanol ethanol 0 0 0 0 0 0 0 0 7 0 NN IN NN NNP NNP O
treatment. treatment. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP NN O
Microsurgical Microsurgical 1 0 0 0 0 0 0 0 13 0 NN NNP NNP NN IN O
removal removal 0 0 0 0 0 0 0 0 7 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
telophase-stage telophase-stage 0 0 1 0 0 0 0 0 15 0 IN DT JJ NN IN B_TIMEXCCP
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
small small 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN IN O
volume volume 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
cytoplasm cytoplasm 0 0 0 0 0 0 0 0 9 0 NN IN NN NN TO O
adjacent adjacent 0 0 0 0 0 0 0 0 8 0 IN NN NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT JJ NN O
second second 0 0 0 0 0 0 0 0 6 0 TO DT JJ NN NN O
polar polar 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN VBD O
body body 0 0 0 0 0 0 0 0 4 0 JJ NN NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD RB JJR O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NN VBD RB JJR JJ O
more more 0 0 0 0 0 0 0 0 4 0 VBD RB JJR JJ IN O
effective effective 0 0 0 0 0 0 0 0 9 0 RB JJR JJ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJR JJ IN NN IN O
enucleating enucleating 0 0 0 0 0 0 0 0 11 0 JJ IN NN IN NN O
than than 0 0 0 0 0 0 0 0 4 0 IN NN IN NN IN O
aspiration aspiration 0 0 0 0 0 0 0 0 10 0 NN IN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN DT JJR O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJR NN O
larger larger 0 0 0 0 0 0 0 0 6 0 IN DT JJR NN NN O
cytoplasm cytoplasm 0 0 0 0 0 0 0 0 9 0 DT JJR NN NN VBG O
volume volume 0 0 0 0 0 0 0 0 6 0 JJR NN NN VBG DT O
surrounding surrounding 0 0 0 0 0 0 0 0 11 0 NN NN VBG DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 VBG DT JJ NN NN O
polar polar 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN IN O
body body 0 0 0 0 0 0 0 0 4 0 JJ NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNS O
metaphase-arrested metaphase-arrested 0 0 1 0 0 0 0 0 18 0 NN IN JJ NNS -NONE- B_TIMEXCCP
oocytes oocytes 0 0 0 0 0 0 0 0 7 0 IN JJ NNS -NONE- VBZ O
(98% (98% 0 0 0 0 0 0 0 1 4 0 JJ NNS -NONE- VBZ CD O
versus versus 0 0 0 0 0 0 0 0 6 0 NNS -NONE- VBZ CD NNP O
59%; 59%; 0 0 0 0 0 0 0 1 4 0 -NONE- VBZ CD NNP NNP O
P P 1 1 0 0 0 0 0 0 1 0 VBZ CD NNP NNP NNP O
< < 0 0 0 0 0 0 0 0 1 0 CD NNP NNP NNP NNP O
0.01). 0.01). 0 0 0 0 0 0 0 1 6 0 NNP NNP NNP NNP VBD O
Moreover, Moreover, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP VBD IN O
compared compared 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NNP VBD IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBD IN DT JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN NN O
transfer transfer 0 0 0 0 0 0 0 0 8 0 DT JJ NN NN VBN O
protocol protocol 0 0 0 0 0 0 0 0 8 0 JJ NN NN VBN IN O
based based 0 0 0 0 0 0 0 0 5 0 NN NN VBN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NN VBN IN NN IN O
enucleation enucleation 0 0 0 0 0 0 0 0 11 0 VBN IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NNS O
metaphase-arrested metaphase-arrested 0 0 1 0 0 0 0 0 18 0 NN IN JJ NNS VBN B_TIMEXCCP
oocytes oocytes 0 0 0 0 0 0 0 0 7 0 IN JJ NNS VBN IN O
followed followed 0 0 0 0 0 0 0 0 8 0 JJ NNS VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBN IN NN CC O
aging aging 0 0 0 0 0 0 0 0 5 0 VBN IN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NNP RBR O
cooling, cooling, 0 0 0 0 1 0 0 0 8 0 NN CC NNP RBR JJ O
more more 0 0 0 0 0 0 0 0 4 0 CC NNP RBR JJ NN O
(38% (38% 0 0 0 0 0 0 0 1 4 0 NNP RBR JJ NN CD O
versus versus 0 0 0 0 0 0 0 0 6 0 RBR JJ NN CD NNP O
16%; 16%; 0 0 0 0 0 0 0 1 4 0 JJ NN CD NNP NNP O
P P 1 1 0 0 0 0 0 0 1 0 NN CD NNP NNP CD O
< < 0 0 0 0 0 0 0 0 1 0 CD NNP NNP CD CC O
0.001) 0.001) 0 0 0 0 0 0 0 1 6 0 NNP NNP CD CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP CD CC JJ NNS O
better-quality better-quality 0 0 1 0 0 0 0 0 14 0 CD CC JJ NNS -NONE- O
blastocytes blastocytes 0 0 0 0 0 0 0 0 11 0 CC JJ NNS -NONE- VBZ O
(126 (126 0 0 0 0 0 0 0 1 4 0 JJ NNS -NONE- VBZ CD O
versus versus 0 0 0 0 0 0 0 0 6 0 NNS -NONE- VBZ CD NN O
84 84 0 0 0 0 0 0 1 1 2 0 -NONE- VBZ CD NN IN O
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 VBZ CD NN IN JJ O
per per 0 0 0 0 0 0 0 0 3 0 CD NN IN JJ NNP O
blastocyst; blastocyst; 0 0 0 0 0 0 0 0 11 0 NN IN JJ NNP NNP O
P P 1 1 0 0 0 0 0 0 1 0 IN JJ NNP NNP CD O
< < 0 0 0 0 0 0 0 0 1 0 JJ NNP NNP CD VBD O
0.02) 0.02) 0 0 0 0 0 0 0 1 5 0 NNP NNP CD VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP CD VBD VBN IN O
obtained obtained 0 0 0 0 0 0 0 0 8 0 CD VBD VBN IN NNS O
from from 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNS VBN O
embryos embryos 0 0 0 0 0 0 0 0 7 0 VBN IN NNS VBN VBG O
reconstructed reconstructed 0 0 0 0 0 0 0 0 13 0 IN NNS VBN VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 NNS VBN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN VBG DT NN NNP O
telophase telophase 0 0 0 0 0 0 0 0 9 0 VBG DT NN NNP NNP B_TIMEXCCP
procedure. procedure. 0 0 0 0 0 0 0 0 10 0 DT NN NNP NNP NN O
Higher Higher 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NN NN O
development development 0 0 0 0 0 0 0 0 11 0 NNP NNP NN NN IN O
potential potential 0 0 0 0 0 0 0 0 9 0 NNP NN NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNS VBN O
embryos embryos 0 0 0 0 0 0 0 0 7 0 NN IN NNS VBN IN O
reconstructed reconstructed 0 0 0 0 0 0 0 0 13 0 IN NNS VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NN O
telophase telophase 0 0 0 0 0 0 0 0 9 0 IN DT NN NN MD B_TIMEXCCP
procedure procedure 0 0 0 0 0 0 0 0 9 0 DT NN NN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN NN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB VBN TO O
attributed attributed 0 0 0 0 0 0 0 0 10 0 MD VB VBN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 VB VBN TO NNP DT O
(1) (1) 0 0 0 0 0 0 0 1 3 0 VBN TO NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO NNP DT NN IN O
selection selection 0 0 0 0 0 0 0 0 9 0 NNP DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS WDT O
oocytes oocytes 0 0 0 0 0 0 0 0 7 0 NN IN NNS WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 IN NNS WDT NN CC O
activate activate 0 0 0 0 0 0 0 0 8 0 NNS WDT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 WDT NN CC NN IN O
respond respond 0 0 0 0 0 0 0 0 7 0 NN CC NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 CC NN IN NN DT O
extruding extruding 0 0 0 0 0 0 0 0 9 0 NN IN NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT JJ NN O
second second 0 0 0 0 0 0 0 0 6 0 NN DT JJ NN NN O
polar polar 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN NN O
body, body, 0 0 0 0 1 0 0 0 5 0 JJ NN NN NN VBG O
(2) (2) 0 0 0 0 0 0 0 1 3 0 NN NN NN VBG DT O
avoiding avoiding 0 0 0 0 0 0 0 0 8 0 NN NN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT NN IN O
use use 0 0 0 0 0 0 0 0 3 0 VBG DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNS O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNS CC O
dyes dyes 0 0 0 0 0 0 0 0 4 0 IN NNP NNS CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNS CC VB JJ O
ultraviolet ultraviolet 0 0 0 0 0 0 0 0 11 0 NNS CC VB JJ CC O
irradiation, irradiation, 0 0 0 0 1 0 0 0 12 0 CC VB JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VB JJ CC JJ DT O
(3) (3) 0 0 0 0 0 0 0 1 3 0 JJ CC JJ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CC JJ DT JJ NN O
limited limited 0 0 0 0 0 0 0 0 7 0 JJ DT JJ NN IN O
removal removal 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
cytoplasm cytoplasm 0 0 0 0 0 0 0 0 9 0 NN IN NN IN NNP O
during during 0 0 0 0 0 0 0 0 6 0 IN NN IN NNP NNP O
enucleation. enucleation. 0 0 0 0 0 0 0 0 12 0 NN IN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NN IN O
ease ease 0 0 0 0 0 0 0 0 4 0 NNP NNP NN IN WDT O
with with 0 0 0 0 0 0 0 0 4 0 NNP NN IN WDT NN O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT NN NN O
telophase telophase 0 0 0 0 0 0 0 0 9 0 IN WDT NN NN MD B_TIMEXCCP
enucleation enucleation 0 0 0 0 0 0 0 0 11 0 WDT NN NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN NN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB VBN VBZ O
performed performed 0 0 0 0 0 0 0 0 9 0 MD VB VBN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 VB VBN VBZ JJ TO O
likely likely 0 0 0 0 0 0 0 0 6 0 VBN VBZ JJ TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO NN DT O
render render 0 0 0 0 0 0 0 0 6 0 JJ TO NN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 TO NN DT NN RB O
technique technique 0 0 0 0 0 0 0 0 9 0 NN DT NN RB JJ O
widely widely 0 0 0 0 0 0 0 0 6 0 DT NN RB JJ IN O
useful useful 0 0 0 0 0 0 0 0 6 0 NN RB JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 RB JJ IN NN CC O
research research 0 0 0 0 0 0 0 0 8 0 JJ IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN IN O
practice practice 0 0 0 0 0 0 0 0 8 0 NN CC NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NNP O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNP NNP O
cloning. cloning. 0 0 0 0 0 0 0 0 8 0 IN JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
9406193 9406193 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Copresentation Copresentation 1 0 0 0 0 0 0 0 14 0 NONE NONE NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NNP CC O
Antigen Antigen 1 0 0 0 0 0 0 0 7 0 NN IN NNP CC NNPS O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNPS IN O
Ligands Ligands 1 0 0 0 0 0 0 0 7 0 NNP CC NNPS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NNPS IN JJ NNS O
Siglec-G Siglec-G 1 0 1 0 0 0 0 0 8 0 NNPS IN JJ NNS NNP O
Induces Induces 1 0 0 0 0 0 0 0 7 0 IN JJ NNS NNP NNP O
B B 1 1 0 0 0 0 0 0 1 0 JJ NNS NNP NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NNS NNP NNP NNP NNP O
Tolerance Tolerance 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP IN O
Independent Independent 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
CD22. CD22. 1 1 0 0 0 0 0 1 5 0 NNP IN NNP NNP NNP O
Pfrengle Pfrengle 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Macauley Macauley 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
MS, MS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Kawasaki Kawasaki 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Paulson Paulson 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
JC. JC. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP CC NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 CC NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Scripps Scripps 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Institute, Institute, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
La La 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Jolla, Jolla, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
CA CA 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
92037. 92037. 0 0 0 0 0 0 0 1 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Differentiation Differentiation 1 0 0 0 0 0 0 0 15 0 NNP NNP NNP IN PRP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN PRP IN O
self self 0 0 0 0 0 0 0 0 4 0 NNP IN PRP IN PRP O
from from 0 0 0 0 0 0 0 0 4 0 IN PRP IN PRP VBZ O
nonself nonself 0 0 0 0 0 0 0 0 7 0 PRP IN PRP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 IN PRP VBZ JJ IN O
indispensable indispensable 0 0 0 0 0 0 0 0 13 0 PRP VBZ JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN NN NNP O
maintaining maintaining 0 0 0 0 0 0 0 0 11 0 JJ IN NN NNP NN O
B B 1 1 0 0 0 0 0 0 1 0 IN NN NNP NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NNP NN NN IN O
tolerance tolerance 0 0 0 0 0 0 0 0 9 0 NNP NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNP O
peripheral peripheral 0 0 0 0 0 0 0 0 10 0 NN IN JJ NNP NNP O
tissues. tissues. 0 0 0 0 0 0 0 0 8 0 IN JJ NNP NNP CC O
CD22 CD22 1 1 0 0 0 0 0 1 4 0 JJ NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ JJ O
Siglec-G Siglec-G 1 0 1 0 0 0 0 0 8 0 NNP CC JJ JJ JJ O
(sialic (sialic 0 0 0 0 0 0 0 0 7 0 CC JJ JJ JJ JJ O
acid-binding acid-binding 0 0 1 0 0 0 0 0 12 0 JJ JJ JJ JJ NN O
Ig-like Ig-like 1 0 1 0 0 0 0 0 7 0 JJ JJ JJ NN NN O
lectin lectin 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NN VBP O
G) G) 1 1 0 0 0 0 0 0 2 0 JJ NN NN VBP CD O
are are 0 0 0 0 0 0 0 0 3 0 NN NN VBP CD JJ O
two two 0 0 0 0 0 0 0 0 3 0 NN VBP CD JJ NNS O
inhibitory inhibitory 0 0 0 0 0 0 0 0 10 0 VBP CD JJ NNS IN O
coreceptors coreceptors 0 0 0 0 0 0 0 0 11 0 CD JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP IN O
BCR BCR 1 1 0 0 0 0 0 0 3 0 IN DT NNP IN VBP O
that that 0 0 0 0 0 0 0 0 4 0 DT NNP IN VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NNP IN VBP VBN IN O
implicated implicated 0 0 0 0 0 0 0 0 10 0 IN VBP VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBP VBN IN NN IN O
maintenance maintenance 0 0 0 0 0 0 0 0 11 0 VBN IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN TO O
tolerance tolerance 0 0 0 0 0 0 0 0 9 0 NN IN NN TO PRP O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO PRP NNP O
self self 0 0 0 0 0 0 0 0 4 0 NN TO PRP NNP NNP O
Ags. Ags. 1 0 0 0 0 0 0 0 4 0 TO PRP NNP NNP NN O
Enforced Enforced 1 0 0 0 0 0 0 0 8 0 PRP NNP NNP NN IN O
ligation ligation 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP CC O
CD22 CD22 1 1 0 0 0 0 0 1 4 0 NN IN NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP CC DT NNP IN O
BCR BCR 1 1 0 0 0 0 0 0 3 0 CC DT NNP IN DT O
by by 0 0 0 0 0 0 0 0 2 0 DT NNP IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT NN VBG O
nanoparticle nanoparticle 0 0 0 0 0 0 0 0 12 0 IN DT NN VBG DT O
displaying displaying 0 0 0 0 0 0 0 0 10 0 DT NN VBG DT NNP O
both both 0 0 0 0 0 0 0 0 4 0 NN VBG DT NNP CC O
Ag Ag 1 0 0 0 0 0 0 0 2 0 VBG DT NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC NNP NNS O
CD22 CD22 1 1 0 0 0 0 0 1 4 0 NNP CC NNP NNS NNS O
ligands ligands 0 0 0 0 0 0 0 0 7 0 CC NNP NNS NNS DT O
induces induces 0 0 0 0 0 0 0 0 7 0 NNP NNS NNS DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS NNS DT JJ NN O
tolerogenic tolerogenic 0 0 0 0 0 0 0 0 11 0 NNS DT JJ NN VBG O
circuit circuit 0 0 0 0 0 0 0 0 7 0 DT JJ NN VBG IN O
resulting resulting 0 0 0 0 0 0 0 0 9 0 JJ NN VBG IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN VBG IN NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 VBG IN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
Ag-reactive Ag-reactive 1 0 1 0 0 0 0 0 11 0 IN DT JJ NNP NNP O
B B 1 1 0 0 0 0 0 0 1 0 DT JJ NNP NNP NNP O
cell. cell. 0 0 0 0 0 0 0 0 5 0 JJ NNP NNP NNP NNP O
Whether Whether 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP RB O
Siglec-G Siglec-G 1 0 1 0 0 0 0 0 8 0 NNP NNP NNP RB VBZ O
also also 0 0 0 0 0 0 0 0 4 0 NNP NNP RB VBZ DT O
has has 0 0 0 0 0 0 0 0 3 0 NNP RB VBZ DT NN O
this this 0 0 0 0 0 0 0 0 4 0 RB VBZ DT NN VBZ O
property property 0 0 0 0 0 0 0 0 8 0 VBZ DT NN VBZ RB O
has has 0 0 0 0 0 0 0 0 3 0 DT NN VBZ RB VBN O
not not 0 0 0 0 0 0 0 0 3 0 NN VBZ RB VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 VBZ RB VBN VBN IN O
investigated investigated 0 0 0 0 0 0 0 0 12 0 RB VBN VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN JJ NN O
large large 0 0 0 0 0 0 0 0 5 0 VBN IN JJ NN VBG O
part part 0 0 0 0 0 0 0 0 4 0 IN JJ NN VBG TO O
owing owing 0 0 0 0 0 0 0 0 5 0 JJ NN VBG TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN VBG TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBG TO DT NN IN O
lack lack 0 0 0 0 0 0 0 0 4 0 TO DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ JJ O
selective selective 0 0 0 0 0 0 0 0 9 0 IN DT JJ JJ NNP O
Siglec-G Siglec-G 1 0 1 0 0 0 0 0 8 0 DT JJ JJ NNP NNP O
ligand. ligand. 0 0 0 0 0 0 0 0 7 0 JJ JJ NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
article, article, 0 0 0 0 1 0 0 0 8 0 NNP DT NN PRP NN O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP NN DT O
report report 0 0 0 0 0 0 0 0 6 0 NN PRP NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP NN DT NN IN O
development development 0 0 0 0 0 0 0 0 11 0 NN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
selective selective 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN NN O
high-affinity high-affinity 0 0 1 0 0 0 0 0 13 0 DT JJ NN NN IN O
ligand ligand 0 0 0 0 0 0 0 0 6 0 JJ NN NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN JJ CC O
Siglec-G Siglec-G 1 0 1 0 0 0 0 0 8 0 NN IN JJ CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 JJ CC PRP$ NN IN O
application application 0 0 0 0 0 0 0 0 11 0 CC PRP$ NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 PRP$ NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
chemical chemical 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN TO O
tool tool 0 0 0 0 0 0 0 0 4 0 DT JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB DT O
investigate investigate 0 0 0 0 0 0 0 0 11 0 NN TO VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJ NN O
tolerogenic tolerogenic 0 0 0 0 0 0 0 0 11 0 VB DT JJ NN IN O
potential potential 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
Siglec-G. Siglec-G. 1 0 1 0 0 0 0 0 9 0 NN IN NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 IN NNP NNP VBP IN O
find find 0 0 0 0 0 0 0 0 4 0 NNP NNP VBP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBP IN JJ NNS O
liposomal liposomal 0 0 0 0 0 0 0 0 9 0 VBP IN JJ NNS VBN O
nanoparticles nanoparticles 0 0 0 0 0 0 0 0 13 0 IN JJ NNS VBN IN O
decorated decorated 0 0 0 0 0 0 0 0 9 0 JJ NNS VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBN IN NNP CC O
Ag Ag 1 0 0 0 0 0 0 0 2 0 VBN IN NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC JJ NN O
Siglec-G Siglec-G 1 0 1 0 0 0 0 0 8 0 NNP CC JJ NN NN O
ligand ligand 0 0 0 0 0 0 0 0 6 0 CC JJ NN NN NNP O
inhibit inhibit 0 0 0 0 0 0 0 0 7 0 JJ NN NN NNP NN O
BCR BCR 1 1 0 0 0 0 0 0 3 0 NN NN NNP NN IN O
signaling signaling 0 0 0 0 0 0 0 0 9 0 NN NNP NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NNP O
both both 0 0 0 0 0 0 0 0 4 0 NN IN DT NNP CC O
B1 B1 1 1 0 0 0 0 0 1 2 0 IN DT NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC NNP NNP O
B2 B2 1 1 0 0 0 0 0 1 2 0 NNP CC NNP NNP VBZ O
B B 1 1 0 0 0 0 0 0 1 0 CC NNP NNP VBZ VBN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ VBN IN O
compared compared 0 0 0 0 0 0 0 0 8 0 NNP VBZ VBN IN NNS O
with with 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN NNS VBG O
liposomes liposomes 0 0 0 0 0 0 0 0 9 0 VBN IN NNS VBG NNP O
displaying displaying 0 0 0 0 0 0 0 0 10 0 IN NNS VBG NNP NNP O
Ag Ag 1 0 0 0 0 0 0 0 2 0 NNS VBG NNP NNP NNP O
alone. alone. 0 0 0 0 0 0 0 0 6 0 VBG NNP NNP NNP RB O
Not Not 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP RB VBZ O
only only 0 0 0 0 0 0 0 0 4 0 NNP NNP RB VBZ NN O
is is 0 0 0 0 0 0 0 0 2 0 NNP RB VBZ NN IN O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 RB VBZ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBZ NN IN NNP NN O
B B 1 1 0 0 0 0 0 0 1 0 NN IN NNP NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN NNP NN NN VBN O
activation activation 0 0 0 0 0 0 0 0 10 0 NNP NN NN VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 NN NN VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN VBN IN NN DT O
ligating ligating 0 0 0 0 0 0 0 0 8 0 VBN IN NN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NNP IN O
BCR BCR 1 1 0 0 0 0 0 0 3 0 NN DT NNP IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 DT NNP IN JJ CC O
Siglec-G, Siglec-G, 1 0 1 0 1 0 0 0 9 0 NNP IN JJ CC JJ O
but but 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NN O
robust robust 0 0 0 0 0 0 0 0 6 0 JJ CC JJ NN IN O
tolerance tolerance 0 0 0 0 0 0 0 0 9 0 CC JJ NN IN JJ O
toward toward 0 0 0 0 0 0 0 0 6 0 JJ NN IN JJ CC O
T-independent T-independent 1 0 1 0 0 0 0 0 13 0 NN IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NNS O
T-dependent T-dependent 1 0 1 0 0 0 0 0 11 0 JJ CC JJ NNS VBZ O
Ags Ags 1 0 0 0 0 0 0 0 3 0 CC JJ NNS VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 JJ NNS VBZ RB VBN O
also also 0 0 0 0 0 0 0 0 4 0 NNS VBZ RB VBN IN O
induced induced 0 0 0 0 0 0 0 0 7 0 VBZ RB VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN NNP NNP O
mice. mice. 0 0 0 0 0 0 0 0 5 0 VBN IN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NN IN O
ability ability 0 0 0 0 0 0 0 0 7 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ TO O
Siglec-G Siglec-G 1 0 1 0 0 0 0 0 8 0 NN IN JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN JJ TO VB NNP O
inhibit inhibit 0 0 0 0 0 0 0 0 7 0 JJ TO VB NNP NN O
B B 1 1 0 0 0 0 0 0 1 0 TO VB NNP NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VB NNP NN NN RB O
activation activation 0 0 0 0 0 0 0 0 10 0 NNP NN NN RB IN O
equally equally 0 0 0 0 0 0 0 0 7 0 NN NN RB IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN RB IN DT NNP O
both both 0 0 0 0 0 0 0 0 4 0 RB IN DT NNP CC O
B1 B1 1 1 0 0 0 0 0 1 2 0 IN DT NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC NNP NNS O
B2 B2 1 1 0 0 0 0 0 1 2 0 NNP CC NNP NNS VBZ O
subsets subsets 0 0 0 0 0 0 0 0 7 0 CC NNP NNS VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNS VBZ JJ IN O
consistent consistent 0 0 0 0 0 0 0 0 10 0 NNS VBZ JJ IN PRP$ O
with with 0 0 0 0 0 0 0 0 4 0 VBZ JJ IN PRP$ NN O
our our 0 0 0 0 0 0 0 0 3 0 JJ IN PRP$ NN WDT O
observation observation 0 0 0 0 0 0 0 0 11 0 IN PRP$ NN WDT -NONE- O
that that 0 0 0 0 0 0 0 0 4 0 PRP$ NN WDT -NONE- VBZ O
Siglec-G Siglec-G 1 0 1 0 0 0 0 0 8 0 NN WDT -NONE- VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 WDT -NONE- VBZ VBN IN O
expressed expressed 0 0 0 0 0 0 0 0 9 0 -NONE- VBZ VBN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN DT RB O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT RB JJ O
relatively relatively 0 0 0 0 0 0 0 0 10 0 IN DT RB JJ NN O
constant constant 0 0 0 0 0 0 0 0 8 0 DT RB JJ NN IN O
level level 0 0 0 0 0 0 0 0 5 0 RB JJ NN IN JJ O
throughout throughout 0 0 0 0 0 0 0 0 10 0 JJ NN IN JJ NNP O
numerous numerous 0 0 0 0 0 0 0 0 8 0 NN IN JJ NNP NN O
B B 1 1 0 0 0 0 0 0 1 0 IN JJ NNP NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NNP NN NNP NNP O
subsets. subsets. 0 0 0 0 0 0 0 0 8 0 NNP NN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNP NNS VBP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN JJ MD O
Siglec-G Siglec-G 1 0 1 0 0 0 0 0 8 0 VBP IN JJ MD VB O
may may 0 0 0 0 0 0 0 0 3 0 IN JJ MD VB TO O
contribute contribute 0 0 0 0 0 0 0 0 10 0 JJ MD VB TO VB O
to to 0 0 0 0 0 0 0 0 2 0 MD VB TO VB IN O
maintenance maintenance 0 0 0 0 0 0 0 0 11 0 VB TO VB IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 TO VB IN NNP NN O
B B 1 1 0 0 0 0 0 0 1 0 VB IN NNP NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN NNP NN NN IN O
tolerance tolerance 0 0 0 0 0 0 0 0 9 0 NNP NN NN IN NN O
toward toward 0 0 0 0 0 0 0 0 6 0 NN NN IN NN NNS O
self self 0 0 0 0 0 0 0 0 4 0 NN IN NN NNS IN O
Ags Ags 1 0 0 0 0 0 0 0 3 0 IN NN NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NNP O
various various 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NNP NN O
B B 1 1 0 0 0 0 0 0 1 0 IN JJ NNP NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NNP NN NNP NNP O
compartments. compartments. 0 0 0 0 0 0 0 0 13 0 NNP NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
23836061 23836061 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : IN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ : IN JJ NONE O
process] process] 0 0 0 0 0 0 0 0 8 0 : IN JJ NONE NONE O
Pre-Weaning Pre-Weaning 1 0 1 0 0 0 0 0 11 0 NONE NONE JJ NN NNP O
Growth Growth 1 0 0 0 0 0 0 0 6 0 NONE JJ NN NNP NNP O
Hormone Hormone 1 0 0 0 0 0 0 0 7 0 JJ NN NNP NNP NNP O
Treatment Treatment 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP NNP O
Ameliorates Ameliorates 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
Bone Bone 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Marrow Marrow 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Macrophage Macrophage 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP IN O
Inflammation Inflammation 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Adult Adult 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Male Male 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNP O
Rat Rat 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP VBG O
Offspring Offspring 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP VBG NNP O
following following 0 0 0 0 0 0 0 0 9 0 NNP NNP VBG NNP NNP O
Maternal Maternal 1 0 0 0 0 0 0 0 8 0 NNP VBG NNP NNP NNP O
Undernutrition. Undernutrition. 1 0 0 0 0 0 0 0 15 0 VBG NNP NNP NNP NNP O
Reynolds Reynolds 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
CM, CM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Gray Gray 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Vickers Vickers 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
MH. MH. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Liggins Liggins 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP CC O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Gravida, Gravida, 1 0 0 0 1 0 0 0 8 0 NNP CC NNP NNP NNP O
National National 1 0 0 0 0 0 0 0 8 0 CC NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Centre Centre 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP CC O
Growth Growth 1 0 0 0 0 0 0 0 6 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Development, Development, 1 0 0 0 1 0 0 0 12 0 NNP CC NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Auckland, Auckland, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Auckland, Auckland, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
New New 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Zealand. Zealand. 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
Maternal Maternal 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NN -NONE- O
undernutrition undernutrition 0 0 0 0 0 0 0 0 14 0 NNP NNP NN -NONE- VBZ O
(UN) (UN) 0 1 0 0 0 0 0 0 4 0 NNP NN -NONE- VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN -NONE- VBZ VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 -NONE- VBZ VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
development development 0 0 0 0 0 0 0 0 11 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN CC O
obesity obesity 0 0 0 0 0 0 0 0 7 0 NN IN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC JJ NNS O
metabolic metabolic 0 0 0 0 0 0 0 0 9 0 NN CC JJ NNS IN O
complications complications 0 0 0 0 0 0 0 0 13 0 CC JJ NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NNP O
adult adult 0 0 0 0 0 0 0 0 5 0 NNS IN NN NNP NNP O
offspring. offspring. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP DT O
While While 1 0 0 0 0 0 0 0 5 0 NN NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
role role 0 0 0 0 0 0 0 0 4 0 NNP DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
inflammation inflammation 0 0 0 0 0 0 0 0 12 0 NN IN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NN CC O
obesity obesity 0 0 0 0 0 0 0 0 7 0 NN IN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC JJ NNS O
related related 0 0 0 0 0 0 0 0 7 0 NN CC JJ NNS VBZ O
comorbidities comorbidities 0 0 0 0 0 0 0 0 13 0 CC JJ NNS VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 JJ NNS VBZ VBN RB O
been been 0 0 0 0 0 0 0 0 4 0 NNS VBZ VBN RB -NONE- O
well well 0 0 0 0 0 0 0 0 4 0 VBZ VBN RB -NONE- EX O
established, established, 0 0 0 0 1 0 0 0 12 0 VBN RB -NONE- EX VBZ O
there there 0 0 0 0 0 0 0 0 5 0 RB -NONE- EX VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 -NONE- EX VBZ JJ NN O
little little 0 0 0 0 0 0 0 0 6 0 EX VBZ JJ NN VBG O
evidence evidence 0 0 0 0 0 0 0 0 8 0 VBZ JJ NN VBG DT O
regarding regarding 0 0 0 0 0 0 0 0 9 0 JJ NN VBG DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 VBG DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ JJ O
maternal maternal 0 0 0 0 0 0 0 0 8 0 NNS IN JJ JJ NN O
UN-induced UN-induced 1 0 1 0 0 0 0 0 10 0 IN JJ JJ NN IN O
programming programming 0 0 0 0 0 0 0 0 11 0 JJ JJ NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
immune immune 0 0 0 0 0 0 0 0 6 0 NN IN NN NN IN O
function function 0 0 0 0 0 0 0 0 8 0 IN NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
male male 0 0 0 0 0 0 0 0 4 0 NN IN JJ NN NNP O
adult adult 0 0 0 0 0 0 0 0 5 0 IN JJ NN NNP NNP O
offspring. offspring. 0 0 0 0 0 0 0 0 10 0 JJ NN NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NN VBZ O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ DT O
examines examines 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT NNS NN O
effects effects 0 0 0 0 0 0 0 0 7 0 VBZ DT NNS NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 DT NNS NN NN NN O
hormone hormone 0 0 0 0 0 0 0 0 7 0 NNS NN NN NN WDT O
(GH), (GH), 0 1 0 0 1 0 0 0 5 0 NN NN NN WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN WDT VBZ VBN TO O
known known 0 0 0 0 0 0 0 0 5 0 WDT VBZ VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ VBN TO VB JJ O
induce induce 0 0 0 0 0 0 0 0 6 0 VBN TO VB JJ NN O
anti-inflammatory anti-inflammatory 0 0 1 0 0 0 0 0 17 0 TO VB JJ NN IN O
effects, effects, 0 0 0 0 1 0 0 0 8 0 VB JJ NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ JJ O
maternal maternal 0 0 0 0 0 0 0 0 8 0 NN IN JJ JJ NN O
UN-induced UN-induced 1 0 1 0 0 0 0 0 10 0 IN JJ JJ NN NN O
bone bone 0 0 0 0 0 0 0 0 4 0 JJ JJ NN NN NN O
marrow marrow 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN NN O
macrophage macrophage 0 0 0 0 0 0 0 0 10 0 NN NN NN NN NN O
(BMM) (BMM) 0 1 0 0 0 0 0 0 5 0 NN NN NN NN IN O
function function 0 0 0 0 0 0 0 0 8 0 NN NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
adult adult 0 0 0 0 0 0 0 0 5 0 NN IN NN NN NNP O
male male 0 0 0 0 0 0 0 0 4 0 IN NN NN NNP NNP O
offspring. offspring. 0 0 0 0 0 0 0 0 10 0 NN NN NNP NNP NNS O
Sprague-Dawley Sprague-Dawley 1 0 1 0 0 0 0 0 14 0 NN NNP NNP NNS VBD O
rats rats 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD VBN TO O
assigned assigned 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB JJ O
chow chow 0 0 0 0 0 0 0 0 4 0 VBN TO VB JJ CC O
(C) (C) 0 1 0 0 0 0 0 0 3 0 TO VB JJ CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 VB JJ CC NNP NNP O
UN UN 1 1 0 0 0 0 0 0 2 0 JJ CC NNP NNP NN O
(50% (50% 0 0 0 0 0 0 0 1 4 0 CC NNP NNP NN -NONE- O
ad ad 0 0 0 0 0 0 0 0 2 0 NNP NNP NN -NONE- JJ O
libitum; libitum; 0 0 0 0 0 0 0 0 8 0 NNP NN -NONE- JJ NN O
UN) UN) 1 1 0 0 0 0 0 0 3 0 NN -NONE- JJ NN IN O
diet diet 0 0 0 0 0 0 0 0 4 0 -NONE- JJ NN IN NNP O
throughout throughout 0 0 0 0 0 0 0 0 10 0 JJ NN IN NNP NNP O
gestation. gestation. 0 0 0 0 0 0 0 0 10 0 NN IN NNP NNP NNP O
Male Male 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP CC O
C C 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNS O
UN UN 1 1 0 0 0 0 0 0 2 0 NNP CC NNP NNS VBD O
pups pups 0 0 0 0 0 0 0 0 4 0 CC NNP NNS VBD NN O
received received 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD NN -NONE- O
saline saline 0 0 0 0 0 0 0 0 6 0 NNS VBD NN -NONE- CC O
(CS/UNS) (CS/UNS) 0 1 0 1 0 0 0 0 8 0 VBD NN -NONE- CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 NN -NONE- CC NNP NNP O
GH GH 1 1 0 0 0 0 0 0 2 0 -NONE- CC NNP NNP NNP O
(2.5 (2.5 0 0 0 0 0 0 0 1 4 0 CC NNP NNP NNP NNP O
µg/g/d; µg/g/d; 0 0 0 1 0 0 0 0 7 0 NNP NNP NNP NNP IN O
CGH/UNGH) CGH/UNGH) 1 1 0 1 0 0 0 0 9 0 NNP NNP NNP IN NN O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNP IN NN CD O
day day 0 0 0 0 0 0 0 0 3 0 NNP IN NN CD NNP O
3-21. 3-21. 0 0 1 0 0 0 0 1 5 0 IN NN CD NNP NN O
Bone Bone 1 0 0 0 0 0 0 0 4 0 NN CD NNP NN JJ O
marrow marrow 0 0 0 0 0 0 0 0 6 0 CD NNP NN JJ NNS O
hematopoietic hematopoietic 0 0 0 0 0 0 0 0 13 0 NNP NN JJ NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NN JJ NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD VBN TO O
differentiated differentiated 0 0 0 0 0 0 0 0 14 0 NNS VBD VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN TO DT NN NN O
macrophage macrophage 0 0 0 0 0 0 0 0 10 0 TO DT NN NN IN O
phenotype phenotype 0 0 0 0 0 0 0 0 9 0 DT NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
presence presence 0 0 0 0 0 0 0 0 8 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ -NONE- O
M-CSF M-CSF 1 1 1 0 0 0 0 0 5 0 NN IN JJ -NONE- NNP O
(50 (50 0 0 0 0 0 0 0 1 3 0 IN JJ -NONE- NNP NNP O
ng/ml). ng/ml). 0 0 0 1 0 0 0 0 7 0 JJ -NONE- NNP NNP NN O
Differentiated Differentiated 1 0 0 0 0 0 0 0 14 0 -NONE- NNP NNP NN NN O
bone bone 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN NNS O
marrow marrow 0 0 0 0 0 0 0 0 6 0 NNP NN NN NNS -NONE- O
macrophages macrophages 0 0 0 0 0 0 0 0 11 0 NN NN NNS -NONE- VBD O
(BMM) (BMM) 0 1 0 0 0 0 0 0 5 0 NN NNS -NONE- VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNS -NONE- VBD VBN IN O
stimulated stimulated 0 0 0 0 0 0 0 0 10 0 -NONE- VBD VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNP NNP O
LPS LPS 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NNP NNP O
(100 (100 0 0 0 0 0 0 0 1 4 0 IN NNP NNP NNP IN O
ng/ml) ng/ml) 0 0 0 1 0 0 0 0 6 0 NNP NNP NNP IN CD O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN CD NNP O
6 6 0 0 0 0 0 0 1 1 1 0 NNP IN CD NNP JJ O
h. h. 0 0 0 0 0 0 0 0 2 0 IN CD NNP JJ NNP O
UNS-derived UNS-derived 1 0 1 0 0 0 0 0 11 0 CD NNP JJ NNP VBD O
BMM BMM 1 1 0 0 0 0 0 0 3 0 NNP JJ NNP VBD RB O
had had 0 0 0 0 0 0 0 0 3 0 JJ NNP VBD RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNP VBD RB VBN NN O
increased increased 0 0 0 0 0 0 0 0 9 0 VBD RB VBN NN CC O
secretion secretion 0 0 0 0 0 0 0 0 9 0 RB VBN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VBN NN CC NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NN CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP CC O
IL-1β IL-1β 1 0 1 0 0 0 0 1 5 0 NN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP VBG O
IL-6 IL-6 1 1 1 0 0 0 0 1 4 0 NNP CC NNP VBG NNP O
following following 0 0 0 0 0 0 0 0 9 0 CC NNP VBG NNP NNP O
LPS LPS 1 1 0 0 0 0 0 0 3 0 NNP VBG NNP NNP NNP O
stimulation. stimulation. 0 0 0 0 0 0 0 0 12 0 VBG NNP NNP NNP VBD O
This This 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
accompanied accompanied 0 0 0 0 0 0 0 0 11 0 NNP VBD VBN IN VBN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN VBN NN O
increased increased 0 0 0 0 0 0 0 0 9 0 VBN IN VBN NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 IN VBN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNP NNP O
IL-1R1, IL-1R1, 1 1 1 0 1 0 0 1 7 0 NN IN NNP NNP CC O
IL-6R IL-6R 1 1 1 0 0 0 0 1 5 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
TLR4. TLR4. 1 1 0 0 0 0 0 1 5 0 NNP CC NNP NNP NNP O
Pre-weaning Pre-weaning 1 0 1 0 0 0 0 0 11 0 CC NNP NNP NNP NN O
GH GH 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NN VBD O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBD DT O
reversed reversed 0 0 0 0 0 0 0 0 8 0 NNP NN VBD DT JJ O
this this 0 0 0 0 0 0 0 0 4 0 NN VBD DT JJ NNP O
pro-inflammatory pro-inflammatory 0 0 1 0 0 0 0 0 16 0 VBD DT JJ NNP NNP O
phenotype. phenotype. 0 0 0 0 0 0 0 0 10 0 DT JJ NNP NNP NNP O
Furthermore Furthermore 1 0 0 0 0 0 0 0 11 0 JJ NNP NNP NNP VBD O
UNGH UNGH 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP VBD VBN O
displayed displayed 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD VBN NN O
increased increased 0 0 0 0 0 0 0 0 9 0 NNP VBD VBN NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 VBD VBN NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNS IN O
markers markers 0 0 0 0 0 0 0 0 7 0 NN IN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN JJ NN O
alternative alternative 0 0 0 0 0 0 0 0 11 0 NNS IN JJ NN NN O
(M2) (M2) 0 1 0 0 0 0 0 1 4 0 IN JJ NN NN NN O
macrophage macrophage 0 0 0 0 0 0 0 0 10 0 JJ NN NN NN NN O
activation, activation, 0 0 0 0 1 0 0 0 11 0 NN NN NN NN NN O
mannose mannose 0 0 0 0 0 0 0 0 7 0 NN NN NN NN CC O
receptor receptor 0 0 0 0 0 0 0 0 8 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
PPARγ. PPARγ. 1 0 0 0 0 0 0 0 6 0 NN CC NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 CC NNP NNP NN VBZ O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ IN O
demonstrates demonstrates 0 0 0 0 0 0 0 0 12 0 NNP NN VBZ IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NN VBZ IN JJ NNP O
fetal fetal 0 0 0 0 0 0 0 0 5 0 VBZ IN JJ NNP NN O
UN UN 1 1 0 0 0 0 0 0 2 0 IN JJ NNP NN VBZ O
exposure exposure 0 0 0 0 0 0 0 0 8 0 JJ NNP NN VBZ JJ O
primes primes 0 0 0 0 0 0 0 0 6 0 NNP NN VBZ JJ NN O
hematopoietic hematopoietic 0 0 0 0 0 0 0 0 13 0 NN VBZ JJ NN NNS O
immune immune 0 0 0 0 0 0 0 0 6 0 VBZ JJ NN NNS TO O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO DT RBR O
a a 0 0 0 0 0 0 0 0 1 0 NNS TO DT RBR JJ O
more more 0 0 0 0 0 0 0 0 4 0 TO DT RBR JJ JJ O
potent potent 0 0 0 0 0 0 0 0 6 0 DT RBR JJ JJ NN O
pro-inflammatory pro-inflammatory 0 0 1 0 0 0 0 0 16 0 RBR JJ JJ NN IN O
phenotype phenotype 0 0 0 0 0 0 0 0 9 0 JJ JJ NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN JJ NN O
heightened heightened 0 0 0 0 0 0 0 0 10 0 NN IN JJ NN NN O
cytokine cytokine 0 0 0 0 0 0 0 0 8 0 IN JJ NN NN CC O
secretion secretion 0 0 0 0 0 0 0 0 9 0 JJ NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NNP O
receptor receptor 0 0 0 0 0 0 0 0 8 0 NN CC NN NNP NNP O
expression. expression. 0 0 0 0 0 0 0 0 11 0 CC NN NNP NNP DT O
Furthermore Furthermore 1 0 0 0 0 0 0 0 11 0 NN NNP NNP DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP DT NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 DT NNS VBP JJ TO O
pre-disposed pre-disposed 0 0 1 0 0 0 0 0 12 0 NNS VBP JJ TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 VBP JJ TO JJ NNP O
pro-inflammatory pro-inflammatory 0 0 1 0 0 0 0 0 16 0 JJ TO JJ NNP NN O
M1 M1 1 1 0 0 0 0 0 1 2 0 TO JJ NNP NN NN O
macrophage macrophage 0 0 0 0 0 0 0 0 10 0 JJ NNP NN NN WDT O
phenotype phenotype 0 0 0 0 0 0 0 0 9 0 NNP NN NN WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBZ JJ O
has has 0 0 0 0 0 0 0 0 3 0 NN WDT VBZ JJ CC O
wide-reaching wide-reaching 0 0 1 0 0 0 0 0 13 0 WDT VBZ JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBZ JJ CC JJ NNS O
important important 0 0 0 0 0 0 0 0 9 0 JJ CC JJ NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 CC JJ NNS IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNS IN O
terms terms 0 0 0 0 0 0 0 0 5 0 NNS IN NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN NN CC O
obesity obesity 0 0 0 0 0 0 0 0 7 0 NNS IN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC JJ NNP O
metabolic metabolic 0 0 0 0 0 0 0 0 9 0 NN CC JJ NNP NONE O
disease. disease. 0 0 0 0 0 0 0 0 8 0 CC JJ NNP NONE NONE O
Use Use 1 0 0 0 0 0 0 0 3 0 NONE NONE NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
Chinchilla Chinchilla 1 0 0 0 0 0 0 0 10 0 IN DT NNP NNP TO O
Model Model 1 0 0 0 0 0 0 0 5 0 DT NNP NNP TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNP NNP TO NNP DT O
Evaluate Evaluate 1 0 0 0 0 0 0 0 8 0 NNP TO NNP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 TO NNP DT NNP NNP O
Vaccinogenic Vaccinogenic 1 0 0 0 0 0 0 0 12 0 NNP DT NNP NNP IN O
Potential Potential 1 0 0 0 0 0 0 0 9 0 DT NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP VBZ O
Moraxella Moraxella 1 0 0 0 0 0 0 0 9 0 IN DT NNP VBZ NNP O
catarrhalis catarrhalis 0 0 0 0 0 0 0 0 11 0 DT NNP VBZ NNP NNP O
Filamentous Filamentous 1 0 0 0 0 0 0 0 11 0 NNP VBZ NNP NNP NNP O
Hemagglutinin-like Hemagglutinin-like 1 0 1 0 0 0 0 0 18 0 VBZ NNP NNP NNP NNP O
Proteins Proteins 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP CC O
MhaB1 MhaB1 1 0 0 0 0 0 0 1 5 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
MhaB2. MhaB2. 1 0 0 0 0 0 0 1 6 0 NNP CC NNP NNP NNP O
Shaffer Shaffer 1 0 0 0 0 0 0 0 7 0 CC NNP NNP NNP NNP O
TL, TL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Balder Balder 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Buskirk Buskirk 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
SW, SW, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Hogan Hogan 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
RJ, RJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Lafontaine Lafontaine 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
ER. ER. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Microbiology, Microbiology, 1 0 0 0 1 0 0 0 13 0 NNP IN NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Georgia, Georgia, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP NNP O
Athens, Athens, 1 0 0 0 1 0 0 0 7 0 IN NNP NNP NNP NNP O
Georgia, Georgia, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNPS O
United United 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNPS IN O
States States 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
America. America. 1 0 0 0 0 0 0 0 8 0 NNPS IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP VBZ O
Moraxella Moraxella 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP VBZ NNS O
catarrhalis catarrhalis 0 0 0 0 0 0 0 0 11 0 NNP NNP VBZ NNS JJ O
causes causes 0 0 0 0 0 0 0 0 6 0 NNP VBZ NNS JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 VBZ NNS JJ NN NN O
health health 0 0 0 0 0 0 0 0 6 0 NNS JJ NN NN VBG O
problems, problems, 0 0 0 0 1 0 0 0 9 0 JJ NN NN VBG CD O
including including 0 0 0 0 0 0 0 0 9 0 NN NN VBG CD IN O
15-20% 15-20% 0 0 1 0 0 0 0 1 6 0 NN VBG CD IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 VBG CD IN NNS NNS O
otitis otitis 0 0 0 0 0 0 0 0 6 0 CD IN NNS NNS NNS O
media media 0 0 0 0 0 0 0 0 5 0 IN NNS NNS NNS IN O
cases cases 0 0 0 0 0 0 0 0 5 0 NNS NNS NNS IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 NNS NNS IN NNS CC O
children children 0 0 0 0 0 0 0 0 8 0 NNS IN NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC NN IN O
∼10% ∼10% 0 0 0 0 0 0 0 1 4 0 NNS CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NNS O
respiratory respiratory 0 0 0 0 0 0 0 0 11 0 NN IN NN NNS IN O
infections infections 0 0 0 0 0 0 0 0 10 0 IN NN NNS IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNS IN O
adults adults 0 0 0 0 0 0 0 0 6 0 NNS IN NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN JJ JJ O
chronic chronic 0 0 0 0 0 0 0 0 7 0 NNS IN JJ JJ JJ O
obstructive obstructive 0 0 0 0 0 0 0 0 11 0 IN JJ JJ JJ NNP O
pulmonary pulmonary 0 0 0 0 0 0 0 0 9 0 JJ JJ JJ NNP NNP O
disease. disease. 0 0 0 0 0 0 0 0 8 0 JJ JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
lack lack 0 0 0 0 0 0 0 0 4 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT JJ NN O
efficacious efficacious 0 0 0 0 0 0 0 0 11 0 IN DT JJ NN DT O
vaccine, vaccine, 0 0 0 0 1 0 0 0 8 0 DT JJ NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT JJ NN O
rapid rapid 0 0 0 0 0 0 0 0 5 0 NN DT JJ NN IN O
emergence emergence 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
antibiotic antibiotic 0 0 0 0 0 0 0 0 10 0 NN IN JJ NN IN O
resistance resistance 0 0 0 0 0 0 0 0 10 0 IN JJ NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
clinical clinical 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN CC O
isolates, isolates, 0 0 0 0 1 0 0 0 9 0 IN JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 NN CC JJ NN NNS O
carriage carriage 0 0 0 0 0 0 0 0 8 0 CC JJ NN NNS VBD O
rates rates 0 0 0 0 0 0 0 0 5 0 JJ NN NNS VBD IN O
reported reported 0 0 0 0 0 0 0 0 8 0 NN NNS VBD IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBD IN NNS VBP O
children children 0 0 0 0 0 0 0 0 8 0 VBD IN NNS VBP NN O
are are 0 0 0 0 0 0 0 0 3 0 IN NNS VBP NN IN O
cause cause 0 0 0 0 0 0 0 0 5 0 NNS VBP NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 VBP NN IN NNP NNP O
concern. concern. 0 0 0 0 0 0 0 0 8 0 NN IN NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 IN NNP NNP NNP DT O
addition, addition, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
effectiveness effectiveness 0 0 0 0 0 0 0 0 13 0 NNP DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
conjugate conjugate 0 0 0 0 0 0 0 0 9 0 NN IN NN NNS IN O
vaccines vaccines 0 0 0 0 0 0 0 0 8 0 IN NN NNS IN VBG O
at at 0 0 0 0 0 0 0 0 2 0 NN NNS IN VBG DT O
reducing reducing 0 0 0 0 0 0 0 0 8 0 NNS IN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN VBG DT NN IN O
incidence incidence 0 0 0 0 0 0 0 0 9 0 VBG DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS NNS O
otitis otitis 0 0 0 0 0 0 0 0 6 0 NN IN NNS NNS VBN O
media media 0 0 0 0 0 0 0 0 5 0 IN NNS NNS VBN IN O
caused caused 0 0 0 0 0 0 0 0 6 0 NNS NNS VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBN IN NNP NN O
Streptococcus Streptococcus 1 0 0 0 0 0 0 0 13 0 VBN IN NNP NN CC O
pneumoniae pneumoniae 0 0 0 0 0 0 0 0 10 0 IN NNP NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC JJ NNP O
nontypeable nontypeable 0 0 0 0 0 0 0 0 11 0 NN CC JJ NNP NN O
Haemophilus Haemophilus 1 0 0 0 0 0 0 0 11 0 CC JJ NNP NN VBP O
influenzae influenzae 0 0 0 0 0 0 0 0 10 0 JJ NNP NN VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNP NN VBP IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NN VBP IN NNP VBZ O
M. M. 1 1 0 0 0 0 0 0 2 0 VBP IN NNP VBZ NNS O
catarrhalis catarrhalis 0 0 0 0 0 0 0 0 11 0 IN NNP VBZ NNS MD O
infections infections 0 0 0 0 0 0 0 0 10 0 NNP VBZ NNS MD VB O
may may 0 0 0 0 0 0 0 0 3 0 VBZ NNS MD VB RB O
become become 0 0 0 0 0 0 0 0 6 0 NNS MD VB RB RBR O
even even 0 0 0 0 0 0 0 0 4 0 MD VB RB RBR NNP O
more more 0 0 0 0 0 0 0 0 4 0 VB RB RBR NNP NNP O
prevalent. prevalent. 0 0 0 0 0 0 0 0 10 0 RB RBR NNP NNP NNP O
Hence, Hence, 1 0 0 0 1 0 0 0 6 0 RBR NNP NNP NNP VBZ O
M. M. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP VBZ VBZ O
catarrhalis catarrhalis 0 0 0 0 0 0 0 0 11 0 NNP NNP VBZ VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP VBZ VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 VBZ VBZ DT JJ CC O
important important 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC VBG NN O
emerging emerging 0 0 0 0 0 0 0 0 8 0 JJ CC VBG NN IN O
cause cause 0 0 0 0 0 0 0 0 5 0 CC VBG NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBG NN IN JJ NN O
infectious infectious 0 0 0 0 0 0 0 0 10 0 NN IN JJ NN IN O
disease disease 0 0 0 0 0 0 0 0 7 0 IN JJ NN IN WDT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN WDT DT O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN WDT DT NN IN O
development development 0 0 0 0 0 0 0 0 11 0 WDT DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN VBZ O
vaccine vaccine 0 0 0 0 0 0 0 0 7 0 IN DT NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ RB NNP O
highly highly 0 0 0 0 0 0 0 0 6 0 NN VBZ RB NNP NNP O
desirable. desirable. 0 0 0 0 0 0 0 0 10 0 VBZ RB NNP NNP DT O
Studying Studying 1 0 0 0 0 0 0 0 8 0 RB NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
pathogenesis pathogenesis 0 0 0 0 0 0 0 0 12 0 NNP DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP VBZ O
M. M. 1 1 0 0 0 0 0 0 2 0 NN IN NNP VBZ CC O
catarrhalis catarrhalis 0 0 0 0 0 0 0 0 11 0 IN NNP VBZ CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NNP VBZ CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBZ CC DT NN IN O
testing testing 0 0 0 0 0 0 0 0 7 0 CC DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
vaccine vaccine 0 0 0 0 0 0 0 0 7 0 NN IN NN NNS VBP O
candidates candidates 0 0 0 0 0 0 0 0 10 0 IN NN NNS VBP DT O
have have 0 0 0 0 0 0 0 0 4 0 NN NNS VBP DT VBN O
both both 0 0 0 0 0 0 0 0 4 0 NNS VBP DT VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 VBP DT VBN VBN IN O
hindered hindered 0 0 0 0 0 0 0 0 8 0 DT VBN VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBN VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
lack lack 0 0 0 0 0 0 0 0 4 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT JJ NN O
animal animal 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN WDT O
model model 0 0 0 0 0 0 0 0 5 0 DT JJ NN WDT NNS O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT NNS VBP O
mimics mimics 0 0 0 0 0 0 0 0 6 0 NN WDT NNS VBP NN O
human human 0 0 0 0 0 0 0 0 5 0 WDT NNS VBP NN CC O
colonization colonization 0 0 0 0 0 0 0 0 12 0 NNS VBP NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VBP NN CC NNP NNP O
infection. infection. 0 0 0 0 0 0 0 0 10 0 NN CC NNP NNP NN O
To To 1 0 0 0 0 0 0 0 2 0 CC NNP NNP NN NN O
address address 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN PRP O
this, this, 0 0 0 0 1 0 0 0 5 0 NNP NN NN PRP RB O
we we 0 0 0 0 0 0 0 0 2 0 NN NN PRP RB VBN O
intranasally intranasally 0 0 0 0 0 0 0 0 12 0 NN PRP RB VBN NN O
infected infected 0 0 0 0 0 0 0 0 8 0 PRP RB VBN NN IN O
chinchilla chinchilla 0 0 0 0 0 0 0 0 10 0 RB VBN NN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBN NN IN NNP NNS O
M. M. 1 1 0 0 0 0 0 0 2 0 NN IN NNP NNS TO O
catarrhalis catarrhalis 0 0 0 0 0 0 0 0 11 0 IN NNP NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNP NNS TO VB NN O
investigate investigate 0 0 0 0 0 0 0 0 11 0 NNS TO VB NN CC O
colonization colonization 0 0 0 0 0 0 0 0 12 0 TO VB NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VB NN CC NN DT O
examine examine 0 0 0 0 0 0 0 0 7 0 NN CC NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC NN DT NN IN O
efficacy efficacy 0 0 0 0 0 0 0 0 8 0 NN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NNP O
protein-based protein-based 0 0 1 0 0 0 0 0 13 0 IN DT JJ NNP NNP O
vaccine. vaccine. 0 0 0 0 0 0 0 0 8 0 DT JJ NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NNS VBP O
data data 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS VBP IN O
reveal reveal 0 0 0 0 0 0 0 0 6 0 NNP NNS VBP IN VBN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN VBN NNS O
infected infected 0 0 0 0 0 0 0 0 8 0 VBP IN VBN NNS VBP O
chinchillas chinchillas 0 0 0 0 0 0 0 0 11 0 IN VBN NNS VBP NNS O
produce produce 0 0 0 0 0 0 0 0 7 0 VBN NNS VBP NNS IN O
antibodies antibodies 0 0 0 0 0 0 0 0 10 0 NNS VBP NNS IN NNS O
against against 0 0 0 0 0 0 0 0 7 0 VBP NNS IN NNS VBN O
antigens antigens 0 0 0 0 0 0 0 0 8 0 NNS IN NNS VBN TO O
known known 0 0 0 0 0 0 0 0 5 0 IN NNS VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBN TO VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB JJ NNS O
major major 0 0 0 0 0 0 0 0 5 0 TO VB JJ NNS IN O
targets targets 0 0 0 0 0 0 0 0 7 0 VB JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
immune immune 0 0 0 0 0 0 0 0 6 0 IN DT NN NN IN O
response response 0 0 0 0 0 0 0 0 8 0 DT NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP RB O
humans, humans, 0 0 0 0 1 0 0 0 7 0 NN IN NNP RB VBG O
thus thus 0 0 0 0 0 0 0 0 4 0 IN NNP RB VBG NN O
establishing establishing 0 0 0 0 0 0 0 0 12 0 NNP RB VBG NN NNS O
immune immune 0 0 0 0 0 0 0 0 6 0 RB VBG NN NNS IN O
parallels parallels 0 0 0 0 0 0 0 0 9 0 VBG NN NNS IN NNS O
between between 0 0 0 0 0 0 0 0 7 0 NN NNS IN NNS CC O
chinchillas chinchillas 0 0 0 0 0 0 0 0 11 0 NNS IN NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC NNS IN O
humans humans 0 0 0 0 0 0 0 0 6 0 NNS CC NNS IN NNP O
during during 0 0 0 0 0 0 0 0 6 0 CC NNS IN NNP NNS O
M. M. 1 1 0 0 0 0 0 0 2 0 NNS IN NNP NNS NNP O
catarrhalis catarrhalis 0 0 0 0 0 0 0 0 11 0 IN NNP NNS NNP NNP O
infection. infection. 0 0 0 0 0 0 0 0 10 0 NNP NNS NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 NNS NNP NNP NNS RB O
data data 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS RB VBP O
also also 0 0 0 0 0 0 0 0 4 0 NNP NNS RB VBP IN O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 NNS RB VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 RB VBP IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBP IN DT JJ NN O
mutant mutant 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN NN O
lacking lacking 0 0 0 0 0 0 0 0 7 0 DT JJ NN NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 JJ NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNS O
adherence adherence 0 0 0 0 0 0 0 0 9 0 IN DT NN NNS NNP O
proteins proteins 0 0 0 0 0 0 0 0 8 0 DT NN NNS NNP CC O
MhaB1 MhaB1 1 0 0 0 0 0 0 1 5 0 NN NNS NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNS NNP CC NNP VBZ O
MhaB2 MhaB2 1 0 0 0 0 0 0 1 5 0 NNP CC NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 CC NNP VBZ VBN IN O
impaired impaired 0 0 0 0 0 0 0 0 8 0 NNP VBZ VBN IN PRP$ O
in in 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 VBN IN PRP$ NN TO O
ability ability 0 0 0 0 0 0 0 0 7 0 IN PRP$ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 PRP$ NN TO VB DT O
colonize colonize 0 0 0 0 0 0 0 0 8 0 NN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN NN O
chinchilla chinchilla 0 0 0 0 0 0 0 0 10 0 VB DT NN NN CC O
nasopharynx, nasopharynx, 0 0 0 0 1 0 0 0 12 0 DT NN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NN CC IN NN IN O
immunization immunization 0 0 0 0 0 0 0 0 12 0 CC IN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN VBN O
polypeptide polypeptide 0 0 0 0 0 0 0 0 11 0 IN DT NN VBN IN O
shared shared 0 0 0 0 0 0 0 0 6 0 DT NN VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN VBN IN NNP CC O
MhaB1 MhaB1 1 0 0 0 0 0 0 1 5 0 VBN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNS O
MhaB2 MhaB2 1 0 0 0 0 0 0 1 5 0 NNP CC NNP NNS NNS O
elicits elicits 0 0 0 0 0 0 0 0 7 0 CC NNP NNS NNS VBG O
antibodies antibodies 0 0 0 0 0 0 0 0 10 0 NNP NNS NNS VBG IN O
interfering interfering 0 0 0 0 0 0 0 0 11 0 NNS NNS VBG IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBG IN NNP NNP O
colonization. colonization. 0 0 0 0 0 0 0 0 13 0 VBG IN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNS VBP O
findings findings 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBP DT O
underscore underscore 0 0 0 0 0 0 0 0 10 0 NNP NNS VBP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBP DT NN IN O
importance importance 0 0 0 0 0 0 0 0 10 0 VBP DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
adherence adherence 0 0 0 0 0 0 0 0 9 0 NN IN NN NNS IN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 IN NN NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN CC O
colonization colonization 0 0 0 0 0 0 0 0 12 0 NNS IN NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VB DT O
emphasize emphasize 0 0 0 0 0 0 0 0 9 0 NN CC VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC VB DT NN IN O
relevance relevance 0 0 0 0 0 0 0 0 9 0 VB DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
chinchilla chinchilla 0 0 0 0 0 0 0 0 10 0 IN DT NN NN TO O
model model 0 0 0 0 0 0 0 0 5 0 DT NN NN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO NN NNP O
study study 0 0 0 0 0 0 0 0 5 0 NN TO NN NNP NNP O
M. M. 1 1 0 0 0 0 0 0 2 0 TO NN NNP NNP NNP O
catarrhalis-host catarrhalis-host 0 0 1 0 0 0 0 0 16 0 NN NNP NNP NNP NONE O
interactions. interactions. 0 0 0 0 0 0 0 0 13 0 NNP NNP NNP NONE NONE O
Subtle Subtle 1 0 0 0 0 0 0 0 6 0 NONE NONE NNP NN NN O
paranodal paranodal 0 0 0 0 0 0 0 0 9 0 NONE NNP NN NN VBZ O
injury injury 0 0 0 0 0 0 0 0 6 0 NNP NN NN VBZ NN O
slows slows 0 0 0 0 0 0 0 0 5 0 NN NN VBZ NN NN O
impulse impulse 0 0 0 0 0 0 0 0 7 0 NN VBZ NN NN IN O
conduction conduction 0 0 0 0 0 0 0 0 10 0 VBZ NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
mathematical mathematical 0 0 0 0 0 0 0 0 12 0 IN DT JJ NN IN O
model model 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN VBN NNP O
myelinated myelinated 0 0 0 0 0 0 0 0 10 0 NN IN VBN NNP NNP O
axons. axons. 0 0 0 0 0 0 0 0 6 0 IN VBN NNP NNP NNP O
Babbs Babbs 1 0 0 0 0 0 0 0 5 0 VBN NNP NNP NNP NNP O
CF, CF, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Shi Shi 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
R. R. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Basic Basic 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP IN O
Center Center 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNP O
Paralysis Paralysis 1 0 0 0 0 0 0 0 9 0 NNP IN NNP NNP CC O
Research, Research, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Weldon Weldon 1 0 0 0 0 0 0 0 6 0 NNP CC NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biomedical Biomedical 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Engineering, Engineering, 1 0 0 0 1 0 0 0 12 0 IN NNP NNP NNP NNP O
Purdue Purdue 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
West West 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Lafayette, Lafayette, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Indiana, Indiana, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNPS O
United United 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNPS IN O
States States 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
America. America. 1 0 0 0 0 0 0 0 8 0 NNPS IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NN VBZ O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ IN O
explores explores 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN VBZ IN NN DT O
detail detail 0 0 0 0 0 0 0 0 6 0 VBZ IN NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT JJ NNS O
functional functional 0 0 0 0 0 0 0 0 10 0 NN DT JJ NNS IN O
consequences consequences 0 0 0 0 0 0 0 0 12 0 DT JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NN O
subtle subtle 0 0 0 0 0 0 0 0 6 0 NNS IN NN NN CC O
retraction retraction 0 0 0 0 0 0 0 0 10 0 IN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
detachment detachment 0 0 0 0 0 0 0 0 10 0 NN CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN IN O
myelin myelin 0 0 0 0 0 0 0 0 6 0 NN IN NN IN DT O
around around 0 0 0 0 0 0 0 0 6 0 IN NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS IN O
nodes nodes 0 0 0 0 0 0 0 0 5 0 IN DT NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NNP VBG O
Ranvier Ranvier 1 0 0 0 0 0 0 0 7 0 NNS IN NNP VBG JJ O
following following 0 0 0 0 0 0 0 0 9 0 IN NNP VBG JJ NN O
mild-to-moderate mild-to-moderate 0 0 1 0 0 0 0 0 16 0 NNP VBG JJ NN CC O
crush crush 0 0 0 0 0 0 0 0 5 0 VBG JJ NN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 JJ NN CC NN VBD O
stretch stretch 0 0 0 0 0 0 0 0 7 0 NN CC NN VBD NNP O
mediated mediated 0 0 0 0 0 0 0 0 8 0 CC NN VBD NNP NNP O
injury. injury. 0 0 0 0 0 0 0 0 7 0 NN VBD NNP NNP NN O
An An 1 0 0 0 0 0 0 0 2 0 VBD NNP NNP NN JJ O
equivalent equivalent 0 0 0 0 0 0 0 0 10 0 NNP NNP NN JJ NN O
electrical electrical 0 0 0 0 0 0 0 0 10 0 NNP NN JJ NN NN O
circuit circuit 0 0 0 0 0 0 0 0 7 0 NN JJ NN NN IN O
model model 0 0 0 0 0 0 0 0 5 0 JJ NN NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN IN O
series series 0 0 0 0 0 0 0 0 6 0 IN DT NN IN RB O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN RB VBN O
equally equally 0 0 0 0 0 0 0 0 7 0 NN IN RB VBN NNS O
spaced spaced 0 0 0 0 0 0 0 0 6 0 IN RB VBN NNS IN O
nodes nodes 0 0 0 0 0 0 0 0 5 0 RB VBN NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBN NNS IN NNP VBD O
Ranvier Ranvier 1 0 0 0 0 0 0 0 7 0 NNS IN NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 IN NNP VBD VBN VBG O
created created 0 0 0 0 0 0 0 0 7 0 NNP VBD VBN VBG JJ O
incorporating incorporating 0 0 0 0 0 0 0 0 13 0 VBD VBN VBG JJ CC O
extracellular extracellular 0 0 0 0 0 0 0 0 13 0 VBN VBG JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBG JJ CC JJ NN O
axonal axonal 0 0 0 0 0 0 0 0 6 0 JJ CC JJ NN NN O
resistances, resistances, 0 0 0 0 1 0 0 0 12 0 CC JJ NN NN NN O
paranodal paranodal 0 0 0 0 0 0 0 0 9 0 JJ NN NN NN NN O
resistances, resistances, 0 0 0 0 1 0 0 0 12 0 NN NN NN NN NN O
nodal nodal 0 0 0 0 0 0 0 0 5 0 NN NN NN NN NN O
capacitances, capacitances, 0 0 0 0 1 0 0 0 13 0 NN NN NN NN VBG O
time time 0 0 0 0 0 0 0 0 4 0 NN NN NN VBG NN O
varying varying 0 0 0 0 0 0 0 0 7 0 NN NN VBG NN CC O
sodium sodium 0 0 0 0 0 0 0 0 6 0 NN VBG NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VBG NN CC NN NN O
potassium potassium 0 0 0 0 0 0 0 0 9 0 NN CC NN NN CC O
currents, currents, 0 0 0 0 1 0 0 0 9 0 CC NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
realistic realistic 0 0 0 0 0 0 0 0 9 0 NN CC JJ NN CC O
resting resting 0 0 0 0 0 0 0 0 7 0 CC JJ NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBD NN O
threshold threshold 0 0 0 0 0 0 0 0 9 0 NN CC VBD NN NNS O
membrane membrane 0 0 0 0 0 0 0 0 8 0 CC VBD NN NNS IN O
potentials potentials 0 0 0 0 0 0 0 0 10 0 VBD NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT VBN O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT VBN NN O
myelinated myelinated 0 0 0 0 0 0 0 0 10 0 IN DT VBN NN NN O
axon axon 0 0 0 0 0 0 0 0 4 0 DT VBN NN NN IN O
segment segment 0 0 0 0 0 0 0 0 7 0 VBN NN NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN CD JJ O
21 21 0 0 0 0 0 0 1 1 2 0 NN IN CD JJ NNP O
successive successive 0 0 0 0 0 0 0 0 10 0 IN CD JJ NNP NNP O
nodes. nodes. 0 0 0 0 0 0 0 0 6 0 CD JJ NNP NNP NNS O
Differential Differential 1 0 0 0 0 0 0 0 12 0 JJ NNP NNP NNS VBG O
equations equations 0 0 0 0 0 0 0 0 9 0 NNP NNP NNS VBG NN O
describing describing 0 0 0 0 0 0 0 0 10 0 NNP NNS VBG NN NNS O
membrane membrane 0 0 0 0 0 0 0 0 8 0 NNS VBG NN NNS IN O
potentials potentials 0 0 0 0 0 0 0 0 10 0 VBG NN NNS IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NN O
each each 0 0 0 0 0 0 0 0 4 0 NNS IN DT NN NN O
nodal nodal 0 0 0 0 0 0 0 0 5 0 IN DT NN NN VBD O
region region 0 0 0 0 0 0 0 0 6 0 DT NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN -NONE- O
solved solved 0 0 0 0 0 0 0 0 6 0 NN VBD VBN -NONE- NNP O
numerically. numerically. 0 0 0 0 0 0 0 0 12 0 VBD VBN -NONE- NNP NN O
Subtle Subtle 1 0 0 0 0 0 0 0 6 0 VBN -NONE- NNP NN VBD O
injury injury 0 0 0 0 0 0 0 0 6 0 -NONE- NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
simulated simulated 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN VBG O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN VBG DT O
increasing increasing 0 0 0 0 0 0 0 0 10 0 VBN IN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN VBG DT NN IN O
width width 0 0 0 0 0 0 0 0 5 0 VBG DT NN IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN VBN JJ O
exposed exposed 0 0 0 0 0 0 0 0 7 0 NN IN VBN JJ NN O
nodal nodal 0 0 0 0 0 0 0 0 5 0 IN VBN JJ NN IN O
membrane membrane 0 0 0 0 0 0 0 0 8 0 VBN JJ NN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS CD O
nodes nodes 0 0 0 0 0 0 0 0 5 0 NN IN NNS CD IN O
8 8 0 0 0 0 0 0 1 1 1 0 IN NNS CD IN CD O
through through 0 0 0 0 0 0 0 0 7 0 NNS CD IN CD IN O
20 20 0 0 0 0 0 0 1 1 2 0 CD IN CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN CD IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT NNP NNP O
model. model. 0 0 0 0 0 0 0 0 6 0 IN DT NNP NNP NN O
Such Such 1 0 0 0 0 0 0 0 4 0 DT NNP NNP NN VBZ O
injury injury 0 0 0 0 0 0 0 0 6 0 NNP NNP NN VBZ NN O
diminishes diminishes 0 0 0 0 0 0 0 0 10 0 NNP NN VBZ NN NN O
action action 0 0 0 0 0 0 0 0 6 0 NN VBZ NN NN NN O
potential potential 0 0 0 0 0 0 0 0 9 0 VBZ NN NN NN CC O
amplitude amplitude 0 0 0 0 0 0 0 0 9 0 NN NN NN CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBZ NN O
slows slows 0 0 0 0 0 0 0 0 5 0 NN CC VBZ NN NN O
conduction conduction 0 0 0 0 0 0 0 0 10 0 CC VBZ NN NN IN O
velocity velocity 0 0 0 0 0 0 0 0 8 0 VBZ NN NN IN CD O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN CD JJ O
19.1 19.1 0 0 0 0 0 0 0 1 4 0 NN IN CD JJ IN O
m/sec m/sec 0 0 0 1 0 0 0 0 5 0 IN CD JJ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 CD JJ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT JJ NN O
normal normal 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN TO O
region region 0 0 0 0 0 0 0 0 6 0 DT JJ NN TO CD O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO CD JJ O
7.8 7.8 0 0 0 0 0 0 0 1 3 0 NN TO CD JJ IN O
m/sec m/sec 0 0 0 1 0 0 0 0 5 0 TO CD JJ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 CD JJ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT JJ NNP O
crushed crushed 0 0 0 0 0 0 0 0 7 0 IN DT JJ NNP NNP O
region. region. 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NNP IN O
Detachment Detachment 1 0 0 0 0 0 0 0 10 0 JJ NNP NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ NN O
paranodal paranodal 0 0 0 0 0 0 0 0 9 0 NNP IN JJ NN VBG O
myelin, myelin, 0 0 0 0 1 0 0 0 7 0 IN JJ NN VBG NN O
exposing exposing 0 0 0 0 0 0 0 0 8 0 JJ NN VBG NN NN O
juxtaparanodal juxtaparanodal 0 0 0 0 0 0 0 0 14 0 NN VBG NN NN NN O
potassium potassium 0 0 0 0 0 0 0 0 9 0 VBG NN NN NN NNS O
channels, channels, 0 0 0 0 1 0 0 0 9 0 NN NN NN NNS NN O
decreases decreases 0 0 0 0 0 0 0 0 9 0 NN NN NNS NN NN O
conduction conduction 0 0 0 0 0 0 0 0 10 0 NN NNS NN NN RB O
velocity velocity 0 0 0 0 0 0 0 0 8 0 NNS NN NN RB TO O
further further 0 0 0 0 0 0 0 0 7 0 NN NN RB TO CD O
to to 0 0 0 0 0 0 0 0 2 0 NN RB TO CD NN O
6.6 6.6 0 0 0 0 0 0 0 1 3 0 RB TO CD NN DT O
m/sec, m/sec, 0 0 0 1 1 0 0 0 6 0 TO CD NN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 CD NN DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 NN DT NN IN VBZ O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NN IN VBZ RB JJ O
partially partially 0 0 0 0 0 0 0 0 9 0 IN VBZ RB JJ IN O
reversible reversible 0 0 0 0 0 0 0 0 10 0 VBZ RB JJ IN NN O
with with 0 0 0 0 0 0 0 0 4 0 RB JJ IN NN NN O
potassium potassium 0 0 0 0 0 0 0 0 9 0 JJ IN NN NN NN O
ion ion 0 0 0 0 0 0 0 0 3 0 IN NN NN NN NNP O
channel channel 0 0 0 0 0 0 0 0 7 0 NN NN NN NNP NNP O
blockade. blockade. 0 0 0 0 0 0 0 0 9 0 NN NN NNP NNP NN O
Conduction Conduction 1 0 0 0 0 0 0 0 10 0 NN NNP NNP NN NNS O
velocity velocity 0 0 0 0 0 0 0 0 8 0 NNP NNP NN NNS IN O
decreases decreases 0 0 0 0 0 0 0 0 9 0 NNP NN NNS IN NN O
as as 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NN O
node node 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN NNS O
width width 0 0 0 0 0 0 0 0 5 0 IN NN NN NNS CC O
increases increases 0 0 0 0 0 0 0 0 9 0 NN NN NNS CC IN O
or or 0 0 0 0 0 0 0 0 2 0 NN NNS CC IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 NNS CC IN JJ NN O
paranodal paranodal 0 0 0 0 0 0 0 0 9 0 CC IN JJ NN NNP O
resistance resistance 0 0 0 0 0 0 0 0 10 0 IN JJ NN NNP NNP O
falls. falls. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP VBD O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP VBD NNS O
calculated calculated 0 0 0 0 0 0 0 0 10 0 NNP NNP VBD NNS IN O
changes changes 0 0 0 0 0 0 0 0 7 0 NNP VBD NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBD NNS IN NN NN O
conduction conduction 0 0 0 0 0 0 0 0 10 0 NNS IN NN NN IN O
velocity velocity 0 0 0 0 0 0 0 0 8 0 IN NN NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN NN NN O
subtle subtle 0 0 0 0 0 0 0 0 6 0 NN IN NN NN NN O
paranodal paranodal 0 0 0 0 0 0 0 0 9 0 IN NN NN NN NN O
injury injury 0 0 0 0 0 0 0 0 6 0 NN NN NN NN IN O
agree agree 0 0 0 0 0 0 0 0 5 0 NN NN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ NNP O
experimental experimental 0 0 0 0 0 0 0 0 12 0 NN IN JJ NNP NNP O
observations. observations. 0 0 0 0 0 0 0 0 13 0 IN JJ NNP NNP IN O
Nodes Nodes 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP VBP O
Ranvier Ranvier 1 0 0 0 0 0 0 0 7 0 NNP IN NNP VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 IN NNP VBP RB JJ O
highly highly 0 0 0 0 0 0 0 0 6 0 NNP VBP RB JJ CC O
effective effective 0 0 0 0 0 0 0 0 9 0 VBP RB JJ CC RB O
but but 0 0 0 0 0 0 0 0 3 0 RB JJ CC RB JJ O
somewhat somewhat 0 0 0 0 0 0 0 0 8 0 JJ CC RB JJ NNS O
fragile fragile 0 0 0 0 0 0 0 0 7 0 CC RB JJ NNS IN O
devices devices 0 0 0 0 0 0 0 0 7 0 RB JJ NNS IN VBG O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN VBG NN O
increasing increasing 0 0 0 0 0 0 0 0 10 0 NNS IN VBG NN NN O
nerve nerve 0 0 0 0 0 0 0 0 5 0 IN VBG NN NN NN O
conduction conduction 0 0 0 0 0 0 0 0 10 0 VBG NN NN NN CC O
velocity velocity 0 0 0 0 0 0 0 0 8 0 NN NN NN CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBG NN O
decreasing decreasing 0 0 0 0 0 0 0 0 10 0 NN CC VBG NN NN O
reaction reaction 0 0 0 0 0 0 0 0 8 0 CC VBG NN NN IN O
time time 0 0 0 0 0 0 0 0 4 0 VBG NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NNP O
vertebrate vertebrate 0 0 0 0 0 0 0 0 10 0 NN IN NN NNP NNP O
animals. animals. 0 0 0 0 0 0 0 0 8 0 IN NN NNP NNP JJ O
Their Their 1 0 0 0 0 0 0 0 5 0 NN NNP NNP JJ NN O
fundamental fundamental 0 0 0 0 0 0 0 0 11 0 NNP NNP JJ NN NN O
design design 0 0 0 0 0 0 0 0 6 0 NNP JJ NN NN VBZ O
limitation limitation 0 0 0 0 0 0 0 0 10 0 JJ NN NN VBZ IN O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ IN RB O
that that 0 0 0 0 0 0 0 0 4 0 NN VBZ IN RB JJ O
even even 0 0 0 0 0 0 0 0 4 0 VBZ IN RB JJ JJ O
small small 0 0 0 0 0 0 0 0 5 0 IN RB JJ JJ NNS O
mechanical mechanical 0 0 0 0 0 0 0 0 10 0 RB JJ JJ NNS IN O
retractions retractions 0 0 0 0 0 0 0 0 11 0 JJ JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN IN O
myelin myelin 0 0 0 0 0 0 0 0 6 0 NNS IN NN IN RB O
from from 0 0 0 0 0 0 0 0 4 0 IN NN IN RB JJ O
very very 0 0 0 0 0 0 0 0 4 0 NN IN RB JJ NNS O
narrow narrow 0 0 0 0 0 0 0 0 6 0 IN RB JJ NNS CC O
nodes nodes 0 0 0 0 0 0 0 0 5 0 RB JJ NNS CC NN O
or or 0 0 0 0 0 0 0 0 2 0 JJ NNS CC NN VBG O
slight slight 0 0 0 0 0 0 0 0 6 0 NNS CC NN VBG IN O
loosening loosening 0 0 0 0 0 0 0 0 9 0 CC NN VBG IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN VBG IN JJ NN O
paranodal paranodal 0 0 0 0 0 0 0 0 9 0 VBG IN JJ NN WDT O
myelin, myelin, 0 0 0 0 1 0 0 0 7 0 IN JJ NN WDT VBP O
which which 0 0 0 0 0 0 0 0 5 0 JJ NN WDT VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NN WDT VBP JJ TO O
difficult difficult 0 0 0 0 0 0 0 0 9 0 WDT VBP JJ TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VBP JJ TO NN IN O
notice notice 0 0 0 0 0 0 0 0 6 0 JJ TO NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 TO NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ JJ O
light light 0 0 0 0 0 0 0 0 5 0 IN DT JJ JJ NN O
microscopic microscopic 0 0 0 0 0 0 0 0 11 0 DT JJ JJ NN IN O
level level 0 0 0 0 0 0 0 0 5 0 JJ JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP MD O
observation, observation, 0 0 0 0 1 0 0 0 12 0 NN IN NNP MD VB O
can can 0 0 0 0 0 0 0 0 3 0 IN NNP MD VB JJ O
cause cause 0 0 0 0 0 0 0 0 5 0 NNP MD VB JJ NNS O
large large 0 0 0 0 0 0 0 0 5 0 MD VB JJ NNS IN O
changes changes 0 0 0 0 0 0 0 0 7 0 VB JJ NNS IN VBN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN VBN NN O
myelinated myelinated 0 0 0 0 0 0 0 0 10 0 NNS IN VBN NN NN O
nerve nerve 0 0 0 0 0 0 0 0 5 0 IN VBN NN NN NNP O
conduction conduction 0 0 0 0 0 0 0 0 10 0 VBN NN NN NNP NONE O
velocity. velocity. 0 0 0 0 0 0 0 0 9 0 NN NN NNP NONE NONE O
Yield Yield 1 0 0 0 0 0 0 0 5 0 NONE NONE NNP IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NONE NNP IN CD JJ O
two two 0 0 0 0 0 0 0 0 3 0 NNP IN CD JJ NN O
consecutive consecutive 0 0 0 0 0 0 0 0 11 0 IN CD JJ NN NNS O
sputum sputum 0 0 0 0 0 0 0 0 6 0 CD JJ NN NNS IN O
specimens specimens 0 0 0 0 0 0 0 0 9 0 JJ NN NNS IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
effective effective 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN IN O
diagnosis diagnosis 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNP O
pulmonary pulmonary 0 0 0 0 0 0 0 0 9 0 NN IN JJ NNP NNP O
tuberculosis. tuberculosis. 0 0 0 0 0 0 0 0 13 0 IN JJ NNP NNP NNP O
Islam Islam 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP NNP NNP O
MR, MR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Khatun Khatun 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Uddin Uddin 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
MK, MK, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Khan Khan 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
MS, MS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Rahman Rahman 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
MT, MT, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Ahmed Ahmed 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Banu Banu 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
S. S. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Biochemistry Biochemistry 1 0 0 0 0 0 0 0 12 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP CC NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 CC NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Dhaka, Dhaka, 1 0 0 0 1 0 0 0 6 0 NNP IN NNP NNP NNP O
Dhaka, Dhaka, 1 0 0 0 1 0 0 0 6 0 IN NNP NNP NNP NNP O
Bangladesh. Bangladesh. 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP RB O
From From 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP RB JJ O
long long 0 0 0 0 0 0 0 0 4 0 NNP NNP RB JJ PRP O
instances, instances, 0 0 0 0 1 0 0 0 10 0 NNP RB JJ PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 RB JJ PRP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 JJ PRP VBZ JJ IN O
debatable debatable 0 0 0 0 0 0 0 0 9 0 PRP VBZ JJ IN CD O
whether whether 0 0 0 0 0 0 0 0 7 0 VBZ JJ IN CD NN O
three three 0 0 0 0 0 0 0 0 5 0 JJ IN CD NN NNS O
sputum sputum 0 0 0 0 0 0 0 0 6 0 IN CD NN NNS VBP O
specimens specimens 0 0 0 0 0 0 0 0 9 0 CD NN NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NN NNS VBP VBN IN O
required required 0 0 0 0 0 0 0 0 8 0 NNS VBP VBN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBP VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
diagnosis diagnosis 0 0 0 0 0 0 0 0 9 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
pulmonary pulmonary 0 0 0 0 0 0 0 0 9 0 NN IN JJ NN NN O
tuberculosis tuberculosis 0 0 0 0 0 0 0 0 12 0 IN JJ NN NN CC O
(TB) (TB) 0 1 0 0 0 0 0 0 4 0 JJ NN NN CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 NN NN CC NNP MD O
TB TB 1 1 0 0 0 0 0 0 2 0 NN CC NNP MD VB O
can can 0 0 0 0 0 0 0 0 3 0 CC NNP MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NNP MD VB VBN RB O
diagnosed diagnosed 0 0 0 0 0 0 0 0 9 0 MD VB VBN RB VBG O
effectively effectively 0 0 0 0 0 0 0 0 11 0 VB VBN RB VBG CD O
using using 0 0 0 0 0 0 0 0 5 0 VBN RB VBG CD JJ O
two two 0 0 0 0 0 0 0 0 3 0 RB VBG CD JJ NN O
consecutive consecutive 0 0 0 0 0 0 0 0 11 0 VBG CD JJ NN NNP O
sputum sputum 0 0 0 0 0 0 0 0 6 0 CD JJ NN NNP NNP O
specimens. specimens. 0 0 0 0 0 0 0 0 10 0 JJ NN NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN RP O
set set 0 0 0 0 0 0 0 0 3 0 NN VBD VBN RP TO O
out out 0 0 0 0 0 0 0 0 3 0 VBD VBN RP TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN RP TO VB DT O
evaluate evaluate 0 0 0 0 0 0 0 0 8 0 RP TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
significance significance 0 0 0 0 0 0 0 0 12 0 VB DT NN IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN VBG NN O
examining examining 0 0 0 0 0 0 0 0 9 0 NN IN VBG NN NN O
multiple multiple 0 0 0 0 0 0 0 0 8 0 IN VBG NN NN NNS O
sputum sputum 0 0 0 0 0 0 0 0 6 0 VBG NN NN NNS IN O
specimens specimens 0 0 0 0 0 0 0 0 9 0 NN NN NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN IN O
diagnosis diagnosis 0 0 0 0 0 0 0 0 9 0 NNS IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNP O
TB. TB. 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 IN NNP NNP NNP RB O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP RB VBD O
retrospectively retrospectively 0 0 0 0 0 0 0 0 15 0 NNP NNP RB VBD DT O
reviewed reviewed 0 0 0 0 0 0 0 0 8 0 NNP RB VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 RB VBD DT JJ NN O
acid-fast acid-fast 0 0 1 0 0 0 0 0 9 0 VBD DT JJ NN NN O
bacillus bacillus 0 0 0 0 0 0 0 0 8 0 DT JJ NN NN NN O
(AFB) (AFB) 0 1 0 0 0 0 0 0 5 0 JJ NN NN NN CC O
smear smear 0 0 0 0 0 0 0 0 5 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NNS O
culture culture 0 0 0 0 0 0 0 0 7 0 NN CC NN NNS IN O
results results 0 0 0 0 0 0 0 0 7 0 CC NN NNS IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN CD JJ O
three three 0 0 0 0 0 0 0 0 5 0 NNS IN CD JJ NN O
consecutive consecutive 0 0 0 0 0 0 0 0 11 0 IN CD JJ NN NN O
days' days' 0 0 0 0 0 1 0 0 5 0 CD JJ NN NN NNS O
sputum sputum 0 0 0 0 0 0 0 0 6 0 JJ NN NN NNS IN O
specimens specimens 0 0 0 0 0 0 0 0 9 0 NN NN NNS IN CD O
from from 0 0 0 0 0 0 0 0 4 0 NN NNS IN CD VBN O
413 413 0 0 0 0 0 0 1 1 3 0 NNS IN CD VBN NNP O
confirmed confirmed 0 0 0 0 0 0 0 0 9 0 IN CD VBN NNP NNS O
TB TB 1 1 0 0 0 0 0 0 2 0 CD VBN NNP NNS WDT O
patients patients 0 0 0 0 0 0 0 0 8 0 VBN NNP NNS WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 NNP NNS WDT VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNS WDT VBD VBN IN O
detected detected 0 0 0 0 0 0 0 0 8 0 WDT VBD VBN IN NN O
as as 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN IN O
part part 0 0 0 0 0 0 0 0 4 0 VBN IN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN DT JJR O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJR JJ O
larger larger 0 0 0 0 0 0 0 0 6 0 IN DT JJR JJ NN O
active active 0 0 0 0 0 0 0 0 6 0 DT JJR JJ NN NN O
case case 0 0 0 0 0 0 0 0 4 0 JJR JJ NN NN NN O
finding finding 0 0 0 0 0 0 0 0 7 0 JJ NN NN NN IN O
study study 0 0 0 0 0 0 0 0 5 0 NN NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
Dhaka Dhaka 1 0 0 0 0 0 0 0 5 0 NN IN NNP NNP NNP O
Central Central 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP DT O
Jail, Jail, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJS JJ O
largest largest 0 0 0 0 0 0 0 0 7 0 NNP DT JJS JJ NN O
correctional correctional 0 0 0 0 0 0 0 0 12 0 DT JJS JJ NN IN O
facility facility 0 0 0 0 0 0 0 0 8 0 JJS JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
Bangladesh. Bangladesh. 1 0 0 0 0 0 0 0 11 0 NN IN NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 IN NNP NNP NNP VBD O
AFB AFB 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
detected detected 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN IN CD O
from from 0 0 0 0 0 0 0 0 4 0 VBD VBN IN CD JJ O
81% 81% 0 0 0 0 0 0 0 1 3 0 VBN IN CD JJ NN O
(n (n 0 0 0 0 0 0 0 0 2 0 IN CD JJ NN CD O
= = 0 0 0 0 0 0 0 0 1 0 CD JJ NN CD NN O
334) 334) 0 0 0 0 0 0 0 1 4 0 JJ NN CD NN IN O
patients, patients, 0 0 0 0 1 0 0 0 9 0 NN CD NN IN WDT O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN WDT CD O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT CD -NONE- O
89% 89% 0 0 0 0 0 0 0 1 3 0 IN WDT CD -NONE- : O
(n (n 0 0 0 0 0 0 0 0 2 0 WDT CD -NONE- : CD O
= = 0 0 0 0 0 0 0 0 1 0 CD -NONE- : CD VBD O
297) 297) 0 0 0 0 0 0 0 1 4 0 -NONE- : CD VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 : CD VBD VBN IN O
diagnosed diagnosed 0 0 0 0 0 0 0 0 9 0 CD VBD VBN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 VBD VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ CC O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC JJ CD O
additional additional 0 0 0 0 0 0 0 0 10 0 JJ CC JJ CD JJ O
9% 9% 0 0 0 0 0 0 0 1 2 0 CC JJ CD JJ NN O
(n (n 0 0 0 0 0 0 0 0 2 0 JJ CD JJ NN CD O
= = 0 0 0 0 0 0 0 0 1 0 CD JJ NN CD VBD O
30) 30) 0 0 0 0 0 0 0 1 3 0 JJ NN CD VBD IN O
were were 0 0 0 0 0 0 0 0 4 0 NN CD VBD IN DT O
from from 0 0 0 0 0 0 0 0 4 0 CD VBD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT JJ NN O
second second 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN NNP O
sputum sputum 0 0 0 0 0 0 0 0 6 0 DT JJ NN NNP NNP O
specimen. specimen. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NNP NN O
M. M. 1 1 0 0 0 0 0 0 2 0 NN NNP NNP NN NN O
tuberculosis tuberculosis 0 0 0 0 0 0 0 0 12 0 NNP NNP NN NN VBD O
growth growth 0 0 0 0 0 0 0 0 6 0 NNP NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN CD O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN CD NNS O
406 406 0 0 0 0 0 0 1 1 3 0 VBN IN CD NNS CC O
patients patients 0 0 0 0 0 0 0 0 8 0 IN CD NNS CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD NNS CC CD JJ O
85% 85% 0 0 0 0 0 0 0 1 3 0 NNS CC CD JJ NN O
(n (n 0 0 0 0 0 0 0 0 2 0 CC CD JJ NN CD O
= = 0 0 0 0 0 0 0 0 1 0 CD JJ NN CD VBD O
343) 343) 0 0 0 0 0 0 0 1 4 0 JJ NN CD VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN CD VBD VBN IN O
obtained obtained 0 0 0 0 0 0 0 0 8 0 CD VBD VBN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 VBD VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN CC O
sputum sputum 0 0 0 0 0 0 0 0 6 0 DT JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ CD O
additional additional 0 0 0 0 0 0 0 0 10 0 NN CC JJ CD JJ O
10% 10% 0 0 0 0 0 0 0 1 3 0 CC JJ CD JJ NN O
(n (n 0 0 0 0 0 0 0 0 2 0 JJ CD JJ NN CD O
= = 0 0 0 0 0 0 0 0 1 0 CD JJ NN CD VBD O
42) 42) 0 0 0 0 0 0 0 1 3 0 JJ NN CD VBD IN O
were were 0 0 0 0 0 0 0 0 4 0 NN CD VBD IN DT O
from from 0 0 0 0 0 0 0 0 4 0 CD VBD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT JJ NNP O
second second 0 0 0 0 0 0 0 0 6 0 IN DT JJ NNP NNP O
one. one. 0 0 0 0 0 0 0 0 4 0 DT JJ NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP JJ NNS O
third third 0 0 0 0 0 0 0 0 5 0 NNP NNP JJ NNS RB O
specimen specimen 0 0 0 0 0 0 0 0 8 0 NNP JJ NNS RB VBP O
didn't didn't 0 0 0 0 0 1 0 0 6 0 JJ NNS RB VBP JJ O
show show 0 0 0 0 0 0 0 0 4 0 NNS RB VBP JJ JJ O
significant significant 0 0 0 0 0 0 0 0 11 0 RB VBP JJ JJ JJ O
additional additional 0 0 0 0 0 0 0 0 10 0 VBP JJ JJ JJ NN O
diagnostic diagnostic 0 0 0 0 0 0 0 0 10 0 JJ JJ JJ NN IN O
value value 0 0 0 0 0 0 0 0 5 0 JJ JJ NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
detection detection 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
AFB AFB 1 1 0 0 0 0 0 0 3 0 NN IN NNP IN NN O
by by 0 0 0 0 0 0 0 0 2 0 IN NNP IN NN CC O
microscopy microscopy 0 0 0 0 0 0 0 0 10 0 NNP IN NN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 IN NN CC NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 NN CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
M. M. 1 1 0 0 0 0 0 0 2 0 IN DT NNP NNP NNP O
tuberculosis. tuberculosis. 0 0 0 0 0 0 0 0 13 0 DT NNP NNP NNP NNP O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 NNP NNP NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBD IN O
concluded concluded 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD IN PRP$ O
from from 0 0 0 0 0 0 0 0 4 0 NNP VBD IN PRP$ NN O
our our 0 0 0 0 0 0 0 0 3 0 VBD IN PRP$ NN NNS O
study study 0 0 0 0 0 0 0 0 5 0 IN PRP$ NN NNS WDT O
results results 0 0 0 0 0 0 0 0 7 0 PRP$ NN NNS WDT VBG O
that that 0 0 0 0 0 0 0 0 4 0 NN NNS WDT VBG CD O
examining examining 0 0 0 0 0 0 0 0 9 0 NNS WDT VBG CD JJ O
two two 0 0 0 0 0 0 0 0 3 0 WDT VBG CD JJ NN O
consecutive consecutive 0 0 0 0 0 0 0 0 11 0 VBG CD JJ NN NNS O
sputum sputum 0 0 0 0 0 0 0 0 6 0 CD JJ NN NNS VBZ O
specimens specimens 0 0 0 0 0 0 0 0 9 0 JJ NN NNS VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN NNS VBZ JJ RB O
sufficient sufficient 0 0 0 0 0 0 0 0 10 0 NNS VBZ JJ RB IN O
enough enough 0 0 0 0 0 0 0 0 6 0 VBZ JJ RB IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ RB IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT JJ NN O
effective effective 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN IN O
diagnosis diagnosis 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
TB. TB. 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNP MD O
It It 1 0 0 0 0 0 0 0 2 0 IN NNP NNP MD RB O
can can 0 0 0 0 0 0 0 0 3 0 NNP NNP MD RB VB O
also also 0 0 0 0 0 0 0 0 4 0 NNP MD RB VB DT O
decrease decrease 0 0 0 0 0 0 0 0 8 0 MD RB VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VB DT NN NN O
laboratory laboratory 0 0 0 0 0 0 0 0 10 0 VB DT NN NN CC O
workload workload 0 0 0 0 0 0 0 0 8 0 DT NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN VB O
hence hence 0 0 0 0 0 0 0 0 5 0 NN CC NN VB DT O
improve improve 0 0 0 0 0 0 0 0 7 0 CC NN VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VB DT NN IN O
quality quality 0 0 0 0 0 0 0 0 7 0 VB DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
work work 0 0 0 0 0 0 0 0 4 0 NN IN NN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NNS IN O
settings settings 0 0 0 0 0 0 0 0 8 0 NN IN NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN JJ NNP O
high high 0 0 0 0 0 0 0 0 4 0 NNS IN JJ NNP NN O
TB TB 1 1 0 0 0 0 0 0 2 0 IN JJ NNP NN IN O
burden burden 0 0 0 0 0 0 0 0 6 0 JJ NNP NN IN NNP O
like like 0 0 0 0 0 0 0 0 4 0 NNP NN IN NNP NONE O
Bangladesh. Bangladesh. 1 0 0 0 0 0 0 0 11 0 NN IN NNP NONE NONE O
Posttranslational Posttranslational 1 0 0 0 0 0 0 0 17 0 NONE NONE NNP NNS IN O
modifications modifications 0 0 0 0 0 0 0 0 13 0 NONE NNP NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN CD O
histone histone 0 0 0 0 0 0 0 0 7 0 IN DT NN CD NN O
3 3 0 0 0 0 0 0 1 1 1 0 DT NN CD NN CC O
tail tail 0 0 0 0 0 0 0 0 4 0 NN CD NN CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 CD NN CC PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 NN CC PRP$ NN IN O
impact impact 0 0 0 0 0 0 0 0 6 0 CC PRP$ NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 PRP$ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
histone histone 0 0 0 0 0 0 0 0 7 0 NN IN NN NN NNS O
lysine lysine 0 0 0 0 0 0 0 0 6 0 IN NN NN NNS IN O
demethylases demethylases 0 0 0 0 0 0 0 0 12 0 NN NN NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP NNP O
vitro. vitro. 0 0 0 0 0 0 0 0 6 0 NNS IN NNP NNP NNP O
Lohse Lohse 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Helgstrand Helgstrand 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kristensen Kristensen 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
JB, JB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Leurs Leurs 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
U, U, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Cloos Cloos 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
PA, PA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Kristensen Kristensen 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
JL, JL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Clausen Clausen 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
RP. RP. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Drug Drug 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP CC O
Design Design 1 0 0 0 0 0 0 0 6 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Pharmacology, Pharmacology, 1 0 0 0 1 0 0 0 13 0 NNP CC NNP NNP IN O
Faculty Faculty 1 0 0 0 0 0 0 0 7 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Health Health 1 0 0 0 0 0 0 0 6 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP CC NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 CC NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Copenhagen, Copenhagen, 1 0 0 0 1 0 0 0 11 0 NNP IN NNP NNP NNP O
Copenhagen, Copenhagen, 1 0 0 0 1 0 0 0 11 0 IN NNP NNP NNP NNP O
Denmark. Denmark. 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNS O
Posttranslational Posttranslational 1 0 0 0 0 0 0 0 17 0 NNP NNP NNP NNS -NONE- O
modifications modifications 0 0 0 0 0 0 0 0 13 0 NNP NNP NNS -NONE- IN O
(PTMs) (PTMs) 0 0 0 0 0 0 0 0 6 0 NNP NNS -NONE- IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNS -NONE- IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- IN DT NN NNP O
histone histone 0 0 0 0 0 0 0 0 7 0 IN DT NN NNP NN O
H3 H3 1 1 0 0 0 0 0 1 2 0 DT NN NNP NN JJ O
tail tail 0 0 0 0 0 0 0 0 4 0 NN NNP NN JJ IN O
such such 0 0 0 0 0 0 0 0 4 0 NNP NN JJ IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 NN JJ IN JJ NN O
methylation, methylation, 0 0 0 0 1 0 0 0 12 0 JJ IN JJ NN CC O
acetylation acetylation 0 0 0 0 0 0 0 0 11 0 IN JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 NN CC NN NN JJ O
play play 0 0 0 0 0 0 0 0 4 0 CC NN NN JJ NNS O
important important 0 0 0 0 0 0 0 0 9 0 NN NN JJ NNS IN O
roles roles 0 0 0 0 0 0 0 0 5 0 NN JJ NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NNP O
epigenetic epigenetic 0 0 0 0 0 0 0 0 10 0 NNS IN JJ NNP NNP O
signaling. signaling. 0 0 0 0 0 0 0 0 10 0 IN JJ NNP NNP PRP O
Here Here 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP DT O
study study 0 0 0 0 0 0 0 0 5 0 NNP PRP VBP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBP DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 VBP DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT IN O
some some 0 0 0 0 0 0 0 0 4 0 NN IN DT IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN DT IN DT NNP O
these these 0 0 0 0 0 0 0 0 5 0 DT IN DT NNP IN O
PTMs PTMs 1 0 0 0 0 0 0 0 4 0 IN DT NNP IN DT O
on on 0 0 0 0 0 0 0 0 2 0 DT NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN NNS O
demethylation demethylation 0 0 0 0 0 0 0 0 13 0 IN DT NN NNS IN O
rates rates 0 0 0 0 0 0 0 0 5 0 DT NN NNS IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN VBN NN O
methylated methylated 0 0 0 0 0 0 0 0 10 0 NNS IN VBN NN CD O
lysine lysine 0 0 0 0 0 0 0 0 6 0 IN VBN NN CD IN O
9 9 0 0 0 0 0 0 1 1 1 0 VBN NN CD IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN CD IN NN VBG O
vitro vitro 0 0 0 0 0 0 0 0 5 0 CD IN NN VBG NN O
using using 0 0 0 0 0 0 0 0 5 0 IN NN VBG NN NNS O
peptide peptide 0 0 0 0 0 0 0 0 7 0 NN VBG NN NNS VBG O
substrates substrates 0 0 0 0 0 0 0 0 10 0 VBG NN NNS VBG NN O
mimicking mimicking 0 0 0 0 0 0 0 0 9 0 NN NNS VBG NN NNP O
histone histone 0 0 0 0 0 0 0 0 7 0 NNS VBG NN NNP NNP O
H3. H3. 1 1 0 0 0 0 0 1 3 0 VBG NN NNP NNP NNS O
Various Various 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NNS IN O
combinations combinations 0 0 0 0 0 0 0 0 12 0 NNP NNP NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNS IN JJ NNS O
other other 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NNS VBD O
PTMs PTMs 1 0 0 0 0 0 0 0 4 0 IN JJ NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD VBN TO O
employed employed 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO NN JJ O
study study 0 0 0 0 0 0 0 0 5 0 VBN TO NN JJ JJ O
possible possible 0 0 0 0 0 0 0 0 8 0 TO NN JJ JJ NNS O
cross-talk cross-talk 0 0 1 0 0 0 0 0 10 0 NN JJ JJ NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 JJ JJ NNS IN VBG O
by by 0 0 0 0 0 0 0 0 2 0 JJ NNS IN VBG NN O
comparing comparing 0 0 0 0 0 0 0 0 9 0 NNS IN VBG NN JJ O
enzyme enzyme 0 0 0 0 0 0 0 0 6 0 IN VBG NN JJ NNP O
kinetic kinetic 0 0 0 0 0 0 0 0 7 0 VBG NN JJ NNP NNP O
characteristics. characteristics. 0 0 0 0 0 0 0 0 16 0 NN JJ NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP VBD DT O
compared compared 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NNS IN O
kinetics kinetics 0 0 0 0 0 0 0 0 8 0 VBD DT NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NN NN O
histone histone 0 0 0 0 0 0 0 0 7 0 NNS IN NN NN VBZ O
tail tail 0 0 0 0 0 0 0 0 4 0 IN NN NN VBZ IN O
substrates substrates 0 0 0 0 0 0 0 0 10 0 NN NN VBZ IN VBN O
for for 0 0 0 0 0 0 0 0 3 0 NN VBZ IN VBN NN O
truncated truncated 0 0 0 0 0 0 0 0 9 0 VBZ IN VBN NN NN O
histone histone 0 0 0 0 0 0 0 0 7 0 IN VBN NN NN NNS O
lysine lysine 0 0 0 0 0 0 0 0 6 0 VBN NN NN NNS NNP O
demethylases demethylases 0 0 0 0 0 0 0 0 12 0 NN NN NNS NNP CC O
KDM4A KDM4A 1 1 0 0 0 0 0 1 5 0 NN NNS NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNS NNP CC NNP NN O
KDM4C KDM4C 1 1 0 0 0 0 0 1 5 0 NNP CC NNP NN RB O
containing containing 0 0 0 0 0 0 0 0 10 0 CC NNP NN RB DT O
only only 0 0 0 0 0 0 0 0 4 0 NNP NN RB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN RB DT JJ NN O
catalytic catalytic 0 0 0 0 0 0 0 0 9 0 RB DT JJ NN NN O
core core 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN CC O
(cc) (cc) 0 0 0 0 0 0 0 0 4 0 JJ NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT NNS O
some some 0 0 0 0 0 0 0 0 4 0 NN CC DT NNS VBD O
combinations combinations 0 0 0 0 0 0 0 0 12 0 CC DT NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 DT NNS VBD VBN IN O
characterized characterized 0 0 0 0 0 0 0 0 13 0 NNS VBD VBN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NN O
full full 0 0 0 0 0 0 0 0 4 0 VBN IN JJ NN NN O
length length 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN NNP O
(FL) (FL) 0 1 0 0 0 0 0 0 4 0 JJ NN NN NNP CC O
KDM4A KDM4A 1 1 0 0 0 0 0 1 5 0 NN NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP NNP O
KDM4C. KDM4C. 1 1 0 0 0 0 0 1 6 0 NNP CC NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 CC NNP NNP VBD IN O
found found 0 0 0 0 0 0 0 0 5 0 NNP NNP VBD IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBD IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NNS VBG O
substrates substrates 0 0 0 0 0 0 0 0 10 0 IN DT NNS VBG VBN O
combining combining 0 0 0 0 0 0 0 0 9 0 DT NNS VBG VBN NNP O
trimethylated trimethylated 0 0 0 0 0 0 0 0 13 0 NNS VBG VBN NNP CC O
K4 K4 1 1 0 0 0 0 0 1 2 0 VBG VBN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VBN NNP CC NNP VBD O
K9 K9 1 1 0 0 0 0 0 1 2 0 NNP CC NNP VBD IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 CC NNP VBD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP VBD IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBD IN DT JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 IN DT JJ NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
catalytic catalytic 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NNP NNP O
FL-KDM4A. FL-KDM4A. 1 1 1 0 0 0 0 1 9 0 NN IN NNP NNP DT O
For For 1 0 0 0 0 0 0 0 3 0 IN NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NNS O
truncated truncated 0 0 0 0 0 0 0 0 9 0 NNP DT JJ NNS IN O
versions versions 0 0 0 0 0 0 0 0 8 0 DT JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP CC O
KDM4A KDM4A 1 1 0 0 0 0 0 1 5 0 NNS IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP DT O
KDM4C KDM4C 1 1 0 0 0 0 0 1 5 0 NNP CC NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 CC NNP DT JJ NN O
two-fold two-fold 0 0 1 0 0 0 0 0 8 0 NNP DT JJ NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
catalytic catalytic 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN JJ O
toward toward 0 0 0 0 0 0 0 0 6 0 JJ NN IN JJ NNS O
bis-trimethylated bis-trimethylated 0 0 1 0 0 0 0 0 17 0 NN IN JJ NNS MD O
substrates substrates 0 0 0 0 0 0 0 0 10 0 IN JJ NNS MD VB O
could could 0 0 0 0 0 0 0 0 5 0 JJ NNS MD VB NNP O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB NNP NNP O
observed. observed. 0 0 0 0 0 0 0 0 9 0 MD VB NNP NNP DT O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 VB NNP NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 NNP DT JJ NN IN O
difference difference 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
catalytic catalytic 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN VBN O
between between 0 0 0 0 0 0 0 0 7 0 JJ NN IN VBN CC O
dimethylated dimethylated 0 0 0 0 0 0 0 0 12 0 NN IN VBN CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 IN VBN CC VBN NNS O
trimethylated trimethylated 0 0 0 0 0 0 0 0 13 0 VBN CC VBN NNS VBD O
substrates substrates 0 0 0 0 0 0 0 0 10 0 CC VBN NNS VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 VBN NNS VBD VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 NNS VBD VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN JJ NN O
full full 0 0 0 0 0 0 0 0 4 0 VBN IN JJ NN NNS O
length length 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNS IN O
demethylases demethylases 0 0 0 0 0 0 0 0 12 0 JJ NN NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN IN O
line line 0 0 0 0 0 0 0 0 4 0 NNS IN NN IN WP O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN WP VBZ O
what what 0 0 0 0 0 0 0 0 4 0 NN IN WP VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 IN WP VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 WP VBZ VBN VBN RB O
reported reported 0 0 0 0 0 0 0 0 8 0 VBZ VBN VBN RB IN O
previously previously 0 0 0 0 0 0 0 0 10 0 VBN VBN RB IN VBN O
for for 0 0 0 0 0 0 0 0 3 0 VBN RB IN VBN NNP O
truncated truncated 0 0 0 0 0 0 0 0 9 0 RB IN VBN NNP NNP O
demethylases. demethylases. 0 0 0 0 0 0 0 0 13 0 IN VBN NNP NNP NN O
Histone Histone 1 0 0 0 0 0 0 0 7 0 VBN NNP NNP NN VBZ O
peptide peptide 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBZ VBN O
substrates substrates 0 0 0 0 0 0 0 0 10 0 NNP NN VBZ VBN IN O
phosphorylated phosphorylated 0 0 0 0 0 0 0 0 14 0 NN VBZ VBN IN NNP O
at at 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN NNP MD O
T11 T11 1 1 0 0 0 0 0 1 3 0 VBN IN NNP MD RB O
could could 0 0 0 0 0 0 0 0 5 0 IN NNP MD RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NNP MD RB VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 MD RB VB VBN IN O
demethylated demethylated 0 0 0 0 0 0 0 0 12 0 RB VB VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VB VBN IN DT VBN O
neither neither 0 0 0 0 0 0 0 0 7 0 VBN IN DT VBN CC O
truncated truncated 0 0 0 0 0 0 0 0 9 0 IN DT VBN CC JJ O
nor nor 0 0 0 0 0 0 0 0 3 0 DT VBN CC JJ NN O
full full 0 0 0 0 0 0 0 0 4 0 VBN CC JJ NN NNP O
length length 0 0 0 0 0 0 0 0 6 0 CC JJ NN NNP CC O
KDM4A KDM4A 1 1 0 0 0 0 0 1 5 0 JJ NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP NN O
KDM4C, KDM4C, 1 1 0 0 1 0 0 1 6 0 NNP CC NNP NN WDT O
suggesting suggesting 0 0 0 0 0 0 0 0 10 0 CC NNP NN WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 NNP NN WDT NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 NN WDT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 WDT NN IN NN CD O
threonine threonine 0 0 0 0 0 0 0 0 9 0 NN IN NN CD NNS O
11 11 0 0 0 0 0 0 1 1 2 0 IN NN CD NNS NN O
prevents prevents 0 0 0 0 0 0 0 0 8 0 NN CD NNS NN IN O
demethylation demethylation 0 0 0 0 0 0 0 0 13 0 CD NNS NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNS NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
H3K9me3 H3K9me3 1 0 0 0 0 0 0 1 7 0 IN DT NNP NN IN O
mark mark 0 0 0 0 0 0 0 0 4 0 DT NNP NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
same same 0 0 0 0 0 0 0 0 4 0 IN DT JJ NNP NNP O
peptide. peptide. 0 0 0 0 0 0 0 0 8 0 DT JJ NNP NNP IN O
Acetylation Acetylation 1 0 0 0 0 0 0 0 11 0 JJ NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP VBD O
K14 K14 1 1 0 0 0 0 0 1 3 0 NNP IN NNP VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 IN NNP VBD RB VBN O
also also 0 0 0 0 0 0 0 0 4 0 NNP VBD RB VBN TO O
found found 0 0 0 0 0 0 0 0 5 0 VBD RB VBN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 RB VBN TO NN NN O
influence influence 0 0 0 0 0 0 0 0 9 0 VBN TO NN NN NNS O
demethylation demethylation 0 0 0 0 0 0 0 0 13 0 TO NN NN NNS NNP O
rates rates 0 0 0 0 0 0 0 0 5 0 NN NN NNS NNP NNP O
significantly. significantly. 0 0 0 0 0 0 0 0 14 0 NN NNS NNP NNP IN O
Thus, Thus, 1 0 0 0 1 0 0 0 5 0 NNS NNP NNP IN VBN O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN VBN -NONE- O
truncated truncated 0 0 0 0 0 0 0 0 9 0 NNP IN VBN -NONE- NN O
KDM4A, KDM4A, 1 1 0 0 1 0 0 1 6 0 IN VBN -NONE- NN IN O
acetylation acetylation 0 0 0 0 0 0 0 0 11 0 VBN -NONE- NN IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 -NONE- NN IN NNP IN O
K14 K14 1 1 0 0 0 0 0 1 3 0 NN IN NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN NNS O
substrate substrate 0 0 0 0 0 0 0 0 9 0 IN DT NN NNS TO O
leads leads 0 0 0 0 0 0 0 0 5 0 DT NN NNS TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NNS TO DT NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 TO DT NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ JJ O
enzymatic enzymatic 0 0 0 0 0 0 0 0 9 0 NN IN JJ JJ NN O
catalytic catalytic 0 0 0 0 0 0 0 0 9 0 IN JJ JJ NN NN O
efficiency efficiency 0 0 0 0 0 0 0 0 10 0 JJ JJ NN NN NN O
(k (k 0 0 0 0 0 0 0 0 2 0 JJ NN NN NN NN O
cat/K cat/K 0 0 0 1 0 0 0 0 5 0 NN NN NN NN IN O
m), m), 0 0 0 0 1 0 0 0 3 0 NN NN NN IN IN O
while while 0 0 0 0 0 0 0 0 5 0 NN NN IN IN VBN O
for for 0 0 0 0 0 0 0 0 3 0 NN IN IN VBN NNP O
truncated truncated 0 0 0 0 0 0 0 0 9 0 IN IN VBN NNP PRP O
KDM4C KDM4C 1 1 0 0 0 0 0 1 5 0 IN VBN NNP PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 VBN NNP PRP VBZ DT O
induces induces 0 0 0 0 0 0 0 0 7 0 NNP PRP VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 PRP VBZ DT NN RB O
decrease, decrease, 0 0 0 0 1 0 0 0 9 0 VBZ DT NN RB VBN O
primarily primarily 0 0 0 0 0 0 0 0 9 0 DT NN RB VBN IN O
caused caused 0 0 0 0 0 0 0 0 6 0 NN RB VBN IN NNS O
by by 0 0 0 0 0 0 0 0 2 0 RB VBN IN NNS IN O
changes changes 0 0 0 0 0 0 0 0 7 0 VBN IN NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN NNP NNP O
K K 1 1 0 0 0 0 0 0 1 0 NNS IN NNP NNP NNP O
m. m. 0 0 0 0 0 0 0 0 2 0 IN NNP NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NN VBZ O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ IN O
demonstrates demonstrates 0 0 0 0 0 0 0 0 12 0 NNP NN VBZ IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NN VBZ IN NN NNS O
demethylation demethylation 0 0 0 0 0 0 0 0 13 0 VBZ IN NN NNS NNS O
activities activities 0 0 0 0 0 0 0 0 10 0 IN NN NNS NNS VBD O
towards towards 0 0 0 0 0 0 0 0 7 0 NN NNS NNS VBD NNP O
trimethylated trimethylated 0 0 0 0 0 0 0 0 13 0 NNS NNS VBD NNP VBP O
H3K9 H3K9 1 1 0 0 0 0 0 1 4 0 NNS VBD NNP VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 VBD NNP VBP RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNP VBP RB VBN IN O
influenced influenced 0 0 0 0 0 0 0 0 10 0 VBP RB VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 RB VBN IN JJ NNS O
other other 0 0 0 0 0 0 0 0 5 0 VBN IN JJ NNS IN O
PTMs PTMs 1 0 0 0 0 0 0 0 4 0 IN JJ NNS IN DT O
on on 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
same same 0 0 0 0 0 0 0 0 4 0 IN DT JJ NN CC O
peptide, peptide, 0 0 0 0 1 0 0 0 8 0 DT JJ NN CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBZ DT O
emphasizes emphasizes 0 0 0 0 0 0 0 0 10 0 NN CC VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC VBZ DT NN IN O
importance importance 0 0 0 0 0 0 0 0 10 0 VBZ DT NN IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN VBG DT O
studying studying 0 0 0 0 0 0 0 0 8 0 NN IN VBG DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 IN VBG DT NNS IN O
interactions interactions 0 0 0 0 0 0 0 0 12 0 VBG DT NNS IN DT O
at at 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
peptide peptide 0 0 0 0 0 0 0 0 7 0 IN DT NN NN TO O
level level 0 0 0 0 0 0 0 0 5 0 DT NN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO VB DT O
get get 0 0 0 0 0 0 0 0 3 0 NN TO VB DT RBR O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT RBR JJ O
more more 0 0 0 0 0 0 0 0 4 0 VB DT RBR JJ NN O
detailed detailed 0 0 0 0 0 0 0 0 8 0 DT RBR JJ NN IN O
understanding understanding 0 0 0 0 0 0 0 0 13 0 RBR JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS IN O
dynamics dynamics 0 0 0 0 0 0 0 0 8 0 IN DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NNP O
epigenetic epigenetic 0 0 0 0 0 0 0 0 10 0 NNS IN JJ NNP NONE O
marks. marks. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NONE NONE O
Subglacial Subglacial 1 0 0 0 0 0 0 0 10 0 NONE NONE JJ NN NN O
lake lake 0 0 0 0 0 0 0 0 4 0 NONE JJ NN NN NN O
vostok vostok 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN NN O
(antarctica) (antarctica) 0 0 0 0 0 0 0 0 12 0 NN NN NN NN NN O
accretion accretion 0 0 0 0 0 0 0 0 9 0 NN NN NN NN VBZ O
ice ice 0 0 0 0 0 0 0 0 3 0 NN NN NN VBZ DT O
contains contains 0 0 0 0 0 0 0 0 8 0 NN NN VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT JJ NN O
diverse diverse 0 0 0 0 0 0 0 0 7 0 VBZ DT JJ NN IN O
set set 0 0 0 0 0 0 0 0 3 0 DT JJ NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS IN O
sequences sequences 0 0 0 0 0 0 0 0 9 0 NN IN NNS IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 IN NNS IN NNP NN O
aquatic, aquatic, 0 0 0 0 1 0 0 0 8 0 NNS IN NNP NN CC O
marine marine 0 0 0 0 0 0 0 0 6 0 IN NNP NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC JJ NN O
sediment-inhabiting sediment-inhabiting 0 0 1 0 0 0 0 0 19 0 NN CC JJ NN CC O
bacteria bacteria 0 0 0 0 0 0 0 0 8 0 CC JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP NNP O
eukarya. eukarya. 0 0 0 0 0 0 0 0 8 0 NN CC NNP NNP NNP O
Shtarkman Shtarkman 1 0 0 0 0 0 0 0 9 0 CC NNP NNP NNP NNP O
YM, YM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Koçer Koçer 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
ZA, ZA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Edgar Edgar 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Veerapaneni Veerapaneni 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
RS, RS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
D'Elia D'Elia 1 0 0 0 0 1 0 0 6 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Morris Morris 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
PF, PF, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Rogers Rogers 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
SO. SO. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biological Biological 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Bowling Bowling 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Green Green 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
State State 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Bowling Bowling 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Green, Green, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
Ohio, Ohio, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNPS O
United United 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNPS IN O
States States 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
America. America. 1 0 0 0 0 0 0 0 8 0 NNPS IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
Lake Lake 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP DT O
Vostok, Vostok, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP DT CD O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT CD JJS O
7(th) 7(th) 0 0 0 0 0 0 0 1 5 0 NNP DT CD JJS JJ O
largest largest 0 0 0 0 0 0 0 0 7 0 DT CD JJS JJ NN O
(by (by 0 0 0 0 0 0 0 0 3 0 CD JJS JJ NN CC O
volume) volume) 0 0 0 0 0 0 0 0 7 0 JJS JJ NN CC CD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC CD NN O
4(th) 4(th) 0 0 0 0 0 0 0 1 5 0 NN CC CD NN NN O
deepest deepest 0 0 0 0 0 0 0 0 7 0 CC CD NN NN IN O
lake lake 0 0 0 0 0 0 0 0 4 0 CD NN NN IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP VBZ O
Earth, Earth, 1 0 0 0 1 0 0 0 6 0 NN IN NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ VBN IN O
covered covered 0 0 0 0 0 0 0 0 7 0 NNP VBZ VBN IN RBR O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN RBR IN O
more more 0 0 0 0 0 0 0 0 4 0 VBN IN RBR IN CD O
than than 0 0 0 0 0 0 0 0 4 0 IN RBR IN CD NN O
3,700 3,700 0 0 0 0 1 0 0 1 5 0 RBR IN CD NN IN O
m m 0 0 0 0 0 0 0 0 1 0 IN CD NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN NNP VBG O
ice, ice, 0 0 0 0 1 0 0 0 4 0 NN IN NNP VBG PRP O
making making 0 0 0 0 0 0 0 0 6 0 IN NNP VBG PRP DT O
it it 0 0 0 0 0 0 0 0 2 0 NNP VBG PRP DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 VBG PRP DT JJS JJ O
largest largest 0 0 0 0 0 0 0 0 7 0 PRP DT JJS JJ NN O
subglacial subglacial 0 0 0 0 0 0 0 0 10 0 DT JJS JJ NN NNP O
lake lake 0 0 0 0 0 0 0 0 4 0 JJS JJ NN NNP NNP O
known. known. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
combination combination 0 0 0 0 0 0 0 0 11 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NN O
cold, cold, 0 0 0 0 1 0 0 0 5 0 NN IN NNP NN -NONE- O
heat heat 0 0 0 0 0 0 0 0 4 0 IN NNP NN -NONE- JJ O
(from (from 0 0 0 0 0 0 0 0 5 0 NNP NN -NONE- JJ JJ O
possible possible 0 0 0 0 0 0 0 0 8 0 NN -NONE- JJ JJ NN O
hydrothermal hydrothermal 0 0 0 0 0 0 0 0 12 0 -NONE- JJ JJ NN NN O
activity), activity), 0 0 0 0 1 0 0 0 10 0 JJ JJ NN NN NN O
pressure pressure 0 0 0 0 0 0 0 0 8 0 JJ NN NN NN DT O
(from (from 0 0 0 0 0 0 0 0 5 0 NN NN NN DT VBG O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT VBG NN O
overriding overriding 0 0 0 0 0 0 0 0 10 0 NN DT VBG NN VBN O
glacier), glacier), 0 0 0 0 1 0 0 0 9 0 DT VBG NN VBN NNS O
limited limited 0 0 0 0 0 0 0 0 7 0 VBG NN VBN NNS CC O
nutrients nutrients 0 0 0 0 0 0 0 0 9 0 NN VBN NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBN NNS CC JJ NN O
complete complete 0 0 0 0 0 0 0 0 8 0 NNS CC JJ NN NNS O
darkness darkness 0 0 0 0 0 0 0 0 8 0 CC JJ NN NNS VBP O
presents presents 0 0 0 0 0 0 0 0 8 0 JJ NN NNS VBP NNS O
extreme extreme 0 0 0 0 0 0 0 0 7 0 NN NNS VBP NNS TO O
challenges challenges 0 0 0 0 0 0 0 0 10 0 NNS VBP NNS TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 VBP NNS TO NNP NNP O
life. life. 0 0 0 0 0 0 0 0 5 0 NNS TO NNP NNP PRP O
Here, Here, 1 0 0 0 1 0 0 0 5 0 TO NNP NNP PRP NN O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP NN JJ O
report report 0 0 0 0 0 0 0 0 6 0 NNP PRP NN JJ NN O
metagenomic/metatranscriptomic metagenomic/metatranscriptomic 0 0 0 1 0 0 0 0 30 0 PRP NN JJ NN NNS O
sequence sequence 0 0 0 0 0 0 0 0 8 0 NN JJ NN NNS IN O
analyses analyses 0 0 0 0 0 0 0 0 8 0 JJ NN NNS IN CD O
from from 0 0 0 0 0 0 0 0 4 0 NN NNS IN CD NN O
four four 0 0 0 0 0 0 0 0 4 0 NNS IN CD NN NN O
accretion accretion 0 0 0 0 0 0 0 0 9 0 IN CD NN NN NNS O
ice ice 0 0 0 0 0 0 0 0 3 0 CD NN NN NNS IN O
sections sections 0 0 0 0 0 0 0 0 8 0 NN NN NNS IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NN NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP CD O
Vostok Vostok 1 0 0 0 0 0 0 0 6 0 IN DT NNP CD NN O
5G 5G 0 1 0 0 0 0 0 1 2 0 DT NNP CD NN NNP O
ice ice 0 0 0 0 0 0 0 0 3 0 NNP CD NN NNP NNP O
core. core. 0 0 0 0 0 0 0 0 5 0 CD NN NNP NNP NNS O
Two Two 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS VBD O
sections sections 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBD IN O
accreted accreted 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN IN O
vicinity vicinity 0 0 0 0 0 0 0 0 8 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT NN IN O
embayment embayment 0 0 0 0 0 0 0 0 9 0 IN DT NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
southwestern southwestern 0 0 0 0 0 0 0 0 12 0 IN DT NN NN IN O
end end 0 0 0 0 0 0 0 0 3 0 DT NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ CC O
lake, lake, 0 0 0 0 1 0 0 0 5 0 IN DT JJ CC DT O
and and 0 0 0 0 0 0 0 0 3 0 DT JJ CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ CC DT JJ CD O
other other 0 0 0 0 0 0 0 0 5 0 CC DT JJ CD JJ O
two two 0 0 0 0 0 0 0 0 3 0 DT JJ CD JJ NN O
represented represented 0 0 0 0 0 0 0 0 11 0 JJ CD JJ NN IN O
part part 0 0 0 0 0 0 0 0 4 0 CD JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
southern southern 0 0 0 0 0 0 0 0 8 0 IN DT NN NN NNP O
main main 0 0 0 0 0 0 0 0 4 0 DT NN NN NNP NNP O
basin. basin. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBD CD O
obtained obtained 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD CD NN O
3,507 3,507 0 0 0 0 1 0 0 1 5 0 NNP VBD CD NN NN O
unique unique 0 0 0 0 0 0 0 0 6 0 VBD CD NN NN NNS O
gene gene 0 0 0 0 0 0 0 0 4 0 CD NN NN NNS IN O
sequences sequences 0 0 0 0 0 0 0 0 9 0 NN NN NNS IN NNS O
from from 0 0 0 0 0 0 0 0 4 0 NN NNS IN NNS IN O
concentrates concentrates 0 0 0 0 0 0 0 0 12 0 NNS IN NNS IN CD O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN CD NN O
500 500 0 0 0 0 0 0 1 1 3 0 NNS IN CD NN IN O
ml ml 0 0 0 0 0 0 0 0 2 0 IN CD NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN CD JJ O
0.22 0.22 0 0 0 0 0 0 0 1 4 0 NN IN CD JJ NN O
µm-filtered µm-filtered 0 0 1 0 0 0 0 0 11 0 IN CD JJ NN NN O
accretion accretion 0 0 0 0 0 0 0 0 9 0 CD JJ NN NN NNP O
ice ice 0 0 0 0 0 0 0 0 3 0 JJ NN NN NNP NNP O
meltwater. meltwater. 0 0 0 0 0 0 0 0 10 0 NN NN NNP NNP NNS O
Taxonomic Taxonomic 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NNS -NONE- O
classifications classifications 0 0 0 0 0 0 0 0 15 0 NNP NNP NNS -NONE- VBZ O
(to (to 0 0 0 0 0 0 0 0 3 0 NNP NNS -NONE- VBZ JJ O
genus genus 0 0 0 0 0 0 0 0 5 0 NNS -NONE- VBZ JJ NN O
and/or and/or 0 0 0 1 0 0 0 0 6 0 -NONE- VBZ JJ NN VBD O
species) species) 0 0 0 0 0 0 0 0 8 0 VBZ JJ NN VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 JJ NN VBD JJ IN O
possible possible 0 0 0 0 0 0 0 0 8 0 NN VBD JJ IN CD O
for for 0 0 0 0 0 0 0 0 3 0 VBD JJ IN CD IN O
1,623 1,623 0 0 0 0 1 0 0 1 5 0 JJ IN CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN CD IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT NNP NNP O
sequences. sequences. 0 0 0 0 0 0 0 0 10 0 IN DT NNP NNP NNS O
Species Species 1 0 0 0 0 0 0 0 7 0 DT NNP NNP NNS IN O
determinations determinations 0 0 0 0 0 0 0 0 14 0 NNP NNP NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NN IN O
combination combination 0 0 0 0 0 0 0 0 11 0 NNS IN NN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN NNP NN O
mRNA mRNA 0 0 0 0 0 0 0 0 4 0 NN IN NNP NN NN O
gene gene 0 0 0 0 0 0 0 0 4 0 IN NNP NN NN NNS O
sequence sequence 0 0 0 0 0 0 0 0 8 0 NNP NN NN NNS VBD O
results results 0 0 0 0 0 0 0 0 7 0 NN NN NNS VBD NN O
allowed allowed 0 0 0 0 0 0 0 0 7 0 NN NNS VBD NN IN O
deduction deduction 0 0 0 0 0 0 0 0 9 0 NNS VBD NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNS O
metabolic metabolic 0 0 0 0 0 0 0 0 9 0 IN DT JJ NNS VBD O
pathways pathways 0 0 0 0 0 0 0 0 8 0 DT JJ NNS VBD IN O
represented represented 0 0 0 0 0 0 0 0 11 0 JJ NNS VBD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN NN O
accretion accretion 0 0 0 0 0 0 0 0 9 0 IN DT NN NN NN O
ice ice 0 0 0 0 0 0 0 0 3 0 DT NN NN NN IN O
and, and, 0 0 0 0 1 0 0 0 4 0 NN NN NN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP IN O
extension, extension, 0 0 0 0 1 0 0 0 10 0 NN IN NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP NNP O
lake. lake. 0 0 0 0 0 0 0 0 5 0 IN DT NNP NNP CD O
Approximately Approximately 1 0 0 0 0 0 0 0 13 0 DT NNP NNP CD IN O
94% 94% 0 0 0 0 0 0 0 1 3 0 NNP NNP CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP CD IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT NNS VBD O
sequences sequences 0 0 0 0 0 0 0 0 9 0 IN DT NNS VBD IN O
were were 0 0 0 0 0 0 0 0 4 0 DT NNS VBD IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NNP CC O
Bacteria Bacteria 1 0 0 0 0 0 0 0 8 0 VBD IN NNP CC CD O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC CD VBD O
6% 6% 0 0 0 0 0 0 0 1 2 0 NNP CC CD VBD IN O
were were 0 0 0 0 0 0 0 0 4 0 CC CD VBD IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 CD VBD IN NNP NNP O
Eukarya. Eukarya. 1 0 0 0 0 0 0 0 8 0 VBD IN NNP NNP CD O
Only Only 1 0 0 0 0 0 0 0 4 0 IN NNP NNP CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 NNP NNP CD NNS VBD O
sequences sequences 0 0 0 0 0 0 0 0 9 0 NNP CD NNS VBD IN O
were were 0 0 0 0 0 0 0 0 4 0 CD NNS VBD IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NNP NNP O
Archaea. Archaea. 1 0 0 0 0 0 0 0 8 0 VBD IN NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 IN NNP NNP NNP DT O
general, general, 0 0 0 0 1 0 0 0 8 0 NNP NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN VBD O
taxa taxa 0 0 0 0 0 0 0 0 4 0 NNP DT NN VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 DT NN VBD JJ TO O
similar similar 0 0 0 0 0 0 0 0 7 0 NN VBD JJ TO NNS O
to to 0 0 0 0 0 0 0 0 2 0 VBD JJ TO NNS RB O
organisms organisms 0 0 0 0 0 0 0 0 9 0 JJ TO NNS RB VBD O
previously previously 0 0 0 0 0 0 0 0 10 0 TO NNS RB VBD IN O
described described 0 0 0 0 0 0 0 0 9 0 NNS RB VBD IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 RB VBD IN NNP JJ O
lakes, lakes, 0 0 0 0 1 0 0 0 6 0 VBD IN NNP JJ NN O
brackish brackish 0 0 0 0 0 0 0 0 8 0 IN NNP JJ NN NN O
water, water, 0 0 0 0 1 0 0 0 6 0 NNP JJ NN NN NN O
marine marine 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN NN O
environments, environments, 0 0 0 0 1 0 0 0 13 0 NN NN NN NN NN O
soil, soil, 0 0 0 0 1 0 0 0 5 0 NN NN NN NN NN O
glaciers, glaciers, 0 0 0 0 1 0 0 0 9 0 NN NN NN NN NN O
ice, ice, 0 0 0 0 1 0 0 0 4 0 NN NN NN NN NN O
lake lake 0 0 0 0 0 0 0 0 4 0 NN NN NN NN NN O
sediments, sediments, 0 0 0 0 1 0 0 0 10 0 NN NN NN NN NN O
deep-sea deep-sea 0 0 1 0 0 0 0 0 8 0 NN NN NN NN NN O
sediments, sediments, 0 0 0 0 1 0 0 0 10 0 NN NN NN NN NN O
deep-sea deep-sea 0 0 1 0 0 0 0 0 8 0 NN NN NN NN NN O
thermal thermal 0 0 0 0 0 0 0 0 7 0 NN NN NN NN NNS O
vents, vents, 0 0 0 0 1 0 0 0 6 0 NN NN NN NNS CC O
animals animals 0 0 0 0 0 0 0 0 7 0 NN NN NNS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NNP NNPS O
plants. plants. 0 0 0 0 0 0 0 0 7 0 NNS CC NNP NNPS IN O
Sequences Sequences 1 0 0 0 0 0 0 0 9 0 CC NNP NNPS IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNPS IN NNP NNP O
aerobic, aerobic, 0 0 0 0 1 0 0 0 8 0 NNPS IN NNP NNP NNP O
anaerobic, anaerobic, 0 0 0 0 1 0 0 0 10 0 IN NNP NNP NNP NNP O
psychrophilic, psychrophilic, 0 0 0 0 1 0 0 0 14 0 NNP NNP NNP NNP NNP O
thermophilic, thermophilic, 0 0 0 0 1 0 0 0 13 0 NNP NNP NNP NNP NNP O
halophilic, halophilic, 0 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
alkaliphilic, alkaliphilic, 0 0 0 0 1 0 0 0 13 0 NNP NNP NNP NNP NNP O
acidophilic, acidophilic, 0 0 0 0 1 0 0 0 12 0 NNP NNP NNP NNP JJ O
desiccation-resistant, desiccation-resistant, 0 0 1 0 1 0 0 0 22 0 NNP NNP NNP JJ CC O
autotrophic autotrophic 0 0 0 0 0 0 0 0 11 0 NNP NNP JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP JJ CC JJ NNS O
heterotrophic heterotrophic 0 0 0 0 0 0 0 0 13 0 JJ CC JJ NNS VBD O
organisms organisms 0 0 0 0 0 0 0 0 9 0 CC JJ NNS VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD JJ VBG O
present, present, 0 0 0 0 1 0 0 0 8 0 NNS VBD JJ VBG DT O
including including 0 0 0 0 0 0 0 0 9 0 VBD JJ VBG DT NN O
a a 0 0 0 0 0 0 0 0 1 0 JJ VBG DT NN IN O
number number 0 0 0 0 0 0 0 0 6 0 VBG DT NN IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 DT NN IN JJ NNP O
multicellular multicellular 0 0 0 0 0 0 0 0 13 0 NN IN JJ NNP NONE O
eukaryotes. eukaryotes. 0 0 0 0 0 0 0 0 11 0 IN JJ NNP NONE NONE O
Differential Differential 1 0 0 0 0 0 0 0 12 0 NONE NONE JJ NN NNS O
Movement Movement 1 0 0 0 0 0 0 0 8 0 NONE JJ NN NNS IN O
Patterns Patterns 1 0 0 0 0 0 0 0 8 0 JJ NN NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP NNP O
Juvenile Juvenile 1 0 0 0 0 0 0 0 8 0 NNS IN NNP NNP NNP O
Tengmalms Tengmalms 1 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP NNP O
Owls Owls 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
(Aegolius (Aegolius 0 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP IN O
funereus) funereus) 0 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN DT O
during during 0 0 0 0 0 0 0 0 6 0 NNP NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ NNP O
Post-Fledging Post-Fledging 1 0 1 0 0 0 0 0 13 0 IN DT JJ NNP NNP O
Dependence Dependence 1 0 0 0 0 0 0 0 10 0 DT JJ NNP NNP IN O
Period Period 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP IN CD O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN CD NNS O
Two Two 1 0 0 0 0 0 0 0 3 0 NNP IN CD NNS IN O
Years Years 1 0 0 0 0 0 0 0 5 0 IN CD NNS IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 CD NNS IN NNP NNP O
Contrasting Contrasting 1 0 0 0 0 0 0 0 11 0 NNS IN NNP NNP NNP O
Prey Prey 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNP O
Abundance. Abundance. 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Kouba Kouba 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Bartoš Bartoš 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Stastný Stastný 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
K. K. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Ecology, Ecology, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP IN O
Faculty Faculty 1 0 0 0 0 0 0 0 7 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Environmental Environmental 1 0 0 0 0 0 0 0 13 0 NNP IN NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Czech Czech 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNPS O
Life Life 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNPS NNP O
Sciences Sciences 1 0 0 0 0 0 0 0 8 0 IN NNP NNPS NNP NNP O
Prague, Prague, 1 0 0 0 1 0 0 0 7 0 NNP NNPS NNP NNP NNP O
Prague, Prague, 1 0 0 0 1 0 0 0 7 0 NNPS NNP NNP NNP NNP O
Czech Czech 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Republic. Republic. 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP PRP$ O
Fledgling Fledgling 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP PRP$ CC O
behaviour behaviour 0 0 0 0 0 0 0 0 9 0 NNP NNP PRP$ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP PRP$ CC NN NNS O
movement movement 0 0 0 0 0 0 0 0 8 0 PRP$ CC NN NNS IN O
patterns patterns 0 0 0 0 0 0 0 0 8 0 CC NN NNS IN DT O
throughout throughout 0 0 0 0 0 0 0 0 10 0 NN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
post-fledging post-fledging 0 0 1 0 0 0 0 0 13 0 IN DT JJ NN NN O
dependence dependence 0 0 0 0 0 0 0 0 10 0 DT JJ NN NN NN O
period period 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN RB O
(PFDP), (PFDP), 0 1 0 0 1 0 0 0 7 0 NN NN NN RB IN O
especially especially 0 0 0 0 0 0 0 0 10 0 NN NN RB IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN RB IN NN TO O
relation relation 0 0 0 0 0 0 0 0 8 0 RB IN NN TO VBG O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VBG JJ O
changing changing 0 0 0 0 0 0 0 0 8 0 NN TO VBG JJ NN O
environmental environmental 0 0 0 0 0 0 0 0 13 0 TO VBG JJ NN VBP O
conditions, conditions, 0 0 0 0 1 0 0 0 11 0 VBG JJ NN VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 JJ NN VBP VBN RB O
been been 0 0 0 0 0 0 0 0 4 0 NN VBP VBN RB -NONE- O
rarely rarely 0 0 0 0 0 0 0 0 6 0 VBP VBN RB -NONE- IN O
studied, studied, 0 0 0 0 1 0 0 0 8 0 VBN RB -NONE- IN DT O
despite despite 0 0 0 0 0 0 0 0 7 0 RB -NONE- IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- IN DT NN IN O
fact fact 0 0 0 0 0 0 0 0 4 0 IN DT NN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN VBZ O
period period 0 0 0 0 0 0 0 0 6 0 IN DT NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ VBN RB O
recognized recognized 0 0 0 0 0 0 0 0 10 0 NN VBZ VBN RB IN O
as as 0 0 0 0 0 0 0 0 2 0 VBZ VBN RB IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBN RB IN JJ NN O
crucial crucial 0 0 0 0 0 0 0 0 7 0 RB IN JJ NN IN O
significance significance 0 0 0 0 0 0 0 0 12 0 IN JJ NN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS IN O
terms terms 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 NNS IN JJ NN IN O
mortality mortality 0 0 0 0 0 0 0 0 9 0 IN JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
juveniles. juveniles. 0 0 0 0 0 0 0 0 10 0 NN IN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP MD O
PFDP PFDP 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NNP NNP MD VB IN O
extend extend 0 0 0 0 0 0 0 0 6 0 NNP MD VB IN JJ O
over over 0 0 0 0 0 0 0 0 4 0 MD VB IN JJ DT O
quite quite 0 0 0 0 0 0 0 0 5 0 VB IN JJ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 IN JJ DT JJ NN O
protracted protracted 0 0 0 0 0 0 0 0 10 0 JJ DT JJ NN RB O
period, period, 0 0 0 0 1 0 0 0 7 0 DT JJ NN RB IN O
particularly particularly 0 0 0 0 0 0 0 0 12 0 JJ NN RB IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 NN RB IN NNS IN O
birds birds 0 0 0 0 0 0 0 0 5 0 RB IN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN JJ CC O
prey, prey, 0 0 0 0 1 0 0 0 5 0 NNS IN JJ CC DT O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC DT NN O
a a 0 0 0 0 0 0 0 0 1 0 JJ CC DT NN IN O
knowledge knowledge 0 0 0 0 0 0 0 0 9 0 CC DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBZ O
movement movement 0 0 0 0 0 0 0 0 8 0 IN DT NN VBZ IN O
patterns patterns 0 0 0 0 0 0 0 0 8 0 DT NN VBZ IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NN VBZ IN NNS VBZ O
individuals individuals 0 0 0 0 0 0 0 0 11 0 VBZ IN NNS VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 IN NNS VBZ JJ IN O
fundamental fundamental 0 0 0 0 0 0 0 0 11 0 NNS VBZ JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN NN NNS O
understanding understanding 0 0 0 0 0 0 0 0 13 0 JJ IN NN NNS VBG O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 IN NN NNS VBG JJ O
underlying underlying 0 0 0 0 0 0 0 0 10 0 NN NNS VBG JJ NN O
survival, survival, 0 0 0 0 1 0 0 0 9 0 NNS VBG JJ NN NN O
habitat habitat 0 0 0 0 0 0 0 0 7 0 VBG JJ NN NN CC O
use use 0 0 0 0 0 0 0 0 3 0 JJ NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
dispersion. dispersion. 0 0 0 0 0 0 0 0 11 0 NN CC NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 CC NNP NNP VBD CD O
radiotracked radiotracked 0 0 0 0 0 0 0 0 12 0 NNP NNP VBD CD NNS O
39 39 0 0 0 0 0 0 1 1 2 0 NNP VBD CD NNS IN O
fledglings fledglings 0 0 0 0 0 0 0 0 10 0 VBD CD NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
Tengmalm's Tengmalm's 1 0 0 0 0 1 0 0 10 0 IN DT JJ NN JJ O
owl owl 0 0 0 0 0 0 0 0 3 0 DT JJ NN JJ NN O
(Aegolius (Aegolius 0 0 0 0 0 0 0 0 9 0 JJ NN JJ NN IN O
funereus) funereus) 0 0 0 0 0 0 0 0 9 0 NN JJ NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 NN IN CD NNS IN O
years years 0 0 0 0 0 0 0 0 5 0 IN CD NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 CD NNS IN JJ NN O
different different 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NN IN O
availability availability 0 0 0 0 0 0 0 0 12 0 IN JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP CD O
prey: prey: 0 0 0 0 0 0 0 0 5 0 NN IN NNP CD JJ O
2010 2010 0 0 0 0 0 0 1 1 4 0 IN NNP CD JJ NN O
(n (n 0 0 0 0 0 0 0 0 2 0 NNP CD JJ NN CD O
= = 0 0 0 0 0 0 0 0 1 0 CD JJ NN CD CC O
29) 29) 0 0 0 0 0 0 0 1 3 0 JJ NN CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NN CD CC CD JJ O
2011 2011 0 0 0 0 0 0 1 1 4 0 CD CC CD JJ NN O
(n (n 0 0 0 0 0 0 0 0 2 0 CC CD JJ NN CD O
= = 0 0 0 0 0 0 0 0 1 0 CD JJ NN CD CC O
10) 10) 0 0 0 0 0 0 0 1 3 0 JJ NN CD CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NN CD CC VBD CD O
obtained obtained 0 0 0 0 0 0 0 0 8 0 CD CC VBD CD JJ O
1455 1455 0 0 0 0 0 0 1 1 4 0 CC VBD CD JJ NNP O
daily daily 0 0 0 0 0 0 0 0 5 0 VBD CD JJ NNP NNP O
locations. locations. 0 0 0 0 0 0 0 0 10 0 CD JJ NNP NNP VBD O
Fledglings Fledglings 1 0 0 0 0 0 0 0 10 0 JJ NNP NNP VBD NN O
reached reached 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD NN IN O
independence independence 0 0 0 0 0 0 0 0 12 0 NNP VBD NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 VBD NN IN JJ IN O
average average 0 0 0 0 0 0 0 0 7 0 NN IN JJ IN CD O
in in 0 0 0 0 0 0 0 0 2 0 IN JJ IN CD NNS O
45 45 0 0 0 0 0 0 1 1 2 0 JJ IN CD NNS IN O
days days 0 0 0 0 0 0 0 0 4 0 IN CD NNS IN VBG O
after after 0 0 0 0 0 0 0 0 5 0 CD NNS IN VBG IN O
fledging fledging 0 0 0 0 0 0 0 0 8 0 NNS IN VBG IN CD O
in in 0 0 0 0 0 0 0 0 2 0 IN VBG IN CD JJ O
2010 2010 0 0 0 0 0 0 1 1 4 0 VBG IN CD JJ NN O
(n (n 0 0 0 0 0 0 0 0 2 0 IN CD JJ NN CD O
= = 0 0 0 0 0 0 0 0 1 0 CD JJ NN CD CC O
22) 22) 0 0 0 0 0 0 0 1 3 0 JJ NN CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NN CD CC CD NNS O
57 57 0 0 0 0 0 0 1 1 2 0 CD CC CD NNS IN O
days days 0 0 0 0 0 0 0 0 4 0 CC CD NNS IN CD O
in in 0 0 0 0 0 0 0 0 2 0 CD NNS IN CD JJ O
2011 2011 0 0 0 0 0 0 1 1 4 0 NNS IN CD JJ NN O
(n (n 0 0 0 0 0 0 0 0 2 0 IN CD JJ NN CD O
= = 0 0 0 0 0 0 0 0 1 0 CD JJ NN CD NNP O
6). 6). 0 0 0 0 0 0 0 1 3 0 JJ NN CD NNP NNP O
Within Within 1 0 0 0 0 0 0 0 6 0 NN CD NNP NNP DT O
years, years, 0 0 0 0 1 0 0 0 6 0 CD NNP NNP DT RBS O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT RBS JJ O
most most 0 0 0 0 0 0 0 0 4 0 NNP DT RBS JJ NNS O
important important 0 0 0 0 0 0 0 0 9 0 DT RBS JJ NNS VBG O
measures measures 0 0 0 0 0 0 0 0 8 0 RBS JJ NNS VBG DT O
influencing influencing 0 0 0 0 0 0 0 0 11 0 JJ NNS VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBG DT NN VBD O
distance distance 0 0 0 0 0 0 0 0 8 0 VBG DT NN VBD IN O
moved moved 0 0 0 0 0 0 0 0 5 0 DT NN VBD IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NN VBD IN DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT JJS NN O
nest nest 0 0 0 0 0 0 0 0 4 0 IN DT JJS NN VBD O
box box 0 0 0 0 0 0 0 0 3 0 DT JJS NN VBD NN O
were were 0 0 0 0 0 0 0 0 4 0 JJS NN VBD NN IN O
age age 0 0 0 0 0 0 0 0 3 0 NN VBD NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN NNS CC O
fledglings fledglings 0 0 0 0 0 0 0 0 10 0 NN IN NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC NN IN O
number number 0 0 0 0 0 0 0 0 6 0 NNS CC NN IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN VBG NNS O
surviving surviving 0 0 0 0 0 0 0 0 9 0 NN IN VBG NNS NNP O
siblings siblings 0 0 0 0 0 0 0 0 8 0 IN VBG NNS NNP NNP O
present. present. 0 0 0 0 0 0 0 0 8 0 VBG NNS NNP NNP NN O
Individual Individual 1 0 0 0 0 0 0 0 10 0 NNS NNP NNP NN NN O
home home 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN NN O
range range 0 0 0 0 0 0 0 0 5 0 NNP NN NN NN CC O
size size 0 0 0 0 0 0 0 0 4 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
duration duration 0 0 0 0 0 0 0 0 8 0 NN CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP IN O
PFDP PFDP 1 1 0 0 0 0 0 0 4 0 NN IN NNP IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN JJ VBD O
particular particular 0 0 0 0 0 0 0 0 10 0 NNP IN JJ VBD NN O
were were 0 0 0 0 0 0 0 0 4 0 IN JJ VBD NN IN O
dependent dependent 0 0 0 0 0 0 0 0 9 0 JJ VBD NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 VBD NN IN JJ NN O
maximal maximal 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN IN O
number number 0 0 0 0 0 0 0 0 6 0 IN JJ NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS VBN O
siblings siblings 0 0 0 0 0 0 0 0 8 0 NN IN NNS VBN IN O
seen seen 0 0 0 0 0 0 0 0 4 0 IN NNS VBN IN DT O
outside outside 0 0 0 0 0 0 0 0 7 0 NNS VBN IN DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJS NNP O
nest nest 0 0 0 0 0 0 0 0 4 0 IN DT JJS NNP NNP O
box. box. 0 0 0 0 0 0 0 0 4 0 DT JJS NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 JJS NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
season season 0 0 0 0 0 0 0 0 6 0 NNP DT NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 DT NN IN JJ NN O
low low 0 0 0 0 0 0 0 0 3 0 NN IN JJ NN NN O
prey prey 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN NNS O
availability availability 0 0 0 0 0 0 0 0 12 0 JJ NN NN NNS VBD O
fledglings fledglings 0 0 0 0 0 0 0 0 10 0 NN NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN JJR O
at at 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJR NNS O
greater greater 0 0 0 0 0 0 0 0 7 0 VBN IN JJR NNS IN O
distances distances 0 0 0 0 0 0 0 0 9 0 IN JJR NNS IN DT O
from from 0 0 0 0 0 0 0 0 4 0 JJR NNS IN DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJS NN O
nest nest 0 0 0 0 0 0 0 0 4 0 IN DT JJS NN IN O
box box 0 0 0 0 0 0 0 0 3 0 DT JJS NN IN IN O
than than 0 0 0 0 0 0 0 0 4 0 JJS NN IN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN IN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN IN DT NN IN O
year year 0 0 0 0 0 0 0 0 4 0 IN DT NN IN JJR O
with with 0 0 0 0 0 0 0 0 4 0 DT NN IN JJR NN O
higher higher 0 0 0 0 0 0 0 0 6 0 NN IN JJR NN NN O
prey prey 0 0 0 0 0 0 0 0 4 0 IN JJR NN NN JJ O
availability availability 0 0 0 0 0 0 0 0 12 0 JJR NN NN JJ NN O
(mean (mean 0 0 0 0 0 0 0 0 5 0 NN NN JJ NN CD O
distance: distance: 0 0 0 0 0 0 0 0 9 0 NN JJ NN CD NN O
350 350 0 0 0 0 0 0 1 1 3 0 JJ NN CD NN IN O
m m 0 0 0 0 0 0 0 0 1 0 NN CD NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN CD CC O
2010 2010 0 0 0 0 0 0 1 1 4 0 NN IN CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 IN CD CC CD NN O
650 650 0 0 0 0 0 0 1 1 3 0 CD CC CD NN IN O
m m 0 0 0 0 0 0 0 0 1 0 CC CD NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN CD CC O
2011) 2011) 0 0 0 0 0 0 0 1 5 0 NN IN CD CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 IN CD CC VBD JJR O
occupied occupied 0 0 0 0 0 0 0 0 8 0 CD CC VBD JJR NN O
larger larger 0 0 0 0 0 0 0 0 6 0 CC VBD JJR NN NNS O
home home 0 0 0 0 0 0 0 0 4 0 VBD JJR NN NNS -NONE- O
ranges ranges 0 0 0 0 0 0 0 0 6 0 JJR NN NNS -NONE- CD O
(mean: (mean: 0 0 0 0 0 0 0 0 6 0 NN NNS -NONE- CD NN O
30.3 30.3 0 0 0 0 0 0 0 1 4 0 NNS -NONE- CD NN IN O
ha ha 0 0 0 0 0 0 0 0 2 0 -NONE- CD NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN CD CC O
2010 2010 0 0 0 0 0 0 1 1 4 0 NN IN CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 IN CD CC CD NN O
57.7 57.7 0 0 0 0 0 0 0 1 4 0 CD CC CD NN IN O
ha ha 0 0 0 0 0 0 0 0 2 0 CC CD NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN CD DT O
2011). 2011). 0 0 0 0 0 0 0 1 6 0 NN IN CD DT JJ O
The The 1 0 0 0 0 0 0 0 3 0 IN CD DT JJ NN O
main main 0 0 0 0 0 0 0 0 4 0 CD DT JJ NN VBG O
factor factor 0 0 0 0 0 0 0 0 6 0 DT JJ NN VBG DT O
causing causing 0 0 0 0 0 0 0 0 7 0 JJ NN VBG DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NN VBG DT NNS IN O
differences differences 0 0 0 0 0 0 0 0 11 0 VBG DT NNS IN NNS O
between between 0 0 0 0 0 0 0 0 7 0 DT NNS IN NNS VBD O
years years 0 0 0 0 0 0 0 0 5 0 NNS IN NNS VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 IN NNS VBD RB DT O
probably probably 0 0 0 0 0 0 0 0 8 0 NNS VBD RB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBD RB DT JJ NN O
different different 0 0 0 0 0 0 0 0 9 0 RB DT JJ NN IN O
availability availability 0 0 0 0 0 0 0 0 12 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
prey prey 0 0 0 0 0 0 0 0 4 0 NN IN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN DT CD O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT CD JJ O
two two 0 0 0 0 0 0 0 0 3 0 IN DT CD JJ NN O
years, years, 0 0 0 0 1 0 0 0 6 0 DT CD JJ NN VBG O
affecting affecting 0 0 0 0 0 0 0 0 9 0 CD JJ NN VBG NN O
breeding breeding 0 0 0 0 0 0 0 0 8 0 JJ NN VBG NN CC O
success success 0 0 0 0 0 0 0 0 7 0 NN VBG NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBG NN CC JJ NN O
post-fledging post-fledging 0 0 1 0 0 0 0 0 13 0 NN CC JJ NN IN O
survivorship survivorship 0 0 0 0 0 0 0 0 12 0 CC JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
Tengmalm's Tengmalm's 1 0 0 0 0 1 0 0 10 0 IN DT JJ NNP NONE O
owls. owls. 0 0 0 0 0 0 0 0 5 0 DT JJ NNP NONE NONE O
Randomized Randomized 1 0 0 0 0 0 0 0 10 0 NONE NONE JJ JJ NN O
clinical clinical 0 0 0 0 0 0 0 0 8 0 NONE JJ JJ NN IN O
trial trial 0 0 0 0 0 0 0 0 5 0 JJ JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ JJ O
thrice-weekly thrice-weekly 0 0 1 0 0 0 0 0 13 0 NN IN JJ JJ NN O
4-month 4-month 0 0 1 0 0 0 0 1 7 0 IN JJ JJ NN CC O
moxifloxacin moxifloxacin 0 0 0 0 0 0 0 0 12 0 JJ JJ NN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 JJ NN CC NN VBG O
gatifloxacin gatifloxacin 0 0 0 0 0 0 0 0 12 0 NN CC NN VBG NNS O
containing containing 0 0 0 0 0 0 0 0 10 0 CC NN VBG NNS IN O
regimens regimens 0 0 0 0 0 0 0 0 8 0 NN VBG NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBG NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
new new 0 0 0 0 0 0 0 0 3 0 NN IN JJ NN JJ O
sputum sputum 0 0 0 0 0 0 0 0 6 0 IN JJ NN JJ NN O
positive positive 0 0 0 0 0 0 0 0 8 0 JJ NN JJ NN NN O
pulmonary pulmonary 0 0 0 0 0 0 0 0 9 0 NN JJ NN NN NNP O
tuberculosis tuberculosis 0 0 0 0 0 0 0 0 12 0 JJ NN NN NNP NNP O
patients. patients. 0 0 0 0 0 0 0 0 9 0 NN NN NNP NNP NNP O
Jawahar Jawahar 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NNP NNP O
MS, MS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Banurekha Banurekha 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
VV, VV, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Paramasivan Paramasivan 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
CN, CN, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Rahman Rahman 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ramachandran Ramachandran 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Venkatesan Venkatesan 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Balasubramanian Balasubramanian 1 0 0 0 0 0 0 0 15 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Selvakumar Selvakumar 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ponnuraja Ponnuraja 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Iliayas Iliayas 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
AS, AS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Gangadevi Gangadevi 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
NP, NP, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Raman Raman 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Baskaran Baskaran 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kumar Kumar 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
SR, SR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Kumar Kumar 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
MM, MM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Mohan Mohan 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
V, V, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ganapathy Ganapathy 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kumar Kumar 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
V, V, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Shanmugam Shanmugam 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Charles Charles 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sakthivel Sakthivel 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
MR, MR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Jagannath Jagannath 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Chandrasekar Chandrasekar 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Parthasarathy Parthasarathy 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
RT, RT, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Narayanan Narayanan 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
PR. PR. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
National National 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP IN O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP IN NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NNP O
Tuberculosis Tuberculosis 1 0 0 0 0 0 0 0 12 0 NNP IN NNP NNP NNP O
(formerly (formerly 0 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP NNP O
Tuberculosis Tuberculosis 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Centre), Centre), 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Chennai, Chennai, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
India. India. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NN O
Shortening Shortening 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NN -NONE- O
tuberculosis tuberculosis 0 0 0 0 0 0 0 0 12 0 NNP NNP NN -NONE- NN O
(TB) (TB) 0 1 0 0 0 0 0 0 4 0 NNP NN -NONE- NN NN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NN -NONE- NN NN VBZ O
duration duration 0 0 0 0 0 0 0 0 8 0 -NONE- NN NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT NN NNP O
research research 0 0 0 0 0 0 0 0 8 0 VBZ DT NN NNP NNP O
priority. priority. 0 0 0 0 0 0 0 0 9 0 DT NN NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NN NNS O
paper paper 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NNS NNS O
presents presents 0 0 0 0 0 0 0 0 8 0 NNP NN NNS NNS IN O
data data 0 0 0 0 0 0 0 0 4 0 NN NNS NNS IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NNS NNS IN DT RB O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT RB VBN O
prematurely prematurely 0 0 0 0 0 0 0 0 11 0 IN DT RB VBN VBN O
terminated terminated 0 0 0 0 0 0 0 0 10 0 DT RB VBN VBN JJ O
randomized randomized 0 0 0 0 0 0 0 0 10 0 RB VBN VBN JJ NN O
clinical clinical 0 0 0 0 0 0 0 0 8 0 VBN VBN JJ NN IN O
trial, trial, 0 0 0 0 1 0 0 0 6 0 VBN JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
4-month 4-month 0 0 1 0 0 0 0 1 7 0 NN IN JJ NN CC O
moxifloxacin moxifloxacin 0 0 0 0 0 0 0 0 12 0 IN JJ NN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 JJ NN CC NN NN O
gatifloxacin gatifloxacin 0 0 0 0 0 0 0 0 12 0 NN CC NN NN IN O
regimens, regimens, 0 0 0 0 1 0 0 0 9 0 CC NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
South South 1 0 0 0 0 0 0 0 5 0 NN IN NNP NNP NNP O
India. India. 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Newly Newly 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP JJ O
diagnosed, diagnosed, 0 0 0 0 1 0 0 0 10 0 NNP NNP NNP JJ JJ O
sputum-positive sputum-positive 0 0 1 0 0 0 0 0 15 0 NNP NNP JJ JJ JJ O
HIV-negative HIV-negative 1 0 1 0 0 0 0 0 12 0 NNP JJ JJ JJ NNP O
pulmonary pulmonary 0 0 0 0 0 0 0 0 9 0 JJ JJ JJ NNP NNS O
TB TB 1 1 0 0 0 0 0 0 2 0 JJ JJ NNP NNS VBD O
patients patients 0 0 0 0 0 0 0 0 8 0 JJ NNP NNS VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD RB VBN O
randomly randomly 0 0 0 0 0 0 0 0 8 0 NNS VBD RB VBN TO O
allocated allocated 0 0 0 0 0 0 0 0 9 0 VBD RB VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 RB VBN TO VB NN O
receive receive 0 0 0 0 0 0 0 0 7 0 VBN TO VB NN CC O
gatifloxacin gatifloxacin 0 0 0 0 0 0 0 0 12 0 TO VB NN CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 VB NN CC JJ IN O
moxifloxacin, moxifloxacin, 0 0 0 0 1 0 0 0 13 0 NN CC JJ IN IN O
along along 0 0 0 0 0 0 0 0 5 0 CC JJ IN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 JJ IN IN JJ CC O
isoniazid isoniazid 0 0 0 0 0 0 0 0 9 0 IN IN JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC NN IN O
rifampicin rifampicin 0 0 0 0 0 0 0 0 10 0 JJ CC NN IN CD O
for for 0 0 0 0 0 0 0 0 3 0 CC NN IN CD NNS O
4 4 0 0 0 0 0 0 1 1 1 0 NN IN CD NNS IN O
months months 0 0 0 0 0 0 0 0 6 0 IN CD NNS IN NN O
with with 0 0 0 0 0 0 0 0 4 0 CD NNS IN NN IN O
pyrazinamide pyrazinamide 0 0 0 0 0 0 0 0 12 0 NNS IN NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 IN NN IN JJ CD O
first first 0 0 0 0 0 0 0 0 5 0 NN IN JJ CD NNS O
2 2 0 0 0 0 0 0 1 1 1 0 IN JJ CD NNS JJ O
months months 0 0 0 0 0 0 0 0 6 0 JJ CD NNS JJ CC O
(G (G 0 1 0 0 0 0 0 0 2 0 CD NNS JJ CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 NNS JJ CC JJ CC O
M) M) 1 1 0 0 0 0 0 0 2 0 JJ CC JJ CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 CC JJ CC JJ CC O
isoniazid isoniazid 0 0 0 0 0 0 0 0 9 0 JJ CC JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 CC JJ CC NN IN O
rifampicin rifampicin 0 0 0 0 0 0 0 0 10 0 JJ CC NN IN CD O
for for 0 0 0 0 0 0 0 0 3 0 CC NN IN CD NNS O
6 6 0 0 0 0 0 0 1 1 1 0 NN IN CD NNS IN O
months months 0 0 0 0 0 0 0 0 6 0 IN CD NNS IN NN O
with with 0 0 0 0 0 0 0 0 4 0 CD NNS IN NN CC O
ethambutol ethambutol 0 0 0 0 0 0 0 0 10 0 NNS IN NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VB IN O
pyrazinamide pyrazinamide 0 0 0 0 0 0 0 0 12 0 NN CC VB IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 CC VB IN JJ CD O
first first 0 0 0 0 0 0 0 0 5 0 VB IN JJ CD NNS O
2 2 0 0 0 0 0 0 1 1 1 0 IN JJ CD NNS NNP O
months months 0 0 0 0 0 0 0 0 6 0 JJ CD NNS NNP NNP O
(C). (C). 0 1 0 0 0 0 0 0 4 0 CD NNS NNP NNP VBZ O
All All 1 0 0 0 0 0 0 0 3 0 NNS NNP NNP VBZ VBD O
regimens regimens 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBD VBN -NONE- O
administered administered 0 0 0 0 0 0 0 0 12 0 VBZ VBD VBN -NONE- NNP O
thrice-weekly. thrice-weekly. 0 0 1 0 0 0 0 0 14 0 VBD VBN -NONE- NNP CC O
Clinical Clinical 1 0 0 0 0 0 0 0 8 0 VBN -NONE- NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NNP CC JJ NNS O
bacteriological bacteriological 0 0 0 0 0 0 0 0 15 0 NNP CC JJ NNS VBD O
assessments assessments 0 0 0 0 0 0 0 0 11 0 CC JJ NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD VBN JJ O
done done 0 0 0 0 0 0 0 0 4 0 NNS VBD VBN JJ IN O
monthly monthly 0 0 0 0 0 0 0 0 7 0 VBD VBN JJ IN NN O
during during 0 0 0 0 0 0 0 0 6 0 VBN JJ IN NN CC O
treatment treatment 0 0 0 0 0 0 0 0 9 0 JJ IN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC IN CD O
for for 0 0 0 0 0 0 0 0 3 0 NN CC IN CD NNS O
24 24 0 0 0 0 0 0 1 1 2 0 CC IN CD NNS NNP O
months months 0 0 0 0 0 0 0 0 6 0 IN CD NNS NNP NNP O
post-treatment. post-treatment. 0 0 1 0 0 0 0 0 15 0 CD NNS NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNS NNP NNP NNP CC O
Data Data 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Safety Safety 1 0 0 0 0 0 0 0 6 0 NNP CC NNP NNP NNP O
Monitoring Monitoring 1 0 0 0 0 0 0 0 10 0 CC NNP NNP NNP VBD O
Board Board 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP VBD NN O
recommended recommended 0 0 0 0 0 0 0 0 11 0 NNP NNP VBD NN IN O
termination termination 0 0 0 0 0 0 0 0 11 0 NNP VBD NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN JJ O
trial trial 0 0 0 0 0 0 0 0 5 0 IN DT NN JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 DT NN JJ TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NN JJ TO JJ NNP O
high high 0 0 0 0 0 0 0 0 4 0 JJ TO JJ NNP NN O
TB TB 1 1 0 0 0 0 0 0 2 0 TO JJ NNP NN NNS O
recurrence recurrence 0 0 0 0 0 0 0 0 10 0 JJ NNP NN NNS IN O
rates rates 0 0 0 0 0 0 0 0 5 0 NNP NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP CC O
G G 1 1 0 0 0 0 0 0 1 0 IN DT NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC NNP NNP O
M M 1 1 0 0 0 0 0 0 1 0 NNP CC NNP NNP NNP O
regimens. regimens. 0 0 0 0 0 0 0 0 9 0 CC NNP NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNP CD O
Of Of 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNS O
416 416 0 0 0 0 0 0 1 1 3 0 NNP NNP CD NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 NNP CD NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 CD NNS IN JJ NN O
intent-to-treat intent-to-treat 0 0 1 0 0 0 0 0 15 0 NNS IN JJ NN CD O
analysis, analysis, 0 0 0 0 1 0 0 0 9 0 IN JJ NN CD NN O
6 6 0 0 0 0 0 0 1 1 1 0 JJ NN CD NN IN O
(5%) (5%) 0 0 0 0 0 0 0 1 4 0 NN CD NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN CD CD O
124, 124, 0 0 0 0 1 0 0 1 4 0 NN IN CD CD JJ O
2 2 0 0 0 0 0 0 1 1 1 0 IN CD CD JJ IN O
(2%) (2%) 0 0 0 0 0 0 0 1 4 0 CD CD JJ IN CD O
of of 0 0 0 0 0 0 0 0 2 0 CD JJ IN CD CC O
110 110 0 0 0 0 0 0 1 1 3 0 JJ IN CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 IN CD CC CD NN O
2 2 0 0 0 0 0 0 1 1 1 0 CD CC CD NN IN O
(2%) (2%) 0 0 0 0 0 0 0 1 4 0 CC CD NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN CD NNS O
137 137 0 0 0 0 0 0 1 1 3 0 NN IN CD NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 IN CD NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 CD NNS IN JJ NNP O
drug-susceptible drug-susceptible 0 0 1 0 0 0 0 0 16 0 NNS IN JJ NNP IN O
TB TB 1 1 0 0 0 0 0 0 2 0 IN JJ NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 IN DT NN NNP CC O
M M 1 1 0 0 0 0 0 0 1 0 DT NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP NNS O
C C 1 1 0 0 0 0 0 0 1 0 NNP CC NNP NNS RB O
arms arms 0 0 0 0 0 0 0 0 4 0 CC NNP NNS RB VBD O
respectively respectively 0 0 0 0 0 0 0 0 12 0 NNP NNS RB VBD JJ O
had had 0 0 0 0 0 0 0 0 3 0 NNS RB VBD JJ NN O
unfavorable unfavorable 0 0 0 0 0 0 0 0 11 0 RB VBD JJ NN IN O
response response 0 0 0 0 0 0 0 0 8 0 VBD JJ NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
end end 0 0 0 0 0 0 0 0 3 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
treatment; treatment; 0 0 0 0 0 0 0 0 10 0 NN IN NNP IN DT O
during during 0 0 0 0 0 0 0 0 6 0 IN NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ CD O
next next 0 0 0 0 0 0 0 0 4 0 IN DT JJ CD NN O
24 24 0 0 0 0 0 0 1 1 2 0 DT JJ CD NN CD O
months, months, 0 0 0 0 1 0 0 0 7 0 JJ CD NN CD NN O
17 17 0 0 0 0 0 0 1 1 2 0 CD NN CD NN IN O
(15%) (15%) 0 0 0 0 0 0 0 1 5 0 NN CD NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN CD CD O
115, 115, 0 0 0 0 1 0 0 1 4 0 NN IN CD CD JJ O
11 11 0 0 0 0 0 0 1 1 2 0 IN CD CD JJ IN O
(11%) (11%) 0 0 0 0 0 0 0 1 5 0 CD CD JJ IN CD O
of of 0 0 0 0 0 0 0 0 2 0 CD JJ IN CD CC O
104 104 0 0 0 0 0 0 1 1 3 0 JJ IN CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 IN CD CC CD JJ O
8 8 0 0 0 0 0 0 1 1 1 0 CD CC CD JJ IN O
(6%) (6%) 0 0 0 0 0 0 0 1 4 0 CC CD JJ IN CD O
of of 0 0 0 0 0 0 0 0 2 0 CD JJ IN CD NNS O
132 132 0 0 0 0 0 0 1 1 3 0 JJ IN CD NNS -NONE- O
patients patients 0 0 0 0 0 0 0 0 8 0 IN CD NNS -NONE- VBD O
respectively, respectively, 0 0 0 0 1 0 0 0 13 0 CD NNS -NONE- VBD NNP O
had had 0 0 0 0 0 0 0 0 3 0 NNS -NONE- VBD NNP NNP O
TB TB 1 1 0 0 0 0 0 0 2 0 -NONE- VBD NNP NNP NNP O
recurrence. recurrence. 0 0 0 0 0 0 0 0 11 0 VBD NNP NNP NNP CD O
Of Of 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP CD JJ O
38 38 0 0 0 0 0 0 1 1 2 0 NNP NNP CD JJ NNS O
drug-resistant drug-resistant 0 0 1 0 0 0 0 0 14 0 NNP CD JJ NNS CD O
patients patients 0 0 0 0 0 0 0 0 8 0 CD JJ NNS CD IN O
1 1 0 0 0 0 0 0 1 1 1 0 JJ NNS CD IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NNS CD IN CD CC O
8 8 0 0 0 0 0 0 1 1 1 0 CD IN CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 IN CD CC CD IN O
3 3 0 0 0 0 0 0 1 1 1 0 CD CC CD IN CD O
of of 0 0 0 0 0 0 0 0 2 0 CC CD IN CD IN O
26 26 0 0 0 0 0 0 1 1 2 0 CD IN CD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN CD IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT NNP CC O
G G 1 1 0 0 0 0 0 0 1 0 IN DT NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC NNP NNS O
C C 1 1 0 0 0 0 0 0 1 0 NNP CC NNP NNS RB O
arms arms 0 0 0 0 0 0 0 0 4 0 CC NNP NNS RB VBD O
respectively respectively 0 0 0 0 0 0 0 0 12 0 NNP NNS RB VBD JJ O
had had 0 0 0 0 0 0 0 0 3 0 NNS RB VBD JJ NN O
unfavourable unfavourable 0 0 0 0 0 0 0 0 12 0 RB VBD JJ NN IN O
response response 0 0 0 0 0 0 0 0 8 0 VBD JJ NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
end end 0 0 0 0 0 0 0 0 3 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP CC O
treatment; treatment; 0 0 0 0 0 0 0 0 10 0 NN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NN O
TB TB 1 1 0 0 0 0 0 0 2 0 NNP CC NNP NN VBD O
recurrence recurrence 0 0 0 0 0 0 0 0 10 0 CC NNP NN VBD IN O
occurred occurred 0 0 0 0 0 0 0 0 8 0 NNP NN VBD IN CD O
in in 0 0 0 0 0 0 0 0 2 0 NN VBD IN CD IN O
2 2 0 0 0 0 0 0 1 1 1 0 VBD IN CD IN CD O
of of 0 0 0 0 0 0 0 0 2 0 IN CD IN CD CC O
7 7 0 0 0 0 0 0 1 1 1 0 CD IN CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 IN CD CC CD IN O
2 2 0 0 0 0 0 0 1 1 1 0 CD CC CD IN CD O
of of 0 0 0 0 0 0 0 0 2 0 CC CD IN CD JJ O
23 23 0 0 0 0 0 0 1 1 2 0 CD IN CD JJ NNP O
patients, patients, 0 0 0 0 1 0 0 0 9 0 IN CD JJ NNP NNP O
respectively. respectively. 0 0 0 0 0 0 0 0 13 0 CD JJ NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NNS IN O
differences differences 0 0 0 0 0 0 0 0 11 0 NNP NNP NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NNP NN O
TB TB 1 1 0 0 0 0 0 0 2 0 NNS IN NNP NN NNS O
recurrence recurrence 0 0 0 0 0 0 0 0 10 0 IN NNP NN NNS IN O
rates rates 0 0 0 0 0 0 0 0 5 0 NNP NN NNS IN DT O
between between 0 0 0 0 0 0 0 0 7 0 NN NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP CC O
G G 1 1 0 0 0 0 0 0 1 0 IN DT NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC NNP NNS O
C C 1 1 0 0 0 0 0 0 1 0 NNP CC NNP NNS VBD O
arms arms 0 0 0 0 0 0 0 0 4 0 CC NNP NNS VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNS VBD RB JJ O
statistically statistically 0 0 0 0 0 0 0 0 13 0 NNS VBD RB JJ JJ O
significant significant 0 0 0 0 0 0 0 0 11 0 VBD RB JJ JJ NN O
(p (p 0 0 0 0 0 0 0 0 2 0 RB JJ JJ NN CD O
= = 0 0 0 0 0 0 0 0 1 0 JJ JJ NN CD JJ O
0.02). 0.02). 0 0 0 0 0 0 0 1 6 0 JJ NN CD JJ NNS O
Gastro-intestinal Gastro-intestinal 1 0 1 0 0 0 0 0 17 0 NN CD JJ NNS VBD O
symptoms symptoms 0 0 0 0 0 0 0 0 8 0 CD JJ NNS VBD IN O
occurred occurred 0 0 0 0 0 0 0 0 8 0 JJ NNS VBD IN CD O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBD IN CD CD O
23%, 23%, 0 0 0 0 1 0 0 1 4 0 VBD IN CD CD CC O
22% 22% 0 0 0 0 0 0 0 1 3 0 IN CD CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD CD CC CD IN O
9% 9% 0 0 0 0 0 0 0 1 2 0 CD CC CD IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 CC CD IN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 CD IN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 IN DT NN NNP CC O
M M 1 1 0 0 0 0 0 0 1 0 DT NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP NNS O
C C 1 1 0 0 0 0 0 0 1 0 NNP CC NNP NNS -NONE- O
arms arms 0 0 0 0 0 0 0 0 4 0 CC NNP NNS -NONE- CC O
respectively, respectively, 0 0 0 0 1 0 0 0 13 0 NNP NNS -NONE- CC JJS O
but but 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC JJS NNS O
most most 0 0 0 0 0 0 0 0 4 0 -NONE- CC JJS NNS VBD O
reactions reactions 0 0 0 0 0 0 0 0 9 0 CC JJS NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJS NNS VBD VBN CC O
mild mild 0 0 0 0 0 0 0 0 4 0 NNS VBD VBN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBD VBN CC JJ IN O
manageable manageable 0 0 0 0 0 0 0 0 10 0 VBN CC JJ IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 CC JJ IN JJ NN O
symptomatic symptomatic 0 0 0 0 0 0 0 0 11 0 JJ IN JJ NN CD O
measures; measures; 0 0 0 0 0 0 0 0 9 0 IN JJ NN CD VBN O
1% 1% 0 0 0 0 0 0 0 1 2 0 JJ NN CD VBN NNS O
required required 0 0 0 0 0 0 0 0 8 0 NN CD VBN NNS NNP O
regimen regimen 0 0 0 0 0 0 0 0 7 0 CD VBN NNS NNP NNP O
modification. modification. 0 0 0 0 0 0 0 0 13 0 VBN NNS NNP NNP CD O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 NNS NNP NNP CD JJ O
4-month 4-month 0 0 1 0 0 0 0 1 7 0 NNP NNP CD JJ NNS O
thrice-weekly thrice-weekly 0 0 1 0 0 0 0 0 13 0 NNP CD JJ NNS IN O
regimens regimens 0 0 0 0 0 0 0 0 8 0 CD JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN CC O
gatifloxacin gatifloxacin 0 0 0 0 0 0 0 0 12 0 NNS IN NN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 IN NN CC NN IN O
moxifloxacin moxifloxacin 0 0 0 0 0 0 0 0 12 0 NN CC NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 CC NN IN JJ NN O
isoniazid, isoniazid, 0 0 0 0 1 0 0 0 10 0 NN IN JJ NN CC O
rifampicin rifampicin 0 0 0 0 0 0 0 0 10 0 IN JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP VBD O
pyrazinamide, pyrazinamide, 0 0 0 0 1 0 0 0 13 0 NN CC NNP VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 CC NNP VBD JJ TO O
inferior inferior 0 0 0 0 0 0 0 0 8 0 NNP VBD JJ TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 VBD JJ TO JJ JJ O
standard standard 0 0 0 0 0 0 0 0 8 0 JJ TO JJ JJ NN O
6-month 6-month 0 0 1 0 0 0 0 1 7 0 TO JJ JJ NN IN O
treatment, treatment, 0 0 0 0 1 0 0 0 10 0 JJ JJ NN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 NN IN NNS IN RB O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN RB VBN O
newly newly 0 0 0 0 0 0 0 0 5 0 NNS IN RB VBN NN O
diagnosed diagnosed 0 0 0 0 0 0 0 0 9 0 IN RB VBN NN JJ O
sputum sputum 0 0 0 0 0 0 0 0 6 0 RB VBN NN JJ NN O
positive positive 0 0 0 0 0 0 0 0 8 0 VBN NN JJ NN NNP O
pulmonary pulmonary 0 0 0 0 0 0 0 0 9 0 NN JJ NN NNP NONE O
TB TB 1 1 0 0 0 0 0 0 2 0 JJ NN NNP NONE NONE O
